PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
9876042-5	1998	Under stimulation of phorbol ester, expression of IL-6 and nerve growth factor mRNA was up-regulated.	Phorbol Esters	21-34	interleukin 6	Mus musculus	50-54
9835525-9	1998	The addition of CAP18106-137 to aztreonam along with the bacteria did decrease the level of antibiotic-induced release of inflammatory mediators including tumor necrosis factor alpha, interleukin-6, and nitric oxide and also improved the survival of the mice.	cap18106-137	16-28	interleukin 6	Mus musculus	184-197
9835525-9	1998	The addition of CAP18106-137 to aztreonam along with the bacteria did decrease the level of antibiotic-induced release of inflammatory mediators including tumor necrosis factor alpha, interleukin-6, and nitric oxide and also improved the survival of the mice.	Aztreonam	32-41	interleukin 6	Mus musculus	184-197
9870868-6	1998	RESULTS: In mice with CIA, excess production of IL-6 in sera was observed within 24 hours after the first CII immunization, and then rapidly decreased.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	106-109	interleukin 6	Mus musculus	48-52
9870868-11	1998	CONCLUSION: IL-6 produced after CII immunization appears to play an essential role in the immunity to CII, and anti-IL-6R antibody reduces the development of CIA by suppressing IL-6 signal transduction.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	32-35	interleukin 6	Mus musculus	12-16
9870868-11	1998	CONCLUSION: IL-6 produced after CII immunization appears to play an essential role in the immunity to CII, and anti-IL-6R antibody reduces the development of CIA by suppressing IL-6 signal transduction.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	102-105	interleukin 6	Mus musculus	12-16
10068056-0	1998	Increased sensitivity of IL-6-deficient mice to carbon tetrachloride hepatotoxicity and protection with an IL-6 receptor-IL-6 chimera.	Carbon Tetrachloride	48-68	interleukin 6	Mus musculus	25-29
10068056-1	1998	Interleukin-6 (IL-6)-deficient mice were found to be much more sensitive to liver injury by carbon tetrachloride (CCl4) than mice with an intact IL-6 system.	Carbon Tetrachloride	92-112	interleukin 6	Mus musculus	0-13
9862355-0	1998	Production of reactive oxygen intermediates following CD40 ligation correlates with c-Jun N-terminal kinase activation and IL-6 secretion in murine B lymphocytes.	reactive oxygen	14-29	interleukin 6	Mus musculus	123-127
10068056-1	1998	Interleukin-6 (IL-6)-deficient mice were found to be much more sensitive to liver injury by carbon tetrachloride (CCl4) than mice with an intact IL-6 system.	Carbon Tetrachloride	92-112	interleukin 6	Mus musculus	15-19
9862355-5	1998	Blocking ROI production by preincubation with the antioxidant N-acetyl-L-cysteine inhibits JNK activation, NF-kappaB-driven luciferase activity, and IL-6 secretion following CD40 ligation, suggesting a role for ROI in CD40-mediated signaling events.	Acetylcysteine	62-81	interleukin 6	Mus musculus	149-153
9820483-3	1998	SCF/IL-6/IL-10 transiently elicited a cell subpopulation with the phenotype (c-kit(high)Thy-1(low)) of fetal blood promastocytes at 3 wk of culture that progressed within 1 wk to FcepsilonRI-bearing PrMC, designated PrMCTriad.	prmc	199-203	interleukin 6	Mus musculus	4-8
9845374-3	1998	An additional increase of Meg colonies by KT6352 was observed in the serum-free culture containing rmIL-3 plus recombinant mouse interleukin-6 or rmIL-3 plus recombinant mouse stem cell factor.	KT-6352	42-48	interleukin 6	Mus musculus	129-142
9804916-1	1998	Interleukin (IL)-1, IL-2 and IL-6 influence central monoamine activity in a cytokine-specific manner.	monoamine	52-61	interleukin 6	Mus musculus	29-33
9850153-0	1998	Glucocorticoids protect against suppression of T cell responses in a murine model of acute ethanol exposure and thermal injury by regulating IL-6.	Ethanol	91-98	interleukin 6	Mus musculus	141-145
11904059-5	1998	RESULTS: The production and secretion of interleukin 1 (IL-1), interleukin 6 (IL-6), tumor necrosis factor (TNF) and prostaglandin E-2 (PGE-2) could be abrogated after macrophages were treated with 25 &mgr;g/mL mitomycin-C for 30 minutes.	Adenosine Monophosphate	202-205	interleukin 6	Mus musculus	63-76
11904059-5	1998	RESULTS: The production and secretion of interleukin 1 (IL-1), interleukin 6 (IL-6), tumor necrosis factor (TNF) and prostaglandin E-2 (PGE-2) could be abrogated after macrophages were treated with 25 &mgr;g/mL mitomycin-C for 30 minutes.	Mitomycin	215-226	interleukin 6	Mus musculus	63-76
9766520-0	1998	Differential kinetics for induction of interleukin-6 mRNA expression in murine peritoneal macrophages: evidence for calcium-dependent and independent-signalling pathways.	Calcium	116-123	interleukin 6	Mus musculus	39-52
9784546-7	1998	In D-galactosamine-sensitized mice, however, thioglycolate treatment significantly decreased mortality due to LPS, as well as levels of circulating TNF-alpha and IL-6.	Thioglycolates	45-58	interleukin 6	Mus musculus	162-166
9766520-6	1998	In contrast, experiments using either thapsigargin or PAF showed rapid and dramatic elevations in [Ca2+]i with marked increases in IL-6 mRNA expression, as quickly as 15 min after initial exposure.	Thapsigargin	38-50	interleukin 6	Mus musculus	131-135
9766520-6	1998	In contrast, experiments using either thapsigargin or PAF showed rapid and dramatic elevations in [Ca2+]i with marked increases in IL-6 mRNA expression, as quickly as 15 min after initial exposure.	Platelet Activating Factor	54-57	interleukin 6	Mus musculus	131-135
9766520-7	1998	Elevations in mRNA encoding IL-6 by thapsigargin and PAF were found to occur in a dose-dependent manner, mirroring their ability to elicit elevations in [Ca2+]i.	Thapsigargin	36-48	interleukin 6	Mus musculus	28-32
9766520-7	1998	Elevations in mRNA encoding IL-6 by thapsigargin and PAF were found to occur in a dose-dependent manner, mirroring their ability to elicit elevations in [Ca2+]i.	Platelet Activating Factor	53-56	interleukin 6	Mus musculus	28-32
9766634-0	1998	TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury.	Bleomycin	46-55	interleukin 6	Mus musculus	8-12
9780270-3	1998	In contrast, cortisone-treated animals had, first, an altered clearance of conidia and delayed cytokine production and inflammatory cell recruitment; second, an invasive process in lungs, recruitment of PMNL, and release of IL-6 and IL-1beta; and third, widespread tissue necrosis, sustained release of IL-6 and IL-1beta, further increases in PMNL trafficking but no monocyte recruitment, respiratory failure, and 100% mortality within 5 days.	Cortisone	13-22	interleukin 6	Mus musculus	224-228
9780270-3	1998	In contrast, cortisone-treated animals had, first, an altered clearance of conidia and delayed cytokine production and inflammatory cell recruitment; second, an invasive process in lungs, recruitment of PMNL, and release of IL-6 and IL-1beta; and third, widespread tissue necrosis, sustained release of IL-6 and IL-1beta, further increases in PMNL trafficking but no monocyte recruitment, respiratory failure, and 100% mortality within 5 days.	Cortisone	13-22	interleukin 6	Mus musculus	303-307
9756751-7	1998	CEF totally abrogated the pneumococcus-induced tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) secretion in bronchoalveolar lavage fluid.	cefodizime	0-3	interleukin 6	Mus musculus	91-104
9756751-7	1998	CEF totally abrogated the pneumococcus-induced tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) secretion in bronchoalveolar lavage fluid.	cefodizime	0-3	interleukin 6	Mus musculus	106-110
9763144-4	1998	PMA pretreatment of calvariae greatly blocked IL-6 mRNA induction by a subsequent dose of PMA and decreased induction by PTH and forskolin to a much lesser extent.	Tetradecanoylphorbol Acetate	0-3	interleukin 6	Mus musculus	46-50
9763144-9	1998	These data support the conclusion that PTH transcriptionally induces IL-6 gene expression in murine calvarial organ cultures mainly through the cAMP-PKA signaling pathway.	Cyclic AMP	144-148	interleukin 6	Mus musculus	69-73
9762014-3	1998	Both the anti-IL-6-antibody- and control-antibody-pretreated mice showed the same extent of plasma ACTH and corticosterone increases during stress, and no significant difference was found between the two groups of animals.	Corticosterone	108-122	interleukin 6	Mus musculus	14-18
9824538-4	1998	Moreover, EF cells maintained with IL-6/sIL-6R in the presence of ascorbic acid and beta-glycerophosphate expressed osteocalcin messenger RNA (mRNA) by 2 weeks and formed a matrix containing mineralized collagen fibers by 3 weeks.	Ascorbic Acid	66-79	interleukin 6	Mus musculus	35-39
9824538-4	1998	Moreover, EF cells maintained with IL-6/sIL-6R in the presence of ascorbic acid and beta-glycerophosphate expressed osteocalcin messenger RNA (mRNA) by 2 weeks and formed a matrix containing mineralized collagen fibers by 3 weeks.	beta-glycerophosphoric acid	84-105	interleukin 6	Mus musculus	35-39
23604378-7	1998	CR decreases the Sjogren"s syndrome-like chronic inflammation of salivary glands of B/W animals while increasing expression of the immunosuppressive cytokine TGFbeta1 and decreasing expression of the pro-inflammatory cytokines IL-6 and TNFalpha.	Chromium	0-2	interleukin 6	Mus musculus	227-231
9759847-0	1998	Neonatal murine B lymphocytes respond to polysaccharide antigens in the presence of IL-1 and IL-6.	Polysaccharides	41-55	interleukin 6	Mus musculus	93-97
9766634-9	1998	Based on the data presented here, we propose that TNF and IL-6 are part of a cytokine network that modulates MIP-1alpha protein expression in the profibrotic inflammatory lesion during the response to intratracheal bleomycin challenge.	Bleomycin	215-224	interleukin 6	Mus musculus	58-62
9766634-4	1998	In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice.	Bleomycin	194-203	interleukin 6	Mus musculus	105-118
9766634-4	1998	In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice.	Bleomycin	194-203	interleukin 6	Mus musculus	120-124
9766634-5	1998	Elevated levels of bioactive TNF and IL-6 were detected in bronchoalveolar lavage (BAL) fluid and lung homogenates from bleomycin-treated CBA/J mice at time points post-bleomycin challenge, which precede MIP-1alpha protein expression.	Bleomycin	120-129	interleukin 6	Mus musculus	37-41
9765333-5	1998	In the restraint-stressed animals, muscimol and baclofen inhibited the stress-induced plasma IL-6 levels from the dose of 50 and 15 ng, respectively.	Muscimol	35-43	interleukin 6	Mus musculus	93-97
9766634-5	1998	Elevated levels of bioactive TNF and IL-6 were detected in bronchoalveolar lavage (BAL) fluid and lung homogenates from bleomycin-treated CBA/J mice at time points post-bleomycin challenge, which precede MIP-1alpha protein expression.	Bleomycin	169-178	interleukin 6	Mus musculus	37-41
9765333-5	1998	In the restraint-stressed animals, muscimol and baclofen inhibited the stress-induced plasma IL-6 levels from the dose of 50 and 15 ng, respectively.	Baclofen	48-56	interleukin 6	Mus musculus	93-97
9766634-6	1998	Treatment of bleomycin-challenged mice with soluble TNF receptor (sTNFr) or anti-IL-6 antibodies significantly decreased MIP-1alpha protein expression in the lungs.	Bleomycin	13-22	interleukin 6	Mus musculus	81-85
9761131-4	1998	In vivo exposure to propanil caused the reduction of interleukin (IL)-2, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon (IFN)-gamma production in concanavalin A-stimulated spleen cell cultures established 2 d after exposure.	Propanil	20-28	interleukin 6	Mus musculus	73-77
9844399-8	1998	2) In an effort to analyse the immunological changes induced by the administration of Procainamide, there observed the expression of Th1-derived cytokines mRNA such as IFN-gamma, IL-2 and tumour necrosis factor-beta, and except for interleukin (IL)-10, there also observed the disappearance of Th2-derived cytokines mRNA such as IL-4, IL-5 and IL-6 in the murine spleen.	Procainamide	86-98	interleukin 6	Mus musculus	344-348
9826123-0	1998	Effects of fibroblast-mediated interleukin 3 and interleukin 6 gene therapy on hematopoiesis in mice treated with 5-fluorouracil.	Fluorouracil	114-128	interleukin 6	Mus musculus	49-62
9761131-6	1998	Continuous in vitro treatment of normal spleen cells with propanil decreased IL-2, IL-6, GM-CSF, and IFN-gamma production after concanavalin A activation.	Propanil	58-66	interleukin 6	Mus musculus	83-87
9761131-7	1998	Pulsing normal spleen cell cultures with propanil for up to 8 h before T-cell activation resulted in reduced IL-6 but not IL-2 or IFN-gamma production.	Propanil	41-49	interleukin 6	Mus musculus	109-113
9706871-0	1998	Sphingosine modulates interleukin-6 synthesis in osteoblasts.	Sphingosine	0-11	interleukin 6	Mus musculus	22-35
9917862-2	1998	Previous data support the hypothesis that during inflammation, interleukin (IL)-1 beta and IL-6 are involved in fever, in activation of the hypothalamic-pituitary-adrenal (HPA) axis, and in the induction of eicosanoids.	Eicosanoids	207-218	interleukin 6	Mus musculus	91-95
9917862-3	1998	Most of the pathophysiologic effects of IL-1 beta and Il-6 are mediated by prostaglandins (PGs), modulated by other cytokines, and antagonized by glucocorticoids (GC), a final product of the HPA axis.	Prostaglandins	75-89	interleukin 6	Mus musculus	54-58
9917862-3	1998	Most of the pathophysiologic effects of IL-1 beta and Il-6 are mediated by prostaglandins (PGs), modulated by other cytokines, and antagonized by glucocorticoids (GC), a final product of the HPA axis.	Prostaglandins	91-94	interleukin 6	Mus musculus	54-58
9730900-0	1998	Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus.	pristane	113-121	interleukin 6	Mus musculus	0-13
9730900-3	1998	The goal of this study was to evaluate the role of IL-6 in autoantibody production in pristane-induced lupus.	pristane	86-94	interleukin 6	Mus musculus	51-55
9730900-5	1998	Pristane induced high levels of immunoglobulin (Ig)G anti-single-stranded DNA, -double-stranded (ds)DNA, and -chromatin antibodies in IL-6(+/+), but not IL-6(-/-) mice by enzyme-linked immunosorbent assay.	pristane	0-8	interleukin 6	Mus musculus	134-138
9730900-10	1998	These results suggest that IgG anti-DNA and chromatin antibodies in pristane-treated mice are strictly IL-6 dependent, whereas induction of anti-nRNP/Sm and Su autoantibodies is IL-6 independent.	pristane	68-76	interleukin 6	Mus musculus	103-107
9786512-12	1998	We observed that IB-MECA (1-300 microM) inhibited, in a dose-dependent manner, the production of IL-12, IL-6, and, to a lesser extent, nitric oxide in the immunostimulated cultured macrophages.	N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine	17-24	interleukin 6	Mus musculus	104-108
9917862-9	1998	IL-1 beta KO mice showed deficiency in IL-6 following turpentine, but not LPS, injection.	Turpentine	54-64	interleukin 6	Mus musculus	39-43
9917863-1	1998	Bacterial lipopolypolysaccharide (LPS)-induced fever involves induction of the proinflammatory cytokines interleukin (IL)-1 alpha, IL-1 beta, tumor necrosis factor-alpha (TNF-alpha), and IL-6, both in the periphery and in the brain.	lipopolypolysaccharide	10-32	interleukin 6	Mus musculus	187-191
9743240-0	1998	Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17beta-estradiol.	Estradiol	97-113	interleukin 6	Mus musculus	14-27
9706871-3	1998	In the present study, among sphingomyelin metabolites, we examined the effect of sphingosine on IL-6 synthesis induced by various agonists in MC3T3-E1 cells.	Sphingosine	81-92	interleukin 6	Mus musculus	96-100
9706871-4	1998	Sphingosine inhibited the IL-6 synthesis induced by PGF2alpha or 12-O-tetradecanoylphorbol-13-acetate, an activator of PKC.	Sphingosine	0-11	interleukin 6	Mus musculus	26-30
9706871-4	1998	Sphingosine inhibited the IL-6 synthesis induced by PGF2alpha or 12-O-tetradecanoylphorbol-13-acetate, an activator of PKC.	Dinoprost	52-61	interleukin 6	Mus musculus	26-30
9706871-4	1998	Sphingosine inhibited the IL-6 synthesis induced by PGF2alpha or 12-O-tetradecanoylphorbol-13-acetate, an activator of PKC.	Tetradecanoylphorbol Acetate	65-101	interleukin 6	Mus musculus	26-30
9706871-5	1998	Sphingosine suppressed the PGE1-induced IL-6 synthesis.	Sphingosine	0-11	interleukin 6	Mus musculus	40-44
9706871-5	1998	Sphingosine suppressed the PGE1-induced IL-6 synthesis.	Alprostadil	27-31	interleukin 6	Mus musculus	40-44
9706871-6	1998	The IL-6 synthesis induced by cholera toxin, forskolin, or dibutyryl cAMP was inhibited by sphingosine.	Colforsin	45-54	interleukin 6	Mus musculus	4-8
9706871-6	1998	The IL-6 synthesis induced by cholera toxin, forskolin, or dibutyryl cAMP was inhibited by sphingosine.	Bucladesine	59-73	interleukin 6	Mus musculus	4-8
9706871-6	1998	The IL-6 synthesis induced by cholera toxin, forskolin, or dibutyryl cAMP was inhibited by sphingosine.	Sphingosine	91-102	interleukin 6	Mus musculus	4-8
9706871-1	1998	We previously reported that prostaglandin (PG)E1 and PGF2alpha induce the synthesis of interleukin-6 (IL-6) via activation of protein kinase (PK)A and PKC, respectively, in osteoblast-like MC3T3-E1 cells.	Alprostadil	28-48	interleukin 6	Mus musculus	87-100
9706871-7	1998	Sphingosine inhibited the IL-6 synthesis induced by bFGF or A23187.	Sphingosine	0-11	interleukin 6	Mus musculus	26-30
9706871-7	1998	Sphingosine inhibited the IL-6 synthesis induced by bFGF or A23187.	Calcimycin	60-66	interleukin 6	Mus musculus	26-30
9706871-1	1998	We previously reported that prostaglandin (PG)E1 and PGF2alpha induce the synthesis of interleukin-6 (IL-6) via activation of protein kinase (PK)A and PKC, respectively, in osteoblast-like MC3T3-E1 cells.	Alprostadil	28-48	interleukin 6	Mus musculus	102-106
9706871-9	1998	On the contrary, sphingosine enhanced the TNF-induced IL-6 synthesis.	Sphingosine	17-28	interleukin 6	Mus musculus	54-58
9706871-1	1998	We previously reported that prostaglandin (PG)E1 and PGF2alpha induce the synthesis of interleukin-6 (IL-6) via activation of protein kinase (PK)A and PKC, respectively, in osteoblast-like MC3T3-E1 cells.	Dinoprost	53-62	interleukin 6	Mus musculus	87-100
9706871-11	1998	These results indicate that sphingosine modulates the IL-6 synthesis stimulated by various agonists in osteoblasts.	Sphingosine	28-39	interleukin 6	Mus musculus	54-58
9706871-1	1998	We previously reported that prostaglandin (PG)E1 and PGF2alpha induce the synthesis of interleukin-6 (IL-6) via activation of protein kinase (PK)A and PKC, respectively, in osteoblast-like MC3T3-E1 cells.	Dinoprost	53-62	interleukin 6	Mus musculus	102-106
9743211-0	1998	Prostaglandin-independent stimulation of interleukin-6 production by fibrinogen degradation product D in perfused murine liver.	Prostaglandins	0-13	interleukin 6	Mus musculus	41-54
9743211-2	1998	The aim of the present study was to compare the role of prostaglandins in the enhancement of IL-6 production by LPS or FDP-D in perfused mouse livers.	Prostaglandins	56-70	interleukin 6	Mus musculus	93-97
9721981-0	1998	Acute ethanol exposure prior to thermal injury results in decreased T-cell responses mediated in part by increased production of IL-6.	Ethanol	6-13	interleukin 6	Mus musculus	129-133
9738948-0	1998	The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler"s murine encephalomyelitis virus by a receptor-mediated pathway.	Cannabinoids	15-26	interleukin 6	Mus musculus	50-63
9738948-0	1998	The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler"s murine encephalomyelitis virus by a receptor-mediated pathway.	anandamide	27-37	interleukin 6	Mus musculus	50-63
9738948-4	1998	In this study we investigated whether anandamide can modify interleukin-6 production by primary cultures of murine brain cortical astrocytes infected with TMEV.	anandamide	38-48	interleukin 6	Mus musculus	60-73
9712916-17	1998	Treatment of the NIH 3T3 cells with specific cytokines (i.e. interleukin-6) and other agonists (i.e. lipopolysaccharide) caused a substantially increased level of 125I-UG binding but the same cells, when treated with platelet-derived growth factor, tumor necrosis factor-alpha, interferon-gamma, and phorbol 12-myristate 13-acetate, did not alter the UG binding.	Tetradecanoylphorbol Acetate	300-331	interleukin 6	Mus musculus	61-74
9715255-5	1998	Maximum ear swelling induced by anthralin coincided with the elevation of cytokine mRNA expression in the skin, including interleukin-6, granulocyte-macrophage colony-stimulating factor, macrophage inflammatory protein-2, and tumor necrosis factor alpha at 24 h post challenge.	Anthralin	32-41	interleukin 6	Mus musculus	122-135
9721981-2	1998	Ethanol exposure and burn injury are independently known to result in elevated IL-6, a cytokine with potent immunosuppressive properties.	Ethanol	0-7	interleukin 6	Mus musculus	79-83
9721981-5	1998	In contrast, burn + ethanol treated mice showed a profound suppression of splenocyte proliferation (20% of control) and significantly elevated circulating IL-6 levels (738+/-218 pg/mL).	Ethanol	20-27	interleukin 6	Mus musculus	155-159
9721981-7	1998	Furthermore, IL-6 production was significantly elevated (p < .05) in splenic macrophage cultures from burn + ethanol mice (159+/-6 pg/mL) when compared with burn alone (109+/-10 pg/mL).	Ethanol	112-119	interleukin 6	Mus musculus	13-17
9721981-8	1998	Treatment of the splenocyte cultures from burn + ethanol mice with an anti-IL6 monoclonal antibody resulted in partial restoration of splenocyte proliferation.	Ethanol	49-56	interleukin 6	Mus musculus	75-78
9707511-10	1998	However, when VT-fed mice were also challenged with an oral dose of VT equivalent to daily intake at 2 h prior to RNA isolation, vigorous mRNA responses were observed for IL-1beta, IL-6, TNF-alpha, IL-12p40, IL-12p35, IL-2, IFN-gamma, IL-4, and IL-10.	deoxynivalenol	14-16	interleukin 6	Mus musculus	181-185
11819306-4	1998	The serum TBIL of mice and the degree of liver necrosis increased after injection of IL-1, IL-6 with D-GAL and rTNF-alpha.CONCLUSION: Cytokines, like IL-1, IL-6, IFN&agr and TNF-&agr;joined in the process of hepatocyte necrosis.They can enhance the degree of liver necrosis induced by D-GAL.	Bilirubin	10-14	interleukin 6	Mus musculus	91-95
11819306-4	1998	The serum TBIL of mice and the degree of liver necrosis increased after injection of IL-1, IL-6 with D-GAL and rTNF-alpha.CONCLUSION: Cytokines, like IL-1, IL-6, IFN&agr and TNF-&agr;joined in the process of hepatocyte necrosis.They can enhance the degree of liver necrosis induced by D-GAL.	Bilirubin	10-14	interleukin 6	Mus musculus	156-160
9761458-0	1998	Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism.	Tryptophan	64-74	interleukin 6	Mus musculus	6-19
9761458-0	1998	Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism.	Serotonin	79-88	interleukin 6	Mus musculus	6-19
9761458-2	1998	Intravenous (iv) or intraperitoneal (ip) injection of mIL-6 caused a rapid and short-lived activation of the hypothalamo-pituitary-adrenocortical (HPA) axis, as indicated by increases in plasma ACTH and corticosterone, with peak responses around 30-60 min.	Corticosterone	203-217	interleukin 6	Mus musculus	54-59
9761458-5	1998	However, tryptophan concentrations were elevated in most brain regions studied 1-2 h following iv mIL-6, and 2 h following ip mIL-6, significantly later than the peak HPA response.	Tryptophan	9-19	interleukin 6	Mus musculus	98-103
9761458-11	1998	Intracerebroventricular injection of mIL-6 also elevated tryptophan and 5-HIAA in the hypothalamus and brain stem.	Tryptophan	57-67	interleukin 6	Mus musculus	37-42
9761458-11	1998	Intracerebroventricular injection of mIL-6 also elevated tryptophan and 5-HIAA in the hypothalamus and brain stem.	Hydroxyindoleacetic Acid	72-78	interleukin 6	Mus musculus	37-42
9761458-15	1998	It is possible that the increases of tryptophan and serotonin metabolism may contribute to some of the biological effects of IL-6.	Tryptophan	37-47	interleukin 6	Mus musculus	125-129
9761458-15	1998	It is possible that the increases of tryptophan and serotonin metabolism may contribute to some of the biological effects of IL-6.	Serotonin	52-61	interleukin 6	Mus musculus	125-129
9721981-9	1998	Taken together, these data strongly suggest that the immune dysfunction observed in ethanol-exposed, thermally injured mice is mediated in part by elevated levels of IL-6.	Ethanol	84-91	interleukin 6	Mus musculus	166-170
9776476-5	1998	We found that TauCl, but not taurine alone, inhibited the production of NO, prostaglandin E2, interleukin-6 and tumor necrosis factor-alpha, in a dose-dependent manner.	N-chlorotaurine	14-19	interleukin 6	Mus musculus	94-139
9718206-10	1998	Interferon-gamma, interleukin-6 and colony stimulating factor concentrations in sera of indomethacin/beta-glucan-treated mice were significantly elevated.	Indomethacin	88-100	interleukin 6	Mus musculus	18-31
9718206-10	1998	Interferon-gamma, interleukin-6 and colony stimulating factor concentrations in sera of indomethacin/beta-glucan-treated mice were significantly elevated.	beta-Glucans	101-112	interleukin 6	Mus musculus	18-31
9730089-4	1998	The effect of DHEA paralleled a delay in the expression of IL-10 and IL-6 and an earlier detection of IL-12 transcripts.	Dehydroepiandrosterone	14-18	interleukin 6	Mus musculus	69-73
9678170-6	1998	IL-6 and, to a lesser extent, TNF-alpha production were also increased when the macrophages were costimulated with lipopolysaccharide and cells of the three groups of lactic acid bacteria.	Lactic Acid	167-178	interleukin 6	Mus musculus	0-4
9698211-4	1998	However, L-4-oxalysine functionally antagonized the alpha-fetoprotein-induced suppression of the mitogen- and one-way mixed lymphocyte culture-induced proliferation of spleen lymphocytes and interleukin-6 production by these cells in mice bearing the hepatoma-22 tumor.	4-oxalysine	9-22	interleukin 6	Mus musculus	191-204
9637509-5	1998	ELISA data confirmed the reduced levels of IL-1 and IL-6 at disease onset in GL3-treated animals, and pathologic analysis demonstrated a marked reduction in meningeal infiltrates at the same time point.	GL3	77-80	interleukin 6	Mus musculus	52-56
9637522-3	1998	IL-6 mRNA expression and the production of IL-6 were reduced drastically within the nonparenchymal liver cell population derived from mice rendered Kupffer cell depleted by pretreatment with liposome-encapsulated dichloromethylene diphosphonate.	Clodronic Acid	213-244	interleukin 6	Mus musculus	0-4
9637522-3	1998	IL-6 mRNA expression and the production of IL-6 were reduced drastically within the nonparenchymal liver cell population derived from mice rendered Kupffer cell depleted by pretreatment with liposome-encapsulated dichloromethylene diphosphonate.	Clodronic Acid	213-244	interleukin 6	Mus musculus	43-47
9632532-0	1998	Interleukin 6, but not ciliary neurotrophic factor or leukaemia inhibitory factor, is responsible for the acute phase response to turpentine-induced myositis.	Turpentine	130-140	interleukin 6	Mus musculus	0-13
10065113-7	1998	Furthermore, NP treatment stimulated the production of IL-6 and GM-CSF by stromal cells.	Neopterin	13-15	interleukin 6	Mus musculus	55-59
9632532-6	1998	The findings suggest that IL-6, but not other members of its superfamily, is primarily responsible for the hepatic acute phase response, and contributes to the anorexia, associated with turpentine-induced myositis.	Turpentine	186-196	interleukin 6	Mus musculus	26-30
9626133-2	1998	In these diseases or during aging, the decrease in production of sex hormones such as dehydroepiandrosterone (DHEA) is thought to play an important role in IL-6-mediated pathogenetic effects in mice.	Dehydroepiandrosterone	86-108	interleukin 6	Mus musculus	156-160
9626133-2	1998	In these diseases or during aging, the decrease in production of sex hormones such as dehydroepiandrosterone (DHEA) is thought to play an important role in IL-6-mediated pathogenetic effects in mice.	Dehydroepiandrosterone	110-114	interleukin 6	Mus musculus	156-160
9605127-7	1998	Like males, testosterone-treated CRPtg/IL-6-/- females expressed CRP constitutively, and their transgene responded to injection of IL-6.	Testosterone	12-24	interleukin 6	Mus musculus	39-43
9605127-7	1998	Like males, testosterone-treated CRPtg/IL-6-/- females expressed CRP constitutively, and their transgene responded to injection of IL-6.	Testosterone	12-24	interleukin 6	Mus musculus	131-135
9605127-10	1998	We conclude that in vivo, both constitutive and IL-6-dependent acute-phase expression of the CRP transgene require testosterone.	Testosterone	115-127	interleukin 6	Mus musculus	48-52
9605146-3	1998	Because of the putative role of IL-6 in facilitating HSV-1 reactivation in mice, the effect of hyperthermic stress and cyanoketone treatment on IL-6 expression in the trigeminal ganglion was also measured.	Cyanoketone	119-130	interleukin 6	Mus musculus	144-148
9657254-0	1998	Regulation of interleukin-6, and macrophage colony-stimulating factor mRNA levels by histamine in stromal cell line (MC3T3-G2/PA6).	Histamine	85-94	interleukin 6	Mus musculus	14-27
9581864-0	1998	Tiludronate inhibits interleukin-6 synthesis in osteoblasts: inhibition of phospholipase D activation in MC3T3-E1 cells.	tiludronic acid	0-11	interleukin 6	Mus musculus	21-34
9581864-1	1998	In previous studies, we have reported that PGF2alpha stimulates phosphoinositide hydrolysis by phospholipase C and phosphatidylcholine hydrolysis by phospholipase D through heterotrimeric GTP-binding protein in osteoblast-like MC3T3-E1 cells, and that PGF2alpha and PGE1 induce interleukin-6 (IL-6) synthesis via activation of protein kinase C and protein kinase A, respectively.	Dinoprost	43-52	interleukin 6	Mus musculus	278-291
9581864-1	1998	In previous studies, we have reported that PGF2alpha stimulates phosphoinositide hydrolysis by phospholipase C and phosphatidylcholine hydrolysis by phospholipase D through heterotrimeric GTP-binding protein in osteoblast-like MC3T3-E1 cells, and that PGF2alpha and PGE1 induce interleukin-6 (IL-6) synthesis via activation of protein kinase C and protein kinase A, respectively.	Dinoprost	43-52	interleukin 6	Mus musculus	293-297
9581864-1	1998	In previous studies, we have reported that PGF2alpha stimulates phosphoinositide hydrolysis by phospholipase C and phosphatidylcholine hydrolysis by phospholipase D through heterotrimeric GTP-binding protein in osteoblast-like MC3T3-E1 cells, and that PGF2alpha and PGE1 induce interleukin-6 (IL-6) synthesis via activation of protein kinase C and protein kinase A, respectively.	Phosphatidylcholines	115-134	interleukin 6	Mus musculus	278-291
9581864-1	1998	In previous studies, we have reported that PGF2alpha stimulates phosphoinositide hydrolysis by phospholipase C and phosphatidylcholine hydrolysis by phospholipase D through heterotrimeric GTP-binding protein in osteoblast-like MC3T3-E1 cells, and that PGF2alpha and PGE1 induce interleukin-6 (IL-6) synthesis via activation of protein kinase C and protein kinase A, respectively.	Phosphatidylcholines	115-134	interleukin 6	Mus musculus	293-297
9581864-1	1998	In previous studies, we have reported that PGF2alpha stimulates phosphoinositide hydrolysis by phospholipase C and phosphatidylcholine hydrolysis by phospholipase D through heterotrimeric GTP-binding protein in osteoblast-like MC3T3-E1 cells, and that PGF2alpha and PGE1 induce interleukin-6 (IL-6) synthesis via activation of protein kinase C and protein kinase A, respectively.	Guanosine Triphosphate	188-191	interleukin 6	Mus musculus	278-291
9581864-1	1998	In previous studies, we have reported that PGF2alpha stimulates phosphoinositide hydrolysis by phospholipase C and phosphatidylcholine hydrolysis by phospholipase D through heterotrimeric GTP-binding protein in osteoblast-like MC3T3-E1 cells, and that PGF2alpha and PGE1 induce interleukin-6 (IL-6) synthesis via activation of protein kinase C and protein kinase A, respectively.	Guanosine Triphosphate	188-191	interleukin 6	Mus musculus	293-297
9581864-3	1998	Tiludronate significantly suppressed the PGF2alpha-induced IL-6 secretion in a dose-dependent manner in the range between 0.1 and 30 microM.	tiludronic acid	0-11	interleukin 6	Mus musculus	59-63
9581864-3	1998	Tiludronate significantly suppressed the PGF2alpha-induced IL-6 secretion in a dose-dependent manner in the range between 0.1 and 30 microM.	Dinoprost	41-50	interleukin 6	Mus musculus	59-63
9581864-4	1998	However, the IL-6 secretion induced by PGE1 or (Bu)2cAMP was hardly affected by tiludronate.	Alprostadil	39-43	interleukin 6	Mus musculus	13-17
9581864-4	1998	However, the IL-6 secretion induced by PGE1 or (Bu)2cAMP was hardly affected by tiludronate.	(bu)2camp	47-56	interleukin 6	Mus musculus	13-17
9576761-2	1998	We studied whether after Con A-induced liver injury, TNF- and IL-6-dependent signaling pathways known to be related to hepatocyte proliferation are activated.	con	25-28	interleukin 6	Mus musculus	62-66
9653168-4	1998	Safranin O staining demonstrated that articular cartilage was well preserved in IL-6 -/- mice, whereas it was destroyed completely in IL-6 +/+ mice.	phenosafranine	0-10	interleukin 6	Mus musculus	80-84
9657254-1	1998	OBJECTIVE: The aim of this study was to examine the role of histamine in regulation of IL-6 and M-CSF gene expression in bone marrow stromal cells.	Histamine	60-69	interleukin 6	Mus musculus	87-91
9657254-4	1998	RESULTS: Histamine caused a distinct accumulation of IL-6 mRNA in the cells, whereas it decreased M-CSF transcripts.	Histamine	9-18	interleukin 6	Mus musculus	53-57
9657254-5	1998	Both pyridylethylamine, a H1 agonist, and dimaprit, a H2 agonist, caused a large increase in the level of IL-6 mRNA in PA6 cells.	2-(2-aminoethyl)pyridine	5-22	interleukin 6	Mus musculus	106-110
9657254-6	1998	The histamine-induced expression of IL-6 mRNA was associated with enhanced secretion of IL-6, as determined by ELISA.	Histamine	4-13	interleukin 6	Mus musculus	36-40
9657254-6	1998	The histamine-induced expression of IL-6 mRNA was associated with enhanced secretion of IL-6, as determined by ELISA.	Histamine	4-13	interleukin 6	Mus musculus	88-92
9657254-7	1998	CONCLUSIONS: These results, together with the results of our previous studies, suggest that histamine produced by stromal macrophages differentially regulates the production of IL-6 and M-CSF in other kinds of stromal cells and hence promotes differentiation and/or proliferation of hematopoietic progenitor cells.	Histamine	92-101	interleukin 6	Mus musculus	177-181
9580629-3	1998	Inhibition of PC-PLC by the specific inhibitor tricyclodecan-9-yl-xanthogenate (D609) before LPS reduced the release of interleukin-1 beta, interleukin-6 and nitric oxide (NO) in vivo.	tricyclodecan-9-yl-xanthogenate	47-78	interleukin 6	Mus musculus	140-153
12016997-0	1998	[Effects of leukotrienes on production of interleukin 6 from mouse peritoneal macrophages].	Leukotrienes	12-24	interleukin 6	Mus musculus	42-55
9580629-3	1998	Inhibition of PC-PLC by the specific inhibitor tricyclodecan-9-yl-xanthogenate (D609) before LPS reduced the release of interleukin-1 beta, interleukin-6 and nitric oxide (NO) in vivo.	tricyclodecane-9-yl-xanthogenate	80-84	interleukin 6	Mus musculus	140-153
9572155-7	1998	DHEA, MLT, and DHEA + MLT help to regulate immune function in aged female C57BL/6 mice by significantly (P < 0.05) increasing Th1 cytokines, IL-2, and IFN-gamma or significantly (P < 0.05) decreasing Th2 cytokines, IL-6, and IL-10, thus regulating cytokine production.	Dehydroepiandrosterone	0-4	interleukin 6	Mus musculus	221-225
9572155-7	1998	DHEA, MLT, and DHEA + MLT help to regulate immune function in aged female C57BL/6 mice by significantly (P < 0.05) increasing Th1 cytokines, IL-2, and IFN-gamma or significantly (P < 0.05) decreasing Th2 cytokines, IL-6, and IL-10, thus regulating cytokine production.	Dehydroepiandrosterone	15-19	interleukin 6	Mus musculus	221-225
9575962-2	1998	This study extends observations that demonstrated neuronal modulation of spontaneous interleukin-6 (IL-6) secretion in the spleen by norepinephrine (NE) and beta-endorphin.	Norepinephrine	133-147	interleukin 6	Mus musculus	85-98
9575962-2	1998	This study extends observations that demonstrated neuronal modulation of spontaneous interleukin-6 (IL-6) secretion in the spleen by norepinephrine (NE) and beta-endorphin.	Norepinephrine	133-147	interleukin 6	Mus musculus	100-104
9575962-3	1998	Spontaneous IL-6 secretion in vivo was markedly reduced by removal of macrophages with the clodronate technique.	Clodronic Acid	91-101	interleukin 6	Mus musculus	12-16
9575962-5	1998	In the presence of 10(-7) M cortisol, addition of norepinephrine (NE; 10(-5) M) and isoproterenol (10(-6) and 10(-5) M) significantly increased spontaneous IL-6 secretion (+20%; P = 0.0280, P = 0.0005, and P = 0.0050, respectively).	Hydrocortisone	28-36	interleukin 6	Mus musculus	156-160
9575962-5	1998	In the presence of 10(-7) M cortisol, addition of norepinephrine (NE; 10(-5) M) and isoproterenol (10(-6) and 10(-5) M) significantly increased spontaneous IL-6 secretion (+20%; P = 0.0280, P = 0.0005, and P = 0.0050, respectively).	Norepinephrine	50-64	interleukin 6	Mus musculus	156-160
9575962-5	1998	In the presence of 10(-7) M cortisol, addition of norepinephrine (NE; 10(-5) M) and isoproterenol (10(-6) and 10(-5) M) significantly increased spontaneous IL-6 secretion (+20%; P = 0.0280, P = 0.0005, and P = 0.0050, respectively).	Isoproterenol	84-97	interleukin 6	Mus musculus	156-160
9575962-6	1998	In contrast, addition of beta-endorphin significantly inhibited spontaneous IL-6 secretion in the presence of 10(-7) M cortisol (-40%; 10(-11) M, P = 0.0410; 10(-10) M, P = 0.0005).	Hydrocortisone	119-127	interleukin 6	Mus musculus	76-80
9556133-0	1998	Interaction of triiodothyronine with 1alpha,25-dihydroxyvitamin D3 on interleukin-6-dependent osteoclast-like cell formation in mouse bone marrow cell cultures.	Triiodothyronine	15-31	interleukin 6	Mus musculus	70-83
9556133-0	1998	Interaction of triiodothyronine with 1alpha,25-dihydroxyvitamin D3 on interleukin-6-dependent osteoclast-like cell formation in mouse bone marrow cell cultures.	Calcitriol	37-66	interleukin 6	Mus musculus	70-83
9556133-5	1998	Basal interleukin-6 (IL-6) production by cultured marrow cells was significantly stimulated by 1alpha,25(OH)2D3.	1alpha	95-101	interleukin 6	Mus musculus	6-19
9556133-5	1998	Basal interleukin-6 (IL-6) production by cultured marrow cells was significantly stimulated by 1alpha,25(OH)2D3.	1alpha	95-101	interleukin 6	Mus musculus	21-25
9556133-5	1998	Basal interleukin-6 (IL-6) production by cultured marrow cells was significantly stimulated by 1alpha,25(OH)2D3.	(oh)2d3	104-111	interleukin 6	Mus musculus	6-19
9556133-5	1998	Basal interleukin-6 (IL-6) production by cultured marrow cells was significantly stimulated by 1alpha,25(OH)2D3.	(oh)2d3	104-111	interleukin 6	Mus musculus	21-25
9556133-8	1998	Nevertheless, the stimulatory effect of 1alpha,25(OH)2D3 on osteoclastogenesis was partially dependent on IL-6 because it could be significantly blocked by a neutralizing monoclonal anti-IL-6 antibody, and to the same extent by a monoclonal anti-IL-6 receptor antibody.	25(oh)2d3	47-56	interleukin 6	Mus musculus	106-110
9556133-8	1998	Nevertheless, the stimulatory effect of 1alpha,25(OH)2D3 on osteoclastogenesis was partially dependent on IL-6 because it could be significantly blocked by a neutralizing monoclonal anti-IL-6 antibody, and to the same extent by a monoclonal anti-IL-6 receptor antibody.	25(oh)2d3	47-56	interleukin 6	Mus musculus	187-191
9556133-8	1998	Nevertheless, the stimulatory effect of 1alpha,25(OH)2D3 on osteoclastogenesis was partially dependent on IL-6 because it could be significantly blocked by a neutralizing monoclonal anti-IL-6 antibody, and to the same extent by a monoclonal anti-IL-6 receptor antibody.	25(oh)2d3	47-56	interleukin 6	Mus musculus	187-191
9556133-10	1998	Our data provide evidence that 1alpha,25(OH)2D3 induces osteoclast-like cell formation, at least in part, in an IL-6-dependent mode of action, which is also subject to modulation by T3.	25(oh)2d3	38-47	interleukin 6	Mus musculus	112-116
9556135-0	1998	Interleukin-6 synthesis induced by prostaglandin E2: cross-talk regulation by protein kinase C. We previously showed that prostaglandin E2 (PGE2) stimulates multiple intracellular signaling pathways as follows: by activation of adenylate cyclase; phosphoinositide (PI)-hydrolyzing phospholipase C and phosphatidylcholine (PC)-hydrolyzing phospholipase D; and by induction of Ca2+ influx in osteoblast-like MC3T3-E1 cells.	Dinoprostone	35-51	interleukin 6	Mus musculus	0-13
9556135-0	1998	Interleukin-6 synthesis induced by prostaglandin E2: cross-talk regulation by protein kinase C. We previously showed that prostaglandin E2 (PGE2) stimulates multiple intracellular signaling pathways as follows: by activation of adenylate cyclase; phosphoinositide (PI)-hydrolyzing phospholipase C and phosphatidylcholine (PC)-hydrolyzing phospholipase D; and by induction of Ca2+ influx in osteoblast-like MC3T3-E1 cells.	Dinoprostone	122-138	interleukin 6	Mus musculus	0-13
9556135-0	1998	Interleukin-6 synthesis induced by prostaglandin E2: cross-talk regulation by protein kinase C. We previously showed that prostaglandin E2 (PGE2) stimulates multiple intracellular signaling pathways as follows: by activation of adenylate cyclase; phosphoinositide (PI)-hydrolyzing phospholipase C and phosphatidylcholine (PC)-hydrolyzing phospholipase D; and by induction of Ca2+ influx in osteoblast-like MC3T3-E1 cells.	Dinoprostone	140-144	interleukin 6	Mus musculus	0-13
9556135-0	1998	Interleukin-6 synthesis induced by prostaglandin E2: cross-talk regulation by protein kinase C. We previously showed that prostaglandin E2 (PGE2) stimulates multiple intracellular signaling pathways as follows: by activation of adenylate cyclase; phosphoinositide (PI)-hydrolyzing phospholipase C and phosphatidylcholine (PC)-hydrolyzing phospholipase D; and by induction of Ca2+ influx in osteoblast-like MC3T3-E1 cells.	Phosphatidylinositols	247-263	interleukin 6	Mus musculus	0-13
9556135-0	1998	Interleukin-6 synthesis induced by prostaglandin E2: cross-talk regulation by protein kinase C. We previously showed that prostaglandin E2 (PGE2) stimulates multiple intracellular signaling pathways as follows: by activation of adenylate cyclase; phosphoinositide (PI)-hydrolyzing phospholipase C and phosphatidylcholine (PC)-hydrolyzing phospholipase D; and by induction of Ca2+ influx in osteoblast-like MC3T3-E1 cells.	Phosphatidylcholines	322-324	interleukin 6	Mus musculus	0-13
9556135-1	1998	In this study, we investigated the effect of PGE2 on the synthesis of interleukin-6 (IL-6) and its regulatory mechanism in MC3T3-E1 cells.	Dinoprostone	45-49	interleukin 6	Mus musculus	70-83
9556135-1	1998	In this study, we investigated the effect of PGE2 on the synthesis of interleukin-6 (IL-6) and its regulatory mechanism in MC3T3-E1 cells.	Dinoprostone	45-49	interleukin 6	Mus musculus	85-89
9556135-2	1998	PGE2 significantly stimulated IL-6 secretion in a dose-dependent manner in the range between 1 nmol/L and 10 micromol/L.	Dinoprostone	0-4	interleukin 6	Mus musculus	30-34
9556135-3	1998	A23187, a calcium ionophore, or dibutyryl-cAMP significantly induced IL-6 secretion.	Calcimycin	0-6	interleukin 6	Mus musculus	69-73
9568724-4	1998	To observe the protective effects of NIH3T3-IL-6 cells on hematopoietic depression in chemotherapy-treated mice, the mice were preinjected with 5-FU at a dosage of 150 mg/kg before implantation of NIH3T3-IL-6 cells.	Fluorouracil	144-148	interleukin 6	Mus musculus	44-48
9553966-0	1998	Lipopolysaccharide and interleukin-6 enhance lead entry into cerebellar neurons: application of a new and sensitive flow cytometric technique to measure intracellular lead and calcium concentrations.	Calcium	176-183	interleukin 6	Mus musculus	23-36
9553966-8	1998	While [Ca2+]i was not significantly increased in animals treated with either only LPS or IL-6, lead and calcium concentrations were increased in animals exposed to lead and LPS or IL-6 in both the non-swollen and swollen cells, with a mean value of (Pb2+)i of 32 pM and (Ca2+)i of 155 nM in cells not swollen.	Calcium	104-111	interleukin 6	Mus musculus	180-184
9516459-10	1998	SB203580, a highly specific p38 inhibitor, does not affect ICAM-1 and VCAM-1 expression, but strongly inhibits IL-6 production.	SB 203580	0-8	interleukin 6	Mus musculus	111-115
9515939-3	1998	Thus, the effects of Pb on the regulation of interleukin-6 (IL-6), a proinflammatory cytokine that shows high correlation with symptoms of endotoxic shock, and the levels of corticosterone, a hormone produced to prepare the body to cope with stress, upon lipopolysaccharide (LPS; endotoxin) administration were investigated.	Lead	21-23	interleukin 6	Mus musculus	45-58
9515939-3	1998	Thus, the effects of Pb on the regulation of interleukin-6 (IL-6), a proinflammatory cytokine that shows high correlation with symptoms of endotoxic shock, and the levels of corticosterone, a hormone produced to prepare the body to cope with stress, upon lipopolysaccharide (LPS; endotoxin) administration were investigated.	Lead	21-23	interleukin 6	Mus musculus	60-64
9515939-4	1998	After intravenous administration of LPS, the kinetics of IL-6 gene expression by Northern blot analysis revealed a rapid increase of IL-6 mRNA, which peaked by 2 h in the spleens and 3 h in the brains of B6C3F1 female mice, with or without Pb exposure.	Lead	240-242	interleukin 6	Mus musculus	57-61
9515939-4	1998	After intravenous administration of LPS, the kinetics of IL-6 gene expression by Northern blot analysis revealed a rapid increase of IL-6 mRNA, which peaked by 2 h in the spleens and 3 h in the brains of B6C3F1 female mice, with or without Pb exposure.	Lead	240-242	interleukin 6	Mus musculus	133-137
9515939-5	1998	Peak production of IL-6 protein after LPS challenge was observed at 2 h in the spleens and 3 h in the sera regardless of Pb-treatment.	Lead	121-123	interleukin 6	Mus musculus	19-23
9515939-6	1998	However, Pb-exposed mice showed an altered kinetic profile of IL-6 appearance in the brain, in that the levels of IL-6 in the brains peaked at 4 h rather than 3 h, the peak for the control mice.	Lead	9-11	interleukin 6	Mus musculus	62-66
9515939-6	1998	However, Pb-exposed mice showed an altered kinetic profile of IL-6 appearance in the brain, in that the levels of IL-6 in the brains peaked at 4 h rather than 3 h, the peak for the control mice.	Lead	9-11	interleukin 6	Mus musculus	114-118
9515939-7	1998	Moreover, at two time points, the amounts of IL-6 were found to be higher in the brains of Pb-treated mice.	Lead	91-93	interleukin 6	Mus musculus	45-49
9471985-10	1998	Epicutaneous exposure of C3H/HeN mice to oxazolone resulted in the induction of cutaneous IL-6 at levels similar to, or greater than, those observed after identical treatment of BALB/c strain mice.	Oxazolone	41-50	interleukin 6	Mus musculus	90-94
9501955-6	1998	Phorbol ester-stimulated IL-6 levels were also higher in supernatants from bone marrow and spleen cell cultures from orchiectomized mice compared with unoperated or sham-operated mice.	Phorbol Esters	0-13	interleukin 6	Mus musculus	25-29
9576067-9	1998	Exposure to oxazolone under the same conditions resulted in a more widespread and more persistent expression of epidermal mRNA for interleukin 6.	Oxazolone	12-21	interleukin 6	Mus musculus	131-144
9600219-0	1998	Abnormal iron deposition associated with lipid peroxidation in transgenic mice expressing interleukin-6 in the brain.	Iron	9-13	interleukin 6	Mus musculus	90-103
9600219-2	1998	Based on ultrastructural observations showing electron-dense pigment in the brain of the GFAP-IL6 mice, we hypothesized that iron metabolism was altered in the brains of these animals.	Iron	125-129	interleukin 6	Mus musculus	94-97
9600219-9	1998	These results suggest that the IL6-induced BBB defect precipitates iron accumulation in the GFAP-IL6 mouse brain and that subsequent IBP regulation mediates protective responses.	Iron	67-71	interleukin 6	Mus musculus	31-34
9600219-9	1998	These results suggest that the IL6-induced BBB defect precipitates iron accumulation in the GFAP-IL6 mouse brain and that subsequent IBP regulation mediates protective responses.	Iron	67-71	interleukin 6	Mus musculus	97-100
9600219-11	1998	This transgenic mouse model of IL6-mediated neurodegeneration provides a unique opportunity to examine several aspects of iron metabolism in the brain, including its entry at the site of the BBB, its distribution through the IBP, and its mechanisms of toxicity.	Iron	122-126	interleukin 6	Mus musculus	31-34
9610845-5	1998	These results indicate that retinoic acid inhibits IL-6 synthesis induced by prostaglandins in osteoblasts as follows: the inhibitory effect on the PGE1-induced IL-6 synthesis is exerted at a point downstream from cAMP, and the inhibitory effect on the PGF2alpha-induced IL-6 synthesis is exerted at a point downstream from protein kinase C.	Prostaglandins	77-91	interleukin 6	Mus musculus	51-55
9610845-5	1998	These results indicate that retinoic acid inhibits IL-6 synthesis induced by prostaglandins in osteoblasts as follows: the inhibitory effect on the PGE1-induced IL-6 synthesis is exerted at a point downstream from cAMP, and the inhibitory effect on the PGF2alpha-induced IL-6 synthesis is exerted at a point downstream from protein kinase C.	Alprostadil	148-152	interleukin 6	Mus musculus	51-55
9610845-5	1998	These results indicate that retinoic acid inhibits IL-6 synthesis induced by prostaglandins in osteoblasts as follows: the inhibitory effect on the PGE1-induced IL-6 synthesis is exerted at a point downstream from cAMP, and the inhibitory effect on the PGF2alpha-induced IL-6 synthesis is exerted at a point downstream from protein kinase C.	Alprostadil	148-152	interleukin 6	Mus musculus	161-165
9610845-5	1998	These results indicate that retinoic acid inhibits IL-6 synthesis induced by prostaglandins in osteoblasts as follows: the inhibitory effect on the PGE1-induced IL-6 synthesis is exerted at a point downstream from cAMP, and the inhibitory effect on the PGF2alpha-induced IL-6 synthesis is exerted at a point downstream from protein kinase C.	Alprostadil	148-152	interleukin 6	Mus musculus	161-165
9481485-4	1998	BQ123, a selective antagonist of endothelinA (ETA) receptor, inhibited the ET-1-induced IL-6 secretion.	cyclo(Trp-Asp-Pro-Val-Leu)	0-5	interleukin 6	Mus musculus	88-92
9481485-6	1998	12-O-Tetradecanoylphorbol-13-acetate (TPA), a PKC-activating phorbol ester, significantly stimulated IL-6 secretion.	Tetradecanoylphorbol Acetate	0-36	interleukin 6	Mus musculus	101-105
9481485-6	1998	12-O-Tetradecanoylphorbol-13-acetate (TPA), a PKC-activating phorbol ester, significantly stimulated IL-6 secretion.	Tetradecanoylphorbol Acetate	38-41	interleukin 6	Mus musculus	101-105
9481485-6	1998	12-O-Tetradecanoylphorbol-13-acetate (TPA), a PKC-activating phorbol ester, significantly stimulated IL-6 secretion.	Phorbol Esters	61-74	interleukin 6	Mus musculus	101-105
9481485-8	1998	The effect of a combination of ET-1 and TPA on IL-6 secretion was not additive.	Tetradecanoylphorbol Acetate	40-43	interleukin 6	Mus musculus	47-51
9481485-10	1998	Both ET-1- and TPA-induced IL-6 secretion were reduced in PKC downregulated MC3T3-E1 cells.	Tetradecanoylphorbol Acetate	15-18	interleukin 6	Mus musculus	27-31
9570525-2	1998	We report that quinacrine, chloroquine, and structurally related compounds completely inhibit the antiapoptotic effect of CpG-ODN on WEHI 231 murine B lymphoma cells and inhibit CpG-ODN-induced secretion of IL-6 by WEHI 231.	Quinacrine	15-25	interleukin 6	Mus musculus	207-211
9570525-2	1998	We report that quinacrine, chloroquine, and structurally related compounds completely inhibit the antiapoptotic effect of CpG-ODN on WEHI 231 murine B lymphoma cells and inhibit CpG-ODN-induced secretion of IL-6 by WEHI 231.	Chloroquine	27-38	interleukin 6	Mus musculus	207-211
9578149-0	1998	Effect of vitamin D3 on interleukin-6 synthesis induced by prostaglandins in osteoblasts.	Cholecalciferol	10-20	interleukin 6	Mus musculus	24-37
9578149-0	1998	Effect of vitamin D3 on interleukin-6 synthesis induced by prostaglandins in osteoblasts.	Prostaglandins	59-73	interleukin 6	Mus musculus	24-37
9578149-1	1998	In previous studies, we have shown that prostaglandin F2alpha (PGF2alpha) stimulates interleukin-6 (IL-6) synthesis via activation of protein kinase C in osteoblast-like MC3T3-E1 cells, and that prostaglandin E1 (PGE1) induces the synthesis of IL-6 through protein kinase A activation.	Dinoprost	40-61	interleukin 6	Mus musculus	85-98
9578149-1	1998	In previous studies, we have shown that prostaglandin F2alpha (PGF2alpha) stimulates interleukin-6 (IL-6) synthesis via activation of protein kinase C in osteoblast-like MC3T3-E1 cells, and that prostaglandin E1 (PGE1) induces the synthesis of IL-6 through protein kinase A activation.	Dinoprost	40-61	interleukin 6	Mus musculus	100-104
9578149-1	1998	In previous studies, we have shown that prostaglandin F2alpha (PGF2alpha) stimulates interleukin-6 (IL-6) synthesis via activation of protein kinase C in osteoblast-like MC3T3-E1 cells, and that prostaglandin E1 (PGE1) induces the synthesis of IL-6 through protein kinase A activation.	Dinoprost	40-61	interleukin 6	Mus musculus	244-248
9578149-1	1998	In previous studies, we have shown that prostaglandin F2alpha (PGF2alpha) stimulates interleukin-6 (IL-6) synthesis via activation of protein kinase C in osteoblast-like MC3T3-E1 cells, and that prostaglandin E1 (PGE1) induces the synthesis of IL-6 through protein kinase A activation.	Dinoprost	63-72	interleukin 6	Mus musculus	85-98
9578149-1	1998	In previous studies, we have shown that prostaglandin F2alpha (PGF2alpha) stimulates interleukin-6 (IL-6) synthesis via activation of protein kinase C in osteoblast-like MC3T3-E1 cells, and that prostaglandin E1 (PGE1) induces the synthesis of IL-6 through protein kinase A activation.	Dinoprost	63-72	interleukin 6	Mus musculus	100-104
9578149-1	1998	In previous studies, we have shown that prostaglandin F2alpha (PGF2alpha) stimulates interleukin-6 (IL-6) synthesis via activation of protein kinase C in osteoblast-like MC3T3-E1 cells, and that prostaglandin E1 (PGE1) induces the synthesis of IL-6 through protein kinase A activation.	Dinoprost	63-72	interleukin 6	Mus musculus	244-248
9578149-1	1998	In previous studies, we have shown that prostaglandin F2alpha (PGF2alpha) stimulates interleukin-6 (IL-6) synthesis via activation of protein kinase C in osteoblast-like MC3T3-E1 cells, and that prostaglandin E1 (PGE1) induces the synthesis of IL-6 through protein kinase A activation.	Alprostadil	195-211	interleukin 6	Mus musculus	85-98
9578149-1	1998	In previous studies, we have shown that prostaglandin F2alpha (PGF2alpha) stimulates interleukin-6 (IL-6) synthesis via activation of protein kinase C in osteoblast-like MC3T3-E1 cells, and that prostaglandin E1 (PGE1) induces the synthesis of IL-6 through protein kinase A activation.	Alprostadil	195-211	interleukin 6	Mus musculus	100-104
9578149-1	1998	In previous studies, we have shown that prostaglandin F2alpha (PGF2alpha) stimulates interleukin-6 (IL-6) synthesis via activation of protein kinase C in osteoblast-like MC3T3-E1 cells, and that prostaglandin E1 (PGE1) induces the synthesis of IL-6 through protein kinase A activation.	Alprostadil	213-217	interleukin 6	Mus musculus	85-98
9578149-1	1998	In previous studies, we have shown that prostaglandin F2alpha (PGF2alpha) stimulates interleukin-6 (IL-6) synthesis via activation of protein kinase C in osteoblast-like MC3T3-E1 cells, and that prostaglandin E1 (PGE1) induces the synthesis of IL-6 through protein kinase A activation.	Alprostadil	213-217	interleukin 6	Mus musculus	100-104
9578149-2	1998	In the present study, we investigated the effect of vitamin D3 on IL-6 synthesis in MC3T3-E1 cells.	Cholecalciferol	52-62	interleukin 6	Mus musculus	66-70
9578149-3	1998	1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), an active form of vitamin D3, inhibited the IL-6 synthesis induced by PGF2alpha or PGE1.	Calcitriol	0-26	interleukin 6	Mus musculus	85-89
9578149-3	1998	1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), an active form of vitamin D3, inhibited the IL-6 synthesis induced by PGF2alpha or PGE1.	Calcitriol	26-38	interleukin 6	Mus musculus	85-89
9578149-3	1998	1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), an active form of vitamin D3, inhibited the IL-6 synthesis induced by PGF2alpha or PGE1.	Cholecalciferol	14-24	interleukin 6	Mus musculus	85-89
9578149-3	1998	1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), an active form of vitamin D3, inhibited the IL-6 synthesis induced by PGF2alpha or PGE1.	Dinoprost	111-120	interleukin 6	Mus musculus	85-89
9578149-3	1998	1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), an active form of vitamin D3, inhibited the IL-6 synthesis induced by PGF2alpha or PGE1.	Alprostadil	124-128	interleukin 6	Mus musculus	85-89
9578149-7	1998	These results strongly suggest that 1,25-(OH)2D3, an active form of vitamin D3, inhibits IL-6 synthesis at both the protein kinase C pathway and the protein kinase A pathway in osteoblasts.	Calcitriol	36-48	interleukin 6	Mus musculus	89-93
9578149-7	1998	These results strongly suggest that 1,25-(OH)2D3, an active form of vitamin D3, inhibits IL-6 synthesis at both the protein kinase C pathway and the protein kinase A pathway in osteoblasts.	Cholecalciferol	68-78	interleukin 6	Mus musculus	89-93
9574806-12	1998	In view of the above results, this study suggests that the immunosuppressive effect in sera of mice treated with 1,1-dichloroethylene and 1,2-dichlorobenzene may result from tissue damage, and that the increased levels of TNF-alpha and IL-6 in sera may contribute to this effect.	vinylidene chloride	113-133	interleukin 6	Mus musculus	236-240
9574806-12	1998	In view of the above results, this study suggests that the immunosuppressive effect in sera of mice treated with 1,1-dichloroethylene and 1,2-dichlorobenzene may result from tissue damage, and that the increased levels of TNF-alpha and IL-6 in sera may contribute to this effect.	2-dichlorobenzene	138-157	interleukin 6	Mus musculus	236-240
9458784-6	1998	By ELISA, stimulated MPACs showed a significant increase in IL-1 beta (P < 0.03) and IL-6 (P < 0.01) release into supernatants by 10 min that paralleled the time course of amylase release.	mpacs	21-26	interleukin 6	Mus musculus	88-92
9458784-9	1998	This study shows that MPACs synthesize IL-1 beta and IL-6 and release these cytokines from their granules after alpha- and beta-adrenergic stimulation.	mpacs	22-27	interleukin 6	Mus musculus	53-57
9528718-10	1998	Injection of IL-6, TNFalpha and IL-1beta in mice markedly decreased the phosphate serum levels.	Phosphates	72-81	interleukin 6	Mus musculus	13-17
9641797-3	1998	This short review considers some data concerning the effects of several cytokines, interleukin (IL)-1, IL-2, IL-6 and granulocyte-macrophage colony-stimulating factor on scopolamine-induced amnesia for a passive avoidance response, and on hippocampal neurotransmitter amino acid levels in mice.	Scopolamine	170-181	interleukin 6	Mus musculus	109-113
9505140-2	1998	We have previously shown in IL-6-deficient (-/-) mice that IL-6 is absolutely required for the transcriptional induction of acute phase response (APR) genes in the liver following localized tissue damage caused by subcutaneous injection of turpentine oil, but is not required when the inflammatory stimulus is administered systemically by intraperitoneal injection of bacterial lipopolysaccharide (LPS).	Turpentine	240-254	interleukin 6	Mus musculus	59-63
9536117-8	1998	Furthermore, the results also imply that immunopotentiating effects of FCA or Alum adjuvant are both inhibited by IL-6.	Aluminum Hydroxide	78-91	interleukin 6	Mus musculus	114-118
9444964-0	1998	CpG-oligodeoxynucleotide supports growth of IL-6-dependent 7TD1 murine hybridoma cells.	CPG-oligonucleotide	0-24	interleukin 6	Mus musculus	44-48
9444964-3	1998	We report that the phosphorothioate CpG-ODN 5"-ATAATCGACGTTCAAGCAAG-3" (half maximal effect at 0.3 microg/ml) supports the growth of 7TD1 cells in the absence of added IL-6.	Parathion	19-35	interleukin 6	Mus musculus	168-172
9705611-3	1998	We investigated the effect of carrageenan on serum concentrations of complement C3 and interleukin (IL)-6, a potent complement-inducing factor.	Carrageenan	30-41	interleukin 6	Mus musculus	87-105
9705611-5	1998	Prior to the rise in complement C3, a sharp peak of serum IL-6 was observed at 6h after carrageenan treatment.	Carrageenan	88-99	interleukin 6	Mus musculus	58-62
9705611-6	1998	These results indicate potential of carrageenan to enhance host complement systems, which may be associated with, at least in part, an acute induction of IL-6.	Carrageenan	36-47	interleukin 6	Mus musculus	154-158
9391003-4	1997	GFAP-IL6 mice heterozygous or homozygous for the IL-6 transgene had normal basal plasma corticosterone levels but, after restraint stress, showed abnormally increased levels in a gene dose-dependent manner.	Corticosterone	88-102	interleukin 6	Mus musculus	5-8
9391003-4	1997	GFAP-IL6 mice heterozygous or homozygous for the IL-6 transgene had normal basal plasma corticosterone levels but, after restraint stress, showed abnormally increased levels in a gene dose-dependent manner.	Corticosterone	88-102	interleukin 6	Mus musculus	49-53
9391003-5	1997	The increased plasma corticosterone levels in the IL-6 transgenic mice were associated with increased adrenal corticosterone content and hyperplasia of both adrenal cortex and medulla.	Corticosterone	21-35	interleukin 6	Mus musculus	50-54
9391003-5	1997	The increased plasma corticosterone levels in the IL-6 transgenic mice were associated with increased adrenal corticosterone content and hyperplasia of both adrenal cortex and medulla.	Corticosterone	110-124	interleukin 6	Mus musculus	50-54
9391055-3	1997	Upon investigating DEX-mediated repression of interleukin-6 expression induced by tumor necrosis factor, DEX treatment was found to act directly on NF-kappaB-dependent transcription, without changing the expression level of IkappaB.	Dexamethasone	19-22	interleukin 6	Mus musculus	46-59
9391055-3	1997	Upon investigating DEX-mediated repression of interleukin-6 expression induced by tumor necrosis factor, DEX treatment was found to act directly on NF-kappaB-dependent transcription, without changing the expression level of IkappaB.	Dexamethasone	105-108	interleukin 6	Mus musculus	46-59
9402143-7	1997	DHEA also suppressed the production of cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by T helper 2 (Th2) cells which were otherwise stimulated by retrovirus infection.	Dehydroepiandrosterone	0-4	interleukin 6	Mus musculus	49-62
9402143-7	1997	DHEA also suppressed the production of cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by T helper 2 (Th2) cells which were otherwise stimulated by retrovirus infection.	Dehydroepiandrosterone	0-4	interleukin 6	Mus musculus	64-68
9414115-0	1997	Activation of mitogen-activated protein kinase is involved in sphingosine 1-phosphate-stimulated interleukin-6 synthesis in osteoblasts.	sphingosine 1-phosphate	62-85	interleukin 6	Mus musculus	97-110
9414115-1	1997	We previously showed that sphingosine 1-phosphate (SPP) acts as a second messenger for tumor necrosis factor alpha-induced interleukin-6 (IL-6) synthesis in osteoblast-like MC3T3-E1 cells.	sphingosine 1-phosphate	26-49	interleukin 6	Mus musculus	123-136
9414115-1	1997	We previously showed that sphingosine 1-phosphate (SPP) acts as a second messenger for tumor necrosis factor alpha-induced interleukin-6 (IL-6) synthesis in osteoblast-like MC3T3-E1 cells.	sphingosine 1-phosphate	26-49	interleukin 6	Mus musculus	138-142
9414115-1	1997	We previously showed that sphingosine 1-phosphate (SPP) acts as a second messenger for tumor necrosis factor alpha-induced interleukin-6 (IL-6) synthesis in osteoblast-like MC3T3-E1 cells.	sphingosine 1-phosphate	51-54	interleukin 6	Mus musculus	123-136
9414115-1	1997	We previously showed that sphingosine 1-phosphate (SPP) acts as a second messenger for tumor necrosis factor alpha-induced interleukin-6 (IL-6) synthesis in osteoblast-like MC3T3-E1 cells.	sphingosine 1-phosphate	51-54	interleukin 6	Mus musculus	138-142
9414115-4	1997	PD98059, an inhibitor of MAP kinase kinase, suppressed SPP-induced IL-6 synthesis as well as SPP-induced MAP kinase activation.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	interleukin 6	Mus musculus	67-71
9414115-6	1997	TMB-8, an inhibitor of Ca2+ mobilization from intracellular Ca2+ stores, significantly suppressed the SPP-induced IL-6 synthesis.	8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate	0-5	interleukin 6	Mus musculus	114-118
9348179-4	1997	17beta-E2 significantly suppressed basal and 1alpha,25(OH)2D3-stimulated cellular production of interleukin (IL)-6.	17beta-e2	0-9	interleukin 6	Mus musculus	96-114
9348179-4	1997	17beta-E2 significantly suppressed basal and 1alpha,25(OH)2D3-stimulated cellular production of interleukin (IL)-6.	25(oh)2d3	52-61	interleukin 6	Mus musculus	96-114
9348179-7	1997	However, the stimulatory effect of 1alpha,25(OH)2D3 on osteoclastogenesis nevertheless can be significantly reduced by a neutralizing monoclonal anti-IL-6 antibody.	25(oh)2d3	42-51	interleukin 6	Mus musculus	150-154
9348179-9	1997	Our data suggest that induction of osteoclastogenesis by 1alpha,25(OH)2D3 is partially dependent on IL-6 signaling and can be modulated by 17beta-E2 through interference with IL-6 receptor activation, in addition to inhibition of IL-6 production by marrow stromal cells.	17beta-e2	139-148	interleukin 6	Mus musculus	175-179
9348179-9	1997	Our data suggest that induction of osteoclastogenesis by 1alpha,25(OH)2D3 is partially dependent on IL-6 signaling and can be modulated by 17beta-E2 through interference with IL-6 receptor activation, in addition to inhibition of IL-6 production by marrow stromal cells.	17beta-e2	139-148	interleukin 6	Mus musculus	175-179
9566762-6	1997	The MEF.He clone, but not the MEF.HeJ clone, expressed IL-6 mRNA in response to taxol or ceramide, whereas MEF.HeJ clones as well as the MEF.He clone expressed IL-6 mRNA in response to IL-1alpha.	Paclitaxel	80-85	interleukin 6	Mus musculus	55-59
9566762-6	1997	The MEF.He clone, but not the MEF.HeJ clone, expressed IL-6 mRNA in response to taxol or ceramide, whereas MEF.HeJ clones as well as the MEF.He clone expressed IL-6 mRNA in response to IL-1alpha.	Ceramides	89-97	interleukin 6	Mus musculus	55-59
9566762-7	1997	These results indicate that in the responses to LPS, taxol and ceramide, MEF retain the same reactivity as that of the mouse strains from which the MEF were derived, and LPS shares the IL-6 signal transduction pathway with taxol and ceramide, but not with IL-1.	Paclitaxel	53-58	interleukin 6	Mus musculus	185-189
9566762-7	1997	These results indicate that in the responses to LPS, taxol and ceramide, MEF retain the same reactivity as that of the mouse strains from which the MEF were derived, and LPS shares the IL-6 signal transduction pathway with taxol and ceramide, but not with IL-1.	Ceramides	63-71	interleukin 6	Mus musculus	185-189
9566762-7	1997	These results indicate that in the responses to LPS, taxol and ceramide, MEF retain the same reactivity as that of the mouse strains from which the MEF were derived, and LPS shares the IL-6 signal transduction pathway with taxol and ceramide, but not with IL-1.	Paclitaxel	223-228	interleukin 6	Mus musculus	185-189
9566762-7	1997	These results indicate that in the responses to LPS, taxol and ceramide, MEF retain the same reactivity as that of the mouse strains from which the MEF were derived, and LPS shares the IL-6 signal transduction pathway with taxol and ceramide, but not with IL-1.	Ceramides	233-241	interleukin 6	Mus musculus	185-189
9329961-0	1997	Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.	Steroids	70-78	interleukin 6	Mus musculus	49-53
9329961-3	1997	Based on this and evidence that the ligand-binding subunit of the IL-6 receptor (gp80) is a limiting factor for the actions of IL-6 on bone, we hypothesized that sex steroids regulate expression of the IL-6 receptor as well.	Steroids	166-174	interleukin 6	Mus musculus	66-70
9329961-3	1997	Based on this and evidence that the ligand-binding subunit of the IL-6 receptor (gp80) is a limiting factor for the actions of IL-6 on bone, we hypothesized that sex steroids regulate expression of the IL-6 receptor as well.	Steroids	166-174	interleukin 6	Mus musculus	127-131
9329961-3	1997	Based on this and evidence that the ligand-binding subunit of the IL-6 receptor (gp80) is a limiting factor for the actions of IL-6 on bone, we hypothesized that sex steroids regulate expression of the IL-6 receptor as well.	Steroids	166-174	interleukin 6	Mus musculus	127-131
9329961-4	1997	We report that 17beta-estradiol or dihydrotestosterone in vitro decreased the abundance of the gp80 mRNA as well as the mRNA of the signal-transducing subunit of the IL-6 receptor (gp130) in cells of the bone marrow stromal/osteoblastic lineage, and also decreased gp130 protein levels.	Estradiol	15-31	interleukin 6	Mus musculus	166-170
9329961-4	1997	We report that 17beta-estradiol or dihydrotestosterone in vitro decreased the abundance of the gp80 mRNA as well as the mRNA of the signal-transducing subunit of the IL-6 receptor (gp130) in cells of the bone marrow stromal/osteoblastic lineage, and also decreased gp130 protein levels.	Dihydrotestosterone	35-54	interleukin 6	Mus musculus	166-170
9329961-8	1997	The demonstration of increased expression of the IL-6 receptor after loss of sex steroids provides an explanation for why IL-6 is important for skeletal homeostasis in the sex steroid-deficient, but not replete, state.	Steroids	81-89	interleukin 6	Mus musculus	49-53
9329961-8	1997	The demonstration of increased expression of the IL-6 receptor after loss of sex steroids provides an explanation for why IL-6 is important for skeletal homeostasis in the sex steroid-deficient, but not replete, state.	Steroids	81-89	interleukin 6	Mus musculus	122-126
9329961-8	1997	The demonstration of increased expression of the IL-6 receptor after loss of sex steroids provides an explanation for why IL-6 is important for skeletal homeostasis in the sex steroid-deficient, but not replete, state.	Steroids	81-88	interleukin 6	Mus musculus	49-53
9361908-4	1997	administration of 50 mg/kg of oligonucleotide, significant increases in the splenic mRNA levels of IL-6, IL-12p40, IL-1 beta, and IL-1Ra and serum levels of IL-6, IL-12, MIP-1 beta, and MCP-1 were observed.	Oligonucleotides	30-45	interleukin 6	Mus musculus	99-103
9361908-4	1997	administration of 50 mg/kg of oligonucleotide, significant increases in the splenic mRNA levels of IL-6, IL-12p40, IL-1 beta, and IL-1Ra and serum levels of IL-6, IL-12, MIP-1 beta, and MCP-1 were observed.	Oligonucleotides	30-45	interleukin 6	Mus musculus	157-161
9328844-2	1997	Staurosporine and calphostin C, inhibitors of protein kinase C (PKC), significantly enhanced the IL-1-induced secretion of IL-6.	Staurosporine	0-13	interleukin 6	Mus musculus	123-127
9328844-2	1997	Staurosporine and calphostin C, inhibitors of protein kinase C (PKC), significantly enhanced the IL-1-induced secretion of IL-6.	calphostin C	18-30	interleukin 6	Mus musculus	123-127
9317152-1	1997	Activation of macrophages by LPS and taxol results in production of IL-1, IL-6, TNF-alpha, and granulocyte-macrophage CSF (GM-CSF), which are involved in regulating hemopoiesis, inflammation, and immune responses.	Paclitaxel	37-42	interleukin 6	Mus musculus	74-78
9274810-0	1997	Potential role for IL-5 and IL-6 in enhanced IgA secretion by Peyer"s patch cells isolated from mice acutely exposed to vomitoxin.	deoxynivalenol	120-129	interleukin 6	Mus musculus	28-32
9274810-8	1997	IL-6 levels were increased significantly in LPS-treated cultures prepared from PP at 2 and 24 h following exposure to VT.	deoxynivalenol	118-120	interleukin 6	Mus musculus	0-4
9249285-2	1997	OBJECTIVE: The present investigation compared the ability of the skin allergens oxazolone and 2,4-dinitrochlorobenzene (DNCB) and the skin irritant benzalkonium chloride (BZC) to stimulate the cutaneous expression of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in mice.	Benzalkonium Compounds	148-169	interleukin 6	Mus musculus	217-230
9249285-2	1997	OBJECTIVE: The present investigation compared the ability of the skin allergens oxazolone and 2,4-dinitrochlorobenzene (DNCB) and the skin irritant benzalkonium chloride (BZC) to stimulate the cutaneous expression of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in mice.	Benzalkonium Compounds	148-169	interleukin 6	Mus musculus	232-236
9249285-2	1997	OBJECTIVE: The present investigation compared the ability of the skin allergens oxazolone and 2,4-dinitrochlorobenzene (DNCB) and the skin irritant benzalkonium chloride (BZC) to stimulate the cutaneous expression of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in mice.	Benzalkonium Compounds	171-174	interleukin 6	Mus musculus	217-230
9249285-2	1997	OBJECTIVE: The present investigation compared the ability of the skin allergens oxazolone and 2,4-dinitrochlorobenzene (DNCB) and the skin irritant benzalkonium chloride (BZC) to stimulate the cutaneous expression of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in mice.	Benzalkonium Compounds	171-174	interleukin 6	Mus musculus	232-236
9284817-0	1997	Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.	pristane-oil	25-37	interleukin 6	Mus musculus	63-76
9284817-5	1997	Although the pristane-induced inflammatory reaction was less pronounced in IL-6-deficient mice versus their wild-type littermates, both B cell differentiation and plasma cell formation took place, and even morphological evidence of plasma cell transformation was detected, albeit at a low frequency.	pristane	13-21	interleukin 6	Mus musculus	75-79
9281306-0	1997	Thrombin regulates interleukin-6 synthesis through phosphatidylcholine hydrolysis by phospholipase D in osteoblasts.	Phosphatidylcholines	51-70	interleukin 6	Mus musculus	19-32
9281306-4	1997	The depletion of extracellular Ca2+ by EGTA suppressed the thrombin-induced IL-6 synthesis.	Egtazic Acid	39-43	interleukin 6	Mus musculus	76-80
9281306-5	1997	TMB-8, an inhibitor of intracellular Ca2+ mobilization, also inhibited the IL-6 synthesis by thrombin.	8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate	0-5	interleukin 6	Mus musculus	75-79
9281306-6	1997	Propranolol, a phosphatidic acid phosphohydrolase inhibitor, enhanced the IL-6 synthesis by thrombin.	Propranolol	0-11	interleukin 6	Mus musculus	74-78
9328138-5	1997	The results revealed that Freund"s complete adjuvant (FCA), Freund"s incomplete adjuvant (FIA), Al(OH)3 and QuilA administration results in a type-2 (humoral) response, increasing IL-4, IL-5 and IL-13 gene expression, while poly I:C exhibits a type-1 (cell-mediated) response, increasing the production of interferon-gamma (IFN-gamma), IL-2 and IL-6 mRNA.	freund"s	26-34	interleukin 6	Mus musculus	345-349
9328138-5	1997	The results revealed that Freund"s complete adjuvant (FCA), Freund"s incomplete adjuvant (FIA), Al(OH)3 and QuilA administration results in a type-2 (humoral) response, increasing IL-4, IL-5 and IL-13 gene expression, while poly I:C exhibits a type-1 (cell-mediated) response, increasing the production of interferon-gamma (IFN-gamma), IL-2 and IL-6 mRNA.	freund"s incomplete adjuvant	60-88	interleukin 6	Mus musculus	345-349
9328138-5	1997	The results revealed that Freund"s complete adjuvant (FCA), Freund"s incomplete adjuvant (FIA), Al(OH)3 and QuilA administration results in a type-2 (humoral) response, increasing IL-4, IL-5 and IL-13 gene expression, while poly I:C exhibits a type-1 (cell-mediated) response, increasing the production of interferon-gamma (IFN-gamma), IL-2 and IL-6 mRNA.	fia	90-93	interleukin 6	Mus musculus	345-349
9328138-5	1997	The results revealed that Freund"s complete adjuvant (FCA), Freund"s incomplete adjuvant (FIA), Al(OH)3 and QuilA administration results in a type-2 (humoral) response, increasing IL-4, IL-5 and IL-13 gene expression, while poly I:C exhibits a type-1 (cell-mediated) response, increasing the production of interferon-gamma (IFN-gamma), IL-2 and IL-6 mRNA.	Aluminum Hydroxide	96-103	interleukin 6	Mus musculus	345-349
9328138-5	1997	The results revealed that Freund"s complete adjuvant (FCA), Freund"s incomplete adjuvant (FIA), Al(OH)3 and QuilA administration results in a type-2 (humoral) response, increasing IL-4, IL-5 and IL-13 gene expression, while poly I:C exhibits a type-1 (cell-mediated) response, increasing the production of interferon-gamma (IFN-gamma), IL-2 and IL-6 mRNA.	Quil A	108-113	interleukin 6	Mus musculus	345-349
9328138-6	1997	Finally, BeSO4 and poly A:U augment IL-5 and IL-6 mRNA production, while lipopolysaccharide (LPS) and LiCl augment IL-6 and tumour necrosis factor-alpha (TNF-alpha) mRNA production.	beryllium sulfate	9-14	interleukin 6	Mus musculus	45-49
9328138-6	1997	Finally, BeSO4 and poly A:U augment IL-5 and IL-6 mRNA production, while lipopolysaccharide (LPS) and LiCl augment IL-6 and tumour necrosis factor-alpha (TNF-alpha) mRNA production.	Poly A	19-25	interleukin 6	Mus musculus	45-49
9348089-0	1997	Involvement of interleukin-6 in activation of lysosomal cathepsin and atrophy of muscle fibers induced by intramuscular injection of turpentine oil in mice.	Turpentine	133-147	interleukin 6	Mus musculus	15-28
9348089-1	1997	Serum IL-6 level increased after the injection of turpentine oil into the right gastrocnemius muscle in mice.	Turpentine	50-64	interleukin 6	Mus musculus	6-10
9497937-2	1997	We have developed a non-radioactive in-situ hybridization method using digoxigenin-labeled oligonucleotide probes to study the expression of the cytokines interleukin (IL) 1 alpha, Il-1 beta and IL-6 and the growth factors insulin-like growth factor-1 (IGF-1) and transforming growth factor beta (TGF beta 1) during the development of osteoarthritis (OA) in this model.	Digoxigenin	71-82	interleukin 6	Mus musculus	195-199
9281358-10	1997	The addition of SP to CSF-1-primed Mo before LPS, however, further enhanced IL-6 release but not GM-CSF release from the cells.	Staurosporine	16-18	interleukin 6	Mus musculus	76-80
9277378-0	1997	Interleukin-6 secretion in mice is associated with reduced glucose-6-phosphatase and liver glycogen levels.	Glycogen	91-99	interleukin 6	Mus musculus	0-13
9277378-1	1997	Mice bearing interleukin-6 (IL-6)-secreting tumor were used to study the chronic effect of IL-6 on carbohydrate metabolism.	Carbohydrates	99-111	interleukin 6	Mus musculus	91-95
9277378-4	1997	Secretion of IL-6 from the developed tumors was associated with decreased food consumption, reduced body weight, and reduced blood glucose levels.	Glucose	131-138	interleukin 6	Mus musculus	13-17
9212744-9	1997	Zymosan caused a rapid increase in articular IL-1, IL-6, TNF, and NO levels.	Zymosan	0-7	interleukin 6	Mus musculus	51-55
9249578-7	1997	In IL-1 beta +/+ mice, IL-1ra inhibited production of IL-6 after zymosan, without affecting TNF-alpha synthesis.	Zymosan	65-72	interleukin 6	Mus musculus	54-58
9253712-9	1997	In support of this notion, the simultaneous overexpression of IL-6 and the IL-6 receptor in transgenic mice has been shown to result in a constitutive tyrosine phosphorylation of gp130 in the myocardium and cardiac hypertrophy.	Tyrosine	151-159	interleukin 6	Mus musculus	62-66
9253712-9	1997	In support of this notion, the simultaneous overexpression of IL-6 and the IL-6 receptor in transgenic mice has been shown to result in a constitutive tyrosine phosphorylation of gp130 in the myocardium and cardiac hypertrophy.	Tyrosine	151-159	interleukin 6	Mus musculus	75-79
9221836-0	1997	The immunomodulatory effects of the herbicide propanil on murine macrophage interleukin-6 and tumor necrosis factor-alpha production.	Propanil	46-54	interleukin 6	Mus musculus	76-89
9221836-7	1997	propanil exposure resulted in up to a 60-70% reduction in IL-6 and TNF-alpha production by the LPS-stimulated macrophages, depending on the route, postexposure time, and dose of propanil administered.	Propanil	0-8	interleukin 6	Mus musculus	58-62
9223622-3	1997	(1) Dex decreased the accumulation of tumor necrosis factor-alpha induced by IL-6, whereas nitric oxide production was enhanced by Dex.	Dexamethasone	4-7	interleukin 6	Mus musculus	77-81
9223622-5	1997	(2) Cytotoxic activity of Mm1 cells on mouse B16 melanoma cells was much more enhanced by the co-treatment of IL-6 with Dex than IL-6 treatment alone.	Dexamethasone	120-123	interleukin 6	Mus musculus	110-114
9223622-6	1997	(3) Dex promoted further the suppression of proliferation induced by IL-6.	Dexamethasone	4-7	interleukin 6	Mus musculus	69-73
9223622-7	1997	(4) DNA fragmentation, introduced by the treatment of cells with IL-6, was further enhanced in the presence of Dex.	Dexamethasone	111-114	interleukin 6	Mus musculus	65-69
9165025-2	1997	Simultaneous treatment with submaximal doses of IL-1alpha and IL-6 with sIL-6R caused marked induction of osteoclast formation and PGE2 synthesis.	Dinoprostone	131-135	interleukin 6	Mus musculus	62-66
9165025-6	1997	Simultaneous addition of IL-1alpha and IL-6 with sIL-6R to osteoblast cultures cooperatively induced transcription of COX-2, which was associated with a marked increase in COX activity measured by the conversion of arachidonic acid into PGE2.	Arachidonic Acid	215-231	interleukin 6	Mus musculus	39-43
9165025-6	1997	Simultaneous addition of IL-1alpha and IL-6 with sIL-6R to osteoblast cultures cooperatively induced transcription of COX-2, which was associated with a marked increase in COX activity measured by the conversion of arachidonic acid into PGE2.	Dinoprostone	237-241	interleukin 6	Mus musculus	39-43
9165025-7	1997	The increased PGE2 synthesis by osteoblasts may play an important role in osteoclastogenesis induced by submaximal doses of IL-1 and IL-6.	Dinoprostone	14-18	interleukin 6	Mus musculus	133-137
9164945-7	1997	Although DNA-protein binding activity of IL-6-stimulated whole-cell extracts also interacted with a radiolabeled canonical octamer motif, such DNA-protein complexes were not eliminated in competition assays using consensus nuclear factor kappaB or IL-6 oligonucleotides.	Oligonucleotides	253-269	interleukin 6	Mus musculus	41-45
9112382-9	1997	Serum calcium and phosphate concentrations showed an almost linear relationship with plasma PTHrP independently of the tumor line and serum IL-6 levels.	Calcium	6-13	interleukin 6	Mus musculus	140-144
9112382-9	1997	Serum calcium and phosphate concentrations showed an almost linear relationship with plasma PTHrP independently of the tumor line and serum IL-6 levels.	Phosphates	18-27	interleukin 6	Mus musculus	140-144
9112382-11	1997	Administration of neutralizing antibodies to IL-6 to RC-8 animals normalized serum calcium concentrations and PTHrP values and induced a significant inhibition of tumor growth.	Calcium	83-90	interleukin 6	Mus musculus	45-49
9112382-13	1997	The normalization of serum calcium in RC-8 mice is most likely attributed to the growth-inhibiting effect of anti-IL-6 on RC-8 tumor.	Calcium	27-34	interleukin 6	Mus musculus	114-118
9227345-4	1997	When subcutaneously (s.c.) injected in syngeneic mice, TSA-IL6 cells gave rise to tumours that grew significantly slower than TSA-neo cell tumours.	trichostatin A	55-58	interleukin 6	Mus musculus	59-62
9227345-11	1997	The high in vitro TSA-IL6 cell growth rate is attributable to the IL6-induced production of growth factors, some of which possess heparin-binding properties, such as amphiregulin.	Heparin	130-137	interleukin 6	Mus musculus	22-25
9227345-11	1997	The high in vitro TSA-IL6 cell growth rate is attributable to the IL6-induced production of growth factors, some of which possess heparin-binding properties, such as amphiregulin.	Heparin	130-137	interleukin 6	Mus musculus	66-69
9191670-9	1997	The results indicated that GdCl2 treated mice exhibited a marked reduction in circulating IL-6 levels at both 2 and 24 hours after CLP.	gdcl2	27-32	interleukin 6	Mus musculus	90-94
9096599-2	1997	We reexamined the effects of a variety of bile salts with differing hydrophilic-hydrophobic properties on the production of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF alpha) from monocytes and Kupffer cells.	Bile Acids and Salts	42-52	interleukin 6	Mus musculus	124-137
9106265-3	1997	This study examined the effects of two potent protein tyrosine kinase inhibitors, genistein and tyrphostin A25, on lipopolysaccharide (LPS)-induced production of TNF alpha, IL-1 alpha, and IL-6 in mouse primary mixed glia, microglia- or astrocyte-enriched cultures.	Genistein	82-91	interleukin 6	Mus musculus	189-193
9106265-3	1997	This study examined the effects of two potent protein tyrosine kinase inhibitors, genistein and tyrphostin A25, on lipopolysaccharide (LPS)-induced production of TNF alpha, IL-1 alpha, and IL-6 in mouse primary mixed glia, microglia- or astrocyte-enriched cultures.	tyrphostin 25	96-110	interleukin 6	Mus musculus	189-193
9122220-3	1997	Expression of this form of gp130 in lymphocytes significantly suppressed interleukin 6-induced tyrosine phosphorylation of endogenous gp130 and a downstream signaling molecule, signal transducer and activator of transcription 3, indicating that this form has a dominant negative function.	Tyrosine	95-103	interleukin 6	Mus musculus	73-86
9054543-0	1997	Disruption of the disulfide bonds of recombinant murine interleukin-6 induces formation of a partially unfolded state.	Disulfides	18-27	interleukin 6	Mus musculus	56-69
9054543-1	1997	A chemical modification approach was used to investigate the role of the two disulfide bonds of recombinant murine interleukin-6 (mIL-6) in terms of biological activity and conformational stability.	Disulfides	77-86	interleukin 6	Mus musculus	115-128
9054543-1	1997	A chemical modification approach was used to investigate the role of the two disulfide bonds of recombinant murine interleukin-6 (mIL-6) in terms of biological activity and conformational stability.	Disulfides	77-86	interleukin 6	Mus musculus	130-135
9054543-2	1997	Disruption of the disulfide bonds of mIL-6 by treatment with iodoacetic acid (IAA-IL-6) or iodoacetamide (IAM-IL-6) reduced the biological activity, in the murine hybridoma growth factor assay, by 500- and 200-fold, respectively.	Disulfides	18-27	interleukin 6	Mus musculus	37-42
9054543-2	1997	Disruption of the disulfide bonds of mIL-6 by treatment with iodoacetic acid (IAA-IL-6) or iodoacetamide (IAM-IL-6) reduced the biological activity, in the murine hybridoma growth factor assay, by 500- and 200-fold, respectively.	Disulfides	18-27	interleukin 6	Mus musculus	38-42
9054543-2	1997	Disruption of the disulfide bonds of mIL-6 by treatment with iodoacetic acid (IAA-IL-6) or iodoacetamide (IAM-IL-6) reduced the biological activity, in the murine hybridoma growth factor assay, by 500- and 200-fold, respectively.	Disulfides	18-27	interleukin 6	Mus musculus	82-86
9054543-2	1997	Disruption of the disulfide bonds of mIL-6 by treatment with iodoacetic acid (IAA-IL-6) or iodoacetamide (IAM-IL-6) reduced the biological activity, in the murine hybridoma growth factor assay, by 500- and 200-fold, respectively.	Iodoacetic Acid	61-76	interleukin 6	Mus musculus	37-42
9054543-2	1997	Disruption of the disulfide bonds of mIL-6 by treatment with iodoacetic acid (IAA-IL-6) or iodoacetamide (IAM-IL-6) reduced the biological activity, in the murine hybridoma growth factor assay, by 500- and 200-fold, respectively.	Iodoacetic Acid	61-76	interleukin 6	Mus musculus	38-42
9054543-2	1997	Disruption of the disulfide bonds of mIL-6 by treatment with iodoacetic acid (IAA-IL-6) or iodoacetamide (IAM-IL-6) reduced the biological activity, in the murine hybridoma growth factor assay, by 500- and 200-fold, respectively.	Iodoacetic Acid	61-76	interleukin 6	Mus musculus	82-86
9054543-2	1997	Disruption of the disulfide bonds of mIL-6 by treatment with iodoacetic acid (IAA-IL-6) or iodoacetamide (IAM-IL-6) reduced the biological activity, in the murine hybridoma growth factor assay, by 500- and 200-fold, respectively.	indoleacetic acid	78-81	interleukin 6	Mus musculus	37-42
9054543-2	1997	Disruption of the disulfide bonds of mIL-6 by treatment with iodoacetic acid (IAA-IL-6) or iodoacetamide (IAM-IL-6) reduced the biological activity, in the murine hybridoma growth factor assay, by 500- and 200-fold, respectively.	indoleacetic acid	78-81	interleukin 6	Mus musculus	38-42
9054543-2	1997	Disruption of the disulfide bonds of mIL-6 by treatment with iodoacetic acid (IAA-IL-6) or iodoacetamide (IAM-IL-6) reduced the biological activity, in the murine hybridoma growth factor assay, by 500- and 200-fold, respectively.	indoleacetic acid	78-81	interleukin 6	Mus musculus	82-86
9054543-2	1997	Disruption of the disulfide bonds of mIL-6 by treatment with iodoacetic acid (IAA-IL-6) or iodoacetamide (IAM-IL-6) reduced the biological activity, in the murine hybridoma growth factor assay, by 500- and 200-fold, respectively.	Iodoacetamide	91-104	interleukin 6	Mus musculus	37-42
9054543-2	1997	Disruption of the disulfide bonds of mIL-6 by treatment with iodoacetic acid (IAA-IL-6) or iodoacetamide (IAM-IL-6) reduced the biological activity, in the murine hybridoma growth factor assay, by 500- and 200-fold, respectively.	Iodoacetamide	91-104	interleukin 6	Mus musculus	38-42
9054543-3	1997	Both alkylated derivatives as well as the fully reduced (but not modified) molecule (DTT-IL-6) retained a high degree of alpha-helical structure as measured by far-UV CD (37-51%) when compared to the mIL-6 (59%).	Dithiothreitol	85-88	interleukin 6	Mus musculus	89-93
9054543-8	1997	These properties were identical to those observed for DTT-IL-6 in the absence of denaturant.	Dithiothreitol	54-57	interleukin 6	Mus musculus	58-62
9054543-9	1997	DTT-IL-6 appears to form a partially unfolded and highly aggregated conformation under all conditions studied, as showed by a high propensity to self-associate (demonstrated using a biosensor employing surface plasmon resonance), and an increased ability to bind the hydrophobic probe 8-anilino-1-naphthalenesulfonic acid.	Dithiothreitol	0-3	interleukin 6	Mus musculus	4-8
9054543-9	1997	DTT-IL-6 appears to form a partially unfolded and highly aggregated conformation under all conditions studied, as showed by a high propensity to self-associate (demonstrated using a biosensor employing surface plasmon resonance), and an increased ability to bind the hydrophobic probe 8-anilino-1-naphthalenesulfonic acid.	8-anilino-1-naphthalenesulfonic acid	285-321	interleukin 6	Mus musculus	4-8
9054543-10	1997	The observed protein concentration dependence of the fluorescence characteristics of these mIL-6 derivatives is consistent with the aggregation of partially folded forms of DTT-IL-6, IAM-IL-6, and IAA-IL-6 during denaturant-induced unfolding.	Dithiothreitol	173-176	interleukin 6	Mus musculus	91-96
9054543-10	1997	The observed protein concentration dependence of the fluorescence characteristics of these mIL-6 derivatives is consistent with the aggregation of partially folded forms of DTT-IL-6, IAM-IL-6, and IAA-IL-6 during denaturant-induced unfolding.	Dithiothreitol	173-176	interleukin 6	Mus musculus	92-96
9054543-10	1997	The observed protein concentration dependence of the fluorescence characteristics of these mIL-6 derivatives is consistent with the aggregation of partially folded forms of DTT-IL-6, IAM-IL-6, and IAA-IL-6 during denaturant-induced unfolding.	Dithiothreitol	173-176	interleukin 6	Mus musculus	177-181
9054543-10	1997	The observed protein concentration dependence of the fluorescence characteristics of these mIL-6 derivatives is consistent with the aggregation of partially folded forms of DTT-IL-6, IAM-IL-6, and IAA-IL-6 during denaturant-induced unfolding.	Dithiothreitol	173-176	interleukin 6	Mus musculus	177-181
9054543-10	1997	The observed protein concentration dependence of the fluorescence characteristics of these mIL-6 derivatives is consistent with the aggregation of partially folded forms of DTT-IL-6, IAM-IL-6, and IAA-IL-6 during denaturant-induced unfolding.	denaturant	213-223	interleukin 6	Mus musculus	91-96
9054543-10	1997	The observed protein concentration dependence of the fluorescence characteristics of these mIL-6 derivatives is consistent with the aggregation of partially folded forms of DTT-IL-6, IAM-IL-6, and IAA-IL-6 during denaturant-induced unfolding.	denaturant	213-223	interleukin 6	Mus musculus	92-96
9054543-10	1997	The observed protein concentration dependence of the fluorescence characteristics of these mIL-6 derivatives is consistent with the aggregation of partially folded forms of DTT-IL-6, IAM-IL-6, and IAA-IL-6 during denaturant-induced unfolding.	denaturant	213-223	interleukin 6	Mus musculus	177-181
9054543-10	1997	The observed protein concentration dependence of the fluorescence characteristics of these mIL-6 derivatives is consistent with the aggregation of partially folded forms of DTT-IL-6, IAM-IL-6, and IAA-IL-6 during denaturant-induced unfolding.	denaturant	213-223	interleukin 6	Mus musculus	177-181
9038318-6	1997	Antisense oligodeoxynucleotide (ODN) to mannose receptor (MR) mRNA inhibited the expression and function of MR in macrophages as determined by Western blot analysis and 125I-labeled mannose-bovine serum albumin (BSA) binding, and also inhibited the elevation of cytokine IL-1beta, IL-6, and GM-CSF mRNA levels induced by C. albicans attachment.	Oligodeoxyribonucleotides	10-30	interleukin 6	Mus musculus	281-285
9038318-6	1997	Antisense oligodeoxynucleotide (ODN) to mannose receptor (MR) mRNA inhibited the expression and function of MR in macrophages as determined by Western blot analysis and 125I-labeled mannose-bovine serum albumin (BSA) binding, and also inhibited the elevation of cytokine IL-1beta, IL-6, and GM-CSF mRNA levels induced by C. albicans attachment.	Mannose	40-47	interleukin 6	Mus musculus	281-285
9070257-0	1997	Inhibition of IL-1-induced IL-6 production by synthetic retinoids.	Retinoids	56-65	interleukin 6	Mus musculus	27-31
9070257-2	1997	None of the synthetic retinoids examined stimulated IL-6 production, but all of them strongly inhibited IL-6 production induced by mouse IL-1 alpha.	Retinoids	22-31	interleukin 6	Mus musculus	104-108
9124487-0	1997	Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis.	Turpentine	60-70	interleukin 6	Mus musculus	39-52
9002955-7	1997	The actions of TNF-alpha and IL-6 were inhibited by indomethacin, an inhibitor for prostaglandin synthesis, and by neutralizing anti-IFN-gamma and anti-IL-3 antibodies.	Indomethacin	52-64	interleukin 6	Mus musculus	29-33
9002955-7	1997	The actions of TNF-alpha and IL-6 were inhibited by indomethacin, an inhibitor for prostaglandin synthesis, and by neutralizing anti-IFN-gamma and anti-IL-3 antibodies.	Prostaglandins	83-96	interleukin 6	Mus musculus	29-33
9067638-2	1997	PGE1, which induced cAMP accumulation, stimulated IL-6 secretion time-dependently up to 48 h. The stimulative effect of PGE1 was dose-dependent in the range between 10 nM and 10 microM.	Alprostadil	0-4	interleukin 6	Mus musculus	50-54
9067638-2	1997	PGE1, which induced cAMP accumulation, stimulated IL-6 secretion time-dependently up to 48 h. The stimulative effect of PGE1 was dose-dependent in the range between 10 nM and 10 microM.	Alprostadil	120-124	interleukin 6	Mus musculus	50-54
9067638-7	1997	These results indicate that PGE1 stimulates IL-6 secretion via the activation of protein kinase A in osteoblast-like cells.	Alprostadil	28-32	interleukin 6	Mus musculus	44-48
9038718-6	1997	Pretreatment with isoproterenol (10 mg/kg) blunted the LPS-induced TNF response, increased the LPS-induced formation of interleukin-10 and interleukin-6 and reduced the LPS-induced production of NO in conscious mice.	Isoproterenol	18-31	interleukin 6	Mus musculus	139-152
9012363-14	1997	However, the mRNA level for IL-6 was markedly increased following treatment of the infected animals with THC, suggesting the possible involvement of this pro-inflammatory cytokine in increased mortality.	Dronabinol	105-108	interleukin 6	Mus musculus	28-32
9031469-1	1997	The in vivo thrombopoietic activity of polyethylene glycol-modified interleukin-6 (MPEG-IL-6), in which 54% of the 14 lysine amino groups of IL-6 were coupled with PEG, was compared to that of native IL-6.	Polyethylene Glycols	39-58	interleukin 6	Mus musculus	68-81
9031469-1	1997	The in vivo thrombopoietic activity of polyethylene glycol-modified interleukin-6 (MPEG-IL-6), in which 54% of the 14 lysine amino groups of IL-6 were coupled with PEG, was compared to that of native IL-6.	Polyethylene Glycols	39-58	interleukin 6	Mus musculus	88-92
9031469-1	1997	The in vivo thrombopoietic activity of polyethylene glycol-modified interleukin-6 (MPEG-IL-6), in which 54% of the 14 lysine amino groups of IL-6 were coupled with PEG, was compared to that of native IL-6.	Polyethylene Glycols	39-58	interleukin 6	Mus musculus	141-145
9031469-1	1997	The in vivo thrombopoietic activity of polyethylene glycol-modified interleukin-6 (MPEG-IL-6), in which 54% of the 14 lysine amino groups of IL-6 were coupled with PEG, was compared to that of native IL-6.	Polyethylene Glycols	39-58	interleukin 6	Mus musculus	141-145
9031469-1	1997	The in vivo thrombopoietic activity of polyethylene glycol-modified interleukin-6 (MPEG-IL-6), in which 54% of the 14 lysine amino groups of IL-6 were coupled with PEG, was compared to that of native IL-6.	Polyethylene Glycols	84-87	interleukin 6	Mus musculus	88-92
9031469-6	1997	MPEG-IL-6 significantly stimulated platelet recovery in mice treated with 5-fluorouracil, whereas the administration of native IL-6 had a negligible effect.	Fluorouracil	74-88	interleukin 6	Mus musculus	5-9
9031469-8	1997	The decrease in the plasma clearance of MPEG-IL-6 was thought to be due, in part, to the shielding of the proteolytic sites in the IL-6 molecule by the PEG chain.	monomethoxypolyethylene glycol	40-44	interleukin 6	Mus musculus	45-49
9031469-8	1997	The decrease in the plasma clearance of MPEG-IL-6 was thought to be due, in part, to the shielding of the proteolytic sites in the IL-6 molecule by the PEG chain.	monomethoxypolyethylene glycol	40-44	interleukin 6	Mus musculus	131-135
9031469-8	1997	The decrease in the plasma clearance of MPEG-IL-6 was thought to be due, in part, to the shielding of the proteolytic sites in the IL-6 molecule by the PEG chain.	Polyethylene Glycols	41-44	interleukin 6	Mus musculus	45-49
9031469-8	1997	The decrease in the plasma clearance of MPEG-IL-6 was thought to be due, in part, to the shielding of the proteolytic sites in the IL-6 molecule by the PEG chain.	Polyethylene Glycols	41-44	interleukin 6	Mus musculus	131-135
8918689-3	1996	STAT3 is rapidly tyrosine phosphorylated in response to IL-6, ciliary neurotrophic factor, oncostatin M, leukemia inhibitory factor, IL-11, granulocyte colony stimulation factor and epidermal growth factor.	Tyrosine	17-25	interleukin 6	Mus musculus	56-89
9646327-5	1998	Combined treatment of stem cell factor with interleukin-6 synergistically potentiates the ability of 1 alpha,25-(OH)2D3 to generate tartrate-resistant acid phosphatase-positive multinucleated cells.	Calcitriol	101-119	interleukin 6	Mus musculus	44-57
9628464-2	1998	It was reported that cAMP is involved in the regulation of IL-6 production.	Cyclic AMP	21-25	interleukin 6	Mus musculus	59-63
9628464-9	1998	The LPS-induced IL-6 production from macrophages was also potentiated by forskolin 5 microM, an activator of adenylate cyclase.	Colforsin	73-82	interleukin 6	Mus musculus	16-20
9628464-11	1998	These results demonstrate that the LPS-induced IL-6 release is potentiated by CGRP via the activation of cAMP pathway in mouse resident peritoneal macrophages.	Cyclic AMP	105-109	interleukin 6	Mus musculus	47-51
9563506-1	1998	The effect of anandamide, an endogenous ligand for central (CB1) and peripheral (CB2) cannabinoid receptors, was investigated on the growth of the murine IL-6-dependent lymphoid cell line B9 and the murine IL-3-dependent myeloblastic cell line FDC-P1.	anandamide	14-24	interleukin 6	Mus musculus	154-158
9556135-3	1998	A23187, a calcium ionophore, or dibutyryl-cAMP significantly induced IL-6 secretion.	Calcium	10-17	interleukin 6	Mus musculus	69-73
9556135-3	1998	A23187, a calcium ionophore, or dibutyryl-cAMP significantly induced IL-6 secretion.	Bucladesine	32-46	interleukin 6	Mus musculus	69-73
9556135-4	1998	The effect of a combination of A23187 and dibutyryl-cAMP on IL-6 secretion was additive.	Calcimycin	31-37	interleukin 6	Mus musculus	60-64
9556135-4	1998	The effect of a combination of A23187 and dibutyryl-cAMP on IL-6 secretion was additive.	Bucladesine	42-56	interleukin 6	Mus musculus	60-64
9556135-5	1998	The depletion of extracellular Ca2+ by EGTA reduced the PGE2-induced IL-6 secretion.	Egtazic Acid	39-43	interleukin 6	Mus musculus	69-73
9556135-5	1998	The depletion of extracellular Ca2+ by EGTA reduced the PGE2-induced IL-6 secretion.	Dinoprostone	56-60	interleukin 6	Mus musculus	69-73
9556135-6	1998	EP1 receptor antagonist inhibited the PGE2-induced IL-6 secretion.	Dinoprostone	38-42	interleukin 6	Mus musculus	51-55
9556135-7	1998	H-89, an inhibitor of cAMP-dependent protein kinase, decreased the PGE2-induced IL-6 secretion.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	0-4	interleukin 6	Mus musculus	80-84
9556135-7	1998	H-89, an inhibitor of cAMP-dependent protein kinase, decreased the PGE2-induced IL-6 secretion.	Dinoprostone	67-71	interleukin 6	Mus musculus	80-84
9556135-10	1998	Calphostin C, a specific inhibitor of protein kinase C (PKC), enhanced the secretion of IL-6 induced by PGE2.	calphostin C	0-12	interleukin 6	Mus musculus	88-92
9556135-10	1998	Calphostin C, a specific inhibitor of protein kinase C (PKC), enhanced the secretion of IL-6 induced by PGE2.	Dinoprostone	104-108	interleukin 6	Mus musculus	88-92
9556135-11	1998	The stimulative effect of PGE2 on IL-6 secretion was significantly enhanced in PKC downregulated MC3T3-E1 cells.	Dinoprostone	26-30	interleukin 6	Mus musculus	34-38
9556135-12	1998	Pertussis toxin enhanced PGE2-induced IL-6 secretion.	Dinoprostone	25-29	interleukin 6	Mus musculus	38-42
9556135-13	1998	These results strongly suggest that PGE2 stimulates IL-6 synthesis through both Ca2+ mobilization from extracellular space via EP1 receptor and cAMP production via EP2 receptor in osteoblast-like cells, and that the PKC activation by PGE2 itself regulates oversynthesis of IL-6.	Dinoprostone	36-40	interleukin 6	Mus musculus	52-56
9556135-13	1998	These results strongly suggest that PGE2 stimulates IL-6 synthesis through both Ca2+ mobilization from extracellular space via EP1 receptor and cAMP production via EP2 receptor in osteoblast-like cells, and that the PKC activation by PGE2 itself regulates oversynthesis of IL-6.	Dinoprostone	36-40	interleukin 6	Mus musculus	273-277
9556135-13	1998	These results strongly suggest that PGE2 stimulates IL-6 synthesis through both Ca2+ mobilization from extracellular space via EP1 receptor and cAMP production via EP2 receptor in osteoblast-like cells, and that the PKC activation by PGE2 itself regulates oversynthesis of IL-6.	Cyclic AMP	144-148	interleukin 6	Mus musculus	52-56
9546318-8	1998	FL synergized with both SCF and IL-6 with respect to proliferative response and maintenance of undifferentiated cells; however, the numbers of CFC-G/M after 7 or 14 days in culture were significantly lower than those observed with SCF combined with IL-6.	fl	0-2	interleukin 6	Mus musculus	249-253
9566020-0	1998	Esculentoside A inhibits tumor necrosis factor, interleukin-1, and interleukin-6 production induced by lipopolysaccharide in mice.	esculentoside A	0-15	interleukin 6	Mus musculus	67-80
9566020-2	1998	In the present study, we investigated the effects of esculentoside A on the production of tumor necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6) induced by lipopolysaccharide (LPS) in mice.	esculentoside A	53-68	interleukin 6	Mus musculus	144-157
9566020-4	1998	IL-1 and IL-6 secretion was also obviously inhibited in a concentration-dependent manner by esculentoside A from 0.01 to 10 mumol/l.	esculentoside A	92-107	interleukin 6	Mus musculus	9-13
9566020-6	1998	Pretreatment of mice with 5, 10, or 20 mg/kg esculentoside A once a day for 7 consecutive days dose-dependently decreased the TNF, IL-1 and IL-6 levels in the sera of mice following LPS challenge.	esculentoside A	45-60	interleukin 6	Mus musculus	140-144
11244962-1	1998	OBJECTIVE: In order to observe (1) The behavior of growth and metastasis of PG and PGPTS7 in SCID mice and human immune function reconstituted mice; (2) The ability of interleukin-6 autosecreted from PGTS7 in enhancing the anti-tumor activity of the peripheral blood lymphocytes (PBL).	pg	76-78	interleukin 6	Mus musculus	168-181
9500794-5	1998	Using the iNOS inhibitor N6-(iminoethyl)-L-lysine or iNOS knockout mice we found that the activation of the transcriptional factors nuclear factor kappaB and signal transducer and activator of transcription 3 and increases in IL-6 and G-CSF messenger RNA levels in the lungs and livers measured 4 h after resuscitation from hemorrhagic shock were iNOS dependent.	n6-(iminoethyl)-l-lysine	25-49	interleukin 6	Mus musculus	226-230
9514921-8	1998	These findings verify that AM is a rapid and extraordinarily potent regulator of IL-6 production in Swiss 3T3 cells acting through the cAMP-PKA pathway.	Cyclic AMP	135-139	interleukin 6	Mus musculus	81-85
9492065-0	1998	Triiodothyronine modulates interleukin-6 synthesis in osteoblasts: inhibitions in protein kinase A and C pathways.	Triiodothyronine	0-16	interleukin 6	Mus musculus	27-40
9492065-4	1998	T3, which by itself had little effect on IL-6 synthesis, significantly reduced the IL-6 synthesis induced by PGE1 in a dose-dependent manner in the range between 10 pM and 10 nM.	Alprostadil	109-113	interleukin 6	Mus musculus	41-45
9492065-4	1998	T3, which by itself had little effect on IL-6 synthesis, significantly reduced the IL-6 synthesis induced by PGE1 in a dose-dependent manner in the range between 10 pM and 10 nM.	Alprostadil	109-113	interleukin 6	Mus musculus	83-87
9492065-5	1998	T3 also reduced PGE1-induced activation of protein kinase A. T3 inhibited the IL-6 synthesis induced by cholera toxin, an activator of Gs, or forskolin, which directly activates adenylate cyclase.	Alprostadil	16-20	interleukin 6	Mus musculus	78-82
9492065-5	1998	T3 also reduced PGE1-induced activation of protein kinase A. T3 inhibited the IL-6 synthesis induced by cholera toxin, an activator of Gs, or forskolin, which directly activates adenylate cyclase.	Colforsin	142-151	interleukin 6	Mus musculus	78-82
9492065-7	1998	In addition, T3 reduced PGF2alpha-induced IL-6 synthesis dose dependently in the range between 10 pM and 10 nM.	Dinoprost	24-33	interleukin 6	Mus musculus	42-46
9492065-8	1998	T3 also inhibited IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate, an activator of protein kinase C. On the other hand, T3 markedly enhanced IL-1-induced IL-6 synthesis.	Tetradecanoylphorbol Acetate	44-80	interleukin 6	Mus musculus	18-22
9591327-3	1998	During the addition of c-PTIO to the liquid cultures of murine bone marrow cells containing a combination of IL-6 and SCF, colony-forming cells in vitro (CFC) and the colony-forming unit in the spleen (CFU-S) increased about 1.8-fold and 1.7-fold, respectively, higher than the control culture after 7 day of culture.	1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole	23-29	interleukin 6	Mus musculus	109-113
9610840-0	1998	Dietary alpha-linolenic acid increases TNF-alpha, and decreases IL-6, IL-10 in response to LPS: effects of sesamin on the delta-5 desaturation of omega6 and omega3 fatty acids in mice.	alpha-Linolenic Acid	8-28	interleukin 6	Mus musculus	64-68
9610845-0	1998	Retinoic acid suppresses interleukin-6 synthesis induced by prostaglandins in osteoblasts.	Tretinoin	0-13	interleukin 6	Mus musculus	25-38
9610845-0	1998	Retinoic acid suppresses interleukin-6 synthesis induced by prostaglandins in osteoblasts.	Prostaglandins	60-74	interleukin 6	Mus musculus	25-38
9610845-2	1998	Retinoic acid inhibited the IL-6 synthesis induced by PGF2alpha or PGE1 in a dose-dependent manner in the range between 0.1 and 10 nM.	Tretinoin	0-13	interleukin 6	Mus musculus	28-32
9610845-2	1998	Retinoic acid inhibited the IL-6 synthesis induced by PGF2alpha or PGE1 in a dose-dependent manner in the range between 0.1 and 10 nM.	Dinoprost	54-63	interleukin 6	Mus musculus	28-32
9610845-2	1998	Retinoic acid inhibited the IL-6 synthesis induced by PGF2alpha or PGE1 in a dose-dependent manner in the range between 0.1 and 10 nM.	Alprostadil	67-71	interleukin 6	Mus musculus	28-32
9610845-3	1998	Retinoic acid also suppressed the IL-6 synthesis stimulated by 12-O-tetradecanoylphorbol-13-acetate, an activator of protein kinase C. The IL-6 synthesis induced by cholera toxin, forskolin or dibutyryl cAMP was inhibited by retinoic acid.	Tretinoin	0-13	interleukin 6	Mus musculus	34-38
9610845-3	1998	Retinoic acid also suppressed the IL-6 synthesis stimulated by 12-O-tetradecanoylphorbol-13-acetate, an activator of protein kinase C. The IL-6 synthesis induced by cholera toxin, forskolin or dibutyryl cAMP was inhibited by retinoic acid.	Tretinoin	0-13	interleukin 6	Mus musculus	139-143
9610845-3	1998	Retinoic acid also suppressed the IL-6 synthesis stimulated by 12-O-tetradecanoylphorbol-13-acetate, an activator of protein kinase C. The IL-6 synthesis induced by cholera toxin, forskolin or dibutyryl cAMP was inhibited by retinoic acid.	Tetradecanoylphorbol Acetate	63-99	interleukin 6	Mus musculus	34-38
9610845-3	1998	Retinoic acid also suppressed the IL-6 synthesis stimulated by 12-O-tetradecanoylphorbol-13-acetate, an activator of protein kinase C. The IL-6 synthesis induced by cholera toxin, forskolin or dibutyryl cAMP was inhibited by retinoic acid.	Tetradecanoylphorbol Acetate	63-99	interleukin 6	Mus musculus	139-143
9610845-3	1998	Retinoic acid also suppressed the IL-6 synthesis stimulated by 12-O-tetradecanoylphorbol-13-acetate, an activator of protein kinase C. The IL-6 synthesis induced by cholera toxin, forskolin or dibutyryl cAMP was inhibited by retinoic acid.	Cyclic AMP	203-207	interleukin 6	Mus musculus	139-143
9610845-3	1998	Retinoic acid also suppressed the IL-6 synthesis stimulated by 12-O-tetradecanoylphorbol-13-acetate, an activator of protein kinase C. The IL-6 synthesis induced by cholera toxin, forskolin or dibutyryl cAMP was inhibited by retinoic acid.	Tretinoin	225-238	interleukin 6	Mus musculus	139-143
9610845-5	1998	These results indicate that retinoic acid inhibits IL-6 synthesis induced by prostaglandins in osteoblasts as follows: the inhibitory effect on the PGE1-induced IL-6 synthesis is exerted at a point downstream from cAMP, and the inhibitory effect on the PGF2alpha-induced IL-6 synthesis is exerted at a point downstream from protein kinase C.	Tretinoin	28-41	interleukin 6	Mus musculus	51-55
9610845-5	1998	These results indicate that retinoic acid inhibits IL-6 synthesis induced by prostaglandins in osteoblasts as follows: the inhibitory effect on the PGE1-induced IL-6 synthesis is exerted at a point downstream from cAMP, and the inhibitory effect on the PGF2alpha-induced IL-6 synthesis is exerted at a point downstream from protein kinase C.	Tretinoin	28-41	interleukin 6	Mus musculus	161-165
9610845-5	1998	These results indicate that retinoic acid inhibits IL-6 synthesis induced by prostaglandins in osteoblasts as follows: the inhibitory effect on the PGE1-induced IL-6 synthesis is exerted at a point downstream from cAMP, and the inhibitory effect on the PGF2alpha-induced IL-6 synthesis is exerted at a point downstream from protein kinase C.	Tretinoin	28-41	interleukin 6	Mus musculus	161-165
9493504-8	1998	Interleukin-6 also appears to be critically involved in turpentine-induced fever.	Turpentine	56-66	interleukin 6	Mus musculus	0-13
9570551-7	1998	The specific p38 inhibitor SB203580 abrogated the mycoplasma-induced IL-6, IL-1beta, and TNF-alpha synthesis.	SB 203580	27-35	interleukin 6	Mus musculus	69-73
9473534-0	1998	Role of macrophages in elevated IgA and IL-6 production by Peyer"s patch cultures following acute oral vomitoxin exposure.	deoxynivalenol	103-112	interleukin 6	Mus musculus	40-44
9462720-2	1998	IL-6 cDNA was transfected to PCI-43, one of our cultured pancreatic carcinoma cell lines that does not produce IL-6 and generates numerous metastases to the liver.	pci-43	29-35	interleukin 6	Mus musculus	0-4
9462720-3	1998	An IL-6 high-producer clone (PCI-43h) generated few metastases; IL-6 production thus has a direct effect on metastasis, whereas other transfectants (PCI-43l and PCI-43n), which are IL-6 low-, and IL-6 non-producers, respectively, did generate metastases.	pci-43h	29-36	interleukin 6	Mus musculus	3-7
9666273-8	1998	It was found that THC suppressed IL-12, IL-15 and IL-6 and increased IL-1 alpha, IL-1 beta, and TNF alpha in all of the stimulated cultures.	Dronabinol	18-21	interleukin 6	Mus musculus	50-54
9458919-8	1998	In IL-6 +/+ or IL-6 -/- mice, turpentine increased leptin protein to comparable levels.	Turpentine	30-40	interleukin 6	Mus musculus	3-7
9458919-8	1998	In IL-6 +/+ or IL-6 -/- mice, turpentine increased leptin protein to comparable levels.	Turpentine	30-40	interleukin 6	Mus musculus	15-19
9588325-2	1998	This short review considers some data concerning the effects of several cytokines, interleukin (IL)-1, IL-2, IL-6 and granulocyte-macrophage colony-stimulating factor on scopolamine-induced amnesia for a passive avoidance response, and on hippocampal neurotransmitter amino acid levels in mice.	Scopolamine	170-181	interleukin 6	Mus musculus	109-113
9414293-7	1998	IL-6 induction of MCP-1 was partially inhibited by hydrocortisone in U1 cells.	Hydrocortisone	51-65	interleukin 6	Mus musculus	0-4
9561922-15	1998	A single treatment with SDZ 280.636 appeared to increase serum levels of IL-6 up to three fold, while IFN gamma levels decreased.	Sulfadiazine	24-27	interleukin 6	Mus musculus	73-77
9464752-11	1998	In contrast, testosterone-treated female mice that had experienced hemorrhage showed significant depression in splenic and peritoneal macrophage IL-1 and IL-6 production, comparable with the values seen in macrophages from male mice that had experienced hemorrhage.	Testosterone	13-25	interleukin 6	Mus musculus	154-158
9417815-3	1997	Both IL-6-/- and IL-6+/+ mice developed hyperalgesia to mechanical and thermal stimulation after localized carrageenan injection, but the magnitude of the hyperalgesia was less in the IL-6-/- than in the IL-6+/+ controls.	Carrageenan	107-118	interleukin 6	Mus musculus	17-21
9417815-4	1997	IL-6-/- mice also exhibited less plasma extravasation after carrageenan injection.	Carrageenan	60-71	interleukin 6	Mus musculus	0-4
9570135-3	1997	STAT3 is also tyrosine phosphorylated in response to epidermal growth factor (EGF), granulocyte colony-stimulating factor (G-CSF), leptin and other IL-6-type cytokines including ciliary neurotrophic factor (CNTF), oncostatin M and leukemia inhibitory factor (LIF).	Tyrosine	14-22	interleukin 6	Mus musculus	148-152
11596184-4	1997	The effects of PMA and A23187 suggested that the pathway of PKC and calcium is involved in the production and secretion of interleukin 6.	Tetradecanoylphorbol Acetate	15-18	interleukin 6	Mus musculus	123-136
11596184-4	1997	The effects of PMA and A23187 suggested that the pathway of PKC and calcium is involved in the production and secretion of interleukin 6.	Calcimycin	23-29	interleukin 6	Mus musculus	123-136
11596184-4	1997	The effects of PMA and A23187 suggested that the pathway of PKC and calcium is involved in the production and secretion of interleukin 6.	Calcium	68-75	interleukin 6	Mus musculus	123-136
9348179-0	1997	17Beta-estradiol antagonizes effects of 1alpha,25-dihydroxyvitamin D3 on interleukin-6 production and osteoclast-like cell formation in mouse bone marrow primary cultures.	Estradiol	0-16	interleukin 6	Mus musculus	73-86
9348179-0	1997	17Beta-estradiol antagonizes effects of 1alpha,25-dihydroxyvitamin D3 on interleukin-6 production and osteoclast-like cell formation in mouse bone marrow primary cultures.	Calcitriol	40-69	interleukin 6	Mus musculus	73-86
9363904-4	1997	IL-4 and IL-6 production in BMMC stimulated with A23187 was higher in BMMC treated with low concentrations of DEP than in controls, but no increase was seen in BMMC treated with high DEP.	Calcimycin	49-55	interleukin 6	Mus musculus	9-13
9363904-5	1997	IL-4 and IL-6 production in A23187-stimulated BMMC was significantly increased at 0.5 and 1 microg/ml formaldehyde but decreased at 5 microg/ml formaldehyde.	Calcimycin	28-34	interleukin 6	Mus musculus	9-13
9363904-5	1997	IL-4 and IL-6 production in A23187-stimulated BMMC was significantly increased at 0.5 and 1 microg/ml formaldehyde but decreased at 5 microg/ml formaldehyde.	Formaldehyde	102-114	interleukin 6	Mus musculus	9-13
9363904-5	1997	IL-4 and IL-6 production in A23187-stimulated BMMC was significantly increased at 0.5 and 1 microg/ml formaldehyde but decreased at 5 microg/ml formaldehyde.	Formaldehyde	144-156	interleukin 6	Mus musculus	9-13
9312119-2	1997	Staurosporine and calphostin C, inhibitors of protein kinase C (PKC), significantly enhanced the TNF-induced synthesis of IL-6.	Staurosporine	0-13	interleukin 6	Mus musculus	122-126
9312119-2	1997	Staurosporine and calphostin C, inhibitors of protein kinase C (PKC), significantly enhanced the TNF-induced synthesis of IL-6.	calphostin C	18-30	interleukin 6	Mus musculus	122-126
9312119-3	1997	1-Oleoyl-2-acetylglycerol, a specific activator of PKC, inhibited the TNF-induced IL-6 synthesis.	1-oleoyl-2-acetylglycerol	0-25	interleukin 6	Mus musculus	82-86
9312119-11	1997	Neither C2-ceramide nor sphingosine but sphingosine 1-phosphate significantly stimulated the synthesis of IL-6.	sphingosine 1-phosphate	40-63	interleukin 6	Mus musculus	106-110
9312119-12	1997	PKC down-regulation amplified the IL-6 synthesis by sphingosine 1-phosphate.	sphingosine 1-phosphate	52-75	interleukin 6	Mus musculus	34-38
9312119-13	1997	These results strongly suggest that sphingosine 1-phosphate may act as a second messenger for TNF-induced IL-6 synthesis and that TNF autoregulates IL-6 synthesis due to PKC activation via phosphatidylcholine-specific phospholipase C in osteoblast-like cells.	sphingosine 1-phosphate	36-59	interleukin 6	Mus musculus	106-110
9312119-13	1997	These results strongly suggest that sphingosine 1-phosphate may act as a second messenger for TNF-induced IL-6 synthesis and that TNF autoregulates IL-6 synthesis due to PKC activation via phosphatidylcholine-specific phospholipase C in osteoblast-like cells.	Phosphatidylcholines	189-208	interleukin 6	Mus musculus	148-152
9331108-8	1997	The IL-6 responses of mice pretreated with 100 microg/kg genistein were decreased by more than 40%.	Genistein	57-66	interleukin 6	Mus musculus	4-8
9338609-6	1997	The levels of interleukin (IL-)6 were elevated and those of IL-1beta were decreased in mice consuming Quil-A-supplemented diets.	Quil A	102-108	interleukin 6	Mus musculus	14-32
9350286-4	1997	In vitro, primary stromal cultures stimulated with mannuronan produced high levels of interleukin(IL)-1, IL-6 and colony stimulating activity.	mannuronan	51-61	interleukin 6	Mus musculus	105-109
9380718-6	1997	Even though the Cop 1-induced T cells had not been exposed to the autoantigen MBP, they crossreacted with MBP by secretion of interleukin (IL)-4, IL-6, and IL-10.	cop 1	16-21	interleukin 6	Mus musculus	146-150
9249285-2	1997	OBJECTIVE: The present investigation compared the ability of the skin allergens oxazolone and 2,4-dinitrochlorobenzene (DNCB) and the skin irritant benzalkonium chloride (BZC) to stimulate the cutaneous expression of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in mice.	Dinitrochlorobenzene	94-118	interleukin 6	Mus musculus	217-230
9331986-5	1997	Of beta-glucans tested, only SPG-OH and GRN produced high concentrations of IL-6 in the culture supernatants.	beta-Glucans	3-15	interleukin 6	Mus musculus	76-80
9376229-3	1997	The depletion of extracellular Ca2+ by EGTA suppressed the bFGF-induced IL-6 synthesis.	Egtazic Acid	39-43	interleukin 6	Mus musculus	72-76
9376229-4	1997	TMB-8, an inhibitor of intracellular Ca2+ mobilization, also inhibited the IL-6 synthesis by bFGF.	8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate	0-5	interleukin 6	Mus musculus	75-79
9376229-7	1997	Staurosporine, an inhibitor for protein kinases, enhanced the bFGF-induced IL-6 synthesis.	Staurosporine	0-13	interleukin 6	Mus musculus	75-79
9376229-10	1997	U-73122, a phospholipase C inhibitor, enhanced the bFGF-induced IL-6 synthesis.	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	0-7	interleukin 6	Mus musculus	64-68
9376229-11	1997	Propranolol, a phosphatidic acid phosphohydrolase inhibitor, also enhanced the IL-6 synthesis by bFGF.	Propranolol	0-11	interleukin 6	Mus musculus	79-83
9328138-6	1997	Finally, BeSO4 and poly A:U augment IL-5 and IL-6 mRNA production, while lipopolysaccharide (LPS) and LiCl augment IL-6 and tumour necrosis factor-alpha (TNF-alpha) mRNA production.	Lithium Chloride	102-106	interleukin 6	Mus musculus	115-119
9341771-6	1997	A functional consequence was then demonstrated by inducing an up-regulation of interleukin-6 (IL-6) production following ZZ-CD23 incubation with monocytes.	zz	121-123	interleukin 6	Mus musculus	79-92
9341771-6	1997	A functional consequence was then demonstrated by inducing an up-regulation of interleukin-6 (IL-6) production following ZZ-CD23 incubation with monocytes.	zz	121-123	interleukin 6	Mus musculus	94-98
9284114-5	1997	In an additional experiment, we observed that chloramphenicol clearly inhibited P-LPS-stimulated expression of the CD14, IL-1beta, and IL-6 genes in calvarial cells.	Chloramphenicol	46-61	interleukin 6	Mus musculus	135-139
9281358-3	1997	It is shown that resident PMo incubated with protein kinase (PK)C inhibitors, staurosporine (SP) and its derivative GF109203-X, showed a several fold increase in the levels of Il6 mRNA in control and CSF-1-primed PMo and a parallel release of large amounts of protein.	Staurosporine	78-91	interleukin 6	Mus musculus	176-179
9281358-3	1997	It is shown that resident PMo incubated with protein kinase (PK)C inhibitors, staurosporine (SP) and its derivative GF109203-X, showed a several fold increase in the levels of Il6 mRNA in control and CSF-1-primed PMo and a parallel release of large amounts of protein.	Staurosporine	93-95	interleukin 6	Mus musculus	176-179
9281358-5	1997	When SP was added 4 h after CSF-1 priming to block CSF-1-induced protein kinase pathways, an increased amount of IL-6 release was again seen but without any increase in Il6 mRNA levels.	Staurosporine	5-7	interleukin 6	Mus musculus	113-117
9281358-7	1997	Activation of PKC by phorbol myristate acetate (PMA) also resulted in increased Il6 gene expression by control and CSF-1-primed PMo.	Tetradecanoylphorbol Acetate	21-46	interleukin 6	Mus musculus	80-83
9247147-4	1997	IL-1alpha mRNA level reached the maximum after 1 h and the second, lower increase, occurred after 8 h. IL-6 mRNA level showed first maximum after 2 h, but the highest level was found after 8 h. Similarly to NE, the expression of IL-1alpha and IL-6 genes was stimulated by selective beta-adrenergic agonist isoproterenol, beta3-selective agonist CGP-12117, forskoline and db-cAMP.	Isoproterenol	306-319	interleukin 6	Mus musculus	103-107
9247147-4	1997	IL-1alpha mRNA level reached the maximum after 1 h and the second, lower increase, occurred after 8 h. IL-6 mRNA level showed first maximum after 2 h, but the highest level was found after 8 h. Similarly to NE, the expression of IL-1alpha and IL-6 genes was stimulated by selective beta-adrenergic agonist isoproterenol, beta3-selective agonist CGP-12117, forskoline and db-cAMP.	cgp-12117	345-354	interleukin 6	Mus musculus	103-107
9247147-4	1997	IL-1alpha mRNA level reached the maximum after 1 h and the second, lower increase, occurred after 8 h. IL-6 mRNA level showed first maximum after 2 h, but the highest level was found after 8 h. Similarly to NE, the expression of IL-1alpha and IL-6 genes was stimulated by selective beta-adrenergic agonist isoproterenol, beta3-selective agonist CGP-12117, forskoline and db-cAMP.	forskoline	356-366	interleukin 6	Mus musculus	103-107
9247147-4	1997	IL-1alpha mRNA level reached the maximum after 1 h and the second, lower increase, occurred after 8 h. IL-6 mRNA level showed first maximum after 2 h, but the highest level was found after 8 h. Similarly to NE, the expression of IL-1alpha and IL-6 genes was stimulated by selective beta-adrenergic agonist isoproterenol, beta3-selective agonist CGP-12117, forskoline and db-cAMP.	Bucladesine	371-378	interleukin 6	Mus musculus	103-107
9247147-7	1997	When the expression of IL-6 was studied at the protein level, the stimulation of IL-6 gene via beta3-receptors resulted in secretion of IL-6 up to the concentration 10 ng/ml culture media in 24 h. The results indicate a new type of regulation of expression of IL-1alpha and IL-6 genes in brown adipocytes by catecholamines acting via beta3-adrenergic receptors.	Catecholamines	308-322	interleukin 6	Mus musculus	23-27
9247147-7	1997	When the expression of IL-6 was studied at the protein level, the stimulation of IL-6 gene via beta3-receptors resulted in secretion of IL-6 up to the concentration 10 ng/ml culture media in 24 h. The results indicate a new type of regulation of expression of IL-1alpha and IL-6 genes in brown adipocytes by catecholamines acting via beta3-adrenergic receptors.	Catecholamines	308-322	interleukin 6	Mus musculus	81-85
9247147-7	1997	When the expression of IL-6 was studied at the protein level, the stimulation of IL-6 gene via beta3-receptors resulted in secretion of IL-6 up to the concentration 10 ng/ml culture media in 24 h. The results indicate a new type of regulation of expression of IL-1alpha and IL-6 genes in brown adipocytes by catecholamines acting via beta3-adrenergic receptors.	Catecholamines	308-322	interleukin 6	Mus musculus	81-85
9247147-7	1997	When the expression of IL-6 was studied at the protein level, the stimulation of IL-6 gene via beta3-receptors resulted in secretion of IL-6 up to the concentration 10 ng/ml culture media in 24 h. The results indicate a new type of regulation of expression of IL-1alpha and IL-6 genes in brown adipocytes by catecholamines acting via beta3-adrenergic receptors.	Catecholamines	308-322	interleukin 6	Mus musculus	81-85
9266010-6	1997	RESULT: Our results show that 17 beta-estradiol decreases LPS-induced IL-1 alpha, IL-6, and TNF-alpha production but not IL-10, IL-12, and macrophage inflammatory protein (MIP) production by splenic macrophages.	Estradiol	30-47	interleukin 6	Mus musculus	82-86
9222544-19	1997	The above data support the notion that induction of lipocortin by dexamethasone plays a major role in the inhibition by dexamethasone of inflammatory hyperalgesia evoked by carrageenin, bradykinin and the cytokines TNF alpha, IL-1 beta and IL-6, and provides additional evidence that the biological activity of lipocortin resides within the peptide lipocortin-1(2-26).	Dexamethasone	66-79	interleukin 6	Mus musculus	240-244
9222544-19	1997	The above data support the notion that induction of lipocortin by dexamethasone plays a major role in the inhibition by dexamethasone of inflammatory hyperalgesia evoked by carrageenin, bradykinin and the cytokines TNF alpha, IL-1 beta and IL-6, and provides additional evidence that the biological activity of lipocortin resides within the peptide lipocortin-1(2-26).	Dexamethasone	120-133	interleukin 6	Mus musculus	240-244
9202127-6	1997	Forced overexpression of SSI-1 complementary DNA interfered with IL-6- and LIF-mediated apoptosis and macrophage differentiation of M1 cells, as well as IL-6 induced tyrosine-phosphorylation of a receptor glycoprotein component, gp130, and of Stat3.	Tyrosine	166-174	interleukin 6	Mus musculus	153-157
9436466-3	1997	Here, we show that the specific DP IV inhibitors Lys[Z(NO2)]-thiazolidide, Lys[Z(NO2)]-pyrrolidide inhibit DNA synthesis as well as production of IL-2, IL-6 and IL-10 of PHA-stimulated mouse splenocytes and Con A-stimulated mouse thymocytes.	lysyl-(Z(nitro))thiazolidide	49-73	interleukin 6	Mus musculus	152-156
9436466-3	1997	Here, we show that the specific DP IV inhibitors Lys[Z(NO2)]-thiazolidide, Lys[Z(NO2)]-pyrrolidide inhibit DNA synthesis as well as production of IL-2, IL-6 and IL-10 of PHA-stimulated mouse splenocytes and Con A-stimulated mouse thymocytes.	lysyl-(Z(nitro))pyrrolidide	75-98	interleukin 6	Mus musculus	152-156
9467402-8	1997	Lipopolysaccharide and lipid A from S. sputigena both exhibited biological activity in activating the clotting enzyme of Limulus amebocytes, the Schwartzman reaction, mitogenicity for murine lymphocytes and in inducing interleukin-1 alpha and interleukin-6 production in murine macrophages to the same extent as those observed for lipopolysaccharide of the Salmonella serovar typhimurium used as a positive control.	Lipid A	23-30	interleukin 6	Mus musculus	243-256
9166791-0	1997	Roles of histidine 31 and tryptophan 34 in the structure, self-association, and folding of murine interleukin-6.	Histidine	9-18	interleukin 6	Mus musculus	98-111
9166791-0	1997	Roles of histidine 31 and tryptophan 34 in the structure, self-association, and folding of murine interleukin-6.	Tryptophan	26-36	interleukin 6	Mus musculus	98-111
9166791-4	1997	Denaturant-induced equilibrium unfolding experiments monitored by fluorescence and far-UV CD showed that the increased quantum yield and blue shift of the wavelength of the emission maximum observed for mIL-6 at moderate denaturant concentrations were also associated with Trp34, rather than Trp157.	denaturant	0-10	interleukin 6	Mus musculus	203-208
9166791-4	1997	Denaturant-induced equilibrium unfolding experiments monitored by fluorescence and far-UV CD showed that the increased quantum yield and blue shift of the wavelength of the emission maximum observed for mIL-6 at moderate denaturant concentrations were also associated with Trp34, rather than Trp157.	Cadmium	90-92	interleukin 6	Mus musculus	203-208
9166791-4	1997	Denaturant-induced equilibrium unfolding experiments monitored by fluorescence and far-UV CD showed that the increased quantum yield and blue shift of the wavelength of the emission maximum observed for mIL-6 at moderate denaturant concentrations were also associated with Trp34, rather than Trp157.	denaturant	221-231	interleukin 6	Mus musculus	203-208
9189931-0	1997	Interleukin-6 affects scopolamine-induced amnesia, but not brain amino acid levels in mice.	Scopolamine	22-33	interleukin 6	Mus musculus	0-13
9189931-2	1997	In this study, we evaluated the effects of mouse interleukin-6 (IL-6) on the classical behavioural test of scopolamine-induced amnesia for a passive avoidance response in the mouse.	Scopolamine	107-118	interleukin 6	Mus musculus	49-62
9189931-2	1997	In this study, we evaluated the effects of mouse interleukin-6 (IL-6) on the classical behavioural test of scopolamine-induced amnesia for a passive avoidance response in the mouse.	Scopolamine	107-118	interleukin 6	Mus musculus	64-68
9168824-2	1997	In this report, we show that both constitutive and CSF-1-induced IL-6 release were enhanced and prolonged in the presence of the PKC inhibitors, staurosporine (SP) and its derivative, GF-109203X.	Staurosporine	145-158	interleukin 6	Mus musculus	65-69
9168824-2	1997	In this report, we show that both constitutive and CSF-1-induced IL-6 release were enhanced and prolonged in the presence of the PKC inhibitors, staurosporine (SP) and its derivative, GF-109203X.	Staurosporine	160-162	interleukin 6	Mus musculus	65-69
9168824-2	1997	In this report, we show that both constitutive and CSF-1-induced IL-6 release were enhanced and prolonged in the presence of the PKC inhibitors, staurosporine (SP) and its derivative, GF-109203X.	bisindolylmaleimide I	184-194	interleukin 6	Mus musculus	65-69
9168824-4	1997	SP was also shown to activate constitutive IL-6 release by blood monocytes and elicited PM phi but had no effect on their responsiveness to CSF-1.	Staurosporine	0-2	interleukin 6	Mus musculus	43-47
9168824-5	1997	Activation of PKC by exposure of resident PM phi to phorbol myristate acetate (PMA) also resulted in enhanced IL-6 release and PMA was shown to synergize with CSF-1.	Tetradecanoylphorbol Acetate	52-77	interleukin 6	Mus musculus	110-114
9168824-5	1997	Activation of PKC by exposure of resident PM phi to phorbol myristate acetate (PMA) also resulted in enhanced IL-6 release and PMA was shown to synergize with CSF-1.	Tetradecanoylphorbol Acetate	79-82	interleukin 6	Mus musculus	110-114
9174621-6	1997	In addition, TACA is not able to cleave the mouse pro-TNF-alpha and does not catalyze in vitro the processing of other transmembrane proteins susceptible to metalloproteinase-mediated shedding, such as interleukin-6 or TNF receptors.	4-aminocrotonic acid	13-17	interleukin 6	Mus musculus	202-215
9184920-3	1997	A role for IL-12 in the aging process was suggested when it was found that recombinant IL-12 (rIL-12) directly stimulated splenic CD5+ B cells to secrete IL-10, and both CD5+ and CD5- B cells could be directly induced to produce IL-6 in response to rIL-12.	ril-12	94-100	interleukin 6	Mus musculus	229-233
9165671-5	1997	Pretreatment with Zn2+ prior to lipopolysaccharide (LPS) infusion induced an increased heat shock protein 70 (HSP70) expression in the lungs, liver, and kidneys and significantly increased plasma levels of interleukin 6, 6-keto-PGF1 alpha, and thromboxane-B2, compared with untreated controls.	Zinc	18-22	interleukin 6	Mus musculus	206-219
9165673-3	1997	Intraperitoneal treatment of animals with amrinone (100 mg/kg) 30 min before LPS administration decreased both plasma IL-6 and IL-10 concentrations in the first phase of the response, but enhanced plasma levels of these cytokines in the second part.	Amrinone	42-50	interleukin 6	Mus musculus	118-122
9165673-4	1997	In contrast, pretreatment of the animals with theophylline (100 mg/kg) enhanced LPS-induced plasma IL-6 and IL-10 levels during the whole response.	Theophylline	46-58	interleukin 6	Mus musculus	99-103
9108382-5	1997	Moreover, BMCMCs released IL-6 upon challenge with concentrations of SCF that resulted in little or no detectable release of tumor necrosis factor-alpha, leukotriene C4, histamine, or serotonin.	bmcmcs	10-16	interleukin 6	Mus musculus	26-30
9096599-2	1997	We reexamined the effects of a variety of bile salts with differing hydrophilic-hydrophobic properties on the production of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF alpha) from monocytes and Kupffer cells.	Bile Acids and Salts	42-52	interleukin 6	Mus musculus	139-143
9096599-8	1997	In contrast, the addition of 10 nmol/L dexamethasone to monocytes significantly decreased TNF-alpha and IL-6 release (69 +/- 11% and 48 +/- 15%, respectively).	Dexamethasone	39-52	interleukin 6	Mus musculus	104-108
9084435-3	1997	The alpha 2-adrenergic agonist p-aminoclonidine (10(-7) M) inhibited IL-6 secretion (control vs. p-aminoclonidine, 100.0 +/- 4.76 vs. 59.3 +/- 6.6% of control values; p < 0.001).	apraclonidine	31-47	interleukin 6	Mus musculus	69-73
9084435-4	1997	The alpha 1-adrenergic agonist methoxamine (10(-8) M) also inhibited IL-6 secretion (100.0 +/- 4.8 vs. 71.5 +/- 3.8%; p < 0.001).	Methoxamine	31-42	interleukin 6	Mus musculus	69-73
9084435-8	1997	Electrical inhibition of IL-6 secretion was attenuated by phentolamine (10(-7) M; p = 0.0345), by naloxone (10(-6) M; p = 0.0046), by cyprodime (10(-8) M; p = 0.0014), and by the combination of cyprodime (10(-7) M) plus phentolamine (10(-8) M; p < 0.0001).	Phentolamine	58-70	interleukin 6	Mus musculus	25-29
9084435-8	1997	Electrical inhibition of IL-6 secretion was attenuated by phentolamine (10(-7) M; p = 0.0345), by naloxone (10(-6) M; p = 0.0046), by cyprodime (10(-8) M; p = 0.0014), and by the combination of cyprodime (10(-7) M) plus phentolamine (10(-8) M; p < 0.0001).	Naloxone	98-106	interleukin 6	Mus musculus	25-29
9084435-8	1997	Electrical inhibition of IL-6 secretion was attenuated by phentolamine (10(-7) M; p = 0.0345), by naloxone (10(-6) M; p = 0.0046), by cyprodime (10(-8) M; p = 0.0014), and by the combination of cyprodime (10(-7) M) plus phentolamine (10(-8) M; p < 0.0001).	cyprodime	134-143	interleukin 6	Mus musculus	25-29
9084435-8	1997	Electrical inhibition of IL-6 secretion was attenuated by phentolamine (10(-7) M; p = 0.0345), by naloxone (10(-6) M; p = 0.0046), by cyprodime (10(-8) M; p = 0.0014), and by the combination of cyprodime (10(-7) M) plus phentolamine (10(-8) M; p < 0.0001).	cyprodime	194-203	interleukin 6	Mus musculus	25-29
9084435-8	1997	Electrical inhibition of IL-6 secretion was attenuated by phentolamine (10(-7) M; p = 0.0345), by naloxone (10(-6) M; p = 0.0046), by cyprodime (10(-8) M; p = 0.0014), and by the combination of cyprodime (10(-7) M) plus phentolamine (10(-8) M; p < 0.0001).	Phentolamine	220-232	interleukin 6	Mus musculus	25-29
9106265-6	1997	The LPS-induced TNF alpha, IL-1 alpha, and IL-6 production in microglia- or astrocyte-enriched cultures were also inhibited by tyrphostin A25.	Tyrphostins	127-137	interleukin 6	Mus musculus	43-47
9155639-8	1997	The highest dose of DHEAS reduced IL-6 production by splenocytes from uninfected old mice by 75% while increasing their IL-2 secretion by nearly 50%.	Dehydroepiandrosterone Sulfate	20-25	interleukin 6	Mus musculus	34-38
9124324-0	1997	Prostaglandin F2alpha stimulates interleukin-6 synthesis via activation of PKC in osteoblast-like cells.	Dinoprost	0-21	interleukin 6	Mus musculus	33-46
9124324-3	1997	PGF2alpha significantly stimulated IL-6 synthesis in a dose-dependent manner in the range between 10 nM and 10 microM.	Dinoprost	0-9	interleukin 6	Mus musculus	35-39
9124324-4	1997	A PKC-activating phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), induced IL-6 synthesis.	Phorbol Esters	17-30	interleukin 6	Mus musculus	84-88
9124324-4	1997	A PKC-activating phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), induced IL-6 synthesis.	Tetradecanoylphorbol Acetate	32-68	interleukin 6	Mus musculus	84-88
9124324-4	1997	A PKC-activating phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), induced IL-6 synthesis.	Tetradecanoylphorbol Acetate	70-73	interleukin 6	Mus musculus	84-88
9124324-6	1997	The synthesis of IL-6 stimulated by a combination of PGF2alpha and TPA was not additive.	Dinoprost	53-62	interleukin 6	Mus musculus	17-21
9124324-6	1997	The synthesis of IL-6 stimulated by a combination of PGF2alpha and TPA was not additive.	Tetradecanoylphorbol Acetate	67-70	interleukin 6	Mus musculus	17-21
9124324-7	1997	Staurosporine, an inhibitor for protein kinases that suppressed the TPA-induced IL-6 synthesis, significantly inhibited the PGF2alpha-induced IL-6 synthesis.	Staurosporine	0-13	interleukin 6	Mus musculus	80-84
9124324-7	1997	Staurosporine, an inhibitor for protein kinases that suppressed the TPA-induced IL-6 synthesis, significantly inhibited the PGF2alpha-induced IL-6 synthesis.	Staurosporine	0-13	interleukin 6	Mus musculus	142-146
9124324-7	1997	Staurosporine, an inhibitor for protein kinases that suppressed the TPA-induced IL-6 synthesis, significantly inhibited the PGF2alpha-induced IL-6 synthesis.	Tetradecanoylphorbol Acetate	68-71	interleukin 6	Mus musculus	80-84
9124324-7	1997	Staurosporine, an inhibitor for protein kinases that suppressed the TPA-induced IL-6 synthesis, significantly inhibited the PGF2alpha-induced IL-6 synthesis.	Tetradecanoylphorbol Acetate	68-71	interleukin 6	Mus musculus	142-146
9124324-7	1997	Staurosporine, an inhibitor for protein kinases that suppressed the TPA-induced IL-6 synthesis, significantly inhibited the PGF2alpha-induced IL-6 synthesis.	Dinoprost	124-133	interleukin 6	Mus musculus	80-84
9124324-7	1997	Staurosporine, an inhibitor for protein kinases that suppressed the TPA-induced IL-6 synthesis, significantly inhibited the PGF2alpha-induced IL-6 synthesis.	Dinoprost	124-133	interleukin 6	Mus musculus	142-146
9124324-8	1997	Calphostin C, a highly specific PKC inhibitor, also suppressed the PGF2alpha-stimulated synthesis of IL-6.	calphostin C	0-12	interleukin 6	Mus musculus	101-105
9124324-8	1997	Calphostin C, a highly specific PKC inhibitor, also suppressed the PGF2alpha-stimulated synthesis of IL-6.	Dinoprost	67-76	interleukin 6	Mus musculus	101-105
9124324-9	1997	The effect of PGF2alpha on IL-6 synthesis in PKC-downregulated cells was much weaker than that in intact cells.	Dinoprost	14-23	interleukin 6	Mus musculus	27-31
9124324-10	1997	These results strongly suggest that PGF2alpha induces IL-6 synthesis via PKC activation in osteoblast-like cells.	Dinoprost	36-45	interleukin 6	Mus musculus	54-58
9071559-2	1997	IL-6PTK appears 6 h after IL-6 addition and is inhibited by tyrphostin but not genistein.	Tyrphostins	60-70	interleukin 6	Mus musculus	0-4
9073568-6	1997	IL-1 beta treatment provoked a reduction of IL-1 alpha, TNF alpha, and IL-6 without affecting PGE2, while ibuprofen provoked a later increase of IL-1 alpha, TNF alpha, and IL-6, with a decrease of PGE2.	Ibuprofen	106-115	interleukin 6	Mus musculus	172-176
9292205-6	1997	Study 2 tests the hypothesis that chronic upregulation of the neuroactive cytokine interleukin-6 (IL-6), reported to occur from 3 weeks of age in young MRL-Ipr mice, reduces preference for sucrose.	Sucrose	189-196	interleukin 6	Mus musculus	83-96
9292205-6	1997	Study 2 tests the hypothesis that chronic upregulation of the neuroactive cytokine interleukin-6 (IL-6), reported to occur from 3 weeks of age in young MRL-Ipr mice, reduces preference for sucrose.	Sucrose	189-196	interleukin 6	Mus musculus	98-102
9067638-0	1997	Prostaglandin E1 stimulates interleukin-6 secretion via protein kinase A in osteoblast-like cells.	Alprostadil	0-16	interleukin 6	Mus musculus	28-41
9067638-1	1997	We investigated the effect of prostaglandin E1 (PGE1) on the secretion of interleukin-6 (IL-6) in osteoblast-like MC3T3-E1 cells.	Alprostadil	30-46	interleukin 6	Mus musculus	74-87
9067638-1	1997	We investigated the effect of prostaglandin E1 (PGE1) on the secretion of interleukin-6 (IL-6) in osteoblast-like MC3T3-E1 cells.	Alprostadil	30-46	interleukin 6	Mus musculus	89-93
9067638-1	1997	We investigated the effect of prostaglandin E1 (PGE1) on the secretion of interleukin-6 (IL-6) in osteoblast-like MC3T3-E1 cells.	Alprostadil	48-52	interleukin 6	Mus musculus	74-87
9067638-1	1997	We investigated the effect of prostaglandin E1 (PGE1) on the secretion of interleukin-6 (IL-6) in osteoblast-like MC3T3-E1 cells.	Alprostadil	48-52	interleukin 6	Mus musculus	89-93
9155591-4	1997	RESULTS: The histopathological damage in the liver, and the concanavalin A induced release of TNF alpha and IL6 were significantly inhibited by the synthetic Arg-Gly-Asp mimetic (p < 0.001).	Arginine	158-161	interleukin 6	Mus musculus	108-111
9155591-4	1997	RESULTS: The histopathological damage in the liver, and the concanavalin A induced release of TNF alpha and IL6 were significantly inhibited by the synthetic Arg-Gly-Asp mimetic (p < 0.001).	Glycine	162-165	interleukin 6	Mus musculus	108-111
9155591-4	1997	RESULTS: The histopathological damage in the liver, and the concanavalin A induced release of TNF alpha and IL6 were significantly inhibited by the synthetic Arg-Gly-Asp mimetic (p < 0.001).	Aspartic Acid	166-169	interleukin 6	Mus musculus	108-111
9120762-2	1997	IL-6 was lecithinized by covalently binding it with a phosphatidylcholine (lecithin, PC) derivative.	Phosphatidylcholines	54-73	interleukin 6	Mus musculus	0-4
9120762-2	1997	IL-6 was lecithinized by covalently binding it with a phosphatidylcholine (lecithin, PC) derivative.	lecithin	9-17	interleukin 6	Mus musculus	0-4
9120762-2	1997	IL-6 was lecithinized by covalently binding it with a phosphatidylcholine (lecithin, PC) derivative.	pc	85-87	interleukin 6	Mus musculus	0-4
9666962-8	1997	Thalidomide treatment resulted in a significant reduction in tumor necrosis factor-alpha, interleukin 6 (IL-6) and IL-10 protein levels (blood) and mRNA expression (lungs).	Thalidomide	0-11	interleukin 6	Mus musculus	90-103
9666962-8	1997	Thalidomide treatment resulted in a significant reduction in tumor necrosis factor-alpha, interleukin 6 (IL-6) and IL-10 protein levels (blood) and mRNA expression (lungs).	Thalidomide	0-11	interleukin 6	Mus musculus	105-109
9003785-5	1996	While a similar altered pattern of IL-6 and TNF-alpha expression was observed in stimulated Rel-/- peritoneal effusion macrophages, cytotoxic activity, nitric oxide, GM-CSF and G-CSF production by these cells was normal.	Nitric Oxide	152-164	interleukin 6	Mus musculus	35-39
8955187-2	1996	Unmethylated CpG dinucleotides (CpG motif) in bacterial DNA or synthetic oligodeoxynucleotides (CpG DNA) rapidly activate murine B cells to secrete IL-6 and IgM, as well as to proliferate.	cytidylyl-3'-5'-guanosine	13-30	interleukin 6	Mus musculus	148-160
8955187-9	1996	These results suggest that CpG DNA-induced IL-6 production is mediated through a reactive oxygen intermediate-dependent pathway.	Oxygen	90-96	interleukin 6	Mus musculus	43-47
9024507-9	1996	NPC production of interleukin 1 (IL-1) and interleukin-6 (IL-6) in vitro was also increased threefold following treatment of mice with levamisole.	Levamisole	135-145	interleukin 6	Mus musculus	43-56
9024507-9	1996	NPC production of interleukin 1 (IL-1) and interleukin-6 (IL-6) in vitro was also increased threefold following treatment of mice with levamisole.	Levamisole	135-145	interleukin 6	Mus musculus	58-62
9024507-10	1996	IL-6 added in vitro to cells significantly augmented levamisole-induced proliferation of liver T cells while anti-IL-6 reduced proliferative activity to control levels.	Levamisole	53-63	interleukin 6	Mus musculus	0-4
9024507-11	1996	These findings suggested that IFN alpha/beta, IL-6, and IL-1 play important regulatory roles in controlling the proliferative response of murine liver-associated T lymphocytes to levamisole.	Levamisole	179-189	interleukin 6	Mus musculus	46-50
10851497-2	1996	Oral administration of muramyl tripeptide phosphatidylethanolamine (MTP-PE) prevented both disruption of intestinal architecture, and a decrease in the number of macrophages, and it induced the expression of IL-6, G-CSF, GM-CSF, and TNF-alpha in the intestinal tissue.	mifamurtide	23-66	interleukin 6	Mus musculus	208-212
10851497-2	1996	Oral administration of muramyl tripeptide phosphatidylethanolamine (MTP-PE) prevented both disruption of intestinal architecture, and a decrease in the number of macrophages, and it induced the expression of IL-6, G-CSF, GM-CSF, and TNF-alpha in the intestinal tissue.	mifamurtide	68-74	interleukin 6	Mus musculus	208-212
9050745-5	1996	By contrast, CsA inhibited interleukin 6 (IL-6) production only in normal mice (ED50 27 mg/kg p.o.)	Cyclosporine	13-16	interleukin 6	Mus musculus	27-40
9050745-5	1996	By contrast, CsA inhibited interleukin 6 (IL-6) production only in normal mice (ED50 27 mg/kg p.o.)	Cyclosporine	13-16	interleukin 6	Mus musculus	42-46
8940342-0	1996	Induced illness in interleukin-6 (IL-6) knock-out mice: a causal role of IL-6 in the development of the low 3,5,3"-triiodothyronine syndrome.	3,5,3"-triiodothyronine	108-131	interleukin 6	Mus musculus	73-77
9010680-4	1996	We found in erythroid cells, originated from the bone marrow precursors obtained from phenylhydrazine-treated mouse, the expression of the following cytokine genes: IL-1 alpha and IL-1 beta, IL-4, IL-6, GM-CSF, gamma-IFN and TGF-beta.	phenylhydrazine	86-101	interleukin 6	Mus musculus	197-201
8979148-0	1996	Estriol: a potent regulator of TNF and IL-6 expression in a murine model of endotoxemia.	Estriol	0-7	interleukin 6	Mus musculus	39-43
8979148-3	1996	Estradiol, for example, has been reported to regulate TNF, IL-6, IL-1 and JE expression.	Estradiol	0-9	interleukin 6	Mus musculus	59-63
8979148-7	1996	Estriol treated mice also exhibited a rapid elevation in serum IL-6 levels following LPS challenge with the peak increase occurring 1 hr post LPS.	Estriol	0-7	interleukin 6	Mus musculus	63-67
8979148-9	1996	This shift in the kinetics of IL-6 increase by estriol was inhibited by tamoxifen.	Estriol	47-54	interleukin 6	Mus musculus	30-34
8979148-9	1996	This shift in the kinetics of IL-6 increase by estriol was inhibited by tamoxifen.	Tamoxifen	72-81	interleukin 6	Mus musculus	30-34
8979148-12	1996	These results suggest that the estrogen agonist estriol can have significant quantitative, TNF, and kinetic, IL-6, effects on inflammatory monokines produced in response to an endotoxin challenge.	Estriol	48-55	interleukin 6	Mus musculus	109-113
8982101-3	1996	We demonstrated that under septic-like conditions in the presence of bacteria and lipopolysaccharide (LPS), electrically induced inhibition of interleukin 6 (IL-6) secretion was attenuated by the beta-adrenergic antagonist propranolol.	Propranolol	223-234	interleukin 6	Mus musculus	143-156
8982101-3	1996	We demonstrated that under septic-like conditions in the presence of bacteria and lipopolysaccharide (LPS), electrically induced inhibition of interleukin 6 (IL-6) secretion was attenuated by the beta-adrenergic antagonist propranolol.	Propranolol	223-234	interleukin 6	Mus musculus	158-162
8982101-5	1996	Under bacteria-rich conditions, norepinephrine (Emax = 10(-6) M, p = 0.012) and isoproterenol (Emax = 10(-6) M, p = 0.048) concentration-dependently inhibited IL-6 secretion from murine spleen slices in contrast to bacteria-free conditions.	Norepinephrine	32-46	interleukin 6	Mus musculus	159-163
8982101-5	1996	Under bacteria-rich conditions, norepinephrine (Emax = 10(-6) M, p = 0.012) and isoproterenol (Emax = 10(-6) M, p = 0.048) concentration-dependently inhibited IL-6 secretion from murine spleen slices in contrast to bacteria-free conditions.	Isoproterenol	80-93	interleukin 6	Mus musculus	159-163
9014475-3	1996	Marked increase in IL-1 beta and IL-6 was detected in cultured glomeruli of NTN in mice throughout the experiments from disease induction.	ISONICOTINAMIDINE	76-79	interleukin 6	Mus musculus	33-37
8938147-7	1996	The administration of anti-murine IL-6 receptor antibody to C-26-bearing mice reduced the weight loss of the gastrocnemius muscles to 84% of that of the control mice, whose enzymatic activity of cathepsin B+L and mRNA levels of cathepsin L and poly-Ub were significantly suppressed compared with those of the C-26-bearing mice.	poly-ub	244-251	interleukin 6	Mus musculus	34-38
8931762-0	1996	Increased IL-1, IL-6 and TNF alpha secretion and mRNA levels in WEHI-3 cells exposed to cyclopiazonic acid.	cyclopiazonic acid	88-106	interleukin 6	Mus musculus	16-20
8931762-3	1996	Without LPS stimulation, only IL-6 was increased by CPA at 5000 ng/ml after 1, 2 and 3 days.	cyclopiazonic acid	52-55	interleukin 6	Mus musculus	30-34
8931762-6	1996	IL-6 levels were increased in the presence of 100, 500 and 1000 CPA ng/ml at both 12 h and 3 days and in the presence of 100, 500, 1000 and 5000 ng/ml CPA at both 1 day and 2 days.	cyclopiazonic acid	64-67	interleukin 6	Mus musculus	0-4
8931762-6	1996	IL-6 levels were increased in the presence of 100, 500 and 1000 CPA ng/ml at both 12 h and 3 days and in the presence of 100, 500, 1000 and 5000 ng/ml CPA at both 1 day and 2 days.	cyclopiazonic acid	151-154	interleukin 6	Mus musculus	0-4
8902208-12	1996	PGE2, PGF2 alpha, and IL-6 production by decidual explants was significantly greater in tissues taken from RU486-treated mice (n = 6) than in controls (n = 3).	Mifepristone	107-112	interleukin 6	Mus musculus	22-26
8956975-7	1996	The production of the cytokines IL-6 and TNF-alpha were dependent on the dose of acemannan provided.	acemannan	81-90	interleukin 6	Mus musculus	32-36
8956977-4	1996	Semiquantitative reverse transcriptase-polymerase chain reaction analysis revealed that PTX at this dose reduced the mRNA levels for tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta and IL-6 in peripheral blood mononuclear cells (PBMC) of mice with EAE.	Pentoxifylline	88-91	interleukin 6	Mus musculus	196-200
9045947-8	1996	IL-6 values were elevated in about half of the samples treated with lentinan or CDDP and exhibited a modest inverse correlation with GST-II levels (r= -0.46).	Lentinan	68-76	interleukin 6	Mus musculus	0-4
9045947-8	1996	IL-6 values were elevated in about half of the samples treated with lentinan or CDDP and exhibited a modest inverse correlation with GST-II levels (r= -0.46).	Cisplatin	80-84	interleukin 6	Mus musculus	0-4
8906214-11	1996	Surprisingly, dexamethasone enhanced the production of IL-6 while inhibiting all the other cytokines.	Dexamethasone	14-27	interleukin 6	Mus musculus	55-59
8937427-6	1996	Pretreatment with Zn2+ prior to lipopolysaccharide (LPS) infusion induced an increased heat shock protein 70 and metallothionein expression in the lungs, liver, and kidneys and increased plasma levels of TNF alpha, IL-1 beta, IL-6, and TxB2 as opposed to untreated controls.	Zinc	18-22	interleukin 6	Mus musculus	226-230
8888704-6	1996	Suppression of Kupffer cells by previous administration of gadolinium chloride in C3H/HeN mice reduced the increase in both serum TNF-alpha and IL-6 concentrations, reduced PCNA labeling index of hepatocytes by 20%, and disturbed the regeneration of the liver.	gadolinium chloride	59-78	interleukin 6	Mus musculus	144-148
8980879-9	1996	Both IL-1 and IL-6 stimulated proliferation of Crouzon fibroblasts, whereas only IL-6 increased [3H]thymidine incorporation in normal cells.	Tritium	97-99	interleukin 6	Mus musculus	81-85
8805659-1	1996	We have previously reported that cytokines such as IL-9, IL-4, and IL-6 protect murine thymic lymphoma cell lines against dexamethasone-induced apoptosis.	Dexamethasone	122-135	interleukin 6	Mus musculus	67-71
8703029-4	1996	The exposure of BMMC to cycloheximide 0.5 h before the addition of the three exogenous cytokines inhibited by approximately 50% the level of IL-6 mRNA generated but did not inhibit the effects of KL + IL-10, indicating that IL-1beta induces the synthesis of a protein that stabilizes IL-6 mRNA.	bmmc	16-20	interleukin 6	Mus musculus	141-145
8703029-4	1996	The exposure of BMMC to cycloheximide 0.5 h before the addition of the three exogenous cytokines inhibited by approximately 50% the level of IL-6 mRNA generated but did not inhibit the effects of KL + IL-10, indicating that IL-1beta induces the synthesis of a protein that stabilizes IL-6 mRNA.	bmmc	16-20	interleukin 6	Mus musculus	284-288
8703029-4	1996	The exposure of BMMC to cycloheximide 0.5 h before the addition of the three exogenous cytokines inhibited by approximately 50% the level of IL-6 mRNA generated but did not inhibit the effects of KL + IL-10, indicating that IL-1beta induces the synthesis of a protein that stabilizes IL-6 mRNA.	Cycloheximide	24-37	interleukin 6	Mus musculus	141-145
8703029-4	1996	The exposure of BMMC to cycloheximide 0.5 h before the addition of the three exogenous cytokines inhibited by approximately 50% the level of IL-6 mRNA generated but did not inhibit the effects of KL + IL-10, indicating that IL-1beta induces the synthesis of a protein that stabilizes IL-6 mRNA.	Cycloheximide	24-37	interleukin 6	Mus musculus	284-288
8703029-5	1996	The stabilization of IL-6 mRNA was inhibited by the addition of actinomycin D at 0.5 but not 3 h after BMMC were stimulated with IL-1beta in combination with KL + IL-10, suggesting that once transcribed, the stabilizing protein is long-lived.	Dactinomycin	64-77	interleukin 6	Mus musculus	21-25
8703029-6	1996	The addition of cycloheximide to BMMC after stimulation with KL + IL-10 with or without IL-1beta increased the levels of steady-state IL-6 mRNA compared to levels in cells without drug, indicating that in addition to stimulating IL-6 transcription, KL + IL-10 induces a protein factor that destabilizes IL-6 mRNA.	Cycloheximide	16-29	interleukin 6	Mus musculus	134-138
8703029-6	1996	The addition of cycloheximide to BMMC after stimulation with KL + IL-10 with or without IL-1beta increased the levels of steady-state IL-6 mRNA compared to levels in cells without drug, indicating that in addition to stimulating IL-6 transcription, KL + IL-10 induces a protein factor that destabilizes IL-6 mRNA.	Cycloheximide	16-29	interleukin 6	Mus musculus	229-233
8703029-6	1996	The addition of cycloheximide to BMMC after stimulation with KL + IL-10 with or without IL-1beta increased the levels of steady-state IL-6 mRNA compared to levels in cells without drug, indicating that in addition to stimulating IL-6 transcription, KL + IL-10 induces a protein factor that destabilizes IL-6 mRNA.	Cycloheximide	16-29	interleukin 6	Mus musculus	229-233
8703029-6	1996	The addition of cycloheximide to BMMC after stimulation with KL + IL-10 with or without IL-1beta increased the levels of steady-state IL-6 mRNA compared to levels in cells without drug, indicating that in addition to stimulating IL-6 transcription, KL + IL-10 induces a protein factor that destabilizes IL-6 mRNA.	bmmc	33-37	interleukin 6	Mus musculus	134-138
8954184-3	1996	We have demonstrated that IL-6 is found exclusively in lymph node antigen presenting cells (LNAPC), using three different approaches: i) in vitro restimulation of CD4-positive cells, obtained from Oxazolone-treated mice, in the presence of I-A-positive LNAPC, led to a strong IL-6 response, measured in culture supernatants by ELISA.	Oxazolone	197-206	interleukin 6	Mus musculus	26-30
8886850-0	1996	The in vivo and in vitro effects of an alkylating agent, mechlorethamine, on IL-6 production in mice and the role of macrophages.	Mechlorethamine	57-72	interleukin 6	Mus musculus	77-81
8886850-1	1996	Alkylating agents, cyclophosphamide (CY) and the related compound mechlorethamine (NM), significantly increase in vivo the blood level of IL-6 but not of IL-1.	Cyclophosphamide	19-35	interleukin 6	Mus musculus	138-142
8886850-1	1996	Alkylating agents, cyclophosphamide (CY) and the related compound mechlorethamine (NM), significantly increase in vivo the blood level of IL-6 but not of IL-1.	Cyclophosphamide	37-39	interleukin 6	Mus musculus	138-142
8886850-1	1996	Alkylating agents, cyclophosphamide (CY) and the related compound mechlorethamine (NM), significantly increase in vivo the blood level of IL-6 but not of IL-1.	Mechlorethamine	66-81	interleukin 6	Mus musculus	138-142
8886850-1	1996	Alkylating agents, cyclophosphamide (CY) and the related compound mechlorethamine (NM), significantly increase in vivo the blood level of IL-6 but not of IL-1.	Mechlorethamine	83-85	interleukin 6	Mus musculus	138-142
8886850-3	1996	Thioglycollate or oil-induced peritonal macrophages (Mf) of four different mouse strains treated with NM produce significantly more IL-6 than the non-treated cells.	Thioglycolates	0-14	interleukin 6	Mus musculus	132-136
8886850-3	1996	Thioglycollate or oil-induced peritonal macrophages (Mf) of four different mouse strains treated with NM produce significantly more IL-6 than the non-treated cells.	Oils	18-21	interleukin 6	Mus musculus	132-136
8757304-5	1996	In addition, IL-6 production by splenocytes was inhibited by RST; however, IL-6 production by cells from the regional lymph nodes was enhanced.	UNII-Y5T2AJP16N	61-64	interleukin 6	Mus musculus	13-17
8896011-6	1996	IL-6 was measured in 10 mice undergoing halothane anesthesia or combined halothane-spinal anesthesia.	Halothane	40-49	interleukin 6	Mus musculus	0-4
8896011-6	1996	IL-6 was measured in 10 mice undergoing halothane anesthesia or combined halothane-spinal anesthesia.	Halothane	73-82	interleukin 6	Mus musculus	0-4
8751725-0	1996	Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia.	Glutathione	9-20	interleukin 6	Mus musculus	46-59
8751725-0	1996	Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia.	Sulfates	25-32	interleukin 6	Mus musculus	46-59
8751725-3	1996	IL-6 treatment or inoculation of the MCA-105 fibrosarcoma caused a significant increase in hepatic gamma-glutamyl-cysteine synthetase activity and a decrease in the sulfate level, glutamine/urea ratio, and glutamine/glutamate ratio, suggesting that a decrease of the proton generating cysteine catabolism in the liver may increase carbamoyl-phosphate synthesis and urea formation at the expense of net glutamine synthesis.	Sulfates	165-172	interleukin 6	Mus musculus	0-4
8751725-3	1996	IL-6 treatment or inoculation of the MCA-105 fibrosarcoma caused a significant increase in hepatic gamma-glutamyl-cysteine synthetase activity and a decrease in the sulfate level, glutamine/urea ratio, and glutamine/glutamate ratio, suggesting that a decrease of the proton generating cysteine catabolism in the liver may increase carbamoyl-phosphate synthesis and urea formation at the expense of net glutamine synthesis.	Glutamine	180-189	interleukin 6	Mus musculus	0-4
8751725-3	1996	IL-6 treatment or inoculation of the MCA-105 fibrosarcoma caused a significant increase in hepatic gamma-glutamyl-cysteine synthetase activity and a decrease in the sulfate level, glutamine/urea ratio, and glutamine/glutamate ratio, suggesting that a decrease of the proton generating cysteine catabolism in the liver may increase carbamoyl-phosphate synthesis and urea formation at the expense of net glutamine synthesis.	Urea	190-194	interleukin 6	Mus musculus	0-4
8751725-3	1996	IL-6 treatment or inoculation of the MCA-105 fibrosarcoma caused a significant increase in hepatic gamma-glutamyl-cysteine synthetase activity and a decrease in the sulfate level, glutamine/urea ratio, and glutamine/glutamate ratio, suggesting that a decrease of the proton generating cysteine catabolism in the liver may increase carbamoyl-phosphate synthesis and urea formation at the expense of net glutamine synthesis.	Cysteine	114-122	interleukin 6	Mus musculus	0-4
8751725-3	1996	IL-6 treatment or inoculation of the MCA-105 fibrosarcoma caused a significant increase in hepatic gamma-glutamyl-cysteine synthetase activity and a decrease in the sulfate level, glutamine/urea ratio, and glutamine/glutamate ratio, suggesting that a decrease of the proton generating cysteine catabolism in the liver may increase carbamoyl-phosphate synthesis and urea formation at the expense of net glutamine synthesis.	Carbamyl Phosphate	331-350	interleukin 6	Mus musculus	0-4
8751725-3	1996	IL-6 treatment or inoculation of the MCA-105 fibrosarcoma caused a significant increase in hepatic gamma-glutamyl-cysteine synthetase activity and a decrease in the sulfate level, glutamine/urea ratio, and glutamine/glutamate ratio, suggesting that a decrease of the proton generating cysteine catabolism in the liver may increase carbamoyl-phosphate synthesis and urea formation at the expense of net glutamine synthesis.	Urea	365-369	interleukin 6	Mus musculus	0-4
8751725-3	1996	IL-6 treatment or inoculation of the MCA-105 fibrosarcoma caused a significant increase in hepatic gamma-glutamyl-cysteine synthetase activity and a decrease in the sulfate level, glutamine/urea ratio, and glutamine/glutamate ratio, suggesting that a decrease of the proton generating cysteine catabolism in the liver may increase carbamoyl-phosphate synthesis and urea formation at the expense of net glutamine synthesis.	Glutamine	206-215	interleukin 6	Mus musculus	0-4
12016997-1	1998	In the present study, effects of leukotrienes on IL-6 production by mouse resident peritoneal macrophages were explored with a bioassay method involving IL-6 dependent murine hybridoma B9 cell line.	Leukotrienes	33-45	interleukin 6	Mus musculus	49-53
12016997-4	1998	The results suggest that peptide leukotrienes might play important role on IL-6 production in the local milieu of inflammation.	Leukotrienes	33-45	interleukin 6	Mus musculus	75-79
8806467-10	1996	Melatonin-treated mice (50 mg/kg) had lower serum IL-6 levels (368 +/- 154 vs 1078 +/- 146 pg/ml) and lazaroid-treated mice had lower gamma-IFN levels (7 +/- 6 vs 52 +/- 15 pg/ml) compared to those of the untreated group (P < 0.05).	Melatonin	0-9	interleukin 6	Mus musculus	50-54
8806467-13	1996	Melatonin reduced serum IL-6 levels, while lazaroid reduced serum gamma-IFN levels, suggesting different mechanisms of action.	Melatonin	0-9	interleukin 6	Mus musculus	24-28
8674335-8	1996	Plasma TNF and IL-6 concentrations transiently increased during the first 24 hrs after administration of zymosan.	Zymosan	105-112	interleukin 6	Mus musculus	15-19
8703964-0	1996	Mechanism of apoptosis suppression by phorbol ester in IL-6-starved murine plasmacytomas: role of PKC modulation and cell cycle.	Phorbol Esters	38-51	interleukin 6	Mus musculus	55-59
8703964-1	1996	We show here that the mode of cell death in IL-6-starved T1165 and T1198 plasmacytoma cell lines is apoptosis, and that it can be suppressed by phorbol ester (PMA) treatment in a protein kinase C (PKC)-mediated process that involves alpha and/or delta isozymes.	Phorbol Esters	144-157	interleukin 6	Mus musculus	44-48
8703964-1	1996	We show here that the mode of cell death in IL-6-starved T1165 and T1198 plasmacytoma cell lines is apoptosis, and that it can be suppressed by phorbol ester (PMA) treatment in a protein kinase C (PKC)-mediated process that involves alpha and/or delta isozymes.	Tetradecanoylphorbol Acetate	159-162	interleukin 6	Mus musculus	44-48
8757508-0	1996	Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice.	pristane	30-38	interleukin 6	Mus musculus	0-13
8757508-1	1996	Intraperitoneal injection of pristane induces production of interleukin-6 (IL-6) and either plasmacytosis or plasmacytoma in mice, depending upon the genetic background.	pristane	29-37	interleukin 6	Mus musculus	60-73
8757508-1	1996	Intraperitoneal injection of pristane induces production of interleukin-6 (IL-6) and either plasmacytosis or plasmacytoma in mice, depending upon the genetic background.	pristane	29-37	interleukin 6	Mus musculus	75-79
8757508-3	1996	In the present study we determined whether IL-6 is also required for pristane-induced hyperplasia of normal plasma cells.	pristane	69-77	interleukin 6	Mus musculus	43-47
8757508-4	1996	Pristane was injected intraperitoneally into IL-6-/- and IL-6 wild-type (IL-6+/+) mice.	pristane	0-8	interleukin 6	Mus musculus	45-49
8757508-4	1996	Pristane was injected intraperitoneally into IL-6-/- and IL-6 wild-type (IL-6+/+) mice.	pristane	0-8	interleukin 6	Mus musculus	57-80
8757508-10	1996	These data demonstrate that IL-6 is required for pristane-induced hyperplasia of polyclonal plasma cells in mice.	pristane	49-57	interleukin 6	Mus musculus	28-32
8699115-2	1996	Stimulation by beta-glucan (500 microg/mL) or interferon-gamma (IFN-gamma; 100 U/mL) alone had a slight effect on AM functions, but when AMs were incubated together with beta-glucan and IFN-gamma, the production and secretion of some immune mediators, such as nitric oxide, interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-alpha), were markedly augmented.	beta-Glucans	15-26	interleukin 6	Mus musculus	296-300
8891435-4	1996	The results demonstrated that although constitutive cytokine gene expression exists in both cell lines, the level of IL-6 mRNA was prominently elevated by incubation with LEH, rapidly reaching a peak at about 4 h and gradually declining over the next 20 h after LEH treatment.	LEH	171-174	interleukin 6	Mus musculus	117-121
8891435-4	1996	The results demonstrated that although constitutive cytokine gene expression exists in both cell lines, the level of IL-6 mRNA was prominently elevated by incubation with LEH, rapidly reaching a peak at about 4 h and gradually declining over the next 20 h after LEH treatment.	LEH	262-265	interleukin 6	Mus musculus	117-121
8784421-5	1996	Chlovalicin, a ovalicin derivative with a chlorinated methylene moiety at the C-1 position of the cyclohexane ring, dose-dependently inhibited the growth of IL-6 dependent MH60 cells (IC50, 7.5 microM) in the presence of 0.2 U/ml IL-6 and, to a lesser extent, the growth of B16 melanoma cells (IC50, 38 microM).	chlovalicin	0-11	interleukin 6	Mus musculus	157-161
8784421-5	1996	Chlovalicin, a ovalicin derivative with a chlorinated methylene moiety at the C-1 position of the cyclohexane ring, dose-dependently inhibited the growth of IL-6 dependent MH60 cells (IC50, 7.5 microM) in the presence of 0.2 U/ml IL-6 and, to a lesser extent, the growth of B16 melanoma cells (IC50, 38 microM).	chlovalicin	0-11	interleukin 6	Mus musculus	230-234
8784421-5	1996	Chlovalicin, a ovalicin derivative with a chlorinated methylene moiety at the C-1 position of the cyclohexane ring, dose-dependently inhibited the growth of IL-6 dependent MH60 cells (IC50, 7.5 microM) in the presence of 0.2 U/ml IL-6 and, to a lesser extent, the growth of B16 melanoma cells (IC50, 38 microM).	ovalicin	3-11	interleukin 6	Mus musculus	157-161
8784421-5	1996	Chlovalicin, a ovalicin derivative with a chlorinated methylene moiety at the C-1 position of the cyclohexane ring, dose-dependently inhibited the growth of IL-6 dependent MH60 cells (IC50, 7.5 microM) in the presence of 0.2 U/ml IL-6 and, to a lesser extent, the growth of B16 melanoma cells (IC50, 38 microM).	ovalicin	3-11	interleukin 6	Mus musculus	230-234
8683127-6	1996	Similarly, the complex of soluble mIL-11R and IL-11 was capable of mediating an IL-6-type signaling in cells that are naturally deficient in IL-11 response as shown by the activation of STAT1 and STAT3 in mouse embryonal carcinoma cells and human T cells.	mil-11r	34-41	interleukin 6	Mus musculus	80-84
8699115-2	1996	Stimulation by beta-glucan (500 microg/mL) or interferon-gamma (IFN-gamma; 100 U/mL) alone had a slight effect on AM functions, but when AMs were incubated together with beta-glucan and IFN-gamma, the production and secretion of some immune mediators, such as nitric oxide, interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-alpha), were markedly augmented.	beta-Glucans	170-181	interleukin 6	Mus musculus	296-300
8681939-1	1996	The non-conservative substitution of the tyrosine residue at position 121 of human interleukin-1 beta (IL-1 beta) generates protein mutants showing strong reduction of the capacity to induce (a) prostaglandin E2 (PGE2) release from fibroblasts and smooth muscle cells, (b) murine T-cells proliferation and (c) activation of interleukin-6 (IL-6) gene expression.	Tyrosine	41-49	interleukin 6	Mus musculus	324-337
8764378-3	1996	The methylxanthines attenuated systemic release of endogenous tumor necrosis factor (TNF) and interferon-gamma during endotoxic shock, and potently up-regulated early production of circulating interleukin-10 and interleukin-6.	methylxanthine	4-19	interleukin 6	Mus musculus	212-225
8891435-6	1996	These in vitro findings suggest that macrophages and endothelial cells may be the cellular sources of the elevated levels of IL-6 found in serum after in vivo LEH administration.	LEH	159-162	interleukin 6	Mus musculus	125-129
8639830-14	1996	In both cases, SLF synergized with IL-6 produced endogenously by CV-E cells enabling CAFC growth equivalent to that on LIF-stimulated SyS-1.	cafc	85-89	interleukin 6	Mus musculus	35-39
8681939-1	1996	The non-conservative substitution of the tyrosine residue at position 121 of human interleukin-1 beta (IL-1 beta) generates protein mutants showing strong reduction of the capacity to induce (a) prostaglandin E2 (PGE2) release from fibroblasts and smooth muscle cells, (b) murine T-cells proliferation and (c) activation of interleukin-6 (IL-6) gene expression.	Tyrosine	41-49	interleukin 6	Mus musculus	339-343
8681939-1	1996	The non-conservative substitution of the tyrosine residue at position 121 of human interleukin-1 beta (IL-1 beta) generates protein mutants showing strong reduction of the capacity to induce (a) prostaglandin E2 (PGE2) release from fibroblasts and smooth muscle cells, (b) murine T-cells proliferation and (c) activation of interleukin-6 (IL-6) gene expression.	Dinoprostone	213-217	interleukin 6	Mus musculus	324-337
8681939-1	1996	The non-conservative substitution of the tyrosine residue at position 121 of human interleukin-1 beta (IL-1 beta) generates protein mutants showing strong reduction of the capacity to induce (a) prostaglandin E2 (PGE2) release from fibroblasts and smooth muscle cells, (b) murine T-cells proliferation and (c) activation of interleukin-6 (IL-6) gene expression.	Dinoprostone	213-217	interleukin 6	Mus musculus	339-343
9024939-0	1996	Enhancement of in vivo production of IL-1 alpha and IL-6 in mice by Y-25510, a 1H-pyrazolo[3,4-b]pyridine-1 acetic acid derivative.	Y 25510	68-75	interleukin 6	Mus musculus	52-56
8814459-9	1996	Moreover, the production of cytokines (IL-6 and tumor necrosis factor-alpha (TNF-alpha)) and other mediators (prostaglandin E2 (PGE2) and nitric oxide (NO)) by peritoneal macrophages seemed to show no clear correlation with the severity of arthritis in mice.	Dinoprostone	128-132	interleukin 6	Mus musculus	39-43
8678537-8	1996	Since PGE2 has been shown to enhance IL-6 production from Colon 26 in vitro, it was speculated that UFT improve cachexia and prolongs life by decreased IL-6 resulting from decreased PGE2.	Dinoprostone	6-10	interleukin 6	Mus musculus	37-41
9024939-0	1996	Enhancement of in vivo production of IL-1 alpha and IL-6 in mice by Y-25510, a 1H-pyrazolo[3,4-b]pyridine-1 acetic acid derivative.	1H-pyrazolo(3,4-b)pyridine	79-105	interleukin 6	Mus musculus	52-56
9024939-6	1996	In conclusion, Y-25510 enhanced not only the production of endogenous IL-1 alpha and IL-6 but also that of IL-10 in healthy mice.	Y 25510	15-22	interleukin 6	Mus musculus	85-89
9024939-4	1996	The repeated treatment with Y-25510 followed by anti-IL-10 antibody for 14 days was significantly more effective than that with Y-25510 alone in increasing the concentrations of IL-1 alpha and IL-6 in C3H/HeN mice.	Y 25510	28-35	interleukin 6	Mus musculus	193-197
9024939-4	1996	The repeated treatment with Y-25510 followed by anti-IL-10 antibody for 14 days was significantly more effective than that with Y-25510 alone in increasing the concentrations of IL-1 alpha and IL-6 in C3H/HeN mice.	Y 25510	128-135	interleukin 6	Mus musculus	193-197
8642417-0	1996	Endogenous substance P mediates cold water stress-induced increase in interleukin-6 secretion from peritoneal macrophages.	Water	37-42	interleukin 6	Mus musculus	70-83
8642417-3	1996	The stress paradigm involved subjecting male C57BL/6J mice to 5 min swim tests in 10 +/- 2 degrees C water twice daily for 4 d. Cold water stress augments the lipopolysaccharide-induced IL-6 secretion from peritoneal macrophages, elevates immunoreactive SP (iSP) in the peritoneal wash fluid, and reduces iSP in certain peritoneum-containing tissues or organs (i.e., diaphragm, abdominal wall, ileum, and rectum).	Water	101-106	interleukin 6	Mus musculus	186-190
8642417-3	1996	The stress paradigm involved subjecting male C57BL/6J mice to 5 min swim tests in 10 +/- 2 degrees C water twice daily for 4 d. Cold water stress augments the lipopolysaccharide-induced IL-6 secretion from peritoneal macrophages, elevates immunoreactive SP (iSP) in the peritoneal wash fluid, and reduces iSP in certain peritoneum-containing tissues or organs (i.e., diaphragm, abdominal wall, ileum, and rectum).	Water	133-138	interleukin 6	Mus musculus	186-190
8642417-6	1996	Moreover, RP67,580, a specific SP antagonist, eliminates the cold water stress-induced augmentation of IL-6 secretion from peritoneal macrophages.	Water	66-71	interleukin 6	Mus musculus	103-107
8807501-3	1996	We report results here that show that treatment of the macrophage-like cell line RAW 264.7 with the ethylenediamine cell wall (EDA-CW) extract results in an increase in the production of both interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	ethylenediamine	100-115	interleukin 6	Mus musculus	192-205
8807501-3	1996	We report results here that show that treatment of the macrophage-like cell line RAW 264.7 with the ethylenediamine cell wall (EDA-CW) extract results in an increase in the production of both interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	ethylenediamine	100-115	interleukin 6	Mus musculus	207-211
8658528-5	1996	By reverse transcription-polymerase chain reaction we were able to show that the neutralizing antibody also partially prevented TBT-induced in vivo IL-6 expression but no TBT-induced TNF-alpha expression, suggesting a paracrine effect of IL-1alpha on IL-6 production but not TNF-alpha expression and indicating that other inflammatory mediators are involved.	tributyltin	128-131	interleukin 6	Mus musculus	251-255
8658528-5	1996	By reverse transcription-polymerase chain reaction we were able to show that the neutralizing antibody also partially prevented TBT-induced in vivo IL-6 expression but no TBT-induced TNF-alpha expression, suggesting a paracrine effect of IL-1alpha on IL-6 production but not TNF-alpha expression and indicating that other inflammatory mediators are involved.	tributyltin	128-131	interleukin 6	Mus musculus	148-152
8676079-3	1996	IL-1, TNF alpha, PGE2, parathyroid hormone (PTH) and 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25(OH)2D3) similarly induced production of IL-11 by osteoblasts, but IL-6, IL-4, and TGF beta did not.	Calcitriol	53-83	interleukin 6	Mus musculus	162-166
8793556-3	1996	Pretreatment of mice with oxazolone caused a persistent, dose-dependent inhibition of LNC proliferative activity and a parallel reduction of IL-6 secretion when mice were re-exposed, at a different site, to the same chemical.	Oxazolone	26-35	interleukin 6	Mus musculus	141-145
8643498-0	1996	Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2.	Dinoprostone	37-53	interleukin 6	Mus musculus	9-22
8643498-1	1996	Injection of mineral oils such as pristane into the peritoneal cavities of BALB/c mice results in a chronic peritonitis associated with high tissue levels of interleukin 6 (IL-6).	Mineral Oil	13-25	interleukin 6	Mus musculus	158-171
8643498-1	1996	Injection of mineral oils such as pristane into the peritoneal cavities of BALB/c mice results in a chronic peritonitis associated with high tissue levels of interleukin 6 (IL-6).	Mineral Oil	13-25	interleukin 6	Mus musculus	173-177
8643498-1	1996	Injection of mineral oils such as pristane into the peritoneal cavities of BALB/c mice results in a chronic peritonitis associated with high tissue levels of interleukin 6 (IL-6).	pristane	34-42	interleukin 6	Mus musculus	158-171
8723762-1	1996	Microglia rapidly respond to lipoplysaccharide (LPS) by transformation from resting to active states and secretion of several neuro- and immuno-regulators including tumour necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1 beta), and interleukin 6 (IL-6).	lipoplysaccharide	29-46	interleukin 6	Mus musculus	243-256
8723762-1	1996	Microglia rapidly respond to lipoplysaccharide (LPS) by transformation from resting to active states and secretion of several neuro- and immuno-regulators including tumour necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1 beta), and interleukin 6 (IL-6).	lipoplysaccharide	29-46	interleukin 6	Mus musculus	258-262
8675203-5	1996	Keratinocytes expressed detectable IL-6 only following local exposure to the contact allergen oxazolone.	Oxazolone	94-103	interleukin 6	Mus musculus	35-39
8675203-8	1996	Finally, compared with tissue isolated from mice treated with vehicle alone, draining lymph nodes prepared from animals 18 hr following sensitization with oxazolone displayed a substantial increase in both the frequency of dendritic cells and the number of IL-6+ cells within the paracortex.	Oxazolone	155-164	interleukin 6	Mus musculus	257-261
8643498-1	1996	Injection of mineral oils such as pristane into the peritoneal cavities of BALB/c mice results in a chronic peritonitis associated with high tissue levels of interleukin 6 (IL-6).	pristane	34-42	interleukin 6	Mus musculus	173-177
8643498-2	1996	Here we show that increased prostaglandin E2 (PGE2) synthesis causes induction of IL-6 and that expression of an inducible cyclooxygenase, Cox-2, may mediate this process.	Dinoprostone	28-44	interleukin 6	Mus musculus	82-86
8643498-2	1996	Here we show that increased prostaglandin E2 (PGE2) synthesis causes induction of IL-6 and that expression of an inducible cyclooxygenase, Cox-2, may mediate this process.	Dinoprostone	46-50	interleukin 6	Mus musculus	82-86
8643498-3	1996	Levels of both PGE2 and IL-6 are elevated in inflammatory exudates from pristane-treated mice compared with lavage samples from untreated mice.	pristane	72-80	interleukin 6	Mus musculus	24-28
8643498-5	1996	A cause and effect relationship between increased macrophage PGE2 and IL-6 production is shown in vitro.	Dinoprostone	61-65	interleukin 6	Mus musculus	70-74
8643498-7	1996	Cotreatment with 1 microM indomethacin inhibits PGE2 production by the cells and reduces the induction of IL-6 mRNA but has no effect on Cox-2 mRNA, consistent with the fact that the drug inhibits catalytic activity of the cyclooxygenase but does not affect expression of the gene.	Indomethacin	26-38	interleukin 6	Mus musculus	106-110
8643498-8	1996	Addition of exogenous PGE2 to macrophages induces IL-6 protein and mRNA synthesis, indicating that the eicosanoid stimulates IL-6 production at the level of gene expression.	Dinoprostone	22-26	interleukin 6	Mus musculus	50-54
8643498-8	1996	Addition of exogenous PGE2 to macrophages induces IL-6 protein and mRNA synthesis, indicating that the eicosanoid stimulates IL-6 production at the level of gene expression.	Dinoprostone	22-26	interleukin 6	Mus musculus	125-129
8643498-8	1996	Addition of exogenous PGE2 to macrophages induces IL-6 protein and mRNA synthesis, indicating that the eicosanoid stimulates IL-6 production at the level of gene expression.	Eicosanoids	103-113	interleukin 6	Mus musculus	50-54
8643498-8	1996	Addition of exogenous PGE2 to macrophages induces IL-6 protein and mRNA synthesis, indicating that the eicosanoid stimulates IL-6 production at the level of gene expression.	Eicosanoids	103-113	interleukin 6	Mus musculus	125-129
8643498-9	1996	PGE2-stimulated IL-6 production is unaffected by addition of indomethacin.	Dinoprostone	0-4	interleukin 6	Mus musculus	16-20
8643498-10	1996	Taken together with the earlier finding that indomethacin diminishes the elevation of IL-6 in pristane-treated mice, the results show that PGE2 can induce IL-6 production in vivo and implicate expression of the Cox-2 gene in the regulation of this cytokine.	Indomethacin	45-57	interleukin 6	Mus musculus	86-90
8643498-10	1996	Taken together with the earlier finding that indomethacin diminishes the elevation of IL-6 in pristane-treated mice, the results show that PGE2 can induce IL-6 production in vivo and implicate expression of the Cox-2 gene in the regulation of this cytokine.	pristane	94-102	interleukin 6	Mus musculus	86-90
8643498-10	1996	Taken together with the earlier finding that indomethacin diminishes the elevation of IL-6 in pristane-treated mice, the results show that PGE2 can induce IL-6 production in vivo and implicate expression of the Cox-2 gene in the regulation of this cytokine.	pristane	94-102	interleukin 6	Mus musculus	155-159
8643498-10	1996	Taken together with the earlier finding that indomethacin diminishes the elevation of IL-6 in pristane-treated mice, the results show that PGE2 can induce IL-6 production in vivo and implicate expression of the Cox-2 gene in the regulation of this cytokine.	Dinoprostone	139-143	interleukin 6	Mus musculus	86-90
8643498-10	1996	Taken together with the earlier finding that indomethacin diminishes the elevation of IL-6 in pristane-treated mice, the results show that PGE2 can induce IL-6 production in vivo and implicate expression of the Cox-2 gene in the regulation of this cytokine.	Dinoprostone	139-143	interleukin 6	Mus musculus	155-159
9812752-4	1996	RESULTS: Mat (125-500 mg.L-1) obviously inhibited concanavalin A (Con A, 5 mg.L-1)- and lipopolysaccarides (LPS, 10 mg.L-1)-induced splenocyte proliferation and LPS-induced release of IL-1 and IL-6 from mouse peritoneal macrophages.	lipopolysaccarides	88-106	interleukin 6	Mus musculus	193-197
8793556-5	1996	Although in mice pretreated with oxazolone IL-6 secretion by cultured LNC was impaired markedly, the initial IL-6 content of freshly isolated LNC was apparently normal.	Oxazolone	33-42	interleukin 6	Mus musculus	43-47
8793556-6	1996	These data suggest that the down-regulation of lymphocyte proliferative responses induced by exposure of mice to oxazolone, and the consequential impaired responsiveness, is associated with, and possibly secondary to, the reduced secretion by lymph node DC of IL-6, a cytokine that is a costimulator of T lymphocyte activation and the production of which correlates closely with the vigour of LNC proliferative activity.	Oxazolone	113-122	interleukin 6	Mus musculus	260-264
8758269-4	1996	The serum total bilirubin (TBIL) and liver necrosis of mice increased more markedly by using of TNF alpha, IL-6 or IFN gamma separately with D-GAL (TBIL: 46.2 +/- 10.6 micromol/L, 44.6 +/- 12.9 micromol/L, 41.9 +/- 14.9 micromol/L), then by D-GAL alone (TBIL: 27 +/- 11 micromol/L) also the serum TBIL of mice and liver necrosis also increased after injection of IL-1, IL-6 with D-GAL and TNF alpha.	Bilirubin	27-31	interleukin 6	Mus musculus	107-111
8758269-4	1996	The serum total bilirubin (TBIL) and liver necrosis of mice increased more markedly by using of TNF alpha, IL-6 or IFN gamma separately with D-GAL (TBIL: 46.2 +/- 10.6 micromol/L, 44.6 +/- 12.9 micromol/L, 41.9 +/- 14.9 micromol/L), then by D-GAL alone (TBIL: 27 +/- 11 micromol/L) also the serum TBIL of mice and liver necrosis also increased after injection of IL-1, IL-6 with D-GAL and TNF alpha.	Galactosamine	141-146	interleukin 6	Mus musculus	369-373
8739314-7	1996	When the animals were treated with 4-DPD at the reported dosages and infected with T. spiralis the inhibition of TNF alpha and IL-6, were dose-dependent in the first 7 days while IL-4 was reduced only at 400-800 micrograms/bolus.	4-deoxypyridoxine	35-40	interleukin 6	Mus musculus	127-131
8703576-3	1996	This article tests the hypothesis that tartrate-resistant acid phosphatase-positive osteoclasts (TRAP + OC) in neonatal mouse parietal bones are the major source of IL-6.	tartaric acid	39-47	interleukin 6	Mus musculus	165-169
8703576-4	1996	Bones were preincubated with indomethacin to decrease the number of TRAP + OC and the amount of IL-6 produced.	Indomethacin	29-41	interleukin 6	Mus musculus	96-100
8703576-5	1996	Incubation with parathyroid hormone or prostaglandin E2 increased the number of TRAP + OC and the amount of IL-6 produced.	Dinoprostone	39-55	interleukin 6	Mus musculus	108-112
8596046-10	1996	Furthermore, we found that endogenous IL-6 is partially involved in PGE2-stimulated osteoclast formation.	Dinoprostone	68-72	interleukin 6	Mus musculus	38-42
8697140-8	1996	Furthermore, the data presented are consistent with the hypothesis that IL-1 + M-CSF initially acts on a multilineage, 5-FU-resistant target cell and that IL-6 (and possibly IL-3 and GM-CSF) serves as a secondary cytokine further to enhance platelet production during rebound thrombopoiesis in the 5-FU-treated mouse.	Fluorouracil	298-302	interleukin 6	Mus musculus	155-159
8697148-0	1996	Involvement of interleukin-6 and interferon-alpha in the poly(A).Poly(U)-induced 2",5"-oligoadenylate synthetase activity in the mouse monocyte-macrophage cell line, J774A1.	Poly A	57-64	interleukin 6	Mus musculus	15-28
8697148-0	1996	Involvement of interleukin-6 and interferon-alpha in the poly(A).Poly(U)-induced 2",5"-oligoadenylate synthetase activity in the mouse monocyte-macrophage cell line, J774A1.	Poly U	65-72	interleukin 6	Mus musculus	15-28
8697148-3	1996	It was first demonstrated that among the anticytokine antibodies, only monoclonal antibodies directed against IL-6 inhibited the induction of 2",5"-oligoadenylate synthetase by poly(A).poly(U) in a dose-dependent manner.	Poly A	177-183	interleukin 6	Mus musculus	110-114
8697148-4	1996	Moreover, it was established that poly(A).poly(U) elicited IL-6 production in J774A1 cells in a time-and dose-dependent manner.	Poly A	34-41	interleukin 6	Mus musculus	59-63
8697148-4	1996	Moreover, it was established that poly(A).poly(U) elicited IL-6 production in J774A1 cells in a time-and dose-dependent manner.	Poly U	42-49	interleukin 6	Mus musculus	59-63
8920166-5	1996	Progesterone (10(-7) M) modestly (40%) reduced the levels of IL-6 mRNA and protein during culture, whereas LPS dramatically (8-fold) and rapidly induced IL-6 and IL-1 beta mRNAs and proteins.	Progesterone	0-12	interleukin 6	Mus musculus	61-65
8920166-5	1996	Progesterone (10(-7) M) modestly (40%) reduced the levels of IL-6 mRNA and protein during culture, whereas LPS dramatically (8-fold) and rapidly induced IL-6 and IL-1 beta mRNAs and proteins.	lps	107-110	interleukin 6	Mus musculus	153-157
8920166-10	1996	In contrast, after LPS injection (2 h), IL-6 mRNA was abundant in "cords" of cells that traverse the mesometrial deciduum longitudinally, as well as in cells dispersed throughout the myometrium.	lps	19-22	interleukin 6	Mus musculus	40-44
8571396-0	1996	Stimulation by oxazolone of increased IL-6, but not IL-10, in the skin of mice.	Oxazolone	15-24	interleukin 6	Mus musculus	38-42
8571396-2	1996	We have investigated the production of cutaneous IL-6 following topical exposure of mice to oxazolone, a potent contact allergen.	Oxazolone	92-101	interleukin 6	Mus musculus	49-53
8571396-4	1996	Topical application of oxazolone to the ears of mice induced a rapid and dose-dependent increase in IL-6 expression that was maximal 4-8 h following application and remained elevated for up to 24 h. Under the same conditions of exposure the expression of a second epidermal cytokine, interleukin 10, a product of keratinocytes, was unaffected.	Oxazolone	23-32	interleukin 6	Mus musculus	100-104
9074719-6	1996	By in vitro and ex vivo experiments in mice, heparin and other glycosaminoglycans were shown to stimulate megakaryocytopoiesis by acting synergistically with thrombopoietin and interleukin 6, and in the other hand by neutralizing inhibitors of megakaryocytopoiesis such as platelet factor 4 and transforming growth factor beta.	Heparin	45-52	interleukin 6	Mus musculus	177-190
9074719-6	1996	By in vitro and ex vivo experiments in mice, heparin and other glycosaminoglycans were shown to stimulate megakaryocytopoiesis by acting synergistically with thrombopoietin and interleukin 6, and in the other hand by neutralizing inhibitors of megakaryocytopoiesis such as platelet factor 4 and transforming growth factor beta.	Glycosaminoglycans	63-81	interleukin 6	Mus musculus	177-190
8565593-6	1996	Treatment of macrophages with siloxanes resulted in a higher production of interleukin-6 (IL-6) than was exhibited by untreated macrophages.	Siloxanes	30-39	interleukin 6	Mus musculus	75-88
8565593-6	1996	Treatment of macrophages with siloxanes resulted in a higher production of interleukin-6 (IL-6) than was exhibited by untreated macrophages.	Siloxanes	30-39	interleukin 6	Mus musculus	90-94
8704099-3	1996	PAF is a phospholipid mediator of inflammation with stimulates IL-6 production by murine skin fibroblasts.	Phospholipids	9-21	interleukin 6	Mus musculus	63-67
8666421-7	1996	The fraction passed through the heparin column sustained the growth of IL-6-dependent MH60.BSF-2 cells.	Heparin	32-39	interleukin 6	Mus musculus	71-75
8821678-3	1996	In the present study we have addressed this by examination of the local cutaneous production of interleukin 6 (IL-6) following topical exposure of mice to oxazolone, a potent contact allergen, or to benzalkonium chloride (BZC), a skin irritant that is considered not to have a significant potential to cause skin sensitization.	Oxazolone	155-164	interleukin 6	Mus musculus	96-109
8821678-3	1996	In the present study we have addressed this by examination of the local cutaneous production of interleukin 6 (IL-6) following topical exposure of mice to oxazolone, a potent contact allergen, or to benzalkonium chloride (BZC), a skin irritant that is considered not to have a significant potential to cause skin sensitization.	Oxazolone	155-164	interleukin 6	Mus musculus	111-115
8821678-3	1996	In the present study we have addressed this by examination of the local cutaneous production of interleukin 6 (IL-6) following topical exposure of mice to oxazolone, a potent contact allergen, or to benzalkonium chloride (BZC), a skin irritant that is considered not to have a significant potential to cause skin sensitization.	Benzalkonium Compounds	199-220	interleukin 6	Mus musculus	96-109
8821678-4	1996	Both oxazolone and BZC could induce the production of IL-6 as measured by enzyme-linked immunosorbent assay in homogenates prepared from treated skin.	Oxazolone	5-14	interleukin 6	Mus musculus	54-58
8821678-4	1996	Both oxazolone and BZC could induce the production of IL-6 as measured by enzyme-linked immunosorbent assay in homogenates prepared from treated skin.	Benzalkonium Compounds	19-22	interleukin 6	Mus musculus	54-58
8821678-5	1996	However, when these chemicals were applied at concentrations that resulted in equivalent cutaneous inflammatory responses, based on induced oedema, only oxazolone provoked the production in skin of IL-6.	Oxazolone	153-162	interleukin 6	Mus musculus	198-202
8821678-7	1996	These data suggest that the ability of oxazolone to stimulate local IL-6 production is not secondary simply to the induction of local inflammatory responses.	Oxazolone	39-48	interleukin 6	Mus musculus	68-72
8954167-0	1996	Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation.	Eicosanoids	15-26	interleukin 6	Mus musculus	61-64
8954167-13	1996	These results suggest that eicosanoids may prevent the cachexia mediated by IL-6.	Eicosanoids	27-38	interleukin 6	Mus musculus	76-80
8592085-4	1996	Whereas resting cells did not produce IL-6 protein, PMA/A23187-stimulated cells released immunoreactive and biologically active IL-6, as demonstrated and quantitated by enzyme-linked immunosorbent assay and by the use of TEPC 1033 cells, an IL-6-dependent murine plasmacytoma cell line.	Calcimycin	56-62	interleukin 6	Mus musculus	128-132
8592085-4	1996	Whereas resting cells did not produce IL-6 protein, PMA/A23187-stimulated cells released immunoreactive and biologically active IL-6, as demonstrated and quantitated by enzyme-linked immunosorbent assay and by the use of TEPC 1033 cells, an IL-6-dependent murine plasmacytoma cell line.	Calcimycin	56-62	interleukin 6	Mus musculus	128-132
8598393-7	1996	Results showed that naloxone was able to partially block U50,488H suppression while norBNI was able to completely reverse the suppression of IL-6 production.	norbinaltorphimine	84-90	interleukin 6	Mus musculus	141-145
11012219-6	1996	Addition of a cocktail of hemopoietic growth factors to beta-estradiol-treated cells, including interleukin 6 (IL-6), IL-3 and stem cell factor further improved the survival time in culture and increased the percentage of large mature cells, but did not result in immortalization.	Estradiol	56-70	interleukin 6	Mus musculus	96-109
11012219-6	1996	Addition of a cocktail of hemopoietic growth factors to beta-estradiol-treated cells, including interleukin 6 (IL-6), IL-3 and stem cell factor further improved the survival time in culture and increased the percentage of large mature cells, but did not result in immortalization.	Estradiol	56-70	interleukin 6	Mus musculus	111-115
8560486-5	1996	Dexamethasone (Dex), cadmium (Cd), mercury (Hg), or zinc (Zn) increased (three- to fourfold) MT protein in the astrocytes, whereas methyl mercury, lead, and interleukin-1 and -6 were ineffective.	Dexamethasone	0-13	interleukin 6	Mus musculus	157-177
8560486-5	1996	Dexamethasone (Dex), cadmium (Cd), mercury (Hg), or zinc (Zn) increased (three- to fourfold) MT protein in the astrocytes, whereas methyl mercury, lead, and interleukin-1 and -6 were ineffective.	Dexamethasone	0-3	interleukin 6	Mus musculus	157-177
8560486-5	1996	Dexamethasone (Dex), cadmium (Cd), mercury (Hg), or zinc (Zn) increased (three- to fourfold) MT protein in the astrocytes, whereas methyl mercury, lead, and interleukin-1 and -6 were ineffective.	Cadmium	21-28	interleukin 6	Mus musculus	157-177
8597423-3	1995	Macrophages are sensitive to stress in that cold-water stress causes increased cytokine production, either spontaneously (IL-1), or after induction with LPS (IL-6, TNF alpha).	Water	49-54	interleukin 6	Mus musculus	158-162
8597423-17	1995	Capsaicin pretreatment diminished the enhanced cytokine production in response to stress, such that levels of TNF alpha and IL-6 approximated those of control mice.	Capsaicin	0-9	interleukin 6	Mus musculus	124-128
7498364-11	1995	We suggest that the endogenous production of cytokines such as IL-1, IL-6, IL-3, SCF, and GM-CSF in mice treated with AS101 offers protection to circulating blood elements and ameliorates the reconstitution of megakaryocytic and erythroid progenitors.	ammonium trichloro(dioxoethylene-O,O'-)tellurate	118-123	interleukin 6	Mus musculus	69-73
8788232-1	1995	The aim of this study was to evaluate the effect of gallium nitrate, gallium-nitrilotriacetate (NTA) complex, and liposomal gallium-NTA on IL-6, TNF alpha, and nitric oxide (NO) release from activated macrophages.	gallium-nta	124-135	interleukin 6	Mus musculus	139-143
8788232-3	1995	Gallium inhibited dose-dependently the secretion of IL-6, TNF alpha, and NO from the LPS-induced macrophage-like RAW 264 cells.	Gallium	0-7	interleukin 6	Mus musculus	52-56
8964654-5	1995	IL-1, IL-4, and IL-6 modified cell proliferation in general, and their effects had some age-related differences, but these actions were independent of THC.	Dronabinol	151-154	interleukin 6	Mus musculus	16-20
7594495-3	1995	Selective PDE IV inhibitors (rolipram and RO-20-1724), but not selective inhibitors of other types of PDE, significantly augment marcrophage IL-10 production and contribute to the inhibition of TNF-alpha and IL-6 release.	Rolipram	29-37	interleukin 6	Mus musculus	208-212
7594495-3	1995	Selective PDE IV inhibitors (rolipram and RO-20-1724), but not selective inhibitors of other types of PDE, significantly augment marcrophage IL-10 production and contribute to the inhibition of TNF-alpha and IL-6 release.	4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone	42-52	interleukin 6	Mus musculus	208-212
7594495-7	1995	In endotoxemic mice, the administration of rolipram increases serum IL-10 and reduces TNF-alpha and IL-6 levels.	Rolipram	43-51	interleukin 6	Mus musculus	100-104
7491773-7	1995	TNF-alpha, IL-6, and iNOS are also evident in the brains of mice with MHV-induced acute encephalitis, but in marked contrast to the results obtained with the chronically infected mice, most of the cells expressing these cytokines or iNOS had the morphology of macrophages or other mononuclear cells and very few appeared to be astrocytes.	mhv	70-73	interleukin 6	Mus musculus	11-15
8788124-5	1995	However, plasma IFN-gamma was significantly reduced at 24 h and plasma IL-6 levels were elevated 48 h after anti-CD3 injection in TCDD-treated mice.	Polychlorinated Dibenzodioxins	130-134	interleukin 6	Mus musculus	71-75
8788124-6	1995	In addition, TCDD exposure resulted in elevated levels of plasma GM-CSF at 24 and 48 h. Since the body weight of TCDD-treated mice diverged from vehicle-treated mice at 48 h, it suggests that the increased IL-6 and GM-CSF may have contributed to the prolonged loss of body weight.	Polychlorinated Dibenzodioxins	13-17	interleukin 6	Mus musculus	206-210
8788124-6	1995	In addition, TCDD exposure resulted in elevated levels of plasma GM-CSF at 24 and 48 h. Since the body weight of TCDD-treated mice diverged from vehicle-treated mice at 48 h, it suggests that the increased IL-6 and GM-CSF may have contributed to the prolonged loss of body weight.	Polychlorinated Dibenzodioxins	113-117	interleukin 6	Mus musculus	206-210
7595216-3	1995	When dexamethasone was added to the cocultures, IL-6 could stimulate osteoclast formation without the help of soluble IL-6R.	Dexamethasone	5-18	interleukin 6	Mus musculus	48-52
7595216-6	1995	By immunoblotting with antiphosphotyrosine antibody, IL-6 did not tyrosine-phosphorylate a protein with a molecular mass of 130 kD in osteoblastic cells but did so in dexamethasone-pretreated osteoblastic cells.	Tyrosine	34-42	interleukin 6	Mus musculus	53-57
7595216-6	1995	By immunoblotting with antiphosphotyrosine antibody, IL-6 did not tyrosine-phosphorylate a protein with a molecular mass of 130 kD in osteoblastic cells but did so in dexamethasone-pretreated osteoblastic cells.	Dexamethasone	167-180	interleukin 6	Mus musculus	53-57
7547897-2	1995	The urea-induced unfolding of mIL-6 at pH 4.0 can be described by a two-state unfolding mechanism based on the superimposibility of the CD and fluorescence unfolding transitions.	Urea	4-8	interleukin 6	Mus musculus	30-35
7547897-8	1995	The fluorescence emission maximum of mIL-6 at pH 7.4 in the presence of 1.5 M GuHCl, for example, was blue-shifted from 343 nm at a protein concentration of 50 micrograms/mL to 336 nm at 500 micrograms/mL.	guhcl	78-83	interleukin 6	Mus musculus	37-42
7673730-9	1995	The results from Cl2MBP-liposome-treated mice also suggested that splenic macrophages were the primary producers of LPS-induced IL-1 beta, IL-6, IL-12 (p40), and IL-1 receptor antagonist (IL-1ra) mRNA, but not IL-10 and TNF-alpha mRNA.	cl2mbp	17-23	interleukin 6	Mus musculus	139-143
11854843-0	1995	Interleukin-6 Gene Expression by Prostaglandins and Cyclic AMP Mediated by Multiple Regulatory Elements.	Prostaglandins	33-47	interleukin 6	Mus musculus	0-13
11854843-0	1995	Interleukin-6 Gene Expression by Prostaglandins and Cyclic AMP Mediated by Multiple Regulatory Elements.	Cyclic AMP	52-62	interleukin 6	Mus musculus	0-13
11854843-1	1995	We have evaluated the potential role of prostaglandins and their second-messenger Cyclic Adenosine Monophosphate (cAMP) in the activation of interleukin-6 (IL-6) promoter regulatory elements leading to IL-6 expression in monocytic cells.	Prostaglandins	40-54	interleukin 6	Mus musculus	141-154
11854843-1	1995	We have evaluated the potential role of prostaglandins and their second-messenger Cyclic Adenosine Monophosphate (cAMP) in the activation of interleukin-6 (IL-6) promoter regulatory elements leading to IL-6 expression in monocytic cells.	Prostaglandins	40-54	interleukin 6	Mus musculus	156-160
11854843-1	1995	We have evaluated the potential role of prostaglandins and their second-messenger Cyclic Adenosine Monophosphate (cAMP) in the activation of interleukin-6 (IL-6) promoter regulatory elements leading to IL-6 expression in monocytic cells.	Prostaglandins	40-54	interleukin 6	Mus musculus	202-206
11854843-1	1995	We have evaluated the potential role of prostaglandins and their second-messenger Cyclic Adenosine Monophosphate (cAMP) in the activation of interleukin-6 (IL-6) promoter regulatory elements leading to IL-6 expression in monocytic cells.	Cyclic AMP	82-112	interleukin 6	Mus musculus	141-154
11854843-1	1995	We have evaluated the potential role of prostaglandins and their second-messenger Cyclic Adenosine Monophosphate (cAMP) in the activation of interleukin-6 (IL-6) promoter regulatory elements leading to IL-6 expression in monocytic cells.	Cyclic AMP	82-112	interleukin 6	Mus musculus	156-160
11854843-1	1995	We have evaluated the potential role of prostaglandins and their second-messenger Cyclic Adenosine Monophosphate (cAMP) in the activation of interleukin-6 (IL-6) promoter regulatory elements leading to IL-6 expression in monocytic cells.	Cyclic AMP	82-112	interleukin 6	Mus musculus	202-206
11854843-1	1995	We have evaluated the potential role of prostaglandins and their second-messenger Cyclic Adenosine Monophosphate (cAMP) in the activation of interleukin-6 (IL-6) promoter regulatory elements leading to IL-6 expression in monocytic cells.	Cyclic AMP	114-118	interleukin 6	Mus musculus	141-154
11854843-1	1995	We have evaluated the potential role of prostaglandins and their second-messenger Cyclic Adenosine Monophosphate (cAMP) in the activation of interleukin-6 (IL-6) promoter regulatory elements leading to IL-6 expression in monocytic cells.	Cyclic AMP	114-118	interleukin 6	Mus musculus	156-160
11854843-1	1995	We have evaluated the potential role of prostaglandins and their second-messenger Cyclic Adenosine Monophosphate (cAMP) in the activation of interleukin-6 (IL-6) promoter regulatory elements leading to IL-6 expression in monocytic cells.	Cyclic AMP	114-118	interleukin 6	Mus musculus	202-206
11854843-2	1995	We demonstrate that prostaglandins of the E series and their second-messenger cAMP induce the IL-6 promoter in the murine monocytic cell line PU5-1.8.	Prostaglandins	20-34	interleukin 6	Mus musculus	94-98
11854843-2	1995	We demonstrate that prostaglandins of the E series and their second-messenger cAMP induce the IL-6 promoter in the murine monocytic cell line PU5-1.8.	Cyclic AMP	78-82	interleukin 6	Mus musculus	94-98
11854843-4	1995	We show that the endogenous IL-6 gene is induced by cAMP as well, even though to a lesser extent than by LPS, suggesting distinctive effects of cAMP and LPS on posttranscriptional events.	Cyclic AMP	52-56	interleukin 6	Mus musculus	28-32
11854843-4	1995	We show that the endogenous IL-6 gene is induced by cAMP as well, even though to a lesser extent than by LPS, suggesting distinctive effects of cAMP and LPS on posttranscriptional events.	Cyclic AMP	144-148	interleukin 6	Mus musculus	28-32
11854843-8	1995	Our results suggest that cAMP and prostaglandins act through multiple, partially redundant, regulatory elements to induce IL-6 expression in monocytic cells.	Cyclic AMP	25-29	interleukin 6	Mus musculus	122-126
11854843-8	1995	Our results suggest that cAMP and prostaglandins act through multiple, partially redundant, regulatory elements to induce IL-6 expression in monocytic cells.	Prostaglandins	34-48	interleukin 6	Mus musculus	122-126
7554451-10	1995	IL-6 and TNF alpha proteins were undetectable in both young and old CR groups, whereas an increase in IL-6 (4.7-fold) and TNF alpha (9.3-fold) was observed in old AL mice.	Aluminum	163-165	interleukin 6	Mus musculus	102-106
7649114-1	1995	Studies in murine models of osteoporosis have suggested the hypothesis that ovarian steroids may control osteoclastic bone remodeling by limiting the production of interleukin-6 (IL-6) from osteoblasts and bone marrow stromal cells.	Steroids	84-92	interleukin 6	Mus musculus	164-177
7649114-1	1995	Studies in murine models of osteoporosis have suggested the hypothesis that ovarian steroids may control osteoclastic bone remodeling by limiting the production of interleukin-6 (IL-6) from osteoblasts and bone marrow stromal cells.	Steroids	84-92	interleukin 6	Mus musculus	179-183
7590877-3	1995	Animals pretreated for 4 days with 17 alpha ethinyl oestradiol exhibited divergent regulation of TNF and IL-6 levels in sera from endotoxin-stimulated mice.	17 alpha ethinyl oestradiol	35-62	interleukin 6	Mus musculus	105-109
7590877-5	1995	These oestrogenic effects were dose dependent with maximal elevations observed in TNF at 1 mg/kg and maximal reduction in IL-6 at 0.1 mg/kg of 17 alpha ethinyl oestradiol.	alpha ethinyl oestradiol	146-170	interleukin 6	Mus musculus	122-126
7590877-7	1995	Oestrogen-mediated modulation of the TNF and IL-6 response to endotoxin was also apparent in animals implanted with 17 beta oestradiol pellets.	Estradiol	116-134	interleukin 6	Mus musculus	45-49
7590877-10	1995	Oestradiol-treated macrophage cultures produced three- to fourfold lower amounts of IL-6 without any significant modulatory effects on TNF secretion.	Estradiol	0-10	interleukin 6	Mus musculus	84-88
7676455-0	1995	Cadmium-induced renal damage and proinflammatory cytokines: possible role of IL-6 in tubular epithelial cell regeneration.	Cadmium	0-7	interleukin 6	Mus musculus	77-81
7676455-3	1995	Increases in TNF-alpha and IL-6 cytokine mRNA transcripts and secretion were observed in the kidney following exposure of LPS-primed mice to a total of 21 mg/kg body weight cadmium administered over a 14-week period.	Cadmium	173-180	interleukin 6	Mus musculus	27-31
7676455-5	1995	Cadmium, in the presence of LPS, was able to induce IL-6 secretion in vitro from mouse glomerular mesangial cells.	Cadmium	0-7	interleukin 6	Mus musculus	52-56
7676455-8	1995	Taken together, these data suggest that cadmium-induced IL-6 secretion in the kidney may act to support the regeneration of renal tubular epithelial cells that occurs in the course of cadmium nephrotoxicity.	Cadmium	40-47	interleukin 6	Mus musculus	56-60
7676455-8	1995	Taken together, these data suggest that cadmium-induced IL-6 secretion in the kidney may act to support the regeneration of renal tubular epithelial cells that occurs in the course of cadmium nephrotoxicity.	Cadmium	184-191	interleukin 6	Mus musculus	56-60
8579900-5	1995	Both of these steroids exert their effects by inhibiting the transcriptional activity of the IL-6 gene promoter via mechanisms involving their respective specific receptors.	Steroids	14-22	interleukin 6	Mus musculus	93-97
7622893-5	1995	TNF-alpha and IL-6 protein production was reduced 50% by DFO B.	Deferoxamine	57-60	interleukin 6	Mus musculus	14-18
7631152-9	1995	On the other hand, thymocytes augmented IL-6 production by TEC cells in coculture, an effect which could not be reproduced by thymocyte culture supernatant and was not inhibited by thymocyte pretreatment with formaldehyde or emetine.	Emetine	225-232	interleukin 6	Mus musculus	40-44
7638750-10	1995	Pretreatment of endotoxemic mice with indomethacin or NNA blunted the increase in mucosal IL-6.	Indomethacin	38-50	interleukin 6	Mus musculus	90-94
7638750-10	1995	Pretreatment of endotoxemic mice with indomethacin or NNA blunted the increase in mucosal IL-6.	Nitroarginine	54-57	interleukin 6	Mus musculus	90-94
7619065-7	1995	Addition of 1 microM dexamethasone (Dex) and recombinant mouse interleukin-6 (IL-6; 100 units/ml) increased MT accumulation by 8.6-fold in MT+/+ hepatocytes (at 50 microM Zn) and there was an associated parallel increase in intZn.	Dexamethasone	21-34	interleukin 6	Mus musculus	78-82
7619065-7	1995	Addition of 1 microM dexamethasone (Dex) and recombinant mouse interleukin-6 (IL-6; 100 units/ml) increased MT accumulation by 8.6-fold in MT+/+ hepatocytes (at 50 microM Zn) and there was an associated parallel increase in intZn.	Zinc	171-173	interleukin 6	Mus musculus	63-76
7619065-7	1995	Addition of 1 microM dexamethasone (Dex) and recombinant mouse interleukin-6 (IL-6; 100 units/ml) increased MT accumulation by 8.6-fold in MT+/+ hepatocytes (at 50 microM Zn) and there was an associated parallel increase in intZn.	Zinc	171-173	interleukin 6	Mus musculus	78-82
7578978-0	1995	The modulation of IL-6 and TNF-alpha release by nitric oxide following stimulation of J774 cells with LPS and IFN-gamma.	Nitric Oxide	48-60	interleukin 6	Mus musculus	18-22
7578978-3	1995	L-NIO (10-1000 microM) produced a concentration-dependent potentiation of LPS and IFN-gamma induced IL-6 release.	N(G)-iminoethylornithine	0-5	interleukin 6	Mus musculus	100-104
7578978-4	1995	Time-course studies demonstrated a significant potentiation of IL-6 release at 12 h with a maximum effect at 48 h. By contrast to its effects on IL-6, L-NIO significantly attenuated TNF-alpha release, and at 48 h reduced PGE2 release.	N(G)-iminoethylornithine	151-156	interleukin 6	Mus musculus	63-67
7578978-4	1995	Time-course studies demonstrated a significant potentiation of IL-6 release at 12 h with a maximum effect at 48 h. By contrast to its effects on IL-6, L-NIO significantly attenuated TNF-alpha release, and at 48 h reduced PGE2 release.	Dinoprostone	221-225	interleukin 6	Mus musculus	63-67
7578978-5	1995	The NO-donor S-nitroso-N-acetyl-penicillamine (SNAP,300 microM), significantly inhibited LPS and IFN-gamma induced IL-6 release, but potentiated TNF-alpha release.	S-Nitroso-N-Acetylpenicillamine	13-45	interleukin 6	Mus musculus	115-119
7578978-5	1995	The NO-donor S-nitroso-N-acetyl-penicillamine (SNAP,300 microM), significantly inhibited LPS and IFN-gamma induced IL-6 release, but potentiated TNF-alpha release.	S-Nitroso-N-Acetylpenicillamine	47-51	interleukin 6	Mus musculus	115-119
8935661-2	1996	Compared to an enterobacterial LPS (SAE-LPS), B. pseudomallei LPS (BP-LPS) exhibited weaker pyrogenic activity in rabbits, lethal toxicity in galactosamine-sensitized mice and murine macrophage activation, i.e. production of tumor necrosis factor, interleukin-6 and nitric oxide.	bp-lps	67-73	interleukin 6	Mus musculus	248-261
8634432-1	1996	Ciliary neurotrophic factor (CNTF) and interleukin-6 (IL-6) potentiate the elevation of serum corticosterone induced by suboptimal doses of interleukin-1 (IL-1).	Corticosterone	94-108	interleukin 6	Mus musculus	39-52
8634432-1	1996	Ciliary neurotrophic factor (CNTF) and interleukin-6 (IL-6) potentiate the elevation of serum corticosterone induced by suboptimal doses of interleukin-1 (IL-1).	Corticosterone	94-108	interleukin 6	Mus musculus	54-58
8634432-3	1996	Here, we report that four other cytokines (leukemia inhibitory factor [LIF], oncostatin M [OSM], interleukin-11 and cardiotrophin-1) also potentiated the elevation of serum corticosterone and IL-6 levels induced by IL-1.	Corticosterone	173-187	interleukin 6	Mus musculus	192-196
8634432-7	1996	In fact, in IL-6 deficient mice, IL-1 increased serum corticosterone to a level comparable to that observed in wild-type mice.	Corticosterone	54-68	interleukin 6	Mus musculus	12-16
8641750-0	1996	Low-dose lipopolysaccharide (LPS) pretreatment of mouse macrophages modulates LPS-dependent interleukin-6 production in vitro.	DOSE	4-8	interleukin 6	Mus musculus	92-105
8541808-1	1995	The effect of cyclosporin A (CsA) on tumor necrosis factor (TNF) or interleukin-6 (IL-6) production was evaluated in vivo in primed or unprimed mice challenged with lipopolysaccharide (LPS).	Cyclosporine	29-32	interleukin 6	Mus musculus	68-81
8739314-12	1996	4-DPD, an inhibitor of IL-1 and inflammatory reactions, proved to be most effective on TNF alpha and IL-6, which are mainly produced by macrophages.	4-deoxypyridoxine	0-5	interleukin 6	Mus musculus	101-105
7602106-0	1995	Thapsigargin and cyclopiazonic acid initiate rapid and dramatic increases of IL-6 mRNA expression and IL-6 secretion in murine peritoneal macrophages.	Thapsigargin	0-12	interleukin 6	Mus musculus	77-81
7579076-8	1995	AngII and IL-6 were both shown to stimulate DNA synthesis in CMMC, and the blockade of IL-6 signaling with anti-IL-6 receptor antibody abolished the enhanced DNA synthesis induced by AngII.	7-(chlorocarbonylmethoxy)-4-methylcoumarin	61-65	interleukin 6	Mus musculus	10-14
7602106-0	1995	Thapsigargin and cyclopiazonic acid initiate rapid and dramatic increases of IL-6 mRNA expression and IL-6 secretion in murine peritoneal macrophages.	Thapsigargin	0-12	interleukin 6	Mus musculus	102-106
7602106-0	1995	Thapsigargin and cyclopiazonic acid initiate rapid and dramatic increases of IL-6 mRNA expression and IL-6 secretion in murine peritoneal macrophages.	cyclopiazonic acid	17-35	interleukin 6	Mus musculus	77-81
7602106-0	1995	Thapsigargin and cyclopiazonic acid initiate rapid and dramatic increases of IL-6 mRNA expression and IL-6 secretion in murine peritoneal macrophages.	cyclopiazonic acid	17-35	interleukin 6	Mus musculus	102-106
7602106-3	1995	The activity of these inhibitors was linked to an important biologic response, because both cyclopiazonic acid and thapsigargin induced rapid and dramatic increases in IL-6 mRNA expression and secretion.	cyclopiazonic acid	92-110	interleukin 6	Mus musculus	168-172
7602106-3	1995	The activity of these inhibitors was linked to an important biologic response, because both cyclopiazonic acid and thapsigargin induced rapid and dramatic increases in IL-6 mRNA expression and secretion.	Thapsigargin	115-127	interleukin 6	Mus musculus	168-172
7602106-5	1995	The increased mRNA expression was coupled to translation and secretion of this monokine since cyclopiazonic acid and thapsigargin induced significant increases in IL-6 secretion as early as 2 h, and up to approximately 70-fold increases by 20 h, when compared with control cultures.	cyclopiazonic acid	94-112	interleukin 6	Mus musculus	163-167
7602106-5	1995	The increased mRNA expression was coupled to translation and secretion of this monokine since cyclopiazonic acid and thapsigargin induced significant increases in IL-6 secretion as early as 2 h, and up to approximately 70-fold increases by 20 h, when compared with control cultures.	Thapsigargin	117-129	interleukin 6	Mus musculus	163-167
7602106-6	1995	Taken together, these results demonstrate that both cyclopiazonic acid and thapsigargin generate potent intracellular signals that initiate rapid and dramatic production of IL-6.	cyclopiazonic acid	52-70	interleukin 6	Mus musculus	173-177
7602106-6	1995	Taken together, these results demonstrate that both cyclopiazonic acid and thapsigargin generate potent intracellular signals that initiate rapid and dramatic production of IL-6.	Thapsigargin	75-87	interleukin 6	Mus musculus	173-177
7602106-7	1995	Both thapsigargin and cyclopiazonic acid increased IL-6 mRNA expression at 15 min in the absence of Ca2+ influx from the extracellular medium.	Thapsigargin	5-17	interleukin 6	Mus musculus	51-55
7602106-7	1995	Both thapsigargin and cyclopiazonic acid increased IL-6 mRNA expression at 15 min in the absence of Ca2+ influx from the extracellular medium.	cyclopiazonic acid	22-40	interleukin 6	Mus musculus	51-55
7667201-6	1995	Low concentrations of pamidronate, however, induced the IL-6 secretion, and the cytokine inhibitory action at the higher concentrations of pamidronate was attributed to cytotoxicity of the compound.	Pamidronate	22-33	interleukin 6	Mus musculus	56-60
7597700-3	1995	Specifically, IL-1 beta and IL-6 mRNA levels increased in spleen and PP following exposure to VT.	deoxynivalenol	94-96	interleukin 6	Mus musculus	28-32
7598695-1	1995	Regulation of msIL-6R secretion by mIL-6 and 8-bromo cAMP was examined using primarily cell culture of mouse decidua.	msil-6r	14-21	interleukin 6	Mus musculus	35-46
7598695-7	1995	These results suggest that mIL-6 decreases msIL-6R secretion without changing of the steady-state level of mIL-6R mRNA, and that cAMP is one of the second messengers in mouse decidual cells involved in this down regulation of msIL-6R secretion.	msil-6r	43-50	interleukin 6	Mus musculus	27-32
7598695-7	1995	These results suggest that mIL-6 decreases msIL-6R secretion without changing of the steady-state level of mIL-6R mRNA, and that cAMP is one of the second messengers in mouse decidual cells involved in this down regulation of msIL-6R secretion.	msil-6r	226-233	interleukin 6	Mus musculus	27-32
7556403-2	1995	Bradykinin as well as des-Arg9-bradykinin, a bradykinin B1 receptor agonist, were able to induce the release of so-called charge-changing lymphokines, which could be identified as interleukin-1, interleukin-6, interleukin-2 and as interleukin-2 receptor.	des-arg9	22-30	interleukin 6	Mus musculus	195-208
7769130-8	1995	This evidence demonstrates that male sex steroids, acting through the androgen-specific receptor, inhibit the expression of the IL-6 gene; and that IL-6 mediates the upregulation of osteoclastogenesis and therefore the bone loss caused by androgen deficiency, as it does in estrogen deficiency.	Steroids	41-49	interleukin 6	Mus musculus	128-132
7791126-9	1995	Regulation of BMDM phi IL-6 by carbocyclic nucleoside analogues in response to LPS appears to be both concentration and time dependent, because IL-6 mRNA and secreted protein levels were inhibited at only high drug concentrations (100 microM) and effective only at longer exposure times (+4 hr of incubation) to LPS.	Nucleosides	43-53	interleukin 6	Mus musculus	23-27
7791126-9	1995	Regulation of BMDM phi IL-6 by carbocyclic nucleoside analogues in response to LPS appears to be both concentration and time dependent, because IL-6 mRNA and secreted protein levels were inhibited at only high drug concentrations (100 microM) and effective only at longer exposure times (+4 hr of incubation) to LPS.	Nucleosides	43-53	interleukin 6	Mus musculus	144-148
7630130-8	1995	Furthermore, the capacity of splenic and peritoneal macrophages to release IL-6 was restored in the hemorrhaged animals that received GM1892 or conventional heparin.	GM 1892	134-140	interleukin 6	Mus musculus	75-79
7630130-8	1995	Furthermore, the capacity of splenic and peritoneal macrophages to release IL-6 was restored in the hemorrhaged animals that received GM1892 or conventional heparin.	Heparin	157-164	interleukin 6	Mus musculus	75-79
7599173-1	1995	The effects of solvent, pH and temperature on the 1H-NMR spectra of recombinant murine interleukin-6 (IL-6) are described.	Hydrogen	50-52	interleukin 6	Mus musculus	87-100
7599173-1	1995	The effects of solvent, pH and temperature on the 1H-NMR spectra of recombinant murine interleukin-6 (IL-6) are described.	Hydrogen	50-52	interleukin 6	Mus musculus	102-106
7599173-5	1995	The pKa values of the four histidine residues in murine IL-6 has been measured; one has a value of 5.5, approx.	Histidine	27-36	interleukin 6	Mus musculus	56-60
7769130-4	1995	Both testosterone and dihydrotestosterone inhibited IL-6 production by murine bone marrow-derived stromal cells.	Testosterone	5-17	interleukin 6	Mus musculus	52-56
7769130-4	1995	Both testosterone and dihydrotestosterone inhibited IL-6 production by murine bone marrow-derived stromal cells.	Dihydrotestosterone	22-41	interleukin 6	Mus musculus	52-56
7537980-6	1995	Nevertheless, FL enhanced the growth of granulocyte-macrophage progenitors (CFU-GM) in cultures containing SCF, G-CSF, IL-6, or IL-11.	fl	14-16	interleukin 6	Mus musculus	119-123
7539136-3	1995	Offspring overexpressing both IL-6 and IL-6R showed constitutive tyrosine phosphorylation of gp130 and a downstream signaling molecule, acute phase response factor/signal transducer and activator of transcription 3.	Tyrosine	65-73	interleukin 6	Mus musculus	30-34
7537645-0	1995	Effects of hydroxyethyl starch after trauma-hemorrhagic shock: restoration of macrophage integrity and prevention of increased circulating interleukin-6 levels.	Hydroxyethyl starch	11-30	interleukin 6	Mus musculus	139-152
7743561-5	1995	Enhancement of IL-1 alpha, TNF-alpha, TNF-beta, IL-6, IFN-alpha, and IFN-gamma mRNA was seen in the spleens of loxoribine-treated mice.	loxoribine	111-121	interleukin 6	Mus musculus	48-52
7743561-8	1995	ELISA assays on the supernatants of loxoribine-treated spleen cells demonstrated that IL-1 alpha, IL-6, TNF-alpha, and IFN-gamma were all produced in a dose-dependent fashion with TNF-alpha produced first, followed by IL-6 and IFN-gamma, and last by IL-1 alpha.	loxoribine	36-46	interleukin 6	Mus musculus	98-102
7743561-8	1995	ELISA assays on the supernatants of loxoribine-treated spleen cells demonstrated that IL-1 alpha, IL-6, TNF-alpha, and IFN-gamma were all produced in a dose-dependent fashion with TNF-alpha produced first, followed by IL-6 and IFN-gamma, and last by IL-1 alpha.	loxoribine	36-46	interleukin 6	Mus musculus	218-222
7537645-11	1995	Interleukin-6 release by peritoneal macrophages was restored 24 hrs after hydroxyethyl starch infusion; serum interleukin-6 concentrations remained at sham levels.	Hydroxyethyl starch	74-93	interleukin 6	Mus musculus	0-13
7622196-5	1995	Lymphocytes from the DHEA-treated tolerant mice produced more IFN-gamma and less IL-4 and IL-6 than the cells from tolerant animals without DHEA treatment.	Dehydroepiandrosterone	21-25	interleukin 6	Mus musculus	90-94
7535594-6	1995	Culture with either fresh or paraformaldehyde fixed NIH3T3 CD40LT cells upregulates IL-6 secretion in MM cells and MM-derived cell lines, as well as normal and MM bone marrow mononuclear cells (BMMCs), BMSCs, and BMSC lines; this effect can be specifically blocked by anti-CD40 monoclonal antibody (MoAb).	paraform	29-45	interleukin 6	Mus musculus	84-88
7622353-3	1995	Retrovirus infection elevated levels of IL-6 and IL-10 produced by splenocytes, which were significantly normalized by all levels of vitamin E supplementation, respectively.	Vitamin E	133-142	interleukin 6	Mus musculus	40-44
7890366-0	1995	Anti-gamma interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in D-galactosamine-sensitized and unsensitized mice.	Galactosamine	151-166	interleukin 6	Mus musculus	31-44
7890375-5	1995	PCR analysis revealed that interleukin 6 (IL-6) and IL-1 beta gene expression occurs in brain of HCN-treated mice but not in brains of saline-treated controls.	Hydrogen Cyanide	97-100	interleukin 6	Mus musculus	27-40
7890375-5	1995	PCR analysis revealed that interleukin 6 (IL-6) and IL-1 beta gene expression occurs in brain of HCN-treated mice but not in brains of saline-treated controls.	Hydrogen Cyanide	97-100	interleukin 6	Mus musculus	42-46
7890408-4	1995	These analogs exhibited comparable or stronger activities than those of GLA-60 in murine macrophage activation activities to induce mediators such as tumor necrosis factors, interleukin 6, and nitric oxide and in mitogenic activity towards murine spleen cells; however, these activities were weaker than the respective activities of 506.	gamma-Linolenic Acid	72-75	interleukin 6	Mus musculus	174-187
7622353-4	1995	Increased levels of IL-6 and tumor necrosis factor-alpha, produced by splenocytes during progression to murine AIDS, were also significantly normalized by all levels of vitamin E supplementation.	Vitamin E	169-178	interleukin 6	Mus musculus	20-56
7888674-7	1995	In addition, these antibodies abrogate the enhancing effect of AS101 on the secretion of IL-3, IL-6, and granulocyte-macrophage colony-stimulating factor, all of which decrease significantly in sublethally irradiated mice.	ammonium trichloro(dioxoethylene-O,O'-)tellurate	63-68	interleukin 6	Mus musculus	95-99
7536360-6	1995	Modest increases in secretion of TNF-alpha, IL-1 alpha, and IL-6 were observed in response to cadmium which were enhanced in LPS-primed mice.	Cadmium	94-101	interleukin 6	Mus musculus	60-64
7536360-7	1995	Additionally, cadmium exposure increased IL-1 alpha, IL-1 beta, TNF-alpha, MIP-2, IL-6, and ICAM-1 mRNA transcripts in the liver.	Cadmium	14-21	interleukin 6	Mus musculus	82-86
7601503-4	1995	Alveolar macrophages isolated from mice challenged with SRBC released higher levels of IL-1, IL-6, and tumor necrosis factor-alpha (TNF-alpha) upon in vitro lipopolysaccharide (LPS) stimulation compared to unprimed, challenged mice or mice receiving intraperitoneal SRBC alone.	srbc	56-60	interleukin 6	Mus musculus	93-97
7888674-9	1995	These results suggest a role for IL-1, IL-6, TNF alpha, and SCF in the radioprotective effect of AS101.	ammonium trichloro(dioxoethylene-O,O'-)tellurate	97-102	interleukin 6	Mus musculus	39-43
7814878-5	1995	RT-PCR of poly(A)+ RNA isolated from each of the four solid tumors demonstrated the presence of IL-4, IL-5, IL-6, IL-10, TGF-beta 1, and TNF-alpha mRNAs.	Poly A	10-17	interleukin 6	Mus musculus	108-112
7530743-8	1995	Thus, FKBP12 is the dominant cytosolic protein that mediates FK506 inhibition of TNF-alpha and IL-6 transcripts.	Tacrolimus	61-66	interleukin 6	Mus musculus	95-99
7499443-3	1995	A B16 cell clone secreting the highest level of IL-6 was obtained by G418-resistant selection, limiting dilution and IL-6 assay.	antibiotic G 418	69-73	interleukin 6	Mus musculus	48-52
8770556-4	1995	We found that poly(A)+ mRNAs for IL-1, IL-3, IL-6, IL-7, and TNF alpha are differentially expressed at several stages of mouse preimplantation development, including unfertilized oocytes.	Poly A	14-21	interleukin 6	Mus musculus	45-49
7802649-4	1994	Since prostaglandinE2 is an enhancer of ALP activity and collagen biosynthesis in MC3T3-E1 and was found to induce IL-6 production in this study, it is possible that NGF works on MC3T3-E1 cells through the mediation by endogenous prostaglandinE2.	Dinoprostone	6-21	interleukin 6	Mus musculus	115-119
18475629-0	1995	Effects of triazolodiazepine on the production of interleukin-6 from murine spleen cells and rabbit synovial cells in vitro.	WEB 2086	11-28	interleukin 6	Mus musculus	50-63
18475629-5	1995	In this study we found that Tri (0.1-10 mumol/l) exerted strong inhibitory effects on LPS stimulated IL-6 production in murine spleen cells.	WEB 2086	28-31	interleukin 6	Mus musculus	101-105
7721328-6	1994	Treatment of MCMV infected mice with the immunomodulator AS101 [ammonium trichloro (dioxyethylene 0-0")tellurate] restored significantly CSF and IL-6 production by BM cells to levels of uninfected control mice as well as the number of CFU-F and stromal cell elements which consequently led to the restoration of the total number of BM cells.	ammonium trichloro(dioxoethylene-O,O'-)tellurate	57-62	interleukin 6	Mus musculus	145-149
7987845-7	1994	Furthermore, combined treatment with IL-1 beta/IL-6 accelerated and potentiated the recovery of myeloid cells after cyclophosphamide injection, whereas the single regimen treatment was not effective.	Cyclophosphamide	116-132	interleukin 6	Mus musculus	47-51
7534173-9	1994	The release of IL-6 by pM phi and sM phi at 2 and 24 hours after dextran infusion and serum IL-6 remained at the same level as in LRS-treated animals.	Dextrans	65-72	interleukin 6	Mus musculus	15-19
7525853-2	1994	The research presented here demonstrates that the inhibitory effect of PGE2 on tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) production by lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages involves IL-10.	Dinoprostone	71-75	interleukin 6	Mus musculus	123-136
7525853-2	1994	The research presented here demonstrates that the inhibitory effect of PGE2 on tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) production by lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages involves IL-10.	Dinoprostone	71-75	interleukin 6	Mus musculus	138-142
7987845-0	1994	Combined interleukin-1 beta/interleukin-6 treatment in mice: synergistic myelostimulatory activity and myelorestorative effect after cyclophosphamide-induced myelosuppression.	Cyclophosphamide	133-149	interleukin 6	Mus musculus	28-41
7525853-3	1994	In a dose-dependent manner, PGE2 inhibits LPS-induced release of TNF-alpha and IL-6, but not of lactate or nitric oxide.	Dinoprostone	28-32	interleukin 6	Mus musculus	79-83
7525853-7	1994	In vivo, the administration of PGE2 before LPS challenge significantly reduces circulating TNF-alpha and IL-6 levels.	Dinoprostone	31-35	interleukin 6	Mus musculus	105-109
7525853-8	1994	Anti-IL-10 antibody substantially enhanced the LPS-induced TNF-alpha and IL-6 levels in mice that received either LPS alone or LPS plus PGE2.	Dinoprostone	136-140	interleukin 6	Mus musculus	73-77
7721328-6	1994	Treatment of MCMV infected mice with the immunomodulator AS101 [ammonium trichloro (dioxyethylene 0-0")tellurate] restored significantly CSF and IL-6 production by BM cells to levels of uninfected control mice as well as the number of CFU-F and stromal cell elements which consequently led to the restoration of the total number of BM cells.	ammonium trichloro (dioxyethylene 0-0")tellurate	64-112	interleukin 6	Mus musculus	145-149
7956951-4	1994	Troglitazone also prevented the inhibitory effects of interleukin-1, interleukin-6, and leukemia inhibitory factor, but not of transforming growth factor beta on adipocyte differentiation of 3T3-L1 cells.	Troglitazone	0-12	interleukin 6	Mus musculus	69-82
7671121-0	1994	Immobilization stress may increase plasma interleukin-6 via central and peripheral catecholamines.	Catecholamines	83-97	interleukin 6	Mus musculus	42-55
7868298-8	1994	Furthermore, in a dose-dependent manner suramin prevents several IL-1 mediated biological responses, including thymocyte proliferation, PGE-2 synthesis and IL-6 production.	Suramin	40-47	interleukin 6	Mus musculus	156-160
7835943-3	1994	Both interleukin-1 (IL-1) and IL-6 were induced in a biphasic manner following primary exposure of mice to oxazolone or to dicyclohexylmethane-4,4"-diisocyanate (HMDI).	Oxazolone	107-116	interleukin 6	Mus musculus	30-34
7926024-0	1994	Inhibition by N-acetyl-L-cysteine of interleukin-6 mRNA induction and activation of NF kappa B by tumor necrosis factor alpha in a mouse fibroblastic cell line, Balb/3T3.	Acetylcysteine	14-33	interleukin 6	Mus musculus	37-50
7926024-2	1994	In the present study, we investigated the possible role of reactive oxygen species in the induction of interleukin-6 (IL-6) mRNA and in increases in NF kappa B binding activity by tumor necrosis factor (TNF) alpha using a mouse fibroblastic cell line, Balb/3T3.	Reactive Oxygen Species	59-82	interleukin 6	Mus musculus	103-116
7926024-2	1994	In the present study, we investigated the possible role of reactive oxygen species in the induction of interleukin-6 (IL-6) mRNA and in increases in NF kappa B binding activity by tumor necrosis factor (TNF) alpha using a mouse fibroblastic cell line, Balb/3T3.	Reactive Oxygen Species	59-82	interleukin 6	Mus musculus	118-122
7926024-4	1994	We found that: (i) TNF alpha increased IL-6 mRNA levels and this increase was inhibited by N-acetyl-L-cysteine (NAC), a scavenger of reactive oxygen species.	Acetylcysteine	91-110	interleukin 6	Mus musculus	39-43
7926024-4	1994	We found that: (i) TNF alpha increased IL-6 mRNA levels and this increase was inhibited by N-acetyl-L-cysteine (NAC), a scavenger of reactive oxygen species.	Acetylcysteine	112-115	interleukin 6	Mus musculus	39-43
7926024-4	1994	We found that: (i) TNF alpha increased IL-6 mRNA levels and this increase was inhibited by N-acetyl-L-cysteine (NAC), a scavenger of reactive oxygen species.	Reactive Oxygen Species	133-156	interleukin 6	Mus musculus	39-43
7926024-8	1994	These results suggest that the induction of IL-6 mRNA is regulated by a mechanism involving reactive oxygen species and that NF kappa B, whose activity is sensitive to the cellular redox state, plays an important role in this induction in a fibroblastic cell line, Balb/3T3, stimulated with TNF alpha.	Reactive Oxygen Species	92-115	interleukin 6	Mus musculus	44-48
7835943-3	1994	Both interleukin-1 (IL-1) and IL-6 were induced in a biphasic manner following primary exposure of mice to oxazolone or to dicyclohexylmethane-4,4"-diisocyanate (HMDI).	methylene bis(4-cyclohexylisocyanate)	123-160	interleukin 6	Mus musculus	30-34
7835943-3	1994	Both interleukin-1 (IL-1) and IL-6 were induced in a biphasic manner following primary exposure of mice to oxazolone or to dicyclohexylmethane-4,4"-diisocyanate (HMDI).	methylene bis(4-cyclohexylisocyanate)	162-166	interleukin 6	Mus musculus	30-34
7931712-7	1994	Retrovirus-induced elevated production of IL-4, IL-5 and IL-6 by splenocytes in vitro was normalized by vitamin E.	Vitamin E	104-113	interleukin 6	Mus musculus	57-61
7930875-12	1994	Treatment with methylprednisolone and cyclophosphamide dramatically reduced TNF-alpha but not IL-6.	Methylprednisolone	15-33	interleukin 6	Mus musculus	94-98
7930875-12	1994	Treatment with methylprednisolone and cyclophosphamide dramatically reduced TNF-alpha but not IL-6.	Cyclophosphamide	38-54	interleukin 6	Mus musculus	94-98
7818792-8	1994	The production of IL-2 and IL-6 by thymocytes, which was lessened during retrovirus infection, were significantly further suppressed by dietary EtOH at 6 weeks postinfection, whereas levels of IL-4 and IFN-gamma by thymocytes, which were elevated during retrovirus infection, were significantly and slightly further increased by EtOH-treated mice prior to retrovirus infection, respectively.	Ethanol	144-148	interleukin 6	Mus musculus	27-31
7522168-6	1994	Furthermore, IL-6(0/0) mice could be equally well desensitized (by IL-1) to TNF/GalN-induced lethality and tolerized to TNF-induced shock as IL-6+/+ mice.	Galactosamine	80-84	interleukin 6	Mus musculus	13-17
7522168-7	1994	We also observed that, in response to turpentine, TNF or IL-1, IL-6(0/0) mice produced significantly less acute phase proteins (APP) than IL-6+/+ mice.	Turpentine	38-48	interleukin 6	Mus musculus	63-67
7522168-8	1994	In IL-6(0/0) mice, less corticosterone was induced by TNF than in the control mice, while the response to adrenocorticotropic hormone was the same.	Corticosterone	24-38	interleukin 6	Mus musculus	3-7
7868057-3	1994	When colony numbers were compared with those supported by IL-3, IL-6+TPA gave rise to 86 + 47% of colonies formed with IL-3.	Tetradecanoylphorbol Acetate	69-72	interleukin 6	Mus musculus	64-68
7868057-6	1994	Delayed addition of IL-6 or TPA decreased colony numbers, suggesting that both IL-6 and TPA were needed from the start of cultures for maximal colony formation.	Tetradecanoylphorbol Acetate	88-91	interleukin 6	Mus musculus	20-24
7868057-9	1994	Chronic exposure of progenitors to TPA prior to the culture with IL-6+TPA suppressed colony formation.	Tetradecanoylphorbol Acetate	35-38	interleukin 6	Mus musculus	65-69
7953976-1	1994	The cytokine interleukin-6 (IL-6) was produced by neonatal mouse parietal bones during a 6- or 48-hour culture period in response to prostaglandin E2 (PGE2) and bovine parathyroid hormone (PTH) 1-34 fragment but not 1,25-dihydroxyvitamin D3 [1,25(OH)2D3].	Dinoprostone	133-149	interleukin 6	Mus musculus	13-26
7953976-1	1994	The cytokine interleukin-6 (IL-6) was produced by neonatal mouse parietal bones during a 6- or 48-hour culture period in response to prostaglandin E2 (PGE2) and bovine parathyroid hormone (PTH) 1-34 fragment but not 1,25-dihydroxyvitamin D3 [1,25(OH)2D3].	Dinoprostone	133-149	interleukin 6	Mus musculus	28-32
7953976-1	1994	The cytokine interleukin-6 (IL-6) was produced by neonatal mouse parietal bones during a 6- or 48-hour culture period in response to prostaglandin E2 (PGE2) and bovine parathyroid hormone (PTH) 1-34 fragment but not 1,25-dihydroxyvitamin D3 [1,25(OH)2D3].	Dinoprostone	151-155	interleukin 6	Mus musculus	13-26
7953976-1	1994	The cytokine interleukin-6 (IL-6) was produced by neonatal mouse parietal bones during a 6- or 48-hour culture period in response to prostaglandin E2 (PGE2) and bovine parathyroid hormone (PTH) 1-34 fragment but not 1,25-dihydroxyvitamin D3 [1,25(OH)2D3].	Dinoprostone	151-155	interleukin 6	Mus musculus	28-32
7953976-1	1994	The cytokine interleukin-6 (IL-6) was produced by neonatal mouse parietal bones during a 6- or 48-hour culture period in response to prostaglandin E2 (PGE2) and bovine parathyroid hormone (PTH) 1-34 fragment but not 1,25-dihydroxyvitamin D3 [1,25(OH)2D3].	Calcitriol	216-240	interleukin 6	Mus musculus	13-26
7953976-1	1994	The cytokine interleukin-6 (IL-6) was produced by neonatal mouse parietal bones during a 6- or 48-hour culture period in response to prostaglandin E2 (PGE2) and bovine parathyroid hormone (PTH) 1-34 fragment but not 1,25-dihydroxyvitamin D3 [1,25(OH)2D3].	Calcitriol	216-240	interleukin 6	Mus musculus	28-32
7953976-3	1994	TRAP+OC numbers on PGE2-stimulated bones were positively correlated with IL-6 concentration.	Dinoprostone	19-23	interleukin 6	Mus musculus	73-77
7953976-7	1994	Adding an antibody against mouse IL-6 to bone cultures stimulated with PTH or PGE2 neutralized the resulting IL-6 bioactivity by up to 92% but did not inhibit TRAP+OC formation.	Dinoprostone	78-82	interleukin 6	Mus musculus	33-37
7953976-7	1994	Adding an antibody against mouse IL-6 to bone cultures stimulated with PTH or PGE2 neutralized the resulting IL-6 bioactivity by up to 92% but did not inhibit TRAP+OC formation.	Dinoprostone	78-82	interleukin 6	Mus musculus	109-113
8062890-3	1994	On the other hand, increased intracellular cAMP stimulated IL-6 synthesis in +/+(-)1.LDA11 cells.	Cyclic AMP	43-47	interleukin 6	Mus musculus	59-63
8062890-4	1994	In addition, cAMP was additive with either IL-1 or IL-1 plus TNF-alpha in inducing production of soluble IL-6.	Cyclic AMP	13-17	interleukin 6	Mus musculus	105-109
8062890-8	1994	Addition to stromal cells of the soluble cAMP agonist 8-bromo-cAMP (8BrcAMP) at 0.5 to 1 mM stimulated IL-6 mRNA expression acting alone, and it was additive with IL-1 or IL-1 plus TNF-alpha in stimulating IL-6 expression.	Cyclic AMP	41-45	interleukin 6	Mus musculus	103-107
8062890-8	1994	Addition to stromal cells of the soluble cAMP agonist 8-bromo-cAMP (8BrcAMP) at 0.5 to 1 mM stimulated IL-6 mRNA expression acting alone, and it was additive with IL-1 or IL-1 plus TNF-alpha in stimulating IL-6 expression.	8-Bromo Cyclic Adenosine Monophosphate	54-66	interleukin 6	Mus musculus	103-107
8062890-8	1994	Addition to stromal cells of the soluble cAMP agonist 8-bromo-cAMP (8BrcAMP) at 0.5 to 1 mM stimulated IL-6 mRNA expression acting alone, and it was additive with IL-1 or IL-1 plus TNF-alpha in stimulating IL-6 expression.	8-Bromo Cyclic Adenosine Monophosphate	54-66	interleukin 6	Mus musculus	206-210
8062890-8	1994	Addition to stromal cells of the soluble cAMP agonist 8-bromo-cAMP (8BrcAMP) at 0.5 to 1 mM stimulated IL-6 mRNA expression acting alone, and it was additive with IL-1 or IL-1 plus TNF-alpha in stimulating IL-6 expression.	8-Bromo Cyclic Adenosine Monophosphate	68-75	interleukin 6	Mus musculus	103-107
8062890-8	1994	Addition to stromal cells of the soluble cAMP agonist 8-bromo-cAMP (8BrcAMP) at 0.5 to 1 mM stimulated IL-6 mRNA expression acting alone, and it was additive with IL-1 or IL-1 plus TNF-alpha in stimulating IL-6 expression.	8-Bromo Cyclic Adenosine Monophosphate	68-75	interleukin 6	Mus musculus	206-210
8062890-16	1994	These data demonstrate that the intracellular level of cAMP has an important discriminatory role on expression of the cytokines GM-CSF and IL-6 in a model stromal cell line.	Cyclic AMP	55-59	interleukin 6	Mus musculus	139-143
7854332-5	1994	In addition, in all mice treated with 4-DPD there was a strong inhibition of TNF alpha in serum (P < 0.01) and in supernatant fluids (P < 0.05) from minced granuloma, while IL-6 was inhibited in the supernatant fluids (P < 0.05) of minced granulomas but was not detected in the serum of treated and untreated mice.	4-deoxypyridoxine	38-43	interleukin 6	Mus musculus	179-183
8020195-4	1994	Increased levels of IL-6 and tumor necrosis factor-alpha produced by splenocytes during progression to murine AIDS were also inhibited by vitamin E.	Vitamin E	138-147	interleukin 6	Mus musculus	20-56
7911489-4	1994	However, the induction of the IL-3, IL-4, and GM-CSF genes, but not the IL-5, IL-6, and IL-10 genes, was strongly inhibited by cyclosporin A.	Cyclosporine	127-140	interleukin 6	Mus musculus	78-82
7911489-5	1994	Furthermore, IL-5, IL-6, and IL-10 genes were independently induced by IL-1 alpha, the phorbol ester PMA, and by forskolin, an activator of adenylate cyclase.	phorbol ester pma	87-104	interleukin 6	Mus musculus	19-23
7911489-5	1994	Furthermore, IL-5, IL-6, and IL-10 genes were independently induced by IL-1 alpha, the phorbol ester PMA, and by forskolin, an activator of adenylate cyclase.	Colforsin	113-122	interleukin 6	Mus musculus	19-23
7982720-3	1994	On the other hand, hematopoietic recovery in [C3H/He-->C3H/He] bone marrow chimeras injected with IL-6 was different from that in [BALB/c-->C3H/He] bone marrow chimeras, showing no delayed and long-lasting increase in Hb levels but showing an early and transient increase in Hb levels and platelet counts.	Helium	50-52	interleukin 6	Mus musculus	101-105
7514609-2	1994	Although ATP alone did not induce M1 cell differentiation, addition of ATP with the differentiation inducer, interleukin 6 (IL-6), enhanced the induction of differentiation by IL-6 about two-fold.	Adenosine Triphosphate	9-12	interleukin 6	Mus musculus	176-180
7514609-2	1994	Although ATP alone did not induce M1 cell differentiation, addition of ATP with the differentiation inducer, interleukin 6 (IL-6), enhanced the induction of differentiation by IL-6 about two-fold.	Adenosine Triphosphate	71-74	interleukin 6	Mus musculus	109-122
7514609-2	1994	Although ATP alone did not induce M1 cell differentiation, addition of ATP with the differentiation inducer, interleukin 6 (IL-6), enhanced the induction of differentiation by IL-6 about two-fold.	Adenosine Triphosphate	71-74	interleukin 6	Mus musculus	124-128
7514609-2	1994	Although ATP alone did not induce M1 cell differentiation, addition of ATP with the differentiation inducer, interleukin 6 (IL-6), enhanced the induction of differentiation by IL-6 about two-fold.	Adenosine Triphosphate	71-74	interleukin 6	Mus musculus	176-180
7514609-6	1994	Within 3 h of exposure, ATP alone slightly increased the expression of differentiation-related immediate early response genes, c-myc and JunB, and ATP also enhanced the IL-6-induced expression of these genes.	Adenosine Triphosphate	24-27	interleukin 6	Mus musculus	169-173
7514609-6	1994	Within 3 h of exposure, ATP alone slightly increased the expression of differentiation-related immediate early response genes, c-myc and JunB, and ATP also enhanced the IL-6-induced expression of these genes.	Adenosine Triphosphate	147-150	interleukin 6	Mus musculus	169-173
8200968-0	1994	Interleukin-6 attenuates agonist-mediated calcium mobilization in murine osteoblastic cells.	Calcium	42-49	interleukin 6	Mus musculus	0-13
8200968-3	1994	IL-6 did not alter basal intracellular calcium concentration ([Ca2+]i) but inhibited Ca2+ transients induced by parathyroid hormone (PTH), prostaglandin E2 (PGE2), and endothelin-1 in both dose- (100-400 U/ml) and time- (4-48 h) dependent manners.	Dinoprostone	139-155	interleukin 6	Mus musculus	0-4
8200968-3	1994	IL-6 did not alter basal intracellular calcium concentration ([Ca2+]i) but inhibited Ca2+ transients induced by parathyroid hormone (PTH), prostaglandin E2 (PGE2), and endothelin-1 in both dose- (100-400 U/ml) and time- (4-48 h) dependent manners.	Dinoprostone	157-161	interleukin 6	Mus musculus	0-4
8200968-5	1994	The IL-6 effect on the Ca2+ message system was related to suppressed production of hormonally induced inositol 1,4,5-triphosphate and inhibition of Ca2+ release from intracellular stores.	Inositol 1,4,5-Trisphosphate	102-129	interleukin 6	Mus musculus	4-8
8200968-8	1994	With respect to osteoblast function, IL-6, although having no effect on cell proliferation by itself, greatly enhanced the antiproliferative effect of PGE2 and PTH.	Dinoprostone	151-155	interleukin 6	Mus musculus	37-41
8200968-9	1994	Because the production of IL-6 in osteoblasts is stimulated by calciotropic hormones (e.g., PTH and PGE2), the suppressive effect of the cytokine on hormonally induced Ca2+ transients may serve as an autocrine/paracrine mechanism for modulating the effect of hormones on bone metabolism.	Dinoprostone	100-104	interleukin 6	Mus musculus	26-30
7909326-6	1994	In contrast, treatment with exogenous rIL-12 profoundly inhibited primary granuloma formation while increasing IFN-gamma, IL-2, IL-10, and IL-12 pulmonary mRNA levels and suppressing IL-4, IL-5, IL-6, and IL-13 mRNA expression.	ril-12	38-44	interleukin 6	Mus musculus	195-199
7824805-5	1994	Interferon-gamma- and polyinosinic-polycytidylic acid-stimulated secretion of IL1 alpha as well as LPS-stimulated secretion of IL6 decreased with an elevation in ammonium acetate concentrations.	ammonium acetate	162-178	interleukin 6	Mus musculus	127-130
8168150-5	1994	Expression of cytokine mRNAs including TNF-alpha, IL-1 beta, IL-6, and GM-CSF was also enhanced by the treatment with DT-5461a.	DT 5461	118-126	interleukin 6	Mus musculus	61-65
8061551-6	1994	The time course and dose-response to PGE2 of IL-6 production were determined.	Dinoprostone	37-41	interleukin 6	Mus musculus	45-49
8061551-7	1994	After 6 h in culture, 10(-8) M PGE2 produced significantly more IL-6 than the controls (P < 0.005).	Dinoprostone	31-35	interleukin 6	Mus musculus	64-68
8061551-8	1994	PGE2 (10(-6) M) stimulated the production of a mean of 12.8 ng/ml IL-6 over 6 h. Preincubating bones with indomethacin for 20 h prior to a 6 h culture with indomethacin led to a lowering of the production of IL-6 (mean 1.8 ng/ml) compared to bones cultured without the preincubation period (5.8 ng/ml).	Dinoprostone	0-4	interleukin 6	Mus musculus	66-70
8061551-8	1994	PGE2 (10(-6) M) stimulated the production of a mean of 12.8 ng/ml IL-6 over 6 h. Preincubating bones with indomethacin for 20 h prior to a 6 h culture with indomethacin led to a lowering of the production of IL-6 (mean 1.8 ng/ml) compared to bones cultured without the preincubation period (5.8 ng/ml).	Dinoprostone	0-4	interleukin 6	Mus musculus	208-212
8061551-8	1994	PGE2 (10(-6) M) stimulated the production of a mean of 12.8 ng/ml IL-6 over 6 h. Preincubating bones with indomethacin for 20 h prior to a 6 h culture with indomethacin led to a lowering of the production of IL-6 (mean 1.8 ng/ml) compared to bones cultured without the preincubation period (5.8 ng/ml).	Indomethacin	106-118	interleukin 6	Mus musculus	66-70
8061551-8	1994	PGE2 (10(-6) M) stimulated the production of a mean of 12.8 ng/ml IL-6 over 6 h. Preincubating bones with indomethacin for 20 h prior to a 6 h culture with indomethacin led to a lowering of the production of IL-6 (mean 1.8 ng/ml) compared to bones cultured without the preincubation period (5.8 ng/ml).	Indomethacin	106-118	interleukin 6	Mus musculus	208-212
8061551-8	1994	PGE2 (10(-6) M) stimulated the production of a mean of 12.8 ng/ml IL-6 over 6 h. Preincubating bones with indomethacin for 20 h prior to a 6 h culture with indomethacin led to a lowering of the production of IL-6 (mean 1.8 ng/ml) compared to bones cultured without the preincubation period (5.8 ng/ml).	Indomethacin	156-168	interleukin 6	Mus musculus	66-70
8061551-8	1994	PGE2 (10(-6) M) stimulated the production of a mean of 12.8 ng/ml IL-6 over 6 h. Preincubating bones with indomethacin for 20 h prior to a 6 h culture with indomethacin led to a lowering of the production of IL-6 (mean 1.8 ng/ml) compared to bones cultured without the preincubation period (5.8 ng/ml).	Indomethacin	156-168	interleukin 6	Mus musculus	208-212
8061551-9	1994	When the indomethacin preincubation period was used, a significant increase in IL-6 production was found with 10(-9) M PGE2 (P < 0.005), and 10(-6) M PGE2 caused the production of 39.9 ng/ml IL-6 over 6 h. Stripping endocranial and ectocranial membranes from bones demonstrated the membranes to be the major site of IL-6 production.	Indomethacin	9-21	interleukin 6	Mus musculus	79-83
8061551-9	1994	When the indomethacin preincubation period was used, a significant increase in IL-6 production was found with 10(-9) M PGE2 (P < 0.005), and 10(-6) M PGE2 caused the production of 39.9 ng/ml IL-6 over 6 h. Stripping endocranial and ectocranial membranes from bones demonstrated the membranes to be the major site of IL-6 production.	Indomethacin	9-21	interleukin 6	Mus musculus	194-198
8061551-9	1994	When the indomethacin preincubation period was used, a significant increase in IL-6 production was found with 10(-9) M PGE2 (P < 0.005), and 10(-6) M PGE2 caused the production of 39.9 ng/ml IL-6 over 6 h. Stripping endocranial and ectocranial membranes from bones demonstrated the membranes to be the major site of IL-6 production.	Indomethacin	9-21	interleukin 6	Mus musculus	194-198
8061551-9	1994	When the indomethacin preincubation period was used, a significant increase in IL-6 production was found with 10(-9) M PGE2 (P < 0.005), and 10(-6) M PGE2 caused the production of 39.9 ng/ml IL-6 over 6 h. Stripping endocranial and ectocranial membranes from bones demonstrated the membranes to be the major site of IL-6 production.	Dinoprostone	119-123	interleukin 6	Mus musculus	79-83
8061551-9	1994	When the indomethacin preincubation period was used, a significant increase in IL-6 production was found with 10(-9) M PGE2 (P < 0.005), and 10(-6) M PGE2 caused the production of 39.9 ng/ml IL-6 over 6 h. Stripping endocranial and ectocranial membranes from bones demonstrated the membranes to be the major site of IL-6 production.	Dinoprostone	153-157	interleukin 6	Mus musculus	79-83
8061551-9	1994	When the indomethacin preincubation period was used, a significant increase in IL-6 production was found with 10(-9) M PGE2 (P < 0.005), and 10(-6) M PGE2 caused the production of 39.9 ng/ml IL-6 over 6 h. Stripping endocranial and ectocranial membranes from bones demonstrated the membranes to be the major site of IL-6 production.	Dinoprostone	153-157	interleukin 6	Mus musculus	194-198
8061551-9	1994	When the indomethacin preincubation period was used, a significant increase in IL-6 production was found with 10(-9) M PGE2 (P < 0.005), and 10(-6) M PGE2 caused the production of 39.9 ng/ml IL-6 over 6 h. Stripping endocranial and ectocranial membranes from bones demonstrated the membranes to be the major site of IL-6 production.	Dinoprostone	153-157	interleukin 6	Mus musculus	194-198
8070849-0	1994	IL-6 mediated isotype specific suppression of hapten specific IgE in serum of BPO-KLH sensitized mice: role of IFN alpha in maintainance of hapten specific IgE responses.	bpo-klh	78-85	interleukin 6	Mus musculus	0-4
8160837-4	1994	Exposing the aortic rings to recombinant murine IL-6 (50 U/ml) for 180 min significantly suppressed the phenylephrine (10(-9)-10(-5) M)-induced contraction.	Phenylephrine	104-117	interleukin 6	Mus musculus	48-52
8031997-6	1994	Mice primed with Pristane were found to have IL-6 in their sera and peritoneal fluid only at a few time points following Pristane treatment; this was determined by IL-6-specific ELISA.	pristane	17-25	interleukin 6	Mus musculus	45-49
8031997-6	1994	Mice primed with Pristane were found to have IL-6 in their sera and peritoneal fluid only at a few time points following Pristane treatment; this was determined by IL-6-specific ELISA.	pristane	17-25	interleukin 6	Mus musculus	164-168
8198229-5	1994	Production of tumor necrosis factor-alpha and IL-6 by lipopolysaccharide-stimulated splenocytes was significantly and slightly decreased by ETOH compared with controls, respectively.	Ethanol	140-144	interleukin 6	Mus musculus	46-50
8198229-9	1994	The levels of IL-2, IL-4, and IL-6 produced by Con A-stimulated thymocytes were significantly reduced by dietary ETOH compared with control, whereas production of IFN-gamma by thymocytes was not affected.	Ethanol	113-117	interleukin 6	Mus musculus	30-34
8127402-2	1994	When administered systemically, the naturally occurring molecule and its COOH-terminal tripeptide sequence inhibit inflammation induced by peripherally applied irritants and intradermal injections of mediators of inflammation such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF alpha).	tripeptide K-26	87-97	interleukin 6	Mus musculus	256-269
8127402-2	1994	When administered systemically, the naturally occurring molecule and its COOH-terminal tripeptide sequence inhibit inflammation induced by peripherally applied irritants and intradermal injections of mediators of inflammation such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF alpha).	tripeptide K-26	87-97	interleukin 6	Mus musculus	271-275
8122271-0	1994	n-hexane-induced synthesis of hepatic metallothionein is mediated by IL-6 in mouse.	n-hexane	0-8	interleukin 6	Mus musculus	69-73
8122271-5	1994	When the MT synthesis induced by HX was inhibited by dexamethasone pretreatment, the concentration of IL-6 in the serum was suppressed to a very low level.	n-hexane	33-35	interleukin 6	Mus musculus	102-106
8122271-5	1994	When the MT synthesis induced by HX was inhibited by dexamethasone pretreatment, the concentration of IL-6 in the serum was suppressed to a very low level.	Dexamethasone	53-66	interleukin 6	Mus musculus	102-106
8156049-2	1994	LPS, synthetic Escherichia coli-type lipid A (compound 506) and tetraacyl precursor Ia (compound 406) inhibited the binding of 125I-LPS to macrophage-like J774.1 cells and induced the release of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL-6).	Lipid A	37-44	interleukin 6	Mus musculus	239-252
8156049-2	1994	LPS, synthetic Escherichia coli-type lipid A (compound 506) and tetraacyl precursor Ia (compound 406) inhibited the binding of 125I-LPS to macrophage-like J774.1 cells and induced the release of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL-6).	Lipid A	37-44	interleukin 6	Mus musculus	254-258
8156049-2	1994	LPS, synthetic Escherichia coli-type lipid A (compound 506) and tetraacyl precursor Ia (compound 406) inhibited the binding of 125I-LPS to macrophage-like J774.1 cells and induced the release of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL-6).	tetraacyl	64-73	interleukin 6	Mus musculus	239-252
8156049-2	1994	LPS, synthetic Escherichia coli-type lipid A (compound 506) and tetraacyl precursor Ia (compound 406) inhibited the binding of 125I-LPS to macrophage-like J774.1 cells and induced the release of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL-6).	tetraacyl	64-73	interleukin 6	Mus musculus	254-258
8156049-2	1994	LPS, synthetic Escherichia coli-type lipid A (compound 506) and tetraacyl precursor Ia (compound 406) inhibited the binding of 125I-LPS to macrophage-like J774.1 cells and induced the release of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL-6).	125i-lps	127-135	interleukin 6	Mus musculus	239-252
8156049-2	1994	LPS, synthetic Escherichia coli-type lipid A (compound 506) and tetraacyl precursor Ia (compound 406) inhibited the binding of 125I-LPS to macrophage-like J774.1 cells and induced the release of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL-6).	125i-lps	127-135	interleukin 6	Mus musculus	254-258
8295487-6	1994	Secretion of IL-6 and TNF-alpha by splenocytes was significantly enhanced by cocaine administration.	Cocaine	77-84	interleukin 6	Mus musculus	13-17
8295487-7	1994	Secretion of IL-6 by peritoneal macrophages was also significantly enhanced by the cocaine, while production of IL-1 alpha was not affected.	Cocaine	83-90	interleukin 6	Mus musculus	13-17
7940643-7	1994	Vitamin E significantly reduced IL-6 and interferon-gamma production increased during the progression to murine AIDS.	Vitamin E	0-9	interleukin 6	Mus musculus	32-36
8242900-4	1993	A significant stimulation of interleukin 5 (IL-5) and interleukin 6 (IL-6) production by sensitized SPC was detectable when the TC from 3-week or older mice were employed as a stimulant.	Technetium	128-130	interleukin 6	Mus musculus	54-67
8242900-4	1993	A significant stimulation of interleukin 5 (IL-5) and interleukin 6 (IL-6) production by sensitized SPC was detectable when the TC from 3-week or older mice were employed as a stimulant.	Technetium	128-130	interleukin 6	Mus musculus	69-73
8219233-11	1993	Comparison of different sources and preparations of albumin showed differences in the levels of IL-6-inducing activity; three different lots of commercial fatty acid-free BSA and one lot of polymer-enhanced BSA stimulated IL-6 secretion by more than 100-fold over basal levels whereas other preparations showed more limited activity.	commercial fatty acid	144-165	interleukin 6	Mus musculus	96-100
8219233-11	1993	Comparison of different sources and preparations of albumin showed differences in the levels of IL-6-inducing activity; three different lots of commercial fatty acid-free BSA and one lot of polymer-enhanced BSA stimulated IL-6 secretion by more than 100-fold over basal levels whereas other preparations showed more limited activity.	commercial fatty acid	144-165	interleukin 6	Mus musculus	222-226
8219233-11	1993	Comparison of different sources and preparations of albumin showed differences in the levels of IL-6-inducing activity; three different lots of commercial fatty acid-free BSA and one lot of polymer-enhanced BSA stimulated IL-6 secretion by more than 100-fold over basal levels whereas other preparations showed more limited activity.	Polymers	190-197	interleukin 6	Mus musculus	96-100
8219233-11	1993	Comparison of different sources and preparations of albumin showed differences in the levels of IL-6-inducing activity; three different lots of commercial fatty acid-free BSA and one lot of polymer-enhanced BSA stimulated IL-6 secretion by more than 100-fold over basal levels whereas other preparations showed more limited activity.	Polymers	190-197	interleukin 6	Mus musculus	222-226
8219233-13	1993	When the albumin preparations were fractionated by ion exchange and gel filtration chromatography and then analyzed by sodium dodecyl sulfate-gel electrophoresis and Western blot immunoassay, it was found that the IL-6-inducing activity resided in high molecular weight polymers of albumin.	Sodium Dodecyl Sulfate	119-141	interleukin 6	Mus musculus	214-218
8219233-14	1993	The ability of albumin polymers to stimulate IL-6 production represents a novel mechanism for modulation of this cytokine.	Polymers	23-31	interleukin 6	Mus musculus	45-49
8227330-0	1993	Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.	Suramin	0-7	interleukin 6	Mus musculus	24-37
8227330-6	1993	Suramin prevents the binding of IL-6 to its cell surface receptor subunits, as demonstrated by radioreceptor binding assay and affinity crosslinking experiments.	Suramin	0-7	interleukin 6	Mus musculus	32-36
8227330-7	1993	Furthermore, the uptake of radioactive IL-6 by the liver is significantly reduced in suramin-treated mice.	Suramin	85-92	interleukin 6	Mus musculus	39-43
8227330-9	1993	Collectively, these results suggest that suramin inhibits cancer-associated wasting, in part by interfering with the binding of IL-6 to its receptor.	Suramin	41-48	interleukin 6	Mus musculus	128-132
8406825-5	1993	PMA completely restored IL-6 production and partially that of CSF.	Tetradecanoylphorbol Acetate	0-3	interleukin 6	Mus musculus	24-28
8393768-1	1993	We have shown earlier that 17 beta-estradiol inhibits cytokine-induced interleukin-6 (IL-6) production by bone marrow-derived stromal cells as well as osteoblasts, two types of cells with a critical influence on osteoclast development, and that ovariectomy causes an IL-6-mediated up-regulation of osteoclastogenesis in mice.	Estradiol	27-44	interleukin 6	Mus musculus	71-84
8393768-1	1993	We have shown earlier that 17 beta-estradiol inhibits cytokine-induced interleukin-6 (IL-6) production by bone marrow-derived stromal cells as well as osteoblasts, two types of cells with a critical influence on osteoclast development, and that ovariectomy causes an IL-6-mediated up-regulation of osteoclastogenesis in mice.	Estradiol	27-44	interleukin 6	Mus musculus	86-90
8393768-1	1993	We have shown earlier that 17 beta-estradiol inhibits cytokine-induced interleukin-6 (IL-6) production by bone marrow-derived stromal cells as well as osteoblasts, two types of cells with a critical influence on osteoclast development, and that ovariectomy causes an IL-6-mediated up-regulation of osteoclastogenesis in mice.	Estradiol	27-44	interleukin 6	Mus musculus	267-271
8393768-6	1993	Consistent with the functionality of the ER in stromal cells, and specifically its role in the regulation of IL-6 by 17 beta-estradiol, we found that the pure estrogen antagonist ICI 164,384 completely prevented the effect of 17 beta-estradiol on IL-6.	Estradiol	117-134	interleukin 6	Mus musculus	109-113
8393768-6	1993	Consistent with the functionality of the ER in stromal cells, and specifically its role in the regulation of IL-6 by 17 beta-estradiol, we found that the pure estrogen antagonist ICI 164,384 completely prevented the effect of 17 beta-estradiol on IL-6.	Estradiol	226-243	interleukin 6	Mus musculus	247-251
8393776-1	1993	We have previously shown that cytokine-induced production of interleukin-6 (IL-6) by cultured bone marrow-derived stromal and osteoblastic cells is inhibited by 17 beta-estradiol, and that estrogen withdrawal (ovariectomy) in mice causes an up-regulation of osteoclast development which can be prevented by a neutralizing antibody against IL-6 or estrogen replacement.	Estradiol	164-178	interleukin 6	Mus musculus	61-74
8393776-1	1993	We have previously shown that cytokine-induced production of interleukin-6 (IL-6) by cultured bone marrow-derived stromal and osteoblastic cells is inhibited by 17 beta-estradiol, and that estrogen withdrawal (ovariectomy) in mice causes an up-regulation of osteoclast development which can be prevented by a neutralizing antibody against IL-6 or estrogen replacement.	Estradiol	164-178	interleukin 6	Mus musculus	76-80
8393776-4	1993	IL-6 production in ex vivo cultures of bone marrow cells maintained in the presence of 1,25-dihydroxyvitamin D3 or PTH was greater in marrow cells from ovariectomized mice than in those from sham-operated animals or ovariectomized animals receiving estrogen replacement.	Calcitriol	87-111	interleukin 6	Mus musculus	0-4
8393776-5	1993	In line with this finding, addition of 17 beta-estradiol to calvaria cell cultures followed by withdrawal of the steroid caused an increase in the amount of IL-6 produced in response to the subsequent stimulation of these cultures with IL-1 or PTH compared to that in cultures that had never been treated with estradiol; when the inactive isomer 17 alpha-estradiol was used, no change in IL-6 production was observed.	Estradiol	39-56	interleukin 6	Mus musculus	157-161
8393776-5	1993	In line with this finding, addition of 17 beta-estradiol to calvaria cell cultures followed by withdrawal of the steroid caused an increase in the amount of IL-6 produced in response to the subsequent stimulation of these cultures with IL-1 or PTH compared to that in cultures that had never been treated with estradiol; when the inactive isomer 17 alpha-estradiol was used, no change in IL-6 production was observed.	Estradiol	39-56	interleukin 6	Mus musculus	388-392
8393776-5	1993	In line with this finding, addition of 17 beta-estradiol to calvaria cell cultures followed by withdrawal of the steroid caused an increase in the amount of IL-6 produced in response to the subsequent stimulation of these cultures with IL-1 or PTH compared to that in cultures that had never been treated with estradiol; when the inactive isomer 17 alpha-estradiol was used, no change in IL-6 production was observed.	Steroids	113-120	interleukin 6	Mus musculus	157-161
8393776-5	1993	In line with this finding, addition of 17 beta-estradiol to calvaria cell cultures followed by withdrawal of the steroid caused an increase in the amount of IL-6 produced in response to the subsequent stimulation of these cultures with IL-1 or PTH compared to that in cultures that had never been treated with estradiol; when the inactive isomer 17 alpha-estradiol was used, no change in IL-6 production was observed.	Steroids	113-120	interleukin 6	Mus musculus	388-392
8393776-5	1993	In line with this finding, addition of 17 beta-estradiol to calvaria cell cultures followed by withdrawal of the steroid caused an increase in the amount of IL-6 produced in response to the subsequent stimulation of these cultures with IL-1 or PTH compared to that in cultures that had never been treated with estradiol; when the inactive isomer 17 alpha-estradiol was used, no change in IL-6 production was observed.	Estradiol	47-56	interleukin 6	Mus musculus	157-161
8393776-5	1993	In line with this finding, addition of 17 beta-estradiol to calvaria cell cultures followed by withdrawal of the steroid caused an increase in the amount of IL-6 produced in response to the subsequent stimulation of these cultures with IL-1 or PTH compared to that in cultures that had never been treated with estradiol; when the inactive isomer 17 alpha-estradiol was used, no change in IL-6 production was observed.	Estradiol	47-56	interleukin 6	Mus musculus	388-392
8393776-5	1993	In line with this finding, addition of 17 beta-estradiol to calvaria cell cultures followed by withdrawal of the steroid caused an increase in the amount of IL-6 produced in response to the subsequent stimulation of these cultures with IL-1 or PTH compared to that in cultures that had never been treated with estradiol; when the inactive isomer 17 alpha-estradiol was used, no change in IL-6 production was observed.	alfatradiol	349-364	interleukin 6	Mus musculus	157-161
8330647-13	1993	In addition, the activity of CPA could be abrogated by anti-CPA antiserum but remained unchanged after treatment with antibodies to other murine hematopoietic synergizing/stimulating factors, including interleukin-1 (IL-1), IL-3, IL-4, IL-6, and stem cell factor (SCF).	colony promoting activity	29-32	interleukin 6	Mus musculus	236-240
7686504-1	1993	The monoclonal rat anti-c-kit antibody (ACK2), which abrogates colony growth supported by stem cell factor (SCF), significantly inhibited the interleukin-6 (IL-6)-dependent growth of hematopoietic progenitors derived from spleen cells of normal and 5-fluorouracil (5-FU)-treated mice and from bone marrow cells of normal mice in serum-containing culture.	Fluorouracil	249-263	interleukin 6	Mus musculus	142-155
7686504-1	1993	The monoclonal rat anti-c-kit antibody (ACK2), which abrogates colony growth supported by stem cell factor (SCF), significantly inhibited the interleukin-6 (IL-6)-dependent growth of hematopoietic progenitors derived from spleen cells of normal and 5-fluorouracil (5-FU)-treated mice and from bone marrow cells of normal mice in serum-containing culture.	Fluorouracil	249-263	interleukin 6	Mus musculus	157-161
7686504-1	1993	The monoclonal rat anti-c-kit antibody (ACK2), which abrogates colony growth supported by stem cell factor (SCF), significantly inhibited the interleukin-6 (IL-6)-dependent growth of hematopoietic progenitors derived from spleen cells of normal and 5-fluorouracil (5-FU)-treated mice and from bone marrow cells of normal mice in serum-containing culture.	Fluorouracil	265-269	interleukin 6	Mus musculus	142-155
7686504-1	1993	The monoclonal rat anti-c-kit antibody (ACK2), which abrogates colony growth supported by stem cell factor (SCF), significantly inhibited the interleukin-6 (IL-6)-dependent growth of hematopoietic progenitors derived from spleen cells of normal and 5-fluorouracil (5-FU)-treated mice and from bone marrow cells of normal mice in serum-containing culture.	Fluorouracil	265-269	interleukin 6	Mus musculus	157-161
8515056-6	1993	In aged mice, the reduced regulation of IL-6 production could be effectively prevented and/or reversed by supplementing aging animals with dehydroepiandrosterone sulfate, a steroid hormone whose endogenous production is known to decline with advancing age in all species tested.	Dehydroepiandrosterone Sulfate	139-169	interleukin 6	Mus musculus	40-44
8515056-6	1993	In aged mice, the reduced regulation of IL-6 production could be effectively prevented and/or reversed by supplementing aging animals with dehydroepiandrosterone sulfate, a steroid hormone whose endogenous production is known to decline with advancing age in all species tested.	Steroids	173-188	interleukin 6	Mus musculus	40-44
8513511-7	1993	IL-1 alpha, IL-4, IL-6, IL-10, and IFN-gamma levels were decreased by treatment with low doses of DEX (30 mg/kg), whereas higher doses were required to inhibit production of IL-2, IL-3, and TNF.	Dexamethasone	98-101	interleukin 6	Mus musculus	18-22
8510131-2	1993	M1Av stimulated thioglycolate-induced peritoneal macrophages from C3H/HeN and C3H/HeJ mice to release cell-free tumour necrosis factor (TNF) and interleukin (IL)-6, and a cell-associated thymocyte activating factor, probably IL-1.	Thioglycolates	16-29	interleukin 6	Mus musculus	145-163
8477802-6	1993	Quantitative analysis of serum IL-6 in MRL/lpr revealed that the serum sIL-6R level correlated well with the serum IL-6 level.	sil-6r	71-77	interleukin 6	Mus musculus	31-35
7694632-10	1993	This result indicates a possible association between sensitivity to bleomycin-induced fibrosis and inducibility of IL-6 mRNA upon drug treatment.	Bleomycin	68-77	interleukin 6	Mus musculus	115-119
8443377-4	1993	In addition, formation of multilineage colonies from J11d.2+ in both 5-FU-treated and normal mice was augmented by interleukin 6.	Fluorouracil	69-73	interleukin 6	Mus musculus	115-128
8383024-6	1993	The IL-6 activity in culture supernatants was determined by measurement of thymidine uptake in mouse IL-6-dependent cell line (MH60.BSF2).	Thymidine	75-84	interleukin 6	Mus musculus	4-8
8325351-3	1993	We assessed the effect of age on interleukin-1 (IL-1), tumor necrosis factor (TNF), and interleukin-6 (IL-6) in unelicited, thioglycollate (TG)-elicited, and complete Freund"s adjuvant (CFA)-elicited peritoneal macrophages.	Thioglycolates	124-138	interleukin 6	Mus musculus	88-101
8325351-3	1993	We assessed the effect of age on interleukin-1 (IL-1), tumor necrosis factor (TNF), and interleukin-6 (IL-6) in unelicited, thioglycollate (TG)-elicited, and complete Freund"s adjuvant (CFA)-elicited peritoneal macrophages.	Thioglycolates	124-138	interleukin 6	Mus musculus	103-107
8325351-3	1993	We assessed the effect of age on interleukin-1 (IL-1), tumor necrosis factor (TNF), and interleukin-6 (IL-6) in unelicited, thioglycollate (TG)-elicited, and complete Freund"s adjuvant (CFA)-elicited peritoneal macrophages.	Thioglycolates	140-142	interleukin 6	Mus musculus	88-101
8219776-8	1993	Detailed studies to identify further cytokines with GIF activity in the avian and murine systems showed that both IL-6 and tumor necrosis factor-alpha could induce increased plasma corticosterone levels in mice, but not in chickens.	Corticosterone	181-195	interleukin 6	Mus musculus	114-150
1451333-6	1992	Interestingly, the addition of combinations of IL-1 and IL-6 increased the proliferation of T cells in response to KLH presented by either saline- or poly(I:C)-treated M phi.	Sodium Chloride	139-145	interleukin 6	Mus musculus	56-60
1451333-6	1992	Interestingly, the addition of combinations of IL-1 and IL-6 increased the proliferation of T cells in response to KLH presented by either saline- or poly(I:C)-treated M phi.	Poly I-C	150-159	interleukin 6	Mus musculus	56-60
1429553-2	1992	Binding studies using 125I-labeled human and murine IL-6 revealed that LIF caused a decrease in IL-6 binding to M1 cells.	Iodine-125	22-26	interleukin 6	Mus musculus	52-56
1429553-2	1992	Binding studies using 125I-labeled human and murine IL-6 revealed that LIF caused a decrease in IL-6 binding to M1 cells.	Iodine-125	22-26	interleukin 6	Mus musculus	96-100
1384800-0	1992	Retinoic acid inhibits interleukin-6-induced macrophage differentiation and apoptosis in a murine hematopoietic cell line, Y6.	Tretinoin	0-13	interleukin 6	Mus musculus	23-36
1384800-3	1992	Retinoic acid (RA) inhibited such effects of IL-6 on Y6 cells.	Tretinoin	0-13	interleukin 6	Mus musculus	45-49
1384800-3	1992	Retinoic acid (RA) inhibited such effects of IL-6 on Y6 cells.	Tretinoin	15-17	interleukin 6	Mus musculus	45-49
1384800-4	1992	The inhibitory effect of RA on the effects of IL-6 was not caused by the downregulation of the IL-6 receptor, because RA neither affected the expression of IL-6 receptor mRNA nor the expression of IL-6 receptor molecule on the cell surface.	Tretinoin	25-27	interleukin 6	Mus musculus	46-50
1338703-5	1992	The RNA from the mouse glomerular mesangial cells was hybridized in dot blots with a-32pdCTP labeled IL6 cDNA probe, the dot blot autoradiograph showed the expression of IL6 mRNA gene in mouse mesangial cells.	32pdctp	85-92	interleukin 6	Mus musculus	101-104
1338703-5	1992	The RNA from the mouse glomerular mesangial cells was hybridized in dot blots with a-32pdCTP labeled IL6 cDNA probe, the dot blot autoradiograph showed the expression of IL6 mRNA gene in mouse mesangial cells.	32pdctp	85-92	interleukin 6	Mus musculus	170-173
1382702-4	1992	The stimulatory effect of SCF was approximately three to four times as high as that of IL-6 on the primitive progenitors capable of megakaryocytic-lineage expression derived from 5-FU-treated mice.	Fluorouracil	179-183	interleukin 6	Mus musculus	87-91
1395667-11	1992	The concentrations of tumor necrosis factor and interleukin-6 in the plasma were significantly higher when a low dose of lipopolysaccharide was administered to mice that had been pretreated with Pluronic F 127 liquid.	pluronic f 127 liquid	195-216	interleukin 6	Mus musculus	48-61
1527422-2	1992	The effects of pentoxifylline and dexamethasone on the release of tumor necrosis factor (TNF), interleukin (IL)-1, and IL-6 from primary murine microglial cell cultures were explored using bioassays.	Dexamethasone	34-47	interleukin 6	Mus musculus	119-123
1527422-3	1992	When added concomitantly with lipopolysaccharide, pentoxifylline blocked the release of TNF and IL-1 but not IL-6, while dexamethasone inhibited the release of TNF and IL-6.	Dexamethasone	121-134	interleukin 6	Mus musculus	168-172
1382293-2	1992	In BMMCs sensitized with IgE anti-trinitrophenyl, CsA inhibited trinitrophenylated bovine serum albumin-induced increases in mRNA for IL-1 beta, tumor necrosis factor alpha (TNF-alpha), and IL-6 in a dose-related manner (IC50 values of 4, 65, and 130 nM, respectively).	Cyclosporine	50-53	interleukin 6	Mus musculus	190-194
1382293-6	1992	That CsA inhibited IL-1 beta mRNA accumulation in IgE-activated BMMCs with an IC50 similar to that for inhibition of calcineurin activity, whereas the IC50 values were approximately 20-fold higher for the inhibition of TNF-alpha and IL-6 mRNA, suggests that the induction of TNF-alpha and IL-6 is less dependent upon calcineurin activity than is the induction of IL-1 beta.	Cyclosporine	5-8	interleukin 6	Mus musculus	233-237
1382293-6	1992	That CsA inhibited IL-1 beta mRNA accumulation in IgE-activated BMMCs with an IC50 similar to that for inhibition of calcineurin activity, whereas the IC50 values were approximately 20-fold higher for the inhibition of TNF-alpha and IL-6 mRNA, suggests that the induction of TNF-alpha and IL-6 is less dependent upon calcineurin activity than is the induction of IL-1 beta.	Cyclosporine	5-8	interleukin 6	Mus musculus	289-293
1505448-1	1992	Uterine stromal (USC) and uterine epithelial (UEC) cells were isolated from immature and mature mice to determine their ability to secrete interleukin-6 (IL-6) in response to ovarian steroids, IL-1 alpha, and soluble products produced by the heterologous cell type.	Steroids	183-191	interleukin 6	Mus musculus	139-152
1505448-1	1992	Uterine stromal (USC) and uterine epithelial (UEC) cells were isolated from immature and mature mice to determine their ability to secrete interleukin-6 (IL-6) in response to ovarian steroids, IL-1 alpha, and soluble products produced by the heterologous cell type.	Steroids	183-191	interleukin 6	Mus musculus	154-158
1505448-5	1992	The addition of 17 beta-estradiol (E) to UEC cultures markedly inhibited total IL-6 secretion, but did not affect vectorial secretion.	Estradiol	16-33	interleukin 6	Mus musculus	79-83
1505448-10	1992	In addition, there was a synergistic effect of E plus progesterone on inhibition of IL-6 secretion by USC.	Progesterone	54-66	interleukin 6	Mus musculus	84-88
1382324-0	1992	Dimethylnitrosamine (DMN)-induced IL-1 beta, TNF-alpha, and IL-6 inflammatory cytokine expression.	Dimethylnitrosamine	0-19	interleukin 6	Mus musculus	60-64
1382324-0	1992	Dimethylnitrosamine (DMN)-induced IL-1 beta, TNF-alpha, and IL-6 inflammatory cytokine expression.	Dimethylnitrosamine	21-24	interleukin 6	Mus musculus	60-64
1382324-8	1992	IL-1 beta, IL-6, and TNF-alpha serum activities were observed within 2 hr of DMN exposure and returned to vehicle control levels by 3 days even though DMN exposure was maintained.	Dimethylnitrosamine	77-80	interleukin 6	Mus musculus	11-15
1418082-10	1992	In addition, ibuprofen activated mouse macrophages to produce interleukin-6 in a dose dependent way.	Ibuprofen	13-22	interleukin 6	Mus musculus	62-75
1638523-4	1992	Both human and murine IL-6 reduced heparin-releasable LPL activity in 3T3-L1 adipocytes in a dose-dependent manner; half-maximal inhibition of LPL activity was achieved with 5000 hybridoma growth factor units/ml.	Heparin	35-42	interleukin 6	Mus musculus	22-26
1322305-8	1992	Injection with IL-1, interferon-gamma, lipopolysaccharide, or phorbol 12-myristate 13-acetate also induced IL-6 in murine skin.	Tetradecanoylphorbol Acetate	62-93	interleukin 6	Mus musculus	107-111
1499565-4	1992	It was demonstrated that complete disulfide bond formation in murine IL-6 occurred during the early urea washing/guanidine hydrochloride extraction steps, so no refolding step was required.	Disulfides	34-43	interleukin 6	Mus musculus	69-73
1499565-4	1992	It was demonstrated that complete disulfide bond formation in murine IL-6 occurred during the early urea washing/guanidine hydrochloride extraction steps, so no refolding step was required.	Urea	100-104	interleukin 6	Mus musculus	69-73
1499565-4	1992	It was demonstrated that complete disulfide bond formation in murine IL-6 occurred during the early urea washing/guanidine hydrochloride extraction steps, so no refolding step was required.	Guanidine	113-136	interleukin 6	Mus musculus	69-73
1499565-5	1992	When fully reduced murine IL-6 was dissolved in 8 M guanidine hydrochloride and allowed to air-oxidize, complete disulfide bond formation, monitored by analytical reversed-phase HPLC, was shown to occur within 13 h at 6 degrees C. About 25 mg pure protein was obtained from 37 g wet cells.	Guanidine	52-75	interleukin 6	Mus musculus	26-30
1499565-5	1992	When fully reduced murine IL-6 was dissolved in 8 M guanidine hydrochloride and allowed to air-oxidize, complete disulfide bond formation, monitored by analytical reversed-phase HPLC, was shown to occur within 13 h at 6 degrees C. About 25 mg pure protein was obtained from 37 g wet cells.	Disulfides	113-122	interleukin 6	Mus musculus	26-30
1330001-9	1992	This impairment seems not to be mediated by transformation-induced inactivation of the protein kinase C pathway since phorbol 12-myristate 13-acetate (PMA) induced IL-6 production equally well in all C127 cell-derived clones.	Tetradecanoylphorbol Acetate	118-149	interleukin 6	Mus musculus	164-168
1330001-9	1992	This impairment seems not to be mediated by transformation-induced inactivation of the protein kinase C pathway since phorbol 12-myristate 13-acetate (PMA) induced IL-6 production equally well in all C127 cell-derived clones.	Tetradecanoylphorbol Acetate	151-154	interleukin 6	Mus musculus	164-168
1641758-6	1992	Treatment with ATP-MgCl2 after hemorrhage restored macrophage ATP levels (p less than 0.05) and significantly increased (p less than 0.05) macrophage AP, IL-1, IL-6, and TNF release by 110% +/- 21%, 130% +/- 38%, 124% +/- 17%, and 66% +/- 24%, respectively.	atp-mgcl2	15-24	interleukin 6	Mus musculus	160-164
1641758-6	1992	Treatment with ATP-MgCl2 after hemorrhage restored macrophage ATP levels (p less than 0.05) and significantly increased (p less than 0.05) macrophage AP, IL-1, IL-6, and TNF release by 110% +/- 21%, 130% +/- 38%, 124% +/- 17%, and 66% +/- 24%, respectively.	Adenosine Triphosphate	15-18	interleukin 6	Mus musculus	160-164
1621100-3	1992	Interleukin-6 production by bone and marrow stromal cells is suppressed by 17 beta-estradiol in vitro.	Estradiol	75-92	interleukin 6	Mus musculus	0-13
1587308-0	1992	Transient expression of the IL-2 receptor alpha-chain in IL-6-induced myeloid cells is regulated by autocrine production of prostaglandin E2.	Dinoprostone	124-140	interleukin 6	Mus musculus	57-61
1587308-6	1992	IL-2R alpha expression is induced on these cells after treatment by IL-6 for up to 48 h. Treatment of IL-6-induced M1 cells with indomethacin permitted a sustained expression of IL-2R alpha beyond 24 h, and this effect was reversed by the addition of prostaglandin E2 (PGE2).	Indomethacin	129-141	interleukin 6	Mus musculus	68-72
1587308-6	1992	IL-2R alpha expression is induced on these cells after treatment by IL-6 for up to 48 h. Treatment of IL-6-induced M1 cells with indomethacin permitted a sustained expression of IL-2R alpha beyond 24 h, and this effect was reversed by the addition of prostaglandin E2 (PGE2).	Indomethacin	129-141	interleukin 6	Mus musculus	102-106
1587308-6	1992	IL-2R alpha expression is induced on these cells after treatment by IL-6 for up to 48 h. Treatment of IL-6-induced M1 cells with indomethacin permitted a sustained expression of IL-2R alpha beyond 24 h, and this effect was reversed by the addition of prostaglandin E2 (PGE2).	Dinoprostone	251-267	interleukin 6	Mus musculus	68-72
1587308-6	1992	IL-2R alpha expression is induced on these cells after treatment by IL-6 for up to 48 h. Treatment of IL-6-induced M1 cells with indomethacin permitted a sustained expression of IL-2R alpha beyond 24 h, and this effect was reversed by the addition of prostaglandin E2 (PGE2).	Dinoprostone	251-267	interleukin 6	Mus musculus	102-106
1587308-6	1992	IL-2R alpha expression is induced on these cells after treatment by IL-6 for up to 48 h. Treatment of IL-6-induced M1 cells with indomethacin permitted a sustained expression of IL-2R alpha beyond 24 h, and this effect was reversed by the addition of prostaglandin E2 (PGE2).	Dinoprostone	269-273	interleukin 6	Mus musculus	68-72
1587308-6	1992	IL-2R alpha expression is induced on these cells after treatment by IL-6 for up to 48 h. Treatment of IL-6-induced M1 cells with indomethacin permitted a sustained expression of IL-2R alpha beyond 24 h, and this effect was reversed by the addition of prostaglandin E2 (PGE2).	Dinoprostone	269-273	interleukin 6	Mus musculus	102-106
1587308-8	1992	These data show that inducers of macrophage differentiation such as LIF and IL-6 can induce a transient expression of the IL-2R alpha-chain in differentiating murine myeloid M1 cells and that autocrine production of PGE2 is involved in the control of the transient expression of this receptor.	Dinoprostone	216-220	interleukin 6	Mus musculus	76-80
1568463-0	1992	Effects of interleukin 3 and interleukin 6 on platelet recovery in mice treated with 5-fluorouracil.	Fluorouracil	85-99	interleukin 6	Mus musculus	29-42
1568463-7	1992	The combination of IL-3 and IL-6, initiated immediately or 2 days following 5-FU, diminished the platelet nadir and increased platelet counts on individual days during the recovery phase, thus apparently decreasing the time required for recovery to a normal platelet level.	Fluorouracil	76-80	interleukin 6	Mus musculus	28-32
1568463-11	1992	We propose that IL-3 and IL-6 can act synergistically to enhance platelet recovery following 5-FU-mediated thrombocytopenia, but their modification of the response to 5-FU is modest.	Fluorouracil	93-97	interleukin 6	Mus musculus	25-29
1568468-11	1992	These in vitro and in vivo observations strongly suggest that MDP-Lys(L18) indirectly enhances the proliferation and differentiation of mouse CFU-Meg via colony-stimulating factor(s) other than IL-1, probably as a result of the stimulation of macrophages to produce IL-6.	Lysine	66-69	interleukin 6	Mus musculus	266-270
1532365-9	1992	We observed that RU38486 closely mimicked IL-1: both had similar effects on IL-6 induction and sensitized mice to the lethal effects of TNF with comparable efficiency and kinetics.	Mifepristone	17-24	interleukin 6	Mus musculus	76-80
1561635-3	1992	In the present studies we analyzed the effects of benzene treatment of mice on the production of interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) by bone marrow leukocytes.	Benzene	50-57	interleukin 6	Mus musculus	119-132
1561635-3	1992	In the present studies we analyzed the effects of benzene treatment of mice on the production of interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) by bone marrow leukocytes.	Benzene	50-57	interleukin 6	Mus musculus	134-138
1541679-0	1992	17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.	Estradiol	3-17	interleukin 6	Mus musculus	27-40
1541679-1	1992	The effect of 17 beta-estradiol on interleukin-6 (IL-6) synthesis was examined in murine bone marrow-derived stromal cell lines, normal human bone-derived cells, and nontransformed osteoblast cell lines from mice and rats.	Estradiol	14-31	interleukin 6	Mus musculus	35-48
1541679-3	1992	Addition of 17 beta-estradiol in the cultures exerted a dose-dependent inhibition of IL-1-, TNF-, and IL-1 + TNF-induced production of bioassayable IL-6.	Estradiol	12-29	interleukin 6	Mus musculus	148-152
1541679-4	1992	Testosterone and progesterone (but not 17 alpha-estradiol) also inhibited IL-6, but their effective concentrations were two orders of magnitude higher than 17 beta-estradiol.	Testosterone	0-12	interleukin 6	Mus musculus	74-78
1541679-4	1992	Testosterone and progesterone (but not 17 alpha-estradiol) also inhibited IL-6, but their effective concentrations were two orders of magnitude higher than 17 beta-estradiol.	Progesterone	17-29	interleukin 6	Mus musculus	74-78
1541679-5	1992	17 beta-estradiol also decreased the levels of the IL-6 mRNA.	Estradiol	0-17	interleukin 6	Mus musculus	51-55
1541679-6	1992	In addition, estradiol inhibited both TNF-induced IL-6 production and osteoclast development in primary bone cell cultures derived from neonatal murine calvaria.	Estradiol	13-22	interleukin 6	Mus musculus	50-54
1564955-2	1992	Multilineage colony formation from mice that had been treated with 150 mg/kg 5-fluorouracil was assayed in cultures containing interleukin-3, interleukin-6, and erythropoietin.	Fluorouracil	77-91	interleukin 6	Mus musculus	142-155
1581469-2	1992	Arthritic DBA/1 mice had significantly higher serum IL-6 titres than nonarthritic or normal mice at 160 days post pristane injection.	1,2,5,6-dibenzanthracene	10-13	interleukin 6	Mus musculus	52-56
1581469-2	1992	Arthritic DBA/1 mice had significantly higher serum IL-6 titres than nonarthritic or normal mice at 160 days post pristane injection.	pristane	114-122	interleukin 6	Mus musculus	52-56
1581469-6	1992	An association between serum agalactosyl IgG levels and PEF IL-6 in pristane injected DBA/1 was demonstrated.	pristane	68-76	interleukin 6	Mus musculus	60-64
1319763-5	1992	Hydrocortisone in concentrations as low as 10 ng/ml had dramatic inhibitory effects on supernatant levels of TNF and IL-1 and on TNF, IL-1 and IL-6 transcript number.	Hydrocortisone	0-14	interleukin 6	Mus musculus	143-147
1319763-6	1992	Supernatant levels of IL-6 were only slightly diminished by hydrocortisone.	Hydrocortisone	60-74	interleukin 6	Mus musculus	22-26
1319763-11	1992	Thus, physiological and pharmacological concentrations of hydrocortisone had dramatic inhibitory effects on the supernatant levels of TNF and IL-1, and on the number of available TNF, IL-1 and IL-6 transcripts in PEC exposed to LPS, but had minimal effects on supernatant levels of IL-6 bioactivity.	Hydrocortisone	58-72	interleukin 6	Mus musculus	193-197
1319763-11	1992	Thus, physiological and pharmacological concentrations of hydrocortisone had dramatic inhibitory effects on the supernatant levels of TNF and IL-1, and on the number of available TNF, IL-1 and IL-6 transcripts in PEC exposed to LPS, but had minimal effects on supernatant levels of IL-6 bioactivity.	Hydrocortisone	58-72	interleukin 6	Mus musculus	282-286
1319763-12	1992	This hydrocortisone action may be a specific negative feedback system for IL-1 and TNF, with relative sparing of IL-6.	Hydrocortisone	5-19	interleukin 6	Mus musculus	113-117
1294619-1	1992	The effect of several divalent metal cations (Co, Cu, Zn, Hg and Pb) on the proliferative response of B9 hybridoma cells to IL-6 has been investigated.	Metals	31-36	interleukin 6	Mus musculus	124-128
1294619-3	1992	The inhibition by Cd and Pb was dependent on both time of addition of the metal and IL-6 concentration.	Cadmium	18-20	interleukin 6	Mus musculus	84-88
1294619-3	1992	The inhibition by Cd and Pb was dependent on both time of addition of the metal and IL-6 concentration.	Lead	25-27	interleukin 6	Mus musculus	84-88
1294619-4	1992	Cd (10 microM) and Pb (50 microM) added at the same time as IL-6 were inhibitory but added 24h later had no effect.	Cadmium	0-2	interleukin 6	Mus musculus	60-64
1294619-4	1992	Cd (10 microM) and Pb (50 microM) added at the same time as IL-6 were inhibitory but added 24h later had no effect.	Lead	19-21	interleukin 6	Mus musculus	60-64
1294619-5	1992	Increasing the concentration of IL-6 overcame the inhibitory effect of Cd (10 microM) and Pb (50 microM).	Cadmium	71-73	interleukin 6	Mus musculus	32-36
1294619-5	1992	Increasing the concentration of IL-6 overcame the inhibitory effect of Cd (10 microM) and Pb (50 microM).	Lead	90-92	interleukin 6	Mus musculus	32-36
1294619-8	1992	The results suggest that there are at least two distinct metal sensitive events in B9 proliferation, i) IL-6 reversible inhibition by Cd and Pb ii) IL-6 independent inhibition by Co, Cu and Hg.	Metals	57-62	interleukin 6	Mus musculus	104-108
1294619-8	1992	The results suggest that there are at least two distinct metal sensitive events in B9 proliferation, i) IL-6 reversible inhibition by Cd and Pb ii) IL-6 independent inhibition by Co, Cu and Hg.	Metals	57-62	interleukin 6	Mus musculus	148-152
1294619-8	1992	The results suggest that there are at least two distinct metal sensitive events in B9 proliferation, i) IL-6 reversible inhibition by Cd and Pb ii) IL-6 independent inhibition by Co, Cu and Hg.	Cadmium	134-136	interleukin 6	Mus musculus	104-108
1294619-8	1992	The results suggest that there are at least two distinct metal sensitive events in B9 proliferation, i) IL-6 reversible inhibition by Cd and Pb ii) IL-6 independent inhibition by Co, Cu and Hg.	Lead	141-143	interleukin 6	Mus musculus	104-108
1472283-3	1992	LPS-induced IL6 mRNA was inhibited by treatment with cycloheximide (5 micrograms/ml), implicating the participation of a secondary protein mediator in the induction process, or the dependence upon protein synthesis for receptor ligand interactions.	Cycloheximide	53-66	interleukin 6	Mus musculus	12-15
1655506-3	1991	The cytokines tumor necrosis factor, interleukin 1 (alpha and beta), and transforming growth factor beta, as well as forskolin and dibutyryl cyclic AMP, all induce a transient rise in the steady-state level of IL-6 mRNA and an increased release of IL-6 protein.	Colforsin	117-126	interleukin 6	Mus musculus	210-214
1655506-3	1991	The cytokines tumor necrosis factor, interleukin 1 (alpha and beta), and transforming growth factor beta, as well as forskolin and dibutyryl cyclic AMP, all induce a transient rise in the steady-state level of IL-6 mRNA and an increased release of IL-6 protein.	Bucladesine	131-151	interleukin 6	Mus musculus	210-214
1655506-3	1991	The cytokines tumor necrosis factor, interleukin 1 (alpha and beta), and transforming growth factor beta, as well as forskolin and dibutyryl cyclic AMP, all induce a transient rise in the steady-state level of IL-6 mRNA and an increased release of IL-6 protein.	Bucladesine	131-151	interleukin 6	Mus musculus	248-252
1912565-10	1991	Our data indicate that CQ selectively inhibits the release of TNF, IL-6, and PGE2 by KC, while IL-1 secretion was unaffected.	Chloroquine	23-25	interleukin 6	Mus musculus	67-71
1774464-2	1991	Free and encapsulated polynucleotides were compared for their capacity to stimulate secretion of interferon (IFN) and interleukin-6 (IL-6) and to induce cellular toxicity on L929 cells pretreated with IFN-alpha/beta.	Polynucleotides	22-37	interleukin 6	Mus musculus	118-131
1774464-2	1991	Free and encapsulated polynucleotides were compared for their capacity to stimulate secretion of interferon (IFN) and interleukin-6 (IL-6) and to induce cellular toxicity on L929 cells pretreated with IFN-alpha/beta.	Polynucleotides	22-37	interleukin 6	Mus musculus	133-137
1909730-6	1991	PMA induced low level of IL-6 production by highly purified PP B cells.	Tetradecanoylphorbol Acetate	0-3	interleukin 6	Mus musculus	25-29
1959939-4	1991	Enhancement of the serum level of DNP-specific antibody by intraperitoneal injection of IL-6 was inhibited completely with simultaneous administration of the anti-mIL-6R antibody.	2,4-Dinitrophenol	34-37	interleukin 6	Mus musculus	88-92
1959939-5	1991	The level of DNP-specific antibody was decreased, even below the basal value, by the higher dose of anti-mIL-6R antibody, indicating its effect also on endogenous IL-6.	2,4-Dinitrophenol	13-16	interleukin 6	Mus musculus	106-110
1651969-0	1991	Effect of triggering epidermal Fc gamma receptors on the interleukin-2- and interleukin-6-induced upregulation of Ia antigen expression by murine epidermal Langerhans cells: the role of prostaglandins and cAMP.	Prostaglandins	186-200	interleukin 6	Mus musculus	76-89
1651969-0	1991	Effect of triggering epidermal Fc gamma receptors on the interleukin-2- and interleukin-6-induced upregulation of Ia antigen expression by murine epidermal Langerhans cells: the role of prostaglandins and cAMP.	Cyclic AMP	205-209	interleukin 6	Mus musculus	76-89
1647881-2	1991	The presence of IL6 activity in SK-v cell-conditioned media (SK-v CM) was demonstrated by tritiated thymidine incorporation into IL6-dependent B9 murine plasmacytoma cells.	Thymidine	100-109	interleukin 6	Mus musculus	16-19
1907307-0	1991	Reversal of defective IL-6 production in lipopolysaccharide-tolerant mice by phorbol myristate acetate.	Tetradecanoylphorbol Acetate	77-102	interleukin 6	Mus musculus	22-26
1907699-0	1991	Diltiazem restores IL-2, IL-3, IL-6, and IFN-gamma synthesis and decreases host susceptibility to sepsis following hemorrhage.	Diltiazem	0-9	interleukin 6	Mus musculus	31-35
1907699-7	1991	However, diltiazem (400 but not 2400 micrograms/kg) treatment after hemorrhage restored lymphocyte capacity to produce IL-2, IL-3, IL-6, and IFN-gamma (P less than 0.05).	Diltiazem	9-18	interleukin 6	Mus musculus	131-135
1663144-4	1991	PGE2 inhibited IL-6-induced proliferation and potentiated the response to IL-3.	Dinoprostone	0-4	interleukin 6	Mus musculus	15-19
7920017-6	1994	Treatment of sensitized mice with salbutamol increased the ex vivo production of IL-4, IL-5, IL-6 and IL-10 from concanavalin A-activated splenocytes whereas no modification of IFN-gamma synthesis was noticed as compared to nontreated sensitized control mice.	Albuterol	34-44	interleukin 6	Mus musculus	93-97
7805799-3	1994	In addition, interleukin-6 (IL-6) levels were low in DBA/2, and high in ddY and ICR strains.	1,2,5,6-dibenzanthracene	53-56	interleukin 6	Mus musculus	13-26
7805799-3	1994	In addition, interleukin-6 (IL-6) levels were low in DBA/2, and high in ddY and ICR strains.	1,2,5,6-dibenzanthracene	53-56	interleukin 6	Mus musculus	28-32
7520778-2	1994	In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis.	Sirolimus	13-22	interleukin 6	Mus musculus	149-162
7520778-2	1994	In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis.	Sirolimus	13-22	interleukin 6	Mus musculus	164-168
7868057-10	1994	Addition of calphostin C, a specific protein kinase C (PKC) inhibitor or genistein and herbimycin A, specific tyrosine kinase (TK) inhibitors to the culture also decreased colony numbers formed with IL-6 and TPA.	calphostin C	12-24	interleukin 6	Mus musculus	199-203
7868057-10	1994	Addition of calphostin C, a specific protein kinase C (PKC) inhibitor or genistein and herbimycin A, specific tyrosine kinase (TK) inhibitors to the culture also decreased colony numbers formed with IL-6 and TPA.	Genistein	73-82	interleukin 6	Mus musculus	199-203
7868057-10	1994	Addition of calphostin C, a specific protein kinase C (PKC) inhibitor or genistein and herbimycin A, specific tyrosine kinase (TK) inhibitors to the culture also decreased colony numbers formed with IL-6 and TPA.	herbimycin	87-99	interleukin 6	Mus musculus	199-203
7868057-13	1994	Although delayed addition of TPA enhanced IL-6-dependent colony formation, delayed addition of TPA with either the PKC inhibitor or TK inhibitors canceled the increase of colonies.	Tetradecanoylphorbol Acetate	29-32	interleukin 6	Mus musculus	42-46
7978112-8	1994	The levels of IL-5, IL-6, and IL-10 secreted by Con A-induced splenocytes, elevated during murine AIDS, were significantly further enhanced in EtOH-fed mice compared with controls at 6 weeks postinfection, whereas retrovirus-induced elevated release of IL-6 and tumor necrosis factor-alpha, produced by lipopolysaccharide (LPS)-stimulated splenocytes, were further increased in EtOH-fed mice compared with controls at 6 and 9 weeks postinfection, respectively.	Ethanol	143-147	interleukin 6	Mus musculus	20-24
7978112-8	1994	The levels of IL-5, IL-6, and IL-10 secreted by Con A-induced splenocytes, elevated during murine AIDS, were significantly further enhanced in EtOH-fed mice compared with controls at 6 weeks postinfection, whereas retrovirus-induced elevated release of IL-6 and tumor necrosis factor-alpha, produced by lipopolysaccharide (LPS)-stimulated splenocytes, were further increased in EtOH-fed mice compared with controls at 6 and 9 weeks postinfection, respectively.	Ethanol	143-147	interleukin 6	Mus musculus	253-289
7804167-6	1994	DEX suppressed IL-6 production, but augmented TNF and IFN-gamma production within 24 h of infection, whereas production of all three endogenous cytokines was suppressed in the DEX-treated mice on day 3 of infection when the control mice began to die.	Dexamethasone	0-3	interleukin 6	Mus musculus	15-19
7518681-2	1994	Here we report that IL-6 stimulated different patterns of tyrosine phosphorylation of JAK-TYK kinases in IL-6-responsive murine (B9E and T10D) and human (ANBL-6 and OCI-My4) plasma cell tumor lines.	Tyrosine	58-66	interleukin 6	Mus musculus	20-24
7518681-2	1994	Here we report that IL-6 stimulated different patterns of tyrosine phosphorylation of JAK-TYK kinases in IL-6-responsive murine (B9E and T10D) and human (ANBL-6 and OCI-My4) plasma cell tumor lines.	Tyrosine	58-66	interleukin 6	Mus musculus	105-109
7913905-6	1994	48-hr pulsed exposure of CD4+ cells to ConA and vomitoxin resulted in significantly increased production of the T helper cytokines IL-4, IL-5 and IL-6 after 5 additional days of culture, compared with ConA-stimulated CD4+ cells alone.	deoxynivalenol	48-57	interleukin 6	Mus musculus	146-150
7959870-4	1994	The draining lymph node (DLN) cells from mice injected 48 hr previously with carrageenin produced significantly higher levels of proliferation and interleukin-1 (IL-1), IL-2, IL-6 and interferon-gamma (IFN-gamma), but less IL-10, compared to cells from saline-injected controls, when stimulated with concanavalin A (Con A) in vitro.	Carrageenan	77-88	interleukin 6	Mus musculus	175-179
7959870-5	1994	Treatment of the carrageenin-injected mice with L-NMMA had little effect on the proliferative response of the DLN cells, but significantly reduced the production of IL-1, IL-2, IL-6 and IFN-gamma, and increased the secretion of IL-10.	Carrageenan	17-28	interleukin 6	Mus musculus	177-181
7959870-5	1994	Treatment of the carrageenin-injected mice with L-NMMA had little effect on the proliferative response of the DLN cells, but significantly reduced the production of IL-1, IL-2, IL-6 and IFN-gamma, and increased the secretion of IL-10.	omega-N-Methylarginine	48-54	interleukin 6	Mus musculus	177-181
8007951-0	1994	Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide.	Prostaglandins	76-90	interleukin 6	Mus musculus	36-49
8007951-0	1994	Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide.	Cyclic AMP	92-102	interleukin 6	Mus musculus	36-49
8007951-3	1994	We demonstrate that secretion of IL-6 is induced by cAMP in murine monocytic PU5-1.8 cells, even though to a lesser extent than by LPS.	Cyclic AMP	52-56	interleukin 6	Mus musculus	33-37
8007951-4	1994	Nevertheless, cAMP and prostaglandins of the E series in the presence of theophylline induce transcription of the IL-6 promoter more strongly than LPS, suggesting distinctive effects of cAMP and LPS on posttranscriptional events.	Cyclic AMP	14-18	interleukin 6	Mus musculus	114-118
8007951-4	1994	Nevertheless, cAMP and prostaglandins of the E series in the presence of theophylline induce transcription of the IL-6 promoter more strongly than LPS, suggesting distinctive effects of cAMP and LPS on posttranscriptional events.	Prostaglandins	23-37	interleukin 6	Mus musculus	114-118
8007951-4	1994	Nevertheless, cAMP and prostaglandins of the E series in the presence of theophylline induce transcription of the IL-6 promoter more strongly than LPS, suggesting distinctive effects of cAMP and LPS on posttranscriptional events.	Theophylline	73-85	interleukin 6	Mus musculus	114-118
8007951-4	1994	Nevertheless, cAMP and prostaglandins of the E series in the presence of theophylline induce transcription of the IL-6 promoter more strongly than LPS, suggesting distinctive effects of cAMP and LPS on posttranscriptional events.	Cyclic AMP	186-190	interleukin 6	Mus musculus	114-118
8007951-9	1994	Our results suggest that cAMP and prostaglandins act through multiple, partially redundant regulatory elements to induce IL-6 expression in monocytic cells.	Cyclic AMP	25-29	interleukin 6	Mus musculus	121-125
8007951-9	1994	Our results suggest that cAMP and prostaglandins act through multiple, partially redundant regulatory elements to induce IL-6 expression in monocytic cells.	Prostaglandins	34-48	interleukin 6	Mus musculus	121-125
7524893-4	1994	On the other hand, the expression of the IL-6 gene was markedly induced in all the lines by lipopolysaccharide (LPS) and by phorbol 12-myristate 13 acetate (PMA).	Tetradecanoylphorbol Acetate	124-155	interleukin 6	Mus musculus	41-45
7524893-4	1994	On the other hand, the expression of the IL-6 gene was markedly induced in all the lines by lipopolysaccharide (LPS) and by phorbol 12-myristate 13 acetate (PMA).	Tetradecanoylphorbol Acetate	157-160	interleukin 6	Mus musculus	41-45
7951069-4	1994	Inhibition of protein synthesis by cycloheximide and inhibition of RNA synthesis by actinomycin D abrogated the stimulatory effect on pS2 mRNA expression of IL-6 and TNF-alpha, suggesting that new protein synthesis as well as new RNA synthesis was required for their action.	Dactinomycin	84-97	interleukin 6	Mus musculus	157-161
7927490-5	1994	Both DEX and CPZ inhibited TNF production, whereas induction of IL-1 and IL-6 was inhibited by DEX but not by CPZ.	Dexamethasone	95-98	interleukin 6	Mus musculus	73-77
8088863-2	1994	Macrophage-like cells (Mm1) pretreated with IL-6 served as the source of the nitrogen oxides.	Nitrogen Oxides	77-92	interleukin 6	Mus musculus	44-48
8178944-4	1994	Immunosuppression by cyclosporin inhibited the development of glomerulonephritis, decreased class II antigen expression, and abrogated IL-6-mediated effects.	Cyclosporine	21-32	interleukin 6	Mus musculus	135-139
8181074-4	1994	To assess the underlying molecular mechanism of IL-6-regulated apoptosis, two chemical compounds, cycloheximide (CHX) and aurintricarboxylic acid (ATA), were used to treat the cells.	Cycloheximide	98-111	interleukin 6	Mus musculus	48-52
8181074-4	1994	To assess the underlying molecular mechanism of IL-6-regulated apoptosis, two chemical compounds, cycloheximide (CHX) and aurintricarboxylic acid (ATA), were used to treat the cells.	Cycloheximide	113-116	interleukin 6	Mus musculus	48-52
8181074-4	1994	To assess the underlying molecular mechanism of IL-6-regulated apoptosis, two chemical compounds, cycloheximide (CHX) and aurintricarboxylic acid (ATA), were used to treat the cells.	Aurintricarboxylic Acid	122-145	interleukin 6	Mus musculus	48-52
8181074-4	1994	To assess the underlying molecular mechanism of IL-6-regulated apoptosis, two chemical compounds, cycloheximide (CHX) and aurintricarboxylic acid (ATA), were used to treat the cells.	Aurintricarboxylic Acid	147-150	interleukin 6	Mus musculus	48-52
8179617-0	1994	Interleukin-6-induced tyrosine phosphorylation of multiple proteins in murine hematopoietic lineage cells.	Tyrosine	22-30	interleukin 6	Mus musculus	0-13
8179617-2	1994	To elucidate the intracellular signal transduction mechanism through the IL-6 receptor, we investigated IL-6-induced protein tyrosine phosphorylation in murine hematopoietic cell lines, BAFm130 and Y6.	Tyrosine	125-133	interleukin 6	Mus musculus	73-77
8179617-2	1994	To elucidate the intracellular signal transduction mechanism through the IL-6 receptor, we investigated IL-6-induced protein tyrosine phosphorylation in murine hematopoietic cell lines, BAFm130 and Y6.	Tyrosine	125-133	interleukin 6	Mus musculus	104-108
8179617-3	1994	IL-6 stimulated tyrosine phosphorylation of multiple cellular proteins, such as gp130, an IL-6 signal transducer; Jak family of the cytoplasmic tyrosine kinases; and the latent cytoplasmic signal transducer and activator of transcription.	Tyrosine	16-24	interleukin 6	Mus musculus	0-4
8179617-3	1994	IL-6 stimulated tyrosine phosphorylation of multiple cellular proteins, such as gp130, an IL-6 signal transducer; Jak family of the cytoplasmic tyrosine kinases; and the latent cytoplasmic signal transducer and activator of transcription.	Tyrosine	16-24	interleukin 6	Mus musculus	90-94
8179617-3	1994	IL-6 stimulated tyrosine phosphorylation of multiple cellular proteins, such as gp130, an IL-6 signal transducer; Jak family of the cytoplasmic tyrosine kinases; and the latent cytoplasmic signal transducer and activator of transcription.	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	80-85	interleukin 6	Mus musculus	0-4
8179617-3	1994	IL-6 stimulated tyrosine phosphorylation of multiple cellular proteins, such as gp130, an IL-6 signal transducer; Jak family of the cytoplasmic tyrosine kinases; and the latent cytoplasmic signal transducer and activator of transcription.	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	80-85	interleukin 6	Mus musculus	90-94
8179617-4	1994	We showed that the pattern of these tyrosine-phosphorylated molecules was different between BAFm130 and Y6 cells on which IL-6 exhibited different biological activities.	Tyrosine	36-44	interleukin 6	Mus musculus	122-126
8179617-4	1994	We showed that the pattern of these tyrosine-phosphorylated molecules was different between BAFm130 and Y6 cells on which IL-6 exhibited different biological activities.	bafm130	92-99	interleukin 6	Mus musculus	122-126
7518332-1	1994	Cytokine-specific alterations of monoamine activity were evident in the hypothalamus, hippocampus and prefrontal cortex 2 h following peripheral administration of recombinant interleukin (IL)-1 beta, IL-2 and IL-6 (200 ng, i.p.)	monoamine	33-42	interleukin 6	Mus musculus	209-213
8161803-14	1994	Mice treated with TBI + D0 SP developed the most severe acute GVHD and had the highest levels of TNF-alpha, IL-1 alpha, and IL-6.	d0	24-26	interleukin 6	Mus musculus	124-128
8161803-14	1994	Mice treated with TBI + D0 SP developed the most severe acute GVHD and had the highest levels of TNF-alpha, IL-1 alpha, and IL-6.	sp	27-29	interleukin 6	Mus musculus	124-128
8048738-4	1994	Vitamin E supplementation restored production of interleukin-2, -5, -6, -10, and interferon-gamma by concanavalin A (Con A)-stimulated splenocytes and interleukin-6 and tumor necrosis factor-alpha by lipopolysaccharide-stimulated splenocytes, which were suppressed by dietary EtOH.	Vitamin E	0-9	interleukin 6	Mus musculus	151-196
8061551-0	1994	Prostaglandin E2 stimulates the production of interleukin-6 by neonatal mouse parietal bones.	Dinoprostone	0-16	interleukin 6	Mus musculus	46-59
8061551-3	1994	We wished to determine whether prostaglandin E2 (PGE2), which is a mediator of bone resorption, can elicit the production of IL-6.	Dinoprostone	31-47	interleukin 6	Mus musculus	125-129
8061551-3	1994	We wished to determine whether prostaglandin E2 (PGE2), which is a mediator of bone resorption, can elicit the production of IL-6.	Dinoprostone	49-53	interleukin 6	Mus musculus	125-129
8131837-8	1994	These data suggest that endogenous nitric oxide affects the microfilament system of IL-6-treated Mm1 cells and blocks the cell cycle in the early G2+M phase.	Nitric Oxide	35-47	interleukin 6	Mus musculus	84-88
8204205-4	1994	Ethanol also has been shown to impair the ability of human macrophages and murine Kupffer cells to respond to stimulation with tumor necrosis factor (TNF) and granulocyte macrophage colony stimulating factor (GM-CSF), and to produce cytokines such as interleukin-1, interleukin-6, and TNF when properly stimulated.	Ethanol	0-7	interleukin 6	Mus musculus	266-279
7508917-2	1994	We report here that treatment of 3T3-L1 cells with IL-11, IL-6, LIF, and ONC induces overlapping but distinct patterns of tyrosine phosphorylation and activates indistinguishable primary response genes.	Tyrosine	122-130	interleukin 6	Mus musculus	58-62
7515742-0	1994	The induction of interleukin-6 (IL-6) and colony-stimulating factors (CSFs) by FK565 and its thrombopoietic activity following in vivo administration.	heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine	79-84	interleukin 6	Mus musculus	17-30
7515742-0	1994	The induction of interleukin-6 (IL-6) and colony-stimulating factors (CSFs) by FK565 and its thrombopoietic activity following in vivo administration.	heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine	79-84	interleukin 6	Mus musculus	32-36
7515742-1	1994	The induction of macrophage colony-stimulating factor (M-CSF) in monkey plasma following administration of FK565 was observed within 2 h of injection peaked at 4 h, and remained high after 24 h. Interleukin-6 (IL-6) and M-CSF levels increased in monkeys treated with FK565, even at doses as low as 0.01 mg/kg.	heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine	107-112	interleukin 6	Mus musculus	195-208
7515742-1	1994	The induction of macrophage colony-stimulating factor (M-CSF) in monkey plasma following administration of FK565 was observed within 2 h of injection peaked at 4 h, and remained high after 24 h. Interleukin-6 (IL-6) and M-CSF levels increased in monkeys treated with FK565, even at doses as low as 0.01 mg/kg.	heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine	107-112	interleukin 6	Mus musculus	210-214
7507969-9	1994	Polyinosinic acid:polycytidylic acid induced significantly higher amounts of IFN but lower levels of TNF and IL-6 than imiquimod.	Poly I	0-17	interleukin 6	Mus musculus	109-113
7507969-9	1994	Polyinosinic acid:polycytidylic acid induced significantly higher amounts of IFN but lower levels of TNF and IL-6 than imiquimod.	Poly C	18-36	interleukin 6	Mus musculus	109-113
8307040-1	1994	Two synthetic peptides corresponding to the C-terminal 19 residues of human and murine interleukin-6, respectively, have been synthesized and their structures in solution investigated using high-resolution 1H-NMR spectroscopy.	Hydrogen	206-208	interleukin 6	Mus musculus	87-100
8126083-4	1994	Four of the cytokines (interleukin 6, interleukin 11, leukemia inhibitory factor, and oncostatin M) inhibited hydrocortisone-induced adipocyte differentiation in a dose dependent manner based on lipid accumulation and lipoprotein lipase enzyme activity.	Hydrocortisone	110-124	interleukin 6	Mus musculus	23-36
8139381-0	1994	Clodronate (dichloromethylene bisphosphonate) inhibits LPS-stimulated IL-6 and TNF production by RAW 264 cells.	Clodronic Acid	0-10	interleukin 6	Mus musculus	70-74
8139381-0	1994	Clodronate (dichloromethylene bisphosphonate) inhibits LPS-stimulated IL-6 and TNF production by RAW 264 cells.	Clodronic Acid	12-44	interleukin 6	Mus musculus	70-74
8139381-1	1994	Effect of liposome-encapsulated and free clodronate on the IL-6 and TNF production by macrophages was studied using RAW 264 cell line as a macrophage model, and dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA) for analysis of secreted cytokines.	Clodronic Acid	41-51	interleukin 6	Mus musculus	59-63
8139381-3	1994	Liposome-encapsulated clodronate inhibited the production of both cytokines, IL-6 being affected more than TNF, and the effect was mostly due to the drug itself, not to liposomal lipid.	Clodronic Acid	22-32	interleukin 6	Mus musculus	77-81
8243564-5	1993	Continuous infusion of IL-6 for 7 days resulted in elevated levels of circulating IL-6 (mean: 1872 pg/mL vs. 100 pg/mL for phosphate-buffered saline [PBS]-treated controls) and in an accelerated reconstitution of platelets starting at day 12 after irradiation.	Phosphate-Buffered Saline	123-148	interleukin 6	Mus musculus	23-27
8243564-5	1993	Continuous infusion of IL-6 for 7 days resulted in elevated levels of circulating IL-6 (mean: 1872 pg/mL vs. 100 pg/mL for phosphate-buffered saline [PBS]-treated controls) and in an accelerated reconstitution of platelets starting at day 12 after irradiation.	pbs	150-153	interleukin 6	Mus musculus	23-27
8219233-5	1993	Stimulation was clearly visible at concentrations as low as 20 micrograms/mL and reached saturation at 0.5 to 1 mg/mL albumin, at which concentration 1.1 x 10(6) oil-elicited macrophages produced 6,000 +/- 700 B9 units of IL-6 in an overnight incubation.	Oils	162-165	interleukin 6	Mus musculus	222-226
8167900-10	1993	Epidermal growth factor, insulin, and interleukin-6 were able to induce the [3H]thymidine incorporation into DNA in these two cell lines.	Tritium	77-79	interleukin 6	Mus musculus	0-51
7504099-6	1993	The THC-induced mortality resembled cytokine-mediated shock in both kinetics and symptoms; therefore, sera from drug-treated animals were measured for the acute-phase cytokines tumor necrosis factor (TNF) and interleukin 6 (IL6).	Dronabinol	4-7	interleukin 6	Mus musculus	224-227
8409382-8	1993	The thymocyte CD4-CD8 phenotype after 72-h cultures showed that TNF decreased mainly double negative (DN) and single positive (SP) subsets, whereas IL-6 with low or high PHA increased DN and SP, especially the SP CD8+ subset.	sp	191-193	interleukin 6	Mus musculus	148-152
8279663-6	1993	Elevated levels of IL-5 and IL-6 produced in vitro by ConA-stimulated spleen cells during retrovirus infection were significantly further increased by dietary ETOH.	Ethanol	159-163	interleukin 6	Mus musculus	28-32
8223586-0	1993	Specific covalent modification of the tryptophan residues in murine interleukin-6.	Tryptophan	38-48	interleukin 6	Mus musculus	68-81
8223586-2	1993	Modification of recombinant murine interleukin-6 (mIL-6) with the tryptophan-specific reagent 2-nitrophenylsulfenyl chloride under mild acidic conditions, 0.1 M sodium acetate, pH 3.5, yielded a derivative containing 2.02 mol 2-nitrophenylsulfenyl tryptophan/mol protein.	Tryptophan	66-76	interleukin 6	Mus musculus	35-48
8223586-2	1993	Modification of recombinant murine interleukin-6 (mIL-6) with the tryptophan-specific reagent 2-nitrophenylsulfenyl chloride under mild acidic conditions, 0.1 M sodium acetate, pH 3.5, yielded a derivative containing 2.02 mol 2-nitrophenylsulfenyl tryptophan/mol protein.	Tryptophan	66-76	interleukin 6	Mus musculus	50-55
8223586-2	1993	Modification of recombinant murine interleukin-6 (mIL-6) with the tryptophan-specific reagent 2-nitrophenylsulfenyl chloride under mild acidic conditions, 0.1 M sodium acetate, pH 3.5, yielded a derivative containing 2.02 mol 2-nitrophenylsulfenyl tryptophan/mol protein.	2-nitrobenzenesulfenyl chloride	94-124	interleukin 6	Mus musculus	35-48
8223586-2	1993	Modification of recombinant murine interleukin-6 (mIL-6) with the tryptophan-specific reagent 2-nitrophenylsulfenyl chloride under mild acidic conditions, 0.1 M sodium acetate, pH 3.5, yielded a derivative containing 2.02 mol 2-nitrophenylsulfenyl tryptophan/mol protein.	2-nitrobenzenesulfenyl chloride	94-124	interleukin 6	Mus musculus	50-55
8223586-2	1993	Modification of recombinant murine interleukin-6 (mIL-6) with the tryptophan-specific reagent 2-nitrophenylsulfenyl chloride under mild acidic conditions, 0.1 M sodium acetate, pH 3.5, yielded a derivative containing 2.02 mol 2-nitrophenylsulfenyl tryptophan/mol protein.	2-nitrophenylsulfenyl tryptophan	226-258	interleukin 6	Mus musculus	35-48
8223586-5	1993	Sulfenylation of the two tryptophan residues in mIL-6 caused a 50% reduction in both the biological activity in the murine-hybridoma-growth-factor assay using 7TD1 cells and receptor-binding affinity to mIL-6 receptors.	Tryptophan	25-35	interleukin 6	Mus musculus	48-53
8223586-5	1993	Sulfenylation of the two tryptophan residues in mIL-6 caused a 50% reduction in both the biological activity in the murine-hybridoma-growth-factor assay using 7TD1 cells and receptor-binding affinity to mIL-6 receptors.	Tryptophan	25-35	interleukin 6	Mus musculus	203-208
8399854-5	1993	Oil-induced decidualization was associated with increased and prolonged production of IL-1 and IL-6 and decreased production of TNF alpha relative to these values in uninjected controls.	Oils	0-3	interleukin 6	Mus musculus	95-99
8401231-8	1993	For instance, interactions involving Tyr-22 were influenced by the C-terminal amino acids suggesting that the N- and C-termini of mIL-6 are in close proximity.	Tyrosine	37-40	interleukin 6	Mus musculus	130-135
8398910-4	1993	This IL-6 induced TRE binding complex was abolished by anti-Jun specific antibodies and was efficiently competed by an oligonucleotide that comprises the mouse homologue of a previously described human c-myc negative DNA element.	Oligonucleotides	119-134	interleukin 6	Mus musculus	5-9
8401214-2	1993	On decreasing the pH from 8.0 to 4.0, the tryptophan fluorescence of mIL-6 was quenched 40%, the midpoint of the transition occurring at pH 6.9.	Tryptophan	42-52	interleukin 6	Mus musculus	69-74
8401214-3	1993	The change in fluorescence quantum yield was not due to unfolding of the molecule because the conformation of mIL-6, as judged by both urea-gradient gel electrophoresis and CD spectroscopy, was stable over the pH range 2.0-10.0.	Urea	135-139	interleukin 6	Mus musculus	110-115
8401214-3	1993	The change in fluorescence quantum yield was not due to unfolding of the molecule because the conformation of mIL-6, as judged by both urea-gradient gel electrophoresis and CD spectroscopy, was stable over the pH range 2.0-10.0.	Cadmium	173-175	interleukin 6	Mus musculus	110-115
8401214-6	1993	In this regard, similar results were obtained for a 17-residue synthetic peptide, peptide H1, which corresponds to an N-terminal region of mIL-6 (residues Val-27-Lys-43).	Valine	155-158	interleukin 6	Mus musculus	139-144
8401214-6	1993	In this regard, similar results were obtained for a 17-residue synthetic peptide, peptide H1, which corresponds to an N-terminal region of mIL-6 (residues Val-27-Lys-43).	Lysine	162-165	interleukin 6	Mus musculus	139-144
8401214-8	1993	Replacement of His-33 with Ala-33 in peptide H1 alleviated a significant portion of the pH-dependent quenching of fluorescence suggesting that the interaction of the imidazole ring of His-33 with the indole ring of Trp-36 is a major determinant responsible for the quenching of the endogenous protein fluorescence of mIL-6.	imidazole	166-175	interleukin 6	Mus musculus	317-322
8401214-8	1993	Replacement of His-33 with Ala-33 in peptide H1 alleviated a significant portion of the pH-dependent quenching of fluorescence suggesting that the interaction of the imidazole ring of His-33 with the indole ring of Trp-36 is a major determinant responsible for the quenching of the endogenous protein fluorescence of mIL-6.	Histidine	15-18	interleukin 6	Mus musculus	317-322
8401214-8	1993	Replacement of His-33 with Ala-33 in peptide H1 alleviated a significant portion of the pH-dependent quenching of fluorescence suggesting that the interaction of the imidazole ring of His-33 with the indole ring of Trp-36 is a major determinant responsible for the quenching of the endogenous protein fluorescence of mIL-6.	Tryptophan	215-218	interleukin 6	Mus musculus	317-322
7687200-5	1993	In contrast, both PGE2 and PGI2 potentiated the release of IL-3 and IL-6 which both play an important role in stimulating haemopoesis after inflammation.	Dinoprostone	18-22	interleukin 6	Mus musculus	68-72
7687200-5	1993	In contrast, both PGE2 and PGI2 potentiated the release of IL-3 and IL-6 which both play an important role in stimulating haemopoesis after inflammation.	Epoprostenol	27-31	interleukin 6	Mus musculus	68-72
7687200-7	1993	This inhibition, in contrast to the PG-mediated effects on IL-2, IL-3, IL-6, and IFN-gamma was not due to increased intracellular levels of cAMP.	Prostaglandins	36-38	interleukin 6	Mus musculus	71-75
8482846-2	1993	injection of muramyl dipeptide (MDP) before a LPS challenge strongly potentiated serum TNF and IL-6 release in mice.	Acetylmuramyl-Alanyl-Isoglutamine	13-30	interleukin 6	Mus musculus	95-99
8482846-2	1993	injection of muramyl dipeptide (MDP) before a LPS challenge strongly potentiated serum TNF and IL-6 release in mice.	Acetylmuramyl-Alanyl-Isoglutamine	32-35	interleukin 6	Mus musculus	95-99
8365826-4	1993	Effect of TA-383 on IL-6 production was examined in vitro.	2-(4-chlorophenyl)-4,5-diphenyl-2-imidazoline hydrochloride	10-16	interleukin 6	Mus musculus	20-24
8365826-0	1993	Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis--suppressive effect of TA-383 on interleukin 6 production.	Tantalum	108-110	interleukin 6	Mus musculus	118-131
8365826-5	1993	TA-383 inhibited the production of IL-6 by murine synovial fibroblasts stimulated with recombinant interleukin 1 (IL-1) beta in a dose-dependent manner (0.1-10 microM).	2-(4-chlorophenyl)-4,5-diphenyl-2-imidazoline hydrochloride	0-6	interleukin 6	Mus musculus	35-39
8365826-7	1993	The results show that TA-383 possesses an inhibitory activity on IL-6 generation and suggest that the effect may partly contribute to the anti-arthritic effect of TA-383.	2-(4-chlorophenyl)-4,5-diphenyl-2-imidazoline hydrochloride	22-28	interleukin 6	Mus musculus	65-69
8365826-7	1993	The results show that TA-383 possesses an inhibitory activity on IL-6 generation and suggest that the effect may partly contribute to the anti-arthritic effect of TA-383.	2-(4-chlorophenyl)-4,5-diphenyl-2-imidazoline hydrochloride	163-169	interleukin 6	Mus musculus	65-69
8484104-1	1993	Trauma and infection activated a murine mucosal IL-6 response in different ways: the IL-6 response to bacteria was sensitive to Cyclosporin A (CsA); the IL-6 response to trauma was not.	Cyclosporine	143-146	interleukin 6	Mus musculus	48-52
8484104-1	1993	Trauma and infection activated a murine mucosal IL-6 response in different ways: the IL-6 response to bacteria was sensitive to Cyclosporin A (CsA); the IL-6 response to trauma was not.	Cyclosporine	143-146	interleukin 6	Mus musculus	85-89
8484104-1	1993	Trauma and infection activated a murine mucosal IL-6 response in different ways: the IL-6 response to bacteria was sensitive to Cyclosporin A (CsA); the IL-6 response to trauma was not.	Cyclosporine	143-146	interleukin 6	Mus musculus	85-89
8484104-2	1993	The aim of the present study was to identify possible activators of the CsA-insensitive IL-6 secretion at the epithelial cell level.	Cyclosporine	72-75	interleukin 6	Mus musculus	88-92
8484104-9	1993	By contrast, the IL-6 response to E. coli Hu734 and TNF-alpha was inhibited by CsA.	Cyclosporine	79-82	interleukin 6	Mus musculus	17-21
8484104-10	1993	These results demonstrated that the inhibitory effect of CsA depends on the stimulus triggering the IL-6 response.	Cyclosporine	57-60	interleukin 6	Mus musculus	100-104
8459105-11	1993	Addition of cycloheximide (50 micrograms/ml) inhibited formation of IL-2, IL-4 and IL-6 SFC by approximately 90%.	Cycloheximide	12-25	interleukin 6	Mus musculus	83-87
8453672-10	1993	Interleukin-1 alpha (IL-1 alpha), tumor necrosis factor (TNF), and interleukin-6 (IL-6) were all secreted by mouse MNC after in vitro exposure to formalin-killed S. aureus.	Formaldehyde	146-154	interleukin 6	Mus musculus	67-80
8453672-10	1993	Interleukin-1 alpha (IL-1 alpha), tumor necrosis factor (TNF), and interleukin-6 (IL-6) were all secreted by mouse MNC after in vitro exposure to formalin-killed S. aureus.	Formaldehyde	146-154	interleukin 6	Mus musculus	82-86
8454355-0	1993	Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model.	Galactosamine	59-72	interleukin 6	Mus musculus	19-32
8473513-0	1993	IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1,25 dihydroxyvitamin D3.	Calcitriol	107-131	interleukin 6	Mus musculus	31-35
8473513-5	1993	Vitamin D3 increases IL-1R expression dose- and metabolite-dependently, with 1,25-(OH)2D3 having the greatest potency, and also enhances IL-1"s capacity to stimulate IL-6 production at low IL-1 levels.	Cholecalciferol	0-10	interleukin 6	Mus musculus	166-170
8454938-11	1993	Plasma levels of IL-6 were unchanged in AZT-treated normal mice but decreased in AZT-treated MAIDS mice.	Zidovudine	40-43	interleukin 6	Mus musculus	17-21
8454938-11	1993	Plasma levels of IL-6 were unchanged in AZT-treated normal mice but decreased in AZT-treated MAIDS mice.	Zidovudine	81-84	interleukin 6	Mus musculus	17-21
8331927-8	1993	Mean serum IL-6 levels 3 hr after intraperitoneal IL-1 alpha (10 micrograms/kg) were: PBS, 3730 +/- 526 (mean +/- SEM pg/ml); IL-1ra (LD), 1156 +/- 398; and IL-1ra (HD), 594 +/- 30 (P < 0.01, IL-1ra HD or LD vs PBS).	pbs	86-89	interleukin 6	Mus musculus	11-15
7678814-5	1993	The administration of dexamethasone (dex) alone induced only a slight increase in IL-1R expression but synergized with granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), IL-3 and IL-6 to upregulate IL-1R expression.	Dexamethasone	22-35	interleukin 6	Mus musculus	212-216
7678814-5	1993	The administration of dexamethasone (dex) alone induced only a slight increase in IL-1R expression but synergized with granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), IL-3 and IL-6 to upregulate IL-1R expression.	Dexamethasone	22-25	interleukin 6	Mus musculus	212-216
8437110-6	1993	In vitro addition of interleukin (IL)-6, IL-1 beta or interferon-gamma (0.5-50 U/ml) attenuated the suppression of the PFC response in cells from morphine-treated mice, whereas higher doses (100 U/ml) restored completely the PFC response to control levels.	Morphine	146-154	interleukin 6	Mus musculus	21-39
8237606-7	1993	Addition of normal splenic macrophages to in vitro cultures restored immune responses, as did IL-1, IL-6 and IFN-gamma, suggesting that morphine-induced immunosuppression is due to a deficit in macrophage function.	Morphine	136-144	interleukin 6	Mus musculus	100-104
7685182-4	1993	The capacity to produce interleukin 1-beta and TNF-alpha of peritoneal macrophages and also that to produce IL-6 of spleen cells were significantly enhanced by the in vivo administration of rhG-CSF in CY-treated mice.	Cyclophosphamide	201-203	interleukin 6	Mus musculus	108-112
8151159-7	1993	Vitamin E significantly reduced IL-6, and interferon-gamma production increased in murine AIDS.	Vitamin E	0-9	interleukin 6	Mus musculus	32-36
1384800-6	1992	IL-6-induced macrophage differentiation of Y6 cells was preceded by the downregulation of the c-myc gene, which was also prevented by RA.	Tretinoin	134-136	interleukin 6	Mus musculus	0-4
1384800-7	1992	Because the inhibitory effect of RA on Y6 cells was reversible and seemed not to require de novo protein synthesis, the RA receptor by itself might be directly involved in the inhibition of the IL-6 signal transduction pathway.	Tretinoin	33-35	interleukin 6	Mus musculus	194-198
1425926-0	1992	Selective and differential binding of interleukin (IL)-1 alpha, IL-1 beta, IL-2 and IL-6 to glycosaminoglycans.	Glycosaminoglycans	92-110	interleukin 6	Mus musculus	84-88
1425926-1	1992	The binding of interleukin (IL)-1 alpha, IL-1 beta, IL-2 and IL-6 to acidic polysaccharides was investigated by affinity chromatography of the recombinant, radioiodinated interleukins on columns of immobilized polysaccharide.	Polysaccharides	76-91	interleukin 6	Mus musculus	61-65
1425926-1	1992	The binding of interleukin (IL)-1 alpha, IL-1 beta, IL-2 and IL-6 to acidic polysaccharides was investigated by affinity chromatography of the recombinant, radioiodinated interleukins on columns of immobilized polysaccharide.	Polysaccharides	76-90	interleukin 6	Mus musculus	61-65
1430707-4	1992	Injection of recombinant murine IL-6 (rmIL-6) either systemically or locally during antidinitrophenyl IgE skin sensitization resulted in increased vasopermeability at the PCA site after DNP30-40-HSA.	dnp30-40-hsa	186-198	interleukin 6	Mus musculus	32-36
1398912-6	1992	TNF was detectable between 6 and 60 h, with peak levels at 24 h. Both TNF and IL-6 levels were significantly higher in cyclophosphamide-treated mice than in normal mice.	Cyclophosphamide	119-135	interleukin 6	Mus musculus	78-82
1522390-1	1992	Thioglycolate-elicited peritoneal macrophages from normal C57B1/6J mice were examined in vitro for bacterial lipopolysaccharide (LPS)-stimulated interleukin-1 (IL-1), IL-6, and tumor necrosis factor (TNF) production.	Thioglycolates	0-13	interleukin 6	Mus musculus	167-171
1522390-8	1992	Immunoprecipitation studies of supernatants from biosynthetically labeled macrophages also revealed augmented IL-1 production and decreased IL-6 and TNF, indicating that levamisole may have affected cytokine production at the translational level.	Levamisole	170-180	interleukin 6	Mus musculus	140-152
1522390-9	1992	Kinetics studies revealed that ex vivo release of IL-6 and TNF by macrophages from levamisole-dosed mice was delayed compared to production of these cytokines by macrophages harvested from mice given vehicle only.	Levamisole	83-93	interleukin 6	Mus musculus	50-54
1337557-3	1992	IL-6, but not IL-1, stimulated prostaglandin E2 (PGE2) production.	Dinoprostone	31-47	interleukin 6	Mus musculus	0-4
1337557-3	1992	IL-6, but not IL-1, stimulated prostaglandin E2 (PGE2) production.	Dinoprostone	49-53	interleukin 6	Mus musculus	0-4
1337557-4	1992	The differentiative effect of IL-6 however, was not suppressed by indomethacin, although PGE2 induction by IL-6 was completely inhibited.	Dinoprostone	89-93	interleukin 6	Mus musculus	107-111
1291290-7	1992	The G418 resistant SP2/0 cells secreted IL-6.	antibiotic G 418	4-8	interleukin 6	Mus musculus	40-44
1322305-0	1992	Synergistic induction of interleukin-6 by tumor necrosis factor and lithium chloride in mice: possible role in the triggering and exacerbation of psoriasis by lithium treatment.	Lithium Chloride	68-84	interleukin 6	Mus musculus	25-38
1322305-0	1992	Synergistic induction of interleukin-6 by tumor necrosis factor and lithium chloride in mice: possible role in the triggering and exacerbation of psoriasis by lithium treatment.	Lithium	68-75	interleukin 6	Mus musculus	25-38
1322305-5	1992	IL-6 levels in skin extracts of mice treated s.c. with a combination of TNF and LiCl were considerably increased as compared to the levels found in skin extracts from mice treated with TNF or LiCl alone.	Lithium Chloride	80-84	interleukin 6	Mus musculus	0-4
1322305-5	1992	IL-6 levels in skin extracts of mice treated s.c. with a combination of TNF and LiCl were considerably increased as compared to the levels found in skin extracts from mice treated with TNF or LiCl alone.	Lithium Chloride	192-196	interleukin 6	Mus musculus	0-4
1428359-1	1992	The effect of dexamethasone and two non-steroidal anti-inflammatory agents ibuprofen and indomethacin on the production of serum interleukin 6(IL-6) and tumor necrosis factor (TNF) levels in mice treated with endotoxin (2.5 micrograms/mouse, i.p.)	Dexamethasone	14-27	interleukin 6	Mus musculus	129-142
1428359-1	1992	The effect of dexamethasone and two non-steroidal anti-inflammatory agents ibuprofen and indomethacin on the production of serum interleukin 6(IL-6) and tumor necrosis factor (TNF) levels in mice treated with endotoxin (2.5 micrograms/mouse, i.p.)	Dexamethasone	14-27	interleukin 6	Mus musculus	143-147
1428359-1	1992	The effect of dexamethasone and two non-steroidal anti-inflammatory agents ibuprofen and indomethacin on the production of serum interleukin 6(IL-6) and tumor necrosis factor (TNF) levels in mice treated with endotoxin (2.5 micrograms/mouse, i.p.)	Ibuprofen	75-84	interleukin 6	Mus musculus	129-142
1428359-1	1992	The effect of dexamethasone and two non-steroidal anti-inflammatory agents ibuprofen and indomethacin on the production of serum interleukin 6(IL-6) and tumor necrosis factor (TNF) levels in mice treated with endotoxin (2.5 micrograms/mouse, i.p.)	Ibuprofen	75-84	interleukin 6	Mus musculus	143-147
1428359-1	1992	The effect of dexamethasone and two non-steroidal anti-inflammatory agents ibuprofen and indomethacin on the production of serum interleukin 6(IL-6) and tumor necrosis factor (TNF) levels in mice treated with endotoxin (2.5 micrograms/mouse, i.p.)	Indomethacin	89-101	interleukin 6	Mus musculus	129-142
1428359-1	1992	The effect of dexamethasone and two non-steroidal anti-inflammatory agents ibuprofen and indomethacin on the production of serum interleukin 6(IL-6) and tumor necrosis factor (TNF) levels in mice treated with endotoxin (2.5 micrograms/mouse, i.p.)	Indomethacin	89-101	interleukin 6	Mus musculus	143-147
1428359-6	1992	potentiated the production of both IL-6 (+ 80% with INDO; + 100% with IBU) and TNF (+ 500% with INDO; + 50% with IBU).	Indomethacin	52-56	interleukin 6	Mus musculus	35-39
1428359-6	1992	potentiated the production of both IL-6 (+ 80% with INDO; + 100% with IBU) and TNF (+ 500% with INDO; + 50% with IBU).	Ibuprofen	70-73	interleukin 6	Mus musculus	35-39
1428359-6	1992	potentiated the production of both IL-6 (+ 80% with INDO; + 100% with IBU) and TNF (+ 500% with INDO; + 50% with IBU).	Indomethacin	96-100	interleukin 6	Mus musculus	35-39
1428359-6	1992	potentiated the production of both IL-6 (+ 80% with INDO; + 100% with IBU) and TNF (+ 500% with INDO; + 50% with IBU).	Ibuprofen	113-116	interleukin 6	Mus musculus	35-39
1428359-8	1992	These data indicate that IL-6 and TNF production are differently susceptible to glucocorticoids, and that prostaglandins can physiologically provide a negative feedback regulation of IL-6 and TNF synthesis.	Prostaglandins	106-120	interleukin 6	Mus musculus	183-187
1506776-5	1992	Assessment of fibrosis by measuring lung hydroxyproline levels showed that challenged mice given anti-IL-6 developed more significant fibrosis than control mice.	Hydroxyproline	41-55	interleukin 6	Mus musculus	102-106
1638511-3	1992	Thioglycollate-elicited macrophages required only LPS plus IFN-gamma for cytostatic activity which was expressed concomitantly with the release of high levels of TNF, IL-1 and IL-6, whereas C3H/HeJ macrophages produced low levels of monokines and were not cytostatic.	Thioglycolates	0-14	interleukin 6	Mus musculus	176-180
1611085-0	1992	Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin.	Indomethacin	97-109	interleukin 6	Mus musculus	13-26
1611085-4	1992	By using the B9 cell bioassay, it was found that injection of pristane caused a marked and prolonged elevation of interleukin-6 (IL-6) levels in the peritoneal cavities of the mice.	pristane	62-70	interleukin 6	Mus musculus	114-127
1611085-4	1992	By using the B9 cell bioassay, it was found that injection of pristane caused a marked and prolonged elevation of interleukin-6 (IL-6) levels in the peritoneal cavities of the mice.	pristane	62-70	interleukin 6	Mus musculus	129-133
1611085-5	1992	IL-6 was undetectable (less than 15 U/mL) in the peritoneal fluids of unprimed mice and during the first week after injecting pristane.	pristane	126-134	interleukin 6	Mus musculus	0-4
1611085-10	1992	Serum levels of IL-6 were also elevated in pristane-primed mice but were substantially lower than those found in the peritoneal cavity.	pristane	43-51	interleukin 6	Mus musculus	16-20
1611085-11	1992	Chronic administration of the nonsteroidal anti-inflammatory drug indomethacin decreased the levels of IL-6 by 75% to 80%.	Indomethacin	66-78	interleukin 6	Mus musculus	103-107
1611085-12	1992	Experiments performed in vitro showed that pristane-elicited macrophages secreted low levels of IL-6 constitutively and high levels of IL-6 in the presence of lipopolysaccharide.	pristane	43-51	interleukin 6	Mus musculus	96-100
1611085-12	1992	Experiments performed in vitro showed that pristane-elicited macrophages secreted low levels of IL-6 constitutively and high levels of IL-6 in the presence of lipopolysaccharide.	pristane	43-51	interleukin 6	Mus musculus	135-139
1611085-13	1992	Both IL-6 and prostaglandin E2 production were inhibited by addition of indomethacin to macrophage cultures in vitro.	Indomethacin	72-84	interleukin 6	Mus musculus	5-9
1611085-14	1992	Treatment of mice with pristane may provide a model system for studying the inflammatory pathways that control IL-6 levels in vivo.	pristane	23-31	interleukin 6	Mus musculus	111-115
1405592-5	1992	However, ibuprofen treatment increased (P less than 0.05) SPL proliferation, lymphokine (IL-2, IFN-gamma, and IL-6) synthesis, and IL-1 release by sM phi compared to hemorrhage alone.	Ibuprofen	9-18	interleukin 6	Mus musculus	110-114
1588038-9	1992	In vivo expression in the spleen of 10 cytokine genes was also examined, and mRNA encoding IL-1 beta and IL-6 were significantly elevated in splenocytes of anilide-treated mice.	Anilides	156-163	interleukin 6	Mus musculus	105-109
1604240-0	1992	Histamine modulates the interleukin-6-regulated acute phase protein synthesis in cultured murine hepatocytes.	Histamine	0-9	interleukin 6	Mus musculus	24-37
1577194-0	1992	Interleukin-1, interleukin-6, and tumor necrosis factor alpha are produced in the mouse uterus during the estrous cycle and are induced by estrogen and progesterone.	Progesterone	152-164	interleukin 6	Mus musculus	15-28
1577194-9	1992	Significant amounts of IL-6 and TNF alpha mRNA appeared only following the exposure of ovariectomized mice to estrogen plus progesterone.	Progesterone	124-136	interleukin 6	Mus musculus	23-27
1601798-1	1992	mRNA from lungs of mice exposed to high-dose oxygen (greater than 95%) for 3 days demonstrated increased expression of the genes for tumor necrosis factor (TNF), interleukin-1, and interleukin-6 compared with mRNA from lungs of mice exposed to room air.	Oxygen	45-51	interleukin 6	Mus musculus	181-194
1572902-6	1992	Four mEq/L LiCl stimulated increased expression of G-CSF, GM-CSF, IL-6, and, in the nonirradiated stroma continuously exposed to lithium, CSF-1 mRNA.	Lithium Chloride	11-15	interleukin 6	Mus musculus	66-70
1593907-0	1992	Selective regulation by hydrocortisone of induction of in vivo differentiation of myeloid leukemic cells with granulocyte-macrophage colony-stimulating factor, interleukin 6 and interleukin 1 alpha.	Hydrocortisone	24-38	interleukin 6	Mus musculus	160-197
1593907-2	1992	Using such leukemic clones, we studied the regulation by hydrocortisone of induction of in vivo differentiation by injection of recombinant interleukin 6 (IL-6), interleukin 1 alpha (IL-1 alpha), and granulocyte-macrophage colony-stimulating factor (GM-CSF).	Hydrocortisone	57-71	interleukin 6	Mus musculus	140-153
1593907-2	1992	Using such leukemic clones, we studied the regulation by hydrocortisone of induction of in vivo differentiation by injection of recombinant interleukin 6 (IL-6), interleukin 1 alpha (IL-1 alpha), and granulocyte-macrophage colony-stimulating factor (GM-CSF).	Hydrocortisone	57-71	interleukin 6	Mus musculus	155-159
1593907-7	1992	After hydrocortisone pretreatment, the number of peritoneal cells and their ability to produce GM-CSF and IL-6 were suppressed.	Hydrocortisone	6-20	interleukin 6	Mus musculus	106-110
1562722-9	1992	These studies suggest that while hematopoietic growth factor granulocyte CSF-, granulocyte-macrophage CSF-, interleukin-3 (IL-3)-, or IL-6-, whose receptors are members of the hematopoietin receptor family, induced cell proliferation is associated with a common mechanism involving nuclear localization of the 68-Kd CaM-BP, the CSF-1-induced proliferation seems to involve 68-Kd CaM-BP-independent pathways.	Benzo(a)pyrene	320-322	interleukin 6	Mus musculus	134-138
1532365-0	1992	The glucocorticoid antagonist RU38486 mimics interleukin-1 in its sensitization to the lethal and interleukin-6-inducing properties of tumor necrosis factor.	Mifepristone	30-37	interleukin 6	Mus musculus	98-111
1540091-5	1992	Burned mice that received either interleukin 1 beta or indomethacin alone demonstrated tumor necrosis factor and interleukin 6 production and survival intermediate between the interleukin 1 beta-indomethacin-treated group and the vehicle control group.	Indomethacin	55-67	interleukin 6	Mus musculus	113-126
1596738-5	1992	The ICV administration was more efficacious than the IP injection in elevating serum corticosterone and IL-6 concentrations, whereas no difference was evident in the IL-1 beta-induced hypoglycemia.	icv	4-7	interleukin 6	Mus musculus	104-108
1374741-6	1992	The serum level of IL-6 in 5-FU-treated mice was increased by SPR-901.	Fluorouracil	27-31	interleukin 6	Mus musculus	19-23
1765652-5	1991	The MTT assay can also be used to quantify IL-6.	monooxyethylene trimethylolpropane tristearate	4-7	interleukin 6	Mus musculus	43-47
1912565-6	1991	The administration of CQ led to a significant reduction in the hemorrhage-induced elevation of TNF, IL-6, and PGE2 release by KC; however, IL-1 secretion was not affected by CQ.	Chloroquine	22-24	interleukin 6	Mus musculus	100-104
1912565-7	1991	In addition, CQ treatment abolished the hemorrhage-induced increase in circulating TNF and IL-6.	Chloroquine	13-15	interleukin 6	Mus musculus	91-95
1679380-1	1991	Mycobacterium bovis BCG and its subcellular components (bacterial extract, culture filtrate, purified protein derivative, and muramyl dipeptide MDP) are potent in vitro IL-6 inducers in spleen cell cultures from uninfected and BCG-infected BALB/c mice.	Dipeptides	134-143	interleukin 6	Mus musculus	169-173
1909967-3	1991	The expression of interleukin 6, and of oncogenes c-myc and c-fos were inhibited when the cells were treated with 2% DMSO from the beginning of serum-stimulated growth but not after 3 h of mitogenic stimuli.	Dimethyl Sulfoxide	117-121	interleukin 6	Mus musculus	18-31
1718855-3	1991	Although MH166 completely neutralized hIL-6 activity in vitro, treatment in vivo with hIL-6 and MH166 combined unexpectedly increased both anti-dinitrophenyl (DNP) and anti-sheep red blood cell (SRBC) antibody production more than treatment with IL-6 alone did.	mh166	96-101	interleukin 6	Mus musculus	39-43
1786996-5	1991	In a mammalian COS cell expression system the ovine cDNA was found to encode a protein which was able to lyse actinomycin-D treated WEHI-164 cells and induce COS cells to produce and secrete interleukin 6 (IL-6).	carbonyl sulfide	15-18	interleukin 6	Mus musculus	191-204
1786996-5	1991	In a mammalian COS cell expression system the ovine cDNA was found to encode a protein which was able to lyse actinomycin-D treated WEHI-164 cells and induce COS cells to produce and secrete interleukin 6 (IL-6).	carbonyl sulfide	15-18	interleukin 6	Mus musculus	206-210
1786996-5	1991	In a mammalian COS cell expression system the ovine cDNA was found to encode a protein which was able to lyse actinomycin-D treated WEHI-164 cells and induce COS cells to produce and secrete interleukin 6 (IL-6).	Dactinomycin	110-123	interleukin 6	Mus musculus	191-204
1786996-5	1991	In a mammalian COS cell expression system the ovine cDNA was found to encode a protein which was able to lyse actinomycin-D treated WEHI-164 cells and induce COS cells to produce and secrete interleukin 6 (IL-6).	Dactinomycin	110-123	interleukin 6	Mus musculus	206-210
1786996-5	1991	In a mammalian COS cell expression system the ovine cDNA was found to encode a protein which was able to lyse actinomycin-D treated WEHI-164 cells and induce COS cells to produce and secrete interleukin 6 (IL-6).	carbonyl sulfide	158-161	interleukin 6	Mus musculus	191-204
1786996-5	1991	In a mammalian COS cell expression system the ovine cDNA was found to encode a protein which was able to lyse actinomycin-D treated WEHI-164 cells and induce COS cells to produce and secrete interleukin 6 (IL-6).	carbonyl sulfide	158-161	interleukin 6	Mus musculus	206-210
1657127-4	1991	Indomethacin and dexamethasone, either of which shows a clear protection against TNF/LPS lethality in normal mice, did not change the clearance of injected mTNF, but both reduced the TNF-induced IL-6 levels.	Indomethacin	0-12	interleukin 6	Mus musculus	195-199
1657127-4	1991	Indomethacin and dexamethasone, either of which shows a clear protection against TNF/LPS lethality in normal mice, did not change the clearance of injected mTNF, but both reduced the TNF-induced IL-6 levels.	Dexamethasone	17-30	interleukin 6	Mus musculus	195-199
1657127-6	1991	The circulating TNF and IL-6 concentrations after LPS injection in mice pretreated with dexamethasone were very considerably reduced.	Dexamethasone	88-101	interleukin 6	Mus musculus	24-28
1657127-8	1991	We conclude that the strongly enhanced sensitivity of GalN-treated mice towards mTNF-induced or LPS-induced lethality was not reflected in circulating TNF or IL-6 levels, and that dexamethasone and indomethacin both reduce circulating IL-6 concentrations in mice treated with TNF and LPS.	Galactosamine	54-58	interleukin 6	Mus musculus	235-239
1657127-8	1991	We conclude that the strongly enhanced sensitivity of GalN-treated mice towards mTNF-induced or LPS-induced lethality was not reflected in circulating TNF or IL-6 levels, and that dexamethasone and indomethacin both reduce circulating IL-6 concentrations in mice treated with TNF and LPS.	Dexamethasone	180-193	interleukin 6	Mus musculus	235-239
1657127-8	1991	We conclude that the strongly enhanced sensitivity of GalN-treated mice towards mTNF-induced or LPS-induced lethality was not reflected in circulating TNF or IL-6 levels, and that dexamethasone and indomethacin both reduce circulating IL-6 concentrations in mice treated with TNF and LPS.	Indomethacin	198-210	interleukin 6	Mus musculus	235-239
2070071-4	1991	These procedures have allowed us to ascribe the following features to the cells mainly responsible for IL-3-induced IL-6 production: (1) they possess a low density and a relatively high forward and perpendicular light scatter (FLS/PLS); (2) they are characterized by a high rhodamine (Rh) retention; and (3) their enrichment in various subpopulations is similar to that obtained for progenitors forming colonies in the methylcellulose assay colony-forming units (CFU-C).	Rhodamines	274-283	interleukin 6	Mus musculus	116-120
2070071-4	1991	These procedures have allowed us to ascribe the following features to the cells mainly responsible for IL-3-induced IL-6 production: (1) they possess a low density and a relatively high forward and perpendicular light scatter (FLS/PLS); (2) they are characterized by a high rhodamine (Rh) retention; and (3) their enrichment in various subpopulations is similar to that obtained for progenitors forming colonies in the methylcellulose assay colony-forming units (CFU-C).	Rhodamines	285-287	interleukin 6	Mus musculus	116-120
1651781-2	1991	This study shows the in vitro effect of LiCl on the TNF-induced or interleukin 1 (IL-1)-induced expression of IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-3, IL-2, and the IL-2 receptor-alpha (IL-2R alpha).	Lithium Chloride	40-44	interleukin 6	Mus musculus	110-114
1651781-3	1991	The levels of IL-6 and GM-CSF in the medium of TNF-treated L929 fibrosarcoma cells were increased by cotreatment with LiCl.	Lithium Chloride	118-122	interleukin 6	Mus musculus	14-18
1651781-4	1991	In contrast, enhancement of IL-6 production by dibutyryl cyclic AMP or cycloheximide was not affected by LiCl.	Bucladesine	47-67	interleukin 6	Mus musculus	28-32
1651781-4	1991	In contrast, enhancement of IL-6 production by dibutyryl cyclic AMP or cycloheximide was not affected by LiCl.	Cycloheximide	71-84	interleukin 6	Mus musculus	28-32
1651781-7	1991	However, LiCl potentiated the IL-1-induced synthesis of IL-6, GM-CSF, IL-3, and IL-2 in PC60 murine T-cell hybridoma cells.	Lithium Chloride	9-13	interleukin 6	Mus musculus	56-60
1651781-8	1991	TNF alone induced only GM-CSF production in these cells, but in the presence of LiCl, increased amounts of GM-CSF as well as small amounts of IL-2 and IL-6 could be detected.	Lithium Chloride	80-84	interleukin 6	Mus musculus	151-155
1908334-0	1991	In vitro cytokine release by activated murine peritoneal macrophages: role of prostaglandins in the differential regulation of tumor necrosis factor alpha, interleukin 1, and interleukin 6.	Prostaglandins	78-92	interleukin 6	Mus musculus	175-188
1908334-7	1991	The release of TNF-alpha is inhibited by prostaglandins, whereas increased levels of PGE2 and PGI2 correlate with higher levels of IL-6.	Dinoprostone	85-89	interleukin 6	Mus musculus	131-135
1908334-7	1991	The release of TNF-alpha is inhibited by prostaglandins, whereas increased levels of PGE2 and PGI2 correlate with higher levels of IL-6.	Epoprostenol	94-98	interleukin 6	Mus musculus	131-135
1850327-4	1991	Since activated macrophages produce prostaglandins (PGE2) which may participate in the autoregulation of cytokine production by stimulation of adenylate cyclase and the induction of cAMP-dependent signal pathways, we determined the effects of PGE on the production of IL-6 and MIP-1-related proteins.	Dinoprostone	52-56	interleukin 6	Mus musculus	268-272
1850327-4	1991	Since activated macrophages produce prostaglandins (PGE2) which may participate in the autoregulation of cytokine production by stimulation of adenylate cyclase and the induction of cAMP-dependent signal pathways, we determined the effects of PGE on the production of IL-6 and MIP-1-related proteins.	Prostaglandins E	52-55	interleukin 6	Mus musculus	268-272
1850327-6	1991	Pharmacologic agents alone did not induce IL-6 production but incubation of macrophages with combinations of adenylate cyclase stimulators and LPS or dcAMP and LPS led to the dose-dependent enhancement of IL-6 secretion and mRNA expression.	dcamp	150-155	interleukin 6	Mus musculus	205-209
1772482-3	1991	The recombinant mIL-6 (remIL-6) was isolated from bacterial inclusion bodies by solubilization in 4 M guanidine hydrochloride followed by gel-filtration chromatography.	remil-6	23-30	interleukin 6	Mus musculus	16-21
1772482-3	1991	The recombinant mIL-6 (remIL-6) was isolated from bacterial inclusion bodies by solubilization in 4 M guanidine hydrochloride followed by gel-filtration chromatography.	Guanidine	102-125	interleukin 6	Mus musculus	16-21
2037066-3	1991	The two forms of mIL-6 were isolated and found to have identical N-terminal sequences initiated by Met-Phe-Pro-Thr-Ser-Gln-.	met-phe-pro-thr	99-114	interleukin 6	Mus musculus	17-22
2037066-3	1991	The two forms of mIL-6 were isolated and found to have identical N-terminal sequences initiated by Met-Phe-Pro-Thr-Ser-Gln-.	Serine	115-118	interleukin 6	Mus musculus	17-22
2037066-3	1991	The two forms of mIL-6 were isolated and found to have identical N-terminal sequences initiated by Met-Phe-Pro-Thr-Ser-Gln-.	Glutamine	119-122	interleukin 6	Mus musculus	17-22
1903722-2	1991	We here report that both D factor/LIF and IL-6 inhibit the differentiation of mouse teratocarcinoma F9 cells induced by retinoic acid alone or combined with dibutyryl cAMP.	Tretinoin	120-133	interleukin 6	Mus musculus	42-46
1903722-2	1991	We here report that both D factor/LIF and IL-6 inhibit the differentiation of mouse teratocarcinoma F9 cells induced by retinoic acid alone or combined with dibutyryl cAMP.	Bucladesine	157-171	interleukin 6	Mus musculus	42-46
1709793-2	1991	Murine recombinant IL-6 significantly increased the number of VSMC and stimulated tritiated thymidine incorporation into VSMC in a dose-dependent manner.	vsmc	62-66	interleukin 6	Mus musculus	19-23
1709793-2	1991	Murine recombinant IL-6 significantly increased the number of VSMC and stimulated tritiated thymidine incorporation into VSMC in a dose-dependent manner.	Thymidine	92-101	interleukin 6	Mus musculus	19-23
1709793-2	1991	Murine recombinant IL-6 significantly increased the number of VSMC and stimulated tritiated thymidine incorporation into VSMC in a dose-dependent manner.	vsmc	121-125	interleukin 6	Mus musculus	19-23
2055290-0	1991	Poly(A)-poly(U) induces circulating colony-stimulating activity resulting from interactions between endogeneous interleukin 6 and serum components.	Poly A	0-7	interleukin 6	Mus musculus	112-125
2055290-0	1991	Poly(A)-poly(U) induces circulating colony-stimulating activity resulting from interactions between endogeneous interleukin 6 and serum components.	Poly U	8-15	interleukin 6	Mus musculus	112-125
2055290-5	1991	These sera are devoid of detectable interleukin 3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF), but contain large amounts of interleukin 6 (IL-6) that are perfectly correlated with circulating CSA levels.	Cyclosporine	216-219	interleukin 6	Mus musculus	148-161
2019285-10	1991	Since oil granulomata are known to secrete interleukin 6, which has B cell-regulatory properties and is secreted by rheumatoid synovial cells, we tested sera from interleukin 6-transgenic mice, and found a strikingly raised percentage of Gal(O).	cyclohexenoesculetin-beta-galactoside	238-241	interleukin 6	Mus musculus	43-56
2002280-4	1991	Interleukin-1 and interleukin-6 in combination were synergistic and induced tritiated thymidine incorporation in D10.G4.1 cells equal to 15% of that obtained with optimal concentrations of concanavalin A.	Thymidine	86-95	interleukin 6	Mus musculus	18-31
1705005-2	1991	IL-6 stimulation of IL-6-deprived cells resulted in the rapid and transient tyrosine phosphorylation of a 160-kDa cellular protein (p160).	Tyrosine	76-84	interleukin 6	Mus musculus	0-4
1705005-2	1991	IL-6 stimulation of IL-6-deprived cells resulted in the rapid and transient tyrosine phosphorylation of a 160-kDa cellular protein (p160).	Tyrosine	76-84	interleukin 6	Mus musculus	20-24
1993216-6	1991	In eight separate experiments, it was shown that IL-6 (40,000 U, 4 micrograms), when given to rebound-thrombocytotic mice in four injections over a 2-day period, produced a small but significant (P less than .005) increase in percent 35S incorporation into platelets.	Sulfur-35	234-237	interleukin 6	Mus musculus	49-53
1825107-4	1991	The administration of high doses of m-PDS (50 mg/kg) 2 to 3 h before the mAb resulted in an almost complete inhibition of the systemic release of TNF-alpha, IL-2, and IL-6.	Methylprednisolone	36-41	interleukin 6	Mus musculus	167-171
1991164-8	1991	For example, compared with normal control values (N), femoral and splenic CFU-s numbers in IL-6-treated mice 17 days postirradiation were 27% N and 136% N versus 2% N and 10% N in saline-treated mice.	Nitrogen	142-143	interleukin 6	Mus musculus	91-95
1984801-6	1991	Platelet production, as measured by 75Se-selenomethionine incorporation, increased by approximately 120% in animals that had received IL-6 or IL-3 plus IL-6.	Selenomethionine	41-57	interleukin 6	Mus musculus	134-138
1829649-2	1991	In this study, we found that these mAbs induced TNF-alpha and IL-6 production in FDC-P2/185-4 cells.	fdc-p2	81-87	interleukin 6	Mus musculus	62-66
1703493-9	1991	When sorted WGA+Lin- spleen cells of the 5-FU-treated mice were cultured in vitro in the presence of recombinant interleukin 3 (IL-3), interleukin 6 (IL-6), and granulocyte colony-stimulating factor (G-CSF), colony formation was observed only in wells with IL-3, whereas unfractionated spleen cells formed colonies in the presence of IL-3, IL-6, or G-CSF.	Fluorouracil	41-45	interleukin 6	Mus musculus	135-148
1703493-9	1991	When sorted WGA+Lin- spleen cells of the 5-FU-treated mice were cultured in vitro in the presence of recombinant interleukin 3 (IL-3), interleukin 6 (IL-6), and granulocyte colony-stimulating factor (G-CSF), colony formation was observed only in wells with IL-3, whereas unfractionated spleen cells formed colonies in the presence of IL-3, IL-6, or G-CSF.	Fluorouracil	41-45	interleukin 6	Mus musculus	150-154
1703493-9	1991	When sorted WGA+Lin- spleen cells of the 5-FU-treated mice were cultured in vitro in the presence of recombinant interleukin 3 (IL-3), interleukin 6 (IL-6), and granulocyte colony-stimulating factor (G-CSF), colony formation was observed only in wells with IL-3, whereas unfractionated spleen cells formed colonies in the presence of IL-3, IL-6, or G-CSF.	Fluorouracil	41-45	interleukin 6	Mus musculus	340-344
1937867-1	1991	We compared the effects of platelet-activating factor (PAF), interleukin-1 beta (IL-1 beta) and polyriboinositic-polyribocytidylic acid (poly-I:C) on IL-6 production by confluent L929 mouse fibroblasts.	polyriboinositic-polyribocytidylic acid	96-135	interleukin 6	Mus musculus	150-154
1937867-1	1991	We compared the effects of platelet-activating factor (PAF), interleukin-1 beta (IL-1 beta) and polyriboinositic-polyribocytidylic acid (poly-I:C) on IL-6 production by confluent L929 mouse fibroblasts.	poly I:C	137-145	interleukin 6	Mus musculus	150-154
1940049-1	1991	Mometasone furoate (9 alpha, 21 dichloro-11 beta, 17 alpha dihydroxy-16 alpha methyl-1,4 pregnadiene-3, 20 dione-17-[2"] furoate) was an unexpectedly potent inhibitor of the in vitro production of three inflammatory cytokines, IL-1(1), IL-6, and TNF-alpha.	Mometasone Furoate	0-18	interleukin 6	Mus musculus	236-240
1860783-0	1991	Effect of the double-stranded polynucleotide complex polyadenylate-polyuridylate (poly A-U) on interleukin-6 production by mouse fibroblasts.	Polynucleotides	30-44	interleukin 6	Mus musculus	95-108
1860783-0	1991	Effect of the double-stranded polynucleotide complex polyadenylate-polyuridylate (poly A-U) on interleukin-6 production by mouse fibroblasts.	Poly A-U	53-80	interleukin 6	Mus musculus	95-108
1860783-0	1991	Effect of the double-stranded polynucleotide complex polyadenylate-polyuridylate (poly A-U) on interleukin-6 production by mouse fibroblasts.	Poly A	82-88	interleukin 6	Mus musculus	95-108
1860783-2	1991	The aim of the present study was to investigate the effect of Poly A-U on IL-6 production by this cell type.	Poly A	62-68	interleukin 6	Mus musculus	74-78
1860783-4	1991	Poly A-U increased IL-6 activity in supernatants in a dose-dependent manner at doses higher than 50 micrograms/ml, the maximum activity being observed at the highest concentration of Poly A-U used, i.e. 500 micrograms/ml.	Poly A	0-6	interleukin 6	Mus musculus	19-23
1860783-4	1991	Poly A-U increased IL-6 activity in supernatants in a dose-dependent manner at doses higher than 50 micrograms/ml, the maximum activity being observed at the highest concentration of Poly A-U used, i.e. 500 micrograms/ml.	Poly A	183-189	interleukin 6	Mus musculus	19-23
1860783-5	1991	beta Interleukin-1 (beta IL-1) and poly-cytidylic-polyinosinic (Poly I-C) have been shown to be inducers of IL-6 in fibroblast culture and thus their effect was compared to that of Poly A-U.	poly-cytidylic-polyinosinic	35-62	interleukin 6	Mus musculus	108-112
1860783-5	1991	beta Interleukin-1 (beta IL-1) and poly-cytidylic-polyinosinic (Poly I-C) have been shown to be inducers of IL-6 in fibroblast culture and thus their effect was compared to that of Poly A-U.	poly I:C	64-72	interleukin 6	Mus musculus	108-112
1860783-6	1991	The IL-6 activity in supernatants induced by 500 micrograms/ml Poly I-C (58.4 +/- 16.4 U/ml; n = 4) was higher than that evoked by 100 U/ml beta IL-1 (5.7 +/- 0.4 U/ml) or 500 micrograms/ml Poly A-U (39.6 +/- 7.8 U/ml).	poly I:C	63-71	interleukin 6	Mus musculus	4-8
1860783-6	1991	The IL-6 activity in supernatants induced by 500 micrograms/ml Poly I-C (58.4 +/- 16.4 U/ml; n = 4) was higher than that evoked by 100 U/ml beta IL-1 (5.7 +/- 0.4 U/ml) or 500 micrograms/ml Poly A-U (39.6 +/- 7.8 U/ml).	Poly A	190-196	interleukin 6	Mus musculus	4-8
1860783-7	1991	The increased production of IL-6 by Poly A-U may explain part of its previously reported immunomodulatory effects.	Poly A	36-42	interleukin 6	Mus musculus	28-32
7931712-8	1994	Elevated release of IL-6, TNF-alpha, IgA and IgG produced by splenocytes in vitro during murine AIDS were also completely or partially normalized by vitamin E.	Vitamin E	149-158	interleukin 6	Mus musculus	20-24
2228317-9	1990	When tumor cells from cachectic mice were placed into long-term cell culture, immune reactive TNF-alpha and IL-1 alpha were produced, but IL-6 bioactivity ws not produced in measurable amounts.	Tungsten	155-157	interleukin 6	Mus musculus	138-142
1987692-4	1991	Similarly, cyclosporine potentiated the inhibitory effects of rapamycin upon proliferation of IL-2 (CTLL-2) and IL-6 (MH60.BSF-2) lymphokine-dependent cell lines.	Cyclosporine	11-23	interleukin 6	Mus musculus	112-116
1987692-4	1991	Similarly, cyclosporine potentiated the inhibitory effects of rapamycin upon proliferation of IL-2 (CTLL-2) and IL-6 (MH60.BSF-2) lymphokine-dependent cell lines.	Sirolimus	62-71	interleukin 6	Mus musculus	112-116
2237286-0	1990	Tumour necrosis factor alpha (TNF-alpha) and interleukin 6 in a zymosan-induced shock model.	Zymosan	64-71	interleukin 6	Mus musculus	45-58
1978727-0	1990	In vivo treatment with benzodiazepines inhibits murine phagocyte oxidative metabolism and production of interleukin 1, tumor necrosis factor and interleukin-6.	Benzodiazepines	23-38	interleukin 6	Mus musculus	145-158
2145578-4	1990	One such line, PU-34, was found to produce a variety of growth factors, including an activity that stimulates the proliferation of an interleukin 6-dependent murine plasmacytoma cell line.	Plutonium	15-17	interleukin 6	Mus musculus	134-147
2237286-3	1990	TNF and IL-6 release in mice treated with zymosan was investigated.	Zymosan	42-49	interleukin 6	Mus musculus	8-12
2237286-10	1990	In contrast, maximal IL-6 release was reached upon stimulation with zymosan-activated serum only, while the presence of zymosan particles lowered this response.	Zymosan	68-75	interleukin 6	Mus musculus	21-25
2163322-0	1990	Production of interleukin-6 by anterior pituitary cells is stimulated by increased intracellular adenosine 3",5"-monophosphate and vasoactive intestinal peptide.	Cyclic AMP	97-126	interleukin 6	Mus musculus	14-27
2382217-11	1990	IL-6 synthesis was only increased with high doses of diltiazem, whereas both diltiazem doses decreased TNF production.	Diltiazem	53-62	interleukin 6	Mus musculus	0-4
2151766-10	1990	Enhancement of 2",5"-AS gene expression by IL 6 was observed even when protein synthesis was inhibited by cycloheximide.	Cycloheximide	106-119	interleukin 6	Mus musculus	43-47
2163322-8	1990	These data suggest that anterior pituitary cells produce IL-6 in response to increased intracellular cAMP, and that the neuropeptide vasoactive intestinal peptide may act to regulate IL-6 production.	Cyclic AMP	101-105	interleukin 6	Mus musculus	57-61
2163322-2	1990	We recently demonstrated that IL-6 is produced by anterior pituitary cells in response to the bacterial endotoxin lipopolysaccharide and phorbol diester in vitro.	Phorbol Esters	137-152	interleukin 6	Mus musculus	30-34
2163322-4	1990	In addition, we now report that IL-6 production by anterior pituitary cells is stimulated by agents that elevate intracellular cAMP concentrations.	Cyclic AMP	127-131	interleukin 6	Mus musculus	32-36
2347366-4	1990	IL 6 from the culture medium of transfected NIH/3T3 cells exhibited at least eight bands on Western blots after sodium dodecyl sulfate-polyacrylamide gel electrophoresis, indicating that human IL 6 expressed in NIH/3T3 cells shows a complex glycosylation pattern.	polyacrylamide	135-149	interleukin 6	Mus musculus	0-4
2165202-9	1990	The role for regulators of intracellular cAMP was specific because any of the cAMP agonists alone, or in the presence of cytokine stimulators of stromal cells, strongly enhanced IL-6 production, an event known to be cAMP-responsive.	Cyclic AMP	41-45	interleukin 6	Mus musculus	178-182
2165202-9	1990	The role for regulators of intracellular cAMP was specific because any of the cAMP agonists alone, or in the presence of cytokine stimulators of stromal cells, strongly enhanced IL-6 production, an event known to be cAMP-responsive.	Cyclic AMP	78-82	interleukin 6	Mus musculus	178-182
2165202-9	1990	The role for regulators of intracellular cAMP was specific because any of the cAMP agonists alone, or in the presence of cytokine stimulators of stromal cells, strongly enhanced IL-6 production, an event known to be cAMP-responsive.	Cyclic AMP	78-82	interleukin 6	Mus musculus	178-182
2165202-10	1990	Thus, acute formation of intracellular cAMP is a negative regulator of stromal cell GM-CSF production mediated by cytokines, but positively regulates IL-6 production and may be an important determinant of cytokine-directed marrow microenvironmental function.	Cyclic AMP	39-43	interleukin 6	Mus musculus	150-154
2350576-3	1990	The megakaryocytic progenitors that survive exposure to 5-fluorouracil (5-FU) exhibited a more significant response to IL-6 and IL-3.	Fluorouracil	56-70	interleukin 6	Mus musculus	119-123
2350576-3	1990	The megakaryocytic progenitors that survive exposure to 5-fluorouracil (5-FU) exhibited a more significant response to IL-6 and IL-3.	Fluorouracil	72-76	interleukin 6	Mus musculus	119-123
2361734-9	1990	Metabolic incorporation of [35S]methionine into mouse SAP occurred in response to both IL-1 and IL-6.	Sulfur-35	28-31	interleukin 6	Mus musculus	96-100
2361734-9	1990	Metabolic incorporation of [35S]methionine into mouse SAP occurred in response to both IL-1 and IL-6.	Methionine	32-42	interleukin 6	Mus musculus	96-100
2334892-0	1990	Interleukin 6 perfusion stimulates reconstitution of the immune and hematopoietic systems after 5-fluorouracil treatment.	Fluorouracil	96-110	interleukin 6	Mus musculus	0-13
2334892-3	1990	IL-6 perfusion significantly augmented anti-sheep RBC antibody responses depressed by 5-FU (150 mg/kg) treatment.	Fluorouracil	86-90	interleukin 6	Mus musculus	0-4
2334892-4	1990	IL-6 also was shown to stimulate hematological recovery in mice treated with 5-FU.	Fluorouracil	77-81	interleukin 6	Mus musculus	0-4
2334892-7	1990	Furthermore, it was found that the endogenous IL-6 level in serum increased after 5-FU treatment, which suggests that IL-6 may play some role in the recovery of the immune and hematopoietic systems.	Fluorouracil	82-86	interleukin 6	Mus musculus	46-50
2334892-7	1990	Furthermore, it was found that the endogenous IL-6 level in serum increased after 5-FU treatment, which suggests that IL-6 may play some role in the recovery of the immune and hematopoietic systems.	Fluorouracil	82-86	interleukin 6	Mus musculus	118-122
2347366-3	1990	Cadmium-stimulated transfected NIH/3T3 cells synthesized and exported biologically active IL 6 (1.7 x 10(4) U/10(6) cells/24 h).	Cadmium	0-7	interleukin 6	Mus musculus	90-94
2347366-4	1990	IL 6 from the culture medium of transfected NIH/3T3 cells exhibited at least eight bands on Western blots after sodium dodecyl sulfate-polyacrylamide gel electrophoresis, indicating that human IL 6 expressed in NIH/3T3 cells shows a complex glycosylation pattern.	Sodium Dodecyl Sulfate	112-134	interleukin 6	Mus musculus	0-4
2224057-3	1990	IL-1 and IL-6 are also known to enhance GM colony formation.	gm	40-42	interleukin 6	Mus musculus	9-13
2307935-0	1990	Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6.	lps	68-71	interleukin 6	Mus musculus	147-160
2307935-0	1990	Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6.	lps	103-106	interleukin 6	Mus musculus	147-160
2307935-4	1990	The protection afforded by O side chain-specific antisera against endotoxin lethality was associated with decreased LPS-induced serum TNF and IL-6 levels, whereas core LPS antibodies had no effect on TNF or IL-6 levels.	lps	116-119	interleukin 6	Mus musculus	142-146
2320952-0	1990	Ciclosporin-dependent, nu-independent, mucosal interleukin 6 response to gram-negative bacteria.	Cyclosporine	0-11	interleukin 6	Mus musculus	47-60
2105854-0	1990	IL-2, IL-6, and IFN-gamma have distinct effects on the IL-4 plus PMA-induced proliferation of thymocyte subpopulations.	Tetradecanoylphorbol Acetate	65-68	interleukin 6	Mus musculus	6-10
33798789-6	2021	Moreover, ISO effectively ameliorated the changes in IL-1beta, IL-6, and TNF-alpha concentrations in BALF, prevented IkappaB degradation, and inhibited the phosphorylation of NF-kappaB p65 subunit in lung tissues; furthermore, it enhanced the nuclear translocation of Nrf2 and inhibited IL-1beta, IL-6, TNF-alpha, iNOS, COX-2, and ROS production in lipopolysaccharide-treated RAW264.7 cells.	isorhapontigenin	10-13	interleukin 6	Mus musculus	63-67
33765609-6	2021	Importantly, H2S ameliorated high glucose-induced inflammation in HT-22 cells, evidenced by NaHS or SAMe inhibited the pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha) expression in HT-22 cells exposed to high glucose.	Deuterium	13-16	interleukin 6	Mus musculus	157-161
33773150-8	2021	The ELISA results displayed that 100 muM PFOA exposure induced macrophage activation and enhanced cytokines secretion, including TNF-alpha, IL-1, IL-6, and IL-12.	perfluorooctanoic acid	41-45	interleukin 6	Mus musculus	146-150
33773208-10	2021	Treatment with either IC87114 or AMG319 not only attenuated LPS-induced edema, lung injury and neutrophilc inflammation, reduced total protein concentration and IL-6, TNF-alpha secretion in BALF, but also restored epithelial E-cadherin and claudin-2 expression.	IC 87114	22-29	interleukin 6	Mus musculus	161-165
33773208-10	2021	Treatment with either IC87114 or AMG319 not only attenuated LPS-induced edema, lung injury and neutrophilc inflammation, reduced total protein concentration and IL-6, TNF-alpha secretion in BALF, but also restored epithelial E-cadherin and claudin-2 expression.	N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine	33-39	interleukin 6	Mus musculus	161-165
33798737-4	2021	In addition, icariin improved the intestinal integrity of the aged mice by upregulating tight junction adhesion molecules and the Paneth and goblet cells, along with the reduction of iNOS and pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-2 and IL-6, and IL-12).	icariin	13-20	interleukin 6	Mus musculus	250-254
33798789-6	2021	Moreover, ISO effectively ameliorated the changes in IL-1beta, IL-6, and TNF-alpha concentrations in BALF, prevented IkappaB degradation, and inhibited the phosphorylation of NF-kappaB p65 subunit in lung tissues; furthermore, it enhanced the nuclear translocation of Nrf2 and inhibited IL-1beta, IL-6, TNF-alpha, iNOS, COX-2, and ROS production in lipopolysaccharide-treated RAW264.7 cells.	isorhapontigenin	10-13	interleukin 6	Mus musculus	297-301
33822771-8	2021	Conversely, the immediate reductions in fasting blood glucose observed with acute amlexanox treatment were mediated by suppression of hepatic glucose production via the activation of STAT3 by adipocyte-secreted IL-6.	amlexanox	82-91	interleukin 6	Mus musculus	211-215
34022267-10	2021	Moreover, DMY decreased the abundance of IL-6 but increased the abundance of IL-2 of D-Gal-exposed mice.	dihydromyricetin	10-13	interleukin 6	Mus musculus	41-45
33771600-7	2021	In the next phase, BPME and piperine were found to significantly attenuate the BMP-6 and IL-6 induced hepcidin overexpression by downregulating the increased level of pSMAD1 and pSTAT3 proteins.	bpme	19-23	interleukin 6	Mus musculus	89-93
33771600-7	2021	In the next phase, BPME and piperine were found to significantly attenuate the BMP-6 and IL-6 induced hepcidin overexpression by downregulating the increased level of pSMAD1 and pSTAT3 proteins.	piperine	28-36	interleukin 6	Mus musculus	89-93
33821300-5	2021	RESULTS: DEX significantly inhibited LPS-induced increases in the lung weight/body weight ratio and lung wet/dry weight ratio, decreased inflammatory cell infiltration, and decreased the production of proinflammatory factors, such as interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF-alpha)in the lungs.	Dexmedetomidine	9-12	interleukin 6	Mus musculus	264-268
33971906-10	2021	RESULTS: Knockdown of the endogenous lncRNA Gm13568 remarkably inhibits the Notch1 expression, astrocytosis, and the phosphorylation of signal transducer and activator of transcription 3 (p-STAT3) as well as the production of inflammatory cytokines and chemokines (IL-6, TNF-alpha, IP-10) in IL-9-activated astrocytes, in which Gm13568 associates with the transcriptional co-activators CBP/P300 which are enriched in the promoter of Notch1 genes.	gm13568	44-51	interleukin 6	Mus musculus	265-269
33761623-13	2021	Additionally, direct evidence pointed to TSG as a therapeutically active molecule in the prevention and treatment of UC by significantly reducing the production of these pro-inflammatory cytokines like TNF-alpha, IL-1beta, and IL-6 (p < 0.05-0.001) and increasing the levels of anti-inflammatory cytokine IL-10 (p < 0.05-0.001).	2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside	41-44	interleukin 6	Mus musculus	227-231
33940104-5	2021	Typically, PSF with UV/H2O2 treatment for 2 h (PSF-T2) could effectively inhibit pro-inflammatory molecules production (including NO, IL-1beta, IL-6 and TNF-alpha), and down-regulate related genes expression (including Tlr4, Irak, Il-1beta, Il-6, Il-12 and Tnf-alpha).	Hydrogen Peroxide	23-27	interleukin 6	Mus musculus	144-148
33940104-5	2021	Typically, PSF with UV/H2O2 treatment for 2 h (PSF-T2) could effectively inhibit pro-inflammatory molecules production (including NO, IL-1beta, IL-6 and TNF-alpha), and down-regulate related genes expression (including Tlr4, Irak, Il-1beta, Il-6, Il-12 and Tnf-alpha).	Hydrogen Peroxide	23-27	interleukin 6	Mus musculus	241-245
33973707-9	2021	Inhibition of miR-138-5p led to attenuated inflammatory responses of hMSCs upon TNF-alpha and IL-6 stimulation, and allergic symptoms in mice, as well as histamine and ovalbumin-specific IgG release.	mir-138-5p	14-24	interleukin 6	Mus musculus	94-98
33822229-12	2021	PTC923-treated mice showed a reduction in inflammatory mediators, especially IL-6 and IL-1b.	sepiapterin	0-6	interleukin 6	Mus musculus	77-81
33825397-2	2021	METHODS: Maximal non-toxic dose (MNTD) of methanol extract of P. ginseng root culture on BV2 microglia cells was first determined via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, followed by treatment and LPS stimulation of cells, and the measurement of NO using Griess assay and TNF-alpha, IL-6, and IL-10 using ELISA assay.	Methanol	42-50	interleukin 6	Mus musculus	314-318
33771933-6	2021	PVB decreased the production of IL-1beta, IL-6, and CXCL1 mRNA in the lungs of LPS-treated mice and decreased the serum levels of liver transaminases (alanine aminotransferase and aspartate aminotransferase) at multiple time points and doses tested.	pinaverium	0-3	interleukin 6	Mus musculus	42-46
33826131-8	2021	Histopathological changes in the brain, elevation of inflammatory factors (Tnf, Il-6), and significant alterations in oxidative stress markers were also observed after treatment with CuONPs.	cuonps	183-189	interleukin 6	Mus musculus	80-84
33812014-7	2021	RESULTS: Five days of repeated exposure to the comintation of LPS and glyphosate resulted in higher neutrophil counts, myloperoxidase, TNF-alpha, IL-6, KC levels, and ICAM-1 and TLR-2 expression compared to the same length of treatment to LPS or glyphosate alone.	glyphosate	70-80	interleukin 6	Mus musculus	146-150
33818184-4	2021	Mechanistically, FK866 enhanced autophagy, reduced protein aggregation, and inhibited neuroinflammation indicated by decreasing TNFalpha, IL-6, GFAP, and Iba1 levels in the aged mouse brain.	N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide	17-22	interleukin 6	Mus musculus	138-142
33824698-10	2021	Conclusion: Inflammation and IL-6/STAT3 signaling were activated in TAC-induced HF in mice, while sustained IL-6 incubation elicited oxidative stress and mitophagy-related protein increase in H9c2 myoblasts, all of which were inhibited by raloxifene.	tac	68-71	interleukin 6	Mus musculus	29-33
33798807-4	2021	In in vivo experiments, curcumin significantly alleviated lung inflammation, histopathological injury and MPO activity, serum concentrations of CCL7, IL-6 and TNF-alpha, and mortality in mice compared to the model group.	Curcumin	24-32	interleukin 6	Mus musculus	150-154
33774704-9	2021	Clozapine reliably increased proinflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) expression in murine pancreatic tissue.	Clozapine	0-9	interleukin 6	Mus musculus	66-70
33805209-4	2021	Methods: Papaverine 3D pharmacophore mimetic compounds were selected by the LigandScout software from our in-house, anti-cancer chemical library and assessed for their anti-inflammatory activities by a HMGB1-RAGE-mediated interleukin-6 production assay using macrophage-like RAW264.7 cells.	Papaverine	9-19	interleukin 6	Mus musculus	222-235
33807110-18	2021	NP-OmpA could down-regulate the inflammation-related gene expression of TNF-a, IL-6, and IL-10 in the spleen, liver, and kidney, and the antioxidant factors MDA and SOD in the liver, and reduce injury in the liver and kidney of mice induced by E. coli.	np-ompa	0-7	interleukin 6	Mus musculus	79-83
33588680-8	2021	Furthermore, schizandrin could dramatically inhibit the neuroinflammation in mice by reducing pro-inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6) through regulating NF-kappaB/NLRP3/Iba-1 signaling.	schizandrin	13-24	interleukin 6	Mus musculus	147-151
33824698-0	2021	Alleviation of Inflammation and Oxidative Stress in Pressure Overload-Induced Cardiac Remodeling and Heart Failure via IL-6/STAT3 Inhibition by Raloxifene.	Raloxifene Hydrochloride	144-154	interleukin 6	Mus musculus	119-123
33824698-5	2021	Echocardiographic and histological results showed that cardiac hypertrophy, fibrosis, and left ventricular dysfunction were manifested in mice after TAC treatment of eight weeks, with aggravation of macrophage infiltration and interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) expression in the myocardium.	tac	149-152	interleukin 6	Mus musculus	227-240
33824698-10	2021	Conclusion: Inflammation and IL-6/STAT3 signaling were activated in TAC-induced HF in mice, while sustained IL-6 incubation elicited oxidative stress and mitophagy-related protein increase in H9c2 myoblasts, all of which were inhibited by raloxifene.	Raloxifene Hydrochloride	239-249	interleukin 6	Mus musculus	108-112
33824698-5	2021	Echocardiographic and histological results showed that cardiac hypertrophy, fibrosis, and left ventricular dysfunction were manifested in mice after TAC treatment of eight weeks, with aggravation of macrophage infiltration and interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) expression in the myocardium.	tac	149-152	interleukin 6	Mus musculus	242-246
33824698-7	2021	Importantly, IL-6/gp130/STAT3 inhibition by raloxifene alleviated TAC-induced myocardial inflammation, cardiac remodeling, and dysfunction.	Raloxifene Hydrochloride	44-54	interleukin 6	Mus musculus	13-17
33824698-7	2021	Importantly, IL-6/gp130/STAT3 inhibition by raloxifene alleviated TAC-induced myocardial inflammation, cardiac remodeling, and dysfunction.	tac	66-69	interleukin 6	Mus musculus	13-17
33776432-8	2021	Results: It showed that the proinflammatory responses elicited by the gamma-Fe2O3 NPs were weaker than that by Gd-DTPA, evidenced by the relatively much lower level of IL-1beta, IL-6, IL-18, TNF-alpha, C-reactive protein (CRP) and Ferritin.	Gadolinium DTPA	111-118	interleukin 6	Mus musculus	178-182
33824698-9	2021	Sustained IL-6 stimulation increased intracellular reactive oxygen species, repressed mitochondrial membrane potential (MMP), decreased intracellular content of ATP, and led to decreased SOD activity, an increase in iNOS protein expression, and increased protein expression of Pink1, Parkin, and Bnip3 involving in mitophagy, all of which were reversed by raloxifene.	Oxygen	60-66	interleukin 6	Mus musculus	10-14
33824698-9	2021	Sustained IL-6 stimulation increased intracellular reactive oxygen species, repressed mitochondrial membrane potential (MMP), decreased intracellular content of ATP, and led to decreased SOD activity, an increase in iNOS protein expression, and increased protein expression of Pink1, Parkin, and Bnip3 involving in mitophagy, all of which were reversed by raloxifene.	Adenosine Triphosphate	161-164	interleukin 6	Mus musculus	10-14
33824698-9	2021	Sustained IL-6 stimulation increased intracellular reactive oxygen species, repressed mitochondrial membrane potential (MMP), decreased intracellular content of ATP, and led to decreased SOD activity, an increase in iNOS protein expression, and increased protein expression of Pink1, Parkin, and Bnip3 involving in mitophagy, all of which were reversed by raloxifene.	Raloxifene Hydrochloride	356-366	interleukin 6	Mus musculus	10-14
33776432-8	2021	Results: It showed that the proinflammatory responses elicited by the gamma-Fe2O3 NPs were weaker than that by Gd-DTPA, evidenced by the relatively much lower level of IL-1beta, IL-6, IL-18, TNF-alpha, C-reactive protein (CRP) and Ferritin.	gamma-fe2o3	70-81	interleukin 6	Mus musculus	178-182
33808759-9	2021	Moreover, CDG treatment has regulated the expression of pro-inflammatory cytokines, such as IL-6 and IL-1beta.	cdg	10-13	interleukin 6	Mus musculus	92-96
33767622-10	2021	Alcohol increased the expression of neuroinflammation markers including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1) and C-C chemokine receptor 2 (CCR2).	Alcohols	0-7	interleukin 6	Mus musculus	72-85
33802935-6	2021	Moreover, CM-SD significantly reduced lipopolysaccharides (LPS)-mediated interleukin (IL)-6 production in the conditioned medium.	cm-sd	10-15	interleukin 6	Mus musculus	73-91
33767697-8	2021	Hydrogen significantly improved the survival rate of mice, reduced pulmonary edema and hemorrhage, infiltration of neutrophils, and IL-6 secretion.	Hydrogen	0-8	interleukin 6	Mus musculus	132-136
33809388-10	2021	Furthermore, both N275 and N400 treatments decreased serum triglyceride (TG) and induced hepatic TG, whereas N800 treatment significantly increased interleukin-6, hepatic TG, and total cholesterol levels.	(S)-2-Hydroxy-1,2,2-triphenylethyl acetate	109-113	interleukin 6	Mus musculus	148-161
33777165-11	2021	The anti-inflammatory mechanism of action of RIAF was to reduce inflammation-associated gene expression (iNOS, COX-2, IL-1beta, IL-6) by regulating the phosphorylation of the mitogen-activated protein kinases (MAPK) pathway and interventing the activation of the NF-kappaB pathway, which partly illustrated the basis of treatment of Isatidis Radix on cold, fever, sore throat, mumps, and tonsillitis in clinics.	riaf	45-49	interleukin 6	Mus musculus	128-132
33767622-10	2021	Alcohol increased the expression of neuroinflammation markers including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1) and C-C chemokine receptor 2 (CCR2).	Alcohols	0-7	interleukin 6	Mus musculus	87-91
33777316-7	2021	Results showed that CS significantly decreased the activities of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) and upregulated the expressions of malondialdehyde (MDA), tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), IL-8, and IL-1beta in serum.	Cesium	20-22	interleukin 6	Mus musculus	227-240
33807620-6	2021	The average number of colonic tumors and the levels of IL-6 and TNF-alpha in the CC + GL group were significantly lower than those in the CC group.	Glycyrrhizic Acid	86-88	interleukin 6	Mus musculus	55-59
33777316-7	2021	Results showed that CS significantly decreased the activities of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) and upregulated the expressions of malondialdehyde (MDA), tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), IL-8, and IL-1beta in serum.	Cesium	20-22	interleukin 6	Mus musculus	242-246
33236160-2	2021	Furthermore, nardostachin inhibited the production of inducible nitric oxide synthase and cyclooxygenase-2 as well as pro-inflammatory cytokines, including interleukin (IL)-1beta, IL-6, IL-12 and tumor necrosis factor-alpha in LPS-stimulated BV2 and rat primary microglial cells.	nardostachin	13-25	interleukin 6	Mus musculus	180-184
33146542-7	2021	Focusing on hyper-IL-6 (which also inhibited thiamin uptake by primary mouse PACs), the inhibition in thiamin uptake was found to be associated with significant reduction in THTR-1 & -2 proteins and mRNAs expression as well as in activity of the SLC19A2 and SLC19A3 promoters; it was also associated with reduction in level of expression of the transcription factor Sp1 (which is required for activity of these promoters).	Thiamine	45-52	interleukin 6	Mus musculus	18-22
33146542-7	2021	Focusing on hyper-IL-6 (which also inhibited thiamin uptake by primary mouse PACs), the inhibition in thiamin uptake was found to be associated with significant reduction in THTR-1 & -2 proteins and mRNAs expression as well as in activity of the SLC19A2 and SLC19A3 promoters; it was also associated with reduction in level of expression of the transcription factor Sp1 (which is required for activity of these promoters).	Thiamine	102-109	interleukin 6	Mus musculus	18-22
33146542-8	2021	Finally, blocking the intracellular Stat3 signaling pathway was found to lead to a significant reversal in the inhibitory effect of hyper IL-6 on thiamin uptake by PAC 266-6.	Thiamine	146-153	interleukin 6	Mus musculus	138-142
32795894-6	2020	CHBP administration inhibited interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha production at both the protein and mRNA levels.	chbp	0-4	interleukin 6	Mus musculus	54-58
33034242-5	2020	Loganin obviously inhibited the mRNA and protein levels of IL-6, TNF-alpha and IL-1beta in colon tissues from UC mice.	loganin	0-7	interleukin 6	Mus musculus	59-63
33588632-5	2021	Here, we observed that TEC significantly promoted cell survival, impeded cell apoptosis, inhibited ROS and inflammatory cytokines IL-1beta, IL-6, TNF-alpha production in OGD/R-induced HT-22 cells.	tectorigenin	23-26	interleukin 6	Mus musculus	140-144
30853175-4	2019	Our results indicated that PR could inhibit PMMA-induced osteoclastogenesis in RAW264.7 cells with a dose-dependent manner in vitro and effectively down-regulate mRNA and protein expressions of matrix metalloprotein 9 (MMP-9), tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and receptor activator of nuclear factor (NF)-kappaB (RANK), primarily via the suppression of NF-kappaB signaling.	Polymethyl Methacrylate	44-48	interleukin 6	Mus musculus	262-280
33233220-4	2020	In colitis mice, both DOP and EDOP could dramatically attenuate the clinical signs via blocking pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, and their related mRNA), restoring the levels of short-chain fatty acids (SCFAs), activating the G-protein coupled receptors (GPRs) and modulating the gut microbiota.	Diethylhexyl Phthalate	22-25	interleukin 6	Mus musculus	135-139
33233220-4	2020	In colitis mice, both DOP and EDOP could dramatically attenuate the clinical signs via blocking pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, and their related mRNA), restoring the levels of short-chain fatty acids (SCFAs), activating the G-protein coupled receptors (GPRs) and modulating the gut microbiota.	edop	30-34	interleukin 6	Mus musculus	135-139
33034881-4	2020	The results showed that PA (750 muM) evoked lipotoxicity as a reduction in cell viability, increased IL-6 and TNF-alpha expression, and enhanced reactive oxygen species (ROS).	Palmitic Acid	24-26	interleukin 6	Mus musculus	101-105
33034881-5	2020	However, SFN pretreatment attenuated the levels of, IL-6 and TNF-alpha in C2C12 myotubes exposure to PA.	Palmitic Acid	101-103	interleukin 6	Mus musculus	52-56
32796543-5	2020	Moreover, the six flavonoids differentially prevented the inflammatory response caused by oxidative stress by inhibiting interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha levels, and restoring IL-10 levels.	Flavonoids	18-28	interleukin 6	Mus musculus	145-149
32798296-14	2020	Phyllanthin appreciably suppressed the pro-inflammatory regulators that is, NF-alphaB p65, IL-6, IL-1beta, and TNF-alpha and enhanced the antioxidant marker expressions.	phyllanthin	0-11	interleukin 6	Mus musculus	91-95
32510702-10	2020	A mechanistic study demonstrated a role of Tregs in suppressing the expression of M1 macrophage markers (Tnfa, Il6, iNos, Ip10) and promoting the expression of M2 macrophage markers (Mrc1, Arg1, Il10) in bone-marrow-derived macrophages or in SAT from male or female mice.	tregs	43-48	interleukin 6	Mus musculus	111-114
30853175-7	2019	In vivo, PR was observed to attenuate PMMA-induced osteoclastogenesis, osteolysis, mRNA expressions of receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) and RANK, as well as protein levels of MMP-9, TNF-alpha, IL-6, and p65 in a murine calvarial osteolysis model.	Polymethyl Methacrylate	38-42	interleukin 6	Mus musculus	224-228
33236445-10	2021	In vitro, IL-6 treatment upregulated exosome biogenesis-related genes and subsequently promoted macrophages to release miR-223-enriched exosomes that were able to reduce pro-fibrotic TAZ expression in hepatocytes via exosomal transfer.	3-(BIPHENYL-4-YL)-5-(4-TERT-BUTYLPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOLE	183-186	interleukin 6	Mus musculus	10-14
31736980-5	2019	We also demonstrated that prophylactic oral administration of OLT1177 led to marked reduction (~2- to 3-fold) in the protein levels of IL-1beta and IL-18, as well as, IL-6 and TNFalpha, in the spinal cord of EAE mice.	nesosteine	62-69	interleukin 6	Mus musculus	167-171
29566712-6	2018	IL1ss and IL6 had a subtle but significant negative effect on cell viability and testosterone concentrations, with a marked significant decrease in progesterone concentration at all concentrations investigated.	Testosterone	81-93	interleukin 6	Mus musculus	10-13
29566712-6	2018	IL1ss and IL6 had a subtle but significant negative effect on cell viability and testosterone concentrations, with a marked significant decrease in progesterone concentration at all concentrations investigated.	Progesterone	148-160	interleukin 6	Mus musculus	10-13
29752615-12	2018	Simvastatin reduced plasma levels of presepsin, IL-1beta, and IL-6.	Simvastatin	0-11	interleukin 6	Mus musculus	62-66
29867884-9	2018	TNF-alpha and IL-6 upregulation by FOLFOX treatment was attenuated by Lcr35.	Folfox protocol	35-41	interleukin 6	Mus musculus	14-18
26553587-8	2015	In parallel, AA blocked a DNCB-induced reduction in serum levels of IL-4 and IL-10 associated with an attenuation of DNCB-induced increases in serum TNF-alpha, IL-6, IgE and caspase-3.	Dinitrochlorobenzene	117-121	interleukin 6	Mus musculus	160-164
19615773-7	2009	RESULTS: Lovastatin attenuated IR-induced activation of NF-kappaB, mRNA expression of cell adhesion molecules and mRNA expression of pro-inflammatory and pro-fibrotic marker genes (i.e. TNFalpha, IL-6, TGFbeta, CTGF, and type I and type III collagen) in a tissue- and time-dependent manner.	Lovastatin	9-19	interleukin 6	Mus musculus	196-200
27784235-9	2016	RESULTS: Genistein suppressed the expressions of IL-1beta, IL-6 and TNF-alpha in the serum.	Genistein	9-18	interleukin 6	Mus musculus	59-63
22848208-5	2012	Plasma IL-6 levels were higher in PPAR-alpha KO mice on day 12 of Ang II infusion (30 +- 4 versus 8 +- 2 pg/mL) and fenofibrate reduced plasma IL-6 in Ang II-treated WT mice (10 +- 3 pg/mL).	Fenofibrate	116-127	interleukin 6	Mus musculus	143-147
20102572-2	2010	IL-6-deficient mice are more susceptible to alcohol-induced hepatocyte apoptosis and steatosis and elevation of serum alanine transaminase (ALT); however, whereas hepatocyte-specific STAT3 knockout mice are more susceptible to alcohol-induced hepatic steatosis, they have similar hepatocyte apoptosis and serum ALT after alcohol feeding compared with wild-type mice.	Alcohols	44-51	interleukin 6	Mus musculus	0-4
20102572-2	2010	IL-6-deficient mice are more susceptible to alcohol-induced hepatocyte apoptosis and steatosis and elevation of serum alanine transaminase (ALT); however, whereas hepatocyte-specific STAT3 knockout mice are more susceptible to alcohol-induced hepatic steatosis, they have similar hepatocyte apoptosis and serum ALT after alcohol feeding compared with wild-type mice.	Alcohols	227-234	interleukin 6	Mus musculus	0-4
20102572-2	2010	IL-6-deficient mice are more susceptible to alcohol-induced hepatocyte apoptosis and steatosis and elevation of serum alanine transaminase (ALT); however, whereas hepatocyte-specific STAT3 knockout mice are more susceptible to alcohol-induced hepatic steatosis, they have similar hepatocyte apoptosis and serum ALT after alcohol feeding compared with wild-type mice.	Alcohols	227-234	interleukin 6	Mus musculus	0-4
20102572-9	2010	In addition, ethanol-fed STAT3(E-/-) mice displayed greater hepatic inflammation and substantially elevated serum and hepatic levels of IL-6 and TNF-alpha compared with wild-type mice.	Ethanol	13-20	interleukin 6	Mus musculus	136-140
34958877-12	2022	Further, ESE inhibited the phosphorylation of IkappaB and NF-kappaB in LPS-induced Raw264.7 cells and expression of COX-2, iNOS, IL-1beta, IL-6, and TNF-alpha.	2-(Ethylsulfonyl)ethanol	9-12	interleukin 6	Mus musculus	139-143
34788645-8	2022	RESULTS: Keguan-1 improved the survival rate, respiratory condition, and pathological lung injury; decreased the production of proinflammatory factors (TNF-alpha, IL-6, IL-1beta, KC, and MIP2) in BALF and the number of neutrophils in the lung tissues; and ameliorated inflammatory injury in the lung tissues of the mice with LPS-induced ALI.	keguan-1	9-17	interleukin 6	Mus musculus	163-167
34942323-11	2022	RESULTS: Treatment with pteryxin reduced the lung W/D weight ratio, total protein (TP) level and levels of inflammatory cytokines (TNFalpha, IL-6 and IL-1 beta) significantly.	pteryxin	24-32	interleukin 6	Mus musculus	141-145
34874107-5	2022	Moreover, AOF was able to protect neurons through the PI3K/AKT signaling pathway and significantly decrease NF-kappaB, IL-6, IL-1beta, and TNF-alpha levels in the hippocampal and cortex tissues, which were reversed through the use of LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	234-242	interleukin 6	Mus musculus	119-123
34906594-6	2022	At this selected time point, additional mice were exposed to FA or UA (n = 12 per group) and alveolar macrophage PM uptake and nitric oxide (NO) production was observed in UA-exposed mice, together with increased pro-inflammatory cytokine levels (TNF-alpha and IL-6) in BAL and plasma.	ulmoside A	67-69	interleukin 6	Mus musculus	261-265
34906594-6	2022	At this selected time point, additional mice were exposed to FA or UA (n = 12 per group) and alveolar macrophage PM uptake and nitric oxide (NO) production was observed in UA-exposed mice, together with increased pro-inflammatory cytokine levels (TNF-alpha and IL-6) in BAL and plasma.	ulmoside A	172-174	interleukin 6	Mus musculus	261-265
34740508-6	2022	Moreover, PS-MPs exposure increased the IL-6 level and decreased malondialdehyde (MDA) level in mouse ovaries.	ps-mps	10-16	interleukin 6	Mus musculus	40-44
34634699-6	2022	Mechanistically, activation of COX-dependent PGE2 production promotes IL-6 expression in splenic macrophages, which subsequently results in splenic EMH and increased platelet counts in circulation.	Dinoprostone	45-49	interleukin 6	Mus musculus	70-74
34763041-8	2022	Expression of the inflammatory factors, such as tumor necrosis factor-alpha, interleukin-1beta (IL-1beta), IL-6, monocyte chemoattractant protein-1, and intercellular adhesion molecule 1, was significantly reduced in CBBP-treated cholestatic mice.	phosphon	217-221	interleukin 6	Mus musculus	107-111
34737012-17	2022	The levels of pro-inflammatory factors TNF-alpha, IL-6, and IL-1beta and their mRNA levels in blood, BALF, and lung tissue were reduced following PB pretreatment.	physalin B	146-148	interleukin 6	Mus musculus	50-54
34906860-6	2022	In pharmacodynamic (PD) studies, oral administration of compound b12 showed robust and dose-dependent inhibition of IL-6 and IL-17A cytokine expression.	zwittergent 3-12	65-68	interleukin 6	Mus musculus	116-120
34986435-7	2022	Moreover, significant elevations in expression levels of mRNA for collagen overproduction (Col1A1, Col1A2, Col3A1, alpha-SMA, MMP9, TGF-beta1) and proinflammatory cytokines (IL-1beta, IL-6, CXCL1, CXCL2) were observed in VDR conditional KO versus control mice following HOCl treatment.	Hypochlorous Acid	270-274	interleukin 6	Mus musculus	184-188
34896967-10	2022	Here inhibition mechanism of 6-gingerol is demonstrated on excessive hypertrophy and hyperplasia of adipocytes in white adipose tissue (WAT), which may be related to the regulation of adipocytokines, such as PPARgamma, C/EBPalpha, FABP4 and adiponectin, and the TLR3/IL-6/JAK1/STAT3 axis.	gingerol	29-39	interleukin 6	Mus musculus	267-271
34906860-7	2022	The ability of compound b12 to reduce the levels of IL-6 and IL-17A in vivo after oral dosing in mice, and a corresponding reduction in skin inflammation further supports the potential of small molecule RORgammat modulation as a therapeutic target for the treatment of inflammatory diseases.	zwittergent 3-12	24-27	interleukin 6	Mus musculus	52-56
34710452-6	2022	Exercise decreased the mRNA expressions of IL-1beta, IL-6, TNF-alpha, TLR2 and NF-kappaB (p65) in fluoride-exposed mice, and restored the gene levels of Occludin and ZO-1 in the duodenum, as well as Occludin, ZO-1, and Claudin-1 in the colon.	Fluorides	98-106	interleukin 6	Mus musculus	53-57
34656620-8	2022	Of all the groups, the gastric organ index and MPO, IL6, and TNF-alpha levels were highest in the mice treated with the mixture of PE-MPs and H. pylori.	pe-mps	131-137	interleukin 6	Mus musculus	52-55
34874516-10	2022	Meanwhile, HQD-H and 5-ASA significantly decreased the serum IL-1beta, IL-6 and TNF-alpha levels of mice (P<0.05).	Mesalamine	21-26	interleukin 6	Mus musculus	71-75
34896691-7	2022	Furthermore, HM treatment resulted in a notable reduction in the mRNA expression of Th1 cytokines (TNF-alpha and IFN-gamma), Th2 cytokines (IL-4 and IL-6), Th17 (IL-17), and TSLP.	hm treatment	13-25	interleukin 6	Mus musculus	149-153
34970349-12	2022	In addition the protein expression levels of RIP1 and RIP3 and the cytokines NF-kappaB, TNF-alpha, IL-1beta and IL-6 were downregulated compared with the TBI group, which demonstrated that hydrogen-rich saline-induced inhibition of necroptosis and neuroinflammation ameliorated neuronal death following TBI.	Hydrogen	189-197	interleukin 6	Mus musculus	112-116
34970349-12	2022	In addition the protein expression levels of RIP1 and RIP3 and the cytokines NF-kappaB, TNF-alpha, IL-1beta and IL-6 were downregulated compared with the TBI group, which demonstrated that hydrogen-rich saline-induced inhibition of necroptosis and neuroinflammation ameliorated neuronal death following TBI.	Sodium Chloride	203-209	interleukin 6	Mus musculus	112-116
34779007-6	2022	In CCL21-induced arthritis and differentiated RA MPhis, the inflammatory imprint was uniquely intercepted by 2-DG via IL-6 downregulation.	Deoxyglucose	109-113	interleukin 6	Mus musculus	118-122
34409550-8	2022	Emodin also inhibited the expression of NLRP3 and reduced the levels of pro-inflammatory factors, including interleukin-1 beta (IL-1beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha).	Emodin	0-6	interleukin 6	Mus musculus	139-143
34862858-7	2022	Compared to the lipopolysaccharide (LPS) group and the LPS + exosome + Ah6809 group, the lipopolysaccharide (LPS) + exosome group and the LPS + butaprost group showed a significant decrease in alpha-SMA expression, a decrease in the number of F4/80+ CD86+ and F4/80+ CD206+ cells, a decrease in interleukin (IL)-6 and an increase in IL-10 levels.	6-isopropoxy-9-oxoxanthene-2-carboxylic acid	71-77	interleukin 6	Mus musculus	295-313
34821534-5	2022	RESULTS: MCXB significantly inhibited the LPS-stimulated production of nitric oxide (NO), prostaglandin E2 (PGE2), interleukin-6 (IL-6), and tumor necrosis factor (TNF)-alpha in RAW264.7 and BV2 cells.	macluraxanthone B	9-13	interleukin 6	Mus musculus	115-128
34821534-5	2022	RESULTS: MCXB significantly inhibited the LPS-stimulated production of nitric oxide (NO), prostaglandin E2 (PGE2), interleukin-6 (IL-6), and tumor necrosis factor (TNF)-alpha in RAW264.7 and BV2 cells.	macluraxanthone B	9-13	interleukin 6	Mus musculus	130-134
34974400-12	2022	In addition, (R)-BMB decreased the expression of IL-6, IL-17, retinoic acid receptor-related orphan receptor-gamma t (RORt), and phosphorylated STAT3 (p-STAT3) in a dose-dependent manner in the colon tissues.	(r)-bmb	13-20	interleukin 6	Mus musculus	49-53
34346509-6	2022	Resveratrol could significantly upregulate the secretion of secretory immunoglobulin A and promote the transcriptional levels of test cytokines, including tumor necrosis factor alpha, interferon-gamma, interleukin-4 and interleukin-6 in jejunum and ileum mucosa, suggesting improved intestinal immune barrier by resveratrol.	Resveratrol	0-11	interleukin 6	Mus musculus	220-233
34953890-7	2022	Moreover, cytotoxic T cells were professionally induced in mice receiving TEX-miR-34a and the secretion of interleukin (IL)-6, IL-17A and tumor necrosis factor (TGF)-beta was reduced in DLNs.	tex-mir-34a	74-85	interleukin 6	Mus musculus	107-125
34913079-12	2022	WLGO treatment also reduced the concentration and mRNA expression levels of proinflammatory cytokines, including interleukin-1beta, interleukin-6 and tumor necrosis factor alpha, in DSS-induced UC model mice and lipopolysaccharide-treated Caco-2 cells.	wlgo	0-4	interleukin 6	Mus musculus	132-145
34894076-7	2022	Short-term vitamin D3 supplementation prevented Lipopolysaccharide-induced ALI by preventing pro-inflammatory cytokines including IL-1beta, IL-6, and TNF-alpha.	Cholecalciferol	11-21	interleukin 6	Mus musculus	140-144
34826047-4	2022	In this study, the level of interleukin (IL)-6 in the hippocampus of mice and N2A cells treated with sevoflurane was increased, and long noncoding RNA (LncRNA) Riken was sufficient to decrease sevoflurane-induced neurotoxicity, and the level of inflammatory cytokine IL-6.	Sevoflurane	101-112	interleukin 6	Mus musculus	28-46
34826047-4	2022	In this study, the level of interleukin (IL)-6 in the hippocampus of mice and N2A cells treated with sevoflurane was increased, and long noncoding RNA (LncRNA) Riken was sufficient to decrease sevoflurane-induced neurotoxicity, and the level of inflammatory cytokine IL-6.	Sevoflurane	193-204	interleukin 6	Mus musculus	28-46
34826047-8	2022	Finally, we also demonstrated that MAPK phosphatase 1 (MKP-1) was a downstream target of miR-101a, and lncRNA Riken can regulate the expression of MKP-1; the JNK signal transduction pathway has been implicated in sevoflurane-induced IL-6 secretion.	Sevoflurane	213-224	interleukin 6	Mus musculus	233-237
34863858-7	2022	Besides, the M1 markers expression (IL-6, TNF-alpha and IL-1beta) were significantly increased after PQ treatment, which suggested that PQ induced the increase of M1 phenotype of BV-2 microglia.	Paraquat	101-103	interleukin 6	Mus musculus	36-40
34742568-10	2022	The expression of plasminogen-activating inhibitor, interleukin-1, interleukin-6, tumor necrosis factor-alpha, vascular endothelial growth factor, malondialdehyde, and nitric oxide was decreased, while the expression of tissue-type plasminogen activator, glutathione, superoxide dismutase, and Nrf2 was increased in the peritoneal ischemic buttons after mitoquinone treatment.	mitoquinone	354-365	interleukin 6	Mus musculus	67-80
34863858-7	2022	Besides, the M1 markers expression (IL-6, TNF-alpha and IL-1beta) were significantly increased after PQ treatment, which suggested that PQ induced the increase of M1 phenotype of BV-2 microglia.	Paraquat	136-138	interleukin 6	Mus musculus	36-40
34606948-10	2022	XFBD can reduce bleomycin-induced pulmonary fibrosis by inhibiting IL-6/STAT3 activation and related macrophage infiltration.	Bleomycin	16-25	interleukin 6	Mus musculus	67-71
34416296-13	2022	QFZTC inhibited the expression of the c-Fos pain marker and reduced the expression of the TNF-alpha, IL-6, and IL-1beta inflammatory factors.	qfztc	0-5	interleukin 6	Mus musculus	101-105
34896465-6	2022	Importantly, AMP prevented the over-expression of proinflammatory cytokines TNF-alpha, IL-1beta and IL-6, and decreased the infiltration of neutrophils in colon.	Adenosine Monophosphate	13-16	interleukin 6	Mus musculus	100-104
34364971-16	2022	In addition, CO99EL strongly inhibited LPS-induced interleukin (IL)-1beta, IL-6, IL-27, and C-C motif chemokine ligand (CCL)-1 production and directly inhibited LPS-induced JAK/STAT phosphorylation in RAW264.7 cells.	co99el	13-19	interleukin 6	Mus musculus	75-79
34823118-5	2022	In PP, IFN-gamma+/CD4+ T or IL-6+/CD4+ T cell numbers were higher in the muscarine or atropine groups, respectively.	Atropine	86-94	interleukin 6	Mus musculus	28-32
34826699-2	2022	As interleukin-6 (IL-6) is overexpressed in sunitinib-resistant cells, the purpose of this study was to explore the potential of IL-6 inhibition with tocilizumab, an IL-6 receptor inhibitor, to overcome resistance.	Sunitinib	44-53	interleukin 6	Mus musculus	3-16
34520827-14	2022	DHDMP significantly decreased the production of proinflammatory mediators, such as nitric oxide, tumor necrosis factor-alpha, interleukin-6, inducible nitric oxide synthase, and cyclooxygenase-2 in BV2 cells.	2,3-dihydro-5,6-dimethylpyrazine	0-5	interleukin 6	Mus musculus	126-139
34704526-7	2022	The expression levels of HMGB1, tumor necrosis factor-alpha and interleukin-6 in both the serum and myocardium were upregulated in response to TAC, while they were significantly reduced by losartan.	tac	143-146	interleukin 6	Mus musculus	64-77
34704526-7	2022	The expression levels of HMGB1, tumor necrosis factor-alpha and interleukin-6 in both the serum and myocardium were upregulated in response to TAC, while they were significantly reduced by losartan.	Losartan	189-197	interleukin 6	Mus musculus	64-77
34826699-2	2022	As interleukin-6 (IL-6) is overexpressed in sunitinib-resistant cells, the purpose of this study was to explore the potential of IL-6 inhibition with tocilizumab, an IL-6 receptor inhibitor, to overcome resistance.	Sunitinib	44-53	interleukin 6	Mus musculus	18-22
34826699-2	2022	As interleukin-6 (IL-6) is overexpressed in sunitinib-resistant cells, the purpose of this study was to explore the potential of IL-6 inhibition with tocilizumab, an IL-6 receptor inhibitor, to overcome resistance.	Sunitinib	44-53	interleukin 6	Mus musculus	129-133
34826699-7	2022	In vitro, tocilizumab induced significant cell death, and reduced the expression of IL-6, VEGF, and Bcl-2 in sunitinib-resistant cells.	Sunitinib	109-118	interleukin 6	Mus musculus	84-88
34864308-4	2022	In the non-toxic concentration range (from 20 to 100 muM), cristacarpin suppressed pro-inflammatory mediators such as interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha, while stimulating anti-inflammatory mediators such as IL-4 and IL-10 in LPS-stimulated RAW 264.7 cells and uveitis mouse models.	cristacarpin	59-71	interleukin 6	Mus musculus	118-136
34581003-6	2022	m17.ASC spheroids efficiently reduced the lipopolysaccharide-induced increase in plasma concentrations of interleukin-6 and tumor necrosis factor-alpha.	asc spheroids	4-17	interleukin 6	Mus musculus	106-119
34775235-5	2022	In addition, DA-9805 prevented the production of IL-1beta, IL-6, TNF-alpha and nitric oxide through inhibition of NF-kappaB activation in BV2 microglial cells stimulated with lipopolysaccharides (LPS).	da-9805	13-20	interleukin 6	Mus musculus	59-63
34697081-7	2022	When exposed to a low dose of CPT-11 (10 mg/kg), hUGT1A1HEP mice displayed greater intestinal inflammatory (IL-1beta and IL-6) insult in addition to p53-triggered apoptotic responses.	Irinotecan	30-36	interleukin 6	Mus musculus	121-125
34819259-7	2022	AZI pretreatment elevated the levels of IL-4, IL-6, and IL-17A in the ear skin of AD model mice, but it increased serum TNF-alpha and IL-6.	Azithromycin	0-3	interleukin 6	Mus musculus	134-138
34819259-7	2022	AZI pretreatment elevated the levels of IL-4, IL-6, and IL-17A in the ear skin of AD model mice, but it increased serum TNF-alpha and IL-6.	Azithromycin	0-3	interleukin 6	Mus musculus	46-50
34915410-11	2022	DMF reduced the secretion of TNF-alpha and IL-6 whereas increased the secretion of IL-10 and Arg-1 in BMDMs after LPS stimulation.	Dimethyl Fumarate	0-3	interleukin 6	Mus musculus	43-47
34859959-10	2022	Furthermore, pancreas isolated from KC mice fed with an ethanol-containing diet show higher expression of inflammatory cytokines (TNF-alpha, IL-6, and IL-8) and PTGS-2 (COX-2) gene than those isolated from mice fed with a control diet.	Ethanol	56-63	interleukin 6	Mus musculus	141-145
34364883-9	2022	Gene expression analysis identified upregulation of Mxa, Il1b, Tnfa, Il6, Il12, Il23, Il17 and Ifng in TG>WT>KO following IMQ treatment.	Imiquimod	122-125	interleukin 6	Mus musculus	69-72
34813868-6	2022	IL-6 content in serum of mice was significantly higher than that of the control group provided with cyclophosphamide (CTX).	Cyclophosphamide	100-116	interleukin 6	Mus musculus	0-4
34861585-9	2022	The circulating level of IL-6 but not TNF-alpha was significantly decreased by AL.	alantolactone	79-81	interleukin 6	Mus musculus	25-29
34716926-13	2022	PM-treated mice exhibited the lower expression of IL-6 and VCAM-1 in gingival tissues if they previously received surfactin.	surfactin peptide	114-123	interleukin 6	Mus musculus	50-54
34843736-9	2022	Overexpression of IL-9 relieved the injury and reduced the serum levels of IL-6, TNF-alpha in EtOH-induced ALI mouse model.	Ethanol	94-98	interleukin 6	Mus musculus	75-79
34843736-11	2022	In vitro, mouse recombinant protein IL-9 inhibited the expression of IL-6, TNF-alpha in EtOH-induced RAW264.7 cells.	Ethanol	88-92	interleukin 6	Mus musculus	69-73
34861585-12	2022	AL also ameliorated C2C12 myotube atrophy induced by IL-6 and inhibited IL-6-mediated STAT3 activation.	alantolactone	0-2	interleukin 6	Mus musculus	53-57
34861585-12	2022	AL also ameliorated C2C12 myotube atrophy induced by IL-6 and inhibited IL-6-mediated STAT3 activation.	alantolactone	0-2	interleukin 6	Mus musculus	72-76
34978399-9	2021	Similarly, there was a 9-fold reduction in interleukin-6 produced in RAW 264.7 cells when exposed to the highest concentration of SPL.	SPL	130-133	interleukin 6	Mus musculus	43-56
34718095-7	2022	Of note, AO induced hepatotoxicity in a gender-dependent manner, characterized by liver dysfunction, increased hepatocyte necrosis with inflammatory infiltration, and up-regulated mRNAs of Il-6, Tnf-alpha and monocyte chemotactic protein 1(Mcp1) in the female mice after 28-day oral administration.	aurantio-obtusin	9-11	interleukin 6	Mus musculus	189-193
34974362-6	2021	The expression of P-IKK protein, PP65 protein and P-STAT3 protein increased in the TCE sensitization positive group, and the downstream inflammatory factors IL-1beta and IL-6 also increased in the TCE sensitization positive group.	Trichloroethylene	83-86	interleukin 6	Mus musculus	170-174
34974362-6	2021	The expression of P-IKK protein, PP65 protein and P-STAT3 protein increased in the TCE sensitization positive group, and the downstream inflammatory factors IL-1beta and IL-6 also increased in the TCE sensitization positive group.	Trichloroethylene	197-200	interleukin 6	Mus musculus	170-174
34964214-8	2022	Furthermore, protein expression of phosphorylated nuclear factor kappa light chain enhancer of activated B cells (pNFkappaB65), proliferating cell nuclear antigen, interleukin-6, apoptosis-associated speck-like protein containing a caspase-recruitment domain, and cysteine-containing aspartate-specific proteases-1 (caspase-1) significantly increased in the DSS + DB group of male animals as compared to female.	Dextran Sulfate	358-361	interleukin 6	Mus musculus	164-218
34974362-7	2021	After using the TNFR1 inhibitor R7050, we found that M1 Kupffer cell polarization, TNF-alpha expression, signal pathway expression and inflammatory factors IL-1beta and IL-6 expression declined, and the liver damage relieved.	R-7050	32-37	interleukin 6	Mus musculus	169-173
34958971-11	2022	The mice implanted with the bio-mimicking M2-PCL nanofibers effectively inhibited toll like receptors signaling induced NF-kB and IRF-5 and their target genes such as Edn-1, IL-6, iNOS, TNF-alpha, etc.	polycaprolactone	45-48	interleukin 6	Mus musculus	174-178
34961864-7	2021	The results showed that, compared with control group, LPS/D-Gal enhanced ALT and AST activity, increased TNF-alpha and IL-6 levels, as well as MPO activity, up-regulated LC3-II and P62 protein expression levels, and significantly induced pathological damage in liver tissue.	Galactose	58-63	interleukin 6	Mus musculus	119-123
34939324-3	2022	It was found that boc-leucine mono peimisine ester monoamide (compound G, 25 mug mL-1 ) had increased cell survival rate and reduced the TNF-alpha, IL-1beta, IL-6 and iNOS levels in RAW 264.7 by LPS stimulated.	Leucine	22-29	interleukin 6	Mus musculus	158-162
34939529-10	2021	The extract inhibited NO and IL-6 production at 100 and 200 microg/mL, while flavonoid-rich fraction possessed significant anti-inflammatory activity at the concentration of 50 and 100 microg/mL via NO and IL-6 production, respectively.	Flavonoids	77-86	interleukin 6	Mus musculus	206-210
34987380-10	2021	In addition, emodin could inhibit the expressions of TNF-alpha, IL-6 and MDA in serum and tissue, and increase the levels of SOD and GSH.	Emodin	13-19	interleukin 6	Mus musculus	64-68
34931590-5	2022	Curcumin effectively upregulated the change rate of mouse weight, colonic length, down-regulated colonic weight, index of colonic weight, colonic damage score and the levels of pro-inflammatory cytokines IL-6, IL-12, IL-23 and TGF-(Formula: see text)1 in colonic tissues of colitis mice.	Curcumin	0-8	interleukin 6	Mus musculus	204-208
34987397-4	2021	In this study, fluorofenidone alleviated lung tissue structure injury and reduced mortality, decreased the pulmonary inflammatory cell accumulation and level of inflammatory cytokines IL-1beta, IL-6, and TNF-alpha in the bronchoalveolar lavage fluid, and attenuated pulmonary apoptosis in LPS-induced ALI mice.	5-methyl-1-(3-fluorophenyl)-2-(1H)-pyridone	15-29	interleukin 6	Mus musculus	194-198
34959718-0	2021	Protective Effect of Carotenoid Extract from Orange-Fleshed Sweet Potato on Gastric Ulcer in Mice by Inhibition of NO, IL-6 and PGE2 Production.	Carotenoids	21-31	interleukin 6	Mus musculus	119-123
34945705-6	2021	In addition, the production of cytokines (TNF-alpha, IL-1beta, and IL-6) in cells treated with poricoic acid B decreased in a dose-dependent manner in the concentration range from 10 to 40 mug/mL.	Poricoic acid B	95-110	interleukin 6	Mus musculus	67-71
34943110-0	2021	An Intercellular Flow of Glutathione Regulated by Interleukin 6 Links Astrocytes and the Liver in the Pathophysiology of Amyotrophic Lateral Sclerosis.	Glutathione	25-36	interleukin 6	Mus musculus	50-63
34949747-7	2022	In addition, GBP significantly stimulated mRNA expression levels of immune-associated genes including interleukin-1beta (IL-1beta), IL-2, IL-4, IL-6, tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), Toll-like receptor 4 (TLR-4), and cyclooxygenase-2 (COX-2) in CY-treated mice.	Cyclophosphamide	283-285	interleukin 6	Mus musculus	144-148
34960054-6	2021	In addition, DMEE reduced the release of proinflammatory cytokines, mainly IL-6 and IL-1beta, in RAW 264.7 cells by inhibiting the phosphorylation of JNK, ERK and p65.	dmee	13-17	interleukin 6	Mus musculus	75-79
34960054-7	2021	Furthermore, treatment with DMEE increased the survival rate and decreased the level of IL-6 in plasma in LPS-induced septic shock mice.	dmee	28-32	interleukin 6	Mus musculus	88-92
34960054-8	2021	Our findings suggest that DMEE elicits an anti-inflammatory effect in LPS-stimulated RAW 264.7 macrophages and an anti-septic effect on septic mouse model through the inhibition of the ERK/JNK/NF-kappaB signaling cascades and production of IL-6.	dmee	26-30	interleukin 6	Mus musculus	240-244
34975889-5	2021	Intraperitoneal injections of Antcin K (10 mg/kg or 30 mg/kg) attenuated paw swelling, cartilage degradation and bone erosion, and decreased serum levels of TNF-alpha, IL-1beta, IL-8 in collagen-induced arthritis (CIA) mice; in further experiments, IL-6 levels were similarly reduced.	antcin K	30-38	interleukin 6	Mus musculus	249-253
34975482-4	2021	Furthermore, brevinin-2MP has been found to inhibit the lipopolysaccharide (LPS)-induced expression of pro-inflammatory NO, MCP-1, IL-6, and TNF-alpha via binding unidentified targets on the cell membrane and consequently suppressing the activation of MAPK/NF-kappaB signaling cascades induced by LPS in RAW 264.7 cells.	brevinin-2mp	13-25	interleukin 6	Mus musculus	131-135
34808102-6	2021	It was found that RSV could exert a protective role in CLP-induced ALI/ARDS, as evidenced by moderate levels of inflammatory cell infiltration and interstitial edema, as well as decreased levels of C-reactive protein (P<0.01), interleukin (IL)-6 (P<0.01), IL-1beta (P<0.01) and tumor necrosis factor-alpha (P<0.01).	Resveratrol	18-21	interleukin 6	Mus musculus	227-245
34426332-7	2021	In addition, propamocarb exposure significantly increased the mRNA levels of IL-1beta, TNF-alpha, ICAM-1, and VCAM-1 in the aorta and the serum IL-1beta, IL-6, and TNF-alpha levels in HFD groups treated with propamocarb.	propamocarb	13-24	interleukin 6	Mus musculus	154-158
34910341-10	2022	The expression levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-6, and inducible nitric oxide synthase (iNOs) were down-regulated after infection in caffeine-treated mice.	Caffeine	184-192	interleukin 6	Mus musculus	96-100
34970573-9	2021	Treatment with 8-OH-DPAT was associated with the gene expression of more inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) compared with treatment with WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	interleukin 6	Mus musculus	105-118
34970573-9	2021	Treatment with 8-OH-DPAT was associated with the gene expression of more inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) compared with treatment with WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	interleukin 6	Mus musculus	120-124
34970573-9	2021	Treatment with 8-OH-DPAT was associated with the gene expression of more inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) compared with treatment with WAY-100635.	N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide	278-288	interleukin 6	Mus musculus	105-118
34970573-9	2021	Treatment with 8-OH-DPAT was associated with the gene expression of more inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) compared with treatment with WAY-100635.	N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide	278-288	interleukin 6	Mus musculus	120-124
34426332-7	2021	In addition, propamocarb exposure significantly increased the mRNA levels of IL-1beta, TNF-alpha, ICAM-1, and VCAM-1 in the aorta and the serum IL-1beta, IL-6, and TNF-alpha levels in HFD groups treated with propamocarb.	propamocarb	208-219	interleukin 6	Mus musculus	154-158
34904193-9	2022	PECS-101 also decreased PTX-induced increase in Tnf, Il6, and Aif1 (Iba-1) gene expression in the DRGs and the loss of intra-epidermal nerve fibers.	pecs-101	0-8	interleukin 6	Mus musculus	53-56
34894925-9	2022	Moreover, high glucose increased the release of IL-1beta, IL-6, TNF-alpha, and MCP-1.	Glucose	15-22	interleukin 6	Mus musculus	58-62
34903784-6	2021	We find that, 4 h after the administration, both poly I:C and resiquimod elevated the levels of IL-6, TNFalpha, and chemokines including CCL2 and CCL5, in maternal plasma.	Poly I-C	49-57	interleukin 6	Mus musculus	96-100
34904193-9	2022	PECS-101 also decreased PTX-induced increase in Tnf, Il6, and Aif1 (Iba-1) gene expression in the DRGs and the loss of intra-epidermal nerve fibers.	Paclitaxel	24-27	interleukin 6	Mus musculus	53-56
34903784-6	2021	We find that, 4 h after the administration, both poly I:C and resiquimod elevated the levels of IL-6, TNFalpha, and chemokines including CCL2 and CCL5, in maternal plasma.	resiquimod	62-72	interleukin 6	Mus musculus	96-100
34895335-13	2021	Western blotting validated the anti-inflammatory effects of melatonin by downregulating interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) levels via the extracellular regulated kinase (ERK)/nuclear factor erythroid 2-related factor 2 (NRF2)/heme oxygenase-1 (HO-1) signaling pathway.	Melatonin	60-69	interleukin 6	Mus musculus	88-101
34938384-8	2021	Finally, ceftriaxone treatment increased the expression of the tight junction proteins zona occludens-1(ZO-1) and occludin in the colon, decreased the expression of the inflammation-related proteins TLR4, MyD88, and NF-kappaB in the colon, and decreased the serum concentration of the proinflammatory cytokines interleukin-1beta (IL-1beta), IL-6, and tumour necrosis factor-alpha (TNF-alpha).	Ceftriaxone	9-20	interleukin 6	Mus musculus	341-345
34895335-13	2021	Western blotting validated the anti-inflammatory effects of melatonin by downregulating interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) levels via the extracellular regulated kinase (ERK)/nuclear factor erythroid 2-related factor 2 (NRF2)/heme oxygenase-1 (HO-1) signaling pathway.	Melatonin	60-69	interleukin 6	Mus musculus	103-107
34895335-15	2021	In vivo experiments demonstrated that the newly formed bone in the melatonin plus Matrigel group had higher trabecular bone volume per tissue volume (BV/TV) and bone mineral density values with lower IL-6 and TNF-alpha levels than in the irradiation and the Matrigel groups (P < 0.05).	Melatonin	67-76	interleukin 6	Mus musculus	200-204
34903499-8	2021	RESULTS: DSS-induced colitis increased steatosis, inflammatory (IL-6, TNFalpha, NLRP3, MCP-1) as well as fibrotic (TGF-beta, alpha-SMA) mediator expression in HFD-FG mice.	Dextran Sulfate	9-12	interleukin 6	Mus musculus	64-68
34948107-11	2021	In addition, inflammatory cytokines such as granulocyte colony-stimulating factors (G-CSF), interleukin (IL)-6, and tumor necrosis factor alpha (TNF-alpha) were found to be significantly decreased after H2 treatment in both serum and brain lysates.	Deuterium	203-205	interleukin 6	Mus musculus	92-110
34955852-7	2021	Meanwhile, MaR1 administration obviously diminished pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, and MCP-1), downregulated BAX and cleaved caspase-3 expression, and upregulated BCL-2 expression in the injured kidney tissues and TCMK-1 cells.	7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid	11-15	interleukin 6	Mus musculus	91-95
34880414-0	2022	MiR-200c-3p targets SESN1 and represses the IL-6/AKT loop to prevent cholangiocyte activation and cholestatic liver fibrosis.	-200c-3p	3-11	interleukin 6	Mus musculus	44-48
34924815-9	2021	Butyrate supplementation resulted in a lower abundance of monocyte/macrophages in the bone marrow, as well as reduced circulating proinflammatory IL-6 levels compared to antibiotic- and control-treated mice.	Butyrates	0-8	interleukin 6	Mus musculus	146-150
34938192-6	2021	Additionally, PEG-Loxe considerably inhibited oxidative stress, decreased pro-inflammatory factor (TNF-alpha, IL-6, and MCP-1) levels, and increased anti-inflammatory factor IL-10 levels.	polyethylene glycol loxenatide	14-22	interleukin 6	Mus musculus	110-114
34736968-5	2021	Oral administration of niclosamide reduced TAC-induced increase of serum IL-6 in heart failure mice.	Niclosamide	23-34	interleukin 6	Mus musculus	73-77
34736968-7	2021	At the concentrations more than 0.1 muM, niclosamide reduced the increased interleukin- 6 (IL-6) mRNA expression in lipopolysaccharide (LPS)-stimulated RAW264.7 and THP-1 derived macrophages.	Niclosamide	41-52	interleukin 6	Mus musculus	75-89
34736968-5	2021	Oral administration of niclosamide reduced TAC-induced increase of serum IL-6 in heart failure mice.	tac	43-46	interleukin 6	Mus musculus	73-77
34736968-7	2021	At the concentrations more than 0.1 muM, niclosamide reduced the increased interleukin- 6 (IL-6) mRNA expression in lipopolysaccharide (LPS)-stimulated RAW264.7 and THP-1 derived macrophages.	Niclosamide	41-52	interleukin 6	Mus musculus	91-95
34736968-8	2021	In cultured primary cardiomyocytes and cardiac fibroblasts, niclosamide (more than 0.1 muM) suppressed IL-6- and phenylephrine-induced cardiomyocyte hypertrophy, and inhibited collagen secretion from cardiac fibroblasts.	Niclosamide	60-71	interleukin 6	Mus musculus	103-107
34863307-6	2021	The vitro model of asthma treated with miRNA-221-5p mimic resulted in the reduction of IL-6, IL-17, IL-21 and IL-22 levels, and induction of IL-10, IL-35 and TGF-beta levels.	mirna-221-5p	39-51	interleukin 6	Mus musculus	87-91
34736968-9	2021	In conclusion, niclosamide attenuates heart failure in mice and the underlying mechanisms include enhancing mitochondrial respiration of cardiomyocytes, inhibiting collagen secretion from cardiac fibroblasts, and reducing the elevated serum inflammatory mediator IL-6.	Niclosamide	15-26	interleukin 6	Mus musculus	263-267
34938991-7	2022	In vitro and vivo experiments demonstrated that PMMSN-RES decreased reactive oxygen species (ROS) and malondialdehyde (MDA), increased superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activities, reduced the expression of inflammatory (TNF-alpha, IL-1beta and IL-6) and apoptotic cytokines (cleaved caspase-3) in spinal cord tissue after SCI.	pmmsn-res	48-57	interleukin 6	Mus musculus	274-278
34860610-6	2022	Bel treatment reduced the sensitivities of model mice to mechanical and thermal stimulations, and it inhibited activation of microglia and the secretion of inflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 in tissues.	beta-elemene	0-3	interleukin 6	Mus musculus	252-256
34884834-8	2021	Moreover, in vivo imiquimod-induced psoriatic skin treated with ATCC12228EVs reduced the characteristic psoriatic skin features, such as acanthosis and cellular infiltrate, as well as VEGF-A, IL-6, KC, IL-23, IL-17F, IL-36gamma, and IL-36R expression in a more efficient manner than 983EVs; however, in contrast, Foxp3 expression did not significantly change, and IL-36 receptor antagonist (IL-36Ra) was found to be increased.	Imiquimod	18-27	interleukin 6	Mus musculus	192-196
34884834-8	2021	Moreover, in vivo imiquimod-induced psoriatic skin treated with ATCC12228EVs reduced the characteristic psoriatic skin features, such as acanthosis and cellular infiltrate, as well as VEGF-A, IL-6, KC, IL-23, IL-17F, IL-36gamma, and IL-36R expression in a more efficient manner than 983EVs; however, in contrast, Foxp3 expression did not significantly change, and IL-36 receptor antagonist (IL-36Ra) was found to be increased.	atcc12228evs	64-76	interleukin 6	Mus musculus	192-196
34192478-7	2021	SB and HFB-treated mice showed lower levels of leptin, IL-6, and TNF-alpha compared with the SC and HF groups (p<0.01).	Antimony	0-2	interleukin 6	Mus musculus	55-59
34945535-4	2021	Regarding anti-inflammatory activity, CEE and EtOAc reduced the production of NO and cytokine secretion (PGE2, IL-6, and IL-1beta) but displayed less effect on tumor necrosis factor alpha (TNF-alpha) release in lipopolysaccharide (LPS)-induced RAW 264.7 cells.	cee	38-41	interleukin 6	Mus musculus	111-115
34945535-4	2021	Regarding anti-inflammatory activity, CEE and EtOAc reduced the production of NO and cytokine secretion (PGE2, IL-6, and IL-1beta) but displayed less effect on tumor necrosis factor alpha (TNF-alpha) release in lipopolysaccharide (LPS)-induced RAW 264.7 cells.	ethyl acetate	46-51	interleukin 6	Mus musculus	111-115
34192478-7	2021	SB and HFB-treated mice showed lower levels of leptin, IL-6, and TNF-alpha compared with the SC and HF groups (p<0.01).	hexafluorobenzene	7-10	interleukin 6	Mus musculus	55-59
33380244-4	2021	Intraperitoneally administered 4-HPR particularly at dose of 100 mg/kg obviously alleviated UC symptoms and restrained the mRNA expression of colonic IL-1beta, IL-6, and TNF-alpha in dextran sulfate sodium (DSS)-induced mice.	Fenretinide	31-36	interleukin 6	Mus musculus	160-164
34895060-9	2021	Inhibiting HBP expression by injecting heparin before AP can alleviate pancreatic necrosis and inhibit F4/80 labeled M1 macrophage infiltration and IL-6, TNF-alpha, and iNOS mRNA expression.	Heparin	39-46	interleukin 6	Mus musculus	148-152
34895060-10	2021	Clodronate liposome (CLDL) intraperitoneally treated mice showed no change in pancreatic HBP levels, but pancreatic macrophage-specific antigen F4/80 and TNF-alpha, IL-1beta, and IL-6 mRNA levels decreased after CLDL treatment.	Clodronic Acid	0-10	interleukin 6	Mus musculus	179-183
34895060-11	2021	HBP is critical for pancreatic necrosis response in acute pancreatitis by increasing the infiltration of M1 macrophages and promoting the secretion of inflammatory factors, such as TNF-alpha, IL-6, IL-1beta, which can be reduced by heparin.	Heparin	232-239	interleukin 6	Mus musculus	192-196
34348577-3	2021	The results indicated that, N2O exposure elevated TXNIP/NLRP3 expression in vivo and in vitro, led to declined learning and memory capabilities in mice, reduced apoptosis rate in hippocampal neuron and Nissl bodies, elevated inflammatory factors TNF-alpha, IL-1beta and IL-6 levels, as well as cleaved caspase-3 and Bax expressions, and reduced Bcl-2 expression.	Nitrous Oxide	28-31	interleukin 6	Mus musculus	270-274
34697992-9	2021	Moreover, Valsartan significantly suppressed the expressions of pro-inflammatory cytokines such as macrophage chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) against high glucose.	Valsartan	10-19	interleukin 6	Mus musculus	148-161
34515620-9	2021	Levels of the inflammatory cytokines, interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha, were increased by treatment with isoproterenol; these increases were significantly reduced by lycorine, with involvement of the NF-kappaB signaling pathway.	Isoproterenol	134-147	interleukin 6	Mus musculus	62-66
34515620-9	2021	Levels of the inflammatory cytokines, interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha, were increased by treatment with isoproterenol; these increases were significantly reduced by lycorine, with involvement of the NF-kappaB signaling pathway.	lycorine	195-203	interleukin 6	Mus musculus	62-66
34697992-9	2021	Moreover, Valsartan significantly suppressed the expressions of pro-inflammatory cytokines such as macrophage chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) against high glucose.	Valsartan	10-19	interleukin 6	Mus musculus	163-167
34738873-3	2021	In vitro, p-CA decreases the expression of LPS/IFN-gamma-induced M1 macrophage markers (TNF-alpha, IL-6, iNOS and CCL2) and increases IL-4 induced M2 macrophages markers (IL-10, CD206, Arg1 and Mrc) in mouse bone marrow-derived macrophages (BMDMs).	p-coumaric acid	10-14	interleukin 6	Mus musculus	99-103
34460100-9	2021	Topical administration of H-151 attenuated the skin lesions in IMQ-induced psoriatic mouse model, while the secretion of proinflammatory cytokines (IL-17, IL-23 and IL-6), M1 macrophage infiltration and Th17 cells differentiation were significantly suppressed by H-151 treatment.	H-151	263-268	interleukin 6	Mus musculus	165-169
34783294-4	2021	Sevoflurane treatment caused inflammatory markers IL6, IL-10 and TNF-alpha high expression in primary hippocampal neurons and blood samples.	Sevoflurane	0-11	interleukin 6	Mus musculus	50-53
34783296-9	2021	DSS promotes pathological injury, the levels of pro-inflammatory factors containing tumor necrosis factor alpha (TNF-alpha), Interleukin- 6 (IL-6) and myeloperoxidase (MPO), and cell apoptosis in the mouse colon.	dss	0-3	interleukin 6	Mus musculus	125-139
34783296-9	2021	DSS promotes pathological injury, the levels of pro-inflammatory factors containing tumor necrosis factor alpha (TNF-alpha), Interleukin- 6 (IL-6) and myeloperoxidase (MPO), and cell apoptosis in the mouse colon.	dss	0-3	interleukin 6	Mus musculus	141-145
34612715-9	2021	The protective effects of PEMF on chondrocyte apoptosis and autophagy are regulated by TNF-alpha and IL-6 signaling.	pemf	26-30	interleukin 6	Mus musculus	101-105
34529884-6	2021	GO-Y030 also controlled the metabolism in cultured CD4+ T cells in the presence of TGF-beta + IL-6; however, it did not prevent Th17 differentiation.	1,5-bis(3,5-bis(methoxymethoxy)phenyl)penta-1,4-dien-3-one	0-7	interleukin 6	Mus musculus	94-98
33517789-10	2021	Real-time RT-PCR demonstrated that matrine could significantly reduce the expression of AKT1, TP53, TNF, IL6 and ATM in mice with liver injury or lung injury (P < 0.05), and increase the expression of BCL2L1 to a certain extent (P > 0.05).	matrine	35-42	interleukin 6	Mus musculus	105-108
34507070-6	2021	After treatment of the cells with DMF alone or with polymer carriers, the expression of IL-1beta, IL-6 and TNF-alpha cytokine genes was significantly reduced.	Dimethyl Fumarate	34-37	interleukin 6	Mus musculus	98-102
34487425-5	2021	LC3-II/LC3-I, Beclin-1, IL-6, and IL-1beta protein expression in the bladder smooth muscle tissues of ketamine-treated mice was significantly increased.	Ketamine	102-110	interleukin 6	Mus musculus	24-28
34618622-6	2021	Tofacitinib also showed anti-inflammatory effect by alleviating the cuprizone-induced increase in the central levels of interferon-gamma (IFN-gamma), interleukin (IL)-6, IL-1beta, and tumor necrosis alpha (TNF-alpha).	tofacitinib	0-11	interleukin 6	Mus musculus	150-168
34659514-9	2021	Furthermore, the levels of IL-6, cyclooxygenase-2, TNF-alpha and p65 were reduced after administration of DHEP.	diclofenac hydroxyethylpyrrolidine	106-110	interleukin 6	Mus musculus	27-31
34752732-5	2021	At low concentration Fh12 modulates the LPS-induced DCs maturation status by suppressing the MHC-II, and co-stimulatory molecules CD40 and CD80 surface expression together with the pro-inflammatory cytokines IL-12p70 and IL-6 production whereas increase the IL-10 levels.	fh12	21-25	interleukin 6	Mus musculus	221-225
34618622-6	2021	Tofacitinib also showed anti-inflammatory effect by alleviating the cuprizone-induced increase in the central levels of interferon-gamma (IFN-gamma), interleukin (IL)-6, IL-1beta, and tumor necrosis alpha (TNF-alpha).	Cuprizone	68-77	interleukin 6	Mus musculus	150-168
34523052-7	2021	The intestinal injuries induced by CS were also attenuated by berberine, which was associated with inhibition of the production of systemic IL-6, IL-1beta, and TNF-alpha.	Cesium	35-37	interleukin 6	Mus musculus	140-144
34523052-7	2021	The intestinal injuries induced by CS were also attenuated by berberine, which was associated with inhibition of the production of systemic IL-6, IL-1beta, and TNF-alpha.	Berberine	62-71	interleukin 6	Mus musculus	140-144
34085161-7	2021	Vanillin also suppressed the levels of TNF-alpha, IL-1beta, and IL-6 in BALF.	vanillin	0-8	interleukin 6	Mus musculus	64-68
34613566-7	2021	Our results revealed that treatment with LPS caused significant elevation in serum cytokine levels while administration of 50 and 100 mg/kg TRDF and TREF significantly reduced elevated serum levels of cytokines (TNF-alpha, IL-1beta, IL-6) in LPS-challenged mice.	trdf	140-144	interleukin 6	Mus musculus	233-237
34597702-5	2021	In dextran sulfate sodium (DSS) induced mouse-acute-colitis model, the results indicated that RSPP-A could down- regulate the secretion of IL-6 and IL-1beta, and promote the secretion of IL-10 in serum and colon, which also suggested that RSPP-A could enhance the contents of short chain fatty acids(SCFAs) and up-regulate the expression of G protein-coupled receptor (GPR41) in colon.	rspp-a	94-100	interleukin 6	Mus musculus	139-143
34597702-5	2021	In dextran sulfate sodium (DSS) induced mouse-acute-colitis model, the results indicated that RSPP-A could down- regulate the secretion of IL-6 and IL-1beta, and promote the secretion of IL-10 in serum and colon, which also suggested that RSPP-A could enhance the contents of short chain fatty acids(SCFAs) and up-regulate the expression of G protein-coupled receptor (GPR41) in colon.	rspp-a	239-245	interleukin 6	Mus musculus	139-143
34628148-6	2021	Meanwhile, BA pretreatment markedly attenuated T-2 toxin-induced renal inflammatory response by decreasing the mRNA expression of IL-1beta, TNF-alpha and IL-10, and increasing IL-6 mRNA expression.	betulinic acid	11-13	interleukin 6	Mus musculus	176-180
34613566-7	2021	Our results revealed that treatment with LPS caused significant elevation in serum cytokine levels while administration of 50 and 100 mg/kg TRDF and TREF significantly reduced elevated serum levels of cytokines (TNF-alpha, IL-1beta, IL-6) in LPS-challenged mice.	tref	149-153	interleukin 6	Mus musculus	233-237
34725110-6	2021	The Acsl4-deficient rpMACs stimulated with opZym also demonstrated an acute reduction in mRNA expression of the inflammatory cytokines, Il6, Ccl2, Nos2, and Ccl5 When Acsl4-deficient rpMACs were incubated in vitro with the TLR4 agonist, LPS, the levels of leukotriene B4 and PGE2 were also significantly decreased.	rpmacs	20-26	interleukin 6	Mus musculus	136-139
34784210-3	2021	Meanwhile, l-theanine pretreatment decreased the levels of TNF-alpha, IL-1beta, IL-6, iNOS, and COX2 on DSS-induced colitis.	theanine	11-21	interleukin 6	Mus musculus	80-84
34850494-6	2022	Treatment with daidzein (10, 25, and 50 microM/ml) to LPS-induced BV2 microglia exhibited significantly (p < 0.05) decreased NO, pro-inflammatory mediators PGE2, IL6, and IlL-1beta.	daidzein	15-23	interleukin 6	Mus musculus	162-165
34850494-8	2022	Additionally, levels of dopamine were significantly reduced, and pro-inflammatory mediators tumor necrosis factor alpha (TNF-alpha), IL-1beta, IL6 were found to be increased in MPTP-induced C57BL6 PD mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	177-181	interleukin 6	Mus musculus	143-146
34850494-9	2022	Administering daidzein significantly restored the functional levels of dopamine and pro-inflammatory mediators TNF-alpha, IL-1beta, IL6 to near normal physiology as seen in healthy C57BL6 mice controls.	daidzein	14-22	interleukin 6	Mus musculus	132-135
34725110-6	2021	The Acsl4-deficient rpMACs stimulated with opZym also demonstrated an acute reduction in mRNA expression of the inflammatory cytokines, Il6, Ccl2, Nos2, and Ccl5 When Acsl4-deficient rpMACs were incubated in vitro with the TLR4 agonist, LPS, the levels of leukotriene B4 and PGE2 were also significantly decreased.	rpmacs	183-189	interleukin 6	Mus musculus	136-139
34271099-4	2021	Mycelium fermentation of Lactobacillus rhamnosus (L. rhamnosus) EH8 strain yielded butyric acid, which can down-regulate the PDE4B expression and IL-6 secretion in macrophages.	Butyric Acid	83-95	interleukin 6	Mus musculus	146-150
34939379-8	2021	TP-E and CTP-E effectively inhibit the expression of iNOS and COX-2, thereby inhibiting its downstream proinflammatory regulators, the extracellular signal-related kinase-1/2, that decreases the expression of IL-1beta, IL-6 and TNF-alpha.	tp-e	0-4	interleukin 6	Mus musculus	219-223
34676584-5	2021	Cinnamaldehyde and eugenol pre-treatments decreased TNF-alpha, IL-1beta, and IL-6 levels as compared to LPS group at all concentrations.	cinnamaldehyde	0-14	interleukin 6	Mus musculus	77-81
34676584-5	2021	Cinnamaldehyde and eugenol pre-treatments decreased TNF-alpha, IL-1beta, and IL-6 levels as compared to LPS group at all concentrations.	Eugenol	19-26	interleukin 6	Mus musculus	77-81
34974662-6	2021	Macrophages stimulated with TCM produced higher levels of CCL2, IL-6, TNF-alpha, their mRNAs than macrophages stimulated with CM.	tcm	28-31	interleukin 6	Mus musculus	64-68
34491479-10	2021	EOAZ efficiently protected the hippocampus against KET-induced oxidative imbalance, IL-6 increments, and BDNF impairment.	eoaz	0-4	interleukin 6	Mus musculus	84-88
34939379-8	2021	TP-E and CTP-E effectively inhibit the expression of iNOS and COX-2, thereby inhibiting its downstream proinflammatory regulators, the extracellular signal-related kinase-1/2, that decreases the expression of IL-1beta, IL-6 and TNF-alpha.	ctp-e	9-14	interleukin 6	Mus musculus	219-223
34939382-6	2021	RESULTS: BQLM formula (2 and 10 g/kg, orally) significantly improved the damages of liver tissues and functions caused by ConA in mice, reduced the infiltration of inflammatory cells into liver and inhibited the inflammatory cytokine secretion of interferon-gamma, tumor necrosis factor-alpha and interleukin-6.	bqlm	9-13	interleukin 6	Mus musculus	297-310
34857278-5	2021	The addition of PSL-G decreased the levels of pro-inflammatory cytokines (e.g., IL-1alpha, IL-6, and TNF-alpha), but increased the level of the anti-inflammatory cytokine IL-10 in macrophages treated with lipopolysaccharide and/or interferon-gamma.	psl-g	16-21	interleukin 6	Mus musculus	91-95
34857262-4	2021	Results demonstrated that Chit-IOCO significantly reduced the expression of TNF-alpha and COX-2, while Chit-TPP-IOCO reduced IL-6 in the LPS-stimulated macrophages RAW264.7.	tetraphenylporphine sulfonate	108-111	interleukin 6	Mus musculus	125-129
34858556-11	2021	RESULTS: Serum IL-6 levels were significantly higher in the HFCD group than in groups fed a HFCD with PEITC or DIM.	phenethyl isothiocyanate	102-107	interleukin 6	Mus musculus	15-19
34857270-6	2021	In an anti-inflammatory assay, ZnO/DNA-HCl NGs significantly inhibited TNF-alpha, IL-6, iNOS and COX-2 expression in LPS-stimulated Raw264.7 cells.	Zinc Oxide	31-34	interleukin 6	Mus musculus	82-86
34857270-6	2021	In an anti-inflammatory assay, ZnO/DNA-HCl NGs significantly inhibited TNF-alpha, IL-6, iNOS and COX-2 expression in LPS-stimulated Raw264.7 cells.	Hydrochloric Acid	39-42	interleukin 6	Mus musculus	82-86
33907040-6	2021	The results revealed that rutin pretreatment reduced the expression of the proinflammatory cytokines tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 and increased the secretion of interleukin-10.	Rutin	26-31	interleukin 6	Mus musculus	153-166
34858556-11	2021	RESULTS: Serum IL-6 levels were significantly higher in the HFCD group than in groups fed a HFCD with PEITC or DIM.	3,3'-diindolylmethane	111-114	interleukin 6	Mus musculus	15-19
33556301-7	2021	RESULTS: In CIA mice, alantolactone at 50 mg/kg attenuated RA symptoms, including high arthritis scores, infiltrating inflammatory cells, synovial hyperplasia, bone erosion and levels of the proinflammatory cytokines TNF-alpha, IL-6 and IL-17A, but not IL-10 in paw tissues.	alantolactone	22-35	interleukin 6	Mus musculus	228-232
34537380-13	2021	The CB2 agonist HU308 strongly inhibited mBMDM M1-type polarization following stimulation with either IL-1beta or conditioned medium from IL-1beta-treated mFLS, which was characterized by reductions in Il1b, Mmp1b, and Il6 and increases in Cd206 gene expression.	HU 308	16-21	interleukin 6	Mus musculus	219-222
34357837-8	2021	Moreover, curcumin decreased the levels of IL-6 and TNF-alpha by 44.52 and 46.17%, respectively.	Curcumin	10-18	interleukin 6	Mus musculus	43-47
34214019-10	2021	Moreover, Sch A treatment repressed the proportions of iNOS+/Iba-1+ cells and IL-6 expression, while enhanced the proportions of Arg-1+/Iba-1+ cells and IL-10 expression in APP/PS1 mice.	schizandrin A	10-15	interleukin 6	Mus musculus	78-82
34214019-11	2021	In vitro, Sch A treatment reduced the proportions of CD16/32+ cells, iNOS expression and IL-6 levels (25.7 +- 5.3 pg/mL) repressed M1 polarisation, and enhanced the proportions of CD206 cells, Arg-1 expression and IL-10 levels (75.9 +- 12.8 pg/mL) in BV2 cells.	schizandrin A	10-15	interleukin 6	Mus musculus	89-93
34400214-6	2021	Exposure to LPS increased interleukin-1 beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF-alpha) in mice and HK-2 cells, but were reduced after Ala treatment.	alamandine	154-157	interleukin 6	Mus musculus	57-61
34669271-5	2021	Conversely, the LPS-induced secretion of RANTES, TIMP1, IL-6, and IL-10 was dramatically suppressed by FJU-C28.	fju-c28	103-110	interleukin 6	Mus musculus	56-60
34590530-11	2021	Pristimerin significantly reduced all cytokine levels: TNF-alpha by 18 +- 0.6 pg/mg, IL-1beta by 43 +- 1.3 pg/mg and IL-6 by 34 +- 1.12 pg/mg.	pristimerin	0-11	interleukin 6	Mus musculus	117-121
34757891-10	2021	Compared to OP mice, AU-treated mice exhibited decreased serum concentrations of TRAP5b (19.6% to 28.4%), IL-1 (12.2% to 12.6%), IL-6 (12.1%) and ROS (5.9% to 10.7%) and increased serum concentrations of SOD (14.6% to 19.4%) and CAT (17.2% to 27.4%).	aucubin	21-23	interleukin 6	Mus musculus	129-133
34669271-7	2021	FJU-C28 blocked the secretion of IL-6 and RANTES in LPS-activated macrophages by regulating the activation of JNK, p38 mitogen-activated protein kinase (MAPK) and nuclear factor-kappaB (NF-kappaB).	fju-c28	0-7	interleukin 6	Mus musculus	33-37
34669271-9	2021	FJU-C28 also reduced neutrophil infiltration in the interstitium, lung damage and circulating levels of IL-6 and RANTES in mice with systemic inflammation.	fju-c28	0-7	interleukin 6	Mus musculus	104-108
34669271-10	2021	In conclusion, these findings suggest that FJU-C28 possesses anti-inflammatory activities to prevent endotoxin-induced lung function decrease and lung damages by down-regulating proinflammatory cytokines including IL-6 and RANTES via suppressing the JNK, p38 MAPK and NF-kappaB signaling pathways.	fju-c28	43-50	interleukin 6	Mus musculus	214-218
34375775-17	2021	Finally, ELISA revealed that the property of ALA-PDT to stimulate transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF) and inhibit IL (interleukin) -1beta and IL-6 outweighed that of hUC-MSCs, and this function of the combination overwhelmed that of any single therapy.	Alanine	45-48	interleukin 6	Mus musculus	197-201
34773881-7	2021	The population of CD8+T cells, the ratio of CD8/CD4, and plasma interleukin-6 levels were increased by Ang II infusion, and were decreased by AC-11 both in pregnant and non-pregnant mice.	AC-11	142-147	interleukin 6	Mus musculus	64-77
34867011-9	2021	The TNF-alpha, IL-1beta, and IL-6 levels in the carrageenan-induced mice were effectively depleted by the butein.	Carrageenan	48-59	interleukin 6	Mus musculus	29-33
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	interleukin 6	Mus musculus	400-404
34187277-13	2021	These results delineate that THC prevents sepsis-induced AKI by suppressing inflammation and oxidative stress through activating the SIRT1 signaling.Abbreviation: Ac-p65: acetylated p65; Ac-foxo 1: acetylated forkhead box O1; AKI: acute kidney injury; BUN: blood urea nitrogen; CAT: catalase; DHE: dihydroethidium; GPx: glutathione peroxidase; GSH: reduced glutathione; IL-1beta: Interleukin-1 beta; IL-6: Interleukin-6; KIM-1: kidney injury molecule 1; MDA: malondialdehyde; SCr: serum creatinine; SIRT1: silent information regulator 1; SOD: superoxide dismutase; THC: tetrahydrocurcumin; TNF-alpha: tumor necrosis factor-alpha; TUNEL: TdT-mediated dUTP Nick-End Labeling; UAlb/Cr: urine micro albumin/creatinine.	tetrahydrocurcumin	29-32	interleukin 6	Mus musculus	406-419
34853335-12	2021	Cytokine analyses on the BALF revealed elevated levels of G-CSF, KC, IP-10, IL-6, and IL-5 in ozone-exposed mice.	Ozone	94-99	interleukin 6	Mus musculus	76-80
34867011-9	2021	The TNF-alpha, IL-1beta, and IL-6 levels in the carrageenan-induced mice were effectively depleted by the butein.	butein	106-112	interleukin 6	Mus musculus	29-33
34530192-8	2021	Levels of IL-10, IL-6, and VEGF in the cell free ascites of mice treated with CIS-platin decreased (p > .05).	Cisplatin	78-88	interleukin 6	Mus musculus	17-21
34884814-10	2021	Our results showed that TAK 242 significantly inhibited the production of inflammatory cytokines in the peritoneal lavage fluid of mice with peritonitis, including IL-6, IFN-gamma, IL-1beta, NO, and TNF-alpha.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	24-31	interleukin 6	Mus musculus	164-168
34884728-10	2021	Administration of ABR-238901 also inhibited the CLP-induced increase of CXCL-1, CXCL-2 and IL-6 in plasma and lungs.	ABR-238901	18-28	interleukin 6	Mus musculus	91-95
34726063-3	2021	Furthermore, siegesbeckialide I suppressed the protein expression of iNOS and COX2, as well as the release of PGE2, IL-1beta, IL-6, and TNF-alpha in LPS-stimulated RAW264.7 cells.	Siegesbeckialide I	13-31	interleukin 6	Mus musculus	126-130
34747418-4	2021	The D-gal-induced accelerated aging model in vivo demonstrated that Uro B could elevate the activities of superoxide dismutase, catalase, glutathione peroxidase, and total anti-oxidation capability, decrease malondialdehyde content, regulate the levels of inflammatory cytokines (IL-6, TNF-alpha, IFN-gamma, IL-4, and IL-1beta) in the small intestine, and reshape the composition of gut microbiota and decrease the intestinal barrier injury in aging mice.	urolithin B	68-73	interleukin 6	Mus musculus	280-284
34849108-6	2022	Further, D-CQNP potentially stimulate the RAW 264.7 cells through the production of nitric oxide (NO), upregulating inducible nitric oxide synthase (iNOS) and various pro-inflammatory cytokines including interleukin (IL)-1beta, IL-6, IL-10, and tumor necrosis factor-alpha (TNF-alpha).	d-cqnp	9-15	interleukin 6	Mus musculus	228-232
34836549-7	2021	The number of cells positive for ionized calcium-binding adaptor molecule 1 (Iba1), a glial fibrillary acidic protein (GFAP), increased with the high expression of interleukin 6 (IL-6) in Cx3cr1CreERIL-10-/- mice.	Calcium	41-48	interleukin 6	Mus musculus	164-177
34836549-7	2021	The number of cells positive for ionized calcium-binding adaptor molecule 1 (Iba1), a glial fibrillary acidic protein (GFAP), increased with the high expression of interleukin 6 (IL-6) in Cx3cr1CreERIL-10-/- mice.	Calcium	41-48	interleukin 6	Mus musculus	179-183
34818963-4	2022	DMXAA exposure resulted in modest apoptosis of C1498 AML cells with a subtle increase in PD-L1 expression and limited production of IL-6 and IFN-beta.	vadimezan	0-5	interleukin 6	Mus musculus	132-136
34956620-8	2021	In HK-2 cells, fructose promoted the secretion of TNF-alpha, IL-1beta and IL-6 and increased the levels of RAGE, p-IkappaBalpha, p-NF-kappaB, bax, caspase-3 and caspase-9, but decreased the levels of Bcl-2.	Fructose	15-23	interleukin 6	Mus musculus	74-78
34840584-8	2021	CPP upregulated the contents of cytokines (IL-2, IL-6, IFN-gamma, and TNF-alpha) in serum, which were downregulated by cyclophosphamide.	Cyclophosphamide	119-135	interleukin 6	Mus musculus	49-53
34887852-11	2021	Buparlisib and dactolisib further reduced cellular redox, mitochondrial membrane potential, cleaved caspase-3 and p53, nuclear integrity, and attenuated NF-kappaB, IL-1beta, IL-6, TNF-alpha, and TGF-beta1 and TGF-beta2 signaling both in vitro and in vivo post-PILO and LPS+PILO inductions; however, rapamycin mitigated the same only in the PILO model.	NVP-BKM120	0-10	interleukin 6	Mus musculus	174-178
34899328-12	2021	Geniposide treatment also decreased the levels of interleukin (IL)-6, IL-1beta, and tumor necrosis factor-alpha (TNF-a) in liver tissue homogenate.	geniposide	0-10	interleukin 6	Mus musculus	50-68
34821076-8	2022	Mice lacking Il6st, encoding gp130, in myocytes (cKO) and WT controls, as well as mice treated with the JAK2 inhibitor AG490 or vehicle were exposed to CLP or sham surgery for 24 or 96 h. RESULTS: Analyses of differentially expressed genes in RNAseq (>=2-log2-fold change, P < 0.01) revealed an activation of IL-6-signalling and JAK/STAT-signalling pathways in muscle of septic mice, which occurred after 24 h and lasted at least for 96 h during sepsis.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	119-124	interleukin 6	Mus musculus	309-313
34887852-11	2021	Buparlisib and dactolisib further reduced cellular redox, mitochondrial membrane potential, cleaved caspase-3 and p53, nuclear integrity, and attenuated NF-kappaB, IL-1beta, IL-6, TNF-alpha, and TGF-beta1 and TGF-beta2 signaling both in vitro and in vivo post-PILO and LPS+PILO inductions; however, rapamycin mitigated the same only in the PILO model.	dactolisib	15-25	interleukin 6	Mus musculus	174-178
34858728-10	2021	Further study revealed that the expressions of IL-6 and JAK/STAT3 signaling pathways were upregulated by chronic stress in mice, and this upregulation could be inhibited by propranolol.	Propranolol	173-184	interleukin 6	Mus musculus	47-51
34858728-12	2021	Besides, propranolol inhibited the expression of IL-6 in supernatant of 4T1 cells induced by isoproterenol and reduced the proportion of inducible MDSCs in vitro.	Propranolol	9-20	interleukin 6	Mus musculus	49-53
34858728-12	2021	Besides, propranolol inhibited the expression of IL-6 in supernatant of 4T1 cells induced by isoproterenol and reduced the proportion of inducible MDSCs in vitro.	Isoproterenol	93-106	interleukin 6	Mus musculus	49-53
34880751-7	2021	Cinacalcet also reduced production of the inflammatory cytokines TNFalpha, IL-1beta, and IL-6 in the colon and sera of mice with DSS-induced colitis.	Cinacalcet	0-10	interleukin 6	Mus musculus	89-93
34806822-9	2022	In lipopolysaccharide (LPS) treated cell model, emodin treatment markedly decreased LPS-induced release of IL-1, IL-6, and tumor necrosis factor (TNF)-alpha, inhibited LPS-induced cell apoptosis and suppressed protein levels of P-P65/P65 and HMGB1.	Emodin	48-54	interleukin 6	Mus musculus	113-117
34808003-8	2021	Inflammatory markers such as interleukins, IL-1beta and IL-6, and TNF- decreased significantly in the EBN groups.	CHEMBL3344321	102-105	interleukin 6	Mus musculus	56-60
34624394-5	2021	In addition, scutellarin inhibited LPS-induced elevation of TNFalpha, IL-1beta, IL-6 and iNOS, and reversed the downregulation of IL-4 and BDNF in astrocytes in vitro.	scutellarin	13-24	interleukin 6	Mus musculus	80-84
34880751-8	2021	In vitro studies revealed that cinacalcet suppressed the translocation of P65 and inhibited production of the inflammatory cytokines IL-1beta and IL-6.	Cinacalcet	31-41	interleukin 6	Mus musculus	146-150
34794379-14	2021	The in vivo expressions of IL-1beta, IL-6, and TNF-alpha were suppressed by TBHQ treatment.	2-tert-butylhydroquinone	76-80	interleukin 6	Mus musculus	37-41
34827723-7	2021	On the other hand, the levels of myeloperoxidase (MPO) and interleukin (IL)-6 significantly decreased in DOX-treated adult animals.	Doxorubicin	105-108	interleukin 6	Mus musculus	59-77
34867346-4	2021	Interestingly, compared with LPS treatment group, remimazolam remarkably improved survival rate of endotoxemia mice and decreased the release of LPS-induced inflammatory mediators (such as TNF-alpha, IL-6, and IL-1beta).	remimazolam	50-61	interleukin 6	Mus musculus	200-204
34830364-5	2021	Treatment of primary murine macrophages with two different statins, i.e., simvastatin and cerivastatin, impaired phagocytotic activity and, concurrently, enhanced pro-inflammatory responses upon short-term lipopolysaccharide challenge, as characterized by an induction of tumor necrosis factor (TNF), interleukin (IL) 1beta, and IL6.	Simvastatin	74-85	interleukin 6	Mus musculus	329-332
34830364-5	2021	Treatment of primary murine macrophages with two different statins, i.e., simvastatin and cerivastatin, impaired phagocytotic activity and, concurrently, enhanced pro-inflammatory responses upon short-term lipopolysaccharide challenge, as characterized by an induction of tumor necrosis factor (TNF), interleukin (IL) 1beta, and IL6.	cerivastatin	90-102	interleukin 6	Mus musculus	329-332
34511050-6	2021	Treatment with NK112 also improved K1-induced myeloperoxidase activity, IL-6 and TNF-alpha expression, and NF-kappaB activation in the colon and reduced K1-induced Proteobacteria population in the gut microbiota.	nk112	15-20	interleukin 6	Mus musculus	72-76
34789242-6	2021	Knockdown of circFOXO3 attenuated the release of CXCL1 and IL-6 as well as inflammatory processes in the lungs of CS-exposed mice.	circfoxo3	13-22	interleukin 6	Mus musculus	59-63
34784929-6	2021	RESULTS: Compared with CS plus LPS-exposed mice, mice in the PJH-treated group showed significantly decreased inflammatory cells count and reduced inflammatory cytokines including interleukin-1 beta (IL-1beta), IL-6 and tumor necrosis factor alpha (TNF-alpha) levels in broncho-alveolar lavage fluid (BALF) and lung tissue.	N-Methylnicotinamide	61-64	interleukin 6	Mus musculus	211-215
34832320-5	2021	Here, we show that ADL reduced lipopolysaccharide (LPS)-induced macrophage polarization of the pro-inflammatory (M1) phenotype, indicated by attenuated Interleukin 1 (IL1), Interleukine 6 (IL6)and cyclooxygenase 2 (COX2) expression.	ADL	19-22	interleukin 6	Mus musculus	189-192
34832320-7	2021	Similarly, when RAW 264.7 macrophages were incubated with other agonists of Toll-like receptor (TLR) signaling e.g., FSL1, Polyinosinic-polycytidylic acid High Molecular Weight (Poly (1:C) HMW), Pam3CSK4, and imiquimod, ADL reduced the IL6 expression.	Poly I-C	123-154	interleukin 6	Mus musculus	236-239
34789242-6	2021	Knockdown of circFOXO3 attenuated the release of CXCL1 and IL-6 as well as inflammatory processes in the lungs of CS-exposed mice.	Cesium	114-116	interleukin 6	Mus musculus	59-63
34668909-2	2021	Sulfated polysaccharide from pacific abalone (AGSP) reduced the level of lipopolysaccharides (LPS) and increased the production of short chain fatty acids in the colon of mice, and it reduced the levels of interleukin (IL)-6, IL-1beta and tumor necrosis factor (TNF)-alpha and increased the IL-10 level in in vitro cell models, suggesting that it can be used as a probiotic agent to inhibit intestinal inflammation.	sulfated polysaccharide	0-23	interleukin 6	Mus musculus	206-224
34668909-2	2021	Sulfated polysaccharide from pacific abalone (AGSP) reduced the level of lipopolysaccharides (LPS) and increased the production of short chain fatty acids in the colon of mice, and it reduced the levels of interleukin (IL)-6, IL-1beta and tumor necrosis factor (TNF)-alpha and increased the IL-10 level in in vitro cell models, suggesting that it can be used as a probiotic agent to inhibit intestinal inflammation.	agsp	46-50	interleukin 6	Mus musculus	206-224
34673859-5	2021	qPCR results indicated that DHQ supplementation significantly downregulated IL-1beta, IL-6, and TNF-alpha, and upregulated IL-10 gene mRNA expression.	taxifolin	28-31	interleukin 6	Mus musculus	86-90
34311061-14	2021	Both ABEA and ABA reduced LPS-mediated expression of TNF-alpha, IL-6, iNOS, and COX-2 at both mRNA and protein levels.	Abscisic Acid	14-17	interleukin 6	Mus musculus	64-68
34311061-19	2021	The mechanism used by the AB involves the scavenging of free radicals and the reduction of proinflammatory mediators, including IL-1beta, IL-6, TNF-alpha, NO, iNOS and COX-2.	ab	26-28	interleukin 6	Mus musculus	138-142
34332065-13	2021	The levels of IL-1beta, IL-6, and TNF-alpha in serum were suppressed in mice treated with VYE as compared to the DNCB-induced model group.	Dinitrochlorobenzene	113-117	interleukin 6	Mus musculus	24-28
34339793-11	2021	SZ-A reduced the levels of IL-6 and TNF-alpha secreted by LPS-induced RAW264.7 and BMDM cells.	sz-a	0-4	interleukin 6	Mus musculus	27-31
34339793-12	2021	Simultaneously, the mRNA expression levels of IL-6 and TNF-alpha were all significantly suppressed by SZ-A in a concentration-dependent manner.	sz-a	102-106	interleukin 6	Mus musculus	46-50
34774071-9	2021	Inhibition of glycolysis by 2-DG significantly alleviated the surgical trauma induced increase of M1 (CD86+CD206-) phenotype in enriched microglia from hippocampus and up-regulation of pro-inflammatory mediators (IL-1beta and IL-6) expression in hippocampus.	Deoxyglucose	28-32	interleukin 6	Mus musculus	226-230
34339793-14	2021	We also observed that DNJ, DAB, FAG, and ARG markedly downregulated IL-6 and TNF-alpha cytokine levels, while APS did not have an obvious effect.	1,4-dideoxy-1,4-iminoarabinitol	27-30	interleukin 6	Mus musculus	68-72
34339793-14	2021	We also observed that DNJ, DAB, FAG, and ARG markedly downregulated IL-6 and TNF-alpha cytokine levels, while APS did not have an obvious effect.	fagomine	32-35	interleukin 6	Mus musculus	68-72
34339793-14	2021	We also observed that DNJ, DAB, FAG, and ARG markedly downregulated IL-6 and TNF-alpha cytokine levels, while APS did not have an obvious effect.	Arginine	41-44	interleukin 6	Mus musculus	68-72
34833950-0	2021	Nifuroxazide Mitigates Angiogenesis in Ehlrich"s Solid Carcinoma: Molecular Docking, Bioinformatic and Experimental Studies on Inhibition of Il-6/Jak2/Stat3 Signaling.	nifuroxazide	0-12	interleukin 6	Mus musculus	141-145
34833950-8	2021	Furthermore, nifuroxazide downregulated IL-6, TNF-alpha, NFk-beta, angiostatin, and Jak2 proteins, and it also reduced tumoral VEGF, as indicated by ELISA and immunohistochemical analysis.	nifuroxazide	13-25	interleukin 6	Mus musculus	40-44
34833103-3	2021	In the co-cultured C2C12 cells, EPS increased the expression of PGC-1a (p = 0.129; d = 0.73) and IL-6 (p = 0.09; d = 1.13) protein levels.	eps	32-35	interleukin 6	Mus musculus	97-101
34833103-4	2021	When EPS was applied, we found that co-culturing led to increases in UCP1 (p = 0.044; d = 1.29) and IL-6 (p = 0.097; d = 1.13) protein expression in the 3T3-L1 adipocytes.	eps	5-8	interleukin 6	Mus musculus	100-104
34754093-5	2021	In a mouse OA model incurred by DMM (destabilization of medial meniscus), administration of CDDO-Im (2.5 mg/kg, ip, every other day for 8 weeks) effectively reduced knee joint cartilage erosion and serum levels of inflammatory cytokines IL-1beta and IL-6.	1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole	92-99	interleukin 6	Mus musculus	250-254
34858181-11	2021	The results showed that the docking of paeoniflorin with glyceraldehyde 3-phosphate dehydrogenase (GAPDH), paeoniflorin and loganin with SRC, ginsenoside Rb1 with NR3C2, ursolic acid and oleanolic acid with IL-6, paeoniflorin docking VEGFA, and MMP9.	peoniflorin	39-51	interleukin 6	Mus musculus	207-211
34858181-11	2021	The results showed that the docking of paeoniflorin with glyceraldehyde 3-phosphate dehydrogenase (GAPDH), paeoniflorin and loganin with SRC, ginsenoside Rb1 with NR3C2, ursolic acid and oleanolic acid with IL-6, paeoniflorin docking VEGFA, and MMP9.	Oleanolic Acid	187-201	interleukin 6	Mus musculus	207-211
34777683-9	2021	We found that TLB suppressed glial activation by inhibiting the TLR4-MYD88-NFkappaB pathway, which leads to the inflammatory factor TNF-alpha, IL-1beta, and IL-6 reduction.	trilobatin	14-17	interleukin 6	Mus musculus	157-161
34833865-7	2021	Additionally, chondroitin sulfate showed its antioxidant potential by restoring the various biochemical levels and anti-inflammatory properties by reducing NF-kB levels and pro-inflammatory mediators like TNF-alpha, IL-1beta, and IL-6, indicating the neuroprotective effect as well as the suppressed levels of caspase-3, which indicated a neuroprotective treatment strategy in epilepsy.	Chondroitin Sulfates	14-33	interleukin 6	Mus musculus	230-234
34833865-9	2021	Further, the molecular docking of chondroitin sulfate at the active pockets of TNF-alpha, IL-1beta, and IL-6 showed excellent interactions with critical amino acid residues.	Chondroitin Sulfates	34-53	interleukin 6	Mus musculus	104-108
34174740-5	2021	In a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis (UC), compound 4 showed anti-inflammatory property and reduced the levels of pro-inflammatory cytokines (TNF-alpha and IL-6).	Dextran Sulfate	5-27	interleukin 6	Mus musculus	195-199
34174740-5	2021	In a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis (UC), compound 4 showed anti-inflammatory property and reduced the levels of pro-inflammatory cytokines (TNF-alpha and IL-6).	Dextran Sulfate	29-32	interleukin 6	Mus musculus	195-199
34803678-13	2021	Topical treatment of the wounds with Lp2621 gel resulted in the upregulation of pro-inflammatory cytokine IL-6 in the early phase of wound healing and enhanced IL-10 expression in the later phase.	lp2621	37-43	interleukin 6	Mus musculus	106-110
34737421-6	2021	Among the screened compounds, flavokawain B (FKB) significantly reduced LPS-induced pro-inflammatory IL-6 secretion in macrophages.	flavokawain B	30-43	interleukin 6	Mus musculus	101-105
34737421-6	2021	Among the screened compounds, flavokawain B (FKB) significantly reduced LPS-induced pro-inflammatory IL-6 secretion in macrophages.	flavokawain B	45-48	interleukin 6	Mus musculus	101-105
34769347-5	2021	BTZ treatment promoted a precocious upregulation of KDM6A, PPARs, and IL-6, and a delayed increase of PK2 and IL-1beta.	Bortezomib	0-3	interleukin 6	Mus musculus	70-74
34829636-6	2021	Melatonin inhibited the expression of various inflammatory mediators, including TNF-alpha, IL-6, and IL-1beta, in SiONPs-exposed mice and SiONPs-stimulated H292 cells; this inhibition contributed to a decline in inflammatory cell accumulation in the lung tissues.	Melatonin	0-9	interleukin 6	Mus musculus	91-95
34803679-5	2021	The results revealed that NFPX alleviated lung edema evaluated by lung ultrasound, decreased lung wet/Dry ratio, the total cell numbers of bronchoalveolar lavage fluid (BALF), and IL-1beta, IL-6, and TNF-alpha levels in BALF and serum, and ameliorated lung pathology in a dose-dependent manner.	nfpx	26-30	interleukin 6	Mus musculus	190-194
34803690-10	2021	Following icariin treatment, significant decreases were observed in CoCrMo wear particle-induced TNF-alpha and IL-6 mRNA expression in BMDMs, and osteolysis in mice calvaria.	icariin	10-17	interleukin 6	Mus musculus	111-115
34724865-7	2022	In addition, the results showed that LPEs markedly alleviated the expression of interleukin (IL)-6, IL-17, transforming growth factor (TGF)-beta, and alpha-smooth muscle actin (alpha-SMA).	lpes	37-41	interleukin 6	Mus musculus	80-98
34672564-4	2021	Consequently, we found that the apocarotenoids 3-hydroxy-beta-ionone (1) and apo-13-zeaxanthinones (2a/2b) significantly repressed expression of IL-1beta (9.5 +- 1.5 and 28.7 +- 0.6%, respectively) and IL-6 (10.1 +- 0.7 and 6.1 +- 0.4%, respectively) at 10 mug/mL (p < 0.05) using RAW 264.7 mouse macrophages.	apocarotenoids	32-46	interleukin 6	Mus musculus	202-206
34672564-4	2021	Consequently, we found that the apocarotenoids 3-hydroxy-beta-ionone (1) and apo-13-zeaxanthinones (2a/2b) significantly repressed expression of IL-1beta (9.5 +- 1.5 and 28.7 +- 0.6%, respectively) and IL-6 (10.1 +- 0.7 and 6.1 +- 0.4%, respectively) at 10 mug/mL (p < 0.05) using RAW 264.7 mouse macrophages.	3-hydroxy-beta-ionone	47-68	interleukin 6	Mus musculus	202-206
34672564-4	2021	Consequently, we found that the apocarotenoids 3-hydroxy-beta-ionone (1) and apo-13-zeaxanthinones (2a/2b) significantly repressed expression of IL-1beta (9.5 +- 1.5 and 28.7 +- 0.6%, respectively) and IL-6 (10.1 +- 0.7 and 6.1 +- 0.4%, respectively) at 10 mug/mL (p < 0.05) using RAW 264.7 mouse macrophages.	apo-13-zeaxanthinones	77-98	interleukin 6	Mus musculus	202-206
34765000-14	2021	Subsequently, animal-based experiments revealed the intraperitoneal injection of friedelin ameliorated DSS-induced body weight loss, DAI decrease, colon length shortening and colonic pathological damage with lower myeloperoxidase and proinflammatory cytokines (IL-1beta and IL-6) and higher IL-10 levels, and more autophagosomes in transmission electron microscope results.	friedelin	81-90	interleukin 6	Mus musculus	274-278
34765000-14	2021	Subsequently, animal-based experiments revealed the intraperitoneal injection of friedelin ameliorated DSS-induced body weight loss, DAI decrease, colon length shortening and colonic pathological damage with lower myeloperoxidase and proinflammatory cytokines (IL-1beta and IL-6) and higher IL-10 levels, and more autophagosomes in transmission electron microscope results.	Dextran Sulfate	103-106	interleukin 6	Mus musculus	274-278
34727296-8	2021	Early but not the late intrathecal injection of C-176 attenuated SNI-induced pain hypersensitivity, microglia activation, proinflammatory factors, and phosphorylated JAK2/STAT3 in the spinal cord dorsal horn, and the analgesic effect of C-176 was greatly abolished by recombinant IL-6 following SNI.	C-176	48-53	interleukin 6	Mus musculus	280-284
34727296-8	2021	Early but not the late intrathecal injection of C-176 attenuated SNI-induced pain hypersensitivity, microglia activation, proinflammatory factors, and phosphorylated JAK2/STAT3 in the spinal cord dorsal horn, and the analgesic effect of C-176 was greatly abolished by recombinant IL-6 following SNI.	sni	65-68	interleukin 6	Mus musculus	280-284
34727296-8	2021	Early but not the late intrathecal injection of C-176 attenuated SNI-induced pain hypersensitivity, microglia activation, proinflammatory factors, and phosphorylated JAK2/STAT3 in the spinal cord dorsal horn, and the analgesic effect of C-176 was greatly abolished by recombinant IL-6 following SNI.	C-176	237-242	interleukin 6	Mus musculus	280-284
34709954-12	2021	The numbers of rubbing and sneezing, the percentage of Th17 cells, and the levels of OVA-specific IgE, IL-4, IL-6, and IL-17 in AR mice were decreased by miR-10b-5p overexpression, which was reversed by MIAT overexpression.	mir-10b-5p	154-164	interleukin 6	Mus musculus	109-113
34734506-9	2021	Nasal administration of quinpirole (Quin, a dopamine D2 receptor agonist, 3 mg/kg) improved olfactory function in mice, inhibited the expression of toll-like receptor 4 (TLR4)/nuclear factor-kappaB (NF-kappaB) signalings and the levels of tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 in the olfactory bulb.	Quinpirole	24-34	interleukin 6	Mus musculus	295-299
34734506-9	2021	Nasal administration of quinpirole (Quin, a dopamine D2 receptor agonist, 3 mg/kg) improved olfactory function in mice, inhibited the expression of toll-like receptor 4 (TLR4)/nuclear factor-kappaB (NF-kappaB) signalings and the levels of tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 in the olfactory bulb.	Quinpirole	36-40	interleukin 6	Mus musculus	295-299
34734816-6	2021	RESULTS: At the end of the 9-day study duration, QRS, ST, QT intervals, QT/PQ index and TAS, TOS, TNF-alpha, IL-1beta, IL-6 levels were significantly higher in the DOX group than in the control group (p<0.001).	Doxorubicin	164-167	interleukin 6	Mus musculus	119-123
34734816-8	2021	QRS, ST, QT intervals, and QT/PQ index, TAS, TOS, TNF-alpha, IL-1beta, IL-6 levels were significantly lower in the Sac/Val+ DOX group compared with the DOX group (p<0.001).	Valine	119-122	interleukin 6	Mus musculus	71-75
34734816-8	2021	QRS, ST, QT intervals, and QT/PQ index, TAS, TOS, TNF-alpha, IL-1beta, IL-6 levels were significantly lower in the Sac/Val+ DOX group compared with the DOX group (p<0.001).	Doxorubicin	124-127	interleukin 6	Mus musculus	71-75
34988203-9	2021	Sal reduced the levels of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and IL-8.	rhodioloside	0-3	interleukin 6	Mus musculus	67-85
34384137-9	2021	Serum levels of amylase, IL-6, TNFalpha, IL-17, and IL-23 decreased upon SR1001 treatment.	SR1001	73-79	interleukin 6	Mus musculus	25-29
34311083-4	2021	Similarly, thioglycollate-elicited peritoneal cells isolated from wildtype mice treated with TP-064 showed lowered mRNA expression levels and cytokine production of pro-inflammatory mediators interleukin (IL)-1beta, IL-6, IL-12p40, and tumor necrosis factor-alpha in response to lipopolysaccharide exposure.	Thioglycolates	11-25	interleukin 6	Mus musculus	216-220
34311083-4	2021	Similarly, thioglycollate-elicited peritoneal cells isolated from wildtype mice treated with TP-064 showed lowered mRNA expression levels and cytokine production of pro-inflammatory mediators interleukin (IL)-1beta, IL-6, IL-12p40, and tumor necrosis factor-alpha in response to lipopolysaccharide exposure.	TP-064	93-99	interleukin 6	Mus musculus	216-220
34433707-8	2021	ELISA results showed that increased levels of ROS, TNF-alpha, IL-1beta and IL-6 in hippocampal tissues induced by oAbeta injection were remarkably inhibited after AS-IV treatment.	oabeta	114-120	interleukin 6	Mus musculus	75-79
34474343-9	2021	Furthermore, PC potently suppressed LPS-stimulated overproduction of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta) and IL-6 in RAW 264.7 macrophages.	pc	13-15	interleukin 6	Mus musculus	187-191
34353430-6	2021	KHG26700 significantly attenuated the expression of several pro-inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6, in these cells, as well as the LPS-induced increases in NLRP3, NF-kappaB, and phospho-IkBalpha levels.	khg26700	0-8	interleukin 6	Mus musculus	150-163
34482419-6	2021	MiR-129-5p upregulation decreased the concentrations and protein levels of proinflammatory cytokines (IL-6, IL-1beta and TNF-alpha), indicating the inhibitory role of miR-129-5p in inflammation.	mir-129-5p	0-10	interleukin 6	Mus musculus	102-106
34736034-10	2021	Moreover, MT treatment also suppressed the Cd-induced inflammation by reducing the inflammatory mediators, including IL-1beta, IL-6, TNF-alpha and iNOS.	Cadmium	43-45	interleukin 6	Mus musculus	127-131
34509498-7	2021	FA and TA were found to dramatically reduce the expression of CCL2, IL-6, and IL-8 in Muller glia in vitro after inflammatory challenge with IL-1beta or TNF-alpha (P < 0.05).	Triamcinolone Acetonide	7-9	interleukin 6	Mus musculus	68-72
34482419-6	2021	MiR-129-5p upregulation decreased the concentrations and protein levels of proinflammatory cytokines (IL-6, IL-1beta and TNF-alpha), indicating the inhibitory role of miR-129-5p in inflammation.	mir-129-5p	167-177	interleukin 6	Mus musculus	102-106
34478946-13	2021	RT-PCR study revealed that mRNA levels of the inflammatory mediators (IL-1beta, IL-6, TNF-alpha) were significantly reduced, while the expression of antioxidant Nrf2 was significantly increased.The molecular docking studies further confirmed that the 2NCP showed excellent binding affinities for NF-kappaB and cholinesterases.	2ncp	251-255	interleukin 6	Mus musculus	80-84
34699875-8	2021	M1 marks such as tumor necrosis factor alpha (TNF-alpha), inducible NOS(iNOS), interleukin-6 (IL-6), and Fc receptor (CD16 and CD32) significantly downregulated by progesterone treatment whether at 3 days or 7 days after ONC.	Progesterone	164-176	interleukin 6	Mus musculus	79-92
34699875-8	2021	M1 marks such as tumor necrosis factor alpha (TNF-alpha), inducible NOS(iNOS), interleukin-6 (IL-6), and Fc receptor (CD16 and CD32) significantly downregulated by progesterone treatment whether at 3 days or 7 days after ONC.	Progesterone	164-176	interleukin 6	Mus musculus	94-98
34603520-3	2021	The results revealed that FFO treatment inhibited the secretion and mRNA expression of the pro-inflammatory cytokines IL-6, IL-1beta, TNF-alpha.	ffo	26-29	interleukin 6	Mus musculus	118-122
34558577-6	2021	Meanwhile, CGA caused strong inhibition against the increase of liver injury markers (i.e. AST, ALT and ALP), hepatic inflammatory cytokines (i.e. IL-1, IL-6, TNF-alpha and TNF-beta) and dyslipidemia (i.e. TC, TG, LDL-C and HDL-C) in L-carnitine-fed mice (p < 0.05).	Carnitine	234-245	interleukin 6	Mus musculus	153-157
34790666-10	2021	We found that oral administration of luteolin (10 mg/Kg) for eight consecutive days could decrease the immobility time on tail suspension test, a mouse behavioral test measuring depression-like behavior, and attenuate LPS-induced inflammatory responses by significantly decreasing IL-6 production in mice brain-derived astrocytes and serum, and TNFalpha and corticosterone levels in serum.	Luteolin	37-45	interleukin 6	Mus musculus	281-285
34478790-8	2021	Additionally, SeMPN had a higher increase effect on RAW 264.7 cells"s pinocytic and phagocytic capacity, as well as their production of NO, TNF-alpha, and IL-6.	sempn	14-19	interleukin 6	Mus musculus	155-159
34476871-11	2021	Moreover, pevonedistat decreased CIS-induced upregulation of IL-6, TNF-alpha, IL-1beta, and NF-kappaB protein expressions in renal tissue.	pevonedistat	10-22	interleukin 6	Mus musculus	61-65
34384829-8	2021	However, combined prophylactic and therapeutic use of (R)-ketamine (15 mg/kg) significantly increased 14-day survival rate, attenuated sepsis-induced marked drop in the rectal temperature and increase in the plasma levels of inflammatory cytokines (i.e., interleukin (IL)-6, IL-17A, tumor necrosis factor (TNF)-alpha, IL-1beta, and IL-10) 12 h after CLP.	(R)-Ketamine	54-66	interleukin 6	Mus musculus	255-273
34543978-3	2021	In the present study, G-Rg1 significantly inhibited the inflammatory response to mice colitis induced by dextran sodium sulfate (DSS), as evidenced by increased body weight and colon length, decreased colon weight, reduced colon weight index and histopathological scores, lower levels of IL-6 and TNF-alpha, and increased IL-10 levels.	ginsenoside Rg1	22-27	interleukin 6	Mus musculus	288-292
34543978-3	2021	In the present study, G-Rg1 significantly inhibited the inflammatory response to mice colitis induced by dextran sodium sulfate (DSS), as evidenced by increased body weight and colon length, decreased colon weight, reduced colon weight index and histopathological scores, lower levels of IL-6 and TNF-alpha, and increased IL-10 levels.	dextran sodium sulfate	105-127	interleukin 6	Mus musculus	288-292
34628205-4	2021	Interestingly, topical application of OS-LL11 protected mouse skin against UVB irradiation damage by up-regulating the levels of superoxide dismutase, glutathione, and nitric oxide, but down-regulating the levels of H2O2, IL-1alpha, IL-1beta, IL-6, TNF-alpha, 8-OHdG, Bcl-2, and Bax, as well as the number of apoptotic bodies.	os-ll11	38-45	interleukin 6	Mus musculus	243-247
34510720-6	2021	Moreover, curcumin supplementation reduced expression of other key pro-inflammatory genes, such as NF-kappaB p65 subunit (p65), Stat1, Tlr4, and Il6, in WAT (p<0.05).	Curcumin	10-18	interleukin 6	Mus musculus	145-148
34478848-9	2021	Gene expression of pro-inflammatory/phagocytic markers in the hippocampus were not different between male and female WT mice, and in TgAPP mice of both sexes, some cytokines (IL-6 and IFNgamma) were higher than in WT mice on LFD, more so in female TgAPP (IL-6).	tgapp	133-138	interleukin 6	Mus musculus	175-179
34508846-11	2021	In parallel, we observed increased peripheral levels of IL-6 and IL-10 alongside increased hippocampal levels of NGF but decreased GDNF in mice treated with nicotine compared to controls.	Nicotine	157-165	interleukin 6	Mus musculus	56-60
34782040-6	2021	ASX treatment significantly reversed PO and HX-induced hyperuricemia and kidney inflammation in mice as evidenced by decreased serum levels of uric acid (UA), creatinine (Cr), blood urea nitrogen (BUN), and inflammatory factors (IL-1beta, IL-6, and TNF-alpha) and increased activities of antioxidant enzymes (CAT, SOD and GSH-Px).	astaxanthine	0-3	interleukin 6	Mus musculus	239-243
34333674-10	2021	Neither in the prefrontal cortex nor hippocampus pterostilbene affected mRNA expression of IL-1beta, IL-6, GABRA1A, and GRIN2B augmented by PTZ kindling.	Pentylenetetrazole	140-143	interleukin 6	Mus musculus	101-105
34724970-15	2021	Moreover, L-carnitine reduced the serum levels of IL-1 and IL-6, factors known to induce cancer cachexia.	Carnitine	10-21	interleukin 6	Mus musculus	59-63
34652342-5	2021	Mice were fed sugar water (SUG; control) or TCW for a week and then subjected to 60 min of liver ischemia followed by reperfusion for 6 h. Plasma alanine transaminase levels, tissue damage, and mRNA levels of Nos2, Tnf, and Il6 were significantly lower in mice fed TCW prior to I/R.	Water	20-25	interleukin 6	Mus musculus	224-227
34652342-5	2021	Mice were fed sugar water (SUG; control) or TCW for a week and then subjected to 60 min of liver ischemia followed by reperfusion for 6 h. Plasma alanine transaminase levels, tissue damage, and mRNA levels of Nos2, Tnf, and Il6 were significantly lower in mice fed TCW prior to I/R.	Tolcapone	44-47	interleukin 6	Mus musculus	224-227
34652342-5	2021	Mice were fed sugar water (SUG; control) or TCW for a week and then subjected to 60 min of liver ischemia followed by reperfusion for 6 h. Plasma alanine transaminase levels, tissue damage, and mRNA levels of Nos2, Tnf, and Il6 were significantly lower in mice fed TCW prior to I/R.	Tolcapone	265-268	interleukin 6	Mus musculus	224-227
34652342-10	2021	The levels of Nos2, Il1b, Tnf, and Il6 were decreased while Il10 and Hmox1 mRNA levels were significantly up-regulated upon LPS stimulation of TCW pretreated RAW264.7 macrophages.	Tolcapone	143-146	interleukin 6	Mus musculus	35-38
34217897-9	2021	Substantial Fe dependent cell injury (decreased MTT uptake), and Fe independent increases in HO-1/IL-6 mRNA expression were observed.	Iron	65-67	interleukin 6	Mus musculus	98-102
34365219-4	2021	Previously, we identified a novel mechanism of biphasic activation of STAT3 in response to gp130-linked cytokines, including IL6, in which activation of STAT3 is prolonged by circumventing the negative regulatory mechanisms induced by its initial activationTo target prolonged STAT3 activation, we used the small molecule inhibitor bazedoxifene (BZA), which blocks formation of the IL6 receptor-gp130 complex.	bazedoxifene	332-344	interleukin 6	Mus musculus	125-128
34365219-4	2021	Previously, we identified a novel mechanism of biphasic activation of STAT3 in response to gp130-linked cytokines, including IL6, in which activation of STAT3 is prolonged by circumventing the negative regulatory mechanisms induced by its initial activationTo target prolonged STAT3 activation, we used the small molecule inhibitor bazedoxifene (BZA), which blocks formation of the IL6 receptor-gp130 complex.	bazedoxifene	332-344	interleukin 6	Mus musculus	382-385
34365219-4	2021	Previously, we identified a novel mechanism of biphasic activation of STAT3 in response to gp130-linked cytokines, including IL6, in which activation of STAT3 is prolonged by circumventing the negative regulatory mechanisms induced by its initial activationTo target prolonged STAT3 activation, we used the small molecule inhibitor bazedoxifene (BZA), which blocks formation of the IL6 receptor-gp130 complex.	bazedoxifene	346-349	interleukin 6	Mus musculus	125-128
34365219-4	2021	Previously, we identified a novel mechanism of biphasic activation of STAT3 in response to gp130-linked cytokines, including IL6, in which activation of STAT3 is prolonged by circumventing the negative regulatory mechanisms induced by its initial activationTo target prolonged STAT3 activation, we used the small molecule inhibitor bazedoxifene (BZA), which blocks formation of the IL6 receptor-gp130 complex.	bazedoxifene	346-349	interleukin 6	Mus musculus	382-385
34719405-8	2021	When the mRNA levels of pro-inflammatory cytokines were examined 7 days after bleomycin administration, interleukin (IL)-6, IL-4 and IL-13 were significantly lower in the BH group than in the BA group.	Bleomycin	78-87	interleukin 6	Mus musculus	104-122
34450323-9	2021	RESULTS: Curcumol reduced IL-1beta, IL-6 and TNF-alpha production in NPCs, and the phosphorylation of proteins in the PI3K/Akt/NF-kappaB signaling pathway was also decreased.	curcumol	9-17	interleukin 6	Mus musculus	36-40
34719405-8	2021	When the mRNA levels of pro-inflammatory cytokines were examined 7 days after bleomycin administration, interleukin (IL)-6, IL-4 and IL-13 were significantly lower in the BH group than in the BA group.	Barium	192-194	interleukin 6	Mus musculus	104-122
34776934-4	2021	Here, we found that gliquidone suppressed LPS-mediated microgliosis, microglial hypertrophy, and proinflammatory cytokine COX-2 and IL-6 levels in wild-type mice, with smaller effects on astrogliosis.	gliquidone	20-30	interleukin 6	Mus musculus	132-136
34517011-3	2021	Our present work showed that trimebutine suppresses interleukin-6 (IL-6) production in lipopolysaccharide (LPS, a stimulant of TLR4)-stimulated macrophages of RAGE-knockout mice.	Trimebutine	29-40	interleukin 6	Mus musculus	52-65
34517011-3	2021	Our present work showed that trimebutine suppresses interleukin-6 (IL-6) production in lipopolysaccharide (LPS, a stimulant of TLR4)-stimulated macrophages of RAGE-knockout mice.	Trimebutine	29-40	interleukin 6	Mus musculus	67-71
34517011-5	2021	Importantly, trimebutine suppresses IL-6 production induced by TLR2-and TLR7/8/9 stimulants.	Trimebutine	13-24	interleukin 6	Mus musculus	36-40
34771569-9	2021	The proinflammatory cytokines IL-1beta, IL-6, and TNF-alpha were also found to be significantly greater in vehicle-treated mice than TAK-242-treated mice.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	133-140	interleukin 6	Mus musculus	40-44
34778302-13	2021	The inflammatory cytokines and chemokines, such as TNFalpha, IL1b, IL-6, and CXCL1, were also kept in check in responder AstroRx-treated mice and were not upregulated as in the sham-injected mice (P < 0.05).	astrorx	121-128	interleukin 6	Mus musculus	67-71
34711820-4	2021	The chemotherapeutic doxorubicin is curative in IL-6-deficient mice through the induction of CD8+ T-cell-mediated anti-cancer responses, while moderately extending lifespan in wild type tumor-bearing mice.	Doxorubicin	21-32	interleukin 6	Mus musculus	48-52
34829567-11	2021	In conclusion, rutin and rutin glycoside showed differences in antioxidant activities in vitro, while they were similar in the reduction of NO, PGE2, TNF-alpha and IL-6 in vitro.	Rutin	15-20	interleukin 6	Mus musculus	164-168
34453837-9	2021	While NM exposure did not result in mast cell degranulation, we observed an upregulation in PGD2 and IL-6 levels following exposure to NM.	Mechlorethamine	6-8	interleukin 6	Mus musculus	101-105
34453837-9	2021	While NM exposure did not result in mast cell degranulation, we observed an upregulation in PGD2 and IL-6 levels following exposure to NM.	Mechlorethamine	135-137	interleukin 6	Mus musculus	101-105
34805020-7	2021	Concentrations of TNF-alpha, IL-1beta, and IL-6 were significantly enhanced by alcohol treatment.	Alcohols	79-86	interleukin 6	Mus musculus	43-47
34827410-6	2021	The results showed that dutasteride significantly reduced the levels of IL-6 and TNF-alpha in the supernatants of LPS-stimulated BV2 cells, and decreased the levels of IL-6 in the hippocampus and plasma, and the number of activated microglia in the brain of LPS administration mice.	Dutasteride	24-35	interleukin 6	Mus musculus	72-76
34827410-6	2021	The results showed that dutasteride significantly reduced the levels of IL-6 and TNF-alpha in the supernatants of LPS-stimulated BV2 cells, and decreased the levels of IL-6 in the hippocampus and plasma, and the number of activated microglia in the brain of LPS administration mice.	Dutasteride	24-35	interleukin 6	Mus musculus	168-172
34699564-9	2021	In addition, piperonylic acid modulated the gene expression of interleukin (Il)-6, il-1beta, tumor necrosis factor (Tnf)-alpha, il-10, monocyte chemoattractant protein (Mcp)-1 and insulin-like growth factor (Igf)-1, which are important for the healing process.	piperonylic acid	13-29	interleukin 6	Mus musculus	63-81
34805020-8	2021	Alcohol with LPS treatment significantly enhanced concentrations of TNF-alpha, IL-1beta, and IL-6 more than alcohol alone treatment.	Alcohols	0-7	interleukin 6	Mus musculus	93-97
34805020-8	2021	Alcohol with LPS treatment significantly enhanced concentrations of TNF-alpha, IL-1beta, and IL-6 more than alcohol alone treatment.	Alcohols	108-115	interleukin 6	Mus musculus	93-97
34805020-9	2021	Alcohol with CCL4 treatment significantly enhanced TNF-alpha, IL-1beta, and IL-6 concentrations more than alcohol alone treatment.	Alcohols	0-7	interleukin 6	Mus musculus	76-80
34805020-9	2021	Alcohol with CCL4 treatment significantly enhanced TNF-alpha, IL-1beta, and IL-6 concentrations more than alcohol alone treatment.	Alcohols	106-113	interleukin 6	Mus musculus	76-80
34805020-10	2021	Alcohol with LPS and CCL4 treatment increased TNF-alpha, IL-1beta, and IL-6 concentrations more than alcohol with CCL4 treatment, but it was not statistically significant.	Alcohols	0-7	interleukin 6	Mus musculus	71-75
34500237-6	2021	Total flavonoids also reversed changes in serum cytokines IL-2, IL-6, and GM-CSF.	Flavonoids	6-16	interleukin 6	Mus musculus	64-68
34689333-5	2022	Fucoidan administration caused reductions in MDA, IL-6, IL-1beta, and TNF-alpha levels and improved SOD, GSH-Px, and CAT activities in the liver and kidney of CTX-induced mice.	fucoidan	0-8	interleukin 6	Mus musculus	50-54
34925810-4	2021	In connection with its free radical scavenging activity and CAA, DAS-rich EVOO significantly normalized the serum ALT and AST levels and prevented the increase in interleukin-6 in CCl4-intoxicated mice.	Carbon Tetrachloride	180-184	interleukin 6	Mus musculus	163-176
34746206-8	2021	Furthermore, the inflammatory responses detected in the infected groups which include the concentrations of IL-1beta, TNF-alpha, IL-6, and immunoglobulin G (IgG) in the serum and secretory immunoglobulin (SigA) in the colon, and nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) activity in the jejunum, were also alleviated (P < 0.05) by BA40 treatment.	ba40	361-365	interleukin 6	Mus musculus	129-133
34832856-6	2021	The normalization of the level of the pro-inflammatory cytokine IL-6 in the serum and the recovery of cell populations in the spleen were observed in immunosuppressed mice following treatment with the polysaccharides.	Polysaccharides	201-216	interleukin 6	Mus musculus	64-68
34674107-10	2021	Besides, linarin suppresses alterations in the inflammatory system, i.e., NF-kappaB p65/IKKbeta, by reducing NF-kappaB p65, IKKbeta, IL-6, and TNF-alpha in the bone of Cd-exposed animals.	linarin	9-16	interleukin 6	Mus musculus	133-137
34674107-10	2021	Besides, linarin suppresses alterations in the inflammatory system, i.e., NF-kappaB p65/IKKbeta, by reducing NF-kappaB p65, IKKbeta, IL-6, and TNF-alpha in the bone of Cd-exposed animals.	Cadmium	168-170	interleukin 6	Mus musculus	133-137
34454177-7	2021	Furthermore, compared with non-irradiated mice, mice in the 25 Gy + PBS group showed a high senescence-associated-beta-galactosidase-positive cell number and upregulated senescence-related gene (p16INK4a, p19Arf, p21) and senescence-associated secretory phenotypic factor (MMP3, IL-6, PAI-1, NF-kappaB, and TGF-beta) expression, all of which were downregulated in the hDPSC-sEV group.	pbs	68-71	interleukin 6	Mus musculus	279-283
34755672-7	2021	Chrysin treatment significantly reduced the release of IL-6, MCP-1, and TNF-alpha and the level of NO (P < 0.01), and inhibited the mRNA and protein expressions of iNOS and COX-2 (P < 0.01) in the cells.	chrysin	0-7	interleukin 6	Mus musculus	55-59
34833355-6	2021	The prophylactic administration of BB in the murine model of UC reduced histological damage, decreased the expression of IL-1beta (61.12%), IL-6 (94.70%), and TNF-alpha (68.88%), and increased the expression of INF-gamma (177.06%), IL-4 (541.36%), and IL-10 (531.97%).	boeravinone B	35-37	interleukin 6	Mus musculus	140-144
34768735-8	2021	As a result, we found that the ferulic acid derivative S-52372 not only had certain scavenging effects on free radicals in biochemical experiments, but also prevented inflammation and oxidative stress in LPS-stimulated RAW264.7 cells in the cellular environment; intracellular ROS and inflammatory mediators, including iNOS, COX-2, TNF-alpha, and IL-6, were also suppressed.	ferulic acid	31-43	interleukin 6	Mus musculus	347-351
34768735-8	2021	As a result, we found that the ferulic acid derivative S-52372 not only had certain scavenging effects on free radicals in biochemical experiments, but also prevented inflammation and oxidative stress in LPS-stimulated RAW264.7 cells in the cellular environment; intracellular ROS and inflammatory mediators, including iNOS, COX-2, TNF-alpha, and IL-6, were also suppressed.	s-52372	55-62	interleukin 6	Mus musculus	347-351
34681909-4	2021	We found that palmitic acid (a potent inducer of lipotoxicity), induced a rapid (~24 h) and significant increase in IL-6 in RAW264.7 cells.	Palmitic Acid	14-27	interleukin 6	Mus musculus	116-120
34671017-4	2021	We find that bilobalide inhibits Abeta-induced and STAT3-dependent expression of TNF-alpha, IL-1beta, and IL-6 in primary astrocyte culture.	bilobalide	13-23	interleukin 6	Mus musculus	106-110
34712101-7	2021	Basal levels of splenic interleukin- (IL-) 1beta and pancreatic IL-6 in the STZ group were decreased.	Streptozocin	76-79	interleukin 6	Mus musculus	64-68
34663855-11	2021	Furthermore, the IL-6, IL-10, and TNF-alpha plasma levels were down-regulated on day 1, 7, and 14 of heat stress in mice receiving the oral administration of chitosan.	Chitosan	158-166	interleukin 6	Mus musculus	17-21
34364600-3	2021	The results indicated that Fuc-Sc could stimulate the RAW264.7 cells by promoting the production of NO, TNF-alpha, IL-6 and IL-10.	fuc-sc	27-33	interleukin 6	Mus musculus	115-119
34364630-4	2021	Further experiments in DSS-induced colitis model showed that oral administration of NeoGOS-P70 could significantly improve DSS-induced colitis symptoms, such as weight loss, reduction in colon shortening, and suppression of inflammatory mediators, including interleukin-6, tumor necrosis factor-alpha, and myeloperoxidase secretion from colon of ulcerative colitis mice.	neogos-p70	84-94	interleukin 6	Mus musculus	258-271
34681815-6	2021	Both dextran sulfate sodium- and 2, 4, 6-trinitrobenzene sulfonic acid-induced murine IBD models revealed that orally delivered fexofenadine was therapeutic against IBD, evidenced by mitigated clinical symptoms, decreased secretions of the proinflammatory cytokine IL-6 and IL-1beta, lowered intestinal inflammation, and reduced p-p65 and p-IkBalpha.	fexofenadine	128-140	interleukin 6	Mus musculus	265-269
34721041-11	2021	Results: Compared with the ATO group, the HES treatment groups reduced the levels of CK, LDH, cTnI, ROS, MDA, TNF-alpha, IL-6, Bax, Caspase-3, cleaved-Caspase-3 and Keap1 and enhanced the levels of SOD, GSH, CAT, Bcl-2, p62 and Nrf2.	Arsenic Trioxide	27-30	interleukin 6	Mus musculus	121-125
34364104-3	2021	In this study, intraperitoneal administration of DOX reduced significantly the acute inflammatory markers like IL-6 and CD3, microglial migration to the damaged area marked with Iba-1, and neuronal apoptosis assessed with TUNEL assay at 72 h after the trauma.	Doxycycline	49-52	interleukin 6	Mus musculus	111-115
34517056-5	2021	PFOA significantly decreased the pro-inflammatory cytokines IL-17alpha and IL-1alpha, decreased (non-significantly but dose-response) IL-6, and a significantly increased TNFalpha.	perfluorooctanoic acid	0-4	interleukin 6	Mus musculus	134-138
34721041-11	2021	Results: Compared with the ATO group, the HES treatment groups reduced the levels of CK, LDH, cTnI, ROS, MDA, TNF-alpha, IL-6, Bax, Caspase-3, cleaved-Caspase-3 and Keap1 and enhanced the levels of SOD, GSH, CAT, Bcl-2, p62 and Nrf2.	Hesperidin	42-45	interleukin 6	Mus musculus	121-125
34675753-8	2021	Results: Sodium butyrate administration improved the body weight and survival rate of NEC mice; relieved intestinal pathological injury; reduced the intestinal expression of HMGB1, TLR4, NF-kappaB, interleukin- (IL-) 1beta, IL-6, IL-8, and TNF-alpha; and increased the intestinal expression of IL-10 (P < 0.05).	Butyric Acid	9-24	interleukin 6	Mus musculus	224-228
34679730-6	2021	Simultaneously, ZER attenuated the inflammatory response via significantly reducing the levels of pro-inflammatory factors, including interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha) in serum.	Cerium	16-19	interleukin 6	Mus musculus	164-168
34712695-7	2021	Varenicline decreased LPS-induced cytokines and chemokines including TNFalpha, IL-6, and IL-1beta via alpha7nAChRs to a similar level that observed with dexamethasone.	Varenicline	0-11	interleukin 6	Mus musculus	79-83
34712695-7	2021	Varenicline decreased LPS-induced cytokines and chemokines including TNFalpha, IL-6, and IL-1beta via alpha7nAChRs to a similar level that observed with dexamethasone.	Dexamethasone	153-166	interleukin 6	Mus musculus	79-83
34675513-7	2021	Results: The H-CeO2-PEG showed good ROS scavenging efficacy and decreased the levels of proinflammatory cytokines (IL-6, IL-1beta, IL-18, and TNF-alpha) in DSS-induced colitis mice.	h-ceo2-peg	13-23	interleukin 6	Mus musculus	115-119
34633988-9	2021	Moreover, the increase of IL-6 in the serum of mice in the low-dose group is related to the activation of inflammatory factors after alcohol-induced liver injury.	Alcohols	133-140	interleukin 6	Mus musculus	26-30
34684537-4	2021	In RAW264.7 cells, 4,5-diCQA pretreatment significantly inhibited lipopolysaccharide-induced expression of nitric oxide, prostaglandin E2, nitric oxide synthase, cyclooxygenase-2, tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6, without inducing cytotoxicity.	4,5-dicaffeoyl quinic acid	19-28	interleukin 6	Mus musculus	232-245
34675506-8	2021	After CS exposure, total proteins, total white cells, neutrophils, lymphocytes, IL-6, and matrix metalloproteinase-9 increased significantly in lung of Glipr1-/- mice than those in lung of WT mice.	Cesium	6-8	interleukin 6	Mus musculus	80-84
34613372-5	2022	Intracolonic administration of BIBP (but not BIIE) significantly reduced clinical, endoscopic, and histological scores, and serum TNF, interleukin (IL)-6, and IL-12p70 in DSS colitis; it also significantly attenuated histological damage and serum IL-6 in T-cell colitis (P < .05).	bibp	31-35	interleukin 6	Mus musculus	135-153
34613372-5	2022	Intracolonic administration of BIBP (but not BIIE) significantly reduced clinical, endoscopic, and histological scores, and serum TNF, interleukin (IL)-6, and IL-12p70 in DSS colitis; it also significantly attenuated histological damage and serum IL-6 in T-cell colitis (P < .05).	bibp	31-35	interleukin 6	Mus musculus	247-251
34675899-10	2021	The levels of the inflammatory factors IL-1beta, IL-6, IL-8, and TNFalpha in the mice spleen were significantly increased in the + ompA strain treatment group compared with the DeltaompA strain group (all P < 0.05).	octamethyl pyrophosphoramide	131-135	interleukin 6	Mus musculus	49-53
34107329-18	2021	The NO level, IL-4, IL-6 and phagocytosis in the LPS stimulated macrophage was effectively lowered by 25 mug/ml of taraxerone.	taraxerone	115-125	interleukin 6	Mus musculus	20-24
34685639-7	2021	Cultured macrophages assumed an M1 pro-inflammatory phenotype in response to high glucose as indicated by increased TNF-alpha, CCL2, and IL-6.	Glucose	82-89	interleukin 6	Mus musculus	137-141
34671254-10	2021	Moreover, ginsenoside Rk3 slowed or halted increases in malondialdehyde, matrix metalloproteinase (MMP)-1, and MMP-3 levels in the blood and levels of interleukin 1, interleukin 6, and tumor necrosis factor alpha in skin tissues.	Ginsenosides	10-21	interleukin 6	Mus musculus	166-179
34639071-4	2021	As a result, we found that both N-docosahexaenoylethanolamine (synaptamide) and N-eicosapentaenoylethanolamine (EPEA) prevents an LPS-mediated increase in the proinflammatory cytokines TNF-alpha and IL-6 production in the SIM-A9 microglia culture.	synaptamide	32-61	interleukin 6	Mus musculus	199-203
34388231-4	2021	Meanwhile, LF and MF also significantly suppressed the overproduction of TNF-alpha, IFN-gamma, and IL-6 in the colon; however, LF can restore the decrease in the levels of TNF-alpha and IL-6 in the small intestine and the decrease in the levels of TNF-alpha, IFN-gamma, and IL-6 in the cecum induced by cefoperazone in mice.	Cefoperazone	303-315	interleukin 6	Mus musculus	99-103
34388231-4	2021	Meanwhile, LF and MF also significantly suppressed the overproduction of TNF-alpha, IFN-gamma, and IL-6 in the colon; however, LF can restore the decrease in the levels of TNF-alpha and IL-6 in the small intestine and the decrease in the levels of TNF-alpha, IFN-gamma, and IL-6 in the cecum induced by cefoperazone in mice.	Cefoperazone	303-315	interleukin 6	Mus musculus	186-190
34388231-4	2021	Meanwhile, LF and MF also significantly suppressed the overproduction of TNF-alpha, IFN-gamma, and IL-6 in the colon; however, LF can restore the decrease in the levels of TNF-alpha and IL-6 in the small intestine and the decrease in the levels of TNF-alpha, IFN-gamma, and IL-6 in the cecum induced by cefoperazone in mice.	Cefoperazone	303-315	interleukin 6	Mus musculus	274-278
34639071-4	2021	As a result, we found that both N-docosahexaenoylethanolamine (synaptamide) and N-eicosapentaenoylethanolamine (EPEA) prevents an LPS-mediated increase in the proinflammatory cytokines TNF-alpha and IL-6 production in the SIM-A9 microglia culture.	synaptamide	63-74	interleukin 6	Mus musculus	199-203
34639071-4	2021	As a result, we found that both N-docosahexaenoylethanolamine (synaptamide) and N-eicosapentaenoylethanolamine (EPEA) prevents an LPS-mediated increase in the proinflammatory cytokines TNF-alpha and IL-6 production in the SIM-A9 microglia culture.	N-eicosapentaenoylethanolamine	80-110	interleukin 6	Mus musculus	199-203
34639071-4	2021	As a result, we found that both N-docosahexaenoylethanolamine (synaptamide) and N-eicosapentaenoylethanolamine (EPEA) prevents an LPS-mediated increase in the proinflammatory cytokines TNF-alpha and IL-6 production in the SIM-A9 microglia culture.	Eicosapentaenoyl Ethanolamide	112-116	interleukin 6	Mus musculus	199-203
34685627-4	2021	Moreover, pretreatment with fluorocitrate, an inhibitor of reactive astrocytes, could also reverse the alteration in protein expression levels of GFAP, S100B, Iba-1, CD11b, TNF-alpha, IL-6, iNOS, VCAM-1, ICAM-1, MMP-9, occludin, and claudin 5 in the brain of 1,2-DCE intoxicated mice.	fluorocitrate	28-41	interleukin 6	Mus musculus	184-188
34639071-4	2021	As a result, we found that both N-docosahexaenoylethanolamine (synaptamide) and N-eicosapentaenoylethanolamine (EPEA) prevents an LPS-mediated increase in the proinflammatory cytokines TNF-alpha and IL-6 production in the SIM-A9 microglia culture.	sim-a9	222-228	interleukin 6	Mus musculus	199-203
34685627-4	2021	Moreover, pretreatment with fluorocitrate, an inhibitor of reactive astrocytes, could also reverse the alteration in protein expression levels of GFAP, S100B, Iba-1, CD11b, TNF-alpha, IL-6, iNOS, VCAM-1, ICAM-1, MMP-9, occludin, and claudin 5 in the brain of 1,2-DCE intoxicated mice.	ethylene dichloride	259-266	interleukin 6	Mus musculus	184-188
34685620-8	2021	STZ-induced diabetic cardiomyopathy significantly increased inflammasome formation (TLR4, NLRP3, Nek7, and GBP5), pyroptosis markers (caspase-1, IL-1beta, and IL-18), inflammatory cytokines (IL-6 and TNF-alpha), MMP9, and infiltration of monocytes (CD14), macrophage (iNOS), and dendritic cells (CD11b and CD11c) (p < 0.05).	Streptozocin	0-3	interleukin 6	Mus musculus	191-195
34600581-8	2021	The effect of shikonin on expression of interleukin-6, interleukin-1beta and tumor necrosis factor-alpha was measured by enzyme linked immunosorbent assay.	shikonin	14-22	interleukin 6	Mus musculus	40-53
34600581-13	2021	Meanwhile, shikonin suppressed tumor necrosis factor-alpha-induced invasion, adhesion and migration of fibroblast like synoviocytes and reduced the expression of interleukin-6, interleukin-1beta and tumor necrosis factor-alpha.	shikonin	11-19	interleukin 6	Mus musculus	162-175
34405716-9	2021	Furthermore, co-culture assays indicated that regulating expression of miR-128 in colonic epithelial cells induced the secretion of IL-6 and TNF-alpha by macrophages.	mir-128	71-78	interleukin 6	Mus musculus	132-136
34385100-7	2021	Significantly, dCPP could inhibit the proliferation of IL-4-induced M2-like TAMs, and significantly increase the mRNA expression levels of IL-1, IL-6, iNOS and TNF-a, thereby promoting the repolarization of M2-like TAMs to M1-like TAMs.	4,4-dicarboxy-5-pyridoxylproline	15-19	interleukin 6	Mus musculus	145-149
34385100-7	2021	Significantly, dCPP could inhibit the proliferation of IL-4-induced M2-like TAMs, and significantly increase the mRNA expression levels of IL-1, IL-6, iNOS and TNF-a, thereby promoting the repolarization of M2-like TAMs to M1-like TAMs.	tams	215-219	interleukin 6	Mus musculus	145-149
34289209-6	2021	Consistent with the changes in MDSCs, the serum level of IL-6, IL-1beta was the lowest in the APS group.	aps	94-97	interleukin 6	Mus musculus	57-61
34271086-9	2021	Though the intracellular levels of pyroptosis-related cytokine caspase-1, cleaved caspase-1, NLRP3, IL-18, IL-1beta were upregulated both in MI and H2O2 stimulation, knockout of TN-C resisted such injury and alleviated cardiac pyroptosis, which further decreased IL-6, TNF-alpha, MCP-1 expression.	Hydrogen Peroxide	148-152	interleukin 6	Mus musculus	263-267
34242900-8	2021	Furthermore, MET in combination with genistein reduced the expression of TNF-alpha, IL-1beta, MCP-1, and IL-6 and increased the expression of IL-10 in comparison with genistein and MET groups alone.	Genistein	37-46	interleukin 6	Mus musculus	105-109
34333083-14	2021	Furthermore, miR-150-5p agomir decreased BUN and Scr levels in the septic AKI mice model repressed TNF-alpha, IL-6 and IL-1beta, and up-regulated SOD and CAT down-regulated MDA in the kidney tissues.	mir-150-5p	13-23	interleukin 6	Mus musculus	110-114
34242900-8	2021	Furthermore, MET in combination with genistein reduced the expression of TNF-alpha, IL-1beta, MCP-1, and IL-6 and increased the expression of IL-10 in comparison with genistein and MET groups alone.	Genistein	167-176	interleukin 6	Mus musculus	105-109
34547141-6	2021	Herein, treating with 3-MA markedly suppressed the expression of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-6, promoted that of IL-10, IL-33, and ST2, while RAP administration reverted SWH-induced the up-regulation of these inflammatory cytokines mentioned above.	3-methyladenine	22-26	interleukin 6	Mus musculus	120-124
34224996-9	2021	TNF-alpha, IL-1beta and IL-6 were decreased in the plasma and lung tissues from CLP mice treated with SEI (P < 0.05 compared with DMSO + CLP group).	Dimethyl Sulfoxide	130-134	interleukin 6	Mus musculus	24-28
34547141-7	2021	Importantly, Verteporfin administration not only down-regulated the expression levels of YAP, TNF-alpha, and IL-6 but also up-regulated that of IL-33 and IL-10.	Verteporfin	13-24	interleukin 6	Mus musculus	109-113
34812690-7	2021	Our results showed that LPS exposure led to increased production of TNF-alpha, IL-6, and monocyte chemoattractant protein-1 (MCP-1), which was impaired by bergamottin pre-treatment.	bergamottin	155-166	interleukin 6	Mus musculus	79-83
34233232-6	2021	Surfactin significantly enhanced levels of IgE and immune-enhancing mediators, such as interferon-gamma, interleukin (IL)-2, IL-6, IL-12, and tumor necrosis factor-alpha in serum and melanoma tissues.	surfactin peptide	0-9	interleukin 6	Mus musculus	125-129
34217990-7	2021	Thus, it was concluded that IL-6 represses hepatic CESs via the NF-kappaB pathway in DSS-induced colitis.	Dextran Sulfate	85-88	interleukin 6	Mus musculus	28-32
34117816-10	2021	Naringenin decreased serum levels of pro-inflammatory cytokines interleukin (IL)-2, IL-6 and tumor necrosis factor alpha (TNF-alpha), while increased IL-10.	naringenin	0-10	interleukin 6	Mus musculus	84-88
34273637-5	2021	qRT-PCR analysis showed that DMOG inhibited the M1-like polarization of both RAW264.7 macrophages and murine bone marrow macrophages (BMMs) and downregulated TNF-alpha, IL-6, CD86, and MCP-1 expression in vitro.	oxalylglycine	29-33	interleukin 6	Mus musculus	169-173
34273637-9	2021	DMOG treatment of mice decreased the ratio of M1/M2 (CD86+/CD206+) macrophages in periodontal tissues, resulting in the downregulation of proinflammatory cytokines such as TNF-alpha and IL-6 and increased levels of anti-inflammatory factors such as IL-4 and IL-10.	oxalylglycine	0-4	interleukin 6	Mus musculus	186-190
34303280-4	2021	As a result, (-)-SYR significantly reduced lipopolysaccharide (LPS)-induced production of interleukin - 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), interleukin -1 beta (IL-1beta), cycloxygenase-2 (COX-2), and nitric oxide (NO) in BV2 microglia cells.	syringaresinol	17-20	interleukin 6	Mus musculus	90-105
34303280-4	2021	As a result, (-)-SYR significantly reduced lipopolysaccharide (LPS)-induced production of interleukin - 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), interleukin -1 beta (IL-1beta), cycloxygenase-2 (COX-2), and nitric oxide (NO) in BV2 microglia cells.	syringaresinol	17-20	interleukin 6	Mus musculus	107-111
34333357-8	2021	We also found that BA caused a reduction in the expression of proinflammatory cytokines, such as TNF-alpha and IL-6.	baicalin	19-21	interleukin 6	Mus musculus	111-115
34364303-6	2021	Our results demonstrated that nilotinib significantly suppressed LPS-induced neuroinflammation by reducing the production of pro-inflammatory factors including iNOS, COX-2, IL-1beta, IL-6 and TNF-alpha in BV2 cells.	nilotinib	30-39	interleukin 6	Mus musculus	183-187
34384800-5	2021	CPS 3 and 4 fractions increased the production of TNF-alpha (15 and 17-fold, respectively) and IL-6 (20 and 18-fold, respectively) and iNOS (65 and 35-fold, respectively) expression at concentration 12.5 mug/mL compared with levels in non-treated RAW 264.7 cells.	cps	0-3	interleukin 6	Mus musculus	95-99
34426115-9	2021	Furthermore, the IL-6, IL-10, TNF-alpha serum levels were also upregulated in mice under heat stress, but in mice receiving the oral administration of terpinen4-ol, the IL-6, IL-10, TNF-alpha level was down-regulated on day 1, 7, and 14 of heat stress.	terpinenol-4	151-163	interleukin 6	Mus musculus	17-21
34426115-9	2021	Furthermore, the IL-6, IL-10, TNF-alpha serum levels were also upregulated in mice under heat stress, but in mice receiving the oral administration of terpinen4-ol, the IL-6, IL-10, TNF-alpha level was down-regulated on day 1, 7, and 14 of heat stress.	terpinenol-4	151-163	interleukin 6	Mus musculus	169-173
34339076-12	2021	Moreover, PD-AuNP and Dox-AuNP have the ability to decrease IL-6 production.	pd-aunp	10-17	interleukin 6	Mus musculus	60-64
34339076-12	2021	Moreover, PD-AuNP and Dox-AuNP have the ability to decrease IL-6 production.	Doxorubicin	22-25	interleukin 6	Mus musculus	60-64
34665110-8	2021	Further, polyI:C stimulation of bone marrow-derived macrophages (BMDMs) induced TNF-alpha, IFN-beta, IL-6 and Nos-2, but responses were not different in BMDMs generated from WT or vip-/- mice.	Poly I-C	9-16	interleukin 6	Mus musculus	101-105
34414450-1	2021	Omega-3 polyunsaturated fatty acids (n-3 PUFAs) exert a negative effect on IL-6 production in several liver disorders, including cirrhosis, acute liver failure and fatty liver disease.	Fatty Acids, Omega-3	0-35	interleukin 6	Mus musculus	75-79
34414450-1	2021	Omega-3 polyunsaturated fatty acids (n-3 PUFAs) exert a negative effect on IL-6 production in several liver disorders, including cirrhosis, acute liver failure and fatty liver disease.	Fatty Acids, Omega-3	37-46	interleukin 6	Mus musculus	75-79
34281416-13	2021	In vitro, isoginkgetin markedly suppressed the production of IL-1beta, IL-6, tumor necrosis factor-alpha, cyclooxygenase-2, inducible nitric oxide, and reactive oxygen species, which are released from LPS-stimulated BV2 cells.	isoginkgetin	10-22	interleukin 6	Mus musculus	71-75
34334202-3	2021	The results of the allergic mouse model showed that oral administration of 2"-FL or HMO reduced beta-lactoglobulin (beta-LG)-induced serum-specific IgE secretion and mast cell degranulation, while reducing the inflammatory cytokines, TNF-alpha, IL-4, and IL-6 production and promoting the miR-146a expression.	2'-fucosyllactose	75-80	interleukin 6	Mus musculus	255-259
34309687-1	2021	This study is to compare the tissue distribution and metabolism of AN1284 after subcutaneous and oral administration at doses causing maximal reductions in IL-6 in plasma and tissues of mice.	AN1284	67-73	interleukin 6	Mus musculus	156-160
34368872-8	2021	The results revealed that G-Re significantly inhibited the production of IL-6, TNF-alpha, nitric oxide (NO) and ROS in BV2 microglial cells, and that of NO in mouse primary microglia, without affecting cell viability.	ginsenoside Re	26-30	interleukin 6	Mus musculus	73-77
34309687-4	2021	IL-6 protein levels were measured after 4 h. Using a liquid chromatography/mass spectrometry method we developed, we showed that AN1284 is rapidly metabolized to the indole (AN1422), a 7-OH derivative (AN1280) and its glucuronide.	AN1284	129-135	interleukin 6	Mus musculus	0-4
34309687-6	2021	AN1284 (0.5 mg/kg) caused maximal reductions in IL-6 in the plasma, brain, and liver when injected subcutaneously and after gavage only in the liver.	AN1284	0-6	interleukin 6	Mus musculus	48-52
34400050-15	2021	MCTA significantly decreased the production of NO, IL-1beta, IL-6 and TNF-alpha in LPS-induced RAW 264.7 macrophages.	mcta	0-4	interleukin 6	Mus musculus	61-65
34435401-7	2021	Furthermore, IBC significantly inhibited LPS-triggered secretion of TNF-alpha, IL-6, and nitrite, and nuclear translocation of NF-kappaB p65, in RAW264.7 cells.	isobavachalcone	13-16	interleukin 6	Mus musculus	79-83
34488188-18	2021	In addition, treatment with YFJP significantly decreased the expression of inflammatory and immunosuppressive cytokines (including IL-1beta, IL-6, and IL-10) in the serum and tumor tissues whereas enhancing that of effector cytokines TNF-alpha, and IFN-gamma.	yfjp	28-32	interleukin 6	Mus musculus	141-145
34400050-17	2021	Moreover, the in vivo experiment exhibited that MCTA pretreatment markedly alleviated the xylene-induced ear edema and carrageenan-induced paw edema in mice and decreased the IL-1beta, IL-6 and TNF-alpha expressions.	mcta	48-52	interleukin 6	Mus musculus	185-189
34400050-17	2021	Moreover, the in vivo experiment exhibited that MCTA pretreatment markedly alleviated the xylene-induced ear edema and carrageenan-induced paw edema in mice and decreased the IL-1beta, IL-6 and TNF-alpha expressions.	Xylenes	90-96	interleukin 6	Mus musculus	185-189
34310252-5	2021	In addition, the expressions of TNF-alpha, IL-1beta, IL-6 and COX2 in the gastric mucosa and serum of CAG mice were higher than those control mice, which were reduced in CAG mice treated with either 100 or 200 mg/kg PDTC.	pyrrolidine dithiocarbamic acid	216-220	interleukin 6	Mus musculus	53-57
34588880-7	2021	It was observed that the level of cytokines pro-inflammatory (IL-17, IL-6, IL-2, IL-4, INF-gamma) in serum was normalized in mice treated with ICE, which would indicate that polyP prevents the local inflammatory response in the respiratory tract.	Water	143-146	interleukin 6	Mus musculus	69-73
34588880-7	2021	It was observed that the level of cytokines pro-inflammatory (IL-17, IL-6, IL-2, IL-4, INF-gamma) in serum was normalized in mice treated with ICE, which would indicate that polyP prevents the local inflammatory response in the respiratory tract.	Polyphosphates	174-179	interleukin 6	Mus musculus	69-73
34588910-9	2021	ASPP 092 treatment also modulated the expressions of inflammatory cytokines including Tumor Necrosis Factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-1beta (IL-1beta), and Matrix metalloproteinase-13 (MMP-13).	(3S)-7-(3,4-dihydroxyphenyl)-1-phenyl-(1E)-1-hepten-3-ol	0-8	interleukin 6	Mus musculus	127-140
34588910-9	2021	ASPP 092 treatment also modulated the expressions of inflammatory cytokines including Tumor Necrosis Factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-1beta (IL-1beta), and Matrix metalloproteinase-13 (MMP-13).	(3S)-7-(3,4-dihydroxyphenyl)-1-phenyl-(1E)-1-hepten-3-ol	0-8	interleukin 6	Mus musculus	142-146
34233590-6	2021	In vivo studies have shown that curcumin significantly reduces the mortality of mice and control the occurrence and size of liver tumors by inhibiting the IL-6/STAT3 signaling pathway.	Curcumin	32-40	interleukin 6	Mus musculus	155-159
34402860-10	2021	In addition, our data indicated that overexpression of mmu-miR-133a-3p alleviated the pro-inflammatory cytokines IL-1beta and IL-6 production induced by lipopolysaccharide (LPS), indicating that mmu-miR-133a-3p has a negative effect on microglial activation.	mmu-mir-133a-3p	55-70	interleukin 6	Mus musculus	126-130
34509916-11	2021	Effects of IL-6 on activating NOX2-dependent ROS production and upregulation of MCP-1 were also completely attenuated by 17beta-estradiol.	Reactive Oxygen Species	45-48	interleukin 6	Mus musculus	11-15
34509916-11	2021	Effects of IL-6 on activating NOX2-dependent ROS production and upregulation of MCP-1 were also completely attenuated by 17beta-estradiol.	Estradiol	121-137	interleukin 6	Mus musculus	11-15
34402860-10	2021	In addition, our data indicated that overexpression of mmu-miR-133a-3p alleviated the pro-inflammatory cytokines IL-1beta and IL-6 production induced by lipopolysaccharide (LPS), indicating that mmu-miR-133a-3p has a negative effect on microglial activation.	mmu-mir-133a-3p	195-210	interleukin 6	Mus musculus	126-130
34298051-5	2021	The findings indicated the reduced tumor-derived exosome secretion and protein cargo as reflected by lower levels of CD63, TSG101, heparinase and IL-6 in exosomes derived from heparin-induced B16F10 cells as compared with 6-O-desulfated heparin-induced tumor cells.	Heparin	176-183	interleukin 6	Mus musculus	146-150
34298051-5	2021	The findings indicated the reduced tumor-derived exosome secretion and protein cargo as reflected by lower levels of CD63, TSG101, heparinase and IL-6 in exosomes derived from heparin-induced B16F10 cells as compared with 6-O-desulfated heparin-induced tumor cells.	Heparin	237-244	interleukin 6	Mus musculus	146-150
34658856-13	2021	Our results predicted that astragalin and rosmarinic acid might regulate the JAK-STAT pathway by targeting PIM2 and STAT1, respectively, while paeoniflorin and rosmarinic acid were likely to regulate inflammatory responses by targeting TNFalpha, IL-6, and IL-4 during T2D.	astragalin	27-37	interleukin 6	Mus musculus	246-250
34638977-2	2021	In the present study, we found that 10 or 50 muM donepezil significantly decreased the LPS-induced increases in the mRNA levels of a number of proinflammatory cytokines in BV2 microglial cells, whereas 50 muM rivastigmine significantly diminished only LPS-stimulated IL-6 mRNA levels.	Rivastigmine	209-221	interleukin 6	Mus musculus	267-271
34638977-6	2021	In LPS-treated wild-type mice, a model of neuroinflammatory disease, donepezil significantly attenuated LPS-induced microglial activation, microglial density/morphology, and proinflammatory cytokine COX-2 and IL-6 levels.	Donepezil	69-78	interleukin 6	Mus musculus	209-213
34658856-13	2021	Our results predicted that astragalin and rosmarinic acid might regulate the JAK-STAT pathway by targeting PIM2 and STAT1, respectively, while paeoniflorin and rosmarinic acid were likely to regulate inflammatory responses by targeting TNFalpha, IL-6, and IL-4 during T2D.	rosmarinic acid	42-57	interleukin 6	Mus musculus	246-250
34658856-13	2021	Our results predicted that astragalin and rosmarinic acid might regulate the JAK-STAT pathway by targeting PIM2 and STAT1, respectively, while paeoniflorin and rosmarinic acid were likely to regulate inflammatory responses by targeting TNFalpha, IL-6, and IL-4 during T2D.	peoniflorin	143-155	interleukin 6	Mus musculus	246-250
34658856-13	2021	Our results predicted that astragalin and rosmarinic acid might regulate the JAK-STAT pathway by targeting PIM2 and STAT1, respectively, while paeoniflorin and rosmarinic acid were likely to regulate inflammatory responses by targeting TNFalpha, IL-6, and IL-4 during T2D.	rosmarinic acid	160-175	interleukin 6	Mus musculus	246-250
34587166-6	2021	Lipopolysaccharide-induced pro-inflammatory cytokine (TNF-alpha, IL-6, IL-1beta, and GM-CSF), chemokine (CXCL-1, CXCL-2, and CCL-2), and MMP-9 levels were significantly and dose-dependently reduced in mouse lung tissue with lefamulin; effects were comparable to or more potent than with dexamethasone or azithromycin.	lefamulin	224-233	interleukin 6	Mus musculus	65-69
34638882-8	2021	Thus, it was observed that GGOH dose-dependently suppressed the LPS-induced increase in the mRNA levels of Il-1beta, Tnf-alpha, Il-6, and Cox-2.	ggoh	27-31	interleukin 6	Mus musculus	128-132
34544857-8	2021	These data reveal a mechanism through which IL-6 regulates serine biosynthesis, with potential relevance to the therapy of tumors with mTORC1 hyperactivity.	Serine	59-65	interleukin 6	Mus musculus	44-48
34621323-11	2021	Furthermore, the serum levels of interleukin 12 (IL-12) and chemokine (C-C motif) ligand 2 (CCL2) as well as the mRNA levels of cardiac IL-12, IL-6, and C-C motif chemokine receptor 2 (Ccr2) reduced after FTZ treatment.	CHEMBL1354522	205-208	interleukin 6	Mus musculus	143-147
34650431-8	2021	Geniposide and vitamin D could significantly decrease the levels of TNF-alpha and IL-6 in serum and colon, and increase the level of IL-10 in the colon.	geniposide	0-10	interleukin 6	Mus musculus	82-86
34650431-8	2021	Geniposide and vitamin D could significantly decrease the levels of TNF-alpha and IL-6 in serum and colon, and increase the level of IL-10 in the colon.	Vitamin D	15-24	interleukin 6	Mus musculus	82-86
34551194-7	2022	Ablation of IL-6 overcame hyperlipidemia-induced changes in Tregs, but was not sufficient to overcome resistance to costimulatory molecule blockade induced tolerance.	tregs	60-65	interleukin 6	Mus musculus	12-16
34551194-9	2022	While alterations in Tregs were overcome by ablation of IL-6, the reversal of hyperlipidemia-induced changes in Tregs was not sufficient to overcome increased Th1-type anti-donor T cell responses, suggesting that hyperlipidemia induced IL-6-independent effects on recipient immunity prevent tolerance induction.	tregs	21-26	interleukin 6	Mus musculus	56-60
34630408-5	2021	In KNT-127-treated mice, the levels of an inflammatory cytokine IL-6 in the serum, and macrophages in the mesenteric lymph nodes (MLNs) were decreased in the progression stage, and those of regulatory T cells (Tregs) in the MLN were increased in the recovery stage.	KNT 127	3-10	interleukin 6	Mus musculus	64-68
34680413-7	2021	We demonstrated that a combination of butyrate and active vitamin D (1 alpha, 25-dihydroxyvitamin D3) synergically reduced the severity of Salmonella colitis in C57BL/6 mice and reduced cecal inflammatory mIL-6, mIL-8, mTNF-alpha, and mIL-1beta mRNA expression, but enhanced the antimicrobial peptide mhBD-3 mRNA, compared to a single treatment.	Butyrates	38-46	interleukin 6	Mus musculus	205-210
34680413-7	2021	We demonstrated that a combination of butyrate and active vitamin D (1 alpha, 25-dihydroxyvitamin D3) synergically reduced the severity of Salmonella colitis in C57BL/6 mice and reduced cecal inflammatory mIL-6, mIL-8, mTNF-alpha, and mIL-1beta mRNA expression, but enhanced the antimicrobial peptide mhBD-3 mRNA, compared to a single treatment.	Vitamin D	58-67	interleukin 6	Mus musculus	205-210
34680413-7	2021	We demonstrated that a combination of butyrate and active vitamin D (1 alpha, 25-dihydroxyvitamin D3) synergically reduced the severity of Salmonella colitis in C57BL/6 mice and reduced cecal inflammatory mIL-6, mIL-8, mTNF-alpha, and mIL-1beta mRNA expression, but enhanced the antimicrobial peptide mhBD-3 mRNA, compared to a single treatment.	Calcitriol	69-100	interleukin 6	Mus musculus	205-210
34616305-7	2021	LcS + geniposide also decreased the amount of inflammatory-related indicators of TNF-alpha, IL-6, and IL-1beta, and the oxidation-related levels of malondialdehyde (MDA) in the hippocampi of septic mice, and it increased the oxidase activities of superoxide dismutase (SOD) and catalase (CAT).	geniposide	6-16	interleukin 6	Mus musculus	92-96
34549671-5	2021	Proinflammatory cytokines, IL-2, IL-17A, IFN-Upsilon, and anti-inflammatory cytokines, IL-4, IL-6 and IL-10, were also measured in serum.Results: Consistent with previous studies, cerebral capillary dysfunction and astroglial cell activation were markedly greater in the alcohol-only group (AO); however, the AO-induced effects were profoundly attenuated with the AMED combination.	Alcohols	271-278	interleukin 6	Mus musculus	93-97
34537066-12	2021	CYR119 attenuated LPS-induced elevation of interleukin 6 (IL-6) and tumor necrosis factor (TNF) in mouse microglial cells.	cyr119	0-6	interleukin 6	Mus musculus	43-56
34180933-12	2021	RSV also downregulated the expression of the inflammatory cytokines, interleukin IL-6, IL-1beta and tumor necrosis factor (TNF)-alpha in the liver and kidneys of ageing mice.	Resveratrol	0-3	interleukin 6	Mus musculus	81-85
34537066-12	2021	CYR119 attenuated LPS-induced elevation of interleukin 6 (IL-6) and tumor necrosis factor (TNF) in mouse microglial cells.	cyr119	0-6	interleukin 6	Mus musculus	58-62
34576160-8	2021	After treatment with IRE1alpha inhibitor STF-083010, the results showed that the expression of adipocyte inflammation-related genes interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFalpha) significantly were decreased.	STF 083010	41-51	interleukin 6	Mus musculus	132-145
34573120-10	2021	Il6-deficient mice were susceptible to O3-induced protein hyperpermeability, indicating its defensive role, while Tnf-deficient mice were resistant to overall lung injury caused by O3.	Ozone	39-41	interleukin 6	Mus musculus	0-3
34557016-11	2021	qPCR and ELISA analysis identified that allergen induced increases in IL-5, IL-13, IL-33, IFN-gamma and IL-1beta cytokines mRNA in whole lungs and the levels of IL-6, IL-1beta and TNF-alpha proteins in BALF were significantly attenuated upon oral SPAB treatment.	spab	247-251	interleukin 6	Mus musculus	161-165
34576160-8	2021	After treatment with IRE1alpha inhibitor STF-083010, the results showed that the expression of adipocyte inflammation-related genes interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFalpha) significantly were decreased.	STF 083010	41-51	interleukin 6	Mus musculus	147-151
34530920-11	2021	SF-MSCs inhibited the reduction in serum transforming growth factor-beta1 and the increase of interleukin-6 in both the serum and the bronchoalveolar lavage fluid during bleomycin-induced pulmonary fibrosis.	Bleomycin	170-179	interleukin 6	Mus musculus	94-107
34615595-11	2022	IL-6 promoted glycolysis in TC-1 cells, which resulted in Acetyl-CoA accumulation.	Acetyl Coenzyme A	58-68	interleukin 6	Mus musculus	0-4
34216747-7	2021	Furthermore, Selenogefitinib decreased the levels of pro-inflammatory markers IL-4, IL-6, and TNF-alpha more significantly than gefitinib, which indicated that it exhibited a higher anti-inflammatory activity.	selenogefitinib	13-28	interleukin 6	Mus musculus	84-88
34129880-7	2021	After 28 days, STZ treated mice exhibited memory impairment in radial arm maze, depression-like behavior in forced swim test and anxiety-like behavior in elevated plus maze along with increased expression of pro-inflammatory cytokines like TNF-alpha, IL-1beta, IL-6, IL-10 and reduced agmatine and BDNF levels in the hippocampus and prefrontal cortex compared to the control animals.	Streptozocin	15-18	interleukin 6	Mus musculus	261-265
34595202-5	2021	Furthermore, daily supplementation of ellagic acid alleviated hepatic antioxidant activities (glutathione peroxidase, catalase, malondialdehyde, superoxide dismutase, and glutathione), proinflammatory cytokines levels (IL-6, IL-1beta, and TNF-alpha), genes expressions (Tlr4, Myd88, Cd14, Cox2, Nos2, and Nfkappab1), and histopathological features in alcohol-induced liver injured mice.	Ellagic Acid	38-50	interleukin 6	Mus musculus	219-223
34192596-7	2021	Biochemical assays showed that serum alanine aminotransferase, aspartate aminotransferase and hepatic lipids were significantly decreased in MCD-induced NAFLD mice orally administered of DMTHB (50 mg/kg or 150 mg/g body weight daily) for 30 d. qPCR and ELISA analysis demonstrated that DMTHB reduced the expression of serum proinflammatory cytokines, such as TNF-alpha, IL-1beta and IL-6.	dmthb	187-192	interleukin 6	Mus musculus	383-387
34192596-7	2021	Biochemical assays showed that serum alanine aminotransferase, aspartate aminotransferase and hepatic lipids were significantly decreased in MCD-induced NAFLD mice orally administered of DMTHB (50 mg/kg or 150 mg/g body weight daily) for 30 d. qPCR and ELISA analysis demonstrated that DMTHB reduced the expression of serum proinflammatory cytokines, such as TNF-alpha, IL-1beta and IL-6.	dmthb	286-291	interleukin 6	Mus musculus	383-387
34515915-6	2021	The co-administration of CeO2-NPs also ameliorated the lead acetate-induced dysregulation in the expression levels of p53, K-ras, interleukin-6, and cyclooxygenase-2 in the kidney and heart.	lead acetate	55-67	interleukin 6	Mus musculus	130-143
34245977-10	2021	Cisplatin-induced production of TNF-alpha and IL-6, and renal tubular cell apoptosis was attenuated in Dok3-/- mice.	Cisplatin	0-9	interleukin 6	Mus musculus	46-50
34576095-9	2021	TiO2NPs treated cells exhibited an increase in the mRNA and protein expression of interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha with an elevation of TXNIP signaling compared to non-treated cells.	tio2nps	0-7	interleukin 6	Mus musculus	106-110
34510498-9	2022	Mechanistically, increased ATP secretion facilitates the early activation of kupffer cells and production of TNF, IL-6 and HB-EGF accelerating the priming phase and the progression through G1/S transition during liver regeneration.	Adenosine Triphosphate	27-30	interleukin 6	Mus musculus	114-118
34245977-11	2021	In vitro experiments demonstrated that HK2 cells overexpressing Dok3 exhibited exacerbated cisplatin-induced apoptosis and production of TNF-alpha and IL-6.	Cisplatin	91-100	interleukin 6	Mus musculus	151-155
34568098-7	2021	Inhibition of S100B by pentamidine reduced the synthesis of IL-1beta, IL-18, IL-6, GMCSF, TNF-alpha, IL-17, IL-23, and IL-2 and downregulated a variety of NFkappaB-related genes, increased the transcription (SOCS2 and Bcl-2) of protective mediators, reduced neutrophil recruitment, and ameliorated intestinal damage and diarrhea severity in mice.	Pentamidine	23-34	interleukin 6	Mus musculus	77-81
34566567-8	2021	In addition, oxytocin administration normalized ketamine-induced inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta levels.	Ketamine	48-56	interleukin 6	Mus musculus	109-113
34566640-4	2021	Based on the results, PTX inhibited the migration of RA-FLS in a dose-dependent manner and significantly reduced the spontaneous expression of IL-6, IL-8, and RANKL mRNA and TNF-alpha-induced transcription of the IL-1 beta, IL-8, MMP-8, and MMP-9 genes.	Paclitaxel	22-25	interleukin 6	Mus musculus	143-147
34568404-7	2021	In macrophages from obese mice fed with CRL1446 and CRL1434, after LPS stimulus, lower levels of MCP-1, TNF-alpha, IL-6 compared to obese control were observed.	crl1446	40-47	interleukin 6	Mus musculus	115-119
34568404-7	2021	In macrophages from obese mice fed with CRL1446 and CRL1434, after LPS stimulus, lower levels of MCP-1, TNF-alpha, IL-6 compared to obese control were observed.	crl1434	52-59	interleukin 6	Mus musculus	115-119
34568098-8	2021	In EGCs, TcdA and TcdB upregulated S100B-mediated IL-6 expression via activation of RAGE/PI3K/NFkappaB.	tcda	9-13	interleukin 6	Mus musculus	50-54
34568098-8	2021	In EGCs, TcdA and TcdB upregulated S100B-mediated IL-6 expression via activation of RAGE/PI3K/NFkappaB.	trimethylaminocarboxyldihydroboran	18-22	interleukin 6	Mus musculus	50-54
34573062-0	2021	Ergosta-7,9(11),22-trien-3beta-ol Attenuates Inflammatory Responses via Inhibiting MAPK/AP-1 Induced IL-6/JAK/STAT Pathways and Activating Nrf2/HO-1 Signaling in LPS-Stimulated Macrophage-like Cells.	ergosta-7,9	0-11	interleukin 6	Mus musculus	101-105
34573062-0	2021	Ergosta-7,9(11),22-trien-3beta-ol Attenuates Inflammatory Responses via Inhibiting MAPK/AP-1 Induced IL-6/JAK/STAT Pathways and Activating Nrf2/HO-1 Signaling in LPS-Stimulated Macrophage-like Cells.	),22-trien-3beta-ol	14-33	interleukin 6	Mus musculus	101-105
34217824-5	2021	FK506@EHCh NPs significantly suppressed secretion of TNF-alpha, IL-1beta and IL-6 by LPS-activated Raw 264.7 macrophages.	Tacrolimus	0-5	interleukin 6	Mus musculus	77-81
34246743-8	2021	Consistently, DOX-induced activities of ABC transporters, CXCL-1, GM-CSF and IL-6, which are tumor protective events downstream to the pro-inflammatory signaling, were also minimal in Nano-DOX-treated cancer cells.	Doxorubicin	14-17	interleukin 6	Mus musculus	77-81
34373409-12	2021	Investigation of the anti-inflammatory effects of alpha-tocopherol or delta-tocopherol in co-cultured 3T3-L1 cells and RAW264.7 cells showed that delta-tocopherol inhibited increased gene expression of the inflammatory cytokines, IL-1beta, IL-6, and iNOS.	alpha-Tocopherol	50-66	interleukin 6	Mus musculus	240-244
34373409-12	2021	Investigation of the anti-inflammatory effects of alpha-tocopherol or delta-tocopherol in co-cultured 3T3-L1 cells and RAW264.7 cells showed that delta-tocopherol inhibited increased gene expression of the inflammatory cytokines, IL-1beta, IL-6, and iNOS.	delta-tocopherol	70-86	interleukin 6	Mus musculus	240-244
34373409-12	2021	Investigation of the anti-inflammatory effects of alpha-tocopherol or delta-tocopherol in co-cultured 3T3-L1 cells and RAW264.7 cells showed that delta-tocopherol inhibited increased gene expression of the inflammatory cytokines, IL-1beta, IL-6, and iNOS.	delta-tocopherol	146-162	interleukin 6	Mus musculus	240-244
34539617-5	2021	Compared with the control group, mice supplemented with RSV had decreased mRNA expression of genes related to inflammatory cytokines (IL-6 and IL-1beta), but increased mRNA expression of genes related to host defense peptides (Defa3, Defa5, Defa20, and Lyz) and short-chain fatty acids (SCFAs) production (propionic acid, isobutyric acid, butyric acid, and isovaleric acid).	Resveratrol	56-59	interleukin 6	Mus musculus	134-138
34480023-4	2021	Interestingly, 6- and 14-month D + Q cohorts show lower incidences of degeneration, and the treatment results in a significant decrease in senescence markers p16INK4a, p19ARF, and SASP molecules IL-6 and MMP13.	d + q	31-36	interleukin 6	Mus musculus	195-199
34118224-4	2021	Besides, Scutellarin attenuated mouse serum concentrations of TNF-alpha and IL-6, heightened Bax expression and diminished B-cell lymphoma-2 (Bcl-2) level in CAC tissues of mice, through down-regulating Wnt/beta-catenin signaling cascade.	scutellarin	9-20	interleukin 6	Mus musculus	76-80
34500784-3	2021	The effects of 6-MC on the production and levels of pro-inflammatory cytokines (interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha) and inflammatory mediators (nitric oxide (NO), prostaglandin E2 (PGE2)) in LPS-stimulated RAW 264.7 cells were examined.	6-methylcoumarin	15-19	interleukin 6	Mus musculus	104-108
34564408-6	2021	SP challenge caused a significant concentration-dependent increase in proinflammatory markers (TLR4, p-p38 MAPK, NF-kappaB) paralleled to a marked upregulation of inflammasome-dependent inflammatory pathways (NLRP3, Caspase-1) with IL-6, IL-1beta, TNF-alpha over-release, compared to vehicle group.	sp	0-2	interleukin 6	Mus musculus	232-236
34059563-4	2021	Intrarectal treatment of moderate and severe colitis with 5-ASA alone or HA alone at a dose of 30 mg/kg led to a significant decrease in clinical activity and histology scores, myeloperoxidase activity (MPO), TNF-alpha, IL-6 and IL-1beta in colitis mice compared to untreated animals.	Mesalamine	58-63	interleukin 6	Mus musculus	220-224
34126350-0	2021	Olive polyphenols attenuate TNF-alpha-stimulated M-CSF and IL-6 synthesis in osteoblasts: Suppression of Akt and p44/p42 MAP kinase signaling pathways.	Polyphenols	6-17	interleukin 6	Mus musculus	59-63
34126350-2	2021	The aim of this study is to elucidate the effects and the underlying mechanisms of hydroxytyrosol and oleuropein on the tumor necrosis factor-alpha (TNF-alpha)-induced macrophage colony-stimulating factor (M-CSF) and interleukin-6 (IL-6) synthesis in osteoblasts.	3,4-dihydroxyphenylethanol	83-97	interleukin 6	Mus musculus	232-236
34126350-2	2021	The aim of this study is to elucidate the effects and the underlying mechanisms of hydroxytyrosol and oleuropein on the tumor necrosis factor-alpha (TNF-alpha)-induced macrophage colony-stimulating factor (M-CSF) and interleukin-6 (IL-6) synthesis in osteoblasts.	oleuropein	102-112	interleukin 6	Mus musculus	232-236
34126350-10	2021	Hydroxytyrosol and oleuropein attenuated the TNF-alpha-stimulated IL-6 release.	3,4-dihydroxyphenylethanol	0-14	interleukin 6	Mus musculus	66-70
34126350-10	2021	Hydroxytyrosol and oleuropein attenuated the TNF-alpha-stimulated IL-6 release.	oleuropein	19-29	interleukin 6	Mus musculus	66-70
34126350-11	2021	Hydroxytyrosol suppressed the TNF-alpha-induced mRNA expressions of M-CSF and IL-6.	3,4-dihydroxyphenylethanol	0-14	interleukin 6	Mus musculus	78-82
34126350-13	2021	CONCLUSION: Our present findings strongly suggest that olive oil polyphenols hydroxytyrosol and oleuropein down-regulates TNF-alpha signaling at the points upstream of Akt and p44/p42 MAP kinase in osteoblasts, leading to the attenuation of M-CSF and IL-6 synthesis.	polyphenols hydroxytyrosol	65-91	interleukin 6	Mus musculus	251-255
34126350-13	2021	CONCLUSION: Our present findings strongly suggest that olive oil polyphenols hydroxytyrosol and oleuropein down-regulates TNF-alpha signaling at the points upstream of Akt and p44/p42 MAP kinase in osteoblasts, leading to the attenuation of M-CSF and IL-6 synthesis.	oleuropein	96-106	interleukin 6	Mus musculus	251-255
34126352-10	2021	Moreover, CBD restores the PLAE-induced increased levels of TNFalpha and IL-6 in the hippocampus.	Cannabidiol	10-13	interleukin 6	Mus musculus	73-77
34328106-10	2021	Tissue gene expression of psoriatic core cytokines induced by imiquimod (including IL-23, IL-17A, IL-22, TNF-alpha, and IL-6) were greatly decreased by capsaicin application.	Capsaicin	152-161	interleukin 6	Mus musculus	120-124
34422538-4	2021	Furthermore, CC34 significantly lowered the levels of select inflammatory cytokines, including TNF-alpha, IL-1beta, and IL-6.	cc34	13-17	interleukin 6	Mus musculus	120-124
34350676-7	2021	It was found that Tanshinone IIA alleviated the development of vitiligo, impaired PMEL CD8+ T cells accumulation in the ear skin, and inhibited LPS-induced TNF-alpha, IL-6, and IL-1beta expression and secretion in BMDMs, which could also inhibit IL-4-induced Arg-1 and Mrc-1 expression in BMDMs.	tanshinone	18-32	interleukin 6	Mus musculus	167-171
34144202-8	2021	Meanwhile, we observed that melatonin reduced activated gliosis via attenuation of Iba1, and inhibited increase of anti-inflammatory cytokines (IL-4 and IL-10) and the decrease of pro-inflammatory cytokines (IL-6 and TNF-alpha).	Melatonin	28-37	interleukin 6	Mus musculus	208-212
34116287-5	2021	PAMK pretreatment could relieved histopathological damage caused by LPS, and could activate the TLR4-MyD88-NFkappaB signalling pathway, reduce the levels of IL-1beta, IL-6 and TNF-alpha, increase IL-4 levels, inhibit the levels of GSH-PX and MDA.	pamk	0-4	interleukin 6	Mus musculus	167-171
34303829-8	2021	IL-6 and IL-1beta secretions induced by heme in the presence of PRRs agonists were inhibited by chloroquine, but not by calcium chelator BAPTA or inhibitor of endosomal acidification concamycin B.	Heme	40-44	interleukin 6	Mus musculus	0-4
34303829-8	2021	IL-6 and IL-1beta secretions induced by heme in the presence of PRRs agonists were inhibited by chloroquine, but not by calcium chelator BAPTA or inhibitor of endosomal acidification concamycin B.	Chloroquine	96-107	interleukin 6	Mus musculus	0-4
34061465-3	2021	These macrophages were pretreated with rigosertib and then induced with LPS or poly I:C. RESULTS: Rigosertib suppressed LPS or poly I:C-induced expression of inflammatory cytokines (tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and IL-23) in WT bone marrow-derived macrophages while failed to affect the upregulation of TNF-alpha and IL-6 in LPS-treated bone marrow-derived macrophages from MEK1DD mice.	ON 01910	98-108	interleukin 6	Mus musculus	226-239
34061465-3	2021	These macrophages were pretreated with rigosertib and then induced with LPS or poly I:C. RESULTS: Rigosertib suppressed LPS or poly I:C-induced expression of inflammatory cytokines (tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and IL-23) in WT bone marrow-derived macrophages while failed to affect the upregulation of TNF-alpha and IL-6 in LPS-treated bone marrow-derived macrophages from MEK1DD mice.	ON 01910	98-108	interleukin 6	Mus musculus	241-245
34061465-3	2021	These macrophages were pretreated with rigosertib and then induced with LPS or poly I:C. RESULTS: Rigosertib suppressed LPS or poly I:C-induced expression of inflammatory cytokines (tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and IL-23) in WT bone marrow-derived macrophages while failed to affect the upregulation of TNF-alpha and IL-6 in LPS-treated bone marrow-derived macrophages from MEK1DD mice.	Poly I	127-133	interleukin 6	Mus musculus	226-239
34061465-3	2021	These macrophages were pretreated with rigosertib and then induced with LPS or poly I:C. RESULTS: Rigosertib suppressed LPS or poly I:C-induced expression of inflammatory cytokines (tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and IL-23) in WT bone marrow-derived macrophages while failed to affect the upregulation of TNF-alpha and IL-6 in LPS-treated bone marrow-derived macrophages from MEK1DD mice.	Poly I	127-133	interleukin 6	Mus musculus	241-245
34061465-3	2021	These macrophages were pretreated with rigosertib and then induced with LPS or poly I:C. RESULTS: Rigosertib suppressed LPS or poly I:C-induced expression of inflammatory cytokines (tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and IL-23) in WT bone marrow-derived macrophages while failed to affect the upregulation of TNF-alpha and IL-6 in LPS-treated bone marrow-derived macrophages from MEK1DD mice.	Carbon	134-135	interleukin 6	Mus musculus	226-239
34061465-3	2021	These macrophages were pretreated with rigosertib and then induced with LPS or poly I:C. RESULTS: Rigosertib suppressed LPS or poly I:C-induced expression of inflammatory cytokines (tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and IL-23) in WT bone marrow-derived macrophages while failed to affect the upregulation of TNF-alpha and IL-6 in LPS-treated bone marrow-derived macrophages from MEK1DD mice.	Carbon	134-135	interleukin 6	Mus musculus	241-245
34118645-4	2021	Additionally, in the early stages of inflammation, DHL administration inhibited the infiltration of inflammatory cells and downregulated the expression of TGF-beta, TNF-alpha, and IL-6, indicating that DHL treatment effectively alleviated BLM-induced pulmonary fibrosis and inflammation in a dose-dependent manner.	dehydrocostus lactone	51-54	interleukin 6	Mus musculus	180-184
34118645-4	2021	Additionally, in the early stages of inflammation, DHL administration inhibited the infiltration of inflammatory cells and downregulated the expression of TGF-beta, TNF-alpha, and IL-6, indicating that DHL treatment effectively alleviated BLM-induced pulmonary fibrosis and inflammation in a dose-dependent manner.	dehydrocostus lactone	202-205	interleukin 6	Mus musculus	180-184
34153674-10	2021	Serum myeloperoxidase, IgG2a, IL-1beta, IL-6, IL-17, and TNF-alpha and spleen CD4+IFN-gamma+IL-17+ T lymphocytes were reduced after PD1 treatment in IMQ-induced psoriasiform mouse models.	Imiquimod	149-152	interleukin 6	Mus musculus	40-44
34153665-5	2021	The results showed that Z-312 significantly decreased the production of nitric oxide (NO), interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha and IL-6 in LPS-stimulated microglial cells.	z-312	24-29	interleukin 6	Mus musculus	153-157
34153665-5	2021	The results showed that Z-312 significantly decreased the production of nitric oxide (NO), interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha and IL-6 in LPS-stimulated microglial cells.	lps	161-164	interleukin 6	Mus musculus	153-157
34337860-6	2021	On the other hand, artesunate strongly inhibited the mRNA expression of inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha), protein levels of inflammatory signals (iNOS and NF-kappaB) and necroptosis signals (RIPK1, RIPK3 and MLKL) in kidney of AKI mouse.	Artesunate	19-29	interleukin 6	Mus musculus	106-110
34174702-7	2021	The results of our mouse model study revealed that Irbesartan could reduce BBB permeability, restore the expression of Occludin, and suppress the expression of inflammatory mediators, including interleukin-6, monocyte chemoattractant protein-1, and intercellular adhesion molecule-1.	Irbesartan	51-61	interleukin 6	Mus musculus	194-207
34102196-6	2021	GS-Moxi decreased the expression of IL-1beta, IL-6, and TNF-alpha.	gs-moxi	0-7	interleukin 6	Mus musculus	46-50
34250696-13	2021	Rosmarinic acid downregulated the cytokines like interleukin-6, tumor necrosis factor-alpha, interleukin-1beta; inflammatory parameter includes prostaglandin E2 , cyclooxygenase-2, and inducible nitric oxide synthase at a dose-dependently.	rosmarinic acid	0-15	interleukin 6	Mus musculus	49-62
34391968-11	2021	Resveratrol also inhibited the induction effect of rotenone on IL-6, IL-1beta, and TNF-alpha.	Resveratrol	0-11	interleukin 6	Mus musculus	63-67
34278508-7	2021	The results showed that DEX treatment markedly increased the survival rate and neurological score, increased neuron survival, decreased the expression of the LC3, Beclin-1 and NF-kappaB proteins, as well as the cytokines IL-1beta, IL-6 and TNF-alpha, which indicated that DEX-mediated inhibition of autophagy and neuroinflammation ameliorated neuronal death following TBI.	Dexmedetomidine	24-27	interleukin 6	Mus musculus	231-235
34278508-7	2021	The results showed that DEX treatment markedly increased the survival rate and neurological score, increased neuron survival, decreased the expression of the LC3, Beclin-1 and NF-kappaB proteins, as well as the cytokines IL-1beta, IL-6 and TNF-alpha, which indicated that DEX-mediated inhibition of autophagy and neuroinflammation ameliorated neuronal death following TBI.	Dexmedetomidine	272-275	interleukin 6	Mus musculus	231-235
34391968-11	2021	Resveratrol also inhibited the induction effect of rotenone on IL-6, IL-1beta, and TNF-alpha.	Rotenone	51-59	interleukin 6	Mus musculus	63-67
34247115-9	2021	Further, RT-PCR showed that the ectopic transcription of inflammation-associated genes including TNFalpha, IL-1beta, IL-6, COX-2, iNOS, and p65 was reversed in 5XFAD mice treated with tetrandrine.	tetrandrine	184-195	interleukin 6	Mus musculus	117-121
34250649-8	2021	To this end, treatment with SB alleviated inflammatory components, including IL-1beta, IL-6, and TNF-alpha in the fibrotic tissue.	Silybin	28-30	interleukin 6	Mus musculus	87-91
34175668-3	2021	Here, we report that S-nitrosoglutathione (GSNO) and GSNO-reductase (GSNOR) inhibitor N6022 drive upregulation of regulatory cytokine (IL-10) and downregulation of pathogenic effector cytokine (IL-6) in B cells and protected against the neuroinflammatory disease of experimental autoimmune encephalomyelitis (EAE).	S-Nitrosoglutathione	21-41	interleukin 6	Mus musculus	194-198
34175668-3	2021	Here, we report that S-nitrosoglutathione (GSNO) and GSNO-reductase (GSNOR) inhibitor N6022 drive upregulation of regulatory cytokine (IL-10) and downregulation of pathogenic effector cytokine (IL-6) in B cells and protected against the neuroinflammatory disease of experimental autoimmune encephalomyelitis (EAE).	S-Nitrosoglutathione	43-47	interleukin 6	Mus musculus	194-198
34175668-3	2021	Here, we report that S-nitrosoglutathione (GSNO) and GSNO-reductase (GSNOR) inhibitor N6022 drive upregulation of regulatory cytokine (IL-10) and downregulation of pathogenic effector cytokine (IL-6) in B cells and protected against the neuroinflammatory disease of experimental autoimmune encephalomyelitis (EAE).	N6022	86-91	interleukin 6	Mus musculus	194-198
34175668-4	2021	In human and mouse B cells, the GSNO/N6022-mediated regulation of IL-10 vs. IL-6 was not limited to regulatory B cells but also to a broad range of B cell subsets and antibody-secreting cells.	S-Nitrosoglutathione	32-36	interleukin 6	Mus musculus	76-80
34175668-4	2021	In human and mouse B cells, the GSNO/N6022-mediated regulation of IL-10 vs. IL-6 was not limited to regulatory B cells but also to a broad range of B cell subsets and antibody-secreting cells.	N6022	37-42	interleukin 6	Mus musculus	76-80
34502316-6	2021	Proinflammatory cytokines (e.g., IL-6, TNF-alpha, and IL-1) have been identified as a driver of the pathological mechanisms underlying involuntary weight loss and impaired physical function, i.e., cachexia, during cancer; in the present study, we showed that farrerol attenuates TNF-alpha-induced lipolysis and increases adipogenic differentiation in 3T3-L1 cells.	farrerol	259-267	interleukin 6	Mus musculus	33-37
34504642-6	2021	Moreover, the status of oxidative stress and levels of inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, and MCP-1) were markedly inhibited by YSPDF treatment.	yspdf	144-149	interleukin 6	Mus musculus	90-94
34511967-8	2021	Compared to the antibiotic alone or PBS groups, the combination group had higher levels of IL-1alpha, IL-1beta and IFN-gamma and lower levels of IL-6, IL-10, TNF-alpha.	Lead	36-39	interleukin 6	Mus musculus	145-149
34448973-13	2021	Interleukin (IL) 1beta, IL-6, IL-8, and TNFalpha were also increased in the T1DM mice with water deprivation.	Water	91-96	interleukin 6	Mus musculus	24-28
34497658-10	2021	LBO could also effectively downregulate the expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and interferon-beta and the activation of P65 and IRF3 in Poly I:C-treated cells.	Poly I-C	168-176	interleukin 6	Mus musculus	103-107
34574102-6	2021	Besides significant prevention of retinal dysfunction shown in ERG recordings, ACE oil-enriched diet upregulated the expression of the anti-inflammatory markers PPARgamma, PPARalpha and IL-10, while reducing that of major proinflammatory biomarkers, IL-1beta, IL-6, TNF-alpha and COX-2.	ace oil	79-86	interleukin 6	Mus musculus	260-264
34424818-9	2021	Furthermore, HDL from the REP-based diet-fed mice significantly suppressed the inflammatory cytokine response of human umbilical vein endothelial cells than that from the casein-based diet-fed mice (MCP-1, p = 0.010; IL-6, p = 0.011; IL-1beta, p = 0.028).	N,N-DIETHYLBENZAMIDE	26-29	interleukin 6	Mus musculus	217-221
34576700-8	2021	The in vivo study demonstrated the combination of probiotic Bifidobacterium longum and active vitamin D3 had the synergistic effects on reducing the severity of Salmonella colitis and body weight loss in C57BL/6 mice by reducing cecal inflammatory mIL-6, mIL-8, mTNF-alpha and mIL-1beta mRNA responses, blocking the translocation of bacteria while enhancing the antimicrobial peptide mhBD-3 mRNA in comparison to the infection only group.	Cholecalciferol	94-104	interleukin 6	Mus musculus	248-253
34504808-8	2021	By the end of treatment, STAT3 inhibition with TTI-101 eliminated cardiac fibrosis and fibrosis biomarkers but increased cardiac inflammation; serum levels of interleukin-6 (IL-6), and IFN-gamma; cardiac gene expression of STAT1 and nuclear factor-kappaB (NF-kappaB); and upregulation of IL-6 and Type I and Type II IFN responses.	C188-9	47-54	interleukin 6	Mus musculus	159-172
34504808-8	2021	By the end of treatment, STAT3 inhibition with TTI-101 eliminated cardiac fibrosis and fibrosis biomarkers but increased cardiac inflammation; serum levels of interleukin-6 (IL-6), and IFN-gamma; cardiac gene expression of STAT1 and nuclear factor-kappaB (NF-kappaB); and upregulation of IL-6 and Type I and Type II IFN responses.	C188-9	47-54	interleukin 6	Mus musculus	174-178
34504808-8	2021	By the end of treatment, STAT3 inhibition with TTI-101 eliminated cardiac fibrosis and fibrosis biomarkers but increased cardiac inflammation; serum levels of interleukin-6 (IL-6), and IFN-gamma; cardiac gene expression of STAT1 and nuclear factor-kappaB (NF-kappaB); and upregulation of IL-6 and Type I and Type II IFN responses.	C188-9	47-54	interleukin 6	Mus musculus	288-292
34497510-10	2021	Meanwhile, the administration of RSV induced downregulated the expressions of TNF-alpha, IFN-gamma, IL-1beta, IL-6, and IL-4.	Resveratrol	33-36	interleukin 6	Mus musculus	110-114
34456580-9	2021	Furthermore, repetitive exposure to PDSSDE led to decreased neutrophil and eosinophilic influx and IL-6 release in mice compared to SSDE-challenged mice.	pdssde	36-42	interleukin 6	Mus musculus	99-103
34490261-5	2021	Furthermore, Zdhhc11 knockout mice had a lower level of serum IL6 upon treatment with LPS and D-galactosamine or HSV-1 infection than control mice.	Galactosamine	94-109	interleukin 6	Mus musculus	62-65
34456580-9	2021	Furthermore, repetitive exposure to PDSSDE led to decreased neutrophil and eosinophilic influx and IL-6 release in mice compared to SSDE-challenged mice.	ssde	132-136	interleukin 6	Mus musculus	99-103
34421084-7	2021	Dex inhibited the inflammatory response through decreasing the release and the mRNA expression of IL-1beta, IL-6, and TNF-alpha while increasing that of IL-10.	Dexmedetomidine	0-3	interleukin 6	Mus musculus	108-112
34457020-10	2021	Our results showed that GLGZD pretreatment significantly induced IL10 release and decreased the production of TNF-alpha, IL6, and IFN-gamma.	glgzd	24-29	interleukin 6	Mus musculus	121-124
34416638-6	2021	The results showed that exposure to TCS enhanced NF-kappaB activation, increased inflammatory cytokine expression including interleukin (IL) 1beta, IL-6, and tumor necrosis factor (TNF) alpha in the BV-2 cells.	Triclosan	36-39	interleukin 6	Mus musculus	148-152
34404751-6	2021	This trap, called cs-130Fc, exhibited improved inhibition of as well as increased selectivity for IL-6 trans-signaling compared to the conventional fusion protein sgp130Fc.	Cesium	18-20	interleukin 6	Mus musculus	98-102
34404751-7	2021	We introduced affinity-enhancing mutations in cs-130Fc and sgp130Fc that further improved selectivity toward IL-6 trans-signaling.	Cesium	46-48	interleukin 6	Mus musculus	109-113
34404751-8	2021	Moreover, cs-130Fc efficiently inhibited the expansion of T helper 17 (TH17) cells in cultures of mouse CD4+ T cells treated with IL-6:sIL-6R.	cs-130fc	10-18	interleukin 6	Mus musculus	130-134
34484184-8	2021	), administration of aSP-D attenuated the severity of ALI, accompanied by lower neutrophil infiltrates and expression of IL-1beta and IL-6.	asp-d	21-26	interleukin 6	Mus musculus	134-138
34539991-6	2021	Results: Galangin treatment suppressed the expression of IL-1beta-induced inflammatory cytokines, such as nitric oxide synthase, cyclooxygenase-2, TNF-alpha, and IL-6.	galangin	9-17	interleukin 6	Mus musculus	162-166
34400718-9	2021	In vivo, 14,15-DHET and IL-6 serum concentrations were decreased after burn injury with TPPU administration.	TPPU	88-92	interleukin 6	Mus musculus	24-28
34383250-10	2021	KC01 also suppressed LPS-induced generation of intracellular reactive oxygen species and cytokines such as interleukin-6.	KC01	0-4	interleukin 6	Mus musculus	107-120
34439517-6	2021	In addition, melatonin recovered mitochondrial architecture, reduced apoptosis and multivesicular bodies" formation, and decreased expressions of beta-MHC, IL-1alpha, and IL-6.	Melatonin	13-22	interleukin 6	Mus musculus	171-175
34422067-11	2021	Moreover, docetaxel injection increased levels of TNF-alpha and IL-6 in plasma and expressions of phospho-NF-kappaB and phospho-STAT3 in both of lumbar spinal cord and sciatic nerves, while SH003 treatment inhibited those changes.	Docetaxel	10-19	interleukin 6	Mus musculus	64-68
34380504-9	2021	RESULTS: HE ameliorated colitis in HFD mice by reducing colonic myeloperoxidase activity (by 2.3-fold), macrophage accumulation (by 2.6-fold) and mRNA expression of IL-6 (by 2.3-fold) in HFD mice.	Helium	9-11	interleukin 6	Mus musculus	165-169
34414236-7	2021	BE-BJO treatment improved the morphology of colon tissue, inhibited the production and release of TNF-alpha, IFN-gamma, IL-6, and IL-1beta in the colon tissue, and reversed the decreased expressions of ZO-1, occludin, claudin-1, and E-cadherin induced by DSS but augmented claudin-2 expression.	be-bjo	0-6	interleukin 6	Mus musculus	120-124
34363008-8	2022	(R)-TML104 treatment markedly induced the SIRT1-signal transducer and activator of transcription 3 (STAT3) interaction and reduced acetylation of STAT3, thus inhibiting the inflammatory response mediated by the interleukin 6-STAT3 pathway.	(r)-tml104	0-10	interleukin 6	Mus musculus	211-224
34171426-8	2021	Importantly, compared to MTX oral administration, topical application of MTX/NIC cerosomes on imiquimod (IMQ)-induced psoriatic mouse model exhibited a superior performance in ameliorating skin lesions, reducing spleen index and epidermal thickness, and downregulating the mRNA expression levels of proinflammatory cytokines including TNFalpha, IL-23, IL-17A, IL-6, IL-1beta, and IL-22.	Methotrexate	73-76	interleukin 6	Mus musculus	360-364
34171426-8	2021	Importantly, compared to MTX oral administration, topical application of MTX/NIC cerosomes on imiquimod (IMQ)-induced psoriatic mouse model exhibited a superior performance in ameliorating skin lesions, reducing spleen index and epidermal thickness, and downregulating the mRNA expression levels of proinflammatory cytokines including TNFalpha, IL-23, IL-17A, IL-6, IL-1beta, and IL-22.	Niacinamide	77-80	interleukin 6	Mus musculus	360-364
34171426-8	2021	Importantly, compared to MTX oral administration, topical application of MTX/NIC cerosomes on imiquimod (IMQ)-induced psoriatic mouse model exhibited a superior performance in ameliorating skin lesions, reducing spleen index and epidermal thickness, and downregulating the mRNA expression levels of proinflammatory cytokines including TNFalpha, IL-23, IL-17A, IL-6, IL-1beta, and IL-22.	Imiquimod	105-108	interleukin 6	Mus musculus	360-364
34421890-8	2021	JUG reversed the DSS-induced up-regulation of proinflammatory cytokines, including interleukin (IL)-6, 12, 21, and 23, and tumor necrosis factor-alpha, and anti-inflammatory cytokines, such as IL-10 and transforming growth factor-beta, in the serum of the colitis mice.	Dextran Sulfate	17-20	interleukin 6	Mus musculus	83-101
34445223-10	2021	In vivo, co-injection of LPS (5 mg/kg body weight) and PF8380 (30 mg/kg body weight), or LPS/AS2717638 (10 mg/kg body weight), significantly attenuated LPS-induced iNOS, TNFalpha, IL-1beta, IL-6, and CXCL2 mRNA expression in the mouse brain.	6-(3-(piperazin-1-yl)propanoyl)benzo(d)oxazol-2(3H)-one	55-61	interleukin 6	Mus musculus	190-194
34445223-10	2021	In vivo, co-injection of LPS (5 mg/kg body weight) and PF8380 (30 mg/kg body weight), or LPS/AS2717638 (10 mg/kg body weight), significantly attenuated LPS-induced iNOS, TNFalpha, IL-1beta, IL-6, and CXCL2 mRNA expression in the mouse brain.	AS2717638	93-102	interleukin 6	Mus musculus	190-194
34421682-8	2021	GUO also mitigated the OBX-induced hippocampal neuroinflammation (IL-1, IL-6, TNF-alpha, INF-gamma, and IL-10).	Guanosine	0-3	interleukin 6	Mus musculus	72-76
34348746-10	2021	RESULTS: 3,3",4,5"-TMS and 3,4",5-TMS suppressed LPS-induced NO release and pro-inflammatory cytokines (IL-6 and TNF-alpha) secretions in a dose-dependent manner in RAW 264.7 cells.	3,3',4,5'-tetramethoxystilbene	9-22	interleukin 6	Mus musculus	104-108
34348746-10	2021	RESULTS: 3,3",4,5"-TMS and 3,4",5-TMS suppressed LPS-induced NO release and pro-inflammatory cytokines (IL-6 and TNF-alpha) secretions in a dose-dependent manner in RAW 264.7 cells.	3,4',5-trimethoxystilbene	27-37	interleukin 6	Mus musculus	104-108
34413784-7	2021	There was also a dose-dependent decrease in the CCl4-induced inflammatory indices, such as the levels of interleukin-1, interleukin-6, tumor necrosis factor-alpha, and myeloperoxidase, with MIP administration.	mip	190-193	interleukin 6	Mus musculus	120-133
34128029-4	2021	The results demonstrated that treatment with AH could prevent the reduction in spleen and thymus indices as well as body weight, and significantly increase the Peyer"s patch count in CY-induced mice and the levels of IL-2, IL-6, and TNF-alpha in serum, suggesting the role of Alhagi honey polysaccharides in alleviating the immunosuppression induced by CY.	alhagi honey polysaccharides	276-304	interleukin 6	Mus musculus	223-227
34128029-4	2021	The results demonstrated that treatment with AH could prevent the reduction in spleen and thymus indices as well as body weight, and significantly increase the Peyer"s patch count in CY-induced mice and the levels of IL-2, IL-6, and TNF-alpha in serum, suggesting the role of Alhagi honey polysaccharides in alleviating the immunosuppression induced by CY.	Cyclophosphamide	353-355	interleukin 6	Mus musculus	223-227
34128029-4	2021	The results demonstrated that treatment with AH could prevent the reduction in spleen and thymus indices as well as body weight, and significantly increase the Peyer"s patch count in CY-induced mice and the levels of IL-2, IL-6, and TNF-alpha in serum, suggesting the role of Alhagi honey polysaccharides in alleviating the immunosuppression induced by CY.	ah	45-47	interleukin 6	Mus musculus	223-227
34181491-8	2021	Notably, not all EL-EPS responses were augmented by high glucose because EL-EPS increased phosphorylated c-Jun N-terminal kinase and interleukin-6 secretion independent of glucose availability.	Glucose	57-64	interleukin 6	Mus musculus	133-146
34115225-12	2021	Importantly, a significant decrease in pro-inflammatory mediators (NO, IL-6 and TNF-alpha) levels in dose-dependent manner was reported in plasma, and culture supernatants of colonic explants and peritoneal macrophages from DSS + PLAE-treated mice compared to the DSS group.	Dextran Sulfate	224-227	interleukin 6	Mus musculus	71-75
34115225-12	2021	Importantly, a significant decrease in pro-inflammatory mediators (NO, IL-6 and TNF-alpha) levels in dose-dependent manner was reported in plasma, and culture supernatants of colonic explants and peritoneal macrophages from DSS + PLAE-treated mice compared to the DSS group.	Dextran Sulfate	264-267	interleukin 6	Mus musculus	71-75
34429860-4	2021	Pseudomonas aeruginosa-induced murine lung injury model was established, and survival rate, as well as WBC counts, histology, IL-6, TNF-alpha and IL-10 levels in bronchoalveolar lavage fluid (BALF) were measured to explore the optimal therapeutic dose of haMSC-EVs through the nebulized route.	hamsc-evs	255-264	interleukin 6	Mus musculus	126-130
34804419-8	2021	Results: Atorvastatin treatment along with HFD and Zym inhibited vascular inflammation by suppressing the levels of aortic TLR2, cardiac NF-kB and decrease in serum TNF-alpha and IL-6.	Atorvastatin	9-21	interleukin 6	Mus musculus	179-183
34804419-11	2021	Conclusion: Atorvastatin attenuates vascular inflammation mediated by HFD and Zym through suppression of TLR2, NF-kB, TNF-alpha, IL-6, and upregulation of LDLR levels.	Atorvastatin	12-24	interleukin 6	Mus musculus	129-133
34467731-9	2021	Compared with the model group, the SASP group and high-dose Sishen Pills group showed elevated body weight, colon length, and T-AOC, lowered IL-6, TNF-alpha, MDA, and ROS levels, and increased protein and mRNA expression of Nrf2, HO-1, and NQO-1 in the colon tissues.	sishen	60-66	interleukin 6	Mus musculus	141-145
34413167-0	2021	Cystathionine beta-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis.	tregs	78-83	interleukin 6	Mus musculus	43-47
34413167-11	2021	Mechanistically, CBS facilitated the expression cleaved Caspase-3 in tumor cells, and on the other hand, suppressed Foxp3 expression in Tregs via inactivating IL-6/STAT3 pathway.	tregs	136-141	interleukin 6	Mus musculus	159-163
34080030-8	2021	In addition, perampanel treatment downregulated the protein expression levels of receptor interacting serine/threonine kinase (RIP) 1, RIP3, and mixed lineage kinase domain like pseudokinase, and of the cytokines IL-1beta, IL-6, TNF-alpha, and NF-kappaB.	perampanel	13-23	interleukin 6	Mus musculus	223-227
34393797-0	2021	EGFR-IL-6 Signaling Axis Mediated the Inhibitory Effect of Methylseleninic Acid on Esophageal Squamous Cell Carcinoma.	methylselenic acid	59-79	interleukin 6	Mus musculus	5-9
34393797-9	2021	Furthermore, MSA treatment inhibited EGFR pathway and subsequntly reduced Interleukin-6 (IL-6) secretion in the supernatant of cancer cell lines.	methylselenic acid	13-16	interleukin 6	Mus musculus	74-87
34393797-9	2021	Furthermore, MSA treatment inhibited EGFR pathway and subsequntly reduced Interleukin-6 (IL-6) secretion in the supernatant of cancer cell lines.	methylselenic acid	13-16	interleukin 6	Mus musculus	89-93
34393797-10	2021	MSA-induced IL-6 suppression was EGFR-dependent.	methylselenic acid	0-3	interleukin 6	Mus musculus	12-16
34393797-12	2021	The results showed that IL-6 deficiency did not affect esophageal tumorigenesis in mice, but the inhibitory effect of MSA was abolished in IL-6 KO mice.	methylselenic acid	118-121	interleukin 6	Mus musculus	139-143
34393797-14	2021	The inhibitory effect of MSA on esophageal cancer was IL-6 dependent.	methylselenic acid	25-28	interleukin 6	Mus musculus	54-58
34393799-11	2021	The levels of inflammatory mediators (TNF-alpha, IL-1beta, IL-6, IL-17A, MCP-1, MIG, IP-10, and CRP) in the lung homogenate were reduced after ISOF treatment.	Isof	143-147	interleukin 6	Mus musculus	59-63
34373698-3	2021	Results: The results showed that naloxone dose-dependently promoted cell proliferation in LPS-induced BV-2 cells, downregulated the expression of proinflammatory cytokines (TNF-alpha, IL-1beta, and IL-6) and proinflammatory enzymes iNOS and COX-2 as well as the expression of free radical molecule NO, and reduced the expression of Iba-1-positive microglia in LPS-stimulated BV-2 cells and mouse brain.	Naloxone	33-41	interleukin 6	Mus musculus	198-202
34361736-10	2021	Finally, GT-73 reduced the levels of IL-1beta, IL-6, and MCP-1 in bronchoalveolar lavage fluid (BALF).	gt-73	9-14	interleukin 6	Mus musculus	47-51
34393713-7	2021	Chronic apigenin treatment decreased the number of Iba-1+ microglia in the hippocampus of GFAP-IL6 mice and changed microglial morphology.	Apigenin	8-16	interleukin 6	Mus musculus	95-98
34316030-5	2022	We found that pirfenidone alleviated silica-induced lung dysfunction, secretion of inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and deposition of fibrotic proteins (collagen I and fibronectin) in both early and advanced silicosis models.	pirfenidone	14-25	interleukin 6	Mus musculus	128-132
34261306-7	2021	Based on the advantage of the combination of hybrid nanoparticles-in-microparticles, oral administration of Mag@CS-Zein NPsinMPs significantly alleviated colitis symptoms in DSS-treated mice by regulating the expression levels of proinflammatory cytokines (TNF-alpha, IL-6, and IL-1beta) and anti-inflammatory cytokines (IL-10) and factor accelerated colonic mucosal barrier repair via upregulating the expression of ZO-1 and occludin.	magnolol	108-111	interleukin 6	Mus musculus	268-272
34393786-6	2021	Moreover, CR attenuated chronic colitis in mice in a dosing time-dependent manner based on measurements of disease activity index, colon length, malondialdehyde/myeloperoxidase activities and IL-1beta/IL-6 levels.	Chromium	10-12	interleukin 6	Mus musculus	201-205
34393790-5	2021	These effects of the TMP were associated with a significant reduction in levels of inflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and MMP-9 in the ischemic brain tissues.	tetramethylpyrazine	21-24	interleukin 6	Mus musculus	165-169
34366843-7	2021	Indigo naturalis, indigo, and indirubin could reduce IL-1beta,IL-6, and TNF-alpha by inhibiting TLR4/MyD88/NF-kappaB signal transduction.	Indigo Carmine	0-6	interleukin 6	Mus musculus	62-66
34381810-4	2021	Immunofluorescence staining, Western blot assay and Real-time PCR assays were conducted to determine the activation of Iba-1, the protein levels of iNOS and COX2 and the mRNA levels of IL-1beta, IL-6, and TNF-alpha in vivo, showing that both pre-treatment and post-treatment of aminooxyacetic acid (AOAA) - an MAS inhibitor - profoundly decreased the LPS-induced neuroinflammation in mice.	Aminooxyacetic Acid	278-297	interleukin 6	Mus musculus	195-199
34381810-4	2021	Immunofluorescence staining, Western blot assay and Real-time PCR assays were conducted to determine the activation of Iba-1, the protein levels of iNOS and COX2 and the mRNA levels of IL-1beta, IL-6, and TNF-alpha in vivo, showing that both pre-treatment and post-treatment of aminooxyacetic acid (AOAA) - an MAS inhibitor - profoundly decreased the LPS-induced neuroinflammation in mice.	Aminooxyacetic Acid	299-303	interleukin 6	Mus musculus	195-199
34367186-14	2021	Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation.	ruxolitinib	13-16	interleukin 6	Mus musculus	146-150
34293804-5	2021	Results showed that suffrutines A and B could remarkably inhibit the production of nitric oxide, prostaglandin E2, interleukin-6, inducible nitric oxide synthase, and cyclooxygenase-2 in lipopolysaccharide-induced RAW264.7 cells.	suffrutines a and b	20-39	interleukin 6	Mus musculus	115-128
34366843-7	2021	Indigo naturalis, indigo, and indirubin could reduce IL-1beta,IL-6, and TNF-alpha by inhibiting TLR4/MyD88/NF-kappaB signal transduction.	Indigo Carmine	18-24	interleukin 6	Mus musculus	62-66
34366843-7	2021	Indigo naturalis, indigo, and indirubin could reduce IL-1beta,IL-6, and TNF-alpha by inhibiting TLR4/MyD88/NF-kappaB signal transduction.	indirubin	30-39	interleukin 6	Mus musculus	62-66
34354703-3	2021	We observed that treatment with DZ and Lipopolysaccharide (LPS) on macrophages or dendritic cells (DCs) induced a defective secretion of IL-12, TNF-alpha, IL-6 and a lesser expression of classical activation markers as NO production and CD40 in comparison with LPS condition.	Diazepam	32-34	interleukin 6	Mus musculus	155-159
34354662-18	2021	Further, fisetin administration ameliorated kindling-induced neuroinflammation as evident from decreased levels of HMGB1, TLR-4, IL-1R1, IL-1beta, IL-6, and TNF-alpha in the hippocampus and cortex of the kindled mice.	fisetin	9-16	interleukin 6	Mus musculus	147-151
34299601-6	2021	In addition, nagilactone B downregulated tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-8 levels in LPS-induced macrophages and colonic epithelial cells.	Nagilactone C	13-24	interleukin 6	Mus musculus	76-94
34272410-7	2021	Comp23 treatment attenuated the ex vivo permeability of colonic sacs, the clinical symptoms, and mucosal expression of Tgfb1, Il1b, Il6 and Il10 of DSS-treated mice.	dss	148-151	interleukin 6	Mus musculus	132-135
34299559-6	2021	The experiments showed that BBM and EBM significantly reduced production of the inflammatory mediators interleukin-6 (IL-6), prostaglandin E2 (PGE2), and nitric oxide (NO) in a dose-dependent manner, but only slightly affected TNF-alpha in LPS-induced RAW 264.7 macrophages.	Santowhite powder	28-31	interleukin 6	Mus musculus	103-116
34082000-5	2021	Using an interleukin-6-induced cell model, we found that Cur@GA-TPGS-ES displayed desirable suppression of inflammation response and oxidative stress damage.	ga-tpgs	61-68	interleukin 6	Mus musculus	9-22
34299559-6	2021	The experiments showed that BBM and EBM significantly reduced production of the inflammatory mediators interleukin-6 (IL-6), prostaglandin E2 (PGE2), and nitric oxide (NO) in a dose-dependent manner, but only slightly affected TNF-alpha in LPS-induced RAW 264.7 macrophages.	Santowhite powder	28-31	interleukin 6	Mus musculus	118-122
34299559-7	2021	This suggests that modifying melatonin at either the N1-position or the N-acetyl side chain affected production of NO, PGE2 and IL-6 in in vitro model.	Melatonin	29-38	interleukin 6	Mus musculus	128-132
34359943-4	2021	When BMDCs were stimulated with the mannooligosaccharides, only beta-Man-(1 4)-Man significantly induced production of cytokines that included IL-6, IL-10, TNF-alpha, and IFN-beta, and enhanced CD4+ T-cell stimulatory capacity.	mannooligosaccharides	36-57	interleukin 6	Mus musculus	143-147
34197081-6	2021	One intra-articular injection of DEX-muPL (1 mg kg-1) decreased the expression of interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, IL-6, and matrix metalloproteinase (MMP)-13 by approximately half compared to free DEX at 4 weeks post-treatment.	dex-mupl	33-41	interleukin 6	Mus musculus	141-145
34262136-7	2022	We showed that in both models, diosmetin administration significantly decreased DAI score and ameliorated microscopic colon tissue damage; increased the expression of tight junction proteins (occludin, claudin-1, and zonula occludens-1), and reduced the secretion of proinflammatory cytokines IL-1beta, IL-6, TNF-alpha, and Cox-2 in colon tissue.	diosmetin	31-40	interleukin 6	Mus musculus	303-307
34359943-4	2021	When BMDCs were stimulated with the mannooligosaccharides, only beta-Man-(1 4)-Man significantly induced production of cytokines that included IL-6, IL-10, TNF-alpha, and IFN-beta, and enhanced CD4+ T-cell stimulatory capacity.	beta-man-(1 4)-man	64-82	interleukin 6	Mus musculus	143-147
34359943-6	2021	Interestingly, beta-Man-(1 4)-Man prolonged the production of pro-inflammatory cytokines (IL-6 and TNF-alpha), but not of the IL-10 anti-inflammatory cytokine during extended culture of BMDCs, associated with high glucose consumption.	beta-man-(1 4)-man	15-33	interleukin 6	Mus musculus	90-94
34299102-6	2021	In addition, phenylheptatriyne and 4",7-dimethoxyflavanone reduced the secretion of inflammatory cytokines, tumor necrosis factor alpha (TNF-alpha), and interleukin (IL)-6.	phenylheptatriyne	13-30	interleukin 6	Mus musculus	153-171
34261799-4	2021	Using NF2 mouse models, we found that losartan treatment normalized the TME by (i) reducing neuroinflammatory IL-6/STAT3 signaling and preventing hearing loss, (ii) normalizing tumor vasculature and alleviating neuro-edema, and (iii) increasing oxygen delivery and enhancing efficacy of radiation therapy.	Losartan	38-46	interleukin 6	Mus musculus	110-114
34299102-6	2021	In addition, phenylheptatriyne and 4",7-dimethoxyflavanone reduced the secretion of inflammatory cytokines, tumor necrosis factor alpha (TNF-alpha), and interleukin (IL)-6.	4",7-dimethoxyflavanone	35-58	interleukin 6	Mus musculus	153-171
34322027-5	2021	Mechanistically, C646 not only inhibits NF-kappaB activation, leading to the decreased expression of pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) and NLRP3, but also suppresses the NLRP3 inflammasome assembly by disrupting the interaction between NLRP3 and ASC.	C646	17-21	interleukin 6	Mus musculus	139-143
34371902-0	2021	alpha-Hydroxyisocaproic Acid Decreases Protein Synthesis but Attenuates TNFalpha/IFNgamma Co-Exposure-Induced Protein Degradation and Myotube Atrophy via Suppression of iNOS and IL-6 in Murine C2C12 Myotube.	alpha-hydroxyisocaproic acid	0-28	interleukin 6	Mus musculus	178-182
34240327-11	2022	Moreover, GB-S reduced the MPO activity, inhibits TNF-alpha, IL-6 release, and downregulates NF-kappaB immunopositive cell expression in mice hippocampus.	gb-s	10-14	interleukin 6	Mus musculus	61-65
34307396-12	2021	Importantly, the top 30 DEGs under EAP in the Stat5-cKO mice were enriched in the IL-6/STAT3 signaling pathway.	phosphorylethanolamine	35-38	interleukin 6	Mus musculus	82-86
34244555-7	2021	The W group had higher expression levels of IL-6 in the thalamus as well.	Water	4-5	interleukin 6	Mus musculus	44-48
34267552-11	2021	Mag also blocked the activation of p38 mitogen-activated protein kinase (MAPK) and other pain-related cytokines such as IL-6, TNF-alpha and IL-1beta.	magnolol	0-3	interleukin 6	Mus musculus	120-124
34305926-4	2021	Moreover, butorphanol also decreased the expression of M1 phenotype markers (TNF-alpha, IL-6, IL-1beta and iNOS) and enhanced the expression of M2 marker (CD206) in alveolar macrophages in the bronchoalveolar lavage fluid (BALF) of LPS-stimulated mice.	Butorphanol	10-21	interleukin 6	Mus musculus	88-92
34305926-6	2021	Furthermore, we found that butorphanol-mediated suppression of the LPS-induced increases in M1 phenotype marker expression (TNF-alpha, IL-6, IL-1beta and iNOS) in bone marrow-derived macrophages (BMDMs), and this effect was reversed by kappa-opioid receptor (KOR) antagonists.	Butorphanol	27-38	interleukin 6	Mus musculus	135-139
34285923-7	2021	In BMSCs, curculigoside treatment suppressed the Ti-induced cell formation and suppressed the TNF-alpha, IL-1beta, and IL-6 production and F-actin ring formation.	curculigoside	10-23	interleukin 6	Mus musculus	119-123
34285923-6	2021	As the results indicated, in MC3T3-E1 cells, curculigoside treatment attenuated the Ti-induced inhibition on cell differentiation and apoptosis, increased alkaline phosphatase activity (ALP) and cell mineralization, and inhibited TNF-alpha, IL-1beta, and IL-6 production and ROS generation.	curculigoside	45-58	interleukin 6	Mus musculus	255-259
34279352-6	2021	Moreover, MAN-CS-OVA-PLGA-MPs promoted cytokine (IFN-gamma, IL-4, and IL-6) production in mice.	man-cs	10-16	interleukin 6	Mus musculus	70-74
34285923-6	2021	As the results indicated, in MC3T3-E1 cells, curculigoside treatment attenuated the Ti-induced inhibition on cell differentiation and apoptosis, increased alkaline phosphatase activity (ALP) and cell mineralization, and inhibited TNF-alpha, IL-1beta, and IL-6 production and ROS generation.	Titanium	84-86	interleukin 6	Mus musculus	255-259
34285659-9	2021	Diacerein reduced the IL-6, IL-8, and MCP-1 expression in ARPE-19 cells.	diacerein	0-9	interleukin 6	Mus musculus	22-26
34215755-6	2021	This enhanced intradermal IL-6 may alleviate imiquimod-induced skin inflammation.	Imiquimod	45-54	interleukin 6	Mus musculus	26-30
34278932-11	2021	Furthermore, mice in group TB showed significant loss of body weight and muscle weight in which XO activity, 8-OHdG, and expression of IL-6 were significantly increased compared to those in group C. Febuxostat administration not only significantly improved the body weight and muscleweight, but also reduced markers of oxidative stress and pro-inflammatory cytokines.	Terbium	27-29	interleukin 6	Mus musculus	135-139
34124763-5	2021	BEOV administration significantly decreased the levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1beta (IL-1beta), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) both in the hippocampus of APPswe/PS1E9 mice and in the Abeta-stimulated BV2 microglia.	beov	0-4	interleukin 6	Mus musculus	99-112
34124763-5	2021	BEOV administration significantly decreased the levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1beta (IL-1beta), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) both in the hippocampus of APPswe/PS1E9 mice and in the Abeta-stimulated BV2 microglia.	beov	0-4	interleukin 6	Mus musculus	114-118
34278932-11	2021	Furthermore, mice in group TB showed significant loss of body weight and muscle weight in which XO activity, 8-OHdG, and expression of IL-6 were significantly increased compared to those in group C. Febuxostat administration not only significantly improved the body weight and muscleweight, but also reduced markers of oxidative stress and pro-inflammatory cytokines.	Febuxostat	199-209	interleukin 6	Mus musculus	135-139
34350835-0	2021	IL-6 production of C2C12 cells is enhanced in the presence of macrophages and pravastatin.	Pravastatin	78-89	interleukin 6	Mus musculus	0-4
34350835-6	2021	Pravastatin, known to induce myopathy, also stimulates IL-6 production in monocultured C2C12 cells and elevates IL-6 concentration in the culture medium of the co-cultures.	Pravastatin	0-11	interleukin 6	Mus musculus	55-59
34490833-8	2021	Levels of SOD, GSH, NQO-1, Nrf2, and HO-1 were decreased, MDA, LDH, TNF-alpha, IL-6, and KIM-1, and miR-199b-3p were increased in the CLP group and LPS-induced HK-2 cells, while the effect was reversed after DMY treatment.	dihydromyricetin	208-211	interleukin 6	Mus musculus	79-83
34350835-6	2021	Pravastatin, known to induce myopathy, also stimulates IL-6 production in monocultured C2C12 cells and elevates IL-6 concentration in the culture medium of the co-cultures.	Pravastatin	0-11	interleukin 6	Mus musculus	112-116
34490833-12	2021	TNF-alpha, IL-6, KIM-1, and miR-199b-3p levels were increased; Nrf2, NQO-1, and HO-1 levels were decreased in the LPS + DMY + mimics-miR group.	dihydromyricetin	120-123	interleukin 6	Mus musculus	11-15
34182490-10	2021	Ethanol increased the hepatic release of tumor necrosis factor-alpha, transforming growth factor-beta1, interleukin (IL)-1beta and IL-6.	Ethanol	0-7	interleukin 6	Mus musculus	131-135
34162163-4	2021	The results showed that varying doses of TH-GLs can significantly improve colon lesions caused by DSS, reduce histological scores, increase mucus secretion, extend colon length, increase weight, and inhibit the occurrence of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), Interleukin-1beta (IL-1beta), and Interleukin- 6 (IL-6).	th-gls	41-47	interleukin 6	Mus musculus	361-375
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	123-126	interleukin 6	Mus musculus	68-72
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	172-175	interleukin 6	Mus musculus	68-72
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	T16AInh-A01	180-191	interleukin 6	Mus musculus	68-72
34376914-6	2021	We found that glycyrrhizin ameliorated the extravasation of melanoma cells into the lungs and suppressed the plasma levels of interleukin-6, tumor necrosis factor-alpha, and transforming growth factor-beta.	Glycyrrhizic Acid	14-26	interleukin 6	Mus musculus	126-139
34162163-4	2021	The results showed that varying doses of TH-GLs can significantly improve colon lesions caused by DSS, reduce histological scores, increase mucus secretion, extend colon length, increase weight, and inhibit the occurrence of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), Interleukin-1beta (IL-1beta), and Interleukin- 6 (IL-6).	th-gls	41-47	interleukin 6	Mus musculus	377-381
34358312-11	2021	Rutin co-administration also caused a significant (P < 0.001) increase in tumor necrosis factor-alpha, interleukin-6, and immunoglobulin M levels, while interleukin-1beta and immunoglobulin G decreased significantly (P < 0.001) compared with parasitized control.	Rutin	0-5	interleukin 6	Mus musculus	103-116
34280033-8	2021	Compared to those in the DSS-induced mice, histological damage and IL-6 cytokine levels were significantly reduced in SCGB1-fed mice.	Dextran Sulfate	25-28	interleukin 6	Mus musculus	67-71
34121036-7	2021	Pretreatment with LPLs significantly inhibited the LPS-induced expression of IL-6 in SIM-A9 cells.	Lysophospholipids	18-22	interleukin 6	Mus musculus	77-81
34374265-13	2021	In vitro experiments, compared with PBS group, PGRN level was decreased (P<0.05), IL-6 level was increased (P<0.01), phosphorylation of p38 was activated in IL-13 treatment group.	Lead	36-39	interleukin 6	Mus musculus	82-86
34152136-6	2021	The results demonstrated that PTS significantly attenuated HFD and DSS-induced plasma interleukin-6 accumulation.	pterostilbene	30-33	interleukin 6	Mus musculus	86-99
34152136-6	2021	The results demonstrated that PTS significantly attenuated HFD and DSS-induced plasma interleukin-6 accumulation.	Dextran Sulfate	67-70	interleukin 6	Mus musculus	86-99
34209652-6	2021	We further reveal that DON exposure increased the intracellular reactive oxygen species level, reduced the mitochondrial membrane potential and ATP, and upregulated Tnfalpha (tumor necrosis factor alpha), Il6 (interleukin 6), and Il1beta (interleukin 1 beta) gene expression.	deoxynivalenol	23-26	interleukin 6	Mus musculus	205-208
34234439-8	2021	The in vitro results demonstrated that milrinone could inhibit the secretion of interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha via regulation of NLRP3 inflammasomes and TLR4/MyD88/NF-kappaB signalling pathway.	Milrinone	39-48	interleukin 6	Mus musculus	104-108
34209652-6	2021	We further reveal that DON exposure increased the intracellular reactive oxygen species level, reduced the mitochondrial membrane potential and ATP, and upregulated Tnfalpha (tumor necrosis factor alpha), Il6 (interleukin 6), and Il1beta (interleukin 1 beta) gene expression.	deoxynivalenol	23-26	interleukin 6	Mus musculus	210-223
34209813-7	2021	The effects on oxidative stress and interleukin-6 (IL-6) expression were assessed in ATDC5 cells using superoxide measurement, qPCR, ELISA, and Western blotting.	Superoxides	103-113	interleukin 6	Mus musculus	51-55
34202218-5	2021	Similar beneficial effects of GMI on the suppression of MDSC expansion and IL-6 expression are also observed in the whole blood and reduces the accumulation of MDSCs in the infected bone region in a mouse PJI infection model.	misonidazole-glutathione conjugate	30-33	interleukin 6	Mus musculus	75-79
34209813-11	2021	P* reduced IL-6 levels in both ATDC5 cells and primary chondrocytes dependent on H2S release.	Deuterium	81-84	interleukin 6	Mus musculus	11-15
34183381-0	2021	3-Hydroxykynurenine Regulates Lipopolysaccharide-Stimulated IL-6 Production and Protects against Endotoxic Shock in Mice.	3-hydroxykynurenine	0-19	interleukin 6	Mus musculus	60-64
34201978-11	2021	Moreover, the addition of Q in the PLA/GO matrix stimulated the production of IL-6 at 24 h, which could be linked to an acute inflammatory response in the exposed fibroblast cells, as a potential effect of wound healing.	Quercetin	26-27	interleukin 6	Mus musculus	78-82
34201978-11	2021	Moreover, the addition of Q in the PLA/GO matrix stimulated the production of IL-6 at 24 h, which could be linked to an acute inflammatory response in the exposed fibroblast cells, as a potential effect of wound healing.	graphene oxide	39-41	interleukin 6	Mus musculus	78-82
34202301-8	2021	Furthermore, alantolactone treatment in mice significantly alleviated the severity of skin lesions (erythema, scaling and epidermal thickness, and inflammatory cell infiltration) and decreased the mRNA expression of inflammatory cytokines (e.g., TNF-alpha, IL-6, IL-1beta, IL-8, IL-17A, and IL-23) in an IMQ-induced-like mouse model.	alantolactone	13-26	interleukin 6	Mus musculus	257-261
34248633-11	2021	Conclusion: The beneficial effect of UAMC-00050 on inflammation was apparent via a reduction of Tbet, IFN-gamma, TNF-alpha, IL-1beta and IL-6.	uamc	37-41	interleukin 6	Mus musculus	137-141
34168254-4	2021	Accelerated maturation in IL-6 newborns was suggested by early expression of podocyte-specific protein podocin in glomeruli, increased 5-methyl-cytosine (LC-MS analysis for CpG DNA methylation) and altered expression of certain genes of cell-cycle and apoptosis (RT-qPCR array-analysis).	5-Methylcytosine	135-152	interleukin 6	Mus musculus	26-30
34189397-9	2021	Lastly, we observed that the intraperitoneal injection of rhZPI significantly decreased LPS-induced IL-6 and TNF-alpha production in mouse plasma.	rhzpi	58-63	interleukin 6	Mus musculus	100-104
34202859-8	2021	The anti-inflammatory activity of SSZ-loaded MPs was studied by quantifying interleukins IL-1, IL-6 and TNF-alpha in macrophages.	Sulfasalazine	34-37	interleukin 6	Mus musculus	95-99
34202859-10	2021	Gene expression of IL-1, IL-6 and TNF-alpha was decreased by SSZ-loaded MPs.	Sulfasalazine	61-64	interleukin 6	Mus musculus	25-29
34239908-5	2021	GL significantly (P < 0.05) increased secretion of inflammatory cytokines (IFN-gamma, IL-12p70, IL-6, and IL-10) in spleen and IL-12p40 mRNA expression in liver.	Glycyrrhizic Acid	0-2	interleukin 6	Mus musculus	96-100
34239908-6	2021	Meanwhile, GL or GM pre-infection treatments significantly (P < 0.05) decreased ST-induced pro-inflammatory cytokine (IFN-gamma, TNF-alpha, and IL-6) expression in both spleen and liver and increased (P < 0.05) anti-inflammatory cytokine IL-10 secretion in spleen.	Glycyrrhizic Acid	11-13	interleukin 6	Mus musculus	144-148
34239908-6	2021	Meanwhile, GL or GM pre-infection treatments significantly (P < 0.05) decreased ST-induced pro-inflammatory cytokine (IFN-gamma, TNF-alpha, and IL-6) expression in both spleen and liver and increased (P < 0.05) anti-inflammatory cytokine IL-10 secretion in spleen.	Gentamicins	17-19	interleukin 6	Mus musculus	144-148
34183994-4	2021	Compared with NC and MC groups, treatment with DESP significantly increased the spleen index and decreased the thymus index; increased the serum concentrations of immunoglobulin (Ig)A, IgG, IgM, hemolysin, IL-1beta, and IL-2; delayed the allergic reaction; and improved the splenic lymphocyte transformation ability; and enhanced the phagocytosis of macrophages and the ability to secrete IL-6, TNF-alpha, caspase-1, and NO with DESP supplementation.	desp	47-51	interleukin 6	Mus musculus	389-393
34207356-3	2021	The results demonstrated that piplartine suppresses iNOS and COX-2 expression, reduces PGE2, TNF-alpha and IL-6 production, decreases the phosphorylation of MAPKs and NF-kappaB and attenuates NF-kappaB activity by LPS-activated macrophages.	piplartine	30-40	interleukin 6	Mus musculus	107-111
34163116-14	2021	The elevation of serum IL-6 levels was also ameliorated in the CM group.	Curium	63-65	interleukin 6	Mus musculus	23-27
34163116-15	2021	These results indicate that the conditioned mADSCs secretome suppressed the synthesis of inflammatory cytokines in damaged colon tissue and the elevation of serum IL-6 concentration in DSS-induced mice.	Dextran Sulfate	185-188	interleukin 6	Mus musculus	163-167
34207356-5	2021	Moreover, piplartine reduces the production of nitric oxide (NO) and TNF-alpha, IL-6 and IL-1beta, decreases LPS-induced tissue damage, attenuates infiltration of inflammatory cells and enhances the survival rate.	piplartine	10-20	interleukin 6	Mus musculus	80-84
34142149-10	2021	However, ABT-263 did not reduce senescence markers in vivo, and significantly reduced monocyte and platelet counts and IL6 as a marker of systemic inflammation.	navitoclax	9-16	interleukin 6	Mus musculus	119-122
34218553-15	2021	Compared with the model group, evodiamine could reduce the mRNA and protein levels of IL-6, IL-1beta and TNF-alpha in liver tissue of liver fibrosis mice (P<0.05) .	evodiamine	31-41	interleukin 6	Mus musculus	86-90
34220460-6	2021	Reserpine-induced increases in plasma corticosterone concentrations were attenuated by the administration of FX and its components, which were also found to decrease the reserpine-induced enhancement of mRNA levels of interleukin (IL)-12 p40, IL-6, and tumor necrosis factor (TNF)-alpha, pro-inflammatory cytokines.	Reserpine	0-9	interleukin 6	Mus musculus	243-247
34220460-6	2021	Reserpine-induced increases in plasma corticosterone concentrations were attenuated by the administration of FX and its components, which were also found to decrease the reserpine-induced enhancement of mRNA levels of interleukin (IL)-12 p40, IL-6, and tumor necrosis factor (TNF)-alpha, pro-inflammatory cytokines.	Reserpine	170-179	interleukin 6	Mus musculus	243-247
34204220-4	2021	Our results showed that astaxanthin reduced the expressions of LPS-induced inflammatory cytokines (TNF-alpha, IL-6, and IL-10) and phenotypic markers (MHCII, CD40, CD80, and CD86) by DCs.	astaxanthine	24-35	interleukin 6	Mus musculus	110-114
34168482-11	2021	In BV2 cells exposed to isoflurane, genistein treatment decreased IL-1beta, TNF-alpha, IL-6 and IL-8 mRNA expressions, promoted M2 and suppressed M1 microglia polarization.	Isoflurane	24-34	interleukin 6	Mus musculus	87-91
34168482-11	2021	In BV2 cells exposed to isoflurane, genistein treatment decreased IL-1beta, TNF-alpha, IL-6 and IL-8 mRNA expressions, promoted M2 and suppressed M1 microglia polarization.	Genistein	36-45	interleukin 6	Mus musculus	87-91
34168409-10	2021	The inflammatory cytokines, such as tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta, were induced in the DSS-treated mice, in which the depletion of EZH2 could reverse this effect.	dss	123-126	interleukin 6	Mus musculus	65-78
34234834-8	2021	KXS protected against DOX-induced neuroinflammation by decreasing levels of proinflammatory cytokines interleukin-6, interleukin-12p70, and tumor necrosis factor-alpha in both serum and brain and interleukin-1beta in the brain, increasing the anti-inflammatory cytokines interleukin-4 in the serum and interleukin-10 in the hippocampus, and inhibiting the astrocytic hyperplasia and microglial polarization in the hippocampus.	Doxorubicin	22-25	interleukin 6	Mus musculus	102-115
34221003-10	2021	In the LPS-induced HT22 cells, hyperoside promotes cell survival; alleviates the level of IL-1beta, IL-6, IL-8, TNF-alpha, ROS, MDA, Bax, and caspase-3; and increases the expression of CAT, SOD, GSH, Bcl-2, BDNF, TrkB, and NGF.	hyperoside	31-41	interleukin 6	Mus musculus	100-104
34135611-12	2021	Finally, obviously alleviated systemic inflammation was exhibited through AODCEA treatment by detection of lipopolysaccharide (LPS) and interleukin-6 (IL-6) in serum.	aodcea	74-80	interleukin 6	Mus musculus	136-149
34135611-12	2021	Finally, obviously alleviated systemic inflammation was exhibited through AODCEA treatment by detection of lipopolysaccharide (LPS) and interleukin-6 (IL-6) in serum.	aodcea	74-80	interleukin 6	Mus musculus	151-155
34103688-5	2022	Furthermore, 8-O-cAMP administration restored CCAAT/enhancer binding protein beta (C/EBP-beta) expression and further upregulated the expression of Suppressor of cytokine signaling 3 (SOCS3), while inhibiting p-STAT3, MCP-1, IL-6, and TNF-alpha expression in the kidney cortex in db/db mice.	8-(4-chloro-phenylthio)-2'-O-methyladenosine-3'-5'-cyclic monophosphate	13-21	interleukin 6	Mus musculus	225-229
34114347-12	2021	Both in vivo and in vitro results revealed that the level of IL-6, TNF-alpha, VCAM-1 and VEGF was significantly down-regulated after being treated with resveratrol.	Resveratrol	152-163	interleukin 6	Mus musculus	61-65
34194517-5	2021	HPAC reduced LPS-induced inflammatory mediators such as IL-6, IL-1beta, TNF-alpha, NO, and PGE2 in RAW 264.7 cells.	hpac	0-4	interleukin 6	Mus musculus	56-60
34086140-7	2021	KET-PABA strongly inhibited proinflammatory cytokines such as IL1 alpha, IL1 beta, IL6 and TNF alpha, and other proinflammatory inducers such as NRF2, compared to vehicle.	ket-paba	0-8	interleukin 6	Mus musculus	83-86
34098585-10	2021	Furthermore, desmethylbellidifolin remarkably ameliorated colonic inflammation through suppressing the expression of interleukin-6 and tumor necrosis factor-alpha.	demethylbellidifolin	13-34	interleukin 6	Mus musculus	117-130
34134453-7	2021	MiR-25-3p expression showed a strong positive correlation with the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1alpha, and IL-6 pro-inflammatory cytokines.	mir-25-3p	0-9	interleukin 6	Mus musculus	151-155
34136217-10	2021	However, CS-induced CXCL1, IL-6, TNF-alpha and IFN-gamma levels were reduced by ILC deficiency.	Cesium	9-11	interleukin 6	Mus musculus	27-31
34092298-6	2021	Moreover, HSBDF could alleviate the expression levels of IL-6 and TNF-alpha in the cell models, indicating that the antiviral effects of HSBDF might be associated with regulation of the inflammatory cytokines production in RAW264.7 cells.	hsbdf	137-142	interleukin 6	Mus musculus	57-61
34075160-6	2021	Daphnetin pretreatment significantly reduced SAP-induced pancreatic and lung tissue damage, reduced interleukin-6 and tumour necrosis factor-alpha concentrations in both serum and lung tissues, reduced serum amylase and myeloperoxidase activities, and reduced macrophage (CD11b) and neutrophil (Ly6G) infiltration and cell apoptosis in the lung tissue.	daphnetin	0-9	interleukin 6	Mus musculus	100-113
34467691-5	2021	The results revealed that the main compounds of Euodiae Fructus, such as berberine and rutaecarpine, participated in the biological processes(such as neurotransmitter receptor activity) by regulating C-reactive protein(CRP), estrogen receptor 1(ESR1), 5-hydroxytryptamine(5-HT) receptor, and interleukin-6(IL-6) to exert sedative, anxiolytic, and antidepressant effects.	Berberine	73-82	interleukin 6	Mus musculus	292-305
34075113-5	2021	We showed that Il6 deficiency increases daily sperm production, the number of spermatids, and the testicular testosterone and dihydrotestosterone levels.	Testosterone	109-121	interleukin 6	Mus musculus	15-18
34075113-5	2021	We showed that Il6 deficiency increases daily sperm production, the number of spermatids, and the testicular testosterone and dihydrotestosterone levels.	Dihydrotestosterone	126-145	interleukin 6	Mus musculus	15-18
34467691-5	2021	The results revealed that the main compounds of Euodiae Fructus, such as berberine and rutaecarpine, participated in the biological processes(such as neurotransmitter receptor activity) by regulating C-reactive protein(CRP), estrogen receptor 1(ESR1), 5-hydroxytryptamine(5-HT) receptor, and interleukin-6(IL-6) to exert sedative, anxiolytic, and antidepressant effects.	rutecarpine	87-99	interleukin 6	Mus musculus	292-305
34467691-8	2021	The results demonstrated that berberine was potent in reducing the activities and standing times of mice, down-regulating the levels of CRP and IL-6 mRNA in the hypothalamus, and up-regulating the expression of 5-HT(P<0.01); however, no significant effect on ESR1 was observed.	Berberine	30-39	interleukin 6	Mus musculus	144-148
34071594-6	2021	The productions of TNF-alpha, IL-6, MMP-2 and MMP- 9 were reduced by KMUP-1 pretreatment in LPS-induced inflammation of RAW264.7 cells.	KMUP 1	69-75	interleukin 6	Mus musculus	30-34
34071363-5	2021	In addition, the expression of two prototypic inflammatory enzymes, cyclooxygenase-2 and inducible nitric oxide synthase, and transcription of some pro-inflammatory cytokines (Tnf, Il6, Il1b, Il10) were significantly lower in TauCl-treated mice than vehicle-treated control mice.	N-chlorotaurine	226-231	interleukin 6	Mus musculus	181-184
34071911-7	2021	The 70% EtOH, CH2Cl2-soluble fraction, and water-soluble fraction inhibited the production of prostaglandin E2, interleukin-6, and tumor necrosis factor-alpha, as well as markedly blocking LPS-induced expression of inducible NO synthase and cyclooxygenase-2 via inactivation of the nuclear factor-kappa B pathway.	Ethanol	8-12	interleukin 6	Mus musculus	112-125
34072430-7	2021	AUY-922 suppressed the LPS-induced inflammation by inhibiting major pro-inflammatory pathways (e.g., JAK2/STAT3, MAPKs), and downregulated the IL-1beta, IL-6, MCP-1 and TNFalpha.	5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide	0-7	interleukin 6	Mus musculus	153-157
34122127-11	2021	Besides, UA decreased serum DAO content, upregulated mRNA expression of ZO-1, claudin-1 and occludin and downregulated TNF-alpha and IL-6.	ursolic acid	9-11	interleukin 6	Mus musculus	133-137
34071911-7	2021	The 70% EtOH, CH2Cl2-soluble fraction, and water-soluble fraction inhibited the production of prostaglandin E2, interleukin-6, and tumor necrosis factor-alpha, as well as markedly blocking LPS-induced expression of inducible NO synthase and cyclooxygenase-2 via inactivation of the nuclear factor-kappa B pathway.	Methylene Chloride	14-20	interleukin 6	Mus musculus	112-125
34122400-14	2021	In addition, CbTP significantly increased the production of the cytokine TNF-alpha and IL-6, and the immunoglobulins IgA, IgM, and IgG.	cbtp	13-17	interleukin 6	Mus musculus	87-91
34071911-7	2021	The 70% EtOH, CH2Cl2-soluble fraction, and water-soluble fraction inhibited the production of prostaglandin E2, interleukin-6, and tumor necrosis factor-alpha, as well as markedly blocking LPS-induced expression of inducible NO synthase and cyclooxygenase-2 via inactivation of the nuclear factor-kappa B pathway.	Water	43-48	interleukin 6	Mus musculus	112-125
34079330-6	2021	Similarly, plasma IL-6 levels in ALL, ALL-tocilizumab (TCZ, an IL-6 receptor inhibitor) and ALL-S3I-201 (a selective inhibitor of STAT3) mice were increased compared to the control group.	tioconazole	55-58	interleukin 6	Mus musculus	18-22
34073506-6	2021	Moreover, MTX-treated adult mice had enhanced expression of NF-kappaB p52 and tumour necrosis factor (TNF-alpha), while decreasing interleukin-6 (IL-6).	Mitoxantrone	10-13	interleukin 6	Mus musculus	131-144
34073506-6	2021	Moreover, MTX-treated adult mice had enhanced expression of NF-kappaB p52 and tumour necrosis factor (TNF-alpha), while decreasing interleukin-6 (IL-6).	Mitoxantrone	10-13	interleukin 6	Mus musculus	146-150
34079330-6	2021	Similarly, plasma IL-6 levels in ALL, ALL-tocilizumab (TCZ, an IL-6 receptor inhibitor) and ALL-S3I-201 (a selective inhibitor of STAT3) mice were increased compared to the control group.	s3i	96-99	interleukin 6	Mus musculus	18-22
34073872-6	2021	Moreover, um-PEA could also decrease cytokines release of interleukin (IL)-6, interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha and interleukin (IL)-18.	um-pea	10-16	interleukin 6	Mus musculus	58-76
34108880-5	2021	Effects of SS and TGT on collagen-induced arthritis (CIA) were evaluated by measuring TNF-alpha and IL-6 levels.	H-SER-SER-OH	11-13	interleukin 6	Mus musculus	100-104
34108880-10	2021	Moreover, strychnine, brucine, and triptolide significantly inhibited the proliferation of fibroblast-like synoviocytes, and reduced the production of TNF-alpha and IL-6 and the mRNAs of TNF-alpha, IL-6, COX-2, and iNOS, suggesting that they possessed an anti-arthritis activity.	Strychnine	10-20	interleukin 6	Mus musculus	165-169
34108880-10	2021	Moreover, strychnine, brucine, and triptolide significantly inhibited the proliferation of fibroblast-like synoviocytes, and reduced the production of TNF-alpha and IL-6 and the mRNAs of TNF-alpha, IL-6, COX-2, and iNOS, suggesting that they possessed an anti-arthritis activity.	Strychnine	10-20	interleukin 6	Mus musculus	198-202
34108880-10	2021	Moreover, strychnine, brucine, and triptolide significantly inhibited the proliferation of fibroblast-like synoviocytes, and reduced the production of TNF-alpha and IL-6 and the mRNAs of TNF-alpha, IL-6, COX-2, and iNOS, suggesting that they possessed an anti-arthritis activity.	brucine	22-29	interleukin 6	Mus musculus	165-169
34108880-10	2021	Moreover, strychnine, brucine, and triptolide significantly inhibited the proliferation of fibroblast-like synoviocytes, and reduced the production of TNF-alpha and IL-6 and the mRNAs of TNF-alpha, IL-6, COX-2, and iNOS, suggesting that they possessed an anti-arthritis activity.	brucine	22-29	interleukin 6	Mus musculus	198-202
34108880-10	2021	Moreover, strychnine, brucine, and triptolide significantly inhibited the proliferation of fibroblast-like synoviocytes, and reduced the production of TNF-alpha and IL-6 and the mRNAs of TNF-alpha, IL-6, COX-2, and iNOS, suggesting that they possessed an anti-arthritis activity.	triptolide	35-45	interleukin 6	Mus musculus	165-169
34108880-10	2021	Moreover, strychnine, brucine, and triptolide significantly inhibited the proliferation of fibroblast-like synoviocytes, and reduced the production of TNF-alpha and IL-6 and the mRNAs of TNF-alpha, IL-6, COX-2, and iNOS, suggesting that they possessed an anti-arthritis activity.	triptolide	35-45	interleukin 6	Mus musculus	198-202
34065421-8	2021	Pathway analysis showed IL10 signaling as a major contributing pathway to the altered immunophenotype after Rapamycin treatment compared to vehicle with significantly lower cytokines Tnfa, Il1b, and Il6, while regulators of mitochondrial content Pgc1a, Tfam, and Ho1 remained elevated.	Sirolimus	108-117	interleukin 6	Mus musculus	199-202
34065201-2	2021	With the similar structures to the binding domains of the three cytokines to their cognate receptors, the novel peptide KCF18 can simultaneously inhibit TNF-alpha, IL-1beta, and IL-6.	kcf18	120-125	interleukin 6	Mus musculus	178-182
34094856-11	2021	Losartan treatment or PPARgamma activation contributes to reduced levels of IL-6, IL-1beta, TNF-alpha, and COX-2, expression of TGF-beta1, MMP-13, ADAMTS-4, ADAMTS-5, HtrA1, and iNOS, along with reduced Smad2 and Smad3 phosphorylation, but elevated PPARgamma and Collagen II expression in vivo and in vitro.	Losartan	0-8	interleukin 6	Mus musculus	76-80
34134952-7	2021	The mice in DSS group had severe pathologies in the colon with significantly increased ratios of CD4+ and CD4+/CD8+ T cells in peripheral blood and LPL, increased levels of IL-6 and MCP-1 but no obvious changes in IL-10 in colon homogenate, and significantly augmented phosphorylation levels of ERK1/2, JNK and P38.	dss	12-15	interleukin 6	Mus musculus	173-177
34134952-8	2021	Compared with those in DSS group, the mice in DSS+ rCsHscB group showed ameliorated colon pathologies with decreased CD4+T/CD8+T cell ratio in the peripheral blood and LPL, significantly decreased IL-6 and MCP-1 levels and increased IL-10 in colon homogenate, and lowered phosphorylation levels of ERK1/2, JNK and P38.	dss	23-26	interleukin 6	Mus musculus	197-201
34134952-8	2021	Compared with those in DSS group, the mice in DSS+ rCsHscB group showed ameliorated colon pathologies with decreased CD4+T/CD8+T cell ratio in the peripheral blood and LPL, significantly decreased IL-6 and MCP-1 levels and increased IL-10 in colon homogenate, and lowered phosphorylation levels of ERK1/2, JNK and P38.	dss	46-49	interleukin 6	Mus musculus	197-201
34134952-8	2021	Compared with those in DSS group, the mice in DSS+ rCsHscB group showed ameliorated colon pathologies with decreased CD4+T/CD8+T cell ratio in the peripheral blood and LPL, significantly decreased IL-6 and MCP-1 levels and increased IL-10 in colon homogenate, and lowered phosphorylation levels of ERK1/2, JNK and P38.	rcshscb	51-58	interleukin 6	Mus musculus	197-201
34589770-8	2021	We found that irradiation increased serum levels of IL-6, a change that was partially reversed in mice treated with minocycline or lacking MyD88.	Minocycline	116-127	interleukin 6	Mus musculus	52-56
34069822-9	2021	In addition, SA reduced renal p65 and urinary prostaglandin E2, prostaglandin F1alpha, and interleukin-6 in both WT and TRPV1-/- mice (all p < 0.05).	Salicylates	13-15	interleukin 6	Mus musculus	91-104
34069911-6	2021	We further found that increases in hepatocyte death and suppression of compensatory proliferation in the livers of DEN-injured Pgrmc1-null mice were concomitant with decreases in nuclear factor kappaB (NF-kappaB)-dependent production of interleukin-6 (IL-6).	Diethylnitrosamine	115-118	interleukin 6	Mus musculus	237-250
34069911-6	2021	We further found that increases in hepatocyte death and suppression of compensatory proliferation in the livers of DEN-injured Pgrmc1-null mice were concomitant with decreases in nuclear factor kappaB (NF-kappaB)-dependent production of interleukin-6 (IL-6).	Diethylnitrosamine	115-118	interleukin 6	Mus musculus	252-256
34262419-10	2021	Results: The network analysis revealed that the key active components of chenpi (nobiletin, naringenin, hesperetin) regulate five core targets (AKT1, TP53, IL6, VEGFA, MMP9).	nobiletin	81-90	interleukin 6	Mus musculus	156-159
34262419-10	2021	Results: The network analysis revealed that the key active components of chenpi (nobiletin, naringenin, hesperetin) regulate five core targets (AKT1, TP53, IL6, VEGFA, MMP9).	naringenin	92-102	interleukin 6	Mus musculus	156-159
34069081-8	2021	PCEP induced significant production of IL-6 and reduced IL-12 production in muscle but it did not lead to elevated TGFbeta production.	pcep	0-4	interleukin 6	Mus musculus	39-43
34262419-10	2021	Results: The network analysis revealed that the key active components of chenpi (nobiletin, naringenin, hesperetin) regulate five core targets (AKT1, TP53, IL6, VEGFA, MMP9).	hesperetin	104-114	interleukin 6	Mus musculus	156-159
34262419-15	2021	Meanwhile, hesperetin could suppress the protein expression of AKT1, IL6, VEGFA, MMP9 and up-regulate the protein expression of TP53, and thus reduced the risk of COPD progression to lung cancer.	hesperetin	11-21	interleukin 6	Mus musculus	69-72
34262419-16	2021	Conclusion: Hesperetin is a candidate compound of chenpi that helps in preventing COPD and its progression to lung cancer by regulating AKT1, IL6, VEGFA, MMP9 and TP53.	hesperetin	12-22	interleukin 6	Mus musculus	142-145
34602421-5	2021	Elevated CD4+ T and CD8+ T cells and macrophages in spleen, decreased serum IL-6 level and increased serum IFN-gamma and TNF-alpha levels were observed in mice treated with the combination of aconitine and CMP compare with control group (P<0.05).	Aconitine	192-201	interleukin 6	Mus musculus	76-80
34066479-7	2021	LPS-stimulated cells treated with EO-ACET displayed low levels of nitrite and interleukins (IL"s), IL-1beta, IL-6 and IL-12, when compared to untreated cells.	eo-acet	34-41	interleukin 6	Mus musculus	109-113
34602421-5	2021	Elevated CD4+ T and CD8+ T cells and macrophages in spleen, decreased serum IL-6 level and increased serum IFN-gamma and TNF-alpha levels were observed in mice treated with the combination of aconitine and CMP compare with control group (P<0.05).	4-chloro-2-cresol	206-209	interleukin 6	Mus musculus	76-80
34231485-11	2021	ICA significantly inhibited expressions of IL-6 and TNF-alpha compared to the DSS group (P < .05).	icariin	0-3	interleukin 6	Mus musculus	43-47
34231485-11	2021	ICA significantly inhibited expressions of IL-6 and TNF-alpha compared to the DSS group (P < .05).	dss	78-81	interleukin 6	Mus musculus	43-47
34538121-8	2021	Interleukin-6 and tumor necrosis factor-alpha messenger RNA levels were decreased, and the abundance of lymphocytes, based on immunohistochemistry, was also decreased in ADSC-infused mice (P < 0.05).	adsc	170-174	interleukin 6	Mus musculus	0-13
34674602-11	2021	In RNA sequencing analysis, AzA suppressed LPS-induced activation of inflammatory pathways and reduced TNF-alpha and IL-6 expression, thereby improving intestinal permeability.	azelaic acid	28-31	interleukin 6	Mus musculus	117-121
34279193-10	2021	In STZ induced diabetes mice models, microglia NLRP3, ASC, and caspase-1 proteins were highly expressed, and serum cytokines IL-1beta, IL6, IL18, and TNFalpha were remarkably increased.	Streptozocin	3-6	interleukin 6	Mus musculus	135-138
34384259-10	2021	Moreover, AM1241 inhibited the protein and gene expression levels of TNF-alpha, IL-6 and IFN-gamma in the livers of mice.	AM 1241	10-16	interleukin 6	Mus musculus	80-84
34587405-12	2021	The status of pro-inflammatory markers, i.e., IL-4, IL-5, IL-6, IL-33 and TNF-alpha was found to be decreased in the cirsilineol administered AR mice.	cirsilineol	117-128	interleukin 6	Mus musculus	58-62
35403732-6	2022	Administration of fexofenadine, a histamine H1 receptor antagonist, suppressed tumor growth in HFD-fed mice by reducing the number of myeloid-derived suppressor cells and suppressing IL6/STAT3 signaling.	fexofenadine	18-30	interleukin 6	Mus musculus	183-186
34193671-13	2021	BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice.	boeravinone B	0-2	interleukin 6	Mus musculus	151-164
34193671-13	2021	BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice.	boeravinone B	0-2	interleukin 6	Mus musculus	166-170
35490774-0	2022	Myricitrin exhibits antidepressant-like effects and reduces IL-6 hippocampal levels in the chronic mild stress model.	myricitrin	0-10	interleukin 6	Mus musculus	60-64
34707001-9	2021	In immunized mice with recombinant protein Rv2654, the expression of IFN-gamma, TNF-alpha, IL-2, IL-4, IL-6, IL-10 and other cytokines in peripheral blood was elevated (all P<0.05).	rv2654	43-49	interleukin 6	Mus musculus	103-107
35490774-7	2022	Myricitrin (10 mg/kg, intraperitoneally, for 14 days) reversed depressive-like behaviors induced by CMS (increased immobility in the FST, the TST and anhedonia), as well as decreased adrenal hypertrophy and hippocampal levels of IL-6 in stressed mice.	myricitrin	0-10	interleukin 6	Mus musculus	229-233
35474551-7	2022	The results showed that gastrodin treatment ameliorated acute liver injury caused by APAP, as indicated by serum alanine aminotransferase level, hepatic myeloperoxidase activity, and cytokine (TNF-alpha, IL-1beta, and IL-6) production.	gastrodin	24-33	interleukin 6	Mus musculus	218-222
35623171-7	2022	Hydralazine downregulated NF-kappaB/p38 signaling pathways and reduced TNF-alpha/IL-6 expressions in high glucose-stimulated renal proximal tubular epithelial cells.	Hydralazine	0-11	interleukin 6	Mus musculus	81-85
35567986-8	2022	PA inhibited inflammation by decreasing the levels of IL-6, TNF-alpha, IL-17 and CRP, which also been blocked in the IFD mice.	Proanthocyanidins	0-2	interleukin 6	Mus musculus	54-58
35341816-9	2022	Besides, the dysregulation of pro-inflammatory genes (TNF-alpha,IL-6 and SAA3) showed that BPA exposure promoted progression of hepatic inflammation.	bisphenol A	91-94	interleukin 6	Mus musculus	64-68
35623175-0	2022	Pharmacological effects of a complex alpha-bisabolol/beta-cyclodextrin in a mice arthritis model with involvement of IL-1beta, IL-6 and MAPK.	alpha-Bisabolol	37-52	interleukin 6	Mus musculus	127-131
35594680-13	2022	These findings provide a unique insight into the role of IL-6 in the expansion of the MDSC population which causes inflammatory changes and increased Th-17 responses during ECM.	Thorium	150-152	interleukin 6	Mus musculus	57-61
35427741-6	2022	This prepared water-soluble luteolin inhibits the polarization of inflammatory macrophages by decreasing the expression of pro-inflammatory cytokine genes interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in vitro.	Water	14-19	interleukin 6	Mus musculus	155-168
35427741-6	2022	This prepared water-soluble luteolin inhibits the polarization of inflammatory macrophages by decreasing the expression of pro-inflammatory cytokine genes interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in vitro.	Water	14-19	interleukin 6	Mus musculus	170-174
35461005-13	2022	After geraniin treatment, plasma levels of IL-1beta, IL-6, and TNF-alpha in mice were significantly reduced, and IL-10 levels were significantly increased.	Geraniin	6-14	interleukin 6	Mus musculus	53-57
35470093-1	2022	OBJECTIVE: IL-6 is an important contributor to glucose and energy homeostasis through changes in whole-body glucose disposal, insulin sensitivity, food intake and energy expenditure.	Glucose	47-54	interleukin 6	Mus musculus	11-15
35470093-1	2022	OBJECTIVE: IL-6 is an important contributor to glucose and energy homeostasis through changes in whole-body glucose disposal, insulin sensitivity, food intake and energy expenditure.	Glucose	108-115	interleukin 6	Mus musculus	11-15
35506641-8	2022	RESULTS: Our data showed that tectoridin attenuated the LPS-up-regulated nitric oxide (NO), interleukin-6, (IL-6) and interleukin-18, (IL-18) from macrophages and tumor necrosis factor-alpha, (TNF-alpha); (IL-6) and (IL-1beta) in the serum levels.	tectoridin	30-40	interleukin 6	Mus musculus	206-210
35351577-7	2022	Serum IL-1beta and IL-6 levels were increased in mice given oral TP after antibiotic pretreatment.	triptolide	65-67	interleukin 6	Mus musculus	19-23
35561751-7	2022	Further, the increased levels of TNF-alpha, IL-1beta and IL-6 were confined with Sal administration under the HH condition.	rhodioloside	81-84	interleukin 6	Mus musculus	57-61
35278152-12	2022	The transfection of miR-629-3p mimics inhibited 16HBE cells" viability, and promoted the apoptosis and the secretion of chemokines CCL11, CCL26, CCL-2/MCP-1, IL-1b, and IL-6 of 16HBE cells, whereas inhibiting miR-629-3p had the opposite effects.	mir-629-3p	20-30	interleukin 6	Mus musculus	169-173
35506641-8	2022	RESULTS: Our data showed that tectoridin attenuated the LPS-up-regulated nitric oxide (NO), interleukin-6, (IL-6) and interleukin-18, (IL-18) from macrophages and tumor necrosis factor-alpha, (TNF-alpha); (IL-6) and (IL-1beta) in the serum levels.	tectoridin	30-40	interleukin 6	Mus musculus	92-105
35506641-8	2022	RESULTS: Our data showed that tectoridin attenuated the LPS-up-regulated nitric oxide (NO), interleukin-6, (IL-6) and interleukin-18, (IL-18) from macrophages and tumor necrosis factor-alpha, (TNF-alpha); (IL-6) and (IL-1beta) in the serum levels.	tectoridin	30-40	interleukin 6	Mus musculus	108-112
35348629-5	2022	Improved efficacy of gemcitabine is observed when IL-6 is deleted from aSMA+ CAFs but not from FAP+ CAFs employing dual-recombinase genetic PDAC models.	gemcitabine	21-32	interleukin 6	Mus musculus	50-54
35348629-5	2022	Improved efficacy of gemcitabine is observed when IL-6 is deleted from aSMA+ CAFs but not from FAP+ CAFs employing dual-recombinase genetic PDAC models.	cafs	77-81	interleukin 6	Mus musculus	50-54
35348629-6	2022	Improved gemcitabine efficacy due to lack of IL-6 synergizes with anti-PD1 immunotherapy to significantly improve survival of PDAC mice.	gemcitabine	9-20	interleukin 6	Mus musculus	45-49
35489284-5	2022	Moreover, we found that several senescence-associated secretory phenotype factors, such as IL-6, CCL5, CCL7, CXCL12, and SCF, induced MMP-1 expression in dermal fibroblasts, which decreased after treatment with ABT-263 and ABT-737 in vivo and in vitro.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	211-214	interleukin 6	Mus musculus	91-95
35489284-5	2022	Moreover, we found that several senescence-associated secretory phenotype factors, such as IL-6, CCL5, CCL7, CXCL12, and SCF, induced MMP-1 expression in dermal fibroblasts, which decreased after treatment with ABT-263 and ABT-737 in vivo and in vitro.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	223-226	interleukin 6	Mus musculus	91-95
35359021-6	2022	Celecoxib successfully prevented gentamicin-induced kidney damage as indicated by reducing blood BUN, SCr, and tissue MDA levels and increasing renal tissue GSH levels as well as lowering the blood IL-6 and TNF-alpha in comparison to mice received gentamicin.	Celecoxib	0-9	interleukin 6	Mus musculus	198-202
35359021-7	2022	Furthermore, celecoxib has inhibited COX-2, NF-kappaB, IL-6, and TNF-alpha expression in the renal tissue.	Celecoxib	13-22	interleukin 6	Mus musculus	55-59
35359022-7	2022	Isorhamnetin at the higher dose of 100 mg/kg significantly lowered serum levels of ALT, ALP, and AST in addition to reduction of ROS, TBARS, IL-6, TNFalpha, NF-kB, NLRP3, caspase 1, and MPO and significantly prevented reduction of GSH, SOD activity, sirtuin 1, and Nrf2.	3-methylquercetin	0-12	interleukin 6	Mus musculus	141-145
35486318-8	2022	Furthermore, administration of BRD5529 prior to the intratracheal inoculation of fungal beta-glucans, which are known proinflammatory mediators via the Dectin-1-CARD9 pathway, resulted in significant reductions in lung tissue interleukin-6 and tumor necrosis factor-alpha, suggesting the exciting possibility of the use of this CARD9 inhibitor as an additional therapeutic tool in fungal infections.	beta-Glucans	88-100	interleukin 6	Mus musculus	226-239
35486318-8	2022	Furthermore, administration of BRD5529 prior to the intratracheal inoculation of fungal beta-glucans, which are known proinflammatory mediators via the Dectin-1-CARD9 pathway, resulted in significant reductions in lung tissue interleukin-6 and tumor necrosis factor-alpha, suggesting the exciting possibility of the use of this CARD9 inhibitor as an additional therapeutic tool in fungal infections.	BRD5529	31-38	interleukin 6	Mus musculus	226-239
35430334-7	2022	Increased CD86 and decreased CD206 expression were observed four weeks after PQ exposure, accompanied by increased TNF-alpha and IL-6 levels and decreased IL-10 and TGF-beta levels.	Paraquat	77-79	interleukin 6	Mus musculus	129-133
35413383-3	2022	In the present study, our results revealed that 3-Ac-DON significantly decreased spleen index, elevated MPO activity, upregulated mRNA and protein levels of IL-1alpha, IL-1beta, IL-6, IL-17A, TNF-alpha, M-CSF, G-CSF, CCL2, IFN-beta, and IL-10 in the spleen and serum.	3-acetyldeoxynivalenol	48-56	interleukin 6	Mus musculus	178-182
35583558-6	2022	SAL treatment alleviated Cd-induced oxidative stress, glial cell activation, and elevation of pro-inflammatory factors including TNF-alpha, IL-1beta, and IL-6.	rhodioloside	0-3	interleukin 6	Mus musculus	154-158
35297281-8	2022	RESULTS: ISO effectively inhibited CFA-induced NO production with no cytotoxicity on MH-S cells and pro-inflammatory mediators and cytokines were also inhibited (except tumor necrosis factor alpha and interleukin-6).	iso	9-12	interleukin 6	Mus musculus	201-214
35297281-8	2022	RESULTS: ISO effectively inhibited CFA-induced NO production with no cytotoxicity on MH-S cells and pro-inflammatory mediators and cytokines were also inhibited (except tumor necrosis factor alpha and interleukin-6).	cfa	35-38	interleukin 6	Mus musculus	201-214
35588304-3	2022	The results indicated that CCHP administration alleviated the histological changes of DSS-induced colitis in mice and downregulated the mRNA level of TNF-alpha, IL-1beta, IL-6 and Cox-2.	cchp	27-31	interleukin 6	Mus musculus	171-175
35240143-15	2022	Chymase and histamine did not affect TSLP production, but histamine triggered IL-6, IL-8, and stem cell factor.	Histamine	58-67	interleukin 6	Mus musculus	78-82
35588304-3	2022	The results indicated that CCHP administration alleviated the histological changes of DSS-induced colitis in mice and downregulated the mRNA level of TNF-alpha, IL-1beta, IL-6 and Cox-2.	dss	86-89	interleukin 6	Mus musculus	171-175
35367468-8	2022	DRDE-30 abrogated the activation of pro-inflammatory NF-kappaB and p38/MAPK signaling cascades, suppressing the release of pro-inflammatory cytokines (IL-1beta: p < 0.05; TNF-alpha: p < 0.05; IL-6: p < 0.05) and up-regulation of CAMs on the endothelial cell surface.	drde-30	0-7	interleukin 6	Mus musculus	192-196
35289014-9	2022	Arg could inhibit the M1 polarization of BV2 cells, decrease the levels of TNF-alpha, IL-1beta, IL-6, iNOS, and IL-12, and simultaneously inhibit the expression of P50 and p-P50.	arglabin	0-3	interleukin 6	Mus musculus	96-100
35502484-5	2022	IM156 also inhibited the apoptosis of splenocytes and the production of inflammatory cytokines including IL-1beta, IL-6 and IL-10 in CLP mice.	UNII-4G3BUV6ZSK	0-5	interleukin 6	Mus musculus	115-119
35257304-7	2022	Findings revealed that treatment with Yokukansan significantly decreased the duration of pentobarbital-induced loss of righting reflex by attenuating the LPS-induced increase in interleukin-6 and tumor necrosis factor-alpha levels in the hippocampus.	Pentobarbital	89-102	interleukin 6	Mus musculus	178-191
35383125-5	2022	Our results showed that Anisodamine significantly reduced lung damage, myeloperoxidase (MPO) activity, lung wet/dry ratio, total cell number and protein concentrations in bronchoalveolar lavage fluid (BALF), and decreased IL-6 level and the levels of M1 phenotypic markers, while increased IL-10 level and the levels of M2 phenotypic markers in mice with a nasal instillation of lipopolysaccharide (LPS).	anisodamine	24-35	interleukin 6	Mus musculus	222-226
34983317-9	2022	RESULTS: RSDS significantly increased the levels of TNF-alpha, IL-6, IL-1beta, and VCAM-1 in the serum; it also increased both mRNA and protein expression of these in the brain.	rsds	9-13	interleukin 6	Mus musculus	63-67
35313341-6	2022	Cediranib-resistant tumors had intrinsically high levels of IL-6 and JAK/STAT signaling and treatment increased endothelial STAT3 activation.	cediranib	0-9	interleukin 6	Mus musculus	60-64
35313341-8	2022	In a third HGSOC model, that had lower inherent IL-6 JAK/STAT3 signaling in the TME but high PD1 signaling, long-term cediranib treatment significantly increased overall survival.	cediranib	118-127	interleukin 6	Mus musculus	48-52
35411035-6	2022	Mechanistically, DEN-challenged L-Gab2 mice produced more IL-6, and IL-6 depletion significantly deprived Gab2-overexpression-mediated tumor-promotion phenomena, accompanied by the impairment of MDSCs-initiated immunosuppression function.	Diethylnitrosamine	17-20	interleukin 6	Mus musculus	58-62
35344847-7	2022	Furthermore, rmCXCL10 could enhance the spinal expression of pro-inflammatory cytokines, including TNF-alpha, IL-6, and IL-1beta, which could be blocked by PI3K inhibitor.	rmcxcl10	13-21	interleukin 6	Mus musculus	110-114
35411035-6	2022	Mechanistically, DEN-challenged L-Gab2 mice produced more IL-6, and IL-6 depletion significantly deprived Gab2-overexpression-mediated tumor-promotion phenomena, accompanied by the impairment of MDSCs-initiated immunosuppression function.	Diethylnitrosamine	17-20	interleukin 6	Mus musculus	68-72
35442233-10	2022	Expression of TLR4, IL-1beta, IL-6, and TNF-alpha was decreased in SPAKO pups reared with WT dams compared to SPAKO pups reared with SPAKO dams, with a peak effect at DOL 14.	dalfopristin	167-170	interleukin 6	Mus musculus	30-34
35489123-6	2022	Additionally, the increased TNF-alpha, IL-6, and IL-1beta expression induced by LPS was inhibited by DAPT and rescued by jagged1, a Notch1 ligand.	dapt	101-105	interleukin 6	Mus musculus	39-43
35430302-7	2022	Additionally, co-culture with DNA, a polyanionic compound, clearly inhibited PHMG-P-induced necrosis, and increased IL-1beta and TNF-alpha level and decreased IL-6 and IL-8 levels were observed following exposure to PHMG-P.	polyhexamethyleneguanidine	216-222	interleukin 6	Mus musculus	159-163
35635122-4	2022	Lipopolysaccharide (LPS) binds the TLR4 receptor, which in CPEB1-deficient mice leads to elevated expression of ionized calcium binding adaptor molecule 1 (Iba1), a microglial protein that increases with inflammation, and increased levels of the cytokine IL6.	Calcium	120-127	interleukin 6	Mus musculus	255-258
35354761-5	2022	Treatment with heat-killed LP8 induced the production of NO and pro-inflammatory cytokines, including TNF-alpha, IL-6, and IL-1beta.	3-{[(4-methylphenyl)sulfonyl]amino}propyl pyridin-4-ylcarbamate	27-30	interleukin 6	Mus musculus	113-117
35618921-6	2022	RESULTS: It was shown that AABD alleviated the symptoms of colitis by reducing the histological scores of mice colon, suppressing the expression of pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha) and upregulating the expression of tight junction proteins.	aabd	27-31	interleukin 6	Mus musculus	186-190
35612602-6	2022	To assess the effects of Codeine gel on the wound healing process, the wound area, histological parameters, and the relative protein expression of CXCR1, CXCR2, IL-6, IL-6R, PDGF, PDGFR, and COL1A along with the plasma concentrations of IL-1beta, IL-10, and TNF-alpha were investigated on days 3, 7, and 14.	Codeine	25-32	interleukin 6	Mus musculus	161-165
35536225-7	2022	Furthermore, caffeine impaired NF-kappaB activation by stabilizing IkappaBalpha, resulting in a reduction of proinflammatory mediators interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha).	Caffeine	13-21	interleukin 6	Mus musculus	135-148
35623503-8	2022	RESULTS: We demonstrated that H. littoralis prominently dampened production of nitric oxide (NO) in LPS-, poly I:C-, or pam3CSK-stimulated RAW264.7 cells; down-regulated the expression levels of interleukin 6 (IL-6) and inducible nitric oxide synthase; and markedly attenuated the luciferase activities of AP-1 reporter promoters.	Nitric Oxide	79-91	interleukin 6	Mus musculus	195-208
35536225-7	2022	Furthermore, caffeine impaired NF-kappaB activation by stabilizing IkappaBalpha, resulting in a reduction of proinflammatory mediators interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha).	Caffeine	13-21	interleukin 6	Mus musculus	150-154
35623503-8	2022	RESULTS: We demonstrated that H. littoralis prominently dampened production of nitric oxide (NO) in LPS-, poly I:C-, or pam3CSK-stimulated RAW264.7 cells; down-regulated the expression levels of interleukin 6 (IL-6) and inducible nitric oxide synthase; and markedly attenuated the luciferase activities of AP-1 reporter promoters.	Nitric Oxide	79-91	interleukin 6	Mus musculus	210-214
35623502-1	2022	We previously reported that delivery of nickel nanoparticles (NiNPs) and bacterial lipopolysaccharide (LPS) into the lungs of mice synergistically increased IL-6 production and inflammation, and male mice were more susceptible than female mice.	Nickel	40-46	interleukin 6	Mus musculus	157-161
35611989-5	2022	The effects induced by calcitriol supplementation on interleukin-6 (IL-6) signaling and the tumor immune microenvironment following RT were also examined.	Calcitriol	23-33	interleukin 6	Mus musculus	53-66
35611989-5	2022	The effects induced by calcitriol supplementation on interleukin-6 (IL-6) signaling and the tumor immune microenvironment following RT were also examined.	Calcitriol	23-33	interleukin 6	Mus musculus	68-72
35611989-6	2022	Our data revealed that calcitriol supplementation attenuated tumor aggressive behavior, decrease IL-6 expression, and augmented radiation-induced tumor inhibition.	Calcitriol	23-33	interleukin 6	Mus musculus	97-101
35611989-9	2022	Furthermore, When the primary liver tumor was irradiated with larger dose per fraction, calcitriol induced a smaller size of synchronous unirradiated tumor in mice, which linked with attenuated IL-6 signaling and MDSC recruitment.	Calcitriol	88-98	interleukin 6	Mus musculus	194-198
35611989-11	2022	The inhibited IL-6 signaling and subsequently enhanced antitumor immunity might be responsible to augment radiation-induced tumoricidal effect induced by calcitriol.	Calcitriol	154-164	interleukin 6	Mus musculus	14-18
35623504-12	2022	In RAW264.7 cells stimulated with lipopolysaccharide (LPS), costunolide and dehydrocostus lactone significantly reduced the mRNA levels of interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha, suggesting that these two sesquiterpene lactones had strong anti-inflammatory activity.	costunolide	60-71	interleukin 6	Mus musculus	163-167
35625945-0	2022	Tamoxifen Ameliorates Cholestatic Liver Fibrosis in Mice: Upregulation of TGFbeta and IL6 Is a Potential Protective Mechanism.	Tamoxifen	0-9	interleukin 6	Mus musculus	86-89
35625945-8	2022	Tamoxifen per se, injected into standard-diet-fed mice, increased the expression of genes for Il6 (p < 0.01 and p < 0.001 in male and female mice, respectively) and Tgfbeta (p < 0.01 for both sexes), and had no adverse effects.	Tamoxifen	0-9	interleukin 6	Mus musculus	94-97
35122975-12	2022	The levels of inflammatory factors, including tumor necrosis factor-alpha, interleukin-1beta and interleukin-6 were significantly reduced after quercetin administration.	Quercetin	144-153	interleukin 6	Mus musculus	97-110
35157952-13	2022	FCF exerted its protective effect by suppressing the expression of both inducible nitric oxide synthase (iNOS) and cycooxygenase 2 (COX-2) to inhibit the synthesis of pro-inflammatory factors and cytokines, including NO, PGE2, TNF-alpha, IL-6 and IL-1beta.	3-[(1e,7e)-8-(2,6-Dioxo-1,2,3,6-Tetrahydropyrimidin-4-Yl)-3,6-Dioxa-2,7-Diazaocta-1,7-Dien-1-Yl]benzoic Acid	0-3	interleukin 6	Mus musculus	238-242
35314251-9	2022	In I/R mice, PCA pPoCo attenuated lipid peroxidation, inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, interleukin-6), and myeloperoxidase activity.	ppoco	17-22	interleukin 6	Mus musculus	126-139
35605643-5	2022	Moreover, morphine treatment causes an increase in systemic IL-6 level, which plays an important role in morphine-induced delayed gastric emptying and gastric damage.	Morphine	10-18	interleukin 6	Mus musculus	60-64
35605643-5	2022	Moreover, morphine treatment causes an increase in systemic IL-6 level, which plays an important role in morphine-induced delayed gastric emptying and gastric damage.	Morphine	105-113	interleukin 6	Mus musculus	60-64
35605643-6	2022	IL-6KO mice show a significant level of reduction in morphine-induced gastric delaying, acid retention and gastric damage.	Morphine	53-61	interleukin 6	Mus musculus	0-4
35633920-8	2022	Chlorogenic acid significantly reduced the levels of TNF-alpha, IL-6, IL-1beta, and IFN-alpha.	Chlorogenic Acid	0-16	interleukin 6	Mus musculus	64-68
35628627-4	2022	In addition, xanthotoxol treatment decreased the PGE2, IL-6, and IL-1beta production caused by LPS stimulation in a concentration-dependent manner.	xanthotoxol	13-24	interleukin 6	Mus musculus	55-59
35630676-4	2022	In the present study, we demonstrated that spiramycin significantly decreased nitric oxide (NO), interleukin (IL)-1beta, and IL-6 levels in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells.	Spiramycin	43-53	interleukin 6	Mus musculus	125-129
35574842-2	2022	In diabetes, IL (interleukin)-6 induces salt sensitivity through a dysregulation of the epithelial sodium channel.	Sodium	99-105	interleukin 6	Mus musculus	13-31
35574842-11	2022	CONCLUSIONS: Renal tubular epithelial cell-derived IL-1beta polarizes renal macrophages towards a proinflammatory phenotype that promotes salt sensitivity through the accumulation of renal IL-6.	Salts	138-142	interleukin 6	Mus musculus	189-193
35578571-13	2022	CONCLUSION: Biological activity of IL-6/gp130 axis promoted N-inv in murine model and was upregulated in PDAC patients with severe N-inv.	Nitrogen	131-132	interleukin 6	Mus musculus	35-39
35578169-7	2022	RESULTS: Famotidine administered IP significantly reduced serum and splenic LPS-stimulated tumor necrosis factor (TNF) and IL-6 concentrations, significantly improving survival.	Famotidine	9-19	interleukin 6	Mus musculus	123-127
35630676-7	2022	This indicated that spiramycin attenuates macrophages" secretion of IL-6, IL-1beta, and NO, inducing iNOS expression via the inhibition of the NF-kappaB and MAPK signaling pathways.	Spiramycin	20-30	interleukin 6	Mus musculus	68-72
35367419-8	2022	The regulatory role of GA in downregulating Col I, Col III, fibronectin in NRCFs, and enhancing levels of ANP, BNP and beta-MHC in NRCMs were reversed by MMP9 overexpression, so as the downregulation of IL-1beta, IL-6 and TNF-alpha in Ang II-induced NRCFs and NRCMs.	ginkgolide A	23-25	interleukin 6	Mus musculus	213-217
35631220-6	2022	Moreover, oral administration of Lactobacillus plantarum NK151, Bifidobacterium longum NK173, and Bifidobacterium bifidum NK175, which inhibited LPS-induced IL-6 expression in macrophages, alleviated cGm-induced depression-like behaviors, hippocampal NF-kappaB+Iba1+ cell numbers and IL-1beta and IL-6 expression, blood LPS, IL-6, and creatinine levels, and colonic NF-kappaB+CD11c+ number and IL-1beta and IL-6 expression in mice.	Creatinine	335-345	interleukin 6	Mus musculus	157-161
35554836-4	2022	STZ-induced diabetes was associated with increased levels of blood glucose, ROS, and IL-6 and decreased levels of IL-2, IL-7, IL-4, and GSH.	Streptozocin	0-3	interleukin 6	Mus musculus	85-89
35554836-7	2022	Interestingly, oral supplementation with BG restored the levels of blood glucose, ROS, IL-6, IL-2, IL-4, IL-7, and GSH in diabetic mice.	O(6)-benzylguanine	41-43	interleukin 6	Mus musculus	87-91
35628252-6	2022	The levels of nitric oxide (NO) and interleukin-6 (IL-6) were determined using a NO detection kit and IL-6 ELISA kit, respectively, and showed a significant decrease in NO and IL-6 in PUG-treated cells.	Nitric Oxide	14-26	interleukin 6	Mus musculus	102-106
35628311-6	2022	A 14-day treatment with pioglitazone significantly decreased IL-6 and TNFalpha levels in the prefrontal cortex and led to the downregulation of Tnfrsf1a expression and the upregulation of Cav1 expression in both brain regions of diabetic mice.	Pioglitazone	24-36	interleukin 6	Mus musculus	61-65
35628290-6	2022	Here, we show that Oxy210 also inhibits diet-induced white adipose tissue inflammation in APOE*3-Leiden.CETP mice, evidenced by the inhibition of adipose tissue expression of IL-6, MCP-1, and CD68 macrophage marker.	oxy210	19-25	interleukin 6	Mus musculus	175-179
35631731-7	2022	Semiquantitative RT-PCR, quantitative real-time PCR, and ELISA showed that Ac-EE inhibits the production of proinflammatory mediators, including iNOS and COX-2, and cytokines, such as TNF-alpha, IL-1beta, and IL-6.	ac-ee	75-80	interleukin 6	Mus musculus	209-213
35549900-13	2022	N6-COOH-miniPEG improved the survival rates of mice challenged with E. coli or S. pullorum, downregulated the levels of TNF-alpha, IL-6, IL-1beta and IL-10 in the serum of LPS-infected mice, and alleviated multiple-organ injuries (the liver, spleen, kidney, and lung), superior to antibiotics, but slightly inferior to N6.	n6-cooh-minipeg	0-15	interleukin 6	Mus musculus	131-135
35549900-13	2022	N6-COOH-miniPEG improved the survival rates of mice challenged with E. coli or S. pullorum, downregulated the levels of TNF-alpha, IL-6, IL-1beta and IL-10 in the serum of LPS-infected mice, and alleviated multiple-organ injuries (the liver, spleen, kidney, and lung), superior to antibiotics, but slightly inferior to N6.	n6	319-321	interleukin 6	Mus musculus	131-135
35628252-6	2022	The levels of nitric oxide (NO) and interleukin-6 (IL-6) were determined using a NO detection kit and IL-6 ELISA kit, respectively, and showed a significant decrease in NO and IL-6 in PUG-treated cells.	Nitric Oxide	14-26	interleukin 6	Mus musculus	176-180
35561478-5	2022	Intratracheal (IT) and intraperitoneal (IP) administration of NFA notably attenuated hyperoxia-induced infiltration of inflammatory cells, alveolar-capillary leakage, upregulation of proinflammatory cytokine levels (IL-6 and TNFalpha) into the BAL fluid, and resolution of inflammation in the lung.	nfa	62-65	interleukin 6	Mus musculus	216-220
35569308-9	2022	We found that the expressions of IgA, MHCII, TGF-beta1, IL-6, and pIgR were significantly increased (P < 0.05) 1 h after exposure to COS.	carbonyl sulfide	133-136	interleukin 6	Mus musculus	56-60
35631174-8	2022	Iron overload inhibited the increase in the expression of NF-kappaB and its downstream inflammatory cytokines (IL-6, TNFalpha, iNOS, COX2, and IL-1beta), likely due to the elevated expression of antioxidant genes (SOD1, TXN, GPX1, GPX4, CAT, HMOX1, and NQO1).	Iron	0-4	interleukin 6	Mus musculus	111-115
35416187-6	2022	Accordingly, in FL-276.1 and FL-228.1 groups, the genes of zonula occludens-1 (ZO-1), claudin-4, occludin and mucin 2 (Muc2) in mouse colonic tissues were significantly upregulated, while TNF-alpha, IL-1beta and IL-6 were downregulated.	Fluorides	16-18	interleukin 6	Mus musculus	212-216
35626942-5	2022	The content of proinflammatory factor IL-6 of colon tissues in the sodium-alginate group (1.02 ng/mL) was lower (p < 0.05) than that in chitosan, curdlan-gum and konjac-gum groups (1.29, 1.31 and 1.31 ng/mL, respectively).	Alginates	67-82	interleukin 6	Mus musculus	38-42
35077826-12	2022	Mechanistically, DNJ treatment suppressed the circulating levels of LPS, IL-6, and TNF-alpha in plasma and decreased the inflammatory infiltration in liver and colon tissues.	1-Deoxynojirimycin	17-20	interleukin 6	Mus musculus	73-77
35085745-9	2022	GLY also protected the intestinal mucosal barrier by increasing the expression of the tight junction proteins, occludin, claudin-1 and ZO-1 and by reducing the serum LPS content and decreasing the expression of TLR4, MyD88, NF-kappaB, IL-6, IL-1beta, and TNF-alpha proteins in colon.	Glycine	0-3	interleukin 6	Mus musculus	235-239
35538293-14	2022	And miR-665 knockdown attenuated the effect of DEX on inflammation damage (the levels of TNF-alpha, IL-1beta and IL-6 increased 1.36 times, 1.31 times, 1.43 time, respectively, and IL-10 decreased 1.68 times) and apoptosis from 17 to 25% (P < 0.01).	Dexmedetomidine	47-50	interleukin 6	Mus musculus	113-117
35537703-7	2022	RA-XII treatment restored the colitis damage in colon, reduced colon tumors numbers and decreased inflammatory factors (IL-6, IL-10 and TNF-alpha).	RA XII	0-6	interleukin 6	Mus musculus	120-124
35532076-0	2022	Regenerating Myofiber Directs Tregs and Th17 Responses in Inflamed Muscle through the Intrinsic TGF-beta Signaling Mediated IL-6 Production.	tregs	30-35	interleukin 6	Mus musculus	124-128
35521965-10	2022	In addition, carnosol decreased the levels of MDA, LPO, TNF-alpha, IL-1beta and IL-6, and increased the levels of GSH, SOD, IL-4 and IL-10 in the OGD treated BV2 cells.	carnosol	13-21	interleukin 6	Mus musculus	80-84
35534842-7	2022	RESULTS: The metabolic phenotypes of DIO mouse were ameliorated after 6-week oral administration of JPQHF; Meanwhile,JPQHF downregulated levels of IL-1beta,IL-6, TNF-alpha and IFN-gamma but upregulated the ratio of M2/M1 macrophages in the small intestine.	jpqhf	100-105	interleukin 6	Mus musculus	156-160
35534842-7	2022	RESULTS: The metabolic phenotypes of DIO mouse were ameliorated after 6-week oral administration of JPQHF; Meanwhile,JPQHF downregulated levels of IL-1beta,IL-6, TNF-alpha and IFN-gamma but upregulated the ratio of M2/M1 macrophages in the small intestine.	jpqhf	117-122	interleukin 6	Mus musculus	156-160
35526523-12	2022	RSG treatment decreased serum levels of creatinine, blood urea nitrogen, CXCL13, tumor necrosis factor-alpha, and interleukin-6, downregulated CXCL13 in peritoneal macrophages, and enhanced the survival rate of sepsis mice.	Rosiglitazone	0-3	interleukin 6	Mus musculus	114-127
35533916-14	2022	The combined administration of peimine, peiminine, and forsythoside A had a strongly inhibitory effects on the W/D weight ratio, total protein (TP) level and the inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, and IL-17) level in acute lung injury mice, compared to combined administration of two compounds or individual administration.	verticine	31-38	interleukin 6	Mus musculus	197-201
35533916-14	2022	The combined administration of peimine, peiminine, and forsythoside A had a strongly inhibitory effects on the W/D weight ratio, total protein (TP) level and the inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, and IL-17) level in acute lung injury mice, compared to combined administration of two compounds or individual administration.	peiminine	40-49	interleukin 6	Mus musculus	197-201
35533916-14	2022	The combined administration of peimine, peiminine, and forsythoside A had a strongly inhibitory effects on the W/D weight ratio, total protein (TP) level and the inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, and IL-17) level in acute lung injury mice, compared to combined administration of two compounds or individual administration.	forsythiaside	55-69	interleukin 6	Mus musculus	197-201
35574272-8	2022	In addition, DSS treatment induced downregulation of tight junction (TJ) protein, anti-inflammatory cytokines (IL-10 and TGF-beta), and the number of anti-inflammatory B cells (CD1d+) in intestinal epithelial tissues, while upregulated proinflammatory cytokines (IL-6 and TNF-alpha), proinflammatory B cells (CD138+), and DNA methylation level.	dss	13-16	interleukin 6	Mus musculus	263-267
35629363-9	2022	Additionally, DXM reduced the mRNA levels of the cytokines TNF-alpha, IL-6, IL-17A, and IL-22 in skin and the percentage of IL-17A and IL-22 producing T cell receptor gammadelta T cells (TCRgammadeltaT).	Dextromethorphan	14-17	interleukin 6	Mus musculus	70-74
35143636-11	2022	MAPC1591 inhibited joint-bleed induced inflammatory cytokine IL-6 expression and vascular leakage in joints, whereas MPC1609 had no significant effect.	mapc1591	0-8	interleukin 6	Mus musculus	61-65
35510373-7	2022	Hypersecretion of pro-inflammatory cytokines, mainly IL-6, and increased infiltration of CD4+ and CD8+ T cells were observed in ascites mice treated by OH2, compared with those treated by 5-fluorouracil or nonresponders.	Water	152-155	interleukin 6	Mus musculus	53-57
35510373-8	2022	Furthermore, the initial-stage blocking of the IL-6 pathway was able to considerably suppress antitumor immune responses driven by OH2.	Water	131-134	interleukin 6	Mus musculus	47-51
35510373-10	2022	CONCLUSIONS: OH2 could safely eliminate malignant ascites of colon cancer and convert the cold immune microenvironment by inducing a remarkably regional cytokine storm in ascites, mainly IL-6, in the early stage of antitumor immune responses beyond directed oncolytic virotherapy.	Water	13-16	interleukin 6	Mus musculus	187-191
35524664-10	2022	CONCLUSION- In molecular docking assay, which investigated potential targets, THL presented sat-isfactory energy values for: nNOs, SGC, IL-6, 5-HT1A, NMDAr, and D1.	Orlistat	78-81	interleukin 6	Mus musculus	136-140
35525219-3	2022	In this study, 12.5 mumol/Kg body weight CdTe QDs triggered systemic and local inflammatory response in mice and activated macrophages, then the mechanism of activating macrophages to overexpress IL-1beta and IL-6 was explored.	cdte qds	41-49	interleukin 6	Mus musculus	209-213
35566338-9	2022	Results: In vivo, the improved levels of LPS-induced pro-inflammatory factors, including TNF-alpha, IL-6, IL-1beta, MCP-1 and ICAM-1 in the cortex and hippocampus, were reduced after ST2825 treatment.	ST2825	183-189	interleukin 6	Mus musculus	100-104
35566338-10	2022	In vitro, the levels of LPS-induced pro-inflammatory factors, including NO, TNF-alpha, IL-6, IL-1beta, MCP-1, iNOS, COX2 and ROS, were remarkably decreased after ST2825 treatment.	ST2825	162-168	interleukin 6	Mus musculus	87-91
35500571-10	2022	In the autografted+l-carnitine group, serum concentrations of IL-6, TNF-alpha and MDA were significantly decreased compared to the autografted group.	Carnitine	19-30	interleukin 6	Mus musculus	62-66
35508128-4	2022	NR4A B cells co-express lymphotoxins alpha and beta and IL-6, supporting functions in ELS promotion.	N-[(2S,3S,4R)-3,4-dihydroxy-8-oxo-8-[(4-pentylphenyl)amino]-1-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}octan-2-yl]hexacosanamide	86-89	interleukin 6	Mus musculus	56-60
35511600-6	2022	Dextran sodium sulfate (DSS) upregulated the mRNA levels of IL-6, IL-1beta, IL-17, IL-12, tumor necrosis factor-alpha, C-C chemokine receptor type 5 and Bax in splenic lymphocytes (SPLs) and colon tissues, while G3c/D665 treatment conversely inhibited the increase in mRNA levels of these genes.	dextran sodium sulfate	0-22	interleukin 6	Mus musculus	60-64
35511600-6	2022	Dextran sodium sulfate (DSS) upregulated the mRNA levels of IL-6, IL-1beta, IL-17, IL-12, tumor necrosis factor-alpha, C-C chemokine receptor type 5 and Bax in splenic lymphocytes (SPLs) and colon tissues, while G3c/D665 treatment conversely inhibited the increase in mRNA levels of these genes.	dss	24-27	interleukin 6	Mus musculus	60-64
35507968-4	2022	METHODS: PCCL was orally administered at a dose of 20 mg kg-1 for 7 days and its protective effect on 5-FU-induced IM (5-FU, 50 mg kg-1 for 5 days) was evaluated by monitoring changes in body weight, degree of diarrhea, levels of tissue inflammatory factors (tumor necrosis factor alpha, interleukin 6, and interleukin 1beta levels), apoptosis rates, and the expression levels of caspase-3, Bax and Bcl-2.	pccl	9-13	interleukin 6	Mus musculus	288-301
35502492-9	2022	Isorhamnetin significantly reduced APAP-induced oxidative stress and inflammation by increasing TAS levels and decreasing TOS, TNF-alpha, IL-1beta, and IL-6 levels (p < 0.05).	3-methylquercetin	0-12	interleukin 6	Mus musculus	152-156
35501470-8	2022	A robust decrease of the spinal proinflammatory cytokines content (IL-6, IL-1ss) was also observed after SUM52 treatment.	sum52	105-110	interleukin 6	Mus musculus	67-71
35510377-8	2022	It was observed that DXP decreased the expressions of TNF-alpha, IL-1beta, IL-6, and MCP-1 in the serum of CLP-induced mice, attenuated the functional impairment, pathological damage, inflammation, and cell apoptosis of kidney tissue.	dexpanthenol	21-24	interleukin 6	Mus musculus	75-79
35586052-7	2022	GLY diminished the inflammatory cell infiltration of the cornea, as well as reduced the expression of IL-1beta, IL-6, and TNF-alpha.	Glycyrrhizic Acid	0-3	interleukin 6	Mus musculus	112-116
35549989-2	2022	The results showed that the overexpression of lincRNA-EPS was able to reduce the levels of interleukin-6, tumor necrosis factor-alpha and interleukin-1beta stimulated in the OGD-treated Neuro-2a (N-2a) cells.	lincrna-eps	46-57	interleukin 6	Mus musculus	91-104
35609329-10	2022	Moreover, curcumin suppressed the inflammatory response by reducing TNF-alpha, IL-6, and IL-17 secretion in CIA-stimulated mice.	Curcumin	10-18	interleukin 6	Mus musculus	79-83
35609329-11	2022	Curcumin has an excellent anti-RA effect in vivo and in vitro, which is exerted by inhibiting the expression of pro-inflammatory factors TNF-a, IL-6 and IL-17 and inhibiting the activation of PI3K/AKT signaling pathway.	Curcumin	0-8	interleukin 6	Mus musculus	144-148
35416331-8	2022	Finally, when these rHDL formulations were administered to dyslipidemic low-density lipoprotein (LDL)-receptor knockout mice fed a high-cholesterol diet, circulating IL-6 levels were significantly reduced only in PC/PS-rHDL-treated mice.	Cholesterol	136-147	interleukin 6	Mus musculus	166-170
35158218-6	2022	A significant immune response with high TNF-alpha and IL-6 cytokine secretion was confirmed for the co-incubation of AC-IO-Ova with RAW 264.7 or HaCaT cells.	ac-io-ova	117-126	interleukin 6	Mus musculus	54-58
35230485-5	2022	We concluded that IL-6: (i) does not affect insulin action on actin cellular distribution; (ii) modulates the effect of insulin on myosin light chain kinase (Mylk) distribution by preventing its shift toward cytoplasm; (iii) mimics the effect of insulin on dynein distribution by increasing its near-nuclear accumulation; (iv) mimics the effect of insulin on glucose transporter Glut4 distribution, especially by increasing its near-nuclear accumulation; (v) supports insulin action on early endosome marker Rab4A near-nuclear accumulation.	Glucose	359-366	interleukin 6	Mus musculus	18-22
35493436-7	2022	In addition, co-administration with aCD47 effectively reduced the expression of Bax, collagen I, interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha in murine DCM.	acd47	36-41	interleukin 6	Mus musculus	97-115
34981658-5	2022	Mechanistically, the LXRalpha-responsive up-regulation of interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling pathway and the complement system, and down-regulation of bile acid metabolism, may have contributed to increased tumorigenesis.	Bile Acids and Salts	206-215	interleukin 6	Mus musculus	73-77
35405468-5	2022	ML365 suppressed the release of tumor necrosis factor-alpha, interleukin (IL)-6 and IL-1beta measured using enzyme-linked immunosorbent assay and quantitative polymerase chain reaction assays.	ML365	0-5	interleukin 6	Mus musculus	61-79
35247859-10	2022	Colonic IL-6 was significantly lower in both PPS- and combination-treated groups accompanied by a significantly higher IL-35 level and its EBI3 subunit mRNA expression.	Pentosan Sulfuric Polyester	45-48	interleukin 6	Mus musculus	8-12
35369899-5	2022	TPNA10168 significantly reduced the transcription of inflammatory genes, including TNF-alpha, IL-1beta, IL-6, and iNOS; however, the inhibition of proinflammatory cytokine gene expression was not attenuated by inhibitors of Nrf2-regulated enzymes.	tpna10168	0-9	interleukin 6	Mus musculus	104-108
35203043-8	2022	MSM treatment reduced the ethanol-induced inflammatory factors including myeloperoxidase (MPO), iNOS/NO, cyclooxygenase (COX)-2, nuclear factor kappa B (NF-kappaB), NLRP3 inflammasome and proinflammatory cytokines including TNF-alpha, IL-1beta, IL-6 and MCP-1.	dimethyl sulfone	0-3	interleukin 6	Mus musculus	245-249
35203043-8	2022	MSM treatment reduced the ethanol-induced inflammatory factors including myeloperoxidase (MPO), iNOS/NO, cyclooxygenase (COX)-2, nuclear factor kappa B (NF-kappaB), NLRP3 inflammasome and proinflammatory cytokines including TNF-alpha, IL-1beta, IL-6 and MCP-1.	Ethanol	26-33	interleukin 6	Mus musculus	245-249
35218798-5	2022	In addition, PSB decreased the levels of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-1beta (IL-1beta), IL-6, and IL-18 in the colon and suppressed DSS-induced activation of the nuclear factor kappa B (NF-kappaB) and signal transducer and activator of transcription 3 (STAT3) pathways.	psb	13-16	interleukin 6	Mus musculus	173-177
35244189-14	2022	Furthermore, CID16020046 significantly decreased the contents of TNF-alpha, IL-6 and IL-1beta in the serum and renal tissue of septic mice, and reduced cell apoptosis.	4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid	13-24	interleukin 6	Mus musculus	76-80
35373399-9	2022	Moreover, SI treatment significantly suppressed nuclear factor kappa B p65, nitric oxide synthase, and cyclooxygenase 2 activation, as well as the pro-inflammatory cytokines (Tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta)) release in the hippocampus of CSD-treated mice.	Isoflavones	10-12	interleukin 6	Mus musculus	216-229
35551509-5	2022	Mechanistically, KLB interacts with and stabilizes the cytokine receptor subunit GP130 by blockage of ubiquitin-dependent lysosomal degradation, thereby facilitating interleukin-6-evoked STAT3-HIF1alpha signaling, which in turn transactivates a cluster of glycolytic genes for adenosine triphosphate production and GSIS.	Adenosine	277-286	interleukin 6	Mus musculus	166-179
34706635-14	2022	Modafinil lowered NO metabolites, TNF-alpha, and IL-6 levels (P<0.001).	Modafinil	0-9	interleukin 6	Mus musculus	49-53
35373399-9	2022	Moreover, SI treatment significantly suppressed nuclear factor kappa B p65, nitric oxide synthase, and cyclooxygenase 2 activation, as well as the pro-inflammatory cytokines (Tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta)) release in the hippocampus of CSD-treated mice.	Isoflavones	10-12	interleukin 6	Mus musculus	231-235
35535157-6	2022	MI/R-induced expression of IL-6, TNF-alpha, and IL-1beta in the hearts was reduced by LrB treatment.	Arginine	3-4	interleukin 6	Mus musculus	27-31
35535157-6	2022	MI/R-induced expression of IL-6, TNF-alpha, and IL-1beta in the hearts was reduced by LrB treatment.	loureirin B	86-89	interleukin 6	Mus musculus	27-31
35217078-5	2022	The TNF-alpha, IL-6 and TLR4 content in RAW 264.7 cells treated with different GM products in the presence or absence of TAK-242 (TLR4 inhibitor) suggested that the immunomodulatory activity of GM and its degradation products is TLR4-dependent.	galactomannan	79-81	interleukin 6	Mus musculus	15-19
35217078-5	2022	The TNF-alpha, IL-6 and TLR4 content in RAW 264.7 cells treated with different GM products in the presence or absence of TAK-242 (TLR4 inhibitor) suggested that the immunomodulatory activity of GM and its degradation products is TLR4-dependent.	galactomannan	194-196	interleukin 6	Mus musculus	15-19
35571141-4	2022	Our results showed that DHA decreased the serum levels of IL-1beta and IL-6, alleviated paw oedema, and reduced bone destruction in DBA/1J mice with CIA.	dihydroarteannuin	24-27	interleukin 6	Mus musculus	71-75
35485445-5	2022	PEA also inhibited both mRNA and protein levels of IL-6 in bone marrow derived dendritic cells (BMDCs) and B cells stimulated with CpG-ODN.	CPG-oligonucleotide	131-138	interleukin 6	Mus musculus	51-55
35485445-7	2022	Moreover, PEA treatment significantly reduced mortality and serum IL-6 levels in mice injected with CpG-ODN plus D-galactosamine.	CPG-oligonucleotide	100-107	interleukin 6	Mus musculus	66-70
35485445-7	2022	Moreover, PEA treatment significantly reduced mortality and serum IL-6 levels in mice injected with CpG-ODN plus D-galactosamine.	Galactosamine	113-128	interleukin 6	Mus musculus	66-70
35528510-10	2022	DEAC (100 mug/mL), as well as CM (50 and 100 mug/mL) and AMB (25 mug/mL), reduced at least 50% of NO produced and markedly decrease the production of TNF-alpha and IL-6 but they did not significantly affect IL-10 levels.	deac	0-4	interleukin 6	Mus musculus	164-168
35528510-10	2022	DEAC (100 mug/mL), as well as CM (50 and 100 mug/mL) and AMB (25 mug/mL), reduced at least 50% of NO produced and markedly decrease the production of TNF-alpha and IL-6 but they did not significantly affect IL-10 levels.	coumarin	30-32	interleukin 6	Mus musculus	164-168
35528510-10	2022	DEAC (100 mug/mL), as well as CM (50 and 100 mug/mL) and AMB (25 mug/mL), reduced at least 50% of NO produced and markedly decrease the production of TNF-alpha and IL-6 but they did not significantly affect IL-10 levels.	amburoside A	57-60	interleukin 6	Mus musculus	164-168
35528525-5	2022	In addition, we observed that IL-6 KO promoted the expression of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) and inhibited CLP-induced mitochondrial reactive oxygen species (ROS) production in skeletal muscles (all P < 0.05).	Reactive Oxygen Species	186-209	interleukin 6	Mus musculus	30-34
35487253-5	2022	Ethanol-induced acute gastric ulcer was restored by OCT alone at doses of 2.5 mg/kg, or combined with OME as indicated by markedly reducing Gastrin, Il-6 and Il1b expression through induction of Muc5ac and Occludin, significantly improving hyperacidity and gastric bleeding.	Ethanol	0-7	interleukin 6	Mus musculus	149-153
35487253-5	2022	Ethanol-induced acute gastric ulcer was restored by OCT alone at doses of 2.5 mg/kg, or combined with OME as indicated by markedly reducing Gastrin, Il-6 and Il1b expression through induction of Muc5ac and Occludin, significantly improving hyperacidity and gastric bleeding.	Octreotide	52-55	interleukin 6	Mus musculus	149-153
35487253-5	2022	Ethanol-induced acute gastric ulcer was restored by OCT alone at doses of 2.5 mg/kg, or combined with OME as indicated by markedly reducing Gastrin, Il-6 and Il1b expression through induction of Muc5ac and Occludin, significantly improving hyperacidity and gastric bleeding.	Omeprazole	102-105	interleukin 6	Mus musculus	149-153
35528525-5	2022	In addition, we observed that IL-6 KO promoted the expression of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) and inhibited CLP-induced mitochondrial reactive oxygen species (ROS) production in skeletal muscles (all P < 0.05).	Reactive Oxygen Species	211-214	interleukin 6	Mus musculus	30-34
35528525-6	2022	However, the knockdown of PGC-1alpha abolished the protective effects of IL-6 KO in CLP-induced skeletal muscle atrophy and reversed the changes in mitochondrial ROS production (all P < 0.05).	Reactive Oxygen Species	162-165	interleukin 6	Mus musculus	73-77
35528525-7	2022	Ex vivo experiments found that exogenous IL-6 inhibited PGC-1alpha expression, promoted mitochondrial ROS production, and induced proteolysis in C2C12 cells (all P < 0.05).	Reactive Oxygen Species	102-105	interleukin 6	Mus musculus	41-45
35467779-4	2022	Here, we found that ACA inhibits lipopolysaccharide-induced expression and production of proinflammatory cytokines such as interleukin 6 and TNFalpha by macrophages.	Acetates	20-23	interleukin 6	Mus musculus	123-136
35528515-5	2022	MgH2 can exert an anti-inflammatory effect by down-regulating the expressions of inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha).	magnesium;hydride	0-4	interleukin 6	Mus musculus	115-119
35548331-3	2022	The results show that BO effectively inhibited the release of intestinal inflammatory cytokines such as IL-6, TNF-alpha, and IL-1beta.	borage oil	22-24	interleukin 6	Mus musculus	104-108
35547139-6	2022	The results showed that parishin treatment ameliorates aging-induced cardiopulmonary fibrosis and increase in serum p16 Ink4a , GDF15, and IL-6 levels.	Parishin A	24-32	interleukin 6	Mus musculus	139-143
35502210-8	2022	Results: PM increased the expression of inflammatory cytokines and protein, including IL-6, IL-1alpha, IL-1beta, and COX-2, while these alternations were significantly alleviated following EDA treatment in a dose-dependent manner.	Edaravone	189-192	interleukin 6	Mus musculus	86-90
35448938-7	2022	In a 5-FU-induced chemoentermuctis mouse model, Lactobacillus rhamnoides can increase the concentrations of three SCFAs in faeces and increase the concentrations of IL-1beta, IL-6 and IgA in serum, and decrease the expressions of NLRP3 and IL-17 in spleen cells.	Fluorouracil	5-9	interleukin 6	Mus musculus	175-179
35563745-6	2022	The injection of 18S rRNA/Pam2 into mice increased the cytokine levels of TNF-alpha, IL-6, and MCP-1 in the peritoneal lavage.	18s rrna/pam2	17-30	interleukin 6	Mus musculus	85-89
35497929-9	2022	In contrast, noscapine significantly reduced the ear length, thickness, severity of skin inflammation, psoriatic itch and body weight, tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta), interferon-gamma (IFN-gamma), interleukin 6 (IL-6), IL-17, and IL-23p19 in a concentration-dependent manner (P < 0.001-0.05 for all cases).	Noscapine	13-22	interleukin 6	Mus musculus	250-263
35497929-9	2022	In contrast, noscapine significantly reduced the ear length, thickness, severity of skin inflammation, psoriatic itch and body weight, tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta), interferon-gamma (IFN-gamma), interleukin 6 (IL-6), IL-17, and IL-23p19 in a concentration-dependent manner (P < 0.001-0.05 for all cases).	Noscapine	13-22	interleukin 6	Mus musculus	265-269
35448938-7	2022	In a 5-FU-induced chemoentermuctis mouse model, Lactobacillus rhamnoides can increase the concentrations of three SCFAs in faeces and increase the concentrations of IL-1beta, IL-6 and IgA in serum, and decrease the expressions of NLRP3 and IL-17 in spleen cells.	rhamnoides	62-72	interleukin 6	Mus musculus	175-179
35182973-5	2022	In the caerulein-induced mild acute pancreatitis (MAP) model, we found that Pae administration reduced serum levels of amylase, lipase, IL-1beta and IL-6 and alleviated the histopathological manifestations of pancreatic tissue in a dose-dependent manner.	paeonol	76-79	interleukin 6	Mus musculus	149-153
35559378-7	2022	RESULTS: Network pharmacology suggested that curcumin treated EM through the HIF signaling pathway, of which IL-6, HIF-1alpha, and VEGFA are key targets.	Curcumin	45-53	interleukin 6	Mus musculus	109-113
35565666-8	2022	The concentrations of inflammatory factors in the serum and liver, such as interleukin-6 and tumor necrosis factor-alpha, were downregulated by MFE.	mfe	144-147	interleukin 6	Mus musculus	75-88
35354611-9	2022	In multiplex screens, higher airway accumulations of IL-6, TNF-alpha, and MCP-3 (CCL7) were observed in Il27ra-/- mice, whereas rmIL-27 treatment showed a reciprocal effect.	rmil	128-132	interleukin 6	Mus musculus	53-57
35426091-12	2022	Clodronate liposome treatment also decreased the mRNA expression levels of inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6) in the kidney after exhaustive exercise.	Clodronic Acid	0-10	interleukin 6	Mus musculus	124-128
35458359-9	2022	MvFL (5 and 10 mg/kg) was efficient in reducing neutrophil infiltration, pro-inflammatory cytokines (IL-6, IL-17, and TNF-alpha), NO, and protein content in the peritoneal fluid.	mvfl	0-4	interleukin 6	Mus musculus	101-105
35492613-8	2022	Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and cTNT decreased, while interleukin-10 (IL-10) increased with rutin pretreatment.	Rutin	143-148	interleukin 6	Mus musculus	72-76
35426250-3	2022	Nasal administration of liquid coco-caprylate/caprate (LCC) onto Staphylococcus epidermidis (S. epidermidis)-colonized mice significantly attenuated NPP-induced IL-6.	dodecyl decanoate;dodecyl octanoate	31-53	interleukin 6	Mus musculus	161-165
35426250-3	2022	Nasal administration of liquid coco-caprylate/caprate (LCC) onto Staphylococcus epidermidis (S. epidermidis)-colonized mice significantly attenuated NPP-induced IL-6.	[(1R,3R,4R,7S)-7-HYDROXY-3-(5-METHYLCYTOSIN-1-YL)-2,5-DIOXABICYCLO[2.2.1]HEPT-1-YL]METHYL DIHYDROGEN PHOSPHATE	55-58	interleukin 6	Mus musculus	161-165
35426250-3	2022	Nasal administration of liquid coco-caprylate/caprate (LCC) onto Staphylococcus epidermidis (S. epidermidis)-colonized mice significantly attenuated NPP-induced IL-6.	npp	149-152	interleukin 6	Mus musculus	161-165
35426250-5	2022	Inhibition of Ffar2 impeded the effect of S. epidermidis plus LCC on the reduction of NPP-induced IL-6.	npp	86-89	interleukin 6	Mus musculus	98-102
35448536-7	2022	While LPS-induced acute pneumonia caused an increase in cytokine/chemokine mRNA expression, including that of IL-1beta, -6, TNF-alpha, MCP-1, TauCl treatment attenuated IL-6, and TNF-alpha expression, but not IL-1beta and MCP-1.	taucl	142-147	interleukin 6	Mus musculus	169-173
35347990-3	2022	Furthermore, poricoic acid GM induced HO-1 protein expression and inhibited iNOS and COX2 protein expression as well as the release of PGE2, IL-1beta, IL-6, TNF-alpha, and reactive oxygen species (ROS) in LPS-induced RAW264.7 cells.	poricoic acid	13-26	interleukin 6	Mus musculus	151-155
35347990-3	2022	Furthermore, poricoic acid GM induced HO-1 protein expression and inhibited iNOS and COX2 protein expression as well as the release of PGE2, IL-1beta, IL-6, TNF-alpha, and reactive oxygen species (ROS) in LPS-induced RAW264.7 cells.	Gentamicins	27-29	interleukin 6	Mus musculus	151-155
35492705-5	2022	We also found that the Si-based agent suppressed the expressions of inflammation-associated genes Ifna1 and Il-6 in the mouse brain.	Silicon	23-25	interleukin 6	Mus musculus	108-112
35410316-7	2022	Co-application of HG and LPS significantly increased the secretion of IL-6, IL-1beta, and TNF-alpha, and ATP levels, whereas 3TC decreased cell inflammation, apoptosis, and pyroptosis.	Mercury	18-20	interleukin 6	Mus musculus	70-74
35465355-9	2022	alpha-Bisabolol treatment also reduced the expression of proinflammatory cytokines (IL-6, IL1beta, TNF-alpha, and IL-17A) at the protein and mRNA levels.	alpha-Bisabolol	0-15	interleukin 6	Mus musculus	84-88
35455983-19	2022	However, drinking alcohol during exercise exacerbates dyslipidemia and oxidative stress, with hepatocyte IL-6-p47phox downregulated.	Alcohols	18-25	interleukin 6	Mus musculus	105-109
35415887-4	2022	The results indicated that RAW264.7 cells treated with F1 released the highest level of nitric oxide, reactive oxygen species, interleukin-6, and tumor necrosis factor-alpha.	Deoxyguanosine	55-57	interleukin 6	Mus musculus	127-140
35455979-5	2022	Our results are supported by literature data, particularly the DMBA generated ROS-induced inflammatory and proliferative signal transducers, such as TNF, IL1, IL6, and NF-kappaB; as well as oncogenes, namely RAS and MYC.	9,10-Dimethyl-1,2-benzanthracene	63-67	interleukin 6	Mus musculus	159-162
35455979-5	2022	Our results are supported by literature data, particularly the DMBA generated ROS-induced inflammatory and proliferative signal transducers, such as TNF, IL1, IL6, and NF-kappaB; as well as oncogenes, namely RAS and MYC.	ros	78-81	interleukin 6	Mus musculus	159-162
35412062-11	2022	DEX treatment or miR-329-3p downregulation caused attenuated cognitive dysfunction and microglia activation as well as reduced IL-1beta, IL-6, and TNF-alpha levels in the hippocampus of the postoperative NCD mice.	Dexmedetomidine	0-3	interleukin 6	Mus musculus	137-141
35412062-11	2022	DEX treatment or miR-329-3p downregulation caused attenuated cognitive dysfunction and microglia activation as well as reduced IL-1beta, IL-6, and TNF-alpha levels in the hippocampus of the postoperative NCD mice.	mir-329-3p	17-27	interleukin 6	Mus musculus	137-141
35411090-3	2022	In the present report we demonstrate that, in mouse Balb/c3T3 fibroblasts, mutationally activated Src527F also increases Rac levels, leading to secretion of IL6 family cytokines and gp130 activation, which triggers the Stat3-ptyr705 increase.	ptyr705	225-232	interleukin 6	Mus musculus	157-160
35410593-5	2022	Lastly, the effect of BHA on NO release, iNOS expression, IL-1beta, IL-6, and TNF-alpha mRNA in LPS-induced RAW264.7 cells was detected.	Butylated Hydroxyanisole	22-25	interleukin 6	Mus musculus	68-72
35495917-7	2022	Treatment with Fru also increased the concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), IL-17, and C-reactive protein in sera and the expression of IL-6, TNF-alpha, IL-17, and IL-1beta mRNA in liver tissues of pregnant mice.	Fructose	15-18	interleukin 6	Mus musculus	56-69
35495917-7	2022	Treatment with Fru also increased the concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), IL-17, and C-reactive protein in sera and the expression of IL-6, TNF-alpha, IL-17, and IL-1beta mRNA in liver tissues of pregnant mice.	Fructose	15-18	interleukin 6	Mus musculus	71-75
35495917-7	2022	Treatment with Fru also increased the concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), IL-17, and C-reactive protein in sera and the expression of IL-6, TNF-alpha, IL-17, and IL-1beta mRNA in liver tissues of pregnant mice.	Fructose	15-18	interleukin 6	Mus musculus	179-183
35541893-7	2022	ER stress and ROS production facilitated the release of ICD-related danger-associated molecular patterns (DAMPs) from TNBC cells, which activated the immune response in vivo, as indicated by the release of antitumor cytokines such as IL-6, IL-1beta, IFN-gamma, and TNF-alpha, increases in CD86+ and MHC-II dendritic cells and CD4+ and CD8+ T cells and a decrease in regulatory T cells (Tregs).	Reactive Oxygen Species	14-17	interleukin 6	Mus musculus	234-238
35441176-10	2022	Famotidine administered IP significantly reduced serum and splenic LPS-stimulated tumor necrosis factor alpha and interleukin-6 concentrations, significantly improving survival.	Famotidine	0-10	interleukin 6	Mus musculus	114-127
35410593-11	2022	Furthermore, benzoylhypaconine reduced the release of NO, inhibited the expression of iNOS, decreased the mRNA levels of IL-1beta, IL-6, and TNF-alpha.	benzoylhypaconine	13-30	interleukin 6	Mus musculus	131-135
35394127-10	2022	RESULTS: Compared with the control group, the number of times the mice crossed the platform, and the time spent at the circumjacent area I and II of the platform were significantly decreased in the isoflurane group; the TLR4, TNF-alpha and IL-6 expressions were significantly increased in the isoflurane group, as compared to control; the results were reversed after the TLR4 interference.	Isoflurane	198-208	interleukin 6	Mus musculus	240-244
35101458-9	2022	DMY suppressed the expression of microglia markers CD11b, accompanied by reduced expression of pro-inflammatory cytokines, such as TNFalpha, IL-6, IL-1beta, COX-2, and iNOS in a dose-dependent manner.	dihydromyricetin	0-3	interleukin 6	Mus musculus	141-145
35437448-8	2022	Results: Fisetin treatment significantly suppressed ear swelling and associated inflammatory cell infiltration, besides reducing the production of Th17 cytokines (IL-17, TNF-alpha, and IL-6) and the expression of the Th17 lineage transcription factor RORgammat while simultaneously enhancing Treg-specific cytokine production (TGF-beta and IL-10) and the expression of the Treg lineage transcription factor Foxp3, thereby restoring the Th17/Treg cell in ACD mice.	fisetin	9-16	interleukin 6	Mus musculus	185-189
35432562-10	2022	Mechanistic evaluation revealed that GPS treatment reduced intestinal permeability and serum levels of inflammatory factors: IL-1, IL-6, and TNF-alpha, while increasing serum levels of the anti-inflammatory factor IL-10, suggesting that GPS"s mechanism in UC is related to reducing intestinal permeability and inhibiting the inflammatory response, with intestinal permeability implicated as the initiating mechanism.	(9R,10R)-9-(S-GLUTATHIONYL)-10-HYDROXY-9,10-DIHYDROPHENANTHRENE	37-40	interleukin 6	Mus musculus	131-135
35400322-8	2022	Betaine alleviates the mechanism of MIF-mediated effects in TAA-induced nephrotoxicity, reducing MDA, IL-6, TNF- , TGF- 1, and PDGF-BB, and increasing SOD and CAT activity, as well as GSH levels.	Betaine	0-7	interleukin 6	Mus musculus	102-106
35479080-9	2022	Nicotine partially prevented the IL1beta-induced expression and production of IL6, MMP3, and RANKL in WT osteoblasts.	Nicotine	0-8	interleukin 6	Mus musculus	78-81
35479080-10	2022	The effect for IL6 and MMP was mediated by alpha7nAchR since nicotine had no effect on Chrna7-/- osteoblasts while the RANKL decrease persisted.	Nicotine	61-69	interleukin 6	Mus musculus	15-18
35393391-6	2022	Oral administration of nanocarrier-packaged carnosic acid (CA) reduced the aberrant activation of microglia and astrocytes and diminished mature IL-1beta, TNFalpha and IL-6 production in the APP/PS1 mouse brain.	salvin	44-57	interleukin 6	Mus musculus	168-172
35464414-4	2022	Also, silica-exposed macrophages generated higher levels of ROS, together with the upregulated expression of NLRP3, ASC, Caspase-1, GSDMD, IL-1beta, and IL-6.	Silicon Dioxide	6-12	interleukin 6	Mus musculus	153-157
35453404-12	2022	Our results showed that 15d-PGJ2-induced HO-1 could mitigate the lipopolysaccharide-triggered interleukin-6 expression and secretion, as measured by an ELISA assay kit.	15-deoxy-delta(12,14)-prostaglandin J2	24-32	interleukin 6	Mus musculus	94-107
35453404-0	2022	Induction of Heme Oxygenase-1 by 15d-Prostaglandin J2 Mediated via a ROS-Dependent Sp1 and AP-1 Cascade Suppresses Lipopolysaccharide-Triggered Interleukin-6 Expression in Mouse Brain Microvascular Endothelial Cells.	15-deoxyprostaglandin J2	33-53	interleukin 6	Mus musculus	144-157
35462928-17	2022	Cobalt chloride (CoCl2) increased the protein expression of IL-6 and p-STAT3 in AML12 cells.	cobaltous chloride	0-15	interleukin 6	Mus musculus	60-64
35462928-17	2022	Cobalt chloride (CoCl2) increased the protein expression of IL-6 and p-STAT3 in AML12 cells.	cobaltous chloride	17-22	interleukin 6	Mus musculus	60-64
35332348-10	2022	HES also reduced the CP-induced release of the inflammatory factors tumour necrosis factor (TNF)-alpha and interleukin (IL)-6.	Hesperidin	0-3	interleukin 6	Mus musculus	107-125
35409384-5	2022	With bone marrow-derived macrophages, BG induced only TNF-alpha (most prominent with Pachyman), while LPS with BG additively increased several cytokines (TNF-alpha, IL-6, and IL-10); inflammatory genes (iNOS, IL-1beta, Syk, and NF-kappaB); and cell energy alterations (extracellular flux analysis).	O(6)-benzylguanine	111-113	interleukin 6	Mus musculus	165-169
35418806-10	2022	Results: The results showed that Pomiferin inhibited the production of ROS, NO, and proinflammatory mediators (IL-6, TNF-alpha, iNOS, and COX2) in BV2 cells.	pomiferin	33-42	interleukin 6	Mus musculus	111-115
35409364-6	2022	An exposure of cells to CoCl2 caused an increase in inflammatory mediator interleukin (IL)-6, inducible nitric oxide synthase (iNOS), and cyclooxygenase (COX)-2 expression, which were significantly ameliorated by EGCG via inhibition of NF-kappaB pathway.	cobaltous chloride	24-29	interleukin 6	Mus musculus	74-92
35409364-8	2022	Furthermore, the suppression of hypoxia-induced IL-6 production by EGCG was mediated via the inhibition of HIF-1alpha expression and the suppression of ROS generation in BV2 cells.	epigallocatechin gallate	67-71	interleukin 6	Mus musculus	48-52
35409364-8	2022	Furthermore, the suppression of hypoxia-induced IL-6 production by EGCG was mediated via the inhibition of HIF-1alpha expression and the suppression of ROS generation in BV2 cells.	ros	152-155	interleukin 6	Mus musculus	48-52
35453592-11	2022	Likewise, the renal concentrations of proinflammatory cytokines, tumor necrosis factor alpha, interleukin (IL)-6 and IL-1beta that were elevated in CP group were significantly reduced in mice treated with BIS and CP.	1,1,5,5-tetrafluorophosphopentylphosphonic acid adenylate ester	205-208	interleukin 6	Mus musculus	94-112
35202579-3	2022	The in vitro studies revealed that gelsevirine treatment mitigated IL-1beta-induced inflammatory response and degeneration in cultured chondrocytes, evidenced by reduced apoptosis and expression of MMP3, MMP9, MMP13, IFNbeta, TNFalpha, and Il6, and increased expression of Col2A and Il10.	Gelsevirine	35-46	interleukin 6	Mus musculus	240-243
35085799-6	2022	Conversely, culturing of pro-inflammatory activated primary murine macrophages in HA-GA gels resulted in a significant reduction of pro-inflammatory TNF-alpha, IL-1beta, SOCS3 and IL-6 marker expression, and upregulated expression of anti-inflammatory cytokines including TGF-beta.	Gallium	85-87	interleukin 6	Mus musculus	180-184
35189442-0	2022	Design, molecular Docking, synthesis and evaluation of xanthoxylin hybrids as dual inhibitors of IL-6 and acetylcholinesterase for Alzheimer"s disease.	xanthoxyline	55-66	interleukin 6	Mus musculus	97-101
35443853-5	2022	In vitro, PYY 3-36 remarkably inhibited the production of proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) from lipopolysaccharide (LPS)-induced macrophages.	peptide YY (3-36)	10-18	interleukin 6	Mus musculus	128-141
35443853-5	2022	In vitro, PYY 3-36 remarkably inhibited the production of proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) from lipopolysaccharide (LPS)-induced macrophages.	peptide YY (3-36)	10-18	interleukin 6	Mus musculus	143-147
35183993-8	2022	In aGVHD mice, C0127 enhanced the preventive effects of CSA including decreasing mortality, maintaining weight, reducing GVHD score and reducing the expression of IL-6 and TNF-alpha in serum.	c0127	15-20	interleukin 6	Mus musculus	163-167
35189442-4	2022	Literature review reveals that xanthoxylin and a disubstituted or a carbamoyl amine are pharmacophore for IL-6 and AChE inhibition, respectively.	xanthoxyline	31-42	interleukin 6	Mus musculus	106-110
35183993-8	2022	In aGVHD mice, C0127 enhanced the preventive effects of CSA including decreasing mortality, maintaining weight, reducing GVHD score and reducing the expression of IL-6 and TNF-alpha in serum.	Cyclosporine	56-59	interleukin 6	Mus musculus	163-167
35189442-4	2022	Literature review reveals that xanthoxylin and a disubstituted or a carbamoyl amine are pharmacophore for IL-6 and AChE inhibition, respectively.	carbamoyl amine	68-83	interleukin 6	Mus musculus	106-110
35189442-9	2022	Compound Y13g is found to be the most potent inhibitor of EeAChE, BuChE and IL-6.	Y13g	9-13	interleukin 6	Mus musculus	76-80
35202908-4	2022	BN82002 (50 muM) suppressed the mRNA levels of cyclooxygenase (COX)-2, inducible nitric oxide synthase (iNOS), tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 in LPS-treated peritoneal macrophages without cytotoxicity.	BN82002	0-7	interleukin 6	Mus musculus	174-178
35217279-7	2022	RESULTS: The results showed that SYQ treatment obviously attenuated LPS-induced intestinal injury and reduced the production of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), and interleukin 6 (IL-6).	(S)-N-(1-cyclopropylethyl)-6-methylpicolinamide	33-36	interleukin 6	Mus musculus	203-216
35217279-7	2022	RESULTS: The results showed that SYQ treatment obviously attenuated LPS-induced intestinal injury and reduced the production of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), and interleukin 6 (IL-6).	(S)-N-(1-cyclopropylethyl)-6-methylpicolinamide	33-36	interleukin 6	Mus musculus	218-222
35202908-9	2022	Gene expression levels of IL-1beta and IL-6 were decreased in lung, kidney, and liver in the BN82002 (20 mg/kg) group.	BN82002	93-100	interleukin 6	Mus musculus	39-43
35263019-7	2022	SCU prevented alcohol stimulation triggered inflammatory response in colon tissues through significantly downregulating the iNOS activity, transcript levels of Tnf-alpha, Il-1beta and Il-6, and phosphorylation levels of NF-kappaB p65.	Alcohols	14-21	interleukin 6	Mus musculus	184-188
35217377-5	2022	Among them, ganoresinoid A showed notably restrained nitric oxide (NO), IL-1beta, IL-6 and TNF-alpha levels in LPS-activated BV-2 microglial cells via suppressing TLR-4/ NF-kappaB and MAPK signaling pathway.	ganoresinoid a	12-26	interleukin 6	Mus musculus	82-86
35202987-5	2022	We showed that the treatment with 300 microg/mL of LAEPAL induces a significant decrease in the CD4 and CD8 T effector lymphocytes proliferation from diabetic but not in non-diabetic mice, followed by a reduction of the IL-6 and IFN-gamma cytokines release in the cell cultures supernatants.	laepal	51-57	interleukin 6	Mus musculus	220-224
35120712-11	2022	Plasma pro-inflammatory cytokines, such as interleukin-6 and CC chemokine ligand (CCL)2, CCL3, and CCL5, were reduced by midazolam, whereas these cytokines increased with PK11195.	Midazolam	121-130	interleukin 6	Mus musculus	43-56
35176423-9	2022	SB was significantly reduced the inflammation in LPS-induced RAW cells via IL-6 and TNF-alpha cytokines at 200 mug/mL (P < 0.001) and paw edema via COX-2 and iNOS (P < 0.001).	Antimony	0-2	interleukin 6	Mus musculus	75-79
34997497-5	2022	The results indicated that PQQ decreased the serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and the malondialdehyde (MDA), interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha (TNF-alpha) levels in the liver tissues.	PQQ Cofactor	27-30	interleukin 6	Mus musculus	172-176
35176423-10	2022	3-O-methyl kaempferol, isolated from SB, reduced the production of NO, IL-6 and TNF-alpha in LPS-stimulated macrophages at 50 muM (P < 0.001); it significantly diminished inflammation-induced edema and COX-2, iNOS, and NF-kappaB protein levels were reduced compared to control group (P < 0.001).	3-o-methyl kaempferol	0-21	interleukin 6	Mus musculus	71-75
35176423-10	2022	3-O-methyl kaempferol, isolated from SB, reduced the production of NO, IL-6 and TNF-alpha in LPS-stimulated macrophages at 50 muM (P < 0.001); it significantly diminished inflammation-induced edema and COX-2, iNOS, and NF-kappaB protein levels were reduced compared to control group (P < 0.001).	Antimony	37-39	interleukin 6	Mus musculus	71-75
35217120-5	2022	Proanthocyanidins 15 and 16 significantly attenuated the LPS-induced inflammatory response of COX-2, iNOS, IL-1beta, IL-6, TNF-alpha in RAW 264.7 cells.	Proanthocyanidins	0-17	interleukin 6	Mus musculus	117-121
35094257-0	2022	RI75, a curcumin analogue, inhibits tumor necrosis factor-alpha and interleukin-6 production and exhibits antiallodynic and antiedematogenic activities in mice.	ri75	0-4	interleukin 6	Mus musculus	68-81
35094257-14	2022	also reduced tumor necrosis factor-alpha and interleukin-6 production and myeloperoxidase activity induced by carrageenan.	Carrageenan	110-121	interleukin 6	Mus musculus	45-58
35121224-12	2022	RESULTS: CIH treatment increased the expression of pro-inflammatory factors (TNF-alpha and IL-6), resulting in lung tissue structure disorder, inflammatory cell infiltration, increased pulmonary capillary permeability, and pulmonary edema.	cih	9-12	interleukin 6	Mus musculus	91-95
35235107-4	2022	In cultured macrophages, LXA4 inhibited LPS-induced inflammatory polarization, thereby decreasing the release of proinflammatory cell factors (IL-1beta, IL-6, TNF-alpha) and increasing the release of anti-inflammatory cytokines (IL-4 and IL-10).	lipoxin A4	25-29	interleukin 6	Mus musculus	153-157
35191221-7	2022	RESULTS: Mice exposed to enhanced levels of IL-6 during endurance exercise bouts showed superior improvements in endurance performance (33% more work and 12% greater peak power compared with baseline), fatigue resistance in situ (P = 0.0014 vs. Sed+Saline; P = 0.0199 vs. Sed+IL-6; and P = 0.0342 vs. Ex+Saline), motor coordination (rotarod performance, P = 0.0428), and gait (gait speed, P = 0.0053) following training.	Sodium Chloride	249-255	interleukin 6	Mus musculus	44-48
35365162-8	2022	RESULTS: We found that kirenol inhibited IL-1beta-induced expression of NO, PGE2, TNF-alpha, IL-6, COX-2, iNOS, ADAMTS-5.	kirenol	23-30	interleukin 6	Mus musculus	93-97
35392531-11	2022	CONCLUSIONS: Our results indicated that UA improves the IS-induced impairment of mitochondrial biogenesis by affecting differentiation, ATP levels, and IL-6 secretion in C2C12 cells.	ursolic acid	40-42	interleukin 6	Mus musculus	152-156
35392531-11	2022	CONCLUSIONS: Our results indicated that UA improves the IS-induced impairment of mitochondrial biogenesis by affecting differentiation, ATP levels, and IL-6 secretion in C2C12 cells.	Indican	56-58	interleukin 6	Mus musculus	152-156
35212163-3	2022	We initially found that the glycolytic inhibitor 2-deoxy-d-glucose (2-DG), a simple monosaccharide, attenuated cellular responses to IL-6 by inhibiting N-linked glycosylation of the IL-6 receptor gp130.	Glucose	59-66	interleukin 6	Mus musculus	133-137
35212163-3	2022	We initially found that the glycolytic inhibitor 2-deoxy-d-glucose (2-DG), a simple monosaccharide, attenuated cellular responses to IL-6 by inhibiting N-linked glycosylation of the IL-6 receptor gp130.	Deoxyglucose	68-72	interleukin 6	Mus musculus	133-137
35212163-3	2022	We initially found that the glycolytic inhibitor 2-deoxy-d-glucose (2-DG), a simple monosaccharide, attenuated cellular responses to IL-6 by inhibiting N-linked glycosylation of the IL-6 receptor gp130.	Monosaccharides	84-98	interleukin 6	Mus musculus	133-137
35212163-3	2022	We initially found that the glycolytic inhibitor 2-deoxy-d-glucose (2-DG), a simple monosaccharide, attenuated cellular responses to IL-6 by inhibiting N-linked glycosylation of the IL-6 receptor gp130.	Nitrogen	152-153	interleukin 6	Mus musculus	133-137
35259481-8	2022	In in vivo and in vitro culture experiments, the mRNA expression of Nos2, Tnf-alpha, Il-6, and Il-1beta increased under TMAO stimulation.	trimethyloxamine	120-124	interleukin 6	Mus musculus	85-89
34990773-6	2022	The results showed that nano-TiO2 increased the secretions of pro-inflammatory cytokines (IL-1alpha, IL-6, and TNF-alpha) and decreased the expressions of TGF-beta1 and SMAD1/2/3 proteins in BV2 cells.	titanium dioxide	29-33	interleukin 6	Mus musculus	101-105
35366203-5	2022	MPTP administration also showed significant imbalance of inflammatory (increased TNF-alpha, IL-6 and NF-kappab) versus anti-inflammatory cytokines (decreased IL-10 levels).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	interleukin 6	Mus musculus	92-96
35431807-4	2022	The lipopolysaccharide (LPS)-induced release of interleukin (IL)-6 by primary murine macrophages was inhibited by pCF3-diEPP, while phosphocholine was ineffective presumably because of instability.	pcf3-diepp	114-124	interleukin 6	Mus musculus	48-66
35063480-4	2022	Treatment with CDs (except GlcNL) increased IL-10 level, reduced levels of IL-1beta, IL-6, TNF-alpha, myeloperoxidase, and inducible nitric oxide synthase, and enhanced expression of tight junction proteins significantly.	cds	15-18	interleukin 6	Mus musculus	85-89
35202709-0	2022	Protocatechuic acid protects against thioacetamide-induced chronic liver injury and encephalopathy in mice via modulating mTOR, p53 and the IL-6/ IL-17/ IL-23 immunoinflammatory pathway.	protocatechuic acid	0-19	interleukin 6	Mus musculus	140-144
35202709-0	2022	Protocatechuic acid protects against thioacetamide-induced chronic liver injury and encephalopathy in mice via modulating mTOR, p53 and the IL-6/ IL-17/ IL-23 immunoinflammatory pathway.	Thioacetamide	37-50	interleukin 6	Mus musculus	140-144
35063480-4	2022	Treatment with CDs (except GlcNL) increased IL-10 level, reduced levels of IL-1beta, IL-6, TNF-alpha, myeloperoxidase, and inducible nitric oxide synthase, and enhanced expression of tight junction proteins significantly.	glcnl	27-32	interleukin 6	Mus musculus	85-89
35453334-5	2022	MH extract inhibited the production of proinflammatory enzymes and mediators nitric oxide (NO), NO synthase, cyclooxygenase-2, tumor necrosis factor-alpha, and interleukin-6 in LPS-stimulated cells.	mh extract	0-10	interleukin 6	Mus musculus	160-173
35349119-4	2022	We show here that DMF suppresses LPS-induced TNFalpha secretion from RAW 264.7 cells and IL-6 and IL-8 secretion from HTR-8 cells at concentrations that do not significantly affect cell viability.	Dimethylformamide	18-21	interleukin 6	Mus musculus	89-93
35001008-0	2022	Latilactobacillus curvatus BYB3 Isolated from Kimchi Alleviates Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice by Inhibiting IL-6 and TNF-R1 Production.	Dextran Sulfate	64-86	interleukin 6	Mus musculus	131-135
35346284-12	2022	Anemonin inhibited DSS-induced colon tissue inflammation as the release of IL-1beta, TNF-alpha, and IL-6 was significantly suppressed.	anemonin	0-8	interleukin 6	Mus musculus	100-104
35346284-12	2022	Anemonin inhibited DSS-induced colon tissue inflammation as the release of IL-1beta, TNF-alpha, and IL-6 was significantly suppressed.	dss	19-22	interleukin 6	Mus musculus	100-104
35001008-0	2022	Latilactobacillus curvatus BYB3 Isolated from Kimchi Alleviates Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice by Inhibiting IL-6 and TNF-R1 Production.	Dextran Sulfate	88-91	interleukin 6	Mus musculus	131-135
35001008-6	2022	In addition, significantly lower levels of IL-6 and tumor necrosis factor receptor 1 upregulation were seen in the DSS+BYB3 group (compared to that in the DSS group).	Dextran Sulfate	115-118	interleukin 6	Mus musculus	43-47
35001008-6	2022	In addition, significantly lower levels of IL-6 and tumor necrosis factor receptor 1 upregulation were seen in the DSS+BYB3 group (compared to that in the DSS group).	Dextran Sulfate	155-158	interleukin 6	Mus musculus	43-47
35399505-5	2022	We subsequently describe that CD11b+ macrophages served as the mainly cellular source of reactive oxygen species (ROS) production via vimentin-ROS-pSTAT3-interleukin-6 inflammatory pathways.	Reactive Oxygen Species	89-112	interleukin 6	Mus musculus	154-167
35399505-5	2022	We subsequently describe that CD11b+ macrophages served as the mainly cellular source of reactive oxygen species (ROS) production via vimentin-ROS-pSTAT3-interleukin-6 inflammatory pathways.	Reactive Oxygen Species	114-117	interleukin 6	Mus musculus	154-167
35399505-5	2022	We subsequently describe that CD11b+ macrophages served as the mainly cellular source of reactive oxygen species (ROS) production via vimentin-ROS-pSTAT3-interleukin-6 inflammatory pathways.	Reactive Oxygen Species	143-146	interleukin 6	Mus musculus	154-167
35337221-3	2022	Furthermore, an in vivo study revealed that WESCL could alleviate the disease development of osteoarthritis (OA) and decrease the level of interleukin-6 (IL-6) in mice.	wescl	44-49	interleukin 6	Mus musculus	139-152
35337221-3	2022	Furthermore, an in vivo study revealed that WESCL could alleviate the disease development of osteoarthritis (OA) and decrease the level of interleukin-6 (IL-6) in mice.	wescl	44-49	interleukin 6	Mus musculus	154-158
35408922-4	2022	In accordance with these results, agmatine suppresses inflammatory NF-kB, and stimulates antioxidant Nrf2 pathway, resulting in decreased TNF, IL-1 beta, and IL-6 release, and reduced iNOS and COX-2 levels.	Agmatine	34-42	interleukin 6	Mus musculus	158-162
35401244-5	2022	Our results illustrated that Iso treatment significantly reduced leukocyte recruitment and excessive secretion of interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and regulated upon activation, normal T-cell expressed and secreted (RANTES) in BALF of CS-induced COPD mice in a dose-dependent manner.	3-methylquercetin	29-32	interleukin 6	Mus musculus	114-127
35401244-5	2022	Our results illustrated that Iso treatment significantly reduced leukocyte recruitment and excessive secretion of interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and regulated upon activation, normal T-cell expressed and secreted (RANTES) in BALF of CS-induced COPD mice in a dose-dependent manner.	3-methylquercetin	29-32	interleukin 6	Mus musculus	129-133
35408882-7	2022	Combined IL-6/TNF inhibition, but not individual blockade of these two cytokines, led to complex anti-inflammatory effects including reduced Th2-induced eosinophilia and less prominent Th17/Th1-mediated neutrophilic infiltrate in the airways.	th2	141-144	interleukin 6	Mus musculus	9-13
35405962-5	2022	In addition, RSO supplementation showed an anti-inflammatory effect by reducing the production of NO, IL-1beta, IL-6, and TNF-alpha while promoting the production of IL-10.	rubber seed oil	13-16	interleukin 6	Mus musculus	112-116
35405969-2	2022	In LPS-stimulated RAW264.7 cells, a 100 microg/mL dose of SCLE significantly reduced the production of nitric oxide (NO), interleukin-1beta (IL-1beta), tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and prostaglandin E2 (PGE2).	scle	58-62	interleukin 6	Mus musculus	194-207
35405969-2	2022	In LPS-stimulated RAW264.7 cells, a 100 microg/mL dose of SCLE significantly reduced the production of nitric oxide (NO), interleukin-1beta (IL-1beta), tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and prostaglandin E2 (PGE2).	scle	58-62	interleukin 6	Mus musculus	209-213
35372817-5	2022	In a dextran sulfate sodium-induced acute colitis murine model, LUT@TPGS-PBTE NPs alleviated body weight loss, colon length shortening, and damage to the colonic tissues due to the suppression of ROS and proinflammatory cytokines (e.g., IL-17A, IL-6, interferon-gamma, tumor necrosis factor-alpha), as well as upregulation of glutathione and anti-inflammatory factors (e.g., IL-10, IL-4).	Glutathione	326-337	interleukin 6	Mus musculus	245-249
35391841-10	2022	Mechanically, an increased level of tumor necrosis factor alpha (TNFalpha), interleukin (IL)-1beta, IL-6, and MCP-1 were found in MI/R hearts, and Rg2 treatment significantly inhibit the expression of these factors.	rg2	147-150	interleukin 6	Mus musculus	100-104
35372817-5	2022	In a dextran sulfate sodium-induced acute colitis murine model, LUT@TPGS-PBTE NPs alleviated body weight loss, colon length shortening, and damage to the colonic tissues due to the suppression of ROS and proinflammatory cytokines (e.g., IL-17A, IL-6, interferon-gamma, tumor necrosis factor-alpha), as well as upregulation of glutathione and anti-inflammatory factors (e.g., IL-10, IL-4).	Dextran Sulfate	5-27	interleukin 6	Mus musculus	245-249
35355866-6	2022	Moreover, GSPE attenuated lung inflammation by reducing the total number of cells in bronchoalveolar lavage (BAL) fluid and decreasing the expression of IL-6.	gspe	10-14	interleukin 6	Mus musculus	153-157
35371065-9	2022	Analysis of the macrophage phenotypes in the epicentre of the SCI in mice showed that PBM mainly inhibited the neurotoxic activation of macrophages in the SCI area and reduced the secretion of inflammatory factors such as IL-1alpha and IL-6; PBM had no effect on M2 macrophages.	pbm	86-89	interleukin 6	Mus musculus	236-240
35147423-0	2022	P38 MAPK, NF-kappaB, and JAK-STAT3 Signaling Pathways Involved in Capecitabine-Induced Hand-Foot Syndrome via Interleukin 6 or Interleukin 8 Abnormal Expression.	Capecitabine	66-78	interleukin 6	Mus musculus	110-123
35147423-9	2022	Finally, the P38 MAPK, NF-kappaB, and JAK-STAT3 signaling pathways, which mediate high levels of expression of IL6 or IL8, were identified as potential pathways underlying CAP-induced HFS.	Capecitabine	172-175	interleukin 6	Mus musculus	111-114
35341154-10	2022	Despite an additive effect against NO, KM plus AZM at an equal dose could synergistically suppress overrelease of the inflammatory cytokines TNF-alpha and IL-6 by LPS-induced RAW 264.7 cells.	Azithromycin	47-50	interleukin 6	Mus musculus	155-159
35059715-5	2022	In addition, Liriodendrin can reduce the levels of pro-inflammatory cytokines (IL-6 and TNF-alpha), and it is suggested through flow cytometry that the proportion of neutrophils in the intestinal tissue can decrease due to the existence of Liriodendrin.	liriodendrin	13-25	interleukin 6	Mus musculus	79-83
35290462-6	2022	Cells were treated with irisin (100 ng/ml) for various time lengths ranging from 0 to 72 hours, and then qRT-PCR was used to detect the expression of osteoclastogenesis-related genes, including RANKL, IL-6, M-CSF, OPG, Wnt5A, Sema3A.	irisin	24-30	interleukin 6	Mus musculus	201-205
35189519-6	2022	Two inflammatory signalling pathways, i.e., TLR2/MyD88/NF-kappaB and IL-6/STAT-3, were activated, along with inflammatory cell infiltration and the elevated mRNA expression of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IFN-gamma) and myeloperoxidase (MPO) in the gastric tissue of mice exposed to arsenic.	Arsenic	306-313	interleukin 6	Mus musculus	69-73
35189519-9	2022	The arsenic-mediated gene expression of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IFN-gamma), MPO and IL-6/STAT3 and TLR2/MyD88/NF-kappaB pathways was found down-regulated.	Arsenic	4-11	interleukin 6	Mus musculus	112-116
35290462-11	2022	The expression of RANKL and IL-6 was significantly enhanced by irisin, suggesting a possible promotive effect on cementoblast-mediated osteoclastogenesis.	irisin	63-69	interleukin 6	Mus musculus	28-32
35359858-8	2022	The results showed that pre-administration with a single dose of RoMS could inhibit the increase of serum transaminase induced by LPS, alleviate the pathological damage of liver tissue, and decrease the levels of tumor necrosis factor-alpha and interleukin-6.	roms	65-69	interleukin 6	Mus musculus	245-258
35370749-7	2022	In LPS-induced ALI mice, FOL administration showed inhibition of IL-1beta, IL-6, and TNF-alpha in Bronchoalveolar lavage fluid (BALF) and decreased protein expression levels of PI3K, AKT, NF-kappaB p50, and NF-kappaB p65, and elevated protein expression levels of Bax and cleaved-caspase-3 significantly.	Folic Acid	25-28	interleukin 6	Mus musculus	75-79
35328530-5	2022	We demonstrate that a pretreatment of these cells with A5+ causes significant reduction of inflammation, resulting in a decrease in pro-inflammatory cytokines (IFN-gamma, IL-6, TNF-alpha, and CXCL1), a reduction in ROS production and activation of extracellular signal-regulated kinases (ERK)1/2, and a decrease in apoptotic mechanisms with the related increase in cell viability.	a5+	55-58	interleukin 6	Mus musculus	171-175
35274377-9	2022	Aged mouse skin treated with ABT-263 or ABT-737 showed increased collagen density, epidermal thickness, and proliferation of keratinocytes, as well as decreased senescence-associated secretory phenotypes, such as MMP-1 and IL-6.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	29-32	interleukin 6	Mus musculus	223-227
35274377-9	2022	Aged mouse skin treated with ABT-263 or ABT-737 showed increased collagen density, epidermal thickness, and proliferation of keratinocytes, as well as decreased senescence-associated secretory phenotypes, such as MMP-1 and IL-6.	ABT-737	40-47	interleukin 6	Mus musculus	223-227
35370629-9	2022	KCF18 could effectively decrease the p65 nucleus translocation induced by cytokines, and a mice endotoxemia experiment demonstrated that KCF18 could reduce the expression of IL-6 and the increase of white blood cells in the blood stimulated by lipopolysaccharides.	kcf18	137-142	interleukin 6	Mus musculus	174-178
35287352-11	2022	Molecular docking results suggest that EGCG has a high affinity for the crystal structure of six targets (IL-6 (interleukin-6), TNF (tumor necrosis factor), Caspase3, MAPK3 (Mitogen-activated protein kinase 3), AKT1, and VEGFA (vascular endothelial growth factor)), and the experimental verification result showed levated expression of these 6 hub targets in the LPS group, but there is an obvious decrease in expression in the LPS + EGCG group.	epigallocatechin gallate	39-43	interleukin 6	Mus musculus	106-110
35287352-15	2022	The anti-inflammatory and anti-apoptotic effects of EGCG occur not only through direct binding to six target proteins (IL-6,TNF-alpha, Caspase3, MAPK3, AKT1, and VEGFA) but also by reducing their expression.	epigallocatechin gallate	52-56	interleukin 6	Mus musculus	119-123
35287352-11	2022	Molecular docking results suggest that EGCG has a high affinity for the crystal structure of six targets (IL-6 (interleukin-6), TNF (tumor necrosis factor), Caspase3, MAPK3 (Mitogen-activated protein kinase 3), AKT1, and VEGFA (vascular endothelial growth factor)), and the experimental verification result showed levated expression of these 6 hub targets in the LPS group, but there is an obvious decrease in expression in the LPS + EGCG group.	epigallocatechin gallate	39-43	interleukin 6	Mus musculus	112-125
35371322-6	2022	Furthermore, TA treatment suppressed the levels of carbohydrate antigen 125, interleukin-6, and tumor necrosis factor-alpha in the plasma.	Tranexamic Acid	13-15	interleukin 6	Mus musculus	77-90
35323499-7	2022	Our findings indicate that the agonist PNU282987 significantly reduced the expression of the IL-6 gene and protein in inflammatory macrophages to attenuate the inflammatory response, but the antagonists MLA and alpha-conotoxin (A10L)PnIA had the opposite effects.	PNU-282987	39-48	interleukin 6	Mus musculus	93-97
35166735-4	2022	FMPH reduced the serum LPS level, increased intestinal ZO-1 and occludin expression, inhibited NF-kappaB phosphorylation, and reduced the levels of TNF-alpha and IL-6.	fmph	0-4	interleukin 6	Mus musculus	162-166
35167638-6	2022	Pb(Ac)2 exposure significantly increased cellular oxidative damage and the levels of pro-inflammatory cytokines (interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha (TNF-alpha), ionized calcium binding adaptor molecule 1 (Iba1) and pro-apoptotic proteins (caspase 3, caspase 9 and Bax), while downregulating the expression of Bcl-2 in the brain.	pb(ac)2	0-7	interleukin 6	Mus musculus	137-141
35414769-0	2022	Disruption of peroxisome proliferator-activated receptor alpha in hepatocytes protects against acetaminophen-induced liver injury by activating the IL-6/STAT3 pathway.	Acetaminophen	95-108	interleukin 6	Mus musculus	148-152
35414769-10	2022	Mechanistically, hepatocyte-specific Ppara knockout mice had upregulated activation of the hepatoprotective pathway IL-6/STAT3 compared to wild-type mice, as evidenced by hepatic Il6 mRNA levels, hepatic protein levels of STAT3 and phosphorylated STAT3 were much higher in hepatocyte-specific Ppara knockout mice than in wild-type mice post acetaminophen injection.	Acetaminophen	341-354	interleukin 6	Mus musculus	116-120
35414769-11	2022	Conclusions: Hepatocyte-specific disruption of the Ppara gene protects against acetaminophen-induced liver injury by reducing oxidative stress and upregulating the hepatoprotective IL-6/STAT3 signaling pathway.	Acetaminophen	79-92	interleukin 6	Mus musculus	181-185
35085518-5	2022	Herein, an in vitro study revealed that 20 muM of Sch B-treated bone-marrow-derived DCs exhibited a semi-mature phenotype that secreted low amounts of proinflammatory cytokines including interleukin (IL)-12, IL-1beta, IL-6, and tumor necrosis factor (TNF)-alpha, and expressed decreased levels of surface molecules of cluster of differentiation 80 (CD80) and CD86.	schizandrin B	50-55	interleukin 6	Mus musculus	218-222
35093323-11	2022	Treatment with loureirin B inhibited the elevation of inflammatory factors (interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha), transforming growth factor-beta1 (TGF-beta1), and Pin1 induced by TAC.	loureirin B	15-26	interleukin 6	Mus musculus	95-108
35279615-9	2022	RESULTS: Loganin and morroniside relieved the pathological symptom of lung tissue in acute lung injury, pro-inflammatory factors such as IL-6, IL-1beta, TNF-alpha mRNA were inhibited.	loganin	9-16	interleukin 6	Mus musculus	137-141
35279615-9	2022	RESULTS: Loganin and morroniside relieved the pathological symptom of lung tissue in acute lung injury, pro-inflammatory factors such as IL-6, IL-1beta, TNF-alpha mRNA were inhibited.	morroniside	21-32	interleukin 6	Mus musculus	137-141
35268775-6	2022	Furthermore, RPP-2a exhibited significant macrophage activation activity by increasing the production of nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1beta (IL-1beta), and the expression of inducible nitric oxide synthase (iNOS) and cytokines at the transcriptional level in RAW264.7 cells.	rpp-2a	13-19	interleukin 6	Mus musculus	165-178
35308280-4	2022	LP-KFY05 could also reduce tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1beta) levels in sera and renal tissues of thrombotic mice.	lp-kfy05	0-8	interleukin 6	Mus musculus	68-81
35308280-4	2022	LP-KFY05 could also reduce tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1beta) levels in sera and renal tissues of thrombotic mice.	lp-kfy05	0-8	interleukin 6	Mus musculus	83-87
35268775-6	2022	Furthermore, RPP-2a exhibited significant macrophage activation activity by increasing the production of nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1beta (IL-1beta), and the expression of inducible nitric oxide synthase (iNOS) and cytokines at the transcriptional level in RAW264.7 cells.	rpp-2a	13-19	interleukin 6	Mus musculus	180-184
35153246-3	2022	We used ELISA to detect the effect of swertiamarin on the expression of inflammation related indicators such as IL-1beta, il-6, IL-18 and TNF-alpha.	swertiamarin	38-50	interleukin 6	Mus musculus	122-126
35310096-3	2022	Using a mouse model of SD, we found that modafinil improved learning and memory, reduced proinflammatory factor (IL-1beta, TNF-alpha, and IL-6) production, and increased the expression of anti-inflammatory factors (IL-10).	Modafinil	41-50	interleukin 6	Mus musculus	138-142
35434019-8	2022	The IL-6 levels of the Glycerol + HE group were also higher than those of the Saline + HE groups at 6 and 12 h (P<0.05).	Glycerol	23-31	interleukin 6	Mus musculus	4-8
35084215-9	2022	Supplementation of CNM normalized diabetes-induced altered gastric antrum protein expression of (1) p-AKT/p-p38MAPK/p-GSK-3beta, (2) BH4 (cofactor of nNOS) biosynthesis enzyme GCH-1, (3) nNOSalpha (4) TLR4, NFkappaB, and (5) inflammatory cytokines (TNF alpha, IL-1beta, IL-6).	sapropterin	133-136	interleukin 6	Mus musculus	270-274
35007167-4	2022	BoxA treatment significantly ameliorated AR symptoms, decreased level of histamine, OVA-specific antibodies, suppressed the infiltration of immune cells in nasal tissues, inhibited the expression of IL-4, IL-6, IL-5, TNF-alpha, IL-13, IL-17, IL-2 while promoting the expression of IL-10, suppressed the expression of HMGB1, TLR2, and TLR4 in AR mice.	boxa	0-4	interleukin 6	Mus musculus	205-209
35245993-5	2022	We found that the increased diffusion of sodium fluorescein and Evan"s blue, declined expression of Claudin-5, and increased production of interleukin- 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were observed in Hcy-treated mice, which were all significantly reversed by butorphanol tartrate.	Homocysteine	222-225	interleukin 6	Mus musculus	139-153
35245993-5	2022	We found that the increased diffusion of sodium fluorescein and Evan"s blue, declined expression of Claudin-5, and increased production of interleukin- 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were observed in Hcy-treated mice, which were all significantly reversed by butorphanol tartrate.	Homocysteine	222-225	interleukin 6	Mus musculus	155-159
35245993-5	2022	We found that the increased diffusion of sodium fluorescein and Evan"s blue, declined expression of Claudin-5, and increased production of interleukin- 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were observed in Hcy-treated mice, which were all significantly reversed by butorphanol tartrate.	Butorphanol	281-301	interleukin 6	Mus musculus	139-153
35245993-5	2022	We found that the increased diffusion of sodium fluorescein and Evan"s blue, declined expression of Claudin-5, and increased production of interleukin- 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were observed in Hcy-treated mice, which were all significantly reversed by butorphanol tartrate.	Butorphanol	281-301	interleukin 6	Mus musculus	155-159
35434019-8	2022	The IL-6 levels of the Glycerol + HE group were also higher than those of the Saline + HE groups at 6 and 12 h (P<0.05).	Helium	34-36	interleukin 6	Mus musculus	4-8
35086063-5	2022	The anti-inflammatory mechanism of ABAI-30 was examined and found to be inhibiting the TLR4-pp65 and NLRP3-caspase-1 signaling pathway, thus leading to the downregulation of IL6, IL-1beta and TNFalpha at both transcriptional and translational levels.	ABAI-30	35-42	interleukin 6	Mus musculus	174-177
35098641-7	2022	Moreover, PEG upregulated the activities of CAT, GSH-Px, SOD and decreased MDA level, and suppressed the production of IL-1beta, IL-6, PGE 2 , TNF-alpha, and COX-2 in UV-irradiated mice.	Polyethylene Glycols	10-13	interleukin 6	Mus musculus	129-133
35369960-9	2022	AMPKalpha knockdown abolished the inhibitory effects of ESMW on IL-6 and HSL pSer-660, revealing that the antilipolytic and anti-inflammatory activities of ESMW are AMPK dependent.	esmw	56-60	interleukin 6	Mus musculus	64-68
35122997-7	2022	Notably, elabela strikingly alleviated Ang II-induced upregulation of iron levels and lipid peroxidation in hypertensive mice by suppressing cardiac interleukin-6 (IL-6)/STAT3 signaling and activating the xCT/glutathione peroxidase (GPX4) signaling.	Iron	70-74	interleukin 6	Mus musculus	164-168
35369960-9	2022	AMPKalpha knockdown abolished the inhibitory effects of ESMW on IL-6 and HSL pSer-660, revealing that the antilipolytic and anti-inflammatory activities of ESMW are AMPK dependent.	esmw	156-160	interleukin 6	Mus musculus	64-68
34987187-0	2022	TP0586532, a non-hydroxamate LpxC inhibitor, reduces LPS release and IL-6 production both in vitro and in vivo.	TP0586532	0-9	interleukin 6	Mus musculus	69-73
34987187-8	2022	Furthermore, the effects of TP0586532 on LPS release and interleukin (IL)-6 production in the lung were determined using a murine model of pneumonia caused by K. pneumoniae.	TP0586532	28-37	interleukin 6	Mus musculus	57-75
34987187-9	2022	As observed in the in vitro study, TP0586532 showed the marked inhibitory effect on LPS release in the lungs, whereas meropenem- and ciprofloxacin-treated mice showed higher levels of LPS release and IL-6 production in the lungs as compared to those in the lungs of vehicle-treated mice.	Meropenem	118-127	interleukin 6	Mus musculus	200-204
34987187-9	2022	As observed in the in vitro study, TP0586532 showed the marked inhibitory effect on LPS release in the lungs, whereas meropenem- and ciprofloxacin-treated mice showed higher levels of LPS release and IL-6 production in the lungs as compared to those in the lungs of vehicle-treated mice.	Ciprofloxacin	133-146	interleukin 6	Mus musculus	200-204
34987187-10	2022	Moreover, TP0586532 used in combination with meropenem and ciprofloxacin attenuated the LPS release and IL-6 production induced by meropenem and ciprofloxacin in the lung.	TP0586532	10-19	interleukin 6	Mus musculus	104-108
34987187-10	2022	Moreover, TP0586532 used in combination with meropenem and ciprofloxacin attenuated the LPS release and IL-6 production induced by meropenem and ciprofloxacin in the lung.	Meropenem	45-54	interleukin 6	Mus musculus	104-108
34987187-10	2022	Moreover, TP0586532 used in combination with meropenem and ciprofloxacin attenuated the LPS release and IL-6 production induced by meropenem and ciprofloxacin in the lung.	Ciprofloxacin	59-72	interleukin 6	Mus musculus	104-108
34987187-10	2022	Moreover, TP0586532 used in combination with meropenem and ciprofloxacin attenuated the LPS release and IL-6 production induced by meropenem and ciprofloxacin in the lung.	Meropenem	131-140	interleukin 6	Mus musculus	104-108
34987187-10	2022	Moreover, TP0586532 used in combination with meropenem and ciprofloxacin attenuated the LPS release and IL-6 production induced by meropenem and ciprofloxacin in the lung.	Ciprofloxacin	145-158	interleukin 6	Mus musculus	104-108
35140132-8	2022	G-CSF expanded pDC and CD8+ DC numbers and IL-6 production by ipDCs and CD4+ DCs, and it improved the quality of Ab response, increasing the localization of Ag-specific T cells to the GC.	ipdcs	62-67	interleukin 6	Mus musculus	43-47
35074616-0	2022	MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.	mir-197-3p	0-10	interleukin 6	Mus musculus	75-79
35059728-4	2022	The results revealed that common DEGs in AKI induced by cisplatin and IR were enriched in the inflammatory response pathway, including hub genes CSF-1, CXCL1, CXCL10, IL-1beta, IL-34, IL-6 and TLR2.	Cisplatin	56-65	interleukin 6	Mus musculus	184-188
35063609-7	2022	Moreover, administration of anti CL-11 reduced leukocytes infiltration into lung tissues and reduced the inflammatory mediators TNF-alpha, IL-6, and IL-1beta in infected mice.	cl-11	33-38	interleukin 6	Mus musculus	139-143
35030388-15	2022	Not only in-vitro but also in-vivo, POH has abridged cytokine levels IL-1beta, IL-6, and TNF-alpha.	perillyl alcohol	36-39	interleukin 6	Mus musculus	79-83
35080289-6	2022	Curcumin exhibited antiinflammatory pharmacological effects, as reflected by inhibition of inflammatory factors (e.g., interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha).	Curcumin	0-8	interleukin 6	Mus musculus	143-147
35074616-0	2022	MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.	Bortezomib	19-29	interleukin 6	Mus musculus	75-79
35074616-2	2022	METHODS: The expression of miR-197-3p, MEAF6 and IL-6 in BTZ-resistant MM cells was measured.	Bortezomib	57-60	interleukin 6	Mus musculus	49-53
35074616-8	2022	RESULTS: MiR-197-3p was lowly expressed, and MEAF6 and IL-6 were highly expressed in BTZ-resistant MM cells.	Bortezomib	85-88	interleukin 6	Mus musculus	55-59
35074616-9	2022	Overexpression of miR-197-3p increased drug sensitivity in BTZ-resistant MM cells, which was counteracted by overexpression of IL-6.	Bortezomib	59-62	interleukin 6	Mus musculus	127-131
35074616-11	2022	Mechanistically, miR-197-3p suppressed the expression of IL-6 by inhibiting MEAF6-mediated histone H3 acetylation in IL-6 promoter.	-197-3p	20-27	interleukin 6	Mus musculus	57-61
35074616-11	2022	Mechanistically, miR-197-3p suppressed the expression of IL-6 by inhibiting MEAF6-mediated histone H3 acetylation in IL-6 promoter.	-197-3p	20-27	interleukin 6	Mus musculus	117-121
35074616-13	2022	CONCLUSION: miR-197-3p reduces BTZ resistance in MM by inhibiting acetylation-mediated expression of IL-6 and by inactivating JAK/STAT3 signaling pathway.	mir-197-3p	12-22	interleukin 6	Mus musculus	101-105
35074616-13	2022	CONCLUSION: miR-197-3p reduces BTZ resistance in MM by inhibiting acetylation-mediated expression of IL-6 and by inactivating JAK/STAT3 signaling pathway.	Bortezomib	31-34	interleukin 6	Mus musculus	101-105
35066371-10	2022	Following, Andrograpanin significantly reduced the mRNA and protein level of IL-1beta, IL-6, and TNF-alpha both in vivo and in vitro.	andrograpanin	11-24	interleukin 6	Mus musculus	87-91
35138518-7	2022	The serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1-beta (IL-1beta) and interleukin-6 (IL-6) were significantly decreased by TP in HFD-fed mice.	tp	148-150	interleukin 6	Mus musculus	95-108
35138518-7	2022	The serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1-beta (IL-1beta) and interleukin-6 (IL-6) were significantly decreased by TP in HFD-fed mice.	tp	148-150	interleukin 6	Mus musculus	110-114
35498227-7	2022	Meanwhile, DN elicited a decline in the hepatic production and release of the anti-inflammatory cytokines IL-22 and IL-6, which was intensified by digoxin, especially at a dose 0.5 mg/kg.	Diethylnitrosamine	11-13	interleukin 6	Mus musculus	116-120
35498227-7	2022	Meanwhile, DN elicited a decline in the hepatic production and release of the anti-inflammatory cytokines IL-22 and IL-6, which was intensified by digoxin, especially at a dose 0.5 mg/kg.	Digoxin	147-154	interleukin 6	Mus musculus	116-120
35295707-8	2022	Moreover, the study examined the effect of quercetin on astrocytes activation and neuroinflammation, and the results indicated that it significantly attenuated the activation of astrocytes and reduced the levels of IL-1beta, TNFalpha but not IL-6.	Quercetin	43-52	interleukin 6	Mus musculus	242-246
35295759-10	2022	That effect was largely pronounced after treatment with aEVs, probably because the lung TNF-alpha, IFN-gamma, IL-6, and MCP-1 concentrations were specially increased in aEV-treated when compared with vEV-treated mice.	aevs	56-60	interleukin 6	Mus musculus	110-114
35295759-10	2022	That effect was largely pronounced after treatment with aEVs, probably because the lung TNF-alpha, IFN-gamma, IL-6, and MCP-1 concentrations were specially increased in aEV-treated when compared with vEV-treated mice.	2-(4,5-Dichloro-1h-Benzimidazol-2-Yl)-5-Methyl-4-[(1r)-3-Oxo-1,3-Dihydro-2-Benzofuran-1-Yl]-1,2-Dihydro-3h-Pyrazol-3-One	169-172	interleukin 6	Mus musculus	110-114
35088071-9	2022	Following intervention with ASTF, different therapeutic effects were shown according to the various dosages tested, all of which resulted in improved intestinal morphology and an increased number of intestinal goblet cells, while the contents of IL-1beta, IL-6, PGE2 and TNF-alpha and the related mRNA expression level were significantly reduced.	astf	28-32	interleukin 6	Mus musculus	256-260
35343159-12	2022	Compared with the model mice, XQ treatment decreased the body weight, abdominal circumference, Lee index, and visceral fat mass, lowered the levels of TG, TC, and LDL-c in se-rum, down-regulated the gene levels of ACC1, FAS, and DGAT1 in liver tissue, up-regulated the gene level of HTGL, and down-regulated the mRNA and protein levels of IL-6.	xq	30-32	interleukin 6	Mus musculus	339-343
35281058-5	2022	In lipopolysaccharide (LPS)/lipopolysaccharide + adenosine triphosphate (LPS+ATP)-stimulated macrophages, our results showed that HSC remarkably inhibited the secretion of interleukin-6 (IL-6), IL-1beta, and tumor necrosis factor-alpha (TNF-alpha).	Adenosine	49-58	interleukin 6	Mus musculus	172-185
35282365-6	2022	Exposure of human smooth muscle cells and murine NIH/3T3 fibroblasts in vitro to alphaIL-17A Affibody molecule markedly reduced IL6 and CXCL1 release in supernatants compared with sham exposure.	alphail-17a	81-92	interleukin 6	Mus musculus	128-131
35269666-7	2022	Noteworthy, BPA led to an augmented rate of metastasis to the lung associated with higher intratumoral expression of IL-1beta, IL-6, IFN-gamma, TNF-alpha, and VEGF.	bisphenol A	12-15	interleukin 6	Mus musculus	127-131
35336732-5	2022	AR281 significantly decreased the critical osteoclast activator, the ratio of the receptor activator for nuclear factor kappa B (NF-kappaB) ligand (RANKL) to osteoprotegerin, and pro-inflammatory osteoclastogenic mediators, such as IL-1, IL-6, and IL-17, which can increase the RANKL expression.	ar281	0-5	interleukin 6	Mus musculus	238-242
35250385-4	2022	At a high concentration of CCE, the LPS-induced high levels of NO, tumor necrosis factor-alpha, interleukin- (IL-) 1beta, and IL-6 were decreased via downregulation of inducible NO synthase and proinflammatory cytokine mRNA expression.	Carbamylcholine	27-30	interleukin 6	Mus musculus	126-130
35199308-8	2022	Co-treatment with PACAP or VIP prevented rotenone-induced increase of NO, CD11b, MMP-9 and IL-6.	Rotenone	41-49	interleukin 6	Mus musculus	91-95
35156814-5	2022	Notably, MP-HCQ exhibited favorable properties of less than 50 nm size, glutathione-accelerated HCQ release, and M1 phenotype macrophage (M1M) targetability, leading to repolarization of macrophages to anti-inflammatory M2 phenotype (M2M), reduced secretion of pro-inflammatory cytokines (IL-6), and upregulation of anti-inflammatory cytokines (IL-10).	mp-hcq	9-15	interleukin 6	Mus musculus	289-293
35267944-6	2022	Elevated serum levels of inflammatory markers such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 were observed in the stressed mice, while TMC3115 only reduced the IL-6 level.	tmc3115	153-160	interleukin 6	Mus musculus	178-182
35210510-10	2022	SB-505124 significantly suppressed IL-6 production by synovial explants.	2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride	0-9	interleukin 6	Mus musculus	35-39
35237058-12	2022	DKV-O further reduced OXA-stimulated induction of inflammatory lesions, neutrophil influx, and release of Interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha, and myeloperoxidase.	Oxazolone	22-25	interleukin 6	Mus musculus	130-134
35190960-5	2022	Serum content of IgG, IL-2, and IL-10 reduced in the Piroxicam group, whereas IgG, TNF-alpha, and IL-6 increased in the Piroxicam group in comparison to the other groups.	Piroxicam	120-129	interleukin 6	Mus musculus	98-102
35284456-7	2022	Additionally, GTPs abrogated dysregulation in hepatic Kelch-like ECH-associated protein 1 and nuclear factor erythroid 2-related factor 2 (Nrf2) and its downstream target gene expression (heme oxygenase 1, NAD(P)H:quinone oxidoreductase 1, and GST) and inhibited tumor necrosis factor-alpha, transforming growth factor-beta, and interleukin (IL)-1beta and IL-6 in the liver of treated mice.	gtps	14-18	interleukin 6	Mus musculus	356-360
35190960-13	2022	TNF-alpha and IL-6 genes had significantly upregulated in the colon of the Piroxicam group compared to the control group, while they were significantly downregulated in the SB group.	Piroxicam	75-84	interleukin 6	Mus musculus	14-18
35190960-13	2022	TNF-alpha and IL-6 genes had significantly upregulated in the colon of the Piroxicam group compared to the control group, while they were significantly downregulated in the SB group.	Antimony	173-175	interleukin 6	Mus musculus	14-18
35112126-5	2022	Moreover, L-theanine countered the increase in inflammatory factors TNF-alpha, IL-6, and IL-1beta and antioxidant enzymes SOD and CAT; it also counteracted GSH-Px inactivation, the upregulation of AST and ALT enzyme activity, and MDA production.	theanine	10-20	interleukin 6	Mus musculus	79-83
35142767-7	2022	In vitro assays suggested that this combinatory group alleviated LPS-induced inflammation in BV-2 cells, as assessed by the downregulation of nitric oxide, COX-2, and IL-6 compared to 10-HDAA or aspirin treatment alone.	Aspirin	195-202	interleukin 6	Mus musculus	167-171
35189918-12	2022	The SAL coating had anti-inflammatory activity by reducing the levels of TNF-alpha and IL-6 in vivo.	rhodioloside	4-7	interleukin 6	Mus musculus	87-91
35273606-10	2022	Lipopolysaccharide-induced expression of Il1b and Il6 was less in 2610528A11Rik deficient mouse keratinocytes than in wild-type, and imiquimod-induced psoriatic dermatitis was blunted in 2610528A11Rik deficient mice.	Imiquimod	133-142	interleukin 6	Mus musculus	50-53
35243014-8	2022	Treatment with AM-3-conditioned medium induced inflammatory cytokine production of IL-6, MCP-1, and RANTES from MC3T3-E1 cells.	Immunoferon	15-19	interleukin 6	Mus musculus	83-87
35251033-8	2022	Although no signs of hyperinflammatory toxicity were observed, mice with IPM receiving ICIs, particularly anti-PD-1, had elevated serum levels of IL-6, a cytokine linked to ICI toxicities.	ipm	73-76	interleukin 6	Mus musculus	146-150
35179009-13	2022	RESULTS: SophorOx  at 10 microM concentration, exhibited an anti-inflammatory property with significant inhibitory levels of TNF-alpha (~28.25%) and IL-6 (~32.25%).	sophorox	9-17	interleukin 6	Mus musculus	149-153
35365455-8	2022	KN93 treatment obviously alleviated pathological injuries of the pancreas in SAP mice, and significantly lowered serum levels of lipase, amylase and inflammatory factors (TNF-alpha and IL-6) and phosphorylation levels of NF-kappaB, ERK and MAPK proteins (P < 0.05).	KN 93	0-4	interleukin 6	Mus musculus	185-189
35181718-9	2022	Moreover, bone marrow derived macrophages isolated from P2X4-deficient mice revealed a reduced ATP-mediated release of CCL-2, CC chemokine ligand 5 (CCL-5), Interleukin-1beta (IL-1beta) and IL-6.	Adenosine Triphosphate	95-98	interleukin 6	Mus musculus	190-194
35179009-17	2022	Data suggests, that SophorOx  reduced levels of nitric oxide, intracellular ROS and pro-inflammatory cytokines (TNF-alpha & IL-6) at low concentrations without affecting the viability of RAW cells.	sophorox	20-28	interleukin 6	Mus musculus	124-128
35101576-6	2022	A large amount of IL-6 release and increased expression of CD11b protein were detected 24 hours after inflammatory stimulation, while pretreatment with MEL inhibited the release of IL-6 and increased the expression of CD11b.	Melatonin	152-155	interleukin 6	Mus musculus	18-22
35222675-21	2022	Tetrandrine treatment significantly increased the cartilage areas and decreased serum IL-6 significantly (from 5.954 +- 2.127 to 2.882 +- 2.013; P < 0.01).	tetrandrine	0-11	interleukin 6	Mus musculus	86-90
35222675-23	2022	The qPCR assays and ELISAs showed that tetrandrine had an anti-inflammatory effect in vitro by significantly inhibiting IL-6 (P < 0.01).	tetrandrine	39-50	interleukin 6	Mus musculus	120-124
35183883-6	2022	Moreover, Cd exposure elicits the inflammatory response, as indicated by increased IL-1beta, IL-6 and TNF-alpha expressions.	Cadmium	10-12	interleukin 6	Mus musculus	93-97
35183883-9	2022	Pretreatment with TEMPO, a specific mitochondrial ROS (mtROS) scavenger, efficiently antagonizes Cd cytotoxicity, which is indicated by attenuating Cd-induced mitochondrial dysfunction, suppressing IL-1beta, IL-6 and TNF-alpha expressions, ameliorating insulin production dysfunction and preserving cell viability in MIN6 cells.	Cadmium	97-99	interleukin 6	Mus musculus	208-212
34998794-8	2022	RESULTS: gamma-Mangostin alleviated Abeta42 oligomer-induced inflammation by decreasing the levels of interleukin (IL) -6, IL-1beta, and tumor necrosis factor-alpha, while attenuating OS through decreasing ROS/NO generation, and suppressing cyclo-oxygenase-2 and inducible NO synthase expressions.	gamma-mangostin	9-24	interleukin 6	Mus musculus	102-121
34999086-7	2022	Moreover, ISO also signally decreased oxidative stress and suppressed the content of interleukin-6 (IL-6) in BALF.	homoorientin	10-13	interleukin 6	Mus musculus	85-98
34999086-7	2022	Moreover, ISO also signally decreased oxidative stress and suppressed the content of interleukin-6 (IL-6) in BALF.	homoorientin	10-13	interleukin 6	Mus musculus	100-104
35172141-7	2022	These data suggest that IL-6-induced CISR leads to toxic neuronal iron accumulation, contributing to synuclein-induced neurodegeneration.	Iron	66-70	interleukin 6	Mus musculus	24-28
35210764-10	2022	Both preventive and therapeutic HC-067047 administration restored Cst and inhibited the increase in total protein, KC and IL-6 levels in BAL fluid, compared to RB.	HC-067047	32-41	interleukin 6	Mus musculus	122-126
35101576-6	2022	A large amount of IL-6 release and increased expression of CD11b protein were detected 24 hours after inflammatory stimulation, while pretreatment with MEL inhibited the release of IL-6 and increased the expression of CD11b.	Melatonin	152-155	interleukin 6	Mus musculus	181-185
35041834-7	2022	Western blotting and quantitative RT-PCR confirmed that diHEP-DPA or TH-DPA administration modulated the expression of inflammation-related genes (TNF-alpha and IL-6) and inhibited activation of the NF-kappaB signaling pathway in livers of HFD-fed mice.	dihep-dpa	56-65	interleukin 6	Mus musculus	161-165
35041834-7	2022	Western blotting and quantitative RT-PCR confirmed that diHEP-DPA or TH-DPA administration modulated the expression of inflammation-related genes (TNF-alpha and IL-6) and inhibited activation of the NF-kappaB signaling pathway in livers of HFD-fed mice.	th-dpa	69-75	interleukin 6	Mus musculus	161-165
35016880-10	2022	Anti-inflammatory changes such as increased IL-10 and decrease IL-6 as well as S100A8+ cells were observed following olvanil treatment.	olvanil	117-124	interleukin 6	Mus musculus	63-67
35203277-4	2022	In vitro, 10 mg/dL sUA decreased reactive oxygen species and interleukin-6 production in macrophages, while enhancing fatty acid oxidation as compared with a physiological concentration of 5 mg/dL sUA or medium.	sua	19-22	interleukin 6	Mus musculus	61-74
35209110-5	2022	Consistently, in primary murine macrophages, both flavonoids decreased the inflammatory response by lowering LPS-induced IL1 and IL6 expression.	Flavonoids	50-60	interleukin 6	Mus musculus	129-132
35157175-9	2022	The subsequent in vitro and in vivo experiments indicated that naringin could inhibit the expression of the proinflammatory cytokines (COX-2, iNOS, IL-1beta and IL-6) induced by LPS in Raw macrophage cell line, and may restrain cytokine through inhibiting HMGB1 expression in a mouse model.	naringin	63-71	interleukin 6	Mus musculus	161-165
35214966-8	2022	The in vivo pharmacodynamics of THC-SLNs gel in 2,4-dinitrochlorobenzene (DNCB)-induced AD mice showed enhanced bioactivity; reduced levels of TNF-alpha and IL-6; and complete healing, as evident from histopathological studies.	tetrahydrocurcumin	32-35	interleukin 6	Mus musculus	157-161
35203267-6	2022	However, the co-stimulation with prostaglandin (PG) E2 resulted in a marked increase in the secretion of various cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-6, and IL-13, accompanied by an increase in their mRNA levels.	Prostaglandins	33-46	interleukin 6	Mus musculus	161-179
35203267-6	2022	However, the co-stimulation with prostaglandin (PG) E2 resulted in a marked increase in the secretion of various cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-6, and IL-13, accompanied by an increase in their mRNA levels.	Dinoprostone	48-54	interleukin 6	Mus musculus	161-179
35186104-15	2022	Conclusions: Danlong Dingchuan Decoction may act on key targets (such as IL-6, TNF, CXCL8, VEGFA, and MAPK3) with key active ingredients (such as quercetin, xanthine, lysine, kaempferol, and ss-sitosterol) to reduce the expression levels of IL-4, IL-6, IL-8, and other Th2 cytokines.	Xanthine	157-165	interleukin 6	Mus musculus	247-251
35186104-11	2022	Enrichment analysis showed that quercetin, xanthine, lysine, kaempferol, ss-sitosterol, and four other active compounds were the main components of Danlong Dingchuan Decoction; IL-6, TNF, CXCL8, VEGFA, MAPK3, IL-10, PTGS2, IL-1beta, IL-4, and TLR4 were the potential targets for therapy.	Quercetin	32-41	interleukin 6	Mus musculus	177-181
35200662-4	2022	Moreover, DHB suppressed the secretion and/or the expression of the allergic cytokines, interleukin (IL)-4, IL-5, IL-6, IL-13, and tumor necrosis factor (TNF)-alpha, and the chemokine, thymus activation-regulated chemokine (TARC), by regulating the phosphorylation of IkappaBalpha and the translocation of cytoplasmic NF-kappaB into the nucleus.	protocatechualdehyde	10-13	interleukin 6	Mus musculus	114-118
35186104-11	2022	Enrichment analysis showed that quercetin, xanthine, lysine, kaempferol, ss-sitosterol, and four other active compounds were the main components of Danlong Dingchuan Decoction; IL-6, TNF, CXCL8, VEGFA, MAPK3, IL-10, PTGS2, IL-1beta, IL-4, and TLR4 were the potential targets for therapy.	Xanthine	43-51	interleukin 6	Mus musculus	177-181
35186104-11	2022	Enrichment analysis showed that quercetin, xanthine, lysine, kaempferol, ss-sitosterol, and four other active compounds were the main components of Danlong Dingchuan Decoction; IL-6, TNF, CXCL8, VEGFA, MAPK3, IL-10, PTGS2, IL-1beta, IL-4, and TLR4 were the potential targets for therapy.	Lysine	53-59	interleukin 6	Mus musculus	177-181
35186104-11	2022	Enrichment analysis showed that quercetin, xanthine, lysine, kaempferol, ss-sitosterol, and four other active compounds were the main components of Danlong Dingchuan Decoction; IL-6, TNF, CXCL8, VEGFA, MAPK3, IL-10, PTGS2, IL-1beta, IL-4, and TLR4 were the potential targets for therapy.	ss-sitosterol	73-86	interleukin 6	Mus musculus	177-181
35222229-4	2021	Trichostatin (pan-HDAC inhibitor) treatment of MG-PBMCs (n = 2) also exhibited reduced production of induced IL-6.	trichostatin A	0-12	interleukin 6	Mus musculus	109-113
35222229-4	2021	Trichostatin (pan-HDAC inhibitor) treatment of MG-PBMCs (n = 2) also exhibited reduced production of induced IL-6.	mg-pbmcs	47-55	interleukin 6	Mus musculus	109-113
35138387-8	2022	After incubation with indoxyl sulfate, Caco-2 enterocytes had higher IL-8, NFkappaB expression, and lower TEER value, and HK2 cells demonstrated higher gene expression of TNF-alpha, IL-6, and collagen (type III and type IV).	Indican	22-37	interleukin 6	Mus musculus	182-186
35099982-7	2022	Moreover, these surface-engineered Au nanoparticles were found to be suitable in subsiding key pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1beta (IL-1beta).	Gold	35-37	interleukin 6	Mus musculus	130-143
35215376-6	2022	Additionally, pre-administration with BBR suppressed the expression of pro-inflammatory factors (interleukin (IL)-6, IL-1beta, cyclooxygenase (COX)-2 and tumor necrosis factor (TNF)-alpha) and the cell-proliferation marker Ki67, while expression of the tight junction proteins (ZO-1 and occludin) were increased in colon tissue.	Berberine	38-41	interleukin 6	Mus musculus	97-115
35099982-7	2022	Moreover, these surface-engineered Au nanoparticles were found to be suitable in subsiding key pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1beta (IL-1beta).	Gold	35-37	interleukin 6	Mus musculus	145-149
35178163-5	2022	(R)-sal treatment noticeably diminished the levels of inflammatory cytokines (such as TNF-alpha, IL-6, IL-1beta, and IFN-gamma).	(r)-sal	0-7	interleukin 6	Mus musculus	97-101
35129942-2	2022	The study demonstrated that isoxanthanol inhibited excessive release of interleukin-6, NO and PGE2 in RAW264.7 cells treated with LPS in dose dependent manner.	[(2R,4R)-4-[(3aR,7S,8aS)-7-methyl-3-methylidene-2-oxo-4,7,8,8a-tetrahydro-3aH-cyclohepta[b]furan-6-yl]-4-hydroxybutan-2-yl] acetate	28-40	interleukin 6	Mus musculus	72-85
35163768-7	2022	Buspirone attenuated the induction of interleukin-1beta and interleukin-6 expression by rotenone, and this was paralleled by the upregulation of arginase-1, brain-derived neurotrophic factor (BDNF), and activity-dependent neuroprotective protein (ADNP) in the midbrain, striatum, prefrontal cortex, amygdala, and hippocampus.	Buspirone	0-9	interleukin 6	Mus musculus	60-73
35163768-7	2022	Buspirone attenuated the induction of interleukin-1beta and interleukin-6 expression by rotenone, and this was paralleled by the upregulation of arginase-1, brain-derived neurotrophic factor (BDNF), and activity-dependent neuroprotective protein (ADNP) in the midbrain, striatum, prefrontal cortex, amygdala, and hippocampus.	Rotenone	88-96	interleukin 6	Mus musculus	60-73
35173455-10	2022	The overexpression of miR-24-3p suppressed LPS-induced secretion of inflammatory cytokines (IL-1beta, IL-6, IL-8 and TNF-alpha) and deactivation of NF-kB/MAPK pathways.	mir-24-3p	22-31	interleukin 6	Mus musculus	102-106
35074739-6	2022	Meanwhile, high nitrite induced skin lesions in mice, accompanied with increased serum ALT, colon IL-6, TNF-alpha, and MDA levels, together with decreased serum Cr, colon sIgA, and T-AOC levels.	Nitrites	16-23	interleukin 6	Mus musculus	98-102
35114692-10	2022	The effect of CM-352 could be related to MMP-10 inhibition since Mmp10-/- mice showed lower haemorrhage volume, better neurological score, reduced IL-6 levels and neutrophil infiltration, and increased PAI-1 after experimental ICH.	4-(4-((3-(hydroxycarbamoyl)-8-azaspiro(4.5)decan-3-yl)sulfonyl)phenoxy)-N-methylbenzamide	14-20	interleukin 6	Mus musculus	147-151
35129051-12	2022	CBT inhibited inflammation triggered by LPS, evidenced by reduced levels of TNF-alpha, IL-6 and IL-1beta.	columbianetin	0-3	interleukin 6	Mus musculus	87-91
34998820-7	2022	BaP also suppressed colonic expression of inflammation-associated genes and plasma interleukin-6 secretion induced by DSS treatment.	Benzo(a)pyrene	0-3	interleukin 6	Mus musculus	83-96
34998820-7	2022	BaP also suppressed colonic expression of inflammation-associated genes and plasma interleukin-6 secretion induced by DSS treatment.	Dextran Sulfate	118-121	interleukin 6	Mus musculus	83-96
34981522-3	2022	PSPLP inhibited the levels of cytokines (IL-1beta, IL-6, and TNF-alpha) in monosodium urate-induced RAW264.7 cells.	Uric Acid	75-91	interleukin 6	Mus musculus	51-55
35307625-14	2022	While expression levels of interferon gamma, tumor necrosis factor alpha, and interleukin-6 significantly reduced in the liver after lipoxin A4 treatment, an anti-inflammatory cytokine interleukin-10 expression was almost at similar levels in all experimental groups.	lipoxin A4	133-143	interleukin 6	Mus musculus	78-91
35178419-7	2021	In vitro immunostimulating assays indicated that DCP activates RAW264.7 cells, thus markedly promoting macrophage proliferation and phagocytosis and increasing the levels of nitric oxide, interferon-gamma, interleukin-6, and interleukin-1beta.	dcp	49-52	interleukin 6	Mus musculus	206-219
35064430-9	2022	Treatment with crude extract (TSETOH) and fractions (TSHEX, TSTOL) significantly reduced (P < 0.001) the mRNA expression of pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha) and nitric oxide (NO) production in LPS-stimulated inflammation in RAW 264.7 cells in a dose-dependent manner.	tsetoh	30-36	interleukin 6	Mus musculus	162-166
35020533-7	2022	Sesamin also dose-dependently inhibited mRNA levels of HG-induced inflammatory cytokines, including TNFalpha, interleukin (IL)-1beta and IL-6, activated NF-kappaB signaling pathway, and reduced oxidative stress by decreasing reactive oxygen species levels and increasing antioxidant enzymes in the BV2 and primary retinal microglia.	sesamin	0-7	interleukin 6	Mus musculus	137-141
34981816-8	2022	Compared with VILI mice or CS-treated AMs, NEAT1 knockdown accelerated the phenotypic transformation from M1 to M2, and decreased the expression levels of IL-1beta, IL-6, TNF-alpha and iNOS.	Cesium	27-29	interleukin 6	Mus musculus	165-169
35102779-13	2022	Furthermore, GXP ameliorated the aorta morphological damage and reduced the serum TNF-alpha, IL-6, and IL-1beta levels.	GXP	13-16	interleukin 6	Mus musculus	93-97
35204172-5	2022	The combined treatment of LGSP with CO (20 mug/mL and 1 mg/mL) synergistically suppressed the production of NO, TNF-alpha, IL-6 and ROS.	lgsp	26-30	interleukin 6	Mus musculus	123-127
35204172-5	2022	The combined treatment of LGSP with CO (20 mug/mL and 1 mg/mL) synergistically suppressed the production of NO, TNF-alpha, IL-6 and ROS.	Cobalt	36-38	interleukin 6	Mus musculus	123-127
35173613-11	2021	Further, chronic lenrispodun treatment decreased TNF-alpha and IL-10 plasma levels while the elevated level of IL-6 in SMC-KO mice remained unchanged after treatment.	ITI-214	17-28	interleukin 6	Mus musculus	111-115
35203954-6	2022	In addition, gelsemine decreased the levels of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6, in the hypothalamus and hippocampus of CUMS mice.	gelsemine	13-22	interleukin 6	Mus musculus	112-116
35164229-3	2022	Ethyl acetate (ARE) and methanol (ARM) extracts significantly decreased mRNA levels of IL-6, TNF-alpha, MCP-1, COX-2, and iNOS.	ethyl acetate	0-13	interleukin 6	Mus musculus	87-91
35164229-3	2022	Ethyl acetate (ARE) and methanol (ARM) extracts significantly decreased mRNA levels of IL-6, TNF-alpha, MCP-1, COX-2, and iNOS.	Methanol	24-32	interleukin 6	Mus musculus	87-91
35164229-7	2022	Furthermore, chlorogenic acid, tyramine derivatives, and the mixture of the six identified major compounds significantly decreased IL-6 secretion by LPS-activated J774 cells.	Chlorogenic Acid	13-29	interleukin 6	Mus musculus	131-135
35164229-7	2022	Furthermore, chlorogenic acid, tyramine derivatives, and the mixture of the six identified major compounds significantly decreased IL-6 secretion by LPS-activated J774 cells.	Tyramine	31-39	interleukin 6	Mus musculus	131-135
35163503-10	2022	In vitro, eupatilin significantly reduced LPS-stimulated NO, IL-6, and ROS production.	eupatilin	10-19	interleukin 6	Mus musculus	61-65
35499019-5	2022	Which proved that DOLP inhibited the expression of pro-inflammatory cytokines (TNF-alpha, TGF- beta1, IL-6, IL-1beta) and promoted the expression of anti-inflammatory cytokines (IL-10).	dolp	18-22	interleukin 6	Mus musculus	102-106
35132324-7	2022	Moreover, SXYH also modulated the inflammation response by regulating affinity proinflammatory cytokines release (e.g., IL-6 and TNF-alpha).	sxyh	10-14	interleukin 6	Mus musculus	120-124
35153686-14	2021	Abeta or LPS + IFN-gamma promoted the production of cytokines IL-6 and TNF-alpha but decreased cytokine IL-10 in the BV2 cells.	UNII-042A8N37WH	0-5	interleukin 6	Mus musculus	62-66
35090386-7	2022	RESULTS: Omega-3 FAs inhibited CLP-induced intestinal injury and ameliorated LPS-induced intestinal epithelial cell injury by down-regulating miR-1-3p, as evidenced by decreased levels of tumor necrosis factor-alpha, interleukin-1beta (IL-1beta) and IL-6, in addition to diminished levels of reactive oxygen species, malondialdehyde levels and superoxide dismutase activity.	Fatty Acids, Omega-3	9-20	interleukin 6	Mus musculus	250-254
35159514-4	2022	TVE also decreased the protein expression of LPS-induced inducible NO synthase and cyclooxygenase-2 and suppressed the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1beta.	tve	0-3	interleukin 6	Mus musculus	200-218
35386464-7	2022	Further results revealed that Rh2@HMnO2-AM enhanced the secretion of IL-6, IFN-gamma and TNF-alpha in serum and inhibited the generation of FOXP3+ T cells (Tregs) in tumors.	rh2	30-33	interleukin 6	Mus musculus	69-73
35089938-5	2022	The post-weaning Omega-3 diet reduced hippocampal expression of IL-6 and this reduction of IL-6 was significantly associated with diminished performance in the fear conditioning task.	Fatty Acids, Omega-3	17-24	interleukin 6	Mus musculus	64-68
35089938-5	2022	The post-weaning Omega-3 diet reduced hippocampal expression of IL-6 and this reduction of IL-6 was significantly associated with diminished performance in the fear conditioning task.	Fatty Acids, Omega-3	17-24	interleukin 6	Mus musculus	91-95
35145506-6	2022	Our results showed that diet of beta-carotin and green tea powder reduced the joint swelling and pain in mice with gout, reduced the levels of serum uric acid (UA) and three types of pro-inflammatory cytokines, i.e., interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), improved the gut microbiota profile, and reduced the metabolic levels of purines and pyrimidines.	beta Carotene	32-44	interleukin 6	Mus musculus	247-260
35386464-7	2022	Further results revealed that Rh2@HMnO2-AM enhanced the secretion of IL-6, IFN-gamma and TNF-alpha in serum and inhibited the generation of FOXP3+ T cells (Tregs) in tumors.	hmno2-am	34-42	interleukin 6	Mus musculus	69-73
35145506-6	2022	Our results showed that diet of beta-carotin and green tea powder reduced the joint swelling and pain in mice with gout, reduced the levels of serum uric acid (UA) and three types of pro-inflammatory cytokines, i.e., interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), improved the gut microbiota profile, and reduced the metabolic levels of purines and pyrimidines.	beta Carotene	32-44	interleukin 6	Mus musculus	262-266
35163276-8	2022	PHZ treatment in Wt induced inflammatory markers (IL-6, TNFalpha) but not Hamp1.	phenylhydrazine	0-3	interleukin 6	Mus musculus	50-54
35163272-8	2022	After subcutaneous injection into mice, SA-CpG1668/tripodna induced significantly higher interleukin (IL)-12 p40 production in the draining lymph nodes than SA-CpG1668 or CpG1668/tripodna, with reduced IL-6 levels in plasma.	sa-cpg1668	40-50	interleukin 6	Mus musculus	202-206
35200626-3	2022	COS also significantly inhibited the levels of nitric oxide (NO) and IL-6 in lipopolysaccharide-stimulated RAW 264.7 cells.	carbonyl sulfide	0-3	interleukin 6	Mus musculus	69-73
35163272-8	2022	After subcutaneous injection into mice, SA-CpG1668/tripodna induced significantly higher interleukin (IL)-12 p40 production in the draining lymph nodes than SA-CpG1668 or CpG1668/tripodna, with reduced IL-6 levels in plasma.	tripodna	51-59	interleukin 6	Mus musculus	202-206
34984422-5	2022	Compounds 1, 2, 7 and 8 showed significant NO inhibitory ability in IL-1beta-stimulated mouse primary chondrocytes, and we further confirmed the anti-inflammatory activity of 1 (glycyuralin Q) by evaluating its effect on osteoarthritis-related iNOS, COX-2, TNF-alpha, IL-6, MMP3, MMP13 and NF-kappaB based on various experimental methods.	glycyuralin q	178-191	interleukin 6	Mus musculus	268-272
35072290-7	2022	PPAR-gamma antagonist GW9662 further enhanced IL-6 and TNF-alpha levels and decreased cell viability in the presence of LPS treatment.	2-chloro-5-nitrobenzanilide	22-28	interleukin 6	Mus musculus	46-50
34726736-0	2022	APAP-induced IkappaBbeta/NFkappaB signaling drives hepatic IL6 expression and associated sinusoidal dilation.	Acetaminophen	0-4	interleukin 6	Mus musculus	59-62
35200626-4	2022	Importantly, COS inhibited the activation of the NF-kappaB signaling pathway via activating PPARgamma and SIRT1, thus reducing the production of NO and IL-6.	carbonyl sulfide	13-16	interleukin 6	Mus musculus	152-156
35075211-4	2022	M-CSF blockade enhanced inflammatory cytokine secretion, further increased systemic neutrophil counts, and led to tissue iron sequestration that was dependent, in part, on augmented IL-6 secretion which induced hepcidin.	Iron	121-125	interleukin 6	Mus musculus	182-186
35163177-4	2022	Meanwhile, TP modulated the infiltration of neutrophils and macrophages (Ly6G staining and CD68 staining) and decreased the levels of proinflammatory factors (TNF-alpha and IL-6) through inhibiting the transactivation of nuclear factor-kappaB (NF-kappaB) in caerulein-treated mice.	triptolide	11-13	interleukin 6	Mus musculus	173-177
35075227-7	2022	Kidney iron loading, predominantly in distal tubules, increased in time, along with urinary kidney injury molecule-1 and 24p3 concentration, as well as kidney mRNA expression of Interleukin-6 (Il-6) and Heme oxygenase-1 (Ho-1).	Iron	7-11	interleukin 6	Mus musculus	193-197
35126352-10	2021	Ingenuity Pathway Analysis (IPA) revealed that IL-1beta, TNF-alpha, and IL-6 were among the top upstream regulators of the cSiO2-induced protein response.	csio2	123-128	interleukin 6	Mus musculus	72-76
35161266-8	2022	ETL dose-dependently reduced the production of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) in LPS-induced RAW264.7 cells, in a dose-dependent manner.	etl	0-3	interleukin 6	Mus musculus	159-172
35161266-8	2022	ETL dose-dependently reduced the production of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) in LPS-induced RAW264.7 cells, in a dose-dependent manner.	etl	0-3	interleukin 6	Mus musculus	174-178
35079379-13	2022	Conclusion: TAK1 inhibition with LLZ may become a novel treatment strategy to effectively alleviate inflammasome-mediated inflammation and RANKL-induced osteoclastic bone destruction in joints alongside its potent suppression of TNF-alpha and IL-6 production and proteinase-mediated pathological processes in RA.	LL Z1640-2	33-36	interleukin 6	Mus musculus	243-247
35126160-10	2022	Moreover, AO-I treatment significantly inhibited APAP-induced activation of pro-inflammatory factors, such as IL-1beta, IL-6, and TNF-alpha, at both the mRNA and protein levels.	atractylenolide I	10-14	interleukin 6	Mus musculus	120-124
35126160-10	2022	Moreover, AO-I treatment significantly inhibited APAP-induced activation of pro-inflammatory factors, such as IL-1beta, IL-6, and TNF-alpha, at both the mRNA and protein levels.	Acetaminophen	49-53	interleukin 6	Mus musculus	120-124
35048969-10	2022	IL-6 derived from IgE-stimulated MCs promoted reactive oxygen species (ROS) production and decreased the levels of phosphorylated endothelial nitric oxide synthase (p-eNOS) in ECs, leading to endothelial dysfunction.	Reactive Oxygen Species	46-69	interleukin 6	Mus musculus	0-4
35048969-10	2022	IL-6 derived from IgE-stimulated MCs promoted reactive oxygen species (ROS) production and decreased the levels of phosphorylated endothelial nitric oxide synthase (p-eNOS) in ECs, leading to endothelial dysfunction.	Reactive Oxygen Species	71-74	interleukin 6	Mus musculus	0-4
35126176-13	2021	IL-6, TNF-alpha expression (P < 0.0001 for both) decreased, and SOD activity (P = 0.0038), GSH/GSSG ratio (P = 0.002) significantly increased in skeletal muscle after injection of levosimendan.	Simendan	180-192	interleukin 6	Mus musculus	0-4
35043776-13	2022	Moreover, predimenol significantly inhibited the LPS-induced production of NO, TNF-alpha, IL-1beta, IL-2 and IL-6.	predimenol	10-20	interleukin 6	Mus musculus	109-113
35097132-7	2022	Clodronate treatment prevented the alteration in cytokines, TNFalpha and IL-6, and increase in gene expression of connective tissue growth factor (CTGF), TGFbeta-1, matrix metalloproteinase-9 (MMP9), fibronectin, laminin, and collagen in FHKO mice with CSS (P < 0.05).	Clodronic Acid	0-10	interleukin 6	Mus musculus	73-77
35118141-8	2021	Bazedoxifene also suppressed LPS-induced IL-6 transcription.	bazedoxifene	0-12	interleukin 6	Mus musculus	41-45
35173832-4	2022	Interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in mouse serum were detected by Enzyme-linked immunosorbent assay (ELISA); fibronectin (FN) and type I collagen (Col-I) in renal tissue were detected by Western blotting; serum creatinine (Cr) and blood urea nitrogen (BUN) were analyzed by kits.	Urea	268-272	interleukin 6	Mus musculus	0-13
35173832-4	2022	Interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in mouse serum were detected by Enzyme-linked immunosorbent assay (ELISA); fibronectin (FN) and type I collagen (Col-I) in renal tissue were detected by Western blotting; serum creatinine (Cr) and blood urea nitrogen (BUN) were analyzed by kits.	Nitrogen	273-281	interleukin 6	Mus musculus	0-13
35173832-4	2022	Interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in mouse serum were detected by Enzyme-linked immunosorbent assay (ELISA); fibronectin (FN) and type I collagen (Col-I) in renal tissue were detected by Western blotting; serum creatinine (Cr) and blood urea nitrogen (BUN) were analyzed by kits.	Creatinine	242-252	interleukin 6	Mus musculus	0-13
35173832-4	2022	Interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in mouse serum were detected by Enzyme-linked immunosorbent assay (ELISA); fibronectin (FN) and type I collagen (Col-I) in renal tissue were detected by Western blotting; serum creatinine (Cr) and blood urea nitrogen (BUN) were analyzed by kits.	Creatinine	254-256	interleukin 6	Mus musculus	0-13
35012572-3	2022	This study assessed the effects of simvastatin on cytotoxicity and the release of IL-6 (Interleukin-6) production when incorporated in zinc oxide eugenol and methacrylate resin-based sealers.	Simvastatin	35-46	interleukin 6	Mus musculus	88-101
35055106-4	2022	DSS-exposed Parp7-/- mice had less body weight loss, lower disease index scores, and reduced expression of several inflammation genes, including interleukin IL-6, C-x-c motif chemokine ligand 1 (Cxcl1), and lipocalin-2, when compared with wild-type mice.	Dextran Sulfate	0-3	interleukin 6	Mus musculus	157-161
35017318-9	2022	The results demonstrated that atorvastatin significantly deactivated glial cells by reducing the expression of glial fibrillary acidic protein (GFAP), Ionized calcium binding adapter molecule 1 (Iba1), tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6 in ICH model mice.	Atorvastatin	30-42	interleukin 6	Mus musculus	241-259
35341135-12	2022	In SS mice, levels of AKT1, HIF-1alpha, TNF-alpha, IL-6, and IL-17A were increased, while decreased after QZF treatment.	qzf	106-109	interleukin 6	Mus musculus	51-55
35095894-8	2021	The expression of M1 macrophage-associated proinflammatory cytokines and genes, including interleukin (IL)-6, IL-12, and inducible nitric oxide synthase (iNOS), was also decreased after corilagin treatment.	corilagin	186-195	interleukin 6	Mus musculus	90-108
35172258-16	2022	Pretreatment of EST dose-dependently suppressed the LPS-induced production of IL-6, TNF-alpha and CXCL1 in peritoneal macrophages.	Aloxistatin	16-19	interleukin 6	Mus musculus	78-82
35069225-10	2021	Caffeine was also able to reduce IL-6 mRNA levels in the retina of I/R eyes.	Caffeine	0-8	interleukin 6	Mus musculus	33-37
35055377-11	2022	The expression of IL-6, IL-17, and Ki-67 was downregulated in the forsythoside-A-treated groups.	forsythiaside	66-80	interleukin 6	Mus musculus	18-22
34979499-8	2022	Hippocampal IL-1beta, IL-6, and MCP-1 levels were significantly decreased in NKS-treated SAMP8 mice.	CHEMBL1089210	77-80	interleukin 6	Mus musculus	22-26
35058751-11	2021	Moreover, CCH effectively reduced the activity of lactate dehydrogenase and decreased malondialdehyde, TNF-alpha and IL-6 generation in hippocampus.	1-acetyl-2-(coumariniminecarboxamide-3-yl)hydrazine	10-13	interleukin 6	Mus musculus	117-121
35058778-10	2021	Compared with MgIG treatment, activation of autophagy by RAPA also promoted the expression of liver inflammation markers (IL-1beta, IL-6, TNF-alpha, CXCL-1, CXCL-2, CXCL-10, etc.)	Sirolimus	57-61	interleukin 6	Mus musculus	132-136
35451424-9	2022	Histone H3 acetyl lysine 9 (H3K9ac) enrichment of TNF-alpha and IL-6 promoter was detected by ChIP.	acetyl lysine	11-24	interleukin 6	Mus musculus	64-68
35451424-13	2022	Besides, apelin-13 decreased the enrichment of H3K9ac at the promoter region of TNF-alpha and IL-6 to inhibit inflammatory response, which was reversed by histone deacetylase antagonist valproate.	Valproic Acid	186-195	interleukin 6	Mus musculus	94-98
35114907-10	2022	The effects of SCZ and FCZ on levels of the inflammatory cytokines (tumor necrosis factor-(Formula: see text), interleukin-6, interleukin-1(Formula: see text), mucoprotein (MUC2), tight protein (ZO-1, occludin), and the activation of macrophages were determined using immunohistochemistry (IHC) and immunofluorescence (IF).	SCZ	15-18	interleukin 6	Mus musculus	111-124
34477530-0	2022	Maslinic Acid Inhibits Cervical Intraepithelial Neoplasia by Suppressing Interleukin-6 and Enhancing Apoptosis in a Mouse Model.	maslinic acid	0-13	interleukin 6	Mus musculus	73-86
35114907-10	2022	The effects of SCZ and FCZ on levels of the inflammatory cytokines (tumor necrosis factor-(Formula: see text), interleukin-6, interleukin-1(Formula: see text), mucoprotein (MUC2), tight protein (ZO-1, occludin), and the activation of macrophages were determined using immunohistochemistry (IHC) and immunofluorescence (IF).	Fluconazole	23-26	interleukin 6	Mus musculus	111-124
34477530-2	2022	OBJECTIVE: As maslinic acid exhibits anti-IL-6 property, the present study sought to determine the effect of maslinic acid on CIN in vitro and in vivo using cell cultures and mouse CIN models, respectively.	maslinic acid	14-27	interleukin 6	Mus musculus	42-46
34477530-6	2022	In the CIN mouse model, serum IL-6 level and cervical expression of IL-6R were elevated, which could be repressed by maslinic acid administration dose-dependently.	maslinic acid	117-130	interleukin 6	Mus musculus	30-34
34477530-8	2022	CONCLUSION: Maslinic acid exhibits potent anti-IL-6 property in the CIN mouse model, and alleviates the disease-related abnormality in proliferation potential and apoptosis state of the cervical tissue cells, demonstrating its usefulness as a promising agent in treating CIN.	maslinic acid	12-25	interleukin 6	Mus musculus	47-51
35015568-5	2022	Tys-inhibited Rho and myosin light chain (MLC) activation after MRSA and blocked MRSA-induced NF-kappaB activation and release of the proinflammatory cytokines, IL-6 and IL-8.	TYS	0-3	interleukin 6	Mus musculus	161-165
35015568-8	2022	Posttreatment with Tys significantly reduced levels of bronchoalveolar lavage (BAL) VCAM-1 and plasma IL-6 and KC induced by MRSA.	TYS	19-22	interleukin 6	Mus musculus	102-106
34968163-5	2022	In AD mice model, streptozotocin induced the locomotor impairment and cognitive deficit, up-regulated levels of MDA, TNF-alpha, IL-6, and CRP, while down-regulated levels of GSH, SOD, and miR-200c.	Streptozocin	18-32	interleukin 6	Mus musculus	128-132
35261646-7	2022	Anti-inflammation results demonstrated that the NAL-SA-MVs could reduce the pro-inflammation factors (iNOS, TNF-alpha, IL-1beta, IL-6) and increase the expression of anti-inflammation factors (IL-10) at the cell and animal level.	Naloxone	48-51	interleukin 6	Mus musculus	129-133
35261646-7	2022	Anti-inflammation results demonstrated that the NAL-SA-MVs could reduce the pro-inflammation factors (iNOS, TNF-alpha, IL-1beta, IL-6) and increase the expression of anti-inflammation factors (IL-10) at the cell and animal level.	Alginates	52-54	interleukin 6	Mus musculus	129-133
35145895-7	2022	Results: The results showed that all AA extracts (100, 200, and 400 mg/kg) and metformin (250 mg/kg) significantly reduced the serum levels of free fatty acids, TNF-alpha, IL-6, LDL/HDL ratio, and HOMA-IR in diabetic mice compared to untreated diabetic mice (p<0.0001).	Metformin	79-88	interleukin 6	Mus musculus	172-176
35145895-8	2022	Notably, the 400 mg/kg dose of cold-water extract was more effective than metformin in reduction of TNF-alpha and IL-6 (p<0.01 and p<0.05, respectively).	Water	36-41	interleukin 6	Mus musculus	114-118
35145895-8	2022	Notably, the 400 mg/kg dose of cold-water extract was more effective than metformin in reduction of TNF-alpha and IL-6 (p<0.01 and p<0.05, respectively).	Metformin	74-83	interleukin 6	Mus musculus	114-118
34968163-8	2022	Magnolol also down-regulated the levels of MDA, TNF-alpha, IL-6, and CRP, and up-regulated the levels of GSH, SOD, and miR-200c in the hippocampus tissues of AD mice.	magnolol	0-8	interleukin 6	Mus musculus	59-63
34986499-8	2022	Therefore, these results strongly suggest that incretins enhance the PGF2alpha-induced synthesis of IL-6 and osteoprotegerin in osteoblast-like MC3T3-E1 cells.	Dinoprost	69-78	interleukin 6	Mus musculus	100-104
34655413-6	2022	Furthermore, the plasma levels of proinflammatory molecules (C5a, ICAM-1, IL-6, MCP-1, IL-1beta and TNF-alpha) were found to be elevated (3-fold) in dAGE-fed mice.	dage	149-153	interleukin 6	Mus musculus	74-78
34986499-0	2022	Incretins Enhance PGF2alpha-Induced Synthesis of IL-6 and Osteoprotegerin in Osteoblasts.	Dinoprost	18-27	interleukin 6	Mus musculus	49-53
34654783-7	2022	In renal tissue, the levels of pro-inflammatory cytokines TNF-alpha and IL-6 were evidently decreased after catalpol intervention.	catalpol	108-116	interleukin 6	Mus musculus	72-76
34986499-2	2022	We have previously reported that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of interleukin-6 (IL-6) and osteoprotegerin in osteoblast-like MC3T3-E1 cells, and that IL-6 and osteoprotegerin release are mediated through the p44/p42 mitogen-activated protein (MAP) kinase, p38 MAP kinase or stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) pathways.	Dinoprost	33-54	interleukin 6	Mus musculus	95-108
34986499-2	2022	We have previously reported that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of interleukin-6 (IL-6) and osteoprotegerin in osteoblast-like MC3T3-E1 cells, and that IL-6 and osteoprotegerin release are mediated through the p44/p42 mitogen-activated protein (MAP) kinase, p38 MAP kinase or stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) pathways.	Dinoprost	33-54	interleukin 6	Mus musculus	110-114
34986499-2	2022	We have previously reported that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of interleukin-6 (IL-6) and osteoprotegerin in osteoblast-like MC3T3-E1 cells, and that IL-6 and osteoprotegerin release are mediated through the p44/p42 mitogen-activated protein (MAP) kinase, p38 MAP kinase or stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) pathways.	Dinoprost	33-54	interleukin 6	Mus musculus	180-184
34986499-2	2022	We have previously reported that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of interleukin-6 (IL-6) and osteoprotegerin in osteoblast-like MC3T3-E1 cells, and that IL-6 and osteoprotegerin release are mediated through the p44/p42 mitogen-activated protein (MAP) kinase, p38 MAP kinase or stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) pathways.	Dinoprost	56-65	interleukin 6	Mus musculus	95-108
34986499-2	2022	We have previously reported that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of interleukin-6 (IL-6) and osteoprotegerin in osteoblast-like MC3T3-E1 cells, and that IL-6 and osteoprotegerin release are mediated through the p44/p42 mitogen-activated protein (MAP) kinase, p38 MAP kinase or stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) pathways.	Dinoprost	56-65	interleukin 6	Mus musculus	110-114
34986499-2	2022	We have previously reported that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of interleukin-6 (IL-6) and osteoprotegerin in osteoblast-like MC3T3-E1 cells, and that IL-6 and osteoprotegerin release are mediated through the p44/p42 mitogen-activated protein (MAP) kinase, p38 MAP kinase or stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) pathways.	Dinoprost	56-65	interleukin 6	Mus musculus	180-184
34986499-3	2022	In the present study, we investigated the effects of incretins including GLP-1 and GIP, on the PGF2alpha-induced synthesis of IL-6 and osteoprotegerin and examined the detailed mechanism in osteoblast-like MC3T3-E1 cells.	Dinoprost	95-104	interleukin 6	Mus musculus	126-130
34986499-4	2022	We found that GIP and GLP-1 significantly stimulated the PGF2alpha-induced synthesis of IL-6 in osteoblast-like MC3T3-E1 cells.	Dinoprost	57-66	interleukin 6	Mus musculus	88-92
34986499-5	2022	In addition, GIP and GLP-1 significantly enhanced the PGF2alpha-induced mRNA expression levels of IL-6.	Dinoprost	54-63	interleukin 6	Mus musculus	98-102
34482320-7	2022	Circulating levels of IL-6, IL-1beta, TNFalpha, and IL-23 were equivalent 24 h after CS-injection; however, IL-17A was uniquely increased in HFD-fed mice.	Cesium	85-87	interleukin 6	Mus musculus	22-26
35008094-11	2022	Treatment with ASP suppressed IL-6 and TNF-alpha and regulated oxidative stress-related biomarkers.	asperulosidic acid	15-18	interleukin 6	Mus musculus	30-34
34172609-12	2022	Na2S2O3 significantly increased renal tissue IkappaBalpha and heme oxygenase-1 expression, whereas it lowered kidney IL-6 and MCP-1 levels.	sodium thiosulfate	0-7	interleukin 6	Mus musculus	117-121
34976218-7	2022	Mechanistically, 5Aza stimulated primary mouse macrophages toward to a M1-like phenotype characterized by the increase of p65 phosphorylation and IL-6 expression.	Decitabine	17-21	interleukin 6	Mus musculus	146-150
34976218-9	2022	5Aza induced cholesterol accumulation, p65 phosphorylation and IL-6 expression in an ABC A9-dependent manner.	Decitabine	0-4	interleukin 6	Mus musculus	63-67
34976218-10	2022	Pharmacological inhibition of NF-kappaB, or genetic depletion of IL-6 abolished the antitumor effect of 5Aza in mice.	Decitabine	104-108	interleukin 6	Mus musculus	65-69
35178994-10	2022	As for the animal experiment, the levels of IL-6 and TNF-alpha in the peripheral serum of the miR-17-5 p inhibitor group and the astragaloside IV group were lower(P<0.05) and the serum level of IL-10 was higher(P<0.05) than that of the model group.	mir-17-5 p	94-104	interleukin 6	Mus musculus	44-48
35058371-3	2022	In hyperalgesic priming induced by activation of interleukin 6 (IL-6) signaling, CGRP receptor antagonists, olcegepant and CGRP8-37, both given intrathecally, blocked and reversed hyperalgesic priming only in females.	olcegepant	108-118	interleukin 6	Mus musculus	49-62
35058371-3	2022	In hyperalgesic priming induced by activation of interleukin 6 (IL-6) signaling, CGRP receptor antagonists, olcegepant and CGRP8-37, both given intrathecally, blocked and reversed hyperalgesic priming only in females.	olcegepant	108-118	interleukin 6	Mus musculus	64-68
35215831-5	2022	The results show that beta-glucans induced the expression of Dectin-1, costimulatory molecules (CD80/86) and cytokines IL-6, IL-1beta, IFN-beta and IL-10 in murine bone marrow dendritic cells (BMDCs).	beta-Glucans	22-34	interleukin 6	Mus musculus	119-123
35480858-7	2022	The results showed that C2S extract (150 mug/ml) induced TNF-alpha, IL-1beta and IL-6 production in macrophages.	A(2)C	24-27	interleukin 6	Mus musculus	81-85
34999342-3	2022	Furthermore, LP obviously alleviated the injury of spleen and thymus; significantly promoted Interleukin-2 (IL-2), IL-6, tumor necrosis factor alpha (TNF-alpha), immunoglobulin (IgA, IgG and IgM) secretion; and improved the richness of gut microbiota and the contents of short-chain fatty acids (SCFAs) in immunosuppressive mice.	leucylproline	13-15	interleukin 6	Mus musculus	115-119
2481572-3	1989	DEX(10(-7) M) in DMEM supplemented with 5 per cent FCS, enhanced the IL-6 effect on the three positive acute phase proteins.	Dextromethorphan	0-3	interleukin 6	Mus musculus	69-73
2680971-2	1989	The IL-6 response was controlled by the lipopolysaccharide gene, Lps; in C3H/HeN mice (Lpsn/Lpsn), the urinary IL-6 levels increased within 30 min after challenge with Escherichia coli, but no response occurred in C3H/HeJ mice (Lpsd/Lpsd).	lpsn	87-91	interleukin 6	Mus musculus	4-8
2680971-2	1989	The IL-6 response was controlled by the lipopolysaccharide gene, Lps; in C3H/HeN mice (Lpsn/Lpsn), the urinary IL-6 levels increased within 30 min after challenge with Escherichia coli, but no response occurred in C3H/HeJ mice (Lpsd/Lpsd).	lpsn	87-91	interleukin 6	Mus musculus	111-115
2680971-2	1989	The IL-6 response was controlled by the lipopolysaccharide gene, Lps; in C3H/HeN mice (Lpsn/Lpsn), the urinary IL-6 levels increased within 30 min after challenge with Escherichia coli, but no response occurred in C3H/HeJ mice (Lpsd/Lpsd).	lpsn	92-96	interleukin 6	Mus musculus	4-8
2680971-2	1989	The IL-6 response was controlled by the lipopolysaccharide gene, Lps; in C3H/HeN mice (Lpsn/Lpsn), the urinary IL-6 levels increased within 30 min after challenge with Escherichia coli, but no response occurred in C3H/HeJ mice (Lpsd/Lpsd).	lpsn	92-96	interleukin 6	Mus musculus	111-115
2680971-2	1989	The IL-6 response was controlled by the lipopolysaccharide gene, Lps; in C3H/HeN mice (Lpsn/Lpsn), the urinary IL-6 levels increased within 30 min after challenge with Escherichia coli, but no response occurred in C3H/HeJ mice (Lpsd/Lpsd).	lpsd	228-232	interleukin 6	Mus musculus	4-8
2680971-2	1989	The IL-6 response was controlled by the lipopolysaccharide gene, Lps; in C3H/HeN mice (Lpsn/Lpsn), the urinary IL-6 levels increased within 30 min after challenge with Escherichia coli, but no response occurred in C3H/HeJ mice (Lpsd/Lpsd).	lpsd	228-232	interleukin 6	Mus musculus	111-115
2680971-2	1989	The IL-6 response was controlled by the lipopolysaccharide gene, Lps; in C3H/HeN mice (Lpsn/Lpsn), the urinary IL-6 levels increased within 30 min after challenge with Escherichia coli, but no response occurred in C3H/HeJ mice (Lpsd/Lpsd).	lpsd	233-237	interleukin 6	Mus musculus	4-8
2680971-2	1989	The IL-6 response was controlled by the lipopolysaccharide gene, Lps; in C3H/HeN mice (Lpsn/Lpsn), the urinary IL-6 levels increased within 30 min after challenge with Escherichia coli, but no response occurred in C3H/HeJ mice (Lpsd/Lpsd).	lpsd	233-237	interleukin 6	Mus musculus	111-115
25604220-12	2014	Yet after a pretreatment of losartan, the pulmonary level of IL-6 markedly decreased.	Losartan	28-36	interleukin 6	Mus musculus	61-65
2681491-4	1989	Feline HGF/IL-6 was eluted into the fractions corresponding to a molecular weight of 30,000-40,000 in gel filtration, and into the fractions at a salt concentration of 0.2-0.3 M NaCl in anion exchange chromatography.	Sodium Chloride	178-182	interleukin 6	Mus musculus	11-15
2481572-3	1989	DEX(10(-7) M) in DMEM supplemented with 5 per cent FCS, enhanced the IL-6 effect on the three positive acute phase proteins.	dmem	17-21	interleukin 6	Mus musculus	69-73
2789259-4	1989	rIL-1 alpha or purified IL-6 only slightly enhanced synthesis of IgM over minimal baseline levels in Peyer"s patch T cell-depleted cell cultures; however, when IL-6 was added to cultures also containing rIL-1, IgM synthesis was very substantially increased.	ril-1	0-5	interleukin 6	Mus musculus	160-164
2499626-10	1989	In addition, the sera of untreated TB mice contained levels of IL-6 which paralleled the extent of tumor burden (serum IL-6 in day 30 MCA 106 TB mice = 420 HGF U/ml).	Terbium	35-37	interleukin 6	Mus musculus	63-67
2668410-7	1989	Addition of 10 micrograms/ml cyclosporine A to the medium abolishes the effect of 2-ME and of all of the cytokines except IL-2 and IL-6.	Cyclosporine	29-43	interleukin 6	Mus musculus	131-135
2550553-6	1989	Synthetic oligonucleotides representing the binding sites of the H-2Kb class I and IL-6 genes for these factors compete with the C4 promoter for the complex formation with a HepG2 nuclear factor.	Oligonucleotides	10-26	interleukin 6	Mus musculus	83-87
2476639-4	1989	Addition of IL-6 or granulocyte colony-stimulating factor (G-CSF), which act synergistically with IL-3 on dormant progenitors, partially neutralized the inhibition by TGF beta of colony formation from cells of 5-FU-treated mice.	Fluorouracil	210-214	interleukin 6	Mus musculus	12-16
2499626-10	1989	In addition, the sera of untreated TB mice contained levels of IL-6 which paralleled the extent of tumor burden (serum IL-6 in day 30 MCA 106 TB mice = 420 HGF U/ml).	Terbium	35-37	interleukin 6	Mus musculus	119-123
2499626-14	1989	Although the exact role of IL-6 in TB animals remains to be elucidated, its known pleotrophic immune and metabolic effects may be important in the host response to malignancy.	Terbium	35-37	interleukin 6	Mus musculus	27-31
2469502-4	1989	Furthermore, day 4 but not day 2 post-5-FU BM showed enhanced GM colony formation when stimulated with IL-6 plus interleukin-4 (IL-4) or granulocyte colony-stimulating factor (G-CSF).	gm	62-64	interleukin 6	Mus musculus	103-107
2784054-0	1989	Production of interleukin 6 and its relation to the macrophage differentiation of mouse myeloid leukemia cells (M1) treated with differentiation-inducing factor and 1 alpha,25-dihydroxyvitamin D3.	Calcitriol	165-195	interleukin 6	Mus musculus	14-27
3264498-0	1988	Appearance of hybridoma growth factor/interleukin-6 in the serum of mice bearing a methylcholanthrene-induced sarcoma.	Methylcholanthrene	83-101	interleukin 6	Mus musculus	38-51
3263278-4	1988	Recombinant IL-6 was able to support multilineage colony formation by spleen cells from 5-fluorouracil (5-FU)-treated mice.	Fluorouracil	88-102	interleukin 6	Mus musculus	12-16
3263278-4	1988	Recombinant IL-6 was able to support multilineage colony formation by spleen cells from 5-fluorouracil (5-FU)-treated mice.	Fluorouracil	104-108	interleukin 6	Mus musculus	12-16
3264498-1	1988	Serum concentrations of hybridoma growth factor/interleukin-6 progressively increased in mice bearing a transplantable methylcholanthrene-induced sarcoma with tumor growth.	Methylcholanthrene	119-137	interleukin 6	Mus musculus	48-61
3264498-2	1988	Elevated HGF/interleukin-6 concentrations were also positively correlated with increased serum concentrations of the hepatic acute phase reactant protein, amyloid P. Daily Indomethacin treatment of sarcoma-bearing mice prolonged survival and reduced the magnitude of the serum amyloid P response, but failed to attenuate either tumor growth or serum HGF/interleukin-6 responses.	Indomethacin	172-184	interleukin 6	Mus musculus	13-26
3264498-2	1988	Elevated HGF/interleukin-6 concentrations were also positively correlated with increased serum concentrations of the hepatic acute phase reactant protein, amyloid P. Daily Indomethacin treatment of sarcoma-bearing mice prolonged survival and reduced the magnitude of the serum amyloid P response, but failed to attenuate either tumor growth or serum HGF/interleukin-6 responses.	Indomethacin	172-184	interleukin 6	Mus musculus	354-367
2967865-0	1988	Identification of IL-6 as a T cell-derived factor that enhances the proliferative response of thymocytes to IL-4 and phorbol myristate acetate.	Tetradecanoylphorbol Acetate	117-142	interleukin 6	Mus musculus	18-22
3264160-0	1988	Characterization of a recombinant murine interleukin-6: assignment of disulfide bonds.	Disulfides	70-79	interleukin 6	Mus musculus	41-54
3264160-4	1988	The two disulfide bridges in mIL-6 have been identified by Staphylococcus aureus V8 protease peptide mapping and Edman degradation of cystine-containing peptides.	Disulfides	8-17	interleukin 6	Mus musculus	29-34
3264160-4	1988	The two disulfide bridges in mIL-6 have been identified by Staphylococcus aureus V8 protease peptide mapping and Edman degradation of cystine-containing peptides.	Cystine	134-141	interleukin 6	Mus musculus	29-34
3305041-4	1987	It could be traced to a single component, which behaved like HP1 in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and reverse phase high performance liquid chromatography, and was completely inhibited by a rabbit anti-HP1 antiserum.	Sodium Dodecyl Sulfate	68-90	interleukin 6	Mus musculus	61-64
3260187-4	1988	The half-maximum tritiated thymidine uptake by MH60.BSF2 cells could be achieved by picogram amounts of rIL 6, making this hybridoma clone an indicator cell for specific and sensitive detection of the IL 6 activity in test samples.	Thymidine	27-36	interleukin 6	Mus musculus	105-109
3260187-7	1988	Both mAb specifically reacted with IL 6 as demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting analysis.	Sodium Dodecyl Sulfate	59-81	interleukin 6	Mus musculus	35-39
3260187-7	1988	Both mAb specifically reacted with IL 6 as demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting analysis.	polyacrylamide	82-96	interleukin 6	Mus musculus	35-39
3261378-4	1988	Dexamethasone (DEX), a potent inhibitor of macrophage IL-1, TNF and IL-6 synthesis, was utilized to analyze the endogenous mediators of SAA synthesis in mice injected with lipopolysaccharide (LPS).	Dexamethasone	0-13	interleukin 6	Mus musculus	68-72
3261378-4	1988	Dexamethasone (DEX), a potent inhibitor of macrophage IL-1, TNF and IL-6 synthesis, was utilized to analyze the endogenous mediators of SAA synthesis in mice injected with lipopolysaccharide (LPS).	Dexamethasone	15-18	interleukin 6	Mus musculus	68-72
2452746-6	1988	By contrast, in conjunction with interleukin 1, HP1 became a major growth and differentiation factor not only for B cells activated with anti-immunoglobulin antibodies but also for dextran sulfate-stimulated and even for unstimulated B cells.	Dextran Sulfate	181-196	interleukin 6	Mus musculus	48-51
3265877-3	1988	Our serial observations (mapping studies) of the development of blast cell colonies from spleen cells harvested from mice 4 days after the injection of 150 mg/kg 5-fluorouracil revealed that the blast cell colonies appeared earlier in culture in the presence of Il-6 and Il-3 than with either factor alone.	Fluorouracil	162-176	interleukin 6	Mus musculus	262-266
3305041-4	1987	It could be traced to a single component, which behaved like HP1 in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and reverse phase high performance liquid chromatography, and was completely inhibited by a rabbit anti-HP1 antiserum.	Sodium Dodecyl Sulfate	68-90	interleukin 6	Mus musculus	230-233
3305041-4	1987	It could be traced to a single component, which behaved like HP1 in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and reverse phase high performance liquid chromatography, and was completely inhibited by a rabbit anti-HP1 antiserum.	polyacrylamide gels	91-109	interleukin 6	Mus musculus	61-64
3305041-4	1987	It could be traced to a single component, which behaved like HP1 in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and reverse phase high performance liquid chromatography, and was completely inhibited by a rabbit anti-HP1 antiserum.	polyacrylamide gels	91-109	interleukin 6	Mus musculus	230-233
33845143-17	2021	Subsequent animal-based in vivo experiments revealed that JQP ameliorated symptoms and histological changes in DSS colitis by significantly impairing DSS"s ability to induce high expression levels of NF-kappaB/p65, IL-1beta, IL-6, and TNF-alpha.	dss	150-153	interleukin 6	Mus musculus	225-229
33957261-3	2021	Current results showed that PGG significantly inhibited secretions of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), interleukin-6 (IL-6) and mediator nitric oxide (NO) in LPS-stimulated RAW264.7 cells.	pentagalloylglucose	28-31	interleukin 6	Mus musculus	142-155
33957261-3	2021	Current results showed that PGG significantly inhibited secretions of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), interleukin-6 (IL-6) and mediator nitric oxide (NO) in LPS-stimulated RAW264.7 cells.	pentagalloylglucose	28-31	interleukin 6	Mus musculus	157-161
33957261-4	2021	In addition, the expression of genes nitric oxide synthase (iNOS), TNF-alpha, IL-1beta and IL-6 in LPS- stimulated RAW264.7 cells was reduced by PGG.	pentagalloylglucose	145-148	interleukin 6	Mus musculus	91-95
33898245-10	2021	Results: Repetitive injection of TH and/or R7050 reduced the symptoms of BD and significantly decreased IL-6, IL-1beta, and TNFalpha in blood sera.	Thorium	33-35	interleukin 6	Mus musculus	104-108
33898245-10	2021	Results: Repetitive injection of TH and/or R7050 reduced the symptoms of BD and significantly decreased IL-6, IL-1beta, and TNFalpha in blood sera.	R-7050	43-48	interleukin 6	Mus musculus	104-108
33831464-19	2021	The increased IL-6 and NO by the stimulation of LPS in RAW264.7 cells were significantly inhibited by FLA in the dosedependent manner.	fla	102-105	interleukin 6	Mus musculus	14-18
34007335-11	2021	Furthermore, treatment with miR-135a mimic and fluoxetine significantly reduced the CUMS-induced increase in the expression levels of inflammatory factors (IL-1beta, IL-6 and TNF-alpha) in the hippocampus of the mice.	mir-135a	28-36	interleukin 6	Mus musculus	166-170
33862517-8	2021	In addition, 13f significantly reduced the production of NO and IL-6 induced by LPS in BV2 cells, which confirmed its anti-inflammatory activity as a Nrf2 activator.	13F	13-16	interleukin 6	Mus musculus	64-68
34007335-11	2021	Furthermore, treatment with miR-135a mimic and fluoxetine significantly reduced the CUMS-induced increase in the expression levels of inflammatory factors (IL-1beta, IL-6 and TNF-alpha) in the hippocampus of the mice.	Fluoxetine	47-57	interleukin 6	Mus musculus	166-170
34055084-7	2021	At low and moderate doses, etomidate decreased pathological damage in the lung tissue, decreased the LIS and W/D ratio, upregulated Nrf2 and HO-1 mRNA and protein expression, decreased IL-1beta, IL-6, and TNF-alpha concentrations, increased MPO activity and IL-10 levels, suppressed the production of the oxidation product MDA, and enhanced the activities of the antioxidant enzymes CAT and SOD.	Etomidate	27-36	interleukin 6	Mus musculus	195-199
33892001-9	2021	Rotenone significantly increased the expression of IL-1beta, IL-6, and TNF-alpha levels in both cells.	Rotenone	0-8	interleukin 6	Mus musculus	61-65
33639371-11	2021	H2 treatment attenuated serum interleukin-6 and tumor necrosis factor-alpha levels at 24 h after CLP, and blood glucose levels were maintained in the H2-treated group.	Deuterium	0-2	interleukin 6	Mus musculus	30-43
33028985-4	2021	In lipopolysaccharides (LPS)-stimulated mouse bone marrow-derived macrophages (BMDMs), Tan-IIA (10 muM) significantly decreased succinate-boosted IL-1beta and IL-6 production, accompanied by upregulation of IL-1RA and IL-10 release via inhibiting succinate dehydrogenase (SDH).	Succinic Acid	128-137	interleukin 6	Mus musculus	159-163
33836343-5	2021	Prucalopride treatment also ameliorated intestinal barrier impairment and increased IL-6 release in PD model mice.	prucalopride	0-12	interleukin 6	Mus musculus	84-88
33757812-11	2021	RESULTS: (1) Network pharmacology analysis shows that QZLX alleviates psoriasis"s epidermal inflammation, and neovascularization may be achieved by inhibiting the IL6/STAT3 signaling pathway.	qzlx	54-58	interleukin 6	Mus musculus	163-166
33757812-13	2021	(3) QZLX inhibits the IL6/STAT3 signaling pathway and reduces the expression of IL-17, IL-23, and TNF-alpha related to inflammation in peripheral blood, as well as the expression of S100A7 in the lesion area.	qzlx	4-8	interleukin 6	Mus musculus	22-25
33836205-5	2021	Moreover, compound 11e markedly inhibited the expression of pro-inflammatory cytokines, including inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), and cyclooxygenase-2 (COX-2), in LPS-induced RAW 264.7 cells.	N-[(2-Amino-1,3-Benzothiazol-6-Yl)carbonyl]glycine	19-22	interleukin 6	Mus musculus	138-151
33836205-5	2021	Moreover, compound 11e markedly inhibited the expression of pro-inflammatory cytokines, including inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), and cyclooxygenase-2 (COX-2), in LPS-induced RAW 264.7 cells.	N-[(2-Amino-1,3-Benzothiazol-6-Yl)carbonyl]glycine	19-22	interleukin 6	Mus musculus	153-157
33512718-4	2021	The expression pattern of lincRNA-EPS is negatively correlated with the typical inflammatory genes such as IL-6, IL-1beta, CXCL1, and CXCL2.	lincrna-eps	26-37	interleukin 6	Mus musculus	107-111
33839416-7	2021	HDL-cholesterol increased 2-fold, serum cholesterol efflux capacity increased by ~30%, and the levels of MCP-1 and IL-6 were reduced with EG treatment of mice.	ethyl gallate	138-140	interleukin 6	Mus musculus	115-119
33677255-4	2021	The increases of inflammatory factors including tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-6 in the kidneys of LPS-treated mice or NRK-52E cells were inhibited by GA administration.	ginkgolide A	185-187	interleukin 6	Mus musculus	110-114
33401964-10	2021	LPS-induced IL-1beta, IL-6, and TNF-alpha increase both attenuated with CP 55,940 and ACEA treatments.	cp 55	72-77	interleukin 6	Mus musculus	22-26
33910373-7	2021	In addition, inhibition of lymphangiogenesis by MAZ51, a specific VEGFR3 (vascular endothelial cell growth factor receptor 3) inhibitor, resulted in enhanced inflammatory cell infiltration, gene expression of TNF (tumor necrosis factor)-alpha, IL (interleukin)-1beta, IL-6, TGF (transforming growth factor)-beta, angiostatin, vasohibin, and endostatin, and tissue edema, resulting in reduced angiogenesis.	MAZ51	48-53	interleukin 6	Mus musculus	268-272
32671618-5	2021	MP-10 inhibited nitric oxide, tumor necrosis factor alpha, and interleukin (IL)-6 production, while it promoted IL-10 production in lipopolysaccharide (LPS)-stimulated BV2 microglial cells.	2-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline	0-5	interleukin 6	Mus musculus	63-81
33401964-10	2021	LPS-induced IL-1beta, IL-6, and TNF-alpha increase both attenuated with CP 55,940 and ACEA treatments.	arachidonyl-2-chloroethylamide	86-90	interleukin 6	Mus musculus	22-26
33945919-13	2021	In HNEpCs, HG inhibited the histamine-induced mRNA expression and secretion of interleukin (IL)-6, and IL-8, as well as the expression of MUC5AC and the phosphorylation of NF-kappaB.	Histamine	28-37	interleukin 6	Mus musculus	79-97
33675462-8	2021	We found that UTBinh-14 significantly attenuated LPS-induced production of TNFalpha and IL-6 from BV2 cells, accompanied by reduced release of NO.	utbinh-14	14-23	interleukin 6	Mus musculus	88-92
34053236-8	2021	Pre- and post-treatment of mice with olaparib partly alleviated cecal ligation and puncture-induced organ injury by decreasing the amounts of the pro-inflammatory mediators TNF-alpha and IL-6 as well as bacterial burden in the serum, peritoneal lavage fluid, and organs (P < 0.05).	olaparib	37-45	interleukin 6	Mus musculus	187-191
34047943-6	2021	Melatonin was found to reduce both paw thickness and the inflammation index in the mouse model, and melatonin also reduced the mRNA levels of interleukin-1 beta (IL-1beta), IL-6 and NLR family pyrin domain containing 3 (NLRP3) inflammasome.	Melatonin	100-109	interleukin 6	Mus musculus	173-177
34047943-9	2021	The mRNA expression levels of IL-1beta and IL-6 were also inhibited by melatonin.	Melatonin	71-80	interleukin 6	Mus musculus	43-47
34052462-10	2021	CONCLUSION: We show for the first time that tofacitinib suppresses the expression level of JAK1/TNF-alpha/IL-6 by upregulating miR-149-5p level.	tofacitinib	44-55	interleukin 6	Mus musculus	106-110
34053448-9	2021	RESULTS: Baicalin improved lung function evidenced by reduction in inflammatory cell infiltration and Muc5AC, TNF-alpha, IL-6 and IL-8 levels observed in BALF in mice.	baicalin	9-17	interleukin 6	Mus musculus	121-125
34053448-10	2021	Baicalin was further observed to elevate cell viability while inhibited apoptosis and TNF-alpha, IL-6 and IL-8 levels in MLE-12 cells.	baicalin	0-8	interleukin 6	Mus musculus	97-101
34052195-12	2021	LPS-GalN induced an increase in the concentration of interleukin-6 in plasma and accumulation of neutrophils in liver.	lps-galn	0-8	interleukin 6	Mus musculus	53-66
34052462-11	2021	Our findings revealed the functional association between proinflammatory JAK1/TNF-alpha/IL-6 signaling and ACs development and highlight the therapeutic potential of tofacitinib in OA.	tofacitinib	166-177	interleukin 6	Mus musculus	88-92
34044723-12	2021	Q-3-R restored the total leukocyte counts and serum IL-6 levels, further supporting its role in promoting hematopoiesis.	Rutin	0-5	interleukin 6	Mus musculus	52-56
33993695-7	2021	EGCG markedly induced the production of cytokines and chemokines in macrophages and mouse peritoneal lavage, including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), IL-6, CXC chemokine ligands 1 and 2 (CXCL1 and 2), and monocyte chemotactic protein-1 (MCP-1).	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	191-195
34051206-7	2021	Using ELISA and commercial enzyme kits, we found that anemoside B4 decreased serum TNF-alpha, IL-6, and IL-1beta levels and increased CAT, SOD and GSH activities.	anemoside B4	54-66	interleukin 6	Mus musculus	94-98
34046717-9	2021	Moreover, OLZ-induced increases in serum interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha levels were improved by A. muciniphilasub in both obese and lean mice.	Olanzapine	10-13	interleukin 6	Mus musculus	41-59
34038497-7	2021	In addition, S-equol administration significantly decreased the levels of pro-inflammatory cytokines (tumor necrosis factor, interleukin-6, interleukin-10, interleukin-1beta), increased the levels of 5-hydroxytryptamine and norepinephrine, and normalized the release of tryptophan and kynurenine in the hippocampi of lipopolysaccharide-treated mice.	Equol	13-20	interleukin 6	Mus musculus	125-138
34022882-0	2021	Three chemotypes of thyme (Thymus vulgaris L.) essential oil and their main compounds affect differently the IL-6 and TNFalpha cytokine secretions of BV-2 microglia by modulating the NF-kappaB and C/EBPbeta signalling pathways.	Oils, Volatile	47-60	interleukin 6	Mus musculus	109-113
34028652-7	2021	Polyinosinic: polycytidylic acid (poly [I:C])-stimulated macrophage cells and 10-7 M 1,25 OH-vitamin D3 significantly decreased gene expression of ICAM1, TLR3, IL6, IL8, and TNFalpha (P < 0.0001).	Poly C	14-32	interleukin 6	Mus musculus	160-163
34028652-7	2021	Polyinosinic: polycytidylic acid (poly [I:C])-stimulated macrophage cells and 10-7 M 1,25 OH-vitamin D3 significantly decreased gene expression of ICAM1, TLR3, IL6, IL8, and TNFalpha (P < 0.0001).	Poly I-C	34-44	interleukin 6	Mus musculus	160-163
34028652-7	2021	Polyinosinic: polycytidylic acid (poly [I:C])-stimulated macrophage cells and 10-7 M 1,25 OH-vitamin D3 significantly decreased gene expression of ICAM1, TLR3, IL6, IL8, and TNFalpha (P < 0.0001).	1,25 oh-vitamin d3	85-103	interleukin 6	Mus musculus	160-163
34021860-9	2021	H2S pretreatment significantly attenuated LPS-induced apoptosis and inflammation by decreasing c-Jun and caspase-3 levels and inhibiting TNF-alpha and IL-6, respectively.	Deuterium	0-3	interleukin 6	Mus musculus	151-155
34040072-4	2021	EGCG treatment attenuated LPS-stimulated ALI in mice as manifested as improved lung injury scores, decreased total cell amounts, neutrophil amounts and macrophage amounts, inhibited the activity of MPO, decreased wet-to-dry weight ratio of lung tissues, and inhibited release of inflammatory cytokines TNF-alpha, IL-1beta, and IL-6.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	327-331
34028652-7	2021	Polyinosinic: polycytidylic acid (poly [I:C])-stimulated macrophage cells and 10-7 M 1,25 OH-vitamin D3 significantly decreased gene expression of ICAM1, TLR3, IL6, IL8, and TNFalpha (P < 0.0001).	polyinosinic	0-12	interleukin 6	Mus musculus	160-163
34022882-9	2021	Considering the changes of IL-6 and TNFalpha secretions the best reduction of inflammatory cytokines could be reached by the pretreatment with the essential oils.	Oils, Volatile	147-161	interleukin 6	Mus musculus	27-31
33722893-9	2021	RT-qPCR results showed that the relative gene expression of ZO-1, occludin, MyD88, IL-1beta, and IL-6 was decreased in fluconazole-treated group compared to the control.	Fluconazole	119-130	interleukin 6	Mus musculus	97-101
34029285-0	2021	IL-6 and IL-1beta upregulation and tau protein phosphorylation in response to chronic alcohol exposure in the mouse hippocampus.	Alcohols	86-93	interleukin 6	Mus musculus	0-4
34029285-9	2021	Our results showed that chronic alcohol exposure impaired the spatial recognition ability of mice upregulated the expression of IL-1beta and IL-6 in the serum and hippocampus and increased the phosphorylation of tau protein in the hippocampus.	Alcohols	32-39	interleukin 6	Mus musculus	141-145
34029285-11	2021	The present results indicate that hippocampal IL-1beta, IL-6, and phosphorylated tau proteins may be involved in the neurotoxic mechanism of chronic alcohol exposure by mediating synaptic dysfunction.	Alcohols	149-156	interleukin 6	Mus musculus	56-60
34008607-8	2021	In addition, treatment with PSPPs decreased the levels of IL-1beta, IL-6 and TNF-alpha but increased the level of IL-10 in the intestines of mice (p < 0.01).	pspps	28-33	interleukin 6	Mus musculus	68-72
34022666-7	2021	Administration of catalpol also suppressed production of prostaglandin D2 (PGD2), interleukin (IL)-6, and IL-13, while not affecting tumor necrosis factor (TNF)-alpha production.	catalpol	18-26	interleukin 6	Mus musculus	82-100
34023442-14	2021	RESULTS: Que treatment decreased the clinical score and left ankle thickness of CIA mice, attenuated the synovial inflammation and hyperplasia and bone/cartilage destruction in ankle joints, and decreased the secretion of IL-6, TNF-alpha, IL-1beta, IL-8, IL-13, and IL-17.	Quercetin	9-12	interleukin 6	Mus musculus	222-226
34008261-4	2021	Our results showed that baicalein treatment effectively reduced the levels of IL-6, TNF-alpha, PAI-1, and MMP-9 released by these cells upon stimulation with Ang II or ox-LDL.	baicalein	24-33	interleukin 6	Mus musculus	78-82
33999341-9	2021	Moreover, the miR-135b-5p inhibitor significantly reduced the CUMS-induced increase of the inflammatory factors IL-1beta, IL-6 and TNF-alpha in the hippocampal mouse samples, while significantly increasing the expression levels of SIRT1.	mir-135b-5p	14-25	interleukin 6	Mus musculus	122-126
33999341-9	2021	Moreover, the miR-135b-5p inhibitor significantly reduced the CUMS-induced increase of the inflammatory factors IL-1beta, IL-6 and TNF-alpha in the hippocampal mouse samples, while significantly increasing the expression levels of SIRT1.	cums	62-66	interleukin 6	Mus musculus	122-126
33713693-7	2021	We confirmed that 90- and 180-day ethanol exposure can lead to depressive-like mouse behavior, cell apoptosis, neuronal degeneration, a reduction in GluA1 and brain-derived neurotrophic factor (BDNF) expression, and an increase in IL-6 and IL-1beta in the mouse hippocampus.	Ethanol	34-41	interleukin 6	Mus musculus	231-235
33988779-6	2021	Both aloe-emodin and emodic-acid inhibited the secretion of the pro-tumorigenic cytokines IL-1beta and IL-6, and VEGF and MMP expression, and subsequently inhibited the invasive and migratory potential of 4T1 cells.	aloe emodin	5-16	interleukin 6	Mus musculus	103-107
33705800-8	2021	The effect of CurDDG correlated well with the inhibition of TNF-alpha and IL-6 levels in both the sciatic nerve and the spinal cord, as compared to its respective control groups.	curddg	14-20	interleukin 6	Mus musculus	74-78
33675782-3	2021	Treatment with resveratrol in macrophages stimulated with primary lipopolysaccharide (LPS) resulted in the increased production of TNF-alpha and IL-6 induced by a 2nd dose of LPS (by 74.5 +- 12.9% and 63.4 +- 12%, respectively, compared to untreated cells, P<0.05).	Resveratrol	15-26	interleukin 6	Mus musculus	145-149
33988779-6	2021	Both aloe-emodin and emodic-acid inhibited the secretion of the pro-tumorigenic cytokines IL-1beta and IL-6, and VEGF and MMP expression, and subsequently inhibited the invasive and migratory potential of 4T1 cells.	Emodic acid	21-32	interleukin 6	Mus musculus	103-107
34054527-9	2021	LIQ treatment also reduced mRNA expression of TNFalpha, IL-6 and IL-1beta, inhibited inflammatory cell migration, suppressed cardiac oxidative stress and apoptosis, and improved metabolism.	liquiritin	0-3	interleukin 6	Mus musculus	56-60
33992630-3	2021	Treatment with cynandione A and the specific alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist PHA-543613 remarkably reduced overexpression of proinflammatory cytokines, including tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta in lipopolysaccharide (LPS)-treated RAW264.7 cells and primary peritoneal macrophages, and endotoxemic mice.	cynandione A	15-27	interleukin 6	Mus musculus	228-246
33268669-5	2021	The spleen organ index of dams was significantly lower and the offspring serum interleukin-6 levels were significantly higher in ceftriaxone-treated mice compared with the control group.	Ceftriaxone	129-140	interleukin 6	Mus musculus	79-92
33705800-9	2021	Similarly, in the in vitro study, CurDDG significantly reduced the LPS-induced expression of TNF-alpha and IL-6.	curddg	34-40	interleukin 6	Mus musculus	107-111
33980987-7	2021	Microglia from tau knockout mice took up tau and p-tau when treated with sevoflurane-conditioned neuron culture medium, leading to IL-6 generation.	Sevoflurane	73-84	interleukin 6	Mus musculus	131-135
33508366-17	2021	HA and CPO decreased INF-gamma, IL-1beta, IL-6, IL-10, and TNF-alpha at 24 and 72 h in the multi-spot system.	cpo	7-10	interleukin 6	Mus musculus	42-46
34012288-15	2021	Moreover, punicalagin (50mg/kg/d) alleviated arthritis severity and bone destruction, and decreased serum IL-6 and TNF-alpha in CIA mice.	punicalagin	10-21	interleukin 6	Mus musculus	106-110
34045963-10	2021	Our experimental results indicated that zerumbone inhibited the production of NO, PGE2 and IL-6, suppressed the expression of iNOS and COX-2, repressed the phosphorylation of ERK, and decreased the activity of NF-kappaB in LPS-activated J774A.1 cells.	zerumbone	40-49	interleukin 6	Mus musculus	91-95
33975617-11	2021	In addition, sitagliptin reduced the activation of NF-kappaB signaling pathway and inhibited the expression of iNOS, IL-1beta, IL-6 and the proinflammatory DAM subset gene CD44.	Sitagliptin Phosphate	13-24	interleukin 6	Mus musculus	127-131
33969534-8	2022	In addition, thiazolidinediones caused a significant (p < 0.05) downregulation of the mRNA expression of adra2a,bsn,col15a1,fosl1,Il6,bpifa1,plau, and reg3b genes.	Thiazolidinediones	13-31	interleukin 6	Mus musculus	130-133
34035824-5	2021	Additionally, AME supplementation diminished the ethanol diet-induced hepatic leukocyte infiltration and expressions of IL-6 and TNFalpha.	ame	14-17	interleukin 6	Mus musculus	120-124
34035824-5	2021	Additionally, AME supplementation diminished the ethanol diet-induced hepatic leukocyte infiltration and expressions of IL-6 and TNFalpha.	Ethanol	49-56	interleukin 6	Mus musculus	120-124
33956815-0	2021	Combination treatment of dendrosomal nanocurcumin and low-level laser therapy develops proliferation and migration of mouse embryonic fibroblasts and alter TGF-beta, VEGF, TNF-alpha and IL-6 expressions involved in wound healing process.	nanocurcumin	37-49	interleukin 6	Mus musculus	186-190
33979652-10	2021	Most importantly, RS102895, an antagonist of CCR2, diminished chemotaxis of macrophages and inhibited colitis in Il6-/- mice.	RS 102895	18-26	interleukin 6	Mus musculus	113-116
34025642-6	2021	Meanwhile we proved that hyperforin suppressed infiltration of CD3+ T cells and downregulated expression of Il1, Il6, Il23, Il17a, Il22, antimicrobial peptides (AMPs) in the skin lesion.	hyperforin	25-35	interleukin 6	Mus musculus	113-116
33949204-10	2021	p55PIK deficiency and TAT-N15 significantly inhibited lung inflammatory infiltration, reduced levels of IL-6, KC in mice lung homogenate, and inhibited activation of the Akt and the NF-kappaB signaling in COPD mice lungs.	tat-n15	22-29	interleukin 6	Mus musculus	104-108
34025639-6	2021	The elevated disease activity index and histological score of colon as well as the up-regulated mRNA and protein levels of TNF-alpha, IL-1beta, and IL-6 in the colonic tissue of CPT-11-treated mice were significantly decreased by TFGU.	Irinotecan	178-184	interleukin 6	Mus musculus	148-152
33951335-8	2021	Interestingly, CS and its analogues exhibited stronger inhibitive effects on muscle atrophy induced by tumour necrosis factor-alpha (TNF-alpha) (CS, P < 0.001; DCS, P < 0.001; DCSD, P < 0.001) in C2C12 myoblasts than on muscle atrophy induced by IL-6 (CS, P < 0.05; DCS, P = 0.08; DCSD, P < 0.05).	carnosol	15-17	interleukin 6	Mus musculus	246-250
34025642-7	2021	Hyperforin significantly inhibited imiquimod-induced splenomegaly, reduced serum levels of TNF-alpha and IL-6, and IL-17A in splenocytes and draining lymph nodes.	hyperforin	0-10	interleukin 6	Mus musculus	105-109
33976540-7	2021	Silymarin treatment also increased the SOD, CAT, GSH, GSH-Px, T-AOC, IL-10, and IL-12 levels, as well as reduced the MDA, NO, IL-6, IL-1beta, TNF-alpha, IFN-gamma levels in the mouse serum and liver tissues.	Silymarin	0-9	interleukin 6	Mus musculus	126-130
33369105-7	2021	In lung tissues, NaHS prevented the elevation of IL-1beta level at 1000muM, and IL-6 and TNF-alpha levels at 100muM concentrations.	sodium bisulfide	17-21	interleukin 6	Mus musculus	80-84
33947424-9	2021	These results suggest that metformin treatment has anti-inflammatory effects on lymphocytes via the inhibition of IL-17 and cytokines related to Th17 differentiation, such as IL-1beta, IL-6, and TNF-alpha.	Metformin	27-36	interleukin 6	Mus musculus	185-189
33731332-9	2021	Blocking inflammation, with either mycophenolate mofetil or by reducing IL-6 levels with a neutralizing anti-IL-6 antibody, prevented the development of salt sensitivity in male db/db mice.	Salts	153-157	interleukin 6	Mus musculus	72-76
33731332-9	2021	Blocking inflammation, with either mycophenolate mofetil or by reducing IL-6 levels with a neutralizing anti-IL-6 antibody, prevented the development of salt sensitivity in male db/db mice.	Salts	153-157	interleukin 6	Mus musculus	109-113
33957479-8	2021	Furthermore, inhibiting the activity of the IRE-1alpha/XBP-1s pathway by STF-083010 significantly mitigated the increased levels of IL-1beta, TNF-alpha, and IL-6 in macrophages treated by the anti-TREM-1 antibody.	STF 083010	73-83	interleukin 6	Mus musculus	157-161
33485121-6	2021	BPA further induced inflammatory responses by upregulating the gene abundance of key factors of the innate immune system (TLR2, TLR4, MyD88, and NF-kappaB), the transcriptional activity of NF-kB, and the secretion of pro-inflammatory cytokines (IL-1beta, IL-6, IL-8, and TNF-alpha).	bisphenol A	0-3	interleukin 6	Mus musculus	255-259
33369105-8	2021	Incubation with GYY4137 (100microM) and AP39 (30nM and 300nM) inhibited the increase in IL-6 and TNF-alpha levels, but not IL-1beta at concentrations that they affected tracheal hyperreactivity.	GYY 4137	16-23	interleukin 6	Mus musculus	88-92
33736212-5	2021	Elevated levels of inflammatory cytokines tumor necrosis factor-alpha and interleukin-6 of the kidney further suggested inflammatory status as a result of phthalate exposure in both high dose groups.	phthalic acid	155-164	interleukin 6	Mus musculus	74-87
33556877-14	2021	The DOX + APG groups had much lower tissue MDA, IL-6, TNF-alpha, NLRP3, caspase-1, and IL-1beta levels and generation of intracellular ROS, but significantly higher SOD activity and GSH levels compared to those of the DOX group.	Doxorubicin	4-7	interleukin 6	Mus musculus	48-52
33556877-14	2021	The DOX + APG groups had much lower tissue MDA, IL-6, TNF-alpha, NLRP3, caspase-1, and IL-1beta levels and generation of intracellular ROS, but significantly higher SOD activity and GSH levels compared to those of the DOX group.	Apigenin	10-13	interleukin 6	Mus musculus	48-52
33561536-8	2021	GEN treatment also regulated microglia polarization towards anti-inflammatory phenotype M2 and inhibited the production of pro-inflammatory cytokines IL-6 and TNF-alpha.	geniposide	0-3	interleukin 6	Mus musculus	150-154
33652342-2	2021	Compounds 5r-5u (2.04, 2.50, 3.25 and 2.48 muM, respectively) with acidic or neutral amino acid showed potent anti-inflammatory activity (IC50 = 2-3 muM for NO inhibition), amongst them, compound 5r also inhibited tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in a dose-dependent manner.	5r-5u	10-15	interleukin 6	Mus musculus	258-271
33652342-2	2021	Compounds 5r-5u (2.04, 2.50, 3.25 and 2.48 muM, respectively) with acidic or neutral amino acid showed potent anti-inflammatory activity (IC50 = 2-3 muM for NO inhibition), amongst them, compound 5r also inhibited tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in a dose-dependent manner.	5r-5u	10-15	interleukin 6	Mus musculus	273-277
33347706-10	2021	Dieckol also diminished the pro-inflammatory modulators like IL-6, IL-1beta and TNF-alpha.	dieckol	0-7	interleukin 6	Mus musculus	61-65
32447612-0	2021	Alcohol alters IL-6 Signal Transduction in the CNS of Transgenic Mice with Increased Astrocyte Expression of IL-6.	Alcohols	0-7	interleukin 6	Mus musculus	15-19
32447612-0	2021	Alcohol alters IL-6 Signal Transduction in the CNS of Transgenic Mice with Increased Astrocyte Expression of IL-6.	Alcohols	0-7	interleukin 6	Mus musculus	109-113
32447612-2	2021	Elevated expression of IL-6 occurs in the CNS in a variety of disorders associated with altered CNS function, including excessive alcohol use.	Alcohols	130-137	interleukin 6	Mus musculus	23-27
32447612-3	2021	Alcohol-induced production of IL-6 has been reported for several CNS regions including the cerebellum.	Alcohols	0-7	interleukin 6	Mus musculus	30-34
32447612-6	2021	Thus, alcohol-induced IL-6 production could contribute to cerebellar effects of alcohol by altering gene expression, especially under conditions of chronic alcohol abuse, where IL-6 levels could be habitually elevated.	Alcohols	6-13	interleukin 6	Mus musculus	22-26
32447612-6	2021	Thus, alcohol-induced IL-6 production could contribute to cerebellar effects of alcohol by altering gene expression, especially under conditions of chronic alcohol abuse, where IL-6 levels could be habitually elevated.	Alcohols	6-13	interleukin 6	Mus musculus	177-181
32447612-6	2021	Thus, alcohol-induced IL-6 production could contribute to cerebellar effects of alcohol by altering gene expression, especially under conditions of chronic alcohol abuse, where IL-6 levels could be habitually elevated.	Alcohols	80-87	interleukin 6	Mus musculus	22-26
32447612-9	2021	Results show that the both IL-6 and chronic intermittent alcohol exposure/withdrawal affect IL-6 signal transduction partners and that the actions of IL-6 and alcohol interact to alter activation/expression of IL-6 signal transduction partners.	Alcohols	57-64	interleukin 6	Mus musculus	92-96
32447612-9	2021	Results show that the both IL-6 and chronic intermittent alcohol exposure/withdrawal affect IL-6 signal transduction partners and that the actions of IL-6 and alcohol interact to alter activation/expression of IL-6 signal transduction partners.	Alcohols	57-64	interleukin 6	Mus musculus	92-96
32447612-9	2021	Results show that the both IL-6 and chronic intermittent alcohol exposure/withdrawal affect IL-6 signal transduction partners and that the actions of IL-6 and alcohol interact to alter activation/expression of IL-6 signal transduction partners.	Alcohols	57-64	interleukin 6	Mus musculus	92-96
32447612-9	2021	Results show that the both IL-6 and chronic intermittent alcohol exposure/withdrawal affect IL-6 signal transduction partners and that the actions of IL-6 and alcohol interact to alter activation/expression of IL-6 signal transduction partners.	Alcohols	159-166	interleukin 6	Mus musculus	27-31
32447612-10	2021	The alcohol/IL-6 interactions may contribute to cerebellar actions of alcohol, whereas the effects of IL-6 alone may have relevance to cerebellar changes occurring in CNS disorders associated with elevated levels of IL-6.	Alcohols	70-77	interleukin 6	Mus musculus	12-16
33648941-8	2021	In an acute UV induced skin damage and inflammation mouse model using a single irradiation of 300 mJ/cm2 UV, topical treatment with R-carvedilol dose-dependently attenuated skin edema and reduced epidermal thickening, Ki-67 staining, COX-2 protein, IL-6 and IL-1beta mRNA levels similar to carvedilol.	Carvedilol	132-144	interleukin 6	Mus musculus	249-253
33648941-8	2021	In an acute UV induced skin damage and inflammation mouse model using a single irradiation of 300 mJ/cm2 UV, topical treatment with R-carvedilol dose-dependently attenuated skin edema and reduced epidermal thickening, Ki-67 staining, COX-2 protein, IL-6 and IL-1beta mRNA levels similar to carvedilol.	Carvedilol	134-144	interleukin 6	Mus musculus	249-253
33450110-10	2021	Furthermore, cytokine analysis revealed significantly less IL-6 and significantly greater anti-inflammatory IL-10 in skin of curc-np-treated mice as compared to controls.	curc-np	125-132	interleukin 6	Mus musculus	59-63
33877377-6	2021	RESULTS: Glycine decreased the expression and concentration of TNF-alpha and IL-6; this effect did not occur in the absence of TNF-alpha receptor due to siRNA.	Glycine	9-16	interleukin 6	Mus musculus	77-81
33747183-9	2021	Magnolol activated peroxisome proliferator-activated receptor-gamma, and also significantly inhibited the protein expression of interleukin (IL)-23, IL-1beta, IL-6, tumor necrosis factor-alpha and interferon-gamma.	magnolol	0-8	interleukin 6	Mus musculus	159-163
33945874-7	2021	Histological analysis revealed that following the administration of NB-DHA in mice with colitis, the infiltration of inflammatory cells and levels of proinflammatory factors, such as tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and myeloperoxidase, decreased, whereas the level of the anti-inflammatory factor IL-10 increased.	nb-dha	68-74	interleukin 6	Mus musculus	236-240
33747168-5	2021	EAFM significantly inhibited the expression of inflammatory factors including NO, IL-6 and TNF-alpha at non-toxic concentrations.	eafm	0-4	interleukin 6	Mus musculus	82-86
33877377-7	2021	In contrast, glycine produced only slight changes in the expression of TNF-alpha and IL-6 in the absence of the glycine receptor due to siRNA.	Glycine	13-20	interleukin 6	Mus musculus	85-89
33834616-10	2021	More importantly, an in vivo study demonstrated that pre-treatment with GW4869 decreased lung fibrosis and the expression of TNF-alpha, IL-1beta and IL-6 in BALF.	GW 4869	72-78	interleukin 6	Mus musculus	149-153
33760144-15	2021	LY294002 pre-treatment also significantly downregulated the TNF-alpha, IL-6 and IL-8 protein levels.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	interleukin 6	Mus musculus	71-75
34016718-12	2021	CONCLUSION: SOCS3 expressed in podocytes plays protective roles for the development of glomerulonephritis and inhibits autoantibody production in the imiquimod-induced lupus model presumably by suppressing IL-6 production of podocytes.	Imiquimod	150-159	interleukin 6	Mus musculus	206-210
33200254-7	2021	We demonstrate that gene-targeting of either TNFalpha, IL-6 or IL-1 or treatment with etanercept, a TNFalpha inhibitor, or a neutralizing antibody against IL-6 can antagonize ONJ development caused by combined tooth extraction and zoledronate treatment.	Zoledronic Acid	231-242	interleukin 6	Mus musculus	155-159
33657463-4	2021	Attenuated secretion of IL-6 and IL-10 were observed 48 h postincubation in the bone marrow-derived macrophages (BMDMs) treated with the FPR2 antagonist WRW4.	WRW4	153-157	interleukin 6	Mus musculus	24-28
33844304-10	2021	Together, farrerol also suppressed the pro-inflammatory cytokines TNF-alpha, IL-6, and IL-1beta.	farrerol	10-18	interleukin 6	Mus musculus	77-81
34025136-7	2021	Rg3-KRGE repressed increases of proinflammatory transcripts cyclooxygenase-2, inducible nitric oxide synthase, interleukin (IL)-1 beta, IL-6, and tumor necrosis factor-alpha, but enhanced expression levels of anti-inflammatory transcripts arginase-1 and IL-10 in the spinal cord following EAE induction.	ginsenoside Rg3	0-3	interleukin 6	Mus musculus	136-140
31198052-5	2021	Furthermore, the increase of pro-inflammatory cytokines TNF-alpha, IL-1beta, IL-6 and IL-18 levels were significantly suppressed by isostrictiniin pretreatment compared with model group (P &lt; 0.05).	isostrictiniin	132-146	interleukin 6	Mus musculus	77-81
33760163-10	2021	In conclusion, the findings of the present study suggested that in a D-GalN/LPS-induced ALF model, TNF-alpha and IL-6 signaling may increase MLCK and ROCK expression levels, further mediate phosphorylation of MLC, which may result in tight junction dysregulation and intestinal barrier dysfunction.	Galactosamine	69-75	interleukin 6	Mus musculus	113-117
33116044-10	2021	In addition, the clinical-mimicking dose of sirolimus reduced the thickness of the intestinal mucosal layer, increased the intestinal permeability, and enriched the circulating pro-inflammatory factors, including IL-12, IL-6, MCP-1, GM-CSF, and IL-1beta.	Sirolimus	44-53	interleukin 6	Mus musculus	220-224
33932312-7	2021	In addition, gamma-oryzanol inhibited TGF-beta-Smad-NADPH oxidase 4 pathway and inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6, and p65 NF-kappaB subunit, which cause skeletal muscle weakness.	gamma-oryzanol	13-27	interleukin 6	Mus musculus	136-140
34007853-8	2021	UA alleviated UC inflammation and lowered serum and colon IL-6 levels.	ursolic acid	0-2	interleukin 6	Mus musculus	58-62
34007853-9	2021	Three classical inflammatory pathways: MAPKs, IL-6/STAT3, and PI3K were downregulated by UA treatment.	ursolic acid	89-91	interleukin 6	Mus musculus	46-50
33749143-7	2021	Pro-inflammatory factors, such as interleukin (IL)-1beta, IL-6, monocyte chemoattractant protein (MCP)-1, and tumor necrosis factor (TNF)-alpha were significantly decreased in AMM/T injected CIA mice compared with their AMM injected counterparts.	AMM	176-179	interleukin 6	Mus musculus	58-62
34012471-4	2021	Our data indicated that Mog significantly inhibited the LPS-induced production of proinflammatory factors, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-18, IL-6, cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and high mobility group box 1 (HMGB1) in BV-2 cells.	mogroside V	24-27	interleukin 6	Mus musculus	193-197
33987030-10	2021	Results: We found the inductive effects of LPS on liver IL-6 mRNA expression to be more pronounced under parenteral iron loading.	Iron	116-120	interleukin 6	Mus musculus	56-60
33947113-3	2021	In RAW 264.7 cells, treatment with cardamonin showed a reduced nitrous oxide production without affecting the cell viability and decreased the expression of iNOS, TNF-alpha, and IL-6, and inhibited NF-kB signaling which emphasizes the role of cardamonin as an anti-inflammatory molecule.	cardamonin	35-45	interleukin 6	Mus musculus	178-182
33997008-7	2021	Besides, the F-EO, L-EO, and S-EO significantly inhibited the production of proinflammatory mediator nitric oxide (NO) (93.15-94.72%) and cytokines interleukin-6 (IL-6) (23.99-77.81%) and tumor necrosis factor-alpha (TNF-alpha) (17.69-24.93%) in LPS-stimulated RAW264.7 cells at the dose of 128 mug/mL in the absence of cytotoxicity.	f-eo	13-17	interleukin 6	Mus musculus	148-161
33997008-7	2021	Besides, the F-EO, L-EO, and S-EO significantly inhibited the production of proinflammatory mediator nitric oxide (NO) (93.15-94.72%) and cytokines interleukin-6 (IL-6) (23.99-77.81%) and tumor necrosis factor-alpha (TNF-alpha) (17.69-24.93%) in LPS-stimulated RAW264.7 cells at the dose of 128 mug/mL in the absence of cytotoxicity.	f-eo	13-17	interleukin 6	Mus musculus	163-167
33997008-7	2021	Besides, the F-EO, L-EO, and S-EO significantly inhibited the production of proinflammatory mediator nitric oxide (NO) (93.15-94.72%) and cytokines interleukin-6 (IL-6) (23.99-77.81%) and tumor necrosis factor-alpha (TNF-alpha) (17.69-24.93%) in LPS-stimulated RAW264.7 cells at the dose of 128 mug/mL in the absence of cytotoxicity.	l-eo	19-23	interleukin 6	Mus musculus	148-161
33997008-7	2021	Besides, the F-EO, L-EO, and S-EO significantly inhibited the production of proinflammatory mediator nitric oxide (NO) (93.15-94.72%) and cytokines interleukin-6 (IL-6) (23.99-77.81%) and tumor necrosis factor-alpha (TNF-alpha) (17.69-24.93%) in LPS-stimulated RAW264.7 cells at the dose of 128 mug/mL in the absence of cytotoxicity.	l-eo	19-23	interleukin 6	Mus musculus	163-167
33997008-7	2021	Besides, the F-EO, L-EO, and S-EO significantly inhibited the production of proinflammatory mediator nitric oxide (NO) (93.15-94.72%) and cytokines interleukin-6 (IL-6) (23.99-77.81%) and tumor necrosis factor-alpha (TNF-alpha) (17.69-24.93%) in LPS-stimulated RAW264.7 cells at the dose of 128 mug/mL in the absence of cytotoxicity.	s-eo	29-33	interleukin 6	Mus musculus	148-161
33997008-7	2021	Besides, the F-EO, L-EO, and S-EO significantly inhibited the production of proinflammatory mediator nitric oxide (NO) (93.15-94.72%) and cytokines interleukin-6 (IL-6) (23.99-77.81%) and tumor necrosis factor-alpha (TNF-alpha) (17.69-24.93%) in LPS-stimulated RAW264.7 cells at the dose of 128 mug/mL in the absence of cytotoxicity.	s-eo	29-33	interleukin 6	Mus musculus	163-167
33911101-7	2021	Topical application of SHR168442 in Vaseline exhibited excellent efficacy in the imiquimod-induced and IL-23-induced psoriasis-like skin inflammation mouse models and correlated with the reduction of Th17 pathway cytokines, IL-6, TNFalpha and IL-17A.	SCHEMBL23000454	23-32	interleukin 6	Mus musculus	224-228
33711354-7	2021	Treatment with IC-87114 or AMG319 after TDI exposure led to significantly decreased airway hyperresponsiveness (AHR), less neutrophil and eosinophil accumulation, attenuated airway smooth muscle (ASM) thickening, less M1 and M2 macrophages in lung, as well as lower levels of IL-4, IL-5, IL-6 and IL-18 in bronchoalveolar lavage fluid (BALF) and recovered IL-10 production.	IC 87114	15-23	interleukin 6	Mus musculus	288-292
33711354-7	2021	Treatment with IC-87114 or AMG319 after TDI exposure led to significantly decreased airway hyperresponsiveness (AHR), less neutrophil and eosinophil accumulation, attenuated airway smooth muscle (ASM) thickening, less M1 and M2 macrophages in lung, as well as lower levels of IL-4, IL-5, IL-6 and IL-18 in bronchoalveolar lavage fluid (BALF) and recovered IL-10 production.	N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine	27-33	interleukin 6	Mus musculus	288-292
33711354-8	2021	While mice treated with AS252424 or AS605240 had increased AHR, more severe ASM thickening, larger numbers of neutrophils and eosinophils, more M1 but less M2 macrophages, and higher BALF levels of IL-4, IL-5, IL-6, IL-10, IL-12, IL-18 when compared with those treated with vehicle.	5-(5-(4-fluoro-2-hydroxyphenyl)furan-2-ylmethylene)thiazolidine-2,4-dione	24-32	interleukin 6	Mus musculus	210-214
33711354-8	2021	While mice treated with AS252424 or AS605240 had increased AHR, more severe ASM thickening, larger numbers of neutrophils and eosinophils, more M1 but less M2 macrophages, and higher BALF levels of IL-4, IL-5, IL-6, IL-10, IL-12, IL-18 when compared with those treated with vehicle.	5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione	36-44	interleukin 6	Mus musculus	210-214
33908449-7	2021	The immune system was significantly activated by docetaxel (DTX)-loaded NPs after SDT treatment due to the enhanced secretion of IFN-gamma, TNF-alpha, IL-2 and IL-6 cytokines and tumor-infiltrating CD4+ and CD8+ T cell contents.	Docetaxel	49-58	interleukin 6	Mus musculus	160-164
33908449-7	2021	The immune system was significantly activated by docetaxel (DTX)-loaded NPs after SDT treatment due to the enhanced secretion of IFN-gamma, TNF-alpha, IL-2 and IL-6 cytokines and tumor-infiltrating CD4+ and CD8+ T cell contents.	Docetaxel	60-63	interleukin 6	Mus musculus	160-164
33927358-7	2021	We demonstrated that co-administration of GA ameliorated 5-FU-induced peripheral muscle fatigue-like behavior via improving muscle quality and mitochondria function, increasing glycogen content and ATP production, reducing lactic acid content and LDH activity, and inhibiting p-AMPK, IL-6 and TNF-alpha expression in skeletal muscle.	ganoderic acid	42-44	interleukin 6	Mus musculus	284-288
33927358-7	2021	We demonstrated that co-administration of GA ameliorated 5-FU-induced peripheral muscle fatigue-like behavior via improving muscle quality and mitochondria function, increasing glycogen content and ATP production, reducing lactic acid content and LDH activity, and inhibiting p-AMPK, IL-6 and TNF-alpha expression in skeletal muscle.	Fluorouracil	57-61	interleukin 6	Mus musculus	284-288
33927358-8	2021	Co-administration of GA also retarded the 5-FU-induced central fatigue-like behavior accompanied by down-regulating the expression of IL-6, iNOS and COX2 in the hippocampus through inhibiting TLR4/Myd88/NF-kappaB pathway.	ganoderic acid	21-23	interleukin 6	Mus musculus	134-138
33927358-8	2021	Co-administration of GA also retarded the 5-FU-induced central fatigue-like behavior accompanied by down-regulating the expression of IL-6, iNOS and COX2 in the hippocampus through inhibiting TLR4/Myd88/NF-kappaB pathway.	Fluorouracil	42-46	interleukin 6	Mus musculus	134-138
33911101-7	2021	Topical application of SHR168442 in Vaseline exhibited excellent efficacy in the imiquimod-induced and IL-23-induced psoriasis-like skin inflammation mouse models and correlated with the reduction of Th17 pathway cytokines, IL-6, TNFalpha and IL-17A.	Petrolatum	36-44	interleukin 6	Mus musculus	224-228
33925479-10	2021	In mechanistic terms, H2S attenuated IL-6 induced a pathological VSMC phenotypical switch through NO modulation by N(G)-monomethyl-L-arginine acetate salt (L-NMMA) stimulation.	Deuterium	22-25	interleukin 6	Mus musculus	37-41
33995381-10	2021	Interleukin 6 (IL-6) was lower in the ibuprofen group as compared to the treated control, EPA/DHA and untreated control groups at 4 days PT (p = 0.019, p = 0.019 and p = 0.002, respectively).	Ibuprofen	38-47	interleukin 6	Mus musculus	0-13
33995381-10	2021	Interleukin 6 (IL-6) was lower in the ibuprofen group as compared to the treated control, EPA/DHA and untreated control groups at 4 days PT (p = 0.019, p = 0.019 and p = 0.002, respectively).	Ibuprofen	38-47	interleukin 6	Mus musculus	15-19
33995381-10	2021	Interleukin 6 (IL-6) was lower in the ibuprofen group as compared to the treated control, EPA/DHA and untreated control groups at 4 days PT (p = 0.019, p = 0.019 and p = 0.002, respectively).	dehydroacetic acid	94-97	interleukin 6	Mus musculus	0-13
33909081-8	2021	Additionally, Xanthohumol increased superoxide dismutase level and reduced Interleukin-6 and Interleukin-1beta levels both in serum and hippocampus.	xanthohumol	14-25	interleukin 6	Mus musculus	75-88
33925479-10	2021	In mechanistic terms, H2S attenuated IL-6 induced a pathological VSMC phenotypical switch through NO modulation by N(G)-monomethyl-L-arginine acetate salt (L-NMMA) stimulation.	n(g)-monomethyl-l-arginine acetate salt	115-154	interleukin 6	Mus musculus	37-41
33925479-10	2021	In mechanistic terms, H2S attenuated IL-6 induced a pathological VSMC phenotypical switch through NO modulation by N(G)-monomethyl-L-arginine acetate salt (L-NMMA) stimulation.	omega-N-Methylarginine	156-162	interleukin 6	Mus musculus	37-41
33948087-8	2021	Importantly, hyperglycemia-induced renal inflammation evidenced by NF-kappaB activation and TNFalpha and IL-6 overexpression was greatly ameliorated with LG4 treatment.	2-Amino-5-methylpyridine	154-157	interleukin 6	Mus musculus	105-109
33915494-7	2021	Juglone treatment significantly inhibited the protein levels of IL-6, TNF-alpha and IL-1beta, improved the protein expression of IL-10.	juglone	0-7	interleukin 6	Mus musculus	64-68
33915494-9	2021	Juglone treatment also inhibited the protein expressions of IL-6, STAT3 and RORgammat, meanwhile improved the protein level of FOXP3.	juglone	0-7	interleukin 6	Mus musculus	60-64
33926126-6	2021	Dt-EE clearly and dose-dependently inhibited the expression of pro-inflammatory cytokines such as IL-6, TNF-alpha, and IL-1beta in lipopolysaccharide (LPS)-treated RAW264.7 cells.	dt-ee	0-5	interleukin 6	Mus musculus	98-102
33923336-11	2021	Crassolide after LPS stimulation suppressed DC maturation and secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-12 and IL-23, and downstream T cell activation.	crassolide	0-10	interleukin 6	Mus musculus	110-128
33899584-15	2021	The serum levels of IL-6, TNF-alpha, and IL-1beta in the PD + Abx group were higher than those of the Con group (P < 0.05).	CHEMBL369125	62-65	interleukin 6	Mus musculus	20-24
33968046-7	2021	In streptozotocin-induced diabetic mice, inhibition of CCL4 controlled blood sugar, increased serum insulin levels, increased islet cell proliferation and decreased pancreatic interleukin (IL)-6 expression.	Streptozocin	3-17	interleukin 6	Mus musculus	176-194
33893687-8	2021	In animal study, PA-treated mice showed reduced intravesical IL-1, IL-6 levels, and lactate dehydrogenase content, downregulated TNF-alpha and upregulated TP53 proteins in bladder samples.	pachymic acid	17-19	interleukin 6	Mus musculus	67-71
33892139-6	2021	High molecular weight (HMW) poly I:C (1-6kb, 12 mg/kg) produced more robust sickness behavior and more robust IL-6, IFN-I and TNF-alpha responses than poly I:C of <500 bases (low MW) preparations.	Poly I-C	28-36	interleukin 6	Mus musculus	110-114
33976703-6	2021	In LPS-challenged cells, pretreatment with NJ20 inhibited the LPS-induced excessive production of proinflammatory mediators, such as nitric oxide, prostaglandin E2, interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor-alpha.	nj20	43-47	interleukin 6	Mus musculus	191-195
33878733-7	2021	WS-fed mice showed a decrease in malondialdehyde and an increase in superoxide dismutase levels in the brain; additionally, IL-6 and TNF-alpha levels significantly decreased, whereas IL-2 levels and the proportion of lymphocytes, CD3+CD8+ T, and CD4+IFNgamma+T cells increased in WS-fed mice.	H-TRP-SER-OH	0-2	interleukin 6	Mus musculus	124-128
33892139-8	2021	In aged animals, poly I:C induced exaggerated IL-6, IL-1beta and IFN-I in the plasma and similar exaggerated brain cytokine responses.	Poly I-C	17-25	interleukin 6	Mus musculus	46-50
33968024-4	2021	Furthermore, we found that pathological concentration of CDCA could significantly inhibited IL-6 expression in RAW 264.7 cells after LPS stimulation.	Chenodeoxycholic Acid	57-61	interleukin 6	Mus musculus	92-96
33968024-5	2021	Since CDCA is a well-known natural high-affinity ligand for the bile acid receptor farnesoid-x-receptor (FXR) while GW4064 is the synthetic specific agonist of this receptor, we then revealed that GW4064 significantly decreased IL-6 expression in RAW 264.7 cells and bone marrow-derived macrophages but not in FXR-/- macrophages upon LPS stimulation.	Chenodeoxycholic Acid	6-10	interleukin 6	Mus musculus	228-232
33968024-5	2021	Since CDCA is a well-known natural high-affinity ligand for the bile acid receptor farnesoid-x-receptor (FXR) while GW4064 is the synthetic specific agonist of this receptor, we then revealed that GW4064 significantly decreased IL-6 expression in RAW 264.7 cells and bone marrow-derived macrophages but not in FXR-/- macrophages upon LPS stimulation.	GW 4064	197-203	interleukin 6	Mus musculus	228-232
33959014-13	2021	Besides, DHB remarkably and dose-dependently ameliorated renal damage, as evidenced by considerably reducing serum creatinine and blood urea nitrogen (BUN) levels, inflammatory cytokine (TNF-alpha, IL-1beta, IL-6 and IL-18) levels and restoring kidney histological deteriorations.	dihydroberberine	9-12	interleukin 6	Mus musculus	208-212
33874887-11	2021	RESULTS: The pancreatic pathological changes, plasma amylase and lipase activity, and the increase of plasma IL-1 and IL-6 levels in AP mice were significantly improved by the hydrogen-rich gases pretreatment, Meanwhile, the pancreatic GSH content increased and the pancreatic MDA content decreased.	Hydrogen	176-184	interleukin 6	Mus musculus	118-122
33994911-7	2021	The levels of hepatic IL-6 and IL-18 were significantly decreased in the fucoidan group.	fucoidan	73-81	interleukin 6	Mus musculus	22-26
33919457-8	2021	The FCPLJ treatment decreased the level of GM-CSF, GRO-alpha, IL-1 beta, IL-6, MCP-1 and MIP-1 beta in the plasma of the infected mice.	fcplj	4-9	interleukin 6	Mus musculus	73-77
33919457-9	2021	The intracellular IL-6 and viral RNA levels in the liver of infected mice were decreased by the FCPLJ treatment.	fcplj	96-101	interleukin 6	Mus musculus	18-22
33923700-6	2021	The results further showed that hydroxyapatite-coated SPIONs can induce minor TNF-alpha and IL-6 release by murine macrophages at a concentration of 100 microg Fe/mL.	Durapatite	32-46	interleukin 6	Mus musculus	92-96
33878544-5	2021	In vitro cell experiments, the inflammatory response in chondrocytes is mediated via interleukin-1beta (IL-1beta), which led to abnormal secretion of pro-inflammatory factors, such as prostaglandin E2 (PGE2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), cyclooxygenase-2 (COX-2), nitric oxide (NO) and inducible nitric oxide synthase (iNOS).	Dinoprostone	202-206	interleukin 6	Mus musculus	209-222
33878544-5	2021	In vitro cell experiments, the inflammatory response in chondrocytes is mediated via interleukin-1beta (IL-1beta), which led to abnormal secretion of pro-inflammatory factors, such as prostaglandin E2 (PGE2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), cyclooxygenase-2 (COX-2), nitric oxide (NO) and inducible nitric oxide synthase (iNOS).	Dinoprostone	202-206	interleukin 6	Mus musculus	224-228
33561444-5	2021	In the in vitro experiments, we observed inhibitory effects of p-coumaric acid against IL-6 and IL-8 production in stimulated A549 cells, as well as reactive oxygen species generation by neutrophils.	p-coumaric acid	63-78	interleukin 6	Mus musculus	87-91
33872750-13	2021	LHQW (1000 mg/kg/d) administered prophylactically significantly decreased the lung viral titers (P<0.05), slightly downregulated IL-6 but TNF-alpha, IL-1beta levels and improved lung pathological inflammation including neutrophil infiltration, necrosis, which is consistent with the expression of inflammatory factors.	lhqw	0-4	interleukin 6	Mus musculus	129-133
33674828-12	2021	Atorvastatin could also reverse the surgery-induced increase of systemic and hippocampal cytokines, including IL-1beta, TNF-alpha, and IL-6, accompanied by inhibiting the nuclear factor kappa-B (NF-kappaB) pathway and Nucleotide-Binding Oligomerization Domain, or Leucine Rich Repeat and Pyrin Domain Containing 3 (NLRP3) inflammasome activation, as well as hippocampal neuronal apoptosis.	Atorvastatin	0-12	interleukin 6	Mus musculus	135-139
33617822-6	2021	Repeated administration of (R)-ketamine (10 mg/kg/day, 14 days or last 7 days), but not (S)-ketamine (10 mg/kg/day, 14 days or last 7 days), significantly ameliorated the increased DAI score and increased blood levels of interleukin-6 (IL-6) in DSS-treated mice.	(R)-Ketamine	27-39	interleukin 6	Mus musculus	221-234
33617822-6	2021	Repeated administration of (R)-ketamine (10 mg/kg/day, 14 days or last 7 days), but not (S)-ketamine (10 mg/kg/day, 14 days or last 7 days), significantly ameliorated the increased DAI score and increased blood levels of interleukin-6 (IL-6) in DSS-treated mice.	(R)-Ketamine	27-39	interleukin 6	Mus musculus	236-240
33617822-8	2021	Furthermore, DSS-induced increased DAI score and blood IL-6 levels were significantly ameliorated after subsequent repeated administration of (R)-ketamine (10 mg/kg/day for last 7 days), but not 5-aminosalicyclic acid (50 mg/kg/day for last 7 days).	Dextran Sulfate	13-16	interleukin 6	Mus musculus	55-59
33617822-8	2021	Furthermore, DSS-induced increased DAI score and blood IL-6 levels were significantly ameliorated after subsequent repeated administration of (R)-ketamine (10 mg/kg/day for last 7 days), but not 5-aminosalicyclic acid (50 mg/kg/day for last 7 days).	(R)-Ketamine	142-154	interleukin 6	Mus musculus	55-59
33897258-9	2021	Significant downregulation of TNF-alpha, IL-6, and IL-1beta and dramatic upregulation of IL-10 were observed in the colons of both mice with CAC and colitis treated with GDC-0575.	GDC-0575	170-178	interleukin 6	Mus musculus	41-45
33789980-9	2021	TNF-alpha and IL-6 were essential for the decreased serum tryptophan and disease development, which were ameliorated by treatment with anti-TNF-alpha neutralizing Abs or dexamethasone.	Dexamethasone	170-183	interleukin 6	Mus musculus	14-18
33789980-10	2021	Peritoneal macrophages from C57BL/6 mice produced TNF-alpha, IL-6, and IDO-1 via interaction with anti-P Abs through activating FcgammaRs, which were required for disease development.	Phosphorus	0-1	interleukin 6	Mus musculus	61-65
33789980-9	2021	TNF-alpha and IL-6 were essential for the decreased serum tryptophan and disease development, which were ameliorated by treatment with anti-TNF-alpha neutralizing Abs or dexamethasone.	Tryptophan	58-68	interleukin 6	Mus musculus	14-18
33864821-9	2021	Both doses suppressed cisplatin-induced expression of iNOS and NF-KB p65 subunit and pro-inflammatory cytokines (IL-6 and TNF-alpha).	Cisplatin	22-31	interleukin 6	Mus musculus	113-117
33924467-8	2021	Results showed that kurarinone treatment reduced arthritis severity of CIA mice, as well as their levels of proinflammatory cytokines, TNF-alpha, IL-6, IFN-gamma, and IL-17A, in the serum and paw tissues.	kurarinone	20-30	interleukin 6	Mus musculus	146-150
33847914-5	2021	The effects of TNF-alpha and/or IL-6 on the osteogenic differentiation and apoptosis of CBDCs were analyzed in vitro.	cbdcs	88-93	interleukin 6	Mus musculus	32-36
33844454-11	2021	Se@SiO2 nanocomposites evidently affected the reduction of pancreatic enzymes and inflammatory cytokines (IL-6, IL-1beta, TNF-alpha).	Selenium	0-2	interleukin 6	Mus musculus	106-110
33954180-9	2021	In TPA model, both hydrocortisone and emollient significantly decreased expression levels of IL-1alpha, IL-1beta, IL-6, and TNFalpha mRNA.	Tetradecanoylphorbol Acetate	3-6	interleukin 6	Mus musculus	114-118
33954180-9	2021	In TPA model, both hydrocortisone and emollient significantly decreased expression levels of IL-1alpha, IL-1beta, IL-6, and TNFalpha mRNA.	Hydrocortisone	19-33	interleukin 6	Mus musculus	114-118
33897686-11	2021	IL-6 serum levels were enhanced in LCWE-injected mice and normalized by anakinra.	lcwe	35-39	interleukin 6	Mus musculus	0-4
33840704-8	2021	RESULTS: CY/ZA significantly increased the relative expression levels of IL-6 and decreased those of IL-10 and IGF-1 when compared with those in VC.	Cyclophosphamide	9-11	interleukin 6	Mus musculus	73-77
33840704-8	2021	RESULTS: CY/ZA significantly increased the relative expression levels of IL-6 and decreased those of IL-10 and IGF-1 when compared with those in VC.	Zoledronic Acid	12-14	interleukin 6	Mus musculus	73-77
33844454-11	2021	Se@SiO2 nanocomposites evidently affected the reduction of pancreatic enzymes and inflammatory cytokines (IL-6, IL-1beta, TNF-alpha).	Silicon Dioxide	3-7	interleukin 6	Mus musculus	106-110
33838231-10	2021	Further, TC and FO decreased plasma IL6 levels, especially in females, without additive or synergistic effects of these two.	Technetium	9-11	interleukin 6	Mus musculus	36-39
33916928-6	2021	T-2054 treatment significantly relieved the release of NO, as well as mRNA and protein expression levels of inflammatory cytokines (IL-6, IL-8 and TNF-alpha) in LPS-induced RAW 264.7 cells.	t-2054	0-6	interleukin 6	Mus musculus	132-136
33916928-8	2021	Moreover, T-2054 could relieve the infiltration of inflammatory cells and degeneration of the cartilage matrix and decrease the levels of serum IL-6, IL-8 and TNF-alpha in DMM-induced C57BL/6 mice models.	t-2054	10-16	interleukin 6	Mus musculus	144-148
33866132-8	2021	In vivo, BBD significantly inhibited the release of IL-6, thus resulting in increased survival rates in mice.	5-tert-butyl-1,3-benzodioxole	9-12	interleukin 6	Mus musculus	52-56
33720247-2	2021	In acute alcoholic liver injury mice, AdA ameliorated alcoholic exposure-induced hepatic lipid deposition (TC and TG), oxidative stress (MDA), inflammation (TNF-alpha, IL-1beta, IL-6, IL-17 and IFN-gamma), and liver damage via modulating microbiome and metabolomic responses.	antrodin A	38-41	interleukin 6	Mus musculus	178-182
33838231-10	2021	Further, TC and FO decreased plasma IL6 levels, especially in females, without additive or synergistic effects of these two.	Fish Oils	16-18	interleukin 6	Mus musculus	36-39
33075119-12	2021	MiR-590-3p also inhibited the induction of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6.	mir-590-3p	0-10	interleukin 6	Mus musculus	105-109
33733818-10	2021	The cytokine levels of interleukin-6 and interleukin-17 at 24 hours after tMCAO (n=3-5), and for interleukin-17 at 72 hours after tMCAO (n=5), were lower in the MR1-/- mice.	tmcao	74-79	interleukin 6	Mus musculus	23-36
33916809-8	2021	Although regulatory T cells were retained at greater levels in GM-treated mice, there were significantly fewer Th17 cells and interleukin (IL)-6-producing macrophages in cGVHD-targeted organs in these mice.	Gentamicins	63-65	interleukin 6	Mus musculus	126-144
33617842-8	2021	Vincristine promoted the pro-inflammatory macrophages activation individually or in coordination with LPS and increased the expression of pro-inflammatory factors IL-1beta, IL-6, TNF-alpha via increasing the phosphorylation of ERK1/2 and p38.	Vincristine	0-11	interleukin 6	Mus musculus	173-177
33692243-6	2021	In lipopolysaccharide-stimulated murine macrophage-like RAW264.7 cells, seco-beta-apo-8"-carotenal inhibited the secretion and mRNA expression of inflammatory mediators such as nitric oxide, interleukin (IL)-6 and IL-1beta, and monocyte chemoattractant protein-1.	seco-beta-apo-8"-carotenal	72-98	interleukin 6	Mus musculus	191-209
33823428-10	2021	RESULTS: ISO-1 treatment alleviated pathological damage in pancreatic and renal tissues, and reduced the serum levels of amylase, lipase, creatinine, uric acid, IL-6 and TNF-alpha.	ISO-1	9-14	interleukin 6	Mus musculus	161-165
33893966-5	2021	In contrast to granulocytic CSF, administration of Polymuramyl was followed by an increase in the level of granulocyte-macrophage CSF and a tendency to an increase in the serum content of IL-6, which indicates the involvement of these cytokines in the hematopoietic activity of Polymuramyl.	polymuramyl	51-62	interleukin 6	Mus musculus	188-192
33675774-7	2021	The results showed that pretreatment with CGP57380 not only significantly attenuated LPS-induced lung wet/dry ratio, as well as protein content, total cells and neutrophils in bronchoalveolar lavage fluid (BALF), but also decreased the production of pro-inflammatory mediators such as interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha) and keratinocyte-derived chemoattractant (KC).	CGP 57380	42-50	interleukin 6	Mus musculus	285-298
33675774-7	2021	The results showed that pretreatment with CGP57380 not only significantly attenuated LPS-induced lung wet/dry ratio, as well as protein content, total cells and neutrophils in bronchoalveolar lavage fluid (BALF), but also decreased the production of pro-inflammatory mediators such as interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha) and keratinocyte-derived chemoattractant (KC).	CGP 57380	42-50	interleukin 6	Mus musculus	300-304
33893966-5	2021	In contrast to granulocytic CSF, administration of Polymuramyl was followed by an increase in the level of granulocyte-macrophage CSF and a tendency to an increase in the serum content of IL-6, which indicates the involvement of these cytokines in the hematopoietic activity of Polymuramyl.	polymuramyl	278-289	interleukin 6	Mus musculus	188-192
33987329-5	2021	Lycopene inhibited F4/80+ macrophage and Ly6G+ neutrophil accumulation, which further decreased the levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin 6 (IL-6).	Lycopene	0-8	interleukin 6	Mus musculus	185-198
33987329-5	2021	Lycopene inhibited F4/80+ macrophage and Ly6G+ neutrophil accumulation, which further decreased the levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin 6 (IL-6).	Lycopene	0-8	interleukin 6	Mus musculus	200-204
33166053-9	2021	Treatment with borneol significantly inhibited TNF-alpha, IL-1beta, IL-6, and inducible nitric oxide synthase expression in cerulein-induced AP mouse model.	isoborneol	15-22	interleukin 6	Mus musculus	68-72
32361923-9	2021	The administration of BJ-1108 inhibited the colonic mRNA expression of IL-6 and IL-1beta in vivo.	BJ-1108	22-29	interleukin 6	Mus musculus	71-75
33429006-4	2021	High-sugar/fat (HSF) diet augmented the levels of the pro-inflammatory mediators MCP-1, IL-6, COX-2, and PGE2 in mammary tissue, and this was accompanied by crown-like structures of breast (CLS-B) formation and aromatase/estrogen upregulation.	Sugars	5-10	interleukin 6	Mus musculus	88-92
33429006-5	2021	Treatment with a COX-2 selective inhibitor, etoricoxib, decreased PGE2, IL-6, MCP-1, and CLS-B formation as well as reduced aromatase protein and estrogen levels in the mammary tissue of mice fed a HSF diet.	Etoricoxib	44-54	interleukin 6	Mus musculus	72-76
33868441-6	2021	In the anti-inflammatory assays, treatment with PTE (1 mg/mL) significantly inhibited expression levels of LPS-induced COX-2 and iNOS, as well as the production of PGE2, NO, TNF-alpha, and IL-6.	pte	48-51	interleukin 6	Mus musculus	189-193
33868442-7	2021	It also decreased the levels of TNF-alpha, IL-1beta, IL-6 in the supernatant of MH-S cells induced by SiO2, inhibited the expression of p38 MAPK, blocked the activation of NF-kappaB, and controlled the upstream inflammatory response by multiple targeting.	Silicon Dioxide	102-106	interleukin 6	Mus musculus	53-57
33868268-6	2021	We measured liver tissue and found that the EGCG gavage treatment significantly inhibited the pro-inflammatory factors (TNF-alpha, IL-1beta, IL-6, MCP-1, MIP-2, IFN-gamma) and oxidation indicators (MPO, NO, ALT, and AST) levels increase.	epigallocatechin gallate	44-48	interleukin 6	Mus musculus	141-145
33083887-4	2021	Compared to the LPS/D-GalN group, the TAK-242 pretreatment group showed significantly prolonged survival, reduced serum alanine aminotransferase and aspartate aminotransferase levels, relieved oxidative stress, and reduced inflammatory interleukin (IL)-6, IL-12, and tumor necrosis factor-alpha levels.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	38-45	interleukin 6	Mus musculus	236-254
33393705-13	2021	APAP administration increased lipid peroxidation, TNF-alpha, IL-1beta, and IL-6 protein expressions.	Acetaminophen	0-4	interleukin 6	Mus musculus	75-79
33851975-11	2021	The rmIL-36alpha treatment of C57BL/6 mice increased clinical score, MPO levels, macrophage infiltration, and expression of the proinflammatory cytokines IL-1beta, IL-6, and TNF-alpha compared with the infected controls, which showed a decrease due to IL-36alpha Ab treatment.	rmil-36alpha	4-16	interleukin 6	Mus musculus	164-168
33851975-13	2021	The rmIL-36alpha treatment upregulated IL-1beta, IL-6, and phosphorylated nuclear factor (NF)-kappaB expression, which was significantly inhibited by rmIL-36Ra.	rmil	4-8	interleukin 6	Mus musculus	49-53
33851975-13	2021	The rmIL-36alpha treatment upregulated IL-1beta, IL-6, and phosphorylated nuclear factor (NF)-kappaB expression, which was significantly inhibited by rmIL-36Ra.	rmil	150-154	interleukin 6	Mus musculus	49-53
33006074-8	2021	Pte also inhibits LPS/D-Gal-induced secretion of pro-inflammatory cytokine tumor necrosis factor-a (TNF-alpha), interleukin 6 (IL-6), and interleukin 1beta (IL-1beta) in liver tissues.	Galactose	22-27	interleukin 6	Mus musculus	112-125
33006074-8	2021	Pte also inhibits LPS/D-Gal-induced secretion of pro-inflammatory cytokine tumor necrosis factor-a (TNF-alpha), interleukin 6 (IL-6), and interleukin 1beta (IL-1beta) in liver tissues.	Galactose	22-27	interleukin 6	Mus musculus	127-131
33029757-9	2021	Administration of dimethyl itaconate enhanced survival rate, decreased serum level of TNF-alpha and IL-6, and ameliorated lung injury in septic mice.	dimethyl itaconate	18-36	interleukin 6	Mus musculus	100-104
33029757-10	2021	Dimethyl itaconate also suppressed LPS-induced production of TNF-alpha, IL-6, and NOS2 in BMDMs.	dimethyl itaconate	0-18	interleukin 6	Mus musculus	72-76
33051781-6	2021	QE alleviated inflammatory mediators TNF-alpha, IL-6, and IL-10 in experiments.	Gln-Glu	0-2	interleukin 6	Mus musculus	48-52
33404076-7	2021	Notably, nicorandil suppressed FA-induced inflammation; it reduced renal levels of nuclear factor-kappaB, tumor necrosis factor-alpha, and interleukin-6.	Nicorandil	9-19	interleukin 6	Mus musculus	139-152
33388350-9	2021	Furthermore, the levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were markedly increased after sevoflurane exposure.	Sevoflurane	122-133	interleukin 6	Mus musculus	27-40
33421258-10	2021	Also, the enzyme-linked immunosorbent assay results indicate that trelagliptin-treated mice displayed anti-inflammatory properties by reducing the levels of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha.	trelagliptin	66-78	interleukin 6	Mus musculus	187-191
33528053-7	2021	AFNC dose-dependently increased levels of IL-2, IL-6, TNF-alpha, IL-10, IL-12, interferon-gamma, or IL-4 in the serum and spleen of immunosuppressed mice.	afnc	0-4	interleukin 6	Mus musculus	48-52
32910356-8	2021	Furthermore, LPS-induced expression of pro-inflammatory cytokines (i.e., TNF-alpha, IL-6, and IL-1beta) was notably reversed by melatonin pre-treatment.	Melatonin	128-137	interleukin 6	Mus musculus	84-88
32852718-5	2021	Moreover, we found that hexahydrocurcumin treatment could decrease interleukin-6 levels by attenuating p65 of nuclear factor kappa-light-chain-enhancer (NF-kappaB) of activated beta cells.	hexahydrocurcumin	24-41	interleukin 6	Mus musculus	67-80
33388350-9	2021	Furthermore, the levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were markedly increased after sevoflurane exposure.	Sevoflurane	122-133	interleukin 6	Mus musculus	42-46
33732362-9	2021	In addition, the results demonstrated that curcumin inhibited the TLR4/NF-kappaB signaling pathway and the expression of inflammatory factors, including IL-6, IL-1beta, prostaglandin E2 and cyclooxygenase-2, in mouse xenograft tumors.	Curcumin	43-51	interleukin 6	Mus musculus	153-157
33350533-7	2021	The results showed that PCP inhibited the serum inflammatory mediators (tumor necrosis factor-alpha, interleukin-6, and nitric oxide) and lipids (low-density lipoprotein-cholesterol, triglyceride, and total cholesterol) increase.	pcp	24-27	interleukin 6	Mus musculus	101-114
33247953-7	2021	Remarkably, SvAg-treated mice infected with T. gondii presented reduced inflammatory lesions in the small intestine than infected untreated mice and decreased intestinal and systemic levels of IFN-gamma, TNF-alpha and IL-6.	svag	12-16	interleukin 6	Mus musculus	218-222
33640781-0	2021	Gegen Qinlian decoction relieved DSS-induced ulcerative colitis in mice by modulating Th17/Treg cell homeostasis via suppressing IL-6/JAK2/STAT3 signaling.	Dextran Sulfate	33-36	interleukin 6	Mus musculus	129-133
33640781-10	2021	Furthermore, the production of proinflammatory factors, such as IL-1beta, TNF-alpha and IL-6, was dramatically reduced after GQ administration.	glycylglutamine	125-127	interleukin 6	Mus musculus	88-92
33640781-14	2021	CONCLUSIONS: Taken together, these results indicated that GQ alleviated DSS-induced UC by suppressing IL-6/JAK2/STAT3 signaling to restore Treg and Th17 cell homeostasis in colonic tissue.	glycylglutamine	58-60	interleukin 6	Mus musculus	102-106
33640781-14	2021	CONCLUSIONS: Taken together, these results indicated that GQ alleviated DSS-induced UC by suppressing IL-6/JAK2/STAT3 signaling to restore Treg and Th17 cell homeostasis in colonic tissue.	Dextran Sulfate	72-75	interleukin 6	Mus musculus	102-106
33652358-10	2021	It revealed that the extract of D. odorifera and nine flavonoids in the noncytotoxic range could alleviated lipopolysaccharide-stimulated inflammation in RAW 264.7 cells by decreasing the production of proinflammatory mediators such as nitric oxide and interleukin-6.	Flavonoids	54-64	interleukin 6	Mus musculus	253-266
33544844-8	2021	Additionally, antagomiR-741 suppressed the radiation-induced production of pro-inflammatory cytokines IL-6 and TNF-alpha in the hippocampus and S100B in the serum.	antagomir-741	14-27	interleukin 6	Mus musculus	102-106
33429011-7	2021	In addition, the absence of serotonin significantly inhibited the release of several inflammatory cytokines, including interleukin-6 (IL-6), interferon-gamma (IFN-gamma), tumor necrosis-alpha (TNF-alpha), and transforming growth factor beta1 (TGF-beta1).	Serotonin	28-37	interleukin 6	Mus musculus	119-132
33421025-7	2021	In addition, liproxstatin-1 decreased the activation of microglia and the release of IL-6, IL-1beta, and TNF-alpha.	liproxstatin-1	13-27	interleukin 6	Mus musculus	85-89
33790360-7	2021	Intratumoral co-injections of IL-6 significantly reduced the anti-tumor effects of cGAMP.	cyclic guanosine monophosphate-adenosine monophosphate	83-88	interleukin 6	Mus musculus	30-34
33476619-6	2021	Moreover, compound 11 also inhibited the expressions of proinflammatory cytokines, such as NO, TNF-alpha, IL-6 and IL-1beta, induced by Cu2+ + Abeta1-42 in BV2 microglial cells.	cu2+ +	136-142	interleukin 6	Mus musculus	106-110
33784949-9	2021	The IL-6 expression in blood detected using ELISA was significantly reduced compared with MPTP group.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	90-94	interleukin 6	Mus musculus	4-8
33859564-6	2021	OCOP treatment also suppressed the mRNA expression and release of inflammatory mediators (TGF-beta, TNF-alpha, IL-6, IL-18, IL-1beta and IFN-gamma) and elevated the transcriptional and translational levels of anti-inflammatory cytokine (IL-10) as well as the mRNA expression levels of adhesion molecules (ICAM-1 and VCAM-1).	ocop	0-4	interleukin 6	Mus musculus	111-115
33859711-14	2021	Moreover, GGDE suppressed the LPS-induced production of NO, TNF-alpha, IL-1beta, and IL-6 in BV2 cells.	ggde	10-14	interleukin 6	Mus musculus	85-89
33645621-6	2021	In addition, ACG treatment notably decreased the inflammatory cell numbers in bronchoalveolar lavage fluid (BALF) and the levels of pro-inflammatory cytokines (including IL-6, IL-17, IL-23, TNF-alpha, IL-1beta and TGF-beta) in lung tissue of asthmatic mice.	acg	13-16	interleukin 6	Mus musculus	170-174
33781961-10	2021	Sitagliptin increased GLP-1-induced cytosolic levels of beta-catenin compared with GLP-1 alone, resulted in increasing the expression of survivin, and suppressed proinflammatory cytokines, i.e., interleukin-6(IL-6) and tumor necrosis factor-alpha(TNF-alpha), production in response to H2O2.	Sitagliptin Phosphate	0-11	interleukin 6	Mus musculus	195-208
33781961-10	2021	Sitagliptin increased GLP-1-induced cytosolic levels of beta-catenin compared with GLP-1 alone, resulted in increasing the expression of survivin, and suppressed proinflammatory cytokines, i.e., interleukin-6(IL-6) and tumor necrosis factor-alpha(TNF-alpha), production in response to H2O2.	Sitagliptin Phosphate	0-11	interleukin 6	Mus musculus	209-213
33769212-10	2021	Venlafaxine treatment reduced the striatal IL-6/IL-10 ratio and increased hippocampal GR expression, although it did not reverse stress-induced behavioral changes.	Venlafaxine Hydrochloride	0-11	interleukin 6	Mus musculus	43-47
33884175-5	2021	GAS ameliorated Pb-induced inflammation in kidneys by reducing the TNF-alpha and IL-6 levels.	Lead	16-18	interleukin 6	Mus musculus	81-85
33152425-11	2021	Carvacrol inhibited the expression of inflammation-associated cytokines including IFN-gamma, IL-2, IL-4, IL-5, IL-12 and TNF-alpha, IL-1, IL-10, IL-6.	carvacrol	0-9	interleukin 6	Mus musculus	145-149
33849832-5	2021	Compared with the heat exposure group, amiodarone resulted in significantly decreased survival rate of the atrial myocytes (P < 0.01), obviously decreased SOD activity (P < 0.05), and increased cell apoptosis rate (P < 0.05) and IL-1beta, IL-6, MDA and TNF-alpha levels (P < 0.01 or 0.001).	Amiodarone	39-49	interleukin 6	Mus musculus	239-243
33650604-3	2021	QTW and QTE significantly inhibited the alanine aminotransaminase, aspartate aminotransaminase, tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta levels in the serum.	[(2~{R},3~{S},4~{S},5~{R})-3,4-bis(oxidanyl)-5-[3-[4-[(~{E})-phenylcarbonyliminomethyl]-1,2,3-triazol-1-yl]propyl]oxan-2-yl]methyl ~{N}-[(2~{S})-2-azanyl-4-methyl-pentanoyl]sulfamate	0-3	interleukin 6	Mus musculus	125-138
33752688-10	2021	Moreover, topical treatment with SPD enhanced the expression of IL-6 and TNF-alpha in wound sites.	Spermidine	33-36	interleukin 6	Mus musculus	64-68
33994251-0	2021	Natural flavonol fisetin attenuated hyperuricemic nephropathy via inhibiting IL-6/JAK2/STAT3 and TGF-beta/SMAD3 signaling.	3-hydroxyflavone	8-16	interleukin 6	Mus musculus	77-81
33740180-7	2022	Concurrently, CuSO4 caused inflammation by increasing the mRNA levels of interleukin-1beta (IL-1beta), IL-2, IL-4, IL-6, IL-12, tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma).	Copper Sulfate	14-19	interleukin 6	Mus musculus	115-119
33650604-3	2021	QTW and QTE significantly inhibited the alanine aminotransaminase, aspartate aminotransaminase, tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta levels in the serum.	cyclohexylmethanol	8-11	interleukin 6	Mus musculus	125-138
33758353-7	2021	In BV2 microglial cells treated with LPS (100 ng/mL), pre-application of artemisinin (40 muMu) significantly reduced the production of proinflammatory cytokines (i.e., TNF-alpha, IL-6) and suppressed microglial migration.	artemisinin	73-84	interleukin 6	Mus musculus	179-183
33731782-11	2021	The ischemic limbs of female mice treated with NIM-811 showed significantly lower levels of MCP-1, IL-23, IL-6, and IL-1alpha compared to limbs of vehicle-treated mice.	(melle-4)cyclosporin	47-54	interleukin 6	Mus musculus	106-110
33482179-5	2021	Fidarestat further attenuated Dox-induced upregulation of IL-6, IL-1beta, and Nos2 in murine BMDMs.	fidarestat	0-10	interleukin 6	Mus musculus	58-62
33790957-6	2021	The selective PPARbeta/delta agonist GW0742 significantly decreased inflammation-related mRNA expression in hDPCs (IL6, IL1beta, TNFalpha, MMP1, and MMP2) and RAW264.7 cells (Il6 and Tnfalpha).	GW0742	37-43	interleukin 6	Mus musculus	115-118
33790957-6	2021	The selective PPARbeta/delta agonist GW0742 significantly decreased inflammation-related mRNA expression in hDPCs (IL6, IL1beta, TNFalpha, MMP1, and MMP2) and RAW264.7 cells (Il6 and Tnfalpha).	GW0742	37-43	interleukin 6	Mus musculus	175-178
33729573-6	2021	RESULTS: The in vitro results showed that TAK-242 blocked the overproduction of IL-1, IL-6, TNF-alpha and RANKL in HGEC treated with LPS.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	42-49	interleukin 6	Mus musculus	86-90
33485944-7	2021	In contrast, reduced levels of pro-inflammatory cytokines/chemokines (IL-1beta, IL-6, IL-9, IL-12, CCL11) was observed in the nucleus accumbens (NAc) of oxycodone and withdrawal-treated males as compared to female mice.	Oxycodone	153-162	interleukin 6	Mus musculus	80-84
33482179-5	2021	Fidarestat further attenuated Dox-induced upregulation of IL-6, IL-1beta, and Nos2 in murine BMDMs.	Doxorubicin	30-33	interleukin 6	Mus musculus	58-62
33712964-6	2021	In addition, transethosomes-in-gel containing RA (RA-TE-Gel) formulations produced a great reduction in the punch edema (P < 0.001) and in TNF-alpha and IL-6 (P < 0.05).	rosmarinic acid	46-48	interleukin 6	Mus musculus	153-157
33791311-10	2021	Quantitative PCR also revealed that GI254023X mitigated up-regulation of the pro-inflammatory markers Il6, Tnfa, and Lcn2 but not the up-regulation of the pan-microglia marker Aif1, the M2 microglia marker Arg1 and the reactive astrocyte marker Gfap.	3-(formylhydroxyamino)-2-(3-phenyl-1-propyl)butanoic acid (2,2-dimethyl-1-methylcarbamoyl-1-propyl)amide	36-45	interleukin 6	Mus musculus	102-105
33712964-6	2021	In addition, transethosomes-in-gel containing RA (RA-TE-Gel) formulations produced a great reduction in the punch edema (P < 0.001) and in TNF-alpha and IL-6 (P < 0.05).	ra-te	50-55	interleukin 6	Mus musculus	153-157
33678756-3	2021	The results indicated that treatment with SRT1720 inhibited LPS/D-Gal-induced elevation of ALT and AST, alleviated the histological abnormalities, suppressed the induction of TNF-alpha and IL-6, mitigated the phosphorylation of JNK, downregulated the activities of caspase 8, caspase 9 and caspase 3, decreased the level of cleaved caspase 3, reduced the TUNEL-positive cells, and improved the survival rate of the LPS/D-Gal-exposed mice.	SRT1720	42-49	interleukin 6	Mus musculus	189-193
33790896-5	2021	Mechanistically, melatonin treatment enhanced NF-kappaB deacetylation and subsequently reduced the inflammatory response and decreased the TNF-alpha, IL-6, and IL-10 serum levels; these effects were abolished by SIRT1 inhibition with the selective blocker, Ex527.	Melatonin	17-26	interleukin 6	Mus musculus	150-154
33750416-9	2021	However, gm9795 in NASH cell models significantly promoted the expression of TNF [Formula: see text], IL-6, IL-1[Formula: see text], the important inflammatory mediators in NASH.	gm9795	9-15	interleukin 6	Mus musculus	102-106
33678756-3	2021	The results indicated that treatment with SRT1720 inhibited LPS/D-Gal-induced elevation of ALT and AST, alleviated the histological abnormalities, suppressed the induction of TNF-alpha and IL-6, mitigated the phosphorylation of JNK, downregulated the activities of caspase 8, caspase 9 and caspase 3, decreased the level of cleaved caspase 3, reduced the TUNEL-positive cells, and improved the survival rate of the LPS/D-Gal-exposed mice.	Galactose	64-69	interleukin 6	Mus musculus	189-193
33493826-4	2021	Compound d5 showed a strong inhibitory effect on NO (half maximal inhibitory concentration = 2.34 +- 0.7 muM) and tumor necrosis factor-alpha, interleukin (IL)-1beta, and (IL-6).	decamethylcyclopentasiloxane	9-11	interleukin 6	Mus musculus	172-176
33676551-9	2021	In addition, overexpression of miR-29 markedly reduced the concentration of OVA-specific IgE, the levels of IL-4, IL-6, IL-10, and IFN-gamma, the pathological alterations and eosinophils infiltration in the nasal mucosa.	mir-29	31-37	interleukin 6	Mus musculus	114-118
33119198-8	2021	Moreover, dendrobine reduced the secretion of inflammatory cytokines by T-helper 17 (Th17) cells, including interleukin-1beta, interleukin-6, tumour necrosis factor-alpha and interleukin-17.	dendrobine	10-20	interleukin 6	Mus musculus	127-140
33460615-8	2021	Glz pretreatment significantly (P < 0.05) inhibited the AGEs-induced pro-inflammatory mediators (NO , reactive oxygen species, i-NOS), and production of pro-inflammatory cytokines, including IL-1beta, IL-6, and TNF-alpha.	Gliclazide	0-3	interleukin 6	Mus musculus	201-205
33674189-11	2021	Blockage of IL-6 or ICOS-L significantly reduced Tfh cell induction.	tfh	49-52	interleukin 6	Mus musculus	12-16
33087287-9	2021	The results showed that after PS-MPS exposure, the expression of the pro-inflammatory molecule NF-kappaB and that of the inflammatory factors interleukin (IL)-1beta and IL-6 increased significantly, whereas that of the anti-inflammatory molecule Nrf2/HO-1 decreased.	ps-mps	30-36	interleukin 6	Mus musculus	169-173
33547923-14	2021	Amprolium-resistant strain A9 has neuroprotective effect and prevents IL-6 increase.	Amprolium	0-9	interleukin 6	Mus musculus	70-74
33395605-5	2021	We found that SIN significantly inhibited the secretion of IL-6 and IL-33 and ROS production in RASFs to mediate protective effect on bone destruction to mediate anti-arthritis effect.	sinomenine	14-17	interleukin 6	Mus musculus	59-63
33513342-12	2021	Our results demonstrate that CBD produced antidepressant-like effects in the LPS neuroinflammatory model, associated to a reduction in the kynurenine pathway activation, IL-6 levels and NF-kB activation.	Cannabidiol	29-32	interleukin 6	Mus musculus	170-174
32812529-6	2021	7,3",4"-THIF significantly suppressed the production of the proinflammatory mediators nitric oxide (NO), inducible nitric oxide synthase (iNOS), and cyclooxygenase- 2 (COX-2) as well as of the proinflammatory cytokine interleukin-6 (IL-6) in LPS-stimulated BV2 microglial cells.	7,3",4"-thif	0-12	interleukin 6	Mus musculus	218-231
32812529-6	2021	7,3",4"-THIF significantly suppressed the production of the proinflammatory mediators nitric oxide (NO), inducible nitric oxide synthase (iNOS), and cyclooxygenase- 2 (COX-2) as well as of the proinflammatory cytokine interleukin-6 (IL-6) in LPS-stimulated BV2 microglial cells.	7,3",4"-thif	0-12	interleukin 6	Mus musculus	233-237
32468223-4	2021	Iron overload upregulated the pro-inflammatory cytokines (IL-1beta, IL-2, IL-6, TNF-alpha), while downregulated the anti-inflammatory cytokines (IL-4, IL-10) and sIgA.	Iron	0-4	interleukin 6	Mus musculus	74-78
33581600-10	2021	Significantly low levels of IL-1beta, IL-1Ra, IL-6, and TNF-alpha were observed in the hippocampus of PTZ + EMB (10 and 20 mg/kg)-treated groups compared with PTZ+ vehicle-treated group.	Pentylenetetrazole	102-105	interleukin 6	Mus musculus	46-50
33383371-12	2021	Also, BBD reduced the mortality of mice with endotoxin shock/endotoxemia; serum levels of ALT, AST, IL-1beta, IL-6 and TNF-alpha; gene expression of IL-1beta, IL-6 and TNF-alpha in the liver, brain and lung, and tissue damage in the liver and lung.	5-tert-butyl-1,3-benzodioxole	6-9	interleukin 6	Mus musculus	110-114
33383371-12	2021	Also, BBD reduced the mortality of mice with endotoxin shock/endotoxemia; serum levels of ALT, AST, IL-1beta, IL-6 and TNF-alpha; gene expression of IL-1beta, IL-6 and TNF-alpha in the liver, brain and lung, and tissue damage in the liver and lung.	5-tert-butyl-1,3-benzodioxole	6-9	interleukin 6	Mus musculus	159-163
33128285-8	2021	Highly expressed IL-6 and IL17, and lowly expressed IL-10 and TGF-beta in lymphocytes from SLE mice were repressed and facilitated following CuIIb treatment, respectively.Overall, our data proved that CuIIb improved kidney injury in SLE mice through balancing the percentage of Th17 and Treg cells.	cucurbitacin IIb	141-146	interleukin 6	Mus musculus	17-21
33581600-10	2021	Significantly low levels of IL-1beta, IL-1Ra, IL-6, and TNF-alpha were observed in the hippocampus of PTZ + EMB (10 and 20 mg/kg)-treated groups compared with PTZ+ vehicle-treated group.	embelin	108-111	interleukin 6	Mus musculus	46-50
33581600-11	2021	Significantly lower levels of IL-1Ra, IL-6, and TNF-alpha compared with PTZ+ vehicle-treated group were observed in the cortex of PTZ + EMB (10 and 20 mg/kg)-treated groups, while IL-1beta levels were found to be significantly lower only in the cortex of PTZ + EMB (20 mg/kg)-treated group.	Pentylenetetrazole	130-133	interleukin 6	Mus musculus	38-42
33581600-11	2021	Significantly lower levels of IL-1Ra, IL-6, and TNF-alpha compared with PTZ+ vehicle-treated group were observed in the cortex of PTZ + EMB (10 and 20 mg/kg)-treated groups, while IL-1beta levels were found to be significantly lower only in the cortex of PTZ + EMB (20 mg/kg)-treated group.	embelin	136-139	interleukin 6	Mus musculus	38-42
33581600-11	2021	Significantly lower levels of IL-1Ra, IL-6, and TNF-alpha compared with PTZ+ vehicle-treated group were observed in the cortex of PTZ + EMB (10 and 20 mg/kg)-treated groups, while IL-1beta levels were found to be significantly lower only in the cortex of PTZ + EMB (20 mg/kg)-treated group.	Pentylenetetrazole	130-133	interleukin 6	Mus musculus	38-42
33613705-8	2021	Treatment with 4-MA significantly ameliorated cell viability, LDH release and the levels of NO and pro-inflammatory factors TNF-alpha, IL-1beta and IL-6 as a result of OGD/Rep.	anisyl alcohol	15-19	interleukin 6	Mus musculus	148-152
33497689-4	2021	Ocular topical application of the DG-Gen ophthalmic solution significantly prompted corneal re-epithelialization and nerve regeneration in diabetic mice, and this efficacy might be due to the inhibition of HMGB1 signaling through down-regulation of HMGB1 and its receptors RAGE and TLR4, as well as inflammatory factor interleukin (IL)-6 and IL-1beta.	dg-gen	34-40	interleukin 6	Mus musculus	319-337
33332758-0	2021	miR-223 improves intestinal inflammation through inhibiting the IL-6/STAT3 signaling pathway in dextran sodium sulfate-induced experimental colitis.	dextran sodium sulfate	96-118	interleukin 6	Mus musculus	64-68
33523066-13	2021	EPA also inhibited NLRP3/IL-1beta and IL-6/STAT3 inflammatory pathways and up-regulated the Wnt/beta-catenin pathway.	Eicosapentaenoic Acid	0-3	interleukin 6	Mus musculus	38-42
33496702-6	2021	SES also reduced TNF-alpha, IL-1beta and IL-6 production caused by DSS.	Dextran Sulfate	67-70	interleukin 6	Mus musculus	41-45
33332758-11	2021	CONCLUSIONS: The upregulation of miR-223 by agomir administration alleviated colonic inflammation in a DSS-induced colitis model, which was likely mediated by inhibiting the production of pro-inflammatory cytokines via the IL-6/STAT3 signaling pathway.	dss	103-106	interleukin 6	Mus musculus	223-227
33454639-13	2021	TAK-242 treatment significantly reduced the level of IL-1beta, IL-6, and TNF-alpha mRNA expression, as well as activation of microglia and astrocytes in the OB tissues.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	0-7	interleukin 6	Mus musculus	63-67
32506802-9	2021	The level of IL-6 and TNF-alpha secreted from J774A.1 macrophages interacted with CD200-coated TCPS surface was reduced by 36.3% and 32.4%, respectively.	tcps	95-99	interleukin 6	Mus musculus	13-17
33122120-13	2021	RESULTS: M. pruriens seed extract significantly inhibited the release of inflammatory mediators including nitric oxide (NO), IL-1beta, IL-6, and TNF-alpha in LPS-stimulated BV2 microglial cells.	pruriens seed extract	12-33	interleukin 6	Mus musculus	135-139
33451905-8	2021	Furthermore, tofacitinib suppressed adaptive and innate immune responses by reducing splenocytes, total lymphocytes, CD4+ T helper cells (especially Th2 and Th17 subtypes), IL-6-producing effector B cells, PDCA-1+ dendritic cells in the spleen, and infiltration of F4/80+, CD206+ and CD163+ macrophages in the skin and lungs.	tofacitinib	13-24	interleukin 6	Mus musculus	173-177
33189843-12	2021	Furthermore, the isochlorogenic acid-rich and biflavonoid-rich fractions and isochlorogenic acids A and C, and ochnaflavone could significantly down-regulate the mRNA expression of TNF-alpha and IL-6 in LPS-induced RAW 264.7 macrophages.	isochlorogenic acid	17-36	interleukin 6	Mus musculus	195-199
33129947-8	2021	RESULTS: CJT administration significantly reduced the secretion of Th2 cytokines, TNF-alpha, IL-6, immunoglobulin E (IgE) and histamine, and the recruitment of eosinophils in an OVA-exposed mice.	CHEMBL4279192	9-12	interleukin 6	Mus musculus	93-97
33129947-12	2021	In an in vitro study, CJT pretreatment suppressed the LPS-induced TNF-alpha secretion in RAW264.7 cells and attenuated the PMA-induced IL-6, IL-8 and MCP-1 secretion in A549 cells.	Tetradecanoylphorbol Acetate	123-126	interleukin 6	Mus musculus	135-139
33189843-12	2021	Furthermore, the isochlorogenic acid-rich and biflavonoid-rich fractions and isochlorogenic acids A and C, and ochnaflavone could significantly down-regulate the mRNA expression of TNF-alpha and IL-6 in LPS-induced RAW 264.7 macrophages.	Biflavonoids	46-57	interleukin 6	Mus musculus	195-199
33189843-12	2021	Furthermore, the isochlorogenic acid-rich and biflavonoid-rich fractions and isochlorogenic acids A and C, and ochnaflavone could significantly down-regulate the mRNA expression of TNF-alpha and IL-6 in LPS-induced RAW 264.7 macrophages.	isochlorogenic acid	77-97	interleukin 6	Mus musculus	195-199
33189843-12	2021	Furthermore, the isochlorogenic acid-rich and biflavonoid-rich fractions and isochlorogenic acids A and C, and ochnaflavone could significantly down-regulate the mRNA expression of TNF-alpha and IL-6 in LPS-induced RAW 264.7 macrophages.	ochnaflavone	111-123	interleukin 6	Mus musculus	195-199
32767187-14	2021	Furthermore, naringin reduced pro-inflammatory cytokines (TNF-alpha, IL-6), malondialdehyde, nitrite concentrations, and increased glutathione levels in a region-dependent manner.	naringin	13-21	interleukin 6	Mus musculus	69-73
33118665-4	2021	The production of nitric oxide, prostaglandin E2, tumor necrosis factor-alpha and interleukin-6 were increased by MPP+ treatment, which were abolished by irigenin treatment.	mangion-purified polysaccharide (Candida albicans)	114-118	interleukin 6	Mus musculus	82-95
32901371-10	2021	Our results suggest that acute pain and CCI-induced chronic pain might aggravate postoperative cognitive dysfunction via neurotransmitters and by changing the levels of inflammatory factors such as IL-1beta and IL-6.	CCI	40-43	interleukin 6	Mus musculus	211-215
33249188-7	2021	Also, naringenin blocked the chemotaxis and antigen-presenting function of cDCs that resulted in reducing T-cell secreting cytokines (IFN-gamma, IL-17, and IL-6) in the spleen.	naringenin	6-16	interleukin 6	Mus musculus	156-160
33085047-7	2021	E2 treatment also significantly inhibited TLR4 and NF-kappaB protein expression, and significantly reduced the expression of the proinflammatory factors IL-1beta, IL-6, and TNF-alpha.	Estradiol	0-2	interleukin 6	Mus musculus	163-167
33073684-5	2021	Systemic administration of GMSC-EVs attenuated aging-associated elevation in the expression levels of p21, mTOR/pS6, interleukin 6, and tumor necrosis factor alpha in skin and heart tissues of aged mice.	gmsc-evs	27-35	interleukin 6	Mus musculus	117-130
33602508-6	2021	Besides, panaxytriol inhibited the mRNA expression of proinflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6.	panaxytriol	9-20	interleukin 6	Mus musculus	113-117
33124100-4	2021	Capsidiol resulted in a significant reduction in the anti-CD3/CD28 (alphaCD3/CD28)-induced IFN-gamma+ CD4+ (Th1) and IFN-gamma+ CD8+ (Tc1) populations as well as in the production of cytokines (IFN-gamma, IL-17A, IL-6, IL-2, TNF-alpha, and IP-10).	capsidiol	0-9	interleukin 6	Mus musculus	213-217
33118665-4	2021	The production of nitric oxide, prostaglandin E2, tumor necrosis factor-alpha and interleukin-6 were increased by MPP+ treatment, which were abolished by irigenin treatment.	irigenin	154-162	interleukin 6	Mus musculus	82-95
33124100-8	2021	Capsidiol treatment resulted in diminished levels of IFN-gamma-induced nitric oxide and IL-6; expression of iNOS and COX-2 were suppressed by 50 muM capsidiol in IFN-gamma-stimulated BV2 cells.	capsidiol	0-9	interleukin 6	Mus musculus	88-92
33495836-8	2021	CFA also robustly suppressed apoptosis induced by H2O2 in murine chondrocytes and reduced the expression of matrix metalloproteinase (MMP)1, MMP3, interleukin (IL)-1 and IL-6 in vivo.	coniferaldehyde	0-3	interleukin 6	Mus musculus	170-174
33728026-5	2021	Moreover, oxyberberine inhibited inflammation, as indicated by the changes of neutrophil accumulation and production of proinflammatory cytokines including tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), and IL-6 in both the lung and bronchoalveolar lavage fluid (BALF) in ALI mice.	8-oxoberberine	10-22	interleukin 6	Mus musculus	231-235
33708168-8	2021	Meanwhile, we found the expression levels of interleukin (IL)-1beta, tumor necrosis factor alpha (TNF-alpha), and IL-6 in the brains of mice exposed to ISO were significantly increased.	Isoflurane	152-155	interleukin 6	Mus musculus	114-118
33421465-6	2021	LCP-05 was found to be able to significantly induce the production of NO, IL-6, and TNF-alpha in RAW 264.7 cells, and to induce RAW 264.7 cell"s suppressive effect on both cell growth and cell migration of 4 T1 mammary breast cancer cells.	lcp-05	0-6	interleukin 6	Mus musculus	74-78
33664584-5	2021	The modulation of dysiarenone on anti-inflammation was detected by enzyme-linked immunosorbent assay by measuring the release of inflammatory cytokines (TNF-alpha and IL-6), and inflammatory mediators (LTB4).	dysiarenone	18-29	interleukin 6	Mus musculus	167-171
33664584-8	2021	Results: Our study unraveled that dysiarenone between 2 and 8 microM reduces the inflammation responses via suppressing the production of inflammatory cytokines (TNF-alpha and IL-6) and inflammatory mediators (LTB4).	dysiarenone	34-45	interleukin 6	Mus musculus	176-180
33618332-0	2021	Cholecalciferol (vitamin D3) has a direct protective activity against interleukin 6-induced atrophy in C2C12 myotubes.	Cholecalciferol	0-15	interleukin 6	Mus musculus	70-83
33618332-0	2021	Cholecalciferol (vitamin D3) has a direct protective activity against interleukin 6-induced atrophy in C2C12 myotubes.	Cholecalciferol	17-27	interleukin 6	Mus musculus	70-83
33647318-10	2021	Taken together, the results indicate a protective role of miR-223-3p that inhibits both medial and atherosclerotic vascular calcification by regulating IL-6/STAT3 signaling mediated VSMC transdifferentiation.	mir-223-3p	58-68	interleukin 6	Mus musculus	152-156
33718268-9	2021	The therapeutic effect of Sj-Cys-induced M2 macrophages on sepsis was also reflected by the reduced pathological damages in organs of heart, lung, liver and kidney and reduced serological levels of tissue damage-related ALT, AST, BUN and Cr, associated with downregulated pro-inflammatory cytokines (IFN-gamma and IL-6) and upregulated regulatory anti-inflammatory cytokines (IL-10 and TGF-beta).	sj-cys	26-32	interleukin 6	Mus musculus	314-318
33617553-6	2021	Likewise, dietary palmitate was also increased the circulatory levels of classic proinflammatory cytokines, including IL-6 and TNF-alpha.	dietary palmitate	10-27	interleukin 6	Mus musculus	118-122
33664740-5	2020	Supplementation of taxifolin significantly inhibited the secretions of tumor necrosis factor-alpha, interleukin (IL)-1beta, and IL-6 and significantly increased the secretions of IL-10, secretory immunoglobulin A, superoxide dismutase, and immunoglobulins (IgA, IgG, and IgM) in DSS-induced colitis mice.	taxifolin	19-28	interleukin 6	Mus musculus	128-132
33616474-10	2021	Administration of NPHEL46-61/Rapa to TCR-TrpHEL mice ameliorated vitiligo, promoted Treg production, and suppressed IFN-gamma and IL-6 production, while induced IL-10 production.	nphel46-61	18-28	interleukin 6	Mus musculus	130-134
33592002-9	2021	The joints from sulforaphane-treated CIA mice showed decreased expression of interleukin (IL)-6, IL-17, tumor necrosis factor (TNF)-alpha, receptor activator of NF-kappaB ligand, and tartrate-resistant acid phosphatase.	sulforaphane	16-28	interleukin 6	Mus musculus	77-95
33347820-8	2021	In the ApoE-/- mice fed with HFD, daily Bazedoxifene administration effectively attenuated atherosclerotic plaque area (P<0.01), down-regulated IL-6 levels (P<0.01), decreased STAT3 phosphorylation, reduced VSMCs proliferation and increased endothelial coverage in aortic vessels.	bazedoxifene	40-52	interleukin 6	Mus musculus	144-148
33347820-0	2021	Bazedoxifene exhibits anti-inflammation and anti-atherosclerotic effects via inhibition of IL-6/IL-6R/STAT3 signaling.	bazedoxifene	0-12	interleukin 6	Mus musculus	91-95
33443518-9	2021	In vitro assays showed that the maltol pre-treatment significantly inhibited the expressions of multiple inflammatory factors induced by IL-1beta, such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), nitric oxide (NO), interleukin-6 (IL-6) and tumor necrosis factor (TNF-alpha).	maltol	32-38	interleukin 6	Mus musculus	265-278
33443518-9	2021	In vitro assays showed that the maltol pre-treatment significantly inhibited the expressions of multiple inflammatory factors induced by IL-1beta, such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), nitric oxide (NO), interleukin-6 (IL-6) and tumor necrosis factor (TNF-alpha).	maltol	32-38	interleukin 6	Mus musculus	280-284
33668543-5	2021	CCl4 administration increased hepatic inflammation (which was augmented by the upregulation of nuclear factor kappa-light-chain enhancer of activated B cells (NF-kB), tumor necrosis factor (TNF)-alpha, and interleukin 6 (IL-6) and induced fibrosis, as determined using histopathology and electron microscopy.	Carbon Tetrachloride	0-4	interleukin 6	Mus musculus	206-219
33433547-12	2021	Besides, ICA inhibited the expressions of TLR4, p-NF-kappaB p65, TNF-alpha and IL-6 remarkably in renal tissues.	icariin	9-12	interleukin 6	Mus musculus	79-83
33439200-0	2021	Citrus peel flavonoid nobiletin alleviates lipopolysaccharide-induced inflammation by activating IL-6/STAT3/FOXO3a-mediated autophagy.	Flavonoids	12-21	interleukin 6	Mus musculus	97-101
33439200-9	2021	Mechanistically, we found that nobiletin treatment leads to activation of the IL-6/STAT3/FOXO3a signal pathway through the down-regulation of IL-6 and STAT3 phosphorylation and the upregulation of FOXO3a phosphorylation in the cell nucleus, which is responsible for induction of macrophage autophagy.	nobiletin	31-40	interleukin 6	Mus musculus	78-82
33593395-8	2021	EAE evidently reduced the level of NO in a dose-dependent manner with an IC50 value of 18.12 mug/mL, and the mRNA expression of TNF-alpha, IL-1beta, IL-6, iNOS and COX-2 in LPS-treated RAW264.7 cells.	EAE	0-3	interleukin 6	Mus musculus	149-153
33628372-5	2021	Here, we showed that Senkyunolide I treatment improved the 7-day survival rate and reduced the excessive release of cytokines including TNF-alpha, IL-6, and IL-1beta.	senkyunolide I	21-35	interleukin 6	Mus musculus	147-151
33628372-7	2021	Senkyunolide I treatment also decreased the phosphorylation levels of inflammatory signaling proteins, including p-ERK, p-JNK, p-P38, and p-P65, and the level of inflammatory cytokines, including TNF-alpha, IL-6, and IL-1beta, in the hippocampus homogenate.	senkyunolide I	0-14	interleukin 6	Mus musculus	207-211
33439200-9	2021	Mechanistically, we found that nobiletin treatment leads to activation of the IL-6/STAT3/FOXO3a signal pathway through the down-regulation of IL-6 and STAT3 phosphorylation and the upregulation of FOXO3a phosphorylation in the cell nucleus, which is responsible for induction of macrophage autophagy.	nobiletin	31-40	interleukin 6	Mus musculus	142-146
33668543-5	2021	CCl4 administration increased hepatic inflammation (which was augmented by the upregulation of nuclear factor kappa-light-chain enhancer of activated B cells (NF-kB), tumor necrosis factor (TNF)-alpha, and interleukin 6 (IL-6) and induced fibrosis, as determined using histopathology and electron microscopy.	Carbon Tetrachloride	0-4	interleukin 6	Mus musculus	221-225
33643287-6	2020	We now confirm that induction of S100-alarmins in an imiquimod-induced murine model of psoriasis-like skin inflammation was associated with an increased expression of interleukin (IL)-1alpha, IL-6, IL-17A, or TNFalpha.	Imiquimod	53-62	interleukin 6	Mus musculus	192-196
33429196-9	2021	Finally, uric acid reduced the release of the proinflammatory cytokines TNF-alpha, IL1beta, and IL6 caused by OGD/R in BV2 cells by dampening HMGB1-TLR4-NF-kappaB signaling, which was reversed by probenecid treatment, an inhibitor of the uric acid channel.	Uric Acid	9-18	interleukin 6	Mus musculus	96-99
33633700-5	2021	In the murine infection model, P4 (1 mg/day) inhibited the inflammatory effects induced by gonococcal infections which led to decreased neutrophil infiltration, reduced polymorphonuclear neutrophils (PMNs) numbers, IL-1beta, TNF-alpha, and IL-6 levels in vaginal secretions.	propiverine	31-33	interleukin 6	Mus musculus	240-244
33220278-11	2021	Furthermore, T0070907 reversed the anti-inflammatory effects of DEX on TNFalpha and IL-6 productions in the cells.	T 0070907	13-21	interleukin 6	Mus musculus	84-88
33543862-6	2021	RESULTS: Multiomics analyses showed that ethanol impaired skeletal muscle mTORC1 signaling, mitochondrial oxidative pathways, including intermediary metabolite regulatory genes, interleukin-6, and amino acid degradation pathways are beta-hydroxymethyl-butyrate targets.	Ethanol	41-48	interleukin 6	Mus musculus	178-191
33543862-6	2021	RESULTS: Multiomics analyses showed that ethanol impaired skeletal muscle mTORC1 signaling, mitochondrial oxidative pathways, including intermediary metabolite regulatory genes, interleukin-6, and amino acid degradation pathways are beta-hydroxymethyl-butyrate targets.	beta-hydroxymethyl-butyrate	233-260	interleukin 6	Mus musculus	178-191
33562046-4	2021	The results showed that stevioside was capable of down-regulating lipopolysaccharide (LPS)-induced expression and production of pro-inflammatory cytokines and mediators in macrophages from different sources, such as IL-6, TNF-alpha, IL-1beta, iNOS/NO, COX2, and HMGB1, whereas it up-regulated the anti-inflammatory cytokines IL-10 and TGF-beta1.	stevioside	24-34	interleukin 6	Mus musculus	216-220
33574657-5	2021	Results: The results of in vitro studies revealed that derivatives 3d, 3e, 3L, and 3o are comparable to that of the oleanolic acid on the inhibition of TNF-alpha and IL-6 release.	Oleanolic Acid	116-130	interleukin 6	Mus musculus	166-170
33220278-11	2021	Furthermore, T0070907 reversed the anti-inflammatory effects of DEX on TNFalpha and IL-6 productions in the cells.	Dexmedetomidine	64-67	interleukin 6	Mus musculus	84-88
33399208-4	2021	The quantitative real-time polymerase chain reaction and western blot analysis results showed that edpetiline significantly inhibited the content and mRNA expression levels of proinflammatory cytokines (TNF-alpha and IL-6) in LPS-induced RAW264.7 cells, significantly increased the mRNA expression of IL-4 (anti-inflammatory cytokine), and markedly downregulated the inflammatory mediators inductible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) mRNA and protein expression levels.	Edpetiline	99-109	interleukin 6	Mus musculus	217-221
33293358-5	2021	The induction of hippocampal IL-6 after pilocarpine SE was nearly abolished in EP2 conditional knockout mice.	Pilocarpine	40-51	interleukin 6	Mus musculus	29-33
33546405-8	2021	Exercise, alone or in combination with DHA, significantly reversed the induction of proinflammatory genes (Mcp1, Il6, Tnfalpha, Tlr4) in DIO mice.	Docosahexaenoic Acids	39-42	interleukin 6	Mus musculus	113-116
33633749-8	2021	Moreover, 15d-PGJ2 treated mice exhibited the significantly reduced proportion of macrophages expressing the pro-inflammatory cytokine, IL-6 with concomitant suppression of STAT3 phosphorylation in the colonic mucosa of mice administered 2.5% DSS in drinking water.	15-deoxy-delta(12,14)-prostaglandin J2	10-18	interleukin 6	Mus musculus	136-140
33220278-9	2021	DEX inhibited LPS-induced TNFalpha, IL-6, and PGE2 productions and COX-2 mRNA expression, and the effects of DEX were reversed by yohimbine.	Dexmedetomidine	0-3	interleukin 6	Mus musculus	36-40
33220278-9	2021	DEX inhibited LPS-induced TNFalpha, IL-6, and PGE2 productions and COX-2 mRNA expression, and the effects of DEX were reversed by yohimbine.	Yohimbine	130-139	interleukin 6	Mus musculus	36-40
33542347-12	2021	MK4 diminished levels of several cytokines and chemokines in liver, including IL-6, TNFalpha and MCP1, as measured by hepatic cytokine array.	menatetrenone	0-3	interleukin 6	Mus musculus	78-82
33604333-6	2020	Application of HYP9 in vivo alleviated the brain infarct lesion, astrocytes population, apoptosis, and interleukin-6 (IL-6) and IL-1beta release in mouse cortices after ischemia.	Hyp9	15-19	interleukin 6	Mus musculus	103-116
33604333-6	2020	Application of HYP9 in vivo alleviated the brain infarct lesion, astrocytes population, apoptosis, and interleukin-6 (IL-6) and IL-1beta release in mouse cortices after ischemia.	Hyp9	15-19	interleukin 6	Mus musculus	118-122
33536347-5	2021	Cellular experiments data showed that Linarin suppressed lipopolysaccharide (LPS)-caused the overproduction of nitric oxide (NO), prostaglandin E2 (PGE2), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) in chondrocyte.	linarin	38-45	interleukin 6	Mus musculus	155-168
33536347-5	2021	Cellular experiments data showed that Linarin suppressed lipopolysaccharide (LPS)-caused the overproduction of nitric oxide (NO), prostaglandin E2 (PGE2), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) in chondrocyte.	linarin	38-45	interleukin 6	Mus musculus	170-174
32915501-2	2021	Most of these compounds displayed greater inhibitory ability against NO production than the lead compound 4-o-methyl-benzenesulfonyl benzoxazolone, and the most active compound 2h exhibited the strongest inhibitory activity against NO, IL-1beta, and IL-6 production with IC50 values 17.67, 20.07 and 8.61 muMu, respectively.	Deuterium	177-179	interleukin 6	Mus musculus	250-254
32948825-8	2021	In db/db mice, TUG-891 administration significantly inhibited the mRNA and protein expression of fibronectin, collagen IV, alpha-SMA, TGF-beta1, and IL-6, and downregulated the phosphorylation of Smad3 and STAT3 to alleviate glomerulosclerosis.	3-(4-((4-fluoro-4'-methyl-(1,1'-biphenyl)-2-yl)methoxy)phenyl)propanoic acid	15-22	interleukin 6	Mus musculus	149-153
33221976-9	2021	CIA mice treated with LXA4 and SB203580 had lower levels of TNF-alpha, IL-6, IL-1beta, and IFN-gamma, accompanying decreased MDA as well as increased SOD, CAT,and GPx.	lipoxin A4	22-26	interleukin 6	Mus musculus	71-75
33221976-9	2021	CIA mice treated with LXA4 and SB203580 had lower levels of TNF-alpha, IL-6, IL-1beta, and IFN-gamma, accompanying decreased MDA as well as increased SOD, CAT,and GPx.	SB 203580	31-39	interleukin 6	Mus musculus	71-75
32940862-10	2021	We also found that treatment with raloxifene inhibited the release of IL-6 and suppressed the phosphorylation of STAT3Y705 in PDAC cells.	Raloxifene Hydrochloride	34-44	interleukin 6	Mus musculus	70-74
33575081-6	2021	Taken together, these results suggest that both the differentiation-inducing agent dbcAMP and the chemotherapy drug TMZ are able to drive GBM cells to senescence, and the latter releases IL-6 to potentiate glycolysis, suggesting that IL-6 is a target for adjuvant chemotherapy in GBM treatment.	Temozolomide	116-119	interleukin 6	Mus musculus	187-191
33575081-6	2021	Taken together, these results suggest that both the differentiation-inducing agent dbcAMP and the chemotherapy drug TMZ are able to drive GBM cells to senescence, and the latter releases IL-6 to potentiate glycolysis, suggesting that IL-6 is a target for adjuvant chemotherapy in GBM treatment.	Temozolomide	116-119	interleukin 6	Mus musculus	234-238
32409965-10	2021	In murine PC models, intraperitoneal CMP-001 treatment elicited an anti-tumor immune response including an increase in chemokines (RANTES and MIP-1beta), pro-inflammatory cytokines (IFNgamma, interleukin 6 [IL-6], and IL-12), and peritoneal/tumor immune infiltration (CD4+/CD8+ T and natural killer [NK] cells).	Cytidine Monophosphate	37-40	interleukin 6	Mus musculus	192-205
32409965-10	2021	In murine PC models, intraperitoneal CMP-001 treatment elicited an anti-tumor immune response including an increase in chemokines (RANTES and MIP-1beta), pro-inflammatory cytokines (IFNgamma, interleukin 6 [IL-6], and IL-12), and peritoneal/tumor immune infiltration (CD4+/CD8+ T and natural killer [NK] cells).	Cytidine Monophosphate	37-40	interleukin 6	Mus musculus	207-211
33503557-5	2021	In invitro models of senescent foamy macrophages and senescent endothelial cells stimulated with oxidized high-density-lipoprotein, the CD9 antibody-modified mesoporous silica nanoparticles exhibit high cellular uptake; reduce the reactive oxygen species level, high-density lipoprotein oxidation, and production of TNF-alpha and IL-6; and attenuate the senescence process, contributing to improved cell viability.	mesoporous silica	158-175	interleukin 6	Mus musculus	330-334
33130971-4	2021	The following in vivo and in vitro results demonstrated that LIG prevented experimental mice colitis induced by dextran sulfate sodium (DSS) via suppressing inflammatory cell infiltration, the activity of MPO and iNOS, and the expression and production of IL-1beta, IL-6, and TNF-alpha.	ligustilide	61-64	interleukin 6	Mus musculus	266-270
33146827-7	2021	Compared with group S, groups Au and Al had significantly shorter aortic diameters (group S vs Au vs Al; 2.29 vs 1.40 vs 1.36 mm, respectively, p < 0.01), reduced MMP-2 and MMP-9 activities, downregulated IL-6 and MCP-1 and upregulated expression of IGF-1 and TIMP-2.	Aluminum	37-39	interleukin 6	Mus musculus	205-209
32940862-12	2021	CONCLUSIONS: Inhibition of ERbeta and the IL-6/gp130/STAT3 signaling pathway by raloxifene leads to potent reduction of PDAC growth in vitro and in vivo.	Raloxifene Hydrochloride	80-90	interleukin 6	Mus musculus	42-46
32915501-6	2021	The results indicated that the anti-inflammatory effect of 2h might be realized through the regulation of ERK- and p38-mediated mitogen-activated protein kinase (MAPK)-NF-kappaB/iNOS signaling, thereby reducing the excessive release of NO, IL-1beta, and IL-6.	Deuterium	59-61	interleukin 6	Mus musculus	254-258
33641782-10	2021	The results showed that mangiferin treatment significantly reduced NO, IL-1beta, IL-6 and TNF-alpha production, also reduced the mRNA and protein of iNOS and COX-2, promoted the polarization of inflammatory toward anti-inflammatory, and inhibited activation of NF-kappaB and NLRP3 inflammasome.	mangiferin	24-34	interleukin 6	Mus musculus	81-85
33200943-8	2021	RESULTS: Dural injection of interleukin-6 in the presence of anisomycin or 4EGI-1 or in eIF4ES209Amice resulted in the partial attenuation of acute facial hypersensitivity and complete block of hyperalgesic priming.	Anisomycin	61-71	interleukin 6	Mus musculus	28-41
33049506-6	2021	By contrast, limited HO-1 expression by HO-1 inhibitor ZnPP specifically alleviated As-mediated down-regulation of CD80, chemokine factor C-C chemokine receptor 7 (CCR7), tumor necrosis factor (TNF) -alpha, Interleukin (IL)-23 and IL-6, which reminds us the peculiarity of HO-1 in As-induced immune tolerance in murine DCs.	zinc protoporphyrin	55-59	interleukin 6	Mus musculus	231-235
32766955-5	2021	In addition, cudraflavanone B suppressed the production of pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha in LPS-induced RAW264.7 and BV2 cells.	Cudraflavanone B	13-29	interleukin 6	Mus musculus	94-107
33206422-5	2021	In addition, topical CLA significantly dose-dependently inhibited pro-inflammatory cytokines including interleukin (IL)-6, IL-1beta, tumor necrosis factor (TNF)-alpha, and pro-inflammatory enzyme expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in inflamed mice skin.	Linoleic Acids, Conjugated	21-24	interleukin 6	Mus musculus	103-121
33352218-4	2021	We observe that alphaT and gammaTmT mitigated DSS-caused fecal bleeding, diarrhea and elevation of IL-6.	alpha-Tocopherol	16-22	interleukin 6	Mus musculus	99-103
33352218-4	2021	We observe that alphaT and gammaTmT mitigated DSS-caused fecal bleeding, diarrhea and elevation of IL-6.	gammatmt	27-35	interleukin 6	Mus musculus	99-103
33352218-4	2021	We observe that alphaT and gammaTmT mitigated DSS-caused fecal bleeding, diarrhea and elevation of IL-6.	Dextran Sulfate	46-49	interleukin 6	Mus musculus	99-103
32978698-10	2021	Acetate reduced the levels of IL-1beta and IL-6 and acetate + propionate reduced IL-6 more significantly than butyrate.	Acetates	0-7	interleukin 6	Mus musculus	43-47
32789555-6	2021	NE (10-6 M) triggered inflammatory cytokine secretion by TMJ chondrocytes, and Yohimbine suppressed IL-1beta- or NE-induced IL-6 upregulation in TMJ chondrocytes with the nuclear factor (NF)-kappaB pathway inhibition.	Yohimbine	79-88	interleukin 6	Mus musculus	124-128
32978698-10	2021	Acetate reduced the levels of IL-1beta and IL-6 and acetate + propionate reduced IL-6 more significantly than butyrate.	Acetates	52-59	interleukin 6	Mus musculus	81-85
32978698-10	2021	Acetate reduced the levels of IL-1beta and IL-6 and acetate + propionate reduced IL-6 more significantly than butyrate.	Propionates	62-72	interleukin 6	Mus musculus	81-85
33221959-10	2021	The increase in IL-6 level induced by OCS was maintained for 24 h. The OCS also increased the number of white blood cells and the percentage of neutrophils in BALFs.	L-Cysteic acid	38-41	interleukin 6	Mus musculus	16-20
33165140-7	2021	In addition, treatment of astragalin markedly decreased the secretion of inflammatory factors, including IL-6, MCP-1, TNF-alpha and IL-1beta.	astragalin	26-36	interleukin 6	Mus musculus	105-109
33491226-3	2021	Orally administered SCP exhibited potent anti-inflammatory activity in lipopolysaccharide (LPS)-challenged mice by suppressing serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-8 (IL-8), as well as nitric oxide (NO).	Sulfachlorpyridazine	20-23	interleukin 6	Mus musculus	184-197
33350058-12	2021	Reducing interleukin 6 levels counteracted the change in expression of genes involved in the hepatobiliary transport, bile acid synthesis, and inflammation.	Bile Acids and Salts	118-127	interleukin 6	Mus musculus	9-22
33423569-5	2021	Results: Propofol inhibited the production of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 in the pouch.	Propofol	9-17	interleukin 6	Mus musculus	84-102
33423569-7	2021	Conclusion: Propofol has an anti-inflammatory property in the carrageenan-induced mouse air pouch local inflammation model, by inhibiting the production of pro-inflammatory cytokines (TNF-alpha and IL-6), as well as by inhibiting the production of chemokines (KC and MIP-2), which might be associated with the inhibition of intra-pouch recruitment of white blood cells.	Propofol	12-20	interleukin 6	Mus musculus	198-202
33491226-3	2021	Orally administered SCP exhibited potent anti-inflammatory activity in lipopolysaccharide (LPS)-challenged mice by suppressing serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-8 (IL-8), as well as nitric oxide (NO).	Sulfachlorpyridazine	20-23	interleukin 6	Mus musculus	199-203
33183460-7	2021	After 24 hours of administration, the data shows that simvastatin-NLCs inhibit the levels of IL-6 and TNF-alpha inflammatory factor in the lungs of mice.	Simvastatin	54-65	interleukin 6	Mus musculus	93-97
32812186-5	2021	Analyzed data showed that sinomenine reduces severity of the clinical signs and to some extent decreases tissue level of pro-inflammatory cytokines IL-1beta, IL-6, IL-18, TNFalpha, IL-17A, and increases level of anti-inflammatory IL-10.	sinomenine	26-36	interleukin 6	Mus musculus	158-162
33313945-5	2021	Following shikonin treatment, the accumulation of pulmonary neutrophils and expression of TNFalpha, IL-1beta and IL-6 were decreased in mice with LTA-induced ALI.	shikonin	10-18	interleukin 6	Mus musculus	113-117
33044639-19	2021	The main mechanism in the cell death and inflammatory effects of IFNgamma is mediated by stimulation of ROS-mediated caspase (caspase -3 and - 9) activations and cytokine production (TNF-alpha, IL-1beta, and IL-6) via TRPM2 activation, respectively.	Reactive Oxygen Species	104-107	interleukin 6	Mus musculus	208-212
33377310-4	2021	METHODS AND RESULTS: In LPS-stimulated mouse bone marrow-derived macrophages, lactucopicrin inhibited NF-kappaB activation and concomitantly repressed the expression of IL-1beta, IL-6 and tumor necrosis factor alpha.	intybin	78-91	interleukin 6	Mus musculus	179-183
33313945-5	2021	Following shikonin treatment, the accumulation of pulmonary neutrophils and expression of TNFalpha, IL-1beta and IL-6 were decreased in mice with LTA-induced ALI.	lipoteichoic acid	146-149	interleukin 6	Mus musculus	113-117
33300057-0	2021	The mRNA expression of Il6 and Pdcd1 are predictive and protective factors for doxorubicin-induced cardiotoxicity.	Doxorubicin	79-90	interleukin 6	Mus musculus	23-26
33572597-9	2021	Also, pro-inflammatory cytokines, such as interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha, reduced by loganin treatment.	loganin	122-129	interleukin 6	Mus musculus	66-70
32750462-14	2021	The ethanol extracts of GR-SC65 exerted a stronger anti-inflammatory activity than GR by inhibiting pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in LPS-induced RAW264.7 macrophages.	Ethanol	4-11	interleukin 6	Mus musculus	177-190
32750462-14	2021	The ethanol extracts of GR-SC65 exerted a stronger anti-inflammatory activity than GR by inhibiting pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in LPS-induced RAW264.7 macrophages.	Ethanol	4-11	interleukin 6	Mus musculus	192-196
33572505-10	2021	In addition, mice experiments data revealed that upregulation of Nogo-A in notexin- and tunicamycin-treated muscles was associated with upregulation of CHOP, IL-6 and TNF-alpha in WT group, while in Nogo-KO group resulted in low expression level of CHOP, IL-6 and TNF-alpha.	Tunicamycin	88-99	interleukin 6	Mus musculus	158-162
33572505-10	2021	In addition, mice experiments data revealed that upregulation of Nogo-A in notexin- and tunicamycin-treated muscles was associated with upregulation of CHOP, IL-6 and TNF-alpha in WT group, while in Nogo-KO group resulted in low expression level of CHOP, IL-6 and TNF-alpha.	Tunicamycin	88-99	interleukin 6	Mus musculus	255-259
33572510-7	2021	Kirenol significantly inhibited the secretion of cytokines, IL-1beta, IL6, and TNFalpha, into the BALF of the mice with LPS-induced ALI through NFkappaB activation.	kirenol	0-7	interleukin 6	Mus musculus	70-73
33628094-8	2021	Results: G-Rg1 could decrease ALT, AST, TNF-alpha, IL-1beta and IL-6 in mice with CCl4-induced acute liver injury.	ginsenoside Rg1	9-14	interleukin 6	Mus musculus	64-68
33584285-8	2020	Finally, we also found that arbidol reduced serum levels of pro-inflammatory factors such as TNF-alpha and IL-6 induced by fecal dilution.	umifenovir	28-35	interleukin 6	Mus musculus	107-111
33503995-3	2021	Mice were fed diets containing whole LP powder, MetOH extract, and MetOH residue for 16 d. DSS administration for 9 d induced bodyweight loss, reduced colon length, reduced the colonic expression of tight junction proteins including zonula occludens-1 and -2, and claudin-3 and -7, and upregulated colonic mRNA expression of interleukin 6, chemokine (C-X-C motif) ligand 2, and C-C motif chemokine ligand 2.	Dextran Sulfate	91-94	interleukin 6	Mus musculus	325-372
32891820-0	2021	Baitouweng decoction alleviates dextran sulfate sodium-induced ulcerative colitis by regulating intestinal microbiota and the IL-6/STAT3 signaling pathway.	Dextran Sulfate	32-54	interleukin 6	Mus musculus	126-130
32891820-9	2021	RESULTS: BTW effectively reduced the symptoms and histopathological score of UC mice, and it reduced the production of IL-6, IL-1beta and TNF-alpha.	BTW	9-12	interleukin 6	Mus musculus	119-123
32891820-10	2021	Activation of the IL-6/STAT3 pathway was also suppressed by BTW treatment.	BTW	60-63	interleukin 6	Mus musculus	18-22
32891820-15	2021	CONCLUSION: BTW significantly improved the inflammatory symptoms of mice with acute colitis, and the latent mechanism of BTW may be related to various signaling pathways, including the modulation of intestinal microflora and inflammatory signaling pathways, such as IL-6/STAT3.	BTW	12-15	interleukin 6	Mus musculus	266-270
32891820-15	2021	CONCLUSION: BTW significantly improved the inflammatory symptoms of mice with acute colitis, and the latent mechanism of BTW may be related to various signaling pathways, including the modulation of intestinal microflora and inflammatory signaling pathways, such as IL-6/STAT3.	BTW	121-124	interleukin 6	Mus musculus	266-270
33509279-7	2021	DSS led to edema, epithelial layer disruption, inflammatory cell infiltration, and cytokine induction (tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta) in the colon tissues.	Dextran Sulfate	0-3	interleukin 6	Mus musculus	132-145
33575163-13	2021	Compared with the LPS group, APS pretreatment could inhibit the expression of inflammatory factors including TNF-alpha, IL-1 beta, IL-6, and IL-8 (all P < 0.05), reducing the number of apoptotic cells (P < 0.05), suppressing the expression of caspase-3, caspase-9, and Bax, but upregulating the expression levels of Bcl-2.	aps	29-32	interleukin 6	Mus musculus	131-135
33480036-9	2021	A significant reduction in IL-1beta, IL-6, myeloperoxidase (MPO) and oxidative stress was observed by desidustat treatment.	desidustat	102-112	interleukin 6	Mus musculus	37-41
33747442-4	2021	MP alleviated UC symptoms through reducing colon shortening and tissue damage, decreasing neutrophil infiltration, maintaining the mucous layer integrity, and suppressing the expression of TNF-alpha, IL-17A, IL-6, and IL-1beta.	mp	0-2	interleukin 6	Mus musculus	208-212
33478532-0	2021	HSP22 (HSPB8) positively regulates PGF2alpha-induced synthesis of interleukin-6 and vascular endothelial growth factor in osteoblasts.	Dinoprost	35-44	interleukin 6	Mus musculus	66-79
33410857-6	2021	Supplementation with aloin significantly reduced serum concentration or liver protein abundance of malondialdehyde, tumor necrosis factor alpha, Interleukin (IL)-1beta and IL-6.	alloin	21-26	interleukin 6	Mus musculus	172-176
33478532-2	2021	We previously demonstrated that prostaglandin F2alpha (PGF2alpha), a potent bone remodeling factor, induces the synthesis of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells.	Dinoprost	32-53	interleukin 6	Mus musculus	125-138
33553120-10	2020	Results:The combination of praziquantel and hydroxyasiaticoside lowered the pathological scores of schistosomiasis-induced hepatic fibrosis, the liver indice, serum AST and ALT levels, improved liver morphology, downregulated the expression levels of hepatic type I and III collagen, inhibited the mRNA expression levels of pro-inflammatory factors (IL-6 and TNF-alpha) in the liver of mice relative to the praziquantel alone.	Praziquantel	27-39	interleukin 6	Mus musculus	350-354
33478532-2	2021	We previously demonstrated that prostaglandin F2alpha (PGF2alpha), a potent bone remodeling factor, induces the synthesis of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells.	Dinoprost	32-53	interleukin 6	Mus musculus	140-144
33553120-10	2020	Results:The combination of praziquantel and hydroxyasiaticoside lowered the pathological scores of schistosomiasis-induced hepatic fibrosis, the liver indice, serum AST and ALT levels, improved liver morphology, downregulated the expression levels of hepatic type I and III collagen, inhibited the mRNA expression levels of pro-inflammatory factors (IL-6 and TNF-alpha) in the liver of mice relative to the praziquantel alone.	hydroxyasiaticoside	44-63	interleukin 6	Mus musculus	350-354
33478532-2	2021	We previously demonstrated that prostaglandin F2alpha (PGF2alpha), a potent bone remodeling factor, induces the synthesis of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells.	Dinoprost	55-64	interleukin 6	Mus musculus	125-138
33478532-2	2021	We previously demonstrated that prostaglandin F2alpha (PGF2alpha), a potent bone remodeling factor, induces the synthesis of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells.	Dinoprost	55-64	interleukin 6	Mus musculus	140-144
33478532-3	2021	In the present study, we investigated whether HSP22 is implicated in the PGF2alpha-induced synthesis of IL-6 and VEGF and the mechanism of MC3T3-E1 cells.	Dinoprost	73-82	interleukin 6	Mus musculus	104-108
33478532-7	2021	RESULTS: The PGF2alpha-induced release of IL-6 in HSP22 knockdown cells was significantly suppressed compared with that in the control cells.	Dinoprost	13-22	interleukin 6	Mus musculus	42-46
33478532-10	2021	CONCLUSIONS: Our results strongly suggest that HSP22 acts as a positive regulator in the PGF2alpha-induced synthesis of IL-6 and VEGF in osteoblasts.	Dinoprost	89-98	interleukin 6	Mus musculus	120-124
33468182-10	2021	RESULTS: Our data showed that ferulic acid significantly inhibited palmitate-induced cell death, rescued mitochondrial membrane potential, reduced reactive oxygen species accumulation, and decreased inflammatory factor activation, including IL-6 and IL-1beta.	ferulic acid	30-42	interleukin 6	Mus musculus	241-245
33542713-4	2020	Pretreatment of macrophages with TEPP-46 resulted in tolerance to LPS stimulation, as demonstrated by a significant reduction in the production of TNF-alpha and IL-6.	TEPP-46	33-40	interleukin 6	Mus musculus	161-165
33091778-7	2021	Exposure to BPA also reduced the anti- and pro-inflammatory cytokines IL-10, IL-6, IFN-gamma, and IL-7 in the epididymis, while the chemotaxis-associated cytokines CCL12, CCL17, CXCL16, and MCP-1 increased.	bisphenol A	12-15	interleukin 6	Mus musculus	77-81
33461456-5	2022	Moreover, treatment with EPA-PC and LPS significantly decreased IL-2, IL-6 and IL-12/IL-23(p40) expression (p < 0.01).	epa-pc	25-31	interleukin 6	Mus musculus	70-74
33461456-7	2022	CONCLUSION: These results suggest that EPA-PC is more effective in decreasing the expression of pro-inflammatory cytokines [IL-2, IFN-gamma, IL-6 and IL-12/IL-23(p40)] upon induction of inflammation.	epa-pc	39-45	interleukin 6	Mus musculus	141-145
33527019-9	2021	In Schisandrin-C-treated groups, the expression levels of CD86, tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-1beta decreased, whereas CD206, IL-10, and transforming growth factor (TGF)-beta expression levels increased.	schizandrin C	3-16	interleukin 6	Mus musculus	99-117
33477973-6	2021	When lipopolysaccharide-stimulated RAW 264.7 cells were treated with the oligosaccharides, the production of nitric oxide was decreased; the expression of inducible nitric oxide synthase, tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-10 was suppressed; and the nuclear factor-kappa B signaling pathway was inhibited.	Oligosaccharides	73-89	interleukin 6	Mus musculus	241-245
33466581-7	2021	In addition, among the carbon sources that drive OXPHOS, glutamine is a very potent inducer of IL6 production.	Carbon	23-29	interleukin 6	Mus musculus	95-98
33186629-9	2021	Mechanism investigation indicated that AAI triggered inflammation in the hippocampus of mice through increasing the activity of Tnf-alpha-NF-kappaB-IL-6 signaling pathway.	aristolochic acid I	39-42	interleukin 6	Mus musculus	148-152
33450992-6	2021	Among them, the non-cytotoxic 2-aminobenzimidazole 49d was the most potent at inhibiting significantly: (i) MSK1 activity, (ii) the release of IL-6 in inflammatory conditions in vitro (IC50~2 microM) and (iii) the inflammatory cell recruitment to the airways in a mouse model of asthma.	2-aminobenzimidazole	30-50	interleukin 6	Mus musculus	143-147
33511217-7	2021	TOFA also suppressed the expression levels of proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6, and IFN-gamma) and the parameters of oxidative stress (MDA, GSH, SOD, and CAT) in kidney tissues.	tofacitinib	0-4	interleukin 6	Mus musculus	94-98
33466581-7	2021	In addition, among the carbon sources that drive OXPHOS, glutamine is a very potent inducer of IL6 production.	Glutamine	57-66	interleukin 6	Mus musculus	95-98
33428604-6	2021	Furthermore, IL-6 treatment significantly activated the PI3K/Akt and STAT3 signaling pathways in the myocardium during MI/R, and the specific inhibitors wortmannin (specific phosphoinositide 3-kinase inhibitor) and Stattic (specific STAT3 inhibitor) substantially abolished HIF2alpha/IL-6-induced cardioprotection.	Wortmannin	153-163	interleukin 6	Mus musculus	13-17
33510636-8	2020	Consistently, KS23 decreased the expression of TNF-alpha and IL-6 in the supernatant of LPS-stimulated RAW 264.7 cells and inhibited the LPS-induced nuclear translocation of NF-kappaB p65 and the phosphorylation of IKKalpha/beta/IkappaBalpha/NF-kappaB.	ks23	14-18	interleukin 6	Mus musculus	61-65
33510646-12	2020	FFA treatment also reduced age associated increases in plasma interleukin 6 and tumor necrosis factor-alpha (TNF-alpha) concentrations which were elevated in 12 and 24-months old mice compared to young mice and decreased age-related muscle damage as indicated by a reduction in serum creatine kinase (CK) activity.	Flufenamic Acid	0-3	interleukin 6	Mus musculus	62-75
33441763-4	2021	Both mechanical HIFU and thermal ablation induced a potent inflammatory response with increased expression of Nlrp3, Jun, Mefv, Il6 and Il1beta and alterations in macrophage polarization compared to control.	hifu	16-20	interleukin 6	Mus musculus	128-131
33442686-6	2021	High molecular weight (HMW) poly I:C (1 to 6 kb, 12 mg/kg) produced more robust sickness behavior and more robust IL-6, IFN-I and TNF alpha responses than poly I:C of less than 500 bases (low MW) preparations.	Poly I-C	28-36	interleukin 6	Mus musculus	114-118
33442686-8	2021	In aged animals, poly I:C induced exaggerated IL-6, IL-1beta and IFN-I in the plasma and similar exaggerated brain cytokine responses.	Poly I-C	17-25	interleukin 6	Mus musculus	46-50
33490128-8	2020	Furthermore, quercetin supplementation markedly activated the expression of Nrf2 and HO-1 mRNAs, but inhibited the expression of NF-kappaB, IL-1beta, IL-6, and TNF-alpha mRNAs.	Quercetin	13-22	interleukin 6	Mus musculus	150-154
33505591-4	2021	In vitro cellular data indicated that MEs suppressed the LPS-induced MAPKs and NF-kappaB activation, therefore inhibiting overproduction of reactive oxygen species, nitric oxide, tumor necrosis factor-alpha, and interleukin-6; blocking microglia activation; and protecting DAergic neurons from the microglia-mediated neurotoxicity.	2-(N-morpholino)ethanesulfonic acid	38-41	interleukin 6	Mus musculus	212-225
33413289-15	2021	The diterpenes DEOX, ICT, and DAM decreased levels of NO (38.34, 47.63, 67.15%), IL-6 (57.84, 60.45, 44.26%), and TNF-alpha (38.90, 31.30, 32.83%), respectively.	Diterpenes	4-14	interleukin 6	Mus musculus	81-85
33413289-18	2021	Furthermore, the diterpenes DEOX, DAM, and ICT showed anti-inflammatory activity by reducing levels of NO, TNF-alpha, and IL-6.	Diterpenes	17-27	interleukin 6	Mus musculus	122-126
33413289-18	2021	Furthermore, the diterpenes DEOX, DAM, and ICT showed anti-inflammatory activity by reducing levels of NO, TNF-alpha, and IL-6.	diacetylmonoxime	34-37	interleukin 6	Mus musculus	122-126
33413289-18	2021	Furthermore, the diterpenes DEOX, DAM, and ICT showed anti-inflammatory activity by reducing levels of NO, TNF-alpha, and IL-6.	icetexone	43-46	interleukin 6	Mus musculus	122-126
33422110-9	2021	The DSS also increased the impact of LPS plus paraquat upon microglial morphology, along with circulating lipocalin-2 (neutrophil marker) and IL-6.	dss	4-7	interleukin 6	Mus musculus	142-146
33406219-7	2021	D+Q-treated mice show significantly lower senescent cell (p16 and p21 expression) and inflammatory (Cxcl1, Il1beta, Il6, Mcp1 and Tnfalpha expression) burden in small and large intestine compared with control mice.	d+q	0-3	interleukin 6	Mus musculus	116-119
33045197-5	2021	Significantly, AS (20 mg/kg) treatment not only enhanced the ability of HC mice to clear bacteria, but also increased spleen index, the levels of pro-inflammatory cytokines from 78.7 +- 12.1 ng/ml (TNF-alpha) and 48.7 +- 8.6 pg/ml (IL-6) to 174.0 +- 90.5 ng/ml and 783.3 +- 90.5 pg/ml, number of white blood cells in blood, and sIgA in colon.	Artesunate	15-17	interleukin 6	Mus musculus	232-236
33442235-6	2021	LP-KSFY06 upregulated the anti-inflammatory factor interleukin (IL)-10 and downregulated the pro-inflammatory factors IL-6, IL-1beta, tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma).	lp-ksfy06	0-9	interleukin 6	Mus musculus	118-122
33205285-10	2021	PFM administration to mice under chemotherapy maintained the anti-cancer/anti-metastasis effect of capecitabine with similar or decreased values for serum IL-10 and TNF-alpha and decreased IL-6, a cytokine related to poor prognosis in advanced cancer patients.	PFM	0-3	interleukin 6	Mus musculus	189-193
33371810-4	2021	In this study, baicalin displayed a suppressing role on IL-1[Formula: see text], TNF[Formula: see text] and IL-6 in both cell and mice models.	baicalin	15-23	interleukin 6	Mus musculus	108-112
33065235-5	2021	Furthermore, benzamil ameliorated HFD-induced impairment of aortic endothelium-dependent dilation by reducing expression of proinflammatory cytokines, including TNF-alpha, IL-1beta, and IL-6 and production of adhesion molecules including VCAM-1 and ICAM-1 in both C57BL/6 and LDLr-/- mice fed with HFD.	benzamil	13-21	interleukin 6	Mus musculus	186-190
33683190-9	2021	Additionally, A2aR agonists enhanced the cell viability of colonic epithelial cells and inhibit the production of cytokines IL-6 and TNF-[Formula: see text] in vitro, which may further influence the pathway of ATP purine signal metabolism and alleviates the gut inflammation of UC mice.	atp purine	210-220	interleukin 6	Mus musculus	124-128
33829964-5	2021	In the animal study, compared with DSS-induced mice, PNS reduced the expression of pro-inflammatory cytokines (TNF-[Formula: see text], IL-6, and MCP-1) in the colon tissues.	4'-phosphopantetheine	53-56	interleukin 6	Mus musculus	136-140
32919904-11	2021	Moreover, BG in the exine stimulated production of TNF-alpha and IL-6 in the BMDCs via a dectin-1-dependent mechanism.	(1----3)-beta-d-glucan	10-12	interleukin 6	Mus musculus	65-69
32919904-11	2021	Moreover, BG in the exine stimulated production of TNF-alpha and IL-6 in the BMDCs via a dectin-1-dependent mechanism.	exine	20-25	interleukin 6	Mus musculus	65-69
33197761-9	2021	Mechanistically, we observed that NXT inhibited neuron atrophy and apoptosis by downregulating inflammatory cytokines, interleukin 1beta (IL-1beta), IL-6 and tumor necrosis factor alpha (TNF-alpha), and inflammation mediators, nuclear factor kappaB (NF-kappaB) and toll-like receptor 4 (TLR4) in the brain.	nxt	34-37	interleukin 6	Mus musculus	149-153
33952827-3	2021	In this study, it showed that Oridonin significantly improved kidney damage, and inhibited the expression of interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha and MCP-1, as well as macrophage marker F4/80 in kidney and the secretion of inflammatory cytokins in serum of AKI mice in vivo.	oridonin	30-38	interleukin 6	Mus musculus	133-137
33840686-8	2021	IL-12p40 and IL-6 synthesis by BM-DCs was completely diminished upon stimulation with HA treated with concanavalin A (ConA)-bound sepharose beads.	Sepharose	130-139	interleukin 6	Mus musculus	13-17
32347046-12	2021	Furthermore, neferine significantly decreased serum levels of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and IL-6 and increased serum levels of anti-inflammatory cytokine IL-10.	neferine	13-21	interleukin 6	Mus musculus	175-179
33035633-11	2021	AM966 treatment and LPA1 CRISPR KO both decreased the expressions of PGE2, EP2, NOX2, NF-kappaB, TNF-alpha, IL-6, and IL-1beta expressions after ICH, which was reversed by butaprost.	(4'-(4-(1-(2-chlorophenyl)ethoxycarbonylamino)-3-methylisoxazol-5-yl)biphenyl-4-yl)acetic acid	0-5	interleukin 6	Mus musculus	108-112
32721223-3	2021	TNF-alpha, IL-1b, IL-6 and IL-8 that leads to a cascade that negatively impacts methionine-metabolism and homocysteine cycling.	Methionine	80-90	interleukin 6	Mus musculus	18-22
32721223-3	2021	TNF-alpha, IL-1b, IL-6 and IL-8 that leads to a cascade that negatively impacts methionine-metabolism and homocysteine cycling.	Homocysteine	106-118	interleukin 6	Mus musculus	18-22
33142660-5	2021	Meanwhile, CGP-BG significantly inhibited nitric oxide and pro-inflammatory cytokine (TNF-alpha, IL-6, and IL-1beta) production in the lipopolysaccharide (LPS)-induced RAW 264.7 cells.	cgp-bg	11-17	interleukin 6	Mus musculus	97-101
32567086-5	2021	Geldanamycin, 17-allylamino-17-demethoxy-geldanamycin (17-AAG) and onalespib, three different HSP90 inhibitors, amplified the ATP-stimulated IL-6 release.	Adenosine Triphosphate	126-129	interleukin 6	Mus musculus	141-145
32567086-6	2021	Geldanamycin increased IL-6 mRNA expression elicited by ATP.	geldanamycin	0-12	interleukin 6	Mus musculus	23-27
32567086-6	2021	Geldanamycin increased IL-6 mRNA expression elicited by ATP.	Adenosine Triphosphate	56-59	interleukin 6	Mus musculus	23-27
32567086-9	2021	SB203580, an inhibitor of p38 MAPK, suppressed ATP-stimulated IL-6 release.	SB 203580	0-8	interleukin 6	Mus musculus	62-66
32567086-9	2021	SB203580, an inhibitor of p38 MAPK, suppressed ATP-stimulated IL-6 release.	Adenosine Triphosphate	47-50	interleukin 6	Mus musculus	62-66
32567086-10	2021	Inhibitors of MEK1/2 (PD98059), JNK (SP600125), upstream kinase of p70 S6 kinase (rapamycin) and Akt (deguelin), all increased IL-6 release.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	22-29	interleukin 6	Mus musculus	127-131
32567086-10	2021	Inhibitors of MEK1/2 (PD98059), JNK (SP600125), upstream kinase of p70 S6 kinase (rapamycin) and Akt (deguelin), all increased IL-6 release.	pyrazolanthrone	37-45	interleukin 6	Mus musculus	127-131
32567086-10	2021	Inhibitors of MEK1/2 (PD98059), JNK (SP600125), upstream kinase of p70 S6 kinase (rapamycin) and Akt (deguelin), all increased IL-6 release.	Sirolimus	82-91	interleukin 6	Mus musculus	127-131
32567086-13	2021	In addition, SB203580 significantly reduced the amplification by geldanamycin of the IL-6 release.	SB 203580	13-21	interleukin 6	Mus musculus	85-89
32567086-13	2021	In addition, SB203580 significantly reduced the amplification by geldanamycin of the IL-6 release.	geldanamycin	65-77	interleukin 6	Mus musculus	85-89
32567086-14	2021	Taken together, our results strongly suggest that HSP90 inhibitors up-regulate extracellular ATP-stimulated IL-6 synthesis via amplification of p38 MAPK activation in osteoblasts.	Adenosine Triphosphate	93-96	interleukin 6	Mus musculus	108-112
32567086-17	2021	In the present study, we investigated whether HSP90 is implicated in extracellular ATP-induced interleukin (IL)-6 synthesis in osteoblast-like MC3T3-E1 cells.	Adenosine Triphosphate	83-86	interleukin 6	Mus musculus	95-113
32567086-18	2021	Our results strongly suggest that HSP90 inhibitors up-regulate extracellular ATP-stimulated IL-6 synthesis via amplification of p38 mitogen-activated protein kinase activation in osteoblasts.	Adenosine Triphosphate	77-80	interleukin 6	Mus musculus	92-96
33310185-2	2021	Mice with methionine choline-deficient (MCD) diet-induced NASH presented an imbalance of pro-(IL-6 and IFN-gamma) and anti-inflammatory cytokines (IL-10) in the intestine.	methionine choline	10-28	interleukin 6	Mus musculus	94-98
33310189-6	2021	In the MIA model of gestational polyinosinic-polycytidylic acid (poly(I:C)) exposure, increased serum levels of IL-6 were observed in both wild-type (WT) and Nox1-deficient mice (Nox1KO).	Poly I-C	32-63	interleukin 6	Mus musculus	112-116
33310189-6	2021	In the MIA model of gestational polyinosinic-polycytidylic acid (poly(I:C)) exposure, increased serum levels of IL-6 were observed in both wild-type (WT) and Nox1-deficient mice (Nox1KO).	Poly I-C	65-74	interleukin 6	Mus musculus	112-116
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	interleukin 6	Mus musculus	150-163
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	interleukin 6	Mus musculus	165-169
32567086-0	2021	HSP90 inhibitors strengthen extracellular ATP-stimulated synthesis of interleukin-6 in osteoblasts: Amplification of p38 MAP kinase.	Adenosine Triphosphate	42-45	interleukin 6	Mus musculus	70-83
32567086-3	2021	Here, we investigated the involvement of HSP90 in extracellular ATP-stimulated interleukin (IL)-6 synthesis and HSP90 downstream signalling in osteoblast-like MC3T3-E1 cells.	Adenosine Triphosphate	64-67	interleukin 6	Mus musculus	79-97
32567086-4	2021	In osteoblasts, extracellular ATP stimulates the synthesis of IL-6, a bone-remodelling agent.	Adenosine Triphosphate	30-33	interleukin 6	Mus musculus	62-66
32567086-5	2021	Geldanamycin, 17-allylamino-17-demethoxy-geldanamycin (17-AAG) and onalespib, three different HSP90 inhibitors, amplified the ATP-stimulated IL-6 release.	geldanamycin	0-12	interleukin 6	Mus musculus	141-145
32567086-5	2021	Geldanamycin, 17-allylamino-17-demethoxy-geldanamycin (17-AAG) and onalespib, three different HSP90 inhibitors, amplified the ATP-stimulated IL-6 release.	tanespimycin	55-61	interleukin 6	Mus musculus	141-145
32567086-5	2021	Geldanamycin, 17-allylamino-17-demethoxy-geldanamycin (17-AAG) and onalespib, three different HSP90 inhibitors, amplified the ATP-stimulated IL-6 release.	(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone	67-76	interleukin 6	Mus musculus	141-145
33006758-6	2021	Further experiments indicated that Tmem106a ablation enhanced the expression of CD80, CD86, and MHC II in mouse macrophages upon LPS stimulation, accompanied with upregulation of tumor necrosis factor-alpha (TNF), interleukin-6 (IL-6), interferon-beta (IFN-beta), and inducible nitric oxide synthase (iNOS), indicating the activation of macrophages and polarization towards M1 inflammatory phenotype.	tmem106a	35-43	interleukin 6	Mus musculus	214-227
32538719-5	2021	In addition, we evaluated the production of major cytokines (Interleukin-6 and -10) related with inflammation and fatty acid composition of several tissues.	Fatty Acids	114-124	interleukin 6	Mus musculus	61-82
33128926-7	2021	In SCW and MSU crystal-induced arthritis, joint swelling, inflammatory cell influx, and synovial levels of IL-1beta, IL-6, and KC were reduced by 50% or greater.	Uric Acid	11-14	interleukin 6	Mus musculus	117-121
32841872-7	2021	Although we were unable to find tumor tissue in mice exposed to Po, we detected evidence of lung inflammation, epithelial-to-mesenchymal transition (EMT) phenotype and severe pulmonary injury; in addition, intraperitoneal injection of PHTPP (an ERbeta inhibitor) showed that the above phenomena have been improved, which demonstrate that Po stimulates IL-6 expression to promote inflammation, EMT phenotype and lung injury through the ERbeta pathway.	PHTPP	235-240	interleukin 6	Mus musculus	352-356
33006758-6	2021	Further experiments indicated that Tmem106a ablation enhanced the expression of CD80, CD86, and MHC II in mouse macrophages upon LPS stimulation, accompanied with upregulation of tumor necrosis factor-alpha (TNF), interleukin-6 (IL-6), interferon-beta (IFN-beta), and inducible nitric oxide synthase (iNOS), indicating the activation of macrophages and polarization towards M1 inflammatory phenotype.	tmem106a	35-43	interleukin 6	Mus musculus	229-233
32891972-8	2021	Furthermore, Western blot analysis indicated that La(NO3)3 significantly down-regulated inflammation-mediated proteins including phosphorylated p38 mitogen-activated protein kinases (p-p38 MAPK), monocyte chemo-attractant protein, intercellular adhesion molecule-1, nuclear factor-kappa B p65 (NF-kappaB p65), tumor necrosis factor-alpha, interleukin-6 and interleukin-1beta, whereas up-regulated the inhibitor of NF-kappaB protein.	la(no3)3	50-58	interleukin 6	Mus musculus	339-352
33254423-7	2021	CAPE also suppressed the CdCl2-induced inflammation by reducing the inflammatory mediators, including TNF-alpha, IL-6 and IL-1beta.	caffeic acid phenethyl ester	0-4	interleukin 6	Mus musculus	113-117
33254423-7	2021	CAPE also suppressed the CdCl2-induced inflammation by reducing the inflammatory mediators, including TNF-alpha, IL-6 and IL-1beta.	Cadmium Chloride	25-30	interleukin 6	Mus musculus	113-117
32865668-9	2021	Moreover, olaparib significantly reduced the level of interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, IL-6, and IL-4 and increased IL-10 in IAV lungs.	olaparib	10-18	interleukin 6	Mus musculus	137-141
32865668-10	2021	Also, olaparib efficiently reduced IL-6, monocyte chemotactic protein (MCP)-1, granulocyte colony-stimulating factor (G-CSF), TNF-alpha, chemokine (C-X-C motif) ligand (CXCL)1, CXCL10, chemokine (C-C motif) ligand (CCL)3, and regulated on activation, normal T cell expressed and secreted (RANTES) release in IAV BALF.	olaparib	6-14	interleukin 6	Mus musculus	35-39
33131725-5	2021	The results of cellular assays showed that saponin 29 significantly inhibited LPS-induced secretion of pro-inflammatory factors TNF-alpha and IL-6 in THP1-derived macrophages.	Saponins	43-50	interleukin 6	Mus musculus	142-146
33285544-11	2021	Ketotifen was observed to rescue the increased expression of TNF-alpha, HRF, and IL-6 caused by SELE overexpression.	Ketotifen	0-9	interleukin 6	Mus musculus	81-85
33290807-8	2021	Moreover, lunasin inhibited IL-6 secretion while promoting interferon gamma (IFN-gamma) and IL-2 production in the splenocytes.	LUNASINE	10-17	interleukin 6	Mus musculus	28-32
33243606-4	2021	Treatment with ROF suppressed LPS-induced expression of interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha in BV-2 microglia cell line.	roflupram	15-18	interleukin 6	Mus musculus	56-74
33191175-8	2021	The numbers of total cells, neutrophils and macrophages, as well as levels of TNF-alpha and IL-6 in BALF were remarkably decreased by MitoQ in a dose-dependent manner.	mitoquinone	134-139	interleukin 6	Mus musculus	92-96
33293260-5	2021	Here, we firstly found that verylowdosesof SA (50 mug/kg) could markedly decrease the infiltration of pulmonary neutrophils, mRNA expression of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6) and then attenuated ALI cause by MRSA infection in mice.	salvinorin A	43-45	interleukin 6	Mus musculus	196-200
33278745-9	2021	RESULTS: The expression levels of AT1R, IL-6, IL-1beta, COX-2, and GFAP in the astrocytes were significantly elevated by stimulation with Ang II and greatly suppressed by the introduction of Ferrostatin-1 in a dose-dependent manner.	ferrostatin-1	191-204	interleukin 6	Mus musculus	40-44
33243606-10	2021	In mice challenged with LPS, ROF improved cognition and decreased the levels of IL-6 and TNF-alpha in both the cortex and hippocampus.	roflupram	29-32	interleukin 6	Mus musculus	80-84
32544478-10	2021	The fewer Treg numbers in biopsies of psoriatic lesions as well as enhanced IL-17-, IL-6- and reduced IL-10- and Foxp3-expression levels were restored by SB.	Butyric Acid	154-156	interleukin 6	Mus musculus	84-88
33326684-9	2021	MET and CGA combination treatment resulted in the polarization of macrophages to the M2 phenotype, reduction of the expression of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6), and decreasing protein level of NF-kB p65.	Chlorogenic Acid	8-11	interleukin 6	Mus musculus	182-186
32865324-6	2021	The results found that palmatine could significantly reduce the expression of IL-6, TNF-alpha, IL-1beta and COX-2 in EpH4-Ev cells.	palmatine	23-32	interleukin 6	Mus musculus	78-82
33217488-8	2021	Results showed that ellagic acid can ameliorate severity of the disease and partially restore tissue level of TNFalpha, IL-6, IL-17A and IL-10.	Ellagic Acid	20-32	interleukin 6	Mus musculus	120-124
33307514-6	2021	Concomitant with enlarged colonic patches, the cultured colon of infected mice treated with berberine secreted significantly higher levels of interleukin-1beta (IL-1beta), IL-6, TNF-alpha, and CCL-2, while NLRP3 inhibitor MMC950 or knockout of NLRP3 gene abrogated berberine-induced hypertrophy of colonic patches, suggesting the involvement of the NLRP3 signaling pathway in this process.	Berberine	92-101	interleukin 6	Mus musculus	172-176
33952739-10	2021	Moreover, serum C-reactive protein (CRP) and interleukin-6 (IL-6) in the vitamin D treatment groups were significantly suppressed by 1,25(OH)2D3 administration compared with the MC group.	Vitamin D	73-82	interleukin 6	Mus musculus	45-58
32761488-6	2021	Moreover, the increasing IL-1beta, IL-6, and TNF-alpha levels induced by MSU were decreased via administration of dioscin in mice and human synoviocytes.	Uric Acid	73-76	interleukin 6	Mus musculus	35-39
32761488-6	2021	Moreover, the increasing IL-1beta, IL-6, and TNF-alpha levels induced by MSU were decreased via administration of dioscin in mice and human synoviocytes.	dioscin	114-121	interleukin 6	Mus musculus	35-39
33277208-14	2021	Further, the IL6/STAT3/P65 signaling pathway was inhibited in the EVO group.	evodiamine	66-69	interleukin 6	Mus musculus	13-16
33952739-10	2021	Moreover, serum C-reactive protein (CRP) and interleukin-6 (IL-6) in the vitamin D treatment groups were significantly suppressed by 1,25(OH)2D3 administration compared with the MC group.	Vitamin D	73-82	interleukin 6	Mus musculus	60-64
33952739-10	2021	Moreover, serum C-reactive protein (CRP) and interleukin-6 (IL-6) in the vitamin D treatment groups were significantly suppressed by 1,25(OH)2D3 administration compared with the MC group.	Calcitriol	133-144	interleukin 6	Mus musculus	45-58
33952739-10	2021	Moreover, serum C-reactive protein (CRP) and interleukin-6 (IL-6) in the vitamin D treatment groups were significantly suppressed by 1,25(OH)2D3 administration compared with the MC group.	Calcitriol	133-144	interleukin 6	Mus musculus	60-64
33179083-9	2021	Moreover, miR-26a-5p overexpression alleviated LPS-induced inflammatory responses in ALI mice via the reduction of total protein, neutrophil and lymphocyte counts and the expression levels of TNF-alpha, IL-1beta, IL-6, MDA and MPO activity in BALF.	mir-26a-5p	10-20	interleukin 6	Mus musculus	213-217
33408300-6	2021	Moreover, pharmacological autophagy inhibitor 3-Methyladenine could reverse GO-induced LC3B and p62 expression levels, reduce expression levels of IL-6, IL-8, TLR4, and CXCL2, and increase the level of IL-10.	3-methyladenine	46-61	interleukin 6	Mus musculus	147-151
33179100-12	2021	Moreover, dexmedetomidine significantly decreased the levels of TNF-alpha, IL-1beta and IL-6 in the hippocampus.	Dexmedetomidine	10-25	interleukin 6	Mus musculus	88-92
33179078-9	2021	IL-10 level in the colon was significantly increased, while inflammatory cytokines IL-6, IL-17 and IL-23 were significantly reduced following curcumin treatment.	Curcumin	142-150	interleukin 6	Mus musculus	83-87
33179083-10	2021	Similarly, miR-26a-5p overexpression decreased apoptosis and the expression of TNF-alpha, IL-1beta and IL-6 in LPS-induced A549 cells.	mir-26a-5p	11-21	interleukin 6	Mus musculus	103-107
33788643-11	2021	The salutary effects of glibenclamide on pain behaviors correlated with reduced expression of IL-6, CCL2 and CXCL1 by dorsal horn astrocytes.	Glyburide	24-37	interleukin 6	Mus musculus	94-98
33166615-10	2021	MeHgCl exposure of BTBR mice significantly increased IL-6-, GM-CSF-, NF-kappaB p65-, and Notch-1-, and decreased IL-27-producing CD14+, and CD40+ cells in the spleen.	methylmercuric chloride	0-6	interleukin 6	Mus musculus	53-57
33166615-10	2021	MeHgCl exposure of BTBR mice significantly increased IL-6-, GM-CSF-, NF-kappaB p65-, and Notch-1-, and decreased IL-27-producing CD14+, and CD40+ cells in the spleen.	btbr	19-23	interleukin 6	Mus musculus	53-57
33166615-11	2021	MeHgCl exposure of BTBR mice upregulated IL-6, GM-CSF, NF-kappaB p65, and Notch-1, and decreased IL-27 mRNA expression levels in brain tissue.	methylmercuric chloride	0-6	interleukin 6	Mus musculus	41-45
33185001-6	2021	Treatment with ASCs decreased cell senescence and suppressed secretion of inflammatory agents (interleukin-6 and tumor necrosis factor alpha).	ascs	15-19	interleukin 6	Mus musculus	95-108
33166615-11	2021	MeHgCl exposure of BTBR mice upregulated IL-6, GM-CSF, NF-kappaB p65, and Notch-1, and decreased IL-27 mRNA expression levels in brain tissue.	btbr	19-23	interleukin 6	Mus musculus	41-45
33166615-12	2021	Moreover, MeHgCl resulted in elevated expression of the IL-6, GM-CSF, and NF-kappaB p65 proteins in brain tissue.	methylmercuric chloride	10-16	interleukin 6	Mus musculus	56-60
33645072-21	2021	The mechanism may be related to the anti-inflammatory effect on UC mice by reducing the levels of IL-1beta, IL-6 and TNF-alpha in colon through limonin, palmatine and berberine regulating IL-17 signal pathway and TNF signal pathway via CASP3 and MMP9 meditated.	Berberine	167-176	interleukin 6	Mus musculus	108-112
33234364-12	2021	RESULTS: Naringenin administration improved metabolic parameters, suppressed hepatic steatosis, regulated expression of genes involved in lipid metabolism (FASN, SCD1, PPARalpha and CPT1alpha), reduced hepatic fibrosis and cell senescence, inhibited hepatic inflammation as evidenced by the decreased macrophage recruitment and content of TNF-alpha and IL-6, and reduced hepatic oxidative stress by suppressing ROS generation and normalizing activities of antioxidant enzymes.	naringenin	9-19	interleukin 6	Mus musculus	353-357
33157413-11	2021	In LPS-treated cultured macrophages, applied kaempferol-3-O-rutinoside potentiated inhibitory effects of exogenous applied VEGF-C on the secretions of pro-inflammatory cytokines, i.e. IL-6 and TNF-alpha, as well as expressions of nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	kaempferol-3-O-rutinoside	45-70	interleukin 6	Mus musculus	184-188
33300458-7	2021	Additionally, SAHA inhibited the rotenone-induced elevation of interleukin 6 and tumor necrosis factor alpha levels in both cell lines.	Vorinostat	14-18	interleukin 6	Mus musculus	63-108
33300458-7	2021	Additionally, SAHA inhibited the rotenone-induced elevation of interleukin 6 and tumor necrosis factor alpha levels in both cell lines.	Rotenone	33-41	interleukin 6	Mus musculus	63-108
33046674-8	2020	Fatty acids transcriptionally controlled the expression of the immune-associated genes; iNOS, IL-1beta, IL-6, COX-2, and TNF-alpha, via the MAPK and NF-kappaB signaling cascades in RAW264.7 cells.	Fatty Acids	0-11	interleukin 6	Mus musculus	104-108
33380403-7	2020	In na?ve RAW264.7 cells, treatment with both ICG-001 and LPS, as compared with LPS alone, significant promoted TNF-alpha and IL-6 secretions, increased intracellular levels of TNF-alpha, IL-6 and iNOS (P < 0.05), and reduced intracellular FKN, Wnt-4 and beta-catenin levels (P < 0.01).	Indocyanine Green	45-48	interleukin 6	Mus musculus	125-129
33380403-7	2020	In na?ve RAW264.7 cells, treatment with both ICG-001 and LPS, as compared with LPS alone, significant promoted TNF-alpha and IL-6 secretions, increased intracellular levels of TNF-alpha, IL-6 and iNOS (P < 0.05), and reduced intracellular FKN, Wnt-4 and beta-catenin levels (P < 0.01).	Indocyanine Green	45-48	interleukin 6	Mus musculus	187-191
33374928-0	2020	Inhalation of Essential Oil from Mentha piperita Ameliorates PM10-Exposed Asthma by Targeting IL-6/JAK2/STAT3 Pathway Based on a Network Pharmacological Analysis.	Oils, Volatile	14-27	interleukin 6	Mus musculus	94-98
33409388-11	2020	Similarly, compared to sham, renal levels of IL-6 mRNA and protein and TNFalpha protein were markedly higher in vehicle-treated renal I/R mice, but significantly lower in MSP68-treated renal I/R mice.	msp68	171-176	interleukin 6	Mus musculus	45-49
33396223-5	2020	RESULTS: LPS/GalN injection generate distinct molecular processes, which includes increased production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), thus causing apoptosis as evident by increased caspase-3 activity.	Galactosamine	13-17	interleukin 6	Mus musculus	150-163
33396223-5	2020	RESULTS: LPS/GalN injection generate distinct molecular processes, which includes increased production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), thus causing apoptosis as evident by increased caspase-3 activity.	Galactosamine	13-17	interleukin 6	Mus musculus	165-169
33305564-6	2020	Treatment of RAW 264.7 cells with cdG@RMSN-PEG-TA markedly stimulated the secretion of IL-6, IL-1beta, and IFN-beta along with phospho-STING (Ser365) protein expression.	cdg	34-37	interleukin 6	Mus musculus	87-91
33305564-6	2020	Treatment of RAW 264.7 cells with cdG@RMSN-PEG-TA markedly stimulated the secretion of IL-6, IL-1beta, and IFN-beta along with phospho-STING (Ser365) protein expression.	rmsn	38-42	interleukin 6	Mus musculus	87-91
33305564-6	2020	Treatment of RAW 264.7 cells with cdG@RMSN-PEG-TA markedly stimulated the secretion of IL-6, IL-1beta, and IFN-beta along with phospho-STING (Ser365) protein expression.	peg-ta	43-49	interleukin 6	Mus musculus	87-91
33379850-30	2020	On PID 6, the content of IL-1beta, TNF-alpha, and IL-6 in wounds of mice in copper oxide group were significantly lower than that in PBS group (t=6.115, 11.762, 11.725, P<0.01).	cupric oxide	76-88	interleukin 6	Mus musculus	50-54
33376303-9	2020	The expression levels of IL-6, IL-8, TNF-alpha, VEGF, TF, VCAM-1, and ICAM-1 were elevated by stimulation with isoflurane, which were significantly suppressed by the administration of agomelatine.	Isoflurane	111-121	interleukin 6	Mus musculus	25-29
33374928-0	2020	Inhalation of Essential Oil from Mentha piperita Ameliorates PM10-Exposed Asthma by Targeting IL-6/JAK2/STAT3 Pathway Based on a Network Pharmacological Analysis.	pm10	61-65	interleukin 6	Mus musculus	94-98
33376303-9	2020	The expression levels of IL-6, IL-8, TNF-alpha, VEGF, TF, VCAM-1, and ICAM-1 were elevated by stimulation with isoflurane, which were significantly suppressed by the administration of agomelatine.	agomelatine	184-195	interleukin 6	Mus musculus	25-29
33374928-11	2020	Collectively, MEO may have an inhibitory effect on asthma under the condition of PM10 exposure through the IL-6/JAK2/STAT3 signaling pathway.	pm10	81-85	interleukin 6	Mus musculus	107-111
33353230-8	2020	Hepatic expression of interleukin (IL)-6 mRNA was higher in the caffeine and CGA groups than in the CDAHFD group, and the difference was statistically significant for the caffeine group.	Caffeine	64-72	interleukin 6	Mus musculus	22-40
33381582-9	2020	Coenzyme Q10 significantly inhibited the elevation of sequestosome-1, interleukin-1beta, oligomerization domain-like receptor 3 and nucleotide-binding, interleukin-6, and tumor necrosis factor-alpha expression levels; coenzyme Q10 also increased beclin 1 levels.	coenzyme Q10	0-12	interleukin 6	Mus musculus	152-165
33424608-8	2020	In vivo, IQC administration strikingly reduced cisplatin-induced nephrotoxicity as evidenced by the improvement in renal function (serum creatinine and blood urea nitrogen), kidney histology (PAS staining), apoptotic molecules (cleaved caspase-3, caspase-8, Bax and Bcl-2), inflammatory cytokines (IL-1beta, IL-6, TNF-alpha, and COX-2), oxidative stress (MDA and total glutathione) and p-ERK.	isoquercitrin	9-12	interleukin 6	Mus musculus	308-312
33353230-8	2020	Hepatic expression of interleukin (IL)-6 mRNA was higher in the caffeine and CGA groups than in the CDAHFD group, and the difference was statistically significant for the caffeine group.	Caffeine	171-179	interleukin 6	Mus musculus	22-40
33161052-10	2020	The expression levels of TLR3, TLR4, NF-kappaB, IL-1beta, IL-6, and TNF-alpha increased after ethanol exposure in both the hippocampus of mice and H4 cells.	Ethanol	94-101	interleukin 6	Mus musculus	58-62
33332780-10	2020	More importantly, miR-590-3p agomir alleviated pain-related behavior, reduced TNF-alpha, IL-1beta and IL-6 concentrations, and inhibited neural infiltration by immune cells in db/db mice.	mir-590-3p	18-28	interleukin 6	Mus musculus	102-106
33237730-5	2020	We found that administration of Omarigliptin reduced LPS-induced inflammatory responses by inhibiting the expressions of interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-alpha).	2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine	32-44	interleukin 6	Mus musculus	121-134
33237730-5	2020	We found that administration of Omarigliptin reduced LPS-induced inflammatory responses by inhibiting the expressions of interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-alpha).	2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine	32-44	interleukin 6	Mus musculus	136-140
33456488-5	2020	BCP significantly inhibited production of interleukin-1alpha (IL-1alpha), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), reduced the expression of SA-beta-gal and formation of SAHF, as well as ROS level, and stabilized the mitochondrial membrane potential in RAW264.7 cells stimulated with LPS.	bcp	0-3	interleukin 6	Mus musculus	74-87
33456488-5	2020	BCP significantly inhibited production of interleukin-1alpha (IL-1alpha), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), reduced the expression of SA-beta-gal and formation of SAHF, as well as ROS level, and stabilized the mitochondrial membrane potential in RAW264.7 cells stimulated with LPS.	bcp	0-3	interleukin 6	Mus musculus	89-93
33041002-3	2020	Trimebutine was revealed to have more potent suppressive effects on HMGB1-induced production of pro-inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-alpha in macrophage-like RAW264.7 cells and mouse bone marrow primarily differentiated macrophages than did papaverine.	Trimebutine	0-11	interleukin 6	Mus musculus	132-145
33380901-8	2020	Ginsenoside Rd displayed the therapeutic function to EAE by modulating inflammation and autoimmunity, via the downregulation of related proinflammatory cytokines IL-6 and IL-17, upregulation of inhibitory cytokines TGF-beta and IL-10, and modulation of Treg/Th17 imbalance.	Ginsenosides	0-11	interleukin 6	Mus musculus	162-166
33069896-6	2020	BE solution at 5 microM had no anti-inflammatory effects in BV-2 cells while BE-MC could reduce the inflammatory factor TNF-alpha at 5 microM and IL-6 at 20 microM significantly.	be-mc	77-82	interleukin 6	Mus musculus	146-150
33319831-7	2020	Once-daily, intra-tracheal injections of HO-exposed mice with ML335 or BL1249 improved lung compliance, histological lung injury scores, broncho-alveolar lavage protein levels and cell counts, and IL-6 and IP-10 concentrations.	ML335	62-67	interleukin 6	Mus musculus	197-201
33414834-8	2020	The abnormal serum and placental levels of IL-6, ACA, and TNF-alpha in the model group were reversed by AZHJ.	azhj	104-108	interleukin 6	Mus musculus	43-47
33457418-8	2020	In addition, GSPE repressed the PFOS-induced hepatic overproduction of proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	gspe	13-17	interleukin 6	Mus musculus	97-110
33322178-9	2020	Furthermore, treatment with 1 mg/kg BA downregulated the expression of p-NF-kappaB and p-IkappaB-alpha proteins in the intestine, while all doses of BA suppressed the pro-inflammatory cytokines expression of IL-1beta, IL-6 and TNF-alpha mRNAs and increased the anti-inflammatory cytokine expression of IL-10 mRNA in the intestine of T-2 toxin-exposed mice.	betulinic acid	36-38	interleukin 6	Mus musculus	218-222
33307839-10	2020	Similarly, BHE dose-dependently reduced the LPS (1 microg/mL) induced release of pro-inflammatory cytokines including IL-1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) in Raw 264.7 cells.	Octyl 2-O-(6-Deoxy-Alpha-L-Galactopyranosyl)-Beta-D-Galactopyranoside	11-14	interleukin 6	Mus musculus	128-132
33457418-8	2020	In addition, GSPE repressed the PFOS-induced hepatic overproduction of proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	gspe	13-17	interleukin 6	Mus musculus	112-116
33457418-8	2020	In addition, GSPE repressed the PFOS-induced hepatic overproduction of proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	perfluorooctane sulfonic acid	32-36	interleukin 6	Mus musculus	97-110
33457418-8	2020	In addition, GSPE repressed the PFOS-induced hepatic overproduction of proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	perfluorooctane sulfonic acid	32-36	interleukin 6	Mus musculus	112-116
33316945-8	2020	Additionally, we detected a significant increase in pro-inflammatory cytokines (TNF-alpha and IL-6) and inflammatory M1 macrophages in Dox-treated animals.	Doxorubicin	135-138	interleukin 6	Mus musculus	94-98
33323555-6	2020	In this study, Fucoxanthin efficiently reduced the mRNA expression of pro-inflammatory factors, including IL-10, IL-6, iNOS, and Cox-2, and down-regulated the NF-kappaB signaling pathway in Raw264.7 macrophages.	fucoxanthin	15-26	interleukin 6	Mus musculus	113-117
33291425-8	2020	We demonstrate here that EPS suppressed proinflammatory mediators, such as cyclooxygenase-2, interleukin-6, tumor necrosis factor-alpha, and interleukin-1beta, and downregulated the expression of an inducible nitric oxide synthase known to lead to oxidative stress.	eps	25-28	interleukin 6	Mus musculus	93-106
33290154-5	2021	Chronic ethanol consumption increased SBP, creatinine levels, O<sub>2</sub><sup>.</sup><sup>-</sup> and H<sub>2</sub>O<sub>2</sub> levels, lipid peroxidation, catalase activity, Nox4, IL-6 and TNF-alpha levels, and MMP-9/TIMP-1 ratio.	Ethanol	8-15	interleukin 6	Mus musculus	184-188
33363462-5	2020	The results showed that PAMK significantly improved the spleen index, alleviated abnormal splenocytes morphology and death, maintained the balance of Th1/Th2 cells, increased the levels of IL-2, IL-6, TNF-alpha, and IFN-gamma, and increased the mRNA levels of CD28, PLCgamma-1, IP3R, NFAT, and AP-1.	pamk	24-28	interleukin 6	Mus musculus	195-199
33343566-4	2020	All oligosaccharides conjugated with biotin and immobilized on streptavidin-coated plates stimulated production of IL-1alpha, IL-2, IL-4, IL-5, IL-10, IFNgamma, IL-17A, and TNFalpha, but not IL-6 and GM-CSF in monocultured mice splenocytes.	Oligosaccharides	4-20	interleukin 6	Mus musculus	191-195
33343385-9	2020	extract compared to saline administration, which was accompanied by downregulation of the proinflammatory cytokines interleukin (IL)-1beta and IL-6.	Sodium Chloride	20-26	interleukin 6	Mus musculus	143-147
33362775-6	2020	We found that bixin significantly improved the symptoms and pathology in EAE mice, reduced the release of inflammatory cytokines TNF-alpha, IL-6, IL-8, IL-17, and IFN-gamma, and increased the expression of the anti-inflammatory cytokine IL-10.	bixin	14-19	interleukin 6	Mus musculus	140-144
32876525-0	2020	Ursolic acid induces the production of IL6 and chemokines in both adipocytes and adipose tissue.	ursolic acid	0-12	interleukin 6	Mus musculus	39-42
33267751-9	2020	PFM induced mild activation of IECs increasing monocyte chemoattractant protein-1 (MCP-1 or CCL2) and interleukin (IL)-6 production.	PFM	0-3	interleukin 6	Mus musculus	102-120
33344474-8	2020	Mice in the heparin intervention group showed decreased levels of EH4, neutrophil gelatinase-associated lipocalin (NAGL), kidney injury molecule-1 (KIM-1), tumor necrosis factor-alpha (TNF-alpha), and interleukin (IL)-6 in the blood serum, longer average 72-h survival rate, significantly decreased kidney tissue edema, and a clearer glomerular structure coupled with decreased protein and mRNA expression levels of kidney apoptosis-related proteins (cleaved Caspase-3/Caspase-3 and Bax/Bcl-2) compared with those in the sepsis group at 6 h after CLP (P < 0.05).	Heparin	12-19	interleukin 6	Mus musculus	201-219
32412432-4	2020	Perindopril remarkably ameliorated cisplatin-induced perturbations in renal histology, renal levels of tumor necrosis factor-alpha, interleukin-6 and interleukin-10, apoptosis-regulating protein expressions (Bax and Bcl2), and partially normalized Bax to Bcl2 ratio and active caspase 3 protein expression.	Perindopril	0-11	interleukin 6	Mus musculus	132-145
32412432-4	2020	Perindopril remarkably ameliorated cisplatin-induced perturbations in renal histology, renal levels of tumor necrosis factor-alpha, interleukin-6 and interleukin-10, apoptosis-regulating protein expressions (Bax and Bcl2), and partially normalized Bax to Bcl2 ratio and active caspase 3 protein expression.	Cisplatin	35-44	interleukin 6	Mus musculus	132-145
32621659-10	2020	IL-6 production, in both joint tissue and serum, was observed in the CCP-Ab1-treated SKG mice but not in the GL-rev CCP-Ab1-treated group (p < 0.05).	ccp	69-72	interleukin 6	Mus musculus	0-4
32621659-10	2020	IL-6 production, in both joint tissue and serum, was observed in the CCP-Ab1-treated SKG mice but not in the GL-rev CCP-Ab1-treated group (p < 0.05).	ccp-ab1	69-76	interleukin 6	Mus musculus	0-4
32638534-9	2020	Nicotine decreased the IL-1beta-induced IL-6 and MMP expression, in a dose-dependent manner, in WT chondrocytes but not in Chrna7-/- chondrocytes.	Nicotine	0-8	interleukin 6	Mus musculus	40-44
32876525-6	2020	IL6 and MCP1 levels in the cell culture medium and mouse serum were induced by UA treatment.	ursolic acid	79-81	interleukin 6	Mus musculus	0-3
33006786-7	2020	The curcumin restored DC functions in xenogeneic nude mouse model implanted with high IL-6 producing human clear cell ovarian cancer cells.	Curcumin	4-12	interleukin 6	Mus musculus	86-90
33099251-6	2020	RESULTS: Cynaroside inhibited the expression of iNOS, COX-2, TNF-alpha, and IL-6 in LPS-stimulated hPDL and RAW264.7 cells without cytotoxicity.	luteolin-7-glucoside	9-19	interleukin 6	Mus musculus	76-80
32964723-10	2020	Since fibroblasts play a major role in the production and maintenance of extracellular matrix in emphysema, primary lung fibroblasts were treated with the ERK inhibitor LY3214996 or the c-RAF inhibitor GW5074, resulting in less S100A9-induced MMP-3, MMP-9, MCP-1, IL-6, and IL-8.	5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone	202-208	interleukin 6	Mus musculus	264-268
33197847-3	2020	Novel arylpropionic esters bearing multi-functional groups showed significant anti-inflammatory activity, in which, compound 13b exhibited the most potent activity through dose-dependent inhibiting the production of nitric oxide (NO, IC50 = 3.52 muM), TNF-alpha and IL-6 (84.1% and 33.6%, respectively), as well as suppressing the expression of iNOS, COX-2 and TLR4 proteins.	arylpropionic esters	6-26	interleukin 6	Mus musculus	266-270
33197847-3	2020	Novel arylpropionic esters bearing multi-functional groups showed significant anti-inflammatory activity, in which, compound 13b exhibited the most potent activity through dose-dependent inhibiting the production of nitric oxide (NO, IC50 = 3.52 muM), TNF-alpha and IL-6 (84.1% and 33.6%, respectively), as well as suppressing the expression of iNOS, COX-2 and TLR4 proteins.	CHEMBL3741121	125-128	interleukin 6	Mus musculus	266-270
33323164-9	2020	However, mice given NG had a significant reduction in IL6 and TNFalpha in BAL fluid and no significant differences in CCL2, IL4, IL10, CXCL1, CXCL2, and VEGF.	Nitroglycerin	20-22	interleukin 6	Mus musculus	54-57
32767170-12	2020	Serum levels of IL-1alpha, IL-1beta, IL-6, IL-8, ICAM-1, MCP-1, and TNF-alpha were significantly lower in the DM-Acu than in the DM or DM-Sham groups.	dm-acu	110-116	interleukin 6	Mus musculus	37-41
33035507-4	2020	It also reduced mRNA expression of inducible nitric oxide synthase, cyclooxygenase-2, tumor necrosis factor-alpha, interleukin-1beta (IL-1 beta), and IL-6, indicating that 3-DA has anti-inflammatory properties in murine and human macrophages.	3-da	172-176	interleukin 6	Mus musculus	150-154
33052428-10	2020	The results showed that H2 treatment increased survival rates, mitigated cognitive impairment, reduced hippocampal histological damage, decreased EB and water content, and decreased the levels of TNF-alpha, IL-6, HMGB1, Nrf2, HO-1, ZO-1 and Occludin, as compared with the SAE group.	Deuterium	24-26	interleukin 6	Mus musculus	207-211
32677756-4	2020	The results showed that PIPO significantly inhibited cytokine production, including nitric oxide, prostaglandin E2 , tumor necrosis factor-alpha, and interleukin-6.	pipoxolan	24-28	interleukin 6	Mus musculus	150-163
33378042-11	2020	Transfection of miR-135a-5p mimic or sh-CXCL12 could reduce the number of apoptotic myocardial cells and inhibit the level of TNF-alpha, IL-1beta and IL-6 (all p<0.05).	mir-135a-5p	16-27	interleukin 6	Mus musculus	150-154
32997263-8	2020	Simultaneously, both JAK/STAT3 and NF-kappaB pathways inhibitors, WP1066 and BAY11-7082, alleviated IL-6-induced biological effects, respectively.	WP1066	66-72	interleukin 6	Mus musculus	100-104
33178347-5	2020	By utilizing western blotting, ELISA, H&E staining and immunohistochemistry, the results demonstrated that sophocarpine treatment reversed CLP-induced elevations in serum aspartate transaminase, alanine transaminase, interleukin (IL)-6 and IL-1beta levels.	sophocarpine	107-119	interleukin 6	Mus musculus	217-235
33080340-2	2020	In the present study, mice receiving a 12-months 0.3% dextran-iron diet show mild HIO with no detectable oxidative damages in the liver but have infiltrated macrophages and increased IL-6, TNFalpha, AST and ALT since 6-months.	Dextrans	54-61	interleukin 6	Mus musculus	183-187
33080340-2	2020	In the present study, mice receiving a 12-months 0.3% dextran-iron diet show mild HIO with no detectable oxidative damages in the liver but have infiltrated macrophages and increased IL-6, TNFalpha, AST and ALT since 6-months.	Iron	62-66	interleukin 6	Mus musculus	183-187
32942916-8	2020	Plasma levels of TNF-alpha and IL-6 in DSS-treated mice was higher than that of control.	dss	39-42	interleukin 6	Mus musculus	31-35
32997263-8	2020	Simultaneously, both JAK/STAT3 and NF-kappaB pathways inhibitors, WP1066 and BAY11-7082, alleviated IL-6-induced biological effects, respectively.	3-(4-methylphenylsulfonyl)-2-propenenitrile	77-87	interleukin 6	Mus musculus	100-104
32735927-6	2020	More importantly, PRAP inhibited immune inflammatory reactions in EAH model mice, including the hepatic infiltration of inflammatory CD4+ and CD8+ T cells, as well as overexpression of inflammatory cytokines IL-2, IL-6 and IL-10, via inhibition of the NF-kappaB signaling pathway.	prap	18-22	interleukin 6	Mus musculus	214-218
32617861-10	2020	In LPS-induced RAW264.7 cells, 100 mumol/L ROF enhanced cell viability and suppressed the production of TNF-alpha, IL-6, and IL-1beta significantly.	rhoifolin	43-46	interleukin 6	Mus musculus	115-119
32661821-9	2020	Nemonoxacin could significantly reduce the expression of pro-inflammatory cytokines IL-6 and TNF-alpha while increase anti-inflammatory cytokine IL-10 expression, which were induced by LPS in vivo and in vitro.	nemonoxacin	0-11	interleukin 6	Mus musculus	84-88
33225820-9	2020	Furthermore, treating cerebral vessels of young mice with mitochondrial N-formyl peptides upregulated IL-6, increased Parkin, and reduced Claudin-5, a tight junction protein integral to BBB integrity.	n-formyl peptides	72-89	interleukin 6	Mus musculus	102-106
33124775-10	2020	Inhibition of Src kinase by AZM 475271 modifies the IL-6 level.	AZM475271	28-38	interleukin 6	Mus musculus	52-56
33045572-11	2020	The mRNA analysis demonstrated that diosmetin also reduced the level of inflammatory cytokines such as IL-1beta and IL-6.	diosmetin	36-45	interleukin 6	Mus musculus	116-120
33293856-14	2020	Furthermore, TPN treatment inhibited CFA-induced increase of pro-inflammatory cytokines, including TNF-alpha, IL-1beta, and IL-6.	triptonide	13-16	interleukin 6	Mus musculus	124-128
32748687-9	2020	In addition, inhibition of AK028245 downregulated the expression of tumor necrosis factor-alpha and interleukin-6 in the late stages of LPS stimulation and the expression of interferon-gamma and Cxcl12 in the peak stages.	ak028245	27-35	interleukin 6	Mus musculus	100-113
32930406-7	2020	Single, 25 mg/kg UMB effectively attenuated hyperalgesia, lipid peroxidation and IL-6 levels.	umbelliprenin	17-20	interleukin 6	Mus musculus	81-85
33293856-16	2020	Finally, intrathecal treatment with AKT inhibitor IV or MK-2206, attenuated CFA-induced mechanical allodynia and thermal hyperalgesia, and simultaneously decreased the mRNA expression of TNF-alpha, IL-1beta, and IL-6 in DRG.	MK 2206	56-63	interleukin 6	Mus musculus	212-216
32677743-6	2020	Finally, MEMA-suppressed M2 macrophage polarization induced by interleukin (IL)-4/IL-13 or IL-6.	mema	9-13	interleukin 6	Mus musculus	91-95
32980473-8	2020	The real-time PCR results indicated that Cl-amidine inhibited the production of TNF-alpha, IL-1beta and IL-6 in LPS-induced mouse mastitis.	N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide	41-51	interleukin 6	Mus musculus	104-108
32771698-14	2020	HDAC5 may exert beneficial effects through two different mechanisms, transcriptional control of genes required for glucose disposal and utilization, and HDAC5-dependent IL-6 signaling cross talk in order to improve glucose uptake in muscle in response to exercise.	Glucose	115-122	interleukin 6	Mus musculus	169-173
32771698-14	2020	HDAC5 may exert beneficial effects through two different mechanisms, transcriptional control of genes required for glucose disposal and utilization, and HDAC5-dependent IL-6 signaling cross talk in order to improve glucose uptake in muscle in response to exercise.	Glucose	215-222	interleukin 6	Mus musculus	169-173
33258345-12	2020	DXR alleviated visfatin-induced VEC injury via downregulation of TNF-alpha, IL-6, ICAM-1 and VCAM-1 through mitogen-activated protein kinase pathways.	3-(3-Bromobenzyl)-1-Tert-Butyl-1h-Pyrazolo[3,4-D]pyrimidin-4-Amine	0-3	interleukin 6	Mus musculus	76-80
33174019-7	2020	EMfC-treated groups exhibited marked suppression of nitrogen oxide (NO) levels, mRNA expression levels of iNOS/COX-2, levels of all inflammatory cytokines (TNF-alpha, IL-1beta and IL-6) and phosphorylation of MAPK members, as well as recovery of cell cycle progression.	emfc	0-4	interleukin 6	Mus musculus	180-184
33002595-3	2020	We have previously reported that prostaglandin E1 (PGE1) induces the synthesis of both osteoprotegerin (OPG) and interleukin-6 (IL-6), essential regulators of bone metabolism, in osteoblast-like MC3T3-E1 cells.	Alprostadil	33-49	interleukin 6	Mus musculus	113-126
33002595-3	2020	We have previously reported that prostaglandin E1 (PGE1) induces the synthesis of both osteoprotegerin (OPG) and interleukin-6 (IL-6), essential regulators of bone metabolism, in osteoblast-like MC3T3-E1 cells.	Alprostadil	33-49	interleukin 6	Mus musculus	128-132
33002595-3	2020	We have previously reported that prostaglandin E1 (PGE1) induces the synthesis of both osteoprotegerin (OPG) and interleukin-6 (IL-6), essential regulators of bone metabolism, in osteoblast-like MC3T3-E1 cells.	Alprostadil	51-55	interleukin 6	Mus musculus	113-126
33002595-3	2020	We have previously reported that prostaglandin E1 (PGE1) induces the synthesis of both osteoprotegerin (OPG) and interleukin-6 (IL-6), essential regulators of bone metabolism, in osteoblast-like MC3T3-E1 cells.	Alprostadil	51-55	interleukin 6	Mus musculus	128-132
33002595-4	2020	Based upon them, we herein investigated the mechanism whereby the effect of duloxetine on the synthesis of OPG and IL-6 induced by PGE1 in these cells.	Duloxetine Hydrochloride	76-86	interleukin 6	Mus musculus	115-119
33002595-4	2020	Based upon them, we herein investigated the mechanism whereby the effect of duloxetine on the synthesis of OPG and IL-6 induced by PGE1 in these cells.	Alprostadil	131-135	interleukin 6	Mus musculus	115-119
33002595-5	2020	Duloxetine enhanced the release from MC3T3-E1 cells of both OPG and IL-6 stimulated by PGE1.	Duloxetine Hydrochloride	0-10	interleukin 6	Mus musculus	68-72
33002595-5	2020	Duloxetine enhanced the release from MC3T3-E1 cells of both OPG and IL-6 stimulated by PGE1.	Alprostadil	87-91	interleukin 6	Mus musculus	68-72
33002595-7	2020	Oppositely, fluvoxamine and sertraline, agents belonging to the class of selective serotonin reuptake inhibitor, upregulated the PGE1-stimulated release of both OPG and IL-6.	Fluvoxamine	12-23	interleukin 6	Mus musculus	169-173
33002595-7	2020	Oppositely, fluvoxamine and sertraline, agents belonging to the class of selective serotonin reuptake inhibitor, upregulated the PGE1-stimulated release of both OPG and IL-6.	Sertraline	28-38	interleukin 6	Mus musculus	169-173
33002595-7	2020	Oppositely, fluvoxamine and sertraline, agents belonging to the class of selective serotonin reuptake inhibitor, upregulated the PGE1-stimulated release of both OPG and IL-6.	Serotonin	83-92	interleukin 6	Mus musculus	169-173
33002595-7	2020	Oppositely, fluvoxamine and sertraline, agents belonging to the class of selective serotonin reuptake inhibitor, upregulated the PGE1-stimulated release of both OPG and IL-6.	Alprostadil	129-133	interleukin 6	Mus musculus	169-173
33002595-8	2020	Duloxetine amplified the expression of OPG mRNA and IL-6 mRNA stimulated by PGE1.	Duloxetine Hydrochloride	0-10	interleukin 6	Mus musculus	52-56
33002595-8	2020	Duloxetine amplified the expression of OPG mRNA and IL-6 mRNA stimulated by PGE1.	Alprostadil	76-80	interleukin 6	Mus musculus	52-56
33002595-10	2020	SB203880, an inhibitor of p38 MAP kinase, suppressed the amplifying effects by duloxetine or fluvoxamine on the PGE1-stimulated release of OPG and IL-6.	sb203880	0-8	interleukin 6	Mus musculus	147-151
33002595-10	2020	SB203880, an inhibitor of p38 MAP kinase, suppressed the amplifying effects by duloxetine or fluvoxamine on the PGE1-stimulated release of OPG and IL-6.	Duloxetine Hydrochloride	79-89	interleukin 6	Mus musculus	147-151
33002595-10	2020	SB203880, an inhibitor of p38 MAP kinase, suppressed the amplifying effects by duloxetine or fluvoxamine on the PGE1-stimulated release of OPG and IL-6.	Fluvoxamine	93-104	interleukin 6	Mus musculus	147-151
33002595-10	2020	SB203880, an inhibitor of p38 MAP kinase, suppressed the amplifying effects by duloxetine or fluvoxamine on the PGE1-stimulated release of OPG and IL-6.	Alprostadil	112-116	interleukin 6	Mus musculus	147-151
33002595-11	2020	These results strongly suggest that duloxetine could strengthen osteoblast activation by PGE1 through the upregulation of p38 MAP kinase, leading to increasing the synthesis of OPG and IL-6.	Duloxetine Hydrochloride	36-46	interleukin 6	Mus musculus	185-189
33002595-11	2020	These results strongly suggest that duloxetine could strengthen osteoblast activation by PGE1 through the upregulation of p38 MAP kinase, leading to increasing the synthesis of OPG and IL-6.	Alprostadil	89-93	interleukin 6	Mus musculus	185-189
33260074-11	2020	BMS309403 improved glucose and insulin tolerance and transcriptionally repressed the levels of TNF-alpha and IL-6, suggesting a role of FABP4 in inflammation.	2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid	0-9	interleukin 6	Mus musculus	109-113
32866059-9	2020	Moreover, curcumin reduced the levels of IL-6, IL-1beta and TNF-alpha by 22.5%, 30.3% and 26.7%, respectively, and suppressed vimentin expression in UUO mice.	Curcumin	10-18	interleukin 6	Mus musculus	41-45
32866059-11	2020	In LPS-induced HK-2 cells, curcumin decreased the release of IL-6, IL-1beta and TNF-alpha by 43.4%, 38.1% and 28.3%, respectively.	Curcumin	27-35	interleukin 6	Mus musculus	61-65
32043433-6	2020	Liquid chromatography tandem-mass spectrometry was used to determine the protein contents of the BMVs.We found that ceftazidime induced a higher number of BMVs (CAZ-BMV), which carried more LPS, and induced higher expression levels of iNOS, IL-1beta, and IL-6 in macrophages, higher expression of many cytokines in mice, more neutrophil infiltration in lung interstitium, and higher mortality in mice than imipenem-induced BMVs (IMP-BMV).	Ceftazidime	116-127	interleukin 6	Mus musculus	255-259
33126029-8	2020	Transfer of CD4+ mesLNCs additionally increased adrenal weight and secretion of IL-6 from in vitro anti-CD3 stimulated mesLNCs in recipients administered with DSS.	Dextran Sulfate	159-162	interleukin 6	Mus musculus	80-84
33424253-8	2020	In EAE, Flavipin ameliorated disease severity, with reduced CD4+IL-17+ T cells, IL-6 and TNF-alpha and increased CD4+FoxP3+ T cells.	flavipin	8-16	interleukin 6	Mus musculus	80-84
33007731-8	2020	In vitro, stepharine (10, 30 muM) substantially inhibited nitric oxide release as well as the mRNA and protein expression of pro-inflammatory mediators [inducible nitric oxide synthase, interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, IL-1beta] in LPS-activated BV-2 cells.	stepharine	10-20	interleukin 6	Mus musculus	186-204
33292347-10	2020	In addition, catechins could significantly down-regulated the expression of p-NF-kappaB p65 in the uterus and the protein expressions of the pro-inflammatory factors (IL-1beta, IL-6, and TNF-alpha).	Catechin	13-22	interleukin 6	Mus musculus	177-181
33007382-7	2020	Moreover, incubation of splenocytes from TCE-treated mice with HNE-modified proteins resulted in enhanced splenocyte proliferation and cytokine release evidenced by increased expression of cyclin D3, Cyclin-dependent kinase 6 (CDK6) and phospho-pRb as well as increased release of IL-6, TNF-alpha and INF-gamma.	Trichloroethylene	41-44	interleukin 6	Mus musculus	281-285
33260891-9	2020	RESULTS: Oral KLHTT treatment (50 and 100 mg/kg) ameliorated mouse CIA by decreasing the levels of interleukin (IL)-1beta, IL-6, IL-17A, and tumour necrosis factor-alpha in the paw homogenates and serum.	klhtt	14-19	interleukin 6	Mus musculus	123-127
33266362-7	2020	Moreover, live K040706 significantly enhanced IL-6 and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in the splenocytes and Peyer"s patch (PP) cells of mice and increased bone marrow (BM) cell proliferation.	k040706	15-22	interleukin 6	Mus musculus	46-50
33598156-3	2021	The results showed that the LPS + WO group significantly decreased serum tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-1beta levels and increased the jejunum superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) levels compared with the LPS group.	wo	34-36	interleukin 6	Mus musculus	114-127
33598156-3	2021	The results showed that the LPS + WO group significantly decreased serum tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-1beta levels and increased the jejunum superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) levels compared with the LPS group.	wo	34-36	interleukin 6	Mus musculus	129-133
33179910-5	2020	When OVA was combined with poly(I:C) that was either co-entrapped in the same particles or as separate particles, a comparable level of anti-OVA IgG1 antibodies and interleukin-6 (IL-6) was produced in mouse blood plasma, and a similar level of cytotoxic T lymphocyte (CTL) response in mice was stimulated as compared to OVA/Alum particles.	poly	27-31	interleukin 6	Mus musculus	165-178
33312069-8	2020	In addition, relevant inflammatory cytokines (tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6) were also significantly reduced in the calvaria of the Tet-treated groups.	tetrandrine	170-173	interleukin 6	Mus musculus	109-113
34026223-11	2021	Results: Sodium butyrate reversed the LPS-induced tissue-morphology changes and high levels of serum alanine aminotransferase, aspartate transaminase, myeloperoxidase, TUNEL, and pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6.	Butyric Acid	9-24	interleukin 6	Mus musculus	246-259
32828944-12	2020	SIGNIFICANCE: Raloxifene has effects on inhibiting atherosclerosis development, the underlying mechanisms might involve in inhibiting inflammation-related IL-6/STAT3 signaling pathway.	Raloxifene Hydrochloride	14-24	interleukin 6	Mus musculus	155-159
32901495-6	2020	After 2 days, Il-1beta and Il-6 expression was upregulated in the TA of CTX-IBU and CTX-PL vs. PBS.	Lead	95-98	interleukin 6	Mus musculus	27-31
32828944-0	2020	Raloxifene inhibits IL-6/STAT3 signaling pathway and protects against high-fat-induced atherosclerosis in ApoE-/- mice.	Raloxifene Hydrochloride	0-10	interleukin 6	Mus musculus	20-24
33658925-8	2020	Subsequently, we revealed berberine suppressed the expression of pro-inflammatory factors including TNF-alpha and IL-6 through regulating PLA2G4A dysfunction in macrophage RAW 264.7 cells.	Berberine	26-35	interleukin 6	Mus musculus	114-118
32853650-4	2020	First, we proved that the bovine serum albumin (BSA)-induced inflammatory response in HK-2 cells was inhibited by knocking out Rab27a and that Rab27a, IL-6, TNF-alpha and COL-1 expression was markedly increased in an HFD/STZ-induced diabetic mouse model.	Streptozocin	221-224	interleukin 6	Mus musculus	151-155
32828944-2	2020	Our previous studies found that Raloxifene targeted against IL-6/GP130 protein-protein interface and inhibited STAT3 phosphorylation induced by IL-6 in cancer cells.	Raloxifene Hydrochloride	32-42	interleukin 6	Mus musculus	60-64
32828944-2	2020	Our previous studies found that Raloxifene targeted against IL-6/GP130 protein-protein interface and inhibited STAT3 phosphorylation induced by IL-6 in cancer cells.	Raloxifene Hydrochloride	32-42	interleukin 6	Mus musculus	144-148
32828944-3	2020	However, whether Raloxifene could suppress IL-6/STAT3 signaling pathway and attenuate atherosclerosis in high-fat diet (HFD)-induced mice remains unknown.	Raloxifene Hydrochloride	17-27	interleukin 6	Mus musculus	43-47
32828944-9	2020	Histological analysis showed that the expression of IL-6, P-STAT3, ICAM-1, VCAM-1, CD68 and alpha-SMA were significantly decreased in the Raloxifene intervention group compared to HFD group.	Raloxifene Hydrochloride	138-148	interleukin 6	Mus musculus	52-56
33191889-0	2021	Histone Deacetylase Inhibitors Prevented the Development of Morphine Tolerance by Decreasing IL6 Production and Upregulating mu-Opioid Receptors.	Morphine	60-68	interleukin 6	Mus musculus	93-96
32828944-10	2020	Moreover, we observed that IL-6 increased migration and cell viability of VSMCs and RAW264.7 cells, while Raloxifene treatment decreased migration and reduced cell viability of VSMCs and RAW264.7 cells stimulated by IL-6.	Raloxifene Hydrochloride	106-116	interleukin 6	Mus musculus	216-220
33202749-9	2020	Our results suggest that the PAA-induced ROS deregulated Stat3/IL-6 pathway and PAA may be a potential agent targeting breast cancer and CSCs.	Reactive Oxygen Species	41-44	interleukin 6	Mus musculus	63-67
33202848-6	2020	Furthermore, all the six flavonoids could significantly inhibit the secretion of IL-1beta, IL-6, NO (p < 0.01) and the protein expression of NF-kappaB p-p65 (p < 0.01) in LPS-stimulated RAW264.7 cells.	Flavonoids	25-35	interleukin 6	Mus musculus	91-95
33191889-8	2021	Alone administration of morphine also showed an increase in the production of the pro inflammatory mediator, IL-6, and down-regulation of the mu-opioid receptor in the brain tissues.	Morphine	24-32	interleukin 6	Mus musculus	109-113
33442382-12	2020	Paeonol inhibited secreaion of inflammatory cytokines in A549 cells, including tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-1beta, and transforming growth factor (TGF)-beta.	paeonol	0-7	interleukin 6	Mus musculus	114-132
33177483-9	2020	RESULTS In the DSS mouse model of IBD, rifaximin reduced the inflammation severity of the colon and reduced the expression of phospho-p65, p65, TNF-alpha, and IL-6.	Dextran Sulfate	15-18	interleukin 6	Mus musculus	159-163
33177483-9	2020	RESULTS In the DSS mouse model of IBD, rifaximin reduced the inflammation severity of the colon and reduced the expression of phospho-p65, p65, TNF-alpha, and IL-6.	Rifaximin	39-48	interleukin 6	Mus musculus	159-163
32950572-12	2020	The levels of IL-6 and TNF-alpha and nuclear translocation of NF-kappaB were ameliorated after pretreatment of SIN in LPS-induced Raw264.7 cells, while limited attenuations were observed after pretreatment of DS (SNO) even at 200 muM.	sinomenine	111-114	interleukin 6	Mus musculus	14-18
33244300-11	2020	In the non-clinical study, RJX exhibited potent and dose-dependent protective activity, decreased the inflammatory cytokine responses (interleukin-6, tumor necrosis factor alpha, transforming growth factor beta), and improved survival in the LPS-GalN mouse model of sepsis and ARDS.	rjx	27-30	interleukin 6	Mus musculus	135-148
33206750-8	2020	Transmission of Tregs was estimated in different experimental groups based on the mRNA expression of TLR-4, IL-6, HO-1, and Foxp3.	tregs	16-21	interleukin 6	Mus musculus	108-112
33187321-6	2020	HFD-induced inflammation (TNF-alpha, IL-6, IL-1beta, CD14, F4/80, iNOS, and COX2) was normalized by GSEE in mice livers.	gsee	100-104	interleukin 6	Mus musculus	37-41
33182620-6	2020	Biocompatibility assay using macrophage RAW 264.7 cell line resulted in low production of inflammatory cytokines such as IL-6, IL-1beta and TNF-alpha after treatment with TAC-NMF.	tac-nmf	171-178	interleukin 6	Mus musculus	121-125
32763432-5	2020	The ovalbumin (OVA) loaded Eth-HA-GC (OVA@Eth-HA-GC) can promote BMDCs" expression of CD80, CD86 (DCs maturation-associated marker molecules), TNF-alpha, IL-2 and IL-6.	Ethionamide	27-30	interleukin 6	Mus musculus	163-167
32763432-8	2020	Transdermal administration with OVA@Eth-HA-GC/SF mats induced the serum anti-OVA-specific IgG and increased the expression of IFN-gamma, IL-2 and IL-6 by spleen cells in vivo.	Ethionamide	36-39	interleukin 6	Mus musculus	146-150
32763432-8	2020	Transdermal administration with OVA@Eth-HA-GC/SF mats induced the serum anti-OVA-specific IgG and increased the expression of IFN-gamma, IL-2 and IL-6 by spleen cells in vivo.	Hyaluronic Acid	40-42	interleukin 6	Mus musculus	146-150
33223955-4	2020	In LPS challenged mice, mibefradil (20 and 40 mg/kg) dramatically decreased the total cell number, as well as the productions of TNF-alpha and IL-6 in bronchoalveolar lavage fluid (BALF).	Mibefradil	24-34	interleukin 6	Mus musculus	143-147
33224434-9	2020	VPA administration significantly decreased the expression of phosphorylated nuclear factor-kappa B (p-NFkappaB), matrix metalloproteinases 9 (MMP9), tumor necrosis factoralpha (TNFalpha), and interleukin-6 (IL-6), while it enhanced the expression of claudin 5 and occludin in the brain.	Valproic Acid	0-3	interleukin 6	Mus musculus	192-205
33224434-9	2020	VPA administration significantly decreased the expression of phosphorylated nuclear factor-kappa B (p-NFkappaB), matrix metalloproteinases 9 (MMP9), tumor necrosis factoralpha (TNFalpha), and interleukin-6 (IL-6), while it enhanced the expression of claudin 5 and occludin in the brain.	Valproic Acid	0-3	interleukin 6	Mus musculus	207-211
33244198-9	2020	Compared with PSGL-1 +/+ mice, PSGL-1 -/- AP mice induced by caerulein exhibited lower serum amylase, less Interleukin-1beta (IL-1beta) and Interleukin-6 (IL-6) expression, less neutrophil and macrophage infiltration, and reduced peripheral neutrophil and monocyte accounts.	Ceruletide	61-70	interleukin 6	Mus musculus	140-153
33244198-9	2020	Compared with PSGL-1 +/+ mice, PSGL-1 -/- AP mice induced by caerulein exhibited lower serum amylase, less Interleukin-1beta (IL-1beta) and Interleukin-6 (IL-6) expression, less neutrophil and macrophage infiltration, and reduced peripheral neutrophil and monocyte accounts.	Ceruletide	61-70	interleukin 6	Mus musculus	155-159
33191881-14	2021	MoFTI was observed to induce TNF-alpha, IFN-gamma, IL-6, IL-10, and NO release.	mofti	0-5	interleukin 6	Mus musculus	51-55
33171990-5	2020	In the retinas of high-dose COS-treated mice, the nuclear translocation of NF-kappaB subunit (p65) was suppressed, and the expression of several key EAU inflammatory mediators, IFN-gamma, TNF-alpha, IL-1alpha, IL-4, IL-5, IL-6, IL-10, IL-17 and MCP-1 was lowered.	carbonyl sulfide	28-31	interleukin 6	Mus musculus	222-226
33250722-9	2020	Besides, it also dampened microglia activation at lesion sites and rectified cytokines levels (IL-1beta, IL-6, and IL-10) in CPZ-affected regions.	Cuprizone	125-128	interleukin 6	Mus musculus	105-109
32758571-4	2020	The three dihydroxystilbenes inhibited colon carcinogenesis and tumor growth as well as increases in colon IL-1beta, IL-6, MCP-1, and PD-1 levels in AOM/DDS-treated mice (in vivo).	dihydroxystilbenes	10-28	interleukin 6	Mus musculus	117-121
33155932-10	2021	KW-2449 also decreased TNF-alpha, IL-6, CCL-2 inflammatory cytokines and MMP-2 in both brain mRNA expressions and serum levels of EAE mice.	KW 2449	0-7	interleukin 6	Mus musculus	34-38
33152996-7	2020	Compared with the control condition, irinotecan diminished (p < 0.05) intestinal villus height, caused a loss of crypt integrity and intense inflammatory cell infiltration, increased myeloperoxidase (MPO), IL-6 and IL-1beta levels and decreased reduced glutathione (GSH) levels in duodenum segments and increased gastric retention and decreased liquid retention in the medial intestinal segment, resulting in increased intestinal transit, severe diarrhea and reduced survival (approximately 72%).	Irinotecan	37-47	interleukin 6	Mus musculus	206-210
33334792-9	2020	RESULTS: The expressions of TNF-alpha, IL-6, pNF-kappaB and IkappaB-alpha have changed after Naringenin treatment.	naringenin	93-103	interleukin 6	Mus musculus	39-43
33147699-5	2020	Moreover, HMA significantly inhibited the proinflammatory cytokines such as interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha in LPS-stimulated BV-2 microglial cells.	5-(N,N-hexamethylene)amiloride	10-13	interleukin 6	Mus musculus	100-104
32694422-10	2020	The immune response induced by cytokines (as interferon-gamma, interleukin-6, and tumor necrosis factor-alpha) was significantly stronger in mice treated with thioridazine + loratadine + R848.	Thioridazine	159-171	interleukin 6	Mus musculus	63-76
32694422-10	2020	The immune response induced by cytokines (as interferon-gamma, interleukin-6, and tumor necrosis factor-alpha) was significantly stronger in mice treated with thioridazine + loratadine + R848.	Loratadine	174-184	interleukin 6	Mus musculus	63-76
33224034-4	2020	Our study demonstrated that alisol A can effectively inhibit the formation of arterial plaques and blocked the progression of AS in ApoE-/- mice fed with high-fat diet and significantly reduced the expression of inflammatory cytokins in aorta, including ICAM-1, IL-6, and MMP-9.	alisol A	28-36	interleukin 6	Mus musculus	262-266
33313269-14	2020	Moreover, aspirin reduced the levels of inflammatory factors interleukin-6, interleukin-1beta and tumor necrosis factor-alpha and decreased the activation of STAT3 signaling pathway.	Aspirin	10-17	interleukin 6	Mus musculus	61-74
32694422-10	2020	The immune response induced by cytokines (as interferon-gamma, interleukin-6, and tumor necrosis factor-alpha) was significantly stronger in mice treated with thioridazine + loratadine + R848.	resiquimod	187-191	interleukin 6	Mus musculus	63-76
33152903-7	2020	Meanwhile, Marein ameliorated fibrosis and inflammation by suppressing the pro-inflammatory factors interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1), and expression of the extracellular matrix proteins, fibronectin (FN) and collagen 1 (COL1) in diabetic mice.	marein	11-17	interleukin 6	Mus musculus	100-113
33313242-11	2020	Additionally, GB decreased the serum levels of interleukin (IL)-1beta, IL-6, monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor alpha (TNF-alpha), matrix metalloproteinase (MMP)-3 and MMP-13, and increased IL-10.	ginkgolide B	14-16	interleukin 6	Mus musculus	71-75
33313089-12	2020	Results: Pon prevented the release of nitric oxide (NO), prostaglandin E2 (PGE2), interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha (TNF-alpha) in both BV2 cells and primary microglia stimulated with LPS.	poncirin	9-12	interleukin 6	Mus musculus	106-110
33152903-7	2020	Meanwhile, Marein ameliorated fibrosis and inflammation by suppressing the pro-inflammatory factors interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1), and expression of the extracellular matrix proteins, fibronectin (FN) and collagen 1 (COL1) in diabetic mice.	marein	11-17	interleukin 6	Mus musculus	115-119
32593632-7	2020	It is concluded that all tested NPs downregulated the expression of DME genes, with the highest influence exhibited by copper oxide NPs, in correlation with inflammation and il6 gene induction in the liver.	cupric oxide	119-131	interleukin 6	Mus musculus	174-177
32583175-5	2020	The PEG-Mac@NPs, Isorhamnetin (Iso) on the free LPS encouraged endotoxin in BALB/c mice through evaluating the nitric acid, TNF-alpha, and IL-6.	Polyethylene Glycols	4-7	interleukin 6	Mus musculus	139-143
33182019-7	2020	We found that treatment with 5MTP contributed to decreased activation of pro-inflammatory microglia and reduced the generation of inflammatory cytokines, including TNF-alpha, IL-1beta, IL-6 and IL-18, by negative regulation of the p38-MAPK signaling pathway and NLRP3/caspase-1 expression.	5-methoxytryptophan	29-33	interleukin 6	Mus musculus	185-189
32805417-10	2020	The treatment of murine macrophages with rHaCRT induced the expression of immune genes, such as tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), inducible nitric oxide synthase (iNOS), and interleukin-1beta (IL-1beta).	rhacrt	41-47	interleukin 6	Mus musculus	137-150
32805417-10	2020	The treatment of murine macrophages with rHaCRT induced the expression of immune genes, such as tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), inducible nitric oxide synthase (iNOS), and interleukin-1beta (IL-1beta).	rhacrt	41-47	interleukin 6	Mus musculus	152-156
33182050-5	2020	In vitro studies showed that IL-6 directly induced NLRP3 inflammasome activation via cathepsin B (CTSB) in the presence of ATP.	Adenosine Triphosphate	123-126	interleukin 6	Mus musculus	29-33
32871679-7	2020	In addition, crocin-I reduced the levels of lipopolysaccharide (LPS), Interleukin-6and tumor necrosis factor-alpha (TNF-alpha) in serum and TNF-alpha expression in the hippocampus, and increased the hippocampal brain-derived neurotrophic factor.	crocin	13-21	interleukin 6	Mus musculus	70-83
31805776-4	2020	Acetylshikonin could attenuate smoke-induced lung pathological changes, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1beta (IL-1beta), and monocyte chemoattractant protein 1 (MCP-1) productions, and tissue damages caused by oxidative stress.	acetylshikonin	0-14	interleukin 6	Mus musculus	113-126
31805776-4	2020	Acetylshikonin could attenuate smoke-induced lung pathological changes, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1beta (IL-1beta), and monocyte chemoattractant protein 1 (MCP-1) productions, and tissue damages caused by oxidative stress.	acetylshikonin	0-14	interleukin 6	Mus musculus	128-132
32822909-0	2020	Kupffer cell depletion attenuates IL-6/STAT3 mediates hepatocyte apoptosis in immunological liver injury of trichloroethylene sensitized mice.	Trichloroethylene	108-125	interleukin 6	Mus musculus	34-38
32822909-4	2020	In our previous research, we found the activation of Kupffer cells (KCs) which increased IL-6 can aggravate liver cell apoptosis in TCE sensitized mice.	Trichloroethylene	132-135	interleukin 6	Mus musculus	89-93
32822909-5	2020	However, the mechanism of IL-6 in liver damages induced by TCE was not clear.	Trichloroethylene	59-62	interleukin 6	Mus musculus	26-30
32822909-6	2020	This study explored the function of IL-6/STAT3 signal pathway on the TCE induced apoptosis of liver cell.	Trichloroethylene	69-72	interleukin 6	Mus musculus	36-40
32822909-9	2020	All in all, the activation of KCs can increase the expression of IL-6, IL-6R and phosphorylate STAT3, induces hepatocyte apoptosis, and participates in immunity damage of liver which induced by TCE.	Trichloroethylene	194-197	interleukin 6	Mus musculus	65-69
32801029-6	2020	RESULTS: Ethanol increased mRNA expression of interleukin (Il)-6, Il-1b, and tumor necrosis factor alpha with a concomitant increase in nuclear translocation of nuclear factor kappaB, which was abolished by ASTX.	Ethanol	9-16	interleukin 6	Mus musculus	46-64
33182072-7	2020	In the LPS-induced inflammatory response of RAW264.7 macrophages, we also found that PE significantly inhibited the phosphorylation of AKT, ERK1/2, JNK1/2, P65, and P38 to reduce the production of IL-1beta, IL-6, TNF-alpha, COX-2, and iNOS.	pedunculoside	85-87	interleukin 6	Mus musculus	207-211
32941896-0	2020	Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression.	hyaluronate	40-51	interleukin 6	Mus musculus	27-30
32941896-0	2020	Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression.	peg-chitosan	63-75	interleukin 6	Mus musculus	27-30
32941896-0	2020	Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression.	Lactic Acid	76-83	interleukin 6	Mus musculus	27-30
32941896-5	2020	MATERIALS AND METHODS: In this study, we generated and characterized hyaluronate-PEG-Chitosan-Lactate (H-PCL) nanoparticles (NPs) to simultaneously deliver IL6-specific siRNA and BV6 to 4T1 (breast cancer) and CT26 (colon cancer) cells, and investigate the anti-tumor properties of this combination therapy both in vitro and in vivo.	h-pcl	103-108	interleukin 6	Mus musculus	156-159
32890914-11	2020	Silibinin combined with thymol (40 muM and 120 muM respectively, with the molar ratio 1:3) had more potent effects on the inhibition of NO, TNF-alpha, and IL-6 than those exerted by individual administration of these compounds in LPS-induced RAW264.7 cells.	Silybin	0-9	interleukin 6	Mus musculus	155-159
32934728-4	2020	In addition, miR-23b-3p was induced in response to interleukin-6 (IL-6), which is known to be involved in the progression of PC.	mir-23b-3p	13-23	interleukin 6	Mus musculus	51-64
32934728-4	2020	In addition, miR-23b-3p was induced in response to interleukin-6 (IL-6), which is known to be involved in the progression of PC.	mir-23b-3p	13-23	interleukin 6	Mus musculus	66-70
32491281-10	2020	In the asthma model, ISO, in combination with DEX, showed an additive inhibitory effect on AHR, inflammation, and the number of activated MCs in the lungs and decreased the levels of interleukin (IL)-4, IL-5, IL-6, IL-13, tumor necrosis factor (TNF)-a, and C-C motif chemokine ligand (CCL)-2 in bronchoalveolar lavage fluid.	isoimperatorin	21-24	interleukin 6	Mus musculus	209-213
32491281-10	2020	In the asthma model, ISO, in combination with DEX, showed an additive inhibitory effect on AHR, inflammation, and the number of activated MCs in the lungs and decreased the levels of interleukin (IL)-4, IL-5, IL-6, IL-13, tumor necrosis factor (TNF)-a, and C-C motif chemokine ligand (CCL)-2 in bronchoalveolar lavage fluid.	Dexamethasone	46-49	interleukin 6	Mus musculus	209-213
32846405-10	2020	In BV2 cells and spinal cord samples, ZOE, 6-gingerol and 6-shogaol reduced pERK levels, whereas ZOE and terpene fraction reduced HDAC1 protein levels, inhibited NF-kappaB signalling activation and decreased IL-1beta, TNF-alpha and IL-6 release.	Terpenes	105-112	interleukin 6	Mus musculus	232-236
32890914-11	2020	Silibinin combined with thymol (40 muM and 120 muM respectively, with the molar ratio 1:3) had more potent effects on the inhibition of NO, TNF-alpha, and IL-6 than those exerted by individual administration of these compounds in LPS-induced RAW264.7 cells.	Thymol	24-30	interleukin 6	Mus musculus	155-159
32569719-10	2020	Further, the study revealed the mechanistic role of andrographolide in treatment of arthritis by suppressing battery of molecules like COX-2, NF-kappaB, p-p38, CD40, TNF-alpha, IL-1beta and IL-6 involved in arthritis.	andrographolide	52-67	interleukin 6	Mus musculus	190-194
33350241-14	2020	As compared with the 3 MA group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in the low and medium dose piperine groups and rapamycin group(P<0.05); howe-ver, their first foot licking time was significantly prolonged, APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were increased significantly(P<0.05).	Sirolimus	169-178	interleukin 6	Mus musculus	275-279
33350241-15	2020	As compared with the medopar group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in low dose piperine group and rapamycin group(P<0.05), but their first foot licking time was significantly extended, and APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	156-165	interleukin 6	Mus musculus	259-263
32856346-12	2020	Moreover, Ac2-26 inhibited the expressions of TNF-alpha and IL-6 and up-regulated the expressions of IL-10, TGF-beta, and VEGFA during diabetic wound healing.	annexin A1 peptide (2-26)	10-16	interleukin 6	Mus musculus	60-64
33114200-6	2020	Surprisingly, it was found that SM significantly enhanced LPS-induced expression of the pro-inflammatory cytokines interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), and interleukin-1beta (IL-1beta) in RAW264.7 cells via activation of the c-Jun/Toll-like receptor 4 (TLR4) signaling axis.	Samarium	32-34	interleukin 6	Mus musculus	115-128
33138176-8	2020	Intrarectal treatment of colitis with 30 mg/kg chitosan alone and with 30 mg/kg 5-ASA for 3 days led to a significant decrease in MPO, ALP, TNF-alpha, IL-6, IL-1beta and NF-kappaB in colitis mice compared to untreated mice.	Chitosan	47-55	interleukin 6	Mus musculus	151-155
33138176-8	2020	Intrarectal treatment of colitis with 30 mg/kg chitosan alone and with 30 mg/kg 5-ASA for 3 days led to a significant decrease in MPO, ALP, TNF-alpha, IL-6, IL-1beta and NF-kappaB in colitis mice compared to untreated mice.	Mesalamine	80-85	interleukin 6	Mus musculus	151-155
33099539-6	2020	IL-6 KO also reversed the stimulatory effect of doxorubicin (DOX) treatment on Mo1s and the inhibitory effect of DOX treatment on Mo2s in vitro.	Doxorubicin	48-59	interleukin 6	Mus musculus	0-4
33099539-6	2020	IL-6 KO also reversed the stimulatory effect of doxorubicin (DOX) treatment on Mo1s and the inhibitory effect of DOX treatment on Mo2s in vitro.	Doxorubicin	61-64	interleukin 6	Mus musculus	0-4
33099539-6	2020	IL-6 KO also reversed the stimulatory effect of doxorubicin (DOX) treatment on Mo1s and the inhibitory effect of DOX treatment on Mo2s in vitro.	Doxorubicin	113-116	interleukin 6	Mus musculus	0-4
33149573-8	2020	In addition, cytokine estimation revealed ameliorated levels of TNF-alpha, interleukins, IL-6, IL-1beta with evidenced histological observations in ZnO-SYR-treated mice compared to BAP-induced lung cancer mice.	zno-syr	148-155	interleukin 6	Mus musculus	89-93
33114200-6	2020	Surprisingly, it was found that SM significantly enhanced LPS-induced expression of the pro-inflammatory cytokines interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), and interleukin-1beta (IL-1beta) in RAW264.7 cells via activation of the c-Jun/Toll-like receptor 4 (TLR4) signaling axis.	Samarium	32-34	interleukin 6	Mus musculus	130-134
33060784-3	2020	By using a murine model of imiquimod-induced psoriasis-like dermatitis, we further demonstrated that PD-1 deficiency accelerates skin inflammation with activated cytotoxic CD8 T cells into the epidermis, which engage in pathogenic cross-talk with keratinocytes resulting in production of IL-6.	Imiquimod	27-36	interleukin 6	Mus musculus	288-292
33192176-11	2020	The results showed that isoorientin decreased the production of TNF-alpha, IL-6, and IL-1beta and increased the expression of p-GSK3beta in vitro and in vivo, similar to LiCl.	homoorientin	24-35	interleukin 6	Mus musculus	75-79
33192501-8	2020	Hyperoside treatment also reduced the levels of MDA, TNF-alpha, and IL-6 and increased the activity of SOD.	hyperoside	0-10	interleukin 6	Mus musculus	68-72
33081840-20	2020	Daphnetin treatment attenuated IMQ-induced upregulation of inflammatory cytokines including IL-6, IL-23A and IL-17A in skin lesion of mice.	daphnetin	0-9	interleukin 6	Mus musculus	92-96
33081840-20	2020	Daphnetin treatment attenuated IMQ-induced upregulation of inflammatory cytokines including IL-6, IL-23A and IL-17A in skin lesion of mice.	Imiquimod	31-34	interleukin 6	Mus musculus	92-96
33105887-9	2020	Thus, immunohistochemical analysis of VAT showed an increase in MCP-1 and IL-6 staining in HF + PA-fed mice but not in HF + LA-fed mice compared to CD controls.	Palmitic Acid	96-98	interleukin 6	Mus musculus	74-78
33080865-8	2020	Furthermore, citral also reduced interleukin (IL)-6 levels in the hypothalamus of obese mice.	citral	13-19	interleukin 6	Mus musculus	33-51
33194022-4	2020	Finally, then use aFKN, rFKN, or IgG to intervene in polarized Tregs with IL-6, TGF-beta, IL-23, anti-interferon, and Th17 cells with anti-IL-4 after transforming to transform growth factor (TGF)-beta and interleukin (IL)-2 in isolated mouse spleen lymphocytes.	tregs	63-68	interleukin 6	Mus musculus	74-78
32768653-5	2020	Meth significantly activated microglia accompanied by marked increase of TLR4 and TRIF expression, NF-kB and MAPK pathways activation and the production of IL-1beta, TNF-alpha and IL-6.	Methamphetamine	0-4	interleukin 6	Mus musculus	180-184
32512102-6	2020	In vitro, EPS could significantly enhance the proliferation and phagocytic activity as well as induce the production of NO, TNF-alpha, IL-1beta, and IL-6 in RAW264.7 cells.	exophthalmos producing substance	10-13	interleukin 6	Mus musculus	149-153
32798553-12	2020	Regarding the biochemical analysis, repeated CBDA treatment diminished the level of peroxisome proliferator-activated receptor gamma (PPAR-gamma) and increased that of interleukin-6 (IL-6) protein in PFC.	cannabidiolic acid	45-49	interleukin 6	Mus musculus	168-181
32798553-12	2020	Regarding the biochemical analysis, repeated CBDA treatment diminished the level of peroxisome proliferator-activated receptor gamma (PPAR-gamma) and increased that of interleukin-6 (IL-6) protein in PFC.	cannabidiolic acid	45-49	interleukin 6	Mus musculus	183-187
32291451-8	2020	NSPP treatment significantly increased the number of neural stem/progenitor cells after brain irradiation in female animals, inhibited radiation-induced microglia activation and expression of the pro-inflammatory cytokine IL-6.	nspp	0-4	interleukin 6	Mus musculus	222-226
33060792-8	2020	The level of IL-6 and TNF-alpha also increased in irisin lacking mice.	irisin	50-56	interleukin 6	Mus musculus	13-17
33082817-13	2020	In the CAC model, FLCWK synergized with 5-FU to inhibit the phosphorylation of STAT3, preventing IL-6/STAT3 signal transduction and thus further inducing apoptosis and inhibition of colon cancer cell proliferation.	Fluorouracil	40-44	interleukin 6	Mus musculus	97-101
33066442-6	2020	It was observed that hexane and ethyl acetate fractions of the crude extract of the aerial parts of H. noldeae, as well as caffeic acid, isoquercetin, and ER2.4 and ER2.7 fractions revealed significant inhibitory effects on Caspase-1 activities, and on IL-1beta and IL-6 production.	Hexanes	21-27	interleukin 6	Mus musculus	266-270
33240782-4	2020	USP38 specifically removes the monoubiquitin on H2B at lysine 120, which functions as a prerequisite for the subsequent recruitment of demethylase KDM5B to the promoters of proinflammatory cytokines Il6 and Il23a during LPS stimulation.	Lysine	55-61	interleukin 6	Mus musculus	199-202
32833882-7	2020	RESULTS: TMP promoted neurite growth and inhibited TNFalpha, IL-6 and NF-kappa B signaling in a concentration-dependent manner in vitro.	tmp	9-12	interleukin 6	Mus musculus	61-65
32661350-5	2020	We found that fisetin administration significantly alleviated CLP-induced lung, liver and kidney injury, as well as the expression levels of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha and IL-1beta in bronchoalveolar lavage fluid (BALF).	fisetin	14-21	interleukin 6	Mus musculus	141-159
32833882-8	2020	Moreover, compared with the SCI group, the BMS scores and nerve regeneration showed a significant increase, while NF-kappa B signaling, TNFalpha and IL-6 production significantly decreased after TMP treatment.	tmp	195-198	interleukin 6	Mus musculus	149-153
32640308-13	2020	Number of neutrophils, macrophages and T cells, and expression of TNF-alpha, IL-6, IL-17A, IL-21 and IL-23 were decreased in DSS-CHLl-KO mice, while IL-10 expression was increased.	dss	125-128	interleukin 6	Mus musculus	77-81
32627119-5	2020	VSMCs undergoing apoptosis through Fas/CD95 or the protein kinase inhibitor staurosporine transcriptionally activated interleukin 6 (IL-6) and granulocyte-macrophage colony stimulating factor (GM-CSF), leading to their secretion.	Staurosporine	76-89	interleukin 6	Mus musculus	118-131
32627119-5	2020	VSMCs undergoing apoptosis through Fas/CD95 or the protein kinase inhibitor staurosporine transcriptionally activated interleukin 6 (IL-6) and granulocyte-macrophage colony stimulating factor (GM-CSF), leading to their secretion.	Staurosporine	76-89	interleukin 6	Mus musculus	133-137
32627119-10	2020	DT administration induced VSMC apoptosis and VSMC proliferation, and also signficantly induced IL-6 and GM-CSF.	Thymidine	0-2	interleukin 6	Mus musculus	95-99
32418005-6	2020	MTC (5-20 microM) suppressed LPS + IFNgamma-induced release of TNFalpha, IL-6 and IL-1beta, as well as NO/iNOS and PGE2/COX-2 levels in RAW264.7 cells.	mtc	0-3	interleukin 6	Mus musculus	73-77
32649980-8	2020	SAC supplementation also suppressed the rise in cytokines levels (TWEAK/IL6/myostatin) caused by H2O2.	Hydrogen Peroxide	97-101	interleukin 6	Mus musculus	72-75
32768191-5	2020	Different concentrations of Rk1 (10 and 20 mg/kg) and Flu significantly decreased the levels of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 in serum, while Rk1 (5, 10, and 20 mg/kg) and Flu reduced the concentrations of IL-6 in a dose-dependent manner.	Fluoxetine	54-57	interleukin 6	Mus musculus	233-237
32540565-10	2020	Furthermore, BPA up-regulated the expression of Toll-like receptor 4 (TLR4) and phosphorylation of nuclear factor-kappa B (NF-kappaB) in the liver and increased the production of inflammatory cytokines, including interleukin-1beta, interleukin-18, tumour necrosis factor-alpha, and interleukin-6.	bisphenol A	13-16	interleukin 6	Mus musculus	282-295
32083746-2	2020	EPSAH could significantly enhance macrophage phagocytosis and the secretion of nitric oxide, increase the mRNA expression levels of the pro-inflammatory cytokines (IL-1beta, IL-6, IL-12 and TNF-alpha), anti-inflammatory cytokine IL-10, and chemokines (MCP-1 and MIP-1alpha).	epsah	0-5	interleukin 6	Mus musculus	174-178
33008466-6	2020	In the hippocampus, beta-glucan countered the HFFD-induced microglia activation and its engulfment of synaptic puncta, and upregulation of proinflammatory cytokine (TNF-alpha, IL-1beta, and IL-6) mRNA expression.	beta-Glucans	20-31	interleukin 6	Mus musculus	190-194
32735935-7	2020	Socially isolated mice receiving AC therapy demonstrated increased depressive-like and exploratory behaviors with a concurrent increase in hippocampal IL-6.	Actinium	33-35	interleukin 6	Mus musculus	151-155
32735935-8	2020	Whereas, group housing attenuated AC-induced IL-6 and depressive-like behavior.	Actinium	34-36	interleukin 6	Mus musculus	45-49
32735935-10	2020	Intracerebroventricular administration of oxytocin to socially isolated mice recapitulated the protective effects of social enrichment; specifically, oxytocin ameliorated the AC-induced effects on IL-6 and depressive-like behavior.	Actinium	175-177	interleukin 6	Mus musculus	197-201
33026256-8	2020	RESULTS: IR 3T3-L1 adipocytes treated with PCB126 had significantly higher adipokine (adiponectin, IL-6, MCP-1, TNF-alpha) secretion and lower mitochondrial function, glucose uptake, and glycolysis.	3,4,5,3',4'-pentachlorobiphenyl	43-49	interleukin 6	Mus musculus	99-103
32845434-8	2020	PDX treatment lowered the levels of pro-inflammation cytokines IL-1beta, IL-6, TNF-alpha, and MCP-1, and the levels of anti-inflammatory cytokine IL-10 was increased in the BALF.	10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoic acid	0-3	interleukin 6	Mus musculus	73-77
32442574-9	2020	Without significant cytotoxicity on the RAW 264.7 cells, EPS stimulated the macrophage cells to produce pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and prostaglandins (PGs) and nitric oxide (NO) via induction of COX-2 and iNOS expression, respectively, suggesting that this biopolymer potentiates an early innate immune response and can therefore be used as a new immune modulator.	eps	57-60	interleukin 6	Mus musculus	175-188
32442574-9	2020	Without significant cytotoxicity on the RAW 264.7 cells, EPS stimulated the macrophage cells to produce pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and prostaglandins (PGs) and nitric oxide (NO) via induction of COX-2 and iNOS expression, respectively, suggesting that this biopolymer potentiates an early innate immune response and can therefore be used as a new immune modulator.	eps	57-60	interleukin 6	Mus musculus	190-194
32442574-9	2020	Without significant cytotoxicity on the RAW 264.7 cells, EPS stimulated the macrophage cells to produce pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and prostaglandins (PGs) and nitric oxide (NO) via induction of COX-2 and iNOS expression, respectively, suggesting that this biopolymer potentiates an early innate immune response and can therefore be used as a new immune modulator.	Prostaglandins	201-215	interleukin 6	Mus musculus	190-194
32442574-9	2020	Without significant cytotoxicity on the RAW 264.7 cells, EPS stimulated the macrophage cells to produce pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and prostaglandins (PGs) and nitric oxide (NO) via induction of COX-2 and iNOS expression, respectively, suggesting that this biopolymer potentiates an early innate immune response and can therefore be used as a new immune modulator.	Prostaglandins	217-220	interleukin 6	Mus musculus	190-194
32442574-9	2020	Without significant cytotoxicity on the RAW 264.7 cells, EPS stimulated the macrophage cells to produce pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and prostaglandins (PGs) and nitric oxide (NO) via induction of COX-2 and iNOS expression, respectively, suggesting that this biopolymer potentiates an early innate immune response and can therefore be used as a new immune modulator.	Nitric Oxide	226-238	interleukin 6	Mus musculus	190-194
32578916-8	2020	Vin administration ameliorated liver injury as indicated by decreased liver injury parameters; serum aminotransferases, ALK-P, GGT, and bilirubin, restored the anti-oxidant status by decrease MDA and NOx , and increased GSH and SOD, inhibited inflammation (IL-6, TNF-alpha, NFkappaB-p65, and iNOS) and apoptosis (Annexin-V, Bax, and Caspase-3) parameters.	vinpocetine	0-3	interleukin 6	Mus musculus	257-261
32043593-10	2020	DC proliferation was assessed by coculture with carboxyfluorescein succinimidyl ester-labeled BALB/C-derived splenocytes p. Interleukin-6 (IL-6), IL-10, and transforming growth factor-beta (TGF-beta) release were measured by enzyme-linked immunosorbent assay.	5-(6)-carboxyfluorescein diacetate succinimidyl ester	48-85	interleukin 6	Mus musculus	124-137
32429710-7	2020	The increased productions of inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin 1beta (IL-1beta), and IL-6 in MPP+-treated BV-2 cells were also suppressed by PLD.	mangion-purified polysaccharide (Candida albicans)	135-139	interleukin 6	Mus musculus	127-131
32758004-8	2020	In in vitro study, pretreatment with FPE in LPS-stimulated RAW264.7 cells significantly reduced the levels of proinflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta, and inducible nitric oxide synthases (iNOS).	FPE	37-40	interleukin 6	Mus musculus	155-159
32669383-0	2020	Interleukin 6 reduces allopregnanolone synthesis in the brain and contributes to age-related cognitive decline in mice.	Pregnanolone	22-38	interleukin 6	Mus musculus	0-13
32669383-7	2020	Interestingly, IL-6 infusion in young animals significantly reduced the production of allopregnanolone compared to controls.	Pregnanolone	86-102	interleukin 6	Mus musculus	15-19
32669383-9	2020	These findings were supported by in vitro experiments in primary murine astrocyte cultures, indicating that IL-6 decreases production of allopregnanolone and increases corticosterone levels.	Pregnanolone	137-153	interleukin 6	Mus musculus	108-112
32669383-9	2020	These findings were supported by in vitro experiments in primary murine astrocyte cultures, indicating that IL-6 decreases production of allopregnanolone and increases corticosterone levels.	Corticosterone	168-182	interleukin 6	Mus musculus	108-112
32669383-10	2020	Our results indicate that age-related increases in IL-6 levels reduce progesterone substrate availability, resulting in a decline in allopregnanolone levels and an increase in corticosterone.	Progesterone	70-82	interleukin 6	Mus musculus	51-55
32669383-10	2020	Our results indicate that age-related increases in IL-6 levels reduce progesterone substrate availability, resulting in a decline in allopregnanolone levels and an increase in corticosterone.	Pregnanolone	133-149	interleukin 6	Mus musculus	51-55
32669383-10	2020	Our results indicate that age-related increases in IL-6 levels reduce progesterone substrate availability, resulting in a decline in allopregnanolone levels and an increase in corticosterone.	Corticosterone	176-190	interleukin 6	Mus musculus	51-55
32813574-5	2020	After acute exposure to NiNPs and LPS, male mice had elevated cytokines (CXCL1 and IL-6) and more neutrophils in bronchoalveolar lavage fluid (BALF), along with greater STAT3 phosphorylation in lung tissue.	ninps	24-29	interleukin 6	Mus musculus	83-87
32609950-8	2020	MiR-34b-3p could inhibit UBL4A expression and decreased TNF-alpha, IL-1beta and IL-6 contents in LPS-induced RMCs, while overexpression of UBL4A counteract with the suppressive effects of miR-34b-3p on the protein expression.	-34b	3-7	interleukin 6	Mus musculus	80-84
32446872-11	2020	The supplementation of CY-ZnONPs were noticeably diminished the total protein and IL-6, IL-8, and TNF-alpha levels in the BALF of pneumonia mice.	cy-znonps	23-32	interleukin 6	Mus musculus	82-86
32609950-10	2020	Lastly, in vivo injection of miR-34b-3p agomir improved CLP-induced kidney tissues injury with declined ALT, BUN, TNF-alpha, IL-1beta, IL-6, and UBL4A.	mir-34b-3p	29-39	interleukin 6	Mus musculus	135-139
32911426-10	2020	Furthermore, increase in nitrosocysteine, intratumoral IL-6, keratinocyte chemoattractant and TNFalpha, DNA lesion and inhibition of the Akt/mTOR pathway were induced by DFMO in H226 xenograft.	Eflornithine	170-174	interleukin 6	Mus musculus	55-59
32661728-9	2020	The syntheses of IL-1beta and IL-6 were significantly increased in LPC-induced demyelination preparations without PAF but showed a redundancy in PAF-treated wild-type and knockout slices.	Lysophosphatidylcholines	67-70	interleukin 6	Mus musculus	30-34
32813574-9	2020	Males had a greater induction of IL-6 mRNA in liver after acute exposure to NiNPs and LPS, and greater CCL2 mRNA in liver after subchronic NiNP exposure.	ninps	76-81	interleukin 6	Mus musculus	33-37
32813574-9	2020	Males had a greater induction of IL-6 mRNA in liver after acute exposure to NiNPs and LPS, and greater CCL2 mRNA in liver after subchronic NiNP exposure.	ninp	76-80	interleukin 6	Mus musculus	33-37
32960513-6	2020	Our results showed that, after 12 hours of TG treatment, ATG significantly reduced inflammatory cell infiltration in mouse tissues and inhibited the secretion and expression of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) in mice.	arctigenin	57-60	interleukin 6	Mus musculus	177-190
32592701-7	2020	Mechanistic studies revealed that lycopene treatment (20 mg/kg, 12 days) could suppress the SPS-induced increase in levels of interleukin-6 (IL-6), IL-1beta, tumor necrosis factor-alpha (TNF-alpha), and nitrite in the hippocampus and prefrontal cortex in mice, as well as the increased markers that indicate high levels of oxido-nitrosative stress in the hippocampus and prefrontal cortex in SPS mice.	Lycopene	34-42	interleukin 6	Mus musculus	126-139
32945516-9	2020	ATX significantly suppressed the LPS-induced increased production of TNF-alpha and IL-6 and suppressed the protein expression levels of BNP, Bax and Bcl-2 to normal levels.	astaxanthine	0-3	interleukin 6	Mus musculus	83-87
33132722-12	2020	A vigorous elevation in levels of different immunoglobulin (IgG, IgE and IgA) and pro-inflammatory cytokines (IL-6 and -8), that was accompanied by a significant reduction in level of anti-inflammatory cytokine IL-10, was observed in male and female mice groups administrated with sucralose or stevia.	trichlorosucrose	281-290	interleukin 6	Mus musculus	110-121
32592701-7	2020	Mechanistic studies revealed that lycopene treatment (20 mg/kg, 12 days) could suppress the SPS-induced increase in levels of interleukin-6 (IL-6), IL-1beta, tumor necrosis factor-alpha (TNF-alpha), and nitrite in the hippocampus and prefrontal cortex in mice, as well as the increased markers that indicate high levels of oxido-nitrosative stress in the hippocampus and prefrontal cortex in SPS mice.	Lycopene	34-42	interleukin 6	Mus musculus	141-145
32960513-6	2020	Our results showed that, after 12 hours of TG treatment, ATG significantly reduced inflammatory cell infiltration in mouse tissues and inhibited the secretion and expression of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) in mice.	arctigenin	57-60	interleukin 6	Mus musculus	192-196
32993156-8	2020	Furthermore, 4H-7MTC reduced the production of proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6.	4h-7mtc	13-20	interleukin 6	Mus musculus	144-148
32592701-7	2020	Mechanistic studies revealed that lycopene treatment (20 mg/kg, 12 days) could suppress the SPS-induced increase in levels of interleukin-6 (IL-6), IL-1beta, tumor necrosis factor-alpha (TNF-alpha), and nitrite in the hippocampus and prefrontal cortex in mice, as well as the increased markers that indicate high levels of oxido-nitrosative stress in the hippocampus and prefrontal cortex in SPS mice.	Sodium phenolsulfonate	92-95	interleukin 6	Mus musculus	126-139
32592701-7	2020	Mechanistic studies revealed that lycopene treatment (20 mg/kg, 12 days) could suppress the SPS-induced increase in levels of interleukin-6 (IL-6), IL-1beta, tumor necrosis factor-alpha (TNF-alpha), and nitrite in the hippocampus and prefrontal cortex in mice, as well as the increased markers that indicate high levels of oxido-nitrosative stress in the hippocampus and prefrontal cortex in SPS mice.	Sodium phenolsulfonate	92-95	interleukin 6	Mus musculus	141-145
32807044-5	2020	BALB/c mice exposed to oil demonstrated more pronounced irritation compared with C57BL/6 mice, which was characterized by increased acanthosis as well as increased inflammatory cytokine/chemokine protein expression of IL-1beta, IL-6, CXCL10, CCL2, CCL3, CCL4, and CCL11.	Oils	23-26	interleukin 6	Mus musculus	228-232
32673690-13	2020	ELISA kit results showed that fingolimod could down-regulate IL-6 and TNF-alpha and up-regulate IL-10 and TGF-beta1 in serum.	Fingolimod Hydrochloride	30-40	interleukin 6	Mus musculus	61-65
33061293-14	2020	Furthermore, the mice administered with phoenixin 14 had increased hepatic SOD activity, increased production of GSH and reduced MDA activity, as well as reduced production of TNF-alpha and IL-6 suggesting that phoenixin 14 exerts beneficial effects against inflammation and ROS.	phoenixin 14	40-52	interleukin 6	Mus musculus	190-194
32998264-9	2020	Finally, an inverse agonist of ERRgamma, GSK5182, markedly inhibits IL-6 induced hepatic BMP6 expression in vitro and in vivo.	GSK5182	41-48	interleukin 6	Mus musculus	68-72
33072121-7	2020	Results: GENT alone inhibited bacterial growth, IL-1beta, and IL-6 production in blood and organs.	Gentamicins	9-13	interleukin 6	Mus musculus	62-66
32987947-6	2020	DJ-1-/- mice treated with ND-13 presented similar decreased expression of TNF-alpha, IL-6 and TGF-beta.	nd-13	26-31	interleukin 6	Mus musculus	85-89
32977419-7	2020	In rotenone-treated BV2 cells, PQQ dose-dependently decreased lactate dehydrogenase (LDH) release and suppressed the up-regulation of pro-inflammation factors, such as interleukin-1beta (IL-1beta), IL-6 and tumor necrosis factor-alpha (TNF-alpha) in the cultured media, as well as nitric oxide (NO) release induced by rotenone.	Rotenone	3-11	interleukin 6	Mus musculus	198-202
32977419-7	2020	In rotenone-treated BV2 cells, PQQ dose-dependently decreased lactate dehydrogenase (LDH) release and suppressed the up-regulation of pro-inflammation factors, such as interleukin-1beta (IL-1beta), IL-6 and tumor necrosis factor-alpha (TNF-alpha) in the cultured media, as well as nitric oxide (NO) release induced by rotenone.	PQQ Cofactor	31-34	interleukin 6	Mus musculus	198-202
33061293-14	2020	Furthermore, the mice administered with phoenixin 14 had increased hepatic SOD activity, increased production of GSH and reduced MDA activity, as well as reduced production of TNF-alpha and IL-6 suggesting that phoenixin 14 exerts beneficial effects against inflammation and ROS.	phoenixin 14	211-223	interleukin 6	Mus musculus	190-194
32942769-8	2020	Here, we show that succinate can suppress secretion of inflammatory mediators IL-6, tumor necrosis factor (TNF) and nitric oxide (NO), as well as inhibit Il1b mRNA expression of inflammatory macrophages in a SUCNR1-independent manner.	Succinic Acid	19-28	interleukin 6	Mus musculus	78-82
32971852-10	2020	DGLA administered at 100 microM in all forms attenuated the LPS-induced expression of the key inflammatory genes in a concerted manner, in particular iNOS, IL-6, and LxR, in the form of free acid.	8,11,14-Eicosatrienoic Acid	0-4	interleukin 6	Mus musculus	156-160
32945579-9	2021	Treatment with JTE013 reduced IL-1beta, IL-6, and TNF mRNA levels in murine gingival mucosal tissues, inhibited leukocyte infiltration in the periodontal tissues, and decreased the number of osteoclasts in the periodontal tissues compared with controls.	JTE 013	15-21	interleukin 6	Mus musculus	40-44
33042441-7	2020	APAP overdose significantly elevated the serum ALT level, hepatic myeloperoxidase (MPO) activity, cytokines (TNF-alpha, IL-1beta, and IL-6) production, malondialdehyde (MDA) activity, and ERK/JNK MAPK and NF-kappaB protein expressions.	Acetaminophen	0-4	interleukin 6	Mus musculus	134-138
32442587-9	2020	RESULTS: The dose of Physalin B that is not cytotoxic could dramatically reduce the levels of TNF-alpha, IL-6 and IL-1beta on LPS-stimulated RAW 264.7 cells.	physalin B	21-31	interleukin 6	Mus musculus	105-109
32828321-5	2020	RESULTS: In experimental PAD, TMAO treatment increased malondialdehyde (MDA), interleukin (IL)-1beta and IL-6 in the ischemic muscle, impaired perfusion recovery, and decreased capillary density.	trimethyloxamine	30-34	interleukin 6	Mus musculus	105-109
32360800-5	2020	Additionally, LZD significantly reduced colonic inflammation in UC mice by inhibiting the production of bone marrow peroxidase (MPO), superoxide dismutase (SOD), nitric oxide (NO) and cytokines (TNF-alpha, IFN-gamma, IL-1beta and IL-6).	Linezolid	14-17	interleukin 6	Mus musculus	230-234
32828321-6	2020	On the other hand, mice fed with DMB drinking water showed lower TMAO level, interleukin (IL)-1beta and IL-6, and higher vascular endothelial growth factor in the ischemic muscle, and better perfusion recovery after experimental PAD.	3,3-dimethylbutan-1-ol	33-36	interleukin 6	Mus musculus	104-108
32828321-6	2020	On the other hand, mice fed with DMB drinking water showed lower TMAO level, interleukin (IL)-1beta and IL-6, and higher vascular endothelial growth factor in the ischemic muscle, and better perfusion recovery after experimental PAD.	Water	46-51	interleukin 6	Mus musculus	104-108
32927852-7	2020	KM1608 significantly attenuated the disease activity of dextran sodium sulfate-induced colitis in mice and suppressed inflammatory mediators such as myeloperoxidase, proinflammatory cytokines (TNF-alpha and IL-6), and the Th2-type cytokine IL-4 in the colon.	km1608	0-6	interleukin 6	Mus musculus	207-211
32963694-12	2020	In addition, SF treatment obviously suppressed the releases of nitric oxide (NO), TNF-alpha, and IL-6 in the LPS-stimulated BV-2 cells.	sulphoraphene	13-15	interleukin 6	Mus musculus	97-101
32932805-5	2020	Quercetin significantly decreased the hepatic and plasmatic levels of inflammatory cytokines IL-1beta, IL-6, TNF-alpha, inducible nitric oxide synthase, cyclooxygenase-2 and intercellular adhesion molecule-1-provoked by over-exercise.	Quercetin	0-9	interleukin 6	Mus musculus	103-107
32894124-6	2020	PM014 treatment downregulated the pro-inflammatory cytokine expressions including IL-1b, IL-8, IL-6, TNF-alpha, IL-21 and IL-17.	pm014	0-5	interleukin 6	Mus musculus	95-99
32894124-7	2020	ELISA analysis also showed reduced production of IL-1b, IL-6 and IL-17 in PM014-treated mice.	pm014	74-79	interleukin 6	Mus musculus	56-60
32952341-10	2020	RESULTS: The resveratrol treatment group showed a 1.72-fold decrease in disease activity index scores and 1.42, 3.81, and 1.65-fold decrease in the production of the inflammatory cytokine tumor necrosis factor-alpha, interleukin-6 and interleukin-1beta, respectively, in DSS-induced colitis mice compared with DSS group (P < 0.05).	Resveratrol	13-24	interleukin 6	Mus musculus	217-230
32608990-11	2020	In addition, miR-874-3p was found to target and downregulate CXCL12, thus reducing TNF-alpha, IL-1, IL-6, and IL-8 levels, but enhancing IL-10 level.	mir-874-3p	13-23	interleukin 6	Mus musculus	100-104
32901588-7	2021	Morpholine analog 2c dose-dependently reduced various other inflammatory cytokines and mediators, including TNF, IL-6, IL-1beta, NOS2, and COX2.	morpholine	0-10	interleukin 6	Mus musculus	113-117
32880753-6	2020	Mice fed a high-salt diet exhibit increased inflammation with a marked increase in dendritic cell (DC) production of interleukin (IL)-6 and formation of isolevuglandins (IsoLG)-protein adducts, which drive interferon-gamma (IFN-gamma) and IL-17A production by T cells.	Salts	16-20	interleukin 6	Mus musculus	117-135
32592770-6	2020	Further mechanism researches suggested that ZLY16 inhibited liver inflammation and fibrosis by regulating gene expression including COLIA1, TIMP, TGFbeta, TNFalpha, and IL6.	zly16	44-49	interleukin 6	Mus musculus	169-172
32559620-9	2020	Protein levels of VEGF, ICAM-1, TNF-alpha, and IL-6 in the RPE-choroid-sclera complex were significantly downregulated by triptolide treatment on day 3, which was in accordance with the reduced number of infiltrated F4/80+ macrophages and the reduced ratio of M2/F4/80+ macrophages.	triptolide	122-132	interleukin 6	Mus musculus	47-51
31983054-7	2020	The content of IL-6 remarkably increased with increasing fluoride concentrations up to 2 mmol/L, and then markedly decreased at 3, 4, and 5 mmol/L fluoride; the decreasing trend of IL-6 content under high fluoride exposure is consistent with the decrease in Hepa1-6 cell viability observed at the same concentration.	Fluorides	57-65	interleukin 6	Mus musculus	15-19
31983054-7	2020	The content of IL-6 remarkably increased with increasing fluoride concentrations up to 2 mmol/L, and then markedly decreased at 3, 4, and 5 mmol/L fluoride; the decreasing trend of IL-6 content under high fluoride exposure is consistent with the decrease in Hepa1-6 cell viability observed at the same concentration.	Fluorides	147-155	interleukin 6	Mus musculus	15-19
31983054-7	2020	The content of IL-6 remarkably increased with increasing fluoride concentrations up to 2 mmol/L, and then markedly decreased at 3, 4, and 5 mmol/L fluoride; the decreasing trend of IL-6 content under high fluoride exposure is consistent with the decrease in Hepa1-6 cell viability observed at the same concentration.	Fluorides	147-155	interleukin 6	Mus musculus	15-19
32570121-7	2020	Furthermore, EGCG also significantly prevented the release of H2O2, NOS and 8-isoprostane, and reduced the levels of interleukin (IL)-1beta, IL-2,and IL-6 restrained mice.	epigallocatechin gallate	13-17	interleukin 6	Mus musculus	150-154
32540418-5	2020	Application of CP-99994, a selective antagonist of NK1R, inhibited the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), IL-6, inducible macrophage-type nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in activated BV2 cells.	3-(2-methoxybenzylamino)-2-phenylpiperidine	15-23	interleukin 6	Mus musculus	188-192
32953945-15	2020	The functional significance of GSNO treatment of macrophages is shown by reduced beta-glucan-mediated signaling in terms of NF-kappaB function and IL-6 expression.	S-Nitrosoglutathione	31-35	interleukin 6	Mus musculus	147-151
32953945-15	2020	The functional significance of GSNO treatment of macrophages is shown by reduced beta-glucan-mediated signaling in terms of NF-kappaB function and IL-6 expression.	beta-Glucans	81-92	interleukin 6	Mus musculus	147-151
32750218-8	2020	Abx + DSF/Cu2+ significantly reduced the pro-inflammatory cytokines Interleukin-1beta (IL-1beta), IL-6 and tumor necrosis factor alpha (TNF-alpha) in tumors, and significantly reduced the expression of phosphorylated-protein kinase B (p-AKT)/protein kinase B (AKT), toll-like receptors 4 (TLR-4), and phosphorylated- nuclear factor kappa-B (p-NFkappaB)/NFkappaB in tumors.	dsf	6-9	interleukin 6	Mus musculus	98-102
31576928-0	2020	Evaluation of cell damage and modulation of cytokines TNF-alpha, IL-6 and IL-10 in macrophages exposed to PpIX-mediated photodynamic therapy.	protoporphyrin IX	106-110	interleukin 6	Mus musculus	65-69
32750218-8	2020	Abx + DSF/Cu2+ significantly reduced the pro-inflammatory cytokines Interleukin-1beta (IL-1beta), IL-6 and tumor necrosis factor alpha (TNF-alpha) in tumors, and significantly reduced the expression of phosphorylated-protein kinase B (p-AKT)/protein kinase B (AKT), toll-like receptors 4 (TLR-4), and phosphorylated- nuclear factor kappa-B (p-NFkappaB)/NFkappaB in tumors.	CHEMBL369125	0-3	interleukin 6	Mus musculus	98-102
32557032-9	2020	Interleukin (IL)-6 in BALF significantly increased after exposure to Pb (p < 0.05) accompanied by lung inflammatory infiltration.	Lead	69-71	interleukin 6	Mus musculus	0-18
32369227-9	2020	Furthermore, inhibition of miR-103a-3p repressed LPS-caused inflammation through downregulating expression of tumor necrosis factor (TNF-alpha), interleukin 1 beta (IL-1beta), and interleukin 6 in vitro and in vivo.	103a	31-35	interleukin 6	Mus musculus	180-193
32765761-11	2020	SalB also decreased the levels of the inflammatory cytokines TNF-alpha and IL-6 in the serum and the liver of the CLP model mice.	salvianolic acid B	0-4	interleukin 6	Mus musculus	75-79
32686172-5	2020	Pro-inflammatory (TNF-alpha, IL-6) and pro-fibrotic (TGF-beta1) cytokines were significantly increased in plasma and kidneys of 0-copy and A71915-treated 2-copy mice, but to lesser extent in 4-copy mice.	A 71915	139-145	interleukin 6	Mus musculus	29-33
32557032-14	2020	IL-6 in the liver was significantly increased by PM2.5, Ni, V, and Pb after exposure (p < 0.05), accompanied by liver inflammatory infiltration.	Vanadium	60-61	interleukin 6	Mus musculus	0-4
32557032-14	2020	IL-6 in the liver was significantly increased by PM2.5, Ni, V, and Pb after exposure (p < 0.05), accompanied by liver inflammatory infiltration.	Lead	67-69	interleukin 6	Mus musculus	0-4
32590318-6	2020	In cell experiments, we found that the treatment of geraniol inhibited the expression of IL-1beta-induced PGE2, NO, COX-2, iNOS, TNF-alpha and IL-6 by western blot, qRT-PCR and immunofluorescence staining.	geraniol	52-60	interleukin 6	Mus musculus	143-147
32210361-3	2020	Cyclopenol and cyclopenin inhibited the LPS-induced formation of NO and secretion of IL-6 in RAW264.7 cells at nontoxic concentrations.	cyclopenol	0-10	interleukin 6	Mus musculus	85-89
32652505-6	2020	Our study demonstrated that Cirsitakaoside could promote type I IFN expression and inhibit pro-inflammatory cytokines such as IL-6 and TNF-alpha production in mouse peritoneal macrophages infected by VSV.	cirsimarin	28-42	interleukin 6	Mus musculus	126-130
32679538-8	2020	Moreover, pIL-35 pretreatment significantly decreased the levels of cardiac proinflammatory cytokines including TNF-alpha, IL-6, and IL-1beta, and the NLRP3 inflammasome.	pil-35	10-16	interleukin 6	Mus musculus	123-127
32963747-8	2020	In addition, DI markedly inhibited uterine myeloperoxidase (MPO) activity and pro-inflammatory cytokines of tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) induced by LPS.	dimethyl itaconate	13-15	interleukin 6	Mus musculus	152-165
32963747-8	2020	In addition, DI markedly inhibited uterine myeloperoxidase (MPO) activity and pro-inflammatory cytokines of tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) induced by LPS.	dimethyl itaconate	13-15	interleukin 6	Mus musculus	167-171
32210361-3	2020	Cyclopenol and cyclopenin inhibited the LPS-induced formation of NO and secretion of IL-6 in RAW264.7 cells at nontoxic concentrations.	cyclopenin	15-25	interleukin 6	Mus musculus	85-89
32859456-11	2020	DHA diminished expression of IL-10 and IL-6, and increased the expression of IFN-gamma in the tumor and spleen.	artenimol	0-3	interleukin 6	Mus musculus	39-43
33107270-10	2020	Such effects of BC were accompanied by a reduction in the levels of IL-6 and TBARS and an increase of GSH.	beta Carotene	16-18	interleukin 6	Mus musculus	68-72
33004756-11	2020	AG490, an IL-6 inhibitor, inhibited the occurrence of EMT.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	0-5	interleukin 6	Mus musculus	10-14
32618003-8	2020	Administration of SSH extract also ameliorated the expression of UVB-induced pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6) and phosphorylation of MAPK family members (MEK, JNK, ERK and p38) by upregulating the activity of antioxidant enzymes (SOD, CAT, Nrf-2, HO-1 and NQO-1).	ssh extract	18-29	interleukin 6	Mus musculus	129-133
32401077-7	2020	PTX + SPS-NEs increased the release of NO, IL-6 and TNF-alpha, and the expression of p-p65 NF-kappaB, p-I-kappaB, TLR4.	Paclitaxel	0-3	interleukin 6	Mus musculus	43-47
32504759-5	2020	When treated with PQQ, MDA, IL-1beta, IL-6, and TNF-alpha levels have decreased, and SOD, GSH-Px, and CAT activity have increased in the kidney tissues of CTX-induced mice.	PQQ Cofactor	18-21	interleukin 6	Mus musculus	38-42
32701014-6	2020	Our findings showed that pretreatment with Psb protected against L/D-induced ALF by lowering the lethality, improving liver histology, reducing ALT, AST, IL-6, IL-1beta, TNF-alpha, MDA, and MPO levels, and boosting liver GSH content and SOD activity.	pterostilbene	43-46	interleukin 6	Mus musculus	154-158
32705172-8	2020	In NEC mice, vitamin D reduced intestinal tissue damage, decreased the mRNA expression of IL-6, IL-1beta and TNF-alpha, and decreased the protein expression of cleaved caspase-3 and MDA.	Vitamin D	13-22	interleukin 6	Mus musculus	90-94
32770524-5	2020	Astragalin was found also to suppress the inflammatory signaling in the inflamed tissue as exhibited by the decreased myeloperoxidase activity along with the decreased protein and transcriptional level of pro-inflammatory cytokines including tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6.	astragalin	0-10	interleukin 6	Mus musculus	294-307
32556930-6	2020	In addition, NaB upregulated the expression of pro-inflammatory cytokines (IL-6, 3.52-fold, P < 0.05; IL-18, 1.72-fold, P < 0.001) and NLRP3 (3.11-fold, P < 0.001) in the colon of PD mice.	nab	13-16	interleukin 6	Mus musculus	75-79
32707536-1	2020	Recent studies suggest that microbiome derived 3(3,4-dihydroxy-phenyl) propionic acid (DHCA) attenuates IL-6 cytokine production through downregulation of the epigenetic modifier DNA Methyltransferase 1 (DNMT1) expression and inhibition of DNA methylation at the 5"-C-phosphate-G-3" (CpG)-rich IL6 sequence introns 1 and 3 in a mouse model of depression.	3,4-dihydroxyphenylpropionic acid	47-85	interleukin 6	Mus musculus	104-108
32707536-1	2020	Recent studies suggest that microbiome derived 3(3,4-dihydroxy-phenyl) propionic acid (DHCA) attenuates IL-6 cytokine production through downregulation of the epigenetic modifier DNA Methyltransferase 1 (DNMT1) expression and inhibition of DNA methylation at the 5"-C-phosphate-G-3" (CpG)-rich IL6 sequence introns 1 and 3 in a mouse model of depression.	3,4-dihydroxyphenylpropionic acid	47-85	interleukin 6	Mus musculus	294-297
32707536-1	2020	Recent studies suggest that microbiome derived 3(3,4-dihydroxy-phenyl) propionic acid (DHCA) attenuates IL-6 cytokine production through downregulation of the epigenetic modifier DNA Methyltransferase 1 (DNMT1) expression and inhibition of DNA methylation at the 5"-C-phosphate-G-3" (CpG)-rich IL6 sequence introns 1 and 3 in a mouse model of depression.	3,4-dihydroxyphenylpropionic acid	87-91	interleukin 6	Mus musculus	104-108
32707536-1	2020	Recent studies suggest that microbiome derived 3(3,4-dihydroxy-phenyl) propionic acid (DHCA) attenuates IL-6 cytokine production through downregulation of the epigenetic modifier DNA Methyltransferase 1 (DNMT1) expression and inhibition of DNA methylation at the 5"-C-phosphate-G-3" (CpG)-rich IL6 sequence introns 1 and 3 in a mouse model of depression.	3,4-dihydroxyphenylpropionic acid	87-91	interleukin 6	Mus musculus	294-297
32707536-1	2020	Recent studies suggest that microbiome derived 3(3,4-dihydroxy-phenyl) propionic acid (DHCA) attenuates IL-6 cytokine production through downregulation of the epigenetic modifier DNA Methyltransferase 1 (DNMT1) expression and inhibition of DNA methylation at the 5"-C-phosphate-G-3" (CpG)-rich IL6 sequence introns 1 and 3 in a mouse model of depression.	-c-phosphate	265-277	interleukin 6	Mus musculus	104-108
32705202-8	2020	Asiaticoside administration also downregulated the levels of interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha in the hippocampus, and reduced the phosphorylation of nuclear factor (NF)-kappaBp65 and the expression of nod-like receptor protein 3 (NLRP3), thus decreasing the expression of mature caspase-1.	asiaticoside	0-12	interleukin 6	Mus musculus	85-89
32598984-8	2020	On the other hand, pre-treatment with imidazoline I1 receptor antagonist, efaroxan and imidazoline I2 receptor antagonist, BU224 attenuated the effects of agmatine on learning and memory in MWM, IL-6, TNF-alpha and BDNF content.	Imidazolines	38-49	interleukin 6	Mus musculus	195-199
32345916-5	2020	In vitro and in mouse models, CBD significantly attenuated the production of pro-inflammatory cytokines IL-6 and TNF-alpha while elevating levels of anti-inflammatory IL-10.	Cannabidiol	30-33	interleukin 6	Mus musculus	104-108
32598984-8	2020	On the other hand, pre-treatment with imidazoline I1 receptor antagonist, efaroxan and imidazoline I2 receptor antagonist, BU224 attenuated the effects of agmatine on learning and memory in MWM, IL-6, TNF-alpha and BDNF content.	efaroxan	74-82	interleukin 6	Mus musculus	195-199
32859970-6	2020	Ch25h-/- mice with DSS-induced colitis exhibited aggravated injury, including higher clinical colitis scores, severe injury of the epithelial barrier, lower tight junction protein levels and higher levels of IL-6.	Dextran Sulfate	19-22	interleukin 6	Mus musculus	208-212
32598984-8	2020	On the other hand, pre-treatment with imidazoline I1 receptor antagonist, efaroxan and imidazoline I2 receptor antagonist, BU224 attenuated the effects of agmatine on learning and memory in MWM, IL-6, TNF-alpha and BDNF content.	Imidazolines	87-98	interleukin 6	Mus musculus	195-199
32598984-8	2020	On the other hand, pre-treatment with imidazoline I1 receptor antagonist, efaroxan and imidazoline I2 receptor antagonist, BU224 attenuated the effects of agmatine on learning and memory in MWM, IL-6, TNF-alpha and BDNF content.	BU 224	123-128	interleukin 6	Mus musculus	195-199
32634518-1	2020	Physalin A (PA), a withanolide, was isolated from Physalis angulata L. In this study, it is shown that PA can inhibit the production of inflammatory cytokines such as PGE2, NO, IL-1beta, IL-6, and TNF-alpha in LPS-induced RAW 264.7 cells.	physalin A	12-14	interleukin 6	Mus musculus	187-191
32984356-12	2020	Pretreatment of ATII cells with M3 and LP17 significantly decreased the expression of IL-6 by 30 and 47%, respectively, and CXCL2 by 27 and 34%, respectively, compared to vehicle treated ATII cells after stimulation with rmCIRP.	rmcirp	221-227	interleukin 6	Mus musculus	86-90
32856487-5	2021	According to the skin injury model, the application of BBEOs and MSEOs to mice skin can effectively inhibit skin photoaging by down-regulating the expression of inflammatory factors including TNF-alpha, IL-6 and IL-10.	bbeos	55-60	interleukin 6	Mus musculus	203-207
32856487-5	2021	According to the skin injury model, the application of BBEOs and MSEOs to mice skin can effectively inhibit skin photoaging by down-regulating the expression of inflammatory factors including TNF-alpha, IL-6 and IL-10.	mseos	65-70	interleukin 6	Mus musculus	203-207
32522682-8	2020	The results of this study indicate that STZ administration impaired cognitive functions, increased anxiety- and depression-related behaviors, and elevated Abeta-42, glutamate, MDA, TNF-alpha, and IL-6 levels in the hippocampus of mice.	Streptozocin	40-43	interleukin 6	Mus musculus	196-200
32933639-11	2020	Compared with the low-dose ginsenoside Rb1 group, the aspirin group and the high-dose ginsenoside Rb1 group had significant reductions in the levels of TNF-alpha, IL-6, and IL-1beta (P<0.05); the high-dose ginsenoside Rb1 group had significant increases in the expression levels of P-PI3K/PI3K and P-AKT/AKT (P<0.05).	Aspirin	54-61	interleukin 6	Mus musculus	163-167
32933639-11	2020	Compared with the low-dose ginsenoside Rb1 group, the aspirin group and the high-dose ginsenoside Rb1 group had significant reductions in the levels of TNF-alpha, IL-6, and IL-1beta (P<0.05); the high-dose ginsenoside Rb1 group had significant increases in the expression levels of P-PI3K/PI3K and P-AKT/AKT (P<0.05).	Ginsenosides	86-97	interleukin 6	Mus musculus	163-167
32485309-18	2020	The autophagic flux and TNF-alpha, IL-1beta, IL-6 and LC3BII in vitamin D group were significantly lower than those in vitamin D deficiency group.	Vitamin D	64-73	interleukin 6	Mus musculus	45-49
32908937-6	2020	GA also suppressed the mRNA levels of IL-6, TNF-alpha, IL-17, IL-23, and IL-1beta in the skin and increased the proportion of CD4+ Foxp3+ regulatory T cells (Tregs) in both lymph nodes and spleens.	18alpha-glycyrrhetinic acid	0-2	interleukin 6	Mus musculus	38-42
32859970-7	2020	Supplementation with exogenous 25-HC ameliorated disease symptoms and reduced the extent of damage in DSS-induced colitis, which was characterized by lower colon damage, higher tight junction protein expression, significantly decreased local and systemic production of pro-inflammatory cytokines IL-6.	Dextran Sulfate	102-105	interleukin 6	Mus musculus	296-300
32904640-9	2020	Additionally, Huaier extract treatment led to reduced pro-inflammatory cytokine levels (TNF-alpha, IL-6, IFN-gamma and IL-1beta) and a decrease of STAT3 phosphorylation in colon tissue.	extract	21-28	interleukin 6	Mus musculus	99-103
32805983-6	2020	Furthermore, in BMDM, MTX-LIP showed a stronger anti-inflammatory activity than free MTX reducing the expression of IL-1beta by 3-fold, IL-6 by 2-fold and also moderately of TNF-alpha.	Methotrexate	22-25	interleukin 6	Mus musculus	136-140
32842681-4	2020	We demonstrated that OXY strongly decreased the release of IL-6 and MCP-1 from HMC3 cells stimulated with IL-1beta.	puag-haad	21-24	interleukin 6	Mus musculus	59-63
32908633-8	2020	In addition, EGCG treatment significantly decreased the levels of ROS, MDA, 8-OHdG, IL-1beta, IL-6, and TNF-alpha and increased the levels of CAT and SOD.	epigallocatechin gallate	13-17	interleukin 6	Mus musculus	94-98
32592825-10	2020	Also, the decreased cytokine levels by the AEDs showed their association with NF-kappaB, IL-1beta, IL-6, TNF-alpha and TGF-beta pathways in PILO model.	Pilocarpine hydrochloride	140-144	interleukin 6	Mus musculus	99-103
32908628-8	2020	RSV also inhibited expression of interleukin- (IL-) 1beta, IL-6, tumor necrosis factor-alpha, and IL-18 in vivo.	Resveratrol	0-3	interleukin 6	Mus musculus	59-63
32634532-0	2020	Alcohol and IL-6 Alter Expression of Synaptic Proteins in Cerebellum of Transgenic Mice with Increased Astrocyte Expression of IL-6.	Alcohols	0-7	interleukin 6	Mus musculus	127-131
32634532-1	2020	Recent studies indicate that neuroimmune factors, including the cytokine interleukin-6 (IL-6), play a role in the CNS actions of alcohol.	Alcohols	129-136	interleukin 6	Mus musculus	73-86
32634532-1	2020	Recent studies indicate that neuroimmune factors, including the cytokine interleukin-6 (IL-6), play a role in the CNS actions of alcohol.	Alcohols	129-136	interleukin 6	Mus musculus	88-92
32634532-5	2020	This is an important issue because alcohol induces glial production of IL-6, which could then covertly influence the actions of alcohol.	Alcohols	35-42	interleukin 6	Mus musculus	71-75
32634532-5	2020	This is an important issue because alcohol induces glial production of IL-6, which could then covertly influence the actions of alcohol.	Alcohols	128-135	interleukin 6	Mus musculus	71-75
32634532-11	2020	These common targets could provide sites for IL-6/alcohol exposure/withdrawal interactions and play an important role in cerebellar symptoms of alcohol use such as ataxia.	Alcohols	50-57	interleukin 6	Mus musculus	45-49
32973791-0	2020	Heme Induces IL-6 and Cardiac Hypertrophy Genes Transcripts in Sickle Cell Mice.	Heme	0-4	interleukin 6	Mus musculus	13-17
32973791-4	2020	We find that experimental administration of heme 50 mumoles/kg body weight induces IL-6 expression directly in vivo and induces gene expression markers of cardiac hypertrophy in SS mice.	Heme	44-48	interleukin 6	Mus musculus	83-87
32973791-5	2020	We administered heme intravenously and found that within three hours plasma IL-6 protein significantly increased in SS mice compared to AA mice (3248 +- 275 vs. 2384 +- 255 pg/ml, p <= 0.05).	Heme	16-20	interleukin 6	Mus musculus	76-80
32973791-6	2020	In the heart, heme induced a 15-fold increase in IL-6 transcript in SS mice heart compared to controls.	Heme	14-18	interleukin 6	Mus musculus	49-53
32973791-8	2020	Our experiments in Nrf2-deficient mice indicate that the cardiac IL-6 response to heme does not require Nrf2, the usual mediator of transcriptional response to heme for heme detoxification by heme oxygenase-1.	Heme	82-86	interleukin 6	Mus musculus	65-69
32634532-11	2020	These common targets could provide sites for IL-6/alcohol exposure/withdrawal interactions and play an important role in cerebellar symptoms of alcohol use such as ataxia.	Alcohols	144-151	interleukin 6	Mus musculus	45-49
33489857-5	2021	The results demonstrated that the repeated pretreatment of CORT50 strongly enhanced production of IL-6, IL-10, TNF-alpha, and nitric oxide (NO) by RAW 264.7 cells in EP (SL-LPS-primed cells: endotoxin priming) in the absence of LPS compared to those in control (vehicle-pretreated cells), whereas CORT100 reduced production of TNF-alpha and IL-10.	cort50	59-65	interleukin 6	Mus musculus	98-102
32825154-8	2020	AEN also inhibited FFAs-mediated inflammation-related cytokines interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFalpha) expression in cells.	1,5-AEDANS	0-3	interleukin 6	Mus musculus	64-77
32825154-8	2020	AEN also inhibited FFAs-mediated inflammation-related cytokines interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFalpha) expression in cells.	1,5-AEDANS	0-3	interleukin 6	Mus musculus	79-83
32565338-9	2020	Likewise, pharmacologically inhibiting Fyn with 10 mg/kg dasatinib (oral) significantly attenuated LPS-induced increases in plasma TNF-alpha and IL-6 protein levels and hepatic pro-IL-1beta messenger ribonucleic acids (mRNAs).	Dasatinib	57-66	interleukin 6	Mus musculus	145-149
33489857-6	2021	Further, the repeated pretreatment of CORT50 markedly enhanced LPS-induced production of IL-6, IL-10, TNF-alpha, PGE2, and NO by RAW 264.7 cells in EP compared to those in control, whereas CORT100 attenuated LPS-induced production of IL-6, IL-10, and NO.	cort50	38-44	interleukin 6	Mus musculus	89-93
33489857-6	2021	Further, the repeated pretreatment of CORT50 markedly enhanced LPS-induced production of IL-6, IL-10, TNF-alpha, PGE2, and NO by RAW 264.7 cells in EP compared to those in control, whereas CORT100 attenuated LPS-induced production of IL-6, IL-10, and NO.	cort50	38-44	interleukin 6	Mus musculus	234-238
32784977-7	2020	In addition, results of the anti-inflammatory assays showed that the ethyl acetate fraction showed appreciable reductions in the levels of nitric oxide and inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6) in Raw 264.7 cells.	ethyl acetate	69-82	interleukin 6	Mus musculus	205-209
32215551-8	2020	Mice fed the 15%Amylose/Soy/FO diet also had significantly reduced plasma levels of IL-1beta, IL-6, and TNFalpha.	Amylose	16-23	interleukin 6	Mus musculus	94-98
32360799-10	2020	RESULTS: Oroxyloside administration significantly decreased the accumulations of CYP2E1, CYP1A2, IL-6, IL-1beta, ALT and AST induced by APAP in vivo.	oroxylin A-7-O-glucuronide	9-20	interleukin 6	Mus musculus	97-101
32360799-10	2020	RESULTS: Oroxyloside administration significantly decreased the accumulations of CYP2E1, CYP1A2, IL-6, IL-1beta, ALT and AST induced by APAP in vivo.	Acetaminophen	136-140	interleukin 6	Mus musculus	97-101
32806493-4	2020	The results showed that NACOS had similar immune enhancement effects on RAW264.7 cells as COS, including the generation of reactive oxygen species (ROS), phagocytotic activity, and the production of pro-inflammation cytokines (IL-1beta, IL-6, and TNF-alpha).	N-acetylchitooligosaccharide	24-29	interleukin 6	Mus musculus	237-241
32387232-12	2020	The diameter of CFA-induced ipsilateral knee edema was significantly reduced (p < 0.001) by EEMA, which was related to reduced levels of IL-6 and TNF-alpha in the joint knee (p < 0.01).	eema	92-96	interleukin 6	Mus musculus	137-141
32784362-5	2020	SsnB administration restored a normal tight junction protein profile with an increase in Occludin and a parallel decrease in Claudin 2 and inflammatory mediators high mobility group box 1 (HMGB1), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) in the distal intestine.	sparstolonin B	0-4	interleukin 6	Mus musculus	231-244
32784362-5	2020	SsnB administration restored a normal tight junction protein profile with an increase in Occludin and a parallel decrease in Claudin 2 and inflammatory mediators high mobility group box 1 (HMGB1), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) in the distal intestine.	sparstolonin B	0-4	interleukin 6	Mus musculus	246-250
32781605-3	2020	The results demonstrated that simonsinol could antagonize the effect of LPS on morphological changes of RAW264.7 cells, and decrease the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha), and interleukin 6 (IL-6) in LPS-stimulated RAW264.7 cells, as determined by Griess assay and enzyme-linked immunosorbent assay (ELISA).	Simonsinol	30-40	interleukin 6	Mus musculus	215-228
32584792-8	2020	Enhanced PZR tyrosyl phosphorylation in the hearts of NSML mice was found to drive myocardial fibrosis by engaging a Src/NFkB pathway resulting in increased activation of interleukin-6 (IL6).	cyclo(tyrosyl-tyrosyl)	13-20	interleukin 6	Mus musculus	171-184
32584792-8	2020	Enhanced PZR tyrosyl phosphorylation in the hearts of NSML mice was found to drive myocardial fibrosis by engaging a Src/NFkB pathway resulting in increased activation of interleukin-6 (IL6).	cyclo(tyrosyl-tyrosyl)	13-20	interleukin 6	Mus musculus	186-189
32781605-3	2020	The results demonstrated that simonsinol could antagonize the effect of LPS on morphological changes of RAW264.7 cells, and decrease the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha), and interleukin 6 (IL-6) in LPS-stimulated RAW264.7 cells, as determined by Griess assay and enzyme-linked immunosorbent assay (ELISA).	Simonsinol	30-40	interleukin 6	Mus musculus	230-234
32781605-4	2020	Furthermore, simonsinol could downregulate transcription of inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-6 as measured by reverse transcription polymerase chain reaction (RT-PCR), and inhibit phosphorylation of the alpha inhibitor of NF-kappaB (IkappaBalpha) as assayed by Western blot.	Simonsinol	13-23	interleukin 6	Mus musculus	115-119
32748838-10	2020	Based on PCR array, we identified decreased levels of EGFR, EGR3, and IL6, and increased levels of IGFBP7 and NKX3.1, overall supporting anti-PCa effects of quercetin-resveratrol.	Quercetin	157-166	interleukin 6	Mus musculus	70-73
32741960-5	2020	RESULTS Treatment of rheumatoid arthritis with RT-Pt(II) significantly reduced the levels of IL-1ss, IL-6, IL-8, MMP-1, and MMP-13 in synovial fluid of mice in a dose-dependent manner.	rt-pt(ii)	47-56	interleukin 6	Mus musculus	101-105
32615888-4	2020	Further assays showed that Curcumin partly attenuated the LPS-induced injury as the viability was enhanced, TNF-alpha and IL-6 expressions and cell apoptosis rates were reduced.	Curcumin	27-35	interleukin 6	Mus musculus	122-126
32905416-13	2020	Finally, mouse xenograft data indicated that ovatodiolide suppressed tumor growth via down-regulating IL-6, STAT3, beta-catenin expression, and serum exosomal miR-1246.	ovatodiolide	45-57	interleukin 6	Mus musculus	102-106
32281710-5	2020	Furthermore, increased inflammation and apoptosis were observed in the tissues of DSS-induced colitis mice, with increased expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), phosphorylation of nuclear factor kappa B (NF-kappaB)-p65 (p-NF-kB-p65) and cleaved caspase-3, and decreased expression of tight junction (TJ) proteins such as zonula occluden-1 (ZO-1) and occludin.	dss	82-85	interleukin 6	Mus musculus	178-191
32281710-5	2020	Furthermore, increased inflammation and apoptosis were observed in the tissues of DSS-induced colitis mice, with increased expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), phosphorylation of nuclear factor kappa B (NF-kappaB)-p65 (p-NF-kB-p65) and cleaved caspase-3, and decreased expression of tight junction (TJ) proteins such as zonula occluden-1 (ZO-1) and occludin.	dss	82-85	interleukin 6	Mus musculus	193-197
32305864-6	2020	Under in vivo conditions, the concentrations of IL-1beta, IL-6 and TNF-alpha in PD model group achieved by injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intraperitoneally, were significantly higher than those in the control mouse group.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	120-164	interleukin 6	Mus musculus	58-62
32447214-12	2020	Results showed DHTS significantly reduced DAI, intestinal mucosal damage and inflammatory response in CIM mice by decreasing serum IL-6 and TNFalpha.	dhts	15-19	interleukin 6	Mus musculus	131-135
32619849-4	2020	Both Raftilose P95 and alpha3-Sialyllactose oligosaccharides upregulated PGlyRP3 and showed an anti-colitis effect as evidenced by increased survival and reductions in body weight loss, bleeding in stool, diarrhea, and the expression of the cytokine genes IL6, IL1b and TNFalpha.	Oligosaccharides	44-60	interleukin 6	Mus musculus	256-259
32615888-6	2020	Mice SAKI model further indicated that the serum Cystatin C (Cys-C), creatinine (Cr) and blood urea nitrogen (BUN) were increased within 24 h of model construction while those indicators were decreased at 48 h. Pretreated with Curcumin, NF-kappaB inhibitor (PDTC) or JAK2 inhibitor (AG-490) could weaken the renal histological injury and the increased serum Cys-C, Cr and BUN, IL-6 and TNF-alpha induced by CLP.	Curcumin	227-235	interleukin 6	Mus musculus	377-381
32538204-6	2020	Beta cell proliferation was assessed by CCK-8 assay.Results: Our data indicated that administration of calycosin significantly improved the GDM symptoms in pregnant db/+ mice as demonstrated by reduced blood glucose, TNF-a, and IL-6 levels as well as increased insulin level, and body weight.	7,3'-dihydroxy-4'-methoxyisoflavone	103-112	interleukin 6	Mus musculus	228-232
32790968-11	2020	Berberine activated IL6/STAT3 signaling in in vitro culture of G-MSDCs-like population, while inhibition of STAT3 activity attenuated the activation of this population by berberine.	Berberine	0-9	interleukin 6	Mus musculus	20-23
32170997-7	2020	These results suggest that miR-122 agomir can prevent the accumulation of hepatic iron induced by MC-LR, which may be related to the regulation of hepcidin by BMP/SMAD and IL-6/STAT signaling pathways.	Iron	82-86	interleukin 6	Mus musculus	172-176
32170997-7	2020	These results suggest that miR-122 agomir can prevent the accumulation of hepatic iron induced by MC-LR, which may be related to the regulation of hepcidin by BMP/SMAD and IL-6/STAT signaling pathways.	mc-lr	98-103	interleukin 6	Mus musculus	172-176
32454039-4	2020	Among the inflammatory mediators, 2DG caused a significant reduction in levels of cytokines (TNF-alpha, IL-1beta, IL-6) and chemokines (CXCL1 and CXCL2).	Deoxyglucose	34-37	interleukin 6	Mus musculus	114-118
32485352-9	2020	We report that 7,8,3-THF can significantly ameliorate interleukin (IL)-6 and NO production in LTA-stimulated BV2 cells.	lipoteichoic acid	94-97	interleukin 6	Mus musculus	54-72
32451556-9	2020	CONCLUSIONS: All in all, these experimental outcomes indicated that TMEM88 had an indispensable impact on EtOH-induced secretion of inflammatory cytokines (IL-6 and IL-1beta) in RAW264.7 cells through YAP signaling pathway.	Ethanol	106-110	interleukin 6	Mus musculus	156-160
32504994-4	2020	Oral administration of THCA significantly inhibited the activity of elastase, the release of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant protein-1 (MCP-1), myeloperoxidase (MPO) and the numbers of neutrophils and macrophages in the bronchoalveolar lavage fluid (BALF) of experimental COPD mice.	thca	23-27	interleukin 6	Mus musculus	93-106
32485353-5	2020	In vitro, BYA treatment inhibited IL-1beta-mediated inducible nitric oxide synthase, cyclooxygenase-2, tumor necrosis factor-alpha, and IL-6 expression.	9-(2,3-dihydroxy-3-methylbutoxy)-4-methoxy-7H-furo(3,2-g)(1)benzopyran-7-one	10-13	interleukin 6	Mus musculus	136-140
32504994-4	2020	Oral administration of THCA significantly inhibited the activity of elastase, the release of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant protein-1 (MCP-1), myeloperoxidase (MPO) and the numbers of neutrophils and macrophages in the bronchoalveolar lavage fluid (BALF) of experimental COPD mice.	thca	23-27	interleukin 6	Mus musculus	108-112
32164488-6	2020	The levels of IL-6, IL-8, and MDA in BLAF and pulmonary MPO content in the COPD mice were effectively increased, while the levels of SOD and CAT in BLAF were decreased, which could be reversed by budesonide and hesperidin.	Budesonide	196-206	interleukin 6	Mus musculus	14-18
32535536-7	2020	Our data showed that Hig significantly inhibited the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), reactive oxygen species (ROS) as well as NO (mediated by iNOS) and PGE2 (mediated by COX2) in LPS-activated BV2 cells.	higenamine	21-24	interleukin 6	Mus musculus	108-121
32535536-7	2020	Our data showed that Hig significantly inhibited the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), reactive oxygen species (ROS) as well as NO (mediated by iNOS) and PGE2 (mediated by COX2) in LPS-activated BV2 cells.	higenamine	21-24	interleukin 6	Mus musculus	123-127
32439989-3	2020	Here we report that D-Tyr1-tBuSA, a more potent SA derivative, inhibited production of the proinflammatory cytokines Interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) in LPS-stimulated RAW264.7 cells (EC50 = 1.4 and 5.9 muM, respectively).	stylissatin A	30-32	interleukin 6	Mus musculus	117-130
32439989-3	2020	Here we report that D-Tyr1-tBuSA, a more potent SA derivative, inhibited production of the proinflammatory cytokines Interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) in LPS-stimulated RAW264.7 cells (EC50 = 1.4 and 5.9 muM, respectively).	stylissatin A	30-32	interleukin 6	Mus musculus	132-136
32125592-7	2020	NaBu treatment was also able to decrease mast cell recruitment/activation and the levels of CXCL1, CCL2, IL-6, TNF-alpha, and TGF-beta1 in the implants but did not alter the levels of IL-10.	sethoxydim	0-4	interleukin 6	Mus musculus	105-109
32164488-6	2020	The levels of IL-6, IL-8, and MDA in BLAF and pulmonary MPO content in the COPD mice were effectively increased, while the levels of SOD and CAT in BLAF were decreased, which could be reversed by budesonide and hesperidin.	Hesperidin	211-221	interleukin 6	Mus musculus	14-18
32557685-10	2020	Administration of fruit extract of Pithecellobium dulce ameliorates carrageenan-induced acute inflammatory responses, as evidenced by paw edema measurement, expression of antioxidant enzymes such as glutathionine, super oxide dismutase, pro-inflammatory cytokine analysis (IL-1beta, IL-6, and TNF-alpha), vascular permeability measurement, expression of COX-2 and iNOS.	Carrageenan	68-79	interleukin 6	Mus musculus	283-287
32407848-9	2020	In addition, it was found that the diameter of seminiferous tubules, ROS production, as well as the expression of IL1-alpha, IL6, and TNF-alpha genes significantly decreased in the treatment groups by PBM compared to the scrotal hyperthermia induced mice, but there was not a significant difference in terms of testis weight and Sertoli cells between the studied groups.	pbm	201-204	interleukin 6	Mus musculus	125-128
32329325-7	2020	Results The expressions of IL-6, TNF-alpha, and IL-10, and HCIS in DSS-induced colitis mice were increased compared with control.	dss	67-70	interleukin 6	Mus musculus	27-31
32438122-6	2020	Resveratrol intervention alleviated NASH progression; decreased the levels of alanine aminotransferase and aspartate aminotransferase; and down-regulated tumor necrosis factor-alpha, interleukin (IL)-6, IL-1beta and transforming growth factor-beta mRNA and protein levels.	Resveratrol	0-11	interleukin 6	Mus musculus	183-201
32535761-6	2020	MPP-induced increases in apoptosis, death, OS, lipid peroxidation, PARP1, caspase-3 and caspase-9, inflammatory cytokines (IL-1beta, TNF-alpha, IL-6), and intracellular free Zn2+ and Ca2+ levels in the microglia of TRPM2-WT mice were further increased by the BSO treatment, although they were diminished by the GSH treatment.	mangion-purified polysaccharide (Candida albicans)	0-3	interleukin 6	Mus musculus	144-148
32893592-7	2020	For in vitro experiments, both Lonicerae Japonicae Flos extract and Lonicerae Flos extract inhibited NO secretion in RAW264.7 cells, down-regulated the release of IL-1beta, IL-6 and TNF-alpha, and down-regulated iNOS protein and COX2, NF-kappaB p65 protein content.	lonicerae flos extract	68-90	interleukin 6	Mus musculus	173-177
32794353-7	2020	In fact, this co-treatment potentiates the effects of tBHQ on the antioxidant enzyme, HMOX1, and the antibacterial enzyme, IRG1, respectively; moreover, the combined treatment reduces tBHQ activity on the glycolytic enzymes, TALDO1 and TKT, and decreases LPS effects on the metabolic enzyme IDH1, the proliferation-related proteins KI67 and PPAT, and the inflammatory cytokines IL-1beta, IL-6, and TNFalpha.	2-tert-butylhydroquinone	54-58	interleukin 6	Mus musculus	388-392
32794353-7	2020	In fact, this co-treatment potentiates the effects of tBHQ on the antioxidant enzyme, HMOX1, and the antibacterial enzyme, IRG1, respectively; moreover, the combined treatment reduces tBHQ activity on the glycolytic enzymes, TALDO1 and TKT, and decreases LPS effects on the metabolic enzyme IDH1, the proliferation-related proteins KI67 and PPAT, and the inflammatory cytokines IL-1beta, IL-6, and TNFalpha.	2-tert-butylhydroquinone	184-188	interleukin 6	Mus musculus	388-392
32732975-5	2020	Interestingly, we found that canonical signaling pathways that regulate iron, including the Bmp/Smad and IL-6/Jak2/Stat3 pathways, play indispensable roles in mediating AUR"s effects.	Iron	72-76	interleukin 6	Mus musculus	105-109
32643759-8	2020	In vitro, we found that norepinephrine inhibited the production of TNF-alpha, IL-6, and CXCL2/MIP-2 and promoted the secretion of IL-10 from lipopolysaccharide-stimulated murine alveolar macrophages.	Norepinephrine	24-38	interleukin 6	Mus musculus	78-82
32686359-9	2020	Notably, dietary polydatin (PD) supplement has protective effect in mice against PM2.5-induced ovarian dysfunction.These striking findings demonstrate that PM2.5 and/or air pollution is a critical factor for ovarian dysfunction through mitochondria-dependent and NF-kappaB/IL-6-mediated pathway, and PD may serve as a pharmaceutic candidate for air pollution-associated ovarian dysfunction.	polydatin	17-26	interleukin 6	Mus musculus	273-277
32764879-7	2020	Moreover, low-dose 2Abz23S29 significantly decreased the level of the interleukin-6 (IL-6), whereas high-dose 2Abz23S29 increased pro-inflammatory cytokines including IL-6, macrophage inflammatory protein/2 (MIP/2), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1beta (IL-1beta) in infected bladders of mice.	2abz23s29	19-28	interleukin 6	Mus musculus	70-83
32512223-12	2020	In vitro, resveratrol and its derivatives had comparable ability to inhibit IMQ-induced IL-1beta, IL-6, and CXCL8 secretion in activated keratinocytes.	Resveratrol	10-21	interleukin 6	Mus musculus	98-102
32512223-12	2020	In vitro, resveratrol and its derivatives had comparable ability to inhibit IMQ-induced IL-1beta, IL-6, and CXCL8 secretion in activated keratinocytes.	Imiquimod	76-79	interleukin 6	Mus musculus	98-102
32702668-7	2020	In vitro, our study showed that Deh significantly inhibited the expression of IL6, IL-1beta and TNF-alpha in the EpH4-Ev cell line.	dehydroandrographolide	32-35	interleukin 6	Mus musculus	78-81
32792941-8	2020	CoQ10 also decreased the levels of related inflammatory factors (ICAM-1, VCAM-1, IL-6, TNF-alpha and NLRP3).	coenzyme Q10	0-5	interleukin 6	Mus musculus	81-85
32792954-3	2020	Our present research identified that kaempferol had the capability to protect the vascular endothelium in a mouse model of vascular injury and explored the specific mechanisms underlying these effects by investigating oxidative stress, the extent of cardiovascular injury, and inflammatory markers such as NF-kappaB, TNF-alpha, IL-6, and the Nrf2/HO-1 signaling pathway.	kaempferol	37-47	interleukin 6	Mus musculus	328-332
32850823-7	2020	Furthermore, bergenin decreased the serum levels of IL-6, IL-1beta, and TNF-alpha in hyperuricemia mice, and promoted a polarization shift from the M1 to M2 phenotype in RAW264.7 cells.	bergenin	13-21	interleukin 6	Mus musculus	52-56
32493731-6	2020	Mechanistically, we found that myeloid-derived miR-223-3p suppresses the target gene interleukin-6 (Il6), associated with the maintenance of the proinflammatory macrophage phenotype during injury.	mir-223-3p	47-57	interleukin 6	Mus musculus	85-98
32493731-6	2020	Mechanistically, we found that myeloid-derived miR-223-3p suppresses the target gene interleukin-6 (Il6), associated with the maintenance of the proinflammatory macrophage phenotype during injury.	mir-223-3p	47-57	interleukin 6	Mus musculus	100-103
32291445-6	2020	F4/80+CD11b+CD16/32+ M1 macrophage and signature genes, IL-1beta, IL-6, TNF-alpha, CXCL9 and CXCL10 were increased in TMAO-induced GVHD tissues and in TMAO-cultured bone marrow derived macrophages (BMDMs).	trimethyloxamine	118-122	interleukin 6	Mus musculus	66-70
32764879-7	2020	Moreover, low-dose 2Abz23S29 significantly decreased the level of the interleukin-6 (IL-6), whereas high-dose 2Abz23S29 increased pro-inflammatory cytokines including IL-6, macrophage inflammatory protein/2 (MIP/2), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1beta (IL-1beta) in infected bladders of mice.	2abz23s29	19-28	interleukin 6	Mus musculus	85-89
32275999-11	2020	IL-6, L-1beta and TNF-alpha level was remarkably depressed by the knockdown of circ_0000285 and miR-654-3p inhibitors induced that.	mir-654	96-103	interleukin 6	Mus musculus	0-4
32698512-5	2020	Additionally, KMU-470 suppressed LPS-induced up-regulation at the transcriptional level of various pro-inflammatory cytokines such as IL-1beta, TNF-alpha, and IL-6.	kmu-470	14-21	interleukin 6	Mus musculus	159-163
32724493-12	2020	Results: MUC5B was significantly upregulated accompanying the increases in TNF-alpha and IL-6 secretion following PQ treatment in mouse and also in A549 cells after treatment with 50 muM PQ at 24 hours.	Paraquat	114-116	interleukin 6	Mus musculus	89-93
32724493-12	2020	Results: MUC5B was significantly upregulated accompanying the increases in TNF-alpha and IL-6 secretion following PQ treatment in mouse and also in A549 cells after treatment with 50 muM PQ at 24 hours.	Paraquat	187-189	interleukin 6	Mus musculus	89-93
32724493-14	2020	Importantly, siMUC5B could significantly attenuate the secretion of TNF-alpha and IL-6 induced by PQ.	simuc5b	13-20	interleukin 6	Mus musculus	82-86
32724493-14	2020	Importantly, siMUC5B could significantly attenuate the secretion of TNF-alpha and IL-6 induced by PQ.	Paraquat	98-100	interleukin 6	Mus musculus	82-86
32724493-15	2020	As expected, the addition of NAC efficiently suppresses the TNF-alpha and IL-6 secretion stimulated from PQ and also downregulated ERK, JNK, and p65 phosphorylation (ERK/JNK MAPK and NF-kappaB pathways) as well as MUC5B expression.	Acetylcysteine	29-32	interleukin 6	Mus musculus	74-78
32315737-18	2020	Assay of the inflammatory factors showed that sera levels of TNF-alpha, IL-1beta and IL-6 were markedly decreased by TFAI treatment compared to the MI group.	trifluoroacetyllysylalanine-trifluoromethylphenylanilide	117-121	interleukin 6	Mus musculus	85-89
32376269-10	2020	Moreover, MPTP administration increases in the cell number of microglia and astrocytes and the expression of inflammatory factors TNF-alpha, IL-1beta, and IL-6.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	10-14	interleukin 6	Mus musculus	155-159
32698404-7	2020	In addition, Alcaligenes lipid A promoted antigen-specific T helper 17 (Th17) responses in the spleen; upregulated the expression of MHC class II, CD40, CD80, and CD86 on bone marrow-derived dendritic cells (BMDCs); enhanced the production of Th17-inducing cytokines IL-6 and IL-23 from BMDCs.	Lipid A	25-32	interleukin 6	Mus musculus	267-271
32679895-3	2020	We demonstrated that EARDP protected against LPS-induced cell death by inhibiting intracellular reactive oxygen species (ROS) and malondialdehyde (MDA) production, as well as the synthesis of pro-inflammatory mediators and cytokines, such as nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-1beta.	eardp	21-26	interleukin 6	Mus musculus	317-321
32679895-9	2020	In the in vivo animal model, EARDP significantly and dose-dependently reduced TPA-induced secretion of TNF-alpha and IL-6 in mouse ear.	eardp	29-34	interleukin 6	Mus musculus	117-121
32679895-9	2020	In the in vivo animal model, EARDP significantly and dose-dependently reduced TPA-induced secretion of TNF-alpha and IL-6 in mouse ear.	Tetradecanoylphorbol Acetate	78-81	interleukin 6	Mus musculus	117-121
32275999-11	2020	IL-6, L-1beta and TNF-alpha level was remarkably depressed by the knockdown of circ_0000285 and miR-654-3p inhibitors induced that.	p-Bis(2-chloroethyl)amino-o-methoxyphenylalanine	104-106	interleukin 6	Mus musculus	0-4
32645931-7	2020	We found that brine inhalations reduced, as compared to non-inhaled mice, the typical asthma-related symptoms, like airway hyperreactivity (AHR), the infiltration of pro-inflammatory cells into the bronchial tree, and the inflammation of the airways at the level of pro-inflammatory cytokines IL-1alpha, IL-1beta and IL-6.	brine	14-19	interleukin 6	Mus musculus	317-321
32553276-6	2020	Polyamines protected self-RNA released by psoriatic keratinocytes from degradation and facilitated the endocytosis of self-RNA by myeloid dendritic cells to promote toll-like receptor-7 (TLR7)-dependent RNA sensing and IL-6 production.	Polyamines	0-10	interleukin 6	Mus musculus	219-223
32642922-7	2021	Measured with quantitative PCR, IL-1alpha, IL-6 and MIP-1B/CCL-4 gene expression was significantly reduced with 20 microM Li2CO3, whereas IL-10 gene expression was significantly increased with the same concentration.	Lithium Carbonate	122-128	interleukin 6	Mus musculus	43-47
32754030-10	2020	Additionally, reserpine-treated mice exhibited significantly elevated mRNA levels of pro-inflammatory cytokines, but BTS mice showed reduced mRNA levels of interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha in the hippocampus.	Reserpine	14-23	interleukin 6	Mus musculus	180-184
32650550-4	2020	The anti-inflammatory activity of 7AC on viability of treated cells was assessed by measuring the level of expression of NO, PGE2 and pro-inflammatory cytokines, namely interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in 7AC-treated RAW 264.7 macrophages.	7-acetoxycoumarin	34-37	interleukin 6	Mus musculus	199-212
32650550-4	2020	The anti-inflammatory activity of 7AC on viability of treated cells was assessed by measuring the level of expression of NO, PGE2 and pro-inflammatory cytokines, namely interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in 7AC-treated RAW 264.7 macrophages.	7-acetoxycoumarin	34-37	interleukin 6	Mus musculus	214-218
31729642-10	2020	Increased lipid peroxidation, intracellular ROS, mitochondrial membrane depolarization, cell death levels, TNF-alpha, IL-1beta, IL-6, caspase -3, and -9 activities in the DOCX group of LARYN cells were diminished by the treatment of Na-Sel.	docetaxel	171-175	interleukin 6	Mus musculus	128-132
32585463-11	2020	Treatment with mito-TEMPO significantly reduced the increase in mRNA expression and secretion of TNF-alpha, IL-6 and IL-1beta induced by MDM2 overexpression in ox-LDL treated HAECs.	MitoTEMPO	15-25	interleukin 6	Mus musculus	108-112
31650468-12	2020	In the gut tissues, BE treatment significantly reduced inflammatory cytokine levels such as IL-1beta, IL-2, IL-6, IL-10, G-CSF, and GM-CSF.	baicalein	20-22	interleukin 6	Mus musculus	108-112
32251678-4	2020	At the molecular level, loratadine reduced the levels of nitric oxide, iNOS, IL-1beta, TNF-alpha, IL-6, and COX-2 in RAW264.7 cells treated with lipopolysaccharide.	Loratadine	24-34	interleukin 6	Mus musculus	98-102
32632241-8	2020	Mechanistically, DEX induced IL-6 secretion from aHSCs and promoted HCC progression via STAT3 activation.	Dexmedetomidine	17-20	interleukin 6	Mus musculus	29-33
32376338-8	2020	Both pseurotins significantly inhibited production of NO, expression of iNOS and IL-6 production.	pseurotin	5-15	interleukin 6	Mus musculus	81-85
31854454-7	2020	Three times of betamethasone administration (immediately after operation and 12 hours and 24 hours after transplantation) did not change the number of apoptotic cells and osteoclasts, but showed a slight upregulation of IL-4 and a downregulation of IL-6.	Betamethasone	15-28	interleukin 6	Mus musculus	249-253
31854454-8	2020	However, 7 doses of betamethasone administration (over 7 consecutive days) increased the number of apoptotic cells and osteoclasts, which was correlated with a downregulation of IL-4 and an upregulation of IL-6.	Betamethasone	20-33	interleukin 6	Mus musculus	206-210
31854454-10	2020	The results showed beneficial effects of 3 betamethasone administrations for bone regeneration therapy but contrary effects when betamethasone was administered 7 times due to the downregulation of anti-inflammatory cytokines (IL-4) and the upregulation of inflammatory cytokines (IL-6).	Betamethasone	129-142	interleukin 6	Mus musculus	280-284
32443237-6	2020	Metformin significantly attenuated the production of IL-6, mitochondrial damage, cell viability and LDH activity by limiting TLRs/MyD88/NF-kappaB pathway.	Metformin	0-9	interleukin 6	Mus musculus	53-57
32436607-9	2020	Conversely, GAS1-OE mitigated the effect of Parkin-OE on HG-induced P21, IL-6, and TGF-beta1 expression in RTECs.	Mercury	57-59	interleukin 6	Mus musculus	73-77
32325405-7	2020	Besides, bilirubin inhibited the secretion of TNF-alpha and IL-6 in LPS-primed macrophages by reduced phosphorylation of IkappaB-alpha and p65, indicating the inhibition of the NF-kappaB pathway.	Bilirubin	9-18	interleukin 6	Mus musculus	60-64
32304993-7	2020	AMG487 significantly alleviated joint inflammation by decreasing GITR+CD25+, GITR+CD45+, GITR+IL-9+, GITR+NF-kappaB+ CD45+CD4+, CD45+CCR6+, CD45+IL-6+ cells, CD45+IL-17A+, and CD45+IL-21+, and increasing GITR+Foxp3+ and GITR+STAT6+ cells.	N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido(2,3-d)pyrimidin-2-yl)ethyl)-N-pyridin-3-ylmethyl-2-(4-trifluoromethoxyphenyl)acetamide	0-6	interleukin 6	Mus musculus	145-149
32199919-5	2020	Specifically, ASALP significantly inhibited the production of nitric oxide (NO) and pro-inflammatory cytokines (IL-6, IL-1beta and TNF-alpha) in lipopolysaccharide (LPS)-treated macrophages and in the serum of inflammatory mice, but increased the production of the anti-inflammatory cytokines IL-10.	asalp	14-19	interleukin 6	Mus musculus	112-116
32380408-6	2020	MitoQ treatment not only ameliorated NKT cell-independent hyperacute hepatitis within 12 h post Con A administration but also alleviated NKT cell-dependent extended liver injury at 24 h. The underlying mechanisms involved an inhibition of the heightened activation of iNKT cells and conventional T cells, suppression of the excessive production of IFN-gamma, TNF-alpha and IL-6, and modulation of aberrant AMPK and mTORC1 pathways.	mitoquinone	0-5	interleukin 6	Mus musculus	373-377
32377696-10	2020	Reverse transcription-quantitative PCR analysis verified that interleukin-6 and epiregulin expression levels were significantly increased in livers from the group treated with high-dose galunisertib compared with the vehicle-treated group.	LY-2157299	186-198	interleukin 6	Mus musculus	62-75
32361191-6	2020	Additionally, histopathological examinations confirmed that alendronate mitigated inflammation in the spinal cord after EAE induction, suppressed the infiltration of CD68-positive inflammatory cells, and reduced the production of various pro-inflammatory cytokines, including interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha, and interferon (IFN)-gamma, as well as inducible nitric oxide synthase (iNOS).	Alendronate	60-71	interleukin 6	Mus musculus	300-304
32413737-8	2020	Meanwhile, costunolide also suppressed DSS-induced expression of induced nitric oxide synthase (iNOS), interleukin-1beta (IL-1beta), IL-6, tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) in both mRNA and protein levels.	costunolide	11-22	interleukin 6	Mus musculus	133-137
32413737-8	2020	Meanwhile, costunolide also suppressed DSS-induced expression of induced nitric oxide synthase (iNOS), interleukin-1beta (IL-1beta), IL-6, tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) in both mRNA and protein levels.	Dextran Sulfate	39-42	interleukin 6	Mus musculus	133-137
32626914-6	2020	In addition, agomiR-17 injection significantly suppressed LPS-induced inflammation, as evidenced by a reduction in the activity of myeloperoxidase and the production of interleukin (IL)-6, IL-1beta and tumor necrosis factor-alpha in lung tissues.	agomir-17	13-22	interleukin 6	Mus musculus	169-187
32379622-7	2020	Furthermore, CSDS treatment did not alter the plasma levels of interleukin-6 (IL-6) of betaine-treated mice whereas CSDS caused higher plasma levels of IL-6 in water-treated mice.	Water	160-165	interleukin 6	Mus musculus	152-156
32519575-2	2020	IL-6 induced DRG nociceptor excitability is attenuated in mice lacking eIF4E phosphorylation, in MNK1/2-/- mice and by the nonselective MNK1/2 inhibitor cercosporamide.	cercosporamide	153-167	interleukin 6	Mus musculus	0-4
32301120-7	2020	CONCLUSIONS: The observed profile of cytokine modulation (IL-6/ TNF-alpha, IL-8) and inhibition of release of NO and 5-LOX may contribute to the in vivo effects demonstrated by indane dimers and PH46A (1) in murine models of colitis.	indan	177-183	interleukin 6	Mus musculus	58-62
32253103-9	2020	Pravastatin protected the cardiomyocytes against calcium disorders induced by IL-6 via the mitochondrial ROS pathway, which suggests that pravastatin may represent a promising auxiliary therapeutic strategy for cardiac injury under acute inflammation.	Pravastatin	0-11	interleukin 6	Mus musculus	78-82
32253103-9	2020	Pravastatin protected the cardiomyocytes against calcium disorders induced by IL-6 via the mitochondrial ROS pathway, which suggests that pravastatin may represent a promising auxiliary therapeutic strategy for cardiac injury under acute inflammation.	Calcium	49-56	interleukin 6	Mus musculus	78-82
32253103-9	2020	Pravastatin protected the cardiomyocytes against calcium disorders induced by IL-6 via the mitochondrial ROS pathway, which suggests that pravastatin may represent a promising auxiliary therapeutic strategy for cardiac injury under acute inflammation.	ros	105-108	interleukin 6	Mus musculus	78-82
32253103-0	2020	Pravastatin alleviates intracellular calcium dysregulation induced by Interleukin-6 via the mitochondrial ROS pathway in adult ventricular myocytes.	Pravastatin	0-11	interleukin 6	Mus musculus	70-83
32253103-0	2020	Pravastatin alleviates intracellular calcium dysregulation induced by Interleukin-6 via the mitochondrial ROS pathway in adult ventricular myocytes.	Calcium	37-44	interleukin 6	Mus musculus	70-83
32253103-0	2020	Pravastatin alleviates intracellular calcium dysregulation induced by Interleukin-6 via the mitochondrial ROS pathway in adult ventricular myocytes.	ros	106-109	interleukin 6	Mus musculus	70-83
32253103-5	2020	Acute administration of clinically relevant concentrations of IL-6 disturbed calcium handling in ventricular myocytes, which presented as decreased amplitudes, prolonged decay times of Ca2+ transients, and reduced sarcoplasmic reticulum (SR) calcium stores.	Calcium	77-84	interleukin 6	Mus musculus	62-66
32253103-5	2020	Acute administration of clinically relevant concentrations of IL-6 disturbed calcium handling in ventricular myocytes, which presented as decreased amplitudes, prolonged decay times of Ca2+ transients, and reduced sarcoplasmic reticulum (SR) calcium stores.	Calcium	242-249	interleukin 6	Mus musculus	62-66
32253103-6	2020	The frequency of spontaneous Ca2+ release, including calcium sparks and spontaneous calcium waves, was dramatically enhanced in the setting of IL-6.	Calcium	53-60	interleukin 6	Mus musculus	143-147
32253103-9	2020	Pravastatin protected the cardiomyocytes against calcium disorders induced by IL-6 via the mitochondrial ROS pathway, which suggests that pravastatin may represent a promising auxiliary therapeutic strategy for cardiac injury under acute inflammation.	Pravastatin	138-149	interleukin 6	Mus musculus	78-82
32253103-6	2020	The frequency of spontaneous Ca2+ release, including calcium sparks and spontaneous calcium waves, was dramatically enhanced in the setting of IL-6.	Calcium	84-91	interleukin 6	Mus musculus	143-147
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Itraconazole	22-25	interleukin 6	Mus musculus	205-209
32253103-7	2020	Notably, the pretreatment of pravastatin alleviated disturbed Ca2+ cycling, reduced spontaneous Ca2+ leakage induced by IL-6.	Pravastatin	29-40	interleukin 6	Mus musculus	120-124
32444136-7	2020	Furthermore, hepcidin-treated macrophages secreted less IL-1beta and IL-6 upon stimulation with the TLR3 agonist polyinosine-polycytidylic acid.	polyinosine-polycytidylic acid	113-143	interleukin 6	Mus musculus	69-73
31578565-6	2020	Pb-infected mice treated with PTX/ITC presented a reduction in the pulmonary concentrations of OH-proline, associated with lower concentrations of interleukin (IL)-6, IL-17, and transforming growth factor (TGF)-beta1 and higher concentrations of IL-10 compared to the controls.	Pentoxifylline	30-33	interleukin 6	Mus musculus	147-165
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Thalidomide	26-30	interleukin 6	Mus musculus	205-209
31578565-6	2020	Pb-infected mice treated with PTX/ITC presented a reduction in the pulmonary concentrations of OH-proline, associated with lower concentrations of interleukin (IL)-6, IL-17, and transforming growth factor (TGF)-beta1 and higher concentrations of IL-10 compared to the controls.	Itraconazole	34-37	interleukin 6	Mus musculus	147-165
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Trimethoprim, Sulfamethoxazole Drug Combination	35-38	interleukin 6	Mus musculus	205-209
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Thalidomide	39-43	interleukin 6	Mus musculus	205-209
32447828-7	2020	Polyphenols reduced Nrf2 nuclear translocation, and counteracted NFkB pathway activation, IL-6 secretion and the altered production of vasoactive markers mediated by high glucose.	Polyphenols	0-11	interleukin 6	Mus musculus	90-94
32438504-9	2020	Further, [6]-gingerol improved ISO-induced morphological pathologies, reduced the expression of TNF-alpha, IL-6, c-fos, c-jun, Bax, Caspase-3, TLR4, NF-kappaB, p38, p-p38, ERK1/2, p-ERK1/2, JNK, and p-JNK, and increased Bcl-2 protein expression.	gingerol	9-21	interleukin 6	Mus musculus	107-111
32170675-6	2020	We found that the Bex treatment depressed the increase in the number of activated microglia and astrocytes in the frontal cortex, and the increase in the levels of inflammatory cytokines TNF-alpha, IL-1beta and IL-6 in LPS-injected mice.	Bexarotene	18-21	interleukin 6	Mus musculus	211-215
32377738-11	2020	The results of the present study indicated that sevoflurane anesthesia significantly decreased the ATP and SOD levels, but increased ApoE mRNA, total ApoE protein, full-length ApoE, ApoE fragments, phosphorylated tau (AT8 and PHF1) and neuroinflammatory factor (TNF-alpha, IL-6 and IL-1beta) expression levels compared with those in the control group.	Sevoflurane	48-59	interleukin 6	Mus musculus	273-277
32566018-10	2020	In conclusion, erlotinib combined with cisplatin can inhibit the tumor growth of mice with LLC, and inhibition of IL-6 level and upregulation of IL-12 level may be one of its therapeutic mechanisms.	Erlotinib Hydrochloride	15-24	interleukin 6	Mus musculus	114-118
31950223-5	2020	Furthermore, pantoprazole mostly normalized cisplatin-induced distortion of renal levels of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6, interleukin-10) and renal content of apoptosis regulating protein expressions (Bax, Bcl2, and active caspase 3).	pantoprazole	13-25	interleukin 6	Mus musculus	145-158
31950223-5	2020	Furthermore, pantoprazole mostly normalized cisplatin-induced distortion of renal levels of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6, interleukin-10) and renal content of apoptosis regulating protein expressions (Bax, Bcl2, and active caspase 3).	Cisplatin	44-53	interleukin 6	Mus musculus	145-158
32566018-0	2020	Effect of erlotinib combined with cisplatin on IL-6 and IL-12 in mice with Lewis lung cancer.	Erlotinib Hydrochloride	10-19	interleukin 6	Mus musculus	47-51
32363440-6	2020	Consistently, gelsemine inhibited the over-expression of pro-inflammatory cytokines, including interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), in the brain of mice.	gelsemine	14-23	interleukin 6	Mus musculus	125-138
33612466-0	2020	Rutin coated gold nanoparticles prevent rhabdomyolysis-induced kidney injury via down-regulation of NF-kB, iNOS, IL-6 and up-regulation of HO-1 and Kim-1 genes in mice.	Rutin	0-5	interleukin 6	Mus musculus	113-117
32087283-4	2020	We showed that DHT inhibited LPS-induced release of proinflammatory factors, including TNF-alpha, IL-1beta, IL-6; iNOS, COX-2, NO, and PGE2 in BV2 cells and primary microglia by suppressing the TLR4-mediated NF-kappaB and MAPK p38 signaling pathways, thus protecting SH-SY5Y neurons from inflammatory damage induced by activated microglia.	Dihydrotestosterone	15-18	interleukin 6	Mus musculus	108-112
32087283-5	2020	In an LPS-induced neuroinflammation mouse model, endogenous DHT depletion by castration exacerbated inflammatory responses by upregulating the levels of TNF-alpha, IL-1beta, IL-6, iNOS, and COX-2 in the serum and brain by increasing the LR4-mediated NF-kappaB and MAPK pathway activation, but these effects were restored by exogenous DHT supplementation.	Dihydrotestosterone	60-63	interleukin 6	Mus musculus	174-178
32363440-6	2020	Consistently, gelsemine inhibited the over-expression of pro-inflammatory cytokines, including interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), in the brain of mice.	gelsemine	14-23	interleukin 6	Mus musculus	140-144
32333917-4	2020	The underlying mechanisms behind capmatinib protective effect were found to be i) limiting excessive generation of reactive oxygen species by decreasing the level of lipid peroxidation and nitrosative stress products; and ii) suppressing overproduction of pro-inflammatory mediators like TNF-alpha and IL-6 that coincided with less inflammatory cell infiltration as denoted by lower levels of serum MCP-1 and Ly6G immunostaining.	capmatinib	33-43	interleukin 6	Mus musculus	302-306
32422539-4	2020	The purpose of this study was to further explore the relationship between IL-6 trans-signaling and oxidative stress using a streptozotocin (STZ) induced mouse model of early diabetic retinopathy.	Streptozocin	124-138	interleukin 6	Mus musculus	74-78
32422539-4	2020	The purpose of this study was to further explore the relationship between IL-6 trans-signaling and oxidative stress using a streptozotocin (STZ) induced mouse model of early diabetic retinopathy.	Streptozocin	140-143	interleukin 6	Mus musculus	74-78
32629916-6	2020	The results revealed that aspirin inhibited macrophage chemoattractant protein (MCP-1), interleukin (IL-6), IL-1beta, and plasminogen activator inhibitor (PAI-1) production in 3T3-L1 adipocytes stimulated by tumor necrosis factor-alpha (TNF-alpha) and lipopolysaccharide (LPS).	Aspirin	26-33	interleukin 6	Mus musculus	101-105
32665776-7	2020	We found that losartan inhibited lung metastasis of CRC and there was a reduction of the IL-6 expression level in the tissue sample.	Losartan	14-22	interleukin 6	Mus musculus	89-93
32610574-6	2020	Apigenin (100 muM) significantly inhibited nitric oxide (NO) production, cytokine expression (interleukin (IL)-1beta, IL6, cyclooxygenase (COX)-2, and inducible nitric oxide synthase [iNOS]), and phosphorylation of mitogen-activated protein kinase (MAPK) signal molecules, including extracellular signal-regulated kinase (ERK) and c-Jun N-terminal protein kinase (JNK) in RAW264.7 cells.	Apigenin	0-8	interleukin 6	Mus musculus	118-121
32234526-7	2020	Data show that olaparib pre-treatment markedly reduced the neutrophil infiltration, alveolar capillary damage, inflammatory cytokines level (TNF-alpha/IL-1beta/IL-6) and oxidative stress in the lungs at 24 h after ALI induction.	olaparib	15-23	interleukin 6	Mus musculus	160-164
32490531-9	2020	In the macrophages stimulated with AngII or lipopolysaccharide (LPS), DAPT reverted the expression of pro-inflammatory genes Il6 and Il12 back to baseline within 6 h compared with vehicle (P<0.05).	dapt	70-74	interleukin 6	Mus musculus	125-128
32630417-5	2020	Within 4h of DMXAA injection, the expression of Ifnb1, Il6, Tnf, Ifng, and Mx1 was significantly upregulated.	vadimezan	13-18	interleukin 6	Mus musculus	55-58
32585876-8	2020	Moreover, induction of aortas medial calcification and concomitant IL6 expression, with an overdose of vitamin D, was reduced in male C57BL/6J Mir34a-/- mice.	Vitamin D	103-112	interleukin 6	Mus musculus	67-70
32575718-9	2020	Furthermore, EGCG also reduced the expression of proinflammatory M1 mediators iNOS TNF-alpha, IL-1beta and IL-6 in the LPS administered lung microenvironment.	epigallocatechin gallate	13-17	interleukin 6	Mus musculus	107-111
32660181-20	2020	Liver tissue HE staining showed that hepatocyte necrosis and the number of necrotic foci was significantly alleviated after blocking serum IL-6.Immunohistochemical results showed that the expression of activated caspase3 and hepatocyte apoptosis in the IL-6 neutralizing antibody group was decreased.	Helium	13-15	interleukin 6	Mus musculus	139-143
32562098-0	2021	Alcohol Enhances Responses to High Frequency Stimulation in Hippocampus from Transgenic Mice with Increased Astrocyte Expression of IL-6.	Alcohols	0-7	interleukin 6	Mus musculus	132-136
32562098-2	2021	Of these, IL-6 has gained attention because it is involved in a number of important physiological and pathophysiological processes that could be affected by alcohol-induced CNS production of IL-6, particularly under conditions of excessive alcohol use.	Alcohols	157-164	interleukin 6	Mus musculus	10-14
32562098-2	2021	Of these, IL-6 has gained attention because it is involved in a number of important physiological and pathophysiological processes that could be affected by alcohol-induced CNS production of IL-6, particularly under conditions of excessive alcohol use.	Alcohols	157-164	interleukin 6	Mus musculus	191-195
32562098-2	2021	Of these, IL-6 has gained attention because it is involved in a number of important physiological and pathophysiological processes that could be affected by alcohol-induced CNS production of IL-6, particularly under conditions of excessive alcohol use.	Alcohols	240-247	interleukin 6	Mus musculus	10-14
32562098-2	2021	Of these, IL-6 has gained attention because it is involved in a number of important physiological and pathophysiological processes that could be affected by alcohol-induced CNS production of IL-6, particularly under conditions of excessive alcohol use.	Alcohols	240-247	interleukin 6	Mus musculus	191-195
32562098-7	2021	Results are consistent with a role for IL-6-induced neuroadaptive effects on presynaptic mechanisms involved in transmitter release in the resistance of LTP to alcohol in hippocampus from the TG mice.	Alcohols	160-167	interleukin 6	Mus musculus	39-43
32562098-8	2021	These actions are important with respect to a role for IL-6 in physiological and pathophysiological processes in the CNS and in CNS actions of alcohol, especially when excessive alcohol used is comorbid with conditions associated with elevated levels of IL-6 in the CNS.	Alcohols	143-150	interleukin 6	Mus musculus	254-258
32562098-8	2021	These actions are important with respect to a role for IL-6 in physiological and pathophysiological processes in the CNS and in CNS actions of alcohol, especially when excessive alcohol used is comorbid with conditions associated with elevated levels of IL-6 in the CNS.	Alcohols	178-185	interleukin 6	Mus musculus	55-59
32556081-0	2020	Curcumin against imiquimod-induced psoriasis of mice through IL-6/STAT3 signaling pathway.	Curcumin	0-8	interleukin 6	Mus musculus	61-65
32556081-0	2020	Curcumin against imiquimod-induced psoriasis of mice through IL-6/STAT3 signaling pathway.	Imiquimod	17-26	interleukin 6	Mus musculus	61-65
32596245-4	2020	In response to DSS challenge, compared to MK2lyz2-WT mice, MK2Lyz2-KO mice exhibited less damage of epithelial and goblet cells, decreased generation of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, and ROS, as well as reduced Ki67-positive cells and concentrations of myeloperoxidase (MPO) in the intestinal epithelium.	mk2lyz2	59-66	interleukin 6	Mus musculus	153-171
32169445-2	2020	The results indicated that ASPP restored the immune organ indices, increased colon length, improved colonic histopathology in colitis mice as well as inhibited the levels of pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha) in colonic tissue and serum.	aspp	27-31	interleukin 6	Mus musculus	212-216
32056479-4	2020	Increased retinal expression of interleukin (lL)-1beta, IL-1alpha, IL-6, and tumor necrosis factor (TNF)alpha was observed in bTBI mice exposed to blast when compared with shams, which was associated with activation of microglia and macroglia reactivity, assessed via immunohistochemistry with ionized calcium binding adaptor molecule 1 and glial fibrillary acidic protein, respectively, one week post-blast.	btbi	126-130	interleukin 6	Mus musculus	67-71
32385136-4	2020	Administration of Delta9-THC caused a dramatic early upregulation of plasma IL-10 levels, reduced plasma IL-6 and CCL-2 levels, led to better clinical status, and attenuated organ injury in endotoxemic mice.	Dronabinol	18-28	interleukin 6	Mus musculus	105-109
32617135-5	2020	In vitro data show that the nontoxic concentrations of FKA (2-30 muM) significantly suppressed the proinflammatory cytokine (TNF-alpha, IL-1beta, and IL-6) release but induced the secretion of interleukin-10 (IL-10), an anti-inflammatory cytokine.	flavokawain A	55-58	interleukin 6	Mus musculus	150-154
32617135-8	2020	Supporting the in vitro data, the ex vivo data obtained from primary splenocytes derived from the FKA-preadministered BALB/c mice (orally) show that FKA significantly suppressed the proinflammatory cytokine (TNF-alpha, IL-1beta, and IL-6) secretion in control-, LPS-, or Concanavalin A- (Con A-) stimulated cells.	flavokawain A	149-152	interleukin 6	Mus musculus	233-237
32617135-9	2020	A significant decrease in the ratios of pro- and anti-inflammatory cytokines (IL-6/IL-10; TNF-alpha/IL-10) showed that FKA possesses strong anti-inflammatory properties.	flavokawain A	119-122	interleukin 6	Mus musculus	78-82
32545266-1	2020	Hepatic peptide hormone hepcidin, a key regulator of iron metabolism, is induced by inflammatory cytokine interleukin-6 (IL-6) in the pathogenesis of anemia of inflammation or microbial infections.	Iron	53-57	interleukin 6	Mus musculus	106-119
32545266-1	2020	Hepatic peptide hormone hepcidin, a key regulator of iron metabolism, is induced by inflammatory cytokine interleukin-6 (IL-6) in the pathogenesis of anemia of inflammation or microbial infections.	Iron	53-57	interleukin 6	Mus musculus	121-125
32545266-7	2020	In addition, EGCG inhibited IL-6-induced hepcidin expression, which was reversed by SMILE knockdown.	epigallocatechin gallate	13-17	interleukin 6	Mus musculus	28-32
32545266-9	2020	These results reveal a previously unrecognized role of EGCG-inducible SMILE in the IL-6-dependent transcriptional regulation of iron metabolism.	epigallocatechin gallate	55-59	interleukin 6	Mus musculus	83-87
32545266-9	2020	These results reveal a previously unrecognized role of EGCG-inducible SMILE in the IL-6-dependent transcriptional regulation of iron metabolism.	Iron	128-132	interleukin 6	Mus musculus	83-87
32520957-3	2020	Here we report that the inositol-requiring enzyme 1 (IRE1alpha) branch of the UPR is directly involved in the polarization of macrophages in vitro and in vivo, including the up-regulation of interleukin 6 (IL-6), IL-23, Arginase1, as well as surface expression of CD86 and programmed death ligand 1 (PD-L1).	Inositol	24-32	interleukin 6	Mus musculus	191-204
32595492-12	2020	APF also reduced the mRNA and protein expressions of TNFalpha, IL-1beta, and IL-6 in STZ-induced DN mice.	Streptozocin	85-88	interleukin 6	Mus musculus	77-81
32520957-3	2020	Here we report that the inositol-requiring enzyme 1 (IRE1alpha) branch of the UPR is directly involved in the polarization of macrophages in vitro and in vivo, including the up-regulation of interleukin 6 (IL-6), IL-23, Arginase1, as well as surface expression of CD86 and programmed death ligand 1 (PD-L1).	Inositol	24-32	interleukin 6	Mus musculus	206-210
32521253-5	2020	LPS-stimulated B cells of Trpm5-deficient mice exhibit an increased cytosolic calcium concentration, leading to enhanced proliferation and the production of the inflammatory cytokines interleukin-6 and CXCL10.	Calcium	78-85	interleukin 6	Mus musculus	184-197
32521603-7	2020	The antibody response conferred by the nanoparticle adjuvant was also correlated with IL-6 and IL-10 splenic levels.	nanoparticle adjuvant	39-60	interleukin 6	Mus musculus	86-90
32582649-6	2020	Furthermore, the down-regulated effect of CATH-2TP was more pronounced (p < 0.05) on LPS-induced cytotoxic effects, nitric oxide secretion and pro-inflammatory cytokines (TNF-alpha, IL-6, and IL-1beta) in murine RAW264.7 macrophages.	2-(3-{[4-(HYDROXYAMINO)-2-METHYLPYRIMIDIN-5-YL]METHYL}-4-METHYL-2,3-DIHYDRO-1,3-THIAZOL-5-YL)ETHYL TRIHYDROGEN DIPHOSPHATE	47-50	interleukin 6	Mus musculus	182-186
32596340-8	2020	Results: Downregulated miR-331-3p increased the expression of NLRP6 and alleviated the expression of TNF-alpha and IL-6.	mir-331-3p	23-33	interleukin 6	Mus musculus	115-119
32503977-9	2020	Finally, IFN-I stimulates B cells to produce IL-6 to drive pathogenic TH17 differentiation in vitro.	th17	70-74	interleukin 6	Mus musculus	45-49
32518521-5	2020	Results: Dietary fiber and sodium butyrate (NaB) decreased CRC burden by decreasing IL-6 receptor gp130 and blocking IL-6/JAK2/STAT3 axis activation in vitro and in vivo.	Butyric Acid	27-42	interleukin 6	Mus musculus	84-88
32518521-5	2020	Results: Dietary fiber and sodium butyrate (NaB) decreased CRC burden by decreasing IL-6 receptor gp130 and blocking IL-6/JAK2/STAT3 axis activation in vitro and in vivo.	Butyric Acid	27-42	interleukin 6	Mus musculus	117-121
32518521-5	2020	Results: Dietary fiber and sodium butyrate (NaB) decreased CRC burden by decreasing IL-6 receptor gp130 and blocking IL-6/JAK2/STAT3 axis activation in vitro and in vivo.	nab	44-47	interleukin 6	Mus musculus	84-88
32518521-5	2020	Results: Dietary fiber and sodium butyrate (NaB) decreased CRC burden by decreasing IL-6 receptor gp130 and blocking IL-6/JAK2/STAT3 axis activation in vitro and in vivo.	nab	44-47	interleukin 6	Mus musculus	117-121
32532087-3	2020	Hispolon treatment reduced the production of the pro-inflammatory mediator NO, TNF-alpha, IL-1beta, and IL-6 induced by LPS challenge in the lung tissues, as well as decreasing their histological alterations and protein content.	hispolon	0-8	interleukin 6	Mus musculus	104-108
32581538-8	2020	Oral administration of BBR-NLCs significantly alleviated colitis symptoms (DAI, colon length, spleen swelling, MPO activity) through inhibition of NF-kappaB nuclear translocation, decreased expression of pro-inflammatory cytokines (IL-1beta, IL-6, MMP-9, CX3CR1, COX-2, TERT), and increased expression of the tight junction protein ZO-1.	Berberine	23-26	interleukin 6	Mus musculus	242-246
32249638-5	2020	In addition, in the presence of METH-atazanavir, the expression and secretion of a series of pro-inflammatory cytokines TNF-alpha, IL-1beta, IL-6, and IL-8 increased while the expression and secretion of anti-inflammatory cytokine IL-10 decreased.Conclusion: These results demonstrated that METH and atazanavir had a combined impact on the liver immunity, suggesting that the co-treatment could enhance inflammatory response and suppress NK cell activation via CD48.	meth-atazanavir	32-47	interleukin 6	Mus musculus	141-145
32390515-7	2020	ELISA and immunoblot analysis demonstrated that thapsigargin [an activator of store-operated Ca2+ entry (SOCE)], but not the endoplasmic reticulum stress inducer tunicamycin, significantly increased IL-6 content.	Thapsigargin	48-60	interleukin 6	Mus musculus	199-203
31529728-7	2020	In contrast, hepatic and serum levels of the hepato-protective cytokine interleukin (IL)-6, its downstream signal transducer and transcription factor 3 (STAT3) activation in hepatocytes, as well hepatic MPhis IL-6 expression were markedly reduced in HIF-2alpha mye/- mice compared to WT mice post APAP challenge.	Acetaminophen	297-301	interleukin 6	Mus musculus	72-90
31529728-11	2020	CONCLUSION: the data demonstrate that APAP treatment leads to HIF-2alpha stabilization in hepatic MPhis and HIF-2alpha subsequently reprograms hepatic MPhis to produce the hepatoprotective cytokine IL-6, thereby ameliorating AILI.	Acetaminophen	38-42	interleukin 6	Mus musculus	198-202
31916050-6	2020	Additionally, Y-27632 treatment significantly decreased CD68 and proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-17F (IL-17F), and interleukin-6 (IL-6).	Y 27632	14-21	interleukin 6	Mus musculus	200-213
31916050-6	2020	Additionally, Y-27632 treatment significantly decreased CD68 and proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-17F (IL-17F), and interleukin-6 (IL-6).	Y 27632	14-21	interleukin 6	Mus musculus	215-219
32152924-8	2020	Furthermore, the histopathological changes and the expression of TNF-alpha, IL-1beta, and IL-6 were inhibited after the peiminine treatment.	peiminine	120-129	interleukin 6	Mus musculus	90-94
32170603-5	2020	Pretreatment with esculetin significantly attenuated histopathological changes, inflammatory cell infiltration, and production of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6, in the lung tissue.	esculetin	18-27	interleukin 6	Mus musculus	229-233
32220806-5	2020	The elevation of inflammatory cytokines including IL-6, IL-17A, TNF-alpha as well as IFN-gamma in colonic tissues levels were decreased after administration of andrographolide sulfonate.	andrographolide sulfonate	160-185	interleukin 6	Mus musculus	50-54
32222637-6	2020	Isovitexin inhibited CP-induced inflammation by inhibiting TNF-alpha, IL-1ss and IL-6 production in kidney tissues.	isovitexin	0-10	interleukin 6	Mus musculus	81-85
32533502-5	2020	The results showed that LPS-induced TNF-alpha, IL-1beta, and IL-6 production, lung wet/dry (W/D) ratio, ROS, MDA content, and MPO activity were suppressed by fucoidan.	fucoidan	158-166	interleukin 6	Mus musculus	61-65
32333445-8	2020	Moreover, in the prefrontal cortex of SUS mice, IL-6 and TNF-alpha were increased, whereas IL-10 was decreased.	2-Deoxy-3,6-Di-O-Sulfo-2-(Sulfoamino)-Alpha-D-Glucopyranose	38-41	interleukin 6	Mus musculus	48-52
32249638-5	2020	In addition, in the presence of METH-atazanavir, the expression and secretion of a series of pro-inflammatory cytokines TNF-alpha, IL-1beta, IL-6, and IL-8 increased while the expression and secretion of anti-inflammatory cytokine IL-10 decreased.Conclusion: These results demonstrated that METH and atazanavir had a combined impact on the liver immunity, suggesting that the co-treatment could enhance inflammatory response and suppress NK cell activation via CD48.	Methamphetamine	32-36	interleukin 6	Mus musculus	141-145
32249638-5	2020	In addition, in the presence of METH-atazanavir, the expression and secretion of a series of pro-inflammatory cytokines TNF-alpha, IL-1beta, IL-6, and IL-8 increased while the expression and secretion of anti-inflammatory cytokine IL-10 decreased.Conclusion: These results demonstrated that METH and atazanavir had a combined impact on the liver immunity, suggesting that the co-treatment could enhance inflammatory response and suppress NK cell activation via CD48.	Atazanavir Sulfate	37-47	interleukin 6	Mus musculus	141-145
32322483-11	2020	Moreover, DSS exposure induced an increase of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, occludin, zonula occludens-1, p21, p53 and Bcl-2, and decreased the expressions of IL-10, claudin-2 and cleaved caspase-3 in the colon tissue.	Dextran Sulfate	10-13	interleukin 6	Mus musculus	99-103
32251961-7	2020	The increased serum ALT, interleukin-6, or interferon-gamma (IFN-gamma) levels were observed at 2 or 8 h; tumor necrosis factor-alpha levels at 2 h post-Con A administration decreased significantly in the tipifarnib group.	tipifarnib	205-215	interleukin 6	Mus musculus	25-38
32279045-6	2020	Furthermore, western blotting and the results of morphological analysis revealed that shikonin treatments markedly reduced D-gal induced neuroinflammation through inhibition of astrocytosis as determined by glial fibrillary acidic protein (GFAP) detection, and downregulating other inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6.	shikonin	86-94	interleukin 6	Mus musculus	391-395
31960927-5	2020	The expression of the interleukin (IL)-6, inducible nitric oxide (NO) synthase, and cyclooxygenase-2 genes was enhanced by NaHCO3 in a concentration-dependent manner in LPS+IFN-gamma-stimulated RAW264.7 cells.	Sodium Bicarbonate	123-129	interleukin 6	Mus musculus	22-40
31960927-6	2020	Production of IL-6, NO2-, and prostaglandin E2 was also increased by treatment with NaHCO3 in these cells.	Sodium Bicarbonate	84-90	interleukin 6	Mus musculus	14-18
32234318-10	2020	RESULTS: High dose (16 mM) butyrate upregulated inflammatory marker IL-6, while low dose butyrate protected cells from injury by reducing IL-6 expression.	Butyrates	27-35	interleukin 6	Mus musculus	68-72
32212170-10	2020	The findings of the study would pave a separation strategy for potential large-scale preparation of anthocyanins di-glucosides standards for compounds detection and reduce the inflammation symptoms through declining the induction of pro-inflammatory cytokines such as IL-1beta, TNF-alpha and IL-6, which will also enhance the future notification on the structure-activity correlations of anthocyanins di-glucosides.	anthocyanins di-glucosides	100-126	interleukin 6	Mus musculus	292-296
32234318-10	2020	RESULTS: High dose (16 mM) butyrate upregulated inflammatory marker IL-6, while low dose butyrate protected cells from injury by reducing IL-6 expression.	Butyrates	89-97	interleukin 6	Mus musculus	138-142
32234318-11	2020	Similarly, compared with NEC alone, NEC mice who received butyrate had reduced intestinal damage, reduced IL-6 and NF-kB expression, and increased intestinal tight junction marker Claudin-7.	Butyrates	58-66	interleukin 6	Mus musculus	106-110
32539925-6	2020	Moreover, miR-520c-3p overexpression enhanced the viability of damaged cells, inhibited LPS-induced apoptosis, and decreased LPS-induced IL-1beta, IL-6 and TNF-alpha.	mir-520c-3p	10-21	interleukin 6	Mus musculus	147-151
32472295-4	2020	Meanwhile, curcumin decreased the level of cleaved caspase-3 and the release of TNF-alpha, IL-1beta, IL-6, but increased IL-10 release in LPS-treated BV2 cells.	Curcumin	11-19	interleukin 6	Mus musculus	101-105
32460371-6	2020	In a xenografted mouse model of cancer, HEP with 5-Fu significantly suppressed tumor growth, inhibited inflammatory markers such as interferon (IFN)-gamma, interleukin (IL)-1beta, IL-2, IL-6, tumor necrosis factor (TNF)-alpha, and lipopolysaccharide (LPS), and regulated the expression of Akt, CCDN1, CKD4, FOXM1, MMP7, MYC, PPAR-alpha, and PPAR-gamma.	Fluorouracil	49-53	interleukin 6	Mus musculus	186-190
32091294-7	2020	Detection of inflammatory factors, such as TNF-alpha, TGF-beta1, IL-1beta, and IL-6, in brain tissue showed that only high dose of CBNPs exposure increased the expression of cortical TGF-beta1.	cbnps	131-136	interleukin 6	Mus musculus	79-83
32402913-11	2020	TGP (720 mg/kg) treatment increased saliva flow, and reduced organ indexes and serum IL-6 and IFN-gamma concentration.	tgp	0-3	interleukin 6	Mus musculus	85-89
32528626-5	2020	In particular, the serum level of tumor necrosis factor-alpha was reduced only in the 100 mg/kg BW/day of SCS-fed group, whereas the IL-6 level was reduced in the 100 and 200 mg/kg BW/day of SCS-fed groups (P < 0.05).	Scandium	106-109	interleukin 6	Mus musculus	133-137
32528626-5	2020	In particular, the serum level of tumor necrosis factor-alpha was reduced only in the 100 mg/kg BW/day of SCS-fed group, whereas the IL-6 level was reduced in the 100 and 200 mg/kg BW/day of SCS-fed groups (P < 0.05).	Scandium	191-194	interleukin 6	Mus musculus	133-137
32402913-16	2020	After 8 weeks of administration, TGP treatment decreased the concentration of alpha-fodrin in serum, TNF-alpha and IL-6 in SMG, and down-regulated mRNA expressions of IL-17A, TNF-alpha, CXCL9, CXCL13 and BAFF and protein expressions of IL-17A and BAFF in SMG.	tgp	33-36	interleukin 6	Mus musculus	115-119
32595744-11	2020	We found that GL significantly alleviated the intestinal damage and reduced the levels of inflammatory cytokines, such as TNF-alpha, IL-6, IL-1beta, and HMGB1 levels.	Glycyrrhizic Acid	14-16	interleukin 6	Mus musculus	133-137
32536938-6	2020	TUDCA treatment of PGPS-treated mice decreased OM; reduced the expression of CHOP, BIP, and caspase 3; and significantly decreased the proinflammatory gene expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	ursodoxicoltaurine	0-5	interleukin 6	Mus musculus	214-227
33612800-10	2020	B. pseudomallei-infected mice subjected to adjunct treatment with chloroquine and doxycycline significantly (P<0.05) reduced serum levels of pro-inflammatory cytokines (TNF-alpha, IFN-gamma and IL-6) but increased levels of antiinflammatory cytokines (IL-4 and IL-10).	Chloroquine	66-77	interleukin 6	Mus musculus	194-198
33612800-10	2020	B. pseudomallei-infected mice subjected to adjunct treatment with chloroquine and doxycycline significantly (P<0.05) reduced serum levels of pro-inflammatory cytokines (TNF-alpha, IFN-gamma and IL-6) but increased levels of antiinflammatory cytokines (IL-4 and IL-10).	Doxycycline	82-93	interleukin 6	Mus musculus	194-198
32566106-7	2020	Meanwhile, berberine reduced aortic reactive oxygen species (ROS) generation and reduced the serum levels of malondialdehyde (MDA), oxidized low-density lipoprotein (ox-LDL), and interleukin-6 (IL-6).	Berberine	11-20	interleukin 6	Mus musculus	179-192
32566106-7	2020	Meanwhile, berberine reduced aortic reactive oxygen species (ROS) generation and reduced the serum levels of malondialdehyde (MDA), oxidized low-density lipoprotein (ox-LDL), and interleukin-6 (IL-6).	Berberine	11-20	interleukin 6	Mus musculus	194-198
32536938-6	2020	TUDCA treatment of PGPS-treated mice decreased OM; reduced the expression of CHOP, BIP, and caspase 3; and significantly decreased the proinflammatory gene expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	ursodoxicoltaurine	0-5	interleukin 6	Mus musculus	229-233
32448150-11	2020	However, rolipram pretreatment significantly reversed the LPS-induced downregulation of DUSP1 and inhibited LPS-induced upregulation and secretion of TNF-alpha and IL-6 but not IL-1beta.	Rolipram	9-17	interleukin 6	Mus musculus	164-168
32596368-10	2020	The inflammatory response results illustrated that BS treatment can reduce the LPS-induced expression of inflammatory mediators (interleukin-6 (IL-6), inducible nitric oxide (iNOS), tumor necrosis factor-alpha (TNF-alpha), and cyclooxygenase-2(COX-2)).	gamma-sitosterol	51-53	interleukin 6	Mus musculus	129-142
32596368-10	2020	The inflammatory response results illustrated that BS treatment can reduce the LPS-induced expression of inflammatory mediators (interleukin-6 (IL-6), inducible nitric oxide (iNOS), tumor necrosis factor-alpha (TNF-alpha), and cyclooxygenase-2(COX-2)).	gamma-sitosterol	51-53	interleukin 6	Mus musculus	144-148
32165175-10	2020	The rohitukine-enriched fraction of D. binectariferum significantly reduced the production of both pro-inflammatory cytokines TNF-alpha and IL-6 (>50% inhibition at 3.12 mug/mL) in THP-1 cells.	5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4H-1-benzopyran-4-one	4-14	interleukin 6	Mus musculus	140-144
32165175-12	2020	In transgenic mice model (collagen-induced arthritis in DBA/1J mice), rohitukine-enriched fraction at 100 mg/kg (PO, QD) dose has resulted in >75% reduction of TNF-alpha/IL-6 serum levels, 68% reduction in anti-mouse type II collagen IgG1 antibody levels, decreased joint proteoglycan loss and reduced paw edema in DBA/1J mice.	5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4H-1-benzopyran-4-one	70-80	interleukin 6	Mus musculus	170-174
32547156-6	2020	Moreover, IL-1, IL-6, and TNF-alpha knocked-out mice have delayed parturition and lower levels of PGs compared to the wild types.	Prostaglandins	98-101	interleukin 6	Mus musculus	16-20
32508636-4	2020	Here we show DHQ pretreatment effectively reduced the Ten-day mortality in bacterial endotoxin lipopolyssacharide (LPS)-challenged mice, suppressing LPS-induced inflammatory responses reflected by impaired production of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) in the serum of mice.	taxifolin	13-16	interleukin 6	Mus musculus	264-277
32342686-3	2020	High intake of L-carnitine also induced liver injury, which was proved by the increases in the serum AST and ALT activities, production of inflammatory liver cytokines (IL-1, IL-6, TNF-alpha and TNF-beta), lipid metabolism (TC, TG, HDL and LDL) disorder, and the decline in antioxidant ability (SOD, GSH-Px, MDA and RAHFR).	Carnitine	15-26	interleukin 6	Mus musculus	175-179
32229233-6	2020	Furthermore, IL-6 mRNA colonic content of BTBR mice, reduced when compared with C57 mice, was normalized by chronic treatment with FTY720.	btbr	42-46	interleukin 6	Mus musculus	13-17
32508636-4	2020	Here we show DHQ pretreatment effectively reduced the Ten-day mortality in bacterial endotoxin lipopolyssacharide (LPS)-challenged mice, suppressing LPS-induced inflammatory responses reflected by impaired production of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) in the serum of mice.	taxifolin	13-16	interleukin 6	Mus musculus	279-283
32421738-5	2020	Furthermore, a reduction in serum concentration of TNF-alpha, IFN-gamma and IL-6 was observed in the mice provided with Naringenin.	naringenin	120-130	interleukin 6	Mus musculus	76-80
32423469-14	2020	The therapeutic efficacy of rSj-Cys is associated with downregulated pro-inflammatory cytokines (TNF-alpha and IL-6) and upregulated regulatory inflammatory cytokines (IL-10 and TGF-beta), possibly through inhibiting the LPS-MyD88 signal pathway.	rsj-cys	28-35	interleukin 6	Mus musculus	111-115
32428545-6	2020	The expression levels of interleukin-6 and tumor necrosis factor-alpha in lung increased in response to silica exposure across three time points; anti-HMGB-1 could alleviate those expressions at day 28 and 84.	Silicon Dioxide	104-110	interleukin 6	Mus musculus	25-38
32534511-8	2020	The levels of IL-6, IL-17, and IFN-gamma, as well as FBS, was significantly decreased in the treated group with curcumin compared to the diabetic group mice (p<0.05).	Curcumin	112-120	interleukin 6	Mus musculus	14-18
32550901-11	2020	Mechanistically, an ultralow dose of DPI inhibited the production of pro-inflammatory cytokines, (tumor necrosis factor (TNF)-alpha and interleukin (IL)-6), reduced the macrophage infiltration and classical polarization, and induced the ROS generation.	diphenyleneiodonium	37-40	interleukin 6	Mus musculus	136-154
32508949-8	2020	And the anti-inflammatory activity of 4",7-dihydroxyflavone was related to the inhibition of COX-2, TNF-alpha, and IL-6 in LPS-induced BV-2 cells.	4',7-dihydroxyflavone	38-59	interleukin 6	Mus musculus	115-119
32220586-11	2020	Naringenin, a flavanone analog with three hydroxyl moieties, could suppress IL-6 overexpression to baseline control.	naringenin	0-10	interleukin 6	Mus musculus	76-80
31796364-9	2020	In addition, BDE-47 elevated the expression of the cytokines TNFRSF12A, TNF-alpha, IL-1beta and IL-6, and lowered the cytokines SOCS3 and the nuclear receptor PPARalpha.	2,2',4,4'-tetrabromodiphenyl ether	13-19	interleukin 6	Mus musculus	96-100
32220586-11	2020	Naringenin, a flavanone analog with three hydroxyl moieties, could suppress IL-6 overexpression to baseline control.	Hydroxyl Radical	42-50	interleukin 6	Mus musculus	76-80
32429516-8	2020	In conclusion, our results suggest that TTC could have a potential anti-inflammatory effect by reducing IL-6 levels in tissues drastically affected by the disease.	6-thiotheophylline	40-43	interleukin 6	Mus musculus	104-108
32220586-14	2020	Flavanone lessened IL-6 overexpression by 80% in the psoriasiform plaque.	flavanone	0-9	interleukin 6	Mus musculus	19-23
32423132-8	2020	Micotherapy U-care supplementation, starting before 4T1 injection and lasting until the end of the experiment, dramatically reduced the pulmonary metastases density, also triggering a decrease of fibrotic response, and reducing IL-6, NOS, and COX2 expression.	u-care	12-18	interleukin 6	Mus musculus	228-232
32477107-8	2020	The absence of 5-HT, through the pharmaceutical blockade of Tph1 (LP533401) and dietary control (TRP-free diet), suppressed hepatic lipid load and the expression of inflammatory factors (Tnfalpha, Il6, and Mcp-1).	Serotonin	15-19	interleukin 6	Mus musculus	197-200
32316726-7	2020	HPSB significantly reduced the levels of interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) induced by HFD+DSS in mice.	dss	124-127	interleukin 6	Mus musculus	41-54
32489640-9	2020	Quantitative real-time PCR analysis revealed that interleukin 6, stromal cell-derived factor-1, and monocyte chemoattractant protein-1 were upregulated by hypoxia, in which interleukin 6 and monocyte chemoattractant protein-1 were downregulated and stromal cell-derived factor-1 was upregulated by bosentan.	Bosentan	298-306	interleukin 6	Mus musculus	50-63
32508945-13	2020	It also reduced SNL-induced increases in astrocyte GFAP levels, microglial iba1 levels, and plasma IL-6 levels, suggesting that HE-CE reduces neuroinflammation.	he-ce	128-133	interleukin 6	Mus musculus	99-103
32489707-4	2020	Lactulose increased intestinal Claudin 2, 3 and 15, compared to the OVX group, and lowered pro-osteoclastogenic cytokines levels including tumor necrosis factor-alpha, interleukin(IL)-6, receptor activator of nuclear factor kappa-Beta ligand (RANKL), and IL-17 as well as increased the anti-inflammatory cytokine IL-10 in the intestine, peripheral blood, and bone marrow.	Lactulose	0-9	interleukin 6	Mus musculus	168-185
32389649-9	2020	Additionally, DS-TA NPs decreased the expression of proinflammatory cytokines, including IL-1beta, IL-6, and TNF-alpha, in the cartilage tissue.	ds-ta	14-19	interleukin 6	Mus musculus	99-103
32280045-6	2020	ADA-1 treatment also promoted the secretion of the TFH-polarizing cytokine IL-6 from mDCs.	ada-1	0-5	interleukin 6	Mus musculus	75-79
32280045-6	2020	ADA-1 treatment also promoted the secretion of the TFH-polarizing cytokine IL-6 from mDCs.	tfh	51-54	interleukin 6	Mus musculus	75-79
32440151-11	2020	GO and pathway analyses showed core DEGs were mainly enriched in the chemokine signaling and IL-6 signaling pathways, which could lead to immunosuppressive inflammatory monocyte infiltration and radioresistance.	degs	36-40	interleukin 6	Mus musculus	93-97
32087254-9	2020	Among Th17 cell-related factors, DNCB treatment increased mRNA expression of IL-6, IL-17, IL-23, STAT3, and ROR-gammat, but reduced TGF-beta and SOCS 3; While artesunate reverse these changes.	Dinitrochlorobenzene	33-37	interleukin 6	Mus musculus	77-81
32365054-7	2020	Furthermore, honokiol downregulated the expression of pro-inflammatory markers, like tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1beta.	honokiol	13-21	interleukin 6	Mus musculus	114-132
31726018-10	2020	Interleukin-6 and monocyte chemotactic protein-1 levels in the BAL fluid increased significantly from baseline in iron-deficient mice, but not in normal diet mice.	Iron	114-118	interleukin 6	Mus musculus	0-13
32248350-9	2020	The therapeutic mechanism of curcumin in the treatment of influenza viral pneumonia is related to improving the immune function of infected mice and regulating secretion of tumor necrosis-alpha, interleukin-6, and interferon-gamma.	Curcumin	29-37	interleukin 6	Mus musculus	195-208
31976547-10	2020	Moreover, luteolin treatment mitigated irinotecan-induced oxidative stress (i.e. by reducing the levels of ROS and LOOH, and augmenting endogenous antioxidants) and inflammation (i.e. through the decrease of MPO enzyme activity, TNF, IL-1beta, and IL-6 levels; and increasing IL-4 and IL-10).	irinotecan	39-49	interleukin 6	Mus musculus	248-252
32045647-9	2020	Activation of IL6 and TNFalpha transcriptional programs was delayed but remarkably higher in APAP.	Acetaminophen	93-97	interleukin 6	Mus musculus	14-17
31799746-5	2020	To this end, tamoxifen-inducible microglial IL-6-deficient (Il6DeltaMic , using Cx3cr1 CreER model) mice and control (Il6lox/lox ) mice were used.	Tamoxifen	13-22	interleukin 6	Mus musculus	44-48
32171178-9	2020	Glucose intolerance at 7 days postpartum was associated with lower beta- and alpha-cell fractional areas and higher adipose levels of proinflammatory cytokine, interleukin-6.	Glucose	0-7	interleukin 6	Mus musculus	160-173
32185800-3	2020	Rbs contributed to the decrease of inflammatory cytokines (TNF-alpha, IL-13, IL-6, IL-5, and IL-4) inside the BALF of mice with asthma.	rubusoside	0-3	interleukin 6	Mus musculus	77-81
32109485-0	2020	Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.	SB939 compound	0-11	interleukin 6	Mus musculus	121-125
32109485-0	2020	Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.	SB939 compound	13-18	interleukin 6	Mus musculus	121-125
32388084-6	2020	In an acute mouse model of atherosclerosis, ALE suppressed TNF-alpha-induced monocyte infiltration of the vascular endothelium and the expression of genes encoding inflammatory cytokines including IL-1beta, IL-6, TNF-alpha, and MCP-1 in the mouse aorta.	Epinephrine	44-47	interleukin 6	Mus musculus	207-211
32495566-7	2020	Paeonol significantly reduced the LPS and IFN-gamma-induced high expression of F4/80 and CD86, the secretion of inflammatory factors IL-6 and TNF-alpha(P<0.05 or P<0.01), decreased the expression level of miR-155, significantly down-regulated the protein phosphorylation level of JAK1-STAT1 and up-regulated the protein expression of SOCS1(P<0.01) in RAW264.7 cells.	paeonol	0-7	interleukin 6	Mus musculus	133-137
32355189-6	2020	In keratinocytes, IMQ treatment activated TG2, which in turn activated NF-kappaB signaling, leading to the upregulation of IL-6, CCL20, and CXCL8 and increased leukocyte migration, in vitro.	Imiquimod	18-21	interleukin 6	Mus musculus	123-127
32411145-4	2020	In CRISPR/Cas9 human IL-37b knock-in mice, IL-37b could significantly alleviate MC903-stimulated ear tissue swelling, itching sensation and the level of circulating cytokine IL-6 and ear in situ expression of AD-related TNF-alpha, CCL5 and transforming growth factor-beta.	calcipotriene	80-85	interleukin 6	Mus musculus	174-178
32411205-9	2020	Inhibition of MMP with BB-94 ameliorated pancreatic tissue damage and decreased the expression of proinflammatory cytokines (TNFalpha and IL-6) or chemokines (CCL2 and CXCL2) and NF-kappaB activation.	batimastat	23-28	interleukin 6	Mus musculus	138-142
32420378-7	2020	We found that propofol decreased hypoxia-induced proinflammatory cytokines (TNFalpha, IL-1beta, and IL-6) in BV2 microglia, significantly suppressed the excessive production of reactive oxygen species, and increased the total antioxidant capacity and superoxide dismutase activity.	Propofol	14-22	interleukin 6	Mus musculus	100-104
31838828-6	2020	BM2U treatment (0.2-20 mug/ml) significantly suppressed LPS-induced increase in the mRNA expression of proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, and IL-6 (p < 0.05).	bm2u	0-4	interleukin 6	Mus musculus	198-202
32483416-8	2020	Decreased Dicer expression increased DNA damage and cytosolic DNA and promoted interleukin-6 expression upon hydrogen peroxide treatment.	Hydrogen Peroxide	109-126	interleukin 6	Mus musculus	79-92
32326963-10	2020	During pathway analyses in vitro, the use of specific MAPK antagonists (SP600125, SB203580, and PD98059) revealed that JNK and p38 inhibition most efficiently attenuated LPA-induced phosphorylation of proinflammatory transcription factors (STAT1 and -3, p65, and c-Jun) and secretion of IL-6 and TNFalpha.	lysophosphatidic acid	170-173	interleukin 6	Mus musculus	287-291
32390869-5	2020	In response to poly(I:C) stimulation, PKCdelta deficient macrophages displayed an increased production of IL-1beta, IL-6, TNF-alpha, and IL-33, which were associated with an enhanced NF-kappaB activation.	Poly I-C	15-24	interleukin 6	Mus musculus	116-120
32467879-8	2020	In transgenic AD mice, sildenafil was found to rescue deficits in CREB phosphorylation and memory, upregulate brain-derived neurotrophic factor, reduce reactive astrocytes and microglia, decrease interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha, decrease neural apoptosis, increase neurogenesis, and reduce tau hyperphosphorylation.	Sildenafil Citrate	23-33	interleukin 6	Mus musculus	215-228
32236244-0	2020	Large-sized graphene oxide synergistically enhances parenchymal hepatocyte IL-6 expression monitored by dynamic imaging.	graphene oxide	12-26	interleukin 6	Mus musculus	75-79
32236244-3	2020	Herein we chose pleiotropic cytokine IL-6 as the model parameter to investigate inflammation responses upon exposure to GOs.	graphene oxide	120-123	interleukin 6	Mus musculus	37-41
32236244-7	2020	A detailed analysis uncovered that L-GO induced ROS production and TLR-4 activation promoted macrophage polarization and secretion of pro-inflammatory cytokines IL-1beta and TNF-alpha, activated via> the NF-kappaB signaling pathway, which in turn initiated the expression of IL-6 in hepatocytes.	l-go	35-39	interleukin 6	Mus musculus	275-279
32326173-9	2020	FXOH also substantially attenuated the mRNA expression of inflammatory factors, including inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), and markedly reduced the production of TNF-alpha, IL-6, IL-1beta, and nitric oxide (NO).	fxoh	0-4	interleukin 6	Mus musculus	130-143
32326173-9	2020	FXOH also substantially attenuated the mRNA expression of inflammatory factors, including inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), and markedly reduced the production of TNF-alpha, IL-6, IL-1beta, and nitric oxide (NO).	fxoh	0-4	interleukin 6	Mus musculus	145-149
32326173-9	2020	FXOH also substantially attenuated the mRNA expression of inflammatory factors, including inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), and markedly reduced the production of TNF-alpha, IL-6, IL-1beta, and nitric oxide (NO).	fxoh	0-4	interleukin 6	Mus musculus	246-250
32377293-9	2020	Metformin decreased oxidative stress (malondialdehyde and superoxide dismutase) and neuroinflammation (IL-1beta and IL-6) in APP/PS1 mice.	Metformin	0-9	interleukin 6	Mus musculus	116-120
32236445-9	2020	Reduction of CD3- and Ly6G-positive cellsin the skin of albendazole-treated mice associated with inhibition of IL-6, TNF-a, IL-1beta, IL-17A, IL36, CCL17, CXCL1, CXCL2 and CXCL5 expression.Treatment of keratinocyteswith albendazole reduced K6/K16 expression and reversibly inhibited cell growth by promoting accumulation of cells in S-phase.	Albendazole	56-67	interleukin 6	Mus musculus	111-115
32362823-0	2020	Bazedoxifene Attenuates Abdominal Aortic Aneurysm Formation via Downregulation of Interleukin-6/Glycoprotein 130/Signal Transducer and Activator of Transcription 3 Signaling Pathway in Apolipoprotein E-Knockout Mice.	bazedoxifene	0-12	interleukin 6	Mus musculus	82-95
32362823-3	2020	However, it remains unclear whether Bazedoxifene (BAZ) could suppress the activation of IL-6/GP130/STAT3 in vascular cells and the formation of AAA.	bazedoxifene	36-48	interleukin 6	Mus musculus	88-92
32362823-3	2020	However, it remains unclear whether Bazedoxifene (BAZ) could suppress the activation of IL-6/GP130/STAT3 in vascular cells and the formation of AAA.	bazedoxifene	50-53	interleukin 6	Mus musculus	88-92
32362823-8	2020	Furthermore, BAZ suppressed the stimuli-induced (IL-6 or AngII) expression of P-STAT3, MMP2 and MMP9 in vascular smooth muscle cells (VSMCs).	bazedoxifene	13-16	interleukin 6	Mus musculus	49-53
32362823-10	2020	In conclusion, these results indicated that BAZ downregulated IL-6/GP130/STAT3 signaling and interfered with AAA formation induced by AngII in ApoE-/- mice, which indicates a novel potential strategy for the prevention and therapy of AAA.	bazedoxifene	44-47	interleukin 6	Mus musculus	62-66
32109511-10	2020	Montelukast significantly reduced JNK level and NFkappaB p65 expression, and inhibited proinflammatory cytokines (TNF-alpha and IL-6) as well as oxidative stress (MDA, NO, and GSH).	montelukast	0-11	interleukin 6	Mus musculus	128-132
32322251-5	2020	Orally administered MPL16 prior intraperitoneal injection of poly(I:C) significantly reduced the levels of the proinflammatory mediators tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), and IL-15 in the intestinal mucosa.	mpl16	20-25	interleukin 6	Mus musculus	193-197
32322251-5	2020	Orally administered MPL16 prior intraperitoneal injection of poly(I:C) significantly reduced the levels of the proinflammatory mediators tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), and IL-15 in the intestinal mucosa.	Poly I-C	61-70	interleukin 6	Mus musculus	193-197
31918016-13	2020	CONCLUSIONS: NaFTV and QrLx treatment could decrease symptoms and inflammatory colitis, by decreasing of FICZ concentration and AhR signaling in colon, resulting in reducing the expression of IL-6, STAT3, and RORgammat, whereas increasing the expression of FOXP3, consequently reducing the proportion of Th17 cells and increasing the proportion of Treg cells, respectively.	Sodium	13-18	interleukin 6	Mus musculus	192-196
32260486-5	2020	Cytokine production by both liver sinusoidal endothelial cells (IL-6) and in T cells ex vivo (IFNgamma) was decreased in cells from Pioglitazone-treated mice.	Pioglitazone	132-144	interleukin 6	Mus musculus	64-68
32260181-10	2020	(3) Results: Rb-ME reduced the production of NO and mRNA expression of iNOS, COX-2, IL-1beta, and IL-6 without cytotoxicity.	rb-me	13-18	interleukin 6	Mus musculus	98-102
32260181-11	2020	The protein secretion of TNF-alpha and IL-6 was also decreased by Rb-ME.	rb-me	66-71	interleukin 6	Mus musculus	39-43
32317968-0	2020	Trichomicin Suppresses Colorectal Cancer via Comprehensive Regulation of IL-6 and TNFalpha in Tumor Cells, TAMs, and CAFs.	trichomicin	0-11	interleukin 6	Mus musculus	73-77
32317968-5	2020	The expression levels of IL-6 and TNFalpha were reduced in tumor tissues of mice treated with Trichomicin, which was consistent with results of in vitro experiments in which Trichomicin suppressed the expression of IL-6 and TNFalpha in tumor and stromal cells.	trichomicin	94-105	interleukin 6	Mus musculus	25-29
32317968-5	2020	The expression levels of IL-6 and TNFalpha were reduced in tumor tissues of mice treated with Trichomicin, which was consistent with results of in vitro experiments in which Trichomicin suppressed the expression of IL-6 and TNFalpha in tumor and stromal cells.	trichomicin	94-105	interleukin 6	Mus musculus	215-219
32317968-5	2020	The expression levels of IL-6 and TNFalpha were reduced in tumor tissues of mice treated with Trichomicin, which was consistent with results of in vitro experiments in which Trichomicin suppressed the expression of IL-6 and TNFalpha in tumor and stromal cells.	trichomicin	174-185	interleukin 6	Mus musculus	25-29
32317968-5	2020	The expression levels of IL-6 and TNFalpha were reduced in tumor tissues of mice treated with Trichomicin, which was consistent with results of in vitro experiments in which Trichomicin suppressed the expression of IL-6 and TNFalpha in tumor and stromal cells.	trichomicin	174-185	interleukin 6	Mus musculus	215-219
32317968-7	2020	Conclusively, Trichomicin, a promising new drug candidate with antitumor activity, exerted antitumor effects against colon cancer through inhibition of the IL-6 and TNFalpha signaling pathways.	trichomicin	14-25	interleukin 6	Mus musculus	156-160
31726911-0	2020	Odontoblast-like MDPC-23 cells produce pro-inflammatory IL-6 in response to lipoteichoic acid and express the antimicrobial peptide CRAMP.	lipoteichoic acid	76-93	interleukin 6	Mus musculus	56-60
31726911-2	2020	Here, we assess effects of lipopolysaccharide (LPS) and lipoteichoic acid (LTA), produced by Gram-negative and Gram-positive bacteria, respectively, on matrix metalloproteinase-8 (MMP-8), interleukin-6 (IL-6) and cathelin-related antimicrobial peptide (CRAMP) expression in odontoblast-like MDPC-23 cells.Material and methods: Gene activity and protein production was determined by quantitative real-time RT-PCR and ELISA, respectively.	lipoteichoic acid	56-73	interleukin 6	Mus musculus	188-201
32395486-8	2020	It was found that DSS can up-regulate the mRNA levels of IL-6 and IL-17 in serum (by qPCR), and the serum and bowel levels of IL-6 and IL-17 (by ELISA); these levels were significantly different from those of the blank group (P<0.05).	Dextran Sulfate	18-21	interleukin 6	Mus musculus	57-61
32395486-8	2020	It was found that DSS can up-regulate the mRNA levels of IL-6 and IL-17 in serum (by qPCR), and the serum and bowel levels of IL-6 and IL-17 (by ELISA); these levels were significantly different from those of the blank group (P<0.05).	Dextran Sulfate	18-21	interleukin 6	Mus musculus	126-130
32395486-9	2020	Furthermore, 6-gingerol was found to inhibit the increase of mRNA levels and serum and bowel levels of IL-6 and IL-17 induced by DSS, which is similar with mesalazine.	gingerol	13-23	interleukin 6	Mus musculus	103-107
32395486-9	2020	Furthermore, 6-gingerol was found to inhibit the increase of mRNA levels and serum and bowel levels of IL-6 and IL-17 induced by DSS, which is similar with mesalazine.	Dextran Sulfate	129-132	interleukin 6	Mus musculus	103-107
32411769-9	2020	Results: Ruxolitinib was found to significantly reduce NO production, inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-6 expression, suggesting that ruxolitinib blocks LPS signaling that leads to pro-inflammatory factor expression.	ruxolitinib	9-20	interleukin 6	Mus musculus	125-129
32411769-9	2020	Results: Ruxolitinib was found to significantly reduce NO production, inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-6 expression, suggesting that ruxolitinib blocks LPS signaling that leads to pro-inflammatory factor expression.	ruxolitinib	158-169	interleukin 6	Mus musculus	125-129
32120079-6	2020	ELISA analysis demonstrated that pulvones A inhibited the production of both interleukin-6 (IL-6) and IL-1beta while pulvones C showed better suppression effect on IL-1beta production in LPS-stimulated RAW264.7 cells.	pulvones a	33-43	interleukin 6	Mus musculus	77-90
32120079-6	2020	ELISA analysis demonstrated that pulvones A inhibited the production of both interleukin-6 (IL-6) and IL-1beta while pulvones C showed better suppression effect on IL-1beta production in LPS-stimulated RAW264.7 cells.	pulvones a	33-43	interleukin 6	Mus musculus	92-96
31837563-6	2020	Moreover, NaF promoted the nuclear translocation of NF-kappaB, thus increased the production of the pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1beta.	Sodium Fluoride	10-13	interleukin 6	Mus musculus	156-174
31965510-5	2020	Biochemical analysis showed that CPF administration was associated with significant increases in the serum concentrations of interleukin-1beta, IL-6, and tumor necrosis factor-alpha, while it was associated with significant reductions in serum AChE levels in mice.	1-(p-fluorphenacyl)-2-methyl-4-nitroimidazole	33-36	interleukin 6	Mus musculus	144-181
31732838-7	2020	The increased IFN-alpha, IL-6 and TNF-alpha was mitigated by low dose of resveratrol and piperine (RP-1).	resveratrol	73-84	interleukin 6	Mus musculus	25-29
31732838-7	2020	The increased IFN-alpha, IL-6 and TNF-alpha was mitigated by low dose of resveratrol and piperine (RP-1).	piperine	89-97	interleukin 6	Mus musculus	25-29
31776889-7	2020	Topical application of PNA or Delta7-ETrA on mouse back skin suppressed TPA-induced pro-inflammatory mediator production, including IL-1beta, IL-6, TNF-alpha, and PGE2, as well as the phosphorylation of p38- and JNK-mitogen-activated protein kinase (MAPK), but not that of ERK-MAPK.	5,9,12-octadecatrienoic acid	23-26	interleukin 6	Mus musculus	142-146
31810886-0	2020	Sinomenine hydrochloride inhibits the progression of plasma cell mastitis by regulating IL-6/JAK2/STAT3 pathway.	sinomenine	0-24	interleukin 6	Mus musculus	88-92
31810886-10	2020	Mechanistically, we demonstrated that SH inhibited the progression of PCM mainly through downregulating IL-6/JAK2/STAT3 levels.	sinomenine	38-40	interleukin 6	Mus musculus	104-108
31810886-11	2020	Collectively, our results suggested that SH could inhibit the progression of PCM by suppressing IL-6/JAK2/STAT3 cascades and ultimately achieve a therapeutic effect in PCM.	sinomenine	41-43	interleukin 6	Mus musculus	96-100
31832909-9	2020	In addition, ELISA and Western blot results revealed that Phil inhibits the activation of the NF-kappaB and MAPK signaling pathways and decreases the levels of inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) in LPS-induced ARDS mice.	phillyrin	58-62	interleukin 6	Mus musculus	194-198
32058930-6	2020	Furthermore, RO27-3225 decreased the number of activated microglia (Iba1+ cells with a specific morphology) and the expression levels of Iba1, TNFalpha, IL6, and iNOS proteins and increased the number of PDGFRbeta+ cells in the peri-infarct region on day 3 after tMCAO.	butir-His-Phe-Arg-Trp-Sar-NH2	13-22	interleukin 6	Mus musculus	153-156
32058932-13	2020	In both animal and cell research, hydrogen reduced TNF-alpha, IL-6 and HMGB1 levels and M1 polarization, but increased IL-10 and TGF-beta levels and M2 polarization.	Hydrogen	34-42	interleukin 6	Mus musculus	62-66
32070920-5	2020	Moreover, SAMC displayed an anti-inflammatory effect through reducing inflammatory cells infiltration, myeloperoxidase (MPO) formation and inhibiting pro-inflammatory cytokines/mediator production including tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX2) via suppressing the activation of nuclear factor-kappaB (NF-kappaB) signaling pathway.	S-allylmercaptocysteine	10-14	interleukin 6	Mus musculus	278-291
32070920-5	2020	Moreover, SAMC displayed an anti-inflammatory effect through reducing inflammatory cells infiltration, myeloperoxidase (MPO) formation and inhibiting pro-inflammatory cytokines/mediator production including tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX2) via suppressing the activation of nuclear factor-kappaB (NF-kappaB) signaling pathway.	S-allylmercaptocysteine	10-14	interleukin 6	Mus musculus	293-297
32489561-7	2020	Results: Our data indicated that inflammatory cytokines including interleukin-1beta (IL-1beta), IL-6, tumor necrosis factor-alpha (TNF-alpha) and nitric oxide were suppressed by Monascin treatment.	monascin	178-186	interleukin 6	Mus musculus	96-100
31541471-12	2020	Furthermore, reduced expressions of IL-1beta, IL-6, TNF-alpha, and TLR4 were also detected in the 335-Tg-EP group.	Thioguanine	102-104	interleukin 6	Mus musculus	46-50
32037560-7	2020	F018 treatment in collagen-induced arthritis mice significantly attenuated spleen index, lymphocyte proliferation and paw myeloperoxidase (MPO) activity, pro-inflammatory cytokine TNFalpha, IL1beta, and IL6 mRNA expression and enhanced IL10 mRNA expression in paw tissue.	f018	0-4	interleukin 6	Mus musculus	203-206
32228932-8	2020	The acidic PGA degradation products (GA) did not promote IL-10 production, but inhibited IL-1beta, IL-6 and TNF-alpha production in 7-days" culture significantly.	Polyglycolic Acid	11-14	interleukin 6	Mus musculus	99-103
32228932-8	2020	The acidic PGA degradation products (GA) did not promote IL-10 production, but inhibited IL-1beta, IL-6 and TNF-alpha production in 7-days" culture significantly.	Gallium	12-14	interleukin 6	Mus musculus	99-103
32045770-6	2020	SB203580 and PDTC reduced total cells and neutrophils in BALF in LPS-induced mice, accompanying with decreased levels of TNF-alpha, IL-6, MPO, LPO and MDA and the expressions of beclin-1, Atg5 and LC3II, but with the up-regulated activities of SOD and GSH-Px, as well as p62 protein expression.	SB 203580	0-8	interleukin 6	Mus musculus	132-136
32045770-6	2020	SB203580 and PDTC reduced total cells and neutrophils in BALF in LPS-induced mice, accompanying with decreased levels of TNF-alpha, IL-6, MPO, LPO and MDA and the expressions of beclin-1, Atg5 and LC3II, but with the up-regulated activities of SOD and GSH-Px, as well as p62 protein expression.	prolinedithiocarbamate	13-17	interleukin 6	Mus musculus	132-136
30032721-8	2020	L-cycloserine, OA and EPA all counteracted PA-induced intracellular ceramide accumulation leading to a downregulation of IL-6 and TNFalpha.	L-Cycloserine	0-13	interleukin 6	Mus musculus	121-125
30032721-8	2020	L-cycloserine, OA and EPA all counteracted PA-induced intracellular ceramide accumulation leading to a downregulation of IL-6 and TNFalpha.	Eicosapentaenoic Acid	22-25	interleukin 6	Mus musculus	121-125
30032721-8	2020	L-cycloserine, OA and EPA all counteracted PA-induced intracellular ceramide accumulation leading to a downregulation of IL-6 and TNFalpha.	Palmitic Acid	23-25	interleukin 6	Mus musculus	121-125
30032721-8	2020	L-cycloserine, OA and EPA all counteracted PA-induced intracellular ceramide accumulation leading to a downregulation of IL-6 and TNFalpha.	Ceramides	68-76	interleukin 6	Mus musculus	121-125
30032721-10	2020	In conclusion, PA induced the expression of IL-6 and TNFalpha in N42 neuronal cells independently of TLR4 but, partially, via ceramide synthesis with OA and EPA being anti-inflammatory by decreasing PA-induced intracellular ceramide build-up.	Palmitic Acid	15-17	interleukin 6	Mus musculus	44-48
32066880-3	2020	Here, we show that upregulation of monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines, in stromal cells elevates production of reactive oxygen species, triggers an inflammatory response including activation of IL-6, and promotes tumorigenesis in vitro and in vivo.	Biogenic Monoamines	35-44	interleukin 6	Mus musculus	271-275
31976564-7	2020	Pro-inflammatory cytokine genes (TNF-alpha, IL-6, IFN-gamma, IL-1beta, IL-17A and NOS2) were downregulated in the colon tissue and peritoneal macrophages of rWbaMIF-2-treated mice.	rwbamif-2	157-166	interleukin 6	Mus musculus	44-48
32157554-9	2020	Specifically, quercetin significantly inhibited LPS-induced upregulation of NF-kappa-B/P65(RELA), AP-1/C-JUN(JUN), cyclooxygenase-2(PTGS2), and interleukin 6(IL6) in mice myometrium on mRNA level and inhibited the upregulation of P65 and C-JUN on protein level.	Quercetin	14-23	interleukin 6	Mus musculus	144-157
32157554-9	2020	Specifically, quercetin significantly inhibited LPS-induced upregulation of NF-kappa-B/P65(RELA), AP-1/C-JUN(JUN), cyclooxygenase-2(PTGS2), and interleukin 6(IL6) in mice myometrium on mRNA level and inhibited the upregulation of P65 and C-JUN on protein level.	Quercetin	14-23	interleukin 6	Mus musculus	158-161
32337244-5	2020	Preventive nintedanib treatment at both doses significantly reduced CCL4-induced increases in myeloperoxidase (p < 0.01), hepatic collagen (p < 0.001), and interleukin (IL)-6 (p < 0.01) in the liver.	nintedanib	11-21	interleukin 6	Mus musculus	156-174
32337244-8	2020	Increases in tissue inhibitor of metalloproteinase-1 were significantly reduced by nintedanib at 60 mg/kg/day from day 7 only (p < 0.001), and nintedanib completely blocked elevation of IL-6 and IL-1beta levels regardless of dose or start of treatment (p < 0.05-p < 0.001).	nintedanib	143-153	interleukin 6	Mus musculus	186-190
32489022-9	2020	The low dose of Reyanning could effectively increase the percentage of total B lymphocytes(P<0.05), reduce virus load in lung tissue of model mice(P<0.01), reduce the levels of TNF-alpha, IFN-gamma, IL-6, IL-10 in the lung tissue of model mice(P<0.01), reduce the content of motilin in the serum of model mice(P<0.01).	reyanning	16-25	interleukin 6	Mus musculus	199-203
32257389-9	2020	Supplementation with exogenous IL-6 reversed both atorvastatin-induced suppression of STAT3 phosphorylation and hTERT expression and atorvastatin-induced senescence.	Atorvastatin	133-145	interleukin 6	Mus musculus	31-35
32257389-12	2020	Consistent with these results, atorvastatin decreased the IL-6, p-STAT3, and hTERT levels and increased beta-gal expression in tumor sections.	Atorvastatin	31-43	interleukin 6	Mus musculus	58-62
32257389-13	2020	Taken together, these data indicate that atorvastatin can induce atypical cellular senescence in HCC cells to inhibit tumor growth, an effect mediated by downregulation of hTERT through suppression of the IL-6/STAT3 pathway.	Atorvastatin	41-53	interleukin 6	Mus musculus	205-209
32230927-6	2020	We also demonstrated that Octominin could significantly inhibit LPS-induced secretion of pro-inflammatory cytokine (interleukin-beta; IL-1beta, IL-6, and tumor necrosis factor-alpha) and chemokines (CCL3, CCL4, CCL5, and CXCL10) from RAW 264.7 cells.	octominin	26-35	interleukin 6	Mus musculus	144-148
32125844-4	2020	At 10 muM, all of the five stilbene compounds have effectively suppressed the LPS-stimulated BV-2 cell release of proinflammatory mediators such as NO, TNF-alpha, iNOS, IL-1beta, and IL-6.	Stilbenes	27-35	interleukin 6	Mus musculus	183-187
32125844-6	2020	Further investigation in treating BV-2 cells with resveratrol and its analogues revealed the reversal of LPS-induced phenotype molecules from M1 (iNOS, IL-1beta, IL-6, and CD86) to M2 (Arg1, CD163, and IL-10) subtypes, manifesting that these five stilbenes suppressed inflammation through modulating the polarized phenotypes of BV-2 microglia.	Resveratrol	50-61	interleukin 6	Mus musculus	162-166
32218287-9	2020	Here we report that mice consuming F+(15) and F+(25) alleviated CMC-induced increase in epididymal fat-pad, colon histology score, pro-inflammatory cytokine interleukin 6 expression and intestinal permeability compared to mice fed with control diet and F-(15).	Carboxymethylcellulose Sodium	64-67	interleukin 6	Mus musculus	157-170
32139610-8	2020	Our data suggest that excessive H2S produced by the infected WT mice reduce HIF-1alpha levels, thereby suppressing glycolysis and production of IL-1beta, IL-6, and IL-12, and increasing bacterial burden.	Hydrogen Sulfide	32-35	interleukin 6	Mus musculus	154-158
32258175-7	2020	PYR-41 did not alter circulating immune cells determined by flow cytometry but significantly reduced aortic mRNA levels of cytokines related to monocyte recruitment (Mcp-1, Vcam-1, and Icam-1) and macrophage proinflammatory responses (Il-1beta and Il-6).	4(4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl ester	0-6	interleukin 6	Mus musculus	248-252
32258175-9	2020	In vitro, PYR-41 blunted ox-LDL-induced lipid deposition and expression of proinflammatory cytokines (Il-1beta and Il-6) and NADPH oxidases (Nox1, Nox2, and Nox4) in cultured RAW264.7 macrophages.	4(4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl ester	10-16	interleukin 6	Mus musculus	115-119
32178691-8	2020	Overexpression of miR-9-5p reversed the activation of inflammatory pathway in TNF-alpha- and IL-6-treated BMSCs.	mir-9-5p	18-26	interleukin 6	Mus musculus	93-97
32007575-5	2020	Further researches indicated that the combination of exercise and daidzein synergistically mobilized and redistributed natural killer cells through upregulating the level of epinephrine and interleukin-6.	daidzein	66-74	interleukin 6	Mus musculus	190-203
32231564-6	2020	Decreased pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and increased anti-inflammatory IL-10 and adiponectin levels were observed in the high-dose BBR group, but no decrease in IL-6 or increase in IL-10 was evident using the low-dose of BBR.	Berberine	187-190	interleukin 6	Mus musculus	90-94
32231564-6	2020	Decreased pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and increased anti-inflammatory IL-10 and adiponectin levels were observed in the high-dose BBR group, but no decrease in IL-6 or increase in IL-10 was evident using the low-dose of BBR.	Berberine	187-190	interleukin 6	Mus musculus	217-221
32163857-5	2020	We found that esculentoside A suppresses the expression of IL-1beta-induced inflammatory and metabolic factors (IL-6, IL-8, TNF-alpha, MMP2, MMP3 and MMP13).	esculentoside A	14-29	interleukin 6	Mus musculus	112-116
32232349-10	2020	The number of F4/80-positive cells and the levels of TNF-alpha and IL-6 mRNA were significantly reduced in the cornea of the BAC+Feno group.	flubendiamide	129-133	interleukin 6	Mus musculus	67-71
32145511-4	2020	The inhibitory effect of muscone on microglia inflammatory activation was verified by measuring pro-inflammatory cytokines expression (interleukin-6, tumor necrosis factor-alpha, and interleukin-1beta; IL-6, TNF-alpha and IL-1beta).	muscone	25-32	interleukin 6	Mus musculus	135-177
32145511-4	2020	The inhibitory effect of muscone on microglia inflammatory activation was verified by measuring pro-inflammatory cytokines expression (interleukin-6, tumor necrosis factor-alpha, and interleukin-1beta; IL-6, TNF-alpha and IL-1beta).	muscone	25-32	interleukin 6	Mus musculus	202-206
32145512-9	2020	In vitro, dexmedetomidine pretreatment promoted BMDMs M2 activation, as evidenced by increased Arg1 and Mrc1 gene induction, decreased iNOS gene induction, inhibited phosphorated-signal transducer and activator of transcription 1 (p-STAT1) but enhanced p-STAT6 expression, much lower levels of proinflammatory TNF-alpha and IL-6, and higher levels of anti-inflammatory IL-10 cytokine secretion.	Dexmedetomidine	10-25	interleukin 6	Mus musculus	324-328
32123188-4	2020	Resveratrol also led to the polarization of macrophages to the M2 direction, as well as decreasing the expression of a number of M1 pro-inflammatory cytokines [tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1beta) and interleukin 6 (IL-6)].	Resveratrol	0-11	interleukin 6	Mus musculus	235-248
32123188-4	2020	Resveratrol also led to the polarization of macrophages to the M2 direction, as well as decreasing the expression of a number of M1 pro-inflammatory cytokines [tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1beta) and interleukin 6 (IL-6)].	Resveratrol	0-11	interleukin 6	Mus musculus	250-254
31862476-11	2020	IPZ-010 inhibited interleukin-6 secretion and degranulation in BMMCs.	phthalapromine	0-7	interleukin 6	Mus musculus	18-31
31640402-10	2020	The protein levels of PD-L1 were significantly increased 2 h, 4 h and 6 h after treatment, and PD-1 was significantly increased at 2 h and 6 h. The blockade of PD-1 increased acute nitroglycerin-induced hyperalgesia, and this effect was accompanied by a more significant increase in calcitonin gene-related peptide, IL-1beta, TNF-alpha, IL-6 and IL-18 in the trigeminal ganglia.	Nitroglycerin	181-194	interleukin 6	Mus musculus	337-341
31943636-11	2020	Also, IL-6 was downregulated in a PG dose-dependent manner, as observed in mice.	propagermanium	34-36	interleukin 6	Mus musculus	6-10
31732967-7	2020	Furthermore, the increments of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6) and TUNEL-positive apoptotic cells in MPTP-treated mice were ameliorated by miR-29c.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	127-131	interleukin 6	Mus musculus	83-87
32129352-6	2020	We also found that rosmarinic acid inhibited ethanol-induced mRNA expression of tumor necrosis factor-alpha and interleukin 6.	rosmarinic acid	19-34	interleukin 6	Mus musculus	112-125
32129352-6	2020	We also found that rosmarinic acid inhibited ethanol-induced mRNA expression of tumor necrosis factor-alpha and interleukin 6.	Ethanol	45-52	interleukin 6	Mus musculus	112-125
31926446-6	2020	Enzyme-linked immunosorbent assay (ELISA) results showed that SSd pretreatment suppressed LPS-induced overexpression of inflammatory factors such as interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha both in vivo and in vitro.	saikosaponin D	62-65	interleukin 6	Mus musculus	173-177
31860763-2	2020	In this study, our results indicated that eriodictyol could dramatically suppress the inflammatory mediators, including interleukin-6 (IL-6), IL-1beta, prostaglandin E2, and tumor necrosis factor-alpha in bronchoalveolar lavage fluid of LPS-challenged mice.	eriodictyol	42-53	interleukin 6	Mus musculus	120-133
31860763-2	2020	In this study, our results indicated that eriodictyol could dramatically suppress the inflammatory mediators, including interleukin-6 (IL-6), IL-1beta, prostaglandin E2, and tumor necrosis factor-alpha in bronchoalveolar lavage fluid of LPS-challenged mice.	eriodictyol	42-53	interleukin 6	Mus musculus	135-139
31661350-8	2020	Both ADPs groups had significantly decreased concentrations of IL-1beta, IFN-gamma, IL-6, CXCL-9, and CXCL-10 in the conjunctiva than the EDE or BSS group.	adenosine 5'-O-(2-thiodiphosphate)	5-9	interleukin 6	Mus musculus	84-88
33490963-8	2020	In addition, IRF5 ASO treatment in 1K Pkd1 mice reduced Il6 expression in resident macrophages, which was correlated with reduced STAT3 phosphorylation and downstream p-STAT3 target gene expression.	Oligonucleotides, Antisense	18-21	interleukin 6	Mus musculus	56-59
31953157-8	2020	KEY FINDINGS: Adding PTX and TQ to CIS significantly reduced Notch1, Hes1, Jagged1, beta-catenin, TNF-alpha, IL-6, IFN-gamma, and VEGF with increment in IL-2, CD4, CD8, and apoptotic cells.	Pentoxifylline	21-24	interleukin 6	Mus musculus	109-113
31953157-8	2020	KEY FINDINGS: Adding PTX and TQ to CIS significantly reduced Notch1, Hes1, Jagged1, beta-catenin, TNF-alpha, IL-6, IFN-gamma, and VEGF with increment in IL-2, CD4, CD8, and apoptotic cells.	thymoquinone	29-31	interleukin 6	Mus musculus	109-113
31999977-14	2020	In addition, chrysoeriol decreased the production of NO and prostaglandin E2; inhibited the phosphorylation of inhibitor of kappaB (Ser32), p65 (Ser536) and Janus kinase 2 (Tyr1007/1008); decreased nuclear localization of p50, p65 and STAT3; and down-regulated mRNA levels of pro-inflammatory cytokines IL-6, IL-1beta and TNF-alpha that are transcriptionally regulated by NF-kappaB and STAT3 in the cell model.	chrysoeriol	13-24	interleukin 6	Mus musculus	303-307
31954762-9	2020	We further confirmed that DEX pretreatment reversed the EtOH-induced microglia activation in the DG as well as the upregulation of the hippocampal TNFalpha, MCP-1, IL-6, and IL-1beta mRNA levels.	Dexmedetomidine	26-29	interleukin 6	Mus musculus	164-168
32031205-5	2020	It was found that SOG dose-dependently reduced the emergence of inflammation cytokines, such as IL-6 and TNF-alpha in Raw264.7 murine macrophages stimulated by LPS.	11-hydroxy-sec-O-glucosylhamaudol	18-21	interleukin 6	Mus musculus	96-100
32185157-8	2020	Moreover, dictamlimonol D (5), fraxinellone (11), and dasylactone A (13) were found to reduce the LPS-induced expressions of interleukin-6 (IL-6), tumor necrosis factor (TNF-alpha), inducible nitric oxide synthase (iNOS), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB), and cyclooxygenase-2 (COX-2) at the protein levels in a dose-dependent manner.	dictamlimonol d	10-25	interleukin 6	Mus musculus	125-138
32185157-8	2020	Moreover, dictamlimonol D (5), fraxinellone (11), and dasylactone A (13) were found to reduce the LPS-induced expressions of interleukin-6 (IL-6), tumor necrosis factor (TNF-alpha), inducible nitric oxide synthase (iNOS), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB), and cyclooxygenase-2 (COX-2) at the protein levels in a dose-dependent manner.	dictamlimonol d	10-25	interleukin 6	Mus musculus	140-144
32185157-8	2020	Moreover, dictamlimonol D (5), fraxinellone (11), and dasylactone A (13) were found to reduce the LPS-induced expressions of interleukin-6 (IL-6), tumor necrosis factor (TNF-alpha), inducible nitric oxide synthase (iNOS), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB), and cyclooxygenase-2 (COX-2) at the protein levels in a dose-dependent manner.	fraxinellone	31-43	interleukin 6	Mus musculus	125-138
32185157-8	2020	Moreover, dictamlimonol D (5), fraxinellone (11), and dasylactone A (13) were found to reduce the LPS-induced expressions of interleukin-6 (IL-6), tumor necrosis factor (TNF-alpha), inducible nitric oxide synthase (iNOS), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB), and cyclooxygenase-2 (COX-2) at the protein levels in a dose-dependent manner.	fraxinellone	31-43	interleukin 6	Mus musculus	140-144
32185157-8	2020	Moreover, dictamlimonol D (5), fraxinellone (11), and dasylactone A (13) were found to reduce the LPS-induced expressions of interleukin-6 (IL-6), tumor necrosis factor (TNF-alpha), inducible nitric oxide synthase (iNOS), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB), and cyclooxygenase-2 (COX-2) at the protein levels in a dose-dependent manner.	dasylactone	54-65	interleukin 6	Mus musculus	125-138
32185157-8	2020	Moreover, dictamlimonol D (5), fraxinellone (11), and dasylactone A (13) were found to reduce the LPS-induced expressions of interleukin-6 (IL-6), tumor necrosis factor (TNF-alpha), inducible nitric oxide synthase (iNOS), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB), and cyclooxygenase-2 (COX-2) at the protein levels in a dose-dependent manner.	dasylactone	54-65	interleukin 6	Mus musculus	140-144
32003387-6	2020	Immunofluorescence and RT-PCR analysis results showed that BA fully activates the microglia and astrocytes, downregulates the expression of inflammatory factors (TNF-alpha, NF-Kbeta, IL-1beta, IL-6, COX-2, iNOS and CD33) and chemokine receptor CX3CR1, and upregulates the expression of microglia homeostatic factors (TREM2 and TYROBP) and Toll-like receptors (TLR2 and TLR4).	Barium	59-61	interleukin 6	Mus musculus	193-197
32139660-7	2020	Acetate also reduced expression of inflammatory proteins (tumor necrosis factor-alpha, interleukin-1beta and interleukin-6), oxidative stress factors (NADPH oxidase 2, inducible nitric oxide synthase and reactive oxygen species), and signaling molecules (nuclear factor kappa B and mitogen-activated protein kinase) in the hippocampus.	Acetates	0-7	interleukin 6	Mus musculus	109-122
32106625-3	2020	IAA significantly ameliorated LPS-induced expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) as well as generation of reactive oxidative species (ROS) and nitric oxide (NO).	indoleacetic acid	0-3	interleukin 6	Mus musculus	86-99
32106625-3	2020	IAA significantly ameliorated LPS-induced expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) as well as generation of reactive oxidative species (ROS) and nitric oxide (NO).	indoleacetic acid	0-3	interleukin 6	Mus musculus	101-105
32106625-6	2020	Interference of HO-1 activity by tin protoporphyrin IX (SnPP) impeded the alleviative effects of IAA on expression of IL-1beta and IL-6 induced by LPS, whereas demonstrated no effect on its suppression of ROS and NO production.	S-Nitroso-N-propionyl-D,L-penicillamine	56-60	interleukin 6	Mus musculus	131-135
32075957-8	2020	Further, we discovered that both the inhibitor of RIPK1 R-7-Cl-O-Necrostatin-1 (Nec-1s) and MLKL-inhibitor necrosulfonamide (NSA) suppressed necroptosis in HaCaT cells and IMQ mouse models, powerfully blocked IMQ-induced inflammatory responses in vivo, and significantly downregulated the production of inflammatory factors like IL-1beta, IL-6, IL-17A, IL-23a, CXCL1, and CCL20.	N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide	107-123	interleukin 6	Mus musculus	339-343
32075957-8	2020	Further, we discovered that both the inhibitor of RIPK1 R-7-Cl-O-Necrostatin-1 (Nec-1s) and MLKL-inhibitor necrosulfonamide (NSA) suppressed necroptosis in HaCaT cells and IMQ mouse models, powerfully blocked IMQ-induced inflammatory responses in vivo, and significantly downregulated the production of inflammatory factors like IL-1beta, IL-6, IL-17A, IL-23a, CXCL1, and CCL20.	N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide	125-128	interleukin 6	Mus musculus	339-343
32085388-2	2020	In this study, using a lipopolysaccharide (LPS)-induced macrophage cell model, we observed that coixol can effectively reduce the expression of interleukin (IL)-1beta, IL-6, IL-18, tumor necrosis factor (TNF)-alpha, nitric oxide (NO), inducible nitric oxide synthases (iNOS), and cyclooxygenase (COX)-2, but had no effect on the expression of the anti-inflammatory mediator IL-10.	6-methoxybenzoxazolinone	96-102	interleukin 6	Mus musculus	168-172
32079307-7	2020	In particular, AL extract decreased lipopolysaccharide (LPS)-mediated production and secretion of cytokines and chemokine, including IL-6, TNF-alpha, and MCP-1.	Aluminum	15-17	interleukin 6	Mus musculus	133-137
31887864-5	2020	VGPI-a had no cytotoxic effect on macrophage RAW264.7 cells in vitro and significantly enhanced the production and mRNA expression of NO, TNF-alpha, IL-6 and IL-1beta in a dose-dependent manner.	vgpi-a	0-6	interleukin 6	Mus musculus	149-153
31887935-8	2020	Moreover, CSO/Dex/LNPs could significantly reduce the expression of the inflammatory factors TNF-alpha, IL-6 and NO in LPS-stimulated RAW 264.7 cells.	Dexamethasone	14-17	interleukin 6	Mus musculus	104-108
31887935-12	2020	Furthermore, the expression levels of TNF-alpha, IL-6 and NO in the CSO/Dex/LNP-treated group were 37.4 %, 35.5 % and 33.2 % of those in mice with colitis, respectively.	Dexamethasone	72-75	interleukin 6	Mus musculus	49-53
32061917-6	2020	RESULTS: CUR and CIP treatment prevented the S. aureus-induced mouse mastitis increase the levels of IL-2, IL-10, and IFN-gamma and decrease levels of IL-6, IL-8, and TNF-alpha.	Curcumin	9-12	interleukin 6	Mus musculus	151-155
32061917-7	2020	Additionally, RT-PCR results showed that 20 mug/mL curcumin inhibited the mRNA expression of TNF-alpha, IL-6, IL-1beta, TRAF6 and MEKK1 in murine mammary epithelial cells (MMECs).	Curcumin	51-59	interleukin 6	Mus musculus	104-108
32116558-5	2020	Results: Expression levels of inflammatory factors (TNF-alpha, IL-1beta, and IL-6) were increased in mice after 4 weeks of alcohol exposure.	Alcohols	123-130	interleukin 6	Mus musculus	77-81
32026851-6	2020	RKI-1447 reduced the histological changes in the mouse model of NAFLD in mice fed a high-fat diet and significantly inhibited the generations of triglyceride, IL-6, and TNF-alpha.	RKI-1447	0-8	interleukin 6	Mus musculus	159-163
31515529-9	2020	In AVP-treated mice, pre-injection of SR49059 (2 mg/kg, iv) abolished AVP-induced NF-kappaB activation and IL-6 production in hearts.	relcovaptan	38-45	interleukin 6	Mus musculus	107-111
31939851-10	2020	Meanwhile, decreased expression of inflammatory mediators (TNF-alpha, interleukin 1beta, and interleukin 6), as well as decreased activation of astrocytes in the spinal cord, were found after 4-PBA or GSK2606414 treatment.	4-phenylbutylamine	192-197	interleukin 6	Mus musculus	93-106
31939851-10	2020	Meanwhile, decreased expression of inflammatory mediators (TNF-alpha, interleukin 1beta, and interleukin 6), as well as decreased activation of astrocytes in the spinal cord, were found after 4-PBA or GSK2606414 treatment.	7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine	201-211	interleukin 6	Mus musculus	93-106
30320514-2	2020	Pretreatment with 40% PeTP significantly inhibited the LPS-induced expression of nitric oxide (NO), prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and inflammatory cytokines, including tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 in RAW264.7 cells, without inducing cytotoxicity.	petp	22-26	interleukin 6	Mus musculus	293-297
31918274-12	2020	The in vitro data showed that pre-treatment of PI3 K/AKT specific inhibitor LY294002 remarkably abrogated GPR174 over-expression-accelerated expression levels of Iba-1, tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6 in lipopolysaccharide (LPS)-incubated retinal microglial cells.Furthermore, in LPS-exposed retinal microglial cells, PI3 K/AKT and NF-kappaB pathways were further promoted by GPR174 over-expression, which were significantlyabolished by LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	76-84	interleukin 6	Mus musculus	213-231
31144159-9	2020	After quercetin intervention, the areas of AS plaques and the expressions of PCSK9, TNF-alpha and IL-6 were significantly reduced (all P&lt;0.01), while the expressions of ABCA1 and LXR-alpha were increased significantly (all P&lt;0.01).	Quercetin	6-15	interleukin 6	Mus musculus	98-102
31796986-2	2020	In mice, IL-6 improved beta cell function and glucose homeostasis via upregulation of glucagon-like peptide 1 (GLP-1), and IL-6 release from muscle during exercise potentiated this beneficial increase in GLP-1.	Glucose	46-53	interleukin 6	Mus musculus	9-13
31760890-4	2020	The expression of GSK3beta, Nrf2, and NF-kappaB signaling pathways were measured by western blot analysis.Results: Apigenin significantly attenuated LPS-induced TNF-alpha, IL-1beta, and IL-6 production.	Apigenin	115-123	interleukin 6	Mus musculus	186-190
31863920-3	2020	Our results demonstrated that treatment with baicalein remarkably restrained the production of pro-inflammatory factors including nitric oxide (NO), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in LPS-activated BV-2 cells.	baicalein	45-54	interleukin 6	Mus musculus	149-162
31863920-3	2020	Our results demonstrated that treatment with baicalein remarkably restrained the production of pro-inflammatory factors including nitric oxide (NO), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in LPS-activated BV-2 cells.	baicalein	45-54	interleukin 6	Mus musculus	164-168
31748116-4	2020	A proliferation inducing ligand (APRIL) and IL-6 are also known to enhance Gd-IgA1 synthesis in IgAN.	Gadolinium	75-77	interleukin 6	Mus musculus	44-48
31748116-9	2020	However, siRNA knock-down of APRIL completely suppressed overproduction of Gd-IgA1 induced by IL-6.	Gadolinium	75-77	interleukin 6	Mus musculus	94-98
31748116-10	2020	Neutralization of IL-6 decreased CpG-oligonucleotide-induced overproduction of Gd-IgA1.	Gadolinium	79-81	interleukin 6	Mus musculus	18-22
31748116-11	2020	Furthermore, APRIL and IL-6 pathways each independently mediated TLR9-induced overproduction of Gd-IgA1.	Gadolinium	96-98	interleukin 6	Mus musculus	23-27
31748116-13	2020	Hence, APRIL and IL-6 synergistically, as well as independently, enhance synthesis of Gd-IgA1.	Gadolinium	86-88	interleukin 6	Mus musculus	17-21
31728888-11	2020	Ca2+-EA-ALG NPs were superior to free EA in improving increased IL-6 and TNF-alpha.	Calcium	0-4	interleukin 6	Mus musculus	64-68
31728888-11	2020	Ca2+-EA-ALG NPs were superior to free EA in improving increased IL-6 and TNF-alpha.	Ellagic Acid	5-7	interleukin 6	Mus musculus	64-68
31728888-11	2020	Ca2+-EA-ALG NPs were superior to free EA in improving increased IL-6 and TNF-alpha.	Ellagic Acid	38-40	interleukin 6	Mus musculus	64-68
31858378-8	2020	In this acute experiment, we showed that neuronal cultures exposed to desflurane significantly increased interleukin (IL)-6 expression and apoptotic gene caspase-3 activation.	desflurane	70-80	interleukin 6	Mus musculus	105-123
31781893-7	2020	VAT signal transducer and activator of transcription (STAT)3Tyr705 phosphorylation was lower, and VAT hormone-sensitive lipase (HSL)Ser563 phosphorylation was higher in IL-6 iMKO mice than in Floxed mice at rest.	seryl-seryl-seryl-arginine	132-135	interleukin 6	Mus musculus	169-173
31781893-10	2020	In conclusion, the present findings suggest that skeletal muscle IL-6 regulates markers of lipolysis in VAT in the basal state and pyruvate availability for glyceroneogenesis in VAT with exercise.	Pyruvates	131-139	interleukin 6	Mus musculus	65-69
31600583-7	2020	Empagliflozin induced significant decrease in lung weight/body weight ratio, BALF lactate dehydrogenase, total leucocytic count, IL-6, TNF-alpha, TLR4 and TGF-beta1 associated with significant decrease in lung tissue oxidative stress and hydroxyproline and significant increase in the survival rate and tissue Nrf2/HO-1 content compared to bleomycin group.	empagliflozin	0-13	interleukin 6	Mus musculus	129-133
31804693-5	2020	Intratracheal instillation of nZnO intensively aggravated LPS-induced lung inflammation that was accompanied by enhanced expression of interleukin-1beta, interleukin-6, monocyte chemotactic protein-1alpha, and granulocyte-macrophage colony stimulating factor.	nzno	30-34	interleukin 6	Mus musculus	154-167
32027284-10	2020	Compared with the endothelial progenitor cell group, the liver index was higher, the liver function was more abnormal, and the serum expression levels of TNF-alpha and IL-6 were higher in the monocrotaline group.	Monocrotaline	192-205	interleukin 6	Mus musculus	168-172
32076626-11	2020	Meanwhile, mangiferin increased antioxidant enzymes, reduced the TNF-alpha, IL-6, and IL-1beta, as well as MDA and ROS.	mangiferin	11-21	interleukin 6	Mus musculus	76-80
31654705-10	2020	Furthermore, RAW264 cells transfected with a miR-16-5p mimic significantly decreased the mRNA expression of IL-1beta, IL-6, and TNF-alpha under LPS stimulation.	mir-16-5p	45-54	interleukin 6	Mus musculus	118-122
32019160-5	2020	In accordance with these in vivo findings, the in vitro 1,25(OH)2D3 treatment decreased IL-6, MCP-1, and IL-1beta production by SVCs from obese mice, but not by adipocytes.	25-hydroxyvitamin D3-bromoacetate	56-67	interleukin 6	Mus musculus	88-92
31996242-11	2020	Fowlerstefin induced the expression of several pro-inflammatory cytokines and chemokines including IL-6 and TNF in BV-2 microglial cells.	fowlerstefin	0-12	interleukin 6	Mus musculus	99-103
31996242-12	2020	Fowlerstefin-induced expression of IL-6 and TNF in BV-2 microglial cells was regulated by mitogen-activated protein kinase (MAPKs).	fowlerstefin	0-12	interleukin 6	Mus musculus	35-39
31969555-0	2020	Blockade of IL-6 signaling prevents paclitaxel-induced neuropathy in C57Bl/6 mice.	Paclitaxel	36-46	interleukin 6	Mus musculus	12-16
31969555-6	2020	We demonstrate that adult C57BL/6 mice deficient in IL-6 are protected from developing functional and histological changes of paclitaxel-induced neuropathy.	Paclitaxel	126-136	interleukin 6	Mus musculus	52-56
31969555-7	2020	Furthermore, pretreatment with an IL-6-neutralizing antibody resulted in the prevention of paclitaxel-induced neuropathy in C57BL/6 mice.	Paclitaxel	91-101	interleukin 6	Mus musculus	34-38
32020864-0	2020	Ginsenoside Rb1 can ameliorate the key inflammatory cytokines TNF-alpha and IL-6 in a cancer cachexia mouse model.	Ginsenosides	0-11	interleukin 6	Mus musculus	76-80
31813960-8	2020	Aberrant expression of genes involved in vitamin A metabolism was associated with reduced basal mRNA levels of markers of inflammation (Cd68, Tnfalpha, Nos2, Il-6) and fibrosis (Col1a1, Acta2, Tgfbeta, Timp1) in livers of L-G6pc-/- mice.	vitamin A, vitamin E, vitamin K3 drug combination	41-50	interleukin 6	Mus musculus	158-162
31931804-10	2020	RESULTS: In the present paper we showed how NAC supplementation affected parameters of oxidative stress (GSH, MDA, SOD), inflammation such as cytokines levels (IL-1beta, IL-6, TNFalpha) and mast cell activation and consequently on induced pain, during leishmaniosis in BALB\c mice.	Acetylcysteine	44-47	interleukin 6	Mus musculus	170-174
31927537-5	2020	Accordingly, the upregulation of FMO3 mimicked the effects of CR: reduced serum levels of pro-inflammatory cytokine interleukin-6 and fasting insulin; relief of oxidative stress, with lower hepatic malondialdehyde levels and higher superoxide dismutase activity; reduced serum and hepatic levels of total cholesterol and triglyceride, as well as reduced lipid deposition in the liver; and diminished levels of aging-related markers beta-gal and p16.	Chromium	62-64	interleukin 6	Mus musculus	116-129
32420365-10	2020	The results showed that LCZ696 significantly improved heart dysfunction, cardiac hypertrophy, and fibrosis and inhibited the expression of proinflammatory factors IL-6, IL-1beta, and TNF-alpha in the circulating blood and heart tissues of mice.	sacubitril and valsartan sodium hydrate drug combination	24-30	interleukin 6	Mus musculus	163-167
31913329-11	2020	In hepatoma cell line, palmitate increased IL-6 and TNF-alpha expressions and pJNK level.	Palmitates	23-32	interleukin 6	Mus musculus	43-47
31935860-6	2020	Importantly, db-cAMP prevented IFN-gamma/LPS-induced macrophage polarization to M1-like as shown by increased Arg-1 associated to lower levels of M1 cytokines (TNF-alpha/IL-6) and p-STAT1.	Bucladesine	13-20	interleukin 6	Mus musculus	170-174
31998441-8	2020	Serotonin significantly facilitated the release of serum and intrahepatic inflammatory cytokines, including interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-17A (IL-17A), interferon-gamma (IFN-gamma), and tumor necrosis-alpha (TNF-alpha), after the administration of Con A.	Serotonin	0-9	interleukin 6	Mus musculus	145-149
31697926-12	2020	Over expression of TLR4/MyD88/NFkappaB axis and its downstream pro-inflammatory mediators TNF-alpha, IL6 and IFN-gamma were observed in CCl4 induced mice, and these indices were abrogated significantly after GA treatment.	ginkgolide A	208-210	interleukin 6	Mus musculus	101-104
31755162-8	2020	Improvements in physiological function occurred without significant changes in plasma, aortic, and skeletal muscle pro-inflammatory proteins (under resting conditions), whereas pro-/anti-inflammatory IL-6 was greater in recIL-37-treated animals.	recil	220-225	interleukin 6	Mus musculus	200-204
32160757-7	2020	Al-ME downregulated mRNA expression of inflammatory genes (inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2)) and pro-inflammatory cytokines (tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6).	al-me	0-5	interleukin 6	Mus musculus	225-229
32160757-10	2020	Al-ME ameliorated HCl/EtOH-induced gastritis symptoms in mice by suppressing iNOS and IL-6 mRNA expressions and IkappaBalpha phosphorylation.	al-me	0-5	interleukin 6	Mus musculus	86-90
32160757-10	2020	Al-ME ameliorated HCl/EtOH-induced gastritis symptoms in mice by suppressing iNOS and IL-6 mRNA expressions and IkappaBalpha phosphorylation.	Hydrochloric Acid	18-21	interleukin 6	Mus musculus	86-90
32160757-10	2020	Al-ME ameliorated HCl/EtOH-induced gastritis symptoms in mice by suppressing iNOS and IL-6 mRNA expressions and IkappaBalpha phosphorylation.	Ethanol	22-26	interleukin 6	Mus musculus	86-90
32308013-5	2020	In this study, Magnoliae Flos essential oil (MFEO) decreased the production of the cytokines TNF-alpha, IL-6, and IL-12p70 in lipopolysaccharide (LPS)-stimulated DCs.	magnoliae flos essential oil	15-43	interleukin 6	Mus musculus	104-108
32308013-5	2020	In this study, Magnoliae Flos essential oil (MFEO) decreased the production of the cytokines TNF-alpha, IL-6, and IL-12p70 in lipopolysaccharide (LPS)-stimulated DCs.	mfeo	45-49	interleukin 6	Mus musculus	104-108
32086110-8	2020	Although these phytochemicals did not modify telencephalic interleukin 6 production, quercetin augmented 2.51 fold interleukin 6 in the diencephalon, whereas 5 caffeoylquinic acid decreased it 0.43 fold.	Quercetin	85-94	interleukin 6	Mus musculus	115-128
32238714-6	2020	Moreover, DNLA treatment significantly downregulated expressions of interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, IL-6, nitric oxide synthase, janus kinase-signal transducer and activators of transcription (JAK-STATs) signaling in N2A cells, all of which were H2O2-induced.	dnla	10-14	interleukin 6	Mus musculus	127-131
31810123-6	2020	The results indicated that hepatic histopathological changes induced by DSS were normalized by vitexin treatment, administration of vitexin decreased the liver levels of ALT and TC in mice with liver injury and reduced the release amounts of DSS-induced pro-inflammatory cytokines TNF-alpha, IL-6 and IL-1beta.	vitexin	132-139	interleukin 6	Mus musculus	292-296
31634234-8	2020	MEASUREMENTS AND MAIN RESULTS: Serum agmatine levels were significantly decreased in patients with sepsis and lipopolysaccharide-induced mice, and correlated with Acute Physiology and Chronic Health Evaluation II score, procalcitonin, tumor necrosis factor-alpha, and interleukin-6 levels.	Agmatine	37-45	interleukin 6	Mus musculus	268-281
33267758-14	2020	The increased serum IL6 might mediate the retrorsine-induced downregulation of Cyp450s.	retrorsine	42-52	interleukin 6	Mus musculus	20-23
32065089-12	2020	Notably, productions of inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-6 or prostaglandin E2, which were enhanced by lipopolysaccharide (LPS), were repressed by culturing with metaxalone.	metaxalone	204-214	interleukin 6	Mus musculus	87-100
32065090-10	2020	Dexmedetomidine reduced the level of hippocampal IL-6, and it attenuated the increase in their levels caused by LPS.	Dexmedetomidine	0-15	interleukin 6	Mus musculus	49-53
31479873-6	2020	Besides, inhibition of autophagy by chloroquine or 3-methyladenin and its activation by rapamycin were associated with elevated mRNA and protein levels of IL-6 and TNF-alpha inflammatory cytokines in C2C12 cells.	Chloroquine	36-47	interleukin 6	Mus musculus	155-159
31971835-12	2020	Moreover, oral administration of AlCl3 to mice induced pathological alteration, MPO activation, and inflammatory cytokine (TNF-alpha, IL-1beta, and IL-6) production in the colon.	Aluminum Chloride	33-38	interleukin 6	Mus musculus	148-152
31816576-6	2020	Treatment with the five isosteroid alkaloids in appropriate concentrations could reduce the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) in supernatant, and suppressed the mRNA expressions of TNF-alpha and IL-6.	Alkaloids	24-44	interleukin 6	Mus musculus	169-182
31816576-6	2020	Treatment with the five isosteroid alkaloids in appropriate concentrations could reduce the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) in supernatant, and suppressed the mRNA expressions of TNF-alpha and IL-6.	Alkaloids	24-44	interleukin 6	Mus musculus	184-188
31816576-6	2020	Treatment with the five isosteroid alkaloids in appropriate concentrations could reduce the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) in supernatant, and suppressed the mRNA expressions of TNF-alpha and IL-6.	Alkaloids	24-44	interleukin 6	Mus musculus	259-263
32571120-6	2020	Our data revealed that phloretin reduced the process of epidermal thickening and decreased the infiltration of mast cells into the lesion regions, subsequently reducing the levels of histamine and the pro-inflammatory cytokines interleukin (IL)-6, IL-4, thymic stromal lymphopoietin (TSLP), interferon-gamma (IFN-gamma) and IL-17A in the serum.	Phloretin	23-32	interleukin 6	Mus musculus	228-246
31797546-0	2020	Hic-5 deficiency protects cerulein-induced chronic pancreatitis via down-regulation of the NF-kappaB (p65)/IL-6 signalling pathway.	Ceruletide	26-34	interleukin 6	Mus musculus	107-111
31797546-8	2020	We also found that the Hic-5 up-regulation by cerulein activated the NF-kappaB (p65)/IL-6 signalling pathway and regulated the downstream extracellular matrix (ECM) genes such as alpha-SMA and Col1a1.	Ceruletide	46-54	interleukin 6	Mus musculus	85-89
31680279-5	2020	The results showed that supplementation of STVRE with allopurinol significantly attenuated HU, oxidative stress, and inflammation caused by UA via inhibiting the production of uric acid and lowering cyclooxygenase-2, tumor necrosis factor-alpha, prostaglandin E2, interleukin-6, and interleukin 1-beta levels in serum and renal tissues.	Allopurinol	54-65	interleukin 6	Mus musculus	264-277
32523357-12	2020	In vivo experiment results showed that DWYG could shrink tumor size, recover ALT and AST, and decrease IL-6 levels.	dwyg	39-43	interleukin 6	Mus musculus	103-107
31895948-9	2020	RESULTS: CKD-506 suppressed the expression of pro-inflammatory cytokines such as IL-6, IL-8, and TNF-alpha in IECs and macrophages.	N-p-hydroxyphenyl-t-butylamine	9-16	interleukin 6	Mus musculus	81-85
32426105-6	2020	Results: Ghrelin therapy mitigated CI-induced increases in IL-1beta, IL-6, IL-17A, IL-18, KC, and TNF-alpha in serum but sustained G-CSF, KC and MIP-1alpha increases in ileum.	morin	35-37	interleukin 6	Mus musculus	69-73
32411289-8	2020	Moreover, uvaol significantly reduces mRNA expression and production of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, and MCP-1) and infiltration of macrophages in colonic tissues of colitis mice.	uvaol	10-15	interleukin 6	Mus musculus	111-115
32314992-6	2020	Both RLNP and RSNP led to a significant mitigation of mild to moderate experimental colitis, as evident from the substantial reduction of myeloperoxidase (MPO) and alkaline phosphatase (AP) activities (more than two-fold, P < 0.05) and various pro-inflammatory cytokine concentrations (TNF-alpha, IL-1beta, IL-6, IL-12).	rlnp	5-9	interleukin 6	Mus musculus	307-311
32314992-6	2020	Both RLNP and RSNP led to a significant mitigation of mild to moderate experimental colitis, as evident from the substantial reduction of myeloperoxidase (MPO) and alkaline phosphatase (AP) activities (more than two-fold, P < 0.05) and various pro-inflammatory cytokine concentrations (TNF-alpha, IL-1beta, IL-6, IL-12).	rsnp	14-18	interleukin 6	Mus musculus	307-311
32375831-11	2020	Treatment with ATO also attenuated demyelination, alleviated inflammation, reduced microglia activation, and decreased the expression levels of IL-2, IFN-gamma, IL-1beta, IL-6, and TNF-alpha in EAE mice.	Arsenic Trioxide	15-18	interleukin 6	Mus musculus	171-175
32380695-7	2020	EAU induction increased the levels of cytokines (interleukin (IL)-1alpha, IL-1beta, IL-4, IL-6, IL-12, IL-17, and tumor necrosis factor (TNF)-alpha) and chemokines (monocyte chemoattractant protein (MCP)-1) in the retinas of wild-type mice but not in those of Ncf1-/- mice.	Water	0-3	interleukin 6	Mus musculus	90-94
32084361-7	2020	(+)-Naltrexone suppressed the cPAF-induced expression of inflammatory cytokine genes, Il1b, Il6, and Il10 in the decidua, Il6, Il12b, and Il10 in the myometrium, and Il1b and Il6 in the placenta.	Naltrexone	0-14	interleukin 6	Mus musculus	92-95
32084361-7	2020	(+)-Naltrexone suppressed the cPAF-induced expression of inflammatory cytokine genes, Il1b, Il6, and Il10 in the decidua, Il6, Il12b, and Il10 in the myometrium, and Il1b and Il6 in the placenta.	Naltrexone	0-14	interleukin 6	Mus musculus	122-125
32084361-7	2020	(+)-Naltrexone suppressed the cPAF-induced expression of inflammatory cytokine genes, Il1b, Il6, and Il10 in the decidua, Il6, Il12b, and Il10 in the myometrium, and Il1b and Il6 in the placenta.	Naltrexone	0-14	interleukin 6	Mus musculus	122-125
32084361-7	2020	(+)-Naltrexone suppressed the cPAF-induced expression of inflammatory cytokine genes, Il1b, Il6, and Il10 in the decidua, Il6, Il12b, and Il10 in the myometrium, and Il1b and Il6 in the placenta.	1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine	30-34	interleukin 6	Mus musculus	92-95
32084361-7	2020	(+)-Naltrexone suppressed the cPAF-induced expression of inflammatory cytokine genes, Il1b, Il6, and Il10 in the decidua, Il6, Il12b, and Il10 in the myometrium, and Il1b and Il6 in the placenta.	1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine	30-34	interleukin 6	Mus musculus	122-125
32084361-7	2020	(+)-Naltrexone suppressed the cPAF-induced expression of inflammatory cytokine genes, Il1b, Il6, and Il10 in the decidua, Il6, Il12b, and Il10 in the myometrium, and Il1b and Il6 in the placenta.	1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine	30-34	interleukin 6	Mus musculus	122-125
31976547-10	2020	Moreover, luteolin treatment mitigated irinotecan-induced oxidative stress (i.e. by reducing the levels of ROS and LOOH, and augmenting endogenous antioxidants) and inflammation (i.e. through the decrease of MPO enzyme activity, TNF, IL-1beta, and IL-6 levels; and increasing IL-4 and IL-10).	Luteolin	10-18	interleukin 6	Mus musculus	248-252
31696375-9	2020	Atorvastatin reversed all these alterations in parallel with a decrease in circulating levels of cytokines (IL-1beta, IL-4, IL-6, and TNF-alpha) in plasma, inhibited the activities of oxidative stress parameters (lower TBARS levels, ratio of GSH/GSSH, and activities of SOD and CAT), enhanced the activity of citrate synthase in brain, and reduced the number of astrocytes and neuronal cell deaths in CA3 region of hippocampus.	atorvastatin	0-12	interleukin 6	Mus musculus	124-128
32594063-11	2020	On the other hand, resveratrol, and its combination with exercise training, attenuate the aging-related mitochondrial dysfunction involving Bad, caspase 3, and interleukin-6 expressions in SAMP8 mice.	Resveratrol	19-30	interleukin 6	Mus musculus	160-173
32377661-6	2020	Additionally, Pts remarkably reversed the LPS-induced inhibition of interleukin-10 and the release of tumor necrosis factor-alpha, interleukin-6 and interleukin-1beta.	pterostilbene	14-17	interleukin 6	Mus musculus	131-144
32171180-8	2020	Stimulation of hpGCs with DHT resulted in downregulation of PEDF mRNA expression, concomitantly with a significant increase in IL-6 and IL-8 mRNAs expression.	Dihydrotestosterone	26-29	interleukin 6	Mus musculus	127-131
32007662-0	2020	Maize extract rich in ferulic acid and anthocyanins prevents high-fat-induced obesity in mice by modulating SIRT1, AMPK and IL-6 associated metabolic and inflammatory pathways.	ferulic acid	22-34	interleukin 6	Mus musculus	124-128
32007662-0	2020	Maize extract rich in ferulic acid and anthocyanins prevents high-fat-induced obesity in mice by modulating SIRT1, AMPK and IL-6 associated metabolic and inflammatory pathways.	Anthocyanins	39-51	interleukin 6	Mus musculus	124-128
32471963-9	2020	RESULT: Our study showed that NIH 3T3 and RAW 264.7 coculture treated with metformin has higher collagen expression, but lower IL-6 mRNA expression compares to those on co-culture without treatment.	Metformin	75-84	interleukin 6	Mus musculus	127-131
32471963-10	2020	CONCLUSION: Metformin increases fibrosis markers in LPS and high glucose-induced NIH 3T3 and RAW 264.7 coculture despite its ability to improve IL-6 mRNA expression.	Metformin	12-21	interleukin 6	Mus musculus	144-148
32194087-9	2020	NMDEA suppressed the activation of IL-1beta and IL-6, in the hippocampus, and IL-1beta, IL-6, p65, and iNOS, in lipopolysaccharide (LPS)-induced BV-2 cells.	nmdea	0-5	interleukin 6	Mus musculus	48-52
32194087-9	2020	NMDEA suppressed the activation of IL-1beta and IL-6, in the hippocampus, and IL-1beta, IL-6, p65, and iNOS, in lipopolysaccharide (LPS)-induced BV-2 cells.	nmdea	0-5	interleukin 6	Mus musculus	88-92
32359619-6	2020	Furthermore, AGE receptor (RAGE), NFkappab, IL-6, and TNF-alpha gene expressions were downregulated (P < 0.05) by supplementing CCH.	1-acetyl-2-(coumariniminecarboxamide-3-yl)hydrazine	128-131	interleukin 6	Mus musculus	44-48
32232236-4	2020	Fucoxanthin also significantly attenuated the palmitate-induced transcriptional expression of Il-6, Il-1beta, Tnfalpha and Nlrp3 inflammasomes and increased the expression of Tgfb.	fucoxanthin	0-11	interleukin 6	Mus musculus	94-98
32232236-4	2020	Fucoxanthin also significantly attenuated the palmitate-induced transcriptional expression of Il-6, Il-1beta, Tnfalpha and Nlrp3 inflammasomes and increased the expression of Tgfb.	Palmitates	46-55	interleukin 6	Mus musculus	94-98
32410992-7	2020	Quercetin administration decreased lipid deposition in arterial lumina, serum sIcam-1, and IL-6 and Vcam-1 in aorta, while increased the density of Sirt1 in aorta of ApoE-/- mice.	Quercetin	0-9	interleukin 6	Mus musculus	91-95
32483416-10	2020	Furthermore, we found that anastrozole, berberine, and pranoprofen could promote Dicer expression and protect cells from hydrogen peroxide-induced DNA damage, thereby reducing cytosolic DNA and partially repressing interleukin-6 expression upon hydrogen peroxide treatment.	Anastrozole	27-38	interleukin 6	Mus musculus	215-228
32483416-10	2020	Furthermore, we found that anastrozole, berberine, and pranoprofen could promote Dicer expression and protect cells from hydrogen peroxide-induced DNA damage, thereby reducing cytosolic DNA and partially repressing interleukin-6 expression upon hydrogen peroxide treatment.	Berberine	40-49	interleukin 6	Mus musculus	215-228
32483416-10	2020	Furthermore, we found that anastrozole, berberine, and pranoprofen could promote Dicer expression and protect cells from hydrogen peroxide-induced DNA damage, thereby reducing cytosolic DNA and partially repressing interleukin-6 expression upon hydrogen peroxide treatment.	pyranoprofen	55-66	interleukin 6	Mus musculus	215-228
32483416-10	2020	Furthermore, we found that anastrozole, berberine, and pranoprofen could promote Dicer expression and protect cells from hydrogen peroxide-induced DNA damage, thereby reducing cytosolic DNA and partially repressing interleukin-6 expression upon hydrogen peroxide treatment.	Hydrogen Peroxide	245-262	interleukin 6	Mus musculus	215-228
32091204-0	2020	Phytol, a Chlorophyll Component, Produces Antihyperalgesic, Anti-inflammatory, and Antiarthritic Effects: Possible NFkappaB Pathway Involvement and Reduced Levels of the Proinflammatory Cytokines TNF-alpha and IL-6.	Phytol	0-6	interleukin 6	Mus musculus	210-214
31800022-7	2020	Further, the nitric oxide concentration in lipopolysaccharide-simulated macrophage RAW 264.7 cells and the pro-inflammatory cytokines (TNF-alpha and IL-6) were suppressed by acetic ether extract.	Nitric Oxide	13-25	interleukin 6	Mus musculus	149-153
31800022-7	2020	Further, the nitric oxide concentration in lipopolysaccharide-simulated macrophage RAW 264.7 cells and the pro-inflammatory cytokines (TNF-alpha and IL-6) were suppressed by acetic ether extract.	acetic ether extract	174-194	interleukin 6	Mus musculus	149-153
32331440-5	2020	We demonstrate that O-Vanillin inhibits the TLR2 mediated upregulation of MMP 9, MMP 14, IL 6 and iNOS expression.	2-vanillin	20-30	interleukin 6	Mus musculus	89-93
32391376-5	2020	The results showed that b-AP15 treatment significantly reduced the amounts of inflammatory indicators, such as tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) in lipopolysaccharide (LPS)-stimulated THP-1 and macrophages.	b-AP15	24-30	interleukin 6	Mus musculus	155-168
32391376-5	2020	The results showed that b-AP15 treatment significantly reduced the amounts of inflammatory indicators, such as tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) in lipopolysaccharide (LPS)-stimulated THP-1 and macrophages.	b-AP15	24-30	interleukin 6	Mus musculus	170-174
32373115-6	2020	Triptolide significantly reduced infiltration of T lymphocytes and macrophages and inhibited the levels of pro-inflammatory (TNF-alpha, IL-2, and IL-6) and pro-fibrotic factors (TGF-beta, alpha-SMA, and MMP-9) in the graft.	triptolide	0-10	interleukin 6	Mus musculus	146-150
32312281-10	2020	RESULTS: AEW treatment triggers spontaneous scratching and significantly increases the expression of NLRP1, ASC, and caspase-1 and the levels of IL-1beta, IL-18, IL-6, and TNF-alpha in the spinal cord and the skin of mice.	1-(3-Amino-2-Methylbenzyl)-4-Hexylpyridin-2(1h)-One	9-12	interleukin 6	Mus musculus	162-166
32312317-8	2020	Furthermore, in NG-34 stimulated mice splenocytes, cytokine levels of IFN-gamma, IL-1beta, IL-6, IL-10, IL-17 and TNF-alpha were also the highest in the CAF01 + NG-34 mouse group.	caf01	153-158	interleukin 6	Mus musculus	91-95
32295122-9	2020	Furthermore, mice treated with Ogliarola, Coratina and Cima di Mola EVO displayed a reduction of rectal bleeding and IL-1beta, TGFbeta, IL-6 gene expression levels.	ogliarola	31-40	interleukin 6	Mus musculus	136-140
32295122-9	2020	Furthermore, mice treated with Ogliarola, Coratina and Cima di Mola EVO displayed a reduction of rectal bleeding and IL-1beta, TGFbeta, IL-6 gene expression levels.	SCHEMBL9731684	68-71	interleukin 6	Mus musculus	136-140
32447932-14	2020	Low-dose chidamide significantly increased the number and proportion of nTreg cells in mouse splenocytes, and decreased serum IL-6 level in active ITP mice.	N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide	9-18	interleukin 6	Mus musculus	126-130
32351320-7	2020	Furthermore, MitoQ inhibited the LPS-induced intestinal oxidative stress and inflammatory response, evidenced by increased levels of intestinal superoxide dismutase and glutathione, and decreased levels of intestinal IL-1, IL-6, TNF-alpha, and nitric oxide levels.	mitoquinone	13-18	interleukin 6	Mus musculus	223-227
32328062-7	2020	The oral administration of L. plantarum WT to mice prior the intraperitoneal injection of poly(I:C) significantly increased IFN-beta and IL-10 and reduced intraepithelial lymphocytes (CD3+NK1.1+CD8alphaalpha+) and pro-inflammatory mediators (TNF-alpha, IL-6, and IL-15) in the intestinal mucosa.	Poly I-C	90-99	interleukin 6	Mus musculus	253-257
32268567-9	2020	Oral administration of GOS and CTP significantly lowered the tissue cytokine (interleukin-6 and -12, and tumor necrosis factor-alpha) levels.	D-Glucitol-1,6-bisphosphate	23-26	interleukin 6	Mus musculus	78-99
32268567-9	2020	Oral administration of GOS and CTP significantly lowered the tissue cytokine (interleukin-6 and -12, and tumor necrosis factor-alpha) levels.	Cytidine Triphosphate	31-34	interleukin 6	Mus musculus	78-99
32373209-11	2020	PTL treatment downregulated the level of proinflammatory cytokines, including IL-1beta, TNF-alpha, IL-6, and IL-17A and upregulated the immunosuppressive cytokine IL-10 in colon tissue.	parthenolide	0-3	interleukin 6	Mus musculus	99-103
31931676-8	2020	In the intraperitoneal macrophages, DOX increased Clock (ZT10), Rev-Erbalpha (ZT18 and ZT22) and Per2 expressions (ZT18); in the LLC+DOX group was increased Bmal1 (ZT10), Per2 (ZT18) and NF-kB (ZT22) expressions; IL-6 expression increased in the LCC group (ZT02).	Doxorubicin	36-39	interleukin 6	Mus musculus	213-217
31931676-8	2020	In the intraperitoneal macrophages, DOX increased Clock (ZT10), Rev-Erbalpha (ZT18 and ZT22) and Per2 expressions (ZT18); in the LLC+DOX group was increased Bmal1 (ZT10), Per2 (ZT18) and NF-kB (ZT22) expressions; IL-6 expression increased in the LCC group (ZT02).	Doxorubicin	133-136	interleukin 6	Mus musculus	213-217
32170468-7	2020	Further study showed that proline supplementation decreased (P < 0.05) the concentrations of (1) interleukin (IL)-23, IL-1alpha, and IL-6 in plasma; (2) IL-6 in the uterus; and (3) tumor necrosis factor alpha (TNF-alpha), monocyte chemotactic protein (MCP)-1, and IL-17 in the placenta; and (4) interferon (IFN)-gamma in amniotic fluid, compared with controls.	Proline	26-33	interleukin 6	Mus musculus	133-137
32170468-7	2020	Further study showed that proline supplementation decreased (P < 0.05) the concentrations of (1) interleukin (IL)-23, IL-1alpha, and IL-6 in plasma; (2) IL-6 in the uterus; and (3) tumor necrosis factor alpha (TNF-alpha), monocyte chemotactic protein (MCP)-1, and IL-17 in the placenta; and (4) interferon (IFN)-gamma in amniotic fluid, compared with controls.	Proline	26-33	interleukin 6	Mus musculus	153-157
32085963-5	2020	Immunoassay results showed that the five polysaccharides not only promoted the growth of RAW264.7 cells but also stimulated their endocytic/pinocytosis activity and released NO, TNF, IL-6 cytokines, especially BRP.	Polysaccharides	41-56	interleukin 6	Mus musculus	183-187
32020377-6	2020	We found that cisplatin-resistant HNSCC expressed higher levels of N-Cadherin and IL-6, which were significantly inhibited by CmpdA.	Cisplatin	14-23	interleukin 6	Mus musculus	82-86
31062080-11	2020	Gene expression of interleukin-6 was suppressed by GLN supplementation, while expression levels of the peroxisome proliferator-activated receptor gamma and myogenic differentiation 1 genes were elevated in post-ischemic muscles.	Glutamine	51-54	interleukin 6	Mus musculus	19-32
31552548-3	2020	The results showed that CAR caused hemorrhaging and exudation of lung tissues and the release of inflammatory factors (TNF-alpha, IL-6 and IL-1beta), effects that were significantly reduced by treatment with Ori.	oridonin	208-211	interleukin 6	Mus musculus	130-134
31757675-4	2020	Arginine supplementation significantly increased (P &lt; 0.05) cytokines expression in mouse ileal associated with T cell-dependent and T cell-independent pathways of SIgA induction, including IL-5, IL-6, IL-13, transforming growth factor (TGF-)beta2, TGF-beta3, TGF-betaR2, a proliferation-inducing ligand (APRIL), B cell-activating factor (BAFF), vasoactive intestinal peptide (VIP) receptor, and retinal dehydrogenases.	Arginine Vasopressin	0-8	interleukin 6	Mus musculus	199-203
31771816-5	2020	NaHS significantly increased the expressions of tight junction proteins (i.e., ZO-1, Occludin and claudin-1), and reduced apoptosis and secretion of pro-inflammatory cytokines (i.e., TNF-alpha, IL-6 and IL-1beta) in CS-exposed mouse lungs and CSE-incubated A549 cells, indicating H2S inhibits CS-induced inflammation, injury and apoptosis in alveolar epithelial cells.	Sodium	0-4	interleukin 6	Mus musculus	194-198
32062075-7	2020	SSd treatment (8 mg/kg) significantly suppressed the mRNA levels of pro-inflammatory cytokines including TNF-alpha, IL-6 and IL-1beta, increased that of anti-inflammatory cytokine IL-10.	saikosaponin D	0-3	interleukin 6	Mus musculus	116-120
32144443-8	2020	RESULTS: GA suppressed the ET-induced neutrophil infiltration, elevated MPO activity and production of pro-inflammatory cytokines (IL-6/TNF-alpha/IL-1beta) at 24 h. Reduced inflammation was accompanied with normalization of redox balance as reflected by ROS/GSH/MDA/protein carbonyl levels.	Gallic Acid	9-11	interleukin 6	Mus musculus	131-135
32164044-0	2020	Inhibition of Interleukin-6/glycoprotein 130 signalling by Bazedoxifene ameliorates cardiac remodelling in pressure overload mice.	bazedoxifene	59-71	interleukin 6	Mus musculus	14-27
32164044-2	2020	Our group demonstrated that Bazedoxifene suppressed IL-6/gp130 signalling in cancer cells but its effect on myocardial pathology induced by pressure overload is still unknown.	bazedoxifene	28-40	interleukin 6	Mus musculus	52-56
32164044-7	2020	We found Bazedoxifene decreased the mRNA expression of IL-6, MMP2, Col1A1, Col3A1 and periostin in murine hearts after 8-week surgery.	bazedoxifene	9-21	interleukin 6	Mus musculus	55-59
32164044-11	2020	In H9c2 myoblasts, Bazedoxifene suppressed the IL-6-induced STAT3 activation.	bazedoxifene	19-31	interleukin 6	Mus musculus	47-51
32164044-13	2020	Our data suggested Bazedoxifene inhibited IL-6/gp130 signalling and protected against cardiac remodelling together with function deterioration in TAC mice.	bazedoxifene	19-31	interleukin 6	Mus musculus	42-46
31486527-3	2020	Administration of a specific Nln inhibitor Agaricoglyceride A (AgaA) to mice after stroke in a middle cerebral artery occlusion model (MCAO), dose-dependently aggravated injury measured by increased infarct and edema volumes, blood-brain barrier disruption, increased levels of IL-6 and MCP-1, neurological and motor deficit 24 h after stroke.	agaricoglyceride A	43-61	interleukin 6	Mus musculus	278-282
31486527-3	2020	Administration of a specific Nln inhibitor Agaricoglyceride A (AgaA) to mice after stroke in a middle cerebral artery occlusion model (MCAO), dose-dependently aggravated injury measured by increased infarct and edema volumes, blood-brain barrier disruption, increased levels of IL-6 and MCP-1, neurological and motor deficit 24 h after stroke.	agaricoglyceride A	63-67	interleukin 6	Mus musculus	278-282
32186945-6	2020	MCG-PC significantly suppressed colonic neoplasia and decreased the levels of various cytokines (tumor necrosis factor: Tnf, interleukin 1 beta: Il1b, interleukin 6: Il6, and interferon gamma: Ifngamma) in serum and colon tissue of the CRC mice.	mcg-pc	0-6	interleukin 6	Mus musculus	151-164
32186945-6	2020	MCG-PC significantly suppressed colonic neoplasia and decreased the levels of various cytokines (tumor necrosis factor: Tnf, interleukin 1 beta: Il1b, interleukin 6: Il6, and interferon gamma: Ifngamma) in serum and colon tissue of the CRC mice.	mcg-pc	0-6	interleukin 6	Mus musculus	166-169
31909648-5	2020	In vitro experiments showed that CuInS2/ZnS QDs were taken up by cells, promoted cell viability, enhanced release of tumor necrosis factor-alpha, and decreased the level of interleukin (IL)-6 in response to lipopolysaccharide stimulation.	cupric sulfide	33-39	interleukin 6	Mus musculus	173-191
31909648-5	2020	In vitro experiments showed that CuInS2/ZnS QDs were taken up by cells, promoted cell viability, enhanced release of tumor necrosis factor-alpha, and decreased the level of interleukin (IL)-6 in response to lipopolysaccharide stimulation.	Zinc	40-43	interleukin 6	Mus musculus	173-191
31121086-9	2020	Concomitantly, both hemin and DMF significantly reduced the increased interleukin-6 levels and the elevated leukocyte infiltration in the muscularis.	Hemin	20-25	interleukin 6	Mus musculus	70-83
31121086-9	2020	Concomitantly, both hemin and DMF significantly reduced the increased interleukin-6 levels and the elevated leukocyte infiltration in the muscularis.	Dimethyl Fumarate	30-33	interleukin 6	Mus musculus	70-83
31950453-2	2020	Significantly, lower levels of pro-inflammatory cytokines including interleukin (IL)-17, interferon-gamma, Il6, Il12a, and Il23a were observed in brains of daphnetin-treated EAE mice, compared with those in control littermates.	daphnetin	156-165	interleukin 6	Mus musculus	107-110
31950453-3	2020	We also confirmed that daphnetin suppressed the production of IL-1beta, IL-6, and tumor necrosis factor-alpha in lipopolysaccharide-stimulated mouse BV2 microglial cells.	daphnetin	23-32	interleukin 6	Mus musculus	72-76
30032721-3	2020	To elucidate this mechanism, the effect of fatty acids on the expression of the pro-inflammatory cytokines IL-6 and TNFalpha was investigated in the mHypoE-N42 hypothalamic cell line (N42).	Fatty Acids	43-54	interleukin 6	Mus musculus	107-111
32040762-3	2020	This study aims to investigate the expressions of IL-6, MIP-2, and MCP-5, as biomarkers in relation with MeHg-induced CNS impairment and N-acetyl-L-cysteine (NAC) treatment in mice, as well as histopathological changes of brain tissue and clinical symptom such as ataxia.	Mercury	105-109	interleukin 6	Mus musculus	50-54
32040762-3	2020	This study aims to investigate the expressions of IL-6, MIP-2, and MCP-5, as biomarkers in relation with MeHg-induced CNS impairment and N-acetyl-L-cysteine (NAC) treatment in mice, as well as histopathological changes of brain tissue and clinical symptom such as ataxia.	Acetylcysteine	137-156	interleukin 6	Mus musculus	50-54
32040762-5	2020	MeHg induced the expression of IL-6, MIP-2, and MCP-5 in the serum, with median values (those in controls) of 55.06 (9.44), 15.94 (9.30), and 458.91 (239.91) mg/dl, respectively, and a statistical significance was observed only in IL-6 expression (p &lt; 0.05).	Mercury	0-4	interleukin 6	Mus musculus	31-35
32040762-5	2020	MeHg induced the expression of IL-6, MIP-2, and MCP-5 in the serum, with median values (those in controls) of 55.06 (9.44), 15.94 (9.30), and 458.91 (239.91) mg/dl, respectively, and a statistical significance was observed only in IL-6 expression (p &lt; 0.05).	Mercury	0-4	interleukin 6	Mus musculus	231-235
32040762-7	2020	MeHg treatment also increased IL-6 expression in the cerebellum (7.73 and 4.81 mg/dl in MeHg-treated group and controls, respectively), with a marginal significance.	Mercury	0-4	interleukin 6	Mus musculus	30-34
32040762-7	2020	MeHg treatment also increased IL-6 expression in the cerebellum (7.73 and 4.81 mg/dl in MeHg-treated group and controls, respectively), with a marginal significance.	Mercury	88-92	interleukin 6	Mus musculus	30-34
32040762-8	2020	NAC significantly suppressed MeHg-induced IL-6 and MIP-2 expressions in the serum (p &lt; 0.05 for both), and slightly reduced MCP-5 expression in the cerebrum.	Acetylcysteine	0-3	interleukin 6	Mus musculus	42-46
32040762-8	2020	NAC significantly suppressed MeHg-induced IL-6 and MIP-2 expressions in the serum (p &lt; 0.05 for both), and slightly reduced MCP-5 expression in the cerebrum.	Mercury	29-33	interleukin 6	Mus musculus	42-46
32040762-10	2020	These findings suggest that MeHg induced neurotoxicity by elevating the expression of IL-6, MIP-2, and MCP-5 and causing ataxia symptoms, and NAC reduced MeHg-mediated effects on the CNS.	Mercury	28-32	interleukin 6	Mus musculus	86-90
32040762-10	2020	These findings suggest that MeHg induced neurotoxicity by elevating the expression of IL-6, MIP-2, and MCP-5 and causing ataxia symptoms, and NAC reduced MeHg-mediated effects on the CNS.	Mercury	30-32	interleukin 6	Mus musculus	86-90
32302067-0	2020	beta2-adrenergic stimulation induces interleukin-6 by increasing Arid5a, a stabilizer of mRNA, through cAMP/PKA/CREB pathway in cardiac fibroblasts.	Cyclic AMP	103-107	interleukin 6	Mus musculus	37-50
32302067-9	2020	The activation of adenylate cyclase and the enhancement of intracellular cAMP resulted in the upregulation of IL-6 mRNA expression.	Cyclic AMP	73-77	interleukin 6	Mus musculus	110-114
32302067-11	2020	Concomitant with IL-6, the expression of Arid5a, an IL-6 mRNA stabilizing factor, was enhanced by beta2-adrenergic stimulation and by cAMP increase.	Cyclic AMP	134-138	interleukin 6	Mus musculus	17-21
32302067-11	2020	Concomitant with IL-6, the expression of Arid5a, an IL-6 mRNA stabilizing factor, was enhanced by beta2-adrenergic stimulation and by cAMP increase.	Cyclic AMP	134-138	interleukin 6	Mus musculus	52-56
32302067-14	2020	CONCLUSION AND IMPLICATIONS: beta2-adrenergic stimulation post-transcriptionally upregulates the expression of IL-6 by the induction of Arid5a through cAMP/PKA/CREB pathway in adult CFs.	Cyclic AMP	151-155	interleukin 6	Mus musculus	111-115
32256179-12	2020	The increase in the immunoreactivity of IL-6 on day 1 was decreased on day 7 in the spleens of mice treated with 20 nm or 50 nm AuNPs.	aunps	128-133	interleukin 6	Mus musculus	40-44
32257389-0	2020	Atorvastatin-induced senescence of hepatocellular carcinoma is mediated by downregulation of hTERT through the suppression of the IL-6/STAT3 pathway.	Atorvastatin	0-12	interleukin 6	Mus musculus	130-134
32257389-8	2020	Atorvastatin-induced senescence was independent of p53, p14, and p16, and atorvastatin not only decreased the secretion of IL-6, a major senescence-associated secretory phenotype (SASP) factor, and the phosphorylation of STAT3 but also inhibited the expression of hTERT, a catalytic subunit of telomerase.	Atorvastatin	74-86	interleukin 6	Mus musculus	123-127
32257389-9	2020	Supplementation with exogenous IL-6 reversed both atorvastatin-induced suppression of STAT3 phosphorylation and hTERT expression and atorvastatin-induced senescence.	Atorvastatin	50-62	interleukin 6	Mus musculus	31-35
32221318-5	2020	We found that Al particles and BTZ attenuated the expression of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).	Aluminum Oxide	14-16	interleukin 6	Mus musculus	98-102
32221318-5	2020	We found that Al particles and BTZ attenuated the expression of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).	Bortezomib	31-34	interleukin 6	Mus musculus	98-102
32273685-6	2020	Results: In vitro, IL-1beta-induced activation of inflammatory factors (TNF-alpha, IL-6, INOS and COX2) was dramatically suppressed by Morusin.	morusin	135-142	interleukin 6	Mus musculus	83-87
32265711-11	2020	Moreover, CA4P exacerbated the pathological features of colitis and significantly increased proinflammatory cytokines (IL-1beta, IL-6, TNF-alpha) and inflammatory cells (neutrophil, lymphocyte, monocyte).	fosbretabulin	10-14	interleukin 6	Mus musculus	129-133
31955888-8	2020	The inflammatory IL-6 response was comparable between WT and C3 deficient mice, however, it was decreased in CD14 and C3CD14 deficient mice.	c3cd14	118-124	interleukin 6	Mus musculus	17-21
31953338-8	2020	The expression of IL-6 in the liver of obese mice was decreased following the administration of A. muciniphila Furthermore, alterations in the Firmicutes to Bacteroidetes ratio and decrease in bacterial diversity caused by the HFD were restored upon the administration of A. muciniphila These results indicate that A. muciniphila prevents fatty liver disease in obese mice by regulating TG synthesis in the liver and maintaining gut homeostasis.Importance This study investigated the effect of Akkermansia muciniphila on fatty liver disease.	Triglycerides	387-389	interleukin 6	Mus musculus	18-22
32183436-6	2020	The production of other proinflammatory mediators, including COX-2, interleukin (IL)-6, IL-1beta, and tumor necrosis factor (TNF)-alpha, was reduced by ALDE in LPS-stimulated RAW 264.7 cells.	alde	152-156	interleukin 6	Mus musculus	68-86
32256654-11	2020	In addition, CPT-11 increased the productions of tumor necrosis factor-alpha (TNF-alpha), tumor necrosis factor-beta (TNF-beta), interleukin-6 (IL-6), and interleukin-1 (IL-1), but decreased interleukin-15 (IL-15), interleukin-7 (IL-7), and uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1).	Irinotecan	13-19	interleukin 6	Mus musculus	129-142
32256654-11	2020	In addition, CPT-11 increased the productions of tumor necrosis factor-alpha (TNF-alpha), tumor necrosis factor-beta (TNF-beta), interleukin-6 (IL-6), and interleukin-1 (IL-1), but decreased interleukin-15 (IL-15), interleukin-7 (IL-7), and uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1).	Irinotecan	13-19	interleukin 6	Mus musculus	144-148
32256661-8	2020	The expression of TNF-alpha and IL-6 was increased, and the expression of IL-10 and TGF-beta was decreased in IL-4-induced RAW264.7 cells treated with TCM.	tcm	151-154	interleukin 6	Mus musculus	32-36
31862360-7	2020	Treatment with GDR-TPT nanoparticles resulted in a marked decrease in the infiltration of CD3+ T cells and F4/80+ macrophages and reduction of the expression of TNF-alpha, IL-6 and IL-1beta in the inflamed lesions of CIA mice.	triptolide	19-22	interleukin 6	Mus musculus	172-176
31977586-11	2020	Taken together, metformin mitigates LPS-induced depressive-like behavior in mice by regulating the expression level of Lcn-2 and inflammation-related molecules, including IL-1beta, IL-6 and vWF.Video abstract: http://links.lww.com/WNR/A568.	Metformin	16-25	interleukin 6	Mus musculus	181-185
32132609-7	2020	Our results revealed that PGB significantly inhibited the secretion of ConA-induced IL-6 secretion, basal and ConA-induced TNF-alpha and IL-2 secretion in splenocytes in vitro.	Pregabalin	26-29	interleukin 6	Mus musculus	84-88
32132609-8	2020	In vivo, PGB inhibited basal and LPS/ConA-induced IL-6 and TNF-alpha secretion in addition to LPS-induced IL-1beta and ConA-induced IL-2 secretion.	Pregabalin	9-12	interleukin 6	Mus musculus	50-54
31530901-5	2020	PE injection caused cardiac dysfunction and cardiac inflammation, evidenced by the increased expression of inflammatory cytokine IL-6 and chemokines MCP-1 and MCP-5, as well as macrophage infiltration in myocardium.	Phenylephrine	0-2	interleukin 6	Mus musculus	129-133
31918345-9	2020	Auto-polymerized and bisacrylic resins increased IL-6, IL-1beta and TNF-alpha levels mainly at 24 h when compared to the other materials (P < .001).	bisacrylic	21-31	interleukin 6	Mus musculus	49-53
31785407-0	2020	Interleukin-6 plays a critical role in aldosterone-induced macrophage recruitment and infiltration in the myocardium.	Aldosterone	39-50	interleukin 6	Mus musculus	0-13
31785407-2	2020	We hypothesized that IL-6 may be a key mediator of aldosterone-induced macrophage recruitment and infiltration.	Aldosterone	51-62	interleukin 6	Mus musculus	21-25
31785407-9	2020	The increase in F4/80-positive cells in the myocardium was suppressed in the aldosterone-infused mice with the aldosterone antagonist eplerenone or anti-IL-6 antibody treatment.	Aldosterone	77-88	interleukin 6	Mus musculus	153-157
31785407-10	2020	In conclusion, interleukin-6 played an important role in aldosterone-induced macrophage recruitment and infiltration in the myocardium.	Aldosterone	57-68	interleukin 6	Mus musculus	15-28
32057287-11	2020	Also, in ALI mice, low dosage of TM attenuated goblet cell proliferation of tracheal wall, and declined LW/BW ratio, ELGV, total cells and neutrophils, protein concentrations in BALF, and IL-6 and TNF-alpha expression in lung tissues and BALF.	Tunicamycin	33-35	interleukin 6	Mus musculus	188-192
32245588-6	2020	BM at 5-20 mumol L-1 significantly inhibited lipopolysaccharide (LPS) or acetate-induced IL-1beta and IL-6 mRNA expression in RAW264.7 cells.	Acetates	73-80	interleukin 6	Mus musculus	102-106
31931366-4	2020	DMB significantly inhibited the infiltration of CD4+ T cell and Kupffer cell as well as the expression of inflammatory cytokines, such as TNF-alpha, IL-6, IL-1beta and IFN-gamma by ELISA and qPCR analysis.	demethyleneberberine	0-3	interleukin 6	Mus musculus	149-153
31958741-3	2020	In this study, we have shown that lidocaine dose-dependently inhibits lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in macrophages and that lidocaine protects mice from LPS-induced inflammation.	Lidocaine	34-43	interleukin 6	Mus musculus	161-174
31958741-3	2020	In this study, we have shown that lidocaine dose-dependently inhibits lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in macrophages and that lidocaine protects mice from LPS-induced inflammation.	Lidocaine	34-43	interleukin 6	Mus musculus	176-180
31958741-3	2020	In this study, we have shown that lidocaine dose-dependently inhibits lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in macrophages and that lidocaine protects mice from LPS-induced inflammation.	Lidocaine	206-215	interleukin 6	Mus musculus	176-180
31958741-4	2020	Moreover, we have demonstrated that lidocaine reduces the release of TNF-alpha and IL-6 through the reduction of the expression of GLUT1 and HK2 to further suppress HIF1alpha-induced aggravation of inflammatory cascades.	Lidocaine	36-45	interleukin 6	Mus musculus	83-87
31970902-7	2020	Exposure of cultured primary macrophages to VitB6 increased AMP-activated protein kinase (AMPK) Thr172 phosphorylation in a time/dose-dependent manner, which was inhibited by compound C. VitB6 downregulated the inflammatory gene expressions including IL-1beta, IL-6 and TNF-alpha in macrophages challenged with LPS.	Vitamin B 6	44-49	interleukin 6	Mus musculus	261-265
31970902-7	2020	Exposure of cultured primary macrophages to VitB6 increased AMP-activated protein kinase (AMPK) Thr172 phosphorylation in a time/dose-dependent manner, which was inhibited by compound C. VitB6 downregulated the inflammatory gene expressions including IL-1beta, IL-6 and TNF-alpha in macrophages challenged with LPS.	Adenosine Monophosphate	60-63	interleukin 6	Mus musculus	261-265
31970902-7	2020	Exposure of cultured primary macrophages to VitB6 increased AMP-activated protein kinase (AMPK) Thr172 phosphorylation in a time/dose-dependent manner, which was inhibited by compound C. VitB6 downregulated the inflammatory gene expressions including IL-1beta, IL-6 and TNF-alpha in macrophages challenged with LPS.	Vitamin B 6	187-192	interleukin 6	Mus musculus	261-265
31707050-12	2020	The effect of SF-PQR on reversing immunosuppression induced by cyclophosphamide was significantly reduced (P < 0.05) evidenced by the inhibition of net growth rate of body weight, immune organ index, IL-6 level and SOD activity.	Cyclophosphamide	63-79	interleukin 6	Mus musculus	200-204
31248758-12	2020	When treated with Ach, significantly more relaxation was found in the nonthrombosed control IVC segments than in those IVC segments that had had a 2D thrombus from either ligation- or stenosis-derived thrombotic mechanisms in both WT and IL-6-/- mice.	Acetylcholine	18-21	interleukin 6	Mus musculus	238-242
31809762-6	2020	The results revealed that treatment with GW9508 could significantly ameliorate cognitive deficits of APP/PS1 mice, upregulate the expression levels of cAMP, p-CREB and neurotrophic factors in vivo, while GW9508 also ameliorate Abeta1-42-induced neuron damage and downregulate the expression levels of pathological protein such as p-JNK, JNK and apoptosis-related proteins such as IL-6, IL-1beta, TNF-alpha and caspase-3 in vitro.	GW9508	41-47	interleukin 6	Mus musculus	380-384
32146607-0	2020	Reactive oxygen species play a role in P2X7 receptor-mediated IL-6 production in spinal astrocytes.	Oxygen	9-15	interleukin 6	Mus musculus	62-66
32146607-8	2020	In addition, our ELISA data show that P2X7R-induced IL-6 release was dependent on NADPH oxidase-mediated production of ROS.	Reactive Oxygen Species	119-122	interleukin 6	Mus musculus	52-56
32146607-9	2020	Collectively, these results reveal that activation of the P2X7 receptor on spinal astrocytes increases ROS production through NADPH oxidase, subsequently leading to IL-6 release.	Reactive Oxygen Species	103-106	interleukin 6	Mus musculus	165-169
32121228-7	2020	The results demonstrate that TA suppressed the lung histological changes in CS-exposed mice, as evidenced by the diminished generation of pro-inflammatory cytokines, including interleukin 1beta (IL-1beta), IL-2, IL-6, and tumor necrosis factor alpha (TNF-alpha).	Tantalum	29-31	interleukin 6	Mus musculus	212-216
32114412-7	2020	Treatment with vestitol reduced GM-CSF, IL-6, TNF-alpha, IL-4 and TGF-beta levels and increased IL-10 release (P < 0.05).	vestitol	15-23	interleukin 6	Mus musculus	40-44
32174830-6	2020	NDAT and XT199 in combination with cisplatin significantly decreased expression of pro-inflammatory cytokines IL-1beta, IL-6, and TNF-alpha and significantly increased expression of anti-inflammatory cytokine IL-10 in comparison to cisplatin alone.	Cisplatin	35-44	interleukin 6	Mus musculus	120-124
32111036-5	2020	SP decreased the number of inflammatory cells and the levels of TNF-alpha, interleukin (IL)-1beta, and IL-6 in the bronchoalveolar lavage fluid, and inflammatory cell infiltration in the lung tissues of SP-treated mice.	sp	0-2	interleukin 6	Mus musculus	103-107
32109679-5	2020	In the present study, the protective effects of flavonoids from S. uncinata (SUF) and its major compound robustaflavone-4"-dimethyl ether (RDE) against lipopolysaccharide (LPS)-induced ALI were investigated in mice and in neutrophils.The results showed that both SUF and RDE had the same inhibition on LPS-induced lung edema and neutrophil infiltration as well as the increased levels of IL-6, TNF-alpha, P-selectin and ICAM-1 in serum of LPS-challenged mice.	Flavonoids	48-58	interleukin 6	Mus musculus	388-392
32109679-5	2020	In the present study, the protective effects of flavonoids from S. uncinata (SUF) and its major compound robustaflavone-4"-dimethyl ether (RDE) against lipopolysaccharide (LPS)-induced ALI were investigated in mice and in neutrophils.The results showed that both SUF and RDE had the same inhibition on LPS-induced lung edema and neutrophil infiltration as well as the increased levels of IL-6, TNF-alpha, P-selectin and ICAM-1 in serum of LPS-challenged mice.	[2-(Dimethyl-Lambda~4~-Sulfanyl)-1-Hydroxyethane-1,1-Diyl]bis(Phosphonic Acid)	77-80	interleukin 6	Mus musculus	388-392
33005592-9	2020	The production of proinflammatory cytokines such as IL-1beta, IL-6, IFN-gamma, and CCL2, was upregulated by P-PD treatment together with MC903.	4-phenylenediamine	108-112	interleukin 6	Mus musculus	62-66
32084579-7	2020	ALA significantly inhibited the secretion of proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) and increased anti-inflammatory cytokine.	alpha-Linolenic Acid	0-3	interleukin 6	Mus musculus	122-135
32084579-7	2020	ALA significantly inhibited the secretion of proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) and increased anti-inflammatory cytokine.	alpha-Linolenic Acid	0-3	interleukin 6	Mus musculus	137-141
32079232-9	2020	Amphenmulin enhanced wound closure and promoted the healing of wound, which inhibited MRSA bacterial counts in the wound and decreased serum levels of the pro-inflammatory cytokines TNF-alpha, IL-6, and MCP-1.	amphenmulin	0-11	interleukin 6	Mus musculus	193-197
31980524-2	2020	It is established that interleukin 6 (IL6) regulates multiple aspects of metabolism, including glucose disposal, lipolysis, oxidative metabolism, and energy expenditure.	Glucose	95-102	interleukin 6	Mus musculus	23-36
31980524-2	2020	It is established that interleukin 6 (IL6) regulates multiple aspects of metabolism, including glucose disposal, lipolysis, oxidative metabolism, and energy expenditure.	Glucose	95-102	interleukin 6	Mus musculus	38-41
32103929-9	2020	Inflammatory cytokines including IL-6 and IL-1beta in circulation were decreased in IL-17A-/- mice exposed to CS compared with wild-type mice.	Cesium	110-112	interleukin 6	Mus musculus	33-37
32026851-5	2020	The HepG2 human hepatocellular carcinoma cells were treated with or without RKI-1447 for 2 h and treated with oleic acid for 24 h. RESULTS In the mouse model of NAFLD, RKI-1447 reduced insulin resistance and the levels of alanine aminotransferase (ALT), aspartate transaminase (AST), total cholesterol, triglyceride, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), malondialdehyde (MDA), and superoxide dismutase (SOD).	RKI-1447	168-176	interleukin 6	Mus musculus	317-330
32026851-5	2020	The HepG2 human hepatocellular carcinoma cells were treated with or without RKI-1447 for 2 h and treated with oleic acid for 24 h. RESULTS In the mouse model of NAFLD, RKI-1447 reduced insulin resistance and the levels of alanine aminotransferase (ALT), aspartate transaminase (AST), total cholesterol, triglyceride, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), malondialdehyde (MDA), and superoxide dismutase (SOD).	RKI-1447	168-176	interleukin 6	Mus musculus	332-336
32089779-6	2020	The results show that WCC and ECC significantly alleviated cisplatin-induced AKI renal histological changes, serum creatinine (CRE) and blood urea nitrogen (BUN) production, and the levels of NO, TNF-alpha, IL-1beta, and IL-6.	Cisplatin	59-68	interleukin 6	Mus musculus	221-225
32033040-2	2020	In cultures of primary mesencephalic neurons and neuroblastoma cells, we determined the capability of cannabidiol (CBD) and tetrahydrocannabinol (THC) to counteract effects elicited by complex I-inhibitor rotenone by analyzing neuron viability, morphology, gene expression of IL6, CHOP, XBP1, HO-1 (stress response), and HO-2, and in vitro HO activity.	Cannabidiol	102-113	interleukin 6	Mus musculus	276-279
32033040-2	2020	In cultures of primary mesencephalic neurons and neuroblastoma cells, we determined the capability of cannabidiol (CBD) and tetrahydrocannabinol (THC) to counteract effects elicited by complex I-inhibitor rotenone by analyzing neuron viability, morphology, gene expression of IL6, CHOP, XBP1, HO-1 (stress response), and HO-2, and in vitro HO activity.	Dronabinol	146-149	interleukin 6	Mus musculus	276-279
31760766-9	2020	RNA-seq analysis revealed that alcohol feeding increases expression of markers for tumors (Epcam, Krt19, Prom1, Wt1, and Wwtr1), stroma (Dcn, Fn1, and Tnc), and cytokines (Tgfb1 and Tnf) and decreases expression of Fgf21 and Il6 in the pancreatic tumor tissues.	Alcohols	31-38	interleukin 6	Mus musculus	225-228
30990365-8	2020	Cocaine-mediated activation of microglia was further monitored by assessing the expression of the microglial marker (ITGAM) and the inflammatory cytokine (Tnf, Il1b, and Il6) mRNAs.	Cocaine	0-7	interleukin 6	Mus musculus	170-173
31826423-4	2020	Moreover, the LPS-induced expression of IL-6, IL-12, and TNF-alpha in the culture medium of BMDCs and serum dose-dependently decreased by porphyran treatment, which contributed to the inhibition of the intracellular cytokine production in spleen DCs.	porphyran	138-147	interleukin 6	Mus musculus	40-44
31759747-7	2020	Correspondingly, acute 1-NP exposure upregulated pulmonary Il-1beta, Il-6, Tnf-alpha and Kc.	1-nitropyrene	23-27	interleukin 6	Mus musculus	69-73
32096189-17	2020	Fluoxetine could effectively reduce the content of TNF-a, IL-1b, and IL-6 (p<0.01) and increase the content of IL-10 (p<0.01).	Fluoxetine	0-10	interleukin 6	Mus musculus	69-73
31468277-8	2020	Enzyme-linked immunosorbent assay performed on day 7 revealed that hydrogen water reduced the level of the pro-inflammatory cytokine interleukin-6 and increased that of forkhead box P3 transcription factor, suggesting an enhancement of regulatory T cell activity.	Hydrogen	67-75	interleukin 6	Mus musculus	133-146
31468277-8	2020	Enzyme-linked immunosorbent assay performed on day 7 revealed that hydrogen water reduced the level of the pro-inflammatory cytokine interleukin-6 and increased that of forkhead box P3 transcription factor, suggesting an enhancement of regulatory T cell activity.	Water	76-81	interleukin 6	Mus musculus	133-146
32248343-2	2020	In RAW264.7 macrophages and murine bone marrow-derived macrophages (BMDMs) stimulated by lipopolysaccharide (LPS), PPC significantly inhibited the production of IL-6, TNF-alpha, and the mRNA expression of M1-type macrophage markers.	polyene phosphatidylcholine	115-118	interleukin 6	Mus musculus	161-165
31874369-5	2020	We further observed that iloprost-treated DCs displayed tolerogenic characteristics, including low inflammatory cytokine (IL-12, TNF-alpha, IL-6, IL-23) expression levels, high anti-inflammatory cytokine (IL-10) production, and a semimature phenotype.	Iloprost	25-33	interleukin 6	Mus musculus	140-144
31901621-4	2020	Cu-CPT22, a TLR2 antagonist, down-regulated Pam3CSK4-induced production of IL-6, MCP-1, and MIP-1alpha, but not TNF-alpha.	Copper	0-2	interleukin 6	Mus musculus	75-79
31930778-10	2020	Additionally, AOAA attenuated NLRP3-Caspase1/IL-1beta activation and decreased the release of IL-6 and TNF-alpha pro-inflammatory cytokines and reciprocally increased IL-10 anti-inflammatory cytokine level in both ischaemic myocardium and M1 macrophages.	Aminooxyacetic Acid	14-18	interleukin 6	Mus musculus	94-98
31630319-12	2020	Co-administration of venlafaxine (40 mg/kg) with morphine not only inhibited the naloxone-precipitated withdrawal signs including jumping and weight loss, but also reduced the up-regulation of TNF-alpha, IL-1beta, IL-6, NO and MDA contents in mice brain tissue.	venlafaxine	21-32	interleukin 6	Mus musculus	214-218
31630319-12	2020	Co-administration of venlafaxine (40 mg/kg) with morphine not only inhibited the naloxone-precipitated withdrawal signs including jumping and weight loss, but also reduced the up-regulation of TNF-alpha, IL-1beta, IL-6, NO and MDA contents in mice brain tissue.	Morphine	49-57	interleukin 6	Mus musculus	214-218
31630319-12	2020	Co-administration of venlafaxine (40 mg/kg) with morphine not only inhibited the naloxone-precipitated withdrawal signs including jumping and weight loss, but also reduced the up-regulation of TNF-alpha, IL-1beta, IL-6, NO and MDA contents in mice brain tissue.	Naloxone	81-89	interleukin 6	Mus musculus	214-218
31820278-4	2020	Mice treated with rotenone rerecorded significant increase in adenosine A2A receptor (A2AR) gene expression, alpha synuclein, acetylcholinesterase (AchE), malondialdehyde (MDA), angiotensin-II (Ang-II), c-reactive protein (CRP), interleukin-6 (IL-6), caspase-3 (Cas-3) and DNA fragmentation levels as compared with the control group.	Rotenone	18-26	interleukin 6	Mus musculus	229-242
31820278-4	2020	Mice treated with rotenone rerecorded significant increase in adenosine A2A receptor (A2AR) gene expression, alpha synuclein, acetylcholinesterase (AchE), malondialdehyde (MDA), angiotensin-II (Ang-II), c-reactive protein (CRP), interleukin-6 (IL-6), caspase-3 (Cas-3) and DNA fragmentation levels as compared with the control group.	Rotenone	18-26	interleukin 6	Mus musculus	244-248
31871267-8	2020	In both species, there was short-term elevation in serum levels of IL6, IL2, and IFNgamma, although this was not associated with clinical signs of proinflammatory cytokine release, and further, this cytokine elevation could be completely prevented by dexamethasone premedication.	Dexamethasone	251-264	interleukin 6	Mus musculus	67-70
31916204-6	2020	Furthermore, edaravone significantly prevented the increase of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) induced by abdominal surgery in aged mice.	edaravone	13-22	interleukin 6	Mus musculus	137-150
31916204-6	2020	Furthermore, edaravone significantly prevented the increase of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) induced by abdominal surgery in aged mice.	edaravone	13-22	interleukin 6	Mus musculus	152-156
31855808-4	2020	DHEA decreased the malondialdehyde content, superoxide dismutase activity and inducible nitric oxide synthase protein level; meanwhile, DHEA also inhibited the secretion of tumor necrosis factor-alpha, interleukin-1beta and interleukin-6 in DSS-induced colitis mice.	Dehydroepiandrosterone	0-4	interleukin 6	Mus musculus	224-237
31855808-4	2020	DHEA decreased the malondialdehyde content, superoxide dismutase activity and inducible nitric oxide synthase protein level; meanwhile, DHEA also inhibited the secretion of tumor necrosis factor-alpha, interleukin-1beta and interleukin-6 in DSS-induced colitis mice.	Dehydroepiandrosterone	136-140	interleukin 6	Mus musculus	224-237
32011533-6	2020	Eupatilin treatment downregulated cerulein-induced expression of interleukin (IL)-1beta, IL-6, and CC chemokine ligands 2 and 5, but it upregulated expression of IL-4 and IL-10.	eupatilin	0-9	interleukin 6	Mus musculus	89-93
32011533-6	2020	Eupatilin treatment downregulated cerulein-induced expression of interleukin (IL)-1beta, IL-6, and CC chemokine ligands 2 and 5, but it upregulated expression of IL-4 and IL-10.	Ceruletide	34-42	interleukin 6	Mus musculus	89-93
31818196-9	2020	Importantly, enhancing mitophagy in aged, hyperlipidemic mice via oral administration of spermidine prevented the increase in aortic IL-6 and Parkin, attenuated mitochondrial dysfunction, and reduced atherogenesis.	Spermidine	89-99	interleukin 6	Mus musculus	133-137
31606534-11	2020	TSG inhibited inflammation by the down-regulation of IL-6, TNF-alpha, VCAM-1 and MCP-1 expression in serum, and PMRP inhibited inflammation by reducing VCAM-1, ICAM-1 and CCRA expression in aortic tissue.	3,3',4,5'-tetrahydroxystilbene	0-3	interleukin 6	Mus musculus	53-57
32099357-12	2020	Results: Both graphene and GO induced significantly higher TNF-alpha and IL-6 secretion compared with the control in the three-dimensional in vitro model.	Graphite	14-22	interleukin 6	Mus musculus	73-77
32099357-12	2020	Results: Both graphene and GO induced significantly higher TNF-alpha and IL-6 secretion compared with the control in the three-dimensional in vitro model.	graphene oxide	27-29	interleukin 6	Mus musculus	73-77
32099340-10	2020	Results: Anwulignan significantly increased the serum levels of IL-2, IL-4, IFN-gamma, lgG, lgM, and lgA, decreased the content of TNF-alpha and IL-6 in the aging mice, and increased the blood leukocyte number, the phagocytic activity, the lymphocyte proliferation, and the spleen index in vitro.	macelignan	9-19	interleukin 6	Mus musculus	145-149
31825043-6	2020	Resveratrol was also able to prevent mouse body weight loss, reduce the disease activity index, attenuate tissue damage, and down-regulate the expression of pro-inflammatory cytokines such as IL-2, IFN-gamma, GM-CSF, IL-1beta, IL-6, KC/GRO, and TNF-alpha in the colon of DSS-treated mice.	resveratrol	0-11	interleukin 6	Mus musculus	227-231
32047577-8	2020	Furthermore, at the end of the treatment, the plasma levels of two well-known markers of cardiovascular inflammation, TNF-alpha and IL6, are significantly reduced in 12-month-old mice treated with NAR, as well as the cardiovascular risk (total cholesterol/HDL ratio) compared to control mice.	naringenin	197-200	interleukin 6	Mus musculus	132-135
31979265-7	2020	Furthermore, the anti-inflammatory properties of 4-HAB were confirmed in a mouse model of uric acid crystals-mediated peritonitis by the reduced levels of neutrophil influx, IL-1beta, active caspase-1, IL-6 and MCP-1 in lavage fluids.	auxarconjugatin A	49-54	interleukin 6	Mus musculus	202-206
31979095-5	2020	Topical application of fermenting C. acnes, butyric acid or BA-NH-NH-BA onto mouse skin effectively ameliorated CaP-induced skin itching, interleukin (IL)-6 up-regulation in keratinocytes, and extracellular signal-regulated kinase (ERK) 1/2 activation in dorsal root ganglia (DRG).	Butyric Acid	44-56	interleukin 6	Mus musculus	138-156
31979095-5	2020	Topical application of fermenting C. acnes, butyric acid or BA-NH-NH-BA onto mouse skin effectively ameliorated CaP-induced skin itching, interleukin (IL)-6 up-regulation in keratinocytes, and extracellular signal-regulated kinase (ERK) 1/2 activation in dorsal root ganglia (DRG).	Ammonia	63-68	interleukin 6	Mus musculus	138-156
31979095-6	2020	Activation of ERK 1/2 by CaP was markedly reduced in IL-6 knockout mice.	calcium phosphate	25-28	interleukin 6	Mus musculus	53-57
31979095-8	2020	Our results identify a role for the skin fermenting C. acnes in ameliorating CaP-induced activation of IL-6/p-ERK signaling and resulting skin inflammation.	calcium phosphate	77-80	interleukin 6	Mus musculus	103-107
32071789-3	2020	Here, we found that increased TMEM16A expression in the pancreatic tissue was correlated with the interleukin-6 (IL-6) level in the pancreatic tissue and in the serum of a cerulein-induced AP mouse model.	Ceruletide	172-180	interleukin 6	Mus musculus	113-117
31809714-11	2020	RESULTS: GHK-Cu complex inhibited BLM-induced inflammatory and fibrotic pathological changes, alleviated the inflammatory response in the BALF by reducing the levels of the inflammatory cytokines, TNF-alpha and IL-6 and the activity of MPO as well as reduced collagen deposition.	Copper	13-15	interleukin 6	Mus musculus	211-215
31812773-9	2020	Verteporfin inhibited IL-6 and TNF-alpha at mRNA and protein expression levels.	verteporfin	0-11	interleukin 6	Mus musculus	22-26
31998114-5	2019	The data presented demonstrate that PNU282987 protected mice from LPS-induced impairment of episodic memory by decreasing IL-6 levels in the blood, stabilizing the brain mitochondria and up-regulating the brain alpha7-, alpha3-, and alpha4-containing nAChRs.	PNU-282987	36-45	interleukin 6	Mus musculus	122-126
31998114-7	2019	PNU120596 also decreased IL-6, stabilized mitochondria and up-regulated the brain nAChRs.	1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea	0-9	interleukin 6	Mus musculus	25-29
31998114-9	2019	Moreover, cessation of PNU120596 treatment resulted in a sharp increase in IL-1beta and IL-6 levels in the blood.	1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea	23-32	interleukin 6	Mus musculus	88-92
31998129-5	2019	In vivo, we found that intraperitoneal injection of tetrandrine (30 mg/kg) every other day markedly reduced bone loss in ovariectomized mice and the serum levels of TRAcp5b, TNF-a, IL-6, CTX-I, and RANKL/OPG were significantly decreased.	tetrandrine	52-63	interleukin 6	Mus musculus	181-185
31921356-7	2020	Remarkably, the inflammation-ameliorating effects of carvacrol treatment were not restricted to the intestinal tract, but could also be observed in extra-intestinal organs such as liver, kidneys and lungs and, strikingly, systemically as indicated by lower IFN-gamma, TNF, MCP-1 and IL-6 serum concentrations in carvacrol versus placebo treated mice.	carvacrol	53-62	interleukin 6	Mus musculus	283-287
31936237-9	2020	The expression of toll-like receptors (TLRs), MyD88, and serum IL-6 were upregulated following FOLFOX treatment.	Folfox protocol	95-101	interleukin 6	Mus musculus	63-67
31998441-8	2020	Serotonin significantly facilitated the release of serum and intrahepatic inflammatory cytokines, including interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-17A (IL-17A), interferon-gamma (IFN-gamma), and tumor necrosis-alpha (TNF-alpha), after the administration of Con A.	Serotonin	0-9	interleukin 6	Mus musculus	130-143
31790652-3	2020	In murine microglial cell line BV-2 cells, pretreatment with dopamine for 24 h attenuated the lipopolysaccharide (LPS)-induced expression of proinflammatory cytokines such as tumor-necrosis factor-alpha, interleukin-1beta, and interleukin-6.	Dopamine	61-69	interleukin 6	Mus musculus	227-240
32475919-3	2020	Furthermore, Danshensu alleviated oxidative stress injury through potentiating glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) activities; Immunohistochemistry results demonstrated that Danshensu reduced the expression of inflammatory cytokines: interleukin-6 (IL-6) and transforming growth factor-beta (TGF-beta).	3,4-dihydroxyphenyllactic acid	13-22	interleukin 6	Mus musculus	261-274
32475919-3	2020	Furthermore, Danshensu alleviated oxidative stress injury through potentiating glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) activities; Immunohistochemistry results demonstrated that Danshensu reduced the expression of inflammatory cytokines: interleukin-6 (IL-6) and transforming growth factor-beta (TGF-beta).	3,4-dihydroxyphenyllactic acid	13-22	interleukin 6	Mus musculus	276-280
31884136-3	2020	The anti-inflammatory activities assay demonstrated that JG and JA suppressed the production of pro-inflammatory cytokines including NO, IL-1beta, and IL-6 as well as inhibited the expression of iNOS in LPS-induced RAW 264.7 cells in a dose-dependent manner.	jg	57-59	interleukin 6	Mus musculus	151-155
31884136-3	2020	The anti-inflammatory activities assay demonstrated that JG and JA suppressed the production of pro-inflammatory cytokines including NO, IL-1beta, and IL-6 as well as inhibited the expression of iNOS in LPS-induced RAW 264.7 cells in a dose-dependent manner.	jiangrine A	64-66	interleukin 6	Mus musculus	151-155
31902918-4	2020	In the present study, we found that metformin reduced the production of nitric oxide (NO) and the level of proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells.	Metformin	36-45	interleukin 6	Mus musculus	204-208
31676226-7	2020	We found that 8mg/kg DPN (ERbeta-specific agonist) replacement therapy (3 weeks) to the ovariectomized (OVX) mice significantly reduced ischemia injury and alleviated microglia and astrocyte activation, and markedly inhibited the expression of NF-kappaB and proinflammatory cytokines (TNF-alpha, IL-1beta, and IL-6).	NAD	21-24	interleukin 6	Mus musculus	310-314
29808705-6	2020	Results The cetylated fatty acids mixture from Celadrin significantly decreased the production of IL-6, MCP-1, and TNF, key regulators of the inflammatory process, in stimulated RAW264.7 mouse macrophage cells.	Fatty Acids	22-33	interleukin 6	Mus musculus	98-102
29808705-6	2020	Results The cetylated fatty acids mixture from Celadrin significantly decreased the production of IL-6, MCP-1, and TNF, key regulators of the inflammatory process, in stimulated RAW264.7 mouse macrophage cells.	celadrin	47-55	interleukin 6	Mus musculus	98-102
29808705-8	2020	Conclusion The cetylated fatty acids mixture from Celadrin reduces inflammation in vitro by significantly decreasing the expression of IL-6, MCP-1, and TNF in stimulated RAW264.7 mouse macrophage cells.	Fatty Acids	25-36	interleukin 6	Mus musculus	135-139
29808705-8	2020	Conclusion The cetylated fatty acids mixture from Celadrin reduces inflammation in vitro by significantly decreasing the expression of IL-6, MCP-1, and TNF in stimulated RAW264.7 mouse macrophage cells.	celadrin	50-58	interleukin 6	Mus musculus	135-139
31902360-12	2020	HCA had inhibitory effects on calcium oxalate-induced inflammatory cytokines, such as MCP-1, IL-1 beta, and IL-6.	alpha-hydroxycaprylic acid	0-3	interleukin 6	Mus musculus	108-112
31902360-12	2020	HCA had inhibitory effects on calcium oxalate-induced inflammatory cytokines, such as MCP-1, IL-1 beta, and IL-6.	Calcium Oxalate	30-45	interleukin 6	Mus musculus	108-112
31654708-7	2020	In in vitro studies, SA significantly decreased TNF-alpha and IL-6 release levels and altered the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in LPS-stimulated macrophages, which were consistent with the results from in vivo experiments.	salvianolic acid A	21-23	interleukin 6	Mus musculus	62-66
31780368-10	2020	DEX also significantly inhibited the activity of NLRP3 inflammasome and reduced the protein contents of Pro-Caspase-1, Caspase-1, Capase-1/Pro-Caspase-1, IL-1beta, IL-6 and IL-17 in lung tissues.	Dexamethasone	0-3	interleukin 6	Mus musculus	164-168
31820024-10	2020	Concentrations of IL-6, RANTES, and MIP-2 induced by HDM and poly(I:C) were significantly suppressed by EM900 through the suppression of NF-kappaB and p38 phosphorylation in macrophages.	Poly I-C	61-70	interleukin 6	Mus musculus	18-22
31835081-6	2020	Furthermore, melatonin supplementation inverted the SD-induced the decline of antioxidant enzyme activities (T-AOC and CAT etc) and anti-inflammatory cytokines (IL-10 and IFN-gamma) and the increase of oxidative product MDA, pro-inflammatory cytokines (IL-6 and TNF-alpha), p-P65 and p-IkappaB proteins in the SI.	Melatonin	13-22	interleukin 6	Mus musculus	253-257
33259259-6	2020	We demonstrated that the administration of halofuginone significantly reduced the expression levels of pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) in vivo, and markedly suppressed immune cell infiltration into the infected sites.	halofuginone	43-55	interleukin 6	Mus musculus	141-145
32925065-10	2020	CONCLUSION: These findings demonstrated that chronic systemic exposure to P gLPS simultaneously induces inflammation-dependent bone loss and AD-like pathologies by elevating IL-6 and IL-17 from middle age, suggesting that periodontal bacteria induce exacerbation of bone loss and memory decline, resulting in AD progression.	Phosphorus	74-75	interleukin 6	Mus musculus	174-178
31657123-5	2020	Glycyrrhizin decreased the plasma concentrations of HMGB1 and sRAGE as well as TNF-alpha, IL-1beta and IL-6 levels in the bronchoalveolar lavage fluid (BALF).	Glycyrrhizic Acid	0-12	interleukin 6	Mus musculus	103-107
31102492-7	2020	RESULTS: In parallel with the suppression of interleukin-6 and tumor necrosis factor-alpha production in resting and lipopolysaccharide-stimulated macrophages, metformin could induce an increase in Dicer and most miRNAs.	Metformin	160-169	interleukin 6	Mus musculus	45-58
32581181-8	2020	In support of these observations, TCA lowered the saliva-induced expression of IL1alpha, IL1beta and IL6 in RAW 264.7 cells.	Taurocholic Acid	34-37	interleukin 6	Mus musculus	101-104
31415934-10	2020	M51R-treated peritoneal cavities also contained lower concentrations of immunosuppressive monocyte chemoattractant protein-1 and interleukin 6 cytokines relative to controls.	m51r	0-4	interleukin 6	Mus musculus	129-142
32316726-7	2020	HPSB significantly reduced the levels of interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) induced by HFD+DSS in mice.	dss	124-127	interleukin 6	Mus musculus	56-60
31724331-0	2020	Inhibitory effect of alpinetin on IL-6 expression by promoting cytosine methylation in CpG islands in the IL-6 promoter region.	alpinetin	21-30	interleukin 6	Mus musculus	34-38
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	35-45	interleukin 6	Mus musculus	118-131
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	35-45	interleukin 6	Mus musculus	133-137
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	35-45	interleukin 6	Mus musculus	356-360
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	47-51	interleukin 6	Mus musculus	118-131
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	47-51	interleukin 6	Mus musculus	133-137
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	47-51	interleukin 6	Mus musculus	356-360
31746387-4	2020	LXA4 significantly increased the cell survival rates, cell viability, SOD levels and HO-1 expression, reduced the apoptosis rates, and inhibited the MCP-1 and IL-6 levels induced by hyperoxia in cells.	lipoxin A4	0-4	interleukin 6	Mus musculus	159-163
31466071-7	2020	Quantification of inflammatory mediators (IL-10, IL-4, IL-6, IL-1beta, and TNF-alpha) in the brain demonstrated that BbHA and BbMe effectively decreased the effect of LPS on the brain concentration of all measured cytokines.	bbha	117-121	interleukin 6	Mus musculus	55-59
31466071-7	2020	Quantification of inflammatory mediators (IL-10, IL-4, IL-6, IL-1beta, and TNF-alpha) in the brain demonstrated that BbHA and BbMe effectively decreased the effect of LPS on the brain concentration of all measured cytokines.	bbme	126-130	interleukin 6	Mus musculus	55-59
31746387-10	2020	The protection of LXA4 in hyperoxia-induced cell injury may be associated with the downregulation IL-6 and MCP-1 levels via the inhibition of the p38 MAPK and ERK1/2 signaling pathways.	lipoxin A4	18-22	interleukin 6	Mus musculus	98-102
31724331-0	2020	Inhibitory effect of alpinetin on IL-6 expression by promoting cytosine methylation in CpG islands in the IL-6 promoter region.	alpinetin	21-30	interleukin 6	Mus musculus	106-110
31724331-0	2020	Inhibitory effect of alpinetin on IL-6 expression by promoting cytosine methylation in CpG islands in the IL-6 promoter region.	Cytosine	63-71	interleukin 6	Mus musculus	34-38
31724331-0	2020	Inhibitory effect of alpinetin on IL-6 expression by promoting cytosine methylation in CpG islands in the IL-6 promoter region.	Cytosine	63-71	interleukin 6	Mus musculus	106-110
31724331-2	2020	In order to prove that the induced methylation is an important mechanism for alpinetin in regulating the expression of inflammatory factor Interleukin-6 (IL-6), we detected the dinucleotide methylation status of CpG islands in the IL-6 promoter region and IL-6 level after treatment of RAW246.7 murine macrophages with alpinetin.	alpinetin	77-86	interleukin 6	Mus musculus	139-152
31724331-2	2020	In order to prove that the induced methylation is an important mechanism for alpinetin in regulating the expression of inflammatory factor Interleukin-6 (IL-6), we detected the dinucleotide methylation status of CpG islands in the IL-6 promoter region and IL-6 level after treatment of RAW246.7 murine macrophages with alpinetin.	alpinetin	77-86	interleukin 6	Mus musculus	154-158
31724331-2	2020	In order to prove that the induced methylation is an important mechanism for alpinetin in regulating the expression of inflammatory factor Interleukin-6 (IL-6), we detected the dinucleotide methylation status of CpG islands in the IL-6 promoter region and IL-6 level after treatment of RAW246.7 murine macrophages with alpinetin.	alpinetin	77-86	interleukin 6	Mus musculus	231-235
31724331-2	2020	In order to prove that the induced methylation is an important mechanism for alpinetin in regulating the expression of inflammatory factor Interleukin-6 (IL-6), we detected the dinucleotide methylation status of CpG islands in the IL-6 promoter region and IL-6 level after treatment of RAW246.7 murine macrophages with alpinetin.	alpinetin	77-86	interleukin 6	Mus musculus	231-235
31724331-2	2020	In order to prove that the induced methylation is an important mechanism for alpinetin in regulating the expression of inflammatory factor Interleukin-6 (IL-6), we detected the dinucleotide methylation status of CpG islands in the IL-6 promoter region and IL-6 level after treatment of RAW246.7 murine macrophages with alpinetin.	alpinetin	319-328	interleukin 6	Mus musculus	154-158
31724331-2	2020	In order to prove that the induced methylation is an important mechanism for alpinetin in regulating the expression of inflammatory factor Interleukin-6 (IL-6), we detected the dinucleotide methylation status of CpG islands in the IL-6 promoter region and IL-6 level after treatment of RAW246.7 murine macrophages with alpinetin.	alpinetin	319-328	interleukin 6	Mus musculus	231-235
31724331-2	2020	In order to prove that the induced methylation is an important mechanism for alpinetin in regulating the expression of inflammatory factor Interleukin-6 (IL-6), we detected the dinucleotide methylation status of CpG islands in the IL-6 promoter region and IL-6 level after treatment of RAW246.7 murine macrophages with alpinetin.	alpinetin	319-328	interleukin 6	Mus musculus	231-235
31724331-7	2020	RESULTS: Alpinetin promoted dinucleotide methylation status of two CpG islands in the IL-6 promoter region stretching 500-2500 bp upstream of the transcriptional start site (TSS) (p &lt; .05).	alpinetin	9-18	interleukin 6	Mus musculus	86-90
31724331-11	2020	CONCLUSION: Alpinetin could induce dinucleotide methylation status of CpG islands in the IL-6 promoter region by activating methyltransferase, thus inhibiting IL-6 expression in murine macrophages.	alpinetin	12-21	interleukin 6	Mus musculus	89-93
31724331-11	2020	CONCLUSION: Alpinetin could induce dinucleotide methylation status of CpG islands in the IL-6 promoter region by activating methyltransferase, thus inhibiting IL-6 expression in murine macrophages.	alpinetin	12-21	interleukin 6	Mus musculus	159-163
33176302-11	2020	Dexamethasone prevented LPS-induced IL-6 in the HC, PFC, and HT.	Dexamethasone	0-13	interleukin 6	Mus musculus	36-40
31841748-9	2020	Moreover, GA-treated mice had decreased expression of interleukin-6, inducible nitric oxide synthase, cyclooxygenase-2, F4/80, and sterol regulatory element binding transcription factor-1 in their adipose tissue.	Gallic Acid	10-12	interleukin 6	Mus musculus	54-67
31554002-8	2020	In LPS-induced ARDS cell model, astragaloside IV up-regulated cell viability, SOD activity and ZO-1 and LC3B I expressions but down-regulated cell apoptosis, TNF-alpha, IL-6, LC3B II, Beclin-1 and atg5 expressions and LDH and MDA levels.	astragaloside A	32-45	interleukin 6	Mus musculus	169-173
31618743-11	2020	Furthermore, after treated with ML204 or silenced the gene of TRPC5, the releases of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated RAW264.7 cells were significantly increased.	ML 204	32-37	interleukin 6	Mus musculus	109-113
31926632-6	2020	Furthermore, 7-O-cinnamoyltaxifolin and 7-O-feruloyltaxifolin reduced LPS-induced neuroinflammation in BV-2 microglia cells as assessed by effects on the levels of NO, IL6 and TNFalpha.	Superoxides	13-35	interleukin 6	Mus musculus	168-171
31677207-9	2020	ChemoRT-treated mice who received PLAG exhibited no weight loss (Day 0: 25.78+-1.04 g; Day 9: 26.46+-1.68 g) and had lower serum MIP-2 (4.42+-4.04 pg/mL) and IL-6 (205.75+-30.41 pg/mL) levels than ChemoRT-treated mice who did not receive PLAG.	1-palmitoyl-2-linoleoyl-3-acetyl-rac glycerol	34-38	interleukin 6	Mus musculus	158-162
32454488-9	2020	Arg-II knockout enhances Arg-I expression and activity, but inhibits interleukin (IL)-6 expression and secretion and reduces active p38mapk in aging adipose tissue macrophages and stromal cells.	Arginine	0-3	interleukin 6	Mus musculus	69-87
32454488-10	2020	Treatment of aging adipose tissues of WT mice with a specific p38mapk inhibitor SB203580 reduces IL-6 secretion.	SB 203580	80-88	interleukin 6	Mus musculus	97-101
32454488-11	2020	CONCLUSIONS: Arg-II promotes IL-6 production in aging adipose tissues through p38mapk.	arg-ii	13-19	interleukin 6	Mus musculus	29-33
31856083-8	2020	In addition, silymarin inhibited increased secretion of proinflammatory cytokines such as interleukin 1beta, interleukin 6, and tumor necrosis factor alpha.	Silymarin	13-22	interleukin 6	Mus musculus	109-122
31539805-8	2020	Furthermore, S-adenosylmethionine administration promoted enrichment of the euchromatin marker H3K4me3 in the promoters of Tnf-alpha, Il-6, and Nos2 and enhanced the mRNA up-regulation of these genes.	S-Adenosylmethionine	13-33	interleukin 6	Mus musculus	134-138
31926632-6	2020	Furthermore, 7-O-cinnamoyltaxifolin and 7-O-feruloyltaxifolin reduced LPS-induced neuroinflammation in BV-2 microglia cells as assessed by effects on the levels of NO, IL6 and TNFalpha.	Superoxides	40-61	interleukin 6	Mus musculus	168-171
31614297-6	2019	TCE sensitization produced histopathological and functional damage to the kidney, accompanied by increased levels of interleukin (IL-) 1beta, IL-6, and IL-23.	Trichloroethylene	0-3	interleukin 6	Mus musculus	142-146
31513829-11	2019	However, when MS animals were exposed to Poly (I:C), a more robust activation of Tlr3, Il6 and Nfkb1 gene transcription was observed in these mice compared with control animals.	poly	41-45	interleukin 6	Mus musculus	87-90
31513829-11	2019	However, when MS animals were exposed to Poly (I:C), a more robust activation of Tlr3, Il6 and Nfkb1 gene transcription was observed in these mice compared with control animals.	Iodine	47-48	interleukin 6	Mus musculus	87-90
31513829-11	2019	However, when MS animals were exposed to Poly (I:C), a more robust activation of Tlr3, Il6 and Nfkb1 gene transcription was observed in these mice compared with control animals.	Carbon	49-50	interleukin 6	Mus musculus	87-90
32082076-0	2019	Suppressive Effects of GSS on Lipopolysaccharide-Induced Endothelial Cell Injury and ALI via TNF-alpha and IL-6.	gss	23-26	interleukin 6	Mus musculus	107-111
32082076-6	2019	In this study, we found that GSS not only downregulated the levels of TNF-alpha and IL-6 in the lung and serum of mice in vivo but also inhibited the expression and secretion of TNF-alpha and IL-6 in ECs.	gss	29-32	interleukin 6	Mus musculus	84-88
32082076-6	2019	In this study, we found that GSS not only downregulated the levels of TNF-alpha and IL-6 in the lung and serum of mice in vivo but also inhibited the expression and secretion of TNF-alpha and IL-6 in ECs.	gss	29-32	interleukin 6	Mus musculus	192-196
32082076-7	2019	Importantly, we also found that GSS blocked LPS-induced TNF-alpha and IL-6 expression in ECs via the Myd88/NF-kappaB signaling pathway.	gss	32-35	interleukin 6	Mus musculus	70-74
31860659-12	2019	In vivo tests revealed that, ISL significantly reduced TNF-alpha and IL-6 levels, mitigated the destruction of the mammary glands and reversed the production of inflammatory cells in mice.	isoliquiritigenin	29-32	interleukin 6	Mus musculus	69-73
31888063-6	2019	Oral TPC treatment resulted in amelioration of the colitis clinical manifestations exemplified by reduced disease activity index (DAI) score, expansion of mesenteric lymph nodes (MLN) T regulatory cells (shown by Fluorescence Activated Cell Sorting (FACS)), significant reduction in the expression of pro-inflammatory cytokines (IL-1beta, IL17, IL-6, TNFalpha), and elevation in the expression of anti-inflammatory cytokine IL-10 (shown by RT-PCR).	Tuftsin	5-8	interleukin 6	Mus musculus	345-349
31921212-13	2019	In vitro stimulation of macrophages with LPS revealed that IL-6 expression was enhanced in the presence of heme.	Heme	107-111	interleukin 6	Mus musculus	59-63
31907162-7	2019	Kirenol treatment significantly down-regulated the secretion of IFN-gamma, IL-17A, IL-6 and TNF-alpha by the MLNs lymphocytes and increased the apoptosis of lymphocytes, especially CD4+ T cells in the DSS-treated mice.	kirenol	0-7	interleukin 6	Mus musculus	83-87
31842849-10	2019	In a LPS-induced endotoxemia mouse model, a single intraperitoneal injection of Cl-EE (75-300 mg/kg) could lower circulatory TNF-alpha, IL-6 and MCP-1 levels.	cl-ee	80-85	interleukin 6	Mus musculus	136-140
31937024-9	2019	ELISA showed that TNF-alpha, IL-6 and IL-1beta contents in the cell supernatant of the PQ group were significantly higher than those of 0 mumol/L PQ group, especially in 0.03 and 0.06 mumol/L PQ exposed group (P&lt;0.05) .	Paraquat	87-89	interleukin 6	Mus musculus	29-33
31937024-12	2019	Western blot showed that compared with 0 mumol/L PQ group, the expression levels of M1 markers TNF-alpha, IL-6, IL-1beta, iNOS and CD86 were significantly increased in 0.03 and 0.06 mumol/L PQ exposed group, while the expression levels of M2 markers Arg-1 and CD206 protein were decreased in 0.06 and 0.12 mumol/L PQ exposed group (P&lt;0.05) .	Paraquat	49-51	interleukin 6	Mus musculus	106-110
31937024-12	2019	Western blot showed that compared with 0 mumol/L PQ group, the expression levels of M1 markers TNF-alpha, IL-6, IL-1beta, iNOS and CD86 were significantly increased in 0.03 and 0.06 mumol/L PQ exposed group, while the expression levels of M2 markers Arg-1 and CD206 protein were decreased in 0.06 and 0.12 mumol/L PQ exposed group (P&lt;0.05) .	Paraquat	190-192	interleukin 6	Mus musculus	106-110
31937024-12	2019	Western blot showed that compared with 0 mumol/L PQ group, the expression levels of M1 markers TNF-alpha, IL-6, IL-1beta, iNOS and CD86 were significantly increased in 0.03 and 0.06 mumol/L PQ exposed group, while the expression levels of M2 markers Arg-1 and CD206 protein were decreased in 0.06 and 0.12 mumol/L PQ exposed group (P&lt;0.05) .	Paraquat	190-192	interleukin 6	Mus musculus	106-110
31842994-11	2019	Dying cancer cells induced by PS-PDT or PD-PDT emit calreticulin, HMGB1 and ATP and they were efficiently engulfed by BMDCs, which then matured, became activated and produced IL-6.	N-methylglucosamine	33-35	interleukin 6	Mus musculus	175-179
31888253-7	2019	Cinacalcet reduced mucin expression, which coincided with an increase in tumor necrosis factor-alpha (4.4-fold, p &lt; 0.05) and IL-6 (4.9-fold, p &lt; 0.05) in the plasma, compared with vehicle.	cina	0-10	interleukin 6	Mus musculus	129-133
31680514-8	2019	Moreover, we found that PCB29-pQ induced inflammatory cytokines, such as tumor necrosis factor (TNF-alpha), interleukin 6 (IL-6), and IL-1beta, released by activating the mitogen-activated protein kinase (MAPK)-nuclear factor kappa B (NF-kappaB) inflammatory pathway.	2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	24-32	interleukin 6	Mus musculus	108-121
31680514-8	2019	Moreover, we found that PCB29-pQ induced inflammatory cytokines, such as tumor necrosis factor (TNF-alpha), interleukin 6 (IL-6), and IL-1beta, released by activating the mitogen-activated protein kinase (MAPK)-nuclear factor kappa B (NF-kappaB) inflammatory pathway.	2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	24-32	interleukin 6	Mus musculus	123-127
31526918-5	2019	In addition, myricitrin decreased the production of pro-inflammatory factors including IL-1beta, IL-6 and TNFalpha, decreased the level of chemokine MCP-1, and suppressed the expressions of COX-2 and iNOS.	myricitrin	13-23	interleukin 6	Mus musculus	97-101
31934279-7	2019	The results from the present study indicated that ALB dramatically suppressed the expression of inflammatory cytokines including IL-1beta, IL-6, and TNF-alpha, and inflammatory cells.	albiflorin	50-53	interleukin 6	Mus musculus	139-143
31639401-8	2019	Furthermore, Saikosaponin-A administration strongly inhibited pro-inflammatory mediators (TNF-alpha, COX-2, IL-1beta and IL-6) and apoptotic markers (p-JNK, Casp-3).	saikosaponin D	13-27	interleukin 6	Mus musculus	121-125
31836734-10	2019	The LPS-induced bioluminescence of the female hCRP-Luc mice was IL-6-mediated and associated with APP alpha-1-acid glycoprotein expression.	MK 316	102-114	interleukin 6	Mus musculus	64-68
31849448-11	2019	In vitro, LPS-induced production of TNF-alpha and IL-6 and gene expression of TNF-alpha, IL-6, IL-1beta, and COX-2 could be inhibited by the pretreatment with C66 and SP600125.	T-66	159-162	interleukin 6	Mus musculus	50-54
31849448-11	2019	In vitro, LPS-induced production of TNF-alpha and IL-6 and gene expression of TNF-alpha, IL-6, IL-1beta, and COX-2 could be inhibited by the pretreatment with C66 and SP600125.	T-66	159-162	interleukin 6	Mus musculus	89-93
31849448-11	2019	In vitro, LPS-induced production of TNF-alpha and IL-6 and gene expression of TNF-alpha, IL-6, IL-1beta, and COX-2 could be inhibited by the pretreatment with C66 and SP600125.	pyrazolanthrone	167-175	interleukin 6	Mus musculus	89-93
31920668-4	2019	Herein, our study demonstrated that thalidomide protected colon mucosa against trinitro-benzene-sulfonic acid (TNBS)-induced injury, diminished inflammatory infiltration and levels of IFN-gamma, IGF-1, IL-6, IL-17, TNF-alpha, while increased the levels of IL-10 and TGF-gamma.	Thalidomide	36-47	interleukin 6	Mus musculus	202-206
31419499-6	2019	RESULTS: Vp-ME inhibited NO production in RAW264.7 cells stimulated with pam3CSK4, poly I:C or LPS and in LPS-stimulated peritoneal macrophages without cytotoxicity and downregulated mRNA expression of inflammatory enzymes, inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) and pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6.	vp-me	9-14	interleukin 6	Mus musculus	389-393
31835366-10	2019	PEG-GNPs inhibited the production of pro-inflammatory cytokines (IL-1, IL-6, IL-8, TNF-alpha) and Th1-related cytokines (IFN-Upsilon and IL-12p70), and increased the production of Th2 cytokines (IL-4 and IL-5).	poly(ethylene glycol)-poly(caprolactone)-poly(ethylene glycol)	0-3	interleukin 6	Mus musculus	71-75
31824152-8	2019	Results: We found that 20 mg/kg PEG-InP/ZnS QDs increased the number of neutrophils and the levels of IL-6 in both peritoneal lavage fluids and blood, which indicated acute phase inflammation in the mice.	Polyethylene Glycols	32-35	interleukin 6	Mus musculus	102-106
31419499-8	2019	Moreover, Vp-ME exhibited in vivo anti-inflammatory activity by ameliorating gastritis symptoms, inhibiting iNOS and IL-6 mRNA expression and IkappaBalpha activation in mice.	vp-me	10-15	interleukin 6	Mus musculus	117-121
31824152-8	2019	Results: We found that 20 mg/kg PEG-InP/ZnS QDs increased the number of neutrophils and the levels of IL-6 in both peritoneal lavage fluids and blood, which indicated acute phase inflammation in the mice.	Zinc	40-43	interleukin 6	Mus musculus	102-106
31804564-4	2019	Resveratrol suppressed IL-33-induced IL-6, IL-13, and TNF-alpha production in mouse bone marrow-derived mast cells (BMMCs), mouse fetal skin-derived mast cells, and human basophils.	resveratrol	0-11	interleukin 6	Mus musculus	37-41
31824152-9	2019	PEG-InP/ZnS QDs also activated the BMMs and increased the production of IL-6.	Polyethylene Glycols	0-3	interleukin 6	Mus musculus	72-76
31824152-9	2019	PEG-InP/ZnS QDs also activated the BMMs and increased the production of IL-6.	Zinc	8-11	interleukin 6	Mus musculus	72-76
31817202-0	2019	Vanadium Derivative Exposure Promotes Functional Alterations of VSMCs and Consequent Atherosclerosis via ROS/p38/NF-kappaB-Mediated IL-6 Production.	Vanadium	0-8	interleukin 6	Mus musculus	132-136
31817202-5	2019	Furthermore, exposure to NaVO3 or VOSO4 induced cytosolic ROS generation and IL-6 production in VSMCs and promoted VSMC synthetic differentiation, migration, and proliferation.	Sodium metavanadate	25-30	interleukin 6	Mus musculus	77-81
31817202-5	2019	Furthermore, exposure to NaVO3 or VOSO4 induced cytosolic ROS generation and IL-6 production in VSMCs and promoted VSMC synthetic differentiation, migration, and proliferation.	vanadyl sulfate	34-39	interleukin 6	Mus musculus	77-81
31817202-6	2019	The anti-oxidant N-acetylcysteine (NAC) not only suppresses IL-6 production and VSMC pathological responses including migration and proliferation but also prevents atherosclerosis in ApoE-/- mice.	Acetylcysteine	17-33	interleukin 6	Mus musculus	60-64
31817202-6	2019	The anti-oxidant N-acetylcysteine (NAC) not only suppresses IL-6 production and VSMC pathological responses including migration and proliferation but also prevents atherosclerosis in ApoE-/- mice.	Acetylcysteine	35-38	interleukin 6	Mus musculus	60-64
31817202-7	2019	Inhibition experiments with NAC and pharmacological inhibitors demonstrated that NaVO3-induced IL-6 production is signaled by ROS-triggered p38-mediated NF-kappaB-dependent pathways.	Acetylcysteine	28-31	interleukin 6	Mus musculus	95-99
31817202-7	2019	Inhibition experiments with NAC and pharmacological inhibitors demonstrated that NaVO3-induced IL-6 production is signaled by ROS-triggered p38-mediated NF-kappaB-dependent pathways.	Sodium metavanadate	81-86	interleukin 6	Mus musculus	95-99
31817202-7	2019	Inhibition experiments with NAC and pharmacological inhibitors demonstrated that NaVO3-induced IL-6 production is signaled by ROS-triggered p38-mediated NF-kappaB-dependent pathways.	Reactive Oxygen Species	126-129	interleukin 6	Mus musculus	95-99
31817202-8	2019	Neutralizing anti-IL-6 antibodies impaired NaVO3-mediated VSMC migration and proliferation.	Sodium metavanadate	43-48	interleukin 6	Mus musculus	18-22
31817202-9	2019	We concluded that NaVO3 exposure activates the ROS-triggering p38 signaling to selectively induce NF-kappaB-mediated IL-6 production.	Sodium metavanadate	18-23	interleukin 6	Mus musculus	117-121
31817202-9	2019	We concluded that NaVO3 exposure activates the ROS-triggering p38 signaling to selectively induce NF-kappaB-mediated IL-6 production.	Reactive Oxygen Species	47-50	interleukin 6	Mus musculus	117-121
31885501-7	2019	Administration of AUDA also reduced the LPS-induced changes of 14,15-DHET, IL-1beta, and IL-6 in the placentas of pregnant mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	18-22	interleukin 6	Mus musculus	89-93
31703480-5	2019	After 150 d, the results showed a significant increase in testicular cytokines levels including of IL-17A, IL-6, IFN-gamma and TNF-alpha in NaF and EAO groups compared with control group.	Sodium	140-143	interleukin 6	Mus musculus	107-111
31703480-7	2019	In addition, findings showed that in NaF and EAO groups, macrophages and T cells both significantly secreted IL-17A, and the protein and mRNA levels of cytokines (IL-6 and TGF-beta) were significantly increased.	Sodium	37-40	interleukin 6	Mus musculus	163-167
31871424-6	2019	Similarly, the amounts of proinflammatory cytokines, TNF-alpha, IL-6, and IL-1beta were decreased after rosiglitazone-induced brown adipocyte transplantation.	Rosiglitazone	104-117	interleukin 6	Mus musculus	64-68
31800964-2	2019	We previously showed that propranolol reduces choroidal neovascularization (CNV) by decreasing interleukin-6 levels.	Propranolol	26-37	interleukin 6	Mus musculus	95-108
31793343-3	2021	As the incubation time increased, MeHgCl had obvious damage to cell morphology, decreased the ratio of Bcl-2 and Bak and increased the expressions of TNF-alpha, IL-6 and IL-1beta significantly.	Mercuric Chloride	34-40	interleukin 6	Mus musculus	161-165
31793343-4	2021	Furthermore, the expressions of IL-1beta and IL-6 in HgCl2 group were increased significantly in 6 h and 24 h. The apoptotic rates in MeHgCl and HgCl2 group were respectively higher than beta-HgS with 32.2% and 7.30% in 24 h. Our findings indicate that beta-HgS is much less neurotoxicity than MeHgCl and HgCl2 in Neuro-2a cells.	Mercuric Chloride	53-58	interleukin 6	Mus musculus	45-49
31793343-4	2021	Furthermore, the expressions of IL-1beta and IL-6 in HgCl2 group were increased significantly in 6 h and 24 h. The apoptotic rates in MeHgCl and HgCl2 group were respectively higher than beta-HgS with 32.2% and 7.30% in 24 h. Our findings indicate that beta-HgS is much less neurotoxicity than MeHgCl and HgCl2 in Neuro-2a cells.	Mercuric Chloride	134-140	interleukin 6	Mus musculus	45-49
31793343-4	2021	Furthermore, the expressions of IL-1beta and IL-6 in HgCl2 group were increased significantly in 6 h and 24 h. The apoptotic rates in MeHgCl and HgCl2 group were respectively higher than beta-HgS with 32.2% and 7.30% in 24 h. Our findings indicate that beta-HgS is much less neurotoxicity than MeHgCl and HgCl2 in Neuro-2a cells.	Mercuric Chloride	145-150	interleukin 6	Mus musculus	45-49
31793343-4	2021	Furthermore, the expressions of IL-1beta and IL-6 in HgCl2 group were increased significantly in 6 h and 24 h. The apoptotic rates in MeHgCl and HgCl2 group were respectively higher than beta-HgS with 32.2% and 7.30% in 24 h. Our findings indicate that beta-HgS is much less neurotoxicity than MeHgCl and HgCl2 in Neuro-2a cells.	Mercury	192-195	interleukin 6	Mus musculus	45-49
31793343-4	2021	Furthermore, the expressions of IL-1beta and IL-6 in HgCl2 group were increased significantly in 6 h and 24 h. The apoptotic rates in MeHgCl and HgCl2 group were respectively higher than beta-HgS with 32.2% and 7.30% in 24 h. Our findings indicate that beta-HgS is much less neurotoxicity than MeHgCl and HgCl2 in Neuro-2a cells.	Mercury	258-261	interleukin 6	Mus musculus	45-49
31793343-4	2021	Furthermore, the expressions of IL-1beta and IL-6 in HgCl2 group were increased significantly in 6 h and 24 h. The apoptotic rates in MeHgCl and HgCl2 group were respectively higher than beta-HgS with 32.2% and 7.30% in 24 h. Our findings indicate that beta-HgS is much less neurotoxicity than MeHgCl and HgCl2 in Neuro-2a cells.	Mercuric Chloride	294-300	interleukin 6	Mus musculus	45-49
31793343-4	2021	Furthermore, the expressions of IL-1beta and IL-6 in HgCl2 group were increased significantly in 6 h and 24 h. The apoptotic rates in MeHgCl and HgCl2 group were respectively higher than beta-HgS with 32.2% and 7.30% in 24 h. Our findings indicate that beta-HgS is much less neurotoxicity than MeHgCl and HgCl2 in Neuro-2a cells.	Mercuric Chloride	145-150	interleukin 6	Mus musculus	45-49
32042747-14	2019	In vivo, we observed GENT prevented mice from dying in the LPS-induced shock model and decreased the serum levels of IL-1beta and IL-6, the mRNA expression of IL-1beta, IL-6 and TNFalpha in lung tissue, and the amount of M1 macrophage infiltration in the lung.	gentiopicroside	21-25	interleukin 6	Mus musculus	130-134
31802426-4	2019	Hesperetin dramatically suppressed the levels of interleukin-6 and tumor necrosis factor-alpha, as well as the number of inflammatory cells in bronchoalveolar lavage fluid.	hesperetin	0-10	interleukin 6	Mus musculus	49-94
31816942-5	2019	Using a murine model of lipopolysaccharide (LPS)-induced pleurisy, we demonstrated that curine significantly inhibited the recruitment of neutrophils in association with the inhibition of cytokines tumor necrosis factor (TNF-alpha), interleukin (IL)-1beta, IL-6, monocyte chemotactic protein (CCL2/MCP-1) as well as leukotriene B4 in the pleural lavage of mice.	curine	88-94	interleukin 6	Mus musculus	257-261
32042729-0	2019	Toll-like receptor 4 (TLR4) deficiency aggravates dextran sulfate sodium (DSS)-induced intestinal injury by down-regulating IL6, CCL2 and CSF3.	sodium sulfate	58-72	interleukin 6	Mus musculus	124-127
32042747-14	2019	In vivo, we observed GENT prevented mice from dying in the LPS-induced shock model and decreased the serum levels of IL-1beta and IL-6, the mRNA expression of IL-1beta, IL-6 and TNFalpha in lung tissue, and the amount of M1 macrophage infiltration in the lung.	gentiopicroside	21-25	interleukin 6	Mus musculus	169-173
31586906-10	2019	We found that GAAS down-regulated the mRNA expression of IL-1beta, IL-6, TNF-alpha, IFN-gamma, and IL-17A, and it up-regulated the mRNA expression of IL-4 and TGF-beta.	Glycyrrhizic Acid	14-18	interleukin 6	Mus musculus	67-71
31347703-8	2019	Amelioration of pancreatic damage by butyrate was associated with reduced levels of TNF-alpha, IL-6 and MCP-1 and suppressed NLRP3 inflammasome activation in both pancreas and colon.	Butyrates	37-45	interleukin 6	Mus musculus	95-99
31476295-7	2019	Results from multiplex cytokine assay showed that RIPreC treatment decreased IL-6, IL-1 beta and TNF alpha levels in the cortex, while it inhibited IL-6 level in the hippocampus and striatum, and TNF alpha level in the hippocampus.	riprec	50-56	interleukin 6	Mus musculus	77-81
31722779-6	2019	In a TPA-induced animal model, transduced Tat-CIAPIN1 drastically decreased inflammation damage and inhibited COX-2, iNOS, IL-6, and TNF-alpha expression.	Tetradecanoylphorbol Acetate	5-8	interleukin 6	Mus musculus	123-127
31571510-5	2019	Taraxasterol also significantly inhibited the release of pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, interferon-gamma (IFN-gamma) and IL-4.	taraxasterol	0-12	interleukin 6	Mus musculus	126-139
31571510-5	2019	Taraxasterol also significantly inhibited the release of pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, interferon-gamma (IFN-gamma) and IL-4.	taraxasterol	0-12	interleukin 6	Mus musculus	141-145
31356994-7	2019	NaF-inactivated TLR2/MyD88 signaling pathway was identified by prominently downregulated mRNA and protein expression levels of TLR2/MyD88, IRAK4, IRAK1, TRAF6, TAK1, MKK4/MKK7 and c-Jun, which ultimately altered the expression levels of IL-1beta, IL-4, IL-6 and IL-8 to attenuate innate immunity.	Sodium Fluoride	0-3	interleukin 6	Mus musculus	253-257
31545206-5	2019	TBBPA upregulated the expression of pro-inflammatory cytokines, including IL-1beta, IL-6, and TNF-alpha, whereas it attenuated the LPS-stimulated expression of these pro-inflammatory cytokines, and the expression of anti-inflammatory cytokines, including IL-4, IL-10, and IL-13.	tetrabromobisphenol A	0-5	interleukin 6	Mus musculus	84-88
32038944-14	2019	Results: Quercetin treatment for 12 weeks significantly reduced the levels of TC (P<0.001), TG (P<0.05), HDL (P<0.001), LDL (P<0.001), TNF-alpha (P<0.001) and IL-6 (P<0.001) compared with the model group.	Quercetin	9-18	interleukin 6	Mus musculus	159-163
31709729-2	2019	We show that cobalt protoporphyrin IX (CoPP) increases plasma concentrations of G-CSF, IL-6, and MCP-1 in mice, triggering the mobilization of granulocytes and hematopoietic stem and progenitor cells (HSPC).	cobaltiprotoporphyrin	13-37	interleukin 6	Mus musculus	87-91
31727601-6	2019	PD180970 also exerts anti-neuroinflammatory potential by inhibiting the release of proinflammatory cytokines such as IL-6 (interleukin-6) and MCP-1 (monocyte chemoattractant protein-1) through reduction of TLR-4 (toll like receptor-4) mediated NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation.	PD 180970	0-8	interleukin 6	Mus musculus	117-121
31727601-6	2019	PD180970 also exerts anti-neuroinflammatory potential by inhibiting the release of proinflammatory cytokines such as IL-6 (interleukin-6) and MCP-1 (monocyte chemoattractant protein-1) through reduction of TLR-4 (toll like receptor-4) mediated NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation.	PD 180970	0-8	interleukin 6	Mus musculus	123-136
31407330-8	2019	Kaempferol reduced CD3+ T cell infiltration and gene expression of major proinflammatory cytokines, including interleukin (IL)-6, IL-17A and tumor necrosis factor (TNF)-alpha, in the psoriatic skin lesion.	kaempferol	0-10	interleukin 6	Mus musculus	110-128
31334837-0	2019	IL-33-activated murine mast cells control the dichotomy between RORgammat+ and Helios+ Tregs via the MK2/3-mediated IL-6 production in vitro.	Helium	79-85	interleukin 6	Mus musculus	116-120
31709729-2	2019	We show that cobalt protoporphyrin IX (CoPP) increases plasma concentrations of G-CSF, IL-6, and MCP-1 in mice, triggering the mobilization of granulocytes and hematopoietic stem and progenitor cells (HSPC).	cobaltiprotoporphyrin	39-43	interleukin 6	Mus musculus	87-91
31639616-6	2019	Importantly, MNA treatment suppressed the protein expression of nuclear factor-kappa B p65 (NF-kappaB p65), pro-inflammatory cytokines (TNF-alpha, IL-6) and decreased the activation of microglia and astrocytes in the hippocampus and frontal cortex of LPS-induced mice.	N(1)-methylnicotinamide	13-16	interleukin 6	Mus musculus	147-151
31100194-4	2019	PHX-induced generation of the soluble IL-6R by ADAM (a disintegrin and metallo) proteases enables IL-6 trans-signaling, in which IL-6 forms an agonistic complex with the soluble IL-6 receptor (sIL-6R) to activate all cells expressing the signal-transducing receptor chain glycoprotein 130 (gp130).	PHX	0-3	interleukin 6	Mus musculus	38-42
31100194-4	2019	PHX-induced generation of the soluble IL-6R by ADAM (a disintegrin and metallo) proteases enables IL-6 trans-signaling, in which IL-6 forms an agonistic complex with the soluble IL-6 receptor (sIL-6R) to activate all cells expressing the signal-transducing receptor chain glycoprotein 130 (gp130).	PHX	0-3	interleukin 6	Mus musculus	98-102
31100194-4	2019	PHX-induced generation of the soluble IL-6R by ADAM (a disintegrin and metallo) proteases enables IL-6 trans-signaling, in which IL-6 forms an agonistic complex with the soluble IL-6 receptor (sIL-6R) to activate all cells expressing the signal-transducing receptor chain glycoprotein 130 (gp130).	PHX	0-3	interleukin 6	Mus musculus	98-102
31236768-7	2019	Moreover, the blood level of tumor necrosis factor-alpha, interleukin-6, reactive oxygen species (ROS), and matrix metalloproteinase (MMP)-9 was decreased by tranexamic acid administration.	Tranexamic Acid	158-173	interleukin 6	Mus musculus	58-71
31309485-3	2019	Oral paeoniflorin treatment also downregulated the systemic pro-inflammatory cytokines IL-6 (by 52.2%), TNF-alpha (by 57.7%) and IL-1beta (by 34.1%).	peoniflorin	5-17	interleukin 6	Mus musculus	87-91
31309486-8	2019	The IL-6 and TNF-alpha mRNA expression increased in the LPS, LPS + ANTA, and LPS + AGO + ANTA groups when compared to the healthy group in the 2nd and 4th hours.	anta	67-71	interleukin 6	Mus musculus	4-8
31321583-5	2019	Pretreatment with AZD4547 significantly alleviated the expression of the pro-inflammatory factors IL-1beta, IL-6, TNF-alpha, MMP9, and CXCL10 both in vivo and in vitro.	AZD4547	18-25	interleukin 6	Mus musculus	108-112
31634788-2	2019	In this study, 3-O-[(E)-(2-oxo-4-(p-tolyl)but-3-en-1-yl] kaempferol (OTBK) prevented the production of pro-inflammatory mediators TNFalpha, IL-6, PGE2 and nitrite from BV-2 microglia activated with LPS and IFNgamma.	3-o-[(e)-(2-oxo-4-(p-tolyl)but-3-en-1-yl] kaempferol	15-67	interleukin 6	Mus musculus	140-144
31798708-5	2019	In vitro treatment with OV on LPS-stimulated mouse podocyte cell line MPC5 did not affect TLR2 expression but interrupted the interaction between TLR2 and its downstream adaptor MyD88, resulting in the reduction of inflammatory cytokines IL-6 and TNF-alpha expression.	vanillin	24-26	interleukin 6	Mus musculus	238-242
31798708-7	2019	Additionally, inflammatory cytokines TNF-alpha, IL-6 and IL-1beta expression were also significantly reduced in mice with OV treatment.	vanillin	122-124	interleukin 6	Mus musculus	48-52
31522340-5	2019	alpha7nAchR agonist PNU-282987 protected MH-S cells from LPS-induced inflammation by reducing the concentrations of IL-6, TNF-alpha, and IL-1beta.	N-neopentyl-N-nitrosourea	20-23	interleukin 6	Mus musculus	116-120
31669889-4	2019	PSN treatment significantly attenuated HKMRSA-induced pathological injury, pulmonary neutrophil infiltration, tissue permeability and the production of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6) in murine ALI model.	PSN	0-3	interleukin 6	Mus musculus	204-208
31677497-6	2019	In addition, EP decreased microglia enrichment in myelin sheath, and declined TLR4/p-NF-kb/p65 and IL-1beta and IL-6, inhibiting microglia-mediated neuroinflammation.	ethyl pyruvate	13-15	interleukin 6	Mus musculus	112-116
31699670-5	2019	On the other hand, when BaP-treated BV2 cells were further incubated with FA (10, 20, 40, or 80 mg/mL) for another 24 h, a significant reduction in BaP-induced DNA damage and the release of multiple pro-inflammatory and cytotoxic factors (including interleukin-1beta, interleukin-6, NO, and ROS) was observed in a dose-dependent manner.	Benzo(a)pyrene	24-27	interleukin 6	Mus musculus	268-281
31762039-7	2019	We found that TFECG significantly inhibited PM2.5 -stimulated overproduction of TNF-alpha, IL-1beta, IL-6, and IL-18 and increased the numbers of WBC, NEUT, LYMPH, and MONO in BALF.	tfecg	14-19	interleukin 6	Mus musculus	101-105
31282784-8	2019	Nevertheless, and most importantly, pre-exposure to the AgNP for 24 h enhanced RAW 264.7 cell phagocytic ability as well as the release of inflammatory cytokine interleukin-6 in response to lipopolysaccharide (LPS).	agnp	56-60	interleukin 6	Mus musculus	161-174
31545135-4	2019	This study reveals the advantageous effects of Raffinee on PC12 cells by decreasing hypoxia-induced apoptosis in mice with permanent middle cerebral artery occlusion (pMCAO) by increasing the levels of neurotrophic factors such as S100beta, reducing serum inflammatory factors such as matrix metalloproteinases (MMP)-9/MMP-2 ratio, tumor necrosis factor-alpha, and interleukin (IL)-6 level, and increasing IL-10 levels.	raffinee	47-55	interleukin 6	Mus musculus	365-383
31586017-5	2019	EtOH- and lipopolysaccharide-induced expression of INF-gamma, Il-6, and Cxcl1 was attenuated in fat-1 and WT RvD1-treated mice.	Ethanol	0-4	interleukin 6	Mus musculus	62-66
31661121-7	2019	DHA suppressed the LPS-induced infiltration of inflammatory cells, the elevation of myeloperoxidase activity, oxidative stress and the production of pro-inflammatory cytokines, including interleukin (IL)-1beta, tumor necrosis factor-alpha, and IL-6.	artenimol	0-3	interleukin 6	Mus musculus	244-248
31509634-6	2019	Reduced malondialdehyde and increased interleukin 6 levels further indicated the protective effect of quercetin against immune/inflammatory responses and oxidative stress.	Quercetin	102-111	interleukin 6	Mus musculus	38-51
31517429-8	2019	Riclin inhibited TNF-alpha, IL-1beta and IL-6 expression in LPS-stimulated RAW 264.7 macrophage cells in a dose-dependent manner.	riclin	0-6	interleukin 6	Mus musculus	41-45
31517429-9	2019	In addition, Riclin pretreatment increased the survival rate of D-Gal/LPS treated mice, inhibited serum ALT and AST activities and reduced the production of the inflammatory mediators TNF-alpha, IL-1beta and IL-6.	riclin	13-19	interleukin 6	Mus musculus	208-212
31131439-10	2019	Hence, miR-181b-5p moderated proinflammatory chemokine production by targeting IL-6 in cementoblasts and NF-kappaB signaling pathway was involved.	mir-181b-5p	7-18	interleukin 6	Mus musculus	79-83
31422511-5	2019	The levels of TNF-alpha, IL-1beta and IL-6 were decreased after ASHP and SCH + NKT treatment.	ashp	64-68	interleukin 6	Mus musculus	38-42
31494302-7	2019	Furthermore, polydatin treatment remarkably impeded the expression of TNF-alpha, IL-1beta, and IL-6 by ELISA assay.	polydatin	13-22	interleukin 6	Mus musculus	95-99
31422511-5	2019	The levels of TNF-alpha, IL-1beta and IL-6 were decreased after ASHP and SCH + NKT treatment.	schizandrin	73-76	interleukin 6	Mus musculus	38-42
31661120-12	2019	In addition, the activation of glia cells and upregulation of the glia-derived inflammatory mediators, interleukin (IL)-1beta and IL-6 were suppressed by JWH015.	JHW 015	154-160	interleukin 6	Mus musculus	130-134
31590042-14	2019	Curcumin treatment switched the M1 pro-inflammatory phenotype to the M2 anti-inflammatory phenotype by decreasing the expression of M1 markers (i.e., iNOS, IL-1beta, IL-6, and CD16/32) and elevating the expression of M2 markers (i.e., arginase 1, IL-4, IL-10, and CD206).	Curcumin	0-8	interleukin 6	Mus musculus	166-170
31661120-13	2019	In LPS-stimulated primary neurons, IL-1beta and IL-6 were increased, and autophagy flux was impaired; whereas treatment with JWH015 decreased the expression of IL-1beta and IL-6, LC3B-II/LC3B-I ratio and expression of p62.	JHW 015	125-131	interleukin 6	Mus musculus	173-177
31702812-6	2019	In addition, the levels of IL-4, IL-6 and IL-10 in the BMDCs from the vitamin D-deficient mice were significantly decreased compared with the control mice, while the levels of tumor necrosis factor-alpha, IL-5, IL-2, IL-12 and interferon-gamma were significantly increased.	Vitamin D	70-79	interleukin 6	Mus musculus	33-37
31661120-16	2019	Intrathecal administration of the selective CB2 agonist JWH015 ameliorated autophagy flux through the downregulation of IL-1beta and IL-6 and attenuated BCP.	JHW 015	56-62	interleukin 6	Mus musculus	133-137
30897196-9	2019	Blockade of interleukin (IL)-6 signaling rescued peritoneal transport function in Nx + salt mice.	Salts	87-91	interleukin 6	Mus musculus	12-30
30897196-10	2019	In cultured Met-5A, additional NaCl in the medium upregulated IL-6 as well as vascular endothelial growth factor-A, associated with increased expression and nuclear translocation of tonicity-responsive enhancer binding protein (TonEBP).	Sodium Chloride	31-35	interleukin 6	Mus musculus	62-66
31880892-8	2019	Cytokine assays in serum revealed that CXN alone induced IL-6, IFN-gamma, and TNF-alpha in the mouse groups infected with ATCC 29213 or MRSA135, and the combination of these three drugs significantly reduced IL-6, IFN-gamma, and TNF-alpha concentrations.	Cloxacillin	39-42	interleukin 6	Mus musculus	57-61
31626919-9	2019	Mechanistically, miR-124 directly targeted signal transducer and activator of transcription 3 (STAT3) in BV2 cells; in addition, upregulation of miR-124 inhibited the increase of inducible nitric oxide synthetase and proinflammatory cytokines, including IL-6, IL-1beta, TNF-alpha, and MCP-1, in LPS-stimulated BV2 cells.	Nitric Oxide	189-201	interleukin 6	Mus musculus	254-258
31880892-8	2019	Cytokine assays in serum revealed that CXN alone induced IL-6, IFN-gamma, and TNF-alpha in the mouse groups infected with ATCC 29213 or MRSA135, and the combination of these three drugs significantly reduced IL-6, IFN-gamma, and TNF-alpha concentrations.	Cloxacillin	39-42	interleukin 6	Mus musculus	208-212
31880892-18	2019	Cytokine assays in serum revealed that CXN alone induced IL-6, IFN-gamma, and TNF-alpha in the mouse groups infected with ATCC 29213 or MRSA135, and the combination of these three drugs significantly reduced IL-6, IFN-gamma, and TNF-alpha concentrations.	Cloxacillin	39-42	interleukin 6	Mus musculus	57-61
31880892-18	2019	Cytokine assays in serum revealed that CXN alone induced IL-6, IFN-gamma, and TNF-alpha in the mouse groups infected with ATCC 29213 or MRSA135, and the combination of these three drugs significantly reduced IL-6, IFN-gamma, and TNF-alpha concentrations.	Cloxacillin	39-42	interleukin 6	Mus musculus	208-212
31849616-8	2019	Both inhibitors blunted LPA-induced phosphorylation of STAT1 and STAT3, p65, and c-Jun and consequently reduced the secretion of pro-inflammatory cyto-/chemokines (IL-6, TNFalpha, IL-1beta, CXCL10, CXCL2, and CCL5) at non-toxic concentrations.	lysophosphatidic acid	24-27	interleukin 6	Mus musculus	164-168
31452288-7	2019	Not only that, quercetin markedly attenuated T2DM-induced production of interleukin 1 beta, interleukin 6, and TNF-alpha.	Quercetin	15-24	interleukin 6	Mus musculus	92-105
31819402-12	2019	Erythromycin reduced IFN-gamma, IL-17, IL-6 inflammatory cytokines, MLI, and the inflammation score in the lungs of EP-exposed mice.	Erythromycin	0-12	interleukin 6	Mus musculus	39-43
31771617-11	2019	Inhibiting DNMT3b with RNA interference or nanaomycin A (a selective DNMT3b inhibitor) effectively suppressed the IL-6 or STAT-Y640F-induced increase of DNMT3b-OCT4 and ALDH activity in vitro and in vivo.	nanaomycin A	43-55	interleukin 6	Mus musculus	114-118
31671940-4	2019	Meanwhile, DISO resulted in strong inhibition against the elevation of hepatic injury marker (AST, ALT, and ALP) activities and dyslipidemia (TC, TG, LDL-C, and HDL-C), as well as liver inflammatory cytokine (IL-1, IL-6, TNF-alpha, and TNF-beta) release in l-carnitine-fed mice (p < 0.05).	diso	11-15	interleukin 6	Mus musculus	215-219
31710352-9	2019	Mechanistically, CXCL13 induces the expression of PHLPP1, an Akt2 phosphatase, through FAK signaling; and correspondingly we show that CXCL13 and DFO-induced IL-6 and PAI-1 expression was blocked by Phlpp1 knockdown.	Deferoxamine	146-149	interleukin 6	Mus musculus	158-162
31744501-10	2019	RESULTS: A cumulative dose of DOX (10 mg/kg) induced acute cardiotoxicity in mice manifested by altered echocardiographic outcome, and increased tumor necrosis factor, interleukin 6 (IL-6), monocyte chemotactic protein 1, interferon-gamma, and serum AST and LDH levels, as well as cardiac cytoplasmic vacuolation and myofibrillar disarrangement.	Doxorubicin	30-33	interleukin 6	Mus musculus	168-181
31775224-7	2019	OIR3 was able to reduce oxazolone-induced skin inflammation in allergic dermatitis mouse model via the inhibition of TNF-alpha, IL-1beta and IL-6 mRNA expression.	Oxazolone	24-33	interleukin 6	Mus musculus	141-145
31827682-5	2019	DBA induced inflammation in the liver of the mice which is supported by increasing the production of tumor necrosis factor-alpha (TNF-alpha) and the mRNA levels of TNF-alpha, interleukin-6 (IL-6), interleukin-1beta (IL-1beta), and nuclear factor kappaB (NF-kappaB) in the liver.	dibromoacetic acid	0-3	interleukin 6	Mus musculus	175-188
31827682-5	2019	DBA induced inflammation in the liver of the mice which is supported by increasing the production of tumor necrosis factor-alpha (TNF-alpha) and the mRNA levels of TNF-alpha, interleukin-6 (IL-6), interleukin-1beta (IL-1beta), and nuclear factor kappaB (NF-kappaB) in the liver.	dibromoacetic acid	0-3	interleukin 6	Mus musculus	190-194
31744501-10	2019	RESULTS: A cumulative dose of DOX (10 mg/kg) induced acute cardiotoxicity in mice manifested by altered echocardiographic outcome, and increased tumor necrosis factor, interleukin 6 (IL-6), monocyte chemotactic protein 1, interferon-gamma, and serum AST and LDH levels, as well as cardiac cytoplasmic vacuolation and myofibrillar disarrangement.	Doxorubicin	30-33	interleukin 6	Mus musculus	183-187
31803045-10	2019	Melatonin and rapamycin significantly ameliorated the isoflurane-induced cognitive impairment and also led to a decrease in the melatonin levels as well as the expression levels of TNF-alpha, IL-1beta, IL-6, and p-mTOR in the hippocampus.	Melatonin	0-9	interleukin 6	Mus musculus	202-206
31803045-10	2019	Melatonin and rapamycin significantly ameliorated the isoflurane-induced cognitive impairment and also led to a decrease in the melatonin levels as well as the expression levels of TNF-alpha, IL-1beta, IL-6, and p-mTOR in the hippocampus.	Sirolimus	14-23	interleukin 6	Mus musculus	202-206
31814910-14	2019	Meanwhile, AS II decreased the levels of IL-6, TNF-alpha, IL-1beta, NO, MPO and MDA, and increased the level of SOD in colon of DSS-treated mice.	astragaloside II	11-16	interleukin 6	Mus musculus	41-45
31642668-6	2019	We found that pterostilbene significantly attenuated thoracic and abdominal atherosclerotic plaque size in HFD-fed ApoE-/-mice, accompanied by modulated lipid profiles and reduced production of pro-inflammatory cytokines (including IL-6, IFN-gamma and TNF-alpha).	pterostilbene	14-27	interleukin 6	Mus musculus	232-236
31545984-4	2019	Sevoflurane induced IL-6 mRNA significantly, but did not upregulate IL-17.	sevoflurane	0-11	interleukin 6	Mus musculus	20-24
31610190-9	2019	Additionally, VGX-1027 treatment resulted in a substantial decrease in IL-1beta, IL-6, TNF-alpha, IFN-gamma, and NF-kappaB p65 production, but increased IL-10 production in CD4+ T cells.	3-phenyl-4,5-dihydro-5-isoxazole acetic acid	14-22	interleukin 6	Mus musculus	81-85
31752148-8	2019	PLAG significantly decreased plasma levels of the chemokine (C-X-C motif) ligand 1 (CXCL1), CXCL2, interleukin (IL)-6, and C-reactive protein (CRP), which were elevated consistently with the occurrence time of neutropenia, monocytopenia, and thrombocytopenia.	1-palmitoyl-2-linoleoyl-3-acetyl-rac glycerol	0-4	interleukin 6	Mus musculus	99-117
31610207-5	2019	The optimal dose of BCP, 72 mg/kg body weight, inhibited microglial activation and reduced the secretion of proinflammatory cytokines interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and IL-6 by microglia of WT mice.	caryophyllene	20-23	interleukin 6	Mus musculus	197-201
31545984-5	2019	Other volatile anesthetics, including isoflurane, enflurane, and halothane, induced IL-6 mRNA in fetal brains as well as sevoflurane, but propofol did not.	Isoflurane	38-48	interleukin 6	Mus musculus	84-88
31545984-5	2019	Other volatile anesthetics, including isoflurane, enflurane, and halothane, induced IL-6 mRNA in fetal brains as well as sevoflurane, but propofol did not.	Enflurane	50-59	interleukin 6	Mus musculus	84-88
31545984-5	2019	Other volatile anesthetics, including isoflurane, enflurane, and halothane, induced IL-6 mRNA in fetal brains as well as sevoflurane, but propofol did not.	Halothane	65-74	interleukin 6	Mus musculus	84-88
31545984-7	2019	Because IL-6 induction in fetal brains may affect neuronal precursor cells (NPCs), numbers of NPCs in the subventricular zone were studied, revealing that maternal sevoflurane treatment significantly increases NPCs in offspring at 8 weeks after birth (p8wk).	sevoflurane	164-175	interleukin 6	Mus musculus	8-12
31707400-9	2019	RESULTS AB23A improved the survival rate and ameliorated myocardial injury, decreased inflammatory infiltration and the level of IL-6, IL-1ss, and TNF-alpha in the LPS-stimulated mouse model.	alisol B 23-acetate	8-13	interleukin 6	Mus musculus	129-133
31712703-4	2019	In paclitaxel-treated mice, increased fatigue and decreased cognitive performance occurred in parallel with reduced microglia immunoreactivity, increased circulating chemokine expression (CXCL1), as well as transient increases in pro-inflammatory cytokine/chemokine (Il-1beta, Tnfalpha, Il-6, and Cxcl1) gene expression in the brain.	Paclitaxel	3-13	interleukin 6	Mus musculus	287-291
31320134-9	2019	Isolated for the first time from L. chamissonis leaves, glaucolide B presented a significant inhibitory effect on both NO and IL-6 secretion under non-toxic concentrations.	glaucolide B	56-68	interleukin 6	Mus musculus	126-130
31814709-7	2019	The levels of hepatic cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), in addition to myeloperoxidase (MPO) activity, were significantly decreased following DEX treatment.	dextran methacylate phthalate	185-188	interleukin 6	Mus musculus	77-90
31814709-7	2019	The levels of hepatic cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), in addition to myeloperoxidase (MPO) activity, were significantly decreased following DEX treatment.	dextran methacylate phthalate	185-188	interleukin 6	Mus musculus	92-96
31728208-12	2019	Despite of significantly high IL-6 levels, the arthritic symptoms waned off which suggested the participation of IL-6 in LC3b-independent autophagy pathway in the extract prepared in ethyl acetate.	ethyl acetate	183-196	interleukin 6	Mus musculus	113-117
31699146-7	2019	Remarkably, antibiotic treatments restored the levels of several primary and secondary bile acids, which significantly reduced IL-6 expression in RAW macrophages in vitro.	Bile Acids and Salts	87-97	interleukin 6	Mus musculus	127-131
31806959-8	2019	In mice subjected to dextran sulfate sodium-induced colitis, oral administration of BDS-entrapped KO liposomes suppressed tumor necrosis factor-alpha production (by 84.1%), interleukin-6 production (by 35.3%), and the systemic level of endotoxin (by 96.8%), and slightly reduced the macroscopic signs of the disease.	Budesonide	84-87	interleukin 6	Mus musculus	173-186
31780865-8	2019	Results: Rubiadin-1-methyl ether was able to inhibit the pro-inflammatory parameters studied in the in vitro assays (NOx, IL-6, and IL-1beta) and, at the same time, increased the macrophage apoptosis rate.	rubiadin 1-methyl ether	9-32	interleukin 6	Mus musculus	122-126
31694174-6	2019	Furthermore, celastrol effects on ketamine-induced alterations of proinflammatory (TNF-alpha, IL-6 and IL-1beta) and anti-inflammatory (IL-10) cytokines in this brain region were evaluated.	celastrol	13-22	interleukin 6	Mus musculus	94-98
31694174-6	2019	Furthermore, celastrol effects on ketamine-induced alterations of proinflammatory (TNF-alpha, IL-6 and IL-1beta) and anti-inflammatory (IL-10) cytokines in this brain region were evaluated.	Ketamine	34-42	interleukin 6	Mus musculus	94-98
31520133-6	2019	The combination of mesalazine and LAB mixture was the most effective to decrease the intestinal damage at macroscopic and histological levels and to reduce pro-inflammatory cytokines (IL-6 and TNF-alpha) in intestinal fluids.	Mesalamine	19-29	interleukin 6	Mus musculus	184-188
31520133-7	2019	In animals instilled with ethanol, mesalazine produced a loss of body weight and intestinal damages with increased IL-6.	Ethanol	26-33	interleukin 6	Mus musculus	115-119
31520133-7	2019	In animals instilled with ethanol, mesalazine produced a loss of body weight and intestinal damages with increased IL-6.	Mesalamine	35-45	interleukin 6	Mus musculus	115-119
31493866-5	2019	Compared with the HFD group, rosiglitazone did not affect blood glucose levels, but it attenuated serum levels of tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6), ameliorated plaque lipid accumulation and the expression of matrix metalloproteinases-2 and -9, increased the collagen content of plaques, and inhibited perivascular MC degranulation and chymase expression.	Rosiglitazone	29-42	interleukin 6	Mus musculus	157-170
31493866-5	2019	Compared with the HFD group, rosiglitazone did not affect blood glucose levels, but it attenuated serum levels of tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6), ameliorated plaque lipid accumulation and the expression of matrix metalloproteinases-2 and -9, increased the collagen content of plaques, and inhibited perivascular MC degranulation and chymase expression.	Rosiglitazone	29-42	interleukin 6	Mus musculus	172-176
31349026-4	2019	Treatment of LPS injected mice with the 12/15-LO inhibitor, baicalein, significantly reduced levels of renal injury and inflammation markers including urinary thiobarbituric acid reactive substance (TBARs), urinary monocyte chemoattractant protein-1 (MCP-1), renal interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).	baicalein	60-69	interleukin 6	Mus musculus	265-278
31349026-4	2019	Treatment of LPS injected mice with the 12/15-LO inhibitor, baicalein, significantly reduced levels of renal injury and inflammation markers including urinary thiobarbituric acid reactive substance (TBARs), urinary monocyte chemoattractant protein-1 (MCP-1), renal interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).	baicalein	60-69	interleukin 6	Mus musculus	280-284
31469455-9	2019	Beneficially, VC-dosed CG mice resulted in downregulated expressions of endogenous TNF-alpha, IL6, and c-Jun in blood and bladder samples.	cg	23-25	interleukin 6	Mus musculus	94-97
31493747-10	2019	CIM inhibited the overexpression of IL-1beta, IL-6, and IL-24 in HaCaT.	cim	0-3	interleukin 6	Mus musculus	46-50
31493747-5	2019	The cytokines, including TNF-alpha, IL-1beta, IL-6, and IL-17 in psoriasiform skin, can be attenuated to normal baseline by CIM.	cim	124-127	interleukin 6	Mus musculus	46-50
31763378-7	2019	in vitro experiments, using osteoblast cell line, MC3T3-E1, revealed that the expression of IL-6 was increased by LPS stimulation, but decreased after ALA/SFC treatment in mRNA and protein levels.	Aminolevulinic Acid	151-154	interleukin 6	Mus musculus	92-96
31763378-7	2019	in vitro experiments, using osteoblast cell line, MC3T3-E1, revealed that the expression of IL-6 was increased by LPS stimulation, but decreased after ALA/SFC treatment in mRNA and protein levels.	citrate	155-158	interleukin 6	Mus musculus	92-96
31763378-11	2019	ALA/SFC treatment attenuated LPS-mediated IL-6 upregulation.	Aminolevulinic Acid	0-3	interleukin 6	Mus musculus	42-46
31763378-11	2019	ALA/SFC treatment attenuated LPS-mediated IL-6 upregulation.	citrate	4-7	interleukin 6	Mus musculus	42-46
31412132-7	2019	Blocking the RNA/DNA binding protein nucleolin with midkine reduced expression of IL-1beta/TNFalpha and the nucleolin inhibitor AS1411 reduced interleukin-6 release in adult mice cardiomyocytes.	AGRO 100	128-134	interleukin 6	Mus musculus	143-156
31401302-7	2019	Results in the Morris water maze suggest that cognitive flexibility was reduced by the blocking of the IL-6 trans-signaling in young and old Tg2576 female mice.	Water	22-27	interleukin 6	Mus musculus	103-107
31552591-4	2019	Pre-treatment with Sch A significantly decreased the levels of the inflammatory mediators IL-6, IL-1beta, and TNF-alpha and markedly improved antioxidant defences by inhibiting the activity of MDA and increasing that of SOD.	schizandrin A	19-24	interleukin 6	Mus musculus	90-94
31437534-0	2019	Increased IL-6 expression in astrocytes is associated with emotionality, alterations in central amygdala GABAergic transmission, and excitability during alcohol withdrawal.	Alcohols	153-160	interleukin 6	Mus musculus	10-14
31542403-7	2019	In vitro studies of BV-2 microglial cells revealed that lovastatin inhibits multiple effects of LPS, including activation of NFkB; mRNA expression of tumor necrosis factor-a, interleukin-6 and cyclo-oxygenase 2; production of nitric oxide and reactive oxygen species; as well as phagocytic activity.	Lovastatin	56-66	interleukin 6	Mus musculus	175-188
31365830-0	2019	The IL-6/p-BTK/p-ERK signaling mediates the calcium phosphate-induced pruritus.	calcium phosphate	44-61	interleukin 6	Mus musculus	4-8
31209627-7	2019	CCI induced an significant increase of IBA1+ microglia accompanied by the increase of inflammatory cytokines IL-6 and IL-1beta, which were suppressed after lidocaine administration.	CCI	0-3	interleukin 6	Mus musculus	109-113
31209627-7	2019	CCI induced an significant increase of IBA1+ microglia accompanied by the increase of inflammatory cytokines IL-6 and IL-1beta, which were suppressed after lidocaine administration.	Lidocaine	156-165	interleukin 6	Mus musculus	109-113
31504393-6	2019	LPS induced expression of inflammatory cytokines Il1a, Il1b, Il6, Tnf and Il10 in fetal brain, placental and uterine tissues, and (+)-naloxone suppressed LPS-induced cytokine expression.	Naloxone	130-142	interleukin 6	Mus musculus	61-64
31504393-7	2019	Fetal sex-specific regulation of cytokine expression was evident, with higher Il1a, Il1b, Il6 and Il10 induced by LPS in tissues associated with male fetuses, and greater suppression by (+)-naloxone of Il6 in females.	Naloxone	186-198	interleukin 6	Mus musculus	202-205
31365830-5	2019	The inhibition of BTK by ibrutinib noticeably diminish the CaP-induced up-regulation of IL-6 and p-ERK in mice.	ibrutinib	25-34	interleukin 6	Mus musculus	88-92
31365830-7	2019	The expressions of p-BTK and p-ERK in DRG primary cells reached maximum levels at 1 and 10 min, respectively, after treatment of recombinant IL-6 and were significantly reduced by treatment of IL-6 along with ibrutinib.	ibrutinib	209-218	interleukin 6	Mus musculus	141-145
31365830-7	2019	The expressions of p-BTK and p-ERK in DRG primary cells reached maximum levels at 1 and 10 min, respectively, after treatment of recombinant IL-6 and were significantly reduced by treatment of IL-6 along with ibrutinib.	ibrutinib	209-218	interleukin 6	Mus musculus	193-197
31477246-8	2019	Our results showed that treatment of glyburide significantly decreased the expressions of IFN-gamma, TNF-alpha, and IL-6 in the fracture calluses in diabetic-induced fracture model, while bone callus volume and bone volume fraction were increased.	Glyburide	37-46	interleukin 6	Mus musculus	116-120
31762728-13	2019	Curcumin also attenuated inflammation by inhibiting the IkappaBalpha-NF-kappaB pathway, which reduced the production of TNF, IL-1beta, and IL-6.	Curcumin	0-8	interleukin 6	Mus musculus	139-143
31670366-2	2019	The combination of CGA and caffeine effectively decreased body weight gain, intraperitoneal adipose tissue weight, serum LDL-c, FFA, TC, TG, leptin, IL-6 concentrations, and hepatic TG and TC levels and increased the serum adiponectin level.	Caffeine	27-35	interleukin 6	Mus musculus	149-153
31736758-11	2019	Safranal decreased the production and mRNA expression of IL-6 and TNF-alpha in the RAW264.7 cell line and inhibited the phosphorylation and nuclear translocation of components of the MAPK and NF-kappaB pathways.	safranal	0-8	interleukin 6	Mus musculus	57-61
31736758-14	2019	The levels of colonic IL-6 and TNF-alpha also decreased in Safranal-treated colitis mice.	safranal	59-67	interleukin 6	Mus musculus	22-26
31419561-5	2019	In addition, BaltCRP induced inflammatory responses characterized by an increase of leukocytes in the peritoneal cavity of mice, also stimulating the production of mediators such IL-6, IL-1beta, IL-10, PGE2, PGD2, LTB4 and CysLTs.	baltcrp	13-20	interleukin 6	Mus musculus	179-183
31933805-9	2019	Pretreatment with JWH133 improved PaO2/FiO2 ratio, decreased lung TNF-alpha, IL-6, MDA levels and MPO activities, and increased SOD activity.	1,1-dimethylbutyl-1-deoxy-Delta(9)-THC	18-24	interleukin 6	Mus musculus	77-81
30997682-5	2019	Treatment of C2C12 myocytes with asprosin-induced ER stress markers (phosphorylated inositol-requiring enzyme 1 and eukaryotic initiation factor 2, and CHOP expression) as well as inflammation markers (interleukin-6 expression, phosphorylated IkappaB, and nuclear translocated nuclear factor-kappabeta).	asprosin	33-41	interleukin 6	Mus musculus	202-215
31485644-5	2019	The results revealed that PL pretreatment reduced OVA-induced airway inflammatory cell infiltration, reduced Th2 cytokine expression, both in the bronchoalveolar lavage fluid and in lung tissues, reduced the serum IgE level, pro-inflammatory cytokine [tumor necrosis factor (TNF)-alpha and interleukin (IL)-6] and intercellular adhesion molecule expression, as well as nuclear factor (NF)-kappaB activation.	piperlonguminine	26-28	interleukin 6	Mus musculus	290-309
31152671-7	2019	The concentrations of hepatic interleukin-6 and tumor necrosis factor-alpha were 21.4% and 27.3% lower in the ZJ617s + LPS group compared with the LPS group, respectively (P &lt; 0.05).	zj617s	110-116	interleukin 6	Mus musculus	30-75
31425341-7	2019	The inhalation of sevoflurane inhibited increases in myeloperoxidase (MPO), macrophage inflammatory protein-2 (MIP-2), TNF-alpha and IL-1beta levels (P &lt; 0.05) induced by endotoxemia, whereas IL-6 release was facilitated.	Sevoflurane	18-29	interleukin 6	Mus musculus	195-199
30285515-11	2019	With Cl-amidine treatment, serum IL-6 levels were significantly decreased, and IL-6 and TNFalpha gene expression were significantly reduced in joints.	N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide	5-15	interleukin 6	Mus musculus	33-37
31680772-5	2019	The results showed that RA can effectively inhibit the tumor growth through regulating the ratio of CD4+/CD8+ and the secretion of interleukin (IL)-2 and interferon-gamma, inhibiting the expressions of IL-6, IL-10 and signal transducer and activator of transcription 3, thereby up-regulating Bax and Caspase-3 and down-regulating Bcl-2.	rosmarinic acid	24-26	interleukin 6	Mus musculus	202-206
31702035-17	2019	The increased production of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and IL-8 was significantly reduced in the plasma of LCA-treated CIA mice compared with the control.	Lithocholic Acid	138-141	interleukin 6	Mus musculus	81-85
29726702-0	2019	Neolignan glycosides from Spiraea salicifolia and their inhibitory activity on pro-inflammatory cytokine interleukin-6 production in lipopolysaccharide-stimulated RAW 264.7 cells.	neolignan glycosides	0-20	interleukin 6	Mus musculus	105-118
30285515-11	2019	With Cl-amidine treatment, serum IL-6 levels were significantly decreased, and IL-6 and TNFalpha gene expression were significantly reduced in joints.	N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide	5-15	interleukin 6	Mus musculus	79-83
31486774-3	2019	However, emerging evidence suggest that a commonly recommended opioid, buprenorphine, dramatically elevated circulating IL-6 levels and reduced animal survival in male C57BL/6 mice, but not in female mice possibly due to the complex interference of estrous cycles, fueling an ongoing debate regarding the possible impact of analgesic administration on the sepsis-induced systemic inflammation.	Buprenorphine	71-84	interleukin 6	Mus musculus	120-124
31404896-10	2019	Olanzapine also decreased IL-6 mRNA expression, while olanzapine and clozapine increased IL-10 mRNA expression.	Olanzapine	0-10	interleukin 6	Mus musculus	26-30
31486774-4	2019	As per the recommendation of a local government agency, we performed a pilot study and confirmed that repetitive administration of buprenorphine indeed markedly elevated circulating levels of four sepsis surrogate markers (e.g., IL-6, KC, MCP-1 and G-CSF) in 20- 60% of septic animals.	Buprenorphine	131-144	interleukin 6	Mus musculus	229-233
31683684-4	2019	The data showed that the different ratios of BA and MS had different degrees of inhibition of interleukin-1beta (IL-1beta), IL-6, and inducible nitric oxide synthase (iNOS) mRNA expression, down-regulated the phosphor-nuclear factor kappa B/nuclear factor kappa B (p-NF-kB)/(NF-kB), phosphorylated protein kinase b/protein kinase b (p-AKT/AKT), and Toll-like receptor 4 (TLR4) protein expression levels, and increased phospho-PI3 kinase (p-PI3K) protein expression levels.	boswellic acid	45-47	interleukin 6	Mus musculus	124-128
31664952-16	2019	However, IL-6 in the 5-FU group was significantly down-regulated compared to the control, there was no significant difference in expression of IL-6 between the 5-FU and DPP4i + 5-FU group.	Fluorouracil	21-25	interleukin 6	Mus musculus	9-13
31781635-14	2019	Besides, the ELISA results showed that TNF-alpha, IL-1beta, and IL-6 were reduced in LPS-stimulated RAW264.7 cells after interfering with quercetin and quercitrin.	Quercetin	138-147	interleukin 6	Mus musculus	64-68
31781635-14	2019	Besides, the ELISA results showed that TNF-alpha, IL-1beta, and IL-6 were reduced in LPS-stimulated RAW264.7 cells after interfering with quercetin and quercitrin.	quercitrin	152-162	interleukin 6	Mus musculus	64-68
31323300-10	2019	A total of 12 beta-carboline alkaloids were identified in Part1 and they all showed suppressive effect on inflammatory cytokines including MCP-1, TNF-alpha, IL-6 and IL-1beta through inhibition of NF-kb/p65 phosphorylation, and that epithelial-mesenchymal transition (EMT) process was reversed by different compounds in different levels.	beta-carboline alkaloids	14-38	interleukin 6	Mus musculus	157-161
31659208-9	2019	These results indicated that MHP1-AcN could decrease imiquimod-induced IL-6, IL-23 and IL-17A production.	Imiquimod	53-62	interleukin 6	Mus musculus	71-75
31749970-9	2019	Furthermore, empagliflozin decreased plasma levels of interleukin (IL)-6 and monocyte chemoattractant protein-1, but increased plasma levels of IL-33 and adiponectin in obese mice.	empagliflozin	13-26	interleukin 6	Mus musculus	54-72
31671623-5	2019	In addition, FMP treatment suppressed the production of proinflammatory cytokines such as prostaglandin-E2 (PGE2), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in a dose-dependent manner and concomitantly decreased the mRNA expression of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2).	formononetin	13-16	interleukin 6	Mus musculus	115-128
31671623-5	2019	In addition, FMP treatment suppressed the production of proinflammatory cytokines such as prostaglandin-E2 (PGE2), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in a dose-dependent manner and concomitantly decreased the mRNA expression of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2).	formononetin	13-16	interleukin 6	Mus musculus	130-134
31556594-6	2019	In cultured cells, the nanoparticle FT-C60 demonstrated preferential binding to FPR-1 on activated macrophages and significantly attenuated mRNA expressions of proinflammatory factors including interleukin-6, interleukin-1, tumor necrosis factor-alpha, and cyclooxygenase-2.	fullerene C60	39-42	interleukin 6	Mus musculus	194-207
31406023-4	2019	Moreover, inhibition of ER stress by 4-phenylbutyrate (4-PBA) attenuated thapsigargin-(TG, ER stress agonist) or LPS-induced reduction of Cyp19a1 and E2, pro-inflammatory cytokines expression (IL-1beta, IL-6, IL-8, and TNF-alpha), and the expression of CHOP and GRP78.	4-phenylbutyric acid	37-53	interleukin 6	Mus musculus	203-207
31780858-10	2019	The inhibition of LPS-induced increase in serum IL-6 levels by mast cell degranulation was not seen in H1R knockout mice which suggests that mast cell-derived histamine acting through H1R may participate in the regulatory process.	Histamine	159-168	interleukin 6	Mus musculus	48-52
31406023-4	2019	Moreover, inhibition of ER stress by 4-phenylbutyrate (4-PBA) attenuated thapsigargin-(TG, ER stress agonist) or LPS-induced reduction of Cyp19a1 and E2, pro-inflammatory cytokines expression (IL-1beta, IL-6, IL-8, and TNF-alpha), and the expression of CHOP and GRP78.	4-phenylbutyric acid	55-60	interleukin 6	Mus musculus	203-207
31695681-8	2019	Compared with those in the 25 mmol/L glucose control group, expression of CD11b, iNOS, TNF-alpha, and IL-6 in the 75 mmol/L glucose or glucose fluctuation groups of cultured BV-2 cells were significantly increased, while Arg-1 and IL-10 was significantly decreased.	Glucose	124-131	interleukin 6	Mus musculus	102-106
31406023-4	2019	Moreover, inhibition of ER stress by 4-phenylbutyrate (4-PBA) attenuated thapsigargin-(TG, ER stress agonist) or LPS-induced reduction of Cyp19a1 and E2, pro-inflammatory cytokines expression (IL-1beta, IL-6, IL-8, and TNF-alpha), and the expression of CHOP and GRP78.	Thapsigargin	73-85	interleukin 6	Mus musculus	203-207
31652649-6	2019	In contrast, normalization of interstitial collagen in 4-OHT-treated Cx43Cre-ER(T)/fl animals correlated with enhanced MMP-9 activity, IL-6 and NOX2 mRNA expression, and macrophage content, and with reduced  -SMA and SM22  in isolated fibroblasts.	4,17 beta-dihydroxy-4-androstene-3-one	55-60	interleukin 6	Mus musculus	135-139
31695681-8	2019	Compared with those in the 25 mmol/L glucose control group, expression of CD11b, iNOS, TNF-alpha, and IL-6 in the 75 mmol/L glucose or glucose fluctuation groups of cultured BV-2 cells were significantly increased, while Arg-1 and IL-10 was significantly decreased.	Glucose	124-131	interleukin 6	Mus musculus	102-106
31640701-10	2019	Rupintrivir inhibited exaggerated pro-inflammatory cytokine IL-6 and TH-2 cytokine IL-4 in HDM-sensitized mice.	rupintrivir	0-11	interleukin 6	Mus musculus	60-64
31640701-11	2019	CONCLUSIONS: In summary, this study demonstrates that treatment with rupintrivir influences virus-induced IL-4 and IL-6 cytokine release under experimental conditions ex vivo.	rupintrivir	69-80	interleukin 6	Mus musculus	115-119
31623650-0	2019	Mangiferin alleviates experimental peri-implantitis via suppressing interleukin-6 production and Toll-like receptor 2 signaling pathway.	mangiferin	0-10	interleukin 6	Mus musculus	68-81
31469549-9	2019	Cell-associated dose-dependent release of LDH and IL-6 was highlighted in RAW264.7 cells, revealing the higher adverse health risk of pMWCNT due to frustrated phagocytosis and its much higher molybdenum content.	pmwcnt	134-140	interleukin 6	Mus musculus	50-54
31636311-8	2019	However, losartan only reduced CS-induced increases in IL-6 mRNA expression.	Losartan	9-17	interleukin 6	Mus musculus	55-59
31636311-10	2019	In conclusion, losartan did not inhibit CS-induced BALF cellularity despite reducing whole lung IL-6 mRNA and Ang-II receptor expression.	Losartan	15-23	interleukin 6	Mus musculus	96-100
31623650-12	2019	Moreover, qRT-PCR analysis demonstrated lower levels of IL6 gene expression, and western blot analysis showed decreased protein expression of IL6 and TLR2, and suppressed phosphorylation of TLR2 downstream nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun N-terminal kinase after mangiferin treatment.	mangiferin	301-311	interleukin 6	Mus musculus	56-59
31576391-5	2019	Our results showed that HPH20A and HPH60A + 15AF down-regulated TNF-alpha, IL-1beta, and IL-6 mRNA transcriptional levels in LPS-stimulated BV-2 microglial cells.	15af	44-48	interleukin 6	Mus musculus	89-93
31513213-5	2019	Concentrations of hepatic TNF-alpha, IL-1 and IL-6 were decreased after OSO treatment when compared with alcohol-treated mice, respectively (p < 0.05).	oso	72-75	interleukin 6	Mus musculus	46-50
31623220-3	2019	Results indicated that PPC inhibits the production of the inflammatory cytokines TNF-alpha and IL-6, and the inflammatory mediator nitric oxide (NO) in LPS-stimulated RAW 264.7 cells.	ppc	23-26	interleukin 6	Mus musculus	95-99
31488575-2	2019	We used the ability of  IL6 to inhibit the clonal proliferation of the mouse M1 myeloid leukemia cell line in agar to positively screen a cDNA expression library for proteins that inhibited IL6 activity.	Agar	110-114	interleukin 6	Mus musculus	24-27
31488575-2	2019	We used the ability of  IL6 to inhibit the clonal proliferation of the mouse M1 myeloid leukemia cell line in agar to positively screen a cDNA expression library for proteins that inhibited IL6 activity.	Agar	110-114	interleukin 6	Mus musculus	190-193
31600943-7	2019	Although both adjuvants significantly increased the number of bone marrow plasma cells, a stimulation index of lymphocytes (SI) as well as the production of IL-4 and IL-6, SO-VE-GS promoted significantly higher SI and the ratio of CD4+/CD8+ T cells with production of increased IFN-gamma and decreased TGF-beta1 as compared with the ISA 206 group.	Vitamin E	175-177	interleukin 6	Mus musculus	166-170
31606043-12	2019	At the peri-infarct cortex, the ipsilesional SVZ/striatum, and the hippocampus, both the TMF-treated and AHRcKO mice demonstrated downregulated IL-1beta, IL-6, IFN-gamma, CXCL1, and S100beta, and concomitantly upregulated Neurogenin 2 and Neurogenin 1.	6,2',4'-trimethoxyflavone	89-92	interleukin 6	Mus musculus	154-158
31614951-3	2019	The results indicated the suppressive effect of EGCG on lipid accumulation, pro-inflammatory cytokines (TNF-alpha, IL-6, and IL-1beta) release, and microglial activation in both cellular and high-fat-diet rodent models.	epigallocatechin gallate	48-52	interleukin 6	Mus musculus	115-119
31054317-13	2019	Also, the combination therapy of (CUPE + Dox) leads to reducing the levels of serum IL-6, TNF-alpha, IL-1beta and tumor volume compared with untreated tumor-bearing mice and Dox groups.	Doxorubicin	41-44	interleukin 6	Mus musculus	84-88
31590372-9	2019	S4 reduced UVB-induced MMP-1, interleukin (IL)-6, and NF-kB expression in the mouse skin.	Sulfur	0-2	interleukin 6	Mus musculus	30-48
31636566-5	2019	The results showed that amurensin H ameliorated the histological inflammatory alterations in the lung tissues, leading to a decrease in the expression of interleukin 6 (IL-6), IL-17A, tumor necrosis factor alpha (TNF-alpha), and interferon gamma in bronchoalveolar lavage fluid.	amurensin H	24-35	interleukin 6	Mus musculus	154-167
31636619-7	2019	TSA administration effectively reduced the inflammatory factor levels of iNOS, TNF-alpha, IL-5, IL-6, and IL-13 in infected mice.	trichostatin A	0-3	interleukin 6	Mus musculus	96-100
31636566-5	2019	The results showed that amurensin H ameliorated the histological inflammatory alterations in the lung tissues, leading to a decrease in the expression of interleukin 6 (IL-6), IL-17A, tumor necrosis factor alpha (TNF-alpha), and interferon gamma in bronchoalveolar lavage fluid.	amurensin H	24-35	interleukin 6	Mus musculus	169-173
31636566-6	2019	Amurensin H also significantly inhibited the release of IL-1beta, IL-6, IL-8, and TNF-alpha in LPS-stimulated THP-1-derived macrophages.	amurensin H	0-11	interleukin 6	Mus musculus	66-70
31433214-9	2019	Blocking the effect of eATP by suramin led to reduced levels of plasma IL-6 and TNFalpha as well as reduced lung, and pancreatic injury.	eatp	23-27	interleukin 6	Mus musculus	71-75
31581754-7	2019	Matrix metalloproteinase (MMP)-1/-3, cyclooxygenase-2 (COX-2), and interleukin-6 (IL-6) expression was reduced by hydrangenol.	hydrangenol	114-125	interleukin 6	Mus musculus	67-80
31581754-7	2019	Matrix metalloproteinase (MMP)-1/-3, cyclooxygenase-2 (COX-2), and interleukin-6 (IL-6) expression was reduced by hydrangenol.	hydrangenol	114-125	interleukin 6	Mus musculus	82-86
31749886-9	2019	Results: Chronic ISO treatment leads to increased fibrosis of the myocardium in mice lacking IL-6, which is accompanied by increased activity of ERK1/2, p38 and reduced expression of SOCS3.	Isoproterenol	17-20	interleukin 6	Mus musculus	93-97
31749886-10	2019	Administration of ISO in IL-6 KO animals intensified gene expression of proteins activated by MAPK/ERK (myc; CEBPB; BMP4; Fasn; Tank), while it reduced expression of genes repressed by ERK 1/2 (Wisp1, Wnt1).	Isoproterenol	18-21	interleukin 6	Mus musculus	25-29
31433214-9	2019	Blocking the effect of eATP by suramin led to reduced levels of plasma IL-6 and TNFalpha as well as reduced lung, and pancreatic injury.	Suramin	31-38	interleukin 6	Mus musculus	71-75
31325706-8	2019	QFG decreased the serum levels of TNF-alpha, IL-1beta, and IL-6 and increased the levels of IL-10.	qfg	0-3	interleukin 6	Mus musculus	59-63
31545273-5	2019	BA reduced the serum levels of pro-inflammatory cytokines, such as IL-1alpha, IL-1beta, IL-5, IL-6, GM-CSF, KC, MCP-1 and PGE2 in Carr-treated mice, and increased those of anti-inflammatory cytokines, such as IL-12.	betulinic acid	0-2	interleukin 6	Mus musculus	94-98
31250042-3	2019	We aimed to examine whether oxidative stress and pro-inflammatory cytokines such as interleukin (IL)-1beta and IL-6 are involved in the Hcy-induced apoptosis of osteocytes and whether bazedoxifene (BZA) inhibits the detrimental effects of Hcy.	Homocysteine	136-139	interleukin 6	Mus musculus	111-115
31271845-8	2019	DSS treated-P2ry6-/- mice exhibited also higher levels of Th17/Th1 lymphocytes in their colon which correlated with increased levels of IFN-gamma and IL-17A in the sera as well as increased mRNA levels of IFN-gamma, IL-17A, IL-6, IL-23 and IL-1beta in P2ry6-/- colons.	dss	0-3	interleukin 6	Mus musculus	224-228
31250042-7	2019	Nox inhibitors, diphenyleneiodonium chloride and apocynin, significantly suppressed Hcy-induced IL-1beta and IL-6 expressions.	diphenyleneiodonium	16-44	interleukin 6	Mus musculus	109-113
31250042-7	2019	Nox inhibitors, diphenyleneiodonium chloride and apocynin, significantly suppressed Hcy-induced IL-1beta and IL-6 expressions.	acetovanillone	49-57	interleukin 6	Mus musculus	109-113
31250042-7	2019	Nox inhibitors, diphenyleneiodonium chloride and apocynin, significantly suppressed Hcy-induced IL-1beta and IL-6 expressions.	Homocysteine	84-87	interleukin 6	Mus musculus	109-113
31250042-8	2019	In contrast, an IL-1beta receptor antagonist and an IL-6 receptor monoclonal antibody had no effects on Hcy-induced Nox1 and Nox2 expressions, but significantly rescued Hcy-induced apoptosis.	Homocysteine	169-172	interleukin 6	Mus musculus	52-56
31250042-11	2019	Moreover, BZA significantly ameliorated Hcy-induced expressions of Nox1, Nox2, IL-1beta, and IL-6, and ICI canceled the effects of BZA on their expressions.	bazedoxifene	10-13	interleukin 6	Mus musculus	93-97
31250042-11	2019	Moreover, BZA significantly ameliorated Hcy-induced expressions of Nox1, Nox2, IL-1beta, and IL-6, and ICI canceled the effects of BZA on their expressions.	Homocysteine	40-43	interleukin 6	Mus musculus	93-97
31250042-11	2019	Moreover, BZA significantly ameliorated Hcy-induced expressions of Nox1, Nox2, IL-1beta, and IL-6, and ICI canceled the effects of BZA on their expressions.	bazedoxifene	131-134	interleukin 6	Mus musculus	93-97
31250042-12	2019	Hcy increases apoptosis through stimulating Nox 1 and Nox 2-IL-1beta and IL-6 expressions in osteocyte-like cells.	Homocysteine	0-3	interleukin 6	Mus musculus	73-77
31392841-9	2019	SR11302 ablated microglial IL-6 and TNF-alpha production and brain-infiltrating leukocytes in ICH mice.	SR 11302	0-7	interleukin 6	Mus musculus	27-31
30632647-5	2019	Also, GEN-27 suppressed the release of LPS-induced pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-6, and IL-18.	gen-27	6-12	interleukin 6	Mus musculus	159-163
31431500-5	2019	Bufalin also suppressed the expression of proinflammatory mediators [reduced levels of cyclooxygenase-2, tumor TNFalpha, IL1beta, IL6, C-X-C motif chemokine ligand (CXCL)-1, CXCL-2, and CXCL-5] in the colitis-associated colorectal cancer model.	bufalin	0-7	interleukin 6	Mus musculus	130-133
31252312-5	2019	After LPS treatment 6 h, 12 h, the number of CD3+ T cells and CD4/CD8 in the mesenteric lymph nodes of ileum were reduced significantly; the levels of IFN-gamma, TNF-alpha and IL-2 were significantly decreased, and the levels of IL-6 and IL-10 were significantly increased in the ileum.	lps	6-9	interleukin 6	Mus musculus	229-233
31392841-10	2019	In addition, SR11302 treatment diminished thrombin-induced production of IL-6 and TNF-alpha in cultured microglia.	SR 11302	13-20	interleukin 6	Mus musculus	73-77
31442454-7	2019	The Tumor necrosis factor-alpha and Interleukin-6 levels were significantly lower in the cell culture supernatants of the inguinal lymph node in the amiodarone treated group compared to the vehicle and untreated groups.	Amiodarone	149-159	interleukin 6	Mus musculus	36-49
31336350-10	2019	Furthermore, PCB exposure increased the intestinal inflammatory profile (Il6, Il1beta, and Il22), and resulted in dysbiosis of the gut microbiota, including altered beta-diversity, in juvenile DM mice developmentally exposed to 1 mg/kg/d PCBs when compared to WT controls.	Polychlorinated Biphenyls	13-16	interleukin 6	Mus musculus	73-76
31319131-6	2019	We found that the metformin pretreatment alleviated the lung injury and decreased the levels of TNF-a, IL-1beta and IL-6 in the bronchoalveolar lavage fluid (BALF) and in lung tissues, as well as the levels of NLRP3, NLRC4 and cleaved caspase-1 associated with LPS-induced ALI in old mice.	Metformin	18-27	interleukin 6	Mus musculus	116-120
31572546-7	2019	Also Dex inhibited the elevation of serum interleukin-6 and tumor necrosis factor-alpha and increased lung HO-1 activity.	Dexmedetomidine	5-8	interleukin 6	Mus musculus	42-87
31696491-6	2019	The expression of lncRNA SNHG15 was increased in RAW264.7 cells in the PPD group with increased cell proliferation, TRAP-positive cells, IL-6 and TNF-alpha secretion, as well as elevated RANK and RANKL expression which were statistically different compared with the control group (p &lt; 0.05).	Tuberculin	71-74	interleukin 6	Mus musculus	137-141
31696491-7	2019	Transfection of lncRNA SNHG15 siRNA in the PPD model significantly inhibited the expression of lncRNA SNHG15, decreased cell proliferation, TRAP staining positive cells, IL-6 and TNF-alpha secretion, as well as reduced RANK and RANKL expression.	Tuberculin	43-46	interleukin 6	Mus musculus	170-174
31231866-8	2019	Rapamycin mediated decrease of IL-6 secretion suggests a particular mechanistic target of rapamycin (mTOR)-IL-6 link and appeared to be microglia specific.	Sirolimus	0-9	interleukin 6	Mus musculus	107-111
31254592-7	2019	Aloin treatment also reduced the plasma levels of interleukin-6 and tumor necrosis factor-alpha, reduced lethality due to CLP-induced sepsis, increased lipid peroxidation, and markedly enhanced the antioxidant defense system by restoring the levels of superoxide dismutase, glutathione peroxidase, and catalase in kidney tissues.	alloin	0-5	interleukin 6	Mus musculus	50-63
31530042-7	2019	Results: Pretreatment with RSV significantly and dose dependently inhibited LPS-induced production of TNF-alpha, IL-1beta and IL-6 in BV2 cells.	Resveratrol	27-30	interleukin 6	Mus musculus	126-130
31231866-7	2019	Rescuing autophagy by treatment with rapamycin was sufficient to decrease interleukin 6 (IL-6) but not tumor necrosis factor (TNF) secretion in cultured microglia.	Sirolimus	37-46	interleukin 6	Mus musculus	74-87
31231866-7	2019	Rescuing autophagy by treatment with rapamycin was sufficient to decrease interleukin 6 (IL-6) but not tumor necrosis factor (TNF) secretion in cultured microglia.	Sirolimus	37-46	interleukin 6	Mus musculus	89-93
31231866-8	2019	Rapamycin mediated decrease of IL-6 secretion suggests a particular mechanistic target of rapamycin (mTOR)-IL-6 link and appeared to be microglia specific.	Sirolimus	0-9	interleukin 6	Mus musculus	31-35
31421154-5	2019	Our results show that the oral administration of rebamipide suppressed SS progression and the level of inflammatory cytokines, including interleukin (IL)-6, tumor necrosis factor-alpha, and IL-17, in the salivary glands and spleen of NOD/ShiLtJ mice.	rebamipide	49-59	interleukin 6	Mus musculus	137-155
31421154-7	2019	In vitro, rebamipide suppressed IL-6 and IL-17 production by Th17 cells in splenic CD4+ cells from the mice.	rebamipide	10-20	interleukin 6	Mus musculus	32-36
31530042-10	2019	More importantly, the reducion of TNF-alpha, IL-1beta and IL-6 level by RSV were reversed by miR-146a-5p silence via miR-146a-5p inhibitor transfection.	Resveratrol	72-75	interleukin 6	Mus musculus	58-62
31306981-5	2019	In addition, qPCR and ELISA results found that glycitin could dose-dependently decrease the expressions of pro-inflammatory cytokines IL-1beta, IL-6, and TNF-alpha.	glycitin	47-55	interleukin 6	Mus musculus	144-148
31201586-4	2019	In vitro, garcinol reduced the expression of pro-inflammatory cytokines, such as IL-6 and tumor necrosis factor alpha (TNF-alpha).	garcinol	10-18	interleukin 6	Mus musculus	81-85
31401380-6	2019	DHB was also observed to significantly decrease the production and mRNA expression levels of IL-6, IL-1beta, TNF-alpha, NO (iNOS) and PGE2 (COX-2), increase the release of IL-10, and inhibit the activation of NF-kappaB and MAPK signaling pathways.	dihydroberberine	0-3	interleukin 6	Mus musculus	93-97
31401381-4	2019	It was found that sitagliptin decreased the expression of monocyte chemotactic protein-1 (MCP-1), interleukin (IL)-6 and IL-1beta, but up-regulated SIRT6 expression, both in mice and in TNF-alpha-stimulated endothelial cells.	Sitagliptin Phosphate	18-29	interleukin 6	Mus musculus	98-116
31401381-5	2019	Moreover, knockdown of SIRT6 reversed the inhibitory effect of sitagliptin on MCP-1, IL-6 and IL-1beta expression.	Sitagliptin Phosphate	63-74	interleukin 6	Mus musculus	85-89
31401381-6	2019	Further study revealed that sitagliptin also decreased the expression of MCP-1, IL-6 and IL-1beta partly through suppression of reactive oxygen species (ROS).	Sitagliptin Phosphate	28-39	interleukin 6	Mus musculus	80-84
31401381-8	2019	Hyperlipidemia-induced production of MCP-1, IL-6 and IL-1beta was significantly suppressed in the sitagliptin-supplemented animals, but the effect of was abolished by SIRT6 knockout in endothelium.	Sitagliptin Phosphate	98-109	interleukin 6	Mus musculus	44-48
31425975-5	2019	The spinal cord analysis revealed that modafinil treatment decreased interferon (IFN)-gamma and interleukin (IL)-6 protein levels and down regulated genes related to Th1 immunity, such as IFN-gamma and TBX21, without affecting Th17-related genes.	Modafinil	39-48	interleukin 6	Mus musculus	96-114
31432106-10	2019	In addition, ICA suppressed the production of pro-inflammatory cytokines, including interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha in the pancreas.	icariin	13-16	interleukin 6	Mus musculus	108-144
31560611-6	2019	The results showed that PLCP inhibited the excessive production of tumor necrosis factor-alpha, interleukin (IL)-6, IL-10, IL-2, and IL-1beta in mouse serum and liver.	plcp	24-28	interleukin 6	Mus musculus	96-114
31351366-7	2019	In vitro, farrerol markedly decreased the production of inflammatory mediators, including interleukin-6 (IL-6), interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), cyclooxygenase 2 (COX-2) and induced nitric oxide synthase (iNOS), induced by lipopolysaccharide (LPS) in BV-2 cells.	farrerol	10-18	interleukin 6	Mus musculus	90-103
31351366-7	2019	In vitro, farrerol markedly decreased the production of inflammatory mediators, including interleukin-6 (IL-6), interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), cyclooxygenase 2 (COX-2) and induced nitric oxide synthase (iNOS), induced by lipopolysaccharide (LPS) in BV-2 cells.	farrerol	10-18	interleukin 6	Mus musculus	105-109
31378305-7	2019	RESULTS: Topical treatment with anisomycin induced key signatures in psoriasis, such as epidermal thickening, neutrophil infiltration, and gene expression of Il1a, Il1b, Il6, Il24, Cxcl1, Il23a, and Il17a, in treated murine skin.	Anisomycin	32-42	interleukin 6	Mus musculus	170-173
31402771-8	2019	Histological studies revealed reduced demyelination and limited infiltration into CNS, moreover vitamin D3 increased the production of IL-4, IL-10, and TGF-beta, while a significant reduction in the production of IFN-gamma, IL-6, TNF-alpha, and IL-17 was observed.	Cholecalciferol	96-106	interleukin 6	Mus musculus	224-228
30982986-10	2019	In addition, OAA-treated specimens showed the altered localization patterns of inflammatory and bone formation-related signaling molecules including CD31, F4/80, IL-6, and osteocalcin.	Oxaloacetic Acid	13-16	interleukin 6	Mus musculus	162-166
31412290-9	2019	Trehalose reduced the mRNA and secreted cytokines levels of IL-6, IL-8 and MCP-1 in corneal cells under TNF-alpha and desiccation stress mediated inflammation compared to controls.	Trehalose	0-9	interleukin 6	Mus musculus	60-64
31685086-5	2019	Further studies revealed that cepharanthine suppressed the release of cytokines (TNF-alpha, IL-1beta, and IL-6) by LPS-activated microglial cells.	cepharanthine	30-43	interleukin 6	Mus musculus	106-110
31041437-5	2019	Particularly, the inhibition rate of DPEW on NO, IL-6, and TNF-alpha could reach 25 to 27%, 31 to 42%, and 26 to 38%, respectively (P < 0.05).	dpew	37-41	interleukin 6	Mus musculus	49-53
31570110-10	2019	Confocal analysis of Iba1-stained retinal flatmounts and qPCR demonstrated that ONL1204 also abrogated microglia activation and inhibited the induction of multiple genes implicated in glaucoma, including cytokines and chemokines (GFAP, Caspase-8, TNFalpha, IL-1beta, IL-6, IL-18, MIP-1alpha, MIP-1beta, MIP-2, MCPI, and IP10), components of the complement cascade (C3, C1Q), Toll-like receptor pathway (TLR4), and inflammasome pathway (NLRP3).	hydroxylysyl-5-oxonorleucine	80-87	interleukin 6	Mus musculus	267-271
31454532-7	2019	As for macrophage M1/M2 polarization in liver, nano-celastrol reduced the expression of macrophage M1 biomarkers (e.g., IL-6, IL-1beta, TNF-alpha, iNOS) in a dose-dependent manner and marginally increased the expression of macrophage M2 biomarkers (e.g., Arg-1, IL-10).	celastrol	52-61	interleukin 6	Mus musculus	120-124
30270604-6	2019	Moreover, the colonic IL-6 and TNF-alpha expression of the DSS- induced colitis mice treated with L. sakei 07 (L07) - B. bifidum B10 combination (PB) significantly decreased and the IL-10 expression were up-regulated by PB compared to the DSS group.	dss	59-62	interleukin 6	Mus musculus	22-26
31465218-6	2019	Furthermore, unlike apigenin, isolaxifolin only reduced NO, TNF-alpha, and IL-6 secretions in LPS-induced RAW 264.7 cells in a rather modest and dose-independent manner.	Isolaxifolin	30-42	interleukin 6	Mus musculus	75-79
31611876-7	2019	In vitro, rAl-CPI showed a modulatory effect on HmoDCs, lowering the expression of HLA-DR, CD83, and CD86, while inducing IL-10 and IL-6 production.	ral-cpi	10-17	interleukin 6	Mus musculus	132-136
31557885-7	2019	MGO treatment increased mRNA expression of inflammation-related molecules, interleukin (IL)-1beta, IL-6, and toll-like receptor 4 (TLR4).	Pyruvaldehyde	0-3	interleukin 6	Mus musculus	99-103
31561750-3	2019	Baricitinib is a JAK 1/2 inhibitor approved in the USA, EU, and Japan for rheumatoid arthritis, demonstrating potent inhibition of IL-6, D-dimer, CRP, TNF-alpha, IFN-alpha/beta, and other pro-inflammatory cytokines.	baricitinib	0-11	interleukin 6	Mus musculus	131-135
31545785-11	2019	RESULTS As-IV significantly improved cardiac function, myocardial cell viability, and pathological changes and reduced FFA, IL-1ss, IL-6, and TNF-alpha levels.	astragaloside A	8-13	interleukin 6	Mus musculus	132-136
31572984-12	2019	NQC dose-dependently down-regulated the pro-inflammatory cytokines [interleukin (IL)-1beta (13.27 +- 2.37 muM), IL-6 (10.13 +- 0.58 muM) and tumor necrosis factor (TNF)-alpha] (14.41 +- 1.83 muM); and inflammatory mediator, prostaglandin E2 (PGE2) with IC50 values, 15.23 +- 0.91 microM.	Nitrogen	0-3	interleukin 6	Mus musculus	112-116
31616301-8	2019	Moreover, MH dramatically suppressed the inhibitor of kappa B alpha (IkappaBalpha) degradation and subsequent nuclear factor-kappa B (NF-kappaB) p65 translocation into the nucleus and NF-kappaB-mediated cytokines, such as tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-1beta, and IL-6.	morin	10-12	interleukin 6	Mus musculus	291-295
31546603-8	2019	Interestingly, the IL-1beta, IL-6, MCP-1, and ICAM-1 mRNA levels, which were increased in KK-Ay mouse kidneys as compared with normal controls, were suppressed by febuxostat administration.	febuxostat	163-173	interleukin 6	Mus musculus	29-33
31541125-7	2019	The gene profiling and expression analysis showed that THGP suppressed the expression of the nuclear receptor subfamily 4 group A member 2 (NR4A2) gene, which is related to cell death, and the interleukin 6 (IL6) and chemokine (C-X-C motif) ligand 2 (CXCL2) genes, which are related to the inflammatory response.	Propionates	55-59	interleukin 6	Mus musculus	193-206
31353088-5	2019	GR1501 effectively blocks the interaction between IL-17A and its receptor IL-17RA, thereby inhibiting IL-17A-induced CXCL1 and IL-6 release in cells and mice.	gr1501	0-6	interleukin 6	Mus musculus	127-131
31534179-4	2019	Exposure to NTP-treated medium during mast cell activation inhibited the expression and production of IL-6, TNF-alpha and suppressed NF-kappaB activation.	ntp	12-15	interleukin 6	Mus musculus	102-106
31530895-6	2019	(R)-DOI treated mice had significant reductions in expression levels of mRNA for inflammatory markers like Il6 in vascular tissue, normalized glucose homeostasis, and reduced circulating cholesterol levels.	(R)-DOI	0-7	interleukin 6	Mus musculus	107-110
31632570-9	2019	The results revealed that NIM markedly improved pancreatic histological injury and decreased the levels of serum amylase, lipase, TNF-alpha, IL-1beta and IL-6 in a dose-dependent after NIM treatment.	nimesulide	26-29	interleukin 6	Mus musculus	154-158
31466563-5	2019	The copresence of anxiety, decreased hippocampal volume, and elevated systemic interleukin-6 characterized a susceptible phenotype that developed behavioral and neurobiological deficits after exposure to SDS.	sds	204-207	interleukin 6	Mus musculus	79-92
31632570-12	2019	The expression levels of TNF-alpha, IL-1beta and IL-6 proteins were downregulated following NIM treatment.	nimesulide	92-95	interleukin 6	Mus musculus	49-53
31173876-11	2019	In addition, the presence of the anti-TLR4 antibody inhibited AHP-II-induced macrophage IL-6 and TNF-alpha production in the peritoneal macrophages of C3H/HeJ mice.	ahp-ii	62-68	interleukin 6	Mus musculus	88-92
31071567-9	2019	More importantly, AICAR administration led to the significant enhancement of energy metabolism, elevation of AMPK as well as the decreased IL-6 and TNF-alpha in VAT of PM2.5-exposed mice, which suggesting that AMPK activation might attenuate the inflammatory responses in VAT via the inhibition of MAPKs and NFkappaB.	acadesine	18-23	interleukin 6	Mus musculus	139-143
31340160-8	2019	In addition, 5 mg/kg andrographolide treatment also decreased the expression of pro-inflammatory mediators and cytokines (NO, COX-2, iNOS, IL-1beta, IL-6 and TNF-alpha), NF-kappaB signaling (p-p65, p-IkappaBalpha) and NLRP3 inflammasome assembly (NLRP3, ASC and caspase-1) in the prefrontal cortex.	andrographolide	21-36	interleukin 6	Mus musculus	149-153
31572199-9	2019	Furthermore, dioscin obviously decreased the nuclear translocation of nuclear factor kappaB (NF-kappaB) and the mRNA levels of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), and interleukin 6 (IL-6) to suppress inflammation.	dioscin	13-20	interleukin 6	Mus musculus	202-215
31572199-9	2019	Furthermore, dioscin obviously decreased the nuclear translocation of nuclear factor kappaB (NF-kappaB) and the mRNA levels of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), and interleukin 6 (IL-6) to suppress inflammation.	dioscin	13-20	interleukin 6	Mus musculus	217-221
31547327-4	2019	The results showed that EC was able to reduce the levels of nitric oxide (NO), interleukin-6 (IL-6), tumor necrosis factor (TNF)-alpha, and inducible nitric oxide synthase (iNOS) proteins produced by LPS-induced BV2 cells, in addition to inhibiting the expression of NF-kappaB and phosphorylation of IkappaBalpha (p-IkappaBalpha) proteins.	erinacine C	24-26	interleukin 6	Mus musculus	79-92
31547327-4	2019	The results showed that EC was able to reduce the levels of nitric oxide (NO), interleukin-6 (IL-6), tumor necrosis factor (TNF)-alpha, and inducible nitric oxide synthase (iNOS) proteins produced by LPS-induced BV2 cells, in addition to inhibiting the expression of NF-kappaB and phosphorylation of IkappaBalpha (p-IkappaBalpha) proteins.	erinacine C	24-26	interleukin 6	Mus musculus	94-98
31422663-9	2019	Furthermore, glucose enhanced the macrophage induction of TLR4 and inducible nitric oxide synthase and IL-6 production, while it demoted the production of anti-inflammatory arginase-1 and IL-10.	Glucose	13-20	interleukin 6	Mus musculus	103-107
31572805-6	2019	The present study showed that DHM treatment alleviated LPS-induced viability reduction, suppressed the mRNA levels of IL-6, IL-1beta and TNF-alpha, inhibited the mRNA and protein expression of iNOS and COX-2, and attenuated the activation of NF-kB and TLR4 signaling in a concentration-dependent manner.	dihydromyricetin	30-33	interleukin 6	Mus musculus	118-122
31511086-9	2019	The qRT-PCR analysis showed noticeable inhibition of pro-inflammatory cytokines (mRNA expression levels of TNF-alpha, IL-1beta and IL-6) (p &lt; 0.05) in poncirin treated group.	poncirin	154-162	interleukin 6	Mus musculus	131-135
31506423-6	2019	A humanized PRSS1 transgenic mouse was established and treated with caerulein to mimic the development of CP, as evidenced by pathogenic alterations, collagen deposition, and increased expression of the inflammatory factors IL-6, IL-1beta, and TNF-alpha.	Ceruletide	68-77	interleukin 6	Mus musculus	224-228
31489938-8	2019	In the EPI depot, melatonin reversed the increase of leptin, Il-6, Mcp-1 and Tnf-alpha triggered by obesity.	Melatonin	18-27	interleukin 6	Mus musculus	61-65
31583256-4	2019	Sublancin could modulate innate immunity by inducing the production of IL-1beta, IL-6, TNF-alpha, and nitric oxide, enhancing phagocytosis and MRSA-killing activity in both RAW264.7 cells and mouse peritoneal macrophages.	sublancin	0-9	interleukin 6	Mus musculus	81-85
31315930-6	2019	Manipulation of heparan sulfate had a similar effect on IL6-dependent hepcidin expression in vitro and suppressed IL6-mediated iron redistribution induced by lipopolysaccharide in vivo These results provide compelling evidence that hepatocyte heparan sulfate plays a key role in regulating hepcidin expression and iron homeostasis in mice and in human hepatocytes.	Heparitin Sulfate	16-31	interleukin 6	Mus musculus	56-59
31315930-6	2019	Manipulation of heparan sulfate had a similar effect on IL6-dependent hepcidin expression in vitro and suppressed IL6-mediated iron redistribution induced by lipopolysaccharide in vivo These results provide compelling evidence that hepatocyte heparan sulfate plays a key role in regulating hepcidin expression and iron homeostasis in mice and in human hepatocytes.	Heparitin Sulfate	16-31	interleukin 6	Mus musculus	114-117
31315930-6	2019	Manipulation of heparan sulfate had a similar effect on IL6-dependent hepcidin expression in vitro and suppressed IL6-mediated iron redistribution induced by lipopolysaccharide in vivo These results provide compelling evidence that hepatocyte heparan sulfate plays a key role in regulating hepcidin expression and iron homeostasis in mice and in human hepatocytes.	Iron	127-131	interleukin 6	Mus musculus	114-117
31315930-6	2019	Manipulation of heparan sulfate had a similar effect on IL6-dependent hepcidin expression in vitro and suppressed IL6-mediated iron redistribution induced by lipopolysaccharide in vivo These results provide compelling evidence that hepatocyte heparan sulfate plays a key role in regulating hepcidin expression and iron homeostasis in mice and in human hepatocytes.	Heparitin Sulfate	243-258	interleukin 6	Mus musculus	114-117
31315930-6	2019	Manipulation of heparan sulfate had a similar effect on IL6-dependent hepcidin expression in vitro and suppressed IL6-mediated iron redistribution induced by lipopolysaccharide in vivo These results provide compelling evidence that hepatocyte heparan sulfate plays a key role in regulating hepcidin expression and iron homeostasis in mice and in human hepatocytes.	Iron	314-318	interleukin 6	Mus musculus	114-117
31278964-4	2019	We found that GANT-61 and indomethacin synergistically attenuate cartilage damage and serum levels of inflammatory cytokines TNF-alpha, IL-2 and IL-6 in OA mice.	Indomethacin	26-38	interleukin 6	Mus musculus	145-149
31565034-7	2019	Our results showed that pretreatment of HSFE markedly reduced the expression of NO and iNOS without causing cytotoxicity and significantly attenuated secretion of proinflammatory cytokines, including TNF-alpha, IL-6, and IL-1beta.	hsfe	40-44	interleukin 6	Mus musculus	211-215
31278964-5	2019	Moreover, in vitro treatment of GANT-61 and indomethacin synergistically reduced the mRNA expression of TNF-alpha, IL-2 and IL-6 in lipopolysaccharide (LPS)-stimulated C28/I2 chondrocytes.	Indomethacin	44-56	interleukin 6	Mus musculus	124-128
31565031-12	2019	Sakuranetin did not modify in vitro cell viability in RAW 264.7 and reduced NO release and gene expression of IL-1beta and IL-6 induced by LPS in these cells.	sakuranetin	0-11	interleukin 6	Mus musculus	123-127
30611703-12	2019	In AT, the levels of Il6 mRNA, a hepatoprotective cytokine, and that of Arg1, a marker of anti-inflammatory macrophages, were significantly increased in ethanol + Nano-treated mice compared with control mice.	Ethanol	153-160	interleukin 6	Mus musculus	21-24
31286307-8	2019	In the clinical study, serum IL-6 levels were significantly decreased by methylprednisolone (median, 97.5 pg/ml vs. 18.0 pg/ml; P = 0.030).	Methylprednisolone	73-91	interleukin 6	Mus musculus	29-33
31552040-6	2019	At day 6 post-infection, 25-OH-cholecalciferol treated mice displayed lower numbers of colonic innate and adaptive immune cell populations as compared to placebo controls that were accompanied by lower intestinal concentrations of pro-inflammatory mediators including IL-6, MCP1, and IFN-gamma.	25-oh-cholecalciferol	25-46	interleukin 6	Mus musculus	268-272
31480531-8	2019	Furthermore, MEAC treatment prevents LPS-stimulated increases of proinflammatory cytokines, including TNF-alpha, IL-6, and IL-1beta.	meac	13-17	interleukin 6	Mus musculus	113-117
31286307-10	2019	However, methylprednisolone can decrease serum IL-6 levels, thus inhibiting tumor growth and peritoneal seeding.	Methylprednisolone	9-27	interleukin 6	Mus musculus	47-51
31387196-8	2019	RESULT: The skin erythema and histopathological alteration, as well as the elevated pro-inflammatory factors (IL-1beta, IL6, TNFalpha) and TLR2 were significantly ameliorated by ART treatment in LL37-induced rosacea-like mice.	artemisinin	178-181	interleukin 6	Mus musculus	120-123
31167126-5	2019	Our results revealed that ethanol challenge overtly compromised echocardiographic, cardiomyocyte contractile, intracellular Ca2+ and ultrastructural properties along with overt apoptosis, inflammation (elevated MIF, IL-1beta and IL-6) and mitochondrial O2- production (p < 0.01), the effect of which was reconciled by CD74 ablation (p < 0.01 vs. ethanol group) with the exception of MIF expression.	Ethanol	26-33	interleukin 6	Mus musculus	229-233
31151536-5	2019	TSF2 polysaccharide effectively induced RAW264.7 murine macrophages to release nitric oxide, TNF-alpha, IL-1beta and IL-6, and activated NK cells to produce TNF-alpha, INF-gamma, granzyme-B, perforin, NKG2D and FasL through NF-kappaB and MAPKs signaling pathways.	Polysaccharides	5-19	interleukin 6	Mus musculus	117-121
31226639-6	2019	Compared with that in DNCB-induced mice, RGE effectively decreased the mRNA expression levels of interleukin-6 (IL-6), thymic stromal lymphopoietin (TSLP), and tumor necrosis factor-alpha (TNF-alpha), as well as the protein level of thymus and activation-regulated chemokine (TARC).	Dinitrochlorobenzene	22-26	interleukin 6	Mus musculus	97-110
31313354-6	2019	The effects of SA exhibited in DSS-induced mice were associated with significant decrease in the expressions levels of inflammatory mediators such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), pro-inflammatory cytokines (tumor necrosis factor [TNF-alpha], interleukin [IL-1beta and IL-6]), remarkable amelioration of colonic architectural disruption, and a significant reduction in the activity of colonic myeloperoxidase.	syringic acid	15-17	interleukin 6	Mus musculus	305-309
31299241-6	2019	The levels of pro-inflammatory cytokines were determined using ELISA and western blotting assays, showing that paraquat significantly promote the secretion of pro-inflammatory mediators such as tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta) and interleukin 6 (IL-6).	Paraquat	111-119	interleukin 6	Mus musculus	268-281
31299241-6	2019	The levels of pro-inflammatory cytokines were determined using ELISA and western blotting assays, showing that paraquat significantly promote the secretion of pro-inflammatory mediators such as tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta) and interleukin 6 (IL-6).	Paraquat	111-119	interleukin 6	Mus musculus	283-287
31313354-6	2019	The effects of SA exhibited in DSS-induced mice were associated with significant decrease in the expressions levels of inflammatory mediators such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), pro-inflammatory cytokines (tumor necrosis factor [TNF-alpha], interleukin [IL-1beta and IL-6]), remarkable amelioration of colonic architectural disruption, and a significant reduction in the activity of colonic myeloperoxidase.	Dextran Sulfate	31-34	interleukin 6	Mus musculus	305-309
31313354-8	2019	SA dose-dependently inhibited the cytokines TNF-alpha, IL-1beta, and IL-6.	syringic acid	0-2	interleukin 6	Mus musculus	69-73
31287602-7	2019	In addition, treatment with beta-carotene suppressed protein levels of TNF-alpha, IL-1beta and MCP-1, as well as mRNA expression associated with IL-1beta, IL-6, IL-4 and Par-2 in skin tissues.	beta Carotene	28-41	interleukin 6	Mus musculus	155-159
31410125-6	2019	The gene expression of matrix metalloproteinase (MMP)1, MMP3, MMP13, interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha were reduced in the cartilage of OA mice following 7,8-DHF treatment.	6,7-dihydroxyflavone	181-188	interleukin 6	Mus musculus	93-129
31410133-8	2019	The results from the MTT assay identified the optimal concentration of LPS and taraxasterol, and ELISA results demonstrated that taraxasterol treatment decreased the expression levels of IL-6 and TNF-alpha in vitro and in vivo, in a dose-dependent manner.	taraxasterol	129-141	interleukin 6	Mus musculus	187-191
31410159-9	2019	TQ significantly inhibited the elevation of p62, IL-1beta, IL-6, MCP-1 and TNF-alpha levels as well as increased the LC3, beclin 1 and IL-10 levels in LT. PI3K expression in the TQ + CLP group was significantly decreased compared with that in the CLP group.	thymoquinone	0-2	interleukin 6	Mus musculus	59-63
31452696-7	2019	After the mice were given TAK-242, the levels of hs-CPR, MCP-1, IL-6 and IL-1beta in the PT group evidently increased (P&lt;0.01) compared with those in the N group.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	26-33	interleukin 6	Mus musculus	64-68
31277021-6	2019	Results revealed that nAl2O3 could increase ROS levels and decrease GSH levels in lung tissue, promote the increases of the T-IgE, TGF-beta, IL-1beta and IL-6 levels, stimulate the overexpression of transcription factors GATA-3 and RORgammat, decrease the levels of IFN-gamma and IL-10 and increase the levels of IL-4 and IL-17A, resulting in the imbalance of Th1/Th2 and Treg/Th17 immune responses.	nal2o3	22-28	interleukin 6	Mus musculus	154-158
31429848-5	2019	The alcohol exposure increased the levels of ALT, AST, TNF-alpha and IL-6 inflammatory factors and liver steatosis.	Alcohols	4-11	interleukin 6	Mus musculus	69-73
31202180-10	2019	The levels of IL-6 (P < 0.01), TNF-alpha, MDA and the apoptotic rate (P < 0.001) decreased significantly in the autografted + melatonine group compared to the autografted + saline group.	Melatonin	126-136	interleukin 6	Mus musculus	14-18
31463498-4	2019	Our data showed that SEO improved the cognitive ability of mice with Abeta1-42 or lipopolysaccharides (LPS)-induced Alzheimer"s disease (AD) and suppressed the production of tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in the hippocampus.	seo	21-24	interleukin 6	Mus musculus	207-220
31463498-4	2019	Our data showed that SEO improved the cognitive ability of mice with Abeta1-42 or lipopolysaccharides (LPS)-induced Alzheimer"s disease (AD) and suppressed the production of tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in the hippocampus.	seo	21-24	interleukin 6	Mus musculus	222-226
31203155-6	2019	CAG dose-dependently decreased the level of proinflammatory cytokines, including IL-1beta, TNF-alpha and IL-6, in murine psoriatic skin and serum, as well as in IMQ-stimulated, bone-marrow-derived macrophages.	cycloastragenol	0-3	interleukin 6	Mus musculus	105-109
31261036-13	2019	Besides, treatment with CBX could significantly decrease levels of inflammatory factors such as IL-6 (Interleukin 6) and TNF-a (Tumor necrosis factor-a), increase expressions of phosphorylated JAK2 and phosphorylated STAT3, decrease the expressions of SOCS-3, SREBP-1 and FAS in the liver.	Carbenoxolone	24-27	interleukin 6	Mus musculus	96-100
31261036-13	2019	Besides, treatment with CBX could significantly decrease levels of inflammatory factors such as IL-6 (Interleukin 6) and TNF-a (Tumor necrosis factor-a), increase expressions of phosphorylated JAK2 and phosphorylated STAT3, decrease the expressions of SOCS-3, SREBP-1 and FAS in the liver.	Carbenoxolone	24-27	interleukin 6	Mus musculus	102-115
31332890-5	2019	Pretreatment with BHB upregulated the level of tumor necrosis factor alpha and interleukin-6 in plasma, promoted the activities of caspase-3, caspase-8, and caspase-9 and increased the count of terminal deoxynucleotidyl transferase dUTP nick end labeling-positive cells.	3-Hydroxybutyric Acid	18-21	interleukin 6	Mus musculus	79-92
31233937-0	2019	Lysophosphatidic acid induces interleukin-6 and CXCL15 secretion from MLO-Y4 cells through activation of the LPA1 receptor and PKCtheta signaling pathway.	lysophosphatidic acid	0-21	interleukin 6	Mus musculus	30-43
31233937-6	2019	In this study, we report that LPA markedly enhanced IL-6 and CXCL15 (mouse homologue of human IL-8) production in MLO-Y4 cells and that this enhancement was suppressed by the LPA1/3-selective antagonist Ki16425, the Gi/o protein inhibitor PTX or the protein kinase C (PKC) inhibitor sotrastaurin.	lysophosphatidic acid	30-33	interleukin 6	Mus musculus	52-56
31233937-6	2019	In this study, we report that LPA markedly enhanced IL-6 and CXCL15 (mouse homologue of human IL-8) production in MLO-Y4 cells and that this enhancement was suppressed by the LPA1/3-selective antagonist Ki16425, the Gi/o protein inhibitor PTX or the protein kinase C (PKC) inhibitor sotrastaurin.	3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid	203-210	interleukin 6	Mus musculus	52-56
31233937-8	2019	Taken together, the results of the present study demonstrate that LPA may be a potent inducer of IL-6 and CXCL15 production in MLO-Y4 cells and that this induction is associated with the activation of LPA1, Gi/o protein and the PKCtheta pathway.	lysophosphatidic acid	66-69	interleukin 6	Mus musculus	97-101
31441507-7	2019	In addition, supplementation with BRS significantly inhibited the increase in plasma lipopolysaccharide, tumor necrosis factor-alpha, and interleukin-6 levels.	2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL	34-37	interleukin 6	Mus musculus	138-151
30878677-4	2019	cis-Khellactone clearly reduced the level of cytokines in psoriatic skin, including IL-23, TNF-alpha, IL-1beta, and IL-6, while limiting the inhibition of IL-17A, which is produced by T helper type 17 cells.	(+)-cis-Khellactone	0-15	interleukin 6	Mus musculus	116-120
31069623-8	2019	FTY720 directly inhibited MPTP-induced microglial activation in the SNpc, suppressed the production of interleukin (IL)-6, IL-1beta, and tumor necrosis factor-alpha in BV-2 microglial cells treated with 1-methyl-4-phenylpyridinium (MPP+), and subsequently decreased apoptosis in SH-SY5Y neuroblastoma cells.	Fingolimod Hydrochloride	0-6	interleukin 6	Mus musculus	103-121
31069623-8	2019	FTY720 directly inhibited MPTP-induced microglial activation in the SNpc, suppressed the production of interleukin (IL)-6, IL-1beta, and tumor necrosis factor-alpha in BV-2 microglial cells treated with 1-methyl-4-phenylpyridinium (MPP+), and subsequently decreased apoptosis in SH-SY5Y neuroblastoma cells.	1-Methyl-4-phenylpyridinium	203-230	interleukin 6	Mus musculus	103-121
31302373-6	2019	Luteolin supplementation also significantly lowered mRNA expression of inflammatory and M1 markers MCP-1, CD11c, TNF-alpha and IL-6, while maintaining expression of M2 marker MGL1.	Luteolin	0-8	interleukin 6	Mus musculus	127-131
31251998-6	2019	Moreover gliotic specific inflammatory markers like glial fibrillary acidic protein (GFAP), ionized calcium-binding adaptor protein-1 (Iba-1), iNOS and COX-2 were found to be expressed more in MPTP intoxicated mice, Further the levels of proinflammatory cytokines like IL-beta, IL-6, and TNF-alpha were significantly upregulated in MPTP intoxicated mice, these deleterious responses were diminished to extend neuroprotection by PHL treatment.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	193-197	interleukin 6	Mus musculus	278-282
31336111-11	2019	However, pretreatment with MJ, attenuated the parkinsonian-like symptoms and reduced the brain levels of MDA/nitrite, TNF-alpha and IL-6 induced by Rot.	methyl jasmonate	27-29	interleukin 6	Mus musculus	132-136
31153984-9	2019	MSF (4 and 8 mg/kg) and ciprofloxacin, significantly decreased IL-6, IL-8 and TNF-alpha levels, whereas, increased IL-2, IL-4, IL-10, INF-gamma, IgA and IgG levels in mice having diarrhea.	Ciprofloxacin	24-37	interleukin 6	Mus musculus	63-67
31470289-4	2019	DSS administration induced acute colitis in mice, whereas the propolis extract mitigated DSS-induced weight loss; colon shortening; increased plasma levels of lipopolysaccharide-binding protein; reduced expression of TJ proteins, such as zonula occludens, junctional adhesion molecule-A, occludin, and claudins; and increased expression of inflammatory cytokines, such as tumor necrosis factor (TNF) alpha, interleukin (IL) 6, and IL-17a.	dss	89-92	interleukin 6	Mus musculus	407-425
31308264-4	2019	We found that TRPV3 proteins, together with inflammatory factors tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, were upregulated in the skin of mice in a AD-like model induced by topical application of chemical 2,4-dinitrofluorobenzene, as detected by Western blot analysis and immunostaining assays.	Dinitrofluorobenzene	222-246	interleukin 6	Mus musculus	103-121
31308264-6	2019	Furthermore, inhibition of TRPV3 by natural osthole reversed the severity of inflammatory dorsal skin and ear edema in a dose-dependent manner and also decreased expression of inflammatory factors TNF-alpha and IL-6.	osthol	44-51	interleukin 6	Mus musculus	211-215
31470289-6	2019	Baccharin, drupanin, and culifolin, which are also present in Brazilian propolis, reduced the TNF-alpha and/or IL-6 production by suppressing inflammatory signaling in murine RAW 264.7 macrophages.	baccharin	0-9	interleukin 6	Mus musculus	111-115
31470289-6	2019	Baccharin, drupanin, and culifolin, which are also present in Brazilian propolis, reduced the TNF-alpha and/or IL-6 production by suppressing inflammatory signaling in murine RAW 264.7 macrophages.	Drupanin	11-19	interleukin 6	Mus musculus	111-115
31470289-6	2019	Baccharin, drupanin, and culifolin, which are also present in Brazilian propolis, reduced the TNF-alpha and/or IL-6 production by suppressing inflammatory signaling in murine RAW 264.7 macrophages.	CULIFOLIN	25-34	interleukin 6	Mus musculus	111-115
31085374-10	2019	Polydatin also prevented hepatic and aortic inflammation as evidenced by the reduced macrophage infiltration and mRNA expressions of tumor necrosis factor-alpha and interleukin-6 in both aorta and liver.	polydatin	0-9	interleukin 6	Mus musculus	165-178
32305963-4	2019	The inflammatory factors of TNF-alpha, IL-1beta, IL-6, and MCP1 were also significantly reduced by GYY4137.	GYY 4137	99-106	interleukin 6	Mus musculus	49-53
31132306-5	2019	Upon TPPU treatment, the liver steatosis and inflammatory damage were significantly ameliorated in mice with steatohepatitis, paralleled by the downregulation of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) as well as chemokines (CXCL1, MCP-1).	TPPU	5-9	interleukin 6	Mus musculus	211-215
31244052-8	2019	Furthermore, THS reduced mRNA expression of the proinflammatory cytokines, TNF-alpha, IL-6, and IL-1beta and increased synapse-associated proteins (synaptophysin and postsynaptic density protein 95) in the hippocampus of AD mice.	Thorium	13-16	interleukin 6	Mus musculus	86-90
31555126-10	2019	Results: FX was found to decrease the expression of inflammatory cytokines including IL-6, IL-1beta, and TNF-alpha, in a prophylactic manner in the LPS-induced sepsis mouse model.	fucoxanthin	9-11	interleukin 6	Mus musculus	85-89
31555126-13	2019	Furthermore, FX also inhibits the expression of inflammatory factors in a dose-dependent manner with the IC50 inhibition of IL-6 production was 2.19 +- 0.70 muM in Raw267.4 macrophage cells.	fucoxanthin	13-15	interleukin 6	Mus musculus	124-128
31455356-7	2019	RESULTS: Curcumin treatment markedly inhibited the degradation of IkappaBalpha, the activation of NF-kappaB signaling pathway, and the expression levels of the NF-kappaB downstream inflammatory genes such as IL-1beta, IL-6, TNF-alpha, COX-2, and PGE2 in the MSU-stimulated THP-1-derived macrophages.	Curcumin	9-17	interleukin 6	Mus musculus	218-222
31497013-6	2019	THC+CBD treatment also caused a decrease in the levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-gamma, TNF-alpha, IL-1beta, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as FoxP3, STAT5b, IL-4, IL-10, and TGF-beta.	Dronabinol	0-3	interleukin 6	Mus musculus	161-165
31497013-6	2019	THC+CBD treatment also caused a decrease in the levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-gamma, TNF-alpha, IL-1beta, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as FoxP3, STAT5b, IL-4, IL-10, and TGF-beta.	Cannabidiol	4-7	interleukin 6	Mus musculus	161-165
31438590-7	2019	Anthocyanin treatment failed to reverse the effects of the high fat diet on body weight and glucose tolerance, but significantly reduced the leptin and IL-6 levels.	Anthocyanins	0-11	interleukin 6	Mus musculus	152-156
31481925-8	2019	Moreover, SAHA treatment suppressed M1 cytokine expression (IL-6, TNF-alpha, and iNOS) while promoted the transcription of M2 cytokines (Arg-1 and IL-10) in LPS-challenged mouse microglia, and enhanced CD206 (M2 marker) but decreased CD86 (M1 markers) levels in microglia isolated from the ipsilateral hemisphere of MCAO mice.	Vorinostat	10-14	interleukin 6	Mus musculus	60-64
31481965-8	2019	Likewise, the galloyl-HHDP-glucose-treated animals presented reduced expression of the TNF-alpha, IL-6, and IL-1beta genes in the lungs and reduced TNF-alpha, IL-6, IL-1beta, and IL-8 protein levels when compared with the vehicle-treated LPS-challenged mice.	Glucose	27-34	interleukin 6	Mus musculus	98-102
31301368-5	2019	Also, SD induced an increase in the frequency but a decrease in the amplitude of excitatory action-potential dependent PSCs (sEPSCs), both in an IL-6 dependent manner, as well as a generalized (S/R-independent) decrease in the frequency of action potential independent (miniature) excitatory (IL-6 dependent) as well as inhibitory (IL-6 independent) postsynaptic current frequency.	SD 0006	6-8	interleukin 6	Mus musculus	145-149
31301368-5	2019	Also, SD induced an increase in the frequency but a decrease in the amplitude of excitatory action-potential dependent PSCs (sEPSCs), both in an IL-6 dependent manner, as well as a generalized (S/R-independent) decrease in the frequency of action potential independent (miniature) excitatory (IL-6 dependent) as well as inhibitory (IL-6 independent) postsynaptic current frequency.	SD 0006	6-8	interleukin 6	Mus musculus	293-297
31301368-5	2019	Also, SD induced an increase in the frequency but a decrease in the amplitude of excitatory action-potential dependent PSCs (sEPSCs), both in an IL-6 dependent manner, as well as a generalized (S/R-independent) decrease in the frequency of action potential independent (miniature) excitatory (IL-6 dependent) as well as inhibitory (IL-6 independent) postsynaptic current frequency.	SD 0006	6-8	interleukin 6	Mus musculus	293-297
31301368-7	2019	Our results suggest that SD induces behaviorally-relevant synaptic rearrangement in mPFC circuits, part of which is IL-6 dependent.	SD 0006	25-27	interleukin 6	Mus musculus	116-120
31481965-8	2019	Likewise, the galloyl-HHDP-glucose-treated animals presented reduced expression of the TNF-alpha, IL-6, and IL-1beta genes in the lungs and reduced TNF-alpha, IL-6, IL-1beta, and IL-8 protein levels when compared with the vehicle-treated LPS-challenged mice.	Glucose	27-34	interleukin 6	Mus musculus	159-163
31497232-8	2019	Escin also attenuated the hepatic myeloperoxidase (MPO) activity and hepatic pro-inflammatory cytokines (i.e., TNF-alpha, IL-1beta, IL-6 and IL-17).	Escin	0-5	interleukin 6	Mus musculus	132-136
31497235-3	2019	We initially discovered that RSV significantly improved cardiac function and suppressed the expression of fibrosis markers, such as collagen-I, collagen-III, and fibronectin, and pro-inflammatory cytokines, including interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha).	Resveratrol	29-32	interleukin 6	Mus musculus	247-260
31497235-3	2019	We initially discovered that RSV significantly improved cardiac function and suppressed the expression of fibrosis markers, such as collagen-I, collagen-III, and fibronectin, and pro-inflammatory cytokines, including interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha).	Resveratrol	29-32	interleukin 6	Mus musculus	262-266
31414228-11	2019	Immunofluorescence and western blotting studies showed that PEM/Rg3 inhibited the expressions of interleukin 1 (IL-1), interleukin 6 (IL-6), and reactive oxygen species modulator-1 (ROMO1).	3-(2-phenylethyl)-4-methylsydnone	60-63	interleukin 6	Mus musculus	119-132
31414228-11	2019	Immunofluorescence and western blotting studies showed that PEM/Rg3 inhibited the expressions of interleukin 1 (IL-1), interleukin 6 (IL-6), and reactive oxygen species modulator-1 (ROMO1).	3-(2-phenylethyl)-4-methylsydnone	60-63	interleukin 6	Mus musculus	134-138
31414228-11	2019	Immunofluorescence and western blotting studies showed that PEM/Rg3 inhibited the expressions of interleukin 1 (IL-1), interleukin 6 (IL-6), and reactive oxygen species modulator-1 (ROMO1).	ginsenoside Rg3	64-67	interleukin 6	Mus musculus	119-132
31414228-11	2019	Immunofluorescence and western blotting studies showed that PEM/Rg3 inhibited the expressions of interleukin 1 (IL-1), interleukin 6 (IL-6), and reactive oxygen species modulator-1 (ROMO1).	ginsenoside Rg3	64-67	interleukin 6	Mus musculus	134-138
31409825-5	2019	IL-6-mediated activation of STAT3 was repressed after RORalpha activation by either adenoviral infusion of RORalpha or JC1-40 treatment in primary hepatocytes.	jc1-40	119-125	interleukin 6	Mus musculus	0-4
31178135-6	2019	Furthermore, CA-FA inhibited LPS-induced iNOS, COX-2, interleukin-6, and interleukin-1beta mRNA expressions in BV2 cells.	ca-fa	13-18	interleukin 6	Mus musculus	54-67
31416231-8	2019	Although 5 mug/mL E2, DHT, and BPA were not toxic to RAW264.7 cell cultures, the same treatments significantly (p &lt; 0.001) reduced both NO and IL-6 secretion by lipopolysaccharide (LPS)-stimulated RAW264.7 cell cultures.	bisphenol A	31-34	interleukin 6	Mus musculus	146-150
31416231-9	2019	The suppression of NO and IL-6 secretion indicate inhibition of inflammation by DHT, E2, and BPA.	Dihydrotestosterone	80-83	interleukin 6	Mus musculus	26-30
31416231-9	2019	The suppression of NO and IL-6 secretion indicate inhibition of inflammation by DHT, E2, and BPA.	bisphenol A	93-96	interleukin 6	Mus musculus	26-30
31136760-5	2019	CPA increased hepatic infiltration of neutrophils, liver myeloperoxidase (MPO) activity, serum interleukin-6 (IL-6) content, hepatic IL-6 mRNA expression, toll-like receptor-4 (TLR4) expression and nuclear factor kappaB (NFkappaB) activation in mice.	Cyclophosphamide	0-3	interleukin 6	Mus musculus	95-108
31394746-7	2019	A dose of 5 mg/kg Mt-P, but not the natural compound P, reversed intestinal inflammation and increased expression of Tnf-alpha, Ifn-y, and Il-6, while promoted the expansion of regulatory T cells and M2 macrophages.	mt-p	18-22	interleukin 6	Mus musculus	139-143
31082504-10	2019	Besides, IRI reduced renal expressions of PI3K, p-Akt, p-mTOR, and increased the levels of IL-6, TNF-alpha,cl-caspase-3 in kidney, After propofol treatment, these changes were significantly alleviated, but the use of PI3K inhibitor LY294002 could reverse the effects of propofol.	Propofol	137-145	interleukin 6	Mus musculus	91-95
31136760-5	2019	CPA increased hepatic infiltration of neutrophils, liver myeloperoxidase (MPO) activity, serum interleukin-6 (IL-6) content, hepatic IL-6 mRNA expression, toll-like receptor-4 (TLR4) expression and nuclear factor kappaB (NFkappaB) activation in mice.	Cyclophosphamide	0-3	interleukin 6	Mus musculus	110-114
31136760-5	2019	CPA increased hepatic infiltration of neutrophils, liver myeloperoxidase (MPO) activity, serum interleukin-6 (IL-6) content, hepatic IL-6 mRNA expression, toll-like receptor-4 (TLR4) expression and nuclear factor kappaB (NFkappaB) activation in mice.	Cyclophosphamide	0-3	interleukin 6	Mus musculus	133-137
31136760-8	2019	LG and LQ (40, 80 mg/kg) both ameliorated liver sinusoidal endothelial injury, and reduced the increased hepatic infiltration of neutrophils, MPO activity, hepatic IL-6 mRNA expression and NFkappaB activation induced by CPA.	liquiritin	7-9	interleukin 6	Mus musculus	164-168
31153100-0	2019	Structure-based design and synthesis of new 4-methylcoumarin-based lignans as pro-inflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) inhibitors.	4-Methylcoumarin	44-60	interleukin 6	Mus musculus	117-121
31121485-8	2019	Bilirubin treatment decreased myeloperoxidase activity and reduced the levels of inflammatory cytokines (i.e., IL-1beta, TNFalpha and IL-6) in lavage fluid in mice with alum-induced peritonitis.	Bilirubin	0-9	interleukin 6	Mus musculus	134-138
31167986-3	2019	TC-G 1008 also suppressed serum interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha significantly at 6 h after the elicitation, suggesting that the cells producing IL-6 and/or TNF-alpha are the targets of TC-G 1008.	GPR39-C3	0-9	interleukin 6	Mus musculus	32-50
31153100-1	2019	Suppression of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6) along with nitric oxide reduction in RAW 264.7 cells by 7,8-dihydroxy-4-methylcoumarin, ethyl p-coumarate, ethyl caffeate and ethyl ferulate drove us to search structural-analogues of the aforementioned compounds through structure-based drug design.	7,8-dihydroxy-4-methylcoumarin	129-159	interleukin 6	Mus musculus	67-71
31167986-3	2019	TC-G 1008 also suppressed serum interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha significantly at 6 h after the elicitation, suggesting that the cells producing IL-6 and/or TNF-alpha are the targets of TC-G 1008.	GPR39-C3	0-9	interleukin 6	Mus musculus	169-173
31167986-3	2019	TC-G 1008 also suppressed serum interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha significantly at 6 h after the elicitation, suggesting that the cells producing IL-6 and/or TNF-alpha are the targets of TC-G 1008.	GPR39-C3	210-219	interleukin 6	Mus musculus	169-173
31011814-8	2019	In addition, SN-38 abrogated LPS-dependent neutrophil migration and reduced TNF-alpha, IL-6, and keratinocyte chemoattractant levels in the air-pouch model, but failed to inhibit zymosan (a TLR2 agonist)-induced cell migration.	Irinotecan	13-18	interleukin 6	Mus musculus	87-91
31167986-4	2019	One potential target cell appears to be a monocyte-derived macrophages because TC-G 1008 treatment suppressed lipopolysaccharide-induced IL-6 production from U937 macrophages in vitro.	GPR39-C3	79-88	interleukin 6	Mus musculus	137-141
31100371-6	2019	Mechanical allodynia and upregulated pERK, pAKT and pSTAT3 as well as production of TNF-alpha and IL-6 were all attenuated by the noncompetitive NMDA receptor antagonist MK-801.	Dizocilpine Maleate	170-176	interleukin 6	Mus musculus	98-102
31099890-5	2019	Further, our data from mice with phenylhydrazine-induced intravascular hemolysis display a gradual decrease in total neutrophil count, but the number of activated neutrophils and neutrophil-platelet aggregates increases, along with the rise of TNF-alpha, IL-1beta, IL-6 and MPO in circulation.	phenylhydrazine	33-48	interleukin 6	Mus musculus	265-269
31472897-3	2019	In cyclophosphamide-induced immunosuppressed mice, DSP increased serum levels of TNF-alpha, IL-6 and IFN-gamma (enzyme-linked immunosorbent assay, ELISA), and ameliorated the imbalance of the community of gut microbiota as detected by 16S ribosomal RNA gene sequencing.	Cyclophosphamide	3-19	interleukin 6	Mus musculus	92-96
31215797-4	2019	We found that resveratrol (10 and 50 nM) significantly inhibited Abeta-induced proliferation and activation of BV-2 cells, as well as their release of the proinflammatory cytokines, IL-6 and TNF-alpha.	Resveratrol	14-25	interleukin 6	Mus musculus	182-186
31383251-5	2019	Furthermore, LA-Dec inhibited LPS-induced expressions of iNOS, COX-2, interleukin-6, tumor necrosis factor-alpha, and interleukin-1beta mRNA in BV2 cells, whereas the same concentration of LA or Dec was ineffective.	la-dec	13-19	interleukin 6	Mus musculus	70-112
31383251-5	2019	Furthermore, LA-Dec inhibited LPS-induced expressions of iNOS, COX-2, interleukin-6, tumor necrosis factor-alpha, and interleukin-1beta mRNA in BV2 cells, whereas the same concentration of LA or Dec was ineffective.	decursin	16-19	interleukin 6	Mus musculus	70-112
31078568-2	2019	Cisplatin treatment decreases the levels of cochlear LMO4, which acts as a scaffold for IL6-GP130 protein complex.	Cisplatin	0-9	interleukin 6	Mus musculus	88-91
31034776-5	2019	DSS-treated AQP4-/- mice had lower serum levels of IL-6 and TNF, higher IL-10 level, and lesser inflammatory cell infiltration.	Dextran Sulfate	0-3	interleukin 6	Mus musculus	51-55
31363726-11	2019	The results showed that CMP suppressed the expressions of CD68, IL-1beta, IL-6, and MCP-1 mRNA induced by STZ.	Streptozocin	106-109	interleukin 6	Mus musculus	74-78
30937840-4	2019	The results showed that tizoxanide significantly suppressed production of NO as well as pro-inflammatory cytokines, such as IL-1beta, IL-6, and TNF-alpha in dose-dependent manner.	tizoxanide	24-34	interleukin 6	Mus musculus	134-138
31229067-6	2019	In addition, beta-glucan treatment also could decrease the level of interleukin-6 and tumor necrosis factor alpha and increased level of prostaglandin E2, nitric oxide.	beta-Glucans	13-24	interleukin 6	Mus musculus	68-113
31538519-5	2019	In addition, vanillin inhibited LPS-induced TNF-alpha and IL-6 expression in RAW264.7 cells via ERK1/2, p38 and NF-kappaB signaling.	vanillin	13-21	interleukin 6	Mus musculus	58-62
30953227-7	2019	Bergapten also significantly decreased the levels of TNF-alpha and IL-6 and the expression of PARP, COX-2 and iNOS in the spine.	5-Methoxypsoralen	0-9	interleukin 6	Mus musculus	67-71
31078920-10	2019	We found that METH exposure increased LPS-induced IL-6 and TNF-alpha production in the Hip, CPU and NAc regions.	Methamphetamine	14-18	interleukin 6	Mus musculus	50-54
31147743-5	2019	RESULTS: Our in vitro studies showed that LPS-stimulated RAW 264.7 cells treated with GAL reduced the levels of nitrites, IL-6, and TNF-alpha in a concentration-dependent manner.	galangin	86-89	interleukin 6	Mus musculus	122-126
31147743-7	2019	The levels of proinflammatory cytokines (TNF-alpha and IL-6) in colonic tissue and serum were reduced significantly and in GAL + DSS-treated group relative to DSS alone treated group.	Dextran Sulfate	129-132	interleukin 6	Mus musculus	55-59
31108387-5	2019	In addition, irisin reduced the levels of tumor necrosis factor (TNF)-alpha, interleukin(IL)-1beta and interleukin(IL)-6 in the intestine.	irisin	13-19	interleukin 6	Mus musculus	103-120
31078920-12	2019	Moreover, administering SCH-23390 significantly reduced IL-6 and TNF-alpha production and Iba1 expression following LPS challenge.	SCH 23390	24-33	interleukin 6	Mus musculus	56-60
31129421-14	2019	Furthermore, BA inhibited gene expression of pro-inflammatory mediators in skin lesions, including RORgammat, IL-17A, IL-6 and TNFalpha.	betulinic acid	13-15	interleukin 6	Mus musculus	118-122
31129420-9	2019	Serum levels of TgAb, TNF-alpha, IL-6 and IL-1beta were also significantly higher in the NaI group but were dramatically reduced after rmGas6 injection.	Sodium Iodide	89-92	interleukin 6	Mus musculus	33-37
31129420-9	2019	Serum levels of TgAb, TNF-alpha, IL-6 and IL-1beta were also significantly higher in the NaI group but were dramatically reduced after rmGas6 injection.	rmgas6	135-141	interleukin 6	Mus musculus	33-37
31173183-6	2019	Total cell counts and the production of pro-inflammatory cytokines [tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6] in bronchoalveolar fluid were also decreased following treatment with sevoflurane.	Sevoflurane	200-211	interleukin 6	Mus musculus	124-128
30854697-9	2019	In enzyme-linked immunosorbent assay, the comparable data indicated that serological tumor necrosis factor alpha (TNF-alpha), interleukin 6, and heat shock protein 90 (Hsp90) contents were reduced in TFPPL-treated mice.	tfppl	200-205	interleukin 6	Mus musculus	126-139
30927265-6	2019	In addition, transforming growth factor beta, tumor necrosis factor alpha, interleukin 6 (IL-6), IL-23, IL-10, and IL-1beta levels were also greatly induced by high iron diet.	Iron	165-169	interleukin 6	Mus musculus	75-88
31311828-11	2019	CONCLUSIONS: Our data refine the old paradigm, that IL-6 enhances Th17 responses and suppresses Tregs.	tregs	96-101	interleukin 6	Mus musculus	52-56
30927265-6	2019	In addition, transforming growth factor beta, tumor necrosis factor alpha, interleukin 6 (IL-6), IL-23, IL-10, and IL-1beta levels were also greatly induced by high iron diet.	Iron	165-169	interleukin 6	Mus musculus	90-94
31268397-7	2019	The inflammatory markers, interleukin (IL)-1 and IL-6, in the liver were downregulated by RSV treatment.	Resveratrol	90-93	interleukin 6	Mus musculus	49-53
31324991-10	2019	Decrease in IL-6 contributes to downregulation of miR-214 and subsequently upregulated p38/JNK pathway, which is potentially contributes to osteogenic promotion by HAS-G.	hexadehydroastechrome	164-167	interleukin 6	Mus musculus	12-16
30861207-8	2019	Moreover, GZD824 decreased plasma levels of amylase, IL-6, and MMP-9 as well as edema, acinar cell necrosis, hemorrhage, CXC chemokine formation, and neutrophil infiltration in the inflamed pancreas.	olverembatinib	10-16	interleukin 6	Mus musculus	53-57
31168820-7	2019	Also, CuA-SEN reduced the levels of tumour necrosis factor-alpha and interleukin-6 in both serum and liver tissues while aspartate aminotransferase, alanine aminotransferase and malonaldehyde levels were significantly decreased.	cua-sen	6-13	interleukin 6	Mus musculus	69-82
31100405-4	2019	Itaconate is an endogenous metabolite which has recently been reported to regulate the macrophage function and has the ability to reduce the secretion of pro-inflammatory cytokines, such as IL-6 and IL-12.	itaconic acid	0-9	interleukin 6	Mus musculus	190-194
31292344-5	2019	In addition, beta-carotene significantly suppressed protein expression of TNF-alpha, IL-1beta, and MCP-1 and mRNA expression of TSLP, IL-6, IL-1beta, IL-4, IL-5, and Par-2 in AD-like skin tissues.	beta Carotene	13-26	interleukin 6	Mus musculus	134-138
30659419-8	2019	Rg1 suppressed DAC-induced elevation of the proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), but increased levels of the anti-inflammatory cytokines IL-4 and IL-10 in multiple sera and brain tissues.	Decitabine	15-18	interleukin 6	Mus musculus	114-127
30659419-8	2019	Rg1 suppressed DAC-induced elevation of the proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), but increased levels of the anti-inflammatory cytokines IL-4 and IL-10 in multiple sera and brain tissues.	Decitabine	15-18	interleukin 6	Mus musculus	129-133
29451015-5	2019	Anti-inflammatory activity studies on 13 isolated compounds showed that beta-carboline constituents, especially compounds 1 and 2, significantly inhibited the expression of NO, TNF-alpha, IL-6 and IL-1beta in lipopolysaccharide (LPS)-treated RAW264.7 macrophage cells.	norharman	72-86	interleukin 6	Mus musculus	188-192
31029908-11	2019	Curcumin also attenuated the high expression of IL-6, MCP-1, OPN, CD44, alpha-SMA, Collagen I and collagen fibril deposition, which were elevated by hyperoxaluria.	Curcumin	0-8	interleukin 6	Mus musculus	48-52
31173200-17	2019	In addition, DADS markedly inhibited lipid peroxidation by modulating malondialdehyde and superoxide dismutase, and it also decreased tumor necrosis factor-alpha production, interleukin-6 production and macrophage influx, as well as suppressing nuclear factor-kappaB activation, indicating suppression of MCD-induced hepatic inflammation.	diallyl disulfide	13-17	interleukin 6	Mus musculus	174-187
31176103-8	2019	RESULTS: Daily treatment with ALA for 28 days (50, 100, 200 mg/kg, ip) significantly improved insulin sensitivity and cognitive performance in mice by decreasing insulin resistance, corticosterone, IL-6 levels, acetylcholinesterase enzyme activity and oxidative stress in liver, cortex and hippocampus.	Thioctic Acid	30-33	interleukin 6	Mus musculus	198-202
31209984-3	2019	The results showed that TFSB remarkably inhibited lipopolysaccharide/cigarette smoke extract (LPS/CSE)-induced expression of IL-1beta, IL-6, CXCL1, and MUC5AC at both mRNA and protein levels in HBE16 bronchial epithelial cells.	tfsb	24-28	interleukin 6	Mus musculus	135-139
31276378-5	2019	Proinflammatory cytokine (IL-6, IL-12) release by mouse bone-marrow-derived dendritic cells and human peripheral blood mononuclear cells revealed that the potency of silica nanoshells-TLR7 conjugates (NS-TLR) depends on nanoshell size and ligand coating density.	Silicon Dioxide	166-172	interleukin 6	Mus musculus	26-30
31366045-3	2019	We found that filbertone supplementation resulted in significant reductions in body weight gain and lipid accumulation in adipose tissue, with parallel improvements in plasma lipid levels (triglycerides, total cholesterol, and free fatty acids) and proinflammatory cytokines (interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha)).	5-methylhept-2-en-4-one	14-24	interleukin 6	Mus musculus	276-289
31366045-3	2019	We found that filbertone supplementation resulted in significant reductions in body weight gain and lipid accumulation in adipose tissue, with parallel improvements in plasma lipid levels (triglycerides, total cholesterol, and free fatty acids) and proinflammatory cytokines (interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha)).	5-methylhept-2-en-4-one	14-24	interleukin 6	Mus musculus	291-295
31362373-9	2019	In addition, EGCG treatment attenuated colon inflammation by suppressing colonic levels of pro-inflammatory cytokines IL-6, MCP-1, and TNF-alpha, and inhibited CD3+ T cell and CD68+ macrophage infiltration.	epigallocatechin gallate	13-17	interleukin 6	Mus musculus	118-122
31814955-6	2019	Further mechanistic investigations demonstrated that TA combined with GA decreased the levels of TPA-induced interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	tolfenamic acid	53-55	interleukin 6	Mus musculus	139-152
31164200-0	2019	Nitrosporeusine A attenuates sepsis-associated acute kidney injury through the downregulation of IL-6/sIL-6R axis activation-mediated PGC-1alpha suppression.	nitrosporeusine A	0-17	interleukin 6	Mus musculus	97-101
31814955-6	2019	Further mechanistic investigations demonstrated that TA combined with GA decreased the levels of TPA-induced interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	tolfenamic acid	53-55	interleukin 6	Mus musculus	154-158
31814955-6	2019	Further mechanistic investigations demonstrated that TA combined with GA decreased the levels of TPA-induced interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	Glycyrrhizic Acid	70-72	interleukin 6	Mus musculus	139-152
31814955-6	2019	Further mechanistic investigations demonstrated that TA combined with GA decreased the levels of TPA-induced interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	Glycyrrhizic Acid	70-72	interleukin 6	Mus musculus	154-158
31814955-6	2019	Further mechanistic investigations demonstrated that TA combined with GA decreased the levels of TPA-induced interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	4-O-methyl-12-O-tetradecanoylphorbol 13-acetate	97-100	interleukin 6	Mus musculus	139-152
31814955-6	2019	Further mechanistic investigations demonstrated that TA combined with GA decreased the levels of TPA-induced interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	4-O-methyl-12-O-tetradecanoylphorbol 13-acetate	97-100	interleukin 6	Mus musculus	154-158
31346193-4	2019	In addition, we found that Zn and mast cells induce IL-6 production from inflammatory cells such as skin fibroblasts and promote wound healing, a process that involves inflammation.	Zinc	27-29	interleukin 6	Mus musculus	52-56
31350464-5	2019	The levels of IL-1beta in REC group, IL-10 in C-RELAP group, and IL-1beta, IL-6, IL-10 and TNF-alpha in C-PRO group were diminished in the brain.	c-pro	104-109	interleukin 6	Mus musculus	75-79
31283217-3	2019	Systemically, PIP2 inhibits the lipopolysaccharide (LPS)-elicited TNF-alpha, IL-6, and IL-12p40 in a mouse model.	Phosphatidylinositol 4,5-Diphosphate	14-18	interleukin 6	Mus musculus	77-81
31346193-5	2019	Zn induces the production of a variety of pro-inflammatory cytokines including IL-6 through signaling pathways mediated by the Zn receptor GPR39.	Zinc	0-2	interleukin 6	Mus musculus	79-83
31346193-7	2019	Thus, our results show that Zn and mast cells play a critical role in wound healing through activation of the GPR39/IL-6 signaling axis.	Zinc	28-30	interleukin 6	Mus musculus	116-120
31153641-8	2019	Furthermore, ferric ammonium citrate (FAC) was found to induce hepcidin and interleukin-6 (IL-6) expression in THP-1 macrophages and mouse peritoneal macrophages.	ferric ammonium citrate	13-36	interleukin 6	Mus musculus	76-89
31153641-8	2019	Furthermore, ferric ammonium citrate (FAC) was found to induce hepcidin and interleukin-6 (IL-6) expression in THP-1 macrophages and mouse peritoneal macrophages.	ferric ammonium citrate	13-36	interleukin 6	Mus musculus	91-95
31396089-9	2019	Ad libitum HRW consumption also had an inhibitory effect on the METH-induced increase in the expression of Bax/Bcl-2, cleaved caspase-3, glucose-related protein 78 (GRP 78), CCAAT/enhancer-binding protein homologous protein (CHOP), and p-NF-kB p65 expression and elevation of interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha levels in the hippocampus.	Methamphetamine	64-68	interleukin 6	Mus musculus	276-294
31396076-0	2019	The Synthetic Retinoid Acitretin Increases IL-6 in the Central Nervous System of Alzheimer Disease Model Mice and Human Patients.	Retinoids	14-22	interleukin 6	Mus musculus	43-47
31336605-5	2019	In vitro experiments, bakuchiol significantly suppressed the production of PGE2 and IL-6 in LPS-stimulated BV-2 cells, without causing cytotoxicity.	bakuchiol	22-31	interleukin 6	Mus musculus	84-88
31336605-6	2019	In parallel, bakuchiol significantly inhibited the LPS-stimulated expression of iNOS, COX-2, and IL-6 in BV-2 cells.	bakuchiol	13-22	interleukin 6	Mus musculus	97-101
31336605-10	2019	Bakuchiol significantly suppressed LPS-injected production of TNF-alpha and IL-6 in serum.	bakuchiol	0-9	interleukin 6	Mus musculus	76-80
31187838-6	2019	GTP supplementation significantly reduced plasma contents and hepatic mRNA levels of interleukin (IL)-1beta, IL-18, IL-6, and tumor necrosis factor (TNF)-alpha, compared with LPS-treated mice which did not receive GTP treatment.	Guanosine Triphosphate	0-3	interleukin 6	Mus musculus	116-120
31210194-4	2019	Cinnamaldehyde treatment significantly decreased inflammatory cytokine (TNF-alpha, IL-6, NO and MCP-1) overproduction and the serum lipid level.	cinnamaldehyde	0-14	interleukin 6	Mus musculus	83-87
31379505-7	2019	GA-treated retinas showed significantly reduced expression of proinflammatory cytokines such as TNF-alpha, IL-6, IL-1beta, CCL2 and 6, iNOS, and COX-2 (P &lt; 0.05), compared to that in non-treated retinas.	Glycyrrhizic Acid	0-2	interleukin 6	Mus musculus	107-111
31130265-4	2019	Gentiopicroside also down-regulated expression of inflammatory cytokine genes (NFkappaB1, TNFalpha, IL6) compared with vehicle.	gentiopicroside	0-15	interleukin 6	Mus musculus	100-103
31075241-3	2019	Stevioside was observed to significantly inhibit the levels of LPS induced elevation of cytokines, TNF-alpha (P &lt; 0.05) and IL-6 (P &lt; 0.001) as well as the production of reactive oxygen species (P &lt; 0.01) and nitrites (P &lt; 0.001) in RAW264.7 cells.	stevioside	0-10	interleukin 6	Mus musculus	127-131
30933849-4	2019	Salmeterol inhibited the production of LPS-induced mediators of the pro-inflammatory M1 phenotype such as tumor necrosis factor-alpha (TNF-alpha), IL-(interleukin) 18, IL-6, chemokines (CCL2, CCL3, CCL4) and reactive oxygen species from BV2 cells.	Salmeterol Xinafoate	0-10	interleukin 6	Mus musculus	168-172
31295319-5	2019	Because CO is physiologically generated during heme degradation by heme oxygenase 1 (HO-1), an IL-6-inducible enzyme with anti-inflammatory properties, we hypothesized that hepatocellular HO-1 may operate as a physiological feedback regulator of hepcidin that resolves inflammatory signaling.	Carbon Monoxide	8-10	interleukin 6	Mus musculus	95-99
31295319-5	2019	Because CO is physiologically generated during heme degradation by heme oxygenase 1 (HO-1), an IL-6-inducible enzyme with anti-inflammatory properties, we hypothesized that hepatocellular HO-1 may operate as a physiological feedback regulator of hepcidin that resolves inflammatory signaling.	Heme	47-51	interleukin 6	Mus musculus	95-99
31288466-5	2019	Further tests showed that NJP significantly promoted phagocytic capacity, and the secretion of proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta).	NJP	26-29	interleukin 6	Mus musculus	162-175
31354482-9	2019	Acetazolamide (AZ), a CA inhibitor with a chemical structure similar to MTZ, markedly suppressed calcification and reduced CA1, IL-6, IFN-gamma, GM-CSF, and TNF-alpha expression in cultured VSMCs.	Acetazolamide	0-13	interleukin 6	Mus musculus	128-132
31354482-9	2019	Acetazolamide (AZ), a CA inhibitor with a chemical structure similar to MTZ, markedly suppressed calcification and reduced CA1, IL-6, IFN-gamma, GM-CSF, and TNF-alpha expression in cultured VSMCs.	Acetazolamide	15-17	interleukin 6	Mus musculus	128-132
31288466-5	2019	Further tests showed that NJP significantly promoted phagocytic capacity, and the secretion of proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta).	NJP	26-29	interleukin 6	Mus musculus	177-181
30951719-5	2019	Moreover, CT-133 significantly suppressed the primary neutrophil migration toward the PGD2 and robustly inhibited the mRNA and protein expression of IL-1beta, TNF-alpha, IL-6, and KC in primary and RAW264.7 macrophages in response to either LPS- or PGD2 stimulation.	ct-133	10-16	interleukin 6	Mus musculus	170-174
31091120-4	2019	URO-OVA mice developed responses consistent with pelvic and bladder pain after cystitis induction, which was associated with increased splenocyte production of TLR4-mediated proinflammatory cytokines IL-1beta, IL-6, and TNF-alpha.	uro-ova	0-7	interleukin 6	Mus musculus	210-214
31039345-6	2019	The in vivo results showed that sunitinib efficiently depressed the LPS-induced cytokine storm, i.e., rapid and intense production of TNF-alpha and IL-6.	Sunitinib	32-41	interleukin 6	Mus musculus	148-152
31050560-8	2019	This suggests the presence of a targetable adenosine-A2bR-IL-6-axis triggered by adenosine formed by the ischemic heart.	Adenosine	43-52	interleukin 6	Mus musculus	58-62
31091120-7	2019	Intravenous administration of TAK-242 (a TLR4-selective antagonist) significantly attenuated nociceptive responses in cystitis-induced URO-OVA mice, which was associated with reduced splenocyte production of TLR4-mediated IL-1beta, IL-6, and TNF-alpha as well as reduced spinal expression of mRNAs for IL-6, TNF-alpha, CD11b, glial fibrillary acidic protein, and high mobility group box 1.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	30-37	interleukin 6	Mus musculus	232-236
31050560-8	2019	This suggests the presence of a targetable adenosine-A2bR-IL-6-axis triggered by adenosine formed by the ischemic heart.	Adenosine	81-90	interleukin 6	Mus musculus	58-62
31091120-7	2019	Intravenous administration of TAK-242 (a TLR4-selective antagonist) significantly attenuated nociceptive responses in cystitis-induced URO-OVA mice, which was associated with reduced splenocyte production of TLR4-mediated IL-1beta, IL-6, and TNF-alpha as well as reduced spinal expression of mRNAs for IL-6, TNF-alpha, CD11b, glial fibrillary acidic protein, and high mobility group box 1.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	30-37	interleukin 6	Mus musculus	302-306
31050560-11	2019	This suggests an important adenosine-IL-6 axis, which is controlled by A2bR via local adenosine.	Adenosine	27-36	interleukin 6	Mus musculus	37-41
30951938-9	2019	We found that CYN potentiated the effect of bacterial and cyanobacterial LPS that was documented by activation of inflammatory signaling pathways including mitogen-activated protein kinase p38 as well as consequent expression of inducible nitric oxide synthase (iNOS) and increased production of pro-inflammatory mediators such as nitric oxide (NO), TNF-alpha, interleukin-6 (IL-6).	cylindrospermopsin	14-17	interleukin 6	Mus musculus	361-374
31050560-11	2019	This suggests an important adenosine-IL-6 axis, which is controlled by A2bR via local adenosine.	Adenosine	86-95	interleukin 6	Mus musculus	37-41
30685532-6	2019	Meanwhile, TGF-beta, IL-6, and IL-23, the factors which regulate Th17/Treg differentiation, increased their expressions during the development of BCP.	bcp	146-149	interleukin 6	Mus musculus	21-25
31060384-6	2019	TY001 prevented LPS-induced elevations of TNFalpha, IL-1beta, IL-6, and IL-10 in the liver, along with improved histopathology.	ty001	0-5	interleukin 6	Mus musculus	62-66
30951938-9	2019	We found that CYN potentiated the effect of bacterial and cyanobacterial LPS that was documented by activation of inflammatory signaling pathways including mitogen-activated protein kinase p38 as well as consequent expression of inducible nitric oxide synthase (iNOS) and increased production of pro-inflammatory mediators such as nitric oxide (NO), TNF-alpha, interleukin-6 (IL-6).	cylindrospermopsin	14-17	interleukin 6	Mus musculus	376-380
31364133-11	2019	Furthermore, the cardiac functions of the mice in the MI + IL-6 KO group were superior to those in the MI group, with markedly improved FS% and EF% (p&lt;0.05).	Fluorine	136-138	interleukin 6	Mus musculus	59-63
31295342-7	2019	Furthermore, butyrate intervention inhibited expressions of IL-1beta, IL-6 and MCP1/CCL2 in liver, as well as TLR4 in adipose tissue.	Butyrates	13-21	interleukin 6	Mus musculus	70-74
30656591-7	2019	However, IL-6, MCP-1, and TNF-alpha production induced by Pam3CSK4 or lipid A was not augmented when cells were pretreated with curdlan, a dectin-1 ligand, or mannan, a dectin-2 ligand.	Lipid A	70-77	interleukin 6	Mus musculus	9-13
30656591-8	2019	In contrast, pretreatment of cells with TLR ligands upregulated the production of IL-6 and TNF-alpha, but not MCP-1, induced by Pam3CSK4 or lipid A.	Lipid A	140-147	interleukin 6	Mus musculus	82-86
31333447-12	2019	Animal serum biochemistry showed DAR was capable of ameliorating RA induced increase in liver enzyme Alanine Aminotransferase (ALT) and pro-inflammatory cytokine interleukin 6 (IL-6).	dar	33-36	interleukin 6	Mus musculus	162-175
31185753-6	2019	VX-765 inhibited ozone-induced BHR, BAL total cells including neutrophils and eosinophils, and BAL inflammatory cytokines including IL-1alpha, IL-1beta, KC, and IL-6.	belnacasan	0-6	interleukin 6	Mus musculus	161-165
30959371-4	2019	Aloin treatment significantly ameliorated histopathological damage, attenuated the microglia activation and reduced levels of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and IL-6 in the hippocampus.	alloin	0-5	interleukin 6	Mus musculus	232-236
30978647-6	2019	Furthermore, it reduced DSS-induced production of reactive oxygen species (ROS), infiltration of macrophages, and expression of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta.	Dextran Sulfate	24-27	interleukin 6	Mus musculus	174-178
31333447-12	2019	Animal serum biochemistry showed DAR was capable of ameliorating RA induced increase in liver enzyme Alanine Aminotransferase (ALT) and pro-inflammatory cytokine interleukin 6 (IL-6).	dar	33-36	interleukin 6	Mus musculus	177-181
32641944-10	2019	Dizocilpine, particularly with intermediate dose of 1mg/kg significantly improved animal"s weight loss as well as macroscopic and microscopic signs of colitis, reduced colonic levels of IL-1beta, IL-6, TNF-alpha and MPO activity.	Dizocilpine Maleate	0-11	interleukin 6	Mus musculus	196-200
30515825-11	2019	In addition, Cl-amidine decreased pancreatic levels of CXC chemokines, plasma levels of IL-6, and MMP-9 in mice with severe AP.	N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide	13-23	interleukin 6	Mus musculus	88-92
31082627-7	2019	The LPS-induced expression of interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor alpha could be downregulated by clomipramine pre-treatment both in vivo and in vitro.	Clomipramine	124-136	interleukin 6	Mus musculus	60-64
31068381-3	2019	In this study, JFNE was isolated by chromatography to obtain fraction D. We found that pretreatment of LPS-induced RAW264.7 cells with JFNE and fraction D for 3 hours significantly reduced the levels of nitric oxide (NO), interleukin (IL)-1beta, and tumor necrosis factor-alpha (TNF-alpha) in the supernatant of cell cultures, and fraction D could also reduce the level of IL-6.	jfne	15-19	interleukin 6	Mus musculus	373-377
31085628-0	2019	High-saturated-fat diet-induced obesity causes hepatic interleukin-6 resistance via endoplasmic reticulum stress.	saturated	5-14	interleukin 6	Mus musculus	55-68
31085628-1	2019	The relationship between liver interleukin-6 (IL-6) resistance following high-fat diet (HFD)-induced obesity and glucose intolerance is unclear.	Glucose	113-120	interleukin 6	Mus musculus	46-50
31085628-9	2019	Palmitate directly impaired IL-6 signaling in hepatocytes along with inducing ER stress.	Palmitates	0-9	interleukin 6	Mus musculus	28-32
30891759-9	2019	Citral significantly reduced cytokines (IL-1beta, IL-6, TNF-alpha) and oxidative factors (malondialdehyde and hydroxyl radicals) of MRSA-infected mice, whereas it increased gluthtione and superoxide dismutase levels.	citral	0-6	interleukin 6	Mus musculus	50-54
30942960-9	2019	In particular, MOR-treated GMSCs are able to reduce the spinal cord levels of COX-2, GFAP, and inflammatory cytokines IL-1beta and IL-6 and to restore spinal cord normal morphology.	moringin	15-18	interleukin 6	Mus musculus	131-135
30942960-9	2019	In particular, MOR-treated GMSCs are able to reduce the spinal cord levels of COX-2, GFAP, and inflammatory cytokines IL-1beta and IL-6 and to restore spinal cord normal morphology.	gmscs	27-32	interleukin 6	Mus musculus	131-135
30952011-6	2019	In addition, all the specific inhibitors against the mitogen-activated protein kinases (MAPKs) and NF-kappaB significantly suppressed the IL-6 production induced by RAMPtp.	ramptp	165-171	interleukin 6	Mus musculus	138-142
31358372-6	2019	Jaceosidin could down-regulate the levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta), together with up-regulation the levels of interleukin-4 (IL-4) and interleukin-10 (IL-10) in BALF.	jaceosidin	0-10	interleukin 6	Mus musculus	86-99
31358372-6	2019	Jaceosidin could down-regulate the levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta), together with up-regulation the levels of interleukin-4 (IL-4) and interleukin-10 (IL-10) in BALF.	jaceosidin	0-10	interleukin 6	Mus musculus	101-105
31337198-10	2019	Furthermore, imipramine (a selective A-SMase inhibitor) treatment reduced the exercise-induced CK and IL-6 elevations, along with a decrease in cleaved caspase-3 (Cas-3) of gastrocnemius muscles.	Imipramine	13-23	interleukin 6	Mus musculus	102-106
31180535-10	2019	The results indicated that the combined treatment exhibited a similar effect to DEX, both of which attenuated lung structural injuries, downregulated the expressions of IL-6, TNF-alpha, MPO and MDA, and upregulated that of GSH.	Dexamethasone	80-83	interleukin 6	Mus musculus	169-173
31079415-5	2019	Treatment of wild-type C57BL/6 mice with ponatinib and nilotinib but not imatinib, dasatinib or vehicle control for 4 hours significantly increased thrombus growth following ex vivo perfusion on collagen and FeCl3-induced vascular injury of mesenteric arterioles and carotid artery in vivo and increased plasma levels of soluble P-selectin, tumour necrosis factor-alpha, interleukin-6, interferon-gamma and thromboxane B2 (TxB2).	ponatinib	41-50	interleukin 6	Mus musculus	371-384
31079415-5	2019	Treatment of wild-type C57BL/6 mice with ponatinib and nilotinib but not imatinib, dasatinib or vehicle control for 4 hours significantly increased thrombus growth following ex vivo perfusion on collagen and FeCl3-induced vascular injury of mesenteric arterioles and carotid artery in vivo and increased plasma levels of soluble P-selectin, tumour necrosis factor-alpha, interleukin-6, interferon-gamma and thromboxane B2 (TxB2).	nilotinib	55-64	interleukin 6	Mus musculus	371-384
31602840-16	2019	Further studies showed that NF-kappaB p65 overexpression induced by CCl4 was decreased by C-21 steroidal glucosides,leading to the markedly down-regulated protein expression levels of p-IkappaBalpha,i NOS and COX-2,as well as the depression of TNF-alpha and IL-6 mRNA expressions.	Glucosides	105-115	interleukin 6	Mus musculus	258-262
31004726-14	2019	Besides, AP could significantly suppressed the 5-FU-mediated increases of the intestinal inflammatory cytokines (TNF-alpha, IFN-gamma, IL-6, IL-1beta and IL-17), while AMO or PGS only inhibited some of them after 5-FU chemotherapy.	Fluorouracil	47-51	interleukin 6	Mus musculus	135-139
31262006-0	2019	Glucose Ingestion Inhibits Endurance Exercise-Induced IL-6 Producing Macrophage Infiltration in Mice Muscle.	Glucose	0-7	interleukin 6	Mus musculus	54-58
31262006-1	2019	BACKGROUND: Carbohydrate (CHO) supplementation during exercise attenuates exercise-induced increases in plasma Interleukin (IL)-6 concentration.	Carbohydrates	12-24	interleukin 6	Mus musculus	111-129
31262006-1	2019	BACKGROUND: Carbohydrate (CHO) supplementation during exercise attenuates exercise-induced increases in plasma Interleukin (IL)-6 concentration.	CAV protocol	26-29	interleukin 6	Mus musculus	111-129
31262006-2	2019	However, the effects of CHO supplementation on muscle IL-6 production during endurance exercise is controversial.	CAV protocol	24-27	interleukin 6	Mus musculus	54-58
31262006-3	2019	The purpose of this study was to investigate the effects of CHO supplementation on muscle IL-6 production during endurance exercise with a special focus on the IL-6 producing cells.	CAV protocol	60-63	interleukin 6	Mus musculus	90-94
31262006-6	2019	RESULTS: The exercise-induced increases of plasma IL-6 concentration and gastrocnemius IL-6 gene expression were attenuated by glucose ingestion.	Glucose	127-134	interleukin 6	Mus musculus	50-54
31262006-6	2019	RESULTS: The exercise-induced increases of plasma IL-6 concentration and gastrocnemius IL-6 gene expression were attenuated by glucose ingestion.	Glucose	127-134	interleukin 6	Mus musculus	87-91
31262006-8	2019	Furthermore, we observed that macrophages that infiltrated muscle produce IL-6 and glucose ingestion attenuated the infiltration of IL-6-producing macrophages.	Glucose	83-90	interleukin 6	Mus musculus	132-136
31262006-9	2019	CONCLUSION: This study revealed that infiltrating macrophages may be one type of IL-6-producing cells during endurance exercise, and the infiltration of these cells in muscle was attenuated by glucose ingestion.	Glucose	193-200	interleukin 6	Mus musculus	81-85
31262006-10	2019	However, the effects of glucose ingestion on muscle IL-6 production were limited.	Glucose	24-31	interleukin 6	Mus musculus	52-56
31673494-8	2019	Our DFP model resulted in mild neuroinflammation seen by increased IL5, IL12 and MIP2 in brain and plasma IL6 and IL1a.	fluorophosphate	4-7	interleukin 6	Mus musculus	106-109
31242213-7	2019	Synbiotics-treatment suppressed DSS-induced expression of IL-6, STAT-3, COX-2, and TNF-alpha gene transcripts in normal colonic epithelium, indicating the possibility of suppressing tumor development.	dss	32-35	interleukin 6	Mus musculus	58-62
31293430-6	2019	Salidroside alleviated denervation-induced muscle atrophy and inhibited the production of IL6.	rhodioloside	0-11	interleukin 6	Mus musculus	90-93
31293430-8	2019	Finally, all of these responses to salidroside were replicated in neutralizing antibody against IL6.	rhodioloside	35-46	interleukin 6	Mus musculus	96-99
31235854-6	2019	As stated in the main text, data from ELISA analysis of TNFalpha and IL-6 in 4T1 tumors from Balb/c mice treated with GDC-0941 should be provided.	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	118-126	interleukin 6	Mus musculus	69-73
32269953-1	2020	Objective: To investigate the mechanism of the adaptive effect of two compounds in Lonicerae japonica flos (LJF), luteolin (LUT) and chlorogenic acid (CGA), on the expression of interleukin (IL) IL-10 and IL-6.	Luteolin	114-122	interleukin 6	Mus musculus	205-209
31160465-7	2019	Mechanistically, let-7adf promotes IL-6 by directly repressing Tet2 levels and indirectly by enhancing a Tet2 suppressor, the key TCA cycle metabolite, succinate.	Trichloroacetic Acid	130-133	interleukin 6	Mus musculus	35-39
31234344-4	2019	We found that DHA enclosed in RV-SLNs significantly enhanced its ability to contrast the cytotoxic effect of SDS and to inhibit the SDS- and TNF-alpha-induced production of the inflammatory cytokines IL-1beta, IL-6, and 1 MCP-1, in the two keratinocyte cell lines, as well as the NLRP3 inflammasome activation.	Docosahexaenoic Acids	14-17	interleukin 6	Mus musculus	210-214
31320915-7	2019	In addition, the formation of tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), and elevation of myeloperoxidase (MPO) in APAP-exposed mice were inhibited after SAFE treatment.	Acetaminophen	135-139	interleukin 6	Mus musculus	71-84
31320915-7	2019	In addition, the formation of tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), and elevation of myeloperoxidase (MPO) in APAP-exposed mice were inhibited after SAFE treatment.	Acetaminophen	135-139	interleukin 6	Mus musculus	86-90
31212928-4	2019	Furthermore, steamed GSEs exhibited a greater ability to inhibit the production of inflammatory mediators and pro-inflammatory cytokines, such as nitric oxide (NO), interleukin (IL)-6, and tumor necrosis factor (TNF)-alpha in LPS-induced RAW264.7 cells at the same concentration.	gses	21-25	interleukin 6	Mus musculus	165-183
31160465-7	2019	Mechanistically, let-7adf promotes IL-6 by directly repressing Tet2 levels and indirectly by enhancing a Tet2 suppressor, the key TCA cycle metabolite, succinate.	Succinic Acid	152-161	interleukin 6	Mus musculus	35-39
31317039-7	2019	Furthermore, alpha-ketoglutarate also exhibited immunomodulatory effects mediated via downregulation of interleukin (IL)-6, IL-22, tumour necrosis factor (TNF)-alpha, and IL-1beta cytokines.	Ketoglutaric Acids	13-32	interleukin 6	Mus musculus	104-122
30904524-8	2019	Results showed ASPP could inhibit the levels of nitric oxide, interleukin (IL)-6, IL-1beta and TNF-alpha but increase the production of IL-10 in lipopolysaccharide (LPS)-treated RAW 264.7 macrophage cells.	aspp	15-19	interleukin 6	Mus musculus	62-80
30904524-9	2019	In addition ASPP could reduce the secretion of IL-6, IL-1beta and TNF-alpha in LPS-treated mice.	aspp	12-16	interleukin 6	Mus musculus	47-51
31068389-8	2019	In this study, basophil-derived IL-6 that is resistant to suppression by CsA, was largely responsible for allograft fibrosis and limited transplant survival.	Cyclosporine	73-76	interleukin 6	Mus musculus	32-36
30807814-16	2019	In RAW264.7 macrophages, SC containing serum (SC-CS) (5%, 10% and 20%) significantly decreased IL-6, TNF-alpha, TLR4 and MyD88 protein levels and the mRNA expression of IL-6, TNF-alpha and TLR4 (P &lt; 0.05 or P &lt; 0.01).	Scandium	25-27	interleukin 6	Mus musculus	95-99
31128153-4	2019	Consistent with these pulmonary lesions, the inflammatory factors interleukin-6 (IL-6) and interleukin-8 (IL-8) were increased in mice exposed to CS for 4 days.	Cesium	146-148	interleukin 6	Mus musculus	66-79
31128153-4	2019	Consistent with these pulmonary lesions, the inflammatory factors interleukin-6 (IL-6) and interleukin-8 (IL-8) were increased in mice exposed to CS for 4 days.	Cesium	146-148	interleukin 6	Mus musculus	81-85
31128153-8	2019	Finally, we established that, in HBE cells, andrographolide reversed the CSE-induced EMT via decreasing IL-6 levels and, in an animal model, prevented CS-induced lung inflammation and small airway remodeling, indicating that it has potential clinical application for CS-induced pulmonary dysfunction and COPD.	andrographolide	44-59	interleukin 6	Mus musculus	104-108
31128153-8	2019	Finally, we established that, in HBE cells, andrographolide reversed the CSE-induced EMT via decreasing IL-6 levels and, in an animal model, prevented CS-induced lung inflammation and small airway remodeling, indicating that it has potential clinical application for CS-induced pulmonary dysfunction and COPD.	Cesium	73-75	interleukin 6	Mus musculus	104-108
30998353-4	2019	Among the analogues generated, the promising 3-(indol-5-yl)-indazole analogue 22m inhibited lipopolysaccharide (LPS)-induced expression of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) in macrophages with IC50 values of 0.89 and 0.53 muM, respectively.	3-(indol-5-yl)-indazole	45-68	interleukin 6	Mus musculus	183-196
30998353-4	2019	Among the analogues generated, the promising 3-(indol-5-yl)-indazole analogue 22m inhibited lipopolysaccharide (LPS)-induced expression of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) in macrophages with IC50 values of 0.89 and 0.53 muM, respectively.	3-(indol-5-yl)-indazole	45-68	interleukin 6	Mus musculus	198-202
30807814-16	2019	In RAW264.7 macrophages, SC containing serum (SC-CS) (5%, 10% and 20%) significantly decreased IL-6, TNF-alpha, TLR4 and MyD88 protein levels and the mRNA expression of IL-6, TNF-alpha and TLR4 (P &lt; 0.05 or P &lt; 0.01).	Scandium	25-27	interleukin 6	Mus musculus	169-173
30807814-16	2019	In RAW264.7 macrophages, SC containing serum (SC-CS) (5%, 10% and 20%) significantly decreased IL-6, TNF-alpha, TLR4 and MyD88 protein levels and the mRNA expression of IL-6, TNF-alpha and TLR4 (P &lt; 0.05 or P &lt; 0.01).	Cesium	49-51	interleukin 6	Mus musculus	95-99
31212848-8	2019	In this context, polyphenols exerted modulating activities on day 30 TAG/F3 mice, inducing release of interleukin (IL)-10 in hetero mice while abrogating release of IL-2, IFN-gamma, TNF-alpha, IL-6, and IL-4 in homo and hetero mice.	Polyphenols	17-28	interleukin 6	Mus musculus	193-197
30807814-16	2019	In RAW264.7 macrophages, SC containing serum (SC-CS) (5%, 10% and 20%) significantly decreased IL-6, TNF-alpha, TLR4 and MyD88 protein levels and the mRNA expression of IL-6, TNF-alpha and TLR4 (P &lt; 0.05 or P &lt; 0.01).	Cesium	49-51	interleukin 6	Mus musculus	169-173
30999008-10	2019	L-Enano at 20 mug/mL significantly decreased production of monocyte chemoattractant protein-1, tumor necrosis factor alpha, and interleukin-6 from mouse macrophages, while having no effect on their plasma levels compared to the PBS control.	l-enano	0-7	interleukin 6	Mus musculus	128-141
31308853-7	2019	Autophagosomes secreted by FFCT-treated CT26.WT cells can activate M1 type macrophages, accompanied with increased expression of costimulatory molecules CD86 and CD40 on the surface of RAW264.7 cells, and more inflammatory cytokines secretion, such as TNF-alpha, IL-6, MCP-1, and IL-1beta.	ffct	27-31	interleukin 6	Mus musculus	263-267
31186320-5	2019	The beta-lactam-induced Lpls stimulated the production of interleukin-6 and tumor necrosis factor alpha in RAW 264.7 macrophages.	beta-Lactams	4-15	interleukin 6	Mus musculus	58-71
31186320-14	2019	Deletion of lpl significantly decreases proinflammatory cytokine levels in vitro and in vivo The beta-lactam-induced Lpls enhance host inflammatory responses by triggering the Toll-like-receptor-2-mediated expressions of interleukin-6 and tumor necrosis factor alpha.	beta-Lactams	97-108	interleukin 6	Mus musculus	221-266
31174552-5	2019	RESULTS: Paraquat-induced signs of sickness, inflammation (elevated IL-6), and peripheral toxicity (e.g., organ weight) were completely prevented by LRRK2 knockout.	Paraquat	9-17	interleukin 6	Mus musculus	68-72
30807747-4	2019	Results indicated that HES pretreatment significantly attenuated LPS-induced pulmonary pathological injury, total protein concentration, markedly decreased the number of neutrophils and the levels of inflammatory cytokines, TNF-alpha and IL-6, in ALI model in vivo and in vitro.	hesperetin	23-26	interleukin 6	Mus musculus	238-242
31244849-4	2019	In the present study, we found that Kirenol inhibited the migration, invasion, and proinflammatory of IL-6 secretion of RA-associated synovial fibroblasts (FLS) at a concentration of 100-200 mug/ml in vitro.	kirenol	36-43	interleukin 6	Mus musculus	102-106
31214200-9	2019	Silencing of SOCS3 in cardiomyocytes precluded the inhibitory effects of benznidazole on TNF-alpha, IL-6, iNOS expression and NO release.	benzonidazole	73-85	interleukin 6	Mus musculus	100-104
28963443-2	2019	Using hematoxylin-and-eosin (H&amp;E) staining, immunohistochemistry, enzyme-linked immunosorbent assay, quantitative real time PCR and Western blotting, we found that fasudil attenuated LPS-induced lung injury, decreased lung edema, and suppressed inflammatory responses including leukocyte infiltration and IL-6 production.	fasudil	168-175	interleukin 6	Mus musculus	309-313
31214565-6	2019	In vivo experiments also proved that treatment with sorafenib significantly reduced the levels of TNF-alpha and IL-6 in breast tissue from mice mastitis, which was further confirmed by histopathology examination.	Sorafenib	52-61	interleukin 6	Mus musculus	112-116
30892082-4	2019	Here, we report that MLN4924 can markedly reduce the expression of proinflammatory cytokines and chemokines such as IL-1beta, IL-6, and CXCL-1 and neutrophilia in a mouse model of IL-17A adenovirus-induced pulmonary inflammation.	pevonedistat	21-28	interleukin 6	Mus musculus	126-130
30936017-5	2019	Distinctive stress responses resulting from doxorubicin treatment were observed, including upregulation of systemic markers of inflammation (IL-6, IL-1alpha, MCP-1), cardiac damage (ANP, BNP), DNA damage (i.e. DNA double-strand breaks (DSB)), DNA damage response (DDR) and cell death.	Doxorubicin	44-55	interleukin 6	Mus musculus	141-145
30874838-10	2019	TFDG significantly suppressed the expression of IL-1beta, TNF-alpha, and IL-6, as well as the levels of MMP-1, MMP-2, and MMP-3 in the synovium.	theaflavin-3,3'-digallate	0-4	interleukin 6	Mus musculus	73-77
30925455-10	2019	Honokiol significantly decreases the expression of TNF-alpha, IL-1beta and IL-6 and decreases expression level of TRPV1 and P2Y.	honokiol	0-8	interleukin 6	Mus musculus	75-79
31262388-8	2019	In BALB/c mice, Rv0674 adjuvant by DDA/Poly I:C could also induce a high level of IFN-gamma, interleukin-2 and interleukin-6 as well as a high IgG titer in both high- and low-dose groups indicating that Rv0674 is essential in humoral and cellular immunity.	rv0674	16-22	interleukin 6	Mus musculus	111-124
31262388-8	2019	In BALB/c mice, Rv0674 adjuvant by DDA/Poly I:C could also induce a high level of IFN-gamma, interleukin-2 and interleukin-6 as well as a high IgG titer in both high- and low-dose groups indicating that Rv0674 is essential in humoral and cellular immunity.	bis(p-chlorophenyl)acetic acid	35-38	interleukin 6	Mus musculus	111-124
31262388-8	2019	In BALB/c mice, Rv0674 adjuvant by DDA/Poly I:C could also induce a high level of IFN-gamma, interleukin-2 and interleukin-6 as well as a high IgG titer in both high- and low-dose groups indicating that Rv0674 is essential in humoral and cellular immunity.	Poly I-C	39-47	interleukin 6	Mus musculus	111-124
30852762-0	2019	Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.	bazedoxifene	0-12	interleukin 6	Mus musculus	24-28
30852762-9	2019	RESULTS: Our findings demonstrated that bazedoxifene not only decreased the expression of P-STAT3, IL-6/GP130-mediated downstream target genes P-AKT and P-ERK, but also blocked mitogen effects stimulated by IL-6, including cell viability, and overall cell survive, proliferation as well as cell migration.	bazedoxifene	40-52	interleukin 6	Mus musculus	99-103
30852762-9	2019	RESULTS: Our findings demonstrated that bazedoxifene not only decreased the expression of P-STAT3, IL-6/GP130-mediated downstream target genes P-AKT and P-ERK, but also blocked mitogen effects stimulated by IL-6, including cell viability, and overall cell survive, proliferation as well as cell migration.	bazedoxifene	40-52	interleukin 6	Mus musculus	207-211
30852762-12	2019	CONCLUSIONS: Taken together, our data suggest that bazedoxifene may be developed as a promising small molecular therapeutic agent for eradicating TNBC intrinsically associated with constitutively active IL-6/GP130/STAT3 signaling cascade.	bazedoxifene	51-63	interleukin 6	Mus musculus	203-207
30779332-9	2019	Fasudil-modified MNCs inhibited the activation of inflammatory signaling p-NF-kB/P38, accompanied by the decrease of COX-2 and the increase of Arg-1 in spinal cord, as well as the reduction of IL-17, TNF-alpha, IL-6 and the elevation of IL-10 in cultured supernatant of splenocytes.	fasudil	0-7	interleukin 6	Mus musculus	211-215
30941802-9	2019	Furthermore, miR-124a inhibited the expression of the key components of the PIK3/Akt/NF-kappaB signal pathway and inhibited the expression of pro-inflammatory factors TNF-alpha and IL-6.	mir-124a	13-21	interleukin 6	Mus musculus	181-185
29525889-12	2019	In hiFB, the expression of collagen as well as of pro-inflammatory cytokines IL-6, TNF and CCL2 was down-regulated by nobiletin treatment.	nobiletin	118-127	interleukin 6	Mus musculus	77-81
30991142-4	2019	Intraperitoneal injection of acetaminophen (APAP) elicited a progressive course of ALI in mice, which was developed from 12 to 24 h post injection along with liver inflammation evident by macrophage infiltration and upregulations of cytokines (IL-1beta, IL-6 and TNF-alpha); these alterations were concurrently occurred with a robust and progressive production of serum Prdx1.	Acetaminophen	29-42	interleukin 6	Mus musculus	254-258
30836096-1	2019	BACKGROUND &amp; AIMS: Interleukin 6 (IL6) and tumor necrosis factor contribute to the development of colitis-associated cancer (CAC).	Adenosine Monophosphate	12-15	interleukin 6	Mus musculus	23-36
30836096-1	2019	BACKGROUND &amp; AIMS: Interleukin 6 (IL6) and tumor necrosis factor contribute to the development of colitis-associated cancer (CAC).	Adenosine Monophosphate	12-15	interleukin 6	Mus musculus	38-41
30991142-4	2019	Intraperitoneal injection of acetaminophen (APAP) elicited a progressive course of ALI in mice, which was developed from 12 to 24 h post injection along with liver inflammation evident by macrophage infiltration and upregulations of cytokines (IL-1beta, IL-6 and TNF-alpha); these alterations were concurrently occurred with a robust and progressive production of serum Prdx1.	Acetaminophen	44-48	interleukin 6	Mus musculus	254-258
30343452-8	2019	RESULTS: The severity of the arthritic disease was ameliorated in DEX-treated mice, accompanied by the decreased expression of IL-6, IL-8 and TNF-alpha.	Dexamethasone	66-69	interleukin 6	Mus musculus	127-131
31026586-5	2019	The cytokines TNF-alpha, IL-1beta, and IL-6 in colon samples were also significantly downregulated by H2S.	Hydrogen Sulfide	102-105	interleukin 6	Mus musculus	39-43
31119954-9	2019	Paeonol attenuated the level of IL-6 and TNF-alpha, and elevated the activity of GSH-PX, SOD, and CAT with reducing the level of MDA.	paeonol	0-7	interleukin 6	Mus musculus	32-36
30877873-7	2019	Both DHMEQ and tacrolimus suppress DNCB-induced increase of serum total IgE and attenuate expression of inflammatory factors IL-4, IL-6, IL-13, IL-1beta and interferon (IFN)-gamma in the disrupted ear tissues.	dehydroxymethylepoxyquinomicin	5-10	interleukin 6	Mus musculus	131-135
30554371-7	2019	In addition, RSV enhanced the antioxidant enzyme activity; improved the expression of genes related to inflammation; and decreased the malondialdehyde, tumor necrosis factor-alpha, and interleukin-6 concentrations in the kidney of high-fat-diet mice.	Resveratrol	13-16	interleukin 6	Mus musculus	185-198
30877873-7	2019	Both DHMEQ and tacrolimus suppress DNCB-induced increase of serum total IgE and attenuate expression of inflammatory factors IL-4, IL-6, IL-13, IL-1beta and interferon (IFN)-gamma in the disrupted ear tissues.	Tacrolimus	15-25	interleukin 6	Mus musculus	131-135
30877873-7	2019	Both DHMEQ and tacrolimus suppress DNCB-induced increase of serum total IgE and attenuate expression of inflammatory factors IL-4, IL-6, IL-13, IL-1beta and interferon (IFN)-gamma in the disrupted ear tissues.	Dinitrochlorobenzene	35-39	interleukin 6	Mus musculus	131-135
30877874-7	2019	Meanwhile, methane treatment suppressed lipopolysaccharide (LPS)-stimulated phosphorylation of MAPKs pathways and its downstream target TNF-alpha and IL-6 in BV2 cells.	Methane	11-18	interleukin 6	Mus musculus	150-154
30536812-8	2019	Reverse transcription-quantitative-polymerase chain reaction and enzyme-linked immunosorbent assay results demonstrated that propofol attenuates CFA-induced tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and IL-1beta production in the spinal cord as well as in BV2 cells.	Propofol	125-133	interleukin 6	Mus musculus	198-216
30927736-6	2019	Further investigations in an AEC model showed that, taraxasterol alleviated the unfavorable clinical symptoms and attenuated the intestinal inflammation response by reducing the cytokines TNF-alpha, IL-1beta and IL-6 levels.	taraxasterol	52-64	interleukin 6	Mus musculus	212-216
30933843-6	2019	On the other hand, ambroxol treatment significantly reduced imiquimod-induced levels of inflammatory cytokines such as IL-1beta, IL-6, IL-17, IL-22, IL-23, TGF-beta, and TNF-alpha.	Ambroxol	19-27	interleukin 6	Mus musculus	129-133
30536812-9	2019	Taken together, these results demonstrate that propofol attenuates CFA-induced neuroinflammation (TNF-alpha, IL-6, and IL-1beta expression) through a mechanism that involves activation of ERK1/2/NF-kappaB signaling pathway.	Propofol	47-55	interleukin 6	Mus musculus	109-113
31051320-0	2019	Flavanol supplementation protects against obesity-associated increases in systemic interleukin-6 levels without inhibiting body mass gain in mice fed a high-fat diet.	flavanol	0-8	interleukin 6	Mus musculus	83-96
31018175-9	2019	Aortic F4/80, Il-1b and Il-6 expression were significantly inhibited both by testosterone administration.	Testosterone	77-89	interleukin 6	Mus musculus	24-28
31018175-10	2019	Indeed, mice with implanted flutamide exhibited exacerbated AAA formation and aortic F4/80, Il-1b and Il-6 expression were significantly increased.	Flutamide	28-37	interleukin 6	Mus musculus	102-106
31051320-8	2019	Despite lack of improvements to weight gain and glycemic control, it was observed that all flavanol treatment groups were able to significantly reduce interleukin-6 compared to HF control.	flavanol	91-99	interleukin 6	Mus musculus	151-164
31214286-5	2019	Consistent with in vitro studies, BG10 (0.5 mg/mL) not only reduced ear edema but also suppressed the formation of IL-6 and TNF-alpha induced by 12-O-tetradecanoylphorbol-13-acetate in ear tissues of mice.	Tetradecanoylphorbol Acetate	145-181	interleukin 6	Mus musculus	115-119
31009850-12	2019	Bavachin also reduced LPS-induced IL-6 and IL-12p40 production and decreased the activation of MAPKs and NF-kappaB.	bavachin	0-8	interleukin 6	Mus musculus	34-38
30954529-4	2019	Our results showed that both amphotericin B and its liposomal form at various doses induced obvious depression-like behaviors in naive mice, likely owing to increased serum interleukin-6 (IL-6) and IL-1beta levels.	Amphotericin B	29-43	interleukin 6	Mus musculus	173-186
30954529-4	2019	Our results showed that both amphotericin B and its liposomal form at various doses induced obvious depression-like behaviors in naive mice, likely owing to increased serum interleukin-6 (IL-6) and IL-1beta levels.	Amphotericin B	29-43	interleukin 6	Mus musculus	188-192
31155798-8	2019	Furthermore, treatment with kaempferitrin decreased paw thickness and arthritis scores, and reduced the serum levels of IL-1beta, IL-6, and TNF-alpha in a collagen-induced arthritis mouse model.	lespenefril	28-41	interleukin 6	Mus musculus	130-134
31009850-14	2019	Furthermore, bavachin also suppressed the production of NO, IL-6 and IL-12p40 by LPS-stimulated murine peritoneal macrophages.	bavachin	13-21	interleukin 6	Mus musculus	60-64
30953718-5	2019	Results showed that in high fat diet-fed ApoE-/- mice with alpha3-nAChR blocked and in IL-6-stimulated adipocytes with alpha3-nAChR gene silenced the productions of leptin, resistin, triglyceride, cholesterol and low density lipoprotein were significantly increased but the generations of adiponectin and high density lipoprotein were markedly deceased.	Triglycerides	183-195	interleukin 6	Mus musculus	87-91
30953718-5	2019	Results showed that in high fat diet-fed ApoE-/- mice with alpha3-nAChR blocked and in IL-6-stimulated adipocytes with alpha3-nAChR gene silenced the productions of leptin, resistin, triglyceride, cholesterol and low density lipoprotein were significantly increased but the generations of adiponectin and high density lipoprotein were markedly deceased.	Cholesterol	197-208	interleukin 6	Mus musculus	87-91
30572800-14	2019	The cfDNA-stimulated IL6 release by macrophage cells was suppressed by chloroquine, a Toll-like receptor 9 (TLR9) inhibitor.	Chloroquine	71-82	interleukin 6	Mus musculus	21-24
30099700-9	2019	Furthermore, we also found TLR4 deficiency abrogated CIH-induced macrophages (CD68) and fibroblasts (alpha-SMA) recruitment, further reducing expression of extra-cellular matrix protein (collagen I and collagen IV) and inflammatory cytokines release (IL-6, TNF-alpha, and MCP-1).	cih	53-56	interleukin 6	Mus musculus	251-255
31281526-12	2019	Conclusion: Overall, IL-6 trans-signaling may contribute to crucial events in the development of renal fibrosis, and the targeting of IL-6 trans-signaling by Fc-gp130 may provide a novel therapeutic strategy for the treatment of renal fibrosis.	fc-gp130	158-166	interleukin 6	Mus musculus	134-138
30951781-4	2019	We found that 4-MCH suppressed the release of inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in primary liver macrophages isolated from mice and in EtOH-treated RAW264.7 cells.	4-mch	14-19	interleukin 6	Mus musculus	77-90
30951781-4	2019	We found that 4-MCH suppressed the release of inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in primary liver macrophages isolated from mice and in EtOH-treated RAW264.7 cells.	4-mch	14-19	interleukin 6	Mus musculus	92-96
30951781-10	2019	Collectively, these results indicate that 4-MCH alleviated the inflammatory reaction through PPAR-gamma activation via the NF-kappaB-p65 signaling pathway, which regulates the expression of IL-6 and TNF-alpha in AH.	4-mch	42-47	interleukin 6	Mus musculus	190-194
31159225-5	2019	This flavonoid is able to counteract the proliferative effects of IL-22/IL6 pathway by the inhibition of STAT3 activity also in vivo in a psoriatic mouse model.	Flavonoids	5-14	interleukin 6	Mus musculus	72-75
31151139-6	2019	The LPS-induced expression of IL-6 and IL-10 was enhanced by TCDD and FICZ, whereas I3C significantly suppressed these cytokines in BMM.	Polychlorinated Dibenzodioxins	61-65	interleukin 6	Mus musculus	30-34
31115390-9	2019	As a result, the activity of the IL-6/Stat3 pathway was inhibited by DHA.	artenimol	69-72	interleukin 6	Mus musculus	33-37
31140426-5	2019	RESULTS: Quercetin significantly lessened renal pathologies, lowered BUN and creatinine levels (P &amp;lt; 0.05) and inhibited TNF-alpha, IL-1beta, and IL-6 production in mice with LPS-induced AKI (P &amp;lt; 0.05).	Quercetin	9-18	interleukin 6	Mus musculus	152-156
30802614-4	2019	Results indicate that SOL at the concentration range from 25 to 100 mug/mL and its main components, chlorogenic acid, caffeic acid (25-100 muM) significantly reduced the pro-inflammatory cytokine IL-1beta, IL-6, TNF-alpha, attenuated iNOS and COX-2 expression in LPS-stimulated Macrophages.	Chlorogenic Acid	100-116	interleukin 6	Mus musculus	206-210
30802614-4	2019	Results indicate that SOL at the concentration range from 25 to 100 mug/mL and its main components, chlorogenic acid, caffeic acid (25-100 muM) significantly reduced the pro-inflammatory cytokine IL-1beta, IL-6, TNF-alpha, attenuated iNOS and COX-2 expression in LPS-stimulated Macrophages.	caffeic acid	118-130	interleukin 6	Mus musculus	206-210
31115390-11	2019	CONCLUSIONS Our results suggest that the therapeutic effects of DHA on asthma are partially realized via the regulation of miR-183C and IL-6/Stat3 pathway.	artenimol	64-67	interleukin 6	Mus musculus	136-140
31367338-7	2019	The DPODO treatment also significantly lowered the levels of inflammatory markers IL-6 and NF-kappaB in serum and tissue, respectively.	dpodo	4-9	interleukin 6	Mus musculus	82-86
30935688-7	2019	The current results showed that metformin activated autophagy and decreased the mRNA expressions of inflammatory cytokines, IL-1beta, IL-6, and TNF-alpha via inhibition of the STAT3 mRNA and protein expression.	Metformin	32-41	interleukin 6	Mus musculus	134-138
31097691-8	2019	GSK1016790A also increased proinflammatory cytokine IL-1beta, TNF-alpha and IL-6 protein levels, which were blocked by caspase-1 inhibitor Ac-YVAD-cmk.	N-(1-((4-(2-(((2,4-dichlorophenyl)sulfonyl)amino)-3-hydroxypropanoyl)-1-piperazinyl)carbonyl)-3-methylbutyl)-1-benzothiophene-2-carboxamide	0-11	interleukin 6	Mus musculus	76-80
31074472-10	2019	Furthermore, FIS administration markedly restrained the inflammatory response in the kidneys of HFD-challenged mice, as evidenced by the reduced pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), IL-1beta and IL-18, which was attributed to the blockage of nuclear factor kappaB (NF-kappaB) signaling.	fisetin	13-16	interleukin 6	Mus musculus	214-227
31074472-10	2019	Furthermore, FIS administration markedly restrained the inflammatory response in the kidneys of HFD-challenged mice, as evidenced by the reduced pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), IL-1beta and IL-18, which was attributed to the blockage of nuclear factor kappaB (NF-kappaB) signaling.	fisetin	13-16	interleukin 6	Mus musculus	229-233
31171272-3	2019	We discovered that Broussonin E could suppress the LPS-induced pro-inflammatory production in RAW264.7 cells, involving TNF-alpha, IL-1beta, IL-6, COX-2 and iNOS.	broussonin E	19-31	interleukin 6	Mus musculus	141-145
31154731-31	2019	Compared with that in burn group, the serum content of TNF-alpha and IL-6 of mice in burn+ glutamine group was significantly decreased on PBD 5, 10, and 14 (P&lt;0.05).	Glutamine	91-100	interleukin 6	Mus musculus	69-73
31097691-8	2019	GSK1016790A also increased proinflammatory cytokine IL-1beta, TNF-alpha and IL-6 protein levels, which were blocked by caspase-1 inhibitor Ac-YVAD-cmk.	N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone	139-150	interleukin 6	Mus musculus	76-80
31223429-4	2019	Results showed that DMA remarkably inhibited the mRNA and protein expression of receptor for AGEs (RAGE), thereby inhibiting the production of ROS and proinflammatory cytokines, including tumor necrosis factor- (TNF-) alpha, interleukin (IL) 1, IL 6, and monocyte chemoattractant protein- (MCP-) 1 in RAW 264.7 cells.	dma	20-23	interleukin 6	Mus musculus	245-249
30946805-4	2019	Our in vitro study identified that pretreatment of dauricine dose-dependently inhibited pro-inflammatory cytokines including nitric oxide (NO), interleukin-1beta (IL1beta), IL6, tumor necrosis factor-alpha (TNFalpha), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX2) in LPS-stimulated macrophages.	dauricine	51-60	interleukin 6	Mus musculus	173-176
31073117-6	2019	Urocortin treatment induced STAT3 phosphorylation at Y705 and S727 through transactivation of JAK2 in an IL-6-dependent manner, but had no effect on STAT1 activity.	Urocortins	0-9	interleukin 6	Mus musculus	105-109
31193808-9	2019	Interestingly, curcumol-treated IC mice showed that intracellular expressions of PTK2, p-PTK2Tyr397 in bladder samples were reduced, accompanied with lowered blood inflammatory cytokines of interleukin 6 (IL-6), TNF-alpha.	curcumol	15-23	interleukin 6	Mus musculus	190-203
31193808-9	2019	Interestingly, curcumol-treated IC mice showed that intracellular expressions of PTK2, p-PTK2Tyr397 in bladder samples were reduced, accompanied with lowered blood inflammatory cytokines of interleukin 6 (IL-6), TNF-alpha.	curcumol	15-23	interleukin 6	Mus musculus	205-209
30753846-7	2019	The elevation of serum and prefrontal cortex pro-inflammatory cytokines including interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) was decreased by macranthol pretreatment.	macranthol	194-204	interleukin 6	Mus musculus	112-125
31137113-9	2019	The number of total white blood cells, neutrophils, lymphocytes, macrophages and the level of interleukin-6 (IL-6) in BALF of CS and LPS+CS groups were higher than those of CTL group (all P&lt;0.05).	Cesium	126-128	interleukin 6	Mus musculus	94-107
31137113-9	2019	The number of total white blood cells, neutrophils, lymphocytes, macrophages and the level of interleukin-6 (IL-6) in BALF of CS and LPS+CS groups were higher than those of CTL group (all P&lt;0.05).	Cesium	126-128	interleukin 6	Mus musculus	109-113
31137113-10	2019	Furthermore, the number of neutrophils and IL-6 level in BALF of LPS+CS group were higher in comparison with CS group, while the number of macrophages in BALF of LPS+CS group was lower (P&lt;0.05).	Cesium	69-71	interleukin 6	Mus musculus	43-47
31133816-0	2019	Hyperforin Promotes Post-stroke Neuroangiogenesis via Astrocytic IL-6-Mediated Negative Immune Regulation in the Ischemic Brain.	hyperforin	0-10	interleukin 6	Mus musculus	65-69
31133816-7	2019	The astrocytic IL-6 was essential to the promoting effects of hyperforin on the neural precursor cells proliferation, neuronal differentiation, angiogenesis, and functional recovery after stroke.	hyperforin	62-72	interleukin 6	Mus musculus	15-19
31068207-9	2019	RESULTS: The administration of baicalin (especially 60 mg/kg) dramatically ameliorated CUMS-induced depressive-like symptoms; substantially decreased the levels of interleukin-1 beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha) in the hippocampus; and significantly decreased the expression of TLR4.	baicalin	31-39	interleukin 6	Mus musculus	195-208
31133816-8	2019	Furthermore, hyperforin promoted the infiltration of regulatory T cells (Tregs) to the ischemic hemisphere and increased Tregs-derived cytokine IL-10 and transforming growth factor-beta (TGF-beta) in a manner that was dependent on astrocytic IL-6.	hyperforin	13-23	interleukin 6	Mus musculus	242-246
31068207-9	2019	RESULTS: The administration of baicalin (especially 60 mg/kg) dramatically ameliorated CUMS-induced depressive-like symptoms; substantially decreased the levels of interleukin-1 beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha) in the hippocampus; and significantly decreased the expression of TLR4.	baicalin	31-39	interleukin 6	Mus musculus	210-214
31133816-9	2019	Astrocytic IL-6 was critical to the role of hyperforin in promoting the infiltration of T-helper (Th) type 2 cells to the ischemic hemisphere and Th2-derived cytokine IL-4, relative to Th1 and Th1-derived cytokine interferon-gamma (IFN-gamma), which decreased during stroke recovery.	hyperforin	44-54	interleukin 6	Mus musculus	11-15
31133816-12	2019	Our results reveal a previously uncharacterized role of astrocytic IL-6-mediated negative immune regulation in the promoting effects of hyperforin on post-stroke neurovascular regeneration and functional recovery.	hyperforin	136-146	interleukin 6	Mus musculus	67-71
30332888-4	2019	CYC116 also inhibited the secretion of pro-inflammatory cytokines including TNF-alpha (IC50, ~1.10 muM), and IL-6 (IC50, ~1.24 muM).	4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine	0-6	interleukin 6	Mus musculus	109-113
31048563-6	2019	At the molecular level, DMAMCL administration mitigated serum levels of several age-associated inflammatory cytokines, including IL-6, IL-1alpha, IL-1beta, TNF-alpha, IFN-gamma, and CXCL2, and inhibited NF-kappaB activity in several aged tissues.	dimethylaminomicheliolide	24-30	interleukin 6	Mus musculus	129-133
30779630-5	2019	In mice, intramuscular injection of lactate mimicked the exercise-dependent release of IL-6, and pH buffering of lactate production during exercise attenuated IL-6 secretion.	Lactic Acid	36-43	interleukin 6	Mus musculus	87-91
30779630-5	2019	In mice, intramuscular injection of lactate mimicked the exercise-dependent release of IL-6, and pH buffering of lactate production during exercise attenuated IL-6 secretion.	Lactic Acid	113-120	interleukin 6	Mus musculus	159-163
30779630-7	2019	Last, intramuscular injection of the protease hyaluronidase resulted in dramatic increases in serum IL-6 in mice, and immunohistochemical analyses showed that intramuscular lactate and hyaluronidase injections led to release of IL-6-containing intramyocellular vesicles.	Lactic Acid	173-180	interleukin 6	Mus musculus	100-104
30779630-7	2019	Last, intramuscular injection of the protease hyaluronidase resulted in dramatic increases in serum IL-6 in mice, and immunohistochemical analyses showed that intramuscular lactate and hyaluronidase injections led to release of IL-6-containing intramyocellular vesicles.	Lactic Acid	173-180	interleukin 6	Mus musculus	228-232
30779630-9	2019	This protease-dependent release of IL-6 was initiated by lactate production, linking training intensity and lactate production to IL-6 release during strenuous exercise.	Lactic Acid	57-64	interleukin 6	Mus musculus	35-39
30779630-9	2019	This protease-dependent release of IL-6 was initiated by lactate production, linking training intensity and lactate production to IL-6 release during strenuous exercise.	Lactic Acid	57-64	interleukin 6	Mus musculus	130-134
30779630-9	2019	This protease-dependent release of IL-6 was initiated by lactate production, linking training intensity and lactate production to IL-6 release during strenuous exercise.	Lactic Acid	108-115	interleukin 6	Mus musculus	35-39
30779630-9	2019	This protease-dependent release of IL-6 was initiated by lactate production, linking training intensity and lactate production to IL-6 release during strenuous exercise.	Lactic Acid	108-115	interleukin 6	Mus musculus	130-134
31308035-6	2019	RESULTS: Our results reveal that DA reduces the mRNA and protein expression of tumor necrosis factor-a (TNF-alpha), interleukin-6 (IL-6) and interleukin (1L), (IL-1beta) in RAW 264.7 cells stimulated with LPS.	Dopamine	33-35	interleukin 6	Mus musculus	116-129
31308035-6	2019	RESULTS: Our results reveal that DA reduces the mRNA and protein expression of tumor necrosis factor-a (TNF-alpha), interleukin-6 (IL-6) and interleukin (1L), (IL-1beta) in RAW 264.7 cells stimulated with LPS.	Dopamine	33-35	interleukin 6	Mus musculus	131-135
31308035-9	2019	CONCLUSION: Taken together, these findings demonstrate that DA displays potent anti-inflammatory effects that are mediated by the suppression of pro-inflammatory mediators (IL-1beta, IL-6, TNF-alpha), cytokines (iNOS) and the NLRP3 inflammasome activation.	Dopamine	60-62	interleukin 6	Mus musculus	183-187
30686117-3	2019	The expression of IL-1beta, IL-6 and TNF-alpha in both serum and supernate were reduced in miR-125b over-expression groups.	mir-125b	91-99	interleukin 6	Mus musculus	28-32
30735798-5	2019	AGE2 and P-LPS up-regulated the expressions of receptor of AGE (RAGE) and Toll-like receptor 2 (TLR2), respectively, and significantly up-regulated that of sclerostin and interleukin 6 (IL-6) in osteocytes.	p-lps	9-14	interleukin 6	Mus musculus	171-184
30735798-5	2019	AGE2 and P-LPS up-regulated the expressions of receptor of AGE (RAGE) and Toll-like receptor 2 (TLR2), respectively, and significantly up-regulated that of sclerostin and interleukin 6 (IL-6) in osteocytes.	p-lps	9-14	interleukin 6	Mus musculus	186-190
30664361-13	2019	CONCLUSIONS: This study indicates that the three CsA formulations effectively modulated TLR4, TGFbeta1, IL1, and IL6 pathways to reduce corneal epithelium lesions in a mouse model of severe dry eye.	Cyclosporine	49-52	interleukin 6	Mus musculus	113-116
30682503-3	2019	Treatment of cultured spinal astrocytes with specific REV-ERBs agonists SR9009 or GSK4112 significantly prevented lipopolysaccharide (LPS)-induced mRNA upregulation of pronociceptive molecules interleukin-1beta (IL-1beta) mRNA, interleukin-6 (IL-6) mRNA and matrix metalloprotease-9 (MMP-9) mRNA, but not CCL2 mRNA expression.	GSK4112	82-89	interleukin 6	Mus musculus	228-241
30682503-3	2019	Treatment of cultured spinal astrocytes with specific REV-ERBs agonists SR9009 or GSK4112 significantly prevented lipopolysaccharide (LPS)-induced mRNA upregulation of pronociceptive molecules interleukin-1beta (IL-1beta) mRNA, interleukin-6 (IL-6) mRNA and matrix metalloprotease-9 (MMP-9) mRNA, but not CCL2 mRNA expression.	GSK4112	82-89	interleukin 6	Mus musculus	243-247
30734460-5	2019	Significantly increased TNF-alpha, IL-6, IL-8 expressions during DOX-induced inflammatory responses were down regulated by genistein treatment.	Doxorubicin	65-68	interleukin 6	Mus musculus	35-39
30734460-5	2019	Significantly increased TNF-alpha, IL-6, IL-8 expressions during DOX-induced inflammatory responses were down regulated by genistein treatment.	Genistein	123-132	interleukin 6	Mus musculus	35-39
31007758-2	2019	The present study was undertaken to determine the suppressive effects of (+)-catechin, baicalin or beta-caryophyllene on the production of inflammatory cytokines, including TNF-alpha, IL-6 and IL-1beta, which was enhanced by lipopolysaccharide (LPS) in RAW264.7 cells in vitro.	caryophyllene	99-117	interleukin 6	Mus musculus	184-188
30870792-5	2019	In a mouse model of LPS-induced acute inflammation, DSO2-ONJ demonstrated anti-inflammatory activity by inhibiting the production of the pro-inflammatory interleukin-6.	1-dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin	52-60	interleukin 6	Mus musculus	154-167
31007758-2	2019	The present study was undertaken to determine the suppressive effects of (+)-catechin, baicalin or beta-caryophyllene on the production of inflammatory cytokines, including TNF-alpha, IL-6 and IL-1beta, which was enhanced by lipopolysaccharide (LPS) in RAW264.7 cells in vitro.	Catechin	73-85	interleukin 6	Mus musculus	184-188
30339742-9	2019	Spleen cells from immunized mice were collected and re-stimulated with OVA, and results showed significantly augmented production of IFN-gamma, IL-4, IL-5, and IL-6 in mice that received OVA/poly(I:C)-loaded GNPs.	poly	191-195	interleukin 6	Mus musculus	160-164
30796706-6	2019	This study aims to investigate the effect of Hordeum vulgare ethanol extract (HVE) on the suppression of IL-6 expression in BV2 microglia.	Ethanol	61-68	interleukin 6	Mus musculus	105-109
30864870-11	2019	Substance P and cytokines such as interleukin-1beta (IL-1beta), tumor necrosis factor alpha (TNF-alpha), and interleukin-6 (IL-6) were also attenuated with BCP administration.	caryophyllene	156-159	interleukin 6	Mus musculus	109-122
30856394-6	2019	RESULTS: L-THP pretreatment alleviated hepatocyte injury caused by IR and reduced the production of proinflammatory cytokines, such as IL-6 and TNF-alpha.	tetrahydropalmatine	9-14	interleukin 6	Mus musculus	135-139
30864870-11	2019	Substance P and cytokines such as interleukin-1beta (IL-1beta), tumor necrosis factor alpha (TNF-alpha), and interleukin-6 (IL-6) were also attenuated with BCP administration.	caryophyllene	156-159	interleukin 6	Mus musculus	124-128
30811831-5	2019	In females, increased serum leptin, resistin, and IL-6 and reduced adiponectin, caused by visceral obesity, may result in downregulated insulin receptor signaling in muscle and further account for glucose intolerance.	Glucose	197-204	interleukin 6	Mus musculus	50-54
30151726-4	2019	Our in vitro findings demonstrated that exposure of pericytes to cocaine resulted in upregulation of the pro-inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6) in both the intracellular as well as extracellular compartments, thus underpinning pericytes as yet another source of neuroinflammation.	Cocaine	65-72	interleukin 6	Mus musculus	158-162
30151726-8	2019	These findings were also validated in an in vivo model wherein pericytes in the isolated brain microvessels of cocaine injected mice (7 days) exhibited increased expression of both the autophagy marker-LC3 as well as the pro-inflammatory cytokine, IL-6.	Cocaine	111-118	interleukin 6	Mus musculus	248-252
30896853-9	2019	Furthermore, serum levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha, and phosphorylation of MAPK1/3, MAPK14 and MAPK8 in the kidneys were decreased in GDM mice following metformin treatment at E18.5, compared with the untreated GDM group.	Metformin	188-197	interleukin 6	Mus musculus	29-47
30864715-10	2019	Furthermore, pretreatment with PNU-282987 resulted in reductions in TNF-alpha and IL-6 release in a dose- and time-dependent manner and decreased the phosphorylation levels of p38, JNK and ERK under LPS conditions in peritoneal macrophages.	N-neopentyl-N-nitrosourea	31-34	interleukin 6	Mus musculus	82-86
30794846-9	2019	For inflammatory response, PG treatment inhibited inflammatory cytokines releasing, such as TNF-alpha, IFN-gamma, IL-1beta, IL-6, IL-12, IL-17, and IL-23.	propagermanium	27-29	interleukin 6	Mus musculus	124-128
31119329-8	2019	RESULTS: The free fatty acid form of 1,2,3-tri [Z-10-hexadecenoyl] glycerol, 10(Z)-hexadecenoic acid, decreased lipopolysaccharide-stimulated secretion of the proinflammatory cytokine IL-6 ex vivo.	Fatty Acids, Nonesterified	13-28	interleukin 6	Mus musculus	184-188
30738807-7	2019	Moreover, matrine significantly inhibited CCl4-induced neuroinflammation in mice by reducing pro-inflammatory cytokines such as interleukins (IL-1beta, IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels in the hippocampus (HC) and prefrontal cortex (PFC).	matrine	10-17	interleukin 6	Mus musculus	152-156
30864736-5	2019	In the present study, western blot analysis, polymerase chain reaction, immunohistochemistry, ELISA, mouse model experiments and functional experiments were performed to confirm that the interaction between TAMs and colorectal cancer (CRC) cells induced epithelial-mesenchymal transition (EMT)-associated features in CRC cells by activating mitogen-activated protein kinase (MAPK) pathways in TAMs and upregulating the expression of interleukin (IL)-6 and IL-8.	tams	207-211	interleukin 6	Mus musculus	433-451
30878874-18	2019	RESULTS: In an in vitro study, osthole inhibited the production of NO, PGE2, TNF-alpha, and IL-6 in LPS-induced RAW 264.7 cells.	osthol	31-38	interleukin 6	Mus musculus	92-96
31119329-8	2019	RESULTS: The free fatty acid form of 1,2,3-tri [Z-10-hexadecenoyl] glycerol, 10(Z)-hexadecenoic acid, decreased lipopolysaccharide-stimulated secretion of the proinflammatory cytokine IL-6 ex vivo.	1,2,3-tri [z-10-hexadecenoyl] glycerol	37-75	interleukin 6	Mus musculus	184-188
31119329-11	2019	The effects of 10(Z)-hexadecenoic acid on lipopolysaccharide-stimulated secretion of IL-6 were prevented by PPARalpha antagonists and absent in PPARalpha-deficient mice.	10(z)-hexadecenoic acid	15-38	interleukin 6	Mus musculus	85-89
31019233-6	2019	Valsartan or LCZ696 treatment remarkably inhibited the expression of pro-inflammatory genes, including interleukin-6, matrix metalloproteinase-8 and monocyte chemotactic protein-1, in comparison with the control group.	Valsartan	0-9	interleukin 6	Mus musculus	103-116
30848529-4	2019	This effect of BR was more prominent in contact co-culture of adipocytes and macrophages with a 90% and 34% reduction in IL-6 and MCP-1 levels, respectively.	brassinin	15-17	interleukin 6	Mus musculus	121-125
30848529-7	2019	However, knockdown of Nrf2 or HO-1 in RAW264.7 cells restored this BR-mediated inhibition of IL-6 and MCP-1 production.	brassinin	67-69	interleukin 6	Mus musculus	93-97
31327904-1	2019	Background: Streptozotocin (STZ)-induced free radical oxidant activity resulted in muscle wasting due to protein carbonyl (PC), glucose transporter-4 (Glut-4), and interleukin-6 (IL-6) protein alteration.	Streptozocin	12-26	interleukin 6	Mus musculus	179-183
31327904-1	2019	Background: Streptozotocin (STZ)-induced free radical oxidant activity resulted in muscle wasting due to protein carbonyl (PC), glucose transporter-4 (Glut-4), and interleukin-6 (IL-6) protein alteration.	Streptozocin	28-31	interleukin 6	Mus musculus	179-183
31068805-14	2019	We also found the mRNA levels of TNF-alpha, IL-1beta, IL-6 and NF-kappaBp65 were down-regulate after 7 days from the LMZ treatment compared to CFA group.	3-chloro-4-fluoroaniline	143-146	interleukin 6	Mus musculus	54-58
31019233-6	2019	Valsartan or LCZ696 treatment remarkably inhibited the expression of pro-inflammatory genes, including interleukin-6, matrix metalloproteinase-8 and monocyte chemotactic protein-1, in comparison with the control group.	sacubitril and valsartan sodium hydrate drug combination	13-19	interleukin 6	Mus musculus	103-116
30236171-0	2019	PRMT1-Dependent Macrophage IL-6 Production Is Required for Alcohol-Induced HCC Progression.	Alcohols	59-66	interleukin 6	Mus musculus	27-31
31010159-6	2019	The lignan-derived PMMs, equol and enterolactone, exhibited protective effects against nitric oxide production, as well as against pro-inflammatory cytokines (IL-6 and TNF-alpha) in BV-2 microglia.	Lignans	4-10	interleukin 6	Mus musculus	159-163
31010159-6	2019	The lignan-derived PMMs, equol and enterolactone, exhibited protective effects against nitric oxide production, as well as against pro-inflammatory cytokines (IL-6 and TNF-alpha) in BV-2 microglia.	2,3-bis(3'-hydroxybenzyl)butyrolactone	35-48	interleukin 6	Mus musculus	159-163
30236171-8	2019	We found that blocking IL-6 signaling in alcohol-fed mice reduced the number of tumors and liver proliferation in wild-type mice but not in knockout mice suggesting that reduced IL-6 in PRMT1 knockout mice contributes to the protection from alcohol.	Alcohols	41-48	interleukin 6	Mus musculus	23-27
30236171-8	2019	We found that blocking IL-6 signaling in alcohol-fed mice reduced the number of tumors and liver proliferation in wild-type mice but not in knockout mice suggesting that reduced IL-6 in PRMT1 knockout mice contributes to the protection from alcohol.	Alcohols	41-48	interleukin 6	Mus musculus	178-182
30236171-8	2019	We found that blocking IL-6 signaling in alcohol-fed mice reduced the number of tumors and liver proliferation in wild-type mice but not in knockout mice suggesting that reduced IL-6 in PRMT1 knockout mice contributes to the protection from alcohol.	Alcohols	241-248	interleukin 6	Mus musculus	23-27
30236171-12	2019	Taken together, these data suggest that the PRMT1-IL-6-STAT3 axis is an important mechanism of alcohol-associated tumor progression.	Alcohols	95-102	interleukin 6	Mus musculus	50-54
31057355-6	2019	Poly(I:C) increased the circulating levels of cytokines (TNF-alpha, MCP-1, IL-6, IL-10, IFN-alpha, IFN-gamma), an effect amplified by IF.	Poly I-C	0-8	interleukin 6	Mus musculus	75-79
30944150-9	2019	Consistently, LY3009120 decreased DSS-induced colonic inflammation, as indicated by decreased infiltration of macrophages and neutrophils, and decreased colonic TNF-alpha, IL-6, and IL-1beta level in DSS treated mice.	LY3009120	14-23	interleukin 6	Mus musculus	172-176
31178949-6	2019	The results revealed that MC elicited hepatotoxicity and neurotoxicity which was evident due to the significant elevation of serum AST, ALT, gammaGT, ALP, LDH, IL-1beta, IL-6, and TNF-alpha levels.	Methylcholanthrene	26-28	interleukin 6	Mus musculus	170-174
30902828-6	2019	Knockdown of ANXA2 or blocking membrane ANXA2 mitigated bleomycin-induced activation of nuclear factor (NF)-kappaB pathway and production of pro-inflammatory cytokine IL-6 in lung epithelial cells.	Bleomycin	56-65	interleukin 6	Mus musculus	167-171
30986204-10	2019	We also found that AL decreased CUMS-induced increases in the levels of IL-1ss, IL-6, and TNF-alpha in the hippocampi of mice.	avicularin	19-21	interleukin 6	Mus musculus	80-84
30986204-10	2019	We also found that AL decreased CUMS-induced increases in the levels of IL-1ss, IL-6, and TNF-alpha in the hippocampi of mice.	cums	32-36	interleukin 6	Mus musculus	80-84
31024851-6	2019	Furthermore, the combination of MPT0G413 and BTZ enhanced polyubiquitinated protein accumulation and synergistically reduced MM viability, increased caspase-3, caspase-8, caspase-9 levels, and cleaved poly (ADP) ribosome polymerase and also inhibited adherence of MM cells to bone marrow stromal cells (BMSC) and reduced VEGF and IL-6 levels and cell growth in a co-culture system.	Bortezomib	45-48	interleukin 6	Mus musculus	330-334
30947238-6	2019	In contrast, GTS-21 dose-dependently suppresses LPS-induced IL6 and TNF secretion in primary mouse macrophages endogenously expressing alpha7 nAChRs.	3-(2,4-dimethoxybenzylidene)anabaseine	13-19	interleukin 6	Mus musculus	60-63
30947238-9	2019	Further, GTS-21 significantly inhibited LPS-induced IL6 and TNF secretion in macrophages isolated from knockout mice lacking alpha7 nAChRs.	3-(2,4-dimethoxybenzylidene)anabaseine	9-15	interleukin 6	Mus musculus	52-55
30944389-9	2019	Furthermore, oral administration of GlcN reduced peritoneal neutrophils influx and lavage fluids concentrations of IL-1beta, IL-6 MCP-1 and TNF-alpha in uric acid crystal-injected mice.	Glucosamine	36-40	interleukin 6	Mus musculus	125-129
30724800-6	2019	Celecoxib significantly reversed the CUMS-induced decrease and increase in the levels of serotonin (5-HT) and its metabolite (5-hydroxyindole acetic acid) in the prefrontal cortex, and attenuated the CUMS-induced increase in the levels of inflammatory markers such as interleukin-6 and tumor necrosis factor-alpha, and apoptosis marker caspase-3 in the prefrontal cortex.	Celecoxib	0-9	interleukin 6	Mus musculus	268-313
30302948-6	2019	IL-6 transcript stability was determined by actinomycin D chase, and 3"-uridylation of microRNAs was determined by deep sequencing.	Dactinomycin	44-57	interleukin 6	Mus musculus	0-4
30724800-6	2019	Celecoxib significantly reversed the CUMS-induced decrease and increase in the levels of serotonin (5-HT) and its metabolite (5-hydroxyindole acetic acid) in the prefrontal cortex, and attenuated the CUMS-induced increase in the levels of inflammatory markers such as interleukin-6 and tumor necrosis factor-alpha, and apoptosis marker caspase-3 in the prefrontal cortex.	cums	37-41	interleukin 6	Mus musculus	268-313
30970514-5	2019	RESULTS: Levels of nitric oxide, IL-2, IL-6, IL-17 A, TNF, and IFN-gamma were increased by PCP while levels of IL-4 and IL-10 were unaffected.	pcp	91-94	interleukin 6	Mus musculus	39-43
30818140-9	2019	Furthermore, shikonin markedly attenuated the APAP-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) and suppressed the expression of genes related to inflammation.	shikonin	13-21	interleukin 6	Mus musculus	114-127
30818140-9	2019	Furthermore, shikonin markedly attenuated the APAP-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) and suppressed the expression of genes related to inflammation.	shikonin	13-21	interleukin 6	Mus musculus	129-133
30818140-9	2019	Furthermore, shikonin markedly attenuated the APAP-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) and suppressed the expression of genes related to inflammation.	Acetaminophen	46-50	interleukin 6	Mus musculus	114-127
30818140-9	2019	Furthermore, shikonin markedly attenuated the APAP-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) and suppressed the expression of genes related to inflammation.	Acetaminophen	46-50	interleukin 6	Mus musculus	129-133
30721698-4	2019	Furthermore, PGG also inhibited TNF-alpha-induced expression of inflammatory cytokines including IL-6 and MCP-1 in the matured 3T3-L1 adipocytes.	pgg	13-16	interleukin 6	Mus musculus	97-101
30906467-5	2019	Following the treatment, it was determined that, in CLP-model mice, acetic acid could alleviate the inflammatory response by decreasing the expression of cytokines including interleukin-6 and tumor necrosis factor-alpha.	Acetic Acid	68-79	interleukin 6	Mus musculus	174-219
31057649-7	2019	WS-5 significantly inhibited the lipopolysaccharide-induced production of nitric oxide and two proinflammatory cytokines, TNF-alpha and IL-6.	N-(6-aminohexyl)-1-naphthalenesulfonamide	0-4	interleukin 6	Mus musculus	136-140
30794918-3	2019	A bioassay in vitro showed that all lignans possessed anti-inflammatory effects by inhibiting the production of TNF-alpha, NO and/or IL-6 in LPS-stimulated RAW264.7 cells.	Lignans	36-43	interleukin 6	Mus musculus	133-137
30794918-4	2019	Ecdysanol F (17) showed the most strongly effect against NO and IL-6 levels.	ecdysanol f	0-11	interleukin 6	Mus musculus	64-68
30826410-5	2019	Additionally, ginsenoside Rk3 significantly reduced the expression of inflammatory cytokines, such as NF-kappaB, TNF-alpha, IL-6, and IL-1beta in the mice.	Ginsenosides	14-25	interleukin 6	Mus musculus	124-128
30914331-7	2019	Interestingly, PolyP-induced NF-kappaB activation and the productions of TNF-alpha and IL-6 were inhibited by collismycins C in HUVECs.	Polyphosphates	15-20	interleukin 6	Mus musculus	87-91
31084401-6	2019	Neutrophil infiltration and IL-1beta & IL-6 & MCP-1 secretion was also alleviated in lavage fluids from DBA/1 mice with peritonitis due to Madecassoside treatment.	madecassoside	139-152	interleukin 6	Mus musculus	39-43
30506106-4	2019	BCI treatment inhibited LPS-triggered inflammatory cytokine production, including IL-1beta and IL-6, but not TNF-alpha, and also affected macrophage polarization to an M1 phenotype.	(E)-2-Benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one	0-3	interleukin 6	Mus musculus	95-99
30317531-12	2019	IL-6 level in BALF and TNF-alpha and IL-6 mRNA expression in the tissue of the lung, liver, and kidney were significantly reduced by hADSC treatment.	hadsc	133-138	interleukin 6	Mus musculus	0-4
30317531-12	2019	IL-6 level in BALF and TNF-alpha and IL-6 mRNA expression in the tissue of the lung, liver, and kidney were significantly reduced by hADSC treatment.	hadsc	133-138	interleukin 6	Mus musculus	37-41
30682720-11	2019	The release of TNF-alpha, IL-6 and other inflammatory factors was reduced by DATS.	diallyl trisulfide	77-81	interleukin 6	Mus musculus	26-30
30343389-10	2019	TQ inhibited plasma cTnT levels; improved ATP; significantly inhibited p62, NLRP3, caspase-1, IL-1beta, IL-18, IL-6, TNF-alpha, and MCP-1expressions; and increased beclin 1 and IL-10 level.	thymoquinone	0-2	interleukin 6	Mus musculus	111-115
30743203-5	2019	It was found that genistein can significantly improve IMQ-induced pathological scores of cutaneous skin lesions in mice, reduce epidermal thickness, and inhibit the expression of inflammatory factors,including interleukin (IL)-1beta, IL-6, tumour necrosis factor-alpha (TNF-alpha), chemokine ligand 2 (CCL2), IL-17 and IL-23.	Genistein	18-27	interleukin 6	Mus musculus	234-238
30820607-13	2019	Administration of DZNeP suppressed the production of TNF-alpha, MCP-1, IL-6, and IL-18 in IR-treated kidneys.	3-deazaneplanocin	18-23	interleukin 6	Mus musculus	71-75
30590152-6	2019	The secretion and gene expression of NO/iNOS, IL-6 and TNF-alpha in APS-induced macrophage cell were significantly enhanced.	aps	68-71	interleukin 6	Mus musculus	46-50
30590152-9	2019	Therefore, we demonstrated that APS could improve the immune functions of RAW 264.7 macrophages cells by promoting the cell viability and increasing secretion and gene expressions of NO/iNOS, IL-6 and TNF-alpha through the MAPK and NF-kappaB signaling pathways.	aps	32-35	interleukin 6	Mus musculus	192-196
30720064-4	2019	Nitric oxide and pro-inflammatory cytokines, including tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 were decreased by treatment with 6FU, without cell cytotoxicity in LPS-stimulated RAW 264.7 cells, which was measured by a WST-1 assay.	Nitric Oxide	0-12	interleukin 6	Mus musculus	111-115
30816431-3	2019	Magnolol prevented ovariectomy-induced bone loss and osteoclastogenesis in vivo, and decreased the serum levels of C-terminal telopeptide of type 1 collagen, interleukin-6, tumor necrosis factor (TNF)-alpha and tartrate-resistant acid phosphatase 5B.	magnolol	0-8	interleukin 6	Mus musculus	158-171
30370692-1	2019	Hydrogen sulfide (H2 S) has a significant effect on the regulation of interleukin-6 (IL-6) and signal transducer and activator of transcription 3 (STAT3) activities, while IL-6 directly regulates hepcidin expression via STAT3.	Hydrogen Sulfide	0-16	interleukin 6	Mus musculus	70-83
30370692-1	2019	Hydrogen sulfide (H2 S) has a significant effect on the regulation of interleukin-6 (IL-6) and signal transducer and activator of transcription 3 (STAT3) activities, while IL-6 directly regulates hepcidin expression via STAT3.	Hydrogen Sulfide	0-16	interleukin 6	Mus musculus	85-89
30370692-1	2019	Hydrogen sulfide (H2 S) has a significant effect on the regulation of interleukin-6 (IL-6) and signal transducer and activator of transcription 3 (STAT3) activities, while IL-6 directly regulates hepcidin expression via STAT3.	Hydrogen	18-20	interleukin 6	Mus musculus	70-83
30370692-1	2019	Hydrogen sulfide (H2 S) has a significant effect on the regulation of interleukin-6 (IL-6) and signal transducer and activator of transcription 3 (STAT3) activities, while IL-6 directly regulates hepcidin expression via STAT3.	Hydrogen	18-20	interleukin 6	Mus musculus	85-89
30370692-2	2019	We therefore hypothesized that H 2 S has a role in body iron homeostasis by regulating the expression of iron transport proteins via the IL-6/STAT3/Hepcidin pathway.	Iron	56-60	interleukin 6	Mus musculus	137-141
30370692-2	2019	We therefore hypothesized that H 2 S has a role in body iron homeostasis by regulating the expression of iron transport proteins via the IL-6/STAT3/Hepcidin pathway.	Iron	105-109	interleukin 6	Mus musculus	137-141
31179071-9	2019	Results: Compared to the LPS group, GL significantly decreased protein content, inflammatory cell counts, tumor necrosis factor-alpha (TNF-alpha), interleukin-1alpha (IL-1alpha), IL-6, MPO activity, and expressions of COX-2, iNOS, and NF-kappaB in the LPS + GL group.	Glycyrrhizic Acid	36-38	interleukin 6	Mus musculus	179-183
30610438-6	2019	In addition, roflumilast increased the cAMP, phosphorylated cAMP response-element binding protein (p-CREB) and brain-derived neurotrophic factor (BDNF) levels, and reduced the nuclear translocation of nuclear factor-kappa B (NF-kappaB) p65, and proinflammatory cytokine (IL-6, TNF-a and IL-1beta) levels in the hippocampus of APP/PS1 transgenic mice.	Roflumilast	13-24	interleukin 6	Mus musculus	271-275
30739218-9	2019	RESULTS: Ropivacaine pre-treatment significantly reduced AR scores (median 3 [minimum-maximum 2-4] for control vs. 2 [1-2] for ropivacaine, p < 0.001) and plasma levels of tumor necrosis factor-alpha (p = 0.01) compared to control, whereas plasma concentrations of interleukin - 6 (p = 0.008) and - 10 (p < 0.001) were increased by ropivacaine.	Ropivacaine	9-20	interleukin 6	Mus musculus	265-280
30816470-5	2019	In addition, the results indicated that BMSC transplantation may inhibit the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha interleukin (IL)-1beta, IL-6 and IL-10 in the lung tissues of PQ-poisoned mice, and ultimately attenuate the pulmonary fibrosis.	BMSC	40-44	interleukin 6	Mus musculus	181-185
30931933-6	2019	K-80003, a tRXRalpha modulator derived from nonsteroidal anti-inflammatory drug (NSAID) sulindac, suppresses the growth of tRXRalpha-mediated colorectal tumor by inhibiting the NF-kappaB-IL-6-STAT3 signaling cascade.	K-80003	0-7	interleukin 6	Mus musculus	187-191
30794925-4	2019	Our data showed that DHT significantly decreased the release of inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-1beta in lipopolysaccharide (LPS)-stimulated RAW264.7 cells, THP-1 cells, and bone marrow-derived macrophages (BMDMs), and altered the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS).	Dihydrotestosterone	21-24	interleukin 6	Mus musculus	128-141
30794925-4	2019	Our data showed that DHT significantly decreased the release of inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-1beta in lipopolysaccharide (LPS)-stimulated RAW264.7 cells, THP-1 cells, and bone marrow-derived macrophages (BMDMs), and altered the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS).	Dihydrotestosterone	21-24	interleukin 6	Mus musculus	143-147
30802715-11	2019	RESULTS: Ha-EtOAc inhibited the LPS-induced production of NO and decreased the release of TNF-alpha, IL-6 and IL-1beta in RAW264.7 cells in a dose-dependent manner.	histidinoalanine	9-11	interleukin 6	Mus musculus	101-105
30632500-9	2019	Expression of Iba1, tumor necrosis factor-alpha, interleukin-1beta and interleukin-6 was significantly lower in the acacetin group compared with the middle cerebral artery occlusion group.	acacetin	116-124	interleukin 6	Mus musculus	71-84
30802715-11	2019	RESULTS: Ha-EtOAc inhibited the LPS-induced production of NO and decreased the release of TNF-alpha, IL-6 and IL-1beta in RAW264.7 cells in a dose-dependent manner.	ethyl acetate	12-17	interleukin 6	Mus musculus	101-105
30734970-7	2019	MPP+ -induced upregulation of IL-6, IL-1beta, and TNF-alpha was inhibited by farrerol treatment.	mangion-purified polysaccharide (Candida albicans)	0-4	interleukin 6	Mus musculus	30-34
30734970-7	2019	MPP+ -induced upregulation of IL-6, IL-1beta, and TNF-alpha was inhibited by farrerol treatment.	farrerol	77-85	interleukin 6	Mus musculus	30-34
30701601-3	2019	Pretreatment with tectorigenin significantly reduced the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), histological injury, apoptosis, and the mortality of FHF mice, by suppressing the production of inflammatory cytokines such as TNF-alpha and IL-6.	tectorigenin	18-30	interleukin 6	Mus musculus	283-287
30934008-6	2019	Furthermore, mice immunized with rOmpA showed significantly reduced bacterial burden in the lung and reduced levels of pro-inflammatory cytokines (TNF-alpha and IL-6) in bronchoalveolar lavage fluid (BALF) 24 hours after intranasal S. maltophilia infection, indicating that immunization with rOmpA may have protective effects against S. maltophilia challenge in mice.	rompa	33-38	interleukin 6	Mus musculus	161-165
31167688-8	2019	Conclusion AAEO-CP can play the anti-inflammatory effects by increasing the expression of IL-10 protein and decreasing the expression of IL-6 protein, and inhibiting TLR4 protein in LPS-induced RAW264.7 cells.	aaeo-cp	11-18	interleukin 6	Mus musculus	137-141
29664837-8	2019	Serum IL-6 levels were higher and IL-2 levels were lower in alcohol-fed septic mice.	Alcohols	60-67	interleukin 6	Mus musculus	6-10
30776389-9	2019	3PO also suppressed the LPS-induced secretion of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and lactate in the serum, in addition to lactate in the myocardium.	3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	0-3	interleukin 6	Mus musculus	102-106
31049358-2	2019	Early production of TNF-alpha, IL-1beta, and IL-6 in the liver after DEN treatment correlated with tumor development in AIRmax mice.	Diethylnitrosamine	69-72	interleukin 6	Mus musculus	45-49
30925687-5	2019	Furthermore, garcinol suppressed nuclear factor-kappaB (NF-kappaB) and pro-inflammatory cytokines such as tumor necrosis factor-alpha and IL-6, whereas it preserved the nuclear expression of nuclear factor erythroid-derived 2-like factor 2 (Nrf2) and levels of Nrf2-dependent antioxidants including heme oxygense-1, catalase, superoxide dismutase 1, and NAD(P)H:quinone oxidoreductase 1.	garcinol	13-21	interleukin 6	Mus musculus	138-142
31049028-0	2019	Elevation of IL-6 and IL-33 Levels in Serum Associated with Lung Fibrosis and Skeletal Muscle Wasting in a Bleomycin-Induced Lung Injury Mouse Model.	Bleomycin	107-116	interleukin 6	Mus musculus	13-17
30934890-4	2019	The levels of cytokines such as interleukin-6 and tumor necrosis factor-alpha were reduced under catalpalactone exposure in LPS-induced RAW264.7 cells.	Catalpalactone	97-111	interleukin 6	Mus musculus	32-77
31049028-5	2019	Here, we found that BLM-induced lung fibrosis with thickened interstitial lung tissue, including fibronectin and collagen, was correlated with the increased serum concentrations of IL-6 and IL-33 and accompanied by reduced lung function, including FRC (functional residual capacity), C chord (lung compliance), IC (inspiratory capacity), VC (vital capacity), TLC (total lung capacity), and FVC (forced vital capacity) (p &lt; 0.05).	Bleomycin	20-23	interleukin 6	Mus musculus	181-185
31049133-7	2019	Simultaneously, sulforaphane-enriched broccoli sprouts inhibited the LPS-induced activation of the NF-kappaB signaling pathway and the secretions of inflammatory proteins (iNOS, COX-2, TNF-alpha, IL-6, IL-1beta, PGE2, etc.	sulforaphane	16-28	interleukin 6	Mus musculus	196-200
30777331-8	2019	VSMCs from Tg-S1PR1 mice showed greater expression of interleukin-6 (IL-6) compared with nTg mouse-derived VSMCs, and administration of IL-6-neutralizing antibody into Tg-S1PR1 mice suppressed neointimal hyperplasia.	vsmcs	0-5	interleukin 6	Mus musculus	54-67
30777331-8	2019	VSMCs from Tg-S1PR1 mice showed greater expression of interleukin-6 (IL-6) compared with nTg mouse-derived VSMCs, and administration of IL-6-neutralizing antibody into Tg-S1PR1 mice suppressed neointimal hyperplasia.	vsmcs	0-5	interleukin 6	Mus musculus	69-73
30909508-5	2019	Of note, the zoledronate treatment-induced upregulation of the RANKL expression was mediated by autocrine interleukin-6 (IL-6) and subsequent activation of the signal transducer and activator of transcription 3 (STAT3) pathway.	Zoledronic Acid	13-24	interleukin 6	Mus musculus	106-119
30597230-5	2019	Y-27632 or fasudil (Rho-kinase inhibitors) or NSC23766 (an inhibitor of Rac-guanine nucleotide exchange factor interaction) significantly enhanced TGF-beta-stimulated IL-6 release from these cells.	Y 27632	0-7	interleukin 6	Mus musculus	167-171
30597230-5	2019	Y-27632 or fasudil (Rho-kinase inhibitors) or NSC23766 (an inhibitor of Rac-guanine nucleotide exchange factor interaction) significantly enhanced TGF-beta-stimulated IL-6 release from these cells.	fasudil	11-18	interleukin 6	Mus musculus	167-171
30597230-7	2019	We found that SIS3 (a specific inhibitor of TGF-beta-dependent Smad3 phosphorylation) or LY364947 (a TGF-beta type I receptor kinase inhibitor) significantly reduced the IL-6 release.	6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride	14-18	interleukin 6	Mus musculus	170-174
30597230-7	2019	We found that SIS3 (a specific inhibitor of TGF-beta-dependent Smad3 phosphorylation) or LY364947 (a TGF-beta type I receptor kinase inhibitor) significantly reduced the IL-6 release.	Ly-364947	89-97	interleukin 6	Mus musculus	170-174
30909508-0	2019	Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis.	Zoledronic Acid	0-11	interleukin 6	Mus musculus	70-74
30909508-5	2019	Of note, the zoledronate treatment-induced upregulation of the RANKL expression was mediated by autocrine interleukin-6 (IL-6) and subsequent activation of the signal transducer and activator of transcription 3 (STAT3) pathway.	Zoledronic Acid	13-24	interleukin 6	Mus musculus	121-125
30909508-7	2019	Also, the osteoclastogenesis-supporting activity was significantly decreased in zoledronate-treated MLO-Y4 cells in the presence of IL-6 neutralizing IgG compared to that of the control IgG.	Zoledronic Acid	80-91	interleukin 6	Mus musculus	132-136
30862773-9	2019	We also found that montelukast treatment reduced pro-inflammatory factors (TNF-alpha, IL-6, and IL-1ss) production, enhanced superoxide dismutase (SOD) activity, and reduced malondialdehyde (MDA) content in the lung tissues of BPD mice.	montelukast	19-30	interleukin 6	Mus musculus	86-90
30866427-7	2019	Treatment of LPS-challenged RAW 264.7 cells with 10 microM of CADs counteracted the LPS effects and led to significantly lower mRNA and protein levels of inducible nitric oxide synthase, tumor necrosis factor alpha, and interleukin 6, by directly decreasing the translocation of the nuclear factor kappaB/Rel-like containing protein 65 into the nucleus.	cads	62-66	interleukin 6	Mus musculus	220-233
30871261-6	2019	Mouse experiments showed that KTP strongly increased the serum levels of total superoxide dismutase (T-SOD) and catalase (CAT) and reduced those of malondialdehyde, interleukin 6 (IL-6), IL-1beta, and tumor necrosis factor alpha (TNF-alpha) in mice with UVB-induced skin damage.	KTP compound	30-33	interleukin 6	Mus musculus	165-178
30871261-6	2019	Mouse experiments showed that KTP strongly increased the serum levels of total superoxide dismutase (T-SOD) and catalase (CAT) and reduced those of malondialdehyde, interleukin 6 (IL-6), IL-1beta, and tumor necrosis factor alpha (TNF-alpha) in mice with UVB-induced skin damage.	KTP compound	30-33	interleukin 6	Mus musculus	180-184
30930772-8	2019	1,8-Cineole and rosiglitazone reduced the protein and mRNA levels of VCAM-1, E-selectin, IL-6, and IL-8 in LPS-induced HUVECs, which could be reversed by the action of GW9662 (inhibitor of PPAR-gamma).	Eucalyptol	0-11	interleukin 6	Mus musculus	89-93
30930772-8	2019	1,8-Cineole and rosiglitazone reduced the protein and mRNA levels of VCAM-1, E-selectin, IL-6, and IL-8 in LPS-induced HUVECs, which could be reversed by the action of GW9662 (inhibitor of PPAR-gamma).	Rosiglitazone	16-29	interleukin 6	Mus musculus	89-93
30930772-8	2019	1,8-Cineole and rosiglitazone reduced the protein and mRNA levels of VCAM-1, E-selectin, IL-6, and IL-8 in LPS-induced HUVECs, which could be reversed by the action of GW9662 (inhibitor of PPAR-gamma).	2-chloro-5-nitrobenzanilide	168-174	interleukin 6	Mus musculus	89-93
30586550-6	2019	Interestingly, daily intraperitoneal administration of galantamine, an inhibitor of acetylcholinesterase, reversed cognitive dysfunction in surgery mice and attenuated accumulation of microglia and protein levels of IL-1beta, IL-6 and TNF-alpha in the hippocampus.	Galantamine	55-66	interleukin 6	Mus musculus	226-230
30886835-9	2019	We found that rifaximin significantly reduced the severity of AS and resulted in down-regulation of inflammatory factors, such as TNF-alpha, IL-6, IL-17A, and IL-23.	Rifaximin	14-23	interleukin 6	Mus musculus	141-145
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	interleukin 6	Mus musculus	63-67
30658114-11	2019	We further observed that DAPTA downregulated IL-6, IL-9, IL-17A, and RORgammaT, and increased IL-10 and Foxp3 protein and mRNA expression.	DAPTA	25-30	interleukin 6	Mus musculus	45-49
30836660-10	2019	Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).	rhodioloside	14-17	interleukin 6	Mus musculus	203-207
30553055-7	2019	The possibility that IL-6/STAT3-mediated hepatic autophagosome induction and hepatocytic oxygen consumption are involved in the anti-NAFLD effects of caffeine cannot be excluded, based on the findings presented here.	Caffeine	150-158	interleukin 6	Mus musculus	21-25
30097802-7	2019	We found that vanillin significantly decreased the production of nitric oxide and pro-inflammatory cytokines, including interleukin (IL)-1beta, tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6).	vanillin	14-22	interleukin 6	Mus musculus	189-202
30097802-7	2019	We found that vanillin significantly decreased the production of nitric oxide and pro-inflammatory cytokines, including interleukin (IL)-1beta, tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6).	vanillin	14-22	interleukin 6	Mus musculus	204-208
30097802-8	2019	Vanillin also reduced the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), as well as the mRNA expression levels of IL-1beta, TNF-alpha, and IL-6.	vanillin	0-8	interleukin 6	Mus musculus	179-183
30553055-0	2019	Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease.	Caffeine	0-8	interleukin 6	Mus musculus	27-31
30553055-2	2019	We report here that caffeine markedly improved high fat diet-induced NAFLD in mice resulting in a 10-fold increase in circulating IL-6 levels, leading to STAT3 activation in the liver.	Caffeine	20-28	interleukin 6	Mus musculus	130-134
30553055-3	2019	Interestingly, the expression of IL-6 mRNA was not increased in the liver, but increased substantially in the muscles of caffeine-treated mice.	Caffeine	121-129	interleukin 6	Mus musculus	33-37
30553055-4	2019	Caffeine was found to stimulate IL-6 production in cultured myotubes but not in hepatocytes, adipocytes, or macrophages.	Caffeine	0-8	interleukin 6	Mus musculus	32-36
30553055-5	2019	The inhibition of p38/MAPK abrogated caffeine-induced IL-6 production in muscle cells.	Caffeine	37-45	interleukin 6	Mus musculus	54-58
30553055-8	2019	Our results reveal that caffeine ameliorates NAFLD via crosstalk between muscle IL-6 production and liver STAT3 activation.	Caffeine	24-32	interleukin 6	Mus musculus	80-84
30597306-5	2019	Moreover, AGD significantly inhibited LPS/GalN-induced inflammatory responses in mice with ALI by reducing not only the secretion of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 but also the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	Galactosamine	42-46	interleukin 6	Mus musculus	197-201
30572004-9	2019	In a similar manner, both Fut8-KO C6 cells and primary astrocytes treated with 2-fluoro-L-fucose, a specific inhibitor for fucosylation, showed a higher response to IL-6-stimulated phospho-STAT3 signaling, compared with WT cells.	2-fluoro-l-fucose	79-96	interleukin 6	Mus musculus	165-169
30841450-6	2019	In BV2 microglia cells, ICE markedly inhibited production of nitric oxide and proinflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 without causing cytotoxicity.	Water	24-27	interleukin 6	Mus musculus	164-177
30648776-0	2019	Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.	bazedoxifene	0-12	interleukin 6	Mus musculus	63-76
30593001-10	2019	IMQ-induced IL-6/IL-23 levels were significantly diminished by SYK inhibitor, R406 in splenocytic cultures.	Imiquimod	0-3	interleukin 6	Mus musculus	12-16
30600019-6	2019	Orally administered BBG1 and BBG2 significantly decreased the pro-inflammatory mediators of IL-6, iNOS and IL-1beta at protein and/or mRNA levels, as well as colonic mucosal damage and macrophages infiltration in DSS-induced colitis mice.	bbg1	20-24	interleukin 6	Mus musculus	92-96
30600019-6	2019	Orally administered BBG1 and BBG2 significantly decreased the pro-inflammatory mediators of IL-6, iNOS and IL-1beta at protein and/or mRNA levels, as well as colonic mucosal damage and macrophages infiltration in DSS-induced colitis mice.	bbg2	29-33	interleukin 6	Mus musculus	92-96
30648776-12	2019	In addition, pretreatment of BAZ impeded the translocation of STAT3 to nuclei induced by IL-6.	bazedoxifene	29-32	interleukin 6	Mus musculus	89-93
30648776-4	2019	It has been reported that bazedoxifene acetate (BAZ), a selective estrogen receptor modulator approved by the US Food and Drug Administration, could inhibit IL-6/GP130 protein-protein interactions.	bazedoxifene	26-46	interleukin 6	Mus musculus	157-161
30648776-4	2019	It has been reported that bazedoxifene acetate (BAZ), a selective estrogen receptor modulator approved by the US Food and Drug Administration, could inhibit IL-6/GP130 protein-protein interactions.	bazedoxifene	48-51	interleukin 6	Mus musculus	157-161
30648776-10	2019	BAZ inhibited P-STAT3 induced by IL-6, but not by leukemia inhibitory factor.	bazedoxifene	0-3	interleukin 6	Mus musculus	33-37
30558807-7	2019	Additionally, exposure to 8:2 FTOH under unstimulated and LPS-stimulated conditions downregulated the mRNA expression of pro-inflammatory genes, including Il1b, Il6, Cxcl1, and Tnfa, and secreted levels of IL-6 and TNF-alpha.	Fluorocarbons	30-34	interleukin 6	Mus musculus	161-164
30558807-7	2019	Additionally, exposure to 8:2 FTOH under unstimulated and LPS-stimulated conditions downregulated the mRNA expression of pro-inflammatory genes, including Il1b, Il6, Cxcl1, and Tnfa, and secreted levels of IL-6 and TNF-alpha.	Fluorocarbons	30-34	interleukin 6	Mus musculus	206-210
30365413-6	2019	RESULTS: After rebamipide ophthalmic solution was applied, IL-6 concentration in the supernatants of conjunctival epithelial cells treated with and without siRNA showed a significant timewise decrease from 0 to 24 hr (963+-42 to 0.07+-0.05 pg/mL and 932+-168 to 2.2+-0.05 pg/mL, respectively) (P&lt;0.001).	rebamipide	15-25	interleukin 6	Mus musculus	59-63
30445007-11	2019	After DEN injection, levels of tumor necrosis factor, interleukin 6 (IL6), and phosphorylated signal transducer and activator of transcription 3 were increased in livers from WT, but not Nox1-/- or Nox1DeltaMac, mice.	Diethylnitrosamine	6-9	interleukin 6	Mus musculus	54-67
30964190-10	2019	Moreover, dexmedetomidine administration decreased contents of CD11b+CD45int, IL-6, and IL-1beta, but elevated TGF-beta content in treatment group.	Dexmedetomidine	10-25	interleukin 6	Mus musculus	78-82
30783450-0	2019	Effects of paraquat on IL-6 and TNF-alpha in macrophages.	Paraquat	11-19	interleukin 6	Mus musculus	23-27
30783450-11	2019	PQ at a concentration of 1 mmol/l can produce toxicity to macrophages, and greatly increase the ROS fluorescence intensity, the expression levels of IL-6 and TNF-alpha.	Paraquat	0-2	interleukin 6	Mus musculus	149-153
30783450-12	2019	PQ poisoning is expected to be treated though IL-6 and TNF-alpha in the future.	Paraquat	0-2	interleukin 6	Mus musculus	46-50
30445007-11	2019	After DEN injection, levels of tumor necrosis factor, interleukin 6 (IL6), and phosphorylated signal transducer and activator of transcription 3 were increased in livers from WT, but not Nox1-/- or Nox1DeltaMac, mice.	Diethylnitrosamine	6-9	interleukin 6	Mus musculus	69-72
30179264-6	2019	We found that prevention and treatment with CVC reversed alcohol-related increases in liver mRNA and protein expression of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and CCL2.	Alcohols	57-64	interleukin 6	Mus musculus	182-186
30471397-3	2019	Oral administration of a glucan-enriched subfraction induced IL-2 and GM-CSF-producing T lymphocytes in Peyer"s patches, resulting in enhancement of IL-6 production in a hemopoietic microenvironment to boost neutrophil numbers in the peripheral blood stream.	Glucans	25-31	interleukin 6	Mus musculus	149-153
30639962-10	2019	We found that palmitate significantly enhanced IL-6, VEGF and MCP-1 expression, and secretion in MSC cells.	Palmitates	14-23	interleukin 6	Mus musculus	47-51
30654097-3	2019	SAL significantly modified the intestinal microbial diversity and downregulated the circulating levels of serum LPS, IL-6, and TNF-alpha, as well as enhanced the content of IL-10.	rhodioloside	0-3	interleukin 6	Mus musculus	117-121
30660077-9	2019	Butyrate significantly inhibited expressions of IL-1beta, IL-6 and IL-17A, but promoted the expression of IL-10.	Butyrates	0-8	interleukin 6	Mus musculus	58-62
30596540-7	2019	RESULTS: Celastrol significantly inhibited LPS-induced expression of protein and mRNA expression levels encoding the proinflammatory cytokines, IL-6, IL-8, and MCP-1, in both HRPE and ARPE-19 cells.	celastrol	9-18	interleukin 6	Mus musculus	144-148
31933889-8	2019	RESULTS: Pretreatment with lycopene significantly decreased levels of ALT, AST, and TNF-alpha and IL-6, reduced MDA content, and increased activity of SOD in serum compared with the L-C mice.	lycopene	27-35	interleukin 6	Mus musculus	98-102
30512238-4	2019	Furthermore, naringin prevents UVB-induced mitogen-activated protein kinase families and nuclear factor-kappaB (NF-kappaB)-mediated activation of inflammatory factors, that is TNF-alpha, IL-6, IL-10, and COX-2 in NIH-3T3 cells.	naringin	13-21	interleukin 6	Mus musculus	187-191
30563941-4	2019	Pretreatment of altenusin or GW4869 prior to lipopolysaccharide (LPS) stimulation for 4 or 24 hours, significantly downregulated gene expression of the pro-inflammatory mediators TNF-alpha, IL-1beta, IL-6, iNOS, and CCL2 in microglia and reduced the release of nitric oxide and TNF-alpha These nSMase inhibitors also attenuated the release of microparticles and phosphorylation of p38 MAPK and ERK1/2.	altenusin	16-25	interleukin 6	Mus musculus	200-204
30563941-4	2019	Pretreatment of altenusin or GW4869 prior to lipopolysaccharide (LPS) stimulation for 4 or 24 hours, significantly downregulated gene expression of the pro-inflammatory mediators TNF-alpha, IL-1beta, IL-6, iNOS, and CCL2 in microglia and reduced the release of nitric oxide and TNF-alpha These nSMase inhibitors also attenuated the release of microparticles and phosphorylation of p38 MAPK and ERK1/2.	GW 4869	29-35	interleukin 6	Mus musculus	200-204
30539813-8	2019	DAPT decreased the number of glial fibrillary acidic protein- and Notch1-positive cells in the right prefrontal cortex, while also reducing the number of apoptotic cells and decreasing interleukin-6 and tumor necrosis factor-alpha contents, and simultaneously downregulating Hes1 and Hes5 protein expression.	dapt	0-4	interleukin 6	Mus musculus	185-230
30641086-8	2019	We proposed that LPS-stimulated increase in endothelial adenosine deaminase activity could be a result of IL-6/JAK/STAT pathway activation, since the lack of IL-6 in mice was associated with lower vascular and plasma eADA activities.	eada	217-221	interleukin 6	Mus musculus	158-162
30732883-10	2019	Moreover, it inhibited the Cu(II)-evoked production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and IL-1beta and expression of inducible nitric oxide synthase in the hippocampus.	cu(ii)	27-33	interleukin 6	Mus musculus	131-144
30732883-10	2019	Moreover, it inhibited the Cu(II)-evoked production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and IL-1beta and expression of inducible nitric oxide synthase in the hippocampus.	cu(ii)	27-33	interleukin 6	Mus musculus	146-150
30008071-7	2019	DAC treatment resulted in significant elevations in the levels of the proinflammatory cytokines interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) and in significant decreases in the levels of the anti-inflammatory cytokines IL-4 and IL-10 in most of the sera and brain tissues examined.	Decitabine	0-3	interleukin 6	Mus musculus	96-109
30008071-7	2019	DAC treatment resulted in significant elevations in the levels of the proinflammatory cytokines interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) and in significant decreases in the levels of the anti-inflammatory cytokines IL-4 and IL-10 in most of the sera and brain tissues examined.	Decitabine	0-3	interleukin 6	Mus musculus	111-115
30823679-2	2019	Pretreatment with Rh2, R-PHQ, and S-PHQ significantly decreased immobility time in FST and TST with clear dose-dependence, and significantly downregulated levels of serum tumor necrosis factor-alpha and interleukin-6, and upregulated superoxide dismutase activity in the hippocampus of LPS-challenged mice.	rh2	18-21	interleukin 6	Mus musculus	203-216
30823679-2	2019	Pretreatment with Rh2, R-PHQ, and S-PHQ significantly decreased immobility time in FST and TST with clear dose-dependence, and significantly downregulated levels of serum tumor necrosis factor-alpha and interleukin-6, and upregulated superoxide dismutase activity in the hippocampus of LPS-challenged mice.	r-phq	23-28	interleukin 6	Mus musculus	203-216
30406957-10	2019	Endotoxemia-induced IL-6 and TNF-alpha release was also reduced by tVNS.	tvns	67-71	interleukin 6	Mus musculus	20-24
30267577-6	2019	Furthermore, tranexamic acid treatment was observed to suppress increases in the plasma levels of matrix metalloproteinase-9 and interleukin (IL)-6, and skin expression of plasmin, CC chemokine 2, macrophages, signal transducer and activator of transcription (STAT)3, cyclin D and vascular endothelial growth factor (VEGF)-A that occurred in mice subjected to long-term UVA irradiation.	Tranexamic Acid	13-28	interleukin 6	Mus musculus	129-147
30267577-7	2019	These results indicated that the nonmelanoma skin cancer induced by DMBA+UVA long-term irradiation is ameliorated by tranexamic acid through regulation of the plasmin/macrophage/IL-6/STAT3/cyclin D signal transmission pathway.	Tranexamic Acid	117-132	interleukin 6	Mus musculus	178-182
30668443-8	2019	In addition, urolithin B inhibited NO, TNF-alpha, and IL-6 production in lipoteichoic acid (LTA) or polyinosinic-polycytidylic acid (poly(I:C))-stimulated BV2 cells, suggesting that the anti-inflammatory effect of urolithin B is not confined to LPS stimulation.	urolithin B	13-24	interleukin 6	Mus musculus	54-58
30668443-8	2019	In addition, urolithin B inhibited NO, TNF-alpha, and IL-6 production in lipoteichoic acid (LTA) or polyinosinic-polycytidylic acid (poly(I:C))-stimulated BV2 cells, suggesting that the anti-inflammatory effect of urolithin B is not confined to LPS stimulation.	lipoteichoic acid	73-90	interleukin 6	Mus musculus	54-58
30668443-8	2019	In addition, urolithin B inhibited NO, TNF-alpha, and IL-6 production in lipoteichoic acid (LTA) or polyinosinic-polycytidylic acid (poly(I:C))-stimulated BV2 cells, suggesting that the anti-inflammatory effect of urolithin B is not confined to LPS stimulation.	lipoteichoic acid	92-95	interleukin 6	Mus musculus	54-58
30668445-13	2019	Eucalyptol also reduced all inflammatory (MPO, TNF-alpha, IL-1beta, IL-6, KC, and TGF-beta1) and redox marker levels (MDA) when compared to the CS group (at least p &lt; 0.05).	Eucalyptol	0-10	interleukin 6	Mus musculus	68-72
30848106-5	2019	Females exposed to ozone in the follicular phase had significantly higher expression of inflammatory genes, including Ccl2, Cxcl2, Ccl20, and Il6, compared to females exposed in the luteal phase (P < 0.05), and displayed differential activation of regulatory pathways.	Ozone	19-24	interleukin 6	Mus musculus	142-145
30632216-3	2019	In vitro studies revealed that Mc-eWE stimulated the cells by inducing nitric oxide (NO) production and the expression of inflammatory cytokines, such as interleukin (IL)-1beta, IL-6, IL-12, tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma).	mc-ewe	31-37	interleukin 6	Mus musculus	178-182
30380571-13	2019	Both the 20S-epimers [2, 3: , and 20(S)-protopanaxadiol] and 20R-epimers [9, 10: , and 20(R)-protopanaxadiol] inhibited the release of inflammatory cytokine interleukin-6, but mainly the 20S-epimers [2, 3: , and 20(S)-protopanaxadiol] increased the release of anti-inflammatory mediator interleukin-10.	protopanaxadiol	36-55	interleukin 6	Mus musculus	157-170
30380571-13	2019	Both the 20S-epimers [2, 3: , and 20(S)-protopanaxadiol] and 20R-epimers [9, 10: , and 20(R)-protopanaxadiol] inhibited the release of inflammatory cytokine interleukin-6, but mainly the 20S-epimers [2, 3: , and 20(S)-protopanaxadiol] increased the release of anti-inflammatory mediator interleukin-10.	(r)-protopanaxadiol	89-108	interleukin 6	Mus musculus	157-170
30837039-2	2019	Dextran sodium sulfate(DSS) was used to induce acute colitis mouse model in the experimental group.The mRNA expressions of tumor necrosis factor-alpha(TNF-alpha)and interleukin-6(IL-6)in colon were measured by RT-PCR.	dextran sodium sulfate	0-22	interleukin 6	Mus musculus	165-178
30685357-9	2019	Further experiments isolated the KCs from the liver in each group and showed that TCE sensitization resulted activation of MAPK signal pathway which in turn caused release of the pro-inflammatory cytokines, IL-1beta, IL-6, TNF-alpha, in KCs; the antagonist HOE140 again decreased these changes in KCs.	Trichloroethylene	82-85	interleukin 6	Mus musculus	217-221
30837039-2	2019	Dextran sodium sulfate(DSS) was used to induce acute colitis mouse model in the experimental group.The mRNA expressions of tumor necrosis factor-alpha(TNF-alpha)and interleukin-6(IL-6)in colon were measured by RT-PCR.	dextran sodium sulfate	0-22	interleukin 6	Mus musculus	179-183
30931327-9	2019	The expression of TNF-alpha, IL-1beta, IL-6, MMP-1, MMP-3, MMP-13, ADAMTS4, and ADAMTS5 was significantly reduced both in vitro and in vivo by the presence of SA.	sinapinic acid	159-161	interleukin 6	Mus musculus	39-43
30661789-6	2019	Importantly, injection of TLR4 deficient mice with either TNF-alpha and IL-6 partly restored the glucose-induced secretion of GLP-1.	Glucose	97-104	interleukin 6	Mus musculus	72-76
30783144-6	2019	Surface plasmon resonance detection showed that KCF18 bound to both tumor necrosis factor-alpha (TNF-alpha) and interleukin-6, which is consistent with MM/PBSA binding free energy calculations.	kcf18	48-53	interleukin 6	Mus musculus	112-125
30833971-9	2019	Inflammatory cytokines, such as TNF-alpha, IL-6 and IL-1beta, were significantly inhibited in honokiol-treated septic mice compared with the CLP group.	honokiol	94-102	interleukin 6	Mus musculus	43-47
30642628-7	2019	In vitro re-stimulation of splenocytes from external antigen-immunized mice with the same antigen induced IL-2 and IL-6 production, which was significantly suppressed by AMTB.	adenosylmethionine tosylate bis(sulfate)	170-174	interleukin 6	Mus musculus	115-119
30783194-9	2019	Th-17 associated pro-inflammatory gene [interleukin 1 beta (IL-1beta), IL-6, IL-17A, and tumor necrosis factor alpha (TNF-alpha)] expressions were down regulated by GTE and EGCG treatments, which showed no detectable morphological defects in liver and kidney in non-induced and EAU mice.	epigallocatechin gallate	165-168	interleukin 6	Mus musculus	71-75
30783194-9	2019	Th-17 associated pro-inflammatory gene [interleukin 1 beta (IL-1beta), IL-6, IL-17A, and tumor necrosis factor alpha (TNF-alpha)] expressions were down regulated by GTE and EGCG treatments, which showed no detectable morphological defects in liver and kidney in non-induced and EAU mice.	epigallocatechin gallate	173-177	interleukin 6	Mus musculus	71-75
30472298-3	2019	We aimed to assess the Carvacrol effects on clinical manifestations and production of pro-inflammatory (IFN-gamma, IL-6 and IL-17) and anti-inflammatory (TGF-beta, IL-4, and IL-10) cytokines in experimental autoimmune encephalomyelitis (EAE) as MS animal model.	carvacrol	23-32	interleukin 6	Mus musculus	115-119
30472298-8	2019	The amounts of IFN-gamma and IL-6 production by splenocytes of 5 and 10 mg/kg Carvacrol-administered mice were lower than control group (P &lt; 0.001, and P &lt; 0.01 for IFN-gamma respectively; P   0.05 for IL-6).	carvacrol	78-87	interleukin 6	Mus musculus	29-33
30472298-8	2019	The amounts of IFN-gamma and IL-6 production by splenocytes of 5 and 10 mg/kg Carvacrol-administered mice were lower than control group (P &lt; 0.001, and P &lt; 0.01 for IFN-gamma respectively; P   0.05 for IL-6).	carvacrol	78-87	interleukin 6	Mus musculus	208-212
30699879-8	2019	Moreover, simvastatin markedly prevented and ameliorated LPS and CMS-induced neuroinflammation, as shown by the suppressed activation of microglia in hippocampus and decreased hippocampal pro-inflammatory cytokines expressions including IL-1beta, TNF-alpha, IL-6, which might be mediated via the inhibition of NF-kappaB pathway, as shown by the decreased nuclear NF-kappaB p65 expression.	Simvastatin	10-21	interleukin 6	Mus musculus	258-262
30785481-10	2019	VOB also suppressed the pro-inflammatory TNF-alpha and IL-6 cytokines, and NO and O2- production in lipopolysaccharide-stimulated macrophage cells.	vob	0-3	interleukin 6	Mus musculus	55-59
30890898-4	2019	The results demonstrate that melatonin inhibited the mRNA expression of TNF-alpha, IL-1beta, IL-6, CXCL1, MCP-1, and RANTES and the production of these cytokines and chemokines and IgG in LPS-stimulated mouse mammary tissue in vitro.	Melatonin	29-38	interleukin 6	Mus musculus	93-97
30863056-12	2019	Furthermore, ferucarbotran treatment increased the number of CD3+, Iba-1+, IL-6+, Iba-1+TNF-alpha+ and CD3+IFN-gamma+ cells in the spinal cord of EAE mice.	ferumoxides	13-26	interleukin 6	Mus musculus	75-79
30765717-6	2019	Consistent with this, stimulation of endothelial cells (EC) with thrombin caused an increase in BiP/GRP78 levels and inhibition of ER stress with 4-phenylbutyric acid (4-PBA) prevented this response as well as increase in VCAM-1, ICAM-1, IL-6, and IL-8 levels.	4-phenylbutyric acid	146-166	interleukin 6	Mus musculus	238-242
30746687-5	2019	Moreover, myricetin pretreatment induced a significant decrease in the activity of myeloperoxidase (MPO) and the production of TNF-alpha, IL-6, and IL-1beta triggered by LPS.	myricetin	10-19	interleukin 6	Mus musculus	138-142
30792721-0	2019	1,25-Dihydroxyvitamin D3 Ameliorates Collagen-Induced Arthritis via Suppression of Th17 Cells Through miR-124 Mediated Inhibition of IL-6 Signaling.	Calcitriol	0-24	interleukin 6	Mus musculus	133-137
30240278-6	2019	Treatment of silica-challenged mice with anti-IL-9-neutralizing antibody inhibited lung fibrosis, as assessed by lung hydroxyproline level, and suppressed the levels of major mediators, including IL-1beta, IL-6, IL-12, CCL2, CXCL1, and TNF-alpha in BALFs.	Silicon Dioxide	13-19	interleukin 6	Mus musculus	206-210
30736391-5	2019	BV2 murine microglia cells treated with both Abeta25-35 peptide and extract showed a lower pro-inflammatory (IL-6, IL-1beta, TNF-alpha) and a higher anti-inflammatory (IL-4, IL-10, IL-13) cytokine production compared to cells treated with Abeta only.	abeta25-35 peptide	45-63	interleukin 6	Mus musculus	109-113
30406698-7	2019	Zn2+ prevents elevation of IL-6 and IL-8.	Zinc	0-4	interleukin 6	Mus musculus	27-31
30255260-10	2019	Consistently, the expression of taurine transporter (TauT) and adipocyte-specific genes such as adiponectin, leptin, and IL-6 was regulated in a similar pattern by taurine supplementation.	Taurine	32-39	interleukin 6	Mus musculus	121-125
30445165-8	2019	We found that the EPA diet significantly improved maternal insulin sensitivity and decreased plasma levels of inflammatory factors IL-6 and TNFalpha concentration.	Eicosapentaenoic Acid	18-21	interleukin 6	Mus musculus	131-135
30447270-6	2019	RESULTS: Older mice in KO/EtOH group displayed higher IL6 expressions compared to KO/Cont, WT/EtOH and WT/Cont groups of the same age, whereas HGF did not differ.	Ethanol	26-30	interleukin 6	Mus musculus	54-57
30447270-8	2019	Males in KO/EtOH group exhibited higher IL6 expression than females.	Ethanol	12-16	interleukin 6	Mus musculus	40-43
30530291-0	2019	Oxyresveratrol ameliorates ethanol-induced gastric ulcer via downregulation of IL-6, TNF-alpha, NF-kB, and COX-2 levels, and upregulation of TFF-2 levels.	puag-haad	0-14	interleukin 6	Mus musculus	79-83
30459279-11	2019	VIB9600 inhibits IC-induced type I interferons from plasmacytoid dendritic cells (involved in SLE), antineutrophil cytoplasmic antibody (ANCA)-induced production of reactive oxygen species by neutrophils (involved in ANCA-associated vasculitis) and IC-induced tumour necrosis factor alpha and interleukin-6 production (involved in rheumatoid arthritis).	vib9600	0-7	interleukin 6	Mus musculus	293-306
30553196-3	2019	Using a Con A-induced hepatitis model in mice, we found that administration of glycyrrhizin ameliorates Con A-induced liver injury, which manifests as reduction in the production of inflammatory cytokines IFN-gamma, IL-6 and IL-17, as well as serum alanine aminotransferase (ALT).	Glycyrrhizic Acid	79-91	interleukin 6	Mus musculus	216-220
30530291-10	2019	RT-PCR analysis showed significant suppression in the mRNA expression levels of IL-6 (P &lt; 0.001), TNF-alpha (P &lt; 0.01), NF-kB (P &lt; 0.001), and COX-2 (P &lt; 0.05) in oxyresveratrol treated groups, while COX-1 expression levels were found unaltered.	puag-haad	175-189	interleukin 6	Mus musculus	80-84
30530291-13	2019	In conclusion, oxyresveratrol possess significant anti-ulcer property which might be attributed to attenuated expression levels of IL-6, TNF-alpha, NF-kB, and COX-2 and elevated expression levels of TFF-2.	puag-haad	15-29	interleukin 6	Mus musculus	131-135
30554117-5	2019	The production of TNF-alpha, IL-1beta and IL-6 was also significantly inhibited by EVO.	evodiamine	83-86	interleukin 6	Mus musculus	42-46
30446103-5	2019	The CIF2 polysaccharide, as the most immunostimulating polysaccharide, remarkably induced the release of nitric oxide and inflammatory cytokines including TNF-alpha, IL-1beta, IL-6 and IL-10 from RAW264.7 murine macrophage cells through NF-kappaB and PAMKs transduction signaling pathways via cell surface TLR4.	cif2 polysaccharide	4-23	interleukin 6	Mus musculus	176-180
30253123-7	2019	DOP also inhibited the increased hippocampal microglial activation in SAMP8 mice with downregulation of interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), while interleukin-10 (IL-10), neprilysin (NEP) and insulin-degrading enzyme (IDE) were upregulated.	Diethylhexyl Phthalate	0-3	interleukin 6	Mus musculus	178-191
30253123-7	2019	DOP also inhibited the increased hippocampal microglial activation in SAMP8 mice with downregulation of interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), while interleukin-10 (IL-10), neprilysin (NEP) and insulin-degrading enzyme (IDE) were upregulated.	Diethylhexyl Phthalate	0-3	interleukin 6	Mus musculus	193-197
30446103-5	2019	The CIF2 polysaccharide, as the most immunostimulating polysaccharide, remarkably induced the release of nitric oxide and inflammatory cytokines including TNF-alpha, IL-1beta, IL-6 and IL-10 from RAW264.7 murine macrophage cells through NF-kappaB and PAMKs transduction signaling pathways via cell surface TLR4.	Polysaccharides	9-23	interleukin 6	Mus musculus	176-180
30536547-3	2019	Here, we demonstrate that Fas engagement on macrophages, using an agonistic Fas antibody CH11, augments LPS-induced NF-kappaB responses, causing increased production of TNFalpha, IL-8, IL-6 and IL-12.	ammonium ferrous sulfate	26-29	interleukin 6	Mus musculus	185-189
30536526-7	2019	In addition, exposure to 8:2 FTOH reduced the concentration of IL-1beta in serum, and mRNA levels of IL-1beta, IL-6, and TNF-alpha in both the thymus and spleen.	ftoh	29-33	interleukin 6	Mus musculus	111-115
30312114-4	2019	We show that simvastatin reduced the incidence of PTB in a validated intrauterine LPS-induced PTB mouse model, decreased uterine proinflammatory mRNA concentrations (IL-6, Cxcl1, and Ccl2), and reduced serum IL-6 concentration.	Simvastatin	13-24	interleukin 6	Mus musculus	166-170
30312114-4	2019	We show that simvastatin reduced the incidence of PTB in a validated intrauterine LPS-induced PTB mouse model, decreased uterine proinflammatory mRNA concentrations (IL-6, Cxcl1, and Ccl2), and reduced serum IL-6 concentration.	Simvastatin	13-24	interleukin 6	Mus musculus	208-212
30444022-3	2019	In mice with high-fat diet-induced obesity and streptozotocin-induced hyperglycemia, microglia accumulated on the RPE layer, as in those after intravitreal injection of interleukin (IL)-6, which is elevated in ocular fluids of patients with diabetic retinopathy.	Streptozocin	47-61	interleukin 6	Mus musculus	169-187
30444022-8	2019	As STAT3 inhibition reversed the effects of IL-6-treated microglial cells on the RPE monolayer in vitro, it reduced the recruitment of microglial cells and the production of TNF-alpha in RPE tissues in streptozotocin-treated mice.	Streptozocin	202-216	interleukin 6	Mus musculus	44-48
30704333-8	2019	In addition, systemic sclareol treatments reduced local pro-inflammatory cytokine concentrations, including IL-6, IL-1b, TNF-a, IL-4, IFN-g, and IL-17A, on AD-like lesions.	sclareol	22-30	interleukin 6	Mus musculus	108-112
30540970-8	2019	As expected, 1,25(OH)2D3 transformed lipopolysaccharide-induced M1 macrophages to the M2 subset, downregulated tumor necrosis factor-alpha and interleukin (IL)-6 expression and interferon regulatory factor 5 (IRF5) phosphorylation, and upregulated IL-10, arginase-1, VDR, and IRF4 expression.	Calcitriol	13-24	interleukin 6	Mus musculus	143-161
30882084-6	2019	In the inflammatory study, IL-6 (interleukin 6) was decreased and IL-4 and IL-10 increased significantly in DSS group with yogurt fermented at general temperature (DYG) and that with yogurt fermented at low temperature (DYL) compared to that in DSS-induced colitic mice (DC), especially DYL had higher concentration of cytokines IL-4, and IL-10 than DYG.	dss	108-111	interleukin 6	Mus musculus	27-31
30067872-6	2019	Although treatment with ivabradine did not affect blood glucose levels, it attenuated tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 messenger RNA (mRNA) expression, inhibited c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK) activation, reduced histological abnormalities, myocardial apoptosis and collagen deposition, and improved cardiac function in the diabetic mice.	Ivabradine	24-34	interleukin 6	Mus musculus	138-151
30298517-10	2019	Pro-inflammatory cytokines including MCP-1, TNF-alpha, IL-1 and IL-6 were detected through RT-PCR and ELISA in experiment and GME can significantly inhibit the expression of TNF-alpha, IL-1 and IL-6 but have no effect on MCP-1.	gme	126-129	interleukin 6	Mus musculus	64-68
30547416-9	2019	In cuprizone-fed animals, IL6 expression in oligodendrocytes was found in close vicinity of activated microglia cells.	Cuprizone	3-12	interleukin 6	Mus musculus	26-29
30298517-10	2019	Pro-inflammatory cytokines including MCP-1, TNF-alpha, IL-1 and IL-6 were detected through RT-PCR and ELISA in experiment and GME can significantly inhibit the expression of TNF-alpha, IL-1 and IL-6 but have no effect on MCP-1.	gme	126-129	interleukin 6	Mus musculus	194-198
30527488-15	2019	Cytokine expression after GYY4137 administration was altered by the ablation of eNOS in both NEC and I/R injury groups, with significant differences noted in Interleukin 6 and vascular endothelial growth factor.	GYY 4137	26-33	interleukin 6	Mus musculus	158-171
29948949-2	2019	Previously, we showed that arsenic (0.38 mg/kg body weight) exposure induces microglial activation and consequently IL-6/TNF-alpha secretion.	Arsenic	27-34	interleukin 6	Mus musculus	116-120
29948949-6	2019	Higher CD68 staining, increased level of IL-6/TNF-alpha, as well as higher level of IFNgamma, were observed in in vivo arsenic-exposed groups.	Arsenic	119-126	interleukin 6	Mus musculus	41-45
29948949-10	2019	Finally, intracerebral injection of anti-IFNgamma neutralizing antibody in arsenic-exposed brain reduced microglia activation (IL-6 and TNF-alpha and CD68 expression) and subsequently rescued CD200 level.	Arsenic	75-82	interleukin 6	Mus musculus	127-131
29948949-11	2019	Taken together, the study showed that arsenic-mediated compromised blood-brain barrier is a major driving force to induce microglial IL-6 and TNF-alpha production through serum IFNgamma leading to CD200 downregulation.	Arsenic	38-45	interleukin 6	Mus musculus	133-137
29117731-7	2019	Amaroswerin thus inhibits the expression of iNOS, TNF-alpha, IL-6 and IL-1beta by downregulating transcription in LPS-induced RAW264.7 macrophage cells, indicating that amaroswerin may be a valuable therapeutic agent for the treatment of inflammatory diseases.	Amaroswerin	0-11	interleukin 6	Mus musculus	61-65
30782259-5	2019	The result of W/D ratio showed that paeonol could also prevent pulmonary edema, as well as inhibit significantly the levels of TNF-alpha, IL-1beta and IL-6 in serum and proteins expression and mRNA.	paeonol	36-43	interleukin 6	Mus musculus	151-155
29117731-6	2019	Amaroswerin also dose-dependently suppressed production of TNF-alpha, IL-6 and IL-1beta and reduced expression of mRNA for these LPS-stimulated pro-inflammatory mediators.	Amaroswerin	0-11	interleukin 6	Mus musculus	70-74
30661600-8	2019	Cells incubated with ALA had a statistically significantly lower production of VEGF, RANTES, ICAM-1, MCP-1 and IL-6 compared to cells incubated without additional ALA.	alpha-Linolenic Acid	21-24	interleukin 6	Mus musculus	111-115
30353214-8	2019	Urantide and palosuran, UII receptor antagonists, decreased proinflammatory cytokines such as TNF-alpha, IL-1beta, IL-6, NF-kappaB, and also decreased oxidative stress parameters in lung tissue, which are markers of damage.	urotensin II (4-11), Pen(5)-Trp(7)-Orn(8)-	0-8	interleukin 6	Mus musculus	115-119
30353214-8	2019	Urantide and palosuran, UII receptor antagonists, decreased proinflammatory cytokines such as TNF-alpha, IL-1beta, IL-6, NF-kappaB, and also decreased oxidative stress parameters in lung tissue, which are markers of damage.	1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea	13-22	interleukin 6	Mus musculus	115-119
30661600-10	2019	Cells incubated with low LA:ALA ratios had lower production of VEGF, RANTES, MCP-1 and IL-6 when compared with a LA:ALA ratio of 19:1.	alpha-Linolenic Acid	28-31	interleukin 6	Mus musculus	87-91
30661600-11	2019	These findings suggest that a low LA:ALA ratio exerts anti-inflammatory effects by lowering the production VEGF, RANTES, ICAM-1, MCP-1 and IL-6 in TNF-alpha stimulated endothelial cells compared to a high ratio.	alpha-Linolenic Acid	37-40	interleukin 6	Mus musculus	139-143
30989921-5	2019	The swelling degree of ankle joint significantly relief; expression of IL-1beta, IL-6 and TNF-alpha in joint synovium significantly decrease; mRNA and protein expression of NLRP3, ASC and caspase-1 were significantly decrease in PCE treatment group compared with model group.	pce	229-232	interleukin 6	Mus musculus	81-85
30696085-7	2019	In addition, inflammatory mediators, such as myeloperoxidase, TNF-alpha, and IL-6 levels decreased in the lysate of colon tissues treated with KM1608.	km1608	143-149	interleukin 6	Mus musculus	77-81
30691004-3	2019	Cannabisin F suppressed the production and the mRNA levels of pro-inflammatory mediators such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) in a concentration-dependent manner in LPS-stimulated BV2 microglia cell.	cannabisin F	0-12	interleukin 6	Mus musculus	97-110
30683148-0	2019	High dose gabapentin does not alter tumor growth in mice but reduces arginase activity and increases superoxide dismutase, IL-6 and MCP-1 levels in Ehrlich ascites.	Gabapentin	10-20	interleukin 6	Mus musculus	123-127
30691004-3	2019	Cannabisin F suppressed the production and the mRNA levels of pro-inflammatory mediators such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) in a concentration-dependent manner in LPS-stimulated BV2 microglia cell.	cannabisin F	0-12	interleukin 6	Mus musculus	112-116
30658416-10	2019	Besides, BA treatment considerably inhibited inflammatory cytokinesl (IL-1beta, IL-6, TNF-alpha) levels in serum, hippocampus homogenate and cell culture medium.	baicalin	9-11	interleukin 6	Mus musculus	80-84
30682077-6	2019	Systemic inflammation, as evidenced by a chronic elevation in 17 of 18 pro- and anti-inflammatory cytokines and chemokines (P < 0.05 O-SED vs. 2-month-old Y-CON), was potently mitigated by lifelong AET (P < 0.05 O-AET vs. O-SED), including master regulators of the cytokine cascade and cancer progression (IL-1beta, TNF-alpha, and IL-6).	2-(2-Aminoethyl)isothiourea dihydrobromide	198-201	interleukin 6	Mus musculus	331-335
30674715-6	2019	GL-2045 also suppressed disease activity in a therapeutic model of murine collagen-induced arthritis (CIA), which was associated with reduced circulating levels of IL-6.	gl-2045	0-7	interleukin 6	Mus musculus	164-168
30713502-5	2018	In the HFCLP group, dietary fiber supplementation decreased the serum concentrations of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6) and high-mobility group protein 1 (HMG-1) but raised the concentration of interleukin 10 (IL-10), compared with the levels in CLP mice.	Dietary Fiber	28-33	interleukin 6	Mus musculus	164-177
30713502-5	2018	In the HFCLP group, dietary fiber supplementation decreased the serum concentrations of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6) and high-mobility group protein 1 (HMG-1) but raised the concentration of interleukin 10 (IL-10), compared with the levels in CLP mice.	Dietary Fiber	28-33	interleukin 6	Mus musculus	179-183
30336174-5	2019	Additionally, butein treatment enhanced SIRT1 signaling thus decreasing the Ac-NF-kappaB, Ac-FOXO1 and Ac-p53 levels, thus attenuating the brain injury of mice after CLP surgery by decreasing cerebral edema, maintaining the blood-brain barrier integrity, inhibiting neuronal apoptosis, and decreasing pro-inflammatory cytokines production (IL-6, TNF-alpha and IL-1beta) and oxidative stress (downregulation of MDA, and upregulation of SOD and CAT) in both serum and cerebral cortex tissues.	butein	14-20	interleukin 6	Mus musculus	340-344
30521868-9	2019	Further, AP effectively inhibited UVA-induced activation of pro-angiogenic (iNOS and VEGF), inflammatory proteins (TNF-alpha, IL-6, and COX-2) expression and prevented the activation of NF-kappaB p65 in the mouse skin.	uva	34-37	interleukin 6	Mus musculus	126-130
30642005-5	2019	Our data also revealed upregulated CB1R, interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, c-Jun, and type 4 collagen in the glomeruli of streptozotocin (STZ)-induced diabetic mice, whereas the expression of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) was decreased.	Streptozocin	151-165	interleukin 6	Mus musculus	60-102
30635550-4	2019	Vinpocetine decreased adipogenic cell signaling, including the phosphorylation of ERK, AKT, JAK2, and STAT3, and adipokine secretion, including IL-6, IL-10, and IFN-alpha.	vinpocetine	0-11	interleukin 6	Mus musculus	144-148
30642005-5	2019	Our data also revealed upregulated CB1R, interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, c-Jun, and type 4 collagen in the glomeruli of streptozotocin (STZ)-induced diabetic mice, whereas the expression of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) was decreased.	Streptozocin	167-170	interleukin 6	Mus musculus	60-102
30626741-9	2019	In-vivo administration of viniferin reduced production of inflammatory mediators TNF-alpha, MIP-2, IL-6, IL-1beta, and HMGB1, and diminished neutrophil influx and severity of endotoxin-mediated ALI; this protective effect of vinferin was abolished in SIRT3-/- mice.	Viniferin	26-35	interleukin 6	Mus musculus	99-103
30687331-7	2018	Dasatinib treatment inhibited the production of proinflammatory cytokines including IL-1beta, TNF-alpha, and IL-6, and promoted the production of the anti-inflammatory cytokine IL-10.	Dasatinib	0-9	interleukin 6	Mus musculus	109-113
30629626-7	2019	RESULTS: Our CS-induced COPD model exhibited an increased proinflammatory immune response (increased expression of the NF-kappaB, TNF-alpha, CD4, CD8, CD20, IL-17, and IL-6 markers) with a concomitantly decreased anti-inflammatory immune response (FOXP3, IL-10, and TGF-beta markers) compared with the control mice.	Cesium	13-15	interleukin 6	Mus musculus	168-172
30634582-5	2019	However, AzP could decrease production of the inflammatory mediators interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor-necrosis factor-alpha (TNF-alpha).	azp	9-12	interleukin 6	Mus musculus	69-82
30634582-5	2019	However, AzP could decrease production of the inflammatory mediators interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor-necrosis factor-alpha (TNF-alpha).	azp	9-12	interleukin 6	Mus musculus	84-88
30634582-9	2019	In conclusion, the study demonstrated that AzP might regulate the MEK/ERK MAPK signaling pathway to attenuate MCP-1, TNF-alpha, and IL-6 production and provide opportunities for the development of new anti-inflammatory drugs targeting mucositis.	azp	43-46	interleukin 6	Mus musculus	132-136
30626153-3	2019	The results indicated that alpha-COS were more active than beta-COS in promoting the production of nitric oxide (NO) and cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6).	alpha-cos	27-36	interleukin 6	Mus musculus	184-197
30626153-3	2019	The results indicated that alpha-COS were more active than beta-COS in promoting the production of nitric oxide (NO) and cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6).	alpha-cos	27-36	interleukin 6	Mus musculus	199-203
30391747-3	2019	In addition, PPARdelta agonist GW501516 enhanced pro-inflammatory gene expressions (COX-2, IL-6, IL-8 and MCP-1) in inflamed colon.	GW 501516	31-39	interleukin 6	Mus musculus	91-95
30609815-7	2019	Moreover, ATX significantly down-regulated the increased levels of pro-inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor (TNF-alpha) (all p &lt; 0.05 or p &lt; 0.01).	astaxanthine	10-13	interleukin 6	Mus musculus	104-117
30514440-7	2019	RESULTS: Renal function in the 5-ALA/SFC treatment group as assessed by the serum creatinine and serum urea nitrogen levels was superior to that of the CsA-only treatment group, demonstrating that 5-ALA/SFC significantly attenuated CsA-induced kidney tissue inflammation, fibrosis, apoptosis, and tubular atrophy, as well as reducing the mRNA level of TNF-alpha, IL-6, TGF-beta1, and iNOS while increasing HO-1.	Aminolevulinic Acid	31-36	interleukin 6	Mus musculus	363-367
30514440-7	2019	RESULTS: Renal function in the 5-ALA/SFC treatment group as assessed by the serum creatinine and serum urea nitrogen levels was superior to that of the CsA-only treatment group, demonstrating that 5-ALA/SFC significantly attenuated CsA-induced kidney tissue inflammation, fibrosis, apoptosis, and tubular atrophy, as well as reducing the mRNA level of TNF-alpha, IL-6, TGF-beta1, and iNOS while increasing HO-1.	SFC	37-40	interleukin 6	Mus musculus	363-367
30514440-7	2019	RESULTS: Renal function in the 5-ALA/SFC treatment group as assessed by the serum creatinine and serum urea nitrogen levels was superior to that of the CsA-only treatment group, demonstrating that 5-ALA/SFC significantly attenuated CsA-induced kidney tissue inflammation, fibrosis, apoptosis, and tubular atrophy, as well as reducing the mRNA level of TNF-alpha, IL-6, TGF-beta1, and iNOS while increasing HO-1.	Aminolevulinic Acid	197-202	interleukin 6	Mus musculus	363-367
30609815-7	2019	Moreover, ATX significantly down-regulated the increased levels of pro-inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor (TNF-alpha) (all p &lt; 0.05 or p &lt; 0.01).	astaxanthine	10-13	interleukin 6	Mus musculus	119-123
30630344-8	2019	Furthermore, ginsenoside Rh1 suppressed the production of tumor necrosis factor (TNF)- alpha , interleukin (IL)-6, activation of nuclear factor (NF)- kappa B and extracellular signal-regulated kinase (ERK) 1/2 by HMGB1.	ginsenoside Rh1	13-28	interleukin 6	Mus musculus	95-113
31091972-7	2019	Stimulation of murine peritoneal macrophages by GBPP-I showed the greatest enhancement of interleukin (IL)-6 and IL-12 and tumor necrosis factor (TNF)- alpha production.	gbpp-i	48-54	interleukin 6	Mus musculus	90-108
30966773-5	2019	Aloin also suppressed the production of tumor necrosis factor (TNF)- alpha and interleukin (IL)-6, as well as the activation of nuclear factor (NF)- kappa B and extracellular signal-regulated kinase 1/2 (ERK 1/2) by HMGB1.	alloin	0-5	interleukin 6	Mus musculus	79-97
30383412-7	2019	In both control and free fatty acid-treated hepatocytes, IL-6 (20 ng/ml, 75 min) slightly attenuated insulin-stimulated (10 nM; ~15 min) AKT phosphorylation.	Fatty Acids	25-35	interleukin 6	Mus musculus	57-61
30383412-9	2019	NEW & NOTEWORTHY In this study, we used lean and obese mice and found that a single injection of IL-6 improved glucose tolerance, decreased hepatic gluconeogenic gene expression, and increased hepatic phosphorylation of AKT.	Glucose	111-118	interleukin 6	Mus musculus	97-101
30383412-11	2019	Our results show that the beneficial effects of IL-6 on glucose and insulin homeostasis, in vivo, are maintained in obesity.	Glucose	56-63	interleukin 6	Mus musculus	48-52
30460722-5	2019	The results showed that beta-carotene significantly suppressed (p &lt; 0.05) LPS-induced release of IL-1beta, IL-6, and TNF-alpha and their mRNA expression.	beta Carotene	24-37	interleukin 6	Mus musculus	110-114
30470572-5	2019	Recently, the well-known role of IL-6 in causing white adipose tissue lipolysis has been linked to indirectly activating the gluconeogenic enzyme pyruvate carboxylase 1 in the liver, thereby increasing hepatic glucose production.	Glucose	210-217	interleukin 6	Mus musculus	33-37
31645121-6	2019	First, RSBE and GSBE significantly inhibited the production of pro-inflammatory mediators, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), prostaglandinE2 (PGE2), and nitric oxide (NO) in LPS-induced RAW264.7 cells.	rsbe	7-11	interleukin 6	Mus musculus	140-153
31645121-6	2019	First, RSBE and GSBE significantly inhibited the production of pro-inflammatory mediators, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), prostaglandinE2 (PGE2), and nitric oxide (NO) in LPS-induced RAW264.7 cells.	rsbe	7-11	interleukin 6	Mus musculus	155-159
31645121-6	2019	First, RSBE and GSBE significantly inhibited the production of pro-inflammatory mediators, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), prostaglandinE2 (PGE2), and nitric oxide (NO) in LPS-induced RAW264.7 cells.	gsbe	16-20	interleukin 6	Mus musculus	140-153
31645121-6	2019	First, RSBE and GSBE significantly inhibited the production of pro-inflammatory mediators, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), prostaglandinE2 (PGE2), and nitric oxide (NO) in LPS-induced RAW264.7 cells.	gsbe	16-20	interleukin 6	Mus musculus	155-159
31645121-10	2019	In dextran sulfated sodium (DSS)-induced colitis mice model, RSBE restored body weight, colon length, and the levels of pro-inflammatory cytokines, such as TNF-alpha, IL-6, interleukin-1beta (IL-1beta), and interferon-gamma (IFN-gamma).	dextran sulfated sodium	3-26	interleukin 6	Mus musculus	167-171
30399591-4	2019	GA also decreased the expressions of pro-inflammatory cytokines, including TNF-alpha, IL-6 and IL-1beta.	gambogic acid	0-2	interleukin 6	Mus musculus	86-90
30396067-11	2019	Farrerol also inhibited the induction effect of Abeta on IL-6, IL-1beta, and TNF-alpha.	farrerol	0-8	interleukin 6	Mus musculus	57-61
30551352-7	2019	Increased secretion of pro-inflammatory cytokines TNF-alpha, IL-1beta and IL-6, caused by LPSs was reversed by TFE; on the contrary, the anti-inflammatory cytokine IL-10 was upregulated.	lpss	90-94	interleukin 6	Mus musculus	74-78
30551352-7	2019	Increased secretion of pro-inflammatory cytokines TNF-alpha, IL-1beta and IL-6, caused by LPSs was reversed by TFE; on the contrary, the anti-inflammatory cytokine IL-10 was upregulated.	Trifluoroethanol	111-114	interleukin 6	Mus musculus	74-78
30551384-5	2019	The treatment with Bacoside-A downregulated the inflammatory cytokines (IL-6, IL-17a, and TNFalpha) and inflammatory chemokine CCL-5 in EAE mice.	bacoside	19-27	interleukin 6	Mus musculus	72-76
30551456-10	2019	The result showed that CS and LPS stimulation caused inflammation response, a significant increase in the release of cytokines, including TNF-alpha, IL-6, and IFN-gamma, the elevated release of glutamate and protein levels of NR-1 and xCT, increased Ca2+ influx, and the activation of the ERK1/2 pathway in vitro and in vivo.	Cesium	23-25	interleukin 6	Mus musculus	149-153
31366877-5	2019	The arthritis/DSS-treated mice did not demonstrate changes in hind foot volumes or in the concentration of matrix metalloproteinase-3 (MMP-3) in the plasma; however, plasma levels of interleukin-6 (IL-6) and tumor necrosis factor (TNF)-alpha were increased.	dss	14-17	interleukin 6	Mus musculus	183-196
31155592-5	2019	Blood levels of interleukin-6, tumor necrosis factor-alpha, hydrogen peroxide (H2O2), and iron were elevated in DSS-treated mice but lowered by high-dose vitamin C administration.	dss	112-115	interleukin 6	Mus musculus	16-58
31155592-5	2019	Blood levels of interleukin-6, tumor necrosis factor-alpha, hydrogen peroxide (H2O2), and iron were elevated in DSS-treated mice but lowered by high-dose vitamin C administration.	Ascorbic Acid	154-163	interleukin 6	Mus musculus	16-58
31763116-9	2019	The serum interleukin (IL)-6 level and the IL-4/interferon (IFN)-gamma values were significantly higher in the vancomycin-treated mice, but the serum IL-17A level was lower than that in the control group.	Vancomycin	111-121	interleukin 6	Mus musculus	10-28
31241712-8	2019	In addition, EGCG significantly decreased the expression of pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 in the lung, serum, and bronchoalveolar lavage fluid, and alleviated the expression of TLR-4, MyD88, TRIF, and p-p65 in the lung tissue.	epigallocatechin gallate	13-17	interleukin 6	Mus musculus	150-154
31241715-4	2019	Moreover, BA reduced the levels of inflammatory cytokines, such as interleukin 1beta, interleukin 6, and tumor necrosis factor alpha, in serum and in the hippocampus.	baicalin	10-12	interleukin 6	Mus musculus	86-99
31535830-9	2019	Atenolol and losartan reversed the upregulation of TNF-alpha expression, whereas enalapril restored IL-6 levels to Sham levels; both atenolol and enalapril normalized IFN-gamma levels.	Enalapril	81-90	interleukin 6	Mus musculus	100-104
31787724-8	2019	However, the increased IL-6 levels in mice fed a high-fat diet were significantly suppressed by THG-A treatment.	Thioguanine	96-99	interleukin 6	Mus musculus	23-27
26542309-14	2019	The expressions of IL-6, TNF-alpha and IL-1beta increased, and TGF-beta levels decreased in the cirrhotic livers after GSG treatment (IL-6: F=5.457, P=0.004; TNF-alpha: F=6.023, P=0.002; IL-1beta: F=6.658, P=0.001; and TGF-beta1: F=11.239, P=0.000).	SCHEMBL948318	119-122	interleukin 6	Mus musculus	19-23
26542309-14	2019	The expressions of IL-6, TNF-alpha and IL-1beta increased, and TGF-beta levels decreased in the cirrhotic livers after GSG treatment (IL-6: F=5.457, P=0.004; TNF-alpha: F=6.023, P=0.002; IL-1beta: F=6.658, P=0.001; and TGF-beta1: F=11.239, P=0.000).	SCHEMBL948318	119-122	interleukin 6	Mus musculus	134-138
30384060-10	2019	NaF at higher concentration (5 ppm), significantly inhibited myotube formation, increased skeletal muscle catabolism, generated reactive oxygen species (ROS) and inflammatory cytokines (TNF-alpha and IL-6) in C2C12 cells.	Sodium Fluoride	0-3	interleukin 6	Mus musculus	200-204
30539784-9	2019	Moreover, rifampicin significantly lowered the levels of interleukin-6, interleukin-1beta, caspase-12 activity, heme oxygenase-1(HO-1), nitric oxide (NO), and malondialdehyde (MDA) in mice treated with cuprizone.	Rifampin	10-20	interleukin 6	Mus musculus	57-70
31096217-14	2019	IL-6 and phospho-STAT3 (pSTAT3) expression, the downstream pathway of myostatin, were decreased by EPS and this was also reversed by flutamide.	Flutamide	133-142	interleukin 6	Mus musculus	0-4
29792338-10	2019	Our study suggested that ethanol treatment induced more expression of HSP27 and HSP70, faster hepatocyte proliferation, higher level of glycogen, and interleukin-6 signaling pathway activation, but less hepatocyte apoptosis and CYP2E1 expression in male mice than female mice, which could be helpful to understand the molecular mechanism for the influence of sex difference on alcoholic liver injury.	Ethanol	25-32	interleukin 6	Mus musculus	150-163
30481683-7	2019	The results showed that JS1287 small molecule alleviated epidermal thickness, epidermis congestion, edema and inflammatory cell infiltration, decreased release of inflammatory cytokines of IL-6, IL-12 and IL-17A, and further regulated the mRNA expression of ATF1 and protein expression of ERK1/2 in IMQ-induced skin lesions.	js1287	24-30	interleukin 6	Mus musculus	189-193
30342124-7	2019	The EPSs exerted the antiproliferative effectivity; treatment of EPS induced proinflammatory cytokines TNF-alpha, IL-6, IL-12, IL-1beta and IL-17, also engaged in anti-cancer immunity.	epss	4-8	interleukin 6	Mus musculus	114-118
30342124-7	2019	The EPSs exerted the antiproliferative effectivity; treatment of EPS induced proinflammatory cytokines TNF-alpha, IL-6, IL-12, IL-1beta and IL-17, also engaged in anti-cancer immunity.	exophthalmos producing substance	4-7	interleukin 6	Mus musculus	114-118
30791741-8	2019	Tripterine protected ATDC5 cells against LPS-induced chondrocyte loss and the release of IL-6 and TNF-alpha.	celastrol	0-10	interleukin 6	Mus musculus	89-93
30705514-9	2019	Astaxanthin significantly suppressed the mucosal mRNA expression of IL-1beta, IL-6, TNF-alpha, IL-36alpha and IL-36gamma.	astaxanthine	0-11	interleukin 6	Mus musculus	78-82
31337260-7	2019	Berberine inhibited the expression of pro-inflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), and interleukin-1beta (IL-1beta), along with inflammatory proteins including iNOS and COX-2.	Berberine	0-9	interleukin 6	Mus musculus	110-123
31337260-7	2019	Berberine inhibited the expression of pro-inflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), and interleukin-1beta (IL-1beta), along with inflammatory proteins including iNOS and COX-2.	Berberine	0-9	interleukin 6	Mus musculus	125-129
30806288-8	2019	Furthermore, oral administration of DA decreased the level of myeloperoxidase (MPO) and inhibited the expression of p65-NF-kappaB, p-IkappaB-alpha, and p-IKK as well as several inflammatory factors, including TNF-alpha, IL-1beta, and IL-6, in the colonic tissues.	daidzein	36-38	interleukin 6	Mus musculus	234-238
32464007-9	2019	The present study showed that cytokine production, the induction of cell survival molecule NF-kappaB p65, and subsequent prevention of IkappaBalpha phosphorylation are controlled by fucoxanthin, and that interleukins (IL-5, IL-6, and IL-12) support STAT-3 binding to key elements that control IL-17A expression.	fucoxanthin	182-193	interleukin 6	Mus musculus	224-228
30456449-5	2019	In-depth analyses of the treated operated tissues revealed that VPA selectively inhibited the CD45highF4/80low macrophage subset as well as the production of specific proinflammatory cytokines/ chemokines, including CXCL1, IL-5, IL-6, and IL-10 which were reduced by >= 2.0-fold.	Valproic Acid	64-67	interleukin 6	Mus musculus	229-233
30690444-2	2019	Results suggested that ropivacaine causes significant inhibition of generation of nitric oxide (NO), prostaglandin E2, tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-1beta, as well as expression of their synthesizing enzymes, inducible NO synthase, and cyclooxygenase-2.	Ropivacaine	23-34	interleukin 6	Mus musculus	154-172
30359861-8	2019	Moreover, VCO intake induced a lower inflammatory response due to decreased number of leukocytes and TNF-alpha and IL-6 concentrations in adipose tissue, as well as reduced counts of total leukocytes, mononuclear and polymorphonuclear circulating cells.	vco	10-13	interleukin 6	Mus musculus	115-119
30528467-5	2019	RESULTS: Schaftoside inhibited mRNA and protein expressions of proinflammatory cytokines (IL-1beta, TNF-alpha, and IL-6) after 4 h in OGD-stimulated BV2 microglia cells, similar to the effect of TAK242, an inhibitor of TLR4.	schaftoside	9-20	interleukin 6	Mus musculus	115-119
30539754-8	2019	Furthermore, STV-Na pretreatment significantly downregulated expressions of nitric oxide synthase, interleukin-1beta, tumor necrosis factor-alpha, interleukin-6, nuclear factor kappa B (NF-kappaB), and mitogen-activated protein kinase (MAPK) signalings in N2a cells under conditions of CoCl2-induced hypoxia.	stv-na	13-19	interleukin 6	Mus musculus	147-160
30468833-9	2019	Moreover, CT-133 not only reversed the uncontrolled secretion of IL-1beta, IL-6, TNF-alpha and KC from CSE- and PGD2-stimulated RAW 264.7 macrophages but also augmented IL-10 production in both in vivo and in vitro studies.	ct-133	10-16	interleukin 6	Mus musculus	75-79
30517939-7	2019	Further analysis showed that the TUDCA pretreatment (200, 400 mg/kg) not only inhibited the production of proinflammatory cytokines induced by LPS stimulation, such as interleukin-6 and tumor necrosis factor-alpha, but attenuated LPS-triggered oxido-nitrosative stress in the hippocampus and prefrontal cortex.	ursodoxicoltaurine	33-38	interleukin 6	Mus musculus	168-213
30599892-9	2019	The mRNA expression levels of M1 macrophage-related inflammatory factors IL-6, iNOS and IL-1beta were markedly elevated in the spleens of asthmatic mice, but significantly decreased after the 8-week treatment with curcumin.	Curcumin	214-222	interleukin 6	Mus musculus	73-77
30599908-12	2019	Additionally, the carrageenan-induced increases in TNF-alpha, IL-6, IL-1beta, PGE2 and NO productions, and COX-2 and iNOS mRNA expressions were effectually and concentration-dependently suppressed by OBB and BBR pretreatment.	Carrageenan	18-29	interleukin 6	Mus musculus	62-66
30599909-7	2019	RESULTS: Our results showed that Curcumin markedly reduced the mRNA expression and secretion of IL-1beta, IL-6, TNFalpha and MCP-1 in LPS stimulated RAW264.7 cell and the supernatant.	Curcumin	33-41	interleukin 6	Mus musculus	106-110
31039949-11	2019	In the PCOS+l-carnitine group, serum concentrations of FSH and FRAP increased significantly, whereas there were significant decreases in serum concentrations of testosterone, LH, MDA, IL-6 and TNF-alpha, as well as in the percentage of TUNEL-positive apoptotic cells, compared with the PCOS group.	Carnitine	12-23	interleukin 6	Mus musculus	184-188
30372549-8	2019	Accordingly, lung cells from rRv1737c-immunized mice stimulated with killed BCG produced higher levels of multiple cytokines, such as IFN-gamma, IL-10 and IL-6.	bcg	76-79	interleukin 6	Mus musculus	155-159
29997055-7	2019	Furthermore, eugenol (150 mg/kg) was able to inhibit the release of inflammatory cytokines (TNF-alpha, IL-1beta and IL-6), NADPH oxidase activity, as well as antioxidant enzymes activity (superoxide dismutase, catalase and glutathione peroxidase).	Eugenol	13-20	interleukin 6	Mus musculus	116-120
30687752-8	2018	Oridonin treatment significantly inhibited LPS-induced proinflammatory cytokines IL-1beta, IL-6, and MCP-1 production as well as cell adhesion molecules ICAM-1 and VCAM-1.	oridonin	0-8	interleukin 6	Mus musculus	91-95
30602693-3	2018	Baicalein pretreatment significantly alleviated the elevation of IL-6, IL-1beta and TNF-alpha in serum and hepatic in a dose-dependent manner.	baicalein	0-9	interleukin 6	Mus musculus	65-69
30618760-8	2018	Moreover, costunolide significantly decreased the protein expression of proinflammatory cytokines including interleukin 1beta, interleukin 6, and tumor necrosis factor.	costunolide	10-21	interleukin 6	Mus musculus	127-140
30585623-3	2018	The administration of nicotine for 12 weeks increased the area of the atherosclerotic lesion, the number of macrophages infiltrating the plaques, and the circulating levels of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-alpha, in apolipoprotein E-deficient (ApoE-/- ) mice fed a high-fat diet.	Nicotine	22-30	interleukin 6	Mus musculus	208-253
30577526-8	2018	Low PhA-concentrated DHA decreased interleukin (IL)-6 and tumor necrosis factor alpha (TNF-alpha) protein expression in ApoE-/- mice when compared to standard PhA-concentrated DHA.	Docosahexaenoic Acids	21-24	interleukin 6	Mus musculus	35-53
30567499-5	2018	ALA treatment resulted in the attenuation of iNOS and NO expression and the downregulation of proinflammatory cytokines (TNF-alpha, cyclooxygenase2, IL-1beta, IL-6).	5-amino levulinic acid	0-3	interleukin 6	Mus musculus	159-163
30619375-4	2018	Underscoring the importance of IL-6 in TFH generation, we found improved antibody responses accompanied by increased TFH cells and decreased follicular regulatory helper T (TFR) cells, a Foxp3 expressing inhibitory CD4+ T cell occupying the germinal center (GC), when a tetanus toxoid conjugated pneumococcal polysaccharide type 14 vaccine was injected in adult mice together with IL-6.	Polysaccharides	309-323	interleukin 6	Mus musculus	31-35
30563142-4	2018	The results revealed that supplementation with LCBP decreased significantly the levels of IL-2, IL-6, MCP-1, and TNF-alpha in serum, as well as endotoxin levels in both serum and liver in HFD-fed mice.	lcbp	47-51	interleukin 6	Mus musculus	96-100
30567351-8	2018	Furthermore, low sucrose increased gene expression of Shank 1, while EPA + DHA increased expression of Shank 3 and reduced protein concentrations of pro-inflammatory markers IL-5, IL-6 and KC/GRO in the cortex, but not the hippocampus.	dehydroacetic acid	75-78	interleukin 6	Mus musculus	180-184
30557308-9	2018	Intraperitoneal administration of the anti-inflammatory drug indomethacin before each episode of stress prevented this enhancement of IL-6 levels and also reversed the increase in the rewarding effects of cocaine in defeated mice.	Indomethacin	61-73	interleukin 6	Mus musculus	134-138
30399421-6	2018	The results demonstrated that artemisinin B inhibited NO secretion from LPS-induced BV2 cells and significantly reduced the expression levels of the inflammatory cytokines IL-1beta, IL-6 and TNF-alpha.	artemisinin B	30-43	interleukin 6	Mus musculus	182-186
30558188-12	2018	Moreover, puerarin-V treatment reduces the inflammatory milieu in the heart of MI mice, thereby blocking the upregulation of proinflammatory cytokines (TNF-alpha, IL-1beta and IL-6).	puerarin-v	10-20	interleukin 6	Mus musculus	176-180
30420491-9	2018	Moreover, glucose treatment promoted mRNA levels of TNF-alpha, IL-1beta, and IL-6 in mesangial cells.	Glucose	10-17	interleukin 6	Mus musculus	77-81
30523271-3	2018	In present study, we discover that Guanosine 5"-diphosphate (GDP) encapsulated in lipid vesicle (NH+) was found to inhibit NF-kB activation by limiting phosphorylation and degradation of IkBalpha, thus, attenuating IL-6 secretion from macrophage cells.	Guanosine Diphosphate	35-59	interleukin 6	Mus musculus	215-219
30523271-3	2018	In present study, we discover that Guanosine 5"-diphosphate (GDP) encapsulated in lipid vesicle (NH+) was found to inhibit NF-kB activation by limiting phosphorylation and degradation of IkBalpha, thus, attenuating IL-6 secretion from macrophage cells.	Guanosine Diphosphate	61-64	interleukin 6	Mus musculus	215-219
30523271-4	2018	Moreover, the suppressed IL-6 levels down regulated JAK2/STAT3 pathway with decrease inflammation-mediated Hamp mRNA transcription (HepG2) and increase iron absorption (Caco2) in HepG2/Caco2 co-culture model.	caco2	169-174	interleukin 6	Mus musculus	25-29
30326372-2	2018	Novel 2-sulfonylindoles were recently shown to exhibit anti-inflammatory activity through the inhibition of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production.	2-sulfonylindoles	6-23	interleukin 6	Mus musculus	152-165
30326372-2	2018	Novel 2-sulfonylindoles were recently shown to exhibit anti-inflammatory activity through the inhibition of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production.	2-sulfonylindoles	6-23	interleukin 6	Mus musculus	167-171
30326372-6	2018	The compounds 9h and 9k also decreased liposaccharide (LPS)-induced IL-6, IL-1beta and vascular cell adhesion molecule-1 (VCAM-1) mRNA expression, both in vitro and in an in vivo model of ALI.	liposaccharide	39-53	interleukin 6	Mus musculus	68-72
30326372-6	2018	The compounds 9h and 9k also decreased liposaccharide (LPS)-induced IL-6, IL-1beta and vascular cell adhesion molecule-1 (VCAM-1) mRNA expression, both in vitro and in an in vivo model of ALI.	lps	55-58	interleukin 6	Mus musculus	68-72
30564235-2	2018	Cutaneous exposure to Imiquimod (IMQ), a TLR7 agonist, induced acute expression of pro-inflammatory factors (IL1beta, IL6, CXCL1) and neutrophil influx equally in both wildtype and Mmp10 -/- mice.	Imiquimod	22-31	interleukin 6	Mus musculus	118-121
30564235-2	2018	Cutaneous exposure to Imiquimod (IMQ), a TLR7 agonist, induced acute expression of pro-inflammatory factors (IL1beta, IL6, CXCL1) and neutrophil influx equally in both wildtype and Mmp10 -/- mice.	Imiquimod	33-36	interleukin 6	Mus musculus	118-121
30622431-5	2018	Results: L-THP could decrease serum liver enzymes and pathological damage by reducing the release of inflammatory factors like IL-6 and TNF-alpha.	tetrahydropalmatine	9-14	interleukin 6	Mus musculus	127-131
30622665-13	2018	Filtered water treatment suppressed proinflammatory cytokines and decreased the mRNA expression of TNF-alpha, IL-6, IL-1beta, and NF-kappaB P65.	Water	9-14	interleukin 6	Mus musculus	110-114
29958095-0	2018	Carnosol suppresses interleukin-6 production in mouse lungs injured by ischemia-reperfusion operation and in RAW264.7 macrophages treated with lipopolysaccharide.	carnosol	0-8	interleukin 6	Mus musculus	20-33
29958095-3	2018	To elucidate the molecular mechanisms underpinning carnosol-mediated lung protection, we analyzed modes of interleukin-6 (IL-6) gene expression, which is associated with lung ischemia-reperfusion injury.	carnosol	51-59	interleukin 6	Mus musculus	122-126
29958095-5	2018	Carnosol pretreatment lowered the IL-6 protein levels in mouse lung homogenates prepared after the clamp-reperfusion.	carnosol	0-8	interleukin 6	Mus musculus	34-38
29958095-7	2018	IL-6 mRNA levels and gene promoter activities were suppressed by carnosol in RAW264.7 cells, but rescued by ATF3 knockdown.	carnosol	65-73	interleukin 6	Mus musculus	0-4
30312858-16	2018	The expressions of inflammatory cytokine genes, IL-1beta, IL-6, and TNF-alpha, were also significantly increased in the frontal cortex of male, but not female, offspring of ethanol-fed dams.	Ethanol	173-180	interleukin 6	Mus musculus	58-62
29958095-9	2018	These results suggest that carnosol treatment could be a new strategy for protecting lungs from ischemia-reperfusion injury by modulating the ATF3-IL-6 axis.	carnosol	27-35	interleukin 6	Mus musculus	147-151
30372855-12	2018	The protective effect of PFCM in LPS-induced anorexia and sickness behaviour is due to its antioxidant, anti-inflammatory and appetizing activities, inhibiting IL-6 and NF-kappaB.	pfcm	25-29	interleukin 6	Mus musculus	160-164
30391477-5	2018	3-DA attenuated the release of pro-inflammatory cytokines IL-6 and TNF-alpha, inhibited the degradation and phosphorylation of IkappaBalpha, and suppressed the nuclear translocation of NF-kappaB p65 as well as the phosphorylation of Akt at Ser473 in LPS-stimulated RAW 264.7 macrophage cells.	3-da	0-4	interleukin 6	Mus musculus	58-62
30372845-6	2018	Furthermore, DTF was more potent than etanercept in suppressing the expression of inflammatory factors (IL-17 A, IL-6, IL-1beta, IL-23, IL-22 and IL-12) in the serum, spleen and psoriasis-like skin compared with etanercept at the same dose.	dtf	13-16	interleukin 6	Mus musculus	113-117
30172039-16	2018	Moreover, dysregulation of iron homeostasis may be due to MC-LR-induced Hamp1 downregulation, possibly mediated by hypoxia or the IL6-STAT3 and BMP-SMAD signaling pathways.	Iron	27-31	interleukin 6	Mus musculus	130-133
30184260-10	2018	In particular, minocycline initially enhanced IL-1beta, IL-6, IL-22, GM-CSF and IL-4 colonic production and monocyte recruitment to the intestine, subsequently increasing Ly6C- MHCII+ macrophages, Tregs and type 2 intestinal immune responses.	Minocycline	15-26	interleukin 6	Mus musculus	56-60
30172039-16	2018	Moreover, dysregulation of iron homeostasis may be due to MC-LR-induced Hamp1 downregulation, possibly mediated by hypoxia or the IL6-STAT3 and BMP-SMAD signaling pathways.	cyanoginosin LR	58-63	interleukin 6	Mus musculus	130-133
30273672-6	2018	Mechanistically, we found that CWA significantly reduced the LPS-induced nuclear translocation of NF-kappaB, thus decreasing the production of the pro-inflammatory cytokines TNF-alpha and IL-6 in macrophages.	(4R)-4-[5-(difluoromethyl)-1H-imidazol-1-yl]-3,3-dimethyl-3,4-dihydro-1H-2-benzopyran-1-one	31-34	interleukin 6	Mus musculus	188-192
30288860-7	2018	Furthermore, loganin treatment prevented the over-production of Tumor necrosis factor-alpha (TNF-alpha), Interleukin-6 (IL-6), Macrophage Chemotactic Protein 1(MCP-1), Nitric oxide (NO), Prostaglandin E2 (PGE2) and the up-regulation of inducible nitric oxide synthase (iNOS) and Cyclooxygenase 2 (COX-2) in Abeta1-42 -stimulated BV-2 cells.	loganin	13-20	interleukin 6	Mus musculus	105-118
30288860-7	2018	Furthermore, loganin treatment prevented the over-production of Tumor necrosis factor-alpha (TNF-alpha), Interleukin-6 (IL-6), Macrophage Chemotactic Protein 1(MCP-1), Nitric oxide (NO), Prostaglandin E2 (PGE2) and the up-regulation of inducible nitric oxide synthase (iNOS) and Cyclooxygenase 2 (COX-2) in Abeta1-42 -stimulated BV-2 cells.	loganin	13-20	interleukin 6	Mus musculus	120-124
30296514-5	2018	Paeonol decreased the nuclear factor-kappaB activation and over-production of inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	paeonol	0-7	interleukin 6	Mus musculus	145-158
30296514-5	2018	Paeonol decreased the nuclear factor-kappaB activation and over-production of inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	paeonol	0-7	interleukin 6	Mus musculus	160-164
30353943-3	2018	Here, we show a novel murine fecal occult bleeding model induced by the combinatorial treatment of ampicillin and vancomycin, which is accompanied by an enlarged cecum, upregulation of pro-inflammatory cytokines IL-6 and IL-12, a reduction in Ki-67-positive epithelial cell number and an increase in the apoptotic cell number in the colon.	Ampicillin	99-109	interleukin 6	Mus musculus	212-216
30353943-3	2018	Here, we show a novel murine fecal occult bleeding model induced by the combinatorial treatment of ampicillin and vancomycin, which is accompanied by an enlarged cecum, upregulation of pro-inflammatory cytokines IL-6 and IL-12, a reduction in Ki-67-positive epithelial cell number and an increase in the apoptotic cell number in the colon.	Vancomycin	114-124	interleukin 6	Mus musculus	212-216
30353943-6	2018	Interestingly, supplementation of monosodium glutamate or its precursor glutamine suppressed colonic IL-6 and IL-12, protected from cell apoptosis and prevented fecal occult blood indicating that the reduced level of glutamic acid is a possible mechanism of antibiotic-induced fecal occult bleeding.	Sodium Glutamate	34-54	interleukin 6	Mus musculus	101-105
30353943-6	2018	Interestingly, supplementation of monosodium glutamate or its precursor glutamine suppressed colonic IL-6 and IL-12, protected from cell apoptosis and prevented fecal occult blood indicating that the reduced level of glutamic acid is a possible mechanism of antibiotic-induced fecal occult bleeding.	Glutamine	72-81	interleukin 6	Mus musculus	101-105
30143934-5	2018	In vitro, HMA suppressed the production NO, TGF-beta1, TNF-alpha, IL-6, and IL-1beta in LPS-stimulated RAW 264.7 macrophage cells.	2-(hydroxymethyl)anthraquinone	10-13	interleukin 6	Mus musculus	66-70
30273917-8	2018	In this study, leonurine visibly inhibited the IL-1beta-induced production of NO, PGE2, IL-6 and TNF-alpha; and decreased the expression of iNOS, COX-2, MMP-3, MMP-13 and ADAMTS-5 in chondrocytes.	leonurine	15-24	interleukin 6	Mus musculus	88-92
30312879-8	2018	In agreement to its in vitro action, treatment with 100 mg/kg of LASSBio-1386 reduced TNF-alpha and IL-1beta serum levels, while increased IL-6 and IL-10.	N'-(3,4-dimethoxybenzylidene)-4-methoxybenzohydrazide	65-77	interleukin 6	Mus musculus	139-143
30316072-6	2018	Furthermore, simultaneous administration of Nar suppressed PFOS-induced elevation in NF-kappaB activity and generation of inflammatory cytokines TNF-alpha and IL-6 in the liver.	perfluorooctane sulfonic acid	59-63	interleukin 6	Mus musculus	159-163
30336338-0	2018	Dihydroartemisinin derivative DC32 attenuates collagen-induced arthritis in mice by restoring the Treg/Th17 balance and inhibiting synovitis through down-regulation of IL-6.	artenimol	0-18	interleukin 6	Mus musculus	168-172
30381478-6	2018	We now report that exposure of primary murine AEC to hypoxia (1% oxygen) for 24 h results in significant suppression of key innate immune molecules, including GM-CSF, CCL2, and IL-6.	Oxygen	65-71	interleukin 6	Mus musculus	177-181
30408630-11	2018	Further mechanism analysis found that PQ administration could decrease total splenocytes, CD4+ and CD8+ T cells, SOD, GSH-PX, and CAT activity, and increased the levels of MDA and the concentrations of pro-inflammatory cytokines IL-6 and TNF-alpha compared to control mice.	Paraquat	38-40	interleukin 6	Mus musculus	229-233
30308382-5	2018	ASTX significantly decreased LPS-induced mRNA expression of interleukin 6 (Il-6) and Il-1beta by inhibiting nuclear translocation of NFkappaB p65; and attenuated LPS-induced ROS with an increase in NRF2 nuclear translocation, concomitantly decreasing NADPH oxidase 2 expression in RAW 264.7 macrophages.	astaxanthine	0-4	interleukin 6	Mus musculus	60-73
30308382-5	2018	ASTX significantly decreased LPS-induced mRNA expression of interleukin 6 (Il-6) and Il-1beta by inhibiting nuclear translocation of NFkappaB p65; and attenuated LPS-induced ROS with an increase in NRF2 nuclear translocation, concomitantly decreasing NADPH oxidase 2 expression in RAW 264.7 macrophages.	astaxanthine	0-4	interleukin 6	Mus musculus	75-79
30262280-5	2018	ISO (20 mg/kg/day for 10 days) produced cardiac injury as evident by increased plasma LDH and CK-MB, AST, ALT, cardiac hypertrophy, severe myocardial fibrosis (MF) and significantly higher levels of cytokines, IL-6, TGF-beta and TNF-alpha.	Isoproterenol	0-3	interleukin 6	Mus musculus	210-214
30396035-12	2018	Meanwhile, curcumin significantly decreased the expression of multiple inflammatory cytokines (including mature IL-1beta, IL-6, MCP-1), MPO activity, caspase-1 activity as well as histopathological damage.	Curcumin	11-19	interleukin 6	Mus musculus	122-126
30290084-8	2018	Dietary betaine mitigates the high-fat-diet-induced IL-6 expression and significantly increases betaine and butyrobetaine levels in adipose tissue.	Betaine	8-15	interleukin 6	Mus musculus	52-56
30353672-5	2018	Both gene and protein expression levels of pro-inflammatory cytokines IL-1beta, IL-6, and TNF-alpha are markedly attenuated by WCP treatment in the colon of AOM/DSS-treated mice.	CHEMBL3400817	127-130	interleukin 6	Mus musculus	80-84
30501561-6	2018	The expression of proinflammatory cytokines (IL-1beta, IL-6 and TNF-alpha) showed significant decrease upon NY treatment.	nuclear yellow	108-110	interleukin 6	Mus musculus	55-59
30511769-7	2018	At the concentration of 50 to 200 mug/mL, konjac oligosaccharide could activate murine macrophage RAW 264.7 to secret NO and cytokines of IL-10 and IL-6.	konjac oligosaccharide	42-64	interleukin 6	Mus musculus	148-152
30277284-6	2018	In primary cultures, TMT induced significant neuronal death after 24-h intoxication and vigorous secretion of inflammatory cytokines (IL-1alpha/beta, IL-6, TNF-alpha, and MCP-1) in astrocytes.	trimethyltin	21-24	interleukin 6	Mus musculus	150-154
30548229-9	2018	Similarly, IL-6 mRNA and IL-1beta protein were suppressed in Imoxin+LPS compared to LPS alone.	imoxin	61-67	interleukin 6	Mus musculus	11-15
30366666-10	2018	In addition, treatment with URB602 before ischemia increased 2-AG level but decreased metabolites (AA, PGI2, TXB2, LTB4) and inflammatory markers (IL-6, TNF-alpha).	URB602	28-34	interleukin 6	Mus musculus	147-151
30556022-7	2018	Increased brain levels of IL-1beta, IL-6, and TNF-alpha in the LPS-induced mice were reduced by TPA treatment.	Tetradecanoylphorbol Acetate	96-99	interleukin 6	Mus musculus	36-40
30273691-7	2018	APAP-treated mice had elevated hepatic mRNA levels of inflammatory genes (Nf-kappaB, TNF-alpha, IL1-beta and IL-6), an effect blunted in those co-treated with CORM A-1.	Acetaminophen	0-4	interleukin 6	Mus musculus	109-113
30555402-6	2018	Furthermore, an increased expression of pro-inflammatory cytokines, including IL-1beta, IL-6, IL-8, and TNF-alpha, was observed in brain endothelial cells in response to oxygen/glucose depletion/reoxygenation, which was decreased by the shRNA-mediated Atg7 knockdown.	Oxygen	170-176	interleukin 6	Mus musculus	88-92
30555402-6	2018	Furthermore, an increased expression of pro-inflammatory cytokines, including IL-1beta, IL-6, IL-8, and TNF-alpha, was observed in brain endothelial cells in response to oxygen/glucose depletion/reoxygenation, which was decreased by the shRNA-mediated Atg7 knockdown.	Glucose	177-184	interleukin 6	Mus musculus	88-92
30643061-8	2018	:  Conclusion: The IL-6-JAK2 signaling pathway plays an important role in maintaining the BCP by regulating the expression of GFAP in the spinal cord.	bcp	90-93	interleukin 6	Mus musculus	19-23
30643061-9	2018	Intrathecal injection of AG-490 can reduce the BCP, and inhibit the activation of IL-6-JAK2 signaling pathway, which may be one of the mechanisms for spinal astrocyte activation.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	25-31	interleukin 6	Mus musculus	82-86
30474622-11	2018	RESULTS In the HFD mouse model, AICAR treatment inhibited hepatic lipid synthesis and IL-6 expression.	AICA ribonucleotide	32-37	interleukin 6	Mus musculus	86-90
30486874-9	2018	Luminex was used to detect the serum concentration of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNFalpha), and IL-10.	luminex	0-7	interleukin 6	Mus musculus	54-67
30486874-9	2018	Luminex was used to detect the serum concentration of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNFalpha), and IL-10.	luminex	0-7	interleukin 6	Mus musculus	69-73
30474622-12	2018	In the DEN-treated mice, AICAR treatment reduced tumorigenesis, IL-6 signaling, and STAT3 activation.	Diethylnitrosamine	7-10	interleukin 6	Mus musculus	64-68
30474622-12	2018	In the DEN-treated mice, AICAR treatment reduced tumorigenesis, IL-6 signaling, and STAT3 activation.	AICA ribonucleotide	25-30	interleukin 6	Mus musculus	64-68
30598682-5	2018	Ac-ME also suppressed the mRNA expression of inducible nitric oxide (iNOS) and proinflammatory cytokines such as interleukin (IL)-1beta and IL-6.	ac-me	0-5	interleukin 6	Mus musculus	140-144
30581485-6	2018	STE dose-dependently inhibited the productions of inflammatory mediators (NO and PGE2) and proinflammatory cytokines (IL-1beta and IL-6) in LPS-stimulated RAW 264.7 cells.	ste	0-3	interleukin 6	Mus musculus	131-135
30381205-3	2018	The reduced plasma interleukin (IL)-6 and improved liver health may be mediated by cherry fibre and non-anthocyanin phenolics.	Anthocyanins	104-115	interleukin 6	Mus musculus	19-37
30442925-4	2018	When conditioned media from BrdU-labeled irradiated cells were passed through filters of pore size 0.22 microm and incubated with unexposed cells, BrdU-labeled cfCh particles could be seen to readily enter their nuclei to activate H2AX, active Caspase-3, NFkappaB, and IL-6.	Bromodeoxyuridine	28-32	interleukin 6	Mus musculus	269-273
30442925-4	2018	When conditioned media from BrdU-labeled irradiated cells were passed through filters of pore size 0.22 microm and incubated with unexposed cells, BrdU-labeled cfCh particles could be seen to readily enter their nuclei to activate H2AX, active Caspase-3, NFkappaB, and IL-6.	Bromodeoxyuridine	147-151	interleukin 6	Mus musculus	269-273
30114517-8	2018	Moreover, the inhibitory effect on mRNA expression of proinflammatory cytokine IL-1beta, IL-6 and TNF-alpha of fourteen cassane diterpenes obtained from CMC extract were valued using the RAW 264.7 macrophages cell stimulated by lipopolysaccharide (LPS) assay.	Cassane	120-127	interleukin 6	Mus musculus	89-93
30114517-8	2018	Moreover, the inhibitory effect on mRNA expression of proinflammatory cytokine IL-1beta, IL-6 and TNF-alpha of fourteen cassane diterpenes obtained from CMC extract were valued using the RAW 264.7 macrophages cell stimulated by lipopolysaccharide (LPS) assay.	Diterpenes	128-138	interleukin 6	Mus musculus	89-93
30114517-11	2018	Fourteen cassane derivatives as the main constituents of CMC extract showed the promising activity on the expression mRNA of cytokine IL-1beta, IL-6 and TNF-alpha produced by macrophages cells.	Cassane	9-16	interleukin 6	Mus musculus	144-148
30114517-11	2018	Fourteen cassane derivatives as the main constituents of CMC extract showed the promising activity on the expression mRNA of cytokine IL-1beta, IL-6 and TNF-alpha produced by macrophages cells.	cmc	57-60	interleukin 6	Mus musculus	144-148
30441755-6	2018	Lipid deposition, partial inflammatory-related factors (nuclear factor kappa B p65, cyclooxygenase-2, and interleukin-6 levels), and hepatic histopathological alterations were similarly attenuated by five kinds of flavonoids.	Flavonoids	214-224	interleukin 6	Mus musculus	106-119
30466970-3	2018	HYPOTHESIS/PURPOSE: The sesquiterpene lactones (SLs) coronopilin and damsin, which are major secondary metabolites of A. arborescens, have anti-inflammatory activity by attenuation of IL-6 and MCP-1 expression and inhibition of NF-kappaB in human dermal fibroblasts (HDFa) and human keratinocytes (HaCaT).	Sesquiterpenes	24-37	interleukin 6	Mus musculus	184-188
30466970-3	2018	HYPOTHESIS/PURPOSE: The sesquiterpene lactones (SLs) coronopilin and damsin, which are major secondary metabolites of A. arborescens, have anti-inflammatory activity by attenuation of IL-6 and MCP-1 expression and inhibition of NF-kappaB in human dermal fibroblasts (HDFa) and human keratinocytes (HaCaT).	Lactones	38-46	interleukin 6	Mus musculus	184-188
30466970-3	2018	HYPOTHESIS/PURPOSE: The sesquiterpene lactones (SLs) coronopilin and damsin, which are major secondary metabolites of A. arborescens, have anti-inflammatory activity by attenuation of IL-6 and MCP-1 expression and inhibition of NF-kappaB in human dermal fibroblasts (HDFa) and human keratinocytes (HaCaT).	Sodium dodecyl sulfate	48-51	interleukin 6	Mus musculus	184-188
30466970-3	2018	HYPOTHESIS/PURPOSE: The sesquiterpene lactones (SLs) coronopilin and damsin, which are major secondary metabolites of A. arborescens, have anti-inflammatory activity by attenuation of IL-6 and MCP-1 expression and inhibition of NF-kappaB in human dermal fibroblasts (HDFa) and human keratinocytes (HaCaT).	coronopilin	53-64	interleukin 6	Mus musculus	184-188
30466970-17	2018	CONCLUSION: We show that coronopilin and damsin from A. arborescens inhibit pro-inflammatory IL-6 and MCP-1 expression in human skin cells via NF-kappaB inhibition, suggesting that they may be useful for antagonizing inflammatory conditions of the human skin.	coronopilin	25-36	interleukin 6	Mus musculus	93-97
30466979-6	2018	The anti-inflammatory mechanism was explored by measuring the protein and mRNA levels of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6 in the ear of the TPA-treated mice.	Tetradecanoylphorbol Acetate	180-183	interleukin 6	Mus musculus	157-161
30466979-9	2018	Moreover, EWSS and EYSS also remarkably inhibited the protein and mRNA levels of TNF-alpha and IL-6 in the ears of TPA-treated mice.	Tetradecanoylphorbol Acetate	115-118	interleukin 6	Mus musculus	95-99
30429582-3	2018	Galantamine verified its anti-inflammatory effect by elevating acetylcholine (ACh) level, while abating the interleukin-6/ janus kinase 2 (Y1007/1008)/ signal transducer and activator of transcription 3 (Y705) (IL-6/ pY(1007/1008)-JAK2/ pY705-STAT3) inflammatory axis, with a consequent inhibition in suppressor of cytokine signaling 3 (SOCS3).	Galantamine	0-11	interleukin 6	Mus musculus	108-121
30429582-3	2018	Galantamine verified its anti-inflammatory effect by elevating acetylcholine (ACh) level, while abating the interleukin-6/ janus kinase 2 (Y1007/1008)/ signal transducer and activator of transcription 3 (Y705) (IL-6/ pY(1007/1008)-JAK2/ pY705-STAT3) inflammatory axis, with a consequent inhibition in suppressor of cytokine signaling 3 (SOCS3).	Galantamine	0-11	interleukin 6	Mus musculus	211-215
30483238-5	2018	Third, vanillin reduced elevated levels of inflammatory factors including LPS, IL-6, and TNF-alpha in plasma and liver tissue resulting from obesity.	vanillin	7-15	interleukin 6	Mus musculus	79-83
30407111-9	2018	Box A versus PBS therapeutic treatment significantly reduced clinical scores, MPO activity, bacterial load, and protein levels of IL-1beta, CXCL2, and IL-6 in the infected cornea.	pbs	13-16	interleukin 6	Mus musculus	151-155
29989851-6	2018	To understand how SFA and LPS interact to promote IL-6 expression, our in vitro studies showed that palmitic acid (PA), a major SFA, and LPS exerted synergistic effect on the expression of IL-6 in hepatocytes.	Fatty Acids	18-21	interleukin 6	Mus musculus	50-54
29989851-6	2018	To understand how SFA and LPS interact to promote IL-6 expression, our in vitro studies showed that palmitic acid (PA), a major SFA, and LPS exerted synergistic effect on the expression of IL-6 in hepatocytes.	Fatty Acids	18-21	interleukin 6	Mus musculus	189-193
29989851-6	2018	To understand how SFA and LPS interact to promote IL-6 expression, our in vitro studies showed that palmitic acid (PA), a major SFA, and LPS exerted synergistic effect on the expression of IL-6 in hepatocytes.	Palmitic Acid	100-113	interleukin 6	Mus musculus	50-54
29989851-6	2018	To understand how SFA and LPS interact to promote IL-6 expression, our in vitro studies showed that palmitic acid (PA), a major SFA, and LPS exerted synergistic effect on the expression of IL-6 in hepatocytes.	Palmitic Acid	100-113	interleukin 6	Mus musculus	189-193
29989851-6	2018	To understand how SFA and LPS interact to promote IL-6 expression, our in vitro studies showed that palmitic acid (PA), a major SFA, and LPS exerted synergistic effect on the expression of IL-6 in hepatocytes.	Palmitic Acid	115-117	interleukin 6	Mus musculus	50-54
29989851-6	2018	To understand how SFA and LPS interact to promote IL-6 expression, our in vitro studies showed that palmitic acid (PA), a major SFA, and LPS exerted synergistic effect on the expression of IL-6 in hepatocytes.	Palmitic Acid	115-117	interleukin 6	Mus musculus	189-193
29989851-6	2018	To understand how SFA and LPS interact to promote IL-6 expression, our in vitro studies showed that palmitic acid (PA), a major SFA, and LPS exerted synergistic effect on the expression of IL-6 in hepatocytes.	Fatty Acids	128-131	interleukin 6	Mus musculus	189-193
29989851-7	2018	Furthermore, coculture of hepatocytes with macrophages resulted in a greater IL-6 expression than culture of hepatocytes without macrophages in response to the combination of PA and LPS.	Palmitic Acid	175-177	interleukin 6	Mus musculus	77-81
30098312-8	2018	Contrary to ethanol effect, URB597 reduced mRNA levels of Iba-1, Tnfalpha, IL-6 and the monocyte chemoattractant protein-1 (MCP-1/CCL2), as well as cell population expressing iNOS.	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester	28-34	interleukin 6	Mus musculus	75-79
30149233-9	2018	In vivo, HABP2-8-arm PEG-COLBP treatment and the clinical HA comparator Orthovisc lowered levels of inflammatory genes including IL-6, IL-1B, and MMP13 compared to saline treated animals and increased aggrecan expression in young mice.	Polyethylene Glycols	21-24	interleukin 6	Mus musculus	129-133
30188745-9	2018	LPS induced the release of TNFalpha, IL-6, and IL-8 by HLMVECs that were inhibited by sitagliptin.	Sitagliptin Phosphate	86-97	interleukin 6	Mus musculus	37-41
30257328-5	2018	In addition, pro-inflammatory cytokines induced by LPS, such as TNFalpha and IL-6 were also attenuated by chelidonine.	chelidonine	106-117	interleukin 6	Mus musculus	77-81
30257328-8	2018	Finally, we verified that chelidonine striking ly decreased serum TNFalpha, IL-6 and PGE2 levels in LPS stimulated mice.	chelidonine	26-37	interleukin 6	Mus musculus	76-80
30257333-10	2018	IL-17A-induced oxidative stress/IL-6 expression and neutrophilic inflammation was attenuated by NAC treatment, whereas there was no effect on chemokines.	Acetylcysteine	96-99	interleukin 6	Mus musculus	32-36
30257333-11	2018	This suggests that antioxidant NAC attenuates IL-17A-induced pulmonary inflammation by restoring oxidant-antioxidant balance and attenuation of IL-6 in the lung.	Acetylcysteine	31-34	interleukin 6	Mus musculus	144-148
30257400-8	2018	Also, interleukin 6 and tumor necrosis factor alpha showed an enhancement due to dietary restriction of vitamin D.	Vitamin D	104-113	interleukin 6	Mus musculus	6-51
29959142-8	2018	To confirm a correlation with clinical evidence, meta-analyses were employed using the Oncomine database.Results: Our coculture studies identify IL6 and GM-CSF as the pivotal signals released from cancer cell-activated CAFs that cooperate to induce monocyte differentiation into M2-like TAMs.	Tamoxifen	287-291	interleukin 6	Mus musculus	145-148
30138892-8	2018	Moreover, inhibition of miR-92a ameliorated the inflammatory response by reducing the repression of proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and IL-6 in lung tissues.	mir-92a	24-31	interleukin 6	Mus musculus	210-214
30169894-6	2018	We have demonstrated that FKBP51 silencing in a bronchial epithelial cell line resulted in a 10-fold increased potency for dexamethasone towards IL1beta-induced IL6 and IL8, whilst FKBP51 over-expression of FKBP51 reduced significantly the prednisolone sensitivity in a murine HDM-driven pulmonary inflammation model.	Dexamethasone	123-136	interleukin 6	Mus musculus	161-164
30221419-6	2018	Moreover, 5(OH)Trp significantly inhibited keratinocyte activation with decrease in IL-6 production and p-Erk1/2 and p-STAT3 expression.	5(oh)trp	10-18	interleukin 6	Mus musculus	84-88
30221419-7	2018	5(OH)Trp also inhibited the differentiation of IFN-gamma- and IL-17A-expressing CD4+ T cells and related cytokine production (TNF-alpha, IL-6, IL-17A and IFN-gamma) in splenocytes.	Tryptophan	5-8	interleukin 6	Mus musculus	137-141
30375063-8	2018	We found up-regulation of proinflammatory cytokine genes including Il1b, Il6 and Tnfa, among which Tnfa was selectively blocked by minocycline.	Minocycline	131-142	interleukin 6	Mus musculus	73-76
30260716-0	2018	miR-350-3p Contributes to Age-Associated Impairment of IL-6 Production by Macrophages.	mir-350-3p	0-10	interleukin 6	Mus musculus	55-59
30173051-8	2018	H. pylori infected mice also showed a decrease in the serum levels of IL-2, IL-6, IL-10, IL-17, IFN-gamma and TFN-alpha following 2 and 6 weeks of melatonin treatment compared to the untreated mice.	Melatonin	147-156	interleukin 6	Mus musculus	76-80
30173052-7	2018	THC also attenuated the levels of neutrophil elastase (NE), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the BALF and serum.	Dronabinol	0-3	interleukin 6	Mus musculus	104-117
30145467-0	2018	BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway.	bf211	0-5	interleukin 6	Mus musculus	107-111
30173052-7	2018	THC also attenuated the levels of neutrophil elastase (NE), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the BALF and serum.	Dronabinol	0-3	interleukin 6	Mus musculus	119-123
30173053-5	2018	In addition, piceatannol reduced the expression of proinflammatory cytokines, including TNF-alpha, IL-1beta and IL-6, the expression of ER stress markers CHOP and phosphorylated-IRE1alpha, and the generation of oxidative stress in D-GalN/LPS-treated mouse liver.	3,3',4,5'-tetrahydroxystilbene	13-24	interleukin 6	Mus musculus	112-116
30173054-5	2018	The results showed that barbaloin decreased the phosphorylation levels of IkappaBalpha and NF-kappaB p65, leading to a reduction in the expression of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6).	barbaloin	24-33	interleukin 6	Mus musculus	202-206
30195109-12	2018	Gallic acid derivative enhanced the antioxidant status, but reduced the expression of interleukin 6, NADPH oxidase-4.	Gallic Acid	0-11	interleukin 6	Mus musculus	86-99
30402026-9	2018	High-dose fimasartan treatment attenuated the upregulation of TNF-alpha, interleukin (IL)-1beta, and IL-6 in ischemic kidneys.	fimasartan	10-20	interleukin 6	Mus musculus	101-105
30149133-9	2018	Paeoniflorin was found to decrease the phosphorylation of IRAK1 and its downstream proteins induced by LPS and inhibit the expression of TNF-alpha and IL-6.	peoniflorin	0-12	interleukin 6	Mus musculus	151-155
30317896-2	2018	Herein, we established a ZnONPs-induced ALI mouse model, characterized by the histopathological changes (edema and infiltration of inflammatory cells in lung tissues), and the elevation of total protein and cytokine interleukin-6 in bronchoalveolar lavage fluid in time- and dose-dependent manners.	znonps	25-31	interleukin 6	Mus musculus	216-229
30464588-8	2018	Furthermore, CAPE suppressed the phosphorylation of p38 mitogen-activated protein kinase, inhibited the translocation of NF-kappaB and decreased the expression of proinflammatory cytokines tumor necrosis factor-alpha, IL-1beta and IL-6.	caffeic acid phenethyl ester	13-17	interleukin 6	Mus musculus	231-235
30184329-5	2018	Furthermore, DSS-induced increases in reactive oxygen species accumulation, TNF-alpha and IL-6 secretion, and malonyldialdehyde activity and a decrease in reduced glutathione in the colon are ameliorated by Hyp.	Dextran Sulfate	13-16	interleukin 6	Mus musculus	90-94
30459609-11	2018	In addition, pravastatin inhibited levels of epithelial-derived inflammatory cytokines including IL-6, IL-1beta, and TNF-alpha in irradiated InEpC cells.	Pravastatin	13-24	interleukin 6	Mus musculus	97-101
30277425-10	2018	In addition, the concentrations of IL-6 and TNF-alpha were increased by MALAT1 siRNA transfection in CoCl2-treated HK2 cells.	cobaltous chloride	101-106	interleukin 6	Mus musculus	35-39
30367813-7	2018	In addition, injection of CsA decreased total cells (P&lt;.05), neutrophils (P&lt;.05), and total protein (P&lt;.05) in BALF and inflammatory mediators, including tumor necrosis factor-a (TNF-a, P&lt;.05) and interleukin-6 (IL-6, P&lt;.05) in a dose-dependent manner.	Cyclosporine	26-29	interleukin 6	Mus musculus	209-222
30374077-7	2018	These results reveal that Ido2 modulates IL-6/stat3 signalling and is induced by LPS, providing novel options for the treatment of immune disorders.	ido2	26-30	interleukin 6	Mus musculus	41-45
30362468-10	2018	SIN reduced CUMS-induced increases in the levels of IL-1beta, IL-6, and TNF-alpha in the hippocampus of mice.	cums	12-16	interleukin 6	Mus musculus	62-66
30367813-7	2018	In addition, injection of CsA decreased total cells (P&lt;.05), neutrophils (P&lt;.05), and total protein (P&lt;.05) in BALF and inflammatory mediators, including tumor necrosis factor-a (TNF-a, P&lt;.05) and interleukin-6 (IL-6, P&lt;.05) in a dose-dependent manner.	Cyclosporine	26-29	interleukin 6	Mus musculus	224-228
30360404-4	2018	In this study, we found that nuciferine (10 muM) significantly inhibited the lipopolysaccharide (LPS)-induced inflammatory cytokine IL-6 and TNF-alpha production in RAW 264.7 cells.	nuciferine	29-39	interleukin 6	Mus musculus	132-136
30498394-0	2018	Chemopreventive Effects of Silibinin on Colitis-Associated Tumorigenesis by Inhibiting IL-6/STAT3 Signaling Pathway.	Silybin	27-36	interleukin 6	Mus musculus	87-91
30498394-17	2018	In conclusion, silibinin could protect against colitis-associated tumorigenesis in mice via inhibiting IL-6/STAT3, which showed promising chemopreventive potential of CAC.	Silybin	15-24	interleukin 6	Mus musculus	103-107
30356272-6	2018	Using this experimental condition, intracellular calcium flux, rather than the contraction itself, triggered contraction-induced IL-6 secretion.	Calcium	49-56	interleukin 6	Mus musculus	129-133
30340603-13	2018	Notably, Guilu Erxian Liquid (100 mg/kg/day) treatment significantly reduced the mRNA levels of IL-1beta, IL-6, and TNF-alpha as well as relative the protein expression of IL-1beta and TNF-alpha to the effect of celecoxib.	guilu erxian liquid	9-28	interleukin 6	Mus musculus	106-110
30249753-8	2018	Furthermore, pretreatment with FM0807 inhibited the inflammatory factor tumor necrosis factor-alpha (TNF-alpha), interleukin (IL) 1beta (IL-1beta), IL-6, and inducible nitric oxide synthase (iNOS) at the protein and gene levels.	fm0807	31-37	interleukin 6	Mus musculus	148-152
30365818-12	2018	Compared to PBS, treatment with ethacrynic acid (1mg/kg) significantly decreased manipulation-induced IL-6 and iNOS mRNA expression in the wall of the small bowel.	Ethacrynic Acid	32-47	interleukin 6	Mus musculus	102-106
30459751-7	2018	ELISA showed that GL pretreatment significantly decreased proinflammatory cytokine (IFN-gamma, TNF-alpha, IL-6) secretion and increased anti-inflammatory cytokine (IL-10) secretion in the ileum, colon and serum of ST-infected mice.	Glycyrrhizic Acid	18-20	interleukin 6	Mus musculus	106-110
30238111-4	2018	Furthermore, supplementation with combined BC/KGM fiber in HF-fed mice had a more positive effect on obesity-associated hepatic inflammation by reducing levels of TNF-alpha and IL-6 and suppressing the protein expression of Nrf-2/ARE in comparison with supplementation with BC or KGM alone.	biochar	43-45	interleukin 6	Mus musculus	177-181
30093041-5	2018	Further experiments showed that CS could increase the secretion levels of NO, TNF-alpha, IL-6 and IL-10 via activating the corresponding mRNA expression in macrophages through the toll-like receptor 2 (TLR2).	Chondroitin Sulfates	32-34	interleukin 6	Mus musculus	89-93
30099064-6	2018	Analysis of cytokine secretion after BMM activation with heat-killed (hk) salmonellae showed that BaP exposure resulted in suppressed secretion of interleukin (IL)-1beta, IL-6 and the chemokine CXC motif ligand 1 (CXCL1).	Benzo(a)pyrene	98-101	interleukin 6	Mus musculus	171-175
29784301-5	2018	Furthermore, ganoduriporol A was demonstrated to inhibit the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and prostaglandin E2 (PGE2) through the suppression of COX-2, MAPK and NF-kappaB signaling pathway in LPS-induced macrophage cells.	ganoduriporol a	13-28	interleukin 6	Mus musculus	146-159
29784301-5	2018	Furthermore, ganoduriporol A was demonstrated to inhibit the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and prostaglandin E2 (PGE2) through the suppression of COX-2, MAPK and NF-kappaB signaling pathway in LPS-induced macrophage cells.	ganoduriporol a	13-28	interleukin 6	Mus musculus	161-165
29803956-8	2018	Additionally, the proposed Ca2+/Dex-SA supramolecular hydrogel displayed a comparable anti-inflammatory efficacy with Dexp via the downregulation of NO, TNF-alpha and IL-6 expression in lipopolysaccharide (LPS)-activated RAW264.7 macrophage.	dex-sa	32-38	interleukin 6	Mus musculus	167-171
30323246-7	2018	The mechanistic study revealed that inflammatory cytokines (IL-6, TNF-alpha) are transcriptionally activated by an acetylated lysine residue in histone (H3K27ac) of chromatin by binding to its promoter and subsequently regulating gene expression.	Lysine	126-132	interleukin 6	Mus musculus	60-64
30356663-4	2018	Production of the inflammatory cytokines GM-CSF, IL-6, and IFN-gamma was a hallmark of the severe inflammation induced by E. coli strains of Sequence Type 129 (ST129) and ST375 following DSS administration.	Dextran Sulfate	187-190	interleukin 6	Mus musculus	49-53
30130525-7	2018	Trigonelline significantly declined the levels of blood glucose, serum tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta, while increased the levels of serum insulin and adiponectin in diabetic mice.	trigonelline	0-12	interleukin 6	Mus musculus	100-113
29913301-17	2018	In vitro experimental results showed that RSF (25-100 mug/mL) could significantly inhibit the release of pro-inflammatory cytokines NO, TNF-alpha, IL-6 and MCP-1 on LPS-induced RAW264.7 cells.	(3r,3as,6ar)-Hexahydrofuro[2,3-B]furan-3-Ol	42-45	interleukin 6	Mus musculus	147-151
30142311-6	2018	Additionally, the expression of tumor necrosis factor-alpha and interleukin-6 and the activity of myeloperoxidase in colonic tissues were significantly reduced in tussilagone-treated mice.	tussilagone	163-174	interleukin 6	Mus musculus	64-77
29849131-9	2018	Moreover, SM934 administration dose-dependently decreased the mRNA and protein levels of DSS-induced pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha), and the percentage of macrophages and neutrophils in colon tissues.	Dextran Sulfate	89-92	interleukin 6	Mus musculus	139-143
29966974-6	2018	BrdU immunofluorescence found that the IL-6-/- group had the least number of BrdU positive cells, while the IL-6 group had more BrdU positive cells than the model group and the IL-6-/- group.	Bromodeoxyuridine	0-4	interleukin 6	Mus musculus	39-43
29740850-9	2018	In addition, AS significantly suppressed serum levels of histamine and IgE, while Bu-OH significantly suppressed serum levels of histamine, IgE, thymic stromal lymphopoietin (TSLP), interleukin (IL)-4 and IL-6, and DEQA significantly suppressed serum levels of histamine, IgE, TSLP and IL-4 in DNFB-induced AD mice.	Butanols	82-87	interleukin 6	Mus musculus	205-209
29656957-7	2018	PGA alone was sufficient to induce expression of TNF-alpha, IL-6, MCP-1, and MIP1-alpha, whereas MDP alone did not under the same conditions.	Folic Acid	0-3	interleukin 6	Mus musculus	60-64
29751177-8	2018	Furthermore, treatment with AG-490, an inhibitor of JAK family kinases, suppressed activation of the IL-6/JAK2/STAT3 signaling cascade, in turn resulting in a decreased number of plasma cells in the mammary gland and reversing the pathogenesis of PCM.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	28-34	interleukin 6	Mus musculus	101-105
30121232-6	2018	Furthermore, monoterpenoid 4 and alkaloid 15 showed remarkably inhibitory effect on the production of inflammatory mediator (NO) and pro-inflammatory cytokines (TNF-alpha and/or IL-6) in LPS-stimulated RAW264.7 cells.	Monoterpenes	13-26	interleukin 6	Mus musculus	178-182
30114748-6	2018	Meanwhile, AlCl3 exposure decreased LPS-induced IKKbeta activity, IkappaBalpha phosphorylation, the phosphorylation and mRNA expression of NF-kappaB p65, as well the genes expression and concentration in medium supernatant of tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6).	Aluminum Chloride	11-16	interleukin 6	Mus musculus	270-283
30114748-6	2018	Meanwhile, AlCl3 exposure decreased LPS-induced IKKbeta activity, IkappaBalpha phosphorylation, the phosphorylation and mRNA expression of NF-kappaB p65, as well the genes expression and concentration in medium supernatant of tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6).	Aluminum Chloride	11-16	interleukin 6	Mus musculus	285-289
30121232-6	2018	Furthermore, monoterpenoid 4 and alkaloid 15 showed remarkably inhibitory effect on the production of inflammatory mediator (NO) and pro-inflammatory cytokines (TNF-alpha and/or IL-6) in LPS-stimulated RAW264.7 cells.	Alkaloids	33-41	interleukin 6	Mus musculus	178-182
29577374-9	2018	The stereoisomer (+)-cis-EC decreased levels of proinflammatory cytokines IL-1beta, IL-6, and TNFalpha, whereas comparatively (-)-cis-EC did not reduce IL-1beta levels.	(+)-cis-ec	17-27	interleukin 6	Mus musculus	84-88
30118828-9	2018	In addition, phloroglucinol-administered 5XFAD mice displayed lower protein levels of GFAP and Iba-1 and mRNA levels of TNF-alpha and IL-6 compared with vehicle-administered 5XFAD mice.	Phloroglucinol	13-27	interleukin 6	Mus musculus	134-138
30327657-9	2018	In addition, naringenin promoted Treg polarization and also prevented IL-6-induced suppression of Treg development via down-regulation of p-Smad2/3 as well as inhibition of IL-6 signaling, and the latter was further supported by the in vivo results showing lower soluble IL-6R but higher soluble gp130 levels in plasma of naringenin-fed compared to the control EAE mice.	naringenin	13-23	interleukin 6	Mus musculus	70-74
30142454-8	2018	It was confirmed that procyanidin B2 prevented HFD-induced hepatic fat accumulation through down-regulating lipogenesis-related gene expressions (PPARgamma, C/EBPalpha and SREBP-1c), inhibiting pro-inflammatory cytokines production (IL-6 and TNF-alpha) and increasing antioxidant enzymes activity (GPx, SOD and CAT).	procyanidin B2	22-36	interleukin 6	Mus musculus	233-237
28877980-10	2018	As FK866 was also effective in Rag1-/- mice, we mechanistically linked FK866 treatment with altered monocyte/macrophage biology and skewed macrophage polarisation by reducing CD86, CD38, MHC-II and interleukin (IL)-6 and promoting CD206, Egr2 and IL-10.	N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide	71-76	interleukin 6	Mus musculus	198-216
29429001-7	2018	Topical application of EOCl produced anti-inflammatory effects by reducing ear thickness, ear weight and ameliorating the level of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) at protein and mRNA levels as well as regulating the overproduction of oxidative markers and restoring the histopathological damage in a TPA-induced mouse model of inflammation.	eocl	23-27	interleukin 6	Mus musculus	170-174
29644554-4	2018	The results showed that palmitate upregulated the mRNA expression and protein release of IL-6 and TNF-alpha cytokines in C2C12 cells, while pretreatment with curcumin was able to attenuate the effect of palmitate on inflammatory cytokines.	Palmitates	24-33	interleukin 6	Mus musculus	89-93
29644554-4	2018	The results showed that palmitate upregulated the mRNA expression and protein release of IL-6 and TNF-alpha cytokines in C2C12 cells, while pretreatment with curcumin was able to attenuate the effect of palmitate on inflammatory cytokines.	Curcumin	158-166	interleukin 6	Mus musculus	89-93
29948505-3	2018	This study shows that andrographolide downregulates the oxidized low-density lipoprotein (oxLDL)-induced expression of the pro-inflammatory molecules monocyte chemotactic protein (MCP)-1 and interleukin (IL)-6 and blocks the nuclear factor-kappaB signaling pathway in macrophages.	andrographolide	22-37	interleukin 6	Mus musculus	191-209
30327657-9	2018	In addition, naringenin promoted Treg polarization and also prevented IL-6-induced suppression of Treg development via down-regulation of p-Smad2/3 as well as inhibition of IL-6 signaling, and the latter was further supported by the in vivo results showing lower soluble IL-6R but higher soluble gp130 levels in plasma of naringenin-fed compared to the control EAE mice.	naringenin	13-23	interleukin 6	Mus musculus	173-177
30327657-9	2018	In addition, naringenin promoted Treg polarization and also prevented IL-6-induced suppression of Treg development via down-regulation of p-Smad2/3 as well as inhibition of IL-6 signaling, and the latter was further supported by the in vivo results showing lower soluble IL-6R but higher soluble gp130 levels in plasma of naringenin-fed compared to the control EAE mice.	naringenin	322-332	interleukin 6	Mus musculus	70-74
30319187-10	2018	Conversely, cells were treated with citral significantly suppress the expression of PI3K/AKT, PPARgamma, SREBP-1c, FAS, CPD, TNF-alpha, IL-6 and MCP-1 in dose dependent manner.	citral	36-42	interleukin 6	Mus musculus	136-140
30109356-11	2018	Pro-inflammatory cytokines such as IL-17, IL-6 and IL-1beta were decreased, while immunosuppressive factors such as TGF-beta and IL-10 were increased in CIA mice treated with quetiapine.	Quetiapine Fumarate	175-185	interleukin 6	Mus musculus	42-46
30066904-8	2018	It was identified that aloin decreased the level of LPS-induced iNOS expression, inhibiting the release of interleukin (IL)-1beta, IL-6, tumour necrosis factor-alpha and NO dose-dependently.	alloin	23-28	interleukin 6	Mus musculus	131-135
30488739-11	2018	Finally, we found nuclear factor-kappa B (NF-kappaB) inhibitor BAY 11-7082 further decreased secretion levels of TNF-alpha, IL-1beta, and IL-6 and increased IL-10 level.	3-(4-methylphenylsulfonyl)-2-propenenitrile	63-74	interleukin 6	Mus musculus	138-142
30488751-9	2018	Moreover, sesamin alleviated inappropriate changes of renal nuclear factor-kappaB (NF-kappaB), toll-like receptor 4 (TLR4), cyclooxygenase-2 (COX2), tumor necrosis factor alpha (TNFalpha), interleukin-6, DNA fragmentation (an apoptotic index), and nuclear factor (erythroid-derived 2)-like 2 (Nrf2).	sesamin	10-17	interleukin 6	Mus musculus	189-202
30066835-6	2018	The 17-allylamino-17demethoxy-geldanamycin (17-AAG) and 17-dimethylamino-ethylamino-17-demethoxy-geldanamycin (17-DMAG) HSP90 inhibitors significantly enhanced the thrombin-stimulated release of IL-6.	tanespimycin	4-42	interleukin 6	Mus musculus	195-199
30167784-0	2018	Remifentanil suppresses increase in interleukin-6 mRNA in the brain by inhibiting cyclic AMP synthesis.	Remifentanil	0-12	interleukin 6	Mus musculus	36-49
30066835-7	2018	Geldanamycin, another inhibitor of HSP90, also upregulated the release and mRNA expression of IL-6.	geldanamycin	0-12	interleukin 6	Mus musculus	94-98
30066835-9	2018	Additionally, the enhancement by 17-AAG of the thrombin-stimulated release of IL-6 was significantly reduced by SB203580, an inhibitor of p38 MAPK.	tanespimycin	33-39	interleukin 6	Mus musculus	78-82
30066835-9	2018	Additionally, the enhancement by 17-AAG of the thrombin-stimulated release of IL-6 was significantly reduced by SB203580, an inhibitor of p38 MAPK.	SB 203580	112-120	interleukin 6	Mus musculus	78-82
30167784-0	2018	Remifentanil suppresses increase in interleukin-6 mRNA in the brain by inhibiting cyclic AMP synthesis.	Cyclic AMP	82-92	interleukin 6	Mus musculus	36-49
30167784-8	2018	LPS and/or remifentanil-induced changes in intracellular cAMP levels in cultured glial cells were measured, and the effects of cAMP on LPS-induced IL-6 mRNA expression levels were evaluated.	Cyclic AMP	127-131	interleukin 6	Mus musculus	147-151
30167784-9	2018	RESULTS: Remifentanil suppressed increase in IL-6 mRNA levels in the mouse brain, and also inhibited the responses of plasma IL-6, corticosterone, and noradrenaline in an inflammatory state.	Remifentanil	9-21	interleukin 6	Mus musculus	45-49
30167784-9	2018	RESULTS: Remifentanil suppressed increase in IL-6 mRNA levels in the mouse brain, and also inhibited the responses of plasma IL-6, corticosterone, and noradrenaline in an inflammatory state.	Remifentanil	9-21	interleukin 6	Mus musculus	125-129
30167784-11	2018	In cultured cells, remifentanil suppressed increase in IL-6 mRNA levels and intracellular cAMP levels after the administration of LPS, and this enhanced IL-6 mRNA expression in response to LPS.	Remifentanil	19-31	interleukin 6	Mus musculus	55-59
30167784-11	2018	In cultured cells, remifentanil suppressed increase in IL-6 mRNA levels and intracellular cAMP levels after the administration of LPS, and this enhanced IL-6 mRNA expression in response to LPS.	Remifentanil	19-31	interleukin 6	Mus musculus	153-157
30167784-12	2018	CONCLUSION: Remifentanil suppressed increase in IL-6 mRNA levels in the brain in an inflammatory state, and this effect may be attributed to its direct action on neuronal cells through the inhibition of intracellular cAMP rather than corticosterone.	Remifentanil	12-24	interleukin 6	Mus musculus	48-52
30167784-12	2018	CONCLUSION: Remifentanil suppressed increase in IL-6 mRNA levels in the brain in an inflammatory state, and this effect may be attributed to its direct action on neuronal cells through the inhibition of intracellular cAMP rather than corticosterone.	Cyclic AMP	217-221	interleukin 6	Mus musculus	48-52
30138626-8	2018	Moreover, Ciloz reduced the inflammatory milieu in the heart as evinced by decreased F4/80+ and CD68+ cells; IL-1beta and IL-6 gene transcripts.	Cilostazol	10-15	interleukin 6	Mus musculus	122-126
30100034-7	2018	RESULTS: Capsaicin pretreatment reduced wet-to-dry ratio, pathologic score, alveolar-arterial oxygen gradient (A-aDO2), and IL1beta, IL6, and TNFalpha levels in WT mice, with no effects in KO mice.	Capsaicin	9-18	interleukin 6	Mus musculus	133-136
30403186-10	2018	By blocking this pathway with an antagonist, AG490, the expression of TNF-alpha, IL-1beta, and IL-6 was alleviated.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	45-50	interleukin 6	Mus musculus	95-99
30013196-3	2018	A graph of IL-6 levels should be shown in place of the duplication.These results were also incorrectly described in the main text, which originally stated: "At an early time point of infection (6 h), RTX-treated mice showed higher induction of total inflammatory-protein levels in the bronchoalveolar lavage fluid (BALF) (Fig.	resiniferatoxin	200-203	interleukin 6	Mus musculus	11-15
30223923-8	2018	The results showed that TFA significantly inhibited TNF-alpha, IL-1beta, IL-6, iNOS and COX-2 mRNA levels and increased IL-10 mRNA level in LPS-stimulated RAW 264.7 cells in a dose-dependent manner.	Trifluoroacetic Acid	24-27	interleukin 6	Mus musculus	73-77
29729431-11	2018	Coadministration of AM1241 (3 mg/kg) reduced the production of interleukin-1beta, tumor necrosis factor-alpha, and interleukin-6 induced by long-term and acute morphine treatment.	AM 1241	20-26	interleukin 6	Mus musculus	115-128
29729431-11	2018	Coadministration of AM1241 (3 mg/kg) reduced the production of interleukin-1beta, tumor necrosis factor-alpha, and interleukin-6 induced by long-term and acute morphine treatment.	Morphine	160-168	interleukin 6	Mus musculus	115-128
30071186-7	2018	RESULTS: We found that Dex exerted a potent anti-inflammatory effect by reducing the expression of M1 marker genes such as tumor necrosis factor alpha (P &lt; 0.05), interleukin-1beta (IL-1beta) (P &lt; 0.001) and IL-6 (P &lt; 0.001).	Dexmedetomidine	23-26	interleukin 6	Mus musculus	214-218
30323743-7	2018	Furthermore, EpoB treatment ameliorated 6-OHDA induced cytotoxicity to MN9D dopaminergic cells in a co-culture transwell system of BV2/MN9D cells, and redistributed the cytoskeleton of microglial BV2 and caused the morphological transition, inhibited the polarization to the M1 phenotype by suppressing expression of pro-inflammatory factors including interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha.	Oxidopamine	40-46	interleukin 6	Mus musculus	376-380
30344887-11	2018	Taraxasterol also significantly inhibited the secretion of proinflammatory cytokines TNF-alpha and IL-6 induced by ethanol.	taraxasterol	0-12	interleukin 6	Mus musculus	99-103
30333287-5	2018	Compared with the LPS group, sinomenine treatment could reduce the mRNA expression and release of TNF-alpha and IL-6, accompanied by increasess in green fluorescence aggregation of LC3 and HO-1 production (P&lt;0.05).	sinomenine	29-39	interleukin 6	Mus musculus	112-116
30333287-6	2018	HO-1 inhibitor Znpp could weaken the ability of sinomenine through suppressing TNF-alpha and IL-6 expression and decreasing the aggregation of LC3 green fluorescence (P&lt;0.05).	zinc protoporphyrin	15-19	interleukin 6	Mus musculus	93-97
30333287-6	2018	HO-1 inhibitor Znpp could weaken the ability of sinomenine through suppressing TNF-alpha and IL-6 expression and decreasing the aggregation of LC3 green fluorescence (P&lt;0.05).	sinomenine	48-58	interleukin 6	Mus musculus	93-97
30298072-10	2018	Simvastatin induced a greater activation and proliferation of CD4+ T cells, as well as an increase in IL-6 and MCP-1 production, in chemotaxis to the peritoneum and in H2O2 secretion at this site.	Simvastatin	0-11	interleukin 6	Mus musculus	102-106
30241424-8	2018	Of note, when given at the same concentrations, Ferrous Sulfate induced the expression of hepcidin and four different inflammatory markers (Socs3, Saa1, IL6 and CRP), while Sucrosomial  Iron did not.	ferrous sulfate	48-63	interleukin 6	Mus musculus	153-156
30344887-11	2018	Taraxasterol also significantly inhibited the secretion of proinflammatory cytokines TNF-alpha and IL-6 induced by ethanol.	Ethanol	115-122	interleukin 6	Mus musculus	99-103
30275707-7	2018	Meanwhile, the levels of TNF-alpha, IL-6, and MCP-1 in plasma were markedly suppressed in oldhamianoside-treated mice.	oldhamianoside	90-104	interleukin 6	Mus musculus	36-40
30160278-5	2018	Allicin inhibited interleukin-1beta (IL-1beta) induced overproduction of nitric oxide, inducible nitric oxide synthase, prostaglandin E2, and cyclooxygenase-2, as well as pro-inflammatory cytokines tumor necrosis factor alpha and interleukin-6 in chondrocytes in a dose-dependent manner.	allicin	0-7	interleukin 6	Mus musculus	230-243
30327715-7	2018	In addition, heightened inflammatory responses, demonstrated by the increased expression of proinflammatory factors (TNF-alpha, IL-1beta, and IL-6), in hippocampal and prefrontal cortex tissues of CRS mice were inhibited by THSG administration.	3-cresol	197-200	interleukin 6	Mus musculus	142-146
30327715-7	2018	In addition, heightened inflammatory responses, demonstrated by the increased expression of proinflammatory factors (TNF-alpha, IL-1beta, and IL-6), in hippocampal and prefrontal cortex tissues of CRS mice were inhibited by THSG administration.	thsg	224-228	interleukin 6	Mus musculus	142-146
30227623-5	2018	Besides, catalpol co-administrated with LPS increased BMECs survival, decreased their endothelin-1, TNF-Alpha and IL-6 secretion, improved transmembrane electrical resistance in a time-dependent manner, and in addition increased the fluorescein sodium permeability coefficient of BMECs.	lps	40-43	interleukin 6	Mus musculus	114-118
29937116-6	2018	LTG significantly inhibited basal and mitogen-induced IL-6, TNF-alpha and IL-1beta secretion in vivo and in LPS-treated RAW264.7 cells in vitro.	Lamotrigine	0-3	interleukin 6	Mus musculus	54-58
29944852-8	2018	The vitamin D treatments reduced the number of leukocytes in their BALF and they decreased the IL-6, IL-17, TGF-beta and MMP-9 levels and the abrogated collagenase deposits in their lung tissues.	Vitamin D	4-13	interleukin 6	Mus musculus	95-99
30017640-10	2018	Naringenin also significantly decreased elevated pro-inflammatory cytokines like IL-1beta, IL-6, TNF-alpha and NF-kbeta levels.	naringenin	0-10	interleukin 6	Mus musculus	91-95
29937116-7	2018	In PMs, LTG inhibited basal and LPS-induced IL-6 and TNF-alpha secretion.	Lamotrigine	8-11	interleukin 6	Mus musculus	44-48
30208590-7	2018	Post AD-Fish oil animals demonstrated a significant reduction of IL-6, C-X-C motif chemokine 9 (CXCL9), and IL-1beta compared to Post AD-CTL animals.	Oils	13-16	interleukin 6	Mus musculus	65-69
30073232-7	2018	Gene expression analysis of TNF-alpha, IL-6, COX-2, NF-kappaB, Bax and Caspase 3 suggested that pre-treatment with DHICA downregulates the above-mentioned genes and simultaneously upregulates Bcl2 expression.	5,6-dihydroxy-2-indolylcarboxylic acid	115-120	interleukin 6	Mus musculus	39-43
30208590-6	2018	RESULTS: Adenine mice exhibited significantly higher mean serum urea, creatinine, and renal expression of the pro-inflammatory markers Interleukin-6 (IL-6), C-X-C motif chemokine 10 (CXCL10), and Interleukin-1beta (IL-1beta), in addition to prominent renal fibrosis and reduced renal Klotho gene expression compared to the control.	Adenine	9-16	interleukin 6	Mus musculus	135-148
30201855-10	2018	In vitro studies using lipopolysaccharide-activated RAW264.7 cells showed that BPNPs inhibited cyclooxygenase-2, inducible nitric oxide (NO) synthase expression, and the production of proinflammatory mediators, including NO, tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta through suppressing the Toll-like receptor 4/NF-kappaB signaling pathway.	bpnps	79-84	interleukin 6	Mus musculus	254-267
30208590-6	2018	RESULTS: Adenine mice exhibited significantly higher mean serum urea, creatinine, and renal expression of the pro-inflammatory markers Interleukin-6 (IL-6), C-X-C motif chemokine 10 (CXCL10), and Interleukin-1beta (IL-1beta), in addition to prominent renal fibrosis and reduced renal Klotho gene expression compared to the control.	Adenine	9-16	interleukin 6	Mus musculus	150-154
30198495-5	2018	The levels of inflammatory factors, including interleukin-1 (IL1), IL6, IL8, and tumor necrosis factor-alpha (TNF-alpha), in lycopene-treated cells were also reduced by lycopene treatment.	Lycopene	125-133	interleukin 6	Mus musculus	67-70
30214381-2	2018	Results: MSO significantly reduced the production of Interleukin 6 (IL-6) and Tumor Necrosis Factor Alpha (TNFalpha) at 4 and 6 h after LPS-treatment.	Methionine Sulfoximine	9-12	interleukin 6	Mus musculus	53-66
30214381-2	2018	Results: MSO significantly reduced the production of Interleukin 6 (IL-6) and Tumor Necrosis Factor Alpha (TNFalpha) at 4 and 6 h after LPS-treatment.	Methionine Sulfoximine	9-12	interleukin 6	Mus musculus	68-72
30214381-6	2018	In agreement with this hypothesis, the L,R isomer of MSO, which does not inhibit glutamine synthetase and was previously thought to be inert, both significantly reduced IL-6 secretion in isolated macrophages and increased survival in a mouse model for inflammatory liver failure.	Methionine Sulfoximine	53-56	interleukin 6	Mus musculus	169-173
30237706-7	2018	Results: The nucleosides inhibited inflammatory mediator expression of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, and nitric oxide in both the CSE-stimulated RAW264.7 macrophages and mice.	Nucleosides	13-24	interleukin 6	Mus musculus	100-113
30198495-5	2018	The levels of inflammatory factors, including interleukin-1 (IL1), IL6, IL8, and tumor necrosis factor-alpha (TNF-alpha), in lycopene-treated cells were also reduced by lycopene treatment.	Lycopene	169-177	interleukin 6	Mus musculus	67-70
30092402-8	2018	RT-PCR analysis indicated that the miR-29 RNAs in CD11c+ DCs suppressed the production of interleukin-6 (IL-6), transforming growth factor beta (TGF-beta), and IL-23 subunits in DSS-treated mice.	Dextran Sulfate	178-181	interleukin 6	Mus musculus	90-103
30092402-8	2018	RT-PCR analysis indicated that the miR-29 RNAs in CD11c+ DCs suppressed the production of interleukin-6 (IL-6), transforming growth factor beta (TGF-beta), and IL-23 subunits in DSS-treated mice.	Dextran Sulfate	178-181	interleukin 6	Mus musculus	105-109
30189890-5	2018	RESULTS: Oral administration of arhalofenate (250 mg/kg) blunted total leukocyte ingress, neutrophil influx, and air pouch fluid interleukin (IL)-1beta, IL-6, and CXCL1 in response to MSU crystal injection (p &lt; 0.05 for each).	arhalofenate	32-44	interleukin 6	Mus musculus	153-157
29910099-7	2018	RESULTS: Dex significantly suppressed antigen-induced NHR, inflammatory cell infiltration, and IL-4, IL-5, IL-6, and IL-13 expression in immunized mice.	Dexamethasone	9-12	interleukin 6	Mus musculus	107-111
29940171-8	2018	Furthermore, when injected into mice with 5-HI, the expression of Nrf2 was significantly increased, and the LPS-induced mRNA expression of CXCL1, CCL2, TNFalpha, and IL-6 were remarkably inhibited in the kidneys, liver, and lungs, and the production of these cytokines in serum was effectively reduced.	5-hydroxyindole	42-46	interleukin 6	Mus musculus	166-170
29929056-0	2018	N-acetyl cysteine inhibits lipopolysaccharide-mediated induction of interleukin-6 synthesis in MC3T3-E1 cells through the NF-kB signaling pathway.	Acetylcysteine	0-17	interleukin 6	Mus musculus	68-81
29929056-5	2018	However, whether NAC can affect the LPS-mediated reduction of IL-6 synthesis in MC3T3-E1 cells is still unknown.	Acetylcysteine	17-20	interleukin 6	Mus musculus	62-66
29929056-6	2018	AIMS: The aim of this study was to investigate the role of NAC in the LPS -mediated reduction of IL-6 synthesis by MC3T3-E1 cells and to explore the underlying molecular mechanisms.	Acetylcysteine	59-62	interleukin 6	Mus musculus	97-101
29929056-7	2018	In addition, we aimed to determine the involvement of the NF-kB pathway in any changes in IL-6 expression observed in response to LPS and NAC.	Acetylcysteine	138-141	interleukin 6	Mus musculus	90-94
29929056-16	2018	CONCLUSION: NAC inhibits the LPS-mediated induction of IL-6 synthesis in MC3T3-E1 cells through the NF-kB pathway.	Acetylcysteine	12-15	interleukin 6	Mus musculus	55-59
29935959-6	2018	The data demonstrate that the activation of AhR by TCDD and beta-naphthoflavone (beta-NF) decreased protein levels of the pro-inflammatory cytokines TNF-alpha, IL-6 and IL-12 after macrophage activation with LPS/IFNgamma.	beta-Naphthoflavone	60-79	interleukin 6	Mus musculus	160-164
29935959-6	2018	The data demonstrate that the activation of AhR by TCDD and beta-naphthoflavone (beta-NF) decreased protein levels of the pro-inflammatory cytokines TNF-alpha, IL-6 and IL-12 after macrophage activation with LPS/IFNgamma.	beta-Naphthoflavone	81-88	interleukin 6	Mus musculus	160-164
29890468-8	2018	Calycosin treatment reversed the increased serum levels of amylase and lipase, alleviated the pathological damage in the pancreas, and decreased the levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-1beta in mice with AP.	7,3'-dihydroxy-4'-methoxyisoflavone	0-9	interleukin 6	Mus musculus	194-212
29721581-11	2018	Glycyrrhizin was found to significantly decrease the secretion of inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6).	Glycyrrhizic Acid	0-12	interleukin 6	Mus musculus	115-119
29966735-8	2018	OLA also influenced the expression of mRNA encoding pro-inflammatory cytokines (IL-1beta and IL-6) and some lipogenic genes (PPARalpha, SREBP1, FAS, ChREBP, and G6Pase) in liver and adipose tissue.	Oleanolic Acid	0-3	interleukin 6	Mus musculus	93-97
30271595-8	2018	After 6 days in 4 C, the IL6-/- mice exhibited significantly lower body temperature and oxygen consumption compared with Wt mice (P&lt;0.05).	Oxygen	88-94	interleukin 6	Mus musculus	25-28
29990699-11	2018	IFO 400 mg/kg significantly increased visceral hyperalgesia, bladder edema, hemorrhage, vascular permeability, MPO, IL-1beta and IL-6 tissue levels, and COX-2 immunostaining and expression versus the saline group (P &lt; 0.05).	Ifosfamide	0-3	interleukin 6	Mus musculus	129-133
30005227-7	2018	On the other hand, using chromatin immunoprecipitation assays, we demonstrated that cilostazol reduced the LPS-induced transcriptional activities of interleukin-6 and tumor necrosis factor-alpha by preventing the recruitment of NF-kappaB p65 to these gene promoters.	Cilostazol	84-94	interleukin 6	Mus musculus	149-194
30015238-4	2018	We found that SAU reduced the production of pro-inflammatory cytokines, such as nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor alpha (TNF-alpha), and IL-6.	sauchinone	14-17	interleukin 6	Mus musculus	169-173
30025384-5	2018	AST2017-01 and chrysophanol significantly suppressed the levels of histamine, immunoglobulin E, thymic stromal lymphopoietin (TSLP), interleukin (IL)-4, IL-6, and tumor necrosis factor-alpha in serum of AD mice.	chrysophanic acid	15-27	interleukin 6	Mus musculus	153-190
29775715-5	2018	Polysaccharide molecules obtained using Cellic CTec2 enzyme induced RAW264.7 murine macrophage cells to release considerable amount of inflammatory mediators including nitric oxide, IL-1beta, TNF-alpha, IL-6 and IL-10.	Polysaccharides	0-14	interleukin 6	Mus musculus	203-207
29921037-6	2018	Meanwhile, H2 inhibited the overexpression of MCP-1, E-selectin, P-selectin and ICAM-1 in oxidant-induced endothelia and reduced inflammatory cells infiltration and proinflammatory cytokines (TNF-alpha, IL-1, IL-6 and IL-8) production in the wound.	Hydrogen	11-13	interleukin 6	Mus musculus	209-213
28983699-7	2018	Teriparatide significantly inhibited the expression of IL-1beta, IL-6 and TNF-alpha in OVX mice in the early phase of the treatment, while the TRAP5b level in OVX mice was not significantly affected.	Teriparatide	0-12	interleukin 6	Mus musculus	65-69
28983699-8	2018	We demonstrated that the teriparatide-induced rapid improvement effect on pain-like behavior in OVX mice was associated with the downregulation of inflammatory cytokine expression, including IL-1beta, IL-6 and TNF-alpha.	Teriparatide	25-37	interleukin 6	Mus musculus	201-205
29374854-9	2018	RESULTS: PA elevated not only phosphorylation of JNK, IRS1 serines, and IKKalpha/beta, but also the expression of IL-6, TNFalpha and IL-1beta in C2C12-GLUT4myc cells.	Palmitic Acid	9-11	interleukin 6	Mus musculus	114-118
29761425-7	2018	In vitro phosphorylated-nuclear factor kappa-light-chain-enhancer of activated B cells and interleukin-6 were obviously reduced in the genistein treatment group compared with the LPS group in RAW 264.7 murine macrophage cells.	Genistein	135-144	interleukin 6	Mus musculus	91-104
30230981-7	2018	We observed that metformin prevented the stimulating effect of LPS on these chemokines as well as IL-1 and IL-6.	Metformin	17-26	interleukin 6	Mus musculus	107-111
29947589-13	2018	Furthermore, persistent hyperexcitability could be induced by incubation with inflammatory cytokine IL-6 and attenuated with cercosporamide, an inhibitor of the IL-6 sensitization pathway.	cercosporamide	125-139	interleukin 6	Mus musculus	161-165
29947589-9	2018	Acute responsiveness to IL-6 is inhibited by treatment with a MAPK-interacting kinase 1/2 inhibitor, cercosporamide.	cercosporamide	101-115	interleukin 6	Mus musculus	24-28
29248164-8	2018	RESULTS: At 10h after CS injection, serum cytokines IL-6 and IL-1beta in the WT mice were increased by 511- and 43-fold whereas in KO mice, these levels were increased by 166-fold and 22-fold, respectively.	Cesium	22-24	interleukin 6	Mus musculus	52-56
29991481-4	2018	Honokiol reduced glial cell activation and the production of proinflammatory cytokines (TNF-alpha, IL-1beta, and IL-6).	honokiol	0-8	interleukin 6	Mus musculus	113-117
29867078-3	2018	Next, treatments with fecal microbiota of ampicillin-treated mouse (FAP), K. oxytoca, or lipopolysaccharide isolated from K. oxytoca (KL) induced anxiety and colitis in mice and increased blood corticosterone, IL-6, and lipopolysaccharide levels.	Ampicillin	42-52	interleukin 6	Mus musculus	210-214
29867078-3	2018	Next, treatments with fecal microbiota of ampicillin-treated mouse (FAP), K. oxytoca, or lipopolysaccharide isolated from K. oxytoca (KL) induced anxiety and colitis in mice and increased blood corticosterone, IL-6, and lipopolysaccharide levels.	Kraft lignin	134-136	interleukin 6	Mus musculus	210-214
29846873-8	2018	Low PhA-concentrated DHA also decreased COX-2, IL-6, iNOS, GtPx, GtRd, and SOD-1 protein expression when compared to DHA (PhA:500).	Docosahexaenoic Acids	21-24	interleukin 6	Mus musculus	47-51
30200495-3	2018	GRh2 reduced LPS-induced proinflammatory mediator nitric oxide (NO), tumor necrosis factor-alpha, interleukin (IL)-1beta, and anti-inflammatory cytokines (IL-4, IL-6, and IL-10) production in lung tissues.	ginsenoside Rh2	0-4	interleukin 6	Mus musculus	161-165
29853120-9	2018	The cellular immune response test demonstrated the GO-PEG complex enhanced the secretion of IL-6, illustrating it was more stimulus towards macrophage cells.	go-peg	51-57	interleukin 6	Mus musculus	92-96
29876982-5	2018	Casticin decreased reactive oxygen species level and chemocytokines (IL-1beta, IL-6, TNF-alpha) productions in colon tissue.	casticin	0-8	interleukin 6	Mus musculus	79-83
29028769-7	2018	Oxygen-glucose deprivation/reperfusion (OGD/R) was used to make injury in cultured Caco-2 cells pretreated with FXR agonist (INT-747) or DL-propargylglycine (PAG) for 24 h. Cell viability and the expressions of NF-kappaB, TNF-alpha, and IL-6 were assessed.	oxygen-glucose	0-14	interleukin 6	Mus musculus	237-241
29678603-6	2018	Treatment with CA/CI/GA and the whole Triphala extract showed characteristic inhibition of MMP-9, cell proliferation/migration and tube formation as well the expression of IL-6, IL-8 and MCP-1 without affecting cell viability.	chebulinic acid	18-20	interleukin 6	Mus musculus	172-176
29678603-6	2018	Treatment with CA/CI/GA and the whole Triphala extract showed characteristic inhibition of MMP-9, cell proliferation/migration and tube formation as well the expression of IL-6, IL-8 and MCP-1 without affecting cell viability.	Gallic Acid	21-23	interleukin 6	Mus musculus	172-176
30463649-12	2018	Meanwhile, the number of infiltration of macrophages in mesenteric adipose tissues of mice treated with rosiglitazone and the levels of inflammatory mediators IL-6 and MCP-1 were significantly lower than that of the model group.	Rosiglitazone	104-117	interleukin 6	Mus musculus	159-163
30214410-6	2018	In addition, qPCR results showed that magnoflorine dose-dependently decreased the expression of pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6.	magnoflorine	38-50	interleukin 6	Mus musculus	148-152
30186314-9	2018	Rises in IFN-gamma, TNF-alpha and IL-6 were detected at 9 dpi in all infected animals as compared to uninfected mice but only Bz displayed a statistically significant diminution (p = 0.02) in TNF-alpha levels than infected and untreated mice.	3-aminodiphenyleneiodium	58-61	interleukin 6	Mus musculus	34-38
30210234-15	2018	Conclusion: These results demonstrated that a combinatory treatment strategy of nadroparin with fractionated irradiation had a strong synergistic antitumor effect in vivo, which may be associated with the promotion of apoptosis, inhibited secretion of TGF-beta1 and IL-6 and down-regulation of CD34 and survivin expression.	Nadroparin	80-90	interleukin 6	Mus musculus	266-270
30384540-12	2018	In astragaloside IV prevention group and astragaloside IV treatment group, the injury of affected kidney was obviously reduced, and the protein expression levels of TLR4/MyD88 dependent signaling pathway-related molecules were also correspondingly reduced; at the same time, the expressions of terminal inflammatory cytokines (TNF-alpha,IL-6, IFN-gamma) were suppressed.	astragaloside	3-16	interleukin 6	Mus musculus	337-341
30384540-12	2018	In astragaloside IV prevention group and astragaloside IV treatment group, the injury of affected kidney was obviously reduced, and the protein expression levels of TLR4/MyD88 dependent signaling pathway-related molecules were also correspondingly reduced; at the same time, the expressions of terminal inflammatory cytokines (TNF-alpha,IL-6, IFN-gamma) were suppressed.	astragaloside	41-54	interleukin 6	Mus musculus	337-341
30384540-13	2018	Therefore, astragaloside IV may improve renal interstitial fibrosis in mice after IRI by inhibiting the expression of TLR4/MyD88 dependent signaling pathway and the release of inflammatory cytokines (TNF-alpha,IL-6, IFN-gamma), while the TLR4/MyD88 independent signaling pathway may not be involved in the process of renal fibrosis after ischemia-reperfusion injury.	astragaloside	11-24	interleukin 6	Mus musculus	210-214
30220965-5	2018	Cell density-dependent MMP regulation can be directly targeted by the simultaneous inhibition of IL-6 and IL-8 receptors via Tocilizumab and Reparixin to significantly decrease the expression of MMPs in mouse xenograft models and decrease effective metastasis.	reparixin	141-150	interleukin 6	Mus musculus	97-101
30190704-4	2018	Moreover, the administration of 0.5% l-serine decreased the concentrations of leptin, malondialdehyde, interleukin-1beta, and interleukin-6, while it increased those of superoxide dismutase and glutathione, in both the serum and hypothalamus.	Serine	37-45	interleukin 6	Mus musculus	126-139
30134985-12	2018	RESULTS: IL-6 and IL-1beta levels were decreased by 250 mug/ml cefazolin in the LPS-stimulated C8-B4 cells.	Cefazolin	63-72	interleukin 6	Mus musculus	9-13
30134985-17	2018	Cefazolin treatment for 5 days in mice without surgery induced colon dysbiosis and increased IL-6 and IL-1beta in the colon and IL-1beta in the cerebral cortex.	Cefazolin	0-9	interleukin 6	Mus musculus	93-97
30186829-7	2018	In a limited study, the amide induced a &gt;5-fold production of the anti-inflammatory cytokine IL-10 over untreated naive mice and minor increases in the anti-inflammatory IL-4 and pro-inflammatory cytokines TNF-alpha and IL-6, in blood.	Amides	24-29	interleukin 6	Mus musculus	223-227
30126158-5	2018	KM1608 significantly inhibited the inflammatory mediators such as nitric oxide, interleukin (IL)-6, monocyte chemotactic protein 1 (MCP-1) and tumor necrosis factor (TNF)-alpha in LPS-treated RAW264.7 cells.	km1608	0-6	interleukin 6	Mus musculus	80-98
30186862-6	2018	Sitagliptin decreased the levels of proinflammatory factors: TNF-alpha (tumor necrosis factor-alpha), IL-6 (interleukin-6), IL-17 (interleukin-17), and CD-163 (cluster of differentiation 163), and contributed to an increase in levels of anti-inflammatory factors: IL-10 (interleukin-10) and TGF-beta (transforming growth factor beta).	Sitagliptin Phosphate	0-11	interleukin 6	Mus musculus	102-106
30126158-7	2018	In the mouse model, oral administration of KM1608 significantly improved DSS-induced colitis symptoms, such as disease activity index (DAI), colon length, and colon weight, as well as suppressed the expression of IL-6, TNF-alpha, and myeloperoxidase (MPO) in the DSS-induced colitis tissues.	km1608	43-49	interleukin 6	Mus musculus	213-217
30186862-6	2018	Sitagliptin decreased the levels of proinflammatory factors: TNF-alpha (tumor necrosis factor-alpha), IL-6 (interleukin-6), IL-17 (interleukin-17), and CD-163 (cluster of differentiation 163), and contributed to an increase in levels of anti-inflammatory factors: IL-10 (interleukin-10) and TGF-beta (transforming growth factor beta).	Sitagliptin Phosphate	0-11	interleukin 6	Mus musculus	108-121
30126158-7	2018	In the mouse model, oral administration of KM1608 significantly improved DSS-induced colitis symptoms, such as disease activity index (DAI), colon length, and colon weight, as well as suppressed the expression of IL-6, TNF-alpha, and myeloperoxidase (MPO) in the DSS-induced colitis tissues.	dss	73-76	interleukin 6	Mus musculus	213-217
30210674-5	2018	The levels of tumor necrosis factor alpha, interleukin 1 beta, and interleukin 6, as well as total protein and Evans blue concentrations, were all significantly reduced in bronchoalveolar lavage fluid from mice treated with rivaroxaban.	Rivaroxaban	224-235	interleukin 6	Mus musculus	67-80
29856968-6	2018	In an AR animal model, ABT-737 significantly diminished clinical symptoms of AR and the levels of AR biomarkers, specifically IgE, histamine, hypoxia-inducible factor-1alpha, VEGF, TSLP, IL-1beta, IL-4, IL-5, IL-6, IL-13, TNF-alpha, intercellular adhesion molecule-1, and macrophage inflammatory protein-2.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	23-26	interleukin 6	Mus musculus	209-213
30135658-7	2018	Pharmacological inhibition of FABP4 by a highly selective inhibitor BMS309403 significantly reduced serum creatinine level, proinflammatory cytokine mRNA expression of tumor necrosis factor-alpha, interleukin-6, and monocyte chemoattractant protein 1 as well as attenuated renal tubular damage in glycerol-injured kidneys.	2-(2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy)acetic acid	68-77	interleukin 6	Mus musculus	197-210
30110942-7	2018	AS-IV was found to reverse the APAP-induced increased amounts of pro-inflammatory cytokines, including interleukin 1beta (IL-1beta), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha).	Acetaminophen	31-35	interleukin 6	Mus musculus	133-146
30110942-7	2018	AS-IV was found to reverse the APAP-induced increased amounts of pro-inflammatory cytokines, including interleukin 1beta (IL-1beta), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha).	Acetaminophen	31-35	interleukin 6	Mus musculus	148-152
29727734-8	2018	Moreover, all the isolates except daidzein dimethylether prevented the interleukin IL-6 production in 3T3-L1 cells.	daidzein dimethylether	34-56	interleukin 6	Mus musculus	83-87
30058806-5	2018	Levels of cytokines, including interleukin (IL)-1beta, IL-17, IL-4, IL-6, tumor necrosis factor-alpha, and interferon-gamma, were also reduced after Nob and 5-HPMF treatment.	nobiletin	149-152	interleukin 6	Mus musculus	68-72
30058806-5	2018	Levels of cytokines, including interleukin (IL)-1beta, IL-17, IL-4, IL-6, tumor necrosis factor-alpha, and interferon-gamma, were also reduced after Nob and 5-HPMF treatment.	5-hydroxy-6,7,8,3',4'-pentamethoxyflavone	157-163	interleukin 6	Mus musculus	68-72
29580144-5	2018	Naringin attenuated the severity of colitis and colorectal adenomas through inhibiting myeloid-derived suppressor cells (MDSCs), pro-inflammatory mediators GM-CSF/M-CSF, IL-6 and TNF-alpha and the NF-kappaB/IL-6/STAT3 cascades in colorectal tissues.	naringin	0-8	interleukin 6	Mus musculus	170-174
30075804-7	2018	RESULTS: OLT1177 reduced zymosan-induced joint swelling (p &lt; 0.001), cell influx (p &lt; 0.01), and synovial levels of interleukin (IL)-1beta, IL-6, and chemokine (C-X-C motif) ligand 1 (CXCL1) (p &lt; 0.05), respectively, when compared with vehicle-treated mice.	Zymosan	25-32	interleukin 6	Mus musculus	146-150
29580144-5	2018	Naringin attenuated the severity of colitis and colorectal adenomas through inhibiting myeloid-derived suppressor cells (MDSCs), pro-inflammatory mediators GM-CSF/M-CSF, IL-6 and TNF-alpha and the NF-kappaB/IL-6/STAT3 cascades in colorectal tissues.	naringin	0-8	interleukin 6	Mus musculus	207-211
29746822-5	2018	Tabersonine also inhibited LPS-mediated neutrophil infiltration, elevation of MPO activity and the production of TNF-alpha, IL-6 and IL-1beta.	tabersonine	0-11	interleukin 6	Mus musculus	124-128
29772435-5	2018	Aliskiren had anti-inflammatory effects by reducing levels of tumor necrosis factor-alpha and interleukin -6, and by inhibiting myeloperoxidase activity.	aliskiren	0-9	interleukin 6	Mus musculus	94-108
29740932-4	2018	PPARgamma antagonist T0070907 increased the expression of M2 markers, including CD206, IL-4, IGF-1, TGF-beta1, TGF-beta2, TGF-beta3, G-CSF, and GM-CSF, and reduced the expression of M1 markers, such as CD86, Cox-2, iNOS, IL-1beta, IL-6, TNF-alpha, IFN-gamma, and CCL2, thereby inhibiting NFkappaB-IKKbeta activation.	T 0070907	21-29	interleukin 6	Mus musculus	231-235
29787986-15	2018	We found that ASTF significantly inhibited the production of NO, PGE2, TNF-alpha, IL-6, MCP-1 and reactive oxygen species (ROS) in LPS-stimulated RAW 264.7 cells.	astf	14-18	interleukin 6	Mus musculus	82-86
29730778-2	2018	Hepcidin (Hpc), a main iron metabolism regulator, is synthetized by an IL-6 stimuli, among others, in liver and adipose tissue, favoring an association between the inflammatory process and iron metabolism.	Iron	23-27	interleukin 6	Mus musculus	71-75
29730778-2	2018	Hepcidin (Hpc), a main iron metabolism regulator, is synthetized by an IL-6 stimuli, among others, in liver and adipose tissue, favoring an association between the inflammatory process and iron metabolism.	Iron	189-193	interleukin 6	Mus musculus	71-75
29730778-8	2018	Thus, we showed that combined high glucose/high Fe alone or with MCM may contribute to an increase on intracellular iron and inflammatory response in 3T3-L1 differentiated cells, by increased mRNA levels of IL-6, TNF-alpha, MCP-1, Hpc and reducing adiponectin levels, enhancing the inflammatory processes.	Glucose	35-42	interleukin 6	Mus musculus	207-211
29730778-8	2018	Thus, we showed that combined high glucose/high Fe alone or with MCM may contribute to an increase on intracellular iron and inflammatory response in 3T3-L1 differentiated cells, by increased mRNA levels of IL-6, TNF-alpha, MCP-1, Hpc and reducing adiponectin levels, enhancing the inflammatory processes.	Iron	48-50	interleukin 6	Mus musculus	207-211
29859833-7	2018	In addition, co-administration of the mTOR activator 3BDO but not the sirtuin 1 inhibitor EX-527 abolished the effects of metformin on IL-6 induction and pulmonary lesions.	Metformin	122-131	interleukin 6	Mus musculus	135-139
29579546-9	2018	The expression of CD68 kupffer cell and its relative cytokine, including IL-6 and TNF-alpha, increased in TCE sensitization-positive mice and decreased in R715 pretreatment TCE sensitization-positive mice.	Trichloroethylene	106-109	interleukin 6	Mus musculus	73-77
29859833-4	2018	The results indicated that treatment with metformin suppressed LPS-induced upregulation of IL-6 and TNF-alpha, alleviated pulmonary histological abnormalities, improved the survival rate of LPS-challenged mice.	Metformin	42-51	interleukin 6	Mus musculus	91-95
29579546-9	2018	The expression of CD68 kupffer cell and its relative cytokine, including IL-6 and TNF-alpha, increased in TCE sensitization-positive mice and decreased in R715 pretreatment TCE sensitization-positive mice.	Trichloroethylene	173-176	interleukin 6	Mus musculus	73-77
29578616-7	2018	Attenuation of neuroinflammation may be involved in the antidepressant-like effect of TUDCA, as TUDCA treatment (200 mg/kg) normalized the levels of tumor necrosis factor-alpha and interleukin-6 in both hippocampus and prefrontal cortex.	ursodoxicoltaurine	86-91	interleukin 6	Mus musculus	181-194
29674211-8	2018	Exposure to PCBs also resulted in higher body fat percentage, greater size of abdominal subcutaneous adipocytes and increased expression of proinflammatory cytokines including TNF-alpha, iNOS and IL-6.	Polychlorinated Biphenyls	12-16	interleukin 6	Mus musculus	196-200
29883518-7	2018	ONX-0914 alleviated inflammation (CCL3, CXCL1, PTGS2, and IL-6) in myometrium, placenta, fetal brain, amniotic fluid, and maternal serum induced by LPS in pregnant mice.	PR-957	0-8	interleukin 6	Mus musculus	58-62
29578616-7	2018	Attenuation of neuroinflammation may be involved in the antidepressant-like effect of TUDCA, as TUDCA treatment (200 mg/kg) normalized the levels of tumor necrosis factor-alpha and interleukin-6 in both hippocampus and prefrontal cortex.	ursodoxicoltaurine	96-101	interleukin 6	Mus musculus	181-194
29656318-6	2018	Of the eight imidazoles tested, methyl 1-allyl-2-(4-fluorophenyl)-5-phenyl-1H-imidazole-4-acetate (8) inhibited nitric oxide metabolites and pro-inflammatory cytokine (TNF-alpha, IL-6, and IL-1beta) secretion in J774 macrophages stimulated with LPS.	Imidazoles	13-23	interleukin 6	Mus musculus	179-183
29616391-6	2018	Moreover, these sesquiterpenes also attenuated the mRNA expression of pro-inflammatory cytokines including interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha) in LPS-induced BV2 microglial cells.	Sesquiterpenes	16-30	interleukin 6	Mus musculus	137-141
29656318-6	2018	Of the eight imidazoles tested, methyl 1-allyl-2-(4-fluorophenyl)-5-phenyl-1H-imidazole-4-acetate (8) inhibited nitric oxide metabolites and pro-inflammatory cytokine (TNF-alpha, IL-6, and IL-1beta) secretion in J774 macrophages stimulated with LPS.	methyl 1-allyl-2-(4-fluorophenyl)-5-phenyl-1h-imidazole-4-acetate	32-97	interleukin 6	Mus musculus	179-183
29656318-6	2018	Of the eight imidazoles tested, methyl 1-allyl-2-(4-fluorophenyl)-5-phenyl-1H-imidazole-4-acetate (8) inhibited nitric oxide metabolites and pro-inflammatory cytokine (TNF-alpha, IL-6, and IL-1beta) secretion in J774 macrophages stimulated with LPS.	Nitric Oxide	112-124	interleukin 6	Mus musculus	179-183
29778842-10	2018	Furthermore, the secretion of plasma TNF-alpha and IL-6 was notably inhibited in septic mice treated with curcumin and administration with curcumin could improve survival after CLP.	Curcumin	139-147	interleukin 6	Mus musculus	51-55
29778842-10	2018	Furthermore, the secretion of plasma TNF-alpha and IL-6 was notably inhibited in septic mice treated with curcumin and administration with curcumin could improve survival after CLP.	Curcumin	106-114	interleukin 6	Mus musculus	51-55
29933193-4	2018	Independent of this, treatment with miRNA-200b obviously attenuated inflammatory responses, as indicated by down-regulating tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta) and blockade of AKT2-mediated NF-kappaB/IL-6/STAT3 signaling pathway.	mirna-200b	36-46	interleukin 6	Mus musculus	248-252
29890414-7	2018	The NF-kappaB inhibitor JSH-23 and JNK-specific inhibitor SP600125 significantly decreased NO production and IL-6 release in LPS-stimulated BV2 cells, respectively.	pyrazolanthrone	58-66	interleukin 6	Mus musculus	109-113
31949780-10	2018	We found that simvastatin treatment could significantly inhibit inflammation by modulating the expression of mediators, such as IL-1beta, TNF-alpha and IL-6, whose expression were increased remarkably in the activated RAW264.7 cells.	Simvastatin	14-25	interleukin 6	Mus musculus	152-156
29805067-0	2018	The synergistic effects of IL-6/IL-17A promote osteogenic differentiation by improving OPG/RANKL ratio and adhesion of MC3T3-E1 cells on hydroxyapatite.	Durapatite	137-151	interleukin 6	Mus musculus	27-31
29626760-4	2018	More importantly, CDs-RTB can promote macrophages proliferation, improve the generation of NO, IL-6 and TNF-alpha in RAW264.7 cells and increase the expression of mRNA, indicating the enhanced immunomodulatory activity of CDs-RTB.	cds-rtb	18-25	interleukin 6	Mus musculus	95-99
29753615-8	2018	Irbesartan administration to DOX-treated mice induced significant decrease in serum ALT, AST, ALP, total bilirubin, tissue TGF-beta1, TNF-alpha, IL-6 and liver weight/body weight ratio associated with significant increase in food intake, serum albumin, tissue Nrf2/HO-1 content, STAT-3 and antioxidant enzymes and significant improvement in the histopathological picture compared to DOX group.	Irbesartan	0-10	interleukin 6	Mus musculus	145-149
29753615-8	2018	Irbesartan administration to DOX-treated mice induced significant decrease in serum ALT, AST, ALP, total bilirubin, tissue TGF-beta1, TNF-alpha, IL-6 and liver weight/body weight ratio associated with significant increase in food intake, serum albumin, tissue Nrf2/HO-1 content, STAT-3 and antioxidant enzymes and significant improvement in the histopathological picture compared to DOX group.	Doxorubicin	29-32	interleukin 6	Mus musculus	145-149
29505662-0	2018	Exogenous melatonin protects small-for-size liver grafts by promoting monocyte infiltration and releases interleukin-6.	Melatonin	10-19	interleukin 6	Mus musculus	105-118
29505662-11	2018	In the IR+exPH and SFS-LT groups, inhibition of the IL6 co-receptor GP130 through SC144 abolished the beneficial effects of MLT.	SC 144	82-87	interleukin 6	Mus musculus	52-55
29787542-11	2018	RESULTS: In the THFx group, a decreased bone formation after 3 weeks, a reduction of both bone and cartilage after 2 weeks, and an enhanced activation of the RANKL/OPG and IL6 signaling pathway after 1 week were shown in comparison to Fx.	thfx	16-20	interleukin 6	Mus musculus	172-175
29885599-5	2018	We found that naringenin dose-dependently suppressed anti-CD3/CD28 and MOG35-55-induced T cell proliferation, production of T cell cytokines IFN-gamma, IL-17, IL-6 and TNF-alpha.	naringenin	14-24	interleukin 6	Mus musculus	159-163
29368095-4	2018	Pre-treatment of RAW 264.7 cells with FAD suppressed LPS-stimulated mRNA expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFalpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1beta) and thereby reduced the respective protein levels.	falcarindiol	38-41	interleukin 6	Mus musculus	167-180
29861060-2	2018	Mice with folic acid-induced AKI had an increase in bone FGF23 mRNA expression together with an increase in serum FGF23 and several circulating cytokines including interleukin-6 (IL-6).	Folic Acid	10-20	interleukin 6	Mus musculus	164-177
29861060-2	2018	Mice with folic acid-induced AKI had an increase in bone FGF23 mRNA expression together with an increase in serum FGF23 and several circulating cytokines including interleukin-6 (IL-6).	Folic Acid	10-20	interleukin 6	Mus musculus	179-183
29861060-3	2018	Dexamethasone partially prevented the increase in IL-6 and FGF23 in the AKI mice.	Dexamethasone	0-13	interleukin 6	Mus musculus	50-54
29861060-4	2018	IL-6 knock-out mice fed an adenine diet to induce CKD failed to increase bone FGF23 mRNA and had a muted increase in serum FGF23 levels, compared with the increases in wild-type mice with CKD.	Adenine	27-34	interleukin 6	Mus musculus	0-4
29901197-14	2018	IHC demonstrated that the expression of IL-6 and TGF-beta was significantly downregulated in the CXCL9+DMAB mice.	2',3-dimethyl-4-aminobiphenyl	103-107	interleukin 6	Mus musculus	40-44
29368095-4	2018	Pre-treatment of RAW 264.7 cells with FAD suppressed LPS-stimulated mRNA expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFalpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1beta) and thereby reduced the respective protein levels.	falcarindiol	38-41	interleukin 6	Mus musculus	182-186
29956762-7	2018	Results indicated that rCC16 treatment ameliorated pathological damage in the lungs and reduced the production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-8, which were induced by CS exposure.	Cesium	200-202	interleukin 6	Mus musculus	149-167
29916550-9	2018	EGCG 20 mg/kg significantly reduced asthmatic symptoms, lung inflammatory cell infiltration, and the inflammatory factor levels of interleukin (IL)-2, IL-6 and tumor necrosis factor (TNF)-alpha.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	151-155
29787738-0	2018	Altered brain activity during withdrawal from chronic alcohol is associated with changes in IL-6 signal transduction and GABAergic mechanisms in transgenic mice with increased astrocyte expression of IL-6.	Alcohols	54-61	interleukin 6	Mus musculus	92-96
29787738-0	2018	Altered brain activity during withdrawal from chronic alcohol is associated with changes in IL-6 signal transduction and GABAergic mechanisms in transgenic mice with increased astrocyte expression of IL-6.	Alcohols	54-61	interleukin 6	Mus musculus	200-204
29787738-1	2018	Interleukin-6 (IL-6) is an important neuroimmune factor that is increased in the brain by alcohol exposure/withdrawal and is thought to play a role in the actions of alcohol on the brain.	Alcohols	90-97	interleukin 6	Mus musculus	0-13
29787738-1	2018	Interleukin-6 (IL-6) is an important neuroimmune factor that is increased in the brain by alcohol exposure/withdrawal and is thought to play a role in the actions of alcohol on the brain.	Alcohols	90-97	interleukin 6	Mus musculus	15-19
29787738-1	2018	Interleukin-6 (IL-6) is an important neuroimmune factor that is increased in the brain by alcohol exposure/withdrawal and is thought to play a role in the actions of alcohol on the brain.	Alcohols	166-173	interleukin 6	Mus musculus	0-13
29787738-1	2018	Interleukin-6 (IL-6) is an important neuroimmune factor that is increased in the brain by alcohol exposure/withdrawal and is thought to play a role in the actions of alcohol on the brain.	Alcohols	166-173	interleukin 6	Mus musculus	15-19
29787738-3	2018	IL-6/alcohol/withdrawal interactions were identified by genotypic differences in spontaneous brain activity in electroencephalogram (EEG) recordings from the mice, and by Western blot analysis of protein activation or expression in hippocampus obtained from the mice after the final alcohol withdrawal period.	Alcohols	283-290	interleukin 6	Mus musculus	0-4
30384867-15	2018	What"s more, the number of macrophages, the polarization level of M1 macrophages, and the levels of the iconic inflammatory factors IL-6 and IL-12 significantly decreased in IL-16-/- DSS treatment group compared with WT DSS treatment group.	Dextran Sulfate	183-186	interleukin 6	Mus musculus	132-136
29783162-6	2018	Brief extinction training with 12 CS rapidly and acutely increased circulating levels of the cytokine interleukin-6 (IL-6), downstream IL-6 signaling, other IL-6 related pro-inflammatory cytokines.	Cesium	34-36	interleukin 6	Mus musculus	102-115
29783162-6	2018	Brief extinction training with 12 CS rapidly and acutely increased circulating levels of the cytokine interleukin-6 (IL-6), downstream IL-6 signaling, other IL-6 related pro-inflammatory cytokines.	Cesium	34-36	interleukin 6	Mus musculus	117-121
29783162-6	2018	Brief extinction training with 12 CS rapidly and acutely increased circulating levels of the cytokine interleukin-6 (IL-6), downstream IL-6 signaling, other IL-6 related pro-inflammatory cytokines.	Cesium	34-36	interleukin 6	Mus musculus	135-139
29783162-6	2018	Brief extinction training with 12 CS rapidly and acutely increased circulating levels of the cytokine interleukin-6 (IL-6), downstream IL-6 signaling, other IL-6 related pro-inflammatory cytokines.	Cesium	34-36	interleukin 6	Mus musculus	135-139
29783162-9	2018	In addition to effectively diminishing conditioned freezing, extinction training with 40 CS also diminished the subsequent IL-6 response to the CS.	Cesium	89-91	interleukin 6	Mus musculus	123-127
29783162-9	2018	In addition to effectively diminishing conditioned freezing, extinction training with 40 CS also diminished the subsequent IL-6 response to the CS.	Cesium	144-146	interleukin 6	Mus musculus	123-127
30187873-5	2018	RESULTS: DEX alleviated the inflammatory response and reduced the mRNA expressions of IL-6, TNF- a, MCP-1 andICAM-1 at 24 h after LPS injection.	Dexamethasone	9-12	interleukin 6	Mus musculus	86-90
29969892-6	2018	Furthermore, compared with no treatment, pretreatment with theanine significantly decreased the release of interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha, inhibited the expression of several inflammatory factors (including IL-1beta, TNF-alpha, and IL-6), and increased the IL-10/interferon (IFN)-gamma ratio in the hepatic tissues.	theanine	59-67	interleukin 6	Mus musculus	262-266
30060484-5	2018	Treatment with DA inhibited the activation of MAP kinases and the translocation of NFkappaB, and decreased the expression and exogenous secretion of IL-1beta and IL-6.	decursin	15-17	interleukin 6	Mus musculus	162-166
30060484-9	2018	Treatment with DA also inhibited the expression of pro-inflammatory cytokines, such as IL-1beta and IL-6, NOX, and iNOS in Raw 264.7 cells.	decursin	15-17	interleukin 6	Mus musculus	100-104
30049950-5	2018	The results showed that OEO (2.5-10 mug/mL) inhibited the expression and secretion of interleukin-1 beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in RAW264.7 cells treated with LPS (1 mug/mL).	oeo	24-27	interleukin 6	Mus musculus	117-130
30049950-5	2018	The results showed that OEO (2.5-10 mug/mL) inhibited the expression and secretion of interleukin-1 beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in RAW264.7 cells treated with LPS (1 mug/mL).	oeo	24-27	interleukin 6	Mus musculus	132-136
30049950-7	2018	Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibition in Nox2 protein-silenced cells attenuated the mRNA expression of IL-1beta, IL-6, and TNF-alpha in the LPS-induced RAW264.7 cells.	NADP	0-43	interleukin 6	Mus musculus	146-150
30090104-14	2018	Moreover, decreased expression of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta and inhibition of NF-kappaB and STAT pathways were found in EAU mice following TCDD treatment.	Polychlorinated Dibenzodioxins	180-184	interleukin 6	Mus musculus	82-86
29844241-8	2018	Finally, we found that TPL2 inhibition by a specific inhibitor or TPL2 gene ablation significantly reduced TcdB-induced production of TNF-alpha, IL-6, IL-beta, and KC by inhibiting the activation of p38, extracellular signal-regulated kinase (ERK), and c-Jun NH2-terminal kinase (JNK).	trimethylaminocarboxyldihydroboran	107-111	interleukin 6	Mus musculus	145-149
30072984-8	2018	Furthermore, IL-6 serves as an important indirect factor in mediating the expansion of G-MDSCs populations after acute ethanol exposure.	Ethanol	119-126	interleukin 6	Mus musculus	13-17
30083161-5	2018	After blocking the IL-6/STAT3 signaling pathway with the IL-6 receptor antibody or STAT3 antagonist JSI-124 in tumor-bearing mice, significant shrinkage of primary tumors and decrease in lung metastatic nodules were observed in vivo, accompanied by the dramatic decrease of e-MDSC recruitment and recovery of anti-tumor T cell immunity.	cucurbitacin I	100-107	interleukin 6	Mus musculus	19-23
30030497-7	2018	Furthermore, we demonstrate that Ang II-upregulated expression of IL-6, Tnf-alpha, IL-1beta and Tgf-beta1 is significantly attenuated in the mice treated with AS605240.	5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione	159-167	interleukin 6	Mus musculus	66-70
30016332-9	2018	Expression of the Bank1 and Nfkb1 genes and their downstream target genes involved in the intracellular pathway (Tlr9, Il6, Tnf) was investigated in mercury-exposed A.SW and B10.S mice by real-time PCR.	Mercury	149-156	interleukin 6	Mus musculus	119-122
30116260-4	2018	The levels of hepatic necrosis, apoptosis, and autophagy associated with inflammatory cytokines were measured at 2, 8, and 24 h. Results: Fucosterol attenuated serum liver enzyme levels and hepatic necrosis and apoptosis induced by TNF-alpha, IL-6, and IL-1beta.	fucosterol	138-148	interleukin 6	Mus musculus	243-247
29668250-6	2018	Furthermore, baicalein significantly inhibited the release of proinflammatory cytokines such as interleukin-6 (IL-6), interleukin-1 beta (IL-1beta), and tumor necrosis factor-alpha (TNF-alpha) in the brain cortex of SAMP8 mice.	baicalein	13-22	interleukin 6	Mus musculus	96-109
29668250-6	2018	Furthermore, baicalein significantly inhibited the release of proinflammatory cytokines such as interleukin-6 (IL-6), interleukin-1 beta (IL-1beta), and tumor necrosis factor-alpha (TNF-alpha) in the brain cortex of SAMP8 mice.	baicalein	13-22	interleukin 6	Mus musculus	111-115
30093935-7	2018	We determine that RSV administration inhibited the increased production of TNF-alpha, IL-6, and IL-1beta in LPS-stimulated MH-S cells, which was associated with inhibition of the nuclear factor-kappaB, P38, and ERK signaling pathways.	Resveratrol	18-21	interleukin 6	Mus musculus	86-90
30093945-7	2018	Following celastrol pretreatment, mice showed increased mortality rate and aggravated inflammation evidenced by further enhanced inflammatory markers of IL-6, IL-1beta, TNF-alpha, IL-18, MCP-1, and ICAM-1 in circulation, liver, and kidney after LPS treatment.	celastrol	10-19	interleukin 6	Mus musculus	153-157
29572139-2	2018	PCP-dosed mice were used to conducting biochemical assays of serological liver enzyme (ALT), lactate dehydrogenase (LD), inflammatory cytokines (TNF-alpha, IL-6), and immunoassays for functional proteins in the livers.	pcp	0-3	interleukin 6	Mus musculus	156-160
29572139-3	2018	Consequently, APAP-exposed mice resulted in elevated levels of ALT, LD, TNF-alpha, IL-6 in sera.	Acetaminophen	14-18	interleukin 6	Mus musculus	83-87
30005655-8	2018	Leukocyte counts and the levels of IgE, IL-6, IL-10 and IL-12 were decreased in the blood of the DNCB-treated mice.	Dinitrochlorobenzene	97-101	interleukin 6	Mus musculus	40-44
30011811-7	2018	We found that Farrerol observably reduced the production of inflammatory mediators including IL-1beta, IL-6, TNF-alpha, COX-2, and iNOS in LPS-induced RAW264.7 cells via suppressing AKT, ERK1/2, JNK1/2, and NF-kappaB p65 phosphorylation.	farrerol	14-22	interleukin 6	Mus musculus	103-107
30002289-4	2018	ASP and ASPA significantly decreased the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in parallel with the inhibition of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-alpha, and IL-6 mRNA expression in LPS-induced RAW 264.7 cells.	asperuloside	0-3	interleukin 6	Mus musculus	144-157
29792864-2	2018	In the present study, we found that delavatine A substantially suppressed the LPS-induced pro-inflammatory mediators, nitric oxide (NO), and tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), interleukin-1beta (IL-1beta) in BV-2 microglial cells.	delavatine A	36-48	interleukin 6	Mus musculus	174-187
29792864-2	2018	In the present study, we found that delavatine A substantially suppressed the LPS-induced pro-inflammatory mediators, nitric oxide (NO), and tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), interleukin-1beta (IL-1beta) in BV-2 microglial cells.	delavatine A	36-48	interleukin 6	Mus musculus	189-193
30002289-4	2018	ASP and ASPA significantly decreased the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in parallel with the inhibition of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-alpha, and IL-6 mRNA expression in LPS-induced RAW 264.7 cells.	asperuloside	0-3	interleukin 6	Mus musculus	159-163
30002289-4	2018	ASP and ASPA significantly decreased the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in parallel with the inhibition of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-alpha, and IL-6 mRNA expression in LPS-induced RAW 264.7 cells.	asperuloside	0-3	interleukin 6	Mus musculus	281-285
30002289-4	2018	ASP and ASPA significantly decreased the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in parallel with the inhibition of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-alpha, and IL-6 mRNA expression in LPS-induced RAW 264.7 cells.	asperulosidic acid	8-12	interleukin 6	Mus musculus	144-157
30002289-4	2018	ASP and ASPA significantly decreased the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in parallel with the inhibition of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-alpha, and IL-6 mRNA expression in LPS-induced RAW 264.7 cells.	asperulosidic acid	8-12	interleukin 6	Mus musculus	159-163
30002289-4	2018	ASP and ASPA significantly decreased the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in parallel with the inhibition of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-alpha, and IL-6 mRNA expression in LPS-induced RAW 264.7 cells.	asperulosidic acid	8-12	interleukin 6	Mus musculus	281-285
29742623-7	2018	Propofol application also decreased LPS-induced Cox-2, IL-6, iNOS, TNF-alpha, and IL-1beta mRNA expression and induced significant protein kinase B (PKB) phosphorylation in BV2 cells.	Propofol	0-8	interleukin 6	Mus musculus	55-59
30009261-9	2018	A bleomycin-induced scleroderma model was induced in mice with a B cell-specific deficiency in IL-6 or IL-10.	Bleomycin	2-11	interleukin 6	Mus musculus	95-99
29986551-1	2018	Though melatonin is known to improve ultraviolet B (UVB)-induced oxidative damage and inflammatory conditions via the blockade of the nuclear factor (NF)-&amp;kappa;B, interleukin (IL)-6, there is no report on the anti-wrinkle effect of melatonin to date.	Melatonin	7-16	interleukin 6	Mus musculus	168-186
29895144-3	2018	BF-4 significantly reduced the production of nitric oxide (NO), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha) in lipopolysaccharide-stimulated RAW 264.7 cells.	fluoroboric acid	0-4	interleukin 6	Mus musculus	64-77
29895144-3	2018	BF-4 significantly reduced the production of nitric oxide (NO), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha) in lipopolysaccharide-stimulated RAW 264.7 cells.	fluoroboric acid	0-4	interleukin 6	Mus musculus	79-83
30013568-4	2018	Treatment of EAE mice with GL from onset to the peak stage of disease resulted in marked attenuation of EAE severity, reduced inflammatory cell infiltration and demyelination, decreased tumor necrosis factor-alpha (TNF-alpha), IFN-gamma, IL-17A, IL-6, and transforming growth factor-beta 1, and increased IL-4 both in serum and spinal cord homogenate.	Glycyrrhizic Acid	27-29	interleukin 6	Mus musculus	246-289
30034372-8	2018	Tunicamycin-treated bacteria or the bacterial WTA preparation suppressed NF-kappaB and inflammatory cytokine production (TNFalpha, and IL-6) from murine macrophage cell line (RAW 264.7) indicating the reduced WTA level possibly attenuates an inflammatory response.	Tunicamycin	0-11	interleukin 6	Mus musculus	135-139
29557273-2	2018	Irrespectively of viability, oral supplementation of BR-108 altered the cecal microbiota and stimulated gene expression of cytokines such as IL-6 and IL-10 in ileal Peyer"s patches and cecal tissue of mice.	br-108	53-59	interleukin 6	Mus musculus	141-145
30034372-8	2018	Tunicamycin-treated bacteria or the bacterial WTA preparation suppressed NF-kappaB and inflammatory cytokine production (TNFalpha, and IL-6) from murine macrophage cell line (RAW 264.7) indicating the reduced WTA level possibly attenuates an inflammatory response.	5'-O-[(S)-ethoxy(hydroxy)phosphoryl]adenosine	46-49	interleukin 6	Mus musculus	135-139
29655166-5	2018	PA significantly decreased the levels of interleukin-6 (IL-6), IL-1beta, tumor necrosis factor-alpha (TNF-alpha) in serum and hippocampus of MRL/lpr mice.	peoniflorin	0-2	interleukin 6	Mus musculus	41-54
29684360-6	2018	We further identified IL-6 as a systemic mediator of neutrophil recruitment from the bone marrow of dextran sulfate sodium animals.	Dextran Sulfate	100-122	interleukin 6	Mus musculus	22-26
29635128-11	2018	Furthermore, naringin improved impaired intestinal permeability and inhibited the release of TNF-alpha and IL-6, while increased IL-10 level in CLP mice and lipopolysaccharide (LPS)-stimulated MODE-K cells in a dose-dependent manner.	naringin	13-21	interleukin 6	Mus musculus	107-111
29655166-5	2018	PA significantly decreased the levels of interleukin-6 (IL-6), IL-1beta, tumor necrosis factor-alpha (TNF-alpha) in serum and hippocampus of MRL/lpr mice.	peoniflorin	0-2	interleukin 6	Mus musculus	56-60
29229421-7	2018	A novel derivative BA-25, reported first time notably decreased the LPS (1 mug/mL) induced upregulation in the transcription of TNF-alpha, IL-6, iNOS and COX-2.	Barium	19-21	interleukin 6	Mus musculus	139-143
29549584-7	2018	In addition, the expressions of interleukin-1beta, interleukin-6, monocyte chemoattractant protein-1, intercellular adhesion molecule 1 and infiltration of macrophages in kidney tissues were decreased in acetylshikonin-treated diabetic mice.	acetylshikonin	204-218	interleukin 6	Mus musculus	51-64
30140411-9	2018	The expression of TNF-alpha, IL-6 and IL-1beta decreased to 30-50% and 70-75% in the high-dose (160 nM) and low-dose (40 and 80 nM) GBA groups, respectively.	gambogic acid	132-135	interleukin 6	Mus musculus	29-33
30140411-11	2018	Conclusion: These data suggested that GBA inhibited LPS-induced production of pro-inflammatory cytokines including TNF-alpha, IL-6 and IL-1beta mainly through the suppression of the p38 pathway.	gambogic acid	38-41	interleukin 6	Mus musculus	126-130
29505322-11	2018	Our data show that systemic DMXAA treatment rapidly induced the expression of Ifnb1, Il6, and Tnfa in the SGs, and these cytokines were also elevated in circulation.	vadimezan	28-33	interleukin 6	Mus musculus	85-88
29659176-9	2018	A specific AMPK activator metformin increased Wnt3a, beta-catenin, Nrf2 phosphorylation and activation but reduced the levels of IL-6 and IL-8 in NHBE cells and mouse lungs exposed to CSE.	Metformin	26-35	interleukin 6	Mus musculus	129-133
29659176-10	2018	Furthermore, Nrf2 deficiency abolished the protection of metformin against CSE-induced increase in IL-6 and IL-8 in NHBE cells.	Metformin	57-66	interleukin 6	Mus musculus	99-103
29962852-7	2018	In RAW264.7 cells stimulated with LPS, adenine inhibited production of pro-inflammatory cytokines TNF-alpha and IL-6 and inflammatory lipid mediators, prostaglandin E2 and leukotriene B4.	Adenine	39-46	interleukin 6	Mus musculus	112-116
29962852-11	2018	In BMMCs, adenine inhibited the LPS-induced production of TNF-alpha, IL-6 and IL-13 and also hindered phosphorylation of NF-kappaB and Akt.	Adenine	10-17	interleukin 6	Mus musculus	69-73
29962852-12	2018	In peritoneal cavity, adenine suppressed the LPS-induced production of TNF-alpha and IL-6 by peritoneal cells in mice.	Adenine	22-29	interleukin 6	Mus musculus	85-89
29680917-3	2018	The results showed that production of TNF-alpha, IL-1beta, IL-6, and NO and TNF-alpha, IL-1beta, IL-6, and iNOS mRNA were inhibited by scutellarin, which was independent of cytotoxicity as assessed by a CCK8 assay.	scutellarin	135-146	interleukin 6	Mus musculus	59-63
29680917-3	2018	The results showed that production of TNF-alpha, IL-1beta, IL-6, and NO and TNF-alpha, IL-1beta, IL-6, and iNOS mRNA were inhibited by scutellarin, which was independent of cytotoxicity as assessed by a CCK8 assay.	scutellarin	135-146	interleukin 6	Mus musculus	97-101
30111058-5	2018	High dose of BAEB group and Mesalazine group could improve the colonic pathology, decrease IL-6, IL-8, IL-1beta, HBD-2, HBD-3 expression level.	baeb	13-17	interleukin 6	Mus musculus	91-95
29845215-0	2018	Pien Tze Huang ameliorates DSS-induced colonic inflammation in a mouse colitis model through inhibition of the IL-6/STAT3 pathway.	Dextran Sulfate	27-30	interleukin 6	Mus musculus	111-115
29845215-9	2018	Furthermore, PZH treatment significantly inhibited DSS-induced expression of IL-6 in colon tissues.	Dextran Sulfate	51-54	interleukin 6	Mus musculus	77-81
29767573-11	2018	Consistent with our hypothesis, mice that received the IL-6 trans-signaling-specific inhibitor sgp130Fc, a fusion protein of the soluble extracellular portion of gp130 with the constant portion of the mouse IgG1 antibody, showed attenuation of CH-induced increases in right ventricular systolic pressure, right ventricular and pulmonary arterial remodeling as compared to vehicle (saline)-treated control mice.	Sodium Chloride	381-387	interleukin 6	Mus musculus	55-59
29767573-12	2018	In addition, PASMCs cultured in the presence of IL-6 and sIL-6R showed enhanced migration but not proliferation compared to those treated with IL-6 or sIL-6R alone or in the presence of sgp130Fc.	pasmcs	13-19	interleukin 6	Mus musculus	48-52
29767573-12	2018	In addition, PASMCs cultured in the presence of IL-6 and sIL-6R showed enhanced migration but not proliferation compared to those treated with IL-6 or sIL-6R alone or in the presence of sgp130Fc.	pasmcs	13-19	interleukin 6	Mus musculus	58-62
30381123-8	2018	Results beta-aescin can significantly reduce the pathological changes of lung tissue, lower PaCO2 while increase PaO2 and D/W ratio, down-regulate the expression of TNF-alpha, IL-1beta and IL-6 in LPS-ALI mice.	Escin	8-19	interleukin 6	Mus musculus	189-193
29567277-4	2018	MATERIALS AND METHODS: The effects of ethanol extract of CMS (ECMS) on nitricoxide (NO), tumor necrosis factor (TNF)-alpha and interleukin (IL)- 6 productions in lipopolysaccharide (LPS)-treated RAW 264.7 cells were explored by enzyme linked immunosorbent assay (ELISA) in vitro.	Ethanol	38-45	interleukin 6	Mus musculus	127-146
30111058-5	2018	High dose of BAEB group and Mesalazine group could improve the colonic pathology, decrease IL-6, IL-8, IL-1beta, HBD-2, HBD-3 expression level.	Mesalamine	28-38	interleukin 6	Mus musculus	91-95
30111058-6	2018	In conclusion, BAEB could effectively improve the UC symptoms in mice induced by DSS combined with CA colonization, and inhibit the inflammatory factors such as IL-6, imply that BAEB is of important value for the treatment of intestinal fungal-related colitis.	baeb	15-19	interleukin 6	Mus musculus	161-165
29997508-5	2018	We found that 2"-O-GH significantly reduced the production of TNF-alpha, IL-6, and nitric oxide (NO), suppressed the expression levels of iNOS, blocked the translocation of NF-kappaB from the cytosol to nucleus, and decreased the MAPK activation in LPS-activated RAW 264.7 cells.	2"-o-gh	14-21	interleukin 6	Mus musculus	73-77
29997508-7	2018	In addition, the administration of 2"-O-GH attenuated the TNF-alpha and IL-6 production in the serum, infiltration of inflammatory cells, liver tissue damage, and the mortality rate of LPS-challenged mice.	2"-o-gh	35-42	interleukin 6	Mus musculus	72-76
30046601-10	2018	Moreover, GBH attenuated reserpine-induced increases in interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor- (TNF-) alpha mRNA expression in the hippocampus.	gbh	10-13	interleukin 6	Mus musculus	82-86
30046601-10	2018	Moreover, GBH attenuated reserpine-induced increases in interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor- (TNF-) alpha mRNA expression in the hippocampus.	Reserpine	25-34	interleukin 6	Mus musculus	82-86
29752894-13	2018	Tissue homogenate levels of TNF-alpha, IL-6, IL-1beta and the renal expression of tissue nitrites were also significantly decreased in D-Pinitol treated mice.	pinitol	135-144	interleukin 6	Mus musculus	39-43
29946114-6	2018	We found that 2ccPA prevents a TBI-induced increase in the mRNA expression of Il-1beta, Il-6, Tnf-alpha and Tgf-beta1.	2-carba-cyclic phosphatidic acid	14-19	interleukin 6	Mus musculus	88-92
29926065-9	2018	The result showed that salidroside pretreatment decreased the expression of IL-6 and TNF-alpha as well as phosphorylation of p38 and JNK induced by LPS in BV-2 cells.	rhodioloside	23-34	interleukin 6	Mus musculus	76-80
29926065-10	2018	The inhibitors of p38 (SB202190) and JNK (SP600125) could reduce IL-6 and TNF-alpha mRNA expression that was induced by LPS.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	23-31	interleukin 6	Mus musculus	65-69
29926065-10	2018	The inhibitors of p38 (SB202190) and JNK (SP600125) could reduce IL-6 and TNF-alpha mRNA expression that was induced by LPS.	pyrazolanthrone	42-50	interleukin 6	Mus musculus	65-69
30034291-7	2018	Treatment with aspirin inhibited 4T1 cell growth and migration and MCP-1, PAI-1, and IL-6 production.	Aspirin	15-22	interleukin 6	Mus musculus	85-89
30034291-8	2018	In the coculture of both cells, aspirin inhibited secretion of MCP-1, IL-6, and TGF-beta.	Aspirin	32-39	interleukin 6	Mus musculus	70-74
29775573-11	2018	In addition, I3C significantly attenuated DOX-induced inflammation by down-regulation of NF-kbeta, iNOS, COX-2 and IL-6 in cardiac tissue.	Doxorubicin	42-45	interleukin 6	Mus musculus	115-119
29973940-7	2018	Activation of the GPR84 receptor with a selective agonist, 6-(octylamino) pyrimidine-2,4(1H,3H)-dione (6-n-octylaminouracil, 6-OAU), enhanced the expression of phosphorylated Akt, p-ERK, and p65 nuclear translocation under inflammatory conditions and elevated the expression levels of the inflammatory mediators TNFalpha, IL-6, IL-12B, CCL2, CCL5, and CXCL1.	6-(octylamino) pyrimidine-2,4(1h,3h)-dione	59-101	interleukin 6	Mus musculus	322-326
29871974-9	2018	Nobiletin significantly altered the expression of PCNA, VEGF, and E-cadherin in ectopic endometrium, as well as the levels of IL-6, IL-1beta, TNF-alpha, MMP-1, and MMP-3.	nobiletin	0-9	interleukin 6	Mus musculus	126-130
29679536-6	2018	In HL cells in culture, curcumin decreased the expression of relevant anti-inflammatory cytokines (IL-6 and TNF-alpha) in a concentration-dependent manner.	Curcumin	24-32	interleukin 6	Mus musculus	99-103
29654783-8	2018	Resveratrol (20 and 40 mg/kg)-treated mice had significantly decreased in IL-6+, TNF-alpha+, IFN-gamma+, and STAT3+ in CD4+ spleen cells as compared with BTBR control mice.	Resveratrol	0-11	interleukin 6	Mus musculus	74-78
29654783-9	2018	Resveratrol treatment also decreased IL-6, TNF-alpha, IFN-gamma, JAK1, and STAT3 mRNA expression levels as compared with BTBR control mice in the brain tissue.	Resveratrol	0-11	interleukin 6	Mus musculus	37-41
29574133-7	2018	Furthermore, kaempferol markedly attenuated APAP-induced serum TNF-alpha and IL-6 productions, downregulated APAP-induced phosphorylations of JNK and ERK, and decreased early hepatic apoptosis via decreasing Bax/Bcl-2 ratio and caspase 3 activation.	Acetaminophen	44-48	interleukin 6	Mus musculus	77-81
29654783-10	2018	Moreover, resveratrol treatment resulted in decreased protein expression levels of IL-6, IFN-gamma, TNF-alpha, pJAK1, and pSTAT3 (Tyr705) as compared with BTBR control mice in the brain tissues.	Resveratrol	10-21	interleukin 6	Mus musculus	83-87
29680708-5	2018	We also showed that resveratrol treatment decreased IL-1beta, IL-6, TNF-alpha, PCNA, Bcl-2, and acetyl-p65 levels, but increased Bax and caspase 3 levels in hippocampus, suggesting a suppressive effect of resveratrol on cellular neuroinflammation and proliferation while a promotive effect on apoptosis of microglia in hippocampus.	Resveratrol	20-31	interleukin 6	Mus musculus	62-66
29684444-10	2018	More importantly, the strong inhibitory effect of DHA on IL-6 release was also observed in Slo1 KO BMDM.	Docosahexaenoic Acids	50-53	interleukin 6	Mus musculus	57-61
29574133-7	2018	Furthermore, kaempferol markedly attenuated APAP-induced serum TNF-alpha and IL-6 productions, downregulated APAP-induced phosphorylations of JNK and ERK, and decreased early hepatic apoptosis via decreasing Bax/Bcl-2 ratio and caspase 3 activation.	kaempferol	13-23	interleukin 6	Mus musculus	77-81
29902182-7	2018	The results of the present study show that TVE exerts anti-inflammatory properties since it reduces the release of all the evaluated markers of inflammation, such as NO, IL6, TNF alpha and PGE2 in LPS-activated BV2 microglial cells.	tve	43-46	interleukin 6	Mus musculus	170-173
29907781-6	2018	Interestingly, SGRS (30 mg/kg) suppressed carrageenan-induced elevation of iNOS, COX-2, TNF-alpha, IL-1beta, and IL-6 mRNA levels as well as COX-2 and NF-kappaB protein levels, suggesting SGRS may possess anti-inflammatory activities.	Carrageenan	42-53	interleukin 6	Mus musculus	113-117
29530609-0	2018	Protective effect of Sesbania grandiflora on acetic acid induced ulcerative colitis in mice by inhibition of TNF-alpha and IL-6.	Acetic Acid	45-56	interleukin 6	Mus musculus	123-127
29790749-3	2018	Current results showed that 8-OHD inhibited LPS-stimulated production of nitric oxide (NO) and proinflammatory cytokines, such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, by inhibiting gene expression in BV2 microglial cells.	8-ohd	28-33	interleukin 6	Mus musculus	168-186
29656890-1	2018	A library of indolyl-isoxazolidines (6-9) has been synthesized by regio- and stereoselective microwave irradiated 1,3-dipolar cycloadditions of C-(3-indolyl)-N-phenylnitrone (2") with variedly substituted dipolarophiles (3"-5") and screened for their anti-inflammatory activities through inhibition of pro-inflammatory cytokines such as TNF-alpha and IL-6.	indolyl-isoxazolidines	13-35	interleukin 6	Mus musculus	351-355
29874560-2	2018	In mice, interleukin-6 (IL-6) improves glucose tolerance via stimulation of glucagon-like peptide 1 (GLP-1) secretion.	Glucose	39-46	interleukin 6	Mus musculus	9-22
29890681-7	2018	mRNA expression of pro-inflammatory cytokines indicated that broccoli anti-inflammatory action may be through inhibition of the IL-6 trans-signaling pathway, as evidenced by reversal of the DSS-increased expression of IL-6, CCR2 and vascular cell adhesion molecule 1 (VCAM-1).	Dextran Sulfate	190-193	interleukin 6	Mus musculus	128-132
29890681-7	2018	mRNA expression of pro-inflammatory cytokines indicated that broccoli anti-inflammatory action may be through inhibition of the IL-6 trans-signaling pathway, as evidenced by reversal of the DSS-increased expression of IL-6, CCR2 and vascular cell adhesion molecule 1 (VCAM-1).	Dextran Sulfate	190-193	interleukin 6	Mus musculus	218-222
29874560-2	2018	In mice, interleukin-6 (IL-6) improves glucose tolerance via stimulation of glucagon-like peptide 1 (GLP-1) secretion.	Glucose	39-46	interleukin 6	Mus musculus	24-28
29922289-10	2018	In DSS colitis, increased levels of IL-6, CSF3, and IL-17 were further increased in Smox-/- mice.	Dextran Sulfate	3-6	interleukin 6	Mus musculus	36-40
29882826-10	2018	Tiotropium bromide improved bronchoconstriction, and reduced neutrophil numbers, decreased the concentrations of IL-5, IL-6, IL-13, and KC/CXCL1 in BALF.	Tiotropium Bromide	0-18	interleukin 6	Mus musculus	119-123
29236232-9	2018	Murine peritoneal macrophages cultivated with beta-glucan for 6 and 48 h showed an increase in TNF-alpha, IL-6 and nitric oxide release with increased polysaccharide concentrations.	beta-Glucans	46-57	interleukin 6	Mus musculus	106-110
29526885-7	2018	PAGln significantly inhibited inflammatory cytokine (interferon-gamma, interleukin-6, and tumor necrosis factor-alpha) production, decrease of cell number in the spleen cell, and suppressed the expression of inflammatory proteins (nuclear factor kappaB, and inducible nitric oxide synthase).	phenylacetylglutamine	0-5	interleukin 6	Mus musculus	71-117
29494909-9	2018	Furthermore, blockage of TNF-alpha and IL-6 significantly inhibited hepatocyte proliferation by gadolinium chloride (GdCl3) pre-treatment in PFOS-treated mice and primary cultured Kupffer cells.	gadolinium chloride	96-115	interleukin 6	Mus musculus	39-43
29896426-6	2018	More interestingly, the high cholesterol diet not only improved NLRP3 inflammasome activation and IL-1beta expression, but also increased levels of anti-inflammatory cytokines IL-4 and IL-6 in the hippocampus of old mice, suggesting playing pro- and anti-neuroinflammatory effects.	Cholesterol	29-40	interleukin 6	Mus musculus	185-189
29494909-9	2018	Furthermore, blockage of TNF-alpha and IL-6 significantly inhibited hepatocyte proliferation by gadolinium chloride (GdCl3) pre-treatment in PFOS-treated mice and primary cultured Kupffer cells.	gadolinium chloride	117-122	interleukin 6	Mus musculus	39-43
29494909-9	2018	Furthermore, blockage of TNF-alpha and IL-6 significantly inhibited hepatocyte proliferation by gadolinium chloride (GdCl3) pre-treatment in PFOS-treated mice and primary cultured Kupffer cells.	perfluorooctane sulfonic acid	141-145	interleukin 6	Mus musculus	39-43
29549723-11	2018	In parallel, SB-431542 blocked DNCB-induced elevation in serum levels of TNF-alpha, TGF-beta1, TGF-betaR1, LAP, IL-1beta, IL-6 and IgE.	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	13-22	interleukin 6	Mus musculus	122-126
29393507-12	2018	The HuR inhibitor, quercetin, suppressed Pg-induced HuR mRNA expression and IL-6 production in OBA-9.	Quercetin	19-28	interleukin 6	Mus musculus	76-80
29393507-13	2018	An oral inoculation with quercetin also inhibited bone resorption in ligature-induced periodontitis model mice as a result of down-regulation of IL-6.	Quercetin	25-34	interleukin 6	Mus musculus	145-149
29765479-7	2018	Furthermore, evodiamine inhibited significantly glial cell activation and neuroinflammation (TNF-alpha, IL-1beta, and IL-6 levels) in the hippocampus.	evodiamine	13-23	interleukin 6	Mus musculus	118-122
29428678-8	2018	At 20muM dilution, both CHX and EGCG significantly increased the secretion of IL-1beta, IL-10, IL-12, KC, MIP-1alpha, IFN-gamma and IL-6 (p&lt;0.05).	Chlorhexidine	24-27	interleukin 6	Mus musculus	132-136
29428678-8	2018	At 20muM dilution, both CHX and EGCG significantly increased the secretion of IL-1beta, IL-10, IL-12, KC, MIP-1alpha, IFN-gamma and IL-6 (p&lt;0.05).	epigallocatechin gallate	32-36	interleukin 6	Mus musculus	132-136
29549723-11	2018	In parallel, SB-431542 blocked DNCB-induced elevation in serum levels of TNF-alpha, TGF-beta1, TGF-betaR1, LAP, IL-1beta, IL-6 and IgE.	Dinitrochlorobenzene	31-35	interleukin 6	Mus musculus	122-126
29673861-0	2018	IL-6 knockout mice are protected from cocaine-induced kindling behaviors; possible involvement of JAK2/STAT3 and PACAP signalings.	Cocaine	38-45	interleukin 6	Mus musculus	0-4
29732583-12	2018	ECG produced a significant (p &lt; .001) reduction in plasma PGE2 (by 27, 38, and 50%), TNF-alpha (15, 33, and 41%), IL-1beta (17, 25, and 33%), and IL-6 (22, 32, and 43%), at the tested doses, respectively.	epicatechin gallate	0-3	interleukin 6	Mus musculus	149-153
29910732-7	2018	Compared to normal mice, interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha production in bronchoalveolar lavage fluid were increased in NC/Nga mice treated with both DNCB and BLM and in animals treated with DNCB alone.	Dinitrochlorobenzene	173-177	interleukin 6	Mus musculus	25-43
29910732-7	2018	Compared to normal mice, interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha production in bronchoalveolar lavage fluid were increased in NC/Nga mice treated with both DNCB and BLM and in animals treated with DNCB alone.	Dinitrochlorobenzene	214-218	interleukin 6	Mus musculus	25-43
29910735-17	2018	Increased expression of IL-6, HAS2 and Tgm2 was observed in PASMC in an ADORA2B-dependent manner.	pasmc	60-65	interleukin 6	Mus musculus	24-28
29910735-19	2018	Conclusions: Our studies revealed ADORA2B-dependent increased levels of IL-6, hyaluronan and Tgm2 in PASMC, consistent with reduced levels in ADORA2Bf/f- Taglncre mice exposed to HX-SU or BLM.	pasmc	101-106	interleukin 6	Mus musculus	72-76
29910735-20	2018	Taken together, our data indicates that ADORA2B on PASMC mediates the development of PH through the induction of IL-6, hyaluronan and Tgm2.	pasmc	51-56	interleukin 6	Mus musculus	113-117
29673861-2	2018	We aimed to investigate on the interactive role between IL-6 and PACAP in cocaine-induced kindling behaviors.	Cocaine	74-81	interleukin 6	Mus musculus	56-60
29673861-3	2018	Although we found that cocaine (45 mg/kg, i.p./day x 5) significantly increased IL-6 and TNF-alpha expression, it resulted in a decrease in IFN-gamma expression.	Cocaine	23-30	interleukin 6	Mus musculus	80-84
29673861-4	2018	We observed that the cocaine-induced increase in IL-6 expression was more pronounced than that in TNF-alpha expression.	Cocaine	21-28	interleukin 6	Mus musculus	49-53
29673861-5	2018	Genetic depletion of IL-6 significantly activated cocaine kindling behaviors.	Cocaine	50-57	interleukin 6	Mus musculus	21-25
29673861-7	2018	Cocaine-treated IL-6 knockout mice exhibited significantly decreased PACAP and PACAP receptor (PAC1R) mRNA levels and significantly increased TNF-alpha gene expression.	Cocaine	0-7	interleukin 6	Mus musculus	16-20
29508185-11	2018	In addition, gingerol also observably inhibited LPS-induced TNF-alpha, IL-1beta, IL-6, and PGE2 (p &lt; 0.01) expression and secretion in a dose-dependent manner.	gingerol	13-21	interleukin 6	Mus musculus	81-85
29355056-12	2018	TCA treatment also diminished the mRNA expression level and secretion of IL-1beta, IL-6 and TNF-alpha in LPS-activated macrophages.	cinnamaldehyde	0-3	interleukin 6	Mus musculus	83-87
29371151-9	2018	Finally, PIP2-1 significantly enhanced the release of TNF-alpha and IL-6 in RAW264.7 cells.	pip2-1	9-15	interleukin 6	Mus musculus	68-72
29508185-12	2018	At the genetic level, after the intervention of gingerol, mRNA transcriptions of iNOS, COX-2, IL-6, and IL-1beta were all decreased.	gingerol	48-56	interleukin 6	Mus musculus	94-98
29532264-7	2018	The results showed that propofol significantly decreased the number of eosinophils and the levels of IL-4, IL-5, IL-6, IL-13, and TNF-alpha in BALF.	Propofol	24-32	interleukin 6	Mus musculus	113-117
29627576-6	2018	The elevation of prefrontal cortex pro-inflammatory cytokines such as interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) was decreased by magnolol.	magnolol	182-190	interleukin 6	Mus musculus	100-113
29541888-6	2018	Results suggested that treatment with NOB dramatically attenuated lung histopathological changes, wet-to-dry (W/D) ratio, myeloperoxidase (MPO) activity, the numbers of inflammatory cells, and TNF-alpha, IL-6, and NO in BALF induced by LPS.	nobiletin	38-41	interleukin 6	Mus musculus	204-208
29541888-8	2018	In vitro, NOB inhibited NF-kappaB activation and TNF-alpha, IL-6 production in LPS-stimulated A549 cells.	nobiletin	10-13	interleukin 6	Mus musculus	60-64
29627576-6	2018	The elevation of prefrontal cortex pro-inflammatory cytokines such as interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) was decreased by magnolol.	magnolol	182-190	interleukin 6	Mus musculus	115-119
29689496-4	2018	The results indicated that pretreatment with AMSO2 significantly decreased CSE-elevated tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in serum.	amso2	45-50	interleukin 6	Mus musculus	132-145
29655055-3	2018	The levels of the pro-inflammatory cytokines interleukin (IL)-1beta, IL-6 and tumour necrosis factor-alpha were decreased by GE, metformin and fasudil in diabetic db/db mice.	Metformin	129-138	interleukin 6	Mus musculus	69-106
29655055-3	2018	The levels of the pro-inflammatory cytokines interleukin (IL)-1beta, IL-6 and tumour necrosis factor-alpha were decreased by GE, metformin and fasudil in diabetic db/db mice.	fasudil	143-150	interleukin 6	Mus musculus	69-106
29689498-4	2018	Cirsitakaoside could suppress the production of pro-inflammatory cytokines such as interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) in a dose-dependent manner in LPS-stimulated mouse peritoneal macrophages and RAW264.7 cells.	cirsimarin	0-14	interleukin 6	Mus musculus	113-126
29689496-4	2018	The results indicated that pretreatment with AMSO2 significantly decreased CSE-elevated tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in serum.	amso2	45-50	interleukin 6	Mus musculus	147-151
29689498-4	2018	Cirsitakaoside could suppress the production of pro-inflammatory cytokines such as interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) in a dose-dependent manner in LPS-stimulated mouse peritoneal macrophages and RAW264.7 cells.	cirsimarin	0-14	interleukin 6	Mus musculus	128-132
29757062-6	2018	Corneas from the timolol-treated group showed reduced expression of VEGF-A, VEGF-C, TNF-alpha, IL-6, VEGFR-2, and VEGFR-3 compared to corneas from the PBS group (P value <0.05 in all respective comparisons).	Timolol	17-24	interleukin 6	Mus musculus	95-99
29454997-7	2018	Furthermore, when HUVECs were co-cultured with RAW264.7 cells, lipopolysaccharide-induced expression of interleukin (IL)-1beta and IL-6 was enhanced by magnesium deficiency, depending on the presence of RAW264.7 cells.	Magnesium	152-161	interleukin 6	Mus musculus	131-135
29687630-5	2018	Anti-inflammation assay of murine RAW 264.7 cells proves that Dex released from all the scaffolds successfully suppresses lipopolysaccharide induced interleukin-6 and inducible nitric oxide synthase secretion by M1 macrophages.	Dexamethasone	62-65	interleukin 6	Mus musculus	149-162
29571009-7	2018	We found lower plasma levels of interleukin-6 and lower levels of various metabolites, among which are bile acids, in the colonic luminal content of CR-exposed mice as compared to the other diet groups.	Chromium	149-151	interleukin 6	Mus musculus	32-45
29545331-9	2018	We found that metformin partly reversed cisplatin-stimulated IL6 secretion in the stromal fibroblasts and attenuated fibroblast-facilitated tumor growth in 3D organotypic cocultures and murine xenograft models.	Metformin	14-23	interleukin 6	Mus musculus	61-64
29970291-7	2018	Piperlongumine also reduced the expression of inducible nitric oxide synthase and cyclooxygenase-2 as well as proinflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6.	piperlonguminine	0-14	interleukin 6	Mus musculus	176-189
29545331-9	2018	We found that metformin partly reversed cisplatin-stimulated IL6 secretion in the stromal fibroblasts and attenuated fibroblast-facilitated tumor growth in 3D organotypic cocultures and murine xenograft models.	Cisplatin	40-49	interleukin 6	Mus musculus	61-64
29620269-6	2018	MLE-12 cells were divided into 2 groups: The control group was administered sterile PBS; the treatment group was administered 500 ng/ml LPS for 12 h. The mRNA expression of IL-6 in the treatment group was significantly upregulated compared with the control group (P&lt;0.05).	Lead	84-87	interleukin 6	Mus musculus	173-177
29693122-6	2018	The results revealed that the serum levels of TNF-alpha, interleukin (IL)-1beta, IL-4 and IL-6 were significantly upregulated in a mouse model of iodoacetate-induced osteoarthritis compared with healthy mice (P&lt;0.01).	Iodoacetates	146-157	interleukin 6	Mus musculus	90-94
29534932-9	2018	Mice co-treated with both doses of resveratrol displayed significantly lower levels of the proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), but markedly higher levels of the anti-inflammatory cytokines IL-4 and IL-10 in several sera and brain tissues than those co-treated with vehicle.	Resveratrol	35-46	interleukin 6	Mus musculus	161-174
29534932-9	2018	Mice co-treated with both doses of resveratrol displayed significantly lower levels of the proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), but markedly higher levels of the anti-inflammatory cytokines IL-4 and IL-10 in several sera and brain tissues than those co-treated with vehicle.	Resveratrol	35-46	interleukin 6	Mus musculus	176-180
29627690-6	2018	RESULTS: In murine mastitis, kaempferol (10 or 30mg/kg) treatment prevented mastitis development, decreased myeloperoxidase (MPO) production, interleukin (IL)-6 level, tumour necrosis factor-alpha (TNF-alpha) concentration, and ANGPTL2 expression.	kaempferol	29-39	interleukin 6	Mus musculus	142-160
29693192-5	2018	In our study, we found that SR dose-dependently ameliorated skin cancer incidence and the multiplicity in the animal models by reducing the release of inflammation-related cytokines, including tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-18 (IL-18), interleukin-6 (IL-6), cyclooxygenase 2 (COX2) and transforming growth factor beta-1 (TGF-beta1).	rhodioloside	28-30	interleukin 6	Mus musculus	288-301
29693192-5	2018	In our study, we found that SR dose-dependently ameliorated skin cancer incidence and the multiplicity in the animal models by reducing the release of inflammation-related cytokines, including tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-18 (IL-18), interleukin-6 (IL-6), cyclooxygenase 2 (COX2) and transforming growth factor beta-1 (TGF-beta1).	rhodioloside	28-30	interleukin 6	Mus musculus	303-307
29627690-7	2018	In MMEC, kaempferol (1, 3 or 10muM) reduced MPO production, TNF-alpha concentration, IL-6 level, and ANGPTL2 expression.	kaempferol	9-19	interleukin 6	Mus musculus	85-89
29974844-5	2018	The results in murine models of heatstroke verified that GSK2193874, as a selected TRPV4 inhibitor, was injected at heatstroke onset, and then reduced the reduction of core temperature, the death rate, wet/dry ratio of the lung, levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6, coagulation indicators, the degree of organ injury, and caspase-3/7 activity (P&amp;lt;0.05).	GSK2193874	57-67	interleukin 6	Mus musculus	283-301
29505886-4	2018	Moreover, OAA treatment significantly decreased the elevations of IL-1beta, IL-6, TNF-alpha, TGF-beta1, and fibronectin, and the activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome in the lungs of PHMG-P-treated mice.	Oxaloacetic Acid	10-13	interleukin 6	Mus musculus	76-80
30236202-9	2018	Fasudil treatment significantly inhibited LPS-induced the secretion of NO, TNF-alpha and IL-6 and enhanced the production of IL-10 and IL-4.	fasudil	0-7	interleukin 6	Mus musculus	89-93
29691532-4	2018	Our results showed that BRAE decreased the histological score and TNF-alpha mRNA expression in a dose-dependent manner, while BRAE + RA dose-dependently attenuated the histological score and mRNA expression of IL-6.	rosmarinic acid	25-27	interleukin 6	Mus musculus	210-214
29726680-11	2018	The three most potent stilbenoids, piceatannol, pinosylvin, and pterostilbene, were selected for in vivo testing and were found to suppress inflammatory edema and to down-regulate the production of inflammatory mediators IL6 and MCP1 in carrageenan-induced paw inflammation in mice.	stilbenoids	22-33	interleukin 6	Mus musculus	221-224
29726680-11	2018	The three most potent stilbenoids, piceatannol, pinosylvin, and pterostilbene, were selected for in vivo testing and were found to suppress inflammatory edema and to down-regulate the production of inflammatory mediators IL6 and MCP1 in carrageenan-induced paw inflammation in mice.	3,3',4,5'-tetrahydroxystilbene	35-46	interleukin 6	Mus musculus	221-224
29726680-11	2018	The three most potent stilbenoids, piceatannol, pinosylvin, and pterostilbene, were selected for in vivo testing and were found to suppress inflammatory edema and to down-regulate the production of inflammatory mediators IL6 and MCP1 in carrageenan-induced paw inflammation in mice.	pinosylvin	48-58	interleukin 6	Mus musculus	221-224
29726680-11	2018	The three most potent stilbenoids, piceatannol, pinosylvin, and pterostilbene, were selected for in vivo testing and were found to suppress inflammatory edema and to down-regulate the production of inflammatory mediators IL6 and MCP1 in carrageenan-induced paw inflammation in mice.	pterostilbene	64-77	interleukin 6	Mus musculus	221-224
29625124-0	2018	Theophylline suppresses interleukin-6 expression by inhibiting glucocorticoid receptor signaling in pre-adipocytes.	Theophylline	0-12	interleukin 6	Mus musculus	24-37
29667667-3	2018	In this study, we found that alpha-cyperone markedly decreased the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in LPS-induced BV-2 cells.	alpha-cyperone	29-43	interleukin 6	Mus musculus	122-135
29667667-3	2018	In this study, we found that alpha-cyperone markedly decreased the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in LPS-induced BV-2 cells.	alpha-cyperone	29-43	interleukin 6	Mus musculus	137-141
29563064-4	2018	The results showed that alpha-mangostin effectively decreased the serum levels of alanine aminotransferase, aspartate transaminase, tumor necrosis factor (TNF-alpha), interleukin-1beta and 6 (IL-1beta, IL-6), and hepatic malondialdehyde level; and recovered hepatic glutathione (GSH), superoxide dismutase and catalase activities.	mangostin	24-39	interleukin 6	Mus musculus	202-206
29563064-6	2018	According to the analysis of western-blot and RT-PCR detection, alpha-mangostin pretreatment validly inhibited the phosphorylation of ERK, JNK and p38 MAPK induced by APAP, which was consistent with the changes of TNF-alpha, IL-6 and IL-1beta levels; the phosphorylation of IkappaBalpha and the translocation of NF-kappaBp65 were also attenuated by alpha-mangostin.	mangostin	64-79	interleukin 6	Mus musculus	225-229
29625124-4	2018	In this study, we found that theophylline decreased IL-6 secretion by 3T3-L1 pre-adipocytes and mouse-derived primary pre-adipocytes.	Theophylline	29-41	interleukin 6	Mus musculus	52-56
29625124-5	2018	The synthetic glucocorticoid dexamethasone (DEX) induced IL-6 expression in 3T3-L1 pre-adipocytes, and this effect was suppressed by theophylline at the mRNA level.	Dexamethasone	29-42	interleukin 6	Mus musculus	57-61
29625124-5	2018	The synthetic glucocorticoid dexamethasone (DEX) induced IL-6 expression in 3T3-L1 pre-adipocytes, and this effect was suppressed by theophylline at the mRNA level.	Dexamethasone	44-47	interleukin 6	Mus musculus	57-61
29625124-5	2018	The synthetic glucocorticoid dexamethasone (DEX) induced IL-6 expression in 3T3-L1 pre-adipocytes, and this effect was suppressed by theophylline at the mRNA level.	Theophylline	133-145	interleukin 6	Mus musculus	57-61
29625124-6	2018	Knockdown of CCAAT/enhancer binding protein (C/EBP) delta inhibited DEX-induced IL-6 expression, and theophylline suppressed C/EBPdelta expression.	Dexamethasone	68-71	interleukin 6	Mus musculus	80-84
29625124-8	2018	In vivo, glucocorticoid corticosterone treatment (100 mug/mL) increased fasting blood glucose and plasma IL-6 levels in C57BL/6 N mice.	Corticosterone	24-38	interleukin 6	Mus musculus	105-109
29625124-9	2018	Theophylline administration (0.1% diet) reduced corticosterone-increased fasting blood glucose, plasma IL-6 levels, and Il6 gene expression in adipose tissues.	Theophylline	0-12	interleukin 6	Mus musculus	103-107
29625124-9	2018	Theophylline administration (0.1% diet) reduced corticosterone-increased fasting blood glucose, plasma IL-6 levels, and Il6 gene expression in adipose tissues.	Theophylline	0-12	interleukin 6	Mus musculus	120-123
29625124-9	2018	Theophylline administration (0.1% diet) reduced corticosterone-increased fasting blood glucose, plasma IL-6 levels, and Il6 gene expression in adipose tissues.	Corticosterone	48-62	interleukin 6	Mus musculus	103-107
29625124-9	2018	Theophylline administration (0.1% diet) reduced corticosterone-increased fasting blood glucose, plasma IL-6 levels, and Il6 gene expression in adipose tissues.	Corticosterone	48-62	interleukin 6	Mus musculus	120-123
29625124-10	2018	These results show that theophylline administration attenuated glucocorticoid-induced hyperglycemia and IL-6 production by inhibiting GR activity.	Theophylline	24-36	interleukin 6	Mus musculus	104-108
29622518-7	2018	Final experimental results showed that Sit-N significantly decreased the serum activity of aspartate transaminase (AST) and alanine aminotransferase (ALT); Sit-N also markedly reduced tumor necrosis factor (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) levels.	sit-n	39-44	interleukin 6	Mus musculus	267-271
29622518-7	2018	Final experimental results showed that Sit-N significantly decreased the serum activity of aspartate transaminase (AST) and alanine aminotransferase (ALT); Sit-N also markedly reduced tumor necrosis factor (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) levels.	sit-n	39-44	interleukin 6	Mus musculus	252-265
29622518-7	2018	Final experimental results showed that Sit-N significantly decreased the serum activity of aspartate transaminase (AST) and alanine aminotransferase (ALT); Sit-N also markedly reduced tumor necrosis factor (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) levels.	sit-n	156-161	interleukin 6	Mus musculus	252-265
29622518-7	2018	Final experimental results showed that Sit-N significantly decreased the serum activity of aspartate transaminase (AST) and alanine aminotransferase (ALT); Sit-N also markedly reduced tumor necrosis factor (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) levels.	sit-n	156-161	interleukin 6	Mus musculus	267-271
29549113-6	2018	CDD-450 also accelerated TNF-alpha and IL-6 mRNA decay, inhibited inflammation in mice with cryopyrinopathy, and was as efficacious as global p38alpha inhibitors in attenuating arthritis in rats and cytokine expression by cells from patients with cryopyrinopathy and rheumatoid arthritis.	zunsemetinib	0-7	interleukin 6	Mus musculus	39-43
29754152-8	2018	Expression of IL-6 and TNF-alpha significantly increased and expression of IL-10 significantly decreased at protein and mRNA levels after LPS treatment, and these effects were strongly inhibited in a dose-dependent manner by pretreatment of rhBNP.	rhbnp	241-246	interleukin 6	Mus musculus	14-18
29854837-6	2018	Furthermore, sublancin restored the mRNA levels of IL-2, IL-4, and IL-6 in the spleen.	sublancin	13-22	interleukin 6	Mus musculus	67-71
29854837-4	2018	In addition, the mRNA expression of IL-1beta, IL-6, and TNF-alpha in peritoneal macrophages from sublancin- (1.0 mg/kg body weight) administered mice was significantly increased (P &lt; 0.05).	sublancin	97-106	interleukin 6	Mus musculus	46-50
29550483-10	2018	GR24, pinosylvin and resveratrol attenuated adipogenesis via inhibiting the expression of PPARgamma and C/EBPalpha and protected against inflammation by inhibiting TNF-alpha-stimulated IL-6 secretion.	Resveratrol	21-32	interleukin 6	Mus musculus	185-189
29518395-8	2018	Oridonin dramatically inhibited the expression of TNF-alpha-induced endothelial adhesion molecules (intercellular adhesion molecule-1 (ICAM-1); vascular cell adhesion molecule-1 (VCAM-1) and E-selectin) and the pro-inflammatory cytokine (IL-6, IL-8 and monocyte chemoattractant protein-1(MCP-1)).	oridonin	0-8	interleukin 6	Mus musculus	238-242
29728574-8	2018	Finally, we show that IL-6 and IL-23 are implicated in the conversion of Tregs to exFoxp3 cells.	tregs	73-78	interleukin 6	Mus musculus	22-26
29773987-7	2018	Moreover, CSL when administered either alone or in combination with bortezomib inhibited MM tumor growth and decreased serum IL-6 and TNF-alpha levels.	Bortezomib	68-78	interleukin 6	Mus musculus	125-129
29723248-11	2018	The suppression of HBP expression by heparin injection after the establishment of sepsis-induced AKI resulted in a reduction in renal injury severity accompanied with a significant repression of M1 macrophage activation and expression of TNF-alpha and IL-6.	Heparin	37-44	interleukin 6	Mus musculus	252-256
29724065-11	2018	We conclude that TRYP improves the health condition of mice with DSS induced colitis by regulating the TNF-alpha/NF-kappaBp65 and IL-6/STAT3 signaling pathways via inhibiting the degradation of IkappaBalpha and the phosphorylation of STAT3.	Dextran Sulfate	65-68	interleukin 6	Mus musculus	130-134
29656647-0	2018	Tea Polysaccharides Inhibit Colitis-Associated Colorectal Cancer via Interleukin-6/STAT3 Pathway.	tea polysaccharides	0-19	interleukin 6	Mus musculus	69-82
29724065-0	2018	Tryptanthrin Protects Mice against Dextran Sulfate Sodium-Induced Colitis through Inhibition of TNF-alpha/NF-kappaB and IL-6/STAT3 Pathways.	tryptanthrine	0-12	interleukin 6	Mus musculus	120-124
29351455-9	2018	Nootkatone inhibited the increase of plasma concentration of fibrinogen, plasminogen activator inhibitor-1, interleukin-6, and lipid peroxidation induced by DEPs.	nootkatone	0-10	interleukin 6	Mus musculus	108-121
29501766-10	2018	The concentrations and expression levels of pro-inflammatory factors including TNF-alpha, IL-1beta, IL-6, PGE-2, COX-2 were significantly reduced after beta-Amyrin treatment in LPS/IFN-gamma-induced microglial cells (p &lt; 0.05-0.001).	beta-amyrin	152-163	interleukin 6	Mus musculus	100-104
29164679-6	2018	Moreover, purification of 2H-CHH yielded peptide fraction P16, which displayed a high efficacy in decreasing NO production of macrophage RAW 264.7 cells (83.2%) and significantly reduced proinflammatory cytokines and inflammatory mediators interleukin-6 (IL-6), interleukin-1 beta (IL-1beta), and prostaglandin-E2 (PGE2 ) production to about 2.0, 0.3, and 1.9 ng/mL, respectively.	2h-chh	26-32	interleukin 6	Mus musculus	240-253
29670081-10	2018	The increased IL-6 level in seipin-nKO mice was sensitive to rosiglitazone and GSK3beta inhibitor AR-A014418.	Rosiglitazone	61-74	interleukin 6	Mus musculus	14-18
29635905-5	2018	Moreover, DOP could reduce pro-inflammatory cytokines (TNF-alpha, IL-6) and MDA levels and improve estradiol, SOD, GSH-Px, T-AOC and IL-10 levels in serum.	Diethylhexyl Phthalate	10-13	interleukin 6	Mus musculus	66-70
29670081-10	2018	The increased IL-6 level in seipin-nKO mice was sensitive to rosiglitazone and GSK3beta inhibitor AR-A014418.	N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea	98-108	interleukin 6	Mus musculus	14-18
29453978-6	2018	Co-administration of VLF with morphine attenuated morphine-induced analgesic tolerance and prevented the upregulation of proinflammatory cytokines (TNF-alpha, IL-1beta, and IL-6), NO, and malondialdehyde in brains of mice with induced morphine tolerance; chronic VLF administration inhibited this decrease in brain-derived neurotrophic factor, total thiol, and GPx levels.	Morphine	30-38	interleukin 6	Mus musculus	173-177
29673286-7	2018	Consistently, serum inflammatory mediators TNF-alpha and IL-6 were decreased by the treatment of LPS combined with 3-MA as compared with LPS alone, while administration of LPS combined with rapamycin increased the serum TNF-alpha and IL-6 levels.	Sirolimus	190-199	interleukin 6	Mus musculus	234-238
28770639-4	2018	Serum analysis of NRG and MTX groups showed a reduction in the cytokines such as the levels of tumour necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6) and interleukin 1beta (IL-1beta) in comparison to PRG group.	Methotrexate	26-29	interleukin 6	Mus musculus	137-150
28770639-4	2018	Serum analysis of NRG and MTX groups showed a reduction in the cytokines such as the levels of tumour necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6) and interleukin 1beta (IL-1beta) in comparison to PRG group.	Methotrexate	26-29	interleukin 6	Mus musculus	152-156
29266245-5	2018	The protein levels of interleukin-6 (IL-6) and vascular endothelial growth factor A (VEGF-A) were persistently elevated in orthotopic liver tumors, but not in subcutaneous tumors, treated with sorafenib.	Sorafenib	193-202	interleukin 6	Mus musculus	22-35
29266245-5	2018	The protein levels of interleukin-6 (IL-6) and vascular endothelial growth factor A (VEGF-A) were persistently elevated in orthotopic liver tumors, but not in subcutaneous tumors, treated with sorafenib.	Sorafenib	193-202	interleukin 6	Mus musculus	37-41
29266245-8	2018	IL-6, but not VEGF-A, protected Ly6G+ MDSCs from sorafenib-induced cell death in vitro.	Sorafenib	49-58	interleukin 6	Mus musculus	0-4
29266245-9	2018	The combination of anti-Ly6G antibody or anti-IL-6 antibody with sorafenib significantly reduced the cell proportion of Ly6G+ MDSCs in orthotopic liver tumors, enhanced the T cells proliferation and improved the therapeutic effect of sorafenib synergistically.	Sorafenib	65-74	interleukin 6	Mus musculus	46-50
29266245-9	2018	The combination of anti-Ly6G antibody or anti-IL-6 antibody with sorafenib significantly reduced the cell proportion of Ly6G+ MDSCs in orthotopic liver tumors, enhanced the T cells proliferation and improved the therapeutic effect of sorafenib synergistically.	Sorafenib	234-243	interleukin 6	Mus musculus	46-50
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	18-29	interleukin 6	Mus musculus	257-270
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	31-34	interleukin 6	Mus musculus	257-270
29554498-7	2018	Mg2+, especially at 5 mM, raised proliferation rates of MSCs, and modulated immune responses by decreasing levels of IL-1beta and IL-6, and by increasing levels of IL-10 and PGE2 in cells stimulated with LPS or TNF-alpha.	magnesium ion	0-4	interleukin 6	Mus musculus	130-134
29377180-8	2018	Unlike controls, mice receiving TVX + TNF display severe hepatotoxicity with clear pathology and apoptosis, coagulated hepatic vessels and increased alanine aminotransferase levels and interleukin 6/10 ratios.	trovafloxacin	32-35	interleukin 6	Mus musculus	185-201
29544808-3	2018	In addition, DOX induced cardiotoxicity also shows involvement of proinflammatory cytokines such as IL-6 and TNF-alpha.	Doxorubicin	13-16	interleukin 6	Mus musculus	100-104
29554498-10	2018	In addition, conditioned media from MSCs cultured at 5 mM of Mg2+ modulated the production profile of cytokines, especially of IL-1beta and IL-6 in macrophages.	magnesium ion	61-65	interleukin 6	Mus musculus	140-144
29568861-11	2018	In addition, it was demonstrated that salidroside administration suppressed the expression levels of IL-6 and TNF-alpha.	rhodioloside	38-49	interleukin 6	Mus musculus	101-105
29571724-9	2018	We also found that the expression of pro-inflammatory cytokines, TNF-alpha, IL-6 and IL-1beta were inhibited by puerarin.	puerarin	112-120	interleukin 6	Mus musculus	76-80
29568905-7	2018	Myricitrin suppressed mRNA and protein expression of tumor necrosis factor-alpha, interleukin-6 and transforming growth factor-beta1 in ethanol-stimulated AML12 cells.	Ethanol	136-143	interleukin 6	Mus musculus	82-132
29568928-9	2018	The findings suggested that UA may protect against sepsis-induced AKI by inhibiting reactive oxygen species and inflammatory cytokines, including tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6, in the kidney from septic mice.	ursolic acid	28-30	interleukin 6	Mus musculus	202-206
29568861-13	2018	Furthermore, it was demonstrated that the effects of salidroside administration on AD mice were, at least partially, via inhibition of brain oxidative/nitrosative damage, suppression of both IL-6 and TNF-alpha expression levels, and suppression of the hippocampal neuronal apoptotic rate.	rhodioloside	53-64	interleukin 6	Mus musculus	191-195
28884630-7	2018	The IL6 response was significantly inhibited by chloroquine (10 mug/mL), thereby confirming the important role for TLR9 in the response by macrophage cells.	Chloroquine	48-59	interleukin 6	Mus musculus	4-7
29713131-11	2018	NaCl aggravates peritoneal macrophage inflammation by promoting the expressions of interleukin (IL)-1, IL-6 and mouse inducible nitric oxide synthase.	Sodium Chloride	0-4	interleukin 6	Mus musculus	103-107
29755467-9	2018	Silica-exposed males had more lung inflammation, bronchoalveolar lavage fluid cells, IL-6, and autoantibodies.	Silicon Dioxide	0-6	interleukin 6	Mus musculus	85-89
29701676-5	2018	Baicalein at concentrations up to 100 &amp;mu;M significantly inhibited the production of NO, IL-1&amp;alpha;, IL-6, G-CSF, GM-CSF, VEGF, MCP-1, IP-10, LIX, and RANTES as well as calcium release in RAW 264.7 cells induced by poly I:C (50 &amp;micro;g/mL) (all p &lt; 0.05).	baicalein	0-9	interleukin 6	Mus musculus	111-115
29695233-9	2018	Moreover, the mRNA level of pro-inflammatory genes (TNF-alpha and IL-6) were suppressed after apigterin treatment, at high concentration preadipocyte cells.	apigterin	94-103	interleukin 6	Mus musculus	66-70
29287831-7	2018	Our data shows that BTBR mice have increased expression of TLR7/IL-6/IL-23 in systemic DCs but not in skin as compared to C57 mice at baseline.	btbr	20-24	interleukin 6	Mus musculus	64-68
29725297-15	2018	DNJ consumption decreased the levels of IL-6 and TNF-alpha (P &lt; 0.05).	1-Deoxynojirimycin	0-3	interleukin 6	Mus musculus	40-44
29669582-10	2018	Galantamine decreased the expression of microglia and astrocyte markers (CD11b and GFAP), pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha), and NF-kappaB p65 in the hippocampus of LPS-exposed mice.	Galantamine	0-11	interleukin 6	Mus musculus	128-132
29669585-10	2018	Antibody array analysis showed that 4-PBA reduced several angiogenic factors [Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), MCP-1, IL-6] secreted by PVAT.	4-phenylbutyric acid	36-41	interleukin 6	Mus musculus	144-148
29983966-5	2018	Glycine and Pro-Hyp attenuated the DSS-induced rise in colonic IL-6 and TNF-alpha, as well as peripheral IL-1beta, IL-6, and TNF-alpha.	Glycine	0-7	interleukin 6	Mus musculus	63-67
29983966-5	2018	Glycine and Pro-Hyp attenuated the DSS-induced rise in colonic IL-6 and TNF-alpha, as well as peripheral IL-1beta, IL-6, and TNF-alpha.	dss	35-38	interleukin 6	Mus musculus	63-67
29983966-4	2018	Gelatin prevented the DSS-induced increase in interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in the colon, rather than in peripheral blood.	dss	22-25	interleukin 6	Mus musculus	76-89
29983966-4	2018	Gelatin prevented the DSS-induced increase in interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in the colon, rather than in peripheral blood.	dss	22-25	interleukin 6	Mus musculus	91-95
29127899-0	2018	Robust immunosensing system based on biotin-streptavidin coupling for spatially localized femtogram mL-1 level detection of interleukin-6.	Biotin	37-43	interleukin 6	Mus musculus	124-137
29127899-4	2018	Firstly, the biotinylated IL-6 capture antibody was immobilized on the fibre surface by biotin-streptavidin coupling.	Biotin	13-19	interleukin 6	Mus musculus	26-30
29524424-6	2018	Further studies with GTP, ITP, guanosine and inosine showed that pretreatment with these nucleotides/nucleosides also suppressed release of IL-6.	Guanosine Triphosphate	21-24	interleukin 6	Mus musculus	140-144
29524424-6	2018	Further studies with GTP, ITP, guanosine and inosine showed that pretreatment with these nucleotides/nucleosides also suppressed release of IL-6.	Inosine Triphosphate	26-29	interleukin 6	Mus musculus	140-144
29524424-6	2018	Further studies with GTP, ITP, guanosine and inosine showed that pretreatment with these nucleotides/nucleosides also suppressed release of IL-6.	Guanosine	31-40	interleukin 6	Mus musculus	140-144
29524424-6	2018	Further studies with GTP, ITP, guanosine and inosine showed that pretreatment with these nucleotides/nucleosides also suppressed release of IL-6.	Inosine	45-52	interleukin 6	Mus musculus	140-144
29524424-6	2018	Further studies with GTP, ITP, guanosine and inosine showed that pretreatment with these nucleotides/nucleosides also suppressed release of IL-6.	Nucleosides	101-112	interleukin 6	Mus musculus	140-144
29438701-9	2018	Both, ethanol and SL-CLP increased TNF-alpha and IL-6 levels in the MAB.	Ethanol	6-13	interleukin 6	Mus musculus	49-53
29736208-4	2018	Our experimental results demonstrated that Sch B inhibited production of IL-1beta, TNF-alpha, IL-6 and HMGB1 by LPS-activated RAW264.7 cells.	schizandrin B	43-48	interleukin 6	Mus musculus	94-98
29849710-10	2018	Results indicated that berberine hydrochloride significantly attenuated neutrophil infiltration and dose-dependently decreased the secretion and mRNA expressions of TNF-alpha, IL-1beta, and IL-6 within a certain range.	berberine chloride	23-46	interleukin 6	Mus musculus	190-194
29501084-7	2018	Consistently, SR141716A promoted BV-2 microglia to release inflammatory factors (TNF-alpha, IL-1beta, IL-6) while inhibited the production of IL-10 and chemokines (MCP-1, CX3CL1).	Rimonabant	14-23	interleukin 6	Mus musculus	102-106
29642616-5	2018	After nine months of treatment in APP/PS1 double-transgenic mice, scutellarin significantly improves behavior, reduces soluble and insoluble Abeta levels in the brain and plasma, decreases Abeta plaque associated gliosis and levels of proinflammatory cytokines TNF-alpha and IL-6, attenuates neuroinflammation, displays anti-amyloidogenic effects, and highlights the beneficial effects of intervention on development or progression of AD-like neuropathology.	scutellarin	66-77	interleukin 6	Mus musculus	275-279
29510137-7	2018	Our study also showed that CsA could inhibit interleukin-6 expression in BM-MSCs, while promoting programmed death-ligand 2 expression.	Cyclosporine	27-30	interleukin 6	Mus musculus	45-58
29408491-7	2018	Treatment with the RIP2 inhibitor gefitinib showed less intense activation of NF-kB, decreased TNF-alpha and IL-6, attenuated neuronal injury and improved illness.	Gefitinib	34-43	interleukin 6	Mus musculus	109-113
30788945-7	2018	RESULTS: Compared with sham group, serum levels of TNF-alpha, IL-1beta and IL-6, and osteolysis area were increased obviously in TCP group (P&lt;0.05), and serum level of T-AOC and SOD activity were decreased significantly in TCP group (P&lt;0.05), GRP78 expression, the ratio of p-PERK and PERK, p-eIF2alpha and eIF2alpha in the mouse calvaria of TCP group were up-regulated markedly.	N-(3,4,5-trichlorophenyl)succinimide	129-132	interleukin 6	Mus musculus	75-79
30788945-8	2018	Compared with TCP group, serum levels of TNF-alpha, IL-1beta and IL-6, and osteolysis area were decreased markedly in NAC group (P&lt;0.05), serum level of T-AOC and SOD activity were increased obviously in NAC group (P&lt;0.05), and GRP78 expression, the ratio of p-PERK/PERK and p-eIF2alpha/eIF2alpha were obviously down-regulated.	N-(3,4,5-trichlorophenyl)succinimide	14-17	interleukin 6	Mus musculus	65-69
30788945-8	2018	Compared with TCP group, serum levels of TNF-alpha, IL-1beta and IL-6, and osteolysis area were decreased markedly in NAC group (P&lt;0.05), serum level of T-AOC and SOD activity were increased obviously in NAC group (P&lt;0.05), and GRP78 expression, the ratio of p-PERK/PERK and p-eIF2alpha/eIF2alpha were obviously down-regulated.	Acetylcysteine	118-121	interleukin 6	Mus musculus	65-69
29666579-8	2018	Moreover, we demonstrated that D-dencichine was able to modulate the return of hematopoietic factors to normal levels, including thrombopoietin and IL-6.	d-dencichine	31-43	interleukin 6	Mus musculus	148-152
29532413-5	2018	Tryptanthrin (1) also downregulated the production of pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta.	tryptanthrine	0-12	interleukin 6	Mus musculus	100-104
29707119-6	2018	Furthermore, tumorigenesis in IL-6tm1Kopf mice treated with AOM-DSS, an IL-6 knockout mouse strain, was significantly inhibited compared with the control group, suggesting the important role of IL-6 in promoting tumorigenicity.	aom-dss	60-67	interleukin 6	Mus musculus	30-34
29707119-6	2018	Furthermore, tumorigenesis in IL-6tm1Kopf mice treated with AOM-DSS, an IL-6 knockout mouse strain, was significantly inhibited compared with the control group, suggesting the important role of IL-6 in promoting tumorigenicity.	aom-dss	60-67	interleukin 6	Mus musculus	72-76
29438882-4	2018	The encapsulation of immune stimulating biomolecules (monophosphoryl lipid A (MPLA) and CpG oligodeoxynucleotides (CpG ODN)) within EXOs greatly increased intracellular delivery to macrophages via phagocytic pathways, which induced higher TNF-alpha and IL-6 secretion than free MPLA and free CpG ODN.	monophosphoryl	54-68	interleukin 6	Mus musculus	253-257
29355504-8	2018	Furthermore, olaparib down regulated the elastase-induced expression of NF-kappaB dependent pro-inflammatory cytokines (TNF-A, IL-6), chemokine (MIP-2) and growth factor (GCSF) severely both at the mRNA and protein levels.	olaparib	13-21	interleukin 6	Mus musculus	127-131
29508169-18	2018	mRNA levels of NALP3, ASC, IL-1beta, IL-6, caspase-1, TNF-alpha, collagen-1, and collagen-3 significantly increased in the kidneys of the BTBR compared to the WT mice.	btbr	138-142	interleukin 6	Mus musculus	37-41
29627390-7	2018	In vitro, pre-treatment with SB dramatically inhibited the expression of TNF-alpha and IL-6 in LPS-induced RAW246.7 macrophages.	Butyric Acid	29-31	interleukin 6	Mus musculus	87-91
29352742-10	2018	KEY RESULTS: Cambogin attenuated diarrhoea, colon shortening and colon histological injury and IL-6, IFN-gamma and TNF-alpha production in DSS-treated mice.	dss	139-142	interleukin 6	Mus musculus	95-99
29678877-7	2018	DFO significantly improved vital parameters of adipose tissue biology by reducing reactive oxygen species and inflammatory marker (TNFalpha, IL-2, IL-6, and Hepcidin) secretion, by increasing the levels of antioxidant enzymes, hypoxia-inducible factor-1alpha (HIF-1alpha) and HIF-1alpha-targeted proteins, and by altering adipocytic iron-, glucose- and lipid-associated metabolism proteins.	Deferoxamine	0-3	interleukin 6	Mus musculus	147-151
29545877-8	2018	The content of tumor necrosis factor-alpha, interleukin-6 and albumin in bronchoalveolar fluid and MPO in lung tissue was significantly decreased in the 3-MA and DEX groups compared with the model group (P&lt;0.05).	Dexmedetomidine	162-165	interleukin 6	Mus musculus	44-57
29540470-3	2018	Using pre-clinical human and murine mCRPC models, we show that SPRY2 deficiency leads to an androgen self-sufficient form of CRPC Mechanistically, HER2-IL6 signalling axis enhances the expression of androgen biosynthetic enzyme HSD3B1 and increases SRB1-mediated cholesterol uptake in SPRY2-deficient tumours.	Cholesterol	263-274	interleukin 6	Mus musculus	152-155
29545894-6	2018	In TNBS mice receiving AdTGF-2, the increase in IFN-gamma, tumor necrosis factor-alpha, IL-6, IL-17 and IL-23 was significantly prevented by dexamethasone treatment.	Trinitrobenzenesulfonic Acid	3-7	interleukin 6	Mus musculus	88-92
28828622-7	2018	Modafinil suppressed the secretion of pro-inflammatory cytokines IL-6, TNF and IFN-gamma, and promoted secretion of anti-inflammatory cytokines IL-4 and IL-10.	Modafinil	0-9	interleukin 6	Mus musculus	65-69
29545894-6	2018	In TNBS mice receiving AdTGF-2, the increase in IFN-gamma, tumor necrosis factor-alpha, IL-6, IL-17 and IL-23 was significantly prevented by dexamethasone treatment.	Dexamethasone	141-154	interleukin 6	Mus musculus	88-92
29717417-9	2018	NaHS inhibited age-related increase in kidney cortical content of p21, IL-1beta, and IL-6, components of the senescence-associated secretory phenotype.	sodium bisulfide	0-4	interleukin 6	Mus musculus	85-89
29350096-5	2018	RESULTS: CoNPs and Co2+ can induce the increase of ROS and inflammatory cytokines in Balb/3T3 cells, such as tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6).	Cobalt(2+)	19-23	interleukin 6	Mus musculus	183-196
29350096-5	2018	RESULTS: CoNPs and Co2+ can induce the increase of ROS and inflammatory cytokines in Balb/3T3 cells, such as tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6).	Cobalt(2+)	19-23	interleukin 6	Mus musculus	198-202
29459269-7	2018	Chiisanoside administration could effectively reduce serum interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels; at the same time, the changes of related indexes of oxidative stress are improved, such as superoxide dismutase (SOD) and malondialdehyde (MDA).	chiisanoside	0-12	interleukin 6	Mus musculus	59-72
29447014-5	2018	RESULTS: MIF inhibitor Z-590 significantly inhibited the production of NO, TNF-alpha and IL-6 in LPS-activated RAW 264.7 macrophage cells and markedly inhibited LPS-induced expression of TNF-alpha, IL-6, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	z-590	23-28	interleukin 6	Mus musculus	89-93
29447014-5	2018	RESULTS: MIF inhibitor Z-590 significantly inhibited the production of NO, TNF-alpha and IL-6 in LPS-activated RAW 264.7 macrophage cells and markedly inhibited LPS-induced expression of TNF-alpha, IL-6, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	z-590	23-28	interleukin 6	Mus musculus	198-202
29459269-7	2018	Chiisanoside administration could effectively reduce serum interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels; at the same time, the changes of related indexes of oxidative stress are improved, such as superoxide dismutase (SOD) and malondialdehyde (MDA).	chiisanoside	0-12	interleukin 6	Mus musculus	74-78
29475099-7	2018	The expression of TNF-alpha and IL-6 and the activity of myeloperoxidase (MPO) in colonic tissues were significantly reduced in CX-10 supplemented mice.	cx-10	128-133	interleukin 6	Mus musculus	32-36
29133093-5	2018	Polysaccharides induced RAW264.7 macrophage cells to release noticeable amounts of nitric oxide and cytokines including IL-1beta, TNF-alpha, IL-6, IL-10 and IL-12 through NF-kappaB and MAPKs signaling pathways.	Polysaccharides	0-15	interleukin 6	Mus musculus	141-145
29134640-0	2018	Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol.	Inositol	154-166	interleukin 6	Mus musculus	8-12
29336466-2	2018	Magnolol exhibited strong radical scavenging and antioxidant activity, and significantly inhibited the production of interleukin-6, tumor necrosis factor-a and nitrite/nitrate (NOX) in lipopolysaccharide-stimulated BV2 and RAW 264.7 cells when applied at concentrations of 10 and 50 microM, respectively.	magnolol	0-8	interleukin 6	Mus musculus	117-130
29475099-10	2018	In conclusion, CX-10 treatment attenuated DSS-induced UC in mice through inhibiting the activation of NF-kappaB and MAPK pathways and reducing TNF-alpha and IL-6 levels, suggesting that CX-10 is a potential therapeutic drug for UC.	cx-10	15-20	interleukin 6	Mus musculus	157-161
29475099-10	2018	In conclusion, CX-10 treatment attenuated DSS-induced UC in mice through inhibiting the activation of NF-kappaB and MAPK pathways and reducing TNF-alpha and IL-6 levels, suggesting that CX-10 is a potential therapeutic drug for UC.	dss	42-45	interleukin 6	Mus musculus	157-161
29475099-10	2018	In conclusion, CX-10 treatment attenuated DSS-induced UC in mice through inhibiting the activation of NF-kappaB and MAPK pathways and reducing TNF-alpha and IL-6 levels, suggesting that CX-10 is a potential therapeutic drug for UC.	cx-10	186-191	interleukin 6	Mus musculus	157-161
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	interleukin 6	Mus musculus	119-132
29393413-6	2018	In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet.	Berberine	32-35	interleukin 6	Mus musculus	134-138
29881422-4	2018	The zymosan-mediated secretion of tumor necrosis factor-alpha (TNF)-alpha), interleukin (IL)-6), and IL12p40 but not IL-10 in BMDMs was significantly inhibited by pre-treatment with wedelolactone (30 microg/mL, P &lt; 0.001).	Zymosan	4-11	interleukin 6	Mus musculus	76-94
29881422-4	2018	The zymosan-mediated secretion of tumor necrosis factor-alpha (TNF)-alpha), interleukin (IL)-6), and IL12p40 but not IL-10 in BMDMs was significantly inhibited by pre-treatment with wedelolactone (30 microg/mL, P &lt; 0.001).	wedelolactone	182-195	interleukin 6	Mus musculus	76-94
29472382-6	2018	Quinpirole increased the protein and mRNA expression of leptin and IL-6, but not adiponectin and visfatin (24 h).	Quinpirole	0-10	interleukin 6	Mus musculus	67-71
29125882-5	2018	Meanwhile, we suggested that upregulation of miR-137 could inhibit the expression of TNF-alpha and IL-6, two markers of inflammatory response after SCI, and apoptosis in hydrogen peroxide-treated C8-D1A and C8-B4 cells.	Hydrogen Peroxide	170-187	interleukin 6	Mus musculus	99-103
29472382-10	2018	These quinpirole effects on leptin and IL-6 expression were prevented by the D2R antagonist L741,626.	Quinpirole	6-16	interleukin 6	Mus musculus	39-43
29611140-9	2018	The mRNA expression levels of tumor necrosis factor (TNF)-alpha and interferon (INF)-gamma were significantly upregulated; however, those of interleukin (IL)-6 and IL-10 were significantly downregulated in the DSS-CT group than in the control group.	Dextran Sulfate	210-213	interleukin 6	Mus musculus	141-159
29411511-7	2018	Zymosan-A protected bone marrow cells from radiation-induced apoptosis, up-regulated IL-6, IL-12, G-CSF and GM-CSF in bone marrow cells.	Zymosan	0-9	interleukin 6	Mus musculus	85-89
29411511-11	2018	Zymosan-A protected bone marrow cells from radiation-induced apoptosis and up-regulated IL-6, IL-12, G-CSF and GM-CSF.	Zymosan	0-9	interleukin 6	Mus musculus	88-92
29263441-6	2018	Mechanistically, we reveal that pathologic levels of TNFalpha and IL-6 inhibit erythroid colony formation and differentially affect terminal erythropoiesis through reactive oxygen species-induced caspase-3 activation and apoptosis.	Reactive Oxygen Species	164-187	interleukin 6	Mus musculus	66-70
29331869-7	2018	We further showed that pathologic T cell proliferation induced by ex vivo re-stimulation with MOG35-55 and proinflammatory cytokines IL-6 and TNF-alpha were lower in naringenin-fed mice than in the control mice.	naringenin	166-176	interleukin 6	Mus musculus	133-137
29132705-9	2018	The blockage of COX-2 by celecoxib reversed the benefit of IL-pretreated 17A-MSCs on the serum PGE2 concentration, spleen and kidney Tregs percentages, serum creatinine and BUN levels, renal acute tubular necrosis scores, and serum IL-6, TNF-alpha, IFN-gamma, and IL-10 levels of IRI-pretreated mice with AKI, compared with MSCs.	Celecoxib	25-34	interleukin 6	Mus musculus	232-236
29412160-6	2018	After adding p38 inhibitor, SB203580 to culture, the production of IL-1beta, IL-6, IL-10, TNF-alpha was significantly reduced as compared to visfatin only (P &lt; 0.01).	SB 203580	28-36	interleukin 6	Mus musculus	77-81
29363729-4	2018	Flow cytometric analysis indicated that the ratio of CD3+CD4+ to CD3+CD8+ T lymphocytes in the peripheral blood increased in MPTP-treated mice following treatment with EGCG, and EGCG reduced expression of inflammatory factors tumor necrosis factor-alpha and interleukin-6 in serum.	epigallocatechin gallate	178-182	interleukin 6	Mus musculus	258-271
29363729-4	2018	Flow cytometric analysis indicated that the ratio of CD3+CD4+ to CD3+CD8+ T lymphocytes in the peripheral blood increased in MPTP-treated mice following treatment with EGCG, and EGCG reduced expression of inflammatory factors tumor necrosis factor-alpha and interleukin-6 in serum.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	125-129	interleukin 6	Mus musculus	258-271
29670287-3	2018	Itaconate and its membrane-permeable derivative dimethyl itaconate (DI) selectively inhibit a subset of cytokines 2 , including IL-6 and IL-12 but not TNF.	itaconic acid	0-9	interleukin 6	Mus musculus	128-132
29747742-7	2018	RESULTS: The results showed that genistein exerted inhibitory effects on LPS-induced expressions of cyclooxygenase-2 (COX-2), inducible nitric oxide (iNOS), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta) and interleukin-6 (IL-6).	Genistein	33-42	interleukin 6	Mus musculus	232-245
29670287-3	2018	Itaconate and its membrane-permeable derivative dimethyl itaconate (DI) selectively inhibit a subset of cytokines 2 , including IL-6 and IL-12 but not TNF.	dimethyl itaconate	48-66	interleukin 6	Mus musculus	128-132
29670287-3	2018	Itaconate and its membrane-permeable derivative dimethyl itaconate (DI) selectively inhibit a subset of cytokines 2 , including IL-6 and IL-12 but not TNF.	dimethyl itaconate	68-70	interleukin 6	Mus musculus	128-132
29747742-7	2018	RESULTS: The results showed that genistein exerted inhibitory effects on LPS-induced expressions of cyclooxygenase-2 (COX-2), inducible nitric oxide (iNOS), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta) and interleukin-6 (IL-6).	Genistein	33-42	interleukin 6	Mus musculus	247-251
28661933-8	2018	At 20 h after CLP, PYR-41 treatment significantly decreased serum levels of proinflammatory cytokines (TNF-alpha, interleukin [IL]-1beta, and IL-6) and organ injury markers (aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase).	4(4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl ester	19-25	interleukin 6	Mus musculus	142-146
29629026-7	2018	In addition, vitamin C supplementation suppressed mRNA levels of pro-inflammatory mediators and cytokines, including cyclooxygenase-2, microsomal prostaglandin E synthase-2, tumor necrosis factor-alpha, Interleukin (IL)-1beta, and IL-6, and reduced expression of the proliferation marker, proliferating cell nuclear antigen, compared to observations of AOM/DSS animals.	Ascorbic Acid	13-22	interleukin 6	Mus musculus	231-235
28661933-11	2018	PYR-41 inhibited the expression of cytokines (IL-1beta and IL-6), chemokines (keratinocyte-derived chemokine and macrophage inflammatory protein 2), and inflammatory mediators (cyclooxygenase-2 and inducible nitric oxide synthase) in the lungs of septic mice.	4(4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl)-benzoic acid ethyl ester	0-6	interleukin 6	Mus musculus	59-63
29496522-6	2018	DHT inhibited the myeloperoxidase (MPO) activity, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression in colon tissues and decreased serum levels of TNF-alpha, IL-1beta, IL-6, and high-mobility group box 1 (HMGB1).	Dihydrotestosterone	0-3	interleukin 6	Mus musculus	197-201
29228376-13	2018	Most cytokines showed no treatment-related effects, but IL-1beta, IL-6, and IL-12 were slightly reduced in mice treated with DOX + CYP.	Doxorubicin	125-128	interleukin 6	Mus musculus	66-70
29496522-8	2018	In LPS-stimulated RAW264.7 macrophages, DHT significantly inhibited generation of nitric oxide, IL-6, TNF-alpha and protein expression of iNOS, COX-2.	Dihydrotestosterone	40-43	interleukin 6	Mus musculus	96-100
29643857-6	2018	Moreover, FKE, but not FKD, peptides enhanced efferocytosis of apoptotic PMN, reduced TNFalpha and interleukin (IL)-6, and increased IL-10 secretion by lipopolysaccharide-stimulated macrophages ex vivo.	CHEMBL4437968	10-13	interleukin 6	Mus musculus	99-117
32454648-9	2018	Conclusion: Our data indicate that especially 11% ethanol root extract of P. endlicherianum targets the inflammatory response of macrophages via inhibition of COX-2, IL-6, and TNF-alpha through inactivation of the NF-kappaB signalling pathway, supporting the pharmacologic basis of P. endlicherianum as a traditional herbal medicine for the treatment of inflammation and its associated disorders.	Ethanol	50-57	interleukin 6	Mus musculus	166-170
29566694-7	2018	RESULTS: In the present study, we found that 4AAQB exhibits anti-inflammatory effects inhibit tumor necrosis factor-alpha (TNF-alpha)/interleukin-6 (IL-6) releasing and LPS-stimulated phagocytes migration without affect cell growth.	4-acetylantroquinonol B	45-50	interleukin 6	Mus musculus	134-147
29566694-7	2018	RESULTS: In the present study, we found that 4AAQB exhibits anti-inflammatory effects inhibit tumor necrosis factor-alpha (TNF-alpha)/interleukin-6 (IL-6) releasing and LPS-stimulated phagocytes migration without affect cell growth.	4-acetylantroquinonol B	45-50	interleukin 6	Mus musculus	149-153
29040401-8	2018	With the same comparison, the positive cells of TUNEL staining and the expression of IL-6 and IL-1beta were significantly reduced, whereas the total/cleaved caspase-3 and total/pNF-kappaB were significantly increased in the O-HP group.	2-hydroxyphenylacetic acid	224-228	interleukin 6	Mus musculus	85-89
29538417-6	2018	In addition, BB markedly attenuated colonic inflammation by alleviating inflammatory cell infiltration and inhibiting myeloperoxidase (MPO) and cytokines (TNF-alpha, IFN-gamma, IL-1beta, IL-6, IL-4 and IL-10) productions in DSS mice.	berberrubine	13-15	interleukin 6	Mus musculus	187-191
29534036-3	2018	Co-exposure to BaP and PCB153 showed a synergistic effect on TNFalpha and IL6 expression.	Benzo(a)pyrene	15-18	interleukin 6	Mus musculus	74-77
29534036-4	2018	Treatment with BaP and PCBs during only the maturation period up-regulated the INFG (IL6, TNFalpha, CXCL-10 &amp;amp; MCP-1).	Benzo(a)pyrene	15-18	interleukin 6	Mus musculus	85-88
29534036-4	2018	Treatment with BaP and PCBs during only the maturation period up-regulated the INFG (IL6, TNFalpha, CXCL-10 &amp;amp; MCP-1).	Polychlorinated Biphenyls	23-27	interleukin 6	Mus musculus	85-88
29534526-9	2018	In BV-2 cells, peiminine significantly decreased LPS-induced expression of the pro-inflammatory mediators TNF-alpha, IL-6 and IL-1beta, COX-2 and iNOS by inhibiting the phosphorylation of ERK1/2, AKT and NF-kappaB p65.	peiminine	15-24	interleukin 6	Mus musculus	117-121
29541444-4	2018	We found that, in PSGL-1+/+ mice, high salt diet resulted in high blood pressure with the increased expression of serum inflammatory cytokines IL-6, IL-1beta and TNFalpha, vascular injury markers MCP-1, ET-1, and VWF, and renal macrophages and T cells infiltration, and endothelium-dependent acetylcholine vasodilation dysfunction.	Salts	39-43	interleukin 6	Mus musculus	143-147
29713361-5	2018	Scratching behavior and DNCB-induced AD-like skin lesions were also attenuated by AGNE administration through the reduction of serum IgE, histamine, tumor necrosis factor-alpha (TNF-alpha), IL-6 levels, and COX-2 expression in skin tissue from mouse models.	agne	82-86	interleukin 6	Mus musculus	190-194
29593532-9	2018	Results: EGCG administration markedly attenuated atherosclerotic plaque formation in HFD-fed ApoE-/- mice, which were accompanied by increased plasma interleukin-10 (IL-10) level and decreased plasma IL-6 and tumor necrosis factor-alpha (TNF-alpha) levels.	epigallocatechin gallate	9-13	interleukin 6	Mus musculus	200-204
29509670-5	2018	The expression of cytokines, including interleukin-6, tumor necrosis factor-alpha, and chemokine of monocyte chemoattractant protein, was reduced under lupinalbin A exposure in LPS-treated RAW264.7 cells.	Lupinalbin A	152-164	interleukin 6	Mus musculus	39-81
29484750-6	2018	Costunolide treatment attenuated the main components of the fibrovascular tissue, wet weight, vascularization (Hb content), macrophage recruitment (NAG activity), collagen deposition, and the levels of vascular endothelial growth factor (VEGF), interleukin (IL)-1beta, IL-6, IL-17, tumor necrosis factor (TNF)-alpha and transforming growth factor (TGF-beta).	costunolide	0-11	interleukin 6	Mus musculus	269-273
29157127-5	2018	Metformin treatment decreased the expression of IL-1beta and IL-6 in epididymal fat, which was correlated with the abundance of various bacterial genera.	Metformin	0-9	interleukin 6	Mus musculus	61-65
29527115-6	2018	The mRNA and protein expression levels of inflammatory cytokines (IL-1alpha, IL-6, IL-12, and IL-17) were also upregulated after zymosan stimulation.	Zymosan	129-136	interleukin 6	Mus musculus	77-81
29552018-4	2018	The results indicated that pretreatment with 2-DG suppressed LPS-induced elevation of tumor necrosis factor alpha and interleukin 6.	Deoxyglucose	45-49	interleukin 6	Mus musculus	118-131
28960086-8	2018	In the mothers" lungs, e-cigarette exposure with and without nicotine increased the proinflammatory cytokines IL-1beta, IL-6, and TNF-alpha.	Nicotine	61-69	interleukin 6	Mus musculus	120-124
29367111-7	2018	The high levels of triglyceride and cholesterol, and high expression of TNFalpha and IL-6 were decreased by zingerone.	zingerone	108-117	interleukin 6	Mus musculus	85-89
29480020-7	2018	Treatment with quercetin in the pristane-induced LN mice model was nephroprotective, decreasing proteinuria levels and significantly lowering tissue expression of IL-6, TNF-alpha, TGF-beta1, Bax and TBARS.	Quercetin	15-24	interleukin 6	Mus musculus	163-167
29480020-7	2018	Treatment with quercetin in the pristane-induced LN mice model was nephroprotective, decreasing proteinuria levels and significantly lowering tissue expression of IL-6, TNF-alpha, TGF-beta1, Bax and TBARS.	pristane	32-40	interleukin 6	Mus musculus	163-167
29426772-4	2018	The results demonstrated that violacin A attenuated the production of NO, IL-1beta, IL-6, and TNF-alpha as well as inhibited the expression of iNOS in LPS-induced RAW 264.7 cells.	violacin A	30-40	interleukin 6	Mus musculus	84-88
29275159-7	2018	Furthermore, COS effectively inhibited the levels of pro-inflammatory cytokines such as TNF-alpha, IL-1beta and IL-6, and markedly improved the activities of antioxidant enzymes (SOD, GSH-Px, CAT), as well as the content of skin hydroxyproline and moisture.	carbonyl sulfide	13-16	interleukin 6	Mus musculus	112-116
29462849-5	2018	In BV2 microglial cells, 3",4"-dihydroxyflavone successfully inhibited production of chemokines such as nitric oxide and prostaglandin E2 and proinflammatory cytokines such as tumor necrosis factor alpha, interleukin 1 beta, and interleukin 6 in BV2 microglia.	3',4'-dihydroxyflavone	25-47	interleukin 6	Mus musculus	229-242
28969938-8	2018	RESULTS: In mice treated with high-dose GW0742, plasma levels of IL-6, IL-1beta, and MCP-1 were significantly increased compared to the control group mice.	GW0742	40-46	interleukin 6	Mus musculus	65-69
28969938-9	2018	When compared to mice treated with low-dose GW0742 plasma levels of IL-6, IL-1beta, GM-CSF, KC, and MCP-1 were significantly elevated in high-dose-treated mice.	GW0742	44-50	interleukin 6	Mus musculus	68-72
29473075-5	2018	In vitro, monascin treatment inhibited the IL-1beta-induced expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor alpha (TNF-alpha), and interleukin-6 (IL-6).	monascin	10-18	interleukin 6	Mus musculus	229-242
29473075-5	2018	In vitro, monascin treatment inhibited the IL-1beta-induced expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor alpha (TNF-alpha), and interleukin-6 (IL-6).	monascin	10-18	interleukin 6	Mus musculus	244-248
29485160-2	2018	Mice treated with a high concentration of Kuding tea polyphenols (HKTP) had lower serum levels of interleukin-6 (IL-6), IL-12, tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), motilin (MOT), substance P (SP), and endothelin-1 (ET-1), and higher serum levels of somatostatin (SS) and vasoactive intestinal peptide (VIP) than did the mice in the control group.	Polyphenols	53-64	interleukin 6	Mus musculus	98-111
29393707-10	2018	Kaempferol pretreatment showed reduction in cytokines IL-6, IL-1beta, and TNF-alpha in plasma as well as in lung tissue in comparison with septic mice without pretreatment.	kaempferol	0-10	interleukin 6	Mus musculus	54-58
29428410-8	2018	Mechanistic studies showed that these inhibitors could release Nrf2 in H9c2 cells and LPS-inflammatory mouse models and translocate into the nucleus in a dose-response manner, which significantly increased the downstream genes (HO-1, NQO-1) and the pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), while ROS production dramatically decreased.	ros	311-314	interleukin 6	Mus musculus	298-302
29193293-7	2018	CYM5442 treatment during the brief cuprizone exposure significantly prevented Il-1beta, Il-6, Cxcl10, and Cxcl3 induction, resulting in suppression of subsequent reactive gliosis and demyelination.	2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl amino)ethanol	0-7	interleukin 6	Mus musculus	88-92
29485160-2	2018	Mice treated with a high concentration of Kuding tea polyphenols (HKTP) had lower serum levels of interleukin-6 (IL-6), IL-12, tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), motilin (MOT), substance P (SP), and endothelin-1 (ET-1), and higher serum levels of somatostatin (SS) and vasoactive intestinal peptide (VIP) than did the mice in the control group.	Polyphenols	53-64	interleukin 6	Mus musculus	113-117
29485160-2	2018	Mice treated with a high concentration of Kuding tea polyphenols (HKTP) had lower serum levels of interleukin-6 (IL-6), IL-12, tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), motilin (MOT), substance P (SP), and endothelin-1 (ET-1), and higher serum levels of somatostatin (SS) and vasoactive intestinal peptide (VIP) than did the mice in the control group.	hktp	66-70	interleukin 6	Mus musculus	98-111
29485160-2	2018	Mice treated with a high concentration of Kuding tea polyphenols (HKTP) had lower serum levels of interleukin-6 (IL-6), IL-12, tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), motilin (MOT), substance P (SP), and endothelin-1 (ET-1), and higher serum levels of somatostatin (SS) and vasoactive intestinal peptide (VIP) than did the mice in the control group.	hktp	66-70	interleukin 6	Mus musculus	113-117
29485160-5	2018	And HKTP also could reduce the TNF-alpha, IL-1beta (interleukin-1 beta), and IL-6 mRNA expression in gastric injury mice.	hktp	4-8	interleukin 6	Mus musculus	77-81
29129634-3	2018	Further study show that beta-chitosan sulfate significantly promoted the production of NO, prostaglandin E2, tumor necrosis factor (TNF)-alpha, interleukin-6 and interleukin-1beta at the levels of transcription and translation.	beta-chitosan sulfate	24-45	interleukin 6	Mus musculus	144-157
29204872-5	2018	ELISA and qPCR results indicated that RA dose-dependently decreased the expression of TNF-alpha, IL-1beta, and IL-6 both in tissues and mMECs.	rosmarinic acid	38-40	interleukin 6	Mus musculus	111-115
29234949-3	2018	Curc-mPEG454 showed lower cytotoxicity (IC50 57.8 muM) when compared with that of curcumin (IC50 32.6 muM) and inhibited the release of the inflammatory cytokines IL-6, TNF-alpha, IL-1beta, and MCP-1 in a concentration-dependent manner.	curc-mpeg454	0-12	interleukin 6	Mus musculus	163-167
29328945-8	2018	RESULTS: Astaxanthin administration markedly reduced serum digestive enzyme activities, pancreatic histological scores, proinflammatory cytokine levels (tumor necrosis factor-alpha (TNF-alpha), Interleukin-1beta (IL-1beta), and Interleukin-6 (IL-6)), MPO and JAK/STAT3 activity.	astaxanthine	9-20	interleukin 6	Mus musculus	228-241
29328945-8	2018	RESULTS: Astaxanthin administration markedly reduced serum digestive enzyme activities, pancreatic histological scores, proinflammatory cytokine levels (tumor necrosis factor-alpha (TNF-alpha), Interleukin-1beta (IL-1beta), and Interleukin-6 (IL-6)), MPO and JAK/STAT3 activity.	astaxanthine	9-20	interleukin 6	Mus musculus	243-247
29328946-5	2018	The results showed that kaempferol reduced the production of various pro-inflammatory factors and inflammatory proteins including IL-1beta, IL-6, TNF-alpha, MCP-1, COX-2 and iNOS in brain tissues.	kaempferol	24-34	interleukin 6	Mus musculus	140-144
29335159-6	2018	Domperidone treatment increased LPS-induced tumor necrosis factor (TNF) and interleukin (IL)-6 production in the bronchoalveolar lavage fluid, without altering tissue damage and the number of immune cells in the lungs and circulation.	Domperidone	0-11	interleukin 6	Mus musculus	76-94
29335159-6	2018	Domperidone treatment increased LPS-induced tumor necrosis factor (TNF) and interleukin (IL)-6 production in the bronchoalveolar lavage fluid, without altering tissue damage and the number of immune cells in the lungs and circulation.	lps	32-35	interleukin 6	Mus musculus	76-94
29414653-3	2018	Eight genes Ltf, Tnf, Il6, Jun, Il12b, Stat3, Rel and Crem could regulate the inflammatory factors, and TNF signaling pathway and Jak-STAT signaling pathway might play an important role in the mechanism through which DECB protected the liver of mice.	decb	217-221	interleukin 6	Mus musculus	22-25
28144715-11	2018	The attenuation of cardiac depression in irbesartan-treated mice was associated with lower levels of MCP-1 in plasma and a reduction in the levels of TNF-alpha, IL-1beta, and IL-6.	Irbesartan	41-51	interleukin 6	Mus musculus	175-179
29414647-0	2018	Methamphetamine modulates the production of interleukin-6 and tumor necrosis factor-alpha via the cAMP/PKA/CREB signaling pathway in lipopolysaccharide-activated microglia.	Methamphetamine	0-15	interleukin 6	Mus musculus	44-57
29414647-0	2018	Methamphetamine modulates the production of interleukin-6 and tumor necrosis factor-alpha via the cAMP/PKA/CREB signaling pathway in lipopolysaccharide-activated microglia.	Cyclic AMP	98-102	interleukin 6	Mus musculus	44-57
29414647-3	2018	In the present study, the effects of METH on lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) productions were tested in BV-2 cells and primary microglial cells.	Methamphetamine	37-41	interleukin 6	Mus musculus	78-91
29414647-8	2018	In contrast, METH augmented the IL-6 production and inhibited the TNF-alpha production induced by LPS.	Methamphetamine	13-17	interleukin 6	Mus musculus	32-36
29414647-14	2018	These results suggest that the differential regulation of IL-6 and TNF-alpha by METH in LPS-activated microglial cells may be attributable to the cAMP/PKA/CREB signaling pathway.	Methamphetamine	80-84	interleukin 6	Mus musculus	58-62
29414658-7	2018	Sodium butyrate pretreatment markedly inhibited the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	Butyric Acid	0-15	interleukin 6	Mus musculus	148-161
29414647-14	2018	These results suggest that the differential regulation of IL-6 and TNF-alpha by METH in LPS-activated microglial cells may be attributable to the cAMP/PKA/CREB signaling pathway.	Cyclic AMP	146-150	interleukin 6	Mus musculus	58-62
29328388-6	2018	Activation of FXR by GW4064 alleviated hepatic inflammation in the LPS-induced murine liver injury model as reflected by reduced serum levels of aspartate aminotransferase and pro-inflammatory cytokine mRNA expression, including tumor necrosis factor-alpha, as well as interleukin-6 and -1beta in WT mice.	GW 4064	21-27	interleukin 6	Mus musculus	269-293
29414658-7	2018	Sodium butyrate pretreatment markedly inhibited the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	Butyric Acid	0-15	interleukin 6	Mus musculus	163-167
28701059-4	2018	It was also found that TNF-alpha and IL-6 in serum were significantly lower in both groups of BJOE and IND, than in the control group (p &lt; .01).	Indomethacin	103-106	interleukin 6	Mus musculus	37-41
29197723-10	2018	The protective analgesic and anti-inflammatory mechanisms of quercetin included the inhibition of TiO2-induced neutrophil and macrophage recruitment, proteoglycan degradation, oxidative stress, cytokine production (TNF-alpha, IL-1beta, IL-6, and IL-10), COX-2 mRNA expression, and bone resorption as well as activation of Nrf2/HO-1 signaling pathway.	Quercetin	61-70	interleukin 6	Mus musculus	236-240
29328461-6	2018	The tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and IL-18 concentrations, and caspase-3 and caspase-9 were significantly inhibited by gambogic acid in arthritic mice.	gambogic acid	154-167	interleukin 6	Mus musculus	63-67
29344655-10	2018	The results demonstrated that the secretion of the inflammatory cytokines TNF-alpha, IL-6 and IL-1beta by LPS-stimulated BV2 cells was significantly reduced by osthole treatment.	osthol	160-167	interleukin 6	Mus musculus	85-89
29662851-4	2018	Treatment with PC reduced serum levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6 as well as reduced mRNA expression in colon tissue of colitis mice in comparison with other treatments.	pc	15-17	interleukin 6	Mus musculus	109-122
29280507-4	2018	The results showed that injection of SO-GS-R significantly increased the levels of IL-1beta, IL-5, IL-6, G-CSF, KC, MCP-1, MIP-1alpha, and MIP-1beta in both serum and muscle.	sulfur monoxide	37-39	interleukin 6	Mus musculus	99-103
29161446-7	2018	Exposure to e-cigarette aerosols with and without nicotine caused significant reductions in hippocampal gene expression of Ngfr and Bdnf, as well as in serum levels of cytokines IL-1beta, IL-2, and IL-6.	Nicotine	50-58	interleukin 6	Mus musculus	198-202
29773105-10	2018	Results GTP decreased the DAI and inflammatory score, and reduced the levels of TNF-alpha and IL-6 in TNBS-induced colitis mice at three and four weeks after the administration.	Guanosine Triphosphate	8-11	interleukin 6	Mus musculus	94-98
29682158-9	2018	Meanwhile, HC treatment lowered the levels of the proinflammatory cytokines IL-1beta, IL-6, IL-17, and TNF-alpha induced by Dox.	Doxorubicin	124-127	interleukin 6	Mus musculus	86-90
29622848-7	2018	IL-6, TNF-alpha, and Ccl2 gene expression peaked on day 5 in DSS-treated mouse colon, whereas SAHA treatment significantly decreased pro-inflammatory gene expression.	Dextran Sulfate	61-64	interleukin 6	Mus musculus	0-4
29495255-11	2018	GONPs inhibited LPS induced interleukin 6 (IL-6) synthesis and PHA induced interferon gamma (IFNgamma) synthesis by whole blood cell cultures in a dose dependent manner.	gonps	0-5	interleukin 6	Mus musculus	28-41
29495255-11	2018	GONPs inhibited LPS induced interleukin 6 (IL-6) synthesis and PHA induced interferon gamma (IFNgamma) synthesis by whole blood cell cultures in a dose dependent manner.	gonps	0-5	interleukin 6	Mus musculus	43-47
29354820-4	2018	Asiatic acid reduced LPS-induced expression and secretion of inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in BV2 cells.	asiatic acid	0-12	interleukin 6	Mus musculus	169-182
29256438-10	2018	The NW-Sr-CS coatings could modulate the polarization of macrophages towards the wound-healing M2 phenotype, reduce the mRNA expression levels of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and enhance anti-inflammatory cytokines (IL-1ra, IL-10).	Cesium	10-12	interleukin 6	Mus musculus	195-199
29354820-4	2018	Asiatic acid reduced LPS-induced expression and secretion of inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in BV2 cells.	asiatic acid	0-12	interleukin 6	Mus musculus	184-188
29452577-12	2018	Poldip2 expression was upregulated in astrocytes exposed to oxygen and glucose deprivation (OGD) and siRNA-mediated downregulation of Poldip2 abrogated OGD-induced IL-6 and TNF-alpha expression.	Oxygen	60-66	interleukin 6	Mus musculus	164-168
29330324-0	2018	Betaine Ameliorates Experimental Autoimmune Encephalomyelitis by Inhibiting Dendritic Cell-Derived IL-6 Production and Th17 Differentiation.	Betaine	0-7	interleukin 6	Mus musculus	99-103
29330324-3	2018	In this article, we report that betaine treatment ameliorates MS pathogenesis by inhibiting DC-derived IL-6 production and Th17 differentiation.	Betaine	32-39	interleukin 6	Mus musculus	103-107
29330324-6	2018	Interestingly, in the in vitro Th17-differentiation assay, no significant change in Th17 cells was observed between the vehicle- and betaine-treated groups, whereas in the in vitro DC culture experiment, betaine treatment significantly decreased DC-derived IL-6 production.	Betaine	204-211	interleukin 6	Mus musculus	257-261
29330324-8	2018	All of these data demonstrated that betaine inhibited Th17 differentiation indirectly by reducing IL-6 production by DCs.	Betaine	36-43	interleukin 6	Mus musculus	98-102
29497376-10	2018	In vitro, studies further revealed that quercetin efficiently inhibited macrophages activation and M1 polarization, as well as decreased the mRNA expression of M1 macrophage markers such as TNF-alpha, IL-1beta, IL-6, and nitric oxide synthase 2.	Quercetin	40-49	interleukin 6	Mus musculus	211-215
29415054-9	2018	Compared to ALI alone, COS treatment of ALI caused a significant decrease in the wet/dry lung weight ratio, indicating a reduction in lung edema, inflammatory cell infiltration, levels of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-4, IL-6 and nuclear factor kappa B mRNA and protein expression were reduced and IL-10 mRNA and protein expression was increased (P &lt; 0.05).	carbonyl sulfide	23-26	interleukin 6	Mus musculus	247-251
29439712-10	2018	In addition, trovafloxacin treatment significantly reduced mRNA levels of several pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha), which correlates with an overall reduction in the accumulation of inflammatory cell types (neutrophils, microglia/macrophages, and astroglia) at the injury zone.	trovafloxacin	13-26	interleukin 6	Mus musculus	120-124
29926670-10	2018	Compared with ethanol group, addition of CQ increased furtherthe level of LC3-IIexpression, and TG amount, serum AST and ALT activities, and the expression of NF-kappaB p65, TNF-alphaand IL-6.	Chloroquine	41-43	interleukin 6	Mus musculus	187-191
29229533-10	2018	ELISA results revealed that xanthoceraside suppressed IL-6 release and increased IL-4 levels.	xanthoceraside	28-42	interleukin 6	Mus musculus	54-58
29366478-8	2018	There were significant molecular changes such as increased alpha-SMA and collagen type 1 production and increased production of inflammatory cytokines such as IL-6 and TNF-alpha, but not TGF-beta, in the succinate-treated group compared to the control group.	Succinic Acid	204-213	interleukin 6	Mus musculus	159-163
28935544-10	2018	In vivo, we discovered that metformin not only decreased the serum level of the pro-inflammatory cytokines IL-6 and TNF-alpha but also lowered the expression of the M1 macrophage markers CD11c and MCP-1 in adipose tissue.	Metformin	28-37	interleukin 6	Mus musculus	107-111
29410383-6	2018	RESULTS: CAP exposure was associated with significantly higher tumor necrosis factor-alpha (TNFalpha) and interleukin (IL)-6 mRNA in the hypothalamus of control mice, but not IKK2Neu-KO mice.	cap	9-12	interleukin 6	Mus musculus	106-124
29402900-8	2018	Treatment with GSH significantly attenuated the H2O2-induced upregulation of genes related to NADPH oxidase in 3T3-L1 adipocytes, and that of Il6, Tgfb, and Pdgfb in RAW264.7 cells.	Glutathione	15-18	interleukin 6	Mus musculus	142-145
29402900-8	2018	Treatment with GSH significantly attenuated the H2O2-induced upregulation of genes related to NADPH oxidase in 3T3-L1 adipocytes, and that of Il6, Tgfb, and Pdgfb in RAW264.7 cells.	Hydrogen Peroxide	48-52	interleukin 6	Mus musculus	142-145
28935544-11	2018	In vitro, metformin reduced the secretion of IL-6 and TNF-alpha in palmitate-stimulated RAW264.7 macrophages, while compound C treatment blocked the effect of metformin.	Metformin	10-19	interleukin 6	Mus musculus	45-49
29051087-7	2018	Additionally, mRNA levels of inflammation related molecules including IL-1beta, IL-6, tumor necrosis factor (TNF)-alpha, inducible nitric oxide synthase (iNOS) and CD16, were increased after cisplatin treatment.	Cisplatin	191-200	interleukin 6	Mus musculus	80-84
29396460-5	2018	DHCA reduces pro-inflammatory interleukin 6 (IL-6) generations by inhibiting DNA methylation at the CpG-rich IL-6 sequences introns 1 and 3, while Mal-gluc modulates synaptic plasticity by increasing histone acetylation of the regulatory sequences of the Rac1 gene.	3,4-dihydroxyphenylpropionic acid	0-4	interleukin 6	Mus musculus	30-43
29396460-5	2018	DHCA reduces pro-inflammatory interleukin 6 (IL-6) generations by inhibiting DNA methylation at the CpG-rich IL-6 sequences introns 1 and 3, while Mal-gluc modulates synaptic plasticity by increasing histone acetylation of the regulatory sequences of the Rac1 gene.	3,4-dihydroxyphenylpropionic acid	0-4	interleukin 6	Mus musculus	45-49
29396460-5	2018	DHCA reduces pro-inflammatory interleukin 6 (IL-6) generations by inhibiting DNA methylation at the CpG-rich IL-6 sequences introns 1 and 3, while Mal-gluc modulates synaptic plasticity by increasing histone acetylation of the regulatory sequences of the Rac1 gene.	3,4-dihydroxyphenylpropionic acid	0-4	interleukin 6	Mus musculus	109-113
29221711-3	2018	We observed the existence of rather specific negative correlations between the serum sitosterol level and the serum IL-6 and the TNF-alpha levels in both diabetic subjects (n=46) and non-diabetic subjects (n=178).	gamma-sitosterol	85-95	interleukin 6	Mus musculus	116-120
29221711-4	2018	Multiple regression analyses also revealed that the serum IL-6 and TNF-alpha levels exhibited strong negative correlations with the serum sitosterol levels.	gamma-sitosterol	138-148	interleukin 6	Mus musculus	58-62
29421861-9	2018	Simvastatin also reduced the serum cytokine levels and transcriptional levels of tumor necrosis factor-alpha and interleukin-6 in the liver.	Simvastatin	0-11	interleukin 6	Mus musculus	113-126
29276972-9	2018	Deflazacort and omega-3 reduced the plasma levels of the pro-inflammatory (TNF-alpha, INF-gamma, IL-6) and pro-fibrotic (IL-13 and TGF-beta) interleukins and increased the plasma levels of IL-10.	deflazacort	0-11	interleukin 6	Mus musculus	97-101
29191973-6	2018	HMGB1-activated TAMs secreted IL6 to augment enzalutamide-induced NED and directly promote HMGB1 transcription via STAT3.	enzalutamide	45-57	interleukin 6	Mus musculus	30-33
29191973-7	2018	Finally, inhibition of the IL6/STAT3 pathway by tocilizumab combined with HMGB1 knockdown inhibited enzalutamide-induced resistance in an orthotopic prostate cancer mouse model.Conclusions: Enzalutamide elevates HMGB1 levels, which recruits and activates TAMs.	enzalutamide	100-112	interleukin 6	Mus musculus	27-30
29191973-7	2018	Finally, inhibition of the IL6/STAT3 pathway by tocilizumab combined with HMGB1 knockdown inhibited enzalutamide-induced resistance in an orthotopic prostate cancer mouse model.Conclusions: Enzalutamide elevates HMGB1 levels, which recruits and activates TAMs.	enzalutamide	190-202	interleukin 6	Mus musculus	27-30
29191973-8	2018	Moreover, IL6 secreted by HMGB1-activated TAMs facilitates the enzalutamide-induced NED of prostate cancer, forming a positive feedback loop between NED in prostate cancer and TAMs.	enzalutamide	63-75	interleukin 6	Mus musculus	10-13
29276972-9	2018	Deflazacort and omega-3 reduced the plasma levels of the pro-inflammatory (TNF-alpha, INF-gamma, IL-6) and pro-fibrotic (IL-13 and TGF-beta) interleukins and increased the plasma levels of IL-10.	omega-3	16-23	interleukin 6	Mus musculus	97-101
29307283-8	2018	Treatment with opioid growth factor or low-dose naltrexone resulted in elevated expression levels of the IL-6 cytokine, and significantly reduced IL-10 values, relative to saline-treated experimental autoimmune encephalomyelitis mice.	Naltrexone	48-58	interleukin 6	Mus musculus	105-109
29030662-8	2018	Oral givinostat monotherapy did not reverse established diabetes but reduced the in situ production of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).	givinostat	5-15	interleukin 6	Mus musculus	137-141
29307283-11	2018	Validation studies revealed that within six days of immunization, opioid growth factor or low-dose naltrexone modulated IL-6 and IL-10 cytokine expression.	Naltrexone	99-109	interleukin 6	Mus musculus	120-124
29307283-15	2018	Multiplex cytokine assays demonstrated that mice with chronic EAE and treated with either OGF or low-dose naltrexone (LDN) had decreased expression of interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), and the anti-inflammatory cytokine IL-10 within 10 days or treatment, as well as increased serum expression of the pro-inflammatory cytokine IL-6, relative to immunized mice receiving saline.	Naltrexone	106-116	interleukin 6	Mus musculus	363-367
29223854-5	2018	Further in vivo investigations revealed that the hepatoprotective activities of BA was due to the effects on remarkably suppressing the inflammatory cascade, including attenuating the expressions of HMGB1, TLR4, Myd88, NF-kappaB and IkappaB proteins and inhibiting the production of interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha in diabetic mice.	baicalein	80-82	interleukin 6	Mus musculus	307-311
29199487-7	2018	RESULTS AND DISCUSSION: Treatment with the major chalcone 1 significantly attenuated the production of NO and proinflammatory cytokines, tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 in a dose-dependent manner.	Chalcone	49-57	interleukin 6	Mus musculus	189-202
29223854-8	2018	Inflammation condition was also recovered with BA treatment as shown by the changes of HMGB1, TLR4, Myd88, NF-kappaB and IkappaB expressions and the levels of IL-1beta, IL-6 and TNF-alpha.	baicalein	47-49	interleukin 6	Mus musculus	169-173
29207037-3	2018	It was identified that quercetin and galangin markedly reduced the production of nitric oxide (NO), inducible NO synthase and interleukin-6, and the nuclear translocation of nuclear factor-kappaB (NF-kappaB).	Quercetin	23-32	interleukin 6	Mus musculus	126-139
29207167-12	2018	The results of the present study identified that prazosin decreased the expression levels of inflammatory factors, interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, IL-10 and IL-1 in the serum of mice exhibiting hypoxia/reoxygenation injury.	Prazosin	49-57	interleukin 6	Mus musculus	115-133
29448498-6	2018	ND-COOH induced a certain immune response in Raw264.7 cells, leading to a higher expression of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6), especially with a significantly longer incubation time.	Carbonic Acid	3-7	interleukin 6	Mus musculus	139-152
29448498-6	2018	ND-COOH induced a certain immune response in Raw264.7 cells, leading to a higher expression of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6), especially with a significantly longer incubation time.	Carbonic Acid	3-7	interleukin 6	Mus musculus	154-158
29119451-6	2018	Here we show that pristimerin markedly suppressed the release of Regulated on Activation, Normal T Expressed and Secreted (RANTES), transforming growth factor-beta1 (TGF-beta1), IL-6, tumor necrosis factor-alpha (TNF-alpha), and nitric oxide (NO).	pristimerin	18-29	interleukin 6	Mus musculus	178-182
29131494-5	2018	Meanwhile, GML significantly changed the beta-diversity and composition of gut microbiota and upregulated the circulating levels of serum LPS, IL-1beta, IL-6, and TNF-alpha.	monolaurin	11-14	interleukin 6	Mus musculus	153-157
29552299-3	2018	Results: The tulobuterol patch significantly ameliorated inflammatory cell infiltration in the lung tissue, reduced the number of total leukocytes and its differential count, markedly reduced the production of IL-1beta, TNF-alpha, IL-6, CCL-11 and IL-4 in bronchial alveolar lavage fluid, as well as a reduction in IL-4/IFN-gamma ratio.	tulobuterol	13-24	interleukin 6	Mus musculus	231-235
29226586-9	2018	Oral administration of gentiopicroside significantly increased heat shock protein-70 and glutathione levels and superoxide dismutase activity, normalized epidermal growth factor and vascular endothelial growth factor levels, and decreased the levels of tumour necrosis factor-alpha, interleukin-6 and malondialdehyde, and myeloperoxidase activity in gastric tissue.	gentiopicroside	23-38	interleukin 6	Mus musculus	283-296
29307174-5	2018	ELISA results revealed that DHA could enhance the protein expression of cytokines IL-1beta, IL-6, IL-10, IL-12, TNF-alpha, IFN-gamma, and TGF-beta.	Docosahexaenoic Acids	28-31	interleukin 6	Mus musculus	92-96
28969445-9	2018	Treatment with flumazenil also significantly increased TNF-alpha and IL-6 levels in immobilisation stress-free mice treated with IM38.	Flumazenil	15-25	interleukin 6	Mus musculus	69-73
29378573-6	2018	Moreover, cortisol inhibited the mRNA expression of pro-inflammatory cytokines including tumor necrosis factor alpha (TNFalpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) and decreased IL-1beta secretion in an LPS-treated RAW264.7 macrophage cell line.	Hydrocortisone	10-18	interleukin 6	Mus musculus	163-176
29378573-6	2018	Moreover, cortisol inhibited the mRNA expression of pro-inflammatory cytokines including tumor necrosis factor alpha (TNFalpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) and decreased IL-1beta secretion in an LPS-treated RAW264.7 macrophage cell line.	Hydrocortisone	10-18	interleukin 6	Mus musculus	178-182
28961808-8	2018	In vivo, oral administration of NPs-PEG-FA/6-shogaol encapsulated in a hydrogel system [chitosan/alginate] significantly alleviated colitis symptoms and accelerated colitis wound repair in DSS-treated mice by regulating the expression levels of pro-inflammatory [TNF-alpha, IL-6, IL-1beta, and iNOS] and anti-inflammatory [Nrf-2 and HO-1] factors.	peg-fa	36-42	interleukin 6	Mus musculus	274-278
28961808-8	2018	In vivo, oral administration of NPs-PEG-FA/6-shogaol encapsulated in a hydrogel system [chitosan/alginate] significantly alleviated colitis symptoms and accelerated colitis wound repair in DSS-treated mice by regulating the expression levels of pro-inflammatory [TNF-alpha, IL-6, IL-1beta, and iNOS] and anti-inflammatory [Nrf-2 and HO-1] factors.	shogaol	43-52	interleukin 6	Mus musculus	274-278
28961808-8	2018	In vivo, oral administration of NPs-PEG-FA/6-shogaol encapsulated in a hydrogel system [chitosan/alginate] significantly alleviated colitis symptoms and accelerated colitis wound repair in DSS-treated mice by regulating the expression levels of pro-inflammatory [TNF-alpha, IL-6, IL-1beta, and iNOS] and anti-inflammatory [Nrf-2 and HO-1] factors.	Chitosan	88-96	interleukin 6	Mus musculus	274-278
28961808-8	2018	In vivo, oral administration of NPs-PEG-FA/6-shogaol encapsulated in a hydrogel system [chitosan/alginate] significantly alleviated colitis symptoms and accelerated colitis wound repair in DSS-treated mice by regulating the expression levels of pro-inflammatory [TNF-alpha, IL-6, IL-1beta, and iNOS] and anti-inflammatory [Nrf-2 and HO-1] factors.	Alginates	97-105	interleukin 6	Mus musculus	274-278
29269298-9	2018	RESULTS: Dexmedetomidine at 20 mug/kg significantly attenuated pancreatic pathological injury, reduced serum levels of amylase, lipase, IL-1beta, IL-6, and tumor necrosis factor (TNF)-alpha, and decreased the expression of MPO in pancreatic tissue in both mouse models of pancreatitis.	Dexmedetomidine	9-24	interleukin 6	Mus musculus	146-150
29403442-8	2017	Moreover, LH2171 significantly inhibited IL-6 production in vitro from both DC2.4 and RAW264.7 cells, model cell lines of antigen-presenting cells.	lh2171	10-16	interleukin 6	Mus musculus	41-45
29217385-7	2018	4-methylesculetin (25 mg/kg) improved microscopic parameters, decreased MPO activity, reduced the colonic levels of IL-6 and counteracted GSH depletion when compared with DSS-control group.	4-methylesculetin	0-17	interleukin 6	Mus musculus	116-120
29351340-7	2018	HMB and vitamin D inhibited the serum IL-6 surge, downregulated the expression of MuRF1 and atrogin-1 in the soleus muscle, and ameliorated atrophy in the mice.	beta-hydroxyisovaleric acid	0-3	interleukin 6	Mus musculus	38-42
29351340-7	2018	HMB and vitamin D inhibited the serum IL-6 surge, downregulated the expression of MuRF1 and atrogin-1 in the soleus muscle, and ameliorated atrophy in the mice.	Vitamin D	8-17	interleukin 6	Mus musculus	38-42
29338749-7	2018	RESULTS: Clinical analyses showed positive significant association between serum IL-6 and free fatty acid (FFA) both in early- and late-stage cancer cachexia.	Fatty Acids, Nonesterified	90-105	interleukin 6	Mus musculus	81-85
29275229-1	2018	Reactive oxygen species (ROS) are key signaling molecules and their overproduction plays an important role in the inflammation process, the secretion of inflammatory cytokines such as IL-1beta and IL-6 and the progression of inflammatory disorders.	Reactive Oxygen Species	0-23	interleukin 6	Mus musculus	197-201
29275229-1	2018	Reactive oxygen species (ROS) are key signaling molecules and their overproduction plays an important role in the inflammation process, the secretion of inflammatory cytokines such as IL-1beta and IL-6 and the progression of inflammatory disorders.	Reactive Oxygen Species	25-28	interleukin 6	Mus musculus	197-201
29338749-7	2018	RESULTS: Clinical analyses showed positive significant association between serum IL-6 and free fatty acid (FFA) both in early- and late-stage cancer cachexia.	Fatty Acids, Nonesterified	107-110	interleukin 6	Mus musculus	81-85
29269293-5	2018	Herein, we report that the mL2a-pCA-induced production of interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) in C3H/HeN mouse-derived resident peritoneal cells was inhibited by treatment with the Rac1 inhibitor NSC23766 trihydrochloride.	Ponatinib tris-hydrochloride	233-249	interleukin 6	Mus musculus	58-71
29375203-12	2018	Treatment of re-cultured PSCs with Dvitamins was associated with lower expression of IL-6 (-42% to -49%; P &lt; 0.05; also confirmed at the protein level) and increased expression of the vitamin D receptor gene (209%-321% vs controls; P &lt; 0.05).	Vitamin D	35-44	interleukin 6	Mus musculus	85-89
29335597-7	2018	The protective effects of exhaustive exercise against olanzapine-induced increases in blood glucose were intact in whole body IL-6 knockout mice.	Olanzapine	54-64	interleukin 6	Mus musculus	126-130
29329354-8	2018	Palmitate substantially increased the levels of IL-6, TNF-alpha, CHOP, XBP1s, and ATF 4 mRNAs and augmented the levels of CHOP, XBP1s, phospho-PERK and phospho-eIF2alpha proteins.	Palmitates	0-9	interleukin 6	Mus musculus	48-52
29069290-3	2018	Dietary celastrol (31.25 ppm in rodent diet from 8 weeks to 25 weeks of age) is well tolerated and protects against LPS-induced acute inflammation in C57BL/6 mice, potently suppressing LPS-induction of inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, Interleukin (IL)-6 and IL-1beta.	celastrol	8-17	interleukin 6	Mus musculus	266-284
29069290-6	2018	Celastrol chemoprevention of CAC in this new model of intestinal neoplasia was associated with significant suppression of iNOS at 4 months of age, and iNOS, COX-2 and NFkappaB at 6 months of age, with significant reduction in inflammatory cytokines, IL-6 and IL-1beta.	celastrol	0-9	interleukin 6	Mus musculus	250-254
29329563-10	2018	Interleukin-6 (IL-6) was the most significantly changed cytokine in O-PMs-treated A549 cells according to the analysis of the cytokine antibody array.	o-pms	68-73	interleukin 6	Mus musculus	0-13
29329563-10	2018	Interleukin-6 (IL-6) was the most significantly changed cytokine in O-PMs-treated A549 cells according to the analysis of the cytokine antibody array.	o-pms	68-73	interleukin 6	Mus musculus	15-19
29329563-11	2018	The IL-6 receptor inhibitor tocilizumab (TCZ) and small interfering RNA for IL-6 significantly reduced ICAM-1 secretion and expression as well as the reduction of the AKT, p65, and STAT3 phosphorylation in O-PMs-treated A549 cells.	o-pms	206-211	interleukin 6	Mus musculus	4-8
29329563-11	2018	The IL-6 receptor inhibitor tocilizumab (TCZ) and small interfering RNA for IL-6 significantly reduced ICAM-1 secretion and expression as well as the reduction of the AKT, p65, and STAT3 phosphorylation in O-PMs-treated A549 cells.	o-pms	206-211	interleukin 6	Mus musculus	76-80
29175959-4	2018	At 6 h we detect the proinflammatory cytokine IL-6 in the hippocampus, followed up by alterations in the mRNA and protein expression of astrocytic and neuronal proteins necessary for optimal energy supply to the brain and for the reuptake and recycling of glutamate in the synapse.	Glutamic Acid	256-265	interleukin 6	Mus musculus	46-50
29054324-5	2018	6-OHDA administration elevated levels of tumour necrosis factor-alpha, interferon-gamma, interleukin-1beta, interleukin-2, interleukin-6 and nuclear factor-kappa B and decreased the interleukin-10 levels, total reactive antioxidant potential and total antioxidant reactivity in striatum, as well as, modified the calcium-binding protein B (S100B), brain-derived neurotrophic factor, nerve growth factor and glial cell line-derived neurotrophic factor levels.	Oxidopamine	0-6	interleukin 6	Mus musculus	123-163
29113806-3	2018	Ex vivo tests showed that Cynatratoside-C inhibited the expression of TLR4 and pro-inflammatory cytokine (TNF-alpha, IL-6 and IL-1beta) production in LPS-stimulated primary mouse mammary epithelial cells.	cynatratoside-C	26-41	interleukin 6	Mus musculus	117-121
29379500-12	2017	Moreover, reparixin effectively suppressed the increase in serum concentrations of TNF-alpha, IL-6, and CCL3, and the reperfusion-associated tissue damage.	reparixin	10-19	interleukin 6	Mus musculus	94-98
29017959-6	2018	An increase of 8-isoprostane could also be detected in serum 2h after exposure to 200ppm Cl2, which was followed by increased levels of IL-6 and CXCL1/KC and signs of increased fibrinogen and PAI-1.	8-epi-prostaglandin F2alpha	15-28	interleukin 6	Mus musculus	136-140
29017959-6	2018	An increase of 8-isoprostane could also be detected in serum 2h after exposure to 200ppm Cl2, which was followed by increased levels of IL-6 and CXCL1/KC and signs of increased fibrinogen and PAI-1.	Deuterium	61-63	interleukin 6	Mus musculus	136-140
29030272-10	2018	In mice subjected to IL-6 injection, the fasting-induced PXR, PPARalpha and PGC-1alpha mRNA responses were lower than after saline injection.	Sodium Chloride	124-130	interleukin 6	Mus musculus	21-25
29305671-0	2018	Investigation Into the Effects of Tenilsetam on Markers of Neuroinflammation in GFAP-IL6 Mice.	tenilsetam	34-44	interleukin 6	Mus musculus	85-88
29305671-5	2018	RESULTS: Tenilsetam decreased the total number of Iba-1+ microglia in both the cerebellum and the hippocampus of GFAP-IL6 mice at 8 months and in the cerebellum at 18 months.	tenilsetam	9-19	interleukin 6	Mus musculus	118-121
28880016-7	2018	Furthermore, LLDT-8 inhibited inflammation in the kidney evidenced by significantly decreasing C3 and IgG deposition, reducing the levels of the pathogenic cytokines TNF-alpha, IL-6, IL-17, and IFN-gamma, and reducing related chemokine expression and leukocyte infiltration in kidneys.	5alpha-Hydroxytriptolide	13-19	interleukin 6	Mus musculus	177-181
29305671-9	2018	CONCLUSION: Tenilsetam has anti-inflammatory effects evidenced by the decreased number of microglia in both the cerebellum and hippocampus, and decreased TNF-alpha levels in the GFAP-IL6 Tenilsetam fed animals.	tenilsetam	12-22	interleukin 6	Mus musculus	183-186
29305671-9	2018	CONCLUSION: Tenilsetam has anti-inflammatory effects evidenced by the decreased number of microglia in both the cerebellum and hippocampus, and decreased TNF-alpha levels in the GFAP-IL6 Tenilsetam fed animals.	tenilsetam	187-197	interleukin 6	Mus musculus	183-186
29301535-9	2018	Murine studies using Cftr +/+ or Cftr -/- mice verified that SAHA controls Pa-LPS induced IL-6 levels, and neutrophil (MPO levels and/or NIMP-R14), NFkappaB-(inflammation) and Nrf2 (oxidative-stress marker) activities, while promoting FoxP3+ T-reg activity.	Vorinostat	61-65	interleukin 6	Mus musculus	90-94
29737211-6	2018	In mice treated with wedelolactone prior to the induction of CIH, increases of serum concentrations of tumor necrosis factor (TNF)-[Formula: see text], interferon (IFN)-[Formula: see text], and interleukin (IL)-6 were dramatically attenuated.	wedelolactone	21-34	interleukin 6	Mus musculus	194-212
29136951-8	2018	Further analysis showed that Myricetin strongly reduced the levels of inflammatory factors TNF-alpha, IL-1beta, IL-6, NF-kappaB, p-NF-kappaB, cyclooxygenase-2 (COX-2), PCNA and Cyclin D1 in the colonic tissues as analyzed by the assays of immunohistochemical staining, Western blotting and Q-RT-PCR.	myricetin	29-38	interleukin 6	Mus musculus	112-116
29595073-8	2018	Asatone markedly reduced the levels of TNF-[Formula: see text] and IL-6 in the lung and liver, but not in the kidney of mice.	ASATONE	0-7	interleukin 6	Mus musculus	67-71
29793330-7	2018	The increased levels of pro-inflammatory cytokines (IL-6, TNF-alpha, sVE-cadherin) induced by AS were also decreased by baicalin treatment, indicating that baicalin acted as an anti-inflammation regulator in AS.	baicalin	120-128	interleukin 6	Mus musculus	52-56
29113797-8	2018	Teneligliptin treatment (10 nmol/L) suppressed the LPS-induced expression of interleukin (IL)-6 (70%) and tumor necrosis factor-alpha (37%) in peritoneal macrophages isolated from Cav-1+/+ mice.	3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine	0-13	interleukin 6	Mus musculus	77-95
29793330-7	2018	The increased levels of pro-inflammatory cytokines (IL-6, TNF-alpha, sVE-cadherin) induced by AS were also decreased by baicalin treatment, indicating that baicalin acted as an anti-inflammation regulator in AS.	baicalin	156-164	interleukin 6	Mus musculus	52-56
30068871-5	2018	Whereas, high dose THP (30-40 microg/mL) reduced LPS-induced IL-6 production in RAW264.7 cells but NTHP did not effect.	tetrahydropalmatine	19-22	interleukin 6	Mus musculus	61-65
29793331-5	2018	Moreover, MGFE inhibited dermal infiltration of inflammatory cells and reduced serum tumor necrosis factor alpha and interleukin-6 levels.	mgfe	10-14	interleukin 6	Mus musculus	117-130
30355952-0	2018	2-O-Methylmagnolol Induces Apoptosis and Inhibits IL-6/STAT3 Signaling in Oral Squamous Cell Carcinoma.	2-o-methylmagnolol	0-18	interleukin 6	Mus musculus	50-54
30504681-7	2018	Vitamin C and/or irinotecan administration decreased the plasma level of ROS and IL-6 and increased the expression of collagen type I and caspase-1.	Ascorbic Acid	0-9	interleukin 6	Mus musculus	81-85
30504681-7	2018	Vitamin C and/or irinotecan administration decreased the plasma level of ROS and IL-6 and increased the expression of collagen type I and caspase-1.	Irinotecan	17-27	interleukin 6	Mus musculus	81-85
30355939-10	2018	RESULTS: The mice treated with either estradiol or oil had presented to us lowered levels in miR-1192 expression as well as higher levels in both Th17 cell percentage and expression of RORgammat in Th17 cells, along with mRNA and protein expressions of CXCR4, IL-6, IL-17, and IL-23.	Estradiol	38-47	interleukin 6	Mus musculus	260-264
30355939-10	2018	RESULTS: The mice treated with either estradiol or oil had presented to us lowered levels in miR-1192 expression as well as higher levels in both Th17 cell percentage and expression of RORgammat in Th17 cells, along with mRNA and protein expressions of CXCR4, IL-6, IL-17, and IL-23.	Oils	51-54	interleukin 6	Mus musculus	260-264
30448827-6	2018	RESULTS: Butyrate reduced the expression of canonic pro-inflammatory mediators (Nos2, COX-2, IL-6), pro-inflammatory adipokines (lipocalin-2 and nesfatin-1) and adhesion molecule (VCAM-1 and ICAM-1) in IL-1beta-stimulated chondrocytes, inhibiting several inflammatory signalling pathways (NFkappaB, MAPKinase, AMPK-alpha, PI3K/Akt).	Butyrates	9-17	interleukin 6	Mus musculus	93-97
30423565-10	2018	Consistent with the milder inflammatory pathological changes, DSS-treated KO mice had lower levels of IL-1beta, IL-6 and TNF-alpha mRNA in the liver and the colon.	Dextran Sulfate	62-65	interleukin 6	Mus musculus	112-116
29486473-11	2018	JNK inhibitor SP600125 prevented PA-mediated increase of Nox4, IL-8, IL-6 and iTG.	pyrazolanthrone	14-22	interleukin 6	Mus musculus	69-73
29462800-7	2018	Moreover, 5,6-EET, PGE1 decreased the level of TNF-alpha, while 5,6-EET, 5,6-DHET downregulated IL-6 production in macrophages.	5,6-epoxy-8,11,14-eicosatrienoic acid	64-71	interleukin 6	Mus musculus	96-100
29462800-7	2018	Moreover, 5,6-EET, PGE1 decreased the level of TNF-alpha, while 5,6-EET, 5,6-DHET downregulated IL-6 production in macrophages.	5,6-DHET	73-81	interleukin 6	Mus musculus	96-100
29462800-8	2018	Importantly, 14,15-EET and 14S-HDoHE inhibited both IL-6 and TNF-alpha induced by lipopolysaccharide (LPS).	14,15-epoxy-5,8,11-eicosatrienoic acid	13-22	interleukin 6	Mus musculus	52-56
29462800-8	2018	Importantly, 14,15-EET and 14S-HDoHE inhibited both IL-6 and TNF-alpha induced by lipopolysaccharide (LPS).	14s-hdohe	27-36	interleukin 6	Mus musculus	52-56
29486473-11	2018	JNK inhibitor SP600125 prevented PA-mediated increase of Nox4, IL-8, IL-6 and iTG.	Palmitic Acid	33-35	interleukin 6	Mus musculus	69-73
29486473-13	2018	An IkappaB degradation inhibitor, BAY11-7082, prevented PA-induced increase of IL-8 and IL-6 as well as iTG, whereas it only decreased ROS levels slightly and showed no influence on cellular apoptosis.	3-(4-methylphenylsulfonyl)-2-propenenitrile	34-44	interleukin 6	Mus musculus	88-92
29486473-13	2018	An IkappaB degradation inhibitor, BAY11-7082, prevented PA-induced increase of IL-8 and IL-6 as well as iTG, whereas it only decreased ROS levels slightly and showed no influence on cellular apoptosis.	Palmitic Acid	56-58	interleukin 6	Mus musculus	88-92
29554661-6	2018	RESULTS: The contents of pro-inflammatory cytokines interleukin (IL)-1beta, IL-6 and tumour necrosis factor (TNF)-alpha were inhibited by ALK, metformin or fasudil in diabetic db/db mice.	Metformin	143-152	interleukin 6	Mus musculus	76-80
29554661-6	2018	RESULTS: The contents of pro-inflammatory cytokines interleukin (IL)-1beta, IL-6 and tumour necrosis factor (TNF)-alpha were inhibited by ALK, metformin or fasudil in diabetic db/db mice.	fasudil	156-163	interleukin 6	Mus musculus	76-80
29732971-9	2018	Accordingly, cinnamic acid also increased the level of SOCS3 and suppressed the expression of inducible nitric oxide synthase and proinflammatory cytokines (TNFalpha, IL-1beta and IL-6) in LPSstimulated BV-2 microglial cells.	cinnamic acid	13-26	interleukin 6	Mus musculus	180-184
29843136-11	2018	Furthermore, we found that ASP markedly suppressed the expression of interleukin-6 (IL-6), JAK2, p-STAT3, and p-SMAD1/5/8 in liver, suggesting that JAK/STAT and BMP-SMAD pathways were involved in the regulation of hepcidin expression by ASP.	Aspartic Acid	27-30	interleukin 6	Mus musculus	69-82
29843136-11	2018	Furthermore, we found that ASP markedly suppressed the expression of interleukin-6 (IL-6), JAK2, p-STAT3, and p-SMAD1/5/8 in liver, suggesting that JAK/STAT and BMP-SMAD pathways were involved in the regulation of hepcidin expression by ASP.	Aspartic Acid	27-30	interleukin 6	Mus musculus	84-88
29399089-8	2018	GA-A treatment reduced LPS-induced expression of nuclear factor (NF)-kappaB (p65) and its inhibitor, demonstrating that non-toxic suppression of IL-1beta, IL-6 and TNF-alpha production by GA-A is, at least in part, due to suppression of the NF-kappaB signaling pathway.	ganoderic acid A	188-192	interleukin 6	Mus musculus	155-159
29701145-11	2018	Interestingly, Arid5a was identified from an inhibitory effect of CPZ on IL-6 production in macrophages activated by LPS.	Chlorpromazine	66-69	interleukin 6	Mus musculus	73-77
29066299-4	2018	We found that the production of pro-inflammatory mediators, including interleukin-6(IL-6), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), induced by LPS was significantly suppressed by beta-elemene in a dose-dependent manner in RAW264.7 macrophage cell line.	beta-elemene	212-224	interleukin 6	Mus musculus	70-83
29399089-7	2018	The results of the present study demonstrated that GA-A significantly decreased LPS-induced IL-1beta, IL-6 and TNF-alpha release from mouse-derived primary cortical microglial cells in a concentration-dependent manner.	ganoderic acid A	51-55	interleukin 6	Mus musculus	102-106
29399089-8	2018	GA-A treatment reduced LPS-induced expression of nuclear factor (NF)-kappaB (p65) and its inhibitor, demonstrating that non-toxic suppression of IL-1beta, IL-6 and TNF-alpha production by GA-A is, at least in part, due to suppression of the NF-kappaB signaling pathway.	ganoderic acid A	0-4	interleukin 6	Mus musculus	155-159
29136560-3	2018	As a result, cyclophosphamide-induced cystitis in mice showed an increased LD level in serum, and the contents of cytokines (IL-6, TNF-alpha) were elevated.	Cyclophosphamide	13-29	interleukin 6	Mus musculus	125-129
28859237-2	2018	In view of the exceptionally high expression of CBS in the liver and the common interleukin-6 pathway used in the regulatory systems of hydrogen sulfide and hepcidin, we speculate that CBS is involved in body iron homeostasis.	Hydrogen Sulfide	136-152	interleukin 6	Mus musculus	80-93
28859237-2	2018	In view of the exceptionally high expression of CBS in the liver and the common interleukin-6 pathway used in the regulatory systems of hydrogen sulfide and hepcidin, we speculate that CBS is involved in body iron homeostasis.	Iron	209-213	interleukin 6	Mus musculus	80-93
28859237-5	2018	A major cause of the systemic iron overload is the reduced iron usage due to suppressed erythropoiesis, which is consistent with an increase in interleukin-6 and reduced expression of erythropoietin.	Iron	30-34	interleukin 6	Mus musculus	144-157
28859237-5	2018	A major cause of the systemic iron overload is the reduced iron usage due to suppressed erythropoiesis, which is consistent with an increase in interleukin-6 and reduced expression of erythropoietin.	Iron	59-63	interleukin 6	Mus musculus	144-157
29587260-9	2018	At the skin lesion site, verbascoside also inhibited DNCB-induced production of proinflammatory cytokine TNF-alpha, IL-6, and IL-4 mRNA.	acteoside	25-37	interleukin 6	Mus musculus	116-120
29587260-9	2018	At the skin lesion site, verbascoside also inhibited DNCB-induced production of proinflammatory cytokine TNF-alpha, IL-6, and IL-4 mRNA.	Dinitrochlorobenzene	53-57	interleukin 6	Mus musculus	116-120
29136560-4	2018	Interestingly, GAL-treated mice showed decreased LD and inflammatory cytokines of IL-6 and TNF-alpha in blood.	Galactose	15-18	interleukin 6	Mus musculus	82-86
29156356-4	2018	The results showed that Limax extract improved lung function, relieved emphysema and suppressed the inflammation in the lungs of CS-challenged mice, as evidenced by diminished release of IL-6, KC, TNF-alpha, IFN-gamma, Muc5AC, IL-17 and diminished mRNA expression of Muc5B.	limax	24-29	interleukin 6	Mus musculus	187-191
29156356-4	2018	The results showed that Limax extract improved lung function, relieved emphysema and suppressed the inflammation in the lungs of CS-challenged mice, as evidenced by diminished release of IL-6, KC, TNF-alpha, IFN-gamma, Muc5AC, IL-17 and diminished mRNA expression of Muc5B.	Cesium	129-131	interleukin 6	Mus musculus	187-191
29156356-6	2018	More interestingly, Limax extract (0.1mug/ml) inhibited CSE-induced release of IL-6 in vitro, which was substantially abrogated by heat treatment, and filtrate obtained from the deproteinized Limax extract with the 100KD ultrafiltration membrane, inhibited the secretion of IL-6.	limax	20-25	interleukin 6	Mus musculus	79-83
29156356-6	2018	More interestingly, Limax extract (0.1mug/ml) inhibited CSE-induced release of IL-6 in vitro, which was substantially abrogated by heat treatment, and filtrate obtained from the deproteinized Limax extract with the 100KD ultrafiltration membrane, inhibited the secretion of IL-6.	limax	20-25	interleukin 6	Mus musculus	274-278
29202300-8	2018	The in vivo carrageenan-induced mice paw edema study also indicated that treatment with 100 mg/kg of Dihydrofisetin could significantly inhibit carrageenan induced paw edema, decrease the levels of TNF-alpha, IL-6 and MDA, and increase the activity of GSH-Px in paw tissues.	Dihydrofisetin	101-115	interleukin 6	Mus musculus	209-213
29197801-7	2018	The enhanced generation of reactive oxygen intermediates and nitric oxide by macrophages from mice treated with buprenorphine, oxycodone or morphine was also shown, along with increased release of IL-6, TNFalpha and TGFbeta.	Buprenorphine	112-125	interleukin 6	Mus musculus	197-201
29197801-7	2018	The enhanced generation of reactive oxygen intermediates and nitric oxide by macrophages from mice treated with buprenorphine, oxycodone or morphine was also shown, along with increased release of IL-6, TNFalpha and TGFbeta.	Oxycodone	127-136	interleukin 6	Mus musculus	197-201
30317976-10	2018	The concentrations of the inflammatory cytokines, tumor necrosis factor (TNF)-alpha and interleukin-6, in the blood were significantly reduced in the mice administered AD-GL.	ad-gl	168-173	interleukin 6	Mus musculus	88-101
29197801-7	2018	The enhanced generation of reactive oxygen intermediates and nitric oxide by macrophages from mice treated with buprenorphine, oxycodone or morphine was also shown, along with increased release of IL-6, TNFalpha and TGFbeta.	Morphine	140-148	interleukin 6	Mus musculus	197-201
29376847-8	2018	Furthermore, the iron level in the hippocampus was measured by inductively coupled plasma-mass spectrometry as IL6 is mentioned in several studies to take part in iron homeostasis and inflammation and found to be increased in 5XFAD mice hippocampus.	Iron	17-21	interleukin 6	Mus musculus	111-114
29376847-8	2018	Furthermore, the iron level in the hippocampus was measured by inductively coupled plasma-mass spectrometry as IL6 is mentioned in several studies to take part in iron homeostasis and inflammation and found to be increased in 5XFAD mice hippocampus.	Iron	163-167	interleukin 6	Mus musculus	111-114
28782172-3	2018	In vitro and ex vivo, biochemical and histological analysis demonstrated that 3"-sialyllactose was sufficient to restore the synthesis of Col2a1 and accumulation of sulphated proteoglycan, a critical factor for cartilage regeneration in osteoarthritic development, and blocked the expression of Mmp3, Mmp13 and Cox2 induced by IL-1beta, IL-6, IL-17 and TNF-alpha, which mediates cartilage degradation.	3'-sialyllactose	78-94	interleukin 6	Mus musculus	337-341
29138800-5	2018	The present study investigated this belief and demonstrated that BM significantly inhibited the expression of interleukin-1beta (IL-1beta), IL-6, cyclooxygenase-2 and inducible nitric oxide synthase in RAW264.7 cells, but had little influence on the cell viability, cell cycle and apoptosis.	BM	65-67	interleukin 6	Mus musculus	140-144
32288793-6	2018	OMRE treatment increased IL-10 and IL-6 production in concanavalin A- and lipopolysaccharide-induced T- and B- lymphocytes, respectively.	omre	0-4	interleukin 6	Mus musculus	35-39
30650406-5	2018	The GLY group displayed increased interleukin-10 (IL-10) and IL-2 expression and decreased IL-17A and IL-6 expression.	Glycyrrhizic Acid	4-7	interleukin 6	Mus musculus	102-106
29862488-13	2018	In addition, EGCG treatment decreased the circulat-ing tumour necrosis factor-alpha, interleukin-6, monocyte chemoattractant protein-1, and interferon-gamma levels in apolipoprotein E-deficient mice.	epigallocatechin gallate	13-17	interleukin 6	Mus musculus	85-98
29115460-10	2018	Activation of CRF-R1 increased the DAI and histological scores of the colons from DSS-treated mice by promoting M1 macrophage polarization, demonstrated as increased NF-kappaB activation, and TNF-alpha and IL-6 release.	dss	82-85	interleukin 6	Mus musculus	206-210
30465708-7	2018	Pre-administration of S3I-201 attenuated IL-6-mediated changes of most transporters in PXR (+/+) and PXR (-/-) mice.	NSC 74859	22-29	interleukin 6	Mus musculus	41-45
29115475-3	2018	The results revealed that dysifragilone A significantly reduced the release of inflammatory mediators and inflammatory cytokines in activated RAW264.7 cells, including nitric oxide (NO), prostaglandin E2,(PGE2) and interleukin-6 (IL-6).	dysifragilone	26-39	interleukin 6	Mus musculus	215-228
28980448-2	2018	METHODS AND RESULTS: As measured by western blot, RT-PCR, and ELISA, tectochrysin inhibits extracellular signal-related kinase 1/2 (ERK1/2) phosphorylation and sequentially suppressed downstream inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-alpha), and IL-6 transcription as well as the NO, TNF-alpha, and IL-6 in supernatant, but it does not affect extracellular signal-regulated kinase (MEK) phosphorylation levels.	tectochrysin	69-81	interleukin 6	Mus musculus	280-284
28980448-2	2018	METHODS AND RESULTS: As measured by western blot, RT-PCR, and ELISA, tectochrysin inhibits extracellular signal-related kinase 1/2 (ERK1/2) phosphorylation and sequentially suppressed downstream inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-alpha), and IL-6 transcription as well as the NO, TNF-alpha, and IL-6 in supernatant, but it does not affect extracellular signal-regulated kinase (MEK) phosphorylation levels.	tectochrysin	69-81	interleukin 6	Mus musculus	333-337
29115497-6	2018	Additionally, the mRNA expression of hepcidin, FPN and IL-6 was upregulated in osteoblasts after ferric ammonium citrate exposure, while the mRNA expression of BMP6 was inhibited.	ferric ammonium citrate	97-120	interleukin 6	Mus musculus	55-59
29115475-3	2018	The results revealed that dysifragilone A significantly reduced the release of inflammatory mediators and inflammatory cytokines in activated RAW264.7 cells, including nitric oxide (NO), prostaglandin E2,(PGE2) and interleukin-6 (IL-6).	dysifragilone	26-39	interleukin 6	Mus musculus	230-234
28982597-9	2018	Moreover, trans-astaxanthin at 80mg/kg was demonstrated to effectively antagonize IL-1beta, IL-6 and TNF-alpha expression in hippocampus and spinal cord of CCI mice.	astaxantin, calcium, citrus bioflavoid, lycopene, vitamin D3 drug combination	10-27	interleukin 6	Mus musculus	92-96
29115547-7	2018	Hesperidin treatment caused a significant decrease in the levels of TNF-alpha, IL-1beta, IL-6, MCP-1, ICAM-1, MDA, CAT, SOD and caspase-3/9 in mice with AMI.	Hesperidin	0-10	interleukin 6	Mus musculus	89-93
30380983-9	2018	Immunohistochemical staining revealed that THSG blocked the activation of microglia and reduced the release of proinflammatory cytokines TNF-alpha, interleukin 1beta (IL-1beta), and interleukin 6 (IL-6).	thsg	43-47	interleukin 6	Mus musculus	182-195
30380983-9	2018	Immunohistochemical staining revealed that THSG blocked the activation of microglia and reduced the release of proinflammatory cytokines TNF-alpha, interleukin 1beta (IL-1beta), and interleukin 6 (IL-6).	thsg	43-47	interleukin 6	Mus musculus	197-201
30352432-11	2018	The addition of IL-13 to neuronal cultures normalized the palmitate-mediated increase in IL-6 and AgRP expression, suggesting that microglia may protect surrounding neurons, at least in part, through the release of IL-13.	Palmitates	58-67	interleukin 6	Mus musculus	89-93
29261014-10	2018	Macitentan treatment was also associated with a significant reduction in interleukin 6 (IL-6) concentration but there was no significant effect on atherosclerotic burden.	macitentan	0-10	interleukin 6	Mus musculus	73-86
29129239-9	2018	Pretreatment of J774 A.1 macrophages with isohumulone significantly attenuated lipopolysaccharide-induced mRNA expression of inducible nitric oxide synthase and interleukin-6 as well as the release of nitric oxide.	isohumulone	42-53	interleukin 6	Mus musculus	161-174
30587074-3	2018	This study aimed to evaluate the effects of inflammatory stimuli (IL-6, LPS), uric acid, hyperglycemia, fatty acids, flavonoids, statins and nonsteroidal anti-inflammatory drugs on cellular concentration of adenosine triphosphate (ATP), adenosine diphosphate (ADP) and nicotinamide adenine dinucleotide (NAD+) in cultured endothelial cells.	Adenosine	207-216	interleukin 6	Mus musculus	66-70
29889084-7	2018	Phenelzine-treated mice showed decreased levels of pro-inflammatory cytokines, such as interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in the injured spinal cord during the acute phase of inflammation.	Phenelzine	0-10	interleukin 6	Mus musculus	106-152
29261014-10	2018	Macitentan treatment was also associated with a significant reduction in interleukin 6 (IL-6) concentration but there was no significant effect on atherosclerotic burden.	macitentan	0-10	interleukin 6	Mus musculus	88-92
29372003-4	2018	SL-LPS pretreatment strongly enhanced the LPS-induced production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, TNF-alpha/IL-10, prostaglandin E2 (PGE2), and nitric oxide (NO) by RAW 264.7 cells compared to the control, whereas L-LPS increased IL-6 and NO production only.	l-lps	1-6	interleukin 6	Mus musculus	103-121
29372003-4	2018	SL-LPS pretreatment strongly enhanced the LPS-induced production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, TNF-alpha/IL-10, prostaglandin E2 (PGE2), and nitric oxide (NO) by RAW 264.7 cells compared to the control, whereas L-LPS increased IL-6 and NO production only.	l-lps	1-6	interleukin 6	Mus musculus	255-259
29372003-4	2018	SL-LPS pretreatment strongly enhanced the LPS-induced production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, TNF-alpha/IL-10, prostaglandin E2 (PGE2), and nitric oxide (NO) by RAW 264.7 cells compared to the control, whereas L-LPS increased IL-6 and NO production only.	sl-lps	0-6	interleukin 6	Mus musculus	103-121
29372003-6	2018	SL-LPS enhanced the LPS-induced production of IL-6 by Hepa1c1c-7 cells compared to the control, while L-LPS increased IL-6 but decreased IL-1beta and C reactive protein (CRP) levels.	sl-lps	0-6	interleukin 6	Mus musculus	46-50
29372003-4	2018	SL-LPS pretreatment strongly enhanced the LPS-induced production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, TNF-alpha/IL-10, prostaglandin E2 (PGE2), and nitric oxide (NO) by RAW 264.7 cells compared to the control, whereas L-LPS increased IL-6 and NO production only.	sl-lps	0-6	interleukin 6	Mus musculus	255-259
29372003-6	2018	SL-LPS enhanced the LPS-induced production of IL-6 by Hepa1c1c-7 cells compared to the control, while L-LPS increased IL-6 but decreased IL-1beta and C reactive protein (CRP) levels.	l-lps	1-6	interleukin 6	Mus musculus	46-50
29372003-7	2018	SL-LPS pretreatment strongly enhanced the LPS-induced production of TNF-alpha, IL-6, IL-10, PGE2, and NO in RAW 264.7 cells, and the IL-6, IL-1beta, and CRP levels in Hepa1c1c-7 cells, as well as the ratios of IFN-gamma/IL-10 in LPS- and Con A-stimulated EL4 cells compared to L-LPS.	l-lps	1-6	interleukin 6	Mus musculus	79-83
29372003-7	2018	SL-LPS pretreatment strongly enhanced the LPS-induced production of TNF-alpha, IL-6, IL-10, PGE2, and NO in RAW 264.7 cells, and the IL-6, IL-1beta, and CRP levels in Hepa1c1c-7 cells, as well as the ratios of IFN-gamma/IL-10 in LPS- and Con A-stimulated EL4 cells compared to L-LPS.	l-lps	1-6	interleukin 6	Mus musculus	133-137
29372003-7	2018	SL-LPS pretreatment strongly enhanced the LPS-induced production of TNF-alpha, IL-6, IL-10, PGE2, and NO in RAW 264.7 cells, and the IL-6, IL-1beta, and CRP levels in Hepa1c1c-7 cells, as well as the ratios of IFN-gamma/IL-10 in LPS- and Con A-stimulated EL4 cells compared to L-LPS.	sl-lps	0-6	interleukin 6	Mus musculus	79-83
29372003-7	2018	SL-LPS pretreatment strongly enhanced the LPS-induced production of TNF-alpha, IL-6, IL-10, PGE2, and NO in RAW 264.7 cells, and the IL-6, IL-1beta, and CRP levels in Hepa1c1c-7 cells, as well as the ratios of IFN-gamma/IL-10 in LPS- and Con A-stimulated EL4 cells compared to L-LPS.	sl-lps	0-6	interleukin 6	Mus musculus	133-137
29295585-9	2017	The results showed that pre-treatment with acetone-dissolved glycolipids reduced skin edema, epidermal thickness, and pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6, IL-17) in epidermal tissue.	Acetone	43-50	interleukin 6	Mus musculus	177-181
29267231-7	2017	MnTF inhibited the expression of interleukin 6 (IL-6), inducible nitric oxide synthase (iNOS), phospho-p65 (p-p65) and phospho-IkappaBalpha (p-IkappaBalpha), and increased interleukin 10 (IL-10).	mntf	0-4	interleukin 6	Mus musculus	33-46
29267231-7	2017	MnTF inhibited the expression of interleukin 6 (IL-6), inducible nitric oxide synthase (iNOS), phospho-p65 (p-p65) and phospho-IkappaBalpha (p-IkappaBalpha), and increased interleukin 10 (IL-10).	mntf	0-4	interleukin 6	Mus musculus	48-52
29295585-9	2017	The results showed that pre-treatment with acetone-dissolved glycolipids reduced skin edema, epidermal thickness, and pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6, IL-17) in epidermal tissue.	Glycolipids	61-72	interleukin 6	Mus musculus	177-181
29311931-7	2017	In addition, DMY prevented bone loss and decreased serum levels of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6, and with a decrease in the ratio between receptor activator of nuclear factor-kappaB (RANK) ligand (RANKL) and osteoprotegerin (OPG) in vivo.	dihydromyricetin	13-16	interleukin 6	Mus musculus	119-132
29311940-7	2017	qRT-PCR and ELISA experiments suggested that nuciferine inhibited TNF-alpha, IL-6, and IL-1beta secretion in tissues and RAW264.7 cells but increased IL-10 secretion (p &lt; 0.05).	nuciferine	45-55	interleukin 6	Mus musculus	77-81
29253016-6	2017	Non-exercised IL-6 MKO mice had higher plasma lactate and lower plasma non-esterified fatty acids than Controls.	Lactic Acid	46-53	interleukin 6	Mus musculus	14-18
29253016-6	2017	Non-exercised IL-6 MKO mice had higher plasma lactate and lower plasma non-esterified fatty acids than Controls.	Fatty Acids	86-97	interleukin 6	Mus musculus	14-18
29253016-10	2017	These findings indicate that skeletal muscle IL-6 may play an important role in the regulation of substrate utilization in skeletal muscle, basal and exercise-induced adaptations in adipose tissue glucose uptake and lipolysis during recovery from exercise.	Glucose	197-204	interleukin 6	Mus musculus	45-49
28986252-8	2017	Uric acid inhibited the hippocampal expression of IL-1beta and decreased serum and hippocampus levels of interleukin-1beta (IL-1beta), IL-6 and tumor necrosis factor-alpha (TNF-alpha).	Uric Acid	0-9	interleukin 6	Mus musculus	135-139
29246138-13	2017	The polysaccharides also affected the production of various cytokines, by increasing IL 2, IL 6, IL 7 levels and a decreasing TNFalpha levels.	Polysaccharides	4-19	interleukin 6	Mus musculus	91-95
29246138-16	2017	Furthermore, the polysaccharides enhance the levels of serum antitumor cytokines, IL 2, IL 6 and IL 7 while decreasing pro-tumor cytokine TNFalpha.	Polysaccharides	17-32	interleukin 6	Mus musculus	88-92
29311918-14	2017	GHK treatment significantly improved collagen deposition, and MMP-9/TIMP-1 imbalances in lung tissue and also reduced TNF-alpha, IL-6 expression in bronchoalveolar lavage fluid (BALF) and MPO in lung extracts.	glycyl-histidyl-lysine	0-3	interleukin 6	Mus musculus	129-133
29119789-0	2017	Graphene Oxide Thin Film with Dual Function Integrated into a Nanosandwich Device for in Vivo Monitoring of Interleukin-6.	graphene oxide	0-14	interleukin 6	Mus musculus	108-121
29119789-5	2017	For reporting the presence of analyte, the anti-IL-6 detection antibody was covalently modified to the GO, which has been integrated with the redox probe Nile blue (NB).	Nile Blue	154-163	interleukin 6	Mus musculus	48-52
29206849-7	2017	Interestingly, cilostazol decreased miR-221, but enhanced miR-143 and miR-145 in either in vitro or aortic tissue, as well as attenuated several pro-inflammatory mediators, including asymmetrical dimethylarginine, high-sensitivity C-reactive protein, vascular endothelial growth factor in aorta and serum pro-inflammatory cytokines (IL-6 and TNF-alpha).	Cilostazol	15-25	interleukin 6	Mus musculus	333-337
29026975-9	2017	At skin lesion site, ISLG also inhibited DNCB-induced pro-inflammatory cytokines like TNF-alpha, IL-6 as well as IL-4 expressions.	Dinitrochlorobenzene	41-45	interleukin 6	Mus musculus	97-101
28919107-6	2017	Three months later, mice treated with the combination of Abeta suppression and AAV1-mIL-6 showed significantly less plaque pathologic disorder than dox or AAV1-mIL-6 only groups.	Doxycycline	148-151	interleukin 6	Mus musculus	84-89
29079471-3	2017	The optimization study of multi-kinase inhibitor 1 led to the design of a potent and bioavailable hepcidin production inhibitor, 32 (DS28120313), which showed serum hepcidin-lowering effects in an interleukin-6-induced acute inflammatory mouse model.	DS28120313	133-143	interleukin 6	Mus musculus	197-210
29185103-12	2017	Aspirin, ticagrelor, and rosuvastatin decreased serum IL-1beta and IL-6 levels.	Aspirin	0-7	interleukin 6	Mus musculus	67-71
29203637-6	2017	RESULTS: CoNPs and Co2+ can induce the increase of ROS and inflammatory cytokines, such as tumour necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6).	Cobalt(2+)	19-23	interleukin 6	Mus musculus	166-179
29203637-6	2017	RESULTS: CoNPs and Co2+ can induce the increase of ROS and inflammatory cytokines, such as tumour necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6).	Cobalt(2+)	19-23	interleukin 6	Mus musculus	181-185
29185103-12	2017	Aspirin, ticagrelor, and rosuvastatin decreased serum IL-1beta and IL-6 levels.	Ticagrelor	9-19	interleukin 6	Mus musculus	67-71
29185103-12	2017	Aspirin, ticagrelor, and rosuvastatin decreased serum IL-1beta and IL-6 levels.	Rosuvastatin Calcium	25-37	interleukin 6	Mus musculus	67-71
28176019-11	2017	Erlotinib slightly reduced the urinary protein and suppressed the expression of renal injury markers (Lcn2, Lysozyme) and inflammatory cytokines (Il-6, Il-1beta and KC).	Erlotinib Hydrochloride	0-9	interleukin 6	Mus musculus	146-150
28951483-5	2017	DEN administration caused marked acute inflammatory responses in female mice with weight loss, reduced food intake, release of liver enzymes, and increased systemic levels of IL6.	Diethylnitrosamine	0-3	interleukin 6	Mus musculus	175-178
28744946-8	2017	In addition, these TPM treated mice, also showed a marked reduction in aortic superoxide formation and decreased circulating plasma levels of known pro-inflammatory markers IL-6, MCP-1, IL-1beta, IFN-gamma and TNF-alpha.	Topiramate	19-22	interleukin 6	Mus musculus	173-177
28752628-10	2017	A statistically significant reduction in interleukin (IL)-6 levels in the central nervous system (CNS) in the percentage of CD45+ /CD11b+ /lymphocyte antigen 6 complex locus G6D [Ly6G+ and in glial fibrillary acidic protein (GFAP) immunostaining was observed in mice from the i.n.-dexamethasone (DX] group compared to control and i.v.-DX-treated animals.	Dexamethasone	281-294	interleukin 6	Mus musculus	41-59
29285146-6	2017	The results indicated that rBmpA, which induced the transcription and expression of TNF-alpha and IL-6, activated proinflammatory responses in murine macrophages, human macrophages and dendritic cells.	rbmpa	27-32	interleukin 6	Mus musculus	98-102
28970282-4	2017	This effect of miR-155-5p is because of suppression of v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B, which promotes beta-cell function through IL-6-induced GLP-1 production in alpha-cells.	mir-155-5p	15-25	interleukin 6	Mus musculus	163-167
29031221-10	2017	Interleukin (IL)-6 and TNF-alpha levels in ALF were significantly higher in the BLM+PM2.5 group than in the BLM+air group (P&lt;0.05) and significantly higher after four-week exposure than after one-week exposure to PM2.5 (P&lt;0.05).	[4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-(5-PHENETHYL- PYRIDIN-3-YL)-METHANONE	84-87	interleukin 6	Mus musculus	0-18
29054824-6	2017	HA treatment significantly decreased the accumulation of inflammatory cells and production of cytokines, including tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1beta, caused by CS and LPS exposure.	Cesium	188-190	interleukin 6	Mus musculus	144-162
28948855-7	2017	RESULTS: The results showed that ethanol induced gastric injury, increased malondialdehyde (MDA) levels, decreased glutathione (GSH) content, superoxide dismutase (SOD) activity, and prostaglandin E2 (PGE2) levels, increased pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels and myeloperoxidase (MPO) activity, as well as the expression MAPK signaling pathway.	Ethanol	33-40	interleukin 6	Mus musculus	296-309
28948855-7	2017	RESULTS: The results showed that ethanol induced gastric injury, increased malondialdehyde (MDA) levels, decreased glutathione (GSH) content, superoxide dismutase (SOD) activity, and prostaglandin E2 (PGE2) levels, increased pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels and myeloperoxidase (MPO) activity, as well as the expression MAPK signaling pathway.	Ethanol	33-40	interleukin 6	Mus musculus	311-315
28522399-7	2017	Sacran solutions and 0.1%Tacrolimus reduced disease severity, suppressed histological changes and decreased the serum Th-1 (IFN-gamma, TNF-alpha, IL-2) and Th-2 (IL-4, IL-6, IL-10) cytokines in allergic mice (vs. controls).	Tacrolimus	25-35	interleukin 6	Mus musculus	168-172
29031142-10	2017	The levels of inflammatory mediators TNF-alpha, IL-1beta, and IL-6 in BALF were also inhibited by SchB.	schizandrin B	98-102	interleukin 6	Mus musculus	62-66
29134568-5	2017	Co-culture of CD4+ T cells with salbutamol-conditioned mature DC impaired TNFalpha and IL-6 secretion while preserving IL-10 production by T cells.	Albuterol	32-42	interleukin 6	Mus musculus	87-91
28707492-9	2017	Low-dose BPA fits a profile of an agent that exhibits pro-diabetogenic effects via T-cell immunomodulation in the early stages of disease development, i.e. decreases in splenic T-cell subpopulations [especially CD4+ T-cells] along with a trend in elevation of splenic T-cell formation of pro-inflammatory cytokines (IFN-gamma, TNF-alpha, and IL-6).	bisphenol A	9-12	interleukin 6	Mus musculus	342-346
28855315-6	2017	Importantly, eplerenone and MR knockdown attenuated the increase in the expression levels of proIl1b, Il6 and Tnfa, in the eWAT and liver of HFD-fed mice and LPS-stimulated BMDM.	Eplerenone	13-23	interleukin 6	Mus musculus	102-105
29243967-6	2017	The production of IL-10, IL-6, TNF-alpha, and IFN-gamma was induced by PTE treatment of the macrophages, and PTE also enhanced p-IkappaB and p-AKT.	pte	71-74	interleukin 6	Mus musculus	25-29
29399025-3	2017	In addition, administration of DML to D-galactose-treated mice significantly ameliorated the microglial activation and increases of IL-1beta, IL-6, and TNF-alpha levels in the hippocampus.	Galactose	38-49	interleukin 6	Mus musculus	142-146
29399025-1	2017	In the present study, we examined the effects of Dendropanax morbifera Leveille leaf extract (DML) on D-galactose-induced morphological changes in microglia and cytokines, including pro-inflammatory cytokines (interleukin [IL]-1beta, IL-6, and tumor necrosis factor [TNF]-alpha) and anti-inflammatory cytokines (IL-4 and IL-10) in the hippocampus.	dml	94-97	interleukin 6	Mus musculus	234-238
29399025-3	2017	In addition, administration of DML to D-galactose-treated mice significantly ameliorated the microglial activation and increases of IL-1beta, IL-6, and TNF-alpha levels in the hippocampus.	dml	31-34	interleukin 6	Mus musculus	142-146
27646265-10	2017	Reduced PDE11A4 expression may represent a lithium-sensitive pathophysiology, because both C57BL/6J and Pde11a KO mice show increased expression of the pro-inflammatory cytokine interleukin-6 (IL-6) relative to BALB/cJ and PDE11A WT mice, respectively.	Lithium	43-50	interleukin 6	Mus musculus	178-191
27646265-10	2017	Reduced PDE11A4 expression may represent a lithium-sensitive pathophysiology, because both C57BL/6J and Pde11a KO mice show increased expression of the pro-inflammatory cytokine interleukin-6 (IL-6) relative to BALB/cJ and PDE11A WT mice, respectively.	Lithium	43-50	interleukin 6	Mus musculus	193-197
28983597-4	2017	In mice with streptozotocin-induced vascular inflammation, wogonin treatment regulated the production of inflammatory cytokines, including interleukin-6, tumor necrosis factor-alpha and granulocyte macrophage colony-stimulating factor.	Streptozocin	13-27	interleukin 6	Mus musculus	139-181
28064632-13	2017	RESULTS: Apigenin, myricetin and their combination significantly reduced blood BUN, serum Cr, caspase-3TNF-alpha, IL-6, COXI and COXII, MDA levels and significantly increased GSH level and catalase activity parallel to, histopathological improvement in kidney tissues.	myricetin	19-28	interleukin 6	Mus musculus	114-118
28264607-7	2017	RESULTS AND DISCUSSION: Curcumin efficiently inhibited LPS-induced cytokines (TNF-alpha, IL-6) and microRNA-155 (miR-155) expression (p &lt; 0.05) without affecting the normally growth of Raw264.7 and THP-1 cells (IC50 21.8 and 22.3 muM at 48 h, respectively).	Curcumin	24-32	interleukin 6	Mus musculus	89-93
29075987-7	2017	Anthocyanins also maintained the stability of the redox system (GSH-PX, T-SOD and MDA) in plasma and liver structures (p &lt; 0.001) and reduced the levels of inflammatory factors (IL-1, IL-6 and TNF-alpha) in the liver (p &lt; 0.05).	Anthocyanins	0-12	interleukin 6	Mus musculus	187-191
28986232-5	2017	Here, we demonstrate that rifampicin pretreatment alleviated rotenone induced release of IL-1beta and IL-6, and its effects were suppressed when autophagy was inhibited by chloroquine.	Rifampin	26-36	interleukin 6	Mus musculus	102-106
28986232-5	2017	Here, we demonstrate that rifampicin pretreatment alleviated rotenone induced release of IL-1beta and IL-6, and its effects were suppressed when autophagy was inhibited by chloroquine.	Rotenone	61-69	interleukin 6	Mus musculus	102-106
28986232-5	2017	Here, we demonstrate that rifampicin pretreatment alleviated rotenone induced release of IL-1beta and IL-6, and its effects were suppressed when autophagy was inhibited by chloroquine.	Chloroquine	172-183	interleukin 6	Mus musculus	102-106
29192066-0	2017	Epinephrine stimulates CXCL1 IL-1alpha, IL-6 secretion in isolated mouse limb muscle.	Epinephrine	0-11	interleukin 6	Mus musculus	40-44
29192066-1	2017	Catecholamines stimulate interleukin-6 (IL-6) secretion in skeletal muscles.	Catecholamines	0-14	interleukin 6	Mus musculus	25-38
29192066-1	2017	Catecholamines stimulate interleukin-6 (IL-6) secretion in skeletal muscles.	Catecholamines	0-14	interleukin 6	Mus musculus	40-44
29192066-9	2017	Unexpectedly, DFO alone stimulated both IL-6 and CXCL1 secretion, but together with EPI and NOREPI had no additional effects.	Deferoxamine	14-17	interleukin 6	Mus musculus	40-44
29250069-4	2017	A decrease in NF-kappaB and NADPH oxidase 2 with an increase in arginase 1 and P2Y12 receptor was induced by histamine only in the ALS inflammatory environment, but not in the healthy microglia, together with an increase in IL-6, IL-10, CD163, and CD206 phenotypic markers in SOD1-G93A cells.	Histamine	109-118	interleukin 6	Mus musculus	224-228
29166710-16	2017	(2) At PIH 24, the content of HMGB1 and IL-6 in serum and lung tissue of mice in hydrogen group was close to that in sham injury group (with P values above 0.05).	Hydrogen	81-89	interleukin 6	Mus musculus	40-44
29270010-4	2017	Mice immunized with modified PAMAM by TAT peptide showed higher hemagglutination inhibition titer, and larger CD3+/CD4+ T cells and CD3+/CD8+ T cells population, as well as the production of cytokines, namely, interferon (IFN)-gamma, interleukin (IL)-2, IL-15, IL-12, IL-6, and tumor necrosis factor-alpha compared with those immunized with native PAMAM.	Poly(amidoamine)	29-34	interleukin 6	Mus musculus	268-305
28893353-2	2017	Several liver cell types can secrete IL-6 following activation by various signaling molecules including circulating adenosine.	Adenosine	116-125	interleukin 6	Mus musculus	37-41
28893353-3	2017	The aims of this study were to assess whether adenosine can induce IL-6 secretion by cholangiocytes via the A2b adenosine receptor (A2bAR) and to determine the effect of A2bAR-sensitive IL-6 release on injury response in biliary cirrhosis.	Adenosine	46-55	interleukin 6	Mus musculus	67-71
28893353-7	2017	Adenosine induced IL-6 mRNA expression and protein secretion via A2bAR activation.	Adenosine	0-9	interleukin 6	Mus musculus	18-22
28893353-11	2017	Extracellular adenosine induces cholangiocyte IL-6 release via the A2bAR.	Adenosine	14-23	interleukin 6	Mus musculus	46-50
28893353-13	2017	Adenosine upregulates IL-6 release by cholangiocytes via the A2bAR in a calcium-sensitive fashion.	Adenosine	0-9	interleukin 6	Mus musculus	22-26
28893353-13	2017	Adenosine upregulates IL-6 release by cholangiocytes via the A2bAR in a calcium-sensitive fashion.	Calcium	72-79	interleukin 6	Mus musculus	22-26
28784305-8	2017	After hepatic I/R injury, WT and NLRC5-/- mice pre-treated with DEX exhibited attenuated histological disruption, and reduced pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, IL-1beta and inducible nitric oxide synthase (iNOS), which was associated with the inactivated NF-kappaB pathway.	Dexmedetomidine	64-67	interleukin 6	Mus musculus	205-223
29166710-18	2017	The content of HMGB1 and IL-6 in serum and lung tissue of mice in burn+ hydrogen group was significantly lower than that in pure burn group (with P values below 0.001).	Hydrogen	72-80	interleukin 6	Mus musculus	25-29
28933476-4	2017	In vitro, piceatannol not only attenuated the over-production of inflammatory mediators and cytokines-such as nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor alpha (TNF-alpha), and interleukin-6 (IL-6)-but also suppressed the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) at both the mRNA and protein levels.	3,3',4,5'-tetrahydroxystilbene	10-21	interleukin 6	Mus musculus	199-212
29181306-6	2017	The itraconazole group showed reduced expression of VEGF-A, VEGFR-2, TNF-alpha, IL-6 than the PBS group (all P&lt;0.05).	Itraconazole	4-16	interleukin 6	Mus musculus	80-84
28933476-4	2017	In vitro, piceatannol not only attenuated the over-production of inflammatory mediators and cytokines-such as nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor alpha (TNF-alpha), and interleukin-6 (IL-6)-but also suppressed the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) at both the mRNA and protein levels.	3,3',4,5'-tetrahydroxystilbene	10-21	interleukin 6	Mus musculus	214-218
28923390-0	2017	TNF-alpha and IL-6 inhibitors: Conjugates of N-substituted indole and aminophenylmorpholin-3-one as anti-inflammatory agents.	n-substituted indole	45-65	interleukin 6	Mus musculus	14-18
28923390-0	2017	TNF-alpha and IL-6 inhibitors: Conjugates of N-substituted indole and aminophenylmorpholin-3-one as anti-inflammatory agents.	aminophenylmorpholin-3-one	70-96	interleukin 6	Mus musculus	14-18
29184437-0	2017	Antiallodynic and antihyperalgesic activities of zerumbone via the suppression of IL-1beta, IL-6, and TNF-alpha in a mouse model of neuropathic pain.	zerumbone	49-58	interleukin 6	Mus musculus	92-96
28821450-7	2017	Administration of carvedilol significantly inhibited expression of IL-1beta, TNF-alpha, and IL-6 at both the mRNA and protein levels.	Carvedilol	18-28	interleukin 6	Mus musculus	92-96
29032686-0	2017	3"-Hydroxypterostilbene Suppresses Colitis-Associated Tumorigenesis by Inhibition of IL-6/STAT3 Signaling in Mice.	3'-hydroxypterostilbene	0-23	interleukin 6	Mus musculus	85-89
29032686-4	2017	Molecular analysis exhibited the anti-inflammatory activity of 3"-hydroxypterostilbene by a significant decrease in the levels of inducible nitric oxide synthase, cyclooxygenase-2, and interleukin-6 (IL-6) (p &lt; 0.05).	3'-hydroxypterostilbene	63-86	interleukin 6	Mus musculus	185-198
29032686-4	2017	Molecular analysis exhibited the anti-inflammatory activity of 3"-hydroxypterostilbene by a significant decrease in the levels of inducible nitric oxide synthase, cyclooxygenase-2, and interleukin-6 (IL-6) (p &lt; 0.05).	3'-hydroxypterostilbene	63-86	interleukin 6	Mus musculus	200-204
29032686-5	2017	Moreover, dietary 3"-hydroxypterostilbene also significantly diminished IL-6/signal transducer and activator of transcription signaling and restored colonic suppressor of cytokine signaling 3 levels in the colonic tissue of mice (p &lt; 0.05).	3'-hydroxypterostilbene	18-41	interleukin 6	Mus musculus	72-76
28890346-12	2017	MFA treatment remarkably inhibited the expression of inflammatory factors tumour necrosis factor (TNF)-alpha, monocyte chemoattractant protein 1 (MCP-1), interleukin (IL)-1beta and IL-6.	mfa	0-3	interleukin 6	Mus musculus	181-185
29019238-5	2017	Generally, a range of penchinone A derivatives potently inhibited NO, TNF-alpha, and IL-6 productions, compared to dexamethasone as a positive control.	penchinone A	22-34	interleukin 6	Mus musculus	85-89
28954384-10	2017	Moreover, EFTB down regulated the mRNA expression of TNF-alpha, IL-6, COX-2 and NF-kappaB against LPS stimulation.	eftb	10-14	interleukin 6	Mus musculus	64-68
29095915-10	2017	In db/db mice, mRNA and protein expression of IL-6 and superoxide (O2-) production were higher, but reduced by anti-IL-6 treatment.	Superoxides	55-65	interleukin 6	Mus musculus	111-120
29095915-10	2017	In db/db mice, mRNA and protein expression of IL-6 and superoxide (O2-) production were higher, but reduced by anti-IL-6 treatment.	Superoxides	67-69	interleukin 6	Mus musculus	111-120
28800679-6	2017	KEY RESULTS: The results show that SB decreased LPS-induced disruption in mammary tissues, infiltration of inflammatory cells and the levels of TNF-alpha, IL-6 and IL-1beta.	Butyric Acid	35-37	interleukin 6	Mus musculus	155-159
29067115-0	2017	Advanced glycation end products and lipopolysaccharides stimulate interleukin-6 secretion via the RAGE/TLR4-NF-kappaB-ROS pathways and resveratrol attenuates these inflammatory responses in mouse macrophages.	Reactive Oxygen Species	118-121	interleukin 6	Mus musculus	66-79
28757362-10	2017	The higher mortality in the Et30cH group was related to increased inflammation in the heart and a higher concentration of IL-6 and TNF-alpha cytokines, characterizing the Th1 response.	et30ch	28-34	interleukin 6	Mus musculus	122-126
29067115-8	2017	IL-6 secretion was dependent on nuclear factor (NF)-kappaB activation and the production of reactive oxygen species (ROS; P&lt;0.05).	Reactive Oxygen Species	92-115	interleukin 6	Mus musculus	0-4
29067115-8	2017	IL-6 secretion was dependent on nuclear factor (NF)-kappaB activation and the production of reactive oxygen species (ROS; P&lt;0.05).	Reactive Oxygen Species	117-120	interleukin 6	Mus musculus	0-4
29067115-9	2017	Resveratrol suppressed mRNA expression and intracellular IL-6 production, resulting in significantly decreased IL-6 secretion after treatment with LPS or AGE (P&lt;0.01).	Resveratrol	0-11	interleukin 6	Mus musculus	57-61
29067115-9	2017	Resveratrol suppressed mRNA expression and intracellular IL-6 production, resulting in significantly decreased IL-6 secretion after treatment with LPS or AGE (P&lt;0.01).	Resveratrol	0-11	interleukin 6	Mus musculus	111-115
29067115-10	2017	Furthermore, treatment with Ex527, which is a sirtuin-1 (SIRT1) inhibitor, significantly attenuated the anti-inflammatory effect of resveratrol (P&lt;0.05), and treatment with 5-aminoimidazole-4-carboxamide ribonucleotide, which is a 5" adenosine monophosphate-activated protein kinase (AMPK) activator, resulted in a significant decrease in IL-6 secretion in J774 macrophages (P&lt;0.05).	6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide	28-33	interleukin 6	Mus musculus	342-346
29067115-11	2017	The results of the present study indicated that AGE and LPS increase IL-6 secretion depending on NF-kappaB activation and ROS production through RAGE and/or TLR4 in the J774 murine macrophage cell line.	Reactive Oxygen Species	122-125	interleukin 6	Mus musculus	69-73
28952835-4	2017	The results indicated that treatment with the selective SIRT1 inhibitor EX-527 suppressed LPS-induced elevation of TNF-alpha and IL-6 in plasma.	6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide	72-78	interleukin 6	Mus musculus	129-133
28974441-6	2017	Pro-inflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1beta, and IL-6, were reduced by tyrosol in bronchoalveolar lavage fluid and lung tissue.	4-hydroxyphenylethanol	115-122	interleukin 6	Mus musculus	93-97
28910744-8	2017	The ERK1/2 inhibitor U0126, the P38 inhibitor SB239063 and the STAT3 inhibitor S3I-201 all attenuated the effects of AGEs on MLO-Y4 cell apoptosis and IL-6 and VEGF-A secretion.	U 0126	21-26	interleukin 6	Mus musculus	151-155
28952835-8	2017	Meanwhile, the inhibitory effects of EX-527 on IL-6 induction and the beneficial effects of EX-527 on lung injury were partially reversed by 3BDO.	6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide	37-43	interleukin 6	Mus musculus	47-51
28910744-8	2017	The ERK1/2 inhibitor U0126, the P38 inhibitor SB239063 and the STAT3 inhibitor S3I-201 all attenuated the effects of AGEs on MLO-Y4 cell apoptosis and IL-6 and VEGF-A secretion.	NSC 74859	79-86	interleukin 6	Mus musculus	151-155
29016795-10	2017	Furthermore, leonurine (60 mg/kg) significantly inhibited the production of proinflammatory cytokine interleukin-1beta, interleukin-6 and TNF-alpha, and suppressed the nuclear factor kappa B signaling pathway.	leonurine	13-22	interleukin 6	Mus musculus	120-133
29117277-6	2017	Further, naringenin inhibited alkali-induced cytokine (IL-1beta and IL-6) production, Vegf, Pdgf, and Mmp14 mRNA expression, and the reduction of ferric reducing antioxidant power and Azinobis-(3-Ethylbenzothiazoline 6-Sulfonic acid) radical scavenging capacity as well as increased the reduced glutathione and protein-bound sulfhydryl groups levels.	naringenin	9-19	interleukin 6	Mus musculus	68-72
28976750-4	2017	Arctii Fructus water extract (AFW) or ethanol extract (AFE) and ARC reduced the production of histamine and pro-inflammatory cytokines such as interleukin (IL)-1beta, IL-6, IL-8, and TNF-alpha in mast cells.	Water	15-20	interleukin 6	Mus musculus	167-171
28956670-7	2017	More specifically, glyceollins reduced plasma levels of inflammatory cytokines, such as tumor necrosis factor-alpha and interleukin-6, which were otherwise markedly increased by DSS treatment.	Dextran Sulfate	178-181	interleukin 6	Mus musculus	120-133
28976750-4	2017	Arctii Fructus water extract (AFW) or ethanol extract (AFE) and ARC reduced the production of histamine and pro-inflammatory cytokines such as interleukin (IL)-1beta, IL-6, IL-8, and TNF-alpha in mast cells.	Ethanol	38-45	interleukin 6	Mus musculus	167-171
28910180-6	2017	Additionally, halleridone removed intramicroglial Abeta1-42 and suppressed the production of inflammatory mediators such as interleukin (IL)-1beta, IL-6, prostaglandin E2, and nitric oxide (NO) induced by artificially overexpressed Abeta1-42 and decreased pNF-kappaB accumulation in the nucleus and the expression of inducible NO synthase and cyclooxygenase II in BV-2 cells.	halleridone	14-25	interleukin 6	Mus musculus	148-152
29078883-8	2017	In a murine breast cancer model, sphingosine kinase 1, S1P receptor 1, interleukin 6, and STAT3 were overexpressed in the doxorubicin-treated group, whereas all of them were significantly suppressed with addition of FTY720.	Doxorubicin	122-133	interleukin 6	Mus musculus	71-84
28759012-4	2017	A mechanistic study identified that these inhibitory effects of berberine occurred through blocking interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) expression in colonic macrophages.	Berberine	64-73	interleukin 6	Mus musculus	100-113
28849172-8	2017	Artesunate attenuated TNF-alpha and IL-6 levels, suppressed alpha-SMA, TLR4, MyD88, NF-kappaB p65 and TGF-beta1 protein expression, and decreased caspase-3 activity in nephritis mice.	Artesunate	0-10	interleukin 6	Mus musculus	36-40
28759012-4	2017	A mechanistic study identified that these inhibitory effects of berberine occurred through blocking interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) expression in colonic macrophages.	Berberine	64-73	interleukin 6	Mus musculus	115-119
28759012-7	2017	Furthermore, in vivo administration of IL-6 to DSS-treated ApcMin/+ mice effectively weakened the inhibitory effects of berberine on tumorigenesis and EGFR-ERK signaling in colon tissues.	Dextran Sulfate	47-50	interleukin 6	Mus musculus	39-43
28759012-7	2017	Furthermore, in vivo administration of IL-6 to DSS-treated ApcMin/+ mice effectively weakened the inhibitory effects of berberine on tumorigenesis and EGFR-ERK signaling in colon tissues.	Berberine	120-129	interleukin 6	Mus musculus	39-43
28884396-0	2017	Ginsenoside Re Protects Trimethyltin-Induced Neurotoxicity via Activation of IL-6-Mediated Phosphoinositol 3-Kinase/Akt Signaling in Mice.	Ginsenosides	0-11	interleukin 6	Mus musculus	77-81
28884396-0	2017	Ginsenoside Re Protects Trimethyltin-Induced Neurotoxicity via Activation of IL-6-Mediated Phosphoinositol 3-Kinase/Akt Signaling in Mice.	trimethyltin	24-36	interleukin 6	Mus musculus	77-81
28884396-5	2017	In addition, Re attenuated the TMT-induced decreases in IL-6 protein level.	trimethyltin	31-34	interleukin 6	Mus musculus	56-60
28884396-13	2017	The results suggest that ginsenoside Re requires IL-6-dependent PI3K/Akt signaling for its protective potential against TMT-induced neurotoxicity.	Ginsenosides	25-36	interleukin 6	Mus musculus	49-53
29098024-9	2017	AZM also down-regulated the concentration and mRNA expression of interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha and transforming growth factor-beta1.	Azithromycin	0-3	interleukin 6	Mus musculus	89-93
27256583-0	2017	Resveratrol suppressed seizures by attenuating IL-1beta, IL1-Ra, IL-6, and TNF-alpha in the hippocampus and cortex of kindled mice.	Resveratrol	0-11	interleukin 6	Mus musculus	65-69
28561205-0	2017	Treatment with Mountain-Cultivated Ginseng Alleviates Trimethyltin-Induced Cognitive Impairments in Mice via IL-6-Dependent JAK2/STAT3/ERK Signaling.	trimethyltin	54-66	interleukin 6	Mus musculus	109-113
28921708-4	2017	Both scopoletin and metformin lowered blood glucose and HbA1c , serum ALT, TNF-alpha and IL-6 levels, glucose intolerance, and hepatic lipid accumulation compared with the diabetic control group.	Scopoletin	5-15	interleukin 6	Mus musculus	89-93
28921708-4	2017	Both scopoletin and metformin lowered blood glucose and HbA1c , serum ALT, TNF-alpha and IL-6 levels, glucose intolerance, and hepatic lipid accumulation compared with the diabetic control group.	Metformin	20-29	interleukin 6	Mus musculus	89-93
28921708-5	2017	Scopoletin or metformin down-regulated hepatic gene expression of triglyceride (Pparg, Plpp2, and Dgat2) and cholesterol (Hmgcr) synthesis as well as inflammation (Tlr4, Myd88, Nfkb1, Tnfa, and Il6), while it up-regulated Cyp7a1 gene.	Scopoletin	0-10	interleukin 6	Mus musculus	194-197
28921708-5	2017	Scopoletin or metformin down-regulated hepatic gene expression of triglyceride (Pparg, Plpp2, and Dgat2) and cholesterol (Hmgcr) synthesis as well as inflammation (Tlr4, Myd88, Nfkb1, Tnfa, and Il6), while it up-regulated Cyp7a1 gene.	Metformin	14-23	interleukin 6	Mus musculus	194-197
28561205-3	2017	We previously reported that interleukin-6 plays a protective role against trimethyltin-induced cognitive dysfunction.	trimethyltin	74-86	interleukin 6	Mus musculus	28-41
28561205-6	2017	With this study, we sought to determine whether the interleukin-6-dependent modulation of the Janus kinase 2/signal transducer activator of transcription 3 and extracellular signal-regulated kinase signaling network is also associated with the pharmacological activity of mountain-cultivated ginseng against trimethyltin-induced cognitive dysfunction.	trimethyltin	308-320	interleukin 6	Mus musculus	52-65
28561205-9	2017	Trimethyltin-induced cognitive impairments were more pronounced in interleukin-6 (-/-) mice than wild-type mice, and they were markedly reduced by treatment with either mountain-cultivated ginseng or recombinant interleukin-6 protein (6 ng, intracerebroventricular).	trimethyltin	0-12	interleukin 6	Mus musculus	67-80
28561205-9	2017	Trimethyltin-induced cognitive impairments were more pronounced in interleukin-6 (-/-) mice than wild-type mice, and they were markedly reduced by treatment with either mountain-cultivated ginseng or recombinant interleukin-6 protein (6 ng, intracerebroventricular).	trimethyltin	0-12	interleukin 6	Mus musculus	212-225
28561205-12	2017	Our results, therefore, suggest that mountain-cultivated ginseng acts through interleukin-6-dependent activation of Janus kinase 2/signal transducer activator of transcription 3/extracellular signal-regulated kinase signaling in order to reverse cognitive impairment caused by trimethyltin treatment.	trimethyltin	277-289	interleukin 6	Mus musculus	78-91
29268844-6	2017	Chromatin immunoprecipitation (ChIP) was done to evaluate the effect of KAT6B on the recruitment of acetylation of histone 3 lysine 23 (H3K23ac) within IL-6 promoter region.	Lysine	125-131	interleukin 6	Mus musculus	152-156
28515388-0	2017	Nitric oxide is critical for avoiding hepatic lipid overloading via IL-6 induction during liver regeneration after partial hepatectomy in mice.	Nitric Oxide	0-12	interleukin 6	Mus musculus	68-72
29903197-27	2017	Compared with those of the mice with pure water, significant decrease in IL-6(( 201.	Water	42-47	interleukin 6	Mus musculus	73-77
29073894-0	2017	Propofol inhibits the release of interleukin-6, 8 and tumor necrosis factor-alpha correlating with high-mobility group box 1 expression in lipopolysaccharides-stimulated RAW 264.7 cells.	Propofol	0-8	interleukin 6	Mus musculus	33-46
29073894-2	2017	This study is to disclose whether the propofol affects the expression of high-mobility group box 1 (HMGB1) in lipopolysaccharides (LPS)-stimulated RAW 264.7 cells and the release of interleukin-6 (IL-6), 8 (IL-8) and tumor necrosis factor-alpha (TNF-alpha).	Propofol	38-46	interleukin 6	Mus musculus	182-195
29073894-2	2017	This study is to disclose whether the propofol affects the expression of high-mobility group box 1 (HMGB1) in lipopolysaccharides (LPS)-stimulated RAW 264.7 cells and the release of interleukin-6 (IL-6), 8 (IL-8) and tumor necrosis factor-alpha (TNF-alpha).	Propofol	38-46	interleukin 6	Mus musculus	197-201
28515388-5	2017	IL-6 was robustly secreted into circulating blood in L-NAME (-) group, but not in L-NAME (+) group.	NG-Nitroarginine Methyl Ester	53-59	interleukin 6	Mus musculus	0-4
29061958-11	2017	ALA (100 and 300 mg/kg) intervention to estrogen-deficiency induced bone loss mice (ovariectomized) showed reductions in TRAP+ osteoclasts count, CTX-I expression, levels of IL-1beta, IL-2, IL-6, IL10, TNF-alpha and MCP-1 and iNOS and COX-2.	alpha-Linolenic Acid	0-3	interleukin 6	Mus musculus	190-194
29073894-9	2017	CONCLUSION: Propofol inhibited the releases of IL-6, IL-8 and TNF-alpha in LPS-stimulated RAW 264.7 cells, and the levels of IL-6, IL-8 and TNF-alpha intimately correlated with the expression of HMGB1, which indicating that propofol may prevent inflammatory responses through reducing the releases of these cytokines and inflammatory mediators.	Propofol	12-20	interleukin 6	Mus musculus	47-51
29073894-9	2017	CONCLUSION: Propofol inhibited the releases of IL-6, IL-8 and TNF-alpha in LPS-stimulated RAW 264.7 cells, and the levels of IL-6, IL-8 and TNF-alpha intimately correlated with the expression of HMGB1, which indicating that propofol may prevent inflammatory responses through reducing the releases of these cytokines and inflammatory mediators.	Propofol	12-20	interleukin 6	Mus musculus	125-129
28803048-3	2017	alpha,beta-Unsaturated glycyrrhetic acids showed better activity, among them, compounds 6k and 6l with piperazine unit exhibited the most potent nitric oxide (NO) and interleukin-6 (IL-6) inhibitory activity (IC50 = 13.3 and 15.5 muM respectively).	alpha,beta-unsaturated glycyrrhetic acids	0-41	interleukin 6	Mus musculus	167-180
28803048-3	2017	alpha,beta-Unsaturated glycyrrhetic acids showed better activity, among them, compounds 6k and 6l with piperazine unit exhibited the most potent nitric oxide (NO) and interleukin-6 (IL-6) inhibitory activity (IC50 = 13.3 and 15.5 muM respectively).	alpha,beta-unsaturated glycyrrhetic acids	0-41	interleukin 6	Mus musculus	182-186
28803048-3	2017	alpha,beta-Unsaturated glycyrrhetic acids showed better activity, among them, compounds 6k and 6l with piperazine unit exhibited the most potent nitric oxide (NO) and interleukin-6 (IL-6) inhibitory activity (IC50 = 13.3 and 15.5 muM respectively).	Piperazine	103-113	interleukin 6	Mus musculus	182-186
29057883-8	2017	IH-induced IL-6 secretion and vesicle-associated membrane protein-associated vesicles re-organization were inhibited in presence of the inhibitor of protein secretion, brefeldin A, or ML-7.	Brefeldin A	168-179	interleukin 6	Mus musculus	11-15
29053632-10	2017	Furthermore, ZJF attenuated APAP-induced inflammatory mediator production, such as nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta).	zjf	13-16	interleukin 6	Mus musculus	143-156
29053632-10	2017	Furthermore, ZJF attenuated APAP-induced inflammatory mediator production, such as nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta).	zjf	13-16	interleukin 6	Mus musculus	158-162
29040966-5	2017	Celastrol down-regulated the mRNA levels of macrophage M1 biomarkers (e.g., IL-6, IL-1beta, TNF-alpha, iNOS) in cell culture and in mice.	celastrol	0-9	interleukin 6	Mus musculus	76-80
29044196-5	2017	WACNA identified the interplay between transcript and metabolite subnetworks linked to lipid metabolism, inflammation and glycerophospholipid metabolism that were associated with IL6, AMPK and PPAR signal pathways.	Glycerophospholipids	122-141	interleukin 6	Mus musculus	179-182
28993631-4	2017	We demonstrate that females susceptible to RSDS display social avoidance, anxiety-like behavior, reduction of body weight, and elevated levels of circulating interleukin 6.	rsds	43-47	interleukin 6	Mus musculus	158-171
29038604-0	2017	Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis.	Bleomycin	107-116	interleukin 6	Mus musculus	26-30
29038604-5	2017	Airway physiology measurements at day 21 demonstrated that overexpression of OSM or IL-6 exacerbated bleomycin-induced lung elastance, consistent with histopathological assessment of extracellular matrix and myofibroblast accumulation.	Bleomycin	101-110	interleukin 6	Mus musculus	84-88
29038604-8	2017	In conclusion, the gp130 cytokines IL-6 and OSM contribute to the accumulation of profibrotic macrophages and enhancement of bleomycin-induced lung fibrosis.	Bleomycin	125-134	interleukin 6	Mus musculus	35-39
28677156-5	2017	Conversely, dioscin improved the secretion of pro-inflammatory cytokines (IL-6, TNFalpha, and IL-1beta), and the phagocytic capacity of tumor-associated macrophages by increasing M2-to-M1 phenotype transition.	dioscin	12-19	interleukin 6	Mus musculus	74-78
28993616-5	2017	The phenotype depends on sex-steroid hormones: dihydrotestosterone treatment of gonadectomized female Dmp1Cre.Socs3 f/f mice restores normal cortical morphology, whereas in males, estradiol treatment, or IL-6 deletion, recapitulates the female phenotype.	Dihydrotestosterone	47-66	interleukin 6	Mus musculus	204-208
28993616-5	2017	The phenotype depends on sex-steroid hormones: dihydrotestosterone treatment of gonadectomized female Dmp1Cre.Socs3 f/f mice restores normal cortical morphology, whereas in males, estradiol treatment, or IL-6 deletion, recapitulates the female phenotype.	Estradiol	180-189	interleukin 6	Mus musculus	204-208
28982132-3	2017	In this study we examined the role of IL-6 in the pathogenesis of experimental AAA induced by a periaortic exposure to CaCl2 in mice.	Calcium Chloride	119-124	interleukin 6	Mus musculus	38-42
28599809-6	2017	Moreover, the chronic ethanol administration elevated the gene expression of pro-inflammatory cytokines such as tumor-necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the liver tissue.	Ethanol	22-29	interleukin 6	Mus musculus	156-169
28599809-6	2017	Moreover, the chronic ethanol administration elevated the gene expression of pro-inflammatory cytokines such as tumor-necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the liver tissue.	Ethanol	22-29	interleukin 6	Mus musculus	171-175
28599809-7	2017	The CCA co-administration, however, significantly (p&lt;0.05) increased the activities of the SOD, CAT, and GPx and caused the down-regulation of the TNF-alpha- and IL-6-gene expressions in the liver tissue.	1-methylcyclohexanecarboxylic acid	4-7	interleukin 6	Mus musculus	165-169
28666100-2	2017	Here, multifunctional polymer-coated carbon nanodots with an interleukin-6 (IL-6) fragment peptide for receptor-targeting (pCDPI) were prepared for drug delivery.	Polymers	22-29	interleukin 6	Mus musculus	61-74
28726304-4	2017	Cholesterol-modified DNA forms a hydrogel, Dgel(chol), and induces IL-6 mRNA expression in mouse skin after intradermal injection, as DNA without cholesterol does.	Cholesterol	0-11	interleukin 6	Mus musculus	67-71
28666100-2	2017	Here, multifunctional polymer-coated carbon nanodots with an interleukin-6 (IL-6) fragment peptide for receptor-targeting (pCDPI) were prepared for drug delivery.	Polymers	22-29	interleukin 6	Mus musculus	76-80
28666100-2	2017	Here, multifunctional polymer-coated carbon nanodots with an interleukin-6 (IL-6) fragment peptide for receptor-targeting (pCDPI) were prepared for drug delivery.	Carbon	37-43	interleukin 6	Mus musculus	61-74
28666100-2	2017	Here, multifunctional polymer-coated carbon nanodots with an interleukin-6 (IL-6) fragment peptide for receptor-targeting (pCDPI) were prepared for drug delivery.	Carbon	37-43	interleukin 6	Mus musculus	76-80
28666100-4	2017	In vitro and in vivo results demonstrated that pCDPI can overcome the blood-brain barrier (BBB) and deeply penetrate into orthotopic glioma in mice, to inhibit IL-6-induced cell proliferation and achieve imaging-guided targeted drug delivery.	pcdpi	47-52	interleukin 6	Mus musculus	160-164
28810537-7	2017	The IL-6, IL-1beta and TNF-a levels were all decreased by cilostazol.	Cilostazol	58-68	interleukin 6	Mus musculus	4-8
28718891-10	2017	Chlorine exposure increased VEGF, IL-6, the chemokines KC and CCL3 in BAL fluid.	Chlorine	0-8	interleukin 6	Mus musculus	34-38
28812425-3	2017	We found that nasunin reduced the LPS-induced secretion of tumor necrosis factor-alpha, interleukin-6 and nitric oxide, and expression of inducible nitric oxide synthase in a dose-dependent manner.	nasunin	14-21	interleukin 6	Mus musculus	88-101
28718891-11	2017	Montelukast treatment prevented chlorine-induced increases in VEGF and IL-6.	montelukast	0-11	interleukin 6	Mus musculus	71-75
28718891-11	2017	Montelukast treatment prevented chlorine-induced increases in VEGF and IL-6.	Chlorine	32-40	interleukin 6	Mus musculus	71-75
28718891-12	2017	Anti-IL-6 antibody inhibited chlorine-induced neutrophilia and reduced AHR.	Chlorine	29-37	interleukin 6	Mus musculus	5-9
28912118-8	2017	In a single-dose UV (200 mJ/cm2)-induced skin inflammation mouse model, carvedilol (10 mumol/L), applied topically after UV exposure, reduced skin hyperplasia and the levels of cyclobutane pyrimidine dimers, IL1beta, IL6, and COX-2 in skin.	Carvedilol	72-82	interleukin 6	Mus musculus	217-220
28746799-9	2017	Finally, we confirmed that in vivo injection of an anti-PD-L1 antibody or a Toll-like receptor 3 ligand, polyinosinic-polycytidylic acid, effectively inhibited tumorigenesis under the IL-6-deficient condition.	Poly I-C	105-136	interleukin 6	Mus musculus	184-188
27374794-8	2017	Moreover, higher expression levels of IL-6, TNF-alpha, p65, CXCL-1 and iNOS, and an increased level of NF-kappaB (p65) nuclear translocation were also found in the DSS-treated BRD7-/- mice.	dss	164-167	interleukin 6	Mus musculus	38-42
29103460-8	2017	Ginsenoside Rk1 inhibited lipopolysaccharide-induced expression of nitric oxide (NO), interleukin (IL)-6, IL-1beta, tumor necrosis factor (TNF)-alpha, and monocyte chemotactic protein (MCP)-1.	Ginsenosides	0-11	interleukin 6	Mus musculus	86-104
29140131-10	2017	Correspondingly, the number of eosinophils and neutrophils and IL-6 levels in BALF after budesonide treatment were found to be decreased, whereas the IFN-gamma levels in BALF were increased.	Budesonide	89-99	interleukin 6	Mus musculus	63-67
28811235-8	2017	Moreover, the effect of sodium butyrate on protection of injuries of the liver and upper small intestine could be due to inhibition of toll-like receptor 4 signaling pathway, as well as its down-regulation of inflammatory cytokines - interleukin-6 and tumor necrosis factor-a.	Butyric Acid	24-39	interleukin 6	Mus musculus	234-247
28646427-8	2017	TSA-treated mice showed a significant reduction of C-reactive protein (CRP), ox-LDL, IL-1beta, IL-6, IL-12, and TNF-alpha in ELISA data.	tanshinone	0-3	interleukin 6	Mus musculus	95-99
28646427-9	2017	Real-time PCR analyses showed that TSA decreased the expression of CCL-2, CD40, IL-1beta, IL-6, TNF-alpha, and MMP-2 in heart and aorta tissues.	tanshinone	35-38	interleukin 6	Mus musculus	90-94
28667502-6	2017	In the kidney, LPA pretreatment significantly reduced the upregulation of inflammatory cytokines (IL-6, TNFalpha, monocyte chemoattractant protein-1 (MCP-1)), and completely prevented downregulation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha and upregulation of heme oxygenase-1 caused by LPS.	lysophosphatidic acid	15-18	interleukin 6	Mus musculus	98-102
28806641-7	2017	A significant difference in the cytokine profile was still observed 24h post injury in the ethanol pretreated mice, as shown by the delayed peak in IL-6 and by the suppression of GM-CSF, IFN-gamma, and IL-3.	Ethanol	91-98	interleukin 6	Mus musculus	148-152
28688098-7	2017	These processes inhibited the LPS-induced activation (phosphorylation) of NF-kappaB and STAT-3, in turn blocked the transcriptional activation of inducible NO synthase (iNOS), interleukin-6 (IL-6), and TNF-alpha, and finally attenuated the productions of nitric oxide (NO), IL-6, and TNF-alpha.	Nitric Oxide	255-267	interleukin 6	Mus musculus	176-189
28822324-0	2017	Preventive effects of interleukin-6 in lipopolysaccharide/d-galactosamine induced acute liver injury via regulating inflammatory response in hepatic macrophages.	Galactosamine	58-73	interleukin 6	Mus musculus	22-35
28688098-7	2017	These processes inhibited the LPS-induced activation (phosphorylation) of NF-kappaB and STAT-3, in turn blocked the transcriptional activation of inducible NO synthase (iNOS), interleukin-6 (IL-6), and TNF-alpha, and finally attenuated the productions of nitric oxide (NO), IL-6, and TNF-alpha.	Nitric Oxide	255-267	interleukin 6	Mus musculus	191-195
28688098-7	2017	These processes inhibited the LPS-induced activation (phosphorylation) of NF-kappaB and STAT-3, in turn blocked the transcriptional activation of inducible NO synthase (iNOS), interleukin-6 (IL-6), and TNF-alpha, and finally attenuated the productions of nitric oxide (NO), IL-6, and TNF-alpha.	Nitric Oxide	255-267	interleukin 6	Mus musculus	274-278
28822324-1	2017	Lipopolysaccharide/d-Galactosamine (LPS/d-Gal)-induced acute liver injury is characterized by significant inflammatory responses including TNF-alpha and interleukin-6 (IL-6) and is a widely applied experimental model for inflammation research.	Galactosamine	19-34	interleukin 6	Mus musculus	153-166
28843178-6	2017	Additionally, EsA decreased beta-amyloid1-42 (Abeta1-42)-induced production of TNF-alpha, IL-1beta and IL-6 in primary microglia.	esculentoside A	14-17	interleukin 6	Mus musculus	103-107
28822324-1	2017	Lipopolysaccharide/d-Galactosamine (LPS/d-Gal)-induced acute liver injury is characterized by significant inflammatory responses including TNF-alpha and interleukin-6 (IL-6) and is a widely applied experimental model for inflammation research.	Galactosamine	19-34	interleukin 6	Mus musculus	168-172
28816630-3	2017	All protein and polysaccharide samples of the plants led to greater lymphocyte proliferation and TNF-alpha and IL-6 production in cultured splenocytes than did the crude water extracts at the same concentrations tested.	Polysaccharides	16-30	interleukin 6	Mus musculus	111-115
28797835-4	2017	Treatment with ethanol increased tumor necrosis factor-alpha and interleukin-6 levels in aortas with or without PVAT (PVAT+ and PVAT-, respectively) from WT mice, but not TNFR1-/-.	Ethanol	15-22	interleukin 6	Mus musculus	65-78
28598954-6	2017	RESULTS: Noradrenaline treatment resulted in a pronounced increase in SGLT2 and interleukin (IL)-6 expression in HK2 cells and promoted translocation of SGLT2 to the cell surface.	Norepinephrine	9-22	interleukin 6	Mus musculus	80-98
28796285-5	2017	In our study, we have identified that selective HDAC inhibition with inhibitors apicidin, MS-275 or MI-192, or specific knockdown of HDAC1 or 2 using siRNA, suppresses the expression of cytokines interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) in BV-2 murine microglia activated with lipopolysaccharide (LPS).	apicidin	80-88	interleukin 6	Mus musculus	196-209
28924088-5	2017	In RAW264.7 cells stimulated by lipopolysaccharide (LPS), n-3 DPA significantly down-regulated mRNA expression of pro-inflammatory factors such as IL-6, IL-1beta, iNOS and COX-2.	n-3 dpa	58-65	interleukin 6	Mus musculus	147-151
28924088-6	2017	Production of IL-6 was also reduced by n-3 DPA in a dose-dependent manner.	n-3 dpa	39-46	interleukin 6	Mus musculus	14-18
28924088-7	2017	We found that n-3 DPA treatment resulted in greater IL-6 mRNA down-regulation than that achieved with EPA treatment, and was similar to that of DHA treatment.	n-3 dpa	14-21	interleukin 6	Mus musculus	52-56
28924088-8	2017	Furthermore, expression levels of IL-6 and IL-1beta mRNAs were measured in the presence of the delta-6 desaturase inhibitor SC26196 in the culture medium to inhibit the conversion of n-3 DPA to DHA.	SC 26196	124-131	interleukin 6	Mus musculus	34-38
28924088-8	2017	Furthermore, expression levels of IL-6 and IL-1beta mRNAs were measured in the presence of the delta-6 desaturase inhibitor SC26196 in the culture medium to inhibit the conversion of n-3 DPA to DHA.	n-3 dpa	183-190	interleukin 6	Mus musculus	34-38
28924088-8	2017	Furthermore, expression levels of IL-6 and IL-1beta mRNAs were measured in the presence of the delta-6 desaturase inhibitor SC26196 in the culture medium to inhibit the conversion of n-3 DPA to DHA.	Docosahexaenoic Acids	194-197	interleukin 6	Mus musculus	34-38
28802904-11	2017	Moreover, increased levels of inflammatory cytokines, such as TNF-alpha, IL-1beta, and IL-6, have been identified in damaged colon tissue, which was noticeably reduced by baicalin treatment.	baicalin	171-179	interleukin 6	Mus musculus	87-91
28681199-8	2017	Also, we observed in the hippocampus of ICV palmitate infused mice an elevation in the pro-inflammatory cytokine levels TNFalpha and IL6.	icv palmitate	40-53	interleukin 6	Mus musculus	133-136
27722928-4	2017	In vitro analysis of activated microglia showed that HDAC inhibitor, sodium butyrate (SB), alters H3K9ac enrichment and transcription at the promoters of pro-inflammatory (Tnf-alpha, Nos2, Stat1, Il6) and anti-inflammatory (Il10) genes while inducing the expression of genes downstream of the IL10/STAT3 anti-inflammatory pathway.	Butyric Acid	69-84	interleukin 6	Mus musculus	196-199
27722928-4	2017	In vitro analysis of activated microglia showed that HDAC inhibitor, sodium butyrate (SB), alters H3K9ac enrichment and transcription at the promoters of pro-inflammatory (Tnf-alpha, Nos2, Stat1, Il6) and anti-inflammatory (Il10) genes while inducing the expression of genes downstream of the IL10/STAT3 anti-inflammatory pathway.	Butyric Acid	86-88	interleukin 6	Mus musculus	196-199
28849116-8	2017	The present study demonstrated that scutellarin prevented CIA, and inhibited the expression of inflammation factors, IL-1beta, IL-6 and TNF-alpha.	scutellarin	36-47	interleukin 6	Mus musculus	127-131
28849050-9	2017	In addition, mRNA and protein expression levels of TNF-alpha, IL-1beta, IL-6 and TGF-beta1 were downregulated following naringenin treatment.	naringenin	120-130	interleukin 6	Mus musculus	72-76
28941865-10	2017	RESULTS: The experiment showed that curcumin markedly inhibited SCI-induced production of inflammatory mediators, including TNF-alpha, IL-1beta, IL-6 (ELISA assay) and nitrite oxide (Griess method) in a concentration-dependent manner.	Curcumin	36-44	interleukin 6	Mus musculus	145-149
28712049-6	2017	Interestingly, Meth treatment significantly increased TLR4 expression, activated the NF-kappaB signaling pathway, and promoted TNF-alpha, IL-6 and IL-1beta excretion.	Methamphetamine	15-19	interleukin 6	Mus musculus	138-142
28628850-9	2017	AN1297 and AN1284 (0.075mg/kg) prevented the rise in TNF-alpha and IL-6 in the liver.	AN1297	0-6	interleukin 6	Mus musculus	67-71
28628850-9	2017	AN1297 and AN1284 (0.075mg/kg) prevented the rise in TNF-alpha and IL-6 in the liver.	AN1284	11-17	interleukin 6	Mus musculus	67-71
28623824-8	2017	Mechanistically, nitrate treatment reduced renal superoxide generation, pro-inflammatory cytokines (IL-1beta, IL-6 and IL-12 p70) and macrophage infiltration in the kidney.	Nitrates	17-24	interleukin 6	Mus musculus	110-114
28623824-10	2017	In another cohort of mice, two weeks of nitrate supplementation lowered superoxide generation and IL-6 expression in bone marrow-derived macrophages.	Nitrates	40-47	interleukin 6	Mus musculus	98-102
28946914-7	2017	Comparing with control group, the IL-6 levels were significantly higher in the culture medium of the cultured differentiated 3T3-L1 cells in LPS group and 17beta-E2 + LPS group (all P &lt; 0.05).	lps	141-144	interleukin 6	Mus musculus	34-38
29169413-8	2017	The levels of TNF-alpha, IL-1beta, IL-6, NO and PGE2 were significantly up-regulated in cell culture media after stimulated with LPS, but the levels of those inflammatory mediators were reduced by DAPT.	dapt	197-201	interleukin 6	Mus musculus	35-39
28743499-6	2017	Furthermore, bleomycin upregulated EphA2, EphrinA1, PI3K 110gamma, Akt, IL-6 and TNF-alpha.	Bleomycin	13-22	interleukin 6	Mus musculus	72-76
28743499-8	2017	In addition, ATRA suppressed IL-6 and TNF-alpha production induced by bleomycin-induced injury.	Tretinoin	13-17	interleukin 6	Mus musculus	29-33
28743499-8	2017	In addition, ATRA suppressed IL-6 and TNF-alpha production induced by bleomycin-induced injury.	Bleomycin	70-79	interleukin 6	Mus musculus	29-33
28946914-7	2017	Comparing with control group, the IL-6 levels were significantly higher in the culture medium of the cultured differentiated 3T3-L1 cells in LPS group and 17beta-E2 + LPS group (all P &lt; 0.05).	lps	167-170	interleukin 6	Mus musculus	34-38
28836571-9	2017	CLI-095 or PDTC administration suppressed proinflammatory cytokine (TNF-alpha, IL-6, and IL-1beta) production and macrophage infiltration into the kidney (P &lt; 0.01).	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	0-7	interleukin 6	Mus musculus	79-83
28951356-7	2017	MRP14 protein and its calcium binding motifs such as EF hand-1, EF hand-2, EF hand-1+2, but not CT terminal domain, all induced TNF-alpha, IP-10 and IL-6 expressions (P&lt;0.01).	Calcium	22-29	interleukin 6	Mus musculus	149-153
28951356-9	2017	TNF-alpha, IP-10 and IL-6 levels were inhibited by TAK242 (P&lt;0.05); IL-6 level in the cells was also partially inhibited by RAGE neutralizing antibody (P&lt;0.05).	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	51-57	interleukin 6	Mus musculus	21-25
28836571-9	2017	CLI-095 or PDTC administration suppressed proinflammatory cytokine (TNF-alpha, IL-6, and IL-1beta) production and macrophage infiltration into the kidney (P &lt; 0.01).	pyrrolidine dithiocarbamic acid	11-15	interleukin 6	Mus musculus	79-83
28778453-0	2017	Reduced cuprizone-induced cerebellar demyelination in mice with astrocyte-targeted production of IL-6 is associated with chronically activated, but less responsive microglia.	Cuprizone	8-17	interleukin 6	Mus musculus	97-101
28931916-8	2017	Salidroside significantly decreased the serum TNF-alpha, IL-6, NO, and HMGB1 productions, pulmonary inducible NO synthase (iNOS) and phosphorylated NF-kappaB-p65 protein expressions, and pulmonary HMGB1 nuclear translocation in CLP septic mice.	rhodioloside	0-11	interleukin 6	Mus musculus	57-61
29207662-7	2017	Our results point to a unique mechanism in which TAMs promote tumor cells that lack amplification of an oncogene common to the malignancy by up-regulating transcriptional expression of a distinct oncogene from the same gene family, and underscore the role of IL-6-independent activation of STAT3 in this mechanism.	tams	49-53	interleukin 6	Mus musculus	259-263
28778453-7	2017	CONCLUSIONS: Our results show that chronic transgenic production of IL-6 reduced cuprizone-induced cerebellar demyelination and induced a specific activation state of the resident microglia population (Iba1+, CD11b+, MHCII+, CD68-), likely rendering them less responsive to subsequent injury signals.	Cuprizone	81-90	interleukin 6	Mus musculus	68-72
28966615-5	2017	In mice with LPS, sodium propionate attenuates the LPS-induced histopathological changes, inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) production, myeloperoxidase activity in mammary tissues.	sodium propionate	18-35	interleukin 6	Mus musculus	154-167
28966615-5	2017	In mice with LPS, sodium propionate attenuates the LPS-induced histopathological changes, inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) production, myeloperoxidase activity in mammary tissues.	sodium propionate	18-35	interleukin 6	Mus musculus	169-173
28966615-9	2017	Finally, we examine the possibility that propionate acts as a histone deacetylase (HDAC) inhibitor, the results show that both sodium propionate and trichostatin A increase the level of histone H3 acetylation and inhibit the increased production of TNF-alpha, IL-6, and IL-1beta in LPS-stimulated mMECs.	Propionates	41-51	interleukin 6	Mus musculus	260-264
28966615-9	2017	Finally, we examine the possibility that propionate acts as a histone deacetylase (HDAC) inhibitor, the results show that both sodium propionate and trichostatin A increase the level of histone H3 acetylation and inhibit the increased production of TNF-alpha, IL-6, and IL-1beta in LPS-stimulated mMECs.	sodium propionate	127-144	interleukin 6	Mus musculus	260-264
28966615-9	2017	Finally, we examine the possibility that propionate acts as a histone deacetylase (HDAC) inhibitor, the results show that both sodium propionate and trichostatin A increase the level of histone H3 acetylation and inhibit the increased production of TNF-alpha, IL-6, and IL-1beta in LPS-stimulated mMECs.	trichostatin A	149-163	interleukin 6	Mus musculus	260-264
28955241-12	2017	Moreover, TNBS instillation enhanced local synthesis of inflammatory mediators associated with a neutrophilic response, i.e., CXCL1, CXCL2, and interleukin-6.	Trinitrobenzenesulfonic Acid	10-14	interleukin 6	Mus musculus	144-157
28552343-4	2017	Edaravone and compound edaravone concentration-dependently decreased LPS-induced interleukin-6 (IL-6) production and cyclooxygenase-2 (COX-2) expression in RAW264.7 cells.	Edaravone	0-9	interleukin 6	Mus musculus	81-94
28552343-4	2017	Edaravone and compound edaravone concentration-dependently decreased LPS-induced interleukin-6 (IL-6) production and cyclooxygenase-2 (COX-2) expression in RAW264.7 cells.	Edaravone	0-9	interleukin 6	Mus musculus	96-100
28552343-4	2017	Edaravone and compound edaravone concentration-dependently decreased LPS-induced interleukin-6 (IL-6) production and cyclooxygenase-2 (COX-2) expression in RAW264.7 cells.	Edaravone	23-32	interleukin 6	Mus musculus	81-94
28552343-4	2017	Edaravone and compound edaravone concentration-dependently decreased LPS-induced interleukin-6 (IL-6) production and cyclooxygenase-2 (COX-2) expression in RAW264.7 cells.	Edaravone	23-32	interleukin 6	Mus musculus	96-100
28552343-8	2017	Further study demonstrated that compound edaravone suppressed LPS-induced TNF-alpha and IL-6 increase in mouse serum and bronchoalveolar lavage (BAL) fluid, and inhibited LPS-induced nuclear factor-kappaB (NF-kappaB) activation and COX-2 expression in mice lung tissues.	Edaravone	41-50	interleukin 6	Mus musculus	88-92
29104510-10	2017	Significantly increased fasting blood glucose concentrations and impairment of oral glucose tolerance tests were also observed in mice modelling osteomyelitis, which were accompanied by elevated TNF-alpha and IL-6 levels.	Glucose	38-45	interleukin 6	Mus musculus	209-213
28900117-3	2017	Herein, we found that DXM treatment attenuated arthritis severity and proinflammatory cytokine expression levels, including TNF-alpha, IL-6, and IL-17A, in paw tissues of CIA mice.	Dextromethorphan	22-25	interleukin 6	Mus musculus	135-139
28900117-4	2017	DXM treatment also reduced serum TNF-alpha, IL-6, and IL-17A levels of CIA mice and patients with RA.	Dextromethorphan	0-3	interleukin 6	Mus musculus	44-48
28789997-8	2017	AFB1 also induced secretion of pro-inflammatory cytokines (i.e. TNF-alpha and IL-6) on both microglial cells (more TNF-alpha) and astrocytes (more IL-6).	Aflatoxin B1	0-4	interleukin 6	Mus musculus	78-82
28789997-8	2017	AFB1 also induced secretion of pro-inflammatory cytokines (i.e. TNF-alpha and IL-6) on both microglial cells (more TNF-alpha) and astrocytes (more IL-6).	Aflatoxin B1	0-4	interleukin 6	Mus musculus	147-151
29080614-7	2017	AGNE inhibited the production of IL-6 and TNF-alpha in serum and colon tissue.	agne	0-4	interleukin 6	Mus musculus	33-37
28552908-11	2017	Furthermore, treatment with Xyl-B significantly attenuated ROS overproduction in brain tissues; increased the MnSOD protein levels, suppressed TLR4, NF-kappaB and iNOS protein levels; and downregulated the mRNA levels of proinflammatory cytokines, including IL-1beta, TNF-alpha, IL-6 and IFN-gamma.	xyloketal B	28-33	interleukin 6	Mus musculus	279-283
28622591-7	2017	Administration of rosuvastatin and/or ubiquinone to TRZ-treated mice induced significant increase in tissue GPx, CAT and STAT-3 with significant decrease in serum CK-MB, LDH, troponin I, NT-pro BNP, tissue MDA, TGF-beta1 and IL-6 and improved the histopathological, immunohistochemical, echocardiographic and electron microscopic changes compared to the group that received TRZ alone.	Rosuvastatin Calcium	18-30	interleukin 6	Mus musculus	225-229
28622591-7	2017	Administration of rosuvastatin and/or ubiquinone to TRZ-treated mice induced significant increase in tissue GPx, CAT and STAT-3 with significant decrease in serum CK-MB, LDH, troponin I, NT-pro BNP, tissue MDA, TGF-beta1 and IL-6 and improved the histopathological, immunohistochemical, echocardiographic and electron microscopic changes compared to the group that received TRZ alone.	Ubiquinone	38-48	interleukin 6	Mus musculus	225-229
28840833-10	2017	RA treatments lowered the hepatic level of IL-6, TNF-alpha, and PGE2, as well as the activity of COX-2 (p &lt; 0.05).	rosmarinic acid	0-2	interleukin 6	Mus musculus	43-47
28616865-8	2017	KEY RESULTS: Isoacteoside suppressed COX-2, iNOS, TNF-alpha, IL-6 and IL-1beta expression.	isoacteoside	13-25	interleukin 6	Mus musculus	61-65
28700976-6	2017	After coptisine treatment, the serum level of TC, TG and LDL-C decreased; the serum level of IL-6, IL-1beta and TNF-alpha were decreased; the mRNA levels of NF-kappaBp65, VCAM-1, ICAM-1, IL-6 and IL-1beta in both aorta and liver were down-regulated; the p-p38 and p-JNK1/2 protein expression level were decreased.	coptisine	6-15	interleukin 6	Mus musculus	93-97
28700976-6	2017	After coptisine treatment, the serum level of TC, TG and LDL-C decreased; the serum level of IL-6, IL-1beta and TNF-alpha were decreased; the mRNA levels of NF-kappaBp65, VCAM-1, ICAM-1, IL-6 and IL-1beta in both aorta and liver were down-regulated; the p-p38 and p-JNK1/2 protein expression level were decreased.	coptisine	6-15	interleukin 6	Mus musculus	187-191
28901888-5	2017	Supplementation with GMNL-32, GMNL-89 and GMNL-263 significantly increased antioxidant activity, reduced IL-6 and TNF-alpha levels and significantly decreased the toll-like receptors/myeloid differentiation primary response gene 88 signalling in NZB/W F1 mice.	gmnl	21-25	interleukin 6	Mus musculus	105-109
28901888-5	2017	Supplementation with GMNL-32, GMNL-89 and GMNL-263 significantly increased antioxidant activity, reduced IL-6 and TNF-alpha levels and significantly decreased the toll-like receptors/myeloid differentiation primary response gene 88 signalling in NZB/W F1 mice.	gmnl	30-34	interleukin 6	Mus musculus	105-109
28901888-5	2017	Supplementation with GMNL-32, GMNL-89 and GMNL-263 significantly increased antioxidant activity, reduced IL-6 and TNF-alpha levels and significantly decreased the toll-like receptors/myeloid differentiation primary response gene 88 signalling in NZB/W F1 mice.	gmnl	30-34	interleukin 6	Mus musculus	105-109
28608285-8	2017	Lixisenatide-treated mice also displayed diminished IL-6 levels, proinflammatory Ly6Chigh monocytes and activated T cells.	lixisenatide	0-12	interleukin 6	Mus musculus	52-56
28229819-9	2017	Moreover, early dabigatran treatment induced a profibrotic and inflammatory skin gene expression signature with upregulated expression of Col5a1, Timp1, Tweakr, Vwf, Il6, Il33, Il4 and Ifng.	Dabigatran	16-26	interleukin 6	Mus musculus	166-169
28608285-9	2017	In vitro analysis showed that, in macrophages from Apoe -/- Irs2 +/- mice, lixisenatide reduced the secretion of the proinflammatory cytokine IL-6 accompanied by enhanced activation of signal transducer and activator of transcription (STAT) 3, which is a determinant for M2 macrophage differentiation.	lixisenatide	75-87	interleukin 6	Mus musculus	142-146
28962151-10	2017	It was found that hesperetin reduced the expression levels of TNF-alpha, IL-1beta, IL-6 and CTGF as well as collagen I and III.	hesperetin	18-28	interleukin 6	Mus musculus	83-87
28962154-0	2017	Interleukin 6 inhibition by triptolide prevents inflammation in a mouse model of ulcerative colitis.	triptolide	28-38	interleukin 6	Mus musculus	0-13
28962154-1	2017	The present study aimed to assess interleukin (IL)-6 expression in a murine model of ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) and its potential association with the anti-colitis effects of triptolide (TL).	Dextran Sulfate	120-142	interleukin 6	Mus musculus	34-52
28962154-1	2017	The present study aimed to assess interleukin (IL)-6 expression in a murine model of ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) and its potential association with the anti-colitis effects of triptolide (TL).	Dextran Sulfate	144-147	interleukin 6	Mus musculus	34-52
28962154-1	2017	The present study aimed to assess interleukin (IL)-6 expression in a murine model of ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) and its potential association with the anti-colitis effects of triptolide (TL).	triptolide	212-222	interleukin 6	Mus musculus	34-52
28962154-1	2017	The present study aimed to assess interleukin (IL)-6 expression in a murine model of ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) and its potential association with the anti-colitis effects of triptolide (TL).	triptolide	224-226	interleukin 6	Mus musculus	34-52
28962154-4	2017	The expression of IL-6 was weak in mucosa specimens from normal control animals and upregulated in DSS-induced mice.	Dextran Sulfate	99-102	interleukin 6	Mus musculus	18-22
28644965-4	2017	In addition, DBL markedly reduced the total cell number, the leukocytes, the protein concentrations, and decreased the release of nitrite, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and the activities of matrix metalloproteinase (MMP)-2 and -9 in the bronchoalveolar lavage fluid.	disialyllactose	13-16	interleukin 6	Mus musculus	198-202
28646664-6	2017	In this study, we found that wogonin significantly attenuated inflammatory response in EtOH-fed mice, and reduced the expression of inflammatory cytokines such as TNF-alpha and IL-6 in EtOH-induced RAW264.7 cells.	Ethanol	185-189	interleukin 6	Mus musculus	177-181
28646664-9	2017	Moreover, forced expression of PPAR-gamma further suppressed the expression of TNF-alpha and IL-6 when treated with wogonin on EtOH-induced RAW264.7 cells.	Ethanol	127-131	interleukin 6	Mus musculus	93-97
28962154-5	2017	In model mice treated with TL (0.4 and 0.6 mg/kg), dexamethasone or mesalazine, IL-6 expression was significantly reduced compared with that in model mice treated with normal saline or propylene glycol (P&lt;0.05), while TL at 0.2 mg/kg did not elicit any significant inhibitory effect.	triptolide	27-29	interleukin 6	Mus musculus	80-84
28962154-5	2017	In model mice treated with TL (0.4 and 0.6 mg/kg), dexamethasone or mesalazine, IL-6 expression was significantly reduced compared with that in model mice treated with normal saline or propylene glycol (P&lt;0.05), while TL at 0.2 mg/kg did not elicit any significant inhibitory effect.	Dexamethasone	51-64	interleukin 6	Mus musculus	80-84
28962154-5	2017	In model mice treated with TL (0.4 and 0.6 mg/kg), dexamethasone or mesalazine, IL-6 expression was significantly reduced compared with that in model mice treated with normal saline or propylene glycol (P&lt;0.05), while TL at 0.2 mg/kg did not elicit any significant inhibitory effect.	Mesalamine	68-78	interleukin 6	Mus musculus	80-84
28962154-5	2017	In model mice treated with TL (0.4 and 0.6 mg/kg), dexamethasone or mesalazine, IL-6 expression was significantly reduced compared with that in model mice treated with normal saline or propylene glycol (P&lt;0.05), while TL at 0.2 mg/kg did not elicit any significant inhibitory effect.	Propylene Glycol	185-201	interleukin 6	Mus musculus	80-84
28962154-5	2017	In model mice treated with TL (0.4 and 0.6 mg/kg), dexamethasone or mesalazine, IL-6 expression was significantly reduced compared with that in model mice treated with normal saline or propylene glycol (P&lt;0.05), while TL at 0.2 mg/kg did not elicit any significant inhibitory effect.	triptolide	221-223	interleukin 6	Mus musculus	80-84
28059488-5	2017	In addition, JNK and P38 inhibitors could significantly attenuate palmitate-induced mRNA expression of TNF-alpha and IL-6, respectively, whereas NF-kappaB inhibitor reduced the expression of both cytokines in palmitate-treated cells.	Palmitates	66-75	interleukin 6	Mus musculus	117-121
31966802-7	2017	However, celastrol pre-treatment compromised the increased MPO, MDA, TNF-alpha, IL-1beta, IL-6 (all P&lt;0.01) and significantly increased SOD (P=0.035&lt;0.05) and IL-10 (P&lt;0.01).	celastrol	9-18	interleukin 6	Mus musculus	90-94
28059488-9	2017	N-acetyl cysteine (NAC), a known scavenger of ROS, could protect palmitate-induced expression of TNF-alpha and IL-6.	Acetylcysteine	0-17	interleukin 6	Mus musculus	111-115
28059488-6	2017	Resveratrol pretreatment significantly prevented palmitate-induced TNF-alpha and IL-6 mRNA expression and protein secretion in C2C12 cells.	Resveratrol	0-11	interleukin 6	Mus musculus	81-85
28059488-9	2017	N-acetyl cysteine (NAC), a known scavenger of ROS, could protect palmitate-induced expression of TNF-alpha and IL-6.	Acetylcysteine	19-22	interleukin 6	Mus musculus	111-115
28059488-6	2017	Resveratrol pretreatment significantly prevented palmitate-induced TNF-alpha and IL-6 mRNA expression and protein secretion in C2C12 cells.	Palmitates	49-58	interleukin 6	Mus musculus	81-85
28059488-9	2017	N-acetyl cysteine (NAC), a known scavenger of ROS, could protect palmitate-induced expression of TNF-alpha and IL-6.	Reactive Oxygen Species	46-49	interleukin 6	Mus musculus	111-115
28747347-4	2017	TRIM8 deficiency leads to increased polyinosinic-polycytidylic acid- and LPS-triggered induction of downstream anti-microbial genes including TNF, Il6, Rantes, and Ifnb, evaluated serum cytokine levels, and increased susceptibility of mice to polyinosinic-polycytidylic acid- and LPS-induced inflammatory death as well as Salmonella typhimurium infection-induced loss of body weight and septic shock.	Poly I-C	36-67	interleukin 6	Mus musculus	147-150
28059488-9	2017	N-acetyl cysteine (NAC), a known scavenger of ROS, could protect palmitate-induced expression of TNF-alpha and IL-6.	Palmitates	65-74	interleukin 6	Mus musculus	111-115
28720320-9	2017	NaHS treatment significantly improved wound healing in ob/ob mice, which was associated with reduced neutrophil and macrophage infiltration, decreased production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6.	sodium bisulfide	0-4	interleukin 6	Mus musculus	200-218
28271317-1	2017	Indoline carbamates, AN680 and AN917 decrease cytokines, TNF-alpha and IL-6 in peritoneal macrophages activated by lipopolysaccharide (LPS) and in mouse tissues after LPS injection.	indoline carbamates	0-19	interleukin 6	Mus musculus	71-75
28271317-8	2017	AN680 (5 mg/kg) reduced DAI, colon shrinkage, weight loss, histopathological signs of colon damage, MPO activity, TNF-alpha, IL-1beta and IL-6 levels without inhibiting ChE.	an680	0-5	interleukin 6	Mus musculus	138-142
28271317-9	2017	AN917 (5 mg/kg) and rivastigmine (1 mg/kg) inhibited ChE in plasma and colon by 65%, reduced DAI, MPO activity and IL-6, but not TNF-alpha or IL-1beta.	an917	0-5	interleukin 6	Mus musculus	115-119
28271317-9	2017	AN917 (5 mg/kg) and rivastigmine (1 mg/kg) inhibited ChE in plasma and colon by 65%, reduced DAI, MPO activity and IL-6, but not TNF-alpha or IL-1beta.	Rivastigmine	20-32	interleukin 6	Mus musculus	115-119
28271317-11	2017	Mecamylamine abolished the reduction of DAI, MPO activity and IL-6 by AN917 and rivastigmine, indicating they were mediated by alpha7nAChR.	Mecamylamine	0-12	interleukin 6	Mus musculus	62-66
28271317-11	2017	Mecamylamine abolished the reduction of DAI, MPO activity and IL-6 by AN917 and rivastigmine, indicating they were mediated by alpha7nAChR.	Rivastigmine	80-92	interleukin 6	Mus musculus	62-66
28457022-4	2017	Subsequently, quercetin treatment inhibited the phenotypic and functional maturation of DCs, as evidenced not only by downregulation of CD80, CD86, MHC-II, IL-6 and IL-12 but also by a reduction in the ability to stimulate T cell allogeneic proliferation.	Quercetin	14-23	interleukin 6	Mus musculus	156-160
28684599-9	2017	We found a significant decrease in IL-6 and TGF-beta after ethanol and burn; IL-23 was undetectable.	Ethanol	59-66	interleukin 6	Mus musculus	35-39
28677768-5	2017	In vitro studies demonstrated that SQ29548 inhibited LPS-stimulated BV2 activation and reduced the mRNA expression levels of interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha and inducible NO synthase via inhibition of MAPKs and the NF-kappaB signaling pathway.	SQ 29548	35-42	interleukin 6	Mus musculus	149-153
28666844-6	2017	EsA also inhibited LPS-induced TNF-alpha, IL-1beta, and IL-6 production.	esculentoside A	0-3	interleukin 6	Mus musculus	56-60
28677809-8	2017	Treatment with the AR inhibitor attenuated the level of lipid accumulation and oxidative stress, activated AMPK, and suppressed the mRNA expression of TNF-alpha, interleukin-6 and transforming growth factor-beta1 in ethanol-treated AML12 cells.	Ethanol	216-223	interleukin 6	Mus musculus	162-212
28230708-7	2017	CDNP-treated mice demonstrated decreased peritoneal interleukin 6 levels and an approximately 2-log lower bacterial load compared with control mice 24 h after CLP.	cenderitide	0-4	interleukin 6	Mus musculus	52-65
28779377-4	2017	The optimal inhibitory combinations of EPA (0.125 muM) with the phytonutrients caused a synergistic inhibition of prostaglandin E2 (PGE2) release, IL-6 secretion, superoxide and NO production and prevention of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) upregulation and elevated CD40 expression in microglia exposed to LPS or interferon-gamma (IFN-gamma), representing infection or inflammation, respectively.	Eicosapentaenoic Acid	39-42	interleukin 6	Mus musculus	147-151
28481031-0	2017	Interleukin 6 trans-signaling regulates basal synaptic transmission and sensitivity to pentylenetetrazole-induced seizures in mice.	Pentylenetetrazole	87-105	interleukin 6	Mus musculus	0-13
28854223-11	2017	Finally, treatment with TMSC[x4] significantly reversed the mRNA levels of IL-1beta and IL-6, although expression of all pro-inflammatory cytokines tested was induced in colitis mice.	tmsc	24-28	interleukin 6	Mus musculus	88-92
28955792-0	2017	STAT3 and NF-kappaB are common targets for kaempferol-mediated attenuation of COX-2 expression in IL-6-induced macrophages and carrageenan-induced mouse paw edema.	kaempferol	43-53	interleukin 6	Mus musculus	98-102
28852144-6	2017	ELISA analyses showed that inhalation of hydrogen-oxygen mixed gas blocked CMS-induced increase in the serum levels of corticosterone, adrenocorticotropic hormone, interleukin-6, and tumor necrosis factor-alpha in mice exposed to chronic mild stress.	Hydrogen	41-49	interleukin 6	Mus musculus	164-210
28852144-6	2017	ELISA analyses showed that inhalation of hydrogen-oxygen mixed gas blocked CMS-induced increase in the serum levels of corticosterone, adrenocorticotropic hormone, interleukin-6, and tumor necrosis factor-alpha in mice exposed to chronic mild stress.	Oxygen	50-56	interleukin 6	Mus musculus	164-210
28872080-13	2017	Compared with the CLP group, the 7 d survival rate, lung SOD activity and the expressions of LC3B and Beclin-1 were increased significantly in the allicin treatment group (P&lt;0.05); the lung morphological damage scores, the levels of TNF-alpha and IL-6 in the BALF and MDA content in the lung were decreased obviously in the allicin treatment group (P&lt;0.05).	allicin	147-154	interleukin 6	Mus musculus	250-254
28872080-14	2017	Compared with the allicin treatment group, the 7 d survival rate, lung SOD activity, and the expressions of LC3B and Beclin-1 were decreased in the 3-MA group (P&lt;0.05); the lung morphological damage scores, the levels of TNF-alpha and IL-6 in the BALF, and MDA content in the lung were increased significantly in the 3-MA group (P&lt;0.05).	allicin	18-25	interleukin 6	Mus musculus	238-242
28955792-3	2017	Kaempferol deactivated and prevented nuclear localization of two major transcription factors STAT3 and NF-kappaB, mutually responsible for COX-2 induction in response to IL-6.	kaempferol	0-10	interleukin 6	Mus musculus	170-174
28872080-14	2017	Compared with the allicin treatment group, the 7 d survival rate, lung SOD activity, and the expressions of LC3B and Beclin-1 were decreased in the 3-MA group (P&lt;0.05); the lung morphological damage scores, the levels of TNF-alpha and IL-6 in the BALF, and MDA content in the lung were increased significantly in the 3-MA group (P&lt;0.05).	3-methyladenine	148-152	interleukin 6	Mus musculus	238-242
28693884-7	2017	Rutin also induced a decrease in the mRNA levels of TNF, IL1beta, IL6 and iNOS, reduced the production of IL6, TNF, and nitric oxide, and increased production of the M2 regulatory cytokine IL10 and arginase.	Rutin	0-5	interleukin 6	Mus musculus	66-69
28647362-6	2017	Interesting, GW4064 suppresses NACHT, LRR and PYD domains-containing protein 3 (NALP3) inflammasome mediates tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and IL-1beta, as well as mitochondrial respiratory complexes mRNA expression in WT and FXR KO mice treated with LPS.	GW 4064	13-19	interleukin 6	Mus musculus	150-168
28647370-5	2017	OLA prevented the high glucose induced cell injury and decreased the level of MMP-13, PGE2 and IL-6 due to decreasing mitochondrial membrane potential and stimulated the ATP production.	Oleanolic Acid	0-3	interleukin 6	Mus musculus	95-99
28693884-7	2017	Rutin also induced a decrease in the mRNA levels of TNF, IL1beta, IL6 and iNOS, reduced the production of IL6, TNF, and nitric oxide, and increased production of the M2 regulatory cytokine IL10 and arginase.	Rutin	0-5	interleukin 6	Mus musculus	106-109
28838312-13	2017	RESULTS: In vivo, a single injection of AceDoPC or PC-DHA decreased LPS-induced IL-6 production in the hippocampus of mice.	1-acetyl-2-docosahexaenoyl-glycerophosphocholine	40-47	interleukin 6	Mus musculus	80-84
28890700-12	2017	Finally, the low- and high-capsaicin diets significantly increased the fecal butyrate and plasma total GLP-1 levels, but decreased plasma total ghrelin, TNF-alpha, IL-1beta, and IL-6 levels as compared with the normal diet.	Capsaicin	27-36	interleukin 6	Mus musculus	178-182
28838312-13	2017	RESULTS: In vivo, a single injection of AceDoPC or PC-DHA decreased LPS-induced IL-6 production in the hippocampus of mice.	pc-dha	51-57	interleukin 6	Mus musculus	80-84
28838312-15	2017	In addition, AceDoPC or PC-DHA reduced IL-6 receptor while only AceDoPC decreased IL-6-induced STAT3 phosphorylation.	pc-dha	24-30	interleukin 6	Mus musculus	39-43
28601639-6	2017	Our results showed that Tofacitinib did not change plasma lipids, while significantly reduced the levels of plasma pro-inflammatory cytokines IL-6 and TNF-alpha.	tofacitinib	24-35	interleukin 6	Mus musculus	142-146
28839206-6	2017	In in vitro experiments, GSP dose-dependently inhibited mRNA expression of interleukin (IL)-1beta, IL-6 and monocyte chemoattractant protein-1 (MCP-1), and significantly inhibited expression and activity of MMP-2 and MMP-9, thus prevented elastin from degradation.	gamma-Thio-GTP	25-28	interleukin 6	Mus musculus	99-103
28835272-13	2017	Invasions of T cells, neutrophils and natural killer (NK) cells were attenuated profoundly after atorvastatin therapy, as was the production of pro-inflammatory cytokines (IFN-gamma and IL-6) and chemokines (RANTES and IP-10).	Atorvastatin	97-109	interleukin 6	Mus musculus	186-190
28525841-5	2017	Similar to LL-37, KR-12-a5 and its analogs significantly inhibited the expression and secretion of NO, TNF-alpha, IL-6 and MCP-1 from LPS-stimulated RAW264.7 cells.	Krypton	18-20	interleukin 6	Mus musculus	114-118
28478040-9	2017	Importantly, DOCA/salt-induced cardiac fibrosis, inflammation and the expression of collagen I, collagen III, alpha-SMA, IL-1beta, IL-6 and TNF-alpha in the wild-type hearts, which were markedly attenuated by beta2i knockout.	Desoxycorticosterone Acetate	13-17	interleukin 6	Mus musculus	131-135
28478040-9	2017	Importantly, DOCA/salt-induced cardiac fibrosis, inflammation and the expression of collagen I, collagen III, alpha-SMA, IL-1beta, IL-6 and TNF-alpha in the wild-type hearts, which were markedly attenuated by beta2i knockout.	Salts	18-22	interleukin 6	Mus musculus	131-135
28817116-4	2017	TTN suppressed the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) and the secretion of TNF-alpha, IL-6, and IL-1beta in RAW264.7 cells, bone marrow-derived macrophages, and THP-1 cells.	Tartronic acid	0-3	interleukin 6	Mus musculus	133-137
28848542-5	2017	We found that the anesthesia/surgery increased mouse BBB permeability to 10-kDa dextran, but not to 70-kDa dextran, in an IL-6-dependent and age-associated manner.	10-kda dextran	73-87	interleukin 6	Mus musculus	122-126
29050341-4	2017	In vivo, GOH treatment markedly ameliorated pathological injury and pulmonary cell apoptosis and reduced the wet/dry (W/D) weight ratio of lungs, myeloperoxidase (MPO) activity and the production of pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha).	5-[2-Cyclopropyl-5-(1h-Pyrrol-1-Yl)-1,3-Oxazol-4-Yl]-1h-1,2,3,4-Tetrazole	9-12	interleukin 6	Mus musculus	237-241
28800777-14	2017	Following two injections of Bz, serum IL-6 and TNF-alpha levels were significantly more elevated in 14-week-old than in 10-week-old mice.	Bortezomib	28-30	interleukin 6	Mus musculus	38-42
28571904-5	2017	Notably, evodiamine and rutaecarpine administered using ME-Gel effectively down-regulated serum levels of prostaglandin E2, interleukin 6, and tumor necrosis factor alpha in formaldehyde-induced mouse pain models, possibly reflecting the improved transdermal permeability of ME-Gel co-delivered evodiamine and rutaecarpine, particularly with hyaluronic acid as the hydrogel matrix.	evodiamine	9-19	interleukin 6	Mus musculus	124-137
28571904-5	2017	Notably, evodiamine and rutaecarpine administered using ME-Gel effectively down-regulated serum levels of prostaglandin E2, interleukin 6, and tumor necrosis factor alpha in formaldehyde-induced mouse pain models, possibly reflecting the improved transdermal permeability of ME-Gel co-delivered evodiamine and rutaecarpine, particularly with hyaluronic acid as the hydrogel matrix.	rutecarpine	24-36	interleukin 6	Mus musculus	124-137
28782757-6	2017	Additionally, in vitro analyses revealed that osthole-treated bone-marrow-derived DCs had a partial maturation phenotype, secreting large amounts of IL-10 and low levels of proinflammatory cytokines, such as IL-12, IL-6 and tumor necrosis factor-alpha, and displaying reduced levels of MHC class II surface molecules.	osthol	46-53	interleukin 6	Mus musculus	215-251
28848542-5	2017	We found that the anesthesia/surgery increased mouse BBB permeability to 10-kDa dextran, but not to 70-kDa dextran, in an IL-6-dependent and age-associated manner.	Dextrans	80-87	interleukin 6	Mus musculus	122-126
28777298-5	2017	Short-term luseogliflozin treatment normalized the expression of inflammation-related genes such as F4/80, TNFalpha, IL-1beta, IL-6, ICAM-1, PECAM-1, MMP2 and MMP9 in the NA/STZ-treated ApoE KO mice, which showed marked elevations as compared with untreated ApoE KO mice.	1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol	11-25	interleukin 6	Mus musculus	127-131
28771545-11	2017	Finally, administration of anti-IL-6 antibody abolished an increase in tyrosine phosphorylation of STAT3, a major signaling molecule downstream of IL-6, in the transgenic mouse heart and prevented development of cardiac hypertrophy in transgenic mice.	Tyrosine	71-79	interleukin 6	Mus musculus	32-36
28774345-7	2017	When injected into the partially hepatectomized mice, the 1% pO2 secretome most significantly increased the number of Ki67-positive cells, reduced serum levels of proinflammatory mediators (IL-6 and TNF-alpha), and reduced serum levels of liver transaminases.	PO-2	61-64	interleukin 6	Mus musculus	190-194
28774345-8	2017	In addition, analysis of the liver specimens indicated that injection with the 1% pO2 secretome maximized the expression of the intermediate molecules of the PIP3/Akt and IL-6/STAT3 signaling pathways, all of which are known to promote liver regeneration.	PO-2	82-85	interleukin 6	Mus musculus	171-175
28824430-5	2017	In addition, PPD and PPT dramatically ameliorated the inflammatory responses by suppressing the secretion of pro-inflammatory cytokines like tumor necrosis factor-alpha and interleukin-6 in serum level and gene expression in liver level, and improved the antioxidant capacity by increasing the superoxide dismutase and decreasing malondialdehyde levels in the serum of T2DM mice.	protopanaxatriol	21-24	interleukin 6	Mus musculus	173-186
28771545-11	2017	Finally, administration of anti-IL-6 antibody abolished an increase in tyrosine phosphorylation of STAT3, a major signaling molecule downstream of IL-6, in the transgenic mouse heart and prevented development of cardiac hypertrophy in transgenic mice.	Tyrosine	71-79	interleukin 6	Mus musculus	147-151
28603288-8	2017	Moreover, in LPS-stimulated mouse peritoneal macrophages, SB203580 strongly inhibited the restored expression of IL-1beta, IL-6, COX2, and MCP-1, which was achieved by abolishing the suppressive effects of osthole with the PKA inhibitors.	SB 203580	58-66	interleukin 6	Mus musculus	123-127
28603288-6	2017	In mouse peritoneal macrophages, pretreatment with osthole (50 mumol/L) significantly attenuated the LPS-induced elevation of cytokines at the mRNA level; inhibition of PKA completely reversed the inhibitory effects of osthole on IL-1beta, IL-6, COX2, and MCP-1 but not on TNFalpha.	osthol	51-58	interleukin 6	Mus musculus	240-244
28669409-7	2017	In addition, GSI also significantly down-regulated mRNA levels of cytokines IL-4, IL-6 and IL-13 induced by A23187, and this effect was dependent on MAPK pathway.	Calcimycin	108-114	interleukin 6	Mus musculus	82-86
28438557-5	2017	ABI-4 (0.32mg/kg) blocked LPS-induced release of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) in blood and brain of mice.	abi-4	0-5	interleukin 6	Mus musculus	98-102
28267649-13	2017	EAU activity correlates with ocular IL-6 and IL-17 levels.	Water	0-3	interleukin 6	Mus musculus	36-40
28829493-10	2017	RESULTS: LPS model group had lower RBC, Hb, HCT, MCV and iron content in Hb, plus elevated hepcidin, IL-6, TNF-alpha, TfR2 and STAT3 expression (p &lt; 0.05 compared to the control group).	lps	9-12	interleukin 6	Mus musculus	101-105
28458167-7	2017	Administration of AS605240 to LPS-treated mice reduced some patho-physiological characteristics of SIMD and reduced TNF-alpha, IL-6, cTnI and H-FABP production.	5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione	18-26	interleukin 6	Mus musculus	127-131
28416580-7	2017	In collagenase-induced ICH mice, the protection of etifoxine was associated with reduced leukocyte infiltration into the brain and microglial production of IL-6 and TNF-alpha.	etifoxine	51-60	interleukin 6	Mus musculus	156-160
28810657-3	2017	Treatment with sodium ferulate combined with oxymatrine was shown to significantly inhibit acetic acid-induced vascular permeability in the peritonitis model mice and furthermore to significantly decrease the optical density of Evans blue, the leukocyte number and the levels of interleukin-6, C-reactive protein and interferon-gamma in peritoneal lavage fluid.	ferulic acid	15-30	interleukin 6	Mus musculus	279-292
28810657-3	2017	Treatment with sodium ferulate combined with oxymatrine was shown to significantly inhibit acetic acid-induced vascular permeability in the peritonitis model mice and furthermore to significantly decrease the optical density of Evans blue, the leukocyte number and the levels of interleukin-6, C-reactive protein and interferon-gamma in peritoneal lavage fluid.	oxymatrine	45-55	interleukin 6	Mus musculus	279-292
28555509-4	2017	In this study, we demonstrated for the first time that propofol inhibited both interleukin (IL)-6 plus transforming growth factor-beta (TGF-beta)-induced Th17 cell differentiation in vitro and in LPS-challenged mice.	Propofol	55-63	interleukin 6	Mus musculus	79-97
28595959-6	2017	Furthermore, the plasma levels of interleukin-6 and tumor necrosis factor-alpha were suppressed by CTXA post-treatment.	cudratricusxanthone A	99-103	interleukin 6	Mus musculus	34-79
28228641-7	2017	In vivo, 4 days after systemic administration of beta-glucan, mice were more responsive to LPS challenge as shown by the increased serum levels of TNFalpha, IL-6 and IL-10, an effect shown to be short lived as enhanced cytokine production was lost by day 20.	beta-Glucans	49-60	interleukin 6	Mus musculus	157-161
28555509-5	2017	Propofol also suppressed the IL-6-induced phosphorylation of Janus kinase-2 (JAK2)/signal transducer and activator of transcription (STAT3) pathway, a cytokine-activated essential transcription factor in Th17 cell development, which occurred concomitantly with the enhancement of suppressor of cytokine signaling-3 (SOCS3) expression involved in the downregulation of STAT3 phosphorylation.	Propofol	0-8	interleukin 6	Mus musculus	29-33
28555511-5	2017	We found that dexmedetomidine dose-dependently inhibited the production of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 in the pouch and decreased the number of white blood cells (WBC) recruited into the pouch.	Dexmedetomidine	14-29	interleukin 6	Mus musculus	113-131
28363651-6	2017	Alcalase assistant alginate stimulated RAW264.7 cells to release nitric oxide and inflammatory cytokines TNF-alpha, IL-1, IL-6, IL-10 and IL-12.	Alginates	19-27	interleukin 6	Mus musculus	122-126
28558302-5	2017	After administration of EGCG, the number of sneezes and the occurrence of nasal rubbing were significantly decreased, the concentrations of immunoglobulin E (IgE) and histamine were suppressed in AR mouse serum, the levels of interleukin (IL)-1beta, IL-4, and IL-6 were reduced in AR mice nasal lavage fluid (NLF), and the nasal mucosa mRNA and protein expression of cyclooxygenase 2 (COX-2), IL-1beta, IL-4, and IL-6 were inhibited.	epigallocatechin gallate	24-28	interleukin 6	Mus musculus	260-264
28493080-10	2017	Honokiol significantly inhibited leukocyte infiltration and upregulation of proinflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6) and inducible nitric oxide synthase in the ileal muscle layer of postoperative ileus model mice.	honokiol	0-8	interleukin 6	Mus musculus	155-168
28550734-12	2017	Pte reduced the serum inflammatory cytokine (TNF-alpha and IL-6) levels and hepatic mRNA levels of TNF-alpha and IL-6.	pterostilbene	0-3	interleukin 6	Mus musculus	59-63
28550734-12	2017	Pte reduced the serum inflammatory cytokine (TNF-alpha and IL-6) levels and hepatic mRNA levels of TNF-alpha and IL-6.	pterostilbene	0-3	interleukin 6	Mus musculus	113-117
28595081-0	2017	Pioglitazone attenuates lipopolysaccharide-induced depression-like behaviors, modulates NF-kappaB/IL-6/STAT3, CREB/BDNF pathways and central serotonergic neurotransmission in mice.	Pioglitazone	0-12	interleukin 6	Mus musculus	98-102
28595081-7	2017	Moreover, Western blot analysis revealed the effects of PIO on inhibiting activation of the nuclear factor kappa B/interleukin 6/signal transducer and activator of transcription 3 (NF-kappaB/IL-6/STAT3) pathway, improving down-regulation of the cAMP response-element-binding protein/brain derived neurotrophic factor (CREB/BDNF) pathway, as well as regulating disturbed expression of proteins involved in central serotonergic neurotransmission following LPS administration.	Cyclic AMP	245-249	interleukin 6	Mus musculus	191-195
27791278-11	2017	Gene expressions studies revealed the drastic upregulation of GLUT4 gene and significant reduction in IL6 and PAI1 gene in both 3T3L1 and C2C12 cells, indicating possible mechanism of glucose uptake with concomitant decrease in inflammation.	Glucose	184-191	interleukin 6	Mus musculus	102-105
28558302-5	2017	After administration of EGCG, the number of sneezes and the occurrence of nasal rubbing were significantly decreased, the concentrations of immunoglobulin E (IgE) and histamine were suppressed in AR mouse serum, the levels of interleukin (IL)-1beta, IL-4, and IL-6 were reduced in AR mice nasal lavage fluid (NLF), and the nasal mucosa mRNA and protein expression of cyclooxygenase 2 (COX-2), IL-1beta, IL-4, and IL-6 were inhibited.	epigallocatechin gallate	24-28	interleukin 6	Mus musculus	413-417
28422377-4	2017	Interestingly, the increased ROS and inflammatory factor IL-6 levels were reversed after GDQ intervention.	gardiquimod	89-92	interleukin 6	Mus musculus	57-61
28500787-9	2017	CPO and DFP alone caused cortical and hippocampal neuroinflammation assessed by qPCR of tumor necrosis factor-alpha, IL-6, C-C chemokine ligand 2, IL-1beta, leukemia inhibitory factor and oncostatin M; CORT pretreatment markedly augmented these effects.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	0-3	interleukin 6	Mus musculus	117-121
28422377-7	2017	Our current result highlight that pre-administration of GDQ ameliorated sepsis induced hepatotoxicity and reduced the generation of IL-6 and OS responses, which was associated with downregulation of JNK/c-Jun pathway.	gardiquimod	56-59	interleukin 6	Mus musculus	132-136
28844021-6	2017	Cells transfected with TRIF, TRAF6, RIP1 or TAK1 all decreased production of poly(I:C)-induced IL-1alpha, IL-1beta, IL-6, GRO-alpha, IL-8, MCP-1, ICAM-1 and MMP-9 expression.	Poly I-C	77-86	interleukin 6	Mus musculus	116-120
28396117-5	2017	The levels of IL-6 and CCL2 were reduced in the oATP group.	2',3'-dialdehyde ATP	48-52	interleukin 6	Mus musculus	14-18
28303409-3	2017	We report herein that db/db mice concomitantly fed the Western diet and treated with the anti-inflammatory agent methotrexate display a less aggressive inflammatory (lower serum IL-1beta, IL-6, SDF-1, and TNFalpha levels; higher circulating adiponectin, IL-12p70 and IL-10 concentrations; lower aortic VCAM-1 levels) profile than their saline-treated counterpart.	Methotrexate	113-125	interleukin 6	Mus musculus	188-192
29067466-9	2017	Furthermore, miR-128 mimic or p38 inhibitor decreased the mRNA expression and secretion of interleukin (IL)-6 and IL-10 cytokines and increased the level of IL-12 in DCs, whereas an miR-128 inhibitor exhibited the opposite effects.	mir-128	13-20	interleukin 6	Mus musculus	91-109
28404518-4	2017	Immunohistochemistry showed similar massive IBA1 positive macrophage infiltration surrounding implanted disk material among groups, but IL-1beta and IL-6 expression was decreased in the fullerol treated group.	fullerol	186-194	interleukin 6	Mus musculus	149-153
28587938-7	2017	RESULTS: Treatment of J774.1 cells with etidronate down-regulated TLR2 ligand-induced production of IL-6, TNF-alpha, MCP-1, and MIP-1alpha.	Etidronic Acid	40-50	interleukin 6	Mus musculus	100-104
28539257-8	2017	In addition, beta-blocker propranolol prevented the NF-kB nuclear translocation and the increase in phospho-IkappaB-alpha (Ser32) and in interleukin(IL)-6 expression in aorta of obese mice, without significant changes in either aortic reactive oxygen species production or in circulating IL-6 and TNF-alpha levels.	Propranolol	26-37	interleukin 6	Mus musculus	137-154
28539257-8	2017	In addition, beta-blocker propranolol prevented the NF-kB nuclear translocation and the increase in phospho-IkappaB-alpha (Ser32) and in interleukin(IL)-6 expression in aorta of obese mice, without significant changes in either aortic reactive oxygen species production or in circulating IL-6 and TNF-alpha levels.	Propranolol	26-37	interleukin 6	Mus musculus	288-292
28431044-8	2017	Results: Leonurine treatment significantly decreased the production of pro-inflammatory cytokines (IL-1beta, IL-6, IL-8 and TNFalpha) and MMPs (MMP-1 and MMP-3) and suppressed the migration and invasion of RA fibroblast-like synoviocytes.	leonurine	9-18	interleukin 6	Mus musculus	109-113
29050290-0	2017	GMI ablates cancer stemness and cisplatin resistance in oral carcinomas stem cells through IL-6/Stat3 signaling inhibition.	misonidazole-glutathione conjugate	0-3	interleukin 6	Mus musculus	91-95
28282360-5	2017	GTS-21 dose-dependently (0 muM, 100 muM, and 200 muM) significantly increased IL-6 levels in myoblasts and myotubes at 6 and 9 h. GTS-21-induced IL-6 release in myotubes was attenuated by methyllycaconitine (alpha7AChR antagonist), and by Stat-3 or Stat-5 inhibitors.	methyllycaconitine	188-206	interleukin 6	Mus musculus	145-149
28282360-10	2017	The in vitro findings suggest that GTS-21-induced IL-6 release from muscle is mediated via alpha7AChRs upstream of Stat-3 and -5 pathways and is associated with myonuclear accretion, possibly via MyoD and Pax7 expression.	3-(2,4-dimethoxybenzylidene)anabaseine	35-41	interleukin 6	Mus musculus	50-54
29050290-5	2017	Our results suggested that the tumor suppressive effect of GMI was mediated through inhibition of IL-6/Stat3 signaling pathway.	misonidazole-glutathione conjugate	59-62	interleukin 6	Mus musculus	98-102
28759565-4	2017	Only DCs matured under CThi conditions secreted IL-1beta, IL-6 and IL-23 leading to the instruction of Th17 cell polarization.	cthi	23-27	interleukin 6	Mus musculus	58-62
28551404-7	2017	In an LPS-challenged mouse model, harmine markedly averted inflammatory damage of the lung, and decreased serum TNF-alpha, interleukin-1beta (IL-1beta) and IL-6 levels.	Harmine	34-41	interleukin 6	Mus musculus	156-160
28754131-10	2017	In addition, etifoxine treatment led to decreased expression of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, and inducible nitric oxide synthase by microglia.	etifoxine	13-22	interleukin 6	Mus musculus	83-125
28759625-8	2017	Mean serum IL-6 was lower in mice treated with azithromycin alone (66+-52 pg/ml) or combination of ampicillin plus azithromycin (52+-22 pg/ml) compared to ampicillin alone (260+-160 pg/ml) (p&lt;0.005).	Azithromycin	47-59	interleukin 6	Mus musculus	11-15
28759625-8	2017	Mean serum IL-6 was lower in mice treated with azithromycin alone (66+-52 pg/ml) or combination of ampicillin plus azithromycin (52+-22 pg/ml) compared to ampicillin alone (260+-160 pg/ml) (p&lt;0.005).	Ampicillin	99-109	interleukin 6	Mus musculus	11-15
28759625-8	2017	Mean serum IL-6 was lower in mice treated with azithromycin alone (66+-52 pg/ml) or combination of ampicillin plus azithromycin (52+-22 pg/ml) compared to ampicillin alone (260+-160 pg/ml) (p&lt;0.005).	Azithromycin	115-127	interleukin 6	Mus musculus	11-15
28785146-10	2017	HRW treatment significantly reduced EtOH-induced increases in serum alanine aminotransferase, aspartate aminotransferase, triglycerol and total cholesterol levels, hepatic lipid accumulation and inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6.	Ethanol	36-40	interleukin 6	Mus musculus	273-291
28751740-6	2017	The levels of inflammatory cytokines in the serum (TNF-alpha, IL-6, IL-12, TGF-beta, and VEGF) were down regulated by DMDD.	2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione	118-122	interleukin 6	Mus musculus	62-66
28938606-4	2017	The production of IL-1beta, IL-6 and TNF-alpha in colon was also markedly reduced by oroxylin A.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	85-95	interleukin 6	Mus musculus	28-32
28785217-13	2017	Curcumin treatment concentration-dependently reduced the expression of pro-inflammatory cytokines, including TNF-alpha, IL-6 and IL-12p70, in the absence of any toxic effect on microglial cell survival.	Curcumin	0-8	interleukin 6	Mus musculus	120-124
28726741-5	2017	Moreover, colonic pro-inflammatory cytokines (TNF-alpha, IL-6, and IL-1beta) induced by colitis were dramatically decreased by magnolol.	magnolol	127-135	interleukin 6	Mus musculus	57-61
29228558-0	2017	1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol ameliorates arthritic joints through reducing neutrophil infiltration mediated by IL-6/STAT3 and MIP-2 activation.	1-palmitoyl-2-linoleoyl-3-acetyl-rac glycerol	0-45	interleukin 6	Mus musculus	128-132
29228558-3	2017	In this study, we show that 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) decreases neutrophil migration by regulating the activity of STAT3, a regulator of IL-6 and MIP-2 expression.	1-palmitoyl-2-linoleoyl-3-acetyl-rac glycerol	28-73	interleukin 6	Mus musculus	164-168
28554870-6	2017	Cirsimaritin inhibited interleukin-6, tumor necrosis factor-alpha, and NO production in a concentration-dependent manner in lipopolysaccharide (LPS)-stimulated RAW264.7 cells.	cirsimaritin	0-12	interleukin 6	Mus musculus	23-65
28714872-4	2017	In addition, OSA-PG increased the production of IL-6 and TNF-alpha by enhancing their gene expression.	osa	13-16	interleukin 6	Mus musculus	48-52
28674400-3	2017	In naive BMMCs, LPS stimulation induced a transient decline in the trimethylation of lysine 9 of the core histone H3 (H3K9me3), a suppressive chromatin mark, at the Il6/Tnf promoters, which correlated with p50(NFkappaB) and p65(NFkappaB) binding.	Lysine	85-91	interleukin 6	Mus musculus	165-168
28708884-11	2017	Finally, cytokine array revealed that 1,25D3 and PGE2 stimulated secretion of interleukin-6 (IL-6), IL-11, and leukemia inhibitory factor in the co-culture.	Dinoprostone	49-53	interleukin 6	Mus musculus	78-91
28708884-11	2017	Finally, cytokine array revealed that 1,25D3 and PGE2 stimulated secretion of interleukin-6 (IL-6), IL-11, and leukemia inhibitory factor in the co-culture.	Dinoprostone	49-53	interleukin 6	Mus musculus	93-97
28740344-7	2017	Multiplex ELISA analysis revealed that rosuvastatin treatment reduced the DSS-induced increase of serum IL-2, IL-4, IL-5, IL-6, IL-12 and IL-17, and G-CSF levels.	Rosuvastatin Calcium	39-51	interleukin 6	Mus musculus	122-126
28740344-7	2017	Multiplex ELISA analysis revealed that rosuvastatin treatment reduced the DSS-induced increase of serum IL-2, IL-4, IL-5, IL-6, IL-12 and IL-17, and G-CSF levels.	Dextran Sulfate	74-77	interleukin 6	Mus musculus	122-126
28672025-0	2017	Interleukin-6 regulates iron-related proteins through c-Jun N-terminal kinase activation in BV2 microglial cell lines.	Iron	24-28	interleukin 6	Mus musculus	0-13
28672025-5	2017	In the present study, we aimed to determine how iron levels affect interleukin-6 (IL-6) synthesis, and the effect of IL-6 on cellular iron metabolism in BV2 microglial cells.IL-6 mRNA was up-regulated after FAC treatment for 12 h in BV2 cells.	Iron	48-52	interleukin 6	Mus musculus	67-80
28672025-5	2017	In the present study, we aimed to determine how iron levels affect interleukin-6 (IL-6) synthesis, and the effect of IL-6 on cellular iron metabolism in BV2 microglial cells.IL-6 mRNA was up-regulated after FAC treatment for 12 h in BV2 cells.	Iron	48-52	interleukin 6	Mus musculus	82-86
28672025-5	2017	In the present study, we aimed to determine how iron levels affect interleukin-6 (IL-6) synthesis, and the effect of IL-6 on cellular iron metabolism in BV2 microglial cells.IL-6 mRNA was up-regulated after FAC treatment for 12 h in BV2 cells.	Iron	134-138	interleukin 6	Mus musculus	117-121
28672025-5	2017	In the present study, we aimed to determine how iron levels affect interleukin-6 (IL-6) synthesis, and the effect of IL-6 on cellular iron metabolism in BV2 microglial cells.IL-6 mRNA was up-regulated after FAC treatment for 12 h in BV2 cells.	Iron	134-138	interleukin 6	Mus musculus	117-121
28672025-7	2017	Phosphorylated JNK increased significantly compared to the control after BV2 cells were treated with IL-6 for 1 h. Pretreatment with SP600125 attenuated the up-regulation of IRP1 and DMT1 and down-regulation of FPN1 (compared to IL-6-treated group).	pyrazolanthrone	133-141	interleukin 6	Mus musculus	101-105
28672025-7	2017	Phosphorylated JNK increased significantly compared to the control after BV2 cells were treated with IL-6 for 1 h. Pretreatment with SP600125 attenuated the up-regulation of IRP1 and DMT1 and down-regulation of FPN1 (compared to IL-6-treated group).	pyrazolanthrone	133-141	interleukin 6	Mus musculus	229-233
28672025-8	2017	These results suggest that iron load could increase IL-6 mRNA expression in BV2 cells.	Iron	27-31	interleukin 6	Mus musculus	52-56
28276710-6	2017	The gene expression of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6 and COX2, significantly increased in the cerebrum of KBrO3-treated group.	kbro3	138-143	interleukin 6	Mus musculus	71-84
28402587-4	2017	Upon engulfment into macrophages, MTX SPNs intracellularly release their anti-inflammatory cargo significantly lowering the production of proinflammatory cytokine (interleukin 6 and tumor necrosis factor alpha) already at 0.06 mg mL-1 of MTX.	mtx spns	34-42	interleukin 6	Mus musculus	164-209
28402587-4	2017	Upon engulfment into macrophages, MTX SPNs intracellularly release their anti-inflammatory cargo significantly lowering the production of proinflammatory cytokine (interleukin 6 and tumor necrosis factor alpha) already at 0.06 mg mL-1 of MTX.	Methotrexate	34-37	interleukin 6	Mus musculus	164-209
28428003-6	2017	The lungs of mice exposed to CS showed an increase in the release of interleukin-6 (IL-6) and keratinocyte-derived chemokine (KC), as well as an accumulation of inflammatory cells, indicating high Rac1 activity.	Cesium	29-31	interleukin 6	Mus musculus	69-82
28370033-4	2017	Under defined ELF-EMF exposure conditions, the production of nitric oxide and pro-inflammatory cytokines, TNF-alpha, IL-1beta, and IL-6, were increased in RAW 264.7 cells and the expression of those genes was also upregulated.	Nitric Oxide	61-73	interleukin 6	Mus musculus	131-135
28428003-6	2017	The lungs of mice exposed to CS showed an increase in the release of interleukin-6 (IL-6) and keratinocyte-derived chemokine (KC), as well as an accumulation of inflammatory cells, indicating high Rac1 activity.	Cesium	29-31	interleukin 6	Mus musculus	84-88
28511344-8	2017	trans-anethole reduced the serum concentrations of pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), as well as significantly reducing blood pressure during chronic inflammation.	anethole	0-14	interleukin 6	Mus musculus	89-102
28511344-8	2017	trans-anethole reduced the serum concentrations of pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), as well as significantly reducing blood pressure during chronic inflammation.	anethole	0-14	interleukin 6	Mus musculus	104-108
28511344-9	2017	Trans-anethole ameliorated chronic lung inflammation in a mouse model of COPD by reducing the serum concentrations of pro-inflammatory cytokines such as TNF-alpha and IL-6, and by reducing blood pressure.	anethole	0-14	interleukin 6	Mus musculus	167-171
28672957-10	2017	In the palmitate-activated and RIP140-overexpressing MIN6 cells, TNF-alpha and IL-6 secretion increased significantly (both P&lt;0.05) and macrophage chemotaxis towards MIN6 cells was enhanced.	Palmitates	7-16	interleukin 6	Mus musculus	79-83
28500865-6	2017	RESULTS: (1) Dihydromyricetin ameliorated hyperlipidemia, reduced serum ox-LDL, IL-6 and TNF-alpha levels in HFD-fed LDLr-/- mice.	dihydromyricetin	13-29	interleukin 6	Mus musculus	80-84
28468928-6	2017	Polyps in sildenafil treated mice were also less inflamed; they exhibited reduced myeloid-cell infiltration and reduced expression of iNOS, IFNgamma, and IL6 compared with untreated controls.	Sildenafil Citrate	10-20	interleukin 6	Mus musculus	154-157
28251819-6	2017	Additionally, we found that the mRNA levels of the pro-inflammatory factors IL-1beta, IL-6, CXCL-1, and TNF-alpha, in peritoneal macrophages, the spleen, and the thymus were inhibited in the cis-BF-treated groups.	cis-bf	191-197	interleukin 6	Mus musculus	86-90
28400195-18	2017	EGFR-deficient myeloid cells in the colon of DSS-treated LysM-Cre; Egfrf/f mice had reduced expression of interleukin 6 (IL6), and epithelial STAT3 activation was reduced compared with controls.	dss	45-48	interleukin 6	Mus musculus	106-119
28400195-18	2017	EGFR-deficient myeloid cells in the colon of DSS-treated LysM-Cre; Egfrf/f mice had reduced expression of interleukin 6 (IL6), and epithelial STAT3 activation was reduced compared with controls.	dss	45-48	interleukin 6	Mus musculus	121-124
28400195-19	2017	Administration of recombinant IL6 to LysM-Cre; Egfrf/f mice given DSS protected them from weight loss and restored epithelial proliferation and STAT3 activation, compared with administration of DSS alone to these mice.	dss	66-69	interleukin 6	Mus musculus	30-33
28400195-19	2017	Administration of recombinant IL6 to LysM-Cre; Egfrf/f mice given DSS protected them from weight loss and restored epithelial proliferation and STAT3 activation, compared with administration of DSS alone to these mice.	dss	194-197	interleukin 6	Mus musculus	30-33
28375547-8	2017	Importantly, pre-treatment with pFTY720 significantly attenuated both bolus H2 O2 and GOX-CAT-induced demyelination and the GOX-CAT-induced decrease in vimentin in cerebellar slices, without altering levels of the proinflammatory cytokines such as IL-6 and CX3CL1.	pfty720	32-39	interleukin 6	Mus musculus	248-252
28409189-7	2017	Both in vivo and in vitro study showed that daphnetin prevented the production of pro-inflammatory factors including TNF-alpha, IL-1beta, IL-6, NO, and PGE2 after LPS challenge.	daphnetin	44-53	interleukin 6	Mus musculus	138-142
28486212-6	2017	In addition, treatment with 5-AZA suppressed APAP-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6) and nitric oxide (NO), 5-AZA also reversed the upregulation of myeloperoxidase (MPO) in the liver of APAP-exposed mice.	Azacitidine	28-33	interleukin 6	Mus musculus	113-126
28486212-6	2017	In addition, treatment with 5-AZA suppressed APAP-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6) and nitric oxide (NO), 5-AZA also reversed the upregulation of myeloperoxidase (MPO) in the liver of APAP-exposed mice.	Azacitidine	28-33	interleukin 6	Mus musculus	128-132
28486212-6	2017	In addition, treatment with 5-AZA suppressed APAP-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6) and nitric oxide (NO), 5-AZA also reversed the upregulation of myeloperoxidase (MPO) in the liver of APAP-exposed mice.	Acetaminophen	45-49	interleukin 6	Mus musculus	113-126
28486212-6	2017	In addition, treatment with 5-AZA suppressed APAP-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6) and nitric oxide (NO), 5-AZA also reversed the upregulation of myeloperoxidase (MPO) in the liver of APAP-exposed mice.	Acetaminophen	45-49	interleukin 6	Mus musculus	128-132
28486212-6	2017	In addition, treatment with 5-AZA suppressed APAP-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6) and nitric oxide (NO), 5-AZA also reversed the upregulation of myeloperoxidase (MPO) in the liver of APAP-exposed mice.	Azacitidine	157-162	interleukin 6	Mus musculus	113-126
28486212-6	2017	In addition, treatment with 5-AZA suppressed APAP-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6) and nitric oxide (NO), 5-AZA also reversed the upregulation of myeloperoxidase (MPO) in the liver of APAP-exposed mice.	Azacitidine	157-162	interleukin 6	Mus musculus	128-132
28486213-6	2017	The results showed that corynoline markedly inhibited LPS-induced neutrophils influx, MPO activity, and inflammatory cytokines IL-1beta, TNF-alpha and IL-6 release.	corynoline	24-34	interleukin 6	Mus musculus	151-155
28295316-4	2017	KEY FINDINGS: In this regard, we showed that HF and DHF dose-dependently reduced the production of NO, PGE2 , TNF-alpha and IL-6 through downregulating mRNA expression of inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX2), TNF-alpha and IL-6, respectively.	6,7-dihydroxyflavone	52-55	interleukin 6	Mus musculus	124-128
28498464-6	2017	Our data also showed that inhibition of NF-kappaB with pyrrolidine dithiocarbamate (PDTC) significantly reduced the secretion of TNF-alpha and IL-6 from BV-2 microglial cells treated with S100A8/A9.	pyrrolidine dithiocarbamic acid	55-82	interleukin 6	Mus musculus	143-147
28498464-6	2017	Our data also showed that inhibition of NF-kappaB with pyrrolidine dithiocarbamate (PDTC) significantly reduced the secretion of TNF-alpha and IL-6 from BV-2 microglial cells treated with S100A8/A9.	pyrrolidine dithiocarbamic acid	84-88	interleukin 6	Mus musculus	143-147
28911649-10	2017	LCBs decreased serum proinflammatory cytokines levels, namely interleukin (IL)-1beta, tumor necrosis factor-alpha, IL-6, macrophage inflammatory protein 1, and c-reactive protein, and increased anti-inflammatory cytokine IL-10 concentration.	lcbs	0-4	interleukin 6	Mus musculus	115-119
28911655-9	2017	Moreover, in D-Asp-treated mice, the serum level of interleukin 6 was significantly lower than that in control animals, whereas the total antioxidant capacity was significantly higher.	D-Aspartic Acid	13-18	interleukin 6	Mus musculus	52-65
28295316-6	2017	CONCLUSIONS: Consider together, these findings suggest that DHF and HF can inhibit LPS-induced inflammation via attenuating the production of NO, PGE2 , TNF-alpha and IL-6, indicating that they may be lead compounds for developing anti-inflammatory agent.	6,7-dihydroxyflavone	60-63	interleukin 6	Mus musculus	167-171
28295316-4	2017	KEY FINDINGS: In this regard, we showed that HF and DHF dose-dependently reduced the production of NO, PGE2 , TNF-alpha and IL-6 through downregulating mRNA expression of inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX2), TNF-alpha and IL-6, respectively.	6,7-dihydroxyflavone	52-55	interleukin 6	Mus musculus	250-254
28522175-6	2017	Pretreatment with TPPU resulted in a decrease of ulceration in mice treated with DCF with a significant decrease in the level of apoptosis, TNF-alpha and IL-6 in the serum in comparison to diclofenac-treated mice.	TPPU	18-22	interleukin 6	Mus musculus	154-158
28522175-6	2017	Pretreatment with TPPU resulted in a decrease of ulceration in mice treated with DCF with a significant decrease in the level of apoptosis, TNF-alpha and IL-6 in the serum in comparison to diclofenac-treated mice.	Diclofenac	81-84	interleukin 6	Mus musculus	154-158
28839376-10	2017	Finally, DDRC decreased production levels of IFN-gamma, TNF-alpha and IL-6 induced by repeated application of DNFB (P &lt; 0.05).	ddrc	9-13	interleukin 6	Mus musculus	70-74
28501482-10	2017	The neuroinflammatory analysis showed that ciproxifan reduced both COX-1 and COX-2 activities, decreased the level of pro-inflammatory cytokines IL-1alpha, IL-1beta and IL-6 and increased the level of anti-inflammatory cytokine TGF-1beta.	ciproxifan	43-53	interleukin 6	Mus musculus	169-173
28839376-10	2017	Finally, DDRC decreased production levels of IFN-gamma, TNF-alpha and IL-6 induced by repeated application of DNFB (P &lt; 0.05).	Dinitrofluorobenzene	110-114	interleukin 6	Mus musculus	70-74
28410218-7	2017	Our results revealed that 6-Shogaol inhibited LPS-induced TNF-alpha, IL-1beta, IL-6, and PGE2 production in a concentration dependent manner.	shogaol	26-35	interleukin 6	Mus musculus	79-83
28713337-8	2017	Furthermore, DeltaprtX demonstrated increased in vitro immune stimulation of IL-6, IL-12, and IL-10 compared to wild-type, when exposed to mouse dendritic cells.	deltaprtx	13-22	interleukin 6	Mus musculus	77-81
28661454-7	2017	Moreover, ChA could significantly suppress the secretion of IFNgamma, TNFalpha, and IL-6 and the colonic infiltration of F4/80+ macrophages, CD3+ T cells, and CD177+ neutrophils via inhibition of the active NF-kappaB signaling pathway.	Chlorogenic Acid	10-13	interleukin 6	Mus musculus	84-88
28561086-5	2017	Here, we showed that the heparin-mimetic PA gel can support tissue neovascularization, enhance the deposition of collagen and expression of alpha-smooth muscle actin (alpha-SMA), and eliminate the sustained presence of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in the diabetic wound site.	Heparin	25-32	interleukin 6	Mus musculus	219-232
28561086-5	2017	Here, we showed that the heparin-mimetic PA gel can support tissue neovascularization, enhance the deposition of collagen and expression of alpha-smooth muscle actin (alpha-SMA), and eliminate the sustained presence of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in the diabetic wound site.	Heparin	25-32	interleukin 6	Mus musculus	234-238
28561086-5	2017	Here, we showed that the heparin-mimetic PA gel can support tissue neovascularization, enhance the deposition of collagen and expression of alpha-smooth muscle actin (alpha-SMA), and eliminate the sustained presence of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in the diabetic wound site.	Protactinium	41-43	interleukin 6	Mus musculus	219-232
28561086-5	2017	Here, we showed that the heparin-mimetic PA gel can support tissue neovascularization, enhance the deposition of collagen and expression of alpha-smooth muscle actin (alpha-SMA), and eliminate the sustained presence of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in the diabetic wound site.	Protactinium	41-43	interleukin 6	Mus musculus	234-238
28638152-8	2017	HSHF exacerbated these effects, increasing IR, lipolysis, mRNA expression of F4/80 and leptin in AT, Tlr-4 in soleus muscle and IL-6, IL-1beta, VCAM-1, and ICAM-1 protein in AT.	hshf	0-4	interleukin 6	Mus musculus	128-132
28634361-6	2017	The levels of proinflammatory cytokines IL-6, IL-1beta and TNF in serum as well as mRNA expression in colon were significantly reduced in the uridine treated groups.	Uridine	142-149	interleukin 6	Mus musculus	40-44
28881825-11	2017	Global increase of hepatic interleukin-1beta, interleukin-6, tumor necrosis factor-alpha and hepatocyte growth factor was detected in low-fat/high-carbohydrate and high-fat with respect to standard diet fed mice as well as in tumor with respect to non-tumor bearing mice.	Carbohydrates	147-159	interleukin 6	Mus musculus	46-88
28630262-9	2017	In lipopolysaccharide-stimulated RAW264.7 cells, anagliptin treatment significantly reduced the production of tumor necrosis factor alpha, MCP-1, and IL-6 (interleukin 6) independent of GLP-1 (glucagon-like peptide 1), the key mediator in the antidiabetic effects of DPP-4 inhibitors.	anagliptin	49-59	interleukin 6	Mus musculus	150-154
28630262-9	2017	In lipopolysaccharide-stimulated RAW264.7 cells, anagliptin treatment significantly reduced the production of tumor necrosis factor alpha, MCP-1, and IL-6 (interleukin 6) independent of GLP-1 (glucagon-like peptide 1), the key mediator in the antidiabetic effects of DPP-4 inhibitors.	anagliptin	49-59	interleukin 6	Mus musculus	156-169
28670276-5	2017	In addition, UA also reversed gamma irradiation induced inflammatory responses, as indicated by the decreased production of TNF-alpha, IL-6, and IL-1beta.	ursolic acid	13-15	interleukin 6	Mus musculus	135-139
28499868-8	2017	Besides, PM2.5 activated NFkappaB pathway and increased gene expression of IL-1beta and IL-6 in NMVMs with hypoxia, which could be effectively reversed by SN-50-induced blockade of NFkappaB translocation to the nucleus.	SN-50	155-160	interleukin 6	Mus musculus	88-92
28977826-5	2017	In addition, the levels of TGF-beta, IL-6, TNF-alpha and IL-1beta in the tissues dramatically reduced in the irradiated mice pretreated with Ilomastat.	ilomastat	141-150	interleukin 6	Mus musculus	37-41
28730071-8	2017	The sorafenib group showed reduced expression of VEGF-C, tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, VEGFR-2 and VEGFR-3 compared with DMSO group and PBS group (all P&lt;0.05).	Sorafenib	4-13	interleukin 6	Mus musculus	92-110
28489606-9	2017	Our results indicated that pantoprazole treatment can decrease the levels of serum IL-6 and TNF-alpha (56.3% and 67.6%, respectively), and inhibit the activation of the JAK2/STAT3 signaling pathway.	Pantoprazole	27-39	interleukin 6	Mus musculus	83-87
28594906-4	2017	Braylin (10-40 muM) reduced the production of nitrite, IL-1beta, TNF-alpha and IL-6 by J774 cells or peritoneal exudate macrophages stimulated with LPS and IFN-gamma.	Braylin	0-7	interleukin 6	Mus musculus	79-83
28659919-7	2017	Postoperative heparanase levels positively correlated with noradrenalin dose at 12 h after ICU admission and showed a high predictive value of vasopressor requirements within the first 24 h. Postoperative heparan sulfate showed a strong positive correlation with interleukin-6 levels day 0, 1, and 2 post-ICU admission and a strong negative correlation with lactate clearance during the first 6 h post-ICU admission.	Heparitin Sulfate	205-220	interleukin 6	Mus musculus	263-276
28659919-7	2017	Postoperative heparanase levels positively correlated with noradrenalin dose at 12 h after ICU admission and showed a high predictive value of vasopressor requirements within the first 24 h. Postoperative heparan sulfate showed a strong positive correlation with interleukin-6 levels day 0, 1, and 2 post-ICU admission and a strong negative correlation with lactate clearance during the first 6 h post-ICU admission.	Lactic Acid	358-365	interleukin 6	Mus musculus	263-276
28465253-3	2017	MATERIALS AND METHODS: Anti-inflammatory activity of CMEP-NQ was investigated in LPS-treated RAW264.7 cells by measuring the levels of NO, PGE2, and cytokines (IL1beta, IL-6, TNF-alpha) in the culture supernatants and the TLR4-mediated intracellular events including association of MyD88 with IRAK1, activation of IRAK1, TAK1, MAPKs, NF-kappaB/AP-1, and IRF3, and generation of ROS.	2-carbomethoxy-2,3-epoxy-3-prenyl-1,4-naphthoquinone	53-60	interleukin 6	Mus musculus	169-173
28594379-4	2017	The results demonstrated that alisol F and 25-anhydroalisol F could suppress LPS-induced production of nitric oxide (NO), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and interleukin-1beta (IL-1beta), as well as inhibit the mRNA and protein levels of inducible nitric oxide (iNOS) and cyclooxygenase-2 (COX-2).	alisol F	30-38	interleukin 6	Mus musculus	122-135
28594379-4	2017	The results demonstrated that alisol F and 25-anhydroalisol F could suppress LPS-induced production of nitric oxide (NO), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and interleukin-1beta (IL-1beta), as well as inhibit the mRNA and protein levels of inducible nitric oxide (iNOS) and cyclooxygenase-2 (COX-2).	alisol F	30-38	interleukin 6	Mus musculus	137-141
28594379-4	2017	The results demonstrated that alisol F and 25-anhydroalisol F could suppress LPS-induced production of nitric oxide (NO), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and interleukin-1beta (IL-1beta), as well as inhibit the mRNA and protein levels of inducible nitric oxide (iNOS) and cyclooxygenase-2 (COX-2).	25-Anhydroalisol F	43-61	interleukin 6	Mus musculus	122-135
28594379-4	2017	The results demonstrated that alisol F and 25-anhydroalisol F could suppress LPS-induced production of nitric oxide (NO), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and interleukin-1beta (IL-1beta), as well as inhibit the mRNA and protein levels of inducible nitric oxide (iNOS) and cyclooxygenase-2 (COX-2).	25-Anhydroalisol F	43-61	interleukin 6	Mus musculus	137-141
28977876-4	2017	In vitro, wogonoside decreased the production of pro-inflammatory cytokines like Nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor alpha (TNF-alpha), and interleukin-6 (IL-6).	wogonoside	10-20	interleukin 6	Mus musculus	170-183
28603455-8	2017	Within 3 days after CCI, TMP attenuated activation of microglia and astrocytes, levels of SP, iNOS, and CGRP in trigeminal pathway, and levels of proinflammatory cytokines (including IL-6, TNF-alpha, IL-12).	tetramethylpyrazine	25-28	interleukin 6	Mus musculus	183-187
28574437-8	2017	Quercetin may inhibit cytokine production, especially in IL-6 and IL-8 and may upgrade the level of HO-1.	Quercetin	0-9	interleukin 6	Mus musculus	57-61
28977876-4	2017	In vitro, wogonoside decreased the production of pro-inflammatory cytokines like Nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor alpha (TNF-alpha), and interleukin-6 (IL-6).	wogonoside	10-20	interleukin 6	Mus musculus	185-189
28364631-3	2017	Antigen-presenting cells treated with SVNP-OVA and SVNP-IC showed higher uptake of OVA and poly (I:C) and higher secretion of inflammatory cytokines (TNF-alpha, IL-6) and type I interferon (IFN-alpha, IFN-beta) than those treated with OVA and poly (I:C) alone.	svnp-ova	38-46	interleukin 6	Mus musculus	161-165
30108861-1	2017	Based on the SAR analysis of glycyrrhizin, 18alpha-glycyrrhetinic acid monoglucuronide (18alpha-GAMG) with strong inhibition against LPS-induced NO and IL-6 production in RAW264.7 cells was discovered.	Glycyrrhizic Acid	29-41	interleukin 6	Mus musculus	152-156
30108861-1	2017	Based on the SAR analysis of glycyrrhizin, 18alpha-glycyrrhetinic acid monoglucuronide (18alpha-GAMG) with strong inhibition against LPS-induced NO and IL-6 production in RAW264.7 cells was discovered.	18alpha-glycyrrhetinic acid monoglucuronide	43-86	interleukin 6	Mus musculus	152-156
30108861-1	2017	Based on the SAR analysis of glycyrrhizin, 18alpha-glycyrrhetinic acid monoglucuronide (18alpha-GAMG) with strong inhibition against LPS-induced NO and IL-6 production in RAW264.7 cells was discovered.	18alpha-gamg	88-100	interleukin 6	Mus musculus	152-156
28243801-5	2017	Ribavirin significantly suppressed toll-like receptor 2 and 4 expression in the lung and decreased the level of IL-1beta, IL-6, TNF-alpha, and IFN-gamma in lung tissues of mice infected with influenza virus.	Ribavirin	0-9	interleukin 6	Mus musculus	122-126
28364631-3	2017	Antigen-presenting cells treated with SVNP-OVA and SVNP-IC showed higher uptake of OVA and poly (I:C) and higher secretion of inflammatory cytokines (TNF-alpha, IL-6) and type I interferon (IFN-alpha, IFN-beta) than those treated with OVA and poly (I:C) alone.	svnp	38-42	interleukin 6	Mus musculus	161-165
28282624-9	2017	In contrast, TDCIPP exposure had no effect at steady state DCs but suppressed the expression of MHCII, costimulatory molecules, and the IL-6 production in HDM exposed DCs.	tris(1,3-dichloro-2-propyl)phosphate	13-19	interleukin 6	Mus musculus	136-140
28549777-6	2017	Furthermore, MEFs treated with chloramphenicol, an inhibitor of mitochondrial translation, produced excessive IL-6 via ATF4 pathways.	Chloramphenicol	31-46	interleukin 6	Mus musculus	110-114
28612711-8	2017	APAP treatment enhanced hepatic levels of interleukin-6, tumor necrosis factor-alpha and monocyte chemoattractant protein-1.	Acetaminophen	0-4	interleukin 6	Mus musculus	42-84
28587416-8	2017	Berberine also significantly inhibited the expression of interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha mRNA and phosphorylation of signal transducer and activator of transcription 3.	Berberine	0-9	interleukin 6	Mus musculus	81-117
28108937-4	2017	We reported that glycyrrhizin treatment ameliorated colitis and decreased the production of inflammatory mediators HMGB1, IFN-gamma, IL-6, TNF-alpha, and IL-17.	Glycyrrhizic Acid	17-29	interleukin 6	Mus musculus	133-137
28273362-8	2017	Moreover, interleukin-6 elevation induced by CBLB502 is an important protective factor against Con A-induced liver injury.	CBLB502	45-52	interleukin 6	Mus musculus	10-23
28161732-5	2017	Results showed picroside II significantly decreased the concentrations of TNF-alpha, IL-1beta, and IL-6 in cells and mice.	picroside II	15-27	interleukin 6	Mus musculus	99-103
28315999-10	2017	Furthermore, artesunate significantly inhibited the levels of TNF-alpha, IL-1beta, and IL-6.	Artesunate	13-23	interleukin 6	Mus musculus	87-91
28303415-6	2017	In addition, the inhibition of Sch B on TNF-alpha, IL-6, IL-1beta, and PGE2 production were reversed by PPAR-gamma antagonist GW9662.	2-chloro-5-nitrobenzanilide	126-132	interleukin 6	Mus musculus	51-55
28315999-11	2017	Artesunate also inhibited LPS-induced IL-6 and IL-8 production in the A549 cells.	Artesunate	0-10	interleukin 6	Mus musculus	38-42
28474500-5	2017	Levels of non-esterified fatty acids and lipid peroxidation products were significantly lower in the group supplemented with additional Vitamin D3 , as were systemic markers of inflammation (serum endotoxin and IL-6).	Cholecalciferol	136-146	interleukin 6	Mus musculus	211-215
28342021-8	2017	For inflammatory response, these results showed that Arg-Arg can decrease the LPS-induced expression of IL-1beta and the rSEC-induced expression of TNF-alpha; however, it can upregulate the LPS-induced expression of IL-6 and TNF-alpha and the rSEC-induced expression level of IL-1beta.	Arg-arg	53-60	interleukin 6	Mus musculus	216-220
28474508-10	2017	We also treated EAM-resistant IL-6 knockout mice with recombinant IL-6 around the time of the first immunization, on days -1 to 2, completely restoring disease susceptibility, showing that the requirement for IL-6 coincides with primary immunization.	molibresib	16-19	interleukin 6	Mus musculus	30-34
28474508-10	2017	We also treated EAM-resistant IL-6 knockout mice with recombinant IL-6 around the time of the first immunization, on days -1 to 2, completely restoring disease susceptibility, showing that the requirement for IL-6 coincides with primary immunization.	molibresib	16-19	interleukin 6	Mus musculus	66-70
28474508-10	2017	We also treated EAM-resistant IL-6 knockout mice with recombinant IL-6 around the time of the first immunization, on days -1 to 2, completely restoring disease susceptibility, showing that the requirement for IL-6 coincides with primary immunization.	molibresib	16-19	interleukin 6	Mus musculus	66-70
28474508-16	2017	In addition, IL-6 deficient mice resistance to EAM could be reversed by injecting IL-6 around first immunization.	molibresib	47-50	interleukin 6	Mus musculus	13-17
28474508-16	2017	In addition, IL-6 deficient mice resistance to EAM could be reversed by injecting IL-6 around first immunization.	molibresib	47-50	interleukin 6	Mus musculus	82-86
28363108-4	2017	We found that FC-99 inhibited the expression of CD40 and inflammatory mediators (IL-6, IL-12, and CXCL-10), as well as R848-induced phosphorylation of IkappaB-alpha.	Fluorad FC99	14-19	interleukin 6	Mus musculus	81-85
28279768-4	2017	PAP (50, 100mg/kg) significantly inhibited the CCl4-incuded overproduction of inflammatory cytokines including tumor necrosis factor alpha (TNF-alpha), cytokines interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) in serum and liver.	Carbon Tetrachloride	47-51	interleukin 6	Mus musculus	196-209
28279768-4	2017	PAP (50, 100mg/kg) significantly inhibited the CCl4-incuded overproduction of inflammatory cytokines including tumor necrosis factor alpha (TNF-alpha), cytokines interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) in serum and liver.	Carbon Tetrachloride	47-51	interleukin 6	Mus musculus	211-215
28410530-3	2017	In the present study, we found that treatment with metformin inhibited the cardiac expression of pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1beta) and interleukin 6 (IL-6) in endotoxin-challenged mice.	Metformin	51-60	interleukin 6	Mus musculus	209-222
28410530-3	2017	In the present study, we found that treatment with metformin inhibited the cardiac expression of pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1beta) and interleukin 6 (IL-6) in endotoxin-challenged mice.	Metformin	51-60	interleukin 6	Mus musculus	224-228
28330776-0	2017	Topical application of glycolic acid suppresses the UVB induced IL-6, IL-8, MCP-1 and COX-2 inflammation by modulating NF-kappaB signaling pathway in keratinocytes and mice skin.	glycolic acid	23-36	interleukin 6	Mus musculus	64-68
27530729-8	2017	Pioglitazone dose-dependently decreased Tnf, Il6, Ccl2, Ptgs2, and Socs3 expression in WAT, in association with upregulation of Lpl, Ap2, Slc2a4, and Adipoq expression, indicating improvement in endotoxin-induced IR.	Pioglitazone	0-12	interleukin 6	Mus musculus	45-48
28330776-7	2017	RESULTS: GA reduced the production of UVB-induced nuclear factor kappa B (NF-kappaB)-dependent inflammatory mediators [interleukin (IL)-1beta, IL-6, IL-8, cyclooxygenase (COX)-2, tumor necrosis factor-alpha, and monocyte chemoattractant protein (MCP-1)] at both mRNA and protein levels.	glycolic acid	9-11	interleukin 6	Mus musculus	143-147
28330776-10	2017	The topical application of GA inhibited the genes expression of IL-1beta, IL-6, IL-8, COX-2, and MCP-1 in UVB-exposed mouse skin.	glycolic acid	27-29	interleukin 6	Mus musculus	74-78
28451684-5	2017	Furthermore, EN supplemented with CPs diminished the phosphorylation of intestinal NF-kappaB p65 and simultaneously down-regulated the mRNA expression of TNF-alpha and IL-6 in small intestine (p &lt; 0.05 vs. BE).	cps	34-37	interleukin 6	Mus musculus	168-172
27859576-8	2017	Increased expressions of pro-inflammatory cytokines TNF-alpha and IL-6 and chemokines CCL2, CCL3, CCL4, and CCL5 result in exacerbation of hepatitis in CCR5 knockout mice after ethanol feeding.	Ethanol	177-184	interleukin 6	Mus musculus	66-70
28373962-8	2017	In general, both modes of CR significantly reduced serum IL-6, TNF-alpha, IGF-I and leptin levels compared to AL with IL-6 levels 24 and 3.5 fold and TNF-alpha levels t 11 and 1.5 fold lower in ICR and CCR groups, respectively at study termination.	Chromium	26-28	interleukin 6	Mus musculus	57-61
28373962-8	2017	In general, both modes of CR significantly reduced serum IL-6, TNF-alpha, IGF-I and leptin levels compared to AL with IL-6 levels 24 and 3.5 fold and TNF-alpha levels t 11 and 1.5 fold lower in ICR and CCR groups, respectively at study termination.	Aluminum	110-112	interleukin 6	Mus musculus	118-122
28504577-2	2017	Oral administration of IM12 (0.2x109, 1x109 or 5x109 cfu/mouse, once a day for 3 days) in mice with CIE significantly suppressed the increase of oedema volume and thickness, as well as myeloperoxidase activity and IL-6, IL-17, NO, and prostaglandin E2 levels in the carrageenan-stimulated paw.	chlorimuron ethyl	100-103	interleukin 6	Mus musculus	214-218
28254410-3	2017	We demonstrate that paclitaxel or docetaxel treatment induces IL-6 secretion and results in expansion of CSCs in TNBC cell lines.	Paclitaxel	20-30	interleukin 6	Mus musculus	62-66
28254410-3	2017	We demonstrate that paclitaxel or docetaxel treatment induces IL-6 secretion and results in expansion of CSCs in TNBC cell lines.	Docetaxel	34-43	interleukin 6	Mus musculus	62-66
28603496-8	2017	Mechanistic studies indicated that AC exerted its anti-inflammatory activity by inhibiting the mRNA expression levels of inducible nitric oxide synthase, cyclooxygenase-2, TNF-alpha, interleukin (IL)-1beta, and IL-6 and by suppressing the production of inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6 in LPS-treated RAW 264.7 cells.	anhuienoside C	35-37	interleukin 6	Mus musculus	211-215
28603496-8	2017	Mechanistic studies indicated that AC exerted its anti-inflammatory activity by inhibiting the mRNA expression levels of inducible nitric oxide synthase, cyclooxygenase-2, TNF-alpha, interleukin (IL)-1beta, and IL-6 and by suppressing the production of inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6 in LPS-treated RAW 264.7 cells.	anhuienoside C	35-37	interleukin 6	Mus musculus	309-313
32264287-5	2017	Studies suggest that SNP-ApAGP (2.5 mug mL-1) up-regulates ROS generation, NO generation, and pro-inflammatory cytokine release (IL-12, IFN-gamma, TNF-alpha, and IL-6).	snp-apagp	21-30	interleukin 6	Mus musculus	162-166
28596945-6	2017	These results were associated with (i) decreased pulmonary and cerebral fungal burden and (ii) increased inflammatory infiltrate and modulatory of IFNgamma, IL-6, IL-10, and IL-17A cytokines in mice treated with pCramoll.	pcramoll	212-220	interleukin 6	Mus musculus	157-161
28542188-0	2017	HSP90 inhibitors potentiate PGF2alpha-induced IL-6 synthesis via p38 MAP kinase in osteoblasts.	Dinoprost	28-37	interleukin 6	Mus musculus	46-50
28542188-2	2017	We have previously reported that prostaglandin F2alpha (PGF2alpha), a potent bone remodeling mediator, stimulates the synthesis of interleukin-6 (IL-6) through p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells, and that Rho-kinase acts at a point upstream of p38 MAP kinase.	Dinoprost	33-54	interleukin 6	Mus musculus	131-144
28542188-2	2017	We have previously reported that prostaglandin F2alpha (PGF2alpha), a potent bone remodeling mediator, stimulates the synthesis of interleukin-6 (IL-6) through p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells, and that Rho-kinase acts at a point upstream of p38 MAP kinase.	Dinoprost	33-54	interleukin 6	Mus musculus	146-150
28542188-2	2017	We have previously reported that prostaglandin F2alpha (PGF2alpha), a potent bone remodeling mediator, stimulates the synthesis of interleukin-6 (IL-6) through p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells, and that Rho-kinase acts at a point upstream of p38 MAP kinase.	Dinoprost	56-65	interleukin 6	Mus musculus	131-144
28542188-2	2017	We have previously reported that prostaglandin F2alpha (PGF2alpha), a potent bone remodeling mediator, stimulates the synthesis of interleukin-6 (IL-6) through p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells, and that Rho-kinase acts at a point upstream of p38 MAP kinase.	Dinoprost	56-65	interleukin 6	Mus musculus	146-150
28542188-3	2017	In the present study, we investigated the involvement of HSP90 in the PGF2alpha-stimulated IL-6 synthesis and the underlying mechanism in MC3T3-E1 cells.	Dinoprost	70-79	interleukin 6	Mus musculus	91-95
28542188-4	2017	Geldanamycin, an inhibitor of HSP90, significantly amplified both the PGF2alpha-stimulated IL-6 release and the mRNA expression levels.	geldanamycin	0-12	interleukin 6	Mus musculus	91-95
28542188-4	2017	Geldanamycin, an inhibitor of HSP90, significantly amplified both the PGF2alpha-stimulated IL-6 release and the mRNA expression levels.	Dinoprost	70-79	interleukin 6	Mus musculus	91-95
28542188-9	2017	Furthermore, SB203580, an inhibitor of p38 MAP kinase, significantly suppressed the amplification by geldanamycin, 17-AAG or 17-DMAG of the PGF2alpha-stimulated IL-6 release.	SB 203580	13-21	interleukin 6	Mus musculus	161-165
28542188-9	2017	Furthermore, SB203580, an inhibitor of p38 MAP kinase, significantly suppressed the amplification by geldanamycin, 17-AAG or 17-DMAG of the PGF2alpha-stimulated IL-6 release.	geldanamycin	101-113	interleukin 6	Mus musculus	161-165
28542188-9	2017	Furthermore, SB203580, an inhibitor of p38 MAP kinase, significantly suppressed the amplification by geldanamycin, 17-AAG or 17-DMAG of the PGF2alpha-stimulated IL-6 release.	tanespimycin	115-121	interleukin 6	Mus musculus	161-165
28542188-9	2017	Furthermore, SB203580, an inhibitor of p38 MAP kinase, significantly suppressed the amplification by geldanamycin, 17-AAG or 17-DMAG of the PGF2alpha-stimulated IL-6 release.	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	125-132	interleukin 6	Mus musculus	161-165
28542188-9	2017	Furthermore, SB203580, an inhibitor of p38 MAP kinase, significantly suppressed the amplification by geldanamycin, 17-AAG or 17-DMAG of the PGF2alpha-stimulated IL-6 release.	Dinoprost	140-149	interleukin 6	Mus musculus	161-165
28542188-10	2017	Our results strongly suggest that HSP90 negatively regulates the PGF2alpha-stimulated IL-6 synthesis in osteoblasts, and that the effect of HSP90 is exerted through regulating p38 MAP kinase activation.	Dinoprost	65-74	interleukin 6	Mus musculus	86-90
28524081-9	2017	These results suggest that the hepatoprotective effects of TA may be related to its anti-inflammatory effect by decreasing thiobarbituric acid reactive substances (TBARS), iNOS, COX-2, TNF-alpha, IL-1beta, and IL-6, and inhibiting NF-kappaB and MAPK activation.	euscaphic acid	59-61	interleukin 6	Mus musculus	210-214
28524081-6	2017	Additionally, TA attenuated the APAP-induced production of nitric oxide (NO), reactive oxygen species (ROS), tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6.	Acetaminophen	32-36	interleukin 6	Mus musculus	184-188
28508871-6	2017	We show that the hepatocyte-specific deletion of Stat3, genetic ablation of Il6, treatment with a neutralizing anti-IL-6 antibody or administration of a small-molecule JAK inhibitor, abolishes FGF19-induced tumorigenesis, while the regulatory functions of FGF19 in bile acid, glucose and energy metabolism remain intact.	Bile Acids and Salts	265-274	interleukin 6	Mus musculus	116-120
28508871-6	2017	We show that the hepatocyte-specific deletion of Stat3, genetic ablation of Il6, treatment with a neutralizing anti-IL-6 antibody or administration of a small-molecule JAK inhibitor, abolishes FGF19-induced tumorigenesis, while the regulatory functions of FGF19 in bile acid, glucose and energy metabolism remain intact.	Glucose	276-283	interleukin 6	Mus musculus	116-120
28322842-2	2017	Chronic administration of 3-nitropropionic acid (3-NP) depletes ATP and NAD+; and increases TNFalpha, IL-6 and glutamate content resulting in "immunoexcitotoxicity".	3-nitropropionic acid	26-47	interleukin 6	Mus musculus	102-106
28322842-2	2017	Chronic administration of 3-nitropropionic acid (3-NP) depletes ATP and NAD+; and increases TNFalpha, IL-6 and glutamate content resulting in "immunoexcitotoxicity".	3-nitropropionic acid	49-53	interleukin 6	Mus musculus	102-106
28411188-3	2017	RKIP deficiency or silencing significantly decreases polyinosinic:polycytidylic acid [Poly(I:C)]-induced IFN-beta, IL-6, and TNF-alpha production without affecting the counterpart induced by LPS or CpG.	Poly C	66-84	interleukin 6	Mus musculus	115-119
28411188-3	2017	RKIP deficiency or silencing significantly decreases polyinosinic:polycytidylic acid [Poly(I:C)]-induced IFN-beta, IL-6, and TNF-alpha production without affecting the counterpart induced by LPS or CpG.	poly	86-90	interleukin 6	Mus musculus	115-119
28484277-9	2017	Pre-treatment of adipocytes or macrophages with the TKI gefitinib inhibited Nod1-induced Cxcl1 and Il-6 secretion.	Gefitinib	56-65	interleukin 6	Mus musculus	99-103
28559895-13	2017	Blockade of autophagy by Atg5 siRNA or bafilomycin A1 attenuated the inhibitory effect of PNU282987 on IL-6, IL-1beta, IL-18, and TNF-alpha mRNA.	bafilomycin	39-50	interleukin 6	Mus musculus	103-107
28485773-4	2017	In a dorsal root ganglion (DRG) culture, curcumin effectively inhibited TNF-alpha-induced neuroinflammation, in a dose-dependent manner, as shown by mRNA and protein expression of IL-6 and COX-2.	Curcumin	41-49	interleukin 6	Mus musculus	180-184
28482922-10	2017	The rSj-Cys conferred therapeutic efficacy was associated with upregualted IL-10 and TGF-beta1 cytokines and reduced pro-inflammatory cytokines TNF-alpha, IL-6, IL-1beta.	rsj-cys	4-11	interleukin 6	Mus musculus	155-159
28302560-6	2017	Furthermore, we showed that TCDD up-regulated the expression and secretion of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in a dose-dependent manner in cultured HSCs.	Polychlorinated Dibenzodioxins	28-32	interleukin 6	Mus musculus	153-166
28481246-8	2017	Moreover, CMP in combination with 5-FU alleviated severe liver injury induced by 5-FU via reducing the levels of ROS, IL-1beta, and IL-6, decreasing expression of p-IkappaB-alpha, NF-kappaB, p-NF-kappaB, pp38 and Bax, and elevating levels of Nrf2, GCL, HO-1 and Bcl-2.	Fluorouracil	34-38	interleukin 6	Mus musculus	132-136
28302560-6	2017	Furthermore, we showed that TCDD up-regulated the expression and secretion of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in a dose-dependent manner in cultured HSCs.	Polychlorinated Dibenzodioxins	28-32	interleukin 6	Mus musculus	168-172
28273337-1	2017	BACKGROUND: Ethanol (EtOH) consumption leads to an increase of proinflammatory signaling via activation of Toll-like receptors (TLRs) such as TLR3 and TLR4 that leads to kinase activation (ERK1/2, p38, TBK1), transcription factor activation (NFkappaB, IRF3), and increased transcription of proinflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6.	Ethanol	12-19	interleukin 6	Mus musculus	349-353
28466852-4	2017	Mice with T cell-specific deficiency of IL-6 receptor-alpha (IL-6RalphaT-KO) exposed to a HFD display improved glucose tolerance, insulin sensitivity and inflammation in liver and EWAT after 8 weeks.	Glucose	111-118	interleukin 6	Mus musculus	40-44
28283478-9	2017	Annexin A2 gene deletion in mice reduced bleomycin-induced increases in bronchoalveolar lavage fluid (BALF) IL-6 levels and cell number (*P &lt; 0.05; n = 4-12).	Bleomycin	41-50	interleukin 6	Mus musculus	108-112
28273337-1	2017	BACKGROUND: Ethanol (EtOH) consumption leads to an increase of proinflammatory signaling via activation of Toll-like receptors (TLRs) such as TLR3 and TLR4 that leads to kinase activation (ERK1/2, p38, TBK1), transcription factor activation (NFkappaB, IRF3), and increased transcription of proinflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6.	Ethanol	21-25	interleukin 6	Mus musculus	349-353
28254441-5	2017	Both EPA and DHA suppressed the production of the pro-inflammatory cytokines TNF-alpha and IL-6 by LPS-stimulated MG6 cells, and this was also observed in LPS-stimulated BV-2 cells, the other microglial line.	Eicosapentaenoic Acid	5-8	interleukin 6	Mus musculus	91-95
27853831-0	2017	Role of the lipid-regulated NF-kappaB/IL-6/STAT3 axis in alpha-naphthyl isothiocyanate-induced liver injury.	1-Naphthylisothiocyanate	57-86	interleukin 6	Mus musculus	38-42
28254441-5	2017	Both EPA and DHA suppressed the production of the pro-inflammatory cytokines TNF-alpha and IL-6 by LPS-stimulated MG6 cells, and this was also observed in LPS-stimulated BV-2 cells, the other microglial line.	Docosahexaenoic Acids	13-16	interleukin 6	Mus musculus	91-95
28549492-12	2017	Finally, ginsenoside Rb1 mitigated the isoflurane/surgery-induced elevation levels of reactive oxygen species, tumor necrosis factor-alpha and interleukin-6 in the mice hippocampus.	Isoflurane	39-49	interleukin 6	Mus musculus	143-156
28282790-10	2017	Improvement in the glucose tolerance and amelioration of insulin resistance was observed as revealed by reduction in serum IL6, serum oxidised LDL, histological sections of liver and subcutaneous adipose.	Glucose	19-26	interleukin 6	Mus musculus	123-126
28558868-5	2017	Moreover, vaticaffinol markedly down-regulated renal protein levels of NOD-like receptor 3 (NLRP3), apoptosis-associated speck-like (ASC), and Caspase-1, resulting in the reduction of interleukin (IL)-1beta, IL-18, IL-6 and tumor necrosis factor-alpha (TNF-alpha) levels in this animal model.	vaticaffinol	10-22	interleukin 6	Mus musculus	215-219
28212864-9	2017	Further, topical application of GPR43 agonist, phenylacetamide led to enhanced ear thickness with concomitant epidermal IL-6 signaling as well as dual oxidase-2 upregulation which may be responsible for increased psoriasis-like inflammation.	2-phenylacetamide	47-62	interleukin 6	Mus musculus	120-124
28249220-7	2017	In addition, the inflammatory responses induced by paraquat were inhibited after treatment with chloroquine, as indicated by the decreased number of leukocytes, the reduced levels of TNF-alpha, IL-1beta and IL-6 in the bronchoalveolar lavage fluid, the reduced NO content, and downregulation of iNOS expression in lung tissues.	Paraquat	51-59	interleukin 6	Mus musculus	207-211
28440734-6	2017	Further, alpha7nAChR activation could suppress the production of pro-inflammatory molecules TNFalpha and interleukin-6 produced from palmitate-treated co-cultured macrophages.	Palmitates	133-142	interleukin 6	Mus musculus	105-118
27421062-6	2017	Pioglitazone also decreased plasma alanine aminotransferase levels, liver weight, hepatic triglyceride content, and hepatic expression of other fibrosis-related genes such as TGFB1, SPP1, TIMP1, and IL6.	Pioglitazone	0-12	interleukin 6	Mus musculus	199-202
28224201-11	2017	DEX suppressed the infiltration of macrophages and T cells into the kidneys following cisplatin treatment, which was involved in the inhibition of NF-kappaB activation and decreased expression of TNF-alpha, IL-1beta, IL-6, and MCP-1.	Dexmedetomidine	0-3	interleukin 6	Mus musculus	217-221
28224201-11	2017	DEX suppressed the infiltration of macrophages and T cells into the kidneys following cisplatin treatment, which was involved in the inhibition of NF-kappaB activation and decreased expression of TNF-alpha, IL-1beta, IL-6, and MCP-1.	Cisplatin	86-95	interleukin 6	Mus musculus	217-221
28249220-7	2017	In addition, the inflammatory responses induced by paraquat were inhibited after treatment with chloroquine, as indicated by the decreased number of leukocytes, the reduced levels of TNF-alpha, IL-1beta and IL-6 in the bronchoalveolar lavage fluid, the reduced NO content, and downregulation of iNOS expression in lung tissues.	Chloroquine	96-107	interleukin 6	Mus musculus	207-211
28273557-6	2017	Treatment with curcumin significantly reduced IL-6 and IL-23 production by dendritic cells (DC).	Curcumin	15-23	interleukin 6	Mus musculus	46-50
28067111-4	2017	Furthermore, air toluene induced the expression of Hsp72 and enhanced IL-1, IL-6, and TNF-alpha in blood plasma, which is indicative of a pro-inflammatory response.	Toluene	17-24	interleukin 6	Mus musculus	76-80
28284148-8	2017	Furthermore, UA effectively moderated the histopathological changes, reduced the content of MDA, HYP, TNF-alpha, IL-1beta, IL-6 and TGF-beta1, and increased the level of SOD when combined with BLM in lung tissues of H22-bearing mice, which was believed to be related to the inhibition on the protein level of p-Smad2/3 and enhancement of Smad7 expression.	usnic acid	13-15	interleukin 6	Mus musculus	123-127
28314223-8	2017	GV1001 treatment of lipopolysaccharide-stimulated macrophages derived from THP-1 and RAW 264.7 monocytes significantly reduced TNF-alpha and IL-6 secretion (THP-1: all p&lt;0.05; RAW 264.7: all p&lt;0.01).	gv1001	0-6	interleukin 6	Mus musculus	141-145
27580405-6	2017	In a co-culture model with microglia and endothelial cells under a high glucose condition, the microglia-derived IL-6 induced STAT3 activation in the retinal endothelial cells, leading to increasing endothelial permeability.	Glucose	72-79	interleukin 6	Mus musculus	113-117
28208071-8	2017	Additionally, anthocyanin significantly reduced the expression and secretion of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in the calvaria of CoCrMo-stimulated mice.	Anthocyanins	14-25	interleukin 6	Mus musculus	154-167
27639185-6	2017	Upon stimulation of immature DC with LPS, VPA, and lithium both reduced the secretion of IL-6 and TNF-alpha.	Valproic Acid	42-45	interleukin 6	Mus musculus	89-93
27639185-6	2017	Upon stimulation of immature DC with LPS, VPA, and lithium both reduced the secretion of IL-6 and TNF-alpha.	Lithium	51-58	interleukin 6	Mus musculus	89-93
28584401-7	2017	Moreover, erythromycin reduced the levels of interleukin-6 and cyclooxygenase-2 mRNA expression in intestinal polyps.	Erythromycin	10-22	interleukin 6	Mus musculus	45-58
28244110-14	2017	Stretch or BzATP led to IL-6 release from both astrocytes and isolated retinal ganglion cells.	3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate	11-16	interleukin 6	Mus musculus	24-28
28208071-8	2017	Additionally, anthocyanin significantly reduced the expression and secretion of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in the calvaria of CoCrMo-stimulated mice.	Anthocyanins	14-25	interleukin 6	Mus musculus	169-173
28447893-4	2017	RESULTS: Ultra-small SAN-Dex strongly reduced the levels of TNF-alpha, IL-6 and IL-12 on J774A1 cells stimulated with lipopolysaccharides as compared with free Dex or loaded in ordinary solid lipid nanoparticles-Dex.	Dexamethasone	25-28	interleukin 6	Mus musculus	71-75
28459871-9	2017	On day 1 post-treatment, major upregulations of Ifng, Foxp3, Il1b, Il2, and Il6 genes in colon were only observed in the mice simultaneously treated with ampicillin.	Ampicillin	154-164	interleukin 6	Mus musculus	76-79
27997959-9	2017	This modulation may be related to the lower levels of IL-12p40 and IL-6 after treatment with parthenolide.	parthenolide	93-105	interleukin 6	Mus musculus	67-71
28363255-13	2017	Serum levels of thyroglobulin antibodies, HMGB1, tumor necrosis factor alpha, IL-6, and IL-1beta were significantly increased in the NaI group, but they were dramatically attenuated with GL injection.	Glycyrrhizic Acid	187-189	interleukin 6	Mus musculus	78-82
30263572-3	2017	Monoolein pretreatment in lipopolysaccharide (LPS)-stimulated primary murine bone marrow-derived dendritic cells (BMDCs) showed strong dose-dependent inhibition of interleukin (IL)-12 p40, IL-6, and TNF-alpha cytokine production with IC50 values of 1.69+-0.02, 6.87+-0.37, and 5.19+-0.56 muM, respectively.	monoolein	0-9	interleukin 6	Mus musculus	189-193
28263744-3	2017	Using 3T3-L1 adipocytes, we found that agonizing GPR120 using its synthetic ligand, GSK137647, attenuated both basal and lipopolysaccharide-induced production of interleukin-6 (IL-6) and C-C motif chemokine ligand 2 (CCL2).	GSK137647	84-93	interleukin 6	Mus musculus	162-175
28468284-4	2017	The results demonstrated that the most of the monoterpenoids suppressed the LPS-induced production of NO, interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha).	Monoterpenes	46-60	interleukin 6	Mus musculus	106-119
28468284-4	2017	The results demonstrated that the most of the monoterpenoids suppressed the LPS-induced production of NO, interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha).	Monoterpenes	46-60	interleukin 6	Mus musculus	121-125
28491039-8	2017	Specifically, SDR induced IL-6, TNF-alpha, IL-1beta, and MCP-1, while DME suppressed IL-6, TNF-alpha, IL-10, CXCL1, and anti-dsDNA autoantibodies.	dme	70-73	interleukin 6	Mus musculus	85-89
28263744-3	2017	Using 3T3-L1 adipocytes, we found that agonizing GPR120 using its synthetic ligand, GSK137647, attenuated both basal and lipopolysaccharide-induced production of interleukin-6 (IL-6) and C-C motif chemokine ligand 2 (CCL2).	GSK137647	84-93	interleukin 6	Mus musculus	177-181
28263744-6	2017	Inhibition of protein kinase C (PKC) augmented the down-regulatory effect of GSK137647 on IL-6 and CCL2 mRNA.	GSK137647	77-86	interleukin 6	Mus musculus	90-94
28263744-7	2017	Using a luciferase assay to measure promoter activity of the IL-6 gene in mouse embryonic fibroblasts, we demonstrated that exogenous transfection of GPR120 alone reduced the promoter activity, which was augmented by GSK137647.	GSK137647	217-226	interleukin 6	Mus musculus	61-65
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	ZSTK474	28-35	interleukin 6	Mus musculus	91-95
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	Niclosamide	39-50	interleukin 6	Mus musculus	91-95
29736382-6	2018	Genistein also decreased the expression of TNF-alpha and IL-6 (1.04 and 1.3 mg/day) compared with the endometriosis group, reaching level comparable to that of the control group (p &gt; 0.05).	Genistein	0-9	interleukin 6	Mus musculus	57-61
28694755-3	2017	TTH significantly decreased the production of nitric oxide (NO), prostaglandin E2 (PGE2), interleukin (IL)-6, and IL-1beta in LPS-stimulated RAW 264.7 cells.	tth	0-3	interleukin 6	Mus musculus	90-108
28404919-10	2017	In vivo studies demonstrated that paeonol inhibited SUV-induced increase of TOPK, the phosphorylation of p38, JNKs and H2AX, and the secretion of IL-6 and TNF-alpha in Babl/c mouse.	paeonol	34-41	interleukin 6	Mus musculus	146-150
28420165-12	2017	Acetazolamide could inhibit polyp formation through suppressing local/general cytokine levels, i.e., IL-6, via NRF2 activation.	Acetazolamide	0-13	interleukin 6	Mus musculus	101-105
28420165-7	2017	Moreover, the mRNA expression level of proinflammatory cytokines, such as IL-6, involved in the cell proliferation was decreased in the polyp part of the acetazolamide-treated group.	Acetazolamide	154-167	interleukin 6	Mus musculus	74-78
28469769-7	2017	The transcription and expression of IFN-gamma, IL-4, IL-6, and TNF-alpha involved in inflammatory response were significantly up-regulated by rSEs at a low dose (20 ng/mL) except rSEU in vitro and in vivo.	rses	142-146	interleukin 6	Mus musculus	53-57
28397806-5	2017	Our experimental results demonstrated that corylin inhibited the production of TNF-alpha, IL-6 and NO by both LPS-activated RAW 264.7 cells and LPS-activated murine peritoneal macrophages.	corylin	43-50	interleukin 6	Mus musculus	90-94
28402851-2	2017	Here, we find that central application of IL-6 in mice suppresses feeding and improves glucose tolerance.	Glucose	87-94	interleukin 6	Mus musculus	42-46
28394269-5	2017	We showed that GA could suppress the expression of pro-inflammatory mediators (cyclooxygenase-2 (COX-2) and nitric oxide (NO) and pro-inflammatory cytokines (tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta) in LPS-treated mouse peritoneal macrophages, mouse macrophage RAW264.7 cells, and differentiated human monocytes (dTHP-1) in vitro.	ginkgolide A	15-17	interleukin 6	Mus musculus	193-211
28394269-7	2017	Consistently, GA was also shown to inhibit the LPS-stimulated release of TNF-alpha and IL-6 in mice.	ginkgolide A	14-16	interleukin 6	Mus musculus	87-91
28388962-9	2017	Concomitantly, CPT-11 enhanced tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels and inducible nitric oxide synthase (iNOS) gene expression, associated with an increase in the total number macrophages (positive cells for ionized calcium-binding adapter molecule, Iba-1) and degranulated mast cells in the small intestine segments and caused significant weight loss.	Irinotecan	15-21	interleukin 6	Mus musculus	90-94
28387378-5	2017	In fact, we demonstrate that TNFalpha-, IL-1alpha/beta- or IL-6-deficient mice as well as wild-type mice administered a TNFalpha-inhibitor were significantly resistant to development of osteonecrosis accompanying infectious myelitis, even under bisphosphonate treatment.	Diphosphonates	245-259	interleukin 6	Mus musculus	59-63
28388962-9	2017	Concomitantly, CPT-11 enhanced tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels and inducible nitric oxide synthase (iNOS) gene expression, associated with an increase in the total number macrophages (positive cells for ionized calcium-binding adapter molecule, Iba-1) and degranulated mast cells in the small intestine segments and caused significant weight loss.	Irinotecan	15-21	interleukin 6	Mus musculus	75-88
28423560-7	2017	LPS-induced TNF-alpha, IL-6 and IL-1beta production were markedly suppressed by treatment of geraniin.	Geraniin	93-101	interleukin 6	Mus musculus	23-27
28383063-7	2017	In addition, RA resulted in the reduction of the inflammatory-related cytokines, such as IL-6, IL-1beta, and IL-22, and protein levels of COX-2 and iNOS in mice with DSS-induced colitis.	rosmarinic acid	13-15	interleukin 6	Mus musculus	89-93
28383063-7	2017	In addition, RA resulted in the reduction of the inflammatory-related cytokines, such as IL-6, IL-1beta, and IL-22, and protein levels of COX-2 and iNOS in mice with DSS-induced colitis.	dss	166-169	interleukin 6	Mus musculus	89-93
28367982-5	2017	Okanin significantly suppressed LPS-induced iNOS expression and also inhibited IL-6 and TNF-alpha production and mRNA expression in LPS-stimulated BV-2 cells.	okanin	0-6	interleukin 6	Mus musculus	79-83
28245985-4	2017	We demonstrated that 4-PBA, which further prevented the activation of the NF-kappaB pathway, decreased the release of the pro-inflammatory mediators IL-1beta, TNF-alpha and IL-6, significantly inhibited LPS-activated ER stress.	4-phenylbutyric acid	21-26	interleukin 6	Mus musculus	173-177
28369137-14	2017	Furthermore, proinflammatory cytokines such as IL-6, IL-8, IL-1beta were all remarkably inhibited after atorvastatin treatment.	Atorvastatin	104-116	interleukin 6	Mus musculus	47-51
28319548-13	2017	Moreover, it attenuated the production of the neuroinflammatory mediators interleukin (IL)-1beta and IL-6 (normalized sevoflurane versus sevoflurane+Tan IIA [20 mg/kg]: IL-1beta: 0.75, 0.47-1.0; P &lt; .0001; IL-6: 0.66, 0.35-0.97; P &lt; .0001; n = 10 per group).	Sevoflurane	118-129	interleukin 6	Mus musculus	101-105
28373694-4	2017	We demonstrated that TM6 (2.5, 5 and 10 nmol/g) alleviated the histological changes in the lung tissues as well as myeloperoxtidase (MPO) activity, lung W/D ratio, the production of TNF-alpha, IL-1beta and IL-6 induced by LPS.	tm6	21-24	interleukin 6	Mus musculus	206-210
28100505-4	2017	A decreased expression of the inflammatory cytokines IFN-gamma, IL-17, IL-6, and TNF-alpha was also observed in the kidney of LLDT-8 treated MRL/lpr mice.	5alpha-Hydroxytriptolide	126-132	interleukin 6	Mus musculus	71-75
28100505-7	2017	In the human proximal tubule epithelial cell line and mouse mesangial cell line, consistent with our in vivo experimental results, LLDT-8 suppressed the expression of related chemokines and IL-6.	5alpha-Hydroxytriptolide	131-137	interleukin 6	Mus musculus	190-194
28122718-3	2017	Therefore, the aim of this study was to investigate the role of skeletal muscle IL-6 on hepatic glucose regulation and substrate choice during prolonged exercise.	Glucose	96-103	interleukin 6	Mus musculus	80-84
28122718-6	2017	Hepatic glycogen was higher in IL-6 MKO mice than control mice at rest, but decreased similarly during exercise in the two genotypes, and hepatic glucose content was lower in IL-6 MKO than control mice at 120 min of exercise.	Glycogen	8-16	interleukin 6	Mus musculus	31-35
28122718-8	2017	Furthermore, IL-6 MKO mice had higher hepatic pyruvate dehydrogenase (PDH)Ser232 and PDHSer300 phosphorylation than control mice at rest.	pdhser300	85-94	interleukin 6	Mus musculus	13-17
27789465-8	2017	Systemic blockade of IL-6 by MR16-1 alleviated DMM-induced OA cartilage lesions, impaired the osteophyte formation and the extent of synovitis.	dimethylmyleran	47-50	interleukin 6	Mus musculus	21-25
28087471-0	2017	IL-6 promotes M2 macrophage polarization by modulating purinergic signaling and regulates the lethal release of nitric oxide during Trypanosoma cruzi infection.	Nitric Oxide	112-124	interleukin 6	Mus musculus	0-4
27789465-12	2017	Systemic blockade of IL-6 or STAT-3 can alleviate DMM-induced OA in mice.	dimethylmyleran	50-53	interleukin 6	Mus musculus	21-25
28131916-5	2017	The mitochondria-targeted antioxidant plastoquinonyl decyltriphenylphosphonium (SkQ1) which also catalyzes FFA-dependent uncoupling revealed similar protective effects and downregulated expression of the NFkappaB-regulated genes (VCAM1, ICAM1, MCP1, and IL-6) involved in the inflammatory response of endothelium in aortas of the TNF-treated mice.	decyltriphenylphosphonium	53-78	interleukin 6	Mus musculus	254-258
27585815-9	2017	In contrast, estradiol administration to lupus-prone female mice increased the expression of co-stimulatory molecules, enhanced the immunogenicity and produced large amounts of IL-6, IL-12 and TNF-alpha by bone marrow-derived DCs.	Estradiol	13-22	interleukin 6	Mus musculus	177-181
28177770-8	2017	Using both pharmacological and molecular inhibitor approaches, we further identified that IL-6-mediated activation of NF-kappaB-iNOS-NO-ROS signaling in activated HSCs plays a critical role in BMOL-cell-mediated apoptosis of activated HSCs.	ros	136-139	interleukin 6	Mus musculus	90-94
28122300-4	2017	5mg/kg Y-27632 was intravenously injected to inhibit the ROCK expressions.Y-27632 significantly decreased the serum levels of interleukin-6 (IL-6), IL-1beta, tumor necrosis factor-alpha (TNF-alpha) and increased IL-10 level in serum of MRL/lpr mice.	Y 27632	7-14	interleukin 6	Mus musculus	126-139
28223218-5	2017	We also demonstrated that OMZ-SPT can inhibit expression of the inflammatory cytokines tumor necrosis factor-alpha, interleukin-1beta and interleukin-6 by ELISA in mice suffering from LPS-induced ALI and a mouse macrophage line (RAW264.7 cells).	omz-spt	26-33	interleukin 6	Mus musculus	138-151
28095354-13	2017	The paw tissue immunochemistry assay demonstrated the IL-6 protein level changes in carrageenan-induced paw edema model under heliangin administration.	Carrageenan	84-95	interleukin 6	Mus musculus	54-58
28122300-4	2017	5mg/kg Y-27632 was intravenously injected to inhibit the ROCK expressions.Y-27632 significantly decreased the serum levels of interleukin-6 (IL-6), IL-1beta, tumor necrosis factor-alpha (TNF-alpha) and increased IL-10 level in serum of MRL/lpr mice.	Y 27632	7-14	interleukin 6	Mus musculus	141-145
28122300-4	2017	5mg/kg Y-27632 was intravenously injected to inhibit the ROCK expressions.Y-27632 significantly decreased the serum levels of interleukin-6 (IL-6), IL-1beta, tumor necrosis factor-alpha (TNF-alpha) and increased IL-10 level in serum of MRL/lpr mice.	Y 27632	74-81	interleukin 6	Mus musculus	126-139
28122300-4	2017	5mg/kg Y-27632 was intravenously injected to inhibit the ROCK expressions.Y-27632 significantly decreased the serum levels of interleukin-6 (IL-6), IL-1beta, tumor necrosis factor-alpha (TNF-alpha) and increased IL-10 level in serum of MRL/lpr mice.	Y 27632	74-81	interleukin 6	Mus musculus	141-145
26833290-7	2017	RESULTS: DSS induced significant body weight loss, morphological changes in the colon, increased myeloperoxidase (MPO) activity and up-regulated colonic mRNA expression of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-12 and monocyte chemoattractant protein (MCP)-1, as well as associated histological changes.	dss	9-12	interleukin 6	Mus musculus	207-225
26833290-9	2017	However, the novel PF, but not standard PF, completely suppressed TNF-alpha, IL-6 and IL-8 levels from cultured biopsies.	pf	19-21	interleukin 6	Mus musculus	77-81
27679493-8	2017	Genetic deletion of the miR-223 gene exacerbated ethanol-induced hepatic injury, neutrophil infiltration, reactive oxygen species (ROS) and upregulated hepatic expression of interleukin (IL)-6 and phagocytic oxidase (phox) p47phox.	Ethanol	49-56	interleukin 6	Mus musculus	174-192
28084562-3	2017	DBE significantly stimulated the production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by both J774.1 cells and peritoneal macrophages by enhancing the cytokine gene expression levels.	Ethylene Dibromide	0-3	interleukin 6	Mus musculus	91-104
28084562-3	2017	DBE significantly stimulated the production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by both J774.1 cells and peritoneal macrophages by enhancing the cytokine gene expression levels.	Ethylene Dibromide	0-3	interleukin 6	Mus musculus	106-110
28084562-7	2017	TNF-alpha production enhanced by DBE was partially inhibited by treatment with TLR4 inhibitor TAK-242, whereas IL-6 production enhanced by DBE was almost inhibited.	Ethylene Dibromide	139-142	interleukin 6	Mus musculus	111-115
27873354-6	2017	Analysis of inflammatory cytokines indicated that esculin pretreatment markedly suppressed the increased expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in ethanol-treated mice.	Ethanol	187-194	interleukin 6	Mus musculus	163-176
27873354-6	2017	Analysis of inflammatory cytokines indicated that esculin pretreatment markedly suppressed the increased expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in ethanol-treated mice.	Ethanol	187-194	interleukin 6	Mus musculus	178-182
28192731-5	2017	Isotrifoliol reduced LPS-mediated induction of mRNA expression of inducible nitric-oxide synthase (iNOS), cyclooxygenase-2 (COX-2), interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha (TNFalpha), and chemokines, such as chemokine (C-C motif) ligand (CCL) 2, CCL3, and CCL4.	isotrifoliol	0-12	interleukin 6	Mus musculus	156-160
28213267-5	2017	Then, we found that CUMS significantly caused interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) up-regulation, microglia, NF-kappaB signaling and NLRP3 inflammasome activation in the prefrontal cortex.	cums	20-24	interleukin 6	Mus musculus	76-89
28213267-5	2017	Then, we found that CUMS significantly caused interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) up-regulation, microglia, NF-kappaB signaling and NLRP3 inflammasome activation in the prefrontal cortex.	cums	20-24	interleukin 6	Mus musculus	91-95
28213268-10	2017	We found that fisetin inhibited IL-1beta-induced expression of NO, PGE2, TNF-alpha, IL-6, COX-2, iNOS, MMP-3, MMP-13, ADAMTS-5.	fisetin	14-21	interleukin 6	Mus musculus	84-88
28219839-5	2017	In addition, sinigrin significantly suppressed the production of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 via suppression of MAPK phosphorylation and nuclear factor-kappa B (NF-kappaB) activity.	sinigrin	13-21	interleukin 6	Mus musculus	103-121
28204823-9	2017	Dibutyryl cAMP, a permeable analogue of cAMP, which suppressed the TNF-alpha-induced IkappaB phosphorylation, amplified the IL-6 release.	Cyclic AMP	10-14	interleukin 6	Mus musculus	124-128
28204823-5	2017	Wedelolactone, an inhibitor of IkappaB kinase, amplified the TNF-alpha-induced IL-6 release.	wedelolactone	0-13	interleukin 6	Mus musculus	79-83
28204823-9	2017	Dibutyryl cAMP, a permeable analogue of cAMP, which suppressed the TNF-alpha-induced IkappaB phosphorylation, amplified the IL-6 release.	Cyclic AMP	40-44	interleukin 6	Mus musculus	124-128
28204823-8	2017	H-89, an inhibitor of protein kinase A, significantly suppressed the enhancement by GLP-1 of TNF-alpha-stimulated IL-6 release.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	0-4	interleukin 6	Mus musculus	114-118
28170292-6	2017	In addition, pretreatment with NAH attenuated intestinal injury, inhibited neutrophil infiltration and suppressed the production of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6) in the intestine during sepsis, and it also significantly reduced the elevation of inflammatory cytokines in the serum 24 hr after CLP.	Niacin	31-34	interleukin 6	Mus musculus	208-221
28204823-9	2017	Dibutyryl cAMP, a permeable analogue of cAMP, which suppressed the TNF-alpha-induced IkappaB phosphorylation, amplified the IL-6 release.	dibutyryl	0-9	interleukin 6	Mus musculus	124-128
28406731-5	2017	The group supplemented with high concentrations of hyaluronic acid appeared significantly better than control group for collagen, matrix metalloproteinase 1, interleukin (IL)-1beta, and IL-6 assay.	Hyaluronic Acid	51-66	interleukin 6	Mus musculus	186-190
28406732-4	2017	We found that BAB decreased the concentrations of LPS and various circulating proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 in mice with HD-induced obesity.	bab	14-17	interleukin 6	Mus musculus	175-179
28259984-2	2017	Previous evidence has indicated that HIF regulates angiogenesis-osteogenesis coupling in bone metabolism, and it has previously been reported that mimosine inhibits prostaglandin (PG)F2alpha-induced osteoprotegerin (OPG) synthesis without affecting interleukin-6 (IL-6) production in osteoblast-like MC3T3-E1 cells.	Mimosine	147-155	interleukin 6	Mus musculus	249-262
27796565-12	2017	Pretreatment with JTW (4.2 and 8.4 g/kg) or fluoxetine (20 mg/kg) effectively attenuated LPS-induced upregulations of the serum TNF-alpha and IL-6 contents and JTW (4.2 and 8.4 g/kg) or fluoxetine (20 mg/kg) effectively increased the contents of 5-HT and NE compared with LPS-treated group.	Fluoxetine	44-54	interleukin 6	Mus musculus	142-146
28259984-2	2017	Previous evidence has indicated that HIF regulates angiogenesis-osteogenesis coupling in bone metabolism, and it has previously been reported that mimosine inhibits prostaglandin (PG)F2alpha-induced osteoprotegerin (OPG) synthesis without affecting interleukin-6 (IL-6) production in osteoblast-like MC3T3-E1 cells.	Mimosine	147-155	interleukin 6	Mus musculus	264-268
28259984-2	2017	Previous evidence has indicated that HIF regulates angiogenesis-osteogenesis coupling in bone metabolism, and it has previously been reported that mimosine inhibits prostaglandin (PG)F2alpha-induced osteoprotegerin (OPG) synthesis without affecting interleukin-6 (IL-6) production in osteoblast-like MC3T3-E1 cells.	Dinoprost	165-190	interleukin 6	Mus musculus	264-268
28259984-3	2017	In addition, PGE1 has been demonstrated to induce OPG synthesis via activation of p38 mitogen-activated protein (MAP) kinase and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in these cells, and PGE1 stimulates IL-6 production via the activation of protein kinase A.	Alprostadil	13-17	interleukin 6	Mus musculus	232-236
28259984-4	2017	In the present study, the effects of mimosine on the PGE1-stimulated synthesis of OPG and IL-6 were investigated in osteoblast-like MC3T3-E1 cells.	Alprostadil	53-57	interleukin 6	Mus musculus	90-94
28364027-11	2017	Upregulation of the proinflammatory citochines TNF-a and IL6 and an increased expression of NF-kB and MuRF-1 were observed in CCl4 mice.	Carbon Tetrachloride	126-130	interleukin 6	Mus musculus	57-60
28224333-7	2017	This study demonstrated that grossamide significantly inhibited the secretion of pro-inflammatory mediators such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha), and decreased the level of LPS-mediated IL-6 and TNF-alpha mRNA.	GROSSAMIDE	29-39	interleukin 6	Mus musculus	116-129
28224333-7	2017	This study demonstrated that grossamide significantly inhibited the secretion of pro-inflammatory mediators such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha), and decreased the level of LPS-mediated IL-6 and TNF-alpha mRNA.	GROSSAMIDE	29-39	interleukin 6	Mus musculus	131-135
28224333-7	2017	This study demonstrated that grossamide significantly inhibited the secretion of pro-inflammatory mediators such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha), and decreased the level of LPS-mediated IL-6 and TNF-alpha mRNA.	GROSSAMIDE	29-39	interleukin 6	Mus musculus	222-226
27997528-8	2017	Furthermore, interleukin (IL)-6 mRNA was markedly attenuated by IVIG+losartan.	Losartan	69-77	interleukin 6	Mus musculus	13-31
27737478-5	2017	In addition, we examined the effect of nortrachelogenin on carrageenan-induced paw inflammation in mice.Interestingly, nortrachelogenin reduced carrageenan-induced paw inflammation in mice and inhibited the production of inflammatory factors nitric oxide, prostaglandin E2, interleukin-6, and monocyte chemotactic protein-1 in J774 macrophages in vitro.	nortrachelogenin	119-135	interleukin 6	Mus musculus	274-287
28539710-10	2017	SUMMARY: KOTMIN13 decrease the production of No, PGE2, and proinflammatory cytokine (TNF- , IL-1beta,IL-6).KOTMIN13 Suppressed the degradation of NF-kbeta and IKbetaalpha and the phosorylation of MAP Kinases.Topical application of KOTMIN13 reduced mouse ear edema.Oral administration of KOTMIN13 decreased carrageenan-induced paw edema.	Carrageenan	306-317	interleukin 6	Mus musculus	101-105
27648694-8	2017	Strikingly, CLP mice treated with GdCl3 were protected against liver injury as evidenced by decreased LSECs defenestration and damage, MPO, ALT and AST activities, liver tissue damage, and inflammatory cytokines TNF-alpha, IL-6 and IL-1beta, and chemokines MCP-1 and MIP-2alpha.	gadolinium chloride	34-39	interleukin 6	Mus musculus	223-227
27943364-8	2017	Pretreatment with butyrate led to significant attenuation of the LPS-induced elevation of TNF-alpha, IL-6 and IL-1beta levels.	Butyrates	18-26	interleukin 6	Mus musculus	101-105
27943364-10	2017	Pretreatment of RAW 264.7 cells with butyrate led to downregulation of LPS-induced pro-inflammatory mediators, IL-6 and IL-1beta, but did not affect the level of TNF-alpha, and increased IL-10 (P &lt; 0.01).	Butyrates	37-45	interleukin 6	Mus musculus	111-115
28395719-10	2017	Results In the alphacalcidol combined with dexamethasone group, IL-1beta, IL-6, TNF-alpha and TGF-beta1, cell count, Sazpiel score, Hyp values were lower than those in the other groups except for the control group, and the alveolar inflammation and fibrin deposition were also lower than those in the other groups except for the control group.	alfacalcidol	15-28	interleukin 6	Mus musculus	74-78
29260020-8	2017	The results suggest that acrolein becomes a trigger for the production of IL-6 and CRP, as previously observed in a mouse model of stroke and in cell culture systems.	Acrolein	25-33	interleukin 6	Mus musculus	74-86
28400700-8	2017	The p38 inhibitor (SB203580) attenuated RBP4-stimulated vascular cell adhesion molecule 1 (VCAM-1), intracellular adhesion molecule 1 (ICAM-1), monocyte chemoattractant protein (MCP-1), and interleukin 6 (IL-6) production, while the JNK inhibitor (SP600125) reduced RBP4-stimulated sICAM-1, endothelial cell selectin (E-selectin), and MCP-1 production.	SB 203580	19-27	interleukin 6	Mus musculus	190-203
28400700-8	2017	The p38 inhibitor (SB203580) attenuated RBP4-stimulated vascular cell adhesion molecule 1 (VCAM-1), intracellular adhesion molecule 1 (ICAM-1), monocyte chemoattractant protein (MCP-1), and interleukin 6 (IL-6) production, while the JNK inhibitor (SP600125) reduced RBP4-stimulated sICAM-1, endothelial cell selectin (E-selectin), and MCP-1 production.	SB 203580	19-27	interleukin 6	Mus musculus	205-209
28333137-8	2017	Adoptive transfer of rapamycin-treated MDSCs also downregulated the serum levels of IL-1beta, IL-6 and IFN-gamma and upregulated the serum levels of TGF-beta1 compared with the IR group and PBS-treated MDSC group.	Sirolimus	21-30	interleukin 6	Mus musculus	94-98
28292183-6	2017	N-Docosahexaenoyl dopamine significantly suppressed the production of nitric oxide (NO), the cytokine interleukin-6 (IL-6), and the chemokines macrophage-inflammatory protein-3alpha (CCL20) and monocyte chemoattractant protein-1 (MCP-1), whereas its parent compounds, dopamine and DHA, were ineffective.	Dopamine	18-26	interleukin 6	Mus musculus	102-115
28352288-6	2017	RESULTS: Exposure to elevated CO2 significantly increased the expression of pro-inflammatory markers, IL-6 and KC, in BAL fluid as compared to dust exposure alone.	N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide	30-33	interleukin 6	Mus musculus	102-113
28373844-8	2017	Moreover, we found that ketamine increased the hippocampal levels of IL-6 and IL-1beta after single, multiple and long-term administration in a dose-dependent manner.	Ketamine	24-32	interleukin 6	Mus musculus	69-73
28373844-12	2017	Our results suggest that the alterations in the levels of inflammatory cytokines IL-6, IL-1beta, and TNF-alpha may be involved in the neurotoxicity of ketamine.	Ketamine	151-159	interleukin 6	Mus musculus	81-85
28292183-6	2017	N-Docosahexaenoyl dopamine significantly suppressed the production of nitric oxide (NO), the cytokine interleukin-6 (IL-6), and the chemokines macrophage-inflammatory protein-3alpha (CCL20) and monocyte chemoattractant protein-1 (MCP-1), whereas its parent compounds, dopamine and DHA, were ineffective.	N-docosahexaenoyl dopamine	0-26	interleukin 6	Mus musculus	102-115
28292183-6	2017	N-Docosahexaenoyl dopamine significantly suppressed the production of nitric oxide (NO), the cytokine interleukin-6 (IL-6), and the chemokines macrophage-inflammatory protein-3alpha (CCL20) and monocyte chemoattractant protein-1 (MCP-1), whereas its parent compounds, dopamine and DHA, were ineffective.	Dopamine	18-26	interleukin 6	Mus musculus	117-121
28292183-6	2017	N-Docosahexaenoyl dopamine significantly suppressed the production of nitric oxide (NO), the cytokine interleukin-6 (IL-6), and the chemokines macrophage-inflammatory protein-3alpha (CCL20) and monocyte chemoattractant protein-1 (MCP-1), whereas its parent compounds, dopamine and DHA, were ineffective.	N-docosahexaenoyl dopamine	0-26	interleukin 6	Mus musculus	117-121
28119078-4	2017	In RAW264.7 cells, diazinon induced the production of TNF-alpha and IL-6.	Diazinon	19-27	interleukin 6	Mus musculus	68-72
28386326-7	2017	We found that Ach inhibited LPS-induced IL-1beta and IL-6 elevation and promoted IL-4 and IL-10 production and that knockdown of the alpha7 nAChR abolished these effects of Ach.	Acetylcholine	14-17	interleukin 6	Mus musculus	53-57
28069457-10	2017	Further, CUS elevated the levels of oxidative stress markers (TBARS, nitric oxide), lowered antioxidants (total thiol, catalase), enhanced expression of pro-inflammatory cytokines (IL-6, TNF-alpha, IL-1beta and COX-2) in the hippocampus and damaged hippocampal neurons.	cus	9-12	interleukin 6	Mus musculus	181-185
28119078-6	2017	ERK and p38, but not JNK and p65 were involved in diazinon-induced IL-6 expression in RAW264.7 cells.	Diazinon	50-58	interleukin 6	Mus musculus	67-71
26061710-8	2017	Moreover, pimozide reversed the stem-like cell tumorigenic phenotypes induced by IL-6 treatment in HCC cells.	Pimozide	10-18	interleukin 6	Mus musculus	81-85
28153725-7	2017	Pretreatment with AMG9810 or CPZ significantly suppressed the release of IL-6, IL-1beta and IL-18, and COX-2 expression, whereas SB366791 and BCTC were less effective.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	18-25	interleukin 6	Mus musculus	73-77
28153725-7	2017	Pretreatment with AMG9810 or CPZ significantly suppressed the release of IL-6, IL-1beta and IL-18, and COX-2 expression, whereas SB366791 and BCTC were less effective.	capsazepine	29-32	interleukin 6	Mus musculus	73-77
28316773-6	2017	We co-administered the hormonally active form of vitamin D, 1alpha,25 dihydroxy vitamin D3 (1,25OHD), simultaneously with poly(I:C) and examined (i) social interaction, stereotyped behavior, emotional learning and memory, and innate anxiety-like behavior in juveniles and (ii) the levels of the pro-inflammatory cytokines IL-1beta, IL-6 and TNF-alpha in maternal plasma and fetal brains.	Vitamin D	49-58	interleukin 6	Mus musculus	332-336
28264025-10	2017	Serum MCP-1 levels were elevated in the anti-TNF group relative to the CTLA4 Ig and PBS groups, whereas IL-6 levels were higher in PBS controls than in the other two groups.	Lead	131-134	interleukin 6	Mus musculus	104-108
28096466-8	2017	We found that GRAB phosphorylation at Ser-169 was required for the secretion of the promyogenic cytokine interleukin 6 (IL-6).	Serine	38-41	interleukin 6	Mus musculus	105-118
28259154-10	2017	Furthermore, CTEtOH (1.0 g/kg) reduced the level of IL-6.	ctetoh	13-19	interleukin 6	Mus musculus	52-56
28259175-9	2017	The levels of TNF-alpha, IL-6, and MCP-1 in response to LPS were significantly increased in the PFC of PTN-Tg mice compared to that of WT mice.	Thioguanine	107-109	interleukin 6	Mus musculus	25-29
28096466-8	2017	We found that GRAB phosphorylation at Ser-169 was required for the secretion of the promyogenic cytokine interleukin 6 (IL-6).	Serine	38-41	interleukin 6	Mus musculus	120-124
28424540-4	2017	MC4 showed stronger inhibitory effects than FK866 on CLP-induced mortality, serum tumor necrosis factor alpha (TNFalpha) levels, pulmonary myeloperoxidase activity, alveolar injury, and interleukin 6 and interleukin1beta messenger RNA levels.	SCHEMBL639538	0-3	interleukin 6	Mus musculus	186-199
27884587-11	2017	The overexpression of proinflammatory factors, TNF-alpha, IL-6 and LTB4, in heart tissues induced by sepsis was significantly alleviated by butyrate pretreatment (P&lt;0.01).	Butyrates	140-148	interleukin 6	Mus musculus	58-62
28401002-8	2017	Furthermore, pharmacological inhibition of the activation of the IL-6/STAT3 pathway enhanced hepatic fibrosis and promoted DEN plus CCl4-induced carcinogenesis in Gpr110-/- mice.	Diethylnitrosamine	123-126	interleukin 6	Mus musculus	65-69
28401002-8	2017	Furthermore, pharmacological inhibition of the activation of the IL-6/STAT3 pathway enhanced hepatic fibrosis and promoted DEN plus CCl4-induced carcinogenesis in Gpr110-/- mice.	Carbon Tetrachloride	132-136	interleukin 6	Mus musculus	65-69
28007523-5	2017	The optimal dose of pinocembrin (5mg/kg) suppressed microglial activation as evidenced by decreases in CD68-positive microglia and reduced proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6.	pinocembrin	20-31	interleukin 6	Mus musculus	228-232
28028037-2	2017	Interleukin (IL)-6 has been proposed to be released from muscle with concomitant effects on both glucose and fat utilization.	Glucose	97-104	interleukin 6	Mus musculus	0-18
28068635-6	2017	Interestingly, the IP6 was found to down-regulate the mRNA expression of tumor necrosis factor (TNF)-alpha, Interleukin (IL)-1beta, and IL-6 in iron overloaded liver tissues.	Phytic Acid	19-22	interleukin 6	Mus musculus	136-140
28068635-6	2017	Interestingly, the IP6 was found to down-regulate the mRNA expression of tumor necrosis factor (TNF)-alpha, Interleukin (IL)-1beta, and IL-6 in iron overloaded liver tissues.	Iron	144-148	interleukin 6	Mus musculus	136-140
27800648-0	2017	Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice.	Docosahexaenoic Acids	39-55	interleukin 6	Mus musculus	97-101
28096316-11	2017	BAY 11-7082 reduced pNF-kappaB, NLRP3, tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and IL-1beta expression, blunted the phosphorylation of signal transducer and activators of transcription 3 (STAT3) and decreased IL-23 levels.	3-(4-methylphenylsulfonyl)-2-propenenitrile	0-11	interleukin 6	Mus musculus	81-99
27800648-0	2017	Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice.	Metformin	60-69	interleukin 6	Mus musculus	97-101
28298895-12	2017	Further, Dex also inhibited mRNA expression of interleukin-6 and NADPH oxidase 4.	Dexmedetomidine	9-12	interleukin 6	Mus musculus	47-60
28484748-3	2017	Tangeretin decreased nitric oxide production and the expression of interleukin (IL)-6, IL-1beta, tumor necrosis factor-alpha, inducible nitric oxide synthase, and cyclooxygenase-2 in a coculture of 3T3-L1 adipocytes and RAW 264.7 cells.	tangeretin	0-10	interleukin 6	Mus musculus	67-85
28450905-3	2017	Administration of BPA to male CD-1 mice for 10 days caused a significant increase in the number of cells immunopositive for interleukin 6 and tumor necrosis factor-alpha, pro-inflammatory cytokines that mediate the hepatic inflammatory response.	bisphenol A	18-21	interleukin 6	Mus musculus	124-169
27979980-1	2017	Interleukin-6 (IL-6) is released from skeletal muscle cells and induced by exercise, heat, catecholamine, glucose, lipopolysaccharide, reactive oxygen species, and inflammation.	Catecholamines	91-104	interleukin 6	Mus musculus	0-13
27998743-5	2017	In addition, LPS-induced production of pro-inflammatory cytokines such as interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) was obviously reduced by Amp.	ampelopsin	173-176	interleukin 6	Mus musculus	98-102
27979980-1	2017	Interleukin-6 (IL-6) is released from skeletal muscle cells and induced by exercise, heat, catecholamine, glucose, lipopolysaccharide, reactive oxygen species, and inflammation.	Catecholamines	91-104	interleukin 6	Mus musculus	15-19
27979980-1	2017	Interleukin-6 (IL-6) is released from skeletal muscle cells and induced by exercise, heat, catecholamine, glucose, lipopolysaccharide, reactive oxygen species, and inflammation.	Glucose	106-113	interleukin 6	Mus musculus	0-13
27979980-1	2017	Interleukin-6 (IL-6) is released from skeletal muscle cells and induced by exercise, heat, catecholamine, glucose, lipopolysaccharide, reactive oxygen species, and inflammation.	Glucose	106-113	interleukin 6	Mus musculus	15-19
27979980-1	2017	Interleukin-6 (IL-6) is released from skeletal muscle cells and induced by exercise, heat, catecholamine, glucose, lipopolysaccharide, reactive oxygen species, and inflammation.	Reactive Oxygen Species	135-158	interleukin 6	Mus musculus	0-13
27979980-1	2017	Interleukin-6 (IL-6) is released from skeletal muscle cells and induced by exercise, heat, catecholamine, glucose, lipopolysaccharide, reactive oxygen species, and inflammation.	Reactive Oxygen Species	135-158	interleukin 6	Mus musculus	15-19
27979980-9	2017	Intracellular calcium flux and IL-6 mRNA expression were increased by the TRPV1 agonists capsaicin and N-arachidonoyldopamine and decreased by the TRPV1 antagonists AMG9810 and SB366791 and siRNA-mediated knockdown of TRPV1.	Capsaicin	89-98	interleukin 6	Mus musculus	31-35
27979980-9	2017	Intracellular calcium flux and IL-6 mRNA expression were increased by the TRPV1 agonists capsaicin and N-arachidonoyldopamine and decreased by the TRPV1 antagonists AMG9810 and SB366791 and siRNA-mediated knockdown of TRPV1.	arachidonyl dopamine	103-125	interleukin 6	Mus musculus	31-35
27979980-12	2017	PKC inhibitors, Go6983 and staurosporine, CREB inhibitors, curcumin and naphthol AS-E, and knockdown of CREB suppressed the heat-induced increases in IL-6.	2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide	16-22	interleukin 6	Mus musculus	150-154
27979980-12	2017	PKC inhibitors, Go6983 and staurosporine, CREB inhibitors, curcumin and naphthol AS-E, and knockdown of CREB suppressed the heat-induced increases in IL-6.	Staurosporine	27-40	interleukin 6	Mus musculus	150-154
27979980-12	2017	PKC inhibitors, Go6983 and staurosporine, CREB inhibitors, curcumin and naphthol AS-E, and knockdown of CREB suppressed the heat-induced increases in IL-6.	Naphthols	72-80	interleukin 6	Mus musculus	150-154
27979980-13	2017	These results indicate that heat increases IL-6 in skeletal muscle cells through the TRPV1, PKC, and CREB signal transduction pathway.NEW &amp; NOTEWORTHY Heat increases the release of interleukin-6 (IL-6) from skeletal muscle cells.	Adenosine Monophosphate	139-142	interleukin 6	Mus musculus	43-47
27979980-13	2017	These results indicate that heat increases IL-6 in skeletal muscle cells through the TRPV1, PKC, and CREB signal transduction pathway.NEW &amp; NOTEWORTHY Heat increases the release of interleukin-6 (IL-6) from skeletal muscle cells.	Adenosine Monophosphate	139-142	interleukin 6	Mus musculus	185-198
27979980-13	2017	These results indicate that heat increases IL-6 in skeletal muscle cells through the TRPV1, PKC, and CREB signal transduction pathway.NEW &amp; NOTEWORTHY Heat increases the release of interleukin-6 (IL-6) from skeletal muscle cells.	Adenosine Monophosphate	139-142	interleukin 6	Mus musculus	200-204
28302448-9	2017	Furtherly, the levels of PGE2, IL-17a and IL-6, were found to have decreased in aconitine treated mice.	Aconitine	80-89	interleukin 6	Mus musculus	42-46
27383524-4	2017	RESULTS: Tunicamycin not only induced ER stress in mouse bronchial epithelial cells, but also increased expression of inflammation indicators such as IL-6, IL-8, and TNF-alpha via PERK-ATF4-CHOP signaling.	Tunicamycin	9-20	interleukin 6	Mus musculus	150-154
26852411-10	2017	SUC also suppressed striatal astroglial activation and increased interleukin-6 levels in MPTP-intoxicated mice.	succinobucol	0-3	interleukin 6	Mus musculus	65-78
28400838-5	2017	HemoHIM reduced the inflammatory cell count and levels of tumor necrosis factor receptor (TNF)-alpha, interleukin (IL)-6 and IL-1beta in the broncho-alveolar lavage fluid (BALF) induced by CS+LPS exposure.	Cesium	189-191	interleukin 6	Mus musculus	102-120
26852411-10	2017	SUC also suppressed striatal astroglial activation and increased interleukin-6 levels in MPTP-intoxicated mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	89-93	interleukin 6	Mus musculus	65-78
28138699-5	2017	The therapeutic effect of 5-ASA-SiO2 NPs was assessed based on their disease activity index (DAI), colon histopathology, myeloperoxidase (MPO) and levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	Mesalamine	26-31	interleukin 6	Mus musculus	201-214
27749006-5	2017	EVOO diets improved plasma lipid profile and reduced body weight, plasma and epididymal fat INF-gamma, IL-6 and leptin levels, and macrophage infiltration.	evoo	0-4	interleukin 6	Mus musculus	92-107
28138699-10	2017	Expression of IL-6 and TNF-alpha mRNA in colonic mucosa in the normal dosage, high dosage and 5-ASA-SiO2 NP group was significantly lower than that in the model group.	Mesalamine	94-99	interleukin 6	Mus musculus	14-18
28138699-5	2017	The therapeutic effect of 5-ASA-SiO2 NPs was assessed based on their disease activity index (DAI), colon histopathology, myeloperoxidase (MPO) and levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	Mesalamine	26-31	interleukin 6	Mus musculus	216-220
28138699-10	2017	Expression of IL-6 and TNF-alpha mRNA in colonic mucosa in the normal dosage, high dosage and 5-ASA-SiO2 NP group was significantly lower than that in the model group.	Silicon Dioxide	100-104	interleukin 6	Mus musculus	14-18
28138699-11	2017	Colonic mucosal IL-6 and TNF-alpha mRNA expression in the high dosage and 5-ASA-SiO2 NP groups was significantly lower than that in the normal dosage group (P&lt;0.05).	Mesalamine	74-79	interleukin 6	Mus musculus	16-20
28011166-6	2017	On the other hand, while STZ group showed decreased IL-6 level, it was increased in SNP group but IFN-Upsilon level increased in both the treated groups compared to control.	Streptozocin	25-28	interleukin 6	Mus musculus	52-56
28138699-11	2017	Colonic mucosal IL-6 and TNF-alpha mRNA expression in the high dosage and 5-ASA-SiO2 NP groups was significantly lower than that in the normal dosage group (P&lt;0.05).	Silicon Dioxide	80-84	interleukin 6	Mus musculus	16-20
27889490-7	2017	Cathepsin X inhibitor AMS36 significantly reduced LPS-induced production of nitric oxide, reactive oxygen species and the pro-inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha from BV2 cells.	ams36	22-27	interleukin 6	Mus musculus	149-194
28039905-5	2017	The levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha in the blood were increased in AOM + DSS-treated mice; however, those levels were reduced by UVA eye irradiation.	dss	108-111	interleukin 6	Mus musculus	14-32
28102026-7	2017	In addition, piperine inhibited B cell synthesis of interleukin (IL)-6 and IL-10 cytokines, as well as IgM, IgG2b, and IgG3 immunoglobulins.	piperine	13-21	interleukin 6	Mus musculus	52-70
28127806-3	2017	EPS suppressed LPS-induced nitric oxide, prostaglandin E2 , TNF-alpha, interleukin-6 and interleukin-1beta at production and mRNA levels in LPS-induced RAW 264.7 macrophages.	eps	0-3	interleukin 6	Mus musculus	71-84
28293084-9	2017	Inflammatory factors were assessed, and the results showed that the DSS + HRW group exhibited significantly reduced levels of TNF-alpha, IL-6 and IL-1beta compared with the DSS group (P &lt; 0.05).	Dextran Sulfate	68-71	interleukin 6	Mus musculus	137-141
27974241-4	2017	The A2BAR agonist 2-[[6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]-2-pyridinyl]thio]-acetamide (BAY60-6583) stimulated IL-6 increase under normoxia and hypoxia, in a dose- and time-dependent way.	BAY 60-6583	18-102	interleukin 6	Mus musculus	127-131
28275108-8	2017	Offspring of HFD dams had higher BALF cell counts, higher neutrophil percentage, greater total protein, and IL-6 in the BALF These results demonstrate that a maternal diet high in saturated fat through pregnancy and lactation plays a key role in programming adult offspring AHR.	saturated fat	180-193	interleukin 6	Mus musculus	108-112
29979844-6	2017	We found that Api did not affect splenocyte viability, butinhibited the production of pro-inflammatory cytokine IL-1beta, IL-6 and TNF-alpha, not anti-inflammatory cytokineIL-10.	Apigenin	14-17	interleukin 6	Mus musculus	122-126
28264445-6	2017	Equol inhibited the lipopolysaccharide (LPS)-induced TLR4 activation, MAPK activation, NF-kB-mediated transcription of inflammatory mediators, production of nitric oxide (NO), release of prostaglandin E2 (PGE-2), secretion of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6), in Lipopolysaccharide (LPS)-activated murine microglia cells.	Equol	0-5	interleukin 6	Mus musculus	270-283
28264445-6	2017	Equol inhibited the lipopolysaccharide (LPS)-induced TLR4 activation, MAPK activation, NF-kB-mediated transcription of inflammatory mediators, production of nitric oxide (NO), release of prostaglandin E2 (PGE-2), secretion of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6), in Lipopolysaccharide (LPS)-activated murine microglia cells.	Equol	0-5	interleukin 6	Mus musculus	285-289
28245556-6	2017	The results suggested that the oral administration of CISCFE combined with BLM could markedly prolong the life span, attenuate the BLM-induced pulmonary fibrosis, suppress the production of pro-inflammatory cytokines (interleukin-6), tumor necrosis factor-alpha, activities of myeloperoxidase, and malondiadehyde.	ciscfe	54-60	interleukin 6	Mus musculus	218-231
28723139-1	2017	We demonstrated a cytokine detection device based on gold nanoparticle modified silica optical fiber for the monitoring of locally variable cytokine interleukin-6 (IL-6) concentrations using a sandwich immunoassay scheme.	Silicon Dioxide	80-86	interleukin 6	Mus musculus	149-162
28723139-1	2017	We demonstrated a cytokine detection device based on gold nanoparticle modified silica optical fiber for the monitoring of locally variable cytokine interleukin-6 (IL-6) concentrations using a sandwich immunoassay scheme.	Silicon Dioxide	80-86	interleukin 6	Mus musculus	164-168
28723139-8	2017	The device has the linear detection range of 1-400 pg mL-1 and spatial resolution on the order of 200-450 mum, and it is capable of detecting localized IL-6 secreted by live BV2 cells following their liposaccharide stimulation.	liposaccharide	200-214	interleukin 6	Mus musculus	152-156
28027904-11	2017	In addition, TBB (4, 5, 6, 7-tetrabromo-2-benzotriazole, a pharmacological inhibitor of CK2) blocked IL-6 release in a dose-dependent manner, whereas co-treatment of cells with EsA and TBB did not have an additive effect.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	13-16	interleukin 6	Mus musculus	101-105
28027904-11	2017	In addition, TBB (4, 5, 6, 7-tetrabromo-2-benzotriazole, a pharmacological inhibitor of CK2) blocked IL-6 release in a dose-dependent manner, whereas co-treatment of cells with EsA and TBB did not have an additive effect.	4, 5, 6, 7-tetrabromo-2-benzotriazole	18-55	interleukin 6	Mus musculus	101-105
28219355-7	2017	RESULTS: In this study, we demonstrated that vaccaria hypaphorine dramatically ameliorated LPS-induced nitric oxide (NO) release and productions of proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-6, IL-10, monocyte chemoattractant protein 1 (MCP-1) and prostaglandin E2 (PGE2) in RAW 264.7 cells.	lenticin	54-65	interleukin 6	Mus musculus	255-259
28217805-12	2017	On the contrary, although wildtype MEF could also be induced into senescence by MMC treatment for 12 h or 24 h, embodied by the enlarged cell volume, increased ratios of beta-gal-positive cells (up to 71.7% and 80.2%, respectively) and enhanced expression of P21 protein, the secretion of IL-6 displayed no significant change.	Mitomycin	80-83	interleukin 6	Mus musculus	289-293
28216638-3	2017	TQ strongly inhibited the production of nitric oxide (NO) and repressed NO synthase (iNOS), tumor necrosis factor (TNF)-alpha, cyclooxygenase (COX)-2, interleukin (IL)-6, and IL-1beta expression in LPS-activated RAW264.7 cells.	thymoquinone	0-2	interleukin 6	Mus musculus	151-169
28017669-12	2017	Moreover, astaxanthin could down-regulate the expression of IL-6, IL-1beta and COX-2 in the hippocampus.	astaxanthine	10-21	interleukin 6	Mus musculus	60-64
28104349-7	2017	In vitro study, the results showed that IA inhibited production of IL-1beta, IL-6 and TNF-alpha at transcriptional and translational levels in RAW 264.7 cells induced by LPS.	lps	170-173	interleukin 6	Mus musculus	77-81
28062699-5	2017	CWA decreased IL-6 production in the serum, jejunum, and colon of EHEC-infected mice.	(4R)-4-[5-(difluoromethyl)-1H-imidazol-1-yl]-3,3-dimethyl-3,4-dihydro-1H-2-benzopyran-1-one	0-3	interleukin 6	Mus musculus	14-18
28207754-0	2017	Ascofuranone inhibits lipopolysaccharide-induced inflammatory response via NF-kappaB and AP-1, p-ERK, TNF-alpha, IL-6 and IL-1beta in RAW 264.7 macrophages.	ascofuranone	0-12	interleukin 6	Mus musculus	113-117
27987983-7	2017	BALB/c mice that were subcutaneously pre-immunized with three doses of 0.5, 2.5 and 5.0mg of beta-glucan/mouse, showed a significant increase in IL-2, IL-6, IL-10, TNF-alpha and IL-17A production compared to non-immunized mice.	beta-Glucans	93-104	interleukin 6	Mus musculus	151-155
28208679-9	2017	The in vitro studies demonstrated that vanillin reduces LPS-induced expression of inducible nitric oxide (iNOS), cyclooxygenase-2 (COX-2), IL-1beta, and IL-6 through regulating ERK1/2, p38 and NF-kappaB signaling.	vanillin	39-47	interleukin 6	Mus musculus	153-157
28065862-8	2017	In vitro, free berberine significantly inhibited IL-6 secretion (IC50=10.4muM), whereas encapsulated berberine did not as it was not released from the formulation in the time frame of the in vitro study.	Berberine	15-24	interleukin 6	Mus musculus	49-53
27796295-9	2017	In Con A-challenged mice, preinjection with betulin (20 mg kg-1 d-1) significantly decreased the levels of proinflammatory cytokines IFN-gamma, TNF-alpha and IL-6, and ameliorated liver injury.	betulin	44-51	interleukin 6	Mus musculus	158-162
28182002-0	2017	Rapamycin upregulates glutamate transporter and IL-6 expression in astrocytes in a mouse model of Parkinson"s disease.	Sirolimus	0-9	interleukin 6	Mus musculus	48-52
28182002-5	2017	Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model.	Sirolimus	0-9	interleukin 6	Mus musculus	20-33
28182002-5	2017	Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model.	Sirolimus	0-9	interleukin 6	Mus musculus	35-39
28182002-5	2017	Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model.	Sirolimus	0-9	interleukin 6	Mus musculus	168-172
28182002-5	2017	Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	180-184	interleukin 6	Mus musculus	35-39
28182002-5	2017	Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	180-184	interleukin 6	Mus musculus	168-172
28217374-11	2017	Plecanatide also decreased secretion of pro-inflammatory cytokines (IL-6, IL1 TNF), chemokines (MIP-1, IP-10) and growth factors (GCSF and GMCSF) from colon explants derived from mice with acute DSS-induced inflammation.	plecanatide	0-11	interleukin 6	Mus musculus	68-72
28017961-5	2017	Treatment with a omega-3 fatty acid alpha-linolenic acid (ALA, 50 mumol/L) produced moderate reduction in LPS-stimulated inflammatory cytokines and NO production (TNF-alpha and IL-6 were decreased by 46% and 42%, respectively).	Fatty Acids, Omega-3	17-35	interleukin 6	Mus musculus	177-181
28017961-5	2017	Treatment with a omega-3 fatty acid alpha-linolenic acid (ALA, 50 mumol/L) produced moderate reduction in LPS-stimulated inflammatory cytokines and NO production (TNF-alpha and IL-6 were decreased by 46% and 42%, respectively).	alpha-Linolenic Acid	36-56	interleukin 6	Mus musculus	177-181
28017961-5	2017	Treatment with a omega-3 fatty acid alpha-linolenic acid (ALA, 50 mumol/L) produced moderate reduction in LPS-stimulated inflammatory cytokines and NO production (TNF-alpha and IL-6 were decreased by 46% and 42%, respectively).	alpha-Linolenic Acid	58-61	interleukin 6	Mus musculus	177-181
28017961-6	2017	Pre-incubation with Rb2 (1 or 10 mumol/L) for 12 h before ALA treatment dramatically amplified the inhibitory effects of ALA (TNF-alpha and IL-6 were decreased by 74% and 86%, respectively).	alpha-Linolenic Acid	121-124	interleukin 6	Mus musculus	140-144
27344344-10	2017	Inhibition of p-p65 dependent on PPARalpha activation by PFDA stopped the inflammatory cascade, as indicated by negative response of Il-6, Tnf-alpha, and STAT3 signaling.	perfluorodecanoic acid	57-61	interleukin 6	Mus musculus	133-137
27796295-10	2017	Furthermore, pretreatment with betulin (20 mg kg-1 d-1) significantly inhibited the Con A-induced activation of NKT and conventional T cells, and decreased production of proinflammatory cytokines IFN-gamma, TNF-alpha and IL-6 in these two cell populations.	betulin	31-38	interleukin 6	Mus musculus	221-225
27793708-9	2017	In primary mouse bone marrow-derived macrophages (BMDM), ChS-exposure increased the secretion of IL-1beta, TNF-alpha and IL-6.	cholesteryl succinate	57-60	interleukin 6	Mus musculus	121-125
27826751-7	2017	Interestingly, PolyP-induced NF-kappaB activation and the productions of TNF-alpha and IL-6 were inhibited by PEL in HUVECs.	Polyphosphates	15-20	interleukin 6	Mus musculus	87-91
28082453-12	2017	Elevated levels of the cardiac inflammatory cytokines IL-6 and TNFalpha leading to impaired insulin signalling may partially explain the peripheral glucose intolerance.	Glucose	148-155	interleukin 6	Mus musculus	54-58
27862161-8	2017	beta-eudesmol suppresses the serum levels of histamine, IgE, interleukin (IL)-1beta, IL-4, IL-5, IL-6, IL-13, and vascular endothelial growth factor (VEGF) under PCA mice as well as PCA reactions.	beta-eudesmol	0-13	interleukin 6	Mus musculus	97-101
27978494-6	2017	Sal also inhibited the generations of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in serum and lungs.	rhodioloside	0-3	interleukin 6	Mus musculus	116-129
27978494-6	2017	Sal also inhibited the generations of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in serum and lungs.	rhodioloside	0-3	interleukin 6	Mus musculus	131-135
27866224-10	2017	Empagliflozin treatment reduced weight and fat mass, lipid droplets in the liver, fat cell size, mRNA expression of Tnf, Il6 and Mcp-1 (also known as Ccl2) and the infiltration of inflammatory cells in plaque and adipose tissue compared with the control or glimepiride group.	empagliflozin	0-13	interleukin 6	Mus musculus	121-124
27866224-9	2017	Insulin resistance and circulating concentrations of TNF-alpha, IL-6, monocyte chemoattractant protein-1 (MCP-1), serum amyloid A and urinary microalbumin decreased after empagliflozin treatment, and this significantly correlated with plaque size.	empagliflozin	171-184	interleukin 6	Mus musculus	64-68
26990366-6	2017	The results showed that R-IPC and R-IPOST significantly decreased APAP-induced serum levels of ALT, AST, TNF-alpha, IL-6, hepatic MDA, as well as nitrotyrosine formation.	r-ipc	24-29	interleukin 6	Mus musculus	116-120
26990366-6	2017	The results showed that R-IPC and R-IPOST significantly decreased APAP-induced serum levels of ALT, AST, TNF-alpha, IL-6, hepatic MDA, as well as nitrotyrosine formation.	r-ipost	34-41	interleukin 6	Mus musculus	116-120
26990366-6	2017	The results showed that R-IPC and R-IPOST significantly decreased APAP-induced serum levels of ALT, AST, TNF-alpha, IL-6, hepatic MDA, as well as nitrotyrosine formation.	Acetaminophen	66-70	interleukin 6	Mus musculus	116-120
27692982-4	2017	Although rapamycin did not affect the increase in body weight and adiposity, it exacerbated the glucose intolerance and adipose tissue inflammation induced by HFD feeding, as evidenced by the increased adipose tissue percentage of M1 macrophages, naive and activated cytotoxic T lymphocytes, and mRNA levels of proinflammatory molecules, such as TNF-alpha, IL-6 and MCP-1.	Sirolimus	9-18	interleukin 6	Mus musculus	357-361
27717524-6	2017	Furthermore, STA-21 prevented the production of TNF-alpha and IL-6 in peripheral blood and increased IL-27 production by CD14+ cells.	STA-21	13-19	interleukin 6	Mus musculus	62-66
27817102-8	2017	Moreover, increased placental TNF-alpha, IL-1beta, and IL-6 expressions in LPS-treated group were significantly suppressed after curcumin administration.	Curcumin	129-137	interleukin 6	Mus musculus	55-59
28352315-5	2017	In addition, daphnetin treatment significantly decreased the serum levels of tumor necrosis factor-alpha and interleukin-6, inhibited nuclear factor (NF)-kappaB activity, suppressed the protein expression of nuclear factor of activated T-cells and promoted A20 protein expression in SLE-prone NZB/W F1 mice.	daphnetin	13-22	interleukin 6	Mus musculus	109-122
28054242-6	2017	We observed that SFN dose-dependently attenuated CCI-induced pain behavioral hypersensitivity, accompanied by reduction in pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and upregulation of an anti-inflammatory cytokine (IL-10).	sulforaphane	17-20	interleukin 6	Mus musculus	172-176
27900412-7	2017	RESULTS: In vivo, DMB significantly alleviated the weight loss and diminished myeloperoxidase (MPO) activity, while significantly reduced the production of pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-alpha), and inhibited the activation of NF-kappaB signaling pathway.	demethyleneberberine	18-21	interleukin 6	Mus musculus	192-210
28071183-6	2017	RESULTS: 5-ASA suppressed the production of NO and IL-6, and also decreased the expression of iNOS in LPS-induced RAW264.7 cells.	Mesalamine	9-14	interleukin 6	Mus musculus	51-55
28379390-7	2017	Thus, reduction of ROS production in Arid5a-deficient mice could mitigate OxPAPC production, which in turn decreases IL-6 production in vivo due to dysregulated post-transcriptional regulation by loss of Arid5a.	Reactive Oxygen Species	19-22	interleukin 6	Mus musculus	117-121
28078603-6	2017	Interleukin-6 (IL-6) was increased in paws of arthritic mice fed CO compared to shams, but was decreased in arthritic groups fed 0.5% c9t11 and 5 mg/kg celecoxib, compared to arthritic mice fed CO (Ps &lt;= 0.05).	Celecoxib	152-161	interleukin 6	Mus musculus	0-13
27951472-8	2017	DSS increased colonic interleukin (IL)-1beta, IL-6, and monocyte chemotactic protein-1 expression.	Dextran Sulfate	0-3	interleukin 6	Mus musculus	46-50
28078603-6	2017	Interleukin-6 (IL-6) was increased in paws of arthritic mice fed CO compared to shams, but was decreased in arthritic groups fed 0.5% c9t11 and 5 mg/kg celecoxib, compared to arthritic mice fed CO (Ps &lt;= 0.05).	Celecoxib	152-161	interleukin 6	Mus musculus	15-19
28017899-7	2017	For the in vivo tests, nocodazole -treated mice displayed elevated levels of IFN-gamma, MCP-1 and IL-10 while Brucella-infected nocodazole -treated mice showed high levels of TNF, IFN-gamma, MCP-1, IL-10 and IL-6 as compared to controls.	Nocodazole	128-138	interleukin 6	Mus musculus	208-212
27980107-13	2017	Niclosamide prevents oxaliplatin-induced increased levels of IL6, TNFalpha, and advanced oxidized protein products.	Niclosamide	0-11	interleukin 6	Mus musculus	61-64
27980107-13	2017	Niclosamide prevents oxaliplatin-induced increased levels of IL6, TNFalpha, and advanced oxidized protein products.	Oxaliplatin	21-32	interleukin 6	Mus musculus	61-64
27984078-5	2017	In accordance, MT-031 was shown to reduce reactive oxygen species accumulation, increase the levels of anti-inflammatory cytokines, IL-10 and decrease the levels of the pro-inflammatory cytokines, IL-1beta, IL-6, IL-17 and interferon-gamma (IFN-gamma) in activated mouse splenocytes and microglial cells.	SCHEMBL16948183	15-21	interleukin 6	Mus musculus	207-211
28017641-7	2017	Further analysis showed that WY-14643 pretreatment not only inhibited the production of pro-inflammatory cytokines induced by LPS, such as interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), but also prevented the LPS-induced enhancement of oxidative and nitrosative stress in the hippocampus and prefrontal cortex.	tryptophyltyrosine	29-31	interleukin 6	Mus musculus	139-152
28017641-7	2017	Further analysis showed that WY-14643 pretreatment not only inhibited the production of pro-inflammatory cytokines induced by LPS, such as interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), but also prevented the LPS-induced enhancement of oxidative and nitrosative stress in the hippocampus and prefrontal cortex.	tryptophyltyrosine	29-31	interleukin 6	Mus musculus	154-158
27525509-4	2017	The expression of TNFalpha, monocyte chemotactic protein-1, interleukin-1beta, and interleukin-6 were decreased in the coculture insert system using fully differentiated 3T3-L1 cells with RAW 264.7 macrophages treated with 6-gingerol.	gingerol	223-233	interleukin 6	Mus musculus	83-96
27827561-5	2017	In addition, one of the sbC-PEGylated aptamers, 17M-382, inhibited the interleukin-6 (IL-6) production induced by IL-17A in NIH3T3 cells in a concentration-dependent manner, and the half-maximal inhibitory concentration of sbC-PEGylated 17M-382 was two times lower than that of non-PEGylated 17M-382.	1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE	24-27	interleukin 6	Mus musculus	71-84
27827561-5	2017	In addition, one of the sbC-PEGylated aptamers, 17M-382, inhibited the interleukin-6 (IL-6) production induced by IL-17A in NIH3T3 cells in a concentration-dependent manner, and the half-maximal inhibitory concentration of sbC-PEGylated 17M-382 was two times lower than that of non-PEGylated 17M-382.	1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE	24-27	interleukin 6	Mus musculus	86-90
27827561-5	2017	In addition, one of the sbC-PEGylated aptamers, 17M-382, inhibited the interleukin-6 (IL-6) production induced by IL-17A in NIH3T3 cells in a concentration-dependent manner, and the half-maximal inhibitory concentration of sbC-PEGylated 17M-382 was two times lower than that of non-PEGylated 17M-382.	17m-382	48-55	interleukin 6	Mus musculus	71-84
27827561-5	2017	In addition, one of the sbC-PEGylated aptamers, 17M-382, inhibited the interleukin-6 (IL-6) production induced by IL-17A in NIH3T3 cells in a concentration-dependent manner, and the half-maximal inhibitory concentration of sbC-PEGylated 17M-382 was two times lower than that of non-PEGylated 17M-382.	17m-382	48-55	interleukin 6	Mus musculus	86-90
27827561-5	2017	In addition, one of the sbC-PEGylated aptamers, 17M-382, inhibited the interleukin-6 (IL-6) production induced by IL-17A in NIH3T3 cells in a concentration-dependent manner, and the half-maximal inhibitory concentration of sbC-PEGylated 17M-382 was two times lower than that of non-PEGylated 17M-382.	1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE	223-226	interleukin 6	Mus musculus	71-84
27827561-5	2017	In addition, one of the sbC-PEGylated aptamers, 17M-382, inhibited the interleukin-6 (IL-6) production induced by IL-17A in NIH3T3 cells in a concentration-dependent manner, and the half-maximal inhibitory concentration of sbC-PEGylated 17M-382 was two times lower than that of non-PEGylated 17M-382.	1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE	223-226	interleukin 6	Mus musculus	86-90
27827561-5	2017	In addition, one of the sbC-PEGylated aptamers, 17M-382, inhibited the interleukin-6 (IL-6) production induced by IL-17A in NIH3T3 cells in a concentration-dependent manner, and the half-maximal inhibitory concentration of sbC-PEGylated 17M-382 was two times lower than that of non-PEGylated 17M-382.	17m-382	237-244	interleukin 6	Mus musculus	71-84
27827561-5	2017	In addition, one of the sbC-PEGylated aptamers, 17M-382, inhibited the interleukin-6 (IL-6) production induced by IL-17A in NIH3T3 cells in a concentration-dependent manner, and the half-maximal inhibitory concentration of sbC-PEGylated 17M-382 was two times lower than that of non-PEGylated 17M-382.	17m-382	237-244	interleukin 6	Mus musculus	86-90
27827561-5	2017	In addition, one of the sbC-PEGylated aptamers, 17M-382, inhibited the interleukin-6 (IL-6) production induced by IL-17A in NIH3T3 cells in a concentration-dependent manner, and the half-maximal inhibitory concentration of sbC-PEGylated 17M-382 was two times lower than that of non-PEGylated 17M-382.	17m-382	237-244	interleukin 6	Mus musculus	71-84
27827561-5	2017	In addition, one of the sbC-PEGylated aptamers, 17M-382, inhibited the interleukin-6 (IL-6) production induced by IL-17A in NIH3T3 cells in a concentration-dependent manner, and the half-maximal inhibitory concentration of sbC-PEGylated 17M-382 was two times lower than that of non-PEGylated 17M-382.	17m-382	237-244	interleukin 6	Mus musculus	86-90
27827561-6	2017	Furthermore, the intraperitoneal administration of sbC-PEGylated 17M-382 significantly inhibited the IL-6 production induced by IL-17A in a mouse air pouch model.	1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE	51-54	interleukin 6	Mus musculus	101-105
27827561-6	2017	Furthermore, the intraperitoneal administration of sbC-PEGylated 17M-382 significantly inhibited the IL-6 production induced by IL-17A in a mouse air pouch model.	17m-382	65-72	interleukin 6	Mus musculus	101-105
27807897-5	2017	In cultured macrophages (RAW 264.7 cells), the application of polysaccharide-enriched extract of DBT significantly increased the expressions of mRNA and protein levels of interleukin-1beta, interleukin-6 and tumor necrosis factor.	Polysaccharides	62-76	interleukin 6	Mus musculus	190-203
28197150-6	2017	Our results show that curcumin induced a higher percentage of M2 macrophages together with a higher concentration of anti-inflammatory cytokine IL-10, and a lower percentage of M1 macrophages with a lower concentration of pro-inflammatory cytokines (TNF-alpha and IL-6).	Curcumin	22-30	interleukin 6	Mus musculus	264-268
28110777-7	2017	Transmission electron microscope and Dot-blot analyses indicated that rss04 represses capsular polysaccharide (CPS) production, which in turn facilitates SS adherence and invasion of mouse brain microvascular endothelial cells bEnd.3 in vitro and activates the mRNA expression of TLR2, CCL2, IL-6 and TNF-alpha in mouse brain in vivo at 12h post-infection.	rss04	70-75	interleukin 6	Mus musculus	292-296
27393133-6	2017	Bilirubin supplementation of islet media also decreased the release of DAMPs (HMGB1), inflammatory cytokines (IL-1beta and IL-6), and chemokines (MCP-1).	Bilirubin	0-9	interleukin 6	Mus musculus	123-127
28139747-3	2017	Roxatidine suppressed the mRNA and protein expression of inflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta in PMACI-stimulated HMC-1 and compound 48/80-induced anaphylactic mice.	roxatidine acetate	0-10	interleukin 6	Mus musculus	99-103
28117761-6	2017	A mouse in vivo study of LPS-stimulated lung inflammation showed that phloretin effectively suppressed the levels of TNF-alpha, IL-1beta, and IL-6 in lung tissue with low cytotoxicity.	Phloretin	70-79	interleukin 6	Mus musculus	142-146
28134765-5	2017	Treatment with dTBP2 also decreased the serum levels of IgE and reduced IL-17A content in skin lesions and inhibited the expression of mRNAs of interleukin IL-4, IL-5, IL-6, IL-13, macrophage-derived chemokine (MDC), thymus and activation-regulated chemokine (TARC) and thymic stromal lymphopoietin (TSLP).	dtbp2	15-20	interleukin 6	Mus musculus	168-172
28114268-11	2017	Furthermore, miR-128 overexpression obviously decreased the concentration of TNF-alpha, IL-1beta, and IL-6.	mir-128	13-20	interleukin 6	Mus musculus	102-106
28115915-8	2017	RESULTS: Administration of low dose poly I:C upregulated the expression of PD-L1, induced neutrophilia and increased keratinocyte-derived chemokine (KC), macrophage inflammatory protein-1beta (MIP-1beta), and IL-6 in BALF.	Poly I	36-42	interleukin 6	Mus musculus	209-213
27902467-7	2017	Nude mice injected with IL-6 silenced clones develop tumors contrary to MtT/S wild type that do not, demonstrating that clones that escape senescence are capable of becoming tumorigenic.	monooxyethylene trimethylolpropane tristearate	72-75	interleukin 6	Mus musculus	24-28
27902475-8	2017	Furthermore, osthole can suppress NF-kappaB signal pathway through the inhibition of the nuclear translocation by regulating phosphorylation of IkappaBalpha and IKKbeta and hinder the production of chemoattractant (MCP-1 and IL-8) and proinflammatory cytokines (TNF-alpha, IL-1beta and IL-6).	osthol	13-20	interleukin 6	Mus musculus	286-290
28115915-8	2017	RESULTS: Administration of low dose poly I:C upregulated the expression of PD-L1, induced neutrophilia and increased keratinocyte-derived chemokine (KC), macrophage inflammatory protein-1beta (MIP-1beta), and IL-6 in BALF.	Carbon	43-44	interleukin 6	Mus musculus	209-213
27979367-4	2017	Our data conclude that the novel saccharide has immunostimulatory activity on mouse macrophages as indicated by the elevated levels of IL-6 and TNF-alpha in culture supernatants.	Carbohydrates	33-43	interleukin 6	Mus musculus	135-139
28104981-7	2017	Endotoxin-associated genes such as TLR4 and Myd88, pro-inflammation genes such as MCP-1, TNF-alpha, IL-1, IL-2, IL-6 and IFN-gamma in liver or epididymal fat were obviously downregulated after NaB intervention.	nab	193-196	interleukin 6	Mus musculus	112-116
28056291-6	2017	And more obvious significance was detected at 16 weeks treat-ment (P&lt;0.01); (4) 16 weeks treatment with testosterone induced the increase of AUC of the blood glucose following ITT(P&lt;0.01); (5) the serum IL-6 and MCP-1 in testosterone treat-ment was higher than that in thecontrols (P&lt;0.05).	Testosterone	107-119	interleukin 6	Mus musculus	209-213
27876617-6	2017	Along with these metabolic corrections, canagliflozin attenuated the increases in the mRNA levels of the proinflammatory biomarkers Iba1 and Il6 and the number of macrophages/microglia in the nodose ganglion and hypothalamus.	Canagliflozin	40-53	interleukin 6	Mus musculus	141-144
28056291-8	2017	Conclusions: Treatment with testosterone in adult fe-male mice can induce insulin resistance by blocking insulin signal transduction, without in-fluencing body weight and body fat content.Testosterone could activate the NF-kappaB to pro-mote the expression of IL-6 and MCP-1.	Testosterone	28-40	interleukin 6	Mus musculus	260-264
28849450-4	2017	TauCl markedly inhibited interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) production.	N-chlorotaurine	0-5	interleukin 6	Mus musculus	25-38
28056291-8	2017	Conclusions: Treatment with testosterone in adult fe-male mice can induce insulin resistance by blocking insulin signal transduction, without in-fluencing body weight and body fat content.Testosterone could activate the NF-kappaB to pro-mote the expression of IL-6 and MCP-1.	Testosterone	188-200	interleukin 6	Mus musculus	260-264
28849450-4	2017	TauCl markedly inhibited interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) production.	N-chlorotaurine	0-5	interleukin 6	Mus musculus	40-44
28081632-9	2017	BA treatment at 30[Formula: see text]mg/kg after APAP overdose reduced elevated hepatic cytokine (TNF-[Formula: see text] and IL-6) levels, and macrophage recruitment around the area of hepatotoxicity in immunohistochemical staining.	baicalin	0-2	interleukin 6	Mus musculus	126-130
28458349-10	2017	Expression of IL-6 and MCP-1 stimulated by CLP was reduced by pioglitazone treatment.	Pioglitazone	62-74	interleukin 6	Mus musculus	14-18
27615440-11	2017	(4) In primary myometrial smooth muscle cell and ex vivo uteri from wild-type mice, lactate decreased interleukin-1beta-induced transcription of key proinflammatory Il1b, Il6, Ccl2, and Pghs2; suppressive effects of lactate were not observed in cells and tissues from GPR81-/- mice.	Lactic Acid	84-91	interleukin 6	Mus musculus	171-174
27722916-6	2017	We found that rIL6scFv could bind to commercial recombinant mouse IL-6.	ril6scfv	14-22	interleukin 6	Mus musculus	66-70
28769008-5	2017	CRS exposure caused depressive-like behaviors in mice, which was associated with increased pre-inflammatory cytokines (interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha and IL-6) levels, reactive microglia numbers and up-regulated regulatory molecules such as TLR4/p38 and P2X7 receptor in hippocampus.	3-cresol	0-3	interleukin 6	Mus musculus	181-185
27903426-4	2017	Our results indicated that treatment with BI markedly decreased the levels of interleukin-6 (IL-6), IL-1beta and tumor necrosis factor-alpha (TNF-alpha) in vivo.	bilobalide	42-44	interleukin 6	Mus musculus	78-91
27903426-4	2017	Our results indicated that treatment with BI markedly decreased the levels of interleukin-6 (IL-6), IL-1beta and tumor necrosis factor-alpha (TNF-alpha) in vivo.	bilobalide	42-44	interleukin 6	Mus musculus	93-97
28867726-8	2017	The elevated concentrations of interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha and IL-6, and the activation of nuclear factor-kappaB (NF-kappaB) p65 by ethanol stimulation was also reduced by acetate.	Acetates	202-209	interleukin 6	Mus musculus	93-97
28421194-8	2017	The DHM treatment normalized body weight, preserved cardiac function, attenuated oxidative stress (MDA, SOD, and GSH-Px), reduced the levels of inflammation factors (IL-6, TNF-alpha), alleviated pathological changes, improved mitochondrial function (ATP content, CS activity, and complex Iota/IotaIota/IotaIotaIota/IotaV/V activities), inhibited cardiac apoptosis, and restored autophagy in diabetic mice.	dihydromyricetin	4-7	interleukin 6	Mus musculus	166-170
27640899-8	2017	Treatment of human monocytes (THP-1) and mouse microglia (SIM-A9) cell lines with fluoxetine significantly increased TNFAIP3 mRNA expression and suppressed IL-6 levels.	Fluoxetine	82-92	interleukin 6	Mus musculus	156-160
27778412-8	2017	However, the increased IL-6 was blocked by pre-treatment of MLO-Y4 cells with the ERK1/2 inhibitor U0126 (10 microM), and the enhanced RANKL was blocked by the STAT3 inhibitor S3I-201 (100 microM).	U 0126	99-104	interleukin 6	Mus musculus	23-27
27769789-8	2017	The results revealed that resveratrol exerted a neuroprotective effect as shown by the improved mNSS and beam latency, anti-inflammatory effects as indicated by the decreased level of IL-1beta, TNF-alpha and IL-6.	Resveratrol	26-37	interleukin 6	Mus musculus	208-212
27778412-8	2017	However, the increased IL-6 was blocked by pre-treatment of MLO-Y4 cells with the ERK1/2 inhibitor U0126 (10 microM), and the enhanced RANKL was blocked by the STAT3 inhibitor S3I-201 (100 microM).	NSC 74859	176-183	interleukin 6	Mus musculus	23-27
29262401-0	2017	CpG-Oligodeoxynucleotides Improved Irradiation-Induced Injuries by G-CSF and IL-6 Up-Regulation.	CPG-oligonucleotide	0-25	interleukin 6	Mus musculus	77-81
28142150-5	2017	RESULTS: Induction of diabetes by streptozotocin was associated with reduction of body weight and insulin level, increase in glucose level and pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha), and reduction in IL-2 and IL-4 levels.	Streptozocin	34-48	interleukin 6	Mus musculus	181-185
27797827-8	2017	Additionally, GTN suppressed production of IL-6, IL-17 and TNF-alpha in tumor tissue, as well as abrogated stromal immune cell activation and nuclear translocation of NF-kappaB.	goniothalamin	14-17	interleukin 6	Mus musculus	43-47
27797827-9	2017	Finally, in a tamoxifen inducible model of sporadic CRC, GTN-treated mice had significantly fewer tumors and decreased levels of IL-17A, IL-6, S100A9 and TNF-alpha protein within the tumors.	goniothalamin	57-60	interleukin 6	Mus musculus	137-141
28245471-11	2017	Betaine also diminished the WPS-induced increase of plasma concentrations of interleukin 6 and tumor necrosis factor alpha, and attenuated the increase of lipid peroxidation and superoxide dismutase.	Betaine	0-7	interleukin 6	Mus musculus	77-122
28222448-12	2017	RESULTS: PolyI:C exposure (4h) significantly elevated maternal plasma IL-6 (P&lt;0.001) and increased [3H]digoxin accumulation in the fetal brain (P&lt;0.05).	Poly I-C	9-16	interleukin 6	Mus musculus	70-74
28222448-12	2017	RESULTS: PolyI:C exposure (4h) significantly elevated maternal plasma IL-6 (P&lt;0.001) and increased [3H]digoxin accumulation in the fetal brain (P&lt;0.05).	4h	27-29	interleukin 6	Mus musculus	70-74
28810254-7	2017	Furthermore, PI3-kinase inhibition by wortmannin decreased TNF-alpha release, and inhibition by LY294002 decreased both TNF-alpha and IL-6 levels after LPS-insulin treatment.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	96-104	interleukin 6	Mus musculus	134-138
28738346-8	2017	In the infection model, the mice survival were increased markedly, the inflammations of infected lungs were improved greatly along with reduced IL-6, IL-8 and ascended IL-10 at 0.8 mg/kg of AZM combined with 3.2 mg/kg of BER.	Azithromycin	190-193	interleukin 6	Mus musculus	144-148
28810254-8	2017	PD98059, which inhibits the ERK upstream activators MAPK kinase (MKK) 1 and MKK2, reduced the effect promoted by insulin in BMDM stimulated by LPS In tissue-specific macrophages, insulin reduced LPS-induced TNF-alpha, IL-6 and IL-1beta secretion in alveolar and peritoneal macrophages.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	interleukin 6	Mus musculus	218-222
29132134-11	2017	Proinflammatory markers MCP-1, TNF-alpha, CXCL11, IL-6, and CD68 were significantly increased in the intestinal epithelia in CCI4-treated mice.	cci4	125-129	interleukin 6	Mus musculus	50-54
28922655-10	2017	Zymosan-A also promoted cell viability and inhibited cell apoptosis caused by radiation, induced radioprotective effects via TLR2, upregulated IL-6, IL-11, IL-12, and TNF-alpha in vivo.	Zymosan	0-9	interleukin 6	Mus musculus	143-147
27401064-9	2017	Fasudil intervention also inhibited TLR-2/4, p-NF-kappaB/p65, MyD88, interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha for TLRs-NF-kappaB-MyD88 inflammatory cytokine axis and the induction of interleukin-10.	fasudil	0-7	interleukin 6	Mus musculus	88-101
27377869-10	2017	The decreased total liver weight, hepatic triglyceride deposition and serum ALT concentration induced by Mir-26a was also abrogated completely by IL-6 over-expression.	Triglycerides	42-54	interleukin 6	Mus musculus	146-150
29456573-7	2017	The results also showed that CRME can reduce the levels of IL-1, IL-6, TNF-alpha, and PGE2 and inhibit the expression of NF-kappaB p65.	crme	29-33	interleukin 6	Mus musculus	65-69
28246539-7	2017	The expression levels of inflammatory cytokines TNF-a, IL-1beta, and IL-6 were decreased after oral administration of SLE, probably because lignans inhibited the NF-kappaB activity.	Lignans	140-147	interleukin 6	Mus musculus	69-73
28458714-2	2017	Application of the D-galactose induced accelerated-aging model employing male ICR mice showed that oral administration of some combinations of B, Y, P, and A significantly improved spatial memory in Y-maze test and reduced brain levels of tumor necrosis factor-alpha and interleukin-6 based on immunoassays and oxidative stress marker malondialdehyde, based on the thiobarbituric acid test, and the loss of whiskers, indicating antiaging and antineurodegeneration effects.	Galactose	19-30	interleukin 6	Mus musculus	271-284
28676833-9	2017	Andrographolide dose-dependently inhibited the release and mRNA expression of TNF-alpha, IL-6, and IL-1beta in LPS-stimulated RAW264.7 cells.	andrographolide	0-15	interleukin 6	Mus musculus	89-93
28584524-12	2017	Moreover, DSS treatment markedly increased serum IL-6 and FGF21 levels.	Dextran Sulfate	10-13	interleukin 6	Mus musculus	49-53
28337225-7	2017	In a mouse model of PM2.5-induced inflammation established with intranasal instillation of PM2.5 suspension, BFHX significantly reduced pathological response and inflammatory mediators including IL-4, IL-6, IL-10, IL-8, TNF-alpha, and IL-1beta.	bfhx	109-113	interleukin 6	Mus musculus	201-205
27732877-8	2017	Similarly, the secretion of TNF-alpha and IL-6 were significantly decreased by the treatment of NiCl2.	nickel chloride	96-101	interleukin 6	Mus musculus	42-46
27875748-4	2017	The results showed that piperine significantly inhibited LPS-induced TNF-alpha, IL-6, IL-1beta, and PGE2 production in BV2 cells.	piperine	24-32	interleukin 6	Mus musculus	80-84
28004106-4	2017	Resveratrol downregulated the expression of inflammatory markers, such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, induced by LPS, and inhibited the phosphorylation of mitogen-activated protein kinases (MAPKs) and signal transducer and activator of transcription (STAT)1/STAT3.	Resveratrol	0-11	interleukin 6	Mus musculus	112-130
27773938-9	2017	Using NPY/AgRP hypothalamic cell lines, we found that palmitate provoked a mixed inflammatory response on a panel of inflammatory and endoplasmic reticulum (ER) stress genes, whereas TNF-alpha significantly upregulated IkappaBalpha, nuclear factor (NF)-kappaB and interleukin-6 mRNA levels.	Palmitates	54-63	interleukin 6	Mus musculus	264-277
29201923-5	2017	We found that the loss of IL-6 decreased macrophage recruitment to the spleen and the peritoneal cavity during pristane-induced inflammation.	pristane	111-119	interleukin 6	Mus musculus	26-30
28133531-8	2017	Both of coumarin and ICE were capable to reduce the PGE2, TNF-alpha, NO, IL-6, and IL-beta level in LPS-induced RAW264.7 cells.	coumarin	8-16	interleukin 6	Mus musculus	73-77
28133531-10	2017	CONCLUSION: Coumarin and ICE possess anti-inflammatory properties through inhibition of PGE2 and NO along with pro-inflammatory cytokines TNF-alpha, IL-6, IL-1beta production.	coumarin	12-20	interleukin 6	Mus musculus	149-153
28133531-10	2017	CONCLUSION: Coumarin and ICE possess anti-inflammatory properties through inhibition of PGE2 and NO along with pro-inflammatory cytokines TNF-alpha, IL-6, IL-1beta production.	Water	25-28	interleukin 6	Mus musculus	149-153
29617099-0	2017	A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.	Doxorubicin	45-56	interleukin 6	Mus musculus	67-71
28584821-3	2017	RESULTS: DSS-resistant BALB/c mice were characterized by low levels of IFN-gamma and TNF-alpha but high levels of IL-4, IL-6, IL-10, IL-17A, IL-17F, and colon lamina propria and mesenteric lymph node (MLN) CD4+CD25+FoxP3+ T cells when compared to C57BL/6 mice.	Dextran Sulfate	9-12	interleukin 6	Mus musculus	120-124
28616625-5	2017	A major mechanism associated with the impairment of endothelial function with eNOS deficiency and a high fat diet appears to be related to increases in plasma IL-6 that serves to further reduce the bioavailability of NO either directly or indirectly via reductions in eNOS expression or activity and via increases in vascular superoxide.	Superoxides	326-336	interleukin 6	Mus musculus	159-163
27875664-4	2017	Using an established intranasal inhalation exposure model, wild-type (WT) and IL-6 knockout (KO) mice were treated daily with ODE or saline for 3 weeks.	4-O-amino-phenol-4'-demethylepipodophyllotoxin ether	126-129	interleukin 6	Mus musculus	78-82
27836362-8	2017	RESULTS: Compared to controls, MS+PBS mice had shorter crypt lengths, fewer goblet cells per crypt, reduced glutathione peroxidase activity, increased expression of thiobarbituric acid reactive substances and inducible nitric oxide synthase mRNA, as well as increased IL-6, TNFalpha and myeloperoxidase.	pbs	34-37	interleukin 6	Mus musculus	268-272
27697587-18	2017	The hippocampus and striatum of ketamine+melatonin-treated animals had lower levels of IL-6.	Ketamine	32-40	interleukin 6	Mus musculus	87-91
27422938-8	2017	Seabuckthorn oil downregulated the mRNA level of inflammatory factors, including tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and IL-8.	seabuckthorn oil	0-16	interleukin 6	Mus musculus	134-138
27697587-18	2017	The hippocampus and striatum of ketamine+melatonin-treated animals had lower levels of IL-6.	Melatonin	41-50	interleukin 6	Mus musculus	87-91
28167852-6	2017	It was revealed that SNN-containing serum decreased TNF-alpha and IL-6 expression, and microRNA-152 was identified as the potential epigenetic regulator.	snn	21-24	interleukin 6	Mus musculus	66-70
28880739-9	2017	Methionine-deprived diet exerted pro-inflammatory consequences as evidenced by elevated levels of cytokines IL-1ss, TNF-alpha, and IL-6 noted in liver.	Methionine	0-10	interleukin 6	Mus musculus	131-135
28880739-10	2017	Methionine-supplemented diet increased hepatic IL-6 and cardiac TNF-alpha.	Methionine	0-10	interleukin 6	Mus musculus	47-51
27597295-12	2017	In addition, in vitro experiments showed that overexpression of 6alpha-ethyl-23(S)-methylcholic acid (INT-777)-activated TGR5 directly down-regulated tumor necrosis factor alpha (TNF-alpha) and interleukin (IL) 6 expression but up-regulated IL10 expression in hypoxia/reoxygenation-induced primary TGR5+/+ macrophages.	6alpha-ethyl-23(S)-methylcholic acid	64-100	interleukin 6	Mus musculus	194-212
28572711-4	2017	Buprenorphine administration altered the expression of cytokines, IFN-gamma, IL-6, and MMP-3, and oxidative markers, for example, iNOS, superoxide dismutase (SOD1), and catalase (CAT), in the CIA mice.	Buprenorphine	0-13	interleukin 6	Mus musculus	77-81
28751820-6	2017	In macrophages, HMFO inhibited several cytokines and enzymes involved in inflammation such as prostaglandin E2, nitric oxide, tumor necrosis factor-alpha, interleukin-6, inducible nitric oxide synthase, and cyclooxygenase-2 by attenuating nuclear factor-kappaB (NF-kappaB) and mitogen-activated protein kinases.	hmfo	16-20	interleukin 6	Mus musculus	155-168
29358851-8	2017	Anti-IL-22 nAb significantly alleviated the severity of hypertrophy, prevented systolic and diastolic abnormalities, reduced cardiac fibrosis, STAT3 and ERK phosphorylation, and downregulated the mRNA expression of IL-17, IL-6, IL-1beta, IFN-gamma, and TNF-alpha.	nab	11-14	interleukin 6	Mus musculus	222-226
28326946-6	2017	In addition, dendrimer-conjugated triamcinolone acetonide administration (intrathecal) inhibited peripheral nerve injury-induced spinal cord microglial activation and the expression of pain-related genes in the spinal cord, including Nox2, IL-1beta, TNF-alpha, and IL-6.	Triamcinolone Acetonide	34-57	interleukin 6	Mus musculus	265-269
29038619-6	2017	Among various cytokines, levels of IL-1alpha, IL-1beta, IL-4, IL-6, and IL-13 were significantly elevated in nose or lung tissue from the CIH group.	cih	138-141	interleukin 6	Mus musculus	62-66
28243356-6	2017	Isoorientin treated RAW 264.7 cells and animals showed reduced expression of inflammatory proteins like COX-2, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), 5-lipoxygenase (5-LOX), and interleukin 1-beta (IL-1-beta) both in vitro and in vivo.	homoorientin	0-11	interleukin 6	Mus musculus	152-165
29131114-6	2017	RESULTS: RA attenuated the expression of the M1 marker iNOS and the levels of proinflammatory factors, including TNF-alpha, IL-1beta, and IL-6; it increased the expression of the M2 marker Arg-1, and inhibited, at least in part, ROS generation and loss of mitochondrial outer membrane permeabilization through the inhibition of cleaved caspase-3 activation.	rosmarinic acid	9-11	interleukin 6	Mus musculus	138-142
28243356-6	2017	Isoorientin treated RAW 264.7 cells and animals showed reduced expression of inflammatory proteins like COX-2, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), 5-lipoxygenase (5-LOX), and interleukin 1-beta (IL-1-beta) both in vitro and in vivo.	homoorientin	0-11	interleukin 6	Mus musculus	167-171
28751937-4	2017	Myricitrin also markedly suppressed the production of NO, TNF-alpha, IL-6, and MCP-1 in RAW264.7 macrophage cells.	myricitrin	0-10	interleukin 6	Mus musculus	69-73
28819543-4	2017	Diosmin treatment ameliorated the MTX-induced elevation of serum alkaline phosphatase, aminotransferases, urea, creatinine, lactate dehydrogenase, and creatine kinases as well as plasma proinflammatory cytokines (interleukin-1-beta, interleukin-6, and tumor necrosis factor-alpha).	Diosmin	0-7	interleukin 6	Mus musculus	233-246
28024724-10	2017	Rosiglitazone significantly inhibited radiation-induced tnfalpha, Il-6 and Il-1beta gene expression.	Rosiglitazone	0-13	interleukin 6	Mus musculus	66-70
28566583-9	2017	In addition, Bergamottin decreased the TNF-alpha-induced increase in the mRNA levels of pro-inflammatory adipokines, monocyte chemoattractant protein-1 and interleukin-6.	bergamottin	13-24	interleukin 6	Mus musculus	156-169
28912935-10	2017	In addition to that, baicalin attenuated microglial cell secretion of IL-1beta and IL-6 induced by lipopolysaccharide (100 ng/ml) dose dependently.	baicalin	21-29	interleukin 6	Mus musculus	83-87
28082985-7	2016	The increase in lactate concentration in colon promoted protective effects against TNBS-induced colitis preventing histopathological damage, as well as bacterial translocation and rise of IL-6 levels in serum.	Lactic Acid	16-23	interleukin 6	Mus musculus	188-192
27769711-5	2016	Esculetin treatment in diabetic mice fed HFD significantly down-regulated expression of lipid synthesis genes (Fasn, Dgat2 and Plpp2) and inflammation genes (Tlr4, Myd88, Nfkb, Tnfalpha and Il6).	esculetin	0-9	interleukin 6	Mus musculus	190-193
28004071-8	2016	Administration of NAC could attenuate the alveolar wall structure damage induced by O3 exposure and reduce the amount of infiltrated inflammatory cells, total and differential leukocyte counts (P &lt; 0.05), as well as the IL-6, IL-8 (P &lt; 0.01) and MDA release (P &lt; 0.05).	Acetylcysteine	18-21	interleukin 6	Mus musculus	223-227
28004841-4	2016	In LPS-stimulated murine macrophages, naringenin suppressed the expression of TNF-alpha, IL-6, TLR4, inducible NO synthase (iNOS), cyclo-oxygenase-2 (COX2) and NADPH oxidase-2 (NOX2).	naringenin	38-48	interleukin 6	Mus musculus	89-93
27829595-10	2016	In the colons of IMQ-treated mice, mRNA expression of TNF-alpha was decreased, and strong expressions of IL-6, IFN-beta and TGF-beta were detected.	Imiquimod	17-20	interleukin 6	Mus musculus	105-109
27494874-9	2016	DEN-induced tumor related inflammation was further promoted through increased protein concentrations of liver IL-6 and TNF-alpha as compared to WT during carcinogenesis initiation.	Diethylnitrosamine	0-3	interleukin 6	Mus musculus	110-114
27999284-0	2016	Aspirin down Regulates Hepcidin by Inhibiting NF-kappaB and IL6/JAK2/STAT3 Pathways in BV-2 Microglial Cells Treated with Lipopolysaccharide.	Aspirin	0-7	interleukin 6	Mus musculus	60-63
27999284-1	2016	Aspirin down regulates transferrin receptor 1 (TfR1) and up regulates ferroportin 1 (Fpn1) and ferritin expression in BV-2 microglial cells treated without lipopolysaccharides (LPS), as well as down regulates hepcidin and interleukin 6 (IL-6) in cells treated with LPS.	Aspirin	0-7	interleukin 6	Mus musculus	222-235
27999284-1	2016	Aspirin down regulates transferrin receptor 1 (TfR1) and up regulates ferroportin 1 (Fpn1) and ferritin expression in BV-2 microglial cells treated without lipopolysaccharides (LPS), as well as down regulates hepcidin and interleukin 6 (IL-6) in cells treated with LPS.	Aspirin	0-7	interleukin 6	Mus musculus	237-241
27999284-4	2016	We demonstrated that aspirin inhibited hepcidin mRNA as well as NO production in cells treated with LPS, but not in cells without LPS, suppresses IL-6, JAK2, STAT3, and P65 (nuclear factor-kappaB) phosphorylation and has no effect on IRP1 in cells treated with or without LPS.	Aspirin	21-28	interleukin 6	Mus musculus	146-150
27999284-5	2016	These findings provide evidence that aspirin down regulates hepcidin by inhibiting IL6/JAK2/STAT3 and P65 (nuclear factor-kappaB) pathways in the cells under inflammatory conditions, and imply that an aspirin-induced reduction in TfR1 and an increase in ferritin are not associated with IRP1 and NO.	Aspirin	37-44	interleukin 6	Mus musculus	83-86
27983945-9	2016	Memantine significantly attenuated the body weight loss, colon weight, the plasma levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and colon level of tumor necrosis factor-alpha (TNF-alpha) and myeloperoxidase (MPO); as well as macroscopic and microscopic signs of colitis.	Memantine	0-9	interleukin 6	Mus musculus	122-135
27983945-9	2016	Memantine significantly attenuated the body weight loss, colon weight, the plasma levels of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and colon level of tumor necrosis factor-alpha (TNF-alpha) and myeloperoxidase (MPO); as well as macroscopic and microscopic signs of colitis.	Memantine	0-9	interleukin 6	Mus musculus	137-141
27746196-6	2016	Exposure of adult mice to ABP, DEN or CCl4 produced a 2-fold greater acute elevation in serum levels of the hepatotoxicity biomarker alanine aminotransferase (ALT) in males than in females, while levels of the inflammatory biomarker interleukin-6 (IL-6) showed no sex difference.	4-biphenylamine	26-29	interleukin 6	Mus musculus	233-246
27746196-6	2016	Exposure of adult mice to ABP, DEN or CCl4 produced a 2-fold greater acute elevation in serum levels of the hepatotoxicity biomarker alanine aminotransferase (ALT) in males than in females, while levels of the inflammatory biomarker interleukin-6 (IL-6) showed no sex difference.	4-biphenylamine	26-29	interleukin 6	Mus musculus	248-252
27746196-6	2016	Exposure of adult mice to ABP, DEN or CCl4 produced a 2-fold greater acute elevation in serum levels of the hepatotoxicity biomarker alanine aminotransferase (ALT) in males than in females, while levels of the inflammatory biomarker interleukin-6 (IL-6) showed no sex difference.	Diethylnitrosamine	31-34	interleukin 6	Mus musculus	233-246
27746196-6	2016	Exposure of adult mice to ABP, DEN or CCl4 produced a 2-fold greater acute elevation in serum levels of the hepatotoxicity biomarker alanine aminotransferase (ALT) in males than in females, while levels of the inflammatory biomarker interleukin-6 (IL-6) showed no sex difference.	Diethylnitrosamine	31-34	interleukin 6	Mus musculus	248-252
27825966-4	2016	Pretreatment with hypericin (5 muM and 15 muM) significantly suppresses oligomeric Abeta42 (oAbeta42)-induced expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity.	hypericin	18-27	interleukin 6	Mus musculus	154-167
27825966-4	2016	Pretreatment with hypericin (5 muM and 15 muM) significantly suppresses oligomeric Abeta42 (oAbeta42)-induced expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha) and inducible nitric oxide synthase (iNOS) and production of NO in microglia without cytotoxicity.	hypericin	18-27	interleukin 6	Mus musculus	169-173
27783409-8	2016	SPD-MAA stimulated a significant dose-dependent increase in TNF-alpha and interleukin (IL)-6 release from peritoneal macrophages (PMs) of wild-type (WT) mice.	spd-maa	0-7	interleukin 6	Mus musculus	74-92
27994586-8	2016	Interestingly, licofelone increased IL-6 and IL-10 secretion when administered after the LPS stimulus, demonstrating an environment-dependent effect of licofelone.	licofelone	15-25	interleukin 6	Mus musculus	36-40
27664853-4	2016	In RAW264.7 macrophages, IinQ drastically suppressed activation of upstream IKK signaling events including membrane-bound IRAK1 ubiquitination and IKK phosphorylation by the TLR4 ligand, resulting in reduced expression of proinflammatory mediators including IL-6, TNF-alpha, and nitric oxide.	iinq	25-29	interleukin 6	Mus musculus	258-262
27636512-5	2016	RESULTS: Our data revealed that lipopolysaccharide (LPS)-induced interleukin (IL)-1beta, tumor necrosis factor-alpha, and IL-6 productions were markedly inhibited by GL or LG in RAW264.7 macrophages without inducing cytotoxicity.	gl	166-168	interleukin 6	Mus musculus	122-126
27390295-9	2016	IL-6 knockdown abrogated LPA-induced ATX expression in fibroblasts, and ATX inhibition attenuated IL-6 expression in fibroblasts and the skin of bleomycin-challenged mice.	lysophosphatidic acid	25-28	interleukin 6	Mus musculus	0-4
27390295-9	2016	IL-6 knockdown abrogated LPA-induced ATX expression in fibroblasts, and ATX inhibition attenuated IL-6 expression in fibroblasts and the skin of bleomycin-challenged mice.	Bleomycin	145-154	interleukin 6	Mus musculus	0-4
27390295-9	2016	IL-6 knockdown abrogated LPA-induced ATX expression in fibroblasts, and ATX inhibition attenuated IL-6 expression in fibroblasts and the skin of bleomycin-challenged mice.	Bleomycin	145-154	interleukin 6	Mus musculus	98-102
27636512-8	2016	In FST-induced fatigue mouse model, the mice which received the GL or LG for 21days showed significant decreases of IL-1beta, IL-6, and NO serum levels.	gl	64-66	interleukin 6	Mus musculus	126-130
27710897-6	2016	And the results showed that BZ-26 administration attenuated plasma tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) secretion, which are vital cytokines in acute inflammation.	bz-26	28-33	interleukin 6	Mus musculus	111-124
27710897-6	2016	And the results showed that BZ-26 administration attenuated plasma tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) secretion, which are vital cytokines in acute inflammation.	bz-26	28-33	interleukin 6	Mus musculus	126-130
27829543-5	2016	Our results shown that PA significantly decreased the urine levels of uric acid and creatinine, serum and kidney levels of cytokines such as interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), PA also obviously attenuated the histological changes of the kidney tissues caused by CYP.	peoniflorin	23-25	interleukin 6	Mus musculus	141-154
27829543-5	2016	Our results shown that PA significantly decreased the urine levels of uric acid and creatinine, serum and kidney levels of cytokines such as interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), PA also obviously attenuated the histological changes of the kidney tissues caused by CYP.	peoniflorin	23-25	interleukin 6	Mus musculus	156-160
27829544-7	2016	ARG6 significantly improved serum cytokine levels of IL-2, IL-6, IFN-gamma and TNF-alpha, and decreased VEGF compared with ARG.	arctigenin	0-3	interleukin 6	Mus musculus	59-63
27659181-8	2016	While the levels of inflammatory cytokine levels were markedly higher in KC mice versus WT mice challenged with LPS, CDDO-Im significantly decreased the production of IL-6, CCL-2, vascular endothelial growth factor and G-CSF in the KC mice.	1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole	117-124	interleukin 6	Mus musculus	167-171
27619518-8	2016	Carvedilol treatment also significantly reduced the levels of proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, transforming growth factor (TGF)-beta1 and monocyte chemoattractant protein (MCP)-1 in the lung tissue.	Carvedilol	0-10	interleukin 6	Mus musculus	147-151
27716530-5	2016	Furthermore, Naringin inhibited LPS-induced increase of TNF-alpha, IL-1beta and IL-6 activities to alleviate inflammatory response in heart.	naringin	13-21	interleukin 6	Mus musculus	80-84
26296324-5	2016	In addition, vanillin markedly attenuated the expression levels of proinflammatory cytokines, including tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and COX2 and prevented KBrO3 -induced hepatic cell alteration and necrosis, as indicated by histopathological data.	vanillin	13-21	interleukin 6	Mus musculus	152-165
28101182-6	2016	Furthermore, treatment with taraxasterol significantly suppressed tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and nuclear factor-kappaB protein expression levels compared with those in the rheumatoid arthritis model mice.	taraxasterol	28-40	interleukin 6	Mus musculus	119-123
27535761-0	2016	Astrocyte-targeted production of interleukin-6 reduces astroglial and microglial activation in the cuprizone demyelination model: Implications for myelin clearance and oligodendrocyte maturation.	Cuprizone	99-108	interleukin 6	Mus musculus	33-46
27793734-7	2016	Ethanol increased the release of reactive oxygen species, oxidized glutathione, interleukin-6, tumor necrosis factor-alpha, nitric acid and prostaglandin E2.	Ethanol	0-7	interleukin 6	Mus musculus	80-122
27535761-4	2016	Production of a key microglial attracting chemokine CXCL10, as well as CXCL1 and CCL4 was lower in cuprizone-treated GFAP-IL6Tg mice compared with cuprizone-treated WT.	Cuprizone	99-108	interleukin 6	Mus musculus	117-127
27535761-5	2016	Reduced microglial cell accumulation was associated with inefficient removal of degraded myelin and axonal protection in cuprizone-treated GFAP-IL6Tg mice, compared with WT mice at the peak of demyelination.	Cuprizone	121-130	interleukin 6	Mus musculus	139-149
27581278-3	2016	We observed that neougonin A reduced the production of inflammatory mediators (TNFalpha, PGE2, NO, IL-1beta, and IL-6; P &lt; 0.001) and inflammation-related proteins (iNOS and COX-2) induced by LPS in murine macrophage RAW 264.7 cells.	neougonin A	17-28	interleukin 6	Mus musculus	113-117
27535761-7	2016	Indeed, a microglial receptor involved in myelin phagocytosis, TREM2, as well as the phagolysosomal protein CD68 were lower in cuprizone-treated GFAP-IL6Tg compared with WT mice.	Cuprizone	127-136	interleukin 6	Mus musculus	145-155
27535761-8	2016	Our results show for the first time that astrocyte-targeted production of IL-6 may play a role in modulating experimental demyelination induced by cuprizone.	Cuprizone	147-156	interleukin 6	Mus musculus	74-78
27733068-8	2016	RESULTS: Mice submitted to l-arginine injections developed abdominal hyperalgesia and increased serum amylase, lipase, C-reactive protein and IL-6 concentrations; and increased pancreatic myeloperoxidase activity, edema index, MDA, and 3-nitrotyrosine contents.	Arginine	27-37	interleukin 6	Mus musculus	142-146
28164167-8	2016	Following TNBS treatment, IL-6 and artemin mRNA levels were decreased in the distal colon of NMS mice, despite increased MPO activity.	Trinitrobenzenesulfonic Acid	10-14	interleukin 6	Mus musculus	26-30
27614763-2	2016	Data from our lab to characterize the novel compound enaminone E121 have suggested that macrophages stimulated with lipopolysaccharide (LPS) release significantly decreased levels of TNF-alpha and IL-6 as measured by enzyme-linked immunosorbent assay as compared to the DMSO control group.	enaminone	53-62	interleukin 6	Mus musculus	197-201
27682182-6	2016	The overproduction of tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 during acute bacterial infection in mice exposed to different photoperiods was probably regulated by the administration of exogenous melatonin, by reducing neutrophil recruitment to spleen, expression of inducible nitric oxide synthase and cyclooxygenase-2 in hypothalamus, and C-reactive protein in the serum, and was also associated with improved behavioral response.	Melatonin	220-229	interleukin 6	Mus musculus	73-86
27581278-5	2016	It was suggested that the anti-inflammatory actions of neougonin A might be due to the downregulation of TNFalpha, IL-1beta, IL-6, NO, and PGE2 via the suppression of NF-kB signal transduction pathway.	neougonin A	55-66	interleukin 6	Mus musculus	125-129
27590234-5	2016	Compared with the LC-induced mouse, the level of inflammatory cytokines (IL-17, IL-6, TNF-alpha, and TGF-beta) of the BALF in the resveratrol + cigarette smoke-treated mouse had obviously decreased.	Resveratrol	130-141	interleukin 6	Mus musculus	80-84
27177192-5	2016	Here, P. aeruginosa grown in the presence of 2,3-butanediol and encapsulated in agar beads persisted longer in the murine respiratory tract, induced enhanced TNF-alpha and IL-6 responses and resulted in increased colonization in the lung tissue by environmental microbes.	2,3-butylene glycol	45-59	interleukin 6	Mus musculus	172-176
27177192-5	2016	Here, P. aeruginosa grown in the presence of 2,3-butanediol and encapsulated in agar beads persisted longer in the murine respiratory tract, induced enhanced TNF-alpha and IL-6 responses and resulted in increased colonization in the lung tissue by environmental microbes.	Agar	80-84	interleukin 6	Mus musculus	172-176
27702567-9	2016	In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively.	Berberine	13-22	interleukin 6	Mus musculus	71-75
27702567-9	2016	In addition, berberine reduced the elevated levels of serum TNF-alpha, IL-6 and MCP-1 and the expressions of TNF-alpha, IL-6 and MCP-1 and attenuated the phosphorylation of JNK and IKKbeta and the expression of NF-kappaB p65 in the obese adipose tissue, Raw264.7 macrophages and 3T3-L1 adipocytes, respectively.	Berberine	13-22	interleukin 6	Mus musculus	120-124
27878238-6	2016	Treatment with nobiletin reduced serum alanine aminotransferase and aspartate aminotransferase levels, improved hepatic structure, and suppressed hepatic interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha production 24 h after LPS/GalN exposure.	nobiletin	15-24	interleukin 6	Mus musculus	178-214
27774592-5	2016	Furthermore, rifampicin dramatically reduced the disruption of blood-brain barrier integrity, down-regulated serum concentration of IL-6 and IL-17A, inhibited pathological Th17 cell differentiation, and modulated the expression of p-STAT3 and p-p65.	Rifampin	13-23	interleukin 6	Mus musculus	132-136
27782292-5	2016	DMA significantly attenuated the secretion of TNFalpha, IL-6, IL-10, and granulocyte macrophage colony stimulating factor (GM-CSF) from LPS-stimulated RAW 264.7 cells, IL-6 secretion from TNFalpha-stimulated JEG-3 cells and TNFalpha, IL-6, IL-10, GM-CSF and Interleukin-8 (IL-8) from LPS-stimulated human placental explants.	dimethylacetamide	0-3	interleukin 6	Mus musculus	56-60
27782292-5	2016	DMA significantly attenuated the secretion of TNFalpha, IL-6, IL-10, and granulocyte macrophage colony stimulating factor (GM-CSF) from LPS-stimulated RAW 264.7 cells, IL-6 secretion from TNFalpha-stimulated JEG-3 cells and TNFalpha, IL-6, IL-10, GM-CSF and Interleukin-8 (IL-8) from LPS-stimulated human placental explants.	dimethylacetamide	0-3	interleukin 6	Mus musculus	168-172
27788393-7	2016	In addition, the histone deacetylase inhibitor trichostatin A increased miR-142-3p expression by more than 3-fold in LPS-treated macrophages from aged mice compared with young mice, which in turn suppressed LPS-stimulated IL-6 production, suggesting that inhibition of miR-142-3p by histone deacetylation may be involved in the lack of response to LPS stimulation in macrophages of aged mice.	trichostatin A	47-61	interleukin 6	Mus musculus	222-226
27909560-7	2016	RESULTS: Quercetin supplementation decreased levels of inflammatory cytokines (TNFalpha, IL-6) and increased that of the anti-inflammatory cytokine (IL-10) in the livers of HFD-fed mice.	Quercetin	9-18	interleukin 6	Mus musculus	89-93
27387273-8	2016	Examination of cytokine levels (TNF-alpha, IL-1beta and IL-6) in each group proved that silymarin treatment significantly decreased inflammation in DIO mice.	Silymarin	88-97	interleukin 6	Mus musculus	56-60
27252117-11	2016	Moreover, IL-6, TNF-alpha and CRP levels were increased following acetaminophen hepatotoxicity.	Acetaminophen	66-79	interleukin 6	Mus musculus	10-14
27599597-10	2016	Eucalyptol reduced cytokine levels (IL-1beta, IL-6 and KC) at 3 mg/mL and 10 mg/mL concentrations (p &lt; 0.01) compared to the CS group.	Eucalyptol	0-10	interleukin 6	Mus musculus	46-57
27252117-13	2016	The tissue levels of IL-6, TNF-alpha and CRP were markedly decreased by 21-day treatment with metformin (200 mg/kg/d) (p &lt; 0.001).	Metformin	94-103	interleukin 6	Mus musculus	21-25
27558745-9	2016	Exposure of NHBE cells to nicotine for 5 days increased interleukin (IL)-6 and IL-8 secretion.	Nicotine	26-34	interleukin 6	Mus musculus	56-74
27713163-3	2016	By AAI exposure, the liver-like tissue exhibited the paracrine interleukin-6 phenotypic characteristics.	aristolochic acid I	3-6	interleukin 6	Mus musculus	63-76
27916090-8	2016	Gallic acid could reduce the elevated expression levels of TNF-alpha, IL-1 and IL-6 induced by LPS.	Gallic Acid	0-11	interleukin 6	Mus musculus	79-83
27928219-7	2016	The SDS reduced the inflammatory cells in BALF, decreased the wet/dry ratio of lungs, attenuated the LPS-induced histological alterations in the lung, and inhibited the production of TNF-alpha, IL-1beta, and IL-6.	rhodioloside	4-7	interleukin 6	Mus musculus	208-212
27886121-5	2016	Sodium butyrate ameliorated histological colitis and decreased levels of tumor necrosis factor (TNF)-alpha and IL-6 in IL-10-/- mice compared with those without treatment.	Butyric Acid	0-15	interleukin 6	Mus musculus	111-115
27594673-3	2016	Our data show GPER knockout in a diethylnitrosamine (DEN)-induced mouse tumor model significantly accelerated liver tumorigenesis, accompanied by enhanced immune cell infiltration, fibrosis, and the production of inflammatory factors, such as interleukin-6 (IL-6).	Diethylnitrosamine	53-56	interleukin 6	Mus musculus	243-256
27594673-3	2016	Our data show GPER knockout in a diethylnitrosamine (DEN)-induced mouse tumor model significantly accelerated liver tumorigenesis, accompanied by enhanced immune cell infiltration, fibrosis, and the production of inflammatory factors, such as interleukin-6 (IL-6).	Diethylnitrosamine	53-56	interleukin 6	Mus musculus	258-262
27884981-4	2016	Genetic and pharmacological analyses indicate that OSKM-induced senescence requires the Ink4a/Arf locus and, through the production of the cytokine interleukin-6, creates a permissive tissue environment for in vivo reprogramming.	oskm	51-55	interleukin 6	Mus musculus	148-161
27876064-11	2016	Treatment of HFD fed mice with melatonin led to a significant decrease in the expression of TNF-alpha, IL-1beta, and IL-6 measured using quantitative real-time polymerase chain reaction (qRT-PCR).	Melatonin	31-40	interleukin 6	Mus musculus	117-121
27874086-5	2016	In wild-type (WT) mice with CS, Ani/Neo combination increased 24 h survival rate and decreased the levels of H2O2, MPO, NO, TNFalpha, IL-6 and IL-10 in compressed muscle.	anisodamine	32-35	interleukin 6	Mus musculus	134-138
28480385-8	2017	Furthermore, ULL and ULL+cefazolin both could significantly decrease the serum levels of IgG and IgM, and the levels of IL-6, IL-10 in mice lung tissue.	Cefazolin	25-34	interleukin 6	Mus musculus	120-124
27920472-7	2016	RESULTS: The results demonstrated that WIN55 or SB treatment alone or together improved the pathological changes in mice with DSS colitis, decreased the plasma levels of TNF-alpha, and IL-6, and MPO activity in colon.	win55	39-44	interleukin 6	Mus musculus	185-189
27920472-7	2016	RESULTS: The results demonstrated that WIN55 or SB treatment alone or together improved the pathological changes in mice with DSS colitis, decreased the plasma levels of TNF-alpha, and IL-6, and MPO activity in colon.	SB 203580	48-50	interleukin 6	Mus musculus	185-189
27881334-9	2016	RIP140 over-expression inhibited HCM-induced M2 polarization and the activation of NF-kappaB/IL-6 axis in the TAMs, and RIP140- overexpressing TAMs obviously suppressed the growth of H22 cell xenograft in nude mice.	hcm	33-36	interleukin 6	Mus musculus	93-97
27874086-5	2016	In wild-type (WT) mice with CS, Ani/Neo combination increased 24 h survival rate and decreased the levels of H2O2, MPO, NO, TNFalpha, IL-6 and IL-10 in compressed muscle.	neo	36-39	interleukin 6	Mus musculus	134-138
27855209-9	2016	RESULTS: APAP overdose significantly increased the serum alanine transferase (ALT) levels, hepatic activities of myeloperoxidase (MPO), expression of cytokines (TNF-alpha, IL-6, and IL-17), and malondialdehyde (MDA) activity when compared with the control animals.	Acetaminophen	9-13	interleukin 6	Mus musculus	172-176
27855689-13	2016	In bEnd3 cells, morphine did not affect the mRNA expression of interleukin-1beta (IL-1beta), but increased IL-6 and tumor necrosis factor-alpha (TNF-alpha) mRNA expression; the effect was inhibited by metformin.	Morphine	16-24	interleukin 6	Mus musculus	107-111
27895584-10	2016	In addition, iPS cell administration remarkably suppressed BLM-induced up-regulation of pulmonary inflammatory mediators, including tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and prostaglandin E2.	IPS	13-16	interleukin 6	Mus musculus	185-189
27620720-2	2016	By overexpression of TLR2 or TLR4 in HEK293 cells, we demonstrated that TLR2, but not TLR4, recognizes heat-stable compounds of O. tsutsugamushi that were sensitive to treatment with sodium hydroxide, hydrogen peroxide, and proteinase K. TLR2 was required for the secretion of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) by dendritic cells.	Sodium Hydroxide	183-199	interleukin 6	Mus musculus	321-334
27620720-2	2016	By overexpression of TLR2 or TLR4 in HEK293 cells, we demonstrated that TLR2, but not TLR4, recognizes heat-stable compounds of O. tsutsugamushi that were sensitive to treatment with sodium hydroxide, hydrogen peroxide, and proteinase K. TLR2 was required for the secretion of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) by dendritic cells.	Sodium Hydroxide	183-199	interleukin 6	Mus musculus	336-340
27568840-4	2016	Treatment of M1 macrophages with niacin (300muM) resulted in down-regulation of the p65 NF-kappaB phosphorylation, associated with a marked decrease in the levels of M1 markers, including CD86, IL-12, and IL-6, and a significant increase in the expressions of M2 markers, such as CD206, IL-10, and IL-13, suggesting that niacin causes a shift of M1 to M2.	Niacin	33-39	interleukin 6	Mus musculus	205-209
27742831-4	2016	This directly correlates with an inflammatory phenotype because glycolysis inhibition by 2-deoxyglucose abolished GM-CSF-mediated increase of TNF-alpha, IL-1beta, IL-6, and IL-12p70 synthesis upon LPS stimulation.	Deoxyglucose	89-103	interleukin 6	Mus musculus	163-167
27747357-5	2016	Furthermore, oral administration of beta-glucans decreases the concentration of malondialdehyde (MDA) and myeloperoxidase (MPO) and inhibits the expression of iNOS and several inflammatory factors: TNF-alpha, IL-1beta and IL-6 as well as nitric oxide (NO) of the colonic tissues.	beta-Glucans	36-48	interleukin 6	Mus musculus	222-226
27798160-0	2016	Water-in-Oil-Only Adjuvants Selectively Promote T Follicular Helper Cell Polarization through a Type I IFN and IL-6-Dependent Pathway.	Water	0-5	interleukin 6	Mus musculus	111-115
27798160-0	2016	Water-in-Oil-Only Adjuvants Selectively Promote T Follicular Helper Cell Polarization through a Type I IFN and IL-6-Dependent Pathway.	Oils	9-12	interleukin 6	Mus musculus	111-115
27811936-8	2016	DSS-treated TG2-/- mice showed lower interleukin (IL)-6, but higher IL-17A and RORgammat (retinoic acid receptor-related orphan receptor-gammat) expression levels in the colon tissues than that in the wild-type mice.	Dextran Sulfate	0-3	interleukin 6	Mus musculus	37-55
27552320-11	2016	Several pro-inflammatory cytokines (IL-1alpha, IL-1beta, IL-6, IL-33, IL-17alpha, MIP-1beta and TNF-alpha) had decreased in GQDG group compared with Control group.	gqdg	124-128	interleukin 6	Mus musculus	57-61
27440777-7	2016	WT adenine-fed mice were anemic and had low serum iron, elevated Hamp, and elevated IL6 and TNF-alpha.	Adenine	3-10	interleukin 6	Mus musculus	84-87
26825574-8	2016	Meanwhile, functional assays suggested that Hcy not only promoted Bv2 secretion of the pro-inflammatory cytokines IL-1beta, TNF-alpha, and IL-6, but also enhanced Bv2 migration and invasion, with 100 muM being the most effective concentration.	Homocysteine	44-47	interleukin 6	Mus musculus	139-143
27680589-5	2016	Compound 4 pretreatment resulted in markedly suppression of TPA-induced IL-1beta, IL-6, TNF-alpha, and COX-2, respectively.	Tetradecanoylphorbol Acetate	60-63	interleukin 6	Mus musculus	82-86
27562518-7	2016	OGD/R significantly decreased the cell viability and increased the release of IL-1beta, IL-6, IL-8, IL-10, TNF-alpha in BV2 microglia cells; these effects were suppressed by ginkgolide and bilobalide.	bilobalide	189-199	interleukin 6	Mus musculus	88-92
27357266-4	2016	ELISA and western blotting experiments indicated that sn-1,2-diacylglycerols suppress LPS-induced responses, including IL-6 and TNF-alpha production, and COX-2 expression in mouse RAW264.7 macrophages and human endothelial cells, in a dose-dependent manner.	sn-1,2-diacylglycerols	54-76	interleukin 6	Mus musculus	119-123
27543936-6	2016	Our results demonstrate that Z-590 significantly decreases the production of nitric oxide (NO), tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, IL-1beta, cyclooxygenase (COX-2), inducible nitric oxide synthase (iNOS) as well as reactive oxygen species (ROS) involved in inhibiting MAKPs signalling pathway in LPS-stimulated microglia cells.	z-590	29-34	interleukin 6	Mus musculus	138-156
27764742-5	2016	Further, the effects of hyperin on cisplatin-induced TNF-alpha, IL-1beta and IL-6 were detected by ELISA.	Cisplatin	35-44	interleukin 6	Mus musculus	77-81
27847478-10	2016	Compared with the untreated chronic viral myocarditis mice, ivabradine significantly increased the survival rate, attenuated the myocardial lesions and fibrosis, improved the impairment of the left ventricular function, diminished the heart dimension, decreased the production of collagen I and collagen III, reduced the expression of the proinflammatory cytokines TNF-alpha, IL-1beta, and IL-6, and lowered the production of phospho-p38 MAPK.	Ivabradine	60-70	interleukin 6	Mus musculus	390-394
27588909-5	2016	Our subsequent analyses demonstrated that phloretin could significantly suppress LPS-induced neutrophil infiltration of lung tissue, and reduce the levels of IL-6 and tumor necrosis factor (TNF)-alpha in serum and bronchoalveolar lavage fluid.	Phloretin	42-51	interleukin 6	Mus musculus	158-162
27764742-8	2016	The levels of BUN, creatinine, ROS, MDA, TNF-alpha, IL-1beta and IL-6 induced by cisplatin were also inhibited by hyperin.	Cisplatin	81-90	interleukin 6	Mus musculus	65-69
26923552-1	2016	Our previous studies have shown that Dexamethasone (Dex) reduced the expression of matrix-metalloproteinases (MMPs -1,-3,-9,-13), IL-1beta and IL-6, while it significantly increased MMP-8 mRNA transcripts in a concomitant dry eye and corneal alkali burn murine model (CM).	Dexamethasone	37-50	interleukin 6	Mus musculus	143-147
28025996-11	2016	Rosuvastatin significantly decreased the expression levels of pro-inflammatry cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and transforming growth factor (TGF)-beta1.	Rosuvastatin Calcium	0-12	interleukin 6	Mus musculus	132-150
26923552-1	2016	Our previous studies have shown that Dexamethasone (Dex) reduced the expression of matrix-metalloproteinases (MMPs -1,-3,-9,-13), IL-1beta and IL-6, while it significantly increased MMP-8 mRNA transcripts in a concomitant dry eye and corneal alkali burn murine model (CM).	Dexamethasone	37-40	interleukin 6	Mus musculus	143-147
26923552-4	2016	Here we demonstrate that topical Dex treated MMP-8KO mice subjected to CM showed reduced corneal clarity, increased expression of inflammatory mediators (IL-6, CXCL1, and MMP-1 mRNA) and increased neutrophil infiltration at 2D and 5D compared to Dex treated WT mice.	Dexamethasone	33-36	interleukin 6	Mus musculus	154-158
26059902-11	2016	The IR-induced muscle inflammatory mediator gene expressions, blood macrophage percentage, and plasma IL-6 concentration had declined at an early or a late phase of reperfusion when GLN was administered.	Glutamine	182-185	interleukin 6	Mus musculus	102-106
26607631-10	2016	Artemether significantly suppressed pro-inflammatory mediators (NO/iNOS, PGE2/COX-2/mPGES-1, tumour necrosis factor-alpha (TNFalpha) and interleukin (IL)-6); Abeta and BACE-1 in BV2 cells following LPS stimulation.	Artemether	0-10	interleukin 6	Mus musculus	137-155
27494533-0	2016	Chronic exposure to endosulfan induces inflammation in murine colon via beta-catenin expression and IL-6 production.	Endosulfan	20-30	interleukin 6	Mus musculus	100-104
27503807-4	2016	Internalized CpG oligodeoxynucleotide (ODN)-conjugated PPMs (PPM-CpG) greatly enhance the induction of selected cytokines (TNF-alpha and IL-6) in RAW 264.7 cells compared to that by the soluble CpG ODN and ionic complexes.	Oligodeoxyribonucleotides	17-37	interleukin 6	Mus musculus	137-141
27503807-4	2016	Internalized CpG oligodeoxynucleotide (ODN)-conjugated PPMs (PPM-CpG) greatly enhance the induction of selected cytokines (TNF-alpha and IL-6) in RAW 264.7 cells compared to that by the soluble CpG ODN and ionic complexes.	Oligodeoxyribonucleotides	39-42	interleukin 6	Mus musculus	137-141
27859308-6	2016	Importantly, we observed that resatorvid (TAK-242), a molecularly targeted clinical TLR4 antagonist, blocks UV-induced NF-kappaB and MAP kinase/AP-1 activity and cytokine expression (Il-6, Il-8, and Il-10) in cultured keratinocytes and in topically treated murine skin.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	42-49	interleukin 6	Mus musculus	183-187
27401255-8	2016	PD98059, an inhibitor of ERK kinase, attenuated LPS-induced nuclear translocation of NF-kappaB and induction of mRNAs for iNOS, IL-1beta and IL-6.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	interleukin 6	Mus musculus	141-145
27418278-5	2016	MSX (100 mug/mL) decreased H2O2-induced oxidative stress (16.1 % decrease in ROS levels compared to control), and down-regulated the production of lipopolysaccharide (LPS)-stimulated inflammatory markers (22.1, 19.9, 74.8, and 87.6 % decrease in NOS, IL-6, PGE2, and TNFalpha levels, respectively, compared to control) in murine BV-2 microglial cells.	msx	0-3	interleukin 6	Mus musculus	251-255
27687956-2	2016	In this study, we first showed that NaHS caused a concentration dependent reduction in TNFalpha and IL-6 secretion in LPS-stimulated RAW264.7 macrophages in the absence of cell death.	sodium bisulfide	36-40	interleukin 6	Mus musculus	100-104
27687956-8	2016	Moreover, the effect of FW1256 on TNFalpha and IL-6 by FW1256 in LPS-stimulated RAW264.7 macrophages was reversed by treatment with the H2S scavenger, vitamin B12a.	Hydrogen Sulfide	136-139	interleukin 6	Mus musculus	47-51
27687956-8	2016	Moreover, the effect of FW1256 on TNFalpha and IL-6 by FW1256 in LPS-stimulated RAW264.7 macrophages was reversed by treatment with the H2S scavenger, vitamin B12a.	Hydroxycobalamin	151-163	interleukin 6	Mus musculus	47-51
27775054-8	2016	Administration of SQ29548 inhibited microglia/macrophages activation and enrichment, including both M1 and M2 phenotypes, and attenuated ischemia-induced IL-1ss, IL-6, and TNF-alpha up-regulation and iNOS release.	SQ 29548	18-25	interleukin 6	Mus musculus	162-166
27796351-6	2016	Additionally, low receptor activator of nuclear factor-kappaB ligand (RANKL), tumor necrosis factor-alpha, interleukin-1beta, interleukin-6 and p65 immunochemistry staining were observed in strontium-treatment groups.	Strontium	190-199	interleukin 6	Mus musculus	126-139
27569861-3	2016	BHMB also reduced the mRNA expression of TNF-alpha, IL-6, and IL-1beta in LPS-stimulated RAW 264.7 cells.	5-bromo-2-hydroxy-4-methyl-benzaldehyde	0-4	interleukin 6	Mus musculus	52-56
27775097-4	2016	In CII-treated dendritic cells (DCs) and DC/CD4+ T coculture system, pretreatment with pharmacological antagonists of P2X7R (Suramin and A-438079) caused strong inhibition of production of Th17-promoting cytokines (IL-1beta, TGF-beta1, IL-23p19 and IL-6).	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	3-6	interleukin 6	Mus musculus	249-253
27752155-9	2016	The results of our investigation demonstrated that nicotine could reduce significantly the levels of IL-6, and TNF-alpha in serum (P&lt;0.05).	Nicotine	51-59	interleukin 6	Mus musculus	101-105
27938563-5	2016	Results: The results of ELISA showed that compared with the endotoxin+nicotine group of C57 NASH mice, the endotoxin+nicotine group of gene knockout NASH mice had significantly higher levels of IL-6 and TNF-alpha in supernatant (IL-6: 1 599+-65 pg/ml vs 1 465+-45 pg/ml, P &lt; 0.05; TNF-alpha: 1 567+-66 pg/ml vs 1 433+-50 pg/ml, P &lt; 0.05).	Nicotine	117-125	interleukin 6	Mus musculus	194-198
27938563-5	2016	Results: The results of ELISA showed that compared with the endotoxin+nicotine group of C57 NASH mice, the endotoxin+nicotine group of gene knockout NASH mice had significantly higher levels of IL-6 and TNF-alpha in supernatant (IL-6: 1 599+-65 pg/ml vs 1 465+-45 pg/ml, P &lt; 0.05; TNF-alpha: 1 567+-66 pg/ml vs 1 433+-50 pg/ml, P &lt; 0.05).	Nicotine	117-125	interleukin 6	Mus musculus	229-233
27760889-10	2016	Furthermore, GABA directly enhanced production of inflammatory cytokines including IL-6 and TNF-alpha in LPS activated RAW macrophage cells and increased TIB-73 hepatocyte death.	gamma-Aminobutyric Acid	13-17	interleukin 6	Mus musculus	83-87
27373848-5	2016	Donepezil significantly reduced intra- and extracellular levels of various kinds of inflammatory mediators such as TNF-alpha, IL-1beta, IL-2, IL-6 and IL-18 after the LPS stimulation, and attenuated LPS-induced nuclear translocation of nuclear factor-kappa B (NF-kappaB).	Donepezil	0-9	interleukin 6	Mus musculus	142-146
28808187-10	2016	Furthermore, GABA directly enhanced production of inflammatory cytokines including IL-6 and TNF-alpha in LPS activated RAW macrophage cells and increased TIB-73 hepatocyte death.	gamma-Aminobutyric Acid	13-17	interleukin 6	Mus musculus	83-87
27450485-6	2016	Casticin also inhibited the numbers of inflammatory cells and the levels of inflammatory cytokines TNF-alpha, IL-6, and IL-1beta production.	casticin	0-8	interleukin 6	Mus musculus	110-114
27829992-9	2016	As a result, the levels of cytokines (TNF-alpha, IL-6, and IL-1beta) were down-regulated and inflammatory cell infiltration after renal IRI was attenuated by treatment with DEX.	Dexamethasone	173-176	interleukin 6	Mus musculus	49-53
27477353-6	2016	The results showed that taraxasterol attenuated CS-induced lung pathological changes, inflammatory cells infiltration, inflammatory cytokines TNF-alpha, IL-6 and IL-1beta production.	taraxasterol	24-36	interleukin 6	Mus musculus	153-157
27784989-6	2016	Moringin pretreatment normalizes the aberrant Wnt-beta-catenin pathway, resulting in GSK3beta inhibition and beta-catenin upregulation, which regulates T-cell activation (CD4 and FoxP3), suppresses the main inflammatory mediators (IL-1beta, IL-6, and COX2), through activation of PPARgamma.	moringin	0-8	interleukin 6	Mus musculus	241-245
27619992-4	2016	Studies of PMN infiltration during zymosan-induced peritonitis reveal that hyperglycemia enhances PMN recruitment not through inducing a high level of IL-17, which is the case in colitis, but through increasing F4/80+ macrophages in the peritoneal cavity, resulting in elevations of IL-6, IL-1beta, TNF-alpha, and CXCL1 production.	Zymosan	35-42	interleukin 6	Mus musculus	283-287
27316397-4	2016	RESULTS: Artesunate could attenuate the progression of atherosclerosis lesion formation alone or combined with rosuvastatin in WD fed ApoE(-/-) mice without changes in food uptake, body weight and plasma lipids level, but with a significant reduction of pro-inflammatory cytokine, such as TNF-alpha and IL-6.	Artesunate	9-19	interleukin 6	Mus musculus	303-307
27316397-7	2016	CONCLUSION: AS attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through anti-inflammatory effect, resulting in down-regulation of TNF-alpha and IL-6, and further down-regulating IL-8 and MCP-1 expressions in aorta of WD fed ApoE(-/-) mice.	Rosuvastatin Calcium	97-109	interleukin 6	Mus musculus	190-194
27573239-6	2016	Importantly, treatment with the RUNX1 inhibitor, Ro 5-3335, protected mice from LPS-induced endotoxic shock and substantially reduced the IL-6 levels.	Ro 5-3335	49-58	interleukin 6	Mus musculus	138-142
27563010-5	2016	We found that rH-NS induced the production of TNF-alpha, IL-6, and IL-12p40, which relied on the activation of mitogen-activated protein kinases by stimulating the rapid phosphorylation of ERK1/2, p38, and JNK, and on the activation of transcription factor NF-kappaB in macrophages.	rh-ns	14-19	interleukin 6	Mus musculus	57-61
27711160-9	2016	Chronic-binge alcohol induces adipose tissue inflammation in vivo in female mice, which is illustrated by increased expression of TNFalpha, IL-6, and CCL2, compared to only IL-6 induction in male adipose tissue.	Alcohols	14-21	interleukin 6	Mus musculus	140-144
27460706-6	2016	In this study, we evaluate whether inhibiting IL-6 signaling in the brain is sufficient to modulate the autism-like behaviors on the BTBR mice.	btbr	133-137	interleukin 6	Mus musculus	46-50
27522255-7	2016	Aortic mRNA expression of macrophage inflammatory cytokines, including MCP-1, iNOS, IL-1beta, IL-6, CXCL9 and CXCL11, was also reduced in PA-treated mice.	patchouli alcohol	138-140	interleukin 6	Mus musculus	94-98
27223094-5	2016	Imipramine attenuated stress-induced corticosterone and IL-6 responses in plasma.	Imipramine	0-10	interleukin 6	Mus musculus	56-60
27460706-7	2016	The results showed that chronic infusion of an analog of the endogenous IL-6 trans-signaling blocker sgp130Fc protein increased the sociability in BTBR mice.	btbr	147-151	interleukin 6	Mus musculus	72-76
27460706-9	2016	However, inhibition of IL-6 trans-signaling increased the evoked glutamate release in synaptoneurosomes from the cerebral cortex of BTBR mice.	Glutamic Acid	65-74	interleukin 6	Mus musculus	23-27
27460706-9	2016	However, inhibition of IL-6 trans-signaling increased the evoked glutamate release in synaptoneurosomes from the cerebral cortex of BTBR mice.	btbr	132-136	interleukin 6	Mus musculus	23-27
27315014-13	2016	Moreover, mRNA levels of INF-gamma, TNF-alpha, IL-4 and IL-6 in ears of NOR-treated mice were reduced by 78.4, 77.8, 72.3 and 73.9%, respectively, compared with untreated controls.	norisoboldine	72-75	interleukin 6	Mus musculus	56-60
27465039-8	2016	Butein inhibited IL-6, IL-1beta and TNF-alpha production and mRNA expression.	butein	0-6	interleukin 6	Mus musculus	17-21
27440860-5	2016	Sorafenib induces differentiation of BMCs into suppressive dendritic cells that inhibit autologous T-cell proliferation and stimulate CD4(+) T cells to express increased IL-1beta, IL-2, IL-4, IL-10, IFN-gamma and TNF-alpha, and reduced levels of IL-6 and CD25, which indicates that sorafenib-induced dendritic cells represent a distinct cellular subset with unique properties.	Sorafenib	0-9	interleukin 6	Mus musculus	246-250
27498121-9	2016	In addition, liriodendrin decreased the production of the proinflammatory mediators including (TNF-alpha, IL-1beta, MCP-1, and IL-6) in lung tissues.	liriodendrin	13-25	interleukin 6	Mus musculus	127-131
27469104-7	2016	Dexpanthenol also markedly inhibited the LPS-induced neutrophiles influx, protein leakage, and release of TNF-alpha and IL-6 in bronchoalveolar lavage fluid (BALF).	dexpanthenol	0-12	interleukin 6	Mus musculus	120-124
27394986-5	2016	The possible mechanisms of Gent activities were explored by evaluating expression levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-6 using real-time fluorogenic PCR and expression levels of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) using Western blotting.	gentiopicroside	27-31	interleukin 6	Mus musculus	163-167
27161652-5	2016	Increased levels of conjugated dienes, lipid hydroperoxides, malondialdehyde, protein carbonyl and fragmented DNA were significantly lowered by lophirones B and C. Levels of tumour necrosis factor-alpha, interleukin-6 and 8 were significantly lowered in serum of acetaminophen treated mice by the chalcone dimers.	lophirones	144-154	interleukin 6	Mus musculus	204-217
27394986-7	2016	In addition, the mRNA expression of TNF-alpha, IL-1beta, IL-6 and the overexpression of COX-2 and iNOS proteins in the colon were down-regulated by Gent treatment.	gentiopicroside	148-152	interleukin 6	Mus musculus	57-61
27394986-8	2016	To our knowledge, this is the first study to demonstrate that Gent treatment can exert anti-inflammatory effects on experimental acute colitis through attenuating the expression levels of TNF-alpha, IL-1beta, IL-6, iNOS and COX-2, and it may present the therapeutic potential in the treatment of colitis.	gentiopicroside	62-66	interleukin 6	Mus musculus	209-213
27494687-9	2016	Betahistine treatment attenuated the severity of arthritis and reduced the levels of pro-inflammatory cytokines, including TNF-alpha, IL-6, IL-23 and IL-17A, in the paw tissues of CIA mice.	Betahistine	0-11	interleukin 6	Mus musculus	134-138
27497194-10	2016	Moreover, curcumin decreased the level of IL-6 in the tumor tissue and serum from LLC-bearing mice.	Curcumin	10-18	interleukin 6	Mus musculus	42-46
27497194-12	2016	And curcumin reduces the level of IL-6 in tumor-bearing mice to impair the expansion and function of MDSCs.	Curcumin	4-12	interleukin 6	Mus musculus	34-38
27600119-5	2016	The mRNA expression of interleukin (IL)-1beta (1.33+-0.38-fold) and IL-6 (0.64+-0.40-fold) in the brain tissue of beta-PGG-treated animals markedly decreased compared with that observed in the control groups (3.86+-0.91 and 2.45+-1.12-fold, respectively) and in the other LPS-administered groups.	beta-pgg	114-122	interleukin 6	Mus musculus	68-72
27610743-9	2016	Therefore, IL-6-/- and TNF-alpha-/- mice showed different hepatic triglyceride infiltration in response to different diets.	Triglycerides	66-78	interleukin 6	Mus musculus	11-15
26931732-4	2016	alpha-Solanine also reduced the production and mRNA expression of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1beta (IL-1beta) induced by LPS.	alpha-solanine	0-14	interleukin 6	Mus musculus	66-79
26931732-4	2016	alpha-Solanine also reduced the production and mRNA expression of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1beta (IL-1beta) induced by LPS.	alpha-solanine	0-14	interleukin 6	Mus musculus	81-85
26931732-6	2016	In an in vivo experiment of LPS-induced endotoxemia, treatment with alpha-solanine suppressed mRNA expressions of iNOS, COX-2, IL-6, TNF-alpha, and IL-1beta, and the activation of NF-kappaB in liver.	alpha-solanine	68-82	interleukin 6	Mus musculus	127-131
27733273-5	2016	Gomisin N inhibited LPS-induced expression of mRNAs for inflammation-related genes (inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha) in BV-2 cells.	schizandrin B	0-9	interleukin 6	Mus musculus	172-176
27493246-10	2016	IL6(-/-) osteoblasts displayed higher alkaline phosphatase (ALP) activity and higher mRNA levels of Runx2 and Colla1 than those in WT osteoblasts both in the control and PA treatment group (P &lt; 0.05).	Palmitic Acid	170-172	interleukin 6	Mus musculus	0-3
27125291-10	2016	IL-2, IL-4, and IL-6 levels were much higher in pristane-injected HBV(Tg) mice than pristane-injected BALB/c mice.	pristane	48-56	interleukin 6	Mus musculus	16-20
27161245-4	2016	METHODS AND RESULTS: Dietary oligonol supplementation (20 or 200 mg/kg bw) reduced glucose and insulin levels, improved oral glucose tolerance, and suppressed inflammatory markers, MCP-1 and IL-6, in High-Fat diet (HFD) induced obese mice.	oligonol	29-37	interleukin 6	Mus musculus	191-195
27218415-6	2016	EGCG also decreased colonic protein levels of IL-1beta, IL-6, and tumor necrosis factor-alpha, as well as colonic lipid peroxides compared to DSS-treated controls.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	56-93
27234527-8	2016	Furthermore, EGCG decreased MSU-triggered neutrophil cytosolic factor 1 and NLRP3 protein expression, limiting pro-inflammatory mediator secretion such as IL-1beta, IL-6, monocyte chemoattractant protein-1, and serum amyloid A.	epigallocatechin gallate	13-17	interleukin 6	Mus musculus	165-169
27311540-8	2016	While venlafaxine (4 mg/kg) reversed the elevated serum levels of IL-1beta and IL-6 found in chronically stressed mice, agomelatine (4 and 8 mg/kg) failed to show such a reversal.	Venlafaxine Hydrochloride	6-17	interleukin 6	Mus musculus	79-83
27209403-8	2016	Further neurochemical assays suggested that pretreatment with fisetin reversed LPS-induced overexpression of pro-inflammatory cytokine (IL-1beta, IL-6 and TNF-alpha) in the hippocampus and the prefrontal cortex (PFC).	fisetin	62-69	interleukin 6	Mus musculus	146-150
27270592-5	2016	Nimbolide significantly suppressed the expression of inflammatory cytokines (IL-6, IL-8, IL-12, and TNF-alpha) and inhibited the phosphorylation of IkappaBalpha and the DNA-binding affinity of NF-kappaB in IECs and macrophages.	nimbolide	0-9	interleukin 6	Mus musculus	77-81
27224271-4	2016	Gamma-terpinene treatment was found to reduce the production of proinflammatory cytokines, such as interleukin-1beta and interleukin-6, and enhance that of the anti-inflammatory cytokine interleukin-10.	gamma-terpinene	0-15	interleukin 6	Mus musculus	121-134
27557515-0	2016	Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate.	Aspirin	23-30	interleukin 6	Mus musculus	46-50
27224271-7	2016	Moreover, nimesulide treatment also abrogated the inhibitory effect of gamma-terpinene on interleukin-1beta and interleukin-6.	nimesulide	10-20	interleukin 6	Mus musculus	112-125
27224271-7	2016	Moreover, nimesulide treatment also abrogated the inhibitory effect of gamma-terpinene on interleukin-1beta and interleukin-6.	gamma-terpinene	71-86	interleukin 6	Mus musculus	112-125
27706063-6	2016	In addition, koumine-pretreated RAW 264.7 macrophages exhibited reduction of LPS-induced levels of TNF-alpha, IL-1beta, and IL-6 mRNA.	koumine	13-20	interleukin 6	Mus musculus	124-128
27557515-2	2016	Here we showed that therapeutic dosages of aspirin counteract the pro-tumorigenic effects of the inflammatory cytokine interleukin(IL)-6 in cancer and non-cancer cell lines, and in mouse liver in vivo.	Aspirin	43-50	interleukin 6	Mus musculus	119-136
27557515-3	2016	We found that therapeutic dosages of aspirin prevented IL-6 from inducing the down-regulation of p53 expression and the acquisition of the epithelial mesenchymal transition (EMT) phenotypic changes in the cell lines.	Aspirin	37-44	interleukin 6	Mus musculus	55-59
27618864-10	2016	ICV DFX treatment after SAH decreased cerebral IL-6 concentration and trended towards decreased mitochondrial superoxide anion production.	Deferoxamine	4-7	interleukin 6	Mus musculus	47-51
27584700-6	2016	Furthermore, allicin supplementation significantly decreased the levels of proinflammatory tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 and suppressed the expression of sterol regulatory element-binding protein-1 (SREBP-1) (p &lt; 0.05).	allicin	13-20	interleukin 6	Mus musculus	154-158
27663791-8	2016	The DHA-depleted group showed significantly increased TBI-induced expression of pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6 in the brain as well as slower functional recovery from motor deficits compared to the adequate ALA group.	Docosahexaenoic Acids	4-7	interleukin 6	Mus musculus	132-136
27444347-9	2016	Furthermore, the administration of SBE prevented significantly the increase of MPO activity, the NOx content, and the levels of IL-1, IL-6, TNF-alpha, INF-gamma and CRP and was able to increase the IL-10 levels after the inflammation induced by carrageenan in mice.	SBE	35-38	interleukin 6	Mus musculus	134-138
27621627-11	2016	Surprisingly, we found that MWCNT-OVA complex significantly increased the expression of major histocompatibility complex class II on macrophages and production of pro-inflammatory cytokines (tumor necrosis factor-alpha and interleukin 6), while MWCNTs without OVA protein corona did not.	mwcnt-ova	28-37	interleukin 6	Mus musculus	223-236
27672276-11	2016	The expression levels of IL-6 and IL-17 were increased in the serum of mice with DSS colitis but decreased after melatonin injection.	Melatonin	113-122	interleukin 6	Mus musculus	25-29
27464336-11	2016	Although alcohol increased TNF-alpha, IL-6, and IL-1beta mRNA, no change in key components of the NLRP3 inflammasome (NLRP3, ACS, and cleaved caspase-1) was detected suggesting alcohol did not increase pyroptosis.	Alcohols	9-16	interleukin 6	Mus musculus	38-42
27240136-4	2016	In addition, isocyperol downregulated the LPS-induced expression of several proinflammatory cytokines, such as interleukin-1beta (IL-1beta), IL-6, and monocyte chemotactic protein-1 (MCP-1).	isocyperol	13-23	interleukin 6	Mus musculus	141-145
27569388-9	2016	In mice with mild meningitis, edaravone treatment significantly decreased the number of leukocytes and TNF- levels in CSF, as well as the neuronal apoptosis and protein levels of HMGB1 and iNOS in the hippocampus, but did not affect the high levels of IL-10 and IL-6 in the hippocampus.	Edaravone	30-39	interleukin 6	Mus musculus	262-266
27430421-10	2016	Further research showed resveratrol and vitamin E inhibited the secretion of TNF-alpha and IL-6, and the phosphorylation of JNK and p38 MAPK, resulting in improved insulin resistance.	Resveratrol	24-35	interleukin 6	Mus musculus	91-95
27430421-10	2016	Further research showed resveratrol and vitamin E inhibited the secretion of TNF-alpha and IL-6, and the phosphorylation of JNK and p38 MAPK, resulting in improved insulin resistance.	Vitamin E	40-49	interleukin 6	Mus musculus	91-95
27236299-0	2016	Paeoniflorin suppresses IL-6/Stat3 pathway via upregulation of Socs3 in dendritic cells in response to 1-chloro-2,4-dinitrobenze.	peoniflorin	0-12	interleukin 6	Mus musculus	24-28
27240136-8	2016	Furthermore, isocyperol significantly increased the survival rate and attenuated serum levels of NO, PGE2, and IL-6 in LPS-induced septic shock mouse model.	isocyperol	13-23	interleukin 6	Mus musculus	111-115
27236299-0	2016	Paeoniflorin suppresses IL-6/Stat3 pathway via upregulation of Socs3 in dendritic cells in response to 1-chloro-2,4-dinitrobenze.	1-chloro-2,4-dinitrobenze	103-128	interleukin 6	Mus musculus	24-28
27236299-5	2016	In this study, we show clearly that PF markedly decreases IL-6/Stat3 in DCs stimulated with DNCB at both gene and protein levels compared with control DCs in vitro.	Dinitrochlorobenzene	92-96	interleukin 6	Mus musculus	58-62
27376853-11	2016	Notably, berberine treatment rescued surgery-induced cognitive impairment and inhibited the release of IBA1, IL-1beta, and IL-6 in the hippocampus.	Berberine	9-18	interleukin 6	Mus musculus	123-127
27270078-7	2016	Furthermore, parthenolide also significantly reduced the expression of pro-inflammatory cytokines such as IFN-gamma, TNF-alpha, IL-17A, IL-1beta and IL-6 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells in vitro.	parthenolide	13-25	interleukin 6	Mus musculus	149-153
27259840-9	2016	Although there were no significant differences in the bacterial count in the lungs amongst the drugs at 26h post-inoculation, TZD and LZD significantly improved the plasma concentrations of TNF-alpha, IL-6 and MIP-2, in comparison with the control.	tedizolid	126-129	interleukin 6	Mus musculus	201-205
27380619-7	2016	Also cavidine was able to decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), inhibit the up-regulation of cyclo-oxygenase-2 (COX-2) expression and activation of Nuclear factor-kappa B (NF-kappaB) pathway.	cavidine	5-13	interleukin 6	Mus musculus	49-62
27380619-7	2016	Also cavidine was able to decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), inhibit the up-regulation of cyclo-oxygenase-2 (COX-2) expression and activation of Nuclear factor-kappa B (NF-kappaB) pathway.	cavidine	5-13	interleukin 6	Mus musculus	64-68
27259840-9	2016	Although there were no significant differences in the bacterial count in the lungs amongst the drugs at 26h post-inoculation, TZD and LZD significantly improved the plasma concentrations of TNF-alpha, IL-6 and MIP-2, in comparison with the control.	Linezolid	134-137	interleukin 6	Mus musculus	201-205
27112251-7	2016	DSS increased disease severity, serum CRP and cytokines IL-1beta and IL-6, but decreased bacterial species richness, and shifted bacterial community composition.	Dextran Sulfate	0-3	interleukin 6	Mus musculus	69-73
27722140-10	2016	The release and expression of cytokines, such as TNF-alpha, interleukin (IL)-1beta, IL-6, and IL-10, were also significantly increased in response to treatment with WEMF.	wemf	165-169	interleukin 6	Mus musculus	84-88
26928963-8	2016	The CRTH2 antagonist OC-459, but not the DP antagonist MK0524, reduced inflammation scores and decreased TNF-alpha, IL-1beta, and IL-6 as compared with control mice.	(5-fluoro-2-methyl-3-quinolin-2-ylmethylindo-1-yl)acetic acid	21-27	interleukin 6	Mus musculus	130-134
27431288-7	2016	PQ also decreased the production of reactive oxygen species (ROS) and pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 in BALF.	Primaquine	0-2	interleukin 6	Mus musculus	144-162
26748661-7	2016	Tetrandrine could inhibit IL-6, IL-1beta, and TNF-alpha expression via blocking the nuclear translocation of nuclear factor (NF)-kappaB p65 in LPS-induced RAW 264.7 cells.	tetrandrine	0-11	interleukin 6	Mus musculus	26-30
29441852-4	2016	Methyl jasmonate treatment effectively inhibited LPS-induced production of pro-inflammatory mediators (nitric oxide and prostaglandin E2) and cytokines (tumor necrosis factor-alpha, interleukin (IL)-1beta, and IL-6) in a concentration-dependent manner.	methyl jasmonate	0-16	interleukin 6	Mus musculus	210-214
27133730-6	2016	Esculetin significantly reduced LPS-induced elevated levels of pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in serum and hippocampus.	esculetin	0-9	interleukin 6	Mus musculus	100-113
27133730-6	2016	Esculetin significantly reduced LPS-induced elevated levels of pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in serum and hippocampus.	esculetin	0-9	interleukin 6	Mus musculus	115-119
27166928-7	2016	Investigated fatty acids changed mRNA levels of IL6 and MCP1 in young, mature and old cells.	Fatty Acids	13-24	interleukin 6	Mus musculus	48-51
27574993-6	2016	TNFalpha, sTNFrs, IL-6 and IL-10 increased 2h post CLP.	Deuterium	43-45	interleukin 6	Mus musculus	18-22
27621593-6	2016	IL-6 is also implicated in the pathogenesis of SSc in animal models as it is increased in mice with bleomycin-induced fibrosis, whereas neutralization of IL-6 in these mice prevents skin fibrosis.	Bleomycin	100-109	interleukin 6	Mus musculus	0-4
27276653-6	2016	Silibinin treatment significantly attenuated microglial activation; down-regulated the level of the proinflammatory cytokine IL-6, anti-inflammatory cytokine IL-4, and inflammation-associated proteins, iNOS and COX-2; and further modulated MAPK to protect neural cells.	Silybin	0-9	interleukin 6	Mus musculus	125-129
27561705-15	2016	Infusion of soluble fractalkine into AOM-treated mice reduced liver damage, lessened microglia activation, and suppressed expression of chemokine ligand 2, interleukin-6, and tumor necrosis factor alpha compared to saline-infused mice.	Azoxymethane	37-40	interleukin 6	Mus musculus	156-169
27566665-11	2016	Interestingly, siponimod reduced the release of IL-6 and RANTES from activated microglial cells in vitro, which might explain the reduced lymphocyte infiltration.	siponimod	15-24	interleukin 6	Mus musculus	48-52
27527870-9	2016	Ethanol caused pancreatic inflammation which was indicated by the induction of TNF-alpha, IL-1beta, IL-6, MCP-1 and CCR2, and the increase of CD68 positive macrophages in the pancreas.	Ethanol	0-7	interleukin 6	Mus musculus	100-104
27589725-8	2016	Specific TLR9 inhibitor, ODN 2088 pretreatment can significantly attenuate mtDNA induced ALI and systemic inflammation, as demonstrated by improved lung injury score, decreased lung wet/dry ratio, BALF total protein concentration, and decreased systemic level of IL-1beta, IL-6 and HMGB1.	iCpG-ODN	25-33	interleukin 6	Mus musculus	273-277
27563884-9	2016	Taken together, LFs treatment alleviated AOM/DSS induced CAC via P53 and NFkappaB/IL-6/Jak2/Stat3 pathways, highlighting the potential of LFs in preventing CAC.	Dextran Sulfate	45-48	interleukin 6	Mus musculus	82-86
27554194-4	2016	Exogenous PAF inhibited the production of pro-inflammatory cytokines (IL-12p40, IL-6, and TNF-alpha) and increased anti-inflammatory IL-10 in macrophages challenged with Pam3Cys and LPS, but not with Poly (I:C).	Platelet Activating Factor	10-13	interleukin 6	Mus musculus	80-84
27311853-0	2016	N"-[(3-[benzyloxy]benzylidene]-3,4,5-trihydroxybenzohydrazide (1) protects mice against colitis induced by dextran sulfate sodium through inhibiting NFkappaB/IL-6/STAT3 pathway.	n"-[(3-[benzyloxy]benzylidene]-3,4,5-trihydroxybenzohydrazide	0-61	interleukin 6	Mus musculus	158-162
27311853-0	2016	N"-[(3-[benzyloxy]benzylidene]-3,4,5-trihydroxybenzohydrazide (1) protects mice against colitis induced by dextran sulfate sodium through inhibiting NFkappaB/IL-6/STAT3 pathway.	Dextran Sulfate	107-129	interleukin 6	Mus musculus	158-162
27311853-2	2016	In this study, we discovered the inhibitory activity of the polyphenol compound (1) in DSS induced colitis in mice by targeting NFkappaB/IL-6/STAT3 pathway.	Polyphenols	60-70	interleukin 6	Mus musculus	137-141
27578571-8	2016	In MES+CLP group, the mice showed obviously increased 72-h survival with lowered levels of ALT, AST, BUN, Cr, TNF-alpha, IL-6 and IL-1beta, increased levels of IL-10 and TGF-beta, and alleviated liver and kidney damages.	2-(N-morpholino)ethanesulfonic acid	3-6	interleukin 6	Mus musculus	121-125
27528441-4	2016	Diffusion tensor imaging showed that white matter microstructural abnormalities in the posterior corpus callosum were improved following treatment with low dose (1 mg/kg) laquinimod, and were paralleled by reduced levels of interleukin-6 in the periphery of YAC128 HD mice.	yac128	258-264	interleukin 6	Mus musculus	224-237
27267730-5	2016	Up-regulation of proinflammatory cytokines induced by LPS including TNF-alpha, IL-1beta and IL-6 were markedly suppressed by DHC treatment.	dihydrocapsaicin	125-128	interleukin 6	Mus musculus	92-96
27260672-7	2016	Furthermore, cavidine administration inhibited endotoxin-induced production of pro-inflammatory cytokines including TNF-alpha, IL-6 and HMGB1.	cavidine	13-21	interleukin 6	Mus musculus	127-131
27566778-5	2016	We used tissue-specific knockout mice to demonstrate that endothelial production of the proinflammatory cytokine IL-6 promotes chemoresistance and show that the chemotherapeutic doxorubicin induces acute IL-6 release through reactive oxygen species-mediated p38 activation in vitro.	Doxorubicin	178-189	interleukin 6	Mus musculus	204-208
27566778-5	2016	We used tissue-specific knockout mice to demonstrate that endothelial production of the proinflammatory cytokine IL-6 promotes chemoresistance and show that the chemotherapeutic doxorubicin induces acute IL-6 release through reactive oxygen species-mediated p38 activation in vitro.	Reactive Oxygen Species	225-248	interleukin 6	Mus musculus	113-117
27566778-5	2016	We used tissue-specific knockout mice to demonstrate that endothelial production of the proinflammatory cytokine IL-6 promotes chemoresistance and show that the chemotherapeutic doxorubicin induces acute IL-6 release through reactive oxygen species-mediated p38 activation in vitro.	Reactive Oxygen Species	225-248	interleukin 6	Mus musculus	204-208
27260672-9	2016	In summary, cavidine protects mice against LPS-induced endotoxic shock via inhibiting early pro-inflammatory cytokine TNF-alpha, IL-6 and late-phase cytokine HMGB1, and the modulation of HMGB1 may be related with MAPK signal pathway.	cavidine	12-20	interleukin 6	Mus musculus	129-133
27387396-14	2016	The expressions of MPO and MMP-9 and the mRNA levels of pro-inflammatory cytokines (IL-1beta, IL-6 and IL-12p35) in colonic tissue significantly decreased after MQEQ treatment.	mqeq	161-165	interleukin 6	Mus musculus	94-98
27507649-8	2016	Blockade of interleukin-6 (IL-6)-JAK-STAT signaling, NF-kappaB signaling, and bromodomain extraterminal proteins, which recognize acetylated lysines and promote transcriptional elongation, significantly reduced Il-6 and Mmp13 expression in HDAC3-deficient chondrocytes and secondary activation in osteoclasts.	Lysine	141-148	interleukin 6	Mus musculus	12-25
27507649-8	2016	Blockade of interleukin-6 (IL-6)-JAK-STAT signaling, NF-kappaB signaling, and bromodomain extraterminal proteins, which recognize acetylated lysines and promote transcriptional elongation, significantly reduced Il-6 and Mmp13 expression in HDAC3-deficient chondrocytes and secondary activation in osteoclasts.	Lysine	141-148	interleukin 6	Mus musculus	27-31
27547188-18	2016	Correspondingly, NF-kappaB expression in diabetic hearts was increased together with the elevation of S100A8/9 and activation of p38 MAPK signaling after DOX administration, which induced cardiac inflammation as demonstrated by the elevation of cardiac IL-6 level.	Doxorubicin	154-157	interleukin 6	Mus musculus	253-257
27054666-3	2016	In the present study, when mice were continuously exposed to TiO2 NPs at 2.5, 5 or 10mg/kg BW by intragastric administration for 90days, obvious histopathological changes, and great alterations of NF-kappaB and its inhibitor I-kappaB, as well as TNF-alpha, IL-1beta, IL-6 and IFN-alpha expression were induced.	titanium dioxide	61-65	interleukin 6	Mus musculus	267-271
27345627-6	2016	RESULTS: In LPS-treated BV2 cells and primary microglial cells, pretreatment with probucol (1, 5, 10 mumol/L) dose-dependently inhibited the release of NO, PGE2, IL-1beta and IL-6, which occurred at the transcription levels.	Probucol	82-90	interleukin 6	Mus musculus	175-179
27096537-6	2016	The inflammation markers MPO, IL-1beta, IL-6 and mKC (mouse keratinocyte chemoattractant) were increased by DSS and significantly reduced by the L. reuteri strains.	dss	108-111	interleukin 6	Mus musculus	40-44
27068250-4	2016	Myricetin administration decreased the production of NO, iNOS, TNF-alpha, IL-6, and IL-12 in mice.	myricetin	0-9	interleukin 6	Mus musculus	74-78
27329801-6	2016	IMT504 induced early blood glucose decrease and infiltration inhibition, increased beta-cell proliferation and decreased apoptosis, increased islet indoleamine 2,3-dioxygenase (IDO) expression, and increased serum tumor necrosis factor and interleukin-6 (IL-6).	IMT504	0-6	interleukin 6	Mus musculus	240-253
27329801-6	2016	IMT504 induced early blood glucose decrease and infiltration inhibition, increased beta-cell proliferation and decreased apoptosis, increased islet indoleamine 2,3-dioxygenase (IDO) expression, and increased serum tumor necrosis factor and interleukin-6 (IL-6).	IMT504	0-6	interleukin 6	Mus musculus	255-259
27037280-9	2016	The levels of hippocampal interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha were effectively attenuated by the administration of chelidonic acid.	chelidonic acid	141-156	interleukin 6	Mus musculus	50-87
27458759-0	2016	Boswellic acid disables signal transduction of IL-6-STAT-3 in Ehrlich ascites tumor bearing irradiated mice.	boswellic acid	0-14	interleukin 6	Mus musculus	47-51
27458759-2	2016	In this study, we investigated the effect of BA on the IL-6-STAT-3 signalling pathway in irradiated mice bearing solid tumors of Ehrlich ascites carcinoma (EAC).	boswellic acid	45-47	interleukin 6	Mus musculus	55-59
27458759-6	2016	We propose that BA interfered with IL-6-STAT-3 signal transduction, thereby preventing the activation of caspase-3 and subsequently triggering the process of apoptosis.	boswellic acid	16-18	interleukin 6	Mus musculus	35-39
27031380-11	2016	MEASUREMENTS AND MAIN RESULTS: Trametinib inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase signaling 6 hours after cecal ligation and puncture attenuated increases in circulating proinflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and granulocyte macrophage colony-stimulating factor) and hypothermia at 18 hours.	trametinib	31-41	interleukin 6	Mus musculus	290-303
27446282-9	2016	In the present study, curcumin demonstrated marked suppression of the LPS-induced expression of MyD88, NF-kappaB, caspase-3, inducible nitric oxide synthase, tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 in the microglia.	Curcumin	22-30	interleukin 6	Mus musculus	214-218
27138362-5	2016	Our results showed that isorhamnetin markedly decreased TNF-alpha, IL-1beta, and IL-6 concentrations and suppressed the activation of NF-kappaB signaling.	3-methylquercetin	24-36	interleukin 6	Mus musculus	81-85
27052008-9	2016	CONCLUSIONS: Kaliotoxin is able to induce neurological disorders by blocking the K(+) ion channel, and ATX suppresses this alterations with down regulation of IL-6, TNF-alpha and NF-kappaB expression in the brain.	astaxanthine	103-106	interleukin 6	Mus musculus	159-163
27150336-10	2016	The frequencies of Th17 and Tc17 cells, as well as the expressions of IL-6, IL-17, TGF-beta1, and ROR gammat were greater in the lungs of cigarette smoke (CS)-exposed mice, particularly in the 24-week CS-exposed mice.	Cesium	155-157	interleukin 6	Mus musculus	70-74
27351430-4	2016	Moreover, 1,8-cineol efficiently decreased the level of IL-4, IL-5, IL-10, and MCP-1 in nasal lavage fluids and the level of IL-1beta, IL-6, TNF-alpha, and IFN-gamma in lung tissues of mice infected with influenza virus.	Eucalyptol	10-20	interleukin 6	Mus musculus	135-139
27747134-10	2016	While saline and microbead injection increased Bcl-xl and Socs3 mRNA in both WT and IL-6-/- mice, IL-6-/- deficiency led to smaller increases for both Bcl-xl and Socs3.	Sodium Chloride	6-12	interleukin 6	Mus musculus	84-88
26711554-0	2016	Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3.	balsalazide	93-104	interleukin 6	Mus musculus	71-75
27746874-8	2016	Pretreatment with LCB decreased the levels of ALT, AST, MDA, GSSG, IL-6, CRP, TNF-alpha, and the protein expression of p38 and NF-kappaB, increased the level of SOD and GSH, and normalized the hepatic histo-architecture.	licochalcone B	18-21	interleukin 6	Mus musculus	67-71
26794005-0	2016	Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.	pu-erh	0-6	interleukin 6	Mus musculus	127-131
26794005-12	2016	In contrast, PTE inhibited IL-6-induced STAT3 phosphorylation in macrophages.	pte	13-16	interleukin 6	Mus musculus	27-31
27262853-6	2016	In addition, we found that UVB-induced expression of cytokines (interleukin-6; IL-6, interleukin-8; IL-8, and monocyte chemotactic protein-3; MCP3), which were reported as regulators in SC fat metabolism, was attenuated in mouse skin fibroblast cells upon administration of the DCM extract.	dcm	278-281	interleukin 6	Mus musculus	64-77
26956118-5	2016	Furthermore, resveratrol pretreatment inhibited PMA-induced expressions of macrophage surface markers (CD11b, CD14, and CD36) and PMA-induced NF-kappaB transcriptional activation and, thus, suppressed the secretions of proinflammatory cytokines (TNF-alpha, IL-1beta, and IL-6).	Resveratrol	13-24	interleukin 6	Mus musculus	271-275
27262853-7	2016	Collectively, our data suggest that topical administration of DCM extract of NNL, which plays a regulatory role in adipogenesis, could attenuate UVB-induced wrinkle formation and the metabolism of blood lipids by regulating the expression of cytokines such as IL-6, IL-8, and MCP3 in skin fibroblast cells.	dcm	62-65	interleukin 6	Mus musculus	260-264
27031739-6	2016	pGz treatment also accelerated the normalization of CK, TNF-alpha, MCP-1, and IL-6 while further increasing IL-10 concentrations.	Methyl 2-O-[(S)-(Benzyloxy)(Hydroxy)phosphoryl]-3-Deoxy-3-{[(4-Methylphenyl)carbonyl]amino}-1-Thio-Beta-D-Galactopyranoside	0-3	interleukin 6	Mus musculus	78-82
27161367-8	2016	In addition, treatment of experimental stroke mice with isorhamnetin suppressed activity of MPO (a biomarker of neutrophil infiltration) and reduced protein levels of IL-1beta, IL-6, and TNF-alpha in ipsilateral cortex.	3-methylquercetin	56-68	interleukin 6	Mus musculus	177-181
26969793-14	2016	Furthermore, the mRNA expression of IL-6 and IL-23, and the phosphorylation of STAT3 in colon tissues from DSS-treated mice were pronouncedly inhibited by berberine.	Berberine	155-164	interleukin 6	Mus musculus	36-40
27298203-7	2016	Furthermore, in vitro, hBD3 profoundly suppressed the production of TNF-alpha and IL-6 in RAW 264.7 cells induced by Pg-LPS in a dose-dependent manner.	pg-lps	117-123	interleukin 6	Mus musculus	82-86
27109323-6	2016	After injection with BaV, the TLR2(-/-) mice (TLR2(-/-)BaV) had higher levels of IL-6 and CCL-2 than WT animals kept under the same conditions (WTBaV), together with an accumulation of polymorphonuclear leukocytes (PMNs), inhibition of IL-1beta and LTB4 and reduced mononuclear leukocyte influx.	CHEMBL564010	21-24	interleukin 6	Mus musculus	81-85
27462372-7	2016	Hepatic expression of inflammatory genes (tumor necrosis factor-alpha, interleukin-6, and monocyte chemoattractant protein-1) was decreased in the empagliflozin and linagliptin + empagliflozin groups compared with the vehicle group.	empagliflozin	147-160	interleukin 6	Mus musculus	71-84
26918466-6	2016	In saline-treated mice fed control diet, aging increased the proportion of microglia that stained for MHC class II (&lt;3% for adults vs. 23% for aged), IL-1beta (&lt;2% for adults vs. 25% for aged), and IL-6 (&lt;2% for adults vs. 25% for aged), indicating an age-related increase in proinflammatory microglia.	Sodium Chloride	3-9	interleukin 6	Mus musculus	204-208
26918466-7	2016	In saline-treated aged mice fed luteolin, the proportion of microglia that stained for MHC class II, IL-1beta, and IL-6 was reduced by nearly half (to 12%, 13%, and 12%, respectively).	Sodium Chloride	3-9	interleukin 6	Mus musculus	115-119
27462372-7	2016	Hepatic expression of inflammatory genes (tumor necrosis factor-alpha, interleukin-6, and monocyte chemoattractant protein-1) was decreased in the empagliflozin and linagliptin + empagliflozin groups compared with the vehicle group.	Linagliptin	165-176	interleukin 6	Mus musculus	71-84
27757311-6	2016	Our results demonstrate that OSU-53 treatment increases the phosphorylation of AMPK, significantly reduces nitric oxide production, inhibits MDSC migration, and reduces the levels of IL-6 in murine MDSC cell line (MSC2 cells).	osu	29-32	interleukin 6	Mus musculus	183-187
27444332-4	2016	Mechanistic studies with mouse neonatal ventricular cardiomyocytes (mNVCM) reveal that hAFS-CM inhibition of Dox-elicited senescence and apoptosis is associated with decreased DNA damage, nuclear translocation of NF-kB, and upregulation of the NF-kB controlled genes, Il6 and Cxcl1, promoting mNVCM survival.	Doxorubicin	109-112	interleukin 6	Mus musculus	268-271
27154406-12	2016	EEAO treatment, however, significantly reduced emphysema and inflammatory cell infiltration to the lung with concomitant decrease of the production of pro-inflammatory cytokines including TNF-alpha, IL-6, and TGF-beta, signature cytokines of COPD.	eeao	0-4	interleukin 6	Mus musculus	199-203
27138708-4	2016	Downregulation of IL-6 expression by moracin M was mediated by interrupting the c-Jun N-terminal kinase (JNK)/c-Jun pathway.	moracin M	37-46	interleukin 6	Mus musculus	18-22
27184504-5	2016	Furthermore, protein and mRNA levels of pro-inflammatory cytokines, including IL-1beta, TNF-alpha and IL-6 were markedly suppressed by DMF.	Dimethyl Fumarate	135-138	interleukin 6	Mus musculus	102-106
28955931-5	2016	Moreover, the PPE-induced levels of IL-17 and IL-6 in BALF were significantly higher in CD69KO mice than in WT mice at the acute inflammatory phase.	ppe	14-17	interleukin 6	Mus musculus	46-50
27414646-3	2016	Eupafolin decreased the LPS-induced release of inflammatory mediators (iNOS, COX-2 and NO) and proinflammatory cytokines (IL-6 and TNF-alpha) from the RAW264.7 macrophages.	eupafolin	0-9	interleukin 6	Mus musculus	122-126
27391331-3	2016	Pre-cancerogenous events can be modelled in mice by the administration of a single dose of diethylnitrosamine (DEN), with HCC formation depending amongst others on interleukin (IL) 6 production.	Diethylnitrosamine	91-109	interleukin 6	Mus musculus	164-182
27462270-12	2016	It seemed that the anti-inflammatory mechanism of action of OAO-ASA (8) is not simple, even its chronic administration lowered both blood concentration of IL-6 and mRNA IL-6 expression.	oao-asa	60-67	interleukin 6	Mus musculus	155-159
27462270-12	2016	It seemed that the anti-inflammatory mechanism of action of OAO-ASA (8) is not simple, even its chronic administration lowered both blood concentration of IL-6 and mRNA IL-6 expression.	oao-asa	60-67	interleukin 6	Mus musculus	169-173
27391331-11	2016	When combining ABCB4 and TLR4 deficiency with DEN treatment, hepatic IL6 expression and proliferation rates are lowest in fibrotic livers from the double-deficient line.	Diethylnitrosamine	46-49	interleukin 6	Mus musculus	69-72
27388564-12	2016	In addition, LTD4 and PGE2 treatment significantly elevated the plasma levels of cysteinyl leukotrienes and PGE2, as well as levels of IL-1beta, IL-2, IL-6, TNF-alpha and CXCL1/KC/GRO.	Dinoprostone	22-26	interleukin 6	Mus musculus	151-155
27388564-13	2016	In addition, increased mRNA expression of IL-1beta, IL-6 and IL-10 were detected in tumors from mice that had been treated with LTD4 or PGE2.	Leukotriene D4	128-132	interleukin 6	Mus musculus	52-56
27388564-13	2016	In addition, increased mRNA expression of IL-1beta, IL-6 and IL-10 were detected in tumors from mice that had been treated with LTD4 or PGE2.	Dinoprostone	136-140	interleukin 6	Mus musculus	52-56
28852721-7	2016	The results of in vitro experiments showed that TFA stimulated the production of NO and cytokine TNF-alpha, IL-Iotabeta, IL-6 and IFN-gamma in un-stimulated RAW 264.7 macrophages, and inhibited the overproduction of these inflammatory mediators in LPS-stimulated RAW 264.7 macrophages in a dose-dependent manner without exerting cytotoxicity.	Trifluoroacetic Acid	48-51	interleukin 6	Mus musculus	121-125
27405597-4	2016	Here we show that methane-rich saline (MS) ip treatment (16 ml/kg) alleviated endotoxin shock, bacteria-induced sepsis and dextran-sulfate-sodium-induced colitis in mice via decreased production of TNF-alpha and IL-6.	Methane	18-25	interleukin 6	Mus musculus	212-216
27405597-4	2016	Here we show that methane-rich saline (MS) ip treatment (16 ml/kg) alleviated endotoxin shock, bacteria-induced sepsis and dextran-sulfate-sodium-induced colitis in mice via decreased production of TNF-alpha and IL-6.	Sodium Chloride	31-37	interleukin 6	Mus musculus	212-216
27190062-8	2016	Using an established intranasal inhalation exposure model, we found that salbutamol pretreatment reduced airway neutrophil influx and IL-6, TNF-alpha, CXCL1, and CXCL2 release in bronchoalveolar lavage fluid following a one-time exposure to HDE.	Albuterol	73-83	interleukin 6	Mus musculus	134-138
27323762-5	2016	Administration of phillyrin at a dose of 20 mg/kg/day for 3 days significantly prolonged the mean survival time, reduced the lung index, decreased the virus titers and interleukin-6 levels, reduced the expression of HA, and attenuated lung tissue damage in mice infected with influenza A virus.	phillyrin	18-27	interleukin 6	Mus musculus	168-181
26814830-8	2016	Subsequently, everolimus administration to the hepatic IRI-induced mice provided hepatoprotective effects in terms of (1) decreasing the expressions of pro-apoptotic proteins, (2) inhibiting the release of pro-inflammatory cytokines (IL-6 and tumor necrosis factor-alpha), (3) reducing elevated liver enzymes (aspartate transaminase, alanine transaminase, and ammonia), and (4) restoring liver histopathology.	Everolimus	14-24	interleukin 6	Mus musculus	234-270
27240856-5	2016	Mechanistically, ROFA exposure increased the levels of the circulating pro-inflammatory cytokines TNF-alpha, IL-6, and MCP-1, activated myeloid and endothelial cells, and enhanced leukocyte recruitment to the peritoneal cavity and the vascular endothelium.	rofa	17-21	interleukin 6	Mus musculus	109-113
27068262-9	2016	TSA inhibited the increased production of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 in LPS-stimulated RAW264.7 cells.	trichostatin A	0-3	interleukin 6	Mus musculus	80-98
26253096-7	2016	RESULTS: In chondrocytes, BCP crystals stimulated IL-6 secretion, further amplified in an autocrine loop, through signalling pathways involving Syk and PI3 kinases, Jak2 and Stat3 molecules.	bcp	26-29	interleukin 6	Mus musculus	50-54
26253096-8	2016	Exogenous IL-6 promoted calcium-containing crystal formation and upregulation of genes involved in calcification: the pyrophosphate channel Ank, the calcium channel Annexin5 and the sodium/phosphate cotransporter Pit-1.	Calcium	24-31	interleukin 6	Mus musculus	10-14
26253096-10	2016	In meniscectomised mice, increasing deposits of BCP crystals were observed around the joint and correlated with cartilage degradation and IL-6 expression.	bcp	48-51	interleukin 6	Mus musculus	138-142
27068262-10	2016	TSA improved sepsis-induced mortality, attenuated liver injury and decreased serum TNF-alpha and IL-6 levels.	trichostatin A	0-3	interleukin 6	Mus musculus	97-101
27170516-6	2016	Furthermore, sacran significantly suppressed 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse ear edema and mRNA expression levels of cyclooxygenase (COX)-2 as well as pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6.	sacran	13-19	interleukin 6	Mus musculus	274-278
27095137-6	2016	The production of IL-6 was significantly enhanced by peritoneal macrophages from SAE-administered BALB/c mice, suggesting that SAE has a potential to stimulate macrophage activity in vivo.	SELENAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE	81-84	interleukin 6	Mus musculus	18-22
27095137-6	2016	The production of IL-6 was significantly enhanced by peritoneal macrophages from SAE-administered BALB/c mice, suggesting that SAE has a potential to stimulate macrophage activity in vivo.	SELENAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE	127-130	interleukin 6	Mus musculus	18-22
27170516-6	2016	Furthermore, sacran significantly suppressed 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse ear edema and mRNA expression levels of cyclooxygenase (COX)-2 as well as pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6.	Tetradecanoylphorbol Acetate	45-81	interleukin 6	Mus musculus	274-278
27170516-6	2016	Furthermore, sacran significantly suppressed 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse ear edema and mRNA expression levels of cyclooxygenase (COX)-2 as well as pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6.	Tetradecanoylphorbol Acetate	83-86	interleukin 6	Mus musculus	274-278
27074351-6	2016	HKBA-injected mice had significantly lower hemoglobin, hematocrit, mean corpuscular volume, reticulocyte hemoglobin, transferrin saturation (TSAT), and tissue nonheme iron in liver and spleen, enlarged spleen, and up-regulated hepatic expression of inflammatory markers, serum amyloid A1, and TNFalpha, but down-regulated IL-6, bone morphogenic protein 6, and hepcidin compared with saline controls.	hkba	0-4	interleukin 6	Mus musculus	322-326
27207661-0	2016	Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.	icaritin	0-8	interleukin 6	Mus musculus	107-111
27155817-0	2016	Neutralization of IL-6 and TNF-alpha ameliorates intestinal permeability in DSS-induced colitis.	Dextran Sulfate	76-79	interleukin 6	Mus musculus	18-22
26862745-7	2016	Activation of AhR by TCDD caused a significant increase of the inflammatory cytokines Interleukin (IL)-1beta, IL-6 and IL-10, and CXCL chemokines in white epididymal adipose tissue from both wt and AhRR Tg mice.	Polychlorinated Dibenzodioxins	21-25	interleukin 6	Mus musculus	110-114
26971825-1	2016	BACKGROUND &amp; AIMS: Glucose-dependent insulinotropic peptide (GIP) induces production of interleukin 6 (IL6) by adipocytes.	Adenosine Monophosphate	12-15	interleukin 6	Mus musculus	92-105
27424994-0	2016	Role of vitamin D3 in regulation of interleukin-6 and osteopontin expression in liver of diabetic mice.	Cholecalciferol	8-18	interleukin 6	Mus musculus	36-49
27424994-1	2016	OBJECTIVE: To study the link between hepatic interleukin-6 (IL-6) and osteopontin (OPN) gene expression and vitamin D3 status associated with type 1 diabetes in mice; and to evaluate the effects of vitamin D3 treatment (800 IU/kg of body weight for 6 weeks) on diabetes-induced impairments.	Cholecalciferol	108-118	interleukin 6	Mus musculus	45-58
27424994-1	2016	OBJECTIVE: To study the link between hepatic interleukin-6 (IL-6) and osteopontin (OPN) gene expression and vitamin D3 status associated with type 1 diabetes in mice; and to evaluate the effects of vitamin D3 treatment (800 IU/kg of body weight for 6 weeks) on diabetes-induced impairments.	Cholecalciferol	108-118	interleukin 6	Mus musculus	60-64
27424994-6	2016	Vitamin D3 treatment restored 25OHD3 that led to a substantial reduction of OPN and IL-6 mRNA levels.	Cholecalciferol	0-10	interleukin 6	Mus musculus	84-88
27424994-7	2016	CONCLUSIONS: Diabetes-induced vitamin D3 deficiency was associated with increased hepatic levels of IL-6 and OPN mRNA and these changes were countered by vitamin D3 administration.	Cholecalciferol	30-40	interleukin 6	Mus musculus	100-104
26971825-1	2016	BACKGROUND &amp; AIMS: Glucose-dependent insulinotropic peptide (GIP) induces production of interleukin 6 (IL6) by adipocytes.	Adenosine Monophosphate	12-15	interleukin 6	Mus musculus	107-110
26971825-11	2016	Incubation of mouse islets with the sodium glucose transporter 2 inhibitor dapagliflozin induced production of GLP1 and IL6.	dapagliflozin	75-88	interleukin 6	Mus musculus	120-123
27034404-1	2016	IL-6 and IL-23 (IL-6/23) induce IL-17A (IL-17) production by a subpopulation of murine and human neutrophils, resulting in autocrine IL-17 activation, enhanced production of reactive oxygen species, and increased fungal killing.	Reactive Oxygen Species	174-197	interleukin 6	Mus musculus	0-4
27219527-10	2016	The trillin-treated group exhibited reduced AST, ALT, MDA, IL-6, TNF-alpha, and IL-1beta, and increased SOD.	diosgenin glucoside	4-11	interleukin 6	Mus musculus	59-63
27135544-8	2016	Suppression of MyD88 by ST2825 eliminated the inhibitory effects of dioscin on the levels of IRAK1, TRAF6, p-IKK, p-IkappaBalpha, p-NF-kappaB p65, HMGB-1, IL-1beta, IL-6 and TNF-alpha.	ST2825	24-30	interleukin 6	Mus musculus	165-169
27135544-8	2016	Suppression of MyD88 by ST2825 eliminated the inhibitory effects of dioscin on the levels of IRAK1, TRAF6, p-IKK, p-IkappaBalpha, p-NF-kappaB p65, HMGB-1, IL-1beta, IL-6 and TNF-alpha.	dioscin	68-75	interleukin 6	Mus musculus	165-169
26498175-9	2016	Furthermore, osthole obviously reduced the release of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) into the periosteum.	osthol	13-20	interleukin 6	Mus musculus	98-111
26498175-9	2016	Furthermore, osthole obviously reduced the release of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) into the periosteum.	osthol	13-20	interleukin 6	Mus musculus	113-117
27331630-4	2016	Topical administration of AC also reduced the expression of pro-inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6 in TPA-stimulated mouse ears.	Tetradecanoylphorbol Acetate	128-131	interleukin 6	Mus musculus	120-124
27260463-4	2016	We found that naringenin reduced hyperalgesia to mechanical and thermal stimuli, myeloperoxidase (MPO, a neutrophil and macrophage marker) and N-acetyl-beta-D-glucosaminidase (NAG, a macrophage marker) activities, oxidative stress and cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12) production in the paw skin.	naringenin	14-24	interleukin 6	Mus musculus	266-270
27260463-6	2016	In vitro, pre-treatment with naringenin inhibited superoxide anion and cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12) production by LPS-stimulated RAW 264.7 macrophages.	naringenin	29-39	interleukin 6	Mus musculus	102-106
27382358-3	2016	It was found berberine concentration-dependently induced the expressions of ATF-3 at the mRNA and protein levels and concomitantly suppressed the LPS-induced productions of proinflammatory cytokines (TNF-alpha, IL-6, and IL-1beta).	Berberine	13-22	interleukin 6	Mus musculus	211-215
27391633-8	2016	Using immunohistochemistry, fewer neutrophils and macrophages were noted, and cytokine analysis also revealed decreased IL-6 in Bensal HP-treated skin at 24 and 96 hours after shaving.	bensal hp	128-137	interleukin 6	Mus musculus	120-124
27270404-8	2016	Interleukin-1beta and IL-6 were increased in arthritic CO-fed mice compared to NA mice but were reduced in 0.5 % c9t11-CLA- and EB-fed mice through day 42.	Linoleic Acids, Conjugated	119-122	interleukin 6	Mus musculus	22-26
27270404-8	2016	Interleukin-1beta and IL-6 were increased in arthritic CO-fed mice compared to NA mice but were reduced in 0.5 % c9t11-CLA- and EB-fed mice through day 42.	ethylbenzene	128-130	interleukin 6	Mus musculus	22-26
26961887-3	2016	Our results revealed that non-toxic concentrations (6.25-25 muM) of DDA markedly suppressed LPS-induced production of nitric oxide, expression of inducible nitric oxide synthase and cyclooxygenase-2, and release of inflammatory factors, including tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 in a concentration dependent manner.	dda	68-71	interleukin 6	Mus musculus	310-314
27005687-4	2016	Glutamine supplementation increased mouse ileal expression of cytokines associated with T cell-dependent and T cell-independent pathways of SIgA induction, including IL-5, IL-6, IL-13, transforming growth factor (TGF-beta), a proliferation-inducing ligand (APRIL), B cell-activating factor (BAFF), vasoactive intestinal peptide (VIP) receptor, and retinal dehydrogenases.	Glutamine	0-9	interleukin 6	Mus musculus	172-176
27050799-7	2016	Furthermore, OMT administration inhibited the release of inflammatory factors including tumor necrosis factor-alpha, (TNF-alpha) interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), as well as phosphorylated NF-kappaB p65.	oxymatrine	13-16	interleukin 6	Mus musculus	163-176
27177149-8	2016	In mice, SPS injection enhanced immunomodulatory activities by increasing levels of TNF-alpha and IL-6 in tumor-bearing mice.	Sodium phenolsulfonate	9-12	interleukin 6	Mus musculus	98-102
27050799-7	2016	Furthermore, OMT administration inhibited the release of inflammatory factors including tumor necrosis factor-alpha, (TNF-alpha) interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), as well as phosphorylated NF-kappaB p65.	oxymatrine	13-16	interleukin 6	Mus musculus	178-182
27333268-7	2016	IL-6 administration in DIO mice markedly raised circulating levels of lipids, glucose and leptin, elevated fat liver content and aggravated steatosis.	Glucose	78-85	interleukin 6	Mus musculus	0-4
27351842-7	2016	PGE2 increased Il6, Il1b, Il23 and Ccr7 mRNA while reducing Tnfa mRNA through EP4 in isolated myeloid cells.	Dinoprostone	0-4	interleukin 6	Mus musculus	15-18
27351842-8	2016	Consistently, the stimulatory effect of diabetes on peritoneal macrophage Il6 was mediated by PGE2-EP4, while PGE2-EP4 suppressed the effect of diabetes on Tnfa in these cells.	Dinoprostone	94-98	interleukin 6	Mus musculus	74-77
27351842-10	2016	These studies suggest that this mouse model of T1DM is associated with increased myeloid cell PGE2-EP4 signaling, which is required for the stimulatory effect of diabetes on IL-6, markedly blunts the effect of diabetes on TNF-alpha and does not modulate diabetes-accelerated atherogenesis.	Dinoprostone	94-98	interleukin 6	Mus musculus	174-178
27333268-9	2016	These data further implicate IL-6 in fatty liver disease modulation in the context of DIO, and indicate that continuous stimulation with IL-6 attenuates the IL-6-receptor response, which is associated with high serum levels of leptin, glucose and lipids, the lowering levels of lipogenic and Cpt1 hepatic enzymes and with increased Tnf-alpha hepatic expression, a scenario evoking that observed in IL-6-/- mice exposed to DIO and in obese Zucker rats.	3,3'-Dioctadecyloxacarbocyanine perchlorate	86-89	interleukin 6	Mus musculus	29-33
27333268-9	2016	These data further implicate IL-6 in fatty liver disease modulation in the context of DIO, and indicate that continuous stimulation with IL-6 attenuates the IL-6-receptor response, which is associated with high serum levels of leptin, glucose and lipids, the lowering levels of lipogenic and Cpt1 hepatic enzymes and with increased Tnf-alpha hepatic expression, a scenario evoking that observed in IL-6-/- mice exposed to DIO and in obese Zucker rats.	Glucose	235-242	interleukin 6	Mus musculus	137-141
27333268-9	2016	These data further implicate IL-6 in fatty liver disease modulation in the context of DIO, and indicate that continuous stimulation with IL-6 attenuates the IL-6-receptor response, which is associated with high serum levels of leptin, glucose and lipids, the lowering levels of lipogenic and Cpt1 hepatic enzymes and with increased Tnf-alpha hepatic expression, a scenario evoking that observed in IL-6-/- mice exposed to DIO and in obese Zucker rats.	Glucose	235-242	interleukin 6	Mus musculus	137-141
27333268-9	2016	These data further implicate IL-6 in fatty liver disease modulation in the context of DIO, and indicate that continuous stimulation with IL-6 attenuates the IL-6-receptor response, which is associated with high serum levels of leptin, glucose and lipids, the lowering levels of lipogenic and Cpt1 hepatic enzymes and with increased Tnf-alpha hepatic expression, a scenario evoking that observed in IL-6-/- mice exposed to DIO and in obese Zucker rats.	Glucose	235-242	interleukin 6	Mus musculus	137-141
27333268-9	2016	These data further implicate IL-6 in fatty liver disease modulation in the context of DIO, and indicate that continuous stimulation with IL-6 attenuates the IL-6-receptor response, which is associated with high serum levels of leptin, glucose and lipids, the lowering levels of lipogenic and Cpt1 hepatic enzymes and with increased Tnf-alpha hepatic expression, a scenario evoking that observed in IL-6-/- mice exposed to DIO and in obese Zucker rats.	3,3'-Dioctadecyloxacarbocyanine perchlorate	422-425	interleukin 6	Mus musculus	137-141
27333268-9	2016	These data further implicate IL-6 in fatty liver disease modulation in the context of DIO, and indicate that continuous stimulation with IL-6 attenuates the IL-6-receptor response, which is associated with high serum levels of leptin, glucose and lipids, the lowering levels of lipogenic and Cpt1 hepatic enzymes and with increased Tnf-alpha hepatic expression, a scenario evoking that observed in IL-6-/- mice exposed to DIO and in obese Zucker rats.	3,3'-Dioctadecyloxacarbocyanine perchlorate	422-425	interleukin 6	Mus musculus	137-141
27333268-9	2016	These data further implicate IL-6 in fatty liver disease modulation in the context of DIO, and indicate that continuous stimulation with IL-6 attenuates the IL-6-receptor response, which is associated with high serum levels of leptin, glucose and lipids, the lowering levels of lipogenic and Cpt1 hepatic enzymes and with increased Tnf-alpha hepatic expression, a scenario evoking that observed in IL-6-/- mice exposed to DIO and in obese Zucker rats.	3,3'-Dioctadecyloxacarbocyanine perchlorate	422-425	interleukin 6	Mus musculus	137-141
27327080-2	2016	IL-6 is produced in skeletal muscle during exercise in a duration dependent manner and has been reported to increase whole body fatty acid oxidation, muscle glucose uptake and decrease PDHa activity in skeletal muscle of fed mice.	Fatty Acids	128-138	interleukin 6	Mus musculus	0-4
27327080-10	2016	Together, this provides evidence that skeletal muscle IL-6 contributes to the regulation of PDH at rest and during prolonged exercise and suggests that muscle IL-6 normally dampens carbohydrate utilization during prolonged exercise via effects on PDH.	Carbohydrates	181-193	interleukin 6	Mus musculus	159-163
27128363-4	2016	The CONPs release CO in response to cysteine and suppress the production of the pro-inflammatory mediators interleukin 6 (IL-6) and nitric oxide (NO) in lipopolysaccharide (LPS)-stimulated murine macrophages.	Cysteine	36-44	interleukin 6	Mus musculus	107-120
27060662-7	2016	Bilirubin accumulates in brain tissue from hUGT1/Ikkbeta(DeltaIEC) mice inducing an inflammatory state as shown by elevated TNFalpha, IL-1beta and IL-6, all of which can be prevented by neonatal induction of hepatic or intestinal UGT1A1 and lowering of TSB levels.	Bilirubin	0-9	interleukin 6	Mus musculus	147-151
27128363-4	2016	The CONPs release CO in response to cysteine and suppress the production of the pro-inflammatory mediators interleukin 6 (IL-6) and nitric oxide (NO) in lipopolysaccharide (LPS)-stimulated murine macrophages.	Cysteine	36-44	interleukin 6	Mus musculus	122-126
27182608-3	2016	Hesperidin, eriocitrin and eriodictyol increased the serum total antioxidant capacity, and restrained the elevation of interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1), and C-reactive protein (hs-CRP).	Hesperidin	0-10	interleukin 6	Mus musculus	119-132
27182608-3	2016	Hesperidin, eriocitrin and eriodictyol increased the serum total antioxidant capacity, and restrained the elevation of interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1), and C-reactive protein (hs-CRP).	Hesperidin	0-10	interleukin 6	Mus musculus	134-138
27182608-3	2016	Hesperidin, eriocitrin and eriodictyol increased the serum total antioxidant capacity, and restrained the elevation of interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1), and C-reactive protein (hs-CRP).	eriocitrin	12-22	interleukin 6	Mus musculus	119-132
27182608-3	2016	Hesperidin, eriocitrin and eriodictyol increased the serum total antioxidant capacity, and restrained the elevation of interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1), and C-reactive protein (hs-CRP).	eriocitrin	12-22	interleukin 6	Mus musculus	134-138
27182608-3	2016	Hesperidin, eriocitrin and eriodictyol increased the serum total antioxidant capacity, and restrained the elevation of interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1), and C-reactive protein (hs-CRP).	eriodictyol	27-38	interleukin 6	Mus musculus	119-132
27182608-3	2016	Hesperidin, eriocitrin and eriodictyol increased the serum total antioxidant capacity, and restrained the elevation of interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1), and C-reactive protein (hs-CRP).	eriodictyol	27-38	interleukin 6	Mus musculus	134-138
27302110-13	2016	The results showed that curcumin treatment led to less macrophage infiltration and less local inflammatory responses as demonstrated by decreasing TNF-alpha, IL-1, and IL-6 levels.	Curcumin	24-32	interleukin 6	Mus musculus	168-172
27235713-14	2016	RESULTS: LPPI was not toxic to uninfected macrophages (pMO) and significantly increased mRNA expression of TNF-alpha, IL-6, IL-1beta and iNOS.	lppi	9-13	interleukin 6	Mus musculus	118-122
27272194-9	2016	In the formalin test, DHC decreased the expression of caspase 6 (CASP6), TNF-alpha, IL-1beta and IL-6 proteins in the spinal cord.	dehydrocorydalin	22-25	interleukin 6	Mus musculus	97-101
27282478-12	2016	This protective effect of CQ was associated with a reduced expression of the inflammatory mediators interleukin-1beta, interleukin-6, and cyclooxygenase-2, while the levels of matrix metalloproteinases-2 and -9 were not modified.	Chloroquine	26-28	interleukin 6	Mus musculus	119-132
27278808-12	2016	Z-MWCNTs, but not U-MWCNTs, induced IL-6 and CXCL10 mRNA and protein in the lungs of mice and increased IL-6 mRNA in heart and liver.	z-mwcnts	0-8	interleukin 6	Mus musculus	36-40
27278808-12	2016	Z-MWCNTs, but not U-MWCNTs, induced IL-6 and CXCL10 mRNA and protein in the lungs of mice and increased IL-6 mRNA in heart and liver.	z-mwcnts	0-8	interleukin 6	Mus musculus	104-108
27355745-5	2016	RESULTS: Both ONO-5046 and CMT-3, regardless of being used individually or combined, significantly reduced the levels of MMP-9, IL-6, and TNF in lung tissue as well as in BALF, and the WBC and PMN count in BALF.	sivelestat	14-22	interleukin 6	Mus musculus	128-132
27059094-7	2016	The increased gene expressions of TNF-alpha, IL-6, monocyte chemoattractant protein 1 and F4/80 were also down-regulated by metformin and resveratrol.	Metformin	124-133	interleukin 6	Mus musculus	45-49
26976708-7	2016	Treatment with XN at 60 mg/kg/day resulted in reduced plasma LDL-cholesterol (LDL-C), IL-6, insulin and leptin levels by 80%, 78%, 42%, and 41%, respectively, compared to the vehicle control group.	xanthohumol	15-17	interleukin 6	Mus musculus	86-90
27332074-7	2016	Furthermore, UA significantly suppressed the upregulation of IL-1beta, IL-6, and tumor necrosis-alpha factor levels in the hippocampus of Abeta25-35-treated mice.	ursolic acid	13-15	interleukin 6	Mus musculus	71-75
27161000-7	2016	APAP treatment enhanced hepatic levels of interleukin-6, tumor necrosis factor-alpha and monocyte chemoattractant protein-1.	Acetaminophen	0-4	interleukin 6	Mus musculus	42-84
27059094-7	2016	The increased gene expressions of TNF-alpha, IL-6, monocyte chemoattractant protein 1 and F4/80 were also down-regulated by metformin and resveratrol.	Resveratrol	138-149	interleukin 6	Mus musculus	45-49
27207670-9	2016	Furthermore, AOM/DSS + ASA inhibited AOM/DSS-induced enrichment of H3K27ac in the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) that corresponded to the dramatic suppression of the messenger RNA (mRNA) and protein levels.	Dextran Sulfate	17-20	interleukin 6	Mus musculus	179-192
27233783-6	2016	On the contrary, overexpression of SOCS1 in the SC reversed CCI-induced pain behavioral, activation of neurons, astrocytes, microglia, and the expression of proinflammatory cytokines including tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta) and IL-6.	CCI	60-63	interleukin 6	Mus musculus	267-271
27207670-9	2016	Furthermore, AOM/DSS + ASA inhibited AOM/DSS-induced enrichment of H3K27ac in the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) that corresponded to the dramatic suppression of the messenger RNA (mRNA) and protein levels.	Dextran Sulfate	17-20	interleukin 6	Mus musculus	194-198
27207670-9	2016	Furthermore, AOM/DSS + ASA inhibited AOM/DSS-induced enrichment of H3K27ac in the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) that corresponded to the dramatic suppression of the messenger RNA (mRNA) and protein levels.	Aspirin	23-26	interleukin 6	Mus musculus	179-192
27207670-9	2016	Furthermore, AOM/DSS + ASA inhibited AOM/DSS-induced enrichment of H3K27ac in the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) that corresponded to the dramatic suppression of the messenger RNA (mRNA) and protein levels.	Aspirin	23-26	interleukin 6	Mus musculus	194-198
27207670-9	2016	Furthermore, AOM/DSS + ASA inhibited AOM/DSS-induced enrichment of H3K27ac in the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) that corresponded to the dramatic suppression of the messenger RNA (mRNA) and protein levels.	Dextran Sulfate	41-44	interleukin 6	Mus musculus	179-192
27207670-9	2016	Furthermore, AOM/DSS + ASA inhibited AOM/DSS-induced enrichment of H3K27ac in the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) that corresponded to the dramatic suppression of the messenger RNA (mRNA) and protein levels.	Dextran Sulfate	41-44	interleukin 6	Mus musculus	194-198
27207670-11	2016	Collectively, our results suggest that a potential novel epigenetic mechanism underlies the chemopreventive effects of ASA, and this mechanism attenuates CAC in AOM/DSS-induced CF-1 mice via the inhibition of HDACs and the modification of H3K27ac marks that suppress iNOS, TNF-alpha and IL-6.	Aspirin	119-122	interleukin 6	Mus musculus	287-291
27064137-7	2016	Exogenous 2-AG treatment (40 mg/kg) in mBSA-immunized mice led to reduced DTH response, and decreased Th1 and Th17-associated cytokines including IL-6, IL-2, TNF-alpha, and the IgG response.	glyceryl 2-arachidonate	10-14	interleukin 6	Mus musculus	146-150
26762195-7	2016	Blockade of the IL-6-signalling suppressed SC activation around PCa precursor lesions (pancreatic intraepithelial neoplasia (PanIN)) in KC;IL6(-/-) (32.06%+-5.25% of PanINs) and KC;sgp130(tg) (55.84%+-5.51%) mouse models compared with KC mice (78.27%+-3.91%).	Thioguanine	188-190	interleukin 6	Mus musculus	16-20
27039209-7	2016	The ELISA and qRT-PCR results showed that sophocarpine inhibited the expression of TNF-alpha, IL-1beta and IL-6 in a dose-dependent manner.	sophocarpine	42-54	interleukin 6	Mus musculus	107-111
27089391-6	2016	qPCR and ELISA assays demonstrated that plantamajoside suppressed the production of IL-1beta, IL-6 and TNF-alpha in a dose-dependent manner.	plantamajoside	40-54	interleukin 6	Mus musculus	94-98
29219782-12	2016	Similarly a decrease in TNF-alpha and IL-6 levels were also observed after vitamin D treatment.	Vitamin D	75-84	interleukin 6	Mus musculus	38-42
26817611-10	2016	Cytokine arrays of aortic tissue revealed decreased levels of proinflammatory cytokines interleukin (IL)-alpha, IL-6, and IL-17 in flutamide-treated and AR(-/-) groups compared with controls.	Flutamide	131-140	interleukin 6	Mus musculus	112-116
27327581-9	2016	Both Dex drops and Dex-NW significantly decreased expression of IL-1beta, IL-6, and MMP-9 RNA transcripts compared with vehicle drops or wafers 2 and 5 days after the initial lesion.	Dexamethasone	5-8	interleukin 6	Mus musculus	74-78
27427595-8	2016	However, the TiO2 and Fe2O3 NPs can induce strong immune response of Raw264.7 cells, leading to higher expression of TNF-alpha and IL-6, especially at relatively longer incubation time.	titanium dioxide	13-17	interleukin 6	Mus musculus	131-135
27427595-8	2016	However, the TiO2 and Fe2O3 NPs can induce strong immune response of Raw264.7 cells, leading to higher expression of TNF-alpha and IL-6, especially at relatively longer incubation time.	Iron(III) oxide	22-27	interleukin 6	Mus musculus	131-135
27082161-0	2016	16alpha, 17alpha-epoxypregnenolone-20-oxime inhibits NO and IL-6 production in LPS-treated RAW264.7 cells.	16alpha	0-7	interleukin 6	Mus musculus	60-64
27082161-0	2016	16alpha, 17alpha-epoxypregnenolone-20-oxime inhibits NO and IL-6 production in LPS-treated RAW264.7 cells.	17alpha-epoxypregnenolone-20-oxime	9-43	interleukin 6	Mus musculus	60-64
27122221-5	2016	The results of the current study demonstrated that garcinol promoted LPS-induced expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in RAW264.7 cells.	garcinol	51-59	interleukin 6	Mus musculus	139-152
27122221-5	2016	The results of the current study demonstrated that garcinol promoted LPS-induced expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in RAW264.7 cells.	garcinol	51-59	interleukin 6	Mus musculus	154-158
27122221-7	2016	Additionally, treatment with garcinol enhanced LPS-induced expression of TNF-alpha and IL-6, exacerbated LPS-induced lung injury, increased LPS-induced elevation of plasma alanine aminotransferase and blood urea nitrogen, and reduced the survival rate of LPS-challenged mice.	garcinol	29-37	interleukin 6	Mus musculus	87-91
26878122-11	2016	TNF-alpha, IL-6, NO, MPO and MDA were reduced in the mice administered epicatechin, whereas antioxidant enzymes showed increased activity in epicatechin-treated mice and cell line respectively.	Catechin	71-82	interleukin 6	Mus musculus	11-15
27117864-9	2016	Furthermore, mice fed the CD had higher levels of IL-6 and TNF-alpha in the postabsorptive period, with a fivefold higher expression of hepatic NFkappaB compared to mice fed the EKD in both fasting periods.	Cadmium	26-28	interleukin 6	Mus musculus	50-54
27177331-6	2016	Moreover, CaA could significantly suppress the secretion of IL-6, TNFalpha, and IFNgamma and the colonic infiltration of CD3+ T cells, CD177+ neutrophils and F4/80+ macrophages via inhibition of the activation of NF-kappaB signaling pathway.	caffeic acid	10-13	interleukin 6	Mus musculus	60-64
27102647-6	2016	Hypoxia (1% O2) significantly increased mRNA expression of mediators from ASCs, including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF).	Oxygen	12-14	interleukin 6	Mus musculus	90-103
27102647-6	2016	Hypoxia (1% O2) significantly increased mRNA expression of mediators from ASCs, including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF).	Oxygen	12-14	interleukin 6	Mus musculus	105-109
27105502-6	2016	Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF, IL-1beta, IL-6, IL-18, IL-17A and IFN-gamma, were markedly suppressed by MALT1 inhibitors.	Dextran Sulfate	37-40	interleukin 6	Mus musculus	110-114
27230787-8	2016	MPNL-induced neuropathic pain was mediated by glial cells activation and the production of TNF-alpha and IL-6 in the spinal cord.	mpnl	0-4	interleukin 6	Mus musculus	105-109
27102153-7	2016	Moreover, Nebivolol partially inhibited MMT and decreased vascular endothelial growth factor (VEGF) and IL-6 levels in supernatants.In vivo: Twenty-one C57BL/6 mice were divided into 3 groups.	Nebivolol	10-19	interleukin 6	Mus musculus	104-108
27016586-6	2016	A2AR activation with CGS (0.1 mug kg(-1) min(-1) sc) only during sensitization reduced numbers of IL-6(+) and IL-12(+) myeloid cells in the lungs and reversed the effects of OVA rechallenge to increase airway hyperresponsiveness to methacholine.	cysteinylglycine	21-24	interleukin 6	Mus musculus	98-102
27195463-4	2016	Importantly, treatment of mice with oroxylin A reduced viral titers in the pancreas and decreased the serum levels of the inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor (TNF)-alpha.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	36-46	interleukin 6	Mus musculus	155-168
27195463-4	2016	Importantly, treatment of mice with oroxylin A reduced viral titers in the pancreas and decreased the serum levels of the inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor (TNF)-alpha.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	36-46	interleukin 6	Mus musculus	170-174
27347321-5	2016	The results demonstrated that the ethanol extract from POL could exhibit the effective protection for the DSS induced UC by increasing the colon length, decreasing body weight loss and the disease activity index score, inhibiting oxidative stress response through the MDA, NO, SOD activities, reducing the mRNA expressions of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6) and the protein expressions of TNF-alpha and NF-kB p65.	Ethanol	34-41	interleukin 6	Mus musculus	378-382
27289040-0	2016	Arsenic-induced dose-dependent modulation of the NF-kappaB/IL-6 axis in thymocytes triggers differential immune responses.	Arsenic	0-7	interleukin 6	Mus musculus	59-63
27347326-9	2016	We found that the mice that received GRh2 treatment significantly improved their behaviors in all FST, TST and SIT tests, seemingly through decreases in the depression-associated cytokines, interleukin 6 (IL-6), IL-18 and tumor necrosis factor-alpha.	ginsenoside Rh2	37-41	interleukin 6	Mus musculus	190-203
27347326-9	2016	We found that the mice that received GRh2 treatment significantly improved their behaviors in all FST, TST and SIT tests, seemingly through decreases in the depression-associated cytokines, interleukin 6 (IL-6), IL-18 and tumor necrosis factor-alpha.	ginsenoside Rh2	37-41	interleukin 6	Mus musculus	205-209
27144271-9	2016	In addition, the mRNA levels of pro-inflammatory genes such as TNF-alpha, MCP-1, IL-1beta and IL-6 in the liver were dose-dependently reduced by paeonol pre-treatment.	paeonol	145-152	interleukin 6	Mus musculus	94-98
27086850-4	2016	Among the jasmonates tested, only 12-oxo-phytodienoic acid (OPDA) suppressed LPS-induced expression of the typical inflammatory cytokines interleukin-6 and tumor necrosis factor alpha.	12-oxophytodienoic acid	34-58	interleukin 6	Mus musculus	138-183
27086850-4	2016	Among the jasmonates tested, only 12-oxo-phytodienoic acid (OPDA) suppressed LPS-induced expression of the typical inflammatory cytokines interleukin-6 and tumor necrosis factor alpha.	12-oxophytodienoic acid	60-64	interleukin 6	Mus musculus	138-183
26752101-6	2016	Systemic cytokine (IL-4, IL-5, IL-6, IL-17, and IFN-gamma) production and local cytokine (IL-4 and IL-5) production were also reduced significantly after intralymphatic injection with OVA-FlaB.	ova-flab	184-192	interleukin 6	Mus musculus	31-35
26891685-0	2016	Boldine suppresses dextran sulfate sodium-induced mouse experimental colitis: NF-kappaB and IL-6/STAT3 as potential targets.	boldine	0-7	interleukin 6	Mus musculus	92-96
27041460-11	2016	Furthermore, hyperoside decreased LPS-stimulated production of TNF-alpha, IL-6, IL-1 and MMP-9 in the cells.	hyperoside	13-23	interleukin 6	Mus musculus	74-78
26998565-4	2016	Moreover, expression of IL-6 and vascular endothelial growth factor (VEGF) also decreased in the PA + DG cotreated group.	pa + dg	97-104	interleukin 6	Mus musculus	24-28
26998565-5	2016	These results suggest that PA-induced skin inflammation could be successfully suppressed by DG treatment in IL-4/Luc/CNS-1 Tg mice through attenuation of IL-4 and IL-6 expression, as well as decreased IgE concentration and mast cells infiltration.	phthalic anhydride	27-29	interleukin 6	Mus musculus	163-167
26996529-7	2016	Interestingly, miR-152 expression, glycogen synthesis and protein kinase B/glycogen synthase kinase (AKT/GSK) pathway activation were significantly decreased in the liver of mice injected with 16 mug mL(-1) interleukin 6 (IL-6) by pumps for 7 days and in NCTC 1469 cells treated with 10 ng mL(-1) IL-6 for 24 h. Moreover, hepatic overexpression of miR-152 rescued IL-6-induced impaired glycogenesis.	Glycogen	35-43	interleukin 6	Mus musculus	207-220
27104958-7	2016	RT-PCR analysis revealed an increased mRNA expression of IL-6, TNF-alpha, COX-2, iNOS, and NF-kappaB p65 and decreased IL-10 in the LPS group, which were reversed by treatment with DEX in lung tissues.	Dexamethasone	181-184	interleukin 6	Mus musculus	57-61
26953646-5	2016	Mechanistic study showed that resveratrol repressed the expression of pro-inflammatory cytokines, including TNF-alpha, IL-1beta and IL-6, and promoted the expression of anti-inflammatory cytokine IL-10 at the same time, which was further confirmed in a cell model of microglia.	Resveratrol	30-41	interleukin 6	Mus musculus	132-136
26967742-8	2016	In addition, MESNA markedly reduced ethanol-induced lipid peroxidation, myeloperoxidase activity, tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and monocyte chemotactic protein-1 levels.	Mesna	13-18	interleukin 6	Mus musculus	151-155
26540221-6	2016	RESULTS: DMH-CBD treatment downregulated in a dose-dependent manner the mRNA expression of LPS-upregulated pro-inflammatory genes (Il1b, Il6, and Tnf) in BV-2 microglial cells.	Dimenhydrinate	9-12	interleukin 6	Mus musculus	137-140
26908354-7	2016	In vivo, topical treatments with naringin prevented the increase of epidermal thickness, IL-6 production, cell apoptosis and the overexpression of COX-2 in BALB/c mice skin irradiated with UVB.	naringin	33-41	interleukin 6	Mus musculus	89-93
27061742-5	2016	It suggested that HCPS-stimulated immunostrengthening was mediated, at least in part, by TLR-4/NF-kappaB/IL-6 and TLR-4/NF-kappaB/ TNF-alpha signaling pathways.	hcps	18-22	interleukin 6	Mus musculus	105-109
27095301-3	2016	Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice.	nitazoxanide	0-12	interleukin 6	Mus musculus	123-136
25753147-5	2016	Notably, a short-term DMBA/TPA challenge, modeling the initial stages of chemical skin carcinogenesis treatment, elicited an enhanced inflammation in p38delta-null skin compared with skin of wild-type mice, as assessed by measuring the expression of pro-inflammatory cytokines, including IL-1beta, IL-6, IL-17, and TNFalpha.	9,10-Dimethyl-1,2-benzanthracene	22-26	interleukin 6	Mus musculus	298-302
25753147-5	2016	Notably, a short-term DMBA/TPA challenge, modeling the initial stages of chemical skin carcinogenesis treatment, elicited an enhanced inflammation in p38delta-null skin compared with skin of wild-type mice, as assessed by measuring the expression of pro-inflammatory cytokines, including IL-1beta, IL-6, IL-17, and TNFalpha.	Tetradecanoylphorbol Acetate	27-30	interleukin 6	Mus musculus	298-302
27074537-6	2016	SAE at 200 mg/kg BW significantly attenuated IL-6 and enhanced IL-10 expression in mesenteric lymph nodes (MLN), and significantly reduced IL-6 levels in splenocytes.	SELENAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE	0-3	interleukin 6	Mus musculus	45-49
27074537-6	2016	SAE at 200 mg/kg BW significantly attenuated IL-6 and enhanced IL-10 expression in mesenteric lymph nodes (MLN), and significantly reduced IL-6 levels in splenocytes.	SELENAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE	0-3	interleukin 6	Mus musculus	139-143
27074537-7	2016	SAE200 also significantly attenuated DSS-induced increase in IL-6 and IL-1beta, and reductions in IL-10 in colon tissue.	sae200	0-6	interleukin 6	Mus musculus	61-65
27074537-7	2016	SAE200 also significantly attenuated DSS-induced increase in IL-6 and IL-1beta, and reductions in IL-10 in colon tissue.	Dextran Sulfate	37-40	interleukin 6	Mus musculus	61-65
26701313-6	2016	dLGG and simvastatin ameliorated the effects of LPS-induced mitogen-activated protein kinase (MAPK)-dependent activation of cPLA2, cyclooxygenase-2, lipoxygenase, cytochrome P450 and/or epoxide hydrolase lowered systemic TNF-alpha and IL-6 levels and aminotransferase activities and decreased organ-specific infiltration of inflammatory leukocytes and macrophages, and septic shock-induced multiple organ damage.	dlgg	0-4	interleukin 6	Mus musculus	235-239
26096705-6	2016	The protective effects due to pretreatment with SFN were associated with the following: suppression of the formation of a lesion area, neuronal death, succinate dehydrogenase activity, apoptosis, microglial activation, and mRNA or protein expression of inflammatory mediators, including tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, inducible nitric oxide synthase, and cyclooxygenase-2 in the striatum after 3-NP treatment.	sulforaphane	48-51	interleukin 6	Mus musculus	340-344
27035673-6	2016	Resveratrol (10 or 20 mg/kg) partly inhibited LPS-induced hyperalgesia and prevented the increase in tumor necrosis factor-alpha and interleukin 6 levels induced by LPS.	Resveratrol	0-11	interleukin 6	Mus musculus	133-146
26701313-6	2016	dLGG and simvastatin ameliorated the effects of LPS-induced mitogen-activated protein kinase (MAPK)-dependent activation of cPLA2, cyclooxygenase-2, lipoxygenase, cytochrome P450 and/or epoxide hydrolase lowered systemic TNF-alpha and IL-6 levels and aminotransferase activities and decreased organ-specific infiltration of inflammatory leukocytes and macrophages, and septic shock-induced multiple organ damage.	Simvastatin	9-20	interleukin 6	Mus musculus	235-239
27086220-7	2016	Paeonol administration could effectively reverse the alterations in the concentrations of 5-HT, NE and reduce the IL-6 and TNF-alpha levels.	paeonol	0-7	interleukin 6	Mus musculus	114-118
26385227-19	2016	Induction of depression-like behavior by co-administration of IL-1beta and IL-6 was prevented by pretreatment with prazosin alone.	Prazosin	115-123	interleukin 6	Mus musculus	75-79
26391290-7	2016	Cells treated with haloperidol and risperidone also presented higher concentrations of inflammatory cytokines (IL-1beta, IL-6, TNFalpha) and low levels of IL-6 anti-inflammatory cytokine in a dose-dependent manner.	Haloperidol	19-30	interleukin 6	Mus musculus	121-125
26391290-7	2016	Cells treated with haloperidol and risperidone also presented higher concentrations of inflammatory cytokines (IL-1beta, IL-6, TNFalpha) and low levels of IL-6 anti-inflammatory cytokine in a dose-dependent manner.	Haloperidol	19-30	interleukin 6	Mus musculus	155-159
26391290-7	2016	Cells treated with haloperidol and risperidone also presented higher concentrations of inflammatory cytokines (IL-1beta, IL-6, TNFalpha) and low levels of IL-6 anti-inflammatory cytokine in a dose-dependent manner.	Risperidone	35-46	interleukin 6	Mus musculus	121-125
26391290-7	2016	Cells treated with haloperidol and risperidone also presented higher concentrations of inflammatory cytokines (IL-1beta, IL-6, TNFalpha) and low levels of IL-6 anti-inflammatory cytokine in a dose-dependent manner.	Risperidone	35-46	interleukin 6	Mus musculus	155-159
26809801-4	2016	In addition, PA treatment significantly decreased the production of IL-6 (a marker of inflamed tissue) in the toxin A-induced mouse enteritis model.	Protactinium	13-15	interleukin 6	Mus musculus	68-72
27128484-6	2016	And AZD8055 treatment decreases colonic expression of genes encoding the pro-inflammatory cytokines interferon-gamma, interleukin (IL)-17A, IL-1beta,IL-6 and tumor necrosis factor(TNF)-a and increases colonic expression of anti-inflammatory cytokines IL-10.	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	4-11	interleukin 6	Mus musculus	149-153
27016423-10	2016	In vivo studies showed that cefradine down-regulated SUV-induced the phosphorylation of p38, JNKs and H2AX and inhibited the secretion of IL6 and TNF-alpha in Babl/c mice.	Cephradine	28-37	interleukin 6	Mus musculus	138-141
27068103-1	2016	BACKGROUND: Hepcidin, a key regulator of iron metabolism, is produced mainly by interleukin-6 (IL-6) during inflammation.	Iron	41-45	interleukin 6	Mus musculus	80-93
26879835-6	2016	Results showed that Z-guggulsterone reduced inducible nitric oxide (iNOS) protein expression as well as nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production in LPS-stimulated BV-2 cells.	pregna-4,17-diene-3,16-dione	20-35	interleukin 6	Mus musculus	167-180
26879835-6	2016	Results showed that Z-guggulsterone reduced inducible nitric oxide (iNOS) protein expression as well as nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production in LPS-stimulated BV-2 cells.	pregna-4,17-diene-3,16-dione	20-35	interleukin 6	Mus musculus	182-186
26879835-7	2016	Z-guggulsterone also reduced the mRNA level of iNOS, TNF-alpha, and IL-6.	pregna-4,17-diene-3,16-dione	0-15	interleukin 6	Mus musculus	68-72
26947454-8	2016	Oroxyloside decreased several LPS-induced inflammatory cytokines, including IL-1beta, IL-6 and TNF-alpha in RAW264.7 and BMDM.	oroxylin A-7-O-glucuronide	0-11	interleukin 6	Mus musculus	86-90
26998619-4	2016	The results showed that CSA, as well as its synthesized derivatives 5c, 5e and 5h, exhibited strong inhibition activity on the release of NO and inflammatory factor TNF-alpha and IL-6 in lipopolysaccharides (LPS)-stimulated murine macrophages.	3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid	24-27	interleukin 6	Mus musculus	179-183
27068103-1	2016	BACKGROUND: Hepcidin, a key regulator of iron metabolism, is produced mainly by interleukin-6 (IL-6) during inflammation.	Iron	41-45	interleukin 6	Mus musculus	95-99
27068103-14	2016	CONCLUSIONS: Our results suggest that overproduction of hepcidin by IL-6 signaling might be a major factor that leads to functionally iron-deficient cancer-related anemia in the LC-06-JCK model.	Iron	134-138	interleukin 6	Mus musculus	68-72
27053298-4	2016	The increased levels of tumour necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-18 following cold-stress injury were decreased by AC-YVAD-CMK, but not omeprazole, pretreatment.	ac-yvad	141-148	interleukin 6	Mus musculus	78-82
26944017-2	2016	When administered to the C57BL/6J mice after a 3 days period of cigarettes exposure,TAK-242 significantly decreased the accumulation of macrophages, neutrophils, lymphocytes and DCs, and upregulation of IL-6, IL-8 and TNF-alpha in BAL fluid and lungs in a dose-dependent manner, except MCP-1, IL-1beta and IFN-gamma, which demonstrated that TAK-242 inhibits release of various inflammatory mediators induced by cigarette smoke.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	84-91	interleukin 6	Mus musculus	203-207
26961674-5	2016	ISO also remarkably ameliorated HF-induced hepatic oxidative injury and inflammation by decreasing ALT, AST, and ALP levels; enhancing antioxidant enzyme activities; and inhibiting inflammatory cytokine (TNF-alpha, IL-1, IL-6) release.	Hafnium	32-34	interleukin 6	Mus musculus	221-225
26961674-5	2016	ISO also remarkably ameliorated HF-induced hepatic oxidative injury and inflammation by decreasing ALT, AST, and ALP levels; enhancing antioxidant enzyme activities; and inhibiting inflammatory cytokine (TNF-alpha, IL-1, IL-6) release.	homoorientin	0-3	interleukin 6	Mus musculus	221-225
26969520-6	2016	IL-6 and TNF-alpha (TNF-alpha) levels in the serum and liver were clearly increased by acetaminophen-damage (p &lt; 0.05) and AMDS intake significantly suppressed acetaminophen-induced increase of the two cytokines (p &lt; 0.05).	Acetaminophen	87-100	interleukin 6	Mus musculus	0-4
26969520-6	2016	IL-6 and TNF-alpha (TNF-alpha) levels in the serum and liver were clearly increased by acetaminophen-damage (p &lt; 0.05) and AMDS intake significantly suppressed acetaminophen-induced increase of the two cytokines (p &lt; 0.05).	Acetaminophen	163-176	interleukin 6	Mus musculus	0-4
26832323-6	2016	In addition, pretreatment with SchB lowered the number of inflammatory cells and pro-inflammatory cytokines including tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 in BALF.	schizandrin B	31-35	interleukin 6	Mus musculus	170-183
27058537-5	2016	LPS treatment increased nitric oxide production and secretion of pro-inflammatory cytokines, such as tumor necrosis factor-alpha and interleukin-6, in a concentration-dependent manner.	Nitric Oxide	24-36	interleukin 6	Mus musculus	133-146
26879317-3	2016	In this study, we observed that R. mori ethanol extracts (RME) exerted an inhibitory effect on the lipopolysaccharide (LPS)-induced production of the pro-inflammatory cytokine interleukin-6 (IL-6) in Raw264.7 macrophage cells.	Ethanol	40-47	interleukin 6	Mus musculus	176-189
26879317-3	2016	In this study, we observed that R. mori ethanol extracts (RME) exerted an inhibitory effect on the lipopolysaccharide (LPS)-induced production of the pro-inflammatory cytokine interleukin-6 (IL-6) in Raw264.7 macrophage cells.	Ethanol	40-47	interleukin 6	Mus musculus	191-195
26879317-4	2016	Additionally, RME inhibited IL-6 production by blocking the leukotriene B4 receptor- 2 (BLT2)-dependent-NADPH oxidase 1 (NOX1)-reactive oxygen species (ROS) cascade, leading to anti-inflammatory activity.	Reactive Oxygen Species	127-150	interleukin 6	Mus musculus	28-32
26879317-4	2016	Additionally, RME inhibited IL-6 production by blocking the leukotriene B4 receptor- 2 (BLT2)-dependent-NADPH oxidase 1 (NOX1)-reactive oxygen species (ROS) cascade, leading to anti-inflammatory activity.	Reactive Oxygen Species	152-155	interleukin 6	Mus musculus	28-32
26650931-12	2016	Significantly decreased expression of inflammatory cytokines interleukin (IL)-6 and monocyte chemoattractant protein-1 (MCP-1) was also found in the ADMSC-EV-treated group (both p &lt; 0.05).	admsc-ev	149-157	interleukin 6	Mus musculus	61-79
26857263-7	2016	Investigation of the host microenvironment revealed an alcohol-induced inflammatory response marked by elevated TNFalpha, IL1beta, IL6, and IFNgamma protein levels, as well as increased expression of intercellular molecule-1 (ICAM1) in hepatic tissues after 4 weeks of alcohol consumption.	Alcohols	55-62	interleukin 6	Mus musculus	131-134
26841286-5	2016	In addition, LPS-induced the release of TNFalpha and IL6 in the medium was also significantly enhanced or suppressed by the different Cr pretreatment.	Chromium	134-136	interleukin 6	Mus musculus	53-56
26960417-4	2016	Oligonol attenuated serum resistin and IL-6 levels and reduced glomerular hypertrophy and mesangial matrix expansion caused by diabetes.	oligonol	0-8	interleukin 6	Mus musculus	39-43
25823386-5	2016	RESULTS: Lico F inhibited TNFalpha-induced NF-kappaB activation and mRNA expression of TNFalpha, COX-2, IL-6, IL-1beta, and NOS2.	lico f	9-15	interleukin 6	Mus musculus	104-108
26657007-8	2016	Reverse transcriptase-PCR revealed that mRNA expressions of interleukin (Il)-1beta, Il-6, E-selectin, vascular cell adhesion molecule-1 and collagen type 1 were lower in the CPE group compared with the vehicle group.	cpe	174-177	interleukin 6	Mus musculus	84-88
26739065-5	2016	GA suppressed swelling and the expression of inflammatory cytokines, including macrophage inflammatory protein (MIP)-2, interleukin (IL)-6, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma mRNA.	Glycyrrhetinic Acid	0-2	interleukin 6	Mus musculus	120-138
26552405-8	2016	Lico A also suppressed LPS-induced TNF-alpha, IL-6, and IL-1beta production both in serum and kidney tissues.	licochalcone A	0-6	interleukin 6	Mus musculus	46-50
26846885-0	2016	Protective Effects of Nobiletin Against Endotoxic Shock in Mice Through Inhibiting TNF-alpha, IL-6, and HMGB1 and Regulating NF-kappaB Pathway.	nobiletin	22-31	interleukin 6	Mus musculus	94-98
26846885-4	2016	The present study clearly demonstrates that pretreatment with NOB decreases the production of early pro-inflammatory cytokines TNF-alpha, IL-6, and late-phase mediator HMGB1 in serum and tissues of kidney, lung, and liver.	nobiletin	62-65	interleukin 6	Mus musculus	138-142
26846885-7	2016	These results suggest that NOB protects mice against LPS-induced endotoxic shock through inhibiting the production of TNF-alpha, IL-6, and HMGB1 and the activation of NF-kappaB, which elucidate that NOB may be a promising drug candidate for the treatment of septic shock.	nobiletin	27-30	interleukin 6	Mus musculus	129-133
26846885-7	2016	These results suggest that NOB protects mice against LPS-induced endotoxic shock through inhibiting the production of TNF-alpha, IL-6, and HMGB1 and the activation of NF-kappaB, which elucidate that NOB may be a promising drug candidate for the treatment of septic shock.	nobiletin	199-202	interleukin 6	Mus musculus	129-133
27279989-9	2016	CONCLUSION: Our findings showed that riboflavin is capable of suppressing the neurological disability mediated by BDNF and IL-6.	Riboflavin	37-47	interleukin 6	Mus musculus	123-127
26639408-9	2016	Melatonin also attenuated the expressions of NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), cleaved caspase-1, interleukin-1beta (IL-1beta), and interleukin-6 (IL-6); these changes were also associated with an increase in the anti-apoptotic factor (Bcl2) and reduction in the pro-apoptotic factor (Bim).	Melatonin	0-9	interleukin 6	Mus musculus	192-205
26639408-9	2016	Melatonin also attenuated the expressions of NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), cleaved caspase-1, interleukin-1beta (IL-1beta), and interleukin-6 (IL-6); these changes were also associated with an increase in the anti-apoptotic factor (Bcl2) and reduction in the pro-apoptotic factor (Bim).	Melatonin	0-9	interleukin 6	Mus musculus	207-211
27182113-3	2016	Intratracheal instillation of polyhexamethyleneguanidine phosphate induced severe lung inflammation manifested by the infiltration of mononuclear cells and neutrophils and increased production of IL-6, TNF-alpha, CCL2 and CXCL1.	polyhexamethyleneguanidine	30-66	interleukin 6	Mus musculus	196-200
26314836-2	2016	Vitamin K has been shown to inhibit inflammation via interleukin (IL)-6 suppression.	Vitamin K	0-9	interleukin 6	Mus musculus	53-71
26314836-11	2016	CONCLUSIONS: Vitamin K exerts a protective effect against DSS colitis; this effect is associated with IL-6 downregulation.	Vitamin K	13-22	interleukin 6	Mus musculus	102-106
27400472-10	2016	Levels of IL-6, IL-10 and IFN-gamma in mice treated with ribavirin or the combination of both ribavirin and Reduning were all significantly lower than in the untreated group, especially in the combination-treated group.	Ribavirin	57-66	interleukin 6	Mus musculus	10-14
27400472-10	2016	Levels of IL-6, IL-10 and IFN-gamma in mice treated with ribavirin or the combination of both ribavirin and Reduning were all significantly lower than in the untreated group, especially in the combination-treated group.	Ribavirin	94-103	interleukin 6	Mus musculus	10-14
26936418-4	2016	In mice with carrageenan-induced edema, paw thickness and the expression levels of interleukin (IL)-1beta and IL-6 in paw homogenates were significantly decreased in the EOCO (5 and 10 mg/kg) group, as compared with the control group.	Carrageenan	13-24	interleukin 6	Mus musculus	110-114
26936233-6	2016	In addition, treatment with olopatadine and naphazoline hydrochloride was able to reduce the levels of inflammatory factors (TNF-alpha, IL-1beta and IL-6), cytokines (IFN-gamma and IL-4), IgE, GMCSF, and NGF in antigen-induced conjunctival vascular hyperpermeability mice.	Olopatadine Hydrochloride	28-39	interleukin 6	Mus musculus	149-153
26936678-0	2016	Sip-jeon-dea-bo-tang, a traditional herbal medicine, ameliorates cisplatin-induced anorexia via the activation of JAK1/STAT3-mediated leptin and IL-6 production in the fat tissue of mice.	Cisplatin	65-74	interleukin 6	Mus musculus	145-149
26936233-6	2016	In addition, treatment with olopatadine and naphazoline hydrochloride was able to reduce the levels of inflammatory factors (TNF-alpha, IL-1beta and IL-6), cytokines (IFN-gamma and IL-4), IgE, GMCSF, and NGF in antigen-induced conjunctival vascular hyperpermeability mice.	Naphazoline	44-69	interleukin 6	Mus musculus	149-153
26936678-7	2016	In addition, SJDBT maintained the serum leptin level and increased the serum IL-6 level, whereas cisplatin reduced the levels of both serum leptin and IL-6.	sjdbt	13-18	interleukin 6	Mus musculus	77-81
26936678-7	2016	In addition, SJDBT maintained the serum leptin level and increased the serum IL-6 level, whereas cisplatin reduced the levels of both serum leptin and IL-6.	Cisplatin	97-106	interleukin 6	Mus musculus	151-155
26707655-0	2016	Transgenic mice with increased astrocyte expression of IL-6 show altered effects of acute ethanol on synaptic function.	Ethanol	90-97	interleukin 6	Mus musculus	55-59
26707655-3	2016	Recent studies show that ethanol can activate cells of the neuroimmune system, resulting in the elevated production of neuroimmune factors, including the cytokine interleukin-6 (IL-6).	Ethanol	25-32	interleukin 6	Mus musculus	163-176
26707655-3	2016	Recent studies show that ethanol can activate cells of the neuroimmune system, resulting in the elevated production of neuroimmune factors, including the cytokine interleukin-6 (IL-6).	Ethanol	25-32	interleukin 6	Mus musculus	178-182
26707655-4	2016	Here we analyzed the consequences of this CNS action of ethanol using transgenic mice that express elevated levels of IL-6 through increased astrocyte expression (IL-6-tg) to model the increased IL-6 expression that occurs with ethanol use.	Ethanol	56-63	interleukin 6	Mus musculus	118-122
26707655-5	2016	Results show that increased IL-6 expression induces neuroadaptive changes that alter the effects of ethanol.	Ethanol	100-107	interleukin 6	Mus musculus	28-32
26707655-7	2016	In contrast, acute ethanol enhanced the fEPSP and PS in hippocampal slices from IL-6 tg mice.	Ethanol	19-26	interleukin 6	Mus musculus	80-84
26707655-9	2016	Consistent with altered effects of acute ethanol on synaptic function in the IL-6 tg mice, EEG recordings showed a higher level of CNS activity in the IL-6 tg mice than in the non-tg mice during the period of withdrawal from an acute high dose of ethanol.	Ethanol	41-48	interleukin 6	Mus musculus	77-81
26707655-9	2016	Consistent with altered effects of acute ethanol on synaptic function in the IL-6 tg mice, EEG recordings showed a higher level of CNS activity in the IL-6 tg mice than in the non-tg mice during the period of withdrawal from an acute high dose of ethanol.	Ethanol	247-254	interleukin 6	Mus musculus	151-155
26707655-10	2016	These results suggest a potential role for neuroadaptive effects of ethanol-induced astrocyte production of IL-6 as a mediator or modulator of the actions of ethanol on the CNS, including persistent changes in CNS function that contribute to cognitive dysfunction and the development of alcohol dependence.	Ethanol	68-75	interleukin 6	Mus musculus	108-112
26707655-10	2016	These results suggest a potential role for neuroadaptive effects of ethanol-induced astrocyte production of IL-6 as a mediator or modulator of the actions of ethanol on the CNS, including persistent changes in CNS function that contribute to cognitive dysfunction and the development of alcohol dependence.	Ethanol	158-165	interleukin 6	Mus musculus	108-112
27034602-7	2016	Of all the extracts, 80% methanolic extract exhibited the strongest anti-inflammatory activity by inhibiting NO production (P &lt; 0.01), PGE2 (P &lt; 0.05), TNF-alpha, and IL-6 (P &lt; 0.001) release in LPS induced RAW 264.7 cells.	methanolic	25-35	interleukin 6	Mus musculus	173-177
26772899-9	2016	Dex treatment significantly decreased expression of IL-1beta, IL-6, MMPs -1, -9, -13, and TIMP-1 after 2 days but increased levels of MMP-8, while Doxy treatment significantly decreased IL-1beta, IL-6, MMP-8, and -9, compared to vehicle.	Dexamethasone	0-3	interleukin 6	Mus musculus	62-66
26772899-9	2016	Dex treatment significantly decreased expression of IL-1beta, IL-6, MMPs -1, -9, -13, and TIMP-1 after 2 days but increased levels of MMP-8, while Doxy treatment significantly decreased IL-1beta, IL-6, MMP-8, and -9, compared to vehicle.	Dexamethasone	0-3	interleukin 6	Mus musculus	196-200
26772899-9	2016	Dex treatment significantly decreased expression of IL-1beta, IL-6, MMPs -1, -9, -13, and TIMP-1 after 2 days but increased levels of MMP-8, while Doxy treatment significantly decreased IL-1beta, IL-6, MMP-8, and -9, compared to vehicle.	Doxycycline	147-151	interleukin 6	Mus musculus	196-200
26686910-4	2016	Moreover, CX inhibited the LPS-induced up-regulation of tumor necrosis factor alpha (TNF-alpha), interleukin-10 (IL-10), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in Sertoli cells.	Beta-Cryptoxanthin	10-12	interleukin 6	Mus musculus	121-134
27076745-6	2016	Particularly, ellagic acid significantly inhibited production of the proinflammatory cytokines tumor necrosis factor alpha and interleukin-6 in LPS-treated RAW 264.7 cells.	Ellagic Acid	14-26	interleukin 6	Mus musculus	127-140
26686910-4	2016	Moreover, CX inhibited the LPS-induced up-regulation of tumor necrosis factor alpha (TNF-alpha), interleukin-10 (IL-10), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in Sertoli cells.	Beta-Cryptoxanthin	10-12	interleukin 6	Mus musculus	136-140
26618986-5	2016	The PPARgamma agonist rosiglitazone treatment improved clinical status and mortality, while increasing IL-10 production and decreasing TNF-alpha and IL-6 levels, and peritoneal neutrophil accumulation 24 h after CLP.	Rosiglitazone	22-35	interleukin 6	Mus musculus	149-153
26840742-9	2016	Treatment of ApoE(-/-) VSC chondrogenic cultures with interleukin (IL)-6 resulted in significantly increased glycosaminoglycan deposition and expression of characteristic chondrogenic genes at 21 days.	Glycosaminoglycans	109-126	interleukin 6	Mus musculus	54-72
26804033-6	2016	RA failed to mitigate the inflammatory response in most models, while it clearly reduced IL-6 and CXCL1/KC gene expression in murine PCIS at non-toxic concentrations.	rosmarinic acid	0-2	interleukin 6	Mus musculus	89-93
26863933-10	2016	However, the group receiving citrate+sucrose showed augmented fasting glycaemia, glucose intolerance and the expression of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6 and IL-10) in their AT.	Citric Acid	29-36	interleukin 6	Mus musculus	172-176
27033911-9	2016	Moreover, our data clearly showed that melamine-related toxicity suppressed the production of IL-6 and IL-10 in a dose-dependent manner.	melamine	39-47	interleukin 6	Mus musculus	94-98
26863933-10	2016	However, the group receiving citrate+sucrose showed augmented fasting glycaemia, glucose intolerance and the expression of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6 and IL-10) in their AT.	Sucrose	37-44	interleukin 6	Mus musculus	172-176
26933995-5	2016	In addition, IL-6 and TNF-alpha levels were elevated and miR-122 levels were decreased in mouse and rat models of diethylnitrosamine (DEN)-induced HCC.	Diethylnitrosamine	114-132	interleukin 6	Mus musculus	13-17
26933995-5	2016	In addition, IL-6 and TNF-alpha levels were elevated and miR-122 levels were decreased in mouse and rat models of diethylnitrosamine (DEN)-induced HCC.	Diethylnitrosamine	134-137	interleukin 6	Mus musculus	13-17
26852703-5	2016	Caffeine treatment also reduced the expression of pro-inflammatory genes, including inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), interleukin (IL)-3, IL-6 and IL-12, and decreased both IL-6 secretion and phosphorylated p38MAPK expression in LPS-treated RAW264.7 cells.	Caffeine	0-8	interleukin 6	Mus musculus	170-174
26794947-6	2016	In vitro study showed that both polysaccharides samples were able to stimulate the production of secretory molecules (NO, TNF-alpha and IL-6) of RAW264.7 murine macrophages in a dosage dependent manner.	Polysaccharides	32-47	interleukin 6	Mus musculus	136-140
26852703-5	2016	Caffeine treatment also reduced the expression of pro-inflammatory genes, including inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), interleukin (IL)-3, IL-6 and IL-12, and decreased both IL-6 secretion and phosphorylated p38MAPK expression in LPS-treated RAW264.7 cells.	Caffeine	0-8	interleukin 6	Mus musculus	205-209
27011173-4	2016	Koumine induced a decrease in the level of inducible nitric oxide synthase (iNOS) protein, concomitant reduction in the production of nitric oxide (NO) and reduction of the levels of interleukin (IL)-6, tumor necrosis factor-alpha (TNF-alpha) and IL-1beta.	koumine	0-7	interleukin 6	Mus musculus	183-201
26934552-9	2016	Importantly, diclofenac treatment prompted strong expression of phosphorylated Stat3 amongst individual animals and the associated 8- and 4-fold Soc3 and Il-6 induction reinforced Ghr degradation as evidenced by immunoblotting.	Diclofenac	13-23	interleukin 6	Mus musculus	154-158
26880761-7	2016	In addition, maternal injection of FK565 induced robust increases in the amounts of CCL2, IL-6, and TNF proteins as well as NO in maternal, placental and fetal tissues.	heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine	35-40	interleukin 6	Mus musculus	90-94
26972749-0	2016	Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGFbeta1 and miR-29 pathways.	Streptozocin	62-76	interleukin 6	Mus musculus	12-25
26972749-3	2016	Cardiac function of IL-6 knockout mice was significantly improved and interstitial fibrosis was apparently alleviated in comparison with wildtype (WT) diabetic mice induced by streptozotocin (STZ).	Streptozocin	176-190	interleukin 6	Mus musculus	20-24
26972749-3	2016	Cardiac function of IL-6 knockout mice was significantly improved and interstitial fibrosis was apparently alleviated in comparison with wildtype (WT) diabetic mice induced by streptozotocin (STZ).	Streptozocin	192-195	interleukin 6	Mus musculus	20-24
26972749-5	2016	High glucose treatment increased collagen production, which were mitigated in CFs from IL-6 KO mice.	Glucose	5-12	interleukin 6	Mus musculus	87-91
26972749-6	2016	Moreover, IL-6 knockout alleviated the up-regulation of TGFbeta1 in diabetic hearts of mice and cultured CFs treated with high glucose or IL-6.	Glucose	127-134	interleukin 6	Mus musculus	10-14
26972749-8	2016	Overexpression of miR-29 blocked the pro-fibrotic effects of IL-6 on cultured CFs.	mir-29	18-24	interleukin 6	Mus musculus	61-65
26880761-8	2016	Nod1 was highly expressed in fetal vascular tissues, where significantly higher levels of CCL2 and IL-6 mRNAs were induced with maternal injection of FK565 than those in other tissues.	heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine	150-155	interleukin 6	Mus musculus	99-103
27471620-5	2016	LPS/ibrutinib-treated DCs displayed increased IFNbeta and IL-10 synthesis and decreased IL-6, IL-12 and NO production compared to DCs stimulated with LPS alone.	ibrutinib	4-13	interleukin 6	Mus musculus	88-92
26895752-7	2016	Moreover, epinephrine induced a selective mobilization of IL-6-sensitive NK cells, and IL-6-blocking antibodies blunted training-induced tumor suppression, intratumoral NK cell infiltration, and NK cell activation.	Epinephrine	10-21	interleukin 6	Mus musculus	58-62
27022259-7	2016	SiNPs induced a significant elevation in pulmonary and renal interleukin 6 and interleukin-1 beta in the lung, liver, and brain.	sinps	0-5	interleukin 6	Mus musculus	61-74
26951793-7	2016	RT-PCR analysis at a precancerous stage indicated that ethanol significantly increases the expression of cytokines IL-1alpha, IL-6 and TNFalpha, and the chemokines CCL5/RANTES, CXCL9/MIG and CXCL10/IP-10 in the colonic mucosa of AOM/DSS treated mice.	Ethanol	55-62	interleukin 6	Mus musculus	126-130
26852953-5	2016	HTMC concentration-dependently inhibited LPS-induced expression of inflammatory enzymes including inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), nitric oxide (NO) production, and the secretion of inflammatory cytokines, including tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6.	htmc	0-4	interleukin 6	Mus musculus	315-319
26934748-11	2016	Boron further stimulated the secretion of TNF-alpha, IL-6, IL-1beta, NO and the expression of iNOS by the LPS-primed macrophages.	Boron	0-5	interleukin 6	Mus musculus	53-57
26203683-8	2016	C57BL/6 mice exposed to ozone for 1 day had acute neutrophilic rhinitis, with airway epithelial necrosis and overexpression of mucosal Ccl2 (MCP-1), Ccl11 (eotaxin), Cxcl1 (KC), Cxcl2 (MIP-2), Hmox1, Il1b, Il5, Il6, Il13, and Tnf mRNA.	Ozone	24-29	interleukin 6	Mus musculus	211-214
26773728-7	2016	Additional experiment showed that rosiglitazone pretreatment inhibited LPS-induced expressions of tumor necrosis factor (Tnf)-alpha, interleukin (Il)-1beta, Il-6, macrophage inflammatory protein (Mip)-2 and keratinocyte-derived chemokine (Kc) in mouse placenta.	Rosiglitazone	34-47	interleukin 6	Mus musculus	157-161
26849878-6	2016	Furthermore, 4-TBPS significantly inhibited the production of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin- (IL)-1beta, and IL-6.	4-tert-butylphenyl salicylate	13-19	interleukin 6	Mus musculus	169-173
26796146-7	2016	A novel IKKbeta inhibitor, IMD-0560, almost completely inhibited IL-6 production from hAMSCs.	N-(2,5-bis(trifluoromethyl)phenyl)-5-bromo-2-hydroxybenzamide	27-35	interleukin 6	Mus musculus	65-69
26849878-9	2016	Collectively, our data indicate that 4-TBPS significantly (p &lt; 0.01) targets the inflammatory response of macrophages via inhibition of iNOS, COX-2, TNF-alpha, IL-1beta, and IL-6 through downregulation of the NF-kappaB pathway.	4-tert-butylphenyl salicylate	37-43	interleukin 6	Mus musculus	177-181
26848111-1	2016	Sixteen novel hesperetin derivatives containing Mannich base moiety were designed and synthesized and their anti-inflammatory activities were evaluated by inhibiting tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in mouse RAW264.7 macrophages.	hesperetin	14-24	interleukin 6	Mus musculus	210-223
26972403-11	2016	Compared to the control group, serum levels of ALT and AST, and mRNA levels of TNF-alpha, IL-6 and IL-1beta were increased in APAP-induced group.	Acetaminophen	126-130	interleukin 6	Mus musculus	90-94
26972403-13	2016	However, compared to APAP-induced group, GS combined with APAP-induced group displayed a decrease of protein expression levels of ASK1, P-ASK1 and P-JNK, a reduction of serum levels of ALT and AST, a decrease in TNF-alpha, IL-6 and IL-1beta mRNA levels, and a low ration of GSSG/GSH.	Acetaminophen	58-62	interleukin 6	Mus musculus	223-227
26676587-6	2016	IL-6 from the myofibroblasts contributed to the amplification of the AAM phenotype; the selective COX-2 inhibitor, NS-398, significantly reduced the ability of myofibroblasts to promote an AAM phenotype.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	115-121	interleukin 6	Mus musculus	0-4
26848111-1	2016	Sixteen novel hesperetin derivatives containing Mannich base moiety were designed and synthesized and their anti-inflammatory activities were evaluated by inhibiting tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in mouse RAW264.7 macrophages.	hesperetin	14-24	interleukin 6	Mus musculus	225-229
26887341-6	2016	Furthermore, the levels of tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) were obviously decreased in the LM-Fe supplemented groups compared with the model group, while the level of interleukin-2 (IL-2) was significantly increased.	lm-fe	155-160	interleukin 6	Mus musculus	102-115
26750868-2	2016	IL-6 participates in the regulation of fatty acid metabolism in the liver.	Fatty Acids	39-49	interleukin 6	Mus musculus	0-4
26998046-5	2016	In addition, the mRNA expression of inducible nitric oxide synthase, TNF-alpha, IL-6 and IL-1beta was suppressed by treatment with TFHDW in LPS-stimulated RAW 264.7 cells.	tfhdw	131-136	interleukin 6	Mus musculus	80-84
26887341-6	2016	Furthermore, the levels of tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) were obviously decreased in the LM-Fe supplemented groups compared with the model group, while the level of interleukin-2 (IL-2) was significantly increased.	lm-fe	155-160	interleukin 6	Mus musculus	117-121
26612455-0	2016	The molecular events behind ferulic acid mediated modulation of IL-6 expression in LPS-activated Raw 264.7 cells.	ferulic acid	28-40	interleukin 6	Mus musculus	64-68
26784569-6	2016	Administration of astilbin ameliorated IMQ-induced keratinocyte proliferation, infiltration of CD3+ cells to psoriatic lesions and ameliorated elevations in circulating CD4+ and CD8+ T cells and inflammatory cytokines (IL-17A, TNF-alpha, IL-6, IFN-gamma and IL-2).	astilbin	18-26	interleukin 6	Mus musculus	238-242
26621502-7	2016	Interestingly, polyP-induced NF-kappaB activation and the productions of TNF-alpha and IL-6 were inhibited by vicenin-2 and scolymoside in HUVECs.	Polyphosphates	15-20	interleukin 6	Mus musculus	87-91
26621502-7	2016	Interestingly, polyP-induced NF-kappaB activation and the productions of TNF-alpha and IL-6 were inhibited by vicenin-2 and scolymoside in HUVECs.	scolymoside	124-135	interleukin 6	Mus musculus	87-91
26784569-6	2016	Administration of astilbin ameliorated IMQ-induced keratinocyte proliferation, infiltration of CD3+ cells to psoriatic lesions and ameliorated elevations in circulating CD4+ and CD8+ T cells and inflammatory cytokines (IL-17A, TNF-alpha, IL-6, IFN-gamma and IL-2).	Imiquimod	39-42	interleukin 6	Mus musculus	238-242
26818424-11	2016	IL-6(-/-) WT, but not WT WT chimeras, exhibited a blunted thrombosis response to dextran sodium sulfate.	dextran sodium sulfate	81-103	interleukin 6	Mus musculus	0-4
26800098-6	2016	The results showed that pretreatment with pogostone markedly improved survival rate, attenuated the histological alterations in the lung, reduced the MPO and MDA levels, decreased the wet/dry weight ratio of lungs, down-regulated the level of pro-inflammatory mediators including TNF-a, IL-1beta and IL-6.	Pogostone	42-51	interleukin 6	Mus musculus	300-304
26800098-7	2016	Furthermore, pretreatment with pogostone enhanced the Nrf2 dependent genes including NQO-1, GCLC and HO-1 but suppressed NF-kappaB regulated genes including TNF-alpha, IL-1beta and IL-6.	Pogostone	31-40	interleukin 6	Mus musculus	181-185
26829988-6	2016	The presence of PcpA was associated with increased IL-6 levels, suppressed production of TRAIL, and reduced infiltration of polymorphonuclear cells.	Fenclonine	16-20	interleukin 6	Mus musculus	51-55
26291957-3	2016	7-MCPA inhibited lipopolysaccharide (LPS)-induced production of nitric oxide (NO), prostaglandin E2 (PGE2 ), and interleukin-6 (IL-6) in RAW264.7 cells and rescued C57BL/6 mice from LPS-induced lethality in vivo.	7-methoxy-(9H-beta-carbolin-1-il)-(E)-1-propenoic acid	0-6	interleukin 6	Mus musculus	128-132
26291957-4	2016	LPS-induced expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and IL-6 was also significantly suppressed by treatment of 7-MCPA in RAW264.7 cells.	7-methoxy-(9H-beta-carbolin-1-il)-(E)-1-propenoic acid	151-157	interleukin 6	Mus musculus	96-100
26796031-1	2016	BACKGROUND: The aim of this study was to evaluate the effects of photodynamic therapy with curcumin (PDT) comparatively to 5% sodium hypochlorite (NaOCl) and saline solution on cell viability and cytokine (IL-1beta and IL-6) production by mouse fibroblasts.	Curcumin	91-99	interleukin 6	Mus musculus	219-223
26800690-13	2016	The C2S-coated surface stimulated macrophages to express pro-inflammatory mediators, such as TNF-alpha, IL-6 and IL-1beta, and C2S coating caused less IL-6 but greater IL-1beta production than the 45S5 coating.	A(2)C	4-7	interleukin 6	Mus musculus	104-108
26800690-13	2016	The C2S-coated surface stimulated macrophages to express pro-inflammatory mediators, such as TNF-alpha, IL-6 and IL-1beta, and C2S coating caused less IL-6 but greater IL-1beta production than the 45S5 coating.	A(2)C	4-7	interleukin 6	Mus musculus	151-155
26800690-13	2016	The C2S-coated surface stimulated macrophages to express pro-inflammatory mediators, such as TNF-alpha, IL-6 and IL-1beta, and C2S coating caused less IL-6 but greater IL-1beta production than the 45S5 coating.	A(2)C	127-130	interleukin 6	Mus musculus	151-155
26851533-8	2016	The proinflammatory cytokines TNF-alpha, IL-1beta, IL-6 and IL-17A were significantly decreased in the infected mice treated with nicotine compared with methyllycaconitine.	Nicotine	130-138	interleukin 6	Mus musculus	51-55
26838169-7	2016	Kolaviron inhibited the protein levels of NO/iNOS, PGE2/COX-2, cellular ROS and the pro-inflammatory cytokines (TNFalpha and IL-6) in LPS-stimulated microglia.	kolaviron	0-9	interleukin 6	Mus musculus	125-129
27183712-5	2016	One point seven microg/ml (5 microM) corticosterone served as positive control and was able to reduce LPS-induced IL-6 release by 46 +- 4%.	Corticosterone	37-51	interleukin 6	Mus musculus	114-118
26840084-6	2016	In these polyps, mRNA levels of the downstream targets of NF-jB, such as IL-1beta and IL-6, were decreased by irsogladine maleate treatment.	irsogladine	110-129	interleukin 6	Mus musculus	86-90
26424839-12	2016	Both SERMs decreased serum marker of cartilage destruction and LAS reduced serum IL-6 levels.	Lasofoxifene	63-66	interleukin 6	Mus musculus	81-85
26789651-7	2016	Neurotrophic factor BDNF and GDNF as well as immunomodulatory cytokine IL-10 in spinal cord were elevated in Fasudil-treated mice, while inflammatory cytokine IL-17, IL-1beta, IL-6, and TNF-alpha were obviously inhibited, accompanied by the decrease of inflammatory M1 iNOS and the increase of anti-inflammatory M2 Arg-1, providing a microenvironment that contributes to synaptic protection.	fasudil	109-116	interleukin 6	Mus musculus	176-180
25982271-11	2016	As a downstream consequence, expression and secretion of the pro-inflammatory cytokine interleukin-6 is induced by BPDE and CDDP in vitro and by CDDP in the murine lung, and depends on XPC.	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	115-119	interleukin 6	Mus musculus	87-100
26907256-4	2016	Cudraflavanone D (1) also decreased IL-6, TNF-alpha, IL-12, and IL-1beta production, blocked nuclear translocation of NF-kappaB heterodimers (p50 and p65) by interrupting the degradation and phosphorylation of inhibitor of IkappaB-alpha, and inhibited NF-kappaB binding.	cudraflavanone	0-14	interleukin 6	Mus musculus	36-40
25982271-11	2016	As a downstream consequence, expression and secretion of the pro-inflammatory cytokine interleukin-6 is induced by BPDE and CDDP in vitro and by CDDP in the murine lung, and depends on XPC.	Cisplatin	145-149	interleukin 6	Mus musculus	87-100
25982271-11	2016	As a downstream consequence, expression and secretion of the pro-inflammatory cytokine interleukin-6 is induced by BPDE and CDDP in vitro and by CDDP in the murine lung, and depends on XPC.	Cisplatin	124-128	interleukin 6	Mus musculus	87-100
26888669-6	2016	By treating cells with H2O2 and vitamin E (VE), Mark4 accentuated oxidative stress along with increased mRNA level of inflammatory factor interleukin-6 (IL-6) and decreased leptin mRNA.	Hydrogen Peroxide	23-27	interleukin 6	Mus musculus	138-151
26888669-6	2016	By treating cells with H2O2 and vitamin E (VE), Mark4 accentuated oxidative stress along with increased mRNA level of inflammatory factor interleukin-6 (IL-6) and decreased leptin mRNA.	Hydrogen Peroxide	23-27	interleukin 6	Mus musculus	153-157
26888669-6	2016	By treating cells with H2O2 and vitamin E (VE), Mark4 accentuated oxidative stress along with increased mRNA level of inflammatory factor interleukin-6 (IL-6) and decreased leptin mRNA.	Vitamin E	32-41	interleukin 6	Mus musculus	153-157
26888669-6	2016	By treating cells with H2O2 and vitamin E (VE), Mark4 accentuated oxidative stress along with increased mRNA level of inflammatory factor interleukin-6 (IL-6) and decreased leptin mRNA.	Vitamin E	32-41	interleukin 6	Mus musculus	138-151
27158384-7	2016	IL-6 and MCP-1 in lung tissues and BALF in methazolamide-treated mice were statistically decreased.	Methazolamide	43-56	interleukin 6	Mus musculus	0-4
26732631-7	2016	RESULTS: Among the investigated active fractions, the flavonoids from Carthamus tinctorius (Fct), Davallia mariesii (Fdm), and Cinnamomum cassia Twig volatile oils (Vca) from the eight selected herbs effectively promoted IL-1beta and IL-6 release from ANA-1 cells.	Flavonoids	54-64	interleukin 6	Mus musculus	234-238
26929598-6	2016	EGCG decreased the immunoreaction and pathological damage by reducing inflammatory factors, such as TNF-alpha, IL-6, IFN-gamma, and IL-1beta.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	111-115
26929598-7	2016	EGCG also exhibited an antiapoptotic and antiautophagic effect by inhibiting BNIP3 via the IL-6/JAKs/STAT3 pathway.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	91-95
26929598-8	2016	CONCLUSION: EGCG attenuated liver injury in ConA-induced hepatitis by downregulating IL-6/JAKs/STAT3/BNIP3-mediated apoptosis and autophagy.	epigallocatechin gallate	12-16	interleukin 6	Mus musculus	85-89
26926174-10	2016	In addition, neomangiferin inhibited TNBS-induced expression of tumor necrosis factor-alpha, IL-17, IL-6, and IL-1beta, and increased IL-10 expression.	Trinitrobenzenesulfonic Acid	37-41	interleukin 6	Mus musculus	100-104
26773156-7	2016	Furthermore, C1q-deficient pristane-primed resident peritoneal macrophages secreted significantly less CCL3, CCL2, CXCL1, and IL-6 when stimulated in vitro with TLR7 ligand.	pristane	27-35	interleukin 6	Mus musculus	126-130
26872389-3	2016	IL-6 regulation was tested in C2C12 myotubes and in soleus during treatment with epinephrine (EPI) or LPS.	Epinephrine	81-92	interleukin 6	Mus musculus	0-4
26780402-5	2016	At the same time, DOXO causes a significant production of proinflammatory cytokines (such as TNF-alpha and IL-6) with a concomitant reduction of IL-10, a well-known antiinflammatory cytokine.	Doxorubicin	18-22	interleukin 6	Mus musculus	107-111
26739550-11	2016	Production of inflammatory cytokines, i.e., interleukin-6 and tumor necrosis factor (TNF)-alpha, was significantly increased in DSS-induced colitis mice.	Dextran Sulfate	128-131	interleukin 6	Mus musculus	44-57
26698392-8	2016	The results showed that zingerone suppressed LPS-induced BUN, creatinine, and inflammatory cytokines TNF-alpha, IL-6 and IL-1beta levels in a dose-dependent manner.	zingerone	24-33	interleukin 6	Mus musculus	112-116
26842661-8	2016	RESULTS Haloperidol inhibited NF-kappaB activation, and thereby suppressed expression of CD80, as well as secretion of IL-1beta, IL-6, and IL-12 p40.	Haloperidol	8-19	interleukin 6	Mus musculus	129-133
26640239-4	2016	DC production of interleukin (IL)-6, tumor necrosis factor alpha, and monocyte chemoattractant protein-1 in response to lipopolysaccharide stimulation was also reduced following piperine treatment.	piperine	178-186	interleukin 6	Mus musculus	17-35
26856814-7	2016	We also observed that BAF312 moderately attenuated lipopolysaccharide (LPS)- or TNFalpha/IL17-induced levels of IL6 in both astrocyte and microglia cell cultures.	siponimod	22-28	interleukin 6	Mus musculus	112-115
26856814-8	2016	In organotypic slice cultures, BAF312 reduced LPC-induced levels of IL6 and attenuated LPC-mediated demyelination.	siponimod	31-37	interleukin 6	Mus musculus	68-71
25388157-5	2016	The real-time PCR studies showed that (1) inhalational silica induced inflammatory responses in the heart and kidney by elevated mRNA levels of TNF-alpha, IL-6 and MCP-1; (2) early fibrotic responses in the heart were observed as elevated mRNA levels of collagen I and fibronectin.	Silicon Dioxide	55-61	interleukin 6	Mus musculus	155-159
26842246-5	2016	Simultaneous exposure to hog barn dust and alcohol decreases inflammatory mediators, TNF-alpha, IL-6, and IL-8, in mice.	Alcohols	43-50	interleukin 6	Mus musculus	96-100
26695376-8	2016	Additionally, low RANKL, tumor necrosis factor-alpha, interleukin-1beta and interleukin-6 immunochemistry staining were noted in dopamine-treatment groups.	Dopamine	129-137	interleukin 6	Mus musculus	76-89
26103560-8	2016	Following treatment with 1K/DOCA/salt, ASC(-/-) mice displayed blunted pressor responses and were also protected from increases in renal expression of IL-6, IL-17A, CCL2, ICAM-1 and VCAM-1, and accumulation of macrophages and collagen.	Desoxycorticosterone Acetate	28-32	interleukin 6	Mus musculus	151-155
26013851-5	2016	Cells were pre-incubated with GA3 , stimulated with Pseudomonas aeruginosa LPS; IL-6 and IL-8 release, A20, NF-kappaB and IkappaBalpha expression were then evaluated.	gibberellic acid	30-33	interleukin 6	Mus musculus	80-84
26103560-8	2016	Following treatment with 1K/DOCA/salt, ASC(-/-) mice displayed blunted pressor responses and were also protected from increases in renal expression of IL-6, IL-17A, CCL2, ICAM-1 and VCAM-1, and accumulation of macrophages and collagen.	Salts	33-37	interleukin 6	Mus musculus	151-155
26906200-4	2016	In mice receiving SNK-411 in doses of 25 and 50 mg/kg, IL-4 content significantly decreased (by 4.0 and 3.6 times) on days 2-8 of carcinoma development; IL-2 content decreased by 1.4 and 1.2 times and IL-6 content decreased by 2.7 and 1.6 times, respectively, in comparison with control mice with tumors.	2-isobutyl-4,6-dimethyl-5-hydroxypyrimidine	18-25	interleukin 6	Mus musculus	201-205
26434621-8	2016	Moreover, DEX treatment for 21 and 28 days significantly increased the proteins expression of NLRP-1, Caspase-1, Caspase-5, apoptosis associated speck-like protein (ASC), nuclear factor-kappaB (NF-kappaB), p-NF-kappaB, interleukin-1beta (IL-1beta), IL-18 and IL-6 in the frontal cortex and hippocampus brain tissue.	Dexamethasone	10-13	interleukin 6	Mus musculus	259-263
26678224-7	2016	Asbestos-exposed mice fed CTL diet developed acute inflammation, with significant (P &lt; 0.0001) elevations in WBCs and proinflammatory/profibrogenic cytokines (IL-1ss, IL-6, TNFalpha, HMGB1 and active TGFss1) relative to baseline (BL) levels.	Asbestos	0-8	interleukin 6	Mus musculus	170-174
26310139-8	2016	TPPU decreased the transforming growth factor-beta1 (TGF-beta1), interleukin-1beta (IL-1beta) and IL-6 levels in the serum of bleomycin-stimulated mice.	TPPU	0-4	interleukin 6	Mus musculus	98-102
26310139-8	2016	TPPU decreased the transforming growth factor-beta1 (TGF-beta1), interleukin-1beta (IL-1beta) and IL-6 levels in the serum of bleomycin-stimulated mice.	Bleomycin	126-135	interleukin 6	Mus musculus	98-102
26363317-4	2016	Moreover, pretreatment of the RAW264.7 cells with Cd for 24 h inhibited the transcriptional status of TNFalpha, IL6, IL1alpha and IL1beta and the release of these cytokines in response to a 6-h lipopolysaccharide (LPS) treatment in a dose-dependent manner.	Cadmium	50-52	interleukin 6	Mus musculus	112-115
26468152-7	2016	Sesamin suppressed LPS-induced inflammatory cytokines TNF-alpha, IL-6, and IL-1beta production.	sesamin	0-7	interleukin 6	Mus musculus	65-69
26527068-9	2016	Increased adenosine levels were associated with elevation of IL-6 and IL-17, which are important inflammatory cytokines in pulmonary fibrosis.	Adenosine	10-19	interleukin 6	Mus musculus	61-65
26527068-10	2016	These results demonstrate that extracellular adenosine levels are closely associated with the progression of experimental pulmonary fibrosis and that this signaling pathway may mediate fibrosis by regulating IL-6 and IL-17 production.	Adenosine	45-54	interleukin 6	Mus musculus	208-212
26710167-4	2016	We found that asperuloside can significantly downregulate tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-1beta, and IL-6 levels in vitro and in vivo, and treatment with asperuloside significantly reduced the lung wet-to-dry weight, histological alterations and myeloperoxidase activity in a murine model of LPS-induced acute lung injury (ALI).	asperuloside	14-26	interleukin 6	Mus musculus	127-131
26741264-6	2016	Furthermore, ASP pretreatment significantly decreased proinflammatory cytokines (TNF-alpha, IFN-gamma, IL-2 and IL-6) and alleviated oxidative stress by reducing MDA and ROS levels and by enhancing SOD activity after ConA administration in mice.	Aspartic Acid	13-16	interleukin 6	Mus musculus	112-116
26741264-7	2016	Results of Western blot analysis indicated that ASP attenuated Caspase-3-dependent apoptosis by Caspase-8 and JNK-mediated pathway and inhibited the activation of IL-6/STAT3 and NF-kappaB signaling pathways in ConA-induced liver damage in mice.	Aspartic Acid	48-51	interleukin 6	Mus musculus	163-167
26744072-5	2016	In the present study, we investigated the effects of mimosine on the PGF2alpha-induced synthesis of osteoprotegerin or IL-6 in MC3T3-E1 cells.	Dinoprost	69-78	interleukin 6	Mus musculus	119-123
26744072-4	2016	We have also demonstrated that PGF2alpha induced the synthesis of interleukin-6 (IL-6) via p38 MAP kinase and p44/p42 MAP kinase but not SAPK/JNK in these cells.	Dinoprost	31-40	interleukin 6	Mus musculus	66-79
26335543-9	2016	Systemic administration of curcumin significantly decreased the production of TNF-alpha, MIP-2, and IL-6 as well as neutrophil accumulation in bronchoalveolar lavage fluid, and also decreased pulmonary myeloperoxidase levels and the wet/dry weight ratio in mice subjected to LPS treatment.	Curcumin	27-35	interleukin 6	Mus musculus	100-104
26744072-4	2016	We have also demonstrated that PGF2alpha induced the synthesis of interleukin-6 (IL-6) via p38 MAP kinase and p44/p42 MAP kinase but not SAPK/JNK in these cells.	Dinoprost	31-40	interleukin 6	Mus musculus	81-85
26878795-5	2016	Moreover, fisetin reduced the levels of myeloperoxidase activity, the production of proinflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta) and interleukin-6 (IL-6) and the expressions of COX-2 and iNOS in the colon tissues.	fisetin	10-17	interleukin 6	Mus musculus	186-199
26842755-12	2016	Furthermore, sGFP-TatNrf2mer expression decreased IL-1beta and IL-6 in the NaIO3-treated mice, and resulted in a 54% decrease in the number of inflammatory cells in the vitreous body of the endotoxin-induced uveitis mouse model.	sodium iodate	75-80	interleukin 6	Mus musculus	63-67
27042448-6	2016	The immunomodulatory response of DADS to the radiological effects was determined by the estimation of IL-6 levels.	amsonic acid	33-37	interleukin 6	Mus musculus	102-106
26878795-5	2016	Moreover, fisetin reduced the levels of myeloperoxidase activity, the production of proinflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta) and interleukin-6 (IL-6) and the expressions of COX-2 and iNOS in the colon tissues.	fisetin	10-17	interleukin 6	Mus musculus	201-205
26647854-10	2016	GW9662 also eliminated the inhibitory effect of L-carnitine on the expression of cyclooxygenase-2 (Cox-2) in the liver, and on the serum expression levels of pro-inflammatory prostaglandin E2, C-reactive protein, tumor necrosis factor-alpha and interleukin-6 in the cancer cachexia model mice.	2-chloro-5-nitrobenzanilide	0-6	interleukin 6	Mus musculus	245-258
26578392-9	2016	In mouse primary hepatocyte cultures, IL-6 and TNFalpha inhibited high-glucose plus insulin-induced activation of SREBP-1-mediated lipogenic signaling and biosynthesis of non-esterified fatty acid and triglyceride.	Glucose	71-78	interleukin 6	Mus musculus	38-42
26578392-9	2016	In mouse primary hepatocyte cultures, IL-6 and TNFalpha inhibited high-glucose plus insulin-induced activation of SREBP-1-mediated lipogenic signaling and biosynthesis of non-esterified fatty acid and triglyceride.	Fatty Acids	186-196	interleukin 6	Mus musculus	38-42
26578392-9	2016	In mouse primary hepatocyte cultures, IL-6 and TNFalpha inhibited high-glucose plus insulin-induced activation of SREBP-1-mediated lipogenic signaling and biosynthesis of non-esterified fatty acid and triglyceride.	Triglycerides	201-213	interleukin 6	Mus musculus	38-42
26384655-10	2016	Further, GSK3beta inhibition reduced HI-induced gene expression of pro-inflammatory cytokines tnfalpha and Il-6, while promoted the anti-inflammatory factor Il-10.	hi	37-39	interleukin 6	Mus musculus	107-111
26647854-10	2016	GW9662 also eliminated the inhibitory effect of L-carnitine on the expression of cyclooxygenase-2 (Cox-2) in the liver, and on the serum expression levels of pro-inflammatory prostaglandin E2, C-reactive protein, tumor necrosis factor-alpha and interleukin-6 in the cancer cachexia model mice.	Carnitine	48-59	interleukin 6	Mus musculus	245-258
26721437-6	2016	Furthermore, methane treatment obviously suppressed the secretion of proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) and increased anti-inflammatory cytokine interleukin-10 (IL-10).	Methane	13-20	interleukin 6	Mus musculus	176-189
26573958-8	2016	Real-time PCR analysis revealed that colonic mucosal IL-6 mRNA expression, which was significantly upregulated in the ob/ob mice, was significantly suppressed by the long-term administration of STG.	Sitagliptin Phosphate	194-197	interleukin 6	Mus musculus	53-57
26721437-6	2016	Furthermore, methane treatment obviously suppressed the secretion of proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) and increased anti-inflammatory cytokine interleukin-10 (IL-10).	Methane	13-20	interleukin 6	Mus musculus	191-195
26687879-7	2016	On 13 weeks post-injection, the increased percentages of neutrophils and eosinophils, the enhanced release of LDH, and the elevated secretion of IL-8 and IL-6 were clearly observed in the blood of M-FeNP-treated mice compared to the control.	m-fenp	197-203	interleukin 6	Mus musculus	154-158
26789595-0	2016	Histone deacetylase inhibitors restore IL-10 expression in lipopolysaccharide-induced cell inflammation and reduce IL-1beta and IL-6 production in breast silicone implant in C57BL/6J wild-type murine model.	Silicones	154-162	interleukin 6	Mus musculus	128-132
30873458-12	2016	Conclusions: Accelerated DEN-induced HCC in obese/diabetic mice is linked to enhanced growth of dysplastic hepatocytes that cannot be attributed to NF-kappaB or IL-6/STAT3 activation, nor to sustained mTORC1 activation.	Diethylnitrosamine	25-28	interleukin 6	Mus musculus	161-165
26949603-8	2016	It also inhibited the zymosan-induced up-regulation of IL-6, IL-8, and MCP-1 mRNA abundance in these cells.	Zymosan	22-29	interleukin 6	Mus musculus	55-59
26789595-6	2016	Our findings evidenced the ability of such inhibitors to reduce host inflammation in silicone implants promoting a thickness reduction of peri-implant fibrous capsule, upregulating IL-10 expression, and reducing the production of both IL-1beta and IL-6.	Silicones	85-93	interleukin 6	Mus musculus	248-252
27186393-4	2016	Morphine-treated DCs also secreted higher concentrations of IL-10, but lower IL-6 and TNF-alpha.	Morphine	0-8	interleukin 6	Mus musculus	77-81
26518119-3	2016	In this study, we investigated whether inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6) directly influence the lactose synthesis pathway by using two types of murine MEC culture models: the monolayer culture of MECs to induce lactogenesis; and the three-dimensional culture of MECs surrounded by Matrigel to induce reconstitution of the alveolar structure in vitro.	Lactose	117-124	interleukin 6	Mus musculus	88-92
26518119-6	2016	IL-6 caused both up-regulation and down-regulation of the expression levels of lactose synthesis-related genes in MECs.	Lactose	79-86	interleukin 6	Mus musculus	0-4
26518119-7	2016	These results indicate that TNF-alpha, IL-1beta, and IL-6 have different effects on the lactose synthesis pathway in MECs.	Lactose	88-95	interleukin 6	Mus musculus	53-57
26793111-7	2015	In addition, treatment with celastrol inhibited inflammatory responses, as indicated by the decrease of serum tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, down-regulation of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and inactivation of nuclear factor kappaB (NF-kappaB).	celastrol	28-37	interleukin 6	Mus musculus	178-182
26607348-7	2016	Puerarin decreased the level of pro-inflammatory cytokines TNF-alpha and IL-6 in livers.	puerarin	0-8	interleukin 6	Mus musculus	73-77
26154696-6	2016	RESULTS: H2S suppressed lipopolysaccharide (LPS)-induced hepcidin production and regulated iron homeostasis in mice by decreasing serum interleukin-6 (IL-6) and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) activation; similar results were obtained in Huh7 cells exposed to conditioned medium from LPS-challenged THP-1 macrophages.	Hydrogen Sulfide	9-12	interleukin 6	Mus musculus	136-149
26154696-6	2016	RESULTS: H2S suppressed lipopolysaccharide (LPS)-induced hepcidin production and regulated iron homeostasis in mice by decreasing serum interleukin-6 (IL-6) and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) activation; similar results were obtained in Huh7 cells exposed to conditioned medium from LPS-challenged THP-1 macrophages.	Hydrogen Sulfide	9-12	interleukin 6	Mus musculus	151-155
26506421-5	2016	Specifically, cardamonin effectively abolishes chemotherapeutic drug-induced up-regulation of IL-6, IL-8 and MCP-1 and activation of NF-kappaB/IKBalpha and Stat3.	cardamonin	14-24	interleukin 6	Mus musculus	94-98
27627914-5	2016	Xs-ME significantly suppressed the up-regulation of both the activator protein (AP)-1-mediated luciferase activity and the production of LPS-induced proinflammatory cytokines, including interleukin (IL)-1[Formula: see text], IL-6, and tumor necrosis factor (TNF)-[Formula: see text].	xs-me	0-5	interleukin 6	Mus musculus	225-229
26643169-7	2016	Our results indicated that EGCG significantly suppressed the expression of tumor necrosis factor alpha (TNFalpha), interleukin-1beta, interleukin-6, and inducible nitric oxide synthase (iNOS) in Abeta-stimulated EOC 13.31 microglia.	epigallocatechin gallate	27-31	interleukin 6	Mus musculus	134-147
26643169-7	2016	Our results indicated that EGCG significantly suppressed the expression of tumor necrosis factor alpha (TNFalpha), interleukin-1beta, interleukin-6, and inducible nitric oxide synthase (iNOS) in Abeta-stimulated EOC 13.31 microglia.	UNII-042A8N37WH	195-200	interleukin 6	Mus musculus	134-147
26631322-9	2016	The IL-6/STAT3 signaling pathway had protective roles in NaAsO2-induced nephrotoxicity through the suppression of ERK activation.	sodium arsenite	57-63	interleukin 6	Mus musculus	4-8
27430908-3	2016	Here, we found that [Formula: see text]-(1,3)-glucan predominantly induced the tumor necrosis factor (TNF)-[Formula: see text], interleukin (IL)-1[Formula: see text], IL-6, IL-12p70, and nitric oxide, which was dependent on mitogen-activated protein kinases (MAPK) and nuclear factor (NF)-[Formula: see text]B signaling.	(1,3)-glucan	40-52	interleukin 6	Mus musculus	167-171
26916918-7	2016	DMLE treatment suppressed the production of pro-inflammatory cytokines including tumor necrosis factor-[Formula: see text] (TNF-[Formula: see text]), interleukin-6 (IL-6), and nitric oxide (NO) in LPS-stimulated BV2 cells.	dmle	0-4	interleukin 6	Mus musculus	150-163
26916918-7	2016	DMLE treatment suppressed the production of pro-inflammatory cytokines including tumor necrosis factor-[Formula: see text] (TNF-[Formula: see text]), interleukin-6 (IL-6), and nitric oxide (NO) in LPS-stimulated BV2 cells.	dmle	0-4	interleukin 6	Mus musculus	165-169
26645352-9	2016	Furthermore, an increased expression of TLR2, TLR6 and pro-inflammatory markers including chemokine (C-C motif) ligand 2, interleukin (IL)-1beta, tumour necrosis factor alpha and IL-6 was found in DSS-treated mice with L. rhamnosus supplementation.	dss	197-200	interleukin 6	Mus musculus	179-183
27744729-9	2016	Consequently, EGCG pretreatment can effectively inhibit the Th17-related pro-inflammatory cytokine (e.g. IL-17 and IL-6) upregulation induced by TP treatment.	epigallocatechin gallate	14-18	interleukin 6	Mus musculus	115-119
26358659-5	2016	In this study, we reported that orally administered alpha-TQ ameliorated memory impairment in APPswe/PS1dE9 transgenic mice, decreased oxidative stress and the levels of Abeta oligomer in the brains of mice, prevented the production of inducible nitric oxide synthase and inflammatory mediators, such as interleukin-6 and interleukin-1beta, and inhibited microglial activation by inhibiting NF-kappaB signaling pathway.	alpha-tq	52-60	interleukin 6	Mus musculus	304-317
27150139-3	2016	CS-ME concentration-dependently inhibited LPS-induced tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 and IL-1beta production in RAW264.7 macrophages and mouse peritoneal macrophages.	cs-me	0-5	interleukin 6	Mus musculus	92-110
26054709-5	2016	Enzyme-linked immunosorbent assays showed that bafilomycin A1 can significantly decrease the subtoxic concentration of CoNP-induced levels of pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6), but has no effect on anti-inflammatory cytokines (transforming growth factor-beta and interleukin-10) in RAW264.7 cells.	bafilomycin	47-58	interleukin 6	Mus musculus	222-235
26054709-5	2016	Enzyme-linked immunosorbent assays showed that bafilomycin A1 can significantly decrease the subtoxic concentration of CoNP-induced levels of pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6), but has no effect on anti-inflammatory cytokines (transforming growth factor-beta and interleukin-10) in RAW264.7 cells.	conp	119-123	interleukin 6	Mus musculus	222-235
26499331-3	2016	Crebanine inhibited the production of proinflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor-alpha in LPS-induced RAW264.7 cells.	crebanine	0-9	interleukin 6	Mus musculus	74-87
26499331-3	2016	Crebanine inhibited the production of proinflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor-alpha in LPS-induced RAW264.7 cells.	crebanine	0-9	interleukin 6	Mus musculus	89-126
28119924-9	2016	DAP treatment decreased the overexpression of TNF-alpha, IL-1beta, and IL-6 and attenuated neural cells apoptosis.	daphnetin	0-3	interleukin 6	Mus musculus	71-75
27847821-9	2016	Following that, we found rutin and chlorogenic acid (10-100 muM) could significantly increase cell viability and decrease the production of IL-6 in UVB models.	Rutin	25-30	interleukin 6	Mus musculus	140-144
27847821-9	2016	Following that, we found rutin and chlorogenic acid (10-100 muM) could significantly increase cell viability and decrease the production of IL-6 in UVB models.	Chlorogenic Acid	35-51	interleukin 6	Mus musculus	140-144
27213155-3	2016	In addition, the effects of the anti-T20 in vitro, measuring the inhibition of the IL-6 and TNF-alpha production in response to PGN, LTA, and Pam3CSK4-stimulated RAW264.7 cells, were determined.	pgn	128-131	interleukin 6	Mus musculus	83-87
27213155-5	2016	The results showed that anti-T20 specifically bound to TLR2 and significantly inhibited PGN, LTA, and Pam3CSK4-driven TNF-alpha and IL-6 production by RAW264.7 cells.	pgn	88-91	interleukin 6	Mus musculus	132-136
27213155-6	2016	Also, anti-T20 protected OVA allergic mice from PGN-induced lethal anaphylaxis, and the serum levels of TNF-alpha, IL-6, and LTC4 of anti-T20 treated PGN-challenged OVA allergic mice were decreased as compared to isotype control of anti-T20 treated mice.	pgn	150-153	interleukin 6	Mus musculus	115-119
26554632-7	2016	These drugs suppressed the ability of lipopolysaccharide to stimulate the synthesis and secretion of nitric oxide and inflammatory cytokines and chemokines, such as IL6, IL1beta, CXCL2, and CSF3, in macrophage-like RAW264.7 cells.	Nitric Oxide	101-113	interleukin 6	Mus musculus	165-168
26828432-4	2016	Dox can also up-regulate IL-6 and GM-CSF expression via the NF-kappaB and MAPK/ERK pathways.	Doxycycline	0-3	interleukin 6	Mus musculus	25-29
27643515-9	2016	DMDD inhibited inflammatory cytokines IL-6, TNF-alpha and MCP-1 generations in palmitic acid (PA)-induced Min6 cells.	2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione	0-4	interleukin 6	Mus musculus	38-42
26849230-12	2016	It was also observed that Myrtol standardized inhibited TGF-beta1 and a series of pro-inflammatory cytokines including TNF-alpha, IL-1beta, IL-6, PGE2.	myrtol	26-32	interleukin 6	Mus musculus	140-144
26433963-6	2016	The search for mediators of senescent HPMC activity using specific neutralizing antibodies and recombinant exogenous proteins showed that the intensified angiogenic potential of cancer cells was elicited by IL-6 and TGF-beta1.	hydroxypropylmethylcellulose-lactose matrix	38-42	interleukin 6	Mus musculus	207-211
27630735-10	2016	VAL inhibited the production and expression of proinflammatory cytokines IL-1beta and IL-6 in LPS-stimulated RAW 264.7 cells.	valencene	0-3	interleukin 6	Mus musculus	86-90
27042186-6	2016	SDE showed anti-inflammatory activity by inhibiting the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in LPS-induced RAW 264.7 cells.	sde	0-3	interleukin 6	Mus musculus	159-172
27042186-6	2016	SDE showed anti-inflammatory activity by inhibiting the production of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in LPS-induced RAW 264.7 cells.	sde	0-3	interleukin 6	Mus musculus	174-178
26436985-3	2016	The mRNA expression of the pro-inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha in PA-treated myotubes was suppressed by these three test long-chain PUFAs.	Palmitic Acid	103-105	interleukin 6	Mus musculus	54-99
28044086-6	2016	Histological analysis showed that phloretin suppressed the severity of RA and effectively mitigated joint inflammation and cartilage- and bone-destruction via reducing proinflammatory cytokine productions (TNF-alpha, IL-6, IL-1beta, and IL-17).	Phloretin	34-43	interleukin 6	Mus musculus	217-221
26510118-6	2016	In addition, western blot analysis showed that quercitrin suppressed the release of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6).	quercitrin	47-57	interleukin 6	Mus musculus	163-176
26954392-7	2016	RESULTS: Combined treatment of DHA (50 muM) and celecoxib (20 muM) significantly inhibited LPS induced synthesis of NO, TNF-alpha, IL-6 and PGE2 levels in the cells, compared to the individual treatments.	Docosahexaenoic Acids	31-34	interleukin 6	Mus musculus	131-135
26510118-6	2016	In addition, western blot analysis showed that quercitrin suppressed the release of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6).	quercitrin	47-57	interleukin 6	Mus musculus	178-182
29847081-7	2016	STZ, administered once, changed the TNF-alpha &amp; and IL-6 concentrations in a different manner according to the diet.	Streptozocin	0-3	interleukin 6	Mus musculus	56-60
26954392-7	2016	RESULTS: Combined treatment of DHA (50 muM) and celecoxib (20 muM) significantly inhibited LPS induced synthesis of NO, TNF-alpha, IL-6 and PGE2 levels in the cells, compared to the individual treatments.	Celecoxib	48-57	interleukin 6	Mus musculus	131-135
26655878-4	2016	The results showed that mortality rate, lung index, lung histopathological changes, IL-6 and TNF-alpha in serum were significantly attenuated in the treatment of YHPG (15 and 30g/kg) than those in the IFV control group, while the levels of IL-2 was significantly enhanced.	yhpg	162-166	interleukin 6	Mus musculus	84-88
26672918-9	2016	Our results showed that SA attenuated LPS-induced lung pathological changes, edema, the expression of cycloxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in lung tissues, as well as TNF-alpha, IL-6, IL-1beta, and NO production in mice.	soyasaponin Ab	24-26	interleukin 6	Mus musculus	208-212
26672918-11	2016	SA also inhibited LPS-induced TNF-alpha, IL-6 and IL-1beta production as well as NF-kappaB activation in alveolar macrophages.	soyasaponin Ab	0-2	interleukin 6	Mus musculus	41-45
26986950-5	2016	Ozone exposure increased plasma TNFalpha, as well as expression of VCAM-1, iNOS and IL-6 in both pulmonary and adipose tissues.	Ozone	0-5	interleukin 6	Mus musculus	84-88
26604089-7	2016	Butyrate pretreatment also significantly ameliorated contents of malondialdehyde (MDA) and carbonyl proteins, and decreased levels of IL-1beta, TNF-alpha and IL-6.	Butyrates	0-8	interleukin 6	Mus musculus	158-162
26531002-5	2016	Our results revealed that sulforaphane significantly decreased lactate dehydrogenase (LDH) activity (as shown by LDH assay), the wet-to-dry ratio of the lungs and the serum levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) (measured by ELISA), as well as nuclear factor-kappaB protein expression in mice with LPS-induced ALI.	sulforaphane	26-38	interleukin 6	Mus musculus	183-196
26531002-5	2016	Our results revealed that sulforaphane significantly decreased lactate dehydrogenase (LDH) activity (as shown by LDH assay), the wet-to-dry ratio of the lungs and the serum levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) (measured by ELISA), as well as nuclear factor-kappaB protein expression in mice with LPS-induced ALI.	sulforaphane	26-38	interleukin 6	Mus musculus	198-202
26923011-8	2016	The STZ treatment also increased the number of Iba-1-positive and CD68-positive microglial cells, astrocytes, and IL-1beta, IL-6, IL-10, and IL-18 levels in the hippocampus, but not in the midbrain or cerebellum.	Streptozocin	4-7	interleukin 6	Mus musculus	124-128
26041841-10	2016	Vice versa, specific activation of trans-signaling using a recombinant IL-6-sIL-6R fusion molecule (Hyper-IL-6) significantly aggravated NTN and led to increased systolic BP in NTN mice.	ISONICOTINAMIDINE	137-140	interleukin 6	Mus musculus	71-75
26041841-10	2016	Vice versa, specific activation of trans-signaling using a recombinant IL-6-sIL-6R fusion molecule (Hyper-IL-6) significantly aggravated NTN and led to increased systolic BP in NTN mice.	ISONICOTINAMIDINE	137-140	interleukin 6	Mus musculus	77-81
26041841-10	2016	Vice versa, specific activation of trans-signaling using a recombinant IL-6-sIL-6R fusion molecule (Hyper-IL-6) significantly aggravated NTN and led to increased systolic BP in NTN mice.	ISONICOTINAMIDINE	177-180	interleukin 6	Mus musculus	71-75
26041841-10	2016	Vice versa, specific activation of trans-signaling using a recombinant IL-6-sIL-6R fusion molecule (Hyper-IL-6) significantly aggravated NTN and led to increased systolic BP in NTN mice.	ISONICOTINAMIDINE	177-180	interleukin 6	Mus musculus	77-81
26923011-10	2016	When the effects of STZ were compared between Tg601 and NTg mice, microglial proliferation and elevations in IL-6 and phosphorylated tau were higher in Tg601 mice.	Streptozocin	20-23	interleukin 6	Mus musculus	109-113
26406561-8	2016	Inhibition of SUV39H1 with chaetocin in NG-treated macrophages also increased the expression of IL-6, IL-12p40, MIP-1alpha, and MIP-1beta.	chaetocin	27-36	interleukin 6	Mus musculus	96-100
26464379-4	2016	Additionally, immunization with rOhr induced high production of IFN-gamma as well as proinflammatory cytokines such as TNF, MCP-1, IL-12p70, and IL-6, but a lesser amount of IL-10, suggesting that rOhr predominantly elicited a cell-mediated immune response.	rohr	32-36	interleukin 6	Mus musculus	145-149
25975427-3	2016	The results indicated that non-cytotoxic doses of IM-133N effectively up-regulated iNOS, TNFalpha, IL-6, IL-10, IL-8 and IFNgamma gene expression in both the RAW264.7 and THP-1 cells.	im-133n	50-57	interleukin 6	Mus musculus	99-103
26603425-10	2016	DOX or I3C alone or in combination induced significant increase in tumor CAT and SOD with significant decrease in tumor volume, tumor MDA, SphK1 activity and IL-6 and alleviated the histopathological changes with significant increase in the apoptotic index and significant decrease in tissue bcl2 compared to SEC group.	Doxorubicin	0-3	interleukin 6	Mus musculus	158-162
26601598-5	2016	In murine bone marrow-derived mast cells (BMMC), butyrate-suppressed FcepsilonRI-dependent tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) release without affecting beta-Hexosaminidase, but that was associated with decreased mitogen-activated protein kinase extracellular signal-regulated kinase 1/2, p38 and c-Jun N-terminal kinases activation.	Butyrates	49-57	interleukin 6	Mus musculus	135-148
26601598-5	2016	In murine bone marrow-derived mast cells (BMMC), butyrate-suppressed FcepsilonRI-dependent tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) release without affecting beta-Hexosaminidase, but that was associated with decreased mitogen-activated protein kinase extracellular signal-regulated kinase 1/2, p38 and c-Jun N-terminal kinases activation.	Butyrates	49-57	interleukin 6	Mus musculus	150-154
26601598-6	2016	Butyrate treatment substantially enhanced histone 3 acetylation in both P815 and BMMC and decreased FcepsilonRI-dependent mRNA expression of tnf-alpha and il-6 in BMMC, mimicking the effect of Trichostatin A, a known histone deacetylase inhibitor.	Butyrates	0-8	interleukin 6	Mus musculus	155-159
26601598-7	2016	Chromatin immunoprecipitation revealed that butyrate enhanced acetylation of the tnf-alpha and il-6 promoter regions but blocked RNA polymerase II binding to the promoters of tnf-alpha and il-6 genes, indicating suppressed transcription initiation.	Butyrates	44-52	interleukin 6	Mus musculus	95-99
26601598-7	2016	Chromatin immunoprecipitation revealed that butyrate enhanced acetylation of the tnf-alpha and il-6 promoter regions but blocked RNA polymerase II binding to the promoters of tnf-alpha and il-6 genes, indicating suppressed transcription initiation.	Butyrates	44-52	interleukin 6	Mus musculus	189-193
27746589-6	2016	Compared with RBCs stored in CPDA-1 and saline, the addition of SP to stored RBCs restored their oxygen-carrying capacity and SOD activity, reduced the AST activity, BUN concentrations, and LDH activity in the plasma, and decreased the MDA level, MPO activity, and concentrations of IL-6 and TNF-alpha in the liver.	TFF2 protein, human	64-66	interleukin 6	Mus musculus	283-287
26807019-8	2016	Further results showed that CA treatment markedly inhibited APAP-induced pro-inflammatory cytokines TNF-alpha, IL-1beta, IL-6 and MCP-1 mRNA expression and the levels of phosphorylated IkappaBalpha and p65 protein in the liver.	Acetaminophen	60-64	interleukin 6	Mus musculus	121-125
27761062-5	2016	IL-6 and TNF-alpha were significantly lower in colon from COS-feeding mice than those in the control group.	Chitosan	58-61	interleukin 6	Mus musculus	0-4
27761062-7	2016	Overall, the findings revealed that adding 300 mg/kg COS to the diet changed the composition of the intestinal microflora of mice, resulting in suppressed NF-kappaB activation and less production of TNF-alpha and IL-6; and these changes led to better control of inflammation and resolution of infection with C. rodentium.	Chitosan	53-56	interleukin 6	Mus musculus	213-217
28100936-6	2016	Moreover, the mRNA and protein levels of IL-1beta, IL-6, IL-17, IL-18, and TNF-alpha were significantly lower in the group of mice receiving the COS diet; also the jejunal production of toll-like receptor-4 (TLR-4) was suppressed in the COS group.	Chitosan	145-148	interleukin 6	Mus musculus	51-55
26620764-5	2016	FC-99 also suppressed the DSS-induced secretion of interleukin (IL)-1beta, IL-6, and the tumor necrosis factor (TNF)-alpha in the colon and hindered the infiltration of macrophages into colon lamina propria.	Fluorad FC99	0-5	interleukin 6	Mus musculus	75-79
26620764-5	2016	FC-99 also suppressed the DSS-induced secretion of interleukin (IL)-1beta, IL-6, and the tumor necrosis factor (TNF)-alpha in the colon and hindered the infiltration of macrophages into colon lamina propria.	Dextran Sulfate	26-29	interleukin 6	Mus musculus	75-79
26620764-7	2016	Moreover, FC-99 inhibited concentration-dependently the expression of TNF-alpha and IL-6 in vitro from mouse peritoneal macrophages, which were induced by TLR ligands: PamCSK4 and peptidoglycan (PGN, TLR2 ligand) as well as LPS (TLR4 ligand).	Fluorad FC99	10-15	interleukin 6	Mus musculus	84-88
26423427-6	2016	Furthermore, RSV treatment markedly reduced gene expression of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and inducible nitric oxide synthase (iNOS) (all p &lt; 0.05), 4-Hydroxynonenal expression (p &lt; 0.01), and lipid accumulation.	Resveratrol	13-16	interleukin 6	Mus musculus	98-116
26710980-10	2016	Discussion and conclusion The current results suggested that the anti-inflammatory activity of three flavonoids was mainly manifested in the reduction of production of NO and IL-6 production.	Flavonoids	101-111	interleukin 6	Mus musculus	175-179
26728370-8	2016	Furthermore, beta-glucan could prompt BMDCs to secret high levels of IL-6, TNF-alpha, IL-12 p40 and increase the production of CCR7 mRNA.	beta-Glucans	13-24	interleukin 6	Mus musculus	69-73
27504150-5	2016	Intense exercise and thapsigargin- (Tg-) induced ERS (glucose-regulated protein 78, GRP78) and inflammatory cytokines levels (IL-6 and TNF-alpha) were decreased with quercetin.	Thapsigargin	21-33	interleukin 6	Mus musculus	126-130
27504150-5	2016	Intense exercise and thapsigargin- (Tg-) induced ERS (glucose-regulated protein 78, GRP78) and inflammatory cytokines levels (IL-6 and TNF-alpha) were decreased with quercetin.	Thapsigargin	36-38	interleukin 6	Mus musculus	126-130
27504150-5	2016	Intense exercise and thapsigargin- (Tg-) induced ERS (glucose-regulated protein 78, GRP78) and inflammatory cytokines levels (IL-6 and TNF-alpha) were decreased with quercetin.	Quercetin	166-175	interleukin 6	Mus musculus	126-130
26720797-14	2016	Finally, hippocampal IL-6 levels were higher in mice receiving combined radiations compared with mice receiving (56)Fe radiation alone.	Iron	116-118	interleukin 6	Mus musculus	21-25
26605988-9	2015	Therefore, baicalin caused a decrease in Th17 cells by stimulating Treg cells and by inhibiting IL-6 and IL-23.	baicalin	11-19	interleukin 6	Mus musculus	96-100
26651527-5	2015	This inhibitory effect was associated with inhibition on TPA-induced up-regulation of pro-inflammatory cytokines IL-1beta, IL-6, and TNF-alpha.	Tetradecanoylphorbol Acetate	57-60	interleukin 6	Mus musculus	123-127
26702389-6	2015	Our results provided evidence that Dex treatment attenuated LPS-activated NF-kappaB p65 activation, as well as the production of tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta at the level of both mRNA and protein in spleen.	Dexmedetomidine	35-38	interleukin 6	Mus musculus	158-171
26730154-10	2015	Rottlerin treatment also significantly decreased serum levels of HMGB1 at 6, 12, and 24 h, TNF-alpha, IL-6 and IL-1 beta at 12 h compared with the control group (P &lt; 0.01).	rottlerin	0-9	interleukin 6	Mus musculus	102-106
26669765-10	2015	5-HTP administered before induction decreased the disease activities in CIA mice and suppressed the production of TNFalpha, IL-6 and cyclooxygenase-2 in arthritic joints.	5-Hydroxytryptophan	0-5	interleukin 6	Mus musculus	124-128
26673664-8	2015	The early inflammatory response was manifested in the upregulation of TNF-alpha and IL-6 in cisplatin-treated explants of wild-type and STAT1(-/-) mice.	Cisplatin	92-101	interleukin 6	Mus musculus	84-88
26676341-13	2015	Serum HMGB1 levels at 6, 12, and 24 h, as well as serum TNF-alpha, IL-6, and IL-1beta levels at 12 h, were significantly lower in the DMS treatment group than in the control group (P &lt; 0.01 for all).	N,N-dimethylsphingosine	134-137	interleukin 6	Mus musculus	67-71
26658290-4	2015	We found that 15 min exposure to ethanol inhibited antigen-induced degranulation, calcium mobilization, expression of proinflammatory cytokine genes (tumor necrosis factor-alpha, interleukin-6, and interleukin-13), and formation of reactive oxygen species in a dose-dependent manner.	Ethanol	33-40	interleukin 6	Mus musculus	179-192
25850373-3	2015	Bi-daily subcutaneous injections of morphine to mice over 7 days induced thermal hyperalgesia as measured by both the hot-plate and tail-immersion tests, and spinal astroglial activation with increased spinal gene expression of DAAO, glial fibrillary acidic protein (GFAP) and pro-inflammatory cytokines (interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha)).	Morphine	36-44	interleukin 6	Mus musculus	335-348
26588227-9	2015	The pro-inflammatory cytokine expression in the mouse colon, including TNF-alpha, IL-6, INF-gamma, IL-17, and IL-1beta, was significantly up-regulated by DSS treatment, but was inhibited upon PL administration.	dss	154-157	interleukin 6	Mus musculus	82-86
26588227-9	2015	The pro-inflammatory cytokine expression in the mouse colon, including TNF-alpha, IL-6, INF-gamma, IL-17, and IL-1beta, was significantly up-regulated by DSS treatment, but was inhibited upon PL administration.	pl	192-194	interleukin 6	Mus musculus	82-86
25850373-3	2015	Bi-daily subcutaneous injections of morphine to mice over 7 days induced thermal hyperalgesia as measured by both the hot-plate and tail-immersion tests, and spinal astroglial activation with increased spinal gene expression of DAAO, glial fibrillary acidic protein (GFAP) and pro-inflammatory cytokines (interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha)).	Morphine	36-44	interleukin 6	Mus musculus	350-354
28955817-8	2016	Clodronate liposome treatment also decreased the mRNA expression levels of inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6) in the skeletal muscle after exhaustive exercise.	Clodronic Acid	0-10	interleukin 6	Mus musculus	124-128
26505975-6	2015	Real-time PCR detected a remarkable increase in the expression of IL-1beta, IL-6, TNF-alpha, and IL-4 in DSS-treated NHE8(-/-) mice compared with DSS-treated wild-type littermates.	dss	105-108	interleukin 6	Mus musculus	76-80
26630505-8	2015	The depletion of macrophages induced by the liposome clodronate injection improved renal fibrosis with a reduction of kidney IL-6, type IV collagen, and TGF-beta levels.	Clodronic Acid	53-63	interleukin 6	Mus musculus	125-129
26465071-5	2015	Reduced infiltration of leukocytes and macrophages and decreased expression of IL-6 were revealed in the muscles of periodate-oxidized ATP-treated mdx mice.	metaperiodate	116-125	interleukin 6	Mus musculus	79-83
25529480-7	2015	RESULTS: The oral administration of cystine reduced IL-6 levels in the blood and spleen after LPS stimulation and improved survival rates.	Cystine	36-43	interleukin 6	Mus musculus	52-56
26465071-5	2015	Reduced infiltration of leukocytes and macrophages and decreased expression of IL-6 were revealed in the muscles of periodate-oxidized ATP-treated mdx mice.	Adenosine Triphosphate	135-138	interleukin 6	Mus musculus	79-83
25977985-8	2015	In the developed adult brains from vitamin C-deficient Gulo(-/-) mice, the levels of glutathione, MDA, nitrate, IL-6, TNF-alpha, and Bax were increased and the expression of the GABRA6 and calbindin-28k was decreased.	Ascorbic Acid	35-44	interleukin 6	Mus musculus	112-116
25529480-8	2015	The addition of cystine to monocytes suppressed LPS-induced IL-6 production but enhanced IL-10 production.	Cystine	16-23	interleukin 6	Mus musculus	60-64
25529480-9	2015	A neutralising anti-IL-10 antibody eliminated the inhibitory effects of cystine on the LPS-induced production of IL-6.	Cystine	72-79	interleukin 6	Mus musculus	113-117
25529480-10	2015	CONCLUSIONS: The oral administration of cystine suppressed IL-6 production following LPS stimulation and improved survival rates in mice with LPS-induced sepsis.	Cystine	40-47	interleukin 6	Mus musculus	59-63
26668622-0	2015	Epigallocatechin-3-gallate-induced inhibition of interleukin-6 release and adjustment of the regulatory T/T helper 17 cell balance in the treatment of colitis in mice.	epigallocatechin gallate	0-26	interleukin 6	Mus musculus	49-62
26049170-4	2015	Harpagoside significantly inhibited TNF-alpha-induced mRNA synthesis and protein production of the atherogenic adipokines including IL-6, PAI-1, and MCP-1.	harpagoside	0-11	interleukin 6	Mus musculus	132-136
26521029-7	2015	Galantamine reduced the total area of amyloid load within the hippocampus of transgenic APP/PS1 mice, inhibited astrocyte activation as assessed by immunohistochemistry and decreased intracellular TNF-alpha and IL-6 expression as determined by immunofluorescence.	Galantamine	0-11	interleukin 6	Mus musculus	211-215
26668622-8	2015	EGCG could reduce the release of IL-6 and IL-17 and regulate the mouse splenic regulatory T-cell (Treg)/T helper 17 cell (Th17) ratio, while increasing the plasma levels of IL-10 and TGF-beta1 and decreasing the HIF-1alpha and STAT3 protein expression in the colon.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	33-37
26668622-9	2015	The experiments confirmed that EGCG treated mice with experimental colitis by inhibiting the release of IL-6 and regulating the body Treg/Th17 balance.	epigallocatechin gallate	31-35	interleukin 6	Mus musculus	104-108
26345246-3	2015	It was demonstrated that silibinin, applied topically onto mouse ears following TPA stimulation, effectively down-regulated the expressions of TPA-induced interleukin-1beta (IL-1beta), interleukin-6 (IL-6), necrosis factor-alpha (TNF-alpha) and cyclooxygenase-2 (COX-2) in a dose-dependent manner.	Silybin	25-34	interleukin 6	Mus musculus	185-198
26345246-3	2015	It was demonstrated that silibinin, applied topically onto mouse ears following TPA stimulation, effectively down-regulated the expressions of TPA-induced interleukin-1beta (IL-1beta), interleukin-6 (IL-6), necrosis factor-alpha (TNF-alpha) and cyclooxygenase-2 (COX-2) in a dose-dependent manner.	Tetradecanoylphorbol Acetate	143-146	interleukin 6	Mus musculus	185-198
26345246-3	2015	It was demonstrated that silibinin, applied topically onto mouse ears following TPA stimulation, effectively down-regulated the expressions of TPA-induced interleukin-1beta (IL-1beta), interleukin-6 (IL-6), necrosis factor-alpha (TNF-alpha) and cyclooxygenase-2 (COX-2) in a dose-dependent manner.	Silybin	25-34	interleukin 6	Mus musculus	200-228
26345246-3	2015	It was demonstrated that silibinin, applied topically onto mouse ears following TPA stimulation, effectively down-regulated the expressions of TPA-induced interleukin-1beta (IL-1beta), interleukin-6 (IL-6), necrosis factor-alpha (TNF-alpha) and cyclooxygenase-2 (COX-2) in a dose-dependent manner.	Tetradecanoylphorbol Acetate	143-146	interleukin 6	Mus musculus	200-228
26663010-13	2015	In addition, ankaflavin significantly decreased the proliferation of Kupffer cells and the expression of TNF-alpha, IL-6 and IL-1 beta protein in isolated Kupffer cells stimulated by TNF-alpha.	ankaflavin	13-23	interleukin 6	Mus musculus	116-120
26373883-5	2015	We found that serum levels of nonesterified fatty acid (NEFA) and pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-6 increased in CAC mice but decreased significantly after oral treatment of EPA-PL.	epa-pl	238-244	interleukin 6	Mus musculus	145-163
26178478-6	2015	OSR-treated group (250 mg/kg) markedly reduced the inflammatory-related protein prostaglandin E2 (PGE2), tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and interleukin-8 (IL-8).	oxysophoridine	0-3	interleukin 6	Mus musculus	176-189
26111478-5	2015	Incubation of microglial cells with NMIFA suppressed production of LPS-stimulated pro-inflammatory mediators, including nitric oxide (NO), prostaglandin E2 (PGE2), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), as well as the over-expression of inducible nitric oxide synthase (iNOS) and type 2 cyclooxygenase (COX-2).	nmifa	36-41	interleukin 6	Mus musculus	164-177
26178478-6	2015	OSR-treated group (250 mg/kg) markedly reduced the inflammatory-related protein prostaglandin E2 (PGE2), tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and interleukin-8 (IL-8).	oxysophoridine	0-3	interleukin 6	Mus musculus	191-195
26111478-5	2015	Incubation of microglial cells with NMIFA suppressed production of LPS-stimulated pro-inflammatory mediators, including nitric oxide (NO), prostaglandin E2 (PGE2), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), as well as the over-expression of inducible nitric oxide synthase (iNOS) and type 2 cyclooxygenase (COX-2).	nmifa	36-41	interleukin 6	Mus musculus	179-183
26371857-9	2015	DN inhibited the production of inflammatory mediators, such as inducible nitric oxide synthase (iNOS) and its derivative nitric oxide (NO), cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), IL-1beta, IL-6 and TNF-alpha and H3 protein acetylation in murine peritoneal macrophages.	desoxonarchinol A	0-2	interleukin 6	Mus musculus	201-205
26178479-8	2015	The expression levels of TNF-alpha, IL-6, iNOS and COX-2 were significantly downregulated by GL.	Glycyrrhizic Acid	93-95	interleukin 6	Mus musculus	36-40
26178479-9	2015	In conclusion, GL exerts significant anti-inflammatory and analgesic activities by attenuating the expression levels of TNF-alpha, IL-6, iNOS and COX-2.	Glycyrrhizic Acid	15-17	interleukin 6	Mus musculus	131-135
26432179-9	2015	Our results showed that treatment of linalool significantly attenuated CS-induced lung inflammation, coupled with inhibited the infiltration of inflammatory cells and TNF-alpha, IL-6, IL-1beta, IL-8 and MCP-1 production.	linalool	37-45	interleukin 6	Mus musculus	178-182
26526086-4	2015	In this study, HP not only significantly attenuated inflammation in C57BL/6J mice with acute liver injury (ALI), but also reduced the expression of TNF-alpha and IL-6 in lipopolysaccharide (LPS)-induced RAW264.7 cells.	hyperoside	15-17	interleukin 6	Mus musculus	162-166
26490221-11	2015	The production of IL-1beta, IL-6, and TNF-alpha decreased after being treated with GTS-21 in LPS-stimulated RAW 264.7 cells.	3-(2,4-dimethoxybenzylidene)anabaseine	83-89	interleukin 6	Mus musculus	28-32
26526086-7	2015	More importantly, over-expression of PPAR-gamma had an opposite effect on the expression of TNF-alpha and IL-6 in LPS-induced RAW264.7 cells after treatment with HP.	hyperoside	162-164	interleukin 6	Mus musculus	106-110
26590117-5	2015	Melatonin also inhibited LPS-induced inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) production in mammary tissues.	Melatonin	0-9	interleukin 6	Mus musculus	134-147
26548347-6	2015	The mechanistic study showed that the DATS-mediated inhibition of naphthalene-induced oxidative injury and the production of inflammatory responses (i.e., TNF-alpha, IL-6, and IL-8) were attributed to inhibiting the activity of nuclear factor-kappa B (NF-kappaB).	diallyl trisulfide	38-42	interleukin 6	Mus musculus	166-170
26548347-6	2015	The mechanistic study showed that the DATS-mediated inhibition of naphthalene-induced oxidative injury and the production of inflammatory responses (i.e., TNF-alpha, IL-6, and IL-8) were attributed to inhibiting the activity of nuclear factor-kappa B (NF-kappaB).	naphthalene	66-77	interleukin 6	Mus musculus	166-170
26496857-0	2015	Amplification by (-)-epigallocatechin gallate and chlorogenic acid of TNF-alpha-stimulated interleukin-6 synthesis in osteoblasts.	epigallocatechin gallate	17-45	interleukin 6	Mus musculus	91-104
26496857-0	2015	Amplification by (-)-epigallocatechin gallate and chlorogenic acid of TNF-alpha-stimulated interleukin-6 synthesis in osteoblasts.	Chlorogenic Acid	50-66	interleukin 6	Mus musculus	91-104
26496857-4	2015	In the present study, the effects of EGCG and CGA on the TNF-alpha-stimulated interleukin-6 synthesis were investigated in MC3T3-E1 cells.	epigallocatechin gallate	37-41	interleukin 6	Mus musculus	78-91
26496857-5	2015	EGCG and CGA significantly enhanced TNF-alpha-stimulated interleukin-6 release.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	57-70
26496857-6	2015	In addition, the interleukin-6 mRNA expression levels induced by TNF-alpha were supported by EGCG, as well as CGA.	epigallocatechin gallate	93-97	interleukin 6	Mus musculus	17-30
26496857-8	2015	These results strongly suggest that EGCG and CGA enhance the TNF-alpha-stimulated interleukin-6 synthesis in osteoblasts, and that the amplifying effect of EGCG, but not CGA, is exerted via inhibiting p70 S6 kinase.	epigallocatechin gallate	36-40	interleukin 6	Mus musculus	82-95
26590117-5	2015	Melatonin also inhibited LPS-induced inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) production in mammary tissues.	Melatonin	0-9	interleukin 6	Mus musculus	149-153
26590117-6	2015	In vitro, melatonin was found to inhibit LPS-induced TNF-alpha and IL-6 production in mouse mammary epithelial cells.	Melatonin	10-19	interleukin 6	Mus musculus	67-71
25677194-5	2015	Our results indicated that PFOS increased BV2 cells activation and simultaneously increased tumor necrosis factor alpha and interleukin-6 expression.	perfluorooctane sulfonic acid	27-31	interleukin 6	Mus musculus	124-137
26509387-4	2015	Moreover, in mixed gastrocnemius muscle of trained IL-6(-/-) mice enzyme activities tended to be lower (COX: 410.7+-48.4 U g(-1) for sedentary vs. 277.0+-36.5 U g(-1) for trained group and CS: 343.8+-24.6 U g(-1) for sedentary vs. 251.7+-27.1 U g(-1) for trained group).	Cesium	189-191	interleukin 6	Mus musculus	51-55
26014580-5	2015	Importantly, macrophages (RAW 264.7), one of the key cells initiating inflammation and bone resorption, responded significantly less vigorously to the modified polymers, expressing/releasing lower amounts of nitric oxide, matrix metalloproteinases (MMP-9), and pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12p70, IFN-gamma, IL-10).	Polymers	160-168	interleukin 6	Mus musculus	300-304
26509387-6	2015	Concluding, moderate-velocity endurance training-induced increase in COX and CS activities in muscles of WT mice only which suggests that IL-6 regulates training-induced skeletal muscle responses to exercise.	Cesium	77-79	interleukin 6	Mus musculus	138-142
26491118-12	2015	Furthermore, mice fed cellulose+DSS exhibited 1.42, 11.5, 8.48, and 35.5 times greater (P &lt; 0.05) colon mRNA expression of tumor necrosis factor alpha (Tnfa) and interleukin (Il) 1b, Il6, and Il17a, respectively, and 7.10 times greater (P &lt; 0.05) expression of C-X-C motif ligand 1 (Cxc1) compared with mice fed PF+DSS.	Cellulose	22-31	interleukin 6	Mus musculus	186-189
26491118-12	2015	Furthermore, mice fed cellulose+DSS exhibited 1.42, 11.5, 8.48, and 35.5 times greater (P &lt; 0.05) colon mRNA expression of tumor necrosis factor alpha (Tnfa) and interleukin (Il) 1b, Il6, and Il17a, respectively, and 7.10 times greater (P &lt; 0.05) expression of C-X-C motif ligand 1 (Cxc1) compared with mice fed PF+DSS.	dss	32-35	interleukin 6	Mus musculus	186-189
26192255-8	2015	Ob/Ob mice in the high fat diet plus ethylene glycol group had markedly increased expression of osteopontin, monocyte chemoattractant protein-1, interleukin-6 and tumor necrosis factor-alpha.	Ethylene Glycol	37-52	interleukin 6	Mus musculus	145-190
26130565-3	2015	The combined treatment of Se-GTP and HJP also reduced the content of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in splenocytes.	se-gtp	26-32	interleukin 6	Mus musculus	114-127
26130565-3	2015	The combined treatment of Se-GTP and HJP also reduced the content of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in splenocytes.	se-gtp	26-32	interleukin 6	Mus musculus	129-133
26839505-7	2015	Fomentariol effectively suppressed the production of interleukin-1beta and interleukin-6 but not tumor necrosis factor-alpha.	Fomentariol	0-11	interleukin 6	Mus musculus	75-88
26182998-8	2015	Renal mRNA levels of interleukin 1beta, interleukin 6, tumor necrosis factor alpha, keratinocyte-derived chemokine and macrophage inflammatory protein 2 were decreased significantly by 99%, 60%, 53%, 58%, and 43%, with rmGas6 treatment, respectively.	rmgas6	219-225	interleukin 6	Mus musculus	40-82
26498136-13	2015	In the RAW264.7 cells, the mRNA expression levels of MCP-1, interleukin (IL)-1beta, IL-6 and tumor necrosis factor alpha were increased significantly following lipopolysaccharide stimulation, and were not suppressed by hydroxyfasudil.	hydroxyfasudil	219-233	interleukin 6	Mus musculus	84-88
26839505-8	2015	The inhibitory effect of fomentariol against nitric oxide, interleukin-1beta, and interleukin-6 production was possibly mediated by downregulation of the extracellular signal-regulated kinase signaling pathway.	Fomentariol	25-36	interleukin 6	Mus musculus	82-95
26522449-5	2015	KHG26792 also inhibited the ATP-induced increase in IL-6, PGE2, NO, ROS, CXCL2, and CCL3.	3-(naphthalen-2-yl(propoxy)methyl)azetidine hydrochloride	0-8	interleukin 6	Mus musculus	52-56
26522449-5	2015	KHG26792 also inhibited the ATP-induced increase in IL-6, PGE2, NO, ROS, CXCL2, and CCL3.	Adenosine Triphosphate	28-31	interleukin 6	Mus musculus	52-56
26522688-4	2015	We also showed that TfR1 and Fpn1 expressions were significantly higher, while ferritin contents, IL-6, TNF-alpha and hepcidin mRNA levels were lower in cells treated with aspirin plus LPS than those in cells treated with LPS only.	Aspirin	172-179	interleukin 6	Mus musculus	98-102
26615818-2	2015	In vitro, LPS-induced nitric oxide (NO) production was significantly inhibited by MBF extracts via suppressing the expression of proinflammatory molecules, including inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), interleukin-1 beta (IL-beta) and IL-6.	Nitric Oxide	22-34	interleukin 6	Mus musculus	265-269
26361726-10	2015	In addition, RT-PCR analysis revealed increased mRNA expression of IL-6, IL-17, TNF-alpha, and NF-kappaB in the LPS group, while reduced by treatment with diosmin.	Diosmin	155-162	interleukin 6	Mus musculus	67-71
26660551-8	2015	In reconstitution experiments, IL-6 produced concentration-dependent impairment of endothelial responses as well as greater increases in NADPH-stimulated superoxide levels in arteries from eNOS(+/-) mice fed a control diet compared to eNOS(+/+) mice.	NADP	137-142	interleukin 6	Mus musculus	31-35
26660551-8	2015	In reconstitution experiments, IL-6 produced concentration-dependent impairment of endothelial responses as well as greater increases in NADPH-stimulated superoxide levels in arteries from eNOS(+/-) mice fed a control diet compared to eNOS(+/+) mice.	Superoxides	154-164	interleukin 6	Mus musculus	31-35
26660551-11	2015	The impairment produced by a HFD in eNOS(+/-) mice appears to be mediated by IL-6-induced increases in vascular superoxide.	Superoxides	112-122	interleukin 6	Mus musculus	77-81
26664046-10	2015	In addition, TB-II remarkably decreased the levels of renal function biochemical factors, such as kidney index, blood urea nitrogen, serum creatinine, urinary uric acid, urine creatinine, and urine protein, and it reduced lipid metabolism levels of total cholesterol and triglycerides and the levels of inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha in alloxan-induced mice.	timosaponin B-II	13-18	interleukin 6	Mus musculus	326-371
26608030-9	2015	In addition, NZ-HO significantly increased production of the anti-inflammatory cytokine interleukin (IL)-10 and decreased the expression of pro-inflammatory cytokines such as IL-1alpha and IL-6 in the colon compared to a vector control strain.	nz-ho	13-18	interleukin 6	Mus musculus	189-193
26635562-4	2015	Inescapable footshock with SRs induced anxiety and cognitive dysfunction as well as a decrease in the levels of plasma H2S and GSH and an increase in IL-6 levels in 3xTg-AD mice.	srs	27-30	interleukin 6	Mus musculus	150-154
26593910-6	2015	We demonstrated that brazilein decreased the expression of IRAK4 protein led to the suppression of MAPK signaling and IKKbeta, and subsequent inactivation of NF-kappaB and COX2 thus promoting the expression of the downstream target pro-inflammatory cytokines such as IL-1beta, MCP-1, MIP-2, and IL-6 in LPS-induced Raw264.7 macrophage cells.	brazilein	21-30	interleukin 6	Mus musculus	295-299
26576678-10	2015	RESULTS: Stimulation of LPS-activated BV-2 microglia with minocycline significantly diminished the transcription of the pro-inflammatory markers CCL2, IL6, and inducible nitric oxide synthase (iNOS).	Minocycline	58-69	interleukin 6	Mus musculus	151-154
26567045-9	2015	RESULTS: IL-6, IL-8 and MMP-3 (determined only in synovial fibroblasts (SFs)) were downregulated in primary synoviocytes and SFs of RA and OA after AEA, PEA and OEA treatment.	aea	148-151	interleukin 6	Mus musculus	9-13
26610528-7	2015	In addition, phorbaketal A reduced the LPS-induced production of inflammatory cytokines such as tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and monocyte chemotactic protein-1.	phorbaketal A	13-26	interleukin 6	Mus musculus	149-153
26567045-9	2015	RESULTS: IL-6, IL-8 and MMP-3 (determined only in synovial fibroblasts (SFs)) were downregulated in primary synoviocytes and SFs of RA and OA after AEA, PEA and OEA treatment.	N-oleoylethanolamine	161-164	interleukin 6	Mus musculus	9-13
26561804-5	2015	Additionally, ELISA showed that the serum levels of IFN-gamma, TNF-alpha, IL-12, IL-6, and IL-1beta were down-regulated in a TNBS model of colitis.	Trinitrobenzenesulfonic Acid	125-129	interleukin 6	Mus musculus	81-85
26133963-5	2015	In adult mice that received daily poly(I:C) injections, but not in offspring with prenatal exposure to maternal immune activation, frontal cortex mRNA levels were also markedly elevated for IFITM (+304%), multiple cytokines including IL-6 (+493%), and nuclear factor-kappaB (+151%).	poly	34-38	interleukin 6	Mus musculus	234-238
26540166-6	2015	In vivo, the pathological study exhibited the acute toxicity of Malformin C at lethal dosage in BDF1 mice might be caused by an acute yet subtle inflammatory response, consistent with elevated IL-6 in the plasma cytokine assay.	malformin C	64-75	interleukin 6	Mus musculus	193-197
26527454-4	2015	A synergistic reaction between aging and ZnO NP exposure occurred regarding serum interleukin 1 (IL-1) and interleukin 6 (IL-6).	Zinc Oxide	41-44	interleukin 6	Mus musculus	107-120
26527454-4	2015	A synergistic reaction between aging and ZnO NP exposure occurred regarding serum interleukin 1 (IL-1) and interleukin 6 (IL-6).	Zinc Oxide	41-44	interleukin 6	Mus musculus	122-126
26133963-5	2015	In adult mice that received daily poly(I:C) injections, but not in offspring with prenatal exposure to maternal immune activation, frontal cortex mRNA levels were also markedly elevated for IFITM (+304%), multiple cytokines including IL-6 (+493%), and nuclear factor-kappaB (+151%).	Iodine	0-1	interleukin 6	Mus musculus	234-238
26336925-6	2015	Intestinal tissues of infected vitamin D3-deficient mice displayed increased inflammatory cell infiltrates as well as significantly higher gene transcript levels of inflammatory mediators TNF-alpha, IL-1beta, IL-6, TGF-beta, IL-17A, and IL-17F as well as the antimicrobial peptide REG3gamma.	Cholecalciferol	31-41	interleukin 6	Mus musculus	209-213
26374952-10	2015	Levels of IL-6, IL-1beta and IFN-gamma slightly increased on day 7 in mice treated with VACV combined with RAPA compared to VACV alone and then decreased on day 9.	Valacyclovir	88-92	interleukin 6	Mus musculus	10-14
26457732-8	2015	In STK4-deficient mice, treatment with an IRAK1/4 inhibitor after DEN administration reduced serum IL-6 levels and liver tumor numbers to levels similar to those observed in the control mice.	Diethylnitrosamine	66-69	interleukin 6	Mus musculus	99-103
26374952-10	2015	Levels of IL-6, IL-1beta and IFN-gamma slightly increased on day 7 in mice treated with VACV combined with RAPA compared to VACV alone and then decreased on day 9.	Valacyclovir	124-128	interleukin 6	Mus musculus	10-14
26507910-6	2015	In addition, curcumin suppressed the production of inflammatory cytokines, such as TNF-alpha, IL-1beta, IL-6 and IL-8.	Curcumin	13-21	interleukin 6	Mus musculus	104-108
26300484-8	2015	We observed that pre-treatment with GW4869 significantly impaired release of both exosomes and pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) in RAW264.7 macrophages.	GW 4869	36-42	interleukin 6	Mus musculus	144-148
26162692-9	2015	Furthermore, immunohistochemical studies showed that Rs-LPS reduced infiltration of monocytes/macrophages and expression of interleukin (IL)-6 and matrix metalloproteinase-9 in atherosclerotic lesions of diabetic mice.	rs-lps	53-59	interleukin 6	Mus musculus	124-142
26201536-7	2015	In the in-vitro synovial cells, IL-6 pretreatment attenuated the inhibitory effect of DEX on cyclooxygenase (COX)-2 expression and inhibited the nuclear translocation of GR induced by DEX.	Dexamethasone	86-89	interleukin 6	Mus musculus	32-36
26201536-7	2015	In the in-vitro synovial cells, IL-6 pretreatment attenuated the inhibitory effect of DEX on cyclooxygenase (COX)-2 expression and inhibited the nuclear translocation of GR induced by DEX.	Dexamethasone	184-187	interleukin 6	Mus musculus	32-36
26201536-8	2015	In contrast, in MC3T3-E1 osteoblastic cells, IL-6 pretreatment exacerbated the decrease in expression of osteocalcin and the increase in expression of receptor activator of nuclear factor kappa-B ligand (RANKL) by DEX.	Dexamethasone	214-217	interleukin 6	Mus musculus	45-49
26162692-10	2015	Finally, the antagonistic effect of Rs-LPS on TLR4 was demonstrated by our in vitro studies showing that Rs-LPS inhibited IL-6 secretion from macrophages and endothelial cells stimulated by LPS or LPS plus saturated fatty acid palmitate.	rs-lps	36-42	interleukin 6	Mus musculus	122-126
26162692-10	2015	Finally, the antagonistic effect of Rs-LPS on TLR4 was demonstrated by our in vitro studies showing that Rs-LPS inhibited IL-6 secretion from macrophages and endothelial cells stimulated by LPS or LPS plus saturated fatty acid palmitate.	rs-lps	105-111	interleukin 6	Mus musculus	122-126
26162692-10	2015	Finally, the antagonistic effect of Rs-LPS on TLR4 was demonstrated by our in vitro studies showing that Rs-LPS inhibited IL-6 secretion from macrophages and endothelial cells stimulated by LPS or LPS plus saturated fatty acid palmitate.	saturated fatty acid palmitate	206-236	interleukin 6	Mus musculus	122-126
25835814-9	2015	Noncytotoxic levels of SAE significantly attenuated NO( ) production in RAW264.7 cells and also markedly suppressed the expression of iNOS and other proinflammatory mediators, including COX-2 and IL-6, which were upregulated in the presence of LPS.	SELENAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE	23-26	interleukin 6	Mus musculus	196-200
26277481-9	2015	Quercetin also inhibited secretion of the inflammatory cytokines IL-1beta and IL-6 and stimulated that of IL-10, an antiinflammatory cytokine.	Quercetin	0-9	interleukin 6	Mus musculus	78-82
26178442-5	2015	MTX reduced tumor necrosis factor-alpha and IL-6 levels, demonstrating its local antiangiogenic and anti-inflammatory effects.	Methotrexate	0-3	interleukin 6	Mus musculus	44-48
27524686-5	2015	MTX reduced tumor necrosis factor-a and IL-6 levels, demonstrating its local antiangiogenic and anti-inflammatory effects.	Methotrexate	0-3	interleukin 6	Mus musculus	40-44
26397391-5	2015	Investigation of the underlying mechanism showed that nicotine reduced the secretion of the pro-inflammatory cytokines tumor necrosis factor alpha and interleukin 6 in vitro and in vivo.	Nicotine	54-62	interleukin 6	Mus musculus	151-164
25324219-9	2015	Treatment of chemical chaperone 4-phenyle-butyric acid alleviated ER stress in adipose tissue stromal cells and adipose tissue macrophages and attenuated the production of IL-6 and MCP-1 by adipose tissue stromal cells, and TNF-alpha by adipose tissue macrophages from both young and old mice.	4-phenyle-butyric acid	32-54	interleukin 6	Mus musculus	172-176
26607068-5	2015	RESULTS: Daphnetin dose-dependently reduced the release of HMGB1 in RAW264.7 cells and suppressed rhHMGB1-induced iNOS and COX-2 expressions and release of TNF-alpha, IL-6, PGE2, and NO in THP-1 cells.	daphnetin	9-18	interleukin 6	Mus musculus	167-171
26639507-3	2015	Our result revealed that serum concentration of IL6 (P=0.0001) as well as IL-18 (P=0.003) were significantly higher in mice supplemented with creatine monohydrate for 15 weeks than in male albino mice on normal rodent diet following hypoxic ischemic insult indicating that long term creatine monohydrate supplementation up regulates the IL-6 and IL-18 concentrations triggering the neuroinflammatory and neuroprotective responses.	Creatine monohydrate	142-162	interleukin 6	Mus musculus	48-51
26303871-5	2015	The leucine-metformin combinations reduced fat pad mass, normalized liver weight, liver and plasma lipids and inflammatory markers (interleukin 6, interleukin 1 beta, tumor necrosis factor alpha, monocyte chemotactic protein-1, C-reactive protein) comparable to the effects of therapeutic metformin.	Metformin	12-21	interleukin 6	Mus musculus	132-145
26639507-3	2015	Our result revealed that serum concentration of IL6 (P=0.0001) as well as IL-18 (P=0.003) were significantly higher in mice supplemented with creatine monohydrate for 15 weeks than in male albino mice on normal rodent diet following hypoxic ischemic insult indicating that long term creatine monohydrate supplementation up regulates the IL-6 and IL-18 concentrations triggering the neuroinflammatory and neuroprotective responses.	Creatine monohydrate	142-162	interleukin 6	Mus musculus	337-341
26639507-0	2015	Effect of creatine monohydrate supplementation on relative serum level of IL-6 and IL-18 following neonatal hypoxia ischemia in male albino mouse.	Creatine monohydrate	10-30	interleukin 6	Mus musculus	74-78
26639507-3	2015	Our result revealed that serum concentration of IL6 (P=0.0001) as well as IL-18 (P=0.003) were significantly higher in mice supplemented with creatine monohydrate for 15 weeks than in male albino mice on normal rodent diet following hypoxic ischemic insult indicating that long term creatine monohydrate supplementation up regulates the IL-6 and IL-18 concentrations triggering the neuroinflammatory and neuroprotective responses.	Creatine monohydrate	283-303	interleukin 6	Mus musculus	48-51
26639507-2	2015	In the present study, we tried to determine whether 2% Creatine monohydrate supplementation for variable duration influence the IL-6 and 18 concentrations in the serum of male albino mouse following right common carotid artery ligation and hypoxia (8% oxygen) for 25 minutes.	Creatine monohydrate	55-75	interleukin 6	Mus musculus	128-132
26498332-8	2015	Resveratrol administration slowed down NASH progression, decreased the levels of ALT, TG, TBARS, IL-1beta, IL-6, downregulated mRNA expressions of TNF-alpha, IL-1beta, IL-6, and regulated the expressions of proteins involved in autophagy, both in vitro and in vivo.	Resveratrol	0-11	interleukin 6	Mus musculus	107-111
26013839-4	2015	RESULTS: The addition of IL-6 to HRMCs exposed to 20% O2 did not significantly impact either the CFCs or in vivo short-term repopulating cells.	Oxygen	54-56	interleukin 6	Mus musculus	25-29
26013839-6	2015	The exposure of HRMCs to 5% O2 negatively affected the amplification of CFCs, which was not changed by the addition of IL-6 and exhibited a partial enhancing effect on the long-term repopulating cells.	Oxygen	28-30	interleukin 6	Mus musculus	119-123
26013839-7	2015	CONCLUSION: The addition of IL-6 to the cytokine cocktail further improves our expansion procedure based on atmospheric O2 concentration-exposed HRMCs by enhancing the maintenance of the most primitive HSCs without a negative impact on the less primitive HSC populations and CFCs.	Oxygen	120-122	interleukin 6	Mus musculus	28-32
26522348-5	2015	RESULTS: Pam3CSK4, R848 and CpG oligodeoxynucleotide (ODN) promoted the production of IL-12p40 and IL-6 by splenocytes and dendritic cells obviously, and induced the expression of IFN-gamma in antigen specific CD4+ T cells in a time- and dose-dependent manner.	Oligodeoxyribonucleotides	32-52	interleukin 6	Mus musculus	99-103
26522348-5	2015	RESULTS: Pam3CSK4, R848 and CpG oligodeoxynucleotide (ODN) promoted the production of IL-12p40 and IL-6 by splenocytes and dendritic cells obviously, and induced the expression of IFN-gamma in antigen specific CD4+ T cells in a time- and dose-dependent manner.	Oligodeoxyribonucleotides	54-57	interleukin 6	Mus musculus	99-103
26522348-6	2015	Monophosphoryl lipid A from Salmonella minnesota R595 lipopolysaccharide (MPLA-SM) induced low levels of cytokines by splenocytes and couldn"t promote the production of IFN-gamma by antigen specific CD4+ T cells, but increased the expressions of IL-12p40 and IL-6 by DCs.	monophosphoryl lipid A	0-22	interleukin 6	Mus musculus	259-263
26522348-6	2015	Monophosphoryl lipid A from Salmonella minnesota R595 lipopolysaccharide (MPLA-SM) induced low levels of cytokines by splenocytes and couldn"t promote the production of IFN-gamma by antigen specific CD4+ T cells, but increased the expressions of IL-12p40 and IL-6 by DCs.	mpla-sm	74-81	interleukin 6	Mus musculus	259-263
26327363-4	2015	Transient middle cerebral artery occlusion (tMCAO) was induced in mice treated with recombinant IL-6 (rIL-6) or anti-IL-6 neutralizing antibodies (anti-IL-6 mAbs).	tmcao	44-49	interleukin 6	Mus musculus	96-100
26507386-8	2015	The mRNA expressions and protein levels of TNF-alpha, IL-1beta, IL-6, and IL-17A were significantly downregulated in dose-dependent manners in the nicotine treatment groups compared to the infected untreated group.	Nicotine	147-155	interleukin 6	Mus musculus	64-68
26498332-8	2015	Resveratrol administration slowed down NASH progression, decreased the levels of ALT, TG, TBARS, IL-1beta, IL-6, downregulated mRNA expressions of TNF-alpha, IL-1beta, IL-6, and regulated the expressions of proteins involved in autophagy, both in vitro and in vivo.	Resveratrol	0-11	interleukin 6	Mus musculus	168-172
26770316-0	2015	Gingko biloba extract (Ginaton) ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in mice via reducing IL-6/STAT3 and IL-23/IL-17.	Dextran Sulfate	44-66	interleukin 6	Mus musculus	129-133
26114860-5	2015	However, pretreatment with donepezil inhibited MPP+-induced M1 polarization in microglia by suppressing the release of interleukin (IL)-6, IL-1beta, or tumor necrosis factor (TNF)-alpha.	Donepezil	27-36	interleukin 6	Mus musculus	119-137
26114860-5	2015	However, pretreatment with donepezil inhibited MPP+-induced M1 polarization in microglia by suppressing the release of interleukin (IL)-6, IL-1beta, or tumor necrosis factor (TNF)-alpha.	mangion-purified polysaccharide (Candida albicans)	47-51	interleukin 6	Mus musculus	119-137
26439699-5	2015	Piperine-induced increase of mTORC1 activity in resident peritoneal macrophages (pMPhis) is correlated with enhanced production of IL-6 and TNF-alpha upon LPS stimulation.	piperine	0-8	interleukin 6	Mus musculus	131-135
26770316-0	2015	Gingko biloba extract (Ginaton) ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in mice via reducing IL-6/STAT3 and IL-23/IL-17.	Dextran Sulfate	68-71	interleukin 6	Mus musculus	129-133
26306651-9	2015	Pro-inflammatory markers IL-6, TNF-alpha, and inducible nitric oxide synthase in microglial cells are increased following PA exposure, but are reduced by pretreatment with OXA.	Palmitic Acid	122-124	interleukin 6	Mus musculus	25-29
26300395-8	2015	Exercise training and tamoxifen reduced tumor IL-6 levels, NF-kB and STAT3 expressions, and up-regulated TPM1 and PDCD4 expressions (P&lt;0.05).	Tamoxifen	22-31	interleukin 6	Mus musculus	46-50
26491261-5	2015	Our study showed that pretreatment with n-butanol extract from Folium isatidis not only significantly inhibited LPS-induced tumor necrosis factor-alpha and interleukin-6 production but also markedly and dose dependently enhanced the recruitment of MyD88, the phosphorylation of extracellular signal-regulated kinase, and the degradation of IkappaB-alpha.	1-Butanol	40-49	interleukin 6	Mus musculus	156-169
26251468-3	2015	In the present study, we found that cardamonin markedly ameliorated dextran sulfate sodium-induced mouse body weight loss, diarrhea, colon shortening, spleen swelling, and histological damage, which correlated with a decline in the activity of myeloperoxidase and the production of nitric oxide, tumor necrosis factor-alpha and interleukin-6 in the colon.	cardamonin	36-46	interleukin 6	Mus musculus	328-341
26101068-6	2015	The results showed that TM6 inhibited LPS-induced mammary gland histopathologic changes, MPO activity, and TNF-alpha, IL-1beta and IL-6 production in mice.	tm6	24-27	interleukin 6	Mus musculus	131-135
26271896-8	2015	The levels of tumor nectosis factor-alphagene (TNF-alpha) and interleukin-6 (IL-6) both in serum and lung, liver, kidney tissues, as well as the accumulation of nitric oxide (NO) in serum were decreased by delta-amyrone in response to p65 nuclear factors-kappa B (NF-kappaB).	Nitric Oxide	161-173	interleukin 6	Mus musculus	62-75
26271896-8	2015	The levels of tumor nectosis factor-alphagene (TNF-alpha) and interleukin-6 (IL-6) both in serum and lung, liver, kidney tissues, as well as the accumulation of nitric oxide (NO) in serum were decreased by delta-amyrone in response to p65 nuclear factors-kappa B (NF-kappaB).	amyrone	206-219	interleukin 6	Mus musculus	62-75
26271896-8	2015	The levels of tumor nectosis factor-alphagene (TNF-alpha) and interleukin-6 (IL-6) both in serum and lung, liver, kidney tissues, as well as the accumulation of nitric oxide (NO) in serum were decreased by delta-amyrone in response to p65 nuclear factors-kappa B (NF-kappaB).	amyrone	206-219	interleukin 6	Mus musculus	77-81
26251468-3	2015	In the present study, we found that cardamonin markedly ameliorated dextran sulfate sodium-induced mouse body weight loss, diarrhea, colon shortening, spleen swelling, and histological damage, which correlated with a decline in the activity of myeloperoxidase and the production of nitric oxide, tumor necrosis factor-alpha and interleukin-6 in the colon.	Dextran Sulfate	68-90	interleukin 6	Mus musculus	328-341
25406461-3	2015	The purpose of the present study was to determine the specific role of IL-6 in cyclophosphamide-doxorubicin-5-fluorouracil (CAF)-induced changes in fatigue, food intake, and body composition using mice lacking IL-6.	cyclophosphamide-doxorubicin-5-fluorouracil	79-122	interleukin 6	Mus musculus	71-75
25406461-3	2015	The purpose of the present study was to determine the specific role of IL-6 in cyclophosphamide-doxorubicin-5-fluorouracil (CAF)-induced changes in fatigue, food intake, and body composition using mice lacking IL-6.	cafestol palmitate	124-127	interleukin 6	Mus musculus	71-75
25406461-10	2015	Treatment-related decreases in levels of the anabolic hormone insulin-like growth factor-1 (IGF-1) may contribute to LBM and FM loss since CAF decreased IGF-1 levels in an IL-6-dependent manner.	cafestol palmitate	139-142	interleukin 6	Mus musculus	172-176
25971983-10	2015	Furthermore, data showed that astaxanthin could decrease GFAP-positive cells in the brain and down-regulate the cleaved caspase-3, IL-6, and IL-1beta, and up-regulate CBS in the frontal cortex.	astaxanthine	30-41	interleukin 6	Mus musculus	131-135
26481376-7	2015	qRT-PCR results also indicated that PN-S increased the mRNA expression of IL-6, TNF-alpha, INF-gamma, and nitric oxide synthase (iNOS) in the splenocytes.	pn-s	36-40	interleukin 6	Mus musculus	74-78
26148936-6	2015	Silencing TRAF3IP2 blunted Aldo-induced IKKbeta, p65, JNK, and c-Jun activation, IL-18, IL-6 and CT-1 upregulation, and cardiomyocyte hypertrophy.	Aldosterone	27-31	interleukin 6	Mus musculus	88-92
26148936-7	2015	In isolated adult mouse cardiac fibroblasts (CF), Aldo stimulated TRAF3IP2-dependent IL-18 and IL-6 production, CTGF, collagen I and III expression, MMP2 activation, and proliferation and migration.	Aldosterone	50-54	interleukin 6	Mus musculus	95-99
26481376-6	2015	PN-S also increased the levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (INF-gamma), and nitric oxide (NOS) in splenocytes.	pn-s	0-4	interleukin 6	Mus musculus	34-47
25790822-2	2015	To investigate the effects of sex hormone-specific intervention on pathology and progression of NASH, and on the inflammatory TLR-MyD88-IL-6 signaling pathway NASH was modeled in C57/BL6 mice by feeding a methionine and choline-deficient (MCD) diet for 4 weeks.	Methionine	205-215	interleukin 6	Mus musculus	136-140
26481376-6	2015	PN-S also increased the levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (INF-gamma), and nitric oxide (NOS) in splenocytes.	pn-s	0-4	interleukin 6	Mus musculus	49-53
26319951-8	2015	These findings suggest that GA exerts potentially clinically useful anti-inflammatory effects mediated through the suppression of p65-NF-kappaB and IL-6/p-STAT3(Y705) activation.	Gallic Acid	28-30	interleukin 6	Mus musculus	148-152
26252371-10	2015	In addition, gemcitabine upregulated the angiogenic molecules IL-6, IL-8, ENA-78 and MCP-1.	gemcitabine	13-24	interleukin 6	Mus musculus	62-66
26321118-5	2015	Alpinetin also inhibited LPS-induced ROS, MDA, and inflammatory cytokines TNF-alpha, IL-6 and IL-1beta production in kidney tissues.	alpinetin	0-9	interleukin 6	Mus musculus	85-89
26452780-5	2015	In this study, we observed that paeonol exerted direct anticancer activity through inhibition of cell proliferation, induction of apoptosis, and evident anti-inflammatory effects by reducing proinflammatory cytokines secretion (TNF-alpha, IL-1beta, IL-6, and TGF-beta) in the conditioned medium of B16F10 mouse melanoma cells.	paeonol	32-39	interleukin 6	Mus musculus	249-253
26452780-6	2015	Interestingly, we found that paeonol significantly reversed motility phenotypes in TNF-alpha- or IL-6-induced B16F10 singe cell and collective migration and invasion in vitro, which were related to affecting epithelial-to-mesenchymal transition (EMT) makers and MMPs expression.	paeonol	29-36	interleukin 6	Mus musculus	97-101
26452780-7	2015	In particular, paeonol disrupted both TNF-alpha-activated NF-kappaB and IL-6-activated STAT3 signaling pathways in B16F10 cells.	paeonol	15-22	interleukin 6	Mus musculus	72-76
25826740-10	2015	The pathway by which TiO2 nanoparticles increase ROS-induced IR were included in the inflammatory response and phosphokinase, as shown by increased serum levels of TNF-alpha and IL-6 and increased phosphorylation of JNK1 and p38 MAPK in liver.	titanium dioxide	21-25	interleukin 6	Mus musculus	178-182
25826740-10	2015	The pathway by which TiO2 nanoparticles increase ROS-induced IR were included in the inflammatory response and phosphokinase, as shown by increased serum levels of TNF-alpha and IL-6 and increased phosphorylation of JNK1 and p38 MAPK in liver.	Reactive Oxygen Species	49-52	interleukin 6	Mus musculus	178-182
25727991-10	2015	Additionally, SIRT1 antagonist nicotinamide (NAM) attenuated the inhibitory effects of AngsiRNA both on LPS-induced NF-kBp65 expression and IL6 expression.	Niacinamide	31-43	interleukin 6	Mus musculus	140-143
26134251-2	2015	Engaging cell stress via thapsigargin induced CHOP and selectively prolonged lipopolysaccharide-stimulated interleukin-6 (IL-6) expression in bone marrow-derived macrophages from wild-type (WT) but not CHOP knockout (KO) mice.	Thapsigargin	25-37	interleukin 6	Mus musculus	107-120
26198442-12	2015	Similarly to TSLP expression, IL-6, TNF-alpha, IL-8, and IL-36gamma expression induced by TNF-alpha were significantly suppressed by dexamethasone but not by tacrolimus in NHEKs.	Dexamethasone	133-146	interleukin 6	Mus musculus	30-34
26322830-9	2015	Correspondingly, the expression of NF-kappaB-related molecules, matrix metalloproteinase-2, matrix metalloproteinase-9, interleukin-6, and vascular endothelial growth factor, was significantly down-regulated by CpdA in control lines but not in GR-silencing cells.	CPDA	211-215	interleukin 6	Mus musculus	120-133
26059286-8	2015	RESULTS: Mesothelial cells exposed to either crocidolite or chrysotile underwent both apoptosis and necrosis and released cytokines IL-1beta, IL-6 and MIP-2.	Asbestos, Crocidolite	45-56	interleukin 6	Mus musculus	142-146
26059286-11	2015	CONCLUSIONS: Both crocidolite and chrysotile asbestos fibers induced apoptosis and produced an acute inflammatory response characterized by elevated levels of IL-1beta, IL-6 and MIP-2 in cultured mouse PMC.	Asbestos, Crocidolite	18-29	interleukin 6	Mus musculus	169-173
26059286-12	2015	IL-1beta and IL-6, but not MIP-2, were shown to contribute to asbestos-induced injury, especially in the crocidolite group.	Asbestos, Crocidolite	105-116	interleukin 6	Mus musculus	13-17
25849065-5	2015	Furthermore, we observed that CISCFE could obviously decrease UV-induced skin inflammation by inhibiting the production of inflammatory cytokines (interleukin-1beta [IL-1beta, IL-6, IL-10, tumor necrosis factor-alpha), alleviate the abnormal changes of anti-oxidative indicators (superoxide dismutase, catalase, and glutathione peroxidase), and down-regulate the levels of MMP-1 and MMP-3.	ciscfe	30-36	interleukin 6	Mus musculus	176-180
26486161-3	2015	IL-6 knockout (KO) and wild-type (WT) mice were placed on LS diet for 7 days, and MAP was measured 19 h/day with telemetry.	leucylserine	58-60	interleukin 6	Mus musculus	0-4
26053964-7	2015	In addition, rapamycin reduced the production of IL-6 and IL-13 by eosinophils.	Sirolimus	13-22	interleukin 6	Mus musculus	49-53
26429536-10	2015	Compared with the control group, the indexes of thymus and spleen in the RSBCP mixture high-dose group increased obviously; the levels of IgG, IgM, C3, C4, IL-2 and IL-6 were lifted significantly and the level of TNF-alpha decreased significantly.	rsbcp	73-78	interleukin 6	Mus musculus	165-169
26429536-9	2015	Compared with the model group, the indexes of thymus and spleen in the RSBCP mixture groups increased obviously; the levels of IgG, IgM, C3, C4, IL-2 and IL-6 were raised significantly and the level of TNF-alpha decreased significantly.	rsbcp	71-76	interleukin 6	Mus musculus	154-158
26429536-11	2015	The indexes of thymus and spleen and the levels of IgG, IgM, C3, C4, IL-2 and IL-6 in the RSBCP mixture middle- and low-dose groups had no obvious differences from those of the control group.	rsbcp	90-95	interleukin 6	Mus musculus	78-82
26429536-14	2015	CONCLUSION: RSBCP mixture could delay the atrophy of thymus and spleen in the aging mice, dramatically elevate serum levels of IgG, IgM, C3, C4, IL-2, IL-6, lower the level of TNF-alpha, and influence the proportions of T cell subsets.	rsbcp	12-17	interleukin 6	Mus musculus	151-155
26391752-9	2015	Furthermore, oxycodone decreased SNL-induced activation of glial cells (astrocytes and microglia) and plasma levels of proinflammatory cytokines (IL-6, IL-1beta and TNF-alpha).	Oxycodone	13-22	interleukin 6	Mus musculus	146-150
26275708-9	2015	Treatment with SU5416 modestly aggravated hypoxia-induced pulmonary hypertension, right ventricular hypertrophy, and pulmonary arterial vessel wall thickening in ETTG mice in association with increased interleukin-6 expression in blood vessels.	Semaxinib	15-21	interleukin 6	Mus musculus	202-215
26408027-14	2015	TSA also reduced the expression of OA-associated proteins MMP1, MMP3, and MMP13 and proinflammatory cytokines TNF-alpha, IL-1beta, and IL-6.	trichostatin A	0-3	interleukin 6	Mus musculus	135-139
26406888-10	2015	Those mice in 5-FU groups had significantly higher proinflammatory cytokine levels (TNF-alpha: 234.80 vs. 29.10, P&lt;0.001, IL-6: 25.13 vs. 7.43, P&lt;0.001, IFN-gamma: 22.07 vs. 17.06, P = 0.137).	Fluorouracil	14-18	interleukin 6	Mus musculus	125-129
26406888-12	2015	We also found TNF-alpha, IL-1beta and IL-6 mRNA expressions were up-regulated in intestinal mucositis tissues following 5-FU treatment (TNF-alpha: 4.35 vs. 1.18, IL-1beta: 2.29 vs. 1.07, IL-6: 1.49 vs. 1.02) and that probiotics treatment suppressed this up-regulation (P&lt;0.05).	Fluorouracil	120-124	interleukin 6	Mus musculus	38-42
26406888-12	2015	We also found TNF-alpha, IL-1beta and IL-6 mRNA expressions were up-regulated in intestinal mucositis tissues following 5-FU treatment (TNF-alpha: 4.35 vs. 1.18, IL-1beta: 2.29 vs. 1.07, IL-6: 1.49 vs. 1.02) and that probiotics treatment suppressed this up-regulation (P&lt;0.05).	Fluorouracil	120-124	interleukin 6	Mus musculus	187-191
25531319-7	2015	Furthermore, serum interleukin (IL)-1beta and IL-6 levels were higher in PQ-exposed aged Casp2(-/-) mice indicating increased inflammation.	Primaquine	73-75	interleukin 6	Mus musculus	46-50
26101798-8	2015	The alterations in E-cadherin, IFN-gamma, IL-6 and IL-10 were associated with OC, TC and some amino acids, particularly non-protein-type amino acids.	Technetium	82-84	interleukin 6	Mus musculus	42-46
25959443-15	2015	RESULTS: The data showed that treatment with the ZJP markedly attenuated MPO, MDA, TNF-alpha, IL-6, IL-1betaand increased SOD; and ZJP also decreased protein levels of P-NF-kBp65, P-IkBalpha, P-IKKalphaand P-IKKbetain gastric stomachs.	zjp	49-52	interleukin 6	Mus musculus	94-98
26218295-7	2015	This was accompanied by a significant reduction in nitrite and proinflammatory cytokines (TNF-alpha and IL-6) from hyperactive microglia suggesting normalized circuitry function with dPGS treatment.	cyclic (2R)-2,3-bisphosphoglycerate	183-187	interleukin 6	Mus musculus	104-108
26337552-9	2015	Osthole treatment reduced the number of macrophages/microglia and peripheral infiltrating of neutrophils and lowered the level of the proinflammatory cytokines interleukin-6 and tumor necrosis factor alpha in the lesioned cortex.	osthol	0-7	interleukin 6	Mus musculus	160-173
26370415-8	2015	We find that harpagoside could scavenge hypoxia-enhanced inflammatory genes expression (COX-2, IL-1beta and IL-6 genes) and NO synthesis of microglial cells.	harpagoside	13-24	interleukin 6	Mus musculus	108-112
26361331-6	2015	Peritoneal cells prepared from mice injected in vivo with the liposomes containing curcumin apparently decreased interleukin-6-producing activities.	Curcumin	83-91	interleukin 6	Mus musculus	113-126
26102009-8	2015	Furthermore cavidine inhibited the level of TNF-alpha and IL-6 in the serum and colon tissue in response to the regulation of p65 NF-kappaB protein expression.	cavidine	12-20	interleukin 6	Mus musculus	58-62
26138643-4	2015	Results indicated that inflammation (IL-6 levels) and oxidation (F2a-isoprostanes) persisted through 8 wk of life in mice exposed to LPS/O2 perinatally.	Oxygen	137-139	interleukin 6	Mus musculus	37-41
26344074-2	2015	We recently reported that 25-hydroxycholesterol, a representative LXR-activating oxysterol, suppresses IL-6 production in mouse mast cells (MCs) following its engagement of the high-affinity IgE receptor (FcepsilonRI).	25-hydroxycholesterol	26-47	interleukin 6	Mus musculus	103-107
26344074-2	2015	We recently reported that 25-hydroxycholesterol, a representative LXR-activating oxysterol, suppresses IL-6 production in mouse mast cells (MCs) following its engagement of the high-affinity IgE receptor (FcepsilonRI).	Oxysterols	81-90	interleukin 6	Mus musculus	103-107
25541056-4	2015	Butein also decreased TNF-alpha-induced pro-inflammatory mediators, such as IL-6, IP-10 and MCP-1, in HaCaT cells.	butein	0-6	interleukin 6	Mus musculus	76-80
26076332-2	2015	We previously found that a chalcone derivative, L6H21, could inhibit LPS-induced overexpression of TNF-alpha and IL-6 in macrophages.	Chalcone	27-35	interleukin 6	Mus musculus	113-117
24677730-3	2015	Pretreatment with reactive oxygen species (ROS) scavenger, N-acetylcysteine (NAC), attenuated NP-induced ROS production, COX-2 expression, and IL-6 and PGE2 release in TM4 cells.	Reactive Oxygen Species	18-41	interleukin 6	Mus musculus	143-147
26194911-7	2015	In line with this, losartan reduced inflammation and diminished TNF-alpha and IL-6 expression in injured forepaws.	Losartan	19-27	interleukin 6	Mus musculus	78-82
24677730-4	2015	Exposure to NP stimulated activation of NF-kappaB, whereas the NF-kappaB inhibitor, pyrrolidine dithiocarbamate, attenuated NP-enhanced COX-2 expression and IL-6 and PGE2 release in TM4 cells in a dose-dependent manner.	pyrrolidine dithiocarbamic acid	84-111	interleukin 6	Mus musculus	157-161
24677730-3	2015	Pretreatment with reactive oxygen species (ROS) scavenger, N-acetylcysteine (NAC), attenuated NP-induced ROS production, COX-2 expression, and IL-6 and PGE2 release in TM4 cells.	Reactive Oxygen Species	43-46	interleukin 6	Mus musculus	143-147
24677730-3	2015	Pretreatment with reactive oxygen species (ROS) scavenger, N-acetylcysteine (NAC), attenuated NP-induced ROS production, COX-2 expression, and IL-6 and PGE2 release in TM4 cells.	Acetylcysteine	59-75	interleukin 6	Mus musculus	143-147
24677730-3	2015	Pretreatment with reactive oxygen species (ROS) scavenger, N-acetylcysteine (NAC), attenuated NP-induced ROS production, COX-2 expression, and IL-6 and PGE2 release in TM4 cells.	Acetylcysteine	77-80	interleukin 6	Mus musculus	143-147
26147382-8	2015	Moreover, GW0742 increased both aortic Akt and endothelial nitric oxide synthase phosphorylation, and inhibited the increase in caveolin-1/endothelial nitric oxide synthase interaction, ethidium fluorescence, NOX-1, Toll-like receptor 4, tumor necrosis factor-alpha, and interleukin-6 expression, and IkappaBalpha phosphorylation found in aortae from the HFD group.	GW0742	10-16	interleukin 6	Mus musculus	271-284
26190278-8	2015	The amount of pro-inflammatory cytokines, specifically TNF-alpha, IL-1beta and IL-6 and the activity of myeloperoxidase in colon tissue were significantly decreased in geraniol pre-treated mice.	geraniol	168-176	interleukin 6	Mus musculus	79-83
25976094-0	2015	Differential involvement of IL-6 in the early and late phase of 1-methylnicotinamide (MNA) release in Concanavalin A-induced hepatitis.	N(1)-methylnicotinamide	64-84	interleukin 6	Mus musculus	28-32
25976094-0	2015	Differential involvement of IL-6 in the early and late phase of 1-methylnicotinamide (MNA) release in Concanavalin A-induced hepatitis.	N(1)-methylnicotinamide	86-89	interleukin 6	Mus musculus	28-32
26225926-5	2015	Pre-treatment with EVD prevented the oxidative damage and decreased the levels of prostaglandin E2 (PGE2) content, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	evodiamine	19-22	interleukin 6	Mus musculus	115-128
26225926-5	2015	Pre-treatment with EVD prevented the oxidative damage and decreased the levels of prostaglandin E2 (PGE2) content, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	evodiamine	19-22	interleukin 6	Mus musculus	130-134
26007287-5	2015	Furthermore, DHA protected C2C12 myotubes from palmitate- or lipopolysaccharide-induced increase in Ptgs2, interleukin 6 and tumor necrosis factor-alpha mRNA level, probably through the inhibition of p38 MAP kinase and c-Jun amino-terminal kinase.	Docosahexaenoic Acids	13-16	interleukin 6	Mus musculus	107-152
26007287-5	2015	Furthermore, DHA protected C2C12 myotubes from palmitate- or lipopolysaccharide-induced increase in Ptgs2, interleukin 6 and tumor necrosis factor-alpha mRNA level, probably through the inhibition of p38 MAP kinase and c-Jun amino-terminal kinase.	Palmitates	47-56	interleukin 6	Mus musculus	107-152
26180249-8	2015	Mice fed dextrin-based diets secreted 47-88% less colonic IL-1beta, tumor necrosis factor alpha, and IL-23 (SFD-t diet) and IL-12 heterodimer p70, IL-6, and chemokine ligand 1 (CXCL1) (SFD-c diet) (P &lt; 0.05) than did the control group, whereas NRS-fed mice secreted 55-77% less IL-6 and CXCL1 (P &lt; 0.05).	Dextrins	9-16	interleukin 6	Mus musculus	147-151
26180249-8	2015	Mice fed dextrin-based diets secreted 47-88% less colonic IL-1beta, tumor necrosis factor alpha, and IL-23 (SFD-t diet) and IL-12 heterodimer p70, IL-6, and chemokine ligand 1 (CXCL1) (SFD-c diet) (P &lt; 0.05) than did the control group, whereas NRS-fed mice secreted 55-77% less IL-6 and CXCL1 (P &lt; 0.05).	Dextrins	9-16	interleukin 6	Mus musculus	281-285
25998703-4	2015	The present study confirmed the anti-inflammatory effects of heparin in lipopolysaccharide (LPS)-induced murine peritoneal macrophages through decreasing the levels of the inflammatory cytokines tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), IL-8 and IL-1beta.	Heparin	61-68	interleukin 6	Mus musculus	236-249
26221772-7	2015	In response to inflammation, miR-Let-7a participates in the reduction of nitrite production and the expression of inducible nitric oxide synthase (iNOS), interleukin (IL)-6 and is involved in increased expression of brain derived neurotrophic factor (BDNF), interleukin (IL)-10, and IL-4 in microglia.	Nitrites	73-80	interleukin 6	Mus musculus	154-172
26047123-7	2015	BMEV treatment also reduced the serum levels of MCP-1 and IL-6 and their production by splenic cells.	bmev	0-4	interleukin 6	Mus musculus	58-62
25998703-4	2015	The present study confirmed the anti-inflammatory effects of heparin in lipopolysaccharide (LPS)-induced murine peritoneal macrophages through decreasing the levels of the inflammatory cytokines tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), IL-8 and IL-1beta.	Heparin	61-68	interleukin 6	Mus musculus	251-255
26071454-5	2015	Moreover, the increase in serum IL-1beta and IL-6 levels by the treatment of CBZ indicated the occurring of inflammation.	carbendazim	77-80	interleukin 6	Mus musculus	45-49
26044883-5	2015	Cell stimulation with whole TES products was more effective and resulted in secretion of IL-4, IL-5, IL-6, IL-10, and TGF-beta and downregulation of TNF-alpha production.	TES	28-31	interleukin 6	Mus musculus	101-105
26073719-9	2015	However, NVP-BEZ235 enhanced IL-6 and TNF-alpha expression after 24h.	dactolisib	13-19	interleukin 6	Mus musculus	29-33
26141388-3	2015	Our results clearly demonstrate that the exposure of J774A.1 and primary macrophages to NDL-PCB 153 or 180 or all NDL-PCBs mixtures causes a significant reduction in LPS-induced cytokine/chemokine synthesis, such as tumor necrosis factor-alpha and interleukin-6, together with monocyte chemoattractant protein-1, involved in cell recruitment.	ndl-pcbs	114-122	interleukin 6	Mus musculus	248-261
26713531-6	2015	RESULTS: Compared with the saline group, the TNF-alpha and IL-6 levels in pulmonary tissue and peripheral blood were significantly reduced in suramin group at 24 h after LPS treatment(all P&lt;0.01); while there was no significant difference at 72 h between two groups(all P&gt;0.05).	Suramin	142-149	interleukin 6	Mus musculus	59-63
26501160-7	2015	Compared with the model group, total glycosides significantly reduced the levels of the sterol regulatory element binding protein-1c (SREBP-1c) and liver X receptor-a (LXR-alpha) protein, and down-regulated the expression of SREBP-1c, LXR-alpha and interleukin-6 (IL-6) mRNA in the liver.	Glycosides	37-47	interleukin 6	Mus musculus	249-262
26713531-7	2015	The expression of TNF-alpha, IL-6 mRNA and the activity of NF-kappaB was decreased in suramin group at different time points after LPS treatment.	Suramin	86-93	interleukin 6	Mus musculus	29-33
26501160-7	2015	Compared with the model group, total glycosides significantly reduced the levels of the sterol regulatory element binding protein-1c (SREBP-1c) and liver X receptor-a (LXR-alpha) protein, and down-regulated the expression of SREBP-1c, LXR-alpha and interleukin-6 (IL-6) mRNA in the liver.	Glycosides	37-47	interleukin 6	Mus musculus	264-268
26188090-6	2015	Pro-inflammatory cytokines, including monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6), were significantly downregulated, and the anti-inflammatory cytokine IL-10 was significantly upregulated in nor-NOHA-treated co-cultured cells.	norLeu3-A(1-7)	257-265	interleukin 6	Mus musculus	142-146
26234731-5	2015	Subcutaneous injection of gallic acid or catechin significantly reduced MSU-induced IL-1beta and IL-6 secretion in C57BL/6 mice.	Gallic Acid	26-37	interleukin 6	Mus musculus	97-101
26234731-5	2015	Subcutaneous injection of gallic acid or catechin significantly reduced MSU-induced IL-1beta and IL-6 secretion in C57BL/6 mice.	Catechin	41-49	interleukin 6	Mus musculus	97-101
26343372-4	2015	ZOL and ALN mediated significant release of IL-6, TNF-` and IL-1beta, whereas they inhibited IL-10 secretion by osteoclasts.	Alendronate	8-11	interleukin 6	Mus musculus	44-48
26312203-5	2015	Mice exposed to arsenic exhibited significant increased in TNF-alpha (4.3-fold), serum Interleukin-1 beta (threefold), Interleukin-6 (3.8-fold) as compared to controls.	Arsenic	16-23	interleukin 6	Mus musculus	119-132
26289430-11	2015	EIA revealed that BLM-induced IL-6 in BALF was biphasic, with the first increase from 0.5 to 3 dpi followed by the second increase from 8 to 10 dpi.	Bleomycin	18-21	interleukin 6	Mus musculus	30-34
26302442-6	2015	SM supplementation significantly maintained covalently-bound omega-hydroxy ceramide levels and down-regulated mRNA levels of acute inflammation-associated genes, including thymic stromal lymphopoietin, interleukin-1 beta, and interleukin-6.	Sphingomyelins	0-2	interleukin 6	Mus musculus	226-239
26289430-11	2015	EIA revealed that BLM-induced IL-6 in BALF was biphasic, with the first increase from 0.5 to 3 dpi followed by the second increase from 8 to 10 dpi.	3-aminodiphenyleneiodium	95-98	interleukin 6	Mus musculus	30-34
26289430-11	2015	EIA revealed that BLM-induced IL-6 in BALF was biphasic, with the first increase from 0.5 to 3 dpi followed by the second increase from 8 to 10 dpi.	3-aminodiphenyleneiodium	144-147	interleukin 6	Mus musculus	30-34
26426535-7	2015	Analysis of cytokines and histopathological examinations of tissue revealed administration of gelsolin and diclofenac sodium significantly reduced production of pro-inflammatory cytokines, TNF-alpha and IL-6.	Diclofenac	107-124	interleukin 6	Mus musculus	203-207
25975489-7	2015	The results showed that Sal B inhibited CS-induced lung pathological changes, the infiltration of inflammatory cells, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1beta (IL-1beta), and monocyte chemoattractant protein 1 (MCP-1) productions.	salvianolic acid B	24-29	interleukin 6	Mus musculus	159-172
25975489-7	2015	The results showed that Sal B inhibited CS-induced lung pathological changes, the infiltration of inflammatory cells, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1beta (IL-1beta), and monocyte chemoattractant protein 1 (MCP-1) productions.	salvianolic acid B	24-29	interleukin 6	Mus musculus	174-178
26396668-0	2015	Mangiferin suppresses CIA by suppressing the expression of TNF-alpha, IL-6, IL-1beta, and RANKL through inhibiting the activation of NF-kappaB and ERK1/2.	mangiferin	0-10	interleukin 6	Mus musculus	70-74
26195767-5	2015	In mice, erlotinib blocks the LPS-induced expression of tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6) and ameliorates LPS-induced endotoxity, revealing that EGFR is essential for LPS-induced signaling in vivo.	Erlotinib Hydrochloride	9-18	interleukin 6	Mus musculus	99-112
26290634-10	2015	Moreover, DHI (3 g/kg) remarkably decreased LPS-induced protein expression of TNF-alpha (340.55 +- 10.18 for 3 g/kg, P &lt; 0.01), IL-6 (261.34 +- 10.18 for 3 g/kg, P &lt; 0.01), and enzyme activity of caspase-3 (0.93 +- 0.029 for 3 g/kg, P &lt; 0.01).	dehydrosoyasaponin I	10-13	interleukin 6	Mus musculus	131-135
26290634-11	2015	The LPS-induced mRNA expression of TNF-alpha, IL-6 and caspase-3 was also decreased by DHI.	dehydrosoyasaponin I	87-90	interleukin 6	Mus musculus	46-50
26195767-5	2015	In mice, erlotinib blocks the LPS-induced expression of tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6) and ameliorates LPS-induced endotoxity, revealing that EGFR is essential for LPS-induced signaling in vivo.	Erlotinib Hydrochloride	9-18	interleukin 6	Mus musculus	114-118
26241646-8	2015	A higher neutrophil influx and enhanced IL-6, MCP-1 and KC production was observed in Nur77-deficient colons after DSS-treatment.	dss	115-118	interleukin 6	Mus musculus	40-44
26241646-9	2015	TNBS-induced influx of T-cells and inflammatory monocytes into the colon was higher in Nur77-/- mice, along with increased expression of MCP-1, TNFalpha and IL-6, and decreased Foxp3 RNA expression, compared to wild-type mice.	Trinitrobenzenesulfonic Acid	0-4	interleukin 6	Mus musculus	157-161
25882295-0	2015	4-methylumbelliferone inhibits hepatocellular carcinoma growth by decreasing IL-6 production and angiogenesis.	Hymecromone	0-21	interleukin 6	Mus musculus	77-81
26258789-0	2015	Dietary Selenium Levels Affect Selenoprotein Expression and Support the Interferon-gamma and IL-6 Immune Response Pathways in Mice.	Selenium	8-16	interleukin 6	Mus musculus	93-97
26258789-6	2015	Changes in serum cytokine levels were measured which confirmed that interferon-gamma, as well as IL-6, were increased in selenium adequate mice.	Selenium	121-129	interleukin 6	Mus musculus	97-101
26258789-8	2015	These data are consistent with previous reports indicating that adequate selenium levels can support beneficial immune responses, and further identify the IL-6 and interferon-gamma pathways as being responsive to dietary selenium intake.	Selenium	221-229	interleukin 6	Mus musculus	155-159
25985156-12	2015	In addition, immunohistochemical analysis and enzyme-linked immunosorbent assay showed icariin significantly reduced expression and secretion of tumor necrosis factor-alpha, interleukin-1beta and interleukin-6 in the calvariae of titanium-stimulated mice.	icariin	87-94	interleukin 6	Mus musculus	196-209
25425548-5	2015	OxyR inhibited the productions of NO, PGE2, IL-6, and GM-CSF significantly in LPS-stimulated RAW264.7 cells.	puag-haad	0-4	interleukin 6	Mus musculus	44-48
25616906-7	2015	Nicotine downregulated production of IL-6 and MCP-1 in RA-FLSs induced by TNFalpha in a concentration-dependent manner, and IL-10 levels were not significantly different after nicotine pretreatment.	Nicotine	0-8	interleukin 6	Mus musculus	37-41
25616906-11	2015	In conclusion, nicotine has an anti-inflammatory effect on RA by downregulating production of IL-6 and MCP-1 in FLSs, and this is mediated through activation of the JAK2-STAT3 signal pathway.	Nicotine	15-23	interleukin 6	Mus musculus	94-98
25633425-6	2015	Furthermore, AA significantly reduced PQ-induced upregulations of inflammatory mediators such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and IL-8.	Paraquat	38-40	interleukin 6	Mus musculus	156-160
25972311-7	2015	RESULTS: The endotoxin plus MgSO4 group presented lower concentrations of inflammatory mediators (macrophage inflammatory protein 2, tumor necrosis factor alpha, and interleukin 6, lower nuclear concentration of phosphorylated nuclear factor kappaB, lower cytosolic concentration of phosphorylated inhibitor kappaBalpha, and higher concentration of phosphorylated Akt (PI3K activation marker) than the endotoxin group (all P &lt; 0.05).	Magnesium Sulfate	28-33	interleukin 6	Mus musculus	166-179
26026982-6	2015	At the same time, IP3a could promote cytokine secretion (IL-2, IL-6, IL-12 and TNF-alpha) and macrophage phagocytosis in mice.	ip3a	18-22	interleukin 6	Mus musculus	63-67
26109645-0	2015	IL-6 and ICOS Antagonize Bim and Promote Regulatory T Cell Accrual with Age.	bim	25-28	interleukin 6	Mus musculus	0-4
25988231-8	2015	Losartan treatment prevented tumor-induced loss of muscle mass and in vitro c26 cell proliferation, decreased tumor weight, and attenuated myocardial expression of interleukin-6.	Losartan	0-8	interleukin 6	Mus musculus	164-177
25128030-7	2015	Furthermore, bucladesine significantly decreased the production of interleukin-6 pro-inflammatory mediator as well as nuclear factor-kappaB activation and reduced the mean number of apoptotic cells compared to cuprizone-treated mice.	Bucladesine	13-24	interleukin 6	Mus musculus	67-80
25773735-4	2015	KEY FINDINGS: Eucalyptol attenuated inflammation-associated increases in cell numbers, matrix metalloproteinase-9 (MMP-9) expression, production of cytokines (tumour necrosis factor-alpha and interleukin-6) and nitric oxide, and nuclear factor-kappa B (NF-kappaB) and phosphorylated extracellular signal-regulated kinase protein levels induced by LPS in bronchoalveolar lavage fluid from ALI mice.	Eucalyptol	14-24	interleukin 6	Mus musculus	192-205
26147250-8	2015	Reduced IL1A diminished NF-kappaB transcriptional activity, which controls much of the SASP; exogenous IL1A restored IL6 secretion to rapamycin-treated cells.	Sirolimus	134-143	interleukin 6	Mus musculus	117-120
25993999-6	2015	In addition, circulating levels and pancreatic mRNA of the inflammatory cytokines tumor necrosis factor-alpha, interleukin Il-1beta, and Il-6 were reduced in TPPU-treated mice.	TPPU	158-162	interleukin 6	Mus musculus	137-141
26277525-6	2015	CONCLUSION: Survivin ASODN can suppress the invasion and migration capacity of ovarian cancer cells and inhibit peritoneal metastasis of the tumor in nude mice possibly though down-regulation of IL-6/STAT3 signaling pathway.	asodn	21-26	interleukin 6	Mus musculus	195-199
25747604-7	2015	We found l-serine treatment: 1) decreased the neurological deficit score, brain water content, lesion volume, and neurone loss; 2) inhibited activated caspase-3; and 3) reduced the levels of TNF-alpha, IL-1beta and IL-6 and the number of GFAP- and Iba-1-positive cells.	Serine	9-17	interleukin 6	Mus musculus	215-219
25895149-3	2015	The prototypical alpha7nAChR antagonist alpha-bungarotoxin and mecamylamine attenuated the effect of SIN on tumor necrosis factor-alpha and interleukin-6 in RAW264.7 murine macrophage-like cells and primary peritoneal macrophages of mouse induced by lipopolysaccharide.	Mecamylamine	63-75	interleukin 6	Mus musculus	140-153
26109166-7	2015	CONCLUSIONS: These findings indicate that SkM IL-6 affects iWAT mass through regulation of glucose uptake capacity as well as lipogenic and lipolytic factors.	Glucose	91-98	interleukin 6	Mus musculus	46-50
28162277-8	2015	The replacement of Cys259 residue with Ala abolished the inhibitory role of GSNO in IL-6-induced STAT3 phosphorylation and transactivation, suggesting the role of Cys259S-nitrosylation in STAT3phosphorylation.	S-Nitrosoglutathione	76-80	interleukin 6	Mus musculus	84-88
28162277-8	2015	The replacement of Cys259 residue with Ala abolished the inhibitory role of GSNO in IL-6-induced STAT3 phosphorylation and transactivation, suggesting the role of Cys259S-nitrosylation in STAT3phosphorylation.	cys259s	163-170	interleukin 6	Mus musculus	84-88
26447625-6	2015	Tunicamycin significantly enhanced the LPS-induced up-regulation of TNFa, IL-6 and IL-1b expression (TNFa, 1.44+/-0.38, t=2.8, P&lt;0.05; IL-1b, 16.063.40, t =7.93, P&lt;0.05; IL-6, 31.1610.60, t=5.08, P&lt;0.05).	Tunicamycin	0-11	interleukin 6	Mus musculus	74-78
25891417-8	2015	Casticin and chrysosplenol D suppressed LPS-induced release of IL-1 beta, IL-6 and MCP-1, inhibited cell migration, and reduced LPS-induced IkappaB and c-JUN phosphorylation in Raw264.7 cells.	casticin	0-8	interleukin 6	Mus musculus	74-78
25891417-8	2015	Casticin and chrysosplenol D suppressed LPS-induced release of IL-1 beta, IL-6 and MCP-1, inhibited cell migration, and reduced LPS-induced IkappaB and c-JUN phosphorylation in Raw264.7 cells.	Chrysosplenol C	13-26	interleukin 6	Mus musculus	74-78
26447625-6	2015	Tunicamycin significantly enhanced the LPS-induced up-regulation of TNFa, IL-6 and IL-1b expression (TNFa, 1.44+/-0.38, t=2.8, P&lt;0.05; IL-1b, 16.063.40, t =7.93, P&lt;0.05; IL-6, 31.1610.60, t=5.08, P&lt;0.05).	Tunicamycin	0-11	interleukin 6	Mus musculus	176-180
26213566-15	2015	AFS and its main compounds, including hederasaponin B, flaccidoside II, and hemsgiganoside B, significantly inhibited TNF-alpha (P = 0.0022, P = 0.013, P = 0.0015, and P = 0.016) and IL-6 (P = 0.0175, P &lt; 0.001, P &lt; 0.001, and P &lt; 0.001) production in LPS-treated RAW264.7 cells, respectively.	hemsgiganoside b	76-92	interleukin 6	Mus musculus	183-187
26252187-6	2015	The septic mice treated with AICAR exhibited elevated phosphorylation of AMPKalpha in the brain along with reduced serum levels of aspartate aminotransferase, tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6), compared with the vehicle.	AICA ribonucleotide	29-34	interleukin 6	Mus musculus	233-246
26252187-6	2015	The septic mice treated with AICAR exhibited elevated phosphorylation of AMPKalpha in the brain along with reduced serum levels of aspartate aminotransferase, tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6), compared with the vehicle.	AICA ribonucleotide	29-34	interleukin 6	Mus musculus	248-252
26222683-6	2015	Baicalein inhibited the cisplatin-induced expression of iNOS, TNF-alpha, IL-6 and mononuclear cell infiltration and concealed redox-sensitive transcription factor NF-kappaB activation via reduced DNA-binding activity, IkappaBalpha phosphorylation and p65 nuclear translocation in kidneys.	baicalein	0-9	interleukin 6	Mus musculus	73-77
26222683-6	2015	Baicalein inhibited the cisplatin-induced expression of iNOS, TNF-alpha, IL-6 and mononuclear cell infiltration and concealed redox-sensitive transcription factor NF-kappaB activation via reduced DNA-binding activity, IkappaBalpha phosphorylation and p65 nuclear translocation in kidneys.	Cisplatin	24-33	interleukin 6	Mus musculus	73-77
26154512-6	2015	The intraperitoneal treatment with naringenin reduced skin inflammation by inhibiting skin edema, neutrophil recruitment, MMP-9 activity, and pro-inflammatory (TNF-alpha, IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-22, and IL-23) and anti-inflammatory (TGF-beta and IL-10) cytokines.	naringenin	35-45	interleukin 6	Mus musculus	204-208
25968579-1	2015	Members of the IL-6 family, IL-6 and ciliary neurotrophic factor (CNTF), have been shown to increase glucose uptake and fatty acid oxidation in skeletal muscle.	Glucose	101-108	interleukin 6	Mus musculus	15-19
25968579-1	2015	Members of the IL-6 family, IL-6 and ciliary neurotrophic factor (CNTF), have been shown to increase glucose uptake and fatty acid oxidation in skeletal muscle.	Glucose	101-108	interleukin 6	Mus musculus	28-32
25968579-1	2015	Members of the IL-6 family, IL-6 and ciliary neurotrophic factor (CNTF), have been shown to increase glucose uptake and fatty acid oxidation in skeletal muscle.	Fatty Acids	120-130	interleukin 6	Mus musculus	15-19
25968579-1	2015	Members of the IL-6 family, IL-6 and ciliary neurotrophic factor (CNTF), have been shown to increase glucose uptake and fatty acid oxidation in skeletal muscle.	Fatty Acids	120-130	interleukin 6	Mus musculus	28-32
25808405-8	2015	Kaempferol increased CD4+FoxP3+ Tregs both in transplanted mice and in vitro, likely by suppressing DC maturation and their IL-6 expression.	kaempferol	0-10	interleukin 6	Mus musculus	124-128
26205049-3	2015	Furthermore, licorice extract inhibited the expression levels of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6) in the livers of t-BHP-treated mice models.	tert-Butylhydroperoxide	140-145	interleukin 6	Mus musculus	117-121
26169874-10	2015	The protective effects of olaparib were linked to a suppression of Th2 cytokines eotaxin, IL-4, IL-5, IL-6, IL-13, and M-CSF, and ovalbumin-specific IgE with an increase in the Th1 cytokine IFN-gamma.	olaparib	26-34	interleukin 6	Mus musculus	102-106
25987561-4	2015	BMDM from low fat-fed mice exposed to palmitate (PA) for 18 h ex vivo also showed elevated expression of proinflammatory genes (Cxcl1, Il6, Tnf, Nos2, and Il12b) associated with M1 polarization.	Palmitates	38-47	interleukin 6	Mus musculus	135-138
25987561-4	2015	BMDM from low fat-fed mice exposed to palmitate (PA) for 18 h ex vivo also showed elevated expression of proinflammatory genes (Cxcl1, Il6, Tnf, Nos2, and Il12b) associated with M1 polarization.	Palmitates	49-51	interleukin 6	Mus musculus	135-138
25808405-11	2015	Administering IL-6 abrogated allograft tolerance induced by kaempferol and cyclosporine via diminishing CD4+FoxP3+ Tregs.	Cyclosporine	75-87	interleukin 6	Mus musculus	14-18
25808405-11	2015	Administering IL-6 abrogated allograft tolerance induced by kaempferol and cyclosporine via diminishing CD4+FoxP3+ Tregs.	kaempferol	60-70	interleukin 6	Mus musculus	14-18
25686746-10	2015	The levels of TNFalpha and IL-6 were decreased at 48 h. Treatment with sodium butyrate reduced the pathological lesions, the serum levels of HMGB1, TNFalpha, and IL-6, the HMGB1 mRNA levels, and NF-kappaB activity.	Butyric Acid	71-86	interleukin 6	Mus musculus	27-31
25686746-10	2015	The levels of TNFalpha and IL-6 were decreased at 48 h. Treatment with sodium butyrate reduced the pathological lesions, the serum levels of HMGB1, TNFalpha, and IL-6, the HMGB1 mRNA levels, and NF-kappaB activity.	Butyric Acid	71-86	interleukin 6	Mus musculus	162-166
26085110-8	2015	Moreover, the secretion and the mRNA level of TNF-alpha and IL-6 were inhibited by theobromine treatment.	Theobromine	83-94	interleukin 6	Mus musculus	60-64
26035386-1	2015	Interleukin-6 (IL-6) has emerged as an important mediator of fatty acid metabolism with paradoxical effects in the liver.	Fatty Acids	61-71	interleukin 6	Mus musculus	0-13
26035386-1	2015	Interleukin-6 (IL-6) has emerged as an important mediator of fatty acid metabolism with paradoxical effects in the liver.	Fatty Acids	61-71	interleukin 6	Mus musculus	15-19
25912997-6	2015	Moreover, in Muller cells, ebselen reduced the hypoxia-induced increase in protein levels of pro-angiogenic and pro-inflammatory factors including vascular endothelial growth factor, interleukin-6, monocyte chemoattractant-protein 1 and intercellular adhesion molecule-1, and the mRNA levels of glial fibrillary acidic protein (GFAP), a marker of Muller cell injury.	ebselen	27-34	interleukin 6	Mus musculus	183-196
25966976-4	2015	Additionally, consumption of the CAF diet was associated with significantly higher weight gain, abdominal fat, and serum IL-6 levels, as well as more damage in the heart (coronary perivascular fibrosis and steatosis), kidney (chronic interstitial inflammation and glomerular sclerosis), and liver (liver weight, portal fibrosis, apoptosis, and steatosis) compared to the HF diet.	cafestol palmitate	33-36	interleukin 6	Mus musculus	121-125
26044069-0	2015	The Protective Roles of IL-6 Trans-Signaling Regulated by ADAM9 on the Liver in Carbon Tetrachloride-Induced Liver Injury in Mice.	Carbon Tetrachloride	80-100	interleukin 6	Mus musculus	24-28
26002582-10	2015	Luteolin administration significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), malondialdehyde (MDA) levels, as well as glutathione (GSH) depletion and decrease of superoxide dismutase (SOD).	Luteolin	0-8	interleukin 6	Mus musculus	183-196
26002582-10	2015	Luteolin administration significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), malondialdehyde (MDA) levels, as well as glutathione (GSH) depletion and decrease of superoxide dismutase (SOD).	Luteolin	0-8	interleukin 6	Mus musculus	198-202
26002582-10	2015	Luteolin administration significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), malondialdehyde (MDA) levels, as well as glutathione (GSH) depletion and decrease of superoxide dismutase (SOD).	Acetaminophen	48-61	interleukin 6	Mus musculus	183-196
26002582-10	2015	Luteolin administration significantly decreased acetaminophen-induced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), malondialdehyde (MDA) levels, as well as glutathione (GSH) depletion and decrease of superoxide dismutase (SOD).	Acetaminophen	48-61	interleukin 6	Mus musculus	198-202
25655068-6	2015	Preemptive treatment of mice with anti-IL-6R or anti-IL-6 worsened NTN, whereas selective blockade of alternative IL-6 signaling by the fusion protein sgp130Fc did not.	ISONICOTINAMIDINE	67-70	interleukin 6	Mus musculus	53-57
25655068-9	2015	Late application of anti-IL-6 after establishment of adaptive nephritogenic immunity was sufficient to aggravate NTN within 2.5 days, a period when macrophages are active.	ISONICOTINAMIDINE	113-116	interleukin 6	Mus musculus	25-29
25655068-10	2015	Finally, NTN was aggravated in mice with macrophage-specific impairment of IL-6 classic signaling, coincident with enhanced macrophage proliferation and accumulation in the kidney.	ISONICOTINAMIDINE	9-12	interleukin 6	Mus musculus	75-79
26044069-1	2015	Our study was undertaken to evaluate the important role that a disintegrin and metalloproteinase 9 (ADAM9) regulates IL-6 trans-signaling in carbon tetrachloride (CCl4)-induced liver injury in mice.	Carbon Tetrachloride	141-161	interleukin 6	Mus musculus	117-121
25972359-9	2015	BPA tended to decrease serum adiponectin levels and to increase serum interleukin 6 and tumor necrosis factor alpha, although these findings were not statistically significant.	bisphenol A	0-3	interleukin 6	Mus musculus	70-115
25556830-6	2015	In addition, baclofen treatment suppressed dendritic cell (DC)-primed T(H)17 cell differentiation by reducing the production of IL-6 by DCs in vitro.	Baclofen	13-21	interleukin 6	Mus musculus	128-132
25894073-0	2015	Secoiridoid glycosides from the root of Gentiana crassicaulis with inhibitory effects against LPS-induced NO and IL-6 production in RAW264 macrophages.	Iridoid Glycosides	0-22	interleukin 6	Mus musculus	113-117
25750086-6	2015	Among them, 8-epi-kingiside derivatives 1-3; kingiside derivatives 4, 5 and 10; and a sweroside derivative 6 showed inhibition activity against IL-6 production with IC50 values of 51.70-61.10 muM, whereas sweroside derivatives 12 and 15-17 and a swertiamarin derivative 13 showed inhibition effects on both NO and IL-6 productions with IC50 values of 64.74-94.95 and 48.91-75.45 muM, respectively.	8-epi-kingiside	12-27	interleukin 6	Mus musculus	144-148
25750086-6	2015	Among them, 8-epi-kingiside derivatives 1-3; kingiside derivatives 4, 5 and 10; and a sweroside derivative 6 showed inhibition activity against IL-6 production with IC50 values of 51.70-61.10 muM, whereas sweroside derivatives 12 and 15-17 and a swertiamarin derivative 13 showed inhibition effects on both NO and IL-6 productions with IC50 values of 64.74-94.95 and 48.91-75.45 muM, respectively.	8-epi-kingiside	12-27	interleukin 6	Mus musculus	314-318
25750086-6	2015	Among them, 8-epi-kingiside derivatives 1-3; kingiside derivatives 4, 5 and 10; and a sweroside derivative 6 showed inhibition activity against IL-6 production with IC50 values of 51.70-61.10 muM, whereas sweroside derivatives 12 and 15-17 and a swertiamarin derivative 13 showed inhibition effects on both NO and IL-6 productions with IC50 values of 64.74-94.95 and 48.91-75.45 muM, respectively.	Kingiside	18-27	interleukin 6	Mus musculus	144-148
25750086-6	2015	Among them, 8-epi-kingiside derivatives 1-3; kingiside derivatives 4, 5 and 10; and a sweroside derivative 6 showed inhibition activity against IL-6 production with IC50 values of 51.70-61.10 muM, whereas sweroside derivatives 12 and 15-17 and a swertiamarin derivative 13 showed inhibition effects on both NO and IL-6 productions with IC50 values of 64.74-94.95 and 48.91-75.45 muM, respectively.	Kingiside	18-27	interleukin 6	Mus musculus	314-318
25750086-6	2015	Among them, 8-epi-kingiside derivatives 1-3; kingiside derivatives 4, 5 and 10; and a sweroside derivative 6 showed inhibition activity against IL-6 production with IC50 values of 51.70-61.10 muM, whereas sweroside derivatives 12 and 15-17 and a swertiamarin derivative 13 showed inhibition effects on both NO and IL-6 productions with IC50 values of 64.74-94.95 and 48.91-75.45 muM, respectively.	sweroside	86-95	interleukin 6	Mus musculus	144-148
25750086-6	2015	Among them, 8-epi-kingiside derivatives 1-3; kingiside derivatives 4, 5 and 10; and a sweroside derivative 6 showed inhibition activity against IL-6 production with IC50 values of 51.70-61.10 muM, whereas sweroside derivatives 12 and 15-17 and a swertiamarin derivative 13 showed inhibition effects on both NO and IL-6 productions with IC50 values of 64.74-94.95 and 48.91-75.45 muM, respectively.	sweroside	86-95	interleukin 6	Mus musculus	314-318
25750086-6	2015	Among them, 8-epi-kingiside derivatives 1-3; kingiside derivatives 4, 5 and 10; and a sweroside derivative 6 showed inhibition activity against IL-6 production with IC50 values of 51.70-61.10 muM, whereas sweroside derivatives 12 and 15-17 and a swertiamarin derivative 13 showed inhibition effects on both NO and IL-6 productions with IC50 values of 64.74-94.95 and 48.91-75.45 muM, respectively.	sweroside	205-214	interleukin 6	Mus musculus	144-148
25750086-6	2015	Among them, 8-epi-kingiside derivatives 1-3; kingiside derivatives 4, 5 and 10; and a sweroside derivative 6 showed inhibition activity against IL-6 production with IC50 values of 51.70-61.10 muM, whereas sweroside derivatives 12 and 15-17 and a swertiamarin derivative 13 showed inhibition effects on both NO and IL-6 productions with IC50 values of 64.74-94.95 and 48.91-75.45 muM, respectively.	swertiamarin	246-258	interleukin 6	Mus musculus	144-148
25760811-5	2015	This was supported by screening of immune cytokine mRNAs, including interleukin (IL)-1beta and IL-6 from the skin of DNCB-treated mice.	Dinitrochlorobenzene	117-121	interleukin 6	Mus musculus	95-99
25926522-4	2015	DSS treatment (2.5% in drinking water for 6 days) caused more severe colon inflammation, as evidenced by the presence of higher levels of myeloperoxidase and proinflammatory cytokines [tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1beta], and greater weight loss, colonic tissue damage, and colon shortening, in IE-Cpr-null mice than in WT mice.	Dextran Sulfate	0-3	interleukin 6	Mus musculus	214-232
25362520-6	2015	RESULTS: In the NaHS(-) group, severe IRI was apparent by the ALT leakage, tissue injury score, apoptosis, lipid peroxidation, and inflammation (higher plasma TNF-alpha, IL-6, IL-1beta, IFN-gamma, IL-23, IL-17, and CD40L), whereas IRI was significantly ameliorated in the NaHS(+) group.	sodium bisulfide	16-20	interleukin 6	Mus musculus	170-174
25739325-10	2015	Increased production of nitric oxide, C-reactive proteins, and various pro-inflammatory cytokines (TNF-alpha, interleukin-1beta, and interleukin-6) in LPS-stimulated macrophages was significantly reduced by MZ treatment.	meso-zeaxanthin	207-209	interleukin 6	Mus musculus	133-146
26132856-8	2015	Oxysophocarpine significantly suppressed over-expression of cyclooxygenase-2, tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 and prostaglandin E2, and inhibited the over-phosphorylation of extracellular signal-regulated kinase 1/2.	oxysophocarpine	0-15	interleukin 6	Mus musculus	127-140
26132856-9	2015	Based on these findings we propose that oxysophocarpine attenuates inflammatory pain by suppressing the levels of phosphorylation of extracellular signal-regulated kinase 1/2, cyclooxygenase-2, prostaglandin E2, tumor necrosis factor alpha, interleukin-1 beta and interleukin-6.	oxysophocarpine	40-55	interleukin 6	Mus musculus	264-277
25913072-2	2015	alpha-Chaconine inhibited the expressions of cyclooxygenase-2 (COX-2), interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha) at the transcriptional level, and attenuated the transcriptional activity of activator protein-1 (AP-1) by reducing the translocation and phosphorylation of c-Jun.	alpha-chaconine	0-15	interleukin 6	Mus musculus	101-105
25850816-5	2015	We define the pathway of kynurenine induced aryl hydrocarbon receptor activation in MSCs and how it contributes to the upregulation of COX2 expression and IL-6 downregulation.	Kynurenine	25-35	interleukin 6	Mus musculus	155-159
26111969-6	2015	Over-expression of miR-19a ameliorated IL-6-induced reduced glycogen synthesis in hepatocytes.	Glycogen	60-68	interleukin 6	Mus musculus	39-43
26066467-6	2015	Furthermore, the combination of DSS and WAS increased interleukin-6 and growth regulated oncogene-alpha levels in the brain.	Dextran Sulfate	32-35	interleukin 6	Mus musculus	54-67
26100532-11	2015	CONCLUSIONS: L-lysine treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity.	Lysine	13-21	interleukin 6	Mus musculus	145-149
26100532-11	2015	CONCLUSIONS: L-lysine treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity.	Arginine	79-89	interleukin 6	Mus musculus	145-149
26090808-6	2015	Moreover, in vivo administration of GB promoted up-regulation of CD86, MHC class I and MHC class II and production of IL-6, IL-12 and TNF-alpha in spleen DCs.	gb	36-38	interleukin 6	Mus musculus	118-122
26023864-3	2015	Both BF3-1 and mixture of these cyanidins at the same ratio reduced lipopolysaccharide (LPS)-induced protein level of iNOS expression and suppressed mRNA and protein expressions of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-1beta through inhibiting the phosphorylation of mitogen-activated protein kinases (MAPKs) and STAT3 in murine macrophage RAW264.7 cells.	cyanidin	32-41	interleukin 6	Mus musculus	216-234
26041432-8	2015	Significant increases in gene expression (TNF-alpha, IL-6, Nos3; p&lt;0.01; NOX4; p&lt;0.05) were observed in JC and ZH+NiSO4, as well as significantly higher concentrations of VEGF and IL-10 (p&lt;0.01, p&lt;0.001; respectively).	zh	117-119	interleukin 6	Mus musculus	53-57
26074695-5	2015	Resveratrol can also regulate the level of plasma and intestinal mucosal cytokines including interleukin (IL)-10, transforming growth factor-beta1, IL-6, and IL-17.	Resveratrol	0-11	interleukin 6	Mus musculus	148-152
25911098-10	2015	This suggests that HlyA induces ATP release from renal epithelia, which via P2Y2 receptors is the main mediator of HlyA-induced [Ca(2+)]i oscillations and IL-6 release.	Adenosine Triphosphate	32-35	interleukin 6	Mus musculus	155-159
26041432-8	2015	Significant increases in gene expression (TNF-alpha, IL-6, Nos3; p&lt;0.01; NOX4; p&lt;0.05) were observed in JC and ZH+NiSO4, as well as significantly higher concentrations of VEGF and IL-10 (p&lt;0.01, p&lt;0.001; respectively).	nickel sulfate	120-125	interleukin 6	Mus musculus	53-57
25586964-8	2015	The levels of pro-inflammatory cytokines (TNF-alpha, IL-6, and 1L-1beta) were significantly lower in the serum of sappanchalcone-treated mice as compared with the control group.	sappanchalcone	114-128	interleukin 6	Mus musculus	53-57
25907044-8	2015	Furthermore, it is shown that the level of both IL-1beta and IL-6 is correlated with the composition of biominerals, in particular the ratio of Mg(Sr) to Ca, and the pH sensitivity of biominerals.	Magnesium	144-146	interleukin 6	Mus musculus	61-65
25907044-8	2015	Furthermore, it is shown that the level of both IL-1beta and IL-6 is correlated with the composition of biominerals, in particular the ratio of Mg(Sr) to Ca, and the pH sensitivity of biominerals.	Strontium	147-149	interleukin 6	Mus musculus	61-65
26077892-5	2015	ETT (1.0 g/kg po) reduced the level of malondialdehyde in the edemic paw by increasing the activity of antioxidant enzymes, e.g., superoxide dismutase and glutathione reductase, in the liver and reducing TNF-alpha, IL-1beta, and IL-6 activity in the edemic paw.	ett	0-3	interleukin 6	Mus musculus	229-233
25651822-8	2015	Similarly, treatment with YM-58483 after the onset of CIA: (i) reversed the clinical scores; (ii) reduced paw oedema; (iii) attenuated mechanical and thermal hypersensitivity; (iv) improved spontaneous motor activity; (v) decreased periphery production of IL-1beta, IL-6 and TNF-alpha; and (vi) reduced spinal activation of ERK and calmodulin-dependent PKII (CaMKIIalpha).	4-methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide	26-34	interleukin 6	Mus musculus	266-270
25713055-5	2015	We report that intestinally targeted transgenic 15-LOX-1 expression in mice inhibited azoxymethane- and dextran sodium sulfate-induced CAC, IL-6 expression, STAT3 phosphorylation, and IL-6/STAT3 downstream target (Notch3 and MUC1) expression.	Azoxymethane	86-98	interleukin 6	Mus musculus	184-188
25713055-5	2015	We report that intestinally targeted transgenic 15-LOX-1 expression in mice inhibited azoxymethane- and dextran sodium sulfate-induced CAC, IL-6 expression, STAT3 phosphorylation, and IL-6/STAT3 downstream target (Notch3 and MUC1) expression.	dextran sodium sulfate	104-126	interleukin 6	Mus musculus	184-188
25613226-7	2015	Furthermore, icariin or DEX caused a significant reduction in IL-6, IL-17 and TGF-beta level in BALF.	icariin	13-20	interleukin 6	Mus musculus	62-66
25572867-5	2015	Analysis of cytokines in gastric tissue and serum of ethanol-induced mice showed the levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) were decreased by delta-amyrone in response to NF-kappaB p65.	Ethanol	53-60	interleukin 6	Mus musculus	139-152
25613226-7	2015	Furthermore, icariin or DEX caused a significant reduction in IL-6, IL-17 and TGF-beta level in BALF.	Dextromethorphan	24-27	interleukin 6	Mus musculus	62-66
25572867-5	2015	Analysis of cytokines in gastric tissue and serum of ethanol-induced mice showed the levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) were decreased by delta-amyrone in response to NF-kappaB p65.	Ethanol	53-60	interleukin 6	Mus musculus	154-158
25870195-6	2015	Furthermore, compared with wild-type mice, ghrelin knockout mice showed suppression of the cholinergic anti-inflammatory pathway, as indicated by reduced parasympathetic nerve activity and higher plasma interleukin-1beta and interleukin-6 levels.	Ghrelin	43-50	interleukin 6	Mus musculus	225-238
25572867-5	2015	Analysis of cytokines in gastric tissue and serum of ethanol-induced mice showed the levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) were decreased by delta-amyrone in response to NF-kappaB p65.	amyrone	178-191	interleukin 6	Mus musculus	139-152
25572867-5	2015	Analysis of cytokines in gastric tissue and serum of ethanol-induced mice showed the levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) were decreased by delta-amyrone in response to NF-kappaB p65.	amyrone	178-191	interleukin 6	Mus musculus	154-158
25572867-6	2015	These results suggested that delta-amyrone exerts its protective effect on experimental gastric ulcer by inhibiting NF-kappaB signaling pathways, which subsequently reduces overproduction of the inducible enzymes iNOS and suppresses the release of the inflammatory factors TNF-alpha, IL-6 and NO.	amyrone	29-42	interleukin 6	Mus musculus	284-288
25382637-0	2015	C/EBPbeta promotes angiogenesis through secretion of IL-6, which is inhibited by genistein, in EGFRvIII-positive glioblastoma.	Genistein	81-90	interleukin 6	Mus musculus	53-57
25382637-6	2015	In contrast, genistein-mediated upregulation of CHOP impeded C/EBPbeta interaction with the IL-6 promoter, thus disturbing the angiogenic microenvironment.	Genistein	13-22	interleukin 6	Mus musculus	92-96
25914167-0	2015	IL-6 trans-signaling plays important protective roles in acute liver injury induced by acetaminophen in mice.	Acetaminophen	87-100	interleukin 6	Mus musculus	0-4
25907238-4	2015	The results showed that D(-)-Salicin markedly decreased TNF-alpha, IL-1beta and IL-6 concentrations and increased IL-10 concentration.	salicin	24-36	interleukin 6	Mus musculus	80-84
25914167-1	2015	Our study was undertaken to evaluate the important role of interleukin-6 (IL-6) trans-signaling in acetaminophen (AAP)-induced liver injury.	Acetaminophen	99-112	interleukin 6	Mus musculus	59-72
25914167-1	2015	Our study was undertaken to evaluate the important role of interleukin-6 (IL-6) trans-signaling in acetaminophen (AAP)-induced liver injury.	Acetaminophen	99-112	interleukin 6	Mus musculus	74-78
25914167-1	2015	Our study was undertaken to evaluate the important role of interleukin-6 (IL-6) trans-signaling in acetaminophen (AAP)-induced liver injury.	Acetaminophen	114-117	interleukin 6	Mus musculus	59-72
25914167-1	2015	Our study was undertaken to evaluate the important role of interleukin-6 (IL-6) trans-signaling in acetaminophen (AAP)-induced liver injury.	Acetaminophen	114-117	interleukin 6	Mus musculus	74-78
25914167-5	2015	In summary, our study suggested that IL-6 trans-signaling plays important protective roles by regulating the hepatocyte proliferation and apoptosis, angiogenesis, CYP2E1 expression, and glycogen metabolism during AAP-induced liver injury in mice.	Glycogen	186-194	interleukin 6	Mus musculus	37-41
25530272-11	2015	The expression of IL-6 in the sera was lower in the mice treated with Tubastatin A compared with the control.	tubastatin A	70-82	interleukin 6	Mus musculus	18-22
25530272-13	2015	CONCLUSIONS: Tubastatin A successfully ameliorated synovial inflammation and protected against joint destruction in CAIA mice, at least in part, by modulating IL-6 expression.	tubastatin A	13-25	interleukin 6	Mus musculus	159-163
25914167-5	2015	In summary, our study suggested that IL-6 trans-signaling plays important protective roles by regulating the hepatocyte proliferation and apoptosis, angiogenesis, CYP2E1 expression, and glycogen metabolism during AAP-induced liver injury in mice.	Acetaminophen	213-216	interleukin 6	Mus musculus	37-41
25862641-3	2015	Our previous studies have found that a curcumin analog, L48H37 [1-ethyl-3,5-bis(3,4,5-trimethoxybenzylidene)piperidin-4-one], was able to inhibit LPS-induced inflammation, particularly tumor necrosis factor alpha and interleukin 6 production and gene expression in mouse macrophages.	L48H37	64-123	interleukin 6	Mus musculus	217-230
26823989-8	2015	WT diabetic mice displayed elevation in renal interleukin-6 (IL-6) levels and these changes were only reduced in diabetic mice treated with baicalein for 10 weeks (P&lt;0.05).	baicalein	140-149	interleukin 6	Mus musculus	46-59
26823989-8	2015	WT diabetic mice displayed elevation in renal interleukin-6 (IL-6) levels and these changes were only reduced in diabetic mice treated with baicalein for 10 weeks (P&lt;0.05).	baicalein	140-149	interleukin 6	Mus musculus	61-65
25862641-3	2015	Our previous studies have found that a curcumin analog, L48H37 [1-ethyl-3,5-bis(3,4,5-trimethoxybenzylidene)piperidin-4-one], was able to inhibit LPS-induced inflammation, particularly tumor necrosis factor alpha and interleukin 6 production and gene expression in mouse macrophages.	Curcumin	39-47	interleukin 6	Mus musculus	217-230
25634255-6	2015	Furthermore, treatment with emodin (40 mg/ml) markedly inhibited phosphoinositide 3-kinase (PI3K)/Akt activity (P&lt;0.01) and this attenuation was associated with reduced expression levels of tumor necrosis factor-alpha, interleukin-6 and monocyte chemoattractant protein-1 (P&lt;0.05) in the HS tissue.	Emodin	28-34	interleukin 6	Mus musculus	222-235
25862641-3	2015	Our previous studies have found that a curcumin analog, L48H37 [1-ethyl-3,5-bis(3,4,5-trimethoxybenzylidene)piperidin-4-one], was able to inhibit LPS-induced inflammation, particularly tumor necrosis factor alpha and interleukin 6 production and gene expression in mouse macrophages.	1-ethyl-3,5-bis[(3,4,5-trimethoxyphenyl)methylidene]piperidin-4-one	56-62	interleukin 6	Mus musculus	217-230
25824337-8	2015	Moreover, the IL6-induced changes in C57 mice, including augmented MDSC recruitment, increased levels of ROS and p-Stat3 in MDSCs, and higher suppressive function of MDSCs in T-cell proliferation, which were abrogated by calcitriol supplementation.	ros	105-108	interleukin 6	Mus musculus	14-17
25824337-8	2015	Moreover, the IL6-induced changes in C57 mice, including augmented MDSC recruitment, increased levels of ROS and p-Stat3 in MDSCs, and higher suppressive function of MDSCs in T-cell proliferation, which were abrogated by calcitriol supplementation.	Calcitriol	221-231	interleukin 6	Mus musculus	14-17
25858541-5	2015	C-DIM12 inhibited lipopolysaccharide (LPS)-induced expression of NF-kappaB-regulated genes in BV-2 microglia including nitric oxide synthase (NOS2), interleukin-6 (IL-6), and chemokine (C-C motif) ligand 2 (CCL2), and the effects were attenuated by Nurr1-RNA interference.	C-DIM12	0-7	interleukin 6	Mus musculus	149-162
25858541-5	2015	C-DIM12 inhibited lipopolysaccharide (LPS)-induced expression of NF-kappaB-regulated genes in BV-2 microglia including nitric oxide synthase (NOS2), interleukin-6 (IL-6), and chemokine (C-C motif) ligand 2 (CCL2), and the effects were attenuated by Nurr1-RNA interference.	C-DIM12	0-7	interleukin 6	Mus musculus	164-168
25921297-7	2015	Partial block of NFkappaB activation (SN50; 46%, or, BAY-11-7082; 41%) lowered IL-6 to a greater extent than TNFalpha mRNA expression.	3-(4-methylphenylsulfonyl)-2-propenenitrile	53-64	interleukin 6	Mus musculus	79-83
25921297-0	2015	Docosahexaenoic acid differentially affects TNFalpha and IL-6 expression in LPS-stimulated RAW 264.7 murine macrophages.	Docosahexaenoic Acids	0-20	interleukin 6	Mus musculus	57-61
25921297-1	2015	Docosahexaenoic acid (DHA) is generally reported to have anti-inflammatory properties, however, prior work has documented differential effects on individual pro-inflammatory cytokines: reduced IL-6, but not TNFalpha, mRNA expression in macrophages.	Docosahexaenoic Acids	0-20	interleukin 6	Mus musculus	193-197
25921297-1	2015	Docosahexaenoic acid (DHA) is generally reported to have anti-inflammatory properties, however, prior work has documented differential effects on individual pro-inflammatory cytokines: reduced IL-6, but not TNFalpha, mRNA expression in macrophages.	Docosahexaenoic Acids	22-25	interleukin 6	Mus musculus	193-197
25921297-8	2015	The differential effect of DHA on TNFalpha and IL-6 mRNA expression may be mediated via reduction in NFkappaB activity.	Docosahexaenoic Acids	27-30	interleukin 6	Mus musculus	47-51
26006045-11	2015	Using the TRPV4 agonist GSK1016790A, the antagonist HC-067047, and the cytokine IL-6 as a marker of inflammation, we observed that TRPV4 regulates release of IL-6 via p38 and ERK pathways.	N-(1-((4-(2-(((2,4-dichlorophenyl)sulfonyl)amino)-3-hydroxypropanoyl)-1-piperazinyl)carbonyl)-3-methylbutyl)-1-benzothiophene-2-carboxamide	24-35	interleukin 6	Mus musculus	158-162
25931465-7	2015	Pioglitazone treatment reduced the mRNA levels of inflammatory cytokines (monocyte chemoattractant factor-1, interleukin-1, and interleukin-6) that are primarily produced by macrophages in the cerebral arteries.	Pioglitazone	0-12	interleukin 6	Mus musculus	128-141
26942057-3	2016	Cryoablation involves killing of tumor cells through freezing and thawing, resulting in recruitment of tumor-specific T cells, while curcumin stimulates T cells through the reduction of IL-6 in the TME.	Curcumin	133-141	interleukin 6	Mus musculus	186-190
25843059-6	2015	Using qRT-PCR as a follow up to the array, we demonstrated that didox suppresses LPS-induced mRNA levels of iNOS, IL-6, IL-1, TNF-alpha, NF-kappabeta (p65), and p38-alpha, after 24h of treatment.	3,4-dihydroxybenzohydroxamic acid	64-69	interleukin 6	Mus musculus	114-118
25843059-7	2015	Treatment with didox also suppresses the secretion of nitric oxide, IL-6, and IL-10.	3,4-dihydroxybenzohydroxamic acid	15-20	interleukin 6	Mus musculus	68-72
26000566-6	2015	Levels of inflammation markers, including glial fibrillary acidic protein (GFAP), ionized calcium-binding adapter molecule1 (Iba1) and interleukin6 (IL6), were significantly reduced in minocycline-treated Dicer cKO mice.	Minocycline	185-196	interleukin 6	Mus musculus	135-147
26000566-6	2015	Levels of inflammation markers, including glial fibrillary acidic protein (GFAP), ionized calcium-binding adapter molecule1 (Iba1) and interleukin6 (IL6), were significantly reduced in minocycline-treated Dicer cKO mice.	Minocycline	185-196	interleukin 6	Mus musculus	149-152
25747147-10	2015	RESULTS: SP inhibited the LPS-stimulated release of proinflammatory mediators, such as nitric oxide and interleukin (IL)-6 in RAW 264.7 cells.	sp	9-11	interleukin 6	Mus musculus	104-122
25818525-7	2015	RESULTS: The results showed that fucosterol attenuated lung histopathologic changes, wet-to-dry ratio, and tumor necrosis factor-alpha, interleukin (IL)-6 and IL-1beta production in LPS-induced ALI in mice.	fucosterol	33-43	interleukin 6	Mus musculus	136-154
25818525-8	2015	Meanwhile, fucosterol inhibited NF-kappaB activation and tumor necrosis factor-alpha, IL-6, and IL-1beta production in LPS-stimulated alveolar macrophages.	fucosterol	11-21	interleukin 6	Mus musculus	86-90
25895126-5	2015	Metformin treatment in RD and HED mice resulted in a significant reduction in tumor burden in the peritoneum, liver, kidney, spleen and bowel accompanied by decreased levels of growth factors (IGF-1, insulin and leptin), inflammatory cytokines (MCP-1, IL-6) and VEGF in plasma and ascitic fluid, akin to the CR diet mice.	Metformin	0-9	interleukin 6	Mus musculus	252-256
25820907-7	2015	Lactate dehydrogenase release and crystal violet staining revealed that IL-27 or IL-6 significantly attenuated severe hypoxia (SH, 2 % O2)-induced cell damage in H9c2 cardiomyoblasts and primary rat neonatal cardiomyocytes.	Gentian Violet	34-48	interleukin 6	Mus musculus	81-85
25987769-12	2015	DHM could significantly decrease serum ALT, AST, IL-1beta, IL-6 and TNF-alpha and increase serum albumin, SOD and liver SOD compared to the control group after CCl4 treatment (P &lt; 0.05).	dihydromyricetin	0-3	interleukin 6	Mus musculus	59-63
26086027-8	2015	Our study results show ABQ 48 and NBQ-48 to stimulate the release of G-CSF, IL-2, IL-6, and, IFN-gamma when mouse splenocytes are incubated with serial dilutions of these agents.	abq 48	23-29	interleukin 6	Mus musculus	82-86
26086027-8	2015	Our study results show ABQ 48 and NBQ-48 to stimulate the release of G-CSF, IL-2, IL-6, and, IFN-gamma when mouse splenocytes are incubated with serial dilutions of these agents.	nbq-48	34-40	interleukin 6	Mus musculus	82-86
25820907-7	2015	Lactate dehydrogenase release and crystal violet staining revealed that IL-27 or IL-6 significantly attenuated severe hypoxia (SH, 2 % O2)-induced cell damage in H9c2 cardiomyoblasts and primary rat neonatal cardiomyocytes.	Oxygen	135-137	interleukin 6	Mus musculus	81-85
25637482-4	2015	We found a strong immune response in the gut of mice treated with MPTP, as demonstrated by the prominent presence of macrophages derived from CD115(+) CD11b(+) Ly6C(Hi) monocytes, known as M1 monocytes, and increased production of IL-1beta and IL-6.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	66-70	interleukin 6	Mus musculus	244-248
25558818-6	2015	Moreover, gamma-EC and gamma-EV reduced the expression of TNF-alpha, IL-6, INF-gamma, IL-1beta, and IL-17, and increased the expression of IL-10 in the colon, in a CaSR-dependent manner.	gamma-ec	10-18	interleukin 6	Mus musculus	69-73
25558818-6	2015	Moreover, gamma-EC and gamma-EV reduced the expression of TNF-alpha, IL-6, INF-gamma, IL-1beta, and IL-17, and increased the expression of IL-10 in the colon, in a CaSR-dependent manner.	gamma-ev	23-31	interleukin 6	Mus musculus	69-73
25660446-6	2015	Il-6 overexpression elevated mRNA levels of lipolysis genes, triggered phosphorylation of STAT3, AMPK, and ACC, and increased expression of genes involved in fatty acid oxidation in skeletal muscle.	Fatty Acids	158-168	interleukin 6	Mus musculus	0-4
25683697-7	2015	Pro-inflammatory cytokine interleukin-6 (Il6) and Chrna7 gene expression in the wild-type fetal brain were elevated by poly(I:C) injection and were suppressed by gestational choline supplementation.	Choline	174-181	interleukin 6	Mus musculus	26-39
25739561-17	2015	Curcumin blocked lipopolysaccharide-upregulated expression of tumour necrosis factor-alpha, IL-1beta, and IL-6.	Curcumin	0-8	interleukin 6	Mus musculus	106-110
25683697-7	2015	Pro-inflammatory cytokine interleukin-6 (Il6) and Chrna7 gene expression in the wild-type fetal brain were elevated by poly(I:C) injection and were suppressed by gestational choline supplementation.	Choline	174-181	interleukin 6	Mus musculus	41-44
25701613-9	2015	Moreover, 24days of imipramine treatment in RSD mice significantly decreased stress-induced mRNA levels for IL-6 in brain microglia.	Imipramine	20-30	interleukin 6	Mus musculus	108-112
25701613-10	2015	Following ex vivo LPS stimulation, microglia from mice exposed to RSD, had higher mRNA expression of IL-6, TNF-alpha, and IL-1beta, and this was reversed by imipramine treatment.	Imipramine	157-167	interleukin 6	Mus musculus	101-105
25701613-11	2015	In a second experiment, imipramine was added to drinking water confirming the reversal of social avoidant behavior and decrease in mRNA expression of IL-6 in microglia.	Imipramine	24-34	interleukin 6	Mus musculus	150-154
25531554-10	2015	The erlotinib treatment of abdominal aorta was associated with lack of EGFR activation, endoplasmic reticulum (ER) stress, oxidative stress, interleukin-6 induction and matrix deposition.	Erlotinib Hydrochloride	4-13	interleukin 6	Mus musculus	141-154
25583360-9	2015	The ethanol-induced expression levels of cyclo-oxygenase-2 (COX-2) and IL-6 were reduced in the livers of IL-32gamma mice.	Ethanol	4-11	interleukin 6	Mus musculus	71-75
25749189-9	2015	Regarding the levels of inflammatory mediators, pilocarpine injection increased interleukin (IL) 6 in the hippocampus of WT and PI3Kgamma(-/-) animals and in the prefrontal cortex of PI3Kgamma(-/-) animals 24h after the stimulus.	Pilocarpine	48-59	interleukin 6	Mus musculus	80-98
25492506-10	2015	Notably, inhibition of HDAC abolished taurocholate-induced gene expression of cyclooxygenase-2, MIP-2, monocyte chemotactic protein-1, IL-6, and IL-1beta in the pancreas.	Taurocholic Acid	38-50	interleukin 6	Mus musculus	135-139
25737197-6	2015	Oral administration of PGG strongly suppressed production of type 2 T helper (IL-4 and IL-13), type 1 T helper (IFN-gamma), and pro-inflammatory cytokines (TNF-alpha and IL-6), but not anti-inflammatory cytokine (IL-10) from splenocytes of OVA-sensitized mice against OVA re-stimulation.	pgg	23-26	interleukin 6	Mus musculus	170-174
25911309-7	2015	Double immunofluorescence study of the lungs of the BrdU-exposed mice showed overexpression of IL-6 in the airway epithelial and alveolar wall cells, some of which were also double-positive for BrdU.	Bromodeoxyuridine	52-56	interleukin 6	Mus musculus	95-99
25601969-11	2015	Hua-Jian-Ba-Du Ointment at high or moderate dosage inhibited the release of TNF-alpha, IL-6, and PGE2, as well as increased the release of IL-2.	Barium	8-11	interleukin 6	Mus musculus	87-91
25601969-11	2015	Hua-Jian-Ba-Du Ointment at high or moderate dosage inhibited the release of TNF-alpha, IL-6, and PGE2, as well as increased the release of IL-2.	du	12-14	interleukin 6	Mus musculus	87-91
25311527-8	2015	Furthermore, mice treated with high-dose liquiritigenin experienced significantly suppressed tumor necrosis factor-alpha, IL-1beta, and IL-6 as well as enhanced IL-10 expression (all P &lt; 0.05).	liquiritigenin	41-55	interleukin 6	Mus musculus	136-140
25819229-6	2015	The expression of IL-17 and other proinflammatory cytokines, including IL-1beta, IL-6, TNF-alpha and IL-21, were markedly reduced in the arthritic joints of digoxin-treated CIA mice.	Digoxin	157-164	interleukin 6	Mus musculus	81-85
25586053-0	2015	Baicalin inhibits the expression of monocyte chemoattractant protein-1 and interleukin-6 in the kidneys of apolipoprotein E-knockout mice fed a high cholesterol diet.	baicalin	0-8	interleukin 6	Mus musculus	75-88
25687616-4	2015	Our data demonstrated that these three test 18-carbon PUFAs can inhibit PA-induced interleukin-6 and tumor necrosis factor-alpha messenger RNA (mRNA) expression and IR as evidenced by increases in phosphorylated AKT and the 160-kD AKT substrate, mRNA and plasma membrane protein expression of glucose transporter 4, and glucose uptake.	carbon pufas	47-59	interleukin 6	Mus musculus	83-128
25687616-4	2015	Our data demonstrated that these three test 18-carbon PUFAs can inhibit PA-induced interleukin-6 and tumor necrosis factor-alpha messenger RNA (mRNA) expression and IR as evidenced by increases in phosphorylated AKT and the 160-kD AKT substrate, mRNA and plasma membrane protein expression of glucose transporter 4, and glucose uptake.	Palmitic Acid	72-74	interleukin 6	Mus musculus	83-128
25687616-4	2015	Our data demonstrated that these three test 18-carbon PUFAs can inhibit PA-induced interleukin-6 and tumor necrosis factor-alpha messenger RNA (mRNA) expression and IR as evidenced by increases in phosphorylated AKT and the 160-kD AKT substrate, mRNA and plasma membrane protein expression of glucose transporter 4, and glucose uptake.	Glucose	293-300	interleukin 6	Mus musculus	83-128
25586053-9	2015	The expression levels of VCAM-1, MCP-1 and IL-6 in the kidney tissues of the baicalin group were lower compared with those in the high cholesterol diet control group.	baicalin	77-85	interleukin 6	Mus musculus	43-47
25586053-3	2015	The present study investigated whether baicalin can attenuate the expression of vascular cell adhesion molecule 1 (VCAM-1) via a reduction in the expression of monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) in the kidney of apolipoprotein E (ApoE)-knockout (KO) mice fed a high cholesterol diet.	baicalin	39-47	interleukin 6	Mus musculus	207-220
25586053-3	2015	The present study investigated whether baicalin can attenuate the expression of vascular cell adhesion molecule 1 (VCAM-1) via a reduction in the expression of monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) in the kidney of apolipoprotein E (ApoE)-knockout (KO) mice fed a high cholesterol diet.	baicalin	39-47	interleukin 6	Mus musculus	222-226
25461302-10	2015	Sodium sulfide inhibited IL-6-induced activation of primary microglia.	sodium sulfide	0-14	interleukin 6	Mus musculus	25-29
25797259-5	2015	In tumor-bearing mice under chemotherapy, supplementation with fish oil and selenium prevented a rise in IL-6, TNF-alpha and myostatin and muscle atrophy.	Selenium	76-84	interleukin 6	Mus musculus	105-109
25865044-0	2015	Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3.	icaritin	0-8	interleukin 6	Mus musculus	52-56
25865044-6	2015	We also demonstrated that in MM xenograft mouse models, icaritin suppressed tumor growth and decreased serum IL-6 and IgE levels, but did not show adverse reactions such as body weight loss.	icaritin	56-64	interleukin 6	Mus musculus	109-113
25865044-7	2015	The anti-MM activity of icaritin was mainly mediated by inhibiting IL-6/JAK2/STAT3 signaling.	icaritin	24-32	interleukin 6	Mus musculus	67-71
25913077-10	2015	Lower IL-2 and IL-6 levels in treatment groups compared with controls suggest that PAHs cause overt immune inhibition.	Polycyclic Aromatic Hydrocarbons	83-87	interleukin 6	Mus musculus	15-19
25896053-9	2015	The results revealed that compared with control, the DSS mouse showed weight loss (P &lt; 0.05), a shortened colon (P &lt; 0.05), and swelled spleen (P &lt; 0.05), accompanied by higher histological score (P &lt; 0.05), as well as infiltration of macrophages, elevated TNF-alpha and IL-6 levels in plasma (P &lt; 0.01).	Dextran Sulfate	53-56	interleukin 6	Mus musculus	283-287
25896053-12	2015	In vitro, TNF-alpha and IL-6 levels were increased in the supernatant of macrophages from DSS mice colonic tissue (P &lt; 0.05), and after incubation of TNF-alpha or IL-6 with colonic mucosal microvascular endothelial cells, the APC activity was decreased (P &lt; 0.05 or P &lt; 0.01), and expression of EPCR was down regulated (P &lt; 0.05).	Dextran Sulfate	90-93	interleukin 6	Mus musculus	24-28
25738814-3	2015	Lactococcus lactis IL1403, a food-grade strain of lactic acid bacteria (LAB) which is widely used in dairy industry, was used as a host cell to express and secrete the IL-6-CKS9 for a mucosal vaccine adjuvant.	Lactic Acid	50-61	interleukin 6	Mus musculus	168-177
25892964-6	2015	First, we found insulin pre-administration alleviated acute ethanol exposure-induced liver injury and inflammation reflected by the decrease of serum AST and ALT activities, the improvement of pathological alteration and the inhibition of TNF-alpha and IL-6 expressions.	Ethanol	60-67	interleukin 6	Mus musculus	253-257
25871292-0	2015	Diphlorethohydroxycarmalol inhibits interleukin-6 production by regulating NF-kappaB, STAT5 and SOCS1 in lipopolysaccharide-stimulated RAW264.7 cells.	diphlorethohydroxycarmalol	0-26	interleukin 6	Mus musculus	36-49
25871292-3	2015	We found that DPHC strongly reduces the production of interleukin 6 (IL-6), but not that of tumor necrosis factor-alpha (TNF-alpha) induced by LPS.	diphlorethohydroxycarmalol	14-18	interleukin 6	Mus musculus	54-67
25871292-3	2015	We found that DPHC strongly reduces the production of interleukin 6 (IL-6), but not that of tumor necrosis factor-alpha (TNF-alpha) induced by LPS.	diphlorethohydroxycarmalol	14-18	interleukin 6	Mus musculus	69-73
25871292-7	2015	Furthermore, N-tosyl-l-phenylalanine chloromethyl ketone (TPCK) (a specific NF-kappaB inhibitor) and JI (a specific Jak2 inhibitor) reduced the production of IL-6, but not that of tumor necrosis factor-alpha (TNF-alpha) in LPS-stimulated RAW 264.7 macrophages.	PHENYLALANYLMETHYLCHLORIDE	21-56	interleukin 6	Mus musculus	158-162
25871292-8	2015	These findings demonstrate that DPHC inhibits IL-6 production via the downregulation of NF-kappaB and Jak2-STAT5 pathway and upregulation of SOCS1.	diphlorethohydroxycarmalol	32-36	interleukin 6	Mus musculus	46-50
28962394-7	2015	IP6 administration to the predisposed mothers prevented the proliferation, inflammation and enhanced apoptosis in F1 lung as showed by a reduction in PCNA, NF-kappaB (p50), IL-6, COX-2, pSTAT3, STAT3, miR-155 and increase in caspases, cleavage of poly (ADP-ribose) polymerase.	Phytic Acid	0-3	interleukin 6	Mus musculus	173-177
25838003-1	2015	Endotoxic responses to bacterial lipopolysaccharide (LPS) are triggered by Toll-like receptor 4 (TLR4) and involve the production of inflammatory mediators, including interleukin-6 (IL-6), by macrophages.	bacterial lipopolysaccharide	23-51	interleukin 6	Mus musculus	167-180
25838003-1	2015	Endotoxic responses to bacterial lipopolysaccharide (LPS) are triggered by Toll-like receptor 4 (TLR4) and involve the production of inflammatory mediators, including interleukin-6 (IL-6), by macrophages.	bacterial lipopolysaccharide	23-51	interleukin 6	Mus musculus	182-186
25514628-10	2015	On the other hand, STZ-induced diabetic mice presented significant increases in pulmonary neutrophil infiltration, pro-inflammatory cytokines (IL-1beta and IL-6) production, as well as TLR4 expression.	Streptozocin	19-22	interleukin 6	Mus musculus	156-160
25028260-7	2015	The expression of IL-1beta, IL-6, and GFAP was increased in Pb-exposed groups in comparison with the control group (p &lt; 0.05).	Lead	60-62	interleukin 6	Mus musculus	28-32
25581346-5	2015	Furthermore, our findings establish that activation of the TLR-dependent and TLR-independent DNA recognition pathways through combined use of CpG oligonucleotide (ODN) and CDN results in synergistic activity, augmenting cytokine production (IFN-alpha/beta, IL-6, TNF-alpha, IP-10), costimulatory molecule upregulation (MHC class II, CD86), and antigen-specific humoral and cellular immunity.	Oligonucleotides	146-161	interleukin 6	Mus musculus	257-261
25028260-8	2015	The high expression of IL-1beta, IL-6, and GFAP in the hippocampus of pups may contribute to the neurotoxicity associated with maternal Pb exposure.	Lead	136-138	interleukin 6	Mus musculus	33-37
25005005-5	2015	The results showed that punicalagin treatment attenuated LPS-induced lung edema, elevating TNF-alpha, IL-6, and IL-1beta levels in the bronchoalveolar lavage fluid (BALF).	punicalagin	24-35	interleukin 6	Mus musculus	102-106
24950782-9	2015	Cisplatin increased the renal production of the proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and transforming growth factor (TGF)-beta1.	Cisplatin	0-9	interleukin 6	Mus musculus	133-137
25047101-0	2015	MAPK and NF-kappaB pathways are involved in bisphenol A-induced TNF-alpha and IL-6 production in BV2 microglial cells.	bisphenol A	44-55	interleukin 6	Mus musculus	78-82
24958015-4	2015	The treatment of C57BL mice with vitamin D significantly preserves postoperative cognitive function, markedly inhibits surgery-induced interleukin (IL)-17, IL-6, transforming growth factor beta (TGF-beta), and retinoic acid-related orphan receptor (RORgammat) production, and obviously induces IL-10 and forkhead box p3 (Foxp3) expression.	Vitamin D	33-42	interleukin 6	Mus musculus	156-160
25047101-6	2015	Our results indicated that BPA increased BV2 cells activation and simultaneously elevated tumor necrosis factor-alpha and interleukin 6 expression, which could be partially reversed by estrogen receptor antagonist, ICI182780.	bisphenol A	27-30	interleukin 6	Mus musculus	122-135
25047101-6	2015	Our results indicated that BPA increased BV2 cells activation and simultaneously elevated tumor necrosis factor-alpha and interleukin 6 expression, which could be partially reversed by estrogen receptor antagonist, ICI182780.	Fulvestrant	215-224	interleukin 6	Mus musculus	122-135
25373916-7	2015	The data also demonstrated that cavidine significantly inhibited LPS-induced TNF-alpha, interleukin-6 (IL-6), and NO production in peritoneal macrophages.	cavidine	32-40	interleukin 6	Mus musculus	88-101
25373916-7	2015	The data also demonstrated that cavidine significantly inhibited LPS-induced TNF-alpha, interleukin-6 (IL-6), and NO production in peritoneal macrophages.	cavidine	32-40	interleukin 6	Mus musculus	103-107
25749497-5	2015	Thalidomide (Thal) has been used to treat multiple myeloma due to its inhibitory effects on IL-6-induced cell growth.	Thalidomide	0-11	interleukin 6	Mus musculus	92-96
25711693-4	2015	Treatment with AICAR also inhibited the increase of myeloperoxidase (MPO), the induction of TNF-alpha, IL-6, inducible nitric oxide synthase (iNOS), nitric oxide and the upregulation of matrix metalloproteinase 2 (MMP-2), MMP-3 and MMP-9 in mice exposed to CCl4.	acadesine	15-20	interleukin 6	Mus musculus	103-107
25744603-0	2015	Paroxetine differentially modulates LPS-induced TNFalpha and IL-6 production in mouse macrophages.	Paroxetine	0-10	interleukin 6	Mus musculus	61-65
25749497-5	2015	Thalidomide (Thal) has been used to treat multiple myeloma due to its inhibitory effects on IL-6-induced cell growth.	Thalidomide	0-4	interleukin 6	Mus musculus	92-96
25744603-4	2015	Paroxetine treatment of macrophages, however, significantly inhibited LPS-induced IL-6 production.	Paroxetine	0-10	interleukin 6	Mus musculus	82-86
25744603-12	2015	Together these data demonstrate that paroxetine has critical but differential effects on IL-6 and TNFalpha production in macrophages and that it likely regulates these cytokines via distinct mechanisms.	Paroxetine	37-47	interleukin 6	Mus musculus	89-93
25201259-10	2015	In a positive signaling loop HK-1 promoted TNF and IL-6 secretion by MC degranulation and protein synthesis, the latter through the phosphoinositide 3-kinase/Akt/nuclear factor kappaB pathways.	Methylcholanthrene	69-71	interleukin 6	Mus musculus	51-55
25604277-9	2015	Oral therapy with AZM (500 mg/kg) and CIP (30 mg/kg) combination in mice for 4 days showed accelerated clearance of bacteria from kidney and bladder tissue, improved renal histopathology, decreased levels of MDA and NO, significant decline in MIP-2 and IL-6, and increased IL-10 in the kidney (P&lt;0.0001).	Azithromycin	18-21	interleukin 6	Mus musculus	253-257
25042521-6	2015	Apocynin treatment decreased the levels of proinflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6 induced by MG.	Pyruvaldehyde	134-136	interleukin 6	Mus musculus	109-122
25145931-7	2015	Furthermore, the increase in proinflammatory cytokine (CXCL1, MCP-1, TNF-alpha, and IL-6) expression and infiltration of neutrophils and macrophages induced by cisplatin treatment was attenuated by FTY720 in control mice but not in PT-S1P1-null mice.	Cisplatin	160-169	interleukin 6	Mus musculus	84-88
25108596-6	2015	After a relatively short-term treatment of 14 days, 100 mg/kg of baicalin significantly ameliorated memory impairment in the Morris water maze test and probe test, and also attenuated glial cell activations and increase of TNF-alpha and IL-6 expressions induced by Abeta(1-42) protein.	baicalin	65-73	interleukin 6	Mus musculus	237-241
25698557-6	2015	Oral administration of AIII and sarsasapogenin inhibited 2,3,4-trinitrobenzene sulfonic acid (TNBS)-induced colon shortening and myeloperoxidase activity in mice, along with reducing NF-kappaB activation and interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and IL-6 levels, while simultaneously increasing IL-10.	sarsasapogenin	32-46	interleukin 6	Mus musculus	271-275
25698557-6	2015	Oral administration of AIII and sarsasapogenin inhibited 2,3,4-trinitrobenzene sulfonic acid (TNBS)-induced colon shortening and myeloperoxidase activity in mice, along with reducing NF-kappaB activation and interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and IL-6 levels, while simultaneously increasing IL-10.	2,3,4-trinitrobenzene sulfonic acid	57-92	interleukin 6	Mus musculus	271-275
25698557-6	2015	Oral administration of AIII and sarsasapogenin inhibited 2,3,4-trinitrobenzene sulfonic acid (TNBS)-induced colon shortening and myeloperoxidase activity in mice, along with reducing NF-kappaB activation and interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and IL-6 levels, while simultaneously increasing IL-10.	Trinitrobenzenesulfonic Acid	94-98	interleukin 6	Mus musculus	271-275
24930437-6	2015	Mice were injected with turpentine, an established IL-6 inducer.	Turpentine	24-34	interleukin 6	Mus musculus	51-55
25502175-3	2015	In addition, curcumin and tetrahydrocurcumin significantly inhibited the release of prominent cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6); however, hexahydrocurcumin and octahydrocurcumin did not significantly alter cytokine release.	Curcumin	13-21	interleukin 6	Mus musculus	159-172
25502175-3	2015	In addition, curcumin and tetrahydrocurcumin significantly inhibited the release of prominent cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6); however, hexahydrocurcumin and octahydrocurcumin did not significantly alter cytokine release.	Curcumin	13-21	interleukin 6	Mus musculus	174-178
25502175-3	2015	In addition, curcumin and tetrahydrocurcumin significantly inhibited the release of prominent cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6); however, hexahydrocurcumin and octahydrocurcumin did not significantly alter cytokine release.	tetrahydrocurcumin	26-44	interleukin 6	Mus musculus	159-172
25502175-3	2015	In addition, curcumin and tetrahydrocurcumin significantly inhibited the release of prominent cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6); however, hexahydrocurcumin and octahydrocurcumin did not significantly alter cytokine release.	tetrahydrocurcumin	26-44	interleukin 6	Mus musculus	174-178
25681618-7	2015	There was a similar reduction in pro-inflammatory cytokines and chemokines IL-6, KC, and MIP-2 in SBE plus G31P-treated mice.	g31p	107-111	interleukin 6	Mus musculus	75-79
25040147-1	2015	BACKGROUND &amp; AIMS: Various immune mediators such as interleukin-6 (IL-6) have been implicated in the process of liver regeneration.	Adenosine Monophosphate	12-15	interleukin 6	Mus musculus	56-69
25040147-1	2015	BACKGROUND &amp; AIMS: Various immune mediators such as interleukin-6 (IL-6) have been implicated in the process of liver regeneration.	Adenosine Monophosphate	12-15	interleukin 6	Mus musculus	71-75
25798187-6	2015	RESULTS: Compared with the HS group and the Kae T group, pretreatment with kaempferol significantly decreased proinflammatory cytokines TNF-alpha (P = 0.012 and 0.015, respectively) and IL-6 (P = 0.023 and 0.014, respectively) following hemorrhagic shock.	kaempferol	75-85	interleukin 6	Mus musculus	186-190
25526376-14	2015	CONCLUSIONS: Glycyrrhizin inhibited the expression and release of HMGB1 through blocking the p38 mitogen-activated protein kinase/activating protein 1 signaling pathway then inhibited the massive release of tumor necrosis factor alpha and interleukin 6.	Glycyrrhizic Acid	13-25	interleukin 6	Mus musculus	239-252
25730469-5	2015	ACAP also showed significant inhibitory activities on IL-1beta, IL-6, and COX-2 gene expressions in cultured RAW 264.7 mouse macrophage cells.	acap	0-4	interleukin 6	Mus musculus	64-68
25889862-5	2015	METHODS: A series of new curcumin analogs were synthesized and screened for their inhibitory effects on the production of TNF-alpha and IL-6 in mouse peritoneal macrophages by ELISA.	Curcumin	25-33	interleukin 6	Mus musculus	136-140
25798187-9	2015	CONCLUSIONS: Pretreatment of hemorrhagic shock mice with kaempferol significantly decreased plasma levels of TNF-alpha and IL-6; reverted MPO, SOD, and MDA in the heart, lung, and liver; and increased expression of HO-1 in the same organs.	kaempferol	57-67	interleukin 6	Mus musculus	123-127
25788267-2	2015	We found that brassinin (BSN) suppressed both constitutive and IL-6-inducible STAT3 activation in lung cancer cells.	brassinin	14-23	interleukin 6	Mus musculus	63-67
25888448-10	2015	However, gut permeability, colonic serotonin levels and the colonic levels of the cytokines IL-6, INF-gamma, IL-4 and IL-22 were higher in DNBS-treated than in untreated mice.	dinitrobenzenesulfonic acid	139-143	interleukin 6	Mus musculus	92-96
25788267-2	2015	We found that brassinin (BSN) suppressed both constitutive and IL-6-inducible STAT3 activation in lung cancer cells.	brassinin	25-28	interleukin 6	Mus musculus	63-67
25789481-6	2015	Pretreatment with 6-paradol reduced neuroinflammatory responses in LPS-stimulated BV2 microglia by a concentration-dependent manner, which includes reduced NO production by inhibiting iNOS upregulation and lowered secretion of proinflammatory cytokines (IL-6 and TNF-alpha).	6-paradol	18-27	interleukin 6	Mus musculus	254-258
25595981-11	2015	CBD treatment resulted in an increase in BDNF expression in the hippocampus and decreased levels of proinflammatory cytokines in the hippocampus (TNF-alpha) and prefrontal cortex (IL-6).	Cannabidiol	0-3	interleukin 6	Mus musculus	180-184
25834641-5	2015	Obese mice treated with atorvastatin had enhanced in vivo insulin sensitivity, besides increased Slc2a4/GLUT4 expression and reduced Il6 expression in SAT.	Atorvastatin	24-36	interleukin 6	Mus musculus	133-136
25834641-7	2015	CONCLUSIONS: Atorvastatin has beneficial effect upon glycemic homeostasis, which may be related to its positive impact on Il6 and Slc2a4/GLUT4 expression in SAT.	Atorvastatin	13-25	interleukin 6	Mus musculus	122-125
25760924-9	2015	These observations demonstrate that IL6 directly controls SERT levels and consequently serotonin reuptake and identify STAT3-dependent regulation of SERT as conceivable neurobiological substrate for the involvement of IL6 in depression.	Serotonin	87-96	interleukin 6	Mus musculus	36-39
25666385-9	2015	We found that tyrphostin AG490 inhibited Regulated upon activation normal T cell expressed and secreted (RANTES), IL-6 and IL-12 serum levels, decreased the number of CD11b(+)Ly6C(+) and CD3(+)CD69(+) subpopulations in the peritoneal exudate and prevented the decrease of cells expressing C5a receptor and TNF-alpha receptor.	Tyrphostins	14-24	interleukin 6	Mus musculus	114-118
25741592-6	2015	After acute DEN-induced liver injury we observed a reduction in the inflammatory response in gp130(Deltahepa) animals as reflected by decreased levels of IL-6 and oncostatin M.	Diethylnitrosamine	12-15	interleukin 6	Mus musculus	154-158
25742007-0	2015	Nickel ions selectively inhibit lipopolysaccharide-induced interleukin-6 production by decreasing its mRNA stability.	Nickel	0-6	interleukin 6	Mus musculus	59-72
25742007-5	2015	We demonstrated that Ni2+ inhibited the LPS-induced production of interleukin (IL)-6, but not that of tumor necrosis factor (TNF)-alpha both in vivo and in vitro.	Nickel(2+)	21-25	interleukin 6	Mus musculus	66-84
25742007-6	2015	This inhibitory effect was also observed with cobalt ion (Co2+), but not with chloride ion (Cl-), zinc ion (Zn2+), or palladium ion (Pd2+), and was highly selective to the production of IL-6.	Cobalt	46-52	interleukin 6	Mus musculus	186-190
25742007-6	2015	This inhibitory effect was also observed with cobalt ion (Co2+), but not with chloride ion (Cl-), zinc ion (Zn2+), or palladium ion (Pd2+), and was highly selective to the production of IL-6.	Cobalt(2+)	58-62	interleukin 6	Mus musculus	186-190
25742007-8	2015	Although Ni2+ decreased IL-6 mRNA levels, it failed to inhibit the LPS-induced activation of the IL-6 promoter.	Nickel(2+)	9-13	interleukin 6	Mus musculus	24-28
25742007-9	2015	An experiment using actinomycin D, a transcription inhibitor, revealed that Ni2+ decreased the stability of IL-6 mRNA.	Dactinomycin	20-33	interleukin 6	Mus musculus	108-112
25742007-9	2015	An experiment using actinomycin D, a transcription inhibitor, revealed that Ni2+ decreased the stability of IL-6 mRNA.	Nickel(2+)	76-80	interleukin 6	Mus musculus	108-112
25742007-11	2015	These results demonstrated that Ni2+ may have selectively inhibited the LPS-induced production of IL-6 by decreasing the Arid5a-dependent stabilization of IL-6 mRNA.	Nickel(2+)	32-36	interleukin 6	Mus musculus	98-102
25742007-11	2015	These results demonstrated that Ni2+ may have selectively inhibited the LPS-induced production of IL-6 by decreasing the Arid5a-dependent stabilization of IL-6 mRNA.	Nickel(2+)	32-36	interleukin 6	Mus musculus	155-159
25578230-7	2015	PHMG-phosphate induced pro-inflammatory cytokines including IL-1beta, IL-6, and IL-8.	polyhexamethyleneguanidine	0-14	interleukin 6	Mus musculus	70-74
25620130-8	2015	The results showed that acanthoic acid downregulated LPS-induced TNF-alpha, IL-6 and IL-1beta production in BALF.	acanthoic acid	24-38	interleukin 6	Mus musculus	76-80
25620130-11	2015	In vitro, acanthoic acid inhibited inflammatory cytokines TNF-alpha, IL-6 and IL-1beta production and NF-kappaB activation in LPS-stimulated alveolar macrophages.	acanthoic acid	10-24	interleukin 6	Mus musculus	69-73
25501545-5	2015	EtOH PPAR-alpha-/- mice had increased steatosis, serum alanine aminotransferase (ALT), and hepatic CD3+ T cell populations and elevated mRNA encoding CD14, CXCL2, TNF-alpha, IL-6, CD138, transforming growth factor-beta, platelet-derived growth factor receptor-beta (PDGFR-beta), matrix metalloproteinase (MMP)-9, MMP-13, alpha-SMA, and collagen type 1 compared with EtOH WT mice.	Ethanol	0-4	interleukin 6	Mus musculus	174-178
25463220-5	2015	The data suggest that compare with raw MWCNTs and MWCNTs-PEG, the MWCNTs-COOH produces a significant increase in ROS generation, interruption of ATP synthesis, and activation of the MAPK and NF-kappaB signaling pathways, which in turn upregulates IL-1beta, IL-6, TNF-alpha, and iNOS to trigger cell death.	Polyethylene Glycols	57-60	interleukin 6	Mus musculus	257-261
25463220-5	2015	The data suggest that compare with raw MWCNTs and MWCNTs-PEG, the MWCNTs-COOH produces a significant increase in ROS generation, interruption of ATP synthesis, and activation of the MAPK and NF-kappaB signaling pathways, which in turn upregulates IL-1beta, IL-6, TNF-alpha, and iNOS to trigger cell death.	Carbonic Acid	73-77	interleukin 6	Mus musculus	257-261
25463220-5	2015	The data suggest that compare with raw MWCNTs and MWCNTs-PEG, the MWCNTs-COOH produces a significant increase in ROS generation, interruption of ATP synthesis, and activation of the MAPK and NF-kappaB signaling pathways, which in turn upregulates IL-1beta, IL-6, TNF-alpha, and iNOS to trigger cell death.	Reactive Oxygen Species	113-116	interleukin 6	Mus musculus	257-261
25619943-6	2015	Furthermore, roasted curcumin and 4-vinyl guaiacol decreased interleukin-6 gene expression in lipopolysaccharide stimulated murine macrophages.	Curcumin	21-29	interleukin 6	Mus musculus	61-74
25651848-3	2015	Results showed that resveratrol down-regulated the expression of inducible nitric oxide synthase (iNOS) and interleukin-6 (IL-6), therefore, suppressed the production of nitric oxide and the secretion of IL-6 in LPS-stimulated RAW264.7 cells in a dose-dependent manner.	Resveratrol	20-31	interleukin 6	Mus musculus	108-121
25651848-3	2015	Results showed that resveratrol down-regulated the expression of inducible nitric oxide synthase (iNOS) and interleukin-6 (IL-6), therefore, suppressed the production of nitric oxide and the secretion of IL-6 in LPS-stimulated RAW264.7 cells in a dose-dependent manner.	Resveratrol	20-31	interleukin 6	Mus musculus	123-127
25651848-3	2015	Results showed that resveratrol down-regulated the expression of inducible nitric oxide synthase (iNOS) and interleukin-6 (IL-6), therefore, suppressed the production of nitric oxide and the secretion of IL-6 in LPS-stimulated RAW264.7 cells in a dose-dependent manner.	Resveratrol	20-31	interleukin 6	Mus musculus	204-208
25619943-6	2015	Furthermore, roasted curcumin and 4-vinyl guaiacol decreased interleukin-6 gene expression in lipopolysaccharide stimulated murine macrophages.	4-vinylguaiacol	34-50	interleukin 6	Mus musculus	61-74
25630053-6	2015	Meanwhile, hepatic glycogen (HG) and muscle glycogen (MG) concentrations were increased while insulin resistance (IR)-related inflammatory factors IL-6 and TNF-alpha in serum were reduced in STZ-induced diabetic mice.	Streptozocin	191-194	interleukin 6	Mus musculus	147-151
25583024-5	2015	Antrodan significantly increased interleukin (IL)-12 and IL-1beta levels, but decreased TNF-alpha, IL-6 and IL-8 levels in the MMC-CM, which also significantly inhibited invasion, migration, and the activities and protein expression of MMP-2 and MMP-9, but significantly increased protein expression of TIMP-1, TIMP-2, and nm23-H1 in LLC cells.	antrodan	0-8	interleukin 6	Mus musculus	99-103
25519169-9	2015	Furthermore, during DEN-induced initiation of HCC, Ct-HBx- and FL-HBx-transgenic mice showed higher expression of IL-6, TNF-alpha and IL-1beta transcripts, activation of STAT3, ERK and JNK proteins and an increase in cell apoptosis.	Diethylnitrosamine	20-23	interleukin 6	Mus musculus	114-118
25827806-7	2015	RESULTS: The selective TGR5 agonist BTA dose-dependently suppressed disease activity index and mRNA expression of the pro-inflammatory cytokines interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha in the colon.	betulinic acid	36-39	interleukin 6	Mus musculus	169-206
25577467-10	2015	RESULTS: We found that cholesterol significantly increased serum leptin, interleukin-6, liver weight and liver weight/body weight ratio, fibrosis and liver alpha-SMA.	Cholesterol	23-34	interleukin 6	Mus musculus	73-86
25866750-4	2015	TMC pretreatment also increased the hepatic levels of hepatic catalase, superoxide dismutase, glutathione peroxidase, and glutathione, and reduced serum levels of the inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 in mice administered APAP (P&lt;0.05).	tmc	0-3	interleukin 6	Mus musculus	228-246
25410618-9	2015	Moreover, pioglitazone administration could also significantly reverse the hyperglycemia, formation of AGEs, productions of IL-6 and MMP-13, and cartilage damage in STZ-induced diabetic mice.	Pioglitazone	10-22	interleukin 6	Mus musculus	124-128
25837923-9	2015	Additionally, stimulation of alpha7 nAChRs decreased the colon level of interleukin-6 and interferon-gamma upon DSS administration.	Dextran Sulfate	112-115	interleukin 6	Mus musculus	72-85
25866750-5	2015	TMC (500 mg/kg BW) reduced hepatic mRNA levels of TNF-alpha, IL-1beta, IL-6, COX-2, and iNOS by 87%, 84%, 89%, 85%, and 88%, respectively, in mice treated with APAP (P&lt;0.05).	tmc	0-3	interleukin 6	Mus musculus	71-75
25617481-7	2015	Mechanistically, HMC inhibited carrageenan-induced cytokine (TNF-alpha, IL-1beta, IL-6, and IL-10) production, oxidative stress and NF-kappaB activation.	Carrageenan	31-42	interleukin 6	Mus musculus	82-86
28962342-8	2015	Exposure to BPA alone or in combination with phthalates decreased cytokine release (TNFalpha, IL-6, IL-10, IFNgamma, IL-4) from in vitro stimulated splenocytes and lymph node cells, indicating systemic changes in immune function.	bisphenol A	12-15	interleukin 6	Mus musculus	94-98
28962342-8	2015	Exposure to BPA alone or in combination with phthalates decreased cytokine release (TNFalpha, IL-6, IL-10, IFNgamma, IL-4) from in vitro stimulated splenocytes and lymph node cells, indicating systemic changes in immune function.	phthalic acid	45-55	interleukin 6	Mus musculus	94-98
31245436-7	2015	Immunochemical analysis demonstrated that the amount of interleukin-6 (IL-6), a cytokine known to trigger osteoclast formation, was significantly reduced in the maternal milk of mice fed the low-phosphorus diet.	Phosphorus	195-205	interleukin 6	Mus musculus	56-69
25713332-9	2015	The attenuated response to CL 316,243 in white adipose tissue in IL-6(-/-) mice was associated with reductions in whole-body oxygen consumption and energy expenditure in the light phase.	Oxygen	125-131	interleukin 6	Mus musculus	65-69
25695433-7	2015	In addition, benfotiamine significantly decreased production of pro-inflammatory mediators such as inducible form of nitric oxide synthase (iNOS) and NO; cyclooxygenase-2 (COX-2), heat-shock protein 70 (Hsp70), tumor necrosis factor alpha alpha (TNF-alpha), interleukin-6 (IL-6), whereas it increased anti-inflammatory interleukin-10 (IL-10) production in LPS stimulated BV-2 microglia.	benphothiamine	13-25	interleukin 6	Mus musculus	258-271
25695433-7	2015	In addition, benfotiamine significantly decreased production of pro-inflammatory mediators such as inducible form of nitric oxide synthase (iNOS) and NO; cyclooxygenase-2 (COX-2), heat-shock protein 70 (Hsp70), tumor necrosis factor alpha alpha (TNF-alpha), interleukin-6 (IL-6), whereas it increased anti-inflammatory interleukin-10 (IL-10) production in LPS stimulated BV-2 microglia.	benphothiamine	13-25	interleukin 6	Mus musculus	273-277
31245436-7	2015	Immunochemical analysis demonstrated that the amount of interleukin-6 (IL-6), a cytokine known to trigger osteoclast formation, was significantly reduced in the maternal milk of mice fed the low-phosphorus diet.	Phosphorus	195-205	interleukin 6	Mus musculus	71-75
25601921-5	2015	DSS-induced colitis was characterized by higher disease activity index, shortened colon length, elevated activities of myeloperoxidase and eosinophil peroxidase, histologic evidence of inflammation, and increased expression levels of TNF-alpha, IL-6, and IL-8.	dss	0-3	interleukin 6	Mus musculus	245-249
25458285-5	2015	Both polysaccharides were found to stimulate NO production and induce the expression of cytokine mRNAs including IL-1beta, IL-6, IL-10 and TNF-alpha on RAW264.7 cells.	Polysaccharides	5-20	interleukin 6	Mus musculus	123-127
25849971-13	2015	Both dietary intervention with 1% GOS or budesonide treatment significantly decreased the HDM-induced increased concentrations of CCL5 and IL-13 in lung tissue, while budesonide also reduced the HDM-enhanced concentrations of IL-6 and CCL17 in lung tissue.	D-Glucitol-1,6-bisphosphate	34-37	interleukin 6	Mus musculus	226-230
25849971-13	2015	Both dietary intervention with 1% GOS or budesonide treatment significantly decreased the HDM-induced increased concentrations of CCL5 and IL-13 in lung tissue, while budesonide also reduced the HDM-enhanced concentrations of IL-6 and CCL17 in lung tissue.	Budesonide	167-177	interleukin 6	Mus musculus	226-230
25663772-11	2015	Down-regulation of IL-22, IL-17A, IFN-gamma, TNF-alpha, IL-6, IL-1beta, AHR RORgammat, and T-bet gene expression in the liver was observed in the rmIL-22 group (P &lt; 0.01).	rmil	146-150	interleukin 6	Mus musculus	56-60
25530164-11	2015	Lipopolysaccharides markedly increased the expression and secretion of IL-1beta, IL-6, IL-8, and TNF-alpha in the GECs cultured in high glucose medium, which was also partly blocked in the presence of RSV.	Resveratrol	201-204	interleukin 6	Mus musculus	81-85
25654532-4	2015	pretreatment with gedunin (0.005-5 mg/kg) impaired zymosan-induced edema formation, neutrophil accumulation and hypernociception in mouse knee joints, due to decreased expression of preproET-1 mRNA and production of LTB4, PGE2, TNF-alpha and IL-6.	Zymosan	51-58	interleukin 6	Mus musculus	242-246
25530164-9	2015	RSV administration also suppressed the high levels of IL-1beta, IL-6, IL-8, TNF-alpha, and TLR4 in gingival tissue of the mice.	Resveratrol	0-3	interleukin 6	Mus musculus	64-68
25480336-6	2015	Imatinib attenuates LPS-induced lung EC permeability, restores VE-cadherin junctions, and reduces inflammation by suppressing VCAM-1 expression and inflammatory cytokine (IL-8 and IL-6) secretion.	Imatinib Mesylate	0-8	interleukin 6	Mus musculus	180-184
25218901-7	2015	The exacerbation of sickness behavior induced by FK565 or MDP in combination with LPS was paralleled by enhanced plasma protein and cerebral mRNA levels of proinflammatory cytokines (IFN-gamma, IL-1beta, IL-6, TNF-alpha) as well as enhanced plasma levels of kynurenine.	heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine	49-54	interleukin 6	Mus musculus	204-208
25449670-10	2015	Collectively, our data demonstrate that acidified saline injection increases intramuscular IL-1 and IL-6, but not TNF; that intramuscular pre-treatment with an NF-kappaB inhibitor blocks mechanical hypersensitivity; and that genetic manipulation of the IL-1 and IL-6, but not TNF systems, prevents mechanical hypersensitivity following musculoskeletal sensitization.	Sodium Chloride	50-56	interleukin 6	Mus musculus	100-104
25377620-8	2015	Ondansetron inhibited expression of the chemokine CCL2, IL-1beta, IL-6, TNF-alpha and iNOS mRNAs up-regulated by IM, and also ameliorated the delayed gastrointestinal transit.	Ondansetron	0-11	interleukin 6	Mus musculus	66-70
25449670-10	2015	Collectively, our data demonstrate that acidified saline injection increases intramuscular IL-1 and IL-6, but not TNF; that intramuscular pre-treatment with an NF-kappaB inhibitor blocks mechanical hypersensitivity; and that genetic manipulation of the IL-1 and IL-6, but not TNF systems, prevents mechanical hypersensitivity following musculoskeletal sensitization.	Sodium Chloride	50-56	interleukin 6	Mus musculus	262-266
25240298-12	2015	In TNBS-treated mice, supplementation with NS significantly reduced weight loss, and serum proinflammatory cytokine levels (IL-2, IL-6, and IL-12, TNFalpha, IFNgamma) compared with the TNBS group.	Nitrogen	43-45	interleukin 6	Mus musculus	130-134
25467042-9	2015	Interleukin-6 and tumor necrosis factor-alpha levels were significantly reverted back to near normalcy after resveratrol treatment in obese mice.	Resveratrol	109-120	interleukin 6	Mus musculus	0-45
25372661-6	2015	The expression of interleukin-6 (IL-6) under xylitol-induced hypertonic stress was assessed using an enzyme-linked immunosorbent assay (ELISA).	Xylitol	45-52	interleukin 6	Mus musculus	18-31
25372661-6	2015	The expression of interleukin-6 (IL-6) under xylitol-induced hypertonic stress was assessed using an enzyme-linked immunosorbent assay (ELISA).	Xylitol	45-52	interleukin 6	Mus musculus	33-37
25372661-10	2015	Xylitol inhibited lipopolysaccharide (LPS)-induced IL-6 expression after 3 h of hypertonic stress.	Xylitol	0-7	interleukin 6	Mus musculus	51-55
25173887-9	2015	The results showed that magnolol significantly inhibit the LPS-induced TNF-alpha, IL-6, and IL-1beta production both in vivo and vitro.	magnolol	24-32	interleukin 6	Mus musculus	82-86
25318538-8	2015	RESULTS: We found that treatment with 1,25-dihydroxyvitamin D3 reduces IL-6 and IL-10 mRNA expression and increases TGF-beta and Foxp3 mRNA expression levels, and also enhances spleen Treg percentage.	Calcitriol	38-62	interleukin 6	Mus musculus	71-75
25318538-9	2015	CONCLUSIONS: The remarkable reduction of IL-6 and IL-10 gene expressions, significant enhancement of TGF-beta and Foxp3 gene expressions, along with an increase in Treg cell population after oral 1,25-dihydroxyvitamin D3 administration suggest a possible role for this vitamin as a prophylactic supplement in SLE.	Calcitriol	196-220	interleukin 6	Mus musculus	41-45
25189466-8	2015	Therefore, the results demonstrated that leonurine could downregulate the expression of TNF-alpha, IL-6, iNOS, and COX-2 and upregulate the expression of IL-10 mainly by inhibiting the expression of TLR4 and the activation of NF-kappaB and the phosphorylation of p38, ERK, and JNK.	leonurine	41-50	interleukin 6	Mus musculus	99-103
25189466-6	2015	The results showed that leonurine significantly alleviated LPS-induced histopathological changes, downregulated the levels of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), upregulated the level of anti-inflammatory cytokine interleukin-10 (IL-10), and inhibited the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	leonurine	24-33	interleukin 6	Mus musculus	194-207
25523461-4	2015	Protein and mRNA levels of DSS-induced pro-inflammatory cytokines in colon, including TNF-alpha, IL-1beta, IL-6 and IFN-gamma, were markedly suppressed by asiatic acid.	Dextran Sulfate	27-30	interleukin 6	Mus musculus	107-111
25189466-6	2015	The results showed that leonurine significantly alleviated LPS-induced histopathological changes, downregulated the levels of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), upregulated the level of anti-inflammatory cytokine interleukin-10 (IL-10), and inhibited the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	leonurine	24-33	interleukin 6	Mus musculus	209-213
25523461-4	2015	Protein and mRNA levels of DSS-induced pro-inflammatory cytokines in colon, including TNF-alpha, IL-1beta, IL-6 and IFN-gamma, were markedly suppressed by asiatic acid.	asiatic acid	155-167	interleukin 6	Mus musculus	107-111
25596038-7	2015	The detection of inflammatory cytokines indicated that the IL-6 level decreased (p&lt;0.001) and the TNF-alpha level increased (p&lt;0.01) in mice treated with Ilexgenin A.	ilexgenin A	160-171	interleukin 6	Mus musculus	59-63
25433073-18	2015	IL-6 also reduced gastrointestinal permeability, assayed by the accumulation of FITC-dextran in plasma.	fluorescein isothiocyanate dextran	80-92	interleukin 6	Mus musculus	0-4
25408476-7	2015	EPA and DHA significantly reduced TNFalpha secretion by 36 and 41 %, respectively, in cells stimulated for 24 h but not 6 h. In contrast, EPA and DHA significantly reduced IL-6 secretion at both 6 h (67 and 72%, respectively) and 24 h (69 and 72%, respectively).	Eicosapentaenoic Acid	0-3	interleukin 6	Mus musculus	172-176
25066281-0	2015	Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high-fat diet fed mice.	Glucose	101-108	interleukin 6	Mus musculus	12-25
25408476-7	2015	EPA and DHA significantly reduced TNFalpha secretion by 36 and 41 %, respectively, in cells stimulated for 24 h but not 6 h. In contrast, EPA and DHA significantly reduced IL-6 secretion at both 6 h (67 and 72%, respectively) and 24 h (69 and 72%, respectively).	Docosahexaenoic Acids	8-11	interleukin 6	Mus musculus	172-176
25408476-7	2015	EPA and DHA significantly reduced TNFalpha secretion by 36 and 41 %, respectively, in cells stimulated for 24 h but not 6 h. In contrast, EPA and DHA significantly reduced IL-6 secretion at both 6 h (67 and 72%, respectively) and 24 h (69 and 72%, respectively).	Eicosapentaenoic Acid	138-141	interleukin 6	Mus musculus	172-176
25408476-7	2015	EPA and DHA significantly reduced TNFalpha secretion by 36 and 41 %, respectively, in cells stimulated for 24 h but not 6 h. In contrast, EPA and DHA significantly reduced IL-6 secretion at both 6 h (67 and 72%, respectively) and 24 h (69 and 72%, respectively).	Docosahexaenoic Acids	146-149	interleukin 6	Mus musculus	172-176
25528385-12	2015	CYN exposure increased mechanical components, alveolar collapse, PMN cells and fiber deposition in the lungs, as well as the production of IL-1beta, IL-6 and KC in Protocol #1.	cylindrospermopsin	0-3	interleukin 6	Mus musculus	149-153
25635824-7	2015	ELISA analysis of the supernatant of wild type and P2rx7-/- mice precision-cut lung slices showed decreased amounts of IL-6 and TNF-alpha when incubated with nano-silica.	Silicon Dioxide	163-169	interleukin 6	Mus musculus	119-123
25281205-6	2015	The results showed that pretreatment with citral remarkably attenuated pulmonary edema, histological severities, TNF-alpha, IL-6 and IL-1beta production in LPS-induced ALI in vivo.	citral	42-48	interleukin 6	Mus musculus	124-128
25439918-4	2015	Oral administration of COS also reduced serum levels of pro-inflammatory cytokines (tumor necrosis factor-alpha and interleukin-6).	carbonyl sulfide	23-26	interleukin 6	Mus musculus	116-129
25877037-8	2015	DHA decreased the expression of palmitate-caused pro-inflammatory cytokines (MCP-1, IL-6 and iNOS) and oxidative stress and increased the gene expression of insulin signaling pathway (Glut4 and p-IRbeta).	Docosahexaenoic Acids	0-3	interleukin 6	Mus musculus	84-88
25877037-8	2015	DHA decreased the expression of palmitate-caused pro-inflammatory cytokines (MCP-1, IL-6 and iNOS) and oxidative stress and increased the gene expression of insulin signaling pathway (Glut4 and p-IRbeta).	Palmitates	32-41	interleukin 6	Mus musculus	84-88
25281205-7	2015	In vitro, citral inhibited LPS-induced TNF-alpha, IL-6 and IL-1beta production in alveolar macrophages.	citral	10-16	interleukin 6	Mus musculus	50-54
25581158-3	2015	Here we show that acute inhibition of IKK-epsilon and TBK1 with amlexanox treatment increases cAMP levels in subcutaneous adipose depots of obese mice, promoting the synthesis and secretion of the cytokine IL-6 from adipocytes and preadipocytes, but not from macrophages.	amlexanox	64-73	interleukin 6	Mus musculus	206-210
25449459-8	2015	Additionally, the levels of pro-inflammatory cytokines including IL-2, IL-6, TNF-alpha and gamma-IFN were markedly reduced by STDP treatment.	stdp	126-130	interleukin 6	Mus musculus	71-75
25593461-6	2015	Expression levels of IL-6, IL-1beta, interferon (IFN)-gamma and MMP-9 were decreased in the colons of mice exposed to butein, whereas other inflammatory cytokines (IL-17A, IL-21 and IL-22) were unchanged.	butein	118-124	interleukin 6	Mus musculus	21-25
25593461-8	2015	Butein inhibited IL-6-induced activation of STAT3 in Colo 205 cells.	butein	0-6	interleukin 6	Mus musculus	17-21
25569097-6	2015	PW showed anti-inflammatory effects by inhibiting the production of nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) and interleukin-1beta (IL-1beta).	H-Pro-Trp-OH	0-2	interleukin 6	Mus musculus	131-144
25745505-12	2015	Monocyte chemoattractant protein-1 (MCP1/Ccl2) and interleukin 6 (IL-6/Il6) mRNA expression levels were significantly lower in perigonadal adipose tissue of naringenin-supplemented mice.	naringenin	157-167	interleukin 6	Mus musculus	51-64
25745505-12	2015	Monocyte chemoattractant protein-1 (MCP1/Ccl2) and interleukin 6 (IL-6/Il6) mRNA expression levels were significantly lower in perigonadal adipose tissue of naringenin-supplemented mice.	naringenin	157-167	interleukin 6	Mus musculus	66-70
25745505-12	2015	Monocyte chemoattractant protein-1 (MCP1/Ccl2) and interleukin 6 (IL-6/Il6) mRNA expression levels were significantly lower in perigonadal adipose tissue of naringenin-supplemented mice.	naringenin	157-167	interleukin 6	Mus musculus	71-74
25569097-6	2015	PW showed anti-inflammatory effects by inhibiting the production of nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) and interleukin-1beta (IL-1beta).	H-Pro-Trp-OH	0-2	interleukin 6	Mus musculus	146-150
25569518-5	2015	Results showed that astilbin, at non-cytotoxicity concentrations, significantly suppressed the production of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha), as well as the mRNA expression of inducible nitric oxide synthase (iNOS) and TNF-alpha in LPS-induced RAW 264.7 cells, but did not affect interleukin-6 (IL-6) release or its mRNA expression.	astilbin	20-28	interleukin 6	Mus musculus	310-323
25569518-5	2015	Results showed that astilbin, at non-cytotoxicity concentrations, significantly suppressed the production of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha), as well as the mRNA expression of inducible nitric oxide synthase (iNOS) and TNF-alpha in LPS-induced RAW 264.7 cells, but did not affect interleukin-6 (IL-6) release or its mRNA expression.	astilbin	20-28	interleukin 6	Mus musculus	325-329
25460024-8	2015	In addition, administration of FTS decreased pancreatic levels of CXC chemokines as well as circulating levels of interleukin-6 and high-mobility group box 1 in animals exposed to taurocholate.	Tegafur	31-34	interleukin 6	Mus musculus	114-127
25635535-4	2015	Silencing Arg-II or p38alpha in senescent cells recouples eNOS and inhibits IL-6 and IL-8 secretion.	Arginine	10-13	interleukin 6	Mus musculus	76-80
25478868-7	2015	Thalidomide pretreatment significantly reduced the levels of pro-inflammatory cytokines [tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6], malondialdehyde (MDA) and myeloperoxidase (MPO) activity.	Thalidomide	0-11	interleukin 6	Mus musculus	148-152
25635535-6	2015	Moreover, p38 activation and expression of IL-6 and KC (the murine IL-8 homologue) are increased in the heart and/or aortas of wild type (WT) old mice, which is abolished in mice with Arg-II gene deficiency (Arg-II-/-).	Arginine	184-187	interleukin 6	Mus musculus	43-54
26119957-4	2015	alpha-Pinene significantly decreased the LPS-induced production of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and nitric oxide (NO).	alpha-pinene	0-12	interleukin 6	Mus musculus	67-80
26119957-4	2015	alpha-Pinene significantly decreased the LPS-induced production of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and nitric oxide (NO).	alpha-pinene	0-12	interleukin 6	Mus musculus	82-86
26227399-4	2015	Additionally, (+)-catechin suppressed the production of tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6, while augmenting IL-4.	Catechin	14-26	interleukin 6	Mus musculus	100-118
25302613-8	2015	Furthermore, the increased expression of interleukin-6 (IL-6) in fibroblasts, endothelial cells, and immune cells in response to bleomycin in vivo and to lipopolysaccharide in vitro was notably abrogated in the absence of TLR-4.	Bleomycin	129-138	interleukin 6	Mus musculus	41-54
26381032-6	2015	Pa-ME strikingly suppressed the production of LPS-induced pro-inflammatory cytokines including interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha).	1-phenyl-1-aminomethylethene	0-5	interleukin 6	Mus musculus	119-123
25640393-9	2015	The animal model demonstrated that magnesium sulfate induced production of IL-1beta, IL-6, and TNF-alpha.	Magnesium Sulfate	35-52	interleukin 6	Mus musculus	85-89
26043790-9	2015	Increased autophagy contributes to cocaine-mediated activation of microglia since pretreatment of cells with wortmannin resulted in decreased expression and release of inflammatory factors (TNF, IL1B, IL6, and CCL2) in microglial cells.	Wortmannin	109-119	interleukin 6	Mus musculus	201-204
24975165-7	2015	LY294002 and IC87114 prevented Akt phosphorylation as expected and down-regulated the expression of inflammatory factors IL-6, MCP-1,TNFalpha and iNOS.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	interleukin 6	Mus musculus	121-125
24975165-7	2015	LY294002 and IC87114 prevented Akt phosphorylation as expected and down-regulated the expression of inflammatory factors IL-6, MCP-1,TNFalpha and iNOS.	IC 87114	13-20	interleukin 6	Mus musculus	121-125
25302613-8	2015	Furthermore, the increased expression of interleukin-6 (IL-6) in fibroblasts, endothelial cells, and immune cells in response to bleomycin in vivo and to lipopolysaccharide in vitro was notably abrogated in the absence of TLR-4.	Bleomycin	129-138	interleukin 6	Mus musculus	56-60
25728636-3	2015	In the cell model, Dp3-Sam and Delphinidin (Dp) reduced the levels of inflammatory mediators including iNOS, NO, IL-6, MCP-1, and TNF-alpha induced by LPS.	delphinidin	31-42	interleukin 6	Mus musculus	113-117
25728636-3	2015	In the cell model, Dp3-Sam and Delphinidin (Dp) reduced the levels of inflammatory mediators including iNOS, NO, IL-6, MCP-1, and TNF-alpha induced by LPS.	delphinidin	19-21	interleukin 6	Mus musculus	113-117
25728636-5	2015	In animal model, Dp3-Sam and Dp reduced the production of IL-6, MCP-1 and TNF-alpha and attenuated mouse paw edema induced by LPS.	delphinidin	17-19	interleukin 6	Mus musculus	58-62
25884412-3	2015	However, peptides prepared from Mf conjugated with alginate oligosaccharide (AO; 19 mug/mg protein) (dMSA) through the Maillard reaction in the presence of sorbitol significantly reduced the secretion of the pro-inflammatory mediators nitric oxide, tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, as well as mRNA expression of TNF-alpha, IL-6, inducible nitric oxide synthase and cyclooxygenase-2.	alginate oligosaccharide	51-75	interleukin 6	Mus musculus	287-305
26339604-7	2015	We observed that proinflammatory IL-1beta and also CXCL1 were highly upregulated whereas anti-inflammatory or regulatory cytokines IL-6 and IL-10 were suppressed by 10 microM Cd.	Cadmium	175-177	interleukin 6	Mus musculus	131-135
25884412-3	2015	However, peptides prepared from Mf conjugated with alginate oligosaccharide (AO; 19 mug/mg protein) (dMSA) through the Maillard reaction in the presence of sorbitol significantly reduced the secretion of the pro-inflammatory mediators nitric oxide, tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, as well as mRNA expression of TNF-alpha, IL-6, inducible nitric oxide synthase and cyclooxygenase-2.	Acridine Orange	77-79	interleukin 6	Mus musculus	348-352
25884412-3	2015	However, peptides prepared from Mf conjugated with alginate oligosaccharide (AO; 19 mug/mg protein) (dMSA) through the Maillard reaction in the presence of sorbitol significantly reduced the secretion of the pro-inflammatory mediators nitric oxide, tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, as well as mRNA expression of TNF-alpha, IL-6, inducible nitric oxide synthase and cyclooxygenase-2.	alginate oligosaccharide	51-75	interleukin 6	Mus musculus	348-352
25884412-3	2015	However, peptides prepared from Mf conjugated with alginate oligosaccharide (AO; 19 mug/mg protein) (dMSA) through the Maillard reaction in the presence of sorbitol significantly reduced the secretion of the pro-inflammatory mediators nitric oxide, tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, as well as mRNA expression of TNF-alpha, IL-6, inducible nitric oxide synthase and cyclooxygenase-2.	Acridine Orange	77-79	interleukin 6	Mus musculus	287-305
25884412-3	2015	However, peptides prepared from Mf conjugated with alginate oligosaccharide (AO; 19 mug/mg protein) (dMSA) through the Maillard reaction in the presence of sorbitol significantly reduced the secretion of the pro-inflammatory mediators nitric oxide, tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, as well as mRNA expression of TNF-alpha, IL-6, inducible nitric oxide synthase and cyclooxygenase-2.	Succimer	101-105	interleukin 6	Mus musculus	287-305
25884412-3	2015	However, peptides prepared from Mf conjugated with alginate oligosaccharide (AO; 19 mug/mg protein) (dMSA) through the Maillard reaction in the presence of sorbitol significantly reduced the secretion of the pro-inflammatory mediators nitric oxide, tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, as well as mRNA expression of TNF-alpha, IL-6, inducible nitric oxide synthase and cyclooxygenase-2.	Succimer	101-105	interleukin 6	Mus musculus	348-352
25884412-3	2015	However, peptides prepared from Mf conjugated with alginate oligosaccharide (AO; 19 mug/mg protein) (dMSA) through the Maillard reaction in the presence of sorbitol significantly reduced the secretion of the pro-inflammatory mediators nitric oxide, tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, as well as mRNA expression of TNF-alpha, IL-6, inducible nitric oxide synthase and cyclooxygenase-2.	Sorbitol	156-164	interleukin 6	Mus musculus	287-305
25884412-3	2015	However, peptides prepared from Mf conjugated with alginate oligosaccharide (AO; 19 mug/mg protein) (dMSA) through the Maillard reaction in the presence of sorbitol significantly reduced the secretion of the pro-inflammatory mediators nitric oxide, tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, as well as mRNA expression of TNF-alpha, IL-6, inducible nitric oxide synthase and cyclooxygenase-2.	Sorbitol	156-164	interleukin 6	Mus musculus	348-352
25654487-7	2015	Irisflorentin significantly lessened the proinflammatory cytokine production (tumor necrosis factor-alpha, interleukin-6, and interleukin-12p70) by LPS-stimulated DCs.	irisflorentin	0-13	interleukin 6	Mus musculus	107-120
26016702-4	2015	The immunostimulating activities of L2 and L2-calcium complex were measured by enhancing the production of two cytokines TNF-alpha and IL-6 in RAW264.7 cells.	Calcium	46-53	interleukin 6	Mus musculus	135-139
26016702-5	2015	While L2-calcium complex significantly stimulates the secretions of TNF-alpha and IL-6 compared with the control, complex with calcium ion decreased the secretion of them.	l2-calcium	6-16	interleukin 6	Mus musculus	82-86
26016702-5	2015	While L2-calcium complex significantly stimulates the secretions of TNF-alpha and IL-6 compared with the control, complex with calcium ion decreased the secretion of them.	Calcium	9-16	interleukin 6	Mus musculus	82-86
25411359-8	2015	Interleukin-6 treatment and overexpression of STAT3 enhanced anoikis resistance and protected the cells from PL-induced anoikis.	piplartine	109-111	interleukin 6	Mus musculus	0-13
26160269-8	2015	The higher dose of dasatinib caused no changes in lung mechanics, diffuse alveolar damage, neutrophil, or cells expressing TLR4, but increased IL-6, vascular endothelial growth factor (VEGF), and cells expressing Fas receptor in lung in ARDSp.	Dasatinib	19-28	interleukin 6	Mus musculus	143-147
26159678-4	2015	The effects of Escin on the release of pro-inflammatory cytokines such as TNF-alpha, IL-1beta, IL-6 and HMGB1 in the serum of endotoxemic mice and LPS-induced macrophages were evaluated by ELISA.	Escin	15-20	interleukin 6	Mus musculus	95-99
26159678-9	2015	In addition, Escin decreased the level of the pro-inflammatory cytokinesTNF-alpha,IL-1beta, IL-6 and HMGB1 in endotoxemic mice and in LPS-induced macrophages.	Escin	13-18	interleukin 6	Mus musculus	92-96
26159678-11	2015	The release of the pro-inflammatory cytokinesTNF-alpha,IL-1beta, IL-6 could be suppressed in rHMGB1-induced macrophages by Escin.	Escin	123-128	interleukin 6	Mus musculus	65-69
26648769-0	2015	The p38 MAPK inhibitor SB203580 differentially modulates LPS-induced interleukin 6 expression in macrophages.	SB 203580	23-31	interleukin 6	Mus musculus	69-82
26648769-2	2015	Herein, we assessed whether the inhibition of p38 MAPK by SB203580 regulates LPS-induced expression of the inflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) in RAW264.7 and resident peritoneal macrophages.	SB 203580	58-66	interleukin 6	Mus musculus	174-187
26648769-2	2015	Herein, we assessed whether the inhibition of p38 MAPK by SB203580 regulates LPS-induced expression of the inflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) in RAW264.7 and resident peritoneal macrophages.	SB 203580	58-66	interleukin 6	Mus musculus	189-193
26648769-4	2015	The addition of SB203580 to cultures dramatically blocked LPS-induced TNF-alpha production in RAW264.7 and mouse resident peritoneal macrophages, and dramatically blocked LPS-induced IL-6 production in RAW264.7 macrophages, but not in mouse resident peritoneal macrophages.	SB 203580	16-24	interleukin 6	Mus musculus	183-187
26648769-5	2015	Additionally, high concentrations of SB203580 resulted in increased IL-6 production.	SB 203580	37-45	interleukin 6	Mus musculus	68-72
26648769-6	2015	However, LPS-stimulation significantly up-regulated the mRNA transcript levels of TNF-alpha and IL-6 in RAW264.7 and mouse resident peritoneal macrophages, whereas pretreatment with SB203580 dramatically down-regulated LPS-induced mRNA transcript levels of TNF-alpha and IL-6 in these cells.	SB 203580	182-190	interleukin 6	Mus musculus	96-100
26648769-6	2015	However, LPS-stimulation significantly up-regulated the mRNA transcript levels of TNF-alpha and IL-6 in RAW264.7 and mouse resident peritoneal macrophages, whereas pretreatment with SB203580 dramatically down-regulated LPS-induced mRNA transcript levels of TNF-alpha and IL-6 in these cells.	SB 203580	182-190	interleukin 6	Mus musculus	271-275
26648769-7	2015	Our data show that SB203580 differentially modulates LPS-induced production of the inflammatory cytokine IL-6 in two different sources of macrophages, and that this course of regulation occurs at the IL-6 mRNA post-transcriptional stage.	SB 203580	19-27	interleukin 6	Mus musculus	105-109
26648769-7	2015	Our data show that SB203580 differentially modulates LPS-induced production of the inflammatory cytokine IL-6 in two different sources of macrophages, and that this course of regulation occurs at the IL-6 mRNA post-transcriptional stage.	SB 203580	19-27	interleukin 6	Mus musculus	200-204
25226443-3	2015	LPS-induced secretion of IL-6 from peritoneal macrophages suppressed in response to uptake of oligomannose-coated liposomes (OMLs), and the suppression was partly inhibited by treatment with an anti-SIGNR1 antibody.	oligomannose	94-106	interleukin 6	Mus musculus	25-29
26279435-6	2015	RESULTS: As a result the serum fasting blood glucose (FBG), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels were decreased following EACR administration.	eacr	157-161	interleukin 6	Mus musculus	60-73
26279435-6	2015	RESULTS: As a result the serum fasting blood glucose (FBG), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels were decreased following EACR administration.	eacr	157-161	interleukin 6	Mus musculus	75-79
26279435-11	2015	CONCLUSION: These findings suggest that the modulation of the IL-6 and TNF-alpha inflammatory cytokines and the suppression of the TLR4-NF-kappaB pathway are most likely involved in the anti-hyperglycemic effect of EACR in STZ-induced diabetic mice.	eacr	215-219	interleukin 6	Mus musculus	62-66
26279435-11	2015	CONCLUSION: These findings suggest that the modulation of the IL-6 and TNF-alpha inflammatory cytokines and the suppression of the TLR4-NF-kappaB pathway are most likely involved in the anti-hyperglycemic effect of EACR in STZ-induced diabetic mice.	Streptozocin	223-226	interleukin 6	Mus musculus	62-66
25226443-7	2015	Phagocytosis of oligomannose-coated liposomes did not interfere with the transcription of IL-6 mRNA, but did affect IL-6 mRNA stability, leading to suppression of IL-6 secretion.	oligomannose	16-28	interleukin 6	Mus musculus	116-120
25226443-8	2015	Interestingly, treatment of the cells with Ly290042, a PI3 kinase inhibitor, partly blocked the suppression of LPS-induced secretion of IL-6 by OML.	LY 290042	43-51	interleukin 6	Mus musculus	136-140
25226443-6	2015	Suppression of the IL-6 secretion was not observed following treatment with oligomannose-containing soluble polymers or when cells were bound to an oligomannose-coated solid phase.	oligomannose	148-160	interleukin 6	Mus musculus	19-23
25226443-8	2015	Interestingly, treatment of the cells with Ly290042, a PI3 kinase inhibitor, partly blocked the suppression of LPS-induced secretion of IL-6 by OML.	oml	144-147	interleukin 6	Mus musculus	136-140
25226443-7	2015	Phagocytosis of oligomannose-coated liposomes did not interfere with the transcription of IL-6 mRNA, but did affect IL-6 mRNA stability, leading to suppression of IL-6 secretion.	oligomannose	16-28	interleukin 6	Mus musculus	116-120
25501921-9	2015	RESULTS: SB431542 significantly decreased serum amylase, lipase, TNF-alpha, IL-6, TGF-beta, histopathological changes of pancreas and expression of miR-216a in cerulein-induced mouse (P &lt; 0.05).	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	9-17	interleukin 6	Mus musculus	76-80
25528414-8	2015	In addition, the serum levels of tumor necrosis factor alpha (TNFalpha), interleukin 6 (IL6) and interleukin 1beta (IL1beta) increased significantly in the groups treated with 30mg/L CdCl2 for 21 days.	Cadmium Chloride	183-188	interleukin 6	Mus musculus	73-86
25528414-8	2015	In addition, the serum levels of tumor necrosis factor alpha (TNFalpha), interleukin 6 (IL6) and interleukin 1beta (IL1beta) increased significantly in the groups treated with 30mg/L CdCl2 for 21 days.	Cadmium Chloride	183-188	interleukin 6	Mus musculus	88-91
25861362-8	2015	The results showed that the Bxb extract dose-dependent manner produces (a) an increase in levels of H2O2 and spreading and vacuoles formation percentages, (b) a decrease in phagocytic index and in the amounts of TNF, IL-6, and IFN-gamma, and (c) an increase significant in IL-10 and NO production.	Alda-1	28-31	interleukin 6	Mus musculus	217-221
25878717-5	2015	The expression of LPS-induced proinflammatory cytokines including interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) was significantly diminished by Pc-ME.	2,4-diamino-5-cyclohexyl-6-methylpyrimidine	174-179	interleukin 6	Mus musculus	92-96
26604971-3	2015	After an 8 h treatment with 100 mug/mL of Brazilian propolis ethanol extract, expression of various chemokines, including CCL-2 and CCL-5, and cytokines, such as IL-6, increased.	Ethanol	61-68	interleukin 6	Mus musculus	162-166
25960750-3	2015	Farnesol supplementation decreased interleukin (IL)-6/IL-10 level ratios in bronchoalveolar lavage fluid (BALF).	Farnesol	0-8	interleukin 6	Mus musculus	35-53
25691908-5	2015	Inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6 were notably increased in hepatic tissues, and then these were efficiently attenuated by TCW pretreatment.	Tolcapone	152-155	interleukin 6	Mus musculus	58-62
26779276-6	2015	Treatment with DHYW markedly decreased the levels of interleukin-6 (IL-6), IL-1beta, and tumor necrosis factor-alpha (TNF-alpha).	dhyw	15-19	interleukin 6	Mus musculus	53-66
26779276-6	2015	Treatment with DHYW markedly decreased the levels of interleukin-6 (IL-6), IL-1beta, and tumor necrosis factor-alpha (TNF-alpha).	dhyw	15-19	interleukin 6	Mus musculus	68-72
25460360-5	2015	Selenium deficiency also exacerbated UVB-induced cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and IL-6 mRNA expressions.	Selenium	0-8	interleukin 6	Mus musculus	189-193
26514440-3	2015	ES pretreatment at doses of 20 and 40 mg/kg effectively attenuated LPS-induced lung histopathological change, myeloperoxidase or MPO activity, inflammatory cells infiltration, pulmonary wet-to-dry weight ratio, and the generation of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) in vivo and in vitro.	esculetin	0-2	interleukin 6	Mus musculus	345-358
26514440-3	2015	ES pretreatment at doses of 20 and 40 mg/kg effectively attenuated LPS-induced lung histopathological change, myeloperoxidase or MPO activity, inflammatory cells infiltration, pulmonary wet-to-dry weight ratio, and the generation of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) in vivo and in vitro.	esculetin	0-2	interleukin 6	Mus musculus	360-364
26089871-9	2015	Pretreatment with resveratrol ameliorated the pathologic effects of ConA-induced autoimmune hepatitis and significantly inhibited IL-2, IL-6, TNF-alpha, Shh, Gli-1, and Ptc.	Resveratrol	18-29	interleukin 6	Mus musculus	136-140
25577343-9	2015	The Se-deficient mice model was successfully replicated, and Se deficiency exacerbated uterine tissue histopathology; increased the expression of TNF-alpha, IL-1beta, and IL-6; facilitated the activation of TLR4; and enhanced the phosphorylation of IkappaBalpha, p65, ERK, JNK, and p38 in LPS-induced mice endometritis.	Selenium	4-6	interleukin 6	Mus musculus	171-175
25053100-2	2015	Treatment with trilobatin (0.005-5 muM) dose-dependently inhibited the lipopolysaccharide (LPS)-induced mRNA expression and secretion of pro-inflammatory cytokines, including tumor necrosis factor alpha (TNFalpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6), in RAW 264.7 macrophages.	trilobatin	15-25	interleukin 6	Mus musculus	248-261
25053100-2	2015	Treatment with trilobatin (0.005-5 muM) dose-dependently inhibited the lipopolysaccharide (LPS)-induced mRNA expression and secretion of pro-inflammatory cytokines, including tumor necrosis factor alpha (TNFalpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6), in RAW 264.7 macrophages.	trilobatin	15-25	interleukin 6	Mus musculus	263-267
25053100-5	2015	In addition, trilobatin also showed a significant inhibition of LPS-induced TNFalpha and IL-6 at both the mRNA and protein levels in a mouse model.	trilobatin	13-23	interleukin 6	Mus musculus	89-93
26181650-4	2015	The data showed that TBMS1 inhibited ConA-induced T lymphocyte proliferation, decreased the ratio of CD4(+)/CD8(+), suppressed IL-2, IFN-gamma, IL-4 and IL-6 production and mRNA expression, down-regulate activation of NF-kappaB, NFAT2 and AP-1 signal transduction pathways in vitro.	tubeimoside I	21-26	interleukin 6	Mus musculus	153-157
25586484-4	2015	Resveratrol could significantly reduce the levels of pro-inflammatory factors TNF-alpha, IL-1beta, and IL-6 in serum (p&lt;0.01) and greatly elevate the expression level of SIRT1 (p&lt;0.01).	Resveratrol	0-11	interleukin 6	Mus musculus	103-107
26021324-11	2015	In parallel, suramin blocked DNCB-induced elevation in serum TNF-alpha, IL-1beta, IL-6 and IgE.	Suramin	13-20	interleukin 6	Mus musculus	82-86
26021324-11	2015	In parallel, suramin blocked DNCB-induced elevation in serum TNF-alpha, IL-1beta, IL-6 and IgE.	Dinitrochlorobenzene	29-33	interleukin 6	Mus musculus	82-86
25175733-7	2015	Pharmacological tests showed that DHP-4A can significantly stimulate RAW 264.7 macrophage cells to secrete NO, TNF-alpha, IL-6 and IL-10 via activation of p38, ERK, JNK and translocation of nuclear NF-kappaB, indicating this polysaccharide possesses good immunoregulatory activity.	dhp-4a	34-40	interleukin 6	Mus musculus	122-126
25502067-4	2015	Phenyl-beta-D-glucopyranoside also attenuated proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and other inflammation-related genes, such as IL-6 in a concentration-dependent manner.	phenylglucoside	0-29	interleukin 6	Mus musculus	199-203
25304471-3	2015	Here, we tested the hypothesis that deletion of interleukin-6 protects against the development of hypertension, cardiac inflammation, fibrosis, remodeling and dysfunction induced by high salt diet and angiotensin II (Ang II).	Salts	187-191	interleukin 6	Mus musculus	48-61
25479726-7	2015	Also, paeoniflorin pretreatment suppressed the secretion of proinflammatory cytokines (TNF-alpha, INF-gamma, IL-6), compared with Con A group.	peoniflorin	6-18	interleukin 6	Mus musculus	109-113
26761842-4	2015	The anti-inflammatory actions of these two preparations of PPE were evaluated by measuring their inhibitory effects on the production of NO, the expression of iNOS protein, and the expression of iNOS, COX2, TNF-alpha, IL-1beta, and IL-6 mRNA in lipopolysaccharide-stimulated RAW 264.7 cells.	ppe	59-62	interleukin 6	Mus musculus	232-236
25660311-0	2015	HMGB1 Binds to Lipoteichoic Acid and Enhances TNF-alpha and IL-6 Production through HMGB1-Mediated Transfer of Lipoteichoic Acid to CD14 and TLR2.	lipoteichoic acid	111-128	interleukin 6	Mus musculus	60-64
26218715-4	2015	pGLP-2 microspheres showed 20.36% in initial burst and constant release for at least 9 d. In the DSS-treated mice, a single injection of GLP-2 microspheres significantly increased the body weight, colonic length, small intestinal weight and mRNA expression of Occludin, decreased the colonic damage score, mRNA expression of IL-6, IL-10, TNF-alpha and IFN-gamma.	Dextran Sulfate	97-100	interleukin 6	Mus musculus	325-329
25821351-3	2015	The expression of IL-2, IL-6, TNF-alpha, and IFN-gamma was significantly reduced in the NAC-treated groups.	Acetylcysteine	88-91	interleukin 6	Mus musculus	24-28
26347589-7	2015	In addition, the treatment of EAT-bearing mice with indomethacin has stimulated the IL-13 production and has significantly inhibited IL-6 in the 13th day of tumor growth.	Indomethacin	52-64	interleukin 6	Mus musculus	133-137
25878403-9	2015	Interestingly, lung myeloperoxidase and interleukin-6 were concurrently increased by MitoQ in CER-AP.	mitoquinone	85-90	interleukin 6	Mus musculus	40-53
25265201-8	2015	Furthermore, PMWCNTs induced a more severe NASH-like phenotype than TMWCNTs, which was related to consistent up-regulation of interleukin (IL)-6 and plasminogen activator inhibitor (PAI)-1.	pmwcnts	13-20	interleukin 6	Mus musculus	126-144
26783382-8	2015	High-salt significantly promotes IL-6 and MCP-1 production by ARPE-19 cells and is associated with activation of the p38 MAPK, Akt, and NF-kappaB pathway and NFAT-SGK1 pathways.	Salts	5-9	interleukin 6	Mus musculus	33-37
25399297-7	2015	TA prevents the DMBA + croton oil-induced toxicity through a protective mechanism that involves the reduction of oxidative stress as well as COX-2, i-NOS, PCNA protein expression and level of proinflammatory cytokine such as IL-6 release at a very significant level (p &lt; 0.001).	Tannins	0-2	interleukin 6	Mus musculus	225-229
25613602-6	2015	Chloroquine combined with low-dose dexamethasone significantly lessened inflammations around the bronchioles (P&lt;0.05) and blood vessels (P&lt;0.01) in the lung tissue, and obviously lowered IL-6 (P&lt;0.05) and PGF2alpha (P&lt;0.001) in the BALF in the asthmatic mice.	Chloroquine	0-11	interleukin 6	Mus musculus	193-197
25613602-6	2015	Chloroquine combined with low-dose dexamethasone significantly lessened inflammations around the bronchioles (P&lt;0.05) and blood vessels (P&lt;0.01) in the lung tissue, and obviously lowered IL-6 (P&lt;0.05) and PGF2alpha (P&lt;0.001) in the BALF in the asthmatic mice.	Dexamethasone	35-48	interleukin 6	Mus musculus	193-197
25265201-8	2015	Furthermore, PMWCNTs induced a more severe NASH-like phenotype than TMWCNTs, which was related to consistent up-regulation of interleukin (IL)-6 and plasminogen activator inhibitor (PAI)-1.	tmwcnts	68-75	interleukin 6	Mus musculus	126-144
26011019-6	2015	MSeA (3 mg/kg body weight) inhibited tumor growth up to 61% when compared to the control group, and this inhibition was associated with a reduction of plasma tumor necrosis factor (TNFalpha)/interleukin 6 (IL6) level but elevated blood GPx activities.	methylselenic acid	0-4	interleukin 6	Mus musculus	191-204
26452216-10	2015	The elevated serum concentrations of interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-alpha) were decreased by L-carnitine.	Carnitine	118-129	interleukin 6	Mus musculus	37-55
26011019-6	2015	MSeA (3 mg/kg body weight) inhibited tumor growth up to 61% when compared to the control group, and this inhibition was associated with a reduction of plasma tumor necrosis factor (TNFalpha)/interleukin 6 (IL6) level but elevated blood GPx activities.	methylselenic acid	0-4	interleukin 6	Mus musculus	206-209
25462173-4	2015	Doxorubicin increased the cardiac mRNA levels of BNP, IL-6 and CTGF, while the expression of ANP remained unchanged.	Doxorubicin	0-11	interleukin 6	Mus musculus	54-58
25868617-14	2015	PIP dose dependently reduced histamine, NO concentration (p &lt; 0.001), as well as reduced expression of IL-6, IL-1beta, and IgE (p &lt; 0.001) as compared with the control group.	piperine	0-3	interleukin 6	Mus musculus	106-110
26075036-6	2015	These findings suggest that allicin exerts clinically useful anti-inflammatory effects mediated through the suppression of the NF-kappaB and IL-6/p-STAT3(Y705) pathways.	allicin	28-35	interleukin 6	Mus musculus	141-145
26329008-5	2015	In both a mouse AM cell line (AMJ2-C11 cells) and mouse bronchoalveolar fluid cells, we demonstrated that quercetin attenuated TLR7-induced the expression of TNF-alpha and IL-6.	Quercetin	106-115	interleukin 6	Mus musculus	172-176
26329008-7	2015	Notably, tin protoporphyrin IX (SnPP), an inhibitor of HO-1, also attenuated TLR7-induced transcription of the TNF-alpha and IL-6 genes, suggesting that the effect of quercetin is mediated by HO-1.	tin protoporphyrin IX	9-30	interleukin 6	Mus musculus	125-129
26329008-7	2015	Notably, tin protoporphyrin IX (SnPP), an inhibitor of HO-1, also attenuated TLR7-induced transcription of the TNF-alpha and IL-6 genes, suggesting that the effect of quercetin is mediated by HO-1.	S-Nitroso-N-propionyl-D,L-penicillamine	32-36	interleukin 6	Mus musculus	125-129
26329008-7	2015	Notably, tin protoporphyrin IX (SnPP), an inhibitor of HO-1, also attenuated TLR7-induced transcription of the TNF-alpha and IL-6 genes, suggesting that the effect of quercetin is mediated by HO-1.	Quercetin	167-176	interleukin 6	Mus musculus	125-129
26540118-5	2015	In addition, TB inhibited inflammatory cells and cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in BALF.	timosaponin B-II	13-15	interleukin 6	Mus musculus	143-156
26540118-5	2015	In addition, TB inhibited inflammatory cells and cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in BALF.	timosaponin B-II	13-15	interleukin 6	Mus musculus	158-162
25457840-8	2014	The retinal-protective effect of ABT-702 was demonstrated by significant reduction of Iba-1, ENT1, TNF-alpha, IL-6, and iNOS/nNOS protein or mRNA expression in TON as revealed by western blot and real time PCR.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	33-36	interleukin 6	Mus musculus	110-114
25722879-10	2014	The IL-6 level was gradually decreased in the PG group at 4 h. The peak of lymphocytic apoptosis and DNA damage occurred at 24 h and 72 h, respectively.	pg	46-48	interleukin 6	Mus musculus	4-8
25722879-12	2014	SM intoxication also significantly increased the levels of pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha) and inhibited the level of anti-inflammatory cytokine IL-10.	Mustard Gas	0-2	interleukin 6	Mus musculus	97-101
25515685-7	2014	The expression levels of IL-1beta, IL-6, F4/80, CCL2, and CXCL2 mRNA in the colonic mucosa of AOM-treated mice were significantly decreased by astaxanthin.	astaxanthine	143-154	interleukin 6	Mus musculus	35-39
25387343-9	2014	Additionally, there was a significant decrease in LPS-induced IL-6 and TNF-alpha production following PEITC treatment compared with that following CUR in Nrf2(+/+) macrophages, whereas no change was observed in the macrophages from knockout animals.	phenethyl isothiocyanate	102-107	interleukin 6	Mus musculus	62-66
25470242-7	2014	The expression of NF-kappaB target genes, Il6, Nos2, Cxcl1, ccl5 and Cxcl2 induced by IL-1beta and TNFalpha was suppressed after NTP treatment.	neurotropin	129-132	interleukin 6	Mus musculus	42-45
25328157-8	2014	Furthermore, there was a significant decrease in the mRNA abundance of IL-6 in the primary splenocytes isolated from the 0.03% ASTX-supplemented group upon lipopolysaccharide (LPS) stimulation when compared with that in the splenocytes isolated from the control group.	astaxanthine	127-131	interleukin 6	Mus musculus	71-75
25446583-7	2014	RESULTS: We found casticin inhibited the levels of nitric oxide and PGE2, and decreased the production of proinflammatory cytokines such as interleukin (IL)-1beta, IL-6, and tumor necrosis factor alpha (TNF-alpha).	casticin	18-26	interleukin 6	Mus musculus	164-168
25485716-8	2014	Mice immunized with IB010 had significantly lower post-infection tissue bacterial loads and significantly lower serum levels of the pro-inflammatory cytokines IL-1beta, TNF-alpha and IL-6 compared to control mice in a mouse model of disseminated A. baumannii infection.	ib010	20-25	interleukin 6	Mus musculus	183-187
25260144-8	2014	RESULTS: STS inhibited lipopolysaccharide-induced production of cytokines (interleukin-6 [pg/ml]; 313+-164, lipopolysaccharide; 79+-27, lipopolysaccharide+STS [n=10]), lung permeability, histologic lung injury, and nuclear factor-kappaB activation in the lung.	sodium thiosulfate	9-12	interleukin 6	Mus musculus	75-88
24842127-0	2014	Saquinavir-NO inhibits IL-6 production in macrophages.	Saquinavir-NO	0-13	interleukin 6	Mus musculus	23-27
24842127-3	2014	The results demonstrate that Saq-NO, but not Saq, potently decreased interleukin (IL)-10, IL-6 and nitrite accumulation and increased the levels of IL-1beta and tumour necrosis factor (TNF) in supernatants of mouse and rat macrophage cultures in vitro.	saq-no	29-35	interleukin 6	Mus musculus	90-94
24842127-4	2014	Treatment of mice with Saq-NO, but not Saq, inhibited ex vivo secretion of IL-6 from macrophages.	saq-no	23-29	interleukin 6	Mus musculus	75-79
24842127-3	2014	The results demonstrate that Saq-NO, but not Saq, potently decreased interleukin (IL)-10, IL-6 and nitrite accumulation and increased the levels of IL-1beta and tumour necrosis factor (TNF) in supernatants of mouse and rat macrophage cultures in vitro.	Saquinavir	29-32	interleukin 6	Mus musculus	90-94
24842127-4	2014	Treatment of mice with Saq-NO, but not Saq, inhibited ex vivo secretion of IL-6 from macrophages.	Saquinavir	23-26	interleukin 6	Mus musculus	75-79
25293877-5	2014	Intriguingly, lycopene chemopreventive effects in wild-type mice were associated with reduced hepatic proinflammatory signaling (phosphorylation of NK-kappaB p65 and STAT3; IL6 protein) and inflammatory foci.	Lycopene	14-22	interleukin 6	Mus musculus	173-176
24842127-5	2014	Consistent with these findings, Saq-NO also reduced blood levels of IL-6 in lipopolysaccharide-treated mice.	saq-no	32-38	interleukin 6	Mus musculus	68-72
24842127-6	2014	The observed inhibitory influence of Saq-NO on IL-6 generation in macrophages may be involved in the observed antitumour and immunomodulatory effects of the drug.	saq-no	37-43	interleukin 6	Mus musculus	47-51
25152356-8	2014	RESULTS: Tiliroside significantly suppressed TNFalpha, IL-6, nitrite and PGE2 production, as well as iNOS and COX-2 protein expression from LPS+IFNgamma-activated BV2 microglia.	tiliroside	9-19	interleukin 6	Mus musculus	55-59
24101442-6	2014	Moreover, the JNK inhibitor SP600125 decreased production of IL-6 and TNF-alpha induced by LDH.	pyrazolanthrone	28-36	interleukin 6	Mus musculus	61-65
25307205-6	2014	Supplementation with alpha- and mixed-tocopherol reduced systemic concentrations of IL-6 (P &lt; 0.001 and P &lt; 0.001, respectively) and IL-10 (P &lt; 0.05 and P &lt; 0.001, respectively), while alpha-tocopherol also reduced MCP-1 (P &lt; 0.05) and tumor necrosis factor (TNF)-alpha (P &lt; 0.05).	alpha- and mixed-tocopherol	21-48	interleukin 6	Mus musculus	84-88
25251587-7	2014	Macrophages with 5-aza-dC treatment had downregulated expression of genes involved in inflammation (TNF-alpha, IL-6, IL-1beta, and inducible nitric oxidase) and chemotaxis (CD62/L-selectin, chemokine [C-C motif] ligand 2/MCP-1 [CCL2/MCP-1], CCL5, CCL9, and CCL2 receptor CCR2).	Azacitidine	17-22	interleukin 6	Mus musculus	111-115
24715223-13	2014	In vivo, CDDO-Im improved the altered colonic histology, and cytokine (IL-6, and IL-17) contents.	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	9-14	interleukin 6	Mus musculus	71-75
24912504-5	2014	Quercetin markedly rescued lethality, improved survival time, and inhibited serum necrosis factor alpha, interleukin 1beta, and interleukin 6, and nitric oxide (NO), and increased IL-10 secretion.	Quercetin	0-9	interleukin 6	Mus musculus	128-141
25063711-9	2014	In vitro, catalpol inhibited TNF-alpha, IL-6, IL-4 and IL-1beta production and up-regulated IL-10 expression in LPS-stimulated alveolar macrophages.	catalpol	10-18	interleukin 6	Mus musculus	40-44
24854163-5	2014	When pretreated with wogonoside, the TNF-alpha, IL-6, and IL-1beta levels were significantly decreased.	wogonoside	21-31	interleukin 6	Mus musculus	48-52
24912813-4	2014	The results showed that Thd significantly improved the survival rate, reduced the infiltration of inflammatory cells and cytokine (e.g., IL-6, TNF-alpha) and chemokine (e.g., RANTES, IP-10) levels, and inhibited activated p-NFkappaB p65 in infected mice.	Thalidomide	24-27	interleukin 6	Mus musculus	137-141
24928629-4	2014	We found that pretreatment with CHE (1, 5, and 10 mg/kg, po) at 1 and 12 h before injected intraperitoneally with 1 mg/kg LPS markedly decreased the production of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and myeloperoxidase (MPO) and attenuated the lung histopathological changes.	chelerythrine	32-35	interleukin 6	Mus musculus	163-176
24928629-4	2014	We found that pretreatment with CHE (1, 5, and 10 mg/kg, po) at 1 and 12 h before injected intraperitoneally with 1 mg/kg LPS markedly decreased the production of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and myeloperoxidase (MPO) and attenuated the lung histopathological changes.	chelerythrine	32-35	interleukin 6	Mus musculus	178-182
25311666-5	2014	Linalool alleviated serum and hepatic TNF-alpha and IL-6 production, as well as hepatic iNOS and COX-2 expression by inhibiting NF-kappaB activation.	linalool	0-8	interleukin 6	Mus musculus	52-56
25261704-7	2014	In addition, 8,8"-bieckol decreased the production and mRNA expression of the inflammatory cytokine interleukin-6 (IL-6), but not tumor necrosis factor (TNF)-alpha, in RAW 264.7 cells.	8,8'-bieckol	13-25	interleukin 6	Mus musculus	100-113
25261704-7	2014	In addition, 8,8"-bieckol decreased the production and mRNA expression of the inflammatory cytokine interleukin-6 (IL-6), but not tumor necrosis factor (TNF)-alpha, in RAW 264.7 cells.	8,8'-bieckol	13-25	interleukin 6	Mus musculus	115-119
25261704-10	2014	Taken together, these data indicate that the anti-inflammatory properties of 8,8"-bieckol are associated with the suppression of NO, PGE2, and IL-6 via negative regulation of the NF-kappaB pathway and ROS production in LPS-stimulated RAW 264.7 cells.	8,8'-bieckol	77-89	interleukin 6	Mus musculus	143-147
26251760-9	2014	The production of IL-6 was significantly lower at the peak of disease in mice treated with CII-BPI-2 compared to those treated with CII-2 and control.	cii-2	132-137	interleukin 6	Mus musculus	18-22
25467201-4	2014	Treatment with 100 mug/ml ethyl acetate fraction (REF), which was isolated from water extract of the seeds, significantly inhibited LPS-stimulated production of nitric oxide (P &lt; 0.05), interleukin-6 (P &lt; 0.001), and tumor necrosis factor (TNF)-alpha (P &lt; 0.001) in RAW264.7 cells.	ethyl acetate	26-39	interleukin 6	Mus musculus	189-202
25467201-4	2014	Treatment with 100 mug/ml ethyl acetate fraction (REF), which was isolated from water extract of the seeds, significantly inhibited LPS-stimulated production of nitric oxide (P &lt; 0.05), interleukin-6 (P &lt; 0.001), and tumor necrosis factor (TNF)-alpha (P &lt; 0.001) in RAW264.7 cells.	Water	80-85	interleukin 6	Mus musculus	189-202
25365203-6	2014	Production of immunoregulatory cytokine IL-10 was significantly inhibited, while proinflammatory cytokines IL-6, IL-1beta, TNF-alpha and IL-33 were enhanced in CS-exposed BM-MDRC.	Cesium	160-162	interleukin 6	Mus musculus	107-111
25436606-6	2014	Our results discard a role for IL-6 in the action of sorafenib since the drug did not affect the levels of this cytokine.	Sorafenib	53-62	interleukin 6	Mus musculus	31-35
24788682-5	2014	LPS-stimulated TNF-alpha and IL6 mRNA and protein were also reduced in CMVEC treated with an inhibitor of TLR4 signaling, CLI-095, or HO-2 overexpression.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	122-129	interleukin 6	Mus musculus	29-32
25242730-3	2014	NAHNP significantly inhibited the production of pro-inflammatory cytokines such as TNF-alpha, IL-6 and IL-1beta in lipopolysaccharide (LPS)-induced primary mouse macrophages and DC2.4 dendritic cell line.	nahnp	0-5	interleukin 6	Mus musculus	94-98
25101553-5	2014	In the present study 5-aminosalicylic acid (5-ASA), a salicylic acid derivative, was evaluated, in vivo for its potential to suppress TNF-alpha, IL-6 and IL-13 using ovalbumin (OVA) induced allergic asthma in Balb/C mice.	Mesalamine	21-42	interleukin 6	Mus musculus	145-149
25101553-5	2014	In the present study 5-aminosalicylic acid (5-ASA), a salicylic acid derivative, was evaluated, in vivo for its potential to suppress TNF-alpha, IL-6 and IL-13 using ovalbumin (OVA) induced allergic asthma in Balb/C mice.	Mesalamine	44-49	interleukin 6	Mus musculus	145-149
25101553-5	2014	In the present study 5-aminosalicylic acid (5-ASA), a salicylic acid derivative, was evaluated, in vivo for its potential to suppress TNF-alpha, IL-6 and IL-13 using ovalbumin (OVA) induced allergic asthma in Balb/C mice.	Salicylic Acid	28-42	interleukin 6	Mus musculus	145-149
25101553-6	2014	Oral administration of 65, 130 and 195 mg/kg 5-ASA significantly reduced the OVA induced total and differential leucocyte count, TNF-alpha, IL-6, IL-13, nitrite, nitrate, MDA, MPO and TPL levels in the lung lavage samples.	Mesalamine	45-50	interleukin 6	Mus musculus	140-144
25382719-4	2014	GalN/LPS increased serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, while 1 attenuated TNF-alpha levels and further increased IL-6 levels.	Galactosamine	0-4	interleukin 6	Mus musculus	69-82
25264520-8	2014	RESULTS: Following stimulation with poly I:C, MLE-12 cells pre-treated with Th2 cytokines exhibited significantly higher levels of expression of mRNA for the cytokine genes Cxcl10 and Cxcl11, as well as a trend towards increased expression of Cxcl9 and Il6.	Poly I	36-42	interleukin 6	Mus musculus	253-256
25382719-4	2014	GalN/LPS increased serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, while 1 attenuated TNF-alpha levels and further increased IL-6 levels.	Galactosamine	0-4	interleukin 6	Mus musculus	84-88
25382719-4	2014	GalN/LPS increased serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, while 1 attenuated TNF-alpha levels and further increased IL-6 levels.	Galactosamine	0-4	interleukin 6	Mus musculus	156-160
25429137-0	2014	Immune-induced fever is mediated by IL-6 receptors on brain endothelial cells coupled to STAT3-dependent induction of brain endothelial prostaglandin synthesis.	Prostaglandins	136-149	interleukin 6	Mus musculus	36-40
25429137-6	2014	These data show that IL-6, when endogenously released during systemic inflammation, is pyrogenic by binding to IL-6Ralpha on brain endothelial cells to induce prostaglandin synthesis in these cells, probably in concerted action with other peripherally released cytokines.	Prostaglandins	159-172	interleukin 6	Mus musculus	21-25
25407356-7	2014	RESULTS: Treatment of BV-2 microglia with 100 muM MPEP increased intracellular reactive oxygen species (ROS), mitochondrial superoxide, mitochondrial mass as well as inducible nitric oxide synthase (iNOS) and IL-6 expression.	6-methyl-2-(phenylethynyl)pyridine	50-54	interleukin 6	Mus musculus	209-213
25325613-4	2014	Treatment with GalN/LPS resulted in increased levels of serum alanine aminotransferase, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6, as well as increased mortality, all of which were attenuated by treatment with 1.	Galactosamine	15-19	interleukin 6	Mus musculus	127-145
25325613-8	2014	Following GalN/LPS treatment, nuclear translocation of nuclear factor-kappaB and the levels of TNF-alpha and IL-6 mRNA expression increased, which were attenuated by 1.	Galactosamine	10-14	interleukin 6	Mus musculus	109-113
25258409-8	2014	Furthermore, nicotine inhibited the IL-6 production of CD4 T cells in the DSS-induced inflamed colonic mucosa.	Nicotine	13-21	interleukin 6	Mus musculus	36-40
25405982-8	2014	Furthermore, the mice treated with EsA had a lower level of TNF-alpha, Interleukin (IL)-1beta and IL-6 in mRNA expression.	esculentoside A	35-38	interleukin 6	Mus musculus	98-102
25205821-2	2014	Previous work implicates the proinflammatory cytokine interleukin-6 (IL-6) in glucagon secretion.	Glucagon	78-86	interleukin 6	Mus musculus	54-67
25205821-2	2014	Previous work implicates the proinflammatory cytokine interleukin-6 (IL-6) in glucagon secretion.	Glucagon	78-86	interleukin 6	Mus musculus	69-73
25258409-8	2014	Furthermore, nicotine inhibited the IL-6 production of CD4 T cells in the DSS-induced inflamed colonic mucosa.	Dextran Sulfate	74-77	interleukin 6	Mus musculus	36-40
25258409-10	2014	Nicotine markedly inhibited the elevation of TNF-alpha and IL-6 mRNA as well as phosphorylated signal transducer and activator of transcription (Stat) 3 expression in the colons of the tumor model mice.	Nicotine	0-8	interleukin 6	Mus musculus	59-63
25205821-3	2014	IL-6-KO mice have a blunted glucagon response to lipopolysaccharide (LPS) that is restored by intravenous replacement of IL-6.	Glucagon	28-36	interleukin 6	Mus musculus	0-4
25258409-12	2014	Furthermore, it is presumed that nicotine downregulates the expression of inflammatory mediators such as IL-6/Stat3 and TNF-alpha, thereby reducing the colonic tumorigenesis associated with chronic colitis.	Nicotine	33-41	interleukin 6	Mus musculus	105-109
25257464-6	2014	Ghrelin inhibited the inductions of C-reactive protein, tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6, mitigated the reduction of food intake and fat mass, and consequently ameliorated body weight loss in the mouse model of lung adenocarcinoma.	Ghrelin	0-7	interleukin 6	Mus musculus	108-121
25550915-12	2014	Baicalin and mesalazine treatment suppressed the expression of TNF-alpha, IL-6 and IL-13 mRNA (P &lt; 0.05), yet up-regulated the expression of IL-10 mRNA (P &lt; 0.05), compared to the DDS and control groups.	baicalin	0-8	interleukin 6	Mus musculus	74-78
25205821-4	2014	Given that IL-6 has previously been demonstrated to have a transcriptional (i.e., slow) effect on glucagon secretion from islets, we hypothesized that the rapid increase in glucagon following LPS occurred by a faster mechanism, such as by action within the brain.	Glucagon	98-106	interleukin 6	Mus musculus	11-15
25205821-4	2014	Given that IL-6 has previously been demonstrated to have a transcriptional (i.e., slow) effect on glucagon secretion from islets, we hypothesized that the rapid increase in glucagon following LPS occurred by a faster mechanism, such as by action within the brain.	Glucagon	173-181	interleukin 6	Mus musculus	11-15
25205821-6	2014	Contrary to our hypothesis, however, we found that IL-6 amplifies glucagon secretion in two ways; IL-6 not only stimulates glucagon secretion via the brain but also by direct action on islets.	Glucagon	66-74	interleukin 6	Mus musculus	51-55
25205821-6	2014	Contrary to our hypothesis, however, we found that IL-6 amplifies glucagon secretion in two ways; IL-6 not only stimulates glucagon secretion via the brain but also by direct action on islets.	Glucagon	66-74	interleukin 6	Mus musculus	98-102
25205821-6	2014	Contrary to our hypothesis, however, we found that IL-6 amplifies glucagon secretion in two ways; IL-6 not only stimulates glucagon secretion via the brain but also by direct action on islets.	Glucagon	123-131	interleukin 6	Mus musculus	51-55
25205821-6	2014	Contrary to our hypothesis, however, we found that IL-6 amplifies glucagon secretion in two ways; IL-6 not only stimulates glucagon secretion via the brain but also by direct action on islets.	Glucagon	123-131	interleukin 6	Mus musculus	98-102
25205821-7	2014	Interestingly, IL-6 augments glucagon secretion from both sites only in the presence of an accompanying stressor (such as epinephrine).	Glucagon	29-37	interleukin 6	Mus musculus	15-19
25205821-7	2014	Interestingly, IL-6 augments glucagon secretion from both sites only in the presence of an accompanying stressor (such as epinephrine).	Epinephrine	122-133	interleukin 6	Mus musculus	15-19
25396421-7	2014	Nicotine treatments significantly improved survival rate, attenuated myocardial lesions, and downregulated the expression of TNF-alpha and IL-6.	Nicotine	0-8	interleukin 6	Mus musculus	139-143
25396421-8	2014	Methyllycaconitine decreased survival rate, aggravated myocardial lesions, and upregulated the expression of TNF-alpha and IL-6.	methyllycaconitine	0-18	interleukin 6	Mus musculus	123-127
25396421-11	2014	Because nicotine is a alpha7nAchR agonist and methyllycaconitine is a alpha7nAchR antagonist, we conclude that alpha7nAchR activation increases the phosphorylation of STAT3, reduces the expression of TNF-alpha and IL-6, and, ultimately, alleviates viral myocarditis.	methyllycaconitine	46-64	interleukin 6	Mus musculus	214-218
25550915-12	2014	Baicalin and mesalazine treatment suppressed the expression of TNF-alpha, IL-6 and IL-13 mRNA (P &lt; 0.05), yet up-regulated the expression of IL-10 mRNA (P &lt; 0.05), compared to the DDS and control groups.	Mesalamine	13-23	interleukin 6	Mus musculus	74-78
25387351-3	2014	The results showed that pretreated low molecular weight sulfated chitosan oligosaccharides inhibited the production of nitric oxide (NO) and inflammatory cytokines such as IL-6 and TNF-alpha in lipopolysaccharide (LPS)-activated RAW264.7 cells.	chitosan oligosaccharides	65-90	interleukin 6	Mus musculus	172-176
25387351-5	2014	Our investigation suggests sulfated chitosan oligosaccharides inhibit IL-6/TNF-alpha in LPS-induced macrophages, regulated by mitogen-activated protein kinases (MAPKs) pathways dependent on NF-kappaB activation.	Oligosaccharides	45-61	interleukin 6	Mus musculus	70-74
25225121-7	2014	KEY FINDINGS: All the tested dipeptides significantly inhibited the secretion of nitric oxide, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6 from LPS-stimulated RAW 264.7 macrophages.	Dipeptides	29-39	interleukin 6	Mus musculus	134-152
25154664-11	2014	Cytokine ELISA showed that mouse J774 cells exposed to fGNPs produced less IL-6 than did GNP-treated macrophage cells, whereas TNF-alpha levels were low in both treatment groups.	LHRH (1-6)	56-59	interleukin 6	Mus musculus	75-79
25347266-7	2014	As determined from the spleen after the FST: Gly and Arg regulated the effects of IL-1beta; Gly, Pro, and Arg regulated the effects of IL-6; PE and all of the amino acids present in PE regulated the effects of TNF-alpha.	Glycine	92-95	interleukin 6	Mus musculus	135-139
25347266-7	2014	As determined from the spleen after the FST: Gly and Arg regulated the effects of IL-1beta; Gly, Pro, and Arg regulated the effects of IL-6; PE and all of the amino acids present in PE regulated the effects of TNF-alpha.	Arginine	106-109	interleukin 6	Mus musculus	135-139
25347266-9	2014	As determined from the serum after the TST: PE and Gly regulated the effects of TNF-alpha; Gly and Arg regulated the effects of IL-1beta; Gly, Pro, and Arg regulated the effects of IL-6; PE and all of the amino acids present in PE regulated the effects of TNF-alpha.	Arginine	152-155	interleukin 6	Mus musculus	181-185
24756886-7	2014	RESULTS: (1) Morphine induces robust BV-2 cell activation, as evidenced by increased p38 mitogen-activated protein kinase phosphorylation, nuclear factor-kappaB translocation and mRNA expression of pro-inflammatory cytokines [including interleukin-1beta (IL-1beta), IL-6 and tumour necrosis factor-alpha], inducible nitric oxide synthase and Toll-like receptor-4, and these changes are inhibited by resveratrol.	Morphine	13-21	interleukin 6	Mus musculus	266-303
24973254-7	2014	Similarly, galatrox administration into the mouse peritoneal cavity induced significant neutrophil migration and the release of pro-inflammatory cytokines IL-1alpha and IL-6.	galatrox	11-19	interleukin 6	Mus musculus	169-173
24973254-8	2014	Exposure of bone marrow-derived macrophages to galatrox induced generation of pro-inflammatory mediators IL-6, TNF-alpha, and keratinocyte-derived chemokine.	galatrox	47-55	interleukin 6	Mus musculus	105-109
25038318-3	2014	The aim of the present study was to investigate the effects of niacin on the production of pro-inflammatory cytokines TNF-alpha, IL-6 and IL-1beta in LPS-induced mouse alveolar macrophages and explore its underlying mechanism.	Niacin	63-69	interleukin 6	Mus musculus	129-133
25151099-4	2014	The results showed that scoparone treatment remarkably attenuated LPS-induced pulmonary edema, histological severities, myeloperoxidase activity, and TNF-alpha, IL-6 and IL-1beta production in vivo.	scoparone	24-33	interleukin 6	Mus musculus	161-165
25038318-5	2014	The results showed that niacin reduced the levels of TNF-alpha, IL-6 and IL-1beta in LPS-challenged alveolar macrophages.	Niacin	24-30	interleukin 6	Mus musculus	64-68
25151099-5	2014	We also found that scoparone inhibited LPS-induced TLR4 expression, NF-kappaB activation, TNF-alpha, IL-6 and IL-1beta production in alveolar macrophages in vitro.	scoparone	19-28	interleukin 6	Mus musculus	101-105
25149082-7	2014	Moreover, Cd exposure induced a strong increase of Pax3, Pax7 and Myf5 mRNAs expression and stimulated an up-regulation of IL6 and TNF-alpha proinflammatory cytokines.	Cadmium	10-12	interleukin 6	Mus musculus	123-126
25194678-5	2014	DSS-induced degradation of inhibitory kappaBalpha (IkappaBalpha) and the phosphorylation of nuclear factor-kappa B (NF-kappaB) p65 as well as the mRNA expression of pro-inflammatory mediators (inducible NO synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), TNF-alpha, interleukin-1beta (IL-1beta) and IL-6) in the colon were also downregulated by mangiferin treatment.	Dextran Sulfate	0-3	interleukin 6	Mus musculus	311-315
25116192-5	2014	RESULTS: Compared to C, STZ-WT mice had significantly increased macrophage and TLR4 immunostaining in kidney, significant increases in MyD88, Interferon Regulatory Factor-3, NFKappaB activity, TNF-Alpha, IL-6, and MCP-1; all these were significantly decreased in the STZ-TLR4KO compared to STZ-WT mice.	Streptozocin	24-27	interleukin 6	Mus musculus	204-208
24491024-0	2014	Long-term effect of curcumin down-regulates expression of tumor necrosis factor-alpha and interleukin-6 via modulation of E26 transformation-specific protein and nuclear factor-kappaB transcription factors in livers of lymphoma bearing mice.	Curcumin	20-28	interleukin 6	Mus musculus	90-103
24948542-6	2014	After treatment with VPA, the renal level of malondialdehyde and the activity of myeloperoxidase decreased markedly; the activity of superoxide dismutase and the glutathione content increased accordingly; and the serum levels of tumor necrosis factor alpha, interleukin 1beta, and interleukin 6 decreased markedly.	Valproic Acid	21-24	interleukin 6	Mus musculus	281-294
24491024-3	2014	The present work was aimed to analyze the anti-carcinogenic action of curcumin on the expression of TNF-alpha and IL-6 even after withdrawal of treatment.	Curcumin	70-78	interleukin 6	Mus musculus	114-118
24491024-4	2014	Up-regulated expressions of TNF-alpha and IL-6 in terms of mRNA and protein levels in lymphoma bearing mice were significantly down-regulated by curcumin as compared to normal.	Curcumin	145-153	interleukin 6	Mus musculus	42-46
24491024-5	2014	Electrophoretic mobility shift assay (EMSA) results revealed that curcumin reduced binding of nuclear protein with ETS and NF-kappaB binding elements of TNF-alpha and IL-6 promoters, respectively.	Curcumin	66-74	interleukin 6	Mus musculus	167-171
24491024-5	2014	Electrophoretic mobility shift assay (EMSA) results revealed that curcumin reduced binding of nuclear protein with ETS and NF-kappaB binding elements of TNF-alpha and IL-6 promoters, respectively.	ets	115-118	interleukin 6	Mus musculus	167-171
24491024-7	2014	In continuation, the present study suggests that the long-term effect of curcumin may contribute to attenuate cancer progression via the down-regulation of TNF-alpha and IL-6 modulated by E26 transformation-specific protein (ETS) and nuclear factor-kappaB (NF-kappaB), respectively.	Curcumin	73-81	interleukin 6	Mus musculus	170-174
25125332-5	2014	In the present study, we found trehalose inhibited generation of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, and nitric oxide in the conditioned medium released from lipopolysaccharide (LPS)-stimulated BV-2 cells.	Trehalose	31-40	interleukin 6	Mus musculus	84-126
25019567-9	2014	rTB10.4-induced TNF-alpha, IL-6 and IL-12 p40 release was attenuated by the specific IkappaB phosphorylation inhibitor, BAY 11-7082.	3-(4-methylphenylsulfonyl)-2-propenenitrile	120-131	interleukin 6	Mus musculus	27-31
25130202-8	2014	Moreover, myricitrin reduced the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) and IL-6 and partially suppressed ROS production.	myricitrin	10-20	interleukin 6	Mus musculus	111-115
24850793-4	2014	cisplatin had lower mortality rate and improved clinical scores compared with mice in normal saline-treated group, and the level of IL-6 and TNF-alpha was significantly reduced after cisplatin administration in peritoneal fluid of mice underwent CLP.	Cisplatin	183-192	interleukin 6	Mus musculus	132-136
25150062-11	2014	8-Br-cAMP also blocked HDE-stimulated IL-6 and keratinocyte-derived chemokine release in precision-cut mouse lung slices (P &lt; 0.05).	8-Bromo Cyclic Adenosine Monophosphate	0-9	interleukin 6	Mus musculus	38-42
25356907-7	2014	In addition, the evolved strain (Evo) showed transiently increased virulence in a systemic mouse infection model, which correlated with increased organ-specific fungal burden and inflammatory response (TNFalpha and IL-6) in the brain.	SCHEMBL9731684	33-36	interleukin 6	Mus musculus	215-219
25139050-8	2014	In examining cellular cross-talk ex vivo, we show that ligand-dependent VDR signaling in adipocytes significantly inhibits mammary epithelial cell growth in part through the vitamin D3-dependent production of the cytokine IL-6.	Cholecalciferol	174-184	interleukin 6	Mus musculus	222-226
25315906-11	2014	In addition, metformin activated AMPK phosphorylation, inhibited NF-kappaB activation, down-regulated cytokine (IL-1beta, IL-6, TNF-alpha) and ICAM-1 expression following tMCAO (P &lt; 0.05).	Metformin	13-22	interleukin 6	Mus musculus	122-126
25123790-2	2014	TCBQ-treatment causes significant liver injury (the elevation of serum AST and ALT activities, histopathological changes in liver section including centrilobular necrosis and inflammatory cells), oxidative stress (the elevation of TBAR level and the inhibition of SOD and catalase activities) and inflammation (up-regulation of iNOS, COX-2, IL-1beta, IL-6, TNF-alpha and NF-kappaB).	Chloranil	0-4	interleukin 6	Mus musculus	351-355
25314304-4	2014	Our observations showed that pretreatment with PQQ significantly inhibited the production of NO and PGE2 and suppressed the expression of pro-inflammatory mediators such as iNOS, COX-2, TNF-a, IL-1b, IL-6, MCP-1 and MIP-1a in LPS treated primary microglia cells.	PQQ Cofactor	47-50	interleukin 6	Mus musculus	200-204
25213465-4	2014	Ursolic acid suppressed LPS-stimulated interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha, cyclooxygenase (COX)-2, and inducible NO synthetase (iNOS) expression as well as PGE2 and NO levels.	ursolic acid	0-12	interleukin 6	Mus musculus	63-67
24631921-6	2014	Moreover, DBT potentiated the expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	di-n-butyltin	10-13	interleukin 6	Mus musculus	88-101
24631921-6	2014	Moreover, DBT potentiated the expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	di-n-butyltin	10-13	interleukin 6	Mus musculus	103-107
24631921-10	2014	Finally, the calcium chelator BAPTA-AM diminished oxidative stress and induction of IL-6 expression, indicating the involvement of increased intracellular calcium in the enhanced microglia activity upon exposure to DBT.	Calcium	13-20	interleukin 6	Mus musculus	84-88
24631921-10	2014	Finally, the calcium chelator BAPTA-AM diminished oxidative stress and induction of IL-6 expression, indicating the involvement of increased intracellular calcium in the enhanced microglia activity upon exposure to DBT.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	30-38	interleukin 6	Mus musculus	84-88
24631921-10	2014	Finally, the calcium chelator BAPTA-AM diminished oxidative stress and induction of IL-6 expression, indicating the involvement of increased intracellular calcium in the enhanced microglia activity upon exposure to DBT.	Calcium	155-162	interleukin 6	Mus musculus	84-88
24631921-10	2014	Finally, the calcium chelator BAPTA-AM diminished oxidative stress and induction of IL-6 expression, indicating the involvement of increased intracellular calcium in the enhanced microglia activity upon exposure to DBT.	di-n-butyltin	215-218	interleukin 6	Mus musculus	84-88
25213465-9	2014	Ursolic acid (20 mg/kg) also inhibited TNBS-induced IL-1beta, IL-6, TNF-alpha by 93, 86, and 85%, respectively (p &lt; 0.05).	ursolic acid	0-12	interleukin 6	Mus musculus	62-66
25213465-9	2014	Ursolic acid (20 mg/kg) also inhibited TNBS-induced IL-1beta, IL-6, TNF-alpha by 93, 86, and 85%, respectively (p &lt; 0.05).	Trinitrobenzenesulfonic Acid	39-43	interleukin 6	Mus musculus	62-66
24972244-8	2014	Mangiferin (10 muM) inhibited LPS-stimulated expression of TNF-alpha, IL-1beta and IL-6 by 81.0%, 89.5% and 88.3%, respectively, whereas it increased IL-10 expression by 131.8% compared to LPS-nontreated group.	mangiferin	0-10	interleukin 6	Mus musculus	83-87
24972244-8	2014	Mangiferin (10 muM) inhibited LPS-stimulated expression of TNF-alpha, IL-1beta and IL-6 by 81.0%, 89.5% and 88.3%, respectively, whereas it increased IL-10 expression by 131.8% compared to LPS-nontreated group.	lps	30-33	interleukin 6	Mus musculus	83-87
24972244-12	2014	Furthermore, mangiferin (20mg/kg) significantly inhibited TNF-alpha by 78%, IL-1beta by 82%, and IL-6 expressions by 88% (P&lt;0.05), but induced IL-10 expression to 79% of the normal control group (P&lt;0.05).	mangiferin	13-23	interleukin 6	Mus musculus	97-101
25034806-6	2014	The results showed that veratric acid inhibited LPS-induced TNF-alpha, IL-6 and IL-1beta production in a dose dependent manner.	veratric acid	24-37	interleukin 6	Mus musculus	71-75
25118289-9	2014	Furthermore, inhibition of miR-21 by specific Vivo-Morpholino and knock-out of IL-6 in ethanol-treated mice also increased the expression of DR5 and FASLG in vivo during alcoholic liver injury.	Ethanol	87-94	interleukin 6	Mus musculus	79-83
24909493-8	2014	In contrast, intermediate levels of AUCIL6 resulted in high damage, and this was due to the insufficiency of damage recovery driven by anti-inflammatory responses from IL-10 and the activation of positive feedback sustained by IL-6.	aucil6	36-42	interleukin 6	Mus musculus	227-231
24709550-7	2014	The results demonstrated that pterostilbene significantly inhibited microglia activation, showing the obvious decrease of LPS-induced production of NO, TNF-alpha and IL-6 in N9 microglial cells.	pterostilbene	30-43	interleukin 6	Mus musculus	166-170
25305342-4	2014	In microglial cell line BV2 cells, lipopolysaccharide (LPS) time-dependently increased the mRNA expression of proinflammatory cytokines (TNF-alpha, IL-1beta, and IL-6), which was decreased by pretreatment with ligustilide in a dose-dependent manner.	ligustilide	210-221	interleukin 6	Mus musculus	162-166
25305342-7	2014	Intravenous injection of ligustilide prevented LPS-induced mechanical allodynia, and decreased LPS-induced TNF-alpha, IL-1beta, and IL-6 up-regulation in the spinal cord.	ligustilide	25-36	interleukin 6	Mus musculus	132-136
24972834-9	2014	Inflammation in mdx skeletal muscle tissue was also reduced following amitriptyline treatment as indicated by decreased immune cell infiltration of muscle and lower levels of the pro-inflammatory cytokines tumour necrosis factor-alpha and interleukin-6 in the forelimb flexors.	Amitriptyline	70-83	interleukin 6	Mus musculus	239-252
25305342-9	2014	The same treatment of ligustilide also inhibited CFA-induced TNF-alpha, IL-1beta, and IL-6 up-regulation and microglial activation in the spinal cord.	ligustilide	22-33	interleukin 6	Mus musculus	86-90
24452489-8	2014	RESULTS: The CQCQD treatment significantly ameliorated the severity of AP as evidenced by reducing the pancreatic histopathology score (4.5+-0.5 vs. 6.2+-1.7, P&lt;0.05) and the serum IL-6 levels (1228.3+-419.2 pg/mL vs. 1589.6+-337.3 pg/mL, P&lt;0.05).	cqcqd	13-18	interleukin 6	Mus musculus	184-188
24972834-10	2014	Interleukin-6 mRNA expression was remarkably reduced in the amygdala of mdx mice by chronic amitriptyline treatment.	Amitriptyline	92-105	interleukin 6	Mus musculus	0-13
24179040-4	2014	We show that pre-treatment of macrophages with Berenil dramatically suppressed IL-6, IL-12 and TNF-alpha production following LPS, CpG and Poly I:C stimulation without altering the expression of TLRs.	diminazene aceturate	47-54	interleukin 6	Mus musculus	79-83
24179040-4	2014	We show that pre-treatment of macrophages with Berenil dramatically suppressed IL-6, IL-12 and TNF-alpha production following LPS, CpG and Poly I:C stimulation without altering the expression of TLRs.	Poly I-C	139-147	interleukin 6	Mus musculus	79-83
24771071-4	2014	Using intraductal injection of LPS as a mouse model of mastitis, we found that geniposide significantly reduced the infiltration of inflammatory cells and downregulated the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6).	geniposide	79-89	interleukin 6	Mus musculus	262-275
24743918-6	2014	The present results showed that kaempferol markedly reduced infiltration of neutrophilic granulocyte, activation of myeloperoxidase (MPO), expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in a dose-dependent manner, which were increased in LPS-induced mouse mastitis.	kaempferol	32-42	interleukin 6	Mus musculus	194-207
24743918-6	2014	The present results showed that kaempferol markedly reduced infiltration of neutrophilic granulocyte, activation of myeloperoxidase (MPO), expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in a dose-dependent manner, which were increased in LPS-induced mouse mastitis.	kaempferol	32-42	interleukin 6	Mus musculus	209-213
24771071-4	2014	Using intraductal injection of LPS as a mouse model of mastitis, we found that geniposide significantly reduced the infiltration of inflammatory cells and downregulated the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6).	geniposide	79-89	interleukin 6	Mus musculus	277-281
24771071-6	2014	The results of enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qRT-PCR) showed that geniposide inhibited the expression of TNF-alpha, IL-1beta, and IL-6 in a dose-dependent manner.	geniposide	132-142	interleukin 6	Mus musculus	196-200
24803295-11	2014	Preemptive administration of dexmedetomidine significantly attenuated the cytokine response after lipopolysaccharide (LPS) induced endotoxemia (TNF-alpha, IL-1beta, IL-6, P&lt;0.01, respectively).	Dexmedetomidine	29-44	interleukin 6	Mus musculus	165-169
24839088-7	2014	The results showed that PA inhibited the LPS-induced TNF-alpha, IL-6, and IL-1beta production in a dose manner.	patchouli alcohol	24-26	interleukin 6	Mus musculus	64-68
24854162-9	2014	Furthermore, we found that the decreased serum creatinine level and the reduced expression of collagen and smooth muscle actin induced by PTX3 were abolished by additional administration of IL-6.	Creatinine	47-57	interleukin 6	Mus musculus	190-194
24912811-10	2014	Simvastatin significantly reduced MIP-2, KC, TNF-alpha, MPO, IL-6, and P-selectin levels compared to the sham group and I/R plus pretreatment with phosphate-buffered saline (PBS) group (P&lt;0.05).	Simvastatin	0-11	interleukin 6	Mus musculus	61-65
25068825-8	2014	The results in the present study indicated that usnic acid attenuated the expression of TNF-alpha, IL-6, IL-8 and MIP-2.	usnic acid	48-58	interleukin 6	Mus musculus	99-103
24957013-4	2014	CS exposure increased the number of pulmonary inflammatory cells, coupled with elevated production of tumor necrosis factor alpha and interleukin-6 in bronchoalveolar lavage fluids.	Cesium	0-2	interleukin 6	Mus musculus	134-147
25091623-8	2014	Inhibition of HO-1 activity by treatment with tin protoporphyrin IX, a specific HO-1 inhibitor, abrogated the inhibitory effects of 3-DSC on the production of NO and IL-6 in LPS-stimulated RAW264.7 cells.	tin protoporphyrin IX	46-67	interleukin 6	Mus musculus	166-170
24912557-5	2014	Expressions of the IL-6 and FasL genes appeared to be down-regulated by the formulation in TNBS-treated colon tissues, suggesting that the suppression of those genes may be involved in the anti-inflammatory activity of the formulation.	Trinitrobenzenesulfonic Acid	91-95	interleukin 6	Mus musculus	19-23
25051048-13	2014	Data from the present study demonstrated that naloxone reduced the expression levels of NF-kappaB and its upstream protein caspase-3, and reduced the LPS-induced production of nitric oxide, inducible nitric oxide synthase, tumor necrosis factor alpha, interleukin-1beta and interleukin-6 in BV2 microglia.	Naloxone	46-54	interleukin 6	Mus musculus	274-287
24945082-10	2014	MiR497, IL-6, and IL-1ss were upregulated after CCI but not affected by anesthetics.	CCI	48-51	interleukin 6	Mus musculus	8-12
25173422-3	2014	In vitro, Betulin inhibited LPS-induced tumor necrosis factor alpha (TNF-alpha) and (interleukin) IL-6 levels and up-regulated the level of IL-10.	betulin	10-17	interleukin 6	Mus musculus	98-102
25026360-12	2014	Bleomycin led to an increase in TNF-alpha and interleukin-6 (IL-6) (7.9 and 11.8 pg/ml).	Bleomycin	0-9	interleukin 6	Mus musculus	46-59
25324935-8	2014	Myricetin given at 0.12% of the total diet significantly reduced serum levels of leptin, tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in mice fed the HFHS diet.	myricetin	0-9	interleukin 6	Mus musculus	133-146
25324935-8	2014	Myricetin given at 0.12% of the total diet significantly reduced serum levels of leptin, tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in mice fed the HFHS diet.	myricetin	0-9	interleukin 6	Mus musculus	148-152
25026360-12	2014	Bleomycin led to an increase in TNF-alpha and interleukin-6 (IL-6) (7.9 and 11.8 pg/ml).	Bleomycin	0-9	interleukin 6	Mus musculus	61-65
24907647-6	2014	RESULTS: In the present study, we found that sevoflurane increased level of IL-6 and TNF-alpha through activating NF-kappaB signaling, and that 2-DG reduced sevoflurane-induced increase in IL-6 and TNF-alpha and nuclear NF-kappaB in microglia cells.	Sevoflurane	45-56	interleukin 6	Mus musculus	76-80
24907647-6	2014	RESULTS: In the present study, we found that sevoflurane increased level of IL-6 and TNF-alpha through activating NF-kappaB signaling, and that 2-DG reduced sevoflurane-induced increase in IL-6 and TNF-alpha and nuclear NF-kappaB in microglia cells.	Deoxyglucose	144-148	interleukin 6	Mus musculus	189-193
24907647-6	2014	RESULTS: In the present study, we found that sevoflurane increased level of IL-6 and TNF-alpha through activating NF-kappaB signaling, and that 2-DG reduced sevoflurane-induced increase in IL-6 and TNF-alpha and nuclear NF-kappaB in microglia cells.	Sevoflurane	157-168	interleukin 6	Mus musculus	189-193
25612451-9	2014	The glycyrrhizin acid significantly inhibited IL-1beta, IL-3, IL-5, IL-6, IL-10, IL-12 (p40), IL-12 (p70), IL-13, Eotaxin and TNF-alpha secreted by LPS-stimulated RAW264.7 cells (P &lt; 0.05).	glycyrrhizin acid	4-21	interleukin 6	Mus musculus	68-72
25612451-10	2014	The expression levels of IL-6 and Eotaxin were observably decreased in the licorice flavonoids with LPS group (P &lt; 0.05).	licorice flavonoids	75-94	interleukin 6	Mus musculus	25-29
25567153-9	2014	(3) The levels of IL-6 in lung tissue were significantly enhanced in the LPS-induced ALI mice, while it markedly decreased in ALI +losartan group.	Losartan	131-139	interleukin 6	Mus musculus	18-22
25102246-5	2014	The ability of omphalocarpin to modulate the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) was evaluated.	omphalocarpin	15-28	interleukin 6	Mus musculus	119-132
25102246-8	2014	RESULTS: It has been shown that omphalocarpin inhibited lipopolysaccharide (LPS)-stimulated NO production and pro-inflammatory mediators secretion, including TNF-alpha, IL-6 in a dose-dependent manner.	omphalocarpin	32-45	interleukin 6	Mus musculus	169-173
25102246-11	2014	CONCLUSION: These results obtained in vitro and in vivo showed that the anti-inflammatory mechanism of omphalocarpin might be attributed to the inhibition of pro-inflammatory mediators including nitric oxide, IL-6 and TNF-alpha.	omphalocarpin	103-116	interleukin 6	Mus musculus	209-213
25264893-13	2014	In addition, JNK, p-JNK, Bax, TNF-alpha, NF-kappaB, IL2, IL6 and levels were also decreased in NAC-treated mice.	Acetylcysteine	95-98	interleukin 6	Mus musculus	57-60
25119102-10	2014	After purification of fractions of MMME, it indicated that n-hexane fraction mojabanchromanol b was the most active fraction showing the inhibitory effect of IL-6 and TNF-alpha.	mmme	35-39	interleukin 6	Mus musculus	158-162
25119102-10	2014	After purification of fractions of MMME, it indicated that n-hexane fraction mojabanchromanol b was the most active fraction showing the inhibitory effect of IL-6 and TNF-alpha.	n-hexane	59-67	interleukin 6	Mus musculus	158-162
25119102-10	2014	After purification of fractions of MMME, it indicated that n-hexane fraction mojabanchromanol b was the most active fraction showing the inhibitory effect of IL-6 and TNF-alpha.	mojabanchromanol b	77-95	interleukin 6	Mus musculus	158-162
25247786-8	2014	Male offspring exposed to continuous 25 IU vitamin D3/kg diet had lower (p &lt; 0.001) colonic VDR expression and those exposed only to low vitamin D3 until weaning had higher serum IL-6.	Cholecalciferol	140-150	interleukin 6	Mus musculus	182-186
25172655-6	2014	Our results show that alcohol induces transcription of miR 339-5p, IL-6, IL-1beta and TNF-alpha in mouse brain tissue and isolated microglial cells by activating NF-kappaB.	Alcohols	22-29	interleukin 6	Mus musculus	67-71
25162585-3	2014	Results show that 6-DG significantly attenuated inducible nitric oxide synthase (iNOS, NOS2), cyclooxygenase-2 (COX-2), interleukin-1beta (IL-1beta), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in the LPS-mediated murine macrophages (RAW 264.7 cells).	6-dehydrogingerdione	18-22	interleukin 6	Mus musculus	150-163
25162585-3	2014	Results show that 6-DG significantly attenuated inducible nitric oxide synthase (iNOS, NOS2), cyclooxygenase-2 (COX-2), interleukin-1beta (IL-1beta), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in the LPS-mediated murine macrophages (RAW 264.7 cells).	6-dehydrogingerdione	18-22	interleukin 6	Mus musculus	165-169
25162585-5	2014	Moreover, 6-DG increased the ratio of phosphorylated signal transducers and activators of transcription 1 (p-STAT1)/p-STAT3 and down-regulated the gene expression of IL-1beta, IL-6, and IL-10.	6-dehydrogingerdione	10-14	interleukin 6	Mus musculus	176-180
25026504-0	2014	Isoliquiritigenin, a flavonoid from licorice, blocks M2 macrophage polarization in colitis-associated tumorigenesis through downregulating PGE2 and IL-6.	isoliquiritigenin	0-17	interleukin 6	Mus musculus	148-152
24916708-9	2014	Paeoniflorin treatment decreased the levels of proinflammatory cytokines such as TNF-alpha and IL-6.	peoniflorin	0-12	interleukin 6	Mus musculus	95-99
25026505-6	2014	A longitudinal study similarly showed that TCE inhibited macrophage IL-6 production.	Trichloroethylene	43-46	interleukin 6	Mus musculus	68-72
25026505-10	2014	A toxicodynamic model was developed to estimate the effects of TCE on IL-6 signaling and liver pathology under different levels of exposure and rates of repair.	Trichloroethylene	63-66	interleukin 6	Mus musculus	70-74
25026505-13	2014	This information was used to create a novel toxicodynamic model of IL-6-mediated TCE-induced liver inflammation.	Trichloroethylene	81-84	interleukin 6	Mus musculus	67-71
25026504-12	2014	In summary, dietary flavonoid ISL effectively inhibits colitis-associated tumorigenesis through hampering M2 macrophage polarization mediated by the interplay between PGE2 and IL-6.	Flavonoids	20-29	interleukin 6	Mus musculus	176-180
25026505-5	2014	After a 12-week exposure to TCE in drinking water a dose-dependent decrease in macrophage production of IL-6 at both the transcriptional and protein level was observed.	Trichloroethylene	28-31	interleukin 6	Mus musculus	104-108
25026505-5	2014	After a 12-week exposure to TCE in drinking water a dose-dependent decrease in macrophage production of IL-6 at both the transcriptional and protein level was observed.	Drinking Water	35-49	interleukin 6	Mus musculus	104-108
26417323-5	2014	The flavone glycoside markedly inhibited the LPS-induced production of tumor necrosis factor-alpha, interleukin-1ss, and interleukin-6 and increased interleukin-10 release in a concentration-dependent manner.	flavone glycoside	4-21	interleukin 6	Mus musculus	100-134
25064444-10	2014	However, kynurenic acid co-treatment reduced the pro-inflammatory cytokines tumour necrosis factor-alpha and IL-6 and amyloid-beta phagocytosis.	Kynurenic Acid	9-23	interleukin 6	Mus musculus	109-113
26417320-10	2014	The results of present investigation showed protection against DOX-induced oxidative stress (lipid peroxidation), by reverting activities of apoptotic markers (caspase-3 and TNF-alpha), cardiac markers (CK-MB and LDH activities) as well as pro-inflammatory marker IL-6 followed by oral administration of BMAE.	Doxorubicin	63-66	interleukin 6	Mus musculus	264-268
25216247-9	2014	Moreover, Al2O3 nanoparticles, but not carbon black NPs, increased IL-1beta but decreased OPN and IL-6 in THP-1 and PBMC.	Aluminum Oxide	10-15	interleukin 6	Mus musculus	98-102
24995576-5	2014	The administration of MPTP (30 mg/kg for four successive days) significantly induced motor impairments as determined by behavioral studies (narrow beam test, catalepsy and akinesia), lowered dopamine levels and up-regulated the expressions of the inflammatory and apoptotic markers (tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, inducible nitric oxide synthase, glial fibrillary acidic protein, cyclooxygenase-2 and Bax).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	22-26	interleukin 6	Mus musculus	331-344
25078627-9	2014	Dexamethasone increased adiponectin mRNA expression and protein levels at 4 and 6days and decreased leptin, interleukin-6, and tumor necrosis factor alpha mRNA expression at all time periods.	Dexamethasone	0-13	interleukin 6	Mus musculus	108-121
25190648-7	2014	In line with these findings, BAK induced NF-kappaB activation and the secretion of IL-6 and granulocyte-monocyte colony-stimulating factor in an epithelial cell line and in the conjunctiva of instilled mice.	Benzalkonium Compounds	29-32	interleukin 6	Mus musculus	83-138
24787352-9	2014	Glycogen synthase kinase 3beta inhibitor lithium inhibited the sevoflurane-induced glycogen synthase kinase 3beta activation, Tau phosphorylation, increased levels of interleukin-6, and cognitive impairment in the wild-type young mice.	Lithium	41-48	interleukin 6	Mus musculus	167-180
25189223-13	2014	However, IL-6 and TNF-alpha were elevated in the kidneys in all cisplatin-treated groups.	Cisplatin	64-73	interleukin 6	Mus musculus	9-13
25087995-9	2014	RESULTS: UA treatment significantly reduced the incidence and severity of CIA-induced arthritis, accompanied by decreased expression of proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IL-21 and IL-17) and oxidative stress markers (nitrotyrosine and iNOS) in arthritic joints.	ursolic acid	9-11	interleukin 6	Mus musculus	184-188
24859008-3	2014	In this study, we found that IL-6 production is selectively inhibited by the BET bromodomain protein (BRD) inhibitor I-BET151 in RAW264.7 cells stimulated with lipopolysaccharide (LPS), whereas I-BET151 did not alter the production of several other cytokines (TNFalpha, IL-1beta and IL-10) at the concentration of IBET151 used.	GSK1210151A	117-125	interleukin 6	Mus musculus	29-33
24859008-3	2014	In this study, we found that IL-6 production is selectively inhibited by the BET bromodomain protein (BRD) inhibitor I-BET151 in RAW264.7 cells stimulated with lipopolysaccharide (LPS), whereas I-BET151 did not alter the production of several other cytokines (TNFalpha, IL-1beta and IL-10) at the concentration of IBET151 used.	GSK1210151A	314-321	interleukin 6	Mus musculus	29-33
24859008-4	2014	I-BET151 prevented the binding of CBP to the promoter of IL-6, but I-BET151 did not affect acetylation, phosphorylation, nuclear translocation, or DNA binding of p65-NF-kappaB.	GSK1210151A	0-8	interleukin 6	Mus musculus	57-61
24787352-9	2014	Glycogen synthase kinase 3beta inhibitor lithium inhibited the sevoflurane-induced glycogen synthase kinase 3beta activation, Tau phosphorylation, increased levels of interleukin-6, and cognitive impairment in the wild-type young mice.	Sevoflurane	63-74	interleukin 6	Mus musculus	167-180
24787352-11	2014	CONCLUSIONS: These data suggested that sevoflurane induced Tau phosphorylation, glycogen synthase kinase 3beta activation, increase in interleukin-6 and reduction in postsynaptic density protein-95 levels in hippocampus of young mice, and cognitive impairment in the mice.	Sevoflurane	39-50	interleukin 6	Mus musculus	135-148
25044064-4	2014	Unlike what is seen under hypertonic conditions, XO-derived ROS were selectively required for the TLR-induced NFAT5 activation and NFAT5 binding to the IL-6 promoter in RAW 264.7 macrophages under isotonic conditions.	Reactive Oxygen Species	60-63	interleukin 6	Mus musculus	152-156
25044064-7	2014	Moreover, allopurinol, an XO inhibitor, suppressed arthritis severity and decreased the expression of NFAT5 and IL-6 in splenic macrophages in C57BL/6 mice.	Allopurinol	10-21	interleukin 6	Mus musculus	112-116
24830537-7	2014	In addition, loss of the (P)RR in VSMCs induced the expression of monocyte chemotactic protein-1 and interleukin-6 mRNAs.	vsmcs	34-39	interleukin 6	Mus musculus	101-114
24868009-5	2014	Tylotoin also promotes the release of transforming growth factor beta1 (TGF-beta1) and interleukin 6 (IL-6), which are essential in the wound healing response.	tylotoin	0-8	interleukin 6	Mus musculus	87-100
24868009-5	2014	Tylotoin also promotes the release of transforming growth factor beta1 (TGF-beta1) and interleukin 6 (IL-6), which are essential in the wound healing response.	tylotoin	0-8	interleukin 6	Mus musculus	102-106
24837470-9	2014	In vitro, the levels of IL-6, IL-17, IL-23 and TNF-alpha were significantly decreased in the cultures of splenocytes from PL-treated mice compared with those from vehicle-treated mice.	piperlonguminine	122-124	interleukin 6	Mus musculus	24-28
24993179-0	2014	Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis.	dextran sodium sulfate	80-102	interleukin 6	Mus musculus	0-13
24969167-7	2014	Based on the qPCR data, administration of betaine inhibited inflammatory cytokines such TNF-alpha, IL-6, iNOS and COX-2.	Betaine	42-49	interleukin 6	Mus musculus	99-103
24993179-6	2014	Our results, in agreement with those of previous reports, demonstrated that IL-6 mAbs slightly attenuated DSS-induced colitis during the regeneration phase.	dss	106-109	interleukin 6	Mus musculus	76-80
24913217-4	2014	Using two different models (ulcerative colitis like and Crohn"s disease like) of experimental IBD in mice, we demonstrated that isorhamnetin abrogated inflammation through inhibiting the activity of myeloperoxidase, the levels of TNF-alpha and IL-6, the mRNA expression of proinflammatory mediators (iNOS, ICAM-1, COX2, TNF-alpha, IL-2 and IL-6) and the phosphorylation of IkappaBalpha and NF-kappaB p65.	3-methylquercetin	128-140	interleukin 6	Mus musculus	244-248
24913217-4	2014	Using two different models (ulcerative colitis like and Crohn"s disease like) of experimental IBD in mice, we demonstrated that isorhamnetin abrogated inflammation through inhibiting the activity of myeloperoxidase, the levels of TNF-alpha and IL-6, the mRNA expression of proinflammatory mediators (iNOS, ICAM-1, COX2, TNF-alpha, IL-2 and IL-6) and the phosphorylation of IkappaBalpha and NF-kappaB p65.	3-methylquercetin	128-140	interleukin 6	Mus musculus	340-344
25324870-6	2014	Furthermore, the expression of IL-6 among T helper 2 cytokines was higher in the FA treated group than the AOO treated group, while vascular endothelial growth factor (VEGF) levels remained constant.	Atraton	107-110	interleukin 6	Mus musculus	31-35
25066929-0	2014	Glucose dominates the regulation of carboxylesterases induced by lipopolysaccharide or interleukin-6 in primary mouse hepatocytes.	Glucose	0-7	interleukin 6	Mus musculus	87-100
25066929-3	2014	Therefore, how glucose affects the regulation of carboxylesterases by interleukin-6 (IL-6) and lipopolysaccharide (LPS) were investigated.	Glucose	15-22	interleukin 6	Mus musculus	70-83
25066929-3	2014	Therefore, how glucose affects the regulation of carboxylesterases by interleukin-6 (IL-6) and lipopolysaccharide (LPS) were investigated.	Glucose	15-22	interleukin 6	Mus musculus	85-89
25066929-8	2014	Carboxylesterase expression and activity were inhibited by LPS or IL-6 in 25 mM glucose, but stimulated in 5.6 mM glucose.	Glucose	80-87	interleukin 6	Mus musculus	66-70
25571638-12	2014	CONCLUSION: UA can significantly relieve renal damage in mice with diabetic nephropathy induced by alloxan, which might be related to decreased blood glucose level, antioxidation effect and inhibiting the production of inflammatory factors such as TNF-alpha and IL-6.	ursolic acid	12-14	interleukin 6	Mus musculus	262-266
24313917-9	2014	Spleen IL-17 level of nicotine-treated mice was lower than that of the control group, and the mRNA expression of pro-inflammatory cytokines (IL-17A and IL-6) in splenocytes were also lower than that of the control group.	Nicotine	22-30	interleukin 6	Mus musculus	152-156
25016520-8	2014	RESULTS: In a dose-dependent fashion, palmitic acid rapidly reduced mouse locomotor activity by a mechanism that did not rely on TLR4, MyD88, IL-1, IL-6 or TNFalpha but was dependent on fatty acid chain length.	Palmitic Acid	38-51	interleukin 6	Mus musculus	148-152
25216522-7	2014	Over-expression of STAT3 or treatment with IL-6 not only increased anoikis resistance, but also protected the cancer cells from PL-induced anoikis.	piplartine	128-130	interleukin 6	Mus musculus	43-47
25111439-0	2014	Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.	pyrano-isochromanones	0-21	interleukin 6	Mus musculus	25-29
25146101-5	2014	The results showed that GdCl3 had no macrophage depletion effect in colonic mucosa, but significantly suppressed TNBS and DSS-induced TNFalpha, IL-1beta and IL-6 secretions.	gadolinium chloride	24-29	interleukin 6	Mus musculus	157-161
25158758-12	2014	Similarly, recombinant galectin-9 enhanced poly(I:C)-induced microglial TNF and IL-6 production.	Poly I-C	43-52	interleukin 6	Mus musculus	80-84
25088994-4	2014	Histone H3 lysine (K) 9 methylation, but not H3 K27 or K4 methylation, was involved in menin-dependent IL-6 regulation.	Lysine	11-17	interleukin 6	Mus musculus	103-107
25146101-5	2014	The results showed that GdCl3 had no macrophage depletion effect in colonic mucosa, but significantly suppressed TNBS and DSS-induced TNFalpha, IL-1beta and IL-6 secretions.	dss	122-125	interleukin 6	Mus musculus	157-161
24973221-3	2014	Metformin inhibited LPS-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in a concentration-dependent manner and in parallel induction of activating transcription factor-3 (ATF-3), a transcription factor and member of the cAMP-responsive element-binding protein family.	Metformin	0-9	interleukin 6	Mus musculus	90-103
24973221-3	2014	Metformin inhibited LPS-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in a concentration-dependent manner and in parallel induction of activating transcription factor-3 (ATF-3), a transcription factor and member of the cAMP-responsive element-binding protein family.	Metformin	0-9	interleukin 6	Mus musculus	105-109
24973221-3	2014	Metformin inhibited LPS-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in a concentration-dependent manner and in parallel induction of activating transcription factor-3 (ATF-3), a transcription factor and member of the cAMP-responsive element-binding protein family.	Cyclic AMP	260-264	interleukin 6	Mus musculus	105-109
24973221-6	2014	ChIP-PCR analysis revealed that LPS-induced NF-kappaB enrichments on the promoters of IL-6 and TNF-alpha were replaced by ATF-3 upon metformin treatment.	Metformin	133-142	interleukin 6	Mus musculus	86-90
24973221-8	2014	Oral administration of metformin to either mice with LPS-induced endotoxemia or ob/ob mice lowered the plasma and tissue levels of TNF-alpha and IL-6 and increased ATF-3 expression in spleen and lungs.	Metformin	23-32	interleukin 6	Mus musculus	145-149
24773520-12	2014	Brain tissue levels of eotaxin, IP-10, KC, MCP-1, MIP-1alpha, IL-6, and G-CSF were increased after both CCI and CCI+HS.	CCI	104-107	interleukin 6	Mus musculus	62-66
24773520-12	2014	Brain tissue levels of eotaxin, IP-10, KC, MCP-1, MIP-1alpha, IL-6, and G-CSF were increased after both CCI and CCI+HS.	CCI	112-115	interleukin 6	Mus musculus	62-66
25122007-8	2014	Further, in LAG-3-deficient mice, mercury elicited higher amounts of IL-6, IL-4 and IFN-gamma, cytokines known to play a critical role in mercury-induced autoimmunity.	Mercury	34-41	interleukin 6	Mus musculus	69-73
24474144-5	2014	A subsequent short-term experiment revealed that dietary GOFA-L-NAME decreased the mRNA expression of inflammatory enzymes, such as iNOS and COX-2, and proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and macrophage inflammatory protein (MIP)-2 in the colonic mucosa of mice that received 1.5% DSS in their drinking water for 7 days.	4'-geranyloxyferulic acid	57-61	interleukin 6	Mus musculus	240-244
24474144-5	2014	A subsequent short-term experiment revealed that dietary GOFA-L-NAME decreased the mRNA expression of inflammatory enzymes, such as iNOS and COX-2, and proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and macrophage inflammatory protein (MIP)-2 in the colonic mucosa of mice that received 1.5% DSS in their drinking water for 7 days.	NG-Nitroarginine Methyl Ester	62-68	interleukin 6	Mus musculus	240-244
25115332-12	2014	JWH133 inhibited IL-6, MMP-3, and CCL2 production from tumor necrosis factor-alpha-stimulated fibroblast-like synoviocytes (FLS) derived from the rheumatoid joints, and osteoclastogenesis of peripheral blood monocytes.	1,1-dimethylbutyl-1-deoxy-Delta(9)-THC	0-6	interleukin 6	Mus musculus	17-21
24720766-5	2014	We demonstrated that, in MSCs, PL induced nuclear factor kappaB (NF-kappaB) activation, expression of COX-2 and mPGE synthase, and PGE2 production; in an inflammatory microenvironment, PL increased the inflammatory response and promoted the secretion of the proinflammatory cytokine IL-6.	pl	31-33	interleukin 6	Mus musculus	283-287
24852097-12	2014	Up-regulation of inflammatory cytokines including monocyte chemotactic protein-1, tumor necrosis factor-alpha, and interleukin-6 in this DSS-induced colitis was significantly suppressed in SMA/CORM2-treated mice.	Dextran Sulfate	137-140	interleukin 6	Mus musculus	115-128
28962266-12	2014	Reduced leptin and increased IL-6 in CD-BPA and CD-DES mice were not found in their HFD-cohorts.	cd-bpa	37-43	interleukin 6	Mus musculus	29-33
28962266-12	2014	Reduced leptin and increased IL-6 in CD-BPA and CD-DES mice were not found in their HFD-cohorts.	cd-des	48-54	interleukin 6	Mus musculus	29-33
24976178-2	2014	In this study, we demonstrate that acute treatment with AMP-activated protein kinase (AMPK) agonists AICAR and metformin efficiently repressed IL-6-induced hepatic proinflammatory gene expression and activation of STAT3 in a mouse model of diet-induced type 2 diabetes, bringing it back to basal nonstimulated level.	Metformin	111-120	interleukin 6	Mus musculus	143-147
25101848-7	2014	significantly reduced mRNA expressions of inflammatory cytokines, TNF-alpha, IL-6, IL-1beta, in carrageenan-injected mice.	Carrageenan	96-107	interleukin 6	Mus musculus	77-81
25093822-5	2014	We show that TC DCs enhanced B cell proliferation through the production of IL-6 and IFN-gamma, while antibody secretion was only dependent on IL-6.	Technetium	13-15	interleukin 6	Mus musculus	76-80
24953256-9	2014	Ethanol did not affect mRNA expression of IFN-gamma and IL-4, but did enhance IL-6, IL-10, and IL-18 mRNA expression.	Ethanol	0-7	interleukin 6	Mus musculus	78-82
25156286-7	2014	Sappanchalcone blocked cell cycle progression in the G2/M phase, brazilin inhibited TNFalpha/NF-kappaB signaling, while butein inhibited IL-6/STAT3 signaling, as well as TNFalpha/NF-kappaB signaling.	butein	120-126	interleukin 6	Mus musculus	137-141
24934978-7	2014	Serum leptin, insulin, glucose, cholesterol and triglycerides levels were increased by HFD, and in females IL-6 deficiency reversed this effect in the case of insulin and cholesterol.	Cholesterol	171-182	interleukin 6	Mus musculus	107-111
24946851-9	2014	A dose-dependent suppression in TPA-mediated TNF-alpha, IL-6, IFN-gamma, IL-17 and PGE2 levels which was associated with a decrease in infiltration of inflammatory cells was also observed with the treatment.	Tetradecanoylphorbol Acetate	32-35	interleukin 6	Mus musculus	56-60
24771617-11	2014	Furthermore, microglial activation after kainate administration was significantly diminished in Fosb-null hippocampus, as shown by significant reductions in CD68 immunoreactivity, morphological change and reduced levels of Il6 and Tnf mRNAs, although no change in the number of Iba-1-positive cells was observed.	Kainic Acid	41-48	interleukin 6	Mus musculus	223-226
24873723-1	2014	Bacterial lipopolysaccharide (LPS) stimulation of macrophages and inflammation via the Toll-like receptor 4 (TLR4) signaling pathway through NF-kappaBeta generates reactive oxygen species (ROS) and proinflammatory cytokines such as IL-1beta, IL-6, and TNFalpha.	Reactive Oxygen Species	164-187	interleukin 6	Mus musculus	242-246
24873723-1	2014	Bacterial lipopolysaccharide (LPS) stimulation of macrophages and inflammation via the Toll-like receptor 4 (TLR4) signaling pathway through NF-kappaBeta generates reactive oxygen species (ROS) and proinflammatory cytokines such as IL-1beta, IL-6, and TNFalpha.	Reactive Oxygen Species	189-192	interleukin 6	Mus musculus	242-246
24706025-5	2014	Triptolide-treated mice exhibited significantly reduced leukocyte, myeloperoxidase (MPO) activity, edema of the lung, as well as TNF-alpha, IL-1beta, and IL-6 production in the bronchoalveolar lavage fluid compared with LPS-treated mice.	triptolide	0-10	interleukin 6	Mus musculus	154-158
24577726-8	2014	The anti-inflammatory mechanisms of carvacrol may be due to its ability to inhibit NF-kappaB and MAPKs signaling pathways, thereby inhibiting inflammatory cytokines TNF-alpha, IL-6 and IL-1beta production.	carvacrol	36-45	interleukin 6	Mus musculus	176-180
24880019-8	2014	Furthermore, protein expression by Western blot analysis showed that UA significantly decreased production of pro-inflammatory markers including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-17 (IL-17) and cyclooxygenase-2 (COX-2) in CCl4-treated mouse kidney.	ursolic acid	69-71	interleukin 6	Mus musculus	186-199
24219385-3	2014	We demonstrated that baicalin can inhibit beta amyloid peptides (Abeta42)-induced BV2 microglial cell proliferation, reduce the expression of CD11b, decrease chemotactic ability of BV2 cells and significantly inhibit the secretion of IL-6, TNF-alpha and NO.	baicalin	21-29	interleukin 6	Mus musculus	234-238
24880019-8	2014	Furthermore, protein expression by Western blot analysis showed that UA significantly decreased production of pro-inflammatory markers including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-17 (IL-17) and cyclooxygenase-2 (COX-2) in CCl4-treated mouse kidney.	ursolic acid	69-71	interleukin 6	Mus musculus	201-205
24893116-6	2014	On day 3, FTY720 administration reduced PQ-induced increases in lung wet weight/body weight (LW/BW), total protein and cytokine levels including interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in bronchoalceolar lavage fluid (BALF).	Paraquat	40-42	interleukin 6	Mus musculus	175-188
24893116-6	2014	On day 3, FTY720 administration reduced PQ-induced increases in lung wet weight/body weight (LW/BW), total protein and cytokine levels including interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in bronchoalceolar lavage fluid (BALF).	Paraquat	40-42	interleukin 6	Mus musculus	190-194
24659080-5	2014	Expression of IL-1beta and IL-6 was inhibited both by DEX and Am80.	Dexamethasone	54-57	interleukin 6	Mus musculus	27-31
24799355-4	2014	Doxorubicin induced a significant increase in relative kidney weight to body weight, kidney lipid perooxidation, plasma levels of interleukin-6 and tumor necrosis factor-alpha, kidney caspase-3 activity, and kidney prostaglandin E2 (PGE2) content.	Doxorubicin	0-11	interleukin 6	Mus musculus	130-175
24697507-7	2014	In a culture system, both of Il6 and Gfap were up-regulated in wild-type astrocytes treated with forskolin.	Colforsin	97-106	interleukin 6	Mus musculus	29-32
24697507-9	2014	Adenovirus-mediated reexpression of Ndrg2 rescued the reduction of IL-6 expression after forskolin stimulation.	Colforsin	89-98	interleukin 6	Mus musculus	67-71
24659080-5	2014	Expression of IL-1beta and IL-6 was inhibited both by DEX and Am80.	tamibarotene	62-66	interleukin 6	Mus musculus	27-31
26417302-3	2014	Furthermore, DMC suppressed LPS-induced production of pro-inflammatory cytokines such as interleukin (IL)-1ss, IL-6, and tumor necrosis factor (TNF)-alpha.	dmc	13-16	interleukin 6	Mus musculus	111-115
24221357-10	2014	The present findings suggest that IL-6 contributes to regulating the PDHa activity and hence carbohydrate oxidation, but the metabolic state of the muscle seems to determine the outcome of this regulation.	Carbohydrates	93-105	interleukin 6	Mus musculus	34-38
24793808-5	2014	DON markedly induced transient upregulation of TNF-alpha IL-1beta, IL-6, CXCL-2, CCL-2 and CCL-7 mRNA expressions.	deoxynivalenol	0-3	interleukin 6	Mus musculus	67-71
25059342-0	2014	Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis.	Bleomycin	74-83	interleukin 6	Mus musculus	10-14
25059342-11	2014	Thereafter, mice were immunized against a small peptide derived from murine IL-6 and this strategy led in the bleomycin model to a 20% (P = 0.02) and 25% (P = 0.005) decrease of dermal thickness and hydroxyproline content, respectively.	Bleomycin	110-119	interleukin 6	Mus musculus	76-80
25059342-11	2014	Thereafter, mice were immunized against a small peptide derived from murine IL-6 and this strategy led in the bleomycin model to a 20% (P = 0.02) and 25% (P = 0.005) decrease of dermal thickness and hydroxyproline content, respectively.	Hydroxyproline	199-213	interleukin 6	Mus musculus	76-80
25059342-13	2014	Upon bleomycin injections, serum and skin IL-6 levels were increased after treatment with MR16-1 and were significantly reduced after anti-IL-6 active immunization.	Bleomycin	5-14	interleukin 6	Mus musculus	42-46
25059342-13	2014	Upon bleomycin injections, serum and skin IL-6 levels were increased after treatment with MR16-1 and were significantly reduced after anti-IL-6 active immunization.	Bleomycin	5-14	interleukin 6	Mus musculus	139-143
25059342-15	2014	Targeting IL-6 by both passive and active immunization strategies prevented the development of bleomycin-induced dermal fibrosis in mice.	Bleomycin	95-104	interleukin 6	Mus musculus	10-14
24845100-7	2014	Moreover, cardamonin and flavokawain B also modulated the secretion of C-reactive protein, dipeptidyl peptidase IV, interleukin-6, tumor necrosis factor-alpha and fibroblast growth factor-21 in mature adipocytes.	cardamonin	10-20	interleukin 6	Mus musculus	116-158
24845100-7	2014	Moreover, cardamonin and flavokawain B also modulated the secretion of C-reactive protein, dipeptidyl peptidase IV, interleukin-6, tumor necrosis factor-alpha and fibroblast growth factor-21 in mature adipocytes.	flavokawain B	25-38	interleukin 6	Mus musculus	116-158
24901387-8	2014	Finally, HES-MCs equipped with MPLA, anti-CD40, and anti-DEC205 induced the secretion of TNF-alpha, IL-6 by Kupffer cells (KCs), and IFN-gamma and IL-12p70 by liver dendritic cells (DCs).	Hydroxyethyl Starch Derivatives	9-12	interleukin 6	Mus musculus	100-104
24607858-10	2014	Serum IL-6 levels were significantly decreased 3h post PH.	Tritium	47-49	interleukin 6	Mus musculus	6-10
25010770-8	2014	Meanwhile, transplantation of IL-6-expressing Lewis Lung Carcinoma cells caused cachexia in mice, which then received either MR16-1 or 0.9% saline.	Sodium Chloride	140-146	interleukin 6	Mus musculus	30-34
24327098-6	2014	A single acute exposure of RR-PMa (1 mg/kg body weight) after 24 h caused significant (p &lt; 0.05) enrichment in bronchoalveolar total cell number and polymorphonuclear (PNM) fraction, superoxide anion generation, production of pro-inflammatory cytokines TNF-alpha and IL-6, and induction of apoptosis.	rr-pma	27-33	interleukin 6	Mus musculus	270-274
24944625-9	2014	Atorvastatin significantly increased LPS induced expression of TIPE2, downregulated the expression of NOS, COX-2, MIF and NF-kappaB and the production of PGE2, NO, IL-6 and TNF-alpha in a time and dose dependent manner, and increased HO-1 protein expression, reduced ROS production in a dose dependent manner.	Atorvastatin	0-12	interleukin 6	Mus musculus	164-168
24659138-6	2014	The induction of the inflammatory cytokines TGF-beta1, IL-1beta,TNF-alpha, and IL-6 by IR were in turn inhibited in the serum and BALF of the genistein-pretreated mice (P &lt; 0.05).	Genistein	142-151	interleukin 6	Mus musculus	79-83
24944625-10	2014	The observations indicated that atorvastatin upregulated LPS induced expression of TIPE2 and consequently inhibited MIF, NF-kappaB, NOS and COX-2 expression and the production of NO, PGE2, TNF-alpha and IL-6, increased HO-1 expression, and inhibited ROS activity in cultured RAW264.7 cells.	Atorvastatin	32-44	interleukin 6	Mus musculus	203-207
24492981-6	2014	Higher IL-6 levels were also detected in ethanol-treated precision-cut liver slices from ALDH2(-/-) mice and in Kupffer cells isolated from ethanol-fed ALDH2(-/-) mice than those levels in wild-type mice.	Ethanol	41-48	interleukin 6	Mus musculus	7-11
24492981-6	2014	Higher IL-6 levels were also detected in ethanol-treated precision-cut liver slices from ALDH2(-/-) mice and in Kupffer cells isolated from ethanol-fed ALDH2(-/-) mice than those levels in wild-type mice.	Ethanol	140-147	interleukin 6	Mus musculus	7-11
24492981-7	2014	In vitro incubation with MAA enhanced the lipopolysaccharide (LPS)-mediated stimulation of IL-6 production in Kupffer cells.	maa	25-28	interleukin 6	Mus musculus	91-95
24492981-8	2014	In agreement with these findings, hepatic activation of the major IL-6 downstream signaling molecule signal transducer and activator of transcription 3 (STAT3) was higher in ethanol-fed ALDH2(-/-) mice than in wild-type mice.	Ethanol	174-181	interleukin 6	Mus musculus	66-70
24813716-5	2014	delta-Amyrone also decreased the level of nitric oxide (NO), prostaglandin E2 (PGE2), interleukin-6 (IL-6) and leukocyte numbers in acetic acid-induced peritonitis in vivo.	amyrone	0-13	interleukin 6	Mus musculus	86-99
24813716-5	2014	delta-Amyrone also decreased the level of nitric oxide (NO), prostaglandin E2 (PGE2), interleukin-6 (IL-6) and leukocyte numbers in acetic acid-induced peritonitis in vivo.	amyrone	0-13	interleukin 6	Mus musculus	101-105
24815859-6	2014	CLP-0611 also inhibited TNBS-induced expression of TNF-alpha, IL-1beta, and IL-6.	Trinitrobenzenesulfonic Acid	24-28	interleukin 6	Mus musculus	76-80
24813716-7	2014	The data indicated that delta-Amyrone notably inhibited IL-6, TNF-alpha and NO production.	amyrone	24-37	interleukin 6	Mus musculus	56-60
24865431-3	2014	Here, we determined that PM exposure results in the systemic release of catecholamines, which engage the beta2-adrenergic receptor (beta2AR) on murine alveolar macrophages and augment the release of IL-6.	Catecholamines	72-86	interleukin 6	Mus musculus	199-203
24820155-5	2014	The partially hydrolyzed EPS stimulated RAW264.7 cells to induce considerable NO and various cytokine production such as TNF-alpha, IL-1beta, IL-6 and IL-10 via up-regulation of their mRNA expression.	eps	25-28	interleukin 6	Mus musculus	142-146
24830863-4	2014	Pretreatment with rotenone has no obvious effects on hepatic malondialdehyde (MDA) contents but it significantly inhibited the up-regulation of both hepatic mRNA level and plasma protein level of TNF-alpha and IL-6.	Rotenone	18-26	interleukin 6	Mus musculus	210-214
24605772-6	2014	Pretreatment with U0126 or Bay11-7082, respectively, could decrease IL-1beta, IL-6, and TNF-alpha productions induced by OM85-BV.	U 0126	18-23	interleukin 6	Mus musculus	78-82
24605772-6	2014	Pretreatment with U0126 or Bay11-7082, respectively, could decrease IL-1beta, IL-6, and TNF-alpha productions induced by OM85-BV.	3-(4-methylphenylsulfonyl)-2-propenenitrile	27-37	interleukin 6	Mus musculus	78-82
23914806-3	2014	This study used an isogenic mouse model to examine the influence of perinatal BPA exposure via maternal diet on inflammatory mediators associated with asthma in 6-month-old adult offspring by measuring bone marrow-derived mast cell (BMMC) production of lipid mediators (cysteinyl leukotrienes and prostaglandin D2), cytokines (interleukin [IL]-4, IL-5, IL-6, IL-13, and tumor necrosis factor [TNF]-alpha), and histamine.	bisphenol A	78-81	interleukin 6	Mus musculus	353-357
24818579-9	2014	Additionally, resveratrol markedly decreased the expression of TLR4, myd88 and NF-kappaB and decreased the concentration of inflammatory cytokines, including IL-6 and COX-2.	Resveratrol	14-25	interleukin 6	Mus musculus	158-162
24817032-7	2014	Resveratrol treatment also decreased interleukin-6 (IL-6) and tumor necrosis factor-alpha protein levels and reduced IL-6 and cyclooxygenase-2 mRNA expression.	Resveratrol	0-11	interleukin 6	Mus musculus	37-50
24817032-7	2014	Resveratrol treatment also decreased interleukin-6 (IL-6) and tumor necrosis factor-alpha protein levels and reduced IL-6 and cyclooxygenase-2 mRNA expression.	Resveratrol	0-11	interleukin 6	Mus musculus	52-89
24817032-7	2014	Resveratrol treatment also decreased interleukin-6 (IL-6) and tumor necrosis factor-alpha protein levels and reduced IL-6 and cyclooxygenase-2 mRNA expression.	Resveratrol	0-11	interleukin 6	Mus musculus	52-56
24789089-4	2014	Triptolide-treated mice exhibited significantly reduced levels of leukocytes, myeloperoxidase activity and edema of the lung, as well as tumour necrosis factor-alpha, interleukin (IL)-1beta and IL-6 production in the bronchoalveolar lavage fluid compared with LPS-treated mice.	triptolide	0-10	interleukin 6	Mus musculus	194-198
24821729-7	2014	In a dextran sodium sulfate-induced acute colitis model, WT mice lost more weight, had higher histopathology scores, and contained more Cxcl-2 and IL-6 mRNA in their colons than similarly treated Prss31-null mice.	dextran sodium sulfate	5-27	interleukin 6	Mus musculus	147-151
25150121-8	2014	Compared with mice not exposed to heat, quercetin-treated mice had significantly lower interleukin 6 (P &lt; .01) and higher superoxide dismutase levels (P &lt; .01), whereas vehicle-treated mice had significantly lower total glutathione and higher 8-isoprostane levels in the circulation after heat exposure.	Quercetin	40-49	interleukin 6	Mus musculus	87-100
24731292-12	2014	Our findings support the notion that myofibroblasts modulate IL-6/p-Stat3 signaling in DSS-treated Epim(-/-) mice.	dss	87-90	interleukin 6	Mus musculus	61-65
24930935-13	2014	Compared to controls, we observed a vast reduction of RNA levels for proinflammatory cytokines and chemokines like Ccl2, Cxcl10, Tnf and Il6 within the CNS of cuprizone-treated mice.	Cuprizone	159-168	interleukin 6	Mus musculus	137-140
24657456-0	2014	Blockade of IL-6 signaling by MR16-1 inhibits reduction of docosahexaenoic acid-containing phosphatidylcholine levels in a mouse model of spinal cord injury.	Docosahexaenoic Acids	59-79	interleukin 6	Mus musculus	12-16
24952384-8	2014	Pre-treatment with glimepiride significantly reduced TNF, IL-1 and IL-6 secretion from RAW 264 and microglial cells incubated with LPS, Abeta42, alphaSN and PrP82-146.	glimepiride	19-30	interleukin 6	Mus musculus	67-71
24657456-0	2014	Blockade of IL-6 signaling by MR16-1 inhibits reduction of docosahexaenoic acid-containing phosphatidylcholine levels in a mouse model of spinal cord injury.	Phosphatidylcholines	91-110	interleukin 6	Mus musculus	12-16
24412102-4	2014	Incubation with the tigerinins (20 mug/ml) significantly increased production of IL-6 in LPS-stimulated macrophages from C57BL/6 mice but only tigerinin-1V potentiated IL-6 production in LPS-stimulated macrophages from BALB/c mice.	tigerinins	20-30	interleukin 6	Mus musculus	81-85
24959425-8	2014	Moreover, DeltahtrA mutant infected mice displayed lower apoptotic cell numbers in the large intestinal mucosa, less colonic accumulation of neutrophils, macrophages and monocytes, lower large intestinal nitric oxide, IFN-gamma, and IL-6 as well as lower TNF-alpha and IL-6 serum concentrations as compared to WT strain infected mice at day 6 p.i.	deltahtra	10-19	interleukin 6	Mus musculus	233-237
24959425-8	2014	Moreover, DeltahtrA mutant infected mice displayed lower apoptotic cell numbers in the large intestinal mucosa, less colonic accumulation of neutrophils, macrophages and monocytes, lower large intestinal nitric oxide, IFN-gamma, and IL-6 as well as lower TNF-alpha and IL-6 serum concentrations as compared to WT strain infected mice at day 6 p.i.	deltahtra	10-19	interleukin 6	Mus musculus	269-273
24412102-4	2014	Incubation with the tigerinins (20 mug/ml) significantly increased production of IL-6 in LPS-stimulated macrophages from C57BL/6 mice but only tigerinin-1V potentiated IL-6 production in LPS-stimulated macrophages from BALB/c mice.	tigerinins	20-30	interleukin 6	Mus musculus	168-172
24412102-4	2014	Incubation with the tigerinins (20 mug/ml) significantly increased production of IL-6 in LPS-stimulated macrophages from C57BL/6 mice but only tigerinin-1V potentiated IL-6 production in LPS-stimulated macrophages from BALB/c mice.	tigerinin-1v	143-155	interleukin 6	Mus musculus	168-172
24694381-0	2014	Interleukin-6 contributes to early fasting-induced free fatty acid mobilization in mice.	Fatty Acids, Nonesterified	51-66	interleukin 6	Mus musculus	0-13
24694381-1	2014	Contracting muscle releases interleukin-6 (IL-6) enabling the metabolic switch from carbohydrate to fat utilization.	Carbohydrates	84-96	interleukin 6	Mus musculus	28-41
24462946-9	2014	In vitro, glycyrrhizin dose-dependently inhibited the expression of TNF-alpha, IL-6, IL-1beta and RANTES in LPS-stimulated RAW264.7 cells.	Glycyrrhizic Acid	10-22	interleukin 6	Mus musculus	79-83
24694381-1	2014	Contracting muscle releases interleukin-6 (IL-6) enabling the metabolic switch from carbohydrate to fat utilization.	Carbohydrates	84-96	interleukin 6	Mus musculus	43-47
24736977-5	2014	CeCl3 exposure also activated nuclear factor kappaB, increased the expression of tumor necrosis factor alpha, cyclooxygenase-2, heme oxygenase 1, interleukin 2, interleukin 4, interleukin 6, interleukin 8, interleukin 10, interleukin 18, interleukin 1beta, and CYP1A1.	cerous chloride	0-5	interleukin 6	Mus musculus	176-189
24286322-5	2014	Furthermore, salicortin significantly inhibited production of pro-inflammatory cytokines, such as TNF-alpha, IL-1beta and IL-6 in the LPS-stimulated RAW 264.7 cells.	salicortin	13-23	interleukin 6	Mus musculus	122-126
24749675-5	2014	The activation of nuclear factor-kappa B (NF-kappaB) in the nucleus, the phosphorylation of IkappaBalpha and degradation of IkappaBalpha in the cytosol were suppressed by GA. GA decreased the production and mRNA expression of the inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6.	schizandrol B	171-173	interleukin 6	Mus musculus	297-315
24676901-6	2014	LTX-315 induced the release of danger-associated molecular pattern molecules such as the high mobility group box-1 protein in vitro and the subsequent upregulation of proinflammatory cytokines such as interleukin (IL) 1beta, IL6 and IL18 in vivo.	LTX-315	0-7	interleukin 6	Mus musculus	225-228
24698106-7	2014	In vitro, glycyrrhizin dose-dependently inhibited the LPS-induced expression of tumor necrosis factor-alpha, IL-6, and RANTES.	Glycyrrhizic Acid	10-22	interleukin 6	Mus musculus	109-113
23413967-3	2014	The in vitro study showed that paeonol regulated the production of TNF-alpha, IL-1beta, IL-6, and IL-10 via inactivation of IkappaBalpha, ERK1/2, JNK, and p38 MAPK.	paeonol	31-38	interleukin 6	Mus musculus	88-92
24749675-7	2014	In conclusion, these results show that the anti-inflammatory properties of GA potentially result from the inhibition of COX-2, iNOS, IL-6, TNF-alpha and NO through the down-regulation of RIP2 and NF-kappaB activation.	schizandrol B	75-77	interleukin 6	Mus musculus	133-137
24735815-7	2014	Our findings clearly showed that geniposide mainly exerts its anti-inflammatory effects by inhibiting the LPS-induced NF-kappaB, MAPK and AP-1 signaling pathways in macrophages, which subsequently reduces overexpression of the inducible enzymes iNOS and COX-2 and suppresses the expression and release of the inflammatory factors, TNF-alpha, IL-6, NO and PGE2.	geniposide	33-43	interleukin 6	Mus musculus	342-346
24975968-0	2014	Propylene-glycol aggravates LPS-induced sepsis through production of TNF-alpha and IL-6.	Propylene Glycol	0-16	interleukin 6	Mus musculus	83-87
24975968-10	2014	In accordance with that, PG enhanced LPS-induced production of inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in vivo.	Propylene Glycol	25-27	interleukin 6	Mus musculus	141-154
24975968-10	2014	In accordance with that, PG enhanced LPS-induced production of inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in vivo.	Propylene Glycol	25-27	interleukin 6	Mus musculus	156-160
24849676-7	2014	LPS-induced IL-6 production by KUP5 cells was suppressed significantly by pretreatments with non-selective P2 antagonist suramin, P2Y13antagonist MRS2211, and ecto-nucleotidase, whereas P2Y receptor agonists, significantly increased the IL-6 production.	Suramin	121-128	interleukin 6	Mus musculus	12-16
24800670-6	2014	RESULTS: The oral administration of SPH enhanced the gut barrier function via up-regulation of immunoglobulin A-producing cells and intestinal cytokines production, including interleukin-6 and tumor necrosis factor-alpha.	sph	36-39	interleukin 6	Mus musculus	175-220
24655755-9	2014	Prospective stratification (IL-6 cut-off: 14 ng mL(-1) ) suggested increased mortality by MA-MP6H6 treatment in P-SUR that reached 30% difference (vs. MA-Control; P &lt; 0.05) after a retrospective cut-off readjustment to 3.3 ng mL(-1) for better P-SUR homogeneity.	ma-mp6h6	90-98	interleukin 6	Mus musculus	28-32
24813250-7	2014	Notably, we demonstrated that administration of PDX to obese diabetic db/db mice raises skeletal muscle IL-6 levels and substantially improves their insulin sensitivity without any impact on adipose tissue inflammation.	10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoic acid	48-51	interleukin 6	Mus musculus	104-108
24813250-8	2014	Our findings thus support the development of PDX-based selective muscle IL-6 secretagogues as a new class of therapy for the treatment of insulin resistance and type 2 diabetes.	10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoic acid	45-48	interleukin 6	Mus musculus	72-76
24905526-4	2014	Among the synthesized derivatives, the BECT [But-2-enedioic acid bis-(2-carboxy-5-trifluoromethyl-phenyl) ester] significantly decreased production of nitric oxide and other pro-inflammatory cytokines including tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 in microglial cells.	bect [but-2-enedioic acid bis-(2-carboxy-5-trifluoromethyl-phenyl) ester	39-111	interleukin 6	Mus musculus	263-276
24905526-4	2014	Among the synthesized derivatives, the BECT [But-2-enedioic acid bis-(2-carboxy-5-trifluoromethyl-phenyl) ester] significantly decreased production of nitric oxide and other pro-inflammatory cytokines including tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 in microglial cells.	Nitric Oxide	151-163	interleukin 6	Mus musculus	263-276
24730974-4	2014	TCZ is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor and used as an immunosuppressive drug by interfering IL-6 in the pathogenesis of RA.	tioconazole	0-3	interleukin 6	Mus musculus	51-64
24730974-4	2014	TCZ is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor and used as an immunosuppressive drug by interfering IL-6 in the pathogenesis of RA.	tioconazole	0-3	interleukin 6	Mus musculus	66-70
24730974-4	2014	TCZ is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor and used as an immunosuppressive drug by interfering IL-6 in the pathogenesis of RA.	tioconazole	0-3	interleukin 6	Mus musculus	134-138
24842874-4	2014	Our data suggest that IL-6 signaling in effector T cells is required to overcome Treg-mediated suppression in vivo.	treg	81-85	interleukin 6	Mus musculus	22-26
24754514-10	2014	Proinflammatory cytokines (IL-6 and TNF-alpha) were upregulated following arsenic treatment as in the case of the LPS stimulated group without alterations in anti-inflammatory IL-10.	Arsenic	74-81	interleukin 6	Mus musculus	27-31
24886543-7	2014	RESULTS: DHEA was associated with a decrease in the systemic inflammatory response induced by bilateral femoral fracture, especially systemic IL-6 (322.2 vs. 62.5 pg/mL; P = 0.01), IL-1beta (1,422.6 vs. 754.1 pg/mL; P = 0.05), and MCP-1 (219.4 vs. 44.1 pg/mL; P &gt;0.01) levels.	Dehydroepiandrosterone	9-13	interleukin 6	Mus musculus	142-146
24810606-5	2014	Aromatic pyruvates reduced cytotoxicity in UVB-irradiated HaCaT keratinocytes, and also diminished the expression of interleukin 1beta (IL-1beta) and interleukin 6 (IL-6).	aromatic pyruvates	0-18	interleukin 6	Mus musculus	150-163
24810606-5	2014	Aromatic pyruvates reduced cytotoxicity in UVB-irradiated HaCaT keratinocytes, and also diminished the expression of interleukin 1beta (IL-1beta) and interleukin 6 (IL-6).	aromatic pyruvates	0-18	interleukin 6	Mus musculus	165-169
24810606-9	2014	Overproduction of IL-1beta and IL-6 in response to UVB radiation was also suppressed in vivo by the topical administration of IPyr.	indol-3-yl pyruvic acid	126-130	interleukin 6	Mus musculus	31-35
24788117-8	2014	Mice treated with AES significantly ameliorated the severity of the DSS-induced colitis indicated by the reduced disease manifestations, improved macroscopic and microscopic inflammation correlated with the up-regulation of Treg response (increased regulatory cytokines IL-10, TGF-beta and regulatory T cells) and down-regulation of pro-inflammatory cytokines (IFN-gamma, IL-6 and IL-17) in the spleens, MLN and colon of treated mice.	alanylglutamic acid	18-21	interleukin 6	Mus musculus	372-376
24885161-9	2014	SB203580 significantly attenuated lung inflammation (neutrophil infiltration, mRNA expressions of TNF-alpha and MIP-2, protein levels of KC, MIP-1alpha, IL-1beta, and IL-6), proteinase expression (MMP-12 mRNA), oxidative DNA damage, and apoptosis caused by acute CS exposure.	SB 203580	0-8	interleukin 6	Mus musculus	167-171
24705100-9	2014	RESULTS: Marked expression of IL-6 was found in COS-7 cells transfected with pCI-IL-6.	carbonyl sulfide	48-51	interleukin 6	Mus musculus	30-34
24705100-9	2014	RESULTS: Marked expression of IL-6 was found in COS-7 cells transfected with pCI-IL-6.	carbonyl sulfide	48-51	interleukin 6	Mus musculus	81-85
24585402-5	2014	The most potent SO2 -substituted compound (9i) also blocked the LPS-inducible nitric oxide synthase (iNOS) and attenuated the release of several cytokines including IL-1alpha, IL-10, and IL-6.	Sulfur Dioxide	16-19	interleukin 6	Mus musculus	187-191
24470226-6	2014	Furthermore, LiCl directly inhibited IL-6-stimulated activation of STAT-3 signaling.	Lithium Chloride	13-17	interleukin 6	Mus musculus	37-41
24607272-8	2014	PMFA significantly decreased the expression of IL-1beta, IL-6 and TNF-alpha and reduced the infiltration of M1 macrophages in lung.	pmfa	0-4	interleukin 6	Mus musculus	57-61
24375569-5	2014	Inhibition of PI3K/Akt with LY294002 or ERK1/2 with PD98059 significantly attenuated IL-6 upregulation, and IL-6 expression was abolished by inhibiting both pathways.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	52-59	interleukin 6	Mus musculus	85-89
24512768-6	2014	Results demonstrated that orally administered rutin significantly attenuated memory deficits in AD transgenic mice, decreased oligomeric Abeta level, increased super oxide dismutase (SOD) activity and glutathione (GSH)/glutathione disulfide (GSSG) ratio, reduced GSSG and malondialdehyde (MDA) levels, downregulated microgliosis and astrocytosis, and decreased interleukin (IL)-1beta and IL-6 levels in the brain.	Rutin	46-51	interleukin 6	Mus musculus	388-392
24384468-9	2014	Higher levels of IL-2, IL-5 and IL-6 in plasma and an upregulation of the metabotropic receptor 5 (mGluR5) in foetal brains of 10-day-old offspring prenatally exposed to poly I:C was also observed.	Poly I-C	170-178	interleukin 6	Mus musculus	32-36
24940428-6	2014	Following treatment with the combination of SF and OMT, the survival rate increased and the survival time was prolonged; CLP-induced increases in the lung W/D ratio and the levels of ALT, AST, LDH, CRP, IL-6, IFN-gamma and MDA were significantly reduced; and the SOD activity levels were increased, compared with those of the untreated animals with CLP-induced sepsis.	ferulic acid	44-46	interleukin 6	Mus musculus	203-207
24940420-6	2014	In addition, glycyrrhizin pretreatment appeared to ameliorate I/R-induced renal injury via inhibition of inflammatory cell infiltration, as well as the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha, interferon-gamma, interleukin (IL)-1beta and IL-6.	Glycyrrhizic Acid	13-25	interleukin 6	Mus musculus	278-282
24940428-6	2014	Following treatment with the combination of SF and OMT, the survival rate increased and the survival time was prolonged; CLP-induced increases in the lung W/D ratio and the levels of ALT, AST, LDH, CRP, IL-6, IFN-gamma and MDA were significantly reduced; and the SOD activity levels were increased, compared with those of the untreated animals with CLP-induced sepsis.	oxymatrine	51-54	interleukin 6	Mus musculus	203-207
24940429-2	2014	The effect of chloral hydrate on the production of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) by murine peritoneal macrophages with PGN-stimulation was investigated.	Chloral Hydrate	14-29	interleukin 6	Mus musculus	95-108
24940429-2	2014	The effect of chloral hydrate on the production of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) by murine peritoneal macrophages with PGN-stimulation was investigated.	Chloral Hydrate	14-29	interleukin 6	Mus musculus	110-114
24940429-5	2014	It was identified that chloral hydrate reduced the levels of IL-6 and TNF-alpha produced by the peritoneal macrophages stimulated with PGN.	Chloral Hydrate	23-38	interleukin 6	Mus musculus	61-65
24508537-6	2014	The results showed that curcumin attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), and the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in a dose-dependent manner.	Curcumin	24-32	interleukin 6	Mus musculus	186-199
24593990-7	2014	Concurrently, levels of the pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6 were reduced with increasing concentrations of SD.	SD 0006	132-134	interleukin 6	Mus musculus	80-84
24656780-9	2014	Gallium nitrate reduced the serum levels of TNF-alpha, IL-6 and IFN-gamma (p&lt;0.05) and the mRNA expression levels of these cytokine and MMPs (MMP2 and MMP9) in joint tissues.	gallium nitrate	0-15	interleukin 6	Mus musculus	55-59
24508537-6	2014	The results showed that curcumin attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), and the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in a dose-dependent manner.	Curcumin	24-32	interleukin 6	Mus musculus	201-205
24603641-4	2014	Calcium hydroxide rescued the P. endodontalis LPS-suppressed viability of MC3T3-E1 cells and activity of nuclear factor-kappaB (NF-kappaB) in these cells, resulting in the reduced expression of interleukin-6 and tumor necrosis factor-alpha.	Calcium Hydroxide	0-17	interleukin 6	Mus musculus	194-239
24941805-8	2014	RESULTS: Compared with other groups, CsA+Talpha1 group had significant lower IL-1alpha, IL-2, IL-6, IL-17, and significant higher IL-10 at 1 d, 7 d, 14 d, 21 d after the treatments (P &lt; 0.05).	Cyclosporine	37-40	interleukin 6	Mus musculus	94-98
24577942-0	2014	Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.	AZD 1480	56-63	interleukin 6	Mus musculus	82-86
24577942-8	2014	Most importantly, pharmacologic inhibition of Jak1/2 by AZD1480 suppressed IL-6-induced signaling, migratory prostate cancer cell phenotypes, and metastatic dissemination of prostate cancer in vivo in nude mice.	AZD 1480	56-63	interleukin 6	Mus musculus	75-79
24577942-9	2014	In conclusion, we demonstrate that the cytokine IL-6 directly promotes prostate cancer metastasis in vitro and in vivo via Jak-Stat3 signaling pathway, and that IL-6-driven metastasis can be effectively suppressed by pharmacologic targeting of Jak1/2 using Jak1/2 inhibitor AZD1480.	AZD 1480	274-281	interleukin 6	Mus musculus	48-52
24577942-9	2014	In conclusion, we demonstrate that the cytokine IL-6 directly promotes prostate cancer metastasis in vitro and in vivo via Jak-Stat3 signaling pathway, and that IL-6-driven metastasis can be effectively suppressed by pharmacologic targeting of Jak1/2 using Jak1/2 inhibitor AZD1480.	AZD 1480	274-281	interleukin 6	Mus musculus	161-165
24712394-6	2014	GPP-S also had inhibitory activities on IL-1beta, IL-6, and COX-2 gene expressions in RAW 264.7 mouse macrophage cells.	gpp-s	0-5	interleukin 6	Mus musculus	50-54
24789104-0	2014	Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis.	Metformin	0-9	interleukin 6	Mus musculus	23-27
24789104-8	2014	Importantly, metformin inhibited tumor growth and distant metastases in tumor-bearing nude mice and reversed IL-6-induced EMT both in vitro and in vivo.	Metformin	13-22	interleukin 6	Mus musculus	109-113
24789104-9	2014	Furthermore, we found that blockade of STAT3 phosphorylation might be the underlying mechanism of metformin inhibition of IL-6-induced EMT.	Metformin	98-107	interleukin 6	Mus musculus	122-126
24789104-11	2014	We found that metformin could inhibit IL-6-induced EMT possibly by blocking STAT3 phosphorylation.	Metformin	14-23	interleukin 6	Mus musculus	38-42
24742272-12	2014	These advantageous effects of DHA pretreatment were associated with decreased IL-6, LTB4, PGE2 and increased IL-10.	Docosahexaenoic Acids	30-33	interleukin 6	Mus musculus	78-82
24834011-5	2014	In addition, irbesartan significantly decreased the adipose leptin mRNA expression and tended to decrease IL-6 mRNA expression in the adipose tissue of KKAy mice.	Irbesartan	13-23	interleukin 6	Mus musculus	106-110
24534490-10	2014	In conclusion, azithromycin significantly attenuated P. intermedia LPS-induced production of IL-6 in murine macrophages via inhibition of NF-kappaB, STAT1 and STAT3 activation, which is possibly related to the activation of SOCS1 signaling.	Azithromycin	15-27	interleukin 6	Mus musculus	93-97
24834011-7	2014	Collectively, these results suggest that the irbesartan-induced beneficial suppressive effect on the leptin-IL-6 axis in the adipose tissue in KKAy mice is partly mediated by a trend of up-regulation of the adipose ATRAP/AT1R ratio as one of pleiotropic effects of irbesartan.	Irbesartan	45-55	interleukin 6	Mus musculus	108-112
24534490-3	2014	The present study was designed to investigate the effect of the macrolide antibiotic azithromycin on IL-6 generation in murine macrophages treated with lipopolysaccharide (LPS) from Prevotella intermedia, a pathogen implicated in inflammatory periodontal disease, and its mechanisms of action.	Macrolides	64-73	interleukin 6	Mus musculus	101-105
24741294-2	2014	Here, we synthesized 26 asymmetric monocarbonyl analogs of curcumin and evaluated their anti-inflammatory activity by inhibiting the LPS-induced secretion of tumor necrosis factor-alpha and interleukin-6 in mouse RAW264.7 macrophages.	Curcumin	59-67	interleukin 6	Mus musculus	190-203
24534490-3	2014	The present study was designed to investigate the effect of the macrolide antibiotic azithromycin on IL-6 generation in murine macrophages treated with lipopolysaccharide (LPS) from Prevotella intermedia, a pathogen implicated in inflammatory periodontal disease, and its mechanisms of action.	Azithromycin	85-97	interleukin 6	Mus musculus	101-105
24534490-4	2014	Azithromycin significantly suppressed IL-6 production as well as its mRNA expression in P. intermedia LPS-activated RAW264.7 cells.	Azithromycin	0-12	interleukin 6	Mus musculus	38-42
24966921-6	2014	Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-kappaB activation in cerulein-induced AP.	diosmetin	18-27	interleukin 6	Mus musculus	191-195
24524998-8	2014	However, 5-HT combined with a low dose of 2,4,6-trinitrobenzene sulfonic acid (TNBS), the level of which caused a minimal level of colitis, exaggerated colon inflammation accompanied by much more enhanced induction of inflammatory cytokines, IL-6, IL-8, and MCP-1, indicating that colon epithelial cells directly exposed to 5-HT are primed toward inflammation.	Trinitrobenzenesulfonic Acid	42-77	interleukin 6	Mus musculus	242-246
24501215-8	2014	Ad.IL-6 increased hepatic hepcidin messenger RNA levels and decreased serum iron concentrations in Alk2- but not Alk3-deficient mice.	Iron	76-80	interleukin 6	Mus musculus	0-7
24501215-10	2014	These results demonstrate that the ability of IL-6 to induce hepatic hepcidin gene expression and reduce serum iron concentrations is dependent on the BMP type I receptor Alk3.	Iron	111-115	interleukin 6	Mus musculus	46-50
24463858-13	2014	15-Epi-lipoxin A4 also attenuated the production of interleukin-6 and tumor necrosis factor-alpha by lipopolysaccharide- or CpG DNA-stimulated peritoneal macrophages.	lipoxin A4	0-17	interleukin 6	Mus musculus	52-97
24463858-14	2014	Furthermore, 15-epi-lipoxin A4 combined with antibiotics synergistically reduced the production of interleukin-6 and tumor necrosis factor-alpha by peritoneal macrophages stimulated with live E. coli.	lipoxin A4	13-30	interleukin 6	Mus musculus	99-144
24463858-16	2014	The reduced production of interleukin-6 and tumor necrosis factor-alpha by peritoneal macrophages suggested that 15-epi-lipoxin A4 blocked the initial proinflammatory response.	lipoxin A4	113-130	interleukin 6	Mus musculus	26-71
24524998-8	2014	However, 5-HT combined with a low dose of 2,4,6-trinitrobenzene sulfonic acid (TNBS), the level of which caused a minimal level of colitis, exaggerated colon inflammation accompanied by much more enhanced induction of inflammatory cytokines, IL-6, IL-8, and MCP-1, indicating that colon epithelial cells directly exposed to 5-HT are primed toward inflammation.	Trinitrobenzenesulfonic Acid	79-83	interleukin 6	Mus musculus	242-246
24470356-3	2014	Stimulation of P2X7 receptor by ATP (1 mM) or BzATP (500 microM) evoked the mRNA expression and release of proinflammatory cytokines IL-6, TNF-alpha, and the chemokine CCL2 in WT cells but not in P2X7(-/-) cells.	Adenosine Triphosphate	32-35	interleukin 6	Mus musculus	133-137
24470356-3	2014	Stimulation of P2X7 receptor by ATP (1 mM) or BzATP (500 microM) evoked the mRNA expression and release of proinflammatory cytokines IL-6, TNF-alpha, and the chemokine CCL2 in WT cells but not in P2X7(-/-) cells.	3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate	46-51	interleukin 6	Mus musculus	133-137
24234154-3	2014	Plumbagin inhibited LPS-induced nitric oxide, TNF-alpha, IL-6 and prostaglandin-E2 production in a concentration-dependent manner in RAW 264.7 cells without inducing any cell death.	plumbagin	0-9	interleukin 6	Mus musculus	57-61
24393006-9	2014	Polyphenols also exerted an anti-inflammatory effect on preadipocytes exposed to H2O2 by reducing IL-6 secretion.	Polyphenols	0-11	interleukin 6	Mus musculus	98-102
24393006-9	2014	Polyphenols also exerted an anti-inflammatory effect on preadipocytes exposed to H2O2 by reducing IL-6 secretion.	Hydrogen Peroxide	81-85	interleukin 6	Mus musculus	98-102
23764428-3	2014	We observed that resveratrol treatment significantly reduced glial activation, decreasing the levels of IL-1beta, IL-6 and TNF-alpha, as well as their respective receptors in the SNpc of MPTP-treated mice, as demonstrated by Western blotting, RT-PCR and quantitative PCR analysis.	Resveratrol	17-28	interleukin 6	Mus musculus	114-118
24548765-8	2014	The results showed that taraxasterol attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), lung wet/dry ratio, and the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in a dose-dependent manner.	taraxasterol	24-36	interleukin 6	Mus musculus	210-223
24421048-8	2014	An increased pulmonary bacterial burden was observed in alcohol-intoxicated mice at 16 and 24 h and was associated with decreased levels of interleukin 6 (IL-6).	Alcohols	56-63	interleukin 6	Mus musculus	140-153
24421048-8	2014	An increased pulmonary bacterial burden was observed in alcohol-intoxicated mice at 16 and 24 h and was associated with decreased levels of interleukin 6 (IL-6).	Alcohols	56-63	interleukin 6	Mus musculus	155-159
24421048-15	2014	Therefore, acute alcohol intoxication leads to decreased MRSA clearance in part by inhibiting IL-6/STAT3 induction of the antimicrobial protein Reg3gamma in the pulmonary epithelium.	Alcohols	17-24	interleukin 6	Mus musculus	94-98
24548765-8	2014	The results showed that taraxasterol attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), lung wet/dry ratio, and the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in a dose-dependent manner.	taraxasterol	24-36	interleukin 6	Mus musculus	225-229
24646714-7	2014	Additionally, MTX-induced A549 cells exhibited an EMT-like phenotype accompanied by the elevation of the expression of interleukin-6 (IL-6) and transforming growth factor (TGF)-beta1, as well as an enhancement of migration.	Methotrexate	14-17	interleukin 6	Mus musculus	119-132
24022572-0	2014	Exercise sensitizes skeletal muscle to extracellular ATP for IL-6 expression in mice.	Adenosine Triphosphate	53-56	interleukin 6	Mus musculus	61-65
24022572-2	2014	Autocrine/paracrine ATP signaling has been shown to modulate IL-6 expression.	Adenosine Triphosphate	20-23	interleukin 6	Mus musculus	61-65
24022572-3	2014	The aim of this study was to determine whether a period of physical activity modifies the ATP-induced IL-6 expression.	Adenosine Triphosphate	90-93	interleukin 6	Mus musculus	102-106
24022572-6	2014	ATP evoked a concentration-dependent rise in IL-6 mRNA in both SED and VA mice.	Adenosine Triphosphate	0-3	interleukin 6	Mus musculus	45-49
24022572-8	2014	Interestingly, in VA mice we observed a positive correlation between the level of physical activity and the IL-6 mRNA increase following fiber stimulation with 10 muM ATP.	Adenosine Triphosphate	167-170	interleukin 6	Mus musculus	108-112
24534870-4	2014	A non-cytotoxic methanol extract of AT inhibited the expression of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2), leading to significantly reduced levels of nitric oxide (NO) and prostaglandin E2 (PGE2) and of two proteins regulated by these, interleukin-1beta (IL-1beta) and IL-6, in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophage cells.	Methanol	16-24	interleukin 6	Mus musculus	288-292
24646714-7	2014	Additionally, MTX-induced A549 cells exhibited an EMT-like phenotype accompanied by the elevation of the expression of interleukin-6 (IL-6) and transforming growth factor (TGF)-beta1, as well as an enhancement of migration.	Methotrexate	14-17	interleukin 6	Mus musculus	134-138
24430548-3	2014	The experiments in vitro showed that baicalin inhibited both viability of macrophages and the cell"s secretion of HMGB1, tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-1beta induced by lipopolysaccharide.	baicalin	37-45	interleukin 6	Mus musculus	150-163
24456641-8	2014	Doxofylline significantly inhibited IL-6 and TNF-alpha release into BAL fluid in comparison to LPS-treated animals (LPS: 1255.6 +- 143.9 versus doxofylline 1 mg/kg: 527.7 +- 182.9; 0.3 mg/kg: 823.2 +- 102.3 pg/ml).	doxofylline	0-11	interleukin 6	Mus musculus	36-40
24430548-3	2014	The experiments in vitro showed that baicalin inhibited both viability of macrophages and the cell"s secretion of HMGB1, tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-1beta induced by lipopolysaccharide.	baicalin	37-45	interleukin 6	Mus musculus	165-169
24742865-9	2014	Sunitinib plus rapamycin markedly induced versican, IDO, arginase 1, IL-6, and TGF-beta expression in the lungs, whereas it reduced IDO and IL-10 expression in the primary tumor tissues.	Sunitinib	0-9	interleukin 6	Mus musculus	69-73
24742865-9	2014	Sunitinib plus rapamycin markedly induced versican, IDO, arginase 1, IL-6, and TGF-beta expression in the lungs, whereas it reduced IDO and IL-10 expression in the primary tumor tissues.	Sirolimus	15-24	interleukin 6	Mus musculus	69-73
24742865-10	2014	IL-6 levels in the circulation were increased after rapamycin and combination therapies.	Sirolimus	52-61	interleukin 6	Mus musculus	0-4
24645646-11	2014	We also found that EMF exposure significantly increased the secretion of pro-inflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) and the production of NO; however, these increases were efficiently chilled by the addition of curcumin to the culture medium.	Curcumin	226-234	interleukin 6	Mus musculus	112-116
24686517-5	2014	The levels of TNF-alpha and IFN-gamma increased, but IL-6, IL-17A and IL-4 decreased in lamina propria (LP) of colon in immune milk-fed mice with DSS-induced colitis.	dss	146-149	interleukin 6	Mus musculus	53-57
24381131-4	2014	We hypothesized that elevated IL-6 in Adipo(-/-) mice contributes to their augmented responses to ozone via effects on IL-17A expression.	Ozone	98-103	interleukin 6	Mus musculus	30-34
24602493-9	2014	Furthermore, berberine could significantly suppressed the increasing expression of NF-kappaB, IL-6, TNFalpha, and IFNbeta in the RAW264.7 challenged with LPS.	Berberine	13-22	interleukin 6	Mus musculus	94-98
24638037-5	2014	Administration of fasudil, a Rho-kinase inhibitor, significantly reduced the I/R-induced expression of the proinflammatory cytokines interleukin (IL)-6, C-C motif chemoattractant ligand 2 (CCL2), and tumor necrosis factor (TNF)-alpha, in leukocytes, compared with saline as the vehicle.	fasudil	18-25	interleukin 6	Mus musculus	133-151
24744681-10	2014	Dexamethasone also inhibited expressions of TGF-beta, IL-6, and TNF-alpha in bronchoalveolar lavage fluid.	Dexamethasone	0-13	interleukin 6	Mus musculus	54-58
24603712-5	2014	Cotreatment with the beta-agonist isoproterenol potentiated the expression of inflammatory mediators, including Interleukin-6 (IL-6) and several chemokines.	Isoproterenol	34-47	interleukin 6	Mus musculus	112-125
24603712-5	2014	Cotreatment with the beta-agonist isoproterenol potentiated the expression of inflammatory mediators, including Interleukin-6 (IL-6) and several chemokines.	Isoproterenol	34-47	interleukin 6	Mus musculus	127-131
24603712-8	2014	Using the IL-6 promoter as a model, we demonstrated that TNF-alpha/isoproterenol cotreatment provoked phosphorylation of histone H3 at serine 10, concomitant with enhanced promoter accessibility and recruitment of the NF-kappaB p65 subunit, cAMP-response element-binding protein (CREB), CREB-binding protein (CBP) and RNA polymerase II.	Isoproterenol	67-80	interleukin 6	Mus musculus	10-14
24603712-8	2014	Using the IL-6 promoter as a model, we demonstrated that TNF-alpha/isoproterenol cotreatment provoked phosphorylation of histone H3 at serine 10, concomitant with enhanced promoter accessibility and recruitment of the NF-kappaB p65 subunit, cAMP-response element-binding protein (CREB), CREB-binding protein (CBP) and RNA polymerase II.	Serine	135-141	interleukin 6	Mus musculus	10-14
24598860-8	2014	Expression levels of pro-inflammatory cytokines (TNF-alpha, IL-6, iNOS) induced by LPS were decreased obviously by treatment with MEAP.	meap	130-134	interleukin 6	Mus musculus	60-64
24160248-7	2014	Moreover, the expression of P-selectin induced by TPA was abrogated by POH and significantly lower serum concentrations of IL-6 and TNF-alpha were observed in d-Limonene- and POH-treated mice (p&lt;0.04 and 0.03).	Limonene	159-169	interleukin 6	Mus musculus	123-127
24134486-4	2014	The DHA group had the highest bronchoalveolar lavage (BAL) fluid eosinophil and IL-6 levels (P &lt; 0.05).	Docosahexaenoic Acids	4-7	interleukin 6	Mus musculus	80-84
24548426-9	2014	Within the tumor, mRNA expression of bindarit"s primary targets, MCP-1 and IL-12/p35, were significantly decreased by bindarit treatment (P&lt;0.05), and this was consistent with trends for reduced expression of TNF-alpha, IL-6, F4/80, CD206, and IL-10.	bindarit	37-45	interleukin 6	Mus musculus	223-227
24548426-13	2014	These results show that tumor multiplicity in the C3(1)/SV40Tag mouse model of breast cancer is reduced by bindarit, however these effects are independent of changes in plasma levels of MCP-1 and IL-6, but may be related to the attenuated expression of MCP-1 along with several inflammatory mediators and macrophage markers within the tumor.	bindarit	107-115	interleukin 6	Mus musculus	196-200
24520264-8	2014	The concentration of interleukin-6 was downregulated by curcumin only (P&lt;0.01, versus the MCD group).	Curcumin	56-64	interleukin 6	Mus musculus	21-34
24406428-7	2014	This inhibitory effect of maleylated-BSA on LPS-induced IL-6 production was eliminated by treatment with an extracellular signal-regulated kinase (ERK) inhibitor, U0126, indicating the involvement of ERK pathways.	U 0126	163-168	interleukin 6	Mus musculus	56-60
24096333-5	2014	Surprisingly, C. albicans-infected, glycolipid-treated mice exhibited significantly lower survival rates, increased fungal burden, and higher interleukin (IL)-6 production in the kidneys compared with control mice.	Glycolipids	36-46	interleukin 6	Mus musculus	142-160
24565661-1	2014	INTRODUCTION: The aim of this study was to assess the cell viability and messenger RNA expression of interleukin (IL)-1alpha and IL-6 in 3T3 fibroblast cells when in direct contact with Biodentine (Septodont, Saint Maur de Fosses, France) and mineral trioxide aggregate (MTA).	tricalcium silicate	186-196	interleukin 6	Mus musculus	129-133
24565661-1	2014	INTRODUCTION: The aim of this study was to assess the cell viability and messenger RNA expression of interleukin (IL)-1alpha and IL-6 in 3T3 fibroblast cells when in direct contact with Biodentine (Septodont, Saint Maur de Fosses, France) and mineral trioxide aggregate (MTA).	Septodont	198-207	interleukin 6	Mus musculus	129-133
24565661-10	2014	The messenger RNA expression of IL-1alpha and IL-6 by cells in contact with Biodentine was similar to cells in contact with MTA.	tricalcium silicate	76-86	interleukin 6	Mus musculus	46-50
24121404-0	2014	Catecholamine stress alters neutrophil trafficking and impairs wound healing by beta2-adrenergic receptor-mediated upregulation of IL-6.	Catecholamines	0-13	interleukin 6	Mus musculus	131-135
24121404-4	2014	Prolonged systemic exposure of epinephrine resulted in persistent PMN trafficking to the wound site via an IL-6-mediated mechanism, and this in turn impaired wound repair.	Epinephrine	31-42	interleukin 6	Mus musculus	107-111
24121404-5	2014	Further, we demonstrate that beta2-adrenergic receptor-dependent activation of proinflammatory macrophages is critical for epinephrine-mediated IL-6 production.	Epinephrine	123-134	interleukin 6	Mus musculus	144-148
24366217-10	2014	Furthermore, 1,25(OH)2D3-treated DCs secreted much higher levels of IL-10, however lower levels of IL-2 and IL-6 compared with the activated control DCs.	Calcitriol	13-24	interleukin 6	Mus musculus	108-112
24438338-6	2014	Furthermore, ROS induction by Mstn in Smad3(-/-) muscle was not via nuclear factor-kappaB (p65) signaling but due to activated p38, ERK MAPK signaling and enhanced IL-6 levels.	Reactive Oxygen Species	13-16	interleukin 6	Mus musculus	164-168
24339378-12	2014	Adipocytes isolated from PAFR(-/-) mice incubated in media containing normal or high levels of glucose secreted less interleukin-6 and tumor necrosis factor alpha and presented lower rate of lipolysis than WT mice.	Glucose	95-102	interleukin 6	Mus musculus	117-130
24795796-0	2014	A Probiotic Preparation Duolac-Gold Ameliorates Dextran Sulphate Sodium-induced Mouse Colitis by Downregulating the Expression of IL-6.	dextran sulphate sodium	48-71	interleukin 6	Mus musculus	130-134
24606743-13	2014	The 4-palmitoyl-sinomenine inhibited RAW264.7 cell proliferation and IL-6 gene transcription.	4-palmitoyl-sinomenine	4-26	interleukin 6	Mus musculus	69-73
24587317-4	2014	The aim of the present study was to examine the effects of 25(OH)D3, which is stable form of vitamin D3 in blood, and biologically active form 1,25(OH)2D3 on the production of interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) by cells of periodontal ligament.	Calcifediol	59-67	interleukin 6	Mus musculus	191-195
24587317-4	2014	The aim of the present study was to examine the effects of 25(OH)D3, which is stable form of vitamin D3 in blood, and biologically active form 1,25(OH)2D3 on the production of interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) by cells of periodontal ligament.	25(oh)2d3	145-154	interleukin 6	Mus musculus	176-189
24587317-4	2014	The aim of the present study was to examine the effects of 25(OH)D3, which is stable form of vitamin D3 in blood, and biologically active form 1,25(OH)2D3 on the production of interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) by cells of periodontal ligament.	25(oh)2d3	145-154	interleukin 6	Mus musculus	191-195
24587679-9	2014	IL-6, IL-10 and IFN-gamma reached their maxima 4 d after DSS withdrawal and decreased during the late recovery phase.	Dextran Sulfate	57-60	interleukin 6	Mus musculus	0-4
24587010-7	2014	Both Con A- and phorbol ester plus ionomycin-induced expression of TNF-alpha, IFN-gamma and IL-6 proteins was attenuated upon exposure to CuIIb.	Phorbol Esters	16-29	interleukin 6	Mus musculus	92-96
24587010-7	2014	Both Con A- and phorbol ester plus ionomycin-induced expression of TNF-alpha, IFN-gamma and IL-6 proteins was attenuated upon exposure to CuIIb.	Ionomycin	35-44	interleukin 6	Mus musculus	92-96
24586996-8	2014	PolyICLC administration was associated with increases in TNFalpha, IL6, MCP1, MIP1alpha, KC, and MIP1beta levels in the periphery and with the activation of dendritic cells (DCs), NK cells, and B cells.	poly ICLC	0-8	interleukin 6	Mus musculus	67-70
24357729-2	2014	Induction of hepcidin, mediated by interleukin 6, leads to iron-restricted erythropoiesis and anemia.	Iron	59-63	interleukin 6	Mus musculus	35-48
24586264-7	2014	In dendritic cells, Tempol inhibited LPS-induced production of TNF-alpha, IL-6, and IL-12p70, downregulated expression of co-stimulatory molecules, and prevented antigen-dependent lymphocyte proliferation.	tempol	20-26	interleukin 6	Mus musculus	74-78
24558444-5	2014	Our results showed that administration of low dose reconstituted polyphenol OBs inhibited LPS-mediated inflammatory cytokine secretion, including IL-6, IL-23, and IL-12, while increasing IL-10 and IL-1Ralpha production.	Polyphenols	65-75	interleukin 6	Mus musculus	146-150
24533077-8	2014	Surprisingly, plasma lactate concentration during running at 8 m min-1 as well at maximal running velocity in IL-6-/- mice was significantly lower (P&lt;0.01) than in WT mice.	Lactic Acid	21-28	interleukin 6	Mus musculus	110-114
24548878-4	2014	Here we induced MIA in mice by challenge with polyinosinic:polycytidylic phosphate salt-a synthetic analog of double-stranded RNA, which enhances maternal levels of the cytokine interleukin-6 (IL-6)-and demonstrate a depression-like behavioral phenotype in adult offsprings.	polycytidylic phosphate salt-a	59-89	interleukin 6	Mus musculus	178-191
24548878-4	2014	Here we induced MIA in mice by challenge with polyinosinic:polycytidylic phosphate salt-a synthetic analog of double-stranded RNA, which enhances maternal levels of the cytokine interleukin-6 (IL-6)-and demonstrate a depression-like behavioral phenotype in adult offsprings.	polycytidylic phosphate salt-a	59-89	interleukin 6	Mus musculus	193-197
24533077-9	2014	Interestingly, IL-6-/- mice displayed important adaptive mechanisms including significantly lower oxygen cost of running at a given speed accompanied by lower expression of sarcoplasmic reticulum Ca2+-ATPase and lower plasma lactate concentrations during running at submaximal and maximal running velocities.	Oxygen	98-104	interleukin 6	Mus musculus	15-19
24533077-9	2014	Interestingly, IL-6-/- mice displayed important adaptive mechanisms including significantly lower oxygen cost of running at a given speed accompanied by lower expression of sarcoplasmic reticulum Ca2+-ATPase and lower plasma lactate concentrations during running at submaximal and maximal running velocities.	Lactic Acid	225-232	interleukin 6	Mus musculus	15-19
24361136-6	2014	The results show that bosentan treatment induced a bell shaped dose-dependent antidepressant-like effect with increase in circulating IL-6 levels in animals exposed to FST.	Bosentan	22-30	interleukin 6	Mus musculus	134-138
24583651-4	2014	Entolimod-stimulated IL-6 production was essential for Entolimod"s ability to rescue mice from death caused by doses of 5-FU associated with hematopoietic failure.	Fluorouracil	120-124	interleukin 6	Mus musculus	21-25
24361136-5	2014	Moreover, the influence of bosentan treatment on circulating IL-6 levels was also addressed after FST.	Bosentan	27-35	interleukin 6	Mus musculus	61-65
24361136-10	2014	Therefore, this is the first study to demonstrate the antidepressant-like activity of bosentan in mice, unveiling a previous unrecognized role of endothelin in depression and its possible relation with increased circulating IL-6 levels.	Bosentan	86-94	interleukin 6	Mus musculus	224-228
24300194-7	2014	In addition, CHE also significantly inhibited nitric oxide (NO) concentration, pro-inflammatory interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) level in serum and gastric mucosal in the mice exposed to ethanol induced ulceration in a dose-dependent manner.	chelerythrine	13-16	interleukin 6	Mus musculus	111-115
24504121-3	2014	Here, we have found that long-time N-acetyl-L-cysteine treatment at low-concentration increases phosphorylation of extracellular signal-regulated kinase 1/2 and AKT, which are essential for the induction of proinflammatory cytokines including interleukin 1beta and interleukin 6 in lipopolysaccharide-stimulated RAW264.7 cells.	Acetylcysteine	35-54	interleukin 6	Mus musculus	265-278
24490809-9	2014	Moreover, sitagliptin significantly reduced the expression of monocyte chemoattractant protein-1 and interleukin-6 in the aorta (p &lt; 0.01 and p &lt; 0.05), as well as the serum levels of soluble vascular cell adhesion molecule-1 and P-selectin (both p &lt; 0.05).	Sitagliptin Phosphate	10-21	interleukin 6	Mus musculus	101-114
24498418-7	2014	Pretreatment with ethyl pyruvate ameliorated the pathological effects of Con A-induced autoimmune hepatitis and significantly decreased the levels of TNF-alpha, IL-2, IL-6 and IL-1beta at 3h and 6h and the level of HMGB1 at 6h and 24h post injection.	ethyl pyruvate	18-32	interleukin 6	Mus musculus	167-171
24498418-9	2014	CONCLUSION: Taken together, these results indicated that ethyl pyruvate protected against Con A-induced autoimmune hepatitis by decreasing both early (TNF-alpha, IL-2, IL-1beta and IL-6) and late (HMGB1) cytokine expression in mice.	ethyl pyruvate	57-71	interleukin 6	Mus musculus	181-185
24374810-8	2014	In ex vivo studies, treatment of the mice with DZ2002 suppressed the development of pathogenic Th17 cells, significantly decreased IL-17, TGF-beta, IL-6, and IL-23p19 production and impeded activation of the STAT3 protein and JNK/NF-kappaB signaling in splenocytes.	methyl 4-(adenin-9-yl)-2-hydroxybutanoate	47-53	interleukin 6	Mus musculus	148-152
24374810-10	2014	DZ2002 (100 mumol/L) also significantly suppressed TLR agonists-stimulated up-regulation in IL-6 and IL-23p19 production in murine BMDCs, and prevented Th17 differentiation and suppressed IL-17 secretion by the T cells in a BMDC-T cell co-culture system.	methyl 4-(adenin-9-yl)-2-hydroxybutanoate	0-6	interleukin 6	Mus musculus	92-96
24504814-11	2014	Lung fibroblasts isolated from GDF-15-deficient mice showed reduced induction of interleukin-6 and CCL2 upon bleomycin stimulation.	Bleomycin	109-118	interleukin 6	Mus musculus	81-94
24135499-7	2014	Moreover, axitinib suppressed the expressions of proinflammatory cytokines such as IL-6, TNF-alpha, and IFN-gamma.	Axitinib	10-18	interleukin 6	Mus musculus	83-87
23954861-6	2014	Moreover, after poly(I : C) injection, Rip3(-/-) mice displayed decreased levels of pro-inflammatory cytokines (such as TNF-alpha and IL-6) in the retina, and attenuated intravitreal release of high-mobility group box-1 (HMGB1), a major damage-associated molecular pattern (DAMP).	Poly I-C	16-26	interleukin 6	Mus musculus	134-138
23954861-7	2014	In vitro, poly(I : C)-induced necrosis were inhibited in Rip3-deficient RPE cells, which in turn suppressed HMGB1 release and dampened TNF-alpha and IL-6 induction evoked by necrotic supernatants.	Poly I-C	10-21	interleukin 6	Mus musculus	149-153
23408349-9	2014	E2-treated animals showed increased clinical symptoms and Il-6 production upon DSS-induced colitis and enhanced epithelial proliferation.	dss	79-82	interleukin 6	Mus musculus	58-62
24554039-8	2014	Edaravone lowered the levels of TNF-alpha and IL-6 and reduced the number of TUNEL-positive cells.	Edaravone	0-9	interleukin 6	Mus musculus	46-50
24311453-8	2014	Modeling a proinflammatory microglial phenotype by stimulation with LPS in vitro, Fasudil decreased the release of proinflammatory cytokines and chemokines TNFalpha, Il6, CCL2, CCL3, and CCL5 while CXCL1 release was only transiently suppressed.	fasudil	82-89	interleukin 6	Mus musculus	166-169
24296134-3	2014	Although no significant cytotoxicity of PL was observed over the concentration range tested, PL (2.5-7.5 muM) significantly and dose-dependently suppressed the secretion of pro-inflammatory mediators and inhibited the expression of TNF-alpha, IL-1beta, IL-6 and iNOS in LPS-stimulated RAW 264.7 cells.	plumbagin	93-95	interleukin 6	Mus musculus	253-257
24286370-7	2014	Further studies revealed that taraxasterol significantly reduced TNF-alpha, IFN-gamma, IL-1beta, IL-6, NO and PGE2 levels in sera from mice with endotoxic shock.	taraxasterol	30-42	interleukin 6	Mus musculus	97-101
23868687-7	2014	Glucose supplementation attenuated the high contents of IL-6, TNF-alpha and IL-15 in liver, and of IL-6 in serum.	Glucose	0-7	interleukin 6	Mus musculus	56-60
24286371-4	2014	Real-time polymerase chain reaction showed that the mRNA levels of IL-17A, IL-17F, IL-22, IL-1beta, IL-6 and TNF-alpha in ear skin were significantly decreased by clobetasol.	Clobetasol	163-173	interleukin 6	Mus musculus	100-104
24390064-6	2014	The number of immature and mature platelets, activated platelets, and platelet-leukocyte aggregates were measured in wild-type and IL-6 mice with dextran sodium sulfate (DSS)-induced colonic inflammation.	dss	170-173	interleukin 6	Mus musculus	131-135
23868687-7	2014	Glucose supplementation attenuated the high contents of IL-6, TNF-alpha and IL-15 in liver, and of IL-6 in serum.	Glucose	0-7	interleukin 6	Mus musculus	99-103
24387343-7	2014	In an in vitro study using plasmacytoid dendritic cells (DCs), IMQ induced production of interferon (IFN)-alpha, IL-23, IL-6 and tumor necrosis factor (TNF)-alpha.	Imiquimod	63-66	interleukin 6	Mus musculus	120-124
24337047-5	2014	The results showed that following supplementation with EPS, interleukin (IL) 6, IL1beta and tumor necrosis factor (TNF) alpha mRNA expression in VAT were significantly reduced, while Glut4, pAMPK and SirT1 protein expression were markedly increased when compared with KKAy mice gavaged with water.	exophthalmos producing substance	55-58	interleukin 6	Mus musculus	60-78
24342806-7	2014	Consistently, PGE2-EP3 signaling elicited histamine release in mouse peritoneal and bone marrow-derived mast cells, and it exerted degranulation and IL-6 production in a manner sensitive to pertussis toxin and a PI3K inhibitor and dependent on extracellular Ca(2+) ions.	Dinoprostone	14-18	interleukin 6	Mus musculus	149-153
24422705-13	2014	Additionally, CDT also inhibited the increase of TNF-alpha and IL-6 level, and increased the expression of choline acetyltransferase (ChAT), receptor of activated protein kinase C1 (RACK1) and brain-derived neurotrophic factor (BDNF) in brain as compared to model mice.	cdt	14-17	interleukin 6	Mus musculus	63-67
24296978-5	2014	Treatment of the mice with atorvastatin or celecoxib alone caused decrease in the levels of IL-6 and survivin as LNCaP tumors became androgen-independent, but treatment of the mice with a combination of celecoxib and atorvastatin resulted in a much stronger inhibition in the increase in IL-6 and survivin expression.	Atorvastatin	27-39	interleukin 6	Mus musculus	92-96
24296978-5	2014	Treatment of the mice with atorvastatin or celecoxib alone caused decrease in the levels of IL-6 and survivin as LNCaP tumors became androgen-independent, but treatment of the mice with a combination of celecoxib and atorvastatin resulted in a much stronger inhibition in the increase in IL-6 and survivin expression.	Atorvastatin	27-39	interleukin 6	Mus musculus	288-292
24296978-5	2014	Treatment of the mice with atorvastatin or celecoxib alone caused decrease in the levels of IL-6 and survivin as LNCaP tumors became androgen-independent, but treatment of the mice with a combination of celecoxib and atorvastatin resulted in a much stronger inhibition in the increase in IL-6 and survivin expression.	Celecoxib	43-52	interleukin 6	Mus musculus	92-96
24296978-5	2014	Treatment of the mice with atorvastatin or celecoxib alone caused decrease in the levels of IL-6 and survivin as LNCaP tumors became androgen-independent, but treatment of the mice with a combination of celecoxib and atorvastatin resulted in a much stronger inhibition in the increase in IL-6 and survivin expression.	Celecoxib	43-52	interleukin 6	Mus musculus	288-292
24296978-5	2014	Treatment of the mice with atorvastatin or celecoxib alone caused decrease in the levels of IL-6 and survivin as LNCaP tumors became androgen-independent, but treatment of the mice with a combination of celecoxib and atorvastatin resulted in a much stronger inhibition in the increase in IL-6 and survivin expression.	Celecoxib	203-212	interleukin 6	Mus musculus	288-292
24395784-6	2014	Vorinostat treatment increased the frequency of functional regulatory T-cell subsets and their transcription factors Gata3 and FoxP3 in parallel to a decrease in inflammatory dendritic cell subsets and their cytokines IL-6, IL-12, and TNF-alpha.	Vorinostat	0-10	interleukin 6	Mus musculus	218-222
24465472-5	2014	After 12 hr, DHA was the most anti-inflammatory, decreasing MCP1 and IL-6 secretion in the contact system (-57%, -63%, respectively, p &lt;= 0.05) with similar effects in the trans-well system.	Dihydroalprenolol	13-16	interleukin 6	Mus musculus	69-73
24465472-10	2014	Overall, our findings suggest that DHA may lessen the degree of MCP1 and IL-6 secreted from adipocytes, and may reduce the degree of M1 polarization of macrophages recruited to adipose tissue, thereby decreasing the intensity of pro-inflammatory cross-talk between adipocytes and macrophages in obese adipose tissue.	Dihydroalprenolol	35-38	interleukin 6	Mus musculus	73-77
24215755-6	2014	KEY FINDINGS: Observations of the colon and IL-6 plasma level determination demonstrated that DNBS treatment led to stronger inflammation.	2,4-dinitrofluorobenzene sulfonic acid	94-98	interleukin 6	Mus musculus	44-48
24269960-5	2014	Moreover, curcumol inhibits LPS-induced production of TNF-alpha, IL-1beta and IL-6 at both the transcriptional and translational levels.	curcumol	10-18	interleukin 6	Mus musculus	78-82
24407238-8	2014	In vitro biochemical analysis revealed that adenosine directly attenuated recruitment of NF-kappaB to the TNF-alpha and interleukin-6 promoters.	Adenosine	44-53	interleukin 6	Mus musculus	120-133
24177262-12	2014	Correspondingly, folic acid significantly attenuated LPS-induced tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-6 in placentas, maternal serum and amniotic fluid.	Folic Acid	17-27	interleukin 6	Mus musculus	127-131
24516345-13	2014	There was a significant increase in plasma TNF-alpha (p = 0.048) and IL-6 (p = 0.014) levels after formalin-induced pain.	Formaldehyde	99-107	interleukin 6	Mus musculus	69-73
25478170-4	2014	Blood oxygen levels negatively correlate with 7 of 10 quantitative markers of murine lung injury, including neutrophilia and interleukin-6 expression.	Oxygen	6-12	interleukin 6	Mus musculus	125-138
24231956-7	2014	Simultaneously, DETT increased IkappaBalpha, an inhibitor of the p65/p50 heterodimer, even in the presence of stimulants lipopolysaccharide, tumour necrosis factor-alpha, or interleukin-6.	dett	16-20	interleukin 6	Mus musculus	174-187
23909743-8	2014	However, single binge EtOH followed by burn injury induced significant elevations in mRNA and protein concentrations of pro-inflammatory mediators interleukin-6 (IL-6), KC, and monocyte chemoattractant protein 1 compared with either insult alone or sham vehicle group.	Ethanol	22-26	interleukin 6	Mus musculus	147-160
23909743-8	2014	However, single binge EtOH followed by burn injury induced significant elevations in mRNA and protein concentrations of pro-inflammatory mediators interleukin-6 (IL-6), KC, and monocyte chemoattractant protein 1 compared with either insult alone or sham vehicle group.	Ethanol	22-26	interleukin 6	Mus musculus	162-166
24097560-8	2014	In IL-17(-/-) mice, there is reduced expression of IL-6, macrophage inflammatory protein-2, and matrix metalloproteinase-12 compared with wild-type mice after CS exposure.	Cesium	159-161	interleukin 6	Mus musculus	51-55
25004880-6	2014	The JNK-specific inhibitor SP600125 decreased the proteins expression of phospho-JNK, iNOS, COX-2, and the mRNAs expression and levels of IL-6 and TNF-alpha.	pyrazolanthrone	27-35	interleukin 6	Mus musculus	138-142
25004880-13	2014	Besides, the mRNAs and levels of IL-6 and TNF-alpha also decreased by quercetin and catechin treatment in LPS-induced RAW264.7 cells.	Quercetin	70-79	interleukin 6	Mus musculus	33-37
25004880-13	2014	Besides, the mRNAs and levels of IL-6 and TNF-alpha also decreased by quercetin and catechin treatment in LPS-induced RAW264.7 cells.	Catechin	84-92	interleukin 6	Mus musculus	33-37
24232001-7	2014	In accordance with the in vivo results, paeoniflorin downregulated TLR4 expression, blocked nuclear translocation of NF-kappaB p65, and reduced the production of IL-6 in LPS-stimulated mouse macrophage RAW264.7 cells.	peoniflorin	40-52	interleukin 6	Mus musculus	162-166
24583856-0	2014	Caffeic acid reduces cutaneous tumor necrosis factor alpha (TNF-alpha), IL-6 and IL-1beta levels and ameliorates skin edema in acute and chronic model of cutaneous inflammation in mice.	caffeic acid	0-12	interleukin 6	Mus musculus	72-76
24431283-13	2014	Tofacitinib also inhibited the bone destruction caused by TNFalpha and IL-6 in vivo.	tofacitinib	0-11	interleukin 6	Mus musculus	71-75
24401215-15	2014	Curcumin at medium doses of 500-1000 mg/kg diet was effective at reducing fatty streak formation and suppressing aortic expression of IL-6 in the descending aorta and blood levels of several inflammatory cytokines, but at a higher dose (HF + HC, 1500 mg/kg diet), it had adverse effects on some of these parameters.	Curcumin	0-8	interleukin 6	Mus musculus	134-138
24989009-4	2014	Additionally, tomentosin reduced the release of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	tomentosin	14-24	interleukin 6	Mus musculus	128-141
24989009-4	2014	Additionally, tomentosin reduced the release of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	tomentosin	14-24	interleukin 6	Mus musculus	143-147
24724082-5	2014	Furthermore, hepatic levels of interleukin-6, cyclooxygenase-2, and C-reactive protein, markers of inflammatory response, were markedly increased by exposure to PFOA in mice.	perfluorooctanoic acid	161-165	interleukin 6	Mus musculus	31-44
24991574-3	2014	However, there were three interesting findings possibly related to the pleiotropic effects of olmesartan on adipose tissue in KKAy mice: (1) an inhibitory effect on adipocyte hypertrophy, (2) a suppressive effect on IL-6 gene expression, and (3) an ameliorating effect on oxidative stress.	olmesartan	94-104	interleukin 6	Mus musculus	216-220
24991574-5	2014	Collectively, these results suggest that the blood pressure lowering effect of olmesartan in KKAy mice is associated with an improvement in adipocyte, including suppression of adipocyte hypertrophy and inhibition of the adipose IL-6-oxidative stress axis.	olmesartan	79-89	interleukin 6	Mus musculus	228-232
24894548-3	2014	Lipopolysachharide (LPS) and 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced production of proinflammatory cytokines (TNF-alpha and IL-6) in macrophage cells as well as in TPA-induced skin inflammation in mice was significantly inhibited by alpha-(-)-bisabolol.	lipopolysachharide	0-18	interleukin 6	Mus musculus	136-140
26155140-7	2014	By detecting glucose-stimulated insulin secretion in the primary islet, insulin secretion of TLR4-/- HF mice was better than that of the WT HF group, and in the TLR4-/- HF group, at the mRNA level, islet interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and monocyte chemotactic protein 1 (MCP-1) were significantly lower than in the WT HF group.	Glucose	13-20	interleukin 6	Mus musculus	198-217
26155140-7	2014	By detecting glucose-stimulated insulin secretion in the primary islet, insulin secretion of TLR4-/- HF mice was better than that of the WT HF group, and in the TLR4-/- HF group, at the mRNA level, islet interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and monocyte chemotactic protein 1 (MCP-1) were significantly lower than in the WT HF group.	Glucose	13-20	interleukin 6	Mus musculus	219-223
24894548-3	2014	Lipopolysachharide (LPS) and 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced production of proinflammatory cytokines (TNF-alpha and IL-6) in macrophage cells as well as in TPA-induced skin inflammation in mice was significantly inhibited by alpha-(-)-bisabolol.	Tetradecanoylphorbol Acetate	29-66	interleukin 6	Mus musculus	136-140
24894548-3	2014	Lipopolysachharide (LPS) and 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced production of proinflammatory cytokines (TNF-alpha and IL-6) in macrophage cells as well as in TPA-induced skin inflammation in mice was significantly inhibited by alpha-(-)-bisabolol.	Tetradecanoylphorbol Acetate	68-71	interleukin 6	Mus musculus	136-140
24894548-3	2014	Lipopolysachharide (LPS) and 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced production of proinflammatory cytokines (TNF-alpha and IL-6) in macrophage cells as well as in TPA-induced skin inflammation in mice was significantly inhibited by alpha-(-)-bisabolol.	Tetradecanoylphorbol Acetate	176-179	interleukin 6	Mus musculus	136-140
24894548-3	2014	Lipopolysachharide (LPS) and 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced production of proinflammatory cytokines (TNF-alpha and IL-6) in macrophage cells as well as in TPA-induced skin inflammation in mice was significantly inhibited by alpha-(-)-bisabolol.	LEVOMENOL	245-264	interleukin 6	Mus musculus	136-140
24441025-3	2014	The data indicated that the levels of ALT, AST, TG, CRP, IL-6, NF-kappaB and MDA significantly decreased and that SOD activity improved after treatment with the combination of SF and OMT; the same effects were not observed with the same dose of SF or OMT when used alone.	omt	183-186	interleukin 6	Mus musculus	57-61
25668943-1	2014	It was established in experiments on noninbred mice that activation of alpha-7n acetylcholine receptors (alpha-7n AChR) by anabasine in single doses of 1.0 and 5.0 mg/kg for 2 h before modeling sepsis (intraperitoneal injection of E. coli) cause a significant dose-dependent reduction of mortality of mice due to a decrease in the amount of proinflammatory cytokines TNF-alpha, IL-1beta, and IL-6 in the blood.	Anabasine	123-132	interleukin 6	Mus musculus	392-396
24744815-7	2014	EAFA also suppressed the expression of IL-1 beta and IL-6, whereas it elevates the level of heme oxygenase-1.	eafa	0-4	interleukin 6	Mus musculus	53-57
23771791-5	2014	RESULTS: D-galactose treatment, generally similar to NA, increased the lung pro-inflammatory status, as shown in the IL-6 and IL-1beta levels and the expression of phospho-Jun and phospho-JNK, and the fibrotic status as shown in the hydroxyproline level compared to the vehicle.	Galactose	9-20	interleukin 6	Mus musculus	117-121
25276218-3	2014	AC-mix potently suppressed DSS-induced body weight loss, colon shortening, myeloperoxidase activity, and TNF-alpha, IL-1beta, and IL-6 expressions in acute or chronic DSS-stimulated colitic mice.	ac-mix	0-6	interleukin 6	Mus musculus	130-134
24772178-7	2014	DHI inhibited the elevations of hepatic lipid peroxidation (malondialdehyde), caspase-8 activity, and mRNA expression levels of inflammatory cytokines (interleukin-1 beta and interleukin-6) increased by D-GalN/LPS in the liver.	dehydrosoyasaponin I	0-3	interleukin 6	Mus musculus	175-188
25132860-3	2014	Cp-BF strongly inhibited the production of NO and TNF-alpha, release of reactive oxygen species (ROS), phagocytic uptake of FITC-dextran, and mRNA expression levels of interleukin (IL)-6, inducible NO synthase (iNOS), and tumour necrosis factor-alpha (TNF)-alpha in activated RAW264.7 cells.	cp-bf	0-5	interleukin 6	Mus musculus	168-186
25477999-7	2014	PEESG also possessed a significant suppression effect on proinflammatory mediators production, such as nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6), in LPS-induced RAW264.7 cells.	peesg	0-5	interleukin 6	Mus musculus	167-180
25477999-7	2014	PEESG also possessed a significant suppression effect on proinflammatory mediators production, such as nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6), in LPS-induced RAW264.7 cells.	peesg	0-5	interleukin 6	Mus musculus	182-186
25587342-7	2014	Our results indicated that 6 weeks of CUMS exposure induced significant depression-like behavior, with low 5-HT and NE levels, high TNF-alpha and IL-6 in brain and high hippocampal TNF-alpha, IL-6, P-NF-kappaBP65, and 5-HT2AR levels, and low BDNF expression levels.	cums	38-42	interleukin 6	Mus musculus	146-150
25587342-7	2014	Our results indicated that 6 weeks of CUMS exposure induced significant depression-like behavior, with low 5-HT and NE levels, high TNF-alpha and IL-6 in brain and high hippocampal TNF-alpha, IL-6, P-NF-kappaBP65, and 5-HT2AR levels, and low BDNF expression levels.	cums	38-42	interleukin 6	Mus musculus	192-196
25383082-4	2014	The results showed that in vitro propolis flavonoids liposome can significantly enhance the phagocytic function of macrophages and the release of IL-1beta, IL-6, and IFN-gamma.	Flavonoids	42-52	interleukin 6	Mus musculus	156-160
24960169-7	2014	The p38 inhibitor, SB 203580, significantly reduced the LPS-induced IL-6 production.	SB 203580	19-28	interleukin 6	Mus musculus	68-72
24511322-7	2014	Finally, the production of IL-6 and TNF- alpha , involved in rheumatoid arthritis pathogenesis, was suppressed by treatment with platycodin D.	platycodin D	129-141	interleukin 6	Mus musculus	27-31
24812589-6	2014	The results showed that sophoridine inhibited the production of IL-8 in in vitro cell culture supernatant and inhibited the production of TNF alpha , PGE2, and IL-8 in the local inflammatory exudates but had no significant effects on the production of IL-6 in vitro and in vivo.	matrine	24-35	interleukin 6	Mus musculus	252-256
24127072-8	2014	Chlorogenic acid also attenuated pro-inflammatory cytokines (including IL-1beta and TNF-alpha) and other inflammation-related markers such as IL-6 in a dose-dependent manner.	Chlorogenic Acid	0-16	interleukin 6	Mus musculus	142-146
24161429-17	2014	Moreover, dexamethasone (0.5mg/kg, i.p., used as a positive control) inhibited inflammatory cell infiltration and reduced the levels of TNF-alpha, IL-1beta and IL-6 in LPS-injected mice.	Dexamethasone	10-23	interleukin 6	Mus musculus	160-164
24115476-5	2014	Treatment with 7 mg/kg per day PLA stimulated appetite and weight gain, improved lean mass and muscle function, reduced energy expenditure, and normalized the levels of hepatic TNF-alpha and IL-6 mRNA in mice with CKD.	pla	31-34	interleukin 6	Mus musculus	191-195
24285838-3	2014	In these studies, we determined whether IL-6 regulates the Cox-2 PGE2 MMP-9 pathway in murine macrophages.	Dinoprostone	65-69	interleukin 6	Mus musculus	40-44
23697399-4	2014	The results showed that there was a lower production of TNFalpha, IL-6, and IL-1beta in the serum of LPS-challenged mice that had been pre-treated with pinocembrin.	pinocembrin	152-163	interleukin 6	Mus musculus	66-70
24285838-4	2014	IL-6 coinduced Cox-2 and microsomal PGE synthase-1, and inhibited the expression of 15-hydroxyprostaglandin dehydrogenase, leading to increased levels of PGE2.	Dinoprostone	154-158	interleukin 6	Mus musculus	0-4
24285838-5	2014	In addition, IL-6 induced MMP-9 expression, suggesting that the observed proteinase expression was regulated by the synthesis of PGE2.	Dinoprostone	129-133	interleukin 6	Mus musculus	13-17
24285838-6	2014	However, inhibition of PGE2 synthesis partially suppressed IL-6-mediated induction of MMP-9.	Dinoprostone	23-27	interleukin 6	Mus musculus	59-63
24138316-6	2014	alpha-Iso-cubebenol also suppressed the production of tumour necrosis factor-alpha, IL-1beta, IL-6, monocyte chemoattractant protein-1 and reactive oxygen species in a dose-dependent manner, while decreasing the nuclear translocation and transactivity of NF-kappaB by inhibiting the phosphorylation and degradation of the inhibitor of kappaB (IkappaB)alpha.	alpha-iso-cubebenol	0-19	interleukin 6	Mus musculus	94-98
25136646-5	2014	We found that pristane treatment for a period of 12 or 24 weeks triggered macrophage activation syndrome, characterized by hemophagocytosis in spleen and peripheral blood, enhanced lipid phagocytosis by peritoneal macrophages in vitro, erythropenia and leucopenia, increased anti-Smith, lactic dehydrogenase, triglyceride, and ferritin, as well as hypercytokinemia of IFN-gamma, TNF-alpha, IL-4, and IL-6.	pristane	14-22	interleukin 6	Mus musculus	400-404
24623963-8	2014	These results demonstrate that chronic ethanol feeding can improve the responsiveness of macrophage LPS-stimulated IL-6 and TNF-alpha production and indicate that this effect may result from ethanol-induced alterations in intracellular signalling through NF-kappaB.	Ethanol	39-46	interleukin 6	Mus musculus	115-119
24623963-8	2014	These results demonstrate that chronic ethanol feeding can improve the responsiveness of macrophage LPS-stimulated IL-6 and TNF-alpha production and indicate that this effect may result from ethanol-induced alterations in intracellular signalling through NF-kappaB.	Ethanol	191-198	interleukin 6	Mus musculus	115-119
24803746-4	2014	The results showed that BHBA significantly reduced LPS-induced protein and mRNA expression levels of iNOS, COX-2, TNF-alpha, IL-1beta, and IL-6.	3-Hydroxybutyric Acid	24-28	interleukin 6	Mus musculus	139-143
22911886-9	2014	In contrast, suppression of Y705 phosphorylation by a JAK inhibitor in the FBS/IL-6 treated cells did not affect STAT3 nuclear accumulation or cell proliferation.	y705	28-32	interleukin 6	Mus musculus	79-83
24817795-5	2014	We show that the natural polyphenol compound resveratrol (RSV) efficiently suppresses the expression of TNFalpha and IL-6 in an ATGL/PPARalpha dependent manner.	Polyphenols	25-35	interleukin 6	Mus musculus	117-121
24817795-5	2014	We show that the natural polyphenol compound resveratrol (RSV) efficiently suppresses the expression of TNFalpha and IL-6 in an ATGL/PPARalpha dependent manner.	Resveratrol	45-56	interleukin 6	Mus musculus	117-121
24817795-5	2014	We show that the natural polyphenol compound resveratrol (RSV) efficiently suppresses the expression of TNFalpha and IL-6 in an ATGL/PPARalpha dependent manner.	Resveratrol	58-61	interleukin 6	Mus musculus	117-121
25638383-2	2014	The aim of our work was to examine the impact of clozapine on the production of interleukin 6 (IL-6) by the LPS (lipopolysaccharide) stimulated macrophage cells and to confirm or exclude that it regulates the inflammation due to its interaction with alpha 7 nicotinic receptor (nAChR).	Clozapine	49-58	interleukin 6	Mus musculus	80-93
25638383-2	2014	The aim of our work was to examine the impact of clozapine on the production of interleukin 6 (IL-6) by the LPS (lipopolysaccharide) stimulated macrophage cells and to confirm or exclude that it regulates the inflammation due to its interaction with alpha 7 nicotinic receptor (nAChR).	Clozapine	49-58	interleukin 6	Mus musculus	95-99
25638383-6	2014	RESULTS: The IL-6 level produced by cells treated clozapine decreased significantly from IL-6 level created by clozapine-untreated cells.	Clozapine	50-59	interleukin 6	Mus musculus	13-17
25638383-6	2014	RESULTS: The IL-6 level produced by cells treated clozapine decreased significantly from IL-6 level created by clozapine-untreated cells.	Clozapine	50-59	interleukin 6	Mus musculus	89-93
25638383-6	2014	RESULTS: The IL-6 level produced by cells treated clozapine decreased significantly from IL-6 level created by clozapine-untreated cells.	Clozapine	111-120	interleukin 6	Mus musculus	13-17
25638383-6	2014	RESULTS: The IL-6 level produced by cells treated clozapine decreased significantly from IL-6 level created by clozapine-untreated cells.	Clozapine	111-120	interleukin 6	Mus musculus	89-93
23983093-3	2014	According to the results, both MEFA and MELA decreased the intensity of leukocyte infiltration in mouse dorsal skin and cutaneous edema induced by TPA, which appeared to be mediated by inhibition of proinflammatory genes (inducible nitric oxide synthase, cyclooxygenase-2 (COX-2), tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-6) and proinflammatory mediators (TNF-alpha, IL-1beta, and Prostaglandin E2 ).	Tetradecanoylphorbol Acetate	147-150	interleukin 6	Mus musculus	336-340
25638383-7	2014	However, the production of IL-6 in the cells treated with clozapine and simultaneously with selective alpha 7 nAChR antagonist methyllycaconitine did not alter significantly from the IL-6 production in the cells treated just with clozapine.	Clozapine	58-67	interleukin 6	Mus musculus	27-31
25638383-7	2014	However, the production of IL-6 in the cells treated with clozapine and simultaneously with selective alpha 7 nAChR antagonist methyllycaconitine did not alter significantly from the IL-6 production in the cells treated just with clozapine.	methyllycaconitine	127-145	interleukin 6	Mus musculus	27-31
25638383-9	2014	CONCLUSION: Our study confirmed, that clozapine reduces production of IL-6 in LPS-activated macrophage cells nevertheless we denied that it would be mediated through alpha 7 nAChR.	Clozapine	38-47	interleukin 6	Mus musculus	70-74
24364787-6	2014	Thus, findings of the present study suggest that the chemopreventive effect of silibinin is associated with upregulation of endogenous cytoprotective machinery and down regulation of inflammatory mediators (nitric oxide, tumor necrosis factor-alpha, interleukin-6, interleukin -1beta, COX-2, iNOS, and NF-kappaB).	Silybin	79-88	interleukin 6	Mus musculus	250-263
24945996-7	2014	Pu-erh tea reduced the levels of the serum proinflammatory cytokines interleukin (IL)-6, IL-12, tumor necrosis factor-alpha, and interferon-gamma to a greater extent compared with the control mice, and the levels of 200 mug/mL treatment was more close to the normal mice than 100 mug/mL treated mice.	pu-erh	0-6	interleukin 6	Mus musculus	69-87
24201050-9	2014	Pretreatment with fluoxetine (20mg/kg) or PAH (60 and 120 mg/kg) could effectively reverse the alterations in the concentrations of 5-HT and NE, and attenuate LPS-induced increases in TNF-alpha and IL-6 levels.	Fluoxetine	18-28	interleukin 6	Mus musculus	198-202
25147596-5	2014	ISO also reduced the production of tumor necrosis factor-alpha, interleukin-1beta, IL-6, high-mobility group box-1, macrophage inflammatory protein-1alpha, macrophage inflammatory protein-2, and monocyte chemoattractant protein-1 as assessed by enzyme-linked immunosorbent assays.	Isoflurane	0-3	interleukin 6	Mus musculus	83-87
24724468-3	2014	The objective of this study was to determine the effect of commercial nanocolloids of noble metals (silver, gold and copper), recommended by the manufacturer as dietary supplements, on the in vitro viability, proliferative activity and production of cytokines (IL-1beta, IL-2, IL-6, IL-10 and TNF-alpha) by mouse splenocytes.	Copper	117-123	interleukin 6	Mus musculus	277-281
24724468-7	2014	The colloid of gold decreased the level of IL-2, and the colloid of copper caused an increase in IL-2, IL6 and IL-10.	Copper	68-74	interleukin 6	Mus musculus	103-106
24201050-9	2014	Pretreatment with fluoxetine (20mg/kg) or PAH (60 and 120 mg/kg) could effectively reverse the alterations in the concentrations of 5-HT and NE, and attenuate LPS-induced increases in TNF-alpha and IL-6 levels.	perillaldehyde	42-45	interleukin 6	Mus musculus	198-202
25125726-11	2014	Current evidence indicates that production of cytokines including tumor necrosis factor alpha, interleukin 17, and interleukin 6 contribute to hypertension, likely by promoting vasoconstriction, production of reactive oxygen species, and sodium reabsorption in the kidney.	Reactive Oxygen Species	209-232	interleukin 6	Mus musculus	115-128
25125726-11	2014	Current evidence indicates that production of cytokines including tumor necrosis factor alpha, interleukin 17, and interleukin 6 contribute to hypertension, likely by promoting vasoconstriction, production of reactive oxygen species, and sodium reabsorption in the kidney.	Sodium	238-244	interleukin 6	Mus musculus	115-128
24140585-6	2013	RESULTS: In acute model of UC, ellagic acid ameliorated disease severity slightly as observed both macroscopically and through the profile of inflammatory mediators (IL-6, TNF-alpha, and IFN-gamma).	Ellagic Acid	31-43	interleukin 6	Mus musculus	166-170
24336077-5	2013	BAPTA-AM reduced both ER stress responses and caspase activation and strongly suppressed HBHA-induced IL-6 and MCP-1 production in RAW 264.7 cells.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	0-8	interleukin 6	Mus musculus	102-106
24336077-5	2013	BAPTA-AM reduced both ER stress responses and caspase activation and strongly suppressed HBHA-induced IL-6 and MCP-1 production in RAW 264.7 cells.	HBHA	89-93	interleukin 6	Mus musculus	102-106
24349299-5	2013	Further, active TNF-alpha, IL-6, monocyte chemoattractant protein-1 and matrix metalloproteinase-9 expression induced by ox-LDL were attenuated by vinpocetine in a dose-dependent manner.	vinpocetine	147-158	interleukin 6	Mus musculus	27-31
24285707-12	2013	Inhibition of systemic IL-6 signaling by an IL-6 receptor antibody to Apc(Min/+) mice that had already initiated weight loss was sufficient to attenuate a reduction in testes size and circulating testosterone.	Testosterone	196-208	interleukin 6	Mus musculus	23-27
24285707-12	2013	Inhibition of systemic IL-6 signaling by an IL-6 receptor antibody to Apc(Min/+) mice that had already initiated weight loss was sufficient to attenuate a reduction in testes size and circulating testosterone.	Testosterone	196-208	interleukin 6	Mus musculus	44-48
24324736-7	2013	Finally, reduced plasma levels of inflammatory mediators as IL-1alpha, IL-6, IL-17, TNF-alpha and IFN-gamma were detected in TTA-treated mice.	1-(carboxymethylthio)tetradecane	125-128	interleukin 6	Mus musculus	71-75
24324578-6	2013	Treatment with KB3495 was also associated with a reduction of macrophage content in the atherosclerotic plaques and reduced serum levels of IL-1beta, TNFalpha, IL-6, Interferon gamma, MCP-1 and M-CSF.	kb3495	15-21	interleukin 6	Mus musculus	160-164
23808384-7	2013	Furthermore, LPA2 deficiency attenuated the bleomycin-induced expression of fibronectin (FN), alpha-smooth muscle actin (alpha-SMA), and collagen in lung tissue, as well as levels of IL-6, transforming growth factor-beta (TGF-beta), and total protein in bronchoalveolar lavage fluid.	Bleomycin	44-53	interleukin 6	Mus musculus	183-187
24144034-10	2013	CONCLUSIONS: The abnormal expression of COX-2, TNF-alpha and IL-6 may result in RSA.	rabbit sperm membrane autoantigen	80-83	interleukin 6	Mus musculus	61-65
23837438-6	2013	Combined flIL-33 expression and bleomycin injury exerted a synergistic effect on pulmonary lymphocyte and collagen accumulation, which could be explained by synergistic regulation of the cytokines transforming growth factor-beta, IL-6, monocyte chemotactic protein-1, macrophage inflammatory protein\x{2013}1alpha, and tumor necrosis factor-alpha.	flil	9-13	interleukin 6	Mus musculus	230-234
23837438-6	2013	Combined flIL-33 expression and bleomycin injury exerted a synergistic effect on pulmonary lymphocyte and collagen accumulation, which could be explained by synergistic regulation of the cytokines transforming growth factor-beta, IL-6, monocyte chemotactic protein-1, macrophage inflammatory protein\x{2013}1alpha, and tumor necrosis factor-alpha.	Bleomycin	32-41	interleukin 6	Mus musculus	230-234
24092518-5	2013	In addition, 50 muM sodium metasilicate decreased interleukin-6 production, and the degree of suppression was comparable to that of 10 muM TBHQ treatment.	Sodium	20-26	interleukin 6	Mus musculus	50-63
24382222-7	2013	RESULTS: Oleate/palmitate mixture activated the NF-kappaB pathway and induced interleukin-6, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 mRNA expressions in adipocytes from mice deficient in Toll-like receptor 4, and these effects were blocked by siRNA targeting NOD1.	Oleic Acid	9-15	interleukin 6	Mus musculus	78-120
24309563-7	2013	In DMI-treated mice, tumor VEGF, IL-6, and the prometastatic chemokines RANTES, M-CSF, and MIP-2 were reduced.	Desipramine	3-6	interleukin 6	Mus musculus	33-37
24382222-7	2013	RESULTS: Oleate/palmitate mixture activated the NF-kappaB pathway and induced interleukin-6, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 mRNA expressions in adipocytes from mice deficient in Toll-like receptor 4, and these effects were blocked by siRNA targeting NOD1.	Palmitates	16-25	interleukin 6	Mus musculus	78-120
23994089-4	2013	Tyrosol significantly attenuated TNF-alpha, IL-1beta and IL-6 production in serum from mice challenged with LPS, and consistent with the results in vitro.	4-hydroxyphenylethanol	0-7	interleukin 6	Mus musculus	57-61
24028683-7	2013	The TFA diet significantly elevated interleukin (IL)-6, IL-12p40, IL-23p19 and retinoic acid-related orphan receptor (ROR)gammat mRNA levels in the colons of DSS-treated animals.	Trans Fatty Acids	4-7	interleukin 6	Mus musculus	36-54
24005906-5	2013	FFA4 knockdown abrogated DHA effects on COX-2 induction, PGE2 production, and interleukin 6 (IL-6) gene expression.	Docosahexaenoic Acids	25-28	interleukin 6	Mus musculus	78-91
24051194-3	2013	DADS decreased nitric oxide production with a reduction in the levels of interleukins (IL)-1beta and IL-6 in RAW264.7 cells stimulated with LPS.	diallyl disulfide	0-4	interleukin 6	Mus musculus	101-105
24055769-4	2013	We found that AI and 6-OAAI inhibit the production of NO, iNOS, and pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, and MCP-1) in LPS-stimulated RAW264.7 macrophages.	austroinulin	14-16	interleukin 6	Mus musculus	107-111
24055769-4	2013	We found that AI and 6-OAAI inhibit the production of NO, iNOS, and pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, and MCP-1) in LPS-stimulated RAW264.7 macrophages.	6-O-acetyl-austroinulin	21-27	interleukin 6	Mus musculus	107-111
24161485-5	2013	TMF inhibits the productions and mRNA expressions of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, and IL-6 induced by LPS.	5,6,7-trimethoxyflavone	0-3	interleukin 6	Mus musculus	122-126
24161485-8	2013	Taken together, these findings suggest that TMF down-regulates the expressions of the pro-inflammatory iNOS, COX-2, TNF-alpha, IL-1beta, and IL-6 genes in macrophages by interfering with the activation of NF-kappaB, AP-1, and STAT1/3.	5,6,7-trimethoxyflavone	44-47	interleukin 6	Mus musculus	141-145
23954471-4	2013	In RAW264.7 cells, ketanserin significantly inhibited the expression of iNOS and decreased the production of NO, TNFalpha, IL-6, and reactive oxygen species upon lipopolysaccharide (LPS) challenge.	Ketanserin	19-29	interleukin 6	Mus musculus	123-127
23735482-6	2013	Quercetin inhibited LPS-induced NO, PGE2, iNOS, COX-2, TNF-alpha, IL-1beta, IL-6 and GM-CSF mRNA and protein expressions while it promoted HO-1 induction in a dose- and time-dependent manner.	Quercetin	0-9	interleukin 6	Mus musculus	76-80
24082061-8	2013	Indeed, diltiazem prevented the interleukin-6-induced mRNA expression of interleukin-1beta and the monocyte chemoattractant protein CCL12 in peritoneal macrophages and RAW264.7 cells independent of the intracellular calcium concentration.	Diltiazem	8-17	interleukin 6	Mus musculus	32-45
24082061-8	2013	Indeed, diltiazem prevented the interleukin-6-induced mRNA expression of interleukin-1beta and the monocyte chemoattractant protein CCL12 in peritoneal macrophages and RAW264.7 cells independent of the intracellular calcium concentration.	Calcium	216-223	interleukin 6	Mus musculus	32-45
24201082-2	2013	Nicotine injection in full-thickness excisional skin wounds minimally affected inflammatory mediators like TNF, IL-6 and IL-12 while it induced a down-regulation in the expression of growth factors like VEGF, PDGF, TGF-beta1 and TGF-beta2, and the anti-inflammatory cytokine IL-10.	Nicotine	0-8	interleukin 6	Mus musculus	112-116
23922379-8	2013	In contrast to its stimulatory effect on IL-10-induced STAT3 activation, adenosine inhibited IL-6-induced STAT3 phosphorylation and SAA3 expression.	Adenosine	73-82	interleukin 6	Mus musculus	93-97
23959762-2	2013	When added to Raw 264.7 cells in combination with lipopolysaccharide, lovastatin significantly potentiated the release of interleukin-1beta, interleukin-6 and interleukin-12 with respect to lipopolysaccharide alone and showed an additive effect on the release of nitric oxide.	Lovastatin	70-80	interleukin 6	Mus musculus	141-154
23959762-3	2013	Similarly, when lovastatin was intraperitoneally administrated to BALB/c mice, it did not induce any pro-inflammatory effect when used alone, but it significantly potentiated the pro-inflammatory activity of lipopolysaccharide, in terms of number of intraperitoneal cells and serum levels of serum amyloid A, interleukin-1beta, interleukin-6 and interleukin-12.	Lovastatin	16-26	interleukin 6	Mus musculus	328-341
23892791-9	2013	In conclusion, the results show a unique cannabinoid modulation of the autoimmune cytokine milieu combining suppression of the pathogenic IL-17 and IL-6 cytokines along with boosting the expression of the anti-inflammatory cytokine IL-10.	Cannabinoids	41-52	interleukin 6	Mus musculus	148-152
23763486-0	2013	Acrolein stimulates the synthesis of IL-6 and C-reactive protein (CRP) in thrombosis model mice and cultured cells.	Acrolein	0-8	interleukin 6	Mus musculus	37-41
23763486-3	2013	In mice with photochemically induced thrombosis, acrolein produced at the locus of infarction increased the level of IL-6 and then CRP in plasma.	Acrolein	49-57	interleukin 6	Mus musculus	117-121
23763486-4	2013	This was confirmed in cell culture systems - acrolein stimulated the production of IL-6 in mouse neuroblastoma Neuro-2a cells, mouse macrophage-like J774.1 cells, and human umbilical vein endothelial cells (HUVEC), and IL-6 in turn stimulated the production of CRP in human hepatocarcinoma cells.	Acrolein	45-53	interleukin 6	Mus musculus	83-87
23763486-7	2013	IL-6 functioned as a protective factor against acrolein toxicity in Neuro-2a cells and HUVEC.	Acrolein	47-55	interleukin 6	Mus musculus	0-4
23763486-8	2013	These results show that acrolein stimulates the synthesis of IL-6 and CRP, which function as protecting factors against acrolein toxicity, and that the combined measurement of PC-Acro, IL-6, and CRP is effective for identification of silent brain infarction.	Acrolein	24-32	interleukin 6	Mus musculus	61-73
23763486-8	2013	These results show that acrolein stimulates the synthesis of IL-6 and CRP, which function as protecting factors against acrolein toxicity, and that the combined measurement of PC-Acro, IL-6, and CRP is effective for identification of silent brain infarction.	Acrolein	24-32	interleukin 6	Mus musculus	61-65
23763486-8	2013	These results show that acrolein stimulates the synthesis of IL-6 and CRP, which function as protecting factors against acrolein toxicity, and that the combined measurement of PC-Acro, IL-6, and CRP is effective for identification of silent brain infarction.	Acrolein	120-128	interleukin 6	Mus musculus	61-65
23763486-10	2013	The aim of this study was to determine whether acrolein causes increased production of IL-6 and CRP, and indeed acrolein increased IL-6 synthesis and IL-6 in turn increased CRP synthesis.	Acrolein	47-55	interleukin 6	Mus musculus	87-91
23763486-10	2013	The aim of this study was to determine whether acrolein causes increased production of IL-6 and CRP, and indeed acrolein increased IL-6 synthesis and IL-6 in turn increased CRP synthesis.	Acrolein	112-120	interleukin 6	Mus musculus	131-135
23763486-10	2013	The aim of this study was to determine whether acrolein causes increased production of IL-6 and CRP, and indeed acrolein increased IL-6 synthesis and IL-6 in turn increased CRP synthesis.	Acrolein	112-120	interleukin 6	Mus musculus	131-135
23763486-11	2013	Furthermore, IL-6 decreased acrolein toxicity in several cell lines.	Acrolein	28-36	interleukin 6	Mus musculus	13-17
23441850-3	2013	In the current study, we investigated the effect of the flavonoid isorhamnetin on the production of IL-6 in murine macrophages stimulated with lipopolysaccharide (LPS) from Prevotella intermedia, a pathogen implicated in inflammatory periodontal disease, and its mechanisms of action.	Flavonoids	56-65	interleukin 6	Mus musculus	100-104
23441850-3	2013	In the current study, we investigated the effect of the flavonoid isorhamnetin on the production of IL-6 in murine macrophages stimulated with lipopolysaccharide (LPS) from Prevotella intermedia, a pathogen implicated in inflammatory periodontal disease, and its mechanisms of action.	3-methylquercetin	66-78	interleukin 6	Mus musculus	100-104
23441850-11	2013	In addition, inhibition of HO-1 activity by tin protoporphyrin IX blocked the inhibitory effect of isorhamnetin on IL-6 production.	tin protoporphyrin IX	44-65	interleukin 6	Mus musculus	115-119
23441850-11	2013	In addition, inhibition of HO-1 activity by tin protoporphyrin IX blocked the inhibitory effect of isorhamnetin on IL-6 production.	3-methylquercetin	99-111	interleukin 6	Mus musculus	115-119
23441850-15	2013	CONCLUSION: Although further research is required to clarify the detailed mechanism of action, we propose that isorhamnetin may contribute to blockade of the host-destructive processes mediated by IL-6 and could be a highly efficient modulator of the host response in the treatment of inflammatory periodontal disease.	3-methylquercetin	111-123	interleukin 6	Mus musculus	197-201
23911424-5	2013	Besides, sildenafil treatment decreases the serum concentration of interleukin-6.	Sildenafil Citrate	9-19	interleukin 6	Mus musculus	67-80
24158695-10	2013	Consistent with these phenotypic data, we observed the diminishing effects of ATRA treatment on the production of proinflammatory mediators (e.g., TNF-alpha and IL-6) in hippocampal homogenates and LPS-stimulated BV2 cells, and these effects were dose-dependent.	Tretinoin	78-82	interleukin 6	Mus musculus	161-165
24267047-7	2013	Aortic TC content was positively associated with hepatic TC, triglyceride, and GAT triglyceride contents as well as plasma interleukin 6 and monocyte chemoattractant protein-1 concentrations.	Technetium	7-9	interleukin 6	Mus musculus	123-175
23595969-8	2013	Cebpb knockdown attenuates the induction of il6 expression in kdm1a knocked down cells, whereas simultaneous cebpb knockdown and NF-kappabeta inhibition abrogates it.	cebpb	0-5	interleukin 6	Mus musculus	44-47
24120159-2	2013	Oral administration of AS-1 (100 mg/kg/day) to aged BALB/c mice enhanced productions of IL-10, IFN-gamma and IL-6 from Peyer"s patch immunocompetent cells, and its oral administration to ovalbumin (OVA)-fed B10.A mice led to significant suppression on induction of OVA-specific IgE in systemic immune system.	as-1	23-27	interleukin 6	Mus musculus	109-113
23881260-6	2013	Treatment with rmGas6 significantly reduced serum levels of the injury markers aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase, as well as proinflammatory cytokines interleukin 6 (IL-6) and IL-17, compared with the vehicle group (P &lt; 0.05).	rmgas6	15-21	interleukin 6	Mus musculus	197-210
23881260-6	2013	Treatment with rmGas6 significantly reduced serum levels of the injury markers aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase, as well as proinflammatory cytokines interleukin 6 (IL-6) and IL-17, compared with the vehicle group (P &lt; 0.05).	rmgas6	15-21	interleukin 6	Mus musculus	212-216
24211588-0	2013	Serotonin acts as a novel regulator of interleukin-6 secretion in osteocytes through the activation of the 5-HT(2B) receptor and the ERK1/2 signalling pathway.	Serotonin	0-9	interleukin 6	Mus musculus	39-52
24211200-9	2013	Mechanically, Sirt2 deacetylated p65 subunit of nuclear factor-kappa B (NF-kappaB) at lysine 310, resulting in reduced expression of NF-kappaB-dependent genes, including interleukin 1beta (IL-1beta), IL-6, monocyte chemoattractant protein 1(MCP-1), RANTES, matrix metalloproteinase 9 (MMP-9) and MMP-13.	Lysine	86-92	interleukin 6	Mus musculus	200-204
24211588-4	2013	The aim of this study was to evaluate the effect of serotonin on osteocyte expression of IL-6.	Serotonin	52-61	interleukin 6	Mus musculus	89-93
24211588-5	2013	The requirement for the 5-HT receptor(s) and the role of the extracellular signal-regulated kinase 1/2 (ERK1/2) in serotonin-induced IL-6 synthesis were examined.	Serotonin	115-124	interleukin 6	Mus musculus	133-137
24211588-6	2013	In this study, real-time PCR and ELISA were used to analyse IL-6 gene and protein expression in serotonin-stimulated MLO-Y4 cells.	Serotonin	96-105	interleukin 6	Mus musculus	60-64
24211588-8	2013	We found that serotonin significantly activated the ERK1/2 pathway and induced IL-6 mRNA expression and protein synthesis in cultured MLO-Y4 cells.	Serotonin	14-23	interleukin 6	Mus musculus	79-83
24211588-10	2013	Our results indicate that serotonin stimulates osteocyte secretion of IL-6 and that this effect is associated with activation of 5-HT2B receptor and the ERK1/2 pathway.	Serotonin	26-35	interleukin 6	Mus musculus	70-74
24144283-6	2013	We demonstrated that MS436 effectively inhibits BRD4 activity in NF-kappaB-directed production of nitric oxide and proinflammatory cytokine interleukin-6 in murine macrophages.	MS436	21-26	interleukin 6	Mus musculus	140-153
24292417-0	2013	(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.	ixazomib	205-213	interleukin 6	Mus musculus	31-44
24060409-10	2013	A further study revealed that EE, DA and MG (10, 20, 40mug/mL) exhibited stronger inhibitory effects on the production of pro-inflammatory cytokines (including interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha) in MSU crystals-treated RAW 264.7 cells.	doliroside A	34-36	interleukin 6	Mus musculus	179-224
24060409-10	2013	A further study revealed that EE, DA and MG (10, 20, 40mug/mL) exhibited stronger inhibitory effects on the production of pro-inflammatory cytokines (including interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha) in MSU crystals-treated RAW 264.7 cells.	Magnesium	41-43	interleukin 6	Mus musculus	179-224
24167252-7	2013	DeltadblGATA basophils responded poorly ex vivo to stimulation with IgE plus antigens compared with wild-type basophils as assessed by degranulation and production of IL-4 and IL-6.	deltadblgata	0-12	interleukin 6	Mus musculus	176-180
24225056-9	2013	Carvedilol increased the cardiac CREB expression and phosphorylation and decreased the plasma catecholamine levels and the production of IL-6 and TNF-alpha with amelioration of acute viral myocarditis.	Carvedilol	0-10	interleukin 6	Mus musculus	137-141
24223168-0	2013	Dietary iron enhances colonic inflammation and IL-6/IL-11-Stat3 signaling promoting colonic tumor development in mice.	Iron	8-12	interleukin 6	Mus musculus	47-51
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	Berberine	0-3	interleukin 6	Mus musculus	82-86
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	5-12	interleukin 6	Mus musculus	82-86
24223168-5	2013	Colonic inflammation was more severe in mice fed an iron-supplemented compared with a control diet one week post-DSS treatment, with enhanced colonic IL-6 and IL-11 release and Stat3 phosphorylation.	Iron	52-56	interleukin 6	Mus musculus	150-154
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	pyrazolanthrone	16-25	interleukin 6	Mus musculus	82-86
24223168-6	2013	Both IL-6 and ferritin, the iron storage protein, co-localized with macrophages suggesting iron may act directly on IL-6 producing-macrophages.	Iron	91-95	interleukin 6	Mus musculus	5-9
24223168-6	2013	Both IL-6 and ferritin, the iron storage protein, co-localized with macrophages suggesting iron may act directly on IL-6 producing-macrophages.	Iron	91-95	interleukin 6	Mus musculus	116-120
24223168-10	2013	Intratumoral IL-6 and IL-11 expression increased in DSS-treated mice and IL-6, and possibly IL-11, were enhanced by dietary iron.	dss	52-55	interleukin 6	Mus musculus	13-17
24223168-10	2013	Intratumoral IL-6 and IL-11 expression increased in DSS-treated mice and IL-6, and possibly IL-11, were enhanced by dietary iron.	Iron	124-128	interleukin 6	Mus musculus	73-77
24223168-12	2013	Dietary iron and colonic inflammation synergistically activated colonic IL-6/IL-11-Stat3 signaling promoting tumorigenesis.	Iron	8-12	interleukin 6	Mus musculus	72-76
24064280-10	2013	Our data also suggests that icaritin administration remarkably attenuated the increases in serum IL-6 and TNF-alpha level that occur following exposure to social defeat.	icaritin	28-36	interleukin 6	Mus musculus	97-101
23777386-8	2013	Secretion of IL-6 and TNF in the lungs of 10% CO2-exposed mice was decreased 7 hours, but not 15 hours, after the onset of pneumonia, indicating that hypercapnia inhibited the early cytokine response to infection.	N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide	46-49	interleukin 6	Mus musculus	13-17
23941302-9	2013	Oral administration of PGG inhibited colon shortening and myeloperoxidase activity in mice with TNBS-induced colitis, along with reducing NF-kappaB activation and IL-1beta, TNF-alpha, and IL-6 levels, whereas it increased IL-10.	pgg	23-26	interleukin 6	Mus musculus	188-192
23916894-6	2013	Cultured astrocytes from wildtype mice showed increased adenosine release in response to interleukin-6 and the hippocampus of wildtype mice had increased adenosine production 28 days after EAE induction, but the ALKO mutation abolished the increase in both conditions.	Adenosine	56-65	interleukin 6	Mus musculus	89-102
23738811-0	2013	Interleukin-6 neutralization alleviates pulmonary inflammation in mice exposed to cigarette smoke and poly(I:C).	poly	102-106	interleukin 6	Mus musculus	0-13
23738811-3	2013	Here we hypothesized that neutralizing circulating levels of IL-6 would modulate episodes of acute pulmonary inflammation following CS (cigarette smoke) exposure and virus-like challenges.	Cesium	132-134	interleukin 6	Mus musculus	61-65
23929940-5	2013	In the acute phase after tamoxifen treatment, cell infiltration into the myocardium was accompanied by increased expression of pro-inflammatory cytokines (IL-1beta, IL-6, TNFalpha, IFNgamma, Ccl2) and markers of hypertrophy (ANF, BNP, Col3a1).	Tamoxifen	25-34	interleukin 6	Mus musculus	165-169
23738811-7	2013	Our results thus indicate that the systemic neutralization of IL-6 significantly reduces CS/poly(I:C)-induced pulmonary inflammation, which may be a relevant approach to the treatment of episodes of acute pulmonary inflammation associated with COPD.	Cesium	89-91	interleukin 6	Mus musculus	62-66
23738811-7	2013	Our results thus indicate that the systemic neutralization of IL-6 significantly reduces CS/poly(I:C)-induced pulmonary inflammation, which may be a relevant approach to the treatment of episodes of acute pulmonary inflammation associated with COPD.	Poly I-C	92-101	interleukin 6	Mus musculus	62-66
24029595-4	2013	We found that 3-HAA treatment significantly reduced IL-12, IL-6, and TNF-alpha production in bone marrow-derived DCs (BMDCs) stimulated with LPS.	3-Hydroxyanthranilic Acid	14-19	interleukin 6	Mus musculus	59-63
23882124-3	2013	Treatment with 300 muM nicotinic acid (reported EC50 3 muM, peak plasma concentration 50-300 muM), significantly inhibited TNF-alpha, IL-6, IL-12p40, and IL-1beta production (P&lt;0.05) in LPS (1 ng/ml)-stimulated wild-type murine bone marrow-derived macrophages (BMMs) but failed to do so in Hca2(-/-) BMMs.	Niacin	23-37	interleukin 6	Mus musculus	134-138
24052031-3	2013	Furthermore, epinephrine increases IL-6 secretion from skeletal muscle, suggesting that IL-6 could play a role in mediating the lipolytic effects of catecholamines.	Epinephrine	13-24	interleukin 6	Mus musculus	35-39
24076200-4	2013	Meanwhile, the proinflammatory cytokines such as interleukin-6 (IL-6), interferon-gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) in renal tissue of STZ-lesioned mice were reduced by RMP treatment.	Streptozocin	163-166	interleukin 6	Mus musculus	49-62
24076200-4	2013	Meanwhile, the proinflammatory cytokines such as interleukin-6 (IL-6), interferon-gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) in renal tissue of STZ-lesioned mice were reduced by RMP treatment.	Streptozocin	163-166	interleukin 6	Mus musculus	64-68
23968808-6	2013	The proteinuria, blood urea nitrogen, and interleukin 6 levels were significantly reduced after MMF treatment.	Mycophenolic Acid	96-99	interleukin 6	Mus musculus	42-55
23884544-6	2013	We show that palmitate affects the mRNA levels of the pro-inflammatory cytokines interleukin-1beta and interleukin-6.	Palmitates	13-22	interleukin 6	Mus musculus	103-116
24033914-8	2013	Melatonin also inhibited expression of Cxcl1, Ccl20, and Il-6 that was induced by a combination of insulin and IL-17 in the mouse prostatic tissues.	Melatonin	0-9	interleukin 6	Mus musculus	57-61
24052031-3	2013	Furthermore, epinephrine increases IL-6 secretion from skeletal muscle, suggesting that IL-6 could play a role in mediating the lipolytic effects of catecholamines.	Epinephrine	13-24	interleukin 6	Mus musculus	88-92
24052031-3	2013	Furthermore, epinephrine increases IL-6 secretion from skeletal muscle, suggesting that IL-6 could play a role in mediating the lipolytic effects of catecholamines.	Catecholamines	149-163	interleukin 6	Mus musculus	35-39
24052031-3	2013	Furthermore, epinephrine increases IL-6 secretion from skeletal muscle, suggesting that IL-6 could play a role in mediating the lipolytic effects of catecholamines.	Catecholamines	149-163	interleukin 6	Mus musculus	88-92
24052031-4	2013	The purpose of this study was to determine whether IL-6 stimulates skeletal muscle lipolysis in a fiber type dependent manner and is required for epinephrine-stimulated lipolysis in murine skeletal muscle.	Epinephrine	146-157	interleukin 6	Mus musculus	51-55
24052031-6	2013	IL-6 treatment increased 5"-AMP-activated protein kinase and signal transducer and activator of transcription 3 phosphorylation and glycerol release in isolated EDL but not soleus muscles from C57BL/6J mice.	Glycerol	132-140	interleukin 6	Mus musculus	0-4
23816246-6	2013	RESULTS: The results showed that pretreatment with angelicin markedly downregulated TNF-alpha and IL-6 levels in vitro and in vivo, and significantly decreased the amount of inflammatory cells, lung wet-to-dry weight ratio, and myeloperoxidase activity in LPS-induced ALI mice.	angelicin	51-60	interleukin 6	Mus musculus	98-102
23731681-9	2013	Real-time polymerase chain reaction of both aortic wall and perivascular adipose tissue demonstrated the expression of tumor necrosis factor-alpha, interleukin-6, and matrix metalloproteinase-2 was significantly decreased in eplerenone group, and that of monocyte chemoattractant protein-1 in the aortic wall was also significantly decreased.	Eplerenone	225-235	interleukin 6	Mus musculus	148-161
23731681-11	2013	The production of tumor necrosis factor-alpha and interleukin-6 in macrophage culture, which was stimulated by high mobility group box-1 and CpG oligodeoxynucleotides, was also significantly decreased in the eplerenone group.	Eplerenone	208-218	interleukin 6	Mus musculus	50-63
23969038-7	2013	In primary human amniotic epithelial cells, pretreatment with a humanized anti-human IL-6 receptor antibody, tocilizumab, significantly inhibited the production of prostaglandin E2 induced by IL-6.	Dinoprostone	164-180	interleukin 6	Mus musculus	85-89
24002245-8	2013	Results showed that picrasmalignan A suppressed lipopolysaccharide-stimulated NO production and pro-inflammatory cytokine secretion, including TNF-alpha and IL-6, in a dose-dependent manner.	picrasmalignan A	20-36	interleukin 6	Mus musculus	157-161
24400155-8	2013	CLP induction of renal inflammatory gene (IL-6, TNF-alpha, IL-1beta) expression was attenuated by NAH pretreatment.	Niacin	98-101	interleukin 6	Mus musculus	42-46
23867234-0	2013	Cuprizone short-term exposure: astrocytic IL-6 activation and behavioral changes relevant to psychosis.	Cuprizone	0-9	interleukin 6	Mus musculus	42-46
23921153-2	2013	DCBN, but not MMZ, induced inflammation-like pathological changes in OE, and DCBN increased interleukin IL-6 levels in nasal-wash fluid to much greater magnitude and duration than did MMZ.	dichlobanil	77-81	interleukin 6	Mus musculus	104-108
23921153-7	2013	A role for IL-6 in suppressing ORN regeneration in DCBN-treated mice was rejected by the failure of the anti-inflammatory drug dexamethasone to prevent the subsequent respiratory metaplasia in the DMM, suggesting that other factors lead to HBC neuro-incompetence.	dichlobanil	51-55	interleukin 6	Mus musculus	11-15
24048894-10	2013	T+P also blocked the induction of IL-6 to prevent the Th17 response, attenuated the expression of the costimulatory molecule CD86 on myeloid dendritic cells (DCs), and reduced the number of DCs carrying OVA in the lung and mediastinal lymph nodes.	neotetrazolium	0-3	interleukin 6	Mus musculus	34-38
23954279-15	2013	Meanwhile, the mRNA expressions of iNOS, IL-6, IL-1beta, MCP-1 in mice liver and kidney were significantly reduced by DHI.	dehydrosoyasaponin I	118-121	interleukin 6	Mus musculus	41-45
23891859-4	2013	Dimethoate increased mRNA levels of tumor necrosis factor alpha (TNFalpha) and interleukin (IL) 6 in the hippocampus, and increased the proportion of Iba1 immunoreactive cells with reactive phenotype in dentate gyrus and striatum.	Dimethoate	0-10	interleukin 6	Mus musculus	79-97
23891859-6	2013	Some of the effects of lipopolysaccharide (proportion of Iba1 immunoreactive cells with reactive phenotype and IL6 mRNA levels) were amplified in the animals treated with dimethoate, but only in the striatum.	Dimethoate	171-181	interleukin 6	Mus musculus	111-114
23954279-18	2013	The results of ELISA demonstrated that DHI significantly down-regulated the protein productions of IL-6 and MCP-1.	dehydrosoyasaponin I	39-42	interleukin 6	Mus musculus	99-103
23954279-19	2013	Furthermore, the mRNA expressions of iNOS, COX-2, TNF-alpha, IL-1beta, IL-6 and MCP-1 analyzed by real-time RT-PCR were suppressed by DHI.	dehydrosoyasaponin I	134-137	interleukin 6	Mus musculus	71-75
23954279-20	2013	CONCLUSIONS: These results demonstrate that DHI exerts the protective effect through inhibiting the expressions of iNOS, COX-2, IL-1beta, IL-6, MCP-1 and TNF-alpha, which elucidate that DHI may be a strongly multi-target Chinese medicine injection on improving the inflammatory diseases.	dehydrosoyasaponin I	44-47	interleukin 6	Mus musculus	138-142
24063815-3	2013	However, a consensus about the role of IL-6 on glucose metabolism has not been reached.	Glucose	47-54	interleukin 6	Mus musculus	39-43
24063815-4	2013	The aim of the present study is to investigate whether the expression of IL-6 affects glucose metabolism in diet-induced obesity (DIO) mice, a model of type II diabetes and obesity, using gene delivery of IL-6.	Glucose	86-93	interleukin 6	Mus musculus	73-77
24063815-6	2013	DIO mice that received a sustained IL-6 gene transfer showed similar glucose levels to lean mice in a glucose tolerance test.	Glucose	69-76	interleukin 6	Mus musculus	35-39
24063815-6	2013	DIO mice that received a sustained IL-6 gene transfer showed similar glucose levels to lean mice in a glucose tolerance test.	Glucose	102-109	interleukin 6	Mus musculus	35-39
24063815-12	2013	These results indicate that the expression of IL-6 has an effect on obesity and the metabolism of glucose and lipid in diabetic mice and that the expression site of IL-6 is not an important factor.	Glucose	98-105	interleukin 6	Mus musculus	46-50
24116148-6	2013	Compound 1h also reduced secretion of IL-6 and tumor necrosis factor-alpha by LPS-activated J774A.1 murine macrophage cells, primary mice peritoneal macrophages, and JAWSII murine bone marrow-derived dendritic cells and reduced NLRP3 inflammasome-mediated interleukin-1beta (IL-1beta) secretion by LPS + adenosine triphosphate-activated J774A.1 and JAWSII cells.	Hydrogen	9-11	interleukin 6	Mus musculus	38-74
23852084-9	2013	RESULTS: In HepG2 and 3T3-L1 cells, both H2O2 and aldosterone markedly stimulates the expression of MCP-1, TNFalpha, IL-6, p47 and PU.1 genes.	Hydrogen Peroxide	41-45	interleukin 6	Mus musculus	117-121
24090456-8	2013	The treatment of ZYQL (100, 200 and 400 mg/kg) effectively increased the activity of serum lysozyme as well as promoted the serum levels of IL-6 and IFN-gamma in normal mice and immunosuppressed mice.	zyql	17-21	interleukin 6	Mus musculus	140-144
23852084-9	2013	RESULTS: In HepG2 and 3T3-L1 cells, both H2O2 and aldosterone markedly stimulates the expression of MCP-1, TNFalpha, IL-6, p47 and PU.1 genes.	Aldosterone	50-61	interleukin 6	Mus musculus	117-121
24011306-3	2013	SOCS and MAPKinases are involved in the signalling events controlling the expression of IL-6, TNF-alpha and PGE2, which have important roles on chronic inflammatory diseases.	Dinoprostone	108-112	interleukin 6	Mus musculus	88-92
24011306-6	2013	Curcumin potently inhibited LPS-induced expression of IL-6, TNF-alpha and COX-2 mRNA and prevented LPS-induced inhibition of SOCS-1 and -3 expression and the inhibition of the activation of p38 MAPKinase by modulation of its nuclear translocation.	Curcumin	0-8	interleukin 6	Mus musculus	54-58
23851196-0	2013	(-)-Epigallocatechin gallate amplifies interleukin-1-stimulated interleukin-6 synthesis in osteoblast-like MC3T3-E1 cells.	epigallocatechin gallate	0-28	interleukin 6	Mus musculus	64-77
23851196-4	2013	In the present study, we investigated the effect of EGCG on the IL-1 stimulated IL-6 synthesis in osteoblast-like MC3T3-E1 cells.	epigallocatechin gallate	52-56	interleukin 6	Mus musculus	80-84
23851196-5	2013	EGCG significantly enhanced the IL-1-stimulated IL-6 synthesis in a dose-dependent manner in the range between 50 and 100 muM.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	48-52
23851196-6	2013	EGCG increased the mRNA levels of IL-6 stimulated by IL-1.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	34-38
23851196-9	2013	These results strongly suggest that EGCG enhances IL-1-stimulated IL-6 synthesis through inhibiting the AMPK-IkappaB/NF-kappaB pathway at the point between AMPK and IkappaB/NF-kappaB in osteoblasts.	epigallocatechin gallate	36-40	interleukin 6	Mus musculus	66-70
23914844-5	2013	Also, TNF-alpha, IL-6, and PGE2 secretion was decreased by OXO in LPS-stimulated macrophages.	oxo	59-62	interleukin 6	Mus musculus	17-21
23876538-15	2013	As in vivo experiments, administering parthenolide reduced the number, surface area, and weight, the level of Vegf, Il-6, Mcp-1, and Lif gene expression, and the percentage of Ki67-positive cells in murine endometriosis-like lesions.	parthenolide	38-50	interleukin 6	Mus musculus	116-120
23515857-5	2013	We found that magnolol inhibited TNF-alpha and IL-6 production in LPS-stimulated mouse uterine epithelial cells.	magnolol	14-22	interleukin 6	Mus musculus	47-51
23605560-10	2013	Ber pretreatment also profoundly diminished CS-induced secretions of macrophage inflammatory protein 2, tumor necrosis factor alpha, interleukin-6, and monocyte chemotactic protein-1 in BALF, along with less nuclear translocation of the pro-inflammatory transcription factor nuclear factor-kappa B (NF-kappaB) p65 subunit and lower NF-kappaB DNA-binding activity (P &lt; 0.01).	Cesium	44-46	interleukin 6	Mus musculus	133-146
23816535-6	2013	Pre-treatment with DPC-333 significantly suppressed plasma alanine transaminase, aspartate transaminase and cytokines such as TNF-alpha, interferon (IFN)-gamma, interleukin (IL)-2 and IL-6 levels due to acute Con A challenge.	BMS561392	19-26	interleukin 6	Mus musculus	184-188
23905628-6	2013	Meanwhile, CD4(+) /CD25(+) regulatory T cells more significantly increase in NZB/W F1 mice receiving cystamine than in those mice receiving PBS, accompanied by significantly reduced IL-6/phosphorylated STAT-3 expression.	Cystamine	101-110	interleukin 6	Mus musculus	182-186
23810410-10	2013	Thalidomide decreased production of inflammatory and fibrogenic cytokine tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and transforming growth factor (TGF)-beta1.	Thalidomide	0-11	interleukin 6	Mus musculus	132-136
23746933-10	2013	DHA-supplemented animals showed a decreased IL-6 (P=.003) and an increased Wnt7a (P=.003) expression.	Docosahexaenoic Acids	0-3	interleukin 6	Mus musculus	44-48
23905628-7	2013	The above findings suggest the beneficial effects of cystamine in terms of increasing antioxidant activities and CD4(+) /CD25(+) regulatory T cells in lupus-prone mice by suppressing IL-6/STAT3 signalling.	Cystamine	53-62	interleukin 6	Mus musculus	183-187
23912334-3	2013	SP reduces inflammatory responses measured as the decreased number of infiltrating inflammatory macrophages and neutrophils and decreased expression of proinflammatory cytokines interleukin 1beta (IL-1beta), IL-6, and IL-17A.	sepiapterin	0-2	interleukin 6	Mus musculus	208-212
23777984-7	2013	Eritoran administration also led to lower IL-6 levels in plasma and liver and less NF-kappaB activation in liver.	eritoran	0-8	interleukin 6	Mus musculus	42-46
23871159-0	2013	Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells.	Dexamethasone	95-108	interleukin 6	Mus musculus	0-13
23721933-14	2013	Preinjury EtOH treatment was associated with reduced levels of proinflammatory cytokines IL-6, KC, MCP-1, and MIP-1alpha post TBI.	Ethanol	10-14	interleukin 6	Mus musculus	89-93
23871159-0	2013	Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells.	Dexamethasone	64-77	interleukin 6	Mus musculus	0-13
23871159-1	2013	We previously reported the establishment and characteristics of a DXM-resistant cell line (7TD1-DXM) generated from the IL6-dependent mouse B cell hybridoma, 7TD1 cell line.	Dexamethasone	66-69	interleukin 6	Mus musculus	120-123
23871159-1	2013	We previously reported the establishment and characteristics of a DXM-resistant cell line (7TD1-DXM) generated from the IL6-dependent mouse B cell hybridoma, 7TD1 cell line.	Dexamethasone	96-99	interleukin 6	Mus musculus	120-123
23871159-3	2013	Additionally, IL-6 reversed while IL-6 antibody and AG490 enhanced the effects of growth inhibition and apoptosis induced by DXM in 7TD1-WD cells.	Dexamethasone	125-128	interleukin 6	Mus musculus	34-38
25984321-10	2013	Injured TA muscles from alcohol-fed mice had increased TNFalpha and IL6 gene levels compared to controls 2 days after injury.	Alcohols	24-31	interleukin 6	Mus musculus	68-71
23912155-7	2013	However, the administration of NaHS significantly decreased the levels of TNF-alpha, IL-6 and IL-8 but increased the levels of IL-10 in the plasma of mice subjected to burn injuries.	sodium bisulfide	31-35	interleukin 6	Mus musculus	85-89
23912155-9	2013	These results suggested that H2S regulates the inflammatory response induced by burn injury by modulating the levels of TNF-alpha, IL-6, IL-8 and IL-10.	Hydrogen Sulfide	29-32	interleukin 6	Mus musculus	131-135
24312160-6	2013	BBG failed to increase FGF2, which is involved in CNTF-regulated neurogenesis, but induced IL-6, LIF, and EGF, which are known to reduce SVZ proliferation.	coomassie Brilliant Blue	0-3	interleukin 6	Mus musculus	91-95
24103259-9	2013	However, geniposide down-regulated the expression of TNF-alpha, IL-1, and IL-6, and also inhibited the expression of TLR4 and the activity of NF-kappaB.	geniposide	9-19	interleukin 6	Mus musculus	74-78
23769714-4	2013	The results showed that ethanol induced gastric damage, improving nitric oxide (NO) level, increased pro-inflammatory cytokine (TNF-alpha and IL-6) levels and myeloperoxidase (MPO) activity, as well as the expression of nuclear factor-kappaB (NF-kappaB) in the ethanol group.	Ethanol	24-31	interleukin 6	Mus musculus	142-146
24044575-12	2013	Ex vivo incubation of TAM with exosomes from EGCG-treated 4T1 cells led to IKKalpha suppression and concomitant I-kappaB accumulation; increase of IL-6 and TGF-beta; and, decrease of TNF-alpha.	epigallocatechin gallate	45-49	interleukin 6	Mus musculus	147-151
23970467-7	2013	Relative to vehicle, L-carnitine treatment of mouse dry eye for 14 days (days 21 to 35) resulted in a significant reduction in corneal staining, number of TUNEL-positive cells, and expression of TNF-alpha, IL-17, IL-6, or IL-1beta, as well as significantly increased the number of goblet cells.	Carnitine	21-32	interleukin 6	Mus musculus	213-217
24044575-10	2013	Expression of chemokine for monocytes (CSF-1 and CCL-2) were low in tumor cells from EGCG-treated mice, and cytokines of TAM was skewed from M2- into M1-like phenotype by EGCG as evidenced by decreased IL-6 and TGF-beta and increased TNF-alpha.	epigallocatechin gallate	85-89	interleukin 6	Mus musculus	202-206
24044575-12	2013	Ex vivo incubation of TAM with exosomes from EGCG-treated 4T1 cells led to IKKalpha suppression and concomitant I-kappaB accumulation; increase of IL-6 and TGF-beta; and, decrease of TNF-alpha.	tam	22-25	interleukin 6	Mus musculus	147-151
23900151-11	2013	In sharp contrast, DHMEQ treatment markedly improved the normoglycemic rate, which was associated with the suppression of serum high mobility group complex-1 (HMGB1) and proinflammatory cytokines, including tumor necrosis factor-alpha, monocyte chemoattractant protein-1, macrophage inflammatory protein-1beta, interleukin-1beta, and interleukin-6, after PITx.	dehydroxymethylepoxyquinomicin	19-24	interleukin 6	Mus musculus	334-347
23774631-7	2013	In addition, in vivo tropisetron, granisetron or tropisetron plus mCPBG therapy greatly reduced in vitro MOG35-55-stimulated proliferation of mononuclear cells from spleens, and MOG35-55-induced IL-2, IL-6 and IL-17 production by splenocytes isolated from EAE-induced mice (p&lt;0.05).	Tropisetron	21-32	interleukin 6	Mus musculus	201-205
23774631-7	2013	In addition, in vivo tropisetron, granisetron or tropisetron plus mCPBG therapy greatly reduced in vitro MOG35-55-stimulated proliferation of mononuclear cells from spleens, and MOG35-55-induced IL-2, IL-6 and IL-17 production by splenocytes isolated from EAE-induced mice (p&lt;0.05).	Tropisetron	49-60	interleukin 6	Mus musculus	201-205
24069363-5	2013	Indeed, our results demonstrate that 4HPR inhibited the excessive production of inflammatory mediators, including TNF, IL-6, CCL2 and CCL-5 in LPS-stimulated FXR1-KO macrophages, by selectively inhibiting phosphorylation of ERK1/2, which is naturally more phosphorylated in FXR1-KO cells.	Fenretinide	37-41	interleukin 6	Mus musculus	119-123
23707905-5	2013	In addition, ipragliflozin reduced plasma and liver levels of oxidative stress biomarkers (thiobarbituric acid reactive substances and protein carbonyl) and inflammatory markers (interleukin 6, tumor necrosis factor alpha, monocyte chemotactic protein-1, and c-reactive protein), and improved liver injury as assessed by plasma levels of aminotransferases.	ipragliflozin	13-26	interleukin 6	Mus musculus	179-221
23810685-0	2013	Anti-inflammatory effect of tetrahydrocoptisine from Corydalis impatiens is a function of possible inhibition of TNF-alpha, IL-6 and NO production in lipopolysaccharide-stimulated peritoneal macrophages through inhibiting NF-kappaB activation and MAPK pathway.	stylopine	28-47	interleukin 6	Mus musculus	124-128
24040033-8	2013	Subsequently, IFN-gamma-induced expression/secretion of intracellular cell adhesion molecule (ICAM)-1 mRNA, monocyte chemoattractant protein (MCP)-1, and interleukin (IL)-6 was reduced in spermidine-treated cells.	Spermidine	188-198	interleukin 6	Mus musculus	154-172
23810685-7	2013	Our data demonstrated that THC significantly inhibited LPS-induced TNF-alpha, interleukin-6(IL-6) and nitric oxide (NO) production.	stylopine	27-30	interleukin 6	Mus musculus	78-91
23810685-7	2013	Our data demonstrated that THC significantly inhibited LPS-induced TNF-alpha, interleukin-6(IL-6) and nitric oxide (NO) production.	stylopine	27-30	interleukin 6	Mus musculus	92-96
23810685-8	2013	THC inhibited the production of TNF-alpha and IL-6 by down-regulating LPS-induced IL-6 and TNF-alpha mRNA expression.	stylopine	0-3	interleukin 6	Mus musculus	46-50
23810685-8	2013	THC inhibited the production of TNF-alpha and IL-6 by down-regulating LPS-induced IL-6 and TNF-alpha mRNA expression.	stylopine	0-3	interleukin 6	Mus musculus	82-86
23810685-10	2013	Taken together, our data suggest that THC is an active anti-inflammatory constituent by inhibition of TNF-alpha, IL-6 and NO production possibly via down-regulation of NF-kappaB activation, phospho-ERK1/2 and phospho-p38MAPK signal pathways.	stylopine	38-41	interleukin 6	Mus musculus	113-117
24008733-3	2013	Here, we show that amyloid fibrils formed by a mutant form of TTR, A25T, activate microglia, leading to the secretion of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and nitric oxide.	Nitric Oxide	187-199	interleukin 6	Mus musculus	177-181
24008733-7	2013	injection of A25T fibrils caused microgliosis, increased brain TNF-alpha and IL-6 levels and cognitive deficits in mice, which could be prevented by minocycline treatment.	Minocycline	149-160	interleukin 6	Mus musculus	77-81
23313575-7	2013	DIO was observed to selectively increase IL-6 in CAA mice, with IL-1beta and TNF-alpha not increased in CAA mice in response to DIO.	3,3'-Dioctadecyloxacarbocyanine perchlorate	0-3	interleukin 6	Mus musculus	41-45
22086211-9	2013	The glutamine treatment also reduced concentrations of interleukin-6, while increasing concentrations of tumor necrosis factor-alpha and C-reactive protein, in the maternal serum of mice.	Glutamine	4-13	interleukin 6	Mus musculus	55-68
24001203-8	2013	When stimulated mesangial cells overexpressing let-7a were treated with the transcription inhibitor Actinomycin D (ActD), IL-6 was degraded faster, consistent with the direct targeting of the 3" UTR of IL-6 by let-7a.	Dactinomycin	100-113	interleukin 6	Mus musculus	122-126
24001203-8	2013	When stimulated mesangial cells overexpressing let-7a were treated with the transcription inhibitor Actinomycin D (ActD), IL-6 was degraded faster, consistent with the direct targeting of the 3" UTR of IL-6 by let-7a.	Dactinomycin	100-113	interleukin 6	Mus musculus	202-206
23322372-5	2013	Doxorubicin treatment decreased glutathione content, increased reactive oxygen species (ROS), malonyldialdehyde (MDA), interleukin (IL)-6, IL-10, monocyte chemoattractant protein-1 and tumor necrosis factor-alpha levels, declined glutathione peroxidase (GPX) and superoxide dismutase (SOD) activities, and enhanced xanthine oxidases (XO) activity in heart.	Doxorubicin	0-11	interleukin 6	Mus musculus	119-137
23699177-5	2013	PTX treatment (10 mg/kg) reduced cellular influx (by 40%), microvascular permeability (30%), and the release of chemotactic cytokines into the alveolar space (TNF-alpha 60%, IL-6 60%, and CXCL2/3 53%, respectively).	Pentoxifylline	0-3	interleukin 6	Mus musculus	174-178
23566359-9	2013	Pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha) were also reduced significantly in a dose dependent manner in all the TPA treated groups as compared to control.	Tetradecanoylphorbol Acetate	128-131	interleukin 6	Mus musculus	38-42
23732773-7	2013	RESULTS: Colon tissues and mesenteric lymph nodes of Card9-null mice had reduced levels of interleukin (IL)-6, interferon-gamma, and T-helper (Th)17 cytokines after administration of DSS, compared with wild-type mice.	Dextran Sulfate	183-186	interleukin 6	Mus musculus	91-109
23836031-3	2013	Overnight exposure to IL-1B+IL-6 in islets isolated from normal mice and humans disrupted glucose-stimulated intracellular calcium responses; cytokine-induced effects were more severe among islets from prediabetic db/db mice that otherwise showed no signs of dysfunction.	Glucose	90-97	interleukin 6	Mus musculus	28-32
23836031-3	2013	Overnight exposure to IL-1B+IL-6 in islets isolated from normal mice and humans disrupted glucose-stimulated intracellular calcium responses; cytokine-induced effects were more severe among islets from prediabetic db/db mice that otherwise showed no signs of dysfunction.	Calcium	123-130	interleukin 6	Mus musculus	28-32
23836031-4	2013	IL-1B+IL-6 exposure reduced endoplasmic reticulum (ER) calcium storage, activated ER stress responses (Nos2, Bip, Atf4, and Ddit3 [CHOP]), impaired glucose-stimulated insulin secretion, and increased cell death only in islets from prediabetic db/db mice.	Calcium	55-62	interleukin 6	Mus musculus	6-10
23836031-4	2013	IL-1B+IL-6 exposure reduced endoplasmic reticulum (ER) calcium storage, activated ER stress responses (Nos2, Bip, Atf4, and Ddit3 [CHOP]), impaired glucose-stimulated insulin secretion, and increased cell death only in islets from prediabetic db/db mice.	Glucose	148-155	interleukin 6	Mus musculus	6-10
23851146-0	2013	Saucerneol F inhibits tumor necrosis factor-alpha and IL-6 production by suppressing Fyn-mediated pathways in FcepsilonRI-mediated mast cells.	saucerneol F	0-12	interleukin 6	Mus musculus	54-58
23436228-9	2013	Perindopril attenuated the increase in MuRF-1 and IL-6 mRNA expression and enhanced Akt phosphorylation in severely cachectic mice but neither body nor muscle mass was increased.	Perindopril	0-11	interleukin 6	Mus musculus	50-54
23582173-4	2013	Accordingly diarrhoea and DSS-induced colon inflammation were impaired in ST2(-/-) BALB/c mice and exacerbated in wild-type mice by treatment with exogenous recombinant IL-33, associated respectively with reduced and enhanced expression of chemokines (CXCL9 and CXCL10), and inflammatory (IL-4, IL-13, IL-1, IL-6, IL-17) and angiogenic (vascular endothelial growth factor) cytokines in vivo.	dss	26-29	interleukin 6	Mus musculus	308-312
23669335-6	2013	In vitro, we also observed that alpinetin inhibited the expression of TLR4 and the production of TNF-alpha, IL-1beta and IL-6 in LPS-stimulated primary mouse mammary epithelial cells.	alpinetin	32-41	interleukin 6	Mus musculus	121-125
23747315-4	2013	Analysis of cytokine milieu within TME revealed IL-10, TGFbeta, IL-6 rich type 2 characters was significantly switched to type 1 microenvironment with dominance of IFNgamma and IL-2 within NLGP-TME, which was not found in other cases; however Cisplatin-TME appeared better in type 2 to type 1 conversion than Sutent-TME as evidenced by RT-PCR, ELISA and immunohistochemical analysis.	cisplatin-tme	243-256	interleukin 6	Mus musculus	64-68
23747315-4	2013	Analysis of cytokine milieu within TME revealed IL-10, TGFbeta, IL-6 rich type 2 characters was significantly switched to type 1 microenvironment with dominance of IFNgamma and IL-2 within NLGP-TME, which was not found in other cases; however Cisplatin-TME appeared better in type 2 to type 1 conversion than Sutent-TME as evidenced by RT-PCR, ELISA and immunohistochemical analysis.	Sunitinib	309-315	interleukin 6	Mus musculus	64-68
23817837-4	2013	We demonstrated that Egmuc peptides enhance LPS-induced maturation of dendritic cells in vitro by increasing the production of IL-12p40p70 and IL-6 and that Egmuc-treated DCs may activate NK cells, as judged by an increased expression of CD69.	egmuc	21-26	interleukin 6	Mus musculus	143-147
23820591-6	2013	The recombinant RTB-induced production of NO, TNF-alpha and IL-6 was inhibited in the macrophages treated with the pharmacological inhibitors genistein, LY294002, staurosporine, AG490, SB203580 and BAY 11-7082, indicating the possible involvement of protein tyrosine kinases, PI3K, PKC, JAK2, p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-kappaB in the above processes.	Genistein	142-151	interleukin 6	Mus musculus	60-64
23820591-6	2013	The recombinant RTB-induced production of NO, TNF-alpha and IL-6 was inhibited in the macrophages treated with the pharmacological inhibitors genistein, LY294002, staurosporine, AG490, SB203580 and BAY 11-7082, indicating the possible involvement of protein tyrosine kinases, PI3K, PKC, JAK2, p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-kappaB in the above processes.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	153-161	interleukin 6	Mus musculus	60-64
23820591-6	2013	The recombinant RTB-induced production of NO, TNF-alpha and IL-6 was inhibited in the macrophages treated with the pharmacological inhibitors genistein, LY294002, staurosporine, AG490, SB203580 and BAY 11-7082, indicating the possible involvement of protein tyrosine kinases, PI3K, PKC, JAK2, p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-kappaB in the above processes.	Staurosporine	163-176	interleukin 6	Mus musculus	60-64
23835587-9	2013	DMBA/TPA treatment also strongly increased mRNA levels of inflammation markers COX-2 and IL-6.	9,10-Dimethyl-1,2-benzanthracene	0-4	interleukin 6	Mus musculus	89-93
23835587-9	2013	DMBA/TPA treatment also strongly increased mRNA levels of inflammation markers COX-2 and IL-6.	Tetradecanoylphorbol Acetate	5-8	interleukin 6	Mus musculus	89-93
23742179-8	2013	Treatment with TNBS caused colon shortening; increased myeloperoxidase activity; and increased IL-1beta, IL-6 and TNF-alpha expression in mice.	Trinitrobenzenesulfonic Acid	15-19	interleukin 6	Mus musculus	105-109
23913961-10	2013	administration of PGE2 increased the mortality of infected mice, suppressed local IL-6 and IL-17A levels, enhanced neutrophilic inflammation, reduced uterine macrophage populations, and increased bacterial dissemination.	Dinoprostone	18-22	interleukin 6	Mus musculus	82-86
23744643-6	2013	Treatment with GGTI-2133 markedly reduced levels of CXCL2 in the pancreas and IL-6 in the plasma in response to taurocholate challenge.	GGTI-2133	15-24	interleukin 6	Mus musculus	78-82
23744643-6	2013	Treatment with GGTI-2133 markedly reduced levels of CXCL2 in the pancreas and IL-6 in the plasma in response to taurocholate challenge.	Taurocholic Acid	112-124	interleukin 6	Mus musculus	78-82
23906708-3	2013	Surfactin significantly suppressed expression of MMP-9, iNOS and COX-2, as well as production of ROS, NO, PGE2, TNF-alpha, IL-1beta, IL-6 and MCP-1 in Abeta-stimulated BV-2 microglial cells.	surfactin peptide	0-9	interleukin 6	Mus musculus	133-137
24005553-6	2013	The levels of monocyte chemoattractant protein-1, interleukin-2, interleukin-6, and mouse gamma interferon in lung tissue after intranasal exposure to SEB were also significantly reduced in mice given a combination of dexamethasone and NAC versus controls.	Dexamethasone	218-231	interleukin 6	Mus musculus	65-78
23857584-0	2013	FcgammaR-driven release of IL-6 by macrophages requires NOX2-dependent production of reactive oxygen species.	Reactive Oxygen Species	85-108	interleukin 6	Mus musculus	27-31
23727198-8	2013	Rather, low concentration of caffeine (0.1mM) significantly increased IL-6 expression, but unexpectedly inhibited that at a concentration more than 0.3mM.	Caffeine	29-37	interleukin 6	Mus musculus	70-74
23850708-7	2013	RESULTS: In LPS challenged mice, DHI significantly reduced the infiltration of activated neutrophils and decreased the levels of TNF-alpha and IL-6 in bronchoalveolar lavage fluid (BALF).	dehydrosoyasaponin I	33-36	interleukin 6	Mus musculus	143-147
23770004-5	2013	In addition, procyanidin C1 functionally induced macrophage activation by augmenting the expression of cell surface molecules (CD80, CD86, and MHC II) and proinflammatory cytokine production (tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6) via activation of mitogen-activated protein kinase (MAPK), e.g., p38, ERK, and JNK and nuclear factor (NF)-kappaB signaling pathways.	Procyanidin C1	13-27	interleukin 6	Mus musculus	255-259
23796752-6	2013	Furthermore, we found that morphine enhanced the release of IL-1beta, TNF-alpha, IL-6, and of NO via mu-opioid receptor-PKCe signaling pathway in activated microglial cells, mediating a proinflammatory phenotype in mouse microglial cells.	Morphine	27-35	interleukin 6	Mus musculus	81-85
23561100-9	2013	Abrupt increases in proinflammatory cytokines such as IkappaB-alpha, TNF-alpha, IL-1beta and IL-6 in hepatocytes due to a chronic alcohol uptake were significantly suppressed by co-administration of EM-CFs.	Alcohols	130-137	interleukin 6	Mus musculus	93-97
23951204-5	2013	The data indicated that the IL-6 and TNF-alpha mRNA of oroxylin A administered group significantly increased higher than the control within 12 hours after CCl4 treatment.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	55-65	interleukin 6	Mus musculus	28-32
23792039-8	2013	Furthermore, the complex form of 18beta-glycyrrhetinic acid and hydroxypropyl gammacyclodextrin reduced mRNA expressions of TNF-alpha, interleukin (IL)-1beta, and IL-6, which was histologically confirmed in the improvement of indomethacin-induced small intestinal damage.	18alpha-glycyrrhetinic acid	33-59	interleukin 6	Mus musculus	163-167
23792039-8	2013	Furthermore, the complex form of 18beta-glycyrrhetinic acid and hydroxypropyl gammacyclodextrin reduced mRNA expressions of TNF-alpha, interleukin (IL)-1beta, and IL-6, which was histologically confirmed in the improvement of indomethacin-induced small intestinal damage.	hydroxypropyl gammacyclodextrin	64-95	interleukin 6	Mus musculus	163-167
23792039-8	2013	Furthermore, the complex form of 18beta-glycyrrhetinic acid and hydroxypropyl gammacyclodextrin reduced mRNA expressions of TNF-alpha, interleukin (IL)-1beta, and IL-6, which was histologically confirmed in the improvement of indomethacin-induced small intestinal damage.	Indomethacin	226-238	interleukin 6	Mus musculus	163-167
23951204-5	2013	The data indicated that the IL-6 and TNF-alpha mRNA of oroxylin A administered group significantly increased higher than the control within 12 hours after CCl4 treatment.	Carbon Tetrachloride	155-159	interleukin 6	Mus musculus	28-32
23770347-7	2013	Furthermore, immunoblotting analysis of placental tissue harvested from our murine models revealed DMA-mediated regulation of expression of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha, and IL-6, and increased expression of the regulatory inflammatory cytokine IL-10.	dimethylacetamide	99-102	interleukin 6	Mus musculus	213-217
23798681-7	2013	We concluded that IL-6 treatment may impair the activities of the PI3K/AKT/GSK pathway and inhibit the synthesis of glycogen, perhaps via down-regulating miR-200s while augmenting FOG2 expression.	Glycogen	116-124	interleukin 6	Mus musculus	18-22
23788765-8	2013	CONCLUSIONS: Abnormal cGMP/cGKI signaling in nonhematopoietic cells affects thrombopoiesis via elevated interleukin-6 production and results in thrombocytosis in vivo.	Cyclic GMP	22-26	interleukin 6	Mus musculus	104-117
23668485-6	2013	IL-6 and TNF-alpha were increased significantly at 1 and 6 hours after Cl2 exposure in the lungs and at 6 hours in the skin.	Chlorine	71-74	interleukin 6	Mus musculus	0-4
23506745-4	2013	Pre-administration of naringenin significantly reduced the severity of colitis and resulted in down-regulation of pro-inflammatory mediators (inducible NO synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), cyclo-oxygenase-2 (Cox2), TNF-alpha and IL-6 mRNA) in the colon mucosa.	naringenin	22-32	interleukin 6	Mus musculus	300-304
23643967-10	2013	RT-PCR results revealed significant upregulation of TNF-alpha and downregulation of IL-6 cytokines after 6h of FNP administration.	{[7-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALEN-2-YL]-DIFLUORO-METHYL}-PHOSPHONIC ACID	111-114	interleukin 6	Mus musculus	84-88
23995057-3	2013	We previously reported that 10-hydroxy-trans-2-decenoic acid (10H2DA) inhibits lipopolysaccharide (LPS)-induced interleukin (IL)-6 and nitric oxide (NO) production via inhibiting NF-kappaB activation.	10-hydroxy-2-decenoic acid	28-60	interleukin 6	Mus musculus	112-130
23995057-3	2013	We previously reported that 10-hydroxy-trans-2-decenoic acid (10H2DA) inhibits lipopolysaccharide (LPS)-induced interleukin (IL)-6 and nitric oxide (NO) production via inhibiting NF-kappaB activation.	10-hydroxy-2-decenoic acid	62-68	interleukin 6	Mus musculus	112-130
23713790-13	2013	GYY4137 decreased ICAM-1, TNF-alpha and IL-6 mRNA expression as well as superoxide (O2 (-) ) generation in aorta.	GYY 4137	0-7	interleukin 6	Mus musculus	40-44
23727179-6	2013	Furthermore, flavokawain A suppressed LPS-induced expression of pro-inflammatory cytokines, such as TNF-alpha, IL-1beta and IL-6.	flavokawain A	13-26	interleukin 6	Mus musculus	124-128
25788280-6	2013	Furthermore, Q-NPs showed marked reduction (compared to quercetin alone) in production of nitric oxide and cytokine (interleukin-6 and tumor necrosis factor alpha) from lipopolysaccharide-activated macrophages.	Quercetin	56-65	interleukin 6	Mus musculus	117-130
23823704-11	2013	The expression of inflammatory cytokines IL-6 and IL-1beta decreased in tumors in oroxylin A-treated mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	82-92	interleukin 6	Mus musculus	41-45
23480027-7	2013	The therapeutic effects of sirolimus were associated with a down-regulation of pro-inflammatory cytokines tumour necrosis factor-alpha, IL-6 and IL-17A.	Sirolimus	27-36	interleukin 6	Mus musculus	136-140
24009539-5	2013	Metformin reduced the production of NO, PGE2 and pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha) through down-regulation of NF-kappaB translocation in macrophages in a dose-dependent manner.	Metformin	0-9	interleukin 6	Mus musculus	87-91
23823704-12	2013	The IL-6/STAT3 signaling pathway was attenuated in oroxylin A-treated mice.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	51-61	interleukin 6	Mus musculus	4-8
23823704-13	2013	CONCLUSIONS: Our results demonstrated that oroxylin A inhibits colitis-associated carcinogenesis through modulating IL-6/STAT3 pathway in AOM/dextran sodium sulfate mouse model and in HCT-116 cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	43-53	interleukin 6	Mus musculus	116-120
23844578-5	2013	RESULTS: TBMS1 significantly inhibited the production of the pro-inflammatory cytokines, TNF-alpha, IL-6 and IL-1beta in vitro and in vivo.	tubeimoside I	9-14	interleukin 6	Mus musculus	100-104
23651796-5	2013	Furthermore, shikonin significantly reduced the concentrations of TNF-alpha, IL-6 and IL-1beta in bronchoalveolar lavage fluid induced by LPS.	shikonin	13-21	interleukin 6	Mus musculus	77-81
23542345-10	2013	Finally, the direct role of p38 in IL-6 secretion after PH was demonstrated using SB203580, a pharmacological inhibitor.	SB 203580	82-90	interleukin 6	Mus musculus	35-39
23742028-6	2013	Hydrogen has been reported to have the ability to inhibit levels of cytokines such as TNF, IL-6 in vivo.	Hydrogen	0-8	interleukin 6	Mus musculus	91-95
23904364-9	2013	The results showed that the levels of IL-17, IL-6 and Tim-3 were substantially increased and the IL-10 level decreased in BALF in the asthmatic mice, which was significantly reversed by DEX treatment.	Dexamethasone	186-189	interleukin 6	Mus musculus	45-49
23817426-6	2013	Exogenous lactate increased the frequency of MDSCs generated from mouse bone marrow cells with GM-CSF and IL-6 in vitro.	Lactic Acid	10-17	interleukin 6	Mus musculus	106-110
23817085-0	2013	Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6.	Streptozocin	102-116	interleukin 6	Mus musculus	147-151
26155222-4	2013	Lipopolysaccarides (LPS) induced the expression of TNF-alpha, IL-1beta, and IL-6.	lipopolysaccarides	0-18	interleukin 6	Mus musculus	76-80
23797361-6	2013	The colonic levels of mRNAs encoding the inflammatory cytokines CXCL1, interleukin (IL)-6, monocyte chemotactic protein-1, IL-12, and interferon-gamma were significantly lower in DSS-treated PepT1-KO mice than in DSS-treated WT animals.	dss	179-182	interleukin 6	Mus musculus	71-89
26155222-4	2013	Lipopolysaccarides (LPS) induced the expression of TNF-alpha, IL-1beta, and IL-6.	lps	20-23	interleukin 6	Mus musculus	76-80
26155222-11	2013	Fenofibrate inhibited LPS-induced TNF-alpha, IL-1beta, and IL-6 production in the serum and liver.	Fenofibrate	0-11	interleukin 6	Mus musculus	59-63
26155222-11	2013	Fenofibrate inhibited LPS-induced TNF-alpha, IL-1beta, and IL-6 production in the serum and liver.	lps	22-25	interleukin 6	Mus musculus	59-63
23534555-9	2013	In contrast, pretreatment with the PPARalpha-antagonist GW-6471 prevented the up-regulation of LFABP mRNA induced by IL-6 in the late phase of LFABP kinetics.	GW 6471	56-63	interleukin 6	Mus musculus	117-121
26155222-15	2013	CONCLUSIONS: Therefore, fenofibrate decreases the expression and secretion of TNF-alpha, IL-1beta, and IL-6 via the NF-kappaB signaling pathway, thus serving as therapeutic targets to attenuate inflammation that is involved in hepatic pathological progression.	Fenofibrate	24-35	interleukin 6	Mus musculus	103-107
23027684-6	2013	Treatment of Raw 264.7 cells with 12-DHGD significantly inhibited LPS-stimulated production of NO (at 12-DHGD concentrations of 150 and 200 ng/ml), IL-6 (at 50, 100, 150, and 200 ng/ml), and PGE2 (at 200 ng/ml).	12-dehydrogingerdione	34-41	interleukin 6	Mus musculus	148-152
23723143-7	2013	In addition, AAV-ADIPOQ-treated iron-overload mice had lower expression of inflammatory markers, including myeloperoxidase activity, monocyte chemotactic protein-1, tumor necrosis factor-alpha, interleukin-6, and intercellular adhesion molecule-1, than iron-overloaded mice not treated with AAV-ADIPOQ.	Iron	32-36	interleukin 6	Mus musculus	194-207
23027684-6	2013	Treatment of Raw 264.7 cells with 12-DHGD significantly inhibited LPS-stimulated production of NO (at 12-DHGD concentrations of 150 and 200 ng/ml), IL-6 (at 50, 100, 150, and 200 ng/ml), and PGE2 (at 200 ng/ml).	dhgd	37-41	interleukin 6	Mus musculus	148-152
23466506-13	2013	The expression of inflammatory cytokines interleukin 1 beta, interleukin 6, cyclooxygenase-2, and prostaglandin E2, was also inhibited by fullerol in a dose-dependent manner.	fullerol	138-146	interleukin 6	Mus musculus	61-74
23736811-4	2013	Gentamicin alone did not change cochlear cytokine levels, while LPS (+- gentamicin) substantially elevated cochlear expression of several cytokines, particularly interleukin-1alpha, interleukin-6, monocyte chemotactic protein-1, macrophage inflammatory protein-1alpha, and RANTES.	Gentamicins	69-82	interleukin 6	Mus musculus	182-195
24100894-8	2013	Pretreatment with 10 mumol/L BAY-117082 for 1h significantly inhibited P.e-LPS-induced translocation of NF-kappaB .The mRNA and proteins of IL-6 decreased significantly after pretreatment with 10 mumol/L BAY-117082 and the expression of IL-6 proteins was reduced from (774.983+-6.585) ng/L to (377.384+-14.620) ng/L (P&lt;0.01).	3-(4-methylphenylsulfonyl)-2-propenenitrile	29-39	interleukin 6	Mus musculus	140-144
24100894-8	2013	Pretreatment with 10 mumol/L BAY-117082 for 1h significantly inhibited P.e-LPS-induced translocation of NF-kappaB .The mRNA and proteins of IL-6 decreased significantly after pretreatment with 10 mumol/L BAY-117082 and the expression of IL-6 proteins was reduced from (774.983+-6.585) ng/L to (377.384+-14.620) ng/L (P&lt;0.01).	3-(4-methylphenylsulfonyl)-2-propenenitrile	29-39	interleukin 6	Mus musculus	237-241
24100894-8	2013	Pretreatment with 10 mumol/L BAY-117082 for 1h significantly inhibited P.e-LPS-induced translocation of NF-kappaB .The mRNA and proteins of IL-6 decreased significantly after pretreatment with 10 mumol/L BAY-117082 and the expression of IL-6 proteins was reduced from (774.983+-6.585) ng/L to (377.384+-14.620) ng/L (P&lt;0.01).	Hydrogen	44-46	interleukin 6	Mus musculus	140-144
24100894-8	2013	Pretreatment with 10 mumol/L BAY-117082 for 1h significantly inhibited P.e-LPS-induced translocation of NF-kappaB .The mRNA and proteins of IL-6 decreased significantly after pretreatment with 10 mumol/L BAY-117082 and the expression of IL-6 proteins was reduced from (774.983+-6.585) ng/L to (377.384+-14.620) ng/L (P&lt;0.01).	Hydrogen	44-46	interleukin 6	Mus musculus	237-241
24100894-8	2013	Pretreatment with 10 mumol/L BAY-117082 for 1h significantly inhibited P.e-LPS-induced translocation of NF-kappaB .The mRNA and proteins of IL-6 decreased significantly after pretreatment with 10 mumol/L BAY-117082 and the expression of IL-6 proteins was reduced from (774.983+-6.585) ng/L to (377.384+-14.620) ng/L (P&lt;0.01).	3-(4-methylphenylsulfonyl)-2-propenenitrile	204-214	interleukin 6	Mus musculus	140-144
23867654-6	2013	Specifically, the high salt-induced suppression of interleukin-6 (IL-6) production was mediated through the ROS-induced inhibition of NFAT5 binding to the IL-6 promoter.	Salts	23-27	interleukin 6	Mus musculus	51-64
24244814-7	2013	Finally, the production of IL-6 and TNF-alpha, involved in rheumatoid arthritis pathogenesis, were suppressed by treatment with Ca gluconate.	Calcium Gluconate	128-140	interleukin 6	Mus musculus	27-31
23867654-6	2013	Specifically, the high salt-induced suppression of interleukin-6 (IL-6) production was mediated through the ROS-induced inhibition of NFAT5 binding to the IL-6 promoter.	Salts	23-27	interleukin 6	Mus musculus	66-70
23867654-6	2013	Specifically, the high salt-induced suppression of interleukin-6 (IL-6) production was mediated through the ROS-induced inhibition of NFAT5 binding to the IL-6 promoter.	Salts	23-27	interleukin 6	Mus musculus	155-159
23867654-6	2013	Specifically, the high salt-induced suppression of interleukin-6 (IL-6) production was mediated through the ROS-induced inhibition of NFAT5 binding to the IL-6 promoter.	Reactive Oxygen Species	108-111	interleukin 6	Mus musculus	51-64
23867654-6	2013	Specifically, the high salt-induced suppression of interleukin-6 (IL-6) production was mediated through the ROS-induced inhibition of NFAT5 binding to the IL-6 promoter.	Reactive Oxygen Species	108-111	interleukin 6	Mus musculus	66-70
23867654-6	2013	Specifically, the high salt-induced suppression of interleukin-6 (IL-6) production was mediated through the ROS-induced inhibition of NFAT5 binding to the IL-6 promoter.	Reactive Oxygen Species	108-111	interleukin 6	Mus musculus	155-159
23866260-10	2013	In addition, the IL-1beta and IL-6 levels were significantly decreased in the GJHT group.	gjht	78-82	interleukin 6	Mus musculus	30-34
23876229-9	2013	Only EPA-PL significantly reduced serum TNF-alpha and IL-6 levels, and increased serum adiponectin level.	epa-pl	5-11	interleukin 6	Mus musculus	54-58
23685554-4	2013	Here, we tested the relationship of IL-6-signal transducer and activator of transcription-3 signaling with Th17-induced inflammation in the formation of Ang II-induced dissections in C57BL/6 mice.	th17	107-111	interleukin 6	Mus musculus	36-40
23394584-6	2013	In vitro studies demonstrated that oligonol treatment reduced lipopolysaccharide-induced expression of interleukin (IL)-1beta, tumor necrosis factor alpha, il-6, cox-2, and inos in murine macrophage RAW 264.7 cells.	oligonol	35-43	interleukin 6	Mus musculus	156-160
23702424-10	2013	Cerulein increased serum levels of amylase and lipase, and pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6 were also decreased by 1,8-cineole pretreatment, similar to thalidomide, a TNF-alpha inhibitor.	Eucalyptol	139-150	interleukin 6	Mus musculus	111-115
23761083-10	2013	The levels of MCP-1, CCL11, and IL-6 increased after light exposure were suppressed by NAC.	Acetylcysteine	87-90	interleukin 6	Mus musculus	32-36
23761083-11	2013	Light-induced MCP-1 and IL-6 were suppressed by Y-27632.	Y 27632	48-55	interleukin 6	Mus musculus	24-28
23678853-7	2013	However, oral administration of theacrine (10, 20, 30 mg/kg for 7 consecutive days) was found to decrease plasma ALT and AST levels, reduce hepatic mRNA levels of inflammatory mediators (IL-1beta, TNF-alpha, IL-6, and IFN-gamma), and reverse the histologic damages in stressed mice.	1,3,7,9-tetramethyluric acid	32-41	interleukin 6	Mus musculus	208-212
23716625-9	2013	Two weeks after the chemical burn injury, a significant elevation in the corneal IL-6 levels of the positive control group was observed, compared to the levels in the negative control group or the rapamycin group (P &lt; 0.05).	Sirolimus	197-206	interleukin 6	Mus musculus	81-85
23716625-13	2013	Rapamycin protected the cornea from chemical damage via reduction of IL-6 and TGF-beta1 expression.	Sirolimus	0-9	interleukin 6	Mus musculus	69-73
23907982-10	2013	PIC-induced behavioral deficits were abolished by IL-6 antibodies and were mimicked by recombinant IL-6; IL-1beta was not involved.	Poly I-C	0-3	interleukin 6	Mus musculus	50-54
23907982-10	2013	PIC-induced behavioral deficits were abolished by IL-6 antibodies and were mimicked by recombinant IL-6; IL-1beta was not involved.	Poly I-C	0-3	interleukin 6	Mus musculus	99-103
23973876-9	2013	Furthermore, we found that WEV+NP strongly inhibited insulin-like growth factor 1 (EGF-1)- and IL-6-mediated MM cell proliferation, altered the cell cycle and enhanced the induction of apoptosis of MM cells.	wev+np	27-33	interleukin 6	Mus musculus	95-99
23647130-9	2013	Losartan attenuated the increased serum alanine aminotransferase activity, TNF-alpha and IL-6 levels, and nuclear concentrations of NF-kappaB in I/R.	Losartan	0-8	interleukin 6	Mus musculus	89-93
23788175-6	2013	CH was able to counteract zymosan-induced ear-skin inflammation locally (ear swelling) as well as systemically (IL-6 production by lipopolysaccharide (LPS)-stimulated whole blood cells).	Zymosan	26-33	interleukin 6	Mus musculus	112-116
23219369-0	2013	Selective induction of IL-6 by aluminum-induced oxidative stress can be prevented by selenium.	Aluminum	31-39	interleukin 6	Mus musculus	23-27
23535871-7	2013	MG132 reduced tumor growth and the levels of TNF-alpha and IL-6 in serum and gastrocnemius tissue.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	0-5	interleukin 6	Mus musculus	59-63
23535871-11	2013	CONCLUSION: Our results demonstrate that MG132-induced inhibition of the ubiquitin-proteasome pathway in cancer cachexia decreased the activity of NF-kappaB and the degradation of IkappaBalpha, and reduced the levels of TNF-alpha and IL-6 in serum and gastrocnemius tissue, accompanied by downregulation of MuRF1 and MAFbx.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	41-46	interleukin 6	Mus musculus	234-238
23219369-8	2013	Therefore it was concluded that short-term exposure to Al causes adverse effects on the intracellular oxidative stress processes in the liver, as reflected by the selective increase in the IL-6 concentration.	Aluminum	55-57	interleukin 6	Mus musculus	189-193
23219369-0	2013	Selective induction of IL-6 by aluminum-induced oxidative stress can be prevented by selenium.	Selenium	85-93	interleukin 6	Mus musculus	23-27
23219369-3	2013	Short-term exposure (16 h) to Al resulted in an increase in the systemic inflammation parameters IL-6 and PAI-1, whereas serum levels of TNF-alpha remained unaffected.	Aluminum	30-32	interleukin 6	Mus musculus	97-101
23660699-6	2013	LPS-treated N2a cells exhibited a significant increase in the expression levels of IL-1beta, IL-6, TNF-alpha, NF-kappaB and iNOS, while the administration of ketamine eliminated the LPS-induced production of IL-1beta, IL-6, TNF-alpha, NF-kappaB and iNOS.	Ketamine	158-166	interleukin 6	Mus musculus	93-97
23954958-9	2013	The expression of IL-6 in colonic tissue was significantly lower in the B-98 groups than the DSS colitis group (p&lt;0.05).	Dextran Sulfate	93-96	interleukin 6	Mus musculus	18-22
23357788-4	2013	Production of pro-inflammatory IL-6, IL-23, IL-17, TGF-beta, and INF-gamma, significantly induced by LPS, was also markedly reduced by furanodien-6-one treatment.	furanodien-6-one	135-151	interleukin 6	Mus musculus	31-35
23660699-6	2013	LPS-treated N2a cells exhibited a significant increase in the expression levels of IL-1beta, IL-6, TNF-alpha, NF-kappaB and iNOS, while the administration of ketamine eliminated the LPS-induced production of IL-1beta, IL-6, TNF-alpha, NF-kappaB and iNOS.	Ketamine	158-166	interleukin 6	Mus musculus	218-222
23672535-6	2013	We found that both cytokines and IgA increased; furthermore, IL-6 secreted by PP dendritic cells (PPDCs) cultured in the presence of AP-FBG significantly increased.	ap-fbg	133-139	interleukin 6	Mus musculus	61-65
23672535-9	2013	Production of IL-6 and IgA by PP cells and IL-6 production by PPDCs in AP-FBG-fed and CY-treated mice also increased.	ap-fbg	71-77	interleukin 6	Mus musculus	43-47
23500096-9	2013	In cultured microglial cells, DHA dose-dependently reduced lipopolysaccharide (LPS)-induced phosphorylation of p38, production of proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and chemokines (CCL2, CCL3 and CXCL10).	Docosahexaenoic Acids	30-33	interleukin 6	Mus musculus	178-182
23816135-13	2013	Simvastatin was able also reversed the inhibitory effect of IL-6.	Simvastatin	0-11	interleukin 6	Mus musculus	60-64
23806095-10	2013	IL-6 inhibition enhanced the radiation sensitivity of prostate cancer, which was associated with increased p53, RT-induced ROS and oxidative DNA damage.	Reactive Oxygen Species	123-126	interleukin 6	Mus musculus	0-4
23825622-0	2013	Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice.	Curcumin	0-8	interleukin 6	Mus musculus	91-95
23825622-0	2013	Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice.	Imiquimod	18-27	interleukin 6	Mus musculus	91-95
23825622-8	2013	We inferred that curcumin was capable of impacting the IL-23/IL-17A axis by inhibiting IL-1beta/IL-6 and then indirectly down-regulating IL-17A/IL-22 production.	Curcumin	17-25	interleukin 6	Mus musculus	96-100
23825622-6	2013	Real-time PCR showed that mRNA levels of IL-17A, IL-17F, IL-22, IL-1beta, IL-6 and TNF-alpha cytokines were decreased significantly by curcumin in ear skin, an effect similar to that of clobetasol.	Curcumin	135-143	interleukin 6	Mus musculus	74-78
23612420-7	2013	RESULTS AND DISCUSSION: Wogonoside not only dose-dependently decreased the production of inflammatory mediators including NO and PGE2 but also inhibited the release of pro-inflammatory cytokines including TNF-alpha and IL-6 in LPS-induced RAW264.7 cells.	wogonoside	24-34	interleukin 6	Mus musculus	219-223
23567033-14	2013	CONCLUSION: This is the first report that sappanone A, protosappanin E, neoprotosappanin and two unidentified compounds can be considered as possible active compounds that might inhibit IL-6 production.	sappanone A	42-53	interleukin 6	Mus musculus	186-190
23612420-8	2013	Furthermore, wogonoside possessed significantly in vitro inhibitory effects on the gene expression of iNOS, COX2, TNF-alpha and IL-6.	wogonoside	13-23	interleukin 6	Mus musculus	128-132
23567033-14	2013	CONCLUSION: This is the first report that sappanone A, protosappanin E, neoprotosappanin and two unidentified compounds can be considered as possible active compounds that might inhibit IL-6 production.	neoprotosappanin	72-88	interleukin 6	Mus musculus	186-190
23805318-7	2013	PES reduced inducible nitric oxide synthase (iNOS) protein expression as well as serum nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) content in LPS-stimulated mice; iii.	2-phenylacetylenesulfonamide	0-3	interleukin 6	Mus musculus	151-164
23612420-5	2013	The inhibition of wogonoside against nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in LPS-induced RAW264.7 cells were measured.	wogonoside	18-28	interleukin 6	Mus musculus	125-138
23612420-5	2013	The inhibition of wogonoside against nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in LPS-induced RAW264.7 cells were measured.	wogonoside	18-28	interleukin 6	Mus musculus	140-144
23805318-7	2013	PES reduced inducible nitric oxide synthase (iNOS) protein expression as well as serum nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) content in LPS-stimulated mice; iii.	2-phenylacetylenesulfonamide	0-3	interleukin 6	Mus musculus	166-170
23805318-8	2013	PES reduced the mRNA level of iNOS, TNF-alpha, and IL-6 in LPS-stimulated liver.	2-phenylacetylenesulfonamide	0-3	interleukin 6	Mus musculus	51-55
23588118-5	2013	However, PD and PE significantly inhibited the infiltration of activated polymorphonuclear leukocytes (PMNs) and decreased the levels of TNF-alpha and IL-6 in bronchoalveolar lavage fluid at the same dose.	pe	16-18	interleukin 6	Mus musculus	151-155
23787115-8	2013	The concentrations of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and myeloperoxidase in BAL fluid were significantly inhibited by imatinib or nilotinib in mice of ALI during neutropenia recovery.	Imatinib Mesylate	145-153	interleukin 6	Mus musculus	75-79
23787115-8	2013	The concentrations of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and myeloperoxidase in BAL fluid were significantly inhibited by imatinib or nilotinib in mice of ALI during neutropenia recovery.	nilotinib	157-166	interleukin 6	Mus musculus	75-79
23799016-5	2013	Celastrol also decreased IkappaB phosphorylation and degradation and reduced production of inducible nitric oxide synthase (iNOS), nitric oxide (NO) and proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha and IL-6.	celastrol	0-9	interleukin 6	Mus musculus	225-229
23588118-9	2013	We also extended our study to acid-induced acute lung injury and found that these two compounds protected mice from hydrochloric acid (HCl)-induced lung injury by inhibiting PMNs influx, IL-6 release and protein exudation.	Hydrochloric Acid	116-133	interleukin 6	Mus musculus	187-191
23588118-9	2013	We also extended our study to acid-induced acute lung injury and found that these two compounds protected mice from hydrochloric acid (HCl)-induced lung injury by inhibiting PMNs influx, IL-6 release and protein exudation.	Hydrochloric Acid	135-138	interleukin 6	Mus musculus	187-191
23523259-7	2013	Borapetoside A not only attenuated the elevation of plasma glucose induced by an intraperitoneal glucose tolerance test, but also increased the glycogen synthesis of IL-6 treated C2C12 cells.	Glycogen	144-152	interleukin 6	Mus musculus	166-170
23677476-3	2013	Secretion of the cytokines TNF-alpha and IL-6 by cultured macrophages (RAW264.7 cell line) was inhibited by these peptides in response to TLR2 activation by lipoteichoic acid (TLR2/6 activator) or palmitoyl (3)-Cys-Ser-Lys(4)-OH (TLR2/1 activator) but not by LPS (TLR4 activator).	lipoteichoic acid	157-174	interleukin 6	Mus musculus	41-45
23677476-3	2013	Secretion of the cytokines TNF-alpha and IL-6 by cultured macrophages (RAW264.7 cell line) was inhibited by these peptides in response to TLR2 activation by lipoteichoic acid (TLR2/6 activator) or palmitoyl (3)-Cys-Ser-Lys(4)-OH (TLR2/1 activator) but not by LPS (TLR4 activator).	palmitoyl (3)-cys-ser-lys(4)-oh	197-228	interleukin 6	Mus musculus	41-45
23523259-7	2013	Borapetoside A not only attenuated the elevation of plasma glucose induced by an intraperitoneal glucose tolerance test, but also increased the glycogen synthesis of IL-6 treated C2C12 cells.	borapetoside A	0-14	interleukin 6	Mus musculus	166-170
23450347-8	2013	TLR-2 deficiency prevented the pristane-induced systemic release of interleukin-6 (IL-6) and IL-10.	pristane	31-39	interleukin 6	Mus musculus	68-81
23567548-5	2013	Poly(I:C) up-regulated pro-inflammatory cytokines, including TNF-alpha and IL-6, and type I interferons (IFN-alpha/beta).	poly	0-4	interleukin 6	Mus musculus	75-79
23567548-5	2013	Poly(I:C) up-regulated pro-inflammatory cytokines, including TNF-alpha and IL-6, and type I interferons (IFN-alpha/beta).	Iodine	5-6	interleukin 6	Mus musculus	75-79
23567548-5	2013	Poly(I:C) up-regulated pro-inflammatory cytokines, including TNF-alpha and IL-6, and type I interferons (IFN-alpha/beta).	Carbon	7-8	interleukin 6	Mus musculus	75-79
23564508-7	2013	Significantly higher A. fumigatus burden in the lungs of Cl2 exposed mice correlated with enhanced production of IL-6, TNF-alpha, CXCL1, CCL2, and CCL3.	Chlorine	57-60	interleukin 6	Mus musculus	113-117
23450347-8	2013	TLR-2 deficiency prevented the pristane-induced systemic release of interleukin-6 (IL-6) and IL-10.	pristane	31-39	interleukin 6	Mus musculus	83-87
23604539-8	2013	Neocuproine, but not ATP7A deficiency, reduced the production of FGF-9, IL-1alpha, IL-12p70, IL-2, IL-3, IL-4, IL-6, MIP-1beta, MIP-2, RANTES, and TNFalpha.	neocuproine	0-11	interleukin 6	Mus musculus	111-115
23604542-9	2013	Finally, pyrrolidine dithiocarbamate and 2-DG attenuated isoflurane-induced increases in IL-6 and NF-kappaB, and the transcription activity of NF-kappaB.	Isoflurane	57-67	interleukin 6	Mus musculus	89-93
23604542-0	2013	Isoflurane and sevoflurane increase interleukin-6 levels through the nuclear factor-kappa B pathway in neuroglioma cells.	Isoflurane	0-10	interleukin 6	Mus musculus	36-49
23499905-0	2013	IL-6 attenuates trimethyltin-induced cognitive dysfunction via activation of JAK2/STAT3, M1 mAChR and ERK signaling network.	trimethyltin	16-28	interleukin 6	Mus musculus	0-4
23604542-0	2013	Isoflurane and sevoflurane increase interleukin-6 levels through the nuclear factor-kappa B pathway in neuroglioma cells.	Sevoflurane	15-26	interleukin 6	Mus musculus	36-49
23604542-1	2013	BACKGROUND: Isoflurane can increase pro-inflammatory cytokine interleukin (IL)-6 levels.	Isoflurane	12-22	interleukin 6	Mus musculus	62-80
23604542-7	2013	RESULTS: Isoflurane or sevoflurane treatment increased the levels of IL-6 [isoflurane: 410% (54); sevoflurane: 290% (24)], the nuclear levels of NF-kappaB [isoflurane: 170% (36); sevoflurane: 320% (30)], and the transcription activity of NF-kappaB in H4 cells.	Isoflurane	9-19	interleukin 6	Mus musculus	69-73
23604542-7	2013	RESULTS: Isoflurane or sevoflurane treatment increased the levels of IL-6 [isoflurane: 410% (54); sevoflurane: 290% (24)], the nuclear levels of NF-kappaB [isoflurane: 170% (36); sevoflurane: 320% (30)], and the transcription activity of NF-kappaB in H4 cells.	Sevoflurane	23-34	interleukin 6	Mus musculus	69-73
23604542-7	2013	RESULTS: Isoflurane or sevoflurane treatment increased the levels of IL-6 [isoflurane: 410% (54); sevoflurane: 290% (24)], the nuclear levels of NF-kappaB [isoflurane: 170% (36); sevoflurane: 320% (30)], and the transcription activity of NF-kappaB in H4 cells.	Isoflurane	75-85	interleukin 6	Mus musculus	69-73
23604542-9	2013	Finally, pyrrolidine dithiocarbamate and 2-DG attenuated isoflurane-induced increases in IL-6 and NF-kappaB, and the transcription activity of NF-kappaB.	pyrrolidine dithiocarbamic acid	9-36	interleukin 6	Mus musculus	89-93
23604542-9	2013	Finally, pyrrolidine dithiocarbamate and 2-DG attenuated isoflurane-induced increases in IL-6 and NF-kappaB, and the transcription activity of NF-kappaB.	Deoxyglucose	41-45	interleukin 6	Mus musculus	89-93
23499905-1	2013	We previously reported that interleukin (IL)-6 deficiency potentiates trimethyltin (TMT)-induced convulsive neurotoxicity.	trimethyltin	70-82	interleukin 6	Mus musculus	28-46
23499905-1	2013	We previously reported that interleukin (IL)-6 deficiency potentiates trimethyltin (TMT)-induced convulsive neurotoxicity.	trimethyltin	84-87	interleukin 6	Mus musculus	28-46
23499905-6	2013	Inhibition of JAK2 with AG490 or inhibition of cholinergic signaling with the M1 mAChR antagonist dicyclomine counteracted the attenuating effects of rIL-6 on phosphorylated extracellular signal-regulated kinase (ERK) expression, or on cognitive impairment in TMT-treated IL-6(-/-) mice.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	24-29	interleukin 6	Mus musculus	151-155
23499905-6	2013	Inhibition of JAK2 with AG490 or inhibition of cholinergic signaling with the M1 mAChR antagonist dicyclomine counteracted the attenuating effects of rIL-6 on phosphorylated extracellular signal-regulated kinase (ERK) expression, or on cognitive impairment in TMT-treated IL-6(-/-) mice.	Dicyclomine	98-109	interleukin 6	Mus musculus	151-155
23349502-9	2013	Blockade of TLR4 signaling by Eritoran reduced fasting blood glucose and serum interleukin-6 levels in obese Cbl-b(-/-) mice.	eritoran	30-38	interleukin 6	Mus musculus	79-92
23578797-9	2013	Elevated TNF-alpha and IL-6, as determined by enzyme immunoassay, were also found in cone-enriched retinal explants treated with Zaprinast.	zaprinast	129-138	interleukin 6	Mus musculus	23-27
23918873-7	2013	Additionally, 4% Lovaza  significantly decreased anti-dsDNA antibodies, reduced glomerulonephritis and attenuated lipopolysaccharide-induced pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha) in splenocytes compared to placebo.	Omacor	17-23	interleukin 6	Mus musculus	179-183
23623942-12	2013	Moreover, while IFN-gamma and IL-10 were not affected, torilin suppressed CIA-induced serum TNF-alpha, IL-1beta and IL-6 levels.	torilin	55-62	interleukin 6	Mus musculus	116-120
23918873-8	2013	4% Lovaza  was also shown to reduce the expression of inflammatory cytokines, including IL-1beta, IL-6 and TNF-alpha, while increasing renal anti-oxidant enzymes in comparison to placebo.	Omacor	3-9	interleukin 6	Mus musculus	98-102
23464615-3	2013	Pinacidil significantly decreased the production of osteoclast differentiation inducing factors such as TNF-alpha, IL-6 and receptor activator of nuclear factor-kappaB ligand in the presence of antimycin A, which inhibits mitochondrial electron transport.	Pinacidil	0-9	interleukin 6	Mus musculus	115-174
23742082-7	2013	Likewise, interleukin-6 in the brain and lung of Hg(0)-exposed animals were dramatically elevated, whereas it was maintained to the basal level in Hg(0) + SA-exposed animals.	Salicylic Acid	155-157	interleukin 6	Mus musculus	10-23
23643741-2	2013	We previously reported that triptolide showed therapeutic activity in mouse colitis by mechanisms involving suppression of IL-6 trans-signaling.	triptolide	28-38	interleukin 6	Mus musculus	123-127
23197406-7	2013	Moreover, increased gene expression of integrin alpha8, bone morphogenetic protein 2, interleukin-6, and collagen-I was found on P2 alginate-coated TiO2 SC compared to alginate-coated TiO2 SC.	Alginates	132-140	interleukin 6	Mus musculus	86-99
23197406-7	2013	Moreover, increased gene expression of integrin alpha8, bone morphogenetic protein 2, interleukin-6, and collagen-I was found on P2 alginate-coated TiO2 SC compared to alginate-coated TiO2 SC.	titanium dioxide	148-152	interleukin 6	Mus musculus	86-99
23643741-13	2013	CONCLUSIONS: Our results indicated that triptolide therapy may restore the homeostatic balance of LP-T cell apoptosis within the gut, and demonstrate a novel mechanism of action of triptolide therapy mediated through regulation IL-6/STAT3/SOCS3 signaling pathway.	triptolide	40-50	interleukin 6	Mus musculus	228-232
23643741-13	2013	CONCLUSIONS: Our results indicated that triptolide therapy may restore the homeostatic balance of LP-T cell apoptosis within the gut, and demonstrate a novel mechanism of action of triptolide therapy mediated through regulation IL-6/STAT3/SOCS3 signaling pathway.	triptolide	181-191	interleukin 6	Mus musculus	228-232
23603336-4	2013	These findings demonstrated that the increases in TNFalpha and IL-6 mRNA transcripts were highest at 3 hrs and 1 hr after incubation with poly(I:C) and LPS, respectively.	poly	138-142	interleukin 6	Mus musculus	63-67
23246157-1	2013	We recently showed that lycopene inhibited lipopolysaccharide (LPS)-induced productions of nitric oxide (NO) and interleukin-6 (IL-6) in murine RAW264.7 macrophages by mechanisms related to inhibition of ERK and nuclear factor-kappaB.	Lycopene	24-32	interleukin 6	Mus musculus	113-126
23246157-1	2013	We recently showed that lycopene inhibited lipopolysaccharide (LPS)-induced productions of nitric oxide (NO) and interleukin-6 (IL-6) in murine RAW264.7 macrophages by mechanisms related to inhibition of ERK and nuclear factor-kappaB.	Lycopene	24-32	interleukin 6	Mus musculus	128-132
23246157-5	2013	We also found that the lycopene induced inhibition was associated with reduced formation of reactive oxygen species (ROS), which was an upstream mechanism for the effects of lycopene, because treating the cells with the antioxidant N-acetyl-l-cysteine and NADPH oxidase inhibitor diphenyleneiodonium chloride significantly inhibited LPS-induced recruitment of TLR4 into lipid raft-like domains as well as the production of proinflammatory molecule NO and IL-6.	Lycopene	23-31	interleukin 6	Mus musculus	455-459
23246157-5	2013	We also found that the lycopene induced inhibition was associated with reduced formation of reactive oxygen species (ROS), which was an upstream mechanism for the effects of lycopene, because treating the cells with the antioxidant N-acetyl-l-cysteine and NADPH oxidase inhibitor diphenyleneiodonium chloride significantly inhibited LPS-induced recruitment of TLR4 into lipid raft-like domains as well as the production of proinflammatory molecule NO and IL-6.	Reactive Oxygen Species	117-120	interleukin 6	Mus musculus	455-459
23246157-5	2013	We also found that the lycopene induced inhibition was associated with reduced formation of reactive oxygen species (ROS), which was an upstream mechanism for the effects of lycopene, because treating the cells with the antioxidant N-acetyl-l-cysteine and NADPH oxidase inhibitor diphenyleneiodonium chloride significantly inhibited LPS-induced recruitment of TLR4 into lipid raft-like domains as well as the production of proinflammatory molecule NO and IL-6.	Lycopene	174-182	interleukin 6	Mus musculus	455-459
23246159-10	2013	Compared with RAW264.7 cells, gamma-TE shows similar or stronger inhibitory effects on LPS-triggered activation of NF-kappaB, C/EPBbeta and C/EBPdelta and more potently suppresses IL-6 and G-CSF in bone marrow-derived macrophages.	plastochromanol 8	30-38	interleukin 6	Mus musculus	180-184
23596159-5	2013	DSS administration caused severe colon damage and inflammation, as indicated by body weight loss, increased clinical sores, colon shortening, and gene expressions of inflammatory cytokines [interferon-gamma, interleukin (IL)-6, macrophage inflammatory protein-2, and IL-17A).	Dextran Sulfate	0-3	interleukin 6	Mus musculus	208-226
23596159-10	2013	DSS administration moderately induced colon shortening at d 3 and 6 and increased the disease activity index (DAI) and inflammatory cytokine (IL-6 and IL-17A) expression without any significant increases in colonic permeability.	Dextran Sulfate	0-3	interleukin 6	Mus musculus	142-146
23456093-4	2013	Vanadium compounds did not increase PPARgamma transcription but ameliorated PPARgamma degradation induced by inflammatory stimulators TNF-alpha/IL-6.	Vanadium Compounds	0-18	interleukin 6	Mus musculus	144-148
23500058-9	2013	RAW264.7 cells transfected with CD.TNF-alpha siRNA and stimulated with LPS displayed a significant reduction in both gene and protein levels of TNF-alpha and IL-6.	Cyclodextrins	32-34	interleukin 6	Mus musculus	158-162
23499795-6	2013	Moreover, TL2 also decreased Abeta-induced production of TNF-alpha, IL-1beta and IL-6 in BV2 microglia.	UNII-042A8N37WH	29-34	interleukin 6	Mus musculus	81-85
23567805-6	2013	The addition of F or AS and both in the diet significantly counteracted HFD induced body weight gain; hyperlipidemia; TNF-alpha, IL-6; hepatic lipid profile; fatty infiltration; NF-kappaB signaling pathway; ROS; lipid peroxidation and moreover elevated levels of hepatic antioxidant enzymes activity were observed.	Atorvastatin	21-23	interleukin 6	Mus musculus	129-133
23710296-5	2013	The amount of interferon (IFN)-inducible protein-10 (IP10/CXCL10), macrophage chemotactic protein (MCP1/CCL2) and interleukin (IL)-6 secreted by cells activated by DMXAA was quantified using enzyme-linked immunosorbent assay kits according to the instructions of the manufacturers.	vadimezan	164-169	interleukin 6	Mus musculus	114-132
23545357-7	2013	reduced levels of TNF-alpha and IL-6 in hind paw homogenates of formalin-injected mice.	Formaldehyde	64-72	interleukin 6	Mus musculus	32-36
23500883-11	2013	CONCLUSION: The anti-inflammatory activity of alpha-cyperone is associated with the down-regulation of COX-2 and IL-6 via the negative regulation of the NFkappaB pathway in LPS-stimulated RAW 264.7 cells.	alpha-cyperone	46-60	interleukin 6	Mus musculus	113-117
23375938-10	2013	Arctigenin inhibited TNBS-induced IL-1beta, TNF-alpha and IL-6 expression, as well as PI3K, AKT and IKKbeta phosphorylation and NF-kappaB activation in mice, but increased IL-10 and CD204 expression.	Trinitrobenzenesulfonic Acid	21-25	interleukin 6	Mus musculus	58-62
23462222-8	2013	Taken together, our data suggest a causal relationship between IL-6 and the excessive pulmonary inflammation observed after the combined insult of ethanol and burn injury.	Ethanol	147-154	interleukin 6	Mus musculus	63-67
23850963-4	2013	Our results show that TAMs downregulate IL-12p70 but upregulate IL-12p40, IL-23, IL-6 and IL-10.	tams	22-26	interleukin 6	Mus musculus	81-85
23435932-7	2013	RESULTS: Gossypol markedly attenuated the LPS-induced histological alterations in the lung and inhibited the production of TNF-alpha, IL-1beta and IL-6.	Gossypol	9-17	interleukin 6	Mus musculus	147-151
23557800-9	2013	In DSS-treated mice, colon tissues from mIL-21iso-Tg mice had significantly higher gene activation levels for cytokines such as IL-17A, TNF-alpha, IL-6, IL-10, and IL-4, and for transcription factors such as T-bet, GATA-3, RORgammat, and Foxp3, than were found in wild-type mice.	Dextran Sulfate	3-6	interleukin 6	Mus musculus	147-151
23348408-5	2013	Our data indicated that PA inhibits the over-expression of iNOS and IL-6 in protein and mRNA levels in LPS-stimulated RAW264.7 and TNF-alpha stimulated HT-29 cells.	patchouli alcohol	24-26	interleukin 6	Mus musculus	68-72
23566810-7	2013	The results showed that icaritin significantly inhibited the NO, IL-6, IL-10 TNF-alpha, and MCP-1 production both in vitro and in vivo.	icaritin	24-32	interleukin 6	Mus musculus	65-69
23541634-12	2013	Tubastatin showed significant inhibition of IL-6 in paw tissues of arthritic mice.	tubastatin	0-10	interleukin 6	Mus musculus	44-48
23449935-1	2013	Interleukin-6 (IL-6) increases glucose uptake in resting skeletal muscle.	Glucose	31-38	interleukin 6	Mus musculus	0-13
23449935-1	2013	Interleukin-6 (IL-6) increases glucose uptake in resting skeletal muscle.	Glucose	31-38	interleukin 6	Mus musculus	15-19
23449935-3	2013	We report that IL-6 knockout (KO) mice, 4 mo of age, have similar body weight to wild-type (WT), and, under resting conditions, oxygen consumption, food intake, substrate utilization, glucose tolerance, and insulin sensitivity are not different.	Oxygen	128-134	interleukin 6	Mus musculus	15-19
22884451-0	2013	Angiotensin II inhibits interleukin-6 mRNA expression of LPS-stimulated macrophages through down-regulating calcium signaling.	Calcium	108-115	interleukin 6	Mus musculus	24-37
23637159-6	2013	Interleukin-6 (IL-6) is a critical cytokine for mediating the behavioral and transcriptional effects of polyI:C.	Poly I-C	104-111	interleukin 6	Mus musculus	0-13
23637159-6	2013	Interleukin-6 (IL-6) is a critical cytokine for mediating the behavioral and transcriptional effects of polyI:C.	Poly I-C	104-111	interleukin 6	Mus musculus	15-19
23637159-7	2013	We found a more pronounced increase of IL-6 in response to polyI:C in fetal brain in Disc1-L100P(+/-) mice compared with WT or Disc1-Q31L(+/-) mice.	Poly I-C	59-66	interleukin 6	Mus musculus	39-43
22884451-10	2013	Both thapsigargin and A23187 augmented the IL-6 mRNA levels induced by LPS stimulation, but only thapsigargin was able to induce IL-6 mRNA directly.	Thapsigargin	5-17	interleukin 6	Mus musculus	43-47
22884451-10	2013	Both thapsigargin and A23187 augmented the IL-6 mRNA levels induced by LPS stimulation, but only thapsigargin was able to induce IL-6 mRNA directly.	Calcimycin	22-28	interleukin 6	Mus musculus	43-47
22884451-10	2013	Both thapsigargin and A23187 augmented the IL-6 mRNA levels induced by LPS stimulation, but only thapsigargin was able to induce IL-6 mRNA directly.	Thapsigargin	97-109	interleukin 6	Mus musculus	129-133
22884451-11	2013	TMB-8 but not verapamil inhibited LPS-stimulated MO IL-6 mRNA.	8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate	0-5	interleukin 6	Mus musculus	52-56
22884451-13	2013	CONCLUSIONS: Our data show that calcium signaling is closely related to IL-6 mRNA expression.	Calcium	32-39	interleukin 6	Mus musculus	72-76
23101887-7	2013	Mannans lacking the beta-1,2-mannosides induced the production of higher levels of inflammatory cytokines, including IL-6, IL-12p40 and TNF-alpha, in mice dendritic cells compared to wild-type mannan.	Mannans	0-7	interleukin 6	Mus musculus	117-121
23637159-8	2013	Coadministration of an anti-IL-6 antibody with polyI:C reversed schizophrenia-related behavioral phenotypes in Disc1-L100P(+/-) mice.	Poly I-C	47-54	interleukin 6	Mus musculus	28-32
23607370-13	2013	The systemic inflammatory response triggered by intestinal IRI was significantly attenuated in mice pretreated with remifentanil (159 vs 805 pg/ml of IL-6 after saline pretreatment, with 92 pg/ml in the sham groups).	Remifentanil	116-128	interleukin 6	Mus musculus	150-154
23384965-7	2013	DMTU reduced the expression levels of TNF-alpha, Bax and c-fos and increased the expression levels of IL-6, Bcl-xL and Nrf2 in WT mice.	1,3-dimethylthiourea	0-4	interleukin 6	Mus musculus	102-106
23384965-0	2013	Interleukin-6 modulates oxidative stress produced during the development of cisplatin nephrotoxicity.	Cisplatin	76-85	interleukin 6	Mus musculus	0-13
23384965-8	2013	Reduced reactive oxygen species (ROS) by DMTU resulted in increases of IL-6, anti-apoptosis and anti-oxidant gene expression levels.	Reactive Oxygen Species	8-31	interleukin 6	Mus musculus	71-75
23384965-1	2013	AIMS: We reported that interleukin-6 (IL-6) plays a protective role in the development of cisplatin-induced acute renal failure (ARF) through upregulation of anti-oxidative stress factors.	Cisplatin	90-99	interleukin 6	Mus musculus	23-36
23384965-1	2013	AIMS: We reported that interleukin-6 (IL-6) plays a protective role in the development of cisplatin-induced acute renal failure (ARF) through upregulation of anti-oxidative stress factors.	Cisplatin	90-99	interleukin 6	Mus musculus	38-42
23384965-8	2013	Reduced reactive oxygen species (ROS) by DMTU resulted in increases of IL-6, anti-apoptosis and anti-oxidant gene expression levels.	Reactive Oxygen Species	33-36	interleukin 6	Mus musculus	71-75
23384965-8	2013	Reduced reactive oxygen species (ROS) by DMTU resulted in increases of IL-6, anti-apoptosis and anti-oxidant gene expression levels.	1,3-dimethylthiourea	41-45	interleukin 6	Mus musculus	71-75
23384965-9	2013	In IL-6(-/-) mice, DMTU also improved cisplatin-induced renal dysfunction and reduced expression levels of TNF-alpha, Bax and c-fos, but not Bcl-xL and Nrf2.	1,3-dimethylthiourea	19-23	interleukin 6	Mus musculus	3-7
23384965-12	2013	SIGNIFICANCE: In IL-6(-/-) mice, overproduction of ROS by cisplatin results in upregulation of HO-1 expression in order to eliminate oxidative stress.	Reactive Oxygen Species	51-54	interleukin 6	Mus musculus	17-21
23399703-0	2013	Cystamine ameliorates ventricular hypertrophy associated with modulation of IL-6-mediated signaling in lupus-prone mice.	Cystamine	0-9	interleukin 6	Mus musculus	76-80
23384965-12	2013	SIGNIFICANCE: In IL-6(-/-) mice, overproduction of ROS by cisplatin results in upregulation of HO-1 expression in order to eliminate oxidative stress.	Cisplatin	58-67	interleukin 6	Mus musculus	17-21
23399703-6	2013	Moreover, cystamine reduced levels of atrial natriuretic peptide (ANP), C-reactive protein (CRP), heart type-fatty acid binding protein (h-FABP), creatine kinase-MB (CK-MB) and IL-6 in LV tissues of NZB/W-F1 mice (p&lt;0.05).	Cystamine	10-19	interleukin 6	Mus musculus	177-181
23399703-7	2013	Additionally, in LV tissues of NZB/W-F1 mice, suppression of hypertrophic signaling mediated by IL-6 in response to administration of cystamine was revealed, including phosphorylation of MEK5, ERK5, c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38) (p&lt;0.05).	Cystamine	134-143	interleukin 6	Mus musculus	96-100
23399703-8	2013	SIGNIFICANCE: Cystamine alleviated LV hypertrophy in NZB/W-F1 mice as a result of decrease in hypertrophic mediators and suppression of IL-6 mediated hypertrophic signaling.	Cystamine	14-23	interleukin 6	Mus musculus	136-140
23384965-13	2013	IL-6 mediates the generation and elimination of ROS during cisplatin-induced ARF.	Reactive Oxygen Species	48-51	interleukin 6	Mus musculus	0-4
23384965-13	2013	IL-6 mediates the generation and elimination of ROS during cisplatin-induced ARF.	Cisplatin	59-68	interleukin 6	Mus musculus	0-4
23438875-4	2013	In RAW264.7 and mouse peritoneal macrophages, bis-N-norgliovictin dose-dependently inhibited LPS-induced production of TNF-alpha, interleukin-6 (IL-6), interferon-beta (IFN-beta) and monocyte chemoattractant protein (MCP-1), but without suppressing cell viability.	bis-N-norgliovictin	46-65	interleukin 6	Mus musculus	130-143
23593315-4	2013	Here, we investigated the effects of minocycline on IL-6 and its signaling pathways in ovarian cancer.	Minocycline	37-48	interleukin 6	Mus musculus	52-56
23593315-6	2013	Moreover, minocycline down-regulated two major components of IL-6 receptor system (IL-6Ralpha and gp130) and blocked the activation of STAT3 and ERK1/2 pathways leading to suppression of the downstream product MCL-1.	Minocycline	10-21	interleukin 6	Mus musculus	61-65
23593315-7	2013	In female nude mice bearing intraperitoneal OVCAR-3 tumors, acute administration (4 and 24 h) of minocycline (30 mg/kg) led to suppression of IL-6.	Minocycline	97-108	interleukin 6	Mus musculus	142-146
23593315-8	2013	Even single dose of minocycline was effective at significantly lowering plasma and tumor IL-6 levels.	Minocycline	20-31	interleukin 6	Mus musculus	89-93
23593315-11	2013	Thus, the data suggest a potential role for minocycline in suppressing IL-6 expression and activity.	Minocycline	44-55	interleukin 6	Mus musculus	71-75
23438875-4	2013	In RAW264.7 and mouse peritoneal macrophages, bis-N-norgliovictin dose-dependently inhibited LPS-induced production of TNF-alpha, interleukin-6 (IL-6), interferon-beta (IFN-beta) and monocyte chemoattractant protein (MCP-1), but without suppressing cell viability.	bis-N-norgliovictin	46-65	interleukin 6	Mus musculus	145-149
23438875-7	2013	Intravenous injection of bis-N-norgliovictin 1h before LPS challenge dose-dependently inhibited LPS-induced increases in serum levels of TNF-alpha, IL-6, MCP-1 and IL-10, attenuated liver and lung injury and diminished M1 macrophage polarization in liver.	bis-n-norgliovictin 1h	25-47	interleukin 6	Mus musculus	148-152
23435916-4	2013	Similarly, pristimerin inhibited the release of pro-inflammatory cytokines, namely, tumor necrosis factor-alpha and interleukin-6, induced by LPS.	pristimerin	11-22	interleukin 6	Mus musculus	116-129
23180366-5	2013	In addition, pretreatment with limonene inhibited inflammatory cells and proinflammatory cytokines including tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 in BALF.	Limonene	31-39	interleukin 6	Mus musculus	161-174
23274564-5	2013	RESULTS: Minocycline blocked hypoxia-induced surge in interleukin-6 (IL-6), its soluble receptor (sIL-6R) and vascular endothelial growth factor (VEGF) levels in concentration-dependent manner.	Minocycline	9-20	interleukin 6	Mus musculus	54-67
23274564-5	2013	RESULTS: Minocycline blocked hypoxia-induced surge in interleukin-6 (IL-6), its soluble receptor (sIL-6R) and vascular endothelial growth factor (VEGF) levels in concentration-dependent manner.	Minocycline	9-20	interleukin 6	Mus musculus	69-73
23274564-7	2013	IL-6, sIL6R and in particular VEGF levels were highly suppressed in plasma, ascite fluid and tumor tissue by minocycline.	Minocycline	109-120	interleukin 6	Mus musculus	0-4
23356698-9	2013	RESULTS: The findings of this study showed that SMS reduced TNF-alpha and IL-6 production induced by LPS.	sms	48-51	interleukin 6	Mus musculus	74-78
23381991-6	2013	In BALB/c mice, DMPA altered the antigen-specific secretion of IFN-gamma, IL-17, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-6, and monocyte chemotactic protein 1 (MCP-1).	Medroxyprogesterone Acetate	16-20	interleukin 6	Mus musculus	140-144
23381991-5	2013	DMPA also suppressed antigen-specific production of TNF-alpha, G-CSF, IL-10, and IL-6 and induced the production of IP-10 in C57BL/6 mice.	Medroxyprogesterone Acetate	0-4	interleukin 6	Mus musculus	81-85
23184090-8	2013	RESULTS: Curcumin dramatically attenuated the progression and severity of CIA in DBA/1 J mice, accompanied with decrease of BAFF production in serum and spleen cells as well as decrease of serum IFNgamma and IL-6.	Curcumin	9-17	interleukin 6	Mus musculus	208-212
23499643-5	2013	Mechanistically, MSCs-derived PGE2, through the receptors EP2 and EP4, promoted the release of IL-10 and inhibited the production of IL-6 and TNF-alpha by macrophages.	Dinoprostone	30-34	interleukin 6	Mus musculus	133-137
23499680-4	2013	Our results showed that ETH inhibited LPS-induced TNF-alpha and IL-6 release in a dose-dependent manner, and decreased TNF-alpha, IL-1beta, IL-6 and iNOS mRNA production.	1-(4-ethoxyphenyl)-3-(4-nitrophenyl)-prop-2-en-1-one	24-27	interleukin 6	Mus musculus	64-68
23499680-4	2013	Our results showed that ETH inhibited LPS-induced TNF-alpha and IL-6 release in a dose-dependent manner, and decreased TNF-alpha, IL-1beta, IL-6 and iNOS mRNA production.	1-(4-ethoxyphenyl)-3-(4-nitrophenyl)-prop-2-en-1-one	24-27	interleukin 6	Mus musculus	140-144
23318472-5	2013	The beneficial effects of paclitaxel were accompanied by the downregulation of tumor necrosis factor-alpha, interleukin-1, and interleukin-6 production.	Paclitaxel	26-36	interleukin 6	Mus musculus	127-140
23064699-3	2013	In this study, we investigated how EGCG impacts differentiation of naive CD4(+) T cells into different effector lineages and report that EGCG impeded Th1, Th9, and Th17 differentiation and prevented IL-6-induced suppression of Treg development.	epigallocatechin gallate	35-39	interleukin 6	Mus musculus	199-203
23064699-3	2013	In this study, we investigated how EGCG impacts differentiation of naive CD4(+) T cells into different effector lineages and report that EGCG impeded Th1, Th9, and Th17 differentiation and prevented IL-6-induced suppression of Treg development.	epigallocatechin gallate	137-141	interleukin 6	Mus musculus	199-203
23064699-6	2013	EGCG-induced change in Th17/Treg balance may be mediated by its inhibition of IL-6 signaling because EGCG inhibited soluble IL-6R, membrane gp130, and IL-6-induced phosphorylation of STAT3.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	78-82
23064699-6	2013	EGCG-induced change in Th17/Treg balance may be mediated by its inhibition of IL-6 signaling because EGCG inhibited soluble IL-6R, membrane gp130, and IL-6-induced phosphorylation of STAT3.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	124-128
23064699-6	2013	EGCG-induced change in Th17/Treg balance may be mediated by its inhibition of IL-6 signaling because EGCG inhibited soluble IL-6R, membrane gp130, and IL-6-induced phosphorylation of STAT3.	epigallocatechin gallate	101-105	interleukin 6	Mus musculus	78-82
23064699-6	2013	EGCG-induced change in Th17/Treg balance may be mediated by its inhibition of IL-6 signaling because EGCG inhibited soluble IL-6R, membrane gp130, and IL-6-induced phosphorylation of STAT3.	epigallocatechin gallate	101-105	interleukin 6	Mus musculus	124-128
23554035-5	2013	Improvement of monocytosis (p&lt;0.05) in spleen and decreased serum interleukin-6 (IL-6) (p=0.0277) were observed with As4S4 treatment.	as4s4	120-125	interleukin 6	Mus musculus	69-82
23554035-5	2013	Improvement of monocytosis (p&lt;0.05) in spleen and decreased serum interleukin-6 (IL-6) (p=0.0277) were observed with As4S4 treatment.	as4s4	120-125	interleukin 6	Mus musculus	84-88
23360889-3	2013	Surfactin significantly inhibited excessive production of the pro-inflammatory mediators TNF-alpha, IL-1beta, IL-6, monocyte chemoattractant protein-1 (MCP-1), prostaglandin E2 (PGE2), nitric oxide (NO) and reactive oxygen species (ROS), and suppressed the expression of matrix metalloproteinase-9 (MMP-9), inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2).	surfactin peptide	0-9	interleukin 6	Mus musculus	110-114
23376955-0	2013	Anti-IL-6 antibody treatment but not IL-6 knockout improves intestinal barrier function and reduces inflammation after binge ethanol exposure and burn injury.	Ethanol	125-132	interleukin 6	Mus musculus	5-9
23376955-3	2013	Previous work in our laboratory has shown that IL-6 is increased both systemically and in multiple organ systems including the ileum after ethanol exposure and burn injury.	Ethanol	139-146	interleukin 6	Mus musculus	47-51
23376955-6	2013	Zonula occludens protein 1 and occludin localization was also reestablished in wild-type mice given IL-6 antibody after ethanol and burn.	Ethanol	120-127	interleukin 6	Mus musculus	100-104
23376955-7	2013	Interleukin 6-knockout mice given ethanol and burn injury also had reduced intestinal damage; however, no changes in bacterial translocation or tight junction protein localization were observed as compared with similarly treated wild-type mice.	Ethanol	34-41	interleukin 6	Mus musculus	0-13
23376955-8	2013	These data suggest that IL-6 may have a role in intestinal tissue damage observed after the combined insult of binge ethanol exposure and burn injury, although complete loss of IL-6 does not seem to be beneficial in this model.	Ethanol	117-124	interleukin 6	Mus musculus	24-28
23376955-9	2013	Modulation of IL-6 may present a new option for preventing intestinal damage and associated inflammation after a combined insult of ethanol exposure and burn injury.	Ethanol	132-139	interleukin 6	Mus musculus	14-18
23517603-12	2013	Corticosterone and noradrenaline, at pathophysiological levels, increased expression and secretion of IL-6 in B16-F10 cells in vitro.	Corticosterone	0-14	interleukin 6	Mus musculus	102-106
23531302-3	2013	The present study was designed to examine a synergistic role for Interleukin-6 (IL-6) and MSCs therapy in the recovery of carbon tetrachloride (CCl(4)) induced injured hepatocytes in vitro and in vivo.	Carbon Tetrachloride	122-142	interleukin 6	Mus musculus	65-78
23531302-3	2013	The present study was designed to examine a synergistic role for Interleukin-6 (IL-6) and MSCs therapy in the recovery of carbon tetrachloride (CCl(4)) induced injured hepatocytes in vitro and in vivo.	Carbon Tetrachloride	122-142	interleukin 6	Mus musculus	80-84
23531302-3	2013	The present study was designed to examine a synergistic role for Interleukin-6 (IL-6) and MSCs therapy in the recovery of carbon tetrachloride (CCl(4)) induced injured hepatocytes in vitro and in vivo.	Cefaclor	144-147	interleukin 6	Mus musculus	65-78
23531302-3	2013	The present study was designed to examine a synergistic role for Interleukin-6 (IL-6) and MSCs therapy in the recovery of carbon tetrachloride (CCl(4)) induced injured hepatocytes in vitro and in vivo.	Cefaclor	144-147	interleukin 6	Mus musculus	80-84
23517603-12	2013	Corticosterone and noradrenaline, at pathophysiological levels, increased expression and secretion of IL-6 in B16-F10 cells in vitro.	Norepinephrine	19-32	interleukin 6	Mus musculus	102-106
23517603-13	2013	Corticosterone- and noradrenaline-induced transcriptional up-regulation of IL-6 gene involves changes in the DNA binding activity of nuclear factor-kappaB, cAMP response element-binding protein, activator protein-1, and nuclear factor for IL-6.	Corticosterone	0-14	interleukin 6	Mus musculus	75-79
23517603-13	2013	Corticosterone- and noradrenaline-induced transcriptional up-regulation of IL-6 gene involves changes in the DNA binding activity of nuclear factor-kappaB, cAMP response element-binding protein, activator protein-1, and nuclear factor for IL-6.	Corticosterone	0-14	interleukin 6	Mus musculus	239-243
23517603-13	2013	Corticosterone- and noradrenaline-induced transcriptional up-regulation of IL-6 gene involves changes in the DNA binding activity of nuclear factor-kappaB, cAMP response element-binding protein, activator protein-1, and nuclear factor for IL-6.	Norepinephrine	20-33	interleukin 6	Mus musculus	75-79
23517603-13	2013	Corticosterone- and noradrenaline-induced transcriptional up-regulation of IL-6 gene involves changes in the DNA binding activity of nuclear factor-kappaB, cAMP response element-binding protein, activator protein-1, and nuclear factor for IL-6.	Norepinephrine	20-33	interleukin 6	Mus musculus	239-243
23517603-13	2013	Corticosterone- and noradrenaline-induced transcriptional up-regulation of IL-6 gene involves changes in the DNA binding activity of nuclear factor-kappaB, cAMP response element-binding protein, activator protein-1, and nuclear factor for IL-6.	Cyclic AMP	156-160	interleukin 6	Mus musculus	75-79
23321685-8	2013	Osthole also inhibited the release of inflammatory mediators TNF-alpha and IL-6.	osthol	0-7	interleukin 6	Mus musculus	75-79
23503500-5	2013	In recent years, hydrogen was reported to have an ability to inhibit the levels of cytokines, such as tumor necrosis factor and interleukin-6 in vivo, and it also has a strong selective free radical-scavenging ability.	Hydrogen	17-25	interleukin 6	Mus musculus	128-141
23503500-5	2013	In recent years, hydrogen was reported to have an ability to inhibit the levels of cytokines, such as tumor necrosis factor and interleukin-6 in vivo, and it also has a strong selective free radical-scavenging ability.	Free Radicals	186-198	interleukin 6	Mus musculus	128-141
25206704-5	2013	Results demonstrated that brilliant blue G inhibited the release of cyclooxygenase-2 and interleukin-6 in BV2 cells.	coomassie Brilliant Blue	26-42	interleukin 6	Mus musculus	89-102
23314109-6	2013	RESULTS: Sevoflurane anesthesia in pregnant mice induced caspase-3 activation, increased interleukin-6 levels (256 +- 50.98% [mean +- SD] vs. 100 +- 54.12%, P = 0.026), and reduced postsynaptic density-95 (61 +- 13.53% vs. 100 +- 10.08%, P = 0.036) and synaptophysin levels in fetal and offspring mice.	Sevoflurane	9-20	interleukin 6	Mus musculus	89-102
23314109-8	2013	Moreover, interleukin-6 antibody mitigated the sevoflurane-induced reduction in postsynaptic density-95 levels in the neurons.	Sevoflurane	47-58	interleukin 6	Mus musculus	10-23
23314109-9	2013	Finally, environmental enrichment attenuated the sevoflurane-induced increases in interleukin-6 levels, reductions of synapse markers, and learning and memory impairment.	Sevoflurane	49-60	interleukin 6	Mus musculus	82-95
23314110-5	2013	RESULTS: : In this article, the authors show that anesthesia with 3% sevoflurane for 2 h daily for 3 days induced cognitive impairment and neuroinflammation (e.g., increased interleukin-6 levels, 151 +- 2.3% [mean +- SD] vs. 100 +- 9.0%, P = 0.035, n = 6) in young but not in adult mice.	Sevoflurane	69-80	interleukin 6	Mus musculus	174-187
23368428-8	2013	The accumulation of neutrophils and the concentrations of TNF-alpha, IL-1beta, IL-6, and MPO in BAL fluids were also effectively inhibited by pravastatin.	Pravastatin	142-153	interleukin 6	Mus musculus	79-83
23277090-8	2013	Twenty-four hours post-injection (0.33 mg/kg LPS or Saline) we found a LPS-induced upregulation of whole brain TNFalpha, IL-1beta, and IL-10 mRNA, and increased IL-1beta and IL-6 in the spleen and liver; these effects were not attenuated by VWR.	Sodium Chloride	52-58	interleukin 6	Mus musculus	174-178
23143993-4	2013	We tested the hypothesis that glutamine preserves muscle function after SCI and that this is associated with increased heat shock protein and reduced inflammatory factors, interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNFalpha).	Glutamine	30-39	interleukin 6	Mus musculus	172-185
23143993-4	2013	We tested the hypothesis that glutamine preserves muscle function after SCI and that this is associated with increased heat shock protein and reduced inflammatory factors, interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNFalpha).	Glutamine	30-39	interleukin 6	Mus musculus	187-191
23143993-9	2013	Glutamine significantly reduced spinal cord transection-associated increases in IL-6 and TNFalpha compared with placebo (38 +- 6 and 37 +- 8% of placebo, respectively).	Glutamine	0-9	interleukin 6	Mus musculus	80-84
23262293-5	2013	In RAW264.7 macrophage cells, transient transfection of STEAP4v, to a greater extent than STEAP4, repressed the transcription of TNFalpha and IL-6.	steap4v	56-63	interleukin 6	Mus musculus	142-146
23339930-6	2013	The changes 8 h after TPA treatment probably reflected transcriptional regulation, and the genes were divided into three groups, up-regulated (IL-6, MCP-1, HO-1 and SOCS3), unregulated (IL-1beta, TNF-alpha and IL-10) and down-regulated (RANTES) genes.	Tetradecanoylphorbol Acetate	22-25	interleukin 6	Mus musculus	143-147
23370301-5	2013	C-34 also significantly downregulated the secretion of TNF-alpha, IL-1-beta and IL-6 by murine splenocytes and THP-1 cells against LPS induced levels.	Carbon	0-1	interleukin 6	Mus musculus	80-84
23380150-8	2013	Likewise, intraperitoneal administration of CP-AU increased in vivo serum levels of IL-6 and monocyte chemoattractant protein-1 (MCP-1) in mice.	cp-au	44-49	interleukin 6	Mus musculus	84-88
23046379-11	2013	Our findings suggest that IL-6 influences the expression of lipocalin-2, which in turn may be involved in the control of the formation of Cox-2, and hence central PGE(2) -production.	Dinoprostone	163-169	interleukin 6	Mus musculus	26-30
23678544-4	2013	SSAE (10 mg.kg-1, sc) caused a significant change in the level of LH, FSH, progesterone, estradiol, IL-beta, IL-6 and TNF-alpha.	ssae	0-4	interleukin 6	Mus musculus	109-113
23263992-8	2013	Chronic treatment with SDG also affected the body weight of mice and IL-6, IL1beta levels in the frontal cortex.	secoisolariciresinol diglucoside	23-26	interleukin 6	Mus musculus	69-73
23228323-8	2013	RESULTS: Linalool attenuated the production of LPS-induced tumor necrosis-alpha and interleukin-6 both in vitro and in vivo.	linalool	9-17	interleukin 6	Mus musculus	84-97
23261590-5	2013	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.	neoechinulin A	27-41	interleukin 6	Mus musculus	190-203
23261590-5	2013	In addition, we found that neoechinulin A significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.	neoechinulin A	27-41	interleukin 6	Mus musculus	205-209
23426399-5	2013	IL-1, IL-3, IL-6, TNF-alpha, TGF-beta, PDGF, MCP-1 and MIP-1 expression were higher in rapamycin-treated mice compared to the control group, however, IGF-1 expression was lower.	Sirolimus	87-96	interleukin 6	Mus musculus	12-16
23510834-8	2013	Compared with the paraquat poisoning group, the thalidomide treatment groups had significantly decreased levels of TNF-alpha, IL-1beta, IL-6, NF-kappaB mRNA, and nuclear NF-kappaB p65 and wet/dry ratios of the lung (P &lt; 0.05), and the 150 mg/kg thalidomide treatment group showed the most significant decrease in the levels of TNF-alpha, IL-1beta, IL-6, NF-kappaB mRNA, and nuclear NF-kappaB p65.	Thalidomide	48-59	interleukin 6	Mus musculus	136-140
23531921-5	2013	Our data indicate that AZD1480 blocks endogenous as well as IL-6 induced STAT3 activation.	AZD 1480	23-30	interleukin 6	Mus musculus	60-64
23276528-8	2013	RESULTS: Rosuvastatin significantly decreased thrombus weight, plasminogen activator inhibitor-1 expression and plasma levels, expression of molecules related to the interleukin-6 pathway, and neutrophil migration into the vein wall.	Rosuvastatin Calcium	9-21	interleukin 6	Mus musculus	166-179
23510834-7	2013	RESULTS: Compared with the negative control group, the paraquat poisoning group had significantly increased levels of TNF-alpha, IL-1beta, IL-6, NF-kappaB mRNA, and nuclear NF-kappaB p65 and wet/dry ratio of the lung (P &lt; 0.05).	Paraquat	55-63	interleukin 6	Mus musculus	139-143
23510834-8	2013	Compared with the paraquat poisoning group, the thalidomide treatment groups had significantly decreased levels of TNF-alpha, IL-1beta, IL-6, NF-kappaB mRNA, and nuclear NF-kappaB p65 and wet/dry ratios of the lung (P &lt; 0.05), and the 150 mg/kg thalidomide treatment group showed the most significant decrease in the levels of TNF-alpha, IL-1beta, IL-6, NF-kappaB mRNA, and nuclear NF-kappaB p65.	Thalidomide	48-59	interleukin 6	Mus musculus	351-355
23297396-6	2013	PIP5Kalpha knockdown significantly suppressed induction of inflammatory mediators, including IL-6, IL-1beta, and nitric oxide, by lipopolysaccharide.	pip5kalpha	0-10	interleukin 6	Mus musculus	93-97
23333383-8	2013	Both ivabradine and carvedilol similarlyattenuated myocardial lesions and fibrosis, inhibited NO synthesis by iNOS, and decreased the production of TNF-alpha and IL-6.	Ivabradine	5-15	interleukin 6	Mus musculus	162-166
23296151-12	2013	In vitro, treatment with digoxin did not inhibit the proliferation of T cells in a mixed lymphocyte reaction, but it did inhibit the IL-6-mediated conversion of Tregs into Th17 cells.	Digoxin	25-32	interleukin 6	Mus musculus	133-137
23333383-8	2013	Both ivabradine and carvedilol similarlyattenuated myocardial lesions and fibrosis, inhibited NO synthesis by iNOS, and decreased the production of TNF-alpha and IL-6.	Carvedilol	20-30	interleukin 6	Mus musculus	162-166
23406906-0	2013	Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes.	Tacrolimus	44-54	interleukin 6	Mus musculus	59-63
23406906-1	2013	INTRODUCTION: This study investigated whether the calcineurin inhibitor, tacrolimus, suppresses receptor activator of NF-kappaB ligand (RANKL) expression in fibroblast-like synoviocytes (FLS) through regulation of IL-6/Janus activated kinase (JAK2)/signal transducer and activator of transcription-3 (STAT3) and suppressor of cytokine signaling (SOCS3) signaling.	Tacrolimus	73-83	interleukin 6	Mus musculus	214-218
23406906-8	2013	Tacrolimus inhibits RANKL expression in IL-6/sIL-6R-stimulated FLS by suppressing STAT3.	Tacrolimus	0-10	interleukin 6	Mus musculus	40-44
23406906-11	2013	By up-regulating SOCS3, tacrolimus down-regulates activation of the JAK-STAT pathway by IL-6/sIL-6R trans-signaling, thus decreasing RANKL expression in FLS.	Tacrolimus	24-34	interleukin 6	Mus musculus	88-92
23406906-12	2013	CONCLUSIONS: These data suggest that tacrolimus might affect the RANKL expression in IL-6 stimulated FLS through STAT3 suppression, together with up-regulation of SOCS3.	Tacrolimus	37-47	interleukin 6	Mus musculus	85-89
23143138-7	2013	In contrast to mouse ESC with very low endogenous IL6, mouse neural stem/precursor cells (C17.2 clone immortalized by v-myc) with high endogenous production of IL6 exhibited a strong resistance to cytotoxic effects of sodium arsenite that could be decreased by inhibitory anti-IL6 antibody or Stat3 inhibition.	sodium arsenite	218-233	interleukin 6	Mus musculus	160-163
23194644-3	2013	Daily GABA injections (200mg/kg) from day 3 onwards significantly augmented disease severity, which was associated with increased CNS mRNA expression levels of tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-6.	gamma-Aminobutyric Acid	6-10	interleukin 6	Mus musculus	204-222
23194644-5	2013	Moreover, in vitro, the lipopolysaccharide (LPS)-induced increase in interleukin (IL)-6 production by macrophages was enhanced at low GABA concentrations (0.03-0.3mM).	gamma-Aminobutyric Acid	134-138	interleukin 6	Mus musculus	69-87
23143138-7	2013	In contrast to mouse ESC with very low endogenous IL6, mouse neural stem/precursor cells (C17.2 clone immortalized by v-myc) with high endogenous production of IL6 exhibited a strong resistance to cytotoxic effects of sodium arsenite that could be decreased by inhibitory anti-IL6 antibody or Stat3 inhibition.	sodium arsenite	218-233	interleukin 6	Mus musculus	160-163
22633994-4	2013	We found that LCWE induced in vitro macrophage activation with increased production of IL-6, TNF-alpha, and MCP-1, concomitantly with Syk activation, and dectin-1 and TLR2 enhancement.	lcwe	14-18	interleukin 6	Mus musculus	87-91
22634733-7	2013	However, at the same time point, pretreatment with xanthohumol almost completely blunted the I/R-induced AKT and NFkappaB activation and the expression of the proinflammatory genes IL-1alpha, IL-6, MCP-1 and ICAM-1, which are known to play a crucial role in the subacute phase of I/R-induced liver damage.	xanthohumol	51-62	interleukin 6	Mus musculus	192-196
22948514-7	2013	In addition, curcumin inhibited intrahepatic expression of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6 protein.	Curcumin	13-21	interleukin 6	Mus musculus	127-131
23131135-9	2013	Also, tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-1beta, and prostaglandin E(2) (PGE(2)) secretion were decreased by CPS in LPS-stimulated macrophages.	capillarisin	131-134	interleukin 6	Mus musculus	41-59
23229720-5	2013	Overexpression of PTP1B decreased mRNA and protein levels of TNF-alpha and IL-6 in macrophages stimulated with palmitate.	Palmitates	111-120	interleukin 6	Mus musculus	75-79
23229720-7	2013	NF-kB, JNK, p38 and ERK specific inhibitors significantly reduced the production of TNF-alpha and IL-6 in macrophages stimulated with palmitate and also PTP1B knockdown cells.	Palmitates	134-143	interleukin 6	Mus musculus	98-102
23270759-5	2013	In addition, britanin reduced the release of pro-inflammatory cytokines, such as TNF-alpha, IL-1beta, and IL-6.	Britanin	13-21	interleukin 6	Mus musculus	106-110
23352443-4	2013	The results showed that gossypol significantly inhibited the production of LPS-induced TNF-alpha, IL-6 and IL-1beta both in vitro and vivo.	Gossypol	24-32	interleukin 6	Mus musculus	98-102
22290536-0	2013	Synergistic induction of interleukin-6 expression by endothelin-1 and cyclic AMP in adipocytes.	Cyclic AMP	70-80	interleukin 6	Mus musculus	25-38
22290536-2	2013	In this study, we further examined the combined effect of ET-1 and cyclic adenosine monophosphate (cAMP) on IL-6 release.	Cyclic AMP	67-97	interleukin 6	Mus musculus	108-112
22290536-2	2013	In this study, we further examined the combined effect of ET-1 and cyclic adenosine monophosphate (cAMP) on IL-6 release.	Cyclic AMP	99-103	interleukin 6	Mus musculus	108-112
22290536-6	2013	RESULTS: ET-1 and cAMP induced IL-6 release in a synergistic manner that can be attributed to their synergistic induction of IL-6 gene expression, as evidenced by IL-6 mRNA analysis and the IL-6 promoter reporter assay.	Cyclic AMP	18-22	interleukin 6	Mus musculus	31-35
22290536-6	2013	RESULTS: ET-1 and cAMP induced IL-6 release in a synergistic manner that can be attributed to their synergistic induction of IL-6 gene expression, as evidenced by IL-6 mRNA analysis and the IL-6 promoter reporter assay.	Cyclic AMP	18-22	interleukin 6	Mus musculus	125-129
22290536-6	2013	RESULTS: ET-1 and cAMP induced IL-6 release in a synergistic manner that can be attributed to their synergistic induction of IL-6 gene expression, as evidenced by IL-6 mRNA analysis and the IL-6 promoter reporter assay.	Cyclic AMP	18-22	interleukin 6	Mus musculus	125-129
22290536-6	2013	RESULTS: ET-1 and cAMP induced IL-6 release in a synergistic manner that can be attributed to their synergistic induction of IL-6 gene expression, as evidenced by IL-6 mRNA analysis and the IL-6 promoter reporter assay.	Cyclic AMP	18-22	interleukin 6	Mus musculus	125-129
22290536-8	2013	In addition, enhanced IL-6 promoter activity can be similarly induced by ET-1 and catecholamines (epinephrine and norepinephrine).	Catecholamines	82-96	interleukin 6	Mus musculus	22-26
22290536-8	2013	In addition, enhanced IL-6 promoter activity can be similarly induced by ET-1 and catecholamines (epinephrine and norepinephrine).	Epinephrine	98-109	interleukin 6	Mus musculus	22-26
22290536-8	2013	In addition, enhanced IL-6 promoter activity can be similarly induced by ET-1 and catecholamines (epinephrine and norepinephrine).	Norepinephrine	114-128	interleukin 6	Mus musculus	22-26
22290536-9	2013	The cooperative interaction between ET-1 and cAMP on IL-6 expression seems distinctive, as no other proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and IL-1beta, are similarly affected.	Cyclic AMP	45-49	interleukin 6	Mus musculus	53-57
22290536-11	2013	Furthermore, injection of mice with epinephrine and ET-1 induced a tremendously synergistic increase in serum IL-6 levels.	Epinephrine	36-47	interleukin 6	Mus musculus	110-114
22290536-12	2013	Nevertheless, whereas cAMP induced IL-6 expression in RAW264.7 mouse macrophages, ET-1 had no effect on either the basal or the cAMP-induced IL-6 expression.	Cyclic AMP	22-26	interleukin 6	Mus musculus	35-39
22290536-14	2013	SIGNIFICANCE: This study should provide a new perspective for treating IL-6-related diseases, especially those accompanied with elevated ET-1 and catecholamine levels.	Catecholamines	146-159	interleukin 6	Mus musculus	71-75
22951726-7	2013	Upon IMQ treatment of IL-17RA(del) mice, these cells secreted elevated amounts of tumor necrosis factor-alpha, IL-6, and IL-22, accompanied by increased levels of the chemokine CXCL2, suggesting an alternative pathway of neutrophil and macrophage skin infiltration.	Imiquimod	5-8	interleukin 6	Mus musculus	111-115
23354240-12	2013	In addition to Iba1, resveratrol decreased the brain levels of IL-6 (p &lt; 0.0001) and IL-12 (p &lt; 0.004), which were observed in the hippocampus of the placebo group.	Resveratrol	21-32	interleukin 6	Mus musculus	63-67
23023014-9	2013	Infiltrated macrophage numbers and the expression of tumor necrosis factor-alpha, monocyte chemoattractant protein-1 and IL-6 on these cells were decreased after poly I:C treatment.	Poly I-C	162-170	interleukin 6	Mus musculus	121-125
23146835-9	2013	The observed increases in multiantennary N-glycans and in outer branch fucosylation and sialylation were associated with the up-regulation of genes involved in glycosylation in the liver, which is the main producer of serum proteins, and with an increase in the key proinflammatory serum cytokines IL-1beta, IL-6, and TNFalpha, which can regulate the expression of glycosylation genes.	n-glycans	41-50	interleukin 6	Mus musculus	308-312
22573480-4	2013	Diadzein pretreatment was found to significantly suppress the production of the pro-inflammatory factors nitric oxide and IL-6 as well as their mRNA expression in conjunction with reductions in ROS production, p38 MAPK phosphorylation, and NF-kappaB activation.	daidzein	0-8	interleukin 6	Mus musculus	122-126
23098900-5	2013	The anti-inflammatory activity of the crude extracts and the five alkaloids were tested by measuring the amount of TNF-alpha and IL-6 released from LPS stimulated RAW264 cell via ELISA.	Alkaloids	66-75	interleukin 6	Mus musculus	129-133
23440625-4	2013	Both polyphenols proved to have anti-inflammatory activity as evidenced by the decreased nitric oxide (NO), cytokines (IL-1beta , IL-6, and IL-10) and prostaglandin E2 (PGE(2)) levels in lipopolysaccharide (LPS)-stimulated RAW 264.7 murine macrophages.	Polyphenols	5-16	interleukin 6	Mus musculus	130-134
23201088-7	2013	RESULTS: Shikonin administration significantly reduced serum amylase and lipase activities, pancreatic histological scores, TNF-alpha, IL-1beta, IL-6 levels, MPO activity and NF-kappaB activity.	shikonin	9-17	interleukin 6	Mus musculus	145-149
23062010-8	2013	Both SRT1720 and resveratrol suppressed OVA-induced cell proliferation and IL-6 (P &lt; 0.05) and tumour necrosis factor-alpha (TNF-alpha) (P &lt; 0.05) production in splenocytes (P &lt; 0.01).	Resveratrol	17-28	interleukin 6	Mus musculus	75-79
23062010-10	2013	SRT1720 and resveratrol suppressed OVA-induced splenocyte proliferation and TNF-alpha and IL-6 production.	Resveratrol	12-23	interleukin 6	Mus musculus	90-94
23306703-6	2013	Additionally, ASA, but not salicylic acid, suppressed Th17 airway inflammation, which was associated with decreased expression of acetyl-STAT3 (downstream signaling of IL-6) in the lung.	Aspirin	14-17	interleukin 6	Mus musculus	168-172
23363614-5	2013	Secreted interleukin 6 (IL-6) was measured by enzyme-linked immunosorbent assay (ELISA), and its regulation by tumor necrosis factor-alpha (TNF-alpha and corticosterone (the major glucocorticoid in rodents) measured relative to other mesenchymal cell populations.	Corticosterone	154-168	interleukin 6	Mus musculus	9-22
23363614-5	2013	Secreted interleukin 6 (IL-6) was measured by enzyme-linked immunosorbent assay (ELISA), and its regulation by tumor necrosis factor-alpha (TNF-alpha and corticosterone (the major glucocorticoid in rodents) measured relative to other mesenchymal cell populations.	Corticosterone	154-168	interleukin 6	Mus musculus	24-28
23306703-0	2013	Acetyl salicylic acid inhibits Th17 airway inflammation via blockade of IL-6 and IL-17 positive feedback.	Aspirin	0-21	interleukin 6	Mus musculus	72-76
23306703-5	2013	ASA inhibited the production of interleukin (IL)-17 from lung T cells as well as in vitro Th17 polarization induced by IL-6.	Aspirin	0-3	interleukin 6	Mus musculus	119-123
23306703-7	2013	Moreover, the production of IL-6 from inflammatory cells, induced by IL-17, was abolished by treatment with ASA, whereas that induced by LPS was not.	Aspirin	108-111	interleukin 6	Mus musculus	28-32
23306703-8	2013	Altogether, ASA, likely via its acetyl moiety, inhibits Th17 airway inflammation by blockade of IL-6 and IL-17 positive feedback.	Aspirin	12-15	interleukin 6	Mus musculus	96-100
23114963-4	2013	In differentiating C2C12 myoblasts, the upregulation of IL-6 mRNA expression and protein secretion started after increased phosphorylation of STAT3 on tyrosine 705 and increased mRNA expression of Socs3 was observed.	Tyrosine	151-159	interleukin 6	Mus musculus	56-60
23084372-3	2013	Adjudin significantly inhibited LPS-induced IL-6 release and IL-6, IL-1beta, TNF-alpha expression in BV2 microglial cells.	1-(2,4-dichlorobenzyl)indazole-3-carbohydrazide	0-7	interleukin 6	Mus musculus	44-48
22689051-5	2013	Myricetin significantly decreased the secretion of tumour necrosis factor-alpha, interleukin-6 and interleukin-12p70 by LPS-stimulated DCs.	myricetin	0-9	interleukin 6	Mus musculus	81-94
23084372-3	2013	Adjudin significantly inhibited LPS-induced IL-6 release and IL-6, IL-1beta, TNF-alpha expression in BV2 microglial cells.	1-(2,4-dichlorobenzyl)indazole-3-carbohydrazide	0-7	interleukin 6	Mus musculus	61-65
23127653-11	2013	Magnolol inhibited the expression of TNF-alpha, IL-6 and IL-1beta in LPS-stimulated RAW264.7 cells in a dose-dependent manner.	magnolol	0-8	interleukin 6	Mus musculus	48-52
23178269-15	2013	Stachydrine hydrochloride promoted the protein expression of IL-12 and IL-6, as well as the mRNA expression of T-bet and RORgammat, while inhibiting the mRNA expression of GATA-3 and Foxp3.	stachydrine	0-25	interleukin 6	Mus musculus	71-75
23195328-8	2013	Telmisartan and valsartan elevated plasma adiponectin concentration and suppressed the mRNA expressions of TNF-alpha and IL-6 in adipose tissues.	Telmisartan	0-11	interleukin 6	Mus musculus	121-125
23195328-8	2013	Telmisartan and valsartan elevated plasma adiponectin concentration and suppressed the mRNA expressions of TNF-alpha and IL-6 in adipose tissues.	Valsartan	16-25	interleukin 6	Mus musculus	121-125
23060524-6	2013	Furthermore, immunohistochemistry studies showed that Rs-LPS inhibited the expression of interleukin 6 and matrix metalloproteinase-9 and reduced the content of monocytes and macrophages in atherosclerotic plaques.	rs-lps	54-60	interleukin 6	Mus musculus	89-133
23178521-6	2013	We observed that anatabine reduces pro-inflammatory cytokine production (IL-6, IL-1beta and TNF-alpha) in the plasma, kidney and spleen of the animals following the injection of LPS and concomitantly opposes STAT3 phosphorylation induced by LPS in the spleen and kidney.	anatabine	17-26	interleukin 6	Mus musculus	73-77
23178521-8	2013	Following a chronic oral treatment with anatabine, a reduction in brain TNF-alpha and IL-6 levels compared to untreated Tg APPsw mice was observed.	anatabine	40-49	interleukin 6	Mus musculus	86-90
24324956-7	2013	As the results, the mouse model of AS was successfully established, and high-dose allicin could markedly alleviate spine inflammatory injury possibly via reducing the secretion of the inflammatory factors (IL-6, IL-8, and TNF- alpha ) sharply in AS mice.	allicin	82-89	interleukin 6	Mus musculus	206-210
23852503-6	2013	In vivo studies of mice pretreated with saline or 100 mug/kg of IL-11 at 12 and 2 h before 10-Gy total body irradiation (TBI) demonstrated that G-CSF and IL-6 were significantly upregulated, whereas IL-2 and IL-4 were reduced.	Sodium Chloride	40-46	interleukin 6	Mus musculus	154-158
23548793-6	2013	Increased serum interleukin-6 level in PAN-induced nephrosis was also completely suppressed by DHMEQ.	dehydroxymethylepoxyquinomicin	95-100	interleukin 6	Mus musculus	16-29
22905919-7	2013	Furthermore, calcitriol treatment reduced concentrations of various inflammatory markers including TNF-alpha, CRP and IL-6 (p &lt; 0.05).	Calcitriol	13-23	interleukin 6	Mus musculus	118-122
23302642-7	2013	Ginsenoside Rh1 also inhibited the expressions of PPAR-gamma, C/EBP-alpha, fatty acid synthase, adipocyte fatty acid-binding protein, as well as F4/80, CD68, tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-1beta in DIO mice by real time PCR analysis.	ginsenoside Rh1	0-15	interleukin 6	Mus musculus	193-211
23114643-6	2013	Co-administration of nilotinib and doxorubicin to mice decreased the expression of IL-1beta RNA in the liver and suppressed the level of IL-6 protein in the serum compared with mice that were injected with doxorubicin alone.	nilotinib	21-30	interleukin 6	Mus musculus	137-141
24369005-5	2013	The levels of interleukin-6 (IL-6) and interferon-gamma in the bronchoalveolar lavage fluids after infection were significantly decreased in offspring mice exposed to methamidophos.	methamidophos	167-180	interleukin 6	Mus musculus	14-27
24369005-5	2013	The levels of interleukin-6 (IL-6) and interferon-gamma in the bronchoalveolar lavage fluids after infection were significantly decreased in offspring mice exposed to methamidophos.	methamidophos	167-180	interleukin 6	Mus musculus	29-33
24000330-7	2013	The expression of IL-6 and IL-1beta was significantly increased under 10 mM glucose in the presence of NT, while IL-1beta and IL-12 expression significantly decreased under inflammatory and hyperglycemic conditions.	Glucose	76-83	interleukin 6	Mus musculus	18-22
23470753-5	2013	Then they were treated with 25 or 50 microg/mL of KEO for 24 h. KEO suppressed LPS-induced pro-inflammatory cytokine production such as that of nitric oxide (NO), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in a dose-dependent manner.	keo	50-53	interleukin 6	Mus musculus	163-176
23470753-5	2013	Then they were treated with 25 or 50 microg/mL of KEO for 24 h. KEO suppressed LPS-induced pro-inflammatory cytokine production such as that of nitric oxide (NO), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in a dose-dependent manner.	keo	50-53	interleukin 6	Mus musculus	178-182
23470753-5	2013	Then they were treated with 25 or 50 microg/mL of KEO for 24 h. KEO suppressed LPS-induced pro-inflammatory cytokine production such as that of nitric oxide (NO), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in a dose-dependent manner.	keo	64-67	interleukin 6	Mus musculus	163-176
23470753-5	2013	Then they were treated with 25 or 50 microg/mL of KEO for 24 h. KEO suppressed LPS-induced pro-inflammatory cytokine production such as that of nitric oxide (NO), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in a dose-dependent manner.	keo	64-67	interleukin 6	Mus musculus	178-182
24356466-12	2013	SB216763 reduced IL-6, but not TNF-alpha levels in vivo.	SB 216763	0-8	interleukin 6	Mus musculus	17-21
23114643-6	2013	Co-administration of nilotinib and doxorubicin to mice decreased the expression of IL-1beta RNA in the liver and suppressed the level of IL-6 protein in the serum compared with mice that were injected with doxorubicin alone.	Doxorubicin	35-46	interleukin 6	Mus musculus	137-141
23051007-5	2013	Both poly I:C and LPS stimulation in porcine islets induced expression of chemokines (RANTES, MCP-1, IP-10, and IL-8), cytokines (IL-6 and type I interferons), and adhesion molecules (VCAM-1 and ICAM-1).	Poly I-C	5-13	interleukin 6	Mus musculus	130-134
24008771-4	2013	Hydrogen-rich solution was reported to inhibit the levels of cytokines including INF-gamma, TNF-alpha and IL-6 in vivo in recent studies.	Hydrogen	0-8	interleukin 6	Mus musculus	106-110
23026294-7	2013	Septic mice that were pretreated with the selective NF-kappaB inhibitor pyrrolidine dithiocarbamate (PDTC) were found to have a decreased liberation of proinflammtory cytokines such as TNF-alpha, IL-1beta, IL-6, or IFN-gamma.	pyrrolidine dithiocarbamic acid	72-99	interleukin 6	Mus musculus	206-210
23727776-3	2013	The sesquiterpene coumarin derivatives inhibited nitric oxide (NO) and inducible NO synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) gene expression in a murine macrophage-like cell line (RAW264.7), which was activated by lipopolysaccharide (LPS) and recombinant mouse interferon-gamma (IFN-gamma).	Sesquiterpenes	4-17	interleukin 6	Mus musculus	101-114
23727776-3	2013	The sesquiterpene coumarin derivatives inhibited nitric oxide (NO) and inducible NO synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) gene expression in a murine macrophage-like cell line (RAW264.7), which was activated by lipopolysaccharide (LPS) and recombinant mouse interferon-gamma (IFN-gamma).	Sesquiterpenes	4-17	interleukin 6	Mus musculus	116-120
23727776-3	2013	The sesquiterpene coumarin derivatives inhibited nitric oxide (NO) and inducible NO synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) gene expression in a murine macrophage-like cell line (RAW264.7), which was activated by lipopolysaccharide (LPS) and recombinant mouse interferon-gamma (IFN-gamma).	coumarin	18-26	interleukin 6	Mus musculus	101-114
23727776-3	2013	The sesquiterpene coumarin derivatives inhibited nitric oxide (NO) and inducible NO synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) gene expression in a murine macrophage-like cell line (RAW264.7), which was activated by lipopolysaccharide (LPS) and recombinant mouse interferon-gamma (IFN-gamma).	coumarin	18-26	interleukin 6	Mus musculus	116-120
23324285-15	2013	In addition, the inhibitory effect of corticosterone on IL-6 and TNF-alpha in LPS-stimulated splenocyte cultures in vitro was diminished in the asthma-SDR group compared to the asthma group.	Corticosterone	38-52	interleukin 6	Mus musculus	56-60
24371447-0	2013	Propofol reduces lipopolysaccharide-induced, NADPH oxidase (NOX 2) mediated TNF- alpha and IL-6 production in macrophages.	Propofol	0-8	interleukin 6	Mus musculus	91-95
24371447-5	2013	Results showed that propofol attenuated LPS-induced TNF-alpha and IL-6 expression.	Propofol	20-28	interleukin 6	Mus musculus	66-70
24371447-8	2013	We conclude that propofol modulates LPS signaling in macrophages by reducing NOX-mediated production of TNF-alpha and IL-6.	Propofol	17-25	interleukin 6	Mus musculus	118-122
24371447-8	2013	We conclude that propofol modulates LPS signaling in macrophages by reducing NOX-mediated production of TNF-alpha and IL-6.	nicotine 1-N-oxide	77-80	interleukin 6	Mus musculus	118-122
23026294-7	2013	Septic mice that were pretreated with the selective NF-kappaB inhibitor pyrrolidine dithiocarbamate (PDTC) were found to have a decreased liberation of proinflammtory cytokines such as TNF-alpha, IL-1beta, IL-6, or IFN-gamma.	pyrrolidine dithiocarbamic acid	101-105	interleukin 6	Mus musculus	206-210
24023581-9	2013	Reduction of NF- kappa B activation resulted in the attenuation of the expression of IL-6, TGF beta , and RAGE which protected PA-treated mice against DN.	proanthocyanidin	127-129	interleukin 6	Mus musculus	85-89
24223056-5	2013	Preliminary mechanistic studies demonstrated that CISCFE decreased the MDA level via increasing the activities of anti-oxidant enzymes (SOD, GPx, and GRd), attenuated the productions of NF- kappa B, TNF- alpha , IL-1 beta , IL-6, PGE2 and NO, and suppressed the activities of iNOS and COX-2.	ciscfe	50-56	interleukin 6	Mus musculus	224-228
23840259-9	2013	In addition, NG enhanced nitric oxide (NO) synthesis and secretions of cytokines including IL-6 and TNF- alpha .	Nitroglycerin	13-15	interleukin 6	Mus musculus	91-95
24348728-5	2013	Furthermore, the flavonoids decreased production of inflammatory mediators such as inducible nitric oxide synthase, cyclooxygenase-2, interleukin-6, and tumor necrosis factor-alpha and inhibited phosphorylation of nuclear factor-kappa B (NF- kappa B) and mitogen-activated protein kinases (MAPKs) in LPS-induced RAW 264.7 cells.	Flavonoids	17-27	interleukin 6	Mus musculus	134-147
23401705-5	2013	Next we found that EECP could significantly inhibit the production of NO, IL-1beta, and IL-6 in lipopolysaccharide- (LPS-) stimulated RAW 264.7 cells and suppress mRNA expression of iNOS, IL-1beta, and IL-6 in a time- and dose-dependent manner.	eecp	19-23	interleukin 6	Mus musculus	88-92
23401705-5	2013	Next we found that EECP could significantly inhibit the production of NO, IL-1beta, and IL-6 in lipopolysaccharide- (LPS-) stimulated RAW 264.7 cells and suppress mRNA expression of iNOS, IL-1beta, and IL-6 in a time- and dose-dependent manner.	eecp	19-23	interleukin 6	Mus musculus	202-206
23256797-6	2013	RESULTS: UA markedly rescued lethality, improved survival time and lung pathological changes, inhibited TNF-alpha, IL-6, IL-1beta, HMGB1 and NO, and increased IL-10 expression.	ursolic acid	9-11	interleukin 6	Mus musculus	115-119
24324516-4	2013	Here, we report that 7,3",4"-trihydroxyisoflavone (7,3",4"-THIF), a major metabolite of daidzin, effectively inhibited lipopolysaccharide (LPS)-induced nitric oxide (NO), tumor necrosis factor (TNF)- alpha , and interleukin (IL)-6 production in RAW 264.7 cells, and also reduced beta -hexosaminidase secretion in RBL-2H3 cells.	3',4',7-trihydroxyisoflavone	21-49	interleukin 6	Mus musculus	212-230
24324516-4	2013	Here, we report that 7,3",4"-trihydroxyisoflavone (7,3",4"-THIF), a major metabolite of daidzin, effectively inhibited lipopolysaccharide (LPS)-induced nitric oxide (NO), tumor necrosis factor (TNF)- alpha , and interleukin (IL)-6 production in RAW 264.7 cells, and also reduced beta -hexosaminidase secretion in RBL-2H3 cells.	daidzin	88-95	interleukin 6	Mus musculus	212-230
23481064-9	2013	The production of interleukin (IL)-6 and tumour necrosis factor (TNF)-alpha were inhibited by SoSoSo or chrysophanol.	sososo	94-100	interleukin 6	Mus musculus	18-36
23090956-5	2013	Mice treated with LPS alone showed markedly increased plasma levels of tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6, whereas mice that were also treated with GXM showed significantly lower plasma levels of these cytokines.	glucuronoxylomannan	193-196	interleukin 6	Mus musculus	146-150
23481064-9	2013	The production of interleukin (IL)-6 and tumour necrosis factor (TNF)-alpha were inhibited by SoSoSo or chrysophanol.	chrysophanic acid	104-116	interleukin 6	Mus musculus	18-36
23481064-11	2013	SoSoSo or chrysophanol inhibited the productions of IL-6, TNF-alpha, and monocyte chemoattractant protein-1 as well as the reduction of adiponectin production in CM-treated 3T3-L1 cells.	sososo	0-6	interleukin 6	Mus musculus	52-56
23481064-11	2013	SoSoSo or chrysophanol inhibited the productions of IL-6, TNF-alpha, and monocyte chemoattractant protein-1 as well as the reduction of adiponectin production in CM-treated 3T3-L1 cells.	chrysophanic acid	10-22	interleukin 6	Mus musculus	52-56
23159605-11	2013	DHFO inhibited lipopolysaccharide (LPS)-induced pro-inflammatory mediator release (ROS, NO, IL-6 levels) and COX2 expression in RAW264.7 murine macrophages.	6b,11b-dihydroxy-6b,11b-dihydro-7H-indeno(1,2-b)naphtho(2,1-d)furan-7-one	0-4	interleukin 6	Mus musculus	92-96
23610522-10	2013	In addition, the PTX-NPs markedly inhibited interleukin-6 secretion, increased caspase-8, caspase-9, and caspase-3 expression, and induced apoptosis of tumor cells in the treated mice.	ptx	17-20	interleukin 6	Mus musculus	44-57
22915087-5	2013	Salidroside administered 1 h before LPS infusion significantly attenuated inflammatory cell infiltration, reduced the activity of myeloperoxidase in mammary tissue, and decreased the concentration of tumor necrosis factor-alpha, interleukin (IL)-1beta, and IL-6 in a dose-dependent manner.	rhodioloside	0-11	interleukin 6	Mus musculus	257-261
23175106-10	2013	In both studies, ascorbate supplementation of gulo KO mice resulted             in profoundly decreased serum inflammatory cytokine interleukin (IL)-6 (99% decrease,             p=0.01 in the B16F0 study and 85% decrease, p=0.08 in the 4T1 study) compared             to the levels in gulo KO mice deprived of ascorbate.	Ascorbic Acid	17-26	interleukin 6	Mus musculus	132-150
24250585-6	2013	It was shown that oxymatrine inhibited the productions of NO, PGE2, TNF-alpha, IL-1beta and IL-6, attenuated the mRNA levels of iNOS and COX-2, suppressed the phosphorylation of I-kappaBalpha in cytosol, decreased the nuclear levels of p65, and also blocked ERK, p38 and JNK pathway in LPS-stimulated BV2 microglial cells in a dose-dependent manner.	oxymatrine	18-28	interleukin 6	Mus musculus	92-96
24846906-7	2013	RESULTS: STZ resulted in a significant decrease in all tested enzymes and glutathione levels, and an increase in IL-6 level in comparison to control animals (p &lt; 0.05).	Streptozocin	9-12	interleukin 6	Mus musculus	113-117
24846906-9	2013	Concurrent administration of STZ and vitamins caused a significant increase (compared to the diabetes group) in SOD, CAT, GPx, GSH content, and a decrease in IL-6 levels (p &lt; 0.05).	Streptozocin	29-32	interleukin 6	Mus musculus	158-162
23099324-5	2013	GW3965 was able to repress proinflammatory cytokine (TNF-alpha, IL-1beta, IL-6, and IL-12p40) expression in BMMs exposed to LPS alone; however, once BMMs entered the osteoclast lineage following RANKL priming, GW3965 no longer inhibited cytokine expression.	GW 3965	0-6	interleukin 6	Mus musculus	74-78
23139430-4	2013	Moreover, fenretinide attenuated interleukin (IL)-1beta, IL-6, and cyclooxygenase-2 mRNA expression induced by A. actinomycetemcomitans.	Fenretinide	10-21	interleukin 6	Mus musculus	57-61
23139430-5	2013	Fenretinide also decreased IL-1beta, IL-6, and prostaglandin E2 proinflammatory cytokine levels in Raw 264.7 cells induced by A. actinomycetemcomitans.	Fenretinide	0-11	interleukin 6	Mus musculus	37-41
23257732-7	2013	Interestingly, IL-6 mRNA expression dramatically increased in TH+CFA+BP-induced EAO; however, no apparent change in IL-6 mRNA expression occurred in TH-induced EAO.	Benzo(a)pyrene	69-71	interleukin 6	Mus musculus	15-19
23225885-9	2013	CVT-6883 and genetic deletion of A(2B)AR significantly reduced adenosine-mediated IL-6 production.	Adenosine	63-72	interleukin 6	Mus musculus	82-86
22907189-9	2013	Treatment with paclitaxel reduced IL-6 transcript levels in the spinal cord but did not alter the transcript levels of other cytokines or chemokines in the brain, spinal cord or spleen.	Paclitaxel	15-25	interleukin 6	Mus musculus	34-38
23370667-6	2013	CD-101 significantly inhibited the production of inflammatory markers such as nitric oxide, cyclooxygenase-2, and pro-inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6.	CD-101	0-6	interleukin 6	Mus musculus	201-214
22907189-10	2013	The coadministration of COL-3 with paclitaxel significantly increased the transcript levels of IL-6 in the spleen and decreased CX3CL1 transcripts in the brain in comparison to treatment with paclitaxel alone.	Paclitaxel	35-45	interleukin 6	Mus musculus	95-99
23533300-9	2013	However, while the anti-inflammatory effects of dexamethasone treatment were due to the reduced activation of NF- kappa B and AP-1, the ellagic acid treatment led to reduced BALF levels of IL-6 and increased levels of IL-10.	Ellagic Acid	136-148	interleukin 6	Mus musculus	189-193
23710113-3	2013	ISO dramatically attenuated ZY-induced lung neutrophil recruitment and inflammation, as evidenced by the reduced levels of total cells, neutrophils, and proinflammatory cytokines (i.e., tumor necrosis factor- alpha , interleukin- (IL-) 1 beta , IL-6, and macrophage inflammatory protein-2) in bronchoalveolar lavage fluid and of their mRNA expression in lung tissues.	Zymosan	28-30	interleukin 6	Mus musculus	245-249
23781123-0	2013	Biphasic modulation of NOS expression, protein and nitrite products by hydroxocobalamin underlies its protective effect in endotoxemic shock: downstream regulation of COX-2, IL-1beta, TNF-alpha, IL-6, and HMGB1 expression.	Hydroxocobalamin	71-87	interleukin 6	Mus musculus	195-199
24453420-9	2013	Furthermore, ethyl pyruvate inhibited the HMGB1/TLR4/ NF-kappab axis and the release of cytokines (TNF-alpha and IL-6).	ethyl pyruvate	13-27	interleukin 6	Mus musculus	113-117
23237655-4	2013	RESULTS: Under the proliferation conditions, insulin plus palmitic acid promoted a significant increase in the release of interleukin-6, keratinocyte-derived chemokine (KC)/chemokine ligand-1 (CXCL-1), monocyte chemotactic protein-1 (MCP-1), and regulated and normal T cells expressed and presumably secreted (RANTES) by 3T3-L1 preadipocytes.	Palmitic Acid	58-71	interleukin 6	Mus musculus	122-135
23028093-2	2013	Of 51 genes expressed in the Toll-like receptor (TLR) and RIG-I-like receptor (RLR) pathways, mRNA expression of 15 genes in RAW264.7 cells was attenuated by nicotine, of which mRNA expression of IL-6, TNF-alpha, and IL-1beta was confirmed to be attenuated in peritoneal macrophages.	Nicotine	158-166	interleukin 6	Mus musculus	196-200
23028093-3	2013	Concurrently, nicotine treatment attenuated the release of IL-6 and TNF-alpha from poly(I:C)-stimulated macrophages.	Nicotine	14-22	interleukin 6	Mus musculus	59-63
23028093-3	2013	Concurrently, nicotine treatment attenuated the release of IL-6 and TNF-alpha from poly(I:C)-stimulated macrophages.	Poly I-C	83-92	interleukin 6	Mus musculus	59-63
23028093-4	2013	However, when poly(I:C)-stimulated macrophages were challenged with nicotine plus alpha-bungarotoxin (alpha-BTX), secretion of IL-6 and TNF-alpha was found to be in a level seen with poly(I:C) stimulation only, indicating that alpha7-nAChR, a highly Ca(2+) permeable ion channel sensitive to blockade by alpha-BTX, is involved in this process.	Poly I-C	14-23	interleukin 6	Mus musculus	127-131
23028093-4	2013	However, when poly(I:C)-stimulated macrophages were challenged with nicotine plus alpha-bungarotoxin (alpha-BTX), secretion of IL-6 and TNF-alpha was found to be in a level seen with poly(I:C) stimulation only, indicating that alpha7-nAChR, a highly Ca(2+) permeable ion channel sensitive to blockade by alpha-BTX, is involved in this process.	Nicotine	68-76	interleukin 6	Mus musculus	127-131
23028093-4	2013	However, when poly(I:C)-stimulated macrophages were challenged with nicotine plus alpha-bungarotoxin (alpha-BTX), secretion of IL-6 and TNF-alpha was found to be in a level seen with poly(I:C) stimulation only, indicating that alpha7-nAChR, a highly Ca(2+) permeable ion channel sensitive to blockade by alpha-BTX, is involved in this process.	Poly I-C	14-22	interleukin 6	Mus musculus	127-131
22850623-5	2013	RESULTS: Cannabidiol or O-1602 treatment significantly improved the pathological changes of mice with AP and decreased the enzyme activities, IL-6 and tumor necrosis factor alpha; levels, and the myeloperoxidase activities in plasma and in the organ tissues.	Cannabidiol	9-20	interleukin 6	Mus musculus	142-178
22850623-5	2013	RESULTS: Cannabidiol or O-1602 treatment significantly improved the pathological changes of mice with AP and decreased the enzyme activities, IL-6 and tumor necrosis factor alpha; levels, and the myeloperoxidase activities in plasma and in the organ tissues.	mk-1602	24-30	interleukin 6	Mus musculus	142-178
23577207-5	2013	METHODS: To model DILI, we immunized BALB/c, BALB/cBy, IL-6-deficient, and castrated BALB/c mice with trifluoroacetyl chloride-haptenated liver proteins.	trifluoroacetyl chloride	102-126	interleukin 6	Mus musculus	55-59
24175013-4	2013	Herein, the IL-6-induced stress proteins including C-reactive protein (CRP), complement 3 (C3), immunoglobulin M (IgM), and prostaglandin E2 (PGE2) were evaluated after skin injuries given following a mixed radiation environment that might be found after a nuclear incident.	Dinoprostone	142-146	interleukin 6	Mus musculus	12-16
23555869-7	2013	Interestingly, compared with the placebo treatment, the administration of nicaraven significantly decreased the levels of the inflammatory cytokines IL-6 and TNF-alpha in the plasma of mice.	nicaraven	74-83	interleukin 6	Mus musculus	149-153
23565150-4	2013	Furthermore, nano-TiO2 exposure resulted in marked increases of insulin-like growth factor-binding protein 2, epidermal growth factor, tumor necrosis factor-alpha, tissue plasminogen activator, interleukin-1beta, interleukin -6, Fas, and FasL expression, and significant decreases of insulin-like growth factor-1, luteinizing hormone receptor, inhibin alpha, and growth differentiation factor 9 expression in mouse ovary.	titanium dioxide	18-22	interleukin 6	Mus musculus	213-227
23469154-12	2013	A reduction in TNFalpha and IL-6 mRNA levels in the fat were observed from 1 h to 72 h post AuNP injection, with no observable changes in macrophage number.	aunp	92-96	interleukin 6	Mus musculus	28-32
23478252-10	2013	Compared to placebo, coinfected mice treated with linezolid, vancomycin or clindamycin had decreased pulmonary IL-6 and mKC at 4 hours and IFN-gamma at 24 hours after MRSA coinfection (all P&lt;0.05).	Linezolid	50-59	interleukin 6	Mus musculus	111-115
23472193-6	2013	Acetylcorynoline significantly inhibited the secretion of tumor necrosis factor-alpha, interleukin-6, and interleukin-12p70 by LPS-stimulated DCs.	acetylcorynoline	0-16	interleukin 6	Mus musculus	87-100
23478252-10	2013	Compared to placebo, coinfected mice treated with linezolid, vancomycin or clindamycin had decreased pulmonary IL-6 and mKC at 4 hours and IFN-gamma at 24 hours after MRSA coinfection (all P&lt;0.05).	Vancomycin	61-71	interleukin 6	Mus musculus	111-115
23478252-10	2013	Compared to placebo, coinfected mice treated with linezolid, vancomycin or clindamycin had decreased pulmonary IL-6 and mKC at 4 hours and IFN-gamma at 24 hours after MRSA coinfection (all P&lt;0.05).	Clindamycin	75-86	interleukin 6	Mus musculus	111-115
23418608-5	2013	In isolated mouse pancreatic acinar cells, TNF-alpha stimulation increased IL-33 release while IL-33 stimulation increased proinflammatory cytokine release, both involving the ERK MAP kinase pathway; the flavonoid luteolin inhibited IL-33-stimulated IL-6 and CCL2/MCP-1 release.	Flavonoids	204-213	interleukin 6	Mus musculus	250-254
23469098-5	2013	For this, ATP/P2Y1 receptor-mediated mechanisms were required because the IL-6 production was (i) inhibited by a P2Y1 receptor antagonist, MRS2179, (ii) abolished in astrocytes obtained from P2Y1 receptor-knockout mice, and (iii) mimicked by exogenously applied ATP.	Adenosine Triphosphate	10-13	interleukin 6	Mus musculus	74-78
23469098-10	2013	Taken together, when astrocytes sense MeHg, they release ATP that autostimulates P2Y1 receptors to upregulate IL-6, thereby leading to A1 receptor-mediated neuro-protection against MeHg.	Adenosine Triphosphate	57-60	interleukin 6	Mus musculus	110-114
23437352-5	2013	Moreover, salidroside decreased the production of intracellular reactive oxygen species (ROS), and osteoclast differentiation inducing factors such as receptor activator of nuclear factor-kB ligand (RANKL) and IL-6 induced by H(2)O(2).	rhodioloside	10-21	interleukin 6	Mus musculus	210-214
23437361-7	2013	The expression of IL-6, IL-10, IFNgamma, and MCP-1, key chemokines/cytokines implicated in the development of ALI/ARDS, from both the inflammatory infiltrate and whole lung tissue were modulated by curcumin potentially through a reduction in the phosphorylated form of NFkappaB p65.	Curcumin	198-206	interleukin 6	Mus musculus	18-22
23853581-2	2013	Utilizing in vitro neutrophil killing assays and a model of fungal infection of the cornea, we demonstrated that Dectin-1 dependent IL-6 production regulates expression of iron chelators, heme and siderophore binding proteins and hepcidin in infected mice.	Iron	172-176	interleukin 6	Mus musculus	132-136
23382968-3	2013	In the present study, the expressions of mRNAs that encode inflammatory cytokines, TNF-alpha, IL-1beta, IL-6, Il-17A and IL-22, were significantly increased throughout the entire colon of mice that exhibited diarrhea following 5-FU administration.	Fluorouracil	227-231	interleukin 6	Mus musculus	104-108
23104071-8	2012	This extract also induced a decrease in TNF levels and an increase of IL-6, IFN-gamma and NO levels that we observed up to 2h.	Deuterium	123-125	interleukin 6	Mus musculus	70-74
23258328-8	2012	The contents of TNF-alpha, IL-1beta and IL-6 in culture supernatant were all increased by LPS (100 ng/mL), whereas reduced by 40 ng/mL TSA pretreatment (P &lt; 0.05).	trichostatin A	135-138	interleukin 6	Mus musculus	40-44
23323011-11	2012	The expression of interleukin-1alpha (IL-1alpha), IL-2, IL-6, and tumor necrosis factor-alpha (TNF-alpha) was significantly higher in the ADM + APS (50 mg/kg), ADM + APS (100 mg/kg) and ADM + APS (200 mg/kg) groups than in the ADM group; and IL-10 was significantly lower in the above groups than in the ADM group.	Doxorubicin	138-141	interleukin 6	Mus musculus	56-60
23069580-7	2012	Tianeptine, olanzapine and fluoxetine decreased the enhanced levels of plasma ACTH and IL-6.	tianeptine	0-10	interleukin 6	Mus musculus	87-91
22980794-4	2012	The results showed that Pu-erh tea significantly increased the fractions of naive T lymphocytes, CD8(+)CD28(+) T lymphocytes and NK cells in the peripheral blood, but decreased the levels of IL-6 in aged mice.	pu-erh	24-30	interleukin 6	Mus musculus	191-195
23069580-7	2012	Tianeptine, olanzapine and fluoxetine decreased the enhanced levels of plasma ACTH and IL-6.	Olanzapine	12-22	interleukin 6	Mus musculus	87-91
23069580-7	2012	Tianeptine, olanzapine and fluoxetine decreased the enhanced levels of plasma ACTH and IL-6.	Fluoxetine	27-37	interleukin 6	Mus musculus	87-91
23212570-5	2012	RESULTS:                DGLHT inhibited LPS-induced production of NO, PGE(2), and IL-6 productions and the expressions of iNOS and COX-2.	dglht	24-29	interleukin 6	Mus musculus	82-86
23044226-3	2012	The goal of this study was to further evaluate the anti-inflammatory activity of oleocanthal in murine macrophages J774 and murine chondrocytes ATDC5 with a particular focus on the inhibition of gene expression of pro-inflammatory factors such as MIP-1alpha and IL-6.	oleocanthal	81-92	interleukin 6	Mus musculus	262-266
23212570-7	2012	CONCLUSIONS:                DGLHT has inhibitory effects on the LPSinduced production of PGE(2), NO, and IL-6 and on the expressions of iNOS and COX-2 in murine macrophages.	dglht	28-33	interleukin 6	Mus musculus	105-109
23236235-6	2012	The data indicated that the mRNA levels of IL-6 and TNF-alpha significantly increased within 12 h after CCl4 treatment in baicalein administration groups, but at 24, 48 and 72 h, the expression of IL-6 and TNF-alpha was kept at lower levels compared with the control.	baicalein	122-131	interleukin 6	Mus musculus	43-47
23236235-6	2012	The data indicated that the mRNA levels of IL-6 and TNF-alpha significantly increased within 12 h after CCl4 treatment in baicalein administration groups, but at 24, 48 and 72 h, the expression of IL-6 and TNF-alpha was kept at lower levels compared with the control.	baicalein	122-131	interleukin 6	Mus musculus	197-201
23236235-7	2012	The expression of TGF-alpha, HGF and EGF was enhanced dramatically in baicalein administration group at 12, 24, 48 and 72 h. Furthermore, we found that baicalein significantly elevated the serum level of TNF-alpha and IL-6 at the early phase, which indicated that baicalein could facilitate the initiating events in liver regeneration.	baicalein	70-79	interleukin 6	Mus musculus	218-222
23236235-7	2012	The expression of TGF-alpha, HGF and EGF was enhanced dramatically in baicalein administration group at 12, 24, 48 and 72 h. Furthermore, we found that baicalein significantly elevated the serum level of TNF-alpha and IL-6 at the early phase, which indicated that baicalein could facilitate the initiating events in liver regeneration.	baicalein	152-161	interleukin 6	Mus musculus	218-222
23236235-7	2012	The expression of TGF-alpha, HGF and EGF was enhanced dramatically in baicalein administration group at 12, 24, 48 and 72 h. Furthermore, we found that baicalein significantly elevated the serum level of TNF-alpha and IL-6 at the early phase, which indicated that baicalein could facilitate the initiating events in liver regeneration.	baicalein	152-161	interleukin 6	Mus musculus	218-222
23236235-9	2012	Baicalein accelerates liver regeneration by regulating TNF-alpha and IL-6 mediated pathways.	baicalein	0-9	interleukin 6	Mus musculus	69-73
23212583-7	2012	Further, administration of fluoxetine to mice with endogenous overexpression of brain IL-6 (MRL/MpJ-Fas(LPR/LPR) (LPR mice)) failed to produce the expected antidepressant-like effect relative to fluoxetine-treated control mice (MRL/MpJ(+/+)).	Fluoxetine	27-37	interleukin 6	Mus musculus	86-90
22885069-4	2012	Knockdown of TMEM126A also blocked the down-regulation of IL-1beta and IL-6 expressions induced by CD137L in thioglycollate-elicited primary peritoneal macrophages.	Thioglycolates	109-123	interleukin 6	Mus musculus	71-75
23174390-9	2012	Alcohol treatment resulted in detectable levels and significant increases in IL-6 (median, 15.7; range, 10.1-45.9 pg/mL) and KC (median, 45.9; range, 32.5-99.1 pg/mL).	Alcohols	0-7	interleukin 6	Mus musculus	77-81
23174390-15	2012	CONCLUSION: Prenatal alcohol exposure acutely results in a significant elevation of IL-6, G-CSF and the KC, which are known to affect N-methyl-D-aspartate receptors.	Alcohols	21-28	interleukin 6	Mus musculus	84-88
23042820-9	2012	Eicosapentaenoic acid alone or with LPS blunted LPS-mediated stimulation of macrophage proinflammatory interleukin-6, interleukin-12p40, and toll-like receptor-4 mRNA and increased anti-inflammatory interleukin-10 and mannose receptor mRNA.	Eicosapentaenoic Acid	0-21	interleukin 6	Mus musculus	103-116
23027617-7	2012	BCAA supplementation also reduced both the amount of hepatic triglyceride accumulation and the expression of interleukin (IL)-6, IL-1beta, IL-18 and tumor necrosis factor-alpha mRNA in the liver.	Amino Acids, Branched-Chain	0-4	interleukin 6	Mus musculus	109-127
22971573-8	2012	We also observed an inhibitory effect of garcinol on IL-6-induced STAT-3 phosphorylation and production of urokinase-type plasminogen activator, vascular endothelial growth factor and matrix metalloproteinase-9, which might explain the reduced invasion and aggressiveness of cells treated with garcinol.	garcinol	41-49	interleukin 6	Mus musculus	53-57
22971573-8	2012	We also observed an inhibitory effect of garcinol on IL-6-induced STAT-3 phosphorylation and production of urokinase-type plasminogen activator, vascular endothelial growth factor and matrix metalloproteinase-9, which might explain the reduced invasion and aggressiveness of cells treated with garcinol.	garcinol	294-302	interleukin 6	Mus musculus	53-57
23027617-8	2012	Increased macrophage infiltration was inhibited and the expression of IL-6, TNF-alpha, and monocyte chemoattractant protein-1 mRNA in the white adipose tissue were each decreased by BCAA supplementation.	Amino Acids, Branched-Chain	182-186	interleukin 6	Mus musculus	70-74
23399843-4	2012	The inhibitory effects of veratric acid on the generation of interleukin-6 (IL-6) and interferon-gamma (IFN-gamma) was determined.	veratric acid	26-39	interleukin 6	Mus musculus	61-74
23117929-6	2012	Inhibition of autophagy by 3-methylalanine in human and mouse adipose tissue explants led to a significant increase in IL-1beta, IL-6, and IL-8 mRNA expression and protein secretion.	3-toluidine	27-42	interleukin 6	Mus musculus	129-133
23399843-4	2012	The inhibitory effects of veratric acid on the generation of interleukin-6 (IL-6) and interferon-gamma (IFN-gamma) was determined.	veratric acid	26-39	interleukin 6	Mus musculus	76-80
22782595-4	2012	In addition, heparin also inhibited the release of tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6) and IL-1beta in serum and decreased the expression of p-p38, nuclear factor kappaB (NF-kappaB) and p-c-SRC kinase in lungs of septic mice.	Heparin	13-20	interleukin 6	Mus musculus	86-99
22987503-4	2012	Here, we report that ATP enhanced murine IEC production of KC, IL-6, TGF-beta, and thymic stromal lymphopoietin in response to TLR1/2 stimulation by Pam(3) CSK(4)  (PAM).	Adenosine Triphosphate	21-24	interleukin 6	Mus musculus	63-67
22987503-5	2012	Moreover, supernatants from IECs stimulated with ATP+PAM enhanced expression of CD80 on bone marrow derived dendritic cells, and increased their production of IL-12, IL-6, IL-23, TGF-beta, and aldh1a2, suggesting a Th1/Th17 polarizing environment.	atp+pam	49-56	interleukin 6	Mus musculus	166-170
22987503-7	2012	Lastly, colonic administration of nonhydrolysable ATP increased production of IL-6 and Cxcl1 (KC) by IECs.	Adenosine Triphosphate	50-53	interleukin 6	Mus musculus	78-82
22712758-9	2012	Neutrophil migration and cytokine release (TNF-alpha, IL-1beta and IL-6) induced by zymosan and fluid leakage induced by acetic acid were also reduced in BS-treated animals.	Zymosan	84-91	interleukin 6	Mus musculus	67-71
22782595-4	2012	In addition, heparin also inhibited the release of tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6) and IL-1beta in serum and decreased the expression of p-p38, nuclear factor kappaB (NF-kappaB) and p-c-SRC kinase in lungs of septic mice.	Heparin	13-20	interleukin 6	Mus musculus	101-105
23036579-5	2012	Andrographolide sulfonate also remarkably reduced the expression levels of TNF-alpha, IL-1beta, IL-6 and inducible nitric oxide synthase in the injured liver from septic mice.	andrographolide sulfonate	0-25	interleukin 6	Mus musculus	96-100
22878137-6	2012	The results showed that geniposide markedly inhibited the LPS-induced TNF-alpha, IL-6 and IL-1beta production both in vitro and in vivo.	geniposide	24-34	interleukin 6	Mus musculus	81-85
23044435-8	2012	RESULTS: We found that mice with chronic CS exposure showed significant increase in lung Th17 prevalence, retinoic acid orphan receptor (ROR)-gammat mRNA and Th17-related cytokines (IL-17A, IL-6 and IL-23).	Cesium	41-43	interleukin 6	Mus musculus	190-194
23102661-5	2012	LcFC induced the production of cytokines such as IL-10, IL-12, IL-6 and TNF-alpha from murine bone marrow DCs (BMDCs) via MyD88-dependent pathway.	lcfc	0-4	interleukin 6	Mus musculus	63-67
23064268-0	2012	AMP-activated protein kinase inhibitor decreases prostaglandin F2alpha-stimulated             interleukin-6 synthesis through p38 MAP kinase in osteoblasts.	Dinoprost	49-70	interleukin 6	Mus musculus	94-107
23064268-1	2012	We previously showed that prostaglandin F(2alpha) (PGF(2alpha)) stimulates the synthesis of interleukin-6 (IL-6), a potent bone resorptive agent, in part via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase but not stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) among the MAP kinase superfamily in osteoblast-like MC3T3-E1 cells.	Prostaglandins F	26-41	interleukin 6	Mus musculus	92-105
23064268-1	2012	We previously showed that prostaglandin F(2alpha) (PGF(2alpha)) stimulates the synthesis of interleukin-6 (IL-6), a potent bone resorptive agent, in part via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase but not stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) among the MAP kinase superfamily in osteoblast-like MC3T3-E1 cells.	Prostaglandins F	26-41	interleukin 6	Mus musculus	107-111
23064268-1	2012	We previously showed that prostaglandin F(2alpha) (PGF(2alpha)) stimulates the synthesis of interleukin-6 (IL-6), a potent bone resorptive agent, in part via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase but not stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) among the MAP kinase superfamily in osteoblast-like MC3T3-E1 cells.	Prostaglandins F	51-54	interleukin 6	Mus musculus	92-105
23064268-1	2012	We previously showed that prostaglandin F(2alpha) (PGF(2alpha)) stimulates the synthesis of interleukin-6 (IL-6), a potent bone resorptive agent, in part via p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase but not stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) among the MAP kinase superfamily in osteoblast-like MC3T3-E1 cells.	Prostaglandins F	51-54	interleukin 6	Mus musculus	107-111
23064268-2	2012	In the present study, we investigated the involvement of AMP-activated protein kinase (AMPK), an intracellular energy sensor, in PGF(2alpha)-stimulated IL-6 synthesis in MC3T3-E1 cells.	Prostaglandins F	129-132	interleukin 6	Mus musculus	152-156
23064268-4	2012	Compound C, an inhibitor of AMPK, dose-dependently suppressed PGF(2alpha)-stimulated IL-6 release.	Prostaglandins F	62-65	interleukin 6	Mus musculus	85-89
23064268-6	2012	In addition, PGF(2alpha)-stimulated IL-6 release in human osteoblasts was also inhibited by compound C. The IL-6 mRNA expression induced by PGF(2alpha) was markedly reduced by compound C. Downregulation of the AMPK alpha1-subunit by short interfering RNA (siRNA) significantly suppressed the PGF(2alpha)-stimulated IL-6 release.	Prostaglandins F	13-16	interleukin 6	Mus musculus	108-112
23064268-6	2012	In addition, PGF(2alpha)-stimulated IL-6 release in human osteoblasts was also inhibited by compound C. The IL-6 mRNA expression induced by PGF(2alpha) was markedly reduced by compound C. Downregulation of the AMPK alpha1-subunit by short interfering RNA (siRNA) significantly suppressed the PGF(2alpha)-stimulated IL-6 release.	Prostaglandins F	13-16	interleukin 6	Mus musculus	108-112
23064268-6	2012	In addition, PGF(2alpha)-stimulated IL-6 release in human osteoblasts was also inhibited by compound C. The IL-6 mRNA expression induced by PGF(2alpha) was markedly reduced by compound C. Downregulation of the AMPK alpha1-subunit by short interfering RNA (siRNA) significantly suppressed the PGF(2alpha)-stimulated IL-6 release.	Prostaglandins F	140-143	interleukin 6	Mus musculus	108-112
23064268-6	2012	In addition, PGF(2alpha)-stimulated IL-6 release in human osteoblasts was also inhibited by compound C. The IL-6 mRNA expression induced by PGF(2alpha) was markedly reduced by compound C. Downregulation of the AMPK alpha1-subunit by short interfering RNA (siRNA) significantly suppressed the PGF(2alpha)-stimulated IL-6 release.	Prostaglandins F	140-143	interleukin 6	Mus musculus	108-112
23064268-6	2012	In addition, PGF(2alpha)-stimulated IL-6 release in human osteoblasts was also inhibited by compound C. The IL-6 mRNA expression induced by PGF(2alpha) was markedly reduced by compound C. Downregulation of the AMPK alpha1-subunit by short interfering RNA (siRNA) significantly suppressed the PGF(2alpha)-stimulated IL-6 release.	Prostaglandins F	140-143	interleukin 6	Mus musculus	108-112
23064268-6	2012	In addition, PGF(2alpha)-stimulated IL-6 release in human osteoblasts was also inhibited by compound C. The IL-6 mRNA expression induced by PGF(2alpha) was markedly reduced by compound C. Downregulation of the AMPK alpha1-subunit by short interfering RNA (siRNA) significantly suppressed the PGF(2alpha)-stimulated IL-6 release.	Prostaglandins F	140-143	interleukin 6	Mus musculus	108-112
23064268-8	2012	These results strongly suggest that AMPK regulates PGF(2alpha)-stimulated IL-6 synthesis via p38 MAP kinase in osteoblasts.	Prostaglandins F	51-54	interleukin 6	Mus musculus	74-78
23232789-5	2012	In peritoneal macrophages obtained from these mice, eplerenone reduced messenger RNA expression of pro-inflammatory markers, interleukin 6, tumor necrosis factor alpha, monocyte chemotactic protein 1, and increased anti-inflammatory marker arginase 1 to a greater extent in early compared with advanced ATS.	Eplerenone	52-62	interleukin 6	Mus musculus	125-167
23019345-6	2012	O(3) exposure induced significantly less pulmonary inflammation in PrxI(-/-) than in WT mice judging from the reduced infiltrations of neutrophils into the lung and the suppressed production of proinflammatory mediators, such as interleukin-6 and keratinocyte chemoattractant in the bronchoalveolar lavage fluids.	Ozone	0-4	interleukin 6	Mus musculus	229-242
23017059-8	2012	The conditioned medium of 3T3-L1 adipose phenotype significantly stimulated production of IL-6 and IL-12 in J774.1 cells treated with LGG and TMC0356.	tmc0356	142-149	interleukin 6	Mus musculus	90-94
23230342-6	2012	We also observed a significant increase in production of pro-inflammatory cytokines, IL-6 and IFN-gamma, in spleen lymphocytes treated with DSS; however, such an increase was not observed in infected mice treated with DSS.	Dextran Sulfate	140-143	interleukin 6	Mus musculus	85-89
22939219-5	2012	CS Ti decreased the macrophage adherence and up-regulated the release of several pro-inflammatory mediators, including TNF-alpha, IL-6, IL-12.	calcium silicate	0-2	interleukin 6	Mus musculus	130-134
23053946-5	2012	In the ALI group, a rapid cDCs accumulation in the lung was observed, and there were highly significant correlations between the frequency of respiratory cDCs or the percentage of cDC expressing CD80 and the IL-6 concentration.	Chenodeoxycholate 3-sulphate	26-30	interleukin 6	Mus musculus	208-212
23053946-5	2012	In the ALI group, a rapid cDCs accumulation in the lung was observed, and there were highly significant correlations between the frequency of respiratory cDCs or the percentage of cDC expressing CD80 and the IL-6 concentration.	Chenodeoxycholate 3-sulphate	154-158	interleukin 6	Mus musculus	208-212
22772723-3	2012	In vivo, MPTP intoxication is accompanied by a strong microglia response which is characterised by the release of inflammatory molecules such as tumour necrosis factor alpha (TNF-alpha) and interleukin-6 (IL6) that are believed to further drive inflammation-mediated degeneration of mDA neurons.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	9-13	interleukin 6	Mus musculus	190-203
22772723-3	2012	In vivo, MPTP intoxication is accompanied by a strong microglia response which is characterised by the release of inflammatory molecules such as tumour necrosis factor alpha (TNF-alpha) and interleukin-6 (IL6) that are believed to further drive inflammation-mediated degeneration of mDA neurons.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	9-13	interleukin 6	Mus musculus	205-208
23176085-7	2012	Significantly higher levels of IL-6 and lower levels of IL-10 were detected at 4 weeks following 7,12-Dimethylbenz(a)anthracene (DMBA) treatment.	7,12-dimethylbenz(a	97-116	interleukin 6	Mus musculus	31-35
23176085-7	2012	Significantly higher levels of IL-6 and lower levels of IL-10 were detected at 4 weeks following 7,12-Dimethylbenz(a)anthracene (DMBA) treatment.	anthracene	117-127	interleukin 6	Mus musculus	31-35
23190711-10	2012	By converting inactive 11-dehydrocorticosterone to active corticosterone, 11beta-HSD1 essentially modulates the coordinated action of GR and MR. Biphasic effects were observed for 11-dehydrocorticosterone and corticosterone, with an MR-dependent potentiation of IL-6 and tumor necrosis factor-alpha (TNF-alpha) expression and NF-kappaB activation at low/moderate concentrations and a GR-dependent suppression at high concentrations.	11-dehydrocorticosterone	23-47	interleukin 6	Mus musculus	262-266
23176085-7	2012	Significantly higher levels of IL-6 and lower levels of IL-10 were detected at 4 weeks following 7,12-Dimethylbenz(a)anthracene (DMBA) treatment.	9,10-Dimethyl-1,2-benzanthracene	129-133	interleukin 6	Mus musculus	31-35
23190711-10	2012	By converting inactive 11-dehydrocorticosterone to active corticosterone, 11beta-HSD1 essentially modulates the coordinated action of GR and MR. Biphasic effects were observed for 11-dehydrocorticosterone and corticosterone, with an MR-dependent potentiation of IL-6 and tumor necrosis factor-alpha (TNF-alpha) expression and NF-kappaB activation at low/moderate concentrations and a GR-dependent suppression at high concentrations.	11-dehydrocorticosterone	180-204	interleukin 6	Mus musculus	262-266
23070238-4	2012	PEG@AuNPs enhanced LPS-induced production of NO and IL-6 and inducible nitric oxide synthase (iNOS) expression in RAW264.7 cells, partially by activating p38 mitogen-activated protein kinases (p38 MAPK) and nuclear factor-kappaB pathways.	Polyethylene Glycols	0-3	interleukin 6	Mus musculus	52-56
23190711-10	2012	By converting inactive 11-dehydrocorticosterone to active corticosterone, 11beta-HSD1 essentially modulates the coordinated action of GR and MR. Biphasic effects were observed for 11-dehydrocorticosterone and corticosterone, with an MR-dependent potentiation of IL-6 and tumor necrosis factor-alpha (TNF-alpha) expression and NF-kappaB activation at low/moderate concentrations and a GR-dependent suppression at high concentrations.	Corticosterone	58-72	interleukin 6	Mus musculus	262-266
22940439-9	2012	P50 gene deletion in ApoE-p50-DKO mice significantly augmented CIH-induced serum levels of tumor necrosis factor-alpha and IL-6, aortic tumor necrosis factor-alpha, and inducible nitric oxide synthase expression and aortic infiltration of Mac3-positive macrophages.	cih	63-66	interleukin 6	Mus musculus	123-163
23027866-4	2012	Recently, it was reported that the antioxidant N-acetylcysteine (NAC) decreased DMXAA-induced TNF-alpha and IL-6, suggesting that oxidative stress may play a role.	Acetylcysteine	47-63	interleukin 6	Mus musculus	108-112
23027866-4	2012	Recently, it was reported that the antioxidant N-acetylcysteine (NAC) decreased DMXAA-induced TNF-alpha and IL-6, suggesting that oxidative stress may play a role.	Acetylcysteine	65-68	interleukin 6	Mus musculus	108-112
23027866-4	2012	Recently, it was reported that the antioxidant N-acetylcysteine (NAC) decreased DMXAA-induced TNF-alpha and IL-6, suggesting that oxidative stress may play a role.	vadimezan	80-85	interleukin 6	Mus musculus	108-112
23140643-3	2012	The decreased CES3 expression was accomplished by TCDD-stimulated TGFbeta-SMAD3 and IL6-STAT3 signaling, but not by direct AhR signaling.	Polychlorinated Dibenzodioxins	50-54	interleukin 6	Mus musculus	84-87
22822029-8	2012	First, macrophage depletion by clodronate liposomes resulted in significant reductions in airway neutrophil influx and TNF-alpha and IL-6 production after a single exposure to DE.	Clodronic Acid	31-41	interleukin 6	Mus musculus	133-137
23140827-11	2012	The combination of pressure and ethanol further reduced TNF-alpha, IL-6, and MCP-1 secretion by LPS-stimulated microglial cells.	Ethanol	32-39	interleukin 6	Mus musculus	67-71
22986104-3	2012	TPA induced the expression of critical events of tumorigenesis like ornithine decarboxylase, cyclooxygenase-2, interleukin-6 and pSTAT3 in mouse skin after 5h of application, whereas expression of transglutaminase2 was decreased at this time point.	Tetradecanoylphorbol Acetate	0-3	interleukin 6	Mus musculus	111-124
22994384-4	2012	Fasudil inhibited TLR-4, p-NF-kB/p65, and inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) and enhanced IL-10 production in spinal cords.	fasudil	0-7	interleukin 6	Mus musculus	76-80
22523382-2	2012	We investigated the acute and the long-term beneficial effects of IL-6 on exercise-induced glucose uptake in skeletal muscle and insulin sensitivity.	Glucose	91-98	interleukin 6	Mus musculus	66-70
22901832-9	2012	Thalidomide treatment also significantly decreased plasma levels of nitric oxide and pancreatic proinflammatory cytokines [tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-12, IL-17 and interferon (IFN)-gamma)] while increased anti-inflammatory cytokine IL-10.	Thalidomide	0-11	interleukin 6	Mus musculus	182-186
22523382-6	2012	The glucose uptake rate in the extensor digitorum longus muscle was, however, lower in IL-6(-/-) compared with wild-type mice (398 +- 44 versus 657 +- 41 nmol g(-1) min(-1), P &lt; 0.01).	Glucose	4-11	interleukin 6	Mus musculus	87-91
22523382-11	2012	The IL-6(-/-) mice with access to running wheels had a similar decrease in insulin sensitivity to their sedentary littermates (glucose area under the concentration-time curve during an insulin tolerance test in runners versus sedentary IL-6(-/-) HFD mice, 312 +- 14 versus 340 +- 22 mmol min l(-1), P = 0.4) and displayed a 14% increase in serum RBP-4 compared with baseline levels (P &lt; 0.01).	Glucose	127-134	interleukin 6	Mus musculus	4-8
22678775-3	2012	Through measurement with Griess reagent, dioscoreanone was found to reduce NO levels with an IC(50) value of 2.50 +- 0.64 microM, due to the significant suppression of LPS-induced iNOS mRNA expression, as well as IL-1beta and IL-6 levels at a concentration of 6 microM.	dioscoreanone	41-54	interleukin 6	Mus musculus	226-230
22939937-8	2012	RESULTS: BisGMA augmented the generation of IL-1beta, IL-6, nitric oxide and the expression of iNOS in a time- and dose-dependent manner (p&lt;0.05).	Bisphenol A-Glycidyl Methacrylate	9-15	interleukin 6	Mus musculus	54-58
22374925-9	2012	Serum LRG levels were increased in IL-6-deficient mice with LPS-mediated acute inflammation and DSS-induced colitis.	dss	96-99	interleukin 6	Mus musculus	35-39
22910223-5	2012	RESULTS: LPS-induced acute lung injury (ALI) was significantly improved by atropine (a non-selective mAChR antagonist) and 4-DAMP (a M3 mAChR antagonist), as indicated by the diminution of neutrophil infiltration, pulmonary vascular permeability and IL-6 and TNF-alpha production.	Atropine	75-83	interleukin 6	Mus musculus	250-254
22910223-5	2012	RESULTS: LPS-induced acute lung injury (ALI) was significantly improved by atropine (a non-selective mAChR antagonist) and 4-DAMP (a M3 mAChR antagonist), as indicated by the diminution of neutrophil infiltration, pulmonary vascular permeability and IL-6 and TNF-alpha production.	4-diphenylacetoxy-1,1-dimethylpiperidinium	123-129	interleukin 6	Mus musculus	250-254
22917708-3	2012	MLB-C inhibited the production of nitric oxide (NO), prostaglandin E(2) (PGE(2)), interleukin-6 (IL-6), and interferon-gamma (INF-gamma) in a dose-dependent manner.	malabaricone C	0-5	interleukin 6	Mus musculus	82-95
22917708-3	2012	MLB-C inhibited the production of nitric oxide (NO), prostaglandin E(2) (PGE(2)), interleukin-6 (IL-6), and interferon-gamma (INF-gamma) in a dose-dependent manner.	malabaricone C	0-5	interleukin 6	Mus musculus	97-101
22678775-7	2012	In conclusion, the mechanisms of dioscoreanone on the inhibition of NO production and mRNA expression of iNOS, IL-1beta, and IL-6 were due to both the inhibition of NF-kappaB activation and the activation of ERK1/2 proteins.	dioscoreanone	33-46	interleukin 6	Mus musculus	125-129
22537289-5	2012	As expected, melatonin inhibited TLR4-mediated tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-1beta, IL-6, IL-8, and IL-10 in LPS-stimulated macrophages.	Melatonin	13-22	interleukin 6	Mus musculus	112-116
23044165-7	2012	RESULTS: The Arg-Gln and DHA prevented the development of key markers of injury, including histologic changes, myeloperoxidase, lactate dehydrogenase, and inflammatory cytokines interleukin-6 and C-X-C motif ligand 1 (CXCL1)/keratinocyte-derived chemokine (KC).	arginyl-glutamine	13-20	interleukin 6	Mus musculus	178-191
22869926-7	2012	In oxLDL-stimulated macrophages, quercetin inhibited reactive oxygen species production and interleukin (IL)-6 secretion.	Quercetin	33-42	interleukin 6	Mus musculus	92-110
22522886-9	2012	ob/ob mice displayed elevated serum TNF-alpha and IL-6 levels, fat composition and glucose intolerance, the effects of which except glucose intolerance and fat composition were attenuated by lenalidomide.	Lenalidomide	191-203	interleukin 6	Mus musculus	50-54
23044165-7	2012	RESULTS: The Arg-Gln and DHA prevented the development of key markers of injury, including histologic changes, myeloperoxidase, lactate dehydrogenase, and inflammatory cytokines interleukin-6 and C-X-C motif ligand 1 (CXCL1)/keratinocyte-derived chemokine (KC).	Docosahexaenoic Acids	25-28	interleukin 6	Mus musculus	178-191
22956516-5	2012	While cAMP induced significant increases in the expression of important ovulatory response genes including amphiregulin (Areg), epiregulin (Ereg), betacellulin (Btc), or interleukin 6 (Il6), IGF1 alone had no effect.	Cyclic AMP	6-10	interleukin 6	Mus musculus	170-183
22389249-7	2012	A highly suppressive effect was expressed by nigroside VI on IL-6 and NO production and by forsythoside B on TNF-alpha production.	nigroside vi	45-57	interleukin 6	Mus musculus	61-65
22971898-14	2012	Nitidine chloride inhibits LPS-induced TNF alpha, IL-1beta and IL-6 production via the suppression of phosphorylation of MAPK and the translocation of p65.	nitidine	0-17	interleukin 6	Mus musculus	63-67
22982349-11	2012	Furthermore, alpha-pinene pretreatment reduced the production of pancreatic tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 during cerulein-induced AP.	alpha-pinene	13-25	interleukin 6	Mus musculus	139-143
22912384-10	2012	Hcy sequentially stimulated adventitial fibroblasts transformation into myofibroblasts, secretion of interleukin-6 and monocyte chemoattractant protein-1, and consequent recruitment of monocytes/macrophages to adventitial fibroblasts, which was abolished by the NADPH oxidase inhibitor diphenyliodonium.	Homocysteine	0-3	interleukin 6	Mus musculus	101-114
23022181-3	2012	alpha-Iso-cubebenol also significantly attenuates widespread immune cell apoptosis in a mouse CLP sepsis model, and inhibits the production of proinflammatory cytokines including interleukin-1beta (IL-1beta) and IL-6 in CLP mice and lipopolysaccharide-stimulated splenocytes.	alpha-iso-cubebenol	0-19	interleukin 6	Mus musculus	212-216
22956516-5	2012	While cAMP induced significant increases in the expression of important ovulatory response genes including amphiregulin (Areg), epiregulin (Ereg), betacellulin (Btc), or interleukin 6 (Il6), IGF1 alone had no effect.	Cyclic AMP	6-10	interleukin 6	Mus musculus	185-188
22956516-6	2012	However, co-treatment of cells with IGF1 and cAMP had a synergistic effect on Areg, Ereg, Btc, and Il6 mRNA abundance.	Cyclic AMP	45-49	interleukin 6	Mus musculus	99-102
22956516-7	2012	Pretreatment of granulosa cells with the MEK1/2 inhibitor U0126 demonstrated that cAMP-dependent increases in Areg, Ereg, Btc, and Il6 were mediated by extracellular regulated kinase 1/2 phosphorylation.	U 0126	58-63	interleukin 6	Mus musculus	131-134
22956516-7	2012	Pretreatment of granulosa cells with the MEK1/2 inhibitor U0126 demonstrated that cAMP-dependent increases in Areg, Ereg, Btc, and Il6 were mediated by extracellular regulated kinase 1/2 phosphorylation.	Cyclic AMP	82-86	interleukin 6	Mus musculus	131-134
23078640-6	2012	Conditioned media thereof, free of fatty acids, were then tested for their ability to activate RAW264.7 macrophages.Palmitate -but not palmitoleate- induced IL-6, TNFalpha and CCL2 expression in muscle cells, through activation of the NF-kappaB pathway.	Palmitates	116-125	interleukin 6	Mus musculus	157-161
22902631-6	2012	One of the quinazolinone derivatives showed significant anti-inflammatory activity in stimulated macrophage cells by inhibiting the expression of TNF-alpha, IL-1beta, IL-6, iNOS, COX-2, p-IkappaB and NF-kappaBp65.	Quinazolinones	11-24	interleukin 6	Mus musculus	167-171
22983393-12	2012	Moreover, Poly I:C significantly suppressed the pro-inflammatory cytokines TNFalpha and IL-6 production.	Poly I-C	10-18	interleukin 6	Mus musculus	88-92
22968190-7	2012	Melanin also reduced the oxidative stress in hepatic tissue and abrogated immune imbalance by reducing the production of pro-inflammatory cytokines (IL6 and TNFalpha).	Melanins	0-7	interleukin 6	Mus musculus	149-152
22983393-13	2012	In mice subjected to MCAO, administration of Poly I:C significantly attenuated the neurological deficits, reduced infarction volume, and suppressed the increased levels of TNFalpha and IL-6 in the ischemic striatum and cortex.	Poly I	45-52	interleukin 6	Mus musculus	185-189
22958289-13	2012	Lestaurtinib administration also suppressed lung MPO activity, T-bet/GATA-3 mRNA ratio and production of IL-6 and IFN-gamma.	lestaurtinib	0-12	interleukin 6	Mus musculus	105-109
22684115-4	2012	The enhanced expression of MHC II and CD40 on DCs after incubation with amphiphilic polyanhydride particles, and the increased secretion of IL-6, TNF-alpha, and IL-12p40 by hydrophobic polyanhydride particles exemplified the chemistry-dependent activation of DCs by sham-coated particles.	Polyanhydrides	185-198	interleukin 6	Mus musculus	140-144
22796167-6	2012	Graphene significantly stimulates the secretion of Th1/Th2 cytokines including IL-1alpha, IL-6, IL-10, TNF-alpha and GM-CSF as well as chemokines such as MCP-1, MIP-1alpha, MIP-1beta and RANTES, probably by activating TLR-mediated and NF-kappaB-dependent transcription.	Graphite	0-8	interleukin 6	Mus musculus	90-94
22909341-6	2012	We further show that RSVA405 interfered with the inflammatory response by RAW 264.7 cells upon lipopolysaccharide stimulation by inhibiting IkappaB kinase and IkappaBalpha phosphorylation and by decreasing the expression of several cytokines, including the NF-kappaB target genes tumor necrosis factor alpha and interleukin-6.	RSVA405	21-28	interleukin 6	Mus musculus	312-325
22841997-8	2012	In addition to anxiety-like behavior the SDR induced splenomegaly and increase in plasma IL-6, TNFalpha, and MCP-1 were each reversed by pre-treatment with propranolol.	Propranolol	156-167	interleukin 6	Mus musculus	89-93
22841997-10	2012	In addition, supernatants from 18h LPS-stimulated ex vivo cultures of splenocytes from propranolol-treated SDR mice contained less IL-6.	Propranolol	87-98	interleukin 6	Mus musculus	131-135
23044308-10	2012	Pretreatment of WJ-MSCs with H2O2 increased the secretion of interleukin-6 (IL-6) into the cell culture supernatant by approximately 25-fold.	Hydrogen Peroxide	29-33	interleukin 6	Mus musculus	61-74
23044308-10	2012	Pretreatment of WJ-MSCs with H2O2 increased the secretion of interleukin-6 (IL-6) into the cell culture supernatant by approximately 25-fold.	Hydrogen Peroxide	29-33	interleukin 6	Mus musculus	76-80
23044308-11	2012	The culture supernatant from WJ-MSCs-H2O2 significantly increased the migration and proliferation of endothelial cells; these effects could be blocked using an anti-IL-6 antibody.	Hydrogen Peroxide	37-41	interleukin 6	Mus musculus	165-169
23044308-12	2012	CONCLUSIONS: This study demonstrates that H2O2 preconditioning significantly enhanced the therapeutic potential of WJ-MSCs, possibly by stimulating the production of IL-6 by WJ-MSCs, which may cause migration and proliferation of endothelial cells and increase neovascularization.	Hydrogen Peroxide	42-46	interleukin 6	Mus musculus	166-170
22644339-7	2012	The results showed that stevioside dose-dependently inhibited the expression of tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta in LPS-stimulated RAW264.7 cells.	stevioside	24-34	interleukin 6	Mus musculus	109-122
22777957-7	2012	Dexamethasone treatment enhanced the expression and secretion of SAA1 and SAA3 in sciatic nerve explants cultures, suggesting that interleukin-6 and corticosteroids might be major regulators for SAA production in Schwann cells following injury.	Dexamethasone	0-13	interleukin 6	Mus musculus	131-144
22669487-4	2012	The results show that three types of SCFAs (acetate, propionate, and butyrate) reduced the production of proinflammatory factors, including TNF-alpha, IL-1beta, IL-6, and NO, and inhibited the vitality of iNOS.	Acetates	44-51	interleukin 6	Mus musculus	161-165
22669487-4	2012	The results show that three types of SCFAs (acetate, propionate, and butyrate) reduced the production of proinflammatory factors, including TNF-alpha, IL-1beta, IL-6, and NO, and inhibited the vitality of iNOS.	Propionates	53-63	interleukin 6	Mus musculus	161-165
22699806-9	2012	(PhSe)(2) partially protected against the increase in TNF-alpha, IL-1beta, IL-6 and INF-gamma levels induced by carrageenan.	Carrageenan	112-123	interleukin 6	Mus musculus	75-79
22669487-4	2012	The results show that three types of SCFAs (acetate, propionate, and butyrate) reduced the production of proinflammatory factors, including TNF-alpha, IL-1beta, IL-6, and NO, and inhibited the vitality of iNOS.	Butyrates	69-77	interleukin 6	Mus musculus	161-165
23214260-5	2012	S. aureus infected mice exhibited higher synovial TNF-alpha and IL-6, which was also reduced by ampicillin and riboflavin treatment.	Ampicillin	96-106	interleukin 6	Mus musculus	64-68
23214260-5	2012	S. aureus infected mice exhibited higher synovial TNF-alpha and IL-6, which was also reduced by ampicillin and riboflavin treatment.	Riboflavin	111-121	interleukin 6	Mus musculus	64-68
22641092-9	2012	Nilotinib lowered intrahepatic expression of IL-1beta, IL-6, MCP-1, and MIP-2 and systemic levels of IL-6, MCP-1, and TNF.	nilotinib	0-9	interleukin 6	Mus musculus	55-59
22641092-9	2012	Nilotinib lowered intrahepatic expression of IL-1beta, IL-6, MCP-1, and MIP-2 and systemic levels of IL-6, MCP-1, and TNF.	nilotinib	0-9	interleukin 6	Mus musculus	101-105
22943182-6	2012	RESULTS: In primary microglial and BV2 cells, berberine treatment significantly inhibited Abeta-stimulated production of interleukin-6 and monocyte chemotactic protein-1.	Berberine	46-55	interleukin 6	Mus musculus	121-134
22837198-5	2012	In SJL/J and RAW264.7 macrophages, exogenous IL-6 resulted in decreased TMEV replication, earlier activation of STAT1 and STAT3, production of nitric oxide, and earlier upregulation of several antiviral genes downstream of STAT1.	Nitric Oxide	143-155	interleukin 6	Mus musculus	45-49
22837198-9	2012	In contrast, exogenous IL-6 enhances macrophage control of TMEV infection through preemptive antiviral nitric oxide production and antiviral STAT1 activation.	Nitric Oxide	103-115	interleukin 6	Mus musculus	23-27
22766077-2	2012	We have previously shown, with 18 different macrolide molecules, that IL-6 and PGE2 inhibition correlates with macrolide accumulation, as well as with their binding to phospholipids in J774A.1 cells.	Macrolides	44-53	interleukin 6	Mus musculus	70-74
22969062-6	2012	Inhibition of JAK (STAT1/STAT5 kinase) with AG490 markedly reduced the production of IL-6 and TNF-alpha in macrophages.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	44-49	interleukin 6	Mus musculus	85-89
23031399-6	2012	Incision after saline or escalating morphine treatment upregulated skin IL-1beta, IL-6, G-CSF and MIP-1alpha levels in ppt-A(-/-) and wt mice similarly.	Sodium Chloride	15-21	interleukin 6	Mus musculus	82-86
23031399-6	2012	Incision after saline or escalating morphine treatment upregulated skin IL-1beta, IL-6, G-CSF and MIP-1alpha levels in ppt-A(-/-) and wt mice similarly.	Morphine	36-44	interleukin 6	Mus musculus	82-86
22764777-10	2012	Accumulation of glucosylceramide was associated with a delay in liver regeneration and reduced serum levels of IL-6 and TNF-alpha.	Glucosylceramides	16-32	interleukin 6	Mus musculus	111-115
23018345-1	2012	BACKGROUND: The aim of this study was to investigate whether the 3 different substances that can decrease the development of atherosclerosis--nebivolol, AVE 0991 and doxycycline--could at the same time diminish the level of inflammatory indicators interleukin-6 (IL-6), interleukin-12 (IL-12), serum amyloid A (SAA), and monocyte chemotactic protein-1 (MCP-1).	Doxycycline	166-177	interleukin 6	Mus musculus	248-261
23018345-1	2012	BACKGROUND: The aim of this study was to investigate whether the 3 different substances that can decrease the development of atherosclerosis--nebivolol, AVE 0991 and doxycycline--could at the same time diminish the level of inflammatory indicators interleukin-6 (IL-6), interleukin-12 (IL-12), serum amyloid A (SAA), and monocyte chemotactic protein-1 (MCP-1).	Doxycycline	166-177	interleukin 6	Mus musculus	263-267
23018345-6	2012	There was also a tendency to lower MCP-1, IL-6, IL-12 and SAA levels by nebivolol and doxycycline; however, it did not reach statistical significance.	Nebivolol	72-81	interleukin 6	Mus musculus	42-46
22763802-5	2012	Phenelzine increased the lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS), as well as the release of TNF-alpha and IL-6 in BV-2 microglia cells.	Phenelzine	0-10	interleukin 6	Mus musculus	152-156
22763802-6	2012	It is also confirmed that phenelzine increased the levels of NO, TNF-alpha and IL-6 in LPS-activated primary microglia cells.	Phenelzine	26-36	interleukin 6	Mus musculus	79-83
22766077-2	2012	We have previously shown, with 18 different macrolide molecules, that IL-6 and PGE2 inhibition correlates with macrolide accumulation, as well as with their binding to phospholipids in J774A.1 cells.	Macrolides	111-120	interleukin 6	Mus musculus	70-74
22766077-2	2012	We have previously shown, with 18 different macrolide molecules, that IL-6 and PGE2 inhibition correlates with macrolide accumulation, as well as with their binding to phospholipids in J774A.1 cells.	Phospholipids	168-181	interleukin 6	Mus musculus	70-74
22766077-6	2012	Further comparison revealed that in LPS-stimulated J774A.1 cells, the cPLA2 inhibitor showed the same profile of inhibition as azithromycin in inhibiting PGE2, IL-6, IL-12p40 and arachidonic acid release.	Azithromycin	127-139	interleukin 6	Mus musculus	160-164
22940134-3	2012	alpha-Iso-cubebene also significantly attenuated lung inflammation and widespread immune cell apoptosis in a mouse CLP sepsis model, and inhibited the production of proinflammatory cytokines including tumor necrosis factor-alpha, interleukin (IL)-1beta, and IL-6 in CLP mice and lipopolysaccharide-stimulated splenocytes.	alpha-iso-cubebene	0-18	interleukin 6	Mus musculus	258-262
22790598-7	2012	Elevated morphological damage, ileal IL-1beta and IL-6 levels, and bacterial translocation were seen in mice exposed to ethanol and burn injury relative to either insult alone.	Ethanol	120-127	interleukin 6	Mus musculus	50-54
23001459-13	2012	CQCQD may inhibit IL-6 induction and increase IL-10 concentration and HSP70 expression, effectively reducing lung injury.	cqcqd	0-5	interleukin 6	Mus musculus	18-22
22992408-7	2012	Treatment with anti-CXCR3 plus Primaxin 24 hours prior to CLP attenuated hypothermia and IL-6 and macrophage inflammatory protein 2 (MIP-2) production but did not alter bacterial clearance.	Cilastatin, Imipenem Drug Combination	31-39	interleukin 6	Mus musculus	89-93
23107715-4	2012	Pretreated with 10 muM phloretin significantly inhibited the levels of NO, PGE(2), IL-6, TNF-alpha, iNOS and COX-2.	Phloretin	23-32	interleukin 6	Mus musculus	83-87
22820172-5	2012	KEY FINDING: Concurrent use of cilostazol and MTX effectively suppressed proliferation and cell viability associated with enhanced apoptosis of synovial fibroblasts and significantly suppressed cytokine production, including TNF-alpha, IL-1beta, IL-6, and MCP-1 in an additive manner.	Cilostazol	31-41	interleukin 6	Mus musculus	246-250
22820172-5	2012	KEY FINDING: Concurrent use of cilostazol and MTX effectively suppressed proliferation and cell viability associated with enhanced apoptosis of synovial fibroblasts and significantly suppressed cytokine production, including TNF-alpha, IL-1beta, IL-6, and MCP-1 in an additive manner.	Methotrexate	46-49	interleukin 6	Mus musculus	246-250
22904305-5	2012	In a second model of IL-1beta-driven inflammation, NLRP3 activation by monosodium urate crystals similarly increased IL-6.	Uric Acid	71-87	interleukin 6	Mus musculus	117-121
22904308-4	2012	We show in this paper that, Ruxolitinib, a recently described selective inhibitor of JAKs, increases TNF, IL-6, and IL-12 secretion in mouse bone marrow-derived macrophages stimulated with LPS.	ruxolitinib	28-39	interleukin 6	Mus musculus	106-110
22917537-4	2012	Resveratrol inhibited LPS-induced production of nitric oxide (NO); the cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin 1-beta (IL-1beta), and IL-6; and the chemokine monocyte chemotactic protein-1 (MCP-1), which play critical roles in innate immunity, by astrocytes.	Resveratrol	0-11	interleukin 6	Mus musculus	157-161
24049652-3	2012	Biopsies, incubated with UCA derivatives, produced lower levels of proinflammatory cytokines IL-6 and IL-8 as compared to control biopsies.	Urocanic Acid	25-28	interleukin 6	Mus musculus	93-97
22594431-4	2012	LTbetaRIg treatment decreased PD-L1 expression by blood endothelial cells, and decreased VCAM-1 while increasing CXCL1, CXCL2, CXCL12, CCL5, CCL21 and IL-6 expression in fibroblastic reticular cells.	ltbetarig	0-9	interleukin 6	Mus musculus	151-155
22939729-6	2012	RESULTS: Pravastatin reduced interleukin (IL)-1beta and IL-6 mRNA expression in the uterus and cervix, respectively, and serum IL-1beta and granulocyte-macrophage colony-stimulating factor (GM-CSF) concentrations.	Pravastatin	9-20	interleukin 6	Mus musculus	56-60
22939729-7	2012	Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF.	Simvastatin	0-11	interleukin 6	Mus musculus	33-37
22939729-7	2012	Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF.	Simvastatin	0-11	interleukin 6	Mus musculus	70-74
22939729-7	2012	Simvastatin reduced IL-1beta and IL-6 mRNA expressions in the uterus, IL-6 and tumor necrosis factor alpha (TNF-alpha) in the cervix, and IL-1beta, IL-2, IL-12p70, IL-13, TNF-alpha, GM-CSF, and interferon-gamma concentrations in the serum and IL-6 in AF.	Simvastatin	0-11	interleukin 6	Mus musculus	70-74
22684844-3	2012	We examined bleomycin-induced inflammation and fibrosis in mice carrying a mutation in the shared IL-6 family receptor gp130.	Bleomycin	12-21	interleukin 6	Mus musculus	98-102
22687552-3	2012	PCP increased the production of nitric oxide (NO) and the gene expression of IL-1beta, IL-6, and TNF-alpha in RAW 264.7 cells.	pcp	0-3	interleukin 6	Mus musculus	87-91
22728094-7	2012	Ar-turmerone also reduced TNF-alpha, IL-1beta, IL-6, and MCP-1 production in Abeta-stimulated microglial cells.	ar-turmerone	0-12	interleukin 6	Mus musculus	47-51
22706987-7	2012	The authors found that animal exposure to RR-PM caused polymorphonuclear cell lung infiltration, augmentation of O2(-), increase of proinflammatory cytokines (tumor necrosis factor alpha [TNFalpha], interleukin-6 [IL-6]) and apoptosis.	rr-pm	42-47	interleukin 6	Mus musculus	199-212
22706987-7	2012	The authors found that animal exposure to RR-PM caused polymorphonuclear cell lung infiltration, augmentation of O2(-), increase of proinflammatory cytokines (tumor necrosis factor alpha [TNFalpha], interleukin-6 [IL-6]) and apoptosis.	rr-pm	42-47	interleukin 6	Mus musculus	214-218
22713932-3	2012	We found that in vitro pretreatment with pinocembrin remarkably regulated the production of TNF-alpha, IL-1beta, IL-6 and IL-10 via inhibiting the phosphorylation of IkappaBalpha, ERK1/2, JNK and p38MAPK.	pinocembrin	41-52	interleukin 6	Mus musculus	113-117
22761278-0	2012	Physiological concentrations of interleukin-6 directly promote insulin secretion, signal transduction, nitric oxide release, and redox status in a clonal pancreatic beta-cell line and mouse islets.	Nitric Oxide	103-115	interleukin 6	Mus musculus	32-45
22761278-5	2012	IL6 enhanced both glutathione (GSH) and glutathione disulphide (GSSG) by nearly 20% without changing intracellular redox status (GSSG/GSH).	Glutathione	18-29	interleukin 6	Mus musculus	0-3
22761278-5	2012	IL6 enhanced both glutathione (GSH) and glutathione disulphide (GSSG) by nearly 20% without changing intracellular redox status (GSSG/GSH).	Glutathione	31-34	interleukin 6	Mus musculus	0-3
22761278-5	2012	IL6 enhanced both glutathione (GSH) and glutathione disulphide (GSSG) by nearly 20% without changing intracellular redox status (GSSG/GSH).	Glutathione Disulfide	40-62	interleukin 6	Mus musculus	0-3
22761278-5	2012	IL6 enhanced both glutathione (GSH) and glutathione disulphide (GSSG) by nearly 20% without changing intracellular redox status (GSSG/GSH).	Glutathione Disulfide	64-68	interleukin 6	Mus musculus	0-3
22137267-0	2012	The acai flavonoid velutin is a potent anti-inflammatory agent: blockade of LPS-mediated TNF-alpha and IL-6 production through inhibiting NF-kappaB activation and MAPK pathway.	acai flavonoid	4-18	interleukin 6	Mus musculus	103-107
22137267-5	2012	Velutin exhibited the greatest potency among all flavones in reducing TNF-alpha and IL-6 production.	Flavones	49-57	interleukin 6	Mus musculus	84-88
22760541-5	2012	More importantly, B(GMME3) inhibit the reactivation of encephalomyelitis (EAE)-derived or TGFbeta/IL6 differentiated Th17 cells by altering their polarization toward a Th1 or Th2 phenotype.	gmme3	20-25	interleukin 6	Mus musculus	98-101
22228081-10	2012	In addition, Tri-DAP and MDP synergized with TLR agonists to induce the production of IL-8/KC or IL-6 in PC3 and TRAMP-C2 cells.	Acetylmuramyl-Alanyl-Isoglutamine	25-28	interleukin 6	Mus musculus	97-101
23105977-7	2012	Intranasal rapamycin attenuated lung MCP-1, IL-2, IL-6, and IFNgamma by 70%, 30%, 64%, and 68% respectively.	Sirolimus	11-20	interleukin 6	Mus musculus	50-54
22275284-1	2012	Since propolis and phenolic compounds, such as cinnamic and coumaric acids, have several biological properties, their immunomodulatory effect on cytokine production (IL-1beta, IL-6 and IL-10) was investigated.	Coumaric Acids	60-74	interleukin 6	Mus musculus	176-180
22275284-3	2012	Propolis and the acids stimulated IL-1beta production, while IL-6 production was significantly inhibited after incubation with propolis (5, 50 and 100 microg/well), coumaric and cinnamic acids (50 and 100 microg/well).	coumaric	165-173	interleukin 6	Mus musculus	61-65
22275284-3	2012	Propolis and the acids stimulated IL-1beta production, while IL-6 production was significantly inhibited after incubation with propolis (5, 50 and 100 microg/well), coumaric and cinnamic acids (50 and 100 microg/well).	cinnamic acid	178-192	interleukin 6	Mus musculus	61-65
22275284-4	2012	In LPS-challenge protocols, inhibitory concentrations of cinnamic and coumaric acids after LPS incubation prevented efficiently its effects on IL-6 production, whereas propolis inhibited LPS effects both before and after its addition.	Coumaric Acids	70-84	interleukin 6	Mus musculus	143-147
22542583-3	2012	The results obtained showed that paeonol significantly suppressed LPS induced release of pro-inflammatory products such as nitric oxide (NO), prostaglandin E2 (PGE(2)), and cytokines; tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6).	paeonol	33-40	interleukin 6	Mus musculus	258-271
22542583-3	2012	The results obtained showed that paeonol significantly suppressed LPS induced release of pro-inflammatory products such as nitric oxide (NO), prostaglandin E2 (PGE(2)), and cytokines; tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6).	paeonol	33-40	interleukin 6	Mus musculus	273-277
22980649-2	2012	METHODS: Hyper-IL-6 gene was transfected into mouse HCC cells MM45T.Li using Lipofectamine(TM);2000.	Lipofectamine	77-90	interleukin 6	Mus musculus	15-19
22913271-8	2012	Similarly, 6-week feeding of low-dose resveratrol combined with either leucine or its metabolite HMB to DIO mice increased adipose Sirt1 activity, muscle glucose and palmitate uptake (measured via PET/CT), insulin sensitivity (HOMAIR), improved inflammatory stress biomarkers (CRP, IL-6, MCP-1, adiponectin) and reduced adiposity comparable to the effects of high dose resveratrol, while low-dose resveratrol exerted no independent effect.	Resveratrol	38-49	interleukin 6	Mus musculus	282-286
22980649-2	2012	METHODS: Hyper-IL-6 gene was transfected into mouse HCC cells MM45T.Li using Lipofectamine(TM);2000.	Thulium	91-93	interleukin 6	Mus musculus	15-19
23236763-6	2012	RESULT: Dihydroartemisinin significantly inhibited LPS-induced release of TNF-alpha, IL-6 and NO from RAW264.7 in mice with the concentration range of 12.5 - 100 micromol x L(-1), and showed good dose dependence.	artenimol	8-26	interleukin 6	Mus musculus	85-89
23236763-7	2012	Artemisinin only inhibited the IL-6 release to a certain extent.	artemisinin	0-11	interleukin 6	Mus musculus	31-35
23236763-8	2012	CONCLUSION: Dihydroartemisinin inhibits macrophages from releasing inflammatory factors TNF-alpha and IL-6 and inflammatory mediators NO by down-regulating iNOS protein.	artenimol	12-30	interleukin 6	Mus musculus	102-106
22913271-8	2012	Similarly, 6-week feeding of low-dose resveratrol combined with either leucine or its metabolite HMB to DIO mice increased adipose Sirt1 activity, muscle glucose and palmitate uptake (measured via PET/CT), insulin sensitivity (HOMAIR), improved inflammatory stress biomarkers (CRP, IL-6, MCP-1, adiponectin) and reduced adiposity comparable to the effects of high dose resveratrol, while low-dose resveratrol exerted no independent effect.	Leucine	71-78	interleukin 6	Mus musculus	282-286
22909126-7	2012	However, the clinical symptoms of the DSS-treated APNKO mice were worse than WT mice treated with DSS and had increased susceptibility to intestinal inflammation due to increased local STAT3 activation, higher IL-6, TNF-alpha, IL-1beta and IL-10 levels, and as a result had increased intestinal epithelial cell proliferation (p &lt; 0.05).	dss	38-41	interleukin 6	Mus musculus	210-214
22683874-8	2012	Immunohistochemistry results revealed highly expression of inflammatory markers as MDA, NF-kappaB, TNF-alpha, IL-6, VCAM and ICAM by the hepatic cells of the EtOH group; however no immunoreactivity for any of these cytokines was detected after DEC treatment.	Ethanol	158-162	interleukin 6	Mus musculus	110-114
22683568-7	2012	Finally, although simvastatin (20 mg/kg) conferred significant protection in murine ALI as evidenced by decreased bronchoalveolar lavage fluid cell counts, protein, inflammatory cytokines (IL-6, IL-1beta, MCP-1, RANTES), decreased Evans blue dye albumin extravasation in lung tissue, and changes on lung histology, these effects were reversed by the integrin-beta4-blocking antibody (IV, 1 mg/kg, 2 h before LPS).	Simvastatin	18-29	interleukin 6	Mus musculus	189-193
22718803-1	2012	Maternally derived inflammatory mediators, such as IL-6 and IL-8, contribute to preterm delivery, low birth weight, and respiratory insufficiency, which are routinely treated with oxygen.	Oxygen	180-186	interleukin 6	Mus musculus	51-55
22863554-10	2012	The plasma IL-6 levels were reduced by treatment of ZOL.	Zoledronic Acid	52-55	interleukin 6	Mus musculus	11-15
22476617-8	2012	3T3-L1 cells showed an increase in intracellular Fe with high Fe plus either IL-6 or CoCl(2).	Iron	49-51	interleukin 6	Mus musculus	77-81
22476617-10	2012	3T3-L1 cells incubated with 40 muM Fe alone or Fe/glucose and challenged with IL-6 showed increased NF-kappaB mRNA expression and decreased Mfn-2 expression in all experimental conditions.	Iron	35-37	interleukin 6	Mus musculus	78-82
22428664-5	2012	KEY RESULTS: Morphine enhanced release of the proinflammatory cytokines, IL-1beta, TNF-alpha, IL-6, and of NO via micro-opioid receptor in activated microglial cells.	Morphine	13-21	interleukin 6	Mus musculus	94-98
22660171-7	2012	Limiting autophagy in mice with coadministration of chloroquine (CQ) diminishes serum levels of HMGB1, cytokines (IFNG and IL6 but not IL18), and autophagic flux, attenuating weight gain, enhancing DC, T-cell and NK cell numbers, and promoting long-term tumor control in a murine hepatic metastases model.	Chloroquine	52-63	interleukin 6	Mus musculus	123-126
22660171-7	2012	Limiting autophagy in mice with coadministration of chloroquine (CQ) diminishes serum levels of HMGB1, cytokines (IFNG and IL6 but not IL18), and autophagic flux, attenuating weight gain, enhancing DC, T-cell and NK cell numbers, and promoting long-term tumor control in a murine hepatic metastases model.	Chloroquine	65-67	interleukin 6	Mus musculus	123-126
22560875-8	2012	Wedelolactone, an inhibitor of IkappaB kinase, which reduced the phosphorylation both of IkappaB and NF-kappaB, significantly enhanced the IL-1-stimulated IL-6 synthesis.	wedelolactone	0-13	interleukin 6	Mus musculus	155-159
22560326-5	2012	Our results showed that 15d-PGJ(2) inhibited the phagocytic activity and cell proliferation in a dose-dependent manner, and suppressed proinflammatory cytokines expression, such as tumor necrosis factor-alpha, transforming growth factor-beta1, interleukin-6, and monocyte chemotactic protein-1.	15d-pgj	24-31	interleukin 6	Mus musculus	244-257
22348870-8	2012	RESULTS: Treatment with CT inhibited the manipulation-induced increase in IL-6 in the blood and decrease in GSH in the intestine.	ct	24-26	interleukin 6	Mus musculus	74-78
22348870-9	2012	There was a significant negative correlation between IL-6 in the blood and GSH in the intestine.	Glutathione	75-78	interleukin 6	Mus musculus	53-57
22427154-6	2012	Bzb treatment significantly reduced the expression of TNF-alpha, IL-1beta, IL-6, MCP-1, MIP-1alpha, iNOS, and COX-2 and induced the expression of IL-10 in a time-dependent manner.	Bortezomib	0-3	interleukin 6	Mus musculus	75-79
22434264-5	2012	In the GlcN group, serum tumor necrosis factor-alpha and interleukin (IL)-6 concentrations were significantly decreased compared to the control group.	Glucosamine	7-11	interleukin 6	Mus musculus	57-75
22614766-2	2012	We have previously shown that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) via mitogen-activated protein (MAP) kinases, including p44/p42 MAP kinase, p38 MAP kinase and stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) in osteoblast-like MC3T3-E1 cells.	Dinoprost	30-51	interleukin 6	Mus musculus	138-151
22544439-5	2012	IL-6 production by RAW264.7 cells stimulated with lipopolysaccharide (LPS, TLR4 ligand) was enhanced by high amounts of iron present in the culture medium.	Iron	120-124	interleukin 6	Mus musculus	0-4
22776035-4	2012	In addition, salidroside also inhibited the production of several inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-6 (IL-6) and IL-1beta, and the NF-kappaB DNA-binding activation after LPS challenge.	rhodioloside	13-24	interleukin 6	Mus musculus	129-142
22776035-4	2012	In addition, salidroside also inhibited the production of several inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-6 (IL-6) and IL-1beta, and the NF-kappaB DNA-binding activation after LPS challenge.	rhodioloside	13-24	interleukin 6	Mus musculus	144-148
22726258-9	2012	RESULTS: Oral GlcCer administration significantly suppressed mRNA expression of the pro-inflammatory cytokines IL-1beta and IL-6.	Glucosylceramides	14-20	interleukin 6	Mus musculus	124-128
22432744-8	2012	Atorvastatin dampened the post-ischemic induction of thromboxane B2, macrophage inflammatory protein-1a, monocyte chemotactic protein-1, tumor necrosis factor-alpha, interleukin (IL)-12 p40, gamma-interferon, IL-6, and adhesion molecules (vascular cell adhesion molecule-1, E-selectin, vascular endothelial-cadherin), and reduced macrophage and neutrophil recruitment.	Atorvastatin	0-12	interleukin 6	Mus musculus	209-213
22623023-0	2012	A single bout of exercise increases the expression of glucose but not fatty acid transporters in skeletal muscle of IL-6 KO mice.	Glucose	54-61	interleukin 6	Mus musculus	116-120
22623023-4	2012	In the present study we examined fatty acid (FAT/CD36, FABPpm, FATP-1, FATP-4) as well as glucose (GLUT-1, GLUT-4) transporters expression in IL-6 KO mice.	Fatty Acids	33-43	interleukin 6	Mus musculus	142-146
22623023-4	2012	In the present study we examined fatty acid (FAT/CD36, FABPpm, FATP-1, FATP-4) as well as glucose (GLUT-1, GLUT-4) transporters expression in IL-6 KO mice.	Glucose	90-97	interleukin 6	Mus musculus	142-146
22623023-10	2012	In muscles from IL-6 KO mice exercise induced changes only in glucose (GLUT-1: +20 %; GLUT-4: +35 %) but not in the content of FA transporters.	Glucose	62-69	interleukin 6	Mus musculus	16-20
22623023-11	2012	Concomitantly, IL-6 KO mice displayed shorter time toward exhaustion with more pronounced reductions in intramuscular lipid and glycogen content.	Glycogen	128-136	interleukin 6	Mus musculus	15-19
22614766-2	2012	We have previously shown that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) via mitogen-activated protein (MAP) kinases, including p44/p42 MAP kinase, p38 MAP kinase and stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) in osteoblast-like MC3T3-E1 cells.	Dinoprost	30-51	interleukin 6	Mus musculus	153-157
22614766-2	2012	We have previously shown that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) via mitogen-activated protein (MAP) kinases, including p44/p42 MAP kinase, p38 MAP kinase and stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) in osteoblast-like MC3T3-E1 cells.	Dinoprost	53-62	interleukin 6	Mus musculus	138-151
22614766-2	2012	We have previously shown that prostaglandin F2alpha (PGF2alpha) stimulates the synthesis of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) via mitogen-activated protein (MAP) kinases, including p44/p42 MAP kinase, p38 MAP kinase and stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) in osteoblast-like MC3T3-E1 cells.	Dinoprost	53-62	interleukin 6	Mus musculus	153-157
22294776-12	2012	Compared to sham treatment, one dose (1 and 5 mg/kg body weight) of CsA significantly reduced kidney tubular cell apoptosis, serum creatinine, blood urea, serum IL-6 and urinary NGAL 2 days after FA injection.	Cyclosporine	68-71	interleukin 6	Mus musculus	161-165
22614766-3	2012	In the present study, we investigated the effects of Wnt3a on the synthesis of VEGF or IL-6 stimulated by PGF2alpha in MC3T3-E1 cells using an ELISA kit and various antibodies.	Dinoprost	106-115	interleukin 6	Mus musculus	87-91
22716165-7	2012	Increased TNFalpha and IL-6 mRNA in the IRI livers was significantly attenuated by H2 S treatment, as was hepatic influx of Ly-6G positive granulocytes.	Hydrogen	83-85	interleukin 6	Mus musculus	23-27
22977683-8	2012	After 30 days of radiation, interleukin (IL)-1beta and IL-6 secretion decreased significantly in the radiation-quercetin groups.	Quercetin	111-120	interleukin 6	Mus musculus	55-59
22445859-5	2012	Specifically, treatment with AFB(1) or AFB(2) alone significantly decreased (P&lt;0.01) the secretion of the anti-inflammatory cytokine interleukin (IL) 10 (IL-10), while the secretion of the pro-inflammatory cytokine IL-6 was significantly increased (P&lt;0.01).	Aflatoxin B1	29-35	interleukin 6	Mus musculus	218-222
22445859-5	2012	Specifically, treatment with AFB(1) or AFB(2) alone significantly decreased (P&lt;0.01) the secretion of the anti-inflammatory cytokine interleukin (IL) 10 (IL-10), while the secretion of the pro-inflammatory cytokine IL-6 was significantly increased (P&lt;0.01).	aflatoxin B2	39-45	interleukin 6	Mus musculus	218-222
22721419-9	2012	Each polypodna induced the secretion of tumor necrosis factor-alpha and interleukin-6 from macrophage-like RAW264.7 cells, with the greatest induction by those with hexa- and octapodna.	hexa- and octapodna	165-184	interleukin 6	Mus musculus	72-85
22705712-4	2012	DCA treatment also altered expression of HIF1-alpha and pH regulators: VATPase and MCT1 and production of cytokines: IL-10, IL-6 and IFN-gamma.	Dichloroacetic Acid	0-3	interleukin 6	Mus musculus	124-128
22637477-4	2012	With cultured vascular smooth muscle cell, angiotensin II, arachidonic acid, and TNF-alpha markedly induce increased expression of IL-6 and TNF-alpha mRNAs, all of which were suppressed by inhibiting iPLA(2)beta activity or expression with bromoenol lactone, antisense oligonucleotides, and genetic deletion, respectively.	Arachidonic Acid	59-75	interleukin 6	Mus musculus	131-135
22827934-5	2012	RESULTS: Pulchellin-treated mice showed significant immune system activation, characterized by increased release of IFN-gamma and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-beta levels were decreased.	Pulchellin	9-19	interleukin 6	Mus musculus	168-172
22637477-4	2012	With cultured vascular smooth muscle cell, angiotensin II, arachidonic acid, and TNF-alpha markedly induce increased expression of IL-6 and TNF-alpha mRNAs, all of which were suppressed by inhibiting iPLA(2)beta activity or expression with bromoenol lactone, antisense oligonucleotides, and genetic deletion, respectively.	Oligonucleotides	269-285	interleukin 6	Mus musculus	131-135
22637477-4	2012	With cultured vascular smooth muscle cell, angiotensin II, arachidonic acid, and TNF-alpha markedly induce increased expression of IL-6 and TNF-alpha mRNAs, all of which were suppressed by inhibiting iPLA(2)beta activity or expression with bromoenol lactone, antisense oligonucleotides, and genetic deletion, respectively.	6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one	240-257	interleukin 6	Mus musculus	131-135
22698256-10	2012	Consequently, it appears likely that the beneficial nutritional effects of resveratrol and pterostilbene are due at least in part, to their ability to inhibit NF-kappaB activation by the proteasome, thereby suppressing activation of pro-inflammatory cytokines and iNOS genes, resulting in decreased secretion of TNF-alpha, IL-1beta, IL-6, and NO levels, in response to inflammatory stimuli.	Resveratrol	75-86	interleukin 6	Mus musculus	333-337
22698256-10	2012	Consequently, it appears likely that the beneficial nutritional effects of resveratrol and pterostilbene are due at least in part, to their ability to inhibit NF-kappaB activation by the proteasome, thereby suppressing activation of pro-inflammatory cytokines and iNOS genes, resulting in decreased secretion of TNF-alpha, IL-1beta, IL-6, and NO levels, in response to inflammatory stimuli.	pterostilbene	91-104	interleukin 6	Mus musculus	333-337
22772811-2	2012	In the mouse model of LPS-induced acute lung injury, intraperitoneal preconditioning with p-cymene resulted in a significant reduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6), lung water gain, inflammatory cell infiltration, lung tissue myeloperoxidase activity.	4-cymene	90-98	interleukin 6	Mus musculus	190-194
22645149-8	2012	Epoxyazadiradione prevented the release of proinflammatory cytokines such as IL-1alpha, IL-1beta, IL-6, and TNF-alpha when LPS and PyMIF were co-administered to BALB/c mice.	epoxyazadiradione	0-17	interleukin 6	Mus musculus	98-102
22762146-5	2012	RESULTS: Exposure of BM cells to GM-CSF and IL-6 activated, within 24 h, L-Arg metabolizing enzymes which are responsible for the MDSCs immunosuppressive potential.	Arginine	73-78	interleukin 6	Mus musculus	44-48
22762146-10	2012	Moreover, AMP-activated protein kinase (AMPK) was activated during MDSC maturation in GM-CSF and IL-6-treated cultures, as revealed by the continuous increase of AMP-to-ATP ratios and the phosphorylation of AMPK.	Adenosine Monophosphate	10-13	interleukin 6	Mus musculus	97-101
22762146-10	2012	Moreover, AMP-activated protein kinase (AMPK) was activated during MDSC maturation in GM-CSF and IL-6-treated cultures, as revealed by the continuous increase of AMP-to-ATP ratios and the phosphorylation of AMPK.	Adenosine Triphosphate	169-172	interleukin 6	Mus musculus	97-101
22421538-4	2012	pDC ablation resulted in a 5- to 35-fold enhancement of intracellular TNF-alpha and IL-6 production from inflammatory cDCs and exudate macrophages.	Chenodeoxycholate 3-sulphate	118-122	interleukin 6	Mus musculus	84-88
22579116-6	2012	(2) Primary cultured mouse mammary epithelial cells were treated with 0, 5, 15 or 45 mmol/L taurine for 3 h, followed by 10 mug/mL LPS for 24 h. Taurine significantly attenuated the LPS-induced increase in NAGase activity, NO concentrations and the level of TNF-alpha, IL-1beta, IL-6 and LF.	Taurine	145-152	interleukin 6	Mus musculus	279-283
22595195-8	2012	Administration of the spinasterol-Glc significantly decreased the plasma levels of these inflammatory mediators including TNF-alpha, IL-6 and IL-1beta in LPS-injected mice and improved survival of septic mice with lethal endotoxemia.	spinasterol	22-33	interleukin 6	Mus musculus	133-137
22595195-4	2012	Our results showed that spinasterol-Glc inhibited the production of NO and proinflammatory cytokines such as TNF-alpha, IL-6 and IL-1beta in dose-dependent manners in LPS-treated RAW264.7 cells.	spinasterol	24-35	interleukin 6	Mus musculus	120-124
22595195-8	2012	Administration of the spinasterol-Glc significantly decreased the plasma levels of these inflammatory mediators including TNF-alpha, IL-6 and IL-1beta in LPS-injected mice and improved survival of septic mice with lethal endotoxemia.	Glucose	34-37	interleukin 6	Mus musculus	133-137
22595195-4	2012	Our results showed that spinasterol-Glc inhibited the production of NO and proinflammatory cytokines such as TNF-alpha, IL-6 and IL-1beta in dose-dependent manners in LPS-treated RAW264.7 cells.	Glucose	36-39	interleukin 6	Mus musculus	120-124
23034257-12	2012	The two hypoxia-inducing conditions (CoCl2 and 1 percent O2) produced different outcomes in metabolic measurements as well as in the expression of some genes (GLUT-1, ANPGTL4, PPAR-gamma and adiponectin), while it remained similar in others (HIF-1alpha, IL-6 and MCP-1).	Oxygen	57-59	interleukin 6	Mus musculus	254-258
22696397-3	2012	Cardamonin (30 and 100 mg/kg) significantly elevated the survival rate of septic mice, alleviated ALI and lung microvascular leak, and lowered the serum levels of proinflammatory cytokines TNF-alpha, IL-1beta, and IL-6.	cardamonin	0-10	interleukin 6	Mus musculus	214-218
23717127-3	2012	Therefore, in this study, we showed that RGSF containing 20(S)-protopanaxadiol type saponins inhibited nitric oxide production and attenuated the release of tumor necrotic factor (TNF)-alpha, interleukin (IL)-6, granulocyte monocyte colony stimulating factor (GMCSF), and macrophage chemo-attractant protein-1 in lipopolysaccharide (LPS) stimulated murine macrophage RAW264.7 cells.	Saponins	84-92	interleukin 6	Mus musculus	192-210
21938727-6	2012	In cultured osteocyte-like MLO-Y4 cells, MTX treatment significantly increased caspase-3-mediated apoptosis, which was accompanied by the formation of plasma membrane-born apoptotic bodies and an increase in IL-6 (24-fold) and IL-11 (29-fold) mRNA expression.	Methotrexate	41-44	interleukin 6	Mus musculus	208-212
22578249-5	2012	When Jmjd3 was depleted by siRNA, oxygen-glucose deprivation/reperfusion injury-induced up-regulation of IL-6 was significantly inhibited.	oxygen-glucose	34-48	interleukin 6	Mus musculus	105-109
21190757-0	2012	The inhalation anesthetic isoflurane increases levels of proinflammatory TNF-alpha, IL-6, and IL-1beta.	Isoflurane	26-36	interleukin 6	Mus musculus	84-88
21190757-4	2012	Here, we show that a clinically relevant isoflurane anesthesia increased the protein and messenger ribonucleic acid (mRNA) levels of TNF-alpha, IL-6, and IL-1beta in the brain tissues of mice.	Isoflurane	41-51	interleukin 6	Mus musculus	144-148
22475725-5	2012	In addition, nuclear factor kappa B (NF-kappaB) activation, and levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in colonic tissues were suppressed in mice receiving COS.	carbonyl sulfide	192-195	interleukin 6	Mus musculus	118-131
22648862-7	2012	Mice from the 5FU  (5-Fluorouracil) group presented weight loss, ulcerations and inflammatory infiltration of neutrophils and eosinophils, increased expression of IL6 and TNF-alpha and increased intestinal permeability.	Fluorouracil	20-34	interleukin 6	Mus musculus	163-166
22475725-5	2012	In addition, nuclear factor kappa B (NF-kappaB) activation, and levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in colonic tissues were suppressed in mice receiving COS.	carbonyl sulfide	192-195	interleukin 6	Mus musculus	133-137
22453065-3	2012	Our results demonstrated that the local inflammatory response provoked after 2 h of SpV injection in footpad of mice is characterized by release of pivotal pro-inflammatory mediators (TNF, IL-6 and MCP-1).	spv	84-87	interleukin 6	Mus musculus	189-193
22852058-4	2012	Previously, we have shown in a mouse model that exposure to hog dust extract (HDE) collected from a CAFO results in the activation of protein kinase C (PKC), elevated lavage fluid cytokines/chemokines including interleukin-6 (IL-6), and the development of significant lung pathology.	cafo	100-104	interleukin 6	Mus musculus	211-224
22852058-5	2012	Because alcohol blocks airway epithelial cell release of IL-6 in vitro, we hypothesized that alcohol exposure would alter mouse lung inflammatory responses to HDE.	Alcohols	8-15	interleukin 6	Mus musculus	57-61
22852058-5	2012	Because alcohol blocks airway epithelial cell release of IL-6 in vitro, we hypothesized that alcohol exposure would alter mouse lung inflammatory responses to HDE.	Alcohols	93-100	interleukin 6	Mus musculus	57-61
22852058-9	2012	Similarly, alcohol-fed mice demonstrated significantly less IL-6 in lung lavage in response to dust than that observed in control mice instilled with HDE.	Alcohols	11-18	interleukin 6	Mus musculus	60-64
22453065-10	2012	Our results demonstrate that SpV evokes a complex inflammatory reaction stimulating a secretion of TNF, IL-6, MCP-1 and leukocytes recruitment at the site of venom injection.	spv	29-32	interleukin 6	Mus musculus	104-108
22717635-9	2012	Additionally, the up-regulation of pro-inflammatory cytokines TNF-alpha and IL-6 was also suppressed by SB, while the survival rate of mice with lethal endotoxemia was significantly increased by SB pre-treatment.	Butyric Acid	104-106	interleukin 6	Mus musculus	76-80
22445727-6	2012	In cultured RAW 264.7 cells, only ClNP but not clodronate alone led to a decrease in tumor necrosis factor-alpha and interleukin-6 secretion of the activated macrophages.	clnp	34-38	interleukin 6	Mus musculus	117-130
22328203-2	2012	Here we present a study of isoproterenol effects on hearts of IL-6 deficient mice.	Isoproterenol	27-40	interleukin 6	Mus musculus	62-66
22628578-13	2012	In primary mouse splenocytes, L-Hcy promoted rIFNgamma-induced inflammatory MC differentiation, as well as increased TNF-alpha, IL-6, and superoxide anion production in inflammatory MC subsets.	Homocysteine	30-35	interleukin 6	Mus musculus	128-132
22709825-13	2012	Ethanol pretreatment potentiated poly I:C-induced brain TNFalpha (345%), IL-1beta (331%), IL-6 (255%), and MCP-1(190%).	Ethanol	0-7	interleukin 6	Mus musculus	90-94
22709825-13	2012	Ethanol pretreatment potentiated poly I:C-induced brain TNFalpha (345%), IL-1beta (331%), IL-6 (255%), and MCP-1(190%).	Poly I	33-39	interleukin 6	Mus musculus	90-94
22709825-13	2012	Ethanol pretreatment potentiated poly I:C-induced brain TNFalpha (345%), IL-1beta (331%), IL-6 (255%), and MCP-1(190%).	Carbon	40-41	interleukin 6	Mus musculus	90-94
21696761-16	2012	When applying IPA analysis, six main canonical pathways were constantly dysregulated in the same significance order in both the saline and LPS group at 4, 24, and 48 h. These were: Toll-like receptor and NF-kappaB signaling, hepatic cholestasis, interleukin-6, and LPS-mediated MAPK signaling pathways, and pattern recognition receptors of bacterial pathway.	Sodium Chloride	128-134	interleukin 6	Mus musculus	246-259
22539071-19	2012	Moreover, chitin nanofibers suppress myeloperoxidase activation in the colon and decrease serum interleukin-6 concentrations.	Chitin	10-16	interleukin 6	Mus musculus	96-109
22328203-10	2012	Three-day treatment with isoproterenol caused significant increase of indices of RV and LV hypertrophy in both WT and IL-6 KO animals with no significant differences between genotypes.	Isoproterenol	25-38	interleukin 6	Mus musculus	118-122
22488045-10	2012	Selective blocking of the MAPK pathways with p38 inhibitor SB203580 significantly decreased arsenic-induced HO-1 and VEGF expression, while JNKs inhibitor SP600125 increased IL-6 expression.	pyrazolanthrone	155-163	interleukin 6	Mus musculus	174-178
21799119-9	2012	Serum IL-6 was prominently higher in the mice treated with poly IC/d-GalN than in that with poly IC alone or d-GalN alone.	Poly C	59-66	interleukin 6	Mus musculus	6-10
21799119-9	2012	Serum IL-6 was prominently higher in the mice treated with poly IC/d-GalN than in that with poly IC alone or d-GalN alone.	poly	59-63	interleukin 6	Mus musculus	6-10
22391529-5	2012	The levels of these two soluble selectins correlated better than those of MCP-1 and IL-6 with the duration and severity of mucosal inflammation triggered by N9 and two approved proinflammatory compounds, benzalkonium chloride (BZK) and sodium dodecyl sulfate (SDS), but not by two nonproinflammatory compounds, carboxymethyl celluose (CMC; microbicide excipients) and tenofovir (TFV; microbicide candidate).	Nonoxynol	157-159	interleukin 6	Mus musculus	84-88
21794995-5	2012	RESULTS: We found that interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) expression increased significantly after noise exposure, and the expression was suppressed significantly in mice administered with geranylgeranylacetone (GGA), which activates HSF1.	geranylgeranylacetone	208-229	interleukin 6	Mus musculus	23-36
21794995-5	2012	RESULTS: We found that interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) expression increased significantly after noise exposure, and the expression was suppressed significantly in mice administered with geranylgeranylacetone (GGA), which activates HSF1.	geranylgeranylacetone	208-229	interleukin 6	Mus musculus	38-42
22488045-0	2012	Arsenic modulates heme oxygenase-1, interleukin-6, and vascular endothelial growth factor expression in endothelial cells: roles of ROS, NF-kappaB, and MAPK pathways.	Arsenic	0-7	interleukin 6	Mus musculus	36-49
22516063-9	2012	Bortezomib treatment resulted in a significant reduction of superoxide content, lipid peroxidation and protein oxidation products, serum levels of monocyte chemoattractant protein-1, and interleukin-6.	Bortezomib	0-10	interleukin 6	Mus musculus	187-200
21948282-0	2012	Inhibitory effect of 10-hydroxy-trans-2-decenoic acid on LPS-induced IL-6 production via reducing IkappaB-zeta expression.	10-hydroxy-2-decenoic acid	21-53	interleukin 6	Mus musculus	69-73
22220695-8	2012	Formalin increased myeloperoxidase activity, and up-regulated TNF-alpha, IL-1beta and IL-6 in gastrocnemius.	Formaldehyde	0-8	interleukin 6	Mus musculus	86-90
22492561-11	2012	Treatment of primary cortical neurons, mixed glial cultures or immortalized brain endothelia with interleukin 6-induced robust interleukin-6 messenger RNA transcription in each case, whereas oxygen-glucose deprivation did not.	oxygen-glucose	191-205	interleukin 6	Mus musculus	98-111
22492561-12	2012	However, oxygen-glucose deprivation of organotypic brain slices resulted in strong upregulation of interleukin-6 messenger RNA along with increased transcription of key angiogenesis-associated genes.	oxygen-glucose	9-23	interleukin 6	Mus musculus	99-112
22083490-3	2012	Pyranocoumarins significantly inhibited LPS-induced production of nitric oxide, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).	Pyranocoumarins	0-15	interleukin 6	Mus musculus	80-93
22083490-3	2012	Pyranocoumarins significantly inhibited LPS-induced production of nitric oxide, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).	Pyranocoumarins	0-15	interleukin 6	Mus musculus	95-99
21948282-2	2012	10H2DA inhibited LPS-induced IL-6 production dose-dependently, but did not inhibit TNF-alpha production.	10-hydroxy-2-decenoic acid	0-6	interleukin 6	Mus musculus	29-33
22476915-10	2012	IL-6 overexpression in CC mice increased fasting insulin and triglyceride levels, which were normalized by exercise, and associated with increased oxidative capacity, an induction of AKT signaling, and a repression of AMPK signaling in muscle.	Triglycerides	61-73	interleukin 6	Mus musculus	0-4
22483979-4	2012	LFWE inhibited LPS-induced nitric oxide (NO), prostaglandin (PG) E2, tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 production as well as their synthesizing enzyme inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 gene expression.	lfwe	0-4	interleukin 6	Mus musculus	107-125
21340507-4	2012	LLL12 and FLLL32 also inhibit IL-6 induced STAT3 phosphorylation.	FLLL 32	10-16	interleukin 6	Mus musculus	30-34
22456905-3	2012	The immunomodulatory efficacy of both polymers was evaluated via the induced release of pro-inflammatory cytokines (TNF-alpha, IL-1alpha and IL-6) and the acceleration of reactive free radicals.	Polymers	38-46	interleukin 6	Mus musculus	141-145
22422925-4	2012	Extract of G. uralensis suppressed IL-6 and TNF-alpha production induced by lipid A moiety of LPS in RAW264.7 cells.	Lipid A	76-83	interleukin 6	Mus musculus	35-39
22422925-5	2012	Among various G. uralensis-related components of saponins and flavanones/chalcones, GL and ILG could suppress IL-6 production induced by lipid A in dose-dependent manners in RAW264.7 cells.	glycylleucine	84-86	interleukin 6	Mus musculus	110-114
22422925-5	2012	Among various G. uralensis-related components of saponins and flavanones/chalcones, GL and ILG could suppress IL-6 production induced by lipid A in dose-dependent manners in RAW264.7 cells.	Lipid A	137-144	interleukin 6	Mus musculus	110-114
22422925-9	2012	In addition, GL and ILG inhibited NF-kappaB activation and IL-6 production induced by paclitaxel, a nonbacterial TLR4 ligand.	Paclitaxel	86-96	interleukin 6	Mus musculus	59-63
22510152-4	2012	DHAP significantly inhibited NO production via the suppression of iNOS expression and significantly decreased levels of the pro-inflammatory cytokines TNF-alpha and IL-6 via the down-regulation of their mRNA expression in LPS-stimulated RAW264.7 cells.	Dihydroxyacetone Phosphate	0-4	interleukin 6	Mus musculus	165-169
22509928-8	2012	An intravenous injection of isRNA/Lipofectamine complexes into C57BL mice increases IFN-alpha and IL-6 levels in the blood serum up to 15-fold and 3-fold, respectively, compared to the control mice.	isrna	28-33	interleukin 6	Mus musculus	98-102
22283629-7	2012	However, although SC-514 suppressed the release of IL-6 evoked by CRH and LPS, it potentiated the concomitant increase in ACTH release.	SC 514	18-24	interleukin 6	Mus musculus	51-55
22290937-8	2012	In vitro, cAMP-PKA activation diminished macrophage tumor necrosis factor alpha, IL-6, and IL-12 in an IL-10-dependent manner and prevented necrosis/apoptosis in primary mouse hepatocyte cultures.	Cyclic AMP	10-14	interleukin 6	Mus musculus	81-85
22509928-8	2012	An intravenous injection of isRNA/Lipofectamine complexes into C57BL mice increases IFN-alpha and IL-6 levels in the blood serum up to 15-fold and 3-fold, respectively, compared to the control mice.	Lipofectamine	34-47	interleukin 6	Mus musculus	98-102
22442348-5	2012	Early anticoagulation with 14E11 suppressed systemic thrombin- antithrombin complex formation, IL-6, and TNF-alpha levels, and reduced platelet consumption in the circulation and deposition in the blood vessels.	14e11	27-32	interleukin 6	Mus musculus	95-99
22281546-8	2012	Furthermore, rSj16 also significantly decreased the levels of proinflammatory cytokines such as PGE2, IL-1beta, IL-6, IL-12, IL-23, and TNF-alpha, whereas it increased the levels of immunosuppressive cytokine IL-10.	rsj16	13-18	interleukin 6	Mus musculus	112-116
22538477-4	2012	beta-Sitosterol also inhibited the expression of proinflammatory cytokines TNF-alpha, IL-1beta, and IL-6, and an inflammatory enzyme, cyclooxygenase (COX)-2, in the colons of TNBS-induced colitic mice, as well as the activation of NF-kappaB.	gamma-sitosterol	0-15	interleukin 6	Mus musculus	100-104
21431940-7	2012	Activation of FXR by CDCA significantly reduced aminotransferase and inflammatory cytokines IFN-gamma, TNF-alpha, and IL-6 caused by ConA injection in MRL/lpr mice.	Chenodeoxycholic Acid	21-25	interleukin 6	Mus musculus	118-122
22706344-7	2012	IL-6-deficient mice exhibited about 60% less gnawing activity than wild-type mice at 3-4 h after the start of R+G+, slower recovery of glycogen levels (indicating poorer glucose supply) in MM after R+G+, and no significant change in Glut4 mRNA in MM upon R+G+.	Glycogen	135-143	interleukin 6	Mus musculus	0-4
22706344-7	2012	IL-6-deficient mice exhibited about 60% less gnawing activity than wild-type mice at 3-4 h after the start of R+G+, slower recovery of glycogen levels (indicating poorer glucose supply) in MM after R+G+, and no significant change in Glut4 mRNA in MM upon R+G+.	Glucose	170-177	interleukin 6	Mus musculus	0-4
22589273-5	2012	Shortly after cyclophosphamide treatment, there was an abrupt expansion of myeloid lineage cells in the bone marrow and the peripheral blood, associated with increases in cytokines with myelogenic potential such as C-C chemokine ligand (CCL)2, interleukin (IL)-6, and VEGF-A.	Cyclophosphamide	14-30	interleukin 6	Mus musculus	244-262
22366673-6	2012	RESULTS: We found that taraxasterol inhibited NO, PGE(2), TNF-alpha, IL-1beta and IL-6 production in LPS-induced RAW 264.7 macrophages in a dose-dependent manner.	taraxasterol	23-35	interleukin 6	Mus musculus	82-86
22445881-10	2012	In peritoneal exuded macrophages induced by thioglycollate, BTB09089 suppressed the production of TNF-alpha and IL-6 while it increased that of IL-10 when stimulated with lipopolysaccharide.	Thioglycolates	44-58	interleukin 6	Mus musculus	112-116
22445881-10	2012	In peritoneal exuded macrophages induced by thioglycollate, BTB09089 suppressed the production of TNF-alpha and IL-6 while it increased that of IL-10 when stimulated with lipopolysaccharide.	3-((2,4-dichlorobenzyl)thio)-1,6-dimethyl-5,6-dihydro-1H-pyridazino(4,5-e)(1,3,4)thiadiazin-5-one	60-68	interleukin 6	Mus musculus	112-116
22414479-0	2012	HILIC quantification of oenotheralanosterol A and B from Oenothera biennis and their suppression of IL-6 and TNF-alpha expression in mouse macrophages.	oenotheralanosterol	24-43	interleukin 6	Mus musculus	100-104
22414473-11	2012	RESULTS: The secretions of NO, PGE(2) and the mRNA expression of iNOS, COX-2 were significantly inhibited, moreover, the protein and mRNA expressions of IL-6, IL-1beta and TNF-alpha were inhibited by preventing the nuclear translocation of the NF-kappaB p50 and p65 subunits.	Prostaglandins E	31-34	interleukin 6	Mus musculus	153-157
22414473-13	2012	CONCLUSION: These results suggest that the anti-inflammatory properties of ethanol extract from ZJP might be the results from the inhibition of iNOS, COX-2, IL-6, IL-1beta, and TNF-alpha expression through preventing the nuclear translocation of the NF-kappaB p50 and p65 subunits in RAW 264.7 cells.	Ethanol	75-82	interleukin 6	Mus musculus	157-161
22414473-13	2012	CONCLUSION: These results suggest that the anti-inflammatory properties of ethanol extract from ZJP might be the results from the inhibition of iNOS, COX-2, IL-6, IL-1beta, and TNF-alpha expression through preventing the nuclear translocation of the NF-kappaB p50 and p65 subunits in RAW 264.7 cells.	zjp	96-99	interleukin 6	Mus musculus	157-161
22547654-4	2012	We demonstrate that BCDT alleviates central nervous system autoimmunity through ablation of IL-6-secreting pathogenic B cells.	bcdt	20-24	interleukin 6	Mus musculus	92-96
22547654-6	2012	Moreover, BCDT ameliorated EAE only in mice with IL-6-sufficient B cells.	bcdt	10-14	interleukin 6	Mus musculus	49-53
22873067-2	2012	Low dose ammonium induced pro-inflammatory response in cells as judged from enhanced production of TNF-alpha, IF-gamma, and IL-6, and by activation of signal cascades.	Ammonium Compounds	9-17	interleukin 6	Mus musculus	110-128
22873067-3	2012	The increase in production of cytokines, namely TNF, IFN, and IL-6, demonstrated that low-dose ammonium induced a pro-inflammatory cellular response.	Ammonium Compounds	95-103	interleukin 6	Mus musculus	62-66
22103274-4	2012	In this study, we have assessed the role of the exchange protein directly activated by cAMP (Epac) and PKCdelta in p38 MAPK activation and IL-6 production by stimulated by the beta-adrenoceptor agonist isoprenaline in NMCFs.	Cyclic AMP	87-91	interleukin 6	Mus musculus	139-143
22103274-4	2012	In this study, we have assessed the role of the exchange protein directly activated by cAMP (Epac) and PKCdelta in p38 MAPK activation and IL-6 production by stimulated by the beta-adrenoceptor agonist isoprenaline in NMCFs.	Isoproterenol	202-214	interleukin 6	Mus musculus	139-143
22103274-10	2012	Furthermore, knock-down of the PKCdelta isoform using an adenovirus-mediated shRNA markedly down-regulated IL-6 induction by NMCFs stimulated with isoprenaline.	Isoproterenol	147-159	interleukin 6	Mus musculus	107-111
22103274-13	2012	CONCLUSIONS AND IMPLICATIONS beta-Adrenoceptor agonists activate a cAMP/Epac/PKCdelta/p38 MAPK pathway to produce IL-6 in NMCFs.	Cyclic AMP	67-71	interleukin 6	Mus musculus	114-118
22543833-3	2012	In vitro, pretreatment of mesangial cells with HSP90 inhibitor Geldanamycin prior to immune-stimulation showed reduced expression of IL-6, IL-12 and NO.	geldanamycin	63-75	interleukin 6	Mus musculus	133-137
22349108-0	2012	Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models.	Metformin	0-9	interleukin 6	Mus musculus	22-26
22231554-3	2012	We found that salmeterol decreases the production of pro-inflammatory cytokines in a model of allergen-challenged mice that expressed tumor-necrosis factor-alpha, interleukin-1 and interleukin-6.	Salmeterol Xinafoate	14-24	interleukin 6	Mus musculus	181-194
20737580-7	2012	Moreover, PFOS exposure markedly enhanced the ex vivo production of TNF-alpha, IL-1beta and IL-6 by peritoneal and splenic macrophages when stimulated either in vitro or in vivo with lipopolysaccharide (LPS).	perfluorooctane sulfonic acid	10-14	interleukin 6	Mus musculus	92-96
20737580-9	2012	PFOS exposure elevated the expression of pro-inflammatory cytokines TNF-alpha, IL-1beta, IL-6, and proto-oncogene, c-myc, in the spleen.	perfluorooctane sulfonic acid	0-4	interleukin 6	Mus musculus	89-93
22349108-3	2012	Here, we demonstrate that metformin-mediated activation of AMP-activated protein kinase (AMPK) increases SHP protein production and regulates IL-6-induced hepatic insulin resistance.	Metformin	26-35	interleukin 6	Mus musculus	142-146
22349108-4	2012	METHODS: We investigated metformin-mediated SHP production improved insulin resistance through the regulation of an IL-6-dependent pathway (involving signal transducer and activator of transcription 3 [STAT3] and suppressor of cytokine signalling 3 [SOCS3]) in both Shp knockdown and Shp null mice.	Metformin	25-34	interleukin 6	Mus musculus	116-120
22349108-5	2012	RESULTS: IL-6-induced STAT3 transactivation and SOCS3 production were significantly repressed by metformin, adenoviral constitutively active AMPK (Ad-CA-AMPK), and adenoviral SHP (Ad-SHP), but not in Shp knockdown, or with the adenoviral dominant negative form of AMPK (Ad-DN-AMPK).	Metformin	97-106	interleukin 6	Mus musculus	9-13
22349108-9	2012	CONCLUSIONS/INTERPRETATION: Our results demonstrate that SHP upregulation by metformin may prevent hepatic disorders by regulating the IL-6-dependent pathway, and that this pathway can help to ameliorate the pathogenesis of cytokine-mediated metabolic dysfunction.	Metformin	77-86	interleukin 6	Mus musculus	135-139
22105779-6	2012	Inhibition of hsp90 by 17-DMAG prevented LPS-induced increases in serum alanine aminotransferase activity and significantly reduced serum tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6) protein as well as messenger RNA (mRNA) in liver.	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	23-30	interleukin 6	Mus musculus	181-194
22105779-6	2012	Inhibition of hsp90 by 17-DMAG prevented LPS-induced increases in serum alanine aminotransferase activity and significantly reduced serum tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6) protein as well as messenger RNA (mRNA) in liver.	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	23-30	interleukin 6	Mus musculus	196-200
22120983-6	2012	PN7d/DSS mice showed increased intestinal permeability and elevated portal vein LPS levels, evidence of hepatocyte injury and cholestasis (serum aspartate aminotransferase, alanine aminotransferase, bile acids, total bilirubin), and increased KC expression of interleukin-6 (Il6), tumor necrosis factor alpha (Tnfalpha), and transforming growth factor beta (Tgfbeta).	dss	5-8	interleukin 6	Mus musculus	260-273
22105779-12	2012	Inhibition of HSF1, using small interfering RNA, prevented 17-DMAG-mediated down-regulation of NFkappaB-binding activity, TNFalpha, and IL-6 induction, supporting a repressive role for HSF1 on proinflammatory cytokine genes during hsp90 inhibition.	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	59-66	interleukin 6	Mus musculus	136-140
22120983-6	2012	PN7d/DSS mice showed increased intestinal permeability and elevated portal vein LPS levels, evidence of hepatocyte injury and cholestasis (serum aspartate aminotransferase, alanine aminotransferase, bile acids, total bilirubin), and increased KC expression of interleukin-6 (Il6), tumor necrosis factor alpha (Tnfalpha), and transforming growth factor beta (Tgfbeta).	dss	5-8	interleukin 6	Mus musculus	275-278
22430099-0	2012	Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice.	nitazoxanide	0-12	interleukin 6	Mus musculus	24-28
22327510-8	2012	17-DMAG reduced nuclear translocation of NF-kappaB and reduced immune-stimulated production of IL-6, TNF-alpha and NO, but did not decrease inducible nitric oxide synthase expression.	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	0-7	interleukin 6	Mus musculus	95-99
22430099-2	2012	Through a rapid screening system, we found that nitazoxanide, or 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide, which is a well-known antiparasitic agent, suppressed lipopolysaccharide (LPS)-induced production of IL-6 from RAW 264.7 cells and mouse peritoneal macrophages, with 50% inhibitory concentrations (IC(50)s) of 1.54 mM and 0.17 mM, respectively.	nitazoxanide	48-60	interleukin 6	Mus musculus	213-217
22430099-2	2012	Through a rapid screening system, we found that nitazoxanide, or 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide, which is a well-known antiparasitic agent, suppressed lipopolysaccharide (LPS)-induced production of IL-6 from RAW 264.7 cells and mouse peritoneal macrophages, with 50% inhibitory concentrations (IC(50)s) of 1.54 mM and 0.17 mM, respectively.	2-acetyloxy-n-(5-nitro-2-thiazolyl) benzamide	65-110	interleukin 6	Mus musculus	213-217
22430099-3	2012	Nitazoxanide also inhibited the LPS-induced expression of IL-6 mRNA in RAW 264.7 cells.	nitazoxanide	0-12	interleukin 6	Mus musculus	58-62
22430099-6	2012	These data suggest that nitazoxanide could be a promising lead compound for agents against various diseases associated with overproduction of IL-6.	nitazoxanide	24-36	interleukin 6	Mus musculus	142-146
22083209-6	2012	Furthermore, the oral administration of sophocarpine significantly decreased myeloperoxidase activity and the level of interleukin (IL)-1 and IL-6 in serum (P &lt; 0.01), while there was no significant effect on the level of IL-4.	sophocarpine	40-52	interleukin 6	Mus musculus	142-146
22474022-5	2012	Ozone-induced lung inflammation, including increases in BAL neutrophils, protein (an index of lung injury), IL-6, keratinocyte-derived chemokine, LPS-induced CXC chemokine, and G-CSF were augmented in Adipo(-/-) versus wild-type mice.	Ozone	0-5	interleukin 6	Mus musculus	108-112
22472292-7	2012	Cobalt induced the production of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) in a concentration- and time-dependent manner in both N9 cells and primary mouse microglia and increased lipopolysaccharides (LPS)-induced cytokine production.	Cobalt	0-6	interleukin 6	Mus musculus	77-90
22472292-7	2012	Cobalt induced the production of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) in a concentration- and time-dependent manner in both N9 cells and primary mouse microglia and increased lipopolysaccharides (LPS)-induced cytokine production.	Cobalt	0-6	interleukin 6	Mus musculus	92-96
22319198-5	2012	Pretreatment with cobra venom factor (CVF; 15 U/mouse) to deplete complement components abolished APAP-mediated C3b accumulation, and this was accompanied by reductions in plasma ALT activity, hepatocellular necrosis, hepatic neutrophil accumulation, and expression of inflammatory genes (interleukin-6, interleukin-10, and plasminogen activation inhibitor-1) at 24 h after APAP treatment.	Acetaminophen	98-102	interleukin 6	Mus musculus	289-302
22306981-4	2012	40 week MNU treatment induced increased expressions of inflammatory cytokines (IL-1beta, IL-6) of Bcl-2 at mRNA level and NFkappaB and IL-1beta at protein level.	Methylnitrosourea	8-11	interleukin 6	Mus musculus	89-93
22402395-6	2012	We found lower mRNA steady state levels of the inflammatory genes interleukin 6, C-reactive protein, monocyte chemoattractant protein 1, and acyloxyacyl hydrolase in quercetin fed mice.	Quercetin	166-175	interleukin 6	Mus musculus	66-79
22306981-7	2012	This study emphasizes that MNU, a harmful industrial and environmental pollutant, potentially activates inflammatory cytokines (IL-1beta, IL-6) in hepatic cells with increased expression of NFkappaB which might be responsible for hepatocarcinogenesis in Balb/c mice.	Methylnitrosourea	27-30	interleukin 6	Mus musculus	138-142
22546471-0	2012	Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model.	Methotrexate	49-61	interleukin 6	Mus musculus	0-13
22564637-6	2012	The constitutive interleukin-6 and hepatocyte growth factor mRNAs in the remnant liver tended to increase in the PV-BMC group at 3 days after hepatectomy.	pv-bmc	113-119	interleukin 6	Mus musculus	17-30
22546471-12	2012	In an in vitro study using synovial cells from arthritic mice, IL-6 + soluble IL-6 receptor (sIL-6R) weakened the anti-proliferative effect of MTX and reduced SLC19A1 expression.	Methotrexate	143-146	interleukin 6	Mus musculus	63-67
22546471-12	2012	In an in vitro study using synovial cells from arthritic mice, IL-6 + soluble IL-6 receptor (sIL-6R) weakened the anti-proliferative effect of MTX and reduced SLC19A1 expression.	Methotrexate	143-146	interleukin 6	Mus musculus	78-82
22546471-15	2012	CONCLUSIONS: In the present study, we demonstrated for the first time that IL-6 reduced the efficacy of MTX by decreasing the expression of SLC19A1, which is important for MTX uptake into cells.	Methotrexate	104-107	interleukin 6	Mus musculus	75-79
22546471-15	2012	CONCLUSIONS: In the present study, we demonstrated for the first time that IL-6 reduced the efficacy of MTX by decreasing the expression of SLC19A1, which is important for MTX uptake into cells.	Methotrexate	172-175	interleukin 6	Mus musculus	75-79
22533381-13	2012	Sodium salicylate treatment reduced subcutaneous adipose tissue expression of BGN, COL1A1, and COL6A1 and a concurrent downregulation of TNFalpha and IL-6 and TLR4 expression.	Sodium Salicylate	0-17	interleukin 6	Mus musculus	150-154
22860460-0	2012	[Regulation trend of resveratrol on TNFalpha-,IL-1beta, IL-6 expressions in bronchoalveolar lavage fluid of RSV-infected BALB/c mice].	Resveratrol	21-32	interleukin 6	Mus musculus	56-60
22860460-1	2012	OBJECTIVE: To study the regulation trend of resveratrol on TNF-alpha, IL-1beta, IL-6 expressions in bronchoalveolar layage fluid (BALF) of RSV-infected BALB/c mice at different time points.	Resveratrol	44-55	interleukin 6	Mus musculus	80-84
22860460-5	2012	01) after 24 hours of RSV infection, while the expression of TNF-alpha (P &lt; 0.01), IL-1beta (P &lt; 0.05), IL-6 (P &lt; 0.01) in the resveratrol group decreased notably compared with the model group.	Resveratrol	136-147	interleukin 6	Mus musculus	110-114
22860460-9	2012	CONCLUSION: Resveratrol can inhibit the over expression of inflammatory factors TNF-alpha, IL-1beta, IL-6 in bronchoalveolar lavage fluid of RSV-induced BALB/c mice and keep them at a low level with the passing of infection time.	Resveratrol	12-23	interleukin 6	Mus musculus	101-105
22537317-8	2012	Additionally, CD40 ligation of smDC resulted in an increased production of IL-6 but not in an increased expression of CD40.	methyldithiocarbamate	31-35	interleukin 6	Mus musculus	75-79
22400806-8	2012	Enzyme-linked immunosorbent assay results indicated that Lico A can significantly down-regulate TNF-alpha, IL-6, and IL-1beta levels in vitro and in vivo, and treatment with Lico A significantly attenuated alveolar wall thickening, alveolar hemorrhage, interstitial edema, and inflammatory cells infiltration in mice with ALI.	licochalcone A	57-63	interleukin 6	Mus musculus	107-111
22400806-8	2012	Enzyme-linked immunosorbent assay results indicated that Lico A can significantly down-regulate TNF-alpha, IL-6, and IL-1beta levels in vitro and in vivo, and treatment with Lico A significantly attenuated alveolar wall thickening, alveolar hemorrhage, interstitial edema, and inflammatory cells infiltration in mice with ALI.	licochalcone A	174-180	interleukin 6	Mus musculus	107-111
23983374-9	2012	Both of XCHT and biphenyl dicarboxylate significantly decreased the serum IL-6 and TNF-alpha levels and FasmRNA, FasLmRNA, Bax protein expression and increased the Bcl-2 mRNA expression of the liver tissues of model mice (P&lt;0.05).	Biphenyl-4,4'-dicarboxylic acid	17-39	interleukin 6	Mus musculus	74-78
22285432-7	2012	The over-expression of TNFalpha and IL6 in iAs intoxicated mice was down-regulated by [6]-gingerol treatment.	gingerol	90-98	interleukin 6	Mus musculus	36-39
22382902-13	2012	Furthermore, treatment with rosuvastatin decreased the expression levels of TNF-alpha (group H, 65.19 +- 7.06 pg/ml; group L, 108.20 +- 5.28 pg/ml; group N, 239.34 +- 11.65 pg/ml) and IL-6 (group H, 14.33 +- 2.15 pg/ml; group L, 19.67 +- 3.04 pg/ml; group N, 40.39 +- 7.17 pg/ml).	Rosuvastatin Calcium	28-40	interleukin 6	Mus musculus	184-188
22570747-4	2012	RESULTS: EGCG inhibited accumulation of LPS-induced IL-12p40, IL-6, MCP-1, ICAM-1, and VCAM-1 mRNA in BMMs.	epigallocatechin gallate	9-13	interleukin 6	Mus musculus	62-66
22197629-9	2012	TNF-alpha was increased whereas IL-6 was decreased both in the liver and heart of db/db fed methionine-choline deficient diet.	Methionine	92-102	interleukin 6	Mus musculus	32-36
22197629-9	2012	TNF-alpha was increased whereas IL-6 was decreased both in the liver and heart of db/db fed methionine-choline deficient diet.	Choline	103-110	interleukin 6	Mus musculus	32-36
22197629-10	2012	Silibinin reversed heart TNF-alpha and IL-6 expression to control mice levels.	Silybin	0-9	interleukin 6	Mus musculus	39-43
22245015-0	2012	Protective potential of IL-6 against trimethyltin-induced neurotoxicity in vivo.	trimethyltin	37-49	interleukin 6	Mus musculus	24-28
22245015-2	2012	Evaluation of TNF-alpha, interferon-gamma, and interleukin (IL)-6 knockout (-/-) mice showed that the IL-6(-/-) mice had the greatest susceptibility to TMT-induced seizures.	trimethyltin	152-155	interleukin 6	Mus musculus	102-106
22245015-8	2012	Furthermore, in IL-6(-/-) mice, rIL-6 provided significant protection against TMT-induced neuronal degeneration; this effect of rIL-6 was counteracted by the PI3K inhibitor LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	173-181	interleukin 6	Mus musculus	16-20
22245015-9	2012	These results suggest that activation of Nrf2-dependent glutathione homeostasis and PI3K/Akt signaling is required for the neuroprotective effects of IL-6 against TMT.	Glutathione	56-67	interleukin 6	Mus musculus	150-154
22570747-8	2012	U0126 (an inhibitor of MEK-1/2) suppressed the LPS-induced IL-12p40, IL-6, MCP-1, ICAM-1, and VCAM-1 mRNA accumulation in BMMs.	U 0126	0-5	interleukin 6	Mus musculus	69-73
21854107-7	2012	In addition, treatment with EAPS inhibited the production of TNF-alpha in LPS-injected mice and suppressed the production of IL-6 and TNF-alpha in LPS-stimulated splenocytes from BALB/c mice.	eaps	28-32	interleukin 6	Mus musculus	125-129
21854107-4	2012	The results indicated that the ethyl acetate fraction of PS (EAPS) concentration highly suppressed lipopolysaccharide (LPS)-induced nitric oxide (NO) and IL-6 productions without a cytotoxic effect on RAW 264.7 cells.	ethyl acetate	31-44	interleukin 6	Mus musculus	154-158
22369900-7	2012	Intracellular cytokine staining analysis showed that SAHA could downregulate the expression of pro-inflammatory cytokines TNF-alpha, IL-6 and IFN-gamma in T lymphocytes.	Vorinostat	53-57	interleukin 6	Mus musculus	133-137
21678423-8	2012	In an in vitro culture system, high glucose and insulin significantly altered TNF-alpha, IL-6, and NO production and arginase activity of macrophages, which was reversed by the treatment with AKT and ERK inhibitors.	Glucose	36-43	interleukin 6	Mus musculus	89-93
22424317-8	2012	It was found that serrumab inhibited the TsV-induced increases in the production of IL-6, TNFalpha, and IL-10 in J774.1 cells.	(2r,6s,12z,13as,14ar,16as)-6-[(Tert-Butoxycarbonyl)amino]-14a-[(Cyclopropylsulfonyl)carbamoyl]-5,16-Dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-Hexadecahydrocyclopropa[e]pyrrolo[1,2-A][1,4]diazacyclopentadecin-2-Yl 4-Fluoro-2h-Isoindole-2-Carboxylate	41-44	interleukin 6	Mus musculus	84-88
22133189-9	2012	It was discovered that asbestos stimulated the macrophages to increase production of the cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha.	Asbestos	23-31	interleukin 6	Mus musculus	99-117
21549726-7	2012	Furthermore, we observed an increase in peripheral poly I:C-induced IL-6, TNF-alpha, MCP-1, and MIP-1alpha, but not IL-1beta.	Poly I	51-57	interleukin 6	Mus musculus	68-72
21873894-12	2012	RESULTS: Indomethacin caused gastric inflammation and ulcers, neutrophil activation, and increased tissue expression of interleukin-6 and tumor necrosis factor-alpha in mice.	Indomethacin	9-21	interleukin 6	Mus musculus	120-165
22354390-6	2012	Levels of inflammatory mediators, including tumour necrosis factor- alpha (TNF- alpha), interleukin-6 (IL-6), and interleukin-10 (IL-10), were significantly altered after treatment with geniposide.	geniposide	186-196	interleukin 6	Mus musculus	88-101
22354390-6	2012	Levels of inflammatory mediators, including tumour necrosis factor- alpha (TNF- alpha), interleukin-6 (IL-6), and interleukin-10 (IL-10), were significantly altered after treatment with geniposide.	geniposide	186-196	interleukin 6	Mus musculus	103-107
22441336-5	2012	RA significantly decreased the production of LPS-induced TNF-a, IL-6, and IL-1beta compare with the LPS group.	rosmarinic acid	0-2	interleukin 6	Mus musculus	64-68
21549726-7	2012	Furthermore, we observed an increase in peripheral poly I:C-induced IL-6, TNF-alpha, MCP-1, and MIP-1alpha, but not IL-1beta.	Carbon	58-59	interleukin 6	Mus musculus	68-72
22262759-6	2012	We show that carbon monoxide (CO) suppresses hepcidin expression elicited by IL-6- and ER-stress agents by inhibiting STAT-3 phosphorylation and CREBH maturation, respectively.	Carbon Monoxide	13-28	interleukin 6	Mus musculus	77-81
22262759-6	2012	We show that carbon monoxide (CO) suppresses hepcidin expression elicited by IL-6- and ER-stress agents by inhibiting STAT-3 phosphorylation and CREBH maturation, respectively.	Carbon Monoxide	30-32	interleukin 6	Mus musculus	77-81
22209213-5	2012	Moreover, ELISA assay revealed that the production of tumor necrosis factor-alpha and interleukin-6 were significantly suppressed by hydrogen in RAW264.7 macrophages, after stimulation with the isolated non-HDL from treated or untreated mice.	Hydrogen	133-141	interleukin 6	Mus musculus	86-99
22433014-7	2012	Spermidine treatment also attenuated the production of pro-inflammatory cytokines, including IL-6 and TNF-alpha, by suppressing their mRNA expressions.	Spermidine	0-10	interleukin 6	Mus musculus	93-97
22803143-1	2012	Experiments on outbred albino mice have shown that proserine (reversible cholinesterase inhibitor) and nicotine (nicotinic receptor agonist) in a equivalent dose of 0.2 DL(50)injected 2 h before sepsis induction significantly reduced animal mortality from experimental infection due to reduction of blood concentrations of proinflammatory cytokines TNF-alpha, IL-1beta, and IL-6.	Neostigmine	51-60	interleukin 6	Mus musculus	374-378
21801469-6	2012	Moreover, SS increased, while curcumin decreased LPS-stimulated secretion of IL-6, whereas SB had no such effect.	Curcumin	30-38	interleukin 6	Mus musculus	77-81
22803143-1	2012	Experiments on outbred albino mice have shown that proserine (reversible cholinesterase inhibitor) and nicotine (nicotinic receptor agonist) in a equivalent dose of 0.2 DL(50)injected 2 h before sepsis induction significantly reduced animal mortality from experimental infection due to reduction of blood concentrations of proinflammatory cytokines TNF-alpha, IL-1beta, and IL-6.	Nicotine	103-111	interleukin 6	Mus musculus	374-378
22179221-4	2012	RESULTS: GW501516 prevented IL-6-dependent reduction in insulin-stimulated v-akt murine thymoma viral oncogene homologue 1 (AKT) phosphorylation and in IRS-1 and IRS-2 protein levels.	GW 501516	9-17	interleukin 6	Mus musculus	28-32
22150790-6	2012	At 500 mg/kg, Imunoglucan restored the reduced ability of stromal cells to display myeloid progenitors in long-term bone marrow cultures of EAT-bearing mice and upregulated the production of interleukin (IL)-6 and IL-1alpha by these cells, consistent with a higher number of non-adherent cells.	imunoglucan	14-25	interleukin 6	Mus musculus	191-209
22150790-8	2012	The results of the present study suggest that Imunoglucan given orally indirectly modulates immune activity and probably disengages tumour-induced suppression by producing a higher reserve of myeloid progenitors in the bone marrow in consequence of biologically active cytokine release (colony-stimulating factors, IL-1alpha, IL-6 and IFN-gamma).	imunoglucan	46-57	interleukin 6	Mus musculus	326-330
22179221-6	2012	Moreover, GW501516 prevented IL-6-dependent induction of extracellular-related kinase 1/2 (ERK1/2), a serine-threonine protein kinase involved in serine STAT3 phosphorylation; the livers of Pparbeta/delta-null mice showed increased Tyr705- and Ser727-STAT3 as well as phospho-ERK1/2 levels.	Serine	102-108	interleukin 6	Mus musculus	29-33
22250783-12	2012	The expression of IL-17A, IL-10, IL-6, and TGF-beta mRNAs were higher in the bleomycin group than in the normal group.	Bleomycin	77-86	interleukin 6	Mus musculus	33-37
22250783-15	2012	ATRA may ease the bleomycin-induced pulmonary fibrosis by inhibiting the expression of IL-6 and TGF-beta, shifting the Treg/Th17 ratio and reducing the secretion of IL-17A.	Tretinoin	0-4	interleukin 6	Mus musculus	87-91
22250783-15	2012	ATRA may ease the bleomycin-induced pulmonary fibrosis by inhibiting the expression of IL-6 and TGF-beta, shifting the Treg/Th17 ratio and reducing the secretion of IL-17A.	Bleomycin	18-27	interleukin 6	Mus musculus	87-91
22179221-6	2012	Moreover, GW501516 prevented IL-6-dependent induction of extracellular-related kinase 1/2 (ERK1/2), a serine-threonine protein kinase involved in serine STAT3 phosphorylation; the livers of Pparbeta/delta-null mice showed increased Tyr705- and Ser727-STAT3 as well as phospho-ERK1/2 levels.	GW 501516	10-18	interleukin 6	Mus musculus	29-33
22325176-6	2012	RESULTS: In RAW264.7 cells, DHMEQ significantly inhibited tumour necrosis factor (TNF)-alpha and interleukin (IL)-6 production induced by LPS in a dose-dependent manner by blocking the nuclear translocation of NF-kappaB.	dehydroxymethylepoxyquinomicin	28-33	interleukin 6	Mus musculus	97-115
22301548-9	2012	Vitamin D inhibition of LPS-induced IL-6 and TNF-alpha production by BMM from MKP-1(-/-) mice was significantly reduced as compared with wild-type mice.	Vitamin D	0-9	interleukin 6	Mus musculus	36-40
22325176-10	2012	mRNA expression levels of the pro-inflammatory cytokines, such as IL-1beta, TNF-alpha, IL-6, IL-12p40, IL-17, and MCP-1 were also suppressed by DHMEQ administration.	dehydroxymethylepoxyquinomicin	144-149	interleukin 6	Mus musculus	87-91
22445968-6	2012	RESULTS: Compared with the control group, PBS-treated ALI group showed significantly higher protein levels, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and neutrophil count in the BALF and MPO content in the lung tissue, with also severe damage of lung histology.	Lead	42-45	interleukin 6	Mus musculus	149-162
21994003-4	2012	Regulatory effects of vitamin D3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 &amp; CCR3 in spleen tissue.	Cholecalciferol	22-32	interleukin 6	Mus musculus	106-110
22445968-6	2012	RESULTS: Compared with the control group, PBS-treated ALI group showed significantly higher protein levels, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and neutrophil count in the BALF and MPO content in the lung tissue, with also severe damage of lung histology.	Lead	42-45	interleukin 6	Mus musculus	164-168
22128916-8	2012	Although both WT HFF and IL-6-/- HFF mice exhibited renal impairment as measured by increased serum creatinine and urinary albumin/creatinine ratios, this was exacerbated in IL-6-/- mice.	Creatinine	100-110	interleukin 6	Mus musculus	25-29
22128916-8	2012	Although both WT HFF and IL-6-/- HFF mice exhibited renal impairment as measured by increased serum creatinine and urinary albumin/creatinine ratios, this was exacerbated in IL-6-/- mice.	Creatinine	131-141	interleukin 6	Mus musculus	25-29
26781733-7	2012	DSS-induced colitis appeared to induce significant increase in MPO activity, levels of TNF-alpha, IL-6 and IFN-gamma.	dss	0-3	interleukin 6	Mus musculus	98-102
22178768-8	2012	Furthermore, UFPs- and/or CSE-induced Egr-1 mRNA upregulation was attenuated significantly when cells were pre-treated with p38 specific inhibitor, SB 203580, or MEK1/2 inhibitor, PD98059, and Egr-1 siRNA treatment abolished UFPs- and/or CSE-induced overexpression of IL-6.	SB 203580	148-157	interleukin 6	Mus musculus	268-272
22178768-8	2012	Furthermore, UFPs- and/or CSE-induced Egr-1 mRNA upregulation was attenuated significantly when cells were pre-treated with p38 specific inhibitor, SB 203580, or MEK1/2 inhibitor, PD98059, and Egr-1 siRNA treatment abolished UFPs- and/or CSE-induced overexpression of IL-6.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	180-187	interleukin 6	Mus musculus	268-272
22100389-6	2012	Furthermore, R3V6-Dexa reduced the expression of an inflammatory cytokine, interleukin-6 (IL-6), more efficiently in lipopolysaccharide (LPS)-induced Raw264.7 cells than did dexamethasone, suggesting that R3V6-Dexa is also a useful carrier for dexamethasone delivery.	r3v6-dexa	13-22	interleukin 6	Mus musculus	75-88
22100389-6	2012	Furthermore, R3V6-Dexa reduced the expression of an inflammatory cytokine, interleukin-6 (IL-6), more efficiently in lipopolysaccharide (LPS)-induced Raw264.7 cells than did dexamethasone, suggesting that R3V6-Dexa is also a useful carrier for dexamethasone delivery.	r3v6-dexa	13-22	interleukin 6	Mus musculus	90-94
22100389-6	2012	Furthermore, R3V6-Dexa reduced the expression of an inflammatory cytokine, interleukin-6 (IL-6), more efficiently in lipopolysaccharide (LPS)-induced Raw264.7 cells than did dexamethasone, suggesting that R3V6-Dexa is also a useful carrier for dexamethasone delivery.	r3v6-dexa	205-214	interleukin 6	Mus musculus	75-88
22100389-6	2012	Furthermore, R3V6-Dexa reduced the expression of an inflammatory cytokine, interleukin-6 (IL-6), more efficiently in lipopolysaccharide (LPS)-induced Raw264.7 cells than did dexamethasone, suggesting that R3V6-Dexa is also a useful carrier for dexamethasone delivery.	Dexamethasone	244-257	interleukin 6	Mus musculus	75-88
22155353-2	2012	Both Au and SiAu significantly increased the release of Ca, hydrogen peroxide, NO, IL-1alpha, IL-1beta, IL-6, IL-10, IP-10, MCP-1, MCP-3, TNF-alpha, RANTES, G-CSF, GM-CSF, LIF, MIP-2, VEGF, and PGE2 with enhancing expression of STAT1, STAT3, c-Fos, and COX-2 mRNA in RAW 264.7 cells.	Gold	5-7	interleukin 6	Mus musculus	104-108
22252297-8	2012	CP-690,550 selectively inhibited IFN--induced STAT1, IL-4-induced STAT6 and IL-2-induced STAT5 at 3-30nM, while suppression of IL-6-induced STAT3 phosphorylation required a concentration greater than 100nM.	tofacitinib	0-6	interleukin 6	Mus musculus	127-131
22356547-10	2012	Flavocoxid administration improved survival, reduced the expression of NF-kappaB, COX-2, 5-LOX, TNF-alpha and IL-6 and increased IL-10 production.	flavocoxid	0-10	interleukin 6	Mus musculus	110-114
22356547-11	2012	Moreover, flavocoxid inhibited the mitogen-activated protein kinases (MAPKs) pathway, preserved beta-arrestin 2 expression, reduced blood LTB4, PGE2, TNF-alpha and IL-6, and increased IL-10 and lipoxin A4 serum levels.	flavocoxid	10-20	interleukin 6	Mus musculus	164-168
22335738-11	2012	In addition, neutralizing interleukin-6 significantly enhanced the therapeutic efficacy of paclitaxel in mouse models of epithelial ovarian cancer.	Paclitaxel	91-101	interleukin 6	Mus musculus	26-39
22205605-9	2012	The CsA group also exhibited lower expression of IL6 and TNF-alpha (P = 0.01).	Cyclosporine	4-7	interleukin 6	Mus musculus	49-52
22205605-11	2012	CONCLUSIONS: Immunomodulation with CsA reduces the expression of cytokines (IL6) in the cornea and retards regenerative sprouting from transected corneal stromal nerve trunks.	Cyclosporine	35-38	interleukin 6	Mus musculus	76-79
22093924-3	2012	In muscles and C2C12 myotubes, cholinergic excitation by exposure to nicotine or the organophosphorous pesticide, Paraoxon, induced Tristetraprolin overproduction while reducing pro-inflammatory transcripts such as IL-6, CXCL1 (KC) and CCL2 (MCP-1).	Nicotine	69-77	interleukin 6	Mus musculus	215-219
22045314-5	2012	Furthermore, valsartan strongly suppressed LPS-induced productions of cytokines such as interleukin (IL)-1beta, IL-6, and TNFalpha with nuclear factor-kappaB activation and c-Jun NH(2)-terminal kinase phosphorylation in RAW 264.7 and primary murine macrophages.	Valsartan	13-22	interleukin 6	Mus musculus	112-116
22093924-3	2012	In muscles and C2C12 myotubes, cholinergic excitation by exposure to nicotine or the organophosphorous pesticide, Paraoxon, induced Tristetraprolin overproduction while reducing pro-inflammatory transcripts such as IL-6, CXCL1 (KC) and CCL2 (MCP-1).	organophosphorous	85-102	interleukin 6	Mus musculus	215-219
22093924-3	2012	In muscles and C2C12 myotubes, cholinergic excitation by exposure to nicotine or the organophosphorous pesticide, Paraoxon, induced Tristetraprolin overproduction while reducing pro-inflammatory transcripts such as IL-6, CXCL1 (KC) and CCL2 (MCP-1).	Paraoxon	114-122	interleukin 6	Mus musculus	215-219
21692746-7	2012	Intratumoral administration of aspirin was accompanied by alterations in the biophysical, biochemical and immunological composition of the tumour microenvironment with respect to pH, level of dissolved O2, glucose, lactate, nitric oxide, IFNgamma (interferon gamma), IL-4 (interleukin-4), IL-6 and IL-10, whereas the TGF-beta (tumour growth factor-beta) level was unaltered.	Aspirin	31-38	interleukin 6	Mus musculus	289-293
21926578-8	2012	MEASUREMENTS AND MAIN RESULTS: Nicotinamide effectively inhibited nuclear factor-kappaB translocation and binding activity as well as the production of tumor necrosis factor-alpha, nitrite/nitrate, and interleukin-6 in the lipopolysaccharide-stimulated RAW 264.7 and BV2 cells (p &lt; .05, respectively) but exhibited weak antioxidant and radical-scavenging actions.	Niacinamide	31-43	interleukin 6	Mus musculus	202-215
21790535-8	2012	KEY RESULTS: DS, when administered for 7 days, showed intestinal anti-inflammatory effects in TNBS-induced colitis; these effects were observed both macroscopically and through the profile of inflammatory mediators (TNF, IL-1beta, IL-6 and IL-17).	dersalazine	13-15	interleukin 6	Mus musculus	231-235
21790535-10	2012	DS showed beneficial effects on DSS-induced colitis in C57BL/6 mice and reduced colonic pro-inflammatory cytokines IL-1beta, IL-6 and IL-17.	dersalazine	0-2	interleukin 6	Mus musculus	125-129
22030090-4	2012	Curcumin treatment significantly inhibited cell proliferation and colony formation of cancer cells and decreased the secretion of murine IL-6 by MDSCs in a coculture system.	Curcumin	0-8	interleukin 6	Mus musculus	137-141
22089895-8	2012	Increased body weight, hyperglycemia, hyperinsulinemia and increased plasma levels of tumor necrosis factor-alpha and interleukin-6 observed in HFFD-fed mice were significantly improved by ASX addition.	astaxanthine	189-192	interleukin 6	Mus musculus	118-131
22155313-0	2012	Carbon nanotubes provoke inflammation by inducing the pro-inflammatory genes IL-1beta and IL-6.	Carbon	0-6	interleukin 6	Mus musculus	90-94
21400122-8	2012	Mice treated with midazolam had significantly lower serum IL-1beta (p=0.002), TNF-alpha (p=0.002), IL-6 (p=0.016), IL-10 (p=0.009), and TGF-beta (p=0.004) than saline-treated mice, with little impact on serum chemokine levels.	Midazolam	18-27	interleukin 6	Mus musculus	99-103
21465277-3	2012	A WI methanolic extract significantly inhibited NO, PGE(2), IL-6, IL-1beta, and TNF-alpha production in LPS-stimulated RAW 264.7 cells.	methanolic	5-15	interleukin 6	Mus musculus	60-64
21505811-3	2012	JP05-MC significantly inhibited LPS-induced production of NO and the proinflammatory cytokines, TNF-alpha and IL-6, in BV2 cells.	jp05-mc	0-7	interleukin 6	Mus musculus	110-114
22249932-3	2012	RESULTS: PL caused peribronchial and perivascular inflammation that peaked at 18-24 h. Polymorphonuclear cells (PMNs) began to accumulate in bronchoalveolar lavage fluid (BALF) of PL-challenged mice by 4 h and accounted for &gt;90% of leukocytes by 18-24 h. Inflammation was marked by the appearance of MIP-2, KC, TNF-alpha, and IL-6 in the BALF with peak levels attained 4 h after PL administration.	pl	9-11	interleukin 6	Mus musculus	329-333
21442413-6	2012	Moreover, PPH significantly inhibited their secretion of pro-inflammatory cytokines, TNF-alpha- and IL-6, up to 35 and 80%, respectively.	[(1R)-1-amino-2-phenylethyl]phosphonic acid	10-13	interleukin 6	Mus musculus	100-104
21442413-10	2012	Moreover, PPH might have increased IL-6 production in IECs via the stimulation of toll-like receptors (TLRs) family, especially TLR2 and TLR4 since either anti-TLR2 or anti-TLR4 was able to completely abolish PPH-induced IL-6 secretion.	[(1R)-1-amino-2-phenylethyl]phosphonic acid	10-13	interleukin 6	Mus musculus	35-39
21442413-10	2012	Moreover, PPH might have increased IL-6 production in IECs via the stimulation of toll-like receptors (TLRs) family, especially TLR2 and TLR4 since either anti-TLR2 or anti-TLR4 was able to completely abolish PPH-induced IL-6 secretion.	[(1R)-1-amino-2-phenylethyl]phosphonic acid	10-13	interleukin 6	Mus musculus	221-225
21556046-9	2012	Relative to CON mice, CAP-treated mice had reduced adipose and skeletal muscle monocyte chemoattractant protein 1 (MCP-1), adipose interleukin-6 (IL-6), toll-like receptor 4 (TLR4) and uncoupling protein 2 (UCP2) mRNA expressions.	Captopril	22-25	interleukin 6	Mus musculus	131-144
21556046-9	2012	Relative to CON mice, CAP-treated mice had reduced adipose and skeletal muscle monocyte chemoattractant protein 1 (MCP-1), adipose interleukin-6 (IL-6), toll-like receptor 4 (TLR4) and uncoupling protein 2 (UCP2) mRNA expressions.	Captopril	22-25	interleukin 6	Mus musculus	146-150
21381053-6	2012	Trolox prevented the release of receptor activator of nuclear factor-kappaB ligand (RANKL), IL-6, and TNF-alpha induced by AMA.	6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid	0-6	interleukin 6	Mus musculus	92-96
22212354-6	2012	The CBA analyzing results showed that SK&amp;F 96365 pretreatment efficiently inhibited the production of LPS plus IFN-gamma-induced inflammatory cytokines of IL-6, MCP-1, TNF, INF-gamma, and IL-10.	amicloral	38-44	interleukin 6	Mus musculus	159-163
21381053-7	2012	Moreover, the increased IL-6 and TNF-alpha release by AMA was markedly reduced by BAPTA/AM and cyclosporin A.	1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid	82-87	interleukin 6	Mus musculus	24-28
21381053-7	2012	Moreover, the increased IL-6 and TNF-alpha release by AMA was markedly reduced by BAPTA/AM and cyclosporin A.	Cyclosporine	95-108	interleukin 6	Mus musculus	24-28
22032869-6	2012	Additionally, oral treatment with (-)-cassine (3-60 mg/kg) prevented the mechanical hyperalgesia elicited by intraplantar injection of prostaglandin E(2), complete Freund"s adjuvant, interleukin-1beta, interleukin-6 and keratinocyte-derived chemokine.	cassine	34-45	interleukin 6	Mus musculus	202-215
22243794-5	2012	The preadministration of hemin to septic mice increased the expression and activity of HO-1; inhibited thrombosis in the preceding 3 organs; prolonged PT and APTT; inhibited the production of TNF-alpha and IL-6; upregulated the expression of PC and TM in livers; elevated the plasma levels of PC and aPC; and reduced the plasma levels of TM.	Hemin	25-30	interleukin 6	Mus musculus	206-210
22076029-11	2012	Serum level of TNF-alpha and IL-6             was significantly lower in PKRI and PKRI+MPA-treated than in placebo animals (P&lt;0.01).	Medroxyprogesterone Acetate	87-90	interleukin 6	Mus musculus	29-33
21780211-3	2012	DcE inhibited the production of IL-6, IL-8 and MCP-1 in THP-1 cells and the release of IL-6 and MCP-1 in EoL-1 cells after treatment with house dust mite extract.	ethylene dichloride	0-3	interleukin 6	Mus musculus	32-36
21978812-5	2012	The results also demonstrated that sophocarpine (50 and 100mug/ml) suppressed LPS-stimulated NO production and pro-inflammatory cytokines secretion, including tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6).	sophocarpine	35-47	interleukin 6	Mus musculus	203-216
21978812-5	2012	The results also demonstrated that sophocarpine (50 and 100mug/ml) suppressed LPS-stimulated NO production and pro-inflammatory cytokines secretion, including tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6).	sophocarpine	35-47	interleukin 6	Mus musculus	218-222
22667143-3	2012	The immunocompromised mice model was established by intraperitoneal injection cyclophosphamide to detected the content of IL-2, IL-6 in serum, CD4+, CD8+ in the peripheral blood by ELISA and flow cytometry, respectively.	Cyclophosphamide	78-94	interleukin 6	Mus musculus	128-132
22269797-7	2012	Interleukin-6 (IL-6) is thought to play an important role in incision-induced pain and resveratrol potently inhibited IL-6-mediated signaling to ERK in sensory neurons and blocked IL-6-mediated allodynia in vivo through a local mechanism of action.	Resveratrol	87-98	interleukin 6	Mus musculus	118-122
22269797-7	2012	Interleukin-6 (IL-6) is thought to play an important role in incision-induced pain and resveratrol potently inhibited IL-6-mediated signaling to ERK in sensory neurons and blocked IL-6-mediated allodynia in vivo through a local mechanism of action.	Resveratrol	87-98	interleukin 6	Mus musculus	0-13
22269797-7	2012	Interleukin-6 (IL-6) is thought to play an important role in incision-induced pain and resveratrol potently inhibited IL-6-mediated signaling to ERK in sensory neurons and blocked IL-6-mediated allodynia in vivo through a local mechanism of action.	Resveratrol	87-98	interleukin 6	Mus musculus	15-19
22269797-7	2012	Interleukin-6 (IL-6) is thought to play an important role in incision-induced pain and resveratrol potently inhibited IL-6-mediated signaling to ERK in sensory neurons and blocked IL-6-mediated allodynia in vivo through a local mechanism of action.	Resveratrol	87-98	interleukin 6	Mus musculus	118-122
22269797-9	2012	Intraplantar IL-6 injection and plantar incision induces persistent nociceptive sensitization to PGE2 injection into the affected paw after the resolution of allodynia to the initial stimulus.	Dinoprostone	97-101	interleukin 6	Mus musculus	13-17
21561314-7	2012	Carprofen significantly reduced lesion size (p=0.002), decreased water content in the lesioned cortex (p=0.03), reduced the number of microglia in the lesioned cortex (p&lt;0.0001), and lowered the levels of proinflammatory cytokines (IL-1beta, p=0.03; IL-6, p=0.02).	carprofen	0-9	interleukin 6	Mus musculus	253-257
22269797-10	2012	We further show that resveratrol treatment at the time of IL-6 injection or plantar incision completely blocks the development of persistent nociceptive sensitization consistent with the blockade of a transition to a chronic pain state by resveratrol treatment.	Resveratrol	21-32	interleukin 6	Mus musculus	58-62
22174456-4	2012	We demonstrated that rMPT83 induced the production of TNF-alpha, IL-6, and IL-12 p40 and that cytokine induction depended on activated MAPKs, because we observed the rapid phosphorylation of ERK1/2, p38, and JNK in macrophages.	rmpt83	21-27	interleukin 6	Mus musculus	65-69
22041103-9	2012	However, administration of DR-W extract in CIA mice significantly reduced arthritic scores and serum levels of anti-CII IgG2a antibody, PGE(2), TNF-alpha, IL-1beta and IL-6 compared with those in vehicle-treated CIA mice.	dr-w	27-31	interleukin 6	Mus musculus	168-172
21925167-4	2012	Furthermore, treatment with crocetin significantly attenuated LPS-induced mRNA and the protein expressions of interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1), and tumour necrosis factor-alpha (TNF-alpha) in lung tissue.	crocetin	28-36	interleukin 6	Mus musculus	110-123
21925167-4	2012	Furthermore, treatment with crocetin significantly attenuated LPS-induced mRNA and the protein expressions of interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1), and tumour necrosis factor-alpha (TNF-alpha) in lung tissue.	crocetin	28-36	interleukin 6	Mus musculus	125-129
22117528-4	2012	Naringenin treatments dose-dependently reduced renal tumor necrosis factor-alpha level and expression (P &lt; 0.05) but only at 1 and 2% significantly decreased production and expression of interleukin (IL)-1beta, IL-6, and monocyte chemoattractant protein-1 (P &lt; 0.05).	naringenin	0-10	interleukin 6	Mus musculus	214-218
21309947-7	2012	Deletion of B2m, Ctss, Il1rn, Cd14 and Il6 also reduced ethanol consumption in the limited access two bottle choice test for ethanol intake; with the Il1rn and Ctss null mutants showing reduced intake in all three tests (with some variation between males and females).	Ethanol	56-63	interleukin 6	Mus musculus	39-42
21309947-7	2012	Deletion of B2m, Ctss, Il1rn, Cd14 and Il6 also reduced ethanol consumption in the limited access two bottle choice test for ethanol intake; with the Il1rn and Ctss null mutants showing reduced intake in all three tests (with some variation between males and females).	Ethanol	125-132	interleukin 6	Mus musculus	39-42
22062222-6	2012	C57BL/6 mice with BLM induced scleroderma had elevated serum IL-6 levels and more severe dermal sclerosis than Il-6KO mice.	Bleomycin	18-21	interleukin 6	Mus musculus	61-65
22687535-1	2012	Citreorosein (CIT), an anthraquinone component of Polygoni cuspidati (P. cuspidati) radix, suppressed gene expression of proinflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta in mouse bone marrow-derived mast cells (BMMCs) stimulated with phorbol 12-myristate 13-acetate (PMA) plus the calcium ionophore A23187.	citreorosein	0-12	interleukin 6	Mus musculus	192-210
22938487-6	2012	Results indicated that Th1 cytokines such as TNF-alpha, IFNgamma, IL12 and the Th2 cytokines such as IL4, IL6, IL10 which were respectively downregulated and upregulated following arsenic induction were more efficiently restored to their near normal levels by T11TS alone in comparison with the combined regimen.	Arsenic	180-187	interleukin 6	Mus musculus	106-109
22687543-7	2012	Plasma IL-6 levels also significantly increased in the WT group 24 h after CCl(4) administration, but those in the KO group did not increase at any time point.	Cefaclor	75-78	interleukin 6	Mus musculus	7-11
22687535-1	2012	Citreorosein (CIT), an anthraquinone component of Polygoni cuspidati (P. cuspidati) radix, suppressed gene expression of proinflammatory cytokines including tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta in mouse bone marrow-derived mast cells (BMMCs) stimulated with phorbol 12-myristate 13-acetate (PMA) plus the calcium ionophore A23187.	citreorosein	14-17	interleukin 6	Mus musculus	192-210
21807089-5	2012	Resveratrol lessened the colitis-associated decrease in body weight and increased levels of serum amyloid A (SAA), CXCL10 and colon TNF-alpha, IL-6, RANTES, IL-12 and IL-1beta concentrations.	Resveratrol	0-11	interleukin 6	Mus musculus	143-147
22975507-6	2012	Ginsenoside Rg3 at 20 and 30 mg/kg oral doses significantly attenuated up-regulation of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta) and IL-6 mRNA in brain tissue at 4 h after LPS injection.	Ginsenosides	0-11	interleukin 6	Mus musculus	163-167
23156084-8	2012	Noopept (5 mg/kg) reduced the level of IL-6 by a factor of 1.8 in the inflammatory response to Con A.	ethyl phenylacetyl-Pro-Gly	0-7	interleukin 6	Mus musculus	39-43
22281010-2	2012	In this study we quantified the relative abundance of IL-6 mRNA isoforms in a panel of mouse tissues and in C2C12 cells during myoblast differentiation or after treatment with the Ca(2+) ionophore A23187, the AMP-mimetic AICAR and TNF-alpha.	Calcimycin	197-203	interleukin 6	Mus musculus	54-58
22281010-2	2012	In this study we quantified the relative abundance of IL-6 mRNA isoforms in a panel of mouse tissues and in C2C12 cells during myoblast differentiation or after treatment with the Ca(2+) ionophore A23187, the AMP-mimetic AICAR and TNF-alpha.	Adenosine Monophosphate	209-212	interleukin 6	Mus musculus	54-58
22145808-5	2012	Berberine, at 10 mg/kg body weight, showed significant inhibition in tumor-directed capillary formation and in various proangiogenic factors, such as vascular endothelial growth factor (VEGF), and proinflammatory mediators, such as interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha (TNF-alpha), and granulocyte macrophage colony-stimulating factor (GM-CSF), which are involved in tumor angiogenesis.	Berberine	0-9	interleukin 6	Mus musculus	256-260
22991570-8	2012	Additionally, CR(MeOH) also decreased IL-1beta, IL-6, NFkappaB, TNF-alpha, COX-2, and iNOS levels.	Chromium	14-16	interleukin 6	Mus musculus	48-52
22991570-8	2012	Additionally, CR(MeOH) also decreased IL-1beta, IL-6, NFkappaB, TNF-alpha, COX-2, and iNOS levels.	Methanol	17-21	interleukin 6	Mus musculus	48-52
23156084-10	2012	The course administration of noopept (5 mg/kg) significantly decreased the level of IL-6 and reduced by half the level of TNF-alpha.	ethyl phenylacetyl-Pro-Gly	29-36	interleukin 6	Mus musculus	84-88
23243434-5	2012	In addition, TSAV attenuated the serum TNF-alpha and IL-6 levels and inhibited the serum iNOS and NO levels.	tsav	13-17	interleukin 6	Mus musculus	53-57
23243426-2	2012	Activation of hepatic nuclear factor-kappa B (NF-kappaB), IkappaB kinase (IKK alpha/beta) proteins, and TNFalpha and IL-6 expression was investigated in diethylnitrosamine- (DEN-) induced C3H mice-bearing early hepatocarcinogenic changes.	Diethylnitrosamine	153-171	interleukin 6	Mus musculus	117-121
23346188-7	2012	Furthermore, AM(EtOH) decreased the tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, leading to the reduction of prostaglandins and subsequently alleviated edema.	Ethanol	16-20	interleukin 6	Mus musculus	80-93
23243447-5	2012	Additionally, KIOM-MA showed a strong suppressive effect on the inflammatory cytokines production such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	kiom-ma	14-21	interleukin 6	Mus musculus	150-163
23346188-7	2012	Furthermore, AM(EtOH) decreased the tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, leading to the reduction of prostaglandins and subsequently alleviated edema.	Ethanol	16-20	interleukin 6	Mus musculus	95-99
23243447-5	2012	Additionally, KIOM-MA showed a strong suppressive effect on the inflammatory cytokines production such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	kiom-ma	14-21	interleukin 6	Mus musculus	165-169
21526401-4	2012	The production of IL-8 and IL-6 was lowest in delta-tocotrienol (delta-T3)-treated cells followed by gamma-tocotrienol (gamma-T3) and TRF.	delta-t3	65-73	interleukin 6	Mus musculus	27-31
22850641-8	2012	THS induction was associated with significantly increased plasma concentrations of Cr, AST, CPK, IL-6, IL-10, and TNF-alpha from the baseline values by two- to three-fold after the hemorrhage phase, and THS-induced mice demonstrated significantly increased histological injury scores.	THYMIDINE-5'-(DITHIO)PHOSPHATE	0-3	interleukin 6	Mus musculus	97-101
21526401-3	2012	Results showed reduced levels of Interkeukin (IL)-8 and IL-6, two pro-angiogenic cytokines in HUVEC treated with palm tocotrienols compared with alpha-tocopherol (alpha-T) and control cells (P &lt; 0.05).	Tocotrienols	118-130	interleukin 6	Mus musculus	56-60
22116056-4	2012	Moreover, liquiritigenin significantly decreased the production of reactive oxygen species (ROS) and osteoclast differentiation inducing factors such as tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), and receptor activator of nuclear factor-kappaB ligand (RANKL) in the presence of antimycin A, which inhibits mitochondrial electron transport and has been used as a ROS generator.	liquiritigenin	10-24	interleukin 6	Mus musculus	194-207
21526401-4	2012	The production of IL-8 and IL-6 was lowest in delta-tocotrienol (delta-T3)-treated cells followed by gamma-tocotrienol (gamma-T3) and TRF.	tocotrienol, delta	46-63	interleukin 6	Mus musculus	27-31
22068549-5	2012	Peritoneal mast cells cultured ex vivo (PCMCs) were stimulated for 24 h with lipopolysaccharide and Bordetella pertussis antigen and secretion of tumour necrosis factor-alpha, IL-6, IL-4, IL-5, IL-10 and interferon-gamma into supernatant was measured by commercial ELISA.	chlorocresol	40-45	interleukin 6	Mus musculus	176-180
22116056-4	2012	Moreover, liquiritigenin significantly decreased the production of reactive oxygen species (ROS) and osteoclast differentiation inducing factors such as tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), and receptor activator of nuclear factor-kappaB ligand (RANKL) in the presence of antimycin A, which inhibits mitochondrial electron transport and has been used as a ROS generator.	liquiritigenin	10-24	interleukin 6	Mus musculus	209-213
22507316-12	2012	Furthermore, beta-thujaplicin inhibited LPS-induced PGE2, IL-6, and TNF-alpha production as well as iNOS, COX2, and NF- kappaB protein expression more substantially potent than indomethacin.	beta-thujaplicin	13-29	interleukin 6	Mus musculus	58-62
22507316-28	2012	Furthermore, beta-thujaplicin inhibited LPS-induced PGE2, IL-6, and TNF-alpha production as well as iNOS, COX2, and NF-kB protein expression more substantially potent than indomethacin.	beta-thujaplicin	13-29	interleukin 6	Mus musculus	58-62
21964156-10	2012	BDA-410 administration attenuated activation of MMP12, proinflammatory cytokines (IL-6, monocyte chemoattractant protein-1), and macrophage infiltration into the aorta.	N-1-(hydroxy(3-oxo-2-phenyl-1-cyclopropen-1-yl)methyl)-2-methylpropyl-2-benzenesulfonylamino-4-methylpentanamide	0-7	interleukin 6	Mus musculus	82-86
22178196-4	2012	The results showed that alpinetin markedly inhibited the LPS- induced TNF-alpha, IL-6 and IL-1beta production both in vitro and vivo.	alpinetin	24-33	interleukin 6	Mus musculus	81-85
22679371-5	2012	The results showed that liposomal curcumin inhibited nuclear factor-kappaB pathway and downregulated inflammatory factors including tumor necrosis factor-alpha, interleukin (IL)-6, IL-8, and transforming growth factor-beta induced by thoracic irradiation.	Curcumin	34-42	interleukin 6	Mus musculus	161-179
22701318-8	2012	RESULTS: Administration of iron oxide nanoparticles, in a dose-dependent fashion, significantly attenuated inflammatory reactions associated with DTH, including the footpad swelling, the infiltration of T cells and macrophages, and the expression of interferon-gamma, interleukin-6, and tumor necrosis factor-alpha in the inflammatory site.	ferric oxide	27-37	interleukin 6	Mus musculus	268-314
22591281-5	2012	The messenger RNA (mRNA) levels of interleukin (IL)-2 and IL-6 in the endosulfan-treated group were significantly higher than that of the control group.	Endosulfan	70-80	interleukin 6	Mus musculus	58-62
22591281-6	2012	The mRNA levels of IL-6 in the experimental group were lower than that of the endosulfan-treated group, whereas the mRNA levels of IL-2 and interferon-gamma had no significant difference between the 2 groups.	Endosulfan	78-88	interleukin 6	Mus musculus	19-23
22130157-8	2012	Bone marrow-derived dendritic cells expressed upregulated IL-12p40 mRNA but IL-6 and IL-10 mRNA downregulated after coculture with MOSECs cotreated with doxorubicin and cisplatin.	Doxorubicin	153-164	interleukin 6	Mus musculus	76-80
22919282-0	2012	Constitutive over expression of IL-1beta, IL-6, NF-kappaB, and Stat3 is a potential cause of lung tumorgenesis in urethane (ethyl carbamate) induced Balb/c mice.	Urethane	114-122	interleukin 6	Mus musculus	42-46
22919282-0	2012	Constitutive over expression of IL-1beta, IL-6, NF-kappaB, and Stat3 is a potential cause of lung tumorgenesis in urethane (ethyl carbamate) induced Balb/c mice.	Urethane	124-139	interleukin 6	Mus musculus	42-46
22641126-4	2012	The expression of interleukin (IL)-6 and cyclooxygenase-2 in the lesions was enhanced in uOVX mice compared to non-uOVX animals.	uovx	89-93	interleukin 6	Mus musculus	18-36
23038000-8	2012	The activation of MPO and increase in IL-1, IL-6, TNF-alpha and IFN-gamma levels induced by CdCl(2) were also reduced by oxime.	Cadmium Chloride	92-99	interleukin 6	Mus musculus	44-48
23038000-8	2012	The activation of MPO and increase in IL-1, IL-6, TNF-alpha and IFN-gamma levels induced by CdCl(2) were also reduced by oxime.	Oximes	121-126	interleukin 6	Mus musculus	44-48
22641126-4	2012	The expression of interleukin (IL)-6 and cyclooxygenase-2 in the lesions was enhanced in uOVX mice compared to non-uOVX animals.	uovx	115-119	interleukin 6	Mus musculus	18-36
23209347-3	2012	We also demonstrated that OA-induced pulmonary injury is dependent on ERK1/2 activation, since U0126, an inhibitor of ERK1/2 phosphorylation, blocked neutrophil migration, oedema, and lipid body formation as well as IL-6, but not IL-1beta production.	U 0126	95-100	interleukin 6	Mus musculus	216-220
22474400-8	2012	Magnolol significantly (P &lt; 0.05) decreased the production of osteoclast differentiation inducing factors such as RANKL, TNF-alpha, and IL-6 in the presence of antimycin A, which inhibits mitochondrial electron transport and has been used as an ROS generator.	magnolol	0-8	interleukin 6	Mus musculus	139-143
22474400-8	2012	Magnolol significantly (P &lt; 0.05) decreased the production of osteoclast differentiation inducing factors such as RANKL, TNF-alpha, and IL-6 in the presence of antimycin A, which inhibits mitochondrial electron transport and has been used as an ROS generator.	Antimycin A	163-174	interleukin 6	Mus musculus	139-143
22577492-3	2012	Besides, pine pollen reversed D-galactose-induced aging effects in neural activity and inflammatory cytokine levels, as indicated by improved memory latency time and reduced error rate in step-down test and decreased concentrations of IL-6 and TNF-alpha in model mice.	Galactose	30-41	interleukin 6	Mus musculus	235-239
22355243-14	2012	Conjunctival IL-1beta, IL-2, IL-6, IL-17, tumor necrosis factor-alpha (TNF-alpha), and MMP-9 mRNA expression was lower in the ICES+TT group than in the ICES or ICES+PBS group.	6-thiotheophylline	131-133	interleukin 6	Mus musculus	29-33
22172229-6	2012	The expression levels of tumor necrosis factor-alpha, interleukin-6, and cyclooxygenase-2 (COX-2) mRNAs on the colonic mucosa of AOM-treated mice were significantly decreased by curcumin administration.	Curcumin	178-186	interleukin 6	Mus musculus	54-67
23284890-5	2012	CDA-2 and PG significantly reduced NF-kappaB DNA-binding activity in lung cancer cells and in alveolar macrophages of tumor bearing mice and especially decreased the release of inflammatory factors including TNFalpha, IL-6, and KC.	cda-2	0-5	interleukin 6	Mus musculus	218-222
23087136-5	2012	The treatment effects of MGF (50 mg/kg, po, for 7 days) were verified on locomotor behavioral changes in open-field test, and on the oxidant stress-related increase in lipid-peroxidation (malondialdehyde) and interleukin-6 (IL-6) levels in brain tissues.	mangiferin	25-28	interleukin 6	Mus musculus	209-222
23087136-5	2012	The treatment effects of MGF (50 mg/kg, po, for 7 days) were verified on locomotor behavioral changes in open-field test, and on the oxidant stress-related increase in lipid-peroxidation (malondialdehyde) and interleukin-6 (IL-6) levels in brain tissues.	mangiferin	25-28	interleukin 6	Mus musculus	224-228
23087136-9	2012	Also, ketamine-associated increase in brain tissue levels of IL-6 and MDA were significantly lowered in MGF-pretreated mice.	Ketamine	6-14	interleukin 6	Mus musculus	61-65
23251498-8	2012	; once daily for 3 days) in the dorsal hippocampus were associated with a suppression of HI-induced increases in the expression of IL-1beta, TNF-alpha and IL-6.	hi	89-91	interleukin 6	Mus musculus	155-159
23226485-8	2012	Linear regression showed that IL-2, IL-6 and IL-12 levels predicted 66% of corticosterone levels, which were selectively increased in psoriasis mice subject to PSD.	Corticosterone	75-89	interleukin 6	Mus musculus	36-40
23152932-11	2012	Inhibition of Rac1 activation with Z62954982, a novel Rac inhibitor, decreased proliferation, p38 phosphorylation and IL-6 levels in pulmonary arterial smooth muscle cells exposed to hypoxia.	YT 146	35-44	interleukin 6	Mus musculus	118-122
23236370-9	2012	Moreover, oroxylin A significantly attenuated LPS-induced late expression (20 hours after LPS challenge) of IL-1beta and IL-6.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	10-20	interleukin 6	Mus musculus	121-125
22937108-5	2012	The expressions of kidney injury marker neutrophil gelatinase-associated lipocalin and pro-inflammatory cytokines interleukin-6, tumor necrosis factor-alpha and interleukin-1beta were suppressed by MES+HS treatment.	2-(N-morpholino)ethanesulfonic acid	198-201	interleukin 6	Mus musculus	114-156
22962574-7	2012	RESULTS: IL-6 concentrations increased significantly in the colon tissues of DSS-treated mice.	Dextran Sulfate	77-80	interleukin 6	Mus musculus	9-13
22720096-3	2012	In the present study, we show that a novel chromone derivative, DCO-6, significantly reduced lipopolysaccharide (LPS)-induced production of nitric oxide, IL-1beta and IL-6, decreased the levels of iNOS, IL-1beta and IL-6 mRNA expression in both RAW264.7 cells and mouse primary peritoneal macrophages, and inhibited LPS-induced activation of p38 MAPK but not of JNK, ERK.	Chromones	43-51	interleukin 6	Mus musculus	167-171
22720096-3	2012	In the present study, we show that a novel chromone derivative, DCO-6, significantly reduced lipopolysaccharide (LPS)-induced production of nitric oxide, IL-1beta and IL-6, decreased the levels of iNOS, IL-1beta and IL-6 mRNA expression in both RAW264.7 cells and mouse primary peritoneal macrophages, and inhibited LPS-induced activation of p38 MAPK but not of JNK, ERK.	Chromones	43-51	interleukin 6	Mus musculus	216-220
22720096-3	2012	In the present study, we show that a novel chromone derivative, DCO-6, significantly reduced lipopolysaccharide (LPS)-induced production of nitric oxide, IL-1beta and IL-6, decreased the levels of iNOS, IL-1beta and IL-6 mRNA expression in both RAW264.7 cells and mouse primary peritoneal macrophages, and inhibited LPS-induced activation of p38 MAPK but not of JNK, ERK.	5,7-dihydroxy-3-(3-oxo-3-phenylprop-1-en-1-yl)-4H-chromen-4-one	64-69	interleukin 6	Mus musculus	167-171
22720096-3	2012	In the present study, we show that a novel chromone derivative, DCO-6, significantly reduced lipopolysaccharide (LPS)-induced production of nitric oxide, IL-1beta and IL-6, decreased the levels of iNOS, IL-1beta and IL-6 mRNA expression in both RAW264.7 cells and mouse primary peritoneal macrophages, and inhibited LPS-induced activation of p38 MAPK but not of JNK, ERK.	5,7-dihydroxy-3-(3-oxo-3-phenylprop-1-en-1-yl)-4H-chromen-4-one	64-69	interleukin 6	Mus musculus	216-220
22427843-6	2012	With respect to the molecular mechanism, we found that UA down-regulated activation of various pro-inflammatory mediators including, NF-kappaB, STAT3, AKT and IKKalpha/beta phosphorylation in the dorsolateral prostate (DLP) tissues that correlated with the reduction in serum levels of TNF-alpha and IL-6.	ursolic acid	55-57	interleukin 6	Mus musculus	300-304
22363615-10	2012	Treatment of cells with UA prior to allogenic transplantation significantly delayed induction of acute graft-versus-host disease in mice and also significantly reduced the serum levels of pro-inflammatory cytokines IL-6 and IFN-gamma.	ursolic acid	24-26	interleukin 6	Mus musculus	215-219
22196041-10	2011	DITPA-treated group: (n = 6), I/R + DITPA (3.75 mg/kg) by intraperitoneal injection.After the end of reperfusion phase mice were sacrificed, blood samples were collected directly from the heart for determination of serum TNF-a, IL-6, urea and Creatinine.	3,5-diiodothyropropionic acid	0-5	interleukin 6	Mus musculus	228-232
22654663-8	2012	Chitohexaose inhibited LPS induced production of inflammatory molecules TNF-alpha, IL-1beta and IL-6 by macropahges in vitro and in vivo in mice.	chitohexaose	0-12	interleukin 6	Mus musculus	96-100
22020035-11	2012	Concomitantly, administration of JWH-133 led to a lower intensity of Iba1+ microglia/macrophages and a decrease in middle cerebral artery occlusion-induced gene expression of both classic (IL-6, TNF-alpha, MCP-1, MIP-1alpha, RANTES, and iNOS) and alternative mediators/markers (IL-10, TGF-beta, and Ym1) of microglial/macrophage activation after permanent middle cerebral artery occlusion.	1,1-dimethylbutyl-1-deoxy-Delta(9)-THC	33-40	interleukin 6	Mus musculus	189-193
22114936-5	2011	In LPS-stimulated peritoneal macrophages, the oleuropein metabolite, hydroxytyrosol, was shown to inhibit NO production, iNOS expression, NF-kappaB p65 subunit translocation, mRNA expression, and the release of IL-1beta, IL-6, and TNF-alpha.	3,4-dihydroxyphenylethanol	69-83	interleukin 6	Mus musculus	221-225
22189182-14	2011	The 8, 17-epoxide of BrDs played a crucial role in the inhibition of IL-6 expression, and replacement of the C-12 hydroxyl group with longer esters in BrDs gradually decreased this inhibitory activity.	8, 17-epoxide	4-17	interleukin 6	Mus musculus	69-73
22185406-13	2011	The microarray DNA analyses, followed by pathway analyses indicated that quercetin or delta-tocotrienol inhibit several LPS-induced expression of several ageing and pro-inflammatory genes (IL-1beta, IL-1alpha, IL-6, TNF-alpha, IL-12, iNOS, VCAM1, ICAM1, COX2, IL-1RA, TRAF1 and CD40).	Quercetin	73-82	interleukin 6	Mus musculus	210-214
22185406-13	2011	The microarray DNA analyses, followed by pathway analyses indicated that quercetin or delta-tocotrienol inhibit several LPS-induced expression of several ageing and pro-inflammatory genes (IL-1beta, IL-1alpha, IL-6, TNF-alpha, IL-12, iNOS, VCAM1, ICAM1, COX2, IL-1RA, TRAF1 and CD40).	tocotrienol, delta	86-103	interleukin 6	Mus musculus	210-214
22064046-6	2011	However, adult mice prenatally exposed to quercetin had significant increase iron storage in the liver, by upregulating iron-associated cytokine expression (hepcidin, IL-1beta, IL-6 and IL-10).	Quercetin	42-51	interleukin 6	Mus musculus	177-181
22179317-5	2011	Although it protected against endotoxic shock, this ROS-mediated superinduction of ATF3 caused high susceptibility to bacterial and fungal infections through the suppression of interleukin 6 (IL-6).	Reactive Oxygen Species	52-55	interleukin 6	Mus musculus	177-190
22179317-5	2011	Although it protected against endotoxic shock, this ROS-mediated superinduction of ATF3 caused high susceptibility to bacterial and fungal infections through the suppression of interleukin 6 (IL-6).	Reactive Oxygen Species	52-55	interleukin 6	Mus musculus	192-196
22958952-10	2011	Furthermore, we observed that A20 level was suppressed in macrophages of mice treated with alcohol; the levels of tumor necrosis factor, interleukin-6 and nuclear factor kappa B in macrophage were increased.	Alcohols	91-98	interleukin 6	Mus musculus	137-177
22189182-14	2011	The 8, 17-epoxide of BrDs played a crucial role in the inhibition of IL-6 expression, and replacement of the C-12 hydroxyl group with longer esters in BrDs gradually decreased this inhibitory activity.	Esters	141-147	interleukin 6	Mus musculus	69-73
22050227-6	2011	Therefore, the aim of this study is to elucidate the regulation of IL-6-induced gene expression by glucagon.	Glucagon	99-107	interleukin 6	Mus musculus	67-71
22050227-7	2011	We could reveal a novel mechanism of negative regulation of IL-6-induced MAP kinase activation by glucagon in primary murine hepatocytes.	Glucagon	98-106	interleukin 6	Mus musculus	60-64
22050227-8	2011	IL-6-dependent induction of the ERK-dependent target gene Tfpi2, coding for a Kunitz-type serine protease inhibitor, was strongly down-regulated by glucagon treatment.	Glucagon	148-156	interleukin 6	Mus musculus	0-4
22050227-10	2011	The metabolic hormone glucagon interferes in IL-6-induced gene expression.	Glucagon	22-30	interleukin 6	Mus musculus	45-49
21976224-9	2011	PGG glucan enhanced survival in female mice over a 10-day period, but survival in males was improved for only 24 h. In female mice, PGG glucan reduced interleukin-6 (IL-6) and IL-10 levels and reduced the bacterial burden in the liver.	pgg-glucan	132-142	interleukin 6	Mus musculus	151-164
22299314-8	2011	Treatment with OR extract in RPMC also inhibited PMA/A23187-induced production of inflammatory cytokines such as TNF-alpha and IL-6.	rpmc	29-33	interleukin 6	Mus musculus	127-131
22299314-8	2011	Treatment with OR extract in RPMC also inhibited PMA/A23187-induced production of inflammatory cytokines such as TNF-alpha and IL-6.	Calcimycin	53-59	interleukin 6	Mus musculus	127-131
21501145-8	2011	Pretreatment of mice with thymoquinone prevented DEP-induced decrease of SBP and leucocytosis, increased IL-6 concentration and decreased plasma SOD activity.	thymoquinone	26-38	interleukin 6	Mus musculus	105-109
21976224-9	2011	PGG glucan enhanced survival in female mice over a 10-day period, but survival in males was improved for only 24 h. In female mice, PGG glucan reduced interleukin-6 (IL-6) and IL-10 levels and reduced the bacterial burden in the liver.	pgg-glucan	132-142	interleukin 6	Mus musculus	166-170
21925564-2	2011	Previously, we observed a diet supplemented with 5% SM resulted in a twofold increase in plasma IL-6 levels in DBA arthritic mice.	1,2,5,6-dibenzanthracene	111-114	interleukin 6	Mus musculus	96-100
21826694-9	2011	Expression of liver proinflammatory cytokines tumor necrosis factor alpha, interleukin (IL)-1beta, IL-6, KC/IL-8, intercellular adhesion molecule 1, and cluster of differentiation 68 was induced in alcohol-fed WT, but inhibited in MCP-1KO, mice independent of nuclear factor kappa light-chain enhancer of activated B cell activation in KCs.	Alcohols	198-205	interleukin 6	Mus musculus	99-103
21046213-5	2011	In OVX-CIA, SnPP decreased the serum levels of IL-6, MMP-3, and PGD2; down-regulated TNFalpha, COX-2, hPGDS, PGD2, PGE2, and MMP-3 in joint tissues; and also decreased focal bone loss in the inflamed joint.	S-Nitroso-N-propionyl-D,L-penicillamine	12-16	interleukin 6	Mus musculus	47-51
22217712-10	2011	Ascorbate supplementation of gulo KO mice resulted in profoundly decreased serum inflammatory cytokine IL-6 (90% decrease, p = 0.04) and IL-1beta (62% decrease) compared to the levels in gulo KO mice deprived of ascorbate.	Ascorbic Acid	0-9	interleukin 6	Mus musculus	103-107
21401384-4	2011	The anti-allergic effect of gomisin has shown that inhibited PMA + A23187-induced interleukin-6 (IL-6) production.	Calcimycin	67-73	interleukin 6	Mus musculus	82-95
21401384-4	2011	The anti-allergic effect of gomisin has shown that inhibited PMA + A23187-induced interleukin-6 (IL-6) production.	Calcimycin	67-73	interleukin 6	Mus musculus	97-101
21401384-6	2011	The results revealed that gomisin inhibited the PMA + A23187-induced production of IL-6, PGD(2), LTC(4), beta-Hex, and COX-2 protein.	Calcimycin	54-60	interleukin 6	Mus musculus	83-87
21802165-8	2011	Augmented synthesis of NO and IL-6 was prevented by treatment with Polymyxin B, or by exposure to a specific NF-kappaB p65 oligonucleotide antisense, indicating the involvement of TLR4-mediated NF-kappaB activation in the unleashed pro-inflammatory response triggered by TNFRp55 deficiency.	Oligonucleotides	123-138	interleukin 6	Mus musculus	30-34
21996541-7	2011	Furthermore, the production of pro inflammatory cytokines TNF-alpha, interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) was significantly reduced in K68-administered group.	(4,5,6,7-Tetrabromo-1h-Benzimidazol-1-Yl)acetic Acid	153-156	interleukin 6	Mus musculus	103-116
21963450-7	2011	Among the major cytokines, IL-6 is an important signalling molecule, which also regulates iron homeostasis in response to an inflammatory situation.	Iron	90-94	interleukin 6	Mus musculus	27-31
21996541-7	2011	Furthermore, the production of pro inflammatory cytokines TNF-alpha, interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) was significantly reduced in K68-administered group.	(4,5,6,7-Tetrabromo-1h-Benzimidazol-1-Yl)acetic Acid	153-156	interleukin 6	Mus musculus	118-122
22122305-13	2011	NAC also inhibited the transcription of NFkappaB, IL-6, TNF-alpha and COX2 usually induced by LPS.	Acetylcysteine	0-3	interleukin 6	Mus musculus	50-54
21809375-5	2011	In addition, roxatidine reduced the productions and expressions of VEGF-1 and pro-inflammatory cytokines, including those of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6).	roxatidine acetate	13-23	interleukin 6	Mus musculus	200-213
22015602-9	2011	In addition, hydrogen decreased malonaldehyde and nitrotyrosine content, inhibited myeloperoxidase and maintained superoxide dismutase activity in lung tissues and associated with a decrease in the expression of TNF-alpha, IL-1beta, IL-6 and total protein concentrations in the BALF.	Hydrogen	13-21	interleukin 6	Mus musculus	233-237
22019446-4	2011	Salidroside significantly attenuated TNF-alpha, IL-1beta and IL-6 productions in serum from mice challenged with LPS, and consistent with the results in vitro.	rhodioloside	0-11	interleukin 6	Mus musculus	61-65
21809372-5	2011	Pelubiprofen potently diminished PGE(2) productions through inhibition of COX enzyme activity (IC(50) values for COX-1 and COX-2 are 10.66 +- 0.99 and 2.88 +- 1.01 microM, respectively), but also reduced the expressions of COX-2, inducible nitric oxide (iNOS), tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6 at transcriptional level in LPS-induced RAW 264.7 cells.	pelubiprofen	0-12	interleukin 6	Mus musculus	336-340
21809375-5	2011	In addition, roxatidine reduced the productions and expressions of VEGF-1 and pro-inflammatory cytokines, including those of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6).	roxatidine acetate	13-23	interleukin 6	Mus musculus	215-219
21697021-8	2011	In GAS-infected mice, tissue levels of interleukin 6 and tumor necrosis factor alpha were significantly higher in ibuprofen-treated mice than those in the control group.	Ibuprofen	114-123	interleukin 6	Mus musculus	39-84
21826708-4	2011	Similarly, ailanthoidol inhibited the production of inflammatory cytokines induced by LPS in RAW264.7 cells, including interleukin (IL)-1beta and IL-6.	ailanthoidol	11-23	interleukin 6	Mus musculus	146-150
22024414-9	2011	The administration of SR144528 declined interferon-gamma, IL-17, IL-4, IL-10, IL-1beta, IL-6 and tumor necrosis factor-alpha, but increased CX3CL1 in brain and/or spinal cord.	SR 144528	22-30	interleukin 6	Mus musculus	88-124
21952987-3	2011	Splenocytes of infected mice (C3H/HeN) responded to Tc-antigenic stimulus by more than a two-fold increase in NADPH oxidase (NOX) activity, ROS generation, cytokine production (IFN-gamma &gt; IL-4 &gt; TNFalpha &gt; IL1-beta  IL6), and predominant expansion of CD4(+) and CD8(+) T cells.	Technetium	52-54	interleukin 6	Mus musculus	226-229
21962804-10	2011	Treatment with pioglitazone significantly inhibited the increases in the serum interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) levels after CLP and lowered the mRNA expressions of proinflammatory cytokines, interleukin-6, and MCP-1 in omental tissue after CLP.	Pioglitazone	15-27	interleukin 6	Mus musculus	79-92
21962804-10	2011	Treatment with pioglitazone significantly inhibited the increases in the serum interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) levels after CLP and lowered the mRNA expressions of proinflammatory cytokines, interleukin-6, and MCP-1 in omental tissue after CLP.	Pioglitazone	15-27	interleukin 6	Mus musculus	220-233
21940958-3	2011	In this study, we investigated the neuroprotective role of the IL-6 receptor (IL-6R) by IL-6 in the reactive oxygen species defense system after transient focal cerebral ischemia (tFCI).	Reactive Oxygen Species	100-123	interleukin 6	Mus musculus	63-67
22086758-7	2011	At this early stage of injury, RSV significantly reduced TNF-alpha and IL-6 mRNA and decreased the number of Kupffer cells (CD68(+) ) recruited in the injured liver.	Resveratrol	31-34	interleukin 6	Mus musculus	71-75
21963823-4	2011	As results, levels of pro-inflammatory cytokines such as interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha were significantly reduced by treatments of phlorofucofuroeckol A in LPS-stimulated RAW 264.7 cells.	phlorofucofuroeckol A	168-189	interleukin 6	Mus musculus	81-85
21970803-4	2011	MPTP treatment enhanced the release of interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha, IL-4 and IL-10 (P &lt; 0.05).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	interleukin 6	Mus musculus	63-67
21976777-6	2011	Together, these findings suggest that PGI(2) plays a key immunoregulatory role by promoting the development of innate intraepithelial gammadelta-17 cells through an IL-6-dependent mechanism.	Epoprostenol	38-44	interleukin 6	Mus musculus	165-169
21946106-6	2011	In addition, C-721 inhibited TNF-alpha and IL-6 production at 10-50 muM.	Carbon	13-14	interleukin 6	Mus musculus	43-47
21920376-7	2011	Measurements of 6 circulating cytokines indicated elevation of IL-6, IL-12, IFNgamma and TNFalpha in Dox treated WT mice but not p21KO mice.	Doxorubicin	101-104	interleukin 6	Mus musculus	63-67
21925164-6	2011	Treatment with THDCA in doses of 25, 50 and 100mg/kg/day and sulfasalazine in a dose of 500 mg/kg/day used as reference for 7 consecutive days after the induction of colitis, significantly decreased colonic MPO activity, TNF-alpha, IL-6 serum levels and the expression of COX-2 in colon compared with TNBS induced ulcerative colitis model group.	taurohyodeoxycholic acid	15-20	interleukin 6	Mus musculus	232-236
21925164-6	2011	Treatment with THDCA in doses of 25, 50 and 100mg/kg/day and sulfasalazine in a dose of 500 mg/kg/day used as reference for 7 consecutive days after the induction of colitis, significantly decreased colonic MPO activity, TNF-alpha, IL-6 serum levels and the expression of COX-2 in colon compared with TNBS induced ulcerative colitis model group.	Sulfasalazine	61-74	interleukin 6	Mus musculus	232-236
22087354-4	2011	AA, EPA and DHA and their anti-inflammatory products lipoxins (LXs), resolvins and protectins suppress IL-6 and TNF-alpha and PGE(2) production.	Eicosapentaenoic Acid	4-7	interleukin 6	Mus musculus	103-107
22087354-4	2011	AA, EPA and DHA and their anti-inflammatory products lipoxins (LXs), resolvins and protectins suppress IL-6 and TNF-alpha and PGE(2) production.	Docosahexaenoic Acids	12-15	interleukin 6	Mus musculus	103-107
22087354-4	2011	AA, EPA and DHA and their anti-inflammatory products lipoxins (LXs), resolvins and protectins suppress IL-6 and TNF-alpha and PGE(2) production.	Lipoxins	53-61	interleukin 6	Mus musculus	103-107
22087354-4	2011	AA, EPA and DHA and their anti-inflammatory products lipoxins (LXs), resolvins and protectins suppress IL-6 and TNF-alpha and PGE(2) production.	Lipoxins	63-66	interleukin 6	Mus musculus	103-107
21920376-8	2011	Dox induced elevation of IL-6 mRNA was detected in the myocardium of WT mice but not p21KO mice.	Doxorubicin	0-3	interleukin 6	Mus musculus	25-29
21792823-5	2011	RESULTS: Treatment with topo I and CFA, in contrast to treatment with topo I and IFA, induced skin and lung fibrosis with increased interleukin-6 (IL-6), transforming growth factor beta1, and IL-17 production and decreased IL-10 production.	3-chloro-4-fluoroaniline	35-38	interleukin 6	Mus musculus	132-145
22047130-9	2011	RESULTS: Diazoxide inhibited in vitro nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) production and inducible nitric oxide synthase (iNOS) expression by activated microglia without affecting cyclooxygenase-2 (COX-2) expression and phagocytosis.	Diazoxide	9-18	interleukin 6	Mus musculus	101-114
22047130-9	2011	RESULTS: Diazoxide inhibited in vitro nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) production and inducible nitric oxide synthase (iNOS) expression by activated microglia without affecting cyclooxygenase-2 (COX-2) expression and phagocytosis.	Diazoxide	9-18	interleukin 6	Mus musculus	116-120
21792823-5	2011	RESULTS: Treatment with topo I and CFA, in contrast to treatment with topo I and IFA, induced skin and lung fibrosis with increased interleukin-6 (IL-6), transforming growth factor beta1, and IL-17 production and decreased IL-10 production.	3-chloro-4-fluoroaniline	35-38	interleukin 6	Mus musculus	147-151
21733121-5	2011	BaP treatment caused a significant increase in the levels of MDA and IL-6 with significantly increased activity of CYP1A1, creatine kinase and aspartate aminotransferase (AST) and decreased activity of glutathione-S-transferase in the cervix and liver.	Benzo(a)pyrene	0-3	interleukin 6	Mus musculus	69-73
21542833-6	2011	RESULTS: In macrophages, 5alphaTHB increased secretion of IL-10 similarly to corticosterone (180%, 340%; data are % vehicle, treated with 5alphaTHB and corticosterone, respectively) and suppressed LPS-induced secretion of TNF-alpha (21.9%, 74.2%) and IL-6 (16.4%, 69.4%).	5alphathb	25-34	interleukin 6	Mus musculus	251-255
21819972-5	2011	By using selective inhibitors of MAPKs, this study confirms that both activated p38/MK2 pathways and ERK1/2 MAPK play a significant role in regulation of both TNF-alpha and IL-6 protein production induced by DMXAA at the post-transcriptional level.	vadimezan	208-213	interleukin 6	Mus musculus	173-177
21542833-7	2011	In mice with thioglycollate-induced peritonitis, both 5alphaTHB and corticosterone reduced the numbers of neutrophils (58.6%, 49.9%) and inflammatory monocytes (69.5%, 96.4%), and also suppressed MCP-1 (48.7%, 80.9%) and IL-6 (53.5%, 86.7%) in peritoneal exudate.	5alphathb	54-63	interleukin 6	Mus musculus	221-225
21542833-7	2011	In mice with thioglycollate-induced peritonitis, both 5alphaTHB and corticosterone reduced the numbers of neutrophils (58.6%, 49.9%) and inflammatory monocytes (69.5%, 96.4%), and also suppressed MCP-1 (48.7%, 80.9%) and IL-6 (53.5%, 86.7%) in peritoneal exudate.	Corticosterone	68-82	interleukin 6	Mus musculus	221-225
21835903-9	2011	iPS cells mediated a downregulation of the proinflammatory response to endotoxin (reducing tumor necrosis factor-alpha, IL-6, and macrophage inflammatory peptide-2).	IPS	0-3	interleukin 6	Mus musculus	120-124
21767631-11	2011	However, catecholamines inhibit release of IL-6 via alpha1-adrenergic pathways but without any effect on TGF-beta.	Catecholamines	9-23	interleukin 6	Mus musculus	43-47
21767631-12	2011	The co-transmitter adenosine stimulated IL-6 release via A1-adenosine receptors but no influence was recognized on TGF-beta.	Adenosine	19-28	interleukin 6	Mus musculus	40-44
22803040-5	2011	Ladasten was more potent than imipramine in decreasing the content of proinflammatory cytokines TNF-alpha and IL-6 and preventing the development of behavioral disturbances in mice.	Imipramine	30-40	interleukin 6	Mus musculus	110-114
21809356-10	2011	Treatment with neutralizing antibody to HMGB1 protects against FFA-induced tumor necrosis factor alpha and interleukin-6 production.	Fatty Acids, Nonesterified	63-66	interleukin 6	Mus musculus	107-120
21871511-9	2011	Clenbuterol and forskolin caused downregulation of cytokines and chemokines such as IL-6 and MCP-1.	Clenbuterol	0-11	interleukin 6	Mus musculus	84-88
21871511-9	2011	Clenbuterol and forskolin caused downregulation of cytokines and chemokines such as IL-6 and MCP-1.	Colforsin	16-25	interleukin 6	Mus musculus	84-88
21871511-11	2011	The cAMP-raising drug combinations attenuated the upregulation of TNF-alpha and IL-6 mRNA and the secretion of IL-6, but did not affect initial NF-kappaB signalling triggered by the stimulating cytokines.	Cyclic AMP	4-8	interleukin 6	Mus musculus	80-84
21871511-11	2011	The cAMP-raising drug combinations attenuated the upregulation of TNF-alpha and IL-6 mRNA and the secretion of IL-6, but did not affect initial NF-kappaB signalling triggered by the stimulating cytokines.	Cyclic AMP	4-8	interleukin 6	Mus musculus	111-115
21958119-8	2011	Resveratrol also tended to reduce aberrant crypt foci development and decrease circulating interleukin 6 and insulin concentrations in male but not female Wt mice.	Resveratrol	0-11	interleukin 6	Mus musculus	91-104
21632071-0	2011	Deletion of interleukin-6 improves pyruvate tolerance without altering hepatic insulin signaling in the leptin receptor-deficient mouse.	Pyruvic Acid	35-43	interleukin 6	Mus musculus	12-25
21632071-2	2011	This study was designed to assess the impact of the systemic absence of IL-6 on the development of insulin resistance and glucose intolerance in an obese mouse model.	Glucose	122-129	interleukin 6	Mus musculus	72-76
21632071-6	2011	These results suggest that loss of IL-6 in the context of obesity may locally reduce hepatic glucose production from a gluconeogenic precursor.	Glucose	93-100	interleukin 6	Mus musculus	35-39
21538629-4	2011	Several molecules, such as myeloid differentiation factor 88, tumor necrosis factor-alpha and interleukin 6, which are involved in the TLR9 downstream signaling pathway, were also significantly up-regulated in response to icariin stimulation.	icariin	222-229	interleukin 6	Mus musculus	94-107
21841536-13	2011	2-Methoxyestradiol significantly reduced IL-1beta, IL-6, TNF-alpha, and NO levels in septic mice as well as in LPS-stimulated peritoneal macrophages.	2-Methoxyestradiol	0-18	interleukin 6	Mus musculus	51-55
21569043-6	2011	Recipients of phenylhydrazine- or heat-treated RBCs had elevated circulating levels of keratinocyte-derived chemokine/CXCL-1, monocyte chemoattractant protein-1, and interleukin-6 after transfusion.	phenylhydrazine	14-29	interleukin 6	Mus musculus	166-179
22375399-5	2011	On the LPS-induced RAW264.7 cells, APR essential oil reversed LPS-suppressed N-palmitoylethanolamide (PEA) contents in a dose-dependent manner and reduced LPS-induced proinflammatory genes, TNF-alpha and IL-6.	apr essential oil	35-52	interleukin 6	Mus musculus	204-208
21969559-7	2011	Indeed, upon manipulation of the melanoma microenvironment with the phosphodiesterase-5 inhibitor sildenafil, we observed reduced levels of numerous inflammatory mediators (e.g., IL-1beta, IL-6, VEGF, S100A9) in association with decreased MDSC amounts and immunosuppressive function, indicating an antiinflammatory effect of sildenafil.	Sildenafil Citrate	98-108	interleukin 6	Mus musculus	189-193
21987656-4	2011	After AOM+DSS treatment, IL-21 KO mice showed reduced mucosal damage, reduced infiltration of T cells, and diminished production of IL-6 and IL-17A.	Dextran Sulfate	10-13	interleukin 6	Mus musculus	132-136
21993246-7	2011	THSG appears to exert its beneficial effects on acetic acid-induced experimental colitis through upregulation of PPAR-gamma mRNA and protein levels and inhibition of the NF-kappaB pathway, which in turn decreases the protein overexpression of the downstream inflammatory mediators TNF-alpha, IL-6 and COX-2.	2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside	0-4	interleukin 6	Mus musculus	292-296
21993246-7	2011	THSG appears to exert its beneficial effects on acetic acid-induced experimental colitis through upregulation of PPAR-gamma mRNA and protein levels and inhibition of the NF-kappaB pathway, which in turn decreases the protein overexpression of the downstream inflammatory mediators TNF-alpha, IL-6 and COX-2.	Acetic Acid	48-59	interleukin 6	Mus musculus	292-296
21835925-3	2011	Here, we report that lipopolysaccharide (LPS) and Pam(3)CysSerLys(4) exerted more profound effects on release of the proinflammatory cytokines, interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha (TNFalpha), in glia prepared from CD200(-/-) mice compared with wild type mice.	(3)cysserlys	53-65	interleukin 6	Mus musculus	168-172
21835925-3	2011	Here, we report that lipopolysaccharide (LPS) and Pam(3)CysSerLys(4) exerted more profound effects on release of the proinflammatory cytokines, interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha (TNFalpha), in glia prepared from CD200(-/-) mice compared with wild type mice.	pam	50-53	interleukin 6	Mus musculus	168-172
21970837-8	2011	The serum lp-PLA2 activity, hs-CRP and IL-6 levels, however, were significantly reduced in the darpladib group.	darpladib	95-104	interleukin 6	Mus musculus	39-43
21297079-9	2011	Acute (4-day) exposure to cigarette smoke (CS) further augmented the expression of IL-6 in lungs of gp130(F/F) mice, and subchronic (6-week) exposure to CS exacerbated emphysematous and apoptotic changes in the lungs of gp130(F/F) but not gp130(F/F): IL-6(-/-) mice.	Cesium	43-45	interleukin 6	Mus musculus	83-87
21297079-9	2011	Acute (4-day) exposure to cigarette smoke (CS) further augmented the expression of IL-6 in lungs of gp130(F/F) mice, and subchronic (6-week) exposure to CS exacerbated emphysematous and apoptotic changes in the lungs of gp130(F/F) but not gp130(F/F): IL-6(-/-) mice.	Cesium	43-45	interleukin 6	Mus musculus	251-255
21297079-9	2011	Acute (4-day) exposure to cigarette smoke (CS) further augmented the expression of IL-6 in lungs of gp130(F/F) mice, and subchronic (6-week) exposure to CS exacerbated emphysematous and apoptotic changes in the lungs of gp130(F/F) but not gp130(F/F): IL-6(-/-) mice.	Cesium	153-155	interleukin 6	Mus musculus	83-87
21736830-0	2011	A potential role of IL-6 in the chito-oligosaccharide-mediated inhibition of adipogenesis.	oligochitosan	32-53	interleukin 6	Mus musculus	20-24
21297079-9	2011	Acute (4-day) exposure to cigarette smoke (CS) further augmented the expression of IL-6 in lungs of gp130(F/F) mice, and subchronic (6-week) exposure to CS exacerbated emphysematous and apoptotic changes in the lungs of gp130(F/F) but not gp130(F/F): IL-6(-/-) mice.	Cesium	153-155	interleukin 6	Mus musculus	251-255
21778460-7	2011	In addition, TMMC inhibited pancreatic acinar cell death and production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 by inhibiting NF-kappaB and extracellular signal-regulated protein kinase 1/2 (ERK1/2) activation.	2',4',6'-tris(methoxymethoxy) chalcone	13-17	interleukin 6	Mus musculus	138-142
21618208-8	2011	In addition, production of fibrogenic cytokines such as interleukin-6 and transforming growth factor beta1, production of anti-topoisomerase I antibody, and the degree of hypergammaglobulinemia were reduced by edaravone.	Edaravone	210-219	interleukin 6	Mus musculus	56-106
21736830-8	2011	Chito-oligosaccharide-mediated inhibition of adipogenesis was associated with the up-regulation of the IL-6 gene at all concentrations of chito-oligosaccharide examined and the PG-endoperoxide synthase 2 (PTGS2) gene at higher concentrations of chito-oligosaccharide.	oligochitosan	0-21	interleukin 6	Mus musculus	103-107
21736830-8	2011	Chito-oligosaccharide-mediated inhibition of adipogenesis was associated with the up-regulation of the IL-6 gene at all concentrations of chito-oligosaccharide examined and the PG-endoperoxide synthase 2 (PTGS2) gene at higher concentrations of chito-oligosaccharide.	oligochitosan	138-159	interleukin 6	Mus musculus	103-107
21736830-8	2011	Chito-oligosaccharide-mediated inhibition of adipogenesis was associated with the up-regulation of the IL-6 gene at all concentrations of chito-oligosaccharide examined and the PG-endoperoxide synthase 2 (PTGS2) gene at higher concentrations of chito-oligosaccharide.	oligochitosan	245-266	interleukin 6	Mus musculus	103-107
21736830-9	2011	The effect of chito-oligosaccharide on gene expression was validated by measuring IL-6 protein concentrations in the media.	oligochitosan	14-35	interleukin 6	Mus musculus	82-86
21736830-10	2011	Finally, an IL-6 promoter assay was developed to characterise the effect of chito-oligosaccharide on the transcriptional activity of the IL-6 promoter, which was increased in a concentration-dependent manner (P &lt; 0 001).	oligochitosan	76-97	interleukin 6	Mus musculus	12-16
21736830-10	2011	Finally, an IL-6 promoter assay was developed to characterise the effect of chito-oligosaccharide on the transcriptional activity of the IL-6 promoter, which was increased in a concentration-dependent manner (P &lt; 0 001).	oligochitosan	76-97	interleukin 6	Mus musculus	137-141
21736830-11	2011	We conclude that IL-6 is a candidate signalling molecule in the chito-oligosaccharide-mediated inhibition of adipogenesis in 3T3-L1 cells.	oligochitosan	64-85	interleukin 6	Mus musculus	17-21
21951872-8	2011	RESULTS:   Dexamethasone treatment significantly improved the survival rate of endotoxemic mice (P &lt; 0.05), whereas serum alanine aminotransferase, aspartate aminotransferase, tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and gamma-interferon levels were significantly decreased (P &lt; 0.05, respectively).	Dexamethasone	11-24	interleukin 6	Mus musculus	214-232
21320073-0	2011	alpha-Tocopherol attenuates NF-kappaB activation and pro-inflammatory cytokine IL-6 secretion in cancer-bearing mice.	alpha-Tocopherol	0-16	interleukin 6	Mus musculus	79-83
21320073-8	2011	alpha-Tocopherol treatment significantly down-regulates expression, synthesis as well as secretion of pro-inflammatory cytokine IL-6 (interleukin-6) in cancerous mice.	alpha-Tocopherol	0-16	interleukin 6	Mus musculus	128-132
21320073-8	2011	alpha-Tocopherol treatment significantly down-regulates expression, synthesis as well as secretion of pro-inflammatory cytokine IL-6 (interleukin-6) in cancerous mice.	alpha-Tocopherol	0-16	interleukin 6	Mus musculus	134-147
21887695-5	2011	Transitory reductions in IL-10 and IL-12 levels also were observed after swimming at 31 C. The cytokine response to swimming was modified when the water temperature was increased to 38 C. Although exercise at 38 C also led to IL-6 secretion, the peak in IL-6 production occurred 6 h after exercise, and IL-6 levels were significantly lower than those observed after maximum swimming at 31 C (p = 0 030).	Water	147-152	interleukin 6	Mus musculus	226-230
21887695-5	2011	Transitory reductions in IL-10 and IL-12 levels also were observed after swimming at 31 C. The cytokine response to swimming was modified when the water temperature was increased to 38 C. Although exercise at 38 C also led to IL-6 secretion, the peak in IL-6 production occurred 6 h after exercise, and IL-6 levels were significantly lower than those observed after maximum swimming at 31 C (p = 0 030).	Water	147-152	interleukin 6	Mus musculus	254-258
21887695-5	2011	Transitory reductions in IL-10 and IL-12 levels also were observed after swimming at 31 C. The cytokine response to swimming was modified when the water temperature was increased to 38 C. Although exercise at 38 C also led to IL-6 secretion, the peak in IL-6 production occurred 6 h after exercise, and IL-6 levels were significantly lower than those observed after maximum swimming at 31 C (p = 0 030).	Water	147-152	interleukin 6	Mus musculus	254-258
21905822-5	2011	Treatment with thujone downregulated the production of proinflammatory cytokines such as tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and granulocyte-monocyte colony-stimulating factor.	beta-thujone	15-22	interleukin 6	Mus musculus	142-146
22040565-6	2011	Rapa reduced the levels of TNF-alpha (LPS vs. LPS + Rapa, (1672.74 +- 193.73) vs. (539.17 +- 140.48) pg/ml, respectively; P &lt; 0.01) and IL-6 (LPS vs. LPS + Rapa: (7790.88 +- 1170.54) vs. (1968.57 +- 474.62) pg/ml, respectively; P &lt; 0.01) in the BAL fluid.	Sirolimus	0-4	interleukin 6	Mus musculus	139-143
21671066-3	2011	RESULTS: Our data showed that glyceollins effectively inhibited NO production, IL-6 release, and expression of iNOS and COX-2 induced by LPS.	glyceollin	30-41	interleukin 6	Mus musculus	79-83
21951872-10	2011	Consistent with these in vivo experiments, inhibited expression of GITRL, TNF-alpha and IL-6 caused by dexamethasone treatment were also observed in LPS-stimulated KC.	Dexamethasone	103-116	interleukin 6	Mus musculus	88-92
21972810-7	2011	Several molecules, such as myeloid differentiation factor 88, interferon-beta, and interleukin-6, which are involved in the TLR-4 downstream signaling pathway, were upregulated significantly in response to GA stimulation.	Glycyrrhetinic Acid	206-208	interleukin 6	Mus musculus	83-96
21750859-5	2011	Y27632, a specific Rho-kinase inhibitor, significantly reduced thrombin-stimulated IL-6 synthesis as well as the MYPT-1 phosphorylation.	Y 27632	0-6	interleukin 6	Mus musculus	83-87
21750859-6	2011	Fasudil, another inhibitor of Rho-kinase, suppressed thrombin-stimulated IL-6 synthesis.	fasudil	0-7	interleukin 6	Mus musculus	73-77
21778416-13	2011	Vasodilatory response to ACh was impaired when aorta from untreated mice was incubated with ex vivo IL-6 (P = 0.004), whereas in the aorta from mice pretreated with SS, the vasodilatory response did not change with IL-6 incubation (P = 0.387).	Acetylcholine	25-28	interleukin 6	Mus musculus	100-104
21778416-13	2011	Vasodilatory response to ACh was impaired when aorta from untreated mice was incubated with ex vivo IL-6 (P = 0.004), whereas in the aorta from mice pretreated with SS, the vasodilatory response did not change with IL-6 incubation (P = 0.387).	Acetylcholine	25-28	interleukin 6	Mus musculus	215-219
21778416-13	2011	Vasodilatory response to ACh was impaired when aorta from untreated mice was incubated with ex vivo IL-6 (P = 0.004), whereas in the aorta from mice pretreated with SS, the vasodilatory response did not change with IL-6 incubation (P = 0.387).	Simvastatin	165-167	interleukin 6	Mus musculus	215-219
21855149-6	2011	In FLS, low molecular weight hyaluronan (HA)-induced TNFalpha and IL-6 production was increased by overexpression of beta-arrestin 1 but decreased by overexpression of beta-arrestin 2 demonstrating isoform specific regulation.	Hyaluronic Acid	29-39	interleukin 6	Mus musculus	66-70
21645546-7	2011	Therefore, these results suggest that the anti-inflammatory effects of Schisandrin on P. gingivalis LPS-stimulated RAW 264.7 cells may be due to a reduction of NF-kappaB activity and induction of the expression of HO-1, leading to TNF-alpha, IL-1beta, and IL-6 down-regulation.	schizandrin	71-82	interleukin 6	Mus musculus	256-260
21765105-10	2011	Plasma levels of proinflammatory cytokines such as tumor necrosis factor, interleukin 1ss (IL-1ss) and IL-6 were also reduced by CGS 21680.	cysteinylglycine	129-132	interleukin 6	Mus musculus	103-107
21645546-3	2011	First, Schisandrin inhibited LPS-induced pro-inflammatory cytokines, including TNF-alpha, IL-1beta, and IL-6.	schizandrin	7-18	interleukin 6	Mus musculus	104-108
21940443-0	2011	An autocrine neuronal interleukin-6 loop mediates chloride accumulation and NKCC1 phosphorylation in axotomized sensory neurons.	Chlorides	50-58	interleukin 6	Mus musculus	22-35
21940443-4	2011	Functional analysis of cotransporter activity revealed that inhibition of endogenously produced cytokine interleukin-6 (IL-6), with anti-mouse IL-6 antibody or in IL-6-/- mice, prevented chloride accumulation in a subset of axotomized neurons.	Chlorides	187-195	interleukin 6	Mus musculus	105-118
21940443-4	2011	Functional analysis of cotransporter activity revealed that inhibition of endogenously produced cytokine interleukin-6 (IL-6), with anti-mouse IL-6 antibody or in IL-6-/- mice, prevented chloride accumulation in a subset of axotomized neurons.	Chlorides	187-195	interleukin 6	Mus musculus	120-124
21940443-4	2011	Functional analysis of cotransporter activity revealed that inhibition of endogenously produced cytokine interleukin-6 (IL-6), with anti-mouse IL-6 antibody or in IL-6-/- mice, prevented chloride accumulation in a subset of axotomized neurons.	Chlorides	187-195	interleukin 6	Mus musculus	143-147
21940443-4	2011	Functional analysis of cotransporter activity revealed that inhibition of endogenously produced cytokine interleukin-6 (IL-6), with anti-mouse IL-6 antibody or in IL-6-/- mice, prevented chloride accumulation in a subset of axotomized neurons.	Chlorides	187-195	interleukin 6	Mus musculus	143-147
21940443-8	2011	Cell-specific expression of interleukin-6 receptor under pathophysiological conditions is therefore a cellular response by which IL-6 contributes to nerve regeneration through neuronal NKCC1 phosphorylation and chloride accumulation.	Chlorides	211-219	interleukin 6	Mus musculus	28-41
21940443-8	2011	Cell-specific expression of interleukin-6 receptor under pathophysiological conditions is therefore a cellular response by which IL-6 contributes to nerve regeneration through neuronal NKCC1 phosphorylation and chloride accumulation.	Chlorides	211-219	interleukin 6	Mus musculus	129-133
21725996-11	2011	Resistance to steatosis in these mice is attributable to elevation of inflammation-associated hepatic IL-6/STAT3 activation that subsequently down-regulates lipogenic genes but up-regulates fatty acid oxidation-associated genes in the liver.	Fatty Acids	190-200	interleukin 6	Mus musculus	102-106
21763266-8	2011	Trimannose treatment increased the production of other Th1 proinflammatory cytokines (ie, interferon-gamma, IL-6, and tumor necrosis factor-alpha) critical for a productive immune response to either pathogen.	trimannose	0-10	interleukin 6	Mus musculus	108-145
21771572-6	2011	In mouse EWS xenografts, TAMs expressed higher concentrations of cytokines including interleukin-6, keratinocyte-derived chemokine, and monocyte chemotactic protein-1.	tams	25-29	interleukin 6	Mus musculus	85-98
21665267-6	2011	In RAW264.7 cells and DBA/2 mice, ctDNA-F-CLs and ctDNA-N-CLs significantly induced TNF-alpha and IL-6 production compared to free ctDNA.	ctdna-n-cls	50-61	interleukin 6	Mus musculus	98-102
21169556-9	2011	Intratracheal instillations of exogenous IL-6 into IL-6-deficient mice restored these impairments (vasodilatory responses to acetylcholine, P = 0.005; cardiac output, P = 0.025).	Acetylcholine	125-138	interleukin 6	Mus musculus	41-45
21169556-9	2011	Intratracheal instillations of exogenous IL-6 into IL-6-deficient mice restored these impairments (vasodilatory responses to acetylcholine, P = 0.005; cardiac output, P = 0.025).	Acetylcholine	125-138	interleukin 6	Mus musculus	51-55
21169556-12	2011	IL-6 contributes to the cardiovascular dysfunction related to LPS, and pretreatment with budesonide/formoterol reduces the systemic expression of IL-6 and improves cardiovascular dysfunction.	Budesonide	89-99	interleukin 6	Mus musculus	146-150
21169556-12	2011	IL-6 contributes to the cardiovascular dysfunction related to LPS, and pretreatment with budesonide/formoterol reduces the systemic expression of IL-6 and improves cardiovascular dysfunction.	Formoterol Fumarate	100-110	interleukin 6	Mus musculus	146-150
21669192-11	2011	Moreover, in vivo results from mouse lung indicate that psoralidin suppresses IR-induced expression of pro-inflammatory cytokines (TNF-alpha, TGF-beta, IL-6 and IL-1 alpha/beta) and ICAM-1.	psoralidin	56-66	interleukin 6	Mus musculus	152-156
21498419-13	2011	Infiltration of macrophages and T-lymphocytes and mRNA expression of chemokine (C-C motif) ligand-5, interleukin-6, and intercellular adhesion molecule-1 were decreased in the injured vessels of nutlin-3-treated mice.	nutlin 3	195-203	interleukin 6	Mus musculus	101-114
21498084-7	2011	WT+STZ mice exhibited significantly increased levels of serum and macrophage IL-1beta, IL-6, KC/IL-8, IP-10, MCP-1, IFN beta and TNF-alpha compared to WT mice and this was significantly attenuated in TLR4(-/-) +STZ mice (P&lt;0.01).	Streptozocin	3-6	interleukin 6	Mus musculus	87-91
21733838-4	2011	8-OHdG treatment groups significantly reduced pathologic grade of DSS-induced colitis as well as various inflammatory mediators such as TNF-alpha, IL-6, COX-2, and iNOS in a dose-dependent manner.	8-ohdg	0-6	interleukin 6	Mus musculus	147-151
21750200-1	2011	PURPOSE: Previous reports have shown that IL-1alpha-MyD88-IL-6 signaling is essential in promoting hepatocellular carcinoma (HCC) development in a diethylnitrosamine (DEN)-induced mouse model.	Diethylnitrosamine	147-165	interleukin 6	Mus musculus	58-62
21750200-1	2011	PURPOSE: Previous reports have shown that IL-1alpha-MyD88-IL-6 signaling is essential in promoting hepatocellular carcinoma (HCC) development in a diethylnitrosamine (DEN)-induced mouse model.	Diethylnitrosamine	167-170	interleukin 6	Mus musculus	58-62
21247369-6	2011	In addition, vernolide-A significantly down-regulated the serum levels of proinflammatory cytokines such as IL-1beta, IL-6, tumor necrosis factor-alpha (TNF-alpha), and granulocyte-macrophage colony-stimulating factor (GM-CSF) during metastasis.	vernolide-A	13-24	interleukin 6	Mus musculus	118-122
21683614-5	2011	We show that the beta2-adrenoceptor agonist salbutamol enhanced IL-6 production in murine bone marrow-derived DCs stimulated with the nucleotide-binding oligomerization domain 2 ligand muramyl dipeptide.	Albuterol	44-54	interleukin 6	Mus musculus	64-68
21683614-5	2011	We show that the beta2-adrenoceptor agonist salbutamol enhanced IL-6 production in murine bone marrow-derived DCs stimulated with the nucleotide-binding oligomerization domain 2 ligand muramyl dipeptide.	muramyl	185-192	interleukin 6	Mus musculus	64-68
21683614-5	2011	We show that the beta2-adrenoceptor agonist salbutamol enhanced IL-6 production in murine bone marrow-derived DCs stimulated with the nucleotide-binding oligomerization domain 2 ligand muramyl dipeptide.	Dipeptides	193-202	interleukin 6	Mus musculus	64-68
21439396-4	2011	Specifically, the expression of IL-6 and GM-CSF, both at mRNA and protein levels, was found to be increased in a time- and dose-dependent manner with the addition of Dox.	Doxycycline	166-169	interleukin 6	Mus musculus	32-36
21439396-0	2011	Doxycycline up-regulates the expression of IL-6 and GM-CSF via MAPK/ERK and NF-kappaB pathways in mouse thymic epithelial cells.	Doxycycline	0-11	interleukin 6	Mus musculus	43-47
21439396-6	2011	Notably, Dox-induced up-regulation of IL-6 and GM-CSF was largely abolished after pretreatment of MTEC1 with either NF-kappaB inhibitor BAY11-7082 or MEK1/2 inhibitor U0126, supporting the involvement of the two pathways in the process.	Doxycycline	9-12	interleukin 6	Mus musculus	38-42
21439396-6	2011	Notably, Dox-induced up-regulation of IL-6 and GM-CSF was largely abolished after pretreatment of MTEC1 with either NF-kappaB inhibitor BAY11-7082 or MEK1/2 inhibitor U0126, supporting the involvement of the two pathways in the process.	3-(4-methylphenylsulfonyl)-2-propenenitrile	136-146	interleukin 6	Mus musculus	38-42
21439396-6	2011	Notably, Dox-induced up-regulation of IL-6 and GM-CSF was largely abolished after pretreatment of MTEC1 with either NF-kappaB inhibitor BAY11-7082 or MEK1/2 inhibitor U0126, supporting the involvement of the two pathways in the process.	U 0126	167-172	interleukin 6	Mus musculus	38-42
21575743-5	2011	Dehydrocorydaline also prevented increased concentrations of IL-1beta and IL-6 in culture media of LPS-stimulated macrophages.	dehydrocorydalin	0-17	interleukin 6	Mus musculus	74-78
21667204-6	2011	RESULTS: MHNA significantly inhibited the release of NO, IL-1beta and IL-6 as well as the protein expression of iNOS and COX-2 in LPS-stimulated macrophages.	mhna	9-13	interleukin 6	Mus musculus	70-74
21750146-7	2011	TNF-alpha and IL-6 expression was suppressed by dexamethasone, while IL-10 but not TGF-beta was enhanced after TLR stimulation.	Dexamethasone	48-61	interleukin 6	Mus musculus	14-18
21250779-5	2011	Our findings indicate that vanillic acid inhibits LPS-induced production of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6.	Vanillic Acid	27-40	interleukin 6	Mus musculus	114-132
21704694-7	2011	RESULTS: MEMAC inhibited the production of LPS-induced pro-inflammatory cytokines (TNF-alpha and IL-6) and mediators (NO and PGE2) in RAW264.7 cells and human PBMCs.	poly(methyl vinyl ether-co-maleic anhydride)	9-14	interleukin 6	Mus musculus	97-101
25755327-10	2011	Treatment with neutralizing antibody to HMGB1 protects against FFA-induced tumor necrosis factor alpha and interleukin-6 production.	Fatty Acids, Nonesterified	63-66	interleukin 6	Mus musculus	107-120
21813776-2	2011	In this study, we show that in both RAW264.7 macrophage cells and primary bone marrow-derived macrophages, the production of IFN-beta and IL-6, but not TNF, in response to cyclic-di-AMP and cyclic-di-GMP requires MPYS (also known as STING, MITA, and TMEM173).	cyclic diadenosine phosphate	172-185	interleukin 6	Mus musculus	138-142
21813776-2	2011	In this study, we show that in both RAW264.7 macrophage cells and primary bone marrow-derived macrophages, the production of IFN-beta and IL-6, but not TNF, in response to cyclic-di-AMP and cyclic-di-GMP requires MPYS (also known as STING, MITA, and TMEM173).	bis(3',5')-cyclic diguanylic acid	190-203	interleukin 6	Mus musculus	138-142
21575647-5	2011	Our results showed that fluoxetine significantly inhibited lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin- 6 (IL-6) and nitric oxide (NO).	Fluoxetine	24-34	interleukin 6	Mus musculus	147-161
21659471-7	2011	MAGL inhibition fully blocked diclofenac-induced increases in gastric levels of proinflammatory cytokines interleukin (IL)-1beta, IL-6, tumor necrosis factor alpha, and granulocyte colony-stimulating factor, as well as IL-10.	Diclofenac	30-40	interleukin 6	Mus musculus	130-134
21998608-5	2011	Administration of high-dose TBE (400 mg/kg) increased the interleukin-1beta and interleukin-6 levels in the peritoneal cavity over the short term (&lt;1 day) compared with sham controls and low-dose TBE (200 mg/kg) groups.	tbe	28-31	interleukin 6	Mus musculus	80-93
21575647-5	2011	Our results showed that fluoxetine significantly inhibited lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin- 6 (IL-6) and nitric oxide (NO).	Fluoxetine	24-34	interleukin 6	Mus musculus	163-167
21473915-1	2011	Some macrolide antibiotics were reported to inhibit interleukin-6 (IL6) and prostaglandin-E2 (PGE(2)) production by bacterial lipopolysaccharide (LPS) stimulated J774A.1 cells.	Macrolides	5-14	interleukin 6	Mus musculus	52-65
21473915-1	2011	Some macrolide antibiotics were reported to inhibit interleukin-6 (IL6) and prostaglandin-E2 (PGE(2)) production by bacterial lipopolysaccharide (LPS) stimulated J774A.1 cells.	Macrolides	5-14	interleukin 6	Mus musculus	67-70
21473915-4	2011	In LPS-stimulated J774A.1 cells, the extent of inhibition of proinflammatory markers (IL6 and PGE(2)) by macrolides significantly correlated with their extent of accumulation in cells, as well as with the induction of phospholipidosis, and cytotoxic effects in prolonged culture (with correlation coefficients (R) ranging from 0.78 to 0.93).	Macrolides	105-115	interleukin 6	Mus musculus	86-89
21843370-11	2011	Furthermore, GTS-associated recovery from LPS-induced depression-like behavior was paralleled with reduced mRNA levels for IL-1beta, IL-6, TNF-alpha, and IDO in hippocampus.	Glutathionesulfonic acid	13-16	interleukin 6	Mus musculus	133-137
21904636-8	2011	At day 7 the pro-inflammatory cytokines MCP-1 and IL-6 were found to be significantly decreased in regional draining lymph nodes of eplerenone-treated mice, whereas the anti-inflammatory cytokine IL-10 was significantly upregulated.	Eplerenone	132-142	interleukin 6	Mus musculus	50-54
21498061-8	2011	Moreover GTP and its bioactive components (catechin, epigallocatechin and epigallocatechin-3-gallate) assisted in decreasing the leukocytopenia seen after whole mice irradiation and significantly reduced the elevated serum inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6).	Guanosine Triphosphate	9-12	interleukin 6	Mus musculus	272-276
21498061-8	2011	Moreover GTP and its bioactive components (catechin, epigallocatechin and epigallocatechin-3-gallate) assisted in decreasing the leukocytopenia seen after whole mice irradiation and significantly reduced the elevated serum inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6).	Catechin	43-51	interleukin 6	Mus musculus	272-276
21498061-8	2011	Moreover GTP and its bioactive components (catechin, epigallocatechin and epigallocatechin-3-gallate) assisted in decreasing the leukocytopenia seen after whole mice irradiation and significantly reduced the elevated serum inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6).	epigallocatechin gallate	74-100	interleukin 6	Mus musculus	272-276
21705340-5	2011	These IL6-independent clones were dependent on NF-kappaB activity for their survival and proliferation but were resistant to dexamethasone and INCB018424, a selective Janus kinase 1/2 inhibitor.	Dexamethasone	125-138	interleukin 6	Mus musculus	6-9
21596115-5	2011	Further experiments with BV2 microglial cells showed the exposure to Fe(2)O(3) nanoparticles could induce cells proliferation, phagocytosis and generation of ROS and NO, but did not cause significant release of inflammatory factors, including IL-1beta, IL-6 and TNF-alpha.	fe(2)o(3)	69-78	interleukin 6	Mus musculus	253-257
21699244-2	2011	The results revealed that post-treatment with 100 mumol/kg trans-cinnamaldehyde, (-)-aromadendrene, T-cadinol, or alpha-cadinol significantly decreased the aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-alpha (TNF-alpha), and interleukin 6 (IL-6) levels in serum.	cinnamaldehyde	59-79	interleukin 6	Mus musculus	267-280
21699244-2	2011	The results revealed that post-treatment with 100 mumol/kg trans-cinnamaldehyde, (-)-aromadendrene, T-cadinol, or alpha-cadinol significantly decreased the aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-alpha (TNF-alpha), and interleukin 6 (IL-6) levels in serum.	cinnamaldehyde	59-79	interleukin 6	Mus musculus	282-286
21699244-2	2011	The results revealed that post-treatment with 100 mumol/kg trans-cinnamaldehyde, (-)-aromadendrene, T-cadinol, or alpha-cadinol significantly decreased the aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-alpha (TNF-alpha), and interleukin 6 (IL-6) levels in serum.	aromadendrene	81-98	interleukin 6	Mus musculus	267-280
21699244-2	2011	The results revealed that post-treatment with 100 mumol/kg trans-cinnamaldehyde, (-)-aromadendrene, T-cadinol, or alpha-cadinol significantly decreased the aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-alpha (TNF-alpha), and interleukin 6 (IL-6) levels in serum.	aromadendrene	81-98	interleukin 6	Mus musculus	282-286
21699244-2	2011	The results revealed that post-treatment with 100 mumol/kg trans-cinnamaldehyde, (-)-aromadendrene, T-cadinol, or alpha-cadinol significantly decreased the aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-alpha (TNF-alpha), and interleukin 6 (IL-6) levels in serum.	T-cadinol	100-109	interleukin 6	Mus musculus	267-280
21699244-2	2011	The results revealed that post-treatment with 100 mumol/kg trans-cinnamaldehyde, (-)-aromadendrene, T-cadinol, or alpha-cadinol significantly decreased the aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-alpha (TNF-alpha), and interleukin 6 (IL-6) levels in serum.	T-cadinol	100-109	interleukin 6	Mus musculus	282-286
21699244-2	2011	The results revealed that post-treatment with 100 mumol/kg trans-cinnamaldehyde, (-)-aromadendrene, T-cadinol, or alpha-cadinol significantly decreased the aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-alpha (TNF-alpha), and interleukin 6 (IL-6) levels in serum.	cadinol	114-127	interleukin 6	Mus musculus	267-280
21699244-2	2011	The results revealed that post-treatment with 100 mumol/kg trans-cinnamaldehyde, (-)-aromadendrene, T-cadinol, or alpha-cadinol significantly decreased the aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-alpha (TNF-alpha), and interleukin 6 (IL-6) levels in serum.	cadinol	114-127	interleukin 6	Mus musculus	282-286
21705340-5	2011	These IL6-independent clones were dependent on NF-kappaB activity for their survival and proliferation but were resistant to dexamethasone and INCB018424, a selective Janus kinase 1/2 inhibitor.	ruxolitinib	143-153	interleukin 6	Mus musculus	6-9
22111069-4	2011	LPS-induced interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) expression was inhibited by theaflavin.	theaflavin	153-163	interleukin 6	Mus musculus	12-25
22111069-4	2011	LPS-induced interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) expression was inhibited by theaflavin.	theaflavin	153-163	interleukin 6	Mus musculus	27-31
22111069-0	2011	Theaflavin Inhibits LPS-Induced IL-6, MCP-1, and ICAM-1 Expression in Bone Marrow-Derived Macrophages Through the Blockade of NF-kappaB and MAPK Signaling Pathways.	theaflavin	0-10	interleukin 6	Mus musculus	32-36
22111069-7	2011	The inhibitory effect of theaflavin on IL-6, MCP-1, and ICAM-1 expression was completely inhibited by Bay11-7082 (NF-kappaB inhibitor).	theaflavin	25-35	interleukin 6	Mus musculus	39-43
22111069-7	2011	The inhibitory effect of theaflavin on IL-6, MCP-1, and ICAM-1 expression was completely inhibited by Bay11-7082 (NF-kappaB inhibitor).	3-(4-methylphenylsulfonyl)-2-propenenitrile	102-112	interleukin 6	Mus musculus	39-43
22111069-8	2011	The inhibitory effect of theaflavin on IL-6 and ICAM-1 expression was inhibited by SB203580 (p38 MAPK inhibitor).	theaflavin	25-35	interleukin 6	Mus musculus	39-43
22111069-8	2011	The inhibitory effect of theaflavin on IL-6 and ICAM-1 expression was inhibited by SB203580 (p38 MAPK inhibitor).	SB 203580	83-91	interleukin 6	Mus musculus	39-43
22111069-10	2011	These results indicate that theaflavin prevents LPS-induced IL-6, MCP-1, and ICAM-1 expression through blockade of NF-kappaB and MAPK signaling pathways in bone marrow-derived macrophages.	theaflavin	28-38	interleukin 6	Mus musculus	60-64
21567435-15	2011	In primary murine Kupffer cells, FK866 suppressed LPS-induced interleukin (IL)-6 production, whereas incubation with recombinant PBEF resulted in increased IL-6 release.	N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide	33-38	interleukin 6	Mus musculus	62-80
21600784-2	2011	Previous work has revealed a role for IL-6 in mediating glucose uptake, while research on the physiological roles of IL-8 and IL-15 is not so abundant.	Glucose	56-63	interleukin 6	Mus musculus	38-42
21600784-5	2011	Exposure to 20 pg/ml of individual cytokines had no affect on glucose transport while 1 ng/ml enhanced (P&lt;0.05) glucose uptake with IL-6, IL-8 and IL-15, respectively.	Glucose	115-122	interleukin 6	Mus musculus	135-139
21600784-8	2011	These findings demonstrated that the exercise induced myokines IL-6, IL-8 and IL-15 enhance glucose transport at 1 ng/ml, with changes only seen at 20 pg/ml with certain myokine combinations.	Glucose	92-99	interleukin 6	Mus musculus	63-67
21567435-15	2011	In primary murine Kupffer cells, FK866 suppressed LPS-induced interleukin (IL)-6 production, whereas incubation with recombinant PBEF resulted in increased IL-6 release.	lps	50-53	interleukin 6	Mus musculus	62-80
21396483-2	2011	In the present study, we firstly found that artesunate in combination with oxacillin was capable of protecting mice challenged with live MRSA WHO-2 (WHO-2) and the protection was related to the reduced TNF-alpha and IL-6 levels and decreased bacterial load.	Artesunate	44-54	interleukin 6	Mus musculus	216-220
21396483-2	2011	In the present study, we firstly found that artesunate in combination with oxacillin was capable of protecting mice challenged with live MRSA WHO-2 (WHO-2) and the protection was related to the reduced TNF-alpha and IL-6 levels and decreased bacterial load.	Oxacillin	75-84	interleukin 6	Mus musculus	216-220
21396483-4	2011	Artesunate not only inhibited TNF-alpha and IL-6 release but also inhibited mRNA and protein expressions of TLR2 and Nod2, two important receptors, in murine peritoneal macrophages stimulated with heat-killed WHO-2, further demonstrating anti-inflammatory effect of artesunate was related to the inhibition of TLR2- and Nod2-mediated proinflammatory cytokines.	Artesunate	0-10	interleukin 6	Mus musculus	44-48
21746810-3	2011	Here, we show that in a lung injury model, bleomycin induced the secretion of IL-6 by epithelial cells in a transglutaminase 2 (TG2)-dependent manner.	Bleomycin	43-52	interleukin 6	Mus musculus	78-82
21558879-6	2011	Furthermore, immunohistochemistry study showed that diabetes increased interleukin-6 (IL-6) and IL-1beta protein expression in atherosclerotic plaques, but alogliptin treatment attenuated diabetes-augmented IL-6 and IL-1beta expression.	alogliptin	156-166	interleukin 6	Mus musculus	207-211
21620566-6	2011	In addition, alpha,beta-amyrin largely decreased interleukin-1beta (IL-1beta), tumor necrosis factor alpha (TNF-alpha), keratinocyte-derived chemokine (KC) and interleukin 6 (IL-6) levels, and myeloperoxidase activity.	beta-amyrin	19-30	interleukin 6	Mus musculus	160-173
21620566-6	2011	In addition, alpha,beta-amyrin largely decreased interleukin-1beta (IL-1beta), tumor necrosis factor alpha (TNF-alpha), keratinocyte-derived chemokine (KC) and interleukin 6 (IL-6) levels, and myeloperoxidase activity.	beta-amyrin	19-30	interleukin 6	Mus musculus	175-179
21806874-4	2011	Pretreatment of PD98059 or U0126 inhibited TNF-induced IL-6 release and ERK phosphorylation in P815 cells (P&lt;0.05), whereas pretreatment of SB203580 or AG490 hardly affect IL-6 release, with little effect on phosphorylation of p38 and STAT3 respectively.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	16-23	interleukin 6	Mus musculus	55-59
21806874-4	2011	Pretreatment of PD98059 or U0126 inhibited TNF-induced IL-6 release and ERK phosphorylation in P815 cells (P&lt;0.05), whereas pretreatment of SB203580 or AG490 hardly affect IL-6 release, with little effect on phosphorylation of p38 and STAT3 respectively.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	16-23	interleukin 6	Mus musculus	175-179
21806874-4	2011	Pretreatment of PD98059 or U0126 inhibited TNF-induced IL-6 release and ERK phosphorylation in P815 cells (P&lt;0.05), whereas pretreatment of SB203580 or AG490 hardly affect IL-6 release, with little effect on phosphorylation of p38 and STAT3 respectively.	U 0126	27-32	interleukin 6	Mus musculus	55-59
21806874-4	2011	Pretreatment of PD98059 or U0126 inhibited TNF-induced IL-6 release and ERK phosphorylation in P815 cells (P&lt;0.05), whereas pretreatment of SB203580 or AG490 hardly affect IL-6 release, with little effect on phosphorylation of p38 and STAT3 respectively.	U 0126	27-32	interleukin 6	Mus musculus	175-179
21628413-6	2011	We show that iron-deprived mice have a proinflammatory condition, exacerbated by LPS treatment leading to increased IL6 and TNFalpha mRNA in liver and spleen macrophages, and increased serum IL6 (482.29 +- 205.59 pg/mL) versus controls (69.01 +- 17.52 pg/mL; P &lt; .05).	Iron	13-17	interleukin 6	Mus musculus	116-119
21644799-5	2011	Both GA and 18betaGA inhibited the activation of NF-kappaB and the activities of phosphoinositide-3-kinase (PI3K) p110delta and p110gamma isoforms and then reduced the production of LPS-induced tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and IL-1beta in a dose-dependent manner.	Glycyrrhizic Acid	5-7	interleukin 6	Mus musculus	235-253
21628413-6	2011	We show that iron-deprived mice have a proinflammatory condition, exacerbated by LPS treatment leading to increased IL6 and TNFalpha mRNA in liver and spleen macrophages, and increased serum IL6 (482.29 +- 205.59 pg/mL) versus controls (69.01 +- 17.52 pg/mL; P &lt; .05).	Iron	13-17	interleukin 6	Mus musculus	191-194
21512170-10	2011	Concerning the underlying mechanism, we observed that MRS2578 inhibited the release of IL-6 and IL-8/KC by lung epithelial cells in vivo, whereas intrapulmonary application of the P2Y6R agonist uridine-5"-diphosphate increased the bronchoalveolar levels of IL-6 and KC.	N,N''-1,4-butanediylbis(N'-(3-isothiocyanatophenyl))thiourea	54-61	interleukin 6	Mus musculus	87-91
21532335-8	2011	These effects of L-carnitine on cancer cachexia mice were accompanied by the upregulation of mRNA level of CPT I and II and increased enzyme activity of CPT I in the liver, as well as the downregulation of serum TNF-alpha and IL-6 levels.	Carnitine	17-28	interleukin 6	Mus musculus	226-230
21532335-9	2011	Moreover, free carnitine levels were negatively correlated with serum TNF-alpha or IL-6 level.	Carnitine	15-24	interleukin 6	Mus musculus	83-87
21512170-10	2011	Concerning the underlying mechanism, we observed that MRS2578 inhibited the release of IL-6 and IL-8/KC by lung epithelial cells in vivo, whereas intrapulmonary application of the P2Y6R agonist uridine-5"-diphosphate increased the bronchoalveolar levels of IL-6 and KC.	N,N''-1,4-butanediylbis(N'-(3-isothiocyanatophenyl))thiourea	54-61	interleukin 6	Mus musculus	257-261
21683687-5	2011	Furthermore, mutagenesis of a single C-terminal aspartic acid (D234) to alanine (beta-D234A) also significantly impaired IL-6 production.	Aspartic Acid	48-61	interleukin 6	Mus musculus	121-125
21683687-5	2011	Furthermore, mutagenesis of a single C-terminal aspartic acid (D234) to alanine (beta-D234A) also significantly impaired IL-6 production.	d234	63-67	interleukin 6	Mus musculus	121-125
21683687-5	2011	Furthermore, mutagenesis of a single C-terminal aspartic acid (D234) to alanine (beta-D234A) also significantly impaired IL-6 production.	Alanine	72-79	interleukin 6	Mus musculus	121-125
21631112-5	2011	Similarly, in the murine ear edema model, 12-O-tetradecanoylphorbol-13-acetate-induced inflammation was inhibited by mogrosides by down-regulating COX-2 and IL-6 and up-regulating PARP1, BCL2l1, TRP53, MAPK9, and PPARdelta gene expression.	Tetradecanoylphorbol Acetate	42-78	interleukin 6	Mus musculus	157-161
21631112-5	2011	Similarly, in the murine ear edema model, 12-O-tetradecanoylphorbol-13-acetate-induced inflammation was inhibited by mogrosides by down-regulating COX-2 and IL-6 and up-regulating PARP1, BCL2l1, TRP53, MAPK9, and PPARdelta gene expression.	mogrosides	117-127	interleukin 6	Mus musculus	157-161
21631112-4	2011	The results indicate that mogrosides can inhibit inflammation induced by lipopolysaccharides (LPS) in RAW 264.7 cells by down-regulating the expression of key inflammatory genes iNOS, COX-2, and IL-6 and up-regulating some inflammation protective genes such as PARP1, BCL2l1, TRP53, and MAPK9.	mogrosides	26-36	interleukin 6	Mus musculus	195-199
21597011-8	2011	Oral nicotine administration reduced inflammation within the myocardium, decreased the production of interleukin-6 and tumor necrosis factor-alpha, and downregulated the expression of monocyte chemoattractant protein-1, macrophage inflammatory protein-1beta, RANTES, CCR1, CCR2, and CCR5.	Nicotine	5-13	interleukin 6	Mus musculus	101-146
21734632-0	2011	Pentamethylquercetin improves adiponectin expression in differentiated 3T3-L1 cells via a mechanism that implicates PPARgamma together with TNF-alpha and IL-6.	Quercetin pentamethyl ether	0-20	interleukin 6	Mus musculus	154-158
21734632-6	2011	Furthermore, significant decreases of mRNA expression and secretion of TNF-alpha and IL-6 were also observed in PMQ-treated cells.	pmq	112-115	interleukin 6	Mus musculus	85-89
21734632-7	2011	Taken together, our study demonstrated that PMQ up-regulates adiponectin expression via a mechanism that implicates PPARgamma together with TNF-alpha and IL-6, suggesting that PMQ might be a potential candidate for the treatment of metabolic diseases.	pmq	44-47	interleukin 6	Mus musculus	154-158
21734632-7	2011	Taken together, our study demonstrated that PMQ up-regulates adiponectin expression via a mechanism that implicates PPARgamma together with TNF-alpha and IL-6, suggesting that PMQ might be a potential candidate for the treatment of metabolic diseases.	pmq	176-179	interleukin 6	Mus musculus	154-158
21703408-4	2011	In vitro, cytokine release from zymosan-stimulated macrophages was affected by AP214, with approximately 80%, 30%, and 40% reduction in IL-1beta, tumor necrosis factor-alpha, and IL-6, respectively.	Zymosan	32-39	interleukin 6	Mus musculus	179-183
21391981-8	2011	KEY RESULTS: Dex-liposomes attenuated granulocyte infiltration and IL-6 mRNA expression after LV(T) -ventilation, but not after HV(T) -ventilation.	Dextromethorphan	13-16	interleukin 6	Mus musculus	67-71
21439412-7	2011	In addition, microparticle stimulation of DCs also enhanced secretion of the cytokines IL-12p40 and IL-6, a phenomenon found to be dependent on polymer chemistry.	Polymers	144-151	interleukin 6	Mus musculus	100-104
21269574-12	2011	Moreover, 1,25(OH)2D3 influenced Interleukin-6 and TNF-alpha expression in the sera of BD-like mice.	Calcitriol	10-21	interleukin 6	Mus musculus	33-46
21474329-2	2011	This study investigated the inhibitory effect of an extract from the bamboo Phyllostachys edulis (BEX) on lipotoxicity-induced over-production of IL-6 in metabolic cell lines.	BEX	98-101	interleukin 6	Mus musculus	146-150
21437870-9	2011	Dipyridamole treatment of SLE T cells significantly inhibited CD154 expression, interferon-gamma, interleukin-17 (IL-17), and IL-6 production, and T cell-dependent B cell immunoglobulin secretion.	Dipyridamole	0-12	interleukin 6	Mus musculus	126-130
21617181-4	2011	RESULTS: First, we observed that the PPAR-beta/-delta agonist GW501516 prevented both IL-6-dependent reduction in insulin-stimulated Akt phosphorylation and glucose uptake in adipocytes.	GW 501516	62-70	interleukin 6	Mus musculus	86-90
21617181-4	2011	RESULTS: First, we observed that the PPAR-beta/-delta agonist GW501516 prevented both IL-6-dependent reduction in insulin-stimulated Akt phosphorylation and glucose uptake in adipocytes.	Glucose	157-164	interleukin 6	Mus musculus	86-90
21617181-6	2011	This effect was associated with the capacity of the drug to prevent IL-6-induced STAT3 phosphorylation on Tyr(705) and Ser(727) residues in vitro and in vivo.	Tyrosine	106-109	interleukin 6	Mus musculus	68-72
21617181-6	2011	This effect was associated with the capacity of the drug to prevent IL-6-induced STAT3 phosphorylation on Tyr(705) and Ser(727) residues in vitro and in vivo.	Serine	119-122	interleukin 6	Mus musculus	68-72
21617181-7	2011	Moreover, GW501516 prevented IL-6-dependent induction of extracellular signal-related kinase (ERK)1/2, a serine-threonine-protein kinase involved in serine STAT3 phosphorylation.	GW 501516	10-18	interleukin 6	Mus musculus	29-33
21617181-7	2011	Moreover, GW501516 prevented IL-6-dependent induction of extracellular signal-related kinase (ERK)1/2, a serine-threonine-protein kinase involved in serine STAT3 phosphorylation.	Serine	105-111	interleukin 6	Mus musculus	29-33
21474329-8	2011	BEX significantly ameliorated PA-induced upregulation of IL-6 mRNA, which correlated with a reduction in nuclear translocation of p50, p65, and c-fos proteins with the presence of BEX, indicating inhibition of NF-kappaB and AP-1 activation.	BEX	0-3	interleukin 6	Mus musculus	57-61
21474329-8	2011	BEX significantly ameliorated PA-induced upregulation of IL-6 mRNA, which correlated with a reduction in nuclear translocation of p50, p65, and c-fos proteins with the presence of BEX, indicating inhibition of NF-kappaB and AP-1 activation.	Palmitic Acid	30-32	interleukin 6	Mus musculus	57-61
21474329-9	2011	In summary, BEX inhibits lipotoxicity-induced IL-6 overproduction in muscle and adipose cell lines through the NF-kappaB and AP-1 pathways, implicating a potential application of this natural product as a cost-effective anti-inflammation nutraceutical.	BEX	12-15	interleukin 6	Mus musculus	46-50
21564094-8	2011	The secreted IL-6 was biologically active because it fully supported B9 hybridoma proliferation in a [(3) H]thymidine incorporation bioassay.	Thymidine	108-117	interleukin 6	Mus musculus	13-17
21471252-7	2011	Administration of STAT3 inhibitor S31-201 (IC50 of 38.0 +- 7.2 muM for IL-6-induced STAT3 phosphorylation), but not PBS control, to p53(null)CD45.1 mice suppressed Th17 effectors and alleviated autoimmune pathology.	NSC 74859	34-41	interleukin 6	Mus musculus	71-75
21251905-4	2011	Treatment of mice with clodronate liposomes significantly decreased the number of TAMs and osteoclasts in the bone tumors, the expression of IL-6 in the PC3-MM2 cells, and the production of tumor necrosis factor (TNF)-alpha by TAMs.	Clodronic Acid	23-33	interleukin 6	Mus musculus	141-145
21400110-5	2011	RESULTS: alpha,beta-Amyrin and thalidomide significantly attenuated the cerulein-induced increase in tumor necrosis factor (TNF)-alpha, interleukin-6, lipase, amylase, MPO, and TBARS.	alpha,beta-amyrin	9-26	interleukin 6	Mus musculus	136-149
21400110-5	2011	RESULTS: alpha,beta-Amyrin and thalidomide significantly attenuated the cerulein-induced increase in tumor necrosis factor (TNF)-alpha, interleukin-6, lipase, amylase, MPO, and TBARS.	Thalidomide	31-42	interleukin 6	Mus musculus	136-149
21593683-7	2011	Furthermore, a significant increase in IL-6 and MCP-1 was observed in circulation after EtOH intoxication and burn injury compared with either EtOH intoxication or burn injury alone; no other cytokines were detected in circulation.	Ethanol	88-92	interleukin 6	Mus musculus	39-43
21593683-7	2011	Furthermore, a significant increase in IL-6 and MCP-1 was observed in circulation after EtOH intoxication and burn injury compared with either EtOH intoxication or burn injury alone; no other cytokines were detected in circulation.	Ethanol	143-147	interleukin 6	Mus musculus	39-43
20952175-3	2011	In agreement with this hypothesis, we observed a decrease of inflammatory markers such as IL-6, MCP-1 and IL-1beta at both the mRNA and protein level when explants of epididymal adipose tissue from mice fed with a high-fat diet were incubated with lycopene ex vivo.	Lycopene	248-256	interleukin 6	Mus musculus	90-94
21562237-0	2011	Stearidonic and eicosapentaenoic acids inhibit interleukin-6 expression in ob/ob mouse adipose stem cells via Toll-like receptor-2-mediated pathways.	stearidonic	0-11	interleukin 6	Mus musculus	47-60
21765602-7	2011	Levels of interleukin-6, which is associated with the enhancement of fatty acid oxidation, was also increased significantly in the livers of ethanol-fed Fyn-/- mice.	Fatty Acids	69-79	interleukin 6	Mus musculus	10-23
21765602-7	2011	Levels of interleukin-6, which is associated with the enhancement of fatty acid oxidation, was also increased significantly in the livers of ethanol-fed Fyn-/- mice.	Ethanol	141-148	interleukin 6	Mus musculus	10-23
21562237-0	2011	Stearidonic and eicosapentaenoic acids inhibit interleukin-6 expression in ob/ob mouse adipose stem cells via Toll-like receptor-2-mediated pathways.	Eicosapentaenoic Acid	16-38	interleukin 6	Mus musculus	47-60
21562237-4	2011	Based on these findings, we hypothesized that EPA [20:5 (n-3)] and stearidonic acid [SDA, 18:4 (n-3)] would decrease LPS (200 mug/L)-induced IL-6 secretion and IL-6 mRNA content in the adipose stem cells.	stearidonic acid	67-83	interleukin 6	Mus musculus	141-145
21562237-4	2011	Based on these findings, we hypothesized that EPA [20:5 (n-3)] and stearidonic acid [SDA, 18:4 (n-3)] would decrease LPS (200 mug/L)-induced IL-6 secretion and IL-6 mRNA content in the adipose stem cells.	stearidonic acid	67-83	interleukin 6	Mus musculus	160-164
21562237-4	2011	Based on these findings, we hypothesized that EPA [20:5 (n-3)] and stearidonic acid [SDA, 18:4 (n-3)] would decrease LPS (200 mug/L)-induced IL-6 secretion and IL-6 mRNA content in the adipose stem cells.	stearidonic acid	85-88	interleukin 6	Mus musculus	141-145
21562237-4	2011	Based on these findings, we hypothesized that EPA [20:5 (n-3)] and stearidonic acid [SDA, 18:4 (n-3)] would decrease LPS (200 mug/L)-induced IL-6 secretion and IL-6 mRNA content in the adipose stem cells.	stearidonic acid	85-88	interleukin 6	Mus musculus	160-164
21562237-5	2011	SDA (100 mumol/L) and EPA (100 mumol/L) significantly reduced LPS-induced IL-6 secretion and decreased IL-6 mRNA expression.	stearidonic acid	0-3	interleukin 6	Mus musculus	74-78
21562237-5	2011	SDA (100 mumol/L) and EPA (100 mumol/L) significantly reduced LPS-induced IL-6 secretion and decreased IL-6 mRNA expression.	stearidonic acid	0-3	interleukin 6	Mus musculus	103-107
21562237-9	2011	Collectively, our results suggest that EPA and SDA inhibit LPS-induced IL-6 secretion and IL-6 mRNA expression in the adipose stem cells by decreasing TRL2-mediated signaling pathways.	stearidonic acid	47-50	interleukin 6	Mus musculus	71-75
21562237-9	2011	Collectively, our results suggest that EPA and SDA inhibit LPS-induced IL-6 secretion and IL-6 mRNA expression in the adipose stem cells by decreasing TRL2-mediated signaling pathways.	stearidonic acid	47-50	interleukin 6	Mus musculus	90-94
21555210-5	2011	Although MK886 did not attenuate cuprizone-induced demyelination in the corpus callosum or in the cortex, it attenuated cuprizone-induced axonal damage and motor deficits and reduced microglial activation and IL-6 production.	MK-886	9-14	interleukin 6	Mus musculus	209-213
21708076-8	2011	Both the LPS and amyloid-beta peptide enhanced interleukin 1, interleukin 6, and tumor necrosis factor-alpha synthesis and these effects were inhibited by 10(-9)M coumestrol.	Coumestrol	163-173	interleukin 6	Mus musculus	25-108
21438777-5	2011	Glucocorticoid-dependent repression of cAMP-stimulated CRF promoter activity is mediated by both the negative glucocorticoid-response element and the serum-response element, while interleukin-6 (IL-6) stimulates the CRF gene.	Cyclic AMP	39-43	interleukin 6	Mus musculus	180-193
21438777-5	2011	Glucocorticoid-dependent repression of cAMP-stimulated CRF promoter activity is mediated by both the negative glucocorticoid-response element and the serum-response element, while interleukin-6 (IL-6) stimulates the CRF gene.	Cyclic AMP	39-43	interleukin 6	Mus musculus	195-199
21711565-8	2011	The serum levels of tumor necrosis factor (TNF)-alpha and the expression of TNF-alpha and interleukin-6 mRNAs in the liver were decreased by pitavastatin treatment, suggesting attenuation of the chronic inflammation induced by excess fat deposition.	pitavastatin	141-153	interleukin 6	Mus musculus	90-103
21697358-9	2011	Mice with a deletion of IL-6, one of the target genes of NF-kappaB, are resistant to DD-induced depression-like behavior, which suggests a pivotal role for this cytokine in the constant darkness mouse model of depression.	Fumigant 93	85-87	interleukin 6	Mus musculus	24-28
21277908-0	2011	Memantine abolishes the formation of cocaine-induced conditioned place preference possibly via its IL-6-modulating effect in medial prefrontal cortex.	Memantine	0-9	interleukin 6	Mus musculus	99-103
21277908-0	2011	Memantine abolishes the formation of cocaine-induced conditioned place preference possibly via its IL-6-modulating effect in medial prefrontal cortex.	Cocaine	37-44	interleukin 6	Mus musculus	99-103
21277908-5	2011	Three consecutive days of cocaine conditioning increased interleukin-6 (IL-6) but decreased tumor necrosis factor (TNF-alpha) levels in medial prefrontal cortex (mPFC) and nucleus accumbens (Acb).	Cocaine	26-33	interleukin 6	Mus musculus	57-70
21277908-5	2011	Three consecutive days of cocaine conditioning increased interleukin-6 (IL-6) but decreased tumor necrosis factor (TNF-alpha) levels in medial prefrontal cortex (mPFC) and nucleus accumbens (Acb).	Cocaine	26-33	interleukin 6	Mus musculus	72-76
21277908-6	2011	Interestingly, pretreatment with memantine at the lowest effective dose (0.02 mg/kg/injection) reversed cocaine conditioning-enhanced IL-6 and -decreased TNF-alpha levels in these brain regions.	Memantine	33-42	interleukin 6	Mus musculus	134-138
21277908-6	2011	Interestingly, pretreatment with memantine at the lowest effective dose (0.02 mg/kg/injection) reversed cocaine conditioning-enhanced IL-6 and -decreased TNF-alpha levels in these brain regions.	Cocaine	104-111	interleukin 6	Mus musculus	134-138
21277908-10	2011	Finally, intra-mPFC infusion of recombinant IL-6, but not thalidomide, reversed memantine (0.02 mg/kg/injection x 6)-decreased cocaine-induced CPP.	Memantine	80-89	interleukin 6	Mus musculus	44-48
21277908-10	2011	Finally, intra-mPFC infusion of recombinant IL-6, but not thalidomide, reversed memantine (0.02 mg/kg/injection x 6)-decreased cocaine-induced CPP.	Cocaine	127-134	interleukin 6	Mus musculus	44-48
21277908-11	2011	These results, taken together, suggest that cocaine conditioning-enhanced IL-6 in mPFC may be, in part, involved in the acquisition of cocaine-induced CPP.	Cocaine	44-51	interleukin 6	Mus musculus	74-78
21277908-11	2011	These results, taken together, suggest that cocaine conditioning-enhanced IL-6 in mPFC may be, in part, involved in the acquisition of cocaine-induced CPP.	Cocaine	135-142	interleukin 6	Mus musculus	74-78
21277908-12	2011	Moreover, an extremely low dose of memantine may decrease the acquisition of cocaine-induced CPP by reversing cocaine conditioning-increased IL-6 levels in mPFC.	Memantine	35-44	interleukin 6	Mus musculus	141-145
21277908-12	2011	Moreover, an extremely low dose of memantine may decrease the acquisition of cocaine-induced CPP by reversing cocaine conditioning-increased IL-6 levels in mPFC.	Cocaine	77-84	interleukin 6	Mus musculus	141-145
21277908-12	2011	Moreover, an extremely low dose of memantine may decrease the acquisition of cocaine-induced CPP by reversing cocaine conditioning-increased IL-6 levels in mPFC.	Cocaine	110-117	interleukin 6	Mus musculus	141-145
21570986-0	2011	Interleukin-6 plays a protective role in development of cisplatin-induced acute renal failure through upregulation of anti-oxidative stress factors.	Cisplatin	56-65	interleukin 6	Mus musculus	0-13
21640075-7	2011	Captopril lowered the expression levels of TNF-alpha, IL-1beta, IL-6, and PAI-1 mRNAs, while telmisartan lowered the expression levels of COX-2, IL-1beta, IL-6, and PAI-1 mRNAs in the white adipose tissues of these mice.	Captopril	0-9	interleukin 6	Mus musculus	64-68
21570986-2	2011	We previously reported that cisplatin induced more severe renal dysfunction in interleukin-6 (IL-6) knockout (IL-6(-/-)) mice than in wild-type (WT) mice.	Cisplatin	28-37	interleukin 6	Mus musculus	79-92
21570986-2	2011	We previously reported that cisplatin induced more severe renal dysfunction in interleukin-6 (IL-6) knockout (IL-6(-/-)) mice than in wild-type (WT) mice.	Cisplatin	28-37	interleukin 6	Mus musculus	94-98
21570986-2	2011	We previously reported that cisplatin induced more severe renal dysfunction in interleukin-6 (IL-6) knockout (IL-6(-/-)) mice than in wild-type (WT) mice.	Cisplatin	28-37	interleukin 6	Mus musculus	110-114
21570986-3	2011	Expression of a pro-apoptotic protein was significantly increased with cisplatin in IL-6(-/-) mice compared to that in WT mice.	Cisplatin	71-80	interleukin 6	Mus musculus	84-88
21570986-4	2011	IL-6, locally expressed in renal tubular cells after cisplatin administration, prevents the development of renal dysfunction at an early stage.	Cisplatin	53-62	interleukin 6	Mus musculus	0-4
21570986-5	2011	In the present study, we focused on downstream signals of IL-6 and oxidative stress induced by cisplatin in order to evaluate the protective role of IL-6 in the development of acute renal failure.	Cisplatin	95-104	interleukin 6	Mus musculus	58-62
21570986-9	2011	KEY FINDINGS: Cisplatin increased the expression of 4-HNE and cox-2, and phosphorylation of ERK in IL-6(-/-) mice than in WT mice.	Cisplatin	14-23	interleukin 6	Mus musculus	99-103
21570986-10	2011	On the other hand, activity of superoxide dismutase, an anti-oxidative enzyme, was significantly decreased in the kidney obtained from IL-6(-/-) mice after cisplatin administration.	Cisplatin	156-165	interleukin 6	Mus musculus	135-139
21570986-11	2011	SIGNIFICANCE: Our findings suggest that IL-6 plays a protective role in the development of cisplatin-induced acute renal failure through upregulation of anti-oxidative stress factors.	Cisplatin	91-100	interleukin 6	Mus musculus	40-44
21689450-7	2011	Intracellular staining of SP thymocytes for phosphorylated STAT-1 demonstrated that IL-6 signaling was confined to the most mature SP subsets.	sp	26-28	interleukin 6	Mus musculus	84-88
21593380-6	2011	IL-6, stimulated in a cAMP-independent manner, is an important mediator in this pathway.	Cyclic AMP	22-26	interleukin 6	Mus musculus	0-4
21464611-6	2011	Here we demonstrate that doxorubicin induces a systemic increase in IL-1beta and other inflammatory cytokines, chemokines and growth factors including TNF-alpha, IL-6, CXCL1/Gro-alpha, CCL2/MCP-1, granulocyte colony stimulating factor (GCSF), and CXCL10/IP-10.	Doxorubicin	25-36	interleukin 6	Mus musculus	162-166
21464611-7	2011	Studies with IL-1R-deficient mice demonstrate that IL-1 signaling plays a role in doxorubicin-induced increases in IL-6 and GCSF.	Doxorubicin	82-93	interleukin 6	Mus musculus	115-119
25213953-3	2011	Results showed that the fraction with high phenolic and flavonoid contents from the ethanol extracts of adlay bran suppressed LPS-stimulated IL-6 and TNF-alpha secretions in a concentration-dependent manner in RAW 264.7 cells and murine peritoneal macrophages.	Flavonoids	56-65	interleukin 6	Mus musculus	141-145
25213953-3	2011	Results showed that the fraction with high phenolic and flavonoid contents from the ethanol extracts of adlay bran suppressed LPS-stimulated IL-6 and TNF-alpha secretions in a concentration-dependent manner in RAW 264.7 cells and murine peritoneal macrophages.	Ethanol	84-91	interleukin 6	Mus musculus	141-145
21711488-11	2011	Treatment with 17-DMAG significantly reduced the hemorrhage-induced increases in iNOS protein, jejunal alteration, and TNF-alpha and IL-10 concentrations, but 17-DMAG did not affect the hemorrhage-induced increases in p53 and IL-6 concentration.	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	15-22	interleukin 6	Mus musculus	226-230
21513770-5	2011	By using pharmacological antagonists against phophatidycholine- and phosphoinositol-specific phospholipase C, the current study indicated that phospholipase C activity was necessary for MeHg-induced IL-6 release.	phophatidycholine	45-62	interleukin 6	Mus musculus	199-203
21513770-5	2011	By using pharmacological antagonists against phophatidycholine- and phosphoinositol-specific phospholipase C, the current study indicated that phospholipase C activity was necessary for MeHg-induced IL-6 release.	phosphoinositol	68-83	interleukin 6	Mus musculus	199-203
21513770-10	2011	This, in turn, leads to arachidonic acid and lysophosphatidyl choline generation, both of which are potent inducers for IL-6 release.	Arachidonic Acid	24-40	interleukin 6	Mus musculus	120-124
21513770-10	2011	This, in turn, leads to arachidonic acid and lysophosphatidyl choline generation, both of which are potent inducers for IL-6 release.	Lysophosphatidylcholines	45-69	interleukin 6	Mus musculus	120-124
21352507-9	2011	CONCLUSION: In conclusion, IL-6 affects exercise-induced glycogen use, AMPK signalling and TNF-alpha mRNA responses in mouse skeletal muscle.	Glycogen	57-65	interleukin 6	Mus musculus	27-31
21439945-6	2011	Furthermore, resveratrol significantly attenuated the HFD-induced up-regulation of pro-inflammatory cytokines (TNFalpha, IFNalpha, IFNbeta, and IL-6) and their upstream signaling molecules (TLR2/4, MyD88, Tirap, TRIF, TRAF6, IRF5, p-IRF3, and NF-kappaB) in the adipose tissues of mice.	Resveratrol	13-24	interleukin 6	Mus musculus	144-148
21469095-3	2011	Histamine and an H(4)R agonist, JNJ 28610244, induced the production of IL-6 in mouse bone marrow (BM)-derived mast cells.	Histamine	0-9	interleukin 6	Mus musculus	72-76
21469095-5	2011	In addition, histamine acting via the H(4) R potentiated LPS-induced IL-6 production.	Histamine	13-22	interleukin 6	Mus musculus	69-73
21469095-5	2011	In addition, histamine acting via the H(4) R potentiated LPS-induced IL-6 production.	h(4) r	38-44	interleukin 6	Mus musculus	69-73
20490641-3	2011	When RAW 264.7 cells were treated with 2-docoshexaenoyl-lysoPC, a concentration-dependent decrease of LPS-induced formation of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha), or IL-6 was observed.	2-docoshexaenoyl-lysopc	39-62	interleukin 6	Mus musculus	190-194
21469095-6	2011	Histamine-induced IL-6 production could be blocked by inhibitors of ERK and phosphoinositide 3-kinase gamma (PI3Kgamma) pathways.	Histamine	0-9	interleukin 6	Mus musculus	18-22
21315785-11	2011	In female mice, however, corticosterone does appear to mediate the persistent effects of acute ethanol administration on poly I:C- induced IL-6 levels.	Corticosterone	25-39	interleukin 6	Mus musculus	139-143
21080779-5	2011	The results revealed that sinomenine inhibited the PMA plus A23187-induced production of IL-6, PGD(2), LTC(4), beta-Hex, and COX-2 protein.	sinomenine	26-36	interleukin 6	Mus musculus	89-93
21080779-5	2011	The results revealed that sinomenine inhibited the PMA plus A23187-induced production of IL-6, PGD(2), LTC(4), beta-Hex, and COX-2 protein.	Calcimycin	60-66	interleukin 6	Mus musculus	89-93
21315785-11	2011	In female mice, however, corticosterone does appear to mediate the persistent effects of acute ethanol administration on poly I:C- induced IL-6 levels.	Ethanol	95-102	interleukin 6	Mus musculus	139-143
21315785-11	2011	In female mice, however, corticosterone does appear to mediate the persistent effects of acute ethanol administration on poly I:C- induced IL-6 levels.	Poly I-C	121-129	interleukin 6	Mus musculus	139-143
21315785-12	2011	Since many IL-6 related disorders are gender associated, further research into the bidirectional effects of the HPG and HPA axes on alterations in cytokine production mediated by ethanol is warranted.	Ethanol	179-186	interleukin 6	Mus musculus	11-15
21811691-10	2011	gAd derived from E. coli increased the production of IL-6 and IL-8, but polymyxin B, an inhibitor of lipopolysaccharide (LPS), inhibited IL-6 and IL-8 production induced by gAd in both types of cells.	ganoderic acid D	0-3	interleukin 6	Mus musculus	53-57
21525256-6	2011	The EPA/DHA diet reduced neutrophil numbers and KC and IL-6 levels (P &lt; 0.05) in (-/-) males and reduced mortality rate (P &lt; 0.001), lung permeability, and IL-6 level (P &lt; 0.05) in (-/-) females compared with (-/-) mice fed the control diet.	dehydroacetic acid	8-11	interleukin 6	Mus musculus	55-59
21525256-6	2011	The EPA/DHA diet reduced neutrophil numbers and KC and IL-6 levels (P &lt; 0.05) in (-/-) males and reduced mortality rate (P &lt; 0.001), lung permeability, and IL-6 level (P &lt; 0.05) in (-/-) females compared with (-/-) mice fed the control diet.	dehydroacetic acid	8-11	interleukin 6	Mus musculus	162-166
21811692-2	2011	In this study, we investigated the effects of curcumin on the production of interleukin-6 (IL-6) by murine macrophage-like RAW 264.7 cells stimulated with lipopolysaccharide (LPS) from Prevotella intermedia, a major cause of inflammatory periodontal disease, and sought to determine the underlying mechanisms of action.	Curcumin	46-54	interleukin 6	Mus musculus	76-89
21811692-2	2011	In this study, we investigated the effects of curcumin on the production of interleukin-6 (IL-6) by murine macrophage-like RAW 264.7 cells stimulated with lipopolysaccharide (LPS) from Prevotella intermedia, a major cause of inflammatory periodontal disease, and sought to determine the underlying mechanisms of action.	Curcumin	46-54	interleukin 6	Mus musculus	91-95
21811691-10	2011	gAd derived from E. coli increased the production of IL-6 and IL-8, but polymyxin B, an inhibitor of lipopolysaccharide (LPS), inhibited IL-6 and IL-8 production induced by gAd in both types of cells.	ganoderic acid D	0-3	interleukin 6	Mus musculus	137-141
21811692-8	2011	RESULTS: Curcumin strongly suppressed the production of IL-6 at both gene transcription and translation levels in P. intermedia LPS-activated RAW 264.7 cells.	Curcumin	9-17	interleukin 6	Mus musculus	56-60
21811691-10	2011	gAd derived from E. coli increased the production of IL-6 and IL-8, but polymyxin B, an inhibitor of lipopolysaccharide (LPS), inhibited IL-6 and IL-8 production induced by gAd in both types of cells.	ganoderic acid D	173-176	interleukin 6	Mus musculus	137-141
21811692-12	2011	CONCLUSIONS: Although further study is required to explore the detailed mechanism of action, curcumin may contribute to blockade of the host-destructive processes mediated by IL-6 and appears to have potential therapeutic values in the treatment of inflammatory periodontal disease.	Curcumin	93-101	interleukin 6	Mus musculus	175-179
21811692-0	2011	Curcumin suppresses the production of interleukin-6 in Prevotella intermedia lipopolysaccharide-activated RAW 264.7 cells.	Curcumin	0-8	interleukin 6	Mus musculus	38-51
21188449-10	2011	Imatinib dose-dependently inhibited tumor necrosis factor (TNF)-alpha, IL-6, interferon (IFN)-gamma, and IL-17 production by splenocytes in vitro, while nilotinib inhibited only IL-17 and IFN-gamma production in a dose-dependent fashion.	Imatinib Mesylate	0-8	interleukin 6	Mus musculus	71-75
21136209-8	2011	Furthermore, RA07 inhibited IL-6-dependent KT-3 cell proliferation in a dose-dependent manner.	ra07	13-17	interleukin 6	Mus musculus	28-32
21330657-6	2011	EAU was induced in wild-type (WT) mice and in mice lacking IL-6 (IL-6KO), IL-17 (IL-17KO), and IFN-gamma (GKO) on a C57BL/6 background.	Water	0-3	interleukin 6	Mus musculus	59-63
21300114-6	2011	Wy-14643 and fenofibrate inhibited the elevations of TNFalpha, IL-1beta, IL-6, COX-2, ICAM-1, and VCAM-1.	Fenofibrate	13-24	interleukin 6	Mus musculus	73-77
21300114-9	2011	LPS injection also elevated IL-6 protein levels in the brain and serum at 6h, which was inhibited by fenofibrate.	Fenofibrate	101-112	interleukin 6	Mus musculus	28-32
21310253-12	2011	Histological examination and quantitative RT-PCR results showed that OA mice that injected with RA10-6, especially in combination with celecoxib demonstrated inhibition of synovial thickening and reduction in IL-6 levels in the synovial tissue.	Celecoxib	135-144	interleukin 6	Mus musculus	209-213
21310253-14	2011	RA10-6 acted synergistically with celecoxib to inhibit IL-6 expression in synovial tissues.	Celecoxib	34-43	interleukin 6	Mus musculus	55-59
21330657-8	2011	To study the roles of Treg cells, EAU was induced in IL-6KO mice treated with anti-CD25 monoclonal antibody (mAb) to deplete Treg cells in vivo.	Water	34-37	interleukin 6	Mus musculus	53-59
21330657-13	2011	Treg cell depletion in vivo induced EAU in IL-6KO mice.	Water	36-39	interleukin 6	Mus musculus	43-49
21458563-4	2011	After L-165041 treatment, serum TNFalpha, IL-6 and IL-1 levels were significantly decreased in STZ mice.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	6-14	interleukin 6	Mus musculus	42-46
21458563-4	2011	After L-165041 treatment, serum TNFalpha, IL-6 and IL-1 levels were significantly decreased in STZ mice.	Streptozocin	95-98	interleukin 6	Mus musculus	42-46
21575254-8	2011	RESULTS: OMC suppressed LPS-induced secretion of tumor necrosis factor-alpha (TNF-alpha, interleukin-6 (IL-6), and IL-12p40 from RAW264.7 macrophages.	lps	24-27	interleukin 6	Mus musculus	89-102
21592365-11	2011	In vitro, trichostatin A markedly suppressed zymosan A-induced interleukin-12 and interleukin-6 production by BM-DC and up-regulated IDO expression at mRNA and protein levels.	trichostatin A	10-24	interleukin 6	Mus musculus	82-95
21592365-11	2011	In vitro, trichostatin A markedly suppressed zymosan A-induced interleukin-12 and interleukin-6 production by BM-DC and up-regulated IDO expression at mRNA and protein levels.	Zymosan	45-54	interleukin 6	Mus musculus	82-95
21575254-11	2011	Oral administration of OMC markedly suppressed secretion of TNF-alpha and IL-6 in mice challenged with LPS in vivo.	lps	103-106	interleukin 6	Mus musculus	74-78
21575254-8	2011	RESULTS: OMC suppressed LPS-induced secretion of tumor necrosis factor-alpha (TNF-alpha, interleukin-6 (IL-6), and IL-12p40 from RAW264.7 macrophages.	lps	24-27	interleukin 6	Mus musculus	104-108
21393479-7	2011	In mice, treatment with IL-6 or turpentine increased hepcidin expression and reduced serum iron, effects that were inhibited by LDN-193189 or ALK3-Fc.	Iron	91-95	interleukin 6	Mus musculus	24-28
21482732-12	2011	Finally, ex vivo treatment of WT placentas with the substrate for Cyp27b1, 25-hydroxyvitamin D(3), suppressed LPS-induced expression of IL-6 and the chemokine Ccl11.	25-hydroxyvitamin D	75-94	interleukin 6	Mus musculus	136-140
21393247-0	2011	Intertissue flow of glutathione (GSH) as a tumor growth-promoting mechanism: interleukin 6 induces GSH release from hepatocytes in metastatic B16 melanoma-bearing mice.	Glutathione	20-31	interleukin 6	Mus musculus	77-90
21393247-0	2011	Intertissue flow of glutathione (GSH) as a tumor growth-promoting mechanism: interleukin 6 induces GSH release from hepatocytes in metastatic B16 melanoma-bearing mice.	Glutathione	33-36	interleukin 6	Mus musculus	77-90
21393247-0	2011	Intertissue flow of glutathione (GSH) as a tumor growth-promoting mechanism: interleukin 6 induces GSH release from hepatocytes in metastatic B16 melanoma-bearing mice.	Glutathione	99-102	interleukin 6	Mus musculus	77-90
21393247-5	2011	Fractionation of serum-free conditioned medium from cultured B16-F10 cells and monoclonal antibody-induced neutralization techniques facilitated identification of interleukin (IL)-6 as a tumor-derived molecule promoting GSH efflux in hepatocytes.	Glutathione	220-223	interleukin 6	Mus musculus	163-181
21393247-6	2011	IL-6 activates GSH release through a methionine-sensitive/organic anion transporter polypeptide 1- and multidrug resistance protein 1-independent channel located on the sinusoidal site of hepatocytes.	Glutathione	15-18	interleukin 6	Mus musculus	0-4
21393247-6	2011	IL-6 activates GSH release through a methionine-sensitive/organic anion transporter polypeptide 1- and multidrug resistance protein 1-independent channel located on the sinusoidal site of hepatocytes.	Methionine	37-47	interleukin 6	Mus musculus	0-4
21543593-4	2011	Intraplantar injection of IL-6 followed immediately by intrathecal injection of a PKMzeta inhibitor prevented the expression of subsequent PGE(2)-induced allodynia.	pkmzeta	82-89	interleukin 6	Mus musculus	26-30
21393247-8	2011	Our results show that IL-6 (mainly of tumor origin in B16-F10-bearing mice) may facilitate GSH release from hepatocytes and its interorgan transport to metastatic growing foci.	Glutathione	91-94	interleukin 6	Mus musculus	22-26
21545711-13	2011	Both thiopurine derivatives reduced the proportion of apoptotic T helper cells, but a high production of both IL-6 and TGF-beta was observed only in colon of AZA-treated mice.	Azathioprine	158-161	interleukin 6	Mus musculus	110-114
21543593-4	2011	Intraplantar injection of IL-6 followed immediately by intrathecal injection of a PKMzeta inhibitor prevented the expression of subsequent PGE(2)-induced allodynia.	Dinoprostone	139-145	interleukin 6	Mus musculus	26-30
21543593-5	2011	Inhibitors of protein translation were effective in preventing PGE(2)-induced allodynia when given immediately after IL-6, but not after the initial allodynia had resolved.	Dinoprostone	63-69	interleukin 6	Mus musculus	117-121
21543593-6	2011	In contrast, spinal PKMzeta inhibition completely abolished both prolonged allodynia to hindpaw PGE(2) and enhanced nocifensive behaviors evoked by intrathecal mGluR1/5 agonist injection after the resolution of IL-6-induced allodynia.	pkmzeta	20-27	interleukin 6	Mus musculus	211-215
21183660-6	2011	Resistance to SMAO-induced gut injury was also associated with resistance to lung injury, as reflected by decreased levels of myeloperoxidase, IL-6 and IL-10 in the lungs of HIF-1alpha(+/-) mice.	smao	14-18	interleukin 6	Mus musculus	143-147
21514417-6	2011	In line, kidneys of db/db mice on the phosphorus-rich diet displayed significantly increased mRNA expression of the T(H)1 cytokines interferon gamma, IL-6, and tumor necrosis factor alpha.	Phosphorus	38-48	interleukin 6	Mus musculus	150-187
21330607-6	2011	Moreover, expression of interleukin-6 mRNA in response to lipopolysaccharide was enhanced by simultaneous stimulation with thapsigargin, a potent ER stressor, in wild-type cardiomyocytes but not in chop-deficient cardiomyocytes.	Thapsigargin	123-135	interleukin 6	Mus musculus	24-37
21348853-8	2011	Interestingly, CPT1A protected against fatty acid-induced insulin resistance and expression of pro-inflammatory adipokines such as TNF-alpha (tumour necrosis factor-alpha) and IL-6 (interleukin-6) in adipocytes.	Fatty Acids	39-49	interleukin 6	Mus musculus	176-180
21348853-8	2011	Interestingly, CPT1A protected against fatty acid-induced insulin resistance and expression of pro-inflammatory adipokines such as TNF-alpha (tumour necrosis factor-alpha) and IL-6 (interleukin-6) in adipocytes.	Fatty Acids	39-49	interleukin 6	Mus musculus	182-195
21615989-2	2011	Water-soluble extract of S. aureus cell lysate strongly induced human interleukin- 8 in human mast cell line-1 and mouse interleukin-6 in mouse bone marrow-derived mast cells.	Water	0-5	interleukin 6	Mus musculus	121-134
21327868-12	2011	Circulating SAA and SAP did not decrease in either insulin-treated group, but IL-6 levels fell in the glargine-treated mice.	Insulin Glargine	102-110	interleukin 6	Mus musculus	78-82
21272610-3	2011	These inhibitory effects of ADEE were accompanied by the reduced production of tumor necrosis factor alpha and interleukin (IL)-6.	adee	28-32	interleukin 6	Mus musculus	111-129
21327868-13	2011	CONCLUSIONS/INTERPRETATION: While chronic insulin administration did not decrease SAA and SAP, administration of glargine but not detemir insulin improved dyslipidaemia, IL-6 levels and atherosclerosis, and both insulins reduced macrophage accumulation in visceral adipose tissue.	Insulin Glargine	113-121	interleukin 6	Mus musculus	170-174
22977538-4	2011	Pre-treatment with PA at concentrations of 10, 20 or 40 muM dose-dependently decreased the production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, nitric oxide (NO) and prostaglandin E(2) in LPS-stimulated RAW264.7 cells.	patchouli alcohol	19-21	interleukin 6	Mus musculus	164-168
22977538-5	2011	In addition, PA treatment also reversed the increased mRNA expression of TNF-alpha, IL-1beta, IL-6, inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 caused by LPS in RAW264.7 cells.	patchouli alcohol	13-15	interleukin 6	Mus musculus	94-98
22977538-6	2011	These results indicate that PA is an important anti-inflammatory constituent of Pogostemonis Herba and that its anti-inflammatory effect may be mediated, at least in part, by down-regulation of the mRNA expression of a panel of inflammatory mediators, such as TNF-alpha, IL-1beta, IL-6, iNOS and COX-2.	patchouli alcohol	28-30	interleukin 6	Mus musculus	281-285
21246417-6	2011	The treatment of C57 mice with beta-elemene significantly delayed the onset of EAE, markedly suppressed MOG-specific T cell proliferation in a dose-dependent manner, dramatically reduced the IL-17, IL-6, IL-23, and RORgammat production and induced the Foxp3 expression in both the periphery and the inflamed spinal cord.	beta-elemene	31-43	interleukin 6	Mus musculus	198-202
21511827-6	2011	Finally, both genetic and pharmacologic approaches showed that the inflammatory cytokine IL-6 mediates adenosine-induced renal fibrosis downstream of A(2B)R. Taken together, these data suggest that A(2B)R-mediated induction of IL-6 contributes to renal fibrogenesis and shows potential therapeutic targets for CKD.	Adenosine	103-112	interleukin 6	Mus musculus	89-93
21511827-6	2011	Finally, both genetic and pharmacologic approaches showed that the inflammatory cytokine IL-6 mediates adenosine-induced renal fibrosis downstream of A(2B)R. Taken together, these data suggest that A(2B)R-mediated induction of IL-6 contributes to renal fibrogenesis and shows potential therapeutic targets for CKD.	Adenosine	103-112	interleukin 6	Mus musculus	227-231
21145830-1	2011	BACKGROUND &amp; AIMS: Interleukin-6 (IL-6) is a crucial factor in liver regeneration following partial hepatectomy (PH); however, the role of IL-6 and IL-6 trans-signaling in particular, in hepatocyte mitosis remains controversial.	Adenosine Monophosphate	12-15	interleukin 6	Mus musculus	23-36
21246417-7	2011	These findings indicated that beta-elemene amelioration EAE was, to a large extent, due to inhibit differentiation and development of Th17 cells depends on down-regulating expression of IL-6, IL-23, RORgammat signaling, and promoting expansion in Treg cells.	beta-elemene	30-42	interleukin 6	Mus musculus	186-190
22874716-4	2011	Vinpocetine inhibited the production of nitrite oxide and inflammatory factors such as interleukin-1beta (IL-1beta), IL-6 and tumour necrosis factor-alpha (TNF-alpha) in BV-2 microglia, in which cells were treated with LPS or exposed to OGD, regardless of the time Vinpocetine was added.	vinpocetine	0-11	interleukin 6	Mus musculus	117-121
21434774-7	2011	The concentration of serum cytokines (interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha) decreased in the radiation group treated with hesperidin at 50 and 200 mg/kg of body weight compared with the control group on Day 10 after irradiation.	Hesperidin	151-161	interleukin 6	Mus musculus	57-103
21479351-12	2011	In the acute phase, micro- and nano-size rutile and nano-size amorphous TiO2 induced elevated levels of IL-6 and total protein in BALF at the highest dose.	titanium dioxide	72-76	interleukin 6	Mus musculus	104-108
22866112-10	2011	IL-6 and TGF-beta were significantly inhibited following the combined use of etodolac and PSK.	Etodolac	77-85	interleukin 6	Mus musculus	0-4
22866112-13	2011	Combined use of etodolac and PSK did not show any additive effect in the inhibition of the number of hepatic metastases, whereas it inhibited MMP-9, TGF-beta and IL-6, suggesting the benefit of a combined effect.	Etodolac	16-24	interleukin 6	Mus musculus	162-166
21459724-9	2011	Inactivation of Kupffer cells by gadolinium chloride pretreatment protected against concanavalin A-induced injury and significantly reduced hepatic cytokine levels including TNF-alpha, IL-6 and IFN-gamma but not IL-17.	gadolinium chloride	33-52	interleukin 6	Mus musculus	185-189
21083649-7	2011	IL-6 mRNA was expressed in the three parts of the brain with the lowest content in the hippocampus (P &lt; 0.05) coupled to the highest glycogen content (3.2 +- 0.8 mmol kg(-1) ).	Glycogen	136-144	interleukin 6	Mus musculus	0-4
21307008-9	2011	RESULTS: Propofol prolonged survival and attenuated acute lung injury and decreased the expression of HIF-1alpha, interleukin (IL)-6, keratinocyte-derived chemokine, and tumour necrosis factor-alpha (TNF-alpha) in the lungs of endotoxaemic mice.	Propofol	9-17	interleukin 6	Mus musculus	114-132
21307008-12	2011	Propofol also down-regulated, in A549 cells, the expression of IL-6, IL-8, and TNF-alpha, Bcl-2/adenovirus E1B 19 kDa interacting protein 3 (BNIP3), and apoptosis.	Propofol	0-8	interleukin 6	Mus musculus	63-67
20490642-3	2011	By enzyme-linked immunosorbent assay, we observed that CTS reduced significantly the production of proinflammatory mediators (tumor necrosis factor-alpha and interleukin-6) induced by LPS in murine macrophage-like RAW264.7 cells.	cryptotanshinone	55-58	interleukin 6	Mus musculus	158-171
21238621-4	2011	Moreover, elevation of IL-6 and total IgE levels in serum were suppressed by ginsenoside Rh1 (20mg/kg).	ginsenoside Rh1	77-92	interleukin 6	Mus musculus	23-27
21238621-6	2011	The results suggest that ginsenoside Rh1 can alleviate inflammatory symptoms in atopic dermatitis (AD) by reduction of IgE and IL-6 levels in peripheral blood, increase of Foxp3 expression in draining lymph nodes and suppression of inflammation in skin regions.	ginsenoside Rh1	25-40	interleukin 6	Mus musculus	127-131
21321532-0	2011	Blockade of IL-6 signaling exacerbates liver injury and suppresses antiapoptotic gene expression in methionine choline-deficient diet-fed db/db mice.	methionine choline	100-118	interleukin 6	Mus musculus	12-16
21321532-1	2011	Our previous study revealed that blockade of interleukin-6 (IL-6)-STAT3 signaling ameliorated liver injury, although hepatic STAT3(-/-) or GP130(-/-) mice have been reported to develop severe liver injury, in a murine methionine choline deficient (MCD) diet-induced model of non-alcoholic steatohepatitis (NASH).	methionine choline	218-236	interleukin 6	Mus musculus	45-58
21321532-1	2011	Our previous study revealed that blockade of interleukin-6 (IL-6)-STAT3 signaling ameliorated liver injury, although hepatic STAT3(-/-) or GP130(-/-) mice have been reported to develop severe liver injury, in a murine methionine choline deficient (MCD) diet-induced model of non-alcoholic steatohepatitis (NASH).	methionine choline	218-236	interleukin 6	Mus musculus	60-64
21556222-7	2011	The water fraction of hawthorn fruit was determined to be safe and significantly inhibited NO production in LPS-stimulated RAW 264.7 cells and suppressed COX-2, TNF-alpha, IL-1beta, and IL-6 expression.	Water	4-9	interleukin 6	Mus musculus	186-190
21556222-8	2011	The observed anti-inflammatory effects of the water fraction of hawthorn fruit might be attributed to the down-regulation of COX-2, TNF-alpha, IL-1beta, and IL-6 expression in LPS-stimulated RAW 264.7 cells.	Water	46-51	interleukin 6	Mus musculus	157-161
21256148-8	2011	In the present study, our data also show that icariin administration significantly inhibits social defeat-induced increases of corticosterone and IL-6 levels.	icariin	46-53	interleukin 6	Mus musculus	146-150
21116691-6	2011	RESULTS: A hydrodynamic injection of saline induced a significant production of interleukin (IL)-6.	Sodium Chloride	37-43	interleukin 6	Mus musculus	80-98
21116691-7	2011	Depleting Kupffer cells using clodronate liposomes markedly reduced the IL-6 production but had no significant effect on the transgene expression.	Clodronic Acid	30-40	interleukin 6	Mus musculus	72-76
21518517-1	2011	This work was aimed to investigate the effect of quinacrine on peripheral granulocytes and lymphocytes, interleukin 1 (IL-1) and interleukin 6 (IL-6) in peripheral blood serum of inflammatory reaction induced by microwave irradiation, and observe the protective effect of quinacrine against microwave irradiation injury.	Quinacrine	49-59	interleukin 6	Mus musculus	144-148
21518517-8	2011	The level of IL-6 in serum of mice was gradually increased after microwave irradiation with intensity of 50 mW/cm(2) for 7 days, but quinacrine administration could delay the rise of IL-6 level, specially within time of 2 days.	Quinacrine	133-143	interleukin 6	Mus musculus	13-17
21518517-8	2011	The level of IL-6 in serum of mice was gradually increased after microwave irradiation with intensity of 50 mW/cm(2) for 7 days, but quinacrine administration could delay the rise of IL-6 level, specially within time of 2 days.	Quinacrine	133-143	interleukin 6	Mus musculus	183-187
20938376-4	2011	In the sham-operated animals, inhaled H2S and hypothermia alone comparably reduced the plasma chemokine and IL-6 levels, but combining hypothermia and inhaled H2S had no additional effect.	Hydrogen Sulfide	38-41	interleukin 6	Mus musculus	108-112
21518517-9	2011	It is concluded that the quinacrine administration can delay the increase of peripheral granulocytes and lymphocytes inducted by microwave irradiation, and may partially suppress the rise of IL-1beta and IL-6 in serum.	Quinacrine	25-35	interleukin 6	Mus musculus	204-208
21338093-9	2011	Adding a 6-10 length PEG to the TLR7 ligand reduced its potency toward induction of interleukin (IL)-6 by murine macrophages in vitro and IL-6 and tumor necrosis factor (TNF) in vivo.	Polyethylene Glycols	21-24	interleukin 6	Mus musculus	138-142
21111765-8	2011	Importantly, whereas injection of soluble poly(I:C) led to rapid production of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 in serum, administration of poly(I:C) in complex with the cationic DDA/TDB liposomes prevented this non-specific systemic pro-inflammatory response.	Poly I-C	42-50	interleukin 6	Mus musculus	148-166
21111765-8	2011	Importantly, whereas injection of soluble poly(I:C) led to rapid production of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 in serum, administration of poly(I:C) in complex with the cationic DDA/TDB liposomes prevented this non-specific systemic pro-inflammatory response.	Poly I-C	195-203	interleukin 6	Mus musculus	148-166
21408125-5	2011	Propofol also reduced the production of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and IL-10 as detected by enzyme-linked immunosorbent assays.	Propofol	0-8	interleukin 6	Mus musculus	81-99
21307293-0	2011	Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model.	Dopamine	0-8	interleukin 6	Mus musculus	17-21
21307293-5	2011	In human naive CD4(+) T cells, dopamine increased IL-6-dependent IL-17 production via D1-like receptors, in response to anti-CD3 plus anti-CD28 mAb.	Dopamine	31-39	interleukin 6	Mus musculus	50-54
21307293-7	2011	In the RA synovial/SCID mouse chimera model, although a selective D2-like receptor antagonist haloperidol significantly induced accumulation of IL-6(+) and IL-17(+) T cells with exacerbated cartilage destruction, SCH-23390 strongly suppressed these responses.	Haloperidol	94-105	interleukin 6	Mus musculus	144-148
21278785-9	2011	Furthermore, the dose of evodiamine significantly decreased the expression of IL-1beta, IL-6, TNF-alpha, and COX-2 that were involved in the inflammation due to Alzheimer"s disease.	evodiamine	25-35	interleukin 6	Mus musculus	88-92
21307293-8	2011	Taken together, these findings indicate that dopamine released by DCs induces IL-6-Th17 axis and causes aggravation of synovial inflammation of RA, which is the first time, to our knowledge, that actual evidence has shown the pathological relevance of dopaminergic signaling with RA.	Dopamine	45-53	interleukin 6	Mus musculus	78-82
21131162-6	2011	Serum IL-6 peaked at 3h (3957pg/ml) before returning to baseline by 8h, while IL-10 began to appear at 3h, peaked at 8h (734.5pg/ml), and returned to baseline by 36h.	Tritium	21-23	interleukin 6	Mus musculus	6-10
21109230-11	2011	However, these effects were abolished by pre-treatment with Ang II type 1 (AT1) receptor antagonist, losartan, and the ERK1/2 inhibitor, U0126, inhibited Ang II-mediated IL-6 expression and the phosphorylation of ERK1/2.	Losartan	101-109	interleukin 6	Mus musculus	170-174
21109230-11	2011	However, these effects were abolished by pre-treatment with Ang II type 1 (AT1) receptor antagonist, losartan, and the ERK1/2 inhibitor, U0126, inhibited Ang II-mediated IL-6 expression and the phosphorylation of ERK1/2.	U 0126	137-142	interleukin 6	Mus musculus	170-174
21233289-5	2011	Serum levels of total cholesterol and triglyceride were slightly reduced and those of IL-6, leptin, and MCP-1 were decreased by 40-ppm pitavastatin treatment.	pitavastatin	135-147	interleukin 6	Mus musculus	86-90
21227626-7	2011	The results showed that low-molecular-weight heparin oral colon-specific delivery capsule significantly decreased the serum levels of TNF-alpha, IL-6 as well as FXa, while increased the expression of Musashi-1 in colon compared with acetic acid-induced ulcerative colitis model group.	Heparin	45-52	interleukin 6	Mus musculus	145-149
21145172-0	2011	Simvastatin treatment improves survival in a murine model of burn sepsis: Role of interleukin 6.	Simvastatin	0-11	interleukin 6	Mus musculus	82-95
21233289-6	2011	mRNA expression levels of cyclooxygenase-2, IL-6, inducible nitric oxide (iNOS), MCP-1, and Pai-1 were significantly reduced in intestinal nonpolyp parts by pitavastatin treatment.	pitavastatin	157-169	interleukin 6	Mus musculus	44-48
21332406-5	2011	Dietary capsaicin markedly decreased fasting glucose/insulin and triglyceride levels in the plasma and/or liver, as well as expression of inflammatory adipocytokine genes (e.g., monocyte chemoattractant protein-1 and interleukin-6) and macrophage infiltration.	Capsaicin	8-17	interleukin 6	Mus musculus	217-230
20888665-9	2011	rYopJ induced production of NO, TNF-alpha and IL-6 was significantly inhibited in macrophages pretreated with pharmacological inhibitor wortmanin, genestein and H-7 demonstrating the probable involvement of protein tyrosine kinases in the above process.	ryopj	0-5	interleukin 6	Mus musculus	46-50
21206981-5	2011	When stimulated with poly I:C (and also LPS) JAWSII cells produced large amounts of IL-6, TNF-alpha and MCP-1.	Poly I-C	21-29	interleukin 6	Mus musculus	84-88
21467819-0	2011	Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes.	Dinoprostone	99-105	interleukin 6	Mus musculus	0-13
21467819-0	2011	Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes.	Dinoprostone	99-105	interleukin 6	Mus musculus	26-39
21467819-5	2011	Expression of osteoprotegerin (OPG), receptor activator of NF-kappaB ligand (RANKL), COX-2, and prostaglandin E(2) (PGE(2)) increased in cells exposed to IL-6 and sIL-6r, whereas expression of macrophage colony-stimulating factor (M-CSF) and bone resorption-related enzymes decreased.	Dinoprostone	96-114	interleukin 6	Mus musculus	154-158
21467819-6	2011	NS398 blocked the stimulatory/suppressive effects of IL-6 and sIL-6r on the expression of OPG, RANKL, and M-CSF.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	0-5	interleukin 6	Mus musculus	53-57
21388273-8	2011	GT3 and GT3+PTX increased bone marrow plasma G-CSF levels as well as the availability of IL-1alpha, IL-6 and IL-9 in the early postirradiation phase.	Pentoxifylline	12-15	interleukin 6	Mus musculus	100-104
24278544-6	2011	In conclusion,the current study revealed the previously unknown effect of dichloromethane ethyl extract of Auricularia auricula-judae inhibitions of the production of NO, IL-6, TNF-alpha and IL-1beta in LPS-stimulated macrophages.	Methylene Chloride	74-89	interleukin 6	Mus musculus	171-175
21352586-0	2011	Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in high fat diet decrease IL-6 production in murine epididymal adipose tissue and 3T3-L1 adipocytes following LPS stimulation.	alpha-Tocopherol	14-30	interleukin 6	Mus musculus	84-88
20979017-5	2011	The results showed that polydatin treatment downregulated NF- kappaB p65 activity and expression, blocked the expression of TNF- alpha, IL-6 and IL-1 beta at both mRNA and protein levels, decreased myeloperoxidase (MPO) activity, and alleviated inflammatory damage of colitis in mice with UC (p &lt; 0.05), suggesting that the anti-inflammation effects of polydatin can be attributed, at least partially, to the blocking of the NF- kappaB pathway.	polydatin	24-33	interleukin 6	Mus musculus	136-140
21352586-0	2011	Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in high fat diet decrease IL-6 production in murine epididymal adipose tissue and 3T3-L1 adipocytes following LPS stimulation.	Vitamin E	32-41	interleukin 6	Mus musculus	84-88
21352586-0	2011	Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in high fat diet decrease IL-6 production in murine epididymal adipose tissue and 3T3-L1 adipocytes following LPS stimulation.	Cholecalciferol	47-57	interleukin 6	Mus musculus	84-88
21352586-4	2011	We examined the effects of vitamin D3 and vitamin E supplementation on levels of IL-6 and IL-10 (as a marker of anti-inflammatory cytokines since, a balance between pro- and anti-inflammatory cytokines is maintained) protein expression in adipose tissue of mice provided with an HFD.	Cholecalciferol	27-37	interleukin 6	Mus musculus	81-85
21352586-4	2011	We examined the effects of vitamin D3 and vitamin E supplementation on levels of IL-6 and IL-10 (as a marker of anti-inflammatory cytokines since, a balance between pro- and anti-inflammatory cytokines is maintained) protein expression in adipose tissue of mice provided with an HFD.	Vitamin E	42-51	interleukin 6	Mus musculus	81-85
21352586-5	2011	Additionally, we measured the effects of vitamin E and vitamin D3 treatment on LPS-stimulated 3T3-L1 adipocytes IL-6 and IL-10 secretion.	Cholecalciferol	55-65	interleukin 6	Mus musculus	112-116
21352586-7	2011	A 24-hour treatment of vitamin D3 and vitamin E significantly reduced the IL-6 levels in the adipocytes culture medium without affecting IL-10 levels.	Cholecalciferol	23-33	interleukin 6	Mus musculus	74-78
21352586-7	2011	A 24-hour treatment of vitamin D3 and vitamin E significantly reduced the IL-6 levels in the adipocytes culture medium without affecting IL-10 levels.	Vitamin E	38-47	interleukin 6	Mus musculus	74-78
21352586-8	2011	CONCLUSIONS: Vitamin D3 and vitamin E supplementation in an HFD had an anti-inflammatory effect by decreasing IL-6 production in epididymal adipose tissue in mice and in 3T3-L1 adipocytes stimulated with LPS.	Cholecalciferol	13-23	interleukin 6	Mus musculus	110-114
21352586-8	2011	CONCLUSIONS: Vitamin D3 and vitamin E supplementation in an HFD had an anti-inflammatory effect by decreasing IL-6 production in epididymal adipose tissue in mice and in 3T3-L1 adipocytes stimulated with LPS.	Vitamin E	28-37	interleukin 6	Mus musculus	110-114
21147093-9	2011	LPS-induced phosphorylation of IkappaBalpha and p38 MAPK was blocked by Biochanin-A and it inhibited IL-6, IL-1beta and TNF-alpha production in RAW264.7 cells indicating its anti-inflammatory activity in association with anti-proliferation.	lps	0-3	interleukin 6	Mus musculus	101-105
21250651-9	2011	In the oropharyngeal aspiration model in the mouse, iron doping was associated with decreased polymorphonuclear cell counts and IL-6 mRNA production.	Iron	52-56	interleukin 6	Mus musculus	128-132
21129433-4	2011	Exposure to melphalan induced an early burst of the pro-inflammatory cytokines interleukin (IL)-1beta, IL-6 and IL-23 in airways, followed by extensive infiltration of neutrophils in the lung tissue and airways within 24h.	Melphalan	12-21	interleukin 6	Mus musculus	103-107
21316604-4	2011	MSC-derived CAFs that are recruited to the dysplastic stomach express IL-6, Wnt5alpha and BMP4, show DNA hypomethylation, and promote tumor growth.	cafs	12-16	interleukin 6	Mus musculus	70-74
21148317-0	2011	Homocysteine suppresses the expression of the collagen cross-linker lysyl oxidase involving IL-6, Fli1, and epigenetic DNA methylation.	Homocysteine	0-12	interleukin 6	Mus musculus	92-96
21148317-4	2011	Through evaluation of gene arrays, quantitative RT-PCR, immunoblots, and ELISA, we identified a Hcys-dependent stimulation of interleukin 6 (IL-6) and genes involved in IL-6/Janus kinase 2 (JAK2)-dependent signal transduction pathways in pre-osteoblastic MC3T3-E1 cells.	Homocysteine	96-100	interleukin 6	Mus musculus	126-139
21148317-4	2011	Through evaluation of gene arrays, quantitative RT-PCR, immunoblots, and ELISA, we identified a Hcys-dependent stimulation of interleukin 6 (IL-6) and genes involved in IL-6/Janus kinase 2 (JAK2)-dependent signal transduction pathways in pre-osteoblastic MC3T3-E1 cells.	Homocysteine	96-100	interleukin 6	Mus musculus	141-145
21148317-4	2011	Through evaluation of gene arrays, quantitative RT-PCR, immunoblots, and ELISA, we identified a Hcys-dependent stimulation of interleukin 6 (IL-6) and genes involved in IL-6/Janus kinase 2 (JAK2)-dependent signal transduction pathways in pre-osteoblastic MC3T3-E1 cells.	Homocysteine	96-100	interleukin 6	Mus musculus	169-173
21148317-8	2011	Inhibition of the IL-6/JAK2 pathway or of CpG methylation reversed the repressive effect of Hcys on Lox expression.	Homocysteine	92-96	interleukin 6	Mus musculus	18-22
21266900-3	2011	In all the three neurogenic regions of the IL-6 mice there was a significant decrease in the number of 5-bromo-2-deoxyuridine positive (BrdU) proliferating progenitors compared with the IL-6 mice.	Bromodeoxyuridine	103-125	interleukin 6	Mus musculus	43-47
21266900-3	2011	In all the three neurogenic regions of the IL-6 mice there was a significant decrease in the number of 5-bromo-2-deoxyuridine positive (BrdU) proliferating progenitors compared with the IL-6 mice.	Bromodeoxyuridine	136-140	interleukin 6	Mus musculus	43-47
20822161-3	2011	Serum cytokines and blood chemistries were assessed for 96 h. PEG-HDAd reduced IL-6 6-fold in mice and 3-fold in the primate.	Polyethylene Glycols	62-65	interleukin 6	Mus musculus	79-83
20822161-3	2011	Serum cytokines and blood chemistries were assessed for 96 h. PEG-HDAd reduced IL-6 6-fold in mice and 3-fold in the primate.	hdad	66-70	interleukin 6	Mus musculus	79-83
21081706-9	2011	Sitagliptin also reduced adipocyte mRNA expression of inflammatory genes, including IL-6, TNFalpha, IL-12(p35), and IL-12(p40), 2.5- to fivefold as well as 12-lipoxygenase protein expression.	Sitagliptin Phosphate	0-11	interleukin 6	Mus musculus	84-88
20645940-6	2011	RESULTS: Vitamin E (15 mg/day) has been able to decrease abortion rate and to increase IL-6 placental levels, while both treatments increased vascular endothelial growth factor (VEGF) placental levels.	Vitamin E	9-18	interleukin 6	Mus musculus	87-91
21081706-11	2011	Sitagliptin significantly reduced mRNA expression of the following inflammatory cytokines: MCP-1 (3.3-fold), IL-6 (2-fold), IL-12(p40) (2.2-fold), IL-12(p35) (5-fold, P &lt; 0.01), and IP-10 (2-fold).	Sitagliptin Phosphate	0-11	interleukin 6	Mus musculus	109-113
21095260-9	2011	ELISA revealed that addition of heparin inhibited the TNF-alpha and IL-6 released by macrophages RAW264.7 and HUVEC; 10 U/L and 50 U/L of heparin showed the most marked inhibitory effect in RAW264.7 cells and in HUVEC, respectively.	Heparin	32-39	interleukin 6	Mus musculus	68-72
20549194-8	2011	However, within 1 h of exposure, PbTx-2 induced BMMC degranulation and an increase in IL-6 mRNA expression independent of the high-affinity IgE receptor (FcepsilonRI) stimulation.	Ptychodiscus brevis T2 toxin	33-39	interleukin 6	Mus musculus	86-90
21166666-7	2011	We demonstrate that prostaglandin D2 is induced by lipopolysaccharide (LPS), a major component of Gram-negative bacteria, and that transtympanic injection of prostaglandin D2 up-regulates macrophage inflammatory protein 2 (MIP-2), interleukin (IL)-1beta and IL-6 in the middle ear.	Prostaglandin D2	20-36	interleukin 6	Mus musculus	258-262
21166666-7	2011	We demonstrate that prostaglandin D2 is induced by lipopolysaccharide (LPS), a major component of Gram-negative bacteria, and that transtympanic injection of prostaglandin D2 up-regulates macrophage inflammatory protein 2 (MIP-2), interleukin (IL)-1beta and IL-6 in the middle ear.	Prostaglandin D2	158-174	interleukin 6	Mus musculus	258-262
21166666-8	2011	We also show that middle ear inflammatory reactions, including infiltration of inflammatory cells and expression of MIP-2, IL-1beta and IL-6 induced by LPS, are reduced significantly in DP-(/)- mice and DP-(/)- CRTH2-(/)- mice.	dp	186-188	interleukin 6	Mus musculus	136-140
21166666-8	2011	We also show that middle ear inflammatory reactions, including infiltration of inflammatory cells and expression of MIP-2, IL-1beta and IL-6 induced by LPS, are reduced significantly in DP-(/)- mice and DP-(/)- CRTH2-(/)- mice.	dp	203-205	interleukin 6	Mus musculus	136-140
21270264-0	2011	Interleukin-6 enhances glucose-stimulated insulin secretion from pancreatic beta-cells: potential involvement of the PLC-IP3-dependent pathway.	Glucose	23-30	interleukin 6	Mus musculus	0-13
21270264-0	2011	Interleukin-6 enhances glucose-stimulated insulin secretion from pancreatic beta-cells: potential involvement of the PLC-IP3-dependent pathway.	plc-ip3	117-124	interleukin 6	Mus musculus	0-13
21270264-1	2011	OBJECTIVE: Interleukin-6 (IL-6) has a significant impact on glucose metabolism.	Glucose	60-67	interleukin 6	Mus musculus	11-24
21270264-1	2011	OBJECTIVE: Interleukin-6 (IL-6) has a significant impact on glucose metabolism.	Glucose	60-67	interleukin 6	Mus musculus	26-30
21270264-7	2011	RESULTS: Hepatic IL-6 expression raised circulating IL-6 and improved glucose tolerance due to enhancement of glucose stimulated-insulin secretion (GSIS).	Glucose	70-77	interleukin 6	Mus musculus	17-21
21270264-10	2011	An inositol triphosphate (IP(3)) receptor antagonist, Xestospondin C, also abrogated the GSIS enhancement induced by IL-6.	xestospondin c	54-68	interleukin 6	Mus musculus	117-121
21270264-12	2011	The PLC-IP(3)-dependent pathway is likely to be involved in IL-6-mediated enhancements of GSIS.	plc-ip(3)	4-13	interleukin 6	Mus musculus	60-64
21095260-9	2011	ELISA revealed that addition of heparin inhibited the TNF-alpha and IL-6 released by macrophages RAW264.7 and HUVEC; 10 U/L and 50 U/L of heparin showed the most marked inhibitory effect in RAW264.7 cells and in HUVEC, respectively.	Heparin	138-145	interleukin 6	Mus musculus	68-72
21268091-9	2011	Taken together, the results in this study suggest that GJE glycoprotein inhibits the expression of inflammation-related cytokines (TNF-alpha and IL-6) in cadmium chloride-exposed ICR mice.	Cadmium Chloride	154-170	interleukin 6	Mus musculus	145-149
21106721-7	2011	GH+INS+IND treatment was more effective than other treatment combinations in elevating Glu and TGs, reducing TNF-alpha and IL6 levels, and prolonging survival time.	Insulin	3-6	interleukin 6	Mus musculus	123-126
21106721-7	2011	GH+INS+IND treatment was more effective than other treatment combinations in elevating Glu and TGs, reducing TNF-alpha and IL6 levels, and prolonging survival time.	Indomethacin	7-10	interleukin 6	Mus musculus	123-126
21097750-9	2011	Following lipopolysaccharide (LPS), cytosine-phosphate-guanine (CpG), or Imiquimod stimulation, TCDD-BMDCs secreted less interleukin (IL)-6, tumor necrosis factor-alpha (TNF-alpha), IL-10, and IL-12.	tcdd-bmdcs	96-106	interleukin 6	Mus musculus	121-139
21111776-7	2011	Quil-A alone or in combination with MPL induced systemic IL-5 and IL-6 6h after primary immunization.	Quil A	0-6	interleukin 6	Mus musculus	66-70
21034736-7	2011	Montelukast treatment also decreased mRNA levels of IL-6, IL-10, IL-13, and TGF-beta1, all of which were elevated in fibrotic lungs.	montelukast	0-11	interleukin 6	Mus musculus	52-56
21034736-11	2011	These results suggest that montelukast exhibits its beneficial effects by inhibiting the overexpression of IL-6, IL-10, IL-13, and TGF-beta1 and by modulating the homeostatic balance between the cysteinyl-leukotriene type 1 and type 2 receptors.	montelukast	27-38	interleukin 6	Mus musculus	107-111
21734368-10	2011	Furthermore, in the LPS-stimulated HK-2 cells, rosiglitazone downregulated MCP-1, IL-8 and IL-6 expression as well as NF-kappaB activation and increased PPAR-gamma expression (p &lt; 0.05).	Rosiglitazone	47-60	interleukin 6	Mus musculus	91-95
20637579-11	2011	The change of inflammation cytokine, including TNF-alpha and IL-6, may play an important role in the mechanisms of action of curcumin, but the detail mechanism remains unknown.	Curcumin	125-133	interleukin 6	Mus musculus	61-65
21213407-3	2011	In this study, hyperoside was shown to exert an anti-inflammatory action through suppressed production of tumor necrosis factor, interleukin-6, and nitric oxide in lipopolysaccharide-stimulated mouse peritoneal macrophages.	hyperoside	15-25	interleukin 6	Mus musculus	129-142
21213407-4	2011	The maximal inhibition rate of tumor necrosis factor-alpha, interleukin-6, and nitric oxide production by 5 muM hyperoside was 32.31 +- 2.8%, 41.31 +- 3.1%, and 30.31 +- 4.1%, respectively.	hyperoside	112-122	interleukin 6	Mus musculus	60-73
20959538-9	2011	Compared with controls, IL-6 or TNFalpha (20 ng/ml for 24 h) inhibited FITC-insulin uptake as well as the expression of caveolin-1 mRNA and protein (P &lt; 0.05 for each).	Fluorescein-5-isothiocyanate	71-75	interleukin 6	Mus musculus	24-28
21372386-12	2011	NAC and glutathione highly stimulated the hepatic expression of cytokines, particularly interleukin-6, which might be involved in the alleviation of APAP hepatotoxicity.	Acetylcysteine	0-3	interleukin 6	Mus musculus	88-101
20816670-6	2011	In Raw264.7 cells, 8-OHdG was found to be associated with marked attenuations of NOX1, NOXO1, and NOXA1 accompanied with the decreased expressions of LPS-induced inflammatory mediators including COX-2, iNOS, IL-1beta, and IL-6.	8-ohdg	19-25	interleukin 6	Mus musculus	222-226
21415531-7	2011	Our results demonstrated that SKLB010 diminished the increase of macrophage, neutrophil and lymphocyte counts as well as the levels of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, and IL-6 in bronchoalveolar lavage fluid on day 14 (p&lt;0.05).	5-(4-methoxybenzylidene)thiazolidine-2,4-dione	30-37	interleukin 6	Mus musculus	204-208
21532164-6	2011	However, S/B remedy induced STAT3 and subsequently suppressor of cytokine signaling (SOCS3) activation in mouse liver and increased serum IL-6 level in a dose-dependent manner, which could be partially blocked by pretreatment with gadolinium chloride.	gadolinium chloride	231-250	interleukin 6	Mus musculus	138-142
21372386-12	2011	NAC and glutathione highly stimulated the hepatic expression of cytokines, particularly interleukin-6, which might be involved in the alleviation of APAP hepatotoxicity.	Glutathione	8-19	interleukin 6	Mus musculus	88-101
21737940-0	2011	Effects of chondroitin sulfate and its oligosaccharides on toll-like receptor-mediated IL-6 secretion by macrophage-like J774.1 cells.	Chondroitin Sulfates	11-30	interleukin 6	Mus musculus	87-91
22146708-5	2011	The adipose tissue mRNA levels of inflammatory adipocytokines (MCP-1 and IL-6) and the liver mRNA levels of genes related to fatty acid synthesis were lower in the coffee and caffeine groups than those in the control group.	Caffeine	175-183	interleukin 6	Mus musculus	73-77
21737940-0	2011	Effects of chondroitin sulfate and its oligosaccharides on toll-like receptor-mediated IL-6 secretion by macrophage-like J774.1 cells.	Oligosaccharides	39-55	interleukin 6	Mus musculus	87-91
21737940-4	2011	Suppression of IL-6 secretion by smaller sized CS-A was stronger than that by intact CS-A, whereas no such size-dependent suppression was apparent for CS-C.	Chondroitin Sulfates	47-49	interleukin 6	Mus musculus	15-19
21737940-4	2011	Suppression of IL-6 secretion by smaller sized CS-A was stronger than that by intact CS-A, whereas no such size-dependent suppression was apparent for CS-C.	Carbon	47-48	interleukin 6	Mus musculus	15-19
21372418-4	2011	Quassidines E-G (1-3) showed potent inhibitory activity on the production of nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha), or interleukin 6 (IL-6) in mouse monocyte-macrophage RAW264.7 cells stimulated by lipopolysaccharide (LPS).	quassidines	0-11	interleukin 6	Mus musculus	155-159
21071580-10	2011	The serum levels of TNF-alpha and the expression levels of TNF- alpha, IL-6, and IL-1 beta mRNA in the livers of DEN-treated db/db mice were decreased by ACR treatment, suggesting attenuation of the chronic inflammation induced by excessive fatty deposits.	Diethylnitrosamine	113-116	interleukin 6	Mus musculus	71-75
21372424-6	2011	In addition, harmine was found to suppress interleukin-6 (IL-6) production in RAW264 cells.	Harmine	13-20	interleukin 6	Mus musculus	43-56
21239739-13	2011	Protein levels and mRNA expressions of interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha were inhibited by EPPF or RA administration in the nasal mucosa tissue or spleen of OVA-sensitized mice.	rosmarinic acid	126-128	interleukin 6	Mus musculus	63-99
21372424-6	2011	In addition, harmine was found to suppress interleukin-6 (IL-6) production in RAW264 cells.	Harmine	13-20	interleukin 6	Mus musculus	58-62
20956499-7	2011	Intriguingly, mice receiving portal drained transplants from IL-6 knockout mice showed normal glucose tolerance.	Glucose	94-101	interleukin 6	Mus musculus	61-65
20950664-8	2011	CbpA was also found to participate in the induction of IL-6, CCL2, CXCL1, and CXCL8 in the airways of mice upon intranasal challenge with S. pneumoniae.	cbpa	0-4	interleukin 6	Mus musculus	55-59
22264719-2	2011	Hepcidin, a key regulator           of iron metabolism, is up-regulated by iron and inflammatory           stimuli such as interleukin 6, and decreased           by iron deficiency, enhanced erythropoiesis           and hypoxia.	Iron	39-43	interleukin 6	Mus musculus	123-136
20875076-5	2011	Using this system, ganglioside treatment promotes the development of a dendritic cell population characterized by decreased CD86 (B7-2) expression, and decreased interleukin-12 and interleukin-6 production.	Gangliosides	19-30	interleukin 6	Mus musculus	181-194
20886344-0	2011	Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway.	Aspirin	0-7	interleukin 6	Mus musculus	108-112
20886344-1	2011	BACKGROUND AND AIMS: Aspirin is associated with a reduced risk of colorectal cancer (CRC), and it showed inhibited effects on interleukin 6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling pathway which is thought to play an important role in intestinal inflammation and the tumorigenesis of CRC.	Aspirin	21-28	interleukin 6	Mus musculus	126-139
20886344-1	2011	BACKGROUND AND AIMS: Aspirin is associated with a reduced risk of colorectal cancer (CRC), and it showed inhibited effects on interleukin 6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling pathway which is thought to play an important role in intestinal inflammation and the tumorigenesis of CRC.	Aspirin	21-28	interleukin 6	Mus musculus	141-145
20886344-6	2011	The expression level of IL-6, which is an upstream molecule of STAT3 and capable of activating STAT3, was reduced in aspirin-treated mice.	Aspirin	117-124	interleukin 6	Mus musculus	24-28
20886344-8	2011	CONCLUSIONS: Our data suggested that the protective mechanisms of aspirin in CRC may be associated with its effects on induction of CRC cell apoptosis and suppression of IL-6-STAT3 signaling pathway, which implied that aspirin has a potential therapeutic activity in CRC.	Aspirin	66-73	interleukin 6	Mus musculus	170-174
20886344-8	2011	CONCLUSIONS: Our data suggested that the protective mechanisms of aspirin in CRC may be associated with its effects on induction of CRC cell apoptosis and suppression of IL-6-STAT3 signaling pathway, which implied that aspirin has a potential therapeutic activity in CRC.	Aspirin	219-226	interleukin 6	Mus musculus	170-174
21593565-11	2011	A significant reduction was found in the Abeta-induced release of IL-6 and TNF-alpha in the presence of CNI-1493.	UNII-042A8N37WH	41-46	interleukin 6	Mus musculus	66-70
21496386-4	2011	This fraction was found to be composed primarily of saccharides and in vitro intensively stimulated mouse peritoneal macrophages that produce Th1 inflammatory cytokines such as tumor necrosis factor alpha (TNFalpha), interleukin-1beta (IL-1beta), interferon-gamma (IFN-gamma), and interleukin-6 (IL-6).	Carbohydrates	52-63	interleukin 6	Mus musculus	281-294
21496386-4	2011	This fraction was found to be composed primarily of saccharides and in vitro intensively stimulated mouse peritoneal macrophages that produce Th1 inflammatory cytokines such as tumor necrosis factor alpha (TNFalpha), interleukin-1beta (IL-1beta), interferon-gamma (IFN-gamma), and interleukin-6 (IL-6).	Carbohydrates	52-63	interleukin 6	Mus musculus	296-300
21422521-5	2011	treatment with caffeinated coffee greatly and specifically increased plasma levels of granulocyte-colony stimulating factor (GCSF), IL-10, and IL-6.	caffeinated coffee	15-33	interleukin 6	Mus musculus	143-147
21266789-8	2011	The effects on IL-6 secretions of Sito were also significantly less than those of Chol.	gamma-sitosterol	34-38	interleukin 6	Mus musculus	15-19
21131418-9	2011	Th2 skewing was accelerated in the culture of WT CD4 T cells stimulated with Ags and LPS-activated Bcl6-KO BM-derived DCs, which produced more IL-6 and less IL-12 than did WT DCs; the addition of anti-IL-6 Abs to the culture partially abrogated the Th2 skewing.	Silver	77-80	interleukin 6	Mus musculus	201-205
21322097-5	2011	Two cytokines, interleukin-6 (IL-6) and transforming growth factor-beta1 (TGF-beta1), displayed significantly changed transcript levels in the presence of Pb.	Lead	155-157	interleukin 6	Mus musculus	15-28
21322097-5	2011	Two cytokines, interleukin-6 (IL-6) and transforming growth factor-beta1 (TGF-beta1), displayed significantly changed transcript levels in the presence of Pb.	Lead	155-157	interleukin 6	Mus musculus	30-34
21322097-8	2011	Pb also modulated IL-6, TGF-beta1, and IL-18 protein expression in select brain regions.	Lead	0-2	interleukin 6	Mus musculus	18-22
21131418-9	2011	Th2 skewing was accelerated in the culture of WT CD4 T cells stimulated with Ags and LPS-activated Bcl6-KO BM-derived DCs, which produced more IL-6 and less IL-12 than did WT DCs; the addition of anti-IL-6 Abs to the culture partially abrogated the Th2 skewing.	Silver	77-80	interleukin 6	Mus musculus	143-147
20606471-7	2011	The IL-17A induced release of the pro-inflammatory cytokines IL-6, G-CSF, GM-CSF and MCP-1 from VSMC, as detected by the Luminex technology, was completely abolished by NAD(P)H-oxidase inhibition.	vsmc	96-100	interleukin 6	Mus musculus	61-65
21261439-6	2011	Additionally, ex vivo interleukin-4 (IL-4), IL-5, and IL-6 production by in vitro anti-CD3- or phorbol myristate acetate-stimulated CD4+ T-cells was not affected.	Tetradecanoylphorbol Acetate	95-120	interleukin 6	Mus musculus	54-58
20606471-7	2011	The IL-17A induced release of the pro-inflammatory cytokines IL-6, G-CSF, GM-CSF and MCP-1 from VSMC, as detected by the Luminex technology, was completely abolished by NAD(P)H-oxidase inhibition.	NADP	169-175	interleukin 6	Mus musculus	61-65
21071958-6	2011	RESULTS: Correction of renal function in ZDF by pioglitazone, occurring with a glycemia &gt;250 mg/dl, was accompanied by normalization of the renal levels of connective tissue growth factor and fibronectin (fibrosis), TNF-alpha, interleukin-6 and MCP-1 (inflammation), megalin (tubular cells), the PCNA/caspase-3 ratio (positive cell turnover), VEGF (abnormal angiogenesis), and the ratio between eNOS and iNOS (endothelial dysfunction).	Pioglitazone	48-60	interleukin 6	Mus musculus	230-243
20102773-11	2011	Glucose levels in KO + IL-6 mice, while decreased (93 +- 4 mg/dL) at 4 hours, remained higher than those in WT mice.	Glucose	0-7	interleukin 6	Mus musculus	23-27
20102773-13	2011	Acute restoration of the IL-6 response to LPS did not potentiate hypoglycemia but partially restored the glucagon response.	Glucagon	105-113	interleukin 6	Mus musculus	25-29
20102773-14	2011	Thus, although IL-6 promotes glucose intolerance in insulin-resistant states, IL-6 promotes hypoglycemia during acute inflammation.	Glucose	29-36	interleukin 6	Mus musculus	15-19
20031174-12	2011	In littermate mice, the peak expression levels of TNF-alpha and IL-6 in the liver was observed 1h after PH, which was consistent with data in previous reports.	Hydrogen	95-97	interleukin 6	Mus musculus	64-68
20938211-5	2011	In MPTP-treated animals we observed a significant increase in IL-1beta, TNF-alpha and IL-6 mRNA expression levels both in the SN and CP in comparison with untreated mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-7	interleukin 6	Mus musculus	86-90
21772662-7	2011	Real time-PCR from thoracic aortas revealed that rivaroxaban (5 mg/kg/day) treatment reduced mRNA expression of inflammatory mediators, such of IL-6, TNF-alpha, MCP-1, and Egr-1 (P &lt; .05).	Rivaroxaban	49-60	interleukin 6	Mus musculus	144-148
20732383-5	2011	Lithium Chloride (LiCl), which is an inhibitor of GSK3beta, markedly reduced the TNF-alpha-stimulated IL-6 release, similar to the results with Wnt3a.	Lithium Chloride	0-16	interleukin 6	Mus musculus	102-106
20732383-5	2011	Lithium Chloride (LiCl), which is an inhibitor of GSK3beta, markedly reduced the TNF-alpha-stimulated IL-6 release, similar to the results with Wnt3a.	Lithium Chloride	18-22	interleukin 6	Mus musculus	102-106
20732383-9	2011	Lactacystin, a proteasome inhibitor, and bafilomycin A1, a lysosomal protease inhibitor, significantly restored the suppressive effect of Wnt3a on TNF-alpha-stimulated IL-6 release.	lactacystin	0-11	interleukin 6	Mus musculus	168-172
20732383-9	2011	Lactacystin, a proteasome inhibitor, and bafilomycin A1, a lysosomal protease inhibitor, significantly restored the suppressive effect of Wnt3a on TNF-alpha-stimulated IL-6 release.	bafilomycin	41-52	interleukin 6	Mus musculus	168-172
21389736-0	2011	IL-6 mediates 11betaHSD type 2 to effect progression of the mycobacterial cord factor trehalose 6,6"-dimycolate-induced granulomatous response.	Trehalose	86-95	interleukin 6	Mus musculus	0-4
21389736-0	2011	IL-6 mediates 11betaHSD type 2 to effect progression of the mycobacterial cord factor trehalose 6,6"-dimycolate-induced granulomatous response.	6,6"-dimycolate	96-111	interleukin 6	Mus musculus	0-4
21389736-9	2011	A model is proposed linking IL-6 to endocrine-derived factors which allows modification of active corticosterone into inert 11-dehydrocorticosterone at the site of granuloma formation to limit excessive parenchymal damage.	Corticosterone	98-112	interleukin 6	Mus musculus	28-32
21389736-9	2011	A model is proposed linking IL-6 to endocrine-derived factors which allows modification of active corticosterone into inert 11-dehydrocorticosterone at the site of granuloma formation to limit excessive parenchymal damage.	11-dehydrocorticosterone	124-148	interleukin 6	Mus musculus	28-32
22132131-7	2011	TB mice showed a significant increase in serum levels of pro-inflammatory factors IL-6 and MCP-1 measured by CBA.	Terbium	0-2	interleukin 6	Mus musculus	82-86
22870144-6	2011	At 4 weeks after the second dose of B[a]P and after 2 weeks of CG administration in the diet, the 2 and 4% CG diets significantly reduced the levels of IL-6 and TNFalpha (by 70 and 33%, respectively).	Glucaric Acid	107-109	interleukin 6	Mus musculus	152-156
21799929-5	2011	METHODOLOGY/PRINCIPAL FINDINGS: We tested this hypothesis by neutralizing or genetically removing IL-6 in adenosine deaminase (ADA)-deficient mice that develop adenosine dependent pulmonary inflammation and remodeling.	Adenosine	106-115	interleukin 6	Mus musculus	98-102
21909350-7	2011	Notably, serum lp-PLA2 activity as well as hs-CRP (C-reactive protein) and IL-6 (Interleukin-6) levels were significantly reduced in the darapladib group, compared with the vehicle group, while the serum PAF (platelet-activating factor) levels were similar between the two groups.	darapladib	137-147	interleukin 6	Mus musculus	75-79
21909350-7	2011	Notably, serum lp-PLA2 activity as well as hs-CRP (C-reactive protein) and IL-6 (Interleukin-6) levels were significantly reduced in the darapladib group, compared with the vehicle group, while the serum PAF (platelet-activating factor) levels were similar between the two groups.	darapladib	137-147	interleukin 6	Mus musculus	81-94
21637823-6	2011	Serum levels of TNF-alpha and Il-6 were elevated in TG.	Thioguanine	52-54	interleukin 6	Mus musculus	30-34
22439331-1	2011	The objective of this study was to determine the effect of a nonionic silver nanocolloid administered orally for 7 or 14 days at three concentration levels (25 ppm, 2.5 ppm, and 0.25 ppm) on the phagocytic activity and mitogenic response of splenocytes and selected cytokine serum levels (IL-1beta, IL-6, IL-10, IL-12 p70, TNF-alpha) in NMRI mice at the early stage of experimental endotoxemia induced with single 30 microg/mouse dose of bacterial LPS.	silver nanocolloid	70-88	interleukin 6	Mus musculus	299-303
20831192-4	2010	DHA and EPA inhibited LPS-induced COX-2, iNOS, IL-1beta, IL-6, or TNF-alpha, but increased hemeoxygenase (HO-1) expression.	Docosahexaenoic Acids	0-3	interleukin 6	Mus musculus	57-61
22190908-4	2011	This study tested whether the administration of fenofibrate would reduce blood pressure by attenuating plasma IL-6 and renal expression of cyclooxygenase-2 (COX-2), while increasing expression of renal CYP4A during 7 days of DOCA-salt hypertension.	Fenofibrate	48-59	interleukin 6	Mus musculus	110-114
22190908-6	2011	Fenofibrate significantly decreased mean arterial pressure and plasma IL-6.	Fenofibrate	0-11	interleukin 6	Mus musculus	70-74
22190908-9	2011	Our results suggest that the blood pressure lowering effect of PPAR-alpha activation by fenofibrate involves the reduction of plasma IL-6 and COX-2, while increasing CYP4A expression during DOCA-salt hypertension.	Fenofibrate	88-99	interleukin 6	Mus musculus	133-137
21659722-10	2011	The numbers of inflammatory cells and levels of IL-6, IL-1beta and tumor necrosis factor-alpha were decreased in the imatinib and nilotinib groups on days 3 and 7.	Imatinib Mesylate	117-125	interleukin 6	Mus musculus	48-52
21659722-10	2011	The numbers of inflammatory cells and levels of IL-6, IL-1beta and tumor necrosis factor-alpha were decreased in the imatinib and nilotinib groups on days 3 and 7.	nilotinib	130-139	interleukin 6	Mus musculus	48-52
21162750-10	2010	Low concentrations of delta-Tocotrienols (&lt; 20 muM) blocked LPS-induced gene expression of TNF-alpha, IL-1beta, IL-6 and iNOS (&gt; 40%), while higher concentrations (40 muM) increased gene expression of the latter in peritoneal macrophages (prepared from BALB/c mice) as compared to control group.	tocotrienol, delta	22-40	interleukin 6	Mus musculus	115-119
21098227-5	2010	In this study, we demonstrate that the induction of TNF and IL-6 expression by LVS in mouse bone marrow-derived macrophages was markedly enhanced when PI3K activity was inhibited by either of the well-known chemical inhibitors, wortmannin or LY294002.	Wortmannin	228-238	interleukin 6	Mus musculus	60-64
21098227-5	2010	In this study, we demonstrate that the induction of TNF and IL-6 expression by LVS in mouse bone marrow-derived macrophages was markedly enhanced when PI3K activity was inhibited by either of the well-known chemical inhibitors, wortmannin or LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	242-250	interleukin 6	Mus musculus	60-64
20831192-4	2010	DHA and EPA inhibited LPS-induced COX-2, iNOS, IL-1beta, IL-6, or TNF-alpha, but increased hemeoxygenase (HO-1) expression.	Eicosapentaenoic Acid	8-11	interleukin 6	Mus musculus	57-61
20831192-5	2010	DHA was found to be more potent than EPA in inhibiting COX-2, iNOS, IL-1beta, IL-6, and TNF-alpha mRNA expression.	Docosahexaenoic Acids	0-3	interleukin 6	Mus musculus	78-82
20831192-5	2010	DHA was found to be more potent than EPA in inhibiting COX-2, iNOS, IL-1beta, IL-6, and TNF-alpha mRNA expression.	Eicosapentaenoic Acid	37-40	interleukin 6	Mus musculus	78-82
21151872-0	2010	IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis.	Dinoprostone	15-19	interleukin 6	Mus musculus	0-4
21151872-5	2010	The immunomodulatory function of MSCs was mainly attributed to IL-6-dependent secretion of prostaglandin E2 (PGE2) with a minor role for NO.	Dinoprostone	91-107	interleukin 6	Mus musculus	63-67
21151872-5	2010	The immunomodulatory function of MSCs was mainly attributed to IL-6-dependent secretion of prostaglandin E2 (PGE2) with a minor role for NO.	Dinoprostone	109-113	interleukin 6	Mus musculus	63-67
21106771-4	2010	These results proved that it is reliable and effective to use Art to treat LN mice, and its therapeutic mechanisms should closely be related to the fact that Art can obviously decrease the serum levels of TNF-alpha and IL-6 and down-regulate the expression of the NF-kappaBp65 protein and NF-kappaB and TGF-beta1 mRNA in renal tissues.	artemisinin	62-65	interleukin 6	Mus musculus	219-223
20869956-10	2010	Both doses of UA lowered splenic IL-6 levels, whereas metformin increased IFN-gamma, IL-6 and TNF-alpha levels compared to the untreated diabetic mice.	ursolic acid	14-16	interleukin 6	Mus musculus	33-37
20869956-10	2010	Both doses of UA lowered splenic IL-6 levels, whereas metformin increased IFN-gamma, IL-6 and TNF-alpha levels compared to the untreated diabetic mice.	Metformin	54-63	interleukin 6	Mus musculus	85-89
20864798-0	2010	IL-6, VEGF, KC and RANTES are a major cause of a high irritant dermatitis to phthalic anhydride in C57BL/6 inbred mice.	phthalic anhydride	77-95	interleukin 6	Mus musculus	0-4
20858753-6	2010	Probucol-treated mice could induce only a relatively minor corticosterone response upon a LPS challenge compared with controls, which coincided with an approximately twofold increased hepatic expression level of interleukin-6 and tumor necrosis factor (TNF)alpha and an 89% higher TNFalpha response in plasma.	Probucol	0-8	interleukin 6	Mus musculus	212-225
20515643-4	2010	Interleukin-6 (IL-6) and plasminogen activator inhibitor-1 mRNA expression levels in WAT were also decreased by fucoxanthin in KK-A(y) mice.	fucoxanthin	112-123	interleukin 6	Mus musculus	0-13
20515643-5	2010	In differentiating 3T3-F442A adipocytes, fucoxanthinol, which is a fucoxanthin metabolite found in WAT, attenuated TNF-alpha-induced MCP-1 and IL-6 mRNA overexpression and protein secretion into the culture medium.	fucoxanthinol	41-54	interleukin 6	Mus musculus	143-147
22166518-13	2010	Histopathological examination of 4% N-9 treated cervicovaginal tissues on day three showed intensive damage in four mice (sores: 10 - 13) and moderate damage in one mouse (score: 8), which were significantly associated with both inflammatory cytokines IL-17A and IL-6 and anti-inflammatory cytokines IL-4 and IL-10.	Nonoxynol	36-39	interleukin 6	Mus musculus	263-267
20515643-5	2010	In differentiating 3T3-F442A adipocytes, fucoxanthinol, which is a fucoxanthin metabolite found in WAT, attenuated TNF-alpha-induced MCP-1 and IL-6 mRNA overexpression and protein secretion into the culture medium.	fucoxanthin	41-52	interleukin 6	Mus musculus	143-147
20490462-0	2010	IL-6 receptor-mediated lung Th2 cytokine networking in silica-induced pulmonary fibrosis.	Silicon Dioxide	55-61	interleukin 6	Mus musculus	0-4
20490462-8	2010	In parallel, heightened expression of Th2 cytokines (IL-4, IL-5, IL-6) and signal molecules (Stat3 and Socs3) were observed in the airways of silica-exposed mice.	Silicon Dioxide	142-148	interleukin 6	Mus musculus	65-69
20846163-4	2010	We reported recently that two substances (ATRA and thalidomide) have preventive effects on pulmonary fibrosis by inhibiting IL-6-dependent proliferation and TGF-beta1-dependent transdifferentiation of lung fibroblasts.	Tretinoin	42-46	interleukin 6	Mus musculus	124-128
20846163-4	2010	We reported recently that two substances (ATRA and thalidomide) have preventive effects on pulmonary fibrosis by inhibiting IL-6-dependent proliferation and TGF-beta1-dependent transdifferentiation of lung fibroblasts.	Thalidomide	51-62	interleukin 6	Mus musculus	124-128
20352482-4	2010	In vitro, norisoboldine substantially reduced the production of nitric oxide (NO), tumor necrosis factor (TNF)-alpha as well as interleukin (IL)-1beta from RAW264.7 macrophage cells in a concentration-dependent manner, whereas it only slightly reduced the production of interleukin-6 (IL-6) at both protein and transcription levels.	norisoboldine	10-23	interleukin 6	Mus musculus	270-283
20828550-5	2010	Berberine inhibited colonic expression of iNOS, COX-2, IL-1beta, IL-6, and TNF-alpha, but increased IL-10 expression in the colons of TNBS-treated C3H/HeN and C3H/HeJ mice.	Berberine	0-9	interleukin 6	Mus musculus	65-69
20931558-6	2010	CONCLUSION: IL-6 plays a critical role in allowing the liver to recover from significant mtDNA oxidation caused by alcohol.	Alcohols	115-122	interleukin 6	Mus musculus	12-16
20352482-4	2010	In vitro, norisoboldine substantially reduced the production of nitric oxide (NO), tumor necrosis factor (TNF)-alpha as well as interleukin (IL)-1beta from RAW264.7 macrophage cells in a concentration-dependent manner, whereas it only slightly reduced the production of interleukin-6 (IL-6) at both protein and transcription levels.	norisoboldine	10-23	interleukin 6	Mus musculus	285-289
20951668-9	2010	All together our results suggest that orally given Imunoglucan  indirectly modulates immune activity and probably disengages Listeria induced suppression of these responses by inducing a higher reserve of myeloid progenitors in the bone marrow in consequence of biologically active cytokine release (CSFs, IL-1alpha, IL-6, and INF-gamma).	imunoglucan	51-62	interleukin 6	Mus musculus	317-321
20813836-3	2010	In this report, we show that phenylmethimazole (C10) blocks basal IL6 and leptin production as well as basal Socs-3 expression in fully differentiated 3T3L1 cells (3T3L1 adipocytes) without affecting insulin-stimulated AKT signaling.	phenyl methimazole	29-46	interleukin 6	Mus musculus	66-69
20932499-0	2010	Down-regulation of IL-6 production by astaxanthin via ERK-, MSK-, and NF-kappaB-mediated signals in activated microglia.	astaxanthine	38-49	interleukin 6	Mus musculus	19-23
20932499-1	2010	In this study, we investigated the effect of astaxanthin on IL-6 in activated microglial cells because excessive interleukin-6 (IL-6) production by activated brain microglia has been linked to many neurological disorders and proper regulation of IL-6 is critical for maintaining brain homeostasis.	astaxanthine	45-56	interleukin 6	Mus musculus	60-64
20932499-2	2010	Astaxanthin inhibited lipopolysaccharide (LPS)-stimulated IL-6 mRNA and protein in BV-2 microglial cells.	astaxanthine	0-11	interleukin 6	Mus musculus	58-62
20932499-5	2010	IL-6 expression and NF-kappaB transcriptional activation were inhibited by astaxanthin, as well as inhibitors of NF-kappaB and MAPK in LPS-stimulated BV-2 microglial cells.	astaxanthine	75-86	interleukin 6	Mus musculus	0-4
20813836-4	2010	In addition, C10 inhibits palmitate-induced IL6 and iNos up-regulation in both 3T3L1 adipocytes and RAW 264.7 macrophages, LPS-induced NF-kappaB and IFN-beta activation in 3T3L1 cells, and LPS-induced iNos, Ifn-beta, Il1beta, Cxcl10, and Il6 expression in RAW 264.7 macrophages.	Palmitates	26-35	interleukin 6	Mus musculus	44-47
20932499-7	2010	Astaxathin also decreased IL-6 mRNA and protein levels in LPS-stimulated primary microglial cells, RAW264.7 macrophages, and peritoneal macrophages.	astaxathin	0-10	interleukin 6	Mus musculus	26-30
20813836-4	2010	In addition, C10 inhibits palmitate-induced IL6 and iNos up-regulation in both 3T3L1 adipocytes and RAW 264.7 macrophages, LPS-induced NF-kappaB and IFN-beta activation in 3T3L1 cells, and LPS-induced iNos, Ifn-beta, Il1beta, Cxcl10, and Il6 expression in RAW 264.7 macrophages.	Palmitates	26-35	interleukin 6	Mus musculus	238-241
20932499-8	2010	In addition, IL-6 suppression through astaxanthin-induced down-regulation of p-ERK1/2, p-MSK1, and p-NF-kappaB p65 occurred in microglial cells stimulated with LPS or stromal derived factor (SDF)-1alpha.	astaxanthine	38-49	interleukin 6	Mus musculus	13-17
20932499-9	2010	Astaxathin also inhibited the secretion and mRNA expression of IL-6 in SDF-1alpha-stimulated microglial cells.	astaxathin	0-10	interleukin 6	Mus musculus	63-67
20958047-5	2010	We found that oral administration of luteolin (10 mg/kg) efficiently suppressed the neutrophil infiltration as well as TNF-alpha and IL-6 elevation in the bronchoalveolar lavage fluid in bleomycin-instilled C57BL/6J mice.	Luteolin	37-45	interleukin 6	Mus musculus	133-137
20932499-11	2010	Therefore, our results suggest that astaxanthin regulates IL-6 production through a p-ERK1/2-MSK-1- and p-NF-kappaB p65-dependent pathway in activated microglial cells.	astaxanthine	36-47	interleukin 6	Mus musculus	58-62
20980632-4	2010	In vivo administration of CpG, polyinosinic-polycytidylic acid, and Pam(3)CSK(4) in combination with Ag resulted in the increased expression of costimulatory molecules and MHC class II by DCs, increased serum levels of the inflammatory cytokines IL-6 and RANTES, and increased cognate CD4 T cell responses in young and aged mice.	Poly I-C	31-62	interleukin 6	Mus musculus	246-250
21113099-6	2010	In contrast, serum levels of IgG and IgM and serum concentrations of IL-2 and IL-6 were significantly decreased in BA-treated mice compared to the control as assayed by haemagglutination tests and ELISA, respectively.	betulinic acid	115-117	interleukin 6	Mus musculus	78-82
21311678-4	2010	Coinfusion of metformin (150 mg/kg/24 h) with isoproterenol partially inhibited cardiac hypertrophy that was followed by reduced IL-6, TGF-beta, ANP, collagen I and III, and MMP-2.	Metformin	14-23	interleukin 6	Mus musculus	129-133
21311678-4	2010	Coinfusion of metformin (150 mg/kg/24 h) with isoproterenol partially inhibited cardiac hypertrophy that was followed by reduced IL-6, TGF-beta, ANP, collagen I and III, and MMP-2.	Isoproterenol	46-59	interleukin 6	Mus musculus	129-133
24278534-6	2010	When mice were intraperitoneally injected with carbon fullerene, serum cytokine levels of IL-1 and IL-6 were increased with the increased expression of inflammatory genes in peritoneal macrophage and T cell distribution in blood lymphocytes.The results suggested inflammatory responses were induced by carbon fullerene.	carbon fullerene	47-63	interleukin 6	Mus musculus	99-103
24278534-6	2010	When mice were intraperitoneally injected with carbon fullerene, serum cytokine levels of IL-1 and IL-6 were increased with the increased expression of inflammatory genes in peritoneal macrophage and T cell distribution in blood lymphocytes.The results suggested inflammatory responses were induced by carbon fullerene.	carbon fullerene	302-318	interleukin 6	Mus musculus	99-103
20816729-8	2010	Expression of pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha) and chemokine (MIP-1alpha) in lung showed an increase from 1h to 24h after instillation and recovered thereafter.	Hydrogen	132-134	interleukin 6	Mus musculus	52-56
20935208-6	2010	Using the HDAC inhibitor trichostatin A, we demonstrate that ISRE, IFNA, and IL6 promoters require HDAC activity for transactivation and transcription, whereas TNFalpha does not.	trichostatin A	25-39	interleukin 6	Mus musculus	77-80
21118556-10	2010	Selective inhibition of NFkappaB activation by Wedelolactone reduced ET-induced expression of IL-6 mRNA and protein but not iNOS mRNA or NO production, suggesting differences in IL-6 and iNOS regulation via NFkappaB.	wedelolactone	47-60	interleukin 6	Mus musculus	94-98
20944000-8	2010	3-HAA treatment in vitro reduced IL-6 production by activated spleen cells and increased expression of TGF-beta in dendritic cells (DCs), which correlated with enhanced levels of Tregs, suggesting that 3-HAA-induced Tregs contribute to inhibition of Th17 cells.	3,4-Dihydroxyphenylacetic Acid	1-5	interleukin 6	Mus musculus	33-37
20946880-1	2010	We have previously shown that a high cholesterol (HC) diet results in increases in microglia load and levels of the pro-inflammatory cytokine interleukin-6 (IL-6) in the brains of wild type (WT) and apolipoprotein E knockout (ApoE-/-) mice.	Cholesterol	37-48	interleukin 6	Mus musculus	142-155
21085581-9	2010	Finally, we evaluated the therapeutic efficacy of salubrinal to correct proteostasis-imbalance in the adult mice based on its ability to control CLP induced IL-6 secretion or recruitment of pro-inflammatory cells.	salubrinal	50-60	interleukin 6	Mus musculus	157-161
20946880-1	2010	We have previously shown that a high cholesterol (HC) diet results in increases in microglia load and levels of the pro-inflammatory cytokine interleukin-6 (IL-6) in the brains of wild type (WT) and apolipoprotein E knockout (ApoE-/-) mice.	Cholesterol	37-48	interleukin 6	Mus musculus	157-161
20946880-2	2010	In the present investigation, we analyzed whether treatment with rosuvastatin, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, would prevent the increases in inflammatory microglia and IL-6 levels in the brain and plasma of WT and ApoE-/- mice.	Rosuvastatin Calcium	65-77	interleukin 6	Mus musculus	223-227
20946880-5	2010	Rosuvastatin treatment resulted in lowered plasma IL-6 levels in WT mice on a HC diet.	Rosuvastatin Calcium	0-12	interleukin 6	Mus musculus	50-54
20823108-5	2010	Treatment with honokiol significantly inhibited UVB-induced expression of cyclooxygenase-2, prostaglandin E(2) (P &lt; 0.001), proliferating cell nuclear antigen and proinflammatory cytokines, such as tumor necrosis factor-alpha (P &lt; 0.001), interleukin (IL)-1beta (P &lt; 0.01) and IL-6 (P &lt; 0.001) in the skin as well as in skin tumors.	honokiol	15-23	interleukin 6	Mus musculus	286-290
20925384-3	2010	MPTP treatment significantly depleted striatal glutathione content, reduced the activity of glutathione peroxidase (GPX), superoxide dismutase (SOD), and catalase, increased malondialdehyde and reactive oxygen species levels, and elevated interleukin-6, nitrite, and tumor necrosis factor-alpha production as well as enhanced inducible nitric oxide synthase (iNOS) activity in the striatum (P < 0.05).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	interleukin 6	Mus musculus	239-252
20829510-7	2010	Mitogen-activated protein kinase kinase (MEK)-1 inhibitor PD98059, but not p38 inhibitor SB203580, inhibited apoCIII-induced upregulation of MCP-1 and IL-6.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	58-65	interleukin 6	Mus musculus	151-155
20703492-4	2010	High glucose treatment of isolated cardiac fibroblasts, macrophages and cardiomyocytes led to a sustained induction of HMGB1 on the RNA and protein level followed by increased NF-kappaB binding activity with consecutively sustained TNF-alpha and IL-6 expression.	Glucose	5-12	interleukin 6	Mus musculus	246-250
20133359-7	2010	Furthermore, the results also showed that UA significantly reduced the number of activated microglia cells and astrocytes, decreased the expression of CD11b and glial fibrillary acidic protein, downregulated the expression of iNOS and COX-2, and decreased interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha levels in the prefrontal cortex of D-gal-treated mice.	ursolic acid	42-44	interleukin 6	Mus musculus	280-317
20959520-8	2010	In cell lines developed from the KPC mice, the triterpenoids directly interact with both signal transducer and activator of transcription 3 and IkappaB kinase (IKK) to decrease constitutive interleukin-6 secretion, inhibit constitutive signal transducer and activator of transcription 3 phosphorylation, and block the degradation of IkappaBalpha when challenged with tumor necrosis factor alpha.	triterpenoids	47-60	interleukin 6	Mus musculus	190-203
20546811-8	2010	The tumor necrosis factor-alpha, interleukin-6, and nitric oxide synthase 2 mRNA content of both liver and skeletal muscle was increased in TNBS-treated mice; and plasma tumor necrosis factor-alpha and interleukin-6 concentrations were also elevated.	Trinitrobenzenesulfonic Acid	140-144	interleukin 6	Mus musculus	33-46
20697689-7	2010	Microarray analysis from livers of mice fed a HFD revealed that genes associated with oxidative phosphorylation, the electron transport chain and tricarboxylic acid cycle were uniformly decreased in Il6 (-/-) relative to control mice.	Tricarboxylic Acids	146-164	interleukin 6	Mus musculus	199-202
20699419-9	2010	Furthermore, miR-125b mimics increased expression of inflammatory genes, monocyte chemoattractant protein-1, and interleukin-6, and reduced H3K9me3 at their promoters in nondiabetic cells.	mir-125b	13-21	interleukin 6	Mus musculus	113-126
20546811-8	2010	The tumor necrosis factor-alpha, interleukin-6, and nitric oxide synthase 2 mRNA content of both liver and skeletal muscle was increased in TNBS-treated mice; and plasma tumor necrosis factor-alpha and interleukin-6 concentrations were also elevated.	Trinitrobenzenesulfonic Acid	140-144	interleukin 6	Mus musculus	202-215
20709454-7	2010	Furthermore, systemic pre-treatment with the classically used drugs indomethacin, celecoxib, guanetidine, morphine, thalidomide or dexamethasone, also prevented IL-6-induced muscle pain.	Thalidomide	116-127	interleukin 6	Mus musculus	161-165
20613681-8	2010	NAC pretreatment attenuated the increases in TNF-alpha and IL-6 levels, but augmented IL-10 levels at 2 h post-LPS.	Acetylcysteine	0-3	interleukin 6	Mus musculus	59-63
20709454-7	2010	Furthermore, systemic pre-treatment with the classically used drugs indomethacin, celecoxib, guanetidine, morphine, thalidomide or dexamethasone, also prevented IL-6-induced muscle pain.	Dexamethasone	131-144	interleukin 6	Mus musculus	161-165
20709454-7	2010	Furthermore, systemic pre-treatment with the classically used drugs indomethacin, celecoxib, guanetidine, morphine, thalidomide or dexamethasone, also prevented IL-6-induced muscle pain.	Indomethacin	68-80	interleukin 6	Mus musculus	161-165
20709454-7	2010	Furthermore, systemic pre-treatment with the classically used drugs indomethacin, celecoxib, guanetidine, morphine, thalidomide or dexamethasone, also prevented IL-6-induced muscle pain.	Celecoxib	82-91	interleukin 6	Mus musculus	161-165
20709454-9	2010	The intramuscular injection of the selective inhibitors of p38 MAPK (SB203580), ERK (PD98059) or JNK (SP60015) also prevented IL-6-mediated muscular pain.	SB 203580	69-77	interleukin 6	Mus musculus	126-130
20709454-9	2010	The intramuscular injection of the selective inhibitors of p38 MAPK (SB203580), ERK (PD98059) or JNK (SP60015) also prevented IL-6-mediated muscular pain.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	85-92	interleukin 6	Mus musculus	126-130
20709454-7	2010	Furthermore, systemic pre-treatment with the classically used drugs indomethacin, celecoxib, guanetidine, morphine, thalidomide or dexamethasone, also prevented IL-6-induced muscle pain.	guanetidine	93-104	interleukin 6	Mus musculus	161-165
20709454-9	2010	The intramuscular injection of the selective inhibitors of p38 MAPK (SB203580), ERK (PD98059) or JNK (SP60015) also prevented IL-6-mediated muscular pain.	sp60015	102-109	interleukin 6	Mus musculus	126-130
20709454-7	2010	Furthermore, systemic pre-treatment with the classically used drugs indomethacin, celecoxib, guanetidine, morphine, thalidomide or dexamethasone, also prevented IL-6-induced muscle pain.	Morphine	106-114	interleukin 6	Mus musculus	161-165
20709454-12	2010	The IL-6-mediated muscular pain response involves resident cell activation, polymorphonuclear cell infiltration, cytokine production, prostanoids and sympathomimetic amines release and the activation of intracellular pathways, especially MAPKs.	Prostaglandins	134-145	interleukin 6	Mus musculus	4-8
20709454-12	2010	The IL-6-mediated muscular pain response involves resident cell activation, polymorphonuclear cell infiltration, cytokine production, prostanoids and sympathomimetic amines release and the activation of intracellular pathways, especially MAPKs.	Amines	166-172	interleukin 6	Mus musculus	4-8
20957005-11	2010	The study showed that in vitro, compared with control group [(55.10+-16.54) ng/L for IL-6 production and (13.71+-0.84) ng/L for MIP-2], L929 cells pretreated with rmIL-17 at the different concentrations of 20, 100 and 500 mug/L for 24 h then infected with MoPn for 24 h, could significantly increase IL-6 (P &lt;0.01) and MIP-2 secretion (P &lt;0.05).	rmil	163-167	interleukin 6	Mus musculus	300-304
20729464-12	2010	Correlated to this, we found in TCDD-treated mice an increase in interleukin-6 producing CD103+ dendritic cells (DC) present in the gut-draining mesenteric lymph nodes (MLN) and a small increase in the frequency of Th17 cells.	Polychlorinated Dibenzodioxins	32-36	interleukin 6	Mus musculus	65-78
21116409-0	2010	Characterization and online detection of surfactin isomers based on HPLC-MS(n) analyses and their inhibitory effects on the overproduction of nitric oxide and the release of TNF-alpha and IL-6 in LPS-induced macrophages.	surfactin peptide	41-50	interleukin 6	Mus musculus	188-192
21116409-2	2010	Inhibitory activities of surfactin isomers on the overproduction of nitric oxide and the release of TNF-alpha and IL-6 in LPS-induced macrophages were systematically investigated.	surfactin peptide	25-34	interleukin 6	Mus musculus	114-118
21116409-3	2010	It was revealed that the surfactin isomers showed strong inhibitory properties on the overproduction of nitric oxide and the release of IL-6 on LPS-induced murine macrophage cell RAW264.7 with IC(50) values ranging from 1.0 to 7.0 muM.	surfactin peptide	25-34	interleukin 6	Mus musculus	136-140
20415720-7	2010	Moreover, inflammation enhanced by low-dose poly(I:C), but not by high-dose poly(I:C), was impaired in IL-6-deficient mice; this phenotype was accompanied by the down-regulation of IL-17 production from T cells from both lymph nodes and lung tissues.	poly	44-48	interleukin 6	Mus musculus	103-107
20621086-4	2010	7HF significantly and dose-dependently diminished induced and spontaneous production of TNF-alpha and IL-6 from freshly isolated human mononuclear cells, synovial tissue cells isolated from patients with active rheumatoid arthritis and BALB/c mice.	7-hydroxyfrullanolide	0-3	interleukin 6	Mus musculus	102-106
20554970-5	2010	Iron-overloaded mice had increased reactive oxygen species and elevated serum tumor necrosis factor-alpha and interleukin-6 concentrations that correlated with severity of iron overload.	Iron	0-4	interleukin 6	Mus musculus	110-123
20554970-5	2010	Iron-overloaded mice had increased reactive oxygen species and elevated serum tumor necrosis factor-alpha and interleukin-6 concentrations that correlated with severity of iron overload.	Iron	172-176	interleukin 6	Mus musculus	110-123
20608903-9	2010	Consistent with these findings, pulmonary levels of KC and IL-6 were increased in wild-type mice following burn and ethanol compared to burn injury alone as well as to their TLR4 knockout counterparts.	Ethanol	116-123	interleukin 6	Mus musculus	59-63
20415720-8	2010	Airway exposure of low-dose poly(I:C) enhanced the production of VEGF and IL-6, and the production of IL-6 was blocked by treatment with a VEGFR inhibitor (SU5416).	poly	28-32	interleukin 6	Mus musculus	74-78
20415720-8	2010	Airway exposure of low-dose poly(I:C) enhanced the production of VEGF and IL-6, and the production of IL-6 was blocked by treatment with a VEGFR inhibitor (SU5416).	poly	28-32	interleukin 6	Mus musculus	102-106
20415720-8	2010	Airway exposure of low-dose poly(I:C) enhanced the production of VEGF and IL-6, and the production of IL-6 was blocked by treatment with a VEGFR inhibitor (SU5416).	Semaxinib	156-162	interleukin 6	Mus musculus	74-78
20415720-8	2010	Airway exposure of low-dose poly(I:C) enhanced the production of VEGF and IL-6, and the production of IL-6 was blocked by treatment with a VEGFR inhibitor (SU5416).	Semaxinib	156-162	interleukin 6	Mus musculus	102-106
19915153-6	2010	O(3)-induced increases in BAL IL-6 and keratinocyte-derived chemokine (KC), which contribute to O(3)-induced pulmonary neutrophilia, were also greater in wild-type than in Adipo(-/-) mice.	Ozone	0-4	interleukin 6	Mus musculus	30-34
19915153-6	2010	O(3)-induced increases in BAL IL-6 and keratinocyte-derived chemokine (KC), which contribute to O(3)-induced pulmonary neutrophilia, were also greater in wild-type than in Adipo(-/-) mice.	Ozone	96-100	interleukin 6	Mus musculus	30-34
19864106-6	2010	Recently, glycine has been reported to have anti-inflammatory properties which reduce TNF-alpha and IL-6 levels and increase adiponectin in 3T3-L1 adipocytes and in fat tissue of obese mice.	Glycine	10-17	interleukin 6	Mus musculus	100-104
21036709-3	2010	MATERIALS AND METHODS: The capacity of IL-1 Ra anakinra to reduce IL-1-induced production of IL-6 in order to improve the efficacy of a subsequent booster vaccination with survivin-derived peptides and soluble beta-glucan as adjuvant was tested in colon-26 adenocarcinoma-bearing Balb/c-mice.	beta-Glucans	210-221	interleukin 6	Mus musculus	93-97
19864106-10	2010	Interestingly, glycine treatment also suppressed the expression of UCP-2, TNF-alpha and IL-6 in lean mice, and increased adiponectin and insulin serum levels.	Glycine	15-22	interleukin 6	Mus musculus	88-92
20618847-5	2010	All viable strains producing farnesol, regardless of hyphae phenotype, induced IL-6, IL-1beta, IL-10, and TNF-alpha.	Farnesol	29-37	interleukin 6	Mus musculus	79-83
20618847-7	2010	The highest expression of IL-6, TLR2, and dectin-1 occurred when RAW264.7 cells were stimulated with zymosan and farnesol together.	Zymosan	101-108	interleukin 6	Mus musculus	26-30
20618847-7	2010	The highest expression of IL-6, TLR2, and dectin-1 occurred when RAW264.7 cells were stimulated with zymosan and farnesol together.	Farnesol	113-121	interleukin 6	Mus musculus	26-30
20667461-4	2010	In our study phloroglucinol exhibited inhibitory effects not only on oxidative stress but also on the production of inflammatory mediators such as tumor necrosis factor-alpha, interleukin-1beta, interleukin-6 and prostaglandin E(2) in RAW264.7 cells stimulated by lipopolysaccharide.	Phloroglucinol	13-27	interleukin 6	Mus musculus	195-208
20511664-8	2010	Similarly, RAW 264.7 cells treated with iron chelators and then stimulated with lipopolysaccharide showed lower IL-6 mRNA than cells treated with lipopolysaccharide alone.	Iron	40-44	interleukin 6	Mus musculus	112-116
20939756-5	2010	Subacute and chronic CS exposure significantly increased pulmonary IL-6 mRNA expression in lung tissue and IL-6 protein levels in bronchoalveolar lavage fluid of WT mice.	Cesium	21-23	interleukin 6	Mus musculus	67-71
20939756-5	2010	Subacute and chronic CS exposure significantly increased pulmonary IL-6 mRNA expression in lung tissue and IL-6 protein levels in bronchoalveolar lavage fluid of WT mice.	Cesium	21-23	interleukin 6	Mus musculus	107-111
20939756-7	2010	Chonic CS exposure was associated with a significant failure to gain weight in both WT mice and IL-6 KO mice.	Cesium	7-9	interleukin 6	Mus musculus	96-100
19897529-0	2010	Interleukin-6 is essential for zwitterionic polysaccharide-mediated abscess formation.	Polysaccharides	44-58	interleukin 6	Mus musculus	0-13
19897529-9	2010	The data delineate the essential role of IL-6 in the linkage of innate and adaptive immunity in polysaccharide-mediated abscess formation.	Polysaccharides	96-110	interleukin 6	Mus musculus	41-45
20609399-7	2010	SD-0006 or SP600125, a JNK inhibitor, partially blocked the elevation of IL-6 production in RASF following stimulation with TNF-alpha.	SD 0006	0-7	interleukin 6	Mus musculus	73-77
20609399-7	2010	SD-0006 or SP600125, a JNK inhibitor, partially blocked the elevation of IL-6 production in RASF following stimulation with TNF-alpha.	pyrazolanthrone	11-19	interleukin 6	Mus musculus	73-77
20679445-5	2010	SitC not only induced a TLR2-dependent release of IL-6 in primary murine keratinocytes (MKs) but also induced intracellular accumulation of TLR2, which was time and concentration dependent.	sitc	0-4	interleukin 6	Mus musculus	50-54
20804539-7	2010	Interestingly, IL-6(-/-) mice had intact MG formation; however, SG organization was impaired.	Magnesium	41-43	interleukin 6	Mus musculus	15-19
21165322-7	2010	KA-induced gliosis and proinflammatory marker (IL-1beta, TNF-alpha, IL-6, and COX-2) inductions were also suppressed by visnagin administration.	visnagin	120-128	interleukin 6	Mus musculus	68-72
20333481-10	2010	The levels of proinflammatory cytokines (interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha) in the SN were also decreased and induced by MPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	154-158	interleukin 6	Mus musculus	61-107
19894142-6	2010	Free fatty acids (FFA) and tumor necrosis factor-alpha (TNFalpha) could upregulate NYGGF4 mRNA expression in 3T3-L1 adipocytes, while interleukin-6 (IL-6), leptin, and resistin exerted an inhibitory effect.	Fatty Acids, Nonesterified	0-16	interleukin 6	Mus musculus	134-147
19894142-6	2010	Free fatty acids (FFA) and tumor necrosis factor-alpha (TNFalpha) could upregulate NYGGF4 mRNA expression in 3T3-L1 adipocytes, while interleukin-6 (IL-6), leptin, and resistin exerted an inhibitory effect.	Fatty Acids, Nonesterified	0-16	interleukin 6	Mus musculus	149-153
20731354-4	2010	Topical application of TPA to ears of CD-1 mice induced inflammation accompanied with substantial increase in TNF-alpha, IL-1beta, IL-6, LTB4, and PGE2 levels and an elevation in intercellular adhesion molecule-1 (ICAM-1) gene expressions in ear skin tissues.	Tetradecanoylphorbol Acetate	23-26	interleukin 6	Mus musculus	131-135
20690163-7	2010	Furthermore, quercetin also significantly activated the AMP-activated protein kinase (AMPK) via down-regulation of protein phosphatase 2C (PP2C), which reduced the integral optical density (IOD) of activated microglia cells and CD11b expression, down-regulated iNOS and cyclooxygenase-2 (COX-2) expression, and decreased IL-1beta, IL-6, and TNF-alpha expression in the brains of high-cholesterol-fed old mice through the suppression of NF-kappaB p65 nuclear translocation.	Quercetin	13-22	interleukin 6	Mus musculus	331-335
20877234-4	2010	Additionally, chrysophanol inhibited the production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and the expression of cyclooxygenase (COX)-2 levels induced by LPS.	chrysophanic acid	14-26	interleukin 6	Mus musculus	90-108
20806438-8	2010	In addition, immunohistochemistry analysis showed that the levels of the inflammatory cytokines, IL-6 and TNF-alpha were also decreased in AL-treated groups.	Aluminum	139-141	interleukin 6	Mus musculus	97-101
20550948-7	2010	Northern blot analyses and immunohistochemistry of colonic tissue revealed that C10 markedly diminished DSS-induced expression of pertinent inflammatory mediators: TNF-alpha, IL-1beta, IL-6, IL-12, IP-10, TLR-4 and VCAM-1.	Dextran Sulfate	104-107	interleukin 6	Mus musculus	185-189
20557886-9	2010	Finally in castrated male mice, 3beta-Adiol significantly counteracted the LPS mediated mRNA induction of IL-6, ELAM-1and PECAM-1 in the aortas.	Androstane-3,17-diol	32-43	interleukin 6	Mus musculus	106-110
20534383-5	2010	In addition, LPS-induced pro-inflammatory cytokines, including IL-1beta, IL-6, and TNF-alpha, were also decreased by pretreatment with isodojaponin D. This effect was accompanied by a decrease in translocations of Nuclear Factor-KappaB (NF-kappaB) p50 and p65 from the cytoplasm to the nucleus and by a decrease in I kappaB (IkappaB) degradation.	isodojaponin	135-147	interleukin 6	Mus musculus	73-77
20630498-8	2010	Celecoxib blocked the stimulatory effect of IL-17A on the expression of COX-2, IL-1alpha, IL-6, IL-8, and IL-11 as well as PGE(2) production, whereas it did not block TNF-alpha expression.	Celecoxib	0-9	interleukin 6	Mus musculus	90-94
20557886-6	2010	Q-real-time PCR and protein array approaches confirmed that TNF-alpha-induced ICAM-1, VCAM-1 and ELAM-1 as well as MCP-1 and IL-6 induction was affected upon 3beta-Adiol pre-incubation.	Androstane-3,17-diol	158-169	interleukin 6	Mus musculus	125-129
20630498-10	2010	The expression of IL-1alpha, IL-6, IL-8, and IL-11 increased by the addition of PGE(2), whereas TNF-alpha expression was not affected.	Prostaglandins E	80-83	interleukin 6	Mus musculus	29-33
20359854-5	2010	The results showed that LMWH rectal suppository significantly decreased serum levels of TNF-alpha, IL-6 as well as FXa, while increased the expression of Musashi-1 in colon compared with acetic acid induced ulcerative colitis model group.	Heparin, Low-Molecular-Weight	24-28	interleukin 6	Mus musculus	99-103
20684827-9	2010	In addition, aortic expression of proatherogenic molecules including TNF-alpha, IL-1beta, IL-6, MCP-1 and VCAM-1, was lower in the BHB-TZD group than the control group.	3-Hydroxybutyric Acid	131-134	interleukin 6	Mus musculus	90-94
20684827-9	2010	In addition, aortic expression of proatherogenic molecules including TNF-alpha, IL-1beta, IL-6, MCP-1 and VCAM-1, was lower in the BHB-TZD group than the control group.	tzd	135-138	interleukin 6	Mus musculus	90-94
31499267-9	2019	Furthermore treatment with febuxostat significantly reduced the levels of proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and interferon (IFN)-gamma, while increased the levels of IL-10 compared with the colitis group.	Febuxostat	27-37	interleukin 6	Mus musculus	159-163
20597071-8	2010	Indeed, CCl(4)-treated CB2(-/-) mice displayed lower levels of hepatic IL-6 messenger RNA and increased MMP-2 activity.	Cefaclor	8-11	interleukin 6	Mus musculus	71-75
20601188-7	2010	In addition, diosgenin inhibits production of reactive oxygen species (ROS), interleukin-1 (IL-1), and IL-6, but not that of tumor necrosis factor-alpha (TNF-alpha).	Diosgenin	13-22	interleukin 6	Mus musculus	103-107
20609401-5	2010	of DMC (1-50mg/kg) suppressed TNF-alpha, IL-6 and IL-1 beta secretion in LPS-induced mouse blood serum.	methyl carbonate	3-6	interleukin 6	Mus musculus	41-45
20679534-4	2010	We found that nTregs treated with atRA were resistant to Th17 and other Th cell conversion and maintained Foxp3 expression and suppressive activity in the presence of IL-6 in vitro.	Tretinoin	34-38	interleukin 6	Mus musculus	167-171
20609401-2	2010	In a cellular model of inflammation, DMC inhibited production of nitric oxide (NO) and prostaglandin E(2) (PGE(2)) and attenuated expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1 beta, inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2).	methyl carbonate	37-40	interleukin 6	Mus musculus	185-198
20609401-2	2010	In a cellular model of inflammation, DMC inhibited production of nitric oxide (NO) and prostaglandin E(2) (PGE(2)) and attenuated expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1 beta, inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2).	methyl carbonate	37-40	interleukin 6	Mus musculus	200-204
20679534-3	2010	In this study, we report a vital role of atRA in sustaining the stability and functionality of nTregs in the presence of IL-6.	Tretinoin	41-45	interleukin 6	Mus musculus	121-125
20714813-10	2010	Further, 10 nM glycitein significantly decreased the expression of IL-6 (-53%, p &lt; 0.05) and RANKL (-64%, p &lt; 0.05) in osteoblasts but did not change mRNA levels of OPG.	glycitein	15-24	interleukin 6	Mus musculus	67-71
20882700-8	2010	Further immunohistochemical analysis and cytokine determination revealed that Fasudil inhibited inducible nitric oxide synthase immunoreactivity in microglia and pro-inflammatory factors in brain tissue after H/R, which is consistent with the observation wherein Fasudil reduced the pro-inflammatory factors nitric oxide, IL-1beta, IL-6 and TNF-, and increased anti-inflammatory factor IL-10 in cultured microglia under normoxic or hypoxic conditions.	fasudil	78-85	interleukin 6	Mus musculus	332-336
20615550-0	2010	Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and down-regulation of IL-17.	triptolide	0-10	interleukin 6	Mus musculus	91-95
20615550-6	2010	We hypothesized that triptolide would attenuate the experimental colitis by repressing IL-17 and that this would involve down-regulation of IL-6/STAT3 signaling pathway.	triptolide	21-31	interleukin 6	Mus musculus	140-144
20615550-8	2010	Triptolide suppressed the IL-6/STAT3 signaling pathway, as well as repressed gene expression of IL-17 in vivo.	triptolide	0-10	interleukin 6	Mus musculus	26-30
20132051-8	2010	Pam(3)Cys stimulation of E14 ESCs was associated with induced NF-kappaB translocation, enhanced phosphorylation of IKK-alpha/beta, and enhanced mRNA, but not protein, expression of tumor necrosis factor-alpha, interferon-gamma, and IL-6.	(3)cys	3-9	interleukin 6	Mus musculus	232-236
20599223-11	2010	RESULTS: After 3 h, the livers of animals treated with SAHA showed significantly (P &lt; 0.05) decreased expression of the pro-inflammatory MAP kinases phosphorylated p38, phosphorylated ERK, myeloperoxidase and interleukin-6, and increased levels of the anti-inflammatory interleukin-10 compared with controls.	Vorinostat	55-59	interleukin 6	Mus musculus	212-225
21061575-7	2010	Fucoidanes stimulate DC to produce proinflammatory (TNF-alpha, IL-6, IL-1beta) and regulatory (IL-12) cytokines.	fucoidanes	0-10	interleukin 6	Mus musculus	63-67
20730378-8	2010	Taken together, our results implicate a potential role for Kv11.1 in regulating cdk2 and C/EBP Beta activity, where robust transactivation of both IL-6 and MCP-1 transcription is known to be dependent on serine-64 of C/EBP Beta.	Serine	204-210	interleukin 6	Mus musculus	147-151
20712904-8	2010	Resveratrol inhibited LPS-induced expression and release of TNF-alpha, IL-6, MCP-1, and iNOS/NO in both cell types with more potency in microglia, and inhibited LPS-induced expression of IL-1beta in microglia but not astrocytes.	Resveratrol	0-11	interleukin 6	Mus musculus	71-75
20730378-4	2010	Furthermore, inhibitors of Kv11.1 (DOF, E4031, and astemizole), but not Kv1.3 (margatoxin), suppressed the expression of IL-6 and MCP-1 cytokines by murine resident peritoneal macrophages, while again having no effect on TNF alpha.	dofetilide	35-38	interleukin 6	Mus musculus	121-125
20682082-8	2010	Gene expressions of tumor necrosis factor, interleukin 6, and metalloproteinase 2 were significantly suppressed in the hearts of mice treated with cetirizine.	Cetirizine	147-157	interleukin 6	Mus musculus	43-56
20730378-4	2010	Furthermore, inhibitors of Kv11.1 (DOF, E4031, and astemizole), but not Kv1.3 (margatoxin), suppressed the expression of IL-6 and MCP-1 cytokines by murine resident peritoneal macrophages, while again having no effect on TNF alpha.	E 4031	40-45	interleukin 6	Mus musculus	121-125
20730378-4	2010	Furthermore, inhibitors of Kv11.1 (DOF, E4031, and astemizole), but not Kv1.3 (margatoxin), suppressed the expression of IL-6 and MCP-1 cytokines by murine resident peritoneal macrophages, while again having no effect on TNF alpha.	Astemizole	51-61	interleukin 6	Mus musculus	121-125
20730378-6	2010	Using murine P388 cells, which lack endogenous C/EBP Beta expression and are unresponsive to LPS for the expression of both IL-6 and MCP-1, we observed that DOF inhibited LPS-induced expression of IL-6 mRNA following ectopic expression of wild-type C/EBP Beta, but not a serine-64 point mutant.	dofetilide	157-160	interleukin 6	Mus musculus	124-128
20730378-6	2010	Using murine P388 cells, which lack endogenous C/EBP Beta expression and are unresponsive to LPS for the expression of both IL-6 and MCP-1, we observed that DOF inhibited LPS-induced expression of IL-6 mRNA following ectopic expression of wild-type C/EBP Beta, but not a serine-64 point mutant.	dofetilide	157-160	interleukin 6	Mus musculus	197-201
20838478-6	2010	Plasma levels of corticosterone and interleukin (IL)-6 concomitantly increased after aggressive encounters and varied with dominance status and with the low versus high corticosterone response.	Corticosterone	169-183	interleukin 6	Mus musculus	36-54
20628001-7	2010	The cancer-preventive results of omeprazole treatment was based on significant decreases in the levels of nitric oxide, thiobarbituric acid-reactive substance, and interleukin-6 accompanied with attenuated expressions of tumor necrosis factor-alpha, inducible nitric oxide synthase, and cyclooxygenase-2.	Omeprazole	33-43	interleukin 6	Mus musculus	164-177
20506342-7	2010	The production of fibrogenic cytokines, such as interleukin-4 (IL-4), IL-6, IL-17, and transforming growth factor beta1, was attenuated by rapamycin.	Sirolimus	139-148	interleukin 6	Mus musculus	70-74
20411234-7	2010	In the non-fasting state, Il6(-/-) mice showed a mild metabolic alteration including higher plasma glucose and insulin levels, lower NEFA concentrations and slightly increased hepatic PEPCK content.	Glucose	99-106	interleukin 6	Mus musculus	26-29
20610570-2	2010	A role in regulation of labor onset is suggested by observations that IL-6 increases expression of genes controlling prostaglandin synthesis and signaling in isolated uterine cells, but whether IL-6 is essential for normal parturition is unknown.	Prostaglandins	117-130	interleukin 6	Mus musculus	70-74
20653471-10	2010	Intratracheal PPE increased the cell counts in BAL fluid throughout the observation, which was suppressed in IL-6 null mice.	ppe	14-17	interleukin 6	Mus musculus	109-113
20504903-1	2010	The aim of this study is to elucidate the effects of interleukin-6 (IL-6) on the expression and activity of the epithelial sodium channel (ENaC), which is one of the key mechanisms underlying tubular sodium reabsorption.	Sodium	123-129	interleukin 6	Mus musculus	53-66
20504903-1	2010	The aim of this study is to elucidate the effects of interleukin-6 (IL-6) on the expression and activity of the epithelial sodium channel (ENaC), which is one of the key mechanisms underlying tubular sodium reabsorption.	Sodium	123-129	interleukin 6	Mus musculus	68-72
20610570-9	2010	We conclude that IL-6 has a key role in controlling the progression of events culminating in parturition and that it acts downstream of luteolysis in the uterus to regulate genes involved in the prostaglandin-mediated uterine activation cascade.	Prostaglandins	195-208	interleukin 6	Mus musculus	17-21
20411234-7	2010	In the non-fasting state, Il6(-/-) mice showed a mild metabolic alteration including higher plasma glucose and insulin levels, lower NEFA concentrations and slightly increased hepatic PEPCK content.	Fatty Acids, Nonesterified	133-137	interleukin 6	Mus musculus	26-29
20006347-7	2010	RESULTS: PS-341 significantly inhibited NF-kappaB activation, while the pancreatic cell apoptosis was significantly enhanced, resulting in the improved parameters such as serum amylase, C-reactive protein, lactate dehydrogenase, interleukin-1beta, interleukin-6, and pancreatic myeloperoxidase activity.	Bortezomib	9-15	interleukin 6	Mus musculus	248-261
20100194-3	2010	Treatment of the mouse ear with LXA(4) exhibited the inhibitory effects on oedema, neutrophil infiltration, vascular permeability, expressions of interleukin (IL)-1, IL-6 and IL-8 mRNA, DNA-binding activity of nuclear factor-kappaB (NF-kappaB), and on dermal hyperplasia.	N-(1H-benzimidazol-2-ylmethyl)-2-methoxyacetamide	32-35	interleukin 6	Mus musculus	166-170
20113347-6	2010	Topical application of 10 micromol/l ellagic acid diminished production of pro-inflammatory cytokines IL-1beta and IL-6, and blocked infiltration of inflammatory macrophages in the integuments of SKH-1 hairless mice exposed to UV-B for 8 weeks.	Ellagic Acid	37-49	interleukin 6	Mus musculus	115-119
20669364-7	2010	In addition, chloral hydrate treatment in vitro attenuated the upregulation of TNF-alpha and IL-6 by peritoneal macrophages and NF-kappaB activity in RAW264.7 cells stimulated with LPS, suggesting that monocytes/macrophages may be a target of chloral hydrate.	Chloral Hydrate	13-28	interleukin 6	Mus musculus	93-97
20416309-7	2010	Furthermore, ethanol-induced increases in tumor necrosis factor-alpha and interleukin-6 expression at this early time point were suppressed in C1q-deficient mice.	Ethanol	13-20	interleukin 6	Mus musculus	74-87
20663042-6	2010	When peritoneal macrophages were treated in vitro with S. tenuifolia water extract, the inhibition of LPS-induced TNF-alpha was more pronounced than that of IL-6 at the level of secreted protein and mRNA.	Water	69-74	interleukin 6	Mus musculus	157-161
20164045-6	2010	However, 5/6 NX induced a marked increase in plasma concentrations of anti-oxLDL antibodies as well as pro-atherogenic cytokines [interleukin (IL)-2 (IL-2), IL-4, IL-6 and IL-12)] in native mouse LDL (nLDL)-, oxLDL- and PBS-immunized mice.	nx	13-15	interleukin 6	Mus musculus	163-167
20368703-0	2010	Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice.	methionine choline	92-110	interleukin 6	Mus musculus	12-25
20378317-3	2010	We also show that atrovirinone inhibits the secretion of IL-1beta and IL-6 in a dose dependent fashion whereas the secretion of IL-10, the anti-inflammatory cytokine, was enhanced.	atrovirinone	18-30	interleukin 6	Mus musculus	70-74
20457176-10	2010	In contrast, apoE-/- mice on homocysteine diet show pronounced vascular reactivity to IL-6 and IL-8 antibodies.	Homocysteine	29-41	interleukin 6	Mus musculus	86-90
20561658-11	2010	CONCLUSION: We report for the first time that administration of SAHA (50 mg/kg IP) after a lethal dose of LPS significantly improves long-term survival, and attenuates expression of the proinflammatory mediators TNF-alpha and IL-6.	Vorinostat	64-68	interleukin 6	Mus musculus	226-230
20659336-12	2010	Co-cultures of ova-specific CD4+ T cells from naive mice and CD11c+ pulmonary cells from NO2-exposed mice produced IL-1, IL-12p70, and IL-6 in vitro and augmented antigen-induced IL-5 production.	Nitrogen Dioxide	89-92	interleukin 6	Mus musculus	135-139
20362689-8	2010	Furthermore, the CS-induced pulmonary release of leukotriene B(4), interleukin-6, keratinocyte-derived chemokine, monocyte chemotactic protein-1, macrophage inflammatory protein-1 alpha and -2, and tumor necrosis factor alpha was dose-dependently reduced.	Cesium	17-19	interleukin 6	Mus musculus	67-80
20361943-3	2010	Furthermore, obaculactone inhibited alloantigen-specific production of Th1 cytokine IFN-gamma as well as proinflammatory cytokine IL-2, TNFalpha and IL-6.	limonin	13-25	interleukin 6	Mus musculus	149-153
20664801-7	2010	In addition, EPA significantly reduced the protein levels of MCP-1 and IL-6 in the retina and the RPE-choroid complex.	Eicosapentaenoic Acid	13-16	interleukin 6	Mus musculus	71-75
20585009-2	2010	The common receptor of interleukin-6 cytokines, glycoprotein-130 (gp130), signals via janus kinase/signal transducer and activator of transcription (STAT), cytoplasmic protein tyrosine phosphatase/extracellular signal-regulated kinase, and phosphoinositide-3-kinase/Akt pathways, and the regulation of these pathways depends at least in part on the gp130 tyrosine-757 residue.	Tyrosine	176-184	interleukin 6	Mus musculus	23-36
20657653-9	2010	Levels of TNF-alpha and G-CSF were significantly attenuated in the SC-560 and celecoxib groups versus control and IL-6 levels were significantly lower in BAL fluid of celecoxib treated mice versus control and versus the SC-560 group.	Celecoxib	167-176	interleukin 6	Mus musculus	114-118
20554954-3	2010	We show in this study that chronic E2 administration to ovariectomized mice significantly increased both cytokine (IL-1beta, IL-6, and TNF-alpha) and inducible NO synthase mRNA abundance in thioglycolate (TGC)-elicited macrophages.	Thioglycolates	190-203	interleukin 6	Mus musculus	125-129
20524667-9	2010	STG metabolites significantly reduced the production of IL-6 and TNF-alpha in RAW264.7 murine macrophages stimulated with lipopolysaccharide.	sesaminol triglucoside	0-3	interleukin 6	Mus musculus	56-60
20188786-4	2010	Resveratrol, at concentrations ranging from 0.1 to 10 muM, effectively inhibited lipopolysaccharide (LPS)-induced TNF-alpha and IL-6 production with the downregulation of relative genes expression in macrophages.	Resveratrol	0-11	interleukin 6	Mus musculus	128-132
20620996-5	2010	Experiments using PKCzeta/IL-6 double-knockout mice demonstrated that IL-6 production accounts for obesity-associated glucose intolerance induced by PKCzeta deficiency.	Glucose	118-125	interleukin 6	Mus musculus	26-30
20620996-5	2010	Experiments using PKCzeta/IL-6 double-knockout mice demonstrated that IL-6 production accounts for obesity-associated glucose intolerance induced by PKCzeta deficiency.	Glucose	118-125	interleukin 6	Mus musculus	70-74
20188786-6	2010	Pretreatment of CM from resveratrol-treated macrophages reduced the elevated levels of TNF-alpha and IL-6, and significantly reversed inflammation-related changes in adipokine gene expression in 3T3-L1 adipocytes.	Resveratrol	24-35	interleukin 6	Mus musculus	101-105
20616655-9	2010	In addition, levels of KC, interleukin-1beta, and interleukin-6 in the lung were decreased in the ICAM-1 KO mice after ethanol exposure and burn injury.	Ethanol	119-126	interleukin 6	Mus musculus	50-63
20398056-8	2010	Pitavastatin increased the serum levels of adiponectin while conversely decreasing the serum levels of total cholesterol, tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, IL-18, and leptin.	pitavastatin	0-12	interleukin 6	Mus musculus	163-181
20350813-0	2010	Disaccharide derived from chondroitin sulfate A suppressed CpG-induced IL-6 secretion in macrophage-like J774.1 cells.	Disaccharides	0-12	interleukin 6	Mus musculus	71-75
20350813-0	2010	Disaccharide derived from chondroitin sulfate A suppressed CpG-induced IL-6 secretion in macrophage-like J774.1 cells.	Chondroitin Sulfates	26-47	interleukin 6	Mus musculus	71-75
20347815-9	2010	After a single oral dose of MNU, interleukin (IL)-1alpha was up-regulated significantly in control mice compared with Ikkbeta(DeltaST) mice, whereas the levels of IL-1beta, IL-6, and tumor necrosis factor-alpha were unchanged.	Methylnitrosourea	28-31	interleukin 6	Mus musculus	173-210
20570996-8	2010	The expressions of the mRNA of interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and granulocyte macrophage-colony stimulating factor (GM-CSF) in the ICB of the two groups of mice were compared.	indole-2-carboxylic acid	166-169	interleukin 6	Mus musculus	56-60
20004083-5	2010	RESULTS: As the dietary ratio of omega-6/omega-3 fatty acids ascended, so did the expression of hepatic and aortic CRP and hepatic IL-6 protein.	omega-6	33-40	interleukin 6	Mus musculus	131-135
20004083-5	2010	RESULTS: As the dietary ratio of omega-6/omega-3 fatty acids ascended, so did the expression of hepatic and aortic CRP and hepatic IL-6 protein.	Fatty Acids, Omega-3	41-60	interleukin 6	Mus musculus	131-135
19965837-7	2010	RESULTS: ATRA synergised with TGF-beta to induce Foxp3(+) T regulatory cells (Treg) and reciprocally inhibited development of IL-17-producing T helper cells (Th17) induced by TGF-beta and IL-6.	Tretinoin	9-13	interleukin 6	Mus musculus	188-192
20564347-6	2010	We show that insulin and IL-6, but not leptin and IGF-1, induce proliferation in MC-38 cells.	mc-38	81-86	interleukin 6	Mus musculus	25-29
20564347-7	2010	Adiponectin treatment of MC-38 cells did not inhibit insulin-induced cell proliferation but did inhibit IL-6-induced cell proliferation by decreasing STAT-3 phosphorylation and activation.	mc-38	25-30	interleukin 6	Mus musculus	104-108
20564347-8	2010	Nitric oxide (NO) production was increased in MC-38 cells treated with IL-6; co-treatment with adiponectin blocked IL-6-induced iNOS and subsequent NO production.	Nitric Oxide	0-12	interleukin 6	Mus musculus	71-75
20564347-8	2010	Nitric oxide (NO) production was increased in MC-38 cells treated with IL-6; co-treatment with adiponectin blocked IL-6-induced iNOS and subsequent NO production.	Nitric Oxide	0-12	interleukin 6	Mus musculus	115-119
20564347-8	2010	Nitric oxide (NO) production was increased in MC-38 cells treated with IL-6; co-treatment with adiponectin blocked IL-6-induced iNOS and subsequent NO production.	mc-38	46-51	interleukin 6	Mus musculus	71-75
20564347-8	2010	Nitric oxide (NO) production was increased in MC-38 cells treated with IL-6; co-treatment with adiponectin blocked IL-6-induced iNOS and subsequent NO production.	mc-38	46-51	interleukin 6	Mus musculus	115-119
20350561-9	2010	TCDD increased LPS- and CpG-induced IL-6 and TNF-alpha production by BMDCs but decreased their NO production.	Polychlorinated Dibenzodioxins	0-4	interleukin 6	Mus musculus	36-40
19481767-10	2010	The administration of rosiglitazone significantly lowered the plasma levels of inflammatory mediators, including TNF-alpha, IL-6, and MCP-1, in WT mice but not in APN-KO mice during sepsis.	Rosiglitazone	22-35	interleukin 6	Mus musculus	124-128
20533597-6	2010	Quantitative real-time polymerase chain reaction was used to determine liver IL-1beta, IL-1Ra and IL-6 expression during CCl(4)-induced acute liver injury.	Cefaclor	121-124	interleukin 6	Mus musculus	98-102
20533597-10	2010	RESULTS: Quantitative analysis showed a higher level of IL-6 mRNA expression and reduced serum AST and ALT levels in the livers of the rhIL-1Ra-treated group at the early phase of CCl(4)-induced acute liver injury.	Cefaclor	180-183	interleukin 6	Mus musculus	56-60
20564344-5	2010	DIM inhibited the TPA-induced increases in the expression of cyclooxygenase (COX)-2, inducible nitric oxide synthase (iNOS), chemokine (C-X-C motif) ligand (CXCL) 5, and interleukin (IL)-6 in mouse skin.	Tetradecanoylphorbol Acetate	18-21	interleukin 6	Mus musculus	170-188
20406809-7	2010	Recombinant ACF bound an AU-rich region in the IL-6 3"-untranslated region with high affinity and IL-6 mRNA half-life was significantly shorter in KC isolated from Acf(+/-) mice compared with wild-type controls.	Gold	25-27	interleukin 6	Mus musculus	47-51
20488794-1	2010	Retinoic acid (RA), a well-known vitamin A metabolite, mediates inhibition of the IL-6-driven induction of proinflammatory Th17 cells and promotes anti-inflammatory regulatory T cell generation in the presence of TGF-beta, which is mainly regulated by dendritic cells.	Tretinoin	0-13	interleukin 6	Mus musculus	82-86
20488794-1	2010	Retinoic acid (RA), a well-known vitamin A metabolite, mediates inhibition of the IL-6-driven induction of proinflammatory Th17 cells and promotes anti-inflammatory regulatory T cell generation in the presence of TGF-beta, which is mainly regulated by dendritic cells.	Tretinoin	15-17	interleukin 6	Mus musculus	82-86
20488794-1	2010	Retinoic acid (RA), a well-known vitamin A metabolite, mediates inhibition of the IL-6-driven induction of proinflammatory Th17 cells and promotes anti-inflammatory regulatory T cell generation in the presence of TGF-beta, which is mainly regulated by dendritic cells.	Vitamin A	33-42	interleukin 6	Mus musculus	82-86
19834971-9	2010	Moreover, our results clearly demonstrate that IL-19 is required for B-cell infiltration during chronic DSS-induced colitis, which may be mediated by IL-13 and IL-6.	Dextran Sulfate	104-107	interleukin 6	Mus musculus	160-164
20089076-6	2010	Treatment of B6-ILD mice with SB-431542 resulted in improvement of ILD, delay in mortality, reduction of the expression of interferon (IFN)-gamma and IL-6 in the lungs.	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	30-39	interleukin 6	Mus musculus	150-154
20193684-1	2010	BACKGROUND &amp; AIMS: Signal transducer and activator of transcription 3 (Stat3) is the main mediator of interleukin-6-type cytokine signaling required for hepatocyte proliferation and hepatoprotection, but its role in sclerosing cholangitis and other cholestatic liver diseases remains unresolved.	Adenosine Monophosphate	12-15	interleukin 6	Mus musculus	106-119
19773091-1	2010	Endogenous interleukin-6 has been considered as an important anti-inflammatory cytokine controlling both local and systemic acute inflammatory responses; the usefulness of IL-6 in endotoxemia aiming to block the production of reactive oxygen species and the release of inflammatory cytokines is under discussion The aim of the study was to evaluate the protective effects of IL-6 in experimentally induced endotoxemia in mice correlating the changes in tissue anti-oxidant enzymes and circulating cytokines.	Reactive Oxygen Species	226-249	interleukin 6	Mus musculus	11-24
19773091-1	2010	Endogenous interleukin-6 has been considered as an important anti-inflammatory cytokine controlling both local and systemic acute inflammatory responses; the usefulness of IL-6 in endotoxemia aiming to block the production of reactive oxygen species and the release of inflammatory cytokines is under discussion The aim of the study was to evaluate the protective effects of IL-6 in experimentally induced endotoxemia in mice correlating the changes in tissue anti-oxidant enzymes and circulating cytokines.	Reactive Oxygen Species	226-249	interleukin 6	Mus musculus	172-176
20071694-7	2010	Unexpectedly, the n-3 PUFA diet increased B-cell CD69 surface expression, IL-6 and IFNgamma secretion, and it significantly increased body weight gain.	Fatty Acids, Unsaturated	22-26	interleukin 6	Mus musculus	74-78
20512929-7	2010	In addition, berberine effectively inhibited proinflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6 expression.	Berberine	13-22	interleukin 6	Mus musculus	104-108
20417620-4	2010	The combination of palmitate and macrophages, accompanied by a great increase of TNF-alpha and IL-6 in the culture media, additively caused a higher level of PTP1B protein levels in the muscle.	Palmitates	19-28	interleukin 6	Mus musculus	95-99
23956643-10	2010	However, when co-stimulation occurred with beta-glucan and LPS, the cells showed strong synergistic effects by increased IL-6 expression.	beta-Glucans	43-54	interleukin 6	Mus musculus	121-125
20371279-8	2010	RESULTS: The results showed that AS EtOAc extract significantly inhibited NF-kappaB luciferase activity and TNF-alpha, IL-6, macrophage inflammatory protein-2 (MIP-2) and NO secretions from LPS/IFN-gamma-stimulated RAW 264.7 cells.	ethyl acetate	36-41	interleukin 6	Mus musculus	119-123
20822024-1	2010	OBJECTIVE: To investigate the effect of berberine on serum levels of TNF-alpha, IL-6 and adiponectin in obese mice induced by high fat diet and its potential molecular mechanisms.	Berberine	40-49	interleukin 6	Mus musculus	80-84
20822024-11	2010	After two-week treatment of berberine, serum levels of TNF-alpha, IL-6 in BL and BH were lower than those in BM (P &lt; 0.05, respectively).	Berberine	28-37	interleukin 6	Mus musculus	66-70
20822026-8	2010	RESULT: Compared with CLP group, the death rate, the levels of BUN, Cr, IL-6, and iNOS protein expression of asiaticoside groups were significantly reduced.	asiaticoside	109-121	interleukin 6	Mus musculus	72-76
20822026-10	2010	CONCLUSION: Asiaticoside has protective effects against sepsis-induced acute kidney injury, which were probably associated with the inhibition of IL-6 in serum and iNOS protein in kidney tissues.	asiaticoside	12-24	interleukin 6	Mus musculus	146-150
20151299-6	2010	Similarly, the IL-6-regulated gene transcription of Il-6 (also known as Il6) to Hp and the feedback inhibitor of IL-6, Socs3, were also attenuated by rottlerin.	histidylproline	80-82	interleukin 6	Mus musculus	15-19
20189822-1	2010	Interleukin (IL)-6 is a multifunctional cytokine which has been showed to induce up-regulated expression of Fc epsilon RI receptor and histamine production in mast cells.	Histamine	135-144	interleukin 6	Mus musculus	0-18
20189822-7	2010	U0126, PD98059 and LY204002 abolished IL-6 induced IL-13 release when they were preincubated with P815 cells, indicating ERK and Akt cell signaling pathways may be involved in the event.	U 0126	0-5	interleukin 6	Mus musculus	38-42
20189822-7	2010	U0126, PD98059 and LY204002 abolished IL-6 induced IL-13 release when they were preincubated with P815 cells, indicating ERK and Akt cell signaling pathways may be involved in the event.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	7-14	interleukin 6	Mus musculus	38-42
20189822-7	2010	U0126, PD98059 and LY204002 abolished IL-6 induced IL-13 release when they were preincubated with P815 cells, indicating ERK and Akt cell signaling pathways may be involved in the event.	ly204002	19-27	interleukin 6	Mus musculus	38-42
20685261-7	2010	In addition, chloral hydrate treatment in vitro attenuated the upregulation of TNF-alpha and IL-6 by peritoneal macrophages and NF-kappaB activity in RAW264.7 cells stimulated with LPS, suggesting that monocytes/macrophages may be a target of chloral hydrate.	Chloral Hydrate	13-28	interleukin 6	Mus musculus	93-97
20151299-6	2010	Similarly, the IL-6-regulated gene transcription of Il-6 (also known as Il6) to Hp and the feedback inhibitor of IL-6, Socs3, were also attenuated by rottlerin.	rottlerin	150-159	interleukin 6	Mus musculus	15-19
20151299-6	2010	Similarly, the IL-6-regulated gene transcription of Il-6 (also known as Il6) to Hp and the feedback inhibitor of IL-6, Socs3, were also attenuated by rottlerin.	rottlerin	150-159	interleukin 6	Mus musculus	52-56
20151299-6	2010	Similarly, the IL-6-regulated gene transcription of Il-6 (also known as Il6) to Hp and the feedback inhibitor of IL-6, Socs3, were also attenuated by rottlerin.	rottlerin	150-159	interleukin 6	Mus musculus	72-75
20151299-6	2010	Similarly, the IL-6-regulated gene transcription of Il-6 (also known as Il6) to Hp and the feedback inhibitor of IL-6, Socs3, were also attenuated by rottlerin.	rottlerin	150-159	interleukin 6	Mus musculus	113-117
20151299-7	2010	Furthermore, PKCdelta was found to translocate to the nucleus following IL-6 treatment and this was also reduced by rottlerin.	rottlerin	116-125	interleukin 6	Mus musculus	72-76
20151299-6	2010	Similarly, the IL-6-regulated gene transcription of Il-6 (also known as Il6) to Hp and the feedback inhibitor of IL-6, Socs3, were also attenuated by rottlerin.	histidylproline	80-82	interleukin 6	Mus musculus	52-56
20151299-6	2010	Similarly, the IL-6-regulated gene transcription of Il-6 (also known as Il6) to Hp and the feedback inhibitor of IL-6, Socs3, were also attenuated by rottlerin.	histidylproline	80-82	interleukin 6	Mus musculus	72-75
20193778-6	2010	When pretreated with 30mg/kg of ceftiofur, the TNF-alpha, IL-6, and IL-8 levels were significantly decreased.	ceftiofur	32-41	interleukin 6	Mus musculus	58-62
19924809-8	2010	Serum LBP increased in WT mice following TNBS administration, in conjunction with increased serum TNF-alpha, IL-6, and IL-10, and expansion of regulatory T-cell numbers.	Trinitrobenzenesulfonic Acid	41-45	interleukin 6	Mus musculus	109-113
19956958-5	2010	RESULT: Intrarectal treatment of TNBS in mice caused colon shortening and also increased colonic expression of IL-1beta, IL-6, and TNF-alpha expression.	Trinitrobenzenesulfonic Acid	33-37	interleukin 6	Mus musculus	121-125
19956958-6	2010	Oral administration of lancemaside A (10 and 20 mg/kg), inhibited colon shortening and myeloperoxidase activity in TNBS-induced colitic mice and also decreased colonic expression of IL-1beta, IL-6, and TNF-alpha.	lancemaside A	23-36	interleukin 6	Mus musculus	192-196
20215335-5	2010	IL-6-mediated activation of STAT3 and in vitro T(h)17 cell development were all suppressed by Zn.	Zinc	94-96	interleukin 6	Mus musculus	0-4
20169331-9	2010	STAT3 inhibitors, including curcumin, AG490 and a peptide (PpYLKTK), reduced hepcidin1 mRNA expression even when cells were additionally exposed to IL-6.	Curcumin	28-36	interleukin 6	Mus musculus	148-152
20215335-6	2010	Importantly, Zn binding changed the alpha-helical secondary structure of STAT3, disrupting the association of STAT3 with JAK2 kinase and with a phospho-peptide that included a STAT3-binding motif from the IL-6 signal transducer gp130.	Zinc	13-15	interleukin 6	Mus musculus	205-209
19965598-0	2010	Regulation of interleukin-6 expression in osteoblasts by oxidized phospholipids.	Phospholipids	66-79	interleukin 6	Mus musculus	14-27
19965598-11	2010	Taken together, the data suggest that oxidized phospholipids induce IL-6 expression in osteoblasts in part via C/EBP.	Phospholipids	47-60	interleukin 6	Mus musculus	68-72
20372827-6	2010	Forskolin, a direct activator of adenylyl cyclase, or 8-bromoadenosine-3",5"-cyclic monophosphate (8bromo-cAMP), a plasma membrane-permeable cAMP analogue, markedly enhanced the TNF-alpha-induced IL-6 synthesis as well as VIP.	8-Bromo Cyclic Adenosine Monophosphate	54-97	interleukin 6	Mus musculus	196-200
20372827-9	2010	PD98059, a specific inhibitor of MEK1/2, significantly suppressed the enhancement of TNF-alpha-induced IL-6 synthesis by VIP.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	interleukin 6	Mus musculus	103-107
20035621-0	2010	Nitric oxide stimulates interleukin-6 production in skeletal myotubes.	Nitric Oxide	0-12	interleukin 6	Mus musculus	24-37
20035621-7	2010	In addition, NO-induced IL-6 release was inhibited in a concentration-dependent fashion by the MEK1/2 inhibitor PD98059 and the p38 MAPK inhibitor SB203580 but not by the SAPK/JNK inhibitor SP600125.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	112-119	interleukin 6	Mus musculus	24-28
20035621-7	2010	In addition, NO-induced IL-6 release was inhibited in a concentration-dependent fashion by the MEK1/2 inhibitor PD98059 and the p38 MAPK inhibitor SB203580 but not by the SAPK/JNK inhibitor SP600125.	SB 203580	147-155	interleukin 6	Mus musculus	24-28
20035621-8	2010	We conclude that NO-stimulated IL-6 production in differentiated C2C12 myotubes is cGMP-independent and mediated by activation of MAPK pathways.	Cyclic GMP	83-87	interleukin 6	Mus musculus	31-35
20218969-3	2010	Results showed that exogenously added apoE suppressed the LPS and poly(I-C) induction of IL (interleukin)-6, IL-1beta and TNF-alpha (tumour necrosis factor-alpha) secretion by RAW 264.7 cells.	Poly I-C	66-75	interleukin 6	Mus musculus	89-107
20500664-5	2010	In addition, the expression of IL-6 and CXCL1 in mouse embryonic fibroblast (MEF) cells was significantly increased by the ES protein treatment, but we did not detect these effects in the TRIF(-/-) MEF cells.	Einsteinium	123-125	interleukin 6	Mus musculus	31-35
19433409-8	2010	IL6 injection into mice increased the expression of VLDLR in heart, adipose tissue and liver and decreased TC and TG levels.	Technetium	107-109	interleukin 6	Mus musculus	0-3
20130243-5	2010	INCB018424 inhibited interleukin-6 signaling (50% inhibitory concentration [IC(50)] = 281nM), and proliferation of JAK2V617F(+) Ba/F3 cells (IC(50) = 127nM).	ruxolitinib	0-10	interleukin 6	Mus musculus	21-34
20230793-7	2010	In contrast, the inhibition of the NF-kappaB pathway by hesperetin and naringenin suppresses the transcription of IL-6, which induces FFA secretion in an autocrine manner.	hesperetin	56-66	interleukin 6	Mus musculus	114-118
20230793-7	2010	In contrast, the inhibition of the NF-kappaB pathway by hesperetin and naringenin suppresses the transcription of IL-6, which induces FFA secretion in an autocrine manner.	naringenin	71-81	interleukin 6	Mus musculus	114-118
20167866-9	2010	It was found that PGE(2) could directly stimulate IL-6 production in HTSMCs or leukocyte count in bronchoalveolar lavage fluid in mice.	Prostaglandins E	18-21	interleukin 6	Mus musculus	50-54
19433409-8	2010	IL6 injection into mice increased the expression of VLDLR in heart, adipose tissue and liver and decreased TC and TG levels.	Triglycerides	114-116	interleukin 6	Mus musculus	0-3
19433409-9	2010	The injection of anti-IL6R antibody normalised the reduced levels of TC and TG caused by IL6 injection, whereas it had no influence on the levels of TC and TG in normal mice.	Technetium	69-71	interleukin 6	Mus musculus	22-25
19433409-9	2010	The injection of anti-IL6R antibody normalised the reduced levels of TC and TG caused by IL6 injection, whereas it had no influence on the levels of TC and TG in normal mice.	Triglycerides	76-78	interleukin 6	Mus musculus	22-25
20060814-8	2010	We suggest that IL-6 is important for promoting myelin synthesis in aged females, and that drugs which inhibit the synthesis of IL-6 in males may inadvertently affect fatty acid metabolism and augment aging-related neuroinflammation.	Fatty Acids	167-177	interleukin 6	Mus musculus	128-132
19718070-6	2010	TBI alone significantly upregulated transforming growth factor-beta (TGF-beta), IL-6 and p19 mRNA levels in host BALB/c mice, possibly providing the milieu to induce IL-17 in p19-/- donor cells.	Thioacetazone	0-3	interleukin 6	Mus musculus	80-84
20181886-5	2010	Comprehensive serum multiplex cytokine profiling demonstrated a heightened Th1-Th17 profile (increased TNF-alpha, IL-6, and IL-17) in DSS-induced Clcn5 KO mice compared with that in WT DSS colitis mice.	Dextran Sulfate	134-137	interleukin 6	Mus musculus	114-118
20177800-3	2010	Harpagoside, a major iridoid glycoside present in devil"s claw, was found to be one of the active agents in HP-ext and inhibited the production of IL-1beta, IL-6, and TNF-alpha by RAW 264.7.	harpagoside	0-11	interleukin 6	Mus musculus	157-161
20356392-1	2010	BACKGROUND: Dipterinyl calcium pentahydrate (DCP) has previously been shown to inhibit MDA-MB-231 human breast cancer xenographs in nude mice in a manner correlated with increases in plasma IL-12 and IL-4 concentrations, and decreases in plasma IL-6 levels.	Dipterinyl calcium pentahydrate	12-43	interleukin 6	Mus musculus	245-249
20356392-1	2010	BACKGROUND: Dipterinyl calcium pentahydrate (DCP) has previously been shown to inhibit MDA-MB-231 human breast cancer xenographs in nude mice in a manner correlated with increases in plasma IL-12 and IL-4 concentrations, and decreases in plasma IL-6 levels.	dcp	45-48	interleukin 6	Mus musculus	245-249
20432622-8	2010	Kojic acid derivatives also suppressed LPS-induced NO production and interleukin (IL)-6 expression in RAW264.7 cells under lowered or non-cytotoxic concentrations of compounds.	kojic acid	0-10	interleukin 6	Mus musculus	69-87
20138879-3	2010	25-hydroxycholesterol, a representative LXR activating oxysterol, suppressed IL-6 production and degranulation response in BMMCs following engagement of high-affinity IgE receptor (FcepsilonRI).	25-hydroxycholesterol	0-21	interleukin 6	Mus musculus	77-81
20302663-11	2010	Levels of TNFalpha, IL-6 and TGFbeta1 were lowered by iloprost.	Iloprost	54-62	interleukin 6	Mus musculus	20-24
20302663-12	2010	CONCLUSIONS: Iloprost prevents bleomycin-induced pulmonary fibrosis, possibly by upregulating antifibrotic mediators (IFNgamma and CXCL10) and downregulating pro-inflammatory and pro-fibrotic cytokines (TNFalpha, IL-6, and TGFbeta1).	Iloprost	13-21	interleukin 6	Mus musculus	213-217
20302663-12	2010	CONCLUSIONS: Iloprost prevents bleomycin-induced pulmonary fibrosis, possibly by upregulating antifibrotic mediators (IFNgamma and CXCL10) and downregulating pro-inflammatory and pro-fibrotic cytokines (TNFalpha, IL-6, and TGFbeta1).	Bleomycin	31-40	interleukin 6	Mus musculus	213-217
19028402-6	2010	High cholesterol-diet feeding increases the activity of NADPH oxidase subunits (p47(phox) and Rac), extracellular signal-regulated kinase 1/2, janus kinase 2, signal transducer and activator of transcription 3, nuclear factor-kappaB and the expression of tumor necrosis factor-alpha, interleukin 6, monocyte chemoattactant protein-1 and vascular cell adhesion molecule-1 in the aortas.	Cholesterol	5-16	interleukin 6	Mus musculus	284-297
19962977-3	2010	Orally administered 1,7-dimethylxanthine significantly attenuated lung myeloperoxidase-levels, transcription of IL-6, TNF-alpha, MIP1alpha and MIP2 genes as well as PAR-polymer formation in a mouse model of intratracheally LPS-induced acute pulmonary inflammation.	1,7-dimethylxanthine	20-40	interleukin 6	Mus musculus	112-116
19962977-4	2010	Serum amyloid P component and plasma IL-6 were also lowered in 1,7-dimethylxanthine treated mice, indicating a reduced systemic inflammatory response.	1,7-dimethylxanthine	63-83	interleukin 6	Mus musculus	37-41
20006963-8	2010	Moreover, 1% aloperine treatment significantly decreased the up-regulated mRNA and protein levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) induced by DNFB in ear biopsy homogenates.	aloperine	13-22	interleukin 6	Mus musculus	175-188
20006963-8	2010	Moreover, 1% aloperine treatment significantly decreased the up-regulated mRNA and protein levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) induced by DNFB in ear biopsy homogenates.	aloperine	13-22	interleukin 6	Mus musculus	190-194
20006963-10	2010	The therapeutic mechanism might be related to the reduction of TNF-alpha, IL-1beta and IL-6 production induced by DNFB.	Dinitrofluorobenzene	114-118	interleukin 6	Mus musculus	87-91
20140007-8	2010	EGCG activated AMPK and blocked LPS/IFN-gamma-induced inflammatory mediator production (iNOS expression, supernatant NO and interleukin-6).	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	124-137
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	pmbc	15-19	interleukin 6	Mus musculus	169-173
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	interleukin 6	Mus musculus	169-173
20086156-5	2010	The serum levels of MCP-1 and IL-6, after intranasal exposure to SEB, were significantly reduced in mice given rapamycin versus controls.	Sirolimus	111-120	interleukin 6	Mus musculus	30-34
20043322-4	2010	Exposure to physiologic levels of estradiol, in vitro, increased female mouse BEC (mBEC) IL-6 messenger RNA (mRNA) and protein expression, but either inhibited or had no effect on male mBECs.	Estradiol	34-43	interleukin 6	Mus musculus	89-93
19940103-4	2010	Resveratrol reversed the colitis-associated decrease in body weight and increased levels of serum amyloid A, tumor necrosis factor-alpha, interleukin (IL-6), and IL-1beta.	Resveratrol	0-11	interleukin 6	Mus musculus	151-155
19757088-5	2010	RESULTS: Thalidomide administration significantly inhibits TGF-beta1 mRNA expression in a dose-dependant manner following administration of IL-6 and IL-6R.	Thalidomide	9-20	interleukin 6	Mus musculus	140-144
19757088-6	2010	In the analysis of BAL fluids, total BAL inflammatory cell counts, TGF-beta1, and IL-6 levels in thalidomide-treated mice were significantly reduced when compared with bleomycin-treated mice (p &lt; 0.01, p &lt; 0.01, and p &lt; 0.001, respectively).	Thalidomide	97-108	interleukin 6	Mus musculus	82-86
19890701-11	2010	Expression of TNF-alpha and IL-6 decreased in nicotine-pretreated mice compared with model and vagotomy mice; IL-10 levels were not significantly different between the model group and nicotine group.	Nicotine	46-54	interleukin 6	Mus musculus	28-32
20127036-7	2010	Furthermore, GOS inhibited the production of inflammatory cytokines such as IL-1beta, IL-6, IL-17, and tumor necrosis factor-alpha but enhanced production of immunomodulatory IL-10.	D-Glucitol-1,6-bisphosphate	13-16	interleukin 6	Mus musculus	86-90
19950212-0	2010	Effect of arachidonic acid on hypoxia-induced IL-6 production in mouse ES cells: Involvement of MAPKs, NF-kappaB, and HIF-1alpha.	Arachidonic Acid	10-26	interleukin 6	Mus musculus	46-50
19950212-1	2010	This study examined the role of arachidonic acid (AA) in hypoxia-induced production of interleukin (IL)-6 and its related signaling pathways in mouse embryonic stem (ES) cells.	Arachidonic Acid	32-48	interleukin 6	Mus musculus	87-105
19950212-2	2010	Hypoxia with AA induced IL-6 production, which was mediated by reactive oxygen species (ROS).	Reactive Oxygen Species	63-86	interleukin 6	Mus musculus	24-28
19950212-2	2010	Hypoxia with AA induced IL-6 production, which was mediated by reactive oxygen species (ROS).	Reactive Oxygen Species	88-91	interleukin 6	Mus musculus	24-28
19800637-5	2010	Atorvastatin treatment lowered cholesterol, triglyceride, insulin, TNF-alpha, and IL-6 plasma levels, and restored whole-body insulin sensitivity.	Atorvastatin	0-12	interleukin 6	Mus musculus	82-86
20165929-5	2010	Additionally, DHA-lysoPtdCho also reduced the level of TNF-alpha or IL-6, but not PGE(2).	dha-lysoptdcho	14-28	interleukin 6	Mus musculus	68-72
20165929-9	2010	Additionally, mechanistic studies indicated that the anti-inflammatory action of DHA-lysoPtdCho was partially related to the reduced formation of LTC(4,) TNF-alpha, and IL-6.	dha-lysoptdcho	81-95	interleukin 6	Mus musculus	169-173
19800637-6	2010	In adipose tissue, atorvastatin decreased macrophage infiltration and normalized IKK-alpha/beta phosphorylation; TNF-alpha, IL-6, and GLUT4 mRNA; and GLUT4 protein to control levels.	Atorvastatin	19-31	interleukin 6	Mus musculus	124-128
20043298-9	2010	To ascertain the molecular mechanisms implicated in the antitumor promoting activity of eugenol, its effect was investigated on markers of tumor promotion and inflammation: ODC activity and iNOS and COX-2 expression, and on levels of proinflammatory cytokines (IL-6, TNF-alpha, and PGE(2)).	Eugenol	88-95	interleukin 6	Mus musculus	261-265
20093129-9	2010	GlcN-HCl and GlcNAc significantly suppressed the antigen-induced up-regulation of TNF-alpha and IL-6 mRNA.	glcn-hcl	0-8	interleukin 6	Mus musculus	96-100
20072791-6	2010	RESULTS: DSS-treated mice exhibited later timing of vaginal opening relative to both of the other groups, as well as increased colonic inflammation by cytology and increased serum levels of interleukin (IL)-6 and tumor necrosis factor(TNF)-alpha.	dss	9-12	interleukin 6	Mus musculus	190-208
20093129-9	2010	GlcN-HCl and GlcNAc significantly suppressed the antigen-induced up-regulation of TNF-alpha and IL-6 mRNA.	Acetylglucosamine	13-19	interleukin 6	Mus musculus	96-100
20169081-5	2010	Supporting a role for PGE(2) we observed that acetylsalicylic acid impaired the ability of MSC to inhibit the production of inflammatory cytokines and to stimulate the production of IL-10 by LPS-stimulated M. Moreover, we found that MSC constitutively produce PGE2 at levels able to inhibit the production of TNF-alpha and IL-6 by activated M. MSC also inhibited the up-regulation of CD86 and MHC class II in LPS-stimulated M impairing their ability to activate antigen-specific T CD4+ cells.	Aspirin	46-66	interleukin 6	Mus musculus	323-327
19688830-6	2010	The dietary administration with GOFA/beta-CD and AUR/beta-CD inhibited colonic inflammation and also modulated proliferation, apoptosis and the expression of several proinflammatory cytokines, such as nuclear factor-kappaB, tumor necrosis factor-alpha, Stat3, NF-E2-related factor 2, interleukin (IL)-6 and IL-1beta, which were induced in the adenocarcinomas.	gofa	32-36	interleukin 6	Mus musculus	284-302
19857488-4	2010	In addition, hispidol A 25-Me ether inhibits mRNA expressions of major pro-inflammatory cytokines including the tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6).	hispidol a 25-me	13-29	interleukin 6	Mus musculus	186-199
20034680-2	2010	Here we show that GA treatment of mice with experimental autoimmune encephalomyelitis (EAE) biases cytokine production by B cells towards cytokines associated with regulation in MS including interleukin (IL)-4, -10 and -13 and reduces pro-inflammatory IL-6, IL-12, and TNF alpha levels.	Gallium	18-20	interleukin 6	Mus musculus	252-256
19857488-4	2010	In addition, hispidol A 25-Me ether inhibits mRNA expressions of major pro-inflammatory cytokines including the tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6).	hispidol a 25-me	13-29	interleukin 6	Mus musculus	201-205
19879324-4	2010	Rapamycin, an inhibitor of p70 S6 kinase, which attenuated the phosphorylation of p70 S6 kinase induced by TNF-alpha, significantly amplified the TNF-alpha-stimulated IL-6 synthesis.	Sirolimus	0-9	interleukin 6	Mus musculus	167-171
19909737-6	2010	Enzyme-linked immunosorbent assay and radio-immunity assay showed that treatment with neferine alleviated bleomycin-induced increase of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and endothelin-1 in plasma or in tissue.	Bleomycin	106-115	interleukin 6	Mus musculus	206-224
19892861-11	2010	Treatment with rmMFG-E8 significantly suppressed inflammation (TNF-alpha, IL-6, IL-1beta, and myeloperoxidase) and injury of the lungs, liver, and kidneys.	rmmfg-e8	15-23	interleukin 6	Mus musculus	74-78
19879324-6	2010	The amplification by rapamycin of TNF-alpha-induced IL-6 synthesis was reduced by PD98059, a specific inhibitor of MEK1/2, or Akt inhibitor.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	82-89	interleukin 6	Mus musculus	52-56
19966184-5	2010	The aberrant gene expression of MCP-1, IL-6, adiponectin, and factor VII and suppressed insulin receptor substrate-1-Akt signaling in adipose tissue of db/db mice were reversed by argatroban treatment.	argatroban	180-190	interleukin 6	Mus musculus	39-43
19577630-6	2010	We found that SP600125 blocked JNK phosphorylation and significantly decreased IDO expression induced by LPS, which was accompanied by a reduction of LPS-induced expression of TNFalpha and IL-6.	pyrazolanthrone	14-22	interleukin 6	Mus musculus	189-193
19074180-9	2010	Pulse bromodeoxyuridine labelling demonstrated equivalent crypt cell proliferation rates but prolonged enterocyte lifespan and slowed enterocyte migration rates in IL-6 treated mice.	Bromodeoxyuridine	6-23	interleukin 6	Mus musculus	164-168
20093775-9	2010	IL-10 from cDCs reduced production of TNF, IL-6, and ROS by inflammatory monocytes.	Chenodeoxycholate 3-sulphate	11-15	interleukin 6	Mus musculus	43-47
19074180-11	2010	Conversely, Il6 null mice exhibited impaired recovery following massive enterectomy and increased apoptosis after 5-fluorouracil chemotherapy relative to wild-type controls.	Fluorouracil	114-128	interleukin 6	Mus musculus	12-15
19879381-4	2010	Bisabolangelone also inhibited the productions of pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6) by suppressing the cytokine mRNA and protein expressions.	bisabolangelone	0-15	interleukin 6	Mus musculus	102-106
19774506-2	2010	Both madecassic acid and madecassoside inhibited the production of nitric oxide (NO), prostaglandin E(2) (PGE(2)), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and IL-6.	madecassic acid	5-20	interleukin 6	Mus musculus	191-195
19774506-2	2010	Both madecassic acid and madecassoside inhibited the production of nitric oxide (NO), prostaglandin E(2) (PGE(2)), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and IL-6.	madecassoside	25-38	interleukin 6	Mus musculus	191-195
20018613-3	2010	In the current study, we demonstrate that incubation of Prx1 with thioglycollate-elicited murine macrophages or immature bone marrow-derived dendritic cells resulted in TLR4-dependent secretion of TNF-alpha and IL-6 and dendritic cell maturation.	Thioglycolates	66-80	interleukin 6	Mus musculus	211-215
20821827-0	2010	Methyl gallate inhibits the production of interleukin-6 and nitric oxide via down-regulation of extracellular-signal regulated protein kinase in RAW 264.7 cells.	methyl gallate	0-14	interleukin 6	Mus musculus	42-55
20821827-2	2010	Anti-inflammatory activity of MG was evaluated for NO and IL-6 production in RAW 264.7 cells.	methyl gallate	30-32	interleukin 6	Mus musculus	58-62
19907005-1	2010	Expression of the cytokine interleukin-6 (IL-6) by skeletal muscle is hugely increased in response to a single bout of endurance exercise, and this appears to be mediated by increases in intracellular calcium.	Calcium	201-208	interleukin 6	Mus musculus	27-40
19907005-1	2010	Expression of the cytokine interleukin-6 (IL-6) by skeletal muscle is hugely increased in response to a single bout of endurance exercise, and this appears to be mediated by increases in intracellular calcium.	Calcium	201-208	interleukin 6	Mus musculus	42-46
20050854-9	2010	In contrast to ATP, the P2Y(6)-selective agonist UDP increased mRNA expression and activity of inducible nitric oxide synthase and interleukin-6 in J774 macrophages; this effect was blocked by suramin (100-300 microM) or pyridoxal-phosphate-6-azophenyl-2"-4"-disulphonic acid (PPADS, 10-30 microM).	Uridine Diphosphate	49-52	interleukin 6	Mus musculus	131-144
20050854-9	2010	In contrast to ATP, the P2Y(6)-selective agonist UDP increased mRNA expression and activity of inducible nitric oxide synthase and interleukin-6 in J774 macrophages; this effect was blocked by suramin (100-300 microM) or pyridoxal-phosphate-6-azophenyl-2"-4"-disulphonic acid (PPADS, 10-30 microM).	Suramin	193-200	interleukin 6	Mus musculus	131-144
19822443-4	2010	A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism.	haec	92-96	interleukin 6	Mus musculus	60-64
19822443-4	2010	A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism.	haec	92-96	interleukin 6	Mus musculus	237-241
19822443-4	2010	A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism.	pyrrolidine dithiocarbamic acid	136-163	interleukin 6	Mus musculus	60-64
19822443-4	2010	A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism.	pyrrolidine dithiocarbamic acid	136-163	interleukin 6	Mus musculus	237-241
19822443-4	2010	A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism.	pyrrolidine dithiocarbamic acid	165-169	interleukin 6	Mus musculus	60-64
19822443-4	2010	A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism.	pyrrolidine dithiocarbamic acid	165-169	interleukin 6	Mus musculus	237-241
19822443-4	2010	A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism.	epigallocatechin gallate	175-199	interleukin 6	Mus musculus	60-64
19822443-4	2010	A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism.	epigallocatechin gallate	175-199	interleukin 6	Mus musculus	237-241
19822443-4	2010	A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism.	epigallocatechin gallate	201-205	interleukin 6	Mus musculus	60-64
19822443-4	2010	A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism.	epigallocatechin gallate	201-205	interleukin 6	Mus musculus	237-241
19822443-4	2010	A significant and dose-dependent inhibition of IL-4-induced IL-6 expression was observed in HAEC pre-treated with antioxidants, such as pyrrolidine dithiocarbamate (PDTC) and epigallocatechin gallate (EGCG), indicating that IL-4-induced IL-6 expression is mediated via an ROS-dependent mechanism.	Reactive Oxygen Species	272-275	interleukin 6	Mus musculus	60-64
19822443-7	2010	In contrast, overexpression of IL-6 in IL-4-activated HAEC was not affected by inhibiting other ROS generating pathways, such as xanthine oxidase, arachidonic acid metabolism, and the mitochondrial electron transport chain.	Reactive Oxygen Species	96-99	interleukin 6	Mus musculus	31-35
19822443-7	2010	In contrast, overexpression of IL-6 in IL-4-activated HAEC was not affected by inhibiting other ROS generating pathways, such as xanthine oxidase, arachidonic acid metabolism, and the mitochondrial electron transport chain.	Arachidonic Acid	147-163	interleukin 6	Mus musculus	31-35
19822443-8	2010	These results demonstrate that IL-4 up-regulates IL-6 expression in vascular endothelium through NOX-mediated ROS generation.	Reactive Oxygen Species	110-113	interleukin 6	Mus musculus	49-53
19818826-9	2010	GalN/LPS increased the circulating levels of tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6) and IL-10.	Galactosamine	0-4	interleukin 6	Mus musculus	80-93
19818826-9	2010	GalN/LPS increased the circulating levels of tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6) and IL-10.	Galactosamine	0-4	interleukin 6	Mus musculus	95-99
19818826-11	2010	GalN/LPS treatment also increased the levels of TNF-alpha, IL-6 and IL-10 mRNA expression in liver tissue.	Galactosamine	0-4	interleukin 6	Mus musculus	59-63
19533603-4	2010	This study was designed to assess whether estradiol affects the production of IL-6 and IP-10 by primary cultures of newborn mice astrocytes exposed to lipopolysaccharide (LPS), a bacterial endotoxin known to cause neuroinflammation.	Estradiol	42-51	interleukin 6	Mus musculus	78-82
20034026-8	2010	Furthermore, the results obtained in mice treated with DEN to induce hepatocarcinogenesis showed, after treatment with a PARP inhibitor (DPQ), a significant reduction both in preneoplastic foci and in the expression of preneoplastic markers and proinflammatory genes (Gstm3, Vegf, Spp1 [Opn], IL6, IL1b, and Tnf), bromodeoxyuridine incorporation, and NF-kappaB activation in the initial steps of carcinogenesis (P &lt; 0.05).	Diethylnitrosamine	55-58	interleukin 6	Mus musculus	293-296
19896497-3	2010	SSP1 increased the levels of interleukin-6 and tumor necrosis factor-alpha in immunosuppressed mice induced by subcutaneous injection of dexamethasone at 1.25 mg/kg.	Dexamethasone	137-150	interleukin 6	Mus musculus	29-74
19866480-11	2010	Doxycycline and hAAT in combination also inhibited IL-6 expression from LPS-stimulated NIH/3T3 mouse fibroblast cells, indicating a contributing mechanism of arthritis inhibition.	Doxycycline	0-11	interleukin 6	Mus musculus	51-55
19949098-4	2010	Consistently, the mineralocorticoid receptor was expressed by DCs, which showed activation of MAPK pathway and secreted IL-6 and TGF-beta in response to aldosterone.	Aldosterone	153-164	interleukin 6	Mus musculus	120-124
20625233-7	2010	In these assays, D-limonene decreased the expression of TNF-alpha, IL-1beta, and IL-6 in a dose-dependent manner.	Limonene	17-27	interleukin 6	Mus musculus	81-85
21403905-4	2010	We demonstrated that serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and leptin were remarkably reduced with apocynin treatment.	acetovanillone	140-148	interleukin 6	Mus musculus	78-91
21403905-4	2010	We demonstrated that serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and leptin were remarkably reduced with apocynin treatment.	acetovanillone	140-148	interleukin 6	Mus musculus	93-97
20046053-8	2010	Pretreatment with clarithromycin ex vivo decreased CD40 expression on DCs obtained from P. aeruginosa-infected mice and also decreased the production of IL-6, IL-12p40 and TNF-alpha by DCs.	Clarithromycin	18-32	interleukin 6	Mus musculus	153-157
21351447-5	2010	The expression of HBD-2 and IL-6 cytokine on the colon of colitic mice was higher than that of normal control, paeoniflorin and 5-ASA groups (P &lt; 0.05, P &lt; 0.01), but the expression of IL-10 is lower than that of normal control, paeoniflorin and 5-ASA groups (P &lt; 0.05, P &lt; 0.01).	peoniflorin	111-123	interleukin 6	Mus musculus	28-32
21351447-5	2010	The expression of HBD-2 and IL-6 cytokine on the colon of colitic mice was higher than that of normal control, paeoniflorin and 5-ASA groups (P &lt; 0.05, P &lt; 0.01), but the expression of IL-10 is lower than that of normal control, paeoniflorin and 5-ASA groups (P &lt; 0.05, P &lt; 0.01).	5-Aminosalicylic acid	128-133	interleukin 6	Mus musculus	28-32
21351447-5	2010	The expression of HBD-2 and IL-6 cytokine on the colon of colitic mice was higher than that of normal control, paeoniflorin and 5-ASA groups (P &lt; 0.05, P &lt; 0.01), but the expression of IL-10 is lower than that of normal control, paeoniflorin and 5-ASA groups (P &lt; 0.05, P &lt; 0.01).	peoniflorin	235-247	interleukin 6	Mus musculus	28-32
21351447-5	2010	The expression of HBD-2 and IL-6 cytokine on the colon of colitic mice was higher than that of normal control, paeoniflorin and 5-ASA groups (P &lt; 0.05, P &lt; 0.01), but the expression of IL-10 is lower than that of normal control, paeoniflorin and 5-ASA groups (P &lt; 0.05, P &lt; 0.01).	5-Aminosalicylic acid	252-257	interleukin 6	Mus musculus	28-32
21351447-7	2010	It can be concluded that to some extent paeoniflorin effectively alleviate the symptoms of oxazolone-induced colitis through regulating the expression of HBD-2, IL-6 and IL-10.	peoniflorin	40-52	interleukin 6	Mus musculus	161-165
21351447-7	2010	It can be concluded that to some extent paeoniflorin effectively alleviate the symptoms of oxazolone-induced colitis through regulating the expression of HBD-2, IL-6 and IL-10.	Oxazolone	91-100	interleukin 6	Mus musculus	161-165
19853271-9	2009	Ribavirin, UDA, and Ampligen decreased IL-6 expression.	Ribavirin	0-9	interleukin 6	Mus musculus	39-43
19853271-9	2009	Ribavirin, UDA, and Ampligen decreased IL-6 expression.	undecanoic acid	11-14	interleukin 6	Mus musculus	39-43
19850890-6	2009	Mechanistically, PE DHC enhances EAE in mice lacking natural killer T cells, fails to enhance EAE in Toll-like receptor 2 (TLR2)-deficient mice and, in vitro, induces dendritic cell interleukin-6 secretion in a TLR2-dependent manner.	dihydrocodeine	20-23	interleukin 6	Mus musculus	182-195
19812355-5	2009	To isolate further the mineralocorticoid link to IL-6 and blood pressure, DOCA-salt hypertension was induced in IL-6 KO and wild-type (WT) mice.	Desoxycorticosterone Acetate	74-78	interleukin 6	Mus musculus	112-116
19812355-5	2009	To isolate further the mineralocorticoid link to IL-6 and blood pressure, DOCA-salt hypertension was induced in IL-6 KO and wild-type (WT) mice.	Salts	79-83	interleukin 6	Mus musculus	112-116
19812355-6	2009	Plasma IL-6 increased from 4.1 +/- 1.7 to 34.5 +/- 7.0 pg/ml by day 7 of DOCA treatment in the WT mice but was back to control levels by day 14.	Desoxycorticosterone Acetate	73-77	interleukin 6	Mus musculus	7-11
19812355-11	2009	This suggests that aldosterone contributes to the increase in plasma IL-6 in the early stage of ANG II hypertension but that the blood pressure actions of IL-6 in that model are linked most likely to ANG II rather than aldosterone.	Aldosterone	19-30	interleukin 6	Mus musculus	69-73
19481752-5	2009	Hypercholesterolemic, atherosclerotic ApoE(-/-) mice on CD exhibited increased macrophages and T-cells in plaques and periadventitial adipose tissue that revealed elevated expression of MIP-1alpha, IL-1beta, IL-1 receptor, and IL-6.	Cadmium	56-58	interleukin 6	Mus musculus	208-231
19051282-9	2009	PFOA elevated the expression of proinflammatory cytokines (tumor necrosis factor alpha, interleukin-1beta, and interleukin-6) in the spleen, and proto-oncogene, c-myc, in the spleen and thymus.	perfluorooctanoic acid	0-4	interleukin 6	Mus musculus	111-124
19786067-4	2009	MATERIALS AND METHODS: Dasatinib-treated mice were administered intraperitoneally with lipopolysaccharide (LPS) and serum cytokine (tumor necrosis factor-alpha [TNF-alpha], interleukin [IL]-10, and IL-6) levels and neutrophil accumulation in the lungs were analyzed.	Dasatinib	23-32	interleukin 6	Mus musculus	198-202
19786067-6	2009	RESULTS: Dasatinib-treated mice had reduced serum levels of TNF-alpha in response to LPS administration; however, other inflammatory hallmarks of systemic LPS administration, such as secretion of IL-6 and accumulation of neutrophils in the lung, were unaffected.	Dasatinib	9-18	interleukin 6	Mus musculus	196-200
19822651-6	2009	Blocking histamine production decreased both neutrophil influx into lung tissue and the release of proinflammatory mediators, such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha), in the acute phase of infection.	Histamine	9-18	interleukin 6	Mus musculus	134-147
19822651-6	2009	Blocking histamine production decreased both neutrophil influx into lung tissue and the release of proinflammatory mediators, such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha), in the acute phase of infection.	Histamine	9-18	interleukin 6	Mus musculus	149-153
19822651-9	2009	These findings indicate that histamine produced after M. tuberculosis infection may play a regulatory role not only by enhancing the pulmonary neutrophilia and production of IL-6 and TNF-alpha but also by impairing the protective Th1 response, which ultimately restricts mycobacterial growth.	Histamine	29-38	interleukin 6	Mus musculus	174-178
20009662-12	2009	Animals given PTX had decreased intestinal interleukin-6 levels.	Pentoxifylline	14-17	interleukin 6	Mus musculus	43-56
19295475-2	2009	Results showed that RA concentration dependently down-regulated the levels of TNF-alpha, IL-6, and high-mobility group box 1 protein in LPS-induced RAW264.7 cells, inhibited the IkappaB kinase pathway, and modulated nuclear factor-kappaB.	rosmarinic acid	20-22	interleukin 6	Mus musculus	89-93
19833167-0	2009	Interleukin-6 deficiency accelerates cisplatin-induced acute renal failure but not systemic injury.	Cisplatin	37-46	interleukin 6	Mus musculus	0-13
19833167-4	2009	In this study, we analyzed IL-6 regulation during CDDP-induced ARF in wild-type (WT) mice and determined the pathological role of IL-6 using IL-6 knockout ((-/-)) mice.	Cisplatin	50-54	interleukin 6	Mus musculus	27-31
19833167-5	2009	A correlation between increase in serum IL-6 level and blood urea nitrogen level was found in WT mice.	Urea	61-65	interleukin 6	Mus musculus	40-44
19833167-5	2009	A correlation between increase in serum IL-6 level and blood urea nitrogen level was found in WT mice.	Nitrogen	66-74	interleukin 6	Mus musculus	40-44
19833167-6	2009	Renal IL-6 expression in most proximal tubular cells and suppressor of cytokine signaling 3 (SOCS3) gene expression significantly increased in WT mice after administration of CDDP, suggesting active IL-6 signaling during CDDP-induced ARF development.	Cisplatin	175-179	interleukin 6	Mus musculus	6-10
19772942-6	2009	In vitro, CoVaccineHT upregulated the expression of co-stimulatory molecules both on mouse and human dendritic cells and induced the secretion of pro-inflammatory cytokines TNF-alpha, IL-6, IL-1beta and IL-12p70 in mouse- and IL-6 in human dendritic cells.	covaccineht	10-21	interleukin 6	Mus musculus	226-230
19864602-5	2009	Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene.	obeticholic acid	41-70	interleukin 6	Mus musculus	200-204
19864602-5	2009	Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene.	obeticholic acid	72-79	interleukin 6	Mus musculus	200-204
19054826-13	2009	The expression of tumour necrosis factor alpha, IL-1beta, IL-6, matrix metalloproteinase 3, cyclooxygenase 2 and inducible nitric oxide synthase decreased in bortezomib-treated mice compared with untreated mice.	Bortezomib	158-168	interleukin 6	Mus musculus	58-62
19443527-4	2009	Previously, it was reported that all-trans-retinoic acid (ATRA) inhibited the production and function of IL-6 and transforming growth factor (TGF)-beta1 in experiments using lung fibroblasts.	Tretinoin	33-56	interleukin 6	Mus musculus	105-109
19443527-4	2009	Previously, it was reported that all-trans-retinoic acid (ATRA) inhibited the production and function of IL-6 and transforming growth factor (TGF)-beta1 in experiments using lung fibroblasts.	Tretinoin	58-62	interleukin 6	Mus musculus	105-109
19666099-7	2009	Administration of SB 216763 or LiCl inhibited cochlear destruction and the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and IL-6 in cisplatin-injected mice.	SB 216763	18-27	interleukin 6	Mus musculus	163-167
19666099-7	2009	Administration of SB 216763 or LiCl inhibited cochlear destruction and the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and IL-6 in cisplatin-injected mice.	Lithium Chloride	31-35	interleukin 6	Mus musculus	163-167
19666099-7	2009	Administration of SB 216763 or LiCl inhibited cochlear destruction and the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and IL-6 in cisplatin-injected mice.	Cisplatin	171-180	interleukin 6	Mus musculus	163-167
19716438-6	2009	Interleukin-6 (IL-6) was significantly increased in genistein-treated animals 4h after irradiation.	Genistein	52-61	interleukin 6	Mus musculus	0-13
19716438-6	2009	Interleukin-6 (IL-6) was significantly increased in genistein-treated animals 4h after irradiation.	Genistein	52-61	interleukin 6	Mus musculus	15-19
19716438-7	2009	Because G-CSF and IL-6 are important hematopoietic factors, these results support our hypothesis that the previously observed radioprotective efficacy by genistein may be a result of early recovery of hematopoietic cells due to enhanced production of G-CSF and IL-6.	Genistein	154-163	interleukin 6	Mus musculus	18-22
19716438-7	2009	Because G-CSF and IL-6 are important hematopoietic factors, these results support our hypothesis that the previously observed radioprotective efficacy by genistein may be a result of early recovery of hematopoietic cells due to enhanced production of G-CSF and IL-6.	Genistein	154-163	interleukin 6	Mus musculus	261-265
19642894-0	2009	Interleukin-6 trans-signaling regulates glycogen consumption after D-galactosamine-induced liver damage.	Glycogen	40-48	interleukin 6	Mus musculus	0-13
19642894-0	2009	Interleukin-6 trans-signaling regulates glycogen consumption after D-galactosamine-induced liver damage.	Galactosamine	67-82	interleukin 6	Mus musculus	0-13
19721414-13	2009	IL-6 was by far the most induced acute-phase-cytokine in GD- and zymosan-treated livers, although IL-1beta and TNF-alpha were also strongly upregulated by zymosan and to a lesser extent by GD.	Zymosan	65-72	interleukin 6	Mus musculus	0-4
19721414-13	2009	IL-6 was by far the most induced acute-phase-cytokine in GD- and zymosan-treated livers, although IL-1beta and TNF-alpha were also strongly upregulated by zymosan and to a lesser extent by GD.	gadolinium chloride	57-59	interleukin 6	Mus musculus	0-4
19760679-5	2009	Conversely, accumulation of beta-carotene was negatively correlated with the transcription of immune-active molecules, such as IL-1beta, IL-6, and IL-12 p40, in cells stimulated by LPS and INF-gamma.	beta Carotene	28-41	interleukin 6	Mus musculus	137-141
19760679-6	2009	The transcription of the pro-inflammatory cytokines IL-1beta and IL-6 was more sensitive to the accumulation of beta-carotene than was IL-12 p40.	beta Carotene	112-125	interleukin 6	Mus musculus	65-69
19733186-9	2009	KEY FINDINGS: Pre-treatment with C-K significantly inhibited zymosan-mediated secretion of tumor necrosis factor-alpha, interleukin (IL)-6, and IL-12 p40, and the activation of ERK1/2 and p38.	ginsenoside M1	33-36	interleukin 6	Mus musculus	120-138
19733186-9	2009	KEY FINDINGS: Pre-treatment with C-K significantly inhibited zymosan-mediated secretion of tumor necrosis factor-alpha, interleukin (IL)-6, and IL-12 p40, and the activation of ERK1/2 and p38.	Zymosan	61-68	interleukin 6	Mus musculus	120-138
19168699-0	2009	IL-6 protects against hyperoxia-induced mitochondrial damage via Bcl-2-induced Bak interactions with mitofusins.	bakuchiol	79-82	interleukin 6	Mus musculus	0-4
19168699-0	2009	IL-6 protects against hyperoxia-induced mitochondrial damage via Bcl-2-induced Bak interactions with mitofusins.	mitofusins	101-111	interleukin 6	Mus musculus	0-4
19524707-10	2009	IL-6(-/-) splenocytes secreted greater concentrations of TNFalpha in response to titanium particles than WT; addition of exogenous IL-6 to these cultures decreased TNFalpha expression while anti-IL-6 antibody increased TNFalpha.	Titanium	81-89	interleukin 6	Mus musculus	131-135
19524707-10	2009	IL-6(-/-) splenocytes secreted greater concentrations of TNFalpha in response to titanium particles than WT; addition of exogenous IL-6 to these cultures decreased TNFalpha expression while anti-IL-6 antibody increased TNFalpha.	Titanium	81-89	interleukin 6	Mus musculus	131-135
19465115-4	2009	In addition, we demonstrate that LPA and PKC-induced IL-6 and MIP-2 production are abolished in the absence of MEKK3 but not TAK1.	lysophosphatidic acid	33-36	interleukin 6	Mus musculus	53-57
19666143-4	2009	In addition, it was found that pseudocoptisine suppressed the production and mRNA expressions of inflammatory cytokines, such as, TNF-alpha and IL-6.	pseudocoptisine	31-46	interleukin 6	Mus musculus	144-148
19608614-8	2009	The NOD2 agonist muramyl dipeptide (MDP) increased Nf kappa b1-transcriptional activity, -protein expression and IL6 secretion in TtT/GF cells.	Acetylmuramyl-Alanyl-Isoglutamine	17-34	interleukin 6	Mus musculus	113-116
19660865-9	2009	Hind paw injection of IL-6 and NGF dose dependently produced less mechanical allodynia in the ppt-A(-/-) compared to wt mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	94-97	interleukin 6	Mus musculus	22-26
19386481-6	2009	Oral administration of Hesperidin significantly decreased DAI, MPO activity, MDA content and the level of IL-6 in serum (p&lt;0.01), while there was no significantly effect on the level of IL-4 in serum.	Hesperidin	23-33	interleukin 6	Mus musculus	106-110
19625342-5	2009	Real-time PCR and cytokine bead array revealed that oral gavage with DON rapidly (1 h) induced tumor necrosis factor-alpha and interleukin-6 mRNA and protein expression in several organs and plasma, respectively.	deoxynivalenol	69-72	interleukin 6	Mus musculus	127-140
19577625-6	2009	RESULTS: We found that SR significantly inhibited the production of NO, interleukin (IL)-3, IL-6, IL-10, IL-12p40, IL-17, interferon-inducible protein (IP)-10, keratinocyte-derived chemokine (KC), and vascular endothelial growth factor (VEGF) in LPS-induced RAW 264.7 cells at the concentrations of 25, 50, 100, 200 microg/ml (p&lt;0.05).	Strontium	23-25	interleukin 6	Mus musculus	92-96
19693649-5	2009	Upon treatment with hyper-IL-6, IRF4(-/-) mice lost their protective properties towards TNBS application.	Trinitrobenzenesulfonic Acid	88-92	interleukin 6	Mus musculus	26-30
19542021-3	2009	Palmitate exposure induced a &gt;2-fold increase in superoxide levels, an effect associated with activation of NF-kappaB signaling as measured by phospho-IkappaBalpha, NF-kappaB activity, IL-6, and ICAM expression.	Palmitates	0-9	interleukin 6	Mus musculus	188-192
19603141-2	2009	This study shows that the interaction of ICOSIg and its ligand (ICOSL) on mouse bone marrow-derived dendritic cells (DCs) induces a p38-MAPK dependent elevation of interleukin 6 (IL-6).	icosig	41-47	interleukin 6	Mus musculus	164-177
19603141-2	2009	This study shows that the interaction of ICOSIg and its ligand (ICOSL) on mouse bone marrow-derived dendritic cells (DCs) induces a p38-MAPK dependent elevation of interleukin 6 (IL-6).	icosig	41-47	interleukin 6	Mus musculus	179-183
19549173-6	2009	Similarly, celastrol inhibited LPS-induced production of inflammatory cytokines, including tumour necrosis factor-alpha and interleukin-6.	celastrol	11-20	interleukin 6	Mus musculus	124-137
19175801-2	2009	In nephritic MRL(lpr/lpr) mice, transient exposure to bacterial cell wall components such as lipopeptide or lipopolysaccharide (LPS) increased splenomegaly, the production of DNA autoantibodies, and serum interleukin (IL)-6, IL-12 and tumour necrosis factor (TNF) levels, and aggravated lupus nephritis.	Lipopeptides	93-104	interleukin 6	Mus musculus	205-223
19957881-3	2009	The 3betaHSD activity in murine lymphoid organs, as well as the IL-6 levels in serum increased after administration of SRBC and live E. coli cells, as compared to control.	srbc	119-123	interleukin 6	Mus musculus	64-68
19957881-4	2009	Whereas the 17betaHSD activity was decreased in the murine lymphoid organs with a concomitant reduced serum testosterone level was found after particulate antigen administration or IL-6 treatment.	Testosterone	108-120	interleukin 6	Mus musculus	181-185
19277492-0	2009	Interleukin-6 induces prostaglandin E(2) synthesis in mouse astrocytes.	Dinoprostone	22-40	interleukin 6	Mus musculus	0-13
19277492-3	2009	In the present study, we investigated the effect of the pro-inflammatory cytokine interleukin-6 on the production of the inflammatory mediator prostaglandin E(2) in mouse astrocytes.	Dinoprostone	143-161	interleukin 6	Mus musculus	82-95
19277492-4	2009	Interleukin-6 stimulated prostaglandin E(2) production in a time-dependent fashion via a rapid and transient induction of cyclooxygenase-2 messenger RNA, followed by cyclooxygenase-2 protein synthesis.	Dinoprostone	25-43	interleukin 6	Mus musculus	0-13
19277492-6	2009	Simultaneous treatment of astrocytes with interleukin-6 and soluble interleukin-6 receptor caused marked induction of prostaglandin E(2) synthesis, and this effect was suppressed by adding a neutralizing antibody against soluble interleukin-6 receptor.	Dinoprostone	118-136	interleukin 6	Mus musculus	42-55
19277492-6	2009	Simultaneous treatment of astrocytes with interleukin-6 and soluble interleukin-6 receptor caused marked induction of prostaglandin E(2) synthesis, and this effect was suppressed by adding a neutralizing antibody against soluble interleukin-6 receptor.	Dinoprostone	118-136	interleukin 6	Mus musculus	68-81
19277492-6	2009	Simultaneous treatment of astrocytes with interleukin-6 and soluble interleukin-6 receptor caused marked induction of prostaglandin E(2) synthesis, and this effect was suppressed by adding a neutralizing antibody against soluble interleukin-6 receptor.	Dinoprostone	118-136	interleukin 6	Mus musculus	68-81
19277492-7	2009	Furthermore, the mouse 130-kDa glycoprotein antibody suppressed prostaglandin E(2) formation induced by interleukin-6, as well as interleukin-6/soluble interleukin-6 receptor complexes, in a dose-dependent manner.	Dinoprostone	64-82	interleukin 6	Mus musculus	104-117
19277492-8	2009	These results indicate that interleukin-6/soluble interleukin-6 receptor complexes and the signal transducer 130-kDa glycoprotein play an important role in the regulation of cyclooxygenase-2 expression and subsequent prostaglandin E(2) formation in mouse astrocytes and that interleukin-6 is an important regulator of immune and inflammatory processes in the CNS.	Dinoprostone	217-235	interleukin 6	Mus musculus	28-41
19277492-8	2009	These results indicate that interleukin-6/soluble interleukin-6 receptor complexes and the signal transducer 130-kDa glycoprotein play an important role in the regulation of cyclooxygenase-2 expression and subsequent prostaglandin E(2) formation in mouse astrocytes and that interleukin-6 is an important regulator of immune and inflammatory processes in the CNS.	Dinoprostone	217-235	interleukin 6	Mus musculus	50-63
19277492-8	2009	These results indicate that interleukin-6/soluble interleukin-6 receptor complexes and the signal transducer 130-kDa glycoprotein play an important role in the regulation of cyclooxygenase-2 expression and subsequent prostaglandin E(2) formation in mouse astrocytes and that interleukin-6 is an important regulator of immune and inflammatory processes in the CNS.	Dinoprostone	217-235	interleukin 6	Mus musculus	50-63
19429977-7	2009	In leukemic mice, an increase in serum calcium levels correlated with expression of receptor activator of nuclear factor kappa-light-chain-enhancer of activated B cells ligand on leukemic cells and secretion of parathyroid hormone-related protein and interleukin-6.	Calcium	39-46	interleukin 6	Mus musculus	251-264
19954621-9	2009	(4) SB203580 and SP600125 down-regulated allogeneic T lymphocytes-induced VCAM-1, TNF-alpha, IFN-gamma, IL-6 expression in HUVECs.	SB 203580	4-12	interleukin 6	Mus musculus	104-108
19540903-4	2009	The ex vivo production of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6) by peritoneal macrophages isolated from animals treated with PFOA or PFOS was increased modestly.	perfluorooctanoic acid	152-156	interleukin 6	Mus musculus	70-83
19540903-4	2009	The ex vivo production of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6) by peritoneal macrophages isolated from animals treated with PFOA or PFOS was increased modestly.	perfluorooctanoic acid	152-156	interleukin 6	Mus musculus	85-89
19540903-4	2009	The ex vivo production of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6) by peritoneal macrophages isolated from animals treated with PFOA or PFOS was increased modestly.	perfluorooctane sulfonic acid	160-164	interleukin 6	Mus musculus	70-83
19540903-4	2009	The ex vivo production of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6) by peritoneal macrophages isolated from animals treated with PFOA or PFOS was increased modestly.	perfluorooctane sulfonic acid	160-164	interleukin 6	Mus musculus	85-89
19722571-5	2009	PA treatments at 2% and 4% also significantly lowered plasma C-reactive protein and von Willebrand factor levels and reduced interleukin-6, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 levels in heart and kidney.	protocatechuic acid	0-2	interleukin 6	Mus musculus	125-167
19574428-6	2009	Hyaluronan (HA), an endogenous ligand for toll-like receptor (TLR)-4, stimulated B cells, which infiltrates into wounds to produce interleukin-6 and transforming growth factor-beta through TLR4 in a CD19-dependent manner.	Hyaluronic Acid	0-10	interleukin 6	Mus musculus	131-144
19574428-6	2009	Hyaluronan (HA), an endogenous ligand for toll-like receptor (TLR)-4, stimulated B cells, which infiltrates into wounds to produce interleukin-6 and transforming growth factor-beta through TLR4 in a CD19-dependent manner.	Hyaluronic Acid	12-14	interleukin 6	Mus musculus	131-144
19644888-10	2009	CONCLUSION: Our findings indicate that IL-6 is critically involved in the development of CIM.	cim	89-92	interleukin 6	Mus musculus	39-43
19346296-8	2009	Indeed, prior injection of RSV virtually completely attenuated the effects of C5a on vascular permeability, neutrophil migration, release of interleukin 1beta, tumor necrosis factor alpha, interleukin 6, and the chemokine MIP-1alpha.	Resveratrol	27-30	interleukin 6	Mus musculus	189-202
19492424-5	2009	Similarly, the in vivo administration of nontoxic doses of cisplatin prevents liver damage associated with a well-established murine model of hepatic I/R as measured by lower circulating serum aminotransferase levels, lower hepatic inflammatory cytokine levels including tumor necrosis factor alpha and interleukin-6, lower inducible NO synthase expression, and fewer I/R-associated histopathologic changes.	Cisplatin	59-68	interleukin 6	Mus musculus	303-316
19398040-3	2009	Zedoarondiol dose-dependently inhibited LPS-stimulated nitric oxide (NO), prostaglandin E(2) (PGE(2)), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) productions in RAW 264.7 macrophage and in mouse peritoneal macrophage cells.	zedoarondiol	0-12	interleukin 6	Mus musculus	144-157
19398040-3	2009	Zedoarondiol dose-dependently inhibited LPS-stimulated nitric oxide (NO), prostaglandin E(2) (PGE(2)), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) productions in RAW 264.7 macrophage and in mouse peritoneal macrophage cells.	zedoarondiol	0-12	interleukin 6	Mus musculus	159-163
19398040-4	2009	Consistent with these findings, in RAW 264.7 cells, zedoarondiol suppressed the LPS-stimulated protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and the mRNA expressions of iNOS, COX-2, TNF-alpha, IL-6, and IL-1beta in a concentration-dependent manner.	zedoarondiol	52-64	interleukin 6	Mus musculus	233-237
19462411-9	2009	Clodronate liposome-treated mice showed a large reduction in both IFN-beta and IL-6 levels.	Clodronic Acid	0-10	interleukin 6	Mus musculus	79-83
19423842-7	2009	Furthermore, vanillin reduced the expressions of proinflammatory cytokines [interleukin (IL)-1beta, IL-6, interferon-gamma, and tumor necrosis factor-alpha] and stimulated the expression of anti-inflammatory cytokine (IL-4) in colonic tissues.	vanillin	13-21	interleukin 6	Mus musculus	100-104
20628458-4	2009	The real-time quantitative RT-PCR and ELISA analyses showed that nano-anatase TiO2can significantly alter the mRNA and protein expressions of several inflammatory cytokines, including nucleic factor-kappaB, macrophage migration inhibitory factor, tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, cross-reaction protein, interleukin-4, and interleukin-10.	tio2can	78-85	interleukin 6	Mus musculus	276-289
19615666-8	2009	Cells grown on TCP and cpTi expressed an abundance of interleukin (IL-6) and IL-1alpha upon LPS exposure.	tcp	15-18	interleukin 6	Mus musculus	67-71
19477024-7	2009	The combination of N297A dosing with cyclosporine A (CSA) pretreatment showed a significant decrease of TNFalpha, IL-6 and IP-10 without effect on clinical efficacy.	Cyclosporine	37-51	interleukin 6	Mus musculus	114-118
19553536-5	2009	In addition, deficiency of ANXA1 was associated with impairment of the inhibitory effects of dexamethasone (DEX) on LPS-induced IL-6 and TNF in macrophages.	Dexamethasone	93-106	interleukin 6	Mus musculus	128-132
19553536-5	2009	In addition, deficiency of ANXA1 was associated with impairment of the inhibitory effects of dexamethasone (DEX) on LPS-induced IL-6 and TNF in macrophages.	Dexamethasone	108-111	interleukin 6	Mus musculus	128-132
19594948-4	2009	The in vitro experiment then showed that ASEA significantly reduced IL-6 and IL-1beta production and the NF-kappaB trans-activation activity of mitogen-stimulated RAW264.7 cells.	asea	41-45	interleukin 6	Mus musculus	68-72
19376889-6	2009	IL-6 Tg(+) mice exposed to 100% O(2) exhibited enhanced phosphatidylinositol 3-kinase (PI3K)/Akt kinase and increased serine phosphorylation of Bax at Ser(184) compared with WT mice.	o(2)	32-36	interleukin 6	Mus musculus	0-4
19376889-6	2009	IL-6 Tg(+) mice exposed to 100% O(2) exhibited enhanced phosphatidylinositol 3-kinase (PI3K)/Akt kinase and increased serine phosphorylation of Bax at Ser(184) compared with WT mice.	Serine	118-124	interleukin 6	Mus musculus	0-4
19376889-6	2009	IL-6 Tg(+) mice exposed to 100% O(2) exhibited enhanced phosphatidylinositol 3-kinase (PI3K)/Akt kinase and increased serine phosphorylation of Bax at Ser(184) compared with WT mice.	Serine	151-154	interleukin 6	Mus musculus	0-4
19376889-7	2009	The PI3K-specific inhibitor LY-2940002 blocked this IL-6-induced Bax phosphorylation and promoted cell death.	ly-2940002	28-38	interleukin 6	Mus musculus	52-56
19571388-14	2009	In addition, the inflammatory cytokines tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and interleukin (IL)-6 in the serum increased rapidly, within 3 h of the ConA administration, but the administration of syringic acid or vanillic acid significantly suppressed the cytokine levels.	syringic acid	219-232	interleukin 6	Mus musculus	103-121
19299453-6	2009	Moreover, IL-6, together with its soluble receptor (IL-6SR), could bypass the need for either amphiregulin and/or prostaglandin E2 to induce the expansion of COCs.	Dinoprostone	114-130	interleukin 6	Mus musculus	10-14
19363165-5	2009	Inhibition of alpha(1)-AR mediated IL-6 production and secretion by actinomycin D and the increase of intracellular IL-6 levels by alpha(1)-AR activation suggest that alpha(1)-AR mediated IL-6 secretion through de novo synthesis.	Dactinomycin	68-81	interleukin 6	Mus musculus	35-39
19582164-8	2009	Tumors formed by Calu6/beta2 cells in SCID/NOD mice, inoculated subcutaneously or orthotopically, were significantly smaller following IL-12 vs PBS treatment due to inhibition of angiogenesis, and of IL-6 and VEGF-C production.	Lead	144-147	interleukin 6	Mus musculus	200-204
19506106-12	2009	Pretreatment with rosiglitazone inhibited the Ang II-induced expression of angiotensin type 1a Ang II receptor while having no effect on the angiotensin type 2 Ang II receptor, in addition to reducing Ang II-induced expression of E-selectin, tumor necrosis factor-alpha, and interleukin-6.	Rosiglitazone	18-31	interleukin 6	Mus musculus	275-288
19181340-8	2009	The effects of dexmedetomidine on COX-2 expression and the production of PGE2, TNF-alpha, IL-1beta, IL-6, and IL-10 paralleled the effects of dexmedetomidine on iNOS.	Dexmedetomidine	15-30	interleukin 6	Mus musculus	100-104
19356732-6	2009	Atractylenolide I could dose-dependently inhibit the production of nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) activity in the flute of mouse air pouch and the peritoneal macrophages stimulated by lipopolysaccharide (LPS).	atractylenolide I	0-17	interleukin 6	Mus musculus	157-170
19356732-6	2009	Atractylenolide I could dose-dependently inhibit the production of nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) activity in the flute of mouse air pouch and the peritoneal macrophages stimulated by lipopolysaccharide (LPS).	atractylenolide I	0-17	interleukin 6	Mus musculus	172-176
18635336-6	2009	Using enzyme-linked immunosorbent assays, we showed DHMEQ to inhibit LPS-induced secretion of IL-6 and TNF-alpha.	dehydroxymethylepoxyquinomicin	52-57	interleukin 6	Mus musculus	94-98
19483311-6	2009	The increases in plasma concentrations of interleukin-6 suggest that the production of interleukin-6 by Pb administration is involved in the induction of MT in the liver.	Lead	104-106	interleukin 6	Mus musculus	42-55
19483311-6	2009	The increases in plasma concentrations of interleukin-6 suggest that the production of interleukin-6 by Pb administration is involved in the induction of MT in the liver.	Lead	104-106	interleukin 6	Mus musculus	87-100
19373235-6	2009	Resveratrol inhibited the Ang II-induced cAMP-response element-binding protein and nuclear factor-kappa B activity, which are critical for Ang II-induced IL-6 gene activation.	Cyclic AMP	41-45	interleukin 6	Mus musculus	154-158
19373235-7	2009	An increase in the serum concentration of IL-6 induced by Ang II infusion was attenuated by an oral administration of resveratrol.	Resveratrol	118-129	interleukin 6	Mus musculus	42-46
19110542-3	2009	In contrast, IL-6 was required for the attenuation of UVB- or cis-urocanic acid-induced immunosuppression by sequential or concomitant UVA irradiation.	cis-Urocanic acid	62-79	interleukin 6	Mus musculus	13-17
19110542-4	2009	The IL-6 was essential for several reactions previously established to be relevant for UVA photoimmune protection, namely the induction of heme oxygenase-1 (HO-1), the activity of its product carbon monoxide in activating guanylyl cyclase, and the consequent elevation of cutaneous cyclic guanosine monophosphate concentration.	Carbon Monoxide	192-207	interleukin 6	Mus musculus	4-8
19110542-4	2009	The IL-6 was essential for several reactions previously established to be relevant for UVA photoimmune protection, namely the induction of heme oxygenase-1 (HO-1), the activity of its product carbon monoxide in activating guanylyl cyclase, and the consequent elevation of cutaneous cyclic guanosine monophosphate concentration.	Cyclic GMP	282-312	interleukin 6	Mus musculus	4-8
19885031-7	2009	The gene expression of interleukin-6 (IL-6) and transforming growth factor-beta (TGF-beta) in isoproterenol-infused wild-type was measured at 2, 4, 24, and 48-hour and isoproterenol increased both IL-6 (2, 4, 24, and 48-hour) and TGF-beta (4 and 24-hour).	Isoproterenol	94-107	interleukin 6	Mus musculus	23-36
19885031-7	2009	The gene expression of interleukin-6 (IL-6) and transforming growth factor-beta (TGF-beta) in isoproterenol-infused wild-type was measured at 2, 4, 24, and 48-hour and isoproterenol increased both IL-6 (2, 4, 24, and 48-hour) and TGF-beta (4 and 24-hour).	Isoproterenol	94-107	interleukin 6	Mus musculus	38-42
19885031-7	2009	The gene expression of interleukin-6 (IL-6) and transforming growth factor-beta (TGF-beta) in isoproterenol-infused wild-type was measured at 2, 4, 24, and 48-hour and isoproterenol increased both IL-6 (2, 4, 24, and 48-hour) and TGF-beta (4 and 24-hour).	Isoproterenol	168-181	interleukin 6	Mus musculus	23-36
19885031-8	2009	Isoproterenol infusion for 7 days increased the mRNA level of IL-6 and TGF-beta in iNOS KO mice, whereas the gene expression in wild-type mice was not increased.	Isoproterenol	0-13	interleukin 6	Mus musculus	62-66
19449457-4	2009	We found that key regulators of iron homeostasis, hepcidin and IL-6, were increased in gangliosidoses mice.	Iron	32-36	interleukin 6	Mus musculus	63-67
19336499-0	2009	Role of GRP78/BiP degradation and ER stress in deoxynivalenol-induced interleukin-6 upregulation in the macrophage.	deoxynivalenol	47-61	interleukin 6	Mus musculus	70-83
19336499-1	2009	The trichothecene mycotoxin deoxynivalenol (DON) induces systemic expression of the interleukin-6 (IL-6) and other proinflammatory cytokines in the mouse.	Trichothecenes	4-17	interleukin 6	Mus musculus	84-97
19336499-1	2009	The trichothecene mycotoxin deoxynivalenol (DON) induces systemic expression of the interleukin-6 (IL-6) and other proinflammatory cytokines in the mouse.	Trichothecenes	4-17	interleukin 6	Mus musculus	99-103
19336499-1	2009	The trichothecene mycotoxin deoxynivalenol (DON) induces systemic expression of the interleukin-6 (IL-6) and other proinflammatory cytokines in the mouse.	deoxynivalenol	28-42	interleukin 6	Mus musculus	84-97
19336499-1	2009	The trichothecene mycotoxin deoxynivalenol (DON) induces systemic expression of the interleukin-6 (IL-6) and other proinflammatory cytokines in the mouse.	deoxynivalenol	28-42	interleukin 6	Mus musculus	99-103
19336499-1	2009	The trichothecene mycotoxin deoxynivalenol (DON) induces systemic expression of the interleukin-6 (IL-6) and other proinflammatory cytokines in the mouse.	deoxynivalenol	44-47	interleukin 6	Mus musculus	84-97
19336499-1	2009	The trichothecene mycotoxin deoxynivalenol (DON) induces systemic expression of the interleukin-6 (IL-6) and other proinflammatory cytokines in the mouse.	deoxynivalenol	44-47	interleukin 6	Mus musculus	99-103
19336499-2	2009	The purpose of this study was to test the hypothesis that DON triggers an endoplasmic reticulum (ER) stress response in murine macrophages capable of driving IL-6 gene expression.	deoxynivalenol	58-61	interleukin 6	Mus musculus	158-162
19336499-8	2009	GRP78 is critical to the regulation of the two transcription factors, X-box binding protein 1 (XBP1) and activating transcription factor 6 (ATF6), which bind to cAMP-response element (CRE) and drive expression of CRE-dependent genes such as IL-6.	Cyclic AMP	161-165	interleukin 6	Mus musculus	241-245
19336499-10	2009	Knockdown of ATF6 but not XBP1 partially inhibited DON-induced IL-6 expression in the macrophages.	deoxynivalenol	51-54	interleukin 6	Mus musculus	63-67
19336499-12	2009	Taken together, these data suggest that in the macrophage DON induces GRP78 degradation and evokes an ER stress response that could contribute, in part, to DON-induced IL-6 gene expression.	deoxynivalenol	58-61	interleukin 6	Mus musculus	168-172
19336499-12	2009	Taken together, these data suggest that in the macrophage DON induces GRP78 degradation and evokes an ER stress response that could contribute, in part, to DON-induced IL-6 gene expression.	deoxynivalenol	156-159	interleukin 6	Mus musculus	168-172
19443690-0	2009	Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2,4,6,-trinitrobenzensulphonic acid-induced colitis.	2,4,6,-trinitrobenzensulphonic acid	85-120	interleukin 6	Mus musculus	20-24
19443690-10	2009	We also found that supernatants from NT-exposed 3T3-L1-NTR1 preadipocytes and mesenteric fat obtained from wild-type mice 2 days after TNBS administration stimulate an IL-6-dependent macrophage migration measured by a macrophage migration assay, whereas this response is reduced when mesenteric fat from NT KO mice is used.	Trinitrobenzenesulfonic Acid	135-139	interleukin 6	Mus musculus	168-172
19450258-9	2009	Decreased sensitivity to carbachol was associated with increased expression of IL-4 and IL-6 mRNA in jejunum.	Carbachol	25-34	interleukin 6	Mus musculus	88-92
19292976-2	2009	The flavonoid fisetin significantly reduced lung myeloperoxidase-levels and gene-expression of inflammatory mediators such as IL-6, TNF-alpha, IL-1beta, MIP-1alpha and MIP-2.	Flavonoids	4-13	interleukin 6	Mus musculus	126-130
18842266-4	2009	Mice fed the lowest omega-6:EPA+DHA ratio diet had lower circulating concentrations of non-HDL cholesterol (25%, P&lt;0.05) and interleukin-6 (IL-6) (44%, P&lt;0.05) compared to mice fed the HSF omega-6 diet.	omega-6	20-27	interleukin 6	Mus musculus	128-141
18842266-4	2009	Mice fed the lowest omega-6:EPA+DHA ratio diet had lower circulating concentrations of non-HDL cholesterol (25%, P&lt;0.05) and interleukin-6 (IL-6) (44%, P&lt;0.05) compared to mice fed the HSF omega-6 diet.	omega-6	20-27	interleukin 6	Mus musculus	143-147
18842266-4	2009	Mice fed the lowest omega-6:EPA+DHA ratio diet had lower circulating concentrations of non-HDL cholesterol (25%, P&lt;0.05) and interleukin-6 (IL-6) (44%, P&lt;0.05) compared to mice fed the HSF omega-6 diet.	dehydroacetic acid	32-35	interleukin 6	Mus musculus	128-141
18842266-4	2009	Mice fed the lowest omega-6:EPA+DHA ratio diet had lower circulating concentrations of non-HDL cholesterol (25%, P&lt;0.05) and interleukin-6 (IL-6) (44%, P&lt;0.05) compared to mice fed the HSF omega-6 diet.	dehydroacetic acid	32-35	interleukin 6	Mus musculus	143-147
19442625-9	2009	Furthermore, in the presence of the selective cyclooxygenase-1 and -2 inhibitors SC-560 and NS-398 thrombin-induced interleukin-6 release was prevented.	SC 560	81-87	interleukin 6	Mus musculus	116-129
19442625-9	2009	Furthermore, in the presence of the selective cyclooxygenase-1 and -2 inhibitors SC-560 and NS-398 thrombin-induced interleukin-6 release was prevented.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	92-98	interleukin 6	Mus musculus	116-129
19442625-11	2009	Treatment of isolated osteoblast-like cells with a number of synthetic prostanoids stimulated secretion of interleukin-6 with differing potencies.	Prostaglandins	71-82	interleukin 6	Mus musculus	107-120
19325483-16	2009	CONCLUSIONS: Impaired gp130 phosphorylation may be responsible for IL-6 hyporesponsiveness during sepsis.	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	22-27	interleukin 6	Mus musculus	67-71
19416670-5	2009	CINN effectively inhibited the production of tumor necrosis factor alpha (TNF-alpha), nitrite/nitrate, interleukin-6 (IL-6) in lipopolysaccharide (LPS)-stimulated RAW 264.7 and BV2 cells (P&lt;0.05, respectively).	cinn	0-4	interleukin 6	Mus musculus	103-116
19416670-5	2009	CINN effectively inhibited the production of tumor necrosis factor alpha (TNF-alpha), nitrite/nitrate, interleukin-6 (IL-6) in lipopolysaccharide (LPS)-stimulated RAW 264.7 and BV2 cells (P&lt;0.05, respectively).	cinn	0-4	interleukin 6	Mus musculus	118-122
19289654-10	2009	Telmisartan also attenuated serum IL-6 level in TNF-alpha-infused mice and IL-6 production from rat aorta stimulated with TNF-alpha ex vivo.	Telmisartan	0-11	interleukin 6	Mus musculus	34-38
19289654-10	2009	Telmisartan also attenuated serum IL-6 level in TNF-alpha-infused mice and IL-6 production from rat aorta stimulated with TNF-alpha ex vivo.	Telmisartan	0-11	interleukin 6	Mus musculus	75-79
19320827-10	2009	In these mice treated with LPS plus MPC1609, higher blood urea nitrogen (BUN) and creatinine levels suggested that an acute renal failure might contribute to a slow clearance of IL-6.	mpc1609	36-43	interleukin 6	Mus musculus	178-182
19299019-9	2009	These results highlight the complex role of STAT3 in cytokine production and the key role of STAT3 tyrosine phosphorylation in IL-1beta and IL-6 production in response to inflammation.	Tyrosine	99-107	interleukin 6	Mus musculus	140-144
19190174-6	2009	DSS induced a T(H)2 colitis [increased interleukin (IL)-4 and IL-6] with no changes in T(H)1 cytokines.	Dextran Sulfate	0-3	interleukin 6	Mus musculus	62-66
19107859-5	2009	Treatment with PE (10 approximately 50 microg/ml) decreased the TNF-alpha (10(-10) M)-induced production of IL-6 and NO in osteoblasts.	Coconut Oil	15-17	interleukin 6	Mus musculus	108-112
19660045-8	2009	PHx caused a transient increase in tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6 levels and led to weight loss, reflecting the host"s overall response to surgery.	PHX	0-3	interleukin 6	Mus musculus	79-97
19299915-4	2009	Inhibition of JNK by the JNK inhibitor SP600125 induced MMP-9 in the absence of serum and suppressed the expression of TNF-alpha, IL-6 and cyclooxygenase-2 in LPS-treated Raw 264.7 cells.	pyrazolanthrone	39-47	interleukin 6	Mus musculus	130-134
19371610-13	2009	UFP-induced ROS lead to activation of MAPKs through induced phosphorylation of p38 and ERK1/2 MAPKs that may further result in endothelial dysfunction through production of cytokines such as IL-6.	Reactive Oxygen Species	12-15	interleukin 6	Mus musculus	191-195
19251417-2	2009	Elevated levels of IFN-gamma and IL-6 were produced in spleen cells from mice immunised with a C(32) MMG analogue comparable activity to the potent Th1 adjuvant, trehalose 6,6"-di-behenate (TDB).	trehalose 6,6'-dibehenate	162-188	interleukin 6	Mus musculus	33-37
19336883-6	2009	Our results demonstrated that 5-hydroxytryptophan inhibited the lipopolysaccharide (LPS)-induced expression of NO and IL-6.	5-Hydroxytryptophan	30-49	interleukin 6	Mus musculus	118-122
19036857-3	2009	Whereas extracellular poly I:C (naked poly I:C) mainly induced the expression of regulated on activation normal T-cell expressed and secreted (RANTES), interleukin-8 (IL-8), and tumor necrosis factor alpha (TNF-alpha), intracellular delivery of poly I:C (complexed poly I:C) chiefly induced expression of IFN-beta and IL-6.	Poly I-C	22-30	interleukin 6	Mus musculus	318-322
19036857-3	2009	Whereas extracellular poly I:C (naked poly I:C) mainly induced the expression of regulated on activation normal T-cell expressed and secreted (RANTES), interleukin-8 (IL-8), and tumor necrosis factor alpha (TNF-alpha), intracellular delivery of poly I:C (complexed poly I:C) chiefly induced expression of IFN-beta and IL-6.	Poly I-C	38-46	interleukin 6	Mus musculus	318-322
19036857-3	2009	Whereas extracellular poly I:C (naked poly I:C) mainly induced the expression of regulated on activation normal T-cell expressed and secreted (RANTES), interleukin-8 (IL-8), and tumor necrosis factor alpha (TNF-alpha), intracellular delivery of poly I:C (complexed poly I:C) chiefly induced expression of IFN-beta and IL-6.	Poly I-C	38-46	interleukin 6	Mus musculus	318-322
19036857-3	2009	Whereas extracellular poly I:C (naked poly I:C) mainly induced the expression of regulated on activation normal T-cell expressed and secreted (RANTES), interleukin-8 (IL-8), and tumor necrosis factor alpha (TNF-alpha), intracellular delivery of poly I:C (complexed poly I:C) chiefly induced expression of IFN-beta and IL-6.	Poly I-C	38-46	interleukin 6	Mus musculus	318-322
19164130-5	2009	Furthermore, ATP induces expression of several cytokines and chemokines in these cells, including IL-4, IL-6, IFN-gamma, TNF-alpha, RANTES, and MIP-2, at the mRNA level.	Adenosine Triphosphate	13-16	interleukin 6	Mus musculus	104-108
19164426-9	2009	We also confirmed that systemic administration of anti-il-6 receptor antibody ameliorates EAU By suppressing both systemic and regional TH17 responses.	Water	90-93	interleukin 6	Mus musculus	55-59
19428830-3	2009	In vitro, the adjuvant combination of CpG ODN, indolicidin and polyphosphazene (CpG/indol/PP) enhanced the secretion of TNF-alpha, IL-12p40, and IL-6 by bone marrow-derived DCs (BMDCs) when compared to the individual components.	poly(phosphazene)	63-78	interleukin 6	Mus musculus	145-149
19428830-3	2009	In vitro, the adjuvant combination of CpG ODN, indolicidin and polyphosphazene (CpG/indol/PP) enhanced the secretion of TNF-alpha, IL-12p40, and IL-6 by bone marrow-derived DCs (BMDCs) when compared to the individual components.	indole	47-52	interleukin 6	Mus musculus	145-149
19138716-5	2009	Atypical antipsychotics, such as clozapine, olanzapine and risperidone, but not haloperidol, suppressed tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, and up-regulated IL-10.	Clozapine	33-42	interleukin 6	Mus musculus	142-160
19138716-5	2009	Atypical antipsychotics, such as clozapine, olanzapine and risperidone, but not haloperidol, suppressed tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, and up-regulated IL-10.	Olanzapine	44-54	interleukin 6	Mus musculus	142-160
19138716-5	2009	Atypical antipsychotics, such as clozapine, olanzapine and risperidone, but not haloperidol, suppressed tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, and up-regulated IL-10.	Risperidone	59-70	interleukin 6	Mus musculus	142-160
19174151-2	2009	Pretreatment of microglial cells with tBHQ, a phenolic antioxidant activating Nrf2, attenuated the LPS-derived overproduction of pro-inflammatory neurotoxic mediators like TNF-alpha, IL-1beta, IL-6, PGE(2), and NO as well as the morphological changes associated with microglial hyperactivation.	2-tert-butylhydroquinone	38-42	interleukin 6	Mus musculus	193-197
19174150-5	2009	We found that 1,5-AF pretreatment attenuated cytokine release into the serum, including TNF-alpha, IL-6 and macrophage chemoattractant protein (MCP)-1.	1,5-anhydrofructose	14-20	interleukin 6	Mus musculus	99-103
18776134-3	2009	We hypothesized that SOCS-1 is a critical regulator and key mediator of IL-6-induced cytoprotection in HALI.	hali	103-107	interleukin 6	Mus musculus	72-76
18776134-8	2009	In addition, IL-6 Tg(+) mice exposed to 100% oxygen exhibited reduced ASK-1 levels and enhanced SOCS-1 expression compared with wild-type mice.	Oxygen	45-51	interleukin 6	Mus musculus	13-17
18776134-11	2009	These studies demonstrate that SOCS-1 is an important regulator in IL-6-induced cytoprotection against HALI.	hali	103-107	interleukin 6	Mus musculus	67-71
18603252-6	2009	Of importance, treatment with ezetimibe significantly improved endothelial dysfunction as assessed by the vasodilator response to acetylcholine, accompanied by inhibition of interleukin-6 mRNA and an increase in endothelial nitric oxide synthase (eNOS) mRNA in the aorta.	Ezetimibe	30-39	interleukin 6	Mus musculus	174-187
19162127-6	2009	The stimulatory effect of ET-1 on IL-6 secretion was abolished by actinomycin D and ET-1 induced an increase in IL-6 mRNA levels.	Dactinomycin	66-79	interleukin 6	Mus musculus	34-38
19162127-7	2009	ET-1 was able to enhance the IL-6 promoter activity and its stimulatory effect was inhibited by GF109203X, U0126, salicylate, dominant negative CREB and mithramycin A.	U 0126	107-112	interleukin 6	Mus musculus	29-33
19162127-7	2009	ET-1 was able to enhance the IL-6 promoter activity and its stimulatory effect was inhibited by GF109203X, U0126, salicylate, dominant negative CREB and mithramycin A.	Salicylates	114-124	interleukin 6	Mus musculus	29-33
19162127-7	2009	ET-1 was able to enhance the IL-6 promoter activity and its stimulatory effect was inhibited by GF109203X, U0126, salicylate, dominant negative CREB and mithramycin A.	mithramycin A	153-166	interleukin 6	Mus musculus	29-33
19162319-5	2009	However, co-stimulation with the bacterial endotoxin lipopolysaccharide (LPS) and TEGDMA resulted in a concentration-dependent inhibition of LPS-induced release of TNF-alpha, IL-6, and IL-10 by about 90% as detected by ELISA.	triethylene glycol dimethacrylate	82-88	interleukin 6	Mus musculus	175-179
19220291-7	2009	Compared with placebo, plasma levels of interleukin-6, monocyte chemoattractant protein-1, interferon gamma, tumour necrosis factor alpha and CD40, and their mRNA levels in aortic tissue were significantly reduced in sirolimus-treated mice.	Sirolimus	217-226	interleukin 6	Mus musculus	40-53
19184347-6	2009	A considerable reduction in the cytokine and chemokine production, mostly TNFalpha, IL-1beta and IL-6 production in the MPM-treated group, suggested an inhibition of the mediators responsible for leukocyte extravasation.	mpm	120-123	interleukin 6	Mus musculus	97-101
19234212-4	2009	We found that IDO knockout (IDO(-/-)) mice and 1-methyl-D-tryptophan-treated, endotoxin-shocked mice had decreased levels of the cytokines, TNF-alpha, IL-6, and IL-12, and enhanced levels of IL-10.	1-methyltryptophan	47-68	interleukin 6	Mus musculus	151-155
19519162-10	2009	Those studies showed cooperative effects between Pam(3)CSK(4) (Pam(3)) and CpG ODN (CpG-oligodeoxynucleotide) on the induction of IL-6 synthesis by C3H/HeJ spleen cells.	CPG-oligonucleotide	84-108	interleukin 6	Mus musculus	130-134
19066339-10	2009	sFas expression also attenuated Dox-mediated induction of proinflammatory cytokines, tumor necrosis factor-alpha, interleukin (IL)-1beta, and IL-6 in the myocardium.	Doxorubicin	32-35	interleukin 6	Mus musculus	142-146
18665050-10	2009	The addition of ZnPP to inhibit HO-1 partially restored MCP-1 and IL-6 secretion in murine macrophages.	zinc protoporphyrin	16-20	interleukin 6	Mus musculus	66-70
18665050-12	2009	In summary, HBOC incubation of macrophages induced HO-1 expression, which reduced LPS-mediated cytokine release, and that MCP-1 and IL-6 secretion could be partially restored with ZnPP.	zinc protoporphyrin	180-184	interleukin 6	Mus musculus	132-136
19282653-7	2009	Treatment of BMMCs for 3 weeks with montelukast, which caused long-term inhibition of the autocrine cyteinyl LT-derived signal, significantly attenuated the IgE/Ag-dependent degranulation, as judged by the decrease in the release of beta-hexosaminidase, an enzyme contained in the granules, whereas the production of cytokines, such as IL-6 and tumor necrosis factor-alpha, were largely unaffected.	montelukast	36-47	interleukin 6	Mus musculus	336-372
19228423-0	2009	Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J mice.	Tyrosine	18-26	interleukin 6	Mus musculus	38-42
19131594-1	2009	Cytokines such as interleukin-6 induce tyrosine and serine phosphorylation of Stat3 that results in activation of Stat3-responsive genes.	Tyrosine	39-47	interleukin 6	Mus musculus	18-31
19131594-1	2009	Cytokines such as interleukin-6 induce tyrosine and serine phosphorylation of Stat3 that results in activation of Stat3-responsive genes.	Serine	52-58	interleukin 6	Mus musculus	18-31
18688039-5	2009	CS exposure increased the levels of RelB and NF-kappaB-inducing kinase associated with recruitment of RelB on promoters of the IL-6 and macrophage inflammatory protein-2 genes in mouse lung.	Cesium	0-2	interleukin 6	Mus musculus	127-131
19693648-0	2010	Lycopene suppresses LPS-induced NO and IL-6 production by inhibiting the activation of ERK, p38MAPK, and NF-kappaB in macrophages.	Lycopene	0-8	interleukin 6	Mus musculus	39-43
19693648-3	2010	RESULTS: Lycopene inhibited LPS-induced production of nitric oxide (NO) and interleukin-6 (IL-6) with decreased mRNAs of inducible nitric oxide synthase and IL-6 but had no effect on TNF-alpha.	Lycopene	9-17	interleukin 6	Mus musculus	76-89
19693648-3	2010	RESULTS: Lycopene inhibited LPS-induced production of nitric oxide (NO) and interleukin-6 (IL-6) with decreased mRNAs of inducible nitric oxide synthase and IL-6 but had no effect on TNF-alpha.	Lycopene	9-17	interleukin 6	Mus musculus	91-95
19693648-3	2010	RESULTS: Lycopene inhibited LPS-induced production of nitric oxide (NO) and interleukin-6 (IL-6) with decreased mRNAs of inducible nitric oxide synthase and IL-6 but had no effect on TNF-alpha.	Lycopene	9-17	interleukin 6	Mus musculus	157-161
20091060-5	2010	RESULTS: Turpentine injection increased serum IL-6 levels.	Turpentine	9-19	interleukin 6	Mus musculus	46-50
19831872-8	2010	Taurine significantly decreased IL-6 and MPO levels in a dose-dependent manner, significantly reducing the phosphorylation of STAT3 and expression of COX-2 after SCI compared to controls.	Taurine	0-7	interleukin 6	Mus musculus	32-36
19774506-4	2010	Consistent with these observations, madecassic acid inhibited the LPS-induced expression of iNOS and COX-2 at the protein level and of iNOS, COX-2, TNF-alpha, IL-1beta, and IL-6 at the mRNA level in RAW 264.7 macrophage cells, as determined by Western blotting and RT-PCR, respectively.	madecassic acid	36-51	interleukin 6	Mus musculus	173-177
19774506-6	2010	These results suggest that the anti-inflammatory properties of madecassic acid are caused by iNOS, COX-2, TNF-alpha, IL-1beta, and IL-6 inhibition via the downregulation of NF-kappaB activation in RAW 264.7 macrophage cells.	madecassic acid	63-78	interleukin 6	Mus musculus	131-135
19874834-8	2010	The serum levels of interleukin-1beta, interleukin-6 and TNF-alpha were significantly increased in arsenic-exposed groups, while in the arsenic-exposed and jaggery supplemented groups their levels were normal.	Arsenic	99-106	interleukin 6	Mus musculus	39-52
19931343-7	2010	Examination of cytokine expression levels from lungs of bortezomib treated HRSV-infected mice revealed an increase in G-CSF, IL-6, MCP-1, and RANTES levels and a decrease in total IL-12 compared to mock treated-infected control animals.	Bortezomib	56-66	interleukin 6	Mus musculus	125-129
20111595-5	2010	In comparison to control animals, we observed significant changes in the colon mucosa of DSS-treated TC-PTP(+/-) mice, in the ratio of colon to body weight, as well as an up-regulation of mRNA transcripts for IL-6, IL-23, 1L-12beta, IFN-gamma, TNF-alpha.	Dextran Sulfate	89-92	interleukin 6	Mus musculus	209-213
20111595-6	2010	Moreover, up-regulation of serum IL-6 levels in DSS-treated TC-PTP(+/-) mice confirms that mice with a single copy of the TC-PTP gene display increased susceptibility to systemic inflammation due to bowel epithelial erosion resulting from DSS challenge.	Dextran Sulfate	48-51	interleukin 6	Mus musculus	33-37
20111595-6	2010	Moreover, up-regulation of serum IL-6 levels in DSS-treated TC-PTP(+/-) mice confirms that mice with a single copy of the TC-PTP gene display increased susceptibility to systemic inflammation due to bowel epithelial erosion resulting from DSS challenge.	Dextran Sulfate	239-242	interleukin 6	Mus musculus	33-37
20026303-2	2010	In present study, carabrol demonstrated the inhibitory activity on pro-inflammatory cytokines such as IL-1beta, IL-6 and TNF-alpha.	carabrol	18-26	interleukin 6	Mus musculus	112-116
19897006-7	2010	TiO2 and TiO2-silica stimulated the expression of IL-6, MIP-1alpha and TNF-alpha in macrophages, and increased their maturation, antigen presentation and co-stimulation activity.	titanium dioxide	0-4	interleukin 6	Mus musculus	50-54
19897006-7	2010	TiO2 and TiO2-silica stimulated the expression of IL-6, MIP-1alpha and TNF-alpha in macrophages, and increased their maturation, antigen presentation and co-stimulation activity.	tio2-silica	9-20	interleukin 6	Mus musculus	50-54
20023693-10	2010	Atorvastatin treatment decreased expression of IL-6, TNF-alpha, nuclear factor kappaB (NF-kappaB) and I-kappa-B (IkappaB) kinase-beta, but increased the expression of IkappaB, in adipose tissue.	Atorvastatin	0-12	interleukin 6	Mus musculus	47-51
20008131-6	2010	Increased cutaneous production of interleukin-6, tumor necrosis factor-alpha, and platelet-derived chemokines during Arthus reaction was inhibited in busulfan-treated wild-type mice relative to untreated mice, which paralleled the reduction in cutaneous inflammation.	Busulfan	150-158	interleukin 6	Mus musculus	34-76
20008137-0	2010	The absence of interleukin-6 enhanced arsenite-induced renal injury by promoting autophagy of tubular epithelial cells with aberrant extracellular signal-regulated kinase activation.	arsenite	38-46	interleukin 6	Mus musculus	15-28
20008137-1	2010	Sodium arsenite (NaAs)-induced autophagic cell death (ACD) of a mouse renal tubular epithelial cell line (mProx24), which expresses enhanced levels of interleukin-6 (IL-6), was reduced by the suppression of autophagy by 3-methyladenine or Atg7 knockdown.	sodium arsenite	0-15	interleukin 6	Mus musculus	151-164
20008137-1	2010	Sodium arsenite (NaAs)-induced autophagic cell death (ACD) of a mouse renal tubular epithelial cell line (mProx24), which expresses enhanced levels of interleukin-6 (IL-6), was reduced by the suppression of autophagy by 3-methyladenine or Atg7 knockdown.	sodium arsenite	0-15	interleukin 6	Mus musculus	166-170
20008137-1	2010	Sodium arsenite (NaAs)-induced autophagic cell death (ACD) of a mouse renal tubular epithelial cell line (mProx24), which expresses enhanced levels of interleukin-6 (IL-6), was reduced by the suppression of autophagy by 3-methyladenine or Atg7 knockdown.	naas	17-21	interleukin 6	Mus musculus	151-164
20008137-1	2010	Sodium arsenite (NaAs)-induced autophagic cell death (ACD) of a mouse renal tubular epithelial cell line (mProx24), which expresses enhanced levels of interleukin-6 (IL-6), was reduced by the suppression of autophagy by 3-methyladenine or Atg7 knockdown.	naas	17-21	interleukin 6	Mus musculus	166-170
20008137-1	2010	Sodium arsenite (NaAs)-induced autophagic cell death (ACD) of a mouse renal tubular epithelial cell line (mProx24), which expresses enhanced levels of interleukin-6 (IL-6), was reduced by the suppression of autophagy by 3-methyladenine or Atg7 knockdown.	3-methyladenine	220-235	interleukin 6	Mus musculus	151-164
20008137-2	2010	The inhibition of the IL-6/signal transducer and activator of transcription 3 (STAT3) signal pathway by anti-IL-6 antibody or a Jak2 inhibitor (AG490) exaggerated ACD of mProx24 cells after NaAs challenge, attenuating STAT3 activation and reciprocally enhancing extracellular signal-regulated kinase (ERK) phosphorylation.	naas	190-194	interleukin 6	Mus musculus	22-26
20008137-4	2010	Subcutaneous injection of NaAs (12.5 mg/kg) into BALB/c (wild-type) mice enhanced intrarenal expression of IL-6, mainly produced by tubular cells, and caused severe renal injury characterized by hemorrhages, acute tubular necrosis, cast formation, and brush border disappearance, with increases in serum urea nitrogen (blood urea nitrogen) and creatinine levels.	naas	26-30	interleukin 6	Mus musculus	107-111
20008137-5	2010	In addition, IL-6-deficient (IL-6(-/-)) mice exhibited exaggerated histopathological changes with higher blood urea nitrogen and creatinine levels.	Urea	111-115	interleukin 6	Mus musculus	13-17
20008137-5	2010	In addition, IL-6-deficient (IL-6(-/-)) mice exhibited exaggerated histopathological changes with higher blood urea nitrogen and creatinine levels.	Urea	111-115	interleukin 6	Mus musculus	29-33
20008137-5	2010	In addition, IL-6-deficient (IL-6(-/-)) mice exhibited exaggerated histopathological changes with higher blood urea nitrogen and creatinine levels.	Nitrogen	116-124	interleukin 6	Mus musculus	13-17
20008137-5	2010	In addition, IL-6-deficient (IL-6(-/-)) mice exhibited exaggerated histopathological changes with higher blood urea nitrogen and creatinine levels.	Nitrogen	116-124	interleukin 6	Mus musculus	29-33
20008137-5	2010	In addition, IL-6-deficient (IL-6(-/-)) mice exhibited exaggerated histopathological changes with higher blood urea nitrogen and creatinine levels.	Creatinine	129-139	interleukin 6	Mus musculus	13-17
20008137-5	2010	In addition, IL-6-deficient (IL-6(-/-)) mice exhibited exaggerated histopathological changes with higher blood urea nitrogen and creatinine levels.	Creatinine	129-139	interleukin 6	Mus musculus	29-33
20008137-6	2010	Moreover, in IL-6(-/-) mice treated with NaAs, ACD in renal tubular cells was significantly augmented, along with diminished STAT3 activation and reciprocal enhancement of ERK signaling, compared with wild-type mice.	naas	41-45	interleukin 6	Mus musculus	13-17
20008137-7	2010	Finally, the administration of exogenous IL-6 into wild-type mice significantly reduced NaAs-induced ACD along with diminished ERK activation and eventually alleviated acute renal dysfunction.	naas	88-92	interleukin 6	Mus musculus	41-45
20008137-8	2010	Thus, IL-6/STAT3 signal pathway could inhibit ERK activation, a crucial step for ACD, eventually attenuating NaAs-induced renal dysfunction.	naas	109-113	interleukin 6	Mus musculus	6-10
20039434-10	2010	The production of IL-17, TNFalpha, IL-6, and interferon-gamma by lymph node cells and spleen cells from these mice was markedly reduced by treatment with SFN.	sulforaphane	154-157	interleukin 6	Mus musculus	35-39
20834144-5	2010	The fucoidan induced production of nitric oxide, tumor necrosis factor-alpha, and interleukin-6 in RAW 264.7 cells.	fucoidan	4-12	interleukin 6	Mus musculus	82-95
19822999-10	2010	The IL-6 levels were also significantly decreased by the high-CHO diet (p &lt; 0.05).	CAV protocol	62-65	interleukin 6	Mus musculus	4-8
19883714-11	2010	EGCG also increased plasma interleukin-6 and monocyte chemoattractant protein-1.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	27-40
20034026-8	2010	Furthermore, the results obtained in mice treated with DEN to induce hepatocarcinogenesis showed, after treatment with a PARP inhibitor (DPQ), a significant reduction both in preneoplastic foci and in the expression of preneoplastic markers and proinflammatory genes (Gstm3, Vegf, Spp1 [Opn], IL6, IL1b, and Tnf), bromodeoxyuridine incorporation, and NF-kappaB activation in the initial steps of carcinogenesis (P &lt; 0.05).	3,4-dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone	137-140	interleukin 6	Mus musculus	293-296
19824919-7	2010	Notably, Al(OH)(3) specifically induced the release of a significant amount of interleukin (IL)-5, whereas DDA/MPL induced high amounts of tumour necrosis factor-alpha (TNF-alpha), IL-1alpha and IL-6.	al(oh)	9-15	interleukin 6	Mus musculus	195-199
20146564-5	2010	WBH directly targets liver and adipose tissue, resulting in modifications in NF-kappaB and IL-6 signalling pathways, as well as lipid metabolism.	wbh	0-3	interleukin 6	Mus musculus	91-95
22084591-5	2010	We have also found that Suppressor of Cytokine Signaling 3 (SOCS3)-known to interact with phosphotyrosine-containing peptides and be selectively induced by interleukin 6 (IL-6)-binds mouse IDO, recruits the ECS (Elongin-Cullin-SOCS) E3 ligase, and targets the IDO/SOCS3 complex for proteasomal degradation.	Phosphotyrosine	90-105	interleukin 6	Mus musculus	156-169
22084591-5	2010	We have also found that Suppressor of Cytokine Signaling 3 (SOCS3)-known to interact with phosphotyrosine-containing peptides and be selectively induced by interleukin 6 (IL-6)-binds mouse IDO, recruits the ECS (Elongin-Cullin-SOCS) E3 ligase, and targets the IDO/SOCS3 complex for proteasomal degradation.	Phosphotyrosine	90-105	interleukin 6	Mus musculus	171-175
20375552-0	2010	Activity of lymphocyte subpopulations in polymicrobial sepsis and DHEA treatment in IL-6 knockout mice.	Dehydroepiandrosterone	66-70	interleukin 6	Mus musculus	84-88
20706659-9	2010	Melatonin could also decrease the IL-6 and IL-13 production and increase the IL-2 production.	Melatonin	0-9	interleukin 6	Mus musculus	34-38
19626424-6	2010	Furthermore, we examined the ability of the cells to release cytokine when stimulated with both nicotine and LPS and showed that the stimulation with LPS augmented the secretion of IL-1a, IL-1b, IL-6, and TNF-alpha.	Nicotine	96-104	interleukin 6	Mus musculus	195-199
20588062-8	2010	High-dose LC treatment also led to increases in serum creatinine and tumor necrosis factor-alpha levels, and marked increases in interleukin-6 and MCP-1 expression as well as cellular apoptosis in the kidneys.	Leu-Cys	10-12	interleukin 6	Mus musculus	129-142
20160430-8	2010	Immune-like functions of FS cells were impaired since curcumin downregulated Toll-like receptor 4, reduced nuclear factor-kappaB expression and suppressed bacterial endotoxin-induced interleukin-6 (IL-6) secretion.	Curcumin	54-62	interleukin 6	Mus musculus	183-196
20160430-8	2010	Immune-like functions of FS cells were impaired since curcumin downregulated Toll-like receptor 4, reduced nuclear factor-kappaB expression and suppressed bacterial endotoxin-induced interleukin-6 (IL-6) secretion.	Curcumin	54-62	interleukin 6	Mus musculus	198-202
19602992-11	2010	Chlorpromazine-treated hypothermic mice had 2.3-fold and 1.8-fold higher plasma interleukin-6 and interleukin-10 levels at 6 hrs compared with identically treated normothermic mice (p &lt; .05), whereas plasma tumor necrosis factor-alpha and interleukin-1beta were not significantly different at 2 hrs or 6 hrs.	Chlorpromazine	0-14	interleukin 6	Mus musculus	80-93
20056085-0	2010	[N-acetylcysteine antagonizes the Interleukin-18-induced expression of TNF-alpha and IL-6 in mouse vascular smooth muscle cells].	Acetylcysteine	1-17	interleukin 6	Mus musculus	85-89
20056085-7	2010	CONCLUSION: N-acetylcysteine antagonizes the production of TNF-alpha and IL-6 induced by IL-18 in VSMC.	Acetylcysteine	12-28	interleukin 6	Mus musculus	73-77
20056085-7	2010	CONCLUSION: N-acetylcysteine antagonizes the production of TNF-alpha and IL-6 induced by IL-18 in VSMC.	vsmc	98-102	interleukin 6	Mus musculus	73-77
20223119-11	2009	The expression level of TNFalpha, IL-1beta, IL-6 mRNA on hepatocytes in polypeptide treated mice was significantly lower (1.26 +/- 0.37, 0.98 +/- 0.21, 0.43 +/- 0.17, 87.43 +/- 16.7 respectively) than that in the saline treated ones (1.98 +/- 0.56, 1.24 +/- 0.35, 0.64 +/- 0.25 and 236.11 +/- 32.7, respectively) (P &lt; 0.01).	Sodium Chloride	213-219	interleukin 6	Mus musculus	44-48
19681796-9	2009	OV also induced a significantly greater accumulation of hydroxyproline and procollagen-1 mRNA in IL-6(-/-) muscle, when compared with WT muscle after 21 day OV.	Hydroxyproline	56-70	interleukin 6	Mus musculus	97-101
19473187-13	2009	The curcumin-loaded nanofibres also reduced inflammatory induction, as evidenced by low levels of interleukin-6 release from mouse monocyte-macrophages seeded onto the fibres following stimulation by Escherichia coli-derived lipopolysaccharide.	Curcumin	4-12	interleukin 6	Mus musculus	98-111
19696185-6	2009	RESULTS: PD153035 treatment for 1 day decreased the protein expression of inducible nitric oxide synthase, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6 in the stroma vascular fraction, suggesting that this drug reduces the M1 proinflammatory state in ATMs, as an initial effect, in turn reducing the circulating levels of TNF-alpha and IL-6, and initiating an improvement in insulin signaling and sensitivity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	9-17	interleukin 6	Mus musculus	146-164
19696185-6	2009	RESULTS: PD153035 treatment for 1 day decreased the protein expression of inducible nitric oxide synthase, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6 in the stroma vascular fraction, suggesting that this drug reduces the M1 proinflammatory state in ATMs, as an initial effect, in turn reducing the circulating levels of TNF-alpha and IL-6, and initiating an improvement in insulin signaling and sensitivity.	4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	9-17	interleukin 6	Mus musculus	349-353
19765678-5	2009	Furthermore, florfenicol also inhibits the production of several inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) at 6 and 12h, interleukin-6 (IL-6) at 12 and 24h, and interleukin-1ss (IL-1ss) at 12h, in the BALF after LPS challenge.	florfenicol	13-24	interleukin 6	Mus musculus	153-166
19765678-5	2009	Furthermore, florfenicol also inhibits the production of several inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) at 6 and 12h, interleukin-6 (IL-6) at 12 and 24h, and interleukin-1ss (IL-1ss) at 12h, in the BALF after LPS challenge.	florfenicol	13-24	interleukin 6	Mus musculus	168-172
19788934-6	2009	Exposure to KML increased production of cytokines such as interleukin-1 and interleukin-6 by macrophages.	kml	12-15	interleukin 6	Mus musculus	76-89
19327909-10	2009	IL-6 plus RT-induced HBV DNA replication in HepG2.2.15 cells was suppressed by the STAT3 inhibitor AG490 and by transfection with dominant-negative STAT3 plasmid.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	99-104	interleukin 6	Mus musculus	0-4
19776127-2	2009	However, the signaling events that trigger TNF-alpha and IL-6 induction in these cells upon MHV infection remain unknown.	mhv	92-95	interleukin 6	Mus musculus	57-61
19705479-5	2009	Saline/LPS treatment was associated with a 33% reduction in maximal force and elevated serum TNF-alpha and IL-6.	Sodium Chloride	0-6	interleukin 6	Mus musculus	107-111
19705479-7	2009	GLN was found to reduce muscle Hsp70 and IL-6, but only in the presence of LPS.	Glutamine	0-3	interleukin 6	Mus musculus	41-45
19781786-3	2009	In contrast to mice injected with LPS, mice exposed to hyaluronan prior to LPS had greatly decreased serum IL-6 and TNFalpha and were protected from symptoms of sepsis.	Hyaluronic Acid	55-65	interleukin 6	Mus musculus	107-111
19781786-5	2009	Consistent with our findings in vivo, addition of hyaluronan to macrophages before LPS exposure significantly decreased the release of IL-6 and TNFalpha and this effect was not seen in macrophages from Cd44(-/-) mice.	Hyaluronic Acid	50-60	interleukin 6	Mus musculus	135-139
20005342-9	2009	Rapamycin treatment showed minimal effects on postischemic kidney fibrosis with variable effects on various cytokine/chemokine protein expressions, namely, decreasing interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and regulated on activation normal T cell expressed and secreted (RANTES) while increasing IL-4, keratinocyte-derived chemokine (KC), macrophage inflammatory protein (MIP-1alpha), and IL-10 in the ischemic kidney.	Sirolimus	0-9	interleukin 6	Mus musculus	192-196
19833167-6	2009	Renal IL-6 expression in most proximal tubular cells and suppressor of cytokine signaling 3 (SOCS3) gene expression significantly increased in WT mice after administration of CDDP, suggesting active IL-6 signaling during CDDP-induced ARF development.	Cisplatin	175-179	interleukin 6	Mus musculus	199-203
19833167-6	2009	Renal IL-6 expression in most proximal tubular cells and suppressor of cytokine signaling 3 (SOCS3) gene expression significantly increased in WT mice after administration of CDDP, suggesting active IL-6 signaling during CDDP-induced ARF development.	Cisplatin	221-225	interleukin 6	Mus musculus	199-203
19833167-7	2009	Interestingly, renal dysfunction occurred soon after administration of CDDP and became more severe in IL-6(-/-) mice than that in WT mice.	Cisplatin	71-75	interleukin 6	Mus musculus	102-106
19833167-11	2009	Bax might contribute to the development of CDDP-induced ARF at 24h; however, high expression levels of Bcl-x(L) and Bcl-2 might overcome the proapoptosis signaling at 72 h in IL-6(-/-) mice.	Cisplatin	43-47	interleukin 6	Mus musculus	175-179
19833167-12	2009	These results indicated that local and systemic elevation of IL-6 contributes to the development of CDDP-induced ARF and that IL-6 produced in renal tubular cells prevents progression of ARF at the early stage.	Cisplatin	100-104	interleukin 6	Mus musculus	61-65
19833167-13	2009	IL-6 deficiency accelerates CDDP-induced ARF but not development of systemic injury.	Cisplatin	28-32	interleukin 6	Mus musculus	0-4
19682479-9	2009	Expression of pro-inflammatory chemokine MCP-1 and cytokine IL-6 and markers of oxidative stress, protein-HNE and protein-MDA adducts were markedly increased in lesions of arsenic-exposed mice.	Arsenic	172-179	interleukin 6	Mus musculus	60-64
19682479-10	2009	Plasma concentrations of MCP-1, IL-6 and MDA were also significantly elevated in arsenic-exposed mice.	Arsenic	81-88	interleukin 6	Mus musculus	32-36
19699788-3	2009	RESULTS: Here, we report that SB displays anti-inflammatory effects in a zymosan-induced mouse air-pouch model by reducing the expression of nitric oxide (NO), inducible NOS (iNOS), Cyclooxygenase2 (COX-2), Prostaglandin E2 (PGE2), Nuclear Factor-kappaB (NF-kappaB) and IkappaBalpha as well as inflammatory cytokines, such as IL-1beta, IL-2, IL-6, IL-12 and TNF-alpha.	Antimony	30-32	interleukin 6	Mus musculus	342-346
19699788-4	2009	In a similar manner, SB also reduced the production of nitric oxide, PGE2, IL-1beta, IL-2, IL-6, IL-12 and TNF-alpha, by decreasing the expression of iNOS, COX-2, IkappaB kinase alphabeta (IKKalphabeta) phosphorylation, IkappaBalpha and IkappaBalpha phosphorylation in LPS-treated Raw 264.7 cells.	Antimony	21-23	interleukin 6	Mus musculus	91-95
19699788-7	2009	CONCLUSIONS: Taken together, these results confirm the strong anti-inflammatory properties of SB by inhibition of iNOS, COX-2, PGE2, IL-1beta, IL-2, IL-6, IL-12 and TNF-alpha expression.	Antimony	94-96	interleukin 6	Mus musculus	149-153
19219547-4	2009	CAF induced production of nitric oxide (NO), tumor necrosis factor-alpha and interleukin-6 in RAW 264.7 cells.	cafestol palmitate	0-3	interleukin 6	Mus musculus	77-90
19467927-7	2009	Although dendritic cells readily upregulated maturation and activation markers in response to K88 stimulation, accompanied by secretion of interleukin (IL)-12, IL-6, IL-10, and tumour necrosis factor, restimulation of T cells from mice having received EcN-K88 with K88-loaded dendritic cells did not result in detectable T cell proliferation and IL-2 secretion, but rather induced an IL-10 bias.	K88	94-97	interleukin 6	Mus musculus	160-164
19710627-6	2009	Alport mice treated with a general inhibitor of nitric oxide synthase (L-NAME) developed significant hypertension and increased IL-6 and MMP-3 and -10 in their glomeruli relative to those of normotensive Alport mice.	NG-Nitroarginine Methyl Ester	71-77	interleukin 6	Mus musculus	128-132
19561401-9	2009	Secretion of IL6 and levels of JAK1, IL6R and phosphorylated STAT3 were all reduced by triptolide treatment.	triptolide	87-97	interleukin 6	Mus musculus	13-16
19561404-7	2009	We further showed that the synthetic CpG-oligodeoxynucleotides (CpG ODN) coadministered with the rPAL enhanced IL-12 and IL-6 production and expression of CD40, CD80 and MHC II compared to the rPAL treatment alone.	CPG-oligonucleotide	37-62	interleukin 6	Mus musculus	121-125
19168699-9	2009	Taken together, our results suggest that IL-6 induces Bcl-2 expression to perform cytoprotective functions in response to oxygen toxicity, and that this effect is mediated by alterations in the interactions between Bak and Mfns.	Oxygen	122-128	interleukin 6	Mus musculus	41-45
19168699-9	2009	Taken together, our results suggest that IL-6 induces Bcl-2 expression to perform cytoprotective functions in response to oxygen toxicity, and that this effect is mediated by alterations in the interactions between Bak and Mfns.	bakuchiol	215-218	interleukin 6	Mus musculus	41-45
19815878-5	2009	In vitro statin treatment potentiated production of tumor necrosis factor and interleukin-6 by murine peritoneal macrophages in response to P. falciparum glycosylphosphatidyl inositol, a Toll-like receptor 2 (TLR2) ligand.	Glycosylphosphatidylinositols	154-183	interleukin 6	Mus musculus	78-91
19524707-3	2009	In this model, calvarial bone loss and osteoclast formation were increased in titanium-treated IL-6(-/-) mice.	Titanium	78-86	interleukin 6	Mus musculus	95-99
19524707-10	2009	IL-6(-/-) splenocytes secreted greater concentrations of TNFalpha in response to titanium particles than WT; addition of exogenous IL-6 to these cultures decreased TNFalpha expression while anti-IL-6 antibody increased TNFalpha.	Titanium	81-89	interleukin 6	Mus musculus	0-4
20396756-3	2009	Beta-cyclohexylethyl glycoside of muramyl dipeptide was more potent than muramyl dipeptide and other derivatives in increasing in vivo antibacterial resistance and in vitro production of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, and interferon-gamma;.	beta-cyclohexylethyl glycoside	0-30	interleukin 6	Mus musculus	206-248
20396756-3	2009	Beta-cyclohexylethyl glycoside of muramyl dipeptide was more potent than muramyl dipeptide and other derivatives in increasing in vivo antibacterial resistance and in vitro production of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, and interferon-gamma;.	Acetylmuramyl-Alanyl-Isoglutamine	34-51	interleukin 6	Mus musculus	206-248
20396756-3	2009	Beta-cyclohexylethyl glycoside of muramyl dipeptide was more potent than muramyl dipeptide and other derivatives in increasing in vivo antibacterial resistance and in vitro production of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, and interferon-gamma;.	Acetylmuramyl-Alanyl-Isoglutamine	73-90	interleukin 6	Mus musculus	206-248
19481591-3	2009	The alkaloids inhibited TNF-alpha and IL-6 production induced by these ligands.	Alkaloids	4-13	interleukin 6	Mus musculus	38-42
19666143-8	2009	Taken together, these results suggest that pseudocoptisine reduces levels of the pro-inflammatory mediators, such as, iNOS, COX-2, TNF-alpha, and IL-6 through the inhibition of NF-kappaB activation via the suppression of ERK and p38 phosphorylation in RAW 264.7 cells.	pseudocoptisine	43-58	interleukin 6	Mus musculus	146-150
19699326-8	2009	The immunosuppressive effects on IL-1beta and IL-6 production and on TLR expression by stressed mice might have occurred due to a higher corticosterone production during stress.	Corticosterone	137-151	interleukin 6	Mus musculus	46-50
19496170-0	2009	cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.	Cyclic AMP	0-4	interleukin 6	Mus musculus	40-44
19497289-6	2009	Treatment of C2C12 myotubes with cortisone concentration dependently transactivated and transrepressed glutamine synthase and interleukin-6, respectively, which were abrogated by carbenoxolone or RU-486 (mifepristone), a glucocorticoid receptor antagonist.	Cortisone	33-42	interleukin 6	Mus musculus	126-139
19497289-6	2009	Treatment of C2C12 myotubes with cortisone concentration dependently transactivated and transrepressed glutamine synthase and interleukin-6, respectively, which were abrogated by carbenoxolone or RU-486 (mifepristone), a glucocorticoid receptor antagonist.	Carbenoxolone	179-192	interleukin 6	Mus musculus	126-139
19497289-6	2009	Treatment of C2C12 myotubes with cortisone concentration dependently transactivated and transrepressed glutamine synthase and interleukin-6, respectively, which were abrogated by carbenoxolone or RU-486 (mifepristone), a glucocorticoid receptor antagonist.	Mifepristone	196-202	interleukin 6	Mus musculus	126-139
19497289-6	2009	Treatment of C2C12 myotubes with cortisone concentration dependently transactivated and transrepressed glutamine synthase and interleukin-6, respectively, which were abrogated by carbenoxolone or RU-486 (mifepristone), a glucocorticoid receptor antagonist.	Mifepristone	204-216	interleukin 6	Mus musculus	126-139
19717524-6	2009	Mal deficiency boosted IL-6 induction by the TLR3 ligand polyinosinic-polycytidylic acid.	Poly I-C	57-88	interleukin 6	Mus musculus	23-27
19607899-5	2009	MATERIALS AND METHODS: The effect of AEDF on proinflammatory cytokine (IL-1beta and IL-6) production was analyzed by ELISA and real-time RT-PCR.	aedf	37-41	interleukin 6	Mus musculus	84-88
19607899-8	2009	RESULTS: AEDF inhibited the production of IL-1beta and IL-6, NF-kappaB activation, IkappaB-alpha degradation, and IKK, Akt, ERK1/2 and JNK activities in LPS-stimulated mouse peritoneal macrophages.	aedf	9-13	interleukin 6	Mus musculus	55-59
19607899-9	2009	CONCLUSIONS: These results suggest that AEDF inhibits proinflammatory cytokine (IL-1beta and IL-6) production in LPS-stimulated mouse peritoneal macrophages, and that these effects are mediated by the inhibition of the activity of IKK/IkappaB/NF-kappaB and the phosphorylation of Akt, ERK1/2, and JNK.	aedf	40-44	interleukin 6	Mus musculus	93-97
19553566-6	2009	In addition, roscovitine dose dependently inhibited LPS-induced expression of cyclooxygenase-2 (COX)-2, IL-1beta, and IL-6 but not tumor necrosis factor (TNF)-alpha.	Roscovitine	13-24	interleukin 6	Mus musculus	118-122
19497395-6	2009	Co-Cr-Mo alloy particle treatment significantly (p&lt;0.05) up-regulated tumor necrosis factor alpha (TNFalpha) gene expression after 3 and 6 h and TNFalpha protein production after 24 h, but down-regulated interleukin-6 (IL-6) gene expression after 6 h. Co-Cr-Mo alloy particle treatment also induced osteocyte apoptosis after 24 h. This apoptotic effect was partially (40%) dependent on TNFalpha.	Vitallium	0-8	interleukin 6	Mus musculus	207-220
19497395-6	2009	Co-Cr-Mo alloy particle treatment significantly (p&lt;0.05) up-regulated tumor necrosis factor alpha (TNFalpha) gene expression after 3 and 6 h and TNFalpha protein production after 24 h, but down-regulated interleukin-6 (IL-6) gene expression after 6 h. Co-Cr-Mo alloy particle treatment also induced osteocyte apoptosis after 24 h. This apoptotic effect was partially (40%) dependent on TNFalpha.	Vitallium	0-8	interleukin 6	Mus musculus	222-226
19575532-9	2009	Furthermore, treatment of a murine macrophage cell line, RAW264.7, with penicillamine increased the production of TNF-alpha, IL-6, and IL-23, providing additional evidence that penicillamine activates macrophages.	Penicillamine	72-85	interleukin 6	Mus musculus	125-129
19575532-9	2009	Furthermore, treatment of a murine macrophage cell line, RAW264.7, with penicillamine increased the production of TNF-alpha, IL-6, and IL-23, providing additional evidence that penicillamine activates macrophages.	Penicillamine	177-190	interleukin 6	Mus musculus	125-129
19706756-8	2009	For example, vinblastine, a prototypic drug of this class, induced the production of IL-1beta, IL-6, and IL-12, increased surface expression of CD40, CD80, CD86, and MHC class II, and augmented T cell-stimulatory capacity of DCs.	Vinblastine	13-24	interleukin 6	Mus musculus	95-99
19825525-13	2009	Dexamethasone not only completely abolished the IL-1beta-induced AHR to bradykinin, but also abrogated the increased mRNA expression for inflammatory mediators, IL-6, IFN-gamma and Cox-2.	Dexamethasone	0-13	interleukin 6	Mus musculus	161-165
19842847-8	2009	Lavage and perfusate analyses showed significant decreases in the concentrations of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, macrophage inflammatory protein (MIP)-1alpha, and IL-1beta cytokines in DMDP-LPS mice compared to PBS-LPS controls.	Clodronic Acid	211-215	interleukin 6	Mus musculus	84-102
19456897-8	2009	In addition, the concentrations of both interleukin (IL)-6 and IL-10 in serum or hepatic homogenates were also decreased in TSA-treated septic mice.	trichostatin A	124-127	interleukin 6	Mus musculus	40-58
19572781-7	2009	A single intraperitoneal injection of dexamethasone (10 mg/kg body weight) 1 hour after melphalan exposure significantly reduced interleukin (IL)-1 and IL-6 in bronchoalveolar lavage fluid (BALF) and diminished the acute airway inflammation.	Dexamethasone	38-51	interleukin 6	Mus musculus	152-156
19572781-7	2009	A single intraperitoneal injection of dexamethasone (10 mg/kg body weight) 1 hour after melphalan exposure significantly reduced interleukin (IL)-1 and IL-6 in bronchoalveolar lavage fluid (BALF) and diminished the acute airway inflammation.	Melphalan	88-97	interleukin 6	Mus musculus	152-156
19740306-2	2009	We previously described that both intact cells and a cell wall-derived polysaccharide-peptidoglycan complex (PSPG) in a strain of lactobacillus [Lactobacillus casei Shirota (LcS)] inhibited IL-6 production in lipopolysaccharide (LPS)-stimulated lamina propria mononuclear cells (LPMCs) isolated from murine IBD.	polysaccharide-peptidoglycan	71-99	interleukin 6	Mus musculus	190-194
19740306-3	2009	Diets with LcS improve murine IBD by suppression of IL-6 synthesis in LPMCs.	lpmcs	70-75	interleukin 6	Mus musculus	52-56
19740306-6	2009	PSPG derived from LcS, and no other strain of lactobacilli, inhibited IL-6 production in LPS-stimulated murine IBD LPMCs.	lpmcs	115-120	interleukin 6	Mus musculus	70-74
19740306-7	2009	Purified PSPG-I from LcS inhibited IL-6 synthesis in LPS-stimulated murine IBD LPMCs through the inhibition of nuclear factor-kappaB.	lpmcs	79-84	interleukin 6	Mus musculus	35-39
19740306-11	2009	In the IBD model, ingestion of LcS improved ileitis and inhibited activation of IL-6/STAT3 signaling, while ingestion of the LC(DeltaPSPG-I) strain did not.	lcs	31-34	interleukin 6	Mus musculus	80-84
19740306-12	2009	In the CAC model, treatment with LcS, but not the LC(DeltaPSPG-I) strain, showed tumour-suppressive effects with an inhibition of IL-6 production in the colonic mucosa.	lcs	33-36	interleukin 6	Mus musculus	130-134
19740307-5	2009	The induction of IL-6 and TNF-alpha production was related rather to the fixation of the spike (S) protein of MHV3 on Toll-like receptor 2 (TLR2) in regions enriched in heparan sulphate and did not rely on viral replication, as demonstrated with denatured S protein and UV-inactivated virus.	Heparitin Sulfate	169-185	interleukin 6	Mus musculus	17-21
19954621-9	2009	(4) SB203580 and SP600125 down-regulated allogeneic T lymphocytes-induced VCAM-1, TNF-alpha, IFN-gamma, IL-6 expression in HUVECs.	pyrazolanthrone	17-25	interleukin 6	Mus musculus	104-108
19666548-7	2009	Islets from mice deficient in IL-1beta or MyD88 challenged with glucose and palmitate in vitro also produced significantly less IL-6 and chemokines.	Glucose	64-71	interleukin 6	Mus musculus	128-132
19666548-7	2009	Islets from mice deficient in IL-1beta or MyD88 challenged with glucose and palmitate in vitro also produced significantly less IL-6 and chemokines.	Palmitates	76-85	interleukin 6	Mus musculus	128-132
19608872-7	2009	We also measured lower ocular TNF-alpha and IL-6 transcript levels in the mice fed a diet of high n-3 fatty acids.	Fatty Acids, Omega-3	98-113	interleukin 6	Mus musculus	44-48
19638459-14	2009	The tumor testosterone levels were detected at 378 pg/g in tumors generated from IL-6-overexpressing LNCaP-IL6(+) cells inoculated orthotopically into the prostates of castrated male nude mice.	Testosterone	10-22	interleukin 6	Mus musculus	81-85
19482899-0	2009	The effect of interleukin-6 and the interleukin-6 receptor on glucose transport in mouse skeletal muscle.	Glucose	62-69	interleukin 6	Mus musculus	36-49
19482899-2	2009	Interleukin-6 has been found to have equivocal effects on glucose transport, with no studies, to our knowledge, investigating any potential role of IL-6R.	Glucose	58-65	interleukin 6	Mus musculus	0-13
19482899-3	2009	In the present study, we hypothesized that a combined preparation of IL-6 and soluble IL-6R (sIL-6R) would stimulate glucose transport.	Glucose	117-124	interleukin 6	Mus musculus	69-73
19482899-7	2009	At physiological levels, exposure to a combination of IL-6 and sIL-6R (32 ng ml(-1)) resulted in a 1.4-fold increase (P &lt; 0.05) in basal glucose transport with no change to the phosphorylation of AMPK.	Glucose	140-147	interleukin 6	Mus musculus	54-58
19482899-8	2009	Exposure to supraphysiological levels of IL-6 and sIL-6R (120 ng ml(-1)) resulted in an approximately twofold increase (P &lt; 0.05) in basal glucose transport and an increase (P &lt; 0.05) in AMPK phosphorylation.	Glucose	142-149	interleukin 6	Mus musculus	41-45
19470750-4	2009	In this study, we investigated the role of IL-6 in the nitric oxide (NO)-triggered alteration of contractile responses in the urinary bladder under an E. coli-induced inflammatory condition.	Nitric Oxide	55-67	interleukin 6	Mus musculus	43-47
19578789-8	2009	Furthermore, Sn-PP partially restored the HGF-mediated decrease in plasma IL-6 levels, while it inhibited the HGF-stimulated increase in plasma IL-10 levels.	sn-pp	13-18	interleukin 6	Mus musculus	74-78
19596983-6	2009	We now show for the first time that, compared with controls, mice exposed prenatally to secondhand CS exhibit increased lung inflammation (predominant infiltration by eosinophils and polymorphs), atopy, and airway resistance, and produce proinflammatory cytokines (IL-4, IL-5, IL-6, and IL-13, but not IL-2 or IFN-gamma).	Cesium	99-101	interleukin 6	Mus musculus	277-281
19417213-4	2009	In vitro BHQ880 increased OB differentiation, neutralized the negative effect of MM cells on osteoblastogenesis, and reduced IL-6 secretion.	BHQ880	9-15	interleukin 6	Mus musculus	125-129
19324975-8	2009	The decrease in lung SNO was associated with an increase in lung NF-kappaB activity, cytokine/chemokine expression (keratinocyte-derived chemokine, tumor necrosis factor-alpha, and IL-6), airway neutrophil influx, and worsened lung compliance.	S-Nitrosothiols	21-24	interleukin 6	Mus musculus	181-185
19371254-3	2009	Results showed that paeoniflorin concentration-dependently down-regulated the levels of TNF-alpha, IL-6 and high-mobility group-box 1 protein in lipopolysaccharide-induced RAW264.7 cell, inhibited the IkappaB kinase pathway and modulated NF-kappaB.	peoniflorin	20-32	interleukin 6	Mus musculus	99-103
19447225-0	2009	HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages.	Lopinavir	23-32	interleukin 6	Mus musculus	55-59
19447225-3	2009	We have previously shown that HIV PIs induce endoplasmic reticulum (ER) stress, activate the unfolded protein response (UPR), and increase the synthesis of the inflammatory cytokines, TNF-alpha and IL-6, by regulating the intracellular translocation of RNA binding protein HuR in macrophages.	Monothiopyrophosphoric acid	34-37	interleukin 6	Mus musculus	198-202
19447225-6	2009	Lopinavir-induced cytosolic translocation of HuR and TNF-alpha and IL-6 synthesis was attenuated by specific chemical inhibitor of MEK (PD98058) or over-expression of dominant negative mutant of MEK1.	Lopinavir	0-9	interleukin 6	Mus musculus	67-71
19447225-6	2009	Lopinavir-induced cytosolic translocation of HuR and TNF-alpha and IL-6 synthesis was attenuated by specific chemical inhibitor of MEK (PD98058) or over-expression of dominant negative mutant of MEK1.	PD 98058	136-143	interleukin 6	Mus musculus	67-71
19447225-7	2009	In addition, we demonstrated that lopinavir-induced ERK activation and TNF-alpha and IL-6 expression were completely inhibited in macrophages from CHOP null mice.	Lopinavir	34-43	interleukin 6	Mus musculus	85-89
19341822-4	2009	When mice without and with collagen-induced arthritis were pooled, compared to CO2, administration of isoflurane was associated with lower production of the pro-inflammatory cytokines TNF-alpha (pg/ml, mean +/- SEM) (26.1 +/- 2.82 versus 48.1 +/- 7.99) and IL-6 (25.18 +/- 2.73 versus 48.1 +/- 6.82) (ANOVA, p &lt; 0.05).	Isoflurane	102-112	interleukin 6	Mus musculus	257-261
19138107-6	2009	Here we show that transplantation of pre-differentiated ES cells activate both brain-derived neurotrophic factor (BDNF) and interleukin-6 (IL-6) signaling pathways in the host tissue, leading to activation of cAMP/PKA, phosporylation of cofilin and synapsin I, and promoting regenerative growth and neuronal survival.	Cyclic AMP	209-213	interleukin 6	Mus musculus	124-137
19138107-6	2009	Here we show that transplantation of pre-differentiated ES cells activate both brain-derived neurotrophic factor (BDNF) and interleukin-6 (IL-6) signaling pathways in the host tissue, leading to activation of cAMP/PKA, phosporylation of cofilin and synapsin I, and promoting regenerative growth and neuronal survival.	Cyclic AMP	209-213	interleukin 6	Mus musculus	139-143
19376150-8	2009	Moderate concentrations of HOCl (0.35 to 1.4 mM) caused maximal activation of the Nrf2 pathway and innate immune response genes, such as IL-1beta, IL-6, IL-10 and chemokines.	Hypochlorous Acid	27-31	interleukin 6	Mus musculus	147-151
19118846-8	2009	The BAL fluid concentrations of interleukin-1beta, interleukin-6, RANTES, and high mobility group box 1 were significantly increased by pneumonectomy and enhanced by the additional administration of bleomycin.	Bleomycin	199-208	interleukin 6	Mus musculus	51-64
19356732-7	2009	Atractylenolide I displayed a potent inhibitory effect on angiogenesis by a set of down-regulatory actions of NO, TNF-alpha, IL-1beta, IL-6, VEGF and PlGF in chronic inflammation.	atractylenolide I	0-17	interleukin 6	Mus musculus	135-139
19953904-9	2009	RESULTS: (1) The secretion of IL-6 and MCP-1 in the culture medium were higher in the testosterone-treated groups than in the control groups (P &lt; 0.05).	Testosterone	86-98	interleukin 6	Mus musculus	30-34
19953904-13	2009	Likewise, when pretreated by NF-kappaB inhibitor and followed by 10(-5) M testosterone for 12 h, the mRNA expression of IL-6 and MCP-1 decreased significantly.	Testosterone	74-86	interleukin 6	Mus musculus	120-124
19373235-0	2009	Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis.	Resveratrol	0-11	interleukin 6	Mus musculus	46-59
19373235-4	2009	Resveratrol significantly attenuated Ang II-induced IL-6 mRNA expression and IL-6 protein in the supernatant of VSMC in a dose-dependent manner.	Resveratrol	0-11	interleukin 6	Mus musculus	52-56
19373235-4	2009	Resveratrol significantly attenuated Ang II-induced IL-6 mRNA expression and IL-6 protein in the supernatant of VSMC in a dose-dependent manner.	Resveratrol	0-11	interleukin 6	Mus musculus	77-81
19373235-4	2009	Resveratrol significantly attenuated Ang II-induced IL-6 mRNA expression and IL-6 protein in the supernatant of VSMC in a dose-dependent manner.	vsmc	112-116	interleukin 6	Mus musculus	52-56
19373235-4	2009	Resveratrol significantly attenuated Ang II-induced IL-6 mRNA expression and IL-6 protein in the supernatant of VSMC in a dose-dependent manner.	vsmc	112-116	interleukin 6	Mus musculus	77-81
19373235-5	2009	Resveratrol suppressed the IL-6 gene promoter activity.	Resveratrol	0-11	interleukin 6	Mus musculus	27-31
19373235-6	2009	Resveratrol inhibited the Ang II-induced cAMP-response element-binding protein and nuclear factor-kappa B activity, which are critical for Ang II-induced IL-6 gene activation.	Resveratrol	0-11	interleukin 6	Mus musculus	154-158
20107539-7	2009	RESULTS: Cordycepin inhibited the production of NO and pro-inflammatory cytokines such as IL-1beta, IL-6, and TNF-alpha in LPS-activated macrophages via suppressing protein expression of pro-inflammatory mediators.	cordycepin	9-19	interleukin 6	Mus musculus	100-104
19194991-0	2009	5"-N-ethylcarboxamide induces IL-6 expression via MAPKs and NF-kappaB activation through Akt, Ca(2+)/PKC, cAMP signaling pathways in mouse embryonic stem cells.	5"-n-ethylcarboxamide	0-21	interleukin 6	Mus musculus	30-34
19194991-0	2009	5"-N-ethylcarboxamide induces IL-6 expression via MAPKs and NF-kappaB activation through Akt, Ca(2+)/PKC, cAMP signaling pathways in mouse embryonic stem cells.	Cyclic AMP	106-110	interleukin 6	Mus musculus	30-34
19194991-2	2009	This study examined the effects of adenosine on interleukin (IL)-6 expression and its related signal pathways in mouse embryonic stem (ES) cells.	Adenosine	35-44	interleukin 6	Mus musculus	48-66
19194991-3	2009	In this study, the adenosine analogue 5"-N-ethylcarboxamide (NECA) increased IL-6 protein expression level.	Adenosine	19-28	interleukin 6	Mus musculus	77-81
19194991-3	2009	In this study, the adenosine analogue 5"-N-ethylcarboxamide (NECA) increased IL-6 protein expression level.	5"-n-ethylcarboxamide	38-59	interleukin 6	Mus musculus	77-81
19194991-3	2009	In this study, the adenosine analogue 5"-N-ethylcarboxamide (NECA) increased IL-6 protein expression level.	Adenosine-5'-(N-ethylcarboxamide)	61-65	interleukin 6	Mus musculus	77-81
19194991-4	2009	Mouse ES cells expressed the A(1), A(2A), A(2B), and A(3) adenosine receptors (ARs), whose expression levels were increased by NECA and NECA-induced increase of IL-6 mRNA expression or secretion level was inhibited by the non-specific AR inhibitor, caffeine.	Caffeine	249-257	interleukin 6	Mus musculus	161-165
19194991-6	2009	On the other hand, NECA-induced IL-6 secretion was partially inhibited by Akt inhibitor, bisindolylmaleimide I (PKC inhibitor), SQ 22536 (adenylate cyclate inhibitor) and completely blocked by the 3 inhibitor combination treatment.	Adenosine-5'-(N-ethylcarboxamide)	19-23	interleukin 6	Mus musculus	32-36
19194991-6	2009	On the other hand, NECA-induced IL-6 secretion was partially inhibited by Akt inhibitor, bisindolylmaleimide I (PKC inhibitor), SQ 22536 (adenylate cyclate inhibitor) and completely blocked by the 3 inhibitor combination treatment.	bisindolylmaleimide I	89-110	interleukin 6	Mus musculus	32-36
19194991-6	2009	On the other hand, NECA-induced IL-6 secretion was partially inhibited by Akt inhibitor, bisindolylmaleimide I (PKC inhibitor), SQ 22536 (adenylate cyclate inhibitor) and completely blocked by the 3 inhibitor combination treatment.	9-(tetrahydro-2-furyl)-adenine	128-136	interleukin 6	Mus musculus	32-36
19194991-11	2009	Indeed, NECA-induced increase of IL-6 protein expression and secretion was blocked by NF-kappaB inhibitors.	Adenosine-5'-(N-ethylcarboxamide)	8-12	interleukin 6	Mus musculus	33-37
19194991-12	2009	In conclusion, NECA stimulated IL-6 expression via MAPK and NF-kappaB activation through Akt, Ca(2+)/PKC, and cAMP signaling pathways in mouse ES cells.	Cyclic AMP	110-114	interleukin 6	Mus musculus	31-35
19554401-8	2009	The serum IL-6 levels were increased in ciprofloxacin-administered mice, whereas the other fluoroquinolones did not affect the serum IL-6 levels.	Ciprofloxacin	40-53	interleukin 6	Mus musculus	10-14
19554401-12	2009	LPSstimulated IL-6 production was inhibited only by norfloxacin (59.5 % of control).	Norfloxacin	52-63	interleukin 6	Mus musculus	14-18
19375802-9	2009	Hence, concluded that methylglyoxal augmented the IL-6 and IL-1 beta, expression of TLR 4 and TLR 9 and produced MAPKs, important regulators of ROIs and RNIs.	Pyruvaldehyde	22-35	interleukin 6	Mus musculus	50-54
19587437-8	2009	The expression of IL-6 mRNA was significantly higher than that in the NP, LP and PP groups (P&lt;0.05), its protein expression in PT and LP groups was significantly higher than that in the NP and PP groups (P&lt;0.05).	leucylproline	74-76	interleukin 6	Mus musculus	18-22
19587437-8	2009	The expression of IL-6 mRNA was significantly higher than that in the NP, LP and PP groups (P&lt;0.05), its protein expression in PT and LP groups was significantly higher than that in the NP and PP groups (P&lt;0.05).	leucylproline	137-139	interleukin 6	Mus musculus	18-22
19777841-0	2009	[Gastrodine represses expression of IL-1 beta, IL-6 induced by hyperglycemia in gitter cells].	gastrodin	1-11	interleukin 6	Mus musculus	47-51
19777841-2	2009	The aim of this study is to evaluate the inhibitory effect of Gastrodine on the expression of interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) in culturing for gitter cells (BV-2 cells) induced by high concentration of glucose.	gastrodin	62-72	interleukin 6	Mus musculus	126-139
19777841-2	2009	The aim of this study is to evaluate the inhibitory effect of Gastrodine on the expression of interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) in culturing for gitter cells (BV-2 cells) induced by high concentration of glucose.	gastrodin	62-72	interleukin 6	Mus musculus	141-145
19777841-9	2009	The supernatant protein of IL-6 protein also higher in HCG than control group (393.7 +/- 17.51) ng x L(-1) vs (125.85 +/- 36.62) ng x L(-1) (P &lt; 0.01), and lower in the gastrodine groups than HCG (LG 327.06 +/- 23.53) ng x L(-1), MG (217.36 +/- 28.81) ng x L(-1), HG (263.17 +/- 22.32) ng x L(-1) vs (393.7 +/- 17.51) ng x L(-1), P &lt; 0.05).	gastrodin	172-182	interleukin 6	Mus musculus	27-31
19777841-11	2009	The mRNA Expression of IL-6 was higher in HCG than control group (3.97 +/- 0.33) vs (1.05 +/- 0.13) (P &lt; 0.05, but lower in gastrodine groups than HCG LG (3.28 +/- 0.3), MG (2.65 +/- 0.33), HG (3.04 +/- 0.26), vs (3.97 +/- 0.33) (P &lt; 0.05).	gastrodin	127-137	interleukin 6	Mus musculus	23-27
19777841-12	2009	CONCLUSION: Gastrodine can inhibit the expression of IL-1 beta, IL-6 in cultured BV-2 cells induced by high concentration of glucose.	gastrodin	12-22	interleukin 6	Mus musculus	64-68
19777841-12	2009	CONCLUSION: Gastrodine can inhibit the expression of IL-1 beta, IL-6 in cultured BV-2 cells induced by high concentration of glucose.	Glucose	125-132	interleukin 6	Mus musculus	64-68
19014921-10	2009	In addition, treatment of CD-1 mice, another susceptible strain, with an anti-inflammatory polyphenol, resveratrol, protected mice against the acetaminophen-induced liver injury, and the mice with attenuated toxicity revealed lower expression of TNF-alpha and higher expression of IL-6.	Resveratrol	103-114	interleukin 6	Mus musculus	281-285
19426550-6	2009	At 10 ng/ml, GM-CSF significantly enhanced R-848-induced IL-6 release from P815 cells.	resiquimod	43-48	interleukin 6	Mus musculus	57-61
19416544-15	2009	These beneficial effects of AG-490 were related to lowered levels of circulating IL-6, MIP-1alpha and C5a, and to inhibited expression of STAT1, STAT3 and C5aR in kidneys.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	28-34	interleukin 6	Mus musculus	81-85
18795895-8	2009	Furthermore, we found that the IL (interleukin)-6 level in culture medium was significantly increased after stimulation with APN and the IL-6 mRNA level was also markedly increased in CFBs, which can be reversed by siRNA for AdipoR1, but not for AdipoR2, and that anti-IL-6 neutralizing antibody can significantly inhibit APN-induced STAT3 Tyr(705) phosphorylation.	Tyrosine	340-343	interleukin 6	Mus musculus	31-49
18795895-8	2009	Furthermore, we found that the IL (interleukin)-6 level in culture medium was significantly increased after stimulation with APN and the IL-6 mRNA level was also markedly increased in CFBs, which can be reversed by siRNA for AdipoR1, but not for AdipoR2, and that anti-IL-6 neutralizing antibody can significantly inhibit APN-induced STAT3 Tyr(705) phosphorylation.	Tyrosine	340-343	interleukin 6	Mus musculus	137-141
19020550-3	2009	GTPs resulted in reduction in the levels of markers of inflammation (cyclooxygenase-2, prostaglandin E(2), proliferating cell nuclear antigen, and cyclin D1) and proinflammatory cytokines (tumor necrosis factor-alpha, IL-6, and IL-1beta) in chronically UVB-exposed skin and skin tumors of wild-type mice but less effective in IL-12p40-KO mice.	gtps	0-4	interleukin 6	Mus musculus	218-222
18602807-0	2009	Mechanisms for suppression of interleukin-6 expression in peritoneal macrophages from docosahexaenoic acid-fed mice.	Docosahexaenoic Acids	86-106	interleukin 6	Mus musculus	30-43
18602807-1	2009	Consumption of the trichothecene mycotoxin deoxynivalenol (DON) induces interleukin-6 (IL-6)-dependent IgA nephropathy (IgAN) in mice.	Trichothecenes	19-32	interleukin 6	Mus musculus	72-85
18602807-1	2009	Consumption of the trichothecene mycotoxin deoxynivalenol (DON) induces interleukin-6 (IL-6)-dependent IgA nephropathy (IgAN) in mice.	Trichothecenes	19-32	interleukin 6	Mus musculus	87-91
18602807-1	2009	Consumption of the trichothecene mycotoxin deoxynivalenol (DON) induces interleukin-6 (IL-6)-dependent IgA nephropathy (IgAN) in mice.	deoxynivalenol	43-57	interleukin 6	Mus musculus	72-85
18602807-1	2009	Consumption of the trichothecene mycotoxin deoxynivalenol (DON) induces interleukin-6 (IL-6)-dependent IgA nephropathy (IgAN) in mice.	deoxynivalenol	43-57	interleukin 6	Mus musculus	87-91
18602807-1	2009	Consumption of the trichothecene mycotoxin deoxynivalenol (DON) induces interleukin-6 (IL-6)-dependent IgA nephropathy (IgAN) in mice.	deoxynivalenol	59-62	interleukin 6	Mus musculus	72-85
18602807-1	2009	Consumption of the trichothecene mycotoxin deoxynivalenol (DON) induces interleukin-6 (IL-6)-dependent IgA nephropathy (IgAN) in mice.	deoxynivalenol	59-62	interleukin 6	Mus musculus	87-91
18602807-3	2009	The purpose of this study was to identify the signal transduction pathways by which DON up-regulates IL-6 in the peritoneal macrophage and how consumption of fish oil enriched with the n-3 PUFA docosahexaenoic acid (DHA) suppresses these processes.	deoxynivalenol	84-87	interleukin 6	Mus musculus	101-105
18602807-3	2009	The purpose of this study was to identify the signal transduction pathways by which DON up-regulates IL-6 in the peritoneal macrophage and how consumption of fish oil enriched with the n-3 PUFA docosahexaenoic acid (DHA) suppresses these processes.	Docosahexaenoic Acids	194-214	interleukin 6	Mus musculus	101-105
18602807-4	2009	Incubation with DON induced IL-6 expression in naive macrophages maximally at 3 h. Knockdown of the transcription factor cAMP response element-binding protein (CREB) or pharmacologic inhibition of the CREB kinases Akt1/2, MSK1 and RSK1 down-regulated this expression.	deoxynivalenol	16-19	interleukin 6	Mus musculus	28-32
18602807-8	2009	Although cells cultured directly with DHA expressed less IL-6 compared to cells cultured with arachidonic acid (AA), neither fatty acid treatment affected DON-induced protein phosphorylation.	Docosahexaenoic Acids	38-41	interleukin 6	Mus musculus	57-61
18602807-10	2009	These data suggest that DON-induced IL-6 expression is CREB mediated and PKR dependent, and that requisite kinase activities for these pathways were suppressed in macrophages from mice fed DHA for an extended period.	deoxynivalenol	24-27	interleukin 6	Mus musculus	36-40
19299019-0	2009	STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria.	Tyrosine	6-14	interleukin 6	Mus musculus	70-83
19107859-0	2009	Stimulation of osteoblastic differentiation and inhibition of interleukin-6 and nitric oxide in MC3T3-E1 cells by pomegranate ethanol extract.	Ethanol	126-133	interleukin 6	Mus musculus	62-75
19148883-2	2009	The oral administration of PE (100 and 200 mg/kg per day) for 21 days after subcutaneous immunization with FCA, significantly reduced hindpaw swelling and the production of inflammatory cytokines (TNF-alpha, IL-1beta and IL-6) compared with the FCA-induced arthritis group.	pe	27-29	interleukin 6	Mus musculus	221-225
19148883-8	2009	Moreover, administration of PE (100 mg/kg) for 49 days reduced the serum levels of rheumatoid factor, anti-type II collagen antibody, TNF-alpha, IL-1beta, IL-6, protein carbonyl, advanced glycation endproducts, malondialdehyde and LDL-cholesterol compared with that of CIA mice.	pe	28-30	interleukin 6	Mus musculus	155-159
18827741-10	2009	Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP.	Losartan	0-8	interleukin 6	Mus musculus	55-59
19407980-4	2009	TSA significantly decreased the mRNA and protein levels of the proinflammatory cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-1beta, whereas the pretreatment with TSA increased the level of the immunosuppressive cytokine IL-10.	trichostatin A	0-3	interleukin 6	Mus musculus	133-151
19251417-2	2009	Elevated levels of IFN-gamma and IL-6 were produced in spleen cells from mice immunised with a C(32) MMG analogue comparable activity to the potent Th1 adjuvant, trehalose 6,6"-di-behenate (TDB).	trehalose 6,6'-dibehenate	190-193	interleukin 6	Mus musculus	33-37
19189960-5	2009	Dextromethorphan pretreatment significantly suppressed the production of tumour necrosis factor-alpha, monocyte chemoattractant protein-1, interleukin-6, interleukin-10, and superoxide in macrophage cell culture after stimulation.	Dextromethorphan	0-16	interleukin 6	Mus musculus	139-152
19022895-2	2009	The signals that trigger PGE(2) production are thought to include proinflammatory cytokines, such as IL-6.	Dinoprostone	25-31	interleukin 6	Mus musculus	101-105
19022895-4	2009	Here we examined the relationship between IL-6 and PGE(2) in lipopolysaccharide (LPS)-induced fever.	Prostaglandins E	51-54	interleukin 6	Mus musculus	42-46
19022895-5	2009	Immune-challenged IL-6 knockout mice did not produce fever, in contrast to wild-type mice, but the expression of the inducible PGE(2)-synthesizing enzymes, cyclooxygenase-2 and microsomal prostaglandin E synthase-1, was similarly up-regulated in the hypothalamus of both genotypes, which also displayed similarly elevated PGE(2) levels in the cerebrospinal fluid.	Dinoprostone	127-133	interleukin 6	Mus musculus	18-22
19022895-8	2009	Hence, although IL-6 knockout mice have both an intact PGE(2) synthesis and an intact fever-generating pathway downstream of PGE(2), endogenously produced PGE(2) is not sufficient to produce fever in the absence of IL-6.	Prostaglandins E	55-58	interleukin 6	Mus musculus	16-20
19022895-8	2009	Hence, although IL-6 knockout mice have both an intact PGE(2) synthesis and an intact fever-generating pathway downstream of PGE(2), endogenously produced PGE(2) is not sufficient to produce fever in the absence of IL-6.	Prostaglandins E	125-128	interleukin 6	Mus musculus	16-20
19022895-8	2009	Hence, although IL-6 knockout mice have both an intact PGE(2) synthesis and an intact fever-generating pathway downstream of PGE(2), endogenously produced PGE(2) is not sufficient to produce fever in the absence of IL-6.	Prostaglandins E	125-128	interleukin 6	Mus musculus	16-20
19022895-9	2009	The findings suggest that IL-6 controls some factor(s) in the inflammatory cascade, which render(s) IL-6 knockout mice refractory to the pyrogenic action of PGE(2), or that it is involved in the mechanisms that govern release of synthesized PGE(2) onto its target neurons.	Prostaglandins E	157-160	interleukin 6	Mus musculus	26-30
19022895-9	2009	The findings suggest that IL-6 controls some factor(s) in the inflammatory cascade, which render(s) IL-6 knockout mice refractory to the pyrogenic action of PGE(2), or that it is involved in the mechanisms that govern release of synthesized PGE(2) onto its target neurons.	Prostaglandins E	241-244	interleukin 6	Mus musculus	26-30
19133650-5	2009	Within 4 days of ethanol exposure, we observed a striking spike in expression of hepatic proinflammatory cytokines-including tumor necrosis factor alpha (TNF-alpha), interleukin-6, and interferon-gamma-prior to hepatic triglyceride accumulation or increased plasma alanine aminotransferase activities, as well as before the induction of cytochrome P450 2E1 or oxidative stress.	Ethanol	17-24	interleukin 6	Mus musculus	166-179
19291858-9	2009	The most striking differences observed between saline and R(+)-verapamil pretreated animals on combination therapy included down-regulation of TNF-alpha, higher levels of IL-6, and decreased IFN-gamma concentrations.	Sodium Chloride	47-53	interleukin 6	Mus musculus	171-175
19291858-9	2009	The most striking differences observed between saline and R(+)-verapamil pretreated animals on combination therapy included down-regulation of TNF-alpha, higher levels of IL-6, and decreased IFN-gamma concentrations.	Verapamil	58-72	interleukin 6	Mus musculus	171-175
19505382-6	2009	On the other hand, ASBG at relatively lower doses significantly amplified the lung expression of IL-2, IL-6, and IL-12 as compared with vehicle.	asbg	19-23	interleukin 6	Mus musculus	103-107
19505402-4	2009	We observed that apicidin significantly attenuated surface molecule expression in LPS-stimulated DCs, suppressed production of interleukin (IL)-12 and proinflammatory cytokines (IL-6 and TNF-alpha) by DCs, and reduced IFN-gama production by T cells.	apicidin	17-25	interleukin 6	Mus musculus	178-182
18621395-7	2009	We also investigated whether ACh stimulates IL-6 release from Kupffer cells.	Acetylcholine	29-32	interleukin 6	Mus musculus	44-48
18621395-11	2009	Furthermore, ACh stimulated IL-6 release in Kupffer cells in vitro.	Acetylcholine	13-16	interleukin 6	Mus musculus	28-32
18974013-14	2009	IL-6 neutralizing antibodies and piroxicam inhibited the decrease OPG expression, but did not modify RANKL mRNA level, indicating that IL-6 and PGE(2) induce a decrease of the OPG/RANKL ratio.	Piroxicam	33-42	interleukin 6	Mus musculus	135-139
18974013-14	2009	IL-6 neutralizing antibodies and piroxicam inhibited the decrease OPG expression, but did not modify RANKL mRNA level, indicating that IL-6 and PGE(2) induce a decrease of the OPG/RANKL ratio.	Prostaglandins E	144-147	interleukin 6	Mus musculus	0-4
18791496-2	2009	Studies have shown that administration of 17beta-estradiol (estrogen) after trauma-hemorrhage normalized cardiac IL-6 levels and restored cardiac functions under those conditions.	Estradiol	42-58	interleukin 6	Mus musculus	113-117
19526759-6	2009	in vivo studies showed that icariin at the dose of 20 mg/kg significantly lowered serum TNF-alpha and IL-6 levels (P &lt; 0.01), reduced the average fluorescence intensity of adhesion molecules CD11b (P &lt; 0.01), and alleviated pulmonary inflammatory cell infiltration.	icariin	28-35	interleukin 6	Mus musculus	102-106
19526759-7	2009	CONCLUSION: Icariin is a safe and effective natural anti-inflammatory drug, its partial mechanism is possible the multiple links intervention on pro-inflammatory cytokines (TNF-alpha, IL-6), inflammatory mediators (NO) and adhesion molecules (CD11b).	icariin	12-19	interleukin 6	Mus musculus	184-188
19139077-5	2009	Intriguingly, we found, using isoform-specific PI3K inhibitors, that LPS- or cytosine-phosphate-guanosine-induced interleukin-6 (IL-6) is positively regulated by p110alpha, -gamma, and -delta but negatively regulated by p110beta.	cytosine phosphate	77-95	interleukin 6	Mus musculus	114-127
19139077-5	2009	Intriguingly, we found, using isoform-specific PI3K inhibitors, that LPS- or cytosine-phosphate-guanosine-induced interleukin-6 (IL-6) is positively regulated by p110alpha, -gamma, and -delta but negatively regulated by p110beta.	cytosine phosphate	77-95	interleukin 6	Mus musculus	129-133
19139077-5	2009	Intriguingly, we found, using isoform-specific PI3K inhibitors, that LPS- or cytosine-phosphate-guanosine-induced interleukin-6 (IL-6) is positively regulated by p110alpha, -gamma, and -delta but negatively regulated by p110beta.	Guanosine	96-105	interleukin 6	Mus musculus	114-127
19139077-5	2009	Intriguingly, we found, using isoform-specific PI3K inhibitors, that LPS- or cytosine-phosphate-guanosine-induced interleukin-6 (IL-6) is positively regulated by p110alpha, -gamma, and -delta but negatively regulated by p110beta.	Guanosine	96-105	interleukin 6	Mus musculus	129-133
18848983-6	2009	Increased amounts of TNF-alpha and IL-6 were also evident in SDR DC cultures stimulated with poly(I:C).	poly	93-97	interleukin 6	Mus musculus	35-39
18848983-6	2009	Increased amounts of TNF-alpha and IL-6 were also evident in SDR DC cultures stimulated with poly(I:C).	Carbon	99-101	interleukin 6	Mus musculus	35-39
19222121-5	2009	Our results demonstrated that paeonol inhibited LPS induced expression of NO, PGE(2) and IL-6.	paeonol	30-37	interleukin 6	Mus musculus	89-93
18818284-2	2009	Using 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR), a pharmacological activator of 5"-AMP-activated protein kinase (AMPK), we tested the hypothesis that AMPK modulates IL-6 release from isolated muscle.	acadesine	62-67	interleukin 6	Mus musculus	186-190
19027739-12	2009	Histidine inhibited LPS-induced TNF-alpha and IL-6 production by mouse macrophages in a concentration-dependent manner, whereas alanine or histidine-related metabolites had no such effect.	Histidine	0-9	interleukin 6	Mus musculus	46-50
19050899-6	2009	Intrarectal treatment of TNBS in mice caused colon shortening and also increased colonic expression of IL-1beta, IL-6, and TNF-alpha expression.	Trinitrobenzenesulfonic Acid	25-29	interleukin 6	Mus musculus	113-117
19067146-5	2009	The TNBS treatment caused colon shortening, increased myeloperoxidase activity, induced IL-1beta, TNF-alpha, and IL-6 expression in the colon, activated NF-kappaB, and potentiated the GAG-degrading activities of intestinal microflora.	Trinitrobenzenesulfonic Acid	4-8	interleukin 6	Mus musculus	113-117
19204515-11	2009	In contrast, tetrandrine prolonged the LPS-induced elevation in serum IL-10 concentrations only mildly changed the serum IL-6 concentrations.	tetrandrine	13-24	interleukin 6	Mus musculus	121-125
18952294-5	2009	The treatment of BMDM cultures with TMAP stimulated the production of nine cytokines and chemokines (IL-6, MCP-5, MIP-1 alpha, MIP-1 gamma, MIP-2, GCSF, KC, VEGF, and RANTES) that was measured using cytokine antibody array and confirmed by Western blot.	4,4',5'-trimethylazapsoralen	36-40	interleukin 6	Mus musculus	101-105
19173740-8	2009	IL-6 also markedly stimulated PA-SMC migration without affecting proliferation.	pa-smc	30-36	interleukin 6	Mus musculus	0-4
19001548-10	2009	Finally, proinflammatory cytokines [tumor necrosis factor-alpha, interleukin (IL)-1beta, and IL-6] increased thymocyte sensitivity to DHC-induced apoptosis through a mechanism involving 11beta-HSD1.	11-dehydrocorticosterone	134-137	interleukin 6	Mus musculus	93-97
19293443-1	2009	BACKGROUND &amp; OBJECTIVES: The distribution of brain interleukin-6 (IL-6) may be asymmetrical both in cortex and hippocampus.	Adenosine Monophosphate	12-15	interleukin 6	Mus musculus	55-68
19293443-1	2009	BACKGROUND &amp; OBJECTIVES: The distribution of brain interleukin-6 (IL-6) may be asymmetrical both in cortex and hippocampus.	Adenosine Monophosphate	12-15	interleukin 6	Mus musculus	70-74
18996162-1	2009	To investigate the involvement of central or peripheral catecholaminergic systems in the MK-801-induced increase in plasma corticosterone and interleukin-6 levels, we pretreated mice either intracerebroventricularly (i.c.v.)	Dizocilpine Maleate	89-95	interleukin 6	Mus musculus	142-155
19471100-0	2009	Crucial role of interleukin-6 in the development of norepinephrine-induced left ventricular remodeling in mice.	Norepinephrine	52-66	interleukin 6	Mus musculus	16-29
18854367-10	2009	Lower molecular weight hyaluronan induced IL-6 and MCP-1 production in PBMC, but high-molecular-weight hyaluronan did not induce IL-6 and MCP-1 production.	Hyaluronic Acid	23-33	interleukin 6	Mus musculus	42-46
19239176-6	2009	We have shown that TauCl/TauBr and CO inhibit the production of TNF-alpha, IL-12 and IL-6, in a similar dose-dependent manner.	N-chlorotaurine	19-24	interleukin 6	Mus musculus	85-89
19239176-6	2009	We have shown that TauCl/TauBr and CO inhibit the production of TNF-alpha, IL-12 and IL-6, in a similar dose-dependent manner.	N-bromotaurine	25-30	interleukin 6	Mus musculus	85-89
19519907-10	2009	Nicotine also showed a direct anti-inflammatory effect diminishing IL-6 production by stimulated splenocytes in vitro (P &lt; 0.001).	Nicotine	0-8	interleukin 6	Mus musculus	67-71
18854367-11	2009	An anti-CD44 antibody attenuated the induction of both IL-6 and MCP-1 in lower molecular weight hyaluronan-stimulated PBMC.	Hyaluronic Acid	96-106	interleukin 6	Mus musculus	55-59
18854367-12	2009	In both TLR4 mutant and CD44-null mice, the induction of IL-6 by lower molecular weight hyaluronan stimulation was decreased.	Hyaluronic Acid	88-98	interleukin 6	Mus musculus	57-61
18854367-13	2009	SB203580 completely abolished IL-6 production in both TLR4 mutant and CD44-null mononuclear cells, while PD98059 abolished IL-6 production in CD44-null mononuclear cells.	SB 203580	0-8	interleukin 6	Mus musculus	30-34
18854367-13	2009	SB203580 completely abolished IL-6 production in both TLR4 mutant and CD44-null mononuclear cells, while PD98059 abolished IL-6 production in CD44-null mononuclear cells.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	105-112	interleukin 6	Mus musculus	123-127
19172483-3	2009	We found elevated serum corticosterone after 3 weeks of antigen administration in presence of CFA and a higher serum IL-6 level that also alter lymphoid tissue cytokine responses like TNF-alpha, IL-12p70, and IL-6, among which IL-12p70 and TNF-alpha down-regulate the activity of steroidogenic enzymes in the thymus during an immune response.	Corticosterone	24-38	interleukin 6	Mus musculus	209-213
19327545-8	2009	Furthermore, LP cells from the small intestine in Bp-associated mice showed a tendency to produce slightly lower IFN-gamma and IL-6, while the cells from large intestine produced markedly higher IFN-gamma, IL-5 and IL-6 than those in the CONT group.	Benzo(a)pyrene	50-52	interleukin 6	Mus musculus	127-131
19115042-10	2009	In bone marrow-derived dendritic cells, CRDO induced production of TNF-alpha and IL-6.	crdo	40-44	interleukin 6	Mus musculus	81-85
19022403-0	2009	Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression.	Resveratrol	71-82	interleukin 6	Mus musculus	199-203
19022403-10	2009	In addition, resveratrol directly suppressed expression of IL-6 and IL-12/23 p40 but increased expression of IL-12 p35 and IL-23 p19 from macrophages.	Resveratrol	13-24	interleukin 6	Mus musculus	59-63
19022403-11	2009	Therefore resveratrol protection against EAE is not associated with declines in IL-17+ T cells but is associated with rises in IL-17+/IL-10+ T cells and CD4(-)IFN-gamma+ and with repressed macrophage IL-6 and IL-12/23 p40 expression.	Resveratrol	10-21	interleukin 6	Mus musculus	200-204
19167992-1	2009	Analysis of plasma cytokine concentration changes determined that oral dosing with the antitumor agent (1:4 mol:mol) calcium pterin (CaPterin) increased plasma IL-10, decreased plasma IL-6, and decreased plasma IFN-gamma concentrations in nude mice with MDA-MB-231 xenograph tumors [Moheno, P., Pfleiderer, W., Dipasquale, A.G., Rheingold, A.L., Fuchs, D., 2008.	calcium pterin	117-131	interleukin 6	Mus musculus	184-188
19436757-7	2009	CONCLUSIONS: Present results indicate that IL-6 mediates age-related loss of critical PV-expressing GABAergic interneurons through increased neuronal NADPH-oxidase-derived superoxide production, and that rescue of these interneurons preserves cognitive performance in aging mice, suggesting that elevated peripheral IL-6 levels may be directly and mechanistically linked to long-lasting cognitive deficits in even normal older individuals.	Superoxides	172-182	interleukin 6	Mus musculus	43-47
19167992-1	2009	Analysis of plasma cytokine concentration changes determined that oral dosing with the antitumor agent (1:4 mol:mol) calcium pterin (CaPterin) increased plasma IL-10, decreased plasma IL-6, and decreased plasma IFN-gamma concentrations in nude mice with MDA-MB-231 xenograph tumors [Moheno, P., Pfleiderer, W., Dipasquale, A.G., Rheingold, A.L., Fuchs, D., 2008.	capterin	133-141	interleukin 6	Mus musculus	184-188
19167992-9	2009	This DCP/APCP composite measure identifies plasma IL-12 concentration increases, plasma IL-6 concentration decreases, and plasma IL-4 concentration increases correlated to relative tumor volume decreases caused by DCP dosing.	dcp	5-8	interleukin 6	Mus musculus	88-92
19167992-10	2009	The finding that the novel calcium pterins and CaCl(2).2H(2)O treatments decrease plasma IL-6 concentrations corroborates the previous finding that CaPterin dosing decreases plasma IL-6 concentrations in this mouse/tumor system [Moheno, P., Pfleiderer, W., Dipasquale, A.G., Rheingold, A.L., Fuchs, D., 2008.	calcium pterins	27-42	interleukin 6	Mus musculus	89-93
19167992-10	2009	The finding that the novel calcium pterins and CaCl(2).2H(2)O treatments decrease plasma IL-6 concentrations corroborates the previous finding that CaPterin dosing decreases plasma IL-6 concentrations in this mouse/tumor system [Moheno, P., Pfleiderer, W., Dipasquale, A.G., Rheingold, A.L., Fuchs, D., 2008.	calcium pterins	27-42	interleukin 6	Mus musculus	181-185
19167992-10	2009	The finding that the novel calcium pterins and CaCl(2).2H(2)O treatments decrease plasma IL-6 concentrations corroborates the previous finding that CaPterin dosing decreases plasma IL-6 concentrations in this mouse/tumor system [Moheno, P., Pfleiderer, W., Dipasquale, A.G., Rheingold, A.L., Fuchs, D., 2008.	Calcium Chloride	47-61	interleukin 6	Mus musculus	89-93
19167992-10	2009	The finding that the novel calcium pterins and CaCl(2).2H(2)O treatments decrease plasma IL-6 concentrations corroborates the previous finding that CaPterin dosing decreases plasma IL-6 concentrations in this mouse/tumor system [Moheno, P., Pfleiderer, W., Dipasquale, A.G., Rheingold, A.L., Fuchs, D., 2008.	Calcium Chloride	47-61	interleukin 6	Mus musculus	181-185
19167992-10	2009	The finding that the novel calcium pterins and CaCl(2).2H(2)O treatments decrease plasma IL-6 concentrations corroborates the previous finding that CaPterin dosing decreases plasma IL-6 concentrations in this mouse/tumor system [Moheno, P., Pfleiderer, W., Dipasquale, A.G., Rheingold, A.L., Fuchs, D., 2008.	capterin	148-156	interleukin 6	Mus musculus	89-93
19167992-10	2009	The finding that the novel calcium pterins and CaCl(2).2H(2)O treatments decrease plasma IL-6 concentrations corroborates the previous finding that CaPterin dosing decreases plasma IL-6 concentrations in this mouse/tumor system [Moheno, P., Pfleiderer, W., Dipasquale, A.G., Rheingold, A.L., Fuchs, D., 2008.	capterin	148-156	interleukin 6	Mus musculus	181-185
18832108-8	2009	Risperidone (0.1-3.2 mg/kg twice a day) hardly affected the 5-HIAA levels but dose-dependently attenuated the serum IL-6 levels, plasma amylase/lipase levels, platelet counts, histological alterations, and mortality of diet-induced pancreatitis mice.	Risperidone	0-11	interleukin 6	Mus musculus	116-120
19662581-3	2009	This work aimed to investigate the in vivo effect of a water extract of lemongrass on pro-inflammatory cytokine (IL-1beta and IL-6) production by macrophages of BALB/c mice.	Water	55-60	interleukin 6	Mus musculus	126-130
19662581-6	2009	Treatment of mice with water extract of lemongrass inhibited macrophages to produce IL-1beta but induced IL-6 production by these cells.	Water	23-28	interleukin 6	Mus musculus	105-109
18785685-8	2009	SMs induced concentration-related increases in TNF-alpha and IL-6 production; in contrast, the production of these cytokines was shown to decrease with increasing concentrations of SNs.	sms	0-3	interleukin 6	Mus musculus	61-65
19109188-4	2009	In this study we demonstrate that IC/Ig can significantly inhibit LPS-induced secretion of TNF-alpha and IL-6 from macrophages by preferentially inducing PGE(2).	Prostaglandins E	154-157	interleukin 6	Mus musculus	105-109
19109188-6	2009	Furthermore, blockade of PGE(2) by celecoxib restores LPS-induced production of TNF-alpha and IL-6 in the presence of IC both in vitro and in vivo.	Prostaglandins E	25-28	interleukin 6	Mus musculus	94-98
19109188-6	2009	Furthermore, blockade of PGE(2) by celecoxib restores LPS-induced production of TNF-alpha and IL-6 in the presence of IC both in vitro and in vivo.	Celecoxib	35-44	interleukin 6	Mus musculus	94-98
20077215-5	2009	In addition, TBBPA increased the secretion and mRNA levels of proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-1beta.	tetrabromobisphenol A	13-18	interleukin 6	Mus musculus	131-149
19234608-11	2009	IL-6, TNFalpha, and MCP-1 mRNA expression were increased in the colon of TLE-fed, DSS-exposed NF-kappaB(EGFP) mice compared to the control diet.	(5r)-3-Ethyl-4-Hydroxy-5-Methyl-5-[(1e)-2-Methylbuta-1,3-Dien-1-Yl]thiophen-2(5h)-One	73-76	interleukin 6	Mus musculus	0-4
19234608-11	2009	IL-6, TNFalpha, and MCP-1 mRNA expression were increased in the colon of TLE-fed, DSS-exposed NF-kappaB(EGFP) mice compared to the control diet.	Dextran Sulfate	82-85	interleukin 6	Mus musculus	0-4
19738399-7	2009	A subtherapeutic dose of pioglitazone significantly suppresses the expression of TNF-alpha and IL-6 mRNA in WAT, but does not alter the serum glucose, insulin and WAT expression of adiponectin, adipocyte aP2 and LPL.	Pioglitazone	25-37	interleukin 6	Mus musculus	95-99
19738399-8	2009	A therapeutic dose of pioglitazone improves insulin sensitivity, enhances LPL, aP2 and adiponectin expression, and also suppresses TNF-alpha and IL-6 expression.	Pioglitazone	22-34	interleukin 6	Mus musculus	145-149
19091984-4	2008	Removal of IL-6 in neuronal cultures by anti-IL-6 blocking antibodies, or in vivo by use of IL-6-deficient mice, prevented the increase in superoxide by ketamine and rescued the interneurons.	Superoxides	139-149	interleukin 6	Mus musculus	11-15
18775799-0	2008	Sophocarpine and matrine inhibit the production of TNF-alpha and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice.	sophocarpine	0-12	interleukin 6	Mus musculus	65-69
18775799-0	2008	Sophocarpine and matrine inhibit the production of TNF-alpha and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice.	matrine	17-24	interleukin 6	Mus musculus	65-69
18775799-2	2008	The comparative study showed that all sophora alkaloids tested here, including matrine, oxymatrine, sophocarpine, sophoramine, and sophoridine, inhibited TNF-alpha and IL-6 production in both RAW264.7 cells and murine primary macrophages, and sophocarpine showed the most potent inhibitory effect among them.	sophora alkaloids	38-55	interleukin 6	Mus musculus	168-172
18775799-2	2008	The comparative study showed that all sophora alkaloids tested here, including matrine, oxymatrine, sophocarpine, sophoramine, and sophoridine, inhibited TNF-alpha and IL-6 production in both RAW264.7 cells and murine primary macrophages, and sophocarpine showed the most potent inhibitory effect among them.	matrine	79-86	interleukin 6	Mus musculus	168-172
18775799-2	2008	The comparative study showed that all sophora alkaloids tested here, including matrine, oxymatrine, sophocarpine, sophoramine, and sophoridine, inhibited TNF-alpha and IL-6 production in both RAW264.7 cells and murine primary macrophages, and sophocarpine showed the most potent inhibitory effect among them.	oxymatrine	88-98	interleukin 6	Mus musculus	168-172
18775799-2	2008	The comparative study showed that all sophora alkaloids tested here, including matrine, oxymatrine, sophocarpine, sophoramine, and sophoridine, inhibited TNF-alpha and IL-6 production in both RAW264.7 cells and murine primary macrophages, and sophocarpine showed the most potent inhibitory effect among them.	sophocarpine	100-112	interleukin 6	Mus musculus	168-172
18775799-2	2008	The comparative study showed that all sophora alkaloids tested here, including matrine, oxymatrine, sophocarpine, sophoramine, and sophoridine, inhibited TNF-alpha and IL-6 production in both RAW264.7 cells and murine primary macrophages, and sophocarpine showed the most potent inhibitory effect among them.	sophoramine	114-125	interleukin 6	Mus musculus	168-172
18775799-2	2008	The comparative study showed that all sophora alkaloids tested here, including matrine, oxymatrine, sophocarpine, sophoramine, and sophoridine, inhibited TNF-alpha and IL-6 production in both RAW264.7 cells and murine primary macrophages, and sophocarpine showed the most potent inhibitory effect among them.	matrine	131-142	interleukin 6	Mus musculus	168-172
18775799-3	2008	Quantification of TNF-alpha and IL-6 mRNA in RAW264.7 cells by real-time RT-PCR revealed that both sophocarpine and matrine suppressed TNF-alpha and IL-6 expression and sophocarpine has stronger suppressing potency than matrine.	sophocarpine	99-111	interleukin 6	Mus musculus	32-36
18775799-3	2008	Quantification of TNF-alpha and IL-6 mRNA in RAW264.7 cells by real-time RT-PCR revealed that both sophocarpine and matrine suppressed TNF-alpha and IL-6 expression and sophocarpine has stronger suppressing potency than matrine.	sophocarpine	99-111	interleukin 6	Mus musculus	149-153
18775799-3	2008	Quantification of TNF-alpha and IL-6 mRNA in RAW264.7 cells by real-time RT-PCR revealed that both sophocarpine and matrine suppressed TNF-alpha and IL-6 expression and sophocarpine has stronger suppressing potency than matrine.	matrine	116-123	interleukin 6	Mus musculus	32-36
18775799-3	2008	Quantification of TNF-alpha and IL-6 mRNA in RAW264.7 cells by real-time RT-PCR revealed that both sophocarpine and matrine suppressed TNF-alpha and IL-6 expression and sophocarpine has stronger suppressing potency than matrine.	matrine	116-123	interleukin 6	Mus musculus	149-153
18775799-6	2008	Furthermore, sophocarpine and matrine decreased the serum levels of TNF-alpha and IL-6, and sophocarpine showed a better therapeutic effect than matrine.	sophocarpine	13-25	interleukin 6	Mus musculus	82-86
18775799-6	2008	Furthermore, sophocarpine and matrine decreased the serum levels of TNF-alpha and IL-6, and sophocarpine showed a better therapeutic effect than matrine.	matrine	30-37	interleukin 6	Mus musculus	82-86
18775799-7	2008	These results suggest that sophocarpine and matrine exert anti-cachectic effects probably through inhibition of TNF-alpha and IL-6.	sophocarpine	27-39	interleukin 6	Mus musculus	126-130
18775799-7	2008	These results suggest that sophocarpine and matrine exert anti-cachectic effects probably through inhibition of TNF-alpha and IL-6.	matrine	44-51	interleukin 6	Mus musculus	126-130
19091984-4	2008	Removal of IL-6 in neuronal cultures by anti-IL-6 blocking antibodies, or in vivo by use of IL-6-deficient mice, prevented the increase in superoxide by ketamine and rescued the interneurons.	Ketamine	153-161	interleukin 6	Mus musculus	11-15
18948087-7	2008	Following TBI, the spared cortex of the rosiglitazone group showed significantly less numbers of GSI-B4(+) activated microglia/macrophages and ICAM1(+) capillaries, and curtailed induction of pro-inflammatory genes IL6, MCP1 and ICAM1 compared to vehicle group.	Rosiglitazone	40-53	interleukin 6	Mus musculus	215-218
19088199-5	2008	We found that SOCS3-known to interact with phosphotyrosine-containing peptides and be selectively induced by CD28-Ig/IL-6-would bind IDO and target the IDO/SOCS3 complex for ubiquitination and subsequent proteasomal degradation.	Phosphotyrosine	43-58	interleukin 6	Mus musculus	117-121
19088199-5	2008	We found that SOCS3-known to interact with phosphotyrosine-containing peptides and be selectively induced by CD28-Ig/IL-6-would bind IDO and target the IDO/SOCS3 complex for ubiquitination and subsequent proteasomal degradation.	Peptides	70-78	interleukin 6	Mus musculus	117-121
18922884-2	2008	M2AA administration at the time of CLP improved survival, renal function, kidney histology, liver injury, and splenocyte apoptosis, and lowered cytokine levels (TNF-alpha, IL-6, IFN-gamma, and IL-10).	N-acetyldehydroalanine methyl ester	0-4	interleukin 6	Mus musculus	172-176
18929643-5	2008	O(3) -induced lung expression of interleukin-6 was significantly greater in MT(-/-) than in wild-type mice; however, lung expression of the chemokines examined was comparable in both genotypes of mice in the presence of O(3).	Ozone	0-4	interleukin 6	Mus musculus	33-46
18755299-7	2008	THF not only down-regulated TNF-alpha mRNA expression but also decreased TNF-alpha and IL-6 release from RAW264.7 cells induced by LPS in a dose-dependent manner.	2',5,6',7-tetrahydroxyflavanonol	0-3	interleukin 6	Mus musculus	87-91
18930730-4	2008	Our data demonstrate that glycine treatment in lean mice suppressed TNF-alpha transcriptional expression in fat tissue, and serum protein levels of IL-6 were suppressed, while adiponectin levels were increased.	Glycine	26-33	interleukin 6	Mus musculus	148-152
18930730-5	2008	In MSG/Ob mice, glycine suppressed TNF-alpha and IL-6 gene expression in fat tissue and significantly reduced protein levels of IL-6, resistin and leptin.	Glycine	16-23	interleukin 6	Mus musculus	49-53
18930730-5	2008	In MSG/Ob mice, glycine suppressed TNF-alpha and IL-6 gene expression in fat tissue and significantly reduced protein levels of IL-6, resistin and leptin.	Glycine	16-23	interleukin 6	Mus musculus	128-132
18586856-0	2008	In vivo vitamin E administration attenuates interleukin-6 and interleukin-1beta responses to an acute inflammatory insult in mouse skeletal and cardiac muscle.	Vitamin E	8-17	interleukin 6	Mus musculus	44-57
19030026-9	2008	The level of IL-6 was increased by 1.5- and 2-fold in the colon of GM-CSF(-/-) and Wt mice, respectively, following DSS challenge.	Dextran Sulfate	116-119	interleukin 6	Mus musculus	13-17
18586856-2	2008	These experiments tested the hypothesis that vitamin E administration attenuates nuclear factor kappaB (NF-kappaB), IL-6, IL-1beta and tumour necrosis factor alpha (TNFalpha) responses in skeletal and cardiac muscle to an inflammatory challenge induced by systemic LPS.	Vitamin E	45-54	interleukin 6	Mus musculus	116-120
18586856-9	2008	The major results provide the first in vivo evidence that short-term vitamin E administration reduces IL-6 and IL-1beta responses to LPS in skeletal and cardiac muscle and prevents LPS-induced increases in NF-kappaB activation and total oxidized proteins.	Vitamin E	69-78	interleukin 6	Mus musculus	102-106
18989766-6	2008	Mice treated with LPS alone showed markedly increased plasma levels of TNF-alpha, IL-1beta, IL-6 and IL-10, whereas mice pretreated with 20 mg/kg ceftiofur showed significantly decreased plasma levels of TNF-alpha, IL-1beta and IL-6, but increased plasma levels of IL-10.	ceftiofur	146-155	interleukin 6	Mus musculus	92-96
18930781-4	2008	Also, PGHB reduced the carrageenan-induced paw edema at 3h after oral administration, and suppressed the production of serum IL-6 in CIA mice.	pghb	6-10	interleukin 6	Mus musculus	125-129
18989766-6	2008	Mice treated with LPS alone showed markedly increased plasma levels of TNF-alpha, IL-1beta, IL-6 and IL-10, whereas mice pretreated with 20 mg/kg ceftiofur showed significantly decreased plasma levels of TNF-alpha, IL-1beta and IL-6, but increased plasma levels of IL-10.	ceftiofur	146-155	interleukin 6	Mus musculus	228-232
18796617-3	2008	RESULTS: IL-6 per se increased glucose uptake by activating serine/threonine protein kinase 11 (LKB1)/AMP-activated protein kinase/protein kinase B substrate of 160 kDa (AS160) pathway.	Glucose	31-38	interleukin 6	Mus musculus	9-13
18982014-0	2008	Low-dose acetylsalicylic acid inhibits the secretion of interleukin-6 from white adipose tissue.	Aspirin	9-29	interleukin 6	Mus musculus	56-69
19084112-12	2008	Consistent with these finding, colon cultures of DSS-treated Retnla(-/-) mice produced decreased IL-6 and increased IL-10 ex vivo.	dss	49-52	interleukin 6	Mus musculus	97-101
19258660-7	2008	In addition, the IL-6(-/-) genotype increased the saturated FA acid composition of the intramuscular TG fraction.	saturated fa acid	50-67	interleukin 6	Mus musculus	17-21
19258660-7	2008	In addition, the IL-6(-/-) genotype increased the saturated FA acid composition of the intramuscular TG fraction.	Triglycerides	101-103	interleukin 6	Mus musculus	17-21
19258660-9	2008	IL-6 ablation increases fatty acid transporter expression and intramuscular lipid accumulation, particularly the saturated fatty acids.	Fatty Acids	113-134	interleukin 6	Mus musculus	0-4
18982014-3	2008	OBJECTIVE: To investigate whether constitutively active cyclooxygenase (COX)/prostaglandin (PG) pathway in white adipose tissue (WAT) is responsible for basal IL-6 production.	prostaglandin (pg)	77-95	interleukin 6	Mus musculus	159-163
18982014-7	2008	Similarly, in mice, ASA (0.2 and 2.0 mg kg(-1)) suppressed SC WAT 6-keto-PGF(1alpha) (a stable metabolite of prostacyclin) and IL-6 release.	Aspirin	20-23	interleukin 6	Mus musculus	127-131
18982014-9	2008	Both ASA (5 mM) and NS-398 (COX-2 selective inhibitor &lt;or=1 microM), but not SC-560 (COX-1 selective inhibitor &lt;or=1 microM), attenuated IL-6 release from murine WAT in vitro and abolished its depot differences.	Aspirin	5-8	interleukin 6	Mus musculus	143-147
18982014-9	2008	Both ASA (5 mM) and NS-398 (COX-2 selective inhibitor &lt;or=1 microM), but not SC-560 (COX-1 selective inhibitor &lt;or=1 microM), attenuated IL-6 release from murine WAT in vitro and abolished its depot differences.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	20-26	interleukin 6	Mus musculus	143-147
18982014-10	2008	Prostacyclin receptor (IP) and, to a lesser extent, PGE(2) (EP2 and EP4) receptor agonists elevated the release of IL-6 from adipocytes.	Prostaglandins E	52-55	interleukin 6	Mus musculus	115-119
18982014-11	2008	CONCLUSIONS: In adipose tissue, constitutive COX-2-coupled prostacyclin triggers the release of basal IL-6, which in obese subjects is significantly dampened by ASA ingestion, thus offering a novel, modifiable pathway to regulate the potentially pathological component of this cytokine.	Epoprostenol	59-71	interleukin 6	Mus musculus	102-106
18982014-11	2008	CONCLUSIONS: In adipose tissue, constitutive COX-2-coupled prostacyclin triggers the release of basal IL-6, which in obese subjects is significantly dampened by ASA ingestion, thus offering a novel, modifiable pathway to regulate the potentially pathological component of this cytokine.	Aspirin	161-164	interleukin 6	Mus musculus	102-106
18819004-4	2008	While IL6-mediated JAK/STAT3 and PI3K/AKT signaling was important for proliferation of both cell lines, as shown in proliferation assays using the respective pathway inhibitors, AG490 and LY294002, the resistant cells were insensitive to induction of apoptosis using the same.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	188-196	interleukin 6	Mus musculus	6-9
18803240-6	2008	Interestingly, the induction of cyclooxygenase 2 and microsomal prostaglandin E synthase (mPGES), the rate-limiting enzymes for synthesis of PGE2 by LPS, was diminished to a degree that correlated with the absence of IL-6 but not entirely with leptin.	Dinoprostone	141-145	interleukin 6	Mus musculus	217-221
18819004-2	2008	In this report we used the IL6-dependent 7TD1 murine B-cell hybridoma as an in vitro model to study the interactions between IL6-signaling pathways and the development of dexamethasone resistance.	Dexamethasone	171-184	interleukin 6	Mus musculus	27-30
18461018-7	2008	Inability to signal through the CD14/TLR4 pathway (induced by CD14/KO or inhibition of CD14 expression by administration of geldanamycin) attenuated TNF-alpha, IL-1 beta, and IL-6 production in response to burn injury and improved postburn myocardial contractile function.	geldanamycin	124-136	interleukin 6	Mus musculus	175-179
19063842-9	2008	Furthermore, resveratrol could reduce the expression of IL-6 mRNA and intracellular content of IL-6, and decrease the expression of p-STAT3 protein in the liver of leukemic mice at a dose-dependent manner.	Resveratrol	13-24	interleukin 6	Mus musculus	56-60
19063842-9	2008	Furthermore, resveratrol could reduce the expression of IL-6 mRNA and intracellular content of IL-6, and decrease the expression of p-STAT3 protein in the liver of leukemic mice at a dose-dependent manner.	Resveratrol	13-24	interleukin 6	Mus musculus	95-99
19063842-10	2008	CONCLUSION: Resveratrol can function as an antileukemic agent through inducing apoptosis, modulating IL-6 and STAT3 both in vitro and in vivo.	Resveratrol	12-23	interleukin 6	Mus musculus	101-105
18790831-8	2008	The incubation of the microvessels with IL-6 (5 ng/ml) induced endothelial dysfunction in the presence of l-NAME and Indo in WT mice, but anti-IL-6 restored ACh-induced vasodilation in the presence of L-NAME and Indo in db/db mice.	NG-Nitroarginine Methyl Ester	106-112	interleukin 6	Mus musculus	40-44
18790831-8	2008	The incubation of the microvessels with IL-6 (5 ng/ml) induced endothelial dysfunction in the presence of l-NAME and Indo in WT mice, but anti-IL-6 restored ACh-induced vasodilation in the presence of L-NAME and Indo in db/db mice.	Indomethacin	117-121	interleukin 6	Mus musculus	40-44
18790831-8	2008	The incubation of the microvessels with IL-6 (5 ng/ml) induced endothelial dysfunction in the presence of l-NAME and Indo in WT mice, but anti-IL-6 restored ACh-induced vasodilation in the presence of L-NAME and Indo in db/db mice.	Acetylcholine	157-160	interleukin 6	Mus musculus	40-44
18790831-8	2008	The incubation of the microvessels with IL-6 (5 ng/ml) induced endothelial dysfunction in the presence of l-NAME and Indo in WT mice, but anti-IL-6 restored ACh-induced vasodilation in the presence of L-NAME and Indo in db/db mice.	Acetylcholine	157-160	interleukin 6	Mus musculus	138-147
18790831-8	2008	The incubation of the microvessels with IL-6 (5 ng/ml) induced endothelial dysfunction in the presence of l-NAME and Indo in WT mice, but anti-IL-6 restored ACh-induced vasodilation in the presence of L-NAME and Indo in db/db mice.	NG-Nitroarginine Methyl Ester	201-207	interleukin 6	Mus musculus	40-44
18790831-8	2008	The incubation of the microvessels with IL-6 (5 ng/ml) induced endothelial dysfunction in the presence of l-NAME and Indo in WT mice, but anti-IL-6 restored ACh-induced vasodilation in the presence of L-NAME and Indo in db/db mice.	NG-Nitroarginine Methyl Ester	201-207	interleukin 6	Mus musculus	138-147
18790831-8	2008	The incubation of the microvessels with IL-6 (5 ng/ml) induced endothelial dysfunction in the presence of l-NAME and Indo in WT mice, but anti-IL-6 restored ACh-induced vasodilation in the presence of L-NAME and Indo in db/db mice.	Indomethacin	212-216	interleukin 6	Mus musculus	40-44
18790831-8	2008	The incubation of the microvessels with IL-6 (5 ng/ml) induced endothelial dysfunction in the presence of l-NAME and Indo in WT mice, but anti-IL-6 restored ACh-induced vasodilation in the presence of L-NAME and Indo in db/db mice.	Indomethacin	212-216	interleukin 6	Mus musculus	138-147
18790831-9	2008	In db(TNF-)/db(TNF-) mice, EDHF-induced vasodilation was greater and comparable with controls, but IL-6 decreased EDHF-mediated vasodilation.	edhf	114-118	interleukin 6	Mus musculus	99-103
18790831-10	2008	Our results indicate that EDHF compensates for diminished NO-dependent dilation in IL-6-induced endothelial dysfunction by the activation of H2O2 or a K+ channel in type 2 diabetes.	edhf	26-30	interleukin 6	Mus musculus	83-87
18790831-10	2008	Our results indicate that EDHF compensates for diminished NO-dependent dilation in IL-6-induced endothelial dysfunction by the activation of H2O2 or a K+ channel in type 2 diabetes.	Hydrogen Peroxide	141-145	interleukin 6	Mus musculus	83-87
18973601-0	2008	Uncoupling of interleukin-6 from its signalling pathway by dietary n-3-polyunsaturated fatty acid deprivation alters sickness behaviour in mice.	Fatty Acids, Omega-3	67-97	interleukin 6	Mus musculus	14-27
18656556-8	2008	The injection of zymosan resulted in a substantial increase in the serum level of TNF-alpha and IL-6, which was strongly inhibited by AG-490.	Zymosan	17-24	interleukin 6	Mus musculus	96-100
18656556-8	2008	The injection of zymosan resulted in a substantial increase in the serum level of TNF-alpha and IL-6, which was strongly inhibited by AG-490.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	134-140	interleukin 6	Mus musculus	96-100
19330073-0	2008	Pravastatin prevents aortic atherosclerosis via modulation of signal transduction and activation of transcription 3 (STAT3) to attenuate interleukin-6 (IL-6) action in ApoE knockout mice.	Pravastatin	0-11	interleukin 6	Mus musculus	137-150
19330073-0	2008	Pravastatin prevents aortic atherosclerosis via modulation of signal transduction and activation of transcription 3 (STAT3) to attenuate interleukin-6 (IL-6) action in ApoE knockout mice.	Pravastatin	0-11	interleukin 6	Mus musculus	152-156
19330073-1	2008	The purpose of this study was to determine whether pravastatin"s prevention of aortic atherosclerosis via attenuation of IL-6 action depends on modulation of STAT3 activity.	Pravastatin	51-62	interleukin 6	Mus musculus	121-125
19330073-3	2008	After eight weeks, pravastatin significantly prevented atherosclerotic lesion and reduced levels of IL-6 in serum and lesion, and significantly decreased expressions of phosphorylated STAT3 (pSTAT3) and increased suppressor of cytokine signaling 3 (SOCS3) expressions in lesions.	Pravastatin	19-30	interleukin 6	Mus musculus	100-104
19330073-4	2008	Our results suggested that pravastatin"s aortic atherosclerosis preventing action via attenuation of IL-6 action may partially depend on modulation of STAT3 activity.	Pravastatin	27-38	interleukin 6	Mus musculus	101-105
18243243-7	2008	Administration of ATRA attenuated irradiation-induced intestinal fibrosis and reduced mRNA of interleukin-6 and transforming growth factor-beta(1).	Tretinoin	18-22	interleukin 6	Mus musculus	94-146
19008646-10	2008	PSL-induced upregulation of tumor necrosis factor-alpha and interleukin-6, which are essential for neuropathic pain, was suppressed by pioglitazone for the first week.	Pioglitazone	135-147	interleukin 6	Mus musculus	60-73
18397230-6	2008	In vitro studies disclosed that the administration of ATRA reduced (i) the production of TGF-beta1, IL-6 and collagen from HSCs, (ii) TGF-beta-dependent transdifferentiation of the cells and IL-6-dependent cell proliferation and (iii) the activities of nuclear factor-kappaB p65 and p38mitogen-activated protein kinase, which stimulate the production of TGF-beta1 and IL-6, which could be the mechanism underlying the preventive effect of ATRA on liver fibrosis.	Tretinoin	54-58	interleukin 6	Mus musculus	100-104
18397230-6	2008	In vitro studies disclosed that the administration of ATRA reduced (i) the production of TGF-beta1, IL-6 and collagen from HSCs, (ii) TGF-beta-dependent transdifferentiation of the cells and IL-6-dependent cell proliferation and (iii) the activities of nuclear factor-kappaB p65 and p38mitogen-activated protein kinase, which stimulate the production of TGF-beta1 and IL-6, which could be the mechanism underlying the preventive effect of ATRA on liver fibrosis.	Tretinoin	54-58	interleukin 6	Mus musculus	191-195
18397230-6	2008	In vitro studies disclosed that the administration of ATRA reduced (i) the production of TGF-beta1, IL-6 and collagen from HSCs, (ii) TGF-beta-dependent transdifferentiation of the cells and IL-6-dependent cell proliferation and (iii) the activities of nuclear factor-kappaB p65 and p38mitogen-activated protein kinase, which stimulate the production of TGF-beta1 and IL-6, which could be the mechanism underlying the preventive effect of ATRA on liver fibrosis.	Tretinoin	54-58	interleukin 6	Mus musculus	191-195
18985016-4	2008	The levels of TNF-alpha, IL-1beta, IL-6 and iNOS mRNAs determined by RT-PCR propose that the inhibition of these pro-inflammatory mediators by KBH-A42 resulted from inhibiting expression of these genes.	KBH A42	143-150	interleukin 6	Mus musculus	35-39
18991854-0	2008	Methamphetamine-induced early increase of IL-6 and TNF-alpha mRNA expression in the mouse brain.	Methamphetamine	0-15	interleukin 6	Mus musculus	42-46
18991854-3	2008	Therefore, in the present work we evaluated the effect of an acute administration of METH (30 mg/kg in a single intraperitoneal injection) on the interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha mRNA expression levels in the hippocampus, frontal cortex, and striatum of mice.	Methamphetamine	85-89	interleukin 6	Mus musculus	170-174
18991854-5	2008	Regarding IL-6, METH induced an increase in the expression levels of this cytokine in the hippocampus and striatum, 1 h and 30 min post injection, respectively.	Methamphetamine	16-20	interleukin 6	Mus musculus	10-14
18991854-6	2008	In the frontal cortex, the increase in IL-6 mRNA levels was more significant and remained high even after 2 h. Moreover, the expression levels of TNF-alpha were increased in both hippocampus and frontal cortex 30 min post METH administration, with immeasurable levels in the striatum.	Methamphetamine	222-226	interleukin 6	Mus musculus	39-43
18991854-7	2008	We conclude that the pro-inflammatory cytokines IL-6 and TNF-alpha rapidly increase after METH administration, providing a new insight for understanding the effect of this drug of abuse in the brain.	Methamphetamine	90-94	interleukin 6	Mus musculus	48-52
18500674-0	2008	(-)-Epigallocatechin gallate inhibits basic fibroblast growth factor-stimulated interleukin-6 synthesis in osteoblasts.	epigallocatechin gallate	0-28	interleukin 6	Mus musculus	80-93
18500674-2	2008	In the present study, we investigated the exact mechanism of IL-6 and the effects of (-)-epi-gallocatechin gallate (EGCG), one of the major green tea flavonoids, on the synthesis of IL-6.	epigallocatechin gallate	85-114	interleukin 6	Mus musculus	182-186
18500674-2	2008	In the present study, we investigated the exact mechanism of IL-6 and the effects of (-)-epi-gallocatechin gallate (EGCG), one of the major green tea flavonoids, on the synthesis of IL-6.	epigallocatechin gallate	116-120	interleukin 6	Mus musculus	182-186
18500674-3	2008	PD98059, an inhibitor of MEK, but not SP600125, an inhibitor of stress-activated protein kinase/c-Jun N-terminal kinase, suppressed FGF-2-stimulated IL-6 synthesis.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	interleukin 6	Mus musculus	149-153
18500674-4	2008	EGCG significantly reduced the IL-6 synthesis stimulated by FGF-2 in a dose-dependent manner.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	31-35
18500674-6	2008	These results strongly suggest that EGCG inhibits the FGF-2-stimulated synthesis of IL-6 at least partly via suppression of the p44/p42 MAP kinase pathway and the p38 MAP kinase pathway in osteoblasts.	epigallocatechin gallate	36-40	interleukin 6	Mus musculus	84-88
18792393-5	2008	Expression of inflammatory mediators (tumor necrosis factor-alpha and interleukin-6) and TLR4 coreceptors (CD14 and MD2) was significantly higher in livers of alcohol-fed WT, TLR2-KO, or MyD88-KO, but not in TLR4-KO mice, compared to controls.	Alcohols	159-166	interleukin 6	Mus musculus	70-83
18829859-12	2008	The expression of VEGF, MCP-1, IL-6, and ICAM-1 was significantly inhibited in telmisartan-treated mice.	Telmisartan	79-90	interleukin 6	Mus musculus	31-35
18678605-9	2008	CR was associated with increased plasma levels of corticosterone and adiponectin and reduced concentrations of IL-6 and leptin.	Chromium	0-2	interleukin 6	Mus musculus	111-115
18782267-6	2008	Importantly, triptolide inhibited the transcription of interleukin-17 (IL-17) mRNA and IL-6-induced phosphorylation of STAT3, a key signalling molecule involved in the development of Th17 cells.	triptolide	13-23	interleukin 6	Mus musculus	87-91
18717531-4	2008	Decreased expression of NFkappa-B-mediated cytokines Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNFalpha), resultant DNA fragmentation, and spectroscopic analysis revealed the efficient and localized drug-eluting properties of the Parylene A polymeric bilayer.	parylene a	242-252	interleukin 6	Mus musculus	68-72
18786831-3	2008	In this study, quaternized amino glucosamine (QAGlc), a newly synthesized cationic glucosamine (Glc) derivative was found to inhibit LPS-stimulated production of IL-1beta, IL-6, TNF-alpha, and PGE(2) in RAW264.7, mouse macrophages more potently than its starting material Glc.	amino glucosamine	27-44	interleukin 6	Mus musculus	172-176
18786831-3	2008	In this study, quaternized amino glucosamine (QAGlc), a newly synthesized cationic glucosamine (Glc) derivative was found to inhibit LPS-stimulated production of IL-1beta, IL-6, TNF-alpha, and PGE(2) in RAW264.7, mouse macrophages more potently than its starting material Glc.	qaglc	46-51	interleukin 6	Mus musculus	172-176
18786831-3	2008	In this study, quaternized amino glucosamine (QAGlc), a newly synthesized cationic glucosamine (Glc) derivative was found to inhibit LPS-stimulated production of IL-1beta, IL-6, TNF-alpha, and PGE(2) in RAW264.7, mouse macrophages more potently than its starting material Glc.	Glucosamine	33-44	interleukin 6	Mus musculus	172-176
18786831-3	2008	In this study, quaternized amino glucosamine (QAGlc), a newly synthesized cationic glucosamine (Glc) derivative was found to inhibit LPS-stimulated production of IL-1beta, IL-6, TNF-alpha, and PGE(2) in RAW264.7, mouse macrophages more potently than its starting material Glc.	Glucosamine	48-51	interleukin 6	Mus musculus	172-176
18786831-3	2008	In this study, quaternized amino glucosamine (QAGlc), a newly synthesized cationic glucosamine (Glc) derivative was found to inhibit LPS-stimulated production of IL-1beta, IL-6, TNF-alpha, and PGE(2) in RAW264.7, mouse macrophages more potently than its starting material Glc.	Glucosamine	96-99	interleukin 6	Mus musculus	172-176
18598759-9	2008	These results show that exogenous NO can increase COX-2-dependent PGD(2) and IL-6 production by MC in inflammatory environments through the p38 MAPK pathway.	Methylcholanthrene	96-98	interleukin 6	Mus musculus	77-81
18688044-4	2008	Chromatin immunoprecipitation assays showed that levels of histone H3 lysine 4 dimethylation (H3K4me2), a key chromatin mark associated with active gene expression, were significantly elevated at the promoters of the inflammatory genes monocyte chemoattractant protein-1 and interleukin-6 in db/db VSMCs relative to db/+ cells.	Lysine	70-76	interleukin 6	Mus musculus	275-288
18652822-0	2008	The critical role of invading peripheral macrophage-derived interleukin-6 in vincristine-induced mechanical allodynia in mice.	Vincristine	77-88	interleukin 6	Mus musculus	60-73
18652822-9	2008	The expression of IL-6 was increased by vincristine administration and was co-localized in the invading macrophage.	Vincristine	40-51	interleukin 6	Mus musculus	18-22
18652822-10	2008	Moreover, a neutralizing antibody of IL-6, which was injected into areas surrounding the sciatic nerve on day 0, 3, and 6, significantly attenuated vincristine-induced mechanical allodynia from day 7 to day 28.	Vincristine	148-159	interleukin 6	Mus musculus	37-41
18652822-11	2008	In addition, the incidence of vincristine-induced mechanical allodynia in IL-6 knockout mice was lower than that in wild type mice from day 3 to day 28.	Vincristine	30-41	interleukin 6	Mus musculus	74-78
18652822-12	2008	These results suggest that the invading peripheral macrophage-derived IL-6 plays a critical role in vincristine-induced mechanical allodynia.	Vincristine	100-111	interleukin 6	Mus musculus	70-74
18586382-0	2008	Involvement of Rho-kinase in prostaglandin F2alpha-stimulated interleukin-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts.	Dinoprost	29-50	interleukin 6	Mus musculus	62-75
18586382-1	2008	We have previously reported that prostaglandin F(2alpha) (PGF(2alpha)) stimulates interleukin-6 (IL-6), a potent bone resorptive agent, through p44/p42 mitogen-activated protein (MAP) kinase in osteoblast-like MC3T3-E1 cells.	Prostaglandins F	33-48	interleukin 6	Mus musculus	82-95
18586382-1	2008	We have previously reported that prostaglandin F(2alpha) (PGF(2alpha)) stimulates interleukin-6 (IL-6), a potent bone resorptive agent, through p44/p42 mitogen-activated protein (MAP) kinase in osteoblast-like MC3T3-E1 cells.	Prostaglandins F	33-48	interleukin 6	Mus musculus	97-101
18586382-1	2008	We have previously reported that prostaglandin F(2alpha) (PGF(2alpha)) stimulates interleukin-6 (IL-6), a potent bone resorptive agent, through p44/p42 mitogen-activated protein (MAP) kinase in osteoblast-like MC3T3-E1 cells.	Prostaglandins F	58-61	interleukin 6	Mus musculus	82-95
18586382-1	2008	We have previously reported that prostaglandin F(2alpha) (PGF(2alpha)) stimulates interleukin-6 (IL-6), a potent bone resorptive agent, through p44/p42 mitogen-activated protein (MAP) kinase in osteoblast-like MC3T3-E1 cells.	Prostaglandins F	58-61	interleukin 6	Mus musculus	97-101
18586382-4	2008	Y27632, a specific Rho-kinase inhibitor, significantly reduced the PGF(2alpha)-stimulated IL-6 synthesis as well as the MYPT-1 phosphorylation.	Y 27632	0-6	interleukin 6	Mus musculus	90-94
18586382-4	2008	Y27632, a specific Rho-kinase inhibitor, significantly reduced the PGF(2alpha)-stimulated IL-6 synthesis as well as the MYPT-1 phosphorylation.	Prostaglandins F	67-70	interleukin 6	Mus musculus	90-94
18586382-5	2008	Fasudil, another inhibitor of Rho-kinase, suppressed the PGF(2alpha)-stimulated IL-6 synthesis.	fasudil	0-7	interleukin 6	Mus musculus	80-84
18586382-5	2008	Fasudil, another inhibitor of Rho-kinase, suppressed the PGF(2alpha)-stimulated IL-6 synthesis.	Prostaglandins F	57-60	interleukin 6	Mus musculus	80-84
18586382-7	2008	SB203580 and BIRB0796, potent inhibitors of p38 MAP kinase, suppressed the IL-6 synthesis induced by PGF(2alpha).	SB 203580	0-8	interleukin 6	Mus musculus	75-79
18586382-7	2008	SB203580 and BIRB0796, potent inhibitors of p38 MAP kinase, suppressed the IL-6 synthesis induced by PGF(2alpha).	birb0796	13-21	interleukin 6	Mus musculus	75-79
18586382-7	2008	SB203580 and BIRB0796, potent inhibitors of p38 MAP kinase, suppressed the IL-6 synthesis induced by PGF(2alpha).	Prostaglandins F	101-104	interleukin 6	Mus musculus	75-79
18586382-10	2008	These results strongly suggest that Rho-kinase regulates PGF(2alpha)-stimulated IL-6 synthesis via p38 MAP kinase activation in osteoblasts.	Prostaglandins F	57-60	interleukin 6	Mus musculus	80-84
18617512-0	2008	Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFkappaB and AP-1 activation as well as IL-6 gene expression.	Threonine	19-22	interleukin 6	Mus musculus	150-154
18617512-0	2008	Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFkappaB and AP-1 activation as well as IL-6 gene expression.	Threonine	31-34	interleukin 6	Mus musculus	150-154
18719127-8	2008	Further, after high-fat diet feeding, IL-6 KO mice without expansion of alpha-cell mass display decreased fasting glucagon levels.	Glucagon	114-122	interleukin 6	Mus musculus	38-42
18421015-5	2008	Propranolol inhalation resulted in enhanced LPS-induced lung inflammation, which was reflected by a stronger secretion of TNF-alpha, IL-6, and monocyte chemoattractant protein-1 into BALF and by enhanced coagulation activation (thrombin-antithrombin complexes).	Propranolol	0-11	interleukin 6	Mus musculus	133-137
18586954-5	2008	Exposure of LPS-stimulated neutrophils to AICAR or barberine inhibited release of TNF-alpha and IL-6, as well as degradation of IkappaBalpha and nuclear translocation of NF-kappaB, compared with findings in neutrophil cultures that contained LPS without AICAR or barberine.	acadesine	42-47	interleukin 6	Mus musculus	96-100
18586954-5	2008	Exposure of LPS-stimulated neutrophils to AICAR or barberine inhibited release of TNF-alpha and IL-6, as well as degradation of IkappaBalpha and nuclear translocation of NF-kappaB, compared with findings in neutrophil cultures that contained LPS without AICAR or barberine.	barberine	51-60	interleukin 6	Mus musculus	96-100
18781477-6	2008	The in vitro stimulation of splenocytes harvested from Myo4-immunized animals with Myo4 resulted in cellular proliferation with preferential production of the Th1- and Th17-associated cytokines, IFN-gamma, IL-17, and IL-6, respectively.	myo4	55-59	interleukin 6	Mus musculus	217-221
18781477-6	2008	The in vitro stimulation of splenocytes harvested from Myo4-immunized animals with Myo4 resulted in cellular proliferation with preferential production of the Th1- and Th17-associated cytokines, IFN-gamma, IL-17, and IL-6, respectively.	myo4	83-87	interleukin 6	Mus musculus	217-221
18559975-6	2008	Unlike normal myeloid DCs, adenosine-differentiated DCs have impaired allostimulatory activity and express high levels of angiogenic, pro-inflammatory, immune suppressor, and tolerogenic factors, including VEGF, IL-8, IL-6, IL-10, COX-2, TGF-beta, and IDO.	Adenosine	27-36	interleukin 6	Mus musculus	218-222
18279557-10	2008	Both EC-M17 and metronidazole reduced colonic IL-12, IL-6, IL-1beta and interferon-gamma.	Metronidazole	16-29	interleukin 6	Mus musculus	53-57
18536750-8	2008	KEY RESULTS: Mice fed ATL-801 along with DSS showed a significantly lower extent and severity of colitis than mice treated with DSS alone, as shown by reduced clinical symptoms, histological scores, IL-6 levels and proliferation indices.	dss	41-44	interleukin 6	Mus musculus	199-203
18261796-7	2008	Moreover, the pro-inflammatory mediators (TNF-alpha, IL-beta, IL-6), LDH activity, AST, ALT, creatinine and BUN levels were significantly increased in the naphthalene group.	naphthalene	155-166	interleukin 6	Mus musculus	62-66
18710929-6	2008	Further studies using knockout mice showed that IL-6, rather than IL-23 and -17, are essential for oxazolone colitis induction.	Oxazolone	99-108	interleukin 6	Mus musculus	48-52
18714029-9	2008	Eicosanoid modulation of IL-6 and CCL2 expression was suggested by scattergram analyses.	Eicosanoids	0-10	interleukin 6	Mus musculus	25-29
18552204-6	2008	Supernatants from PAMP + ATP-treated glia induced the secretion of IL-6, IL-13, and MCP-1 from the MC/9 mast cell line in a manner similar to exogenous recombinant IL-33.	Adenosine Triphosphate	25-28	interleukin 6	Mus musculus	67-71
18562486-10	2008	Exposure of splenocytes to polyI activated the NF-kappaB pathway followed by the expression of TF and IL-6.	Poly I	27-32	interleukin 6	Mus musculus	102-106
18606228-7	2008	Embryo resorption correlates with the lack of PIBF expression, diminished IL-6 levels and increased IL-2 concentration while metformin was able to reverse the effect of DHEA on both PIBF and COX2 expression and IL-6 levels.	Metformin	125-134	interleukin 6	Mus musculus	74-78
18606228-7	2008	Embryo resorption correlates with the lack of PIBF expression, diminished IL-6 levels and increased IL-2 concentration while metformin was able to reverse the effect of DHEA on both PIBF and COX2 expression and IL-6 levels.	Metformin	125-134	interleukin 6	Mus musculus	211-215
18606228-7	2008	Embryo resorption correlates with the lack of PIBF expression, diminished IL-6 levels and increased IL-2 concentration while metformin was able to reverse the effect of DHEA on both PIBF and COX2 expression and IL-6 levels.	Dehydroepiandrosterone	169-173	interleukin 6	Mus musculus	211-215
18509318-7	2008	Both pravastatin and L-744832 inhibited the injury-induced increase in plasma IL-6 concentration to a similar extent.	Pravastatin	5-16	interleukin 6	Mus musculus	78-82
18509318-7	2008	Both pravastatin and L-744832 inhibited the injury-induced increase in plasma IL-6 concentration to a similar extent.	L 744832	21-29	interleukin 6	Mus musculus	78-82
18523137-6	2008	Furthermore, the amount of interleukin-6 and macrophage-inflammatory protein-2, but not tumor necrosis factor-alpha, released in response to lipopolysaccharide stimulation was significantly enhanced in the presence of UDP, and this effect was lost in the P2Y(6) KO macrophages.	Uridine Diphosphate	218-221	interleukin 6	Mus musculus	27-40
21479465-8	2008	As both telmisartan and losartan attenuated interleukin-6 mRNA expression in the aorta, there was a significant change in endothelial nitric oxide synthase (eNOS) mRNA in the aorta.	Telmisartan	8-19	interleukin 6	Mus musculus	44-57
21479465-8	2008	As both telmisartan and losartan attenuated interleukin-6 mRNA expression in the aorta, there was a significant change in endothelial nitric oxide synthase (eNOS) mRNA in the aorta.	Losartan	24-32	interleukin 6	Mus musculus	44-57
18713088-6	2008	RESULTS: In the LPS-induced ALI mouse model, the administration of edaravone attenuated cellular infiltration into and the concentrations of albumin, IL-6, tumour necrosis factor-alpha, keratinocyte-derived chemokine and macrophage inflammatory protein-2 in BAL fluid.	Edaravone	67-76	interleukin 6	Mus musculus	150-184
18713088-7	2008	In addition, the in vitro studies showed that the elevated IL-6 secretion from MH-S cells in response to LPS was significantly attenuated by co-incubation with edaravone.	Edaravone	160-169	interleukin 6	Mus musculus	59-63
18782259-3	2008	Parallel studies documented an overall impaired production of interleukin (IL)-6 and nitric oxide (NO) production by peritoneal macrophages in EtOH-treated mice following interferon (IFN)-gamma and lipopolysaccharide (LPS) stimuli.	Ethanol	143-147	interleukin 6	Mus musculus	62-80
18782259-6	2008	Moreover, 30 days after the last EtOH administration, lower IL-6 response to INF-gamma and impaired NO production were still observed in response to IFN-gamma/LPS stimuli, with the IL-6 response to IFN-gamma being restored by IFN-gamma/LPS stimuli.	Ethanol	33-37	interleukin 6	Mus musculus	60-64
18782259-6	2008	Moreover, 30 days after the last EtOH administration, lower IL-6 response to INF-gamma and impaired NO production were still observed in response to IFN-gamma/LPS stimuli, with the IL-6 response to IFN-gamma being restored by IFN-gamma/LPS stimuli.	Ethanol	33-37	interleukin 6	Mus musculus	181-185
18588857-7	2008	Lastly, GLN treatment led to a significant decrease in lung TNF-alpha and IL-6 post-sepsis.	Glutamine	8-11	interleukin 6	Mus musculus	74-78
18598692-7	2008	Both pirfenidone and prednisolone suppressed the increase in lung interleukin (IL)-1beta, IL-6, IL-12p40 and monocyte chemoattractant protein (MCP)-1 levels induced by bleomycin.	pirfenidone	5-16	interleukin 6	Mus musculus	90-94
18598692-7	2008	Both pirfenidone and prednisolone suppressed the increase in lung interleukin (IL)-1beta, IL-6, IL-12p40 and monocyte chemoattractant protein (MCP)-1 levels induced by bleomycin.	Prednisolone	21-33	interleukin 6	Mus musculus	90-94
18598692-7	2008	Both pirfenidone and prednisolone suppressed the increase in lung interleukin (IL)-1beta, IL-6, IL-12p40 and monocyte chemoattractant protein (MCP)-1 levels induced by bleomycin.	Bleomycin	168-177	interleukin 6	Mus musculus	90-94
18611916-11	2008	Whereas high-salt treatment markedly increased the expression of inflammatory cytokines (tumor necrosis factor-alpha, interferon-gamma, interleukin (IL)-1 beta and IL-6) in the gastric mucosa, COX-2 overexpression significantly altered the cell kinetics in the MNU-induced gastric cancer model.	Salts	13-17	interleukin 6	Mus musculus	164-168
18761814-7	2008	Furthermore, we found that albaconol used at a lower dosage without apoptosis induction could significantly inhibit LPS-induced TNF-alpha, IL-6, IL-1beta and NO production in RAW264.7 cells.	albaconol	27-36	interleukin 6	Mus musculus	139-143
18596626-10	2008	Hypercapnic acidosis with 2% respectively 4% CO2 significantly attenuated this increase with 25 +/- 32% and 54 +/- 32% (IL-1beta, p &lt; 0.01); 17 +/- 36% and 58 +/- 33% (TNF-alpha, p &lt; 0.02); 22 +/- 34% and 89 +/- 6% (IL-6, p &lt; 0.01); 20 +/- 31% and 67 +/- 17% (IL-10, p &lt; 0.01) and 16 +/- 44% and 45 +/- 30% (keratocyte-derived chemokine, p = 0.07).	N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide	45-48	interleukin 6	Mus musculus	222-226
18664788-12	2008	Interestingly, in mice treated with zymosan and phlebotomies, hepcidin expression was suppressed, despite the persistent increase in interleukin-6.	Zymosan	36-43	interleukin 6	Mus musculus	133-146
18480312-7	2008	A significant decrease in vascular endothelial growth factor-A and an increase in IL-6 were detected in kidneys of these rapamycin-treated mice.	Sirolimus	121-130	interleukin 6	Mus musculus	82-86
18756103-2	2008	A methanol extract of nuruk (NE) attenuated lipopolysaccharide (LPS)- induced nitrite and interleukin (IL)-6 in RAW 264.7 cells.	Methanol	2-10	interleukin 6	Mus musculus	90-108
18756103-3	2008	Both the n-hexane and water fractions from NE (MEH and MW, respectively) inhibited the production of nitrite and IL-6 in RAW 264.7 cells.	n-hexane	9-17	interleukin 6	Mus musculus	113-117
18756103-3	2008	Both the n-hexane and water fractions from NE (MEH and MW, respectively) inhibited the production of nitrite and IL-6 in RAW 264.7 cells.	Water	22-27	interleukin 6	Mus musculus	113-117
18561950-0	2008	An interleukin-6-neutralizing antibody prevents cyclosporine-induced nephrotoxicity in mice.	Cyclosporine	48-60	interleukin 6	Mus musculus	3-16
18561950-24	2008	The current study identifies increased IL-6 expression as a mechanism by which CyA induces renal damage and that the use of an IL-6-neutralizing antibody may be useful in reducing CyA-induced renal damage.	Cyclosporine	79-82	interleukin 6	Mus musculus	39-43
18561950-24	2008	The current study identifies increased IL-6 expression as a mechanism by which CyA induces renal damage and that the use of an IL-6-neutralizing antibody may be useful in reducing CyA-induced renal damage.	Cyclosporine	180-183	interleukin 6	Mus musculus	127-131
18521064-8	2008	These results show that Stat4 suppresses the proliferation of CTMCs by controlling IL-6 via an autocrine mechanism.	ctmcs	62-67	interleukin 6	Mus musculus	83-87
18640288-8	2008	In vitro, hFOB infected with C. pneumoniae was associated with increased IL-6 (p=0.01) and RANKL (p&lt;0.05) mRNA expression; additionally, IL-6 secretion increased in a dose-dependent manner (p&lt;0.05).	hfob	10-14	interleukin 6	Mus musculus	73-77
18640288-8	2008	In vitro, hFOB infected with C. pneumoniae was associated with increased IL-6 (p=0.01) and RANKL (p&lt;0.05) mRNA expression; additionally, IL-6 secretion increased in a dose-dependent manner (p&lt;0.05).	hfob	10-14	interleukin 6	Mus musculus	140-144
18482223-3	2008	Selenite (Se) supplementation influences Se retention in the liver, enhanced IL-5 and eosinophil responses and evoked IL-6 production in mice infected with T. canis.	Selenious Acid	0-8	interleukin 6	Mus musculus	118-122
18482223-3	2008	Selenite (Se) supplementation influences Se retention in the liver, enhanced IL-5 and eosinophil responses and evoked IL-6 production in mice infected with T. canis.	Selenious Acid	0-2	interleukin 6	Mus musculus	118-122
18482223-3	2008	Selenite (Se) supplementation influences Se retention in the liver, enhanced IL-5 and eosinophil responses and evoked IL-6 production in mice infected with T. canis.	Selenious Acid	10-12	interleukin 6	Mus musculus	118-122
18687170-8	2008	RESULTS: Gln promoted RAW264.7 cells to release TNF-alpha, IL-6 and IL-10 in a dose-dependent and time-dependent manner in vitro (P&lt;0.05 or P&lt;0.01), and significantly increased HSP72 expression in 8 mmol/L Gln group at 4 hours after LPS stimulation (both P&lt;0.01).	Glutamine	9-12	interleukin 6	Mus musculus	59-63
18687170-9	2008	In vivo, in animals given Gln intracellular TNF-alpha and IL-6 levels were significantly lower than sepsis animals (P&lt;0.01 and P&lt;0.05), but there was no statistically significant difference in intracellular IL-10 levels among three groups.	Glutamine	26-29	interleukin 6	Mus musculus	58-62
18687170-13	2008	Gln treatment significantly decreases intracellular TNF-alpha and IL-6 levels in vivo during sepsis.	Glutamine	0-3	interleukin 6	Mus musculus	66-70
18474228-4	2008	We found that ceftiofur can downregulate tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), but did not affect interleukin-10 (IL-10) production.	ceftiofur	14-23	interleukin 6	Mus musculus	116-129
18474228-4	2008	We found that ceftiofur can downregulate tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), but did not affect interleukin-10 (IL-10) production.	ceftiofur	14-23	interleukin 6	Mus musculus	131-135
18499671-7	2008	Importantly, syndecan-1 shedding was induced in wild-type mice injected with staphylococcal enterotoxin B, and the administration of heparan sulfate, but not syndecan-1 core protein, rescued syndecan-1-null mice from lethal toxic shock by suppressing the production of TNFalpha and IL-6, and attenuating inflammatory tissue injury.	Heparitin Sulfate	133-148	interleukin 6	Mus musculus	282-286
18493250-6	2008	On day 4, AS111793 also significantly reduced all the inflammation markers that had increased after CS exposure, including soluble TNF receptors I and II, MIP-1gamma, IL-6 and pro-MMP-9 activity in BAL fluids, and KC/CXCL1, fractalkine/CX3CL1, TIMP-1 and I-TAC/CXCL11 in lung parenchyma.	as111793	10-18	interleukin 6	Mus musculus	167-171
18437347-10	2008	CONCLUSIONS/INTERPRETATION: Chronically elevated IL-6 levels lead to inappropriate hyperinsulinaemia, reduced body weight, impaired insulin-stimulated glucose uptake by the skeletal muscles and marked inflammation in the liver.	Glucose	151-158	interleukin 6	Mus musculus	49-53
18403479-10	2008	Furthermore, a decrease of Serine(727) phosphorylation led to an inhibition of osteoclast differentiation, whereas an increase of Tyrosine(705) phosphorylation upon IL-6 stimulation led to the formation of macrophages instead of osteoclasts.	Tyrosine	130-138	interleukin 6	Mus musculus	165-169
18486908-5	2008	The pro-inflammatory cytokine production and gene expression of TNF-alpha, IL-1beta, IL-6 and GM-CSF were down regulated in ursolic acid treated cells compared to nontreated B16F-10 metastatic melanoma cells.	ursolic acid	124-136	interleukin 6	Mus musculus	85-89
18486909-3	2008	We investigated the effects of florfenicol on cytokine production by lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages in vitro, and the results showed that florfenicol reduced tumor necrosis factor (TNF) and interleukin-6 (IL-6) production but had little effect on interleukin-1beta (IL-1beta) and interleukin IL-10 (IL-10) secretion.	florfenicol	165-176	interleukin 6	Mus musculus	217-230
18486909-3	2008	We investigated the effects of florfenicol on cytokine production by lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages in vitro, and the results showed that florfenicol reduced tumor necrosis factor (TNF) and interleukin-6 (IL-6) production but had little effect on interleukin-1beta (IL-1beta) and interleukin IL-10 (IL-10) secretion.	florfenicol	165-176	interleukin 6	Mus musculus	232-236
18486909-5	2008	Florfenicol significantly attenuated TNF and IL-6 production in serum from mice challenged with LPS, and in consistent with the results in vitro.	florfenicol	0-11	interleukin 6	Mus musculus	45-49
18486919-6	2008	As a result, Corilagin could significantly reduce production of pro-inflammatory cytokines and mediators TNF-alpha, IL-1beta, IL-6, NO (iNOS) and COX-2 on both protein and gene level by blocking NF-kappaB nuclear translocation.	corilagin	13-22	interleukin 6	Mus musculus	126-130
18622687-6	2008	Protein and mRNA levels of the pro-inflammatory cytokines IL-6, IL-1beta and TNFalpha in BALF were found to be significantly decreased in GW0742-treated animals (30 mg/kg).	GW0742	138-144	interleukin 6	Mus musculus	58-62
18205183-7	2008	In proximal colon, production of IL-1beta and IL-6 in PACAP-/- mice were significantly upregulated on day 8 after DSS administration, compared to wild-type control mice.	Dextran Sulfate	114-117	interleukin 6	Mus musculus	46-50
18566399-6	2008	In vivo lithium therapy suppressed MOG35-55-reactive effector T cell differentiation, greatly reducing in vitro MOG35-55- stimulated proliferation of mononuclear cells from draining lymph nodes and spleens, and MOG35-55-induced IFN-gamma, IL-6, and IL-17 production by splenocytes isolated from MOG35-55-immunized mice.	Lithium	8-15	interleukin 6	Mus musculus	239-243
18566435-5	2008	Animals treated with sulforaphane displayed a 2-3-fold increase in heme oxygenase-1, a reduced abundance of microglial cells in the hippocampus and an attenuated production of inflammation markers (inducible NO synthase, IL-6, and TNF-alpha) in response to LPS.	sulforaphane	21-33	interleukin 6	Mus musculus	221-225
18597620-4	2008	Our study confirms the work of others showing that a single administration of ethanol suppresses the production of tumor necrosis factor-alpha(TNF-alpha), interleukin-6 (IL-6), and IL-12 in response to LPS.	Ethanol	78-85	interleukin 6	Mus musculus	155-168
18597620-4	2008	Our study confirms the work of others showing that a single administration of ethanol suppresses the production of tumor necrosis factor-alpha(TNF-alpha), interleukin-6 (IL-6), and IL-12 in response to LPS.	Ethanol	78-85	interleukin 6	Mus musculus	170-174
18597620-7	2008	Interestingly, the higher dose of ethanol resulted in sustained suppression of LPS-induced TNF-alpha production at 3 and 6 h after ethanol administration, as well as decreased IL-6 and IL-12 production after 6 h, as compared to control (saline-treated groups).	Ethanol	34-41	interleukin 6	Mus musculus	176-180
18597620-9	2008	LPS-stimulated production of TNF-alpha and IL-6 was reduced at 3 h after ethanol administration, when compared with the saline-treated animals.	Ethanol	73-80	interleukin 6	Mus musculus	43-47
18597620-10	2008	Alveolar macrophages stimulated for 3 h with bacteria also showed decreased TNF-alpha and IL-6 production after harvested from mice given 2.9 g/kg ethanol for 3 h. This time point and high dose of ethanol also resulted in decreased Pseudomonas aeruginosa phagocytosis by alveolar macrophages.	Ethanol	147-154	interleukin 6	Mus musculus	90-94
18597620-10	2008	Alveolar macrophages stimulated for 3 h with bacteria also showed decreased TNF-alpha and IL-6 production after harvested from mice given 2.9 g/kg ethanol for 3 h. This time point and high dose of ethanol also resulted in decreased Pseudomonas aeruginosa phagocytosis by alveolar macrophages.	Ethanol	197-204	interleukin 6	Mus musculus	90-94
18445780-11	2008	The PI3K inhibitor wortmannin abolished the insulin-mediated activation of Akt and the reduction of chemokine and interleukin-6 levels.	Wortmannin	19-29	interleukin 6	Mus musculus	114-127
18451609-0	2008	CD44 and Bak expression in IL-6 or TNF-alpha gene knockout mice after whole lung irradiation.	bakuchiol	9-12	interleukin 6	Mus musculus	27-31
18451609-5	2008	C57BL/6JSlc and TNF KO mice had increased numbers of both CD44-positive and Bak-positive cells after irradiation, while the IL-6 KO mice showed stable levels of CD44 and Bak.	bakuchiol	170-173	interleukin 6	Mus musculus	124-128
18549679-3	2008	Treatment with eutigoside C inhibited LPS-stimulated production of nitric oxide (NO), prostaglandin E(2) (PGE(2)) and interleukin-6 (IL-6).	lps	38-41	interleukin 6	Mus musculus	118-131
18549679-3	2008	Treatment with eutigoside C inhibited LPS-stimulated production of nitric oxide (NO), prostaglandin E(2) (PGE(2)) and interleukin-6 (IL-6).	lps	38-41	interleukin 6	Mus musculus	133-137
18771907-1	2008	We have previously reported that prostaglandin D2 (PGD2) stimulates interleukin-6 (IL-6), a potent bone resorptive agent, in osteoblast-like MC3T3-E1 cells.	Prostaglandin D2	51-55	interleukin 6	Mus musculus	68-81
18771907-1	2008	We have previously reported that prostaglandin D2 (PGD2) stimulates interleukin-6 (IL-6), a potent bone resorptive agent, in osteoblast-like MC3T3-E1 cells.	Prostaglandin D2	51-55	interleukin 6	Mus musculus	83-87
18771907-2	2008	In the present study, we investigated whether Rho-kinase is implicated in the PGD2-stimulated IL-6 synthesis in MC3T3-E1 cells.	Prostaglandin D2	78-82	interleukin 6	Mus musculus	94-98
18771907-4	2008	Y27632, a specific Rho-kinase inhibitor, significantly reduced the PGD2-stimulated IL-6 synthesis as well as the MYPT-1 phosphorylation.	Y 27632	0-6	interleukin 6	Mus musculus	83-87
18771907-4	2008	Y27632, a specific Rho-kinase inhibitor, significantly reduced the PGD2-stimulated IL-6 synthesis as well as the MYPT-1 phosphorylation.	Prostaglandin D2	67-71	interleukin 6	Mus musculus	83-87
18771907-5	2008	Fasudil, another inhibitor of Rho-kinase, suppressed the PGD2-stimulated IL-6 synthesis.	fasudil	0-7	interleukin 6	Mus musculus	73-77
18771907-5	2008	Fasudil, another inhibitor of Rho-kinase, suppressed the PGD2-stimulated IL-6 synthesis.	Prostaglandin D2	57-61	interleukin 6	Mus musculus	73-77
18771907-6	2008	The PGD2-stimulated IL-6 synthesis was reduced by PD98059, a MEK inhibitor, and SB203580, an inhibitor of p38 mitogen-activated protein (MAP) kinase, but not SP600125, an inhibitor of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK).	Prostaglandin D2	4-8	interleukin 6	Mus musculus	20-24
18771907-6	2008	The PGD2-stimulated IL-6 synthesis was reduced by PD98059, a MEK inhibitor, and SB203580, an inhibitor of p38 mitogen-activated protein (MAP) kinase, but not SP600125, an inhibitor of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK).	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	50-57	interleukin 6	Mus musculus	20-24
18771907-6	2008	The PGD2-stimulated IL-6 synthesis was reduced by PD98059, a MEK inhibitor, and SB203580, an inhibitor of p38 mitogen-activated protein (MAP) kinase, but not SP600125, an inhibitor of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK).	SB 203580	80-88	interleukin 6	Mus musculus	20-24
18771907-9	2008	In addition, PGD2 additively induced IL-6 synthesis in combination with endothelin-1 which induces IL-6 synthesis through p38 MAP kinase regulated by Rho-kinase.	Prostaglandin D2	13-17	interleukin 6	Mus musculus	37-41
18771907-9	2008	In addition, PGD2 additively induced IL-6 synthesis in combination with endothelin-1 which induces IL-6 synthesis through p38 MAP kinase regulated by Rho-kinase.	Prostaglandin D2	13-17	interleukin 6	Mus musculus	99-103
18771907-10	2008	These results strongly suggest that Rho-kinase regulates PGD2-stimulated IL-6 synthesis via p38 MAP kinase activation in osteoblasts.	Prostaglandin D2	57-61	interleukin 6	Mus musculus	73-77
17950329-12	2008	Gallbladder saturated free fatty acids and IL-6 levels were highest (P &lt; 0.001) in obese mice on the 45% CHO diet.	CAV protocol	108-111	interleukin 6	Mus musculus	43-47
17950329-13	2008	CONCLUSIONS: These data suggest that (1) both obesity and dietary carbohydrates increase gallbladder total fat, triglycerides, cholesterol, TNF-alpha, and IL-1beta and (2) obesity also increases gallbladder free fatty acids and IL-6.	Carbohydrates	66-79	interleukin 6	Mus musculus	228-232
18499099-9	2008	We demonstrated that when 3T3-L1 cells were treated with glycine, IL-6, resistin and TNF-alpha mRNA expression was decreased, but surprisingly adiponectin and PPAR-gamma were up-regulated.	Glycine	57-64	interleukin 6	Mus musculus	66-70
18433975-6	2008	The functional significance of elevated DON tissue concentrations was assessed by measuring IL-1beta, IL-6, and TNF-alpha mRNA responses in spleen, liver and lung.	deoxynivalenol	40-43	interleukin 6	Mus musculus	102-106
18239189-4	2008	CS exposure to C57BL/6J mice resulted in activation of IKK alpha, leading to phosphorylation of ser10 and acetylation of lys9 on histone H3 on the promoters of IL-6 and MIP-2 genes in mouse lung.	Cesium	0-2	interleukin 6	Mus musculus	160-164
18467694-4	2008	Bleomycin-treated wild-type mice exhibited dermal and lung fibrosis, hyper-gamma-globulinemia, autoantibody production, and enhanced serum and skin expression of various cytokines, including fibrogenic interleukin-4, interleukin-6, and transforming growth factor-beta1, all of which were inhibited by CD19 deficiency.	Bleomycin	0-9	interleukin 6	Mus musculus	217-230
18512810-9	2008	Anti-CD40 treatment induced a higher production of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), IL-10, and tumor necrosis factor alpha in B6.TC DCs.	Technetium	150-152	interleukin 6	Mus musculus	81-85
18512813-11	2008	Production of tumor necrosis factor, interleukin-6, and monocyte chemoattractant protein 1 by spleen cells was also decreased after diterpenoid therapy.	Diterpenes	132-143	interleukin 6	Mus musculus	37-50
18627295-6	2008	In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.	Doxorubicin	3-6	interleukin 6	Mus musculus	152-165
18281385-7	2008	DCPA is known to inhibit the production of two NF-kappaB-inducible cytokines, IL-6 and tumor necrosis factor alpha, by reducing but not completely abrogating NF-kappaB-induced transcription.	dcpa	0-4	interleukin 6	Mus musculus	78-114
18467102-2	2008	The mucilage polysaccharide exhibits specific functions in activating murine splenocytes to produce several cytokines including IFN-gamma, IL-10, IL-6, and IL-1alpha, as well as hematopoietic growth factors GM-CSF and G-CSF.	Polysaccharides	13-27	interleukin 6	Mus musculus	146-150
18485152-3	2008	METHODS AND RESULTS: Evidence provided by the trypan blue dye exclusion assay, 5-bromodeoxyuridine immunoreactivity and Western blot analysis indicated that IL-6 and EGF induced proliferation of these spinal cord-derived NPCs via phosphorylation of Janus-activated kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) and mitogen-activated protein kinases (MAPK), respectively.	Trypan Blue	46-57	interleukin 6	Mus musculus	157-161
18485152-3	2008	METHODS AND RESULTS: Evidence provided by the trypan blue dye exclusion assay, 5-bromodeoxyuridine immunoreactivity and Western blot analysis indicated that IL-6 and EGF induced proliferation of these spinal cord-derived NPCs via phosphorylation of Janus-activated kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) and mitogen-activated protein kinases (MAPK), respectively.	Bromodeoxyuridine	79-98	interleukin 6	Mus musculus	157-161
18485152-5	2008	Furthermore, AG490 and AG1478, JAK2 inhibitor and EGFR inhibitor, respectively, prevented the IL-6- and EGF-induced proliferation of the cells.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	13-18	interleukin 6	Mus musculus	94-98
18485152-5	2008	Furthermore, AG490 and AG1478, JAK2 inhibitor and EGFR inhibitor, respectively, prevented the IL-6- and EGF-induced proliferation of the cells.	RTKI cpd	23-29	interleukin 6	Mus musculus	94-98
18435803-9	2008	The proinflammatory cytokine IL-6 was down-regulated in raloxifene-treated mice compared with controls.	Raloxifene Hydrochloride	56-66	interleukin 6	Mus musculus	29-33
18457905-5	2008	Dietary supplementation with glutamine reversed both the lower concentrations of protein and DNA in the muscle and liver, as well as the reduced capacity of spreading and synthesizing nitric oxide, hydrogen peroxide, TNF-alpha, IL-1 beta and IL-6 in cultures of peritoneal macrophages obtained from the -GLN group (P&lt;0.05).	Glutamine	29-38	interleukin 6	Mus musculus	242-246
18375438-6	2008	Administration of CoPP caused a sustained increase in HO-1 protein, prevented weight gain, decreased visceral and subcutaneous fat content (P &lt; 0.03 and 0.01, respectively, compared with vehicle animals), increased serum adiponectin, and decreased plasma tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and IL-1beta levels (P &lt; 0.05).	COPP protocol	18-22	interleukin 6	Mus musculus	299-317
18434414-4	2008	Hyaluronan fragments or hyaluronidase activated the NFkappaB pathway and induced Il6, Ccl4 and Ccl5 mRNA expression within 2 hours.	Hyaluronic Acid	0-10	interleukin 6	Mus musculus	81-84
18325987-7	2008	IL-1- or IL-6-mediated acute-phase response was inhibited by fenofibrate treatment in liver-specific PPARalpha-expressing mice but not in PPARalpha-deficient mice.	Fenofibrate	61-72	interleukin 6	Mus musculus	9-13
18427964-13	2008	Schindl ethanol extract might be due to the down-regulation of IL-1beta, IL-6, NO, TNF-alpha and COX-2 via the suppression of NF-kappaB activation and conversation of I-kappaB production, and another pathway was up regulating the production of IL-10 and HO-1.	schindl ethanol	0-15	interleukin 6	Mus musculus	73-77
18323466-8	2008	Four hours after the exposure ended, O(3)-induced increases in bronchoalveolar lavage fluid protein, interleukin-6, KC, macrophage inflammatory protein-2, interferon-gamma-inducible protein-10, and eotaxin were greater in mice fed 60 vs. 10% fat diets.	Ozone	37-41	interleukin 6	Mus musculus	101-114
18386091-6	2008	However, dietary perilla oil significantly (P &lt; 0.05) reduced proinflammatory cytokine (TNF-alpha, IL-1beta and IL-6) and Th1 cytokine (IFN-gamma and IL-2) production.	perilla seed oil	17-28	interleukin 6	Mus musculus	115-119
18524936-0	2008	A role for tumour necrosis factor-alpha, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,6"-dimycolate induced granulomatous response.	Trehalose	140-149	interleukin 6	Mus musculus	59-72
18524936-0	2008	A role for tumour necrosis factor-alpha, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,6"-dimycolate induced granulomatous response.	6,6"-dimycolate	150-165	interleukin 6	Mus musculus	59-72
18455658-7	2008	Glutamine in vitro supplementation reversed the decrease in IL-6, nitric oxide, and hydrogen peroxide synthesis and the decrease in the capacity to adhere, spread, and phagocytize in animals of the EW group.	Glutamine	0-9	interleukin 6	Mus musculus	60-64
18831214-4	2008	RESULT: IPS-B2 could not promote mouse peritoneal macrophage production, but it could significantly improve the IL-1beta, IL-6, TNF-alpha content in mouse peritoneal macrophages culture supernatant, and increase the gene expression of IL-1beta, IL-6, TNF-alpha and iNOS.	ips-b2	8-14	interleukin 6	Mus musculus	122-126
18831214-4	2008	RESULT: IPS-B2 could not promote mouse peritoneal macrophage production, but it could significantly improve the IL-1beta, IL-6, TNF-alpha content in mouse peritoneal macrophages culture supernatant, and increase the gene expression of IL-1beta, IL-6, TNF-alpha and iNOS.	ips-b2	8-14	interleukin 6	Mus musculus	245-249
18772604-3	2008	As low-dose warfarin has been reported to have anti-inflammatory effect through suppression of IL-6 secretion and inhibit the immune-associated signal between Tyro3 and its ligand, Gas6, the effect of low-dose warfarin on autoimmune diabetes in NOD mice was examined.	Warfarin	12-20	interleukin 6	Mus musculus	95-99
18772604-4	2008	To investigate the anti-inflammatory effect of warfarin, IL-6 secretion by splenocytes was examined in the presence of various concentrations of warfarin.	Warfarin	145-153	interleukin 6	Mus musculus	57-61
18772604-5	2008	Low concentration of warfarin inhibited IL-6 secretion.	Warfarin	21-29	interleukin 6	Mus musculus	40-44
18473419-9	2008	To further explore the mechanism of rosiglitazone action, we found that rosiglitazone can significantly increase the expression of PPAR gamma [E: -18.212 +/- (-3.909) vs B: -27.315 +/- (-6.348) and C: -25.647 +/- (-5.694), P &lt; 0.05], reduce the NF-kappaB binding activity (E: 88.89 +/- 19.34 vs B: 141.11 +/- 15.37, C: 112.89 +/- 20.17 and D: 108.89 +/- 20.47, P &lt; 0.05), and lower the serum level of TNF-alpha (E: 1.613 +/- 0.420 ng/mL vs B: 2.892 +/- 0.587 ng/mL, C: 2.346 +/- 0.371 ng/mL and D: 2.160 +/- 0.395 ng/mL, P &lt; 0.05) and IL-6 (E: 0.106 +/- 0.021 ng/mL vs B: 0.140 +/- 0.031 ng/mL and C: 0.137 +/- 0.027 ng/mL, P &lt; 0.05) in mice with liver fibrosis.	Rosiglitazone	36-49	interleukin 6	Mus musculus	544-548
18473419-9	2008	To further explore the mechanism of rosiglitazone action, we found that rosiglitazone can significantly increase the expression of PPAR gamma [E: -18.212 +/- (-3.909) vs B: -27.315 +/- (-6.348) and C: -25.647 +/- (-5.694), P &lt; 0.05], reduce the NF-kappaB binding activity (E: 88.89 +/- 19.34 vs B: 141.11 +/- 15.37, C: 112.89 +/- 20.17 and D: 108.89 +/- 20.47, P &lt; 0.05), and lower the serum level of TNF-alpha (E: 1.613 +/- 0.420 ng/mL vs B: 2.892 +/- 0.587 ng/mL, C: 2.346 +/- 0.371 ng/mL and D: 2.160 +/- 0.395 ng/mL, P &lt; 0.05) and IL-6 (E: 0.106 +/- 0.021 ng/mL vs B: 0.140 +/- 0.031 ng/mL and C: 0.137 +/- 0.027 ng/mL, P &lt; 0.05) in mice with liver fibrosis.	Rosiglitazone	72-85	interleukin 6	Mus musculus	544-548
18477398-13	2008	Furthermore, the minocycline associated recovery from LPS-induced sickness behavior was paralleled by reduced mRNA levels of Interleukin (IL)-1beta, IL-6, and indoleamine 2, 3 dioxygenase (IDO) in the cortex and hippocampus.	Minocycline	17-28	interleukin 6	Mus musculus	149-153
18426983-4	2008	The rapid SP was predominantly induced in mesenteric lymph nodes (LNs) but not in peripheral LNs under the influence of intestinal flora and IL-6.	sp	10-12	interleukin 6	Mus musculus	141-145
18426983-5	2008	Indeed, this SP was markedly inhibited by treatment with anti-IL-6 receptor monoclonal antibody (IL-6R mAb) or antibiotic-induced flora depletion, but not by anti-IL-7R mAb and/or in IL-15-deficient conditions.	sp	13-15	interleukin 6	Mus musculus	62-66
18426983-8	2008	Thus, we conclude that IL-6 signaling is crucial for SP under lymphopenic conditions, which subsequently caused severe IL-17-producing CD8(+) T cell-mediated autoimmune colitis.	sp	53-55	interleukin 6	Mus musculus	23-27
18339495-3	2008	Mice subjected to chronic unpredictable stress (CUS, for 7 days) showed significant increase in plasma corticosterone level and depletion of noradrenaline (NA), dopamine (DA) and 5-hydroxytryptamine (5-HT) levels in cortex and hippocampal regions along with an increased level of IL-2 and IL-6 in the same areas.	cus	48-51	interleukin 6	Mus musculus	289-293
18339495-7	2008	was found to be effective in normalizing the CUS induced elevation of plasma corticosterone and IL-2, IL-6 levels in brain.	cus	45-48	interleukin 6	Mus musculus	102-106
18096870-0	2008	Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice.	Bleomycin	25-34	interleukin 6	Mus musculus	8-21
18096870-1	2008	Interleukin-6 (IL-6) is known to be involved in the pathogenesis of various inflammatory diseases, but its role in bleomycin (BLM)-induced lung injury and subsequent fibrotic changes remains to be determined.	Bleomycin	115-124	interleukin 6	Mus musculus	0-13
18096870-6	2008	On Day 2, BLM administration induced significant increases in the numbers of total cells, macrophages, and neutrophils in BAL fluid, which were attenuated in IL-6(-/-) mice (P &lt; 0.05).	Bleomycin	10-13	interleukin 6	Mus musculus	158-162
18192500-10	2008	Gene expression (procollagen 3-a-1, procollagen 1-a-1, and IL-6) linked to fibrogenesis was also increased in lung homogenates of asbestos-exposed Tg- mice, but reduced in asbestos-exposed Tg+ mice.	Thioguanine	147-149	interleukin 6	Mus musculus	59-63
18192500-10	2008	Gene expression (procollagen 3-a-1, procollagen 1-a-1, and IL-6) linked to fibrogenesis was also increased in lung homogenates of asbestos-exposed Tg- mice, but reduced in asbestos-exposed Tg+ mice.	Asbestos	130-138	interleukin 6	Mus musculus	59-63
18359888-5	2008	At 24 h, O3-induced increases in BAL protein and BAL serum albumin were augmented in ob/ob vs. wild-type mice, and anti-IL-6 Ab ablated these obesity-related differences in epithelial barrier injury.	Ozone	9-11	interleukin 6	Mus musculus	120-124
18385461-7	2008	nBMSCs produced lower levels of IL-6 and VEGF, but higher levels of IGF-1 under basal conditions, as well as after stimulation with TNF, but not LPS.	nbmscs	0-6	interleukin 6	Mus musculus	32-36
18323514-4	2008	METHODS AND RESULTS: Pravastatin or pitavastatin treatment of obese mice attenuated an increase in mRNA expressions of proinflammatory genes, including MCP1 and IL6, in adipose tissue.	Pravastatin	21-32	interleukin 6	Mus musculus	161-164
18323514-4	2008	METHODS AND RESULTS: Pravastatin or pitavastatin treatment of obese mice attenuated an increase in mRNA expressions of proinflammatory genes, including MCP1 and IL6, in adipose tissue.	pitavastatin	36-48	interleukin 6	Mus musculus	161-164
18332856-10	2008	Liquiritigenin also suppressed the production of TNF-alpha, IL-1beta and IL-6 from Raw264.7 cells after LPS.	liquiritigenin	0-14	interleukin 6	Mus musculus	73-77
18177479-5	2008	Exposure of mice to CS elicited an increase in the number of macrophages and neutrophils and levels of interleukin (IL)-6, keratinocyte-derived chemokine (KC/CXCL1) and monocyte chemoattractant protein-1 (MCP1/CCL2) in bronchoalveolar lavage fluid (BALF), which were lower in p47 KO mice compared with control mice.	Cesium	20-22	interleukin 6	Mus musculus	103-121
18371088-0	2008	Reduced liver injury in the interleukin-6 knockout mice by chronic carbon tetrachloride administration.	Carbon Tetrachloride	67-87	interleukin 6	Mus musculus	28-41
18371088-10	2008	CONCLUSIONS: Compared to the wild type mice liver regeneration after chronic treatment with carbon tetrachloride proceeds at a slower rate in interleukin-6 deficient mice.	Carbon Tetrachloride	92-112	interleukin 6	Mus musculus	142-155
18222027-6	2008	Ethanol treatment elevated hepatic levels of c-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) (P&lt;0.05), the post-intake of histidine and carnosine significantly and dose-dependently diminished the release of CRP, IL-6, and TNF-alpha (P&lt;0.05).	Ethanol	0-7	interleukin 6	Mus musculus	71-84
18222027-6	2008	Ethanol treatment elevated hepatic levels of c-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) (P&lt;0.05), the post-intake of histidine and carnosine significantly and dose-dependently diminished the release of CRP, IL-6, and TNF-alpha (P&lt;0.05).	Ethanol	0-7	interleukin 6	Mus musculus	86-90
18222027-6	2008	Ethanol treatment elevated hepatic levels of c-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) (P&lt;0.05), the post-intake of histidine and carnosine significantly and dose-dependently diminished the release of CRP, IL-6, and TNF-alpha (P&lt;0.05).	Ethanol	0-7	interleukin 6	Mus musculus	258-262
18222027-7	2008	Ethanol treatment caused down-regulation in both catalase and GPX mRNA expression, and up-regulated both IL-6 and TNF-alpha mRNA expression (P&lt;0.05).	Ethanol	0-7	interleukin 6	Mus musculus	105-109
18222027-8	2008	Histidine and carnosine post-treatments significantly and dose-dependently upregulated catalase mRNA, and down-regulated mRNA expression of IL-6 and TNF-alpha (P&lt;0.05).	Histidine	0-9	interleukin 6	Mus musculus	140-144
18508495-2	2008	Recent studies show that reduced calorie intake and supplementation of diet with n-3 FA delays the onset of autoimmune renal disease, primarily, due to increased antioxidant enzyme activities, decreased NF-kappaB activation and decreased IL-1, IL-6 and TNF-alpha mRNA expression in the kidney tissue.	Fatty Acids, Omega-3	81-87	interleukin 6	Mus musculus	244-248
18424701-4	2008	In this study, we show that, in mice, inflammasome-signaling levels can be modulated to turn dinitrothiocyanobenzene into a sensitizer and DNFB into a tolerizer, and that it correlates with the IL-6 and IL-12 secretion levels, affecting Th1, Th17, and regulatory T cell development.	dinitrothiocyanobenzene	93-116	interleukin 6	Mus musculus	194-198
18040755-0	2008	Dose-dependent effects of Ni (II) ions on production of three inflammatory cytokines (TNF-alpha, IL-1beta and IL-6), superoxide dismutase (SOD) and free radical NO by murine macrophage-like RAW264 cells with or without LPS-stimulation.	ni (ii)	26-33	interleukin 6	Mus musculus	110-114
18040755-2	2008	The purpose of this study was to examine the dose-dependent effects of Ni (II) ions up to 1,000 micromol/L on production of three inflammatory cytokines (TNF-alpha, IL-1beta and IL-6), superoxide dismutase (SOD) and nitric oxide (NO) by murine macrophage-like RAW264 cells with (+) or without (-) lipopolysaccharide (LPS) -stimulation.	ni (ii)	71-78	interleukin 6	Mus musculus	178-182
18040755-3	2008	Ni (II) ions caused LPS (-) RAW264 cells to slightly increase production of TNF-alpha and IL-6, proportionally to the Ni (II) ion concentration while IL-1beta was not produced, and to slightly increase production of SOD and NO.	ni (ii)	0-7	interleukin 6	Mus musculus	90-94
18040755-3	2008	Ni (II) ions caused LPS (-) RAW264 cells to slightly increase production of TNF-alpha and IL-6, proportionally to the Ni (II) ion concentration while IL-1beta was not produced, and to slightly increase production of SOD and NO.	ni (ii)	118-125	interleukin 6	Mus musculus	90-94
17707631-7	2008	Oral administration of DIM, but not intraperitoneal injection, induced elevation of serum cytokines in mice, including IL-6, granulocyte colony-stimulating factor (G-CSF), IL-12 and IFN-gamma.	3,3'-diindolylmethane	23-26	interleukin 6	Mus musculus	119-123
18088370-5	2008	A statistical significant increase of the IL-6 concentration in the perfusate was detected already 60 min after 5"-N-ethylcarboxamidoadenosine administration.	Adenosine-5'-(N-ethylcarboxamide)	112-142	interleukin 6	Mus musculus	42-46
18088370-8	2008	We conclude that adenosine via activation of A2B receptors evokes IL-6 release also in vivo.	Adenosine	17-26	interleukin 6	Mus musculus	66-70
18423275-6	2008	RESULTS: The expression and concentration of IL-1 beta, IL-6, and IL-8 were increased with increasing concentration of 17beta-estradiol.	Estradiol	119-135	interleukin 6	Mus musculus	56-60
18093793-3	2008	The administration of SPG and IND induced the death of C3H/HeJ mice, lowering rectal temperature, reducing body weight, increasing serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, shortening the gastrointestinal tract, and increasing the GOT/GPT level.	spirogermanium	22-25	interleukin 6	Mus musculus	181-194
18093793-3	2008	The administration of SPG and IND induced the death of C3H/HeJ mice, lowering rectal temperature, reducing body weight, increasing serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, shortening the gastrointestinal tract, and increasing the GOT/GPT level.	spirogermanium	22-25	interleukin 6	Mus musculus	196-200
18093793-3	2008	The administration of SPG and IND induced the death of C3H/HeJ mice, lowering rectal temperature, reducing body weight, increasing serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, shortening the gastrointestinal tract, and increasing the GOT/GPT level.	Indomethacin	30-33	interleukin 6	Mus musculus	181-194
18093793-3	2008	The administration of SPG and IND induced the death of C3H/HeJ mice, lowering rectal temperature, reducing body weight, increasing serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, shortening the gastrointestinal tract, and increasing the GOT/GPT level.	Indomethacin	30-33	interleukin 6	Mus musculus	196-200
21479417-7	2008	In addition, treatment with EGCG or Poly E decreased the protein and mRNA expression levels of Cyclooxygenase (COX)-2 and the mRNA expression of inflammatory cytokines (TNF-alpha, IFN-gamma, IL-6, IL-12 and IL-18) in the colonic mucosa.	epigallocatechin gallate	28-32	interleukin 6	Mus musculus	191-195
21479417-7	2008	In addition, treatment with EGCG or Poly E decreased the protein and mRNA expression levels of Cyclooxygenase (COX)-2 and the mRNA expression of inflammatory cytokines (TNF-alpha, IFN-gamma, IL-6, IL-12 and IL-18) in the colonic mucosa.	polyphenon E	36-42	interleukin 6	Mus musculus	191-195
18819004-2	2008	In this report we used the IL6-dependent 7TD1 murine B-cell hybridoma as an in vitro model to study the interactions between IL6-signaling pathways and the development of dexamethasone resistance.	Dexamethasone	171-184	interleukin 6	Mus musculus	125-128
18819004-3	2008	Though in initial stages, 7TD1 cells grew IL6-dependent and were sensitive to dexamethasone-induced apoptosis, chronic exposure to dexamethasone led to a dexamethasone-resistant phenotype (7TD1-Dxm) that grew independent of exogenous IL6.	Dexamethasone	131-144	interleukin 6	Mus musculus	234-237
18819004-3	2008	Though in initial stages, 7TD1 cells grew IL6-dependent and were sensitive to dexamethasone-induced apoptosis, chronic exposure to dexamethasone led to a dexamethasone-resistant phenotype (7TD1-Dxm) that grew independent of exogenous IL6.	Dexamethasone	131-144	interleukin 6	Mus musculus	234-237
18819004-6	2008	Our results suggest a role of entities downstream of IL6-mediated JAK/STAT3 signaling in development of dexamethasone resistance by 7TD1-Dxm cells.	Dexamethasone	104-117	interleukin 6	Mus musculus	53-56
18819004-6	2008	Our results suggest a role of entities downstream of IL6-mediated JAK/STAT3 signaling in development of dexamethasone resistance by 7TD1-Dxm cells.	Dexamethasone	137-140	interleukin 6	Mus musculus	53-56
18272372-4	2008	Among these compounds, (R)-(+)-10a and (6R, 1S)-(+)-22a showed strong inhibitory activity not only against NO production but also against inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in vitro.	r)-(+)-10a	24-34	interleukin 6	Mus musculus	214-227
18471413-0	2008	[Pollen Typhae total flavones inhibit expression of interleukin-6 in C2C12 skeletal muscle cells cultured with palmitate].	Flavones	21-29	interleukin 6	Mus musculus	52-65
18471413-0	2008	[Pollen Typhae total flavones inhibit expression of interleukin-6 in C2C12 skeletal muscle cells cultured with palmitate].	Palmitates	111-120	interleukin 6	Mus musculus	52-65
18471413-1	2008	OBJECTIVE: To observe the effects of Pollen Typhae total flavones (PTF) on expression of interleukin-6 (IL-6) mRNA and protein secretion in C2C12 cell strain of skeletal muscle cells cultured with palmitate, and to explore the mechanism of PTF in relieving insulin resistance (IR).	typhae	44-50	interleukin 6	Mus musculus	89-102
18471413-1	2008	OBJECTIVE: To observe the effects of Pollen Typhae total flavones (PTF) on expression of interleukin-6 (IL-6) mRNA and protein secretion in C2C12 cell strain of skeletal muscle cells cultured with palmitate, and to explore the mechanism of PTF in relieving insulin resistance (IR).	typhae	44-50	interleukin 6	Mus musculus	104-108
18471413-1	2008	OBJECTIVE: To observe the effects of Pollen Typhae total flavones (PTF) on expression of interleukin-6 (IL-6) mRNA and protein secretion in C2C12 cell strain of skeletal muscle cells cultured with palmitate, and to explore the mechanism of PTF in relieving insulin resistance (IR).	Flavones	57-65	interleukin 6	Mus musculus	89-102
18471413-1	2008	OBJECTIVE: To observe the effects of Pollen Typhae total flavones (PTF) on expression of interleukin-6 (IL-6) mRNA and protein secretion in C2C12 cell strain of skeletal muscle cells cultured with palmitate, and to explore the mechanism of PTF in relieving insulin resistance (IR).	Flavones	57-65	interleukin 6	Mus musculus	104-108
18471413-1	2008	OBJECTIVE: To observe the effects of Pollen Typhae total flavones (PTF) on expression of interleukin-6 (IL-6) mRNA and protein secretion in C2C12 cell strain of skeletal muscle cells cultured with palmitate, and to explore the mechanism of PTF in relieving insulin resistance (IR).	Palmitates	197-206	interleukin 6	Mus musculus	89-102
18471413-1	2008	OBJECTIVE: To observe the effects of Pollen Typhae total flavones (PTF) on expression of interleukin-6 (IL-6) mRNA and protein secretion in C2C12 cell strain of skeletal muscle cells cultured with palmitate, and to explore the mechanism of PTF in relieving insulin resistance (IR).	Benzyl methyl sulfide	67-70	interleukin 6	Mus musculus	89-102
18471413-1	2008	OBJECTIVE: To observe the effects of Pollen Typhae total flavones (PTF) on expression of interleukin-6 (IL-6) mRNA and protein secretion in C2C12 cell strain of skeletal muscle cells cultured with palmitate, and to explore the mechanism of PTF in relieving insulin resistance (IR).	Benzyl methyl sulfide	67-70	interleukin 6	Mus musculus	104-108
18471413-6	2008	Compared with the untreated group, the levels of IL-6 mRNA expression in cells and IL-6 protein secretion in supernatant were significantly decreased in the PTF-treated group (P&lt;0.05).	Benzyl methyl sulfide	157-160	interleukin 6	Mus musculus	49-53
18471413-6	2008	Compared with the untreated group, the levels of IL-6 mRNA expression in cells and IL-6 protein secretion in supernatant were significantly decreased in the PTF-treated group (P&lt;0.05).	Benzyl methyl sulfide	157-160	interleukin 6	Mus musculus	83-87
18321049-10	2008	Additionally, the LPS-stimulated IL-1beta, IL-6, and TNF-alpha productions are dose-dependently reduced by spilanthol.	N-isobutyl-2E-decenamide	107-117	interleukin 6	Mus musculus	43-47
18339158-10	2008	In a dose-dependent manner, bupivacaine also significantly inhibited the effects of LPS on the production of TNF-alpha, IL-1beta, and IL-6.	Bupivacaine	28-39	interleukin 6	Mus musculus	134-138
18272372-4	2008	Among these compounds, (R)-(+)-10a and (6R, 1S)-(+)-22a showed strong inhibitory activity not only against NO production but also against inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in vitro.	r)-(+)-10a	24-34	interleukin 6	Mus musculus	229-233
18383034-4	2008	DC treated with ROS scavengers, as well as DC from mice that lack a functional NADPH oxidase (and thereby inherently deficient in ROS production) produced significantly increased levels of IL-1beta, IL-6, TNF-alpha and TGF-beta in response to microbial activation.	Reactive Oxygen Species	16-19	interleukin 6	Mus musculus	199-203
18449509-6	2008	Exogenous PGE(2) enhanced production of IL-6, IL-10, and NO but decreased TNF-alpha by macrophages and augmented IFN-gamma, IL-6, and IL-10 by splenocytes from pristane-induced lupus mice compared to healthy controls.	Prostaglandins E	10-13	interleukin 6	Mus musculus	40-44
18449509-6	2008	Exogenous PGE(2) enhanced production of IL-6, IL-10, and NO but decreased TNF-alpha by macrophages and augmented IFN-gamma, IL-6, and IL-10 by splenocytes from pristane-induced lupus mice compared to healthy controls.	Prostaglandins E	10-13	interleukin 6	Mus musculus	124-128
18449509-7	2008	Exogenous PGE(2) also enhanced production of IFN-gamma, IL-6, and IL-10 by thymocytes from pristane-induced lupus mice.	Prostaglandins E	10-13	interleukin 6	Mus musculus	56-60
18449509-8	2008	Indomethacin (Indo), a PGE(2) synthesis inhibitor, greatly inhibited LPS-induced production of IL-6 and IL-10 by macrophages from pristane-induced lupus mice, while enhanced TNF-alpha.	Indomethacin	0-12	interleukin 6	Mus musculus	95-99
18449509-8	2008	Indomethacin (Indo), a PGE(2) synthesis inhibitor, greatly inhibited LPS-induced production of IL-6 and IL-10 by macrophages from pristane-induced lupus mice, while enhanced TNF-alpha.	Indomethacin	0-4	interleukin 6	Mus musculus	95-99
18449509-8	2008	Indomethacin (Indo), a PGE(2) synthesis inhibitor, greatly inhibited LPS-induced production of IL-6 and IL-10 by macrophages from pristane-induced lupus mice, while enhanced TNF-alpha.	pristane	130-138	interleukin 6	Mus musculus	95-99
18449509-9	2008	Indo remarkably inhibited Con A-increased production of IFN-gamma, IL-6, and IL-10 by splenocytes and thymocytes from pristane-induced lupus mice.	Indomethacin	0-4	interleukin 6	Mus musculus	67-71
18449509-9	2008	Indo remarkably inhibited Con A-increased production of IFN-gamma, IL-6, and IL-10 by splenocytes and thymocytes from pristane-induced lupus mice.	pristane	118-126	interleukin 6	Mus musculus	67-71
18449509-10	2008	Therefore, our findings suggest that endogenous PGE(2) may mediate dysregulation of production of proinflammatory cytokines, such as IL-6, IL-10, and IFN-gamma, and NO in pristane-induced lupus mice.	Prostaglandins E	48-51	interleukin 6	Mus musculus	133-137
18268139-9	2008	Magnesium attenuated renal and cardiac interleukin-6 content and decreased renal VCAM1 and cardiac COX2 expression (P&lt;0.05).	Magnesium	0-9	interleukin 6	Mus musculus	39-52
18437654-18	2008	CONCLUSION: Increased TNFalpha and IL-6 levels induced by LPS correlated well with the occurrence of IN, and a decrease in these levels via cyclooxygenase (COX) inhibition by indomethacin prevented IN from forming in this experimental model.	Indomethacin	175-187	interleukin 6	Mus musculus	35-39
18395094-9	2008	In addition, ethanol feeding elicited an aggravated inflammatory response mediated by Kupffer cells in Nrf2(-/-) mice as shown by an increased tumor necrosis factor-alpha secretion and activation of the interleukin-6/Stat-3 pathway.	Ethanol	13-20	interleukin 6	Mus musculus	203-216
18372239-2	2008	Rapamycin, an inhibitor of p70 S6 kinase, significantly enhanced the FGF-2-stimulated IL-6 synthesis in a dose-dependent manner.	Sirolimus	0-9	interleukin 6	Mus musculus	86-90
20157398-3	2008	Intra-peritoneal pretreatment of mice with decursinol (50 mg/kg) markedly enhanced the LPS/GalN-induced increase of plasma interleukin-10 (IL-10) levels, without affecting plasma TNF-alpha, IL-6 and IL-12 levels.	decursin	43-53	interleukin 6	Mus musculus	190-194
18174358-7	2008	However, phorbol 12-myristate 13-acetate-induced inflammation was only partially inhibited by GR-TR, which efficiently repressed IL-1beta and MMP-3 genes while weakly repressing IL-6 and TNF-alpha.	Tetradecanoylphorbol Acetate	9-40	interleukin 6	Mus musculus	178-182
18661827-1	2008	OBJECTIVE: To observe the effect of asiaticoside (AS) on IL-6,TNF-alpha, IL-10 of bronchoaliveolar lavage fluid (BALF) of acute lung injury (ALI) induced by lipopolysaccharides (LPS).	asiaticoside	36-48	interleukin 6	Mus musculus	57-61
18164693-5	2008	Topical application on mice ears of Tat-SOD also suppressed TPA-induced expression of proinflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6 as well as cyclooxygenase-2 (COX-2) and production of PGE(2).	Tetradecanoylphorbol Acetate	60-63	interleukin 6	Mus musculus	145-149
18426351-9	2008	Significantly reduced release of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 was evident in cerivastatin-treated mice after LPS challenge.	cerivastatin	136-148	interleukin 6	Mus musculus	102-120
18426351-10	2008	Cerivastatin-treated mice showed insignificant reductions in serum TNF-alpha and IL-6 concentrations after bacterial challenge.	cerivastatin	0-12	interleukin 6	Mus musculus	81-85
18083110-4	2008	Treatment with methyl-prednisolone or anti-TNF antibody attenuated the systemic (TNF, IL-6, IL-12p40, and CXCL1) and local (colonic TNF and iNOS mRNA expression) response induced by R-848.	Methylprednisolone	15-34	interleukin 6	Mus musculus	86-90
18661827-1	2008	OBJECTIVE: To observe the effect of asiaticoside (AS) on IL-6,TNF-alpha, IL-10 of bronchoaliveolar lavage fluid (BALF) of acute lung injury (ALI) induced by lipopolysaccharides (LPS).	asiaticoside	50-52	interleukin 6	Mus musculus	57-61
18279797-7	2008	These results suggest that the anti-inflammatory properties of asiatic acid might be the results from the inhibition of iNOS, COX-2, IL-6, IL-1 beta, and TNF-alpha expressions through the down-regulation of NF-kappaB activation via suppression of IKK and MAP kinase (p38, ERK1/2, and JNK) phosphorylation in RAW 264.7 cells.	asiatic acid	63-75	interleukin 6	Mus musculus	133-137
18296743-7	2008	Arsenic exposure increased the expression of inflammation genes, such as TNF-alpha, IL-6, iNOS, chemokines, and macrophage inflammatory protein-2.	Arsenic	0-7	interleukin 6	Mus musculus	84-88
18205805-8	2008	IL-6, IL-10 and IFN-gamma levels in the nicotine-treated mice were higher than those in the control mice.	Nicotine	40-48	interleukin 6	Mus musculus	0-4
18230686-6	2008	Azithromycin-treated J774 macrophages demonstrated a significantly reduced production of the pro-inflammatory cytokines IL-12 and IL-6, increased production of the anti-inflammatory cytokine IL-10 and decreased the ratio of IL-12 to IL-10 by 60%.	Azithromycin	0-12	interleukin 6	Mus musculus	130-134
18191038-3	2008	4-OHDHA inhibited production of nitric oxide and expression of a subset of inflammatory genes including inducible nitric oxide synthase (Nos2/iNOS) and interleukin 6 (Il6) by lipopolysaccharide (LPS)-activated macrophages.	4-hydroxy-5,7,10,13,16,19-docosahexaenoic acid	0-7	interleukin 6	Mus musculus	152-165
18191038-3	2008	4-OHDHA inhibited production of nitric oxide and expression of a subset of inflammatory genes including inducible nitric oxide synthase (Nos2/iNOS) and interleukin 6 (Il6) by lipopolysaccharide (LPS)-activated macrophages.	4-hydroxy-5,7,10,13,16,19-docosahexaenoic acid	0-7	interleukin 6	Mus musculus	167-170
18279792-6	2008	In addition, the treatment of murine peritoneal macrophage cells with AS strongly inhibited the release of TNF-alpha and IL-6 induced by CpG oligodeoxynucleotide (CpG ODN), LPS, or heat-killed E. coli in a dose-dependent manner.	CPG-oligonucleotide	137-161	interleukin 6	Mus musculus	121-125
18204996-4	2008	Interestingly, IL-1beta, IL-6, and iNOS expression was significantly attenuated by treatment with protein kinase C (PKC) inhibitor (staurosporine) as well as p38 MAP kinase inhibitor (SKF86002) in LPS-stimulated RAW 264.7 cells.	Staurosporine	132-145	interleukin 6	Mus musculus	25-29
18279792-6	2008	In addition, the treatment of murine peritoneal macrophage cells with AS strongly inhibited the release of TNF-alpha and IL-6 induced by CpG oligodeoxynucleotide (CpG ODN), LPS, or heat-killed E. coli in a dose-dependent manner.	CPG-oligonucleotide	163-170	interleukin 6	Mus musculus	121-125
18279797-4	2008	In addition, asiatic acid dose-dependently reduced the production of IL-6, IL-1 beta and TNF-alpha in LPS-stimulated RAW 264.7 macrophage cells.	asiatic acid	13-25	interleukin 6	Mus musculus	69-73
17618107-11	2008	Moderate Zn restriction led to greater leukocyte infiltration in the LP after the LPS challenge (P&lt;.05) and higher plasma IL-6 and IL-10 levels 24 h after the LPS challenge (P&lt;.01).	Zinc	9-11	interleukin 6	Mus musculus	125-129
18630677-7	2008	It was also observed that CTL activity, cellular proliferation and IL-6 and TNF-beta secreting levels of lymphocytes that were stimulated by the vaccine cells treated with AS1 were notably enhanced.	(N(omega)-L-arginino)succinic acid	172-175	interleukin 6	Mus musculus	67-71
18187046-4	2008	Furthermore, interleukin (IL)-1- and IL-6-stimulated bone resorption involves PGE(2) production.	Dinoprostone	78-84	interleukin 6	Mus musculus	37-41
18036573-11	2008	Hepatic TNFalpha protein levels were increased in all treatment groups, however, IL-6, a hepatoprotective cytokine which promotes liver regeneration was increased in ethanol-fed mice (2-fold), but decreased in the combination diet-treated mice.	Ethanol	166-173	interleukin 6	Mus musculus	81-85
17991916-3	2008	When replated onto fresh AGM-S1 with the addition of stem cell factor, interleukin-6, and Flt3 ligand, these CS-like cells displayed robust growth and generated almost 100% tryptase/chymase double-positive MCs within 3 weeks.	Cesium	109-111	interleukin 6	Mus musculus	71-84
18761792-7	2008	Extracellular IL-6 increased significantly after exposure to NiSO4 for 1 h, with the maximum at 24 h (2152 pg/ml, P &lt; 0.05).	nickel sulfate	61-66	interleukin 6	Mus musculus	14-18
18761792-8	2008	After exposure to HCA, extracellular IL-6 reached the maximum at 1 h (1403 pg/ml), and then it was decreased quickly, but still higher than the control (P &lt; 0.05), while it didn"t change significantly after treatment with DNCB and SDS, compared with the control (P &gt; 0.05).	Dinitrochlorobenzene	225-229	interleukin 6	Mus musculus	37-41
18761792-8	2008	After exposure to HCA, extracellular IL-6 reached the maximum at 1 h (1403 pg/ml), and then it was decreased quickly, but still higher than the control (P &lt; 0.05), while it didn"t change significantly after treatment with DNCB and SDS, compared with the control (P &gt; 0.05).	Sodium Dodecyl Sulfate	234-237	interleukin 6	Mus musculus	37-41
18761792-10	2008	CONCLUSION: Chemical sensitizer DNCB could induce the high expression of CD86 on DC membrane, and NiSO4 and HCA could induce DC to release IL-1 beta and IL-6.	nickel sulfate	98-103	interleukin 6	Mus musculus	153-157
18761792-10	2008	CONCLUSION: Chemical sensitizer DNCB could induce the high expression of CD86 on DC membrane, and NiSO4 and HCA could induce DC to release IL-1 beta and IL-6.	hexyl cinnamic aldehyde	108-111	interleukin 6	Mus musculus	153-157
18376298-7	2008	Furthermore, plasma interleukin 6 concentration was significantly elevated in mice with taurocholate-induced pancreatitis (12 hours: cerulein, 2.6 +/- 6.1 pg/mL; taurocholate, 2168.8 +/- 941.7 microg/mL; P &lt; 0.001) as compared with all other groups.	Taurocholic Acid	88-100	interleukin 6	Mus musculus	20-33
18376298-7	2008	Furthermore, plasma interleukin 6 concentration was significantly elevated in mice with taurocholate-induced pancreatitis (12 hours: cerulein, 2.6 +/- 6.1 pg/mL; taurocholate, 2168.8 +/- 941.7 microg/mL; P &lt; 0.001) as compared with all other groups.	Taurocholic Acid	162-174	interleukin 6	Mus musculus	20-33
18298378-5	2008	Amentoflavone showed inhibitory effect on the production of various endogenous factors such as IL-1beta, IL-6, TNF-alpha, GM-CSF, and VEGF that control the process of angiogenesis.	amentoflavone	0-13	interleukin 6	Mus musculus	105-109
18294378-10	2008	Mice treated chronically treated with morphine prior to incision were found to have enhanced skin levels of IL-1beta, IL-6, G-CSF, KC and TNFalpha after incision at one or more time points compared to saline pretreated controls.	Morphine	38-46	interleukin 6	Mus musculus	118-122
18039959-9	2008	In addition, rosiglitazone treatment reduced the ability of microparticles to evoke increases in interleukin (IL)-6, IL-8, and nuclear factor (NF)-kappaB transcription, and NF-kappaB expression and activation.	Rosiglitazone	13-26	interleukin 6	Mus musculus	97-115
18093689-4	2008	DEN administration caused greater increases in serum interleukin-6 (IL-6) concentration in males than it did in females.	Diethylnitrosamine	0-3	interleukin 6	Mus musculus	53-66
18093689-4	2008	DEN administration caused greater increases in serum interleukin-6 (IL-6) concentration in males than it did in females.	Diethylnitrosamine	0-3	interleukin 6	Mus musculus	68-72
18093689-6	2008	DEN exposure promoted production of IL-6 in Kupffer cells (KCs) in a manner dependent on the Toll-like receptor adaptor protein MyD88, ablation of which also protected male mice from DEN-induced hepatocarcinogenesis.	Diethylnitrosamine	0-3	interleukin 6	Mus musculus	36-40
18093689-6	2008	DEN exposure promoted production of IL-6 in Kupffer cells (KCs) in a manner dependent on the Toll-like receptor adaptor protein MyD88, ablation of which also protected male mice from DEN-induced hepatocarcinogenesis.	Diethylnitrosamine	183-186	interleukin 6	Mus musculus	36-40
18093689-7	2008	Estrogen inhibited secretion of IL-6 from KCs exposed to necrotic hepatocytes and reduced circulating concentrations of IL-6 in DEN-treated male mice.	Diethylnitrosamine	128-131	interleukin 6	Mus musculus	120-124
18207575-4	2008	EAMG resistance was associated with reduced lymph node cell IL-6 and IL-10 production and increased CD4(+)CD25(+) cell ratios in lymph nodes.	eamg	0-4	interleukin 6	Mus musculus	60-64
18162079-16	2008	In the lung, IL-6 and IL-10 was significantly increased in alcohol-exposed infected mice compared to saline-treated infected mice.	Alcohols	59-66	interleukin 6	Mus musculus	13-17
18162079-16	2008	In the lung, IL-6 and IL-10 was significantly increased in alcohol-exposed infected mice compared to saline-treated infected mice.	Sodium Chloride	101-107	interleukin 6	Mus musculus	13-17
18162079-18	2008	CONCLUSIONS: Ethanol treatment in this surgical model led to a more severe pulmonary infection with K. pneumoniae which was associated with more tissue destruction and increased levels of IL-6 and IL-10 and a worsened clinical score.	Ethanol	13-20	interleukin 6	Mus musculus	188-192
18365876-10	2008	Similarly, nitric oxide production by peritoneal macrophages from G-CSF(- / - )/IL-6(- / - ) mice in response to Candida is comparable to G-CSF(- / - ) mice.	Nitric Oxide	11-23	interleukin 6	Mus musculus	80-84
17965229-5	2008	Stimulation of adenosine receptors with 5"-N-ethylcarboxamidoadenosine (NECA) up-regulated IL-6 and suppressed LPS-induced TNF-alpha in wild-type mice.	Adenosine-5'-(N-ethylcarboxamide)	40-70	interleukin 6	Mus musculus	91-95
17965229-5	2008	Stimulation of adenosine receptors with 5"-N-ethylcarboxamidoadenosine (NECA) up-regulated IL-6 and suppressed LPS-induced TNF-alpha in wild-type mice.	Adenosine-5'-(N-ethylcarboxamide)	72-76	interleukin 6	Mus musculus	91-95
17965229-6	2008	The selective A(2B) antagonists 3-isobutyl-8-pyrrolidinoxanthine and 8-[4-[((4-cyanophenyl)carbamoylmethyl)oxy]phenyl]-1,3-di(n-propyl)xanthine (MRS 1754) inhibited NECA-induced IL-6 release but not the suppression of LPS-induced TNF-alpha secretion from macrophages.	N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide	69-143	interleukin 6	Mus musculus	178-182
18173800-4	2008	In the assays using C3H/HeJ mouse cells, the LPS and native lipid A significantly stimulated splenocytes to cause mitosis, and peritoneal macrophages to induce tumor necrosis factor-alpha and interleukin-6 production.	Lipid A	60-67	interleukin 6	Mus musculus	192-205
18567870-5	2008	Therefore, EAMG/MG could be treated by blocking the activation of classical complement pathway (CCP) and/or IL-6.	eamg	11-15	interleukin 6	Mus musculus	108-112
18036617-9	2008	Simvastatin or pravastatin also decreased the LTI-stimulated interleukin-6 (IL-6) secretion.	Simvastatin	0-11	interleukin 6	Mus musculus	61-74
18036617-9	2008	Simvastatin or pravastatin also decreased the LTI-stimulated interleukin-6 (IL-6) secretion.	Simvastatin	0-11	interleukin 6	Mus musculus	76-80
18036617-9	2008	Simvastatin or pravastatin also decreased the LTI-stimulated interleukin-6 (IL-6) secretion.	Pravastatin	15-26	interleukin 6	Mus musculus	61-74
18036617-9	2008	Simvastatin or pravastatin also decreased the LTI-stimulated interleukin-6 (IL-6) secretion.	Pravastatin	15-26	interleukin 6	Mus musculus	76-80
18036617-11	2008	Y27632, an inhibitor of Rho kinase, also inhibited the LTI-induced NF-kappaB activation and iNOS expression, and decreased the production of NO and IL-6 in 3T3-L1 preadipocytes.	Y 27632	0-6	interleukin 6	Mus musculus	148-152
17996413-2	2008	Here, we report that AR displays anti-inflammatory effects in zymosan air-pouch mice by reducing the expression of iNOS, COX-2, IL-6, IL-1beta and TNF-alpha and by decreasing the production of nitric oxide (NO).	Argon	21-23	interleukin 6	Mus musculus	128-132
17996413-3	2008	In a similar manner, AR reduces the expression of IL-6, iNOS, and COX-2 in lipopolysaccharide (LPS)-treated Raw 264.7 cells.	Argon	21-23	interleukin 6	Mus musculus	50-54
19704783-8	2008	Like other CB(2) ligands also beta-caryophyllene inhibits the pathways triggered by activation of the toll-like receptor complex CD14/TLR4/MD2, which typically lead to the expression of proinflammatory cytokines (IL-1beta, IL-6; IL-8 and TNFalpha) and promotes a TH(1) immune response.	caryophyllene	30-48	interleukin 6	Mus musculus	223-227
18714675-0	2008	Riboflavin inhibits IL-6 expression and p38 activation in islet cells.	Riboflavin	0-10	interleukin 6	Mus musculus	20-24
18714675-5	2008	However, riboflavin prevented the cytokine-induced increase in IL-6 mRNA expression and p38 phosphorylation analyzed by real-time PCR and immunoassay, respectively.	Riboflavin	9-19	interleukin 6	Mus musculus	63-67
18714675-6	2008	In summary, nontoxic doses of riboflavin prevent cytokines-induced p38 phosphorylation and IL-6 upregulation in islet cells.	Riboflavin	30-40	interleukin 6	Mus musculus	91-95
19509460-10	2008	EGT has a protective role on PA-induced cell death, possibly via 2. reduced activity of MAPKs cascade having also 3. an anti-inflammatory action exerted on the IL-6 modulation.	Palmitic Acid	29-31	interleukin 6	Mus musculus	160-164
18253705-12	2008	Some of the beneficial changes by n-3 FA include enhancing antioxidant enzymes and lowering Th-1/Th-2 cytokines, adhesion molecules, COX-2/PGE(2) levels, pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha etc.	n-3 fa	34-40	interleukin 6	Mus musculus	192-196
18569082-11	2008	The highly elevated level of IL-6 (370.1 pg/ml) in control animals was also reduced by the treatment of glycyrrhizic acid (313 pg/ml) and ursolic acid (299 pg/ml).	Glycyrrhizic Acid	104-121	interleukin 6	Mus musculus	29-33
18686102-5	2008	Amentoflavone treatment markedly decreased the mRNA expression of MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, TNF-alpha, IL-1beta, IL-6, and GM-CSF in lung tissues.	amentoflavone	0-13	interleukin 6	Mus musculus	156-160
18618311-4	2008	Mice treated with LPS alone showed markedly increased plasma levels of TNF, IL-1beta, IL-6, and IL-10, while mice pretreated with rifampicin showed significantly lower plasma levels of these cytokines compared to the LPS alone.	Rifampin	130-140	interleukin 6	Mus musculus	86-90
18360069-8	2008	T-cell infiltration of cardiac allografts and expression of interferon-g , interleukin-6, and interleukin-15 in cardiac allografts were suppressed by 4-1BBIg treatment.	4-1bbig	150-157	interleukin 6	Mus musculus	75-88
18504409-8	2008	Simvastatin also inhibited IL-6 production from LPS-stimulated BMMCs.	Simvastatin	0-11	interleukin 6	Mus musculus	27-31
18504409-10	2008	CONCLUSIONS: Simvastatin inhibits the production of TNF-alpha and IL-6 from activated mast cells in part by inhibiting de novo synthesis of their transcripts and the inhibition may account for the anti-inflammatory effect of simvastatin.	Simvastatin	13-24	interleukin 6	Mus musculus	66-70
18504409-10	2008	CONCLUSIONS: Simvastatin inhibits the production of TNF-alpha and IL-6 from activated mast cells in part by inhibiting de novo synthesis of their transcripts and the inhibition may account for the anti-inflammatory effect of simvastatin.	Simvastatin	225-236	interleukin 6	Mus musculus	66-70
18236232-9	2008	NO2 exposure increased goblet cells, eosinophils, and the levels of IL-6, while it decreased the levels of IL-10.	Nitrogen Dioxide	0-3	interleukin 6	Mus musculus	68-72
18301970-9	2008	In conclusion, in CIA mice, celecoxib suppresses arthritis-related increase in bone resorption at low and high doses and prevents trabecular bone mass reduction at high doses in association with suppression of osteoclast development in bone marrow through inhibition of RANKL/OPG ratio and IL-6 mRNA expression in inflammatory synovial tissue.	Celecoxib	28-37	interleukin 6	Mus musculus	290-294
19066129-3	2008	Amentoflavone at a concentration of 10 microg/mL could significantly (p &lt; 0.001) inhibit NO and proinflammatory cytokine (IL-1beta, IL-6, GM-CSF and TNF-alpha) production in B16F-10 cells, TAMs and peritoneal macrophages.	amentoflavone	0-13	interleukin 6	Mus musculus	135-139
18569082-11	2008	The highly elevated level of IL-6 (370.1 pg/ml) in control animals was also reduced by the treatment of glycyrrhizic acid (313 pg/ml) and ursolic acid (299 pg/ml).	ursolic acid	138-150	interleukin 6	Mus musculus	29-33
18220075-0	2008	Effects of serotonergic activation by 5-hydroxytryptophan on sleep and body temperature of C57BL/6J and interleukin-6-deficient mice are dose and time related.	5-Hydroxytryptophan	38-57	interleukin 6	Mus musculus	104-117
17629561-10	2008	Acceleration of IL-6 and MMP-3 productions and attenuation of caspase-3/7 activity in IL-1beta-stimulated SC were abated by edaravone.	Edaravone	124-133	interleukin 6	Mus musculus	16-20
19148296-0	2008	(-)-Epigallocatechin gallate reduces platelet-derived growth factor-BB-stimulated interleukin-6 synthesis in osteoblasts: suppression of SAPK/JNK.	epigallocatechin gallate	0-28	interleukin 6	Mus musculus	82-95
19148296-2	2008	In the present study, we investigated whether (-)-epigallocatechin gallate (EGCG), one of the major green tea flavonoids, affects the synthesis of IL-6 in these cells and the mechanism.	epigallocatechin gallate	46-74	interleukin 6	Mus musculus	147-151
19148296-2	2008	In the present study, we investigated whether (-)-epigallocatechin gallate (EGCG), one of the major green tea flavonoids, affects the synthesis of IL-6 in these cells and the mechanism.	epigallocatechin gallate	76-80	interleukin 6	Mus musculus	147-151
19148296-3	2008	EGCG significantly reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6 synthesis also in primary-cultured osteoblasts.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	31-35
19148296-3	2008	EGCG significantly reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6 synthesis also in primary-cultured osteoblasts.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	50-54
19148296-3	2008	EGCG significantly reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6 synthesis also in primary-cultured osteoblasts.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	50-54
19148296-3	2008	EGCG significantly reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6 synthesis also in primary-cultured osteoblasts.	epigallocatechin gallate	94-98	interleukin 6	Mus musculus	31-35
19148296-3	2008	EGCG significantly reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6 synthesis also in primary-cultured osteoblasts.	epigallocatechin gallate	94-98	interleukin 6	Mus musculus	50-54
19148296-3	2008	EGCG significantly reduced the IL-6 synthesis and IL-6 mRNA expression stimulated by PDGF-BB, EGCG reduced the PDGF-BB-stimulated IL-6 synthesis also in primary-cultured osteoblasts.	epigallocatechin gallate	94-98	interleukin 6	Mus musculus	50-54
19148296-9	2008	These results strongly suggest that EGCG inhibits the PDGF-BB-stimulated synthesis of IL-6 via suppression of SAPK/JNK pathway in osteoblasts.	epigallocatechin gallate	36-40	interleukin 6	Mus musculus	86-90
18052238-5	2007	Results showed that all of the isoflavone powders and genistein standard were effective in inhibiting LPS-induced inflammation, lowering leukocyte number in mice blood and reducing production of IL-1beta, IL-6, NO, and PGE2 in both peritoneal exudate cell supernatant and peritoneal exudate fluid.	Isoflavones	31-41	interleukin 6	Mus musculus	205-209
18052238-5	2007	Results showed that all of the isoflavone powders and genistein standard were effective in inhibiting LPS-induced inflammation, lowering leukocyte number in mice blood and reducing production of IL-1beta, IL-6, NO, and PGE2 in both peritoneal exudate cell supernatant and peritoneal exudate fluid.	Genistein	54-63	interleukin 6	Mus musculus	205-209
17962017-0	2007	Synthesis of andrographolide derivatives and their TNF-alpha and IL-6 expression inhibitory activities.	andrographolide	13-28	interleukin 6	Mus musculus	65-69
17920531-7	2007	SAA concentrations after silver nitrate injection peaked at 24 h, preceded by increases in serum IL-1 beta and IL-6, associated with decreases in blood leukocytes and local tissue inflammation.	Silver Nitrate	25-39	interleukin 6	Mus musculus	111-115
17962017-1	2007	The synthesis of a series of andrographolide derivatives was described and their inhibitory effects on TNF-alpha and IL-6 secretion in mouse macrophages were also evaluated.	andrographolide	29-44	interleukin 6	Mus musculus	117-121
18057724-1	2007	We previously reported that poncirin, a flavanone glycoside isolated from the EtOAc extract of the dried immature fruits of Poncirus trifoliata, is an anti-inflammatory compound that inhibits PGE(2) and IL-6 production.	poncirin	28-36	interleukin 6	Mus musculus	203-207
17962626-1	2007	OBJECTIVE: The goal of this study was to test the hypothesis that IL-6 mediates the increases in superoxide, vascular hypertrophy, and endothelial dysfunction in response to angiotensin II (Ang II).	Superoxides	97-107	interleukin 6	Mus musculus	66-70
17962626-4	2007	IL-6 deficiency also protected against endothelial dysfunction in response to acute (local) Ang II treatment (eg, 100 mumol/L acetylcholine produced 100+/-4 and 98+/-4% relaxation in vehicle-treated and 51+/-4 and 99+/-4% relaxation in Ang II-treated, control, and IL-6-deficient vessels, respectively).	Acetylcholine	126-139	interleukin 6	Mus musculus	0-4
17962626-7	2007	CONCLUSIONS: These data demonstrate that IL-6 is essential for Ang II-induced increases in superoxide, endothelial dysfunction, and vascular hypertrophy.	Superoxides	91-101	interleukin 6	Mus musculus	41-45
18057724-6	2007	Taken together, our data indicate that anti-inflammatory properties of poncirin might be the result from the inhibition iNOS, COX-2, TNF-alpha and IL-6 expression via the down-regulation of NF-kappaB binding activity.	poncirin	71-79	interleukin 6	Mus musculus	147-151
18057724-3	2007	Poncirin reduced lipopolysaccharide (LPS)-induced protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and the mRNA expressions of iNOS, COX-2, tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in a concentration-dependent manner, as determined by Western blotting and RT-PCR, respectively.	poncirin	0-8	interleukin 6	Mus musculus	221-234
18057724-3	2007	Poncirin reduced lipopolysaccharide (LPS)-induced protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and the mRNA expressions of iNOS, COX-2, tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in a concentration-dependent manner, as determined by Western blotting and RT-PCR, respectively.	poncirin	0-8	interleukin 6	Mus musculus	236-240
18096486-7	2007	NAC also resulted in significantly fewer macrophages, lymphocytes and neutrophils as well as IL-1 beta, keratinocyte cytokine (KC), monocyte chemoattractant protein (MCP)-1 and IL-6 levels in BAL taken after reperfusion.	Acetylcysteine	0-3	interleukin 6	Mus musculus	177-181
18025188-8	2007	Both in vitro and in vivo suppression assays also showed that Sle1a expression induced effector T cells to be resistant to Treg suppression, as well as dendritic cells to overproduce IL-6, which inhibits Treg suppression.	treg	204-208	interleukin 6	Mus musculus	183-187
18001439-15	2007	Progesterone reduced the LPS-induced increase in IL-6 production and this may be one of the ways that progesterone reduces the risk of preterm labor.	Progesterone	102-114	interleukin 6	Mus musculus	49-53
17881510-4	2007	We found that IL-33, but not IL-1beta or IL-18, induced IL-13 and IL-6 production by mouse bone marrow-derived, cultured mast cells (BMCMCs) independently of IgE.	bmcmcs	133-139	interleukin 6	Mus musculus	66-70
18050387-8	2007	Synovial inflammation and serum TNF-alpha and IL-6 levels were suppressed by infliximab with or without MTX.	Methotrexate	104-107	interleukin 6	Mus musculus	46-50
17966067-12	2007	Pulmonary TNF-alpha and IL-6 both increased significantly with PM + LPS100 treatment.	lps100	68-74	interleukin 6	Mus musculus	24-28
17935227-7	2007	IL-6(+/+) liver DCs produce IL-6 in response to exposure to lipopolysaccharide (LPS) and cytidine phosphate guanosine oligonucleotides (CpG) but are resistant to maturation compared with IL-6(-/-) liver DCs.	cytidine phosphate guanosine oligonucleotides	89-134	interleukin 6	Mus musculus	0-4
17935227-7	2007	IL-6(+/+) liver DCs produce IL-6 in response to exposure to lipopolysaccharide (LPS) and cytidine phosphate guanosine oligonucleotides (CpG) but are resistant to maturation compared with IL-6(-/-) liver DCs.	cytidine phosphate guanosine oligonucleotides	89-134	interleukin 6	Mus musculus	28-32
17935227-7	2007	IL-6(+/+) liver DCs produce IL-6 in response to exposure to lipopolysaccharide (LPS) and cytidine phosphate guanosine oligonucleotides (CpG) but are resistant to maturation compared with IL-6(-/-) liver DCs.	cytidine phosphate guanosine oligonucleotides	89-134	interleukin 6	Mus musculus	28-32
17825250-4	2007	Y27632, a specific inhibitor of Rho-kinase, significantly suppressed the IL-6 synthesis induced by ET-1 as well as the MYPT-1 phosphorylation.	Y 27632	0-6	interleukin 6	Mus musculus	73-77
17868752-0	2007	Inhibitory effect of phytoglycoprotein on tumor necrosis factor-alpha and interleukin-6 at initiation stage of colon cancer in 1,2-dimethylhydrazine-treated ICR mice.	1,2-Dimethylhydrazine	127-148	interleukin 6	Mus musculus	74-87
17966067-14	2007	For plasma IL-6, all groups tended to rise with a significant increase in the PM + LPS100 group.	lps100	83-89	interleukin 6	Mus musculus	11-15
17761154-4	2007	The results revealed that glycogens with a weight-average molecular weight (M(w)) of more than 10,000K hardly activated RAW264.7, a murine macrophage cell line, whereas glycogens of M(w) 5000K and 6500K strongly stimulated RAW264.7 in the presence of interferon-gamma (IFN-gamma), leading to augmented production of nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6).	Glycogen	26-35	interleukin 6	Mus musculus	380-393
17761154-4	2007	The results revealed that glycogens with a weight-average molecular weight (M(w)) of more than 10,000K hardly activated RAW264.7, a murine macrophage cell line, whereas glycogens of M(w) 5000K and 6500K strongly stimulated RAW264.7 in the presence of interferon-gamma (IFN-gamma), leading to augmented production of nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6).	Glycogen	26-35	interleukin 6	Mus musculus	395-399
17825250-5	2007	Fasudil, another inhibitor of Rho-kinase, reduced the ET-1-stimulated IL-6 synthesis.	fasudil	0-7	interleukin 6	Mus musculus	70-74
17404849-5	2007	PPARbeta/delta-null mice exhibited increased sensitivity to DSS-induced colitis, as shown by marked differences in body weight loss, colon length, colonic morphology, myeloperoxidase activity and increased expression of mRNAs encoding the inflammatory markers interferon gamma, tumor necrosis factor-alpha, and interleukin-6 compared to similarly treated wild-type mice.	dss	60-63	interleukin 6	Mus musculus	311-324
17997851-8	2007	Induction of plasma tumor necrosis factor-alpha, interleukin-6, and interferon-gamma by LPS was greater with HCD than CD.	Cadmium	110-112	interleukin 6	Mus musculus	49-62
17982067-7	2007	The uptake of SM4s-coated apoptotic cells significantly enhanced macrophage production of TGF-beta1, expression of P-selectin, and secretion of IL-6.	sm4s	14-18	interleukin 6	Mus musculus	144-148
17637490-11	2007	Dioscorin (5-100 microg/ml) was found able to induce IL-6, TNF-alpha, and IL-1beta production in RAW264.7 cells and human monocytes.	dioscorin	0-9	interleukin 6	Mus musculus	53-57
17974982-10	2007	These studies show IL-6-independent activation of STAT3 by norepinephrine and epinephrine, proceeding through the beta1/beta2-adrenergic receptors and protein kinase A, resulting in increased matrix metalloproteinase production, invasion, and in vivo tumor growth, which can be ameliorated by the down-regulation of STAT3.	Norepinephrine	59-73	interleukin 6	Mus musculus	19-23
17974982-10	2007	These studies show IL-6-independent activation of STAT3 by norepinephrine and epinephrine, proceeding through the beta1/beta2-adrenergic receptors and protein kinase A, resulting in increased matrix metalloproteinase production, invasion, and in vivo tumor growth, which can be ameliorated by the down-regulation of STAT3.	Epinephrine	62-73	interleukin 6	Mus musculus	19-23
17932564-6	2007	We further demonstrated that IL-6 treatment of isolated mouse islets suppressed glucose-stimulated insulin secretion.	Glucose	80-87	interleukin 6	Mus musculus	29-33
17626110-5	2007	Overventilation increased histone acetylation at H4K12, as well as gene and protein expression of tumour necrosis factor (TNF), macrophage inflammatory protein (MIP)-2alpha and interleukin (IL)-6; these effects were reversed by dexamethasone.	Dexamethasone	228-241	interleukin 6	Mus musculus	177-195
17626110-6	2007	In the presence or absence of dexamethasone, TSA enhanced overventilation-induced induction of TNF and MIP-2alpha, but decreased that of IL-6, indicating that the effects of HDAC are gene dependent.	trichostatin A	45-48	interleukin 6	Mus musculus	137-141
17948064-3	2007	IL-6 formation and release in cultured cardiomyocytes under beta-adrenoceptor stimulation requires the activation of activating protein-1 (AP-1) binding sites and of cAMP response elements (CRE) in the IL-6 promoter, but this release (140 +/- 6 pg/mL medium under 10(-6) M isoproterenol vs. 81 +/- 3 pg/mL unstimulated, P &lt; 0.05) is moderate compared with that under inflammatory stimulation (855 +/- 44 pg/mL, endotoxin 0.1microg/mL).	Cyclic AMP	166-170	interleukin 6	Mus musculus	0-4
18075203-5	2007	At the formalin-treated sites, genes related to neurogenic inflammation, i.e., bradykinin (BK) B2 receptor, IL-6, and membrane metallo endopeptidase (NEP) mRNA were upregulated.	Formaldehyde	7-15	interleukin 6	Mus musculus	108-112
18075203-6	2007	In the TNCB-treated sites, marked upregulation of IFN-gamma, IL-1beta, IL-4, and IL-6 mRNA was observed in addition to B2 receptor mRNA.	Picryl Chloride	7-11	interleukin 6	Mus musculus	81-85
17948064-3	2007	IL-6 formation and release in cultured cardiomyocytes under beta-adrenoceptor stimulation requires the activation of activating protein-1 (AP-1) binding sites and of cAMP response elements (CRE) in the IL-6 promoter, but this release (140 +/- 6 pg/mL medium under 10(-6) M isoproterenol vs. 81 +/- 3 pg/mL unstimulated, P &lt; 0.05) is moderate compared with that under inflammatory stimulation (855 +/- 44 pg/mL, endotoxin 0.1microg/mL).	Cyclic AMP	166-170	interleukin 6	Mus musculus	202-206
18040640-13	2007	Production of IL-1beta, IL-6, and TNF-alpha in the supernatant was also suppressed by EHDP.	Etidronic Acid	86-90	interleukin 6	Mus musculus	24-28
17948064-3	2007	IL-6 formation and release in cultured cardiomyocytes under beta-adrenoceptor stimulation requires the activation of activating protein-1 (AP-1) binding sites and of cAMP response elements (CRE) in the IL-6 promoter, but this release (140 +/- 6 pg/mL medium under 10(-6) M isoproterenol vs. 81 +/- 3 pg/mL unstimulated, P &lt; 0.05) is moderate compared with that under inflammatory stimulation (855 +/- 44 pg/mL, endotoxin 0.1microg/mL).	Isoproterenol	273-286	interleukin 6	Mus musculus	0-4
17850646-13	2007	Data show that cocultures containing purified CD4+ T DO11.10 cells and APC derived from alcohol-consuming mice show decreased IL-6, IL-12, IL-17A, and IFN-gamma and increased IL-13 cytokine production in response to OVA stimulation.	Alcohols	88-95	interleukin 6	Mus musculus	126-130
17575079-11	2007	In addition, these results suggest that the induction of IL-6 via IL-1RI may be important in mediating the effects of O(3) during subacute exposure.	Ozone	118-122	interleukin 6	Mus musculus	57-61
17656448-8	2007	In a less severe form of colitis (1% DSS), GI270384X treatment dose dependently ameliorated the clinical signs of colitis, colonic pathological changes, and serum levels of biomarkers (IL-6 and serum amyloid A).	GI270384X	43-52	interleukin 6	Mus musculus	185-189
17690174-8	2007	CIH caused significant increases in lipid peroxidation in serum and liver tissue; significant increases in hepatic levels of myeloperoxidase and proinflammatory cytokines IL-1beta, IL-6, and CXC chemokine MIP-2; a trend toward an increase in TNF-alpha; and an increase in alpha1(I)-collagen mRNA.	cih	0-3	interleukin 6	Mus musculus	181-185
17697009-0	2007	Acute ethanol exposure combined with burn injury enhances IL-6 levels in the murine ileum.	Ethanol	6-13	interleukin 6	Mus musculus	58-62
17697009-8	2007	In addition, there was an increase in IL-6 levels at 24 hours in intestinal tissue obtained from mice subjected to a combination of acute ethanol and burn injury, compared to the mice receiving burn or sham injury (p &lt; 0.001).	Ethanol	138-145	interleukin 6	Mus musculus	38-42
17697009-10	2007	Additional immunocytochemical localization studies of ileal tissue revealed that there was a substantial increase of IL-6 in intestinal enterocytes subjected to both burn injury alone, or in combination with acute ethanol exposure.	Ethanol	214-221	interleukin 6	Mus musculus	117-121
17697009-11	2007	CONCLUSIONS: The present study suggests that acute ethanol exposure combined with burn injury enhances levels of IL-6 protein in the ileum.	Ethanol	51-58	interleukin 6	Mus musculus	113-117
17645771-4	2007	In the present study, culturing the colon 26 cells under different conditions in vitro revealed that IL-6 production was increased by monolayer culture under a low-glucose condition but not by spheroid culture.	Glucose	164-171	interleukin 6	Mus musculus	101-105
17632100-3	2007	Intravenous administration of TAK-242 to mice 1 h before LPS challenge dose-dependently inhibited LPS-induced increases in serum levels of TNF-alpha, IL-1beta, IL-6, IL-10, MIP-2, and NO metabolites.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	30-37	interleukin 6	Mus musculus	160-164
17898286-8	2007	rmST2- versus PBS-injected mice exhibited increased bacterial load, PMN infiltrate, and higher corneal mRNA levels for IL-1beta, MIP-2, IL-6, IL-1R1, and Th1-type cytokine such as IFN-gamma.	Lead	14-17	interleukin 6	Mus musculus	136-140
17660268-8	2007	In renal mesangial cells, overexpression of FXR or treatment with GW4064 also inhibited SREBP-1c and other lipogenic genes, transforming growth factor-beta, and interleukin-6, suggesting a direct role of FXR in modulating renal lipid metabolism and modulation of fibrosis and inflammation.	GW 4064	66-72	interleukin 6	Mus musculus	161-174
17626835-6	2007	Ozone induced time-dependent increases in inflammatory gene expression of keratinocyte chemoattractant (KC) and IL-6 and of TLR2, TLR4, and MyD88 in WT mice.	Ozone	0-5	interleukin 6	Mus musculus	112-116
17896415-3	2007	DEN administration caused greater increases in serum interleukin-6 (IL-6) concentration in males than it did in females.	Diethylnitrosamine	0-3	interleukin 6	Mus musculus	53-66
17896415-3	2007	DEN administration caused greater increases in serum interleukin-6 (IL-6) concentration in males than it did in females.	Diethylnitrosamine	0-3	interleukin 6	Mus musculus	68-72
17896415-5	2007	DEN exposure promoted production of IL-6 in Kupffer cells (KCs) in a manner dependent on the Toll-like receptor adaptor protein MyD88, ablation of which also protected male mice from DEN-induced hepatocarcinogenesis.	Diethylnitrosamine	0-3	interleukin 6	Mus musculus	36-40
17896415-5	2007	DEN exposure promoted production of IL-6 in Kupffer cells (KCs) in a manner dependent on the Toll-like receptor adaptor protein MyD88, ablation of which also protected male mice from DEN-induced hepatocarcinogenesis.	Diethylnitrosamine	183-186	interleukin 6	Mus musculus	36-40
17896415-6	2007	Estrogen inhibited secretion of IL-6 from KCs exposed to necrotic hepatocytes and reduced circulating concentrations of IL-6 in DEN-treated male mice.	Diethylnitrosamine	128-131	interleukin 6	Mus musculus	120-124
17458900-7	2007	Interestingly, the same C8 ceramide treatment showed opposite effects on cytokine production from LPS-stimulated macrophages, reducing IL-6 and TNF-alpha while not affecting IL-10 production.	Ceramides	27-35	interleukin 6	Mus musculus	135-139
17885684-7	2007	Depletion of macrophages by the intratracheal administration of liposomal clodronate attenuated particulate matter-induced IL-6 production and the resultant prothrombotic tendency.	Clodronic Acid	74-84	interleukin 6	Mus musculus	123-127
17599828-6	2007	Sivelestat completely inhibited both neutrophil elastase and myeloperoxidase activities that were increased by ventilation, and attenuated the histopathological degree of lung damage, neutrophil accumulation and lung water content, as well as the concentration of macrophage inflammatory protein (MIP)-2, interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha in bronchoalveolar lavage fluid and serum.	sivelestat	0-10	interleukin 6	Mus musculus	305-323
17890674-5	2007	PGE(2) (100 ng/mL) and EP4 agonist (1 microM) up-regulated RANKL and IL-6 mRNA levels, while they down-regulated OPG mRNA expression.	Prostaglandins E	0-3	interleukin 6	Mus musculus	69-73
17719033-3	2007	Capsaicin inhibited the expressions of IL-6 and MCP-1 mRNAs and protein release from the adipose tissues and adipocytes of obese mice, whereas it enhanced the expression of the adiponectin gene and protein.	Capsaicin	0-9	interleukin 6	Mus musculus	39-43
17785809-4	2007	Retinoic acid can promote TGF-beta1-dependent generation of FoxP3+ regulatory T cells but decrease the TGF-beta1- and IL-6-dependent generation of inflammatory Th17 cells in mouse T cells.	Tretinoin	0-13	interleukin 6	Mus musculus	118-122
17548806-7	2007	After oral administration, ST2825 dose-dependently inhibited IL-1beta-induced production of IL-6 in treated mice.	ST2825	27-33	interleukin 6	Mus musculus	92-96
17852747-2	2007	We investigated the effects of 5,7-dimethoxy-4-p-methoxylphenylcoumarin and 5,7-dimethoxy-4-phenylcoumarin not only on the formation of nitric oxide (NO), PGE(2), TNF-alpha, IL-6 and IL-1beta, but also on inducible NO synthase and cyclooxygenase-2 (COX-2) in lipopolysaccharide (LPS)-induced murine macrophage RAW 264.7 cells.	5,7-Dimethoxy-4-phenyl-chromen-2-one	76-106	interleukin 6	Mus musculus	174-178
17785839-5	2007	In addition, GPI-based treatment resulted in reduced circulating serum levels of the inflammatory cytokines TNF and IL-6, abrogation of infection-induced LPS hypersensitivity, and an increase in circulating IL-10.	Glycosylphosphatidylinositols	13-16	interleukin 6	Mus musculus	116-120
17785839-6	2007	At the level of trypanosomiasis-associated macrophage activation, the GPI-based treatment resulted in an impaired secretion of TNF by VSG and LPS pulsed macrophages, a reduced expression of the inflammatory cytokine genes TNF, IL-6, and IL-12, and an increased expression of the anti-inflammatory cytokine gene IL-10.	Glycosylphosphatidylinositols	70-73	interleukin 6	Mus musculus	227-231
17630201-0	2007	Resveratrol induces apoptosis, influences IL-6 and exerts immunomodulatory effect on mouse lymphocytic leukemia both in vitro and in vivo.	Resveratrol	0-11	interleukin 6	Mus musculus	42-46
17849370-7	2007	We here report, for the first time, that the prosthetic material surface (non-phagocytable) of as-cast high carbon CoCrMo reduces the pro-inflammatory cytokine IL-6 transcription, the chemokine MCP-1 secretion, and M-CSF secretion by 77%, 36%, and 62%, respectively.	Carbon	108-114	interleukin 6	Mus musculus	160-164
17763443-8	2007	In vivo, IL-6 release occurred only after exposure to high doses of MC-21, whereas application of low doses of the mAb circumvented the release of IL-6.	mc-21	68-73	interleukin 6	Mus musculus	9-13
17763443-10	2007	Activation of basophils with high doses of MC-21 or with antibodies against IgE resulted in a marked aggravation of collagen-induced arthritis and an increased release of IL-6.	mc-21	43-48	interleukin 6	Mus musculus	171-175
17368935-4	2007	We then examined the effect of luteolin on the 3-morpholinosydnonimine (SIN-1)-induced production of oxidative stress markers [nitric oxide (NO) and prostaglan E(2) (PGE(2))] and cytokines [tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6)] in osteoblasts.	linsidomine	47-70	interleukin 6	Mus musculus	234-247
17368935-4	2007	We then examined the effect of luteolin on the 3-morpholinosydnonimine (SIN-1)-induced production of oxidative stress markers [nitric oxide (NO) and prostaglan E(2) (PGE(2))] and cytokines [tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6)] in osteoblasts.	linsidomine	47-70	interleukin 6	Mus musculus	249-253
17965763-6	2007	MCE also reduced the concentration of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in the Raw264.7 cells that were activated by LPS.	lps	178-181	interleukin 6	Mus musculus	112-125
17630201-6	2007	Interleukin-6 cellular content and release are suppressed by resveratrol as well as mRNA expression.	Resveratrol	61-72	interleukin 6	Mus musculus	0-13
17630202-11	2007	These results suggest that through suppression of IL-6, triptolide can reduce production of SAA.	triptolide	56-66	interleukin 6	Mus musculus	50-54
17995665-4	2007	The preintake of these agents significantly attenuated subsequent alcohol-induced lipid oxidation, glutathione (GSH) depletion, and activity reduction of catalase and glutathione peroxidase (P &lt; 0.05); also attenuated were the alcohol-induced elevation of c-reactive protein (CRP), interleukin-6 (IL-6), IL-10 and tumor necrosis factor (TNF)-alpha (P &lt; 0.05).	Alcohols	66-73	interleukin 6	Mus musculus	285-298
17995665-6	2007	In the alleviative study, posttreatments from the 4 agents restored liver GSH content (P &lt; 0.05); however, only SEC and SPC posttreatments significantly reduced lipid oxidation and alleviated the alcohol-induced elevation of CRP, IL-6, IL-10, and TNF-alpha (P &lt; 0.05).	Alcohols	199-206	interleukin 6	Mus musculus	233-237
17995665-4	2007	The preintake of these agents significantly attenuated subsequent alcohol-induced lipid oxidation, glutathione (GSH) depletion, and activity reduction of catalase and glutathione peroxidase (P &lt; 0.05); also attenuated were the alcohol-induced elevation of c-reactive protein (CRP), interleukin-6 (IL-6), IL-10 and tumor necrosis factor (TNF)-alpha (P &lt; 0.05).	Alcohols	66-73	interleukin 6	Mus musculus	300-304
17565047-8	2007	SR140333 injected 30 min before or 1 h after CLP significantly attenuated the increased lung MPO activity and levels of MIP-2, MCP-1, IL-1beta, IL-6, ICAM-1, and E- and P-selectin compared with CLP-operated mice injected with the vehicle.	SR 140333	0-8	interleukin 6	Mus musculus	144-148
17524392-3	2007	ATP also activates IL-6 production and phosphorylation of Stat3 that promotes neuron survival.	Adenosine Triphosphate	0-3	interleukin 6	Mus musculus	19-23
17822719-6	2007	Also, we examined the inhibitory effect of SC-236 on the expression of interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha.	4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide	43-49	interleukin 6	Mus musculus	71-89
17889310-7	2007	The LPS-induced expression of IL-1beta, IL-6, MIF, gp130, and receptors IL-1RI, IL-1RII, and IL-6Ralpha were also significantly impaired by EtOH.	Ethanol	140-144	interleukin 6	Mus musculus	40-44
17724224-8	2007	The mRNA expression and protein levels of ICAM-1, MCP-1, VEGF, and IL-6 after CNV induction were significantly reduced in EPA-supplemented mice.	Eicosapentaenoic Acid	122-125	interleukin 6	Mus musculus	67-71
17724224-9	2007	In vitro, EPA application led to significant inhibition of mRNA and protein levels of ICAM-1 and MCP-1 in endothelial cells and VEGF and IL-6 in macrophages.	Eicosapentaenoic Acid	10-13	interleukin 6	Mus musculus	137-141
17724224-11	2007	EPA supplementation also led to significant reduction of serum levels of IL-6 and CRP after CNV induction.	Eicosapentaenoic Acid	0-3	interleukin 6	Mus musculus	73-77
17637810-0	2007	The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.	givinostat hydrochloride	34-41	interleukin 6	Mus musculus	103-107
17637810-6	2007	Interestingly, ITF2357 inhibited the production of IL-6, vascular endothelial growth factor (VEGF) and interferon-gamma by MSCs by 80-95%.	givinostat hydrochloride	15-22	interleukin 6	Mus musculus	51-55
17675459-6	2007	Finally, IL-6 trans-signaling inhibited Treg-mediated suppression in a murine model of colitis.	treg	40-44	interleukin 6	Mus musculus	9-13
17600119-3	2007	In these current experiments, an agonist monoclonal rat anti-mouse CD200R (DX109) antibody delivered a negative signal to bone marrow-derived macrophages, which suppressed interferon (IFN)gamma-mediated nitric oxide (NO) and interleukin-6 production.	Nitric Oxide	203-215	interleukin 6	Mus musculus	225-238
17803048-7	2007	In summary, carbamoylcholine chloride induces a rapid, elevated IL6 response in the nasal cavity and respiratory tract of mice but does not alter the levels of other Th1, Th2, or proinflammatory cytokines.	Carbachol	12-37	interleukin 6	Mus musculus	64-67
17665454-4	2007	The aim of this study was to investigate whether PGE(2) released in inflammatory foci activates resident dendritic cells (DCs) to express IL-23 (at the expense of IL-12) and IL-6, resulting in a shift toward Th17 cell responses.	Prostaglandins E	49-52	interleukin 6	Mus musculus	174-178
17665454-11	2007	CONCLUSION: Our results indicate that PGE(2) enhances DC-derived IL-6 production and induces a shift in the IL-23/IL-12 balance in favor of IL-23, resulting in increased IL-17 production, presumably through the amplification of self-reactive Th17 cells.	Prostaglandins E	38-41	interleukin 6	Mus musculus	65-69
17803048-0	2007	Carbamoylcholine chloride induces a rapid increase in IL6 in the nasal cavity of C57BL/6 mice.	Carbachol	0-25	interleukin 6	Mus musculus	54-57
17665394-7	2007	The CoPP-induced expression of HO-1 in the joints and liver was associated with marked decreases in IL-1beta, IL-6, and TNFalpha levels, PGE(2) secretion, and MMP-9 activity in serum, and with a marked increase in systemic antioxidant activity.	cobaltiprotoporphyrin	4-8	interleukin 6	Mus musculus	110-114
17629795-8	2007	The levels of TNF-alpha, IL-6, and KC in BAL fluid were increased after oxygen exposure, which was suppressed by the lack of TLR4 signaling.	Oxygen	72-78	interleukin 6	Mus musculus	25-29
17599468-4	2007	LPS-stimulated macrophages significantly reduced their in vitro production of IL-6 and IL-12 after GABA adding to the culture medium.	gamma-Aminobutyric Acid	99-103	interleukin 6	Mus musculus	78-82
17725857-6	2007	Furthermore, the water-soluble low-molecular-weight beta-glucan (100 mg kg(-1)) prevented the reduction of IL-6 and IL-12 production by splenocytes caused by restraint stress.	Water	17-22	interleukin 6	Mus musculus	107-111
17725857-6	2007	Furthermore, the water-soluble low-molecular-weight beta-glucan (100 mg kg(-1)) prevented the reduction of IL-6 and IL-12 production by splenocytes caused by restraint stress.	beta-Glucans	52-63	interleukin 6	Mus musculus	107-111
17725857-7	2007	These findings suggest that the inhibitory actions of water-soluble low-molecular-weight beta-glucan on the increase in corticosterone level and reduction of NK activity induced by restraint stress may be associated with the abrogation of the IL-6 and IL-12 reduction caused by the stress.	Water	54-59	interleukin 6	Mus musculus	243-247
17725857-7	2007	These findings suggest that the inhibitory actions of water-soluble low-molecular-weight beta-glucan on the increase in corticosterone level and reduction of NK activity induced by restraint stress may be associated with the abrogation of the IL-6 and IL-12 reduction caused by the stress.	beta-Glucans	89-100	interleukin 6	Mus musculus	243-247
17803048-2	2007	In our work to determine the basal levels of cytokines in saliva, nasal wash fluid (NWF), bronchoalveolar lavage fluid (BALF), and serum of mice, we found that injection of carbamoylcholine chloride, used to stimulate saliva production, induced variations in the interleukin (IL) 6 levels of NWF and BALF supernatants.	Carbachol	173-198	interleukin 6	Mus musculus	263-281
17537724-8	2007	The reduction in caerulein-induced pancreatic inflammation is dependent upon Tpl2 ablation in non-myeloid cells and is associated with both in vivo and in vitro inhibition of MEK, JNK, and AP-1 activation and the expression of MCP-1, MIP-2, and interleukin-6.	Ceruletide	17-26	interleukin 6	Mus musculus	245-258
17803048-5	2007	To determine whether carbamoylcholine chloride increased Th1 cytokine (IL2, IL12[p70], and interferon gamma), Th2 cytokine (IL4, IL5, and IL10), granulocyte-macrophage colony-stimulating factor (GM-CSF), or proinflammatory cytokine (IL1beta, tumor necrosis factor alpha, and IL6 in saliva and serum) levels, mice were given 10 microg carbamoylcholine chloride and euthanized.	Carbachol	21-46	interleukin 6	Mus musculus	275-278
17669273-7	2007	IL-1-induced IL-6 production was augmented by coincubation with PGE(2).	Prostaglandins E	64-67	interleukin 6	Mus musculus	13-17
17669273-8	2007	The COX inhibitor ibuprofen blocked IL-1-induced IL-6 and PGE(2) production.	Ibuprofen	18-27	interleukin 6	Mus musculus	49-53
17669273-9	2007	These results confirm that IL-1RAcP is essential for IL-1 signaling and that increased production of IL-6 by IL-1 needs the co-induction of PGE(2).	Prostaglandins E	140-143	interleukin 6	Mus musculus	101-105
17512902-4	2007	Consistently, RT-PCR with mRNA and Western blot with anti-cytokine antiserum including TNF-alpha and IL-6 showed that the amount of TNF-alpha and IL-6 secretion in the incubation media recovered with the concentration of chitosan.	Chitosan	221-229	interleukin 6	Mus musculus	146-150
17512902-4	2007	Consistently, RT-PCR with mRNA and Western blot with anti-cytokine antiserum including TNF-alpha and IL-6 showed that the amount of TNF-alpha and IL-6 secretion in the incubation media recovered with the concentration of chitosan.	Chitosan	221-229	interleukin 6	Mus musculus	101-105
17615358-3	2007	DEN administration caused greater increases in serum interleukin-6 (IL-6) concentration in males than it did in females.	Diethylnitrosamine	0-3	interleukin 6	Mus musculus	53-66
17615358-3	2007	DEN administration caused greater increases in serum interleukin-6 (IL-6) concentration in males than it did in females.	Diethylnitrosamine	0-3	interleukin 6	Mus musculus	68-72
17615358-5	2007	DEN exposure promoted production of IL-6 in Kupffer cells (KCs) in a manner dependent on the Toll-like receptor adaptor protein MyD88, ablation of which also protected male mice from DEN-induced hepatocarcinogenesis.	Diethylnitrosamine	0-3	interleukin 6	Mus musculus	36-40
17615358-5	2007	DEN exposure promoted production of IL-6 in Kupffer cells (KCs) in a manner dependent on the Toll-like receptor adaptor protein MyD88, ablation of which also protected male mice from DEN-induced hepatocarcinogenesis.	Diethylnitrosamine	183-186	interleukin 6	Mus musculus	36-40
17615358-6	2007	Estrogen inhibited secretion of IL-6 from KCs exposed to necrotic hepatocytes and reduced circulating concentrations of IL-6 in DEN-treated male mice.	Diethylnitrosamine	128-131	interleukin 6	Mus musculus	120-124
17363730-4	2007	The TLR ligands lipopolysacharride (TLR4), zymosan (TLR2/6), and CpG oligonucleotide (TLR9) caused, in a complement-dependent manner, strikingly elevated plasma interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and IL-1beta, and/or decreased plasma IL-12 levels in mice deficient in the membrane complement inhibitor decay-accelerating factor (DAF).	lipopolysacharride	16-34	interleukin 6	Mus musculus	161-174
17400600-3	2007	We compared the responses to 100% O(2) of NB IL-6 and IL-13 transgenic mice with wild-type littermate controls by evaluating mortality, lung tissue TUNEL staining, and mRNA expression using RT-PCR.	o(2)	34-38	interleukin 6	Mus musculus	45-49
17601777-8	2007	administration of rsCD6 before lethal LPS challenge significantly improved mice survival, and this was concomitant with reduced serum levels of the proinflammatory cytokines TNF-alpha, IL6, and IL-1beta.	rscd6	18-23	interleukin 6	Mus musculus	185-188
17363730-4	2007	The TLR ligands lipopolysacharride (TLR4), zymosan (TLR2/6), and CpG oligonucleotide (TLR9) caused, in a complement-dependent manner, strikingly elevated plasma interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and IL-1beta, and/or decreased plasma IL-12 levels in mice deficient in the membrane complement inhibitor decay-accelerating factor (DAF).	lipopolysacharride	16-34	interleukin 6	Mus musculus	176-180
17494092-8	2007	Urinary IL-6, MCP-1, KC, and GM-CSF also showed a synergistic increase with cisplatin+LPS treatment.	Cisplatin	76-85	interleukin 6	Mus musculus	8-12
17363730-4	2007	The TLR ligands lipopolysacharride (TLR4), zymosan (TLR2/6), and CpG oligonucleotide (TLR9) caused, in a complement-dependent manner, strikingly elevated plasma interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and IL-1beta, and/or decreased plasma IL-12 levels in mice deficient in the membrane complement inhibitor decay-accelerating factor (DAF).	Zymosan	43-50	interleukin 6	Mus musculus	161-174
17363730-4	2007	The TLR ligands lipopolysacharride (TLR4), zymosan (TLR2/6), and CpG oligonucleotide (TLR9) caused, in a complement-dependent manner, strikingly elevated plasma interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and IL-1beta, and/or decreased plasma IL-12 levels in mice deficient in the membrane complement inhibitor decay-accelerating factor (DAF).	Zymosan	43-50	interleukin 6	Mus musculus	176-180
17363730-4	2007	The TLR ligands lipopolysacharride (TLR4), zymosan (TLR2/6), and CpG oligonucleotide (TLR9) caused, in a complement-dependent manner, strikingly elevated plasma interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and IL-1beta, and/or decreased plasma IL-12 levels in mice deficient in the membrane complement inhibitor decay-accelerating factor (DAF).	Oligonucleotides	69-84	interleukin 6	Mus musculus	161-174
17363730-4	2007	The TLR ligands lipopolysacharride (TLR4), zymosan (TLR2/6), and CpG oligonucleotide (TLR9) caused, in a complement-dependent manner, strikingly elevated plasma interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and IL-1beta, and/or decreased plasma IL-12 levels in mice deficient in the membrane complement inhibitor decay-accelerating factor (DAF).	Oligonucleotides	69-84	interleukin 6	Mus musculus	176-180
17481608-3	2007	Therefore, we examined the effects of various types of antidepressants, as well as the mood-stabilizer lithium chloride, on interferon-gamma (IFN-gamma)-induced microglial production of the pro-inflammatory mediators interleukin-6 (IL-6) and nitric oxide (NO).	Lithium Chloride	103-119	interleukin 6	Mus musculus	217-230
17481608-5	2007	Pretreatment with the selective serotonin reuptake inhibitor fluvoxamine, the relatively selective noradrenaline reuptake inhibitor reboxetine, or the non-selective monoaminergic reuptake inhibitor imipramine, significantly inhibited IL-6 and NO production in a dose-dependent manner.	Reboxetine	132-142	interleukin 6	Mus musculus	234-238
17145736-9	2007	Lymphocytes recovered from the mesenteric lymph node of H bilis-colonised mice produced increased levels of interferon gamma, tumour necrosis factor alpha (TNFalpha), interleukin 6 (IL6) and IL12 in response to stimulation with commensal- or H bilis-specific bacterial lysates.	bilis	58-63	interleukin 6	Mus musculus	167-180
17145736-9	2007	Lymphocytes recovered from the mesenteric lymph node of H bilis-colonised mice produced increased levels of interferon gamma, tumour necrosis factor alpha (TNFalpha), interleukin 6 (IL6) and IL12 in response to stimulation with commensal- or H bilis-specific bacterial lysates.	bilis	58-63	interleukin 6	Mus musculus	182-185
17481608-5	2007	Pretreatment with the selective serotonin reuptake inhibitor fluvoxamine, the relatively selective noradrenaline reuptake inhibitor reboxetine, or the non-selective monoaminergic reuptake inhibitor imipramine, significantly inhibited IL-6 and NO production in a dose-dependent manner.	Fluvoxamine	61-72	interleukin 6	Mus musculus	234-238
17481608-5	2007	Pretreatment with the selective serotonin reuptake inhibitor fluvoxamine, the relatively selective noradrenaline reuptake inhibitor reboxetine, or the non-selective monoaminergic reuptake inhibitor imipramine, significantly inhibited IL-6 and NO production in a dose-dependent manner.	Imipramine	198-208	interleukin 6	Mus musculus	234-238
17481608-5	2007	Pretreatment with the selective serotonin reuptake inhibitor fluvoxamine, the relatively selective noradrenaline reuptake inhibitor reboxetine, or the non-selective monoaminergic reuptake inhibitor imipramine, significantly inhibited IL-6 and NO production in a dose-dependent manner.	Norepinephrine	99-112	interleukin 6	Mus musculus	234-238
17311290-9	2007	IL-6 enhanced pre-CFC activity at 1% O(2) and this was correlated to the induction of VEGF.	o(2)	37-41	interleukin 6	Mus musculus	0-4
17880762-7	2007	The post-treatment with ginsan increased the mRNA expression levels of TNF-alpha, IL-1beta, IL-6, SCF, and GM-CSF with respect to that of the CP alone or ginsan pre-treated group.	ginsan	24-30	interleukin 6	Mus musculus	92-96
17880763-4	2007	CSBG exposure induced neutrophilic and eosinophilic inflammation in the lung, which was concomitant with the increased local expression of proinflammatory cytokines including tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, macrophage inflammatory protein -1alpha, macrophage chemoattractant protein -1, RANTES (regulated on activation and normal T cells expressed and secreted), and eotaxin.	csbg	0-4	interleukin 6	Mus musculus	228-232
17579094-4	2007	We have recently reported that IL-6 and TGF-beta(1) plays an important role in proliferation and differentiation of lung fibroblasts, and all-trans-retinoic acid (ATRA) prevented bleomycin-induced lung fibrosis through the inhibition of these cytokines.	Bleomycin	179-188	interleukin 6	Mus musculus	31-35
17579094-5	2007	Thalidomide (Thal) has been used in the treatment of multiple myeloma through the inhibitory effect on IL-6-dependent cell growth and angiogenesis.	Thalidomide	0-11	interleukin 6	Mus musculus	103-107
17579094-5	2007	Thalidomide (Thal) has been used in the treatment of multiple myeloma through the inhibitory effect on IL-6-dependent cell growth and angiogenesis.	Thalidomide	0-4	interleukin 6	Mus musculus	103-107
17400889-0	2007	Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney.	Cisplatin	0-9	interleukin 6	Mus musculus	117-121
17400889-7	2007	Renal IL-6 increased 3-fold; however, IL-6-deficient (IL-6(-/-)) mice still developed cisplatin-induced ARF.	Cisplatin	86-95	interleukin 6	Mus musculus	38-42
17400889-7	2007	Renal IL-6 increased 3-fold; however, IL-6-deficient (IL-6(-/-)) mice still developed cisplatin-induced ARF.	Cisplatin	86-95	interleukin 6	Mus musculus	38-42
17400889-9	2007	In summary, our data demonstrated that cisplatin-induced ARF is associated with increases in the cytokines IL-1beta, IL-18, and IL-6 and neutrophil infiltration in the kidney.	Cisplatin	39-48	interleukin 6	Mus musculus	128-132
17574387-5	2007	RESULTS: The MPTP treatment significantly depleted striatal glutathione content, reduced the activity of glutathione peroxidase (GPX), superoxide dismutase (SOD), and catalase, increased malondialdehyde level, and elevated interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels in striatum (P < 0.05).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	13-17	interleukin 6	Mus musculus	223-236
17574387-5	2007	RESULTS: The MPTP treatment significantly depleted striatal glutathione content, reduced the activity of glutathione peroxidase (GPX), superoxide dismutase (SOD), and catalase, increased malondialdehyde level, and elevated interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels in striatum (P < 0.05).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	13-17	interleukin 6	Mus musculus	238-242
17882951-10	2007	COX-2, PGE2, TNF-alpha and IL-6 production in CIA mice were inhibited by asiaticoside.	asiaticoside	73-85	interleukin 6	Mus musculus	27-31
17445776-8	2007	Treatment of RAW 264.7 cells with CCL-34 also activated TLR4-downstream mitogen-activated protein kinases (ERK, JNK and p38), induced expression of TLR4-downstream genes (TNF-alpha, IL-6, IL-1beta and iNOS) and promoted production of cytokines characteristic of activated macrophages.	Cefaclor	34-37	interleukin 6	Mus musculus	182-186
17347312-8	2007	An increase in plasma adiponectin and decrease in plasma IL-6, triglycerides, and cholesterol levels in response to CR may improve insulin sensitivity.	Chromium	116-118	interleukin 6	Mus musculus	57-61
17510837-3	2007	Diphenyleneiodonium chloride (DPI), a selective inhibitor of NADPH-oxidase, reduced the IL-6 and MIP-2 responses to quartz, SPM and mylonite.	diphenyleneiodonium	0-28	interleukin 6	Mus musculus	88-92
17510837-3	2007	Diphenyleneiodonium chloride (DPI), a selective inhibitor of NADPH-oxidase, reduced the IL-6 and MIP-2 responses to quartz, SPM and mylonite.	diphenyleneiodonium	30-33	interleukin 6	Mus musculus	88-92
17510837-4	2007	N-(3-[Aminomethyl] benzyl) acetamidine (1400W), a selective inhibitor of inducible nitric oxide synthase (iNOS), significantly reduced the Il-6 response to SPM and feldspar in the type 2 cells.	N-(3-(aminomethyl)benzyl)acetamidine	0-38	interleukin 6	Mus musculus	139-143
17510837-4	2007	N-(3-[Aminomethyl] benzyl) acetamidine (1400W), a selective inhibitor of inducible nitric oxide synthase (iNOS), significantly reduced the Il-6 response to SPM and feldspar in the type 2 cells.	N-((3-(aminomethyl)phenyl)methyl)ethanimidamide	40-45	interleukin 6	Mus musculus	139-143
17493959-3	2007	We reported that IL-6 transduces two signaling pathways via tyrosine redidues of the signal transducer gp130: one depends on signal transducers and activators of transcription (STAT)-3 activation and the other on Src homology region 2 domain-containing phosphatase 2 (SHP2)/Grb2 associated binder (Gab)/mitogen-activated protein kinase (MAPK) activation.	gab	298-301	interleukin 6	Mus musculus	17-21
17641834-0	2007	Effect of simvastatin on IL-6 and adiponectin secretion and mRNA expression in 3T3-L1 adipocytes.	Simvastatin	10-21	interleukin 6	Mus musculus	25-29
17641834-1	2007	In order to investigate the effects of simvastatin on secretion and mRNA expression of interleukin-6 (IL-6) and adiponectin in 3T3-L1 adipocytes, mouse 3T3-L1 adipocytes were stimulated with lipopolysaccharide (LPS).	Simvastatin	39-50	interleukin 6	Mus musculus	87-100
17641834-3	2007	The results showed that simvastatin could significantly suppress LPS-induced IL-6 production and mRNA expression in adipocytes (P&lt;0.05), but increase the LPS-induced adiponectin secretion and mRNA expression in a dose-dependent manner (P&lt;0.05).	Simvastatin	24-35	interleukin 6	Mus musculus	77-81
17267173-3	2007	In naive mice, poly I:C (2mg/kg) modestly increased sickness behaviors, plasma IL-6, TNF-alpha and IL-10 levels, but did not affect IL-1, IL-4, or IFN-gamma.	Poly I-C	15-23	interleukin 6	Mus musculus	79-83
17009035-0	2007	Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.	Capecitabine	0-12	interleukin 6	Mus musculus	53-57
17009035-9	2007	Furthermore, capecitabine lowered the levels of PTHrP and IL-6 in plasma and suppressed hypoglycemia and hypercalcemia in this model.	Capecitabine	13-25	interleukin 6	Mus musculus	58-62
17009035-11	2007	CONCLUSIONS: PTHrP and IL-6 were found to be factors in the development of cachexia in a colon 26 cancer model, and capecitabine improved cancer cachexia by suppressing the plasma levels of IL-6 and PTHrP in colon 26 and Y cachectic models.	Capecitabine	116-128	interleukin 6	Mus musculus	190-194
17204391-5	2007	In parallel studies, groups of aged mice given estrogen (17beta-estradiol) prior to scald burn, had significantly improved survival (p&lt;0.05) and lowered serum IL-6 (p&lt;0.05).	Estradiol	57-73	interleukin 6	Mus musculus	162-166
17440992-8	2007	SMC treatments significantly suppressed renal IL-6 and TNF-alpha levels (P &lt; 0.05), but did not affect IL-4 and IL-10 levels (P &lt; 0.05).	S-methylcysteine	0-3	interleukin 6	Mus musculus	46-50
17320860-5	2007	This effect was inhibited by the addition of neutralizing antibody against interleukin 6 (IL-6) in the conditioned medium or the preincubation of RAW264.7 cells with a specific PPARalpha agonist, K-111 (2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid).	2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid	196-201	interleukin 6	Mus musculus	75-88
17320860-5	2007	This effect was inhibited by the addition of neutralizing antibody against interleukin 6 (IL-6) in the conditioned medium or the preincubation of RAW264.7 cells with a specific PPARalpha agonist, K-111 (2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid).	2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid	196-201	interleukin 6	Mus musculus	90-94
17320860-5	2007	This effect was inhibited by the addition of neutralizing antibody against interleukin 6 (IL-6) in the conditioned medium or the preincubation of RAW264.7 cells with a specific PPARalpha agonist, K-111 (2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid).	2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid	203-250	interleukin 6	Mus musculus	75-88
17320860-5	2007	This effect was inhibited by the addition of neutralizing antibody against interleukin 6 (IL-6) in the conditioned medium or the preincubation of RAW264.7 cells with a specific PPARalpha agonist, K-111 (2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid).	2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid	203-250	interleukin 6	Mus musculus	90-94
17320860-6	2007	K-111 reduced both the IL-6 production and mRNA expression in RAW264.7 cells, and its effect was stronger than that of rosiglitazone, a PPARgamma agonist.	2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid	0-5	interleukin 6	Mus musculus	23-27
17320860-8	2007	The blocking of IL-6 production through the SAPK/JNK pathway or by transfection with siRNA specific for IL-6 abolished the inhibitory effect of K-111 on the TNFalpha expression in the 3T3-L1 adipocytes.	2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid	144-149	interleukin 6	Mus musculus	16-20
17320860-8	2007	The blocking of IL-6 production through the SAPK/JNK pathway or by transfection with siRNA specific for IL-6 abolished the inhibitory effect of K-111 on the TNFalpha expression in the 3T3-L1 adipocytes.	2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid	144-149	interleukin 6	Mus musculus	104-108
17350593-4	2007	NO-1886 significantly reduced MCD-induced inflammation by repressing levels of hepatic lipid peroxides and pro-inflammatory tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2).	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-7	interleukin 6	Mus musculus	165-178
17350593-4	2007	NO-1886 significantly reduced MCD-induced inflammation by repressing levels of hepatic lipid peroxides and pro-inflammatory tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2).	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-7	interleukin 6	Mus musculus	180-184
17404266-4	2007	UA increased the protein release of IL-1beta, IL-6, and MIF, but not of TNF-alpha, in dose- and time-dependent manners.	ursolic acid	0-2	interleukin 6	Mus musculus	46-50
17350626-0	2007	(-)-Epigallocatechin gallate suppresses endothelin-1-induced interleukin-6 synthesis in osteoblasts: inhibition of p44/p42 MAP kinase activation.	epigallocatechin gallate	0-28	interleukin 6	Mus musculus	61-74
17350626-2	2007	In the present study, we investigated the effect of (-)-epigallocatechin gallate (EGCG), one of the major flavonoids containing in green tea, on ET-1-induced IL-6 synthesis in osteoblasts and the underlying mechanism.	epigallocatechin gallate	52-80	interleukin 6	Mus musculus	158-162
17350626-2	2007	In the present study, we investigated the effect of (-)-epigallocatechin gallate (EGCG), one of the major flavonoids containing in green tea, on ET-1-induced IL-6 synthesis in osteoblasts and the underlying mechanism.	epigallocatechin gallate	82-86	interleukin 6	Mus musculus	158-162
17350626-3	2007	EGCG significantly reduced the synthesis of IL-6 stimulated by ET-1 in MC3T3-E1 cells as well primary cultured mouse osteoblasts.	epigallocatechin gallate	0-4	interleukin 6	Mus musculus	44-48
17350626-4	2007	SB203580, a specific inhibitor of p38 MAP kinase, but not SP600125, a specific SAPK/JNK inhibitor, suppressed ET-1-stimulated IL-6 synthesis.	SB 203580	0-8	interleukin 6	Mus musculus	126-130
17350626-7	2007	Both the IL-6 synthesis and the phosphorylation of p44/p42 MAP kinase stimulated by 12-O-tetradecanoylphorbol 13-acetate (TPA), a direct activator of PKC, were markedly suppressed by EGCG.	Tetradecanoylphorbol Acetate	84-120	interleukin 6	Mus musculus	9-13
17350626-7	2007	Both the IL-6 synthesis and the phosphorylation of p44/p42 MAP kinase stimulated by 12-O-tetradecanoylphorbol 13-acetate (TPA), a direct activator of PKC, were markedly suppressed by EGCG.	Tetradecanoylphorbol Acetate	122-125	interleukin 6	Mus musculus	9-13
17350626-7	2007	Both the IL-6 synthesis and the phosphorylation of p44/p42 MAP kinase stimulated by 12-O-tetradecanoylphorbol 13-acetate (TPA), a direct activator of PKC, were markedly suppressed by EGCG.	epigallocatechin gallate	183-187	interleukin 6	Mus musculus	9-13
17350626-9	2007	These results strongly suggest that EGCG inhibits ET-1-stimulated synthesis of IL-6 via suppression of p44/p42 MAP kinase pathway in osteoblasts, and the inhibitory effect is exerted at a point between PKC and Raf-1 in the ET-1 signaling cascade.	epigallocatechin gallate	36-40	interleukin 6	Mus musculus	79-83
17209138-7	2007	Eight hours after CLP, both prophylactic and therapeutic administration of PAG significantly reduced the mRNA and protein levels of IL-1beta, IL-6, TNF-alpha, monocyte chemotactic protein-1, and macrophage inflammatory protein-2 in lung and liver coupled with decreased activation and translocation of NF-kappaB in lung and liver.	propargylglycine	75-78	interleukin 6	Mus musculus	142-146
17420605-6	2007	Moreover, CS and alpha-EG suppressed the GalN-induced production of interleukin 6 (IL-6) and liver DNA fragmentation.	Cesium	10-12	interleukin 6	Mus musculus	68-81
17420605-6	2007	Moreover, CS and alpha-EG suppressed the GalN-induced production of interleukin 6 (IL-6) and liver DNA fragmentation.	Cesium	10-12	interleukin 6	Mus musculus	83-87
17420605-6	2007	Moreover, CS and alpha-EG suppressed the GalN-induced production of interleukin 6 (IL-6) and liver DNA fragmentation.	alpha-eg	17-25	interleukin 6	Mus musculus	68-81
17420605-6	2007	Moreover, CS and alpha-EG suppressed the GalN-induced production of interleukin 6 (IL-6) and liver DNA fragmentation.	alpha-eg	17-25	interleukin 6	Mus musculus	83-87
17325656-12	2007	An anti inflammatory effect of MS-275 was also confirmed through its capacity to decrease serum IL-6 and IL-1beta levels in the CIA induced mouse model.	entinostat	31-37	interleukin 6	Mus musculus	96-100
17213200-10	2007	IL-6 also induced serine phosphorylation of K8.	Serine	18-24	interleukin 6	Mus musculus	0-4
17213200-13	2007	Administration of dextran sodium sulfate (DSS) significantly increased intestinal permeability in IL-6-/- mice compared with wild type mice given DSS.	dextran sodium sulfate	18-40	interleukin 6	Mus musculus	98-102
17213200-13	2007	Administration of dextran sodium sulfate (DSS) significantly increased intestinal permeability in IL-6-/- mice compared with wild type mice given DSS.	dss	42-45	interleukin 6	Mus musculus	98-102
17234180-7	2007	Marimastat (100 mg/kg), dexamethasone (10 mg/kg) and rolipram (0.3 mg/kg) reduced significantly IL-6, KC/CXCL1, MIP-1alpha/CCL3 and MMP-9 levels in bronchoalveolar lavage fluid.	marimastat	0-10	interleukin 6	Mus musculus	96-100
17234180-7	2007	Marimastat (100 mg/kg), dexamethasone (10 mg/kg) and rolipram (0.3 mg/kg) reduced significantly IL-6, KC/CXCL1, MIP-1alpha/CCL3 and MMP-9 levels in bronchoalveolar lavage fluid.	Dexamethasone	24-37	interleukin 6	Mus musculus	96-100
17234180-7	2007	Marimastat (100 mg/kg), dexamethasone (10 mg/kg) and rolipram (0.3 mg/kg) reduced significantly IL-6, KC/CXCL1, MIP-1alpha/CCL3 and MMP-9 levels in bronchoalveolar lavage fluid.	Rolipram	53-61	interleukin 6	Mus musculus	96-100
17286434-0	2007	Efficient syntheses of a series of trehalose dimycolate (TDM)/trehalose dicorynomycolate (TDCM) analogues and their interleukin-6 level enhancement activity in mice sera.	Cord Factors	35-55	interleukin 6	Mus musculus	116-129
17286434-0	2007	Efficient syntheses of a series of trehalose dimycolate (TDM)/trehalose dicorynomycolate (TDCM) analogues and their interleukin-6 level enhancement activity in mice sera.	6,6'-dicorynomycolyl trehalose	62-88	interleukin 6	Mus musculus	116-129
17286434-1	2007	We found an IL-6 level-enhancing compound during our synthetic study of trehalose-6,6"-dimycolate (1, TDM, formerly called cord factor) analogues.	Cord Factors	72-97	interleukin 6	Mus musculus	12-16
17302905-4	2007	AZM significantly increased the production of IL-10 and CAM significantly inhibited the production of IL-6 by DCs.	Azithromycin	0-3	interleukin 6	Mus musculus	102-106
17324565-0	2007	Macrolide antibiotics promote the LPS-induced upregulation of prostaglandin E receptor EP2 and thus attenuate macrolide suppression of IL-6 production.	macrolide antibiotics	0-21	interleukin 6	Mus musculus	135-139
17188718-8	2007	Further, BCP significantly suppressed the serum level of IL-6 protein (a 55% reduction) as well as the level of IL-6 mRNA in the tissue.	caryophyllene	9-12	interleukin 6	Mus musculus	57-61
17188718-8	2007	Further, BCP significantly suppressed the serum level of IL-6 protein (a 55% reduction) as well as the level of IL-6 mRNA in the tissue.	caryophyllene	9-12	interleukin 6	Mus musculus	112-116
17366741-4	2007	LPS-stimulated production of IL-6 and IL-10 by splenocytes and macrophages from pristane-induced lupus mice were remarkably up-regulated compared to normal mice, whereas production of macrophage TNF-alpha was significantly down-regulated.	pristane	80-88	interleukin 6	Mus musculus	29-33
16996249-6	2007	Treatment of RAW cells with the exchange protein directly activated by cAMP (EPAC) agonist also resulted in the up-regulation of IL-1beta and IL-6 transcripts.	Cyclic AMP	71-75	interleukin 6	Mus musculus	142-146
16996249-6	2007	Treatment of RAW cells with the exchange protein directly activated by cAMP (EPAC) agonist also resulted in the up-regulation of IL-1beta and IL-6 transcripts.	epac	77-81	interleukin 6	Mus musculus	142-146
17014850-4	2007	Several fold increases of IFN-gamma, TNF-alpha, MCP-1, and IL-6 cytokines were detected after estradiol-treatment of mice, resulting in greatly enhanced inflammation and tissue damage throughout the reproductive tract.	Estradiol	94-103	interleukin 6	Mus musculus	59-63
17256754-2	2007	Levels of IL-6 are elevated in livers of mice treated with a choline-deficient ethionine-supplemented (CDE) diet that induces oval cells, and there is a reduction of oval cells in IL-6 knockout mice.	Choline	61-68	interleukin 6	Mus musculus	10-14
17256754-2	2007	Levels of IL-6 are elevated in livers of mice treated with a choline-deficient ethionine-supplemented (CDE) diet that induces oval cells, and there is a reduction of oval cells in IL-6 knockout mice.	Ethionine	79-88	interleukin 6	Mus musculus	10-14
17237430-3	2007	KC, IL-6 and IL-1beta were increased (p &lt; or = 0.05) in bronchoalveolar lavage fluid (BALF) from asbestos-exposed mice, but to a lesser extent (p &lt; or = 0.05) in Tg(+) vs Tg(-) mice.	Asbestos	100-108	interleukin 6	Mus musculus	4-8
17229471-0	2007	Polychlorinated biphenyls induce proinflammatory cytokine release and dopaminergic dysfunction: protection in interleukin-6 knockout mice.	Polychlorinated Biphenyls	0-25	interleukin 6	Mus musculus	110-123
17229471-3	2007	PCBs induced inflammatory responses in C57BL/6 adult male mice, significantly elevating serum levels of IL-6 (31%), IL-1beta (71%) and TNF-alpha (22%) and significantly reducing striatal dopamine (DA, 21%), tyrosine hydroxylase (TH, 26%), dopamine transporter (DAT, 39%), and synaptophysin (29%) concentrations.	Polychlorinated Biphenyls	0-4	interleukin 6	Mus musculus	104-108
17229471-5	2007	Not only did the PCB-treated IL-6-/- mice exhibit a decrease in serum levels of IL-1beta and TNF-alpha, but they were also protected from PCB-induced striatal dopaminergic dysfunction, displaying no signs of toxicant-induced reductions in DA levels, or TH, DAT or synaptophysin expression.	Dopamine	239-241	interleukin 6	Mus musculus	29-33
17118511-7	2007	RESULTS: Administration of propranolol in septic mice increased the splenocyte apoptosis rate, reduced the proliferative capacity of splenocytes, and modulated cellular cytokine release (IL-6, IFN-gamma).	Propranolol	27-38	interleukin 6	Mus musculus	187-191
17141199-4	2007	We found that PAO dose-dependently inhibited the IL-6 release in response to beta-AR agonist isoproterenol (ISO) in mouse cardiac fibroblasts.	Isoproterenol	93-106	interleukin 6	Mus musculus	49-53
17141199-4	2007	We found that PAO dose-dependently inhibited the IL-6 release in response to beta-AR agonist isoproterenol (ISO) in mouse cardiac fibroblasts.	Isoproterenol	108-111	interleukin 6	Mus musculus	49-53
17141199-5	2007	This effect was probably due to the inhibition of PTPs, resulting in increased tyrosine phosphorylation, since genistein, an inhibitor of protein tyrosine kinases further potentiated ISO-induced IL-6 production and could partially reverse the inhibitory effect of PAO.	Tyrosine	79-87	interleukin 6	Mus musculus	195-199
17141199-5	2007	This effect was probably due to the inhibition of PTPs, resulting in increased tyrosine phosphorylation, since genistein, an inhibitor of protein tyrosine kinases further potentiated ISO-induced IL-6 production and could partially reverse the inhibitory effect of PAO.	Genistein	111-120	interleukin 6	Mus musculus	195-199
17141199-6	2007	PAO also significantly inhibited the IL-6 production by forskolin, an adenylyl cyclase (AC) activator.	oxophenylarsine	0-3	interleukin 6	Mus musculus	37-41
17141199-6	2007	PAO also significantly inhibited the IL-6 production by forskolin, an adenylyl cyclase (AC) activator.	Colforsin	56-65	interleukin 6	Mus musculus	37-41
17141199-7	2007	Furthermore, PAO dose-dependently inhibited the increased cAMP accumulation by either ISO or forskolin and suppressed the phosphorylation of CREB, an important transcriptional factor for IL-6 gene expression.	oxophenylarsine	13-16	interleukin 6	Mus musculus	187-191
17141199-10	2007	To our knowledge, this is the first report that PAO can inhibit ISO-induced IL-6 expression and CREB phosphorylation, demonstrating that PTPs may negatively regulate beta-AR-mediated IL-6 production.	oxophenylarsine	48-51	interleukin 6	Mus musculus	76-80
17141199-10	2007	To our knowledge, this is the first report that PAO can inhibit ISO-induced IL-6 expression and CREB phosphorylation, demonstrating that PTPs may negatively regulate beta-AR-mediated IL-6 production.	oxophenylarsine	48-51	interleukin 6	Mus musculus	183-187
17230620-5	2007	RESULTS: The levels of plasma tumor necrosis factor alpha (TNF-alpha), nitric oxide (NO), ET-1, interleukin-6 (IL-6), and the degree of hepatic tissue injury were decreased in the SNMC-treated groups compared with those in the model group (P &lt; 0.01).	snmc	180-184	interleukin 6	Mus musculus	96-109
17202330-5	2007	The PGI(2) analogs decreased BMDC production of proinflammatory cytokines (IL-12, TNF-alpha, IL-1alpha, IL-6) and chemokines (MIP-1alpha, MCP-1) and increased the production of the anti-inflammatory cytokine IL-10 by BMDCs.	bmdc	29-33	interleukin 6	Mus musculus	104-108
17202332-5	2007	Culture pretreatment with guanosine (10-300 microM), starting 1 h before cytokine or Abeta addition, dose-dependently inhibited the CD40-induced expression as well as functional CD40 signaling by suppressing IL-6 production promoted by IFN-gamma/TNF-alpha challenge in the presence of CD40 cross-linking.	Guanosine	26-35	interleukin 6	Mus musculus	208-212
17095601-7	2007	In a biological readout, we demonstrate that LPA-induced IL-6 production is abolished in the absence of Bcl10.	lysophosphatidic acid	45-48	interleukin 6	Mus musculus	57-61
17438357-1	2007	OBJECTIVES: The aim of this study was to investigate the effect of heparin on TNF-alpha and interleukin (IL)-6 levels and the complement system in liver regeneration in a murine model.	Heparin	67-74	interleukin 6	Mus musculus	92-110
17199550-7	2007	17-phenyl-omega-trinor PGE(2) (an EP(1) agonist) and an EP(4) agonist mimicked PGE(2) enhancement of IL-1alpha-induced IL-6 production in OCCM-30 cells.	17-phenyl-omega-trinor pge	0-26	interleukin 6	Mus musculus	119-123
17199550-8	2007	CONCLUSIONS: From these data, we suggest that IL-1alpha induced PGE(2) production in a COX-2-dependent manner in OCCM-30 cells and that the COX-2-derived PGE(2) upregulates IL-1alpha-elicited IL-6 production via EP(1) and/or EP(4) receptors.	Prostaglandins E	154-157	interleukin 6	Mus musculus	192-196
17202436-2	2007	This study was aimed to assess the effect of pyrrolidine dithiocarbamate (PDTC, an inhibitor of NFkappaB) on interleukin (IL)-6 synthesis and cachexia in colon 26 tumor-bearing mice.	pyrrolidine dithiocarbamic acid	74-78	interleukin 6	Mus musculus	109-127
17014868-7	2006	Significantly reduced levels of IL-6 and TNFalpha were observed in the culture supernatants of Raga treated 3T3L1 cells.	ragaglitazar	95-99	interleukin 6	Mus musculus	32-36
17142776-3	2006	In this study, we show that activation of the calcium-independent or novel protein kinase C (PKC) isoform PKCdelta is a critical event during OSM-mediated up-regulation of IL-6 expression in murine fibroblasts.	Calcium	46-53	interleukin 6	Mus musculus	172-176
16987576-0	2006	Pentavalent vanadium induces hepatic metallothionein through interleukin-6-dependent and -independent mechanisms.	Vanadium	12-20	interleukin 6	Mus musculus	61-74
16987576-11	2006	In IL-6 null mice, hepatic MT induction by AMV administration decreased significantly to about a half of wild-type mice.	ammonium metavanadate	43-46	interleukin 6	Mus musculus	3-7
16987576-12	2006	These data suggest that both IL-6-dependent and -independent mechanisms are involved in MT induction by vanadium compounds in mice.	Vanadium	104-112	interleukin 6	Mus musculus	29-33
16982827-7	2006	Spleen cells from mice immunized with ACV plus CyaA* secreted larger amounts of interleukin-5 (IL-5), IL-6, gamma interferon (IFN-gamma), and granulocyte-macrophage colony-stimulating factor (GM-CSF) than did cells from mice immunized with ACV plus CyaA or ACV alone after stimulation in vitro with a mixture of B. pertussis antigens.	Acv tripeptide	38-41	interleukin 6	Mus musculus	102-106
16982827-7	2006	Spleen cells from mice immunized with ACV plus CyaA* secreted larger amounts of interleukin-5 (IL-5), IL-6, gamma interferon (IFN-gamma), and granulocyte-macrophage colony-stimulating factor (GM-CSF) than did cells from mice immunized with ACV plus CyaA or ACV alone after stimulation in vitro with a mixture of B. pertussis antigens.	cyaa	47-51	interleukin 6	Mus musculus	102-106
17114490-9	2006	Anx-1(-/-) cells were less sensitive to dexamethasone inhibition of IL-6 mRNA expression than WT cells, although inhibition by dexamethasone of IL-6 protein was similar.	Dexamethasone	40-53	interleukin 6	Mus musculus	68-72
17114490-9	2006	Anx-1(-/-) cells were less sensitive to dexamethasone inhibition of IL-6 mRNA expression than WT cells, although inhibition by dexamethasone of IL-6 protein was similar.	Dexamethasone	127-140	interleukin 6	Mus musculus	144-148
18040816-4	2006	New studies were conducted to further evaluate the role of corticosterone in EtOH-mediated changes in production of interleukin-6 (IL-6), IL-10, and IL-12 in serum and peritoneal fluid in mice treated with poly I:C or lipopolysaccharide (LPS).	Corticosterone	59-73	interleukin 6	Mus musculus	116-129
18040816-4	2006	New studies were conducted to further evaluate the role of corticosterone in EtOH-mediated changes in production of interleukin-6 (IL-6), IL-10, and IL-12 in serum and peritoneal fluid in mice treated with poly I:C or lipopolysaccharide (LPS).	Ethanol	77-81	interleukin 6	Mus musculus	116-129
18040816-4	2006	New studies were conducted to further evaluate the role of corticosterone in EtOH-mediated changes in production of interleukin-6 (IL-6), IL-10, and IL-12 in serum and peritoneal fluid in mice treated with poly I:C or lipopolysaccharide (LPS).	Ethanol	77-81	interleukin 6	Mus musculus	131-135
18040816-4	2006	New studies were conducted to further evaluate the role of corticosterone in EtOH-mediated changes in production of interleukin-6 (IL-6), IL-10, and IL-12 in serum and peritoneal fluid in mice treated with poly I:C or lipopolysaccharide (LPS).	Poly C	206-214	interleukin 6	Mus musculus	116-129
16952378-0	2006	N-acetylcysteine attenuates TNF-alpha induced changes in secretion of interleukin-6, plasminogen activator inhibitor-1 and adiponectin from 3T3-L1 adipocytes.	Acetylcysteine	0-16	interleukin 6	Mus musculus	70-83
16952378-9	2006	The present study revealed that NAC inhibited the TNF-alpha-mediated activation of NF-kappaB and improved the adverse changes in the levels of IL-6, PAI-1 and adiponectin in 3T3-L1 adipocytes.	Acetylcysteine	32-35	interleukin 6	Mus musculus	143-147
17084265-8	2006	RESULTS: Naloxone pretreatment significantly suppressed the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6, monocyte chemoattractant protein-1, and superoxide in macrophages after stimulation.	Naloxone	9-17	interleukin 6	Mus musculus	115-128
17174561-2	2006	Inhibition of AR by three distinct AR inhibitors sorbinil, tolrestat or zopolrestat suppressed the LPS-induced production of inflammatory cytokines such as TNF-alpha, IL-6, IL-1beta, IFN-gamma, and chemokine MCP-1 in murine peritoneal macrophages.	sorbinil	49-57	interleukin 6	Mus musculus	167-171
17174561-2	2006	Inhibition of AR by three distinct AR inhibitors sorbinil, tolrestat or zopolrestat suppressed the LPS-induced production of inflammatory cytokines such as TNF-alpha, IL-6, IL-1beta, IFN-gamma, and chemokine MCP-1 in murine peritoneal macrophages.	tolrestat	59-68	interleukin 6	Mus musculus	167-171
17174561-2	2006	Inhibition of AR by three distinct AR inhibitors sorbinil, tolrestat or zopolrestat suppressed the LPS-induced production of inflammatory cytokines such as TNF-alpha, IL-6, IL-1beta, IFN-gamma, and chemokine MCP-1 in murine peritoneal macrophages.	zopolrestat	72-83	interleukin 6	Mus musculus	167-171
17207634-5	2006	Administration of 17beta-estradiol, flutamide and 17beta-estradiol+flutamide following trauma-hemorrhage resulted in a significant increase in the in vitro IL-6 release by splenic MPhi.	Estradiol	18-34	interleukin 6	Mus musculus	156-160
17207634-5	2006	Administration of 17beta-estradiol, flutamide and 17beta-estradiol+flutamide following trauma-hemorrhage resulted in a significant increase in the in vitro IL-6 release by splenic MPhi.	Flutamide	36-45	interleukin 6	Mus musculus	156-160
17207634-5	2006	Administration of 17beta-estradiol, flutamide and 17beta-estradiol+flutamide following trauma-hemorrhage resulted in a significant increase in the in vitro IL-6 release by splenic MPhi.	Estradiol	50-66	interleukin 6	Mus musculus	156-160
17207634-5	2006	Administration of 17beta-estradiol, flutamide and 17beta-estradiol+flutamide following trauma-hemorrhage resulted in a significant increase in the in vitro IL-6 release by splenic MPhi.	Flutamide	67-76	interleukin 6	Mus musculus	156-160
17207634-8	2006	Anti-CD3 stimulation, administration of 17beta-estradiol and 17beta-estradiol+flutamide, but not the administration of flutamide alone resulted in a significant increased release of TNF-alpha, IL-6 and IFN-gamma compared to vehicle-treated animals.	Estradiol	40-56	interleukin 6	Mus musculus	193-197
17207634-8	2006	Anti-CD3 stimulation, administration of 17beta-estradiol and 17beta-estradiol+flutamide, but not the administration of flutamide alone resulted in a significant increased release of TNF-alpha, IL-6 and IFN-gamma compared to vehicle-treated animals.	Estradiol	61-77	interleukin 6	Mus musculus	193-197
17207634-8	2006	Anti-CD3 stimulation, administration of 17beta-estradiol and 17beta-estradiol+flutamide, but not the administration of flutamide alone resulted in a significant increased release of TNF-alpha, IL-6 and IFN-gamma compared to vehicle-treated animals.	Flutamide	78-87	interleukin 6	Mus musculus	193-197
16901963-5	2006	Administration of a low dose of LPS (100 or 10 ng/g) in association with d-galactosamine induced equivalent mortality rates, hepatotoxicity, and serum IL-6 in WT and APN KO mice.	Galactosamine	73-88	interleukin 6	Mus musculus	151-155
17077009-5	2006	The secretion of both TNF-alpha and IL-6 secretion was notably increased after RAW264.7 cells were treated with LPS for 4 h or 8 h. CI-I and dexamethasone(DEX) inhibited these effects, and the combination of DEX and CI-I had synergistic effect.	ci-i	216-220	interleukin 6	Mus musculus	36-40
17077009-6	2006	CONCLUSION: CI-I and DEX can inhibit the decrease of ikappaBalpha expression and prevent TNF-alpha and IL-6 secretion in RAW264.7 cells attacked with LPS, which contributes to the alleviation of cellular injury.	ci-i	12-16	interleukin 6	Mus musculus	103-107
17077009-6	2006	CONCLUSION: CI-I and DEX can inhibit the decrease of ikappaBalpha expression and prevent TNF-alpha and IL-6 secretion in RAW264.7 cells attacked with LPS, which contributes to the alleviation of cellular injury.	Dextromethorphan	21-24	interleukin 6	Mus musculus	103-107
17003255-6	2006	VP-16 activated p38 MAPK and induced IL-6 production in murine macrophages in a p38 MAPK- dependent manner.	Etoposide	0-5	interleukin 6	Mus musculus	37-41
17003255-7	2006	VP-16 administration rapidly increased serum levels of IL-6 in healthy mice and induced sickness-like behaviors as evidenced by a decrease in food intake, body weight, hemoglobin level, and voluntary wheel-running activity.	Etoposide	0-5	interleukin 6	Mus musculus	55-59
16900387-10	2006	The expression of Il6 was increased in islets from transgenic mice and in NIT-1 cells exposed to HuIFNbeta.	huifnbeta	97-106	interleukin 6	Mus musculus	18-21
17010015-0	2006	Up-regulation of interleukin-6 gene expression in cyclophosphamide-induced cystitis in mice: An in situ hybridization histochemical study.	Cyclophosphamide	50-66	interleukin 6	Mus musculus	17-30
16895975-5	2006	Administration of E2, flutamide, or E2 + flutamide following T-H resulted in a significant decrease in systemic TNF-alpha, IL-6, and MCP-1 concentrations under those conditions.	Flutamide	22-31	interleukin 6	Mus musculus	123-127
16895975-5	2006	Administration of E2, flutamide, or E2 + flutamide following T-H resulted in a significant decrease in systemic TNF-alpha, IL-6, and MCP-1 concentrations under those conditions.	Flutamide	41-50	interleukin 6	Mus musculus	123-127
16455769-9	2006	In response to cage-switch stress, the increase in oxygen consumption at both 30 and 20 degrees C was lower in IL-6-/- than in wild-type mice.	Oxygen	51-57	interleukin 6	Mus musculus	111-115
16455769-10	2006	The increase in heart rate was lower in IL-6-/- mice at 30 degrees C. At 4 degrees C, both the oxygen consumption and core temperature were lower in IL-6-/- compared with wild-type mice, suggesting a lower cold-induced thermogenesis in IL-6-/- mice.	Oxygen	95-101	interleukin 6	Mus musculus	40-44
16455769-10	2006	The increase in heart rate was lower in IL-6-/- mice at 30 degrees C. At 4 degrees C, both the oxygen consumption and core temperature were lower in IL-6-/- compared with wild-type mice, suggesting a lower cold-induced thermogenesis in IL-6-/- mice.	Oxygen	95-101	interleukin 6	Mus musculus	149-153
16455769-10	2006	The increase in heart rate was lower in IL-6-/- mice at 30 degrees C. At 4 degrees C, both the oxygen consumption and core temperature were lower in IL-6-/- compared with wild-type mice, suggesting a lower cold-induced thermogenesis in IL-6-/- mice.	Oxygen	95-101	interleukin 6	Mus musculus	149-153
16846835-8	2006	In addition, PPT administration induced a reduction in the percentage of mature B cells in the spleen, and enhanced IFN-gamma production but suppressed IL-6 production from in vitro Con A-stimulated splenocytes as estradiol (E(2)) did, whereas DPN treatment had no effects either alone or with PPT, suggesting ERalpha mediates these estrogen actions.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	interleukin 6	Mus musculus	152-156
16981403-8	2006	The mRNA levels of IL-1beta, IL-6 and COX-2 in the cerebral cortex were up-regulated 24 h after turpentine injection.	Turpentine	96-106	interleukin 6	Mus musculus	29-33
16981403-9	2006	On the other hand, the up-regulated mRNA levels of IL-1beta, IL-6 and COX-2 in the cerebral cortex after turpentine treatment were not suppressed by indomethacin.	Turpentine	105-115	interleukin 6	Mus musculus	61-65
16860472-0	2006	Methylprednisolone attenuates hypothermia- and rewarming-induced cytotoxicity and IL-6 release in isolated primary astrocytes, neurons and BV-2 microglia cells.	Methylprednisolone	0-18	interleukin 6	Mus musculus	82-86
16953121-3	2006	oh(8)dG also suppresses pro-inflammatory cytokines, such as TNF-alpha, IL-6 and IFN-gamma.	oh(8)dg	0-7	interleukin 6	Mus musculus	71-75
16814255-10	2006	Finally, the increased levels of TLR4 observed in ES cells after treatment with 5-aza-dC or TSA confer responsiveness to LPS, as induction of IL-6 and TNFalpha mRNA was detected in endotoxin stimulated ES cells.	Azacitidine	80-85	interleukin 6	Mus musculus	142-146
16814255-10	2006	Finally, the increased levels of TLR4 observed in ES cells after treatment with 5-aza-dC or TSA confer responsiveness to LPS, as induction of IL-6 and TNFalpha mRNA was detected in endotoxin stimulated ES cells.	trichostatin A	92-95	interleukin 6	Mus musculus	142-146
16806109-2	2006	mRNA levels of IL-1beta, IL-6 and TNF-alpha before seizure and mRNA levels of IL-6 and TNF-alpha after seizure were decreased in the brains of the mice with pioglitazone.	Pioglitazone	157-169	interleukin 6	Mus musculus	25-29
16806109-2	2006	mRNA levels of IL-1beta, IL-6 and TNF-alpha before seizure and mRNA levels of IL-6 and TNF-alpha after seizure were decreased in the brains of the mice with pioglitazone.	Pioglitazone	157-169	interleukin 6	Mus musculus	78-82
16513308-4	2006	Cyclooxygenase-2 (COX-2) and tyrosine kinase involve on prostaglandin E2 (PGE2) production in mouse calvarial osteoblasts stimulated by cytokine interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and/or interleukin-6 (IL-6).	Dinoprostone	56-72	interleukin 6	Mus musculus	222-235
16513308-4	2006	Cyclooxygenase-2 (COX-2) and tyrosine kinase involve on prostaglandin E2 (PGE2) production in mouse calvarial osteoblasts stimulated by cytokine interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and/or interleukin-6 (IL-6).	Dinoprostone	56-72	interleukin 6	Mus musculus	237-241
16513308-10	2006	These results indicate that the synergy between IL-beta, TNF-alpha, IL-6 on PGE2 production is due to an enhanced gene expression of COX-2 and that tyrosine kinase(s) are involved in the signal transduction of COX-2 in mouse calvarial osteoblasts.	Dinoprostone	76-80	interleukin 6	Mus musculus	68-72
16510838-4	2006	When added to the apical surface for 48 h before analysis, the TLR2-agonist Pam3Cys-Ser-(Lys)4 and TLR1/6-agonist peptidoglycan increased epithelial cell apical secretion of IL1A, CCL2, and IL6 and apical/basolateral bidirectional secretion of CSF2, TNFA, CSF3, and IL8 when compared to controls.	Lysine	88-92	interleukin 6	Mus musculus	190-193
16764943-8	2006	Interestingly, a combination of 9-cis RA and the PPAR-alpha agonists fenofibrate or gemfibrozil cooperatively inhibited NO, TNF-alpha, IL-1beta, IL-6, and MCP-1 production by these cells.	Radium	38-40	interleukin 6	Mus musculus	145-149
16764943-8	2006	Interestingly, a combination of 9-cis RA and the PPAR-alpha agonists fenofibrate or gemfibrozil cooperatively inhibited NO, TNF-alpha, IL-1beta, IL-6, and MCP-1 production by these cells.	Fenofibrate	69-80	interleukin 6	Mus musculus	145-149
16764943-8	2006	Interestingly, a combination of 9-cis RA and the PPAR-alpha agonists fenofibrate or gemfibrozil cooperatively inhibited NO, TNF-alpha, IL-1beta, IL-6, and MCP-1 production by these cells.	Gemfibrozil	84-95	interleukin 6	Mus musculus	145-149
16804978-1	2006	AIM: To investigate the effect of interaction between enteric epithelial cells and lymphocytes of Peyer"s patch on the release of nitric oxide (NO) and IL-6 in response to Shigella lipopolysaccharide (LPS).	shigella lipopolysaccharide	172-199	interleukin 6	Mus musculus	152-156
16387335-5	2006	Notably, PMN levels and production of IL-6 and CCL2 in the 14 nm CB + LTA were significantly higher than that of 95 nm CB + LTA at 4 h after instillation.	cb + lta	65-73	interleukin 6	Mus musculus	38-42
16513824-9	2006	This increase may result in increased triacylglycerol formation and uptake in IL-6(-/-) adipocytes and thereby contribute to the development of obesity in IL-6(-/-) mice.	Triglycerides	38-53	interleukin 6	Mus musculus	78-82
16513824-9	2006	This increase may result in increased triacylglycerol formation and uptake in IL-6(-/-) adipocytes and thereby contribute to the development of obesity in IL-6(-/-) mice.	Triglycerides	38-53	interleukin 6	Mus musculus	155-159
16644477-0	2006	Suppression of interleukin-6 production in macrophages by furonaphthoquinone NFD-37.	furonaphthoquinone	58-76	interleukin 6	Mus musculus	15-28
16644477-9	2006	Taken together, NFD-37 down-regulated LPS-induced IL-6 expression through NF-kappaB activation, which could provide a pharmacological basis for the anti-inflammatory properties of furonaphthoquinone analogs.	furonaphthoquinone	180-198	interleukin 6	Mus musculus	50-54
16531562-7	2006	Administration of E2 or PPT following trauma-hemorrhage produced a significant reduction in systemic TNF-alpha and IL-6 concentrations in WT and KO mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	24-27	interleukin 6	Mus musculus	115-119
16481161-1	2006	A research program is under way to develop a series of madindoline-based inhibitors targeting interleukin 6.	madindoline A	55-66	interleukin 6	Mus musculus	94-107
16670329-6	2006	Blockade of PI3K with wortmannin resulted in marked enhancement of flagellin-induced gene expression as assessed by measuring levels of inducible NO synthase, IL-6, and IL-8.	Wortmannin	22-32	interleukin 6	Mus musculus	159-163
16771679-9	2006	Reduced nitrite release persisted in spite of normal responsiveness to inflammatory stimulation as measured by tumor necrosis factor alpha and interleukin-6 production and release.	Nitrites	8-15	interleukin 6	Mus musculus	143-156
16534778-5	2006	In vitro studies demonstrated that minocycline suppressed microglial production of IL-1beta, IL-6, TNF, and NGF.	Minocycline	35-46	interleukin 6	Mus musculus	93-97
16458386-7	2006	Furthermore, we found that uptake of CpGs in LSECs results in the activation of transcription factor NF-kappaB and secretion of IL-1beta and IL-6.	CPG-oligonucleotide	37-41	interleukin 6	Mus musculus	141-145
16364651-5	2006	We found that 2-AG decreased BBB permeability and inhibited the acute expression of the main proinflammatory cytokines: TNF-alpha, IL-1beta and IL-6.	glyceryl 2-arachidonate	14-18	interleukin 6	Mus musculus	144-148
16473883-3	2006	In mouse livers and bone marrow-derived macrophages, both interferon-gamma (IFNgamma) and interleukin-6 (IL-6) rapidly induced the tyrosine phosphorylation of signal transducer and activator of transcription-1 (STAT1) and STAT3.	Tyrosine	131-139	interleukin 6	Mus musculus	90-103
16473883-3	2006	In mouse livers and bone marrow-derived macrophages, both interferon-gamma (IFNgamma) and interleukin-6 (IL-6) rapidly induced the tyrosine phosphorylation of signal transducer and activator of transcription-1 (STAT1) and STAT3.	Tyrosine	131-139	interleukin 6	Mus musculus	105-109
16473883-4	2006	STAT3 tyrosine phosphorylation was bi-phasic in response to continuous IL-6 signaling.	Tyrosine	6-14	interleukin 6	Mus musculus	71-75
16681036-6	2006	These results demonstrated that levels of serum IL-6, IL-10 and IFN-gamma and bronchoalveolar lavage (BAL) IL-6 and IFN-gamma were remarkably increased 6 h in LPS-exposed pristane-primed mice compared with pristane-primed controls, while pulmonary vascular permeability and levels of serum and BAL TNF-alpha were not.	pristane	171-179	interleukin 6	Mus musculus	48-52
16681036-6	2006	These results demonstrated that levels of serum IL-6, IL-10 and IFN-gamma and bronchoalveolar lavage (BAL) IL-6 and IFN-gamma were remarkably increased 6 h in LPS-exposed pristane-primed mice compared with pristane-primed controls, while pulmonary vascular permeability and levels of serum and BAL TNF-alpha were not.	pristane	171-179	interleukin 6	Mus musculus	107-111
16681036-7	2006	And levels of BAL TNF-alpha, IL-6 and IL-10 were significantly enhanced 72 h in LPS-exposed pristane-primed mice compared with pristane-primed controls.	pristane	92-100	interleukin 6	Mus musculus	29-33
16681036-8	2006	Also, LPS significantly induced the increased in vitro production of TNF-alpha, IL-6 and IL-10 by lung cells obtained from LPS-exposed pristane-primed mice compared with LPS-exposed normal mice.	pristane	135-143	interleukin 6	Mus musculus	80-84
16650092-8	2006	An injection of 20 micromol of HEMA induced an increased production of IL-6, while injection of 40 micromol depressed both IL-6 and IL-10 production.	hydroxyethyl methacrylate	31-35	interleukin 6	Mus musculus	71-75
16556267-5	2006	SB203580, a p38 MAPK inhibitor, markedly decreased CD40-mediated IL-6 and IL-12 productions in immature DCs.	SB 203580	0-8	interleukin 6	Mus musculus	65-69
16556267-6	2006	In mature DCs, SB203580 significantly decreased CD40-mediated IL-6 but not IL-12 production.	SB 203580	15-23	interleukin 6	Mus musculus	62-66
16239608-10	2006	IL-6 was elevated, whereas IL-12p40 levels were decreased below baseline at 24 h. Corticosterone positively correlated with IL-6, increasing from T(c,Max) to hypothermia, with recovery to baseline by 24 h. Tissue lesions were observed in duodenum, spleen, and kidney at T(c,Max), hypothermia, and 24 h, respectively.	Corticosterone	82-96	interleukin 6	Mus musculus	124-128
16539667-10	2006	Moreover, in cultured cortical primary microglia, rosiglitazone attenuated inflammatory responses by decreasing lipopolysaccharide-induced release of tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6.	Rosiglitazone	50-63	interleukin 6	Mus musculus	206-210
16352705-4	2006	Tipifarnib also inhibited LPS-induced secretion of MMP-9, IL-6, MCP-1, and IL-1beta in THP-1 cells.	tipifarnib	0-10	interleukin 6	Mus musculus	58-62
16352705-6	2006	Similar results were obtained in vivo in a murine model of LPS-induced inflammation, where pretreatment with tipifarnib resulted in significant inhibition of TNF-alpha, IL-6, MCP-1, IL-1beta, and MIP-1alpha production.	tipifarnib	109-119	interleukin 6	Mus musculus	169-173
16434028-4	2006	Kaempferol but not quercetin dose-dependently inhibited tumor necrosis factor alpha (TNFalpha)-induced production of the osteoclastogenic cytokines interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1/CCL2) in osteoblasts.	kaempferol	0-10	interleukin 6	Mus musculus	148-161
16434028-4	2006	Kaempferol but not quercetin dose-dependently inhibited tumor necrosis factor alpha (TNFalpha)-induced production of the osteoclastogenic cytokines interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1/CCL2) in osteoblasts.	kaempferol	0-10	interleukin 6	Mus musculus	163-167
16284237-9	2006	Thus the approximately 30 mmHg greater ANG II hypertension in the WT mice suggests that IL-6 contributes significantly to ANG II-salt hypertension.	Salts	129-133	interleukin 6	Mus musculus	88-92
16269622-5	2006	Lipopolysaccharide (LPS)-mediated activation of TAMs resulted in defective expression of several proinflammatory cytokines (eg, IL-1beta, IL-6, TNF-alpha) and chemokines (eg, CCL3), as opposed to a strong up-regulation of immunosuppressive cytokines (IL-10, TGFbeta) and IFN-inducible chemokines (CCL5, CXCL9, CXCL10, CXCL16).	tams	48-52	interleukin 6	Mus musculus	138-142
16393694-5	2006	The level of testosterone in the day 3 serum was higher than normal serum and the addition of the testosterone in the culture expanded the KSL cells among whole bone marrow cells on MS-5 cells and also upregulated the expression of SDF-1 alpha, IL-11 and IL-6 in MS-5.	Testosterone	13-25	interleukin 6	Mus musculus	255-259
16393694-5	2006	The level of testosterone in the day 3 serum was higher than normal serum and the addition of the testosterone in the culture expanded the KSL cells among whole bone marrow cells on MS-5 cells and also upregulated the expression of SDF-1 alpha, IL-11 and IL-6 in MS-5.	Testosterone	98-110	interleukin 6	Mus musculus	255-259
16397521-6	2006	Actinomycin-D treatment of fibroblast cultures indicated that recombinant mouse IL-6 (rmIL-6) induction of alpha-SMA mRNA appeared to be primarily transcriptionally regulated, and extracellular signal-regulated kinase 1/2 kinase, but not signal transducers and activators of transcription 3 was readily phosphorylated in rmIL-6 treated IL-6KO fibroblasts.	Dactinomycin	0-11	interleukin 6	Mus musculus	80-84
16397521-6	2006	Actinomycin-D treatment of fibroblast cultures indicated that recombinant mouse IL-6 (rmIL-6) induction of alpha-SMA mRNA appeared to be primarily transcriptionally regulated, and extracellular signal-regulated kinase 1/2 kinase, but not signal transducers and activators of transcription 3 was readily phosphorylated in rmIL-6 treated IL-6KO fibroblasts.	Deuterium	12-13	interleukin 6	Mus musculus	80-84
16397521-6	2006	Actinomycin-D treatment of fibroblast cultures indicated that recombinant mouse IL-6 (rmIL-6) induction of alpha-SMA mRNA appeared to be primarily transcriptionally regulated, and extracellular signal-regulated kinase 1/2 kinase, but not signal transducers and activators of transcription 3 was readily phosphorylated in rmIL-6 treated IL-6KO fibroblasts.	rmil	86-90	interleukin 6	Mus musculus	80-84
16397521-6	2006	Actinomycin-D treatment of fibroblast cultures indicated that recombinant mouse IL-6 (rmIL-6) induction of alpha-SMA mRNA appeared to be primarily transcriptionally regulated, and extracellular signal-regulated kinase 1/2 kinase, but not signal transducers and activators of transcription 3 was readily phosphorylated in rmIL-6 treated IL-6KO fibroblasts.	rmil	321-325	interleukin 6	Mus musculus	80-84
16382025-4	2006	In a concentration-dependent manner, EA inhibited secretion of IL-6, IL-10, nitric oxide, and HMGB1.	Ethacrynic Acid	37-39	interleukin 6	Mus musculus	63-67
16009389-4	2006	and treated 8 h later with DON po., the minimum DON doses for inducing IL-1alpha, IL-1beta, IL-6 and TNF-alpha serum proteins and splenic mRNAs were significantly lower than the DON doses required for vehicle-primed mice.	deoxynivalenol	27-30	interleukin 6	Mus musculus	92-96
16009389-4	2006	and treated 8 h later with DON po., the minimum DON doses for inducing IL-1alpha, IL-1beta, IL-6 and TNF-alpha serum proteins and splenic mRNAs were significantly lower than the DON doses required for vehicle-primed mice.	deoxynivalenol	48-51	interleukin 6	Mus musculus	92-96
16166341-8	2006	However, all wild-type mice, whether treated with saline or imipenem, died by 42 h after CLP and had significant hypothermia, metabolic acidosis, and high plasma concentrations of the cytokines interleukin-6, macrophage inflammatory protein-2, and keratinocyte-derived chemokine.	Sodium Chloride	50-56	interleukin 6	Mus musculus	194-207
16166341-8	2006	However, all wild-type mice, whether treated with saline or imipenem, died by 42 h after CLP and had significant hypothermia, metabolic acidosis, and high plasma concentrations of the cytokines interleukin-6, macrophage inflammatory protein-2, and keratinocyte-derived chemokine.	Imipenem	60-68	interleukin 6	Mus musculus	194-207
16391834-8	2006	Edaravone and tempol suppressed the serum IL-6 levels, and significantly suppressed the increased colonic MPO levels.	Edaravone	0-9	interleukin 6	Mus musculus	42-46
16391834-8	2006	Edaravone and tempol suppressed the serum IL-6 levels, and significantly suppressed the increased colonic MPO levels.	tempol	14-20	interleukin 6	Mus musculus	42-46
16374455-4	2006	Moreover, NYT dose-dependently increased the surface expression of major histocompatibility complex (MHC) class II (MHC II), CD40, CD54, CD80, and CD86 by murine bone marrow-derived DCs and triggered their robust production of IL-1beta, IL-6, IL-12, tumor necrosis factor alpha, and macrophage inflammatory protein-1alpha.	Nystatin	10-13	interleukin 6	Mus musculus	237-241
16424113-0	2006	Docosahexaenoic acid consumption inhibits deoxynivalenol-induced CREB/ATF1 activation and IL-6 gene transcription in mouse macrophages.	Docosahexaenoic Acids	0-20	interleukin 6	Mus musculus	90-94
16424113-1	2006	The mycotoxin deoxynivalenol (DON) induces IgA nephropathy in mice by upregulating IL-6 expression, which is suppressed by (n-3) PUFA consumption.	deoxynivalenol	14-28	interleukin 6	Mus musculus	83-87
16424113-1	2006	The mycotoxin deoxynivalenol (DON) induces IgA nephropathy in mice by upregulating IL-6 expression, which is suppressed by (n-3) PUFA consumption.	deoxynivalenol	30-33	interleukin 6	Mus musculus	83-87
16424113-2	2006	The purpose of this study was to test the hypothesis that consumption of the (n-3) PUFA docosahexaenoic acid (DHA) interferes with DON-induced transcriptional and post-transcriptional upregulation of IL-6 mRNA in murine macrophages.	(n-3) pufa docosahexaenoic acid	77-108	interleukin 6	Mus musculus	200-204
16424113-2	2006	The purpose of this study was to test the hypothesis that consumption of the (n-3) PUFA docosahexaenoic acid (DHA) interferes with DON-induced transcriptional and post-transcriptional upregulation of IL-6 mRNA in murine macrophages.	Docosahexaenoic Acids	110-113	interleukin 6	Mus musculus	200-204
16424113-2	2006	The purpose of this study was to test the hypothesis that consumption of the (n-3) PUFA docosahexaenoic acid (DHA) interferes with DON-induced transcriptional and post-transcriptional upregulation of IL-6 mRNA in murine macrophages.	deoxynivalenol	131-134	interleukin 6	Mus musculus	200-204
16424113-3	2006	DON evoked expression of IL-6 mRNA and IL-6 heterogenous nuclear RNA (hnRNA), an indicator of ongoing IL-6 transcription, in macrophages elicited from mice fed control AIN-93G diet for 4 wk, whereas expression of both RNA species was suppressed in macrophages from mice fed AIN-93G modified to contain 30 g DHA/kg diet for the same time period.	deoxynivalenol	0-3	interleukin 6	Mus musculus	25-29
16424113-3	2006	DON evoked expression of IL-6 mRNA and IL-6 heterogenous nuclear RNA (hnRNA), an indicator of ongoing IL-6 transcription, in macrophages elicited from mice fed control AIN-93G diet for 4 wk, whereas expression of both RNA species was suppressed in macrophages from mice fed AIN-93G modified to contain 30 g DHA/kg diet for the same time period.	deoxynivalenol	0-3	interleukin 6	Mus musculus	39-43
16424113-3	2006	DON evoked expression of IL-6 mRNA and IL-6 heterogenous nuclear RNA (hnRNA), an indicator of ongoing IL-6 transcription, in macrophages elicited from mice fed control AIN-93G diet for 4 wk, whereas expression of both RNA species was suppressed in macrophages from mice fed AIN-93G modified to contain 30 g DHA/kg diet for the same time period.	deoxynivalenol	0-3	interleukin 6	Mus musculus	39-43
16424113-4	2006	DON enhanced IL-6 mRNA stability similarly in macrophages from control and DHA-fed mice suggesting that (n-3) PUFA effects were not post-transcriptional.	deoxynivalenol	0-3	interleukin 6	Mus musculus	13-17
16424113-6	2006	DON induced phosphorylation of CREB at Ser-133 and ATF1 at Ser-63 as well as intranuclear binding of phospho-CREB/ATF1 to the cis element of the IL-6 promoter in control macrophages, whereas both activities were inhibited in macrophages from DHA-fed mice.	deoxynivalenol	0-3	interleukin 6	Mus musculus	145-149
16424113-6	2006	DON induced phosphorylation of CREB at Ser-133 and ATF1 at Ser-63 as well as intranuclear binding of phospho-CREB/ATF1 to the cis element of the IL-6 promoter in control macrophages, whereas both activities were inhibited in macrophages from DHA-fed mice.	Docosahexaenoic Acids	242-245	interleukin 6	Mus musculus	145-149
16424113-9	2006	These data suggest that DHA consumption suppresses DON-induced IL-6 transcription in macrophages in part by interfering with AKT-dependent phosphorylation and subsequent binding of CREB/ATF1 to the IL-6 promoter.	Docosahexaenoic Acids	24-27	interleukin 6	Mus musculus	63-67
16424113-9	2006	These data suggest that DHA consumption suppresses DON-induced IL-6 transcription in macrophages in part by interfering with AKT-dependent phosphorylation and subsequent binding of CREB/ATF1 to the IL-6 promoter.	Docosahexaenoic Acids	24-27	interleukin 6	Mus musculus	198-202
16424113-9	2006	These data suggest that DHA consumption suppresses DON-induced IL-6 transcription in macrophages in part by interfering with AKT-dependent phosphorylation and subsequent binding of CREB/ATF1 to the IL-6 promoter.	deoxynivalenol	51-54	interleukin 6	Mus musculus	63-67
16424113-9	2006	These data suggest that DHA consumption suppresses DON-induced IL-6 transcription in macrophages in part by interfering with AKT-dependent phosphorylation and subsequent binding of CREB/ATF1 to the IL-6 promoter.	deoxynivalenol	51-54	interleukin 6	Mus musculus	198-202
16404705-5	2006	A single topical application of TPA to ears of CD-1 mice induced a time- and dose-dependent increase in edema as well as formation of proinflammatory cytokine proteins interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in mouse ears.	Tetradecanoylphorbol Acetate	32-35	interleukin 6	Mus musculus	201-214
16404705-5	2006	A single topical application of TPA to ears of CD-1 mice induced a time- and dose-dependent increase in edema as well as formation of proinflammatory cytokine proteins interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in mouse ears.	Tetradecanoylphorbol Acetate	32-35	interleukin 6	Mus musculus	216-220
16525354-13	2006	The Arg group had higher IL-6 levels at 6 and 12 h in the kidney and intestine and 12 h in the lung after CLP.	Arginine	4-7	interleukin 6	Mus musculus	25-29
16182479-3	2006	The total crude extract (100 microg/ml) prepared with 80% methanol (MeOH extract) and its fractions (100 microg/ml) obtained by solvent partition with hexane and ethyl acetate (EtOAc) significantly blocked the production of interleukin (IL)-1 beta, IL-6 and the tumor necrosis factor (TNF)-alpha from RAW264.7 cells stimulated by lipopolysaccharide (LPS) up to 20-70%.	Methanol	68-72	interleukin 6	Mus musculus	249-253
16182479-3	2006	The total crude extract (100 microg/ml) prepared with 80% methanol (MeOH extract) and its fractions (100 microg/ml) obtained by solvent partition with hexane and ethyl acetate (EtOAc) significantly blocked the production of interleukin (IL)-1 beta, IL-6 and the tumor necrosis factor (TNF)-alpha from RAW264.7 cells stimulated by lipopolysaccharide (LPS) up to 20-70%.	ethyl acetate	162-175	interleukin 6	Mus musculus	249-253
16182479-3	2006	The total crude extract (100 microg/ml) prepared with 80% methanol (MeOH extract) and its fractions (100 microg/ml) obtained by solvent partition with hexane and ethyl acetate (EtOAc) significantly blocked the production of interleukin (IL)-1 beta, IL-6 and the tumor necrosis factor (TNF)-alpha from RAW264.7 cells stimulated by lipopolysaccharide (LPS) up to 20-70%.	ethyl acetate	177-182	interleukin 6	Mus musculus	249-253
16413198-10	2006	Serum AST, ALT, TNF-alpha, IL-6 levels and NF-kappaB activity in the liver were significantly lower in mice administered suramin.	Suramin	121-128	interleukin 6	Mus musculus	27-31
16413198-11	2006	In an in vitro model, suramin preincubation inhibited TNF-alpha and IL-6 production, TNF-alpha and IL-6 mRNA expression, and NF-kappaB activity.	Suramin	22-29	interleukin 6	Mus musculus	68-72
16413198-11	2006	In an in vitro model, suramin preincubation inhibited TNF-alpha and IL-6 production, TNF-alpha and IL-6 mRNA expression, and NF-kappaB activity.	Suramin	22-29	interleukin 6	Mus musculus	99-103
16413198-12	2006	CONCLUSIONS: Suramin inhibits TNF-alpha and IL-6 production through the suppression of NF-kappaB activity from macrophages and shows therapeutic effects on acute liver damage.	Suramin	13-20	interleukin 6	Mus musculus	44-48
16297883-8	2006	Dioscorin also stimulated multiple signaling molecules (NF-kappaB, ERK, JNK, and p38) and induced the expression of cytokines (TNF-alpha, IL-1beta, and IL-6) in murine RAW 264.7 macrophages.	dioscorin	0-9	interleukin 6	Mus musculus	152-156
16394507-6	2006	Treatment with NP induced the production of hematopoietic stimulating factors, including IL-6 and GM-CSF, by bone marrow stromal cells from young SAMs but stromal cells from old SAMs did not respond to NP stimulation.	Neopterin	15-17	interleukin 6	Mus musculus	89-93
16342327-5	2006	However, the production of proinflammatory cytokines, such as TNF-alpha, IL-1beta, IL-6, IFN-gamma, IL-12, and IL-18, was markedly down-regulated in ginsan-treated mice compared with those of control-infected mice.	ginsan	149-155	interleukin 6	Mus musculus	83-87
16328104-7	2006	The improvement of colitis by pioglitazone was associated with decreased colonic interleukin-6, and phospho-signal transducer and activator of transcription-3 levels.	Pioglitazone	30-42	interleukin 6	Mus musculus	81-94
16328104-8	2006	In vitro experiments revealed that culturing lamina propria mononuclear cells in the presence of pioglitazone down-regulated the production of interleukin-6.	Pioglitazone	97-109	interleukin 6	Mus musculus	143-156
16332510-5	2006	In the present study, the combined effects of nicotine and bacterial LPS on the expression of IL-6, IL-8, GRO-alpha and MCP-1 in cell lines of human coronary artery endothelial cells (HCAEC) and pulmonary monocytes (THP-1) were examined by quantitative real-time PCR and ELISA.	Nicotine	46-54	interleukin 6	Mus musculus	94-98
16328020-10	2006	In mouse osteoblasts, nicotine significantly increased IL-6 secretion and estradiol significantly inhibited the nicotine-induced IL-6 release.	Nicotine	22-30	interleukin 6	Mus musculus	55-59
16328020-10	2006	In mouse osteoblasts, nicotine significantly increased IL-6 secretion and estradiol significantly inhibited the nicotine-induced IL-6 release.	Nicotine	112-120	interleukin 6	Mus musculus	129-133
16328023-2	2006	In the course of our study, we examined the effects of triptolide on stimulated murine macrophages and demonstrated that triptolide inhibited superoxide anion production, NO production, and the expression of iNOS mRNA and the mRNA of some key inflammation-related cytokines, namely TNF-alpha, IL-1beta, IL-6 and IFN-gamma.	triptolide	121-131	interleukin 6	Mus musculus	303-307
16426146-6	2006	Increasing concentrations of DHEA significantly increased the production of the Th2 cytokine IL-10 but had no effect on the production of the Th2 cytokine IL-4, the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha), or IL-6.	Dehydroepiandrosterone	29-33	interleukin 6	Mus musculus	234-238
17721724-14	2007	Treatment with FKME showed significant inhibitory effects on histamine, TNF-alpha, IL-6, and IL-8 release from mast cells.	fkme	15-19	interleukin 6	Mus musculus	83-87
17460151-7	2007	SP600125 modulated the expression of a subset of 29 ozone-induced genes; IL-6 and CCL2 expression were further increased, whereas the expression of metallothionein 1, hemopexin, and mitogen-activated 3 kinase 6 was decreased in SP600125-treated ozone-exposed mice.	pyrazolanthrone	0-8	interleukin 6	Mus musculus	73-77
17574387-6	2007	The pre-intake of NAC, SEC, SMC, and SPC significantly attenuated MPTP-induced glutathione loss, retained the activity of GPX and SOD, diminished oxidative stress, and suppressed MPTP-induced elevation of IL-6 and TNF-alpha (P < 0.05).	Acetylcysteine	18-21	interleukin 6	Mus musculus	205-209
17574387-6	2007	The pre-intake of NAC, SEC, SMC, and SPC significantly attenuated MPTP-induced glutathione loss, retained the activity of GPX and SOD, diminished oxidative stress, and suppressed MPTP-induced elevation of IL-6 and TNF-alpha (P < 0.05).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	179-183	interleukin 6	Mus musculus	205-209
17421056-4	2007	The results indicated that AMI improved the hematopoietic microenvironment by enhancing the BMSC survival and proliferation of CFU-F, production of IL-6 as well as GM-CSF by BMSC and bcl-2 protein and mRNA expression in BMSC, which promoted myelopoiesis.	amicoumacin A	27-30	interleukin 6	Mus musculus	148-152
17376428-11	2007	On the endocrine level, direct atorvastatin treatment of differentiated white adipocytes enhanced expression of the pro-inflammatory adipokine interleukin-6 (IL-6), and downregulated expression of the insulin-mimetic and anti-inflammatory adipokines visfatin and adiponectin.	Atorvastatin	31-43	interleukin 6	Mus musculus	143-156
17376428-11	2007	On the endocrine level, direct atorvastatin treatment of differentiated white adipocytes enhanced expression of the pro-inflammatory adipokine interleukin-6 (IL-6), and downregulated expression of the insulin-mimetic and anti-inflammatory adipokines visfatin and adiponectin.	Atorvastatin	31-43	interleukin 6	Mus musculus	158-162
17335558-5	2007	Compound PG-381-5FA, followed by compound PG-381-3FA, induced KC, interleukin-6, and tumour necrosis factor-alpha production in peritoneal macrophages from LPS-responsive C3H/HeN mice, but not in those from LPS-hyporesponsive C3H/HeJ mice.	pg-381-5fa	9-19	interleukin 6	Mus musculus	66-113
17456179-4	2007	Peritoneal macrophages from chloroquine-treated infected mice showed higher H(2)O(2) production and TfR expression, and decreased levels of NO, endogenous and stimulated-TNF-alpha, IL-6 and IL-10 during the three evaluated periods.	Chloroquine	28-39	interleukin 6	Mus musculus	181-185
17493959-3	2007	We reported that IL-6 transduces two signaling pathways via tyrosine redidues of the signal transducer gp130: one depends on signal transducers and activators of transcription (STAT)-3 activation and the other on Src homology region 2 domain-containing phosphatase 2 (SHP2)/Grb2 associated binder (Gab)/mitogen-activated protein kinase (MAPK) activation.	Tyrosine	60-68	interleukin 6	Mus musculus	17-21
17273160-4	2007	Upon a single skin painting with DNFB, C57BL/6 developed within hours a more severe dose-dependent ICD response as compared to BALB/C mice, which was associated with enhanced upregulation of IL-1beta, IL-6, and IL-10.	Dinitrofluorobenzene	33-37	interleukin 6	Mus musculus	201-205
17453481-6	2007	The aim of this investigation was to reveal whether TAMs in HNSCCs secrete IL-6 and MCP-1.	tams	52-56	interleukin 6	Mus musculus	75-79
17418896-5	2007	The specific ERK1/2 inhibitor PD98059 significantly decreased LPS-induced IL-6 and IL-8 production suggesting that IL-6 and IL-8 production is, in part, mediated by ERK 1/2 activation.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	30-37	interleukin 6	Mus musculus	74-78
17418896-5	2007	The specific ERK1/2 inhibitor PD98059 significantly decreased LPS-induced IL-6 and IL-8 production suggesting that IL-6 and IL-8 production is, in part, mediated by ERK 1/2 activation.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	30-37	interleukin 6	Mus musculus	115-119
17328981-8	2007	Bortezomib induced significant decrements of mRNA expression of TNF-alpha and IL-6.	Bortezomib	0-10	interleukin 6	Mus musculus	78-82
17119970-6	2007	Moreover, some cytokines (TNF-alpha, IL-6, IFN-gamma) and MCP-1 levels in the supernatants of spleen cells cultured with pravastatin decreased.	Pravastatin	121-132	interleukin 6	Mus musculus	37-41
17452900-7	2007	Lymphocyte proliferation was inhibited by pitavastatin, and RPA showed down-regulation of interleukin-6 in pitavastatin-treated cardiac allografts.	pitavastatin	107-119	interleukin 6	Mus musculus	90-103
17404308-5	2007	GM-BMM preferentially produced TNF-alpha, IL-6, IL-12p70, and IL-23 whereas, conversely, BMM generated more IL-10 and CCL2; strikingly the latter population could not produce detectable IL-12p70 and IL-23.	gm-bmm	0-6	interleukin 6	Mus musculus	42-46
17184869-8	2007	Feeding of NBFpH6 for 7 days significantly (P&lt;0.05) enhanced IL-6 secretion by small intestine epithelial cells.	nbfph6	11-17	interleukin 6	Mus musculus	64-68
17184869-9	2007	NBFpH6 induced a non-specific mucosal response that was down-regulated for protective immunity, enhancing IL-6 production by epithelial cells and IgA production in the small intestine.	nbfph6	0-6	interleukin 6	Mus musculus	106-110
17185630-9	2007	In addition, arsenite similarly reduced liver neutrophil recruitment and liver nuclear factor-kappaB activation, and attenuated serum levels of tumor necrosis factor-alpha and macrophage inflammatory protein-2, but increased levels of interleukin (IL)-6.	arsenite	13-21	interleukin 6	Mus musculus	235-253
17185630-11	2007	Arsenite-induced reductions in neutrophil accumulation in HSP70 knockout mice were found to be mediated by IL-6.	arsenite	0-8	interleukin 6	Mus musculus	107-111
17420605-6	2007	Moreover, CS and alpha-EG suppressed the GalN-induced production of interleukin 6 (IL-6) and liver DNA fragmentation.	Galactosamine	41-45	interleukin 6	Mus musculus	68-81
17420605-6	2007	Moreover, CS and alpha-EG suppressed the GalN-induced production of interleukin 6 (IL-6) and liver DNA fragmentation.	Galactosamine	41-45	interleukin 6	Mus musculus	83-87
17420605-7	2007	Together these results show that CS and its component, alpha-EG, suppressed GalN-induced liver injury by inhibiting IL-6 production.	Cesium	33-35	interleukin 6	Mus musculus	116-120
17420605-7	2007	Together these results show that CS and its component, alpha-EG, suppressed GalN-induced liver injury by inhibiting IL-6 production.	alpha-eg	55-63	interleukin 6	Mus musculus	116-120
17420605-7	2007	Together these results show that CS and its component, alpha-EG, suppressed GalN-induced liver injury by inhibiting IL-6 production.	Galactosamine	76-80	interleukin 6	Mus musculus	116-120
17301214-7	2007	Studies with mice treated with penicillin revealed similar reductions in CFU and similar levels of IL-6, KC, or MIP-2 expression in A7- and penicillin-treated mice.	Penicillins	31-41	interleukin 6	Mus musculus	99-103
17222822-0	2007	Role of interleukin-6 in a glucan-induced model of granulomatous vasculitis.	Glucans	27-33	interleukin 6	Mus musculus	8-21
17222822-3	2007	Briefly, IL-6-/- mice and C57B/J6 wild type (IL-6+/+) mice were injected intravenously with a suspension of glucan isolated from the cell wall of bakers yeast which results in a granulomatous vasculitis primarily in the pulmonary vasculature.	Glucans	108-114	interleukin 6	Mus musculus	45-49
18958719-12	2007	DCA treatment decreased IL-10 and KC chemokine concentrations in the livers of MRL(+/+) mice, whereas T-helper cell cytokines (IL-4, IL-5, IL-10, IFNgamma, and GM-CSF), pro-inflammatory cytokines (IL-6, IL-12, and G-CSF), and KC chemokine were increased in the livers of DCA-treated B(6)C(3)F(1) mice.	Dichloroacetic Acid	0-3	interleukin 6	Mus musculus	197-201
17379004-0	2007	Limitation by p70 S6 kinase of platelet-derived growth factor-BB-induced interleukin 6 synthesis in osteoblast-like MC3T3-E1 cells.	boeravinone B	62-64	interleukin 6	Mus musculus	73-86
17379004-4	2007	PD98059 (an inhibitor of MAP kinase/extracellular signal-regulated kinase kinase [MEK]), SB203580 (an inhibitor of p38 MAP kinase), or SP600125 (an inhibitor of SAPK/JNK) suppressed the IL-6 synthesis induced by PDGF-BB.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	interleukin 6	Mus musculus	186-190
17379004-5	2007	Rapamycin, an inhibitor of p70 S6 kinase, significantly enhanced the PDGF-BB-stimulated IL-6 synthesis.	Sirolimus	0-9	interleukin 6	Mus musculus	88-92
17414419-11	2007	Isoflurane-treated mice had lower plasma levels of TNF-alpha, KC, and IL-6.	Isoflurane	0-10	interleukin 6	Mus musculus	70-74
17376966-9	2007	In contrast, the numbers of activated microglia and levels of interleukin-6 were significantly reduced in minocycline-treated Tg-SwDI mice compared with saline-treated Tg-SwDI mice.	Minocycline	106-117	interleukin 6	Mus musculus	62-75
17376966-9	2007	In contrast, the numbers of activated microglia and levels of interleukin-6 were significantly reduced in minocycline-treated Tg-SwDI mice compared with saline-treated Tg-SwDI mice.	Thioguanine	126-128	interleukin 6	Mus musculus	62-75
17239853-6	2007	In ccn2+/+ MEFs, the MEK inhibitor U0126 and dominant negative ras reduced expression of IL-6 and lipocalin-2.	U 0126	35-40	interleukin 6	Mus musculus	89-93
17239368-3	2007	The mechanisms underlying the action were investigated and attributed to the anti-inflammatory effect of brazilein, because a decrease of the mRNA level of pro-inflammatory cytokines (tumor necrosis factor-alpha(TNF-alpha) and interleukin-6 (IL-6)) was found in the ischemic animals with brazilein treatment.	brazilein	105-114	interleukin 6	Mus musculus	227-240
17239368-3	2007	The mechanisms underlying the action were investigated and attributed to the anti-inflammatory effect of brazilein, because a decrease of the mRNA level of pro-inflammatory cytokines (tumor necrosis factor-alpha(TNF-alpha) and interleukin-6 (IL-6)) was found in the ischemic animals with brazilein treatment.	brazilein	105-114	interleukin 6	Mus musculus	242-246
17327450-6	2007	In 3T3-L1 adipocytes, mediators of insulin resistance such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6, growth hormone, and insulin increased SOCS3 expression, which was partially inhibited by pioglitazone.	Pioglitazone	207-219	interleukin 6	Mus musculus	103-116
17312143-6	2007	In vivo, gamma-PGA NPs were preferentially internalized by APCs (DCs and macrophages) and induced the production of IL-12p40 and IL-6.	poly(gamma-glutamic acid)	9-18	interleukin 6	Mus musculus	129-133
17416199-8	2007	Treatment with apigenin (10 microM) decreased the TNF-alpha-induced production of IL-6 and NO in osteoblasts.	Apigenin	15-23	interleukin 6	Mus musculus	82-86
17324565-0	2007	Macrolide antibiotics promote the LPS-induced upregulation of prostaglandin E receptor EP2 and thus attenuate macrolide suppression of IL-6 production.	Macrolides	110-119	interleukin 6	Mus musculus	135-139
17324565-1	2007	We studied the influence of the inhibitory effect of clarithromycin (CAM) and erythromycin (EM) on the production of macrophage inflammatory protein (MIP)-2, interleukin-6 (IL-6), and prostaglandin E(2) (PGE(2)), as well as PGE(2) receptor (EP(2)) expression, by LPS-stimulated RAW264.7 cells.	Clarithromycin	53-67	interleukin 6	Mus musculus	158-171
17324565-1	2007	We studied the influence of the inhibitory effect of clarithromycin (CAM) and erythromycin (EM) on the production of macrophage inflammatory protein (MIP)-2, interleukin-6 (IL-6), and prostaglandin E(2) (PGE(2)), as well as PGE(2) receptor (EP(2)) expression, by LPS-stimulated RAW264.7 cells.	Clarithromycin	69-72	interleukin 6	Mus musculus	158-171
17324565-1	2007	We studied the influence of the inhibitory effect of clarithromycin (CAM) and erythromycin (EM) on the production of macrophage inflammatory protein (MIP)-2, interleukin-6 (IL-6), and prostaglandin E(2) (PGE(2)), as well as PGE(2) receptor (EP(2)) expression, by LPS-stimulated RAW264.7 cells.	Erythromycin	92-94	interleukin 6	Mus musculus	158-171
17324565-2	2007	Production of IL-6 was significantly decreased by treatment with CAM or EM in a dose-dependent manner, but the inhibitory effect of CAM was significantly weaker than that of EM.	Clarithromycin	65-68	interleukin 6	Mus musculus	14-18
17324565-2	2007	Production of IL-6 was significantly decreased by treatment with CAM or EM in a dose-dependent manner, but the inhibitory effect of CAM was significantly weaker than that of EM.	Erythromycin	72-74	interleukin 6	Mus musculus	14-18
17324565-7	2007	These results indicate that macrolide antibiotics upregulate the expression of EP(2), which then attenuates the suppressive effect on IL-6 production of these antibiotics, suggesting that these drugs have a variable anti-inflammatory effect that could influence host defenses.	Macrolides	28-37	interleukin 6	Mus musculus	134-138
17305405-0	2007	Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury.	Acetaminophen	86-99	interleukin 6	Mus musculus	8-12
17433708-0	2007	C/EBPbeta serine 64, a phosphoacceptor site, has a critical role in LPS-induced IL-6 and MCP-1 transcription.	Serine	10-16	interleukin 6	Mus musculus	80-84
17433708-7	2007	Thus, serine 64, probably through its phosphorylation, is a critical determinant of C/EBPbeta activity in the transcription of IL-6 and MCP-1.	Serine	6-12	interleukin 6	Mus musculus	127-131
17258730-12	2007	Cytokine profiles of DCs isolated from ethanol-fed mice were characterized by enhanced interleukin (IL)-1beta and IL-10 and decreased tumor necrosis factor alpha, IL-12, interferon gamma, and IL-6 secretion.	Ethanol	39-46	interleukin 6	Mus musculus	192-196
17065364-0	2007	Induction of metallothionein by manganese is completely dependent on interleukin-6 production.	Manganese	32-41	interleukin 6	Mus musculus	69-82
17065364-6	2007	Administration of MnCl(2) caused an increase in mRNA levels of interleukin-6 (IL-6) in the liver as well as an increase in serum levels of IL-6 but not those of other inflammatory cytokines.	manganese chloride	18-25	interleukin 6	Mus musculus	63-76
17065364-6	2007	Administration of MnCl(2) caused an increase in mRNA levels of interleukin-6 (IL-6) in the liver as well as an increase in serum levels of IL-6 but not those of other inflammatory cytokines.	manganese chloride	18-25	interleukin 6	Mus musculus	78-82
17065364-6	2007	Administration of MnCl(2) caused an increase in mRNA levels of interleukin-6 (IL-6) in the liver as well as an increase in serum levels of IL-6 but not those of other inflammatory cytokines.	manganese chloride	18-25	interleukin 6	Mus musculus	139-143
17065364-7	2007	Subsequently, serum levels of serum amyloid A (SAA), an acute-phase protein induced by IL-6, increased with a peak at 24 h. However, no increase in serum alanine aminotransferase activity was observed, suggesting that manganese enhanced the production of IL-6 and SAA without causing liver injury.	Manganese	218-227	interleukin 6	Mus musculus	255-259
17065364-9	2007	In IL-6-null mice, the induction of hepatic MT by treatment with MnCl(2) was completely suppressed to the control level.	manganese chloride	65-72	interleukin 6	Mus musculus	3-7
17065364-10	2007	These results suggest that manganese is a unique metal that induces the synthesis of hepatic MT completely depending on the production of IL-6 without accompanying liver injury.	Manganese	27-36	interleukin 6	Mus musculus	138-142
17065364-10	2007	These results suggest that manganese is a unique metal that induces the synthesis of hepatic MT completely depending on the production of IL-6 without accompanying liver injury.	Metals	49-54	interleukin 6	Mus musculus	138-142
17182172-5	2007	LPS-induced IL-6 production in ATDC5 cells was reduced by Dex or AL-438, showing that AL-438 has similar anti-inflammatory efficacy to Dex in these cells.	Dexamethasone	58-61	interleukin 6	Mus musculus	12-16
17182172-5	2007	LPS-induced IL-6 production in ATDC5 cells was reduced by Dex or AL-438, showing that AL-438 has similar anti-inflammatory efficacy to Dex in these cells.	Aluminum	65-67	interleukin 6	Mus musculus	12-16
17182172-5	2007	LPS-induced IL-6 production in ATDC5 cells was reduced by Dex or AL-438, showing that AL-438 has similar anti-inflammatory efficacy to Dex in these cells.	Aluminum	86-88	interleukin 6	Mus musculus	12-16
17141199-0	2007	Phenylarsine oxide inhibited beta-adrenergic receptor-mediated IL-6 secretion: inhibition of cAMP accumulation and CREB activation in cardiac fibroblasts.	oxophenylarsine	0-18	interleukin 6	Mus musculus	63-67
17141199-0	2007	Phenylarsine oxide inhibited beta-adrenergic receptor-mediated IL-6 secretion: inhibition of cAMP accumulation and CREB activation in cardiac fibroblasts.	Cyclic AMP	93-97	interleukin 6	Mus musculus	63-67
17141199-1	2007	As we previously reported, cAMP and p38 MAPK instead of protein kinase A were involved in beta-adrenergic receptor (beta-AR)-mediated interleukin-6 (IL-6) production in mouse cardiac fibroblasts.	Cyclic AMP	27-31	interleukin 6	Mus musculus	134-147
17141199-1	2007	As we previously reported, cAMP and p38 MAPK instead of protein kinase A were involved in beta-adrenergic receptor (beta-AR)-mediated interleukin-6 (IL-6) production in mouse cardiac fibroblasts.	Cyclic AMP	27-31	interleukin 6	Mus musculus	149-153
17141199-3	2007	To study the role of protein tyrosine phosphatases (PTPs) in beta-AR-mediated IL-6 production, we selected the most widely used PTP inhibitor, phenylarsine oxide (PAO).	oxophenylarsine	143-161	interleukin 6	Mus musculus	78-82
17141199-3	2007	To study the role of protein tyrosine phosphatases (PTPs) in beta-AR-mediated IL-6 production, we selected the most widely used PTP inhibitor, phenylarsine oxide (PAO).	oxophenylarsine	163-166	interleukin 6	Mus musculus	78-82
17141199-4	2007	We found that PAO dose-dependently inhibited the IL-6 release in response to beta-AR agonist isoproterenol (ISO) in mouse cardiac fibroblasts.	oxophenylarsine	14-17	interleukin 6	Mus musculus	49-53
17202330-5	2007	The PGI(2) analogs decreased BMDC production of proinflammatory cytokines (IL-12, TNF-alpha, IL-1alpha, IL-6) and chemokines (MIP-1alpha, MCP-1) and increased the production of the anti-inflammatory cytokine IL-10 by BMDCs.	Epoprostenol	4-10	interleukin 6	Mus musculus	104-108
17097618-7	2007	The levels of interleukin (IL)-1beta, tumor necrosis factor alpha and IL-6 were also decreased by triptolide in the joint tissues and sera as well as the suppression of CIA-mediated expression of their mRNAs in the joints.	triptolide	98-108	interleukin 6	Mus musculus	70-74
17611296-0	2007	Investigations on the interaction of tartaric acid derivative/human serum albumin tissue adhesive with J774A.1 mouse macrophage cells through SEM, IL-6 cytokine and gene expression techniques.	tartaric acid	37-50	interleukin 6	Mus musculus	147-151
17391979-2	2007	The aim of our present work was to study the effect of exogenous leptin and/or ethanol on the secretion of TNF-alpha, IL-6 and TGF-beta1 both in vivo and in vitro.	Ethanol	79-86	interleukin 6	Mus musculus	118-122
17202594-5	2007	Neopterin upregulated the expression of genes for the negative regulators of B lymphopoiesis such as tumor necrosis factor-alpha (TNF-alpha ), interleukin-6 (IL-6), and transforming growth factor-beta (TGF-beta) in cultured stromal cells, implying that neopterin suppressed the CFU-preB colony formation by inducing negative regulators from stromal cells.	Neopterin	0-9	interleukin 6	Mus musculus	143-156
17202594-5	2007	Neopterin upregulated the expression of genes for the negative regulators of B lymphopoiesis such as tumor necrosis factor-alpha (TNF-alpha ), interleukin-6 (IL-6), and transforming growth factor-beta (TGF-beta) in cultured stromal cells, implying that neopterin suppressed the CFU-preB colony formation by inducing negative regulators from stromal cells.	Neopterin	0-9	interleukin 6	Mus musculus	158-162
17202594-6	2007	The intraperitoneal injection of neopterin into non-SCI mice resulted in a marked decrease in the number of femoral CFU-preB within 1 day, along with increases in TNF-alpha and IL-6 expression levels.	Neopterin	33-42	interleukin 6	Mus musculus	177-181
17241879-2	2007	In response to interleukin 6 (IL-6), hepatocytes produce hepcidin that decreases iron release/transfer from enterocytes and macrophages and causes hypoferremia.	Iron	81-85	interleukin 6	Mus musculus	15-28
17241879-2	2007	In response to interleukin 6 (IL-6), hepatocytes produce hepcidin that decreases iron release/transfer from enterocytes and macrophages and causes hypoferremia.	Iron	81-85	interleukin 6	Mus musculus	30-34
17241879-4	2007	METHODS: We generated mice with hepatocyte-specific deletion of the IL-6 signal-transducing gp130 receptor (alfpgp130 (LoxP/LoxP)), with a gp130 receptor lacking the essential region for STAT1 and -3 activation (alfpCre gp130(DeltaSTAT/LoxP)) or mice expressing a gp130 allele lacking the essential tyrosine for RAS-MAPK activation (alfpCregp130(Y757F/LoxP)).	Tyrosine	299-307	interleukin 6	Mus musculus	68-72
17849266-6	2007	In addition, sulforaphane significantly downregulated the serum levels of proinflammatory cytokines such as IL-1beta, IL-6, TNF-alpha, and GM-CSF during metastasis.	sulforaphane	13-25	interleukin 6	Mus musculus	118-122
17849266-7	2007	These data clearly suggest that sulforaphane effectively inhibited the spread of metastatic tumor cells through the stimulation of CMI, upregulation of IL-2 and IFN-gamma, and downregulation of proinflammatory cytokines IL-1beta, IL-6, TNF-alpha, and GM-CSF.	sulforaphane	32-44	interleukin 6	Mus musculus	230-234
17182564-6	2007	B6.TC DCs overproduce IL-6, which is necessary for the blockade of Treg activity, as shown by the effect of anti-IL-6 neutralizing Ab in the suppression assays.	Technetium	3-5	interleukin 6	Mus musculus	22-26
17182564-6	2007	B6.TC DCs overproduce IL-6, which is necessary for the blockade of Treg activity, as shown by the effect of anti-IL-6 neutralizing Ab in the suppression assays.	Technetium	3-5	interleukin 6	Mus musculus	113-117
17199550-0	2007	Cyclooxygenase-2-dependent prostaglandin E(2) upregulates interleukin (IL)-1alpha-induced IL-6 generation in mouse cementoblasts.	Dinoprostone	27-45	interleukin 6	Mus musculus	90-94
17202436-2	2007	This study was aimed to assess the effect of pyrrolidine dithiocarbamate (PDTC, an inhibitor of NFkappaB) on interleukin (IL)-6 synthesis and cachexia in colon 26 tumor-bearing mice.	pyrrolidine dithiocarbamic acid	45-72	interleukin 6	Mus musculus	109-127
17575466-0	2007	IL6 suppression provides renal protection independent of blood pressure in a murine model of salt-sensitive hypertension.	Salts	93-97	interleukin 6	Mus musculus	0-3
17575466-2	2007	We hypothesized that interleukin-6 null mice (IL6-/-) would improve Cyp2c regulation and reduce renal damage in hypertensive mice fed a high salt diet.	Salts	141-145	interleukin 6	Mus musculus	21-34
17575466-2	2007	We hypothesized that interleukin-6 null mice (IL6-/-) would improve Cyp2c regulation and reduce renal damage in hypertensive mice fed a high salt diet.	Salts	141-145	interleukin 6	Mus musculus	46-49
17575466-6	2007	However, the ability to upregulate Cyp2c expression in response to a high salt diet was restored in the ANG/HS IL6 deficient hypertensive mice.	Salts	74-78	interleukin 6	Mus musculus	111-114
18196934-10	2007	MPTP caused an increase in IL-6 in males and females, but this increase was significantly higher in females.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	interleukin 6	Mus musculus	27-31
16925466-6	2007	Furthermore, IL-6 levels were significantly elevated in the sera of mice which were administered DP+AMP either alone or in combination with G-CSF.	dp+amp	97-103	interleukin 6	Mus musculus	13-17
17023731-4	2006	OBJECTIVES: Previously, we reported that all-trans-retinoic acid (ATRA) reduced both irradiation-induced interleukin (IL)-6 production in lung fibroblasts and IL-6-dependent cell growth, and also directly inhibited the proliferation of lung fibroblasts after irradiation.	Tretinoin	41-64	interleukin 6	Mus musculus	105-123
17023731-4	2006	OBJECTIVES: Previously, we reported that all-trans-retinoic acid (ATRA) reduced both irradiation-induced interleukin (IL)-6 production in lung fibroblasts and IL-6-dependent cell growth, and also directly inhibited the proliferation of lung fibroblasts after irradiation.	Tretinoin	41-64	interleukin 6	Mus musculus	159-163
17023731-4	2006	OBJECTIVES: Previously, we reported that all-trans-retinoic acid (ATRA) reduced both irradiation-induced interleukin (IL)-6 production in lung fibroblasts and IL-6-dependent cell growth, and also directly inhibited the proliferation of lung fibroblasts after irradiation.	Tretinoin	66-70	interleukin 6	Mus musculus	105-123
17023731-4	2006	OBJECTIVES: Previously, we reported that all-trans-retinoic acid (ATRA) reduced both irradiation-induced interleukin (IL)-6 production in lung fibroblasts and IL-6-dependent cell growth, and also directly inhibited the proliferation of lung fibroblasts after irradiation.	Tretinoin	66-70	interleukin 6	Mus musculus	159-163
16817229-4	2006	Akt inhibitor, 1L-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate, significantly amplified the synthesis of IL-6 by PDGF-BB.	1L-6-hydroxymethyl-chiro-inositol 2(R)-2-O-methyl-3-O-octadecylcarbonate	15-88	interleukin 6	Mus musculus	131-135
16817229-6	2006	The IL-6 synthesis stimulated by PDGF-BB was markedly enhanced by LY294002 and wortmannin, inhibitors of PI3K.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	66-74	interleukin 6	Mus musculus	4-8
16817229-6	2006	The IL-6 synthesis stimulated by PDGF-BB was markedly enhanced by LY294002 and wortmannin, inhibitors of PI3K.	Wortmannin	79-89	interleukin 6	Mus musculus	4-8
17142776-4	2006	The pan-PKC inhibitor GF109203X (bisindolylmaleimide I) reduced secretion of IL-6; however, use of Go6976, an inhibitor of calcium-dependent PKC enzymes, did not.	bisindolylmaleimide I	22-31	interleukin 6	Mus musculus	77-81
17142776-4	2006	The pan-PKC inhibitor GF109203X (bisindolylmaleimide I) reduced secretion of IL-6; however, use of Go6976, an inhibitor of calcium-dependent PKC enzymes, did not.	bisindolylmaleimide I	33-54	interleukin 6	Mus musculus	77-81
17142776-5	2006	The PKCdelta-selective inhibitory compound rottlerin abrogated expression of IL-6 transcript and protein, but only reduced PKCdelta activity when used at higher concentrations as determined by kinase activity assay, suggesting rottlerin may inhibit IL-6 expression in a PKCdelta-independent manner.	rottlerin	43-52	interleukin 6	Mus musculus	77-81
17142776-5	2006	The PKCdelta-selective inhibitory compound rottlerin abrogated expression of IL-6 transcript and protein, but only reduced PKCdelta activity when used at higher concentrations as determined by kinase activity assay, suggesting rottlerin may inhibit IL-6 expression in a PKCdelta-independent manner.	rottlerin	43-52	interleukin 6	Mus musculus	249-253
17142776-5	2006	The PKCdelta-selective inhibitory compound rottlerin abrogated expression of IL-6 transcript and protein, but only reduced PKCdelta activity when used at higher concentrations as determined by kinase activity assay, suggesting rottlerin may inhibit IL-6 expression in a PKCdelta-independent manner.	rottlerin	227-236	interleukin 6	Mus musculus	77-81
17142776-5	2006	The PKCdelta-selective inhibitory compound rottlerin abrogated expression of IL-6 transcript and protein, but only reduced PKCdelta activity when used at higher concentrations as determined by kinase activity assay, suggesting rottlerin may inhibit IL-6 expression in a PKCdelta-independent manner.	rottlerin	227-236	interleukin 6	Mus musculus	249-253
17142776-7	2006	Furthermore, inhibition of PI3K by use of LY294002 reduces expression of IL-6 at both the mRNA and protein level in murine fibroblasts, and we suggest that PI3K is required for activation of PKCdelta.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	42-50	interleukin 6	Mus musculus	73-77
16835395-4	2006	Epididymal tissue from wild-type mice responded in vitro to noradrenaline and isoprenaline with increased glycerol release, reduced IL-6 release, and increased cAMP accumulation.	Norepinephrine	60-73	interleukin 6	Mus musculus	132-136
16835395-4	2006	Epididymal tissue from wild-type mice responded in vitro to noradrenaline and isoprenaline with increased glycerol release, reduced IL-6 release, and increased cAMP accumulation.	Isoproterenol	78-90	interleukin 6	Mus musculus	132-136
17133481-9	2006	Mechanistic investigations revealed that hepatic message levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta); IL-6, and IL-8 were significantly higher in halothane-treated Balb/c mice compared to DBA/1 and C57BL/6J mice.	Halothane	182-191	interleukin 6	Mus musculus	138-142
17139376-7	2006	In addition, NAC-pentasaccharide significantly reduced IL-6 and MIP-2 expression and injury in the kidney I/R model.	NAC-pentasaccharide	13-32	interleukin 6	Mus musculus	55-59
17110582-4	2006	However, RA potently synergized with GALT-DC-derived interleukin-6 (IL-6) or IL-5 to induce IgA secretion.	Tretinoin	9-11	interleukin 6	Mus musculus	68-72
16978829-5	2006	Using enzyme-linked immunosorbent assays (ELISAs) we showed DHMEQ to inhibit LPS-induced secretion of IL-6, IL-12, interleukin-1beta (IL-1beta), and TNF-alpha.	dehydroxymethylepoxyquinomicin	60-65	interleukin 6	Mus musculus	102-106
17023266-4	2006	Furthermore, oh(8)dG reduced mRNA levels of pro-inflammatory cytokine, such as IL-1beta, IL-6, and TNF-alpha, in activated BV2 cells.	oh(8)dg	13-20	interleukin 6	Mus musculus	89-93
17016612-7	2006	Further, repeated administration of alpha-GalCer to MIFTg mice resulted in a profound reduction of both clinical and histopathological scores of arthritis, with a significant decrease in IL-6.	miftg	52-57	interleukin 6	Mus musculus	187-191
17242471-8	2006	Interleukin-6 deficient mice (IL-6 KO) revealed reduced SB symptoms under hypoxic conditions.	Antimony	56-58	interleukin 6	Mus musculus	0-13
17242471-8	2006	Interleukin-6 deficient mice (IL-6 KO) revealed reduced SB symptoms under hypoxic conditions.	Antimony	56-58	interleukin 6	Mus musculus	30-34
17242471-13	2006	Based on these data we conclude that IL-6 and accumulation of free arachidonic acid in biomembranes contribute to hypoxemia- induced SB.	Antimony	133-135	interleukin 6	Mus musculus	37-41
16906639-8	2006	In the presence of TNF-alpha, culture with CCE (10-100 microg/mL) for 48 h inhibited the production of IL-6 and nitric oxide in osteoblastic MC3T3-E1 cells.	Carbamylcholine	43-46	interleukin 6	Mus musculus	103-107
17077009-5	2006	The secretion of both TNF-alpha and IL-6 secretion was notably increased after RAW264.7 cells were treated with LPS for 4 h or 8 h. CI-I and dexamethasone(DEX) inhibited these effects, and the combination of DEX and CI-I had synergistic effect.	ci-i	132-136	interleukin 6	Mus musculus	36-40
17077009-5	2006	The secretion of both TNF-alpha and IL-6 secretion was notably increased after RAW264.7 cells were treated with LPS for 4 h or 8 h. CI-I and dexamethasone(DEX) inhibited these effects, and the combination of DEX and CI-I had synergistic effect.	Dexamethasone	141-154	interleukin 6	Mus musculus	36-40
17077009-5	2006	The secretion of both TNF-alpha and IL-6 secretion was notably increased after RAW264.7 cells were treated with LPS for 4 h or 8 h. CI-I and dexamethasone(DEX) inhibited these effects, and the combination of DEX and CI-I had synergistic effect.	Dextromethorphan	155-158	interleukin 6	Mus musculus	36-40
17077009-5	2006	The secretion of both TNF-alpha and IL-6 secretion was notably increased after RAW264.7 cells were treated with LPS for 4 h or 8 h. CI-I and dexamethasone(DEX) inhibited these effects, and the combination of DEX and CI-I had synergistic effect.	Dextromethorphan	208-211	interleukin 6	Mus musculus	36-40
16888236-5	2006	AT1-R signaling blockade with telmisartan inhibited various inflammatory mechanisms including macrophage infiltration and upregulation of VEGF, intercellular adhesion molecule-1 (ICAM-1), MCP-1, and IL-6 in the retinal pigment epithelium-choroid complex.	Telmisartan	30-41	interleukin 6	Mus musculus	199-203
16888236-6	2006	A PPAR-gamma antagonist partially but significantly reversed the suppressive effect of telmisartan on in vivo induction of CNV and in vitro upregulation of ICAM-1 and MCP-1 in endothelial cells and IL-6 in macrophages, showing the dual contribution of PPAR-gamma-agonistic and AT1-R-antagonistic actions in the telmisartan treatment.	Telmisartan	87-98	interleukin 6	Mus musculus	198-202
16794011-7	2006	Subsequent treatment with 1% DSS for 7 d resulted in a more severe intestinal inflammation in SD/OC mice, as reflected by an increase in body weight loss, histological damage scores, and secretion of IL-6, TNFalpha, and interferon-gamma from mesenteric lymph node cells and by decreased colon length.	Dextran Sulfate	29-32	interleukin 6	Mus musculus	200-204
17006946-8	2006	This indomethacin-induced injury was associated with activation of IL-6-STAT3 signaling, increased expression of alpha(1)-AT mRNA, and greater accumulation of mutant polymerized alpha(1)-ATZ protein in livers of indomethacin-treated PiZ mice compared to vehicle-treated PiZ animals.	Indomethacin	5-17	interleukin 6	Mus musculus	67-71
16524712-9	2006	Acute DON exposure increased serum levels of IL-6, a cytokine that drives differentiation of IgA-committed B cells to IgA secretion.	deoxynivalenol	6-9	interleukin 6	Mus musculus	45-49
16524712-11	2006	All three indicators of IL-6 expression were suppressed in mice consuming 3% EPA.	Eicosapentaenoic Acid	77-80	interleukin 6	Mus musculus	24-28
16524712-12	2006	Suppressed IL-6 corresponded to decreased binding activity of two factors that regulate transcription of this cytokine, cyclic AMP response element-binding protein and activator protein-1.	Cyclic AMP	120-130	interleukin 6	Mus musculus	11-15
16924582-4	2006	Our data also indicate that gigantol is a potent inhibitor of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) release and influenced the mRNA expression levels of these cytokines in a dose-dependent manner.	gigantol	28-36	interleukin 6	Mus musculus	136-149
16924582-4	2006	Our data also indicate that gigantol is a potent inhibitor of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) release and influenced the mRNA expression levels of these cytokines in a dose-dependent manner.	gigantol	28-36	interleukin 6	Mus musculus	151-155
16924582-5	2006	Furthermore, a reporter gene assay for nuclear factor kappa B (NF-kappaB) and an electromobility shift assay (EMSA) demonstrated that gigantol effectively inhibited the activation of NF-kappaB, which is necessary for the expression of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6.	gigantol	134-142	interleukin 6	Mus musculus	272-276
16798732-7	2006	Palmitate inhibited insulin signal transduction in C2C12 cells beginning 1-2 h after exposure and reached a maximum at 12-16 h. An antagonist TLR2 antibody, mAb 2.5, led to a 50-60% decrease in palmitate-induced IL-6 production and partially restored insulin signal transduction, whereas an isotype-matched control antibody had no effect.	Palmitates	0-9	interleukin 6	Mus musculus	212-216
16798732-8	2006	RNA interference-mediated inhibition of TLR2 and MyD88 expression in C2C12 muscle cells resulted in a near complete inhibition of palmitate-induced insulin resistance and IL-6 production.	Palmitates	130-139	interleukin 6	Mus musculus	171-175
16936255-5	2006	Prior Kupffer cell depletion with gadolinium chloride significantly decreased systemic MCP-1 and interleukin-6 after trauma-hemorrhage and was associated with decreased edema/neutrophil infiltration in lung and liver.	gadolinium chloride	34-53	interleukin 6	Mus musculus	97-110
16936207-7	2006	In cultured adipocytes, ceramide, sphingosine, and S1P induced gene expression of plasminogen activator inhibitor-1, TNF-alpha, monocyte chemoattractant protein-1, interleukin-6, and keratinocyte-derived chemokine.	Ceramides	24-32	interleukin 6	Mus musculus	164-177
16936207-7	2006	In cultured adipocytes, ceramide, sphingosine, and S1P induced gene expression of plasminogen activator inhibitor-1, TNF-alpha, monocyte chemoattractant protein-1, interleukin-6, and keratinocyte-derived chemokine.	Sphingosine	34-45	interleukin 6	Mus musculus	164-177
16981137-4	2006	Akt inhibitor, 1L-6-hydroxymethyl-CHIRO-inositol 2-( R)-2- O-methyl-3-O-octadecylcarbonate, significantly suppressed the TNF-alpha-stimulated IL-6 synthesis, but the inhibitory effect was partial.	1L-6-hydroxymethyl-chiro-inositol 2(R)-2-O-methyl-3-O-octadecylcarbonate	15-90	interleukin 6	Mus musculus	142-146
16981137-6	2006	Wortmannin and LY294002 significantly reduce the TNF-alpha-induced IL-6 synthesis.	Wortmannin	0-10	interleukin 6	Mus musculus	67-71
16981137-6	2006	Wortmannin and LY294002 significantly reduce the TNF-alpha-induced IL-6 synthesis.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	15-23	interleukin 6	Mus musculus	67-71
16981137-9	2006	A combination of Akt inhibitor and PD98059 suppressed the TNF-alpha-induced IL-6 synthesis in an additive manner.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	35-42	interleukin 6	Mus musculus	76-80
16914720-1	2006	Here, we demonstrate that elevation of intracellular cyclic AMP (cAMP) in vascular endothelial cells (ECs) by either a direct activator of adenylyl cyclase or endogenous cAMP-mobilizing G protein-coupled receptors inhibited the tyrosine phosphorylation of STAT proteins by an interleukin 6 (IL-6) receptor trans-signaling complex (soluble IL-6Ralpha/IL-6).	Cyclic AMP	53-63	interleukin 6	Mus musculus	276-289
16914720-1	2006	Here, we demonstrate that elevation of intracellular cyclic AMP (cAMP) in vascular endothelial cells (ECs) by either a direct activator of adenylyl cyclase or endogenous cAMP-mobilizing G protein-coupled receptors inhibited the tyrosine phosphorylation of STAT proteins by an interleukin 6 (IL-6) receptor trans-signaling complex (soluble IL-6Ralpha/IL-6).	Cyclic AMP	53-63	interleukin 6	Mus musculus	291-295
16914720-1	2006	Here, we demonstrate that elevation of intracellular cyclic AMP (cAMP) in vascular endothelial cells (ECs) by either a direct activator of adenylyl cyclase or endogenous cAMP-mobilizing G protein-coupled receptors inhibited the tyrosine phosphorylation of STAT proteins by an interleukin 6 (IL-6) receptor trans-signaling complex (soluble IL-6Ralpha/IL-6).	Cyclic AMP	53-63	interleukin 6	Mus musculus	339-343
16914720-1	2006	Here, we demonstrate that elevation of intracellular cyclic AMP (cAMP) in vascular endothelial cells (ECs) by either a direct activator of adenylyl cyclase or endogenous cAMP-mobilizing G protein-coupled receptors inhibited the tyrosine phosphorylation of STAT proteins by an interleukin 6 (IL-6) receptor trans-signaling complex (soluble IL-6Ralpha/IL-6).	Cyclic AMP	65-69	interleukin 6	Mus musculus	276-289
16914720-1	2006	Here, we demonstrate that elevation of intracellular cyclic AMP (cAMP) in vascular endothelial cells (ECs) by either a direct activator of adenylyl cyclase or endogenous cAMP-mobilizing G protein-coupled receptors inhibited the tyrosine phosphorylation of STAT proteins by an interleukin 6 (IL-6) receptor trans-signaling complex (soluble IL-6Ralpha/IL-6).	Cyclic AMP	65-69	interleukin 6	Mus musculus	291-295
16914720-1	2006	Here, we demonstrate that elevation of intracellular cyclic AMP (cAMP) in vascular endothelial cells (ECs) by either a direct activator of adenylyl cyclase or endogenous cAMP-mobilizing G protein-coupled receptors inhibited the tyrosine phosphorylation of STAT proteins by an interleukin 6 (IL-6) receptor trans-signaling complex (soluble IL-6Ralpha/IL-6).	Cyclic AMP	65-69	interleukin 6	Mus musculus	339-343
16914720-1	2006	Here, we demonstrate that elevation of intracellular cyclic AMP (cAMP) in vascular endothelial cells (ECs) by either a direct activator of adenylyl cyclase or endogenous cAMP-mobilizing G protein-coupled receptors inhibited the tyrosine phosphorylation of STAT proteins by an interleukin 6 (IL-6) receptor trans-signaling complex (soluble IL-6Ralpha/IL-6).	Cyclic AMP	170-174	interleukin 6	Mus musculus	276-289
16914720-1	2006	Here, we demonstrate that elevation of intracellular cyclic AMP (cAMP) in vascular endothelial cells (ECs) by either a direct activator of adenylyl cyclase or endogenous cAMP-mobilizing G protein-coupled receptors inhibited the tyrosine phosphorylation of STAT proteins by an interleukin 6 (IL-6) receptor trans-signaling complex (soluble IL-6Ralpha/IL-6).	Cyclic AMP	170-174	interleukin 6	Mus musculus	291-295
16914720-1	2006	Here, we demonstrate that elevation of intracellular cyclic AMP (cAMP) in vascular endothelial cells (ECs) by either a direct activator of adenylyl cyclase or endogenous cAMP-mobilizing G protein-coupled receptors inhibited the tyrosine phosphorylation of STAT proteins by an interleukin 6 (IL-6) receptor trans-signaling complex (soluble IL-6Ralpha/IL-6).	Cyclic AMP	170-174	interleukin 6	Mus musculus	339-343
16914720-6	2006	Together, these data argue for the existence of a novel cAMP/Epac/Rap1/SOCS-3 pathway for limiting IL-6 receptor signaling in ECs and illuminate a new mechanism by which cAMP may mediate its potent anti-inflammatory effects.	Cyclic AMP	56-60	interleukin 6	Mus musculus	99-103
16914720-6	2006	Together, these data argue for the existence of a novel cAMP/Epac/Rap1/SOCS-3 pathway for limiting IL-6 receptor signaling in ECs and illuminate a new mechanism by which cAMP may mediate its potent anti-inflammatory effects.	Cyclic AMP	170-174	interleukin 6	Mus musculus	99-103
16703442-8	2006	At the 18-h time point, IL-6 levels in the peritoneum were significantly higher in the laparotomy group than in the control or CO2 insufflated groups.	N2,N6-bis(4-(2-aminoethoxy)quinolin-2-yl)-4-((4-fluorobenzyl)oxy)pyridine-2,6-dicarboxamide	127-130	interleukin 6	Mus musculus	24-28
16781673-4	2006	In addition, activation of TLR4 with either LPS or free fatty acids stimulated NFkappaB signaling and expression of inflammatory cytokine genes, such as TNFalpha and IL-6 in 3T3-L1 adipocytes.	Fatty Acids, Nonesterified	51-67	interleukin 6	Mus musculus	166-170
16774945-2	2006	AIRmax mice were more susceptible than AIRmin to acute colitis induced by ingestion of dextran sodium sulfate showing a 3-fold higher disease activity index and presenting an intense inflammatory infiltrate in the base of colon crypts as well as elevated expression of IL-1beta, TNFalpha, IFNgamma and IL-6 mRNA in colon tissue.	dextran sodium sulfate	87-109	interleukin 6	Mus musculus	302-306
16547072-7	2006	Interleukin (IL)-6, IL-1beta, and tumour necrosis factor alpha mRNA levels in colons of PPARgamma(DeltaIEpC) mice treated with DSS were higher than in similarly treated PPARgamma(F/F) mice.	dss	127-130	interleukin 6	Mus musculus	0-18
16977380-6	2006	RESULTS: An intraperitoneal injection of zymosan A induced severe polyarthritis with increased levels of rheumatoid factor and interleukin 6 (IL-6) only in SKG mice.	Zymosan	41-50	interleukin 6	Mus musculus	127-140
16977380-6	2006	RESULTS: An intraperitoneal injection of zymosan A induced severe polyarthritis with increased levels of rheumatoid factor and interleukin 6 (IL-6) only in SKG mice.	Zymosan	41-50	interleukin 6	Mus musculus	142-146
16983496-3	2006	Peritoneal macrophages recruited in mice pretreated with an inhibitory N-alkylnojirimycin displayed a reduced capacity to release either TNFalpha or interleukin-6 when re-exposed to whole killed E. coli in vitro.	n-alkylnojirimycin	71-89	interleukin 6	Mus musculus	149-162
16765938-4	2006	We show that dipyridamole inhibited interleukin-6 and monocyte chemoattractant protein-1 secretion, inducible nitric oxide synthase protein expression, nitrite accumulation, and cyclooxygenase-2 (COX-2) induction in lipopolysaccharide (LPS)-activated RAW 264.7 macrophages.	Dipyridamole	13-25	interleukin 6	Mus musculus	36-49
16677721-15	2006	This may reflect a role for IL-6 in the tryptophan and serotonin responses to IL-1 and LPS.	Tryptophan	40-50	interleukin 6	Mus musculus	28-32
16677721-15	2006	This may reflect a role for IL-6 in the tryptophan and serotonin responses to IL-1 and LPS.	Serotonin	55-64	interleukin 6	Mus musculus	28-32
16504533-8	2006	Reduced lipopolysaccharide-triggered cytokine production (of IL-12p40, IFN-gamma, IL-6 and TNF-alpha) by draining lymph node cells of mice sensitized and challenged with DPCP indicated that no adaptation is induced.	diphenylcyclopropenone	170-174	interleukin 6	Mus musculus	82-86
16835063-0	2006	Uncoupling of ATP-mediated calcium signaling and dysregulated interleukin-6 secretion in dendritic cells by nanomolar thimerosal.	Thimerosal	118-128	interleukin 6	Mus musculus	62-75
16835063-10	2006	THI altered ATP-mediated interleukin-6 secretion, initially enhancing the rate of cytokine secretion but suppressing cytokine secretion overall in DCs.DCs are exquisitely sensitive to THI, with one mechanism involving the uncoupling of positive and negative regulation of Ca2+ signals contributed by RyR1.	Thimerosal	0-3	interleukin 6	Mus musculus	25-38
16835063-10	2006	THI altered ATP-mediated interleukin-6 secretion, initially enhancing the rate of cytokine secretion but suppressing cytokine secretion overall in DCs.DCs are exquisitely sensitive to THI, with one mechanism involving the uncoupling of positive and negative regulation of Ca2+ signals contributed by RyR1.	Adenosine Triphosphate	12-15	interleukin 6	Mus musculus	25-38
16835063-10	2006	THI altered ATP-mediated interleukin-6 secretion, initially enhancing the rate of cytokine secretion but suppressing cytokine secretion overall in DCs.DCs are exquisitely sensitive to THI, with one mechanism involving the uncoupling of positive and negative regulation of Ca2+ signals contributed by RyR1.	Thimerosal	184-187	interleukin 6	Mus musculus	25-38
16754538-6	2006	High doses (2.0 to 20 microg toxin/animal) of atranone A and C induced significant inflammatory responses manifested as differentially elevated macrophage, neutrophil, macrophage inflammatory protein (MIP)-2, tumor necrosis factor (TNF) and interleukin (IL)-6 concentrations in the bronchioalveolar lavage fluid (BALF) of intratracheally exposed mice.	atranone	46-54	interleukin 6	Mus musculus	241-259
16771773-3	2006	After the induction of inflammation with TNBS, the levels of proinflammatory cytokines, such as TNF-alpha, interleukin-1beta and interleukin-6, were elevated both in the inflamed mucosa and muscle layers in the wild-type mice; however, the productions of these cytokines were greatly reduced in the TNF-alpha(-/-) mouse colon.	Trinitrobenzenesulfonic Acid	41-45	interleukin 6	Mus musculus	129-142
16601113-5	2006	Interestingly, inhibition of GSK-3beta by antisense oligonucleotides or pharmacological agent (10 mm lithium) potentiated TNF-induced expression of IL-6 and MCP-1 by 2-6-fold suggesting that inhibition of GSK-3beta under inflammatory conditions (exposure to TNF-alpha and IL-1beta) may contribute to enhanced cytokine expression.	Oligonucleotides	52-68	interleukin 6	Mus musculus	148-152
16601113-5	2006	Interestingly, inhibition of GSK-3beta by antisense oligonucleotides or pharmacological agent (10 mm lithium) potentiated TNF-induced expression of IL-6 and MCP-1 by 2-6-fold suggesting that inhibition of GSK-3beta under inflammatory conditions (exposure to TNF-alpha and IL-1beta) may contribute to enhanced cytokine expression.	Lithium	101-108	interleukin 6	Mus musculus	148-152
17134663-5	2006	Lower dosages of EtOH did not have this effect but did suppress the acute phase response to LPS and the production of interleukin-6 up to 3 h after dosing.	Ethanol	17-21	interleukin 6	Mus musculus	118-131
16644488-8	2006	RT-PCR experiments demonstrated that U50,488 treatment significantly reduced the LPS-mediated increase in IL-6 mRNA and that this effect was also blocked by nor-BNI.	norbinaltorphimine	157-164	interleukin 6	Mus musculus	106-110
16721265-7	2006	Circulating levels of corticosterone were markedly reduced in aged LPS-treated IL-6 KO mice relative to aged WT mice given LPS.	Corticosterone	22-36	interleukin 6	Mus musculus	79-83
16707807-3	2006	Here, we show that the cytokine interleukin-6 (IL-6) is upregulated in DRG neurons after either a conditioning lesion or treatment with dibutyryl-cAMP.	dibutyryl-	136-146	interleukin 6	Mus musculus	32-45
16707807-3	2006	Here, we show that the cytokine interleukin-6 (IL-6) is upregulated in DRG neurons after either a conditioning lesion or treatment with dibutyryl-cAMP.	dibutyryl-	136-146	interleukin 6	Mus musculus	47-51
16707807-3	2006	Here, we show that the cytokine interleukin-6 (IL-6) is upregulated in DRG neurons after either a conditioning lesion or treatment with dibutyryl-cAMP.	Cyclic AMP	146-150	interleukin 6	Mus musculus	32-45
16707807-3	2006	Here, we show that the cytokine interleukin-6 (IL-6) is upregulated in DRG neurons after either a conditioning lesion or treatment with dibutyryl-cAMP.	Cyclic AMP	146-150	interleukin 6	Mus musculus	47-51
16707807-8	2006	We conclude that IL-6 can mimic both the cAMP effect and the conditioning lesion effect but is not an essential component of either response.	Cyclic AMP	41-45	interleukin 6	Mus musculus	17-21
16779518-7	2006	Curcumin-treated mice also exhibited relative decreases in aortic tissue activator protein-1 and nuclear factor kappaB DNA binding activities and significantly lower aortic tissue concentrations of interleukin-1beta (IL-1beta), IL-6, monocyte chemoattractant protein-1, and matrix metalloproteinase-9 (all p &lt; 0.05).	Curcumin	0-8	interleukin 6	Mus musculus	228-232
16484594-0	2006	Synthetic retinoid Am80 reduces scavenger receptor expression and atherosclerosis in mice by inhibiting IL-6.	retinoid am80	10-23	interleukin 6	Mus musculus	104-108
16484594-3	2006	METHODS AND RESULTS: Am80 suppressed IL-6 production induced by 12-myristate 13-acetate (PMA) or angiotensin II in mouse Raw264 macrophages.	12-myristate 13-acetate	64-87	interleukin 6	Mus musculus	37-41
16484594-3	2006	METHODS AND RESULTS: Am80 suppressed IL-6 production induced by 12-myristate 13-acetate (PMA) or angiotensin II in mouse Raw264 macrophages.	Tetradecanoylphorbol Acetate	89-92	interleukin 6	Mus musculus	37-41
16484594-5	2006	Systemic administration of Am80 led to reductions in the areas of atherosclerotic lesions and foam cell accumulation in the aortas of apolipoprotein E (apoE)-deficient mice and reduced serum concentrations of IL-6 and IL-1beta without affecting body weights, serum lipid profiles or IL-10 levels.	tamibarotene	27-31	interleukin 6	Mus musculus	209-213
16299037-9	2006	DHNA significantly attenuated the enhanced expression of MAdCAM-1, the increased beta7 positive cell number, and the increased mRNA levels of IL-1beta, IL-6, and TNF-alpha in DSS treated colon.	1,4-dihydroxy-2-naphthoic acid	0-4	interleukin 6	Mus musculus	152-156
16299037-9	2006	DHNA significantly attenuated the enhanced expression of MAdCAM-1, the increased beta7 positive cell number, and the increased mRNA levels of IL-1beta, IL-6, and TNF-alpha in DSS treated colon.	dss	175-178	interleukin 6	Mus musculus	152-156
16697744-5	2006	RESULTS: Vagotomy or pretreatment with mecamylamine resulted in an enhanced severity of pancreatitis, as reflected by histology, edema, plasma hydrolases, and interleukin-6 levels.	Mecamylamine	39-51	interleukin 6	Mus musculus	159-172
16647840-3	2006	Compared with 5 microg/mL, tilmicosin and tylosin concentrations of 10 microg/mL and 20 microg/mL significantly decreased the production of 6-keto-prostaglandin F(1alpha) (6-keto-PGF(1alpha)), PGE(2), NO, tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, and increased IL-10 production.	tilmicosin	27-37	interleukin 6	Mus musculus	274-278
16647840-3	2006	Compared with 5 microg/mL, tilmicosin and tylosin concentrations of 10 microg/mL and 20 microg/mL significantly decreased the production of 6-keto-prostaglandin F(1alpha) (6-keto-PGF(1alpha)), PGE(2), NO, tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, and increased IL-10 production.	Tylosin	42-49	interleukin 6	Mus musculus	274-278
16647840-3	2006	Compared with 5 microg/mL, tilmicosin and tylosin concentrations of 10 microg/mL and 20 microg/mL significantly decreased the production of 6-keto-prostaglandin F(1alpha) (6-keto-PGF(1alpha)), PGE(2), NO, tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, and increased IL-10 production.	6-keto-prostaglandin f	140-162	interleukin 6	Mus musculus	274-278
16647840-3	2006	Compared with 5 microg/mL, tilmicosin and tylosin concentrations of 10 microg/mL and 20 microg/mL significantly decreased the production of 6-keto-prostaglandin F(1alpha) (6-keto-PGF(1alpha)), PGE(2), NO, tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, and increased IL-10 production.	6-keto-pgf	172-182	interleukin 6	Mus musculus	274-278
16413968-8	2006	The expressions of both Il6 and Tnfalpha by fluoxetine treatment were similar to those of Nos2 and Nfkappab.	Fluoxetine	44-54	interleukin 6	Mus musculus	24-27
16473883-5	2006	In macrophages lacking Socs3, however, continuous IL-6 signaling induced uniformly high levels of STAT3 tyrosine phosphorylation, and early IL-6-inducible genes were inappropriately expressed at intermediate time points.	Tyrosine	104-112	interleukin 6	Mus musculus	50-54
16581004-6	2006	These results thus indicate that IL-6-STAT3 signaling in the liver contributes to insulin action in the brain, leading to the suppression of hepatic glucose production.	Glucose	149-156	interleukin 6	Mus musculus	33-37
16620297-16	2006	The augmentation of IL-6 mRNA in mouse liver was markedly increased by paeoniflorin at 1 h and 3 h after LPS injection.	peoniflorin	71-83	interleukin 6	Mus musculus	20-24
16620297-20	2006	The protective mechanism of paeoniflorin might be partially related to modulation of TNF-alpha, IL-6, LBP and CD14 mRNA expressions in mouse liver.	peoniflorin	28-40	interleukin 6	Mus musculus	96-100
16373423-5	2006	Moreover, female mice treated with melatonin showed a diminution of titers of total serum IgG, IgM, and anti-double-stranded DNA and anti-CII autoantibodies; a decrease in proinflammatory cytokines (IL-2, IL-6, interferon-gamma, TNF-alpha, and IL-1beta), an increase in antiinflammatory cytokines (IL-10), and a decrease in nitrite/nitrate.	Melatonin	35-44	interleukin 6	Mus musculus	205-209
16373689-7	2006	TAK-242 inhibited mRNA expression of IL-6 and TNF-alpha induced by LPS and interferon-gamma in RAW264.7 cells.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	0-7	interleukin 6	Mus musculus	37-41
16649552-8	2006	Significant post-inoculation elevations of interleukin (IL)-1beta, IL-6, and IL-10 were noted in untreated controls over 24 h. Telithromycin attenuated these increases and the suppression of both IL-6 and IL-10 release was observed to be dose dependent.	telithromycin	127-140	interleukin 6	Mus musculus	67-71
16649552-8	2006	Significant post-inoculation elevations of interleukin (IL)-1beta, IL-6, and IL-10 were noted in untreated controls over 24 h. Telithromycin attenuated these increases and the suppression of both IL-6 and IL-10 release was observed to be dose dependent.	telithromycin	127-140	interleukin 6	Mus musculus	196-200
16459330-2	2006	Binding of SOCS3 to the phosphorylated Tyr(759) in the cytoplasmic region of gp130, the common signal transducing receptor chain of all IL-6-type cytokines, is necessary for inhibition of Janus kinase-mediated signaling.	Tyrosine	39-42	interleukin 6	Mus musculus	136-140
16537374-10	2006	IL-6 and IL-10 levels were dramatically up-regulated (50x) in the PTX group, and at lower levels in other experimental groups.	Pentoxifylline	66-69	interleukin 6	Mus musculus	0-4
16537374-11	2006	The protective effect of PTX was lost in IL-6(-/-) mice and protection was restored by a single dose of r-IL-6.	Pentoxifylline	25-28	interleukin 6	Mus musculus	41-45
16537374-13	2006	The superior effects of PTX are mediated by IL-6.	Pentoxifylline	24-27	interleukin 6	Mus musculus	44-48
16418171-4	2006	Moreover, IL-6 induced a rapid and transient phosphorylation of Ser-318 of IRS-1 in muscle cells and in muscle tissue, but not in the liver of IL-6-treated mice, probably via the IL-6-induced co-recruitment of protein kinase C-delta.	Serine	64-67	interleukin 6	Mus musculus	10-14
16418171-6	2006	Noteworthily, two inhibitory mechanisms of IL-6 on insulin action, phosphorylation of the inhibitory Ser-307 residue of IRS-1 and induction of SOCS-3 expression, were only found in liver but not in muscle of IL-6-treated mice.	Serine	101-104	interleukin 6	Mus musculus	43-47
16376434-3	2006	Taking into account that macrophages modulate the adaptive immune response according to the nature of the stimulating antigen and that IL-6 increases the synthesis of asymmetric IgG, in this work we analysed the differential modulation of the synthesis of asymmetric IgG by culture supernatants from peritoneal macrophages (CSPM) stimulated with either OVA-polystyrene beads or soluble OVA.	Polystyrenes	357-368	interleukin 6	Mus musculus	135-139
16376434-4	2006	The levels of IL-10, IL-6 and TNFalpha were determined in CSPM to find elevated levels of IL-6 and TNFalpha only in those cultures stimulated with OVA-coated polystyrene beads.	Polystyrenes	158-169	interleukin 6	Mus musculus	90-94
16517751-6	2006	Furthermore, wild-type microglia dose dependently secreted TNF-alpha and IL-6 after poly(I:C) challenge, whereas TLR3(-/-) microglia produced diminished cytokines.	Poly I-C	84-93	interleukin 6	Mus musculus	73-77
16254126-7	2006	A synthetic tripalmitoylated cysteine-, serine-, and lysine-containing peptide (Pam) and LPS from Porphyromonas gingivalis, two TLR2 ligands, also stimulated IL-6 expression.	Cysteine	29-37	interleukin 6	Mus musculus	158-162
16254126-7	2006	A synthetic tripalmitoylated cysteine-, serine-, and lysine-containing peptide (Pam) and LPS from Porphyromonas gingivalis, two TLR2 ligands, also stimulated IL-6 expression.	Serine	40-46	interleukin 6	Mus musculus	158-162
16254126-7	2006	A synthetic tripalmitoylated cysteine-, serine-, and lysine-containing peptide (Pam) and LPS from Porphyromonas gingivalis, two TLR2 ligands, also stimulated IL-6 expression.	Lysine	53-59	interleukin 6	Mus musculus	158-162
16254126-7	2006	A synthetic tripalmitoylated cysteine-, serine-, and lysine-containing peptide (Pam) and LPS from Porphyromonas gingivalis, two TLR2 ligands, also stimulated IL-6 expression.	Peptides	71-78	interleukin 6	Mus musculus	158-162
16254126-9	2006	LPS- and Pam-stimulated IL-6 expression was inhibited by the proteasome inhibitor MG-132 and the IkappaB kinase-2 (IKK2) inhibitor 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1).	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	82-88	interleukin 6	Mus musculus	24-28
16254126-9	2006	LPS- and Pam-stimulated IL-6 expression was inhibited by the proteasome inhibitor MG-132 and the IkappaB kinase-2 (IKK2) inhibitor 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1).	2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide	131-197	interleukin 6	Mus musculus	24-28
16254126-9	2006	LPS- and Pam-stimulated IL-6 expression was inhibited by the proteasome inhibitor MG-132 and the IkappaB kinase-2 (IKK2) inhibitor 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1).	2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide	199-205	interleukin 6	Mus musculus	24-28
16392107-5	2006	RESULTS: Administration of caerulein and LPS induced an increase in serum amylase and IL-6 levels, severe acute pancreatitis, pancreatitis-associated lung injury, and phosphorylation of signal transducer and activator of transcription (STAT) 3 in the pancreas.	Ceruletide	27-36	interleukin 6	Mus musculus	86-90
16181716-4	2006	Plasma levels of C-reactive protein (CRP), von Willebrand factor (vWF), IL-6, IL-10 and TNF-alpha were significantly increased by acetaminophen treatment (P &lt; 0.05); and SAC or SPC intake significantly suppressed acetaminophen-induced elevation of CRP, vWF and the three cytokines (P &lt; 0.05).	Acetaminophen	130-143	interleukin 6	Mus musculus	72-76
16428073-3	2006	High doses of Hg2+ induce an inflammatory status, increased production of IL-6 and consequent Th1/Th2 imbalance as well as cell-mediated immune depression.	Mercuric cation	14-18	interleukin 6	Mus musculus	74-78
16500244-9	2006	TLR4-mutant (C[3H]/HeJ) mice were protected from HS/R-induced hepatocellular injury and had lower circulating IL-6 and IL-10 levels than WT (p &lt; 0.05).	Tritium	15-17	interleukin 6	Mus musculus	110-114
16466739-0	2006	Noncanonical cAMP pathway and p38 MAPK mediate beta2-adrenergic receptor-induced IL-6 production in neonatal mouse cardiac fibroblasts.	Cyclic AMP	13-17	interleukin 6	Mus musculus	81-85
16466739-1	2006	We previously reported that cardiac fibroblasts, but not cardiomyocytes, are served as the predominant source of IL-6 after isoproterenol stimulation in mouse myocardium.	Isoproterenol	124-137	interleukin 6	Mus musculus	113-117
16466739-2	2006	The present study investigated the molecular mechanism of isoproterenol-mediated secretion of IL-6 in mouse cardiac fibroblasts.	Isoproterenol	58-71	interleukin 6	Mus musculus	94-98
16466739-3	2006	Treatment of cells with isoproterenol-induced a time-dependent accumulation of IL-6, which was mediated by beta(2)-adrenergic receptor (AR), the preponderant beta-AR subtype in cardiac fibroblasts.	Isoproterenol	24-37	interleukin 6	Mus musculus	79-83
16466739-4	2006	Isoproterenol-induced secretion of IL-6 was mainly mediated by Gs-AC-cAMP signaling cascade and could be negatively regulated by Gi and PI3K.	Isoproterenol	0-13	interleukin 6	Mus musculus	35-39
16466739-4	2006	Isoproterenol-induced secretion of IL-6 was mainly mediated by Gs-AC-cAMP signaling cascade and could be negatively regulated by Gi and PI3K.	gs-ac-camp	63-73	interleukin 6	Mus musculus	35-39
16466739-6	2006	p38 MAPK inhibitor SB203580, but not extracellular regulated protein kinase inhibitor, abrogated isoproterenol-induced IL-6 release in cardiac fibroblasts and mouse myocardium.	SB 203580	19-27	interleukin 6	Mus musculus	119-123
16466739-6	2006	p38 MAPK inhibitor SB203580, but not extracellular regulated protein kinase inhibitor, abrogated isoproterenol-induced IL-6 release in cardiac fibroblasts and mouse myocardium.	Isoproterenol	97-110	interleukin 6	Mus musculus	119-123
16466739-8	2006	Finally, multiple transcription factors (AP-1, C/EBP, NF-kappaB and CREB) regulating the IL-6 gene are activated in response to isoproterenol stimulation, which may provide essential linkage between upstream cAMP-p38 MAPK signaling cascade and downstream IL-6 gene transcription.	Isoproterenol	128-141	interleukin 6	Mus musculus	89-93
16466739-8	2006	Finally, multiple transcription factors (AP-1, C/EBP, NF-kappaB and CREB) regulating the IL-6 gene are activated in response to isoproterenol stimulation, which may provide essential linkage between upstream cAMP-p38 MAPK signaling cascade and downstream IL-6 gene transcription.	Isoproterenol	128-141	interleukin 6	Mus musculus	255-259
16466739-8	2006	Finally, multiple transcription factors (AP-1, C/EBP, NF-kappaB and CREB) regulating the IL-6 gene are activated in response to isoproterenol stimulation, which may provide essential linkage between upstream cAMP-p38 MAPK signaling cascade and downstream IL-6 gene transcription.	Cyclic AMP	208-212	interleukin 6	Mus musculus	89-93
16466739-9	2006	The present results suggest that beta(2)-AR mediates IL-6 production through a noncanonical cAMP responsible pathway and p38 MAPK.	Cyclic AMP	92-96	interleukin 6	Mus musculus	53-57
16625056-5	2006	U-73122 and Go6976 reduced AmB-mediated induction of proinflammatory cytokines (tumor necrosis factor (TNF)-alpha and interleukin (IL)-6) in RAW264.7 cells.	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	0-7	interleukin 6	Mus musculus	118-136
16625056-5	2006	U-73122 and Go6976 reduced AmB-mediated induction of proinflammatory cytokines (tumor necrosis factor (TNF)-alpha and interleukin (IL)-6) in RAW264.7 cells.	Go 6976	12-18	interleukin 6	Mus musculus	118-136
16625056-5	2006	U-73122 and Go6976 reduced AmB-mediated induction of proinflammatory cytokines (tumor necrosis factor (TNF)-alpha and interleukin (IL)-6) in RAW264.7 cells.	Amphotericin B	27-30	interleukin 6	Mus musculus	118-136
16625056-7	2006	Finally, U-73122 partially suppressed in vivo production of TNF-alpha and IL-6 induced by AmB administration in BALB/c mice.	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	9-16	interleukin 6	Mus musculus	74-78
16625056-7	2006	Finally, U-73122 partially suppressed in vivo production of TNF-alpha and IL-6 induced by AmB administration in BALB/c mice.	Amphotericin B	90-93	interleukin 6	Mus musculus	74-78
17077645-0	2006	Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic acid-induced colitis in mice.	Trinitrobenzenesulfonic Acid	45-74	interleukin 6	Mus musculus	0-13
17077645-6	2006	METHODS: Acute colitis was induced in wild-type and IL-6-deficient (Il-6(-/-)) mice by intracolonic administration of TNBS.	Trinitrobenzenesulfonic Acid	118-122	interleukin 6	Mus musculus	52-56
17077645-6	2006	METHODS: Acute colitis was induced in wild-type and IL-6-deficient (Il-6(-/-)) mice by intracolonic administration of TNBS.	Trinitrobenzenesulfonic Acid	118-122	interleukin 6	Mus musculus	68-72
17077645-8	2006	RESULTS: In wild-type mice, TNBS administration increased both IL-6 serum levels and local expression of IL-6 by 36 and 9 fold, respectively, compared with control, vehicle-injected mice.	Trinitrobenzenesulfonic Acid	28-32	interleukin 6	Mus musculus	63-67
17077645-8	2006	RESULTS: In wild-type mice, TNBS administration increased both IL-6 serum levels and local expression of IL-6 by 36 and 9 fold, respectively, compared with control, vehicle-injected mice.	Trinitrobenzenesulfonic Acid	28-32	interleukin 6	Mus musculus	105-109
17077645-9	2006	Compared with the wild-type mice, the Il-6(-/-) mice had significantly reduced intestinal inflammation as evidenced by epithelial damage, neutrophil infiltration, colon thickness and proinflammatory cytokine expression, following treatment with TNBS.	Trinitrobenzenesulfonic Acid	245-249	interleukin 6	Mus musculus	38-42
16783963-6	2006	In addition to TNF, protein arrays showed IL-6, IL-10, MIP-1alpha, MIP-2, and RANTES were also secreted following treatment with 10 microg/ml DMXAA alone, and IL-4, IFN-gamma, MCP-5, and TIMP-1 were additionally induced using a higher dose of 300 microg/ml DMXAA.	vadimezan	142-147	interleukin 6	Mus musculus	42-46
16357188-5	2005	We show that DMXAA efficiently activated tumor-associated macrophages to release a variety of immunostimulatory cytokines and chemokines, including TNF-alpha; IFN-inducible protein-10; interleukin-6; macrophage inflammatory protein-2; monocyte chemotactic protein-1; and regulated on activation, normal T-cell expressed, and secreted.	vadimezan	13-18	interleukin 6	Mus musculus	185-198
16273545-7	2005	The production of proinflammatory cytokines, such as interleukin-6 and tumor necrosis factor-alpha in activated microglial cells, was reduced by xanthorrhizol.	xanthorrhizol	145-158	interleukin 6	Mus musculus	53-98
16371932-10	2005	TSC production of IL-6 was also decreased in castrated mice CONCLUSIONS: These data suggest that sex steroid ablation significantly enhances lymphopoiesis following auto-HSCT providing a new strategy for posttransplant immune reconstitution.	Steroids	101-108	interleukin 6	Mus musculus	18-22
16336675-9	2005	The results from in vivo study showed that CAPE treatment decreased the expression of inflammatory cytokines including IL-1 alpha and beta, IL-6, TNF-alpha and TGF- beta, after irradiation.	caffeic acid phenethyl ester	43-47	interleukin 6	Mus musculus	140-144
16260063-2	2005	Results showed that the immunoreactivities of IL-1beta, IL-6, TGF-beta1, fractalkine and MCP-1 were upregulated in the DMV at 14 days and the upregulation persisted at least until 28 days following right vagotomy.	(2R,3R)-2,3-dihydroxy-3-methylpentanoic acid	119-122	interleukin 6	Mus musculus	56-60
16229818-6	2005	Pretreatment with p38 mitogen-activated protein kinase (MAPK) inhibitor blocked AICAR-induced IL-6 production; furthermore, AICAR-activated p38 MAPK phosphorylation by Western blot.	acadesine	80-85	interleukin 6	Mus musculus	94-98
16229818-7	2005	To confirm that the increase in IL-6 production is ascribed to AMPK activation, we used another known AMPK activator, metformin.	Metformin	118-127	interleukin 6	Mus musculus	32-36
16024721-7	2005	Alveolar IL-6, IL-1beta, and macrophage inflammatory protein-2 concentrations were increased after removal of doxycycline, indicating pulmonary inflammation.	Doxycycline	110-121	interleukin 6	Mus musculus	9-13
16333916-4	2005	Tumor necrosis factor (TNF)-alpha, inducible nitric oxide synthase (iNOS), interferon (IFN)-alpha, and interleukin-6 mRNAs were detected to a much greater extent in silica-treated mice compared with control mice after HSV-1 infection, and excessive expression of iNOS mRNA and cytokine mRNAs in the liver may be closely related to massive liver cell apoptosis.	Silicon Dioxide	165-171	interleukin 6	Mus musculus	103-116
16351643-0	2005	Role of interleukin-6 in hypoxic regulation of intestinal iron absorption.	Iron	58-62	interleukin 6	Mus musculus	8-21
16351643-6	2005	A significant positive correlation existed between the total iron uptake and IL-6 levels in circulation.	Iron	61-65	interleukin 6	Mus musculus	77-81
16351643-11	2005	Anti-IL-6 antiserum normalised iron absorption in mice exposed to hypoxia, because of a reduction in the MT.	Iron	31-35	interleukin 6	Mus musculus	5-9
16351643-12	2005	These data indicate that IL-6 can influence iron absorption (especially MT) during the hypoxic exposure, but via a mechanism independent of hepcidin.	Iron	44-48	interleukin 6	Mus musculus	25-29
15846489-4	2005	cDNA for murine IL-6 (mIL-6) was introduced to the CL25 cells, resulting in a high-producer (mIL-6H) clone.	mil-6h	93-99	interleukin 6	Mus musculus	16-20
15846489-4	2005	cDNA for murine IL-6 (mIL-6) was introduced to the CL25 cells, resulting in a high-producer (mIL-6H) clone.	mil-6h	93-99	interleukin 6	Mus musculus	22-27
16150911-6	2005	In contrast, local inflammation induced by turpentine did not decrease liver D1 and D3 activity but increased markedly D3 activity in the muscle/subcutis sample containing the abscess, associated with strongly increased IL-1beta and IL-6 mRNA expression.	Turpentine	43-53	interleukin 6	Mus musculus	233-237
16005558-5	2005	Incubation with sodium acetate for 24 h increased the levels of IL-1beta, IL-8, and TNF-alpha protein and mRNAs (IL-6 was detected but its mRNA was not).	Sodium Acetate	16-30	interleukin 6	Mus musculus	113-117
16275624-5	2005	LLDT-8 (25, 50, 100 nM) dose-dependently reduced the production of Th1 type cytokines (IFN-gamma, IL-2) and inflammatory cytokines (TNF-alpha, IL-6) in vitro.	5alpha-Hydroxytriptolide	0-6	interleukin 6	Mus musculus	143-147
16299325-3	2005	Noncapsulated mannose-containing O3 serotypes (K50/n and K55/n), which react efficiently with SP-D in vitro, triggered high levels of interleukin-1beta (IL-1beta) and IL-6 production.	Mannose	14-21	interleukin 6	Mus musculus	167-171
16198427-0	2005	High cholesterol diet results in increased expression of interleukin-6 and caspase-1 in the brain of apolipoprotein E knockout and wild type mice.	Cholesterol	5-16	interleukin 6	Mus musculus	57-70
16198427-3	2005	In the present study, we have evaluated the effect of high cholesterol (HC) diet on the expression of interleukin-6 (IL-6), a cytokine involved in neurodegeneration, and caspase-1, that is responsible for the cleavage of the precursors of interleukin-1 beta (IL-1 beta) and interleukin-18 (IL-18) in the brain of apolipoprotein E (Apo E) knock-out (KO) and wild type (WT) mice.	Cholesterol	59-70	interleukin 6	Mus musculus	102-115
16198427-3	2005	In the present study, we have evaluated the effect of high cholesterol (HC) diet on the expression of interleukin-6 (IL-6), a cytokine involved in neurodegeneration, and caspase-1, that is responsible for the cleavage of the precursors of interleukin-1 beta (IL-1 beta) and interleukin-18 (IL-18) in the brain of apolipoprotein E (Apo E) knock-out (KO) and wild type (WT) mice.	Cholesterol	59-70	interleukin 6	Mus musculus	117-121
16154758-9	2005	The most potent stimulant properties disclosed PP(Phe)(2)Arg(2) derivative for which the highest values of IL-1beta, IL-6 and NO(2)(-) were noticed.	Phenylalanine	50-53	interleukin 6	Mus musculus	117-121
16154758-9	2005	The most potent stimulant properties disclosed PP(Phe)(2)Arg(2) derivative for which the highest values of IL-1beta, IL-6 and NO(2)(-) were noticed.	Arginine	57-60	interleukin 6	Mus musculus	117-121
16154177-4	2005	We found that LPS- and zymosan-stimulated TNF-alpha and IL-6 production is attenuated in splenic macrophages from aged mice compared to young.	Zymosan	23-30	interleukin 6	Mus musculus	56-60
16421339-4	2005	The effect of 0 to 1 microM TSH on IL-6 protein release into the medium over 0 to 24 hours was assessed.	Thyrotropin	28-31	interleukin 6	Mus musculus	35-39
16421339-7	2005	Forskolin (elevates intracellular cAMP) stimulated IL-6 release from 3T3-L1 adipocytes (n = 3, p &lt; 0.005), and H89, an inhibitor of cAMP-dependent protein kinase A (PKA), reduced TSH-stimulated IL-6 release by 66% (n = 3, p &lt; 0.01), indicating a requirement for cAMP-dependent PKA.	Colforsin	0-9	interleukin 6	Mus musculus	51-55
16421339-7	2005	Forskolin (elevates intracellular cAMP) stimulated IL-6 release from 3T3-L1 adipocytes (n = 3, p &lt; 0.005), and H89, an inhibitor of cAMP-dependent protein kinase A (PKA), reduced TSH-stimulated IL-6 release by 66% (n = 3, p &lt; 0.01), indicating a requirement for cAMP-dependent PKA.	Colforsin	0-9	interleukin 6	Mus musculus	197-201
16421339-7	2005	Forskolin (elevates intracellular cAMP) stimulated IL-6 release from 3T3-L1 adipocytes (n = 3, p &lt; 0.005), and H89, an inhibitor of cAMP-dependent protein kinase A (PKA), reduced TSH-stimulated IL-6 release by 66% (n = 3, p &lt; 0.01), indicating a requirement for cAMP-dependent PKA.	Cyclic AMP	34-38	interleukin 6	Mus musculus	51-55
16421339-10	2005	TSH raised the level of IL-6 mRNA, and blockade of transcription with actinomycin D abrogated IL-6 protein release by TSH (n = 3, p &lt; 0.05).	Dactinomycin	70-83	interleukin 6	Mus musculus	94-98
16421339-11	2005	DISCUSSION: TSH stimulates IL-6 release from differentiated 3T3-L1 adipocytes, but not preadipocytes, by signaling through cAMP-PKA to activate IL-6 gene transcription.	Cyclic AMP	123-127	interleukin 6	Mus musculus	27-31
16421339-11	2005	DISCUSSION: TSH stimulates IL-6 release from differentiated 3T3-L1 adipocytes, but not preadipocytes, by signaling through cAMP-PKA to activate IL-6 gene transcription.	Cyclic AMP	123-127	interleukin 6	Mus musculus	144-148
15942272-6	2005	Olopatadine significantly inhibited the ear swelling and the increased production of IL-4, IL-1beta, IL-6, GM-CSF and NGF in the lesioned ear.	Olopatadine Hydrochloride	0-11	interleukin 6	Mus musculus	101-105
16198389-2	2005	In this study, the effects of BaV on the release of the cytokines IL-1, IL-6 and TNF-alpha and the eicosanoids LTB4 and TXA2 in the peritoneal cavity of mice were analyzed.	CHEMBL564010	30-33	interleukin 6	Mus musculus	72-76
16198389-4	2005	Levels of proinflammatory cytokines IL-6 and TNF-alpha, as well as eicosanoids LTB4 and TXA2 were significantly increased after BaV injection (250 microg/kg), whereas no increment in IL-1 was observed.	CHEMBL564010	128-131	interleukin 6	Mus musculus	36-40
16112685-2	2005	Vitamin B2 at 20 mg/kg (protective effect on mice mortality induced by LPS), intravenously administered 6 h after LPS injection, significantly decreased the plasma elevated levels of IL-6 and MIP-2 at 9 and 12 h. In addition, vitamin B2 lowered the tissue concentration and the mRNA expression of IL-6 in lung and those of MIP-2 in liver at 9 h. Vitamin B2 also reduced concentration of MIP-2 concentration in lung, and inhibited mRNA expression in kidney, respectively.	Riboflavin	0-10	interleukin 6	Mus musculus	183-187
16112685-1	2005	Inhibitory effects of highly purified vitamin B2 (riboflavin-5"-sodium phosphate, &gt;97%) on the interleukin (IL)-6, macrophage inflammatory protein (MIP)-2 and nitric oxide (NO) in LPS-induced shock mice were evaluated.	Riboflavin	38-48	interleukin 6	Mus musculus	98-116
16112685-1	2005	Inhibitory effects of highly purified vitamin B2 (riboflavin-5"-sodium phosphate, &gt;97%) on the interleukin (IL)-6, macrophage inflammatory protein (MIP)-2 and nitric oxide (NO) in LPS-induced shock mice were evaluated.	riboflavin-5"-sodium phosphate	50-80	interleukin 6	Mus musculus	98-116
16112685-2	2005	Vitamin B2 at 20 mg/kg (protective effect on mice mortality induced by LPS), intravenously administered 6 h after LPS injection, significantly decreased the plasma elevated levels of IL-6 and MIP-2 at 9 and 12 h. In addition, vitamin B2 lowered the tissue concentration and the mRNA expression of IL-6 in lung and those of MIP-2 in liver at 9 h. Vitamin B2 also reduced concentration of MIP-2 concentration in lung, and inhibited mRNA expression in kidney, respectively.	Riboflavin	0-10	interleukin 6	Mus musculus	297-301
16112685-2	2005	Vitamin B2 at 20 mg/kg (protective effect on mice mortality induced by LPS), intravenously administered 6 h after LPS injection, significantly decreased the plasma elevated levels of IL-6 and MIP-2 at 9 and 12 h. In addition, vitamin B2 lowered the tissue concentration and the mRNA expression of IL-6 in lung and those of MIP-2 in liver at 9 h. Vitamin B2 also reduced concentration of MIP-2 concentration in lung, and inhibited mRNA expression in kidney, respectively.	Riboflavin	226-236	interleukin 6	Mus musculus	183-187
16112685-2	2005	Vitamin B2 at 20 mg/kg (protective effect on mice mortality induced by LPS), intravenously administered 6 h after LPS injection, significantly decreased the plasma elevated levels of IL-6 and MIP-2 at 9 and 12 h. In addition, vitamin B2 lowered the tissue concentration and the mRNA expression of IL-6 in lung and those of MIP-2 in liver at 9 h. Vitamin B2 also reduced concentration of MIP-2 concentration in lung, and inhibited mRNA expression in kidney, respectively.	Riboflavin	226-236	interleukin 6	Mus musculus	297-301
16202978-0	2005	Interleukin-1beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis.	Dextran Sulfate	55-77	interleukin 6	Mus musculus	26-39
16202978-10	2005	attenuated DSS-induced body weight reduction and shortening of the colorectum (P &lt; 0.05, each), and abrogated the expressions of IL-1beta and IL-6 mRNA in colonic mucosa (P &lt; 0.01, each).	Dextran Sulfate	11-14	interleukin 6	Mus musculus	145-149
16279805-6	2005	Intravenous administration of (R)-(+)-5n at doses of 0.1 mg/kg or more suppressed the production of NO and various cytokines [TNF-alpha, IL-6 and IL-1beta] in the mouse endotoxin shock model.	(r)-(+)-5n	30-40	interleukin 6	Mus musculus	137-141
16225758-7	2005	SM735 dose-dependently inhibited proinflammatory cytokine production [including interleukins (IL)-12, interferon (IFN)-gamma and IL-6] induced by LPS or PMA plus ionomycin.	Tetradecanoylphorbol Acetate	153-156	interleukin 6	Mus musculus	129-133
16285960-7	2005	Lys-to-Arg point mutations (STAT3 K49R/K87R) had no effect on inducible DNA binding, but blocked p300-mediated acetyl(Ac)-STAT3 formation and abrogated IL-6-induced hAGT activation.	Lysine	0-3	interleukin 6	Mus musculus	152-156
16285960-7	2005	Lys-to-Arg point mutations (STAT3 K49R/K87R) had no effect on inducible DNA binding, but blocked p300-mediated acetyl(Ac)-STAT3 formation and abrogated IL-6-induced hAGT activation.	Arginine	7-10	interleukin 6	Mus musculus	152-156
16186163-2	2005	Using an in vitro model of macrophage activation, we show that schistosome larvae possess molecules that directly stimulate both thioglycollate-elicited macrophages (tM) and IFNgamma-activated tM in vitro to produce several cytokines including IL-6, IL-12p40 and IL-10.	Thioglycolates	129-143	interleukin 6	Mus musculus	244-248
16259568-7	2005	However, when mice previously injected with pristane were inoculated with DNA-hsp65 or DNAv, the protective effect was significantly correlated with lower IL-6 and IL-12 levels and higher IL-10 levels.	pristane	44-52	interleukin 6	Mus musculus	155-159
16192425-9	2005	IL-6 that was produced in response to renal ischemia was maladaptive because transgenic knockout of IL-6 ameliorated renal injury as measured by serum creatinine and histology.	Creatinine	151-161	interleukin 6	Mus musculus	0-4
16192425-9	2005	IL-6 that was produced in response to renal ischemia was maladaptive because transgenic knockout of IL-6 ameliorated renal injury as measured by serum creatinine and histology.	Creatinine	151-161	interleukin 6	Mus musculus	100-104
16081681-8	2005	LJP 1207 also reduced serum levels of tumor necrosis factor-alpha and interleukin 6 in lipopolysaccharide (LPS)-challenged mice and prolonged survival post-LPS-induced endotoxemia.	CB 1837	0-3	interleukin 6	Mus musculus	70-83
16164983-4	2005	Inhibition of the MEK/ERK pathway by pretreatment with the MEK inhibitor U 0126 dramatically attenuated G-CSF-induced granulocytic differentiation and IL-6-induced monocytic differentiation.	U 0126	73-79	interleukin 6	Mus musculus	151-155
16249345-7	2005	After oral administration, GW2580 blocked the ability of exogenous CSF-1 to increase LPS-induced IL-6 production in mice, inhibited the growth of CSF-1-dependent M-NFS-60 tumor cells in the peritoneal cavity, and diminished the accumulation of macrophages in the peritoneal cavity after thioglycolate injection.	5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine	27-33	interleukin 6	Mus musculus	97-101
15947070-6	2005	In mice with IL-6 levels &gt;14,000 pg/ml, 25% survived if imipenem was started at 6 h, whereas none survived if antibiotics were started later (P &lt; 0.05).	Imipenem	59-67	interleukin 6	Mus musculus	13-17
16204935-7	2005	Among inflammatory cytokines examined, interleukin 6 (IL-6) exhibited a marked increase in the serum at 3 h after the CeCl3 administration.	cerous chloride	118-123	interleukin 6	Mus musculus	39-52
16204935-7	2005	Among inflammatory cytokines examined, interleukin 6 (IL-6) exhibited a marked increase in the serum at 3 h after the CeCl3 administration.	cerous chloride	118-123	interleukin 6	Mus musculus	54-58
16204935-8	2005	In order to evaluate the involvement of IL-6 in the induction of MT by cerium, we examined MT induction by CeCl3 in IL-6 null mice.	Cerium	71-77	interleukin 6	Mus musculus	40-44
16204935-10	2005	These results suggest that IL-6 plays an important role in the induction of hepatic MT by cerium.	Cerium	90-96	interleukin 6	Mus musculus	27-31
16204952-7	2005	Biochanin A (1-10 microM) decreased the 0.2 mM H2O2-induced production of TNF-alpha, IL-6 and NO in osteoblasts.	Hydrogen Peroxide	47-51	interleukin 6	Mus musculus	85-89
16204073-9	2005	Double culture of accessory cells with CT-26/antisense KITENIN/90K cells revealed increased secretion of IL-1 and IL-6.	CT-26	39-44	interleukin 6	Mus musculus	114-118
16186359-5	2005	Splenocytes and cells of regional lymph nodes near the eye were collected and their proliferation and production of IL-6, IL-10, IFN-gamma, and CCL2 (MCP-1) in response to hIRBP-p stimulation were measured.	hirbp-p	172-179	interleukin 6	Mus musculus	116-120
16040151-6	2005	METHODS: Using IL-6-deficient mice we analyzed the role of interleukin-6 for the hepatic SOCS3 expression in response to turpentine and LPS as models of aseptic and bacterial inflammation, respectively.	Turpentine	121-131	interleukin 6	Mus musculus	59-72
16177209-5	2005	Phytosterol-enriched diets were strongly associated with reduced plasma cholesterol concentrations and atherosclerosis in conjunction with higher anti-inflammatory [interleukin (IL)-10] and lower proinflammatory cytokine [IL-6, tumor necrosis factor (TNF)-alpha] production.	Phytosterols	0-11	interleukin 6	Mus musculus	222-226
16253122-12	2005	Mice that had received whole IgM effluent (1.5 mg/l of anti-LPS O6 IgM antibodies) before the challenge with LPS O6 presented 20.5 microg/l of IL-6 and 1.5 microg/l of TNF-alpha.	lps	60-63	interleukin 6	Mus musculus	143-153
16157881-5	2005	In this context, flagellin exposure to injured colonic mucosa due to DSS administration in mice resulted in a TLR5-associated response evaluated by in vivo activation of mitogen-activated protein kinase/extracellular signal-related kinase 1/2 (MEK1/2) and elevated IL-6, TNF-alpha, and keratinocyte-derived chemokine production, whereas intact colonic mucosa did not respond to flagellin.	Dextran Sulfate	69-72	interleukin 6	Mus musculus	265-269
16026997-0	2005	Dietary glutamine supplementation modulates Th1/Th2 cytokine and interleukin-6 expressions in septic mice.	Glutamine	8-17	interleukin 6	Mus musculus	65-78
16026997-3	2005	This study evaluated the influence of a Gln-enriched diet on interleukin (IL)-6 expression in organs and Th1/Th2 type cytokine production within lymphocytes in septic mice.	Glutamine	40-43	interleukin 6	Mus musculus	61-79
16026997-10	2005	Compared to the control group, the Gln group had higher levels of IL-6 in the liver and lower levels in other organs at various time points.	Glutamine	35-38	interleukin 6	Mus musculus	66-70
16026997-12	2005	These results suggest that Gln supplementation decreased IL-6 production in non-hepatic organs, while reducing intra-lymphocyte IL-4 and enhancing IFN-gamma expressions.	Glutamine	27-30	interleukin 6	Mus musculus	57-61
16109400-2	2005	Nitric oxide is described to modulate the secretion of interleukin-6 in various cell types.	Nitric Oxide	0-12	interleukin 6	Mus musculus	55-68
16109400-3	2005	The aim of the present study was to investigate the effect of nitric oxide on interleukin-1beta induced interleukin-6 secretion.	Nitric Oxide	62-74	interleukin 6	Mus musculus	104-117
16150281-11	2005	Similarly, alcohol increased interleukin-6 levels versus control levels (22.6 +/- 1.4 pg/mL vs 17.3 +/- 0.6 pg/mL; P &lt; .001), and NAPVSIPQ+SALLRSIPA prevented this increase (19.1 +/- 1.0 pg/mL; P &lt;/= .02), with levels similar to control levels (P=.2).	Alcohols	11-18	interleukin 6	Mus musculus	29-42
16160914-5	2005	Expression of mRNA coding for TNF-alpha and IL-6 in liver was significantly lower in arsenite-pretreated animals.	arsenite	85-93	interleukin 6	Mus musculus	44-48
16116197-3	2005	All PPS-containing preparations induced IL-6 and TNF-alpha from wild-type, but not TLR2-/-, macrophages.	pps	4-7	interleukin 6	Mus musculus	40-44
16055120-5	2005	Bio-Plex assay revealed that interleukin (IL)-1alpha, IL-1beta, and IL-6 secretion from RAW264.7 cells were also induced by unsaturated alginate oligomers with similar structure-activity relationship profiles as seen in TNF-alpha, and the most potent activities were observed with G8 and M7.	unsaturated alginate	124-144	interleukin 6	Mus musculus	68-72
15833764-6	2005	E5564 was effective in decreasing the airway hyperreactivity to methacholine, the air space neutrophilia, the interleukin-6 in the lung lavage fluid, and the neutrophil infiltration of the airways 36 h after 5 wk of LPS inhalation.	E5564	0-5	interleukin 6	Mus musculus	110-123
16472714-6	2005	The results indicate that IL-6 production and the effects of Ethanol on IL-6 were similar in vivo and in vitro.	Ethanol	61-68	interleukin 6	Mus musculus	72-76
15996187-8	2005	Hypergammaglobulinaemia and spontaneous anti-DNA/chromatin autoantibody production were associated with interleukin (IL)-6 over-expression in FcgammaRIIB(-/-) mice and were augmented further by pristane treatment when compared to both FcgammaRI/III(-/-) and (+/+) mice.	pristane	194-202	interleukin 6	Mus musculus	104-122
16061877-7	2005	DHMEQ caused a significant decrease of serum IL-6 level in JCA-1 tumor-bearing mice (all P &lt; 0.05).	dehydroxymethylepoxyquinomicin	0-5	interleukin 6	Mus musculus	45-49
16061877-8	2005	CONCLUSIONS: These results suggested an association between serum IL-6 and cachexia in patients with prostate cancer and in JCA-1 tumor-bearing mice and that a new NF-kappaB inhibitor, DHMEQ, could prevent the development of cachexia in JCA-1 tumor-bearing mice presumably through the inhibition of IL-6 secretion.	dehydroxymethylepoxyquinomicin	185-190	interleukin 6	Mus musculus	299-303
15845623-8	2005	Using the hyperinsulinemic-euglycemic clamp technique, insulin-dependent suppression of endogenous glucose production was 89% in IL-6-depleted Lep(ob) mice, in contrast to only 32% in Lep(ob) controls, indicating a marked increase in hepatic insulin sensitivity.	Glucose	99-106	interleukin 6	Mus musculus	129-133
15845623-9	2005	A significant change in glucose uptake in skeletal muscle after IL-6 neutralization was not observed.	Glucose	24-31	interleukin 6	Mus musculus	64-68
15959754-0	2005	Activation of opioid mu-receptors by loperamide to improve interleukin-6-induced inhibition of insulin signals in myoblast C2C12 cells.	Loperamide	37-47	interleukin 6	Mus musculus	59-72
15959754-5	2005	RESULTS: The insulin-stimulated 2-DG uptake was reduced by IL-6.	Deoxyglucose	32-36	interleukin 6	Mus musculus	59-63
15959754-7	2005	Insulin resistance induced by IL-6 was associated with impaired expression of the insulin receptor (IR), IR tyrosine autophosphorylation, IRS-1 protein content and IRS-1 tyrosine phosphorylation.	Tyrosine	108-116	interleukin 6	Mus musculus	30-34
15959754-7	2005	Insulin resistance induced by IL-6 was associated with impaired expression of the insulin receptor (IR), IR tyrosine autophosphorylation, IRS-1 protein content and IRS-1 tyrosine phosphorylation.	Tyrosine	170-178	interleukin 6	Mus musculus	30-34
15959754-9	2005	Loperamide reversed IL-6-induced decrement of these insulin signals.	Loperamide	0-10	interleukin 6	Mus musculus	20-24
16008516-8	2005	Our data further show that 5-FU upregulates serum levels of IL-6, known to contribute to weight loss, in tumor-free mice, and that this increase in IL-6 is significantly less in mice that received Bing De Ling in addition to 5-FU.	Fluorouracil	27-31	interleukin 6	Mus musculus	60-64
15802498-0	2005	Palmitate-induced interleukin 6 production is mediated by protein kinase C and nuclear-factor kappaB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cells.	Palmitates	0-9	interleukin 6	Mus musculus	18-31
15802498-3	2005	Here, we report that exposure of C2C12 skeletal muscle cells to 0.5 mm palmitate results in increased mRNA levels (3.5-fold induction; P &lt; 0.05) and secretion (control 375 +/- 57 vs. palmitate 1129 +/- 177 pg/ml; P &lt; 0.001) of the proinflammatory cytokine IL-6.	Palmitates	71-80	interleukin 6	Mus musculus	262-266
15802498-4	2005	Palmitate increased nuclear factor-kappaB activation and coincubation of the cells with palmitate and the nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate prevented both IL-6 expression and secretion.	pyrrolidine dithiocarbamic acid	138-165	interleukin 6	Mus musculus	181-185
15802498-5	2005	Furthermore, incubation of palmitate-treated cells with calphostin C, a strong and specific inhibitor of protein kinase C, and phorbol myristate acetate, that down-regulates protein kinase C in long-term incubations, abolished induction of IL-6 production.	Palmitates	27-36	interleukin 6	Mus musculus	240-244
15802498-5	2005	Furthermore, incubation of palmitate-treated cells with calphostin C, a strong and specific inhibitor of protein kinase C, and phorbol myristate acetate, that down-regulates protein kinase C in long-term incubations, abolished induction of IL-6 production.	Tetradecanoylphorbol Acetate	127-152	interleukin 6	Mus musculus	240-244
15802498-6	2005	Finally, exposure of skeletal muscle cells to palmitate caused a fall in the mRNA levels of glucose transporter 4 and insulin-stimulated glucose uptake, whereas in the presence of anti-IL-6 antibody, which neutralizes the biological activity of mouse IL-6 in cell culture, these reductions were prevented.	Palmitates	46-55	interleukin 6	Mus musculus	251-255
15802498-6	2005	Finally, exposure of skeletal muscle cells to palmitate caused a fall in the mRNA levels of glucose transporter 4 and insulin-stimulated glucose uptake, whereas in the presence of anti-IL-6 antibody, which neutralizes the biological activity of mouse IL-6 in cell culture, these reductions were prevented.	Glucose	92-99	interleukin 6	Mus musculus	251-255
15802498-7	2005	These findings suggest that IL-6 may mediate several of the prodiabetic effects of palmitate.	Palmitates	83-92	interleukin 6	Mus musculus	28-32
15951548-11	2005	CONCLUSIONS: These results suggest that norepinephrine released from the hepatic sympathetic nerve plays a critical role in protecting the liver from Fas mediated fulminant hepatitis, possibly via mechanisms including antiapoptotic proteins and interleukin 6.	Norepinephrine	40-54	interleukin 6	Mus musculus	245-258
15972524-8	2005	Peak interleukin-6 levels in plasma decreased from 19.3 ng/ml (S) to 3.4 (BIAP-P) and 11.5 (BIAP-ET) and in PLF from 32.6 ng/ml (S) to 13.4 (BIAP-P) and 10.9 (BIAP-ET) (all, P &lt; 0.05).	biap-p	74-80	interleukin 6	Mus musculus	5-18
15972524-8	2005	Peak interleukin-6 levels in plasma decreased from 19.3 ng/ml (S) to 3.4 (BIAP-P) and 11.5 (BIAP-ET) and in PLF from 32.6 ng/ml (S) to 13.4 (BIAP-P) and 10.9 (BIAP-ET) (all, P &lt; 0.05).	2-(3',4'-dihydroxyphenyl-1-azo)benzimidazole	74-78	interleukin 6	Mus musculus	5-18
15972524-8	2005	Peak interleukin-6 levels in plasma decreased from 19.3 ng/ml (S) to 3.4 (BIAP-P) and 11.5 (BIAP-ET) and in PLF from 32.6 ng/ml (S) to 13.4 (BIAP-P) and 10.9 (BIAP-ET) (all, P &lt; 0.05).	biap-p	141-147	interleukin 6	Mus musculus	5-18
15972524-8	2005	Peak interleukin-6 levels in plasma decreased from 19.3 ng/ml (S) to 3.4 (BIAP-P) and 11.5 (BIAP-ET) and in PLF from 32.6 ng/ml (S) to 13.4 (BIAP-P) and 10.9 (BIAP-ET) (all, P &lt; 0.05).	2-(3',4'-dihydroxyphenyl-1-azo)benzimidazole	92-96	interleukin 6	Mus musculus	5-18
16022585-5	2005	Plasma IL-6 and TPO concentrations increased on turpentine injection only in the wild-type mice.	Turpentine	48-58	interleukin 6	Mus musculus	7-11
15944780-4	2005	The tumor weights with MTD of CPM or CPT-11 in combination with anti-IL-6 antibody treatment, which decreases serum IL-6 level and improves cachexia status, were significantly smaller than those in the MTD treatment-alone group with clone 20, but not with clone 5.	Irinotecan	37-43	interleukin 6	Mus musculus	116-120
15987517-4	2005	The objective of this study was to test the hypothesis that parthenolide suppresses lipopolysaccharide (LPS)-induced serum (interleukin) IL-6, tumor necrosis factor (TNF)-alpha, IL-1beta and cyclooxygenase (COX)-2 expression in mice as indicated by reduced splenic and liver mRNA levels.	parthenolide	60-72	interleukin 6	Mus musculus	137-141
15987517-9	2005	RESULTS: LPS induced increases in serum IL-6 and TNF-alpha concentrations with only IL-6 being suppressed in parthenolide-treated mice.	parthenolide	109-121	interleukin 6	Mus musculus	84-88
15987517-10	2005	Induction of IL-6 mRNA was reduced, TNF-alpha and COX-2 mRNAs unchanged, and IL-1beta mRNA increased in spleens of parthenolide plus LPS co-treated animals compared to LPS-only.	parthenolide	115-127	interleukin 6	Mus musculus	13-17
15987517-13	2005	CONCLUSION: In summary, only one gene, IL-6, was modestly suppressed by parthenolide co-exposure which contrasts with many in vitro studies suggesting anti-inflammatory effects of this compound.	parthenolide	72-84	interleukin 6	Mus musculus	39-43
15910996-3	2005	Cell proliferation and tyrosine phosphorylation of signal transducer and activator of transcription-3 (STAT3) were induced by rchIL-6 in the IL-6-dependent murine hybridoma cell line MH60, whereas the recombinant protein exhibited no significant cell proliferation activity in chicken hybridoma cells but induced antibody production and tyrosine phosphorylation of STAT3.	Tyrosine	23-31	interleukin 6	Mus musculus	129-133
15910996-3	2005	Cell proliferation and tyrosine phosphorylation of signal transducer and activator of transcription-3 (STAT3) were induced by rchIL-6 in the IL-6-dependent murine hybridoma cell line MH60, whereas the recombinant protein exhibited no significant cell proliferation activity in chicken hybridoma cells but induced antibody production and tyrosine phosphorylation of STAT3.	Tyrosine	337-345	interleukin 6	Mus musculus	129-133
15976528-4	2005	RESULTS: Increased LPS sensitivity in AFL and NAFL was characterized by elevated serum TNF-alpha and IL-6 induction.	NaFluo	46-50	interleukin 6	Mus musculus	101-105
15665042-7	2005	LPS-mediated lung gene expression was significantly modulated by simvastatin within a number of gene ontologies (e.g., inflammation and immune response, NF-kappaB regulation) and with respect to individual genes implicated in the development or severity of ALI (e.g., IL-6, Toll-like receptor 4).	Simvastatin	65-76	interleukin 6	Mus musculus	268-272
15691869-4	2005	2-Methyl-2-[[1-(phenylmethyl)-1H-indazol-3yl]methoxy]propanoic acid (bindarit) has been shown to preferentially inhibit MCP-1 production in vitro in monocytes and in vivo without affecting the production of the cytokines IL-1, IL-6, or the chemokines IL-8, protein macrophage inflammatory-1alpha, and RANTES.	bindarit	69-77	interleukin 6	Mus musculus	227-231
15915030-2	2005	Subanesthetic doses of ketamine have been shown to reduce interleukin-6 concentrations after surgery and to reduce mortality and the production of tumor necrosis factor alpha and interleukin 6 in septic animals.	Ketamine	23-31	interleukin 6	Mus musculus	58-71
15915030-2	2005	Subanesthetic doses of ketamine have been shown to reduce interleukin-6 concentrations after surgery and to reduce mortality and the production of tumor necrosis factor alpha and interleukin 6 in septic animals.	Ketamine	23-31	interleukin 6	Mus musculus	179-192
15932502-4	2005	We focused the inhibitory effect of LcS on the production of IL-6 in lipopolysaccharide (LPS)-stimulated large intestinal lamina propria mononuclear cells (LI-LPMC) isolated from mice with chronic colitis and in RAW264.7 cells in vitro.	lcs	36-39	interleukin 6	Mus musculus	61-65
15932502-6	2005	Finally, we examined the cellular determinants of LcS for the down-regulation of IL-6 secretion by LI-LPMC, RAW264.7 cells and peripheral blood mononuclear cells (PBMC) derived from patients with ulcerative colitis (UC).	li-lpmc	99-106	interleukin 6	Mus musculus	81-85
15932502-7	2005	LcS, but not other strains of Lactobacillus, inhibited the production of IL-6 in LPS-stimulated LI-LPMC and RAW264.7 cells, down-regulating the nuclear translocation of NF-kappaB.	li-lpmc	96-103	interleukin 6	Mus musculus	73-77
15932502-8	2005	The LcS-diet-improved murine chronic colitis is associated with the reduction of IL-6 synthesis by LI-LPMC.	li-lpmc	99-106	interleukin 6	Mus musculus	81-85
15932502-10	2005	The release of IL-6 in vitro in LPS-stimulated LI-LPMC, RAW 264.7 cells and UC-PBMC was inhibited by a polysaccharide-peptidoglycan complex (PSPG) derived from LcS.	li-lpmc	47-54	interleukin 6	Mus musculus	15-19
15932502-11	2005	This probiotic-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines such as IL-6 and IFN-gamma production in LPMC.	lpmc	190-194	interleukin 6	Mus musculus	157-161
15905495-2	2005	Although B7 engagement by either ligand leads to a mixed cytokine response, a dominant IL-6 production in response to CD28-Ig prevents the IFN-gamma-driven induction of immunosuppressive tryptophan catabolism mediated by IDO.	Tryptophan	187-197	interleukin 6	Mus musculus	87-91
15986771-2	2005	In this study, the effects of inflammatory mediators including prostaglandin (PG) E2, interleukin (IL)-1beta and IL-6 on Na(+)-dependent L-glutamate transport of astrocytes were analyzed using primary murine astrocytes.	Glutamic Acid	137-148	interleukin 6	Mus musculus	113-117
15986771-6	2005	IL-6 suppressed the increase of L-glutamate uptake induced by PGE2.	Glutamic Acid	32-43	interleukin 6	Mus musculus	0-4
15986771-6	2005	IL-6 suppressed the increase of L-glutamate uptake induced by PGE2.	Dinoprostone	62-66	interleukin 6	Mus musculus	0-4
15986771-8	2005	IL-6 suppressed the PGE2-induced V(max) value.	Dinoprostone	20-24	interleukin 6	Mus musculus	0-4
15986771-9	2005	These results suggest that IL-1beta, IL-6 and PGE2 modulate glutamate transport of astrocytes and play a role in the pathogenesis of neurodegenerative disorders such as ALS and AD.	Glutamic Acid	60-69	interleukin 6	Mus musculus	37-41
15910760-7	2005	The results showed that after MPTP treatment, striatal DA content was dramatically decreased, IL-1beta levels increased on day 3, while IL-6 levels increased on day 14.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	30-34	interleukin 6	Mus musculus	136-140
15910760-12	2005	These results have clearly demonstrated our hypotheses, that MPTP can induce increase of plasma IL-1beta and IL-6 levels in mice, and this effect is shaped by behavioral lateralization.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	61-65	interleukin 6	Mus musculus	109-113
15826817-8	2005	EtOH and burn, as well as the combined injury, consistently and impressively reduced serum testosterone, while increasing hypothalamic concentrations of all three of the pro-inflammatory cytokines, TNFalpha, IL-1beta, and IL-6.	Ethanol	0-4	interleukin 6	Mus musculus	222-226
15683736-4	2005	We show that (1) drug-mediated reversible G1 arrest triggered apoptosis despite the presence of IL-6; (2) a short IL-6 pulse to G1-arrested cells was sufficient to induce S phase entry and prevent apoptosis; and (3) phorbol ester and related derivatives promoted S phase entry and survival of IL-6-starved cells without up-regulating bcl-XL expression.	Phorbol Esters	216-229	interleukin 6	Mus musculus	114-118
15683736-4	2005	We show that (1) drug-mediated reversible G1 arrest triggered apoptosis despite the presence of IL-6; (2) a short IL-6 pulse to G1-arrested cells was sufficient to induce S phase entry and prevent apoptosis; and (3) phorbol ester and related derivatives promoted S phase entry and survival of IL-6-starved cells without up-regulating bcl-XL expression.	Phorbol Esters	216-229	interleukin 6	Mus musculus	114-118
15683736-5	2005	Furthermore, that the MAPK kinase (MEK) 1/2 inhibitor, U0126, blocked proliferation and induced death of B9 cells indicate that IL-6 may not exert its survival effect primarily through bcl-XL and emphasizes the key role of Ras-MAPK cascade elements in the regulation of myeloma growth/viability.	U 0126	55-60	interleukin 6	Mus musculus	128-132
15778012-2	2005	Previous studies indicate that elevated interleukin-6 (IL-6) expression is crucial for this model and that DON induction of cyclooxygenase-2 (COX-2) might drive IL-6 upregulation.	deoxynivalenol	107-110	interleukin 6	Mus musculus	161-165
15793843-7	2005	Our results show that iron is able to induce hepcidin gene expression independently of Kupffer cells in the liver and circulating IL-6.	Iron	22-26	interleukin 6	Mus musculus	130-134
15711975-8	2005	Although PTX inhibited the lipopolysaccharide-induced increase in tumor necrosis factor alpha and interleukin 6 expression (but not interleukin 1beta expression) at both mRNA and protein level in a murine macrophage cell line, tumor necrosis factor alpha mRNA expression in the livers of PTX-treated mice was not significantly inhibited.	Pentoxifylline	9-12	interleukin 6	Mus musculus	98-111
15772251-4	2005	TLR3-positive cultured mesangial cells that were exposed to synthetic polyinosinic-cytidylic acid (pI:C) RNA in vitro produced CCL2 and IL-6.	polyinosinic-cytidylic acid	70-97	interleukin 6	Mus musculus	136-140
15885468-5	2005	RESULTS: The presence of titanium particles in WT mice stimulated increased expression of interleukin-6 (IL-6) and macrophage chemoattractant protein-1 (MCP-1) relative to rod only controls.	Titanium	25-33	interleukin 6	Mus musculus	90-103
15885468-5	2005	RESULTS: The presence of titanium particles in WT mice stimulated increased expression of interleukin-6 (IL-6) and macrophage chemoattractant protein-1 (MCP-1) relative to rod only controls.	Titanium	25-33	interleukin 6	Mus musculus	105-109
15885468-6	2005	In contrast, IL-6 and MCP-1 expression were diminished in IL-1r1-KO mice exposed to titanium particles.	Titanium	84-92	interleukin 6	Mus musculus	13-17
15868610-0	2005	Methotrexate suppresses inflammatory agonist induced interleukin 6 synthesis in osteoblasts.	Methotrexate	0-12	interleukin 6	Mus musculus	53-66
15868610-3	2005	Various bone inflammatory agonists such as tumor necrosis factor-alpha (TNF-alpha), IL-1alpha, prostaglandin D2 (PGD2), PGE2, and PGF2alpha, which play important roles in the pathogenesis of RA, induce IL-6 synthesis in osteoblast-like MC3T3-E1 cells.	Dinoprost	130-139	interleukin 6	Mus musculus	202-206
15868610-5	2005	We investigated the effect of MTX on IL-6 synthesis induced by these agents in MC3T3-E1 cells.	Methotrexate	30-33	interleukin 6	Mus musculus	37-41
15868610-8	2005	RESULTS: MTX significantly suppressed IL-6 synthesis stimulated by these agonists in a dose-dependent manner, although MTX alone had no effect on the levels of IL-6.	Methotrexate	9-12	interleukin 6	Mus musculus	38-42
15868610-9	2005	In addition, MTX significantly inhibited the enhancement by IL-17 of TNF-alpha-stimulated IL-6 synthesis.	Methotrexate	13-16	interleukin 6	Mus musculus	90-94
15868610-10	2005	MTX reduced the levels of IL-6 induced by 12-O-tetradecanoylphorbol 13-acetate, a direct activator of protein kinase C (PKC), suggesting that MTX inhibits PKC signals for IL-6 synthesis.	Methotrexate	0-3	interleukin 6	Mus musculus	26-30
15868610-10	2005	MTX reduced the levels of IL-6 induced by 12-O-tetradecanoylphorbol 13-acetate, a direct activator of protein kinase C (PKC), suggesting that MTX inhibits PKC signals for IL-6 synthesis.	Methotrexate	0-3	interleukin 6	Mus musculus	171-175
15868610-10	2005	MTX reduced the levels of IL-6 induced by 12-O-tetradecanoylphorbol 13-acetate, a direct activator of protein kinase C (PKC), suggesting that MTX inhibits PKC signals for IL-6 synthesis.	Tetradecanoylphorbol Acetate	42-78	interleukin 6	Mus musculus	26-30
15868610-10	2005	MTX reduced the levels of IL-6 induced by 12-O-tetradecanoylphorbol 13-acetate, a direct activator of protein kinase C (PKC), suggesting that MTX inhibits PKC signals for IL-6 synthesis.	Tetradecanoylphorbol Acetate	42-78	interleukin 6	Mus musculus	171-175
15868610-10	2005	MTX reduced the levels of IL-6 induced by 12-O-tetradecanoylphorbol 13-acetate, a direct activator of protein kinase C (PKC), suggesting that MTX inhibits PKC signals for IL-6 synthesis.	Methotrexate	142-145	interleukin 6	Mus musculus	26-30
15868610-10	2005	MTX reduced the levels of IL-6 induced by 12-O-tetradecanoylphorbol 13-acetate, a direct activator of protein kinase C (PKC), suggesting that MTX inhibits PKC signals for IL-6 synthesis.	Methotrexate	142-145	interleukin 6	Mus musculus	171-175
15868610-11	2005	CONCLUSION: MTX suppresses IL-6 synthesis stimulated by various inflammatory agonists in osteoblasts.	Methotrexate	12-15	interleukin 6	Mus musculus	27-31
15855927-4	2005	METHODS: Liposome-encapsulated dichloromethylene-diphosphonate, a macrophage-depleting agent, was used before direct pancreatic injection of a recombinant adenovirus expressing a marker gene in C57Bl/6 and IL-6 knockout (KO) mice.	Clodronic Acid	31-62	interleukin 6	Mus musculus	206-210
15862160-0	2005	[Kinetic changes of plasma IL-1 and IL-6 levels in MPTP-induced Parkinson"s disease model mice and their relationship with brain asymmetry].	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	51-55	interleukin 6	Mus musculus	36-40
15862160-7	2005	RESULTS: Plasma IL-6 level in normal control mice was low, but elevated dramatically at 14 days after last time injection of MPTP in PD model mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	125-129	interleukin 6	Mus musculus	16-20
15862160-10	2005	CONCLUSION: IL-6 and IL-1 probably participate in the occurrence and progress of MPTP-induced PD in model mice, and were related with brain asymmetry.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	81-85	interleukin 6	Mus musculus	12-16
15804595-2	2005	The absence of interleukin-6 (IL-6) results in increased vulnerability of dopaminergic neurons to the neurotoxicant, MPTP, and a compromised reactive microgliosis.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	117-121	interleukin 6	Mus musculus	15-28
15804595-2	2005	The absence of interleukin-6 (IL-6) results in increased vulnerability of dopaminergic neurons to the neurotoxicant, MPTP, and a compromised reactive microgliosis.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	117-121	interleukin 6	Mus musculus	30-34
15878720-7	2005	The increased interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha in diabetic mice were significantly suppressed by the intake of histidine or carnosine (P &lt; 0.05).	Histidine	135-144	interleukin 6	Mus musculus	14-32
15843034-0	2005	S-adenosylmethionine (SAMe) modulates interleukin-10 and interleukin-6, but not TNF, production via the adenosine (A2) receptor.	S-Adenosylmethionine	0-20	interleukin 6	Mus musculus	57-70
15843034-7	2005	Importantly, SAMe increased intracellular adenosine levels, and exogenous adenosine supplementation had effects similar to SAMe on TNF, IL-10 and IL-6 production.	Adenosine	74-83	interleukin 6	Mus musculus	146-150
15843034-8	2005	3-Deaza-adenosine (DZA), a specific inhibitor of S-adenosylhomocysteine (SAH) hydrolase, blocked the elevation of IL-10 and IL-6 production induced by SAMe, which was rescued by the addition of exogenous adenosine.	3-deazaadenosine	0-17	interleukin 6	Mus musculus	124-128
15843034-8	2005	3-Deaza-adenosine (DZA), a specific inhibitor of S-adenosylhomocysteine (SAH) hydrolase, blocked the elevation of IL-10 and IL-6 production induced by SAMe, which was rescued by the addition of exogenous adenosine.	3-deazaadenosine	19-22	interleukin 6	Mus musculus	124-128
15843034-8	2005	3-Deaza-adenosine (DZA), a specific inhibitor of S-adenosylhomocysteine (SAH) hydrolase, blocked the elevation of IL-10 and IL-6 production induced by SAMe, which was rescued by the addition of exogenous adenosine.	Adenosine	8-17	interleukin 6	Mus musculus	124-128
15843034-9	2005	Furthermore, the enhancement of LPS-stimulated IL-10 and IL-6 production by both SAMe and adenosine was inhibited by ZM241385, a specific antagonist of the adenosine (A(2)) receptor.	Adenosine	90-99	interleukin 6	Mus musculus	57-61
15843034-9	2005	Furthermore, the enhancement of LPS-stimulated IL-10 and IL-6 production by both SAMe and adenosine was inhibited by ZM241385, a specific antagonist of the adenosine (A(2)) receptor.	ZM 241385	117-125	interleukin 6	Mus musculus	57-61
15843034-10	2005	Our results suggest that increased adenosine levels with subsequent binding to the A(2) receptor account, at least in part, for SAMe modulation of IL-10 and IL-6, but not TNF production, from LPS stimulated monocytes.	Adenosine	35-44	interleukin 6	Mus musculus	157-161
15814731-9	2005	Trehalose dimycolate, when delivered to bone marrow-derived murine macrophages, induced the greatest secretion of IL-1beta, IL-6, and TNF-alpha in vitro.	Cord Factors	0-20	interleukin 6	Mus musculus	124-128
15814801-4	2005	Both SDM and cMMP-3 induced generation of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, and interleukin-1 receptor antagonist but not IL-12 and inducible nitric oxide synthase, which are readily induced by lipopolysaccharide, in microglia, suggesting that there is a characteristic pattern of microglial cytokine induction by apoptotic neurons.	SDM	5-8	interleukin 6	Mus musculus	83-96
15814801-4	2005	Both SDM and cMMP-3 induced generation of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, and interleukin-1 receptor antagonist but not IL-12 and inducible nitric oxide synthase, which are readily induced by lipopolysaccharide, in microglia, suggesting that there is a characteristic pattern of microglial cytokine induction by apoptotic neurons.	SDM	5-8	interleukin 6	Mus musculus	98-102
15814801-4	2005	Both SDM and cMMP-3 induced generation of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, and interleukin-1 receptor antagonist but not IL-12 and inducible nitric oxide synthase, which are readily induced by lipopolysaccharide, in microglia, suggesting that there is a characteristic pattern of microglial cytokine induction by apoptotic neurons.	cmmp-3	13-19	interleukin 6	Mus musculus	83-96
15814801-4	2005	Both SDM and cMMP-3 induced generation of tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, and interleukin-1 receptor antagonist but not IL-12 and inducible nitric oxide synthase, which are readily induced by lipopolysaccharide, in microglia, suggesting that there is a characteristic pattern of microglial cytokine induction by apoptotic neurons.	cmmp-3	13-19	interleukin 6	Mus musculus	98-102
15761213-8	2005	Albumin and PMN content in LPS-injured lungs were reduced to levels found in female mice after administration of estradiol in OVX mice and corresponded to reduced IL-1beta, IL-6, and ICAM-1 levels.	Estradiol	113-122	interleukin 6	Mus musculus	173-177
15818094-11	2005	CONCLUSIONS: These findings suggest that nitric oxide produced by iNOS during endotoxemia may be involved in down-regulation of Th1 cytokines and up-regulation of Th2 cytokines, whereas IL-6 has no such role.	Nitric Oxide	41-53	interleukin 6	Mus musculus	186-190
15825075-7	2005	Treatment of CR gamma -/Y mice with anti-IL-6 receptor monoclonal antibody prevented the formation of colitis via the induction of apoptosis in IL-6-producing CD4 + T cells.	Chromium	13-15	interleukin 6	Mus musculus	41-45
15825075-7	2005	Treatment of CR gamma -/Y mice with anti-IL-6 receptor monoclonal antibody prevented the formation of colitis via the induction of apoptosis in IL-6-producing CD4 + T cells.	Chromium	13-15	interleukin 6	Mus musculus	144-148
15811707-4	2005	When the cultures were incubated with both TNF-alpha and Dex, the levels of KC, MCP-1, MIP-2 and IL-6 were significantly lower than those in cultures treated with TNF-alpha alone.	Dexamethasone	57-60	interleukin 6	Mus musculus	97-101
15710333-6	2005	Ingestion of melanin by mice for four days increases production ex vivo of interferon-gamma by spleen cells and IgA and interleukin-6 by Peyer"s patch cells.	Melanins	13-20	interleukin 6	Mus musculus	120-133
15746247-1	2005	Inhibitory oligonucleotides (IN-ODN) differing from stimulatory CpG ODN (ST-ODN) by as few as two bases can block ST-ODN-induced proliferation, apoptosis protection and IL-6 secretion in B lymphocytes and the production of IL-12p40 by non-B cells.	Oligonucleotides	11-27	interleukin 6	Mus musculus	169-173
15841170-3	2005	A study in this issue of the JCI demonstrates that IL-6 exerts its protective effect against the development of lung injury following exposure of mice to 95% O(2) by increasing the expression of a Bcl-2-related protein, A1.	o(2)	158-162	interleukin 6	Mus musculus	51-55
15763341-5	2005	IL-6-/- mice were treated with an MMP-2 inhibitor and assessment of injury (histology and serum ALT levels), apoptosis by TUNEL assay, and hepatocyte proliferation by BRDU-labeling was performed.	Bromodeoxyuridine	167-171	interleukin 6	Mus musculus	0-4
15778342-6	2005	In addition, ATP stimulation enhanced the expression of several proinflammatory cytokines, such as IL-4, IL-6, IL-13, and TNF-alpha.	Adenosine Triphosphate	13-16	interleukin 6	Mus musculus	105-109
15748950-3	2005	The results show that TZDs and 15d-PGJ(2) are effective in inhibiting production of nitric oxide, the pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6, and the chemokine MCP-1 from microglia and astrocytes.	Thiazolidinediones	22-26	interleukin 6	Mus musculus	154-158
15748950-3	2005	The results show that TZDs and 15d-PGJ(2) are effective in inhibiting production of nitric oxide, the pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6, and the chemokine MCP-1 from microglia and astrocytes.	15d-pgj	31-38	interleukin 6	Mus musculus	154-158
15811520-3	2005	The present study has examined whether administration of L-carnitine to young female mice alters the percentage of immune cells in peritoneal exudates and the uterus as well as the levels of IFN-gamma, TNF-alpha, IL-2, IL-4, IL-6, VEGF, GM-CSF and IGF-I in blood serum, peritoneal fluid and supernatants of uterine cultured cells as tested by immunofluorescence or ELISA techniques, respectively, leading to a pathological disorder resembling human endometriosis.	Carnitine	57-68	interleukin 6	Mus musculus	225-229
15627848-7	2005	Raxofelast, an analog of vitamin E, blunted the increased hepatic nuclear factor-kappaB activity, reduced serum ALT, plasma and liver triglycerides, lowered hepatic MDA levels, prevented liver GSH depletion and decreased TLR-4, TNF-alpha, IL-6 and ICAM-1 hepatic gene expression.	Raxofelast	0-10	interleukin 6	Mus musculus	239-243
15627848-7	2005	Raxofelast, an analog of vitamin E, blunted the increased hepatic nuclear factor-kappaB activity, reduced serum ALT, plasma and liver triglycerides, lowered hepatic MDA levels, prevented liver GSH depletion and decreased TLR-4, TNF-alpha, IL-6 and ICAM-1 hepatic gene expression.	Vitamin E	25-34	interleukin 6	Mus musculus	239-243
15781289-6	2005	Plasma concentrations of cytokines such as IL-6 and TNFalpha were elevated by 4 h; IL-6 levels were 24 times higher after Fe-NTA than that after injection of FeCl(3).	ferric nitrilotriacetate	122-128	interleukin 6	Mus musculus	83-87
15781290-10	2005	There was a positive correlation between the hepatic arsenic level and collagen content (r = 0.8007), LPx (r = 0.779) and IL-6 (r = 0.7801).	Arsenic	53-60	interleukin 6	Mus musculus	122-126
15781291-13	2005	Meanwhile, cotreatment with ketamine and lipopolysaccharide significantly inhibited lipopolysaccharide-induced TNF-alpha, IL-1beta, and IL-6 mRNA levels.	Ketamine	28-36	interleukin 6	Mus musculus	136-140
15647289-10	2005	Ser412 --&gt; Ala TAK1 also inhibited the forskolin-induced up-regulation of interleukin 6 production in RAW264.7 cells treated with lipopolysaccharide.	Alanine	14-17	interleukin 6	Mus musculus	77-90
15647289-10	2005	Ser412 --&gt; Ala TAK1 also inhibited the forskolin-induced up-regulation of interleukin 6 production in RAW264.7 cells treated with lipopolysaccharide.	Colforsin	42-51	interleukin 6	Mus musculus	77-90
15649620-6	2005	In UA-exposed RAW 264.7 cell cultures, TNF-alpha and IL-6 production and TNF-alpha and IL-6 mRNA levels increased.	ursolic acid	3-5	interleukin 6	Mus musculus	53-57
15649620-6	2005	In UA-exposed RAW 264.7 cell cultures, TNF-alpha and IL-6 production and TNF-alpha and IL-6 mRNA levels increased.	ursolic acid	3-5	interleukin 6	Mus musculus	87-91
15649620-7	2005	When antibodies to TNF-alpha or/and IL-6 were added to UA-treated conditioned media from RAW 264.7, the MT induction activity was inhibited.	ursolic acid	55-57	interleukin 6	Mus musculus	36-40
15649620-8	2005	These results demonstrate that UA induces hepatic MT expression through TNF-alpha and IL-6 released from UA-activated macrophages, which may be the mechanism, whereby UA elicits its biological effects.	ursolic acid	31-33	interleukin 6	Mus musculus	86-90
15649620-8	2005	These results demonstrate that UA induces hepatic MT expression through TNF-alpha and IL-6 released from UA-activated macrophages, which may be the mechanism, whereby UA elicits its biological effects.	ursolic acid	105-107	interleukin 6	Mus musculus	86-90
15649620-8	2005	These results demonstrate that UA induces hepatic MT expression through TNF-alpha and IL-6 released from UA-activated macrophages, which may be the mechanism, whereby UA elicits its biological effects.	ursolic acid	105-107	interleukin 6	Mus musculus	86-90
15749902-8	2005	Concentrations of potent neutrophil chemokines (MIP-2, KC) and cytokines (IL-6, IL-1beta) were significantly lower in wild-type compared with phenazine-deficient strain-infected mice at 18 h. We conclude that pyocyanin production by P. aeruginosa suppresses the acute inflammatory response by pathogen-driven acceleration of neutrophil apoptosis and by reducing local inflammation, and that this is advantageous for bacterial survival.	phenazine	142-151	interleukin 6	Mus musculus	74-78
15812227-4	2005	It also reduced PPE-induced elevated levels of tumor necrosis factor alpha, interleukin (IL)-6, and keratinocyte-derived chemokine, and increased the level of anti-inflammatory cytokine IL-10 in BALF.	ppe	16-19	interleukin 6	Mus musculus	76-94
15731053-5	2005	FKS were added to elicited mouse peritoneal macrophages from wild-type, TLR2-/-, and MyD88-/- cells, and wild-type cells made more tumor necrosis factor alpha, MIP-2, and interleukin 6 than did the mutant macrophages.	7-[(3-Aminopropyl)amino]-1,1,1-Trifluoroheptane-2,2-Diol	0-3	interleukin 6	Mus musculus	171-184
15572648-10	2005	IL-6(-/-) mice demonstrated reduced histological evidence of tubular injury and markedly reduced immunohistochemical evidence of ICAM-1, P-selectin, and nitrotyrosine when subjected to renal I/R.	3-nitrotyrosine	153-166	interleukin 6	Mus musculus	0-4
15734480-10	2005	Similarly, serum IL-6 increased over 1-3 h after SHWI and then decreased over the next 6 h. Treatment with an anti-HMGB-1 antibody significantly prolonged survival time in SHWI and THIRI.	thiri	181-186	interleukin 6	Mus musculus	17-21
15794588-3	2005	DES, BPA, EHP and NP stimulated thioglycolate-induced peritoneal exudate cells (macrophages) to produce cytokines such as interleukin (IL)-1, IL-6, IL-12, tumor necrosis factor and macrophage chemotactic protein- 1.	Thioglycolates	32-45	interleukin 6	Mus musculus	142-146
15838484-9	2005	PDTC-treated mice also exhibited significantly lower serum and aortic wall concentrations of interleukin 1beta and interleukin 6, as well as lower amounts of aortic wall MMP-9, as compared with saline-treated controls.	pyrrolidine dithiocarbamic acid	0-4	interleukin 6	Mus musculus	115-128
15718919-3	2005	Glucan phosphate treatment attenuated burn-induced expression of interleukin (IL)-1beta, IL-6, and IL-10 mRNAs in spleen, lung, and heart.	glucan phosphate	0-16	interleukin 6	Mus musculus	89-93
15718919-4	2005	Plasma concentrations of IL-1beta, IL-6, macrophage inflammatory protein (MIP)-2, and IL-10 were also decreased in burned mice treated with glucan phosphate compared with vehicle-treated controls.	glucan phosphate	140-156	interleukin 6	Mus musculus	35-39
15649404-4	2005	This PKCepsilon-induced IL-6 expression could be completely inhibited by U0126, an inhibitor of mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase.	U 0126	73-78	interleukin 6	Mus musculus	24-28
15626481-4	2005	The result showed that sesamin significantly inhibited LPS-stimulated IL-6 mRNA and protein, and to a lesser degree TNF-alpha, in BV-2 microglia.	sesamin	23-30	interleukin 6	Mus musculus	70-74
15626481-6	2005	Furthermore, SB203580, a specific inhibitor of p38 MAP kinase, specifically inhibited LPS-induced IL-6 production.	SB 203580	13-21	interleukin 6	Mus musculus	98-102
15626481-7	2005	These results suggest that sesamin inhibited LPS-induced IL-6 production by suppression of p38 MAPK signal pathway and NF-kappaB activation.	sesamin	27-34	interleukin 6	Mus musculus	57-61
15475383-0	2005	Protective effect of IL-6 on alveolar epithelial cell death induced by hydrogen peroxide.	Hydrogen Peroxide	71-88	interleukin 6	Mus musculus	21-25
15475383-1	2005	The goal of this study was to examine whether IL-6 could directly protect lung resident cells, especially alveolar epithelial cells, from reactive oxygen species (ROS)-induced cell death.	Reactive Oxygen Species	138-161	interleukin 6	Mus musculus	46-50
15475383-1	2005	The goal of this study was to examine whether IL-6 could directly protect lung resident cells, especially alveolar epithelial cells, from reactive oxygen species (ROS)-induced cell death.	Reactive Oxygen Species	163-166	interleukin 6	Mus musculus	46-50
15475383-2	2005	ROS induced IL-6 gene expression in organotypic lung slices of wild-type (WT) mice.	Reactive Oxygen Species	0-3	interleukin 6	Mus musculus	12-16
15475383-3	2005	ROS also induced IL-6 gene expression in mouse primary lung fibroblasts, dose dependently.	Reactive Oxygen Species	0-3	interleukin 6	Mus musculus	17-21
15475383-5	2005	WT resistance against ROS was abrogated by treatment with anti-IL-6 antibody.	Reactive Oxygen Species	22-25	interleukin 6	Mus musculus	63-67
15475383-7	2005	In vitro studies demonstrated that IL-6 reduced ROS-induced A549 alveolar epithelial cell death.	Reactive Oxygen Species	48-51	interleukin 6	Mus musculus	35-39
15475383-8	2005	Together, these data suggest that IL-6 played an antioxidant role in the lung by protecting lung resident cells, especially alveolar epithelial cells, from ROS-induced cell death.	Reactive Oxygen Species	156-159	interleukin 6	Mus musculus	34-38
15516495-2	2005	Subacute (72 h) exposure to 0.3 ppm O(3) significantly elevated bronchoalveolar lavage fluid (BALF) protein, neutrophils, and soluble TNF receptors (sTNFR1 and sTNFR2) in wild-type C57BL/6 (IL-6(+/+)) mice; however, all four outcome indicators were significantly reduced in IL-6-deficient (IL-6(-/-)) compared with IL-6(+/+) mice.	Ozone	36-40	interleukin 6	Mus musculus	190-194
15516495-2	2005	Subacute (72 h) exposure to 0.3 ppm O(3) significantly elevated bronchoalveolar lavage fluid (BALF) protein, neutrophils, and soluble TNF receptors (sTNFR1 and sTNFR2) in wild-type C57BL/6 (IL-6(+/+)) mice; however, all four outcome indicators were significantly reduced in IL-6-deficient (IL-6(-/-)) compared with IL-6(+/+) mice.	Ozone	36-40	interleukin 6	Mus musculus	274-278
15516495-2	2005	Subacute (72 h) exposure to 0.3 ppm O(3) significantly elevated bronchoalveolar lavage fluid (BALF) protein, neutrophils, and soluble TNF receptors (sTNFR1 and sTNFR2) in wild-type C57BL/6 (IL-6(+/+)) mice; however, all four outcome indicators were significantly reduced in IL-6-deficient (IL-6(-/-)) compared with IL-6(+/+) mice.	Ozone	36-40	interleukin 6	Mus musculus	274-278
15516495-2	2005	Subacute (72 h) exposure to 0.3 ppm O(3) significantly elevated bronchoalveolar lavage fluid (BALF) protein, neutrophils, and soluble TNF receptors (sTNFR1 and sTNFR2) in wild-type C57BL/6 (IL-6(+/+)) mice; however, all four outcome indicators were significantly reduced in IL-6-deficient (IL-6(-/-)) compared with IL-6(+/+) mice.	Ozone	36-40	interleukin 6	Mus musculus	274-278
15516495-3	2005	Acute O(3) exposure (2 ppm for 3 h) increased BALF protein, KC, macrophage inflammatory protein(MIP)-2, eotaxin, sTNFR1, and sTNFR2 in IL-6(+/+) mice.	Ozone	6-10	interleukin 6	Mus musculus	135-139
15516495-5	2005	Increases in BALF neutrophils induced by O(3) (2 ppm for 3 h) were also significantly reduced in IL-6(-/-) vs. IL-6(+/+) mice.	Ozone	41-45	interleukin 6	Mus musculus	97-101
15516495-5	2005	Increases in BALF neutrophils induced by O(3) (2 ppm for 3 h) were also significantly reduced in IL-6(-/-) vs. IL-6(+/+) mice.	Ozone	41-45	interleukin 6	Mus musculus	111-115
15789752-4	2005	Moreover, scoparone also attenuated the production of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-6 in LPS-stimulated RAW264.7 cells.	scoparone	10-19	interleukin 6	Mus musculus	116-120
15652231-8	2005	Further, DSS-induced increases in colonic mucosal IL-1 beta levels were blunted significantly in rutin-, but not quercetin-, fed mice (P&lt;0.01), while dietary rutin attenuated the expressions of IL-1 beta and IL-6 mRNA in colonic mucosa (each, P&lt;0.01).	Dextran Sulfate	9-12	interleukin 6	Mus musculus	211-215
15684475-4	2005	GMGHT exerted an anti-inflammatory action through inhibiting lipopolysaccaride (LPS)-induced tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 production in mouse peritoneal macrophages.	lipopolysaccaride	61-78	interleukin 6	Mus musculus	131-149
15681167-5	2005	Deoxynivalenol was found to readily induce expression of cytokines (IL-1alpha, IL-1beta, and IL-6 and IL-11), chemokines (MCP-1, MCP-3, CINC-1 and MIP-2), components of the activator protein-1 (AP-1) transcription factor complex (c-Fos, Fra-2, c-Jun and JunB), as well as two hydrolases (MKP1, CnAbeta).	deoxynivalenol	0-14	interleukin 6	Mus musculus	93-97
15681167-6	2005	Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression.	Fatty Acids, Unsaturated	158-162	interleukin 6	Mus musculus	237-241
15681167-6	2005	Expression of these genes was transient, peaking within 2-4 h and declining thereafter, with the single exception being IL-11 that was elevated at 8 h. (n-3)-PUFA consumption significantly suppressed DON-induced expression of IL-1alpha, IL-6, IL-11, MCP-1, MCP-3, MIP-2 and Fra-2 at 8 h. In contrast, mice fed (n-3)-PUFA exhibited significant increases in MKP1 and CnAbeta expression.	deoxynivalenol	200-203	interleukin 6	Mus musculus	237-241
15456840-11	2005	In addition, endotoxin and IL-6 were also able to suppress PCN-mediated induction of bsep, mrp2, cyp3a11, and PXR.	PREGNENOLONE CARBONITRILE	59-62	interleukin 6	Mus musculus	27-31
15694241-3	2005	Therefore, we here characterized the effects of IL-6 on GSH in clonal hippocampal HT22 cells and in rat neuronal primary hippocampal cells.	Glutathione	56-59	interleukin 6	Mus musculus	48-52
15694241-4	2005	Our results demonstrate significant increases of GSH under most conditions after treatment with IL-6 in a time range of 1 to 48 h (HT22 cells) and 1 to 72 h (primary rat neuronal hippocampal cells).	Glutathione	49-52	interleukin 6	Mus musculus	96-100
15626366-4	2005	As a control, PTX pretreatment was effective at abrogating lethality and serum TNF-alpha increments in mice subjected to endotoxemia induced by injection of Escherichia coli lipopolysaccharide, although it did not affect the increment in IL-1beta and IL-6 in such endotoxic model.	Pentoxifylline	14-17	interleukin 6	Mus musculus	251-255
15627475-9	2005	Real-time RT-PCR analysis revealed that DM administration suppressed the expression of a variety of inflammation-related genes such as macrophage inflammatory protein-2, CXC chemokine, thrombospondin-1, intercellular adhesion molecular-1 and interleukin-6.	Dextromethorphan	40-42	interleukin 6	Mus musculus	242-255
15865214-6	2005	RESULTS: Nelfinavir, ritonavir and saquinavir inhibited adipogenesis and up-regulated the expression of TNF-alpha and IL-6, but this effect was not seen with indinavir, zidovudine and stavudine.	Nelfinavir	9-19	interleukin 6	Mus musculus	118-122
15865214-6	2005	RESULTS: Nelfinavir, ritonavir and saquinavir inhibited adipogenesis and up-regulated the expression of TNF-alpha and IL-6, but this effect was not seen with indinavir, zidovudine and stavudine.	Ritonavir	21-30	interleukin 6	Mus musculus	118-122
15865214-6	2005	RESULTS: Nelfinavir, ritonavir and saquinavir inhibited adipogenesis and up-regulated the expression of TNF-alpha and IL-6, but this effect was not seen with indinavir, zidovudine and stavudine.	Saquinavir	35-45	interleukin 6	Mus musculus	118-122
15865214-8	2005	Co-incubation with rosiglitazone led to a partial attenuation of the change in TNF-alpha, IL-6 and adiponectin secretion.	Rosiglitazone	19-32	interleukin 6	Mus musculus	90-94
15865214-9	2005	CONCLUSIONS: Our data suggest that the PIs nelfinavir, ritonavir and saquinavir have potent effects in inhibiting adipocyte differentiation whilst up-regulating TNF-alpha and IL-6 mRNA levels and decreasing adiponectin levels.	Nelfinavir	43-53	interleukin 6	Mus musculus	175-179
15865214-9	2005	CONCLUSIONS: Our data suggest that the PIs nelfinavir, ritonavir and saquinavir have potent effects in inhibiting adipocyte differentiation whilst up-regulating TNF-alpha and IL-6 mRNA levels and decreasing adiponectin levels.	Ritonavir	55-64	interleukin 6	Mus musculus	175-179
15865214-9	2005	CONCLUSIONS: Our data suggest that the PIs nelfinavir, ritonavir and saquinavir have potent effects in inhibiting adipocyte differentiation whilst up-regulating TNF-alpha and IL-6 mRNA levels and decreasing adiponectin levels.	Saquinavir	69-79	interleukin 6	Mus musculus	175-179
16277688-8	2005	In RA FLS stimulated with tumor necrosis factor-alpha, activities of NF-kappaB components p65 and p50 were inhibited by DHMEQ, leading to suppressed expression of the key inflammatory cytokine IL-6, CC chemokine ligand-2 and -5, matrix metalloproteinase-3, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1.	dehydroxymethylepoxyquinomicin	120-125	interleukin 6	Mus musculus	193-197
15388650-8	2005	Recombinant MIF did not affect the basal release of IL-6 from TtT/GF cells; however, it effectively reversed the inhibitory effects of dexamethasone (1 nM) on the endotoxin-induced release of IL-6 from these cells.	Dexamethasone	135-148	interleukin 6	Mus musculus	192-196
16393471-11	2006	In addition, chloroform and ethyl acetate fractions significantly blocked the expression of inducible nitric oxide synthetase (iNOS) and interleukin-6 (IL-6) from the RAW264.7 cells stimulated by LPS.	Chloroform	13-23	interleukin 6	Mus musculus	137-150
16393471-11	2006	In addition, chloroform and ethyl acetate fractions significantly blocked the expression of inducible nitric oxide synthetase (iNOS) and interleukin-6 (IL-6) from the RAW264.7 cells stimulated by LPS.	Chloroform	13-23	interleukin 6	Mus musculus	152-156
16393471-11	2006	In addition, chloroform and ethyl acetate fractions significantly blocked the expression of inducible nitric oxide synthetase (iNOS) and interleukin-6 (IL-6) from the RAW264.7 cells stimulated by LPS.	ethyl acetate	28-41	interleukin 6	Mus musculus	137-150
16393471-11	2006	In addition, chloroform and ethyl acetate fractions significantly blocked the expression of inducible nitric oxide synthetase (iNOS) and interleukin-6 (IL-6) from the RAW264.7 cells stimulated by LPS.	ethyl acetate	28-41	interleukin 6	Mus musculus	152-156
16419968-6	2006	Alumina particles were only able to stimulate the release of IL-6 by J744 cells when cells were cocultured with osteoblasts.	Aluminum Oxide	0-7	interleukin 6	Mus musculus	61-65
16419968-7	2006	On the other hand, incubation of osteoblasts with alumina particles enhanced the release of IL-6 and GM-CSF.	Aluminum Oxide	50-57	interleukin 6	Mus musculus	92-96
15803865-11	2005	Mercury did not affect LPS-induced interleukin (IL)-1beta expression but decreased LPS-induced IL-6 expression.	Mercury	0-7	interleukin 6	Mus musculus	95-99
15803865-13	2005	Mercury modulates LPS-induced p38 and ERK activation and downstream TNFalpha and IL-6 expression in mouse liver.	Mercury	0-7	interleukin 6	Mus musculus	81-85
15558059-0	2005	Small proline-rich proteins 2 are noncoordinately upregulated by IL-6/STAT3 signaling after bile duct ligation.	Proline	6-13	interleukin 6	Mus musculus	65-69
15496451-6	2005	It is intriguing that another inhibitor of endosomal acidification, bafilomycin A, stimulated the production of TNF-alpha mRNA and its protein after removal of the pDNA/liposome complex and inhibitors, although it inhibited the release of interleukin-6.	bafilomycin A	68-81	interleukin 6	Mus musculus	239-252
15589045-4	2005	ES inhibited IL-6 secretion when animals were sacrificed at 03:00 and 06:00 (both p&lt;0.001) but it increased its secretion from spleen slice removed at 09:00 (p=0.026).	Einsteinium	0-2	interleukin 6	Mus musculus	13-17
15589045-7	2005	This study demonstrates that cooperation of endogenous NE and corticosterone are involved in a time-dependent fall or rise of splenic IL-6 secretion.	Corticosterone	62-76	interleukin 6	Mus musculus	134-138
15804043-8	2005	The cellular phosphotyrosine level in alpha-toxin-treated macrophages was reduced in cultures supplemented with recombinant IL-6 in vitro.	Phosphotyrosine	13-28	interleukin 6	Mus musculus	124-128
15611271-4	2005	Specifically, the study focused on the proinflammatory cytokines IL-6 and TNF-alpha and activation of p38 and ERK1/2 MAPKs after a single in vivo exposure to physiologically relevant level of ethanol followed by ex vivo stimulation with specific TLR ligands.	Ethanol	192-199	interleukin 6	Mus musculus	65-69
15611271-5	2005	Acute ethanol treatment inhibited IL-6 and TNF-alpha synthesis and impaired p38 and ERK1/2 activation induced by TLR2, TLR4, and TLR9 ligands.	Ethanol	6-13	interleukin 6	Mus musculus	34-38
15611271-10	2005	In conclusion, acute ethanol exposure impaired macrophage responsiveness to multiple TLR agonists by inhibiting IL-6 and TNF-alpha production.	Ethanol	21-28	interleukin 6	Mus musculus	112-116
15589033-8	2005	The results showed that MPTP treatment induced dramatic loss of DA in striatum, simultaneously, IL-6 levels decreased in the striatum and increased in hippocampus and hypothalamus, while IL-1beta levels decreased in the striatum, cerebral cortex and hippocampus.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	24-28	interleukin 6	Mus musculus	96-100
15589045-0	2005	Norepinephrine in mice inhibits secretion of splenic IL-6 during the dark period but stimulates its secretion in the light period--possible role of the corticosterone tone.	Norepinephrine	0-14	interleukin 6	Mus musculus	53-57
15567193-6	2004	Analysis of IL-1beta, IL-6, TNF-alpha, IL-12 and iNOS mRNA expression in liver samples taken at 90 min post-LPS showed a marked reduction of the two latter mRNAs in BZL-treated mice.	benzonidazole	165-168	interleukin 6	Mus musculus	22-26
15722603-8	2005	We also found the cytokine response against CADS, levels of inflammatory cytokines interleukin-1 beta, tumor necrosis factor-alpha, and interleukin-6 in sera increased within 24 hr after CADS injection.	cads	187-191	interleukin 6	Mus musculus	136-149
15795517-0	2005	All-trans-retinoic acid inhibits the development of mesangial proliferative glomerulonephritis in interleukin-6 transgenic mice.	Tretinoin	0-23	interleukin 6	Mus musculus	98-111
15795517-1	2005	All-trans-retinoic acid (ATRA), a vitamin A derivative, was reported to suppress the interleukin-6 (IL-6) production and to downregulate the IL-6 receptor (IL-6R) and/or its signal transducer glycoprotein 130.	Tretinoin	0-23	interleukin 6	Mus musculus	85-98
15795517-1	2005	All-trans-retinoic acid (ATRA), a vitamin A derivative, was reported to suppress the interleukin-6 (IL-6) production and to downregulate the IL-6 receptor (IL-6R) and/or its signal transducer glycoprotein 130.	Tretinoin	0-23	interleukin 6	Mus musculus	100-104
15795517-1	2005	All-trans-retinoic acid (ATRA), a vitamin A derivative, was reported to suppress the interleukin-6 (IL-6) production and to downregulate the IL-6 receptor (IL-6R) and/or its signal transducer glycoprotein 130.	Tretinoin	25-29	interleukin 6	Mus musculus	85-98
15795517-1	2005	All-trans-retinoic acid (ATRA), a vitamin A derivative, was reported to suppress the interleukin-6 (IL-6) production and to downregulate the IL-6 receptor (IL-6R) and/or its signal transducer glycoprotein 130.	Tretinoin	25-29	interleukin 6	Mus musculus	100-104
15795517-1	2005	All-trans-retinoic acid (ATRA), a vitamin A derivative, was reported to suppress the interleukin-6 (IL-6) production and to downregulate the IL-6 receptor (IL-6R) and/or its signal transducer glycoprotein 130.	Vitamin A	34-43	interleukin 6	Mus musculus	85-98
15795517-1	2005	All-trans-retinoic acid (ATRA), a vitamin A derivative, was reported to suppress the interleukin-6 (IL-6) production and to downregulate the IL-6 receptor (IL-6R) and/or its signal transducer glycoprotein 130.	Vitamin A	34-43	interleukin 6	Mus musculus	100-104
15795517-2	2005	We investigated the in vivo antinephritic effect of ATRA on IL-6 transgenic mice which had developed mesangial proliferative glomerulonephritis (PGN) as well as its in vitro inhibitory effect on the proliferation of rat mesangial cells.	Tretinoin	52-56	interleukin 6	Mus musculus	60-64
15795517-3	2005	In vivo experiments on IL-6 transgenic mice showed that ATRA administration suppressed proteinuria and hematuria and reduced the IL-6 concentrations; furthermore, histological examination demonstrated that it improved PGN.	Tretinoin	56-60	interleukin 6	Mus musculus	23-27
15795517-3	2005	In vivo experiments on IL-6 transgenic mice showed that ATRA administration suppressed proteinuria and hematuria and reduced the IL-6 concentrations; furthermore, histological examination demonstrated that it improved PGN.	Tretinoin	56-60	interleukin 6	Mus musculus	129-133
15795517-4	2005	In vitro experiments using rat mesangial cells demonstrated that ATRA inhibited cell growth in a dose-dependent manner within a range from 10(-4) to 10(-6) M. This inhibition by ATRA was partially counteracted by the addition of IL-6.	Tretinoin	65-69	interleukin 6	Mus musculus	229-233
15795517-4	2005	In vitro experiments using rat mesangial cells demonstrated that ATRA inhibited cell growth in a dose-dependent manner within a range from 10(-4) to 10(-6) M. This inhibition by ATRA was partially counteracted by the addition of IL-6.	Tretinoin	178-182	interleukin 6	Mus musculus	229-233
15795517-6	2005	These findings indicate that, by blocking of the IL-6 function, ATRA may be therapeutically effective in PGN.	Tretinoin	64-68	interleukin 6	Mus musculus	49-53
15795517-6	2005	These findings indicate that, by blocking of the IL-6 function, ATRA may be therapeutically effective in PGN.	pgn	105-108	interleukin 6	Mus musculus	49-53
15585847-4	2004	In contrast, reversal of Treg anergy is dependent on TLR activation of DCs, and involves the potentiation of Treg responsiveness to IL-2 by cooperative effects of IL-6 and IL-1, both of which are produced by TLR-activated, mature DCs.	treg	25-29	interleukin 6	Mus musculus	163-167
15566950-0	2004	Modulation of endotoxin stimulated interleukin-6 production in monocytes and Kupffer cells by S-adenosylmethionine (SAMe).	S-Adenosylmethionine	94-114	interleukin 6	Mus musculus	35-48
15566950-9	2004	Cycloleucine (CL), an inhibitor for extrahepatic methionine adenosyltransferases (MAT), inhibited LPS-stimulated IL-6 production.	Cycloleucine	0-12	interleukin 6	Mus musculus	113-117
15566950-10	2004	The enhancement of LPS-stimulated IL-6 production by SAMe was inhibited by ZM241385, a specific antagonist of adenosine (A2) receptor.	ZM 241385	75-83	interleukin 6	Mus musculus	34-38
15447943-3	2004	AraLAM induced high lung levels of tumor necrosis factor, interleukin-1beta, interleukin-6, and cytokine-induced neutrophil chemoattractant (KC) and an influx of neutrophils into the pulmonary compartment of WT mice.	aralam	0-6	interleukin 6	Mus musculus	77-90
15531295-4	2004	We also found that piperine could reduce the expression of IL-1beta, IL-6, TNF-alpha, GM-CSF and IL-12p40 genes.	piperine	19-27	interleukin 6	Mus musculus	69-73
15585847-4	2004	In contrast, reversal of Treg anergy is dependent on TLR activation of DCs, and involves the potentiation of Treg responsiveness to IL-2 by cooperative effects of IL-6 and IL-1, both of which are produced by TLR-activated, mature DCs.	treg	109-113	interleukin 6	Mus musculus	163-167
15557373-5	2004	However, serum cholesterol levels and subsequent atherosclerotic lesion formation (oil red O stain) were significantly increased in ApoE-/--IL-6-/- mice compared with ApoE-/-, wild-type (WT), and IL-6-/- mice.	Cholesterol	15-26	interleukin 6	Mus musculus	140-144
15557632-4	2004	The DeltafbpA mutant induced a stronger expression of pulmonary mRNA messages in mice for tumor necrosis factor alpha, interleukin-1 beta (IL-1beta), gamma interferon, IL-6, IL-2, and inducible nitric oxide (NO) synthase, which led to its decline, while H37Rv persisted despite strong immune responses.	deltafbpa	4-13	interleukin 6	Mus musculus	168-172
15345723-8	2004	Consistent with a monocyte nature, CD56dimCD33+ proliferated and produced a variety of cytokines upon lipopolysaccharide stimulation, including IL-8, IL-6, monocyte chemoattractant protein-1, and macrophage-derived chemokine but not interferon-gamma.	cd56dimcd33+	35-47	interleukin 6	Mus musculus	150-154
15284113-5	2004	MgcRacGAP, Rac, and STAT3 formed a complex in IL-6-stimulated M1 cells, where MgcRacGAP interacted with Rac1 and STAT3 through its cysteine-rich domain and GAP domain.	Cysteine	131-139	interleukin 6	Mus musculus	46-50
15599396-8	2004	Instead, they induced the release of LPA from activated platelets which, in turn, promoted tumor cell proliferation and the LPA(1)-dependent secretion of IL-6 and IL-8, 2 potent bone resorption stimulators.	lysophosphatidic acid	37-40	interleukin 6	Mus musculus	154-158
15599400-5	2004	In cultured adipocytes, elevated levels of fatty acids increased oxidative stress via NADPH oxidase activation, and oxidative stress caused dysregulated production of adipocytokines (fat-derived hormones), including adiponectin, plasminogen activator inhibitor-1, IL-6, and monocyte chemotactic protein-1.	Fatty Acids	43-54	interleukin 6	Mus musculus	264-268
15570020-10	2004	The overexpression of interleukin-6 and tumor necrosis factor-alpha in diabetic mice was suppressed by the intake of the 5 cysteine-containing agents (P &lt; 0.05).	Cysteine	123-131	interleukin 6	Mus musculus	22-67
15570035-0	2004	Docosahexaenoic acid attenuates mycotoxin-induced immunoglobulin a nephropathy, interleukin-6 transcription, and mitogen-activated protein kinase phosphorylation in mice.	Docosahexaenoic Acids	0-20	interleukin 6	Mus musculus	80-93
15570035-4	2004	Both splenic interleukin-6 (IL-6) mRNA and heterogeneous nuclear RNA (hnRNA), an indicator of IL-6 transcription, were significantly reduced in DON-fed mice that consumed 5 and 30 g/kg DHA; a similar reduction was observed for cyclooxygenase (COX-2) mRNA.	Docosahexaenoic Acids	185-188	interleukin 6	Mus musculus	94-98
15570035-5	2004	In a subsequent study, acute DON exposure (25 mg/kg body weight) induced splenic IL-6 mRNA and hnRNA as well as COX-2 mRNA in mice fed the control diet, whereas induction of both RNA species was significantly inhibited in mice fed 30 g/kg DHA.	deoxynivalenol	29-32	interleukin 6	Mus musculus	81-85
15613028-5	2004	In electrophoretic mobility shift assays (EMSAs), a radiolabeled oligonucleotide IL6-RE probe formed specific complexes with nuclear proteins from untreated hepatocytic cells.	Oligonucleotides	65-80	interleukin 6	Mus musculus	81-84
15613028-9	2004	Treatment of Hepa 1-6 cells with the mitogen-activated protein kinase (MAPK) inhibitor, PD-98059, inhibited IL-6-stimulated plasminogen promoter activity.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	88-96	interleukin 6	Mus musculus	108-112
15557373-5	2004	However, serum cholesterol levels and subsequent atherosclerotic lesion formation (oil red O stain) were significantly increased in ApoE-/--IL-6-/- mice compared with ApoE-/-, wild-type (WT), and IL-6-/- mice.	oil red O	83-92	interleukin 6	Mus musculus	140-144
15535965-4	2004	This was followed, however, only in the liver of the Mg-deficient animals, by an increase in both alpha 2-macroglobulin (alpha-2m), an acute phase marker, and interleukin-6 transcripts suggesting that an inflammatory response had been initiated.	Magnesium	53-55	interleukin 6	Mus musculus	159-172
15271886-8	2004	Cox-2 expression in the brain was not influenced by IL-6 deficiency, whereas indomethacin, an inhibitor of cyclooxygenases, completely inhibited induction of IL-6.	Indomethacin	77-89	interleukin 6	Mus musculus	158-162
15374628-4	2004	Results from the intestinal cell studies suggest that isoflavones suppress the intestinal response to inflammation by modulating the action of pro-inflammatory cytokine, IL-6.	Isoflavones	54-65	interleukin 6	Mus musculus	170-174
15368270-3	2004	Here, we examined aAb-IL-6 in 4,230 blood donors.	p-Aminoazobenzene	18-21	interleukin 6	Mus musculus	22-26
15313472-1	2004	Cyclooxygenase-2 (COX-2) and tyrosine kinase, which are involved in the biosynthesis of prostaglandin E(2) (PGE(2)) in mouse calvarial osteoblasts, are stimulated by cytokine interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and/or interleukin-6 (IL-6).	Dinoprostone	88-106	interleukin 6	Mus musculus	252-265
15313472-1	2004	Cyclooxygenase-2 (COX-2) and tyrosine kinase, which are involved in the biosynthesis of prostaglandin E(2) (PGE(2)) in mouse calvarial osteoblasts, are stimulated by cytokine interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and/or interleukin-6 (IL-6).	Dinoprostone	88-106	interleukin 6	Mus musculus	267-271
15313472-1	2004	Cyclooxygenase-2 (COX-2) and tyrosine kinase, which are involved in the biosynthesis of prostaglandin E(2) (PGE(2)) in mouse calvarial osteoblasts, are stimulated by cytokine interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and/or interleukin-6 (IL-6).	Prostaglandins E	108-111	interleukin 6	Mus musculus	252-265
15313472-1	2004	Cyclooxygenase-2 (COX-2) and tyrosine kinase, which are involved in the biosynthesis of prostaglandin E(2) (PGE(2)) in mouse calvarial osteoblasts, are stimulated by cytokine interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha) and/or interleukin-6 (IL-6).	Prostaglandins E	108-111	interleukin 6	Mus musculus	267-271
15313472-3	2004	Simultaneous treatment with IL-6 and IL-1beta and TNF-alpha resulted in enhanced COX-2 mRNA levels accompanied by the cooperative stimulation of PGE(2) biosynthesis compared to cells treated with IL-1beta or TNF-alpha or IL-6 alone.	Prostaglandins E	145-148	interleukin 6	Mus musculus	28-32
15313472-6	2004	A novel Src tyrosine kinase inhibitor, Herbimycin A (HERB), reduced COX-2 mRNA levels as well as PGE(2) production induced by IL-1beta, TNF-alpha and IL-6 or a combination of IL-1beta, TNF-alpha, IL-6, whereas COX-1 mRNA levels remained unaffected.	herbimycin	39-51	interleukin 6	Mus musculus	150-154
15679929-12	2004	RESULTS: Both isoforms of MTmRNA and IL-6mRNA increase in old thymus coupled with low zinc ion bioavailability, reduced TECs proliferation, impaired thymulin activity and enhanced plasma corticosterone in comparison with young.	Corticosterone	187-201	interleukin 6	Mus musculus	37-41
15473952-8	2004	A significant increase in KC, pMphi and aMphi TNF-alpha and IL-6 release was observed following Spx.	spx	96-99	interleukin 6	Mus musculus	60-64
15473952-10	2004	In contrast, the release of TNF-alpha, IL-6 and IL-10 was significantly decreased in PBMC after Spx.	spx	96-99	interleukin 6	Mus musculus	39-43
15473952-11	2004	Similarly, TNF-alpha and IL-6 was also decreased in MLN after Spx.	spx	62-65	interleukin 6	Mus musculus	25-29
15514851-0	2004	Inhibitory effect of TCCE on CCl4-induced overexpression of IL-6 in acute liver injury.	tcce	21-25	interleukin 6	Mus musculus	60-64
15514851-2	2004	This study was designed to characterize the protective effects of the chloroform fraction of the ethanol extract of T. catappa leaves (TCCE) against carbon tetrachloride (CCl4)-induced hepatotoxicity in mice, and analyze the changes in expression level of interleukin-6 (IL-6) in the process.	Ethanol	97-104	interleukin 6	Mus musculus	256-269
15514851-2	2004	This study was designed to characterize the protective effects of the chloroform fraction of the ethanol extract of T. catappa leaves (TCCE) against carbon tetrachloride (CCl4)-induced hepatotoxicity in mice, and analyze the changes in expression level of interleukin-6 (IL-6) in the process.	Ethanol	97-104	interleukin 6	Mus musculus	271-275
15514851-7	2004	In conclusion, TCCE is effective in protecting mice from the hepatotoxicity produced by CCl4, and the mechanisms underlying its protective effects may be related to the inhibition on the overexpression of IL-6 mainly around terminal hepatic vein.	tcce	15-19	interleukin 6	Mus musculus	205-209
15205889-7	2004	There was an increase in the production of IL-6 and IFN-gamma mRNAs measured by RT-PCR in STZ-, but not in ethanol- or acetone-treated normal mice.	Streptozocin	90-93	interleukin 6	Mus musculus	43-47
15621690-3	2004	Many inflammatory mediators (e.g. TNF-alpha, IL-1 and IL-6) are involved in the pathogenesis of shock and, among them, nitric oxide (NO).	Nitric Oxide	119-131	interleukin 6	Mus musculus	54-58
15626898-7	2004	Microscopic damage score, myeloperoxidase activity, tumor necrosis factor alpha (TNF-alpha), and interleukin-6 in colonic tissue were significantly diminished by CsA.	Cyclosporine	162-165	interleukin 6	Mus musculus	97-110
15313472-6	2004	A novel Src tyrosine kinase inhibitor, Herbimycin A (HERB), reduced COX-2 mRNA levels as well as PGE(2) production induced by IL-1beta, TNF-alpha and IL-6 or a combination of IL-1beta, TNF-alpha, IL-6, whereas COX-1 mRNA levels remained unaffected.	herbimycin	39-51	interleukin 6	Mus musculus	196-200
15313472-8	2004	These results indicate that the cooperative effects of IL-beta, TNF-alpha, IL-6 on PGE(2) production are due to the enhanced expression of the COX-2 gene and that tyrosine kinase(s) are involved in COX-2 signal transduction in mouse calvarial osteoblasts.	Prostaglandins E	83-86	interleukin 6	Mus musculus	75-79
15271886-9	2004	These observations suggest a mechanism of IL-1-induced febrile response in which IL-1 in the blood activates Cox-2, with the resulting prostaglandin E(2) inducing IL-6 in the brain, leading to the development of fever.	Dinoprostone	135-153	interleukin 6	Mus musculus	163-167
15316034-3	2004	We have previously shown that treatment of mast cells with okadaic acid (OA), a protein phosphatase 2A (PP2A) inhibitor, results in a dose-dependent increase in interleukin (IL)-6 production.	Okadaic Acid	59-71	interleukin 6	Mus musculus	161-179
15364100-7	2004	IL-6 serum levels, in turn, were lowered in C3H/HeCr mice but elevated in CBA mice.	hecr	48-52	interleukin 6	Mus musculus	0-4
15467723-4	2004	Production of interleukin 6 required B7-1 (CD80), B7-2 (CD86) and p38 mitogen-activated protein kinase and prevented interferon-gamma-driven expression of immunosuppressive tryptophan catabolism.	Tryptophan	173-183	interleukin 6	Mus musculus	14-27
15476226-10	2004	Only prednisolone significantly reduced the expression of TNFalpha, IL-1beta, and IL-6 in the joints.	Prednisolone	5-17	interleukin 6	Mus musculus	82-86
15382116-5	2004	The beneficial effects of IL-6 treatment in vivo resulted in part from an increase in mitochondrial beta oxidation of fatty acid and an increase in hepatic export of triglyceride and cholesterol.	Fatty Acids	118-128	interleukin 6	Mus musculus	26-30
15382116-5	2004	The beneficial effects of IL-6 treatment in vivo resulted in part from an increase in mitochondrial beta oxidation of fatty acid and an increase in hepatic export of triglyceride and cholesterol.	Triglycerides	166-178	interleukin 6	Mus musculus	26-30
15382116-5	2004	The beneficial effects of IL-6 treatment in vivo resulted in part from an increase in mitochondrial beta oxidation of fatty acid and an increase in hepatic export of triglyceride and cholesterol.	Cholesterol	183-194	interleukin 6	Mus musculus	26-30
15631710-22	2004	The bone marrow stromal cell differentiation system combining with VEGF, SCF, IL-3, IL-6 and EPO was an optimal system for the generation of HSC with CD(34)(+)/Sca-1(+) surface marker from ESC differentiated in vitro.	Cadmium	150-152	interleukin 6	Mus musculus	84-88
15516795-0	2004	Role of IL-6 and IL-1beta in reactivation by acetylcholine of latently infecting pseudorabies virus.	Acetylcholine	45-58	interleukin 6	Mus musculus	8-12
15516795-4	2004	IL-6 and IL-1beta were detected in mice after stimulation with acetylcholine.	Acetylcholine	63-76	interleukin 6	Mus musculus	0-4
15380476-6	2004	Clodronate (0.01, 0.1, 1 microg/ml) significantly down-regulated the LPS-stimulated microglial secretion of tumor necrosis factor (TNF)-alpha, Interleukin (IL)-1beta and NO, but not of IL-6.	Clodronic Acid	0-10	interleukin 6	Mus musculus	185-189
15380476-7	2004	In contrast, clodronate significantly reduced the microglial IL-6-release induced by M-CSF, indicating different intracellular pathways.	Clodronic Acid	13-23	interleukin 6	Mus musculus	61-65
15473662-2	2004	Stylopine per se had no cytotoxic effect in unstimulated RAW 264.7 cells, but concentration-dependently reduced nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), and the IL-6 production and cyclooxygenase-2 (COX-2) activity caused by the LPS stimulation.	stylopine	0-9	interleukin 6	Mus musculus	238-242
15371230-7	2004	DON was found to induce the cytokines interleukin (IL)-1alpha, IL-1beta, IL-6 and IL-11.	deoxynivalenol	0-3	interleukin 6	Mus musculus	73-77
15356168-6	2004	TNF-alpha, IL-6, NO, and inducible NO synthase expression were inhibited by SAHA.	Vorinostat	76-80	interleukin 6	Mus musculus	11-15
15212763-7	2004	Functional analysis demonstrated that Ad5NIK-induced NF-kappaB transcriptional activity, IL-6 mRNA expression and RelA phosphorylation are inhibited by the p38 inhibitor SB203580, suggesting a role for this MAPK in NIK signaling to NF-kappaB.	SB 203580	170-178	interleukin 6	Mus musculus	89-93
15261785-4	2004	Exposure of RAW 264.7 cells to aged silica particles induced macrophage activation (evidenced by the morphological features observed with scanning electron microscopy and by the release of TNF-alpha and IL-6) and impairment of phagocytosis of test particles, even at noncytotoxic doses.	Silicon Dioxide	36-42	interleukin 6	Mus musculus	203-207
15362044-8	2004	Histamine suppressed the expression of IL-18 and tumor necrosis factor alpha in the liver, leading to the reduced plasma levels of cytokines including IL-18, TNF-alpha, IL-12, IFN-gamma, and IL-6.	Histamine	0-9	interleukin 6	Mus musculus	191-195
15479172-6	2004	Treatment with the NK3 antagonist SR 142801 (10(-6) mol/L, aerosol) did not inhibit the influx of neutrophils, but markedly reduced the increase in TNF-alpha and IL-6 levels at 2.5 h and MMP-9 activity at 20 h. 3.	SR 142801	34-43	interleukin 6	Mus musculus	162-166
15294990-5	2004	EtOH decreased IL-6 and IL-12 (p40), but did not significantly affect IL-10 in peritoneal lavage fluid or in lysates of peritoneal cells.	Ethanol	0-4	interleukin 6	Mus musculus	15-19
15302781-6	2004	We demonstrated that stimulation of wild-type cardiac fibroblasts by isoproterenol markedly increased the production of the interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokines.	Isoproterenol	69-82	interleukin 6	Mus musculus	124-137
15302781-9	2004	CONCLUSIONS: Our results demonstrate for the first time that 5-HT2B receptors are essential for isoproterenol-induced cardiac hypertrophy, which involves the regulation of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by cardiac fibroblasts.	Isoproterenol	96-109	interleukin 6	Mus musculus	172-185
15322018-8	2004	Although the activity of phosphatidylinositol dimannoside was little influenced by palmitoylation of mannose at C-6, a further palmitoylation at inositol C-3 diminished the induction levels of IL-6 and IL-12.	Inositol	37-45	interleukin 6	Mus musculus	193-197
21241555-5	2004	Compared to saline treatment, indomethacin intervention apparently down regulated the levels of IL-1, IL-6 and TNF-alpha ( P &lt; 0.05 ), and remarkably prolonged the survival of mice ( P &lt; 0.05).	Indomethacin	30-42	interleukin 6	Mus musculus	102-106
15313929-7	2004	In vivo stimulation of mice with pIC and CpG-ODN demonstrated synergy for serum IL-6 and IL-12p40 levels that correlated with an enhanced antitumor effect against established B16-F10 experimental pulmonary metastases.	Poly I-C	33-36	interleukin 6	Mus musculus	80-84
15100092-7	2004	Addition of the sympathetic agonists norepinephrine, isoprenaline, or BRL-37344 (beta(3)-agonist) led to falls in NGF gene expression and secretion by 3T3-L1 adipocytes, as did IL-6 and the PPARgamma agonist rosiglitazone.	Norepinephrine	37-51	interleukin 6	Mus musculus	177-181
15100092-7	2004	Addition of the sympathetic agonists norepinephrine, isoprenaline, or BRL-37344 (beta(3)-agonist) led to falls in NGF gene expression and secretion by 3T3-L1 adipocytes, as did IL-6 and the PPARgamma agonist rosiglitazone.	Isoproterenol	53-65	interleukin 6	Mus musculus	177-181
15100092-7	2004	Addition of the sympathetic agonists norepinephrine, isoprenaline, or BRL-37344 (beta(3)-agonist) led to falls in NGF gene expression and secretion by 3T3-L1 adipocytes, as did IL-6 and the PPARgamma agonist rosiglitazone.	BRL 37344	70-79	interleukin 6	Mus musculus	177-181
15100092-7	2004	Addition of the sympathetic agonists norepinephrine, isoprenaline, or BRL-37344 (beta(3)-agonist) led to falls in NGF gene expression and secretion by 3T3-L1 adipocytes, as did IL-6 and the PPARgamma agonist rosiglitazone.	beta(3)	81-88	interleukin 6	Mus musculus	177-181
15298576-8	2004	However, both WT and IL-6-deficient mice exhibited similar levels of airway responsiveness to increasing doses of methacholine, even after repeated exposure to OVA.	Methacholine Chloride	114-126	interleukin 6	Mus musculus	21-25
15044377-7	2004	Interestingly, robust corticosterone responses in CRH-Ab-treated and CRH-KO mice were associated with exaggerated IL-6 levels, and IL-6 and corticosterone concentrations in infected CRH-Ab-treated animals were significantly correlated.	Corticosterone	22-36	interleukin 6	Mus musculus	114-118
15044377-8	2004	Neutralization of IL-6 responses in infected CRH-KO mice reduced corticosterone responses by approximately 70%.	Corticosterone	65-79	interleukin 6	Mus musculus	18-22
15305025-8	2004	Moreover, TAS-3-124 inhibited the production of proinflammatory cytokines including interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha and IL-6 but not T cell derived cytokines in mice.	6-acetoamido-1-acetyl-1-indazole	10-19	interleukin 6	Mus musculus	146-150
15254764-0	2004	Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice.	dextran sodium sulfate	43-65	interleukin 6	Mus musculus	69-82
15332390-6	2004	Salbutamol also substantially decreased IL-6, but not MIP-2 in BAL fluid (6 h).	Albuterol	0-10	interleukin 6	Mus musculus	40-44
15368442-7	2004	In lean mice, in contrast, acute alcohol attenuated LPS-induced TNF-alpha, IL-6 production, and NF-kappaB activation through reduced IkappaB-alpha degradation and induction of p50/p50 homodimers.	Alcohols	33-40	interleukin 6	Mus musculus	75-79
15254764-7	2004	At each assessment, colonic injury was significantly attenuated in DSS-treated IL-6-/- mice compared with DSS-treated IL-6+/+ mice.	Dextran Sulfate	67-70	interleukin 6	Mus musculus	79-83
15254764-7	2004	At each assessment, colonic injury was significantly attenuated in DSS-treated IL-6-/- mice compared with DSS-treated IL-6+/+ mice.	Dextran Sulfate	106-109	interleukin 6	Mus musculus	118-122
15254764-8	2004	Histological study also showed a reduced infiltration of inflammatory cells, especially neutrophils, and mucosal cell disruption in DSS-treated IL-6-/- mice compared with DSS-treated IL-6+/+ mice.	Dextran Sulfate	132-135	interleukin 6	Mus musculus	144-148
15254764-8	2004	Histological study also showed a reduced infiltration of inflammatory cells, especially neutrophils, and mucosal cell disruption in DSS-treated IL-6-/- mice compared with DSS-treated IL-6+/+ mice.	Dextran Sulfate	171-174	interleukin 6	Mus musculus	183-187
15254764-9	2004	In the colons of DSS-treated IL-6-/- mice, the expression of both TNF-alpha mRNA and iNOS mRNA was reduced on day 5.	Dextran Sulfate	17-20	interleukin 6	Mus musculus	29-33
15254764-10	2004	In contrast, IL-10 mRNA expression was enhanced compared with DSS-treated IL-6+/+ mice.	Dextran Sulfate	62-65	interleukin 6	Mus musculus	74-78
15254764-11	2004	In conclusion, DSS-induced inflammation appears to be significantly inhibited in IL-6-/- mice compared to wild-type mice.	Dextran Sulfate	15-18	interleukin 6	Mus musculus	81-85
15191885-0	2004	Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity.	Carbohydrates	10-22	interleukin 6	Mus musculus	74-78
15387364-7	2004	A single injection of AdvmuIL-10 led to a marked reduction in both stool markers of inflammation (IL-1beta, IL-6, and TNFRII) and serum IL-6.	advmuil-10	22-32	interleukin 6	Mus musculus	108-112
15387364-7	2004	A single injection of AdvmuIL-10 led to a marked reduction in both stool markers of inflammation (IL-1beta, IL-6, and TNFRII) and serum IL-6.	advmuil-10	22-32	interleukin 6	Mus musculus	136-140
15191885-2	2004	A previous study reported that IL-6 knockout mice (IL-6(-/-)) developed maturity onset obesity, with disturbed carbohydrate and lipid metabolism, and increased leptin levels.	Carbohydrates	111-123	interleukin 6	Mus musculus	31-35
15191885-9	2004	In the GTT, IL-6(-/-) mice demonstrated elevated postinjection glucose levels by 60% compared with IL-6(+/+) but only in the HF group.	Glucose	63-70	interleukin 6	Mus musculus	12-16
15191552-10	2004	STAT3 tyrosine phosphorylation was induced after barrier disruption in wild-type, but markedly reduced in IL-6-deficient mice.	Tyrosine	6-14	interleukin 6	Mus musculus	106-110
15256726-11	2004	In contrast, the spleen cells from the mice fed beta-carotene produced less IL-4, IL-5, IL-6, IL-10 than those from the control group.	beta Carotene	48-61	interleukin 6	Mus musculus	88-92
15084649-6	2004	Propranolol, but not ODQ, suppressed the inhibitory activity of NCX-950 on neutrophil influx and IL-6 release in BAL fluids.	Propranolol	0-11	interleukin 6	Mus musculus	97-101
15075356-15	2004	PGE(2) can modulate inflammatory reactions via the EP2/4 receptor through its regulation of TNF-alpha and IL-6.	Prostaglandins E	0-3	interleukin 6	Mus musculus	106-110
15010501-7	2004	Real-time reverse transcription-polymerase chain reaction analysis revealed that V-PYRRO/NO administration suppressed the expression of inflammation-related genes such as macrophage inflammatory protein-2, CXC chemokine, thrombospondin-1, intracellular adhesion molecular-1, and interleukin-6.	imidazole	83-88	interleukin 6	Mus musculus	279-292
15223134-2	2004	We show that MPA, like dexamethasone (dex), significantly represses tumour necrosis factor (TNF)-stimulated interleukin-6 (IL-6) protein production in mouse fibroblast (L929sA) cells.	Dexamethasone	23-36	interleukin 6	Mus musculus	108-121
15197737-8	2004	However, GFAP-IL6 mice showed reduced oxidative stress (judged from nitrotyrosine, malondialdehyde, and 8-oxoguanine stainings), neurodegeneration (accumulation of neurofibrillary tangles), and apoptosis (determined from TUNEL and caspase-3).	3-nitrotyrosine	68-81	interleukin 6	Mus musculus	14-17
15197737-8	2004	However, GFAP-IL6 mice showed reduced oxidative stress (judged from nitrotyrosine, malondialdehyde, and 8-oxoguanine stainings), neurodegeneration (accumulation of neurofibrillary tangles), and apoptosis (determined from TUNEL and caspase-3).	Malondialdehyde	83-98	interleukin 6	Mus musculus	14-17
15197737-8	2004	However, GFAP-IL6 mice showed reduced oxidative stress (judged from nitrotyrosine, malondialdehyde, and 8-oxoguanine stainings), neurodegeneration (accumulation of neurofibrillary tangles), and apoptosis (determined from TUNEL and caspase-3).	8-hydroxyguanine	104-116	interleukin 6	Mus musculus	14-17
15455667-3	2004	The potential inhibiting activity of pentoxifylline (POF) as an influence to IL-6 levels, and measure of several acute phase response signs has been evaluated.	Pentoxifylline	37-51	interleukin 6	Mus musculus	77-81
15223134-2	2004	We show that MPA, like dexamethasone (dex), significantly represses tumour necrosis factor (TNF)-stimulated interleukin-6 (IL-6) protein production in mouse fibroblast (L929sA) cells.	Dexamethasone	23-36	interleukin 6	Mus musculus	123-127
15187118-7	2004	Although WT bone marrow cultures died within 4 wk, IL-6(-/-) cultures continued to generate BMDC for &gt;120 days, although the BMDC became immature and less functional.	bmdc	92-96	interleukin 6	Mus musculus	51-55
16219169-5	2004	Ethanol consumption leads to stronger induction of malondialdehyde (MDA) in IL-6 (-/-) mice compared to wild-type control mice, which can be corrected by administration of IL-6.	Ethanol	0-7	interleukin 6	Mus musculus	76-80
15329260-11	2004	The concentration of TNF-alpha (P &lt; 0.05) and IL-6 (P &lt; 0.01) in tumor-bearing mice was reduced after administration of 0.5 mg/kg IND for 7 days.	Indomethacin	136-139	interleukin 6	Mus musculus	49-53
15329260-17	2004	IND may inhibit the activation of NF-kappaB, decrease serum TNF-alpha and IL-6 levels and thus alleviate the cachexia.	Indomethacin	0-3	interleukin 6	Mus musculus	74-78
15188379-4	2004	METHODS: Zymosan was injected intraarticularly into naive wild-type (WT), IL-6(-/-), and STAT-1(-/-) mice to induce arthritis.	Zymosan	9-16	interleukin 6	Mus musculus	74-78
15067010-5	2004	In culture with stem cell factor, FLT3 ligand, and IL-6, a 4-hydroxytamoxifen-inducible form of c-Myc (Myc/ERT) enabled murine Lin(-)Sca-1(+) HSCs to proliferate with the surface phenotype compatible with HSCs for more than 28 days.	hydroxytamoxifen	59-77	interleukin 6	Mus musculus	51-55
16219169-0	2004	IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver.	Ethanol	39-46	interleukin 6	Mus musculus	0-4
16219169-0	2004	IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver.	Ethanol	39-46	interleukin 6	Mus musculus	74-78
16219169-0	2004	IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver.	Ethanol	96-103	interleukin 6	Mus musculus	0-4
16219169-0	2004	IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver.	Ethanol	96-103	interleukin 6	Mus musculus	74-78
16219169-1	2004	Interleukin-6 (IL-6)-deficient mice are prone to ethanol-induced apoptosis and steatosis in the liver; however, the underlying mechanism is not fully understood.	Ethanol	49-56	interleukin 6	Mus musculus	0-13
16219169-1	2004	Interleukin-6 (IL-6)-deficient mice are prone to ethanol-induced apoptosis and steatosis in the liver; however, the underlying mechanism is not fully understood.	Ethanol	49-56	interleukin 6	Mus musculus	15-19
16219169-3	2004	Therefore, we hypothesize that the protective role of IL-6 in ethanol-induced liver injury is mediated via suppression of ethanol-induced oxidative stress and mitochondrial dysfunction.	Ethanol	62-69	interleukin 6	Mus musculus	54-58
16219169-5	2004	Ethanol consumption leads to stronger induction of malondialdehyde (MDA) in IL-6 (-/-) mice compared to wild-type control mice, which can be corrected by administration of IL-6.	Ethanol	0-7	interleukin 6	Mus musculus	172-176
16219169-3	2004	Therefore, we hypothesize that the protective role of IL-6 in ethanol-induced liver injury is mediated via suppression of ethanol-induced oxidative stress and mitochondrial dysfunction.	Ethanol	122-129	interleukin 6	Mus musculus	54-58
16219169-5	2004	Ethanol consumption leads to stronger induction of malondialdehyde (MDA) in IL-6 (-/-) mice compared to wild-type control mice, which can be corrected by administration of IL-6.	Malondialdehyde	51-66	interleukin 6	Mus musculus	76-80
16219169-5	2004	Ethanol consumption leads to stronger induction of malondialdehyde (MDA) in IL-6 (-/-) mice compared to wild-type control mice, which can be corrected by administration of IL-6.	Malondialdehyde	51-66	interleukin 6	Mus musculus	172-176
16219169-7	2004	Administration of IL-6 in vivo also reverses ethanol-induced MDA and ATP depletion in hepatocytes.	Ethanol	45-52	interleukin 6	Mus musculus	18-22
16219169-7	2004	Administration of IL-6 in vivo also reverses ethanol-induced MDA and ATP depletion in hepatocytes.	Adenosine Triphosphate	69-72	interleukin 6	Mus musculus	18-22
16219169-9	2004	In conclusion, IL-6 protects against ethanol-induced oxidative stress and mitochondrial dysfunction in hepatocytes via induction of metallothionein protein expression, which may account for the protective role of IL-6 in alcoholic liver disease.	Ethanol	37-44	interleukin 6	Mus musculus	15-19
16219169-9	2004	In conclusion, IL-6 protects against ethanol-induced oxidative stress and mitochondrial dysfunction in hepatocytes via induction of metallothionein protein expression, which may account for the protective role of IL-6 in alcoholic liver disease.	Ethanol	37-44	interleukin 6	Mus musculus	213-217
16219171-1	2004	The work is to explore the relationship between the levels of cytokines (IL-1beta and IL-6) in C57BL/6J mice treated with MPTP and brain lateralization.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	122-126	interleukin 6	Mus musculus	86-90
16219171-6	2004	The plasma level of IL-6 was lower in left-pawed than that in right-pawed mice (p &lt; 0.005) after MPTP treatment.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	100-104	interleukin 6	Mus musculus	20-24
16219171-10	2004	In conclusion, the level of plasma IL-6 of C57BL/6J mice treated with MPTP increased.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	70-74	interleukin 6	Mus musculus	35-39
14988384-7	2004	During exercise, the young and older IL-6(-/-) mice had a reduced endurance and a progressive decrease in oxygen consumption compared with control mice.	Oxygen	106-112	interleukin 6	Mus musculus	37-41
15203128-5	2004	In vivo assessment using marginal mass syngeneic islet transplantation in mouse model revealed IL-6 conferred significantly better blood glucose control and graft survival rate over 50 days.	Blood Glucose	131-144	interleukin 6	Mus musculus	95-99
15158982-1	2004	Scopoletin (1-50 microg/ml) inhibited the release of PGE2, TNF-alpha, IL-1beta and IL-6 and suppressed the expression of COX-2 in a concentration-dependent manner.	Scopoletin	0-10	interleukin 6	Mus musculus	83-87
15173396-4	2004	Consumption of the DHA + EPA diet for 8 wk significantly abrogated the DON-induced gene expression of interleukin (IL)-6, a requisite cytokine for DON-induced IgA nephropathy, in spleen and Peyer"s patches.	Docosahexaenoic Acids	19-22	interleukin 6	Mus musculus	102-120
15279728-4	2004	Carteolol hydrochloride significantly inhibited the production of TNF-alpha and IL-6 by MPs at 10(-5) M and higher (p &lt; 0.01) or PBMCs at 10(-6) M and higher (p &lt; 0.01) compared to the controls, while the other test agents had no inhibitory effect.	Carteolol	0-23	interleukin 6	Mus musculus	80-84
15203128-3	2004	Freshly isolated islets or MIN6 beta cells, when pre-incubated with IL-6, showed significantly higher viabilities measured by MTT assay and FACS analysis of PI stained cells against pro-apoptotic signaling delivered by IL-1beta, TNF-alpha and IFN-gamma.	monooxyethylene trimethylolpropane tristearate	126-129	interleukin 6	Mus musculus	68-72
15175167-7	2004	A-DEPs stimulated an increase in interleukin-6 (IL-6), tumor necrosis factor alpha, macrophage inhibitory protein-2, and the TH2 cytokine IL-5, whereas SRM 2975 only induced significant levels of IL-6.	DEPS	2-6	interleukin 6	Mus musculus	33-46
15175167-7	2004	A-DEPs stimulated an increase in interleukin-6 (IL-6), tumor necrosis factor alpha, macrophage inhibitory protein-2, and the TH2 cytokine IL-5, whereas SRM 2975 only induced significant levels of IL-6.	DEPS	2-6	interleukin 6	Mus musculus	48-52
15175167-7	2004	A-DEPs stimulated an increase in interleukin-6 (IL-6), tumor necrosis factor alpha, macrophage inhibitory protein-2, and the TH2 cytokine IL-5, whereas SRM 2975 only induced significant levels of IL-6.	DEPS	2-6	interleukin 6	Mus musculus	196-200
15173396-4	2004	Consumption of the DHA + EPA diet for 8 wk significantly abrogated the DON-induced gene expression of interleukin (IL)-6, a requisite cytokine for DON-induced IgA nephropathy, in spleen and Peyer"s patches.	Eicosapentaenoic Acid	25-28	interleukin 6	Mus musculus	102-120
15173396-4	2004	Consumption of the DHA + EPA diet for 8 wk significantly abrogated the DON-induced gene expression of interleukin (IL)-6, a requisite cytokine for DON-induced IgA nephropathy, in spleen and Peyer"s patches.	deoxynivalenol	71-74	interleukin 6	Mus musculus	102-120
15173396-4	2004	Consumption of the DHA + EPA diet for 8 wk significantly abrogated the DON-induced gene expression of interleukin (IL)-6, a requisite cytokine for DON-induced IgA nephropathy, in spleen and Peyer"s patches.	deoxynivalenol	147-150	interleukin 6	Mus musculus	102-120
15173396-6	2004	Taken together, both DHA and EPA, but not ALA, ameliorated the early stages of IgAN, and these effects might be related to a reduced capacity for IL-6 production.	Docosahexaenoic Acids	21-24	interleukin 6	Mus musculus	146-150
15173396-6	2004	Taken together, both DHA and EPA, but not ALA, ameliorated the early stages of IgAN, and these effects might be related to a reduced capacity for IL-6 production.	Eicosapentaenoic Acid	29-32	interleukin 6	Mus musculus	146-150
15491098-1	2004	AIM: To study the effect of catechin, the active component of Spatholobus suberectus Dunn, on bone marrow cell cycle and the expression of IL-6 and GM-CSF mRNA in spleen cells of normal and marrow-depressed mice in order to clarify the mechanism of hematopoietic-supportive effect of catechin.	Catechin	28-36	interleukin 6	Mus musculus	139-143
15491098-2	2004	METHODS: Flow cytometry was adopted to investigate the influence of catechin on bone marrow cell cycle in mice and the expression of IL-6 and GM-CSF mRNA induced by catechin in spleen cells was detected by RT-PCR technique simultaneously.	Catechin	68-76	interleukin 6	Mus musculus	133-137
15491098-2	2004	METHODS: Flow cytometry was adopted to investigate the influence of catechin on bone marrow cell cycle in mice and the expression of IL-6 and GM-CSF mRNA induced by catechin in spleen cells was detected by RT-PCR technique simultaneously.	Catechin	165-173	interleukin 6	Mus musculus	133-137
15491098-4	2004	Being induced by catechin, IL-6 mRNA and GM-CSF mRNA in spleen cells were markedly up-regulated.	Catechin	17-25	interleukin 6	Mus musculus	27-31
15110751-6	2004	Finally, PDI expression was induced by the anti-inflammatory cytokine IL-10, and IL-10-mediated inhibition of LPS-induced IL-6 expression was reduced by bacitracin.	Bacitracin	153-163	interleukin 6	Mus musculus	122-126
15087825-3	2004	Consequently, piceatannol blocks the LPS-induced up-regulation of critical mediators of the inflammatory response such as interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), intercellular adhesion molecule 1 (ICAM-1), and macrophage chemoattractant protein (MCP-1).	3,3',4,5'-tetrahydroxystilbene	14-25	interleukin 6	Mus musculus	122-135
15135806-3	2004	In this study we show that mast cells stimulated by IL-9 and ionomycin or IL-9 and antigen-specific IgE/antigen express several cytokines at mRNA level, among them are IL-5, IL-4, IL-10, IL-9, IL-13, IL-1beta, IL-1Ra, IL-6 and MIF.	Ionomycin	61-70	interleukin 6	Mus musculus	218-222
14722032-0	2004	Epinephrine stimulates IL-6 expression in skeletal muscle and C2C12 myoblasts: role of c-Jun NH2-terminal kinase and histone deacetylase activity.	Epinephrine	0-11	interleukin 6	Mus musculus	23-27
14722032-6	2004	Epinephrine had a similar effect in C2C12 muscle cells, where the hormone increased IL-6 protein and mRNA in a dose- and time-dependent manner.	Epinephrine	0-11	interleukin 6	Mus musculus	84-88
14722032-7	2004	Epinephrine-stimulated IL-6 expression was attenuated by the alpha-adrenergic receptor antagonist phentolamine and completely blocked by either the beta1/2-adrenergic receptor antagonist propranalol or the beta2-antagonist ICI-118551.	Epinephrine	0-11	interleukin 6	Mus musculus	23-27
14722032-7	2004	Epinephrine-stimulated IL-6 expression was attenuated by the alpha-adrenergic receptor antagonist phentolamine and completely blocked by either the beta1/2-adrenergic receptor antagonist propranalol or the beta2-antagonist ICI-118551.	Phentolamine	98-110	interleukin 6	Mus musculus	23-27
14722032-7	2004	Epinephrine-stimulated IL-6 expression was attenuated by the alpha-adrenergic receptor antagonist phentolamine and completely blocked by either the beta1/2-adrenergic receptor antagonist propranalol or the beta2-antagonist ICI-118551.	Propranolol	187-198	interleukin 6	Mus musculus	23-27
14722032-7	2004	Epinephrine-stimulated IL-6 expression was attenuated by the alpha-adrenergic receptor antagonist phentolamine and completely blocked by either the beta1/2-adrenergic receptor antagonist propranalol or the beta2-antagonist ICI-118551.	ici	223-226	interleukin 6	Mus musculus	23-27
14722032-8	2004	The transcriptional inhibitor DRB and the synthetic glucocorticoid dexamethasone also blocked epinephrine-induced IL-6.	Dexamethasone	67-80	interleukin 6	Mus musculus	114-118
14722032-8	2004	The transcriptional inhibitor DRB and the synthetic glucocorticoid dexamethasone also blocked epinephrine-induced IL-6.	Epinephrine	94-105	interleukin 6	Mus musculus	114-118
14722032-9	2004	SP-600125 (a JNK inhibitor) and SB-202190 (a p38 MAP kinase inhibitor) completely blocked epinephrine-induced IL-6 synthesis.	pyrazolanthrone	0-9	interleukin 6	Mus musculus	110-114
14722032-9	2004	SP-600125 (a JNK inhibitor) and SB-202190 (a p38 MAP kinase inhibitor) completely blocked epinephrine-induced IL-6 synthesis.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	32-41	interleukin 6	Mus musculus	110-114
14722032-9	2004	SP-600125 (a JNK inhibitor) and SB-202190 (a p38 MAP kinase inhibitor) completely blocked epinephrine-induced IL-6 synthesis.	Epinephrine	90-101	interleukin 6	Mus musculus	110-114
14722032-11	2004	Trichostatin A (a histone deacetylase inhibitor) blocked both endotoxin- and epinephrine-induced IL-6 expression.	trichostatin A	0-14	interleukin 6	Mus musculus	97-101
14722032-11	2004	Trichostatin A (a histone deacetylase inhibitor) blocked both endotoxin- and epinephrine-induced IL-6 expression.	Epinephrine	77-88	interleukin 6	Mus musculus	97-101
14722032-12	2004	These data suggest that epinephrine induces IL-6 synthesis in skeletal muscle in vivo and myocytes in vitro.	Epinephrine	24-35	interleukin 6	Mus musculus	44-48
14701687-2	2004	In vivo bromodeoxyuridine incorporation analysis indicates that the percentage of Lin(-)Sca-1(+) hematopoietic progenitors undergoing DNA synthesis is diminished in IL-6-deficient (IL-6(-/-)) bone marrow (BM) compared with wild-type BM.	Bromodeoxyuridine	8-25	interleukin 6	Mus musculus	165-169
15095371-2	2004	It has recently been shown that stimulation of adenosine receptors in glial cells induces the release of neuroprotective substances such as NGF, S-100beta, and interleukin-6 (IL-6).	Adenosine	47-56	interleukin 6	Mus musculus	160-173
15095371-2	2004	It has recently been shown that stimulation of adenosine receptors in glial cells induces the release of neuroprotective substances such as NGF, S-100beta, and interleukin-6 (IL-6).	Adenosine	47-56	interleukin 6	Mus musculus	175-179
15001458-0	2004	Modulation of PPARalpha expression and inflammatory interleukin-6 production by chronic glucose increases monocyte/endothelial adhesion.	Glucose	88-95	interleukin 6	Mus musculus	52-65
15001458-7	2004	A known PPARalpha agonist, Wy14,643, prevented glucose-mediated IL-6 production by EC and reduced glucose-mediated monocyte adhesion by 40%.	Glucose	47-54	interleukin 6	Mus musculus	64-68
15001458-13	2004	PPARalpha protects EC from glucose-mediated monocyte adhesion, in part through regulation of IL-6 production.	ec	19-21	interleukin 6	Mus musculus	93-97
15001458-13	2004	PPARalpha protects EC from glucose-mediated monocyte adhesion, in part through regulation of IL-6 production.	Glucose	27-34	interleukin 6	Mus musculus	93-97
15115689-9	2004	The IL-6 response was produced by the non-adherent cellular population, which made 4912 pg/ml IL-6 when treated with water soluble extract at 1 mg/ml.	Water	117-122	interleukin 6	Mus musculus	4-8
15115689-9	2004	The IL-6 response was produced by the non-adherent cellular population, which made 4912 pg/ml IL-6 when treated with water soluble extract at 1 mg/ml.	Water	117-122	interleukin 6	Mus musculus	94-98
15195698-4	2004	Using the MC3T3-E1 as an osteoblastic model, IL-6 secretion was dose dependently decreased by SB203580, a p38 MAPK inhibitor.	SB 203580	94-102	interleukin 6	Mus musculus	45-49
15195698-5	2004	Steady state IL-6 mRNA was decreased with SB203580 (2 microM) ca.	SB 203580	42-50	interleukin 6	Mus musculus	13-17
15195698-9	2004	A more significant effect on IL-6 mRNA stability was observed in the presence of SB203580.	SB 203580	81-89	interleukin 6	Mus musculus	29-33
15159136-6	2004	Aspartate level significantly increased in the brain stem (BS) and hippocampus (HI), while it decreased in the diencephalon (DE) of IL-6(-/-) mice.	Aspartic Acid	0-9	interleukin 6	Mus musculus	132-136
15087825-3	2004	Consequently, piceatannol blocks the LPS-induced up-regulation of critical mediators of the inflammatory response such as interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), intercellular adhesion molecule 1 (ICAM-1), and macrophage chemoattractant protein (MCP-1).	3,3',4,5'-tetrahydroxystilbene	14-25	interleukin 6	Mus musculus	137-141
14695114-10	2004	IL-6 and IL-10 expression (RNA and protein) were reduced with HCl-induced acidification, but IL-10 was reduced much more than IL-6 at low pH.	Hydrochloric Acid	62-65	interleukin 6	Mus musculus	0-4
14764586-3	2004	In the present study, we demonstrate that chronic treatment with the PPARalpha agonist fenofibrate fully prevents the IL-6-induced APR gene expression in wild-type but not in PPARalpha-deficient mice.	Fenofibrate	87-98	interleukin 6	Mus musculus	118-122
14985352-8	2004	Finally, we show that d-galactosamine-sensitized IL-6-deficient mice were partially resistant to endotoxin-induced liver apoptosis and lethality.	Galactosamine	22-37	interleukin 6	Mus musculus	49-53
14695114-11	2004	By contrast, lactic acid significantly decreased LPS-induced NO, IL-6, and IL-10 expression in a dose-dependent manner.	Lactic Acid	13-24	interleukin 6	Mus musculus	65-69
14695114-14	2004	HCl is essentially proinflammatory as assessed by NO release, IL-6-to-IL-10 ratios, and NF-kappa B DNA binding.	Hydrochloric Acid	0-3	interleukin 6	Mus musculus	62-66
15020070-0	2004	alpha-Tocopherol reduces lipopolysaccharide-induced peroxide radical formation and interleukin-6 secretion in primary murine microglia and in brain.	alpha-Tocopherol	0-16	interleukin 6	Mus musculus	83-96
15047622-3	2004	Pretreatment of IL-6 blunted insulin"s ability to suppress hepatic glucose production and insulin-stimulated insulin receptor substrate (IRS)-2-associated phosphatidylinositol (PI) 3-kinase activity in liver.	Glucose	67-74	interleukin 6	Mus musculus	16-20
15034939-5	2004	We previously showed that sphingosine 1-phosphate (S1-P) mediates TNF-alpha-stimulated IL-6 synthesis in these cells.	sphingosine 1-phosphate	26-49	interleukin 6	Mus musculus	87-91
15034939-5	2004	We previously showed that sphingosine 1-phosphate (S1-P) mediates TNF-alpha-stimulated IL-6 synthesis in these cells.	sphingosine 1-phosphate	51-55	interleukin 6	Mus musculus	87-91
15034939-8	2004	SB203580 and PD169316, specific inhibitors of p38 MAP kinase, significantly reduced the enhancement by IL-17 of TNF-alpha-stimulated IL-6 synthesis.	SB 203580	0-8	interleukin 6	Mus musculus	133-137
15034939-8	2004	SB203580 and PD169316, specific inhibitors of p38 MAP kinase, significantly reduced the enhancement by IL-17 of TNF-alpha-stimulated IL-6 synthesis.	2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole	13-21	interleukin 6	Mus musculus	133-137
15034939-10	2004	Anisomycin, an activator of p38 MAP kinase, which alone had no effect on IL-6 level, enhanced the IL-6 synthesis stimulated by TNF-alpha.	Anisomycin	0-10	interleukin 6	Mus musculus	98-102
15034939-11	2004	SB203580 and PD169316 inhibited the amplification by anisomycin of the TNF-alpha-induced IL-6 synthesis.	SB 203580	0-8	interleukin 6	Mus musculus	89-93
15034939-11	2004	SB203580 and PD169316 inhibited the amplification by anisomycin of the TNF-alpha-induced IL-6 synthesis.	2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole	13-21	interleukin 6	Mus musculus	89-93
15034939-11	2004	SB203580 and PD169316 inhibited the amplification by anisomycin of the TNF-alpha-induced IL-6 synthesis.	Anisomycin	53-63	interleukin 6	Mus musculus	89-93
15020070-6	2004	Importantly, three daily injections (20 mg) of alpha-tocopherol increased brain alpha-tocopherol and decreased LPS-induced lipid peroxidation and IL-6 in brain.	alpha-Tocopherol	47-63	interleukin 6	Mus musculus	146-150
15047622-3	2004	Pretreatment of IL-6 blunted insulin"s ability to suppress hepatic glucose production and insulin-stimulated insulin receptor substrate (IRS)-2-associated phosphatidylinositol (PI) 3-kinase activity in liver.	2-associated phosphatidylinositol	142-175	interleukin 6	Mus musculus	16-20
15047622-4	2004	Acute IL-6 treatment also reduced insulin-stimulated glucose uptake in skeletal muscle, and this was associated with defects in insulin-stimulated IRS-1-associated PI 3-kinase activity and increases in fatty acyl-CoA levels in skeletal muscle.	Glucose	53-60	interleukin 6	Mus musculus	6-10
15216955-0	2004	Effects of lactoferrin on IL-6 production by peritoneal and alveolar cells in cyclophosphamide-treated mice.	Cyclophosphamide	78-94	interleukin 6	Mus musculus	26-30
15034063-9	2004	These in vitro results were confirmed by in vivo studies in IL-6(-/-) mice injected with turpentine, an experimental model of acute-phase response.	Turpentine	89-99	interleukin 6	Mus musculus	60-64
15020070-1	2004	The purpose of this study was to determine if alpha-tocopherol-a reactive oxygen species (ROS) scavenging agent-inhibits LPS-induced oxidative stress and interleukin-6 (IL-6) production in murine microglia and brain.	alpha-Tocopherol	46-62	interleukin 6	Mus musculus	154-167
15020070-1	2004	The purpose of this study was to determine if alpha-tocopherol-a reactive oxygen species (ROS) scavenging agent-inhibits LPS-induced oxidative stress and interleukin-6 (IL-6) production in murine microglia and brain.	alpha-Tocopherol	46-62	interleukin 6	Mus musculus	169-173
15020070-1	2004	The purpose of this study was to determine if alpha-tocopherol-a reactive oxygen species (ROS) scavenging agent-inhibits LPS-induced oxidative stress and interleukin-6 (IL-6) production in murine microglia and brain.	Reactive Oxygen Species	65-88	interleukin 6	Mus musculus	154-167
15020070-1	2004	The purpose of this study was to determine if alpha-tocopherol-a reactive oxygen species (ROS) scavenging agent-inhibits LPS-induced oxidative stress and interleukin-6 (IL-6) production in murine microglia and brain.	Reactive Oxygen Species	65-88	interleukin 6	Mus musculus	169-173
15020070-1	2004	The purpose of this study was to determine if alpha-tocopherol-a reactive oxygen species (ROS) scavenging agent-inhibits LPS-induced oxidative stress and interleukin-6 (IL-6) production in murine microglia and brain.	Reactive Oxygen Species	90-93	interleukin 6	Mus musculus	154-167
15020070-1	2004	The purpose of this study was to determine if alpha-tocopherol-a reactive oxygen species (ROS) scavenging agent-inhibits LPS-induced oxidative stress and interleukin-6 (IL-6) production in murine microglia and brain.	Reactive Oxygen Species	90-93	interleukin 6	Mus musculus	169-173
15020070-3	2004	The LPS-induced increase in ROS and IL-6 was reduced by pretreatment of alpha-tocopherol.	alpha-Tocopherol	72-88	interleukin 6	Mus musculus	36-40
15099921-5	2004	The IL-6(-/-) mice exhibited significantly higher seizure susceptibility to PTZ, beta-CCM, DMCM, NMDA, AMPA and KA than did the other mice strains, with the exception of DBA/2 mice.	Pentylenetetrazole	76-79	interleukin 6	Mus musculus	4-8
15099921-5	2004	The IL-6(-/-) mice exhibited significantly higher seizure susceptibility to PTZ, beta-CCM, DMCM, NMDA, AMPA and KA than did the other mice strains, with the exception of DBA/2 mice.	beta-carboline-3-carboxylic acid methyl ester	81-89	interleukin 6	Mus musculus	4-8
14699015-5	2004	Preincubation of VSMCs with IL-6 resulted in an enhanced angiotensin II-induced production of reactive oxygen species, as assessed by DCF fluorescence laser microscopy.	vsmcs	17-22	interleukin 6	Mus musculus	28-32
15099921-5	2004	The IL-6(-/-) mice exhibited significantly higher seizure susceptibility to PTZ, beta-CCM, DMCM, NMDA, AMPA and KA than did the other mice strains, with the exception of DBA/2 mice.	methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate	91-95	interleukin 6	Mus musculus	4-8
15099921-5	2004	The IL-6(-/-) mice exhibited significantly higher seizure susceptibility to PTZ, beta-CCM, DMCM, NMDA, AMPA and KA than did the other mice strains, with the exception of DBA/2 mice.	N-Methylaspartate	97-101	interleukin 6	Mus musculus	4-8
15099921-7	2004	In particular, the major convulsant effects produced by NMDA, AMPA and KA suggest that the excitatory amino acid system is more active in the central nervous system (CNS) of IL-6(-/-) mice.	Excitatory Amino Acids	91-112	interleukin 6	Mus musculus	174-178
14699015-5	2004	Preincubation of VSMCs with IL-6 resulted in an enhanced angiotensin II-induced production of reactive oxygen species, as assessed by DCF fluorescence laser microscopy.	Reactive Oxygen Species	94-117	interleukin 6	Mus musculus	28-32
14699015-5	2004	Preincubation of VSMCs with IL-6 resulted in an enhanced angiotensin II-induced production of reactive oxygen species, as assessed by DCF fluorescence laser microscopy.	Pentostatin	134-137	interleukin 6	Mus musculus	28-32
14699015-6	2004	Treatment of C57BL/6J mice with IL-6 for 18 days increased vascular AT1 receptor expression (real-time RT-PCR) and angiotensin II-induced vasoconstriction, enhanced vascular superoxide production (L-012 chemiluminescence, DHE fluorescence), and impaired endothelium-dependent vasodilatation.	Superoxides	174-184	interleukin 6	Mus musculus	32-36
14699015-6	2004	Treatment of C57BL/6J mice with IL-6 for 18 days increased vascular AT1 receptor expression (real-time RT-PCR) and angiotensin II-induced vasoconstriction, enhanced vascular superoxide production (L-012 chemiluminescence, DHE fluorescence), and impaired endothelium-dependent vasodilatation.	L 012	197-202	interleukin 6	Mus musculus	32-36
14699015-6	2004	Treatment of C57BL/6J mice with IL-6 for 18 days increased vascular AT1 receptor expression (real-time RT-PCR) and angiotensin II-induced vasoconstriction, enhanced vascular superoxide production (L-012 chemiluminescence, DHE fluorescence), and impaired endothelium-dependent vasodilatation.	Dihydroergotamine	222-225	interleukin 6	Mus musculus	32-36
15013990-11	2004	EcN administration to DSS-treated mice reduced the secretion of proinflammatory cytokines (IFN-gamma, 32,477 +/- 6,377 versus 9,734 +/- 1,717 [P = 0.004]; IL-6, 231 +/- 35 versus 121 +/- 17 [P = 0.02]) but had no effect on the mucosal inflammation.	dss	22-25	interleukin 6	Mus musculus	155-159
14758446-8	2004	Higher IL1 expression was detected in islets of vitamin D-deficient mice and their peritoneal macrophages had an aberrant cytokine profile (low IL1 and IL6, high IL15).	Vitamin D	48-57	interleukin 6	Mus musculus	152-155
14978092-7	2004	OVA-induced IL-4, IL-5, IL-6, and IFN-gamma secretion was reduced in thoracic lymph node cultures from simvastatin-treated mice.	Simvastatin	103-114	interleukin 6	Mus musculus	24-28
15040840-12	2004	RAP inhibited PTH- or 1,25(OH)2D3-induced expression of IL-6 in bone marrow cultures.	Calcitriol	22-33	interleukin 6	Mus musculus	56-60
15072229-7	2004	The levels of in vitro proliferation and production of IL-6, TNF-alpha, IL-12, and RANTES by splenocytes following exposure to CpG S-ODN were significantly higher than those induced by CpG O-ODN.	cpg s-odn	127-136	interleukin 6	Mus musculus	55-59
14748844-0	2004	Regulation of interleukin-6 fetoplacental levels could be involved in the protective effect of low-molecular weight heparin treatment on murine spontaneous abortion.	Heparin	116-123	interleukin 6	Mus musculus	14-27
14748844-8	2004	CONCLUSION: This study suggests that regulation of IL-6 fetoplacental levels could be involved in heparin-mediated anticoagulation protection against abortion.	Heparin	98-105	interleukin 6	Mus musculus	51-55
14996414-5	2004	We found that 30 mg/kg of CQ could protect mice from lethal challenge by CpG ODN and LPS, and 25 mg/kg of CQ could decrease serum TNF-alpha and IL-6 in rats injected with sublethal doses of CpG ODN and LPS.	Chloroquine	106-108	interleukin 6	Mus musculus	144-148
14996414-6	2004	In addition, treatment of murine macrophage ANA-1 cells with 2 mM CQ potently inhibited the release of TNF-alpha, IL-6 and IL-12 induced by CpG ODN and LPS.	Chloroquine	66-68	interleukin 6	Mus musculus	114-118
14978019-0	2004	The point mutation of tyrosine 759 of the IL-6 family cytokine receptor gp130 synergizes with HTLV-1 pX in promoting rheumatoid arthritis-like arthritis.	Tyrosine	22-30	interleukin 6	Mus musculus	42-46
15036626-4	2004	DbcAMP increased the IL-1beta level without affecting either the IL-6 or iNOS expression, whereas forskolin repressed the IL-6 and iNOS expression level without affecting IL-1beta in the LPS-stimulated microglia.	Colforsin	98-107	interleukin 6	Mus musculus	122-126
15036418-4	2004	We present data here that demonstrate that aging induced ROS promote aging-associated interleukin-6 (IL-6) gene transcription in mice that are transgenic for the murine IL-6 promoter driving a luciferase reporter cDNA.	Reactive Oxygen Species	57-60	interleukin 6	Mus musculus	86-99
15036418-4	2004	We present data here that demonstrate that aging induced ROS promote aging-associated interleukin-6 (IL-6) gene transcription in mice that are transgenic for the murine IL-6 promoter driving a luciferase reporter cDNA.	Reactive Oxygen Species	57-60	interleukin 6	Mus musculus	101-105
15036418-4	2004	We present data here that demonstrate that aging induced ROS promote aging-associated interleukin-6 (IL-6) gene transcription in mice that are transgenic for the murine IL-6 promoter driving a luciferase reporter cDNA.	Reactive Oxygen Species	57-60	interleukin 6	Mus musculus	169-173
15036418-5	2004	N-acetylcysteine (NAC), an antioxidant, completely reverses the increased endogenous IL-6 promoter activity in the old mice determined by real-time bioluminescence imaging (BLI).	Acetylcysteine	0-16	interleukin 6	Mus musculus	85-89
15036418-5	2004	N-acetylcysteine (NAC), an antioxidant, completely reverses the increased endogenous IL-6 promoter activity in the old mice determined by real-time bioluminescence imaging (BLI).	Acetylcysteine	18-21	interleukin 6	Mus musculus	85-89
14749363-4	2004	In gp130(Delta STAT/Delta STAT) bone marrow-derived macrophages (BMMs), both IL-6- and M-CSF-induced ERK1/2 tyrosine phosphorylation was enhanced.	Tyrosine	108-116	interleukin 6	Mus musculus	77-81
15630180-6	2004	Results indicate that TNF-alpha and IL-6 accumulations were significantly reduced by 5 to 20 microM quercetin treatment, and 20 microM of alpha-tocopherol treatment.	Quercetin	100-109	interleukin 6	Mus musculus	36-40
14573621-8	2004	H. pylori HSP60-induced IL-6 mRNA expression, and NF-kappaB activation in RAW 264.7 cells was abrogated in the presence of MG-132, a proteasome inhibitor.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	123-129	interleukin 6	Mus musculus	24-28
15142274-6	2004	We found that PG-PS-induced responses in vitro, including transient increase in intracellular calcium, activation of nuclear factor-kappaB, and secretion of the cytokines tumor necrosis factor-alpha and interleukin-6, were all strongly inhibited in CD14 knockout macrophages.	PG-PS	14-19	interleukin 6	Mus musculus	203-216
14709897-8	2004	Levels of anti-type II collagen antibody and tumor necrosis factor-alpha (TNF-alpha) in sera were also reduced by LMWCS treatment but not in case of CS, although no significant difference was observed between LMWCS and CS on interleukin-6 (IL-6) induction.	Chondroitin Sulfates	117-119	interleukin 6	Mus musculus	225-238
14709897-8	2004	Levels of anti-type II collagen antibody and tumor necrosis factor-alpha (TNF-alpha) in sera were also reduced by LMWCS treatment but not in case of CS, although no significant difference was observed between LMWCS and CS on interleukin-6 (IL-6) induction.	Chondroitin Sulfates	117-119	interleukin 6	Mus musculus	240-244
14709897-8	2004	Levels of anti-type II collagen antibody and tumor necrosis factor-alpha (TNF-alpha) in sera were also reduced by LMWCS treatment but not in case of CS, although no significant difference was observed between LMWCS and CS on interleukin-6 (IL-6) induction.	lmwcs	114-119	interleukin 6	Mus musculus	225-238
14709897-8	2004	Levels of anti-type II collagen antibody and tumor necrosis factor-alpha (TNF-alpha) in sera were also reduced by LMWCS treatment but not in case of CS, although no significant difference was observed between LMWCS and CS on interleukin-6 (IL-6) induction.	lmwcs	114-119	interleukin 6	Mus musculus	240-244
15630180-6	2004	Results indicate that TNF-alpha and IL-6 accumulations were significantly reduced by 5 to 20 microM quercetin treatment, and 20 microM of alpha-tocopherol treatment.	alpha-Tocopherol	138-154	interleukin 6	Mus musculus	36-40
15630182-0	2004	Production of nitric oxide, tumor necrosis factor-alpha and interleukin-6 by RAW264.7 macrophage cells treated with lactic acid bacteria isolated from kimchi.	Lactic Acid	116-127	interleukin 6	Mus musculus	60-73
15630182-3	2004	Lactobacillus plantarum, a lactic acid bacteria involved in the latent fermentation of kimchi, was the most effective for the generation of NO, TNF-alpha, and IL-6 in macrophage.	Lactic Acid	27-38	interleukin 6	Mus musculus	159-163
14738765-5	2004	Combined biochemical and pharmacological inhibitor (PD98059, U0126, SB203580, SP600125) approaches positioned MEK1/ERK1-2, but not p38 MAPK or JNK, in the IL-6/sIL-6Ralpha signaling pathway upstream of activation of L-selectin/cytoskeletal interactions and L-selectin avidity/affinity.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	52-59	interleukin 6	Mus musculus	155-159
14738765-5	2004	Combined biochemical and pharmacological inhibitor (PD98059, U0126, SB203580, SP600125) approaches positioned MEK1/ERK1-2, but not p38 MAPK or JNK, in the IL-6/sIL-6Ralpha signaling pathway upstream of activation of L-selectin/cytoskeletal interactions and L-selectin avidity/affinity.	SB 203580	68-76	interleukin 6	Mus musculus	155-159
15124859-6	2004	Selective mitogen-activated protein kinase (MAPK) kinase inhibitor PD989059 inhibited both IL-6- and LPS-induced B9 cell proliferation.	pd989059	67-75	interleukin 6	Mus musculus	91-95
15638132-6	2004	The culture supernatants of CpG-S-treated splenocytes contained elevated levels of IL-10 and IL-6.	cpg-s	28-33	interleukin 6	Mus musculus	93-97
14674008-15	2003	Plasma levels of the proinflammatory cytokines tumor necrosis factor, interleukin-1beta, and interleukin-6 were also significantly reduced by rosiglitazone treatment.	Rosiglitazone	142-155	interleukin 6	Mus musculus	93-106
15035778-6	2004	The IL-6 levels are also differ in the wild-type and histamine-deficient animals, suggesting that the effect of histamine is attained through IL-6, although direct effect is not disclosed yet.	Histamine	53-62	interleukin 6	Mus musculus	4-8
15035778-6	2004	The IL-6 levels are also differ in the wild-type and histamine-deficient animals, suggesting that the effect of histamine is attained through IL-6, although direct effect is not disclosed yet.	Histamine	53-62	interleukin 6	Mus musculus	142-146
15035778-6	2004	The IL-6 levels are also differ in the wild-type and histamine-deficient animals, suggesting that the effect of histamine is attained through IL-6, although direct effect is not disclosed yet.	Histamine	112-121	interleukin 6	Mus musculus	4-8
15035778-6	2004	The IL-6 levels are also differ in the wild-type and histamine-deficient animals, suggesting that the effect of histamine is attained through IL-6, although direct effect is not disclosed yet.	Histamine	112-121	interleukin 6	Mus musculus	142-146
14978334-3	2004	However, aminoglycosides showed a significant augmenting effect on IL-6 induction of endotoxin in 28SC cells.	Aminoglycosides	9-24	interleukin 6	Mus musculus	67-71
15153611-5	2004	IL-6R/IL-6 leads to an increase in early chondroitin sulfate proteoglycan positive and late O4 positive progenitors and to a stimulation of maturation into O1 and myelin basic protein expressing oligodendrocytes.	Chondroitin Sulfates	41-60	interleukin 6	Mus musculus	0-4
15277700-6	2004	Intravenously infused HA was found in the bone marrow, where it bound endothelial cells and resident macrophages and increased expression of the hematopoiesis-supportive cytokines interleukin-1 and interleukin-6.	Hyaluronic Acid	22-24	interleukin 6	Mus musculus	198-211
15912192-3	2004	Previous study has demonstrated that CKBM is capable of improving immune responsiveness through the induction of cytokine mediators, such as TNF-alpha and IL-6.	ckbm	37-41	interleukin 6	Mus musculus	155-159
14504727-8	2004	Compared to the control group, TNF-alpha, IL-6 and TGF-beta1 levels in the BAL in both ambroxol- and dexamethasone-treated groups were significantly reduced at 24 and 48 h. The protein in BAL, an index of vascular permeability, was also significantly decreased in the ambroxol- and dexamethasone-treated groups (p&lt;0.05).	Ambroxol	87-95	interleukin 6	Mus musculus	42-46
14504727-8	2004	Compared to the control group, TNF-alpha, IL-6 and TGF-beta1 levels in the BAL in both ambroxol- and dexamethasone-treated groups were significantly reduced at 24 and 48 h. The protein in BAL, an index of vascular permeability, was also significantly decreased in the ambroxol- and dexamethasone-treated groups (p&lt;0.05).	Dexamethasone	101-114	interleukin 6	Mus musculus	42-46
14962099-5	2004	Oxazolone also induced higher expression of the inflammatory cytokines interleukin-1 and interleukin-6 mRNA in the skin.	Oxazolone	0-9	interleukin 6	Mus musculus	89-102
14656653-8	2004	Interestingly, COX-2 was also required for IL-6 production in these assays, which could be rescued by the addition of exogenous PGE2 (10(-6) M).	Dinoprostone	128-132	interleukin 6	Mus musculus	43-47
15249727-7	2004	Treatment with propranolol augmented the epinephrine-induced increase of splenocyte apoptosis, did not affect the decrease of splenocyte proliferation and IL-2 release, augmented the release of IL-6 and antagonized the mobilization of natural killer cells observed in epinephrine-treated animals.	Propranolol	15-26	interleukin 6	Mus musculus	194-198
15249727-9	2004	Coadministration of propranolol and epinephrine augmented the propranolol-induced changes of splenocyte apoptosis and IL-6 release and was associated with the highest mortality of septic mice.	Propranolol	20-31	interleukin 6	Mus musculus	118-122
15249727-9	2004	Coadministration of propranolol and epinephrine augmented the propranolol-induced changes of splenocyte apoptosis and IL-6 release and was associated with the highest mortality of septic mice.	Epinephrine	36-47	interleukin 6	Mus musculus	118-122
15249727-9	2004	Coadministration of propranolol and epinephrine augmented the propranolol-induced changes of splenocyte apoptosis and IL-6 release and was associated with the highest mortality of septic mice.	Propranolol	62-73	interleukin 6	Mus musculus	118-122
14585852-14	2003	MRSA infection significantly increased fibronectin and interleukin-6 levels in plasma of MRSA-infected mice (P&lt;0.05); however, the oral administration of garlic extract and two diallyl sulphides significantly reduced both fibronectin and interleukin-6 levels (P&lt;0.05).	allyl sulfide	180-197	interleukin 6	Mus musculus	55-68
14638500-11	2003	The highest levels of IL-6 were measured in mice given G10 alone or in combination with tobramycin.	Tobramycin	88-98	interleukin 6	Mus musculus	22-26
14585852-14	2003	MRSA infection significantly increased fibronectin and interleukin-6 levels in plasma of MRSA-infected mice (P&lt;0.05); however, the oral administration of garlic extract and two diallyl sulphides significantly reduced both fibronectin and interleukin-6 levels (P&lt;0.05).	allyl sulfide	180-197	interleukin 6	Mus musculus	241-254
14604775-9	2003	These data indicate that COX-2-dependent PGE(2) is critical for the febrile response to IL-6, but not to MIP-1 beta.	Prostaglandins E	41-44	interleukin 6	Mus musculus	88-92
14690764-0	2003	Deoxynivalenol-induced mitogen-activated protein kinase phosphorylation and IL-6 expression in mice suppressed by fish oil.	deoxynivalenol	0-14	interleukin 6	Mus musculus	76-80
14690764-5	2003	DON-induced plasma IL-6 and splenic mRNA elevation in FO-fed mice were significantly suppressed after 8 weeks when compared to the CO-fed group.	deoxynivalenol	0-3	interleukin 6	Mus musculus	19-23
14690764-8	2003	Splenic COX-2 mRNA expression, which has been previously shown to enhance DON-induced IL-6, was also significantly decreased by FO, whereas plasma levels of the COX-2 metabolite, prostaglandin E2, were not affected.	deoxynivalenol	74-77	interleukin 6	Mus musculus	86-90
14690764-10	2003	Consistent with the in vivo findings, both EPA and DHA significantly suppressed IL-6 superinduction by DON, as well as impaired DON-induced ERK1/2 and JNK1/2 phosphorylation.	dehydroacetic acid	51-54	interleukin 6	Mus musculus	80-84
14690764-10	2003	Consistent with the in vivo findings, both EPA and DHA significantly suppressed IL-6 superinduction by DON, as well as impaired DON-induced ERK1/2 and JNK1/2 phosphorylation.	deoxynivalenol	103-106	interleukin 6	Mus musculus	80-84
15617504-0	2003	[Hepatoprotective effects of chloroform extract from leaf of Terminalia catappa in relation to the inhibition of liver IL-6 expression].	Chloroform	29-39	interleukin 6	Mus musculus	119-123
15617504-1	2003	OBJECTIVE: To study the hepatoprotective effects of Terminalia catappa chloroform extract (TCCE) and its effects on IL-6 gene over expression in liver of CCl4-treated mice.	tcce	91-95	interleukin 6	Mus musculus	116-120
14610275-7	2003	Immunomers containing the RpG dinucleotide induced high levels of IL-12 and IFN-gamma, but lower IL-6 in time- and concentration-dependent fashion in mouse spleen-cell cultures costimulated with IL-2.	Dinucleoside Phosphates	30-42	interleukin 6	Mus musculus	97-101
14644033-1	2003	Using a spleen slice microsuperfusion technique in mice, we have previously characterized the role of norepinephrine (NE) and other neurotransmitters for sympathetic modulation of IL-6 and TNF secretion of splenic macrophages.	Norepinephrine	102-116	interleukin 6	Mus musculus	180-184
14644621-3	2003	RNAse protection assay revealed that DON at 100 to 500 ng/ml induced mRNA expression of TNF-alpha as well as IL-6, IFN-gamma, TGFbeta-1, and TGFbeta-3 and that these effects were potentiated by 100 ng/ml lipopolysaccharide (LPS).	deoxynivalenol	37-40	interleukin 6	Mus musculus	109-113
14592424-0	2003	Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone.	Rosiglitazone	123-136	interleukin 6	Mus musculus	8-21
12960176-5	2003	Deleterious effects of PA are associated with the secretion of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and the production of nitric oxide, prostaglandin E2, which are predominantly released by macrophage Raw264.7 cells.	Phosphatidic Acids	23-25	interleukin 6	Mus musculus	146-159
14592424-0	2003	Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone.	Rosiglitazone	123-136	interleukin 6	Mus musculus	23-27
14592424-0	2003	Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone.	Rosiglitazone	123-136	interleukin 6	Mus musculus	49-53
14592424-5	2003	Moreover, IL-6 suppressed the insulin-induced lipogenesis and glucose transport consistent with a diminished expression of GLUT4.	Glucose	62-69	interleukin 6	Mus musculus	10-14
14592424-8	2003	Finally, the effects of IL-6 could be prevented by rosiglitazone, an insulin-sensitizing agent.	Rosiglitazone	51-64	interleukin 6	Mus musculus	24-28
12842862-10	2003	SP-600125 blocked LPS-stimulated IL-6 synthesis dose dependently at both the RNA and protein level.	pyrazolanthrone	0-9	interleukin 6	Mus musculus	33-37
14563491-0	2003	Chemically modified tetracyclines selectively inhibit IL-6 expression in osteoblasts by decreasing mRNA stability.	Tetracyclines	20-33	interleukin 6	Mus musculus	54-58
14563491-3	2003	Our previous studies indicated that non-antimicrobial chemically modified tetracyclines (CMTs) can dose-dependently inhibit IL-1 beta-induced IL-6 secretion in osteoblastic cells.	Tetracyclines	74-87	interleukin 6	Mus musculus	142-146
14563491-3	2003	Our previous studies indicated that non-antimicrobial chemically modified tetracyclines (CMTs) can dose-dependently inhibit IL-1 beta-induced IL-6 secretion in osteoblastic cells.	cmts	89-93	interleukin 6	Mus musculus	142-146
14563491-4	2003	In the present study, we explored the molecular mechanisms underlying the ability of doxycycline analogs CMT-8 and its non-chelating pyrazole derivative, CMT-5 to affect IL-6 gene expression in murine osteoblasts.	Doxycycline	85-96	interleukin 6	Mus musculus	170-174
12842862-11	2003	SP-600125 was as effective as the synthetic glucocorticoid dexamethasone at inhibiting IL-6 expression.	pyrazolanthrone	0-9	interleukin 6	Mus musculus	87-91
12842862-11	2003	SP-600125 was as effective as the synthetic glucocorticoid dexamethasone at inhibiting IL-6 expression.	Dexamethasone	59-72	interleukin 6	Mus musculus	87-91
12842862-12	2003	SP-600125 inhibited IL-6 synthesis when added to cells up to 60 min after LPS stimulation, but its inhibitory effect waned with time.	pyrazolanthrone	0-9	interleukin 6	Mus musculus	20-24
12842862-15	2003	Yet, only SP-600125 and not MG-132 blocked LPS-induced IL-6 mRNA expression.	pyrazolanthrone	10-19	interleukin 6	Mus musculus	55-59
14519947-3	2003	Pretreatment with PL 24 h before LPS administration resulted in a significant inhibition of up to 68% of circulating tumor necrosis factor (TNF)-alpha, a moderate reduction of 45% of interleukine (IL)-12 and 23% of IL-1beta, but no significant reduction in IL-6.	Polysaccharides	18-20	interleukin 6	Mus musculus	257-261
14578297-6	2003	Chronic infusion of IL-6 also reduced hepatic insulin receptor autophosphorylation by 60% and tyrosine phosphorylation of insulin receptor substrates-1 and -2 by 60 and 40%, respectively.	Tyrosine	94-102	interleukin 6	Mus musculus	20-24
14637235-6	2003	Reactivity to LPS and sensitivity to corticosterone (CS) of spleen cells was assessed by measuring the in vitro production of cytokines (IL-6, IFN-gamma and IL-10) in response to LPS under a range of increasing concentrations of CS.	Corticosterone	37-51	interleukin 6	Mus musculus	137-141
14637235-6	2003	Reactivity to LPS and sensitivity to corticosterone (CS) of spleen cells was assessed by measuring the in vitro production of cytokines (IL-6, IFN-gamma and IL-10) in response to LPS under a range of increasing concentrations of CS.	Corticosterone	53-55	interleukin 6	Mus musculus	137-141
14504137-3	2003	NECA-mediated IL-6 release was inhibited by the PLC inhibitor 1-[6-((17beta-3-methoxyestra-1,3,5(10)-tiene-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione, the PI3 kinase inhibitor wortmannin and the PKC inhibitors bisindolylmaleimide 1 and bisindolymaleimide X1 HCl (Ro-32-0432).	Wortmannin	173-183	interleukin 6	Mus musculus	14-18
14504137-3	2003	NECA-mediated IL-6 release was inhibited by the PLC inhibitor 1-[6-((17beta-3-methoxyestra-1,3,5(10)-tiene-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione, the PI3 kinase inhibitor wortmannin and the PKC inhibitors bisindolylmaleimide 1 and bisindolymaleimide X1 HCl (Ro-32-0432).	bisindolylmaleimide I	207-228	interleukin 6	Mus musculus	14-18
14504137-0	2003	Adenosine-induced IL-6 expression in pituitary folliculostellate cells is mediated via A2b adenosine receptors coupled to PKC and p38 MAPK.	Adenosine	0-9	interleukin 6	Mus musculus	18-22
14504137-2	2003	We investigated the action of adenosine A2 receptor agonists on IL-6 and VEGF secretion in two murine FS cell lines (TtT/GF and Tpit/F1), and demonstrated a rank order of potency, 5"-N-ethylcarboxamidoadenosine (NECA)&gt;2-p-(2-carboxyethyl)phenethylamino-5"-N-ethylcarboxamidoadenosine&gt;adenosine, suggesting mediation via the A2b receptor.	Adenosine	30-39	interleukin 6	Mus musculus	64-68
14504137-3	2003	NECA-mediated IL-6 release was inhibited by the PLC inhibitor 1-[6-((17beta-3-methoxyestra-1,3,5(10)-tiene-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione, the PI3 kinase inhibitor wortmannin and the PKC inhibitors bisindolylmaleimide 1 and bisindolymaleimide X1 HCl (Ro-32-0432).	bisindolymaleimide x1 hcl	233-258	interleukin 6	Mus musculus	14-18
14504137-3	2003	NECA-mediated IL-6 release was inhibited by the PLC inhibitor 1-[6-((17beta-3-methoxyestra-1,3,5(10)-tiene-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione, the PI3 kinase inhibitor wortmannin and the PKC inhibitors bisindolylmaleimide 1 and bisindolymaleimide X1 HCl (Ro-32-0432).	1-[6-((17beta-3-methoxyestra-1,3,5(10)-tiene-17-yl)amino)hexyl]-1h-pyrrole-2,5-dione	62-146	interleukin 6	Mus musculus	14-18
14504137-3	2003	NECA-mediated IL-6 release was inhibited by the PLC inhibitor 1-[6-((17beta-3-methoxyestra-1,3,5(10)-tiene-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione, the PI3 kinase inhibitor wortmannin and the PKC inhibitors bisindolylmaleimide 1 and bisindolymaleimide X1 HCl (Ro-32-0432).	Ro 32-0432	260-270	interleukin 6	Mus musculus	14-18
14504137-4	2003	NECA-mediated IL-6 release was attenuated (&lt;50%) by the extracellular signal-regulated kinase MAPK inhibitor 2"-amino-3"-methoxyflavone, and completely (&gt;95%) inhibited by the p38 MAPK inhibitor 4-(4-fluorophenyl)-2-(4-methylsulphinylphenyl)-5-(4-pyridyl)1H-imidazole.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	112-138	interleukin 6	Mus musculus	14-18
14504137-4	2003	NECA-mediated IL-6 release was attenuated (&lt;50%) by the extracellular signal-regulated kinase MAPK inhibitor 2"-amino-3"-methoxyflavone, and completely (&gt;95%) inhibited by the p38 MAPK inhibitor 4-(4-fluorophenyl)-2-(4-methylsulphinylphenyl)-5-(4-pyridyl)1H-imidazole.	4-(4-fluorophenyl)-2-(4-methylsulphinylphenyl)-5-(4-pyridyl)1h-imidazole	201-273	interleukin 6	Mus musculus	14-18
14504137-6	2003	Dexamethasone inhibits NECA-stimulated IL-6 and VEGF secretion.	Dexamethasone	0-13	interleukin 6	Mus musculus	39-43
14504137-6	2003	Dexamethasone inhibits NECA-stimulated IL-6 and VEGF secretion.	Adenosine-5'-(N-ethylcarboxamide)	23-27	interleukin 6	Mus musculus	39-43
14504137-7	2003	These findings indicate that adenosine can stimulate IL-6 secretion in FS cells via the A2b receptor coupled principally to PLC/PKC and p38 MAPK; such an action may be important in the modulation of inflammatory response processes in the pituitary gland.	Adenosine	29-38	interleukin 6	Mus musculus	53-57
12964032-8	2003	The results of this study suggest that IL-6 may play a key role in the stimulation of hepatic glutamine transport following burn injury.	Glutamine	94-103	interleukin 6	Mus musculus	39-43
14519071-4	2003	The IL-6-deficient mice had increased glucose levels and decreased glucose tolerance, and blood lipids were increased in females.	Glucose	38-45	interleukin 6	Mus musculus	4-8
13679052-0	2003	Interleukin 6 and hepatocyte regeneration in acetaminophen toxicity in the mouse.	Acetaminophen	45-58	interleukin 6	Mus musculus	0-13
12969251-3	2003	A sugar-derived post-translational modification of long-lived proteins, advanced glycation endproducts (AGEs), activate specific signal transduction pathways, resulting in the up-regulation of various pro-inflammatory signals such as cytokines [interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha)] and inducible nitric oxide synthase (iNOS).	Sugars	2-7	interleukin 6	Mus musculus	245-258
14505351-5	2003	N-3 PUFA decreased secretion of non-induced IL-6 and TNF-alpha from cultured BMC and IL-1 beta levels in vivo (i.e., in bone marrow plasma), but its main effect was a significant elevation in the secretion of IL-10, a known anti-inflammatory cytokine.	S-benzyl-N-malonylcysteine	77-80	interleukin 6	Mus musculus	44-48
12969251-3	2003	A sugar-derived post-translational modification of long-lived proteins, advanced glycation endproducts (AGEs), activate specific signal transduction pathways, resulting in the up-regulation of various pro-inflammatory signals such as cytokines [interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha)] and inducible nitric oxide synthase (iNOS).	Sugars	2-7	interleukin 6	Mus musculus	260-264
12782633-8	2003	LIF transgenic mice with a null mutation in IL-6 were more sensitive to the toxic effects of 100% O2 than LIF-transgenic animals with a wild-type IL-6 locus.	Oxygen	98-100	interleukin 6	Mus musculus	44-48
14512563-4	2003	Mouse splenocyte cultures treated with HSV DNA or HSV-derived oligodeoxyribonucleotides (ODNs) showed strong proliferative responses and production of inflammatory cytokines (gamma interferon [IFN-gamma], tumor necrosis factor [TNF], and interleukin-6 [IL-6]) in vitro, whereas splenocytes treated with mammalian CV-1 DNA or non-CpG ODN did not.	Oligodeoxyribonucleotides	62-87	interleukin 6	Mus musculus	238-251
14512563-4	2003	Mouse splenocyte cultures treated with HSV DNA or HSV-derived oligodeoxyribonucleotides (ODNs) showed strong proliferative responses and production of inflammatory cytokines (gamma interferon [IFN-gamma], tumor necrosis factor [TNF], and interleukin-6 [IL-6]) in vitro, whereas splenocytes treated with mammalian CV-1 DNA or non-CpG ODN did not.	Oligodeoxyribonucleotides	62-87	interleukin 6	Mus musculus	253-257
14551033-6	2003	The expression of cytokines such as IL-1beta, IL-2, IL-6, IL-12 and IFN-gamma in AMG- and L-NAME treated grafts were significantly decreased (P&lt;0.01), whereas IL-10, TNF-alpha and TGF-beta1 were unchanged or enhanced.	NG-Nitroarginine Methyl Ester	90-96	interleukin 6	Mus musculus	52-56
12957371-3	2003	We have previously shown that in the absence of interleukin-6 (IL-6) dopaminergic neurons are more vulnerable to MPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	113-117	interleukin 6	Mus musculus	63-67
12957371-7	2003	Extensive reactive microgliosis was observed in the SNpc of MPTP-lesioned IL-6 (+/+) mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	60-64	interleukin 6	Mus musculus	74-78
14501948-12	2003	Moreover, DHEA-treated animals demonstrated a reduction in systemic inflammatory effects, as determined by proinflammatory cytokines TNF-alpha, IL-1beta, IL-6, and the antiinflammatory cytokine IL-10.	Dehydroepiandrosterone	10-14	interleukin 6	Mus musculus	154-158
14501948-17	2003	It can be concluded that the protective effect of DHEA in polymicrobial sepsis is mediated IL-6 dependently.	Dehydroepiandrosterone	50-54	interleukin 6	Mus musculus	91-95
14501948-18	2003	DHEA reduces the systemic inflammation, measurable via the proinflammatory cytokines TNF-alpha, IL-1beta, IL-6, and the antiinflammatory cytokine IL-10.	Dehydroepiandrosterone	0-4	interleukin 6	Mus musculus	106-110
14501948-19	2003	IL-6 might be involved in the DHEA-mediated reduction of postseptic complications.	Dehydroepiandrosterone	30-34	interleukin 6	Mus musculus	0-4
12900383-6	2003	The treatment of mice with the neurotoxin 6-hydroxydopamine (6-OHDA, 100 mg x kg-1 x day-1 ip for 3 days) inhibited LPS (icv)-induced expression of IL-6 mRNA in their calvaria.	Oxidopamine	42-59	interleukin 6	Mus musculus	148-152
12900383-6	2003	The treatment of mice with the neurotoxin 6-hydroxydopamine (6-OHDA, 100 mg x kg-1 x day-1 ip for 3 days) inhibited LPS (icv)-induced expression of IL-6 mRNA in their calvaria.	Oxidopamine	61-67	interleukin 6	Mus musculus	148-152
12900383-8	2003	Furthermore, pretreatment with a beta-blocker, propranolol (15 or 25 mg/kg ip), inhibited both stress- and LPS-induced increases in the level of IL-6 mRNA, but pretreatment with an alpha-blocker, phentolamine (5 mg/kg sc), did not inhibit them in mouse calvaria.	Propranolol	47-58	interleukin 6	Mus musculus	145-149
12900383-8	2003	Furthermore, pretreatment with a beta-blocker, propranolol (15 or 25 mg/kg ip), inhibited both stress- and LPS-induced increases in the level of IL-6 mRNA, but pretreatment with an alpha-blocker, phentolamine (5 mg/kg sc), did not inhibit them in mouse calvaria.	Phentolamine	196-208	interleukin 6	Mus musculus	145-149
12900383-9	2003	In addition, treatment of calvaria with isoprenaline or norepinephrine increased IL-6 synthesis in the organ culture system.	Isoproterenol	40-52	interleukin 6	Mus musculus	81-85
12900383-9	2003	In addition, treatment of calvaria with isoprenaline or norepinephrine increased IL-6 synthesis in the organ culture system.	Norepinephrine	56-70	interleukin 6	Mus musculus	81-85
13129557-8	2003	Serum IL-6 levels 6 hours after surgery (OC: 4157+/-1297 pg/ml vs. LC: 2514+/-1417 pg/ml vs. LH: 2255+/-1714 pg/ml) and VEGF levels on postoperative day 12 (OC: 231+/-125 pg/ml vs. LC: 45+/-9 pg/ml vs. LH: 49+/-8 pg/ml), measured by enzyme-linked immunosorbent assay, were significantly higher in the laparotomy group.	Luteinizing Hormone	202-204	interleukin 6	Mus musculus	6-10
12921875-2	2003	Among the 51 compounds examined, 7-amino-4-methylcoumarin (AMC) suppressed the production of interleukin-1alpha, interleukin-6 and tumor necrosis factor (TNF)-alpha, and their lipopolysaccharide-induced mRNAs in P388D1 cells.	7-amino-4-methylcoumarin	33-57	interleukin 6	Mus musculus	113-126
12921875-2	2003	Among the 51 compounds examined, 7-amino-4-methylcoumarin (AMC) suppressed the production of interleukin-1alpha, interleukin-6 and tumor necrosis factor (TNF)-alpha, and their lipopolysaccharide-induced mRNAs in P388D1 cells.	7-amino-4-methylcoumarin	59-62	interleukin 6	Mus musculus	113-126
12889010-7	2003	J774A.1 mouse macrophages were plated on oxide-coated silicone and polystyrene and stimulated to produce superoxide and interleukin-6.	Oxides	41-46	interleukin 6	Mus musculus	120-133
12898533-0	2003	Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamide.	6-Aminonicotinamide	125-144	interleukin 6	Mus musculus	33-46
12898533-3	2003	This study demonstrates that transgenic IL-6 expression significantly increases the 6-AN-induced inflammatory response of reactive astrocytes, microglia/macrophages, and lymphocytes in the brainstem.	6-Aminonicotinamide	84-88	interleukin 6	Mus musculus	40-44
12891556-1	2003	BACKGROUND &amp; AIMS: Interleukin 6 (IL-6) contributes via its signal transducer gp130 to the acute phase response (APR) in hepatocytes.	Adenosine Monophosphate	12-15	interleukin 6	Mus musculus	23-36
12891556-1	2003	BACKGROUND &amp; AIMS: Interleukin 6 (IL-6) contributes via its signal transducer gp130 to the acute phase response (APR) in hepatocytes.	Adenosine Monophosphate	12-15	interleukin 6	Mus musculus	38-42
12964805-3	2003	Selenium supplementation enhanced significantly (p &lt; 0.05) the release of tumor necrosis factor (5-fold), interleukin-1 (3-fold) and interleukin-6 (2.5-fold) after 10 microg/ml lipopolysaccharide stimulation compared to selenium-deficient cells.	Selenium	0-8	interleukin 6	Mus musculus	109-149
12884300-0	2003	ME3738 protects from concanavalin A-induced liver failure via an IL-6-dependent mechanism.	ME3738	0-6	interleukin 6	Mus musculus	65-69
12884300-4	2003	The protective effect of ME3738 prior to Con A injection was associated with a reduction in IL-6 serum levels and NF-kappaB DNA binding in liver nuclear extracts.	ME3738	25-31	interleukin 6	Mus musculus	92-96
12884300-6	2003	Further analysis showed that ME3738 induces IL-6 serum levels and activates STAT3 DNA binding and target gene transcription.	ME3738	29-35	interleukin 6	Mus musculus	44-48
12884300-10	2003	Therefore, we demonstrate that ME3738 triggers IL-6 expression, which activates pathways that are relevant to protect from Con A-induced liver failure.	ME3738	31-37	interleukin 6	Mus musculus	47-51
14514469-8	2003	The data in the present study also showed that pre-treatment of mice with macrolide antibiotics for 4 weeks significantly suppresses not only production of pro-inflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha, but also inducible nitric oxide synthase mRNA expressions, which are enhanced by LPS injection.	macrolide antibiotics	74-95	interleukin 6	Mus musculus	202-248
12956900-7	2003	Applied topically onto the ears before TDI challenge, AWD 12-281, cilomilast and diflorasone diacetate caused total inhibition of ear swelling 24 h after challenge, confirmed by a decrease of the pro-inflammatory cytokines interleukin-4, interleukin-6 and macrophage inhibitory protein-2.	Cilomilast	66-76	interleukin 6	Mus musculus	238-251
12956900-7	2003	Applied topically onto the ears before TDI challenge, AWD 12-281, cilomilast and diflorasone diacetate caused total inhibition of ear swelling 24 h after challenge, confirmed by a decrease of the pro-inflammatory cytokines interleukin-4, interleukin-6 and macrophage inhibitory protein-2.	diflorasone	81-102	interleukin 6	Mus musculus	238-251
12836160-2	2003	Low doses of kainic acid (5 mg/kg) that produced little or no behavioral or electroencephalogram (EEG) alterations in wild type or glial fibrillary acidic protein (GFAP)-TNF animals induced severe tonic-clonic seizures and death in GFAP-IL6 transgenic mice of 2 or 6 months of age.	Kainic Acid	13-24	interleukin 6	Mus musculus	237-240
12836160-3	2003	GFAP-IL6 mice were also significantly more sensitive to N-methyl-D-aspartate (NMDA)- but not pilocarpine-induced seizures.	N-Methylaspartate	56-76	interleukin 6	Mus musculus	5-8
12836160-3	2003	GFAP-IL6 mice were also significantly more sensitive to N-methyl-D-aspartate (NMDA)- but not pilocarpine-induced seizures.	N-Methylaspartate	78-82	interleukin 6	Mus musculus	5-8
12836160-3	2003	GFAP-IL6 mice were also significantly more sensitive to N-methyl-D-aspartate (NMDA)- but not pilocarpine-induced seizures.	Pilocarpine	93-104	interleukin 6	Mus musculus	5-8
12836160-4	2003	Kainic acid uptake in the brain of the GFAP-IL6 mice was higher in the cerebellum but not in other regions.	Kainic Acid	0-11	interleukin 6	Mus musculus	44-47
12836160-5	2003	Kainic acid binding in the brain of GFAP-IL6 mice had a similar distribution and density as wild type controls.	Kainic Acid	0-11	interleukin 6	Mus musculus	41-44
12836160-6	2003	In the hippocampus of GFAP-IL6 mice that survived low dose kainic acid, there was no change in the extent of either neurodegeneration or astrocytosis.	Kainic Acid	59-70	interleukin 6	Mus musculus	27-30
12836160-7	2003	Immunostaining revealed degenerative changes in gamma aminobutyric acid (GABA)- and parvalbumin-positive neurons in the hippocampus of 2-month-old GFAP-IL6 mice which progressed to the loss of these cells at 6 months of age.	gamma-Aminobutyric Acid	48-71	interleukin 6	Mus musculus	152-155
12836160-7	2003	Immunostaining revealed degenerative changes in gamma aminobutyric acid (GABA)- and parvalbumin-positive neurons in the hippocampus of 2-month-old GFAP-IL6 mice which progressed to the loss of these cells at 6 months of age.	gamma-Aminobutyric Acid	73-77	interleukin 6	Mus musculus	152-155
12829195-10	2003	Stress-induced IL-6 release was absent in W/W(v) mast cell-deficient mice and it was partially inhibited by cromolyn in C57BL and ApoE mice.	Cromolyn Sodium	108-116	interleukin 6	Mus musculus	15-19
12967786-8	2003	This was supported by studies in murine kidney reperfusion injury, where deoxyspergualin given 5 h before reperfusion protected renal function and reduced levels of IL-6 and IL-12.	gusperimus	73-88	interleukin 6	Mus musculus	165-169
12698271-7	2003	DOX treatment increased the levels of TNF, but not IL1, mRNA and decreased the levels of IL6 mRNA and protein.	Doxorubicin	0-3	interleukin 6	Mus musculus	89-92
12817006-0	2003	TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex.	Tyrosine	18-26	interleukin 6	Mus musculus	157-161
12817006-5	2003	In this context the cytoplasmic SHP2/SOCS3 recruitment site of gp130 tyrosine 759 is shown to be important for the inhibitory effects of TNF-alpha, since mutation of this residue completely restores IL-6-stimulated activation of STAT3 and, consequently, of a STAT3-dependent promoter.	Tyrosine	69-77	interleukin 6	Mus musculus	199-203
12660147-6	2003	This was apparent in the differences of ER expression, especially that of ER-beta, and an association between increased 17beta-estradiol synthesis and sustained release of IL-2 and IL-6 in T lymphocytes of proestrus females after TH.	Estradiol	120-136	interleukin 6	Mus musculus	181-185
12665535-4	2003	Plasma TNF-alpha, IL-6, and IL-10 levels were elevated after trauma-hemorrhage and normalized by 4-OHA.	formestane	97-102	interleukin 6	Mus musculus	18-22
12791541-8	2003	Exposure to simazine also decreased cytokine production by macrophages, such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-alpha).	Simazine	12-20	interleukin 6	Mus musculus	102-106
12826907-7	2003	CONCLUSION Our findings demonstrate that 15d-PGJ2 attenuates the severity of AP most likely through the inhibition of COX-2 expression, IL-6 production, and NF-kappaB activation.	15-deoxyprostaglandin J2	41-49	interleukin 6	Mus musculus	136-140
12804137-7	2003	EGTA increased BALF cell counts, neutrophils, and murine (m) macrophage inflammatory protein 2, mKC, mIL-6, and mIL-1 beta levels.	Egtazic Acid	0-4	interleukin 6	Mus musculus	101-106
12709512-7	2003	Furthermore, the levels of the inflammation-related genes MCP-1, PAI, TF, IL-6, and ICAM-1 and the extent of lung inflammation were reduced during the initiation of caerulein-induced acute pancreatitis in EGR-1-deficient mice.	Ceruletide	165-174	interleukin 6	Mus musculus	74-78
12773709-8	2003	Lastly, oral administration of PG101 highly increased serum levels of GM-CSF, IL-6, and IL-1beta.	pg101	31-36	interleukin 6	Mus musculus	78-82
12854165-11	2003	The concentration of TNF-alpha (P&lt;0.05) and IL-6 (P&lt;0.01) in tumor-bearing mice was reduced after administration of 0.5 mg x kg(-1) IND for 7 days.	Indomethacin	138-141	interleukin 6	Mus musculus	47-51
12854165-12	2003	But the level of IL-6 was slightly elevated following treatment of IND 2.0 mg x kg(-1).	Indomethacin	67-70	interleukin 6	Mus musculus	17-21
12854165-16	2003	Low dose of indomethacin alleviates the cachexia, decreases the activation of NF-kappaB and the serum levels of TNF-alpha and IL-6, and prevents body weight loss and muscle atrophy, while no further effect is gained by a higher dosage.	Indomethacin	12-24	interleukin 6	Mus musculus	126-130
12787887-6	2003	Nobiletin also interfered with the lipopolysaccharide-induced production of PGE(2) and the gene expression of proinflammatory cytokines including IL-1alpha, IL-1beta, TNF-alpha and IL-6 in mouse J774A.1 macrophages.	nobiletin	0-9	interleukin 6	Mus musculus	181-185
12665506-0	2003	Interleukin-6 family of cytokines mediates isoproterenol-induced delayed STAT3 activation in mouse heart.	Isoproterenol	43-56	interleukin 6	Mus musculus	0-13
12873716-2	2003	Interleukin-6 production was decreased 40% to 60% in osteoblastic cells treated with genistein from either day 8-16 or day 12-16, at dietarily achievable concentrations (10(-10) to 10(-8) M) (P&lt;0.05).	Genistein	85-94	interleukin 6	Mus musculus	0-13
12873716-6	2003	The addition of ICI-182,780, an estrogen receptor blocker, reduced the inhibitory effect of genistein on IL-6 production by 30-50%.	Genistein	92-101	interleukin 6	Mus musculus	105-109
12873716-7	2003	In summary, these findings suggest that the beneficial skeletal effects of genistein, at dietarily achievable levels, appear to be mediated, at least in part, by interleukin-6 and osteoprotegerin, and estrogen receptors play important roles in the inhibition of interleukin-6 synthesis by genistein in osteoblastic MC3T3-E1 cells.	Genistein	75-84	interleukin 6	Mus musculus	162-175
12873716-7	2003	In summary, these findings suggest that the beneficial skeletal effects of genistein, at dietarily achievable levels, appear to be mediated, at least in part, by interleukin-6 and osteoprotegerin, and estrogen receptors play important roles in the inhibition of interleukin-6 synthesis by genistein in osteoblastic MC3T3-E1 cells.	Genistein	75-84	interleukin 6	Mus musculus	262-275
12751959-4	2003	In addition, ginsan induced the endogenous production of cytokines such as Il1, Il6, Ifng and Il12, which are required for hematopoietic recovery, and was able to enhance Th1 function while interfering with the Th2 response in irradiated mice.	ginsan	13-19	interleukin 6	Mus musculus	80-83
12738885-6	2003	7-Thia-8-oxoguanosine, 7-deazaguanosine, and related guanosine analogs activated mouse immune cells in a manner analogous to known TLR ligands, inducing cytokine production in mouse splenocytes (IL-6 and IL-12, type I and II IFNs), bone marrow-derived macrophages (IL-6 and IL-12), and in human peripheral blood leukocytes (type I IFNs, tumor necrosis factor alpha and IL-12).	isatoribine	0-21	interleukin 6	Mus musculus	195-199
12738885-6	2003	7-Thia-8-oxoguanosine, 7-deazaguanosine, and related guanosine analogs activated mouse immune cells in a manner analogous to known TLR ligands, inducing cytokine production in mouse splenocytes (IL-6 and IL-12, type I and II IFNs), bone marrow-derived macrophages (IL-6 and IL-12), and in human peripheral blood leukocytes (type I IFNs, tumor necrosis factor alpha and IL-12).	isatoribine	0-21	interleukin 6	Mus musculus	265-269
12738885-6	2003	7-Thia-8-oxoguanosine, 7-deazaguanosine, and related guanosine analogs activated mouse immune cells in a manner analogous to known TLR ligands, inducing cytokine production in mouse splenocytes (IL-6 and IL-12, type I and II IFNs), bone marrow-derived macrophages (IL-6 and IL-12), and in human peripheral blood leukocytes (type I IFNs, tumor necrosis factor alpha and IL-12).	7-deazaguanosine	23-39	interleukin 6	Mus musculus	195-199
12929579-0	2003	Effects of benzo[alpha]pyrene, 2-bromopropane, phenol and 2,3,7,8-tetrachlorodibenzo-p-dioxin on IL-6 production in mice after single or repeated exposure.	Benzo[alpha]pyrene	11-29	interleukin 6	Mus musculus	97-101
12697697-8	2003	Based on these data, we propose that IL-6 is produced at the local inflammatory site under the control of IL-1 beta and is the circulating afferent signal that is in part responsible for elevated HPAA activity, possibly acting via eicosanoid production within the cerebrovasculature.	Eicosanoids	231-241	interleukin 6	Mus musculus	37-41
12676746-9	2003	SB-208350 and PD-98059 inhibited the increase in IL-6 production induced by IL-1beta.	sb-208350	0-9	interleukin 6	Mus musculus	49-53
12676746-9	2003	SB-208350 and PD-98059 inhibited the increase in IL-6 production induced by IL-1beta.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	14-22	interleukin 6	Mus musculus	49-53
12697697-1	2003	The cytokines IL-1 and IL-6 are able to induce prostaglandin (PG)-dependent activation of the hypothalamo-pituitary-adrenal axis (HPAA) and are thought to play key roles in immune-neuroendocrine interactions during inflammation.	Prostaglandins	47-60	interleukin 6	Mus musculus	23-27
12697697-1	2003	The cytokines IL-1 and IL-6 are able to induce prostaglandin (PG)-dependent activation of the hypothalamo-pituitary-adrenal axis (HPAA) and are thought to play key roles in immune-neuroendocrine interactions during inflammation.	Prostaglandins	62-64	interleukin 6	Mus musculus	23-27
12697697-2	2003	The present study shows that inflammation induced by im injection of turpentine (TPS) in the hind limb of mice causes an increase in the plasma concentration of IL-6, but not that of IL-1 alpha or IL-1 beta, together with a prolonged (&gt;18-h) activation of the HPAA.	Turpentine	69-79	interleukin 6	Mus musculus	161-165
12697697-2	2003	The present study shows that inflammation induced by im injection of turpentine (TPS) in the hind limb of mice causes an increase in the plasma concentration of IL-6, but not that of IL-1 alpha or IL-1 beta, together with a prolonged (&gt;18-h) activation of the HPAA.	tissue polypeptide specific antigen	81-84	interleukin 6	Mus musculus	161-165
12697697-3	2003	IL-6 plays a causal role in the TPS-induced elevation in HPAA activity, because the sustained (8-18 h) increases in 1) plasma corticosterone, 2) plasma ACTH, and 3) induction of c-Fos in the hypothalamic paraventricular nucleus are all markedly blunted in IL-6-deficient (IL-6(-/-)) mice.	tissue polypeptide specific antigen	32-35	interleukin 6	Mus musculus	0-4
12697697-3	2003	IL-6 plays a causal role in the TPS-induced elevation in HPAA activity, because the sustained (8-18 h) increases in 1) plasma corticosterone, 2) plasma ACTH, and 3) induction of c-Fos in the hypothalamic paraventricular nucleus are all markedly blunted in IL-6-deficient (IL-6(-/-)) mice.	tissue polypeptide specific antigen	32-35	interleukin 6	Mus musculus	256-260
12697697-3	2003	IL-6 plays a causal role in the TPS-induced elevation in HPAA activity, because the sustained (8-18 h) increases in 1) plasma corticosterone, 2) plasma ACTH, and 3) induction of c-Fos in the hypothalamic paraventricular nucleus are all markedly blunted in IL-6-deficient (IL-6(-/-)) mice.	tissue polypeptide specific antigen	32-35	interleukin 6	Mus musculus	256-260
12697697-3	2003	IL-6 plays a causal role in the TPS-induced elevation in HPAA activity, because the sustained (8-18 h) increases in 1) plasma corticosterone, 2) plasma ACTH, and 3) induction of c-Fos in the hypothalamic paraventricular nucleus are all markedly blunted in IL-6-deficient (IL-6(-/-)) mice.	Corticosterone	126-140	interleukin 6	Mus musculus	0-4
12697697-4	2003	Peripheral administration of a neutralizing IL-6 antiserum inhibited the plasma corticosterone response of normal (C57BL/6) mice to hind limb inflammation to an extent similar to that seen in IL-6(-/-) mice, suggesting that the IL-6 responsible for the increased HPAA activity is produced, or acts, on the blood side of the blood-brain barrier.	Corticosterone	80-94	interleukin 6	Mus musculus	44-48
12697697-4	2003	Peripheral administration of a neutralizing IL-6 antiserum inhibited the plasma corticosterone response of normal (C57BL/6) mice to hind limb inflammation to an extent similar to that seen in IL-6(-/-) mice, suggesting that the IL-6 responsible for the increased HPAA activity is produced, or acts, on the blood side of the blood-brain barrier.	hpaa	263-267	interleukin 6	Mus musculus	44-48
12929579-0	2003	Effects of benzo[alpha]pyrene, 2-bromopropane, phenol and 2,3,7,8-tetrachlorodibenzo-p-dioxin on IL-6 production in mice after single or repeated exposure.	Polychlorinated Dibenzodioxins	58-93	interleukin 6	Mus musculus	97-101
12797899-8	2003	These findings show for the first time, that L-mimosine may have an anti-inflammatory effect on chronic inflammation and an inhibitory effect on tumor necrosis factor alpha and interleukin-6 generation in supernatant fluids of minced granulomas.	Mimosine	45-55	interleukin 6	Mus musculus	177-190
12929579-4	2003	Serum IL-6 levels were significantly increased in the TCDD-treated group at 24 hours and 48 hours after a single exposure, whereas exposure to phenol, B[alpha]P or 2-BP did not cause a significant difference.	Polychlorinated Dibenzodioxins	54-58	interleukin 6	Mus musculus	6-10
12929579-6	2003	A repeated dose of TCDD (once/week for 4 weeks) resulted in a significant elevation of IL-6 levels in serum and its spontaneous production in culture supernatants of splenocytes.	Polychlorinated Dibenzodioxins	19-23	interleukin 6	Mus musculus	87-91
12929579-8	2003	These results suggest that repeated exposure to TCDD might impair the regulation of immune response by deregulating the production of IL-6.	Polychlorinated Dibenzodioxins	48-52	interleukin 6	Mus musculus	134-138
12736434-0	2003	Interleukin-6 protects skin lesion caused by 7,12-dimethylbenz[a]anthracene.	9,10-Dimethyl-1,2-benzanthracene	45-75	interleukin 6	Mus musculus	0-13
12711143-0	2003	Soybean isoflavones inhibit tumor necrosis factor-alpha-induced apoptosis and the production of interleukin-6 and prostaglandin E2 in osteoblastic cells.	Isoflavones	8-19	interleukin 6	Mus musculus	96-109
12673041-0	2003	Serotonin depletion enhances the intracerebroventricularly administered MK-801-induced plasma interleukin-6 levels in mice.	Serotonin	0-9	interleukin 6	Mus musculus	94-107
12673041-0	2003	Serotonin depletion enhances the intracerebroventricularly administered MK-801-induced plasma interleukin-6 levels in mice.	Dizocilpine Maleate	72-78	interleukin 6	Mus musculus	94-107
12673041-2	2003	administered MK-801-induced plasma interleukin-6 (IL-6) levels, we pretreated mice with parachlorophenylalanine (PCPA, 300 mg/kg, i.p.)	Dizocilpine Maleate	13-19	interleukin 6	Mus musculus	35-48
12673041-2	2003	administered MK-801-induced plasma interleukin-6 (IL-6) levels, we pretreated mice with parachlorophenylalanine (PCPA, 300 mg/kg, i.p.)	Dizocilpine Maleate	13-19	interleukin 6	Mus musculus	50-54
12673041-6	2003	MK-801-induced rise of plasma IL-6 level was markedly enhanced in the PCPA-pretreated mice.	Dizocilpine Maleate	0-6	interleukin 6	Mus musculus	30-34
12673041-6	2003	MK-801-induced rise of plasma IL-6 level was markedly enhanced in the PCPA-pretreated mice.	Fenclonine	70-74	interleukin 6	Mus musculus	30-34
12673041-9	2003	These results suggest that serotonergic system is involved in the suppressive regulation of MK-801-induced plasma IL-6 level.	Dizocilpine Maleate	92-98	interleukin 6	Mus musculus	114-118
12755380-8	2003	RESULTS: Spleen cells from etoposide-treated mice secreted lower amounts of IL-6 and TNF as compared to the control animals.	Etoposide	27-36	interleukin 6	Mus musculus	76-80
12755380-9	2003	In addition, in vitro etoposide-exposed macrophages showed reduced capacity to produce TNF, IL-6 and MIP-1alpha.	Etoposide	22-31	interleukin 6	Mus musculus	92-96
12711143-9	2003	Treatment with soybean isoflavones (10(-5)M), in the presence of TNF-alpha (10(-10)M), for 48 h inhibited production of IL-6 and PGE(2), suggesting the antiresorptive action of soy phytoestrogen may be mediated by decreases in these local factors.	Isoflavones	23-34	interleukin 6	Mus musculus	120-124
12773982-14	2003	CONCLUSION: Our data suggest synergy between increased pO(2) and lipopolysaccharide for macrophage TNF and interleukin-6 production.	PO-2	55-60	interleukin 6	Mus musculus	107-120
12705907-0	2003	Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease.	Acetaminophen	86-99	interleukin 6	Mus musculus	8-21
12705907-3	2003	Following the induction of liver injury with acetaminophen (APAP), a time-dependent increase in liver mRNA expression of IL-6 and its family members IL-11, leukemia inhibitory factor, and oncostatin M was observed in wild type (WT) mice, suggesting a possible hepatoprotective role played by this cytokine family.	Acetaminophen	45-58	interleukin 6	Mus musculus	121-125
12705907-3	2003	Following the induction of liver injury with acetaminophen (APAP), a time-dependent increase in liver mRNA expression of IL-6 and its family members IL-11, leukemia inhibitory factor, and oncostatin M was observed in wild type (WT) mice, suggesting a possible hepatoprotective role played by this cytokine family.	Acetaminophen	60-64	interleukin 6	Mus musculus	121-125
12705907-4	2003	Indeed, mice lacking IL-6 (IL-6-/-) were more susceptible than were WT mice to APAP-induced liver injury.	Acetaminophen	79-83	interleukin 6	Mus musculus	21-25
12705907-4	2003	Indeed, mice lacking IL-6 (IL-6-/-) were more susceptible than were WT mice to APAP-induced liver injury.	Acetaminophen	79-83	interleukin 6	Mus musculus	27-31
12705907-5	2003	The increased susceptibility of the IL-6-/- mice was associated with a deficiency in the expression of hepatic heat shock protein (HSP)25, 32, and 40 as well as inducible HSP70 following APAP treatment.	Acetaminophen	187-191	interleukin 6	Mus musculus	36-40
12673036-3	2003	(+)-Catechin caused a significant elevation of cell survival at 10(-5) and 10(-4) M and alkaline phosphatase activity at 10(-5) M. Also, treatment with (+)-catechin (10(-5) M) decreased bone-resorbing cytokines (TNF-alpha and IL-6) production and apoptosis in osteoblasts.	Catechin	0-12	interleukin 6	Mus musculus	226-230
12673036-3	2003	(+)-Catechin caused a significant elevation of cell survival at 10(-5) and 10(-4) M and alkaline phosphatase activity at 10(-5) M. Also, treatment with (+)-catechin (10(-5) M) decreased bone-resorbing cytokines (TNF-alpha and IL-6) production and apoptosis in osteoblasts.	Catechin	152-164	interleukin 6	Mus musculus	226-230
12736434-2	2003	We here studied possible protective effects of IL-6 on skin damage caused by 7,12-dimethylbenz[a]anthracene (DMBA) by using IL-6 null mice.	9,10-Dimethyl-1,2-benzanthracene	77-107	interleukin 6	Mus musculus	47-51
12540842-7	2003	In the STAP-2(-/-) hepatocytes, the interleukin-6-induced expression of acute-phase (AP) genes and the tyrosine-phosphorylation level of STAT3 were reduced specifically at the late phase (6-24 h) of the response.	Tyrosine	103-111	interleukin 6	Mus musculus	36-49
12736434-7	2003	Recombinant hIL-6 treatment to DMBA-treated IL-6-null mice suppressed the occurrence of the skin damage, indicating.	6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene	31-35	interleukin 6	Mus musculus	13-17
12633505-6	2003	Wortmannin significantly reduced IL-6-induced phosphorylation of Akt and IL-6-dependent growth of 7TD1 cells.	Wortmannin	0-10	interleukin 6	Mus musculus	33-37
12588513-5	2003	In contrast, IL-6 release was already significantly higher 6 h after stimulation and further increased at 24 h. The correlation between accumulated nitrite and secreted IL-6 was 0.84 after 24 h of incubation with LPS.	Nitrites	148-155	interleukin 6	Mus musculus	13-17
12588513-5	2003	In contrast, IL-6 release was already significantly higher 6 h after stimulation and further increased at 24 h. The correlation between accumulated nitrite and secreted IL-6 was 0.84 after 24 h of incubation with LPS.	Nitrites	148-155	interleukin 6	Mus musculus	169-173
12547723-15	2003	The ability of IL-6 to induce tyrosine phosphorylation of STAT3 was abolished in the LNCaP-IL-6+ subline.	Tyrosine	30-38	interleukin 6	Mus musculus	15-19
12547723-15	2003	The ability of IL-6 to induce tyrosine phosphorylation of STAT3 was abolished in the LNCaP-IL-6+ subline.	Tyrosine	30-38	interleukin 6	Mus musculus	91-95
12706293-2	2003	We demonstrate that in FS TtT/GF cells, estradiol (E(2)) inhibits dose dependently pituitary adenylate cyclase activating polypeptide (PACAP)-stimulated IL-6 secretion and transcription.	Estradiol	40-49	interleukin 6	Mus musculus	153-157
12586220-6	2003	A single dose of EtOH suppressed induction of mRNA for IFN-alpha, IFN-beta, IFN-gamma, IL-6, IL-9, IL-12, and IL-15.	Ethanol	17-21	interleukin 6	Mus musculus	87-91
12734774-0	2003	Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor alpha, growth hormone, and IL-6 in 3T3-L1 adipocytes.	Isoproterenol	61-74	interleukin 6	Mus musculus	0-18
12734774-5	2003	Interestingly, treatment of adipocytes with 100 nM insulin, 10 micro M isoproterenol, 10 ng/ml tumour necrosis factor alpha (TNFalpha), and 500 ng/ml growth hormone (GH) for 16 h stimulated IL-6 mRNA expression 2.3-fold, 47-fold, 74-fold, and 1.4-fold, respectively (p &lt; 0.01).	Isoproterenol	71-84	interleukin 6	Mus musculus	190-194
12734774-6	2003	In contrast, treatment with 100 nM dexamethasone significantly decreased IL-6 expression to 32 % of control levels (p &lt; 0.01), whereas triiodothyronine and angiotensin 2 did not have any effect.	Dexamethasone	35-48	interleukin 6	Mus musculus	73-77
12734774-7	2003	Furthermore, stimulation of IL-6 expression was time-dependent with maximal stimulatory effects detectable after 1 h of insulin, isoproterenol, and GH addition and 12 h of TNFalpha, respectively.	Isoproterenol	129-142	interleukin 6	Mus musculus	28-32
12734774-10	2003	Taken together, our results demonstrate that IL-6 expression in adipocytes is governed by an autocrine positive feedback loop and upregulated by insulin, isoproterenol, TNFalpha, and GH.	Isoproterenol	154-167	interleukin 6	Mus musculus	45-49
12649040-0	2003	Cyclooxygenase-2 mediates interleukin-6 upregulation by vomitoxin (deoxynivalenol) in vitro and in vivo.	deoxynivalenol	56-65	interleukin 6	Mus musculus	26-39
12649040-0	2003	Cyclooxygenase-2 mediates interleukin-6 upregulation by vomitoxin (deoxynivalenol) in vitro and in vivo.	deoxynivalenol	67-81	interleukin 6	Mus musculus	26-39
12649040-1	2003	Interleukin-6 (IL-6) is a central mediator of immunotoxicity that is associated with exposure to the trichothecene vomitoxin (VT).	trichothecene vomitoxin	101-124	interleukin 6	Mus musculus	0-13
12649040-1	2003	Interleukin-6 (IL-6) is a central mediator of immunotoxicity that is associated with exposure to the trichothecene vomitoxin (VT).	trichothecene vomitoxin	101-124	interleukin 6	Mus musculus	15-19
12649040-4	2003	Superinduction of lipopolysaccharide (LPS)-mediated IL-6 production by VT in these cells was significantly reduced by the COX inhibitors indomethacin and NS-398, whereas the inhibitors did not affect direct induction of IL-6 by LPS alone.	Indomethacin	137-149	interleukin 6	Mus musculus	52-56
12649040-4	2003	Superinduction of lipopolysaccharide (LPS)-mediated IL-6 production by VT in these cells was significantly reduced by the COX inhibitors indomethacin and NS-398, whereas the inhibitors did not affect direct induction of IL-6 by LPS alone.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	154-160	interleukin 6	Mus musculus	52-56
12649040-7	2003	Also consistent with a putative contributory role for COX-2 was the finding that both induction of splenic IL-6 mRNA and serum IL-6 by VT were significantly reduced by pretreating mice with the COX inhibitors indomethacin or NS-398.	Indomethacin	209-221	interleukin 6	Mus musculus	107-111
12649040-7	2003	Also consistent with a putative contributory role for COX-2 was the finding that both induction of splenic IL-6 mRNA and serum IL-6 by VT were significantly reduced by pretreating mice with the COX inhibitors indomethacin or NS-398.	Indomethacin	209-221	interleukin 6	Mus musculus	127-131
12649040-7	2003	Also consistent with a putative contributory role for COX-2 was the finding that both induction of splenic IL-6 mRNA and serum IL-6 by VT were significantly reduced by pretreating mice with the COX inhibitors indomethacin or NS-398.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	225-231	interleukin 6	Mus musculus	107-111
12649040-7	2003	Also consistent with a putative contributory role for COX-2 was the finding that both induction of splenic IL-6 mRNA and serum IL-6 by VT were significantly reduced by pretreating mice with the COX inhibitors indomethacin or NS-398.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	225-231	interleukin 6	Mus musculus	127-131
12429018-0	2003	Prostaglandin E2 mediates growth arrest in NFS-60 cells by down-regulating interleukin-6 receptor expression.	Dinoprostone	0-16	interleukin 6	Mus musculus	75-88
12429018-3	2003	Here we investigated whether PGE2 can modulate IL-6-stimulated growth in the promyelocytic cell line, NFS-60, by down-regulating IL-6 receptor (IL-6r) expression.	Dinoprostone	29-33	interleukin 6	Mus musculus	47-51
12429018-4	2003	Exposure of NFS-60 cells to PGE2 suppressed IL-6-stimulated proliferation as well as IL-6r expression.	Dinoprostone	28-32	interleukin 6	Mus musculus	44-48
12429018-8	2003	Butaprost (EP2 agonist) but not sulprostone (EP3 agonist) inhibited IL-6-stimulated proliferation.	butaprost	0-9	interleukin 6	Mus musculus	68-72
12633505-6	2003	Wortmannin significantly reduced IL-6-induced phosphorylation of Akt and IL-6-dependent growth of 7TD1 cells.	Wortmannin	0-10	interleukin 6	Mus musculus	73-77
12633505-7	2003	Furthermore, wortmannin blocked IL-6-induced up-regulation of XIAP, but not Bcl-2 in 7TD1 cells.	Wortmannin	13-23	interleukin 6	Mus musculus	32-36
12490370-6	2003	Production of IFN-gamma and IL-6 was increased, for formulated as compared to free antigen, in microcultures from both nai;ve and pre-immunised animals.	Sodium Iodide	119-122	interleukin 6	Mus musculus	28-32
14575147-2	2003	In this paper we report that histamine affects interleukin (IL)-12 and IL-6 production in an immature DC (iDC) line derived from murine spleen.	Histamine	29-38	interleukin 6	Mus musculus	71-75
12496442-5	2003	Cell signaling studies showed that murine OSM, LIF, IL-6, and CT-1 stimulated the tyrosine phosphorylation of STAT-3, suggesting STAT-3 activation is not sufficient for eotaxin induction in NIH 3T3 cells.	Tyrosine	82-90	interleukin 6	Mus musculus	52-56
12413741-3	2002	DNP-KLH immunization with complete Freund"s adjuvant (CFA) markedly augmented anti-DNP antibody production and induced interleukin 6 (IL-6) production in serum.	dnp-klh	0-7	interleukin 6	Mus musculus	119-132
12573707-3	2003	Generally, right cortices had higher interleukin-1beta and interleukin-6 levels than left cortices for both saline and lipopolysaccharide-treated mice.	Sodium Chloride	108-114	interleukin 6	Mus musculus	59-72
12573707-5	2003	For the saline-treated mice: in their left cortices, interleukin-1beta levels were higher for ambidextrous mice than for right-pawed mice (P&lt;0.05); in their right cortices, interleukin-6 levels were higher for ambidextrous mice than for right-/left-pawed mice, and right-pawed mice have higher levels of interleukin-6 than left-pawed mice (P&lt;0.01).	Sodium Chloride	8-14	interleukin 6	Mus musculus	176-189
12573707-5	2003	For the saline-treated mice: in their left cortices, interleukin-1beta levels were higher for ambidextrous mice than for right-pawed mice (P&lt;0.05); in their right cortices, interleukin-6 levels were higher for ambidextrous mice than for right-/left-pawed mice, and right-pawed mice have higher levels of interleukin-6 than left-pawed mice (P&lt;0.01).	Sodium Chloride	8-14	interleukin 6	Mus musculus	307-320
12413741-3	2002	DNP-KLH immunization with complete Freund"s adjuvant (CFA) markedly augmented anti-DNP antibody production and induced interleukin 6 (IL-6) production in serum.	dnp-klh	0-7	interleukin 6	Mus musculus	134-138
12413742-7	2002	Furthermore, MR16-1 completely suppressed IL-6-induced antibody production in DNP-KLH immunized mice.	dnp-klh	78-85	interleukin 6	Mus musculus	42-46
12482232-7	2002	Instead, Kupffer cell depletion by liposome/clodronate led to significant decreases in the levels of hepatic mRNA expression of several hepato-regulatory cytokines and mediators, including IL-6, IL-10, IL-18 binding protein and complement 1q, suggesting that Kupffer cells are a significant source for production of these mediators in this model.	Clodronic Acid	44-54	interleukin 6	Mus musculus	189-193
12528891-2	2002	We previously found that the cAMP-elevators (CTx and 8-Br-cAMP) inhibited IL-12, IL-la, IL-6 gene expression, but increased the transcriptional levels of IL-10 and IL-1Ra in LPS-treated murine peritoneal macrophages.	Cyclic AMP	29-33	interleukin 6	Mus musculus	88-92
12510847-0	2002	Comparative study of the endotoxemia and endotoxin tolerance on the production of Th cytokines and macrophage interleukin-6: differential regulation of indomethacin.	Indomethacin	152-164	interleukin 6	Mus musculus	110-123
12510847-14	2002	Also, endogenous PGE2 may mediate macrophage IL-6 production in the case of endotoxemia to a greater extent than in the case of endotoxin tolerance.	Dinoprostone	17-21	interleukin 6	Mus musculus	45-49
12528891-2	2002	We previously found that the cAMP-elevators (CTx and 8-Br-cAMP) inhibited IL-12, IL-la, IL-6 gene expression, but increased the transcriptional levels of IL-10 and IL-1Ra in LPS-treated murine peritoneal macrophages.	8-Bromo Cyclic Adenosine Monophosphate	53-62	interleukin 6	Mus musculus	88-92
12510847-3	2002	However, the inhibitory effects of PGE2 on the altered polarization of the Th cell and macrophage interleukin (IL)-6 production characterized in part by cellular immune paralysis in a state of endotoxin tolerance is unclear.	Dinoprostone	35-39	interleukin 6	Mus musculus	98-116
12510847-4	2002	This study was undertaken, using indomethacin, to investigate the role of endogenous PGE2 on the Th cytokines and macrophage IL-6 production in a state of endotoxin tolerance compared to those with endotoxemia mice, wherein, in this latter case, the increased production of proinflammatory cytokines and PGE2 is exhibited.	Dinoprostone	85-89	interleukin 6	Mus musculus	125-129
12457286-7	2002	The therapeutic efficacy of AdvmuIL-10 was associated with a decrease in the IFN-gamma and IL-6 levels detected in colonic homogenates from mice with TNBS colitis, whereas no effect was observed on cytokine release from stimulated systemic lymphocytes.	advmuil-10	28-38	interleukin 6	Mus musculus	91-95
12510847-10	2002	Indomethacin in the case of endotoxemia markedly attenuated IFN-gamma and IL-6 production and didnt reverse IL-2 and IL-4 production.	Indomethacin	0-12	interleukin 6	Mus musculus	74-78
12510847-12	2002	Indomethacin in endotoxin tolerance greatly augmented IL-2 production, significantly decreased IL-4 production, and slightly attenuated IL-6 production.	Indomethacin	0-12	interleukin 6	Mus musculus	136-140
12819374-4	2002	10(-6)M phenol inhibited IL-1, IL-6 and TNFalpha gene expression, and 10(-6)M of 2-BP downregulated TNFalpha gene expression.	Phenol	8-14	interleukin 6	Mus musculus	31-35
12460185-6	2002	Interleukin-6 (IL-6) followed by IL-10 were the dominant cytokines detected in in vitro cultures of mouse spleen cells stimulated with T-CHO.	t-cho	135-140	interleukin 6	Mus musculus	0-13
12460185-6	2002	Interleukin-6 (IL-6) followed by IL-10 were the dominant cytokines detected in in vitro cultures of mouse spleen cells stimulated with T-CHO.	t-cho	135-140	interleukin 6	Mus musculus	15-19
12542893-5	2002	Furthermore, the effect of formoterol on IL-6 secretion from mouse amnion cells was determined.	Formoterol Fumarate	27-37	interleukin 6	Mus musculus	41-45
12542893-11	2002	However, at 10(-7) and 10(-5) M, and 10(-6) and 10(-5) M, respectively, they inhibited lipopolysaccharide-induced IL-6 secretion and this inhibitory effect was competitively reversed by addition of ICI-118,551 (beta(2)-adrenoceptor antagonist), but not atenolol (beta(1)-adrenoceptor antagonist).	ICI-118551 hydrochloride	198-205	interleukin 6	Mus musculus	114-118
12542893-11	2002	However, at 10(-7) and 10(-5) M, and 10(-6) and 10(-5) M, respectively, they inhibited lipopolysaccharide-induced IL-6 secretion and this inhibitory effect was competitively reversed by addition of ICI-118,551 (beta(2)-adrenoceptor antagonist), but not atenolol (beta(1)-adrenoceptor antagonist).	Atenolol	253-261	interleukin 6	Mus musculus	114-118
12542893-12	2002	These findings strongly suggest that formoterol can suppress premature delivery mediated by its actions on IL-6 secretion.	Formoterol Fumarate	37-47	interleukin 6	Mus musculus	107-111
12516657-2	2002	Here we analyze whether progesterone (Pg) and estrogen (E2) affect asymmetric antibody synthesis by modulating IL-6 production in hybridoma cells.	Progesterone	24-36	interleukin 6	Mus musculus	111-115
12417753-3	2002	In the course of a screening program aimed at IL-6 inhibitor from microbial products, we found madindoline A (MDL-A) and madindoline B, which have a fuloindoline structure with diketocyclopentene bound to the methyl group.	madindoline A	95-108	interleukin 6	Mus musculus	46-50
12417753-3	2002	In the course of a screening program aimed at IL-6 inhibitor from microbial products, we found madindoline A (MDL-A) and madindoline B, which have a fuloindoline structure with diketocyclopentene bound to the methyl group.	madindoline A	110-115	interleukin 6	Mus musculus	46-50
12417753-3	2002	In the course of a screening program aimed at IL-6 inhibitor from microbial products, we found madindoline A (MDL-A) and madindoline B, which have a fuloindoline structure with diketocyclopentene bound to the methyl group.	madindoline A	121-134	interleukin 6	Mus musculus	46-50
12417753-3	2002	In the course of a screening program aimed at IL-6 inhibitor from microbial products, we found madindoline A (MDL-A) and madindoline B, which have a fuloindoline structure with diketocyclopentene bound to the methyl group.	fuloindoline	149-161	interleukin 6	Mus musculus	46-50
12417753-3	2002	In the course of a screening program aimed at IL-6 inhibitor from microbial products, we found madindoline A (MDL-A) and madindoline B, which have a fuloindoline structure with diketocyclopentene bound to the methyl group.	diketocyclopentene	177-195	interleukin 6	Mus musculus	46-50
12421476-3	2002	RESULTS: Resveratrol (6.25, 12.5, 25 micromol/L) and ethanol (0.2 %, 0.8 %) synergistically inhibited the 24 h production of NO from lipopolysaccharide (LPS, 1 mg/L) and IFN-gamma (5 kU/L) stimulated MPM; resveratrol at higher dose (25 micromol/L) also inhibited IL-6 production.	Resveratrol	9-20	interleukin 6	Mus musculus	263-267
12421476-3	2002	RESULTS: Resveratrol (6.25, 12.5, 25 micromol/L) and ethanol (0.2 %, 0.8 %) synergistically inhibited the 24 h production of NO from lipopolysaccharide (LPS, 1 mg/L) and IFN-gamma (5 kU/L) stimulated MPM; resveratrol at higher dose (25 micromol/L) also inhibited IL-6 production.	Ethanol	53-60	interleukin 6	Mus musculus	263-267
12516657-11	2002	Finally, mainly Pg but also E2 increased IL-6 synthesis, although IL-6 levels did not correlate with asymmetric antibodies synthesized in the presence of E2 or Pg.	Estradiol	28-30	interleukin 6	Mus musculus	41-45
12516657-11	2002	Finally, mainly Pg but also E2 increased IL-6 synthesis, although IL-6 levels did not correlate with asymmetric antibodies synthesized in the presence of E2 or Pg.	Progesterone	16-18	interleukin 6	Mus musculus	41-45
12388834-6	2002	TCDD exposure significantly suppressed the production of Th2 cell-derived cytokines IL-4, IL-5, and IL-6, which were prominently increased from Day 4 onward in control mice.	Polychlorinated Dibenzodioxins	0-4	interleukin 6	Mus musculus	100-104
12384353-4	2002	In Stx-injected mice, azithromycin significantly suppressed Stx-induced TNF-alpha, IL-1beta, and IL-6 levels in serum and improved the outcome as assessed by survival rate.	Azithromycin	22-34	interleukin 6	Mus musculus	97-101
12414762-5	2002	The results demonstrate that tilorone treatment elicits, by a direct effect, the production of proinflammatory cytokines (interleukin-6 [IL-6], tumor necrosis factor alpha [TNF-alpha], and IL-12) by splenic macrophages.	Tilorone	29-37	interleukin 6	Mus musculus	122-135
12414762-5	2002	The results demonstrate that tilorone treatment elicits, by a direct effect, the production of proinflammatory cytokines (interleukin-6 [IL-6], tumor necrosis factor alpha [TNF-alpha], and IL-12) by splenic macrophages.	Tilorone	29-37	interleukin 6	Mus musculus	137-141
12370397-0	2002	Receptors and signaling mechanisms required for prostaglandin E2-mediated regulation of mast cell degranulation and IL-6 production.	Dinoprostone	48-64	interleukin 6	Mus musculus	116-120
12398921-3	2002	Besides TNF-alpha, TFBA also suppressed interleukin-6 and interleukin-10 production of isolated monocytes.	5-ethyl-1-phenyl-5-(3,4,5,6-tetrafluorophthalimido)barbituric acid	19-23	interleukin 6	Mus musculus	40-53
12477282-3	2002	Macrophages respond to such CpG motifs in bacterial DNA or synthetic oligodeoxynucleotides (ODN) by inducing NF-kappaB and secreting proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), but the mechanisms regulating this have been unclear.	Oligodeoxyribonucleotides	69-90	interleukin 6	Mus musculus	168-181
12370259-5	2002	The inhibitory effect of IL-6 on Fas ligand expression during activation-induced cell death (AICD) was augmented in gp130(F759/F759) T cells in a manner dependent on the tyrosine residues of gp130 required for signal transducer and activator of transcription 3 activation.	Tyrosine	170-178	interleukin 6	Mus musculus	25-29
12477282-3	2002	Macrophages respond to such CpG motifs in bacterial DNA or synthetic oligodeoxynucleotides (ODN) by inducing NF-kappaB and secreting proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), but the mechanisms regulating this have been unclear.	Oligodeoxyribonucleotides	69-90	interleukin 6	Mus musculus	183-187
12477282-6	2002	Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of IL-6 and TNF-alpha.	Carmustine	24-28	interleukin 6	Mus musculus	231-235
12358740-0	2002	Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	51-55	interleukin 6	Mus musculus	65-78
12235239-2	2002	In the course of a screening program aimed at IL-6 inhibitor from natural products, we isolated 20S,21-epoxy-resibufogenin-3-formate (ERBF) from bufadienolide and examined the effect of ERBF on activities of various cytokines.	20,21-epoxyresibufogenin-3-formate	96-132	interleukin 6	Mus musculus	46-50
12358740-5	2002	Co-localization experiments identified striatal astrocytes as the source of IL-6 in IL-6 (+/+) mice at 1 and 7 days postinjection of MPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	133-137	interleukin 6	Mus musculus	76-80
12231393-0	2002	Baclofen influences lipopolysaccharide-mediated interleukin-6 release from murine pituicytes.	Baclofen	0-8	interleukin 6	Mus musculus	48-61
12235261-11	2002	Likewise, significantly lower mRNA levels of Mrp2 with a corresponding decrease in cellular efflux of 5-carboxyfluorescein was seen in vitro in IL-6- and IL-1beta-treated Hepa 1-6 cells, whereas bile acids did not have significant effects.	4-carboxyfluorescein	102-122	interleukin 6	Mus musculus	144-148
12239348-4	2002	Coculture of ES cells for 8-12 days with OP9 stromal cells in the presence of thrombopoietin, IL-6, and IL-11 resulted in the development of large, polyploid megakaryocytes that produced proplatelets.	Einsteinium	13-15	interleukin 6	Mus musculus	94-98
12350373-7	2002	These results suggest that aromatase and IL-6 are key molecules in the production of the feminisation undergone by infected male mice and to Fadrozole treatment as a possible new therapeutic approach to cysticercosis.	Fadrozole	141-150	interleukin 6	Mus musculus	41-45
12297145-11	2002	An up to 150-fold induction of interleukin-6 (IL-6) mRNA was detected in the animals exposed to 2 ppm ozone compared to the air-exposed control mice.	Ozone	102-107	interleukin 6	Mus musculus	31-44
12297145-11	2002	An up to 150-fold induction of interleukin-6 (IL-6) mRNA was detected in the animals exposed to 2 ppm ozone compared to the air-exposed control mice.	Ozone	102-107	interleukin 6	Mus musculus	46-50
12297145-12	2002	Also at 1 ppm ozone, the IL-6 mRNA was induced.	Ozone	14-19	interleukin 6	Mus musculus	25-29
12231393-5	2002	The interleukin-6 release was significantly potentiated by the GABA(B) receptor agonist (R)-4-amino-3-(4-chlorophenyl) butanoic acid (R-baclofen; 10, 100 or 500 microM).	(r)-4-amino-3-(4-chlorophenyl) butanoic acid	88-132	interleukin 6	Mus musculus	4-17
12231393-5	2002	The interleukin-6 release was significantly potentiated by the GABA(B) receptor agonist (R)-4-amino-3-(4-chlorophenyl) butanoic acid (R-baclofen; 10, 100 or 500 microM).	Baclofen	134-144	interleukin 6	Mus musculus	4-17
12231393-11	2002	The results suggest that the effect of R-baclofen on lipopolysaccharide-stimulated interleukin-6 secretion is independent of GABA(B) receptors.	Baclofen	39-49	interleukin 6	Mus musculus	83-96
12185005-5	2002	The transcriptional inhibitor 5,6-dichloro-beta-D-ribofuranosyl-benzimidazole blocked LPS-stimulated IL-6 mRNA expression without changing its mRNA half-life.	5,6-dichloro-beta-d-ribofuranosyl-benzimidazole	30-77	interleukin 6	Mus musculus	101-105
12171963-9	2002	The higher susceptibility of homozygous alpha(1)-AGP-transgenic mice to DSS induced acute colitis was also reflected in higher local myeloperoxidase levels, higher inflammation scores of the colon, and higher systemic levels of interleukin 6 and serum amyloid P component.	dss	72-75	interleukin 6	Mus musculus	228-241
12185005-6	2002	The anti-inflammatory glucocorticoid dexamethasone selectively blocked LPS-stimulated IL-6 mRNA accumulation but not TNF-alpha.	Dexamethasone	37-50	interleukin 6	Mus musculus	86-90
12225870-6	2002	Moreover, NS-398 administration significantly attenuated levels of induction for the majority of inflammatory mediators examined, including TNFalpha, IL-1beta, IL-6, iNOS, ICAM-1, and MMP-9.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	10-16	interleukin 6	Mus musculus	160-164
12297111-0	2002	Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms.	Leflunomide	19-30	interleukin 6	Mus musculus	72-76
12297111-0	2002	Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms.	Mycophenolic Acid	35-52	interleukin 6	Mus musculus	72-76
12297111-3	2002	The inhibitors of NO synthase, aminoguanidine and L-NMMA, but not L-NMMA inactive counterpart D-NMMA, mimicked the effects of A77 1726 and MPA on IL-6 generation in L929 fibroblasts.	pimagedine	31-45	interleukin 6	Mus musculus	146-150
12297111-3	2002	The inhibitors of NO synthase, aminoguanidine and L-NMMA, but not L-NMMA inactive counterpart D-NMMA, mimicked the effects of A77 1726 and MPA on IL-6 generation in L929 fibroblasts.	omega-N-Methylarginine	50-56	interleukin 6	Mus musculus	146-150
12297111-3	2002	The inhibitors of NO synthase, aminoguanidine and L-NMMA, but not L-NMMA inactive counterpart D-NMMA, mimicked the effects of A77 1726 and MPA on IL-6 generation in L929 fibroblasts.	omega-N-Methylarginine	94-100	interleukin 6	Mus musculus	146-150
12297111-5	2002	MPA, but not A77 1726, significantly suppressed NO-independent IL-6 release triggered by cAMP-elevating agent rolipram.	Cyclic AMP	89-93	interleukin 6	Mus musculus	63-67
12297111-5	2002	MPA, but not A77 1726, significantly suppressed NO-independent IL-6 release triggered by cAMP-elevating agent rolipram.	Rolipram	110-118	interleukin 6	Mus musculus	63-67
12396470-11	2002	Furthermore, we suggest that the IL-6 detected in the present study is produced by the EAT cells and the suppression of its production could be associated with the antitumor effect of BjV.	N-benzyl-1-{5-[(2-chloro-5-{5-(methylsulfonyl)-1-[3-(morpholin-4-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-methoxyphenyl}methanamine	184-187	interleukin 6	Mus musculus	33-37
12096892-5	2002	With this mouse model, after infection, serum levels of interleukin (IL)-1beta and IL-6 were enhanced in Pb-exposed mice.	Lead	105-107	interleukin 6	Mus musculus	83-87
12096892-7	2002	As a substitute for the infection, mice were injected with IL-1 and/or IL-6; Pb exacerbated sickness behavior only in mice injected peripherally with IL-1 and IL-6.	Lead	77-79	interleukin 6	Mus musculus	71-75
12096892-7	2002	As a substitute for the infection, mice were injected with IL-1 and/or IL-6; Pb exacerbated sickness behavior only in mice injected peripherally with IL-1 and IL-6.	Lead	77-79	interleukin 6	Mus musculus	159-163
12161415-1	2002	OBJECTIVES: The purpose of this study was to evaluate the inhibitory effect of roxithromycin on the production of interleukin (IL)-1beta, IL-6 and tumour necrosis factor-alpha (TNF-alpha) in a murine tibial osteomyelitis model using Staphylococcus aureus.	Roxithromycin	79-92	interleukin 6	Mus musculus	138-142
12151646-4	2002	However, bromodeoxyuridine (BrdU) labeling within terminal bronchiolar epithelium and proximal alveolar regions in IL-6 KO mice exposed to ozone or to ADSS/ozone was significantly reduced compared with IL-6 sufficient mice (WT).	Bromodeoxyuridine	28-32	interleukin 6	Mus musculus	115-119
12133857-6	2002	Interleukin-1beta, major intrinsic protein 2, and interleukin-6 in lung homogenates after 3 days of hyperoxia were significantly higher (P &lt; 0.001) in SP-Bmon(+) mice than SP-Bmon(++) or wild-type mice.	sp-bmon	154-161	interleukin 6	Mus musculus	50-63
12175822-9	2002	Interestingly, mercury alone stimulated the expression of tumor necrosis factor alpha (TNFalpha), and increased LPS-induced TNFalpha and interleukin-6 mRNA expression.	Mercury	15-22	interleukin 6	Mus musculus	137-150
12151646-4	2002	However, bromodeoxyuridine (BrdU) labeling within terminal bronchiolar epithelium and proximal alveolar regions in IL-6 KO mice exposed to ozone or to ADSS/ozone was significantly reduced compared with IL-6 sufficient mice (WT).	Bromodeoxyuridine	9-26	interleukin 6	Mus musculus	115-119
12091165-7	2002	Circulating levels of interleukin-6, tumor necrosis factor-alpha, and soluble tumor necrosis factor type II receptor were decreased in septic mice treated with pentostatin.	Pentostatin	160-171	interleukin 6	Mus musculus	22-64
12182843-4	2002	Supernatants from cultured splenocytes and peritoneal cells taken from Linomide-treated mice contained lower levels of TNFalpha, IL-1 beta, IFN gamma and IL-12 versus higher levels of IL-4, IL-6 and IL-10 in comparison with supernatants from cultures of untreated mice.	roquinimex	71-79	interleukin 6	Mus musculus	190-194
12097416-5	2002	EAMG resistance in IL-6(-/-) mice was associated with a significant reduction in germinal center formation and decreased serum complement C3 levels.	eamg	0-4	interleukin 6	Mus musculus	19-23
12132673-11	2002	Interleukin-6 (IL-6) production of CY+SCG-treated peritoneal exdated cells (PECs), spleen cells and bone marrow cells (BMCs) were higher than that of the CY-treated group.	Cyclophosphamide	35-37	interleukin 6	Mus musculus	0-13
12132673-11	2002	Interleukin-6 (IL-6) production of CY+SCG-treated peritoneal exdated cells (PECs), spleen cells and bone marrow cells (BMCs) were higher than that of the CY-treated group.	Cyclophosphamide	35-37	interleukin 6	Mus musculus	15-19
12132673-12	2002	By in vitro culture of CY-treated PEC and spleen cells, IL-6 production was enhanced by the addition of SCG.	Cyclophosphamide	23-25	interleukin 6	Mus musculus	56-60
12161103-11	2002	These data demonstrate that endogenous IL-6 exerts an anti-inflammatory role during acute pancreatitis, possibly by regulating the expression of adhesion molecules, the subsequent adhesion and activation of neutrophils and finally the generation of cytokine and reactive oxygen or nitrogen species.	reactive oxygen or nitrogen species	262-297	interleukin 6	Mus musculus	39-43
12009512-10	2002	Dietary melatonin had no effect on the responses of TNF-alpha mRNA to LPS but attenuated the reaction of splenic IL-6 mRNA, thus bringing the response closer to that of the younger mice.	Melatonin	8-17	interleukin 6	Mus musculus	113-117
12098600-4	2002	In the murine endotoxin shock model, pirfenidone potently inhibited the production of the proinflammatory cytokines, TNF-alpha, interferon-gamma, and interleukin-6, but enhanced the production of the anti-inflammatory cytokine, interleukin-10.	pirfenidone	37-48	interleukin 6	Mus musculus	150-163
12349954-0	2002	Inhibition of TNF-alpha, IL-1beta, and IL-6 productions and NF-kappa B activation in lipopolysaccharide-activated RAW 264.7 macrophages by catalposide, an iridoid glycoside isolated from Catalpa ovata G. Don (Bignoniaceae).	catalposide	139-150	interleukin 6	Mus musculus	39-43
12349954-1	2002	Catalposide, the major iridoid glycoside isolated from the stem bark of Catalpa ovata G. Don (Bignoniaceae), was found to inhibit the productions of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), and the activation of nuclear factor kappaB (NF-kappaB) in RAW 264.7 macrophages activated with lipopolysaccharide (LPS).	catalposide	0-11	interleukin 6	Mus musculus	239-243
12349954-2	2002	Catalposide also inhibited the expressions of TNF-alpha, IL-1beta, and IL-6 genes and the nuclear translocation of p65 subunit of NF-kappaB in LPS-activated RAW 264.7 cells.	catalposide	0-11	interleukin 6	Mus musculus	71-75
12349954-3	2002	Flow cytometric analysis revealed that catalposide suppressed the binding of FITC-conjugated LPS to CD14 on the surface of cells, probably resulting in the inhibitory effects on TNF-alpha, IL-1beta, and IL-6 productions and NF-kappaB activation.	catalposide	39-50	interleukin 6	Mus musculus	203-207
12349954-3	2002	Flow cytometric analysis revealed that catalposide suppressed the binding of FITC-conjugated LPS to CD14 on the surface of cells, probably resulting in the inhibitory effects on TNF-alpha, IL-1beta, and IL-6 productions and NF-kappaB activation.	Fluorescein-5-isothiocyanate	77-81	interleukin 6	Mus musculus	203-207
12039996-5	2002	Treatment with 15-epi-16-(FPhO)-LXA(4)-Me was also associated with lower IL-1beta, IL-6, and GRO1 mRNA levels, whereas ICAM-1 and VCAM-1 mRNA levels were unchanged.	15-epi-16-(fpho)-lxa(4)-me	15-41	interleukin 6	Mus musculus	83-87
12079426-7	2002	In contrast to PCB 153, coplanar PCBs that are AhR ligands increased endothelial production of interleukin-6.	Polychlorinated Biphenyls	33-37	interleukin 6	Mus musculus	95-108
12045243-3	2002	By contrast, the ctxAB mutant with an additional deletion in the actin-cross-linking repeats-in-toxin (RTX) toxin gene (rtxA) caused a less severe pathology and decreased serum levels of proinflammatory molecules interleukin (IL)-6 and murine macrophage inflammatory protein (MIP)-2.	ctxab	17-22	interleukin 6	Mus musculus	213-231
12045243-6	2002	Compound deletion of ctxAB, hlyA, hapA, and rtxA created strain KFV101, which colonized the lung but induced pulmonary disease with limited inflammation and significantly reduced serum titers of IL-6 and MIP-2.	ctxab	21-26	interleukin 6	Mus musculus	195-199
11994440-1	2002	Immunostimulatory sequence (ISS) DNA containing unmethylated CpG dinucleotides stimulate NK and APC to secrete proinflammatory cytokines, including IFN-alphabeta and -gamma, TNF-alpha, and IL-6 and -12, and to express costimulatory surface molecules such as CD40, B7-1, and B7-2.	Dinucleoside Phosphates	65-78	interleukin 6	Mus musculus	189-193
11979446-7	2002	IL-6 mRNA levels in tumors and spleens and IL-6 protein levels in tumors and sera were significantly lower in tumor-bearing mice treated with CR supplement than in those treated with a normal diet.	Chromium	142-144	interleukin 6	Mus musculus	0-4
11959686-9	2002	PGJ treatment markedly blunted the TNF-alpha-induced increase in leptin, TNF-alpha, and interleukin-6 gene expression in epididymal adipose tissue.	15-deoxy-delta(12,14)-prostaglandin J2	0-3	interleukin 6	Mus musculus	88-101
11970911-1	2002	In the present study we have tested the ability of reactive oxygen species (ROS) to stimulate the production of interleukin (IL)- 6 from skeletal myocytes.	Reactive Oxygen Species	51-74	interleukin 6	Mus musculus	112-131
11979446-7	2002	IL-6 mRNA levels in tumors and spleens and IL-6 protein levels in tumors and sera were significantly lower in tumor-bearing mice treated with CR supplement than in those treated with a normal diet.	Chromium	142-144	interleukin 6	Mus musculus	43-47
11970911-1	2002	In the present study we have tested the ability of reactive oxygen species (ROS) to stimulate the production of interleukin (IL)- 6 from skeletal myocytes.	Reactive Oxygen Species	76-79	interleukin 6	Mus musculus	112-131
11970911-5	2002	Exposure of myotubes to H(2)O(2) increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production.	Dactinomycin	108-121	interleukin 6	Mus musculus	165-169
11970911-5	2002	Exposure of myotubes to H(2)O(2) increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production.	Cycloheximide	125-138	interleukin 6	Mus musculus	56-60
11970911-5	2002	Exposure of myotubes to H(2)O(2) increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production.	Cycloheximide	125-138	interleukin 6	Mus musculus	165-169
11970911-5	2002	Exposure of myotubes to H(2)O(2) increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production.	Reactive Oxygen Species	153-156	interleukin 6	Mus musculus	56-60
11970911-5	2002	Exposure of myotubes to H(2)O(2) increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production.	Reactive Oxygen Species	153-156	interleukin 6	Mus musculus	165-169
11970911-4	2002	In myotubes, superoxide dismutase and catalase blocked the ROS-induced IL-6 release.	Reactive Oxygen Species	59-62	interleukin 6	Mus musculus	71-75
11970911-5	2002	Exposure of myotubes to H(2)O(2) increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production.	h(2)	24-28	interleukin 6	Mus musculus	56-60
11970911-5	2002	Exposure of myotubes to H(2)O(2) increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production.	h(2)	24-28	interleukin 6	Mus musculus	165-169
11970911-5	2002	Exposure of myotubes to H(2)O(2) increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production.	Dactinomycin	108-121	interleukin 6	Mus musculus	56-60
11970911-6	2002	In addition, pretreatment of cells with N-acetyl-cysteine blocked tumor necrosis factor (TNF)-alpha-induced IL-6 release, suggesting that endogenously produced ROS participate in IL-6 production.	Acetylcysteine	40-57	interleukin 6	Mus musculus	108-112
11979446-9	2002	An in vitro study showed that C. rhizoma and its major component, berberine, inhibited IL-1-induced IL-6 mRNA expression in a dose-dependent manner in colon 26/clone 20 cells.	Berberine	66-75	interleukin 6	Mus musculus	100-104
11970911-6	2002	In addition, pretreatment of cells with N-acetyl-cysteine blocked tumor necrosis factor (TNF)-alpha-induced IL-6 release, suggesting that endogenously produced ROS participate in IL-6 production.	Acetylcysteine	40-57	interleukin 6	Mus musculus	179-183
11970911-6	2002	In addition, pretreatment of cells with N-acetyl-cysteine blocked tumor necrosis factor (TNF)-alpha-induced IL-6 release, suggesting that endogenously produced ROS participate in IL-6 production.	Reactive Oxygen Species	160-163	interleukin 6	Mus musculus	108-112
12115237-4	2002	RESULTS: In the presence of AdLacZ-infected FLS, titanium particle-stimulated macrophages exhibited a marked increase in secretion of tumor necrosis factor alpha (TNFalpha) (6.5-fold), IL-6 (13-fold), and IL-1 (5-fold).	Titanium	49-57	interleukin 6	Mus musculus	185-189
11970911-6	2002	In addition, pretreatment of cells with N-acetyl-cysteine blocked tumor necrosis factor (TNF)-alpha-induced IL-6 release, suggesting that endogenously produced ROS participate in IL-6 production.	Reactive Oxygen Species	160-163	interleukin 6	Mus musculus	179-183
11970911-8	2002	Finally, preincubation of myotubes with the pharmacologic inhibitor of NF-kappa B, diethyldithiocarbamate, or transient transfection with an I kappa B-alpha mutant, inhibited the ROS-stimulated IL-6 release.	Ditiocarb	83-105	interleukin 6	Mus musculus	194-198
11970911-8	2002	Finally, preincubation of myotubes with the pharmacologic inhibitor of NF-kappa B, diethyldithiocarbamate, or transient transfection with an I kappa B-alpha mutant, inhibited the ROS-stimulated IL-6 release.	Reactive Oxygen Species	179-182	interleukin 6	Mus musculus	194-198
11970911-9	2002	In conclusion, ROS stimulate IL-6 production from skeletal myotubes in a manner that involves transcriptional activation of the IL-6 gene through an NF-kappa B-dependent pathway.	Reactive Oxygen Species	15-18	interleukin 6	Mus musculus	29-33
11970911-9	2002	In conclusion, ROS stimulate IL-6 production from skeletal myotubes in a manner that involves transcriptional activation of the IL-6 gene through an NF-kappa B-dependent pathway.	Reactive Oxygen Species	15-18	interleukin 6	Mus musculus	128-132
11996904-16	2002	PTH induces IL-6 through PKA activation, whereas fluprostenol induces IL-6 through PKC activation.	fluprostenol	49-61	interleukin 6	Mus musculus	70-74
11996904-17	2002	We found that RGS-2 overexpression significantly inhibited IL-6 promoter activity following fluprostenol treatment, but not following PTH treatment.	fluprostenol	92-104	interleukin 6	Mus musculus	59-63
11981129-1	2002	BACKGROUND: Previous studies from this laboratory showed that the suppression of cell-mediated immunity after the combined injury of ethanol exposure and burn is mediated by increased presence of the proinflammatory cytokine interleukin (IL)-6.	Ethanol	133-140	interleukin 6	Mus musculus	225-243
12010781-11	2002	In wildtype mice, inhibition of p38 or ERK1/2 MAPKs significantly reduced IL-1beta induced IL-6 release, whilst the NFkappaB inhibitor caffeic acid phenethyl ester (CAPE) modulated IL-1 induced IL-6 release by action on NFkappaB and MAPKs pathways.	caffeic acid phenethyl ester	135-163	interleukin 6	Mus musculus	194-198
11830592-7	2002	IL6RIL6 stimulates the interleukin-6 family cytokine receptor gp130, leading to the rapid phosphorylation of Stat3 on tyrosine 705.	Tyrosine	118-126	interleukin 6	Mus musculus	23-36
11981129-9	2002	CONCLUSIONS: These studies suggest that the loss of lymphocyte production of IL-4 after ethanol exposure and burn injury may contribute to the exaggerated production of IL-6, a known mediator of immune suppression after injury.	Ethanol	88-95	interleukin 6	Mus musculus	169-173
11934647-11	2002	IL-6 mRNA was variably increased by PGE2 in both wild-type and knockout cells, although the absolute levels were somewhat lower in both EP2-/- and EP4 -/- cultures.	Dinoprostone	36-40	interleukin 6	Mus musculus	0-4
11934647-5	2002	Finally, PGE2 can increase interleukin-6 (IL-6), which may further enhance osteoclastogenesis.	Dinoprostone	9-13	interleukin 6	Mus musculus	27-40
12128047-4	2002	On the other hand, the humoral response was unaffected with testosterone or dihydrotestosterone restitution, while the treatment with estradiol in both genders augmented the levels of anti-cysticerci IgG, as well as IL-6 and IL-10 production.	Estradiol	134-143	interleukin 6	Mus musculus	216-220
11934647-5	2002	Finally, PGE2 can increase interleukin-6 (IL-6), which may further enhance osteoclastogenesis.	Dinoprostone	9-13	interleukin 6	Mus musculus	42-46
11923614-7	2002	RESULTS: Inosine downregulated the LPS-induced expression of TNF-alpha, IL-1beta, IL-6 and MIP-2 and tended to reduce MIP-1alpha, whereas it enhanced the production of IL-4.	Inosine	9-16	interleukin 6	Mus musculus	82-86
11839379-2	2002	Preincubation of cells with selective protein kinase C (PKC) inhibitors Go6976 and Go6983 leads to enhancement of IL-6-induced p44/p42 MAPK activity.	Go 6976	72-78	interleukin 6	Mus musculus	114-118
12013506-6	2002	The IL-2 administration in combination with LNT exerted the synergistic induction of RMp, resulting in synergistic augmentation of IL-12, NO and reduction of IL-6 production.	Lentinan	44-47	interleukin 6	Mus musculus	158-162
12013506-8	2002	Taken together it is concluded that skewing of Th1/Th2 balance to Th1 by a beta-(1-3)-glucan, LNT, is directed through the distinctive production of IL-12 versus IL-6, IL-10 and prostaglandin E2 (PGE2) by Mps, depending on intracellular GSH redox status.	beta-1,3-glucan	75-92	interleukin 6	Mus musculus	162-166
11960643-0	2002	Immunoregulation of IL-6 secretion by endogenous and exogenous adenosine and by exogenous purinergic agonists in splenic tissue slices.	Adenosine	63-72	interleukin 6	Mus musculus	20-24
11960643-5	2002	Electrical field stimulation markedly reduced IL-6 secretion, which was attenuated by the A1 antagonist DPCPX but not by the A2 antagonist 8-(3-Chlorostyryl)caffeine.	1,3-dipropyl-8-cyclopentylxanthine	104-109	interleukin 6	Mus musculus	46-50
11960643-6	2002	Thus, via A1 adenosine receptors, adenosine was found to be a strong inhibitor of splenic IL-6 secretion.	Adenosine	13-22	interleukin 6	Mus musculus	90-94
12013506-8	2002	Taken together it is concluded that skewing of Th1/Th2 balance to Th1 by a beta-(1-3)-glucan, LNT, is directed through the distinctive production of IL-12 versus IL-6, IL-10 and prostaglandin E2 (PGE2) by Mps, depending on intracellular GSH redox status.	Lentinan	94-97	interleukin 6	Mus musculus	162-166
11839379-2	2002	Preincubation of cells with selective protein kinase C (PKC) inhibitors Go6976 and Go6983 leads to enhancement of IL-6-induced p44/p42 MAPK activity.	2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide	83-89	interleukin 6	Mus musculus	114-118
11867742-3	2002	A single oral administration of SAHA to mice dose-dependently reduced circulating TNF-alpha, IL-1-beta, IL-6, and IFN-gamma induced by lipopolysaccharide (LPS).	Vorinostat	32-36	interleukin 6	Mus musculus	104-108
12054913-0	2002	Interleukin (IL)-17 enhances prostaglandin F(2 alpha)-stimulated IL-6 synthesis in osteoblasts.	Dinoprost	29-53	interleukin 6	Mus musculus	65-69
12054913-3	2002	In the present study, we investigated the effect of IL-17 on the IL-6 synthesis stimulated by PGF(2alpha) in MC3T3-E1 cells.	Prostaglandins F	94-97	interleukin 6	Mus musculus	65-69
12054913-4	2002	IL-17 significantly enhanced the PGF(2alpha)-induced IL-6 synthesis in a dose-dependent manner in the range between 0.1 and 10 ng/ml.	Prostaglandins F	33-36	interleukin 6	Mus musculus	53-57
12054913-5	2002	IL-17 also enhanced the IL-6 synthesis stimulated by 12- O -tetradecanoylphorbol-13-acetate, a direct activator of protein kinase C. In addition, IL-17 amplified the IL-6 synthesis induced by ET-1.	Tetradecanoylphorbol Acetate	53-91	interleukin 6	Mus musculus	24-28
12054913-7	2002	These results strongly suggest that IL-17 enhances the IL-6 synthesis stimulated by PGF(2alpha) as well as ET-1 in osteoblasts, and that the effect is exerted at a point downstream from p44/p42 MAP kinase.	Prostaglandins F	84-87	interleukin 6	Mus musculus	55-59
11803046-0	2002	Inverse regulation of interleukin-6 (IL-6) and IL-6 receptor in histamine deficient histidine decarboxylase-knock-out mice.	Histamine	64-73	interleukin 6	Mus musculus	22-35
11803046-0	2002	Inverse regulation of interleukin-6 (IL-6) and IL-6 receptor in histamine deficient histidine decarboxylase-knock-out mice.	Histamine	64-73	interleukin 6	Mus musculus	47-51
11803046-3	2002	Histamine, in addition to its principal role in immediate type hypersensitivity has been described to modulate IL-6 production and expression of IL-6 receptor.	Histamine	0-9	interleukin 6	Mus musculus	111-115
11803046-3	2002	Histamine, in addition to its principal role in immediate type hypersensitivity has been described to modulate IL-6 production and expression of IL-6 receptor.	Histamine	0-9	interleukin 6	Mus musculus	145-149
11803046-4	2002	In this study, the IL-6 and IL-6 receptor expression was examined in histamine deficient histidine decarboxylase (HDC) knock-out mouse model.	Histamine	69-78	interleukin 6	Mus musculus	19-23
11803046-4	2002	In this study, the IL-6 and IL-6 receptor expression was examined in histamine deficient histidine decarboxylase (HDC) knock-out mouse model.	Histamine	69-78	interleukin 6	Mus musculus	28-32
11803046-5	2002	Our data suggest that in histamine deficient mice the inducibility of IL-6 is significantly reduced, whilst more IL-6 receptor/gp130 mRNA expresses in the liver than in wild type (HDC(+/+)) mice.	Histamine	25-34	interleukin 6	Mus musculus	70-74
11803046-5	2002	Our data suggest that in histamine deficient mice the inducibility of IL-6 is significantly reduced, whilst more IL-6 receptor/gp130 mRNA expresses in the liver than in wild type (HDC(+/+)) mice.	Histamine	25-34	interleukin 6	Mus musculus	113-117
11958817-2	2002	The present study examined the role of IL-6 in the development of corticosterone resistance.	Corticosterone	66-80	interleukin 6	Mus musculus	39-43
11842035-7	2002	Interleukin-6 and macrophage inflammatory protein-2 levels in bronchoalveolar lavage fluid were also increased in 8-wk-old compared with 2-wk-old mice exposed to O(3).	Ozone	162-166	interleukin 6	Mus musculus	0-13
11706031-7	2002	The PP2A inhibitor okadaic acid induced P. aeruginosa-like responses in mast cells including increased PKCalpha phosphorylation, stimulated PKC activity, and augmented IL-6 production, the last being blocked by the PKC inhibitor Ro 31-8220.	Okadaic Acid	19-31	interleukin 6	Mus musculus	168-172
11991672-0	2002	Amiodarone inhibits interleukin 6 production and attenuates myocardial injury induced by viral myocarditis in mice.	Amiodarone	0-10	interleukin 6	Mus musculus	20-33
11991672-7	2002	The HW/BW, histopathologic score of cellular infiltration and myocardial interleukin 6 concentration were significantly lower in the amiodarone-treated group than in the control group.	Amiodarone	133-143	interleukin 6	Mus musculus	73-86
11991672-9	2002	This study suggests that the beneficial effects of amiodarone in viral myocarditis may be mediated by decreasing interleukin 6 production in myocardial tissue.	Amiodarone	51-61	interleukin 6	Mus musculus	113-126
11706031-8	2002	Finally, okadaic acid potentiated the P. aeruginosa-induced IL-6 production.	Okadaic Acid	9-21	interleukin 6	Mus musculus	60-64
11791174-7	2002	Finally, high concentrations of ethanol inhibit IL-6-activated anti-apoptotic signal, but increasing the concentrations of IL-6 is able to overcome such inhibitory effect.	Ethanol	32-39	interleukin 6	Mus musculus	48-52
11895333-0	2002	The effects of IL-6 and IL-10 and their specific antibodies in the acute inflammatory responses induced by carrageenan in the mouse model of pleurisy.	Carrageenan	107-118	interleukin 6	Mus musculus	15-19
11895333-2	2002	injection of interleukin (IL-6) and IL-10 and their specific antibodies on the early (4 h) and late (48 h) inflammatory responses caused by carrageenan (Cg) injected into the mouse pleural cavity.	Carrageenan	140-151	interleukin 6	Mus musculus	13-30
11895333-4	2002	injection of IL-6, 5 min prior to Cg, reduced in a dose-dependent and significant manner, the exudation and total and differential leukocyte migration according to assessment in both the early (4 h) and the late (48 h) phases of Cg inflammatory response (P&lt;0.01).	Carrageenan	34-36	interleukin 6	Mus musculus	13-17
11895333-11	2002	Taken together, the current results confirm and extend previous data from the literature by showing that IL-6 and IL-10 regulate several signs of inflammatory response, here characterized by marked inhibition of polymorphonuclear cell influx and blockage of fluid leakage to the site of Cg-induced pleurisy in the mouse.	Carrageenan	287-289	interleukin 6	Mus musculus	105-109
11856644-12	2002	Consistent with decreased osteoclastogenesis, raloxifene inhibited the mRNA expression of interleukin (IL)-1beta and IL-6 at a low concentration, but not at a high concentration, whereas 17beta-estradiol had similar effects on IL-6 and inhibited IL-1beta at both concentrations.	Raloxifene Hydrochloride	46-56	interleukin 6	Mus musculus	117-121
11856644-12	2002	Consistent with decreased osteoclastogenesis, raloxifene inhibited the mRNA expression of interleukin (IL)-1beta and IL-6 at a low concentration, but not at a high concentration, whereas 17beta-estradiol had similar effects on IL-6 and inhibited IL-1beta at both concentrations.	Raloxifene Hydrochloride	46-56	interleukin 6	Mus musculus	227-231
11809739-2	2002	In this paper we will present the evidence that the T(h)1/T(h)2 balance is regulated by the balance between RMp and OMp due to the disparate production of IL-12 versus IL-6 and IL-10.	rmp	108-111	interleukin 6	Mus musculus	168-172
11926592-5	2002	Incubation of macrophages with TSV increased production of IL-6 and IFN-gamma in a dose-dependent manner.	(2r,6s,12z,13as,14ar,16as)-6-[(Tert-Butoxycarbonyl)amino]-14a-[(Cyclopropylsulfonyl)carbamoyl]-5,16-Dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-Hexadecahydrocyclopropa[e]pyrrolo[1,2-A][1,4]diazacyclopentadecin-2-Yl 4-Fluoro-2h-Isoindole-2-Carboxylate	31-34	interleukin 6	Mus musculus	59-63
11791174-0	2002	Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-x(L) proteins.	Ethanol	30-37	interleukin 6	Mus musculus	9-22
11791174-0	2002	Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-x(L) proteins.	Ethanol	109-116	interleukin 6	Mus musculus	9-22
11791174-2	2002	Here we show that chronic ethanol consumption induces significant apoptosis in the liver of IL-6 (-/-) mice but not IL-6 (+/+) mice.	Ethanol	26-33	interleukin 6	Mus musculus	92-96
11791174-3	2002	IL-6 (-/-) hepatocytes are more susceptible to ethanol- and tumor necrosis factor alpha- (TNFalpha-) induced apoptotic killing, which can be corrected by IL-6.	Ethanol	47-54	interleukin 6	Mus musculus	0-4
11791174-3	2002	IL-6 (-/-) hepatocytes are more susceptible to ethanol- and tumor necrosis factor alpha- (TNFalpha-) induced apoptotic killing, which can be corrected by IL-6.	Ethanol	47-54	interleukin 6	Mus musculus	154-158
11811938-6	2002	Saikogenin D and oroxylin A attenuated IL-6 production in LPS-stimulated alveolar macrophages of B6 more than in that of BALB.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	17-27	interleukin 6	Mus musculus	39-43
11811938-7	2002	Liquiritigenin, which was previously reported to enhance IL-6 production in anti-CD3 monoclonal antibody-stimulated lung mononuclear cells of BALB, showed no effect on that of B6.	liquiritigenin	0-14	interleukin 6	Mus musculus	57-61
11801681-8	2002	Thus, although exogenous prostanoids may contribute to amplification of the inflammatory response by augmenting PGD(2) generation and IL-6 secretion from mast cells, endogenous prostanoids do not play a role.	Prostaglandins	25-36	interleukin 6	Mus musculus	134-138
11791174-8	2002	These findings suggest that elevated serum IL-6 levels in ALD may overcome the inhibitory effect of ethanol on IL-6-mediated anti-apoptotic signals and prevent alcohol-induced hepatic apoptosis by induction of Bcl-2 and Bcl-x(L).	Ethanol	100-107	interleukin 6	Mus musculus	43-47
11791174-8	2002	These findings suggest that elevated serum IL-6 levels in ALD may overcome the inhibitory effect of ethanol on IL-6-mediated anti-apoptotic signals and prevent alcohol-induced hepatic apoptosis by induction of Bcl-2 and Bcl-x(L).	Ethanol	100-107	interleukin 6	Mus musculus	111-115
11791174-8	2002	These findings suggest that elevated serum IL-6 levels in ALD may overcome the inhibitory effect of ethanol on IL-6-mediated anti-apoptotic signals and prevent alcohol-induced hepatic apoptosis by induction of Bcl-2 and Bcl-x(L).	Alcohols	160-167	interleukin 6	Mus musculus	43-47
11751209-5	2002	Ron tk-/- mice succumb to nickel-induced ALI earlier, express larger, early increases in interleukin-6, monocyte chemoattractant protein-1, and macrophage inflammatory protein-2, display greater serum nitrite levels, and exhibit earlier onset of pulmonary pathology and augmented pulmonary tyrosine nitrosylation.	Nickel	26-32	interleukin 6	Mus musculus	89-102
12067102-3	2002	The novel class of Src tyrosine kinase inhibitors, Herbimycin A (HERB) and HHI reduced COX-2 mRNA levels as well as PGE2 production induced by IL-1beta, TNF-alpha and IL-6.	herbimycin	51-63	interleukin 6	Mus musculus	167-171
12067102-6	2002	These results indicate that the synergy between IL-beta, TNF-alpha, IL-6 on PGE2 production is due to an enhanced gene expression of COX-2 and that tyrosine kinase (s) are involved in the signal transduction of COX-2 in mouse calvarial osteoblasts.	Dinoprostone	76-80	interleukin 6	Mus musculus	68-72
11855751-0	2002	Enhanced antitumor activities of TZT-1027 against TNF-alpha or IL-6 secreting Lewis lung carcinoma in vivo.	soblidotin	33-41	interleukin 6	Mus musculus	63-67
11883745-6	2002	RESULTS: In situ hybridization revealed IL-1alpha and IL-6 mRNA localization in normal, dormant and activated blastocysts and a differential expression was observed in relation to the exposure to progesterone and oestrogen.	Progesterone	196-208	interleukin 6	Mus musculus	54-58
12523576-7	2002	Chloroquine significantly suppressed CpG ODN-induced splenic proliferation and interleukin 6 (IL-6) production associated with GVHD.	Chloroquine	0-11	interleukin 6	Mus musculus	79-92
12523576-7	2002	Chloroquine significantly suppressed CpG ODN-induced splenic proliferation and interleukin 6 (IL-6) production associated with GVHD.	Chloroquine	0-11	interleukin 6	Mus musculus	94-98
12436210-2	2002	We previously reported that TauCl inhibits in vitro the production of proinflammatory cytokines (IL-6, IL-8) by RA synoviocytes.	N-chlorotaurine	28-33	interleukin 6	Mus musculus	97-101
12046690-5	2002	Pretreatment of the cells with LY294002 resulted in the inhibition of TNF-alpha and IL-6 production in RAW264.7 cells stimulated with IFN-gamma plus LPS or IFN-gamma plus PMA.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	31-39	interleukin 6	Mus musculus	84-88
12046690-8	2002	In conclusion, the present results suggest that PI3-kinase is involved in the signal transduction pathway responsible for LPS- or PMA-mediated TNF-alpha and IL-6 production, and that LY294002 inhibits NO generation through blocking the degradation of IkappaBalpha in activated RAW264.7 cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	183-191	interleukin 6	Mus musculus	157-161
11743653-4	2002	ii) Tumor promotion by TPA and okadaic acid in IL-6+/+ and IL-6-/- C57/BL6 mice was studied, with TPA producing tumors in 57.1% of IL-6+/+ and 40.0% of IL-6-/- mice at 20 weeks, and okadaic acid in 40.0% of IL-6+/+ and 53.3% of IL-6-/- mice.	Tetradecanoylphorbol Acetate	23-26	interleukin 6	Mus musculus	47-51
11867902-12	2002	In contrast, in vivo the increased IL-6 release at the wound site was decreased in L-arginine-treated mice following hemorrhage.	Arginine	83-93	interleukin 6	Mus musculus	35-39
11852911-9	2002	Pre-treatment with dexamethasone significantly reduced defensin-induced IL-6, IL-8 and ENA-78 synthesis in airway epithelial cells.	Dexamethasone	19-32	interleukin 6	Mus musculus	72-76
11752689-5	2002	Following exposure to ozone or ADSS/ozone, the ability of alveolar macrophages (AM) to release interleukin (IL)-6 under lipopolysaccharide (LPS) stimulation was significantly decreased, while exposure to ADSS or ADSS/ozone caused a significantly increased release of tumor necrosis factor alpha from AM under LPS stimulation.	adss	31-35	interleukin 6	Mus musculus	95-113
11968002-1	2002	In the present study, we investigated whether zinc affects the PGF2alpha-induced IL-6 synthesis in these cells.	Dinoprost	63-72	interleukin 6	Mus musculus	81-85
11968002-2	2002	Zinc complex of l-carnosine (l-CAZ) dose-dependently suppressed the PGF2alpha-stimulated IL-6 synthesis.	l-caz	29-34	interleukin 6	Mus musculus	89-93
11968002-2	2002	Zinc complex of l-carnosine (l-CAZ) dose-dependently suppressed the PGF2alpha-stimulated IL-6 synthesis.	Dinoprost	68-77	interleukin 6	Mus musculus	89-93
11968002-8	2002	These results strongly suggest that zinc reduces PGF2alpha-induced IL-6 synthesis via suppression of phosphoinositide-hydrolyzing phospholipase C and phosphatidylcholine-hydrolyzing phospholipase D in osteoblasts.	Dinoprost	49-58	interleukin 6	Mus musculus	67-71
12038038-6	2002	DTPa immunization induced a Th2 response with production of interleukin 5 and interleukin 6.	Pentetic Acid	0-4	interleukin 6	Mus musculus	78-91
11786910-3	2002	The obese Il6-/- mice had disturbed carbohydrate and lipid metabolism, increased leptin levels and decreased responsiveness to leptin treatment.	Carbohydrates	36-48	interleukin 6	Mus musculus	10-21
11968002-0	2002	Zinc suppresses IL-6 synthesis by prostaglandin F2alpha in osteoblasts: inhibition of phospholipase C and phospholipase D. We previously reported that prostaglandin F2alpha (PGF2alpha) induces phosphoinositide hydrolysis by phospholipase C and phosphatidylcholine hydrolysis by phospholipase D through heterotrimeric GTP-binding protein, resulting in the activation of protein kinase C (PKC) in osteoblast-like MC3T3-E1 cells and that PGF2alpha stimulates the synthesis of interleukin-6 (IL-6) via PKC-dependent p44/p42 mitogen-activated protein (MAP) kinase activation.	Dinoprost	34-55	interleukin 6	Mus musculus	16-20
12230920-6	2002	However, troglitazone treatment significantly reduced LPS-induced plasma IL-6 levels in both WT and PPARalpha null mice.	Troglitazone	9-21	interleukin 6	Mus musculus	73-77
11781073-10	2002	These data suggest that suppression of tolerance to Cd toxicity induced by glucocorticoid may involve hepatic MT synthesis mediated by inflammatory cytokines, such as IL-6.	Cadmium	52-54	interleukin 6	Mus musculus	167-171
11729116-8	2001	Analysis of cytokine levels in colon homogenates showed a significant decrease in TNF-alpha, IL-6, and IL-1beta after rhIL-18BPa treatment but no effect on interferon gamma.	18bpa	123-128	interleukin 6	Mus musculus	93-97
11600195-3	2001	The administration of DHEA profoundly suppressed the spontaneous elevation of both serum IgE and interleukin-6 levels in NC/Nga mice during the observation period.	Dehydroepiandrosterone	22-26	interleukin 6	Mus musculus	97-110
11720844-10	2001	IL-6 was produced by the MC3T3-E1 cells in response to (89)SrCl(2) exposure via a PGE(2)-mediated pathway.	Prostaglandins E	82-86	interleukin 6	Mus musculus	0-4
11750225-9	2001	Activation of MO from EtOH-fed mice with LPS and IFN-gamma produced levels of nitric oxide and TNF only slightly less than the levels seen in MO from control mice, but a significant decrease in IL-6 was seen when MO from EtOH-fed mice were stimulated with this combination.	Ethanol	22-26	interleukin 6	Mus musculus	194-198
11750225-9	2001	Activation of MO from EtOH-fed mice with LPS and IFN-gamma produced levels of nitric oxide and TNF only slightly less than the levels seen in MO from control mice, but a significant decrease in IL-6 was seen when MO from EtOH-fed mice were stimulated with this combination.	Ethanol	221-225	interleukin 6	Mus musculus	194-198
11770048-9	2001	The increase in plasma IL-6 levels after CLP were also significantly attenuated by NS-398 treatment.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	83-89	interleukin 6	Mus musculus	23-27
11883275-1	2001	UNLABELLED: The aim of the study was to determine wether Gram-negative bacterial cell membrane lipopolysaccharides (endotoxine) can change the IL-6 and TNF-alpha cytokine concentration synthetized by fallopian tube endothelial cells.	endotoxine	116-126	interleukin 6	Mus musculus	143-147
11723025-6	2001	Valsartan attenuated the expression of MCP-1, TNF-alpha, IL-6, IL-1beta, and infiltration of leukocytes and macrophages in the injured arteries; however, these effects of valsartan were less prominent in Agtr2- mice.	Valsartan	0-9	interleukin 6	Mus musculus	57-61
11698287-2	2001	It has recently been reported that a cytosolic isoform of PTPepsilon (PTPepsilonC) when over-expressed in murine M1 myeloid cells inhibits interleukin-6 (IL-6)- and leukemia inhibitory factor-induced activation of Janus kinases (JAKs), thereby suppressing STAT3 tyrosine phosphorylation and STAT3 signaling.	Tyrosine	262-270	interleukin 6	Mus musculus	154-158
11770048-10	2001	In vitro Kupffer cell IL-6 production after CLP was significantly reduced by in vivo NS-398 treatment.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	85-91	interleukin 6	Mus musculus	22-26
11582579-7	2001	The protein kinase C (PKC) inhibitor H7 and the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor wortmannin inhibited induction of IL-1beta and IL-6 expression, which suggests that radiation-induced IL-1beta and IL-6 expression is achieved by PKC- and PI3-kinase-mediated signaling.	Wortmannin	101-111	interleukin 6	Mus musculus	148-152
11765048-5	2001	The corticosterone response was significantly reduced in IL-6 -/- mice, but no differences in TNFalpha or in IL-1alpha plasma levels were found between the two strains.	Corticosterone	4-18	interleukin 6	Mus musculus	57-61
11595651-1	2001	Chronic secretion of interleukin-6 (IL-6) in mice causes metabolic alteration in the liver, leading to increased synthesis of hepatic cholesterol and fatty acids (FA).	Cholesterol	134-145	interleukin 6	Mus musculus	21-34
11595651-1	2001	Chronic secretion of interleukin-6 (IL-6) in mice causes metabolic alteration in the liver, leading to increased synthesis of hepatic cholesterol and fatty acids (FA).	Cholesterol	134-145	interleukin 6	Mus musculus	36-40
11595651-1	2001	Chronic secretion of interleukin-6 (IL-6) in mice causes metabolic alteration in the liver, leading to increased synthesis of hepatic cholesterol and fatty acids (FA).	Fatty Acids	150-161	interleukin 6	Mus musculus	21-34
11595651-1	2001	Chronic secretion of interleukin-6 (IL-6) in mice causes metabolic alteration in the liver, leading to increased synthesis of hepatic cholesterol and fatty acids (FA).	Fatty Acids	150-161	interleukin 6	Mus musculus	36-40
11595651-6	2001	Hepatic de novo synthesis of FA and cholesterol, as measured by (3)H(2)O incorporation, was three to five times as high in mice secreting IL-6 (IL-6 mice) as in pair-fed mice bearing nonsecreting tumors.	Cholesterol	36-47	interleukin 6	Mus musculus	138-142
11595651-6	2001	Hepatic de novo synthesis of FA and cholesterol, as measured by (3)H(2)O incorporation, was three to five times as high in mice secreting IL-6 (IL-6 mice) as in pair-fed mice bearing nonsecreting tumors.	Cholesterol	36-47	interleukin 6	Mus musculus	144-148
11699591-4	2001	Furthermore, a reverse transcription-PCR assay revealed that SAA 10 microg/ml could induce mRNA accumulation of tumour necrosis factor-alpha, interleukin (IL)-1beta and IL-6 as well as iNOS.	saa	61-64	interleukin 6	Mus musculus	169-173
11582579-7	2001	The protein kinase C (PKC) inhibitor H7 and the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor wortmannin inhibited induction of IL-1beta and IL-6 expression, which suggests that radiation-induced IL-1beta and IL-6 expression is achieved by PKC- and PI3-kinase-mediated signaling.	Wortmannin	101-111	interleukin 6	Mus musculus	216-220
11564781-11	2001	The effect of morphine on TGF-beta, IL-5, and IL-6 mRNA expression in PPs and ileal segments was determined following oral immunization with CT. Morphine significantly decreased TGF-beta mRNA compared with that in the placebo group, and naltrexone blocked this effect.	Morphine	145-153	interleukin 6	Mus musculus	46-50
11605937-10	2001	Treatment of endotoxic mice with dobutamine significantly decreased interleukin-6 protein (P &lt; 0.05) and mRNA (P &lt; 0.05) expression.	Dobutamine	33-43	interleukin 6	Mus musculus	68-81
11675265-5	2001	Our findings suggest that ROS induced by SSCS will promote hepatic lipid peroxidation and may also contribute to an increase in interleukin-6 cytokine production.	Reactive Oxygen Species	26-29	interleukin 6	Mus musculus	128-141
11602623-3	2001	We used the corticotropin-releasing hormone-deficient (Crh(-/-)) mouse to elucidate the effect of CRH deficiency on IL-6 expression and IL-6-induced HPA axis activation during turpentine-induced inflammation.	Turpentine	176-186	interleukin 6	Mus musculus	136-140
11571641-8	2001	The ability of HoxB8 to bind DNA or to bind Pbx was essential (1) to block differentiation of factor-dependent myeloid progenitors from primary marrow; (2) to block IL-6-induced monocytic differentiation of M1-AML cells; and (3) to block granulocytic differentiation of GM-CSF-dependent ECoM-G cells.	4-Bromobenzene-1,2,3-triol	44-47	interleukin 6	Mus musculus	165-169
11533249-2	2001	In certain IL-6-responsive cell lines, the stat3 gene is autoregulated by STAT3 through a composite IL-6 response element in its promoter that contains a STAT3-binding element (SBE) and a cyclic AMP-responsive element.	Cyclic AMP	188-198	interleukin 6	Mus musculus	11-15
11478964-5	2001	When MPACs were exposed to Jararhagin treated with EDTA, TNF-alpha and IL-1beta production was sustained throughout the culture period and IL-6 production was observed.	mpacs	5-10	interleukin 6	Mus musculus	139-143
11478964-5	2001	When MPACs were exposed to Jararhagin treated with EDTA, TNF-alpha and IL-1beta production was sustained throughout the culture period and IL-6 production was observed.	Edetic Acid	51-55	interleukin 6	Mus musculus	139-143
11478964-6	2001	TNF-alpha, IL-6 and IL-1beta mRNA were detected 4h after stimulation with either native or EDTA-treated jararhagin.	Edetic Acid	91-95	interleukin 6	Mus musculus	11-15
11527818-2	2001	We report here on the influence of CR on the response of peritoneal macrophages to lipopolysaccharide, splenic NF-kappaB and NF-interleukin-6 (IL-6) activities, and mortality in polymicrobial sepsis induced by cecal ligation and puncture (CLP).	Chromium	35-37	interleukin 6	Mus musculus	125-141
11525794-4	2001	In addition, IL-6-deficient mice showed an increased resistance to glutamate toxicity.	Glutamic Acid	67-76	interleukin 6	Mus musculus	13-17
11549547-4	2001	Using a vector expressing murine interleukin-6 (mIL-6) as a marker cytokine for gene expression, we show that budesonide given around exposure to adenovirus to the lung significantly maintained high levels of expressed transgene protein in bronchoalveolar lavage fluid (BALF) after as many as four consecutive injections of virus at two weekly intervals (p = 0.02 versus saline).	Budesonide	110-120	interleukin 6	Mus musculus	33-46
11549547-4	2001	Using a vector expressing murine interleukin-6 (mIL-6) as a marker cytokine for gene expression, we show that budesonide given around exposure to adenovirus to the lung significantly maintained high levels of expressed transgene protein in bronchoalveolar lavage fluid (BALF) after as many as four consecutive injections of virus at two weekly intervals (p = 0.02 versus saline).	Budesonide	110-120	interleukin 6	Mus musculus	48-53
11549547-6	2001	In Week 4, transgene mIL-6 concentration was 2,327 +/- 955 pg/ml in budesonide compared with 336 +/- 246 pg/ml in saline-treated mice (p = 0.001).	Budesonide	68-78	interleukin 6	Mus musculus	21-26
11527818-6	2001	Mice under CR died earlier (P &lt; 0.005) after sepsis induced by CLP, which appeared to be a result of increased levels in serum of the proinflammatory cytokines tumor necrosis factor alpha and IL-6 and splenic NF-kappaB and NF-IL-6 activation 4 h after CLP.	Chromium	11-13	interleukin 6	Mus musculus	195-199
11527818-2	2001	We report here on the influence of CR on the response of peritoneal macrophages to lipopolysaccharide, splenic NF-kappaB and NF-interleukin-6 (IL-6) activities, and mortality in polymicrobial sepsis induced by cecal ligation and puncture (CLP).	Chromium	35-37	interleukin 6	Mus musculus	143-147
11557190-11	2001	The serum IL-6 levels also decreased in the Y-27632-treated mice.	Y 27632	44-51	interleukin 6	Mus musculus	10-14
11592385-12	2001	Furthermore, the gene expression of IL-1alpha, IL-1beta, TNFalpha, and IL-6, as well as the production of IL-1beta and IL-6, were inhibited by triptolide in the LPS-treated mouse macrophages.	triptolide	143-153	interleukin 6	Mus musculus	71-75
11592385-12	2001	Furthermore, the gene expression of IL-1alpha, IL-1beta, TNFalpha, and IL-6, as well as the production of IL-1beta and IL-6, were inhibited by triptolide in the LPS-treated mouse macrophages.	triptolide	143-153	interleukin 6	Mus musculus	119-123
11810767-8	2001	Meanwhile, the serum level of IL-6, TNF-alpha and IL-1 in the INDT group was found to be significantly low in comparison with the NST group.	Indomethacin	62-66	interleukin 6	Mus musculus	30-34
11579142-0	2001	Mechanisms underlying extracellular ATP-evoked interleukin-6 release in mouse microglial cell line, MG-5.	Adenosine Triphosphate	36-39	interleukin 6	Mus musculus	47-60
11579142-2	2001	The ATP-evoked production of interleukin-6 (IL-6) and its intracellular signals were examined using a mouse microglial cell line, MG-5.	Adenosine Triphosphate	4-7	interleukin 6	Mus musculus	29-42
11579142-2	2001	The ATP-evoked production of interleukin-6 (IL-6) and its intracellular signals were examined using a mouse microglial cell line, MG-5.	Adenosine Triphosphate	4-7	interleukin 6	Mus musculus	44-48
11579142-3	2001	ATP, but not its metabolites, produced IL-6 in a concentration-dependent manner.	Adenosine Triphosphate	0-3	interleukin 6	Mus musculus	39-43
11579142-7	2001	The ATP-evoked IL-6 production was attenuated by Go6976, an inhibitor of Ca(2+)-dependent protein kinase C (PKC).	Adenosine Triphosphate	4-7	interleukin 6	Mus musculus	15-19
11579142-7	2001	The ATP-evoked IL-6 production was attenuated by Go6976, an inhibitor of Ca(2+)-dependent protein kinase C (PKC).	Go 6976	49-55	interleukin 6	Mus musculus	15-19
11579142-8	2001	The P2Y receptor responsible for these responses was insensitive to pertussis toxin (PTX) and was linked to phospholipase C. Taken together, ATP acting on PTX-insensitive P2Y receptors activates p38 and Ca(2+)-dependent PKC, thereby resulting in the mRNA expression and release of IL-6 in MG-5.	Adenosine Triphosphate	141-144	interleukin 6	Mus musculus	281-285
11516095-7	2001	Stroma support enhanced the expansion of CAFC week 6 maximally 11-fold to 89-fold with FL + TPO + IL6.	cafc	41-45	interleukin 6	Mus musculus	98-101
11536174-8	2001	Finally, we show that the parasite-induced IL-6 synthesis is mediated by a protein kinase A-dependent pathway that principally targets the cAMP-response element and the nuclear factor-kappaB sites from the -256/+20 region of the IL-6 promoter.	Cyclic AMP	139-143	interleukin 6	Mus musculus	43-47
11459804-7	2001	IL-6 production was only slightly increased by either 8-bromo-cAMP (1 mM) or phorbol 12-myristate 13-acetate (100 nM) alone.	8-Bromo Cyclic Adenosine Monophosphate	54-66	interleukin 6	Mus musculus	0-4
11498461-4	2001	This treatment inhibited lipopolysaccharide- and carrageenan-induced pouch leukocyte recruitment and the exudate production of interleukin-6, monocyte chemotactic protein-1, and RANTES.	Carrageenan	49-60	interleukin 6	Mus musculus	127-140
11459804-7	2001	IL-6 production was only slightly increased by either 8-bromo-cAMP (1 mM) or phorbol 12-myristate 13-acetate (100 nM) alone.	Tetradecanoylphorbol Acetate	77-108	interleukin 6	Mus musculus	0-4
11459804-8	2001	However, IL-6 was synergistically induced in the presence of both 8-bromo-cAMP (1 mM) and phorbol 12myristate 13-acetate (100 nM).	8-Bromo Cyclic Adenosine Monophosphate	66-78	interleukin 6	Mus musculus	9-13
11459804-8	2001	However, IL-6 was synergistically induced in the presence of both 8-bromo-cAMP (1 mM) and phorbol 12myristate 13-acetate (100 nM).	Tetradecanoylphorbol Acetate	90-120	interleukin 6	Mus musculus	9-13
11459804-9	2001	Furthermore, calcitonin-induced IL-6 production was completely suppressed by H-89 (PKA inhibitor) or GF109203X (PKC inhibitor), indicating that the activation of both PKA and PKC is necessary for calcitonin-induced IL-6 production.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	77-81	interleukin 6	Mus musculus	32-36
11459804-9	2001	Furthermore, calcitonin-induced IL-6 production was completely suppressed by H-89 (PKA inhibitor) or GF109203X (PKC inhibitor), indicating that the activation of both PKA and PKC is necessary for calcitonin-induced IL-6 production.	bisindolylmaleimide I	101-110	interleukin 6	Mus musculus	32-36
11448242-3	2001	Zn-DFO also protected against radiation-induced myelosuppression and body weight loss, while soluble Il6 levels in serum were normalized in mice pretreated with Zn-DFO.	zinc-desferrioxamine	161-167	interleukin 6	Mus musculus	101-104
11724314-5	2001	In contrast, the optimum concentration of SN-38 increased interleukin (IL)-6 and IL-12 production by OK-432-activated splenocytes.	Irinotecan	42-47	interleukin 6	Mus musculus	58-76
11441074-5	2001	The activity of IL-6 includes down-regulation of IFN-gammaR expression in the CD8(+) DC subset and correlates to a reduced ability of these cells to metabolize tryptophan and initiate T cell apoptosis in vitro.	Tryptophan	160-170	interleukin 6	Mus musculus	16-20
11368536-10	2001	NS-398 treatment of injured mice decreased PGE(2) production compared to T (3.9 +/- 0.3 vs 3.1 +/- 0.4 pg/microg protein), and significantly decreased IL-6, NO, and TNF-alpha production.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	0-6	interleukin 6	Mus musculus	151-155
11349125-0	2001	Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL.	ammonium ferrous sulfate	31-34	interleukin 6	Mus musculus	0-13
11349125-1	2001	Previous studies showed that following acute carbon tetrachloride (CCl(4)) treatment, interleukin-6 null (IL-6-/-) mice develop increased hepatocellular injury, defective regeneration, delayed wound healing, and increased hepatocyte apoptosis.	Carbon Tetrachloride	45-65	interleukin 6	Mus musculus	86-99
11349125-1	2001	Previous studies showed that following acute carbon tetrachloride (CCl(4)) treatment, interleukin-6 null (IL-6-/-) mice develop increased hepatocellular injury, defective regeneration, delayed wound healing, and increased hepatocyte apoptosis.	Carbon Tetrachloride	45-65	interleukin 6	Mus musculus	106-110
11349125-1	2001	Previous studies showed that following acute carbon tetrachloride (CCl(4)) treatment, interleukin-6 null (IL-6-/-) mice develop increased hepatocellular injury, defective regeneration, delayed wound healing, and increased hepatocyte apoptosis.	Cefaclor	67-70	interleukin 6	Mus musculus	86-99
11349125-1	2001	Previous studies showed that following acute carbon tetrachloride (CCl(4)) treatment, interleukin-6 null (IL-6-/-) mice develop increased hepatocellular injury, defective regeneration, delayed wound healing, and increased hepatocyte apoptosis.	Cefaclor	67-70	interleukin 6	Mus musculus	106-110
11446983-2	2001	Also, trehalose inhibits the secretion of interleukin-6 in bone marrow cell cultures, resulting in a decrease in osteoclast formation.	Trehalose	6-15	interleukin 6	Mus musculus	42-55
11391686-7	2001	RESULTS: Anti-IL-6 Ab (with saline or etoposide) induced tumor apoptosis and regression ( approximately 60% compared to initial tumor size).	Sodium Chloride	28-34	interleukin 6	Mus musculus	14-18
11391686-7	2001	RESULTS: Anti-IL-6 Ab (with saline or etoposide) induced tumor apoptosis and regression ( approximately 60% compared to initial tumor size).	Etoposide	38-47	interleukin 6	Mus musculus	14-18
11410519-5	2001	Bicalutamide, an antiandrogen, abolished the IL-6 effect and IL-6 could not activate the PSA and murine mammary tumor virus reporters in AR-negative DU-145 and PC3 cells.	bicalutamide	0-12	interleukin 6	Mus musculus	45-49
11395027-1	2001	Interleukin-6 (IL-6) gene expressed in bone marrow-derived stromal cells and osteoblasts contributes to the state of mineralization and its control by estradiol may be involved in the development of post-menopausal osteoporosis.	Estradiol	151-160	interleukin 6	Mus musculus	0-13
11395027-1	2001	Interleukin-6 (IL-6) gene expressed in bone marrow-derived stromal cells and osteoblasts contributes to the state of mineralization and its control by estradiol may be involved in the development of post-menopausal osteoporosis.	Estradiol	151-160	interleukin 6	Mus musculus	15-19
11373471-0	2001	Catecholamines play a role in the production of interleukin-6 and interleukin-1alpha in unburned skin after burn injury in mice.	Catecholamines	0-14	interleukin 6	Mus musculus	48-61
11591951-8	2001	Plasma IL-6 and catecholamine in the urine were lower in the CO(2) pneumoperitoneum group than the air insufflation group.	co(2) pneumoperitoneum	61-83	interleukin 6	Mus musculus	7-11
11422407-10	2001	Injection of CP resulted in a 22.5- and 93-fold decrease in GM-CSF and IL-6 levels, respectively, in lung-conditioned medium, while treatment with quinolones resulted in 2-4-fold increase in GM-CSF with no effect on IL-6 production.	Quinolones	147-157	interleukin 6	Mus musculus	216-220
11394936-0	2001	1,5-Benzodiazepine tricyclic derivatives exerting anti-inflammatory effects in mice by inhibiting interleukin-6 and prostaglandinE(2)production.	1H-1,5-Benzodiazepine	0-18	interleukin 6	Mus musculus	98-111
11281645-3	2001	In this report, we demonstrate that cyclic AMP (cAMP)- and IL6-dependent signaling pathways can interact, controlling proliferation of 7TD1 cells through modulation of apoptosis.	Cyclic AMP	36-46	interleukin 6	Mus musculus	59-62
11281645-5	2001	The cAMP-induced inhibition could be reversed after 24 h by the removal of dibutyryl-cAMP from the culture medium and readdition of IL6.	Cyclic AMP	4-8	interleukin 6	Mus musculus	132-135
11329499-8	2001	RESULTS: Ethanol exposure upregulated basal gene expression of IL-1 beta, TNF-alpha, IL-6, and iNOS in the distal ileum, but similar effects of ethanol on the liver were not observed.	Ethanol	9-16	interleukin 6	Mus musculus	85-89
11302724-5	2001	p50 antisense oligonucleotide increased IL-6 mRNA expression.	Oligonucleotides	14-29	interleukin 6	Mus musculus	40-44
11795518-10	2001	Expressions of TNF-alpha and IL-6 were inhibited in the lungs of these mice after treatment with green tea in drinking water for 4 months.	Water	119-124	interleukin 6	Mus musculus	29-33
11373471-1	2001	OBJECTIVE: To investigate the effects of catecholamines on the production of interleukin (IL)-6 and IL-1alpha in unburned skin after a burn injury.	Catecholamines	41-55	interleukin 6	Mus musculus	77-95
11373471-7	2001	MEASUREMENTS AND MAIN RESULTS: Epinephrine and norepinephrine increased the production of IL-6 but not of IL-1alpha in normal abdominal skin, and these increases were reversed by a beta-blocker (propranolol hydrochloride) but not an alpha-blocker (phentolamine mesylate).	Epinephrine	31-42	interleukin 6	Mus musculus	90-94
11373471-7	2001	MEASUREMENTS AND MAIN RESULTS: Epinephrine and norepinephrine increased the production of IL-6 but not of IL-1alpha in normal abdominal skin, and these increases were reversed by a beta-blocker (propranolol hydrochloride) but not an alpha-blocker (phentolamine mesylate).	Norepinephrine	47-61	interleukin 6	Mus musculus	90-94
11373471-7	2001	MEASUREMENTS AND MAIN RESULTS: Epinephrine and norepinephrine increased the production of IL-6 but not of IL-1alpha in normal abdominal skin, and these increases were reversed by a beta-blocker (propranolol hydrochloride) but not an alpha-blocker (phentolamine mesylate).	Propranolol	195-220	interleukin 6	Mus musculus	90-94
11373471-7	2001	MEASUREMENTS AND MAIN RESULTS: Epinephrine and norepinephrine increased the production of IL-6 but not of IL-1alpha in normal abdominal skin, and these increases were reversed by a beta-blocker (propranolol hydrochloride) but not an alpha-blocker (phentolamine mesylate).	Phentolamine	248-269	interleukin 6	Mus musculus	90-94
11254566-1	2001	Bacterial DNA and synthetic oligonucleotides containing CpG sequences (CpG-DNA and CpG-ODN) provoke a proinflammatory cytokine response (tumor necrosis factor alpha [TNF-alpha], interleukin-12 [IL-12], and IL-6) and increased mortality in lipopolysaccharide (LPS)-challenged mice via a TNF-alpha-mediated mechanism.	Oligonucleotides	28-44	interleukin 6	Mus musculus	206-210
11277977-8	2001	Furthermore, fluorescein isothiocyanate (FITC)-dextran intravenous injection demonstrated leaky vessels in IL-6-deficient but not in wild type animals following ACI.	Fluorescein-5-isothiocyanate	13-39	interleukin 6	Mus musculus	107-111
11380602-9	2001	IL-6 decreases after a low dose of Ara-C and increases after a high dose.	Cytarabine	35-40	interleukin 6	Mus musculus	0-4
11277977-8	2001	Furthermore, fluorescein isothiocyanate (FITC)-dextran intravenous injection demonstrated leaky vessels in IL-6-deficient but not in wild type animals following ACI.	fluorescein isothiocyanate dextran	41-54	interleukin 6	Mus musculus	107-111
11295263-0	2001	Superinduction of TNF-alpha and IL-6 in macrophages by vomitoxin (deoxynivalenol) modulated by mRNA stabilization.	deoxynivalenol	55-64	interleukin 6	Mus musculus	32-36
11295263-0	2001	Superinduction of TNF-alpha and IL-6 in macrophages by vomitoxin (deoxynivalenol) modulated by mRNA stabilization.	deoxynivalenol	66-80	interleukin 6	Mus musculus	32-36
11295263-5	2001	Using Northern analysis, the mRNA stabilities of TNF-alpha and IL-6 were studied in DRB-treated cells exposed to VT and LPS in both asynchronous and delayed synchronous modes.	Dichlororibofuranosylbenzimidazole	84-87	interleukin 6	Mus musculus	63-67
11248225-6	2001	We also observed that melatonin, alone, had no effect on IL-1beta secretion but at a concentration of 500 microM induced the secretion of IL-6.	Melatonin	22-31	interleukin 6	Mus musculus	138-142
11259078-2	2001	In particular, a spontaneous increase in serum interleukin-6 (IL-6) levels in five-week old MRL-lpr mice coincides temporally with blunted responsiveness to sucrose and excessive immobility in the forced swim test.	Sucrose	157-164	interleukin 6	Mus musculus	47-60
11250788-6	2001	IL-6 was found in the testes of intact adult mice, mice treated with testosterone for 70 days, cryptorchid testes and sham-operated testes.	Testosterone	69-81	interleukin 6	Mus musculus	0-4
11239501-5	2001	Epinephrine (1 microM) also increased interleukin (IL)-6, IL-11, and cyclooxygenase (COX)-II mRNA levels, as well as increased prostaglandin E(2) (PGE(2)) accumulation in the culture medium.	Epinephrine	0-11	interleukin 6	Mus musculus	38-56
11259078-2	2001	In particular, a spontaneous increase in serum interleukin-6 (IL-6) levels in five-week old MRL-lpr mice coincides temporally with blunted responsiveness to sucrose and excessive immobility in the forced swim test.	Sucrose	157-164	interleukin 6	Mus musculus	62-66
11259078-3	2001	These relationships, along with evidence that sucrose intake drops after systemic IL-6 overexpression is induced in healthy mice, have led to the hypothesis that sustained elevation in serum IL-6 also induces other aspects of AABS.	Sucrose	46-53	interleukin 6	Mus musculus	191-195
11259078-7	2001	The Ad5mIL6 infection (known to induce excessive IL-6 levels over five days) transiently reduced food, water, and sucrose intake, as well as rectal temperature in MRL +/+ and AKR/J mice.	Water	103-108	interleukin 6	Mus musculus	49-53
11259078-7	2001	The Ad5mIL6 infection (known to induce excessive IL-6 levels over five days) transiently reduced food, water, and sucrose intake, as well as rectal temperature in MRL +/+ and AKR/J mice.	Sucrose	114-121	interleukin 6	Mus musculus	49-53
11267928-4	2001	Treatment of mice on day 21 with a subcurative dose of diminazene aceturate (Berenil), a procedure known to induce a mild PTRE, cleared the parasite from the circulation with plasma APP and liver expression of mRNA for IL-6 and TNFalpha returning to the levels in the controls.	diminazene aceturate	55-75	interleukin 6	Mus musculus	219-223
11238717-2	2001	We recently reported that central administration of lipopolysaccharide induces peripheral interleukin-6 responses via both the central and peripheral norepinephrine system.	Norepinephrine	150-164	interleukin 6	Mus musculus	90-103
11238717-6	2001	)-induced plasma interleukin-6 peaked at 2 h post injection, which is earlier than the peak time of the Abeta(1-42)-induced brain interleukin-6, tumor necrosis factor-alpha and interleukin-1beta levels, which was 4, 4 and 24 h, respectively.	UNII-042A8N37WH	104-109	interleukin 6	Mus musculus	130-172
11238717-11	2001	Either central or peripheral norepinephrine depletion effectively inhibited the Abeta(1-42)-induced peripheral interleukin-6 response.	Norepinephrine	29-43	interleukin 6	Mus musculus	111-124
11238717-13	2001	These results demonstrate that centrally administered Abeta(1-42) effectively induces the systemic interleukin-6 response which is mediated, in part, by central Abeta(1-42)-induced activation of the central and the peripheral norepinephrine systems.	Norepinephrine	226-240	interleukin 6	Mus musculus	99-112
11267928-4	2001	Treatment of mice on day 21 with a subcurative dose of diminazene aceturate (Berenil), a procedure known to induce a mild PTRE, cleared the parasite from the circulation with plasma APP and liver expression of mRNA for IL-6 and TNFalpha returning to the levels in the controls.	diminazene aceturate	77-84	interleukin 6	Mus musculus	219-223
11267928-6	2001	A further subcurative dose of Berenil, leading to a more severe PTRE, was associated with elevated serum concentrations of Hp and SAP, increased TNFalpha mRNA in the liver and detectable IL-6 and TNFalpha mRNA in the brain.	diminazene aceturate	30-37	interleukin 6	Mus musculus	187-191
11161464-7	2001	The serum IL-6 value of the steroid group was significantly lower than that of non-steroid group in HEP group.	Steroids	28-35	interleukin 6	Mus musculus	10-14
11181699-6	2001	Development of colitis as well as STAT3 activation was significantly reduced in IL-6-deficient mice treated with DSS, suggesting that STAT3 plays an important role in the perpetuation of colitis.	Dextran Sulfate	113-116	interleukin 6	Mus musculus	80-84
11161464-7	2001	The serum IL-6 value of the steroid group was significantly lower than that of non-steroid group in HEP group.	Steroids	83-90	interleukin 6	Mus musculus	10-14
11161464-6	2001	RESULTS: The post-hepatectomy IL-6 values at 2 and 3 days after CBDL were significantly lower than those in the HEP group, while those at 5 days after CBDL were significantly higher than those in HEP group.	cbdl	64-68	interleukin 6	Mus musculus	30-34
11161464-8	2001	However, no steroid effects were recognized on post-hepatectomy IL-6 values at 3 days after CBDL, steroid inhibited post-hepatectomy IL-6 production at 5 days after CBDL.	Steroids	98-105	interleukin 6	Mus musculus	133-137
11159209-3	2001	Thioglycollate was injected intraperitoneally into BALB/c mice resulting in a dose-dependent increase in neutrophil recruitment and local inflammation, as measured by peritoneal levels of interleukin 6.	Thioglycolates	0-14	interleukin 6	Mus musculus	188-201
11208530-6	2001	These findings indicate that IL-6 is an essential component of the postresuscitation inflammatory cascade in HS and that the local proinflammatory effects of IL-6 on PMN infiltration and organ damage in HS dominate over the anti-inflammatory effects of systemic IL-6.	platensimycin	166-169	interleukin 6	Mus musculus	158-162
11208530-6	2001	These findings indicate that IL-6 is an essential component of the postresuscitation inflammatory cascade in HS and that the local proinflammatory effects of IL-6 on PMN infiltration and organ damage in HS dominate over the anti-inflammatory effects of systemic IL-6.	platensimycin	166-169	interleukin 6	Mus musculus	158-162
11180114-9	2001	Using IL-6(-/-) mice, we demonstrated that in turpentine-induced inflammation production of IL-1Ra mRNA by the liver is regulated by IL-6.	Turpentine	46-56	interleukin 6	Mus musculus	6-10
11180114-9	2001	Using IL-6(-/-) mice, we demonstrated that in turpentine-induced inflammation production of IL-1Ra mRNA by the liver is regulated by IL-6.	Turpentine	46-56	interleukin 6	Mus musculus	133-137
11272276-0	2001	CpG-containing oligodeoxynucleotides induce TNF-alpha and IL-6 production but not degranulation from murine bone marrow-derived mast cells.	Oligodeoxyribonucleotides	15-36	interleukin 6	Mus musculus	58-62
11213271-15	2001	Because IL-6 has been suggested to contribute to the age-related increase in prostaglandin (PG)E2 and nitric oxide (NO) production, we investigated the effect of age on the production of IL-6 by murine peritoneal macrophages (Mphi) as well as the effect of IL-6 on the production of other Mphi inflammatory products.	Dinoprostone	77-97	interleukin 6	Mus musculus	8-12
11213271-15	2001	Because IL-6 has been suggested to contribute to the age-related increase in prostaglandin (PG)E2 and nitric oxide (NO) production, we investigated the effect of age on the production of IL-6 by murine peritoneal macrophages (Mphi) as well as the effect of IL-6 on the production of other Mphi inflammatory products.	Nitric Oxide	102-114	interleukin 6	Mus musculus	8-12
11272276-5	2001	There was a dose-dependent increase in the production of both interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) by mast cells treated with the CpG-containing oligodeoxynucleotides.	Oligodeoxyribonucleotides	173-194	interleukin 6	Mus musculus	62-75
11272276-5	2001	There was a dose-dependent increase in the production of both interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) by mast cells treated with the CpG-containing oligodeoxynucleotides.	Oligodeoxyribonucleotides	173-194	interleukin 6	Mus musculus	77-81
11272279-9	2001	The results revealed that TNF-alpha up-regulated NO, PGE2, and IL-6 synthesis; PGE2 up-regulated NO, but down-regulated TNF-alpha synthesis; and PGE2 and IL-6 mutually up-regulated reciprocally.	Dinoprostone	53-57	interleukin 6	Mus musculus	154-158
11272279-9	2001	The results revealed that TNF-alpha up-regulated NO, PGE2, and IL-6 synthesis; PGE2 up-regulated NO, but down-regulated TNF-alpha synthesis; and PGE2 and IL-6 mutually up-regulated reciprocally.	Dinoprostone	79-83	interleukin 6	Mus musculus	154-158
11272279-9	2001	The results revealed that TNF-alpha up-regulated NO, PGE2, and IL-6 synthesis; PGE2 up-regulated NO, but down-regulated TNF-alpha synthesis; and PGE2 and IL-6 mutually up-regulated reciprocally.	Dinoprostone	79-83	interleukin 6	Mus musculus	154-158
11272279-5	2001	LPS alone triggered the release of PGE2, TNF-alpha, and IL-6; all of which were potentiated by the presence of TG, but not of UTP.	Thapsigargin	111-113	interleukin 6	Mus musculus	56-60
11272279-7	2001	PGE2, TNF-alpha, and IL-6 release by LPS alone were attenuated by Ro 31-8220, Go6976, PD 098059, SB 203580, and PDTC.	Go 6976	78-84	interleukin 6	Mus musculus	21-25
11272279-7	2001	PGE2, TNF-alpha, and IL-6 release by LPS alone were attenuated by Ro 31-8220, Go6976, PD 098059, SB 203580, and PDTC.	Antimony	97-99	interleukin 6	Mus musculus	21-25
11237479-1	2001	Prostaglandins (PG) E1, E2 and F2alpha induce bone resorption in isolated neonatal parietal bone cultures, and an associated increase in interleukin-6 (IL-6) production.	Alprostadil	0-22	interleukin 6	Mus musculus	137-150
11167800-2	2001	A pH-reversible amino-protective reagent, dimethylmaleic anhydride (DMMAn), was used for modification of interleukin-6 (IL-6) with polyethylene glycol (PEG).	2,3-dimethylmaleic anhydride	42-66	interleukin 6	Mus musculus	105-118
11016935-7	2001	Subsequent ATP injection to wild-type animals promotes an increase in IL-1, which in turn leads to additional IL-6 production; similar increases did not occur in ATP-treated, LPS-primed P2X(7)R(-/-) animals.	Adenosine Triphosphate	11-14	interleukin 6	Mus musculus	110-114
11167800-5	2001	The DmPEG-IL-6 Fr.1, having 3-4 PEG chains attached to the cytokine, showed the strongest thrombopoietic effect among the DmPEG-IL-6s with different molecular sizes that were tested.	Polyethylene Glycols	6-9	interleukin 6	Mus musculus	122-132
11237479-1	2001	Prostaglandins (PG) E1, E2 and F2alpha induce bone resorption in isolated neonatal parietal bone cultures, and an associated increase in interleukin-6 (IL-6) production.	Alprostadil	0-22	interleukin 6	Mus musculus	152-156
11237479-1	2001	Prostaglandins (PG) E1, E2 and F2alpha induce bone resorption in isolated neonatal parietal bone cultures, and an associated increase in interleukin-6 (IL-6) production.	Estradiol	24-26	interleukin 6	Mus musculus	137-150
11237479-1	2001	Prostaglandins (PG) E1, E2 and F2alpha induce bone resorption in isolated neonatal parietal bone cultures, and an associated increase in interleukin-6 (IL-6) production.	Estradiol	24-26	interleukin 6	Mus musculus	152-156
11237479-1	2001	Prostaglandins (PG) E1, E2 and F2alpha induce bone resorption in isolated neonatal parietal bone cultures, and an associated increase in interleukin-6 (IL-6) production.	f2alpha	31-38	interleukin 6	Mus musculus	137-150
11237479-1	2001	Prostaglandins (PG) E1, E2 and F2alpha induce bone resorption in isolated neonatal parietal bone cultures, and an associated increase in interleukin-6 (IL-6) production.	f2alpha	31-38	interleukin 6	Mus musculus	152-156
11237479-5	2001	The relatively weak increase in IL-6 production by misoprostol (with respect to resorption) suggests that these responses are controlled by different combination of EP2 and EP4 receptors.	Misoprostol	51-62	interleukin 6	Mus musculus	32-36
11237479-9	2001	PMA induced both resorption and IL-6 production which were both blocked by indomethacin, indicating a role for PKC in the control of prostaglandin production.	Tetradecanoylphorbol Acetate	0-3	interleukin 6	Mus musculus	32-36
11034996-0	2001	Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6.	Phospholipids	9-22	interleukin 6	Mus musculus	117-130
11034996-1	2001	In this study, we tested if interleukin-6 (IL-6) plays a role in mediating the effects of oxidized phospholipids (OXPL).	Phospholipids	99-112	interleukin 6	Mus musculus	28-41
11034996-1	2001	In this study, we tested if interleukin-6 (IL-6) plays a role in mediating the effects of oxidized phospholipids (OXPL).	Phospholipids	99-112	interleukin 6	Mus musculus	43-47
11034996-1	2001	In this study, we tested if interleukin-6 (IL-6) plays a role in mediating the effects of oxidized phospholipids (OXPL).	OXPL	114-118	interleukin 6	Mus musculus	28-41
11034996-1	2001	In this study, we tested if interleukin-6 (IL-6) plays a role in mediating the effects of oxidized phospholipids (OXPL).	OXPL	114-118	interleukin 6	Mus musculus	43-47
11167800-2	2001	A pH-reversible amino-protective reagent, dimethylmaleic anhydride (DMMAn), was used for modification of interleukin-6 (IL-6) with polyethylene glycol (PEG).	2,3-dimethylmaleic anhydride	42-66	interleukin 6	Mus musculus	120-124
11167800-2	2001	A pH-reversible amino-protective reagent, dimethylmaleic anhydride (DMMAn), was used for modification of interleukin-6 (IL-6) with polyethylene glycol (PEG).	2,3-dimethylmaleic anhydride	68-73	interleukin 6	Mus musculus	105-118
11167800-2	2001	A pH-reversible amino-protective reagent, dimethylmaleic anhydride (DMMAn), was used for modification of interleukin-6 (IL-6) with polyethylene glycol (PEG).	2,3-dimethylmaleic anhydride	68-73	interleukin 6	Mus musculus	120-124
11167800-2	2001	A pH-reversible amino-protective reagent, dimethylmaleic anhydride (DMMAn), was used for modification of interleukin-6 (IL-6) with polyethylene glycol (PEG).	Polyethylene Glycols	131-150	interleukin 6	Mus musculus	105-118
11167800-2	2001	A pH-reversible amino-protective reagent, dimethylmaleic anhydride (DMMAn), was used for modification of interleukin-6 (IL-6) with polyethylene glycol (PEG).	Polyethylene Glycols	131-150	interleukin 6	Mus musculus	120-124
11167800-2	2001	A pH-reversible amino-protective reagent, dimethylmaleic anhydride (DMMAn), was used for modification of interleukin-6 (IL-6) with polyethylene glycol (PEG).	Polyethylene Glycols	152-155	interleukin 6	Mus musculus	105-118
11167800-2	2001	A pH-reversible amino-protective reagent, dimethylmaleic anhydride (DMMAn), was used for modification of interleukin-6 (IL-6) with polyethylene glycol (PEG).	Polyethylene Glycols	152-155	interleukin 6	Mus musculus	120-124
11167800-3	2001	The novel PEG-conjugated IL-6 (DmPEG-IL-6), which had been pretreated with DMMAn before PEGylation, showed up to a 140% increase in in vitro specific activity compared with PEG-IL-6 that had been synthesized by the previous method.	Polyethylene Glycols	10-13	interleukin 6	Mus musculus	25-29
11167800-3	2001	The novel PEG-conjugated IL-6 (DmPEG-IL-6), which had been pretreated with DMMAn before PEGylation, showed up to a 140% increase in in vitro specific activity compared with PEG-IL-6 that had been synthesized by the previous method.	Polyethylene Glycols	10-13	interleukin 6	Mus musculus	31-41
11167800-3	2001	The novel PEG-conjugated IL-6 (DmPEG-IL-6), which had been pretreated with DMMAn before PEGylation, showed up to a 140% increase in in vitro specific activity compared with PEG-IL-6 that had been synthesized by the previous method.	Polyethylene Glycols	10-13	interleukin 6	Mus musculus	37-41
11167800-3	2001	The novel PEG-conjugated IL-6 (DmPEG-IL-6), which had been pretreated with DMMAn before PEGylation, showed up to a 140% increase in in vitro specific activity compared with PEG-IL-6 that had been synthesized by the previous method.	2,3-dimethylmaleic anhydride	75-80	interleukin 6	Mus musculus	25-29
11167800-3	2001	The novel PEG-conjugated IL-6 (DmPEG-IL-6), which had been pretreated with DMMAn before PEGylation, showed up to a 140% increase in in vitro specific activity compared with PEG-IL-6 that had been synthesized by the previous method.	2,3-dimethylmaleic anhydride	75-80	interleukin 6	Mus musculus	31-41
11167800-3	2001	The novel PEG-conjugated IL-6 (DmPEG-IL-6), which had been pretreated with DMMAn before PEGylation, showed up to a 140% increase in in vitro specific activity compared with PEG-IL-6 that had been synthesized by the previous method.	2,3-dimethylmaleic anhydride	75-80	interleukin 6	Mus musculus	37-41
11167800-3	2001	The novel PEG-conjugated IL-6 (DmPEG-IL-6), which had been pretreated with DMMAn before PEGylation, showed up to a 140% increase in in vitro specific activity compared with PEG-IL-6 that had been synthesized by the previous method.	Polyethylene Glycols	33-36	interleukin 6	Mus musculus	25-29
11167800-3	2001	The novel PEG-conjugated IL-6 (DmPEG-IL-6), which had been pretreated with DMMAn before PEGylation, showed up to a 140% increase in in vitro specific activity compared with PEG-IL-6 that had been synthesized by the previous method.	Polyethylene Glycols	33-36	interleukin 6	Mus musculus	37-41
11192503-0	2001	Induction of necrosis factor-alpha and interleukin-6 in mice in vivo and in murine peritoneal macrophages and human whole blood cells in vitro by Micrococcus luteus teichuronic acids.	teichuronic acid	165-182	interleukin 6	Mus musculus	39-52
11119551-3	2001	A correlation between the severity of arthritis, the number of GBS in the joints, and local interleukin-6 and interleukin-1beta production was evident.	gbs	63-66	interleukin 6	Mus musculus	92-105
11192503-4	2001	Teichuronic acids, a component of M. luteus cell walls, induced tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in MDP-primed C3H/HeN mice.	teichuronic acid	0-17	interleukin 6	Mus musculus	109-122
11192503-4	2001	Teichuronic acids, a component of M. luteus cell walls, induced tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in MDP-primed C3H/HeN mice.	teichuronic acid	0-17	interleukin 6	Mus musculus	124-128
11192503-8	2001	Purified teichuronic acids also induced TNF-alpha and IL-6 production in C3H/HeN murine peritoneal macrophages and human whole-blood cells in the culture, but reduced teichuronic acids did not.	teichuronic acid	9-26	interleukin 6	Mus musculus	54-58
11192503-9	2001	The purified teichuronic acids induced no TNF-alpha and only low levels of IL-6 in MDP-primed C3H/HeJ mice, and neither cytokine in peritoneal macrophage cultures from C3H/HeJ mice with a single point of mutation in Toll-like receptor 4 (TLR4) gene.	teichuronic acid	13-30	interleukin 6	Mus musculus	75-79
11182244-0	2001	Interleukin-6 deficiency reduces the brain inflammatory response and increases oxidative stress and neurodegeneration after kainic acid-induced seizures.	Kainic Acid	124-135	interleukin 6	Mus musculus	0-13
11150918-7	2001	8 h after antigen challenge, prednisolone clearly inhibited the increase in the number of anaphylactic degranulated and IL-6-positive mast cells by administration 2 h before challenge, but did not affect it by administration 6 h after challenge.	Prednisolone	29-41	interleukin 6	Mus musculus	120-124
11174004-0	2001	Dilazep hydrochloride, an antiplatelet drug, inhibits lipopolysaccharide-induced mouse mesangial cell IL-6 secretion and proliferation.	Dilazep	0-21	interleukin 6	Mus musculus	102-106
11174004-4	2001	The effects of dilazep on cultured MC IL-6 secretion and proliferation were investigated in the present study.	Dilazep	15-22	interleukin 6	Mus musculus	38-42
11174004-8	2001	However, dilazep significantly inhibited this LPS-induced IL-6 secretion from MCs in a dose- and time-dependent manner.	Dilazep	9-16	interleukin 6	Mus musculus	58-62
11182244-2	2001	At 35mg/kg, kainic acid induced convulsions in both control (75%) and interleukin-6 null (100%) mice, and caused a significant mortality (62%) only in the latter mice, indicating that interleukin-6 deficiency increased the susceptibility to kainic acid-induced brain damage.	Kainic Acid	12-23	interleukin 6	Mus musculus	70-83
11182244-2	2001	At 35mg/kg, kainic acid induced convulsions in both control (75%) and interleukin-6 null (100%) mice, and caused a significant mortality (62%) only in the latter mice, indicating that interleukin-6 deficiency increased the susceptibility to kainic acid-induced brain damage.	Kainic Acid	12-23	interleukin 6	Mus musculus	184-197
11182244-2	2001	At 35mg/kg, kainic acid induced convulsions in both control (75%) and interleukin-6 null (100%) mice, and caused a significant mortality (62%) only in the latter mice, indicating that interleukin-6 deficiency increased the susceptibility to kainic acid-induced brain damage.	Kainic Acid	241-252	interleukin 6	Mus musculus	184-197
11198356-13	2001	IL-6 release was partially restored only in splenic macrophages treated with SB203580.	SB 203580	77-85	interleukin 6	Mus musculus	0-4
11182244-8	2001	In kainic acid-injected interleukin-6 null mice, reactive astrogliosis and microgliosis were reduced, while morphological hippocampal damage, oxidative stress and apoptotic neuronal death were increased.	Kainic Acid	3-14	interleukin 6	Mus musculus	24-37
11182244-10	2001	The present results demonstrate that interleukin-6 deficiency increases neuronal injury and impairs the inflammatory response after kainic acid-induced seizures.	Kainic Acid	132-143	interleukin 6	Mus musculus	37-50
11102411-3	2000	Trovafloxacin inhibited the production of tumour necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-6 and IL-8 by PBMCs after stimulation with either LPS or LTA by 83%.	trovafloxacin	0-13	interleukin 6	Mus musculus	114-118
12593702-3	2001	Previous in vivo studies have documented that administration of SR31747A in murine models of sepsis resulted in decreased proinflammatory (IL-1, IL-6, TNF-alpha) and increased anti-inflammatory (IL-10) response (serum, splenocyte).	SR 31747	64-72	interleukin 6	Mus musculus	145-149
11201166-8	2001	On the other hand, the expression of cell surface IL-1RI is inhibited by tyrosine kinase inhibitors, herbimycin and genistein, resulting in reduction of the kinase activity of IRAK (IL-1 receptor associated kinase) and IL-1-induced IL-6 production from the fibroblasts.	herbimycin	101-111	interleukin 6	Mus musculus	232-236
11201166-8	2001	On the other hand, the expression of cell surface IL-1RI is inhibited by tyrosine kinase inhibitors, herbimycin and genistein, resulting in reduction of the kinase activity of IRAK (IL-1 receptor associated kinase) and IL-1-induced IL-6 production from the fibroblasts.	Genistein	116-125	interleukin 6	Mus musculus	232-236
11113077-7	2000	Concurrent plasma levels of interleukin (IL)-6, the major cytokine activating the hypothalamic-pituitary-adrenal axis, were markedly increased (495 +/- 131 vs. 20 +/- 1.5 pg/mL; P &lt; 0.0001), and this cytokine directly stimulated corticosterone secretion by adrenocortical cells in vitro.	Corticosterone	232-246	interleukin 6	Mus musculus	28-46
11113077-9	2000	Treatment of animals with neutralizing anti-IL-6 antibody reduced the TNBS-induced growth and activation of the adrenal cortices.	Trinitrobenzenesulfonic Acid	70-74	interleukin 6	Mus musculus	44-48
11090238-7	2000	On day 14 after SZ, fusidin markedly altered the circulating cytokine profile induced in vivo by ConA, reducing the levels of IFN-gamma, IL-2 and TNF-alpha and augmenting the level of IL-6.	Fusidic Acid	20-27	interleukin 6	Mus musculus	184-188
11102411-5	2000	The relevance of this in vitro observation was explored by examining TNF-alpha and IL-6 responses in trovafloxacin-treated mice.	trovafloxacin	101-114	interleukin 6	Mus musculus	83-87
11102411-7	2000	Reverse transcription- polymerase chain reaction studies of the mechanisms determining cytokine down-regulation demonstrated that trovafloxacin reduced TNF-alpha, IL-1beta and IL-6 mRNA to levels similar to those of unstimulated cells.	trovafloxacin	130-143	interleukin 6	Mus musculus	176-180
11131460-8	2000	Expression of peroxisome proliferator activated receptor-alpha mRNA was increased in both IL-6(-/-) and wild-type mice by nafenopin treatment, but not by CPA treatment.	Nafenopin	122-131	interleukin 6	Mus musculus	90-94
11086097-0	2000	Prostaglandin E2 selectively enhances the IgE-mediated production of IL-6 and granulocyte-macrophage colony-stimulating factor by mast cells through an EP1/EP3-dependent mechanism.	Dinoprostone	0-16	interleukin 6	Mus musculus	69-73
11086097-4	2000	PGE(2) treatment alone specifically enhanced IL-6 production, and neither induced nor inhibited degranulation and the release of other mast cell cytokines, including IL-4, IL-10, IFN-gamma, and GM-CSF.	Prostaglandins E	0-3	interleukin 6	Mus musculus	45-49
11086097-5	2000	IgE/Ag-mediated activation of BMMC induced the secretion of IL-4, IL-6, and GM-CSF, and concurrent PGE(2) stimulation synergistically increased mast cell degranulation and IL-6 and GM-CSF, but not IL-4, production.	bmmc	30-34	interleukin 6	Mus musculus	66-70
11086097-5	2000	IgE/Ag-mediated activation of BMMC induced the secretion of IL-4, IL-6, and GM-CSF, and concurrent PGE(2) stimulation synergistically increased mast cell degranulation and IL-6 and GM-CSF, but not IL-4, production.	bmmc	30-34	interleukin 6	Mus musculus	172-176
11086097-5	2000	IgE/Ag-mediated activation of BMMC induced the secretion of IL-4, IL-6, and GM-CSF, and concurrent PGE(2) stimulation synergistically increased mast cell degranulation and IL-6 and GM-CSF, but not IL-4, production.	Prostaglandins E	99-102	interleukin 6	Mus musculus	172-176
11086097-6	2000	A similar potentiation of degranulation and IL-6 production by PGE(2), in the context of IgE-directed activation, was observed in the well-established IL-3-dependent murine mast cell line, MC/9.	Prostaglandins E	63-66	interleukin 6	Mus musculus	44-48
11129648-4	2000	In contrast, when WBH was applied just after intraperitoneal administration of lipopolysaccharide (LPS), serum concentrations of TNF-alpha and IL-6 were greater than or equal to threefold higher in BALB/c mice compared with LPS-treated controls.	wbh	18-21	interleukin 6	Mus musculus	143-147
11129648-5	2000	LPS-induced IL-6 levels were also enhanced in WBH-treated C57BL/6 mice.	wbh	46-49	interleukin 6	Mus musculus	12-16
11197078-10	2000	However, IL-6 levels were markedly augmented by cisplatin with LPS.	Cisplatin	48-57	interleukin 6	Mus musculus	9-13
11093760-0	2000	Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6.	Methamphetamine	0-15	interleukin 6	Mus musculus	96-109
11093760-5	2000	However, these METH-induced effects were significantly attenuated in IL-6-/- animals.	Methamphetamine	15-19	interleukin 6	Mus musculus	69-73
11071876-4	2000	PGE(2) affected the TNF-alpha and IL-6 production in lipopolysaccharide (LPS)-treated neutrophils; it suppressed the TNF-alpha production and enhanced the IL-6 production.	Prostaglandins E	0-3	interleukin 6	Mus musculus	34-38
11093760-7	2000	Moreover, METH induced decreases in [(125)I]RTI-55-labeled serotonin transporters in the hippocampal CA3 region and in the substantia nigra-reticulata but increases in serotonin transporters in the CPu and cingulate cortex in wild-type animals, all of which were attenuated in IL-6-/- mice.	Methamphetamine	10-14	interleukin 6	Mus musculus	277-281
11093760-8	2000	Additionally, METH caused increased gliosis in the CPu and cortices of wild-type mice as measured by [(3)H]PK-11195 binding; this gliotic response was almost completely inhibited in IL-6-/- animals.	Methamphetamine	14-18	interleukin 6	Mus musculus	182-186
11093760-10	2000	The protective effects against METH toxicity observed in the IL-6-/- mice were not caused by differences in temperature elevation or in METH accumulation in wild-type and mutant animals.	Methamphetamine	31-35	interleukin 6	Mus musculus	61-65
11093760-11	2000	Therefore, these observations support the proposition that IL-6 may play an important role in the neurotoxicity of METH.	Methamphetamine	115-119	interleukin 6	Mus musculus	59-63
11080527-10	2000	exerted an inhibitory effect on neutrophil influx and produce a marked inhibition of carrageenan-produced interleukin-13 and interleukin-6 in pleural exudation.	Carrageenan	85-96	interleukin 6	Mus musculus	125-138
11067924-1	2000	We establish, using an ELISA approach, that recombinant human and murine IL-6 bind to an immobilized heparin-BSA complex.	Heparin	101-108	interleukin 6	Mus musculus	73-77
11071649-5	2000	Further comparison of upstream signaling pathways revealed that JAK-1 was constitutively present in anti-phosphotyrosine immunoprecipitates of IL-6-independent cells; gp130 was constitutively phosphorylated in a subset of IL-6-independent plasmacytomas, whereas other IL-6-independent lines showed no detectable gp130 phosphorylation in the absence of exogenous IL-6.	Phosphotyrosine	105-120	interleukin 6	Mus musculus	143-147
11071876-4	2000	PGE(2) affected the TNF-alpha and IL-6 production in lipopolysaccharide (LPS)-treated neutrophils; it suppressed the TNF-alpha production and enhanced the IL-6 production.	Prostaglandins E	0-3	interleukin 6	Mus musculus	155-159
11071876-6	2000	This is the first study of the enhancement of IL-6 production by cAMP-elevating reagents in neutrophils.	Cyclic AMP	65-69	interleukin 6	Mus musculus	46-50
11084221-6	2000	Four weeks of prolonged administration of citalopram and fluoxetine induces a significant increase in the production of IL-6 and IL-10, a cytokine with immunosuppressive and anti-inflammatory activities.	Citalopram	42-52	interleukin 6	Mus musculus	120-124
11084221-6	2000	Four weeks of prolonged administration of citalopram and fluoxetine induces a significant increase in the production of IL-6 and IL-10, a cytokine with immunosuppressive and anti-inflammatory activities.	Fluoxetine	57-67	interleukin 6	Mus musculus	120-124
11154074-4	2000	Family 2 cystatins, including cystatins C, SA1, SA2, S, and egg white cystatin, upregulated the IL-6 production by two-lasts at physiological concentrations.	Sulfur	43-44	interleukin 6	Mus musculus	96-100
11036044-3	2000	The fluoroquinolones significantly reduced serum levels of interleukin-6 and tumor necrosis factor alpha in LPS-treated mice.	Fluoroquinolones	4-20	interleukin 6	Mus musculus	59-104
11189447-4	2000	The [Ca2+]i inhibitor BAPTA dose dependently inhibited HSP70- but not LPS-induced NF-kappaB activity and subsequent augmentation of proinflammatory cytokine TNF-alpha, IL-1beta, and IL-6 production.	1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid	22-27	interleukin 6	Mus musculus	182-186
11049111-9	2000	Trauma-hemorrhage decreased IL-6 release by T lymphocytes and the release was restored to sham levels with flutamide pre-treatment.	Flutamide	107-116	interleukin 6	Mus musculus	28-32
11018077-0	2000	Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice.	Alcohols	8-15	interleukin 6	Mus musculus	75-79
11018077-6	2000	These findings demonstrate that ethanol induces bone loss through IL-6.	Ethanol	32-39	interleukin 6	Mus musculus	66-70
11215378-8	2000	Intravenous injection of MR-33 prevented the endotoxin-induced increases in TAT, TNF-alpha and IL-6 level and pulmonary vascular permeability in mice.	mr-33	25-30	interleukin 6	Mus musculus	95-99
10996474-1	2000	This study examines the effects of repeated amitriptyline and desipramine administration (10 mg/kg, IP) on the immunoreactivity of saline-injected C57BL/6 mice, as evaluated by the ability of splenocytes to reduce a tetrazolium salt to formazan (MTT test), to proliferate, and to produce cytokines, such as interleukin (IL)-1, IL-2, IL-4, IL-6, IL-10 and interferon gamma (IFN-gamma).	Sodium Chloride	131-137	interleukin 6	Mus musculus	339-343
11034416-3	2000	When compared with wild-type mice, IL-6-/- mice manifest exaggerated inflammation and eosinophilia, increased levels of IL-4, IL-5, and IL-13 protein and mRNA, exaggerated levels of eotaxin, JE/monocyte chemoattractant protein-1, macrophage inflammatory protein-1alpha and -2, and mRNA, increased bronchoalveolar lavage (BAL) TGF-beta1, and exaggerated airway responses to aerosolized methacholine.	Methacholine Chloride	385-397	interleukin 6	Mus musculus	35-39
11034416-5	2000	IL-6 also decreased the expression of endothelial VCAM-1 and airway responsiveness to methacholine in these animals.	Methacholine Chloride	86-98	interleukin 6	Mus musculus	0-4
10974387-0	2000	Molecular design of polyvinylpyrrolidone-conjugated interleukin-6 for enhancement of in vivo thrombopoietic activity in mice.	Povidone	20-40	interleukin 6	Mus musculus	52-65
10940506-5	2000	Tumor IL-6 levels were significantly lower in mice treated with CR supplement than in control mice (P&lt;0.001).	Chromium	64-66	interleukin 6	Mus musculus	6-10
10940506-7	2000	We also confirmed that berberine (8-32 microM), a major component of C. rhizoma, dose-dependently inhibited secretion of IL-6 by YES-2 cells in vitro.	Berberine	23-32	interleukin 6	Mus musculus	121-125
10940506-8	2000	Moreover, reverse transcription-PCR assay showed that treatment of YES-2 cells with berberine (8-32 microM) for 24 h reduced IL-6 mRNA expression.	Berberine	84-93	interleukin 6	Mus musculus	125-129
10940506-9	2000	Our results suggest that C. rhizoma may have an anticachectic effect on esophageal cancer and an effect is associated with the ability of berberine to down-regulate tumor IL-6 production.	Berberine	138-147	interleukin 6	Mus musculus	171-175
10974387-3	2000	Interleukin-6 (IL-6) was covalently conjugated via the formation of amino bonds between the lysine amino groups of IL-6 and PVP.	Lysine	92-98	interleukin 6	Mus musculus	15-19
10974387-3	2000	Interleukin-6 (IL-6) was covalently conjugated via the formation of amino bonds between the lysine amino groups of IL-6 and PVP.	Lysine	92-98	interleukin 6	Mus musculus	115-119
10974387-3	2000	Interleukin-6 (IL-6) was covalently conjugated via the formation of amino bonds between the lysine amino groups of IL-6 and PVP.	Povidone	124-127	interleukin 6	Mus musculus	0-13
10974387-3	2000	Interleukin-6 (IL-6) was covalently conjugated via the formation of amino bonds between the lysine amino groups of IL-6 and PVP.	Povidone	124-127	interleukin 6	Mus musculus	15-19
10974387-3	2000	Interleukin-6 (IL-6) was covalently conjugated via the formation of amino bonds between the lysine amino groups of IL-6 and PVP.	Povidone	124-127	interleukin 6	Mus musculus	115-119
11069722-6	2000	In the presence of 10 microM NS398, a selective COX-2 inhibitor, MCM-stimulated PGE(2) synthesis was almost completely suppressed, while production of IL-6 and TNF-alpha proteins and mRNA also was partially abrogated.	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	29-34	interleukin 6	Mus musculus	151-155
10859312-3	2000	PTPepsilonC expression resulted in lower levels of IL-6-induced tyrosine phosphorylation of Jak1, Tyk2, gp130, and Stat3 compared with parent cells.	Tyrosine	64-72	interleukin 6	Mus musculus	51-55
10859312-4	2000	In M1 transfectants expressing an inactive mutant of PTPepsilonC, both tyrosine phosphorylation and apoptosis induced by IL-6 and LIF were potentiated rather than inhibited.	Tyrosine	71-79	interleukin 6	Mus musculus	121-125
10974387-3	2000	Interleukin-6 (IL-6) was covalently conjugated via the formation of amino bonds between the lysine amino groups of IL-6 and PVP.	Lysine	92-98	interleukin 6	Mus musculus	0-13
11003205-0	2000	Anti-interleukin-6 antibody treatment restores cell-mediated immune function in mice with acute ethanol exposure before burn trauma.	Ethanol	96-103	interleukin 6	Mus musculus	5-18
11003205-1	2000	BACKGROUND: Previous studies from this laboratory reported that suppression of cell-mediated immune function was coincident with elevated interleukin (IL)-6 production after acute ethanol exposure before burn trauma, compared with either insult alone.	Ethanol	180-187	interleukin 6	Mus musculus	138-156
11003205-4	2000	RESULTS: Burn/ethanol mice exhibited a 91% suppression of the DTH response ( &lt; 0.01) and a 76% suppression of mitogen-induced splenocyte proliferation (p &lt; 0.01) at 48 hr postinjury, along with increased levels of circulating and splenic macrophage-derived IL-6, compared with all other treatment groups.	Ethanol	14-21	interleukin 6	Mus musculus	263-267
11003205-2	2000	The goal of this study was to investigate whether treatment with an anti-IL-6 antibody could restore immunocompetence in mice subjected to burn trauma with previous exposure to alcohol, as assessed by delayed-type hypersensitivity (DTH) and mitogen-induced splenocyte proliferative responses.	Alcohols	177-184	interleukin 6	Mus musculus	73-77
11003205-5	2000	After anti-IL-6 antibody administration to burn/ethanol mice, there was a 25% (p &lt; 0.05) and 63% (p &lt; 0.01) recovery of the DTH and splenocyte proliferative responses, respectively.	Ethanol	48-55	interleukin 6	Mus musculus	11-15
11003205-6	2000	Addition of exogenous IL-6 to splenocyte cultures isolated from anti-IL-6 antibody-treated burn/ethanol mice resulted in a 70% inhibition of mitogen-induced proliferative responses (p &lt; 0.03).	Ethanol	96-103	interleukin 6	Mus musculus	22-26
11003205-6	2000	Addition of exogenous IL-6 to splenocyte cultures isolated from anti-IL-6 antibody-treated burn/ethanol mice resulted in a 70% inhibition of mitogen-induced proliferative responses (p &lt; 0.03).	Ethanol	96-103	interleukin 6	Mus musculus	69-73
11003205-8	2000	Furthermore, the ability of the anti-IL-6 antibody treatment to improve cellular immune responses in the burn/ethanol group suggests that blocking this cytokine may be beneficial for the ethanol-exposed, thermally injured individual.	Ethanol	110-117	interleukin 6	Mus musculus	37-41
11003205-8	2000	Furthermore, the ability of the anti-IL-6 antibody treatment to improve cellular immune responses in the burn/ethanol group suggests that blocking this cytokine may be beneficial for the ethanol-exposed, thermally injured individual.	Ethanol	187-194	interleukin 6	Mus musculus	37-41
11003212-0	2000	Dose-dependent effect of ethanol on hepatic oxidative stress and interleukin-6 production after burn injury in the mouse.	Ethanol	25-32	interleukin 6	Mus musculus	65-78
11003212-2	2000	Interleukin (IL)-6 and reactive oxygen species (ROS) production is stimulated independently by alcohol and burn injury.	Alcohols	95-102	interleukin 6	Mus musculus	0-18
11003212-3	2000	The aim of the study was to determine whether increasing levels of alcohol differentially enhance the hepatic production of IL-6 and ROS after burn in a murine model of dorsal scald injury.	Alcohols	67-74	interleukin 6	Mus musculus	124-128
11003212-7	2000	In the saline-treated group, IL-6 circulating and hepatic levels rose after burn injury (p &lt; 0.03).	Sodium Chloride	7-13	interleukin 6	Mus musculus	29-33
11003212-9	2000	IL-6 hepatic production after burn injury was higher in the mice with a BAL of 300 mg/dl than in those with a BAL of 100 mg/dl and the saline-treated group (p = 0.001).	Sodium Chloride	135-141	interleukin 6	Mus musculus	0-4
11003212-11	2000	CONCLUSIONS: Alcohol enhances in a dose-dependent manner the hepatic production of IL-6 induced by burn injury through the modulation of oxidative stress.	Alcohols	13-20	interleukin 6	Mus musculus	83-87
11003212-12	2000	The increased mortality rate of mice exposed to alcohol and burn injury may be due to the adverse effect on immune function induced by IL-6 elevation.	Alcohols	48-55	interleukin 6	Mus musculus	135-139
10925257-3	2000	In thymocytes expressing SSI-1 transgene, tyrosine phosphorylation of STATs in response to cytokines such as IFN-gamma, IL-6, and IL-7 was inhibited, suggesting that SSI-1 suppresses cytokine signaling in primary lymphocytes.	Tyrosine	42-50	interleukin 6	Mus musculus	120-124
10996031-3	2000	PTX also affects the production of other cytokines such as IL-1, IL-6, IL-10, IL-12, and IFN-gamma.	Pentoxifylline	0-3	interleukin 6	Mus musculus	65-69
10974387-4	2000	PVP-conjugated IL-6, in which 60% of the fourteen lysine amino groups of IL-6 were estimated to be coupled with PVP (M-PVP-IL-6), showed more than 50-fold greater thrombopoietic potency in vivo than native IL-6.	Lysine	50-56	interleukin 6	Mus musculus	15-19
10974387-4	2000	PVP-conjugated IL-6, in which 60% of the fourteen lysine amino groups of IL-6 were estimated to be coupled with PVP (M-PVP-IL-6), showed more than 50-fold greater thrombopoietic potency in vivo than native IL-6.	Lysine	50-56	interleukin 6	Mus musculus	73-77
10974387-4	2000	PVP-conjugated IL-6, in which 60% of the fourteen lysine amino groups of IL-6 were estimated to be coupled with PVP (M-PVP-IL-6), showed more than 50-fold greater thrombopoietic potency in vivo than native IL-6.	Lysine	50-56	interleukin 6	Mus musculus	73-77
10974387-4	2000	PVP-conjugated IL-6, in which 60% of the fourteen lysine amino groups of IL-6 were estimated to be coupled with PVP (M-PVP-IL-6), showed more than 50-fold greater thrombopoietic potency in vivo than native IL-6.	Lysine	50-56	interleukin 6	Mus musculus	73-77
10974387-4	2000	PVP-conjugated IL-6, in which 60% of the fourteen lysine amino groups of IL-6 were estimated to be coupled with PVP (M-PVP-IL-6), showed more than 50-fold greater thrombopoietic potency in vivo than native IL-6.	Povidone	0-3	interleukin 6	Mus musculus	15-19
10974387-4	2000	PVP-conjugated IL-6, in which 60% of the fourteen lysine amino groups of IL-6 were estimated to be coupled with PVP (M-PVP-IL-6), showed more than 50-fold greater thrombopoietic potency in vivo than native IL-6.	Povidone	0-3	interleukin 6	Mus musculus	73-77
10974387-4	2000	PVP-conjugated IL-6, in which 60% of the fourteen lysine amino groups of IL-6 were estimated to be coupled with PVP (M-PVP-IL-6), showed more than 50-fold greater thrombopoietic potency in vivo than native IL-6.	Povidone	0-3	interleukin 6	Mus musculus	73-77
10974387-4	2000	PVP-conjugated IL-6, in which 60% of the fourteen lysine amino groups of IL-6 were estimated to be coupled with PVP (M-PVP-IL-6), showed more than 50-fold greater thrombopoietic potency in vivo than native IL-6.	Povidone	0-3	interleukin 6	Mus musculus	73-77
10994635-7	2000	This increase in TNF-alpha and IL-6 production is also observed in peritoneal macrophages of estradiol-injected mice.	Estradiol	93-102	interleukin 6	Mus musculus	31-35
11109026-1	2000	Acute ethanol exposure prior to burn injury increases the immune dysfunction seen with burn alone, which has been partially attributed to increased circulating and splenic macrophage production of interleukin-6 (IL-6).	Ethanol	6-13	interleukin 6	Mus musculus	197-210
11109026-1	2000	Acute ethanol exposure prior to burn injury increases the immune dysfunction seen with burn alone, which has been partially attributed to increased circulating and splenic macrophage production of interleukin-6 (IL-6).	Ethanol	6-13	interleukin 6	Mus musculus	212-216
11109026-4	2000	Interestingly, the increase in macrophage IL-6 secretion seen at the moderate dose was not augmented at the high dose; however, the circulating IL-6 levels did reveal a further increase at the high ethanol dose.	Ethanol	198-205	interleukin 6	Mus musculus	144-148
10864020-0	2000	Stable prostaglandin I1 analog SM-10906 modulates productions of tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in mouse macrophages.	prostaglandin i1	7-23	interleukin 6	Mus musculus	112-125
10903769-7	2000	Stimulation of dendritic cells with heparan sulfate induced release of TNF-alpha, IL-1beta, and IL-6, although the maturation of dendritic cells was independent of these cytokines.	Heparitin Sulfate	36-51	interleukin 6	Mus musculus	96-100
10922080-7	2000	Plasma corticosterone levels after bacterial lipopolysaccharide injection in mice deficient in CRH or IL-6 were significantly lower than in wild-type mice but significantly greater than in mice deficient in both CRH and IL-6.	Corticosterone	7-21	interleukin 6	Mus musculus	102-106
10922080-7	2000	Plasma corticosterone levels after bacterial lipopolysaccharide injection in mice deficient in CRH or IL-6 were significantly lower than in wild-type mice but significantly greater than in mice deficient in both CRH and IL-6.	Corticosterone	7-21	interleukin 6	Mus musculus	220-224
10878381-9	2000	In contrast, production of anti-DNA/chromatin Abs was associated with IL-6 overproduction in pristane-treated mice, but not in lpr mice.	pristane	93-101	interleukin 6	Mus musculus	70-74
10875254-8	2000	The greater increase in circulating levels of IL-6 in PTH-treated ovx mice was paralleled by a greater rise in bone resorption markers with the mean level of urine collagen cross-links in the PTH-treated ovx group being more than 2.5-fold higher than in the PTH-treated sham/ovx animals (236 vs. 88.5 microg/mmol creatinine, P &lt; 0.0001).	Creatinine	313-323	interleukin 6	Mus musculus	46-50
10869288-6	2000	Our results show that the reduction in messenger RNA (mRNA) levels of CYP1A2, CYP2A5, and CYP3A11 during turpentine-induced inflammation was abrogated in IL-6-deficient mice, confirming that IL-6 is an indispensable player for the down-regulation of hepatic CYP during aseptic inflammation.	Turpentine	105-115	interleukin 6	Mus musculus	154-158
10869288-6	2000	Our results show that the reduction in messenger RNA (mRNA) levels of CYP1A2, CYP2A5, and CYP3A11 during turpentine-induced inflammation was abrogated in IL-6-deficient mice, confirming that IL-6 is an indispensable player for the down-regulation of hepatic CYP during aseptic inflammation.	Turpentine	105-115	interleukin 6	Mus musculus	191-195
10823826-7	2000	TLR-2 undergoes a lengthy intracellular maturation process with a half-life of exit from the ER of approximately 3 h. Furthermore, LPS treatment of adipocytes results in dramatic changes at the level of gene expression, including the synthesis of a distinct set of secretory proteins such as interleukin-6.	lps	131-134	interleukin 6	Mus musculus	292-305
10898798-5	2000	By ELISA, MPACs from 10-week-old NODs showed a small but highly significant (p&lt;0.003) increase in IL-1beta and a large significant decrease (p&lt;0.008) in IL-6 compared to 5-week-old NODs.	mpacs	10-15	interleukin 6	Mus musculus	159-163
10807946-7	2000	Similar to the effects on white adipose tissue, troglitazone not only down-regulated the baseline levels of hepatic TNF-alpha and IL-6, but also greatly attenuated the inducing effects of LPS.	Troglitazone	48-60	interleukin 6	Mus musculus	130-134
10807946-9	2000	These data demonstrate that chronic administration of troglitazone is associated with a greatly attenuated responsiveness towards inducers of hepatic TNF-alpha and IL-6 production.	Troglitazone	54-66	interleukin 6	Mus musculus	164-168
10989278-1	2000	We previously showed that sphingosine inhibits prostaglandin F(2alpha) (PGF(2alpha))-stimulated interleukin-6 synthesis in osteoblast-like MC3T3-E1 cells.	Sphingosine	26-37	interleukin 6	Mus musculus	96-109
10989278-1	2000	We previously showed that sphingosine inhibits prostaglandin F(2alpha) (PGF(2alpha))-stimulated interleukin-6 synthesis in osteoblast-like MC3T3-E1 cells.	Prostaglandins F	47-62	interleukin 6	Mus musculus	96-109
10989278-1	2000	We previously showed that sphingosine inhibits prostaglandin F(2alpha) (PGF(2alpha))-stimulated interleukin-6 synthesis in osteoblast-like MC3T3-E1 cells.	Prostaglandins F	72-75	interleukin 6	Mus musculus	96-109
10840457-10	2000	In animals treated with losartan, kidney TGF-beta, IFN-gamma and IL-6 decreased significantly at 3 and 8 weeks as compared with controls, untreated or those treated with NaCl, (p &lt;0.005 respectively).	Losartan	24-32	interleukin 6	Mus musculus	65-69
10748117-5	2000	Allotrap 1258 inhibited concanavalin A- and lipopolysaccharide-induced human and mouse tumor necrosis factor (TNF) production in vitro and in vivo but had no effect on interleukin (IL)-1, IL-2, IL-4, IL-6, or IL-10 expression.	allotrap	0-13	interleukin 6	Mus musculus	200-204
10864020-0	2000	Stable prostaglandin I1 analog SM-10906 modulates productions of tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in mouse macrophages.	SM 10906	31-39	interleukin 6	Mus musculus	112-125
10864020-2	2000	In mouse PEMs, SM-10906 and PGE1 slightly enhanced interleukin (IL)-6 secretion, but had no effects on tumor necrosis factor-alpha (TNF-alpha) or IL-1 production.	SM 10906	15-23	interleukin 6	Mus musculus	51-69
10864020-2	2000	In mouse PEMs, SM-10906 and PGE1 slightly enhanced interleukin (IL)-6 secretion, but had no effects on tumor necrosis factor-alpha (TNF-alpha) or IL-1 production.	Alprostadil	28-32	interleukin 6	Mus musculus	51-69
10864020-3	2000	SM-10906 concentration-dependently inhibited TNF-alpha, IL-1 and IL-6 releases from lipopolysaccharide-activated mouse PEMs, as with PGE1, PGI2 and cAMP analog.	SM 10906	0-8	interleukin 6	Mus musculus	65-69
10894495-6	2000	Also, mice inhaling halothane had significantly decreased activities of pro-inflammatory cytokines interleukin 6 and tumor necrosis factor-alpha in lung homogenates at 24 hours after inoculation, compared with those given pentobarbital IP.	Halothane	20-29	interleukin 6	Mus musculus	99-144
10843736-7	2000	IL-6 had no activity alone, but further enhanced TRAP(+)cell formation in mOSM or DEX (10(-7) M) treated cocultures.	Dexamethasone	82-85	interleukin 6	Mus musculus	0-4
10843736-9	2000	IL-6 mRNA levels and protein secretion were reduced in osteoblasts by costimulation with DEX.	Dexamethasone	89-92	interleukin 6	Mus musculus	0-4
10903797-10	2000	On the other hand, IL-6 inhibition without the unwanted effects on TNF and IL-10 production shown by R-isomers could be correlated to the analgesic effect reported for R-2-arylpropionic acids.	r-2-arylpropionic acids	168-191	interleukin 6	Mus musculus	19-23
10865979-2	2000	Similar 5"-C mu/c-myc+ clones were also detected in pristane-induced peritoneal granulomata (a significant source of IL-6 in situ) of three of 13 (13%) conventional BALB/c mice, but not in lymphoid tissues of pristane-treated BALB/c mice, nor in any tissue of untreated BALB/c mice.	pristane	52-60	interleukin 6	Mus musculus	117-121
10727751-7	2000	TNF-alpha and IL-6 production were significantly enhanced by 1 microg/ml of nicotine when cells were pre-incubated with nicotine for 3 h compared to concurrent incubation relative to LPS stimulation.	Nicotine	76-84	interleukin 6	Mus musculus	14-18
10727751-7	2000	TNF-alpha and IL-6 production were significantly enhanced by 1 microg/ml of nicotine when cells were pre-incubated with nicotine for 3 h compared to concurrent incubation relative to LPS stimulation.	Nicotine	120-128	interleukin 6	Mus musculus	14-18
10727751-9	2000	TNF-alpha production was significantly inhibited by nicotine in young mice, while IL-6 production was significantly inhibited by nicotine in old mice.	Nicotine	129-137	interleukin 6	Mus musculus	82-86
10727753-5	2000	Liquiritigenin, a metabolite of liquiritin which is one of the major ingredients in SST enhanced in vitro IL-6 production in anti-CD3 monoclonal antibody (anti-CD3 mAb)-stimulated lung mononuclear cells in a cell-type specific and dose-dependent manner.	liquiritigenin	0-14	interleukin 6	Mus musculus	106-110
10727753-5	2000	Liquiritigenin, a metabolite of liquiritin which is one of the major ingredients in SST enhanced in vitro IL-6 production in anti-CD3 monoclonal antibody (anti-CD3 mAb)-stimulated lung mononuclear cells in a cell-type specific and dose-dependent manner.	liquiritin	32-42	interleukin 6	Mus musculus	106-110
10865979-4	2000	Taken in conjunction with our previous observation that 5"-C mu/c-myc+ clones are the precursors for pristane-induced BALB/c plasmacytomas, the findings further suggested that IL-6 may play a pivotal role in the early stage of plasmacytoma development, by promoting tumor precursor cells.	pristane	101-109	interleukin 6	Mus musculus	176-180
10793074-3	2000	By 12 weeks after BDL, IL-6(-/-) mice develop significantly higher total serum bilirubin levels (23.2 +/- 2.3 versus 14.9 +/- 2.1 mg/dl, P &lt; 0.0001; delta bilirubin subfraction 16.7 +/- 4.0% versus 9.2 +/- 1.8%; P &lt; 0.002), and the majority (15/18) show "black" gallbladder bile, compared to IL-6(+/+) mice (5/16; P &lt; 0.003).	Bilirubin	79-88	interleukin 6	Mus musculus	23-27
10828279-8	2000	Chronic As exposures produced 2-10 fold elevation of serum interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha levels, with greater increases seen by repeated injections than by oral exposure, and again, MT-null mice had higher serum cytokines than WT mice after As exposure.	Arsenic	8-10	interleukin 6	Mus musculus	78-124
10821951-8	2000	The addition of Stem Cell Factor (SCF) or IL-6 to the standard combination of flt-3L+/-GM-CSF produces a large increase in the proliferation of GM and DC progenitors (28 times and 11 times respectively) in the first step of the culture.	gm	87-89	interleukin 6	Mus musculus	42-46
10799905-10	2000	Finally, PGE2 pretreatment synergistically stimulated LPS-induced expression of IL-1beta and IL-6 genes in mouse macrophages.	Dinoprostone	9-13	interleukin 6	Mus musculus	93-97
10820229-4	2000	Here we report that in primary mouse bone marrow-derived mast cells activated by ionomycin or IgE/Ag, the proinflammatory mediator IL-1 (alpha or beta) up-regulated production of IL-3, IL-5, IL-6, and IL-9 as well as TNF, i.e., cytokines implicated in many inflammatory processes including those associated with allergies and helminthic infections.	Ionomycin	81-90	interleukin 6	Mus musculus	191-195
10793074-3	2000	By 12 weeks after BDL, IL-6(-/-) mice develop significantly higher total serum bilirubin levels (23.2 +/- 2.3 versus 14.9 +/- 2.1 mg/dl, P &lt; 0.0001; delta bilirubin subfraction 16.7 +/- 4.0% versus 9.2 +/- 1.8%; P &lt; 0.002), and the majority (15/18) show "black" gallbladder bile, compared to IL-6(+/+) mice (5/16; P &lt; 0.003).	Bilirubin	158-167	interleukin 6	Mus musculus	23-27
10793074-7	2000	Daily treatment with exogenous recombinant IL-6 for 3-6 weeks starting at 6 weeks after BDL significantly lowers the serum total bilirubin in both groups.	Bilirubin	129-138	interleukin 6	Mus musculus	43-47
10780996-23	2000	pretreatment with 6-hydroxydopamine (20 microg per mouse) markedly inhibited central L-NAME-induced plasma IL-6 levels.	Oxidopamine	18-35	interleukin 6	Mus musculus	107-111
10780996-23	2000	pretreatment with 6-hydroxydopamine (20 microg per mouse) markedly inhibited central L-NAME-induced plasma IL-6 levels.	NG-Nitroarginine Methyl Ester	85-91	interleukin 6	Mus musculus	107-111
10780996-25	2000	and ICI-118,551 (1.5 microg per mouse i. t.) were effective in inhibition of central L-NAME-induced plasma IL-6 levels.	NG-Nitroarginine Methyl Ester	85-91	interleukin 6	Mus musculus	107-111
10780996-33	2000	These results suggest that NOS activity in the brain tonically down-regulates peripheral IL-6 by inhibiting adrenaline release from the adrenal medulla.	Epinephrine	108-118	interleukin 6	Mus musculus	89-93
10799447-9	2000	Furthermore, peritoneal macrophages from silicone- and pristane-treated mice produced higher levels of interleukin-1beta (IL-1beta) and IL-6 than those from PBS-treated mice after lipopolysaccharide stimulation.	Silicones	41-49	interleukin 6	Mus musculus	136-140
10799447-9	2000	Furthermore, peritoneal macrophages from silicone- and pristane-treated mice produced higher levels of interleukin-1beta (IL-1beta) and IL-6 than those from PBS-treated mice after lipopolysaccharide stimulation.	pristane	55-63	interleukin 6	Mus musculus	136-140
10785446-0	2000	IL-6 deficiency leads to reduced metallothionein-I+II expression and increased oxidative stress in the brain stem after 6-aminonicotinamide treatment.	6-Aminonicotinamide	120-139	interleukin 6	Mus musculus	0-4
10937636-10	2000	Interleukin-6 mRNA was first seen 4 hours after the addition of the titanium particles, indicating that the production of this cytokine is secondary to the immediate nuclear transcription factor-kappaB response.	Titanium	68-76	interleukin 6	Mus musculus	0-13
10828746-7	2000	Am-80 inhibited the levels of expression in mice ears of interferon-gamma (IFN-gamma) and interleukin-6 (IL-6), but not tumor necrosis factor-alpha (TNF-alpha) or interleukin-4 (IL-4).	tamibarotene	0-5	interleukin 6	Mus musculus	90-103
10828746-7	2000	Am-80 inhibited the levels of expression in mice ears of interferon-gamma (IFN-gamma) and interleukin-6 (IL-6), but not tumor necrosis factor-alpha (TNF-alpha) or interleukin-4 (IL-4).	tamibarotene	0-5	interleukin 6	Mus musculus	105-109
10828746-8	2000	Furthermore, Am-80 inhibited the antigen-induced production of some cytokines, including IFN-gamma and IL-6, but not IL-4, in vitro.	tamibarotene	13-18	interleukin 6	Mus musculus	103-107
10828746-9	2000	Therefore, Am-80 inhibited hapten-induced contact hypersensitivity through the direct inhibition of inflammatory cytokines such as IFN-gamma and IL-6.	tamibarotene	11-16	interleukin 6	Mus musculus	145-149
10772953-0	2000	Differential stimulation by PGE(2) and calcemic hormones of IL-6 in stromal/osteoblastic cells.	Prostaglandins E	28-31	interleukin 6	Mus musculus	60-64
10772953-3	2000	Therefore, we evaluated the effects of 1,25-(OH)(2)D(3), PTH, and PGE(2) on IL-6 production in stromal/osteoblastic cell lines.	Prostaglandins E	66-69	interleukin 6	Mus musculus	76-80
10772953-6	2000	PGE(2)-stimulated IL-6 release from mesenchymal cells seems to be important for autocrine/paracrine control of osteoclast formation in health and disease.	Dinoprostone	0-6	interleukin 6	Mus musculus	18-22
10768707-7	2000	The depressed proinflammatory cytokine (IL-1 and IL-6) release seen in splenic and peritoneal macrophages was restored in the 17beta-estradiol-treated hemorrhage group.	17beta	126-132	interleukin 6	Mus musculus	49-53
10814840-9	2000	Furthermore, inhibition of NF-kappaB activity with tosyl-Phe-chloromethlyketone (a serine protease inhibitor that prevents degradation of the NF-kappaB-IkappaB complex), completely blocked LPS-induced IL-6 production.	tosyl-phe-chloromethlyketone	51-79	interleukin 6	Mus musculus	201-205
10768707-7	2000	The depressed proinflammatory cytokine (IL-1 and IL-6) release seen in splenic and peritoneal macrophages was restored in the 17beta-estradiol-treated hemorrhage group.	Estradiol	133-142	interleukin 6	Mus musculus	49-53
10768707-9	2000	The increase in circulating IL-6 levels after hemorrhage was significantly attenuated in 17beta-estradiol-treated mice.	Estradiol	89-105	interleukin 6	Mus musculus	28-32
10768707-12	2000	CONCLUSION: Since administration of a single dose of 17beta-estradiol in males after trauma-hemorrhage restores the immune functions and decreases circulating levels of IL-6, hormones with estrogenic properties should be considered as safe and novel therapeutic agents for restoring the immune responsiveness in male trauma victims.	Estradiol	53-69	interleukin 6	Mus musculus	169-173
10759763-1	2000	Cytokines such as IL-1, tumour necrosis factor-alpha (TNF-alpha), IL-6 and IL-8 are increased in inflamed colonic mucosa after administration of mouse DSS.	dss	151-154	interleukin 6	Mus musculus	66-70
10733552-0	2000	Proliferation of hepatic lineage cells of normal C57BL and interleukin-6 knockout mice after cocaine-induced periportal injury.	Cocaine	93-100	interleukin 6	Mus musculus	59-72
10773364-6	2000	STZ induced a low production of interleukin (IL)-2 mRNAs, a mild increase in IL-1alpha and IL-6 mRNAs production, and a dramatic increase in IFN-gamma, IL-1beta, TNF-alpha, IL-12 and IL-2 receptor mRNAs, which correlated with positive PLN responses.	Streptozocin	0-3	interleukin 6	Mus musculus	91-95
10847479-7	2000	Compared to IL-6+/+ controls, IL-6-/- mice showed slightly less BEC proliferation, a trend toward more liver injury, and significantly higher total serum bilirubin (TB) levels, suggestive of impaired biliary tree integrity.	Bilirubin	154-163	interleukin 6	Mus musculus	30-34
10847479-7	2000	Compared to IL-6+/+ controls, IL-6-/- mice showed slightly less BEC proliferation, a trend toward more liver injury, and significantly higher total serum bilirubin (TB) levels, suggestive of impaired biliary tree integrity.	Terbium	165-167	interleukin 6	Mus musculus	30-34
10847479-11	2000	However, the long-term response to BDL results in a distinct phenotype in the IL-6-/- mice, marked by a relentless rise in serum total bilirubin and an inability to maintain compensatory increase in liver mass.	Bilirubin	135-144	interleukin 6	Mus musculus	78-82
10678951-7	2000	Conversely, during infection local production of IL-6 and IL-1ra was significantly greater in mice immunized with Pa than in those immunized with Pw.	Protactinium	114-116	interleukin 6	Mus musculus	49-53
10708595-4	2000	Our data clearly demonstrated that in LPS-treated macrophages, cAMP elevator (CTx and 8-bromo-cAMP) could increase IL-1Ra and IL-10 gene expression, while mRNAs of IL-1alpha, IL-12, IL-6, and MIF were decreased and other cytokines like IL-1beta, and IFN-gamma did not give a definite tendency.	camp elevator	63-76	interleukin 6	Mus musculus	182-186
10708595-4	2000	Our data clearly demonstrated that in LPS-treated macrophages, cAMP elevator (CTx and 8-bromo-cAMP) could increase IL-1Ra and IL-10 gene expression, while mRNAs of IL-1alpha, IL-12, IL-6, and MIF were decreased and other cytokines like IL-1beta, and IFN-gamma did not give a definite tendency.	8-Bromo Cyclic Adenosine Monophosphate	86-98	interleukin 6	Mus musculus	182-186
10715625-6	2000	Adult mice displayed increased sensitivity to O(3), as demonstrated by increased abundance of mRNAs encoding eotaxin, macrophage inflammatory protein (MIP)-1alpha, MIP-2, interleukin (IL)-6, and metallothionein (Mt).	Ozone	46-50	interleukin 6	Mus musculus	171-189
10734156-5	2000	Treatment with taurine and niacin attenuated the BL-induced increases in proinflammatory cytokines such as IL-1alpha, TNF-alpha, IL-6, and TGF-beta in BALF and lung hydroxyproline content of the mice in BL + TN groups.	Taurine	15-22	interleukin 6	Mus musculus	129-133
10734156-5	2000	Treatment with taurine and niacin attenuated the BL-induced increases in proinflammatory cytokines such as IL-1alpha, TNF-alpha, IL-6, and TGF-beta in BALF and lung hydroxyproline content of the mice in BL + TN groups.	Niacin	27-33	interleukin 6	Mus musculus	129-133
10762076-0	2000	Regulation of macrophage interleukin-6 (IL-6) and IL-10 expression by prostaglandin E2: the role of p38 mitogen-activated protein kinase.	Dinoprostone	70-86	interleukin 6	Mus musculus	40-44
10762076-2	2000	We have found that PGE2 can upregulate the levels of both interleukin-10 (IL-10) and IL-6 produced by activated murine macrophages, but the molecular pathways leading to their augmentation differ.	Dinoprostone	19-23	interleukin 6	Mus musculus	85-89
10762076-0	2000	Regulation of macrophage interleukin-6 (IL-6) and IL-10 expression by prostaglandin E2: the role of p38 mitogen-activated protein kinase.	Dinoprostone	70-86	interleukin 6	Mus musculus	25-38
10762076-6	2000	In contrast, PGE2 can augment IL-6 levels regardless of whether or not p38 kinase is active.	Dinoprostone	13-17	interleukin 6	Mus musculus	30-34
10762076-8	2000	We found that p38 kinase inhibitors are able to inhibit IL-6 production in activated macrophages, but this occurs primarily as a result of their concurrent inhibition of cyclooxygenase-2 and endogenous PGE2 synthesis.	Dinoprostone	202-206	interleukin 6	Mus musculus	56-60
10762076-9	2000	These results indicate that macrophage IL-10 and IL-6 expression is differentially regulated by PGE2 and p38 MAP kinase in murine inflammatory macrophages.	Dinoprostone	96-100	interleukin 6	Mus musculus	49-53
11268389-8	2000	IL-6 has effects on serotonin and tryptophan like those of IL-1, but no detected effect on NA.	Serotonin	20-29	interleukin 6	Mus musculus	0-4
10839200-0	2000	Secretion of MCP-1 and IL-6 by cytokine stimulated production of reactive oxygen species in endothelial cells.	Reactive Oxygen Species	65-88	interleukin 6	Mus musculus	23-27
10839200-8	2000	Cytokine induced release of MCP-1 and IL-6 by endothelial cells was completely inhibited in the presence of Tiron and Tempol, whereas NMMA was less effective.	1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt	108-113	interleukin 6	Mus musculus	38-42
10839200-8	2000	Cytokine induced release of MCP-1 and IL-6 by endothelial cells was completely inhibited in the presence of Tiron and Tempol, whereas NMMA was less effective.	tempol	118-124	interleukin 6	Mus musculus	38-42
10839200-9	2000	Collectively these data indicate that cytokine stimulated endothelial cells increase their reactive oxygen species production probably via NADH oxidase and this production may critically be involved in the secretion of MCP-1 and IL-6.	Reactive Oxygen Species	91-114	interleukin 6	Mus musculus	229-233
10841042-3	2000	Arsenite induced the synthesis of IL-6 after 6 h from the stimulation up to 48 h. The effect of arsenite on IL-6 synthesis was dose-dependent in the range between 10 and 500 microM.	arsenite	96-104	interleukin 6	Mus musculus	108-112
10841042-4	2000	The arsenite-induced IL-6 synthesis was enhanced by the pretreatment with indomethacin, an inhibitor of cyclooxygenase.	arsenite	4-12	interleukin 6	Mus musculus	21-25
10841042-4	2000	The arsenite-induced IL-6 synthesis was enhanced by the pretreatment with indomethacin, an inhibitor of cyclooxygenase.	Indomethacin	74-86	interleukin 6	Mus musculus	21-25
10841042-5	2000	Nordihydroguaiaretic acid, a lipoxygenase inhibitor, significantly amplified the arsenite-induced IL-6 synthesis.	Masoprocol	0-25	interleukin 6	Mus musculus	98-102
10841042-5	2000	Nordihydroguaiaretic acid, a lipoxygenase inhibitor, significantly amplified the arsenite-induced IL-6 synthesis.	arsenite	81-89	interleukin 6	Mus musculus	98-102
10841042-6	2000	Melittin, an activator of phospholipase A2, which by itself hardly affected the levels of IL-6, markedly enhanced the arsenite-induced IL-6 synthesis.	arsenite	118-126	interleukin 6	Mus musculus	135-139
10841042-7	2000	These results strongly suggest that chemical stress induces IL-6 synthesis in osteoblasts, and that the IL-6 synthesis is coupled to the arachidonic acid cascade as well as the HSP27 induction by arsenite.	Arachidonic Acid	137-153	interleukin 6	Mus musculus	104-108
10684643-0	2000	The single mutation Phe173 --&gt; Ala induces a molten globule-like state in murine interleukin-6.	Alanine	34-37	interleukin 6	Mus musculus	84-97
10997329-5	2000	Anti-inflammatory indomethacin curtailed the IL-6, but raised the TNF-alpha, G-CSF, and CSA levels in Cu-r mice.	Indomethacin	18-30	interleukin 6	Mus musculus	45-49
10775502-1	2000	Acute IL-6 secretion from osteosarcoma cells induced by the PI-linked hormones PTH(1-34) and endothelin-1 is potentiated by IL-1 beta.	pth	79-82	interleukin 6	Mus musculus	6-10
10623855-3	2000	Although 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) at micromolar concentrations significantly inhibited the production of TNF-alpha and IL-6, four other high affinity PPARgamma ligands failed to affect cytokine production.	14-prostaglandin j2	26-45	interleukin 6	Mus musculus	142-146
10623855-3	2000	Although 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) at micromolar concentrations significantly inhibited the production of TNF-alpha and IL-6, four other high affinity PPARgamma ligands failed to affect cytokine production.	15-deoxy-delta(12,14)-prostaglandin J2	47-55	interleukin 6	Mus musculus	142-146
10707932-16	2000	In addition, NAC pretreatment also reduced hepatic IL-6 production at 3 and 6 hours after starting cerulein challenge.	Acetylcysteine	13-16	interleukin 6	Mus musculus	51-55
10841042-0	2000	Involvement of arachidonic acid in chemical stress-induced interleukin-6 synthesis in osteoblast-like cells: comparison with heat shock protein 27 induction.	Arachidonic Acid	15-31	interleukin 6	Mus musculus	59-72
10841042-2	2000	In the present study, we examined the effect of exposure to arsenite on the synthesis of interleukin-6 (IL-6) in these cells.	arsenite	60-68	interleukin 6	Mus musculus	89-102
10841042-2	2000	In the present study, we examined the effect of exposure to arsenite on the synthesis of interleukin-6 (IL-6) in these cells.	arsenite	60-68	interleukin 6	Mus musculus	104-108
10841042-3	2000	Arsenite induced the synthesis of IL-6 after 6 h from the stimulation up to 48 h. The effect of arsenite on IL-6 synthesis was dose-dependent in the range between 10 and 500 microM.	arsenite	0-8	interleukin 6	Mus musculus	34-38
10841042-3	2000	Arsenite induced the synthesis of IL-6 after 6 h from the stimulation up to 48 h. The effect of arsenite on IL-6 synthesis was dose-dependent in the range between 10 and 500 microM.	arsenite	0-8	interleukin 6	Mus musculus	108-112
10841042-3	2000	Arsenite induced the synthesis of IL-6 after 6 h from the stimulation up to 48 h. The effect of arsenite on IL-6 synthesis was dose-dependent in the range between 10 and 500 microM.	arsenite	96-104	interleukin 6	Mus musculus	34-38
10637096-4	2000	Splenic T cells from mice with EAM produced TNF-alpha and IL-6 but no IL-2.	molibresib	31-34	interleukin 6	Mus musculus	58-62
10714561-6	2000	The amount of 2-DG injected was associated with an increase in TNF-alpha, IL-1beta, and IL-6 concentrations in the blood of mice after one or three injections of 2-DG (p&lt;0.05).	Deoxyglucose	14-18	interleukin 6	Mus musculus	88-92
10714561-6	2000	The amount of 2-DG injected was associated with an increase in TNF-alpha, IL-1beta, and IL-6 concentrations in the blood of mice after one or three injections of 2-DG (p&lt;0.05).	Deoxyglucose	162-166	interleukin 6	Mus musculus	88-92
10623831-0	2000	The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction.	Tyrosine	16-24	interleukin 6	Mus musculus	88-92
10623831-3	2000	Here we describe the analysis of the function of the individual cytoplasmic tyrosine residues of gp130 in the context of the full-length receptor protein in IL-6 signaling as measured by STAT activation, acute phase protein induction, and stimulation of proliferation.	Tyrosine	76-84	interleukin 6	Mus musculus	157-161
10623831-8	2000	Thus, the tyrosine residues in the cytoplasmic part of gp130 were found to contribute differentially to IL-6 signal transduction in the full- length gp130 protein.	Tyrosine	10-18	interleukin 6	Mus musculus	104-108
11268389-8	2000	IL-6 has effects on serotonin and tryptophan like those of IL-1, but no detected effect on NA.	Tryptophan	34-44	interleukin 6	Mus musculus	0-4
10623445-7	2000	In contrast, IL-1beta and IL-6 production by Mbeta from young males was suppressed and IL-10 production enhanced following trauma-haemorrhage, whereas Mstraight phi from aged males produced elevated levels of IL-1beta and IL-6 and suppressed levels of IL-10 following trauma-haemorrhage.	mbeta	45-50	interleukin 6	Mus musculus	26-30
10724443-7	2000	Pretreatment of IL-6 GKO mice with rIL-6 (5 microg/mouse) restored hepatic MT synthesis.	ril-6	35-40	interleukin 6	Mus musculus	16-20
10632101-6	2000	Pups pretreated with interleukin (IL)-1beta, IL-6, IL-9, or tumor necrosis factor-alpha developed significantly larger ibotenate-induced cortical and white matter damage than controls; IL-4 did not produce such an effect.	Ibotenic Acid	119-128	interleukin 6	Mus musculus	45-49
10613740-2	2000	Following acute carbon tetrachloride (CCl(4)) treatment, we found that IL-6-/- mice developed increased hepatocellular injury and defective regeneration with significant blunting of signal transducer-and-activator of transcription protein 3 (STAT3) and nuclear factor-kappaB (NF-kappaB) activation and reduced hepatocyte DNA synthetic and mitotic responses.	Carbon Tetrachloride	16-36	interleukin 6	Mus musculus	71-75
10613740-2	2000	Following acute carbon tetrachloride (CCl(4)) treatment, we found that IL-6-/- mice developed increased hepatocellular injury and defective regeneration with significant blunting of signal transducer-and-activator of transcription protein 3 (STAT3) and nuclear factor-kappaB (NF-kappaB) activation and reduced hepatocyte DNA synthetic and mitotic responses.	Cefaclor	38-41	interleukin 6	Mus musculus	71-75
10613740-3	2000	After CCl(4) treatment, unlike partial hepatectomy, increased hepatocyte apoptosis was noted in IL-6-/- livers.	Cefaclor	6-9	interleukin 6	Mus musculus	96-100
10613740-4	2000	Pretreatment with IL-6 before CCl(4) reduced acute CCl(4) injury and apoptosis and accelerated regeneration in both IL-6+/+ and -/- livers.	Cefaclor	30-33	interleukin 6	Mus musculus	18-22
10613740-4	2000	Pretreatment with IL-6 before CCl(4) reduced acute CCl(4) injury and apoptosis and accelerated regeneration in both IL-6+/+ and -/- livers.	Cefaclor	51-54	interleukin 6	Mus musculus	18-22
10613740-5	2000	Repetitive doses of CCl(4) in the presence or absence of phenobarbital resulted in increased injury and fibrosis in IL-6 -/- compared with +/+ livers.	Cefaclor	20-23	interleukin 6	Mus musculus	116-120
10613740-5	2000	Repetitive doses of CCl(4) in the presence or absence of phenobarbital resulted in increased injury and fibrosis in IL-6 -/- compared with +/+ livers.	Phenobarbital	57-70	interleukin 6	Mus musculus	116-120
10613740-7	2000	These data provide evidence for an important role for IL-6 in reducing CCl(4)-induced acute and chronic liver injury and fibrosis.	Cefaclor	71-74	interleukin 6	Mus musculus	54-58
10660762-10	2000	CONCLUSIONS: These results suggest that the 21-aminosteroid inhibits release of the tumor necrosis factor-alpha and interleukin-6 from lipopolysaccharide-stimulated Kupffer cells by inhibiting nuclear factor-kappa B activation.	21-aminosteroid	44-59	interleukin 6	Mus musculus	116-129
10695042-6	2000	Phosprenyl stimulates some interleukins: gamma-interferon, tumor necrosis factor-alpha, and interleukin-6.	phosprenyl	0-10	interleukin 6	Mus musculus	92-105
10565571-6	1999	A scrambled oligodeoxynucleotide showed much lower IL-6 inhibition in mice.	Oligodeoxyribonucleotides	12-32	interleukin 6	Mus musculus	51-55
10623431-8	1999	In addition, co-administration of IL-6 with mBSA by intra-articular injection into the joint was only partially effective in conferring sensitivity to AIA, suggesting the importance of a systemic effct for IL-6, but also that an additional role for this cytokine can be envisaged in the local inflammatory reaction during establishment of AIA.	aia	151-154	interleukin 6	Mus musculus	34-38
10613412-10	1999	In mice fed 500 IU vit-E diets, the serum IL-6, IL-10, IL-12 and TNF-alpha levels were significantly lower and serum IL-1beta was significantly higher compared to 75 IU-vit-E-fed mice in CO/FO or both.	Vitamin E	19-24	interleukin 6	Mus musculus	42-46
10570287-8	1999	RNase-mapping analysis indicated that IL-1alpha, IL-1beta, IL-1Ra, and IL-6 mRNA levels are constitutively elevated in thioglycolate-elicited IkappaBepsilon-null macrophages in contrast to GM-CSF, G-CSF, and IFN-gamma, which remain undetectable.	Thioglycolates	119-132	interleukin 6	Mus musculus	71-75
10648128-0	1999	B1 B cell numbers and antibodies against phosphorylcholine and LPS are increased in IL-6 gene knockout mice.	Phosphorylcholine	41-58	interleukin 6	Mus musculus	84-88
10606148-5	1999	Both the cell wall and cytoplasmic fractions of lactic acid bacteria were able to stimulate cloned macrophages to produce significant amounts of tumor necrosis factor-alpha, (interleukin) IL-6, and NO.	Lactic Acid	48-59	interleukin 6	Mus musculus	188-192
10580801-8	1999	These results suggested that a shift of T cell responses from Thl to Th2 might explain the resistance of IL-6-deficient mice to EAE.	Orlistat	62-65	interleukin 6	Mus musculus	105-109
10718106-0	1999	Decreased production of interleukin-6 and prostaglandin E2 associated with inhibition of delta-5 desaturation of omega6 fatty acids in mice fed safflower oil diets supplemented with sesamol.	sesamol	182-189	interleukin 6	Mus musculus	24-37
10718106-7	1999	Concomitantly, the concentrations of IL-6 were also lower (P&lt;0.01) in mice fed sesamol diet (63 +/- 11 ng/ml) compared to the controls (143 +/- 22 ng/ml).	sesamol	82-89	interleukin 6	Mus musculus	37-41
10537140-0	1999	Mitogen-activated protein (MAP) kinases are involved in interleukin-1 (IL-1)-induced IL-6 synthesis in osteoblasts: modulation not of p38 MAP kinase, but of p42/p44 MAP kinase by IL-1-activated protein kinase C. We previously reported that interleukin-1alpha (IL-1alpha)-induced activation of protein kinase C (PKC) via phosphatidylcholine-specific phospholipase C (PC-PLC) limits IL-6 synthesis induced by IL-1alpha itself in osteoblast-like MC3T3-E1 cells.	Phosphatidylcholines	320-339	interleukin 6	Mus musculus	85-89
10540190-5	1999	BZL treatment significantly reduced nitrite, IL-6 and IL-10 production, to undetectable levels in some cases, particularly IL-6 and IL-10.	benzonidazole	0-3	interleukin 6	Mus musculus	45-49
10540190-5	1999	BZL treatment significantly reduced nitrite, IL-6 and IL-10 production, to undetectable levels in some cases, particularly IL-6 and IL-10.	benzonidazole	0-3	interleukin 6	Mus musculus	123-127
10537140-3	1999	PD98059, a specific inhibitor of the upstream kinase that activates p42/p44 MAP kinase, inhibited the IL-1alpha-induced IL-6 synthesis as well as the phosphorylation of p42/p44 MAP kinase induced by IL-1alpha.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	interleukin 6	Mus musculus	120-124
10537140-4	1999	SB203580, a specific inhibitor of p38 MAP kinase, also reduced both the phosphorylation of p38 MAP kinase and the IL-6 synthesis.	SB 203580	0-8	interleukin 6	Mus musculus	114-118
10537140-5	1999	1-Oleoyl-2-acetylglycerol, an activator of PKC, suppressed the IL-1alpha-induced IL-6 synthesis.	1-oleoyl-2-acetylglycerol	0-25	interleukin 6	Mus musculus	81-85
10545778-7	1999	The results revealed the positive regulation between PGE(2) and IL-6 synthesis because NS-398 and indomethacin inhibited LPS plus UTP-induced IL-6 release, and IL-6 antibody attenuated LPS plus UTP-induced PGE(2) release.	Prostaglandins E	53-56	interleukin 6	Mus musculus	64-68
10545778-0	1999	Potentiation of lipopolysaccharide-induced IL-6 release by uridine triphosphate in macrophages: cross-interaction with cyclooxygenase-2-dependent prostaglandin E(2) production.	Uridine Triphosphate	59-79	interleukin 6	Mus musculus	43-47
10545778-2	1999	In this study, we found that the amount of interleukin-6 (IL-6) release in response to LPS stimulation was greatly enhanced in the presence of UTP.	Uridine Triphosphate	143-146	interleukin 6	Mus musculus	43-56
10545778-7	1999	The results revealed the positive regulation between PGE(2) and IL-6 synthesis because NS-398 and indomethacin inhibited LPS plus UTP-induced IL-6 release, and IL-6 antibody attenuated LPS plus UTP-induced PGE(2) release.	Prostaglandins E	53-56	interleukin 6	Mus musculus	142-146
10545778-2	1999	In this study, we found that the amount of interleukin-6 (IL-6) release in response to LPS stimulation was greatly enhanced in the presence of UTP.	Uridine Triphosphate	143-146	interleukin 6	Mus musculus	58-62
10545778-7	1999	The results revealed the positive regulation between PGE(2) and IL-6 synthesis because NS-398 and indomethacin inhibited LPS plus UTP-induced IL-6 release, and IL-6 antibody attenuated LPS plus UTP-induced PGE(2) release.	Prostaglandins E	53-56	interleukin 6	Mus musculus	142-146
10545778-4	1999	RT-PCR analysis indicated that the steady-state level of IL-6 mRNA induced by LPS was apparently increased upon co-addition of UTP.	Uridine Triphosphate	127-130	interleukin 6	Mus musculus	57-61
10545778-7	1999	The results revealed the positive regulation between PGE(2) and IL-6 synthesis because NS-398 and indomethacin inhibited LPS plus UTP-induced IL-6 release, and IL-6 antibody attenuated LPS plus UTP-induced PGE(2) release.	Indomethacin	98-110	interleukin 6	Mus musculus	64-68
10545778-7	1999	The results revealed the positive regulation between PGE(2) and IL-6 synthesis because NS-398 and indomethacin inhibited LPS plus UTP-induced IL-6 release, and IL-6 antibody attenuated LPS plus UTP-induced PGE(2) release.	Indomethacin	98-110	interleukin 6	Mus musculus	142-146
10545778-7	1999	The results revealed the positive regulation between PGE(2) and IL-6 synthesis because NS-398 and indomethacin inhibited LPS plus UTP-induced IL-6 release, and IL-6 antibody attenuated LPS plus UTP-induced PGE(2) release.	Indomethacin	98-110	interleukin 6	Mus musculus	142-146
10545778-7	1999	The results revealed the positive regulation between PGE(2) and IL-6 synthesis because NS-398 and indomethacin inhibited LPS plus UTP-induced IL-6 release, and IL-6 antibody attenuated LPS plus UTP-induced PGE(2) release.	Uridine Triphosphate	130-133	interleukin 6	Mus musculus	64-68
10545778-7	1999	The results revealed the positive regulation between PGE(2) and IL-6 synthesis because NS-398 and indomethacin inhibited LPS plus UTP-induced IL-6 release, and IL-6 antibody attenuated LPS plus UTP-induced PGE(2) release.	Uridine Triphosphate	130-133	interleukin 6	Mus musculus	142-146
10545778-7	1999	The results revealed the positive regulation between PGE(2) and IL-6 synthesis because NS-398 and indomethacin inhibited LPS plus UTP-induced IL-6 release, and IL-6 antibody attenuated LPS plus UTP-induced PGE(2) release.	Uridine Triphosphate	130-133	interleukin 6	Mus musculus	142-146
10571688-6	1999	Following the withdrawal of 17beta-estradiol, MOB cultures showed a significant increase in the number of cells synthesizing stromelysin-1; this effect was enhanced by stimulation with either interleukin-1 or interleukin-6.	Estradiol	28-44	interleukin 6	Mus musculus	209-222
10545778-7	1999	The results revealed the positive regulation between PGE(2) and IL-6 synthesis because NS-398 and indomethacin inhibited LPS plus UTP-induced IL-6 release, and IL-6 antibody attenuated LPS plus UTP-induced PGE(2) release.	Uridine Triphosphate	194-197	interleukin 6	Mus musculus	64-68
10545778-7	1999	The results revealed the positive regulation between PGE(2) and IL-6 synthesis because NS-398 and indomethacin inhibited LPS plus UTP-induced IL-6 release, and IL-6 antibody attenuated LPS plus UTP-induced PGE(2) release.	Prostaglandins E	206-209	interleukin 6	Mus musculus	64-68
10528216-10	1999	Treatment of IL-6WT mice with anti-IL-6 (5 microg/day/mouse at 24 and 1 h before carrageenan treatment) also significantly attenuated all the above indicators of lung inflammation.	Carrageenan	81-92	interleukin 6	Mus musculus	13-17
10599927-5	1999	Parasite growth was enhanced by prostaglandin treatment, which provoked poor Con-A responses, low Th1-type cytokines secretion, and high levels of IL-6 and IL-10.	Prostaglandins	32-45	interleukin 6	Mus musculus	147-151
10599927-6	1999	In contrast, mice receiving indomethacin showed a reduction in parasite load parallel to a strong Con-A response and high levels of IL-2 and IFN-gamma, concomitantly with a decrease in IL-4, IL-6 and IL-10 production.	Indomethacin	28-40	interleukin 6	Mus musculus	191-195
10528216-0	1999	Role of IL-6 in the pleurisy and lung injury caused by carrageenan.	Carrageenan	55-66	interleukin 6	Mus musculus	8-12
10528216-2	1999	Compared with carrageenan-treated IL-6 wild-type (IL-6WT) mice, carrageenan-treated IL-6KO mice exhibited a reduced degree of pleural exudation and polymorphonuclear cell migration.	Carrageenan	14-25	interleukin 6	Mus musculus	34-38
10528216-2	1999	Compared with carrageenan-treated IL-6 wild-type (IL-6WT) mice, carrageenan-treated IL-6KO mice exhibited a reduced degree of pleural exudation and polymorphonuclear cell migration.	Carrageenan	64-75	interleukin 6	Mus musculus	34-38
10555997-4	1999	Characteristic of dendritic cell maturation, R-848 treatment induces cell surface expression of CD83 and increases cell surface expression of CD80, CD86, CD40, and HLA-DR. Additionally, R-848 induces cytokine (IL-6, IL-12, TNF-alpha, IFN-alpha) and chemokine (IL-8, MIP-1alpha, MCP-1) secretion from dendritic cells.	resiquimod	45-50	interleukin 6	Mus musculus	210-214
10575665-5	1999	The production of three cytokines, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6, was greater for lipopolysaccharide-stimulated macrophages from mice fed the glutamine-enriched diet.	Glutamine	179-188	interleukin 6	Mus musculus	88-101
10555997-4	1999	Characteristic of dendritic cell maturation, R-848 treatment induces cell surface expression of CD83 and increases cell surface expression of CD80, CD86, CD40, and HLA-DR. Additionally, R-848 induces cytokine (IL-6, IL-12, TNF-alpha, IFN-alpha) and chemokine (IL-8, MIP-1alpha, MCP-1) secretion from dendritic cells.	resiquimod	186-191	interleukin 6	Mus musculus	210-214
10497256-6	1999	PGE(2) appears to act primarily at the level of translation or protein stability, because TNF-alpha and IL-6 mRNA levels were only modestly decreased at high PGE(2) concentrations; concomitantly with this inhibition, PGE(2) up-regulated the levels of IL-1beta mRNA.	Prostaglandins E	158-161	interleukin 6	Mus musculus	104-108
10522646-9	1999	Ergotamine treatment significantly increased IL-6 levels at the 2.0 mg/kg dose and greater and TNF-alpha at the highest dose.	Ergotamine	0-10	interleukin 6	Mus musculus	45-49
10522646-12	1999	Ergotamine affected the proinflammatory cytokine IL-6, and this increase may contribute to fescue tosicosis.	Ergotamine	0-10	interleukin 6	Mus musculus	49-53
10497256-5	1999	More detailed studies of BV-2 cells show that PGE(2) also prevents the secretion of interleukin (IL)-6 but does not significantly modify lipopolysaccharide-stimulated expression of cyclooxygenase-2, pro-IL-1beta, or inducible nitric oxide synthase.	Dinoprostone	46-52	interleukin 6	Mus musculus	84-102
10497256-6	1999	PGE(2) appears to act primarily at the level of translation or protein stability, because TNF-alpha and IL-6 mRNA levels were only modestly decreased at high PGE(2) concentrations; concomitantly with this inhibition, PGE(2) up-regulated the levels of IL-1beta mRNA.	Prostaglandins E	0-3	interleukin 6	Mus musculus	104-108
10549987-4	1999	Alcohol also affected the paracrine/autocrine induction of cytokine transcripts in neuronal cell cultures, which included enhancing the ability of TNFalpha to stimulate IL-6 transcripts.	Alcohols	0-7	interleukin 6	Mus musculus	169-173
10491224-1	1999	We previously showed that sphingosine 1-phosphate acts as a second messenger for tumor necrosis factor alpha-induced interleukin-6 synthesis in osteoblast-like MC3T3-E1 cells and that the synthesis by sphingosine 1-phosphate is dependent on p42/p44 mitogen-activated protein (MAP) kinase activation.	sphingosine 1-phosphate	26-49	interleukin 6	Mus musculus	117-130
10504298-7	1999	Compared to TPA-treated wild-type mice, the epidermis of TPA-treated K5-PKCalpha mice displayed increased expression of cyclooxygenase-2 (COX-2), the neutrophil chemotactic factor macrophage inflammatory protein-2 (MIP-2) mRNA and the proinflammatory cytokine TNFalpha mRNA but not IL-6 or IL-1alpha mRNA.	Tetradecanoylphorbol Acetate	57-60	interleukin 6	Mus musculus	282-286
10497256-6	1999	PGE(2) appears to act primarily at the level of translation or protein stability, because TNF-alpha and IL-6 mRNA levels were only modestly decreased at high PGE(2) concentrations; concomitantly with this inhibition, PGE(2) up-regulated the levels of IL-1beta mRNA.	Prostaglandins E	158-161	interleukin 6	Mus musculus	104-108
10577734-6	1999	CQ treatment of infected mice resulted in parasite clearance that was associated with an earlier production of IL-4, IL-6, and IL-10 when compared with nontreated infected mice.	Chloroquine	0-2	interleukin 6	Mus musculus	117-121
10534116-0	1999	Attenuated liver fibrosis and depressed serum albumin levels in carbon tetrachloride-treated IL-6-deficient mice.	Carbon Tetrachloride	64-84	interleukin 6	Mus musculus	93-97
10500532-6	1999	Serum IL-6 levels were also lowered by 5"-DFUR in nude mice bearing KPL-4 tumors.	doxifluridine	39-46	interleukin 6	Mus musculus	6-10
10477606-7	1999	Although activation of BMCMC induced the expression of mRNAs for the inflammatory cytokines IL-1beta, IL-4, IL-6, TNF-alpha, and the chemokine lymphotactin, mRNAs for IL-1beta, TNF-alpha, and lymphotactin were down-modulated in the presence of alpha-MSH.	bmcmc	23-28	interleukin 6	Mus musculus	108-112
10541880-4	1999	The activity of OCT in vitro was investigated and compared with that of a series of vitamin D3 analogues as to their ability to inhibit murine T lymphocyte proliferation stimulated by con-A, to suppress IL-6 and IL-8 production by keratinocytes stimulated with IL-1alpha and TNFalpha, and to inhibit AP-1- and NFkappaB-dependent reporter gene expression.	maxacalcitol	16-19	interleukin 6	Mus musculus	203-207
10541880-5	1999	OCT inhibited the proliferation of lymphocytes and suppressed IL-8 and IL-6 production by keratinocytes to the same extent as the other vitamin D3 analogues.	maxacalcitol	0-3	interleukin 6	Mus musculus	71-75
10499156-0	1999	Elevation of striatal interleukin-6 and serum corticosterone contents in MPTP-treated mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	73-77	interleukin 6	Mus musculus	22-35
10499156-2	1999	Changes in the content of striatal interleukins (IL-1 beta and IL-6) and serum corticosterone in relation to deterioration of the dopaminergic system induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; a dopaminergic neurotoxin; 20 mg/kg i.p., four administrations/12 h) in C57BL/6J mice were investigated.	1-phenyl-1,2,3,6-tetrahydropyridine	172-205	interleukin 6	Mus musculus	63-67
10499156-8	1999	Increases in IL-6 were observed on days 1 and 7 post-MPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	53-57	interleukin 6	Mus musculus	13-17
10499156-9	1999	The increase in striatal IL-6 content varied with the extent of dopamine depletion, although the IL-1 beta concentration remained unchanged compared with control values on days 1 and 7 post-treatment.	Dopamine	64-72	interleukin 6	Mus musculus	25-29
10499156-14	1999	These results suggest that changes in striatal IL-6 and serum corticosterone are closely associated with the severity of MPTP-induced dopaminergic degeneration.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	121-125	interleukin 6	Mus musculus	47-51
10471580-6	1999	(i) At 12 to 24 h after infection, larger amounts of leukotriene B(4) in bronchoalveolar lavage (BAL) fluid associated with greater neutrophilia in lung tissue and alveolar spaces and more persistent release of tumor necrosis factor alpha, interleukin-1 alpha (IL-1alpha), and IL-6 were observed.	Leukotriene B4	53-66	interleukin 6	Mus musculus	277-281
10438914-3	1999	Such rapid-onset TCR-mediated death of T cells does not involve cell division and is Fas-dependent, inhibited by CD28 (and IL-6) costimulation and enhanced by IL-4 and IL-7; by contrast, spontaneous death of CD4+ cells cultured alone is Fas-independent and inhibited by IL-4 and IL-7.	ammonium ferrous sulfate	85-88	interleukin 6	Mus musculus	123-127
10412048-1	1999	We previously showed that basic fibroblast growth factor (bFGF)-induced activation of protein kinase C (PKC) via phosphatidylinositol-hydrolyzing phospholipase C and phosphatidylcholine-hydrolyzing phospholipase D suppresses interleukin-6 (IL-6) synthesis by bFGF itself in osteoblast-like MC3T3-E1 cells.	Phosphatidylcholines	166-185	interleukin 6	Mus musculus	225-238
10412048-1	1999	We previously showed that basic fibroblast growth factor (bFGF)-induced activation of protein kinase C (PKC) via phosphatidylinositol-hydrolyzing phospholipase C and phosphatidylcholine-hydrolyzing phospholipase D suppresses interleukin-6 (IL-6) synthesis by bFGF itself in osteoblast-like MC3T3-E1 cells.	Phosphatidylcholines	166-185	interleukin 6	Mus musculus	240-244
10412048-4	1999	SB203580, a specific inhibitor of p38 MAP kinase, suppressed the bFGF-induced IL-6 synthesis dose-dependently.	SB 203580	0-8	interleukin 6	Mus musculus	78-82
10412048-7	1999	SB203580 inhibited the A23187-induced synthesis of IL-6.	SB 203580	0-8	interleukin 6	Mus musculus	51-55
10412048-7	1999	SB203580 inhibited the A23187-induced synthesis of IL-6.	Calcimycin	23-29	interleukin 6	Mus musculus	51-55
10412048-8	1999	1-Oleoyl-2-acetyl-sn-glycerol, a synthetic diacylglycerol activating PKC, reduced the bFGF-induced IL-6 synthesis.	1-oleoyl-2-acetylglycerol	0-29	interleukin 6	Mus musculus	99-103
10412048-8	1999	1-Oleoyl-2-acetyl-sn-glycerol, a synthetic diacylglycerol activating PKC, reduced the bFGF-induced IL-6 synthesis.	Diglycerides	43-57	interleukin 6	Mus musculus	99-103
10496318-3	1999	There was a marked increase in the peroxynitrite formation in the plasma of the SAO-shocked IL-6 wild-type (WT) mice after reperfusion.	Peroxynitrous Acid	35-48	interleukin 6	Mus musculus	92-96
10496318-4	1999	Immunohistochemical examination demonstrated a marked increase in the immunoreactivity to nitrotyrosine in the necrotic ileum in shocked IL-6 WT mice.	3-nitrotyrosine	90-103	interleukin 6	Mus musculus	137-141
10474051-10	1999	We examined the effect of dexamethasone (10(-6) M) and indomethacin (10(-4) M) on the release of IL-6 in submaximally stimulated cells.	Dexamethasone	26-39	interleukin 6	Mus musculus	97-101
10474051-10	1999	We examined the effect of dexamethasone (10(-6) M) and indomethacin (10(-4) M) on the release of IL-6 in submaximally stimulated cells.	Indomethacin	55-67	interleukin 6	Mus musculus	97-101
10474051-11	1999	Dexamethasone inhibited the unstimulated and the LPS-stimulated release of IL-6 by 70 and 81%, respectively.	Dexamethasone	0-13	interleukin 6	Mus musculus	75-79
10496318-12	1999	SAO-shocked IL-6 KO mice also show significant reduction of neutrophil infiltration into the reperfused intestine, as evidenced by reduced MPO activity, improved histological status of the reperfused tissues, reduced peroxynitrite formation, reduced MDA levels, and improved survival.	Peroxynitrous Acid	217-230	interleukin 6	Mus musculus	12-16
10582659-0	1999	Prostaglandin D2 induces interleukin-6 synthesis via Ca2+ mobilization in osteoblasts: regulation by protein kinase C. We previously showed that prostaglandin (PG) D2 stimulates Ca2+ influx from extracellular space and activates phosphoinositidic (PI)-hydrolyzing phospholipase C and phosphatidylcholine (PC)-hydrolyzing phospholipase D independently from PGE2 or PGF2alpha in osteoblast-like MC3T3-E1 cells.	Prostaglandin D2	0-16	interleukin 6	Mus musculus	25-38
10582659-0	1999	Prostaglandin D2 induces interleukin-6 synthesis via Ca2+ mobilization in osteoblasts: regulation by protein kinase C. We previously showed that prostaglandin (PG) D2 stimulates Ca2+ influx from extracellular space and activates phosphoinositidic (PI)-hydrolyzing phospholipase C and phosphatidylcholine (PC)-hydrolyzing phospholipase D independently from PGE2 or PGF2alpha in osteoblast-like MC3T3-E1 cells.	Prostaglandin D2	145-166	interleukin 6	Mus musculus	25-38
10582659-1	1999	In the present study, we investigated the effect of PGD2 on the synthesis of interleukin-6 (IL-6) and its regulatory mechanism in MC3T3-E1 cells.	Prostaglandin D2	52-56	interleukin 6	Mus musculus	77-90
10582659-1	1999	In the present study, we investigated the effect of PGD2 on the synthesis of interleukin-6 (IL-6) and its regulatory mechanism in MC3T3-E1 cells.	Prostaglandin D2	52-56	interleukin 6	Mus musculus	92-96
10582659-2	1999	PGD2 significantly stimulated IL-6 synthesis dose-dependently in the range between 10 nM and 10 microM.	Prostaglandin D2	0-4	interleukin 6	Mus musculus	30-34
10582659-3	1999	The depletion of extracellular Ca2+ by EGTA reduced the PGD2-induced IL-6 synthesis.	Egtazic Acid	39-43	interleukin 6	Mus musculus	69-73
10582659-3	1999	The depletion of extracellular Ca2+ by EGTA reduced the PGD2-induced IL-6 synthesis.	Prostaglandin D2	56-60	interleukin 6	Mus musculus	69-73
10582659-4	1999	TMB-8, an inhibitor of intracellular Ca2+ mobilization, significantly inhibited the PGD2-induced IL-6 synthesis.	8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate	0-5	interleukin 6	Mus musculus	97-101
10582659-4	1999	TMB-8, an inhibitor of intracellular Ca2+ mobilization, significantly inhibited the PGD2-induced IL-6 synthesis.	Prostaglandin D2	84-88	interleukin 6	Mus musculus	97-101
10582659-5	1999	On the other hand, calphostin C, a specific inhibitor of protein kinase C (PKC), enhanced the synthesis of IL-6 induced by PGD2.	calphostin C	19-31	interleukin 6	Mus musculus	107-111
10582659-5	1999	On the other hand, calphostin C, a specific inhibitor of protein kinase C (PKC), enhanced the synthesis of IL-6 induced by PGD2.	Prostaglandin D2	123-127	interleukin 6	Mus musculus	107-111
10582659-6	1999	In addition, U-73122, an inhibitor of phospholipase C, and propranolol, a phosphatidic acid phosphohydrolase inhibitor, enhanced the PGD2-induced IL-6 synthesis.	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	13-20	interleukin 6	Mus musculus	146-150
10582659-6	1999	In addition, U-73122, an inhibitor of phospholipase C, and propranolol, a phosphatidic acid phosphohydrolase inhibitor, enhanced the PGD2-induced IL-6 synthesis.	Propranolol	59-70	interleukin 6	Mus musculus	146-150
10582659-6	1999	In addition, U-73122, an inhibitor of phospholipase C, and propranolol, a phosphatidic acid phosphohydrolase inhibitor, enhanced the PGD2-induced IL-6 synthesis.	Prostaglandin D2	133-137	interleukin 6	Mus musculus	146-150
10582659-7	1999	These results strongly suggest that PGD2 stimulates IL-6 synthesis through intracellular Ca2+ mobilization in osteoblasts, and that the PKC activation by PGD2 itself regulates the over-synthesis of IL-6.	Prostaglandin D2	36-40	interleukin 6	Mus musculus	52-56
10582659-7	1999	These results strongly suggest that PGD2 stimulates IL-6 synthesis through intracellular Ca2+ mobilization in osteoblasts, and that the PKC activation by PGD2 itself regulates the over-synthesis of IL-6.	Prostaglandin D2	154-158	interleukin 6	Mus musculus	198-202
10419885-0	1999	Hyaluronate-enhanced hematopoiesis: two different receptors trigger the release of interleukin-1beta and interleukin-6 from bone marrow macrophages.	hyaluronate	0-11	interleukin 6	Mus musculus	105-118
10446861-6	1999	Protection with nasal CTB-CII vaccine was associated with decreased production of interleukin-4 (IL-4), IL-6, and interferon-gamma and with reduced CII-specific IgG1 and IgG2a antibody responses in regional lymph nodes.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	26-29	interleukin 6	Mus musculus	104-108
10415153-4	1999	Twitcher/IL-6-deficient mice had a more severe disease than regular twitcher mice: they had an earlier onset day of twitching, a greater number of PAS-positive cells, a greater susceptibility to LPS, an exaggerated gliotic response around some vessels, an elevated level of TNF-alpha, and a compromised blood-brain barrier, which was evaluated by three independent measures.	Protactinium	147-150	interleukin 6	Mus musculus	9-13
10456660-3	1999	ATRA acts by down-regulating IL-6-receptor-alpha or gp130 on the surface of the myeloma cells.	Tretinoin	0-4	interleukin 6	Mus musculus	29-33
10423326-9	1999	Dexamethasone, but not IL-1 RA or an anti-TNF antibody, inhibited hepatocyte production of IL-6 in response to LPS.	Dexamethasone	0-13	interleukin 6	Mus musculus	91-95
10409106-6	1999	In addition, only DHT-treated animals exhibited increased Kupffer cell IL-6 release (+634%).	Dihydrotestosterone	18-21	interleukin 6	Mus musculus	71-75
10391858-6	1999	Furthermore, the presence in serum of the inflammatory cytokines tumor necrosis factor alpha and interleukin 6 were evaluated as markers of severity of infection, and the results showed that the levels of these cytokines in mice treated with SC-1225 were significantly decreased in comparison with those in BSA-treated control mice.	sc-1225	242-249	interleukin 6	Mus musculus	97-110
10430748-4	1999	l-NAME increased TNF-alpha and IL-6 protein and mRNA expression in lungs.	NG-Nitroarginine Methyl Ester	0-6	interleukin 6	Mus musculus	31-35
10478575-0	1999	Adrenaline influences the release of interleukin-6 from murine pituicytes: role of beta2-adrenoceptors.	Epinephrine	0-10	interleukin 6	Mus musculus	37-50
10478575-1	1999	In this study, we examined the effect of adrenaline and interleukin-1beta on interleukin-6 secretion from cultured murine neurohypophyseal cells.	Epinephrine	41-51	interleukin 6	Mus musculus	77-90
10478575-6	1999	Incubation with adrenaline (10(-6) M) or interleukin-1beta (11 pM) induced maximal secretion of interleukin-6, resulting in a 2.2-fold and 19.8-fold increase, respectively (P&lt;0.01).	Epinephrine	16-26	interleukin 6	Mus musculus	96-109
10385616-0	1999	Central injection of nicotine increases hepatic and splenic interleukin 6 (IL-6) mRNA expression and plasma IL-6 levels in mice: involvement of the peripheral sympathetic nervous system.	Nicotine	21-29	interleukin 6	Mus musculus	60-73
10385616-0	1999	Central injection of nicotine increases hepatic and splenic interleukin 6 (IL-6) mRNA expression and plasma IL-6 levels in mice: involvement of the peripheral sympathetic nervous system.	Nicotine	21-29	interleukin 6	Mus musculus	75-79
10385616-0	1999	Central injection of nicotine increases hepatic and splenic interleukin 6 (IL-6) mRNA expression and plasma IL-6 levels in mice: involvement of the peripheral sympathetic nervous system.	Nicotine	21-29	interleukin 6	Mus musculus	108-112
10385616-4	1999	injection of nicotine on plasma IL-6 levels were investigated in mice.	Nicotine	13-21	interleukin 6	Mus musculus	32-36
10385616-9	1999	Mecamylamine, a nicotinic receptor antagonist, blocked nicotine-induced plasma IL-6 levels.	Mecamylamine	0-12	interleukin 6	Mus musculus	79-83
10385616-9	1999	Mecamylamine, a nicotinic receptor antagonist, blocked nicotine-induced plasma IL-6 levels.	Nicotine	55-63	interleukin 6	Mus musculus	79-83
10385616-10	1999	Depletion of peripheral norepinephrine with 6-hydroxydopamine [100 mg/kg, intraperitoneal (i. p.)] inhibited the nicotine-induced plasma IL-6 levels by 57%, whereas central norepinephrine depletion with 6-hydroxydopamine (50 microgram/mouse, i.c.v.)	Norepinephrine	24-38	interleukin 6	Mus musculus	137-141
10385616-10	1999	Depletion of peripheral norepinephrine with 6-hydroxydopamine [100 mg/kg, intraperitoneal (i. p.)] inhibited the nicotine-induced plasma IL-6 levels by 57%, whereas central norepinephrine depletion with 6-hydroxydopamine (50 microgram/mouse, i.c.v.)	Oxidopamine	44-61	interleukin 6	Mus musculus	137-141
10385616-10	1999	Depletion of peripheral norepinephrine with 6-hydroxydopamine [100 mg/kg, intraperitoneal (i. p.)] inhibited the nicotine-induced plasma IL-6 levels by 57%, whereas central norepinephrine depletion with 6-hydroxydopamine (50 microgram/mouse, i.c.v.)	Nicotine	113-121	interleukin 6	Mus musculus	137-141
10385616-16	1999	), inhibited nicotine-induced plasma IL-6 levels.	Nicotine	13-21	interleukin 6	Mus musculus	37-41
10385616-18	1999	increased IL-6 mRNA expression only in the liver and spleen, which was inhibited by peripheral norepinephrine depletion.	Norepinephrine	95-109	interleukin 6	Mus musculus	10-14
10485327-2	1999	4-deoxypirydoxine is a potent antagonist of vitamin B6 coenzyme which depresses IL-1, TNF and IL-6 and has anti-inflammatory properties.	4-deoxypirydoxine	0-17	interleukin 6	Mus musculus	94-98
10485327-2	1999	4-deoxypirydoxine is a potent antagonist of vitamin B6 coenzyme which depresses IL-1, TNF and IL-6 and has anti-inflammatory properties.	Vitamin B 6	44-54	interleukin 6	Mus musculus	94-98
10415803-0	1999	Non-antimicrobial and antimicrobial tetracyclines inhibit IL-6 expression in murine osteoblasts.	Tetracyclines	36-49	interleukin 6	Mus musculus	58-62
10456660-6	1999	These tumors are induced at about 50% incidence in pristane-primed BALB/c mice by injection of v-raf/v-myc- containing retroviruses and are IL-6 dependent.	pristane	51-59	interleukin 6	Mus musculus	140-144
10354505-2	1999	Expression of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 mRNA in response to LPS stimulation was suppressed in LPS-tolerant macrophages.	lps	91-94	interleukin 6	Mus musculus	52-70
10373405-7	1999	Furthermore, we demonstrated the increased expression of the two NF-kappaB target genes IL-6 and IL-1beta in OAA-exposed mice and a transient OAA-induced accumulation of TNFalpha in vitro.	oleoylanilide	109-112	interleukin 6	Mus musculus	88-92
10354505-2	1999	Expression of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 mRNA in response to LPS stimulation was suppressed in LPS-tolerant macrophages.	lps	125-128	interleukin 6	Mus musculus	52-70
10400825-0	1999	Role of interleukin-6 in a non-septic shock model induced by zymosan.	Zymosan	61-68	interleukin 6	Mus musculus	8-21
10400825-10	1999	In vivo treatment with anti-IL-6 (5,000 ng/day per mouse, 24 and 1 hour before zymosan administration) significantly reduced the inflammatory process.	Zymosan	79-86	interleukin 6	Mus musculus	28-32
10400825-11	1999	Taken together, the present study clearly demonstrates that IL-6 exerts a role in zymosan-induced non-septic shock.	Zymosan	82-89	interleukin 6	Mus musculus	60-64
10234011-4	1999	Blocking of retrograde axonal transport by injection of colchicine into an otherwise normal nerve did not induce interleukin-6 mRNA in primary sensory neurons, but injection of colchicine into the nerve stump prevented induction of interleukin-6 mRNA by nerve transection.	Colchicine	177-187	interleukin 6	Mus musculus	232-245
10400316-0	1999	Effect of ceramide on interleukin-6 synthesis in osteoblast-like cells.	Ceramides	10-18	interleukin 6	Mus musculus	22-35
10400316-1	1999	We previously showed that prostaglandin (PG) E1 stimulates the synthesis of interleukin-6 (IL-6) through activation of protein kinase (PK) A in osteoblast-like MC3T3-E1 cells and that PGF2alpha induces IL-6 synthesis through PKC activation.	Alprostadil	26-47	interleukin 6	Mus musculus	76-89
10400316-1	1999	We previously showed that prostaglandin (PG) E1 stimulates the synthesis of interleukin-6 (IL-6) through activation of protein kinase (PK) A in osteoblast-like MC3T3-E1 cells and that PGF2alpha induces IL-6 synthesis through PKC activation.	Alprostadil	26-47	interleukin 6	Mus musculus	91-95
10400316-1	1999	We previously showed that prostaglandin (PG) E1 stimulates the synthesis of interleukin-6 (IL-6) through activation of protein kinase (PK) A in osteoblast-like MC3T3-E1 cells and that PGF2alpha induces IL-6 synthesis through PKC activation.	Alprostadil	26-47	interleukin 6	Mus musculus	202-206
10400316-1	1999	We previously showed that prostaglandin (PG) E1 stimulates the synthesis of interleukin-6 (IL-6) through activation of protein kinase (PK) A in osteoblast-like MC3T3-E1 cells and that PGF2alpha induces IL-6 synthesis through PKC activation.	Dinoprost	184-193	interleukin 6	Mus musculus	91-95
10400316-1	1999	We previously showed that prostaglandin (PG) E1 stimulates the synthesis of interleukin-6 (IL-6) through activation of protein kinase (PK) A in osteoblast-like MC3T3-E1 cells and that PGF2alpha induces IL-6 synthesis through PKC activation.	Dinoprost	184-193	interleukin 6	Mus musculus	202-206
10400316-2	1999	In other studies, we demonstrated that thrombin stimulates IL-6 synthesis, which depends on intracellular Ca2+ mobilisation in these cells and that tumour necrosis factor-alpha (TNF) induces IL-6 synthesis through sphingosine 1-phosphate, a product of sphingomyelin turnover.	sphingosine 1-phosphate	214-237	interleukin 6	Mus musculus	191-195
10400316-3	1999	In the present study, among sphingomyelin metabolites, we examined the effect of ceramide on the IL-6 synthesis induced by various agonists in MC3T3-E1 cells.	Ceramides	81-89	interleukin 6	Mus musculus	97-101
10400316-4	1999	C2-ceramide, a cell-permeable ceramide analogue, suppressed the PGE1-induced IL-6 synthesis.	N-acetylsphingosine	0-11	interleukin 6	Mus musculus	77-81
10400316-4	1999	C2-ceramide, a cell-permeable ceramide analogue, suppressed the PGE1-induced IL-6 synthesis.	Ceramides	3-11	interleukin 6	Mus musculus	77-81
10400316-4	1999	C2-ceramide, a cell-permeable ceramide analogue, suppressed the PGE1-induced IL-6 synthesis.	Alprostadil	64-68	interleukin 6	Mus musculus	77-81
10400316-5	1999	C2-ceramide inhibited the IL-6 synthesis induced by PGF2alpha or 12-O-tetradecanoylphorbol-13-acetate, an activator of PKC.	N-acetylsphingosine	0-11	interleukin 6	Mus musculus	26-30
10400316-5	1999	C2-ceramide inhibited the IL-6 synthesis induced by PGF2alpha or 12-O-tetradecanoylphorbol-13-acetate, an activator of PKC.	Dinoprost	52-61	interleukin 6	Mus musculus	26-30
10400316-5	1999	C2-ceramide inhibited the IL-6 synthesis induced by PGF2alpha or 12-O-tetradecanoylphorbol-13-acetate, an activator of PKC.	Tetradecanoylphorbol Acetate	65-101	interleukin 6	Mus musculus	26-30
10400316-6	1999	C2-ceramide reduced the IL-6 synthesis induced by cholera toxin, forskolin or dibutyryl cAMP.	N-acetylsphingosine	0-11	interleukin 6	Mus musculus	24-28
10400316-6	1999	C2-ceramide reduced the IL-6 synthesis induced by cholera toxin, forskolin or dibutyryl cAMP.	Colforsin	65-74	interleukin 6	Mus musculus	24-28
10400316-6	1999	C2-ceramide reduced the IL-6 synthesis induced by cholera toxin, forskolin or dibutyryl cAMP.	Bucladesine	78-92	interleukin 6	Mus musculus	24-28
10400316-7	1999	C2-ceramide inhibited the IL-6 synthesis induced by thrombin.	N-acetylsphingosine	0-11	interleukin 6	Mus musculus	26-30
10400316-8	1999	The IL-6 synthesis stimulated by thapsigargin, which is known to stimulate Ca2+ mobilisation from intracellular Ca2+ stores, or A23187, a Ca-ionophore, was also inhibited by C2-ceramide.	Thapsigargin	33-45	interleukin 6	Mus musculus	4-8
10400316-8	1999	The IL-6 synthesis stimulated by thapsigargin, which is known to stimulate Ca2+ mobilisation from intracellular Ca2+ stores, or A23187, a Ca-ionophore, was also inhibited by C2-ceramide.	Calcimycin	128-134	interleukin 6	Mus musculus	4-8
10400316-8	1999	The IL-6 synthesis stimulated by thapsigargin, which is known to stimulate Ca2+ mobilisation from intracellular Ca2+ stores, or A23187, a Ca-ionophore, was also inhibited by C2-ceramide.	N-acetylsphingosine	174-185	interleukin 6	Mus musculus	4-8
10400316-10	1999	On the contrary, C2-ceramide enhanced the TNF-induced IL-6 synthesis.	N-acetylsphingosine	17-28	interleukin 6	Mus musculus	54-58
10400316-12	1999	These results strongly suggest that ceramide modulates the IL-6 synthesis stimulated by various agonists in osteoblasts.	Ceramides	36-44	interleukin 6	Mus musculus	59-63
10320804-7	1999	In PLA2-IIA-deficient mice, indoxam also suppressed the elevation of plasma IL-1beta, IL-6 and NO, and prolonged survival after LPS challenge.	indoxam	28-35	interleukin 6	Mus musculus	86-90
10329406-3	1999	SB 203580 as the specific inhibitor for p38 MAP kinase activity inhibited TNF-alpha-induced IL-6 production by the parental L cells, indicating that TNF-alpha-activated p38 MAP kinase regulates IL-6 production by the cell lines used in this study.	SB 203580	0-9	interleukin 6	Mus musculus	92-96
10329406-3	1999	SB 203580 as the specific inhibitor for p38 MAP kinase activity inhibited TNF-alpha-induced IL-6 production by the parental L cells, indicating that TNF-alpha-activated p38 MAP kinase regulates IL-6 production by the cell lines used in this study.	SB 203580	0-9	interleukin 6	Mus musculus	194-198
10376804-0	1999	p42/p44 mitogen-activated protein kinase activation is involved in prostaglandin F2alpha-induced interleukin-6 synthesis in osteoblasts.	Dinoprost	67-88	interleukin 6	Mus musculus	97-110
10330034-3	1999	Treatment with lisofylline inhibited hyperoxia-associated increases in tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 in the lungs as well as decreased the levels of hyperoxia-induced serum-oxidized free fatty acids.	lisofylline	15-26	interleukin 6	Mus musculus	123-136
10376804-3	1999	PD98059 suppressed the IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), a protein kinase C (PKC) activator, or NaF, an activator of heterotrimeric GTP-binding protein, as well as the p42/p44 MAP kinase activation by TPA or NaF.	Sodium Fluoride	244-247	interleukin 6	Mus musculus	23-27
10376804-5	1999	These results strongly suggest that PKC-dependent p42/p44 MAP kinase activatioin is involved in PGF2alpha-induced IL-6 synthesis in osteoblasts.	Dinoprost	96-105	interleukin 6	Mus musculus	114-118
10376804-2	1999	PD98059, a selective inhibitor of MAP kinase kinase, inhibited PGF2alpha-induced interleukin-6 (IL-6) synthesis as well as PGF2alpha-induced p42/p44 MAP kinase activation.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	interleukin 6	Mus musculus	81-94
10376804-2	1999	PD98059, a selective inhibitor of MAP kinase kinase, inhibited PGF2alpha-induced interleukin-6 (IL-6) synthesis as well as PGF2alpha-induced p42/p44 MAP kinase activation.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	interleukin 6	Mus musculus	96-100
10376804-2	1999	PD98059, a selective inhibitor of MAP kinase kinase, inhibited PGF2alpha-induced interleukin-6 (IL-6) synthesis as well as PGF2alpha-induced p42/p44 MAP kinase activation.	Dinoprost	63-72	interleukin 6	Mus musculus	81-94
10376804-2	1999	PD98059, a selective inhibitor of MAP kinase kinase, inhibited PGF2alpha-induced interleukin-6 (IL-6) synthesis as well as PGF2alpha-induced p42/p44 MAP kinase activation.	Dinoprost	63-72	interleukin 6	Mus musculus	96-100
10376804-3	1999	PD98059 suppressed the IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), a protein kinase C (PKC) activator, or NaF, an activator of heterotrimeric GTP-binding protein, as well as the p42/p44 MAP kinase activation by TPA or NaF.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	interleukin 6	Mus musculus	23-27
10376804-3	1999	PD98059 suppressed the IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), a protein kinase C (PKC) activator, or NaF, an activator of heterotrimeric GTP-binding protein, as well as the p42/p44 MAP kinase activation by TPA or NaF.	Tetradecanoylphorbol Acetate	49-85	interleukin 6	Mus musculus	23-27
10376804-3	1999	PD98059 suppressed the IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), a protein kinase C (PKC) activator, or NaF, an activator of heterotrimeric GTP-binding protein, as well as the p42/p44 MAP kinase activation by TPA or NaF.	Tetradecanoylphorbol Acetate	87-90	interleukin 6	Mus musculus	23-27
10376804-3	1999	PD98059 suppressed the IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), a protein kinase C (PKC) activator, or NaF, an activator of heterotrimeric GTP-binding protein, as well as the p42/p44 MAP kinase activation by TPA or NaF.	Sodium Fluoride	132-135	interleukin 6	Mus musculus	23-27
10376804-3	1999	PD98059 suppressed the IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), a protein kinase C (PKC) activator, or NaF, an activator of heterotrimeric GTP-binding protein, as well as the p42/p44 MAP kinase activation by TPA or NaF.	Guanosine Triphosphate	168-171	interleukin 6	Mus musculus	23-27
10376804-3	1999	PD98059 suppressed the IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), a protein kinase C (PKC) activator, or NaF, an activator of heterotrimeric GTP-binding protein, as well as the p42/p44 MAP kinase activation by TPA or NaF.	Tetradecanoylphorbol Acetate	237-240	interleukin 6	Mus musculus	23-27
10447717-3	1999	The IL-6-/- mice had a defective contact hypersensitivity (CHS) in response to the sensitizers 2,4-dinitrofluorobenzene and oxazolone.	Dinitrofluorobenzene	95-119	interleukin 6	Mus musculus	4-8
10215902-6	1999	The development of tolerance to the analgesic effect of morphine was more rapid in IL-6-deficient mice than in wild-type controls.	Morphine	56-64	interleukin 6	Mus musculus	83-87
10447717-3	1999	The IL-6-/- mice had a defective contact hypersensitivity (CHS) in response to the sensitizers 2,4-dinitrofluorobenzene and oxazolone.	Oxazolone	124-133	interleukin 6	Mus musculus	4-8
10227945-9	1999	RESULTS: Gut-mucosal IL-6 in the RA group was significantly higher than in all other groups: RA, 1,354.5 +/- 117.9* vs. CD, 964.3 +/- 114.0 vs. AP, 960.2 +/- 86.2 vs. PC, 908.0 +/- 83.6; *p &lt; 0.05.	Radium	33-35	interleukin 6	Mus musculus	21-25
10446754-5	1999	This inhibition of interleukin-6 production is closely related to the suppression of prostaglandin E2 generation by interfering cyclooxygenase 1 and 2 enzyme activities.	Dinoprostone	85-101	interleukin 6	Mus musculus	19-32
10374244-0	1999	Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice.	Resveratrol	21-32	interleukin 6	Mus musculus	36-49
10374244-2	1999	The effects of resveratrol on Il-6 release by mouse peritoneal macrophages stimulated with calcium ionophore A23187 and fMLP were explored.	Resveratrol	15-26	interleukin 6	Mus musculus	30-34
10374244-2	1999	The effects of resveratrol on Il-6 release by mouse peritoneal macrophages stimulated with calcium ionophore A23187 and fMLP were explored.	Calcium	91-98	interleukin 6	Mus musculus	30-34
10374244-3	1999	Resveratrol, at a concentration range from 5 x 10(-6) to 4 x 10(-5) mol.l-1, was found to dose-dependently inhibit IL-6 release by cultured macrophages induced by A23187 and fMLP, and showed no direct cytotoxic effect, but induced proliferation of cultured mouse thymus cells.	Resveratrol	0-11	interleukin 6	Mus musculus	115-119
10374244-3	1999	Resveratrol, at a concentration range from 5 x 10(-6) to 4 x 10(-5) mol.l-1, was found to dose-dependently inhibit IL-6 release by cultured macrophages induced by A23187 and fMLP, and showed no direct cytotoxic effect, but induced proliferation of cultured mouse thymus cells.	Calcimycin	163-169	interleukin 6	Mus musculus	115-119
10374244-5	1999	These results suggest that the blocking of calcium ion influx into cells by reveratrol is one of the possible mechanisms of the IL-6 biosynthesis inhibitory action of resveratrol.	Calcium	43-50	interleukin 6	Mus musculus	128-132
10374244-5	1999	These results suggest that the blocking of calcium ion influx into cells by reveratrol is one of the possible mechanisms of the IL-6 biosynthesis inhibitory action of resveratrol.	reveratrol	76-86	interleukin 6	Mus musculus	128-132
10227945-11	1999	Similarly, RA resulted in significant increases in serum IL-6 as compared with AP and PC, whereas CD showed no significant difference: RA, 161.3 +/- 66.2* vs. 95.1 +/- 1 vs. AP, 10.6 +/- 5.3 vs. PC, undetectable; *p &lt; 0.05.	Radium	11-13	interleukin 6	Mus musculus	57-61
10227945-9	1999	RESULTS: Gut-mucosal IL-6 in the RA group was significantly higher than in all other groups: RA, 1,354.5 +/- 117.9* vs. CD, 964.3 +/- 114.0 vs. AP, 960.2 +/- 86.2 vs. PC, 908.0 +/- 83.6; *p &lt; 0.05.	Radium	93-95	interleukin 6	Mus musculus	21-25
10374244-5	1999	These results suggest that the blocking of calcium ion influx into cells by reveratrol is one of the possible mechanisms of the IL-6 biosynthesis inhibitory action of resveratrol.	Resveratrol	167-178	interleukin 6	Mus musculus	128-132
10227945-9	1999	RESULTS: Gut-mucosal IL-6 in the RA group was significantly higher than in all other groups: RA, 1,354.5 +/- 117.9* vs. CD, 964.3 +/- 114.0 vs. AP, 960.2 +/- 86.2 vs. PC, 908.0 +/- 83.6; *p &lt; 0.05.	Cadmium	120-122	interleukin 6	Mus musculus	21-25
10220287-1	1999	We previously reported that SK2 hybridoma cells that secreted anti-human interleukin-6 (hIL-6) monoclonal antibodies (SK2 mAb) were microencapsulated within alginate-poly(L)lysine-alginate (APA) membranes (APA-SK2 cells) for immunoisolation, and a single intraperitoneal injection of these APA-SK2 cells remarkably improved IgG1 plasmacytosis in hIL-6 transgenic mice (hIL-6 Tgm).	Alginates	157-165	interleukin 6	Mus musculus	73-86
10378483-5	1999	AFB1 markedly inhibited TNF-alpha interleukin-1 (IL-1) and IL-6 production by LPS-stimulated macrophages.	Aflatoxin B1	0-4	interleukin 6	Mus musculus	59-63
10230619-0	1999	4-Phenylthiazole derivatives inhibit IL-6 secretion in osteoblastic cells and suppress bone weight loss in ovariectomized mice.	4-Phenylthiazole	0-16	interleukin 6	Mus musculus	37-41
10230619-1	1999	A series of 4-phenylthiazole derivatives were synthesized and tested their inhibitory effect on the interleukin-6 secretion stimulated by PTH in osteoblastic cells.	4-Phenylthiazole	12-28	interleukin 6	Mus musculus	100-113
10221543-5	1999	Both p42/p44 MAP kinase activation and IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), a protein kinase C-activating phorbol ester, were reduced by PD98059.	Tetradecanoylphorbol Acetate	103-106	interleukin 6	Mus musculus	39-43
10221543-5	1999	Both p42/p44 MAP kinase activation and IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), a protein kinase C-activating phorbol ester, were reduced by PD98059.	Phorbol Esters	139-152	interleukin 6	Mus musculus	39-43
10221543-5	1999	Both p42/p44 MAP kinase activation and IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), a protein kinase C-activating phorbol ester, were reduced by PD98059.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	170-177	interleukin 6	Mus musculus	39-43
10221543-6	1999	Calphostin C, a highly specific inhibitor of protein kinase C, suppressed endothelin-1-stimulated p42/p44 MAP kinase activation as well as endothelin-1-induced IL-6 synthesis.	calphostin C	0-12	interleukin 6	Mus musculus	160-164
10216531-9	1999	Epinephrine-tolerant animals had higher levels of TNF-alpha, IL-6, and IL-12 than the controls did.	Epinephrine	0-11	interleukin 6	Mus musculus	61-65
10216531-10	1999	CONCLUSION: Epinephrine tolerance primes for an exaggerated release of TNF-alpha, IL-6, and IL-12 in response to lipopolysaccharide challenge, suggesting anti-inflammatory and immunosuppressive effects by epinephrine.	Epinephrine	12-23	interleukin 6	Mus musculus	82-86
10678095-0	1999	Ro 31-8220 inhibits release of interleukin-1 and interleukin-6 from mouse peritoneal macrophages induced by fibrin fibrinogen degradation products.	Ro 31-8220	0-10	interleukin 6	Mus musculus	49-62
10209307-12	1999	The cAMP production induced by IL-6 stimulation for 30 min and withdrawal of 17beta-E2 was lower and significantly different compared to the control study (P&lt;0.05).	Cyclic AMP	4-8	interleukin 6	Mus musculus	31-35
10209307-13	1999	Also IL-6 activation with continuous oestradiol increased cAMP levels and was significantly different from the control cells (P&lt;0.01).	Estradiol	37-47	interleukin 6	Mus musculus	5-9
10209307-13	1999	Also IL-6 activation with continuous oestradiol increased cAMP levels and was significantly different from the control cells (P&lt;0.01).	Cyclic AMP	58-62	interleukin 6	Mus musculus	5-9
10209307-14	1999	However, 17beta-E2 had no effect on the formation of intracellular IP3, although IL-6 significantly lowered IP3 levels in all the groups compared to the control (P&lt;0.01).	Inositol 1,4,5-Trisphosphate	108-111	interleukin 6	Mus musculus	81-85
10221543-4	1999	PD98059, a specific inhibitor of the upstream kinase that activates p42/p44 MAP kinase, suppressed endothelin-1-induced IL-6 synthesis as well as endothelin-1-activated p42/p44 MAP kinase.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	interleukin 6	Mus musculus	120-124
10221543-5	1999	Both p42/p44 MAP kinase activation and IL-6 synthesis induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), a protein kinase C-activating phorbol ester, were reduced by PD98059.	Tetradecanoylphorbol Acetate	65-101	interleukin 6	Mus musculus	39-43
10098870-0	1999	Differential involvement of central and peripheral norepinephrine in the central lipopolysaccharide-induced interleukin-6 responses in mice.	Norepinephrine	51-65	interleukin 6	Mus musculus	108-121
10098870-2	1999	Recently, it was reported that intraperitoneal administration of alpha-adrenoceptor antagonists inhibits centrally injected LPS-induced increases in plasma IL-6 levels, suggesting the involvement of the norepinephrine (NE) system in the central LPS-induced IL-6 response.	Norepinephrine	203-217	interleukin 6	Mus musculus	156-160
10098870-2	1999	Recently, it was reported that intraperitoneal administration of alpha-adrenoceptor antagonists inhibits centrally injected LPS-induced increases in plasma IL-6 levels, suggesting the involvement of the norepinephrine (NE) system in the central LPS-induced IL-6 response.	Norepinephrine	203-217	interleukin 6	Mus musculus	257-261
10098870-6	1999	Pretreatment with intracerebroventricular 6-OHDA (50 microg/mouse) decreased the LPS-induced plasma IL-6 levels by 39% and the LPS-induced IL-6 mRNA expression in liver, spleen, and lymph nodes, but not in choroid plexus, hypothalamus, pituitary, adrenals, and heart.	Oxidopamine	42-48	interleukin 6	Mus musculus	100-104
10098870-6	1999	Pretreatment with intracerebroventricular 6-OHDA (50 microg/mouse) decreased the LPS-induced plasma IL-6 levels by 39% and the LPS-induced IL-6 mRNA expression in liver, spleen, and lymph nodes, but not in choroid plexus, hypothalamus, pituitary, adrenals, and heart.	Oxidopamine	42-48	interleukin 6	Mus musculus	139-143
10098870-7	1999	Pretreatment with intraperitoneal 6-OHDA (100 mg/kg) decreased the LPS-induced plasma IL-6 levels by 36% and the LPS-induced IL-6 mRNA expression in all the peripheral organs displaying increased IL-6 mRNA.	Oxidopamine	34-40	interleukin 6	Mus musculus	86-90
10098870-7	1999	Pretreatment with intraperitoneal 6-OHDA (100 mg/kg) decreased the LPS-induced plasma IL-6 levels by 36% and the LPS-induced IL-6 mRNA expression in all the peripheral organs displaying increased IL-6 mRNA.	Oxidopamine	34-40	interleukin 6	Mus musculus	125-129
10098870-7	1999	Pretreatment with intraperitoneal 6-OHDA (100 mg/kg) decreased the LPS-induced plasma IL-6 levels by 36% and the LPS-induced IL-6 mRNA expression in all the peripheral organs displaying increased IL-6 mRNA.	Oxidopamine	34-40	interleukin 6	Mus musculus	125-129
10220287-1	1999	We previously reported that SK2 hybridoma cells that secreted anti-human interleukin-6 (hIL-6) monoclonal antibodies (SK2 mAb) were microencapsulated within alginate-poly(L)lysine-alginate (APA) membranes (APA-SK2 cells) for immunoisolation, and a single intraperitoneal injection of these APA-SK2 cells remarkably improved IgG1 plasmacytosis in hIL-6 transgenic mice (hIL-6 Tgm).	alginate-polylysine-alginate	166-188	interleukin 6	Mus musculus	73-86
10193432-2	1999	Two subsets of autoantibodies are induced by pristane: IgG anti-DNA DNA and -chromatin autoantibodies are strongly IL-6-dependent, whereas IgG anti-nRNP/Sm and -Su antibodies are not.	pristane	45-53	interleukin 6	Mus musculus	115-119
10088668-3	1999	In this report, we describe the sequential effects of IL-4 and IL-10 on the production of interleukin-6 (IL-6) induced by IL-1beta in mouse primary astrocytes and compare these effects to those of the synthetic glucocorticoid agonist, dexamethasone.	Dexamethasone	235-248	interleukin 6	Mus musculus	90-103
10088668-3	1999	In this report, we describe the sequential effects of IL-4 and IL-10 on the production of interleukin-6 (IL-6) induced by IL-1beta in mouse primary astrocytes and compare these effects to those of the synthetic glucocorticoid agonist, dexamethasone.	Dexamethasone	235-248	interleukin 6	Mus musculus	105-109
9927337-6	1999	Administration of turpentine into the hind-limb of CRF-R1 -/- mice produced a slightly (15-25%) smaller swelling of the limb, but a 10 fold greater rise in plasma IL-6 levels, compared to CRF-R1 +/+ controls.	Turpentine	18-28	interleukin 6	Mus musculus	163-167
10076194-7	1999	VEGF secretion was also stimulated by interleukin-6 (IL-6) whereas basal, IL-6- and PACAP-stimulated secretion was inhibited by the synthetic glucocorticoid dexamethasone.	Dexamethasone	157-170	interleukin 6	Mus musculus	74-79
10452106-0	1999	Inhibitory effects of nitric oxide and interleukin-10 on production of tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6 in mouse alveolar macrophages.	Nitric Oxide	22-34	interleukin 6	Mus musculus	124-137
10452106-5	1999	SMT inhibited LPS-induced nitric oxide release and increased IL-1 beta and IL-6 secretions in AM, but the TNF alpha levels remained unchanged.	S-Methylisothiourea hemisulfate	0-3	interleukin 6	Mus musculus	75-79
10452106-8	1999	CONCLUSION: Both endogenous and exogenous nitric oxide and IL-10 had inhibitory effects on the LPS-induced TNF alpha, IL-1 beta, and IL-6 secretions in mouse AM.	Nitric Oxide	42-54	interleukin 6	Mus musculus	133-137
9873234-8	1999	Am-80 selectively inhibited bacterial lipopolysaccharide (LPS)-induced IL-6, but not TNF-alpha and IL-1beta, production in mice.	tamibarotene	0-5	interleukin 6	Mus musculus	71-75
9918916-6	1999	Continuous BrdU infusion up to 60 hours after PH showed a cumulative hepatocyte labeling index of 79.5% in IL-6(+/+) mice and 70.8% in IL-6(-/-) mice, respectively (P &lt;.03).	Bromodeoxyuridine	11-15	interleukin 6	Mus musculus	107-111
9918916-6	1999	Continuous BrdU infusion up to 60 hours after PH showed a cumulative hepatocyte labeling index of 79.5% in IL-6(+/+) mice and 70.8% in IL-6(-/-) mice, respectively (P &lt;.03).	Bromodeoxyuridine	11-15	interleukin 6	Mus musculus	135-139
10233692-7	1999	The results showed that the potentiating effect of rCGRP (0.1 nm) on LPS-induced IL-6 release was significantly inhibited by either 100 micrometers NG-monomethyl-L-arginine acetate (L-NMMA; an inhibitor of NO synthase) or 10 micrometers indomethacin (an inhibitor of cyclo-oxygenase).	N(G)-monomethylarginine acetate	148-180	interleukin 6	Mus musculus	81-85
10233692-7	1999	The results showed that the potentiating effect of rCGRP (0.1 nm) on LPS-induced IL-6 release was significantly inhibited by either 100 micrometers NG-monomethyl-L-arginine acetate (L-NMMA; an inhibitor of NO synthase) or 10 micrometers indomethacin (an inhibitor of cyclo-oxygenase).	omega-N-Methylarginine	182-188	interleukin 6	Mus musculus	81-85
10233692-7	1999	The results showed that the potentiating effect of rCGRP (0.1 nm) on LPS-induced IL-6 release was significantly inhibited by either 100 micrometers NG-monomethyl-L-arginine acetate (L-NMMA; an inhibitor of NO synthase) or 10 micrometers indomethacin (an inhibitor of cyclo-oxygenase).	Indomethacin	237-249	interleukin 6	Mus musculus	81-85
10233692-9	1999	These results suggest that rCGRP enhances the NO production elicited by LPS and subsequently increases the PGs production which is involved in the potentiating effect of rCGRP on LPS-induced IL-6 release from the peritoneal macrophages in the mouse.	Prostaglandins	107-110	interleukin 6	Mus musculus	191-195
10027341-9	1999	Moreover, intramuscular injections of MPA (100 mg kg(-1) twice a week) into nude mice bearing KPL-4 transplanted tumours significantly decreased serum IL-6 levels without affecting tumour growth and preserved the bodyweight of recipient mice.	Medroxyprogesterone Acetate	38-41	interleukin 6	Mus musculus	151-155
10022508-1	1999	In osteoblast-like MC3T3-E1 cells, we have recently reported that sphingosine 1-phosphate among sphingomyelin metabolites acts as a second messenger for tumor necrosis factor-alpha (TNF)-induced interleukin-6 (IL-6) synthesis.	sphingosine 1-phosphate	66-89	interleukin 6	Mus musculus	195-208
10022508-1	1999	In osteoblast-like MC3T3-E1 cells, we have recently reported that sphingosine 1-phosphate among sphingomyelin metabolites acts as a second messenger for tumor necrosis factor-alpha (TNF)-induced interleukin-6 (IL-6) synthesis.	sphingosine 1-phosphate	66-89	interleukin 6	Mus musculus	210-214
10022508-1	1999	In osteoblast-like MC3T3-E1 cells, we have recently reported that sphingosine 1-phosphate among sphingomyelin metabolites acts as a second messenger for tumor necrosis factor-alpha (TNF)-induced interleukin-6 (IL-6) synthesis.	Sphingomyelins	96-109	interleukin 6	Mus musculus	195-208
10022508-1	1999	In osteoblast-like MC3T3-E1 cells, we have recently reported that sphingosine 1-phosphate among sphingomyelin metabolites acts as a second messenger for tumor necrosis factor-alpha (TNF)-induced interleukin-6 (IL-6) synthesis.	Sphingomyelins	96-109	interleukin 6	Mus musculus	210-214
10022508-4	1999	Calphostin C, a highly and potent inhibitor of protein kinase C, enhanced sphingomyelinase-induced IL-6 synthesis.	calphostin C	0-12	interleukin 6	Mus musculus	99-103
10022508-5	1999	DL-Threo-dihydrosphingosine, an inhibitor of sphingosine kinase, significantly inhibited the IL-6 synthesis induced by sphingomyelinase.	(2R,3R)-2-aminooctadecane-1,3-diol	0-27	interleukin 6	Mus musculus	93-97
10022508-8	1999	These results strongly suggest that extracellular sphingomyelinase induces sphingomyelin hydrolysis in osteoblasts, resulting in IL-6 synthesis, and that protein kinase C acts as a negative controller of the IL-6 synthesis.	Sphingomyelins	50-63	interleukin 6	Mus musculus	129-133
9873234-11	1999	These findings suggest that the inhibitory effect of Am-80 on CIA is partially by modulating the production of the proinflammatory cytokine, IL-6.	tamibarotene	53-58	interleukin 6	Mus musculus	141-145
10022547-3	1999	We report here that complexes of cationic lipid GL-67 and unmethylated pDNA (pCF1-CAT) instilled into the lungs of BALB/c mice induced highly elevated levels of the cytokines TNF-alpha, IFN-gamma, IL-6, and IL-12 in the bronchoalveolar lavage fluids (BALF).	glycylleucine	48-50	interleukin 6	Mus musculus	197-201
9878816-0	1999	The role of interleukin-6 in the activation of the hypothalamo-pituitary-adrenocortical axis and brain indoleamines by endotoxin and interleukin-1 beta.	indolamine	103-115	interleukin 6	Mus musculus	12-25
9878816-7	1999	Pretreatment of mice with anti-IL-6 significantly attenuated the IL-1-induced increases of plasma ACTH and corticosterone at 2 h, but not at 4 h. The IL-1-induced increases of MHPG, tryptophan and 5-HIAA in hypothalamus and brain stem were not significantly altered.	Corticosterone	107-121	interleukin 6	Mus musculus	31-35
9878816-7	1999	Pretreatment of mice with anti-IL-6 significantly attenuated the IL-1-induced increases of plasma ACTH and corticosterone at 2 h, but not at 4 h. The IL-1-induced increases of MHPG, tryptophan and 5-HIAA in hypothalamus and brain stem were not significantly altered.	Methoxyhydroxyphenylglycol	176-180	interleukin 6	Mus musculus	31-35
9878816-7	1999	Pretreatment of mice with anti-IL-6 significantly attenuated the IL-1-induced increases of plasma ACTH and corticosterone at 2 h, but not at 4 h. The IL-1-induced increases of MHPG, tryptophan and 5-HIAA in hypothalamus and brain stem were not significantly altered.	Tryptophan	182-192	interleukin 6	Mus musculus	31-35
9878816-7	1999	Pretreatment of mice with anti-IL-6 significantly attenuated the IL-1-induced increases of plasma ACTH and corticosterone at 2 h, but not at 4 h. The IL-1-induced increases of MHPG, tryptophan and 5-HIAA in hypothalamus and brain stem were not significantly altered.	Hydroxyindoleacetic Acid	197-203	interleukin 6	Mus musculus	31-35
10052129-5	1999	The mice administered Cy and SPG or SPG-OH expressed and produced higher levels of IL-6 mRNA and protein than the mice administered only Cy.	Cyclophosphamide	22-24	interleukin 6	Mus musculus	83-87
10027081-9	1999	After 2 hours of 2.5 ppm ozone exposure, increases were detected for messages encoding eotaxin, MIP-1 alpha, MIP-2, IL-6, and Mt.	Ozone	25-30	interleukin 6	Mus musculus	116-120